PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Gomis, RR; Cid, E; Garcia-Rocha, M; Ferrer, JC; Guinovart, JJ				Gomis, RR; Cid, E; Garcia-Rocha, M; Ferrer, JC; Guinovart, JJ			Liver glycogen synthase but not the muscle isoform differentiates between glucose 6-phosphate produced by glucokinase or hexokinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REGULATORY PROTEIN; HEPATOCYTES; EXPRESSION; CELLS; GLUCOSE-6-PHOSPHATE; OVEREXPRESSION; ADENOVIRUS; QUANTITIES; STORAGE; BINDING	Using adenovirus-mediated gene transfer into FTO-2B cells, a rat hepatoma cell line, we have overexpressed hexokinase I (HK I), glucokinase (GK), liver glycogen synthase (LGS), muscle glycogen synthase (MGS), and combinations of each of the two glucose-phosphorylating enzymes with each one of the GS isoforms. FTO-2B cells do not synthesize glycogen even when incubated with high doses of glucose. Adenovirus-induced overexpression of HK I and/or LGS, two enzymes endogenously expressed by these cells, did not produce a significant increase in the levels of active GS and the total glycogen content. In contrast, GK overexpression led to the glucose-dependent activation of endogenous or overexpressed LGS and to the accumulation of glycogen. Similarly overexpressed MGS was efficiently activated by the glucose-6-phosphate (GIc-6-P) produced by either endogenous or overexpressed HK I and by overexpressed GK. These results indicate the existence of at least two pools of Glc-6-P in the cell, one of them is accessible to both isoforms of GS and is replenished by the action of GK, whereas LGS is excluded from the cellular compartment where the Gle-6-P produced by HK I is directed. These findings are interpreted in terms of the metabolic role that the two pairs of enzymes, HK I-MGS in the muscle and GK-LGS in the hepatocyte, perform in their respective tissues.	Univ Barcelona, Dept Bioquim & Biol Mol, E-08028 Barcelona, Spain; Univ Barcelona, Dept Biochem & Mol Biol, E-08028 Barcelona, Spain	University of Barcelona; University of Barcelona	Guinovart, JJ (corresponding author), Univ Barcelona, Dept Bioquim & Biol Mol, Marti Franques 1, E-08028 Barcelona, Spain.	guinovart@pcb.ub.es	Cid, Emili/F-7207-2016; Gomis, Roger R/E-9788-2016; Ferrer, Joan C./AAP-2145-2021	Cid, Emili/0000-0002-5025-352X; Gomis, Roger R/0000-0001-6473-2858; Garcia-Rocha, Mar/0000-0003-2467-2090; Ferrer, Joan C./0000-0003-1212-5161				Azpiazu I, 2000, AM J PHYSIOL-ENDOC M, V278, pE234, DOI 10.1152/ajpendo.2000.278.2.E234; BAI G, 1990, J BIOL CHEM, V265, P7843; Baque S, 1998, DIABETES, V47, P1392, DOI 10.2337/diabetes.47.9.1392; BECKER TC, 1994, METHOD CELL BIOL, V43, P161; BELL GI, 1993, J BIOL CHEM, V268, P19161; Bollen M, 1998, BIOCHEM J, V336, P19, DOI 10.1042/bj3360019; BONTEMPS F, 1978, BIOCHEM J, V174, P603, DOI 10.1042/bj1740603; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cardenas ML, 1998, BBA-MOL CELL RES, V1401, P242, DOI 10.1016/S0167-4889(97)00150-X; CHAN TM, 1976, ANAL BIOCHEM, V71, P96, DOI 10.1016/0003-2697(76)90014-2; Cid E, 2000, J BIOL CHEM, V275, P33614, DOI 10.1074/jbc.M005358200; de la Iglesia N, 1999, FEBS LETT, V456, P332, DOI 10.1016/S0014-5793(99)00971-0; FernandezNovell JM, 1997, BIOCHEM J, V321, P227, DOI 10.1042/bj3210227; Ferrer JC, 1997, FEBS LETT, V415, P249, DOI 10.1016/S0014-5793(97)01136-8; Garcia-Bellido J, 2000, J HIGH ENERGY PHYS; Gomis RR, 2000, BIOCHEM J, V351, P811, DOI 10.1042/0264-6021:3510811; KILLARY AM, 1984, CELL, V38, P523, DOI 10.1016/0092-8674(84)90507-5; KUWAJIMA M, 1986, J BIOL CHEM, V261, P8849; LANG G, 1974, METHOD ENZYMAT AN, V3, P1238; Mukhtar M, 1999, FEBS LETT, V462, P453, DOI 10.1016/S0014-5793(99)01580-X; ODoherty RM, 1996, J BIOL CHEM, V271, P20524, DOI 10.1074/jbc.271.34.20524; POLAKIS PG, 1985, ARCH BIOCHEM BIOPHYS, V236, P328, DOI 10.1016/0003-9861(85)90633-2; Roach Peter J., 1998, Journal of Basic and Clinical Physiology and Pharmacology, V9, P139; Seoane J, 1996, J BIOL CHEM, V271, P23756, DOI 10.1074/jbc.271.39.23756; Seoane J, 1999, J BIOL CHEM, V274, P31833, DOI 10.1074/jbc.274.45.31833; THOMAS JA, 1968, ANAL BIOCHEM, V25, P486, DOI 10.1016/0003-2697(68)90127-9; TOBWIN H, 1992, BIOTECHNOLOGY, V24, P145; VALERA A, 1994, EUR J BIOCHEM, V222, P533, DOI 10.1111/j.1432-1033.1994.tb18895.x; VillarPalasi C, 1997, FASEB J, V11, P544, DOI 10.1096/fasebj.11.7.9212078; Wilson JE, 1998, DIABETES, V47, P1544, DOI 10.2337/diabetes.47.10.1544; WILSON JE, 1995, REV PHYSIOL BIOCH P, V126, P65, DOI 10.1007/BFb0049776; Zvibel I, 1998, DIFFERENTIATION, V63, P215, DOI 10.1111/j.1432-0436.1998.00215.x	32	22	22	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 28	2002	277	26					23246	23252		10.1074/jbc.M111208200	http://dx.doi.org/10.1074/jbc.M111208200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	567FX	11882651	hybrid			2022-12-27	WOS:000176475700021
J	Lin, DH; Tatham, MH; Yu, B; Kim, S; Hay, RT; Chen, Y				Lin, DH; Tatham, MH; Yu, B; Kim, S; Hay, RT; Chen, Y			Identification of a substrate recognition site on Ubc9	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBIQUITIN-CONJUGATING ENZYMES; SUMO-1 MODIFICATION; CRYSTAL-STRUCTURE; SACCHAROMYCES-CEREVISIAE; ANGSTROM RESOLUTION; ACTIVATING ENZYME; BINDING INTERFACE; PROTEIN SUMO-1; NUCLEAR-BODIES; YEAST SEPTINS	Human Ubc9 is homologous to ubiquitin-conjugating enzymes. However, instead of conjugating ubiquitin, it conjugates a ubiquitin homologue, small ubiquitin-like modifier 1 (SUMO-1), also known as UBL1, GMP1, SMTP3, PIC1, and sentrin. The SUMO-1 conjugation pathway is very similar to that of ubiquitin with regard to the primary sequences of the ubiquitin-activating enzymes (El), the three-dimensional structures of the ubiquitin-conjugating enzymes (E2), and the chemistry of the overall conjugation pathway. The interaction of substrates with Ubc9 has been studied using NMR spectroscopy. Peptides with sequences that correspond to those of the SUMO-1 conjugation sites from p53 and c-Jun both bind to a surface adjacent to the active site Cys(93) of human Ubc9, which has been previously shown to include residues that demonstrate the most significant dynamics on the microsecond to millisecond time scale. Mutations in this region, Q126A, Q130A, A131D, E132A, Y134A, and T135A, were constructed to evaluate the role of these residues in SUMO-1 conjugation. These alterations have significant effects on the conjugation of SUMO-1 with the target proteins p53, E1B, and promyelocytic leukemia protein and define a substrate binding site on Ubc9. Furthermore, the SUMO-1 conjugation site of p53 does not form any defined secondary structure when either free or bound to Ubc9. This suggests that a defined secondary structure at SUMO-1 conjugation sites in target proteins is not necessary for recognition and conjugation by the SUMO-1 pathway.	City Hope Natl Med Ctr, Beckman Res Inst, Div Immunol, Duarte, CA 91010 USA; Univ St Andrews, Inst Biomol Sci, St Andrews KY16 5ST, Fife, Scotland	City of Hope; Beckman Research Institute of City of Hope; University of St Andrews	Chen, Y (corresponding author), City Hope Natl Med Ctr, Beckman Res Inst, Div Immunol, 1450 E Duarte Rd, Duarte, CA 91010 USA.		Hay, Ronald/F-9338-2011	Hay, Ronald/0000-0001-7113-9024; Tatham, Michael/0000-0001-6986-1691	NIGMS NIH HHS [GM59887] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059887] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Buschmann T, 2000, CELL, V101, P753, DOI 10.1016/S0092-8674(00)80887-9; CHEN Y, 1993, BIOCHEMISTRY-US, V32, P32, DOI 10.1021/bi00052a006; CLORE GM, 1982, J MAGN RESON, V48, P402, DOI 10.1016/0022-2364(82)90073-7; COOK WJ, 1992, J BIOL CHEM, V267, P15116; COOK WJ, 1993, BIOCHEMISTRY-US, V32, P13809, DOI 10.1021/bi00213a009; Cook WJ, 1997, BIOCHEMISTRY-US, V36, P1621, DOI 10.1021/bi962639e; DALZIEL K, 1957, ACTA CHEM SCAND, V11, P1706, DOI 10.3891/acta.chem.scand.11-1706; Desterro JMP, 1998, MOL CELL, V2, P233, DOI 10.1016/S1097-2765(00)80133-1; Desterro JMP, 1997, FEBS LETT, V417, P297, DOI 10.1016/S0014-5793(97)01305-7; Desterro JMP, 1999, J BIOL CHEM, V274, P10618, DOI 10.1074/jbc.274.15.10618; DOUGHERTY WG, 1989, VIROLOGY, V172, P145, DOI 10.1016/0042-6822(89)90116-5; Duprez E, 1999, J CELL SCI, V112, P381; Feher VA, 1999, NATURE, V400, P289, DOI 10.1038/22357; Giraud MF, 1998, ACTA CRYSTALLOGR D, V54, P891, DOI 10.1107/S0907444998002480; Gong LM, 1999, FEBS LETT, V448, P185, DOI 10.1016/S0014-5793(99)00367-1; Gostissa M, 1999, EMBO J, V18, P6462, DOI 10.1093/emboj/18.22.6462; HAAS AL, 1982, J BIOL CHEM, V257, P329; Hamilton KS, 2000, J BIOMOL NMR, V18, P319, DOI 10.1023/A:1026773008237; Hay RT, 2001, TRENDS BIOCHEM SCI, V26, P332, DOI 10.1016/S0968-0004(01)01849-7; IKURA M, 1992, J AM CHEM SOC, V114, P2433, DOI 10.1021/ja00033a019; Jackson PK, 2001, GENE DEV, V15, P3053, DOI 10.1101/gad.955501; JENTSCH S, 1992, ANNU REV GENET, V26, P179, DOI 10.1146/annurev.ge.26.120192.001143; Johnson ES, 2001, CELL, V106, P735, DOI 10.1016/S0092-8674(01)00491-3; Johnson ES, 1997, EMBO J, V16, P5509, DOI 10.1093/emboj/16.18.5509; Kahyo T, 2001, MOL CELL, V8, P713, DOI 10.1016/S1097-2765(01)00349-5; KAY LE, 1992, J AM CHEM SOC, V114, P10663, DOI 10.1021/ja00052a088; Liu Q, 1999, BIOCHEMISTRY-US, V38, P1415, DOI 10.1021/bi981840h; Liu Q, 1999, J BIOL CHEM, V274, P16979, DOI 10.1074/jbc.274.24.16979; Mahajan R, 1998, J CELL BIOL, V140, P259, DOI 10.1083/jcb.140.2.259; Matunis MJ, 1998, J CELL BIOL, V140, P499, DOI 10.1083/jcb.140.3.499; Melchior F, 2000, ANNU REV CELL DEV BI, V16, P591, DOI 10.1146/annurev.cellbio.16.1.591; Michaelis L, 1913, BIOCHEM Z, V49, P333; Miura T, 1999, J MOL BIOL, V290, P213, DOI 10.1006/jmbi.1999.2859; Muller S, 2000, J BIOL CHEM, V275, P13321, DOI 10.1074/jbc.275.18.13321; Muller S, 1998, EMBO J, V17, P61, DOI 10.1093/emboj/17.1.61; Muller S, 2001, NAT REV MOL CELL BIO, V2, P202, DOI 10.1038/35056591; NELSON RM, 1989, ANAL BIOCHEM, V180, P147, DOI 10.1016/0003-2697(89)90103-6; Okuma T, 1999, BIOCHEM BIOPH RES CO, V254, P693, DOI 10.1006/bbrc.1998.9995; Pichler A, 2002, CELL, V108, P109, DOI 10.1016/S0092-8674(01)00633-X; Rodriguez MS, 1999, EMBO J, V18, P6455, DOI 10.1093/emboj/18.22.6455; Rodriguez MS, 2001, J BIOL CHEM, V276, P12654, DOI 10.1074/jbc.M009476200; Rost B, 2000, METH MOL B, V143, P71; Rustandi RR, 2000, NAT STRUCT BIOL, V7, P570; Sachdev S, 2001, GENE DEV, V15, P3088, DOI 10.1101/gad.944801; Sampson DA, 2001, J BIOL CHEM, V276, P21664, DOI 10.1074/jbc.M100006200; Shuker SB, 1996, SCIENCE, V274, P1531, DOI 10.1126/science.274.5292.1531; SPOLAR RS, 1994, SCIENCE, V263, P777, DOI 10.1126/science.8303294; Takahashi Y, 2001, GENE, V275, P223, DOI 10.1016/S0378-1119(01)00662-X; Tatham MH, 2001, J BIOL CHEM, V276, P35368, DOI 10.1074/jbc.M104214200; Tong H, 1997, J BIOL CHEM, V272, P21381, DOI 10.1074/jbc.272.34.21381; VanDemark AP, 2001, CELL, V105, P711, DOI 10.1016/S0092-8674(01)00387-7; Worthylake DR, 1998, J BIOL CHEM, V273, P6271, DOI 10.1074/jbc.273.11.6271; Wright PE, 1999, J MOL BIOL, V293, P321, DOI 10.1006/jmbi.1999.3110; WUTHRICH K, 1986, PROTEIN NMR SPECTROS	55	104	106	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 14	2002	277	24					21740	21748		10.1074/jbc.M108418200	http://dx.doi.org/10.1074/jbc.M108418200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	563YR	11877416	hybrid			2022-12-27	WOS:000176286000082
J	Mc Gee, MM; Campiani, G; Ramunno, A; Nacci, V; Lawler, M; Williams, DC; Zisterer, DM				Mc Gee, MM; Campiani, G; Ramunno, A; Nacci, V; Lawler, M; Williams, DC; Zisterer, DM			Activation of the c-Jun N-terminal kinase (JNK) signaling pathway is essential during PBOX-6-induced apoptosis in chronic myelogenous leukemia (CML) cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PYRROLO-1,5-BENZOXAZEPINES INDUCE APOPTOSIS; GERMINAL CENTER KINASE; BINDING PROTEINS RAC1; TRANSCRIPTION FACTOR; NH2-TERMINAL KINASE; GROWTH-FACTOR; BCR-ABL; CDC42; JNK/SAPK; PHOSPHORYLATION	The mitogen-activated protein (MAP) kinase family is activated in response to a wide variety of external stress signals such as UV irradiation, heat shock, and many chemotherapeutic drugs and leads to the induction of apoptosis. A novel series of pyrrolo-1,5-benzoxazepines have been shown to potently induce apoptosis in chronic myelogenous leukemia (CML) cells, which are resistant to many chemotherapeutic agents. In this study we have delineated part of the mechanism by which a representative compound known as PBOX-6 induces apoptosis. We have investigated whether PBOX-6 induces activation of MAP kinase signaling pathways in CML cells. Treatment of K562 cells with PBOX-6 resulted in the transient activation of two JNK isoforms, JNK1 and JNK2. In contrast, PBOX-6 did not activate the extracellular signal-regulated kinase (ERK) or p38. Apoptosis was found to occur independently of the small GTPases Ras, Rac, and Cdc42 but involved phosphorylation of the JNK substrates, c-Jun and ATF-2. Pretreatment of K562 cells with the JNK inhibitor, dicoumarol, abolished PBOX-6-induced phosphorylation of c-Jun and ATF-2 and inhibited the induced apoptosis, suggesting that JNK activation is an essential component of the apoptotic pathway induced by PBOX-6. Consistent with this finding, transfection of K562 cells with the JNK scaffold protein, JIP-1, inhibited JNK activity and apoptosis induced by PBOX-6. JIP-1 specifically scaffolds JNK, MKK7, and members of the mixed-lineage kinase (MLK) family, implicating these kinases upstream of JNK in the apoptotic pathway induced by PBOX-6 in K562 cells.	Univ Dublin Trinity Coll, Dept Biochem, Dublin 2, Ireland; Univ Siena, Dipartimento Farmacochim Technol, I-53100 Siena, Italy; St James Hosp, Sir Patrick Dun Res Labs, Dept Haematol, Dublin 2, Ireland	Trinity College Dublin; University of Siena; Trinity College Dublin	Zisterer, DM (corresponding author), Univ Dublin Trinity Coll, Dept Biochem, Dublin 2, Ireland.			Campiani, Giuseppe/0000-0001-5295-9529; Zisterer, Daniela/0000-0001-5005-1023				Anafi M, 1997, J BIOL CHEM, V272, P27804, DOI 10.1074/jbc.272.44.27804; BAGRODIA S, 1995, J BIOL CHEM, V270, P27995; Chan-Hui PY, 1998, BIOCHEM J, V336, P599, DOI 10.1042/bj3360599; Clarkson BD, 1997, LEUKEMIA, V11, P1404, DOI 10.1038/sj.leu.2400751; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; Cross JV, 1999, J BIOL CHEM, V274, P31150, DOI 10.1074/jbc.274.44.31150; Davis W, 1999, BIOCHEM J, V338, P387, DOI 10.1042/0264-6021:3380387; Diener K, 1997, P NATL ACAD SCI USA, V94, P9687, DOI 10.1073/pnas.94.18.9687; Faderl S, 1999, ANN INTERN MED, V131, P207, DOI 10.7326/0003-4819-131-3-199908030-00008; Fernandes RS, 1996, LEUKEMIA, V10, pS17; Fuchs SY, 2000, J BIOL CHEM, V275, P12560, DOI 10.1074/jbc.275.17.12560; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; Ichijo H, 1999, ONCOGENE, V18, P6087, DOI 10.1038/sj.onc.1203129; Kang CD, 2000, LEUKEMIA RES, V24, P527, DOI 10.1016/S0145-2126(00)00010-2; Krause D, 2001, J BIOL CHEM, V276, P19244, DOI 10.1074/jbc.M008186200; Leung IWL, 2001, J BIOL CHEM, V276, P1961, DOI 10.1074/jbc.M004092200; LOZZIO CB, 1975, BLOOD, V45, P321, DOI 10.1182/blood.V45.3.321.321; Maroney AC, 2001, J BIOL CHEM, V276, P25302, DOI 10.1074/jbc.M011601200; Mc Gee MM, 2001, J PHARMACOL EXP THER, V296, P31; MCGAHON A, 1994, BLOOD, V83, P1179, DOI 10.1182/blood.V83.5.1179.bloodjournal8351179; Merritt SE, 1999, J BIOL CHEM, V274, P10195, DOI 10.1074/jbc.274.15.10195; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; Minden A., 1997, BIOCHIM BIOPHYS ACTA, V1333, P85, DOI DOI 10.1016/S0304-419X(97)00018-8; Murasawa S, 2000, J BIOL CHEM, V275, P26856; Osborn MT, 1996, J BIOL CHEM, V271, P30950, DOI 10.1074/jbc.271.48.30950; POMBO CM, 1995, NATURE, V377, P750, DOI 10.1038/377750a0; Puls A, 1999, J CELL SCI, V112, P2983; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; Seimiya H, 1997, J BIOL CHEM, V272, P4631, DOI 10.1074/jbc.272.7.4631; Shaulian E, 1999, J BIOL CHEM, V274, P29595, DOI 10.1074/jbc.274.42.29595; Teramoto H, 1996, J BIOL CHEM, V271, P27225, DOI 10.1074/jbc.271.44.27225; Tibbles LA, 1999, CELL MOL LIFE SCI, V55, P1230, DOI 10.1007/s000180050369; Whitmarsh AJ, 1998, SCIENCE, V281, P1671, DOI 10.1126/science.281.5383.1671; Yao ZB, 1999, J BIOL CHEM, V274, P2118, DOI 10.1074/jbc.274.4.2118; Yasuda J, 1999, MOL CELL BIOL, V19, P7245; Zanke BW, 1996, CURR BIOL, V6, P606, DOI 10.1016/S0960-9822(02)00547-X; Zisterer DM, 1998, BIOCHEM PHARMACOL, V55, P397, DOI 10.1016/S0006-2952(97)00500-5; Zisterer DM, 2000, J PHARMACOL EXP THER, V293, P48	38	39	39	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 24	2002	277	21					18383	18389		10.1074/jbc.M112058200	http://dx.doi.org/10.1074/jbc.M112058200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	558PM	11856743	Green Submitted, hybrid			2022-12-27	WOS:000175975800018
J	Paulsson, KM; Kleijmeer, MJ; Griffith, J; Jevon, M; Chen, SW; Anderson, PO; Sjogren, HO; Li, SL; Wang, P				Paulsson, KM; Kleijmeer, MJ; Griffith, J; Jevon, M; Chen, SW; Anderson, PO; Sjogren, HO; Li, SL; Wang, P			Association of tapasin and COPI provides a mechanism for the retrograde transport of major histocompatibility complex (MHC) class I molecules from the Golgi complex to the endoplasmic reticulum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTIGEN PRESENTATION; PEPTIDE REPERTOIRE; LOADING COMPLEX; MUTANT MICE; TAP; PROTEINS; RETENTION; BINDING; GLYCOPROTEIN; SUBUNIT	Tapasin is a subunit of the transporter associated with antigen processing (TAP). It associates with the major histocompatibility complex (MHC) class I. We show that tapasin interacts with beta- and gamma-subunits of COPI coatomer. COPI retrieves membrane proteins from the Golgi network back to the endoplasmic reticulum (ER). The COPI subunit-associated tapasin also interacts with MHC class I molecules suggesting that tapasin acts as the cargo receptor for packing MHC class I molecules as cargo proteins into COPI-coated vesicles. In tapasin mutant cells, neither TAP nor MHC class I are detected in association with the COPI coatomer. Interestingly, tapasin-associated MHC class I molecules are antigenic peptide-receptive and detected in both the ER and the Golgi. Our data suggest that tapasin is required for the COPI vesicle-mediated retrograde transport of immature MHC class I molecules from the Golgi network to the ER.	Lund Univ, Inst Tumor Immunol, S-22362 Lund, Sweden; Univ Med Ctr, Inst Biomembranes, Dept Cell Biol, NL-3584 CX Utrecht, Netherlands; Brunel Univ, Dept Biol Sci, Uxbridge UB8 3PH, Middx, England; Barts & London Sch Med & Dent, Dept Gastroenterol, Immunol Grp, London EC1A 7ED, England	Lund University; Utrecht University; Utrecht University Medical Center; Brunel University; University of London; Queen Mary University London	Li, SL (corresponding author), Lund Univ, Inst Tumor Immunol, Solvegatan 21, S-22362 Lund, Sweden.			Anderson, Per/0000-0002-0958-7990; Wang, Ping/0000-0001-8992-1233				Androlewicz MJ, 1999, IMMUNOL RES, V20, P79, DOI 10.1007/BF02786464; BAAS EJ, 1992, J EXP MED, V176, P147, DOI 10.1084/jem.176.1.147; Bangia N, 1999, EUR J IMMUNOL, V29, P1858, DOI 10.1002/(SICI)1521-4141(199906)29:06<1858::AID-IMMU1858>3.0.CO;2-C; Barnden MJ, 2000, J IMMUNOL, V165, P322, DOI 10.4049/jimmunol.165.1.322; Campbell JL, 1997, P NATL ACAD SCI USA, V94, P837, DOI 10.1073/pnas.94.3.837; Cresswell P, 1999, IMMUNOL REV, V172, P21, DOI 10.1111/j.1600-065X.1999.tb01353.x; DAY PM, 1995, IMMUNITY, V2, P137, DOI 10.1016/S1074-7613(95)80014-X; Garbi N, 2000, NAT IMMUNOL, V1, P234, DOI 10.1038/79775; Grandea AG, 1997, IMMUNOGENETICS, V46, P477, DOI 10.1007/s002510050308; GRANDEA AG, 1995, SCIENCE, V270, P105, DOI 10.1126/science.270.5233.105; Grandea AG, 2000, IMMUNITY, V13, P213, DOI 10.1016/S1074-7613(00)00021-2; Harter C, 2000, Subcell Biochem, V34, P1; Harter C, 1996, P NATL ACAD SCI USA, V93, P1902, DOI 10.1073/pnas.93.5.1902; HELENIUS A, 1994, MOL BIOL CELL, V5, P253, DOI 10.1091/mbc.5.3.253; JACKSON MR, 1990, EMBO J, V9, P3153, DOI 10.1002/j.1460-2075.1990.tb07513.x; KNIPE DM, 1977, J VIROL, V21, P1128, DOI 10.1128/JVI.21.3.1128-1139.1977; Kreis TE, 1995, ANNU REV CELL DEV BI, V11, P677, DOI 10.1146/annurev.cb.11.110195.003333; Lehner PJ, 1998, IMMUNITY, V8, P221, DOI 10.1016/S1074-7613(00)80474-4; Lewis JW, 1998, EUR J IMMUNOL, V28, P3214, DOI 10.1002/(SICI)1521-4141(199810)28:10<3214::AID-IMMU3214>3.3.CO;2-3; Lewis JW, 1996, CURR BIOL, V6, P873, DOI 10.1016/S0960-9822(02)00611-5; Li SL, 1997, P NATL ACAD SCI USA, V94, P8708, DOI 10.1073/pnas.94.16.8708; Li SL, 2000, J BIOL CHEM, V275, P1581, DOI 10.1074/jbc.275.3.1581; Marguet D, 1999, IMMUNITY, V11, P231, DOI 10.1016/S1074-7613(00)80098-9; Neisig A, 1996, J IMMUNOL, V156, P3196; Oliver JD, 1999, MOL BIOL CELL, V10, P2573, DOI 10.1091/mbc.10.8.2573; Ortmann B, 1997, SCIENCE, V277, P1306, DOI 10.1126/science.277.5330.1306; OTSU M, 1995, J BIOL CHEM, V270, P14958, DOI 10.1074/jbc.270.25.14958; Pamer E, 1998, ANNU REV IMMUNOL, V16, P323, DOI 10.1146/annurev.immunol.16.1.323; Paulk M. C., 2000, Cutter IT Journal, V13, P23; PeaceBrewer AL, 1996, IMMUNITY, V4, P505, DOI 10.1016/S1074-7613(00)80416-1; Peh CA, 1998, IMMUNITY, V8, P531, DOI 10.1016/S1074-7613(00)80558-0; Purcell AW, 2001, J IMMUNOL, V166, P1016, DOI 10.4049/jimmunol.166.2.1016; RAPOSO G, 1997, WEIRS HDB EXPT IMMUN, P208; Rothman JE, 1996, SCIENCE, V272, P227, DOI 10.1126/science.272.5259.227; Sadasivan B, 1996, IMMUNITY, V5, P103, DOI 10.1016/S1074-7613(00)80487-2; SARASTE J, 1986, P NATL ACAD SCI USA, V83, P6425, DOI 10.1073/pnas.83.17.6425; Schekman R, 1996, SCIENCE, V271, P1526, DOI 10.1126/science.271.5255.1526; Schoenhals GJ, 1999, EMBO J, V18, P743, DOI 10.1093/emboj/18.3.743; Sijts AJAM, 1997, J EXP MED, V185, P1403, DOI 10.1084/jem.185.8.1403; Solheim JC, 1999, IMMUNOL REV, V172, P11, DOI 10.1111/j.1600-065X.1999.tb01352.x; Spiliotis ET, 2000, IMMUNITY, V13, P841, DOI 10.1016/S1074-7613(00)00081-9; SRIVASTAVA SP, 1991, J BIOL CHEM, V266, P20337; SUH WK, 1994, SCIENCE, V264, P1322, DOI 10.1126/science.8191286; Trombetta ES, 1998, CURR OPIN STRUC BIOL, V8, P587, DOI 10.1016/S0959-440X(98)80148-6; Wang P, 1996, J IMMUNOL, V157, P213; Wang P, 1996, J BIOL CHEM, V271, P24830, DOI 10.1074/jbc.271.40.24830; Williams AP, 2000, IMMUNOGENETICS, V52, P9, DOI 10.1007/s002510000244	47	50	51	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 24	2002	277	21					18266	18271		10.1074/jbc.M201388200	http://dx.doi.org/10.1074/jbc.M201388200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	558PM	11884415	hybrid			2022-12-27	WOS:000175975800005
J	Chen-Hwang, MC; Chen, HR; Elzinga, M; Hwang, YW				Chen-Hwang, MC; Chen, HR; Elzinga, M; Hwang, YW			Dynamin is a minibrain kinase/dual specificity Yak1-related kinase 1A substrate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE; DOWN-SYNDROME; HUMAN HOMOLOG; DYRK PROTEIN; SH3 DOMAIN; FAMILY; GENE; BINDING; AMPHIPHYSIN; PHOSPHORYLATION	The minibrain kinase (Mnbk)/dual specificity Yak 1-related kinase 1A (Dyrk1A) gene is implicated in the mental retardation associated with Down's syndrome. It encodes a proline-directed serine/threonine kinase whose function has yet to be defined. We have used a solid-phase Mnbk/Dyrk1A kinase assay to aid in the search for the cellular Mnbk/Dyrk1A substrates. The assay revealed that rat brain contains two cytosolic proteins, one with a molecular mass of 100 kDa and one with a molecular mass of 140 kDa, that were prominently phosphorylated by Mnbk/Dyrk1A. The 100-kDa protein was purified and identified as dynamin 1. The conclusion was further supported by evidence that a recombinant glutathione S-transferase fusion protein containing dynamin isoform 1aa was phosphorylated by Mnbk/Dyrk1A. In addition to isoform 1aa, Mnbk/Dyrk1A also phosphorylated isoforms lab and 2aa but not human MxA protein when analyzed by the solid-phase kinase assay. Upon Mnbk/Dyrk1A phosphorylation, the interaction of dynamin 1 with the Src homology 3 domain of amphiphysin 1 was reduced. However, when Mnbk/Dyrk1A phosphorylation was allowed to proceed more extensively, the phosphorylation enhanced rather than reduced the binding of dynamin 1 to amphiphysin 1. The result suggests that Mnbk/Dyrk1A can play a dual role in regulating the interaction of dynamin 1 with amphiphysin 1. Mnbk/Dyrk1A phosphorylation also reduced the interaction of dynamin with endophilin 1, whereas the same phosphorylation enhanced the binding of dynamin 1 to Grb2. Nevertheless, the dual function of Mnbk/Dyrk1A phosphorylation was not observed for the interaction of dynamin 1 with endophilin 1 or Grb2. The interactions of dynamin with amphiphysin and endophilin are essential for the formation of endocytic complexes; our results suggest that Mnbk/Dyrk1A may function as a regulator controlling the assembly of endocytic apparatus.	New York State Inst Basic Res Dev Disabil, Dept Mol Biol, Staten Isl, NY 10314 USA; Natl Yang Ming Univ, Dept Life Sci, Taipei 112, Taiwan; CUNY, CSI IBR Ctr Dev Neurosci, New York, NY 10016 USA; CUNY, Grad Program Biol, New York, NY 10016 USA	Institute for Basic Research in Developmental Disabilities; National Yang Ming Chiao Tung University; City University of New York (CUNY) System; Institute for Basic Research in Developmental Disabilities; City University of New York (CUNY) System	Hwang, YW (corresponding author), New York State Inst Basic Res Dev Disabil, Dept Mol Biol, 1050 Forest Hill Rd, Staten Isl, NY 10314 USA.	hwang@postbox.csi.cuny.edu			NICHD NIH HHS [HD35870, HD38295] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R03HD035870, R01HD038295] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Altafaj X, 2001, HUM MOL GENET, V10, P1915, DOI 10.1093/hmg/10.18.1915; ANDO A, 1994, EMBO J, V13, P3033, DOI 10.1002/j.1460-2075.1994.tb06602.x; Bahler J, 2001, EMBO J, V20, P1064, DOI 10.1093/emboj/20.5.1064; Baron V, 1998, ENDOCRINOLOGY, V139, P3034, DOI 10.1210/en.139.6.3034; Becker W, 1999, PROG NUCLEIC ACID RE, V62, P1; Becker W, 1998, J BIOL CHEM, V273, P25893, DOI 10.1074/jbc.273.40.25893; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cestra G, 1999, J BIOL CHEM, V274, P32001, DOI 10.1074/jbc.274.45.32001; Chen HM, 1997, HUM GENET, V99, P262, DOI 10.1007/s004390050350; Daaka Y, 1998, J BIOL CHEM, V273, P685, DOI 10.1074/jbc.273.2.685; David C, 1996, P NATL ACAD SCI USA, V93, P331, DOI 10.1073/pnas.93.1.331; deHeuvel E, 1997, J BIOL CHEM, V272, P8710, DOI 10.1074/jbc.272.13.8710; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; Dubnau J, 2001, NATURE, V411, P476, DOI 10.1038/35078077; FERRELL JE, 1991, METHOD ENZYMOL, V200, P430; Gad H, 2000, NEURON, V27, P301, DOI 10.1016/S0896-6273(00)00038-6; GARRETT S, 1989, GENE DEV, V3, P1336, DOI 10.1101/gad.3.9.1336; Giachino C, 1997, GENOMICS, V41, P427, DOI 10.1006/geno.1997.4645; GOUT I, 1993, CELL, V75, P25, DOI 10.1016/0092-8674(93)90676-H; Grabs D, 1997, J BIOL CHEM, V272, P13419, DOI 10.1074/jbc.272.20.13419; Guimera J, 1997, CYTOGENET CELL GENET, V77, P182, DOI 10.1159/000134571; Guimera J, 1996, HUM MOL GENET, V5, P1305, DOI 10.1093/hmg/5.9.1305; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; Hattori M, 2000, NATURE, V405, P311, DOI 10.1038/35012518; Himpel S, 2000, J BIOL CHEM, V275, P2431, DOI 10.1074/jbc.275.4.2431; HINSHAW JE, 1995, NATURE, V374, P190, DOI 10.1038/374190a0; Hinshaw JE, 2000, ANNU REV CELL DEV BI, V16, P483, DOI 10.1146/annurev.cellbio.16.1.483; Hofmann TG, 2000, BIOCHIMIE, V82, P1123, DOI 10.1016/S0300-9084(00)01196-2; HORISBERGER MA, 1990, J VIROL, V64, P1171, DOI 10.1128/JVI.64.3.1171-1181.1990; Karoor V, 1998, J BIOL CHEM, V273, P33035, DOI 10.1074/jbc.273.49.33035; Kentrup H, 1996, J BIOL CHEM, V271, P3488; Kola I, 1998, CURR OPIN GENET DEV, V8, P316, DOI 10.1016/S0959-437X(98)80088-9; Lee K, 2000, CANCER RES, V60, P3631; Marks B, 2001, NATURE, V410, P231, DOI 10.1038/35065645; McGuire SE, 2001, SCIENCE, V293, P1330, DOI 10.1126/science.1062622; McNiven MA, 2000, TRENDS BIOCHEM SCI, V25, P115, DOI 10.1016/S0968-0004(99)01538-8; Moilanen AM, 1998, MOL BIOL CELL, V9, P2527, DOI 10.1091/mbc.9.9.2527; Ohira M, 1997, GENOME RES, V7, P47, DOI 10.1101/gr.7.1.47; Rahmani Z, 1998, BIOCHEM BIOPH RES CO, V253, P514, DOI 10.1006/bbrc.1998.9803; Ringstad N, 1997, P NATL ACAD SCI USA, V94, P8569, DOI 10.1073/pnas.94.16.8569; Ringstad N, 1999, NEURON, V24, P143, DOI 10.1016/S0896-6273(00)80828-4; ROBINSON PJ, 1987, J NEUROCHEM, V48, P187, DOI 10.1111/j.1471-4159.1987.tb13146.x; ROBINSON PJ, 1993, NATURE, V365, P163, DOI 10.1038/365163a0; Schmid SL, 1998, CURR OPIN CELL BIOL, V10, P504, DOI 10.1016/S0955-0674(98)80066-5; Schmidt A, 1999, NATURE, V401, P133, DOI 10.1038/43613; Sever S, 1999, NATURE, V398, P481, DOI 10.1038/19024; Shang EY, 2000, MOL REPROD DEV, V55, P372, DOI 10.1002/(SICI)1098-2795(200004)55:4&lt;372::AID-MRD3&gt;3.0.CO;2-A; Shindoh N, 1996, BIOCHEM BIOPH RES CO, V225, P92, DOI 10.1006/bbrc.1996.1135; Slepnev VI, 1998, SCIENCE, V281, P821, DOI 10.1126/science.281.5378.821; Smith DJ, 1997, NAT GENET, V16, P28, DOI 10.1038/ng0597-28; So CW, 1997, P NATL ACAD SCI USA, V94, P2563, DOI 10.1073/pnas.94.6.2563; Song WJ, 1997, BIOCHEM BIOPH RES CO, V231, P640, DOI 10.1006/bbrc.1997.6154; Song WJ, 1996, GENOMICS, V38, P331, DOI 10.1006/geno.1996.0636; SONTAG JM, 1994, J BIOL CHEM, V269, P4547; SUNG YJ, 1995, BIOCHEMISTRY-US, V34, P3470, DOI 10.1021/bi00010a040; Sweitzer SM, 1998, CELL, V93, P1021, DOI 10.1016/S0092-8674(00)81207-6; TAKEI K, 1995, NATURE, V374, P186, DOI 10.1038/374186a0; Takenawa T, 1998, CURR TOP MICROBIOL, V228, P325; TEJEDOR F, 1995, NEURON, V14, P287, DOI 10.1016/0896-6273(95)90286-4; VALTORTA F, 1986, ANAL BIOCHEM, V158, P130, DOI 10.1016/0003-2697(86)90600-7; WARNOCK DE, 1995, EMBO J, V14, P1322, DOI 10.1002/j.1460-2075.1995.tb07118.x; Wigge P, 1998, TRENDS NEUROSCI, V21, P339, DOI 10.1016/S0166-2236(98)01264-8; Woods YL, 2001, BIOCHEM J, V355, P609, DOI 10.1042/bj3550609; Woods YL, 2001, BIOCHEM J, V355, P597, DOI 10.1042/bj3550597; YAMAMOTO R, 1995, HUM MOL GENET, V4, P265, DOI 10.1093/hmg/4.2.265; Yang EJ, 2001, J BIOL CHEM, V276, P39819, DOI 10.1074/jbc.M104091200	66	82	82	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 17	2002	277	20					17597	17604		10.1074/jbc.M111101200	http://dx.doi.org/10.1074/jbc.M111101200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	553PR	11877424	hybrid			2022-12-27	WOS:000175685100028
J	Clemens, S; Bloss, T; Vess, C; Neumann, D; Nies, DH; zur Nieden, U				Clemens, S; Bloss, T; Vess, C; Neumann, D; Nies, DH; zur Nieden, U			A transporter in the endoplasmic reticulum of Schizosaccharomyces pombe cells mediates zinc storage and differentially affects transition metal tolerance	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; PHYTOCHELATIN SYNTHASE; CAENORHABDITIS-ELEGANS; CONFERS RESISTANCE; GENE; CADMIUM; YEAST; FAMILY; PEPTIDES; COBALT	The cation diffusion facilitator (CDF) family represents a class of ubiquitous metal transporters. Inactivation of a CDF in Schizosaccharomyces pombe, Zhf, causes drastically different effects on the tolerance toward various metals. A deletion mutant is Zn2+/Co2+-hypersensitive yet displays significantly enhanced Cd2+ and Ni2+ tolerance. Accumulation of zinc, cobalt, and cadmium is reduced in mutant cells. Non-vacuolar zinc content, as measured by analytical electron microscopy, is lower in zhf(-) cells compared with wild-type cells in the presence of elevated Zn2+ concentrations. The protective effect against cadmium toxicity is independent of the phytochelatin detoxification pathway. Phytochelatin synthase-deficient cells show extremely enhanced (about 200-fold) cadmium tolerance when zhf is disrupted. Immunogold labeling indicates endoplasmic reticulum (ER) localization of Zhf. Electron spectroscopic imaging shows that accumulation of zinc coincides with Zhf localization, demonstrating a major role of the ER for metal storage and the involvement of Zhf in cellular zinc homeostasis. Also, these observations indicate that Cd2+ ions exert their toxic effects on cellular metabolism in the ER rather than in the cytosol.	Leibniz Inst Pflanzenbiochem, D-06120 Halle Saale, Germany; Univ Halle Wittenberg, Inst Mikrobiol, D-06120 Halle Saale, Germany	Leibniz Institut fur Pflanzenbiochemie; Martin Luther University Halle Wittenberg	Clemens, S (corresponding author), Leibniz Inst Pflanzenbiochem, Weinberg 3, D-06120 Halle Saale, Germany.		Nies, Dietrich H/H-4143-2011; Clemens, Stephan/A-5107-2009	Clemens, Stephan/0000-0003-0570-1060				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Anton A, 1999, J BACTERIOL, V181, P6876, DOI 10.1128/JB.181.22.6876-6881.1999; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; Bahler J, 1998, YEAST, V14, P943, DOI 10.1002/(SICI)1097-0061(199807)14:10<943::AID-YEA292>3.0.CO;2-Y; Bloss T, 2002, PLANTA, V214, P783, DOI 10.1007/s00425-001-0677-1; Clemens S, 2001, PLANTA, V212, P475, DOI 10.1007/s004250000458; Clemens S, 2001, EUR J BIOCHEM, V268, P3640, DOI 10.1046/j.1432-1327.2001.02293.x; Clemens S, 1999, EMBO J, V18, P3325, DOI 10.1093/emboj/18.12.3325; Cobbett CS, 2000, CURR OPIN PLANT BIOL, V3, P211, DOI 10.1016/S1369-5266(00)00066-2; Cole TB, 1999, P NATL ACAD SCI USA, V96, P1716, DOI 10.1073/pnas.96.4.1716; CONKLIN DS, 1992, MOL CELL BIOL, V12, P3678, DOI 10.1128/MCB.12.9.3678; Corbett EF, 2000, TRENDS BIOCHEM SCI, V25, P307, DOI 10.1016/S0968-0004(00)01588-7; GRILL E, 1989, P NATL ACAD SCI USA, V86, P6838, DOI 10.1073/pnas.86.18.6838; KAMIZONO A, 1989, MOL GEN GENET, V219, P161, DOI 10.1007/BF00261172; Korshunova YO, 1999, PLANT MOL BIOL, V40, P37, DOI 10.1023/A:1026438615520; Li LT, 1998, J BIOL CHEM, V273, P22181, DOI 10.1074/jbc.273.35.22181; Li LT, 2001, J BIOL CHEM, V276, P5036, DOI 10.1074/jbc.M008969200; MacDiarmid CW, 2000, EMBO J, V19, P2845, DOI 10.1093/emboj/19.12.2845; NIES DH, 1995, J BACTERIOL, V177, P2707, DOI 10.1128/jb.177.10.2707-2712.1995; NIES DH, 1992, PLASMID, V27, P17, DOI 10.1016/0147-619X(92)90003-S; O'Halloran TV, 2000, J BIOL CHEM, V275, P25057, DOI 10.1074/jbc.R000006200; ORTIZ DF, 1992, EMBO J, V11, P3491, DOI 10.1002/j.1460-2075.1992.tb05431.x; Outten CE, 2001, SCIENCE, V292, P2488, DOI 10.1126/science.1060331; Palmiter RD, 1996, P NATL ACAD SCI USA, V93, P14934, DOI 10.1073/pnas.93.25.14934; PALMITER RD, 1995, EMBO J, V14, P639, DOI 10.1002/j.1460-2075.1995.tb07042.x; Palmiter RD, 1996, EMBO J, V15, P1784, DOI 10.1002/j.1460-2075.1996.tb00527.x; Paulsen IT, 1997, J MEMBRANE BIOL, V156, P99, DOI 10.1007/s002329900192; Pence NS, 2000, P NATL ACAD SCI USA, V97, P4956, DOI 10.1073/pnas.97.9.4956; Persans MW, 2001, P NATL ACAD SCI USA, V98, P9995, DOI 10.1073/pnas.171039798; Rae TD, 1999, SCIENCE, V284, P805, DOI 10.1126/science.284.5415.805; RAUSER WE, 1995, PLANT PHYSIOL, V109, P1141, DOI 10.1104/pp.109.4.1141; Sneller FEC, 2000, J AGR FOOD CHEM, V48, P4014, DOI 10.1021/jf9903105; STOHS SJ, 1995, FREE RADICAL BIO MED, V18, P321, DOI 10.1016/0891-5849(94)00159-H; van der Zaal BJ, 1999, PLANT PHYSIOL, V119, P1047, DOI 10.1104/pp.119.3.1047; Vatamaniuk OK, 2001, J BIOL CHEM, V276, P20817, DOI 10.1074/jbc.C100152200; Vatamaniuk OK, 2000, J BIOL CHEM, V275, P31451, DOI 10.1074/jbc.M002997200; [No title captured]	37	75	82	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 17	2002	277	20					18215	18221		10.1074/jbc.M201031200	http://dx.doi.org/10.1074/jbc.M201031200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	553PR	11886869	hybrid			2022-12-27	WOS:000175685100104
J	Hellauer, K; Akache, B; MacPherson, S; Sirard, E; Turcotte, B				Hellauer, K; Akache, B; MacPherson, S; Sirard, E; Turcotte, B			Zinc cluster protein Rdr1p is a transcriptional repressor of the PDR5 gene encoding a multidrug transporter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLEIOTROPIC DRUG-RESISTANCE; SACCHAROMYCES-CEREVISIAE; COMPLETE INVENTORY; YEAST; EXPRESSION; DNA; ACTIVATION; BIOSYNTHESIS; STRAINS; FAMILY	The yeast PDR5 gene encodes an efflux pump that confers multidrug resistance. Expression of PDR5 is positively regulated by the transcription factors Pdr1p and Pdr3p that recognize the same pleiotropic drug resistance elements (PDREs) in the PDR5 promoter. Pdr1p and Pdr3p belong to the Gal4p family of zinc cluster proteins. The function of RDR1 (YOR380W), which also encodes a member of this family, is unknown. To identify target genes for Rdr1p, we have performed whole-genome analysis of gene expression with DNA microarrays. Our results show that Rdr1p is a transcriptional repressor of five genes, including PDR5. A Deltardr1 strain has increased resistance to cycloheximide, as expected from the overexpression of PDR5. In addition, the activity of a PDR5-lacZ reporter is increased in a Deltardr1 strain. All (but one) genes affected by removal of Rdr1p contain PDREs in their promoters. We tested if the effect of Rdr1p is mediated through PDREs by inserting this DNA element in front of a minimal promoter. Activity of this reporter was increased in a Deltardr1 strain. Moreover, mutations known to reduce binding of Pdr1/Pdr3p abolished the induction observed in the Deltardr1 strain. Thus, we have identified a transcriptional repressor involved in the control of multidrug resistance.	McGill Univ, Royal Victoria Hosp, Ctr Hlth, Dept Med, Montreal, PQ H3A 1A1, Canada; McGill Univ, Royal Victoria Hosp, Ctr Hlth, Dept Biochem, Montreal, PQ H3A 1A1, Canada; McGill Univ, Royal Victoria Hosp, Ctr Hlth, Dept Microbiol & Immunol, Montreal, PQ H3A 1A1, Canada	McGill University; Royal Victoria Hospital; McGill University; Royal Victoria Hospital; McGill University; Royal Victoria Hospital	Turcotte, B (corresponding author), McGill Univ, Royal Victoria Hosp, Ctr Hlth, Dept Med, 687 Pine Ave W, Montreal, PQ H3A 1A1, Canada.	turcotte@lan1.molone.megill.ca		Akache, Bassel/0000-0002-5377-7193				Akache B, 2001, NUCLEIC ACIDS RES, V29, P2181, DOI 10.1093/nar/29.10.2181; Alarco AM, 1997, J BIOL CHEM, V272, P19304, DOI 10.1074/jbc.272.31.19304; Angus-Hill ML, 2001, MOL CELL, V7, P741, DOI 10.1016/S1097-2765(01)00219-2; Ausubel FM, 1988, MOL REPROD DEV; BAUDIN A, 1993, NUCLEIC ACIDS RES, V21, P3329, DOI 10.1093/nar/21.14.3329; Bauer BE, 1999, BBA-BIOMEMBRANES, V1461, P217, DOI 10.1016/S0005-2736(99)00160-1; Carvajal E, 1997, MOL GEN GENET, V256, P406, DOI 10.1007/s004380050584; Decottignies A, 1997, NAT GENET, V15, P137, DOI 10.1038/ng0297-137; DELAHODDE A, 1995, MOL CELL BIOL, V15, P4043; DeRisi J, 2000, FEBS LETT, V470, P156, DOI 10.1016/S0014-5793(00)01294-1; Devauz F, 2001, EMBO REP, V2, P493, DOI 10.1093/embo-reports/kve114; FORSBURG SL, 1988, MOL CELL BIOL, V8, P647, DOI 10.1128/MCB.8.2.647; Goffeau A, 1997, YEAST, V13, P43, DOI 10.1002/(SICI)1097-0061(199701)13:1<43::AID-YEA56>3.0.CO;2-J; GUARENTE L, 1983, METHOD ENZYMOL, V101, P181; Hallstrom TC, 2001, J BIOL CHEM, V276, P23674, DOI 10.1074/jbc.M101568200; Hallstrom TC, 1998, J BIOL CHEM, V273, P2098, DOI 10.1074/jbc.273.4.2098; Hampsey M, 1997, YEAST, V13, P1099, DOI 10.1002/(SICI)1097-0061(19970930)13:12<1099::AID-YEA177>3.3.CO;2-Z; Hellauer K, 1996, MOL CELL BIOL, V16, P6096; Hellauer K, 2001, J BIOL CHEM, V276, P13587, DOI 10.1074/jbc.M011196200; Hemming SA, 2000, J BIOL CHEM, V275, P35506, DOI 10.1074/jbc.M004721200; HIRATA D, 1994, CURR GENET, V26, P285, DOI 10.1007/BF00310491; KATZMANN DJ, 1995, MOL CELL BIOL, V15, P6875; KATZMANN DJ, 1994, MOL CELL BIOL, V14, P4653, DOI 10.1128/MCB.14.7.4653; Katzmann DJ, 1996, J BIOL CHEM, V271, P23049, DOI 10.1074/jbc.271.38.23049; KOHRER K, 1991, METHOD ENZYMOL, V194, P398; Kolaczkowska A, 1999, DRUG RESIST UPDATE, V2, P403, DOI 10.1054/drup.1999.0113; LEPPERT G, 1990, GENETICS, V125, P13; Lussier M, 1997, GENETICS, V147, P435; Mahe Y, 1996, MOL MICROBIOL, V20, P109, DOI 10.1111/j.1365-2958.1996.tb02493.x; Martens JA, 1996, J BIOL CHEM, V271, P15884, DOI 10.1074/jbc.271.27.15884; MEYERS S, 1992, CURR GENET, V21, P431, DOI 10.1007/BF00351651; Noel J, 1998, J BIOL CHEM, V273, P17463, DOI 10.1074/jbc.273.28.17463; Nourani A, 1997, MOL GEN GENET, V256, P397, DOI 10.1007/s004380050583; Nourani A, 1997, MOL CELL BIOL, V17, P5453, DOI 10.1128/MCB.17.9.5453; PHILIPPSEN P, 1991, METHOD ENZYMOL, V194, P169; Rottensteiner H, 1997, EUR J BIOCHEM, V247, P776, DOI 10.1111/j.1432-1033.1997.00776.x; Schjerling P, 1996, NUCLEIC ACIDS RES, V24, P4599, DOI 10.1093/nar/24.23.4599; Schwabe JWR, 1997, NAT STRUCT BIOL, V4, P680, DOI 10.1038/nsb0997-680; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; Sherman F., 1986, METHODS YEAST GENETI; SIKORSKI RS, 1989, GENETICS, V122, P19; Todd RB, 1997, FUNGAL GENET BIOL, V21, P388, DOI 10.1006/fgbi.1997.0993; Traven A, 2001, J BIOL CHEM, V276, P4020, DOI 10.1074/jbc.M006807200; WACH A, 1994, YEAST, V10, P1793, DOI 10.1002/yea.320101310; WINSTON F, 1995, YEAST, V11, P53, DOI 10.1002/yea.320110107; Wolfger H, 1997, FEBS LETT, V418, P269, DOI 10.1016/S0014-5793(97)01382-3	46	41	47	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 17	2002	277	20					17671	17676		10.1074/jbc.M201637200	http://dx.doi.org/10.1074/jbc.M201637200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	553PR	11882665	hybrid			2022-12-27	WOS:000175685100037
J	Javanbakht, H; Cen, S; Musier-Forsyth, K; Kleiman, L				Javanbakht, H; Cen, S; Musier-Forsyth, K; Kleiman, L			Correlation between tRNA(Lys3) aminoacylation and its incorporation into HIV-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; TRANSFER-RNA-SYNTHETASE; REVERSE-TRANSCRIPTASE; IDENTITY DETERMINANTS; TRANSFER RNA(SER); TRANSFER RNA(LYS); ANTICODON DOMAIN; WILD-TYPE; PR160GAG-POL; PARTICLES	During human immunodeficiency virus type 1 (HIV-1) assembly, tRNA(Lys) is selectively packaged into the virus, where tRNA(Lys3) serves as the primer for reverse transcription. Lysyl-tRNA synthetase is also selectively incorporated into HIV-1 and is therefore a strong candidate for being the signal by which viral proteins interact with tRNA(Lys) isoacceptors. Previously, mutations in the tRNA(Lys3) anticodon have been shown to strongly inhibit the charging of tRNA(Lys3) by lysyl-tRNA synthetase in vitro, and we show here that in vivo aminoacylation is also inhibited by anticodon changes. The order of decreasing in vivo aminoacylation for tRNA(Lys3) anticodon mutants is: wild-type SUU (where S=mcm(5)S(2)U) 100%) -->SGU(49%)-->CGU(40%)-->SGA (0%) and CGA (0%). We found that the ability of these tRNA(Lys3) anticodon variants to be aminoacylated in vivo is directly correlated with their ability to be packaged into HIV-1. These data showed that the anticodon is a major determinant for tRNA(Lys3) packaging and support the conclusion that its productive interaction with lysyl-tRNA synthetase is important for tRNA(Lys3) incorporation into HIV-1.	Jewish Gen Hosp, Lady Davis Inst Med Res, Montreal, PQ H3T 1E2, Canada; Jewish Gen Hosp, McGill AIDS Ctr, Montreal, PQ H3T 1E2, Canada; McGill Univ, Dept Med, Montreal, PQ H3T 1E2, Canada; McGill Univ, Dept Microbiol, Montreal, PQ H3T 1E2, Canada; McGill Univ, Dept Immunol, Montreal, PQ H3T 1E2, Canada; Univ Minnesota, Dept Chem, Minneapolis, MN 55455 USA	Lady Davis Institute; McGill University; McGill University; McGill University; McGill University; McGill University; University of Minnesota System; University of Minnesota Twin Cities	Kleiman, L (corresponding author), Jewish Gen Hosp, Lady Davis Inst Med Res, 3755 Cote St Catherine Rd, Montreal, PQ H3T 1E2, Canada.							ACHSEL T, 1993, EMBO J, V12, P3333, DOI 10.1002/j.1460-2075.1993.tb06003.x; Arts EJ, 1998, J BIOL CHEM, V273, P14523, DOI 10.1074/jbc.273.23.14523; BARAT C, 1989, EMBO J, V8, P3279, DOI 10.1002/j.1460-2075.1989.tb08488.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cen S, 1999, J VIROL, V73, P4485, DOI 10.1128/JVI.73.5.4485-4488.1999; Cen S, 2001, J VIROL, V75, P5043, DOI 10.1128/JVI.75.11.5043-5048.2001; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Francin M, 2002, J BIOL CHEM, V277, P1762, DOI 10.1074/jbc.M109759200; Giege R, 1998, NUCLEIC ACIDS RES, V26, P5017, DOI 10.1093/nar/26.22.5017; HASEGAWA T, 1992, BIOCHEM BIOPH RES CO, V184, P478, DOI 10.1016/0006-291X(92)91219-G; HO YS, 1987, P NATL ACAD SCI USA, V84, P2185, DOI 10.1073/pnas.84.8.2185; Huang Y, 1996, J VIROL, V70, P4700, DOI 10.1128/JVI.70.7.4700-4706.1996; HUANG Y, 1994, J VIROL, V68, P7676, DOI 10.1128/JVI.68.12.7676-7683.1994; JIANG M, 1993, J VIROL, V67, P3246, DOI 10.1128/JVI.67.6.3246-3253.1993; Khorchid A, 2000, J MOL BIOL, V299, P17, DOI 10.1006/jmbi.2000.3709; Ko YG, 2000, J CELL BIOL, V149, P567, DOI 10.1083/jcb.149.3.567; Mak J, 1997, J MOL BIOL, V265, P419, DOI 10.1006/jmbi.1996.0742; MAK J, 1994, J VIROL, V68, P2065, DOI 10.1128/JVI.68.4.2065-2072.1994; Mak J, 1997, J VIROL, V71, P8087, DOI 10.1128/JVI.71.11.8087-8095.1997; PARK J, 1992, J VIROL, V66, P6304, DOI 10.1128/JVI.66.11.6304-6313.1992; SARIHCOTTIN L, 1992, J MOL BIOL, V226, P1, DOI 10.1016/0022-2836(92)90117-3; SCHULMAN LH, 1990, NUCLEIC ACIDS RES, V18, P285, DOI 10.1093/nar/18.2.285; Shiba K, 1997, J BIOL CHEM, V272, P22809, DOI 10.1074/jbc.272.36.22809; SMITH AJ, 1993, J VIROL, V67, P2266, DOI 10.1128/JVI.67.4.2266-2275.1993; STAPULIONIS R, 1995, P NATL ACAD SCI USA, V92, P7158, DOI 10.1073/pnas.92.16.7158; Stello T, 1999, NUCLEIC ACIDS RES, V27, P4823, DOI 10.1093/nar/27.24.4823; Swanstrom R., 1997, P263; TAMURA K, 1992, NUCLEIC ACIDS RES, V20, P2335, DOI 10.1093/nar/20.9.2335; VARSHNEY U, 1991, J BIOL CHEM, V266, P24712; WOHRL BM, 1993, J BIOL CHEM, V268, P13617; WU XQ, 1993, NUCLEIC ACIDS RES, V21, P5589, DOI 10.1093/nar/21.24.5589	31	39	39	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 17	2002	277	20					17389	17396		10.1074/jbc.M112479200	http://dx.doi.org/10.1074/jbc.M112479200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	553PR	11884398	hybrid			2022-12-27	WOS:000175685100004
J	Panopoulou, E; Gillooly, DJ; Wrana, JL; Zerial, M; Stenmark, H; Murphy, C; Fotsis, T				Panopoulou, E; Gillooly, DJ; Wrana, JL; Zerial, M; Stenmark, H; Murphy, C; Fotsis, T			Early endosomal regulation of Smad-dependent signaling in endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLATHRIN-MEDIATED ENDOCYTOSIS; COATED VESICLE FORMATION; TGF-BETA RECEPTORS; GROWTH-FACTOR; PHOSPHATIDYLINOSITOL 3-PHOSPHATE; FYVE-FINGER; PROTEIN-KINASE; RAB5; MEMBRANE; DYNAMIN	Transforming growth factor beta (TGFbeta) receptors require SARA for phosphorylation of the downstream transducing Smad proteins. SARA, a FYVE finger protein, binds to membrane lipids suggesting that activated receptors may interact with downstream signaling molecules at discrete endocytic locations. In the present study, we reveal a critical role for the early endocytic compartment in regulating Smad-dependent signaling. Not only is SARA localized on early endosomes, but also its minimal FYVE finger sequence is sufficient for early endosomal targeting. Expression of a SARA mutant protein lacking the FYVE finger inhibits downstream activin A signaling in endothelial cells. Moreover, a dominant-negative mutant of Rab5, a crucial protein for early endosome dynamics, causes phosphorylation and nuclear translocation of Smads leading to constitutive (i.e. ligand independent) transcriptional activation of a Smad-dependent promoter in endothelial cells. As inhibition of endocytosis using the K44A negative mutant of dynamin and RN-tre did not lead to activation of Smad-dependent transcription, the effects of the dominant-negative Rab5 are likely to be a consequence of altered membrane trafficking of constitutively formed TGFbeta/activin type I/II receptor complexes at the level of early endosomes. The results suggest an important interconnection between early endosomal dynamics and TGFbeta/activin signal transduction pathways.	Univ Ioannina, Sch Med, Biol Chem Lab, GR-45110 Ioannina, Greece; Norwegian Radium Hosp, Dept Biochem, N-0310 Oslo, Norway; Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Toronto, ON M5G 1X5, Canada; Max Planck Inst Mol Cell Biol & Genet, D-01307 Dresden, Germany; Biomed Res Inst, Ioannina 45110, Greece	University of Ioannina; University of Oslo; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; Max Planck Society; Foundation for Research & Technology - Hellas (FORTH)	Fotsis, T (corresponding author), Univ Ioannina, Sch Med, Biol Chem Lab, GR-45110 Ioannina, Greece.		Murphy, Carol/ABE-4282-2021; Stenmark, Harald/B-8868-2008; Wrana, Jeffrey/F-8857-2013	Murphy, Carol/0000-0003-1353-8558; 				Arthur HM, 2000, DEV BIOL, V217, P42, DOI 10.1006/dbio.1999.9534; Barbieri MA, 2000, J CELL BIOL, V151, P539, DOI 10.1083/jcb.151.3.539; Beck L, 1997, FASEB J, V11, P365, DOI 10.1096/fasebj.11.5.9141503; Bourdeau A, 1999, J CLIN INVEST, V104, P1343, DOI 10.1172/JCI8088; Breit S, 2000, CANCER RES, V60, P4596; BUCCI C, 1992, CELL, V70, P715, DOI 10.1016/0092-8674(92)90306-W; Bucci C, 2000, MOL BIOL CELL, V11, P467, DOI 10.1091/mbc.11.2.467; Ceresa BP, 2000, CURR OPIN CELL BIOL, V12, P204, DOI 10.1016/S0955-0674(99)00077-0; Daaka Y, 1998, J BIOL CHEM, V273, P685, DOI 10.1074/jbc.273.2.685; DAMKE H, 1994, J CELL BIOL, V127, P915, DOI 10.1083/jcb.127.4.915; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Dong CM, 2000, MOL CELL, V5, P27, DOI 10.1016/S1097-2765(00)80400-1; Feng XH, 1996, J BIOL CHEM, V271, P13123, DOI 10.1074/jbc.271.22.13123; Galvin KM, 2000, NAT GENET, V24, P171, DOI 10.1038/72835; Gaullier JM, 2000, J BIOL CHEM, V275, P24595, DOI 10.1074/jbc.M906554199; Gillooly DJ, 2000, EMBO J, V19, P4577, DOI 10.1093/emboj/19.17.4577; GORVEL JP, 1991, CELL, V64, P915, DOI 10.1016/0092-8674(91)90316-Q; Griswold-Prenner I, 1998, MOL CELL BIOL, V18, P6595, DOI 10.1128/MCB.18.11.6595; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Henley JR, 1998, J CELL BIOL, V141, P85, DOI 10.1083/jcb.141.1.85; Lanzetti L, 2000, NATURE, V408, P374, DOI 10.1038/35042605; Leof EB, 2000, TRENDS CELL BIOL, V10, P343, DOI 10.1016/S0962-8924(00)01795-5; Massague J, 2000, CELL, V103, P295, DOI 10.1016/S0092-8674(00)00121-5; Miura S, 2000, MOL CELL BIOL, V20, P9346, DOI 10.1128/MCB.20.24.9346-9355.2000; MU FT, 1995, J BIOL CHEM, V270, P13503, DOI 10.1074/jbc.270.22.13503; Nielsen E, 2000, J CELL BIOL, V151, P601, DOI 10.1083/jcb.151.3.601; Nielsen E, 1999, NAT CELL BIOL, V1, P376, DOI 10.1038/14075; Oh P, 1998, J CELL BIOL, V141, P101, DOI 10.1083/jcb.141.1.101; Oh SP, 2000, P NATL ACAD SCI USA, V97, P2626, DOI 10.1073/pnas.97.6.2626; Papini E, 1997, EMBO J, V16, P15, DOI 10.1093/emboj/16.1.15; Peacock AJ, 1999, THORAX, V54, P1107, DOI 10.1136/thx.54.12.1107; Raiborg C, 2001, J CELL SCI, V114, P2255; Sankaran VG, 2001, BIOCHEMISTRY-US, V40, P8581, DOI 10.1021/bi010425d; Simonsen A, 1998, NATURE, V394, P494, DOI 10.1038/28879; STENMARK H, 1994, EMBO J, V13, P1287, DOI 10.1002/j.1460-2075.1994.tb06381.x; Stenmark H, 1999, J CELL SCI, V112, P4175; SUTTER G, 1995, FEBS LETT, V371, P9, DOI 10.1016/0014-5793(95)00843-X; Tamaru M, 1999, J BIOL CHEM, V274, P3753, DOI 10.1074/jbc.274.6.3753; Tsukazaki T, 1998, CELL, V95, P779, DOI 10.1016/S0092-8674(00)81701-8; VANDERBLIEK AM, 1993, J CELL BIOL, V122, P553, DOI 10.1083/jcb.122.3.553; Vieira AV, 1996, SCIENCE, V274, P2086, DOI 10.1126/science.274.5295.2086; WOODROOFE C, 1992, DNA CELL BIOL, V11, P587, DOI 10.1089/dna.1992.11.587; Wrana JL, 2000, CELL, V100, P189, DOI 10.1016/S0092-8674(00)81556-1; Zhang Y, 1996, NATURE, V383, P168, DOI 10.1038/383168a0; Zwaagstra JC, 2001, J BIOL CHEM, V276, P27237, DOI 10.1074/jbc.M100033200	45	115	119	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 17	2002	277	20					18046	18052		10.1074/jbc.M107983200	http://dx.doi.org/10.1074/jbc.M107983200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	553PR	11877415	hybrid			2022-12-27	WOS:000175685100083
J	Reckenfelderbaumer, N; Krauth-Siegel, RL				Reckenfelderbaumer, N; Krauth-Siegel, RL			Catalytic properties, thiol pK value, and redox potential of Trypanosoma brucei tryparedoxin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI THIOREDOXIN; ACTIVE-SITE; DIFFERENTIAL REACTIVITY; CRITHIDIA-FASCICULATA; DEPENDENT SYNTHESIS; CYSTEINE RESIDUES; TRYPANOTHIONE; GLUTATHIONE; PROTEIN; REDUCTASE	The dithiol protein tryparedoxin is a component of the unique trypanothione/trypanothione reductase metabolism of trypanosomatids and is involved in the parasite synthesis of deoxyribonucleotides and the detoxication of hydroperoxides. Tryparedoxin is a highly abundant protein in all life stages of Trypanosoma brucei, the causative agent of African sleeping sickness. As shown here, its functional properties are intermediate between those of classical thioredoxins and glutaredoxins. The redox potential of T. brucei tryparedoxin of -249 mV was determined by protein-protein redox equilibration with Escherichia coli thioredoxin. The trypanothione/tryparedoxin couple is probably the most significant factor determining the cytosolic redox potential of the parasites. The pK value of Cys(40), the first thiol in the WCPPC motif, is 7.2 as derived from the thiolate absorption at 240 nm and the rate of carboxymethylation. Alteration of the active site into that of thioredoxin (CGPC) did not affect the pK value. In contrast, in the mutant with the glutaredoxin motif (CPYC) the pK dropped to less than or equal to4.0. The fact that the pK value of tryparedoxin coincides with the intracellular pH of the parasite may contribute to the reactivity of tryparedoxin in thiol disulfide exchange reactions.	Heidelberg Univ, Biochem Zentrum Heidelberg, D-69120 Heidelberg, Germany	Ruprecht Karls University Heidelberg	Krauth-Siegel, RL (corresponding author), Heidelberg Univ, Biochem Zentrum Heidelberg, Neuenheimer Feld 328, D-69120 Heidelberg, Germany.	krauth-siegel@urz.uni-heidelberg.de						Alphey MS, 1999, J BIOL CHEM, V274, P25613, DOI 10.1074/jbc.274.36.25613; Aslund F, 1997, J BIOL CHEM, V272, P30780, DOI 10.1074/jbc.272.49.30780; Braun H, 1996, EUR J BIOCHEM, V240, P781, DOI 10.1111/j.1432-1033.1996.0781h.x; Chivers PT, 1997, BIOCHEMISTRY-US, V36, P4061, DOI 10.1021/bi9628580; Debarbieux L, 1998, P NATL ACAD SCI USA, V95, P10751, DOI 10.1073/pnas.95.18.10751; Dormeyer M, 2001, J BIOL CHEM, V276, P10602, DOI 10.1074/jbc.M010352200; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; FAIRLAMB AH, 1992, ANNU REV MICROBIOL, V46, P695, DOI 10.1146/annurev.micro.46.1.695; Flohe L, 1999, FREE RADICAL BIO MED, V27, P966, DOI 10.1016/S0891-5849(99)00172-0; FraserLhostis C, 1997, BIOL CHEM, V378, P1039, DOI 10.1515/bchm.1997.378.9.1039; GAN ZR, 1990, ARCH BIOCHEM BIOPHYS, V282, P110, DOI 10.1016/0003-9861(90)90093-E; GILBERT HF, 1990, ADV ENZYMOL RAMB, V63, P69; Gommel DU, 1997, EUR J BIOCHEM, V248, P913, DOI 10.1111/j.1432-1033.1997.t01-1-00913.x; GRAUSCHOPF U, 1995, CELL, V83, P947, DOI 10.1016/0092-8674(95)90210-4; Hofmann B, 2001, BIOL CHEM, V382, P459, DOI 10.1515/BC.2001.056; HOLMGREN A, 1985, ANNU REV BIOCHEM, V54, P237, DOI 10.1146/annurev.bi.54.070185.001321; HOLMGREN A, 1979, J BIOL CHEM, V254, P3672; HOLMGREN A, 1989, J BIOL CHEM, V264, P13963; Ivens AC, 1998, GENOME RES, V8, P135, DOI 10.1101/gr.8.2.135; JENG MF, 1995, BIOCHEMISTRY-US, V34, P10101, DOI 10.1021/bi00032a001; KALLIS GB, 1980, J BIOL CHEM, V255, P261; Keese MA, 1999, FEBS LETT, V447, P135, DOI 10.1016/S0014-5793(99)00296-3; KORTEMME T, 1995, J MOL BIOL, V253, P799, DOI 10.1006/jmbi.1995.0592; KRAUSE G, 1991, J BIOL CHEM, V266, P9494; Krauth-Siegel RL, 1999, PARASITOL TODAY, V15, P404, DOI 10.1016/S0169-4758(99)01516-1; KrauthSiegel RL, 1996, MOL BIOCHEM PARASIT, V80, P203, DOI 10.1016/0166-6851(96)02689-8; Lopez JA, 2000, FREE RADICAL BIO MED, V28, P767, DOI 10.1016/S0891-5849(00)00159-3; Ludemann H, 1998, FEBS LETT, V431, P381, DOI 10.1016/S0014-5793(98)00793-5; May JM, 1997, J BIOL CHEM, V272, P22607, DOI 10.1074/jbc.272.36.22607; Mossner E, 1998, PROTEIN SCI, V7, P1233; MOUTIEZ M, 1994, CHEM PHARM BULL, V42, P2641; NELSON JW, 1994, BIOCHEMISTRY-US, V33, P5974, DOI 10.1021/bi00185a039; Nogoceke E, 1997, BIOL CHEM, V378, P827, DOI 10.1515/bchm.1997.378.8.827; Reckenfelderbaumer N, 2000, J BIOL CHEM, V275, P7547, DOI 10.1074/jbc.275.11.7547; RIVERAMADRID R, 1995, P NATL ACAD SCI USA, V92, P5620, DOI 10.1073/pnas.92.12.5620; SNYDER GH, 1987, BIOCHEMISTRY-US, V26, P688, DOI 10.1021/bi00377a005; SULLIVAN FX, 1991, MOL BIOCHEM PARASIT, V44, P145, DOI 10.1016/0166-6851(91)90231-T; Washburn MP, 1999, BIOCHEMISTRY-US, V38, P268, DOI 10.1021/bi980480v; WINKLER BS, 1994, FREE RADICAL BIO MED, V17, P333, DOI 10.1016/0891-5849(94)90019-1	39	41	43	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 17	2002	277	20					17548	17555		10.1074/jbc.M112115200	http://dx.doi.org/10.1074/jbc.M112115200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	553PR	11867629	hybrid			2022-12-27	WOS:000175685100022
J	Riihimaa, P; Nissi, R; Page, AP; Winter, AD; Keskiaho, K; Kivirikko, KI; Myllyharju, J				Riihimaa, P; Nissi, R; Page, AP; Winter, AD; Keskiaho, K; Kivirikko, KI; Myllyharju, J			Egg shell collagen formation in Caenorhabditis elegans involves a novel prolyl 4-hydroxylase expressed in spermatheca and embryos and possessing many unique properties	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DISULFIDE-ISOMERASE SUBUNIT; ALPHA-SUBUNIT; BACULOVIRUS EXPRESSION; IV COLLAGEN; LYSYL HYDROXYLASE; ENZYME TETRAMER; C-ELEGANS; PROTEIN; CLONING; GENE	The collagen prolyl 4-hydroxylases (EC 1.14.11.2) play a critical role in the synthesis of all collagens. The enzymes from all vertebrate species studied are alpha(2)beta(2) tetramers, in which the beta subunit is identical to protein disulfide isomerase (PDI). Two isoforms of the catalytic a subunit, PHY-1 and PHY-2, have previously been characterized from Caenorhabditis elegans. We report here on the cloning and characterization of a third C. elegans a subunit isoform, PHY-3. It is much shorter than the previously characterized vertebrate and C. elegans a subunits and shows 23-30% amino acid sequence identity to PHY-1 and PHY-2 within the catalytic C-terminal region. Recombinant PHY-3 coexpressed in insect cells with a C. elegans PDI isoform that does not associate with PHY-1 was found to be an active prolyl 4-hydroxylase. The phy-3 gene consists of five exons, and its expression pattern differs distinctly from the hypodermally expressed phy-1 and phy-2 in that it is expressed in embryos, late larval stages, and adult nematodes, expression in the latter being restricted to the spermatheca. Nematodes homozygous for a phy-3 deletion are phenotypically of the wild type and fertile, but the 4-hydroxyproline content of phy-3(-/-) early embryos was reduced by about 90%. PHY-3 is thus likely to be involved in the synthesis of collagens in early embryos, probably of those in the egg shell.	Univ Oulu, Bioctr Oulu, Collagen Res Unit, FIN-90014 Oulu, Finland; Univ Oulu, Dept Med Biochem, FIN-90014 Oulu, Finland; Univ Glasgow, Anderson Coll, Wellcome Ctr Mol Parasitol, Glasgow G11 6NU, Lanark, Scotland	University of Oulu; University of Oulu; University of Glasgow	Myllyharju, J (corresponding author), Univ Oulu, Bioctr Oulu, Collagen Res Unit, POB 5000, FIN-90014 Oulu, Finland.	johanna.myllyharju@oulu.fi						Ackley BD, 2001, J CELL BIOL, V152, P1219, DOI 10.1083/jcb.152.6.1219; Annunen P, 1997, J BIOL CHEM, V272, P17342, DOI 10.1074/jbc.272.28.17342; Annunen P, 1999, J BIOL CHEM, V274, P6790, DOI 10.1074/jbc.274.10.6790; Annunen P, 1998, J BIOL CHEM, V273, P5989, DOI 10.1074/jbc.273.11.5989; Bird, 1991, STRUCTURE NEMATODES, P7; Bruick RK, 2001, SCIENCE, V294, P1337, DOI 10.1126/science.1066373; C elegans Sequencing Consortium, 1998, SCIENCE, V282, P2012, DOI 10.1126/science.282.5396.2012; Epstein ACR, 2001, CELL, V107, P43, DOI 10.1016/S0092-8674(01)00507-4; Eriksson M, 1999, J BIOL CHEM, V274, P22131, DOI 10.1074/jbc.274.32.22131; FIRE A, 1990, GENE, V93, P189, DOI 10.1016/0378-1119(90)90224-F; Friedman L, 2000, P NATL ACAD SCI USA, V97, P4736, DOI 10.1073/pnas.97.9.4736; Graham PL, 1997, J CELL BIOL, V137, P1171, DOI 10.1083/jcb.137.5.1171; Gupta MC, 1997, J CELL BIOL, V137, P1185, DOI 10.1083/jcb.137.5.1185; HELAAKOSKI T, 1989, P NATL ACAD SCI USA, V86, P4392, DOI 10.1073/pnas.86.12.4392; HELAAKOSKI T, 1995, P NATL ACAD SCI USA, V92, P4427, DOI 10.1073/pnas.92.10.4427; Hill KL, 2000, GENETICS, V155, P1139; Johnstone IL, 2000, TRENDS GENET, V16, P21, DOI 10.1016/S0168-9525(99)01857-0; JOHNSTONE IL, 1992, EMBO J, V11, P3857, DOI 10.1002/j.1460-2075.1992.tb05478.x; Kivirikko KI, 1998, MATRIX BIOL, V16, P357, DOI 10.1016/S0945-053X(98)90009-9; KIVIRIKKO KI, 1982, METHOD ENZYMOL, V82, P245; Kivirikko KI, 1998, ADV ENZYMOL RAMB, V72, P325; KRAMER JM, 1990, MOL CELL BIOL, V10, P2081, DOI 10.1128/MCB.10.5.2081; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; Myllyharju J, 1999, EMBO J, V18, P306, DOI 10.1093/emboj/18.2.306; Myllyharju J, 1997, EMBO J, V16, P1173, DOI 10.1093/emboj/16.6.1173; Myllyharju J, 2001, ANN MED, V33, P7, DOI 10.3109/07853890109002055; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; Nissi R, 2001, J HISTOCHEM CYTOCHEM, V49, P1143, DOI 10.1177/002215540104900908; Norman KR, 2000, DEV BIOL, V227, P690, DOI 10.1006/dbio.2000.9897; Page AP, 1997, DNA CELL BIOL, V16, P1335, DOI 10.1089/dna.1997.16.1335; Passoja K, 1998, P NATL ACAD SCI USA, V95, P10482, DOI 10.1073/pnas.95.18.10482; ROGALSKI TM, 1993, GENE DEV, V7, P1471, DOI 10.1101/gad.7.8.1471; Sulston J., 1988, NEMATODE CAENORHABDI, P587; SUZUKI H, 1988, ANAL BIOCHEM, V172, P259, DOI 10.1016/0003-2697(88)90440-X; Veijola J, 1996, BIOCHEM J, V317, P721, DOI 10.1042/bj3170721; VEIJOLA J, 1994, J BIOL CHEM, V269, P26746; VUORI K, 1992, P NATL ACAD SCI USA, V89, P7467, DOI 10.1073/pnas.89.16.7467; Winter AD, 2000, MOL CELL BIOL, V20, P4084, DOI 10.1128/MCB.20.11.4084-4093.2000; Wood W. B., 1988, NEMATODE C ELEGANS, P215	39	24	28	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 17	2002	277	20					18238	18243		10.1074/jbc.M200895200	http://dx.doi.org/10.1074/jbc.M200895200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	553PR	11891226	hybrid			2022-12-27	WOS:000175685100107
J	Andreucci, JJ; Grant, D; Cox, DM; Tome, LK; Prywes, R; Goldhamer, DJ; Rodrigues, N; Bedard, PA; McDermott, JC				Andreucci, JJ; Grant, D; Cox, DM; Tome, LK; Prywes, R; Goldhamer, DJ; Rodrigues, N; Bedard, PA; McDermott, JC			Composition and function of AP-1 transcription complexes during muscle cell differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							JUN ACTIVATION DOMAIN; C-JUN; MYOGENIC DIFFERENTIATION; PROTEIN-KINASE; TERMINAL DIFFERENTIATION; INHIBITS MYOGENESIS; POSITIVE REGULATION; GENE-EXPRESSION; FOS; MYOBLASTS	The role of activating protein-1 (AP-1) in muscle cells is currently equivocal. While some studies propose that AP-1 is inhibitory for myogenesis, others implicate a positive role in this process. We tested whether this variation may be due to different properties of the AP-1 subunit composition in differentiating cells. Using Western analysis we show that c-Jun, Fra-2, and JunD are expressed throughout the time course of differentiation. Phosphatase assays indicate that JunD and Fra-2 are phosphorylated in muscle cells and that at least two isoforms of each are expressed in muscle cells. Electrophoretic mobility shift assays combined with antibody supershifts indicate the appearance of Fra-2 as a major component of the AP-1 DNA binding complex in differentiating cells. In this context it appears that Fra-2 heterodimerizes with c-Jun and JunD. Studying the c-jun enhancer in reporter gene assays we observed that the muscle transcription factors MEF2A and MyoD can contribute to robust transcriptional activation of the c-jun enhancer. In differentiating muscle cells mutation of the MEF2 site reduces transactivation of the c-jun enhancer and MEF2A is the predominant MEF2 isoform binding to this cis element. Transcriptional activation of an AP-1 site containing reporter gene (TRE-Luc) is enhanced under differentiation conditions compared with growth conditions in C2C12 muscle cells. Further studies indicate that Fra-2 containing A-P-1 complexes can transactivate the MyoD enhancer/promoter. Thus, an A-P-1 complex containing Fra-2 and c-Jun or JunD is consistent with muscle differentiation, indicating that AP-1 function during myogenesis is dependent on its subunit composition.	York Univ, Dept Biol, N York, ON M3J 1P3, Canada; Columbia Univ, Dept Biol Sci, New York, NY 10027 USA; Univ Penn, Sch Med, Dept Cell & Dev Biol, Philadelphia, PA 19104 USA	York University - Canada; Columbia University; University of Pennsylvania	McDermott, JC (corresponding author), York Univ, Dept Biol, 327 Farquharson LSB,4700 Keele St, N York, ON M3J 1P3, Canada.							ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; Aurade F, 1997, J CELL SCI, V110, P2771; BENGAL E, 1992, CELL, V68, P507, DOI 10.1016/0092-8674(92)90187-H; BISHOPRIC NH, 1992, J BIOL CHEM, V267, P25535; BossyWetzel E, 1997, EMBO J, V16, P1695, DOI 10.1093/emboj/16.7.1695; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DEVARY Y, 1991, MOL CELL BIOL, V11, P2804, DOI 10.1128/MCB.11.5.2804; Dorman CM, 2000, J BIOL CHEM, V275, P27481; GRIGORIADIS AE, 1994, SCIENCE, V266, P443, DOI 10.1126/science.7939685; GROSSI M, 1991, ONCOGENE, V6, P1767; HAN TH, 1995, MOL CELL BIOL, V15, P2907; HAN TH, 1992, MOL CELL BIOL, V12, P4472, DOI 10.1128/MCB.12.10.4472; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HILBERG F, 1993, NATURE, V365, P179, DOI 10.1038/365179a0; JOHNSON RS, 1993, GENE DEV, V7, P1309, DOI 10.1101/gad.7.7b.1309; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; KOVARY K, 1992, MOL CELL BIOL, V12, P5015, DOI 10.1128/MCB.12.11.5015; Kucharczuk KL, 1999, DEVELOPMENT, V126, P1957; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LAMPH WW, 1988, NATURE, V334, P629, DOI 10.1038/334629a0; LI L, 1992, GENE DEV, V6, P676, DOI 10.1101/gad.6.4.676; McCabe LR, 1996, ENDOCRINOLOGY, V137, P4398, DOI 10.1210/en.137.10.4398; Molkentin JD, 1995, CELL, V83, P1125, DOI 10.1016/0092-8674(95)90139-6; MURUKAMI M, 1997, ONCOGENE, V14, P2435; Musti AM, 1997, SCIENCE, V275, P400, DOI 10.1126/science.275.5298.400; OLSON EN, 1995, DEV BIOL, V172, P2, DOI 10.1006/dbio.1995.0002; Ornatsky OI, 1997, J BIOL CHEM, V272, P33271, DOI 10.1074/jbc.272.52.33271; Ornatsky OI, 1999, NUCLEIC ACIDS RES, V27, P2646, DOI 10.1093/nar/27.13.2646; Ornatsky OI, 1996, J BIOL CHEM, V271, P24927, DOI 10.1074/jbc.271.40.24927; PEDRAZAALVA G, 1994, J BIOL CHEM, V269, P6978; PFARR CM, 1994, CELL, V76, P747, DOI 10.1016/0092-8674(94)90513-4; Schorpp-Kistner M, 1999, EMBO J, V18, P934, DOI 10.1093/emboj/18.4.934; SCUH AC, 1992, ONCOGENE, V7, P667; Sharma SC, 2000, J BIOL CHEM, V275, P33718, DOI 10.1074/jbc.M003555200; SU HY, 1991, ONCOGENE, V6, P1759; Thepot D, 2000, DEVELOPMENT, V127, P143; THINAKARAN G, 1993, BIOCHEM CELL BIOL, V71, P260, DOI 10.1139/o93-040; THINAKARAN G, 1993, FEBS LETT, V319, P271, DOI 10.1016/0014-5793(93)80561-8	41	62	64	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 10	2002	277	19					16426	16432		10.1074/jbc.M110891200	http://dx.doi.org/10.1074/jbc.M110891200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	551MB	11877423	hybrid			2022-12-27	WOS:000175564500013
J	Cipriano, DJ; Bi, YM; Dunn, SD				Cipriano, DJ; Bi, YM; Dunn, SD			Genetic fusions of globular proteins to the epsilon subunit of the Escherichia coli ATP synthase - Implications for in vivo rotational catalysis and epsilon subunit function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-SUBUNIT; ROTARY MOTOR; CONFORMATIONAL-CHANGES; MONOCLONAL-ANTIBODIES; BETA-SUBUNITS; CROSS-LINKING; F-ATPASE; F1-ATPASE; COMPLEX; NUCLEOTIDE	The rotational mechanism of ATP synthase was investigated by fusing three proteins from Escherichia coli, the 12-kDa soluble cytochrome b(562), the 20-kDa flavodoxin, and the 28-kDa flavodoxin reductase, to the C terminus of the epsilon subunit of the enzyme. According to the concept of rotational catalysis, because epsilon is part of the rotor a large domain added at this site should sterically clash with the second stalk, blocking rotation and fully inhibiting the enzyme. E. coli cells expressing the cytochrome b(562) fusion in place of wild-type epsilon grew using acetate as the energy source, indicating their capacity for oxidative phosphorylation. Cells expressing the larger flavodoxin or flavodoxin reductase fusions failed to grow on acetate. Immunoblot analysis showed that the fusion proteins were stable in the cells and that they had no effect on enzyme assembly. These results provide initial evidence supporting rotational catalysis in vivo. In membrane vesicles, the cytochrome b(562) fusion caused an increase in the apparent ATPase activity but a minor decrease in proton pumping. Vesicles bearing ATP synthase containing the larger fusion proteins showed reduced but significant levels of ATPase activity that was sensitive to inhibition by dicyclohexylcarbodiimide (DCCD) but no proton pumping. Thus, all fusions to epsilon generated an uncoupled component of ATPase activity. These results imply that a function of the C terminus of epsilon in F1F0 is to increase the efficiency of the enzyme by specifically preventing the uncoupled hydrolysis of ATP. Given the sensitivity to DCCD, this uncoupled ATP hydrolysis may arise from rotational steps of gammaepsilon in the inappropriate direction after ATP is bound at the catalytic site. It is proposed that the C-terminal domain of epsilon functions to ensure that rotation occurs only in the direction of ATP synthesis when ADP is bound and only in the direction of hydrolysis when ATP is bound.	Univ Western Ontario, Dept Biochem, London, ON N6A 5C1, Canada	Western University (University of Western Ontario)	Dunn, SD (corresponding author), Univ Western Ontario, Dept Biochem, London, ON N6A 5C1, Canada.	sdunn@uwo.ca	Dunn, Stanley/D-3418-2013					ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; AGGELER R, 1992, ARCH BIOCHEM BIOPHYS, V296, P685, DOI 10.1016/0003-9861(92)90627-9; Aggeler R, 1996, J BIOL CHEM, V271, P13888, DOI 10.1074/jbc.271.23.13888; AGGELER R, 1995, BBA-BIOENERGETICS, V1230, P62, DOI 10.1016/0005-2728(95)00040-P; Boyer PD, 1997, ANNU REV BIOCHEM, V66, P717, DOI 10.1146/annurev.biochem.66.1.717; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bulygin VV, 1998, J BIOL CHEM, V273, P31765, DOI 10.1074/jbc.273.48.31765; DALLMANN HG, 1992, J BIOL CHEM, V267, P18953; DUNCAN TM, 1995, P NATL ACAD SCI USA, V92, P10964, DOI 10.1073/pnas.92.24.10964; DUNN SD, 1985, J BIOL CHEM, V260, P418; DUNN SD, 1986, ANAL BIOCHEM, V159, P35, DOI 10.1016/0003-2697(86)90304-0; DUNN SD, 1986, ANAL BIOCHEM, V157, P144, DOI 10.1016/0003-2697(86)90207-1; Ellis RJ, 2001, TRENDS BIOCHEM SCI, V26, P597, DOI 10.1016/S0968-0004(01)01938-7; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; FUTAI M, 1974, P NATL ACAD SCI USA, V71, P2725, DOI 10.1073/pnas.71.7.2725; Gardner JL, 1999, ARCH BIOCHEM BIOPHYS, V361, P302, DOI 10.1006/abbi.1998.0995; Gibbons C, 2000, NAT STRUCT BIOL, V7, P1055; Hara KY, 2001, J BIOL CHEM, V276, P23969, DOI 10.1074/jbc.M009303200; Hasler K, 1998, FEBS LETT, V426, P301, DOI 10.1016/S0014-5793(98)00358-5; Hausrath AC, 2001, J BIOL CHEM, V276, P47227, DOI 10.1074/jbc.M107536200; Hausrath AC, 1999, P NATL ACAD SCI USA, V96, P13697, DOI 10.1073/pnas.96.24.13697; Hoover DM, 1997, PROTEIN SCI, V6, P2525; Ingelman M, 1997, J MOL BIOL, V268, P147, DOI 10.1006/jmbi.1997.0957; Jiang WP, 2001, P NATL ACAD SCI USA, V98, P4966, DOI 10.1073/pnas.081424898; Jones PC, 2000, J BIOL CHEM, V275, P31340, DOI 10.1074/jbc.M003687200; Kato-Yamada Y, 1998, J BIOL CHEM, V273, P19375, DOI 10.1074/jbc.273.31.19375; KLIONSKY DJ, 1984, J BACTERIOL, V160, P1055, DOI 10.1128/JB.160.3.1055-1060.1984; KUKI M, 1988, J BIOL CHEM, V263, P17437; Kuo PH, 1998, FEBS LETT, V426, P217, DOI 10.1016/S0014-5793(98)00337-8; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MATHEWS FS, 1979, J BIOL CHEM, V254, P1699; McCarty RE, 2000, ANNU REV PLANT PHYS, V51, P83, DOI 10.1146/annurev.arplant.51.1.83; McLachlin DT, 2000, BIOCHEMISTRY-US, V39, P3486, DOI 10.1021/bi992586b; MENDELHARTVIG J, 1991, BIOCHEMISTRY-US, V30, P1278, DOI 10.1021/bi00219a017; MENDELHARTVIG J, 1991, BIOCHEMISTRY-US, V30, P10987, DOI 10.1021/bi00109a025; Nakamoto RK, 1999, ANNU REV BIOPH BIOM, V28, P205, DOI 10.1146/annurev.biophys.28.1.205; Noji H, 1997, NATURE, V386, P299, DOI 10.1038/386299a0; Panke O, 2000, FEBS LETT, V472, P34, DOI 10.1016/S0014-5793(00)01436-8; PATEL AM, 1990, MOL MICROBIOL, V4, P1941, DOI 10.1111/j.1365-2958.1990.tb02043.x; PETERSON PL, 2000, J BIOENERG BIOMEMBR, V32, P4; PRIVE GG, 1994, ACTA CRYSTALLOGR D, V50, P375, DOI 10.1107/S0907444993014301; Rodgers AJW, 2000, NAT STRUCT BIOL, V7, P1051; Sambongi Y, 1999, SCIENCE, V286, P1722, DOI 10.1126/science.286.5445.1722; Sambrook J., MOL CLONING LAB MANU; Schulenberg B, 1999, J BIOL CHEM, V274, P28351, DOI 10.1074/jbc.274.40.28351; SKAKOON EN, 1993, ARCH BIOCHEM BIOPHYS, V302, P279, DOI 10.1006/abbi.1993.1211; Stock D, 1999, SCIENCE, V286, P1700, DOI 10.1126/science.286.5445.1700; Tanabe M, 2001, J BIOL CHEM, V276, P15269, DOI 10.1074/jbc.M100289200; TAUSSKY HH, 1953, J BIOL CHEM, V202, P675; Tsunoda SP, 2000, FEBS LETT, V470, P244, DOI 10.1016/S0014-5793(00)01336-3; Tsunoda SP, 2001, P NATL ACAD SCI USA, V98, P6560, DOI 10.1073/pnas.111128098; Uhlin U, 1997, STRUCTURE, V5, P1219, DOI 10.1016/S0969-2126(97)00272-4; VIEIRA J, 1982, GENE, V19, P259, DOI 10.1016/0378-1119(82)90015-4; WALKER JE, 2000, BIOCHIM BIOPHYS ACTA, V1458, P2; WILKENS S, 1994, BIOL CHEM H-S, V375, P43; Wilkens S, 1998, J BIOL CHEM, V273, P26645, DOI 10.1074/jbc.273.41.26645; Yasuda R, 2001, NATURE, V410, P898, DOI 10.1038/35073513; Zhou YT, 1997, P NATL ACAD SCI USA, V94, P10583, DOI 10.1073/pnas.94.20.10583	59	41	41	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 10	2002	277	19					16782	16790		10.1074/jbc.M201349200	http://dx.doi.org/10.1074/jbc.M201349200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	551MB	11875079	hybrid			2022-12-27	WOS:000175564500059
J	Leung-Pineda, V; Kilberg, MS				Leung-Pineda, V; Kilberg, MS			Role of Sp1 and Sp3 in the nutrient-regulated expression of the human asparagine synthetase gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UNFOLDED PROTEIN RESPONSE; AMINO-ACID REGULATION; HUMAN LEUKEMIA-CELLS; ENDOPLASMIC-RETICULUM; TRANSCRIPTIONAL REGULATION; SP-FAMILY; GC BOX; ACTIVATION; ELEMENT; AVAILABILITY	The human asparagine synthetase (AS) gene responds to depletion of mammalian cells for either amino acids or carbohydrates. Five specific cis-elements have been implicated: three GC boxes (GC-I, GC-II and GC-III) and two nutrient-sensing response elements (NSRE-1, -2). This study shows that all three GC boxes are required to maintain basal transcription and to obtain maximal induction of the AS gene by amino acid limitation. However, there is not complete redundancy among the three GC boxes, and there is a hierarchy of importance with regard to transcription (GC-III > GC-H > GC-I). In vitro, two GC boxes formed protein-DNA complexes (GC-II and GC-III) with Sp1 and Sp3. Although transcription of the AS gene is elevated by nutrient limitation, the absolute amount of these protein-DNA complexes and the total pools of Sp1 and Sp3 did not increase. A small, but detectable portion of Sp1 was modified by phosphorylation following amino acid deprivation. In vivo, expression of Sp1 and Sp3 in Drosophila SL2 cells increased AS promoter activity. Sp1 expression increased basal transcription but did not cause a further increase when SL2 cells were amino acid-deprived. Sp3 expression enhanced both the basal and the starvation-induced transcription.	Univ Florida, Coll Med, Dept Biochem & Mol Biol, Gainesville, FL 32610 USA	State University System of Florida; University of Florida	Kilberg, MS (corresponding author), Univ Florida, Coll Med, Dept Biochem & Mol Biol, Box 100245, Gainesville, FL 32610 USA.	mkilberg@ufl.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052064] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-52064] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ammanamanchi S, 2001, J BIOL CHEM, V276, P3348, DOI 10.1074/jbc.M002462200; Aslanian AM, 2001, BIOCHEM J, V357, P321, DOI 10.1042/0264-6021:3570321; Aslanian AM, 2001, BIOCHEM J, V358, P59, DOI 10.1042/0264-6021:3580059; Barbosa-Tessmann IP, 1999, BIOCHEM J, V339, P151, DOI 10.1042/0264-6021:3390151; Barbosa-Tessmann IP, 1999, J BIOL CHEM, V274, P31139, DOI 10.1074/jbc.274.44.31139; Barbosa-Tessmann IP, 2000, J BIOL CHEM, V275, P26976; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; COUREY AJ, 1992, TRANSCRIPTIONAL REGU, P743; Discher DJ, 1998, J BIOL CHEM, V273, P26087, DOI 10.1074/jbc.273.40.26087; Fafournoux P, 2000, BIOCHEM J, V351, P1, DOI 10.1042/0264-6021:3510001; GONG SS, 1991, MOL CELL BIOL, V11, P6059, DOI 10.1128/MCB.11.12.6059; GRECO A, 1989, MOL CELL BIOL, V9, P2350, DOI 10.1128/MCB.9.6.2350; GUERRINI L, 1993, MOL CELL BIOL, V13, P3202, DOI 10.1128/MCB.13.6.3202; HAGEN G, 1994, EMBO J, V13, P3843, DOI 10.1002/j.1460-2075.1994.tb06695.x; Hutson RG, 1997, AM J PHYSIOL-CELL PH, V272, pC1691, DOI 10.1152/ajpcell.1997.272.5.C1691; JACKSON SP, 1990, CELL, V63, P155, DOI 10.1016/0092-8674(90)90296-Q; Kaufman RJ, 1999, GENE DEV, V13, P1211, DOI 10.1101/gad.13.10.1211; KILBERG MS, 1989, METHOD ENZYMOL, V173, P564; Lai CF, 2000, J BIOL CHEM, V275, P36400, DOI 10.1074/jbc.M002131200; Laine RO, 1996, PROG NUCLEIC ACID RE, V53, P219, DOI 10.1016/S0079-6603(08)60146-4; Lania L, 1997, INT J BIOCHEM CELL B, V29, P1313, DOI 10.1016/S1357-2725(97)00094-0; Pahl HL, 1999, PHYSIOL REV, V79, P683, DOI 10.1152/physrev.1999.79.3.683; Patil C, 2001, CURR OPIN CELL BIOL, V13, P349, DOI 10.1016/S0955-0674(00)00219-2; Richards NGJ, 1998, ADV ENZYMOL RAMB, V72, P145; Roy B, 1999, NUCLEIC ACIDS RES, V27, P1437, DOI 10.1093/nar/27.6.1437; Suske G, 1999, GENE, V238, P291, DOI 10.1016/S0378-1119(99)00357-1; Whetstine JR, 2001, J BIOL CHEM, V276, P6350, DOI 10.1074/jbc.M008074200	27	28	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 10	2002	277	19					16585	16591		10.1074/jbc.M110972200	http://dx.doi.org/10.1074/jbc.M110972200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	551MB	11867623	hybrid			2022-12-27	WOS:000175564500034
J	Maeda, M; Hamada, D; Hoshino, M; Onda, Y; Hase, T; Goto, Y				Maeda, M; Hamada, D; Hoshino, M; Onda, Y; Hase, T; Goto, Y			Partially folded structure of flavin adenine dinucleotide-depleted ferredoxin-NADP(+) reductase with residual NADP(+) binding domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLTEN-GLOBULE STATE; X-RAY-SCATTERING; INTERMEDIATE STATES; FOLDING UNITS; PROTEIN; APOMYOGLOBIN; MECHANISM; IDENTIFICATION; OXIDOREDUCTASE; FLAVOPROTEINS	Maize ferredoxin-NADP(+) reductase (FNR) consists of flavin adenine dinucleotide (FAD) and NADP(+) binding domains with a FAD molecule bound noncovalently in the cleft between these domains. The structural changes of FNR induced by dissociation of FAD have been characterized by a combination of optical and biochemical methods. The CD spectrum of the FAD-depleted FNR (apo-FNR) suggested that removal of FAD from holo-FNR produced an intermediate conformational state with partially disrupted secondary and tertiary structures. Small angle x-ray scattering indicated that apo-FNR assumes a conformation that is less globular in comparison with holo-FNR but is not completely chain-like. Interestingly, the replacement of tyrosine 95 responsible for FAD binding with alanine resulted in a molecular form similar to apo-protein of the wild-type enzyme. Both apo- and Y95A-FNR species bound to Cibacron Blue affinity resin, indicating the presence of a native-like conformation for the NADP(+) binding domain. On the other hand, no evidence was found for the existence of folded conformations in the FAD binding domains of these proteins. These results suggested that FAD-depleted FNR assumes a partially folded structure with a residual NADP(+) binding domain but a disordered FAD binding domain.	Osaka Univ, Inst Prot Res, Suita, Osaka 5650871, Japan	Osaka University	Goto, Y (corresponding author), Osaka Univ, Inst Prot Res, 3-2 Yamadaoka, Suita, Osaka 5650871, Japan.	ygoto@protein.osaka-u.ac.jp	Hase, Toshiharu/H-9271-2013; Hamada, Daizo/F-3307-2011; Hamada, Daizo/N-1118-2016	Hamada, Daizo/0000-0002-1799-5476				ANDRADE MA, 1993, PROTEIN ENG, V6, P383, DOI 10.1093/protein/6.4.383; Arai M, 2000, ADV PROTEIN CHEM, V53, P209; Arakaki AK, 1997, FASEB J, V11, P133, DOI 10.1096/fasebj.11.2.9039955; Baker D, 2000, NATURE, V405, P39, DOI 10.1038/35011000; Chamberlain AK, 1996, NAT STRUCT BIOL, V3, P782, DOI 10.1038/nsb0996-782; DOBSON CM, 1994, CURR BIOL, V4, P636, DOI 10.1016/S0960-9822(00)00141-X; Eliezer D, 1998, NAT STRUCT BIOL, V5, P148; Ferguson N, 1999, J MOL BIOL, V286, P1597, DOI 10.1006/jmbi.1998.2548; FERSHT AR, 1995, P NATL ACAD SCI USA, V92, P10869, DOI 10.1073/pnas.92.24.10869; FERSHT AR, 2000, STRUCTURE MECH PROTE, P543; FINK AL, 1995, ANNU REV BIOPH BIOM, V24, P495, DOI 10.1146/annurev.bb.24.060195.002431; Fischer KF, 2000, J MOL BIOL, V302, P701, DOI 10.1006/jmbi.2000.4049; FORTI G, 1966, BROOKHAVEN SYM BIOL, P195; Genzor CG, 1996, PROTEIN SCI, V5, P1376, DOI 10.1002/pro.5560050716; Glatter O., 1982, SMALL ANGLE XRAY SCA; GOTO Y, 1990, BIOCHEMISTRY-US, V29, P3480, DOI 10.1021/bi00466a009; GOTO Y, 1990, P NATL ACAD SCI USA, V87, P573, DOI 10.1073/pnas.87.2.573; HAMADA D, 1993, BIOCHEMISTRY-US, V32, P10351, DOI 10.1021/bi00090a010; HASE T, 1991, PLANT PHYSIOL, V97, P1395, DOI 10.1104/pp.97.4.1395; Hopfner KP, 1998, P NATL ACAD SCI USA, V95, P9813, DOI 10.1073/pnas.95.17.9813; HUGHSON FM, 1990, SCIENCE, V249, P1544, DOI 10.1126/science.2218495; Jackson SE, 1998, FOLD DES, V3, pR81, DOI 10.1016/S1359-0278(98)00033-9; Jaenicke R, 1998, CURR OPIN STRUC BIOL, V8, P738, DOI 10.1016/S0959-440X(98)80094-8; Kataoka M, 1996, FOLD DES, V1, pR107, DOI 10.1016/S1359-0278(96)00047-8; KATAOKA M, 1995, J MOL BIOL, V249, P215, DOI 10.1006/jmbi.1995.0290; Kojima M, 2000, BIOCHEMISTRY-US, V39, P1364, DOI 10.1021/bi991584o; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Kurisu G, 2001, NAT STRUCT BIOL, V8, P117, DOI 10.1038/84097; Lang D, 2000, SCIENCE, V289, P1546, DOI 10.1126/science.289.5484.1546; Matsumura T, 1997, PLANT PHYSIOL, V114, P653, DOI 10.1104/pp.114.2.653; Mayr EM, 1997, J MOL BIOL, V269, P260, DOI 10.1006/jmbi.1997.1033; OHGUSHI M, 1983, FEBS LETT, V164, P21, DOI 10.1016/0014-5793(83)80010-6; Onda Y, 2000, PLANT PHYSIOL, V123, P1037, DOI 10.1104/pp.123.3.1037; Pace C N, 1986, Methods Enzymol, V131, P266; Peng ZY, 2000, ADV PROTEIN CHEM, V53, P1; Phillip S, 1998, EUR J BIOCHEM, V251, P854, DOI 10.1046/j.1432-1327.1998.2510854.x; PORTER TD, 1986, BIOCHEMISTRY-US, V25, P1682, DOI 10.1021/bi00355a036; Privalov PL, 1996, J MOL BIOL, V258, P707, DOI 10.1006/jmbi.1996.0280; RADFORD SE, 1992, NATURE, V358, P302, DOI 10.1038/358302a0; Roder H, 1997, CURR OPIN STRUC BIOL, V7, P15, DOI 10.1016/S0959-440X(97)80004-8; SREERAMA N, 1994, BIOCHEMISTRY-US, V33, P10022, DOI 10.1021/bi00199a028; Steensma E, 1998, J MOL BIOL, V282, P653, DOI 10.1006/jmbi.1998.2045; SVERGUN DI, 1988, ACTA CRYSTALLOGR A, V44, P244, DOI 10.1107/S0108767387011255; Vallon O, 2000, PROTEINS, V38, P95, DOI 10.1002/(SICI)1097-0134(20000101)38:1<95::AID-PROT10>3.0.CO;2-A; ZANETTI G, 1982, EUR J BIOCHEM, V126, P453, DOI 10.1111/j.1432-1033.1982.tb06801.x; Zitzewitz JA, 1999, BIOCHEMISTRY-US, V38, P10205, DOI 10.1021/bi9909041	46	16	16	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 10	2002	277	19					17101	17107		10.1074/jbc.M112002200	http://dx.doi.org/10.1074/jbc.M112002200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	551MB	11872744	hybrid, Green Published			2022-12-27	WOS:000175564500101
J	Chern, MK; Chang, KN; Liu, LF; Tam, TCS; Liu, YC; Liang, YL; Tam, MF				Chern, MK; Chang, KN; Liu, LF; Tam, TCS; Liu, YC; Liang, YL; Tam, MF			Yeast ribosomal protein L12 is a substrate of protein-arginine methyltransferase 2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; N-METHYLTRANSFERASE; METHYLATION; IDENTIFICATION; BINDING; PRMT1; RNA; OLIGOMERIZATION; INTERACTS; RECEPTOR	Type III protein-arginine methyltransferase from the yeast Saccharomyces cerevisiae (RMT2) was expressed in Escherichia coli and purified to apparent homogeneity. The cytosolic, ribosomal, and ribosome salt wash fractions from yeast cells lacking RMT2 were used as substrates for the recombinant RMT2. Using S-adenosyl-L-methionine as co-substrate, RMT2 methylated a protein in the ribosome salt wash fraction. The same protein in the ribosomal fraction was also methylated by RMT2 after pretreating the sample with endonuclease. Amino acid analysis affirmed that the labeling products were delta-N-monomethylarginines. The methylated protein from the ribosomal or the ribosome salt wash fraction was isolated by two-dimensional gel electrophoresis and identified as ribosomal protein L12 by mass spectrometry. Using synthetic peptides, recombinant L12, and its mutant as substrates, we pinpointed Arg(67) on ribosomal protein L12 as the methyl acceptor. L12 was isolated from wild type yeast cells that have been grown in the presence of S-adenosyl-L-[methyl-H-3]methionine and subjected to amino acid analysis. The results indicate that L12 contains delta-N-monomethylarginines.	Acad Sinica, Inst Mol Biol, Taipei 11529, Taiwan	Academia Sinica - Taiwan	Tam, MF (corresponding author), Acad Sinica, Inst Mol Biol, Taipei 11529, Taiwan.	mbr405@ccvax.sinica.edu.tw	Liang, Yi-Ling/F-8770-2012	Liang, Yi-Ling/0000-0001-9173-0145				Abramovich C, 1997, EMBO J, V16, P260, DOI 10.1093/emboj/16.2.260; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chen DG, 1999, SCIENCE, V284, P2174, DOI 10.1126/science.284.5423.2174; ELBARADI TTAL, 1984, EUR J BIOCHEM, V144, P393, DOI 10.1111/j.1432-1033.1984.tb08477.x; Frankel A, 1999, BIOCHEM BIOPH RES CO, V259, P391, DOI 10.1006/bbrc.1999.0779; Gary JD, 1998, PROG NUCLEIC ACID RE, V61, P65, DOI 10.1016/S0079-6603(08)60825-9; Henry MF, 1996, MOL CELL BIOL, V16, P3668; HILL WE, 1969, J MOL BIOL, V44, P89, DOI 10.1016/0022-2836(69)90406-9; Hwang DDW, 1999, BIOCHEM J, V338, P335, DOI 10.1042/0264-6021:3380335; JUANVIDALES F, 1983, EUR J BIOCHEM, V136, P275, DOI 10.1111/j.1432-1033.1983.tb07738.x; Klein S, 2000, J BIOL CHEM, V275, P3150, DOI 10.1074/jbc.275.5.3150; KRUISWIJK T, 1978, BIOCHEM J, V175, P221, DOI 10.1042/bj1750221; Kzhyshkowska J, 2001, BIOCHEM J, V358, P305, DOI 10.1042/0264-6021:3580305; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Landry F, 2000, ANAL BIOCHEM, V279, P1, DOI 10.1006/abio.1999.4468; Lee JH, 2000, BIOCHEM BIOPH RES CO, V274, P105, DOI 10.1006/bbrc.2000.3049; LHOEST J, 1984, EUR J BIOCHEM, V141, P585, DOI 10.1111/j.1432-1033.1984.tb08233.x; Li G, 1997, ELECTROPHORESIS, V18, P391, DOI 10.1002/elps.1150180313; Lin WJ, 1996, J BIOL CHEM, V271, P15034, DOI 10.1074/jbc.271.25.15034; LIU LF, 1993, BIOCHEM J, V296, P189, DOI 10.1042/bj2960189; Mager WH, 1997, NUCLEIC ACIDS RES, V25, P4872, DOI 10.1093/nar/25.24.4872; Mowen KA, 2001, CELL, V104, P731, DOI 10.1016/S0092-8674(02)08085-6; NAJBAUER J, 1993, J BIOL CHEM, V268, P10501; Niewmierzycka A, 1999, J BIOL CHEM, V274, P814, DOI 10.1074/jbc.274.2.814; Perkins DN, 1999, ELECTROPHORESIS, V20, P3551, DOI 10.1002/(SICI)1522-2683(19991201)20:18<3551::AID-ELPS3551>3.0.CO;2-2; Pollack BP, 1999, J BIOL CHEM, V274, P31531, DOI 10.1074/jbc.274.44.31531; PUCCIARELLI MG, 1990, NUCLEIC ACIDS RES, V18, P4409, DOI 10.1093/nar/18.15.4409; RAUE HA, 1991, METHOD ENZYMOL, V194, P453; Rho J, 2001, J BIOL CHEM, V276, P11393, DOI 10.1074/jbc.M008660200; Schurter BT, 2001, BIOCHEMISTRY-US, V40, P5747, DOI 10.1021/bi002631b; Scott HS, 1998, GENOMICS, V48, P330, DOI 10.1006/geno.1997.5190; Smith JJ, 1999, J BIOL CHEM, V274, P13229, DOI 10.1074/jbc.274.19.13229; Strahl BD, 2001, CURR BIOL, V11, P996, DOI 10.1016/S0960-9822(01)00294-9; Tang J, 1998, J BIOL CHEM, V273, P16935, DOI 10.1074/jbc.273.27.16935; Tang J, 2000, J BIOL CHEM, V275, P7723, DOI 10.1074/jbc.275.11.7723; THOMPSON J, 1979, EUR J BIOCHEM, V98, P261, DOI 10.1111/j.1432-1033.1979.tb13184.x; VIDALES FJ, 1981, BIOCHEM BIOPH RES CO, V98, P717; Weiss VH, 2000, NAT STRUCT BIOL, V7, P1165; Wimberly BT, 1999, CELL, V97, P491, DOI 10.1016/S0092-8674(00)80759-X; YEH HI, 1995, BIOCHEM J, V308, P69, DOI 10.1042/bj3080069; Zobel-Thropp P, 1998, J BIOL CHEM, V273, P29283, DOI 10.1074/jbc.273.45.29283	41	44	49	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 3	2002	277	18					15345	15353		10.1074/jbc.M111379200	http://dx.doi.org/10.1074/jbc.M111379200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	550PA	11856739	hybrid			2022-12-27	WOS:000175510400018
J	Eriksson, M; Leppa, S				Eriksson, M; Leppa, S			Mitogen-activated protein kinases and activator protein 1 are required for proliferation and cardiomyocyte differentiation of P19 embryonal carcinoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR MEF2C; SKELETAL-MUSCLE DIFFERENTIATION; SIGNAL-REGULATED KINASE; HEART TUBE FORMATION; C-JUN EXPRESSION; VENTRAL MORPHOGENESIS; CARDIAC MYOCYTES; STRESS-RESPONSE; MAP KINASES; P38	Mitogen-activated protein kinases (MAPKs) have been implicated as regulators of differentiation. The biological effect of MAPK signaling in the nucleus is achieved by signal-responsive transcription factors. Here we have investigated MAPK signaling and activation of AP-1 transcription factors in P19 embryonal carcinoma cells undergoing cardiomyocyte differentiation. We show that aggregation and Me,SO treatment, which trigger the differentiation response, result in sustained activation of JNK1, p38, and ERK1/2 MAPKs and acquisition of AP-1 DNA binding activity. The induced AP-1 activity consists of c-Jun, JunD, and Fra-2 proteins and is accompanied with the increased expression of these proteins. JNK is involved in c-Jun phoshorylation, whereas ERK and p38 activities are essential for maximal c-Jun and Fra-2 expression, and AP-1 DNA binding activity. While the inhibition of ERK can partially prevent the formation of beating cardiomyocytes, the activity of p38 is absolutely required for the differentiation. Expression of dominant negative c-Jun(bZIP) in P19 cells can also inhibit the differentiation response. Surprisingly, however, expression of dominant negative SEK or JNK causes an inhibition of P19 cell proliferation. Taken together, the results show that ERK, JNK, p38, and AP-1 are activated in a coordinated and sustained manner, and contribute to proliferation and cardiomyocyte differentiation of P19 cells.	Univ Helsinki, Biomedicum Helsinki, Mol Canc Biol Res Program, FIN-00014 Helsinki, Finland; Univ Helsinki, Cent Hosp, Dept Oncol, FIN-00029 Huch, Finland	University of Helsinki; University of Helsinki; Helsinki University Central Hospital	Leppa, S (corresponding author), Univ Helsinki, Biomedicum Helsinki, Mol Canc Biol Res Program, POB 63, FIN-00014 Helsinki, Finland.			Leppa, Sirpa/0000-0002-8265-511X				Alonso G, 2000, J BIOL CHEM, V275, P40641, DOI 10.1074/jbc.M007835200; ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; Bakiri L, 2000, EMBO J, V19, P2056, DOI 10.1093/emboj/19.9.2056; BENGAL E, 1992, CELL, V68, P507, DOI 10.1016/0092-8674(92)90187-H; Bennett AM, 1997, SCIENCE, V278, P1288, DOI 10.1126/science.278.5341.1288; Biben C, 1997, GENE DEV, V11, P1357, DOI 10.1101/gad.11.11.1357; BISHOPRIC NH, 1992, J BIOL CHEM, V267, P25535; Chalaux E, 1998, J BIOL CHEM, V273, P537, DOI 10.1074/jbc.273.1.537; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; CHIU R, 1989, CELL, V59, P979, DOI 10.1016/0092-8674(89)90754-X; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Clarke N, 1998, MOL CELL BIOL, V18, P1065, DOI 10.1128/MCB.18.2.1065; Cuenda A, 1999, J BIOL CHEM, V274, P4341, DOI 10.1074/jbc.274.7.4341; Davidson SM, 2000, DEV BIOL, V218, P146, DOI 10.1006/dbio.1999.9596; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; DEGROOT RP, 1990, EMBO J, V9, P1831, DOI 10.1002/j.1460-2075.1990.tb08308.x; DENG TL, 1993, GENE DEV, V7, P479, DOI 10.1101/gad.7.3.479; Eferl R, 1999, J CELL BIOL, V145, P1049, DOI 10.1083/jcb.145.5.1049; Fritz G, 1999, MOL CELL BIOL, V19, P1768; Grepin C, 1997, DEVELOPMENT, V124, P2387; GRUDA MC, 1994, ONCOGENE, V9, P2537; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; Han J, 1997, NATURE, V386, P296, DOI 10.1038/386296a0; HAN TH, 1995, MOL CELL BIOL, V15, P2907; Hazzalin CA, 1996, CURR BIOL, V6, P1028, DOI 10.1016/S0960-9822(02)00649-8; Jochum W, 2001, ONCOGENE, V20, P2401, DOI 10.1038/sj.onc.1204389; Kato Y, 1997, EMBO J, V16, P7054, DOI 10.1093/emboj/16.23.7054; KovacicMilivojevic B, 1996, ENDOCRINOLOGY, V137, P1108, DOI 10.1210/en.137.3.1108; Kuo CT, 1997, GENE DEV, V11, P1048, DOI 10.1101/gad.11.8.1048; Leppa S, 1999, ONCOGENE, V18, P6158, DOI 10.1038/sj.onc.1203173; Leppa S, 1998, EMBO J, V17, P4404, DOI 10.1093/emboj/17.15.4404; Leppa S, 2001, MOL CELL BIOL, V21, P4369, DOI 10.1128/MCB.21.13.4369-4378.2001; Li BY, 1999, EMBO J, V18, P420, DOI 10.1093/emboj/18.2.420; LI L, 1992, GENE DEV, V6, P676, DOI 10.1101/gad.6.4.676; Lin Q, 1997, SCIENCE, V276, P1404, DOI 10.1126/science.276.5317.1404; LORD KA, 1993, MOL CELL BIOL, V13, P841, DOI 10.1128/MCB.13.2.841; LYONS I, 1995, GENE DEV, V9, P1654, DOI 10.1101/gad.9.13.1654; MacLellan WR, 2000, ANNU REV PHYSIOL, V62, P289, DOI 10.1146/annurev.physiol.62.1.289; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MCBURNEY MW, 1982, NATURE, V299, P165, DOI 10.1038/299165a0; Molkentin JD, 1997, GENE DEV, V11, P1061, DOI 10.1101/gad.11.8.1061; Monzen K, 1999, MOL CELL BIOL, V19, P7096; Monzen K, 2001, J CELL BIOL, V153, P687, DOI 10.1083/jcb.153.4.687; Murakami M, 1999, CELL GROWTH DIFFER, V10, P333; Murakami M, 1997, ONCOGENE, V14, P2435, DOI 10.1038/sj.onc.1201077; Nebreda AR, 2000, TRENDS BIOCHEM SCI, V25, P257, DOI 10.1016/S0968-0004(00)01595-4; Nicol RL, 2001, EMBO J, V20, P2757, DOI 10.1093/emboj/20.11.2757; OKAZAKI K, 1995, EMBO J, V14, P5048, DOI 10.1002/j.1460-2075.1995.tb00187.x; Paradis P, 1996, J BIOL CHEM, V271, P10827, DOI 10.1074/jbc.271.18.10827; Sadoshima J, 1997, ANNU REV PHYSIOL, V59, P551, DOI 10.1146/annurev.physiol.59.1.551; SCHUTTE J, 1989, CELL, V59, P987, DOI 10.1016/0092-8674(89)90755-1; Shaulian E, 2001, ONCOGENE, V20, P2390, DOI 10.1038/sj.onc.1204383; SHENG M, 1990, NEURON, V4, P477, DOI 10.1016/0896-6273(90)90106-P; Skerjanc IS, 1998, J BIOL CHEM, V273, P34904, DOI 10.1074/jbc.273.52.34904; SZABO E, 1994, CELL GROWTH DIFFER, V5, P439; Szabowski A, 2000, CELL, V103, P745, DOI 10.1016/S0092-8674(00)00178-1; Treinies I, 1999, MOL CELL BIOL, V19, P321; van Dam H, 2001, ONCOGENE, V20, P2453, DOI 10.1038/sj.onc.1204239; VANDAM H, 1993, EMBO J, V12, P479, DOI 10.1002/j.1460-2075.1993.tb05680.x; VANDAM H, 1995, EMBO J, V14, P1798, DOI 10.1002/j.1460-2075.1995.tb07168.x; Whitmarsh AJ, 1996, J MOL MED-JMM, V74, P589, DOI 10.1007/s001090050063; Wu ZG, 2000, MOL CELL BIOL, V20, P3951, DOI 10.1128/MCB.20.11.3951-3964.2000; Xing J, 1998, MOL CELL BIOL, V18, P1946, DOI 10.1128/MCB.18.4.1946; Zetser A, 1999, J BIOL CHEM, V274, P5193, DOI 10.1074/jbc.274.8.5193	65	66	69	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 3	2002	277	18					15992	16001		10.1074/jbc.M107340200	http://dx.doi.org/10.1074/jbc.M107340200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	550PA	11884386	hybrid			2022-12-27	WOS:000175510400104
J	Hu, B; Senkler, C; Yang, A; Soto, F; Liang, BT				Hu, B; Senkler, C; Yang, A; Soto, F; Liang, BT			P2X(4) receptor is a glycosylated cardiac receptor mediating a positive inotropic response to ATP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-LINKED GLYCOSYLATION; EXPRESSION	Although P2X receptors are suggested to play a role in synaptic neurotransmission, the specific physiological role of each P2X receptor subtype remains largely unknown. We used cultured chick embryo ventricular myocytes as a model to study a potential physiological role of the P2X(4) receptor in mediating the positive inotropic effect of ATP. The chick P2X(4) receptor (cP2X(4)R) mRNA was expressed in the heart and the pharmacological features of the ATP-induced positive inotropic response were similar to those of the cP2X(4)R in terms of insensitivity to blockade by known P2 receptor antagonists and the ineffectiveness of adenosine 5'-(alpha,beta-methylene)triphosphate as an agonist. Treatment of myocytes with antisense oligonucleotides specific to the 5' region of cP2X(4)R abrogated the P2 agonist-stimulated Ca-45 influx. Similarly, antisense oligonucleotide treatment also blocked the 2-methylthio-ATP-stimulated increase in contractile amplitude. The data suggest that the native P2X(4) receptor is involved in mediating the P2 agonist-stimulated response in the heart. In characterizing the biochemical property of the P2X(4) receptor, antibody against cP2X(4)R detected a 44-kDa and a 58-kDa protein in the immunoblot. Inhibition of N-linked glycosylation by tunicamycin converted the 58-kDa protein to the 44-kDa protein, suggesting that the 58-kDa protein was a glycosylated P2X(4) receptor. The nonglycosylated 44-kDa P2X(4) receptor was resistant to various detergent/aqueous extraction, consistent with a role of glycosylation in maintaining its detergent solubility and hydrophilicity. Cross-linking the cell surface proteins with N-hydroxysuccinimide-SS-biotin followed by affinity precipitation with streptavidin-conjugated agarose and subsequent immunoblotting with anti-cP2X(4)R showed that only the glycosylated 58-kDa P2X(4) receptor was expressed on the cell surface, indicating an important role of glycosylation for the receptor's localization on the plasma membrane. These data revealed a novel physiologic function of the P2X(4) receptor and suggested the importance of N-linked glycosylation in its cell surface expression and detergent solubility.	Univ Penn, Dept Med, Philadelphia, PA 19104 USA; Univ Penn, Dept Pharmacol, Philadelphia, PA 19104 USA; Max Planck Inst Expt Med, Abt 300, D-37075 Gottingen, Germany	University of Pennsylvania; University of Pennsylvania; Max Planck Society	Liang, BT (corresponding author), Univ Penn, Med Ctr, Rm 956,BRBII-III,421 Curie Blvd, Philadelphia, PA 19104 USA.	Liangb@mail.med.upenn.edu			NHLBI NIH HHS [R01 HL48225] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL048225] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bisello A, 1996, BIOCHEMISTRY-US, V35, P15890, DOI 10.1021/bi962111+; Girnita L, 2000, ANTI-CANCER DRUG DES, V15, P67; Hu B, 2001, FASEB J, V15, P2739, DOI 10.1096/fj.01-0445fje; Khakh BS, 2001, PHARMACOL REV, V53, P107; Kim M, 1997, BIOCHEM BIOPH RES CO, V240, P618, DOI 10.1006/bbrc.1997.7713; Le KT, 1998, NEUROSCIENCE, V83, P177, DOI 10.1016/S0306-4522(97)00365-5; Mulryan K, 2000, NATURE, V403, P86, DOI 10.1038/47495; Newbolt A, 1998, J BIOL CHEM, V273, P15177, DOI 10.1074/jbc.273.24.15177; Nicke A, 1998, EMBO J, V17, P3016, DOI 10.1093/emboj/17.11.3016; PODRASKY E, 1997, AM J PHYSIOL-HEART C, V273, pH2380; Ralevic V, 1998, PHARMACOL REV, V50, P413; Rettinger J, 2000, J BIOL CHEM, V275, P33542, DOI 10.1074/jbc.M002918200; Rubio ME, 2001, J NEUROSCI, V21, P641, DOI 10.1523/JNEUROSCI.21-02-00641.2001; Ruppelt A, 1999, PROG BRAIN RES, V120, P81; Soto F, 1997, J MEMBRANE BIOL, V160, P91, DOI 10.1007/s002329900298; Souslova V, 2000, NATURE, V407, P1015, DOI 10.1038/35039526; Stoop R, 1999, MOL PHARMACOL, V56, P973, DOI 10.1124/mol.56.5.973; TORDAI A, 1995, BIOCHEM BIOPH RES CO, V206, P857, DOI 10.1006/bbrc.1995.1122; Torres GE, 1998, BIOCHEMISTRY-US, V37, P14845, DOI 10.1021/bi981209g; Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040; XU H, 1992, NUCLEIC ACIDS RES, V20, P6425, DOI 10.1093/nar/20.23.6425	21	39	40	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 3	2002	277	18					15752	15757		10.1074/jbc.M112097200	http://dx.doi.org/10.1074/jbc.M112097200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	550PA	11864978	hybrid			2022-12-27	WOS:000175510400072
J	Lowe, JD; Celver, JP; Gurevich, VV; Chavkin, C				Lowe, JD; Celver, JP; Gurevich, VV; Chavkin, C			mu-Opioid receptors desensitize less rapidly than delta-opioid receptors due to less efficient activation of arrestin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; BETA-ARRESTIN; VISUAL ARRESTIN; CONSTITUTIVE ACTIVITY; MORPHINE-TOLERANCE; CRYSTAL-STRUCTURE; BINDING; PHOSPHORYLATION; INTERNALIZATION; RESENSITIZATION	Receptor desensitization by G-protein receptor kinases (GRK) and arrestins is likely to be an important component underlying the development of tolerance to opioid drugs. Reconstitution of this process in Xenopus oocytes revealed distinct differences in the kinetics of GRK and arrestin regulation of the closely related opioid receptors mu (MOR), delta (DOR), and kappa (KOR). We demonstrated that under identical conditions, GRK and arrestin-dependent desensitization of MOR proceeds dramatically slower than that of DOR. Furthermore, GRK3 phosphorylation sites required for opioid receptor desensitization also greatly differ. The determinants for DOR and KOR desensitization reside in the carboxyl-terminal tail, whereas MOR depends on Thr-180 in the second intracellular loop. Although this later finding might indicate an inefficient phosphorylation of MOR Thr-180, increasing the amount of arrestin expressed greatly increased the rate of MOR desensitization to a rate comparable with that of DOR. Similarly, coexpression of a constitutively active arrestin 2(R169E) with MOR and DOR desensitized both receptors in an agonist-dependent, GRK-independent manner at rates that were indistinguishable. Together, these data suggest that it is the activation of arrestin, rather than its binding, that is the rate-limiting step in MOR desensitization. In addition, mutation of Thr-161 in DOR, homologous to MOR Thr-180, significantly inhibited the faster desensitization of DOR. These results suggest that DOR desensitization involves phosphorylation of both the carboxyl-terminal tail and the second intracellular loop that together leads to a more efficient activation of arrestin and thus faster desensitization.	Univ Washington, Dept Pharmacol, Seattle, WA 98195 USA; Vanderbilt Univ, Dept Pharmacol, Nashville, TN 37232 USA	University of Washington; University of Washington Seattle; Vanderbilt University	Chavkin, C (corresponding author), Univ Washington, Dept Pharmacol, Box 357280, Seattle, WA 98195 USA.	cchavkin@u.washington.edu	Chavkin, Charles/G-2797-2010; Gurevich, Vsevolod/A-3236-2008	Gurevich, Vsevolod/0000-0002-3950-5351	NATIONAL EYE INSTITUTE [R01EY011500] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM063097] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA011672, R37DA011672, T32DA007278] Funding Source: NIH RePORTER; NEI NIH HHS [EY11500] Funding Source: Medline; NIDA NIH HHS [R37 DA011672, DA11672, DA07278] Funding Source: Medline; NIGMS NIH HHS [GM63097] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bhatnagar A, 2001, J BIOL CHEM, V276, P8269, DOI 10.1074/jbc.M006968200; Bohn LM, 2000, NATURE, V408, P720, DOI 10.1038/35047086; Bohn LM, 1999, SCIENCE, V286, P2495, DOI 10.1126/science.286.5449.2495; Cahill CM, 2001, J NEUROSCI, V21, P7598, DOI 10.1523/JNEUROSCI.21-19-07598.2001; Celver JP, 2001, J BIOL CHEM, V276, P4894, DOI 10.1074/jbc.M007437200; Cen B, 2001, MOL PHARMACOL, V59, P758, DOI 10.1124/mol.59.4.758; Chavkin C, 2001, MOL PHARMACOL, V60, P20, DOI 10.1124/mol.60.1.20; Cheng ZJ, 1998, J BIOL CHEM, V273, P24328, DOI 10.1074/jbc.273.38.24328; Daaka Y, 1997, P NATL ACAD SCI USA, V94, P2180, DOI 10.1073/pnas.94.6.2180; DASCAL N, 1993, P NATL ACAD SCI USA, V90, P6596, DOI 10.1073/pnas.90.14.6596; El Kouhen R, 1999, J BIOL CHEM, V274, P9207, DOI 10.1074/jbc.274.14.9207; Ferguson SSG, 2001, PHARMACOL REV, V53, P1; Freedman NJ, 1996, RECENT PROG HORM RES, V51, P319; George SR, 2000, J BIOL CHEM, V275, P26128, DOI 10.1074/jbc.M000345200; Gomes I, 2000, J NEUROSCI, V20, part. no., DOI 10.1523/JNEUROSCI.20-22-j0007.2000; Gray JA, 2001, MOL PHARMACOL, V60, P1020, DOI 10.1124/mol.60.5.1020; GUREVICH VV, 1993, J BIOL CHEM, V268, P11628; GUREVICH VV, 1995, J BIOL CHEM, V270, P6010, DOI 10.1074/jbc.270.11.6010; Hall RA, 1999, J CELL BIOL, V145, P927, DOI 10.1083/jcb.145.5.927; Han M, 2001, STRUCTURE, V9, P869, DOI 10.1016/S0969-2126(01)00644-X; Hirsch JA, 1999, CELL, V97, P257, DOI 10.1016/S0092-8674(00)80735-7; Jin WZ, 1999, J NEUROSCI, V19, P3773; Kieffer BL, 1999, TRENDS PHARMACOL SCI, V20, P19, DOI 10.1016/S0165-6147(98)01279-6; Kovoor A, 1999, J BIOL CHEM, V274, P6831, DOI 10.1074/jbc.274.11.6831; KOVOOR A, 1995, J BIOL CHEM, V270, P589, DOI 10.1074/jbc.270.2.589; Kovoor A, 1997, J BIOL CHEM, V272, P27605, DOI 10.1074/jbc.272.44.27605; Law PY, 2000, MOL PHARMACOL, V58, P388, DOI 10.1124/mol.58.2.388; Maestri-El Kouhen O, 2000, J BIOL CHEM, V275, P36659, DOI 10.1074/jbc.M006788200; MANSOUR A, 1995, TRENDS NEUROSCI, V18, P22, DOI 10.1016/0166-2236(95)93946-U; Nakajima Y, 1996, FEBS LETT, V390, P217, DOI 10.1016/0014-5793(96)00661-8; Nestler EJ, 1997, SCIENCE, V278, P58, DOI 10.1126/science.278.5335.58; Noble F, 1996, BRIT J PHARMACOL, V117, P161, DOI 10.1111/j.1476-5381.1996.tb15169.x; Oakley RH, 2001, J BIOL CHEM, V276, P19452, DOI 10.1074/jbc.M101450200; Oakley RH, 2000, J BIOL CHEM, V275, P17201, DOI 10.1074/jbc.M910348199; Pitcher JA, 1998, ANNU REV BIOCHEM, V67, P653, DOI 10.1146/annurev.biochem.67.1.653; STERNEMARR R, 1993, J BIOL CHEM, V268, P15640; Tsao PI, 2000, J BIOL CHEM, V275, P11130, DOI 10.1074/jbc.275.15.11130; Vishnivetskiy SA, 2000, J BIOL CHEM, V275, P41049, DOI 10.1074/jbc.M007159200; Wang H, 2001, J NEUROSCI, V21, P3242, DOI 10.1523/JNEUROSCI.21-09-03242.2001; Wolf R, 1999, MOL PHARMACOL, V55, P263, DOI 10.1124/mol.55.2.263; Zhu YX, 1999, NEURON, V24, P243, DOI 10.1016/S0896-6273(00)80836-3	41	46	47	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 3	2002	277	18					15729	15735		10.1074/jbc.M200612200	http://dx.doi.org/10.1074/jbc.M200612200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	550PA	11861651	hybrid			2022-12-27	WOS:000175510400069
J	Patrick, SM; Turchi, JJ				Patrick, SM; Turchi, JJ			Xeroderma pigmentosum complementation group A protein (XPA) modulates RPA-DNA interactions via enhanced complex stability and inhibition of strand separation activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE EXCISION-REPAIR; CISPLATIN-MODIFIED DNA; DAMAGED DNA; BINDING-PROTEIN; A RPA; MAMMALIAN-CELLS; IN-VITRO; NUCLEASE; RECOGNITION; RECONSTITUTION	Replication protein A (RPA) participates in many cellular functions including DNA replication and nucleotide excision repair. A direct interaction between RPA and the xeroderma pigmentosum group A protein (XPA) facilitates the assembly of a preincision complex during the processing of DNA damage by the nucleotide excision repair pathway. We demonstrate here the formation of a ternary RPA, XPA, and duplex cisplatin-damaged DNA complex as is evident by electrophoretic supershift analysis. The RPA-YPA complex displays modest specificity for damaged versus undamaged duplex DNA, and the RPA-XPA complex displays a greater affinity for binding duplex cisplatin-damaged DNA when compared with the RPA or XPA proteins alone, consistent with previous results. Using DNA denaturation assays, we demonstrate that the role of XPA is in the stabilization of the duplex DNA structure via inhibition of the strand separation activity of RPA. Rapid kinetic analysis indicates that the bimolecular k(on) of the RPA-XPA complex is 2.5-fold faster than RPA alone for binding a duplex cisplatin-damaged DNA. The dissociation rate, k(off), of the RPA-XPA complex is slower than that of the RPA protein alone, suggesting that the XPA protein stabilizes the initial binding of RPA to duplex DNA as well as maintaining the integrity of the duplex DNA. Interestingly, XPA has no effect on the k(on) of RPA for a single-stranded 40-mer DNA.	Wright State Univ, Sch Med, Dept Biochem & Mol Biol, Dayton, OH 45435 USA	University System of Ohio; Wright State University Dayton	Turchi, JJ (corresponding author), Wright State Univ, Sch Med, Dept Biochem & Mol Biol, 3640 Colonel Glenn Highway, Dayton, OH 45435 USA.		Turchi, John J/B-5807-2015	Turchi, John J/0000-0001-5375-2992	NATIONAL CANCER INSTITUTE [R01CA082741] Funding Source: NIH RePORTER; NCI NIH HHS [CA82741] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABOUSSEKHRA A, 1995, CELL, V80, P859, DOI 10.1016/0092-8674(95)90289-9; Batty D, 2000, J MOL BIOL, V300, P275, DOI 10.1006/jmbi.2000.3857; Bessho T, 1997, J BIOL CHEM, V272, P3833, DOI 10.1074/jbc.272.6.3833; Branum ME, 2001, J BIOL CHEM, V276, P25421, DOI 10.1074/jbc.M101032200; Braun KA, 1997, BIOCHEMISTRY-US, V36, P8443, DOI 10.1021/bi970473r; Burns JL, 1996, J BIOL CHEM, V271, P11607, DOI 10.1074/jbc.271.20.11607; CLEAVER JE, 1989, METABOLIC BASIS INHE; COVERLEY D, 1992, NUCLEIC ACIDS RES, V20, P3873, DOI 10.1093/nar/20.15.3873; de Laat WL, 1998, GENE DEV, V12, P2598, DOI 10.1101/gad.12.16.2598; Fujiwara Y, 1999, J BIOL CHEM, V274, P20027, DOI 10.1074/jbc.274.28.20027; GEORGAKI A, 1992, FEBS LETT, V308, P240, DOI 10.1016/0014-5793(92)81283-R; HE ZG, 1995, NATURE, V374, P566, DOI 10.1038/374566a0; Hermanson IL, 2000, PROTEIN EXPRES PURIF, V19, P1, DOI 10.1006/prep.2000.1224; Hermanson-Miller IL, 2002, BIOCHEMISTRY-US, V41, P2402, DOI 10.1021/bi0112863; HUANG JC, 1994, P NATL ACAD SCI USA, V91, P10394, DOI 10.1073/pnas.91.22.10394; Jamieson ER, 2000, BIOCHEMISTRY-US, V39, P8426, DOI 10.1021/bi000342h; Jamieson ER, 1999, J BIOL CHEM, V274, P12346, DOI 10.1074/jbc.274.18.12346; JONES CJ, 1993, BIOCHEMISTRY-US, V32, P12096, DOI 10.1021/bi00096a021; Lao Y, 2000, BIOCHEMISTRY-US, V39, P850, DOI 10.1021/bi991704s; LI L, 1994, P NATL ACAD SCI USA, V91, P5012, DOI 10.1073/pnas.91.11.5012; LI L, 1995, MOL CELL BIOL, V15, P5396; MATSUDA T, 1995, J BIOL CHEM, V270, P4152, DOI 10.1074/jbc.270.8.4152; Matsunaga T, 1996, J BIOL CHEM, V271, P11047, DOI 10.1074/jbc.271.19.11047; Mu D, 1996, J BIOL CHEM, V271, P8285, DOI 10.1074/jbc.271.14.8285; MU D, 1995, J BIOL CHEM, V270, P2415, DOI 10.1074/jbc.270.6.2415; NAGAI A, 1995, BIOCHEM BIOPH RES CO, V211, P960, DOI 10.1006/bbrc.1995.1905; Patrick SM, 1999, J BIOL CHEM, V274, P14972, DOI 10.1074/jbc.274.21.14972; Patrick SM, 1998, BIOCHEMISTRY-US, V37, P8808, DOI 10.1021/bi9730590; Patrick SM, 2001, J BIOL CHEM, V276, P22630, DOI 10.1074/jbc.M010314200; REARDON JT, 1993, J BIOL CHEM, V268, P21301; SANCAR A, 1995, J BIOL CHEM, V270, P15915, DOI 10.1074/jbc.270.27.15915; Sancar A, 1996, ANNU REV BIOCHEM, V65, P43, DOI 10.1146/annurev.bi.65.070196.000355; Sugasawa K, 1998, MOL CELL, V2, P223, DOI 10.1016/S1097-2765(00)80132-X; Treuner K, 1996, J MOL BIOL, V259, P104, DOI 10.1006/jmbi.1996.0305; Volker M, 2001, MOL CELL, V8, P213, DOI 10.1016/S1097-2765(01)00281-7; Wakasugi M, 1999, J BIOL CHEM, V274, P18759, DOI 10.1074/jbc.274.26.18759; Wakasugi M, 1998, P NATL ACAD SCI USA, V95, P6669, DOI 10.1073/pnas.95.12.6669; Wakasugi M, 2002, J BIOL CHEM, V277, P1637, DOI 10.1074/jbc.C100610200; Wakasugi M, 2001, J BIOL CHEM, V276, P15434, DOI 10.1074/jbc.M011177200; Wood RD, 1997, J BIOL CHEM, V272, P23465, DOI 10.1074/jbc.272.38.23465; Wood RD, 1996, ANNU REV BIOCHEM, V65, P135, DOI 10.1146/annurev.bi.65.070196.001031	41	65	69	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 3	2002	277	18					16096	16101		10.1074/jbc.M200816200	http://dx.doi.org/10.1074/jbc.M200816200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	550PA	11859086	hybrid			2022-12-27	WOS:000175510400117
J	Pfeiffer, M; Koch, T; Schroder, H; Laugsch, M; Hollt, V; Schulz, S				Pfeiffer, M; Koch, T; Schroder, H; Laugsch, M; Hollt, V; Schulz, S			Heterodimerization of somatostatin and opioid receptors cross-modulates phosphorylation, internalization, and desensitization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUNCTIONAL GABA(B) RECEPTOR; PROTEIN; ACTIVATION; RAT; OLIGOMERIZATION; DIMERIZATION; ASSEMBLE; SUBTYPES; RESENSITIZATION; IDENTIFICATION	Heterodimerization has been shown to modulate the ligand binding, signaling, and trafficking properties of G protein-coupled receptors. However, to what extent heterodimerization may alter agonist-induced phosphorylation and desensitization of these receptors has not been documented. We have recently shown that heterodimerization of sst(2A) and sst(3) somatostatin receptors results in inactivation of sst(3) receptor function (Pfeiffer, M., Koch, T., Schroder, H., Klutzny, M., Kirscht, S., Kreienkamp, H. J., Hollt, V., and Schulz, S. (2001) J. Biol. Chem. 276,14027-14036). Here we examine dimerization of the sst(2A) somatostatin receptor and the mu-opioid receptor, members of closely related G protein-coupled receptor families. In coimmunoprecipitation studies using differentially epitope-tagged receptors, we provide direct evidence for heterodimerization of sst(2A) and MOR1 in human embryonic kidney 293 cells. Unlike heteromeric assembly of sst(2A) and sst(3), sst(2A)-MOR1 heterodimerization did not substantially alter the ligand binding or coupling properties of these receptors. However, exposure of the sst(2A)-MOR1 heterodimer to the sst(2A)-selective ligand L-779,976 induced phosphorylation, internalization, and desensitization of sst(2A) as well as MOR1. Similarly, exposure of the sst(2A)-MOR1 heterodimer to the mu-selective ligand [D-Ala(2),Me-Phe(4),Gly(5)-ol]enkephalin induced phosphorylation and desensitization of both MOR1 and sst(2A) but not internalization of sst(2A). Cross-phosphorylation and cross-desensitization of the sst(2A)-MOR1 heterodimer were selective; they were neither observed with the sst(2A)-sst(3) heterodimer nor with the endogenously expressed lysophosphatidic acid receptor. Heterodimerization may thus represent a novel regulatory mechanism that could either restrict or enhance phosphorylation and desensitization of G protein-coupled receptors.	Univ Magdeburg, Dept Pharmacol & Toxicol, D-39120 Magdeburg, Germany	Otto von Guericke University	Schulz, S (corresponding author), Univ Magdeburg, Dept Pharmacol & Toxicol, Leipziger Str 44, D-39120 Magdeburg, Germany.		Laugsch, Magdalena/AAH-8170-2021; Schulz, Stefan/A-6928-2017	Schulz, Stefan/0000-0002-5997-8885				AbdAlla S, 2000, NATURE, V407, P94, DOI 10.1038/35024095; Angers S, 2000, P NATL ACAD SCI USA, V97, P3684, DOI 10.1073/pnas.060590697; Bell JR, 1999, MED J AUSTRALIA, V171, P26, DOI 10.5694/j.1326-5377.1999.tb123493.x; Bereiter DA, 1997, NEUROSCIENCE, V77, P863, DOI 10.1016/S0306-4522(96)00541-6; BETOIN F, 1994, J PHARMACOL EXP THER, V269, P7; Bouvier M, 2001, NAT REV NEUROSCI, V2, P274, DOI 10.1038/35067575; Ciruela F, 2001, J BIOL CHEM, V276, P18345, DOI 10.1074/jbc.M006960200; Devi LA, 2001, TRENDS PHARMACOL SCI, V22, P532, DOI 10.1016/S0165-6147(00)01799-5; George SR, 2000, J BIOL CHEM, V275, P26128, DOI 10.1074/jbc.M000345200; Gomes I, 2001, J MOL MED, V79, P226, DOI 10.1007/s001090100219; Gouldson PR, 1998, PROTEIN ENG, V11, P1181, DOI 10.1093/protein/11.12.1181; Hebert TE, 1996, J BIOL CHEM, V271, P16384, DOI 10.1074/jbc.271.27.16384; Hipkin RW, 2000, J BIOL CHEM, V275, P5591, DOI 10.1074/jbc.275.8.5591; Hipkin RW, 1997, J BIOL CHEM, V272, P13869, DOI 10.1074/jbc.272.21.13869; Jones KA, 1998, NATURE, V396, P674, DOI 10.1038/25348; Jordan BA, 1999, NATURE, V399, P697, DOI 10.1038/21441; Jordan BA, 2001, P NATL ACAD SCI USA, V98, P343, DOI 10.1073/pnas.011384898; Kaupmann K, 1998, NATURE, V396, P683, DOI 10.1038/25360; Koch T, 2000, MOL PHARMACOL, V58, P328, DOI 10.1124/mol.58.2.328; Koch T, 2001, J BIOL CHEM, V276, P31408, DOI 10.1074/jbc.M100305200; Koch T, 1998, J BIOL CHEM, V273, P13652, DOI 10.1074/jbc.273.22.13652; Kuner R, 1999, SCIENCE, V283, P74, DOI 10.1126/science.283.5398.74; MAGGIO R, 1993, P NATL ACAD SCI USA, V90, P3103, DOI 10.1073/pnas.90.7.3103; Ng GYK, 1999, J BIOL CHEM, V274, P7607, DOI 10.1074/jbc.274.12.7607; Pfeiffer M, 2001, J BIOL CHEM, V276, P14027, DOI 10.1074/jbc.M006084200; Rocheville M, 2000, SCIENCE, V288, P154, DOI 10.1126/science.288.5463.154; Rocheville M, 2000, J BIOL CHEM, V275, P7862, DOI 10.1074/jbc.275.11.7862; Rohrer SP, 1998, SCIENCE, V282, P737, DOI 10.1126/science.282.5389.737; Schulz S, 1998, EUR J NEUROSCI, V10, P3700, DOI 10.1046/j.1460-9568.1998.00386.x; Schulz S, 1998, NEUROSCIENCE, V82, P613; Tallent M, 1998, NEUROSCIENCE, V85, P873, DOI 10.1016/S0306-4522(97)00675-1; White JH, 1998, NATURE, V396, P679, DOI 10.1038/25354; Yu YK, 1997, J BIOL CHEM, V272, P28869, DOI 10.1074/jbc.272.46.28869; Zhang L, 1996, J BIOL CHEM, V271, P11449, DOI 10.1074/jbc.271.19.11449	34	213	227	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 31	2002	277	22					19762	19772		10.1074/jbc.M110373200	http://dx.doi.org/10.1074/jbc.M110373200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	557EH	11896051	hybrid			2022-12-27	WOS:000175894800069
J	Gorzalczany, Y; Alloul, N; Sigal, N; Weinbaum, C; Pick, E				Gorzalczany, Y; Alloul, N; Sigal, N; Weinbaum, C; Pick, E			A prenylated p67(phox)-Rac1 chimera elicits NADPH-dependent superoxide production by phagocyte membranes in the absence of an activator and of p47(phox) - Conversion of a pagan NADPH oxidase to monotheism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESPIRATORY BURST OXIDASE; CELL-FREE SYSTEM; SODIUM DODECYL-SULFATE; SRC HOMOLOGY-3 DOMAINS; BINDING; FLAVOCYTOCHROME; PROTEIN; RAC1; MECHANISM; COMPONENT	Activation of the superoxide-generating NADPH oxidase of phagocytes is the result of the assembly of a membrane-localized flavocytochrome (cytochrome b(559)) with the cytosolic components p47(phox), p67(phox), and the small GTPase Rac. Activation can be reproduced in an in vitro system in which cytochrome b(559)-containing membranes are mixed with cytosolic components in the presence of an anionic amphiphile. We proposed that the essential event in activation is the interaction between p67(phox) and cytochrome b(559) and that Rac and p47(phox) serve as carriers for p67(phox) to the membrane. When prenylated, Rac can fulfill the carrier function by itself, supporting oxidase activation by p67(phox) in the absence of p47(phox) and amphiphile. We now show that a single chimeric protein, consisting of residues 1-212 of p67(phox) and full-length Rac1 (residues 1-192), prenylated in vitro and exchanged to GTP, becomes a potent oxidase activator in the absence of any other component or stimulus. Oxidase activation by prenylated chimera P67(phox) (1-212)-Rac1 (1-192) is accompanied by its spontaneous association with membranes. Prenylated chimeras p67(phox) (1-212)-Rac1 (178-192) and p67(phox) (1-212)-Rac1 (189-192), containing specific C-terminal regions of Rac1, are inactive; the activity of the first but not of the second chimera can be rescued by supplementation with exogenous nonprenylated Rac1-GTP. An analysis of prenylated p67(phox)-Rac1 chimeras suggests that the basic requirements for oxidase activation are: (i) a "two signals" membrane-localizing motif present in Rac, comprising the prenyl group and a C-terminal polybasic sequence and (ii) an intrachimeric or extrachimeric protein-protein interaction between p67(phox) and Rac1, causing a conformational change in the "activation domain" in p67(phox).	Tel Aviv Univ, Sackler Sch Med, Julius Friedrich Cohnheim Minerva Ctr Phagocyte R, IL-69978 Tel Aviv, Israel; Tel Aviv Univ, Sackler Sch Med, Ela Kodesz Inst Host Def Infect Dis, IL-69978 Tel Aviv, Israel; Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA	Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv University; Sackler Faculty of Medicine; Duke University	Pick, E (corresponding author), Tel Aviv Univ, Sackler Sch Med, Dept Human Microbiol, IL-69978 Tel Aviv, Israel.		Pick, Edgar/B-1795-2008	Pick, Edgar/0000-0003-4625-3233				Ago T, 1999, J BIOL CHEM, V274, P33644, DOI 10.1074/jbc.274.47.33644; Alloul N, 2001, BIOCHEMISTRY-US, V40, P14557, DOI 10.1021/bi0117347; BROMBERG Y, 1984, CELL IMMUNOL, V88, P213, DOI 10.1016/0008-8749(84)90066-2; BROMBERG Y, 1985, J BIOL CHEM, V260, P3539; CASEY PJ, 1991, P NATL ACAD SCI USA, V88, P8631, DOI 10.1073/pnas.88.19.8631; Cross AR, 1999, J BIOL CHEM, V274, P15519, DOI 10.1074/jbc.274.22.15519; Dang PMC, 2001, P NATL ACAD SCI USA, V98, P3001, DOI 10.1073/pnas.061029698; DELEO FR, 1995, P NATL ACAD SCI USA, V92, P7110, DOI 10.1073/pnas.92.15.7110; Di-Poi N, 2001, BIOCHEMISTRY-US, V40, P10014, DOI 10.1021/bi010289c; Diebold BA, 2001, NAT IMMUNOL, V2, P211, DOI 10.1038/85259; Freeman JL, 1996, J BIOL CHEM, V271, P22578, DOI 10.1074/jbc.271.37.22578; Gorzalczany Y, 2000, J BIOL CHEM, V275, P40073, DOI 10.1074/jbc.M006013200; Grizot S, 2001, J BIOL CHEM, V276, P21627, DOI 10.1074/jbc.M100893200; GUTIERREZ L, 1989, EMBO J, V8, P1093, DOI 10.1002/j.1460-2075.1989.tb03478.x; Han CH, 1998, J BIOL CHEM, V273, P16663, DOI 10.1074/jbc.273.27.16663; Huang J, 1999, J BIOL CHEM, V274, P19731, DOI 10.1074/jbc.274.28.19731; KINSELLA BT, 1991, J BIOL CHEM, V266, P9786; Koshkin V, 1996, J BIOL CHEM, V271, P30326, DOI 10.1074/jbc.271.48.30326; Kreck ML, 1996, BIOCHEMISTRY-US, V35, P15683, DOI 10.1021/bi962064l; Lambeth JD, 2000, J BIOCHEM MOL BIOL, V33, P427; Lapouge K, 2000, MOL CELL, V6, P899, DOI 10.1016/S1097-2765(00)00087-3; LETO TL, 1994, P NATL ACAD SCI USA, V91, P10650, DOI 10.1073/pnas.91.22.10650; Leto TL., 1999, INFLAMMATION BASIC P, P769; Mineo C, 1997, J BIOL CHEM, V272, P10345; Miyano K, 2001, BIOCHEMISTRY-US, V40, P14089, DOI 10.1021/bi010882u; Mochizuki N, 2001, NATURE, V411, P1065, DOI 10.1038/35082594; Nauseef WM, 1999, P ASSOC AM PHYSICIAN, V111, P373, DOI 10.1111/paa.1999.111.5.373; Nisimoto Y, 1999, J BIOL CHEM, V274, P22999, DOI 10.1074/jbc.274.33.22999; Nisimoto Y, 1997, J BIOL CHEM, V272, P18834, DOI 10.1074/jbc.272.30.18834; ROTROSEN D, 1992, SCIENCE, V256, P1459, DOI 10.1126/science.1318579; SEGAL AW, 1992, BIOCHEM J, V284, P781, DOI 10.1042/bj2840781; SHPUNGIN S, 1989, J BIOL CHEM, V264, P9195; SUMIMOTO H, 1994, P NATL ACAD SCI USA, V91, P5345, DOI 10.1073/pnas.91.12.5345; Yu LX, 1998, P NATL ACAD SCI USA, V95, P7993, DOI 10.1073/pnas.95.14.7993; ZHANG FL, 1994, J BIOL CHEM, V269, P23465	35	60	62	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 24	2002	277	21					18605	18610		10.1074/jbc.M202114200	http://dx.doi.org/10.1074/jbc.M202114200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	558PM	11896062	hybrid			2022-12-27	WOS:000175975800049
J	Pedersen, LC; Petrotchenko, E; Shevtsov, S; Negishi, M				Pedersen, LC; Petrotchenko, E; Shevtsov, S; Negishi, M			Crystal structure of the human estrogen sulfotransferase-PAPS complex - Evidence for catalytic role of Ser(137) in the sulfuryl transfer reaction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IDENTIFICATION; BINDING; DOMAIN	Estrogen sulfotransferase (EST) transfers the sulfate group from T-phosphoadenosine 5'-phosphosulfate (PAPS) to estrogenic steroids. Here we report the crystal structure of human EST (hEST) in the context of the V269E mutant-PAPS complex, which is the first structure containing the active sulfate donor for any sulfotransferase. Superimposing this structure with the crystal structure of hEST in complex with the donor product 3'-phosphoadenosine 5'-phosphate (PAP) and the acceptor substrate 17beta-estradiol, the ternary structure with the PAPS and estradiol molecule, is modeled. These structures have now provided a more complete view of the S(N)2-like in-line displacement reaction catalyzed by sulfotransferases. In the PAPS-bound structure, the side chain nitrogen of the catalytic Lys(47) interacts with the side chain hydroxyl of Ser(137) and not with the bridging oxygen between the 5'-phosphate and sulfate groups of the PAPS molecule as is seen in the PAP-bound structures. This conformational change of the side chain nitrogen indicates that the interaction of Lys(47) with Ser(137) may regulate PAPS hydrolysis in the absences of an acceptor substrate. Supporting the structural data, the mutations of Ser(137) to cysteine and alanine decrease gradually k(cat) for PAPS hydrolysis and transfer activity. Thus, Ser(137) appears to play an important role in regulating the side chain interaction of Lys(47) with the bridging oxygen between the 5'-phosphate and the sulfate of PAPS.	NIEHS, Pharmacogenet Sect, Reprod & Dev Toxicol Lab, NIH, Res Triangle Pk, NC 27709 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Negishi, M (corresponding author), NIEHS, Pharmacogenet Sect, Reprod & Dev Toxicol Lab, NIH, Res Triangle Pk, NC 27709 USA.	negishi@niehs.nih.gov	Negishi, Masahiko/F-7805-2019; Pedersen, Lars/C-6173-2019	Negishi, Masahiko/0000-0002-2076-8928; Pedersen, Lars/0000-0002-4488-4077	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES071005] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bidwell LM, 1999, J MOL BIOL, V293, P521, DOI 10.1006/jmbi.1999.3153; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Dajani R, 1999, J BIOL CHEM, V274, P37862, DOI 10.1074/jbc.274.53.37862; Duffel MW, 1997, COMPREHENSIVE TOXICO, V3, P365; Falany CN, 1997, FASEB J, V11, P1; Homma H, 1996, BBA-PROTEIN STRUCT M, V1296, P159, DOI 10.1016/0167-4838(96)00065-9; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kakuta Y, 1999, J BIOL CHEM, V274, P10673, DOI 10.1074/jbc.274.16.10673; Kakuta Y, 1998, TRENDS BIOCHEM SCI, V23, P129, DOI 10.1016/S0968-0004(98)01182-7; Kakuta Y, 1997, NAT STRUCT BIOL, V4, P904, DOI 10.1038/nsb1197-904; Kakuta Y, 1998, J BIOL CHEM, V273, P27325, DOI 10.1074/jbc.273.42.27325; Kakuta Y, 1998, BIOCHEM PHARMACOL, V55, P313, DOI 10.1016/S0006-2952(97)00465-6; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LEYH TS, 1993, CRIT REV BIOCHEM MOL, V28, P515, DOI 10.3109/10409239309085137; Marsolais F, 1995, J BIOL CHEM, V270, P30458, DOI 10.1074/jbc.270.51.30458; Marsolais F, 1997, EUR J BIOCHEM, V247, P1056, DOI 10.1111/j.1432-1033.1997.01056.x; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Ong E, 1999, J BIOL CHEM, V274, P25608, DOI 10.1074/jbc.274.36.25608; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pedersen LC, 2000, FEBS LETT, V475, P61, DOI 10.1016/S0014-5793(00)01479-4; Petrotchenko EV, 2001, FEBS LETT, V490, P39, DOI 10.1016/S0014-5793(01)02129-9; Sueyoshi T, 1998, FEBS LETT, V433, P211, DOI 10.1016/S0014-5793(98)00913-2	24	91	97	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 17	2002	277	20					17928	17932		10.1074/jbc.M111651200	http://dx.doi.org/10.1074/jbc.M111651200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	553PR	11884392	hybrid			2022-12-27	WOS:000175685100069
J	Scheibner, KA; De Angelis, J; Burley, SK; Cole, PA				Scheibner, KA; De Angelis, J; Burley, SK; Cole, PA			Investigation of the roles of catalytic residues in serotonin N-acetyltransferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MELATONIN RHYTHM ENZYME; ACTIVE-SITE; HISTONE ACETYLTRANSFERASES; MECHANISM; PROTEIN; NMR; ISOMERASE; BINDING; ANALOGS; SUBUNIT	Serotonin N-acetyltransferase (arylalkylamine N-acetyltransferase (AANAT)) is a critical enzyme in the light-mediated regulation of melatonin production and circadian rhythm. It is a member of the GNAT (GCN-5-related N-acetyltransferase) superfamily of enzymes, which catalyze a diverse array of biologically important acetyl transfer reactions from antibiotic resistance to chromatin remodeling. In this study, we probed the functional properties of two histidines (His-120 and His-122) and a tyrosine (Tyr-168) postulated to be important in the mechanism of AANAT based on prior x-ray structural and biochemical studies. Using a combination of steady-state kinetic measurements of microviscosity effects and pH dependence on the H122Q, H120Q, and H120Q/H122Q AANAT mutants, we show that His-122 (with an apparent pK(a) of 7.3) contributes similar to6-fold to the acetyltransferase chemical step as either a remote catalytic base or hydrogen bond donor. Furthermore, His-120 and His-122 appear to contribute redundantly to this function. By analysis of the Y168F AANAT mutant, it was demonstrated that Tyr-168 contributes similar to150-fold to the acetyltransferase chemical step and is responsible for the basic limb of the pH-rate profile with an apparent (subnormal) pK(a) of 8.5. Paradoxically, Y168F AANAT showed 10-fold enhanced apparent affinity for acetylCoA despite the loss of a hydrogen bond between the Tyr phenol and the CoA sulfur atom. The X-ray crystal structure of Y168F AANAT bound to a bisubstrate analog inhibitor showed no significant structural perturbation of the enzyme compared with the wild-type complex, but revealed the loss of dual inhibitor conformations present in the wild-type complex. Taken together with kinetic measurements, these crystallographic studies allow us to propose the relevant structural conformations related to the distinct alkyltransferase and acetyltransferase reactions catalyzed by AANAT. These findings have significant implications for understanding GNAT catalysis and the design of potent and selective inhibitors.	Johns Hopkins Univ, Sch Med, Dept Pharmacol & Mol Sci, Baltimore, MD 21205 USA; Rockefeller Univ, Howard Hughes Med Inst, Lab Mol Biophys, New York, NY 10021 USA	Johns Hopkins University; Howard Hughes Medical Institute; Rockefeller University	Cole, PA (corresponding author), Johns Hopkins Univ, Sch Med, Dept Pharmacol & Mol Sci, 725 N Wolfe St, Baltimore, MD 21205 USA.	pcole@jhmi.edu		Burley, Stephen K./0000-0002-2487-9713				Arendt J., 1995, MELATONIN MAMMALIAN; Berg J M, 2001, Science, V291, P203; BLACKLOW SC, 1988, BIOCHEMISTRY-US, V27, P1158, DOI 10.1021/bi00404a013; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; COLE PA, 1994, J BIOL CHEM, V269, P30880; COOK PF, 1982, BIOCHEMISTRY-US, V21, P5794, DOI 10.1021/bi00266a011; De Angelis J, 1998, J BIOL CHEM, V273, P3045, DOI 10.1074/jbc.273.5.3045; Dyda F, 2000, ANNU REV BIOPH BIOM, V29, P81, DOI 10.1146/annurev.biophys.29.1.81; Gastel JA, 1998, SCIENCE, V279, P1358, DOI 10.1126/science.279.5355.1358; Hickman AB, 1999, CELL, V97, P361, DOI 10.1016/S0092-8674(00)80745-X; Ibarra C, 2001, BIOCHEMISTRY-US, V40, P10614, DOI 10.1021/bi010672h; JENCKS WP, 1969, CATALYSIS CHEM ENZYM, P463; Khalil EM, 1998, J BIOL CHEM, V273, P30321, DOI 10.1074/jbc.273.46.30321; Khalil EM, 1998, J AM CHEM SOC, V120, P6195, DOI 10.1021/ja981365a; Khalil EM, 1999, P NATL ACAD SCI USA, V96, P12418, DOI 10.1073/pnas.96.22.12418; Klein DC, 1997, RECENT PROG HORM RES, V52, P307; KULIOPULOS A, 1989, BIOCHEMISTRY-US, V28, P149, DOI 10.1021/bi00427a022; Langer MR, 2001, J BIOL CHEM, V276, P31321, DOI 10.1074/jbc.M103839200; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LEWENDON A, 1994, BIOCHEMISTRY-US, V33, P1944, DOI 10.1021/bi00173a043; Marmorstein R, 2001, J MOL BIOL, V311, P433, DOI 10.1006/jmbi.2001.4859; Neuwald AF, 1997, TRENDS BIOCHEM SCI, V22, P154, DOI 10.1016/S0968-0004(97)01034-7; Obsil T, 2001, CELL, V105, P257, DOI 10.1016/S0092-8674(01)00316-6; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PERONA JJ, 1994, BIOCHEMISTRY-US, V33, P3252, DOI 10.1021/bi00177a016; Rojas JR, 1999, NATURE, V401, P93, DOI 10.1038/43487; Schafer SL, 1996, BIOCHEMISTRY-US, V35, P5662, DOI 10.1021/bi960174m; Tanner KG, 1999, J BIOL CHEM, V274, P18157, DOI 10.1074/jbc.274.26.18157; Thompson J, 2001, P NATL ACAD SCI USA, V98, P9002, DOI 10.1073/pnas.151257098; Warshel A, 1998, J BIOL CHEM, V273, P27035, DOI 10.1074/jbc.273.42.27035; Wei YM, 2001, BIOCHEMISTRY-US, V40, P11279, DOI 10.1021/bi011085z; Wilmouth RC, 2001, NAT STRUCT BIOL, V8, P689, DOI 10.1038/90401; Wolf E, 2002, J MOL BIOL, V317, P215, DOI 10.1006/jmbi.2001.5371; Zheng WP, 2001, CHEM BIOL, V8, P379, DOI 10.1016/S1074-5521(01)00020-5	35	56	58	5	24	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 17	2002	277	20					18118	18126		10.1074/jbc.M200595200	http://dx.doi.org/10.1074/jbc.M200595200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	553PR	11884405	hybrid			2022-12-27	WOS:000175685100093
J	Fekete, RA; Frost, LS				Fekete, RA; Frost, LS			Characterizing the DNA contacts and cooperative binding of F plasmid TraM to its cognate sites at oriT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; BACTERIAL CONJUGATION; SEX FACTOR; TRANSFER REGION; TRANSFER ORIGIN; HELICASE-I; PROTEIN; GENE; REPRESSION; EXPRESSION	TraM is a DNA binding protein required for conjugative transfer of the self-transmissible IncF group of plasmids, including F, R1, and R100. F TraM binds to three sites in F oriT. two high affinity binding sites, sbmA and sbmB, which are direct repeats of nearly identical sequence involved in the autoregulation of the traM gene; and a lower affinity site, sbmC, an inverted repeat important for transfer, which is situated nearest to the nic, site where transfer originates. TraM bound cooperatively to its binding sites at oriT; the presence of sbmA and sbmB increased the affinity for sbmC 10-fold. Bending of oriT DNA by TraM was minimal, suggesting that TraM, a tetramer, was able to loop the DNA when bound to sbmA and sbmB simultaneously. Hydroxyl radical footprinting of DNA of sbmA and sbmC revealed that TraM contacted the DNA within a region previously delineated by DNase I footprinting. TraM protected the CT bases within the sequence CTAG, which occurred at 12-base intervals on the top and bottom strand of sbmA, most consistently with other protected bases. The footprint on sbmC revealed that the predicted inverted repeats were protected by TraM with a pattern that began at the center of the repeats and radiated outward at 11-12 base intervals toward the 5'-ends of either strand. At high protein concentrations, this pattern extended beyond the footprint defined by DNase 1, suggesting that the DNA was wrapped around the protein forming a nucleosome-like structure, which could aid in preparing the DNA for transfer.	Univ Alberta, Dept Biol Sci, Edmonton, AB T6G 2E9, Canada	University of Alberta	Frost, LS (corresponding author), Univ Alberta, Dept Biol Sci, CW405 Biol Sci Bldg, Edmonton, AB T6G 2E9, Canada.		Frost, Laura/A-2639-2014	Frost, Laura/0000-0002-8433-8230				ABO T, 1995, J BACTERIOL, V177, P4350, DOI 10.1128/jb.177.15.4350-4355.1995; ACHTMAN M, 1971, J BACTERIOL, V106, P529, DOI 10.1128/JB.106.2.529-538.1971; AUSUBEL FM, 1987, CURRENT PROTOCOLS S; BIRNBOIM HC, 1979, NUCLEIC ACIDS RES, V7, P1513; Cabezon E, 1997, MOL GEN GENET, V254, P400, DOI 10.1007/s004380050432; CAREY J, 1991, METHOD ENZYMOL, V208, P103; CARLSON NG, 1993, J MOL BIOL, V230, P1108, DOI 10.1006/jmbi.1993.1229; Chatterjee J, 1996, MOL MICROBIOL, V20, P415, DOI 10.1111/j.1365-2958.1996.tb02628.x; DILAURENZIO L, 1992, MOL MICROBIOL, V6, P2951; DILAURENZIO L, 1995, MOL GEN GENET, V247, P726, DOI 10.1007/BF00290404; DisqueKochem C, 1997, J BACTERIOL, V179, P6133, DOI 10.1128/jb.179.19.6133-6137.1997; Fekete RA, 2000, J BACTERIOL, V182, P4022, DOI 10.1128/JB.182.14.4022-4027.2000; FREIFELDER D, 1982, PHYSICAL BIOCH APPL; FROST L, 1989, MOL GEN GENET, V218, P152, DOI 10.1007/BF00330578; Frost LS, 1998, MICROBIOL-SGM, V144, P2579, DOI 10.1099/00221287-144-9-2579; FROST LS, 1994, MICROBIOL REV, V58, P162, DOI 10.1128/MMBR.58.2.162-210.1994; FU YHF, 1991, J BACTERIOL, V173, P1012, DOI 10.1128/jb.173.3.1012-1020.1991; KIM J, 1989, GENE, V85, P15, DOI 10.1016/0378-1119(89)90459-9; Kupelwieser G, 1998, J MOL BIOL, V275, P81, DOI 10.1006/jmbi.1997.1436; Matson SW, 2001, J BIOL CHEM, V276, P2372, DOI 10.1074/jbc.M008728200; MATSON SW, 1993, J BACTERIOL, V175, P2599, DOI 10.1128/JB.175.9.2599-2606.1993; NELSON WC, 1995, J BIOL CHEM, V270, P28374; OEHLER S, 1990, EMBO J, V9, P973, DOI 10.1002/j.1460-2075.1990.tb08199.x; Penfold SS, 1996, MOL MICROBIOL, V20, P549, DOI 10.1046/j.1365-2958.1996.5361059.x; PENFOLD SS, 1995, THESIS U ALBERTA; Sambrook J., 2002, MOL CLONING LAB MANU; TSAI MM, 1990, J BACTERIOL, V172, P4603, DOI 10.1128/jb.172.8.4603-4609.1990; WILLETTS N, 1984, MICROBIOL REV, V48, P24, DOI 10.1128/MMBR.48.1.24-41.1984; ZIEGELIN G, 1992, J BIOL CHEM, V267, P17279	29	23	24	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 10	2002	277	19					16705	16711		10.1074/jbc.M111682200	http://dx.doi.org/10.1074/jbc.M111682200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	551MB	11875064	hybrid			2022-12-27	WOS:000175564500049
J	Gonzalez-Guerrico, AM; Cafferata, EG; Radrizzani, M; Marcucci, F; Gruenert, D; Pivetta, OH; Favaloro, RR; Laguens, R; Perrone, SV; Gallo, GC; Santa-Coloma, TA				Gonzalez-Guerrico, AM; Cafferata, EG; Radrizzani, M; Marcucci, F; Gruenert, D; Pivetta, OH; Favaloro, RR; Laguens, R; Perrone, SV; Gallo, GC; Santa-Coloma, TA			Tyrosine kinase c-Src constitutes a bridge between cystic fibrosis transmembrane regulator channel failure and MUC1 overexpression in cystic fibrosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; EPITHELIAL-CELLS; CONDUCTANCE REGULATOR; PSEUDOMONAS-AERUGINOSA; DIFFERENTIAL DISPLAY; MESSENGER-RNA; CHLORIDE CHANNEL; CFTR; ACTIVATION; EXPRESSION	Cystic fibrosis (CF), a disease caused by mutations in the cystic fibrosis transmembrane regulator (CFTR) chloride channel, is associated in the respiratory system with the accumulation of mucus and impaired lung function. The role of the CFTR channel in the regulation of the intracellular pathways that determine the overexpression of mucin genes is unknown. Using differential display, we have observed the differential expression of several mRNAs that may correspond to putative CFTR-dependent genes. One of these mRNAs was further characterized, and it corresponds to the tyrosine kinase c-Src. Additional results suggest that c-Src is a central element in the pathway connecting the CFTR channel with MUC1 overexpression and that the overexpression of mucins is a primary response to CFTR malfunction in cystic fibrosis, which occurs even in the absence of bacterial infection.	Univ Buenos Aires, CONICET, Inst Invest Bioquim, Fdn Campomar, RA-1405 Buenos Aires, DF, Argentina; ANLIS, Ctr Nacl Genet Med, RA-1425 Buenos Aires, DF, Argentina; Univ Vermont, Dept Med, Human Mol Genet Unit, Burlington, VT 05405 USA; Fdn Favaloro, RA-1093 Buenos Aires, DF, Argentina; Hosp Pediat Prof Dr Juan P Garrahan, RA-1425 Buenos Aires, DF, Argentina	Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); Leloir Institute; University of Buenos Aires; University of Vermont; Hospital de Pediatria Doctor Juan Garrahan	Santa-Coloma, TA (corresponding author), Univ Buenos Aires, CONICET, Inst Invest Bioquim, Fdn Campomar, Av Patricias Argentinas 435, RA-1405 Buenos Aires, DF, Argentina.		Santa-Coloma, Tomas/I-1254-2019	Santa-Coloma, Tomas/0000-0002-3266-1095; Cafferata, Eduardo G/0000-0001-5089-3757				Basbaum C, 1999, AM J RESP CRIT CARE, V160, pS44, DOI 10.1164/ajrccm.160.supplement_1.12; Brocardo MG, 2001, BIOCHEM BIOPH RES CO, V284, P982, DOI 10.1006/bbrc.2001.5066; Brown MT, 1996, BBA-REV CANCER, V1287, P121, DOI 10.1016/0304-419X(96)00003-0; Cafferata EG, 1996, CELL MOL BIOL, V42, P797; Cafferata EG, 2000, BBA-MOL BASIS DIS, V1500, P241, DOI 10.1016/S0925-4439(99)00105-2; Cafferata EGA, 2001, J BIOL CHEM, V276, P15441, DOI 10.1074/jbc.M010061200; CHAMBERS JA, 1994, J CELL SCI, V107, P413; CHENG HC, 1992, J BIOL CHEM, V267, P9248; COZENS AL, 1992, P NATL ACAD SCI USA, V89, P5171, DOI 10.1073/pnas.89.11.5171; DAHIYA R, 1995, BIOCHEM MOL BIOL INT, V35, P351; Dehm S, 2001, FEBS LETT, V487, P367, DOI 10.1016/S0014-5793(00)02354-1; Esen M, 2001, INFECT IMMUN, V69, P281, DOI 10.1128/IAI.69.1.281-287.2001; Fischer H, 1996, BIOPHYS J, V71, P3073, DOI 10.1016/S0006-3495(96)79501-2; Hwang TC, 1999, TRENDS PHARMACOL SCI, V20, P448, DOI 10.1016/S0165-6147(99)01386-3; Ito Y, 2000, BIOCHEM BIOPH RES CO, V274, P230, DOI 10.1006/bbrc.2000.3125; Koegl M, 1995, ONCOGENE, V11, P2317; Kunzelmann K, 1996, GENE THER, V3, P859; Lei DC, 1996, GENE THER, V3, P427; Lepple-Wienhues A, 2000, CELL PHYSIOL BIOCHEM, V10, P307, DOI 10.1159/000016363; LEVITZKI A, 1995, SCIENCE, V267, P1782, DOI 10.1126/science.7892601; Li JD, 1998, P NATL ACAD SCI USA, V95, P5718, DOI 10.1073/pnas.95.10.5718; Li YQ, 2001, J BIOL CHEM, V276, P35239, DOI 10.1074/jbc.C100359200; Li YQ, 2001, BIOCHEM BIOPH RES CO, V281, P440, DOI 10.1006/bbrc.2001.4383; Li YQ, 2001, J BIOL CHEM, V276, P6061, DOI 10.1074/jbc.C000754200; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; LIANG P, 1993, NUCLEIC ACIDS RES, V21, P3269, DOI 10.1093/nar/21.14.3269; Lillehoj EP, 2001, AM J PHYSIOL-LUNG C, V280, pL181, DOI 10.1152/ajplung.2001.280.1.L181; Liu XB, 1999, J BIOL CHEM, V274, P25121, DOI 10.1074/jbc.274.35.25121; Mohler PJ, 1999, J CELL BIOL, V147, P879, DOI 10.1083/jcb.147.4.879; Moyer BD, 1999, J CLIN INVEST, V104, P1353, DOI 10.1172/JCI7453; MUKHOPADHYAY D, 1995, NATURE, V375, P577, DOI 10.1038/375577a0; Osika E, 1999, EUR RESPIR J, V14, P339, DOI 10.1034/j.1399-3003.1999.14b17.x; Parmley RR, 1998, J CLIN INVEST, V102, P1798, DOI 10.1172/JCI3820; Pilewski Joseph M., 1999, Physiological Reviews, V79, pS215; RIORDAN JR, 1989, SCIENCE, V245, P1066; RIORDAN JR, 1993, ANNU REV PHYSIOL, V55, P609, DOI 10.1146/annurev.ph.55.030193.003141; SCHUSTER A, 1995, EUR ARCH ORTORHINO S, V1, P59; Shestakova EA, 2001, P NATL ACAD SCI USA, V98, P7045, DOI 10.1073/pnas.121146098; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; Van Seuningen I, 2001, FRONT BIOSCI-LANDMRK, V6, pD1216; vonOlleschikElbheim L, 1996, J IMMUNOL METHODS, V197, P181, DOI 10.1016/0022-1759(96)00150-0; WAGNER JA, 1992, P NATL ACAD SCI USA, V89, P6785, DOI 10.1073/pnas.89.15.6785; Walsh KB, 1999, BRIT J PHARMACOL, V127, P369, DOI 10.1038/sj.bjp.0702562; Zhang ZR, 2000, J MEMBRANE BIOL, V175, P35, DOI 10.1007/s002320001053	44	34	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 10	2002	277	19					17239	17247		10.1074/jbc.M112456200	http://dx.doi.org/10.1074/jbc.M112456200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	551MB	11872746	hybrid			2022-12-27	WOS:000175564500118
J	Aleksandrov, L; Aleksandrov, AA; Chang, XB; Riordan, JR				Aleksandrov, L; Aleksandrov, AA; Chang, XB; Riordan, JR			The first nucleotide binding domain of cystic fibrosis transmembrane conductance regulator is a site of stable nucleotide interaction, whereas the second is a site of rapid turnover	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CFTR CHLORIDE CHANNEL; PROTEIN-KINASE-A; ATP-BINDING; SULFONYLUREA RECEPTOR; ABC TRANSPORTERS; P-GLYCOPROTEIN; WILD-TYPE; FOLD; SUBUNIT; PHOSPHORYLATION	As in other adenine nucleotide binding cassette (ABC) proteins the nucleotide binding domains of the cystic fibrosis transmembrane conductance regulator (CFTR) bind and hydrolyze ATP and in some manner regulate CFTR ion channel gating. Unlike some other ABC proteins, however, there are preliminary indications that the two domains of CFTR are nonequivalent in their nucleotide interactions (Szabo, K., Szakacs, G., Hegeds, T., and Sarkadi, B. (1999) J. Biol. Chem. 274,12209-12212; Aleksandrov, L., Mengos, A., Chang, X., Aleksandrov, A., and Riordan, J. R. (2001) J. Biol. Chem. 276, 1291812923). We have now characterized the interactions of the 8-azido-photoactive analogues of ATP, ADP, and 5'-adenyl-beta,gamma-imidodiphosphate (AMP-PNP) with the two domains of functional membrane-bound CFTR. The results show that the two domains appear to act independently in the binding and hydrolysis of 8-azido-ATP. At NBD1 binding does not require a divalent cation. This binding is followed by minimal Mg2+-dependent hydrolysis and retention of the hydrolysis product, 8-azido-ADP, but not as a vanadate stabilized post-hydrolysis transition state complex. In contrast, at NBD2, MgN(3)ATP is hydrolyzed as rapidly as it is bound and the nucleoside diphosphate hydrolysis product dissociates immediately. Confirming this characterization of NBD1 as a site of more stable nucleotide interaction and NBD2 as a site of fast turnover, the non-hydrolyzable N(3)AMP-PNP bound preferentially to NBD1. This demonstration of NBD2 as the rapid nucleotide turnover site is consistent with the strong effect on channel gating kinetics of inactivation of this domain by mutagenesis.	Mayo Fdn & Mayo Clin Scottsdale, SC Johnson Med Res Ctr, Scottsdale, AZ 85259 USA	Mayo Clinic; Mayo Clinic Phoenix; SC Johnson & Son	Riordan, JR (corresponding author), Mayo Clin Scottsdale, SC Johnson Med Res Ctr, 13400 E Shea Blvd, Scottsdale, AZ 85259 USA.	riordan@mayo.edu			NIDDK NIH HHS [DK51619] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK051619] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aleksandrov AA, 2000, J PHYSIOL-LONDON, V528, P259, DOI 10.1111/j.1469-7793.2000.00259.x; Aleksandrov L, 2001, J BIOL CHEM, V276, P12918, DOI 10.1074/jbc.M100515200; Ambudkar SV, 1999, ANNU REV PHARMACOL, V39, P361, DOI 10.1146/annurev.pharmtox.39.1.361; Chang XB, 1997, J BIOL CHEM, V272, P30962, DOI 10.1074/jbc.272.49.30962; CHANG XB, 1993, J BIOL CHEM, V268, P11304; Dean M, 2001, GENOME RES, V11, P1156, DOI 10.1101/gr.GR-1649R; Diederichs K, 2000, EMBO J, V19, P5951, DOI 10.1093/emboj/19.22.5951; Duffieux F, 2000, EUR J BIOCHEM, V267, P5306, DOI 10.1046/j.1432-1327.2000.01614.x; ECKSTEIN F, 1985, ANNU REV BIOCHEM, V54, P367, DOI 10.1146/annurev.bi.54.070185.002055; Gadsby D. C., 1999, PHYSIOL REV, V79, pS77; Gao M, 2000, J BIOL CHEM, V275, P13098, DOI 10.1074/jbc.275.17.13098; HARTMAN J, 1992, J BIOL CHEM, V267, P6455; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; Holland IB, 1999, J MOL BIOL, V293, P381, DOI 10.1006/jmbi.1999.2993; Hopfner KP, 2000, CELL, V101, P789, DOI 10.1016/S0092-8674(00)80890-9; Hou YX, 2000, J BIOL CHEM, V275, P20280, DOI 10.1074/jbc.M001109200; Hou YX, 2002, J BIOL CHEM, V277, P5110, DOI 10.1074/jbc.M107133200; Howell LD, 2000, BIOCHEM BIOPH RES CO, V271, P518, DOI 10.1006/bbrc.2000.2659; Hrycyna CA, 1999, BIOCHEMISTRY-US, V38, P13887, DOI 10.1021/bi991115m; Ikuma M, 2000, P NATL ACAD SCI USA, V97, P8675, DOI 10.1073/pnas.140220597; Jones PM, 1999, FEMS MICROBIOL LETT, V179, P187, DOI 10.1111/j.1574-6968.1999.tb08727.x; KARTNER N, 1992, NAT GENET, V1, P321, DOI 10.1038/ng0892-321; KO YH, 1993, J BIOL CHEM, V268, P24330; KO YH, 1995, J BIOL CHEM, V270, P22093, DOI 10.1074/jbc.270.38.22093; Li CH, 1996, J BIOL CHEM, V271, P28463, DOI 10.1074/jbc.271.45.28463; Lu NT, 2000, ARCH BIOCHEM BIOPHYS, V375, P7, DOI 10.1006/abbi.1999.1656; Matsuo M, 2000, J BIOL CHEM, V275, P28757, DOI 10.1074/jbc.M004818200; Matsuo M, 1999, J BIOL CHEM, V274, P37479, DOI 10.1074/jbc.274.52.37479; Nagata K, 2000, J BIOL CHEM, V275, P17626, DOI 10.1074/jbc.M000792200; Neville DCA, 1998, BIOCHEMISTRY-US, V37, P2401, DOI 10.1021/bi972021k; Qu BH, 1996, J BIOL CHEM, V271, P7261, DOI 10.1074/jbc.271.13.7261; Randak C, 1997, FEBS LETT, V410, P180, DOI 10.1016/S0014-5793(97)00574-7; Rosenberg MF, 2001, EMBO J, V20, P5615, DOI 10.1093/emboj/20.20.5615; Saurin W, 1999, J MOL EVOL, V48, P22, DOI 10.1007/PL00006442; Schultz BD, 1996, J MEMBRANE BIOL, V151, P63, DOI 10.1007/s002329900058; Seibert FS, 1999, BBA-BIOMEMBRANES, V1461, P275, DOI 10.1016/S0005-2736(99)00163-7; Senior AE, 1995, FEBS LETT, V377, P285, DOI 10.1016/0014-5793(95)01345-8; Sheppard DN, 1999, PHYSIOL REV, V79, P23; Szabo K, 1999, J BIOL CHEM, V274, P12209, DOI 10.1074/jbc.274.18.12209; Ueda K, 1997, J BIOL CHEM, V272, P22983, DOI 10.1074/jbc.272.37.22983; Yike I, 1996, PROTEIN SCI, V5, P89; Zingman LV, 2002, J BIOL CHEM, V277, P14206, DOI 10.1074/jbc.M109452200; Zou XQ, 2001, BIOCHEMISTRY-US, V40, P5579, DOI 10.1021/bi010133c	43	152	154	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 3	2002	277	18					15419	15425		10.1074/jbc.M111713200	http://dx.doi.org/10.1074/jbc.M111713200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	550PA	11861646	hybrid			2022-12-27	WOS:000175510400027
J	Kawaguchi, M; Onuchic, LF; Huang, SK				Kawaguchi, M; Onuchic, LF; Huang, SK			Activation of extracellular signal-regulated kinase (ERK)1/2, but not p38 and c-Jun N-terminal kinase, is involved in signaling of a novel cytokine, ML-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BRONCHIAL EPITHELIAL-CELLS; PROTEIN-KINASE; ENDOTHELIAL-CELLS; INDUCED EXPRESSION; MAP KINASE; IN-VITRO; RANTES; IDENTIFICATION; INTERLEUKIN-8; INHIBITOR	A novel cytokine, ML-1, was recently discovered, which shares a similar sequence homology with, but is functionally distinct from, IL-17 (Kawaguchi, M Onuchic, L., Li, X. D., Essayan, D. M., Schroeder, J., Xiao H. Q., Liu, M. C., Krishnaswamy, G., Germino, G., Q Huang, S. K. (2001) J. Immunol. 167, 4430-4435). To determine the signaling mechanisms of ML-1, we investigated activation of mitogen-activated protein (MAP) kinases induced by ML-1. Results show that ML-1 induces in a time-dependent fashion the expression of IL-6 and IL-8 in both primary bronchial epithelial cells (PBECs) and human umbilical vein endothelial cells (HUVECs). ML-1 activated a MAP kinase and an extracellular signal-regulated kinase (ERK)1/2 but not p38 or the c-Juu N-terminal kinase (JNK) in both cell types. Selective MAP kinase kinase (MEK)1/2 inhibitors, PD98059 and U0126, inhibited, in a dose-dependent manner, ML-1-induced expression of IL-6 and IL-8. These findings suggest that ML-1-induced IL-6 and IL-8 production is mediated through the activation of ERK1/2 in both cell types.	Johns Hopkins Asthma & Allergy Ctr, Div Clin Immunol, Baltimore, MD 21224 USA; Johns Hopkins Univ, Dept Med, Div Nephrol, Baltimore, MD 21224 USA; Johns Hopkins Univ, Sch Med, Baltimore, MD 21224 USA; Univ Sao Paulo, Sch Med, Div Nephrol, BR-01246903 Sao Paulo, Brazil	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins University; Universidade de Sao Paulo	Huang, SK (corresponding author), Johns Hopkins Asthma & Allergy Ctr, Div Clin Immunol, 5501 Bayview Circle, Baltimore, MD 21224 USA.	skhuang@mail.jhmi.edu	Huang, Shau-Ku/F-5509-2010; Onuchic, Luiz Fernando/H-1589-2012	Onuchic, Luiz Fernando/0000-0002-4053-5419	NIAID NIH HHS [AI-34002, AI-40274] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI040274, R29AI034002] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Chayama K, 2001, P NATL ACAD SCI USA, V98, P4599, DOI 10.1073/pnas.081021898; Chen CC, 1996, CYTOKINE, V8, P58, DOI 10.1006/cyto.1995.0008; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Goebeler M, 1999, BLOOD, V93, P857, DOI 10.1182/blood.V93.3.857.403k03_857_865; Griego SD, 2000, J IMMUNOL, V165, P5211, DOI 10.4049/jimmunol.165.9.5211; Hashimoto S, 2000, CLIN EXP ALLERGY, V30, P48; Hashimoto S, 2000, AM J RESP CRIT CARE, V161, P280, DOI 10.1164/ajrccm.161.1.9904110; Hymowitz SG, 2001, EMBO J, V20, P5332, DOI 10.1093/emboj/20.19.5332; Kampen GT, 2000, BLOOD, V95, P1911, DOI 10.1182/blood.V95.6.1911; Kawaguchi M, 2001, J ALLERGY CLIN IMMUN, V108, P804, DOI 10.1067/mai.2001.119027; Kawaguchi M, 2001, J IMMUNOL, V167, P4430, DOI 10.4049/jimmunol.167.8.4430; Kujime K, 2000, J IMMUNOL, V164, P3222, DOI 10.4049/jimmunol.164.6.3222; KWON OJ, 1994, AM J PHYSIOL-LUNG C, V267, pL398, DOI 10.1152/ajplung.1994.267.4.L398; Lee J, 2001, J BIOL CHEM, V276, P1660, DOI 10.1074/jbc.M008289200; Li HZ, 2000, P NATL ACAD SCI USA, V97, P773, DOI 10.1073/pnas.97.2.773; Matsukura S, 1996, J ALLERGY CLIN IMMUN, V98, P1080, DOI 10.1016/S0091-6749(96)80195-3; May MJ, 1998, AM J PHYSIOL-CELL PH, V274, pC789, DOI 10.1152/ajpcell.1998.274.3.C789; Reibman J, 2000, J IMMUNOL, V165, P1618, DOI 10.4049/jimmunol.165.3.1618; Shi YG, 2000, J BIOL CHEM, V275, P19167, DOI 10.1074/jbc.M910228199; Starnes T, 2001, J IMMUNOL, V167, P4137, DOI 10.4049/jimmunol.167.8.4137; Steerenberg PA, 1998, EXP LUNG RES, V24, P85, DOI 10.3109/01902149809046056; Surapisitchat J, 2001, P NATL ACAD SCI USA, V98, P6476, DOI 10.1073/pnas.101134098; YOO ZB, 1995, J IMMUNOL, V155, P5483	24	36	39	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 3	2002	277	18					15229	15232		10.1074/jbc.C100641200	http://dx.doi.org/10.1074/jbc.C100641200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	550PA	11891214	hybrid			2022-12-27	WOS:000175510400003
J	Potente, M; Michaelis, UR; Fisslthaler, B; Busse, R; Fleming, I				Potente, M; Michaelis, UR; Fisslthaler, B; Busse, R; Fleming, I			Cytochrome P4502C9-induced endothelial cell proliferation involves induction of mitogen-activated protein (MAP) kinase phosphatase-1, inhibition of the c-Jun N-terminal kinase, and up-regulation of cyclin D1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARTERIAL SMOOTH-MUSCLE; ARACHIDONIC-ACID; 11,12-EPOXYEICOSATRIENOIC ACID; EPOXYEICOSATRIENOIC ACIDS; SIGNALING PATHWAYS; CORONARY-ARTERIES; GROWTH-FACTOR; TYROSINE PHOSPHORYLATION; NH2-TERMINAL KINASE; BINDING PROTEIN	Cytochrome P450 (CYP)-derived epoxyeicosatrienoic acids (EETs) are important modulators of endothelial cell homeostasis. We investigated the signaling pathway linking the activation of CYP 2C9 to enhanced endothelial. cell proliferation. Overexpression of CYP 2C9 in cultured human endothelial cells markedly increased proliferation. This effect was paralleled by an up-regulation of the G, phase regulatory protein, cyclin D1. The specific CYP 2C9 inhibitor, sulfaphenazole, prevented both the enhanced cell proliferation and up-regulation of cyclin D1. CYP 2C9 overexpression also decreased the activity of the c-Jun N-terminal kinase (JNK). Coexpression of wild type JNK with CYP 2C9 attenuated the CYP 2C9-induced increase in cyclin D1 expression and abolished the CYP 2C9-induced proliferation response. In contrast, cotransfecting dominant negative JNK with CYP 2C9 restored the CYP 2C9-mediated up-regulation of cyclin D1 and proliferation. The inactivation of JNK is linked to its dephosphorylation by dual specificity mitogen-activated protein (MAP) kinase phosphatases (MKPs). Overexpression of CYP 2C9 significantly increased the expression of MKP-1, as did incubation with 11, 12-EET. These data demonstrate that the mitogenic effect of CYP 2C9 is due to the generation of EETs, which promote the MKP-1-mediated dephosphorylation and inactivation of JNK, effects ultimately culminating in the expression of cyclin D1 and endothelial cell proliferation.	Univ Frankfurt Klinikum, Inst Kardiovasc Physiol, D-60590 Frankfurt, Germany	Goethe University Frankfurt; Goethe University Frankfurt Hospital	Fleming, I (corresponding author), Univ Frankfurt Klinikum, Inst Kardiovasc Physiol, Theodor Stern Kai 7, D-60590 Frankfurt, Germany.		Fleming, Ingrid/AAB-6123-2022; Fleming, Ingrid/L-1225-2014	Fleming, Ingrid/0000-0003-1881-3635; Fleming, Ingrid/0000-0003-1881-3635; Potente, Michael/0000-0002-5689-0036				BAAS AS, 1995, CIRC RES, V77, P29, DOI 10.1161/01.RES.77.1.29; Campbell W B, 2001, Med Sci Monit, V7, P578; Campbell WB, 1996, CIRC RES, V78, P415, DOI 10.1161/01.RES.78.3.415; Chen JK, 1999, J BIOL CHEM, V274, P4764, DOI 10.1074/jbc.274.8.4764; Chen JK, 2001, MOL CELL BIOL, V21, P6322, DOI 10.1128/MCB.21.18.6322-6331.2001; Chen JK, 1998, J BIOL CHEM, V273, P29254, DOI 10.1074/jbc.273.44.29254; Cheng MG, 1999, EMBO J, V18, P1571, DOI 10.1093/emboj/18.6.1571; Cook SJ, 2000, BIOCHEM SOC T, V28, P233, DOI 10.1042/bst0280233; DAIKH BE, 1994, J PHARMACOL EXP THER, V271, P1427; Desbois-Mouthon C, 2000, ENDOCRINOLOGY, V141, P922, DOI 10.1210/en.141.3.922; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; Ekholm SV, 2000, CURR OPIN CELL BIOL, V12, P676, DOI 10.1016/S0955-0674(00)00151-4; Fisslthaler B, 2000, HYPERTENSION, V36, P270, DOI 10.1161/01.HYP.36.2.270; Fisslthaler B, 1999, NATURE, V401, P493, DOI 10.1038/46816; Fisslthaler B, 2001, HYPERTENSION, V38, P1427, DOI 10.1161/hy1201.096532; Fleming I, 1996, J BIOL CHEM, V271, P11009, DOI 10.1074/jbc.271.18.11009; Fleming I, 2001, PFLUG ARCH EUR J PHY, V442, P511, DOI 10.1007/s004240100565; Fleming I, 2001, CIRC RES, V88, P44, DOI 10.1161/01.RES.88.1.44; Fleming I, 2001, CIRC RES, V89, P753, DOI 10.1161/hh2101.099268; Hirsch DD, 1997, J BIOL CHEM, V272, P4568, DOI 10.1074/jbc.272.7.4568; Hoebel BG, 1998, EUR J PHARMACOL, V346, P115, DOI 10.1016/S0014-2999(98)00118-6; Hofken T, 2000, BIOCHEM BIOPH RES CO, V276, P680, DOI 10.1006/bbrc.2000.3530; Imig JD, 1999, HYPERTENSION, V33, P408, DOI 10.1161/01.HYP.33.1.408; Irani K, 2000, CIRC RES, V87, P179, DOI 10.1161/01.RES.87.3.179; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; Li PL, 1997, HYPERTENSION, V29, P262, DOI 10.1161/01.HYP.29.1.262; Li PL, 1999, CIRC RES, V85, P349, DOI 10.1161/01.RES.85.4.349; Li PL, 1997, CIRC RES, V80, P877; LIN JHC, 1996, ENDOTHELIUM, V4, P219; Lin SY, 2001, NAT CELL BIOL, V3, P802, DOI 10.1038/ncb0901-802; Mancy A, 1996, BIOCHEMISTRY-US, V35, P16205, DOI 10.1021/bi961950t; Muthalif MM, 2001, PROSTAG OTH LIPID M, V65, P33, DOI 10.1016/S0090-6980(01)00112-5; Node K, 1999, SCIENCE, V285, P1276, DOI 10.1126/science.285.5431.1276; Oktay M, 1999, J CELL BIOL, V145, P1461, DOI 10.1083/jcb.145.7.1461; Pedram A, 2001, ENDOCRINOLOGY, V142, P1578, DOI 10.1210/en.142.4.1578; Pedram A, 1998, J BIOL CHEM, V273, P26722, DOI 10.1074/jbc.273.41.26722; Rossig L, 2002, J BIOL CHEM, V277, P9684, DOI 10.1074/jbc.M106157200; Ruiz-Gines JA, 2000, J CARDIOVASC PHARM, V35, P109, DOI 10.1097/00005344-200001000-00014; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Tournier C, 1997, EUR J BIOCHEM, V244, P587, DOI 10.1111/j.1432-1033.1997.00587.x; Wilkinson MG, 2000, FASEB J, V14, P2147, DOI 10.1096/fj.00-0102rev; Wong PYK, 2000, PROSTAG OTH LIPID M, V62, P321, DOI 10.1016/S0090-6980(00)00079-4	42	98	101	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 3	2002	277	18					15671	15676		10.1074/jbc.M110806200	http://dx.doi.org/10.1074/jbc.M110806200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	550PA	11867622	hybrid			2022-12-27	WOS:000175510400062
J	Terentis, AC; Thomas, SR; Takikawa, O; Littlejohn, TK; Truscott, RJW; Armstrong, RS; Yeh, SR; Stocker, R				Terentis, AC; Thomas, SR; Takikawa, O; Littlejohn, TK; Truscott, RJW; Armstrong, RS; Yeh, SR; Stocker, R			The heme environment of recombinant human indoleamine 2,3-dioxygenase - Structural properties and substrate-ligand interactions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESONANCE RAMAN-SPECTRA; HORSERADISH-PEROXIDASE; EFFECTOR INTERACTIONS; TRYPTOPHAN BINDING; SUPEROXIDE ANION; CAVITY STRUCTURE; AXIAL LIGAND; MYOGLOBIN; ENZYME; OXYGEN	Indoleamine 2,3-dioxygenase is a heme enzyme that catalyzes the oxidative degradation of L-Trp and other indoleamines. We have used resonance Raman spectroscopy to characterize the heme environment of purified recombinant human indoleamine 2,3-dioxygenase (hIDO). In the absence of L-Trp, the spectrum of the Fe3+ form displayed six-coordinate, mixed high and low spin character. Addition of L-Trp triggered a transition to predominantly low spin with two Fe-OH- stretching modes identified at 546 and 496 cm(-1), suggesting H-bonding between the NH group of the pyrrole ring of L-Trp and heme-bound OH-. The distal pocket of Fe3+ hIDO was explored further by an exogenous heme ligand, CN-; again, binding of L-Trp introduced strong H-bonding and/or steric interactions to the heme-bound CN-. On the other hand, the spectrum of Fe2+ hIDO revealed a five-coordinate and high spin heme with or without L-Trp bound. The proximal Fe-His stretching mode, identified at 236 cm(-1), did not shift Upon L-Trp addition, indicating that the proximal Fe-His bond strength is not affected by binding of the substrate. The high Fe-His stretching frequency suggests that Fe2+ hIDO has a strong "peroxidase-like" Fe-His bond. Using CO as a structural probe for the distal environment of Fe2+ hIDO revealed that binding of L-Trp in the distal pocket converted IDO to a peroxidase-like enzyme. Binding of L-Trp also caused conformational changes to the heme vinyl groups, which were independent of changes of the spin and coordination state of the heme iron. Together these data indicate that the strong proximal Fe-His bond and the strong H-bonding and/or steric interactions between L-Trp and dioxygen in the distal pocket are likely crucial for the enzymatic activity of hIDO.	Heart Res Inst, Biochem Grp, Camperdown, NSW 2050, Australia; Hokkaido Univ, Dept Pharmacol, Sapporo, Hokkaido 0608638, Japan; Univ Wollongong, Australian Cataract Res Fdn, Wollongong, NSW 2522, Australia; Univ Sydney, Sch Chem, Sydney, NSW 2006, Australia; Yeshiva Univ Albert Einstein Coll Med, Dept Physiol & Biophys, Bronx, NY 10461 USA	University of Sydney; Heart Research Institute; Hokkaido University; University of Wollongong; University of Sydney; Yeshiva University; Albert Einstein College of Medicine	Stocker, R (corresponding author), Univ New S Wales, Ctr Thrombosis & Vasc Biol, Sydney, NSW 2052, Australia.	r.stocker@unsw.edu.au	Terentis, Andrew/N-9188-2019; Stocker, Roland/AAV-4489-2021	Terentis, Andrew/0000-0001-6137-8275; Stutchbury, Tamantha/0000-0001-9308-4562; Yeh, Syun-Ru/0000-0002-9858-386X	NHLBI NIH HHS [HL65465] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL065465] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALMUSTAFA J, 1995, J BIOL CHEM, V270, P10449, DOI 10.1074/jbc.270.18.10449; ALMUSTAFA J, 1994, BIOCHEMISTRY-US, V33, P2191, DOI 10.1021/bi00174a028; CADY SG, 1991, ARCH BIOCHEM BIOPHYS, V291, P326, DOI 10.1016/0003-9861(91)90142-6; DASGUPTA S, 1989, J BIOL CHEM, V264, P654; DAWSON JH, 1988, SCIENCE, V240, P433, DOI 10.1126/science.3358128; Feis A, 1998, BIOCHEMISTRY-US, V37, P13575, DOI 10.1021/bi981399v; FEIS A, 1994, BIOCHEMISTRY-US, V33, P4577, DOI 10.1021/bi00181a019; Franzen S, 1998, J AM CHEM SOC, V120, P4658, DOI 10.1021/ja973212d; HAYAISHI O, 1977, J BIOL CHEM, V252, P3548; HAYAISHI O, 1985, BIKEN J, V28, P39; HIRATA F, 1977, J BIOL CHEM, V252, P4637; Hirota S, 1996, J PHYS CHEM-US, V100, P15274, DOI 10.1021/jp953190m; Hu SZ, 1996, J AM CHEM SOC, V118, P12638, DOI 10.1021/ja962239e; LI TS, 1994, BIOCHEMISTRY-US, V33, P1433, DOI 10.1021/bi00172a021; LI XY, 1990, J PHYS CHEM-US, V94, P47, DOI 10.1021/j100364a008; Littlejohn TK, 2000, PROTEIN EXPRES PURIF, V19, P22, DOI 10.1006/prep.2000.1214; NAKAGAWA M, 1977, P NATL ACAD SCI USA, V74, P4730, DOI 10.1073/pnas.74.11.4730; OHNISHI T, 1977, J BIOL CHEM, V252, P4643; Smulevich G, 1998, BIOSPECTROSCOPY, V4, pS3, DOI 10.1002/(SICI)1520-6343(1998)4:5+<S3::AID-BSPY2>3.0.CO;2-R; Smulevich G., 1993, BIOMOLECULAR SPECT A, P163; SONO M, 1980, J BIOL CHEM, V255, P1339; SONO M, 1989, BIOCHEMISTRY-US, V28, P5400, DOI 10.1021/bi00439a013; SONO M, 1989, BIOCHEMISTRY-US, V28, P5392, DOI 10.1021/bi00439a012; SONO M, 1990, BIOCHEMISTRY-US, V29, P1451, DOI 10.1021/bi00458a016; SONO M, 1989, J BIOL CHEM, V264, P1616; SONO M, 1984, BIOCHIM BIOPHYS ACTA, V789, P170, DOI 10.1016/0167-4838(84)90202-4; Southan MD, 1996, MED CHEM RES, V6, P343; Spiro, 1988, BIOL APPL RAMAN SPEC, P1; SUZUKI T, 1992, J MOL BIOL, V228, P698, DOI 10.1016/0022-2836(92)90854-D; Suzuki T, 1998, J PROTEIN CHEM, V17, P817, DOI 10.1023/A:1020782403070; Suzuki T, 1998, COMP BIOCHEM PHYS B, V121, P117, DOI 10.1016/S0305-0491(98)10086-X; TANIGUCHI T, 1979, J BIOL CHEM, V254, P3288; Thomas SR, 1999, REDOX REP, V4, P199, DOI 10.1179/135100099101534927; TONE S, 1990, NUCLEIC ACIDS RES, V18, P367, DOI 10.1093/nar/18.2.367; UCHIDA K, 1985, J BIOL CHEM, V260, P1400; Vogel KM, 2000, INORG CHIM ACTA, V297, P11, DOI 10.1016/S0020-1693(99)00253-4; Wang J., 1996, METHODS NITRIC OXIDE, P427; WITKOP B, 1951, J AM CHEM SOC, V73, P2196, DOI 10.1021/ja01149a080; Yeh SR, 2000, J BIOL CHEM, V275, P1679, DOI 10.1074/jbc.275.3.1679; YOSHIDA R, 1987, METHOD ENZYMOL, V142, P188; Yu N.-T., 1988, BIOL APPLICATIONS RA, V3, P39	41	85	87	1	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 3	2002	277	18					15788	15794		10.1074/jbc.M200457200	http://dx.doi.org/10.1074/jbc.M200457200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	550PA	11867636	hybrid			2022-12-27	WOS:000175510400077
J	Tomer, G; Buermeyer, AB; Nguyen, MM; Liskay, RM				Tomer, G; Buermeyer, AB; Nguyen, MM; Liskay, RM			Contribution of human M1h1 and Pms2 ATPase activities to DNA mismatch repair	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL NUCLEAR ANTIGEN; MUTL; PCNA; HETERODIMER; EXONUCLEASE; HYDROLYSIS; MECHANISM; INTERACTS; PROTEINS; GENE	MutLalpha, a heterodimer composed of Mlh1 and Pms2, is the major MutL activity in mammalian DNA mismatch repair. Highly conserved motifs in the N termini of both subunits predict that the protein is an ATPase. To study the significance of these motifs to mismatch repair, we have expressed in insect cells wild type human MutLa and forms altered in conserved glutamic acid residues, predicted to catalyze ATP hydrolysis of Mlh1, Pms2, or both. Using an in vitro assay, we showed that MutLa proteins altered in either glutamic acid residue were each partially defective in mismatch repair, whereas the double mutant showed no detectable mismatch repair. Neither strand specificity nor directionality of repair was affected in the single mutant proteins. Limited proteolysis studies of MutLa demonstrated that both Mlh1 and Pms2 N-terminal domains undergo ATP-induced conformational changes, but the extent of the conformational change for Mlh1 was more apparent than for Pms2. Furthermore, Mlh1 was protected at lower ATP concentrations than Pms2, suggesting Mlh1 binds ATP with higher affinity. These findings imply that ATP hydrolysis is required for MutLa activity in mismatch repair and that this activity is associated with differential conformational changes in Mlh1 and Pms2.	Oregon Hlth & Sci Univ, Dept Mol & Med Genet, Portland, OR 97201 USA; Oregon State Univ, Dept Environm & Mol Toxicol, Corvallis, OR 97331 USA	Oregon Health & Science University; Oregon State University	Liskay, RM (corresponding author), Oregon Hlth & Sci Univ, Dept Mol & Med Genet, L103,3181 SW Sam Jackson Pk Rd, Portland, OR 97201 USA.	liskaym@ohsu.edu	Buermeyer, Andrew/AAW-4099-2020	Buermeyer, Andrew/0000-0003-4502-4666	NIGMS NIH HHS [GM45413, GM 7R01, R37 GM32741] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM032741, R01GM045413] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aronshtam A, 1996, NUCLEIC ACIDS RES, V24, P2498, DOI 10.1093/nar/24.13.2498; Baker SM, 1996, NAT GENET, V13, P336, DOI 10.1038/ng0796-336; BAKER SM, 1995, CELL, V82, P309, DOI 10.1016/0092-8674(95)90318-6; Ban C, 1998, CELL, V95, P541, DOI 10.1016/S0092-8674(00)81621-9; Ban C, 1999, CELL, V97, P85, DOI 10.1016/S0092-8674(00)80717-5; Blackwell LJ, 2001, J BIOL CHEM, V276, P33233, DOI 10.1074/jbc.M105076200; Bowers J, 2001, J MOL BIOL, V306, P957, DOI 10.1006/jmbi.2001.4467; Brino L, 2000, J BIOL CHEM, V275, P9468, DOI 10.1074/jbc.275.13.9468; Buermeyer AB, 1999, CANCER RES, V59, P538; Buermeyer AB, 1999, ANNU REV GENET, V33, P533, DOI 10.1146/annurev.genet.33.1.533; Burdett V, 2001, P NATL ACAD SCI USA, V98, P6765, DOI 10.1073/pnas.121183298; Clark AB, 2000, J BIOL CHEM, V275, P36498, DOI 10.1074/jbc.C000513200; COOPER DL, 1993, J BIOL CHEM, V268, P11823; DRUMMOND JT, 1995, SCIENCE, V268, P1909, DOI 10.1126/science.7604264; Dutta R, 2000, TRENDS BIOCHEM SCI, V25, P24, DOI 10.1016/S0968-0004(99)01503-0; FANG WH, 1993, J BIOL CHEM, V268, P11838; Flores-Rozas H, 2000, NAT GENET, V26, P375, DOI 10.1038/81708; Grenert JP, 1999, J BIOL CHEM, V274, P17525, DOI 10.1074/jbc.274.25.17525; Gu LY, 1998, NUCLEIC ACIDS RES, V26, P1173, DOI 10.1093/nar/26.5.1173; Guarne A, 2001, EMBO J, V20, P5521, DOI 10.1093/emboj/20.19.5521; Guerrette S, 1999, J BIOL CHEM, V274, P6336, DOI 10.1074/jbc.274.10.6336; Hall MC, 1999, J BIOL CHEM, V274, P1306, DOI 10.1074/jbc.274.3.1306; Hall MC, 2002, J BIOL CHEM, V277, P3673, DOI 10.1074/jbc.M106120200; HOLMES J, 1990, P NATL ACAD SCI USA, V87, P5837, DOI 10.1073/pnas.87.15.5837; Hubbard SJ, 1998, BBA-PROTEIN STRUCT M, V1382, P191, DOI 10.1016/S0167-4838(97)00175-1; JACKSON AP, 1993, P NATL ACAD SCI USA, V90, P11232, DOI 10.1073/pnas.90.23.11232; Jiricny J, 1998, EMBO J, V17, P6427, DOI 10.1093/emboj/17.22.6427; Johnson RE, 1996, J BIOL CHEM, V271, P27987, DOI 10.1074/jbc.271.45.27987; Kampranis SC, 1998, J BIOL CHEM, V273, P26305, DOI 10.1074/jbc.273.41.26305; Kleczkowska HE, 2001, GENE DEV, V15, P724, DOI 10.1101/gad.191201; Kolodner RD, 1999, CURR OPIN GENET DEV, V9, P89, DOI 10.1016/S0959-437X(99)80013-6; LAHUE RS, 1989, SCIENCE, V245, P160, DOI 10.1126/science.2665076; LI GM, 1995, P NATL ACAD SCI USA, V92, P1950, DOI 10.1073/pnas.92.6.1950; Marra G, 2001, CANCER RES, V61, P7719; Mechanic LE, 2000, J BIOL CHEM, V275, P38337, DOI 10.1074/jbc.M006268200; Nicolaides NC, 1998, MOL CELL BIOL, V18, P1635, DOI 10.1128/MCB.18.3.1635; Peltomaki P, 2001, MUTAT RES-REV MUTAT, V488, P77, DOI 10.1016/S1383-5742(00)00058-2; Prodromou C, 2000, EMBO J, V19, P4383, DOI 10.1093/emboj/19.16.4383; Prolla TA, 1998, NAT GENET, V18, P276, DOI 10.1038/ng0398-276; RAHMATULLAH M, 1994, J BIOL CHEM, V269, P3574; Raschle M, 1999, J BIOL CHEM, V274, P32368, DOI 10.1074/jbc.274.45.32368; SANCAR A, 1993, SCIENCE, V259, P1415, DOI 10.1126/science.8451638; Schmutte C, 1998, CANCER RES, V58, P4537; Schmutte C, 2001, J BIOL CHEM, V276, P33011, DOI 10.1074/jbc.M102670200; Schofield MJ, 2001, J BIOL CHEM, V276, P28291, DOI 10.1074/jbc.M103148200; Spampinato C, 2000, J BIOL CHEM, V275, P9863, DOI 10.1074/jbc.275.13.9863; SU SS, 1988, J BIOL CHEM, V263, P6829; Thomas David C., 1995, Methods (Orlando), V7, P187, DOI 10.1006/meth.1995.1024; Tishkoff DX, 1997, P NATL ACAD SCI USA, V94, P7487, DOI 10.1073/pnas.94.14.7487; Tran PT, 2000, MOL CELL BIOL, V20, P6390, DOI 10.1128/MCB.20.17.6390-6398.2000; Tran PT, 2001, P NATL ACAD SCI USA, V98, P9760, DOI 10.1073/pnas.161175998; Umar A, 1996, CELL, V87, P65, DOI 10.1016/S0092-8674(00)81323-9; Williams NL, 2001, J MOL BIOL, V306, P969, DOI 10.1006/jmbi.2001.4468; Yang W, 2000, MUTAT RES-DNA REPAIR, V460, P245, DOI 10.1016/S0921-8777(00)00030-6	54	45	46	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 14	2002	277	24					21801	21809		10.1074/jbc.M111342200	http://dx.doi.org/10.1074/jbc.M111342200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	563YR	11897781	hybrid			2022-12-27	WOS:000176286000089
J	Hoeprich, S; Guo, PX				Hoeprich, S; Guo, PX			Computer modeling of three-dimensional structure of DNA-packaging RNA (pRNA) monomer, dimer, and hexamer of Phi29 DNA packaging motor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIAL-VIRUS PHI29; BACTERIOPHAGE-PHI-29 PROHEAD RNA; PHOTOAFFINITY CROSS-LINKING; PERMUTED TRANSFER-RNAS; BICOID MESSENGER-RNA; RIBONUCLEASE-P RNA; PHAGE PHI-29; CHEMICAL MODIFICATION; IN-VITRO; MODIFICATION INTERFERENCE	A striking common feature in the maturation of all linear double-stranded DNA viruses is that their lengthy genome is translocated with remarkable velocity into the limited space within a preformed protein shell and packaged into near crystalline density. A DNA-translocating motor, powered by ATP hydrolysis, accomplishes this task, which would otherwise be energetically unfavorable. DNA-packaging RNA, pRNA, forms a hexameric complex to serve as a vital component of the DNA translocating motor of bacterial virus Phi29. The sequential action of six pRNA ensures continual function in the DNA translocation process. The Phi29 motor has been assembled with purified components synthesized by chemical or biotechnological approaches and is able to pump the viral DNA into the protein shell in vitro. pRNA dimers are the building blocks of the hexamer. The computer models of the three-dimensional structure of the motor was constructed based on experimental data derived from photoaffinity cross-linking by psoralen, phenphi (cis-Rh (1,10-phenanthroline) (9,10-phenanthrenequinone diimine)Cl-2(+)), and azidophenacyl; chemical modification and chemical modification interference with dimethyl sulfate, 1-cyclohexyl-3-(2-morpholinoethy)carbodiimide metho-p-toluene sulfonate, and kethoxal; complementary modification; and nuclease probing by single- and double-stranded specific RNases. The shapes of these computer models are very similar to the published pRNA images of cryo-atomic force microscopy. pRNA hexamer docking with the connector crystal structure reveals a very impressive match with the available biochemical, genetic, and physical data.	Purdue Univ, Purdue Canc Res Ctr, W Lafayette, IN 47907 USA; Purdue Univ, Dept Pathobiol, W Lafayette, IN 47907 USA	Purdue University System; Purdue University; Purdue University West Lafayette Campus; Purdue University System; Purdue University; Purdue University West Lafayette Campus	Guo, PX (corresponding author), Purdue Univ, Purdue Canc Res Ctr, B-36 Hansen Life Sci Res Bldg, W Lafayette, IN 47907 USA.	guop@purdue.edu	Guo, Peixuan/I-7184-2015; Guo, Peixuan/AAE-2573-2022	Guo, Peixuan/0000-0001-5706-2833	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060529, R01GM059944] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM60529, GM59944] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Anderson Dwight, 1993, P859; BAILEY S, 1990, J BIOL CHEM, V265, P22365; BAZINET C, 1985, ANNU REV MICROBIOL, V39, P109; Black LW, 1988, BACTERIOPHAGES, P321; CARAZO JM, 1986, J MOL BIOL, V192, P853, DOI 10.1016/0022-2836(86)90033-1; Chen CP, 1997, J VIROL, V71, P3864, DOI 10.1128/JVI.71.5.3864-3871.1997; Chen CP, 2000, J BIOL CHEM, V275, P17510, DOI 10.1074/jbc.M909662199; Chen CP, 1999, RNA, V5, P805, DOI 10.1017/S1355838299990350; Chen CP, 1997, J VIROL, V71, P495, DOI 10.1128/JVI.71.1.495-500.1997; CIMINO GD, 1985, ANNU REV BIOCHEM, V54, P1151, DOI 10.1146/annurev.bi.54.070185.005443; Clever JL, 1996, J VIROL, V70, P5902, DOI 10.1128/JVI.70.9.5902-5908.1996; CONWAY L, 1987, EMBO J, V6, P4177, DOI 10.1002/j.1460-2075.1987.tb02764.x; Davenport RJ, 2001, SCIENCE, V291, P807, DOI 10.1126/science.291.5511.2071; EHRESMANN C, 1987, NUCLEIC ACIDS RES, V15, P9109, DOI 10.1093/nar/15.22.9109; Ferrandon D, 1997, EMBO J, V16, P1751, DOI 10.1093/emboj/16.7.1751; Garver K, 1997, RNA, V3, P1068; Garver K, 2000, J BIOL CHEM, V275, P2817, DOI 10.1074/jbc.275.4.2817; Greatorex JS, 1996, NUCLEIC ACIDS RES, V24, P2919, DOI 10.1093/nar/24.15.2919; GRIMES S, 1990, J MOL BIOL, V215, P559, DOI 10.1016/S0022-2836(05)80168-8; GUO PX, 1994, SEMIN VIROL, V5, P27, DOI 10.1006/smvy.1994.1004; GUO PX, 1994, SEMIN VIROL, V5, P1, DOI 10.1006/smvy.1994.1001; GUO PX, 1987, NUCLEIC ACIDS RES, V15, P7081, DOI 10.1093/nar/15.17.7081; GUO PX, 1987, SCIENCE, V236, P690, DOI 10.1126/science.3107124; Guo PX, 1998, MOL CELL, V2, P149, DOI 10.1016/S1097-2765(00)80124-0; Guo PX, 2002, PROG NUCLEIC ACID RE, V72, P415, DOI 10.1016/S0079-6603(02)72076-X; HAASNOOT CAG, 1986, J BIOMOL STRUCT DYN, V3, P843, DOI 10.1080/07391102.1986.10508468; HARRIS ME, 1994, EMBO J, V13, P3953, DOI 10.1002/j.1460-2075.1994.tb06711.x; Hendrix RW, 1998, CELL, V94, P147, DOI 10.1016/S0092-8674(00)81413-0; HUI CF, 1985, P NATL ACAD SCI USA, V82, P1381, DOI 10.1073/pnas.82.5.1381; JIMENEZ J, 1986, SCIENCE, V232, P1113, DOI 10.1126/science.3754654; Laughrea M, 1996, BIOCHEMISTRY-US, V35, P1589, DOI 10.1021/bi951838f; Massire C, 1998, J MOL GRAPH MODEL, V16, P197, DOI 10.1016/S1093-3263(98)80004-1; Mat-Arip Y, 2001, J BIOL CHEM, V276, P32575, DOI 10.1074/jbc.M100045200; MICHEL F, 1990, NATURE, V347, P578, DOI 10.1038/347578a0; MOAZED D, 1986, J MOL BIOL, V187, P399, DOI 10.1016/0022-2836(86)90441-9; Mohammad T, 1999, BIOORG MED CHEM LETT, V9, P1703, DOI 10.1016/S0960-894X(99)00265-6; Morais MC, 2001, J STRUCT BIOL, V135, P38, DOI 10.1006/jsbi.2001.4379; Muriaux D, 1996, J BIOL CHEM, V271, P33686, DOI 10.1074/jbc.271.52.33686; NOLAN JM, 1993, SCIENCE, V261, P762, DOI 10.1126/science.7688143; PAN T, 1991, SCIENCE, V254, P1361, DOI 10.1126/science.1720569; Pecenkova T, 1997, GENE, V199, P157; REID RJD, 1994, J BIOL CHEM, V269, P18656; REID RJD, 1994, J BIOL CHEM, V269, P9084; REID RJD, 1994, J BIOL CHEM, V269, P5157; RYMOND BC, 1988, GENE DEV, V2, P428, DOI 10.1101/gad.2.4.428; SIEBENLIST U, 1980, P NATL ACAD SCI-BIOL, V77, P122, DOI 10.1073/pnas.77.1.122; Simpson AA, 2000, NATURE, V408, P745, DOI 10.1038/35047129; Simpson AA, 2001, ACTA CRYSTALLOGR D, V57, P1260, DOI 10.1107/S0907444901010435; SKRIPKIN E, 1994, P NATL ACAD SCI USA, V91, P4945, DOI 10.1073/pnas.91.11.4945; Smith DE, 2001, NATURE, V413, P748, DOI 10.1038/35099581; Trottier M, 2000, RNA, V6, P1257, DOI 10.1017/S1355838200992501; Trottier M, 1997, J VIROL, V71, P487, DOI 10.1128/JVI.71.1.487-494.1997; Trottier M, 1996, J VIROL, V70, P55, DOI 10.1128/JVI.70.1.55-61.1996; Trottier M, 1997, NUCL ACIDS S SER, V36, P187; TURNER DH, 1988, ANNU REV BIOPHYS BIO, V17, P167; TYC K, 1992, NUCLEIC ACIDS RES, V20, P5375, DOI 10.1093/nar/20.20.5375; Wagner C, 2001, J MOL BIOL, V313, P511, DOI 10.1006/jmbi.2001.5057; WASSARMAN DA, 1993, MOL BIOL REP, V17, P143, DOI 10.1007/BF00996222; WESTHOF E, 1985, J MOL BIOL, V184, P119, DOI 10.1016/0022-2836(85)90048-8; Zhang CL, 1995, RNA, V1, P1041; ZHANG CL, 1995, VIROLOGY, V207, P442, DOI 10.1006/viro.1995.1103; ZHANG CL, 1994, VIROLOGY, V201, P77, DOI 10.1006/viro.1994.1267; ZHANG CL, 1995, VIROLOGY, V211, P568, DOI 10.1006/viro.1995.1439; Zhang CL, 1997, RNA, V3, P315; Zhang CL, 2001, VIROLOGY, V281, P281, DOI 10.1006/viro.2000.0771; Zhang F, 1998, MOL CELL, V2, P141, DOI 10.1016/S1097-2765(00)80123-9; ZUKER M, 1989, SCIENCE, V244, P48, DOI 10.1126/science.2468181	67	63	69	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 7	2002	277	23					20794	20803		10.1074/jbc.M112061200	http://dx.doi.org/10.1074/jbc.M112061200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	562NJ	11886855	hybrid			2022-12-27	WOS:000176204500089
J	Aikawa, R; Huggins, GS; Snyder, RO				Aikawa, R; Huggins, GS; Snyder, RO			Cardiomyocyte-specific gene expression following recombinant adeno-associated viral vector transduction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENOASSOCIATED VIRUS VECTORS; HEAVY-CHAIN GENE; SARCOPLASMIC-RETICULUM CA2+-ATPASE; REPLICATION-DEFECTIVE ADENOVIRUS; LEFT-VENTRICULAR FUNCTION; COAGULATION-FACTOR-IX; IMMUNE-RESPONSE; IN-VIVO; GROWTH-HORMONE; DILATED CARDIOMYOPATHY	Recombinant adeno-associated viral (rAAV) vectors hold promise for delivering genes for heart diseases, but cardiac-specific expression by the use of rAAV has not been demonstrated. To achieve this goal rAAV vectors were generated expressing marker or potentially therapeutic genes under the control of the cardiac muscle-specific alpha myosin heavy chain (MHC) gene promoter. The rAAV-MHC vectors expressed in primary cardiomyocytes with similar kinetics to rAAV-CMV; however, expression by the rAAV-MHC vectors was restricted to cardiomyocytes. rAAV vectors have low cytotoxicity, and it is demonstrated here that rAAV fails to induce apoptosis in cardiomyocytes compared with a recombinant adenoviral vector. rAAV-MHC or rAAV-CMV vectors were administered to mice to determine the specificity of expression in vivo. The rAAV-MHC vectors expressed specifically in cardiomyocytes, whereas the control rAAV-CMV vector expressed in heart, skeletal muscle, and brain. rAAV-MHC transduction resulted in long term (16 weeks) expression of human growth hormone following intracardiac, yet not intramuscular, injection. Finally, we defined the minimal MHC enhancer/promoter sequences required for specific and robust in vivo expression in the context of a rAAV vector. For the first time we describe a panel of rAAV vectors capable of long term cardiac specific expression of intracellular and secreted proteins.	Harvard Univ, Sch Publ Hlth, Cardiovasc Biol Lab, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA; Childrens Hosp, Boston, MA 02115 USA; Massachusetts Gen Hosp, Cardiac Unit, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	Huggins, GS (corresponding author), Harvard Univ, Sch Publ Hlth, Cardiovasc Biol Lab, 677 Huntington Ave, Boston, MA 02115 USA.				NHLBI NIH HHS [R01 HL054592, R01 HL54592-06] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL054592] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Aikawa R, 1997, J CLIN INVEST, V100, P1813, DOI 10.1172/JCI119709; ATCHISON RW, 1965, SCIENCE, V149, P754, DOI 10.1126/science.149.3685.754; BARR E, 1994, GENE THER, V1, P51; Chan SY, 1999, NAT MED, V5, P1143, DOI 10.1038/13467; Cordier L, 2000, MOL THER, V1, P119, DOI 10.1006/mthe.1999.0019; DOUD SK, 1995, J MOL CELL CARDIOL, V27, P2359; Fazio S, 1996, NEW ENGL J MED, V334, P809, DOI 10.1056/NEJM199603283341301; Flannery JG, 1997, P NATL ACAD SCI USA, V94, P6916, DOI 10.1073/pnas.94.13.6916; Flotte T, 1996, HUM GENE THER, V7, P1145, DOI 10.1089/hum.1996.7.9-1145; Franz WM, 1997, CARDIOVASC RES, V35, P560, DOI 10.1016/S0008-6363(97)00154-5; FRENCH BA, 1994, CIRCULATION, V90, P2414, DOI 10.1161/01.CIR.90.5.2414; Genth-Zotz S, 1999, CIRCULATION, V99, P18, DOI 10.1161/01.CIR.99.1.18; GILGENKRANTZ H, 1995, HUM GENE THER, V6, P1265, DOI 10.1089/hum.1995.6.10-1265; Giordano FJ, 1997, CIRCULATION, V96, P400; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Greelish JP, 1999, NAT MED, V5, P439, DOI 10.1038/7439; GULICK J, 1991, J BIOL CHEM, V266, P9180; Gupta M, 1998, MOL CELL BIOL, V18, P7243, DOI 10.1128/MCB.18.12.7243; GUZMAN RJ, 1993, CIRC RES, V73, P1202, DOI 10.1161/01.RES.73.6.1202; Hagstrom JN, 2000, BLOOD, V95, P2536; Hajjar RJ, 1997, CIRC RES, V81, P145, DOI 10.1161/01.RES.81.2.145; Hardy S, 1997, J VIROL, V71, P1842, DOI 10.1128/JVI.71.3.1842-1849.1997; HENDERSON SA, 1989, J BIOL CHEM, V264, P18142; Hongo M, 2000, BASIC RES CARDIOL, V95, P431, DOI 10.1007/s003950070018; Jiang S, 2001, CANCER GENE THER, V8, P469, DOI 10.1038/sj.cgt.7700327; Jooss K, 1998, J VIROL, V72, P4212, DOI 10.1128/JVI.72.5.4212-4223.1998; Kaplitt MG, 1996, ANN THORAC SURG, V62, P1669, DOI 10.1016/S0003-4975(96)00946-0; KAPLITT MG, 1994, NAT GENET, V8, P148, DOI 10.1038/ng1094-148; Klein RL, 1998, EXP NEUROL, V150, P183, DOI 10.1006/exnr.1997.6736; Li J, 1999, GENE THER, V6, P74, DOI 10.1038/sj.gt.3300830; Mandel RJ, 1997, P NATL ACAD SCI USA, V94, P14083, DOI 10.1073/pnas.94.25.14083; MAROULAKOU IG, 1994, ONCOGENE, V9, P1551; Mathews LC, 2002, METHOD ENZYMOL, V346, P393; Miao CH, 2000, J VIROL, V74, P3793, DOI 10.1128/JVI.74.8.3793-3803.2000; Miyamoto MI, 2000, P NATL ACAD SCI USA, V97, P793, DOI 10.1073/pnas.97.2.793; Molkentin JD, 1996, J MOL CELL CARDIOL, V28, P1211, DOI 10.1006/jmcc.1996.0112; Morkin E, 2000, MICROSC RES TECHNIQ, V50, P522, DOI 10.1002/1097-0029(20000915)50:6<522::AID-JEMT9>3.0.CO;2-U; Morral N, 1999, P NATL ACAD SCI USA, V96, P12816, DOI 10.1073/pnas.96.22.12816; NABEL EG, 1995, CIRCULATION, V91, P541, DOI 10.1161/01.CIR.91.2.541; Nuss HB, 1996, GENE THER, V3, P900; Phaneuf D, 2000, MOL MED, V6, P96, DOI 10.1007/BF03401777; Quinones MJ, 1996, CIRCULATION, V94, P1394, DOI 10.1161/01.CIR.94.6.1394; Rendahl KG, 1998, NAT BIOTECHNOL, V16, P757, DOI 10.1038/nbt0898-757; Schroder G, 2000, TRANSPLANTATION, V70, P191; Snyder RO, 1997, NAT GENET, V16, P270, DOI 10.1038/ng0797-270; Snyder RO, 1997, HUM GENE THER, V8, P1891, DOI 10.1089/hum.1997.8.16-1891; Song S, 1998, P NATL ACAD SCI USA, V95, P14384, DOI 10.1073/pnas.95.24.14384; Su H, 1997, P NATL ACAD SCI USA, V94, P13891, DOI 10.1073/pnas.94.25.13891; SUBRAMANIAM A, 1991, J BIOL CHEM, V266, P24613; Svensson EC, 1999, CIRCULATION, V99, P201, DOI 10.1161/01.CIR.99.2.201; Vincent-Lacaze N, 1999, J VIROL, V73, P1949, DOI 10.1128/JVI.73.3.1949-1955.1999; WALSH CE, 1994, J CLIN INVEST, V94, P1440, DOI 10.1172/JCI117481; Wu P, 2000, J VIROL, V74, P8635, DOI 10.1128/JVI.74.18.8635-8647.2000; Xiao X, 2000, J VIROL, V74, P1436, DOI 10.1128/JVI.74.3.1436-1442.2000; Xiao XA, 1996, J VIROL, V70, P8098, DOI 10.1128/JVI.70.11.8098-8108.1996; Yap J, 1997, CARDIOVASC RES, V35, P529, DOI 10.1016/S0008-6363(97)00165-X; Zou LL, 2000, MOL THER, V2, P105, DOI 10.1006/mthe.2000.0104	58	44	47	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 24	2002	277	21					18979	18985		10.1074/jbc.M201257200	http://dx.doi.org/10.1074/jbc.M201257200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	558PM	11889137	hybrid			2022-12-27	WOS:000175975800096
J	Elble, RC; Ji, GJ; Nehrke, K; DeBiasio, J; Kingsley, PD; Kotlikoff, MI; Pauli, BU				Elble, RC; Ji, GJ; Nehrke, K; DeBiasio, J; Kingsley, PD; Kotlikoff, MI; Pauli, BU			Molecular and functional characterization of a murine calcium-activated chloride channel expressed in smooth muscle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT ANOCOCCYGEUS MUSCLE; RABBIT PORTAL-VEIN; ENDOTHELIAL-CELLS; INWARD CURRENTS; BREAST-CANCER; NORADRENALINE; CLONING; LUNG; MEMBRANE; TRACHEA	To identify the gene products responsible for the calcium-activated chloride current in smooth muscle, reverse transcription-PCR with degenerate primers was performed on mouse intestine and other organs. A new member of the CLCA gene family was identified, mCLCA4, that is expressed preferentially in organs containing a high percentage of smooth muscle cells, including intestine, stomach, uterus, bladder, and aorta. Reverse transcription-PCR using template RNA prepared from mouse bladder and stomach smooth muscle layers dissected free of mucosa yielded mCLCA4-specific bands. In situ hybridization with an mCLCA4-specific probe confirmed prominent expression in smooth muscle of major vessels of the heart but not cardiac muscle. High expression was also detected in the gastrointestinal tract, in bronchioles, and in aortic and lung endothelial cells. Transient expression of mCLCA4 in 293T cells resulted in the appearance of a prominent calcium-activated chloride current. Whole-cell currents activated by ionomycin or methacholine were anion-selective and showed minimal rectification or voltage-dependent gating. Similar to endogenous currents in smooth muscle cells, methacholine-induced currents were transient, and spontaneous transient inward currents were occasionally observed at resting membrane potentials. These results link calcium-activated chloride channels in smooth muscle with a gene family whose members have been implicated in cystic fibrosis, cancer, and asthma.	Cornell Univ, Coll Vet Med, Canc Biol Labs, Ithaca, NY 14853 USA; Cornell Univ, Coll Vet Med, Dept Mol Med, Ithaca, NY 14853 USA; Cornell Univ, Coll Vet Med, Dept Biomed Sci, Ithaca, NY 14853 USA; Univ Rochester, Aab Inst Biomed Res, Ctr Oral Biol, Rochester, NY 14642 USA; Univ Rochester, Aab Inst Biomed Res, Ctr Human Genet & Mol Pediat Dis, Rochester, NY 14642 USA	Cornell University; Cornell University; Cornell University; University of Rochester; University of Rochester	Elble, RC (corresponding author), Cornell Univ, Coll Vet Med, Canc Biol Labs, Ithaca, NY 14853 USA.			Nehrke, Keith/0000-0001-9697-726X; Ji, Guangju/0000-0001-8626-3490	NCI NIH HHS [CA47668] Funding Source: Medline; NHLBI NIH HHS [HL41084, HL45239] Funding Source: Medline; NIDCR NIH HHS [DE09692] Funding Source: Medline; NIDDK NIH HHS [DK58795] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA047668] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL041084, R01HL045239, R01HL041084] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE009692] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK058795] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abdel-Ghany M, 2001, J BIOL CHEM, V276, P25438, DOI 10.1074/jbc.M100478200; Agnel M, 1999, FEBS LETT, V455, P295, DOI 10.1016/S0014-5793(99)00891-1; AMEDEE T, 1990, J PHYSIOL-LONDON, V428, P501, DOI 10.1113/jphysiol.1990.sp018224; ANDERSON MP, 1992, AM J PHYSIOL, V263, pL1, DOI 10.1152/ajplung.1992.263.1.L1; Arreola J, 1996, J GEN PHYSIOL, V108, P35, DOI 10.1085/jgp.108.1.35; BYRNE NG, 1987, BRIT J PHARMACOL, V92, P371, DOI 10.1111/j.1476-5381.1987.tb11333.x; BYRNE NG, 1985, BRIT J PHARMACOL, V86, P711, DOI 10.1111/j.1476-5381.1985.tb08950.x; BYRNE NG, 1988, J PHYSIOL-LONDON, V404, P557, DOI 10.1113/jphysiol.1988.sp017306; BYRNE NG, 1987, J PHYSIOL-LONDON, V389, P513, DOI 10.1113/jphysiol.1987.sp016669; CLANCY JP, 1990, AM J PHYSIOL, V258, pL25, DOI 10.1152/ajplung.1990.258.2.L25; Criddle DN, 1996, BRIT J PHARMACOL, V118, P1065, DOI 10.1111/j.1476-5381.1996.tb15507.x; Cunningham SA, 1995, J BIOL CHEM, V270, P31016, DOI 10.1074/jbc.270.52.31016; Dong QG, 1997, ARTERIOSCL THROM VAS, V17, P1599, DOI 10.1161/01.ATV.17.8.1599; Elble RC, 1997, J BIOL CHEM, V272, P27853, DOI 10.1074/jbc.272.44.27853; Elble RC, 2001, J BIOL CHEM, V276, P40510, DOI 10.1074/jbc.M104821200; EVANS MG, 1986, J PHYSIOL-LONDON, V378, P437, DOI 10.1113/jphysiol.1986.sp016229; FLEISCHMANN BK, 1994, P NATL ACAD SCI USA, V91, P11914, DOI 10.1073/pnas.91.25.11914; Gandhi R, 1998, J BIOL CHEM, V273, P32096, DOI 10.1074/jbc.273.48.32096; Gruber A. D., 2000, Current Genomics, V1, P201, DOI 10.2174/1389202003351526; Gruber AD, 1999, AM J PHYSIOL-CELL PH, V276, pC1261; Gruber AD, 1998, HISTOCHEM CELL BIOL, V110, P43, DOI 10.1007/s004180050263; Gruber AD, 1999, CANCER RES, V59, P5488; Gruber AD, 1998, GENOMICS, V54, P200, DOI 10.1006/geno.1998.5562; HARVEY RD, 1989, SCIENCE, V244, P983, DOI 10.1126/science.2543073; HIRST GDS, 1980, J PHYSIOL-LONDON, V303, P43, DOI 10.1113/jphysiol.1980.sp013269; Janssen LJ, 1998, AM J PHYSIOL-LUNG C, V275, pL516, DOI 10.1152/ajplung.1998.275.3.L516; JANSSEN LJ, 1994, PFLUG ARCH EUR J PHY, V427, P473, DOI 10.1007/BF00374263; JANSSEN LJ, 1992, J PHYSIOL-LONDON, V453, P197, DOI 10.1113/jphysiol.1992.sp019224; Komiya T, 1999, BIOCHEM BIOPH RES CO, V255, P347, DOI 10.1006/bbrc.1999.0168; Large WA, 1996, AM J PHYSIOL-CELL PH, V271, pC435; LEVERKOEHNE I, 2002, IN PRESS J HISTOCHEM; MAYER ML, 1985, J PHYSIOL-LONDON, V364, P217, DOI 10.1113/jphysiol.1985.sp015740; MILEDI R, 1982, PROC R SOC SER B-BIO, V215, P491, DOI 10.1098/rspb.1982.0056; MORRIS AP, 1993, AM J PHYSIOL, V264, pC977, DOI 10.1152/ajpcell.1993.264.4.C977; Nakanishi A, 2001, P NATL ACAD SCI USA, V98, P5175, DOI 10.1073/pnas.081510898; Nelson MT, 1997, J PHYSIOL-LONDON, V502, P259, DOI 10.1111/j.1469-7793.1997.259bk.x; Nilius B, 1997, J PHYSIOL-LONDON, V498, P381, DOI 10.1113/jphysiol.1997.sp021865; O'Brien CD, 2001, FASEB J, V15, P1257, DOI 10.1096/fj.00-0467fje; OWEN DG, 1984, NATURE, V311, P567, DOI 10.1038/311567a0; SMITH PM, 1992, J PHYSIOL-LONDON, V449, P109, DOI 10.1113/jphysiol.1992.sp019077; Takano H, 2000, JPN J PHYSIOL, V50, P597, DOI 10.2170/jjphysiol.50.597; THIEMANN A, 1992, NATURE, V356, P57, DOI 10.1038/356057a0; VANHELDEN DF, 1991, J PHYSIOL-LONDON, V437, P511, DOI 10.1113/jphysiol.1991.sp018609; WANG Q, 1992, J PHYSIOL-LONDON, V451, P525, DOI 10.1113/jphysiol.1992.sp019177; Wang YX, 1997, P NATL ACAD SCI USA, V94, P14918, DOI 10.1073/pnas.94.26.14918; Wilkinson D. G., 1990, POSTIMPLANTATION MAM, P155; ZYGMUNT AC, 1991, CIRC RES, V68, P424, DOI 10.1161/01.RES.68.2.424	47	60	67	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 24	2002	277	21					18586	18591		10.1074/jbc.M200829200	http://dx.doi.org/10.1074/jbc.M200829200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	558PM	11896056	hybrid			2022-12-27	WOS:000175975800046
J	Hockin, MF; Jones, KC; Everse, SJ; Mann, KG				Hockin, MF; Jones, KC; Everse, SJ; Mann, KG			A model for the stoichiometric regulation of blood coagulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TISSUE FACTOR PATHWAY; EXTRINSIC XASE COMPLEX; BOVINE FACTOR-V; FACTOR-VIIA; THROMBIN GENERATION; ANTITHROMBIN-III; PROTEIN-C; FACTOR-X; HEMOPHILIA-A; MATHEMATICAL SIMULATION	We have developed a model of the extrinsic blood coagulation system that includes the stoichiometric anticoagulants. The model accounts for the formation, expression, and propagation of the vitamin K-dependent procoagulant complexes and extends our previous model by including: (a) the tissue factor pathway inhibitor (TFPI)-mediated inactivation of tissue factor (TF)-VIIa and its product complexes; (b) the antithrombin-III (AT-III)-mediated inactivation of Ha, m-Ha, factor VIIa, factor IXa, and factor Xa; (e) the initial activation of factor V and factor VIII by thrombin generated by factor Xa-membrane; (d) factor VIIIa dissociation/activity loss; (e) the binding competition and kinetic activation steps that exist between TF and factors VII and VIIa; and (f) the activation of factor VII by Ha, factor Xa, and factor IXa. These additions to our earlier model generate a model consisting of 34 differential equations with 42 rate constants that together describe the 27 independent equilibrium expressions, which describe the fates of 34 species. Simulations are initiated by "exposing" picomolar concentrations of TF to an electronic milieu consisting of factors II, IX X, VII, VIIa, V, and VIIII, and the anticoagulants TFPI and AT-III at concentrations found in normal plasma or associated with coagulation pathology. The reaction followed in terms of thrombin generation, proceeds through phases that can be operationally defined as initiation, propagation, and termination. The generation of thrombin displays a nonlinear dependence upon TF, AT-III, and TFPI and the combination of these latter inhibitors displays kinetic thresholds. At subthreshold TF, thrombin production/ expression is suppressed by the combination of TFPI and AT-M; for concentrations above the TF threshold, the bolus of thrombin produced is quantitatively equivalent. A comparison of the model with empirical laboratory data illustrates that most experimentally observable parameters are captured, and the pathology that results in enhanced or deficient thrombin generation is accurately described.	Univ Vermont, Coll Med, Dept Biochem, Burlington, VT 05405 USA	University of Vermont	Mann, KG (corresponding author), Univ Vermont, Coll Med, Dept Biochem, Burlington, VT 05405 USA.				NHLBI NIH HHS [P0-1 HL 46703, HL 34575] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL034575, R01HL034575, P01HL046703] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Baugh RJ, 2000, J BIOL CHEM, V275, P28826, DOI 10.1074/jbc.M005266200; Baugh RJ, 1998, J BIOL CHEM, V273, P4378, DOI 10.1074/jbc.273.8.4378; Baugh RJ, 1996, J BIOL CHEM, V271, P16126, DOI 10.1074/jbc.271.27.16126; BELTRAMI E, 1995, P NATL ACAD SCI USA, V92, P8744, DOI 10.1073/pnas.92.19.8744; BERESFORD CH, 1988, BLOOD REV, V2, P239, DOI 10.1016/0268-960X(88)90013-6; Bergum PW, 2001, J BIOL CHEM, V276, P10063, DOI 10.1074/jbc.M009116200; BERTINA RM, 1994, NATURE, V369, P64, DOI 10.1038/369064a0; BLOOM JW, 1979, BIOCHEMISTRY-US, V18, P4419, DOI 10.1021/bi00587a023; BoltonMaggs PHB, 1996, BAILLIERE CLIN HAEM, V9, P355, DOI 10.1016/S0950-3536(96)80068-0; BOM VJJ, 1991, THROMB HAEMOSTASIS, V66, P283; BROZE GJ, 1995, THROMB HAEMOSTASIS, V74, P90; Brummel KE, 1999, J BIOL CHEM, V274, P22862, DOI 10.1074/jbc.274.32.22862; Butenas S, 1999, BLOOD, V94, P2169, DOI 10.1182/blood.V94.7.2169.419k22_2169_2178; Butenas S, 1997, J BIOL CHEM, V272, P21527, DOI 10.1074/jbc.272.34.21527; Butenas S, 1996, BIOCHEMISTRY-US, V35, P1904, DOI 10.1021/bi951768c; BUTENAS S, 1994, BIOCHEMISTRY-US, V33, P3449, DOI 10.1021/bi00177a039; Cawthern KM, 1998, BLOOD, V91, P4581, DOI 10.1182/blood.V91.12.4581.412k12_4581_4592; CHIN HCH, 1983, J CLIN INVEST, V72, P493; Chuang YJ, 2001, J BIOL CHEM, V276, P14961, DOI 10.1074/jbc.M011550200; DAVIE EW, 1991, BIOCHEMISTRY-US, V30, P10363, DOI 10.1021/bi00107a001; De Moerloose P, 1998, SEMIN THROMB HEMOST, V24, P321, DOI 10.1055/s-2007-996020; DOYLE MF, 1990, J BIOL CHEM, V265, P10693; Esmon CT, 2000, BBA-PROTEIN STRUCT M, V1477, P349, DOI 10.1016/S0167-4838(99)00266-6; ESMON CT, 1989, J BIOL CHEM, V264, P4743; Fay PJ, 1996, J BIOL CHEM, V271, P6027, DOI 10.1074/jbc.271.11.6027; FAY PJ, 1992, J BIOL CHEM, V267, P13246; FOSTER WB, 1983, J BIOL CHEM, V258, P3970; FOSTER WB, 1983, J BIOL CHEM, V258, P5608; GENTRY R, 1995, BIOPHYS J, V69, P356, DOI 10.1016/S0006-3495(95)79907-6; GRIFFIN JH, 1987, PROG HEMATOL, V15, P39; Hockin MF, 1999, BIOCHEMISTRY-US, V38, P6918, DOI 10.1021/bi981966e; HOYER LW, 1994, NEW ENGL J MED, V330, P38, DOI 10.1056/NEJM199401063300108; JONES KC, 1994, J BIOL CHEM, V269, P23367; JORDAN RE, 1980, J BIOL CHEM, V255, P81; KATZMANN JA, 1981, P NATL ACAD SCI-BIOL, V78, P162, DOI 10.1073/pnas.78.1.162; KESSELS H, 1994, COMPUT BIOL MED, V24, P277, DOI 10.1016/0010-4825(94)90024-8; KRISHNASWAMY S, 1992, J BIOL CHEM, V267, P23696; KRISHNASWAMY S, 1987, J BIOL CHEM, V262, P3291; LAWSON JH, 1993, METHOD ENZYMOL, V222, P177; LAWSON JH, 1993, J BIOL CHEM, V268, P767; LAWSON JH, 1994, J BIOL CHEM, V269, P23357; LOLLAR P, 1992, J BIOL CHEM, V267, P23652; Mann K., 1995, WILLIAMS HEMATOLOGY, P1206; Mannucci PM, 2001, NEW ENGL J MED, V344, P1773, DOI 10.1056/NEJM200106073442307; Mounts WM, 1997, INT J BIOL MACROMOL, V20, P265, DOI 10.1016/S0141-8130(97)00026-3; NESHEIM ME, 1979, J BIOL CHEM, V254, P508; NESHEIM ME, 1981, METHOD ENZYMOL, V80, P249; NESHEIM ME, 1984, J BIOL CHEM, V259, P1447; OBRIEN DP, 1994, BIOCHEMISTRY-US, V33, P14162, DOI 10.1021/bi00251a027; OZSOYLU S, 1973, ACTA HAEMATOL-BASEL, V50, P305; POORT SR, 1994, THROMB HAEMOSTASIS, V72, P819; Rand MD, 1996, BLOOD, V88, P3432, DOI 10.1182/blood.V88.9.3432.bloodjournal8893432; Reitsma PH, 1997, THROMB HAEMOSTASIS, V78, P344; SCHOEN P, 1987, J BIOL CHEM, V262, P11268; Shobe J, 1999, J BIOL CHEM, V274, P24171, DOI 10.1074/jbc.274.34.24171; TRACY PB, 1979, J BIOL CHEM, V254, P354; van't Veer C, 2000, BLOOD, V95, P1330, DOI 10.1182/blood.V95.4.1330.004k28_1330_1335; vantVeer C, 1997, J BIOL CHEM, V272, P4367, DOI 10.1074/jbc.272.7.4367; vantVeer C, 1997, J BIOL CHEM, V272, P7983, DOI 10.1074/jbc.272.12.7983; Zoller B, 1999, HAEMATOLOGICA, V84, P59	60	285	294	1	24	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 24	2002	277	21					18322	18333		10.1074/jbc.M201173200	http://dx.doi.org/10.1074/jbc.M201173200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	558PM	11893748	hybrid			2022-12-27	WOS:000175975800011
J	Ikeda, K; Wang, LH; Torres, R; Zhao, H; Olaso, E; Eng, FJ; Labrador, P; Klein, R; Lovett, D; Yancopoulos, GD; Friedman, SL; Lin, HC				Ikeda, K; Wang, LH; Torres, R; Zhao, H; Olaso, E; Eng, FJ; Labrador, P; Klein, R; Lovett, D; Yancopoulos, GD; Friedman, SL; Lin, HC			Discoidin domain receptor 2 interacts with Src and Shc following its activation by type I collagen	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASES; SIGNAL-TRANSDUCTION; MATRIX METALLOPROTEINASE-2; FAMILY KINASES; CELL-ADHESION; GROWTH-FACTOR; PROTEIN; INTEGRIN; PROLIFERATION; EXPRESSION	Discoidin domain receptor 2 (DDR2) is an unusual receptor tyrosine kinase in that its ligand is fibrillar collagen rather than a growth factor-like peptide. We examined signal transduction pathways of DDR2. Here we show that DDR2 is also unusual in that it requires Src activity to be maximally tyrosine-phosphorylated, and that Src activity also promotes association of DDR2 with Shc. The interaction with Shc involves a portion of She not previously implicated in interaction with receptor tyrosine kinases. These results identify Src kinase and the adaptor protein Shc as key signaling intermediates in DDR2 signal transduction. Furthermore, Src is required for DDR2-mediated transactivation of the matrix metalloproteinase-2 promoter. The data support a model in which Src and the DDR2 receptor cooperate in a regulated fashion to direct the phosphorylation of both the receptor and its targets.	Mt Sinai Sch Med, Dept Med, Div Liver Dis, New York, NY 10029 USA; Regeneron Pharmaceut Inc, Tarrytown, NY 10591 USA; European Mol Biol Lab, Dev Biol Program, D-69117 Heidelberg, Germany; Univ Calif San Francisco, Dept Med, Vet Affairs Med Ctr, San Francisco, CA 94121 USA	Icahn School of Medicine at Mount Sinai; Regeneron; European Molecular Biology Laboratory (EMBL); University of California System; University of California San Francisco; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Friedman, SL (corresponding author), Mt Sinai Sch Med, Dept Med, Div Liver Dis, Box 1123,1425 Madison Ave,Rm 1170F, New York, NY 10029 USA.		Klein, Ruediger/C-6147-2008; Olaso, Elvira/AAA-4497-2019; Labrador, Juan Pablo/C-3018-2014	Klein, Ruediger/0000-0002-3109-0163; Olaso, Elvira/0000-0001-6597-3530; Labrador, Juan Pablo/0000-0003-3671-848X	PHS HHS [R01 56621] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ALVES F, 1995, ONCOGENE, V10, P609; Ankoma-Sey V, 1998, ONCOGENE, V17, P115, DOI 10.1038/sj.onc.1201912; Aplin AE, 1998, PHARMACOL REV, V50, P197; Blake RA, 2000, MOL CELL BIOL, V20, P9018, DOI 10.1128/MCB.20.23.9018-9027.2000; Ellerbroek SM, 1999, CANCER RES, V59, P1635; HARENDZA S, 1995, J BIOL CHEM, V270, P18786, DOI 10.1074/jbc.270.32.18786; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Keegan K, 1996, ONCOGENE, V12, P1537; Klinghoffer RA, 1999, EMBO J, V18, P2459, DOI 10.1093/emboj/18.9.2459; Labrador JP, 2001, EMBO REP, V2, P446, DOI 10.1093/embo-reports/kve094; MORI S, 1993, EMBO J, V12, P2257, DOI 10.1002/j.1460-2075.1993.tb05879.x; Olaso E, 2002, J BIOL CHEM, V277, P3606, DOI 10.1074/jbc.M107571200; Olaso E, 2001, J CLIN INVEST, V108, P1369, DOI 10.1172/JCI12373; Parsons JT, 1997, CURR OPIN CELL BIOL, V9, P187, DOI 10.1016/S0955-0674(97)80062-2; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; ROSEN SD, 1994, CURR OPIN CELL BIOL, V6, P663, DOI 10.1016/0955-0674(94)90092-2; Schlessinger J, 1997, CELL, V91, P869, DOI 10.1016/S0092-8674(00)80477-8; Schmandt R, 1999, ONCOGENE, V18, P1867, DOI 10.1038/sj.onc.1202507; Shrivastava A, 1997, MOL CELL, V1, P25, DOI 10.1016/S1097-2765(00)80004-0; Sternberg PW, 1998, CELL, V95, P447, DOI 10.1016/S0092-8674(00)81612-8; TAKEICHI M, 1995, CURR OPIN CELL BIOL, V7, P619, DOI 10.1016/0955-0674(95)80102-2; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; vanderGeer P, 1996, CURR BIOL, V6, P1435, DOI 10.1016/S0960-9822(96)00748-8; Vogel S, 2000, J LIPID RES, V41, P882; Vogel W, 2000, J BIOL CHEM, V275, P5779, DOI 10.1074/jbc.275.8.5779; Vogel W, 1997, MOL CELL, V1, P13, DOI 10.1016/S1097-2765(00)80003-9; Vogel W, 1999, FASEB J, V13, pS77, DOI 10.1096/fasebj.13.9001.s77	29	106	114	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 24	2002	277	21					19206	19212		10.1074/jbc.M201078200	http://dx.doi.org/10.1074/jbc.M201078200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	558PM	11884411	hybrid			2022-12-27	WOS:000175975800124
J	Backhed, F; Alsen, B; Roche, N; Angstrom, J; von Euler, A; Breimer, ME; Westerlund-Wikstrom, B; Teneberg, S; Richter-Dahlfors, A				Backhed, F; Alsen, B; Roche, N; Angstrom, J; von Euler, A; Breimer, ME; Westerlund-Wikstrom, B; Teneberg, S; Richter-Dahlfors, A			Identification of target tissue glycosphingolipid receptors for uropathogenic, F1C-fimbriated Escherichia coli and its role in mucosal inflammation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							URINARY-TRACT INFECTION; EPITHELIAL-CELLS; F1C FIMBRIAE; BINDING; BACTERIA; SPECTROSCOPY; GLYCOLIPIDS; EXPRESSION; VIRULENCE; CERAMIDE	Bacterial adherence to mucosal cells is a key virulence trait of pathogenic bacteria. The type I fimbriae and the P-fimbriae of Escherichia coli have both been described to be important for the establishment of urinary tract infections. While P-fimbriae recognize kidney glycosphingolipids carrying the Galalpha4Gal determinant, type 1 fimbriae bind to the urothelial mannosylated glycoproteins uroplakin Ia and Ib. The F1C fimbriae are one additional type of fimbria correlated with uropathogenicity. Although it was identified 20 years ago its receptor has remained unidentified. Here we report that F1C-fimbriated bacteria selectively interact with two minor glycosphingolipids isolated from rat, canine, and human urinary tract. Binding-active compounds were isolated and characterized as galactosylceramide, and globotriaosylceramide, both with phytosphingosine and hydroxy fatty acids. Comparison with reference glycosphingolipids revealed that the receptor specificity is dependent on the ceramide composition. Galactosylceramide was present in the bladder, urethers, and kidney while globotriaosylceramide was present only in the kidney. Using a functional assay, we demonstrate that binding of F1C-fimbriated Escherichia coli to renal cells induces interleukin-8 production, thus suggesting a role for F1C-mediated attachment in mucosal defense against bacterial infections.	Univ Gothenburg, Inst Med Biochem, SE-40530 Gothenburg, Sweden; Karolinska Inst, Microbiol & Tumorbiol Ctr, SE-17177 Stockholm, Sweden; Sahlgrenska Univ Hosp, Dept Surg, SE-41345 Gothenburg, Sweden; Univ Helsinki, Dept Biosci, Div Gen Microbiol, FIN-00014 Helsinki, Finland	University of Gothenburg; Karolinska Institutet; Sahlgrenska University Hospital; University of Helsinki	Teneberg, S (corresponding author), Univ Gothenburg, Inst Med Biochem, POB 440, SE-40530 Gothenburg, Sweden.		Backhed, Fredrik/ABE-6613-2020	Backhed, Fredrik/0000-0002-4871-8818; Westerlund-Wikstrom, Benita/0000-0002-5307-3858; Richter-Dahlfors, Agneta/0000-0002-5479-7591				Angstrom J, 1998, GLYCOBIOLOGY, V8, P297, DOI 10.1093/glycob/8.4.297; ARONSON M, 1979, J INFECT DIS, V139, P329, DOI 10.1093/infdis/139.3.329; Backhed F, 2001, CELL MICROBIOL, V3, P153, DOI 10.1046/j.1462-5822.2001.00101.x; BREIMER ME, 1985, J BIOCHEM, V98, P1169, DOI 10.1093/oxfordjournals.jbchem.a135383; BREIMER ME, 1980, ADV MASS SPECTROM, V8, P1097; Connell H, 1996, P NATL ACAD SCI USA, V93, P9827, DOI 10.1073/pnas.93.18.9827; DABROWSKI J, 1980, CHEM PHYS LIPIDS, V26, P187, DOI 10.1016/0009-3084(80)90006-7; HAGBERG L, 1983, INFECT IMMUN, V40, P265, DOI 10.1128/IAI.40.1.265-272.1983; HAKOMORI S, 1983, HDB LIPID RES, V3, P1; HANSSON GC, 1985, ANAL BIOCHEM, V146, P158, DOI 10.1016/0003-2697(85)90410-5; Hedlund M, 1996, J EXP MED, V183, P1037, DOI 10.1084/jem.183.3.1037; HOLGERSSON J, 1991, GLYCOCONJUGATE J, V8, P424, DOI 10.1007/BF00731294; Hugosson S, 1998, J BIOCHEM-TOKYO, V124, P1138, DOI 10.1093/oxfordjournals.jbchem.a022232; JOHNSON JR, 1991, CLIN MICROBIOL REV, V4, P80, DOI 10.1128/CMR.4.1.80-128.1991; KALLENIUS G, 1980, FEMS MICROBIOL LETT, V7, P297, DOI 10.1111/j.1574-6941.1980.tb01608.x; KARLSSON KA, 1987, METHOD ENZYMOL, V138, P212; KARLSSON KA, 1989, ANNU REV BIOCHEM, V58, P309, DOI 10.1146/annurev.bi.58.070189.001521; Khan AS, 2000, INFECT IMMUN, V68, P3541, DOI 10.1128/IAI.68.6.3541-3547.2000; KOERNER TAW, 1983, BIOCHEMISTRY-US, V22, P2676, DOI 10.1021/bi00280a014; KORHONEN TK, 1985, INFECT IMMUN, V48, P486, DOI 10.1128/IAI.48.2.486-491.1985; Langermann S, 1997, SCIENCE, V276, P607, DOI 10.1126/science.276.5312.607; LARSON G, 1987, CARBOHYD RES, V161, P281, DOI 10.1016/S0008-6215(00)90085-5; LEFFLER H, 1980, FEMS MICROBIOL LETT, V8, P127, DOI 10.1111/j.1574-6968.1980.tb05064.x; MARRE R, 1990, INFECT IMMUN, V58, P3434, DOI 10.1128/IAI.58.10.3434-3437.1990; MATTSBYBALTZER I, 1982, INFECT IMMUN, V35, P639, DOI 10.1128/IAI.35.2.639-646.1982; Mulvey MA, 1998, SCIENCE, V282, P1494, DOI 10.1126/science.282.5393.1494; PARKKINEN J, 1986, INFECT IMMUN, V54, P37, DOI 10.1128/IAI.54.1.37-42.1986; PERE A, 1987, J INFECT DIS, V156, P567, DOI 10.1093/infdis/156.4.567; POPPE L, 1990, EUR J BIOCHEM, V189, P313, DOI 10.1111/j.1432-1033.1990.tb15492.x; RHEN M, 1985, J GEN MICROBIOL, V131, P571; ROBERTS JA, 1994, P NATL ACAD SCI USA, V91, P11889, DOI 10.1073/pnas.91.25.11889; SAMUELSSON BE, 1990, METHOD ENZYMOL, V193, P623, DOI 10.1016/0076-6879(90)93442-N; SIITONEN A, 1993, MICROB PATHOGENESIS, V15, P65, DOI 10.1006/mpat.1993.1057; STELLNER K, 1973, ARCH BIOCHEM BIOPHYS, V155, P464, DOI 10.1016/0003-9861(73)90138-0; STROMBERG N, 1988, FEBS LETT, V232, P193, DOI 10.1016/0014-5793(88)80415-0; Uhlen P, 2000, NATURE, V405, P694, DOI 10.1038/35015091; VANDIE I, 1991, RES MICROBIOL, V142, P653, DOI 10.1016/0923-2508(91)90078-O; VIRKOLA R, 1988, INFECT IMMUN, V56, P2615, DOI 10.1128/IAI.56.10.2615-2622.1988; Waldi D., 1962, DUNNSCHICHT CHROMATO, P496; Wu XR, 1996, P NATL ACAD SCI USA, V93, P9630, DOI 10.1073/pnas.93.18.9630; YANG HJ, 1971, J BIOL CHEM, V246, P1192	41	65	66	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 17	2002	277	20					18198	18205		10.1074/jbc.M111640200	http://dx.doi.org/10.1074/jbc.M111640200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	553PR	11877427	hybrid			2022-12-27	WOS:000175685100102
J	Eto, K; Huet, C; Tarui, T; Kupriyanov, S; Liu, HZ; Puzon-McLaughlin, W; Zhang, XP; Sheppard, D; Engvall, E; Takada, Y				Eto, K; Huet, C; Tarui, T; Kupriyanov, S; Liu, HZ; Puzon-McLaughlin, W; Zhang, XP; Sheppard, D; Engvall, E; Takada, Y			Functional classification of ADAMs based on a conserved motif for binding to integrin alpha(9)beta(1) - Implications for sperm-egg binding and other cell interactions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEQUENCE-SPECIFIC INTERACTION; ALPHA-SECRETASE CLEAVAGE; DISINTEGRIN DOMAIN; FERTILIN BETA; METALLOPROTEASE-DISINTEGRIN; SWISS-MODEL; MURINE EGGS; ADHESION; PROTEIN; SUBUNIT	ADAMs (a disintegrin and metalloproteases) are members of the metzincin superfamily of metalloproteases. Among integrins binding to disintegrin domains of ADAMs are alpha(9)beta(1) and alpha(v)beta(3), and they bind in an RGD-independent and an RGD-dependent manner, respectively. Human ADAM15 is the only ADAM with the RGD motif in the disintegrin domain. Thus, both integrin alpha(9)beta(1) and alpha(v)beta(3) recognize the ADAM15 disintegrin domain. We determined how these integrins recognize the ADAM15 disintegrin domain by mutational analysis. We found that the Arg(481) and the Asp-Leu-Pro-Glu-Phe residues (residues 488-492) were critical for alpha(9)beta(1) binding, but the RGD motif (residues 484-486) was not. In contrast, the RGD motif was critical for alpha(v)beta(3) binding, but the other residues flanking the RGD motif were not. As the RX6DLPEF alpha(9)beta(1) recognition motif (residues 481-492) is conserved among ADAMs, except for ADAM10 and 17 we hypothesized that alpha(9)beta(1) may recognize disintegrin domains in all ADAMs except ADAM10 and 17. Indeed we found that alpha(9)beta(1) bound avidly to the disintegrin domains of ADAM1, 2, 3, and 9 but not to the disintegrin domains of ADAM10 and 17. As several ADAMs have been implicated in sperm-oocyte interaction, we tested whether the functional classification of ADAMs, based on specificity for integrin alpha(9)beta(1), applies to sperm-egg binding. We found that the ADAM2 and 15 disintegrin domains bound to oocytes, but the ADAM17 disintegrin domain did not. Furthermore, the ADAM2 and 15 disintegrin domains effectively blocked binding of sperm to oocytes, but the ADAM17 disintegrin domain did not. These results suggest that oocytes and alpha(9)beta(1) have similar binding specificities for ADAMs and that alpha(9)beta(1), or a receptor with similar specificity, may be involved in sperm-egg interaction during fertilization. As alpha(9)beta(1) is a receptor for many ADAM disintegrins and alpha(9)beta(1) and ADAMs are widely expressed, alpha(9)beta(1)-ADAM interaction may be of a broad biological importance.	Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA; Burnham Inst, La Jolla, CA 92037 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Ctr Environm & Occupat Hlth, Lung Biol Ctr, Cardiovasc Res Inst, San Francisco, CA 94143 USA	Scripps Research Institute; Sanford Burnham Prebys Medical Discovery Institute; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Takada, Y (corresponding author), Scripps Res Inst, Dept Cell Biol, VB-6,10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	takada@scripps.edu	Tarui, Takehiko/L-4778-2019	Tarui, Takehiko/0000-0002-2519-7052; takada, yoshikazu/0000-0001-5481-9589	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR045446] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR45446] Funding Source: Medline; NIGMS NIH HHS [GM49899] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALMEIDA EAC, 1995, CELL, V81, P1095, DOI 10.1016/S0092-8674(05)80014-5; Bigler D, 2000, J BIOL CHEM, V275, P11576, DOI 10.1074/jbc.275.16.11576; Black RA, 1998, CURR OPIN CELL BIOL, V10, P654, DOI 10.1016/S0955-0674(98)80042-2; Blobel CP, 1997, CELL, V90, P589, DOI 10.1016/S0092-8674(00)80519-X; Bridges LC, 2002, J BIOL CHEM, V277, P3784, DOI 10.1074/jbc.M109538200; Buxbaum JD, 1998, J BIOL CHEM, V273, P27765, DOI 10.1074/jbc.273.43.27765; Cal S, 2000, MOL BIOL CELL, V11, P1457, DOI 10.1091/mbc.11.4.1457; Eto B, 2000, J BIOL CHEM, V275, P34922, DOI 10.1074/jbc.M001953200; Evans JD, 2001, BIOESSAYS, V23, P62, DOI 10.1002/1521-1878(200101)23:1&lt;62::AID-BIES1008&gt;3.0.CO;2-7; Evans JP, 1997, DEV BIOL, V187, P79, DOI 10.1006/dbio.1997.8611; EVANS JP, 1995, J CELL SCI, V108, P3267; EVANS JP, 1999, FRONT BIOSCI, V4, P114; Gilpin BJ, 1998, J BIOL CHEM, V273, P157, DOI 10.1074/jbc.273.1.157; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Izumi Y, 1998, EMBO J, V17, P7260, DOI 10.1093/emboj/17.24.7260; Lammich S, 1999, P NATL ACAD SCI USA, V96, P3922, DOI 10.1073/pnas.96.7.3922; McLane MA, 1998, P SOC EXP BIOL MED, V219, P109, DOI 10.3181/00379727-219-44322; Miller BJ, 2000, J CELL BIOL, V149, P1289, DOI 10.1083/jcb.149.6.1289; Nath D, 2000, J CELL SCI, V113, P2319; Nath D, 1999, J CELL SCI, V112, P579; PALMER EL, 1993, J CELL BIOL, V123, P1289, DOI 10.1083/jcb.123.5.1289; Pan DJ, 1997, CELL, V90, P271, DOI 10.1016/S0092-8674(00)80335-9; PEITSCH MC, 1995, BIO-TECHNOL, V13, P658, DOI 10.1038/nbt0795-658; Peitsch MC, 1996, BIOCHEM SOC T, V24, P274, DOI 10.1042/bst0240274; PRATER CA, 1991, J CELL BIOL, V112, P1031, DOI 10.1083/jcb.112.5.1031; Qi HL, 1999, SCIENCE, V283, P91, DOI 10.1126/science.283.5398.91; Takagi J, 1997, J BIOL CHEM, V272, P19794, DOI 10.1074/jbc.272.32.19794; Takahashi Y, 2001, MOL BIOL CELL, V12, P809, DOI 10.1091/mbc.12.4.809; Taooka Y, 1999, J CELL BIOL, V145, P413, DOI 10.1083/jcb.145.2.413; WANG A, 1995, DEV DYNAM, V204, P421, DOI 10.1002/aja.1002040408; Werb Z, 1998, SCIENCE, V282, P1279, DOI 10.1126/science.282.5392.1279; WESKAMP G, 1994, P NATL ACAD SCI USA, V91, P2748, DOI 10.1073/pnas.91.7.2748; WOLFSBERG TG, 1995, DEV BIOL, V169, P378, DOI 10.1006/dbio.1995.1152; Wolfsberg TG, 1996, DEV BIOL, V180, P389, DOI 10.1006/dbio.1996.0313; YAGAMIHIROMASA T, 1995, NATURE, V377, P652, DOI 10.1038/377652a0; Yuan RY, 1997, J CELL BIOL, V137, P105, DOI 10.1083/jcb.137.1.105; Zhang XP, 1998, J BIOL CHEM, V273, P7345, DOI 10.1074/jbc.273.13.7345; Zhu XL, 2000, J BIOL CHEM, V275, P7677, DOI 10.1074/jbc.275.11.7677	38	146	164	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 17	2002	277	20					17804	17810		10.1074/jbc.M200086200	http://dx.doi.org/10.1074/jbc.M200086200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	553PR	11882657	hybrid			2022-12-27	WOS:000175685100054
J	Kim, JH; Wilder, PJ; Hou, JW; Nowling, T; Rizzino, A				Kim, JH; Wilder, PJ; Hou, JW; Nowling, T; Rizzino, A			Activation of the murine type II transforming growth factor-beta receptor gene - Up-regulation and function of the transcription factor Elf-3/Ert/Esx/Ese-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EMBRYONAL CARCINOMA-CELLS; UBIQUITIN-MEDIATED PROTEOLYSIS; GASTRIC-CANCER CELLS; TGF-BETA; DNA-BINDING; ETS FAMILY; MICROSATELLITE INSTABILITY; DIFFERENTIAL EXPRESSION; PROMOTER SEQUENCES; AUTO-INHIBITION	Previous studies demonstrated that differentiation of mouse embryonal carcinoma cells leads to transcriptional up-regulation of the mouse type II transforming growth factor-beta receptor (mTbetaR-II) gene. To elucidate the molecular mechanisms regulating transcription of this gene, we isolated the 5'-flanking region of the mTbetaR-II gene and characterized its expression in F9-differentiated cells. Analysis of mTbetaR-II promoter/reporter gene constructs demonstrates that two conserved Ets-binding sites play an important role in the activity of the mTbetaR-II promoter. Importantly, we present evidence that mElf-3, a member of the Ets family, plays a key role in the activation of the mTbetaR-II promoter. Northern blot analysis reveals that the steady-state levels of mTbetaR-II mRNA increase in parallel with those of mElf-3 mRNA during the differentiation of F9 embryonal carcinoma cells. We also demonstrate that mElf-3 contains one or more domains that influence its binding to DNA. Finally, we report that a single amino acid substitution in the transactivation domain of mElf-3 reduces its ability to transactivate and elevates its steady-state levels of expression. In conclusion, our data argue that mElf-3 plays a key role in the regulation of the mTbetaR-II gene, and Elf-3 itself is regulated at multiple levels.	Univ Nebraska, Med Ctr, Eppley Inst Res Canc & Allied Dis, Omaha, NE 68198 USA	University of Nebraska System; University of Nebraska Medical Center	Rizzino, A (corresponding author), Univ Nebraska, Med Ctr, Eppley Inst Res Canc & Allied Dis, 600 S 42nd St, Omaha, NE 68198 USA.				NCI NIH HHS [CA 36727, CA 00476, CA 79491] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA036727, R01CA079491] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Andreoli JM, 1997, NUCLEIC ACIDS RES, V25, P4287, DOI 10.1093/nar/25.21.4287; BAE HW, 1995, J BIOL CHEM, V270, P29460, DOI 10.1074/jbc.270.49.29460; Bojovic BB, 2001, J BIOL CHEM, V276, P4509, DOI 10.1074/jbc.M005509200; Chang CH, 1999, ONCOGENE, V18, P3682, DOI 10.1038/sj.onc.1202674; Chang CH, 1997, ONCOGENE, V14, P1617, DOI 10.1038/sj.onc.1200978; Chang J, 1997, CANCER RES, V57, P2856; Chang J, 2000, ONCOGENE, V19, P151, DOI 10.1038/sj.onc.1203252; Choi SG, 1998, J BIOL CHEM, V273, P110, DOI 10.1074/jbc.273.1.110; Cowley DO, 2000, GENE DEV, V14, P366; DALTON S, 1992, CELL, V68, P597, DOI 10.1016/0092-8674(92)90194-H; Galang CK, 1996, J BIOL CHEM, V271, P7992, DOI 10.1074/jbc.271.14.7992; GIOVANE A, 1994, GENE DEV, V8, P1502, DOI 10.1101/gad.8.13.1502; Goetz TL, 2000, MOL CELL BIOL, V20, P81, DOI 10.1128/MCB.20.1.81-90.2000; Graves BJ, 1998, COLD SPRING HARB SYM, V63, P621, DOI 10.1101/sqb.1998.63.621; Greenall A, 2001, J BIOL CHEM, V276, P16207, DOI 10.1074/jbc.M011582200; Gu TL, 2000, MOL CELL BIOL, V20, P91, DOI 10.1128/MCB.20.1.91-103.2000; HAGMAN J, 1992, P NATL ACAD SCI USA, V89, P8889, DOI 10.1073/pnas.89.19.8889; Hodge DR, 1996, ONCOGENE, V12, P11; INAGAKI M, 1993, P NATL ACAD SCI USA, V90, P5359, DOI 10.1073/pnas.90.11.5359; Jackson RJ, 1999, ARCH BIOCHEM BIOPHYS, V371, P290, DOI 10.1006/abbi.1999.1459; JANKNECHT R, 1993, BIOCHIM BIOPHYS ACTA, V1155, P346, DOI 10.1016/0304-419X(93)90014-4; KALKHOVEN E, 1995, CELL GROWTH DIFFER, V6, P1151; KELLY D, 1992, DEV BIOL, V153, P172, DOI 10.1016/0012-1606(92)90102-M; Kelly D, 1998, J BIOL CHEM, V273, P21115, DOI 10.1074/jbc.273.33.21115; Kelly DL, 1999, ANTICANCER RES, V19, P4791; Kim WY, 1999, EMBO J, V18, P1609, DOI 10.1093/emboj/18.6.1609; Laget MP, 1996, ONCOGENE, V12, P1325; Lazzereschi D, 1997, CANCER RES, V57, P2071; Liu Y, 2000, J BIOL CHEM, V275, P12231, DOI 10.1074/jbc.275.16.12231; LOPEZCASILLAS F, 1993, CELL, V73, P1435, DOI 10.1016/0092-8674(93)90368-Z; MA YG, 1992, DEV BIOL, V154, P45, DOI 10.1016/0012-1606(92)90046-J; MARKOWITZ S, 1995, SCIENCE, V268, P1336, DOI 10.1126/science.7761852; MARTIN GR, 1980, SCIENCE, V209, P768, DOI 10.1126/science.6250214; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; Molinari E, 1999, EMBO J, V18, P6439, DOI 10.1093/emboj/18.22.6439; MunozAntonia T, 1996, CANCER RES, V56, P4831; Neve R, 1998, FASEB J, V12, P1541, DOI 10.1096/fasebj.12.14.1541; Norgaard P, 1996, BRIT J CANCER, V73, P1037, DOI 10.1038/bjc.1996.201; Nowling TK, 2000, J BIOL CHEM, V275, P3810, DOI 10.1074/jbc.275.6.3810; Oettgen P, 1997, MOL CELL BIOL, V17, P4419, DOI 10.1128/MCB.17.8.4419; Oettgen P, 1999, J BIOL CHEM, V274, P29439, DOI 10.1074/jbc.274.41.29439; PANKOV R, 1994, MOL CELL BIOL, V14, P7744, DOI 10.1128/MCB.14.12.7744; PARK KC, 1994, P NATL ACAD SCI USA, V91, P8772, DOI 10.1073/pnas.91.19.8772; PARSONS R, 1995, CANCER RES, V55, P5548; PRICE MA, 1995, EMBO J, V14, P2589, DOI 10.1002/j.1460-2075.1995.tb07257.x; REEVES R, 1990, J BIOL CHEM, V265, P8573; RIZZINO A, 1987, CANCER RES, V47, P4386; Rizzino Angie, 1998, P115; ROSFJORD E, 1994, IN VITRO CELL DEV-AN, V30A, P477; Salghetti SE, 2001, SCIENCE, V293, P1651, DOI 10.1126/science.1062079; Salghetti SE, 1999, EMBO J, V18, P717, DOI 10.1093/emboj/18.3.717; Salghetti SE, 2000, P NATL ACAD SCI USA, V97, P3118, DOI 10.1073/pnas.050007597; SAMBROOK J, 1989, MOL CLONING LAB MANU, P269; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; SETH A, 1993, ONCOGENE, V8, P1783; Slupsky CM, 1998, P NATL ACAD SCI USA, V95, P12129, DOI 10.1073/pnas.95.21.12129; STACEY KJ, 1995, MOL CELL BIOL, V15, P3430; SUN LZ, 1994, J BIOL CHEM, V269, P26449; SUZUKI A, 1994, FEBS LETT, V355, P19, DOI 10.1016/0014-5793(94)01156-7; Tansey WP, 2001, GENE DEV, V15, P1045, DOI 10.1101/gad.896501; Thomas RS, 2000, ADV EXP MED BIOL, V480, P123; TOMODA T, 1994, BIOCHEM BIOPH RES CO, V198, P1054, DOI 10.1006/bbrc.1994.1150; Tymms MJ, 1997, ONCOGENE, V15, P2449, DOI 10.1038/sj.onc.1201427; Wang J, 1996, J BIOL CHEM, V271, P17366, DOI 10.1074/jbc.271.29.17366; WANG J, 1995, J BIOL CHEM, V270, P22044, DOI 10.1074/jbc.270.37.22044; WASYLYK B, 1993, EUR J BIOCHEM, V211, P7, DOI 10.1111/j.1432-1033.1993.tb19864.x; WATSON DK, 1992, CELL GROWTH DIFFER, V3, P705; Wiebe MS, 2000, GENE, V246, P383, DOI 10.1016/S0378-1119(00)00086-X; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; Yang SH, 1999, EMBO J, V18, P5666, DOI 10.1093/emboj/18.20.5666; Yoshida N, 2000, MECH DEVELOP, V97, P27, DOI 10.1016/S0925-4773(00)00419-6; Zhang T, 1997, CANCER RES, V57, P1638	72	25	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 17	2002	277	20					17520	17530		10.1074/jbc.M110434200	http://dx.doi.org/10.1074/jbc.M110434200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	553PR	11893733	hybrid			2022-12-27	WOS:000175685100018
J	LaCount, DJ; Barrett, B; Donelson, JE				LaCount, DJ; Barrett, B; Donelson, JE			Trypanosoma brucei FLA1 is required for flagellum attachment and cytokinesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PARAFLAGELLAR ROD; CELL-CYCLE; AFRICAN TRYPANOSOMES; GLYCOPROTEIN GP72; RNA INTERFERENCE; CRUZI; CYTOSKELETON; GENE; DELETION; ADHESION	The single flagellum of the protozoan parasite Trypanosoma brucei is attached along the length of the cell body by a complex structure that requires the FLA1 protein. We show here that inhibition of FLA1 expression by RNA interference in procyclic trypanosomes causes flagellar detachment and prevents cytokinesis. Despite being unable to divide, these cells undergo mitosis and develop a multinucleated phenotype. The Trypanosoma cruzi FLA1 homolog, GP72, is unable to complement either the flagellar detachment or cytokinesis defects in procyclic T. brucei that have been depleted of FLA1 by RNA interference. Instead, GP72 itself caused flagellar detachment when expressed in T. brucei. In contrast to T. brucei cells depleted of FLA1, procyclic T. brucei expressing GP72 continued to divide despite having detached flagella, demonstrating that flagellar attachment is not absolutely necessary for cytokinesis. We have also identified a FLA1-related gene (FLA2) whose sequence is similar but not identical to FLA1. Inhibition of FLA1 and FLA2 expression in bloodstream T. brucei caused flagellar detachment and blocked cytokinesis but did not inhibit mitosis. These experiments demonstrate that the FLA proteins are essential and suggest that in procyclic T. brucei, the FLA1 protein has separable functions in flagellar attachment and cytokinesis.	Univ Iowa, Dept Biochem, Iowa City, IA 52242 USA	University of Iowa	Donelson, JE (corresponding author), Univ Iowa, Dept Biochem, Iowa City, IA 52242 USA.		Donelson, John E/F-5795-2010		NIAID NIH HHS [AI10512, AI40591] Funding Source: Medline; NIDDK NIH HHS [DK25295] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI040591] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK025295] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bangs JD, 1996, J BIOL CHEM, V271, P18387, DOI 10.1074/jbc.271.31.18387; Bastin P, 1996, PARASITOL TODAY, V12, P302, DOI 10.1016/0169-4758(96)10031-4; Bastin P, 1998, NATURE, V391, P548, DOI 10.1038/35300; COOPER R, 1993, J CELL BIOL, V122, P149, DOI 10.1083/jcb.122.1.149; COOPER R, 1991, MOL BIOCHEM PARASIT, V49, P45, DOI 10.1016/0166-6851(91)90129-T; DEJESUS AR, 1993, J CELL SCI, V106, P1023; ELSAYED NMA, 1995, MOL BIOCHEM PARASIT, V73, P75, DOI 10.1016/0166-6851(95)00098-L; FERGUSON MAJ, 1983, BIOCHEM J, V213, P313, DOI 10.1042/bj2130313; Gull K, 1999, ANNU REV MICROBIOL, V53, P629, DOI 10.1146/annurev.micro.53.1.629; Haynes PA, 1996, J CELL SCI, V109, P2979; Hill KL, 1999, J CELL SCI, V112, P3091; HIRUMI H, 1980, PARASITOLOGY, V80, P371, DOI 10.1017/S0031182000000822; Kohl L, 1999, J EUKARYOT MICROBIOL, V46, P105, DOI 10.1111/j.1550-7408.1999.tb04592.x; Kohl L, 1998, MOL BIOCHEM PARASIT, V93, P1, DOI 10.1016/S0166-6851(98)00014-0; LaCount DJ, 2000, MOL BIOCHEM PARASIT, V111, P67, DOI 10.1016/S0166-6851(00)00300-5; LaCount DJ, 2001, PROTIST, V152, P103, DOI 10.1078/1434-4610-00047; Maga JA, 1999, J CELL SCI, V112, P2753; Moreira-Leite FF, 2001, SCIENCE, V294, P610, DOI 10.1126/science.1063775; Ngo H, 1998, P NATL ACAD SCI USA, V95, P14687, DOI 10.1073/pnas.95.25.14687; Nozaki T, 1996, MOL BIOCHEM PARASIT, V82, P245, DOI 10.1016/0166-6851(96)02741-7; ROBINSON DR, 1995, J CELL BIOL, V128, P1163, DOI 10.1083/jcb.128.6.1163; SHERWIN T, 1989, PHILOS T R SOC B, V323, P573, DOI 10.1098/rstb.1989.0037; Wang ZF, 2000, J BIOL CHEM, V275, P40174, DOI 10.1074/jbc.M008405200; Wirtz E, 1999, MOL BIOCHEM PARASIT, V99, P89, DOI 10.1016/S0166-6851(99)00002-X; WOODWARD R, 1990, J CELL SCI, V95, P49	25	151	151	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 17	2002	277	20					17580	17588		10.1074/jbc.M200873200	http://dx.doi.org/10.1074/jbc.M200873200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	553PR	11877446	hybrid			2022-12-27	WOS:000175685100026
J	Johansson, AS; Mannervik, B				Johansson, AS; Mannervik, B			Active-site residues governing high steroid isomerase activity in human glutathione transferase A3-3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							S-TRANSFERASES; 3-OXO-DELTA(5)-STEROID ISOMERASE; MALEYLACETOACETATE ISOMERASE; CATALYTIC MECHANISM; MU-CLASS; ISOMERIZATION; A1-1; ACID; IDENTIFICATION; PATHWAY	Glutathione transferase (GST) A3-3 is the most efficient human steroid double-bond isomerase known. The activity with Delta(5)-androstene-3,17-dione is highly dependent on the phenolic hydroxyl group of Tyr-9 and the thiolate of glutathione. Removal of these groups caused an 1.1 x 10(5)-fold decrease in k(cat); the Y9F mutant displayed a 150-fold lower isomerase activity in the presence of glutathione and a further 740-fold lower activity in the absence of glutathione. The Y9F mutation in GST A3-3 did not markedly decrease the activity with the alternative substrate 1-chloro-2,4-dinitrobenzene. Residues Phe-10, Leu-111, and Ala-216 selectively govern the activity with the steroid substrate. Mutating residue 111 into phenylalanine caused a 25-fold decrease in k(cat)/K-m for the steroid isomerization. The mutations A216S and F10S, separate or combined, affected the isomerase activity only marginally, but with the additional L111F mutation k(cat)/K-m was reduced to 0.8% of that of the wildtype value. In contrast, the activities with 1-chloro-2,4-dinitrobenzene and phenethylisothiocyanate were not largely affected by the combined mutations F10S/L111F/A216S. K-i values for Delta(5) -androstene-3,17-dione and Delta(4)-androstene-3,17-dione were increased by the triple mutation F10S/L111F/A216S. The pK(a) of the thiol group of active-site-bound glutathione, 6.1, increased to 6.5 in GST A3-3/Y9F. The pK(a) of the active-site Tyr-9 was 7.9 for the wild-type enzyme. The pH dependence of k(cat)/K-m of wild-type GST A3-3 for the isomerase reaction displays two kinetic pk(a) values, 6.2 and 8.1. The basic limb of the pH dependence of k(cat) and k(cat)/K-m disappears in the Y9F mutant. Therefore, the higher kinetic pK(a) reflects ionization of Tyr-9, and the lower one reflects ionization of glutathione. We propose a reaction mechanism for the double-bond isomerization involving abstraction of a proton from C4 in the steroid accompanied by protonation of C6, the thiolate of glutathione serving as a base and Tyr-9 assisting by polarizing the 3-oxo group of the substrate.	Uppsala Univ, Dept Biochem, Ctr Biomed, SE-75123 Uppsala, Sweden	Uppsala University	Mannervik, B (corresponding author), Uppsala Univ, Dept Biochem, Ctr Biomed, Box 576, SE-75123 Uppsala, Sweden.			Jemth, Ann-Sofie/0000-0002-7550-1833				Adler V, 1999, EMBO J, V18, P1321, DOI 10.1093/emboj/18.5.1321; Armstrong RN, 1997, CHEM RES TOXICOL, V10, P2, DOI 10.1021/tx960072x; Atkins WM, 1997, PROTEIN SCI, V6, P873; BARDSLEY WG, 1995, COMPUT CHEM, V19, P75, DOI 10.1016/0097-8485(95)00007-F; BENSON AM, 1977, P NATL ACAD SCI USA, V74, P158, DOI 10.1073/pnas.74.1.158; Beuckmann CT, 2000, NEUROCHEM RES, V25, P733, DOI 10.1023/A:1007579507804; BJORNESTEDT R, 1995, J MOL BIOL, V247, P765; Blackburn AC, 1998, CYTOGENET CELL GENET, V83, P109, DOI 10.1159/000015145; Board PG, 1998, BIOCHEM J, V330, P827; BURGESS JR, 1989, BIOCHEM BIOPH RES CO, V158, P497, DOI 10.1016/S0006-291X(89)80076-2; CAMERON AD, 1995, STRUCTURE, V3, P717, DOI 10.1016/S0969-2126(01)00206-4; Chen H, 1998, BIOCHEM J, V336, P223, DOI 10.1042/bj3360223; CREIGHTON TE, 1993, PROTEINS STRUCTURES, P16; Dietze EC, 1996, BIOCHEMISTRY-US, V35, P11938, DOI 10.1021/bi961073r; Fernandez-Canon JM, 1998, J BIOL CHEM, V273, P329, DOI 10.1074/jbc.273.1.329; Fersht A., 1999, STRUCTURE MECH PROTE, DOI 10.1142/10574; GRAMINSKI GF, 1989, BIOCHEMISTRY-US, V28, P3562, DOI 10.1021/bi00434a062; Gustafsson A, 2001, BIOCHEMISTRY-US, V40, P15835, DOI 10.1021/bi010429i; HABIG WH, 1974, J BIOL CHEM, V249, P7130; Johansson AS, 2001, J BIOL CHEM, V276, P33061, DOI 10.1074/jbc.M104539200; JUNG G, 1972, EUR J BIOCHEM, V24, P438, DOI 10.1111/j.1432-1033.1972.tb19704.x; Kanaoka Y, 1997, CELL, V90, P1085, DOI 10.1016/S0092-8674(00)80374-8; Khojasteh-Bakht SC, 1999, ARCH BIOCHEM BIOPHYS, V370, P59, DOI 10.1006/abbi.1999.1361; Kim SW, 1997, BIOCHEMISTRY-US, V36, P14030, DOI 10.1021/bi971546+; KOLM RH, 1992, BIOCHEM J, V285, P537, DOI 10.1042/bj2850537; KULIOPULOS A, 1989, BIOCHEMISTRY-US, V28, P149, DOI 10.1021/bi00427a022; MEYER DJ, 1995, BIOCHEM J, V306, P565, DOI 10.1042/bj3060565; Pettersson PL, 2001, J BIOL CHEM, V276, P11698, DOI 10.1074/jbc.M009146200; POLLACK RM, 1989, J AM CHEM SOC, V111, P6419, DOI 10.1021/ja00198a066; Sambrook J., 2001, MOL CLONING, V2; SINNING I, 1993, J MOL BIOL, V232, P192, DOI 10.1006/jmbi.1993.1376; STENBERG G, 1991, FEBS LETT, V293, P153, DOI 10.1016/0014-5793(91)81174-7; Thornburg LD, 2001, J AM CHEM SOC, V123, P9912, DOI 10.1021/ja016683f; Wu ZR, 1997, SCIENCE, V276, P415, DOI 10.1126/science.276.5311.415; Zhao TJ, 1999, ARCH BIOCHEM BIOPHYS, V367, P216, DOI 10.1006/abbi.1999.1277	35	41	41	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 10	2002	277	19					16648	16654		10.1074/jbc.M201062200	http://dx.doi.org/10.1074/jbc.M201062200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	551MB	11872752	hybrid			2022-12-27	WOS:000175564500042
J	Laurila, MRL; Makeyev, EV; Bamford, DH				Laurila, MRL; Makeyev, EV; Bamford, DH			Bacteriophage phi 6 RNA-dependent RNA polymerase - Molecular details of initiating nucleic acid synthesis without primer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPATITIS-C VIRUS; DE-NOVO INITIATION; MINUS-STRAND RNA; PROTEIN 5B POLYMERASE; CRYSTAL-STRUCTURE; GENOMIC SEGMENTS; VIRAL-RNA; ESCHERICHIA-COLI; IDENTIFICATION; POLIOVIRUS	Like most RNA polymerases, the polymerase of double-strand RNA bacteriophage phi6 (phi6pol) is capable of primer-independent initiation. Based on the recently solved phi6pol initiation complex structure, a four-amino acid-long loop (amino acids 630-633) has been suggested to stabilize the first two incoming NTPs through stacking interactions with tyrosine, Tyr(630). A similar loop is also present in the hepatitis C virus polymerase, another enzyme capable of de novo initiation. Here, we use a series of phi6pol mutants to address the role of this element. As predicted, mutants at the Tyr(630) position are inefficient in initiation de novo. Unexpectedly, when the loop is disordered by changing Tyr(630)-Lys(631)-Trp(632) to GSG, phi6pol becomes a primer-dependent enzyme, either extending complementary oligonucleotide or, when the template 3' terminus can adopt a hairpin-like conformation, utilizing a "copy-back" initiation mechanism. In contrast to the wild-type phi6pol, the GSG mutant does not require high GTP concentration for its optimal activity. These findings suggest a general model for the initiation of de novo RNA synthesis.	Univ Helsinki, Dept Biosci, FIN-00014 Helsinki, Finland; Univ Helsinki, Inst Biotechnol, FIN-00014 Helsinki, Finland	University of Helsinki; University of Helsinki	Bamford, DH (corresponding author), Univ Helsinki, Dept Biosci, POB 56,Viikinkaari 5, FIN-00014 Helsinki, Finland.	dennis.bamford@helsinki.fi		Makeyev, Eugene/0000-0001-6034-6896				Ackermann M, 2001, J BIOL CHEM, V276, P39926, DOI 10.1074/jbc.M104248200; Ago H, 1999, STRUCTURE, V7, P1417, DOI 10.1016/S0969-2126(00)80031-3; Behrens SE, 1996, EMBO J, V15, P12, DOI 10.1002/j.1460-2075.1996.tb00329.x; BLUMENTHAL T, 1980, P NATL ACAD SCI-BIOL, V77, P2601, DOI 10.1073/pnas.77.5.2601; Bressanelli S, 1999, P NATL ACAD SCI USA, V96, P13034, DOI 10.1073/pnas.96.23.13034; BREWER G, 1992, PROMEGA NOTES, V38, P1; Buck KW, 1996, ADV VIRUS RES, V47, P159, DOI 10.1016/S0065-3527(08)60736-8; Butcher SJ, 2001, NATURE, V410, P235, DOI 10.1038/35065653; Ferrari E, 1999, J VIROL, V73, P1649, DOI 10.1128/JVI.73.2.1649-1654.1999; GOTTLIEB P, 1992, J VIROL, V66, P2611, DOI 10.1128/JVI.66.5.2611-2616.1992; Guyatt KJ, 2001, J VIROL METHODS, V92, P37, DOI 10.1016/S0166-0934(00)00270-6; Hansen JL, 1997, STRUCTURE, V5, P1109, DOI 10.1016/S0969-2126(97)00261-X; HEY TD, 1986, J VIROL, V58, P790, DOI 10.1128/JVI.58.3.790-796.1986; Hong Z, 2001, VIROLOGY, V285, P6, DOI 10.1006/viro.2001.0948; Hoogstraten D, 2000, VIROLOGY, V272, P218, DOI 10.1006/viro.2000.0374; Kao CC, 1996, J VIROL, V70, P6826, DOI 10.1128/JVI.70.10.6826-6830.1996; Kao CC, 2001, VIROLOGY, V287, P251, DOI 10.1006/viro.2001.1039; Kao CC, 1999, VIROLOGY, V253, P1, DOI 10.1006/viro.1998.9517; KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403; Lesburg CA, 1999, NAT STRUCT BIOL, V6, P937; Lohmann V, 1997, J VIROL, V71, P8416, DOI 10.1128/JVI.71.11.8416-8428.1997; LOSICK R, 1976, RNA POLYM; LUBINSKI JM, 1987, J VIROL, V61, P2997, DOI 10.1128/JVI.61.10.2997-3003.1987; Luo GX, 2000, J VIROL, V74, P851, DOI 10.1128/JVI.74.2.851-863.2000; Makeyev EV, 2000, EMBO J, V19, P6275, DOI 10.1093/emboj/19.22.6275; Makeyev EV, 2000, EMBO J, V19, P124, DOI 10.1093/emboj/19.1.124; Makeyev EV, 2001, RNA, V7, P774, DOI 10.1017/S1355838201002060; MINDICH L, 1994, VIROLOGY, V202, P258, DOI 10.1006/viro.1994.1341; Oh JW, 1999, J VIROL, V73, P7694, DOI 10.1128/JVI.73.9.7694-7702.1999; OLLIS DL, 1985, NATURE, V313, P762, DOI 10.1038/313762a0; PAGRATIS N, 1990, VIROLOGY, V177, P273, DOI 10.1016/0042-6822(90)90480-F; Paul AV, 1998, NATURE, V393, P280, DOI 10.1038/30529; Pirttimaa MJT, 2000, RNA, V6, P880, DOI 10.1017/S1355838200992598; Qiao XY, 2000, VIROLOGY, V275, P218, DOI 10.1006/viro.2000.0501; SOUSA R, 1993, NATURE, V364, P593, DOI 10.1038/364593a0; Steffens S, 1999, J GEN VIROL, V80, P2583, DOI 10.1099/0022-1317-80-10-2583; STERN S, 1988, METHOD ENZYMOL, V164, P481; Sun XL, 2000, BIOCHEM BIOPH RES CO, V268, P798, DOI 10.1006/bbrc.2000.2120; Vazquez AL, 2001, ARCH VIROL, V146, P59, DOI 10.1007/s007050170191; Yamashita T, 1998, J BIOL CHEM, V273, P15479, DOI 10.1074/jbc.273.25.15479; Yang HY, 2001, J VIROL, V75, P11088, DOI 10.1128/JVI.75.22.11088-11095.2001; Zhong WD, 2000, J VIROL, V74, P2017, DOI 10.1128/JVI.74.4.2017-2022.2000; Zhong WD, 1998, J VIROL, V72, P9365, DOI 10.1128/JVI.72.11.9365-9369.1998; Zhong WD, 2000, J VIROL, V74, P9134, DOI 10.1128/JVI.74.19.9134-9143.2000	44	55	58	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 10	2002	277	19					17117	17124		10.1074/jbc.M111220200	http://dx.doi.org/10.1074/jbc.M111220200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	551MB	11877396	hybrid			2022-12-27	WOS:000175564500104
J	Yarian, C; Townsend, H; Czestkowski, W; Sochacka, E; Malkiewicz, AJ; Guenther, R; Miskiewicz, A; Agris, PF				Yarian, C; Townsend, H; Czestkowski, W; Sochacka, E; Malkiewicz, AJ; Guenther, R; Miskiewicz, A; Agris, PF			Accurate translation of the genetic code depends on tRNA modified nucleosides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER-RNA BINDING; 30S RIBOSOMAL-SUBUNIT; ESCHERICHIA-COLI; ANTICODON STEM; CRYSTAL-STRUCTURE; SITES; LOOP; RECOGNITION; TETRACYCLINE; ANTIBIOTICS	Transfer RNA molecules translate the genetic code by recognizing cognate mRNA codons during protein synthesis. The anticodon wobble at position 34 and the nucleotide immediately 3' to the anticodon triplet at position 37 display a large diversity of modified nucleosides in the tRNAs of all organisms. We show that tRNA species translating 2-fold degenerate codons require a modified U-34 to enable recognition of their cognate codons ending in A or G but restrict reading of noncognate or near-cognate codons ending in U and C that specify a different amino acid. In particular, the nucleoside modifications 2-thiouridine at position 34 (s(2)U(34)), 5-methylaminomethyluridine at position 34 (mnm(5)U(34)), and 6-threonylcarbamoyladenosine at position 37 (t(6)A(37)) were essential for Watson-Crick (AAA) and wobble (AAG) cognate codon recognition by tRNA(UUU)(Lys), at the ribosomal aminoacyl and peptidyl sites but did not enable the recognition of the asparagine codons (AAU and AAC). We conclude that modified nucleosides evolved to modulate an anticodon domain structure necessary for many tRNA species to accurately translate the genetic code.	N Carolina State Univ, Dept Biochem, Raleigh, NC 27695 USA; Tech Univ Lodz, Inst Organ Chem, PL-90924 Lodz, Poland	University of North Carolina; North Carolina State University; Lodz University of Technology	Agris, PF (corresponding author), N Carolina State Univ, Dept Mol & Struct Biochem, 128 Polk Hall,Box 7622, Raleigh, NC 27695 USA.		Dziergowska, Agnieszka/H-5240-2017; Sochacka, Elzbieta/N-2520-2018	Dziergowska, Agnieszka/0000-0002-8888-380X; Sochacka, Elzbieta/0000-0003-3240-1143	NIGMS NIH HHS [GM23037] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM023037] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ashraf SS, 1999, RNA, V5, P188, DOI 10.1017/S1355838299981529; Benas P, 2000, RNA, V6, P1347, DOI 10.1017/S1355838200000911; Beuning PJ, 1999, BIOPOLYMERS, V52, P1; Brodersen DE, 2000, CELL, V103, P1143, DOI 10.1016/S0092-8674(00)00216-6; CRICK FHC, 1966, J MOL BIOL, V19, P548, DOI 10.1016/S0022-2836(66)80022-0; DIAZ I, 1991, J MOL BIOL, V222, P1161, DOI 10.1016/0022-2836(91)90599-2; ERICSON G, 1995, J MOL BIOL, V250, P407, DOI 10.1006/jmbi.1995.0386; GRAJEVSKAJA RA, 1982, EUR J BIOCHEM, V128, P47; Gumport R I, 1981, Gene Amplif Anal, V2, P313; HARRINGTON KM, 1993, BIOCHEMISTRY-US, V32, P7617, DOI 10.1021/bi00081a003; Joseph S, 1998, EMBO J, V17, P3478, DOI 10.1093/emboj/17.12.3478; KIRILLOV SV, 1980, NUCLEIC ACIDS RES, V8, P183, DOI 10.1093/nar/8.1.183; Li JN, 1997, J MOL BIOL, V271, P209, DOI 10.1006/jmbi.1997.1176; LILL R, 1986, BIOCHEMISTRY-US, V25, P3245, DOI 10.1021/bi00359a025; Lim VI, 2001, RNA, V7, P942, DOI 10.1017/S135583820100214X; LIM VI, 1994, J MOL BIOL, V240, P8, DOI 10.1006/jmbi.1994.1413; MOAZED D, 1990, J MOL BIOL, V211, P135, DOI 10.1016/0022-2836(90)90016-F; MOAZED D, 1987, NATURE, V327, P389, DOI 10.1038/327389a0; Noah JW, 1999, J BIOL CHEM, V274, P16576, DOI 10.1074/jbc.274.23.16576; Ogle JM, 2001, SCIENCE, V292, P897, DOI 10.1126/science.1060612; Parfenov D. V., 1993, Molekulyarnaya Biologiya (Moscow), V27, P827; PARFENOV D V, 1985, Molekulyarnaya Biologiya (Moscow), V19, P1378; Sprinzl M, 1998, NUCLEIC ACIDS RES, V26, P148, DOI 10.1093/nar/26.1.148; Stuart JW, 2000, BIOCHEMISTRY-US, V39, P13396, DOI 10.1021/bi0013039; Sundaram M, 2000, BIOCHEMISTRY-US, V39, P12575, DOI 10.1021/bi0014655; SYLVERS LA, 1993, BIOCHEMISTRY-US, V32, P3836, DOI 10.1021/bi00066a002; Urbonavicius J, 2001, EMBO J, V20, P4863, DOI 10.1093/emboj/20.17.4863; vonAhsen U, 1997, RNA, V3, P49; Yarian C, 2000, BIOCHEMISTRY-US, V39, P13390, DOI 10.1021/bi001302g; YOKOYAMA S, 1985, P NATL ACAD SCI USA, V82, P4905, DOI 10.1073/pnas.82.15.4905; Yokoyama Shigeyuki, 1995, P207; Yusupov MM, 2001, SCIENCE, V292, P883, DOI 10.1126/science.1060089	32	185	192	0	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 10	2002	277	19					16391	16395		10.1074/jbc.M200253200	http://dx.doi.org/10.1074/jbc.M200253200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	551MB	11861649	hybrid			2022-12-27	WOS:000175564500008
J	Adak, S; Aulak, KS; Stuehr, DJ				Adak, S; Aulak, KS; Stuehr, DJ			Direct evidence for nitric oxide production by a nitric-oxide synthase-like protein from Bacillus subtilis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPLETE GENOME SEQUENCE; TETRAHYDROBIOPTERIN; ARGININE; DOMAIN; MECHANISM; REDUCTION; CATALYSIS	Nitric-oxide synthases (NOSs) are widely distributed among prokaryotes and eukaryotes and have diverse functions in physiology. Recent genome sequencing revealed NOS-like protein in bacteria, but whether these proteins generate nitric oxide is unknown. We therefore cloned, expressed, and purified a NOS-like protein from Bacillus subtilis (bsNOS) and characterized its catalytic parameters in both multiple and single turnover reactions. bsNOS was dimeric, bound L-Arg and 6R-tetrahydrobiopterin with similar affinity as mammalian NOS, and generated nitrite from L-Arg when incubated with NADPH and a mammalian NOS reductase domain. Stopped-flow analysis showed that ferrous bsNOS reacted with O-2 to form a transient heme Fe(II)O-2 Species in the presence of either Arg or the reaction intermediate N-hydroxy-L-arginine. In the latter case, disappearance of the Fe(II)O-2 species was kinetically and quantitatively coupled to formation of a transient heme Fe(III)NO product, which then dissociated to form ferric bsNOS. This behavior mirrors mammalian NOS enzymes and unambiguously shows that bsNOS can generate NO. NO formation required a bound tetrahydropteridine, and the kinetic effects of this cofactor were consistent with it donating an electron to the Fe(II)O-2 intermediate during the reaction. Dissociation of the heme Fe(III)NO product was much slower in bsNOS than in mammalian NOS. This constrains allowable rates of ferric heme reduction by a protein redox partner and underscores the utility of using a tetrahydropteridine electron donor in bsNOS.	Cleveland Clin Fdn, Lerner Res Inst, Dept Immunol, Cleveland, OH 44195 USA	Cleveland Clinic Foundation	Adak, S (corresponding author), Cleveland Clin Fdn, Lerner Res Inst, Dept Immunol, 9500 Euclid Ave, Cleveland, OH 44195 USA.				NCI NIH HHS [CA53914] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA053914, R01CA053914] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AbuSoud HM, 1997, J BIOL CHEM, V272, P17349, DOI 10.1074/jbc.272.28.17349; Adak S, 2000, J BIOL CHEM, V275, P33554, DOI 10.1074/jbc.M004337200; Adak S, 2001, J BIOL CHEM, V276, P1244, DOI 10.1074/jbc.M006857200; Adak S, 1999, J BIOL CHEM, V274, P22313, DOI 10.1074/jbc.274.32.22313; Adak S, 2002, P NATL ACAD SCI USA, V99, P107, DOI 10.1073/pnas.012470099; Boggs S, 2000, BIOCHEMISTRY-US, V39, P2332, DOI 10.1021/bi9920228; Crane BR, 1999, EMBO J, V18, P6271, DOI 10.1093/emboj/18.22.6271; Degtyarenko KN, 2001, BIOCHEM SOC T, V29, P139, DOI 10.1042/BST0290139; Golderer G, 2001, GENE DEV, V15, P1299, DOI 10.1101/gad.890501; GRIFFITH OW, 1995, ANNU REV PHYSIOL, V57, P707, DOI 10.1146/annurev.ph.57.030195.003423; Hurshman AR, 1999, BIOCHEMISTRY-US, V38, P15689, DOI 10.1021/bi992026c; Kharitonov VG, 1997, BIOCHEM BIOPH RES CO, V239, P284, DOI 10.1006/bbrc.1997.7470; Klessig DF, 2000, P NATL ACAD SCI USA, V97, P8849, DOI 10.1073/pnas.97.16.8849; Kunst F, 1997, NATURE, V390, P249, DOI 10.1038/36786; Muller U, 1997, PROG NEUROBIOL, V51, P363, DOI 10.1016/S0301-0082(96)00067-6; Rusche KM, 1998, BIOCHEMISTRY-US, V37, P15503, DOI 10.1021/bi9813936; Santolini J, 2001, J BIOL CHEM, V276, P48887, DOI 10.1074/jbc.M108666200; Santolini J, 2001, J BIOL CHEM, V276, P1233, DOI 10.1074/jbc.M006858200; Scheele JS, 1999, J BIOL CHEM, V274, P13105, DOI 10.1074/jbc.274.19.13105; Takami H, 2000, NUCLEIC ACIDS RES, V28, P4317, DOI 10.1093/nar/28.21.4317; Wang ZQ, 2002, J BIOL CHEM, V277, P12830, DOI 10.1074/jbc.M111967200; Wei CC, 2001, J BIOL CHEM, V276, P315, DOI 10.1074/jbc.M008441200; White O, 1999, SCIENCE, V286, P1571, DOI 10.1126/science.286.5444.1571	23	162	166	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 3	2002	277	18					16167	16171		10.1074/jbc.M201136200	http://dx.doi.org/10.1074/jbc.M201136200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	550PA	11856757	hybrid			2022-12-27	WOS:000175510400126
J	Furukawa, M; Ohta, T; Xiong, Y				Furukawa, M; Ohta, T; Xiong, Y			Activation of UBC5 ubiquitin-conjugating enzyme by the RING finger of ROC1 and assembly of active ubiquitin ligases by all cullins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-SUPPRESSOR PROTEIN; CRYSTAL-STRUCTURE; CELL-DIVISION; BOX PROTEINS; U-BOX; IDENTIFICATION; COMPLEX; DOMAIN; SUBUNIT; APC11	Protein ubiquitination plays an important role in regulating the abundance and conformation of a broad range of eukaryotic proteins. This process involves a cascade of enzymes including ubiquitin-activating enzymes (E1), ubiquitin-conjugating enzymes (E2), and ubiquitin ligases (E3). E1 and E2 represent two families of structurally related proteins and are relatively well characterized. In contrast, the nature and mechanism of E3, proposed to contain activities in catalyzing isopeptide bond formation (ubiquitin ligation) and substrate targeting, remains inadeqnately understood. Two major families of E3 ubiquitin ligases, the HECT (for homologous to E6-AP C terminus) family and the RING family, have been identified that utilize distinct mechanisms in promoting isopeptide bond formation. Here, we showed that purified RING finger domain of ROC1, an essential subunit of SKP1-cullin/CDC53-F box protein ubiquitin ligases, was sufficient to activate UBCH5c to synthesize polyubiquitin chains. The sequence flanking the RING finger in ROC1 did not contribute to UBCH5c activation, but was required for binding with CUL1. We demonstrated that all cullins, through their binding with ROC proteins, constituted active ubiquitin ligases, suggesting the existence in vivo of a large number of cullin-RING ubiquitin ligases. These results are consistent with the notion that the RING finger domains allosterically activate E2. We suggest that RING-E2, rather than cullin-RING, constitutes the catalytic core of the ubiquitin ligase and that one major function of the cullin subunit is to assemble the RING-E2 catalytic core and substrates together.	Univ N Carolina, Lineberger Canc Res Ctr, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA; Univ N Carolina, Program Mol Biol & Biotechnol, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Xiong, Y (corresponding author), Univ N Carolina, Lineberger Canc Res Ctr, CB 7295, Chapel Hill, NC 27599 USA.	yxiong@email.unc.edu		Ohta, Tomohiko/0000-0002-9700-7342				Aravind L, 2000, CURR BIOL, V10, pR132, DOI 10.1016/S0960-9822(00)00398-5; BORDEN KLB, 1995, EMBO J, V14, P1532, DOI 10.1002/j.1460-2075.1995.tb07139.x; Chen A, 2000, J BIOL CHEM, V275, P15432, DOI 10.1074/jbc.M907300199; COOK WJ, 1992, J BIOL CHEM, V267, P15116; COOK WJ, 1993, BIOCHEMISTRY-US, V32, P13809, DOI 10.1021/bi00213a009; Cook WJ, 1997, BIOCHEMISTRY-US, V36, P1621, DOI 10.1021/bi962639e; Deshaies RJ, 1999, ANNU REV CELL DEV BI, V15, P435, DOI 10.1146/annurev.cellbio.15.1.435; Feldman RMR, 1997, CELL, V91, P221, DOI 10.1016/S0092-8674(00)80404-3; FREEMONT PS, 1991, CELL, V64, P483, DOI 10.1016/0092-8674(91)90229-R; Furukawa M, 2000, MOL CELL BIOL, V20, P8185, DOI 10.1128/MCB.20.21.8185-8197.2000; Gmachl M, 2000, P NATL ACAD SCI USA, V97, P8973, DOI 10.1073/pnas.97.16.8973; Hatakeyama S, 2001, J BIOL CHEM, V276, P33111, DOI 10.1074/jbc.M102755200; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hochstrasser M, 2000, NAT CELL BIOL, V2, pE153, DOI 10.1038/35019643; HUIBREGTSE JM, 1995, P NATL ACAD SCI USA, V92, P2563, DOI 10.1073/pnas.92.7.2563; Iwai K, 1999, P NATL ACAD SCI USA, V96, P12436, DOI 10.1073/pnas.96.22.12436; Jackson PK, 2000, TRENDS CELL BIOL, V10, P429, DOI 10.1016/S0962-8924(00)01834-1; JENKINS CW, 1995, CELL CYCLE MAT METHO, P250; JENTSCH S, 1992, ANNU REV GENET, V26, P179, DOI 10.1146/annurev.ge.26.120192.001143; Joazeiro CAP, 2000, CELL, V102, P549, DOI 10.1016/S0092-8674(00)00077-5; Kamura T, 1999, GENE DEV, V13, P2928, DOI 10.1101/gad.13.22.2928; King RW, 1996, SCIENCE, V274, P1652, DOI 10.1126/science.274.5293.1652; Kipreos ET, 1996, CELL, V85, P829, DOI 10.1016/S0092-8674(00)81267-2; Koegl M, 1999, CELL, V96, P635, DOI 10.1016/S0092-8674(00)80574-7; Lammer D, 1998, GENE DEV, V12, P914, DOI 10.1101/gad.12.7.914; Leverson JD, 2000, MOL BIOL CELL, V11, P2315, DOI 10.1091/mbc.11.7.2315; Lisztwan J, 1999, GENE DEV, V13, P1822, DOI 10.1101/gad.13.14.1822; Mathias N, 1998, J BIOL CHEM, V273, P4040, DOI 10.1074/jbc.273.7.4040; Michel JJ, 1998, CELL GROWTH DIFFER, V9, P435; Ohh M, 2000, NAT CELL BIOL, V2, P423, DOI 10.1038/35017054; Ohta T, 1999, ONCOGENE, V18, P6758, DOI 10.1038/sj.onc.1203115; Ohta T, 1999, MOL CELL, V3, P535, DOI 10.1016/S1097-2765(00)80482-7; Patton EE, 1998, GENE DEV, V12, P692, DOI 10.1101/gad.12.5.692; PTAK C, 1994, J BIOL CHEM, V269, P26539; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; SCHEFFNER M, 1995, NATURE, V373, P81, DOI 10.1038/373081a0; SCHEFFNER M, 1992, J VIROL, V66, P5100, DOI 10.1128/JVI.66.8.5100-5105.1992; Seol JH, 1999, GENE DEV, V13, P1614, DOI 10.1101/gad.13.12.1614; Skowyra D, 1997, CELL, V91, P209, DOI 10.1016/S0092-8674(00)80403-1; Skowyra D, 1999, SCIENCE, V284, P662, DOI 10.1126/science.284.5414.662; Tan PL, 1999, MOL CELL, V3, P527, DOI 10.1016/S1097-2765(00)80481-5; Tang ZY, 2001, MOL BIOL CELL, V12, P3839, DOI 10.1091/mbc.12.12.3839; Yaron A, 1998, NATURE, V396, P590, DOI 10.1038/25159; Yu HT, 1996, CURR BIOL, V6, P455, DOI 10.1016/S0960-9822(02)00513-4; Yu HT, 1998, SCIENCE, V279, P1219, DOI 10.1126/science.279.5354.1219; Zachariae W, 1999, GENE DEV, V13, P2039, DOI 10.1101/gad.13.16.2039; Zachariae W, 1998, SCIENCE, V279, P1216, DOI 10.1126/science.279.5354.1216; Zheng N, 2000, CELL, V102, P533, DOI 10.1016/S0092-8674(00)00057-X	48	64	66	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 3	2002	277	18					15758	15765		10.1074/jbc.M108565200	http://dx.doi.org/10.1074/jbc.M108565200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	550PA	11861641	hybrid, Green Published			2022-12-27	WOS:000175510400073
J	Shen, MR; Yang, TP; Tang, MJ				Shen, MR; Yang, TP; Tang, MJ			A novel function of BCL-2 overexpression in regulatory volume decrease - Enhancing swelling-activated Ca2+ entry and Cl- channel activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SENSITIVE CHLORIDE CHANNELS; CAPACITATIVE CALCIUM-ENTRY; CERVICAL-CANCER CELLS; KIDNEY-CELLS; MDCK CELLS; APOPTOSIS; KINASE; INVOLVEMENT; LYMPHOCYTES; EXPRESSION	The cellular function of the oncogene bcl-2, a key regulator of apoptosis, is still debated. The goal of this study was to explore the relationship between BCL-2 overexpression and cell volume regulation by using two independent models, Madin-Darby canine kidney (MDCK) cells stably transfected with BCL-2 and MDCK clones with inducible BCL-2 expression by the lac operator/repressor. BCL-2 overexpression enhanced the capability of regulatory volume decrease (RVD), a cellular defensive process against hypotonic stress. In various clones of MDCK cells, hypotonic stress induced an outwardly rectified Cl- current that was significantly upregulated by BCL-2 overexpression. Other fundamental characteristics of this channel were similar among different MDCK clones, such as sensitivity to Cl- channel inhibitor, anion permeability, and time-dependent inactivation at more positive potential. Most importantly, BCL-2 overexpression up-regulates the swelling-activated Ca2+ transient that is a critical signaling for normal RVD and the activation of swelling-activated Cl- channel in MDCK cells. BCL-2 overexpression also enhances the capacitative Ca2+ entry that can be differentiated from the swelling-activated Ca2+ transient by kinetic analysis and sensitivity to Gd3+. Moreover, neutralization of endogenous BCL-2 by antibody blocks the normal RVD response and the activation of swelling-activated Cl- channel in human cervical cancer HT-3 cells. These results provide a new insight into the novel function of BCL-2 overexpression in the regulation of cell volume and ion flux.	Natl Cheng Kung Univ, Coll Med, Dept Physiol, Tainan 701, Taiwan; Natl Cheng Kung Univ, Coll Med, Dept Obstet & Gynecol, Tainan 701, Taiwan; Univ Oxford, Physiol Lab, Oxford OX1 3PT, England	National Cheng Kung University; National Cheng Kung University; University of Oxford	Tang, MJ (corresponding author), Natl Cheng Kung Univ, Coll Med, Dept Physiol, Tainan 701, Taiwan.			Tang, Ming-Jer/0000-0002-0883-4363				Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; BANDERALI U, 1992, J MEMBRANE BIOL, V126, P219; BERRIDGE MJ, 1995, BIOCHEM J, V312, P1, DOI 10.1042/bj3120001; Chen Y, 1996, AM J PHYSIOL-CELL PH, V270, pC1790, DOI 10.1152/ajpcell.1996.270.6.C1790; CHOU CY, 1995, CANCER RES, V55, P6077; Chou CY, 1998, J PHYSIOL-LONDON, V512, P435, DOI 10.1111/j.1469-7793.1998.435be.x; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Haussinger D, 1996, BIOCHEM J, V313, P697; Lang F, 1998, PHYSIOL REV, V78, P247, DOI 10.1152/physrev.1998.78.1.247; Lepple-Wienhues A, 1998, J CELL BIOL, V141, P281, DOI 10.1083/jcb.141.1.281; Lin HH, 1999, KIDNEY INT, V55, P168, DOI 10.1046/j.1523-1755.1999.00249.x; Lin HH, 1997, AM J PHYSIOL-RENAL, V273, pF300, DOI 10.1152/ajprenal.1997.273.2.F300; LIU HS, 1989, P NATL ACAD SCI USA, V86, P9951, DOI 10.1073/pnas.86.24.9951; Maeno E, 2000, P NATL ACAD SCI USA, V97, P9487, DOI 10.1073/pnas.140216197; MCCARTY NA, 1992, PHYSIOL REV, V72, P1037, DOI 10.1152/physrev.1992.72.4.1037; Nilius B, 1996, GEN PHARMACOL-VASC S, V27, P1131, DOI 10.1016/S0306-3623(96)00061-4; OKADA Y, 1997, AM J PHYSIOL, V273, P755; PAULMICHL M, 1989, PFLUG ARCH EUR J PHY, V413, P456, DOI 10.1007/BF00594173; ROSS PE, 1995, J GEN PHYSIOL, V106, P415, DOI 10.1085/jgp.106.3.415; ROY G, 1987, J MEMBRANE BIOL, V100, P83, DOI 10.1007/BF02209143; Shen MR, 1998, CELL SIGNAL, V10, P113, DOI 10.1016/S0898-6568(97)00115-0; Shen MR, 2001, J PHYSIOL-LONDON, V537, P347, DOI 10.1111/j.1469-7793.2001.00347.x; Shen MR, 2000, J PHYSIOL-LONDON, V529, P385, DOI 10.1111/j.1469-7793.2000.00385.x; Shen MR, 1996, BBA-MOL BASIS DIS, V1315, P138, DOI 10.1016/0925-4439(95)00115-8; Szabo I, 1998, P NATL ACAD SCI USA, V95, P6169, DOI 10.1073/pnas.95.11.6169; Tang MJ, 1998, AM J PHYSIOL-CELL PH, V275, pC921, DOI 10.1152/ajpcell.1998.275.4.C921; TSUJIMOTO Y, 1986, P NATL ACAD SCI USA, V83, P5214, DOI 10.1073/pnas.83.14.5214; Urbach V, 1999, J MEMBRANE BIOL, V168, P29, DOI 10.1007/s002329900495; WEISS H, 1992, J MEMBRANE BIOL, V126, P109; Williams SS, 2000, CANCER RES, V60, P4358	30	26	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 3	2002	277	18					15592	15599		10.1074/jbc.M111043200	http://dx.doi.org/10.1074/jbc.M111043200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	550PA	11861644	hybrid			2022-12-27	WOS:000175510400051
J	Li, XP; Kan, HY; Lavrentiadou, S; Krieger, M; Zannis, V				Li, XP; Kan, HY; Lavrentiadou, S; Krieger, M; Zannis, V			Reconstituted discoidal ApoE-phospholipid particles are ligands for the scavenger receptor BI - The amino-terminal 1-165 domain of ApoE suffices for receptor binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-DENSITY-LIPOPROTEIN; HUMAN APOLIPOPROTEIN-E; TOCOPHEROL TRANSFER PROTEIN; E-DEFICIENT MICE; SR-BI; HDL RECEPTOR; III HYPERLIPOPROTEINEMIA; TRANSGENIC MICE; VITAMIN-E; IN-VIVO	The high density lipoprotein receptor, scavenger receptor class B type I (SR-BI), recognizes lipid-bound apolipoprotein A-I (apoA-I) and other apolipoproteins. Here, we have used large scale cultures of apoE-expressing cells to purify apoE and prepare apoE containing reconstituted discoidal 1-palmitoyl-2-oleoyl-L-phosphatidylcholine (POPC)-apoE particles. These particles have been used to examine their binding to wild-type and mutant forms of SR-BI expressed in transfected IdIA-7 cells. Specific binding to SR-BI was determined by subtracting from the total binding, nonspecific values measured using either control untransfected ldlA-7 cells or by inhibiting SR-BI-mediated binding with a high titer antireceptor-blocking antibody. POPC-apoE particles generated using apoE2, apoE3, apoE4, or the carboxyl-terminally truncated forms apoE165, apoE202, apoE229, and apoE259 all bound tightly to wild-type SR-BI with similar affinities (K-d = 35-45 mug/ml). Binding was nearly abolished in a cell line expressing the ldlA (Q402R/Q418R) double mutant form of SR-BI that is unable to bind native high density lipoprotein but binds low density lipoprotein normally. The findings establish that apoE is a ligand for SR-BI and that the receptor binding domain is located in the amino-terminal 1-165-region of the protein. SR-BI-apoE interactions may contribute to cholesterol homeostasis in tissues and cells expressing SR-BI that are accessible to apoE-containing lipoproteins.	Boston Univ, Sch Med, Dept Med, Whitaker Cardiovasc Inst,Sect Mol Genet, Boston, MA 02118 USA; Boston Univ, Sch Med, Dept Med, Dept Biochem, Boston, MA 02118 USA; MIT, Dept Biol, Cambridge, MA 02139 USA	Boston University; Boston University; Massachusetts Institute of Technology (MIT)	Zannis, V (corresponding author), Boston Univ, Sch Med, Dept Med, Whitaker Cardiovasc Inst,Sect Mol Genet, Boston, MA 02118 USA.		Krieger, Marco/AAE-8611-2020	Zannis, Vassilis/0000-0002-1295-7155; Lavrentiadou, Sophia/0000-0002-4062-2336	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL068216, R01HL052212, P01HL041484, R01HL048739] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL52212, HL68216, HL48739, HL41484] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Acton S, 1996, SCIENCE, V271, P518, DOI 10.1126/science.271.5248.518; ACTON SL, 1994, J BIOL CHEM, V269, P21003; Aleshkov S, 1997, BIOCHEMISTRY-US, V36, P10571, DOI 10.1021/bi9626362; Arai T, 1999, J BIOL CHEM, V274, P2366, DOI 10.1074/jbc.274.4.2366; BEISIEGEL U, 1989, NATURE, V341, P162, DOI 10.1038/341162a0; BRENNER AJ, 1995, ANAL BIOCHEM, V226, P80, DOI 10.1006/abio.1995.1194; CLADARAS C, 1987, J BIOL CHEM, V262, P2310; Cullen P, 1998, J CLIN INVEST, V101, P1670, DOI 10.1172/JCI119887; de la Llera-Moya M, 1999, J LIPID RES, V40, P575; Dong LM, 1996, NAT STRUCT BIOL, V3, P718, DOI 10.1038/nsb0896-718; Fazio S, 1997, P NATL ACAD SCI USA, V94, P4647, DOI 10.1073/pnas.94.9.4647; Goti D, 2001, J NEUROCHEM, V76, P498, DOI 10.1046/j.1471-4159.2001.00100.x; Greene DJ, 2001, J BIOL CHEM, V276, P4804, DOI 10.1074/jbc.M008725200; Gu XJ, 2000, J BIOL CHEM, V275, P9120, DOI 10.1074/jbc.275.13.9120; Gu XJ, 1998, J BIOL CHEM, V273, P35388, DOI 10.1074/jbc.273.41.26338; Gu XJ, 2000, J BIOL CHEM, V275, P29993, DOI 10.1074/jbc.275.39.29993; Herz Joachim, 1995, Current Opinion in Lipidology, V6, P97, DOI 10.1097/00041433-199504000-00007; HUANG YD, 1994, P NATL ACAD SCI USA, V91, P1834, DOI 10.1073/pnas.91.5.1834; Husemann J, 2001, AM J PATHOL, V158, P825, DOI 10.1016/S0002-9440(10)64030-8; INNERARITY TL, 1978, BIOCHEMISTRY-US, V17, P1440, DOI 10.1021/bi00601a013; Ji Y, 1997, J BIOL CHEM, V272, P20982, DOI 10.1074/jbc.272.34.20982; Jishage K, 2001, J BIOL CHEM, V276, P1669, DOI 10.1074/jbc.C000676200; Kim DH, 1996, J BIOL CHEM, V271, P8373, DOI 10.1074/jbc.271.14.8373; Kolleck I, 1999, FREE RADICAL BIO MED, V27, P882, DOI 10.1016/S0891-5849(99)00139-2; Kozarsky KF, 1997, NATURE, V387, P414, DOI 10.1038/387414a0; KRIEGER M, 1983, CELL, V33, P413, DOI 10.1016/0092-8674(83)90423-3; Krieger M, 1999, ANNU REV BIOCHEM, V68, P523, DOI 10.1146/annurev.biochem.68.1.523; Kypreos KE, 2001, BIOCHEMISTRY-US, V40, P6027, DOI 10.1021/bi002414a; Kypreos KE, 2001, J BIOL CHEM, V276, P19778, DOI 10.1074/jbc.M100418200; LALAZAR A, 1988, J BIOL CHEM, V263, P3542; LALAZAR A, 1989, J BIOL CHEM, V264, P8447; Landschulz KT, 1996, J CLIN INVEST, V98, P984, DOI 10.1172/JCI118883; Liadaki KN, 2000, J BIOL CHEM, V275, P21262, DOI 10.1074/jbc.M002310200; LINTON MF, 1995, SCIENCE, V267, P1034, DOI 10.1126/science.7863332; LOWY DR, 1978, J VIROL, V26, P291, DOI 10.1128/JVI.26.2.291-298.1978; Mardones P, 2002, J NUTR, V132, P443, DOI 10.1093/jn/132.3.443; MARKWELL MAK, 1982, ANAL BIOCHEM, V125, P427, DOI 10.1016/0003-2697(82)90025-2; MATZ CE, 1982, J BIOL CHEM, V257, P4535; PLUMP AS, 1992, CELL, V71, P343, DOI 10.1016/0092-8674(92)90362-G; RALL SC, 1989, J CLIN INVEST, V83, P1095, DOI 10.1172/JCI113988; RALL SC, 1982, P NATL ACAD SCI-BIOL, V79, P4696, DOI 10.1073/pnas.79.15.4696; REDDICK RL, 1994, ARTERIOSCLER THROMB, V14, P141, DOI 10.1161/01.ATV.14.1.141; Rigotti A, 1997, P NATL ACAD SCI USA, V94, P12610, DOI 10.1073/pnas.94.23.12610; RUSSELL DW, 1989, J BIOL CHEM, V264, P21682; SCHAEFER EJ, 1986, J CLIN INVEST, V78, P1206, DOI 10.1172/JCI112704; SEGE RD, 1986, MOL CELL BIOL, V6, P3268, DOI 10.1128/MCB.6.9.3268; Sehayek E, 1998, P NATL ACAD SCI USA, V95, P10194, DOI 10.1073/pnas.95.17.10194; SHIMANO H, 1995, J CLIN INVEST, V95, P469, DOI 10.1172/JCI117687; SMIT M, 1990, J LIPID RES, V31, P45; Stangl H, 1999, J BIOL CHEM, V274, P32692, DOI 10.1074/jbc.274.46.32692; TAKAHASHI S, 1992, P NATL ACAD SCI USA, V89, P9252, DOI 10.1073/pnas.89.19.9252; Terasawa Y, 2000, P NATL ACAD SCI USA, V97, P13830, DOI 10.1073/pnas.240462697; Thuahnai ST, 2001, J BIOL CHEM, V276, P43801, DOI 10.1074/jbc.M106695200; Trigatti B, 1999, P NATL ACAD SCI USA, V96, P9322, DOI 10.1073/pnas.96.16.9322; Ueda Y, 1999, J BIOL CHEM, V274, P7165, DOI 10.1074/jbc.274.11.7165; Urban S, 2000, J BIOL CHEM, V275, P33409, DOI 10.1074/jbc.M004031200; van Dijk KW, 1999, ARTERIOSCL THROM VAS, V19, P2945, DOI 10.1161/01.ATV.19.12.2945; Wang N, 1998, J BIOL CHEM, V273, P32920, DOI 10.1074/jbc.273.49.32920; WARDELL MR, 1987, J CLIN INVEST, V80, P483, DOI 10.1172/JCI113096; WARDELL MR, 1989, J BIOL CHEM, V264, P21205; Xu SZ, 1997, J LIPID RES, V38, P1289; Yancey PG, 2000, J BIOL CHEM, V275, P36596, DOI 10.1074/jbc.M006924200; ZANNIS VI, 1998, NATO ASI SER, P179; Zhu YH, 1998, P NATL ACAD SCI USA, V95, P7585, DOI 10.1073/pnas.95.13.7585	64	54	54	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 14	2002	277	24					21149	21157		10.1074/jbc.M200658200	http://dx.doi.org/10.1074/jbc.M200658200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	563YR	11861652	hybrid			2022-12-27	WOS:000176286000007
J	Christian, M; Zhang, XH; Schneider-Merck, T; Unterman, TG; Gellersen, B; White, JO; Brosens, JJ				Christian, M; Zhang, XH; Schneider-Merck, T; Unterman, TG; Gellersen, B; White, JO; Brosens, JJ			Cyclic AMP-induced forkhead transcription factor, FKHR, cooperates with CCAAT/enhancer-binding protein beta in differentiating human endometrial stromal cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSULIN-RESPONSE SEQUENCE; PAX3-FKHR FUSION PROTEIN; HUMAN PROLACTIN GENE; KINASE-A; PHOSPHOENOLPYRUVATE CARBOXYKINASE; ALVEOLAR RHABDOMYOSARCOMA; C/EBP-BETA; PROMOTER; EXPRESSION; FAMILY	Decidual transformation of human endometrial stromal (ES) cells requires sustained activation of the protein kinase A (PKA) pathway. In a search for novel transcriptional mediators of this process, we used differential display PCR analysis of undifferentiated primary ES cells and cells stimulated with 8-bromo-cAMP (8-Br-cAMP). We now report on the role of forkhead homologue in rhabdomyosarcoma (FKHR), a recently described member of the forkhead/winged-helix transcription factor family, as a mediator of endometrial differentiation. Sustained 8-Br-cAMP stimulation resulted in the induction and nuclear accumulation of FKHR in differentiating ES cells. Immunohistochemical studies revealed that endometrial stromal expression of FKHR in vivo is confined to decidualizing cells during the late secretory phase of the cycle and coincides with the expression of CCAAT/enhancer-binding protein 13 (C/EBPbeta). Reporter gene studies showed that FKHR potently enhances PKA-dependent activation of the tissue-specific decidual prolactin (dPRL) promoter, a major differentiation marker in human ES cells. Transcriptional augmentation by FKHR was effected through functional cooperation with C/EBPbeta and binding to a composite FKHR-C/EBPbeta response unit in the proximal promoter region. Furthermore, FKHR and C/EBPbeta were shown to interact directly in a glutathione S-transferase pull-down assay. These results provide the first evidence of regulated expression of FKHR and demonstrate that FKHR has an integral role in PKA-dependent endometrial differentiation through its ability to bind and functionally cooperate with C/EBPbeta.	Univ London Imperial Coll Sci Technol & Med, Wolfson & Weston Res Ctr Family Hlth, Hammersmith Hosp, Fac Med,Inst Reprod & Dev Biol, London W12 0NN, England; Univ Illinois, Coll Med, Chicago, IL 60612 USA; Chicago Area Vet Healthcare Syst, W Side Div, Chicago, IL 60612 USA; Univ Hamburg, Inst Hormone & Fertil Res, D-22529 Hamburg, Germany	Imperial College London; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Hamburg	Brosens, JJ (corresponding author), Univ London Imperial Coll Sci Technol & Med, Wolfson & Weston Res Ctr Family Hlth, Hammersmith Hosp, Fac Med,Inst Reprod & Dev Biol, London W12 0NN, England.			Christian, Mark/0000-0002-1616-4179; Brosens, Jan/0000-0003-0116-9329	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK041430, R01DK041430] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK41430] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Anderson MJ, 1998, GENOMICS, V47, P187, DOI 10.1006/geno.1997.5122; BERWAER M, 1994, MOL ENDOCRINOL, V8, P635, DOI 10.1210/me.8.5.635; Biggs WH, 1999, P NATL ACAD SCI USA, V96, P7421, DOI 10.1073/pnas.96.13.7421; Borkhardt A, 1997, ONCOGENE, V14, P195, DOI 10.1038/sj.onc.1200814; Brar AK, 1997, ENDOCRINE, V6, P301, DOI 10.1007/BF02820507; Brosens JJ, 1999, ENDOCRINOLOGY, V140, P4809, DOI 10.1210/en.140.10.4809; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Cass LA, 1999, MOL CELL BIOL, V19, P5882; Christian M, 2002, MOL ENDOCRINOL, V16, P141, DOI 10.1210/me.16.1.141; DAVIS RJ, 1994, CANCER RES, V54, P2869; del Peso L, 1999, ONCOGENE, V18, P7328, DOI 10.1038/sj.onc.1203159; DESCOMBES P, 1991, CELL, V67, P569, DOI 10.1016/0092-8674(91)90531-3; Durham SK, 1999, ENDOCRINOLOGY, V140, P3140, DOI 10.1210/en.140.7.3140; FREDERICKS WJ, 1995, MOL CELL BIOL, V15, P1522; Furuyama T, 2000, BIOCHEM J, V349, P629, DOI 10.1042/0264-6021:3490629; GALILI N, 1993, NAT GENET, V5, P230, DOI 10.1038/ng1193-230; GELLERSEN B, 1994, MOL ENDOCRINOL, V8, P356, DOI 10.1210/me.8.3.356; Ghosh AK, 2001, J BIOL CHEM, V276, P8507, DOI 10.1074/jbc.M008541200; Guo SD, 1999, J BIOL CHEM, V274, P17184, DOI 10.1074/jbc.274.24.17184; Kaufmann E, 1996, MECH DEVELOP, V57, P3, DOI 10.1016/0925-4773(96)00539-4; LAI E, 1993, P NATL ACAD SCI USA, V90, P10421, DOI 10.1073/pnas.90.22.10421; Lee YM, 1996, MOL CELL BIOL, V16, P4257; McNagny KM, 1998, EMBO J, V17, P3669, DOI 10.1093/emboj/17.13.3669; Miau LH, 1997, MOL CELL BIOL, V17, P230, DOI 10.1128/MCB.17.1.230; Mink S, 1997, MOL CELL BIOL, V17, P6609, DOI 10.1128/MCB.17.11.6609; Nakamura N, 2000, MOL CELL BIOL, V20, P8969, DOI 10.1128/MCB.20.23.8969-8982.2000; Nasrin N, 2000, P NATL ACAD SCI USA, V97, P10412, DOI 10.1073/pnas.190326997; OBRIEN RM, 1994, J BIOL CHEM, V269, P30419; OBRIEN RM, 1995, MOL CELL BIOL, V15, P1747; Pohnke Y, 1999, J BIOL CHEM, V274, P24808, DOI 10.1074/jbc.274.35.24808; Rena G, 1999, J BIOL CHEM, V274, P17179, DOI 10.1074/jbc.274.24.17179; RITTENHOUSE J, 1984, ANAL BIOCHEM, V138, P442, DOI 10.1016/0003-2697(84)90836-4; Schuur ER, 2001, J BIOL CHEM, V276, P33554, DOI 10.1074/jbc.M105555200; SHAPIRO DN, 1993, CANCER RES, V53, P5108; Steiger Johann Anselm, 1993, KERYGMA DOGMA, V39, P64; Tang ED, 1999, J BIOL CHEM, V274, P16741, DOI 10.1074/jbc.274.24.16741; Telgmann R, 1997, ENDOCRINOLOGY, V138, P929, DOI 10.1210/en.138.3.929; Tsygankova OM, 2001, MOL CELL BIOL, V21, P1921, DOI 10.1128/MCB.21.6.1921-1929.2001; Wang L, 2001, J BIOL CHEM, V276, P37242, DOI 10.1074/jbc.M105089200; Yeagley D, 2001, J BIOL CHEM, V276, P33705, DOI 10.1074/jbc.M101215200; Zhao HH, 2001, J BIOL CHEM, V276, P27907, DOI 10.1074/jbc.M104278200	41	139	143	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 7	2002	277	23					20825	20832		10.1074/jbc.M201018200	http://dx.doi.org/10.1074/jbc.M201018200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	562NJ	11893744	hybrid			2022-12-27	WOS:000176204500093
J	Braem, CV; Kas, K; Meyen, E; Debiec-Rychter, M; Van de Ven, WJM; Voz, ML				Braem, CV; Kas, K; Meyen, E; Debiec-Rychter, M; Van de Ven, WJM; Voz, ML			Identification of a karyopherin alpha 2 recognition site in PLAG1, which functions as a nuclear localization signal	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ZINC-FINGER PROTEIN; PLEOMORPHIC ADENOMAS; GENE-EXPRESSION; SALIVARY-GLANDS; IMPORTIN-ALPHA; SEQUENCE; BETA; ACTIVATION; REGION; CELLS	The activation of the pleomorphic adenoma gene I (PLAG1) is the most frequent gain-of-function mutation found in pleomorphic adenomas of the salivary glands. To gain more insight into the regulation of PLAG1 function, we searched for PLAG1-interacting proteins. Using the yeast two-hybrid system, we identified karyopherin alpha2 as a PLAG1-interacting protein. Physical interaction between PLAG1 and karyopherin alpha2 was confirmed by an in vitro glutathione S-transferase pull-down assay. Karyopherin alpha2 escorts proteins into the nucleus via interaction with a nuclear localization sequence (NLS) composed of short stretches of basic amino acids. Two putative NLSs were identified in PLAG1. The predicted NLS1 (KRKR) was essential for physical interaction with karyopherin alpha2 in glutathione S-transferase pull-down assay, and its mutation resulted in decreased nuclear import of PLAG1. Moreover, NLS1 was able to drive the nuclear import of the cytoplasmic protein beta-galactosidase. In contrast, predicted NLS2 of PLAG1 (KPRK) was not involved in karyopherin a2 binding nor in its nuclear import. The residual nuclear import of PLAG1 after mutation of the NLS1 was assigned to the zinc finger domain of PLAG1. These observations indicate that the nuclear import of PLAG1 is governed by its zinc finger domain and by NLS1, a karyopherin a2 recognition site.	Catholic Univ Louvain, Dept Human Genet, Mol Oncol Lab, B-3000 Louvain, Belgium; Flanders Interuniv Inst Biotechnol, B-3000 Louvain, Belgium	Universite Catholique Louvain	Van de Ven, WJM (corresponding author), Catholic Univ Louvain, Dept Human Genet, Mol Oncol Lab, Herestr 49, B-3000 Louvain, Belgium.	wim.vandeven@med.kuleuven.ac.be						Abdollahi A, 1997, CANCER RES, V57, P2029; Abdollahi A, 1997, ONCOGENE, V14, P1973, DOI 10.1038/sj.onc.1201034; Astrom AK, 1999, CANCER RES, V59, P918; Conti E, 1998, CELL, V94, P193, DOI 10.1016/S0092-8674(00)81419-1; Debiec-Rychter M, 2001, LAB INVEST, V81, P1289, DOI 10.1038/labinvest.3780342; Furukawa T, 2001, ONCOGENE, V20, P4718, DOI 10.1038/sj.onc.1204647; GIETZ RD, 1995, YEAST, V11, P355, DOI 10.1002/yea.320110408; Gorlich D, 1996, EMBO J, V15, P1810, DOI 10.1002/j.1460-2075.1996.tb00530.x; Kas K, 1998, J BIOL CHEM, V273, P23026, DOI 10.1074/jbc.273.36.23026; Kas K, 1997, GENOMICS, V43, P349, DOI 10.1006/geno.1997.4819; Kobe B, 1999, NAT STRUCT BIOL, V6, P388, DOI 10.1038/7625; Kovac CR, 2000, J BIOL CHEM, V275, P16752, DOI 10.1074/jbc.M001551200; Mirski SEL, 1999, EXP CELL RES, V251, P329, DOI 10.1006/excr.1999.4587; Mo YY, 2000, J BIOL CHEM, V275, P41107, DOI 10.1074/jbc.M003135200; Moroianu J, 1996, P NATL ACAD SCI USA, V93, P6572, DOI 10.1073/pnas.93.13.6572; Nakai A, 2000, J BIOL CHEM, V275, P34665, DOI 10.1074/jbc.M005302200; Nakielny S, 1999, CELL, V99, P677, DOI 10.1016/S0092-8674(00)81666-9; PEIFER M, 1994, CELL, V76, P789, DOI 10.1016/0092-8674(94)90353-0; Schwamborn K, 1998, EXP CELL RES, V244, P206, DOI 10.1006/excr.1998.4177; Sorg G, 1999, BIOTECHNIQUES, V26, P858, DOI 10.2144/99265bm12; Spengler D, 1997, EMBO J, V16, P2814, DOI 10.1093/emboj/16.10.2814; Varrault A, 1998, P NATL ACAD SCI USA, V95, P8835, DOI 10.1073/pnas.95.15.8835; Voz ML, 2000, CANCER RES, V60, P106; Voz ML, 1998, ONCOGENE, V16, P1409, DOI 10.1038/sj.onc.1201660; Weis K, 1996, EMBO J, V15, P1818, DOI 10.1002/j.1460-2075.1996.tb00531.x	25	25	28	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 31	2002	277	22					19673	19678		10.1074/jbc.M112112200	http://dx.doi.org/10.1074/jbc.M112112200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	557EH	11882654	hybrid, Green Submitted			2022-12-27	WOS:000175894800058
J	Garda, HA; Arrese, EL; Soulages, JL				Garda, HA; Arrese, EL; Soulages, JL			Structure of apolipophorin-III in discoidal lipoproteins - Interhelical distances in the lipid-bound state and conformational change upon binding to lipid	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APOLIPOPROTEIN-A-I; ALPHA-HELICES; EXCHANGEABLE APOLIPOPROTEINS; ENERGY-TRANSFER; APOA-I; FLUORESCENCE; DIMYRISTOYLPHOSPHATIDYLCHOLINE; TRANSPORT; MODEL	The structure of apolipophorin III in the lipid-bound state and the extent of the conformational change that takes place when the five-helix bundle apolipoprotein binds to a lipoprotein lipid surface were investigated by fluorescence resonance energy transfer in discoidal lipoproteins. Four intramolecular interhelical distances between helix pairs 1-4, 2-4, 3-4, and 5-4 were estimated by fluorescence resonance energy transfer in both the lipid-free and the lipid-bound states. Depending on the helices pairs, the intramolecular interhelical distances increased between 15 and greater than or equal to 20 Angstrom upon binding of the apolipoprotein to lipid, demonstrating for the first time that binding to lipid is accompanied by a major change in interhelical distances. Using discoidal lipoproteins made with a combination of apolipophorin III molecules containing donor and acceptor groups and apolipophorin III molecules containing neither donor nor acceptor groups, it was possible to obtain information about intermolecular interhelical distances between the helix 4 of one apolipoprotein and the helices 1, 2, 3, and 5 of a second apolipoprotein residing in the same discoidal lipoprotein. Altogether, the estimated intermolecular and intramolecular interhelical distances suggest a model in which the apolipoprotein arranges in pairs of antiparallel and fully extended polypeptide chains surrounding the periphery of the bilayer disc.	Oklahoma State Univ, Dept Biochem & Mol Biol, Noble Res Ctr 355, Stillwater, OK 74078 USA	Oklahoma State University System; Oklahoma State University - Stillwater	Soulages, JL (corresponding author), Oklahoma State Univ, Dept Biochem & Mol Biol, Noble Res Ctr 355, Stillwater, OK 74078 USA.	jose@biochem.okstate.edu			NIGMS NIH HHS [GM55622] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM055622, R29GM055622] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BREITER DR, 1991, BIOCHEMISTRY-US, V30, P603, DOI 10.1021/bi00217a002; Chen Y, 1998, BIOCHEMISTRY-US, V37, P9976, DOI 10.1021/bi980274n; CHEUNG H, 1991, TOPICS FLUORESCENCE, V2, P55; DALE RE, 1976, P NATL ACAD SCI USA, V73, P271, DOI 10.1073/pnas.73.2.271; Dettloff M, 2001, BIOCHEMISTRY-US, V40, P3150, DOI 10.1021/bi0013804; Fielding P. E., 1996, BIOCH LIPIDS LIPOPRO, P495; GRIEP MA, 1990, J BIOL CHEM, V265, P20356; HAAS E, 1978, BIOCHEMISTRY-US, V17, P5064, DOI 10.1021/bi00616a032; HAUGLAND RP, 1996, HDB FLUORESCENT PROB, P23; Jonas A, 2000, BBA-MOL CELL BIOL L, V1529, P245, DOI 10.1016/S1388-1981(00)00153-0; JONAS A, 1989, J BIOL CHEM, V264, P4818; Lakowicz J. R., 1999, PRINCIPLES FLUORESCE, P374; Li HH, 2000, J BIOL CHEM, V275, P37048, DOI 10.1074/jbc.M005336200; McGuire KA, 1996, J LIPID RES, V37, P1519; Morrow JA, 1999, PROTEIN EXPRES PURIF, V16, P224, DOI 10.1006/prep.1999.1069; Narayanaswami V, 2000, BBA-MOL CELL BIOL L, V1483, P15, DOI 10.1016/S1388-1981(99)00176-6; NICHOLS AV, 1986, METHOD ENZYMOL, V128, P417; RAUSSENS V, 1995, J BIOL CHEM, V270, P12542, DOI 10.1074/jbc.270.21.12542; ROTHBLAT GH, 1992, J LIPID RES, V33, P1091; Ryan RO, 2000, ANNU REV ENTOMOL, V45, P233, DOI 10.1146/annurev.ento.45.1.233; RYAN RO, 1995, J LIPID RES, V36, P1066; Segrest JP, 1999, J BIOL CHEM, V274, P31755, DOI 10.1074/jbc.274.45.31755; SEGREST JP, 1992, J LIPID RES, V33, P141; SMITH AF, 1994, J LIPID RES, V35, P1976; Soulages JL, 2000, BIOCHEMISTRY-US, V39, P10574, DOI 10.1021/bi0007223; Soulages JL, 2000, J BIOL CHEM, V275, P17501, DOI 10.1074/jbc.M909661199; Soulages JL, 1998, BIOCHEM BIOPH RES CO, V243, P372, DOI 10.1006/bbrc.1998.8099; SOULAGES JL, 1994, ADV PROTEIN CHEM, V45, P371; Soulages JL, 2001, BIOCHEMISTRY-US, V40, P14279, DOI 10.1021/bi010949d; Soulages JL, 2001, J BIOL CHEM, V276, P34162, DOI 10.1074/jbc.M105836200; Tricerri MA, 2001, BIOCHEMISTRY-US, V40, P5065, DOI 10.1021/bi002815q; Wang N, 2000, J BIOL CHEM, V275, P33053, DOI 10.1074/jbc.M005438200; WEISGRABER KH, 1994, ADV PROTEIN CHEM, V45, P249; WIENTZEK M, 1994, J BIOL CHEM, V269, P4605; Xu SZ, 1997, J LIPID RES, V38, P1289	35	43	43	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 31	2002	277	22					19773	19782		10.1074/jbc.M110089200	http://dx.doi.org/10.1074/jbc.M110089200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	557EH	11896049	hybrid			2022-12-27	WOS:000175894800070
J	Munster, AK; Weinhold, B; Gotza, B; Muhlenhoff, M; Frosch, M; Gerardy-Schahn, R				Munster, AK; Weinhold, B; Gotza, B; Muhlenhoff, M; Frosch, M; Gerardy-Schahn, R			Nuclear localization signal of murine CMP-Neu5Ac synthetase includes residues required for both nuclear targeting and enzymatic activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-ACETYLNEURAMINIC ACID; CELL-ADHESION MOLECULE; ESCHERICHIA-COLI K1; POLYSIALIC ACID; SIALIC-ACID; SEQUENCE REQUIREMENTS; NEURAL DEVELOPMENT; PROTEIN-TRANSPORT; SERUM RESISTANCE; LARGE-T	5-N-Acetylneuraminic acid (Neu5Ac) is the major sialic acid derivative found in animal cells. As a component of cell surface glycoconjugates, Neu5Ac is pivotal to numerous cellular recognition and communication processes including host-parasite interactions. A prerequisite for the synthesis of sialylated glycoconjugates is the activation of Neu5Ac to cytidine-monophosphate N-acetylneuraminic acid (CMP-Neu5Ac). The reaction is catalyzed by CMP-Neu5Ac-synthetase (syn), which, for unknown reasons, resides in the nucleus. Sequence analysis of the cloned murine CMP-Neu5Ac synthetase identified three clusters of basic amino acids (BC1-BC3) that might function as nuclear localization signals (NLS). In the present study chimeric protein and mutagenesis strategies were used to show that BC1 and BC2 are active NLS sequences when attached to the green fluorescent protein (enhanced GFP), but only BC2 is necessary and sufficient to mediate the nuclear import of CMP-Neu5Ac synthetase. Site-directed mutations identified the residues (KRXR)-R-198 to be essential for nuclear transport and Arg(202) to be necessary to complete the transport process. Cytoplasmic forms of CMP-Neu5Ac synthetase generated by single site mutations in BC2 demonstrated that (i) enzyme activity is independent of nuclear localization, and (ii) Arg(199) and Arg(202) are involved in both nuclear transport and synthetase activity. Comparison of all known and predicted CMPsialic acid synthetases reveals Arg(202) and Gln(203) as highly conserved in evolution and critically important for optimal synthetase activity but not for nuclear localization. Combined, the data demonstrate that nuclear transport and enzyme activity are independent functions that share some common amino acid requirements in CMP-Neu5Ac synthetase.	Hannover Med Sch, Inst Physiol Chem Prot Struktur, D-30625 Hannover, Germany; Univ Wurzburg, Inst Hyg & Mikrobiol, D-97080 Wurzburg, Germany	Hannover Medical School; University of Wurzburg	Gerardy-Schahn, R (corresponding author), Hannover Med Sch, Inst Physiol Chem Prot Struktur, Carl Neuberg Str 1, D-30625 Hannover, Germany.	gerardy-schahn.rita@mh-hannover.de						Bliss JM, 1996, MOL MICROBIOL, V21, P221, DOI 10.1046/j.1365-2958.1996.6461357.x; BRATOSIN D, 1995, GLYCOCONJUGATE J, V12, P258, DOI 10.1007/BF00731328; Bruses JL, 2001, BIOCHIMIE, V83, P635, DOI 10.1016/S0300-9084(01)01293-7; CHELSKY D, 1989, MOL CELL BIOL, V9, P2487, DOI 10.1128/MCB.9.6.2487; Cokol M, 2000, EMBO REP, V1, P411, DOI 10.1093/embo-reports/kvd092; Cremer H, 2000, INT J DEV NEUROSCI, V18, P213, DOI 10.1016/S0736-5748(99)00090-8; Daniel L, 2000, CANCER RES, V60, P80; Dell A, 1999, BBA-GEN SUBJECTS, V1473, P196, DOI 10.1016/S0304-4165(99)00179-8; Eckhardt M, 2000, J NEUROSCI, V20, P5234, DOI 10.1523/JNEUROSCI.20-14-05234.2000; EDWARDS U, 1992, FEMS MICROBIOL LETT, V96, P161; EMIG S, 1995, J BIOL CHEM, V270, P13787, DOI 10.1074/jbc.270.23.13787; FROSCH M, 1985, P NATL ACAD SCI USA, V82, P1194, DOI 10.1073/pnas.82.4.1194; GARCIABUSTOS J, 1991, BIOCHIM BIOPHYS ACTA, V1071, P83, DOI 10.1016/0304-4157(91)90013-M; GERARDYSCHAHN R, 1995, MOL MICROBIOL, V16, P441, DOI 10.1111/j.1365-2958.1995.tb02409.x; Gluer S, 1998, BRIT J CANCER, V78, P106, DOI 10.1038/bjc.1998.450; Gorlich D, 1996, SCIENCE, V271, P1513, DOI 10.1126/science.271.5255.1513; Gorlich D, 1999, ANNU REV CELL DEV BI, V15, P607, DOI 10.1146/annurev.cellbio.15.1.607; Guerry P, 1996, MOL MICROBIOL, V19, P369, DOI 10.1046/j.1365-2958.1996.369895.x; Guo N, 2000, J CELL SCI, V113, P3085; Haft RF, 1996, MOL MICROBIOL, V19, P555, DOI 10.1046/j.1365-2958.1996.395931.x; Herrington J, 1999, J BIOL CHEM, V274, P5138, DOI 10.1074/jbc.274.8.5138; Hood DW, 1999, MOL MICROBIOL, V33, P679, DOI 10.1046/j.1365-2958.1999.01509.x; Horton P, 1997, ISMB-97 - FIFTH INTERNATIONAL CONFERENCE ON INTELLIGENT SYSTEMS FOR MOLECULAR BIOLOGY, PROCEEDINGS, P147; Horton P., 1996, P INT SYST MOL BIOL, V4, P109; Inoue S, 2001, J BIOL CHEM, V276, P31863, DOI 10.1074/jbc.M103336200; JANN B, 1990, CURR TOP MICROBIOL, V150, P19; Jans DA, 1996, PHYSIOL REV, V76, P651, DOI 10.1152/physrev.1996.76.3.651; Jimbo T, 2001, INT J CANCER, V94, P192, DOI 10.1002/ijc.1458; KALDERON D, 1984, NATURE, V311, P33, DOI 10.1038/311033a0; KEAN E L, 1991, Glycobiology, V1, P441, DOI 10.1093/glycob/1.5.441; Kelm S, 1997, INT REV CYTOL, V175, P137, DOI 10.1016/S0074-7696(08)62127-0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Luneberg E, 2000, INT J MED MICROBIOL, V290, P37; Malykh YN, 2001, EUR J CELL BIOL, V80, P48, DOI 10.1078/0171-9335-00139; Mattaj IW, 1998, ANNU REV BIOCHEM, V67, P265, DOI 10.1146/annurev.biochem.67.1.265; Moran AP, 1996, FEMS IMMUNOL MED MIC, V16, P105, DOI 10.1111/j.1574-695X.1996.tb00127.x; MORELAND RB, 1985, P NATL ACAD SCI USA, V82, P6561, DOI 10.1073/pnas.82.19.6561; Mosimann SC, 2001, J BIOL CHEM, V276, P8190, DOI 10.1074/jbc.M007235200; Muhlenhoff M, 1998, CURR OPIN STRUC BIOL, V8, P558, DOI 10.1016/S0959-440X(98)80144-9; Munday J, 1999, J LEUKOCYTE BIOL, V66, P705, DOI 10.1002/jlb.66.5.705; Munster AK, 1998, P NATL ACAD SCI USA, V95, P9140, DOI 10.1073/pnas.95.16.9140; Nakata D, 2001, GLYCOBIOLOGY, V11, P685, DOI 10.1093/glycob/11.8.685; Potvin B, 1995, J BIOL CHEM, V270, P30415, DOI 10.1074/jbc.270.51.30415; RICHARD M, 1975, BIOCHEM BIOPH RES CO, V64, P108, DOI 10.1016/0006-291X(75)90225-9; RICHARDSON WD, 1986, CELL, V44, P77, DOI 10.1016/0092-8674(86)90486-1; RIJCKEN WRP, 1993, BIOCHEM J, V293, P207, DOI 10.1042/bj2930207; ROBBINS J, 1991, CELL, V64, P615, DOI 10.1016/0092-8674(91)90245-T; Schauer R, 2000, GLYCOCONJUGATE J, V17, P485, DOI 10.1023/A:1011062223612; SHAULSKY G, 1990, MOL CELL BIOL, V10, P6565, DOI 10.1128/MCB.10.12.6565; SHAW L, 1988, BIOL CHEM H-S, V369, P477, DOI 10.1515/bchm3.1988.369.1.477; Topham MK, 1998, NATURE, V394, P697, DOI 10.1038/29337; Tullius MV, 1996, J BIOL CHEM, V271, P15373, DOI 10.1074/jbc.271.26.15373; VIMR ER, 1985, J BACTERIOL, V164, P854, DOI 10.1128/JB.164.2.854-860.1985; VIMR ER, 1989, J BACTERIOL, V171, P1106, DOI 10.1128/jb.171.2.1106-1117.1989; Vionnet J, 1999, GLYCOBIOLOGY, V9, P481, DOI 10.1093/glycob/9.5.481; Vogel U, 1999, INFECT IMMUN, V67, P954, DOI 10.1128/IAI.67.2.954-957.1999; Yoneda Y, 1999, CELL STRUCT FUNCT, V24, P425, DOI 10.1247/csf.24.425; ZAPATA G, 1989, J BIOL CHEM, V264, P14769	58	35	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 31	2002	277	22					19688	19696		10.1074/jbc.M201093200	http://dx.doi.org/10.1074/jbc.M201093200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	557EH	11893746	hybrid			2022-12-27	WOS:000175894800060
J	Trent, JT; Hargrove, MS				Trent, JT; Hargrove, MS			A ubiquitously expressed human hexacoordinate hemoglobin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE; SULFHEME PROTEINS; FACILITATED DIFFUSION; ESCHERICHIA-COLI; LIGAND-BINDING; PLANT; LEGHEMOGLOBIN; OXYGEN; GENE; MYOGLOBIN	We have identified a new human hemoglobin that we call histoglobin because it is expressed in a wide array of tissues. Histoglobin shares less than 30% identity with the other human hemoglobins, and the gene contains an intron in an unprecedented location. Spectroscopic and kinetic experiments with recombinant human histoglobin indicate that it is a hexacoordinate hemoglobin with significantly different ligand binding characteristics than the other human hexacoordinate hemoglobin, neuroglobin. In contrast to the very high oxygen affinities displayed by most hexacoordinate hemoglobins, the biophysical characteristics of histoglobin indicate that it could facilitate oxygen transport. The discovery of histoglobin demonstrates that humans, like plants, differentially express multiple hexacoordinate hemoglobins.	Iowa State Univ Sci & Technol, Dept Biochem Biophys & Mol Biol, Ames, IA 50011 USA	Iowa State University	Hargrove, MS (corresponding author), Iowa State Univ Sci & Technol, Dept Biochem Biophys & Mol Biol, 4114 Mol Biol Bldg, Ames, IA 50011 USA.	msh@iastate.edu						APPLEBY CA, 1984, ANNU REV PLANT PHYS, V35, P443, DOI 10.1146/annurev.pp.35.060184.002303; Arredondo-Peter R, 1998, PLANT PHYSIOL, V118, P1121, DOI 10.1104/pp.118.4.1121; ArredondoPeter R, 1997, PLANT PHYSIOL, V115, P1259, DOI 10.1104/pp.115.3.1259; Ascoli F, 1981, Methods Enzymol, V76, P72; Awenius C, 2001, BIOCHEM BIOPH RES CO, V287, P418, DOI 10.1006/bbrc.2001.5614; BABIOR BM, 1999, REACTIVE OXYGEN SPEC; BERTIN A, 1992, J MED MICROBIOL, V37, P141, DOI 10.1099/00222615-37-2-141; BERZOFSKY JA, 1972, J BIOL CHEM, V247, P3783; BERZOFSKY JA, 1971, J BIOL CHEM, V246, P7366; BERZOFSKY JA, 1972, J BIOL CHEM, V247, P3774; BERZOFSKY JA, 1971, J BIOL CHEM, V246, P3367; Brunori M, 2001, TRENDS BIOCHEM SCI, V26, P21, DOI 10.1016/S0968-0004(00)01698-4; Burmester T, 2000, NATURE, V407, P520, DOI 10.1038/35035093; *COMP BIOL INF LAB, 2001, ALLGENE VERS 2 2; Couture M, 1999, P NATL ACAD SCI USA, V96, P11223, DOI 10.1073/pnas.96.20.11223; Couture M, 1999, J BIOL CHEM, V274, P6898, DOI 10.1074/jbc.274.11.6898; Couture M, 2000, EUR J BIOCHEM, V267, P4770, DOI 10.1046/j.1432-1327.2000.01531.x; Delledonne M, 1998, NATURE, V394, P585, DOI 10.1038/29087; Delledonne M, 2001, P NATL ACAD SCI USA, V98, P13454, DOI 10.1073/pnas.231178298; Doherty DH, 1998, NAT BIOTECHNOL, V16, P672, DOI 10.1038/nbt0798-672; Duff SMG, 1997, J BIOL CHEM, V272, P16746, DOI 10.1074/jbc.272.27.16746; Dunford B.H., 1999, HEME PEROXIDASES; Flogel U, 2001, P NATL ACAD SCI USA, V98, P735, DOI 10.1073/pnas.011460298; Fukuto JM, 1999, MET IONS BIOL SYST, V36, P547; Gardner PR, 1998, P NATL ACAD SCI USA, V95, P10378, DOI 10.1073/pnas.95.18.10378; Goodman MD, 2001, J BIOL CHEM, V276, P6834, DOI 10.1074/jbc.M009254200; Hardison RC, 1996, P NATL ACAD SCI USA, V93, P5675, DOI 10.1073/pnas.93.12.5675; Hargrove MS, 2000, BIOPHYS J, V79, P2733, DOI 10.1016/S0006-3495(00)76512-X; Hargrove MS, 2000, STRUCTURE, V8, P1005, DOI 10.1016/S0969-2126(00)00194-5; Hausladen A, 1998, P NATL ACAD SCI USA, V95, P14100, DOI 10.1073/pnas.95.24.14100; Helleboid S, 2000, J EXP BOT, V51, P1189, DOI 10.1093/jexbot/51.348.1189; Herbers K, 1996, FEBS LETT, V397, P239, DOI 10.1016/S0014-5793(96)01183-0; Hunt PW, 2001, PLANT MOL BIOL, V47, P677, DOI 10.1023/A:1012440926982; Hvitved AN, 2001, J BIOL CHEM, V276, P34714, DOI 10.1074/jbc.M105175200; HYLDIGNIELSEN JJ, 1982, NUCLEIC ACIDS RES, V10, P689, DOI 10.1093/nar/10.2.689; Jia L, 1996, NATURE, V380, P221, DOI 10.1038/380221a0; Kawada N, 2001, J BIOL CHEM, V276, P25318, DOI 10.1074/jbc.M102630200; LORBERTH R, 1992, PLANT J, V2, P477; Masuhara M, 2000, BIOCHEM BIOPH RES CO, V268, P697, DOI 10.1006/bbrc.2000.2223; Membrillo-Hernandez J, 1999, J BIOL CHEM, V274, P748, DOI 10.1074/jbc.274.2.748; Minning DM, 1999, NATURE, V401, P497, DOI 10.1038/46822; MURRAY JD, 1971, J BIOL CHEM, V246, P5903; OCARRA P, 1976, PORPHYRINS METALLOPO; Ohuchi J, 2001, MOL REPROD DEV, V59, P350, DOI 10.1002/mrd.1041; Olson J S, 1981, Methods Enzymol, V76, P631; PUPPO A, 1980, BIOCHIM BIOPHYS ACTA, V614, P303, DOI 10.1016/0005-2744(80)90220-X; QUILLIN ML, 1995, J MOL BIOL, V245, P416, DOI 10.1006/jmbi.1994.0034; Scott NL, 2000, PROTEIN SCI, V9, P587; SIEVERS G, 1978, BIOCHIM BIOPHYS ACTA, V533, P293, DOI 10.1016/0005-2795(78)90376-8; SPRINGER BA, 1994, CHEM REV, V94, P699, DOI 10.1021/cr00027a007; Sun YJ, 2001, P NATL ACAD SCI USA, V98, P15306, DOI 10.1073/pnas.251466698; TAYLOR ER, 1994, PLANT MOL BIOL, V24, P853, DOI 10.1007/BF00014440; Trent JT, 2001, J BIOL CHEM, V276, P30106, DOI 10.1074/jbc.C100300200; Trent JT, 2001, BIOCHEMISTRY-US, V40, P6155, DOI 10.1021/bi0100790; Trevaskis B, 1997, P NATL ACAD SCI USA, V94, P12230, DOI 10.1073/pnas.94.22.12230; Weber RE, 2001, PHYSIOL REV, V81, P569, DOI 10.1152/physrev.2001.81.2.569; WHITAKER TL, 1995, BIOCHEMISTRY-US, V34, P8221, DOI 10.1021/bi00026a002; WITTENBE.JB, 1966, J BIOL CHEM, V241, P104; WITTENBERG JB, 1972, J BIOL CHEM, V247, P527; WYMAN J, 1966, J BIOL CHEM, V241, P115	60	296	304	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 31	2002	277	22					19538	19545		10.1074/jbc.M201934200	http://dx.doi.org/10.1074/jbc.M201934200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	557EH	11893755	hybrid			2022-12-27	WOS:000175894800041
J	Terraz, C; Brideau, G; Ronco, P; Rossert, J				Terraz, C; Brideau, G; Ronco, P; Rossert, J			A combination of cis-acting elements is required to activate the pro-alpha 1(I) collagen promoter in tendon fibroblasts of transgenic mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-LEVEL; COL1A1 PROMOTER; EXPRESSION; IDENTIFICATION; TRANSCRIPTION; MUTATIONS; SEQUENCE; DISEASES; REGION; GENES	The genes encoding the two type I collagen chains are selectively activated in few cell types, including fibroblasts and osteoblasts. By generating transgenic mice, we have previously shown that the activity of the mouse pro-alpha1(I) promoter was controlled by separate cell-specific cis-acting elements. In particular, a sequence located between -3.2 and -2.3 kb was needed to induce expression of the reporter gene at high levels in tendon fibroblasts. In the present work, by using the same transgenic approach, we have identified two short elements in this sequence, named tendon-specific element (TSE) 1 and TSE2, that were necessary to direct reporter gene expression selectively in tendon fibroblasts. Gel shift assays showed that TSE1 and TSE2 bound proteins specifically present in nuclear extracts from tendon fibroblasts and that the sequence of TSE2 binding a tendon-specific protein corresponded to an E-box. Analysis of transgenic mice further indicated that TSE1 and TSE2 needed to cooperate not only with each other but also with other cis-acting elements of the proximal promoter to activate reporter gene expression in tendon fibroblasts. Similarly, it pointed out that the so-called osteoblast-specific element had to interact with downstream sequences to drive reporter gene expression in osteoblasts of transgenic mice. Thus, expression of the mouse pro-alpha1(I) collagen gene in tendon fibroblasts appears to be the result of a unique combination of different cis-acting elements, including TSE1 and TSE2.	Hop Tenon, INSERM, U489, F-75020 Paris, France; Univ Paris 06, F-75020 Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Tenon - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; UDICE-French Research Universities; Sorbonne Universite	Rossert, J (corresponding author), Hop Tenon, INSERM, U489, 4 Rue Chine, F-75020 Paris, France.	jerome.rossert@tnn.ap-hop-paris.fr	Ronco, Pierre/AAC-8390-2022					Ambrosetti DC, 2000, J BIOL CHEM, V275, P23387, DOI 10.1074/jbc.M000932200; BEDALOV A, 1995, J BONE MINER RES, V10, P1443; BOGDANOVIC Z, 1994, J BONE MINER RES, V9, P285; Byers PH, 1997, AM J MED GENET, V72, P94, DOI 10.1002/(SICI)1096-8628(19971003)72:1<94::AID-AJMG20>3.0.CO;2-O; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Dodig M, 1996, J BIOL CHEM, V271, P16422, DOI 10.1074/jbc.271.27.16422; Gualdi R, 1996, GENE DEV, V10, P1670, DOI 10.1101/gad.10.13.1670; HOGAN B, 1986, MANIPULATING MOUSE E; HOUGLUM K, 1995, J CLIN INVEST, V96, P2269, DOI 10.1172/JCI118282; Kern B, 2001, J BIOL CHEM, V276, P7101, DOI 10.1074/jbc.M006215200; Kuivaniemi H, 1997, HUM MUTAT, V9, P300, DOI 10.1002/(SICI)1098-1004(1997)9:4<300::AID-HUMU2>3.0.CO;2-9; LISKA DJ, 1994, J CELL BIOL, V125, P695, DOI 10.1083/jcb.125.3.695; Niederreither K, 1995, MATRIX BIOL, V14, P705, DOI 10.1016/S0945-053X(05)80013-7; PRIE D, 1991, J CELL BIOL, V113, P951, DOI 10.1083/jcb.113.4.951; PROCKOP DJ, 1984, NEW ENGL J MED, V311, P376, DOI 10.1056/NEJM198408093110606; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; ROSSERT J, 1995, J CELL BIOL, V129, P1421, DOI 10.1083/jcb.129.5.1421; Rossert J., 2002, PRINCIPLES BONE BIOL; Rossert JA, 1996, P NATL ACAD SCI USA, V93, P1027, DOI 10.1073/pnas.93.3.1027; Schweitzer R, 2001, DEVELOPMENT, V128, P3855; Shiojima I, 1999, J BIOL CHEM, V274, P8231, DOI 10.1074/jbc.274.12.8231; SLACK JL, 1991, MOL CELL BIOL, V11, P2066, DOI 10.1128/MCB.11.4.2066; VANDERREST M, 1991, FASEB J, V5, P2814, DOI 10.1096/fasebj.5.13.1916105; WASSARMAN PM, 1993, GUIDES TECHNIQUES MO	24	20	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 24	2002	277	21					19019	19026		10.1074/jbc.M200125200	http://dx.doi.org/10.1074/jbc.M200125200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	558PM	11882659	hybrid			2022-12-27	WOS:000175975800101
J	Wei, WL; Wang, XT; Kusiak, JW				Wei, WL; Wang, XT; Kusiak, JW			Signaling events in amyloid beta-peptide-induced neuronal death and insulin-like growth factor I protection	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; N-TERMINAL KINASE; C-JUN; ALZHEIMERS-DISEASE; PRECURSOR PROTEIN; KAPPA-B; HIPPOCAMPAL-NEURONS; COUPLED RECEPTORS; INDUCED APOPTOSIS; CORTICAL-NEURONS	Amyloid beta-peptide (Abeta) is implicated as the toxic agent in Alzheimer's disease and is the major component of brain amyloid plaques. In vitro, Abeta causes cell death, but the molecular mechanisms are unclear. We analyzed the early signaling mechanisms involved in Abeta toxicity using the SH-SY5Y neuroblastoma cell line. Abeta caused cell death and induced a 2- to 3-fold activation of JNK JNK activation and cell death were inhibited by overexpression of a dominant-negative SEK1 (SEK1-AL) construct. Butyrolactone I, a cdk5 inhibitor, had an additional protective effect against Abeta toxicity in these SEK1-AL-expressing cells suggesting that cdk5 and JNK activation independently contributed to this toxicity. Abeta also weakly activated ERK and Akt but had no effect on p38 kinase. Inhibitors of ERK and phosphoinositide 3-kinase (PI3K) pathways did not affect Abeta-induced cell death, suggesting that these pathways were not important in Abeta toxicity. Insulin-like growth factor I protected against Abeta toxicity by strongly activating ERK and Akt and blocking JNK activation in a PI3K-dependent manner. Pertussis toxin also blocked Abeta-induced cell death and JNK activation suggesting that G(i/o) proteins were upstream activators of JNK. The results suggest that activation of the JNK pathway and cdk5 may be initial signaling cascades in Abeta-induced cell death.	NIA, Mol Neurobiol Unit, Cellular & Mol Biol Lab, Intramural Res Program,Gerontol Res Ctr,NIH, Baltimore, MD 21224 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA)	Wei, WL (corresponding author), NIA, Mol Neurobiol Unit, Cellular & Mol Biol Lab, Intramural Res Program,Gerontol Res Ctr,NIH, 5600 Nathan Shock Dr, Baltimore, MD 21224 USA.	weiwa@grc.nia.nih.gov; jk133r@nih.gov			NATIONAL INSTITUTE ON AGING [Z01AG000500] Funding Source: NIH RePORTER	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Abe K, 2000, NEUROSCI LETT, V292, P1, DOI 10.1016/S0304-3940(00)01415-4; Ahmed NN, 1997, P NATL ACAD SCI USA, V94, P3627, DOI 10.1073/pnas.94.8.3627; Akama KT, 1998, P NATL ACAD SCI USA, V95, P5795, DOI 10.1073/pnas.95.10.5795; Alvarez A, 2001, EXP CELL RES, V264, P266, DOI 10.1006/excr.2001.5152; Anderson AJ, 1996, J NEUROSCI, V16, P1710, DOI 10.1523/jneurosci.16-05-01710.1996; ANDERSON AJ, 1995, J NEUROCHEM, V65, P1487; BEHL C, 1994, BRAIN RES, V645, P253, DOI 10.1016/0006-8993(94)91659-4; BROWN AM, 1990, ANNU REV PHYSIOL, V52, P197, DOI 10.1146/annurev.ph.52.030190.001213; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; Cheng HL, 1998, J BIOL CHEM, V273, P14560, DOI 10.1074/jbc.273.23.14560; Combs CK, 2001, J NEUROSCI, V21, P1179; COSO OA, 1995, J BIOL CHEM, V270, P5620, DOI 10.1074/jbc.270.10.5620; CREWS FT, 1992, J NEUROCHEM, V58, P1205, DOI 10.1111/j.1471-4159.1992.tb11330.x; DIVE C, 1992, BIOCHIM BIOPHYS ACTA, V1133, P275, DOI 10.1016/0167-4889(92)90048-G; Dore S, 1997, NEUROSCIENCE, V80, P1033, DOI 10.1016/S0306-4522(97)00154-1; Dore S, 1997, P NATL ACAD SCI USA, V94, P4772, DOI 10.1073/pnas.94.9.4772; Du YS, 1997, P NATL ACAD SCI USA, V94, P11657, DOI 10.1073/pnas.94.21.11657; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; Ekinci FJ, 1999, J BIOL CHEM, V274, P30322, DOI 10.1074/jbc.274.42.30322; Ferreira A, 1997, MOL CELL NEUROSCI, V9, P220, DOI 10.1006/mcne.1997.0615; Franke TF, 1997, SCIENCE, V275, P665, DOI 10.1126/science.275.5300.665; Giovanni A, 2000, J BIOL CHEM, V275, P11553, DOI 10.1074/jbc.275.16.11553; Gudermann T, 2000, N-S ARCH PHARMACOL, V361, P345, DOI 10.1007/s002109900208; Hara F, 2001, J ORTHOPAED RES, V19, P126, DOI 10.1016/S0736-0266(00)00011-5; Hashimoto Y, 2000, J BIOL CHEM, V275, P34541, DOI 10.1074/jbc.M005332200; Huttunen HJ, 1999, J BIOL CHEM, V274, P19919, DOI 10.1074/jbc.274.28.19919; Iijima K, 2000, J NEUROCHEM, V75, P1085, DOI 10.1046/j.1471-4159.2000.0751085.x; Ikeuchi T, 1998, Hum Cell, V11, P125; IVERSEN LL, 1995, BIOCHEM J, V311, P1; Kajkowski EM, 2001, J BIOL CHEM, V276, P18748, DOI 10.1074/jbc.M011161200; Kihiko ME, 1999, J NEUROCHEM, V73, P2609, DOI 10.1046/j.1471-4159.1999.0732609.x; Konishi H, 1996, P NATL ACAD SCI USA, V93, P7639, DOI 10.1073/pnas.93.15.7639; Kuner P, 1998, J NEUROSCI RES, V54, P798, DOI 10.1002/(SICI)1097-4547(19981215)54:6<798::AID-JNR7>3.3.CO;2-K; Lackey BR, 2000, GROWTH HORM IGF RES, V10, P1, DOI 10.1054/ghir.1999.0129; Le-Niculescu H, 1999, MOL CELL BIOL, V19, P751; Lee MS, 2000, NATURE, V405, P360, DOI 10.1038/35012636; Levresse V, 2000, J NEUROSCI RES, V62, P799; Lorenzo A, 2000, NAT NEUROSCI, V3, P460, DOI 10.1038/74833; Marcus DL, 1998, NEUROBIOL AGING, V19, P393, DOI 10.1016/S0197-4580(98)00077-3; Marinissen MJ, 2001, TRENDS PHARMACOL SCI, V22, P368, DOI 10.1016/S0165-6147(00)01678-3; MATTSON MP, 1993, TRENDS NEUROSCI, V16, P409, DOI 10.1016/0166-2236(93)90009-B; McDonald DR, 1998, J NEUROSCI, V18, P4451; Mograbi B, 2001, J BIOL CHEM, V276, P45307, DOI 10.1074/jbc.M101220200; Morishima Y, 2001, J NEUROSCI, V21, P7551, DOI 10.1523/JNEUROSCI.21-19-07551.2001; Namgung U, 2000, J NEUROSCI, V20, P6442, DOI 10.1523/JNEUROSCI.20-17-06442.2000; Niikura T, 2001, J NEUROSCI, V21, P1902, DOI 10.1523/JNEUROSCI.21-06-01902.2001; NISHIMOTO I, 1993, NATURE, V362, P75, DOI 10.1038/362075a0; Okubo Y, 1998, J BIOL CHEM, V273, P25961, DOI 10.1074/jbc.273.40.25961; Park HS, 2002, J BIOL CHEM, V277, P2573, DOI 10.1074/jbc.M110299200; Patrick GN, 1999, NATURE, V402, P615, DOI 10.1038/45159; Rapoport M, 2000, J NEUROCHEM, V74, P125, DOI 10.1046/j.1471-4159.2000.0740125.x; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; Rymer DL, 2001, J BIOL CHEM, V276, P2523, DOI 10.1074/jbc.M005800200; Selkoe DJ, 2001, PHYSIOL REV, V81, P741, DOI 10.1152/physrev.2001.81.2.741; Shoji M, 2000, MOL BRAIN RES, V85, P221, DOI 10.1016/S0169-328X(00)00245-X; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; Troy CM, 2001, J NEUROCHEM, V77, P157, DOI 10.1046/j.1471-4159.2001.00218.x; Verheij M, 1996, NATURE, V380, P75, DOI 10.1038/380075a0; Wang XT, 1998, BIOCHEM J, V333, P291, DOI 10.1042/bj3330291; Wolozin B, 1996, SCIENCE, V274, P1710, DOI 10.1126/science.274.5293.1710; Wylie PG, 1999, BIOCHEM J, V338, P619, DOI 10.1042/0264-6021:3380619; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yaar M, 2002, J BIOL CHEM, V277, P7720, DOI 10.1074/jbc.M110929200; Yaar M, 1997, J CLIN INVEST, V100, P2333, DOI 10.1172/JCI119772; Yamatsuji T, 1996, SCIENCE, V272, P1349, DOI 10.1126/science.272.5266.1349; Yamauchi J, 2000, J BIOL CHEM, V275, P7633, DOI 10.1074/jbc.275.11.7633; YAN MH, 1994, NATURE, V372, P798; ZHENG WH, 2000, J NEURAL TRANSM-SUPP, V60, pS261; Zhu XW, 2001, J NEUROCHEM, V76, P435, DOI 10.1046/j.1471-4159.2001.00046.x	69	164	180	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 17	2002	277	20					17649	17656		10.1074/jbc.M111704200	http://dx.doi.org/10.1074/jbc.M111704200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	553PR	11882652	hybrid			2022-12-27	WOS:000175685100034
J	Collinson, EJ; Wheeler, GL; Garrido, EO; Avery, AM; Avery, SV; Grant, CM				Collinson, EJ; Wheeler, GL; Garrido, EO; Avery, AM; Avery, SV; Grant, CM			The yeast glutaredoxins are active as glutathione peroxidases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXIDATIVE STRESS-RESPONSE; SACCHAROMYCES-CEREVISIAE; REACTIVE OXYGEN; THIOLTRANSFERASE GLUTAREDOXIN; ESCHERICHIA-COLI; ERYTHROASCORBIC ACID; STATIONARY-PHASE; REDUCTASE; PROTEIN; PURIFICATION	The yeast Saccharomyces cerevisiae contains two glutaredoxins, encoded by GRX1 and GRX2, which are active as glutathione-dependent oxidoreductases. Our studies show that changes in the levels of glutaredoxins affect the resistance of yeast cells to oxidative stress induced by hydroperoxides. Elevating the gene dosage of GRX1 or GRX2 increases resistance to hydroperoxides including hydrogen peroxide, tert-butyl hydroperoxide and cumene hydroperoxide. The glutaredoxin-mediated resistance to hydroperoxides is dependent on the presence of an intact glutathione system, but does not require the activity of phospholipid hydroperoxide glutathione peroxidases (GPX1-3). Rather, the mechanism appears to be mediated via glutathione conjugation and removal from the cell because it is absent in strains lacking glutathione-S-transferases (GTT1, GTT2) or the GS-X pump (YCF1). We show that the yeast glutaredoxins can directly reduce hydroperoxides in a catalytic manner, using reducing power provided by NADPH, GSH, and glutathione reductase. With cumene hydroperoxide, high pressure liquid chromatography analysis confirmed the formation of the corresponding cumyl alcohol. We propose a model in which the glutathione peroxidase activity of glutaredoxins converts hydroperoxides to their corresponding alcohols; these can then be conjugated to GSH by glutathione-S-transferases and transported into the vacuole by Ycf1.	Univ Manchester, Inst Sci & Technol, Dept Biomol Sci, Manchester M60 1QD, Lancs, England; Univ Nottingham, Sch Life & Environm Sci, Nottingham NG7 2RD, England	University of Manchester; University of Nottingham	Grant, CM (corresponding author), Univ Manchester, Inst Sci & Technol, Dept Biomol Sci, POB 88, Manchester M60 1QD, Lancs, England.	chris.grant@umist.ac.uk	Avery, Simon/U-5816-2019; Avery, Simon/AAS-5291-2021; Wheeler, Glen L/E-5034-2011	Avery, Simon/0000-0002-2102-2255; Grant, Chris/0000-0002-0616-6576	NIGMS NIH HHS [R01 GM57945] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057945] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Avery AM, 2001, J BIOL CHEM, V276, P33730, DOI 10.1074/jbc.M105672200; BJORNSTEDT M, 1994, J BIOL CHEM, V269, P29382; BORA PS, 1989, P NATL ACAD SCI USA, V86, P4470, DOI 10.1073/pnas.86.12.4470; BUSHWELLER JH, 1992, BIOCHEMISTRY-US, V31, P9288, DOI 10.1021/bi00153a023; Carmel-Harel O, 2000, ANNU REV MICROBIOL, V54, P439, DOI 10.1146/annurev.micro.54.1.439; Choi JH, 1998, J BIOL CHEM, V273, P29915, DOI 10.1074/jbc.273.45.29915; Chrestensen CA, 2000, J BIOL CHEM, V275, P26556, DOI 10.1074/jbc.M004097200; CHRESTENSEN CA, 1995, FEBS LETT, V374, P25, DOI 10.1016/0014-5793(95)01066-N; Davis DA, 1997, J BIOL CHEM, V272, P25935, DOI 10.1074/jbc.272.41.25935; Demple B, 1998, SCIENCE, V279, P1655, DOI 10.1126/science.279.5357.1655; FRANKENBERG D, 1993, INT J RADIAT BIOL, V64, P511, DOI 10.1080/09553009314551721; Garrido EO, 2002, MOL MICROBIOL, V43, P993, DOI 10.1046/j.1365-2958.2002.02795.x; Grant CM, 2001, MOL MICROBIOL, V39, P533, DOI 10.1046/j.1365-2958.2001.02283.x; Grant CM, 1996, CURR GENET, V29, P511, DOI 10.1007/BF02426954; Grant CM, 1996, MOL MICROBIOL, V22, P739, DOI 10.1046/j.1365-2958.1996.d01-1727.x; Grant CM, 1996, MOL MICROBIOL, V21, P171, DOI 10.1046/j.1365-2958.1996.6351340.x; Grant CM, 2000, BBA-GENE STRUCT EXPR, V1490, P33, DOI 10.1016/S0167-4781(99)00234-1; HALLIWELL B, 1991, AM J MED, V91, pS14, DOI 10.1016/0002-9343(91)90279-7; HOLMGREN A, 1976, P NATL ACAD SCI USA, V73, P2275, DOI 10.1073/pnas.73.7.2275; HOLMGREN A, 1990, GLUTATHIONE METABOLI, P146; Inoue Y, 1999, J BIOL CHEM, V274, P27002, DOI 10.1074/jbc.274.38.27002; JACOBSON FS, 1989, J BIOL CHEM, V264, P1488; Jamieson DJ, 1998, YEAST, V14, P1511, DOI 10.1002/(SICI)1097-0061(199812)14:16<1511::AID-YEA356>3.3.CO;2-J; KIM HS, 1993, J FOOD SCI, V58, P845, DOI 10.1111/j.1365-2621.1993.tb09373.x; Lee JC, 2001, FEMS YEAST RES, V1, P57; Lefer DJ, 2000, AM J MED, V109, P315, DOI 10.1016/S0002-9343(00)00467-8; LEVINE RL, 1994, METHOD ENZYMOL, V233, P346; Luikenhuis S, 1998, MOL BIOL CELL, V9, P1081, DOI 10.1091/mbc.9.5.1081; MEISTER A, 1994, J BIOL CHEM, V269, P9397; MoradasFerreira P, 1996, MOL MICROBIOL, V19, P651, DOI 10.1046/j.1365-2958.1996.403940.x; Mukhopadhyay R, 2000, J BIOL CHEM, V275, P21149, DOI 10.1074/jbc.M910401199; NICK JA, 1986, PLANT SCI, V46, P181, DOI 10.1016/0168-9452(86)90190-1; Park JB, 1996, BIOCHEM J, V315, P931, DOI 10.1042/bj3150931; Rietsch A, 1998, ANNU REV GENET, V32, P163, DOI 10.1146/annurev.genet.32.1.163; Rodriguez-Manzaneque MT, 1999, MOL CELL BIOL, V19, P8180; Schulz JB, 2000, EUR J BIOCHEM, V267, P4904, DOI 10.1046/j.1432-1327.2000.01595.x; STEELS EL, 1994, MICROBIOL-SGM, V140, P569, DOI 10.1099/00221287-140-3-569; Stewart EJ, 1998, EMBO J, V17, P5543, DOI 10.1093/emboj/17.19.5543; SZCZYPKA MS, 1994, J BIOL CHEM, V269, P22853; TRAN LT, 1993, BIOCHIM BIOPHYS ACTA, V1164, P166, DOI 10.1016/0167-4838(93)90244-L; Vergauwen B, 2001, J BIOL CHEM, V276, P20890, DOI 10.1074/jbc.M102026200; WELLS WW, 1990, J BIOL CHEM, V265, P15361; Wiseman H, 1996, BIOCHEM J, V313, P17, DOI 10.1042/bj3130017; YU BP, 1994, PHYSIOL REV, V74, P139, DOI 10.1152/physrev.1994.74.1.139; ZESHENG L, 1996, J BIOL CHEM, V271, P5609; Zhao TJ, 1999, ARCH BIOCHEM BIOPHYS, V367, P216, DOI 10.1006/abbi.1999.1277	46	104	108	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 10	2002	277	19					16712	16717		10.1074/jbc.M111686200	http://dx.doi.org/10.1074/jbc.M111686200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	551MB	11875065	hybrid			2022-12-27	WOS:000175564500050
J	Kim, YM; Barak, LS; Caron, MG; Benovic, JL				Kim, YM; Barak, LS; Caron, MG; Benovic, JL			Regulation of arrestin-3 phosphorylation by casein kinase II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; BETA-ADRENERGIC-RECEPTOR; CLATHRIN-MEDIATED ENDOCYTOSIS; BETA(2)-ADRENERGIC RECEPTOR; VISUAL ARRESTIN; ACTIVATION; BETA-ARRESTIN1; INTERNALIZATION; RESENSITIZATION; UBIQUITINATION	Arrestins play an important role in regulating the function of G protein-coupled receptors including receptor desensitization, internalization, down-regulation, and signaling via nonreceptor tyrosine kinases and mitogen-activated protein kinases. Previous studies have revealed that arrestins themselves are also subject to regulation. In the present study, we focused on identifying potential mechanisms involved in regulating the function of arrestin-3. Using metabolic labeling, phosphoamino acid analysis, and mutagenesis studies, we found that arrestin-3 is constitutively phosphorylated at Thr-382 and becomes dephosphorylated upon beta(2)-adrenergic receptor activation in COS-1 cells. Casein kinase II (CKII) appears to be the major kinase mediating arrestin-3 phosphorylation, since 1) Thr-382 is contained within a canonical consensus sequence for CKII phosphorylation and 2) wild type arrestin-3 but not a T382A mutant is phosphorylated by CKII in vitro. Functional analysis reveals that mutants mimicking the phosphorylated (T382E) and dephosphorylated (T382A or T382V) states of arrestin-3 promote beta(2)-adrenergic receptor internalization and bind clathrin, beta-adaptin, and Src to comparable levels as wild type arrestin-3. This suggests that the phosphorylation of arrestin-3 does not directly regulate interaction with endocytic (clathrin, beta-adaptin) or signaling (Src) components and is in contrast to arrestin-2, where phosphorylation appears to regulate interaction with clathrin and Src. However, additional analysis reveals that arrestin-3 phosphorylation may regulate formation of a large arrestin-3-containing protein complex. Differences between the regulatory roles of arrestin-2 and -3 phosphorylation may contribute to the different cellular functions of these proteins in G protein-coupled receptor signaling and regulation.	Thomas Jefferson Univ, Kimmel Canc Ctr, Dept Microbiol & Immunol, Philadelphia, PA 19107 USA; Duke Univ, Howard Hughes Med Inst, Dept Cell Biol, Durham, NC 27710 USA	Jefferson University; Duke University; Howard Hughes Medical Institute	Benovic, JL (corresponding author), Thomas Jefferson Univ, Kimmel Canc Ctr, Dept Microbiol & Immunol, Philadelphia, PA 19107 USA.		Kim, You-Me/I-5553-2013	Kim, You-Me/0000-0001-8780-704X				ALLENDE JE, 1995, FASEB J, V9, P313, DOI 10.1096/fasebj.9.5.7896000; Alloway PG, 1999, P NATL ACAD SCI USA, V96, P6072, DOI 10.1073/pnas.96.11.6072; BARAK LS, 1994, J BIOL CHEM, V269, P2790; Barak LS, 1997, J BIOL CHEM, V272, P27497, DOI 10.1074/jbc.272.44.27497; Barlic J, 2000, NAT IMMUNOL, V1, P227, DOI 10.1038/79767; CHEN CY, 1993, J BIOL CHEM, V268, P7825; Claing A, 2001, J BIOL CHEM, V276, P42509, DOI 10.1074/jbc.M108399200; Cvejic S, 1997, J BIOL CHEM, V272, P26959, DOI 10.1074/jbc.272.43.26959; Daunt DA, 1997, MOL PHARMACOL, V51, P711, DOI 10.1124/mol.51.5.711; DeFea KA, 2000, J CELL BIOL, V148, P1267, DOI 10.1083/jcb.148.6.1267; DeFea KA, 2000, P NATL ACAD SCI USA, V97, P11086, DOI 10.1073/pnas.190276697; DUA HS, 1992, CURR EYE RES, V11, P107, DOI 10.3109/02713689208999519; Ferguson SSG, 2001, PHARMACOL REV, V53, P1; FERGUSON SSG, 1995, J BIOL CHEM, V270, P24782, DOI 10.1074/jbc.270.42.24782; Goodman OB, 1996, NATURE, V383, P447, DOI 10.1038/383447a0; Hebert TE, 1996, J BIOL CHEM, V271, P16384, DOI 10.1074/jbc.271.27.16384; Imamura T, 2001, J BIOL CHEM, V276, P43663, DOI 10.1074/jbc.M105364200; ISSINGER OG, 1993, PHARMACOL THERAPEUT, V59, P1, DOI 10.1016/0163-7258(93)90039-G; Krupnick JG, 1997, J BIOL CHEM, V272, P32507, DOI 10.1074/jbc.272.51.32507; Krupnick JG, 1998, ANNU REV PHARMACOL, V38, P289, DOI 10.1146/annurev.pharmtox.38.1.289; KUNAPULI P, 1994, J BIOL CHEM, V269, P10209; Laney JD, 1999, CELL, V97, P427, DOI 10.1016/S0092-8674(00)80752-7; Laporte SA, 1999, P NATL ACAD SCI USA, V96, P3712, DOI 10.1073/pnas.96.7.3712; Lin FT, 1997, J BIOL CHEM, V272, P31051, DOI 10.1074/jbc.272.49.31051; Lin FT, 1999, J BIOL CHEM, V274, P15971, DOI 10.1074/jbc.274.23.15971; LOHSE MJ, 1990, SCIENCE, V248, P1547, DOI 10.1126/science.2163110; Luttrell LM, 2001, P NATL ACAD SCI USA, V98, P2449, DOI 10.1073/pnas.041604898; Luttrell LM, 1999, SCIENCE, V283, P655, DOI 10.1126/science.283.5402.655; MATSUMOTO H, 1994, NEURON, V12, P997, DOI 10.1016/0896-6273(94)90309-3; McDonald PH, 2000, SCIENCE, V290, P1574, DOI 10.1126/science.290.5496.1574; McDonald PH, 1999, J BIOL CHEM, V274, P10677, DOI 10.1074/jbc.274.16.10677; MURAKAMI A, 1993, FEBS LETT, V334, P203, DOI 10.1016/0014-5793(93)81712-9; Oakley RH, 1999, J BIOL CHEM, V274, P32248, DOI 10.1074/jbc.274.45.32248; Oakley RH, 2000, J BIOL CHEM, V275, P17201, DOI 10.1074/jbc.M910348199; ONORATO JJ, 1991, BIOCHEMISTRY-US, V30, P5118, DOI 10.1021/bi00235a002; Orsini MJ, 1998, J BIOL CHEM, V273, P34616, DOI 10.1074/jbc.273.51.34616; Penn RB, 2001, J BIOL CHEM, V276, P32648, DOI 10.1074/jbc.M104143200; Pierce KL, 2001, NAT REV NEUROSCI, V2, P727, DOI 10.1038/35094577; PITCHER JA, 1995, P NATL ACAD SCI USA, V92, P8343, DOI 10.1073/pnas.92.18.8343; RAPOPORT B, 1992, MOL CELL ENDOCRINOL, V84, pR39, DOI 10.1016/0303-7207(92)90038-8; Shenoy SK, 2001, SCIENCE, V294, P1307, DOI 10.1126/science.1063866; Shih ML, 1999, J BIOL CHEM, V274, P1588, DOI 10.1074/jbc.274.3.1588; STERNEMARR R, 1993, J BIOL CHEM, V268, P15640; Wilkinson KD, 2000, SEMIN CELL DEV BIOL, V11, P141, DOI 10.1006/scdb.2000.0164; YAMAKI K, 1987, BIOCHEM BIOPH RES CO, V142, P904, DOI 10.1016/0006-291X(87)91499-9; Zhang J, 1997, J BIOL CHEM, V272, P27005, DOI 10.1074/jbc.272.43.27005	46	51	53	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 10	2002	277	19					16837	16846		10.1074/jbc.M201379200	http://dx.doi.org/10.1074/jbc.M201379200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	551MB	11877451	hybrid			2022-12-27	WOS:000175564500066
J	Thongboonkerd, V; Luengpailin, J; Cao, JK; Pierce, WM; Cai, J; Klein, JB; Doyle, RJ				Thongboonkerd, V; Luengpailin, J; Cao, JK; Pierce, WM; Cai, J; Klein, JB; Doyle, RJ			Fluoride exposure attenuates expression of streptococcus pyogenes virulence factors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROUP-A STREPTOCOCCI; CYSTEINE PROTEASE; 2-DIMENSIONAL ELECTROPHORESIS; WATER FLUORIDATION; SURFACE PROTEIN; RHEUMATIC-FEVER; HEART-DISEASE; INHIBITION; BINDING; MUTANS	Fluoridation causes an obvious reduction of dental caries by interference with cariogenic streptococci. However, the effect of fluoride on group A streptococci that causes rheumatic fever and acute poststreptococcal glomerulonephritis is not known. We have used proteomic analysis to create a reference proteome map for Streptococcus pyogenes and to determine fluoride-induced protein changes in the streptococci. Cellular and extracellular proteins were resolved by two-dimensional polyacrylamide gel electrophoresis and identified by matrix-assisted laser desorption ionization mass spectrometry. 183 protein spots were visualized, and 74 spots representing 60 unique proteins were identified. A 16-h exposure to sodium fluoride caused decreased expression of proteins required to respond to cellular stress, including anti-oxidants, glycolytic enzymes, transcriptional and translational regulators, and protein folding. Fluoride caused decreased cellular expression of two well-characterized S. pyogenes virulence factors. Fluoride decreased expression of glyceraldehyde-3-phosphate dehydrogenase, which acts to bind fibronectin and promote bacterial adherence. We also performed proteomic analysis of protein released by S. pyogenes into the culture supernatant and observed decreased expression of M proteins following fluoride exposure. These data provide evidence that fluoride causes decreased expression by S. pyogenes proteins used to respond to stress, virulence factors, and implicated in non-suppurative complications of S. pyogenes, including glomerulonephritis and rheumatic fever.	Univ Louisville, Kidney Dis Program, Cor Proteom Lab, Dept Med, Louisville, KY 40202 USA; Chiang Mai Univ, Fac Med, Dept Med, Chiang Mai 50200, Thailand; Univ Louisville, Dept Microbiol & Immunol, Louisville, KY 40202 USA; Vet Adm Med Ctr, Louisville, KY 40202 USA; Univ Louisville, Dept Biochem & Mol Biol, Louisville, KY 40202 USA; Univ Louisville, Dept Pharmacol & Toxicol, Louisville, KY 40202 USA	University of Louisville; Chiang Mai University; University of Louisville; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Louisville; University of Louisville	Klein, JB (corresponding author), Univ Louisville, Kidney Dis Program, Cor Proteom Lab, Dept Med, 570 S Preston St, Louisville, KY 40202 USA.	jon.klein@louisville.edu	Klein, Jon/B-9833-2013; Thongboonkerd, Visith/C-6920-2009	Thongboonkerd, Visith/0000-0001-7865-0765	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL066358] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL66358-01] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AGARWAL BL, 1981, LANCET, V2, P910; Anderson NL, 1998, ELECTROPHORESIS, V19, P1853, DOI 10.1002/elps.1150191103; BENNASR A, 1995, BIOCHEM J, V305, P173, DOI 10.1042/bj3050173; BISNO AL, 1985, JAMA-J AM MED ASSOC, V254, P538, DOI 10.1001/jama.254.4.538; Boyle MDP, 2001, J MICROBIOL METH, V46, P87, DOI 10.1016/S0167-7012(01)00279-2; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURT BA, 1995, BRIT DENT J, V178, P49, DOI 10.1038/sj.bdj.4808645; Chaussee MS, 1996, J INFECT DIS, V173, P901, DOI 10.1093/infdis/173.4.901; Cunningham MW, 2000, CLIN MICROBIOL REV, V13, P470, DOI 10.1128/CMR.13.3.470-511.2000; CURRAN TM, 1994, FEMS MICROBIOL LETT, V119, P283; EASLEY MW, 1995, BRIT DENT J, V178, P72, DOI 10.1038/sj.bdj.4808658; EISENBERG AD, 1980, ARCH ORAL BIOL, V25, P133, DOI 10.1016/0003-9969(80)90089-8; Ekenback SB, 2001, EUR J ORAL SCI, V109, P182, DOI 10.1034/j.1600-0722.2001.00005.x; Ferretti JJ, 2001, P NATL ACAD SCI USA, V98, P4658, DOI 10.1073/pnas.071559398; Fontan PA, 2000, J INFECT DIS, V182, P1712, DOI 10.1086/317604; Hytonen J, 2001, MOL MICROBIOL, V39, P512, DOI 10.1046/j.1365-2958.2001.02269.x; Jayaraman GC, 1997, MOL MICROBIOL, V25, P329, DOI 10.1046/j.1365-2958.1997.4671835.x; Jensen ON, 1999, METH MOL B, V112, P513; JUNGBLUT P, 1995, J BIOTECHNOL, V41, P111, DOI 10.1016/0168-1656(95)00006-C; Kansal RG, 2000, INFECT IMMUN, V68, P6362, DOI 10.1128/IAI.68.11.6362-6369.2000; KAPUR V, 1993, P NATL ACAD SCI USA, V90, P7676, DOI 10.1073/pnas.90.16.7676; KAUFMANN M, 1992, CARIES RES, V26, P110, DOI 10.1159/000261494; KLOSE J, 1995, ELECTROPHORESIS, V16, P1034, DOI 10.1002/elps.11501601175; Lei BF, 2000, INFECT IMMUN, V68, P6807, DOI 10.1128/IAI.68.12.6807-6818.2000; Lemos JAC, 1998, J MED MICROBIOL, V47, P711, DOI 10.1099/00222615-47-8-711; Luengpailin S, 2000, BBA-GEN SUBJECTS, V1474, P346, DOI 10.1016/S0304-4165(00)00024-6; Lukomski S, 2000, INFECT IMMUN, V68, P6542, DOI 10.1128/IAI.68.12.6542-6553.2000; Lyon WR, 1998, EMBO J, V17, P6263, DOI 10.1093/emboj/17.21.6263; Meier B, 1998, BIOCHEM J, V331, P403, DOI 10.1042/bj3310403; MESTERS JR, 1993, FEBS LETT, V321, P149, DOI 10.1016/0014-5793(93)80097-E; Nordstrand A, 1999, SCAND J INFECT DIS, V31, P523, DOI 10.1080/00365549950164382; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; Pancholi V, 1997, J EXP MED, V186, P1633, DOI 10.1084/jem.186.10.1633; PANCHOLI V, 1993, P NATL ACAD SCI USA, V90, P8154, DOI 10.1073/pnas.90.17.8154; PANCHOLI V, 1992, J EXP MED, V176, P415, DOI 10.1084/jem.176.2.415; Perrin C, 2000, ELECTROPHORESIS, V21, P949, DOI 10.1002/(SICI)1522-2683(20000301)21:5&lt;949::AID-ELPS949&gt;3.0.CO;2-5; Quinn A, 1998, INFECT IMMUN, V66, P4418; Quinn A, 2001, INFECT IMMUN, V69, P4072, DOI 10.1128/IAI.69.6.4072-4078.2001; RIPA LW, 1993, J PUBLIC HEALTH DENT, V53, P17; Shanley TP, 1996, INFECT IMMUN, V64, P870, DOI 10.1128/IAI.64.3.870-877.1996; SUTTON SVW, 1987, INFECT IMMUN, V55, P2597, DOI 10.1128/IAI.55.11.2597-2603.1987; TALKINGTON DF, 1993, INFECT IMMUN, V61, P3369, DOI 10.1128/IAI.61.8.3369-3374.1993; VANDERIJN I, 1980, INFECT IMMUN, V27, P444, DOI 10.1128/IAI.27.2.444-448.1980; VYSE T, 1991, BRIT MED J, V302, P518, DOI 10.1136/bmj.302.6775.518; Wendrich TM, 1997, MOL MICROBIOL, V26, P65, DOI 10.1046/j.1365-2958.1997.5511919.x; Wilkins JC, 2001, APPL ENVIRON MICROB, V67, P3396, DOI 10.1128/AEM.67.8.3396-3405.2001; Yoshizawa N, 2000, INTERNAL MED, V39, P687, DOI 10.2169/internalmedicine.39.687	47	79	81	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 10	2002	277	19					16599	16605		10.1074/jbc.M200746200	http://dx.doi.org/10.1074/jbc.M200746200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	551MB	11867637	hybrid			2022-12-27	WOS:000175564500036
J	Ferkey, DM; Kimelman, D				Ferkey, DM; Kimelman, D			Glycogen synthase kinase-3 beta mutagenesis identifies a common binding domain for GBP and axin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENOMATOUS POLYPOSIS-COLI; WNT SIGNALING PATHWAY; APC TUMOR-SUPPRESSOR; BETA-CATENIN; KINASE 3-BETA; NEGATIVE REGULATOR; XENOPUS-EMBRYOS; SUBSTRATE-SPECIFICITY; PROTEIN INTERACTIONS; EYE DEVELOPMENT	Glycogen synthase kinase-3beta (GSK-3) is a key downstream target of Wnt signaling and is regulated by its interactions with activating and inhibitory proteins. We and others have shown that GSK-3 activity toward nonprimed substrates is regulated in part through a competition between its activating (Axin) and inhibitory (GBP/ FRAT) binding partners. Here we use a reverse two-hybrid screen to identify mutations in GSK-3 that alter binding to GBP and Axin. We find that these mutations overlap and propose that GBP and Axin compete for binding to the same region of GSK-3. We use these mutations to examine the ability of GSK-3 to block eye development in Xenopus embryos and suggest that GSK-3 regulates eye development through a non-Wnt pathway.	Univ Washington, Dept Biochem, Seattle, WA 98195 USA; Univ Washington, Ctr Dev Biol, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Kimelman, D (corresponding author), Univ Washington, Dept Biochem, Seattle, WA 98195 USA.	kimelman@u.washington.edu			EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [T32HD007183] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD027262] Funding Source: NIH RePORTER; NICHD NIH HHS [HD27262, T32-HD07183] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; Bax B, 2001, STRUCTURE, V9, P1143, DOI 10.1016/S0969-2126(01)00679-7; Chow RL, 2001, ANNU REV CELL DEV BI, V17, P255, DOI 10.1146/annurev.cellbio.17.1.255; Cohen P, 2001, NAT REV MOL CELL BIO, V2, P769, DOI 10.1038/35096075; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Dajani R, 2001, CELL, V105, P721, DOI 10.1016/S0092-8674(01)00374-9; Ding VW, 2000, J BIOL CHEM, V275, P32475, DOI 10.1074/jbc.M005342200; DOMINGUEZ I, 1995, P NATL ACAD SCI USA, V92, P8498, DOI 10.1073/pnas.92.18.8498; Dominguez I, 2001, DEV BIOL, V235, P303, DOI 10.1006/dbio.2001.0317; Fagotto F, 1999, J CELL BIOL, V145, P741, DOI 10.1083/jcb.145.4.741; Farr GH, 2000, J CELL BIOL, V148, P691, DOI 10.1083/jcb.148.4.691; Ferkey DM, 2000, DEV BIOL, V225, P471, DOI 10.1006/dbio.2000.9816; Frame S, 2001, MOL CELL, V7, P1321, DOI 10.1016/S1097-2765(01)00253-2; FRASER E, 2001, J BIOL CHEM; Hart MJ, 1998, CURR BIOL, V8, P573, DOI 10.1016/S0960-9822(98)70226-X; HE X, 1995, NATURE, V374, P617, DOI 10.1038/374617a0; Hedgepeth CM, 1999, MOL CELL BIOL, V19, P7147; Heisenberg CP, 2001, GENE DEV, V15, P1427, DOI 10.1101/gad.194301; Hinoi T, 2000, J BIOL CHEM, V275, P34399, DOI 10.1074/jbc.M003997200; HOLLENBERG SM, 1995, MOL CELL BIOL, V15, P3813; HUGHES K, 1992, BIOCHEM J, V288, P309, DOI 10.1042/bj2880309; Ikeda S, 1998, EMBO J, V17, P1371, DOI 10.1093/emboj/17.5.1371; Inouye C, 1997, GENETICS, V147, P479; Itoh K, 1995, DEVELOPMENT, V121, P3979; Itoh K, 1998, CURR BIOL, V8, P591, DOI 10.1016/S0960-9822(98)70229-5; Kawahara K, 2000, J BIOL CHEM, V275, P8369, DOI 10.1074/jbc.275.12.8369; Kishida S, 1999, MOL CELL BIOL, V19, P4414; Kishida S, 1998, J BIOL CHEM, V273, P10823, DOI 10.1074/jbc.273.18.10823; MA J, 1987, CELL, V51, P113, DOI 10.1016/0092-8674(87)90015-8; Moon R. T., 1989, TECHNIQUE, V1, P76; MUNEMITSU S, 1995, P NATL ACAD SCI USA, V92, P3046, DOI 10.1073/pnas.92.7.3046; Nakamura T, 1998, GENES CELLS, V3, P395, DOI 10.1046/j.1365-2443.1998.00198.x; NEWPORT J, 1982, CELL, V30, P675, DOI 10.1016/0092-8674(82)90272-0; Ogino H, 2000, DEV GROWTH DIFFER, V42, P437; Orford K, 1997, J BIOL CHEM, V272, P24735, DOI 10.1074/jbc.272.40.24735; PIERCE SB, 1995, DEVELOPMENT, V121, P755; Rasmussen JT, 2001, P NATL ACAD SCI USA, V98, P3861, DOI 10.1073/pnas.071586298; Rubinfeld B, 1996, SCIENCE, V272, P1023, DOI 10.1126/science.272.5264.1023; SAITO Y, 1994, BIOCHEM J, V303, P27, DOI 10.1042/bj3030027; Sakanaka C, 1998, P NATL ACAD SCI USA, V95, P3020, DOI 10.1073/pnas.95.6.3020; Salic A, 2000, MOL CELL, V5, P523, DOI 10.1016/S1097-2765(00)80446-3; Shaw M, 1999, FEBS LETT, V461, P120, DOI 10.1016/S0014-5793(99)01434-9; STAMBOLIC V, 1994, BIOCHEM J, V303, P701, DOI 10.1042/bj3030701; SUTHERLAND C, 1993, BIOCHEM J, V296, P15, DOI 10.1042/bj2960015; ter Haar E, 2001, NAT STRUCT BIOL, V8, P593, DOI 10.1038/89624; Thomas GM, 1999, FEBS LETT, V458, P247, DOI 10.1016/S0014-5793(99)01161-8; Tu H, 1997, MOL CELL BIOL, V17, P5876, DOI 10.1128/MCB.17.10.5876; TURNER DL, 1994, GENE DEV, V8, P1434, DOI 10.1101/gad.8.12.1434; van de Water S, 2001, DEVELOPMENT, V128, P3877; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WELSH GI, 1993, BIOCHEM J, V294, P625, DOI 10.1042/bj2940625; Yost C, 1998, CELL, V93, P1031, DOI 10.1016/S0092-8674(00)81208-8; Yuan HD, 1999, J BIOL CHEM, V274, P30419, DOI 10.1074/jbc.274.43.30419; ZHOU YH, 1991, NUCLEIC ACIDS RES, V19, P6052, DOI 10.1093/nar/19.21.6052	54	51	53	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 3	2002	277	18					16147	16152		10.1074/jbc.M112363200	http://dx.doi.org/10.1074/jbc.M112363200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	550PA	11861647	hybrid			2022-12-27	WOS:000175510400123
J	Ishida, N; Hara, T; Kamura, T; Yoshida, M; Nakayama, K; Nakayama, KI				Ishida, N; Hara, T; Kamura, T; Yoshida, M; Nakayama, K; Nakayama, KI			Phosphorylation of p27(Kip1) on serine 10 is required for its binding to CRM1 and nuclear export	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT-KINASE INHIBITOR; CELL-CYCLE; CDK INHIBITORS; MICE LACKING; P27; DEGRADATION; HYPERPLASIA; CANCER; SKP2; CKS1	Phosphorylation of the cyclin-dependent kinase inhibitor p27(Kip1) has been thought to regulate its stability. Ser(10) is the major phosphorylation site of p27(Kip1), and phosphorylation of this residue affects protein stability. Phosphorylation of p27(Kip1) on Ser(10) has now been shown to be required for the binding of CRM1, a carrier protein for nuclear export. The p27(Kip1) protein was translocated from the nucleus to the cytoplasm at the Go-G, transition of the cell cycle, and this export was inhibited by leptomycin B, a specific inhibitor of CRM1-dependent nuclear export. The nuclear export and subsequent degradation of p27(Kip1) at the Go-G, transition were observed in cells lacking Skp2, the F-box protein component of an SCF ubiquitin ligase complex, indicating that these early events are independent of Skp2-mediated proteolysis. Substitution of Ser(10) with Ala (S10A) markedly reduced the extent of p27(Kip1) export, whereas substitution of Ser(10) with Asp (S10D) or Glu (S10E) promoted export. Co-immunoprecipitation analysis showed that CRM1 preferentially interacted with S10D and S10E but not with S10A, suggesting that the phosphorylation of p27(Kip1) on Ser(10) is required for its binding to CRM1 and for its subsequent nuclear export.	Kyushu Univ, Med Inst Bioregulat, Dept Mol & Cellular Biol, Higashi Ku, Fukuoka 8128582, Japan; Kyushu Univ, Med Inst Bioregulat, Dept Mol Genet, Higashi Ku, Fukuoka 8128582, Japan; Japan Sci & Technol Corp, Core Res Evolut Sci & Technol, Kawaguchi, Saitama 3320012, Japan; Univ Tokyo, Grad Sch Agr & Life Sci, Dept Biotechnol, Bunkyo Ku, Tokyo 1138657, Japan	Kyushu University; Kyushu University; Japan Science & Technology Agency (JST); University of Tokyo	Nakayama, KI (corresponding author), Kyushu Univ, Med Inst Bioregulat, Dept Mol & Cellular Biol, Higashi Ku, 3-1-1 Maidashi, Fukuoka 8128582, Japan.		Yoshida, Minoru/C-8049-2014	Yoshida, Minoru/0000-0002-4376-5674				Carrano AC, 1999, NAT CELL BIOL, V1, P193, DOI 10.1038/12013; Coats S, 1996, SCIENCE, V272, P877, DOI 10.1126/science.272.5263.877; Fero ML, 1996, CELL, V85, P733, DOI 10.1016/S0092-8674(00)81239-8; Fero ML, 1998, NATURE, V396, P177, DOI 10.1038/24179; Ganoth D, 2001, NAT CELL BIOL, V3, P321, DOI 10.1038/35060126; Hara T, 2001, J BIOL CHEM, V276, P48937, DOI 10.1074/jbc.M107274200; Hatakeyama S, 2001, J BIOL CHEM, V276, P33111, DOI 10.1074/jbc.M102755200; Hatakeyama S, 1999, P NATL ACAD SCI USA, V96, P3859, DOI 10.1073/pnas.96.7.3859; Ishida N, 2000, J BIOL CHEM, V275, P25146, DOI 10.1074/jbc.M001144200; Kiyokawa H, 1996, CELL, V85, P721, DOI 10.1016/S0092-8674(00)81238-6; Montagnoli A, 1999, GENE DEV, V13, P1181, DOI 10.1101/gad.13.9.1181; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; Nakayama K, 1998, BIOESSAYS, V20, P1020, DOI 10.1002/(SICI)1521-1878(199812)20:12<1020::AID-BIES8>3.0.CO;2-D; Nakayama K, 2000, EMBO J, V19, P2069, DOI 10.1093/emboj/19.9.2069; Nakayama K, 1996, CELL, V85, P707, DOI 10.1016/S0092-8674(00)81237-4; NOURSE J, 1994, NATURE, V372, P570, DOI 10.1038/372570a0; OssarehNazari B, 1997, SCIENCE, V278, P141, DOI 10.1126/science.278.5335.141; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; Rodier G, 2001, EMBO J, V20, P6672, DOI 10.1093/emboj/20.23.6672; Sheaff RJ, 1997, GENE DEV, V11, P1464, DOI 10.1101/gad.11.11.1464; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Spruck C, 2001, MOL CELL, V7, P639, DOI 10.1016/S1097-2765(01)00210-6; Sutterluty H, 1999, NAT CELL BIOL, V1, P207, DOI 10.1038/12027; Tomoda K, 1999, NATURE, V398, P160, DOI 10.1038/18230; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; Tsihlias J, 1999, ANNU REV MED, V50, P401; Vlach J, 1997, EMBO J, V16, P5334, DOI 10.1093/emboj/16.17.5334; Yoshida M, 1999, ANN NY ACAD SCI, V886, P23, DOI 10.1111/j.1749-6632.1999.tb09397.x	31	223	235	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 26	2002	277	17					14355	14358		10.1074/jbc.C100762200	http://dx.doi.org/10.1074/jbc.C100762200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	545EH	11889117	hybrid			2022-12-27	WOS:000175203000002
J	Khachigian, LM; Fahmy, RG; Zhang, GS; Bobryshev, YV; Kaniaros, A				Khachigian, LM; Fahmy, RG; Zhang, GS; Bobryshev, YV; Kaniaros, A			c-Jun regulates vascular smooth muscle cell growth and neointima formation after arterial injury - Inhibition by a novel DNA enzyme targeting c-Jun	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NH2-TERMINAL KINASE; ANTISENSE OLIGODEOXYNUCLEOTIDES; TRANSCRIPTIONAL ACTIVITY; GENE-EXPRESSION; FACTOR-BETA; IN-VITRO; OLIGONUCLEOTIDES; FOS; RNA; PHOSPHORYLATION	Neointima formation is a characteristic feature of common vascular pathologies, such as atherosclerosis and post-angioplasty restenosis, and involves smooth muscle cell proliferation. Determination of whether the bZIP transcription factor c-Jun plays a direct regulatory role in arterial lesion formation, or indeed in other disease, has been hampered by the lack of a potent and specific pharmacological inhibitor. c-Jun is poorly expressed in the uninjured artery wall and transiently induced following arterial injury in animal models. Here we generated a gene-specific DNAzyme-targeting c-Jun. We show that c-Jun protein is expressed in human atherosclerotic lesions. Dz13, a catalytically active c-Jun DNAzyme, cleaved c-Jun RNA and inhibited inducible c-Jun protein expression in vascular smooth muscle cells. Dz13 blocked vascular smooth muscle cell proliferation with potency exceeding its exact non-catalytic antisense oligodeoxynucleotide equivalent. Moreover, Dz13 abrogated smooth muscle cell repair following scraping injury in vitro and intimal thickening in injured rat carotid arteries in vivo. These studies demonstrate the positive influence on neointima formation by c-Jun and the therapeutic potential of a DNAzyme controlling its expression.	Univ New S Wales, Dept Pathol, Ctr Thrombosis & Vasc Res, Sydney, NSW 2052, Australia; Prince Wales Hosp, Dept Haematol, Sydney, NSW 2052, Australia	University of New South Wales Sydney	Khachigian, LM (corresponding author), Univ New S Wales, Dept Pathol, Ctr Thrombosis & Vasc Res, Sydney, NSW 2052, Australia.		Bobryshev, Yuri/J-2838-2013; Khachigian, Levon/AAZ-7458-2020	Khachigian, Levon/0000-0003-3446-0323				AUTIERI MV, 1995, BIOCHEM BIOPH RES CO, V213, P827, DOI 10.1006/bbrc.1995.2204; BAUTERS C, 1994, CIRCULATION, V89, P2327, DOI 10.1161/01.CIR.89.5.2327; BENNETT MR, 1994, J CLIN INVEST, V93, P820, DOI 10.1172/JCI117036; Buschmann T, 2001, MOL CELL BIOL, V21, P2743, DOI 10.1128/MCB.21.8.2743-2754.2001; CHEN B, 1992, J CLIN INVEST, V90, P1778, DOI 10.1172/JCI116052; Deng XM, 2001, J BIOL CHEM, V276, P23681, DOI 10.1074/jbc.M100279200; Dennler S, 2000, J BIOL CHEM, V275, P28858, DOI 10.1074/jbc.M910358199; GILLARDON F, 1995, BRIT J OPHTHALMOL, V79, P277, DOI 10.1136/bjo.79.3.277; Gupta S, 1996, EMBO J, V15, P2760, DOI 10.1002/j.1460-2075.1996.tb00636.x; Izumi Y, 2001, CIRC RES, V88, P1120, DOI 10.1161/hh1101.091267; Kanatani Y, 1996, CELL GROWTH DIFFER, V7, P187; Khachigian LM, 1999, CIRC RES, V84, P1258, DOI 10.1161/01.RES.84.11.1258; Khachigian LM, 1996, SCIENCE, V271, P1427, DOI 10.1126/science.271.5254.1427; Kondo T, 2000, HISTOCHEM J, V32, P509, DOI 10.1023/A:1004164905041; Kuwabara T, 1997, NUCLEIC ACIDS RES, V25, P3074, DOI 10.1093/nar/25.15.3074; Lowe HC, 2001, CIRC RES, V89, P670, DOI 10.1161/hh2001.097867; Metzler B, 2000, AM J PATHOL, V156, P1875, DOI 10.1016/S0002-9440(10)65061-4; MIANO JM, 1990, AM J PATHOL, V137, P761; MIANO JM, 1993, ARTERIOSCLER THROMB, V13, P211, DOI 10.1161/01.ATV.13.2.211; MORISHITA R, 1993, P NATL ACAD SCI USA, V90, P8474, DOI 10.1073/pnas.90.18.8474; Nishio H, 2001, HISTOCHEM J, V33, P167, DOI 10.1023/A:1017952310800; Noguchi K, 1999, J BIOL CHEM, V274, P32580, DOI 10.1074/jbc.274.46.32580; Pessah M, 2001, P NATL ACAD SCI USA, V98, P6198, DOI 10.1073/pnas.101579798; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; ROSS R, 1986, NEW ENGL J MED, V314, P488, DOI 10.1056/NEJM198602203140806; Santiago FS, 1999, NAT MED, V5, P1264, DOI 10.1038/15215; Santiago FS, 2001, J BIOL CHEM, V276, P41143, DOI 10.1074/jbc.M104913200; Santiago FS, 1999, AM J PATHOL, V155, P897, DOI 10.1016/S0002-9440(10)65189-9; Santoro SW, 1998, BIOCHEMISTRY-US, V37, P13330, DOI 10.1021/bi9812221; Santoro SW, 1997, P NATL ACAD SCI USA, V94, P4262, DOI 10.1073/pnas.94.9.4262; Shevde NK, 2000, P NATL ACAD SCI USA, V97, P7829, DOI 10.1073/pnas.130200197; Silverman ES, 1999, AM J PATHOL, V155, P1311, DOI 10.1016/S0002-9440(10)65233-9; SIMONS M, 1994, J CLIN INVEST, V93, P2351, DOI 10.1172/JCI117240; SIMONS M, 1992, NATURE, V359, P67, DOI 10.1038/359067a0; van Dam H, 2001, ONCOGENE, V20, P2453, DOI 10.1038/sj.onc.1204239; Wagner EF, 2001, ONCOGENE, V20, P2334, DOI 10.1038/sj.onc.1204416; Wakisaka S, 1998, ANN RHEUM DIS, V57, P487, DOI 10.1136/ard.57.8.487; Wang NP, 2001, ARTERIOSCL THROM VAS, V21, P1414, DOI 10.1161/hq0901.095549; Watson L, 2000, EUR J CLIN INVEST, V30, P11; ZUKER M, 1989, SCIENCE, V244, P48, DOI 10.1126/science.2468181	40	94	98	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 21	2002	277	25					22985	22991		10.1074/jbc.M200977200	http://dx.doi.org/10.1074/jbc.M200977200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	564KM	11891228	hybrid			2022-12-27	WOS:000176313600113
J	Liu, T; Krieger, M; Kan, HY; Zannis, VI				Liu, T; Krieger, M; Kan, HY; Zannis, VI			The effects of mutations in helices 4 and 6 of ApoA-I on scavenger receptor class B type I (SR-BI)-mediated cholesterol efflux suggest that formation of a productive complex between reconstituted high density lipoprotein and SR-BI is required for efficient lipid transport	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APOLIPOPROTEIN-A-I; TOCOPHEROL TRANSFER PROTEIN; ONE-STEP PURIFICATION; HDL RECEPTOR; SELECTIVE UPTAKE; TANGIER-DISEASE; PHOSPHOLIPID-COMPOSITION; RECOMBINANT PROTEINS; 6XHIS TAG; BINDING	We have studied the effects of mutations in apoA-I on reconstituted high density lipoprotein (HDL) particle (rHDL(apoA-I)) binding to and cholesterol efflux from wild-type (WT) and mutant forms of the HDL receptor SR-BI expressed by ldlA-7 cells. Mutations in helix 4 or helix 6 of the apoA-I reduced efflux by 79 and 51%, respectively, without substantially altering receptor binding (apparent K-d values of 1.1-4.4 mug of protein/ml). SR-BI with an M158R mutation bound poorly to rHDL with WT and helix 4 mutant apoA-I; the helix 6 mutant restored tight binding to SR-BI(M158R) (Kd values of 48, 60, and 7 mug of protein/ml, respectively). SR-BI(M158R)mediated cholesterol efflux rates, normalized for binding, were high for all three rHDLs (71-111% of control). In contrast, absolute (12-19%) and binding-corrected (24-47%) efflux rates for all three rHDLs mediated by SR-BI with Q402R/Q418R mutations were very low. We propose that formation of a productive complex between apoA-I in rHDL and SR-BI, in which the lipoprotein and the receptor must either be precisely aligned or have the capacity to undergo appropriate conformational changes, is required for efficient SR-BI-mediated cholesterol efflux. Some mutations in apoA-I and/or SR-BI can result in high affinity, but non-productive, binding that does not permit efficient cholesterol efflux.	Boston Univ, Sch Med, Dept Med & Biochem, Whitaker Cardiovasc Inst,Sect Mol Genet, Boston, MA 02118 USA; MIT, Dept Biol, Cambridge, MA 02139 USA	Boston University; Massachusetts Institute of Technology (MIT)	Zannis, VI (corresponding author), Boston Univ, Sch Med, Dept Med & Biochem, Whitaker Cardiovasc Inst,Sect Mol Genet, Boston, MA 02118 USA.	vzannis@bu.edu	Eckhardt, Erik/G-1567-2010; Krieger, Marco/AAE-8611-2020		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL048739, R01HL052212, P01HL066105] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL52212, HL48739, HL66105] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Acton S, 1996, SCIENCE, V271, P518, DOI 10.1126/science.271.5248.518; ACTON SL, 1994, J BIOL CHEM, V269, P21003; Anderson D., 1995, FOCUS, V17, P53; Arai T, 1999, P NATL ACAD SCI USA, V96, P12050, DOI 10.1073/pnas.96.21.12050; Arai T, 1999, J BIOL CHEM, V274, P2366, DOI 10.1074/jbc.274.4.2366; Bodzioch M, 1999, NAT GENET, V22, P347, DOI 10.1038/11914; Borhani DW, 1997, P NATL ACAD SCI USA, V94, P12291, DOI 10.1073/pnas.94.23.12291; BRENNER AJ, 1995, ANAL BIOCHEM, V226, P80, DOI 10.1006/abio.1995.1194; Brooks-Wilson A, 1999, NAT GENET, V22, P336, DOI 10.1038/11905; Calvo D, 1997, ARTERIOSCL THROM VAS, V17, P2341, DOI 10.1161/01.ATV.17.11.2341; CASTRO GR, 1988, BIOCHEMISTRY-US, V27, P25, DOI 10.1021/bi00401a005; Connelly MA, 1999, J BIOL CHEM, V274, P41, DOI 10.1074/jbc.274.1.41; Crowe J, 1995, MOL BIOTECHNOL, V4, P247, DOI 10.1007/BF02779018; Crowe J, 1996, Methods Mol Biol, V58, P491; de Beer MC, 2001, J BIOL CHEM, V276, P15832, DOI 10.1074/jbc.M100228200; de la Llera-Moya M, 1999, J LIPID RES, V40, P575; Fidge NH, 1999, J LIPID RES, V40, P187; FIELDING CJ, 1995, J LIPID RES, V36, P211; FIELDING CJ, 1972, BIOCHEM BIOPH RES CO, V46, P1493, DOI 10.1016/0006-291X(72)90776-0; FIELDING CJ, 1990, ADV CHOLESTEROL RES, P271; FORTE TM, 1993, J LIPID RES, V34, P317; FORTE TM, 1995, J LIPID RES, V36, P148; Goti D, 2001, J NEUROCHEM, V76, P498, DOI 10.1046/j.1471-4159.2001.00100.x; Greene DJ, 2001, J BIOL CHEM, V276, P4804, DOI 10.1074/jbc.M008725200; Gu XJ, 2000, J BIOL CHEM, V275, P9120, DOI 10.1074/jbc.275.13.9120; Gu XJ, 1998, J BIOL CHEM, V273, P35388, DOI 10.1074/jbc.273.41.26338; Gu XJ, 2000, J BIOL CHEM, V275, P29993, DOI 10.1074/jbc.275.39.29993; HARA H, 1991, J BIOL CHEM, V266, P3080; Ji Y, 1997, J BIOL CHEM, V272, P20982, DOI 10.1074/jbc.272.34.20982; Jishage K, 2001, J BIOL CHEM, V276, P1669, DOI 10.1074/jbc.C000676200; KARATHANASIS SK, 1985, BIOCH BIOL PLASMA PR, V2, P475; Kolleck I, 1999, FREE RADICAL BIO MED, V27, P882, DOI 10.1016/S0891-5849(99)00139-2; Kozarsky KF, 2000, ARTERIOSCL THROM VAS, V20, P721, DOI 10.1161/01.ATV.20.3.721; Krieger M, 2001, J CLIN INVEST, V108, P793, DOI 10.1172/JCI200114011; Krieger M, 1999, ANNU REV BIOCHEM, V68, P523, DOI 10.1146/annurev.biochem.68.1.523; Lawn RM, 1999, J CLIN INVEST, V104, pR25, DOI 10.1172/JCI8119; Liadaki KN, 2000, J BIOL CHEM, V275, P21262, DOI 10.1074/jbc.M002310200; LUCKOW VA, 1993, J VIROL, V67, P4566, DOI 10.1128/JVI.67.8.4566-4579.1993; Mardones P, 2002, J NUTR, V132, P443, DOI 10.1093/jn/132.3.443; MATZ CE, 1982, J BIOL CHEM, V257, P4535; NOLTE RT, 1992, BIOPHYS J, V63, P1221, DOI 10.1016/S0006-3495(92)81698-3; Phillips JC, 1997, BIOPHYS J, V73, P2337, DOI 10.1016/S0006-3495(97)78264-X; Pilon A, 2000, ARTERIOSCL THROM VAS, V20, P1074, DOI 10.1161/01.ATV.20.4.1074; Plump AS, 1996, J CLIN INVEST, V97, P2660, DOI 10.1172/JCI118716; Rigotti A, 1997, P NATL ACAD SCI USA, V94, P12610, DOI 10.1073/pnas.94.23.12610; Rinninger F, 1998, BBA-LIPID LIPID MET, V1393, P277, DOI 10.1016/S0005-2760(98)00082-4; Rust S, 1999, NAT GENET, V22, P352, DOI 10.1038/11921; SEGE RD, 1986, MOL CELL BIOL, V6, P3268, DOI 10.1128/MCB.6.9.3268; Segrest JP, 1999, J BIOL CHEM, V274, P31755, DOI 10.1074/jbc.274.45.31755; Segrest JP, 2000, CURR OPIN LIPIDOL, V11, P105, DOI 10.1097/00041433-200004000-00002; SorciThomas MG, 1996, J LIPID RES, V37, P673; SOUTAR AK, 1975, BIOCHEMISTRY-US, V14, P3057, DOI 10.1021/bi00685a003; Stangl H, 1999, J BIOL CHEM, V274, P32692, DOI 10.1074/jbc.274.46.32692; Terasawa Y, 2000, P NATL ACAD SCI USA, V97, P13830, DOI 10.1073/pnas.240462697; Thuahnai ST, 2001, J BIOL CHEM, V276, P43801, DOI 10.1074/jbc.M106695200; Trigatti B, 2000, CURR OPIN LIPIDOL, V11, P123, DOI 10.1097/00041433-200004000-00004; Trigatti B, 1999, P NATL ACAD SCI USA, V96, P9322, DOI 10.1073/pnas.96.16.9322; Ueda Y, 2000, J BIOL CHEM, V275, P20368, DOI 10.1074/jbc.M000730200; Urban S, 2000, J BIOL CHEM, V275, P33409, DOI 10.1074/jbc.M004031200; Williams DL, 2000, J BIOL CHEM, V275, P18897, DOI 10.1074/jbc.M002411200; Xu SZ, 1997, J LIPID RES, V38, P1289; Yancey PG, 2000, J BIOL CHEM, V275, P36596, DOI 10.1074/jbc.M006924200; ZANNIS VI, 1985, ADV HUM GENET, V14, P125; ZANNIS VI, 1993, ADV HUM GENET, V21, P145	64	83	88	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 14	2002	277	24					21576	21584		10.1074/jbc.M112103200	http://dx.doi.org/10.1074/jbc.M112103200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	563YR	11882653	hybrid			2022-12-27	WOS:000176286000061
J	Lee, G; Elwood, F; McNally, J; Weiszmann, J; Lindstrom, M; Amaral, K; Nakamura, M; Miao, S; Cao, P; Learned, RM; Chen, JL; Li, Y				Lee, G; Elwood, F; McNally, J; Weiszmann, J; Lindstrom, M; Amaral, K; Nakamura, M; Miao, S; Cao, P; Learned, RM; Chen, JL; Li, Y			T0070907, a selective ligand for peroxisome proliferator-activated receptor gamma, functions as an antagonist of biochemical and cellular activities	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINOID-X-RECEPTOR; INHIBITS ADIPOCYTE DIFFERENTIATION; NUCLEAR HORMONE RECEPTORS; PPAR-GAMMA; CRYSTAL-STRUCTURE; BINDING; ACID; COACTIVATORS; ALPHA; ADIPOGENESIS	The nuclear hormone receptor peroxisome proliferator-activated receptor gamma (PPARgamma (NR1C3)) plays a central role in adipogenesis and is the molecular target for the thiazolidinedione (TZD) class of antidiabetic drugs. In a search for novel non-TZD ligands for PPARgamma, T0070907 was identified as a potent and selective PPARgamma antagonist. With an apparent binding affinity (concentration at 50% inhibition of [H-3]rosiglitazone binding or IC50) of 1 nM, T0070907 covalently modifies PPARgamma on cysteine 313 in helix 3 of human PPARgamma2. T0070907 blocked PPARgamma function in both cell-based reporter gene and adipocyte differentiation assays. Consistent with its role as an antagonist of PPARgamma, T0070907 blocked agonist-induced recruitment of coactivator-derived peptides to PPARgamma in a homogeneous time-resolved fluorescence-based assay and promoted recruitment of the transcriptional corepressor NCoR to PPARgamma in both glutathione S-transferase pull-down assays and a PPARgamma/retinoid X receptor (RXR) alpha-dependent gel shift assay. Studies with mutant receptors suggest that T0070907 modulates the interaction of PPARgamma with these cofactor proteins by affecting the conformation of helix 12 of the PPARgamma ligand-binding domain. Interestingly, whereas the T0070907-induced NCoR recruitment to PPARgamma/RXRalpha heterodimer can be almost completely reversed by the simultaneous treatment with RXRalpha agonist LGD1069, T0070907 treatment has only modest effects on LGD1069-induced coactivator recruitment to the PPARgamma/RXRalpha heterodimer. These results suggest that the activity of PPARgamma antagonists can be modulated by the availability and concentration of RXR agonists. T0070907 is a novel tool for the study of PPARgamma/RXRalpha heterodimer function.	Tularik Inc, San Francisco, CA 94080 USA		Li, Y (corresponding author), Tularik Inc, 2 Corp Dr, San Francisco, CA 94080 USA.							Auwerx J, 1999, CELL, V97, P161; BOEHM MF, 1994, J MED CHEM, V37, P2930, DOI 10.1021/jm00044a014; Brown PJ, 1997, CHEM BIOL, V4, P909, DOI 10.1016/S1074-5521(97)90299-4; Camp HS, 2001, ENDOCRINOLOGY, V142, P3207, DOI 10.1210/en.142.7.3207; DiRenzo J, 1997, MOL CELL BIOL, V17, P2166, DOI 10.1128/MCB.17.4.2166; Egea PF, 2000, EMBO J, V19, P2592, DOI 10.1093/emboj/19.11.2592; Elbrecht A, 1999, J BIOL CHEM, V274, P7913, DOI 10.1074/jbc.274.12.7913; Fajas L, 1998, FEBS LETT, V438, P55, DOI 10.1016/S0014-5793(98)01273-3; Fajas L, 1997, J BIOL CHEM, V272, P18779, DOI 10.1074/jbc.272.30.18779; Gampe RT, 2000, MOL CELL, V5, P545, DOI 10.1016/S1097-2765(00)80448-7; Gurnell M, 2000, J BIOL CHEM, V275, P5754, DOI 10.1074/jbc.275.8.5754; Hu X, 1999, NATURE, V402, P93, DOI 10.1038/47069; Janowski BA, 1999, P NATL ACAD SCI USA, V96, P266, DOI 10.1073/pnas.96.1.266; KLIEWER SA, 1992, NATURE, V358, P771, DOI 10.1038/358771a0; Lowell BB, 1999, CELL, V99, P239, DOI 10.1016/S0092-8674(00)81654-2; Nagy L, 1999, GENE DEV, V13, P3209, DOI 10.1101/gad.13.24.3209; Nolte RT, 1998, NATURE, V395, P137, DOI 10.1038/25931; Oberfield JL, 1999, P NATL ACAD SCI USA, V96, P6102, DOI 10.1073/pnas.96.11.6102; Papac DI, 1996, ANAL CHEM, V68, P3215, DOI 10.1021/ac960324z; Perissi V, 1999, GENE DEV, V13, P3198, DOI 10.1101/gad.13.24.3198; Robyr D, 2000, MOL ENDOCRINOL, V14, P329, DOI 10.1210/me.14.3.329; Rocchi S, 2001, MOL CELL, V8, P737, DOI 10.1016/S1097-2765(01)00353-7; Rosen ED, 2001, J BIOL CHEM, V276, P37731, DOI 10.1074/jbc.R100034200; Rosenfeld MG, 2001, J BIOL CHEM, V276, P36865, DOI 10.1074/jbc.R100041200; RUBIN CS, 1978, J BIOL CHEM, V253, P7570; Wang YP, 2000, MOL ENDOCRINOL, V14, P1550, DOI 10.1210/me.14.10.1550; Willson TM, 2001, ANNU REV BIOCHEM, V70, P341, DOI 10.1146/annurev.biochem.70.1.341; Willson TM, 2000, J MED CHEM, V43, P527, DOI 10.1021/jm990554g; Wilm M, 1996, ANAL CHEM, V68, P527, DOI 10.1021/ac950875+; Wright HM, 2000, J BIOL CHEM, V275, P1873, DOI 10.1074/jbc.275.3.1873; Yang W, 2000, MOL CELL BIOL, V20, P8008, DOI 10.1128/MCB.20.21.8008-8017.2000; Zamir I, 1997, GENE DEV, V11, P835, DOI 10.1101/gad.11.7.835; Zhang JS, 1999, MOL CELL BIOL, V19, P6448; Zhou GC, 1998, MOL ENDOCRINOL, V12, P1594, DOI 10.1210/me.12.10.1594	34	247	255	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 31	2002	277	22					19649	19657		10.1074/jbc.M200743200	http://dx.doi.org/10.1074/jbc.M200743200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	557EH	11877444	hybrid			2022-12-27	WOS:000175894800055
J	Legendre-Guillemin, V; Metzler, M; Charbonneau, M; Gan, L; Chopra, V; Philie, J; Hayden, MR; McPherson, PS				Legendre-Guillemin, V; Metzler, M; Charbonneau, M; Gan, L; Chopra, V; Philie, J; Hayden, MR; McPherson, PS			HIP1 and HIP12 display differential binding to F-actin, AP2, and clathrin - Identification of a novel interaction with clathrin light chain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COATED VESICLES; TERMINAL DOMAIN; PROTEIN HIP1R; HUNTINGTIN; ENDOCYTOSIS; FAMILY; AP-2; LOCALIZATION; CYTOSKELETON; APPENDAGE	Huntingtin-interacting protein 1 (HIP1) and HIP12 are orthologues of Sla2p, a yeast protein with essential functions in endocytosis and regulation of the actin cytoskeleton. We now report that HIP1 and HIP12 are major components of the clathrin coat that interact but differ in their ability to bind clathrin and the clathrin adaptor AP2. HIP1 contains a clathrin-box and AP2 consensus-binding sites that display high affinity binding to the terminal domain of the clathrin heavy chain and the ear domain of the AP2 alpha subunit, respectively. These consensus sites are poorly conserved in HIP12 and correspondingly, HIP12 does not bind to AP2 nor does it demonstrate high affinity clathrin binding. Moreover, HIP12 co-sediments with F-actin in contrast to HIP1, which exhibits no interaction with actin in vitro. Despite these differences, both proteins efficiently stimulate clathrin assembly through their central helical domain. Interestingly, in both HIP1 and HIP12, this domain binds directly to the clathrin light chain. Our data suggest that HIP1 and HIP12 play related yet distinct functional roles in clathrin-mediated endocytosis.	McGill Univ, Montreal Neurol Inst, Dept Neurol & Neurosurg, Montreal, PQ H3A 2B4, Canada; Univ British Columbia, Dept Med Genet, Ctr Mol Med & Therapeut, Vancouver, BC V5Z 4H4, Canada	McGill University; University of British Columbia	McPherson, PS (corresponding author), McGill Univ, Montreal Neurol Inst, Dept Neurol & Neurosurg, 3801 Rue Univ, Montreal, PQ H3A 2B4, Canada.	peter.mcpherson@mcgil.ca	Hayden, Michael R/D-8581-2011	Hayden, Michael R/0000-0001-5159-1419				AHLE S, 1988, EMBO J, V7, P919, DOI 10.1002/j.1460-2075.1988.tb02897.x; Bennett EM, 2001, TRAFFIC, V2, P851, DOI 10.1034/j.1600-0854.2001.21114.x; Chopra VS, 2000, MAMM GENOME, V11, P1006, DOI 10.1007/s003350010195; De Camilli P, 2002, FEBS LETT, V513, P11, DOI 10.1016/S0014-5793(01)03306-3; DIFIGLIA M, 1995, NEURON, V14, P1075, DOI 10.1016/0896-6273(95)90346-1; Drake MT, 2000, J BIOL CHEM, V275, P6479, DOI 10.1074/jbc.275.9.6479; Drake MT, 2001, J BIOL CHEM, V276, P28700, DOI 10.1074/jbc.M104226200; Engqvist-Goldstein AEY, 2001, J CELL BIOL, V154, P1209, DOI 10.1083/jcb.200106089; Engqvist-Goldstein AEY, 1999, J CELL BIOL, V147, P1503, DOI 10.1083/jcb.147.7.1503; Faber PW, 1998, HUM MOL GENET, V7, P1463, DOI 10.1093/hmg/7.9.1463; Ford MGJ, 2001, SCIENCE, V291, P1051, DOI 10.1126/science.291.5506.1051; Gaidarov I, 1999, NAT CELL BIOL, V1, P1, DOI 10.1038/8971; HOLTZMAN DA, 1993, J CELL BIOL, V122, P635, DOI 10.1083/jcb.122.3.635; Itoh T, 2001, SCIENCE, V291, P1047, DOI 10.1126/science.291.5506.1047; Kalchman MA, 1997, NAT GENET, V16, P44, DOI 10.1038/ng0597-44; Kay BK, 1999, PROTEIN SCI, V8, P435; KEEN JH, 1979, CELL, V16, P303, DOI 10.1016/0092-8674(79)90007-2; Kegel KB, 2000, J NEUROSCI, V20, P7268, DOI 10.1523/jneurosci.20-19-07268.2000; Kelly MA, 2001, MOL BIOL CELL, V12, p156A; Laporte SA, 1999, P NATL ACAD SCI USA, V96, P3712, DOI 10.1073/pnas.96.7.3712; Marsh M, 1999, SCIENCE, V285, P215, DOI 10.1126/science.285.5425.215; MAYCOX PR, 1992, J CELL BIOL, V118, P1379, DOI 10.1083/jcb.118.6.1379; McPherson PS, 1999, CELL SIGNAL, V11, P229, DOI 10.1016/S0898-6568(98)00059-X; Metzler M, 2001, J BIOL CHEM, V276, P39271, DOI 10.1074/jbc.C100401200; Micheva KD, 2001, J CELL BIOL, V154, P355, DOI 10.1083/jcb.200102098; Mishra SK, 2001, J BIOL CHEM, V276, P46230, DOI 10.1074/jbc.M108177200; Morgan JR, 1999, J NEUROSCI, V19, P10201; Owen DJ, 1999, CELL, V97, P805, DOI 10.1016/S0092-8674(00)80791-6; Qualmann B, 2000, J CELL BIOL, V150, pF111, DOI 10.1083/jcb.150.5.F111; Ramjaun AR, 1997, J BIOL CHEM, V272, P16700, DOI 10.1074/jbc.272.26.16700; Ramjaun AR, 1998, J NEUROCHEM, V70, P2369; RATHS S, 1993, J CELL BIOL, V120, P55, DOI 10.1083/jcb.120.1.55; Schmid SL, 1997, ANNU REV BIOCHEM, V66, P511, DOI 10.1146/annurev.biochem.66.1.511; Seki N, 1998, J HUM GENET, V43, P268, DOI 10.1007/s100380050087; Sittler A, 1998, MOL CELL, V2, P427, DOI 10.1016/S1097-2765(00)80142-2; Slepnev VI, 2000, J BIOL CHEM, V275, P17583, DOI 10.1074/jbc.M910430199; Slepnev VI, 2000, NAT REV NEUROSCI, V1, P161, DOI 10.1038/35044540; Teo M, 2001, J BIOL CHEM, V276, P18392, DOI 10.1074/jbc.M008795200; Traub LM, 1999, P NATL ACAD SCI USA, V96, P8907, DOI 10.1073/pnas.96.16.8907; Tukamoto T, 1997, MOL BRAIN RES, V51, P8, DOI 10.1016/S0169-328X(97)00205-2; Velier J, 1998, EXP NEUROL, V152, P34, DOI 10.1006/exnr.1998.6832; Waelter S, 2001, HUM MOL GENET, V10, P1807, DOI 10.1093/hmg/10.17.1807; Wanker EE, 1997, HUM MOL GENET, V6, P487, DOI 10.1093/hmg/6.3.487; Wesp A, 1997, MOL BIOL CELL, V8, P2291, DOI 10.1091/mbc.8.11.2291; Wilde A, 1999, CELL, V96, P677, DOI 10.1016/S0092-8674(00)80578-4; Yang S, 1999, MOL BIOL CELL, V10, P2265, DOI 10.1091/mbc.10.7.2265; Yang WN, 2001, J BIOL CHEM, V276, P17468, DOI 10.1074/jbc.M010893200; Ybe JA, 1998, EMBO J, V17, P1297, DOI 10.1093/emboj/17.5.1297	48	81	84	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 31	2002	277	22					19897	19904		10.1074/jbc.M112310200	http://dx.doi.org/10.1074/jbc.M112310200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	557EH	11889126	Green Accepted, hybrid			2022-12-27	WOS:000175894800087
J	Asadi, A; Jorgensen, J; Jacobsson, A				Asadi, A; Jorgensen, J; Jacobsson, A			Elovl1 and p55Cdc genes are localized in a tail-to-tail array and are co-expressed in proliferating cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANAPHASE-PROMOTING COMPLEX; DOUBLE-STRANDED-RNA; CHAIN FATTY-ACIDS; SACCHAROMYCES-CEREVISIAE; CYCLE GENE; PROTEIN; EXPRESSION; BIOSYNTHESIS; FAMILY; ELONGATION	Elovl1 is a ubiquitously expressed gene, the product of which belongs to a highly conserved family of microsomal enzymes, which are involved in the formation of very long chain fatty acids and sphingolipids in yeast to man. To elucidate the structure and regulation of the Elovl gene we have isolated a lambda phage genomic DNA clone containing the entire mouse gene and found that Elovl1 consists of eight exons that are dispersed over 5.4 kb of genomic sequence. Interestingly, sequencing of the lambda clone to completion revealed that the insert contained a segment of the cell cycle gene p55Cdc directed in the opposite orientation. The genes are very tightly linked so that the 3'-end of the long mRNA species are complementary over a short, stretch of nucleotides. Although both Elovl1 and p55Cdc are highly conserved genes, a BLAST search implies that the tail-to-tail arrangement has evolved in vertebrates. Despite the non-similar expression pattern in different tissues, mRNA analysis of the two genes disclosed simultaneous transcription during a proliferation-differentiation transition state, which suggests that the two genes may be regulated through a common bi-directional transcription mechanism under specific conditions.	Stockholm Univ, Arrhenius Labs F3, Wenner Gren Inst, SE-10691 Stockholm, Sweden	Stockholm University	Jacobsson, A (corresponding author), Stockholm Univ, Arrhenius Labs F3, Wenner Gren Inst, SE-10691 Stockholm, Sweden.	anders.jacobsson@wgi.su.se						ANTONSON P, 1995, EUR J BIOCHEM, V232, P397, DOI 10.1111/j.1432-1033.1995.tb20824.x; Bass BL, 2000, CELL, V101, P235, DOI 10.1016/S0092-8674(02)71133-1; Batshake B, 1996, BIOCHEM BIOPH RES CO, V227, P70, DOI 10.1006/bbrc.1996.1469; Beaudoin F, 2000, P NATL ACAD SCI USA, V97, P6421, DOI 10.1073/pnas.110140197; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; Campbell HD, 1997, GENOMICS, V42, P46, DOI 10.1006/geno.1997.4709; CINTI DL, 1992, PROG LIPID RES, V31, P1, DOI 10.1016/0163-7827(92)90014-A; DAWSON IA, 1995, J CELL BIOL, V129, P725, DOI 10.1083/jcb.129.3.725; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; Domeier ME, 2000, SCIENCE, V289, P1928, DOI 10.1126/science.289.5486.1928; Fang GW, 1998, GENE DEV, V12, P1871, DOI 10.1101/gad.12.12.1871; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; HANADA K, 1992, J BIOL CHEM, V267, P23527; Kramer ER, 1998, CURR BIOL, V8, P1207, DOI 10.1016/S0960-9822(07)00510-6; LAIRD PW, 1991, NUCLEIC ACIDS RES, V19, P4293, DOI 10.1093/nar/19.15.4293; Leonard AE, 2000, BIOCHEM J, V350, P765, DOI 10.1042/0264-6021:3500765; LERNER A, 1993, J IMMUNOL, V151, P3152; Millar AA, 1999, PLANT CELL, V11, P825, DOI 10.1105/tpc.11.5.825; Millar AA, 1997, PLANT J, V12, P121, DOI 10.1046/j.1365-313X.1997.12010121.x; Oh CS, 1997, J BIOL CHEM, V272, P17376, DOI 10.1074/jbc.272.28.17376; POULOS A, 1994, ANN NEUROL, V36, P741, DOI 10.1002/ana.410360509; REVARDEL E, 1995, BBA-GENE STRUCT EXPR, V1263, P261, DOI 10.1016/0167-4781(95)00124-Y; ROSS SR, 1992, P NATL ACAD SCI USA, V89, P7561, DOI 10.1073/pnas.89.16.7561; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SETHI N, 1991, MOL CELL BIOL, V11, P5592, DOI 10.1128/MCB.11.11.5592; SHAPIRO MB, 1987, NUCLEIC ACIDS RES, V15, P7155, DOI 10.1093/nar/15.17.7155; Stewart ME, 1999, J LIPID RES, V40, P1434; Tvrdik P, 2000, J CELL BIOL, V149, P707, DOI 10.1083/jcb.149.3.707; Tvrdik P, 1999, J BIOL CHEM, V274, P26387, DOI 10.1074/jbc.274.37.26387; Tvrdik P, 1997, J BIOL CHEM, V272, P31738, DOI 10.1074/jbc.272.50.31738; Weinstein J, 1997, J BIOL CHEM, V272, P28501, DOI 10.1074/jbc.272.45.28501; WEINSTEIN J, 1994, MOL CELL BIOL, V14, P3350, DOI 10.1128/MCB.14.5.3350; Weinstein J, 1998, MOL GENET METAB, V64, P52, DOI 10.1006/mgme.1998.2698; WELLS GB, 1983, J BIOL CHEM, V258, P200; Zhang K, 2001, NAT GENET, V27, P89, DOI 10.1038/83817	35	7	8	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 24	2002	277	21					18494	18500		10.1074/jbc.M111503200	http://dx.doi.org/10.1074/jbc.M111503200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	558PM	11891222	hybrid			2022-12-27	WOS:000175975800033
J	Gao, ZG; Chen, A; Barak, D; Kim, SK; Muller, CE; Jacobson, KA				Gao, ZG; Chen, A; Barak, D; Kim, SK; Muller, CE; Jacobson, KA			Identification by site-directed mutagenesis of residues involved in ligand recognition and activation of the human A(3) adenosine receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING-SITE; TRANSMEMBRANE DOMAIN; MOLECULAR-CLONING; PHOSPHOLIPASE-C; RHODOPSIN; EXPRESSION; STIMULATION; INHIBITION; HYDROLYSIS; MECHANISMS	Ligand recognition has been extensively explored in G protein-coupled A(1), A(2A), and A(2B) adenosine receptors but not in the As receptor, which is cerebroprotective and cardioprotective. We mutated several residues of the human A(3) adenosine receptor within transmembrane domains 3 and 6 and the second extracellular loop, which have been predicted by previous molecular modeling to be involved in the ligand recognition, including His(95), Trp(243), Leu(244), Ser(247), Asn(250), and Lys(152). The N250A mutant receptor lost the ability to bind both radiolabeled agonist and antagonist. The H95A mutation significantly reduced affinity of both agonists and antagonists. In contrast, the K152A (EL2), W243A (6.48), and W243F (6.48) mutations did not significantly affect the agonist binding but decreased antagonist affinity by similar to3-38-fold, suggesting that these residues were critical for the high affinity of A(3) adenosine receptor antagonists. Activation of phospholipase C by wild type (WT) and mutant receptors was measured. The As agonist 2-chloro-N-6-(3-iodobenzyl)-5'-N-methylcarbamoyladenosine stimulated phosphoinositide turnover in the WT but failed to evoke a response in cells expressing W243A and W243F mutant receptors, in which agonist binding was less sensitive to guanosine 5'-gamma-thiotriphosphate than in WT. Thus, although not important for agonist binding, Trp(243) was critical for receptor activation. The results were interpreted using a rhodopsin-based model of ligand-A(3) receptor interactions.	NIDDK, Mol Recognit Sect, Bioorgan Chem Lab, NIH, Bethesda, MD 20892 USA; Univ Bonn, Inst Pharmaceut, D-53115 Bonn, Germany	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); University of Bonn	Jacobson, KA (corresponding author), NIDDK, Mol Recognit Sect, Bioorgan Chem Lab, NIH, Bldg 8A,Rm B1A-19, Bethesda, MD 20892 USA.	kajacobs@helix.nih.gov	Jacobson, Kenneth Alan/A-1530-2009; Müller, Christa Elisabeth/C-7748-2014	Jacobson, Kenneth Alan/0000-0001-8104-1493; Müller, Christa Elisabeth/0000-0002-0013-6624	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK031115, Z01DK031117] Funding Source: NIH RePORTER; Intramural NIH HHS [Z01 DK031117-20] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Abbracchio MP, 1995, MOL PHARMACOL, V48, P1038; Barbhaiya H, 1996, MOL PHARMACOL, V50, P1635; Befort K, 1996, J BIOL CHEM, V271, P10161, DOI 10.1074/jbc.271.17.10161; BERRIDGE MJ, 1983, BIOCHEM J, V212, P473, DOI 10.1042/bj2120473; Beukers MW, 2000, MOL PHARMACOL, V58, P1349, DOI 10.1124/mol.58.6.1349; BLUML K, 1994, J BIOL CHEM, V269, P18870; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chen A, 2001, BIOCHEM BIOPH RES CO, V284, P596, DOI 10.1006/bbrc.2001.5027; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; CULLEN BR, 1987, METHOD ENZYMOL, V152, P684; Dunham TD, 1999, J BIOL CHEM, V274, P1683, DOI 10.1074/jbc.274.3.1683; Fredholm BB, 2000, N-S ARCH PHARMACOL, V362, P364, DOI 10.1007/s002100000313; Gao ZG, 2000, BIOCHEM PHARMACOL, V60, P661, DOI 10.1016/S0006-2952(00)00357-9; Gether U, 2000, ENDOCR REV, V21, P90, DOI 10.1210/er.21.1.90; HARDEN TK, 1988, BIOCHEM J, V252, P583, DOI 10.1042/bj2520583; HIBERT MF, 1993, TRENDS PHARMACOL SCI, V14, P7, DOI 10.1016/0165-6147(93)90106-T; Jacobson KA, 1997, NEUROPHARMACOLOGY, V36, P1157, DOI 10.1016/S0028-3908(97)00104-4; Jacobson KA, 2001, J MED CHEM, V44, P4125, DOI 10.1021/jm010232o; JAVITCH JA, 1995, NEURON, V14, P825, DOI 10.1016/0896-6273(95)90226-0; Jiang QL, 1996, MOL PHARMACOL, V50, P512; Kaiser SM, 1999, DRUG DISCOV TODAY, V4, P542, DOI 10.1016/S1359-6446(99)01421-X; KIM JH, 1995, J BIOL CHEM, V270, P13987, DOI 10.1074/jbc.270.23.13987; Lee K, 2001, BIOORG MED CHEM LETT, V11, P1333, DOI 10.1016/S0960-894X(01)00213-X; Liang BT, 1998, P NATL ACAD SCI USA, V95, P6995, DOI 10.1073/pnas.95.12.6995; Linden J, 2001, ANNU REV PHARMACOL, V41, P775, DOI 10.1146/annurev.pharmtox.41.1.775; Marie J, 2001, J BIOL CHEM, V276, P41100, DOI 10.1074/jbc.M104875200; Mouledous L, 2000, MOL PHARMACOL, V57, P495, DOI 10.1124/mol.57.3.495; Muller CE, 2002, BIOORG MED CHEM LETT, V12, P501, DOI 10.1016/S0960-894X(01)00785-5; NAKAYAMA TA, 1990, J BIOL CHEM, V265, P15762; OLAH ME, 1992, J BIOL CHEM, V267, P10764; Olah ME, 2000, PHARMACOL THERAPEUT, V85, P55, DOI 10.1016/S0163-7258(99)00051-0; OLAH ME, 1995, ANNU REV PHARMACOL, V35, P581, DOI 10.1146/annurev.pa.35.040195.003053; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; PARDO L, 1992, P NATL ACAD SCI USA, V89, P4009, DOI 10.1073/pnas.89.9.4009; PERLMAN JH, 1995, MOL PHARMACOL, V47, P480; PERLMAN JH, 1994, J BIOL CHEM, V269, P23383; RAMKUMAR V, 1993, J BIOL CHEM, V268, P16887; Rivkees SA, 1999, J BIOL CHEM, V274, P3617, DOI 10.1074/jbc.274.6.3617; Sajjadi FG, 1996, J IMMUNOL, V156, P3435; SALVATORE CA, 1993, P NATL ACAD SCI USA, V90, P10365, DOI 10.1073/pnas.90.21.10365; Salvatore CA, 2000, J BIOL CHEM, V275, P4429, DOI 10.1074/jbc.275.6.4429; TUCKER AL, 1994, J BIOL CHEM, V269, P27900; Unger VM, 1997, NATURE, V389, P203, DOI 10.1038/38316; vanRhee AM, 1996, DRUG DEVELOP RES, V37, P1, DOI 10.1002/(SICI)1098-2299(199601)37:1<1::AID-DDR1>3.0.CO;2-S; von Lubitz DKJE, 1999, ANN NY ACAD SCI, V890, P93; VONLUBITZ DKJE, 1994, EUR J PHARMACOL, V263, P59, DOI 10.1016/0014-2999(94)90523-1; YAMANO Y, 1995, J BIOL CHEM, V270, P14024, DOI 10.1074/jbc.270.23.14024; ZHOU QY, 1992, P NATL ACAD SCI USA, V89, P7432, DOI 10.1073/pnas.89.16.7432; ZOFFMANN S, 1993, FEBS LETT, V336, P506, DOI 10.1016/0014-5793(93)80865-R	49	140	142	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 24	2002	277	21					19056	19063		10.1074/jbc.M110960200	http://dx.doi.org/10.1074/jbc.M110960200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	558PM	11891221	Green Accepted, hybrid			2022-12-27	WOS:000175975800106
J	Liu, CY; Wong, HN; Schauerte, JA; Kaufman, RJ				Liu, CY; Wong, HN; Schauerte, JA; Kaufman, RJ			The protein kinase/endoribonuclease IRE1 alpha that signals the unfolded protein response has a luminal N-terminal ligand-independent dimerization domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM STRESS; GLUCOSE-REGULATED PROTEINS; ER STRESS; TRANSLATIONAL CONTROL; TRANSMEMBRANE PROTEIN; MAMMALIAN-CELLS; IRE1; PERK; SECRETION; IDENTIFICATION	In response to accumulation of unfolded proteins in the endoplasmic reticulum (ER), cells activate an intracellular signal transduction pathway called the unfolded protein response (UPR). IRE and PERK are the two type-I ER transmembrane protein kinase receptors that signal the UPR. The N-terminal luminal domains (NLDs) of IRE1 and PERK sense ER stress conditions by a common mechanism and transmit the signal to regulate the cytoplasmic domains of these receptors. To provide an experimental system amenable to detailed biochemical and structural analysis to elucidate the mechanism of ER-transmembrane signaling mechanism mediated by the NLD, we overexpressed the soluble luminal domain of human IRE1a in COS-1 cells by transient DNA transfection. Here we report the expression, purification, and characterization of the soluble NLD. The biological function of the NLD was confirmed by its ability to associate with itself and to interact with both the membrane-bound full-length IRE1alpha receptor and the ER chaperone BiP. Functional and spectral studies suggested that the highly conserved N-linked glycosylation site is not required for proper protein folding and self-association. Interestingly, we demonstrated that the NLD forms stable dimers linked by intermolecular disulfide bridges. Our data support that the luminal domain represents a novel ligand-independent dimerization domain.	Univ Michigan, Med Ctr, Sch Med, Howard Hughes Med Inst, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Dept Biol Chem, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Div Biophys Res, Ann Arbor, MI 48109 USA	Howard Hughes Medical Institute; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Kaufman, RJ (corresponding author), Univ Michigan, Med Ctr, Sch Med, Howard Hughes Med Inst, 4570 MSRB 2,1150 W Med Ctr Dr, Ann Arbor, MI 48109 USA.		Longo, Kenneth A/A-5631-2010; Liu, Andrew C/B-3548-2009	Liu, Andrew C/0000-0003-1927-0900				Bertolotti A, 2000, NAT CELL BIOL, V2, P326, DOI 10.1038/35014014; Brewer JW, 2000, P NATL ACAD SCI USA, V97, P12625, DOI 10.1073/pnas.220247197; Brewer JW, 1999, P NATL ACAD SCI USA, V96, P8505, DOI 10.1073/pnas.96.15.8505; Butler SA, 1999, J MOL ENDOCRINOL, V22, P185, DOI 10.1677/jme.0.0220185; Chapman R, 1998, ANNU REV CELL DEV BI, V14, P459, DOI 10.1146/annurev.cellbio.14.1.459; DORNER AJ, 1990, METHOD ENZYMOL, V185, P577; DORNER AJ, 1989, J BIOL CHEM, V264, P20602; Harding HP, 2001, MOL CELL, V7, P1153, DOI 10.1016/S1097-2765(01)00264-7; Harding HP, 1999, NATURE, V397, P271, DOI 10.1038/16729; Harding HP, 2000, MOL CELL, V5, P897, DOI 10.1016/S1097-2765(00)80330-5; Haze K, 1999, MOL BIOL CELL, V10, P3787, DOI 10.1091/mbc.10.11.3787; HILLENKAMP F, 1991, ANAL CHEM, V63, pA1193; Kaufman RJ, 1999, GENE DEV, V13, P1211, DOI 10.1101/gad.13.10.1211; LEMMON MA, 1994, TRENDS BIOCHEM SCI, V19, P459, DOI 10.1016/0968-0004(94)90130-9; Liu CY, 2000, J BIOL CHEM, V275, P24881, DOI 10.1074/jbc.M004454200; Mori K, 2000, CELL, V101, P451, DOI 10.1016/S0092-8674(00)80855-7; Morris JA, 1997, J BIOL CHEM, V272, P4327, DOI 10.1074/jbc.272.7.4327; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; Nakagawa T, 2000, NATURE, V403, P98, DOI 10.1038/47513; Niwa M, 1999, CELL, V99, P691, DOI 10.1016/S0092-8674(00)81667-0; Okamura K, 2000, BIOCHEM BIOPH RES CO, V279, P445, DOI 10.1006/bbrc.2000.3987; Scheuner D, 2001, MOL CELL, V7, P1165, DOI 10.1016/S1097-2765(01)00265-9; Shi YG, 1998, MOL CELL BIOL, V18, P7499, DOI 10.1128/MCB.18.12.7499; Tirasophon W, 2000, GENE DEV, V14, P2725, DOI 10.1101/gad.839400; Tirasophon W, 1998, GENE DEV, V12, P1812, DOI 10.1101/gad.12.12.1812; Urano F, 2000, SCIENCE, V287, P664, DOI 10.1126/science.287.5453.664; Wang XZ, 1998, EMBO J, V17, P5708, DOI 10.1093/emboj/17.19.5708; Ye J, 2000, MOL CELL, V6, P1355, DOI 10.1016/S1097-2765(00)00133-7; Yoneda T, 2001, J BIOL CHEM, V276, P13935, DOI 10.1074/jbc.M010677200; Yoshida H, 1998, J BIOL CHEM, V273, P33741, DOI 10.1074/jbc.273.50.33741	30	86	91	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 24	2002	277	21					18346	18356		10.1074/jbc.M112454200	http://dx.doi.org/10.1074/jbc.M112454200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	558PM	11897784	hybrid			2022-12-27	WOS:000175975800014
J	Matsuzaki, T; Hanai, S; Kishi, H; Liu, ZH; Bao, YL; Kikuchi, A; Tsuchida, K; Sugino, F				Matsuzaki, T; Hanai, S; Kishi, H; Liu, ZH; Bao, YL; Kikuchi, A; Tsuchida, K; Sugino, F			Regulation of endocytosis of activin type II receptors by a novel PDZ protein through Ral/Ral-binding protein 1-dependent pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-BETA; PUTATIVE EFFECTOR PROTEIN; FSH-RELEASING PROTEIN; EH-DOMAIN; IDENTIFICATION; ACTIVATION; FAMILY; GRADIENT; SIGNAL; RAS	Using yeast two-hybrid screening, we have identified a mouse Postsynaptic density 95/Discs large/Zona occludens-1 (PDZ) protein that interacts with activin. type II receptors (ActRIIs). We named the protein activin receptor-interacting protein 2 (ARIP2). ARIP2 was found to have one PDZ domain in the NH2-terminal region and interact specifically with ActRIIs among the receptors for the transforming growth factor beta family by the PDZ domain. Interestingly, overexpression of ARIP2 enhances endocytosis of ActRIIs and reduces activin-induced transcription in Chinese hamster ovary K1 cells. In addition, immunofluorescence co-localization studies indicated the direct involvement of ARIP2 in the intracellular translocation of ActRIIs by PDZ domain-mediated interaction. Moreover, we have identified that the COOH-terminal region of ARIP2 interacts with Ral-binding protein 1 (RaIBP1). RaIBP1 is a potential effector protein of small GTP-binding protein Ral and regulates endocytosis of epidermal growth factor and insulin receptors. The studies using deletion mutants of RaIBP1 and constitutively GTP and GDP binding forms of Ral indicate that ARIP2 regulates endocytosis of ActRIIs through the Ral/RaIBP1-dependent pathway, and the GDP-GTP exchange of Ral is critical for this regulation.	Univ Tokushima, Inst Enzyme Res, Tokushima 7708503, Japan; Hiroshima Univ, Fac Med, Dept Biochem, Minami Ku, Hiroshima 7348551, Japan	Tokushima University; Hiroshima University	Tsuchida, K (corresponding author), Univ Tokushima, Inst Enzyme Res, 3-18-15 Kuramoto, Tokushima 7708503, Japan.	tsuchida@ier.tokushima-u.ac.jp	Tsuchida, Kunihiro/A-4501-2012	Tsuchida, Kunihiro/0000-0002-3983-5756				Anders RA, 1997, MOL BIOL CELL, V8, P2133, DOI 10.1091/mbc.8.11.2133; ASASHIMA M, 1990, ROUX ARCH DEV BIOL, V198, P330, DOI 10.1007/BF00383771; Attisano L, 1996, MOL CELL BIOL, V16, P1066; ATTISANO L, 1992, CELL, V68, P97, DOI 10.1016/0092-8674(92)90209-U; CANTOR SB, 1995, MOL CELL BIOL, V15, P4578; Cao TT, 1999, NATURE, V401, P286, DOI 10.1038/45816; Chen H, 1998, NATURE, V394, P793, DOI 10.1038/29555; Chen Y, 2001, NATURE, V411, P607, DOI 10.1038/35079121; Dore JJE, 1998, J BIOL CHEM, V273, P31770, DOI 10.1074/jbc.273.48.31770; Dubois L, 2001, CELL, V105, P613, DOI 10.1016/S0092-8674(01)00375-0; Dyson S, 1998, CELL, V93, P557, DOI 10.1016/S0092-8674(00)81185-X; Ehrlich M, 2001, J CELL SCI, V114, P1777; Entchev EV, 2000, CELL, V103, P981, DOI 10.1016/S0092-8674(00)00200-2; Ethier JF, 1997, ENDOCRINOLOGY, V138, P2425, DOI 10.1210/en.138.6.2425; Feig LA, 1996, TRENDS BIOCHEM SCI, V21, P438, DOI 10.1016/S0968-0004(96)10058-X; Fialka I, 1999, J BIOL CHEM, V274, P26233, DOI 10.1074/jbc.274.37.26233; Gotthardt M, 2000, J BIOL CHEM, V275, P25616, DOI 10.1074/jbc.M000955200; GREEN JBA, 1990, NATURE, V347, P391, DOI 10.1038/347391a0; GURDON JB, 1994, NATURE, V371, P487, DOI 10.1038/371487a0; HAGE W, 1997, J CELL BIOL, V136, P811; HEMMATIBRIVANLOU A, 1992, DEV DYNAM, V194, P1, DOI 10.1002/aja.1001940102; HENIS YI, 1994, J CELL BIOL, V126, P139, DOI 10.1083/jcb.126.1.139; Hofer F, 1998, CURR BIOL, V8, P839, DOI 10.1016/S0960-9822(98)70327-6; Hu LYA, 2000, J BIOL CHEM, V275, P38659, DOI 10.1074/jbc.M005938200; Ikeda M, 1998, J BIOL CHEM, V273, P814, DOI 10.1074/jbc.273.2.814; Itoh S, 2000, EUR J BIOCHEM, V267, P6954, DOI 10.1046/j.1432-1327.2000.01828.x; Iwahori Y, 1997, BRAIN RES, V760, P52, DOI 10.1016/S0006-8993(97)00275-8; Jonk LJC, 1998, J BIOL CHEM, V273, P21145, DOI 10.1074/jbc.273.33.21145; Kishida S, 1997, ONCOGENE, V15, P2899, DOI 10.1038/sj.onc.1201473; Lamaze C, 1996, NATURE, V382, P177, DOI 10.1038/382177a0; LING N, 1986, NATURE, V321, P779, DOI 10.1038/321779a0; MATHEWS LS, 1994, ENDOCR REV, V15, P310, DOI 10.1210/er.15.3.310; MATHEWS LS, 1993, J BIOL CHEM, V268, P19013; MATHEWS LS, 1991, CELL, V65, P973, DOI 10.1016/0092-8674(91)90549-E; Matsubara K, 1997, FEBS LETT, V410, P169, DOI 10.1016/S0014-5793(97)00633-9; McDowell N, 1997, CURR BIOL, V7, P671, DOI 10.1016/S0960-9822(06)00294-6; MOGAMI H, 1995, ENDOCRINOLOGY, V136, P2960, DOI 10.1210/en.136.7.2960; Morinaka K, 1999, ONCOGENE, V18, P5915, DOI 10.1038/sj.onc.1202974; Nakashima S, 1999, EMBO J, V18, P3629, DOI 10.1093/emboj/18.13.3629; OGAWA Y, 1992, J BIOL CHEM, V267, P14233; Okazaki M, 1997, ONCOGENE, V14, P515, DOI 10.1038/sj.onc.1200860; Parks WT, 2001, J BIOL CHEM, V276, P19332, DOI 10.1074/jbc.M100606200; Ridley AJ, 1996, CURR BIOL, V6, P1256, DOI 10.1016/S0960-9822(02)70711-2; SHIBATA H, 1993, FEBS LETT, V329, P194, DOI 10.1016/0014-5793(93)80220-O; Shoji H, 1998, BIOCHEM BIOPH RES CO, V246, P320, DOI 10.1006/bbrc.1998.8613; Shoji H, 2000, J BIOL CHEM, V275, P5485, DOI 10.1074/jbc.275.8.5485; Song JW, 1999, DEV BIOL, V213, P157, DOI 10.1006/dbio.1999.9370; TAKANO K, 1992, BIOCHEM BIOPH RES CO, V182, P1408, DOI 10.1016/0006-291X(92)91890-3; Teleman AA, 2001, CELL, V105, P559, DOI 10.1016/S0092-8674(01)00377-4; TISDALE EJ, 1992, J CELL BIOL, V119, P749, DOI 10.1083/jcb.119.4.749; TSUCHIDA K, 1995, ENDOCRINOLOGY, V136, P5493, DOI 10.1210/en.136.12.5493; Urano T, 1996, EMBO J, V15, P810, DOI 10.1002/j.1460-2075.1996.tb00416.x; VALE W, 1986, NATURE, V321, P776, DOI 10.1038/321776a0; Willis SA, 1996, MOL ENDOCRINOL, V10, P367, DOI 10.1210/me.10.4.367; Wolthuis RMF, 1998, MOL CELL BIOL, V18, P2486, DOI 10.1128/MCB.18.5.2486; Wurthner JU, 2001, J BIOL CHEM, V276, P19495, DOI 10.1074/jbc.M006473200; Xia J, 2000, NEURON, V28, P499, DOI 10.1016/S0896-6273(00)00128-8; YU J, 1987, NATURE, V330, P765, DOI 10.1038/330765a0	58	71	95	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 24	2002	277	21					19008	19018		10.1074/jbc.M112472200	http://dx.doi.org/10.1074/jbc.M112472200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	558PM	11882656	hybrid			2022-12-27	WOS:000175975800100
J	Murakami, M; Yoshihara, K; Shimbara, S; Lambeau, G; Gelb, MH; Singer, AG; Sawada, M; Inagaki, N; Nagai, H; Ishihara, M; Ishikawa, Y; Ishii, T; Kudo, I				Murakami, M; Yoshihara, K; Shimbara, S; Lambeau, G; Gelb, MH; Singer, AG; Sawada, M; Inagaki, N; Nagai, H; Ishihara, M; Ishikawa, Y; Ishii, T; Kudo, I			Cellular arachidonate-releasing function and inflammation-associated expression of group IIF secretory phospholipase A(2)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECOMBINANT EXPRESSION; ACID RELEASE; MAST-CELLS; PANCREATIC PHOSPHOLIPASE-A2; PROSTAGLANDIN GENERATION; POTENTIAL ROLE; CLONING; BINDING; MOUSE; RAT	Here we report the cellular arachidonate (AA)-releasing function of group IIF secretory phospholipase A(2) (sPLA(2)-IIF), a sPLA(2) enzyme uniquely containing a longer C-terminal extension. sPLA(2)-IIF increased spontaneous and stimulus-dependent release of AA, which was supplied to downstream cyclooxygenases and 5-lipoxygenase for eicosanoid production. sPLA(2)-IIF also enhanced interleukin 1-stimulated expression of cyclooxygenase-2 and microsomal prostaglandin E synthase. AA release by sPLA(2)-IIF was facilitated by oxidative modification of cellular membranes. Cellular actions of sPLA(2)-IIF occurred independently of the heparan sulfate proteoglycan glypican, which acts as a functional adaptor for other group II subfamily sPLA(2)s. Confocal microscopy revealed the location of sPLA(2)-IIF on the plasma membrane. The unique C-terminal extension was crucial for its plasma membrane localization and optimal cellular functions. sPLA(2)-IIF expression was increased in various tissues from lipopolysaccharide-treated mice and in ears of mice with experimental atopic dermatitis. In human rheumatoid arthritic joints, sPLA2-IIF was detected in synovial lining cells, capillary endothelial cells, and plasma cells. These results suggest that sPLA(2)-IIF is a potent regulator of AA metabolism and participates in the inflammatory process under certain conditions.	Showa Univ, Sch Pharmaceut Sci, Dept Hlth Chem, Shinagawa Ku, Tokyo 1428555, Japan; Univ Washington, Dept Chem, Seattle, WA 98195 USA; Univ Washington, Dept Biochem, Seattle, WA 98195 USA; Inst Pharmacol Mol & Cellulaire, CNRS, UPR 411, F-06560 Valbonne, France; Gifu Pharmaceut Univ, Dept Pharmacol, Higashi Ku, Gifu 5028585, Japan; Toho Univ, Sch Med, Dept Pathol, Ohta Ku, Tokyo 1438540, Japan	Showa University; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur	Murakami, M (corresponding author), Showa Univ, Sch Pharmaceut Sci, Dept Hlth Chem, Shinagawa Ku, 1-5-8 Hatanodai, Tokyo 1428555, Japan.		Lambeau, Gerard/GRJ-5624-2022	gelb, michael/0000-0001-7000-5219; Lambeau, Gerard/0000-0002-9239-518X				Akiba S, 1997, J BIOCHEM-TOKYO, V122, P859; Baker SF, 1998, BIOCHEMISTRY-US, V37, P13203, DOI 10.1021/bi981223t; Balsinde J, 1998, P NATL ACAD SCI USA, V95, P7951, DOI 10.1073/pnas.95.14.7951; Bezzine S, 2000, J BIOL CHEM, V275, P3179, DOI 10.1074/jbc.275.5.3179; CHEN J, 1994, J BIOL CHEM, V269, P2365; CHEN J, 1994, J BIOL CHEM, V269, P23018; Cupillard L, 1997, J BIOL CHEM, V272, P15745, DOI 10.1074/jbc.272.25.15745; Degousee N, 2002, J BIOL CHEM, V277, P5061, DOI 10.1074/jbc.M109083200; Enomoto A, 2000, BIOCHEM BIOPH RES CO, V276, P667, DOI 10.1006/bbrc.2000.3468; Enomoto A, 2000, J IMMUNOL, V165, P4007, DOI 10.4049/jimmunol.165.7.4007; Gelb MH, 2000, J BIOL CHEM, V275, P39823, DOI 10.1074/jbc.C000671200; Han SK, 1999, J BIOL CHEM, V274, P11881, DOI 10.1074/jbc.274.17.11881; Hanasaki K, 1997, J BIOL CHEM, V272, P32792, DOI 10.1074/jbc.272.52.32792; Hanasaki K, 1999, J BIOL CHEM, V274, P34203, DOI 10.1074/jbc.274.48.34203; Ishizaki J, 1999, J BIOL CHEM, V274, P24973, DOI 10.1074/jbc.274.35.24973; Jamal OS, 1998, ANN RHEUM DIS, V57, P550, DOI 10.1136/ard.57.9.550; Kim KP, 2001, J BIOL CHEM, V276, P11126, DOI 10.1074/jbc.M004604200; Kim YJ, 2002, J BIOL CHEM, V277, P9358, DOI 10.1074/jbc.M110987200; Koduri RS, 1998, J BIOL CHEM, V273, P32142, DOI 10.1074/jbc.273.48.32142; KRAMER RM, 1989, J BIOL CHEM, V264, P5768; Kuwata H, 2000, J IMMUNOL, V165, P4024, DOI 10.4049/jimmunol.165.7.4024; Laine VJO, 1999, J IMMUNOL, V162, P7402; Lambeau G, 1999, TRENDS PHARMACOL SCI, V20, P162, DOI 10.1016/S0165-6147(99)01300-0; MACPHEE M, 1995, CELL, V81, P957, DOI 10.1016/0092-8674(95)90015-2; Morioka Y, 2000, ARCH BIOCHEM BIOPHYS, V381, P31, DOI 10.1006/abbi.2000.1977; Morioka Y, 2000, FEBS LETT, V487, P262, DOI 10.1016/S0014-5793(00)02350-4; Mounier C, 1996, EUR J BIOCHEM, V237, P778, DOI 10.1111/j.1432-1033.1996.0778p.x; Murakami M, 1999, J BIOL CHEM, V274, P3103, DOI 10.1074/jbc.274.5.3103; Murakami M, 1996, J BIOL CHEM, V271, P30041, DOI 10.1074/jbc.271.47.30041; Murakami M, 1999, J BIOL CHEM, V274, P31435, DOI 10.1074/jbc.274.44.31435; Murakami M, 2000, J BIOL CHEM, V275, P32783, DOI 10.1074/jbc.M003505200; Murakami M, 2001, ADV IMMUNOL, V77, P163, DOI 10.1016/S0065-2776(01)77017-4; Murakami M, 2001, J BIOL CHEM, V276, P10083, DOI 10.1074/jbc.M007877200; Murakami M, 1999, J BIOL CHEM, V274, P29927, DOI 10.1074/jbc.274.42.29927; Murakami M, 1998, J BIOL CHEM, V273, P14411, DOI 10.1074/jbc.273.23.14411; Nagai H, 2000, BRIT J PHARMACOL, V129, P299, DOI 10.1038/sj.bjp.0703054; Nigam S, 2000, BBA-MOL CELL BIOL L, V1488, P167, DOI 10.1016/S1388-1981(00)00119-0; OKA S, 1991, J BIOL CHEM, V266, P9956; PFEILSCHIFTER J, 1993, J CLIN INVEST, V92, P2516, DOI 10.1172/JCI116860; PRUZANSKI W, 1991, IMMUNOL TODAY, V12, P143, DOI 10.1016/0167-5699(91)90077-7; Reddy ST, 1997, J BIOL CHEM, V272, P13591, DOI 10.1074/jbc.272.21.13591; Sawada H, 1999, EUR J BIOCHEM, V263, P826, DOI 10.1046/j.1432-1327.1999.00565.x; SEILHAMER JJ, 1989, J BIOL CHEM, V264, P5335; Suzuki N, 2000, J BIOL CHEM, V275, P5785, DOI 10.1074/jbc.275.8.5785; Tietge UJF, 2000, J BIOL CHEM, V275, P10077, DOI 10.1074/jbc.275.14.10077; TOJO H, 1988, J BIOL CHEM, V263, P5724; Valentin E, 1999, J BIOL CHEM, V274, P31195, DOI 10.1074/jbc.274.44.31195; Valentin E, 2000, BIOCHEM BIOPH RES CO, V279, P223, DOI 10.1006/bbrc.2000.3908; Valentin E, 1999, J BIOL CHEM, V274, P19152, DOI 10.1074/jbc.274.27.19152; Valentin E, 2000, J BIOL CHEM, V275, P7492, DOI 10.1074/jbc.275.11.7492; Valentin E, 2000, BBA-MOL CELL BIOL L, V1488, P59, DOI 10.1016/S1388-1981(00)00110-4; Weinrauch Y, 1998, J CLIN INVEST, V102, P633, DOI 10.1172/JCI3121; Zhang YP, 1999, J BIOL CHEM, V274, P27726, DOI 10.1074/jbc.274.39.27726; Zvaritch E, 1996, J BIOL CHEM, V271, P250, DOI 10.1074/jbc.271.1.250	54	58	60	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 24	2002	277	21					19145	19155		10.1074/jbc.M112385200	http://dx.doi.org/10.1074/jbc.M112385200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	558PM	11877435	hybrid			2022-12-27	WOS:000175975800117
J	Shu, LM; Lee, L; Shayman, JA				Shu, LM; Lee, L; Shayman, JA			Regulation of phospholipase C-gamma activity by glycosphingolipids	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUCOSYLCERAMIDE SYNTHASE; MEMBRANE DOMAINS; PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE; PHOSPHORYLATION CASCADE; INOSITOL TRISPHOSPHATE; CHOLESTEROL DEPLETION; ENDOTHELIAL-CELLS; KIDNEY-CELLS; CAVEOLAE; KINASE	Glycosphingolipid-enriched domains are hot spots for cell signaling within plasma membranes and are characterized by the enrichment of glycosphingolipids. A role for glucosylceramide-based glycosphingolipids in phospholipase C-mediated inositol 1,4,5-trisphosphate formation has been previously documented. These earlier studies utilized a first generation glucosylceramide synthase inhibitor to deplete cells of their glycosphingolipids. Recently, more active and specific glucosylceramide synthase inhibitors, including D-threo-ethylendioxyphenyl-2-palmitoylamino-3-pyrrolidinopropanol (D-t-EtDO-P4), have been designed. D-t-EtDO-P4 has the advantage of blocking glucosylceramide synthase at low nanomolar concentrations but does not cause secondary elevations in cell ceramide levels. In the present study, D-t-EtDO-P4 depleted cellular glucosylceramide and lactosylceramide in cultured ECV304 cells at nanomolar concentrations without obvious cellular toxicity. The expression of several signaling proteins was evaluated in glycosphingolipid-depleted ECV304 cells to study the role of glycosphingolipids in phospholipase C-mediated signaling. No difference was observed in the cellular expression of phospholipase C-gamma between controls and glycolipid-depleted cells. Western blot analysis, however, revealed that depletion of endogenous glycosphingolipids in cultured ECV304 cells with D-t-EtDO-P4 induced tyrosine phosphorylation of phospholipase C-gamma in a concentration-dependent manner with maximum induction at 100 nM. The phosphorylation of phospholipase C-gamma induced by D-t-EtDO-P4 was abolished by exogenously added glucosylceramide, consistent with a specific glycosphingolipid-phospholipase C-gamma interaction. The phospholipase C-gamma phosphorylation was maximally enhanced by bradykinin when cells were exposed to 100 nM D-t-EtDO-P4. The measurement of cellular activity of phospholipase C-gamma, by myoinositol 1,4,5-trisphosphate radioreceptor assay, demonstrated that depletion of glucosylceramide-based glycosphingolipids in cultured ECV304 cells with D-t-EtDO-P4 resulted in significantly increased formation of inositol 1,4,5-trisphosphate above base line, and an increased sensitivity of phospholipase C-gamma to bradykinin stimulation. Thus, the activation of phospholipase C-gamma is negatively regulated by membrane glycosphingolipids in ECV304 cells.	Univ Michigan, Sch Med, Dept Internal Med, Div Nephrol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Shayman, JA (corresponding author), Univ Michigan, Sch Med, Dept Internal Med, Div Nephrol, Box 0676,Rm 1560,MSRB 2,1150 W Med Ctr Dr, Ann Arbor, MI 48109 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK055823] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK55823] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abe A, 2000, J CLIN INVEST, V105, P1563, DOI 10.1172/JCI9711; Abe A, 1996, J BIOL CHEM, V271, P14383, DOI 10.1074/jbc.271.24.14383; Ames B.N., 1966, METHOD ENZYMOL, V8, P115, DOI [10.1016/0076-6879(66)08014-5, DOI 10.1016/0076-6879(66)08014-5]; CHUN MY, 1994, P NATL ACAD SCI USA, V91, P11728, DOI 10.1073/pnas.91.24.11728; DeMali KA, 1997, J BIOL CHEM, V272, P9011; deWeerd WFC, 1997, J BIOL CHEM, V272, P17858, DOI 10.1074/jbc.272.28.17858; Dobrowsky RT, 2000, METHOD ENZYMOL, V311, P184; Feron O, 1996, J BIOL CHEM, V271, P22810, DOI 10.1074/jbc.271.37.22810; Furuchi T, 1998, J BIOL CHEM, V273, P21099, DOI 10.1074/jbc.273.33.21099; Ishizaka N, 1998, HYPERTENSION, V32, P459, DOI 10.1161/01.HYP.32.3.459; Iwabuchi K, 2000, METHOD ENZYMOL, V312, P488; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee L, 1999, J BIOL CHEM, V274, P14662, DOI 10.1074/jbc.274.21.14662; Liu PS, 1996, J BIOL CHEM, V271, P10299, DOI 10.1074/jbc.271.17.10299; Liu YM, 1998, BIOCHEM BIOPH RES CO, V245, P684, DOI 10.1006/bbrc.1998.8329; MAHDIYOUN S, 1992, ARCH BIOCHEM BIOPHYS, V292, P506, DOI 10.1016/0003-9861(92)90023-P; Mineo C, 1996, J BIOL CHEM, V271, P11930, DOI 10.1074/jbc.271.20.11930; Myers SJ, 1999, ATHEROSCLEROSIS, V143, P389, DOI 10.1016/S0021-9150(98)00331-1; Pike LJ, 1996, J BIOL CHEM, V271, P26453, DOI 10.1074/jbc.271.43.26453; Pike LJ, 1998, J BIOL CHEM, V273, P22298, DOI 10.1074/jbc.273.35.22298; PREISS J, 1986, J BIOL CHEM, V261, P8597; RANI CSS, 1995, J BIOL CHEM, V270, P2859, DOI 10.1074/jbc.270.6.2859; SHAYMAN JA, 1990, J BIOL CHEM, V265, P12135; Shayman JA, 2000, METHOD ENZYMOL, V311, P373; Shu LM, 2000, ARCH BIOCHEM BIOPHYS, V373, P83, DOI 10.1006/abbi.1999.1553; Smith RM, 1998, CELL SIGNAL, V10, P355, DOI 10.1016/S0898-6568(97)00170-8; Stan RV, 1997, MOL BIOL CELL, V8, P595, DOI 10.1091/mbc.8.4.595; Toselli M, 2001, J PHYSIOL-LONDON, V536, P361, DOI 10.1111/j.1469-7793.2001.0361c.xd; Ushio-Fukai M, 2001, J BIOL CHEM, V276, P48269, DOI 10.1074/jbc.M105901200; Wu CB, 1997, J BIOL CHEM, V272, P3554, DOI 10.1074/jbc.272.6.3554; YAMADA E, 1955, J BIOPHYS BIOCHEM CY, V1, P455	31	18	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 24	2002	277	21					18447	18453		10.1074/jbc.M111363200	http://dx.doi.org/10.1074/jbc.M111363200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	558PM	11886852	hybrid			2022-12-27	WOS:000175975800026
J	Ugi, S; Sharma, PM; Ricketts, W; Imamura, T; Olefsky, JM				Ugi, S; Sharma, PM; Ricketts, W; Imamura, T; Olefsky, JM			Phosphatidylinositol 3-kinase is required for insulin-stimulated tyrosine phosphorylation of Shc in 3T3-L1 adipocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; PHOSPHOTYROSINE-BINDING DOMAIN; ACTIVATED PROTEIN-KINASE; PHOSPHOINOSITIDE 3-KINASE; SIGNAL-TRANSDUCTION; FACTOR RECEPTORS; RAS ACTIVATION; MAP KINASE; IN-VIVO; INHIBITION	The interactions between the phosphatidylinositol 3-kinase (PI 3-kinase) and Ras/MAPK kinase pathways have been the subject of considerable interest. In the current studies, we find that epidermal growth factor (EGF) and platelet-derived growth factor (PDGF) lead to rapid phosphorylation of She (maximum at 1-2 min), whereas insulin-mediated She phosphorylation is relatively delayed (maximum. at 5-10 min), suggesting that an intermediary step may be necessary for insulin stimulation of Shc phosphorylation. The Src homology-2 (SH2) domain of Shc is necessary for PDGF- and EGF-mediated Shc phosphorylation, whereas the phosphotyrosine binding (PTB) domain is critical for the actions of insulin. Because the Shc PTB domain can interact with phospholipids, we postulated that PI 3-kinase might be a necessary intermediary step facilitating insulin-stimulated phosphorylation of Shc. In support of this' we found that the PI 3-kinase inhibitors, wortmannin and LY294002, blocked insulin-stimulated but not EGF- or PDGF-stimulated Shc phosphorylation. Furthermore, overexpression of a dominant negative PI 3-kinase construct (p85N-SH2) blocked insulin, but not EGF- or PDGF-induced Shc phosphorylation. All three growth factors cause localization of Shc to the plasma membrane, but only the effect of insulin was inhibited by wortmannin, supporting the view that PI 3-kinase-generated phospholipids mediate insulin-stimulated She phosphorylation. Consistent with this, expression of a constitutively active PI 3-kinase (p110(CAAX)) increased membrane localization of Shc, and this was completely blocked by wortmannin. A mutant She with a disrupted PTB domain (Shc S154) did not localize to the membrane in p110(CAAX)-expressing cells or after insulin stimulation and was not phosphorylated by insulin. In summary, 1) PI 3-kinase is a necessary early step in insulin-stimulated Shc phosphorylation, whereas the effects of EGF and PDGF on Shc phosphorylation are independent of PI 3-kinase. 2) PI 3-kinase-stimulated generation of membrane phospholipids can localize Shc to the plasma membrane through the She PTB domain facilitating phosphorylation by the insulin receptor.	Univ Calif San Diego, Dept Med, Div Endocrinol & Metab, La Jolla, CA 92093 USA; San Diego Vet Affairs Hosp, Res Serv, La Jolla, CA 92161 USA; Whittier Diabet Inst, La Jolla, CA 92037 USA	University of California System; University of California San Diego	Olefsky, JM (corresponding author), Univ Calif San Diego, Dept Med 0673, 9500 Gilman Dr, La Jolla, CA 92093 USA.				NIDDK NIH HHS [DK 33651] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK033651, R01DK033651] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Avruch J, 1998, MOL CELL BIOCHEM, V182, P31, DOI 10.1023/A:1006823109415; Ceresa BP, 1998, MOL CELL BIOCHEM, V182, P23, DOI 10.1023/A:1006819008507; DePaolo D, 1996, MOL CELL BIOL, V16, P1450; DHAND R, 1994, EMBO J, V13, P522, DOI 10.1002/j.1460-2075.1994.tb06290.x; DOWNWARD J, 1994, FEBS LETT, V338, P113, DOI 10.1016/0014-5793(94)80346-3; DRAZNIN B, 1993, J BIOL CHEM, V268, P19998; Duckworth BC, 1997, J BIOL CHEM, V272, P27665, DOI 10.1074/jbc.272.44.27665; Egawa K, 1999, J BIOL CHEM, V274, P14306, DOI 10.1074/jbc.274.20.14306; GUSTAFSON TA, 1995, MOL CELL BIOL, V15, P2500; HARA K, 1994, P NATL ACAD SCI USA, V91, P7415, DOI 10.1073/pnas.91.16.7415; HU QJ, 1995, SCIENCE, V268, P100, DOI 10.1126/science.7701328; Isakoff SJ, 1996, J BIOL CHEM, V271, P3959; LAM K, 1994, J BIOL CHEM, V269, P20648; Marte BM, 1997, CURR BIOL, V7, P63, DOI 10.1016/S0960-9822(06)00028-5; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PIPER RC, 1991, AM J PHYSIOL, V260, P570; Rameh LE, 1997, J BIOL CHEM, V272, P22059, DOI 10.1074/jbc.272.35.22059; Ravichandran KS, 1997, MOL CELL BIOL, V17, P5540, DOI 10.1128/MCB.17.9.5540; Ricketts WA, 1996, J BIOL CHEM, V271, P26165, DOI 10.1074/jbc.271.42.26165; Ricketts WA, 1999, MOL ENDOCRINOL, V13, P1988, DOI 10.1210/me.13.12.1988; RODRIGUEZVICIANA P, 1994, NATURE, V370, P527, DOI 10.1038/370527a0; Sakaguchi K, 1998, MOL ENDOCRINOL, V12, P536, DOI 10.1210/me.12.4.536; SASAOKA T, 1994, J BIOL CHEM, V269, P32621; SASAOKA T, 1994, J BIOL CHEM, V269, P13689; Sharma PM, 1998, J BIOL CHEM, V273, P18528, DOI 10.1074/jbc.273.29.18528; Shepherd PR, 1998, BIOCHEM J, V333, P471, DOI 10.1042/bj3330471; Suga J, 1997, DIABETES, V46, P735, DOI 10.2337/diabetes.46.5.735; Ugi S, 2002, MOL CELL BIOL, V22, P2375, DOI 10.1128/MCB.22.7.2375-2387.2002; VANDERGEER P, 1995, CURR BIOL, V5, P404, DOI 10.1016/S0960-9822(95)00081-9; YAMAUCHI K, 1993, J BIOL CHEM, V268, P14597; Yang CM, 2000, MOL ENDOCRINOL, V14, P317, DOI 10.1210/me.14.2.317; YOKOTE K, 1994, J BIOL CHEM, V269, P15337	32	7	8	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 24	2002	277	21					18592	18597		10.1074/jbc.M201019200	http://dx.doi.org/10.1074/jbc.M201019200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	558PM	11897789	hybrid			2022-12-27	WOS:000175975800047
J	Germain, M; Mathai, JP; Shore, GC				Germain, M; Mathai, JP; Shore, GC			BH-3-only BIK functions at the endoplasmic reticulum to stimulate cytochrome c release from mitochondria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERMEABILITY TRANSITION PORE; BCL-2 FAMILY PROTEINS; P53-DEPENDENT APOPTOSIS; BH3-ONLY PROTEINS; CELL-DEATH; P53; BAX; INTERACTS; MEMBRANE; ADENOVIRUS	Stimulation of apoptosis by p53 is accompanied by induction of the BH-3-only proapoptotic member of the BCL-2 family, BIK, and ectopic expression of BIK in p53-null cells caused the release of cytochrome c from mitochondria and activation of caspases, dependent on a functional BH-3 domain. A significant fraction of BIK, which contains a predicted transmembrane segment at its COOH terminus, was found inserted in the endoplasmic reticulum (ER) membrane, with the bulk of the protein facing the cytosol. Restriction of BIK to this membrane by replacing its transmembrane segment with the ER-selective membrane anchor of cytochrome b(5) also retained the cytochrome c release and cell death-inducing activity of BIK. Whereas induction of cell death by BIK was strongly inhibited by the caspase inhibitor benzyloxycarbonyl-Val-Ala-Asp-fluoromethylketone, the inhibitor was without effect on the ability of BIK to stimulate egress of cytochrome c from mitochondria. This benzyloxycarbonyl-Val-Ala-Asp-fluoromethylketone-insensitive pathway for stimulating cytochrome c release from mitochondria by ER BIK was successfully reconstituted in vitro and identified the requirement for components present in the light membrane (ER) and cytosol as necessary for this activity. Collectively, the results identify BIK as an initiator of cytochrome a release from mitochondria operating from a location at the ER.	McGill Univ, Dept Biochem, Montreal, PQ H3G 1Y6, Canada	McGill University	Shore, GC (corresponding author), McGill Univ, Dept Biochem, McIntyre Med Sci Bldg,3655 Promenade Sir William, Montreal, PQ H3G 1Y6, Canada.	gordon.shore@mcgill.ca						Adams JM, 2001, TRENDS BIOCHEM SCI, V26, P61, DOI 10.1016/S0968-0004(00)01740-0; Adrain C, 2001, TRENDS BIOCHEM SCI, V26, P390, DOI 10.1016/S0968-0004(01)01844-8; AKAO Y, 1994, CANCER RES, V54, P2468; BOYD JM, 1995, ONCOGENE, V11, P1921; Elangovan B, 1997, J BIOL CHEM, V272, P24494, DOI 10.1074/jbc.272.39.24494; Eskes R, 1998, J CELL BIOL, V143, P217, DOI 10.1083/jcb.143.1.217; Ferri KF, 2001, BIOESSAYS, V23, P111, DOI 10.1002/1521-1878(200102)23:2<111::AID-BIES1016>3.3.CO;2-P; Goping IS, 1998, J CELL BIOL, V143, P207, DOI 10.1083/jcb.143.1.207; GOPING IS, 1995, FEBS LETT, V373, P45; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Han J, 1996, MOL CELL BIOL, V16, P5857; Hegde R, 1998, J BIOL CHEM, V273, P7783, DOI 10.1074/jbc.273.14.7783; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Huang DCS, 2000, CELL, V103, P839, DOI 10.1016/S0092-8674(00)00187-2; Lin YP, 2000, NAT GENET, V26, P122, DOI 10.1038/79102; Marzo I, 1998, J EXP MED, V187, P1261, DOI 10.1084/jem.187.8.1261; Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3; Ng FWH, 1997, J CELL BIOL, V139, P327, DOI 10.1083/jcb.139.2.327; NGUYEN M, 1994, J BIOL CHEM, V269, P16521; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; Oda K, 2000, CELL, V102, P849, DOI 10.1016/S0092-8674(00)00073-8; Pedrazzini E, 2000, J CELL BIOL, V148, P899, DOI 10.1083/jcb.148.5.899; Pinton P, 2001, EMBO J, V20, P2690, DOI 10.1093/emboj/20.11.2690; Puthalakath H, 2001, SCIENCE, V293, P1829, DOI 10.1126/science.1062257; Querido E, 1997, J VIROL, V71, P3526, DOI 10.1128/JVI.71.5.3526-3533.1997; Rudner J, 2001, J CELL SCI, V114, P4161; Shimizu S, 1999, NATURE, V399, P483, DOI 10.1038/20959; Soengas MS, 1999, SCIENCE, V284, P156, DOI 10.1126/science.284.5411.156; Vousden KH, 2000, CELL, V103, P691, DOI 10.1016/S0092-8674(00)00171-9; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Wei MC, 2000, GENE DEV, V14, P2060; Yu J, 2001, MOL CELL, V7, P673, DOI 10.1016/S1097-2765(01)00213-1; Zong WX, 2001, GENE DEV, V15, P1481, DOI 10.1101/gad.897601	33	119	124	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 17	2002	277	20					18053	18060		10.1074/jbc.M201235200	http://dx.doi.org/10.1074/jbc.M201235200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	553PR	11884414	hybrid			2022-12-27	WOS:000175685100084
J	Humbert, O; Hermine, T; Hernandez, H; Bouget, T; Selves, J; Laurent, G; Salles, B; Lautier, D				Humbert, O; Hermine, T; Hernandez, H; Bouget, T; Selves, J; Laurent, G; Salles, B; Lautier, D			Implication of protein kinase C in the regulation of DNA mismatch repair protein expression and function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MICROSATELLITE INSTABILITY; CELL-LINES; GENE HMSH2; O-6-METHYLGUANINE-DNA METHYLTRANSFERASE; ACQUIRED-RESISTANCE; MUTATOR PHENOTYPE; P53 MUTATIONS; LEUKEMIA; MSH2; DEFECTS	The DNA mismatch repair (MMR) proteins are essential for the maintenance of genomic stability of human cells. Compared with hereditary or even sporadic carcinomas, MMR gene mutations are very uncommon in leukemia. However, genetic instability, attested by either loss of heterozygosity or microsatellite instability, has been extensively documented in chronic or acute malignant myeloid disorders. This observation suggests that in leukemia some internal or external signals may interfere with MMR protein expression and/or function. We investigated the effects of protein kinase C (PKC) stimulation by 12-O-tetradecanoylphorbol-13-acetate (TPA) on MMR protein expression and activity in human myeloid leukemia cell lines. First, we show here that unstimulated U937 cells displayed low level of PKC activity as well as MMR protein expression and activity compared with a panel of myeloid cell lines. Second, treatment of U937 cells with TPA significantly increased (3-5-fold) hMSH2 expression and, to a lesser extent, hMSH6 and hPMS2 expression, correlated to a restoration of MMR function. In addition, diacylglycerol, a physiological PKC agonist, induced a significant increase in hMSH-2 expression, whereas chelerythrine or calphostin C, two PKC inhibitors, significantly decreased TPA-induced hMSH2 expression. Reciprocally, treatment of HEL and KG1a cells that exhibited a high level of PKC expression, with chelerythrine significantly decreased hMSH2 and hMSH6 expression. Moreover, the alteration of MMR protein expression paralleled the difference in microsatellite instability and cell sensitivity to 6-thioguanine. Our results suggest that PKC could play a role in regulating MMR protein expression and function in some myeloid leukemia cells.	Inst Pharmacol & Biol Struct, CNRS, UMR 5089, F-31077 Toulouse, France; Inst Claudius Regaud, INSERM E9910, F-31052 Toulouse, France; Hop Purpan, Anat Pathol Lab, F-31059 Toulouse, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Institut Claudius Regaud; CHU de Toulouse	Lautier, D (corresponding author), Inst Pharmacol & Biol Struct, CNRS, UMR 5089, 205 Route Narbonne, F-31077 Toulouse, France.	lautier@icr.fnclcc.fr	Lautier, Dominique/G-3959-2017; salles, bernard/B-8531-2008					Aebi S, 1996, CANCER RES, V56, P3087; BAILLY JD, 1995, LEUKEMIA, V9, P799; BenYehuda D, 1996, BLOOD, V88, P4296; Boldogh I, 1998, CANCER RES, V58, P3950; BOYER JC, 1995, CANCER RES, V55, P6063; BRANCH P, 1993, NATURE, V362, P652, DOI 10.1038/362652a0; Brimmell M, 1998, ONCOGENE, V16, P1803, DOI 10.1038/sj.onc.1201704; Canitrot Y, 1997, BIOCHEM BIOPH RES CO, V234, P573, DOI 10.1006/bbrc.1997.6674; Chang DK, 2000, J BIOL CHEM, V275, P18424, DOI 10.1074/jbc.M001140200; CHEN JS, 1995, CANCER RES, V55, P174; Chen Y, 2001, CANCER RES, V61, P4112; Christmann M, 2000, J BIOL CHEM, V275, P36256, DOI 10.1074/jbc.M005377200; Clave E, 1996, INT J RADIAT ONCOL, V35, P709, DOI 10.1016/0360-3016(96)00137-X; delasAlas MM, 1997, J NATL CANCER I, V89, P1537, DOI 10.1093/jnci/89.20.1537; Drummond JT, 1997, P NATL ACAD SCI USA, V94, P10144, DOI 10.1073/pnas.94.19.10144; Drummond JT, 1996, J BIOL CHEM, V271, P19645, DOI 10.1074/jbc.271.33.19645; FISHEL R, 1995, CURR OPIN GENET DEV, V5, P382, DOI 10.1016/0959-437X(95)80055-7; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; GESCHER A, 1989, ANTI-CANCER DRUG DES, V4, P93; Hampson R, 1997, J BIOL CHEM, V272, P28596, DOI 10.1074/jbc.272.45.28596; Hangaishi A, 1997, BLOOD, V89, P1740, DOI 10.1182/blood.V89.5.1740.1740_1740_1747; Herman JG, 1998, P NATL ACAD SCI USA, V95, P6870, DOI 10.1073/pnas.95.12.6870; HUG H, 1993, BIOCHEM J, V291, P329, DOI 10.1042/bj2910329; Humbert O, 1999, CARCINOGENESIS, V20, P205, DOI 10.1093/carcin/20.2.205; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; INDRACCOLO S, 1995, LEUKEMIA, V9, P1517; Indraccolo S, 1999, BLOOD, V94, P2424, DOI 10.1182/blood.V94.7.2424.419k09_2424_2432; Inoue K, 2000, LEUKEMIA RES, V24, P255, DOI 10.1016/S0145-2126(99)00182-4; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; Jaken S, 2000, BIOESSAYS, V22, P245, DOI 10.1002/(SICI)1521-1878(200003)22:3<245::AID-BIES6>3.0.CO;2-X; Jiricny J, 1998, EMBO J, V17, P6427, DOI 10.1093/emboj/17.22.6427; Karran P, 1996, CHEM BIOL, V3, P875, DOI 10.1016/S1074-5521(96)90175-1; KARRAN P, 1993, J BIOL CHEM, V268, P15878; Kodera T, 1999, GENE CHROMOSOME CANC, V26, P267, DOI 10.1002/(SICI)1098-2264(199911)26:3<267::AID-GCC13>3.0.CO;2-V; Kolodner RD, 1999, CURR OPIN GENET DEV, V9, P89, DOI 10.1016/S0959-437X(99)80013-6; Lautier D, 1997, INT J CANCER, V71, P292; Leach FS, 1996, CANCER RES, V56, P235; Levati L, 1998, GENE CHROMOSOME CANC, V23, P159, DOI 10.1002/(SICI)1098-2264(199810)23:2<159::AID-GCC9>3.0.CO;2-1; Li QD, 1998, J BIOL CHEM, V273, P23419, DOI 10.1074/jbc.273.36.23419; LIU B, 1994, CANCER RES, V54, P4590; Lowsky R, 1997, BLOOD, V89, P2276, DOI 10.1182/blood.V89.7.2276; Macpherson P, 1998, MUTAT RES-DNA REPAIR, V408, P55, DOI 10.1016/S0921-8777(98)00017-2; Mansat V, 1997, CANCER RES, V57, P5300; Marra G, 1998, P NATL ACAD SCI USA, V95, P8568, DOI 10.1073/pnas.95.15.8568; Marra G, 1996, ONCOGENE, V13, P2189; Modrich P, 1996, ANNU REV BIOCHEM, V65, P101, DOI 10.1146/annurev.bi.65.070196.000533; Newton AC, 1997, CURR OPIN CELL BIOL, V9, P161, DOI 10.1016/S0955-0674(97)80058-0; O'Driscoll M., 1998, NUCL ACID M, V12, P173; Oda S, 2000, EMBO J, V19, P1711, DOI 10.1093/emboj/19.7.1711; Pabst T, 1996, BLOOD, V88, P1026, DOI 10.1182/blood.V88.3.1026.bloodjournal8831026; Rimsza LM, 2000, LEUKEMIA, V14, P1044, DOI 10.1038/sj.leu.2401699; Scherer SJ, 2000, J BIOL CHEM, V275, P37469, DOI 10.1074/jbc.M006990200; Shcherbakova PV, 2001, MOL CELL BIOL, V21, P940, DOI 10.1128/MCB.21.3.940-951.2001; Sill H, 1996, BRIT J CANCER, V74, P255, DOI 10.1038/bjc.1996.347; Srivenugopal KS, 2000, CANCER RES, V60, P282; STEPHENSON C, 1989, J BIOL CHEM, V264, P21177; SUNDSTROM C, 1976, INT J CANCER, V17, P565, DOI 10.1002/ijc.2910170504; Swann PF, 1996, SCIENCE, V273, P1109, DOI 10.1126/science.273.5278.1109; Tasaka T, 1997, BRIT J HAEMATOL, V98, P219, DOI 10.1046/j.1365-2141.1997.1672985.x; UMAR A, 1994, J BIOL CHEM, V269, P14367; Veigl ML, 1998, P NATL ACAD SCI USA, V95, P8698, DOI 10.1073/pnas.95.15.8698; WADA C, 1994, BLOOD, V83, P3449, DOI 10.1182/blood.V83.12.3449.bloodjournal83123449; WILSON TM, 1995, CANCER RES, V55, P5146; WOOSTER R, 1994, NAT GENET, V6, P152, DOI 10.1038/ng0294-152; Zhu YM, 1999, BLOOD, V94, P733, DOI 10.1182/blood.V94.2.733.414k03_733_740	65	21	23	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 17	2002	277	20					18061	18068		10.1074/jbc.M103451200	http://dx.doi.org/10.1074/jbc.M103451200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	553PR	11880362	hybrid			2022-12-27	WOS:000175685100085
J	Lemeshko, VV				Lemeshko, VV			Cytochrome c sorption-desorption effects on the external NADH oxidation by mitochondria - Experimental and computational study	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER MITOCHONDRIA; PROGRAMMED CELL-DEATH; ELECTRON-TRANSPORT; OUTER-MEMBRANE; APOPTOSIS; ACTIVATION; SYSTEM; CHAIN; AGE	The rupture of the outer mitochondrial membrane is known to be critical for cell death, but the mechanism, specifically its redox-signaling aspects, still needs to be studied in more detail. In this work, the external NADH oxidation by rat liver mitochondria was studied under the outer membrane rupture induced by the mitochondria hypotonic treatment or the inner membrane permeability transition. The saturation of the oxidation rate was observed as a function of mitochondrial protein concentration. This effect was shown to result from cytochrome e binding to the mitochondrial membranes. At a relatively high concentration of mitochondria, the oxidation rate was strongly activated by 4 mm Mg2+ due to cytochrome c desorption from the membranes. A minimal kinetic model was developed to explain the main phenomena of the external NADH oxidation modulated by cytochrome e and Mg2+ in mitochondria with the ruptured outer membrane. The computational behavior of the model closely agreed with the experimental data. We suggest that the redox state of the released cytochrome c, considered by other authors to be important for apoptosis, may strongly depend on its oxidation by the fraction of mitochondria with the ruptured outer membrane and on the cytoplasmic cytochrome c reductase activity.	Univ Nacl Colombia, Fac Ciencias, Sch Phys, Dept Sci,Medellin Branch, AA-3840 Medellin, Colombia	Universidad Nacional de Colombia	Lemeshko, VV (corresponding author), Univ Nacl Colombia, Fac Ciencias, Sch Phys, Dept Sci,Medellin Branch, Calle 65,Cra 64, AA-3840 Medellin, Colombia.	vvasilie@perseus.unalmed.edu.co						BERNARDI P, 1981, J BIOL CHEM, V256, P7187; Bodrova ME, 1998, FEBS LETT, V435, P269, DOI 10.1016/S0014-5793(98)01072-2; Cai JY, 2000, FREE RADICAL BIO MED, V29, P334, DOI 10.1016/S0891-5849(00)00312-9; Cai JY, 1998, BBA-BIOENERGETICS, V1366, P139, DOI 10.1016/S0005-2728(98)00109-1; Cai JY, 1999, J BIOENERG BIOMEMBR, V31, P327, DOI 10.1023/A:1005423818280; COOPER CE, 1990, BIOCHIM BIOPHYS ACTA, V1017, P187, DOI 10.1016/0005-2728(90)90184-6; Cortese JD, 1998, BIOCHEMISTRY-US, V37, P6402, DOI 10.1021/bi9730543; HACKENBROCK CR, 1986, J BIOENERG BIOMEMBR, V18, P331, DOI 10.1007/BF00743010; Hancock JT, 2001, FREE RADICAL BIO MED, V31, P697, DOI 10.1016/S0891-5849(01)00646-3; La Piana G, 1998, BIOCHEM BIOPH RES CO, V246, P556; Lemeshko V. V., 1995, Ukrainskii Biokhimicheskii Zhurnal, V67, P28; LEMESHKO VV, 1993, MECH AGEING DEV, V68, P221, DOI 10.1016/0047-6374(93)90153-I; Lemeshko VV, 2000, FEBS LETT, V472, P5, DOI 10.1016/S0014-5793(00)01419-8; Lemeshko VV, 2001, ARCH BIOCHEM BIOPHYS, V388, P60, DOI 10.1006/abbi.2000.2214; LEMESHKO VV, 1982, BIOFIZIKA+, V27, P837; LEMESHKO VV, 2001, KEYSTONE S, P107; LOFRUMENTO NE, 1991, ARCH BIOCHEM BIOPHYS, V288, P293, DOI 10.1016/0003-9861(91)90198-R; Martinou JC, 2000, NAT CELL BIOL, V2, pE41, DOI 10.1038/35004069; MARZULLI D, 1995, ARCH BIOCHEM BIOPHYS, V319, P36, DOI 10.1006/abbi.1995.1264; Marzulli D, 1999, BIOCHEM BIOPH RES CO, V259, P325, DOI 10.1006/bbrc.1999.0787; MATLIB MA, 1976, ARCH BIOCHEM BIOPHYS, V173, P27, DOI 10.1016/0003-9861(76)90230-7; Mokhova E. N., 1977, BIOCHIM BIOPHYS ACTA, V501, P415; NICHOLLS P, 1969, FEBS LETT, V3, P242, DOI 10.1016/0014-5793(69)80147-X; NICHOLLS P, 1974, BIOCHIM BIOPHYS ACTA, V346, P261, DOI 10.1016/0304-4173(74)90003-2; Pan ZH, 1999, CELL DEATH DIFFER, V6, P683, DOI 10.1038/sj.cdd.4400544; Petit PX, 1996, FEBS LETT, V396, P7, DOI 10.1016/0014-5793(96)00988-X; Skulachev VP, 2001, EXP GERONTOL, V36, P995, DOI 10.1016/S0531-5565(01)00109-7; Skulachev VP, 1998, FEBS LETT, V423, P275, DOI 10.1016/S0014-5793(98)00061-1; SKULACHEV VP, 1969, ACCUMULATION ENERGY; SOTTOCASA GL, 1967, J CELL BIOL, V32, P415, DOI 10.1083/jcb.32.2.415; Susin SA, 1998, BBA-BIOENERGETICS, V1366, P151, DOI 10.1016/S0005-2728(98)00110-8; TAYLOR DD, 1992, MITOCHONDRIA HLTH DI; WIKSTROM M, 1985, FEBS LETT, V183, P293, DOI 10.1016/0014-5793(85)80796-1; WILLIAMS JN, 1964, ARCH BIOCHEM BIOPHYS, V107, P537, DOI 10.1016/0003-9861(64)90313-3; WILLIAMS JN, 1968, BIOCHIM BIOPHYS ACTA, V162, P175, DOI 10.1016/0005-2728(68)90100-X; Wojtczak L, 1974, Rev Roum Physiol, V11, P173	36	26	28	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 17	2002	277	20					17751	17757		10.1074/jbc.M201002200	http://dx.doi.org/10.1074/jbc.M201002200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	553PR	11886867	hybrid			2022-12-27	WOS:000175685100047
J	Yang, LT; Alexandropoulos, K; Sap, J				Yang, LT; Alexandropoulos, K; Sap, J			c-SRC mediates neurite outgrowth through recruitment of Crk to the scaffolding protein Sin/Efs without altering the kinetics of ERK activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE-PHOSPHATASE-ALPHA; FOCAL ADHESION KINASE; NERVE GROWTH-FACTOR; PC12 CELL-DIFFERENTIATION; ADAPTER PROTEIN; PTP-ALPHA; V-SRC; SIGNALING PATHWAY; FAMILY KINASES; IN-VIVO	SRC family kinases have been consistently and recurrently implicated in neurite extension events, yet the mechanism underlying their neuritogenic role has remained elusive. We report that epidermal growth factor (EGF) can be converted from a non-neuritogenic into a neuritogenic factor through moderate activation of endogenous SRC by receptor-protein-tyrosine phosphatase a (a physiological SRC activator). We show that such a qualitative change in the response to EGF is not accompanied by changes in the extent or kinetics of ERK induction in response to this factor. Instead, the pathway involved relies on increased tyrosine phosphorylation of, and recruitment of Crk to, the SRC substrate Sin/Efs. The latter is a scaffolding protein structurally similar to the SRC substrate Cas, tyrosine phosphorylation of which is critical for migration in fibroblasts and epithelial cells. Expression of a dominant negative version of Sin interfered with receptor-protein-tyrosine phosphatase alpha/EGF- as well as fibroblast growth factor-induced neurite outgrowth. These observations uncouple neuritogenic signaling in PC12 cells from sustained activation of ERK kinases and for the first time identify an effector of SRC function in neurite extension.	NYU, Sch Med, Dept Pharmacol, New York, NY 10016 USA; Columbia Univ Coll Phys & Surg, Dept Pharmacol, New York, NY 10032 USA	New York University; Columbia University	Sap, J (corresponding author), NYU, Sch Med, Dept Pharmacol, 550 1st Ave, New York, NY 10016 USA.		Yang, Liang-Tung/B-2661-2010		NCI NIH HHS [CA68365] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA068365] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aftab DT, 1997, P NATL ACAD SCI USA, V94, P3028, DOI 10.1073/pnas.94.7.3028; ALEMA S, 1985, NATURE, V316, P557, DOI 10.1038/316557a0; Alexandropoulos K, 1996, GENE DEV, V10, P1341, DOI 10.1101/gad.10.11.1341; Altun-Gultekin ZF, 1998, MOL CELL BIOL, V18, P3044, DOI 10.1128/MCB.18.5.3044; BEGGS HE, 1994, J CELL BIOL, V127, P825, DOI 10.1083/jcb.127.3.825; Beggs HE, 1997, J BIOL CHEM, V272, P8310, DOI 10.1074/jbc.272.13.8310; Bhandari V, 1998, J BIOL CHEM, V273, P8691, DOI 10.1074/jbc.273.15.8691; Boyer B, 1997, EMBO J, V16, P5904, DOI 10.1093/emboj/16.19.5904; Burnham MR, 2000, MOL CELL BIOL, V20, P5865, DOI 10.1128/MCB.20.16.5865-5878.2000; Cary LA, 1998, J CELL BIOL, V140, P211, DOI 10.1083/jcb.140.1.211; COOPER JA, 1986, MOL CELL BIOL, V6, P4467, DOI 10.1128/MCB.6.12.4467; DENHERTOG J, 1994, EMBO J, V13, P3020, DOI 10.1002/j.1460-2075.1994.tb06601.x; DENHERTOG J, 1993, EMBO J, V12, P3789, DOI 10.1002/j.1460-2075.1993.tb06057.x; Dolfi F, 1998, P NATL ACAD SCI USA, V95, P15394, DOI 10.1073/pnas.95.26.15394; Fincham VJ, 1998, EMBO J, V17, P81, DOI 10.1093/emboj/17.1.81; Hakak Y, 1999, MOL CELL BIOL, V19, P6953; Harder KW, 1998, J BIOL CHEM, V273, P31890, DOI 10.1074/jbc.273.48.31890; Heasley LE, 1996, MOL CELL BIOL, V16, P648; Helmke S, 1998, J CELL SCI, V111, P2465; Honda H, 1998, NAT GENET, V19, P361, DOI 10.1038/1246; IGNELZI MA, 1994, NEURON, V12, P873, DOI 10.1016/0896-6273(94)90339-5; Ishino M, 1995, ONCOGENE, V11, P2331; Kiyokawa E, 1998, GENE DEV, V12, P3331, DOI 10.1101/gad.12.21.3331; Klemke RL, 1998, J CELL BIOL, V140, P961, DOI 10.1083/jcb.140.4.961; Kobayashi S, 1997, J BIOL CHEM, V272, P16262, DOI 10.1074/jbc.272.26.16262; Kobayashi S, 1998, J BIOCHEM-TOKYO, V123, P624; KREMER NE, 1991, J CELL BIOL, V115, P809, DOI 10.1083/jcb.115.3.809; Kuo WL, 1997, MOL CELL BIOL, V17, P4633, DOI 10.1128/MCB.17.8.4633; Lammers R, 2000, J BIOL CHEM, V275, P3391, DOI 10.1074/jbc.275.5.3391; Law SF, 1996, MOL CELL BIOL, V16, P3327; Luo LQ, 1997, CURR OPIN NEUROBIOL, V7, P81, DOI 10.1016/S0959-4388(97)80124-9; MACHIDA CM, 1991, J CELL BIOL, V114, P1037, DOI 10.1083/jcb.114.5.1037; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MUNOZ A, 1993, J CELL BIOL, V121, P423, DOI 10.1083/jcb.121.2.423; O'Neill GM, 2000, TRENDS CELL BIOL, V10, P111, DOI 10.1016/S0962-8924(99)01714-6; Oldham SM, 1998, ONCOGENE, V16, P2565, DOI 10.1038/sj.onc.1201784; PENG X, 1995, NEURON, V15, P395, DOI 10.1016/0896-6273(95)90043-8; Petrone A, 2000, J CELL SCI, V113, P2345; Ponniah S, 1999, CURR BIOL, V9, P535, DOI 10.1016/S0960-9822(99)80238-3; Rusanescu G, 1995, NEURON, V15, P1415, DOI 10.1016/0896-6273(95)90019-5; Schwartzberg PL, 1998, ONCOGENE, V17, P1463, DOI 10.1038/sj.onc.1202176; Stofega MR, 1997, CELL GROWTH DIFFER, V8, P113; Stoker A, 1998, BIOESSAYS, V20, P463, DOI 10.1002/(SICI)1521-1878(199806)20:6<463::AID-BIES4>3.0.CO;2-N; Su J, 1999, CURR BIOL, V9, P505, DOI 10.1016/S0960-9822(99)80234-6; SU J, 1996, J BIOL CHEM, V271, P28026; Tanaka S, 1997, P NATL ACAD SCI USA, V94, P2356, DOI 10.1073/pnas.94.6.2356; VAILLANCOURT RR, 1995, MOL CELL BIOL, V15, P3644; Weinstein DE, 1999, DEV BRAIN RES, V116, P29, DOI 10.1016/S0165-3806(99)00072-3; Wu YY, 1996, J BIOL CHEM, V271, P13033, DOI 10.1074/jbc.271.22.13033; Xing LZ, 2000, MOL CELL BIOL, V20, P7363, DOI 10.1128/MCB.20.19.7363-7377.2000; YANG LT, 1989, THESIS NEW YORK U NE; Yano H, 2000, P NATL ACAD SCI USA, V97, P9076, DOI 10.1073/pnas.97.16.9076; York RD, 1998, NATURE, V392, P622, DOI 10.1038/33451; Zeng L, 1999, J CELL BIOL, V147, P707, DOI 10.1083/jcb.147.4.707; Zheng XM, 2000, EMBO J, V19, P964, DOI 10.1093/emboj/19.5.964; ZHENG XM, 1992, NATURE, V359, P336, DOI 10.1038/359336a0; Zhong HY, 1999, BIOCHEM J, V344, P889, DOI 10.1042/0264-6021:3440889	57	45	47	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 17	2002	277	20					17406	17414		10.1074/jbc.M111902200	http://dx.doi.org/10.1074/jbc.M111902200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	553PR	11867627	hybrid			2022-12-27	WOS:000175685100006
J	Abe, MK; Saelzler, MP; Espinosa, R; Kahle, KT; Hershenson, MB; Le Beau, MM; Rosner, MR				Abe, MK; Saelzler, MP; Espinosa, R; Kahle, KT; Hershenson, MB; Le Beau, MM; Rosner, MR			ERK-8, a new member of the mitogen-activated protein kinase family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SRC SH2 DOMAIN; MAP KINASE; V-SRC; SIGNAL-TRANSDUCTION; C-SRC; IDENTIFICATION; SEQUENCE; PATHWAYS; ALIGNMENT; PP60C-SRC	The ERKs are a subfamily of the MAPKs that have been implicated in cell growth and differentiation. By using the rat ERK7 cDNA to screen a human multiple tissue cDNA library, we identified a new member of the ERK family, ERK8, that shares 69% amino acid sequence identity with ERK7. Northern analysis demonstrates that ERK8 is present in a number of tissues with maximal expression in the lung and kidney. Fluorescence in situ hybridization localized the ERK8 gene to chromosome 8, band q24.3. Expression of ERK8 in COS cells and bacteria indicates that, in contrast to constitutively active ERK7, ERK8 has minimal basal kinase activity and a unique substrate profile. ERK8, which contains two SH3-binding motifs in its C-terminal region, associates with the c-Src SH3 domain in vitro and co-immunoprecipitates with c-Src in vivo. Co-transfection with either v-Src or a constitutively active c-Src increases ERK8 activation indicating that ERK8 can be activated downstream of c-Src. ERK8 is also activated following serum stimulation, and the extent of this activation is reduced by pretreatment with the specific Src family inhibitor PP2. The ERK8 activation by serum or Src was not affected by the MEK inhibitor U0126 indicating that activation of ERK8 does not require MEK1, MEK2, or MEK5. Although most closely related to ERK7, the relatively low sequence identity, minimal basal activity, and different substrate profile identify ERK8 as a distinct member of the MAPK family that is activated by an Src-dependent signaling pathway.	Univ Chicago, Ben May Inst Canc Res, Dept Pediat, Chicago, IL 60637 USA; Univ Chicago, Dept Neurobiol Pharmacol & Physiol, Sect Hematol & Oncol, Chicago, IL 60637 USA; Univ Chicago, Dept Med, Chicago, IL 60637 USA; Univ Chicago, Canc Res Ctr, Chicago, IL 60637 USA	University of Chicago; University of Chicago; University of Chicago; University of Chicago	Abe, MK (corresponding author), Univ Chicago, Ben May Inst Canc Res, Dept Pediat, 5841 S Maryland Ave,MC4064, Chicago, IL 60637 USA.				NCI NIH HHS [CA40046] Funding Source: Medline; NHLBI NIH HHS [HL63314, HL03867, HL54685, HL56399] Funding Source: Medline; NIGMS NIH HHS [GM61038] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL054685, P50HL056399, R01HL063314] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061038] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abe MK, 2001, J BIOL CHEM, V276, P21272, DOI 10.1074/jbc.M100026200; Abe MK, 1999, MOL CELL BIOL, V19, P1301; ABE MK, 1994, AM J RESP CELL MOL, V11, P577, DOI 10.1165/ajrcmb.11.5.7946386; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Brown MT, 1996, BBA-REV CANCER, V1287, P121, DOI 10.1016/0304-419X(96)00003-0; Chao TSO, 1997, CANCER RES, V57, P3168; COZENS AL, 1994, AM J RESP CELL MOL, V10, P38, DOI 10.1165/ajrcmb.10.1.7507342; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; Espinosa R 3rd, 1997, Methods Mol Biol, V68, P53; FLYNN DC, 1993, MOL CELL BIOL, V13, P7892, DOI 10.1128/MCB.13.12.7892; FUMAGALLI S, 1994, NATURE, V368, P871, DOI 10.1038/368871a0; Hanke JH, 1996, J BIOL CHEM, V271, P695, DOI 10.1074/jbc.271.2.695; Janulis M, 2001, MOL CELL BIOL, V21, P2235, DOI 10.1128/MCB.21.6.2235-2247.2001; JOHNSON PJ, 1985, MOL CELL BIOL, V5, P1073, DOI 10.1128/MCB.5.5.1073; Kamakura S, 1999, J BIOL CHEM, V274, P26563, DOI 10.1074/jbc.274.37.26563; Kasler HG, 2000, MOL CELL BIOL, V20, P8382, DOI 10.1128/MCB.20.22.8382-8389.2000; KMIECIK TE, 1987, CELL, V49, P65, DOI 10.1016/0092-8674(87)90756-2; LEE JD, 1995, BIOCHEM BIOPH RES CO, V213, P715, DOI 10.1006/bbrc.1995.2189; Lewis TS, 1998, ADV CANCER RES, V74, P49, DOI 10.1016/S0065-230X(08)60765-4; LIU XQ, 1993, MOL CELL BIOL, V13, P5225, DOI 10.1128/MCB.13.9.5225; Mody N, 2001, FEBS LETT, V502, P21, DOI 10.1016/S0014-5793(01)02651-5; OKAMURA H, 1995, J BIOL CHEM, V270, P26613, DOI 10.1074/jbc.270.44.26613; Pearson G, 2001, ENDOCR REV, V22, P153, DOI 10.1210/er.22.2.153; Robinson MJ, 1997, CURR OPIN CELL BIOL, V9, P180, DOI 10.1016/S0955-0674(97)80061-0; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TURNER CE, 1994, J CELL SCI, V107, P1583; WASKIEWICZ AJ, 1995, CURR OPIN CELL BIOL, V7, P798, DOI 10.1016/0955-0674(95)80063-8; XING Z, 1994, MOL BIOL CELL, V5, P413, DOI 10.1091/mbc.5.4.413; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0; Xu WQ, 1999, MOL CELL, V3, P629, DOI 10.1016/S1097-2765(00)80356-1; Yan C, 2001, J BIOL CHEM, V276, P10870, DOI 10.1074/jbc.M009286200; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0; ZHOU GC, 1995, J BIOL CHEM, V270, P12665, DOI 10.1074/jbc.270.21.12665	35	89	96	2	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 10	2002	277	19					16733	16743		10.1074/jbc.M112483200	http://dx.doi.org/10.1074/jbc.M112483200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	551MB	11875070	hybrid			2022-12-27	WOS:000175564500053
J	Evellin, S; Nolte, J; Tysack, K; vom Dorp, F; Thiel, M; Weernink, MAO; Jakobs, KH; Webb, EJ; Lomasney, JW; Schmidt, M				Evellin, S; Nolte, J; Tysack, K; vom Dorp, F; Thiel, M; Weernink, MAO; Jakobs, KH; Webb, EJ; Lomasney, JW; Schmidt, M			Stimulation of phospholipase C-epsilon by the M-3 muscarinic acetylcholine receptor mediated by cyclic AMP and the GTPase Rap2B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							G-PROTEINS; ADENYLYL-CYCLASE; HEK-293 CELLS; RGS14; EFFECTOR; KINASE; TOXIN; SENSITIZATION; REGULATORS; C-DELTA-1	Stimulation of phospholipase C (PLC) by G(q)-coupled receptors such as the M-3 muscarinic acetylcholine receptor (mAChR) is caused by direct activation of PLC-beta enzymes by Galpha(q) proteins. We have recently shown that G(s)-coupled receptors can stimulate PLC-epsilon, apparently via formation of cyclic AMP and activation of the Ras-related GTPase Rap2B. Here we report that PLC stimulation by the M-3 mAChR expressed in HEK-293 cells also involves, in part, similar mechanisms. M-3 mAChR-mediated PLC stimulation and [Ca2+](i) increase were reduced by 2',5'-dideoxyadenosine (dd-Ado), a direct adenylyl cyclase inhibitor. On the other hand, overexpression of Galpha(s) or Epac1, a cyclic AMP-regulated guanine nucleotide exchange factor for Rap GTPases, enhanced M-3 mAChR-mediated PLC stimulation. Inactivation of Ras-related GTPases with clostridial toxins suppressed the M-3 mAChR responses. The inhibitory toxin effects were mimicked by expression of inactive Rap2B, but not of other inactive GTPases (Rac1, Ras, RalA Rap1A, and Rap2A). Activation of the M-3 mAChR induced GTP loading of Rap2B, an effect strongly enhanced by overexpression of Galpha(s) and inhibited by dd-Ado. Overexpression of PLC-epsilon and PLC-beta1, but not PLC-gamma1 or PLC-delta1, enhanced M, mAChR-mediated PLC stimulation and [Ca2+](i) increase. In contrast, expression of a catalytically inactive PLC-epsilon mutant reduced PLC stimulation by the M-3 mAChR and abrogated the potentiating effect of Galpha(s). In conclusion, our findings suggest that PLC stimulation by the M-3 mAChR is a composite action of PLC-beta1 stimulation by Galpha(q) and stimulation of PLC-epsilon apparently mediated by G(s)-dependent cyclic AMP formation and subsequent activation of Rap2B.	Univ Klinikum Essen, Inst Pharmakol, D-45122 Essen, Germany; Northwestern Univ, Sch Med, Dept Pathol, Chicago, IL 60611 USA; Northwestern Univ, Sch Med, Dept Pharmacol, Chicago, IL 60611 USA	University of Duisburg Essen; Northwestern University; Northwestern University	Schmidt, M (corresponding author), Univ Klinikum Essen, Inst Pharmakol, Hufelandstr 55, D-45122 Essen, Germany.							BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; Chaves-Olarte E, 1999, J BIOL CHEM, V274, P11046, DOI 10.1074/jbc.274.16.11046; Cho H, 2000, MOL PHARMACOL, V58, P569, DOI 10.1124/mol.58.3.569; Davare MA, 2001, SCIENCE, V293, P98, DOI 10.1126/science.293.5527.98; de Rooij J, 2000, J BIOL CHEM, V275, P20829, DOI 10.1074/jbc.M001113200; de Rooij J, 1998, NATURE, V396, P474, DOI 10.1038/24884; de Rooij J, 1999, J BIOL CHEM, V274, P38125, DOI 10.1074/jbc.274.53.38125; De Vries L, 2000, ANNU REV PHARMACOL, V40, P235, DOI 10.1146/annurev.pharmtox.40.1.235; Erlenbach I, 2001, J NEUROCHEM, V77, P1327, DOI 10.1046/j.1471-4159.2001.00344.x; Exton JH, 1996, ANNU REV PHARMACOL, V36, P481, DOI 10.1146/annurev.pa.36.040196.002405; Hanoune J, 2001, ANNU REV PHARMACOL, V41, P145, DOI 10.1146/annurev.pharmtox.41.1.145; Hollinger S, 2001, J NEUROCHEM, V79, P941, DOI 10.1046/j.1471-4159.2001.00629.x; Jin TG, 2001, J BIOL CHEM, V276, P30301, DOI 10.1074/jbc.M103530200; Kawasaki H, 1998, SCIENCE, V282, P2275, DOI 10.1126/science.282.5397.2275; Kawasaki H, 1998, P NATL ACAD SCI USA, V95, P13278, DOI 10.1073/pnas.95.22.13278; Kelley GG, 2001, EMBO J, V20, P743, DOI 10.1093/emboj/20.4.743; Kim YH, 1999, J BIOL CHEM, V274, P26127, DOI 10.1074/jbc.274.37.26127; Kimple RJ, 2001, J BIOL CHEM, V276, P29275, DOI 10.1074/jbc.M103208200; Lopez I, 2001, J BIOL CHEM, V276, P2758, DOI 10.1074/jbc.M008119200; Murthy SNP, 1999, P NATL ACAD SCI USA, V96, P11815, DOI 10.1073/pnas.96.21.11815; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; OFFERMANNS S, 1994, MOL PHARMACOL, V45, P890; PERALTA EG, 1988, NATURE, V334, P434, DOI 10.1038/334434a0; Rhee SG, 2001, ANNU REV BIOCHEM, V70, P281, DOI 10.1146/annurev.biochem.70.1.281; Ross EM, 2000, ANNU REV BIOCHEM, V69, P795, DOI 10.1146/annurev.biochem.69.1.795; Rumenapp U, 2001, J BIOL CHEM, V276, P2474, DOI 10.1074/jbc.M004957200; SCHMIDT M, 1995, J BIOL CHEM, V270, P19949, DOI 10.1074/jbc.270.34.19949; Schmidt M, 2000, J BIOL CHEM, V275, P32603, DOI 10.1074/jbc.M004784200; Schmidt M, 1998, J BIOL CHEM, V273, P7413, DOI 10.1074/jbc.273.13.7413; Schmidt M, 1996, N-S ARCH PHARMACOL, V354, P87, DOI 10.1007/BF00178707; Schmidt M, 2001, NAT CELL BIOL, V3, P1020, DOI 10.1038/ncb1101-1020; Snow BE, 1998, J BIOL CHEM, V273, P17749, DOI 10.1074/jbc.273.28.17749; Song C, 2001, J BIOL CHEM, V276, P2752, DOI 10.1074/jbc.M008324200; Traver S, 2000, BIOCHEM J, V350, P19, DOI 10.1042/0264-6021:3500019; Weernink PAO, 2000, J BIOL CHEM, V275, P10168, DOI 10.1074/jbc.275.14.10168; Wess J, 1996, CRIT REV NEUROBIOL, V10, P69, DOI 10.1615/CritRevNeurobiol.v10.i1.40	36	57	65	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 10	2002	277	19					16805	16813		10.1074/jbc.M112024200	http://dx.doi.org/10.1074/jbc.M112024200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	551MB	11877431	hybrid			2022-12-27	WOS:000175564500062
J	Grams, J; Morris, JC; Drew, ME; Wang, ZF; Englund, PT; Hajduk, SL				Grams, J; Morris, JC; Drew, ME; Wang, ZF; Englund, PT; Hajduk, SL			A trypanosome mitochondrial RNA polymerase is required for transcription and replication	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINETOPLAST DNA MINICIRCLES; ENCODE GUIDE RNAS; YEAST MITOCHONDRIAL; GENE-EXPRESSION; INTERFERENCE; BRUCEI; BACTERIOPHAGE-T3; ORGANIZATION; EVOLUTION; SEQUENCES	Understanding mitochondrial transcription is a requisite first step toward understanding the regulation of mitochondrial gene expression in kinetoplastids. Here we report the identification and functional characterization of a mitochondrial RNA polymerase (mtRNAP) from Trypanosoma brucei, the first trans-acting factor involved in kinetoplast mitochondrial transcription to be identified. Using sequences conserved among the catalytic domains of the single-subunit mtRNAPs, we were able to obtain a full-length sequence for a candidate mtRNAP from T. brucei. Sequence comparison indicates that it shares homology in its catalytic domain with other single-subunit mtRNAPs, including functionally conserved residues that are identical in all single-subunit RNAPs. We used RNA interference to functionally knock out the gene product to determine whether the candidate gene represents an mtRNAP. As predicted for a mitochondrial specific RNA polymerase, reduction of the gene product resulted in a specific decrease of mitochondrial versus nuclear transcripts. Additionally, similar to the mtRNAP of other organisms, the mtRNAP characterized here is involved in replication of the mitochondrial genome. Thus, based on sequence comparison and functional studies, we have cloned an mtRNAP from trypanosomes.	Univ Alabama Birmingham, Sch Med, Dept Biochem & Mol Genet, Birmingham, AL 35294 USA; Univ Alabama Birmingham, Sch Dent, Dept Biochem & Mol Genet, Birmingham, AL 35294 USA; Johns Hopkins Sch Med, Dept Biol Chem, Baltimore, MD 21205 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; Johns Hopkins University; Johns Hopkins Medicine	Hajduk, SL (corresponding author), Univ Alabama Birmingham, Sch Med, Dept Biochem & Mol Genet, Birmingham, AL 35294 USA.	shajduk@uab.edu	Drew, Mark/E-2993-2011	Wang, Zefeng/0000-0002-6605-3637; Morris, James/0000-0003-2515-5714	NIAID NIH HHS [AI21401] Funding Source: Medline; NIGMS NIH HHS [5T32GM08361, GM27608] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI021401, R21AI021401] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM027608, R01GM027608, T32GM008361] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alfonzo JD, 1997, NUCLEIC ACIDS RES, V25, P3751, DOI 10.1093/nar/25.19.3751; BASS B, 2001, NATURE, V411, P235; BENNE R, 1986, CELL, V46, P819, DOI 10.1016/0092-8674(86)90063-2; Cermakian N, 1997, J MOL EVOL, V45, P671, DOI 10.1007/PL00006271; Cermakian N, 1996, NUCLEIC ACIDS RES, V24, P648, DOI 10.1093/nar/24.4.648; Clement SL, 2001, GENE, V272, P209, DOI 10.1016/S0378-1119(01)00538-8; CUNNINGHAM I, 1977, J PROTOZOOL, V24, P325, DOI 10.1111/j.1550-7408.1977.tb00987.x; FEAGIN JE, 1985, NUCLEIC ACIDS RES, V13, P4577, DOI 10.1093/nar/13.12.4577; FEAGIN JE, 1988, MOL CELL BIOL, V8, P1259, DOI 10.1128/MCB.8.3.1259; Fire A, 1999, TRENDS GENET, V15, P358, DOI 10.1016/S0168-9525(99)01818-1; Grams J, 2000, EMBO J, V19, P5525, DOI 10.1093/emboj/19.20.5525; Gray MW, 1998, TRENDS MICROBIOL, V6, P1, DOI 10.1016/S0966-842X(97)01182-7; HAJDUK SL, 1998, MODIFICATION EDITING, P377; Hammond SM, 2001, NAT REV GENET, V2, P110, DOI 10.1038/35052556; IGLOI GL, 1992, CRIT REV PLANT SCI, V10, P525, DOI 10.1080/07352689209382326; JASMER DP, 1986, MOL BIOCHEM PARASIT, V18, P257, DOI 10.1016/0166-6851(86)90084-8; Klingbeil MM, 2001, PROTIST, V152, P255, DOI 10.1078/1434-4610-00066; Koslowsky DJ, 1997, MOL BIOCHEM PARASIT, V90, P81, DOI 10.1016/S0166-6851(97)00133-3; KOSTYUK DA, 1995, FEBS LETT, V369, P165, DOI 10.1016/0014-5793(95)00732-O; Lang BF, 1999, J EUKARYOT MICROBIOL, V46, P320, DOI 10.1111/j.1550-7408.1999.tb04611.x; Lang BF, 1997, NATURE, V387, P493, DOI 10.1038/387493a0; LEARN B, 1993, COLD SPRING HARB SYM, V58, P389, DOI 10.1101/SQB.1993.058.01.046; Lecrenier N, 2000, GENE, V246, P37, DOI 10.1016/S0378-1119(00)00107-4; Li CJ, 1997, J BIOL CHEM, V272, P20787, DOI 10.1074/jbc.272.33.20787; Li JN, 2001, MOL BIOCHEM PARASIT, V113, P261, DOI 10.1016/S0166-6851(01)00223-7; MASTERS BS, 1987, CELL, V51, P89, DOI 10.1016/0092-8674(87)90013-4; MICHELOTTI EF, 1987, J BIOL CHEM, V262, P927; MICHELOTTI EF, 1992, MOL BIOCHEM PARASIT, V54, P31, DOI 10.1016/0166-6851(92)90092-X; Ngo H, 1998, P NATL ACAD SCI USA, V95, P14687, DOI 10.1073/pnas.95.25.14687; NTAMBI JM, 1985, J BIOL CHEM, V260, P5574; OSUMIDAVIS PA, 1992, J MOL BIOL, V226, P37, DOI 10.1016/0022-2836(92)90122-Z; PATRA D, 1992, J MOL BIOL, V224, P307, DOI 10.1016/0022-2836(92)90996-W; POLLARD VW, 1990, CELL, V63, P783, DOI 10.1016/0092-8674(90)90144-4; READ LK, 1992, J BIOL CHEM, V267, P1123; SHAPIRO TA, 1995, ANNU REV MICROBIOL, V49, P117, DOI 10.1146/annurev.mi.49.100195.001001; Sharp PA, 2001, GENE DEV, V15, P485, DOI 10.1101/gad.880001; Shi HF, 2000, RNA, V6, P1069, DOI 10.1017/S1355838200000297; SIMPSON L, 1986, INT REV CYTOL, V99, P119; SOUSA R, 1993, NATURE, V364, P593, DOI 10.1038/364593a0; SOUSA R, 1995, EMBO J, V14, P4609, DOI 10.1002/j.1460-2075.1995.tb00140.x; STEINERT M, 1980, PLASMID, V3, P7, DOI 10.1016/S0147-619X(80)90030-X; Stuart K, 1997, MICROBIOL MOL BIOL R, V61, P105, DOI 10.1128/.61.1.105-120.1997; STURM NR, 1990, CELL, V61, P879, DOI 10.1016/0092-8674(90)90198-N; Tuschl T, 2001, CHEMBIOCHEM, V2, P239, DOI 10.1002/1439-7633(20010401)2:4<239::AID-CBIC239>3.0.CO;2-R; VANDERSPEK H, 1991, EMBO J, V10, P1217, DOI 10.1002/j.1460-2075.1991.tb08063.x; Wang ZF, 2001, EMBO J, V20, P4674, DOI 10.1093/emboj/20.17.4674; Wang ZF, 2000, J BIOL CHEM, V275, P40174, DOI 10.1074/jbc.M008405200; Woody AYM, 1996, BIOCHEMISTRY-US, V35, P144, DOI 10.1021/bi952037f; ZOMERDIJK JCBM, 1990, EMBO J, V9, P2791, DOI 10.1002/j.1460-2075.1990.tb07467.x	49	49	49	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 10	2002	277	19					16952	16959		10.1074/jbc.M200662200	http://dx.doi.org/10.1074/jbc.M200662200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	551MB	11859084	hybrid			2022-12-27	WOS:000175564500082
J	Jeong, ST; Kim, HK; Kim, SJ; Chi, SW; Pan, JG; Oh, TK; Ryu, SE				Jeong, ST; Kim, HK; Kim, SJ; Chi, SW; Pan, JG; Oh, TK; Ryu, SE			Novel zinc-binding center and a temperature switch in the Bacillus stearothermophilus L1 lipase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THERMOSTABLE LIPASE; CRYSTAL-STRUCTURE; OPEN CONFORMATION; ESCHERICHIA-COLI; THERMOALKALOPHILIC LIPASE; THERMOPHILIC LIPASE; PSEUDOMONAS-CEPACIA; GENE CLONING; PURIFICATION; THERMOCATENULATUS	The bacterial thermoalkalophilic lipases optimally hydrolyze saturated fatty acids at elevated temperatures. They also have significant sequence homology with staphylococcal lipases, and both the thermoalkalophilic and staphylococcal lipases are grouped as the lipase family 1.5. We report here the first crystal structure of the lipase family 1.5, the structure of a thermoalkalophilic lipase from Bacillus stearothermophilus L1 (L1 lipase) determined at 2.0-Angstrom resolution. The structure is in a closed conformation, and the active site is buried under a long lid helix. Unexpectedly, the structure exhibits a zinc-binding site in an extra domain that accounts for the larger molecular size of the family 1.5 enzymes in comparison to other microbial lipases. The zinc-coordinated extra domain makes tight interactions with the loop extended from the C terminus of the lid helix, suggesting that the activation of the family 1.5 lipases may be regulated by the strength of the interactions. The unusually long lid helix makes strong hydrophobic interactions with its neighbors. The structural information together with previous biochemical observations indicate that the temperature-mediated lid opening is triggered by the thermal dissociation of the hydrophobic interactions.	Korea Res Inst Biosci & Biotechnol, Ctr Cellular Switch Prot Struct, Yusong Gu 305806, Daejon, South Korea	Korea Research Institute of Bioscience & Biotechnology (KRIBB)	Ryu, SE (corresponding author), Korea Res Inst Biosci & Biotechnol, Ctr Cellular Switch Prot Struct, 52 Euh Eun Dong, Yusong Gu 305806, Daejon, South Korea.							Abrahams JP, 1996, ACTA CRYSTALLOGR D, V52, P30, DOI 10.1107/S0907444995008754; BARTON GJ, 1993, PROTEIN ENG, V6, P37, DOI 10.1093/protein/6.1.37; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CAFLISCH A, 1995, J MOL BIOL, V252, P672, DOI 10.1006/jmbi.1995.0528; Carson M, 1997, METHOD ENZYMOL, V277, P493, DOI 10.1016/S0076-6879(97)77027-7; Cho AR, 2000, FEMS MICROBIOL LETT, V186, P235, DOI 10.1016/S0378-1097(00)00150-6; CHUNG GH, 1991, APPL MICROBIOL BIOT, V35, P237; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; DEVEER AM, 1992, THESIS RIJKSUNIVERSI; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; Fujii T, 1996, NAT STRUCT BIOL, V3, P834, DOI 10.1038/nsb1096-834; GROCHULSKI P, 1993, J BIOL CHEM, V268, P12843; Jaeger KE, 1999, ANNU REV MICROBIOL, V53, P315, DOI 10.1146/annurev.micro.53.1.315; Jakob U, 2000, J BIOL CHEM, V275, P38302, DOI 10.1074/jbc.M005957200; Jeong ST, 2001, ACTA CRYSTALLOGR D, V57, P1300, DOI 10.1107/S0907444901010332; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kim HK, 1998, BIOSCI BIOTECH BIOCH, V62, P66, DOI 10.1271/bbb.62.66; Kim KK, 1997, STRUCTURE, V5, P173, DOI 10.1016/S0969-2126(97)00177-9; Kim MH, 2000, BIOSCI BIOTECH BIOCH, V64, P280, DOI 10.1271/bbb.64.280; Kim MH, 2000, J MICROBIOL BIOTECHN, V10, P764; Kim SJ, 2001, NAT STRUCT BIOL, V8, P459, DOI 10.1038/87639; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Lang D, 1996, J MOL BIOL, V259, P704, DOI 10.1006/jmbi.1996.0352; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Leslie AGW, 1999, ACTA CRYSTALLOGR D, V55, P1696, DOI 10.1107/S090744499900846X; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Nardini M, 2000, J BIOL CHEM, V275, P31219, DOI 10.1074/jbc.M003903200; NOBEL MEM, 1993, FEBS LETT, V331, P123; Oh BC, 1999, FEMS MICROBIOL LETT, V179, P385, DOI 10.1016/S0378-1097(99)00439-5; RABINDRAN SK, 1993, SCIENCE, V259, P230, DOI 10.1126/science.8421783; Rosenstein R, 2000, BIOCHIMIE, V82, P1005, DOI 10.1016/S0300-9084(00)01180-9; Rua ML, 1998, APPL MICROBIOL BIOT, V49, P405, DOI 10.1007/s002530051190; SCHMIDTDANNERT C, 1994, BBA-LIPID LIPID MET, V1214, P43, DOI 10.1016/0005-2760(94)90008-6; SchmidtDannert C, 1997, METHOD ENZYMOL, V284, P194; Schrag JD, 1997, STRUCTURE, V5, P187, DOI 10.1016/S0969-2126(97)00178-0; Simons JWFA, 1999, BIOCHEMISTRY-US, V38, P2, DOI 10.1021/bi981869l; Sinchaikul S, 2001, BIOCHEM BIOPH RES CO, V283, P868, DOI 10.1006/bbrc.2001.4854; SUGIHARA A, 1992, J BIOCHEM, V112, P598, DOI 10.1093/oxfordjournals.jbchem.a123946; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673	39	83	85	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 10	2002	277	19					17041	17047		10.1074/jbc.M200640200	http://dx.doi.org/10.1074/jbc.M200640200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	551MB	11859083	hybrid			2022-12-27	WOS:000175564500093
J	Kostic, TS; Tomic, M; Andric, SA; Stojilkovic, SS				Kostic, TS; Tomic, M; Andric, SA; Stojilkovic, SS			Calcium-independent and cAMP-dependent modulation of soluble guanylyl cyclase activity by G protein-coupled receptors in pituitary cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE SYNTHASE; INTRACELLULAR CA2+ CONCENTRATION; CORTICOTROPIN-RELEASING FACTOR; PURIFIED RAT SOMATOTROPHS; GROWTH-HORMONE SECRETION; KINASE-C; PHOSPHORYLATION; EXPRESSION; GLAND; GONADOTROPHS	It is well established that G protein-coupled receptors stimulate nitric oxide-sensitive soluble guanylyl cyclase by increasing intracellular Ca2+ and activating Ca2+-dependent nitric-oxide synthases. In pituitary cells receptors that stimulated adenylyl cyclase, growth hormone-releasing hormone, corticotropin-releasing factor, and thyrotropin-releasing hormone also stimulated calcium signaling and increased cGMP levels, whereas receptors that inhibited adenylyl cyclase, endothelin-A, and dopamine-2 also inhibited spontaneous calcium transients and decreased cGMP levels. However, receptor-controlled up- and down-regulation of cyclic nucleotide accumulation was not blocked by abolition of Ca2+ signaling, suggesting that cAMP production affects cGMP accumulation. Agonist-induced cGMP accumulation was observed in cells incubated in the presence of various phosphodiesterase and soluble guanylyl cyclase inhibitors, confirming that G(s)-coupled receptors stimulated de novo cGMP production. Furthermore, cholera toxin (an activator of G(s)), forskolin (an activator of adenylyl cyclase), and 8-Br-cAMP (a permeable cAMP analog) mimicked the stimulatory action of G(s)-coupled receptors on cGMP production. Basal, agonist-, cholera toxin-, and forskolin-stimulated cGMP production, but not cAMP production, was significantly reduced in cells treated with H89, a protein kinase A inhibitor. These results indicate that coupling seven plasma membrane-domain receptors to an adenylyl cyclase signaling pathway provides an additional calcium-independent and cAMP-dependent mechanism for modulating soluble guanylyl cyclase activity in pituitary cells.	NICHHD, Sect Cellular Signaling, ERRB, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Stojilkovic, SS (corresponding author), NICHHD, Sect Cellular Signaling, ERRB, NIH, Bldg 49,Room 6A-36,49 convent Dr, Bethesda, MD 20892 USA.	stankos@helix.nih.gov	Kostic, Tatjana S/H-4038-2012; Tomic, Melanija/C-3371-2016	Andric, Silvana/0000-0002-2908-8136; Kostic, Tatjana/0000-0003-3440-8998	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD000195] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD000195] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ABOUSAMRA AB, 1987, J BIOL CHEM, V262, P1129; ALLGEIER A, 1994, J BIOL CHEM, V269, P13733; Andric SA, 2001, J BIOL CHEM, V276, P844, DOI 10.1074/jbc.M004406200; ANTONI FA, 1989, BIOCHEM BIOPH RES CO, V158, P824, DOI 10.1016/0006-291X(89)92796-4; BEAVO JA, 1995, PHYSIOL REV, V75, P725, DOI 10.1152/physrev.1995.75.4.725; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; Bluet-Pajot MT, 1998, CELL MOL NEUROBIOL, V18, P101, DOI 10.1023/A:1022579327647; BREDT DS, 1992, J BIOL CHEM, V267, P10976; Bugajski J, 1998, J PHYSIOL PHARMACOL, V49, P607; BURRIS TP, 1991, EUR J PHARMACOL, V198, P223, DOI 10.1016/0014-2999(91)90627-3; Butt E, 2000, J BIOL CHEM, V275, P5179, DOI 10.1074/jbc.275.7.5179; CECCATELLI S, 1993, P NATL ACAD SCI USA, V90, P11292, DOI 10.1073/pnas.90.23.11292; Christopoulos A, 1998, LIFE SCI, V64, P1, DOI 10.1016/S0024-3205(98)00348-8; Conti M, 2000, MOL ENDOCRINOL, V14, P1317, DOI 10.1210/me.14.9.1317; Dimmeler S, 1999, NATURE, V399, P601, DOI 10.1038/21224; Freeman ME, 2000, PHYSIOL REV, V80, P1523, DOI 10.1152/physrev.2000.80.4.1523; Fulton D, 1999, NATURE, V399, P597, DOI 10.1038/21218; Garrel G, 1998, ENDOCRINOLOGY, V139, P2163, DOI 10.1210/en.139.4.2163; GARTHWAITE J, 1995, MOL PHARMACOL, V48, P184; GRIFFITH OW, 1995, ANNU REV PHYSIOL, V57, P707, DOI 10.1146/annurev.ph.57.030195.003423; GUERINEAU N, 1991, ENDOCRINOLOGY, V129, P409, DOI 10.1210/endo-129-1-409; Hinkle PM, 1996, TRENDS ENDOCRIN MET, V7, P370, DOI 10.1016/S1043-2760(96)00188-9; IMAI T, 1992, BIOMED RES-TOKYO, V13, P371, DOI 10.2220/biomedres.13.371; KANYICSKA B, 1993, AM J PHYSIOL, V265, pE601, DOI 10.1152/ajpendo.1993.265.4.E601; KATO M, 1992, ENDOCRINOLOGY, V131, P2133, DOI 10.1210/en.131.5.2133; Koshimizu T, 2000, ENDOCRINOLOGY, V141, P4091, DOI 10.1210/en.141.11.4091; Kostic TS, 2001, MOL ENDOCRINOL, V15, P1010, DOI 10.1210/me.15.6.1010; KURYSHEV YA, 1995, ENDOCRINOLOGY, V136, P3925, DOI 10.1210/en.136.9.3925; Kwiecien R, 1997, J PHYSIOL-LONDON, V499, P613, DOI 10.1113/jphysiol.1997.sp021954; LOUIS JC, 1993, BIOCHIM BIOPHYS ACTA, V1177, P299, DOI 10.1016/0167-4889(93)90126-A; Lozach A, 1998, MOL CELL ENDOCRINOL, V143, P43, DOI 10.1016/S0303-7207(98)00135-X; Lucas KA, 2000, PHARMACOL REV, V52, P375; LUSSIER BT, 1991, ENDOCRINOLOGY, V128, P570, DOI 10.1210/endo-128-1-570; LUSSIER BT, 1991, ENDOCRINOLOGY, V128, P592, DOI 10.1210/endo-128-1-592; Missale C, 1998, PHYSIOL REV, V78, P189, DOI 10.1152/physrev.1998.78.1.189; NAUMOV AP, 1994, PFLUG ARCH EUR J PHY, V427, P414, DOI 10.1007/BF00374255; OHTA K, 1993, J ENDOCRINOL, V138, P429, DOI 10.1677/joe.0.1380429; Olesen SP, 1998, BRIT J PHARMACOL, V123, P299, DOI 10.1038/sj.bjp.0701603; Parkinson SJ, 1999, BIOCHEMISTRY-US, V38, P6441, DOI 10.1021/bi990154v; Rybalkin SD, 2002, J BIOL CHEM, V277, P3310, DOI 10.1074/jbc.M106562200; SAMSON WK, 1992, BIOCHEM BIOPH RES CO, V187, P590, DOI 10.1016/0006-291X(92)91235-I; STOJILKOVIC SS, 1992, ENDOCRINOLOGY, V130, P465, DOI 10.1210/en.130.1.465; Stojilkovic SS, 2000, PRINCIPLES OF MOLECULAR REGULATION, P149; TAKANO K, 1996, AM J PHYSIOL, V270, pE1014; Tomic M, 1999, J NEUROSCI, V19, P7721; Tsumori W, 1999, J NEUROENDOCRINOL, V11, P451; Vankelecom H, 1997, J HISTOCHEM CYTOCHEM, V45, P847, DOI 10.1177/002215549704500609; VESELY DL, 1985, MOL CELL BIOCHEM, V66, P145; WOLFF D, 1992, BIOCHEM J, V128, P201; Xu X, 1997, CELL CALCIUM, V22, P217, DOI 10.1016/S0143-4160(97)90015-4; Xu XY, 2000, BIOCHEM PHARMACOL, V59, P509, DOI 10.1016/S0006-2952(99)00352-4; Zagotta WN, 1996, ANNU REV NEUROSCI, V19, P235, DOI 10.1146/annurev.ne.19.030196.001315; ZWILLER J, 1985, J BIOL CHEM, V260, P1350; ZWILLER J, 1981, BIOCHEM BIOPH RES CO, V101, P1381, DOI 10.1016/0006-291X(81)91600-4	54	18	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 10	2002	277	19					16412	16418		10.1074/jbc.M112439200	http://dx.doi.org/10.1074/jbc.M112439200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	551MB	11867632	hybrid			2022-12-27	WOS:000175564500011
J	Lesieur, C; Cliff, MJ; Carter, R; James, RFL; Clarke, AR; Hirst, TR				Lesieur, C; Cliff, MJ; Carter, R; James, RFL; Clarke, AR; Hirst, TR			A kinetic model of intermediate formation during assembly of cholera toxin B-subunit pentamers	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-LABILE ENTEROTOXIN; ESCHERICHIA-COLI; CRYSTAL-STRUCTURE; GANGLIOSIDE GM1; MOLECULAR-BASIS; SECRETION; VACCINE	Cholera toxin is the most important virulence factor produced by Vibrio cholerae. The pentameric B-subunit of the toxin can bind to GM1-ganglioside receptors, leading to toxin entry into mammalian cells. Here, the in vitro disassembly and reassembly of CtxB(5) (the B subunit pentamer of cholera toxin) is investigated. When CtxB(5) was acidified at pH 1.0 and then neutralized, the B-subunits disassembled and could no longer migrate as SDS-stable pentamers on polyacrylamide gels or be captured by GM1. However, continued incubation at neutral pH resulted in the B-subunits regaining the capacity to be detected by GM1 enzyme-linked immunosorbent assay (t(1/2) similar to 8 min) and to migrate as SDS-stable pentamers (t(1/2) similar to 15 min). Time-dependent changes in Trp fluorescence intensity during B-subunit reassembly occurred with a half-time of similar to8 min, similar to that detected by GM1 enzyme-linked immunosorbent assay, suggesting that both methods monitor earlier events than B-pentamer formation alone. Based on the Trp fluorescence intensity measurements, a kinetic model of the pathway of CtxB(5) reassembly was generated that depended on trans to cis isomerization of Pro-93 to give an interface capable of subunit-subunit interaction. The model suggests formation of intermediates in the reaction, and these were successfully detected by glutaraldehyde cross-linking.	Univ Bristol, Sch Med Sci, Dept Pathol, Bristol BS8 1TD, Avon, England; Univ Leicester, Dept Surg, Leicester LE2 7LX, Leics, England; Univ Bristol, Sch Med Sci, Dept Microbiol, Bristol BS8 1TD, Avon, England; Univ Bristol, Sch Med Sci, Dept Biochem, Bristol BS8 1TD, Avon, England	University of Bristol; University of Leicester; University of Bristol; University of Bristol	Hirst, TR (corresponding author), Univ Bristol, Sch Med Sci, Dept Pathol, Bristol BS8 1TD, Avon, England.	T.R.Hirst@bristol.ac.uk		Cliff, Matthew/0000-0002-7482-0234				Aman AT, 2001, P NATL ACAD SCI USA, V98, P8536, DOI 10.1073/pnas.161273098; AMIN T, 1994, PROTEIN EXPRES PURIF, V5, P198, DOI 10.1006/prep.1994.1031; Bergerot I, 1997, P NATL ACAD SCI USA, V94, P4610, DOI 10.1073/pnas.94.9.4610; de Haan L, 2000, J NAT TOXINS, V9, P281; DEWOLF MJS, 1994, BBA-MOL CELL RES, V1223, P285, DOI 10.1016/0167-4889(94)90239-9; Falnes PO, 2000, CURR OPIN CELL BIOL, V12, P407, DOI 10.1016/S0955-0674(00)00109-5; Fersht A., 1999, STRUCTURE MECH PROTE, DOI 10.1142/10574; FINKELSTEIN RA, 1974, J IMMUNOL, V113, P145; FISHMAN PH, 1980, J BIOL CHEM, V255, P7657; FISHMAN PH, 1978, BIOCHEMISTRY-US, V17, P711, DOI 10.1021/bi00597a024; Galzitskaya OV, 2001, FEBS LETT, V489, P113, DOI 10.1016/S0014-5793(01)02092-0; HARDY SJS, 1988, P NATL ACAD SCI USA, V85, P7109, DOI 10.1073/pnas.85.19.7109; HIRST TR, 1984, J BACTERIOL, V157, P637, DOI 10.1128/JB.157.2.637-642.1984; Hirst TR, 1998, J APPL MICROBIOL, V84, p26S; HIRST TR, 1999, COMPREHENSIVE SOURCE, P104; HOLMGREN J, 1975, P NATL ACAD SCI USA, V72, P2520, DOI 10.1073/pnas.72.7.2520; Kaper JB, 1998, CURR OPIN MICROBIOL, V1, P103, DOI 10.1016/S1369-5274(98)80149-5; Lencer WI, 1999, BBA-MOL CELL RES, V1450, P177, DOI 10.1016/S0167-4889(99)00070-1; Lesieur C, 1997, MOL MEMBR BIOL, V14, P45, DOI 10.3109/09687689709068435; MEKALANOS JJ, 1983, NATURE, V306, P551, DOI 10.1038/306551a0; MEKALANOS JJ, 1985, CURR TOP MICROBIOL, V118, P97; NEILL RJ, 1983, SCIENCE, V221, P289, DOI 10.1126/science.6857285; PTITSYN OB, 1995, CURR OPIN STRUC BIOL, V5, P74, DOI 10.1016/0959-440X(95)80011-O; Reimer U, 1998, J MOL BIOL, V279, P449, DOI 10.1006/jmbi.1998.1770; Richards CM, 2001, J VIROL, V75, P1664, DOI 10.1128/JVI.75.4.1664-1671.2001; RUDDOCK LW, 1995, J BIOL CHEM, V270, P29953; Ruddock LW, 1996, J BIOL CHEM, V271, P19118, DOI 10.1074/jbc.271.32.19118; SIXMA TK, 1991, NATURE, V351, P371, DOI 10.1038/351371a0; SIXMA TK, 1993, J MOL BIOL, V230, P890, DOI 10.1006/jmbi.1993.1209; SUN JB, 1994, P NATL ACAD SCI USA, V91, P10795, DOI 10.1073/pnas.91.23.10795; Sun JB, 1996, P NATL ACAD SCI USA, V93, P7196, DOI 10.1073/pnas.93.14.7196; Widmann M, 2000, J BIOL CHEM, V275, P18619, DOI 10.1074/jbc.C000156200; Williams NA, 1997, P NATL ACAD SCI USA, V94, P5290, DOI 10.1073/pnas.94.10.5290; ZHANG RG, 1995, J MOL BIOL, V251, P563, DOI 10.1006/jmbi.1995.0456; ZHANG RG, 1995, J MOL BIOL, V251, P550, DOI 10.1006/jmbi.1995.0455	35	31	32	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 10	2002	277	19					16697	16704		10.1074/jbc.M110561200	http://dx.doi.org/10.1074/jbc.M110561200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	551MB	11877421	hybrid			2022-12-27	WOS:000175564500048
J	Surinya, HH; Molina, L; Soos, MA; Brand, J; Kristensen, C; Siddle, K				Surinya, HH; Molina, L; Soos, MA; Brand, J; Kristensen, C; Siddle, K			Role of insulin receptor dimerization domains in ligand binding, cooperativity, and modulation by anti-receptor antibodies	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALANINE-SCANNING MUTAGENESIS; FACTOR-I RECEPTORS; MONOCLONAL-ANTIBODIES; ALPHA-SUBUNIT; EXTRACELLULAR DOMAIN; STRUCTURAL BASIS; SPECIFICITY; IDENTIFICATION; DETERMINANTS; AFFINITY	To define the structures within the insulin receptor (IR) that are required for high affinity ligand binding, we have used IR fragments consisting of four amino-terminal domains (L1, cysteine-rich, L2, first fibronectin type III domain) fused to sequences encoded by exon 10 (including the carboxyl terminus of the alpha-subunit). The fragments contained one or both cysteine residues (amino acids 524 and 682) that form disulfides between alpha-subunits in native IR. A dimeric fragment designated IR593.CT (amino acids 1-593 and 704-719) bound I-125-insulin with high affinity comparable to detergent-solubilized wild. type IR and mIR.Fn0/Ex10 (amino acids 1-601 and 650-719) and greater than that of dimeric mIR.Fn0 (amino acids 1-601 and 704-719) and monomeric IR473.CT (amino acids 1-473 and 704-719). However, neither IR593.CT nor mIR.Fn0 exhibited negative cooperativity (a feature characteristic of the native insulin receptor and mIR.Fn0/Ex10), as shown by failure of unlabeled insulin to accelerate dissociation of bound I-125-insulin. Anti-receptor monoclonal antibodies that recognize epitopes in the first fibronectin type III domain (amino acids 471-593) and inhibit insulin binding to wild type IR inhibited insulin binding to mIR.Fn0/Ex10 but not IR593.CT or mIR.Fn0. We conclude the following: 1) precise positioning of the carboxyl-terminal sequence can be a critical determinant of binding affinity; 2) dimerization via the first fibronectin domain alone can contribute to high affinity ligand binding; and 3) the second dimerization domain encoded by exon 10 is required for ligand cooperativity and modulation by antibodies.	Univ Cambridge, Addenbrookes Hosp, Dept Clin Biochem, Cambridge CB2 2QR, England; Novo Nordisk AS, Insulin Res, DK-2880 Bagsvaerd, Denmark	Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; Novo Nordisk	Siddle, K (corresponding author), Univ Cambridge, Addenbrookes Hosp, Dept Clin Biochem, Hills Rd, Cambridge CB2 2QR, England.		Kristensen, Claus/O-8047-2015	Surinya, Kathy/0000-0003-0507-2962; Kristensen, Claus/0000-0002-2594-7722				ANDERSEN AS, 1992, J BIOL CHEM, V267, P13681; Bass J, 1996, J BIOL CHEM, V271, P19367, DOI 10.1074/jbc.271.32.19367; BONISCHNETZLER M, 1987, J BIOL CHEM, V262, P8395; Brandt J, 2001, J BIOL CHEM, V276, P12378, DOI 10.1074/jbc.M009402200; Cosgrove L, 1995, PROTEIN EXPRES PURIF, V6, P789, DOI 10.1006/prep.1995.0010; DEMEYTS P, 1994, DIABETOLOGIA, V37, P135; EBINA Y, 1985, P NATL ACAD SCI USA, V82, P8014, DOI 10.1073/pnas.82.23.8014; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FABRY M, 1992, J BIOL CHEM, V267, P8950; Garrett TPJ, 1998, NATURE, V394, P395, DOI 10.1038/28668; GUSTAFSON TA, 1990, J BIOL CHEM, V265, P18663; Hoyne PA, 2000, FEBS LETT, V479, P15, DOI 10.1016/S0014-5793(00)01872-X; KADOWAKI H, 1990, J BIOL CHEM, V265, P21285; KJELDSEN T, 1994, J BIOL CHEM, V269, P32942; Kristensen C, 1998, J BIOL CHEM, V273, P17780, DOI 10.1074/jbc.273.28.17780; Kristensen C, 1999, J BIOL CHEM, V274, P37351, DOI 10.1074/jbc.274.52.37351; KUROSE T, 1994, J BIOL CHEM, V269, P29190; Marino-Buslje C, 1998, FEBS LETT, V441, P331, DOI 10.1016/S0014-5793(98)01509-9; Marino-Buslje C, 1999, BIOCHEM SOC T, V27, P715, DOI 10.1042/bst0270715; MCCLAIN DA, 1987, J BIOL CHEM, V262, P14663; Molina L, 2000, FEBS LETT, V467, P226, DOI 10.1016/S0014-5793(00)01161-3; Mulhern TD, 1998, TRENDS BIOCHEM SCI, V23, P465, DOI 10.1016/S0968-0004(98)01288-2; Mynarcik DC, 1996, J BIOL CHEM, V271, P2439, DOI 10.1074/jbc.271.5.2439; Mynarcik DC, 1997, J BIOL CHEM, V272, P18650, DOI 10.1074/jbc.272.30.18650; SCHAFFER L, 1994, EUR J BIOCHEM, V221, P1127, DOI 10.1111/j.1432-1033.1994.tb18833.x; SCHAFFER L, 1992, BIOCHEM BIOPH RES CO, V189, P650, DOI 10.1016/0006-291X(92)92250-2; SCHUMACHER R, 1993, J BIOL CHEM, V268, P1087; Siddle K, 2001, BIOCHEM SOC T, V29, P513, DOI 10.1042/BST0290513; SIDDLE K, 1987, BIOCHEM SOC T, V15, P47, DOI 10.1042/bst0150047; SOOS MA, 1986, BIOCHEM J, V235, P199, DOI 10.1042/bj2350199; Sparrow LG, 1997, J BIOL CHEM, V272, P29460, DOI 10.1074/jbc.272.47.29460; SWEET LJ, 1987, J BIOL CHEM, V262, P6939; SWEET LJ, 1987, J BIOL CHEM, V262, P16730; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; Ward CW, 1999, GROWTH FACTORS, V16, P315, DOI 10.3109/08977199909069149; WHITTAKER J, 1994, MOL ENDOCRINOL, V8, P1521, DOI 10.1210/me.8.11.1521; WILLIAMS PF, 1995, J BIOL CHEM, V270, P3012, DOI 10.1074/jbc.270.7.3012; YAMAGUCHI Y, 1993, ENDOCRINOLOGY, V132, P1132, DOI 10.1210/en.132.3.1132; ZHANG B, 1991, P NATL ACAD SCI USA, V88, P9858, DOI 10.1073/pnas.88.21.9858; ZHANG B, 1991, BIOCHEMISTRY-US, V30, P5113, DOI 10.1021/bi00235a001	40	29	52	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 10	2002	277	19					16718	16725		10.1074/bjc.M112014200	http://dx.doi.org/10.1074/bjc.M112014200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	551MB	11875066				2022-12-27	WOS:000175564500051
J	Crider-Pirkle, S; Billingsley, P; Faust, C; Hardy, DM; Lee, V; Weitlauf, H				Crider-Pirkle, S; Billingsley, P; Faust, C; Hardy, DM; Lee, V; Weitlauf, H			Cubilin, a binding partner for galectin-3 in the murine utero-placental complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NATURAL-KILLER-CELLS; FACTOR-VITAMIN B-12; YOLK-SAC; TERATOGENIC ANTIBODIES; METRIAL GLAND; EPITHELIAL-CELLS; MEDIATED ENDOCYTOSIS; GLYCOPROTEIN 280; PROTEIN; RECEPTOR	Galectin-3 is a lectin important in animal development and regulatory processes and is found selectively localized at the implantation site of the mouse embryo. To better understand the role of galectin-3 at the maternal-fetal interface, a binding partner was isolated and characterized. Homogenates of uteroplacental tissue were incubated with immobilized recombinant galectin-3, and specifically bound proteins were eluted using lactose. The principal protein, p400, had an M-r of 400,000 in SDS-PAGE. Physical properties of p400 and amino acid sequences of seven tryptic peptides were similar to cubilin from rats, humans, and dogs, identifying p400 as the murine ortholog of cubilin. This was further supported by the tissue distribution observed only in yolk sac, kidney, and ileum with monospecific antiserum for p400. Cubilin occurred in yolk sac epithelium throughout pregnancy, but galectin-3 was there only during the last week. Unexpectedly, cubilin was found only in perforin-containing granules of uterine natural killer (uNK) cells, although galectin-3 occurred throughout the cell cytoplasm. In situ hybridization revealed cubilin mRNA in yolk sac epithelium but not uNK cells, implying that yolk sac-derived cubilin is endocytosed by uNK cells via galectin-3. This is consistent with cubilin being an endogenous partner of galectin-3 at the maternal-fetal interface and suggests an important role for cubilin in uNK cell function.	Texas Tech Univ, Hlth Sci Ctr, Dept Cell Biol & Biochem, Lubbock, TX 79430 USA; Texas Tech Univ, Hlth Sci Ctr, Dept Obstet & Gynecol, Lubbock, TX 79430 USA	Texas Tech University System; Texas Tech University; Texas Tech University Health Science Center; Texas Tech University System; Texas Tech University; Texas Tech University Health Science Center	Weitlauf, H (corresponding author), Texas Tech Univ, Hlth Sci Ctr, Dept Cell Biol & Biochem, 3601 4th St, Lubbock, TX 79430 USA.	harry.weitlauf@ttuhsc.edu	Hardy, Daniel/AAP-5823-2020	Hardy, Daniel/0000-0002-7297-3093	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD029801, R29HD035166] Funding Source: NIH RePORTER; NICHD NIH HHS [HD-35166, HD-29801, HD-07271] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		AGRWAL N, 1993, J BIOL CHEM, V268, P14932; BAUTMAN V, 1998, AM J PHYSIOL, V275, pF246; Birn H, 1997, J BIOL CHEM, V272, P26497, DOI 10.1074/jbc.272.42.26497; BORK P, 1993, J MOL BIOL, V231, P539, DOI 10.1006/jmbi.1993.1305; BRENT RL, 1990, TERATOLOGY, V41, P405, DOI 10.1002/tera.1420410406; BURKHARDT JK, 1990, J CELL BIOL, V111, P2327, DOI 10.1083/jcb.111.6.2327; CHERAYIL BJ, 1989, J EXP MED, V170, P1959, DOI 10.1084/jem.170.6.1959; Croy BA, 1996, NAT IMMUN, V15, P22; CROY BA, 1991, J REPROD IMMUNOL, V19, P149; CROY BA, 1991, CELL IMMUNOL, V133, P116, DOI 10.1016/0008-8749(91)90184-D; GAMBEL P, 1985, CELL IMMUNOL, V93, P303, DOI 10.1016/0008-8749(85)90136-4; Hammad SM, 2000, J BIOL CHEM, V275, P12003, DOI 10.1074/jbc.275.16.12003; Hammad SM, 1999, P NATL ACAD SCI USA, V96, P10158, DOI 10.1073/pnas.96.18.10158; Head JR, 1996, NAT IMMUN, V15, P7; Hickox JR, 2001, J BIOL CHEM, V276, P41502, DOI 10.1074/jbc.M106795200; JOLLIE WP, 1990, TERATOLOGY, V41, P361, DOI 10.1002/tera.1420410403; KAWASAKI A, 1990, INT IMMUNOL, V2, P677, DOI 10.1093/intimm/2.7.677; KNISLEY KA, 1993, J REPROD FERTIL, V97, P521; Kozyraki R, 1999, NAT MED, V5, P656, DOI 10.1038/9504; Kozyraki R, 2001, P NATL ACAD SCI USA, V98, P12491, DOI 10.1073/pnas.211291398; Kristiansen M, 1999, J BIOL CHEM, V274, P20540, DOI 10.1074/jbc.274.29.20540; Kusakabe K, 1999, J VET MED SCI, V61, P947, DOI 10.1292/jvms.61.947; Kusakabe K, 1999, J VET MED SCI, V61, P1093, DOI 10.1292/jvms.61.1093; Lee VH, 1998, BIOL REPROD, V58, P1277, DOI 10.1095/biolreprod58.5.1277; LePanse S, 1997, EUR J CELL BIOL, V72, P257; LEPANSE S, 1994, AM J PATHOL, V145, P1526; LePanse S, 1997, EXP NEPHROL, V5, P375; LLOYD JB, 1990, TERATOLOGY, V41, P383, DOI 10.1002/tera.1420410404; Moestrup SK, 1998, J BIOL CHEM, V273, P5235, DOI 10.1074/jbc.273.9.5235; PARR EL, 1990, J IMMUNOL, V145, P2365; PARR EL, 1987, BIOL REPROD, V37, P1327, DOI 10.1095/biolreprod37.5.1327; Perillo NL, 1998, J MOL MED, V76, P402, DOI 10.1007/s001090050232; Phillips B, 1996, BIOL REPROD, V55, P548, DOI 10.1095/biolreprod55.3.548; SAHALI D, 1992, AM J PATHOL, V140, P33; SAHALI D, 1988, J EXP MED, V167, P213, DOI 10.1084/jem.167.1.213; SAHALI D, 1993, AM J PATHOL, V142, P1654; Seetharam B, 1997, J CLIN INVEST, V99, P2317, DOI 10.1172/JCI119411	37	24	26	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 3	2002	277	18					15904	15912		10.1074/jbc.M200331200	http://dx.doi.org/10.1074/jbc.M200331200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	550PA	11856751	hybrid			2022-12-27	WOS:000175510400093
J	Sato, O; Kuriki, C; Fukui, Y; Motojima, K				Sato, O; Kuriki, C; Fukui, Y; Motojima, K			Dual promoter structure of mouse and human fatty acid translocase/CD36 genes and unique transcriptional activation by peroxisome proliferator-activated receptor alpha and gamma ligands	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PPAR-GAMMA; SCAVENGER RECEPTOR; INSULIN-RESISTANCE; SR-BI; CD36; EXPRESSION; IDENTIFICATION; DIFFERENTIATION; BINDING; RAT	Fatty acid translocase (FAT)/CD36 is a glycoprotein involved in multiple membrane functions including uptake of long-chain fatty acids and oxidized low density lipoprotein. In mice, expression of the gene is regulated by peroxisome proliferator-activated receptor (PPAR) alpha in the liver and by PPARgamma in the adipose tissues (Motojima, K., Passilly, P. P., Peters, J. M., Gonzalez, F. J., and Latruffe, N. (1998) J. Biol. Chem. 273, 16710-16714). However, the time course of PPARalpha ligand-induced expression of FAT/CD36 in the liver, and also in the cultured hepatoma cells, is significantly slower than those of other PPARalpha target genes. To study the molecular mechanism of the slow transcriptional activation of the gene by a PPAR ligand, we first cloned the 5' ends of the mRNA and then the mouse gene promoter region from a genomic bacterial artificial chromosome library. Sequencing analyses showed that transcription of the gene starts at two initiation sites 16 kb apart and splicing occurs alternatively, producing at least three mRNA species with different 5'-noneoding regions. The PPARalpha ligand-responsive promoter in the liver was identified as the new upstream promoter where we found several possible binding sites for lipid metabolism-related transcriptional factors but not for PPAR. Neither promoter responded to a PPARalpha ligand in the in vitro or in vivo reporter assays using cultured hepatoma cells and the liver of living mice. We also have cloned the human FAT/CD36 gene from a bacterial artificial chromosome library and identified a new independent promoter that is located 13 kb upstream of the previously reported promoter. Only the upstream promoter responded to PPARalpha and PPARgamma ligands in a cell type-specific manner. The absence of PPRE in the responding upstream promoter region, the delayed activation by the ligand, and the results of the reporter assays all suggested that transcriptional activation of the FAT/CD36 gene by PPAR ligands is indirectly dependent on PPAR.	Meiji Pharmaceut Univ, Dept Biochem, Tokyo 2048588, Japan; Toho Univ, Sch Pharmaceut Sci, Dept Biochem, Chiba 2748510, Japan	Meiji Pharmaceutical University; Toho University	Motojima, K (corresponding author), Meiji Pharmaceut Univ, Dept Biochem, Noshio 2-522-1, Tokyo 2048588, Japan.	motojima@my-pharm.ac.jp						Abumrad N, 1998, J LIPID RES, V39, P2309; ABUMRAD NA, 1993, J BIOL CHEM, V268, P17665; Acton S, 1996, SCIENCE, V271, P518, DOI 10.1126/science.271.5248.518; Aitman TJ, 1999, NAT GENET, V21, P76, DOI 10.1038/5013; Aoyama T, 1998, J BIOL CHEM, V273, P5678, DOI 10.1074/jbc.273.10.5678; ARMESILLA AL, 1994, J BIOL CHEM, V269, P18985; ASCH AS, 1987, J CLIN INVEST, V79, P1054, DOI 10.1172/JCI112918; Chawla A, 2001, NAT MED, V7, P48, DOI 10.1038/83336; Chinetti G, 2001, NAT MED, V7, P53, DOI 10.1038/83348; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Dawson DW, 1997, J CELL BIOL, V138, P707, DOI 10.1083/jcb.138.3.707; DEVILLIERS WJS, 1994, J EXP MED, V180, P705, DOI 10.1084/jem.180.2.705; ENDEMANN G, 1993, J BIOL CHEM, V268, P11811; Espinosa JM, 2001, MOL CELL, V8, P57, DOI 10.1016/S1097-2765(01)00283-0; Febbraio M, 1999, J BIOL CHEM, V274, P19055, DOI 10.1074/jbc.274.27.19055; Fukui Y, 2000, DIABETES, V49, P759, DOI 10.2337/diabetes.49.5.759; Fukuwatari T, 1997, FEBS LETT, V414, P461, DOI 10.1016/S0014-5793(97)01055-7; GREENWALT DE, 1992, BLOOD, V80, P1105; Griffin E, 2001, NAT MED, V7, P840, DOI 10.1038/89969; Hsu MH, 2001, J BIOL CHEM, V276, P27950, DOI 10.1074/jbc.M100258200; Iizuka Y, 2001, LANCET, V358, P243, DOI 10.1016/S0140-6736(01)05429-0; JugeAubry C, 1997, J BIOL CHEM, V272, P25252, DOI 10.1074/jbc.272.40.25252; KODAMA T, 1988, P NATL ACAD SCI USA, V85, P9238, DOI 10.1073/pnas.85.23.9238; LAKE BG, 1989, TOXICOL APPL PHARM, V99, P148, DOI 10.1016/0041-008X(89)90120-8; Lazar MA, 2001, NAT MED, V7, P23, DOI 10.1038/83301; Li AC, 2000, J CLIN INVEST, V106, P523, DOI 10.1172/JCI10370; LI YS, 1993, MOL CELL BIOCHEM, V126, P61, DOI 10.1007/BF01772208; Miyaoka K, 2001, LANCET, V357, P686, DOI 10.1016/S0140-6736(00)04138-6; Moore KJ, 2001, NAT MED, V7, P41, DOI 10.1038/83328; MOTOJIMA K, 1993, CELL STRUCT FUNCT, V18, P267, DOI 10.1247/csf.18.267; Motojima K, 1998, J BIOL CHEM, V273, P16710, DOI 10.1074/jbc.273.27.16710; Motojima K, 1997, BIOCHIMIE, V79, P101, DOI 10.1016/S0300-9084(97)81498-8; MOULTON KS, 1992, P NATL ACAD SCI USA, V89, P8102, DOI 10.1073/pnas.89.17.8102; Nagy L, 1998, CELL, V93, P229, DOI 10.1016/S0092-8674(00)81574-3; Osada S, 1996, ANN NY ACAD SCI, V804, P706, DOI 10.1111/j.1749-6632.1996.tb18674.x; Pravenec M, 2001, NAT GENET, V27, P156, DOI 10.1038/84777; REN Y, 1995, J EXP MED, V181, P1857, DOI 10.1084/jem.181.5.1857; RIGOTTI A, 1995, J BIOL CHEM, V270, P16221, DOI 10.1074/jbc.270.27.16221; TALLE MA, 1983, CELL IMMUNOL, V78, P83, DOI 10.1016/0008-8749(83)90262-9; Tanaka T, 2001, J LIPID RES, V42, P751; TANDON NN, 1989, J BIOL CHEM, V264, P7576; TANG YL, 1994, J BIOL CHEM, V269, P6011; TAYLOR KT, 1993, GENE, V133, P205, DOI 10.1016/0378-1119(93)90639-K; Tontonoz P, 1998, CELL, V93, P241, DOI 10.1016/S0092-8674(00)81575-5; Yesner LM, 1996, ARTERIOSCL THROM VAS, V16, P1019, DOI 10.1161/01.ATV.16.8.1019	45	126	135	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 3	2002	277	18					15703	15711		10.1074/jbc.M110158200	http://dx.doi.org/10.1074/jbc.M110158200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	550PA	11867619	hybrid			2022-12-27	WOS:000175510400066
J	Mashima, R; Tilley, L; Siomos, MA; Papalexis, V; Raftery, MJ; Stocker, R				Mashima, R; Tilley, L; Siomos, MA; Papalexis, V; Raftery, MJ; Stocker, R			Plasmodium falciparum histidine-rich protein-2 (PfHRP2) modulates the redox activity of ferri-protoporphyrin IX (FePPIX) - Peroxidase-like activity of the PfHRP2-FePPIX complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VINCKEI-INFECTED ERYTHROCYTES; PROSTAGLANDIN-H SYNTHASE; ASCORBIC-ACID CONTENT; MALARIA PARASITE; LINOLEATE HYDROPEROXIDES; HORSERADISH-PEROXIDASE; HEMOGLOBIN DEGRADATION; OXIDATIVE STRESS; HEME-BINDING; PLASMA	Histidine-rich protein-2 from Plasmodium falciparum (PfHRP2) binds up to 50 molecules of ferri-protoporphyrin IX (FePPIX) (Choi, C. Y., Cerda, J. F., Chu, H. A., Babcock, G. T., and Marletta, M. A. (1999) Biochemistry 38, 16916-16924). We reasoned that the PfHRP2-FePPIX complex has antioxidant properties that could be beneficial to the parasite. Therefore, we examined whether binding to PfHRP2 modulated the redox properties of FePPIX. We observed that PfHRP2 completely inhibited the auto-oxidation of ascorbate mediated by free Fe-PIX We also investigated the peroxidase activity of PfHRP2-FePPIX using 13-hydroperoxy-9,11-octadienoate (18:2-OOH) as substrate. Reaction of PfHRP2-FePPIX with 18:2-OOH in the presence of added reducing agents gave 13-hydroxy-9,11-octadienoate (18:2-OH) as a major product and 13-keto-9,11-octadienoate (18:2=O) and 9,12,13-trihydroxy-10-octadecaenoate as minor products. Binding of FePPIX to PfHRP2 lowered the rate of decomposition of 18:2-OOH and increased the 18:2-OH to 18:2=O ratio. Similar to other authentic peroxidases, phenols, amines, and biological reductants like ascorbate promoted 18:2-OH production, and NaCN inhibited 18:2-OH production. Thioanisole also acted as a reductant and was converted to thioanisole sulfoxide, suggesting formation of compound I during the reaction. These data show that PfHRP2 modulates the redox activity of FePPIX and that the PfHRP2-FePPIX complex may have previously unrecognized antioxidant properties.	Heart Res Inst, Biochem Grp, Camperdown, NSW 2050, Australia; La Trobe Univ, Dept Biochem, Bundoora, Vic 3086, Australia; Univ New S Wales, Sch Pathol, Cytokine Res Unit, Kensington, NSW 2052, Australia	University of Sydney; Heart Research Institute; La Trobe University; University of New South Wales Sydney	Stocker, R (corresponding author), Univ New S Wales, Sch Med Sci, Ctr Thrombosis & Vasc Res, Sydney, NSW 2052, Australia.		Tilley, Leann/AAU-5281-2020; Stocker, Roland/AAV-4489-2021	Tilley, Leann/0000-0001-9910-0199				BUETTNER GR, 1988, J BIOCHEM BIOPH METH, V16, P27, DOI 10.1016/0165-022X(88)90100-5; CHAN HWS, 1977, LIPIDS, V12, P99, DOI 10.1007/BF02532979; Choi CYH, 1999, BIOCHEMISTRY-US, V38, P16916, DOI 10.1021/bi991665k; CHOU AC, 1981, J CLIN INVEST, V68, P672, DOI 10.1172/JCI110302; DEMONTELLANO PRO, 1987, BIOCHEMISTRY-US, V26, P5310, DOI 10.1021/bi00391a014; DEMONTELLANO PRO, 1985, J BIOL CHEM, V260, P9265; DIX TA, 1985, J BIOL CHEM, V260, P5351; Dunford H. B, 1999, HEME PEROXIDASES, P1; Egawa T, 2000, J BIOL CHEM, V275, P34858, DOI 10.1074/jbc.M004026200; Francis SE, 1997, ANNU REV MICROBIOL, V51, P97, DOI 10.1146/annurev.micro.51.1.97; GOLDBERG DE, 1990, P NATL ACAD SCI USA, V87, P2931, DOI 10.1073/pnas.87.8.2931; Green MD, 1996, MOL BIOCHEM PARASIT, V83, P183, DOI 10.1016/S0166-6851(96)02769-7; HARRIS RZ, 1993, J BIOL CHEM, V268, P1637; HOWARD RJ, 1986, J CELL BIOL, V103, P1269, DOI 10.1083/jcb.103.4.1269; HUNT NH, 1990, BLOOD CELLS, V16, P499; Landino LM, 1997, J BIOL CHEM, V272, P21565, DOI 10.1074/jbc.272.34.21565; Loria P, 1999, BIOCHEM J, V339, P363, DOI 10.1042/0264-6021:3390363; Lynn A, 1999, FEBS LETT, V459, P267, DOI 10.1016/S0014-5793(99)01260-0; Marnett Lawrence J., 1995, P49; Mashima R, 2000, J LIPID RES, V41, P109; Mashima R, 1998, J LIPID RES, V39, P1133; PANTON LJ, 1989, MOL BIOCHEM PARASIT, V35, P149, DOI 10.1016/0166-6851(89)90117-5; Papalexis V, 2001, MOL BIOCHEM PARASIT, V115, P77, DOI 10.1016/S0166-6851(01)00271-7; PARRA ME, 1991, J CLIN MICROBIOL, V29, P1629, DOI 10.1128/JCM.29.8.1629-1634.1991; PLE P, 1989, J BIOL CHEM, V264, P13983; POULOS TL, 1980, J BIOL CHEM, V255, P8199; SAMOKYSZYN VM, 1987, J BIOL CHEM, V262, P14119; STOCKER R, 1986, BIOCHIM BIOPHYS ACTA, V876, P294, DOI 10.1016/0005-2760(86)90287-0; STOCKER R, 1986, BIOCHIM BIOPHYS ACTA, V881, P391, DOI 10.1016/0304-4165(86)90031-0; STOCKER R, 1987, LIPIDS, V22, P51, DOI 10.1007/BF02534875; STOCKER R, 1985, P NATL ACAD SCI USA, V82, P548, DOI 10.1073/pnas.82.2.548; Sullivan DJ, 1996, SCIENCE, V271, P219, DOI 10.1126/science.271.5246.219; TAPPEL AL, 1953, ARCH BIOCHEM BIOPHYS, V44, P378, DOI 10.1016/0003-9861(53)90056-3; WELLEMS TE, 1986, P NATL ACAD SCI USA, V83, P6065, DOI 10.1073/pnas.83.16.6065; Ziegler J, 1999, J AM CHEM SOC, V121, P2395, DOI 10.1021/ja983220+	35	18	18	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 26	2002	277	17					14514	14520		10.1074/jbc.M109386200	http://dx.doi.org/10.1074/jbc.M109386200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	545EH	11859069	hybrid			2022-12-27	WOS:000175203000023
J	Zurovec, M; Sehnal, F				Zurovec, M; Sehnal, F			Unique molecular architecture of silk fibroin in the waxmoth, Galleria mellonella	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOMBYX-MORI; MESSENGER-RNA; SPIDER SILKS; CODON USAGE; GENE; PROTEIN; IDENTIFICATION; EVOLUTION; SEQUENCE; CHAIN	Proteins of silk fibers are characterized by reiterations of amino acid repeats. Physical properties of the fiber are determined by the amino acid composition, the complexity of repetitive units, and arrangement of these units into higher order arrays. Except for very short motifs of 6-10 residues, the length of repetitive units and the number of these units concatenated in higher order assemblies vary in all spider and lepidopteran silks analyzed so far. This paper describes an exceptional silk protein represented by the 500-kDa heavy chain fibroin (H-fibroin) of the waxmoth, Galleria mellonella. Its non-repetitive N-terminal (175 residues) and C-terminal (60 residues) parts, the overall gene organization, and the nucleotide sequence around the TATA box show that it is homologous to the H-fibroins of other Lepidoptera. However, over 95% of the protein consists of highly ordered repetitive structures that are unmatched in other species. The repetitive region includes 11 assemblies AB(1)AB(1)AB(1)AB(2)(AB(2))AB(2) of remarkably conserved polypeptide repeats A (63 amino acid residues), B-1 (43 residues), and B-2 (18 residues). The repeats contain a high proportion of Gly (31.6%), Ala (23.8%), Ser (18.1%), and of residues with long hydrophobic side chains (16% for Leu, Ile, and Val combined). The presence of the GLGGLG and SSAASAA(AA) motifs suggests formation of pleated beta-sheets and their stacking into crystallites. Conspicuous conservation of the apolar sequence VIVI followed by DD or ED is interpreted as indicating the importance of hydrophobicity and electrostatic charge in H-fibroin cross-linking. The environment of G. mellonella larvae within bee cultures requires continuous production of silk that must be both strong and elastic. The spectacular arrangement of the repetitive H-fibroin region apparently evolved to meet these requirements.	Acad Sci Czech Republ, Inst Entomol, CR-37005 Ceske Budejovice, Czech Republic; Univ S Bohemia, Fac Biol Sci, Ceske Budejovice 37005, Czech Republic	Czech Academy of Sciences; Biology Centre of the Czech Academy of Sciences; Czech Academy of Sciences; University of South Bohemia Ceske Budejovice	Sehnal, F (corresponding author), Acad Sci Czech Republ, Inst Entomol, Branisovska 31, CR-37005 Ceske Budejovice, Czech Republic.	sehnal@entu.cas.cz	Zurovec, Michal/H-2562-2014; Zurovec, Michal/AAE-8185-2021	Zurovec, Michal/0000-0002-0913-166X; Zurovec, Michal/0000-0002-0913-166X				ARMOUR JAL, 1993, GENOME ANAL, V7, P43; Beckwitt R, 1998, INSECT BIOCHEM MOLEC, V28, P121, DOI 10.1016/S0965-1748(97)00083-0; BONNOT G, 1970, Annales de Zoologie Ecologie Animale, V2, P595; CHERBAS L, 1993, INSECT BIOCHEM MOLEC, V23, P81, DOI 10.1016/0965-1748(93)90085-7; Datta A, 2001, INSECT BIOCHEM MOLEC, V31, P1013, DOI 10.1016/S0965-1748(01)00049-2; Denny M.W., 1980, Symposia of the Society for Experimental Biology, P247; DOVER G, 1982, NATURE, V299, P111, DOI 10.1038/299111a0; GAREL JP, 1970, FEBS LETT, V7, P327, DOI 10.1016/0014-5793(70)80196-X; Gatesy J, 2001, SCIENCE, V291, P2603, DOI 10.1126/science.1057561; Gosline JM, 1999, J EXP BIOL, V202, P3295; Hayashi CY, 2000, SCIENCE, V287, P1477, DOI 10.1126/science.287.5457.1477; Hayashi CY, 1998, J MOL BIOL, V275, P773, DOI 10.1006/jmbi.1997.1478; HEPBURN HR, 1979, INSECT BIOCHEM, V9, P69, DOI 10.1016/0020-1790(79)90028-3; Inoue S, 2000, J BIOL CHEM, V275, P40517, DOI 10.1074/jbc.M006897200; KUSUDA J, 1986, MOL GEN GENET, V203, P359, DOI 10.1007/BF00422057; Lucas F., 1968, Comprehensive Biochem, V26, P475; LUCAS F, 1960, J MOL BIOL, V2, P339, DOI 10.1016/S0022-2836(60)80045-9; MANNING RF, 1980, J BIOL CHEM, V255, P9451; MARSH RE, 1955, ACTA CRYSTALLOGR, V8, P710, DOI 10.1107/S0365110X5500217X; MARSH RE, 1955, BIOCHIM BIOPHYS ACTA, V16, P1, DOI 10.1016/0006-3002(55)90178-5; Meeds T, 2001, J MOL EVOL, V53, P180, DOI 10.1007/s002390010208; MICHALIK J, 1984, ACTA BIOCHIM POL, V31, P139; MITA K, 1988, J MOL BIOL, V203, P917, DOI 10.1016/0022-2836(88)90117-9; NAKAMURA T, 1991, FEBS LETT, V289, P123, DOI 10.1016/0014-5793(91)80923-Q; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; Nirmala X., 2001, EUR J BIOCHEM, V268, P1; OHSHIMA Y, 1977, P NATL ACAD SCI USA, V74, P5363, DOI 10.1073/pnas.74.12.5363; PAULING L, 1953, P NATL ACAD SCI USA, V39, P253, DOI 10.1073/pnas.39.4.253; PROUDFOOT N, 1991, CELL, V64, P671, DOI 10.1016/0092-8674(91)90495-K; SEHNAL F, 1990, INT J INSECT MORPHOL, V19, P79, DOI 10.1016/0020-7322(90)90022-H; SEHNAL F, 1966, Z WISS ZOOL ABT A, V174, P53; Sezutsu H, 2000, J MOL EVOL, V51, P329, DOI 10.1007/s002390010095; SMITH GP, 1976, SCIENCE, V191, P528, DOI 10.1126/science.1251186; SUZUKI Y, 1972, J MOL BIOL, V63, P409, DOI 10.1016/0022-2836(72)90437-8; TAMURA T, 1987, MOL GEN GENET, V207, P189, DOI 10.1007/BF00331577; TAMURA T, 1989, WILD SILKMOTHS, V88, P67; TANAKA K, 1993, J BIOCHEM-TOKYO, V114, P1; Tanaka K, 1999, BBA-PROTEIN STRUCT M, V1432, P92, DOI 10.1016/S0167-4838(99)00088-6; TANAKA K, 2001, INSECT BIOCHEM MOLEC, V31, P685; TERMONIA Y, 1994, MACROMOLECULES, V27, P7378, DOI 10.1021/ma00103a018; TSUJIMOTO Y, 1979, CELL, V18, P591, DOI 10.1016/0092-8674(79)90075-8; WARWICKER JO, 1960, J MOL BIOL, V2, P350, DOI 10.1016/S0022-2836(60)80046-0; Yang CS, 1998, GENE, V209, P157, DOI 10.1016/S0378-1119(98)00029-8; Zhou CZ, 2000, NUCLEIC ACIDS RES, V28, P2413, DOI 10.1093/nar/28.12.2413; ZHOU CZ, 2001, PROTEIN-STRUCT FUNCT, V448, P119; Zurovec M, 1998, J BIOL CHEM, V273, P15423, DOI 10.1074/jbc.273.25.15423; ZUROVEC M, 1995, MOL GEN GENET, V247, P1, DOI 10.1007/BF00425815; ZUROVEC M, 1992, INSECT BIOCHEM MOLEC, V22, P55, DOI 10.1016/0965-1748(92)90100-S; Zurovec M, 1998, MOL GEN GENET, V257, P264, DOI 10.1007/s004380050647	49	42	47	1	14	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 21	2002	277	25					22639	22647		10.1074/jbc.M201622200	http://dx.doi.org/10.1074/jbc.M201622200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	564KM	11886872	hybrid			2022-12-27	WOS:000176313600070
J	Doray, B; Bruns, K; Ghosh, P; Kornfeld, S				Doray, B; Bruns, K; Ghosh, P; Kornfeld, S			Interaction of the cation-dependent mannose 6-phosphate receptor with GGA proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-II RECEPTOR; EAR HOMOLOGY DOMAIN; CYTOPLASMIC DOMAIN; GAMMA-ADAPTIN; PHOSPHORYLATION SITE; MUTATIONAL ANALYSIS; CARBOXYL-TERMINUS; TRANS-GOLGI; VHS DOMAINS; BINDING	The GGAs (Golgi-localizing, (&gamma;) under bar -adaptin ear homology domain, ARF-binding) are a multidomain family of proteins implicated in protein trafficking between the Golgi and endosomes. Recent evidence has established that the cation-independent (Cl) and cation-dependent (CD) mannose 6-phosphate receptors (MPRs) bind specifically to the VHS domains of the GGAs through acidic cluster-dileucine motifs at the carboxyl ends of their cytoplasmic tails. However, the CD-MPR binds the VHS domains more weakly than the CI-MPR. Alignment of the C-terminal residues of the two receptors revealed a number of non-conservative differences in the acidic cluster-dileucine motifs and the flanking residues. Mutation of these residues in the CD-MPR cytoplasmic tail to the corresponding residues in the CI-MPR conferred either full binding (H63D mutant), intermediate binding (R60S), or unchanged binding (E56F/S57H) to the GGAs as determined by in vitro glutathione S-transferase pull-down assays. Furthermore, the C-terminal methionine of the CD-MPR, but not the C-terminal valine of the CI-MPR, inhibited GGA binding. Addition of four alanines to the C-terminal valine of the Cl-MPR also severely reduced GGA binding, demonstrating the importance of the spacing of the acidic cluster-dileucine motif relative to the C terminus for optimal GGA interaction. Mouse L cells stably expressing CD-MPRs with mutations that enhance GGA binding sorted cathepsin D more efficiently than wild-type CD-MPR. These studies provide an explanation for the observed differences in the relative affinities of the two MPRs for the GGA proteins. Furthermore, they indicate that the GGAs participate in lysosomal enzyme sorting mediated by the CD-MPR.	Washington Univ, Sch Med, Div Hematol, Dept Internal Med, St Louis, MO 63110 USA; Southwestern Univ, Dept Chem, Georgetown, TX 78627 USA	Washington University (WUSTL)	Kornfeld, S (corresponding author), Washington Univ, Sch Med, Div Hematol, Dept Internal Med, 660 S Euclid Ave,Campus Box 8125, St Louis, MO 63110 USA.			Doray, Balraj/0000-0003-3347-5013	NATIONAL CANCER INSTITUTE [R01CA008759, R37CA008759] Funding Source: NIH RePORTER; NCI NIH HHS [CA08759] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Black MW, 2000, J CELL BIOL, V151, P587, DOI 10.1083/jcb.151.3.587; Boman AL, 2000, MOL BIOL CELL, V11, P1241, DOI 10.1091/mbc.11.4.1241; Breuer P, 1997, MOL BIOL CELL, V8, P567, DOI 10.1091/mbc.8.4.567; CHEN HJ, 1993, J BIOL CHEM, V268, P22338; Chen HJ, 1997, J BIOL CHEM, V272, P7003, DOI 10.1074/jbc.272.11.7003; Dell'Angelica EC, 2000, J CELL BIOL, V149, P81, DOI 10.1083/jcb.149.1.81; Denzer K, 1997, BIOCHEM J, V326, P497, DOI 10.1042/bj3260497; Drake MT, 2000, J BIOL CHEM, V275, P6479, DOI 10.1074/jbc.275.9.6479; Hirst J, 2000, J CELL BIOL, V149, P67, DOI 10.1083/jcb.149.1.67; Honing S, 1997, J BIOL CHEM, V272, P19884, DOI 10.1074/jbc.272.32.19884; JOHNSON KF, 1990, P NATL ACAD SCI USA, V87, P10010, DOI 10.1073/pnas.87.24.10010; JOHNSON KF, 1992, J CELL BIOL, V119, P249, DOI 10.1083/jcb.119.2.249; JOHNSON KF, 1992, J BIOL CHEM, V267, P17110; KORNFELD S, 1992, ANNU REV BIOCHEM, V61, P307, DOI 10.1146/annurev.bi.61.070192.001515; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; LOBEL P, 1989, CELL, V57, P787, DOI 10.1016/0092-8674(89)90793-9; Mauxion F, 1996, J BIOL CHEM, V271, P2171, DOI 10.1074/jbc.271.4.2171; Misra S, 2002, NATURE, V415, P933, DOI 10.1038/415933a; Nielsen MS, 2001, EMBO J, V20, P2180, DOI 10.1093/emboj/20.9.2180; Poussu A, 2000, J BIOL CHEM, V275, P7176, DOI 10.1074/jbc.275.10.7176; Puertollano R, 2001, SCIENCE, V292, P1712, DOI 10.1126/science.1060750; Puertollano R, 2001, CELL, V105, P93, DOI 10.1016/S0092-8674(01)00299-9; Shiba T, 2002, NATURE, V415, P937, DOI 10.1038/415937a; Takatsu H, 2000, BIOCHEM BIOPH RES CO, V271, P719, DOI 10.1006/bbrc.2000.2700; Takatsu H, 2001, J BIOL CHEM, V276, P28541, DOI 10.1074/jbc.C100218200; Zhdankina O, 2001, YEAST, V18, P1, DOI 10.1002/1097-0061(200101)18:1<1::AID-YEA644>3.0.CO;2-5; Zhu YX, 2001, SCIENCE, V292, P1716, DOI 10.1126/science.1060896	27	48	51	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 24	2002	277	21					18477	18482		10.1074/jbc.M201879200	http://dx.doi.org/10.1074/jbc.M201879200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	558PM	11886874	hybrid			2022-12-27	WOS:000175975800030
J	Martins, LO; Soares, CM; Pereira, MM; Teixeira, M; Costa, T; Jones, GH; Henriques, AO				Martins, LO; Soares, CM; Pereira, MM; Teixeira, M; Costa, T; Jones, GH; Henriques, AO			Molecular and biochemical characterization of a highly stable bacterial laccase that occurs as a structural component of the Bacillus subtilis endospore coat	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYPHENOL OXIDASE; ASCORBATE OXIDASE; CRYSTAL-STRUCTURE; GENE; PURIFICATION; EXPRESSION; CLONING; TRANSGLUTAMINASE; BIOSYNTHESIS; PROTEINS	The Bacillus subtilis endospore coat protein CotA shows laccase activity. By using comparative modeling techniques, we were able to derive a model for CotA based on the known x-ray structures of zucchini ascorbate oxidase and Cuprinus cereneus laccase. This model of CotA contains all the structural features of a laccase, including the reactive surface-exposed copper center (T1) and two buried copper centers (T2 and T3). Single amino acid substitutions in the CotA T1 copper center (H497A, or M502L) did not prevent assembly of the mutant proteins into the coat and did not alter the pattern of extractable coat polypeptides. However, in contrast to a wild type strain, both mutants produced unpigmented colonies and spores unable to oxidize syringaldazine (SGZ) and 2'2-azino-bis-(3-ethylbenzothiazoline-6-sulfonic acid) (ABTS). The CotA protein was purified to homogeneity from an overproducing Escherichia coli strain. The purified CotA shows an absorbance and a EPR spectra typical of blue multicopper oxidases. Optimal enzymatic activity was found at less than or equal topH 3.0 and at pH 7.0 for ABTS or SGZ oxidation, respectively. The apparent K-m values for ABTS and SGZ at 37 degreesC were of 106 +/- 11 and 26 +/- 2 muM, respectively, with corresponding k(cat) values of 16.8 +/- 0.8 and 3.7 +/- 0.1 s(-1). Maximal enzyme activity was observed at 75 degreesC with AETS as substrate. Remarkably, the coat-associated or the purified enzyme showed a half-life of inactivation at 80 degreesC of about 4 and 2 h, respectively, indicating that CotA is intrinsically highly thermostable.	Univ Nova Lisboa, Inst Tecnol Quim & Biol, P-2781901 Oeiras, Portugal; Univ Lusofona Humanidades & Tecnol, Dept Engn & Tecnol, P-1749024 Lisbon, Portugal; Emory Univ, Dept Biol, Atlanta, GA 30322 USA	Universidade Nova de Lisboa; Lusofona University; Emory University	Henriques, AO (corresponding author), Univ Nova Lisboa, Inst Tecnol Quim & Biol, Av Republ, P-2781901 Oeiras, Portugal.	aoh@itqb.unl.pt	Teixeira, Miguel/M-1509-2019; Martins, Lígia O./C-2513-2009; Pereira, Manuela M./B-9029-2011; Teixeira, Miguel/A-9098-2011; Costa, Teresa/C-7247-2012; Soares, Claudio M/E-2675-2012	Teixeira, Miguel/0000-0003-4124-6237; Martins, Lígia O./0000-0003-0082-9591; Pereira, Manuela M./0000-0003-2033-4553; Teixeira, Miguel/0000-0003-4124-6237; Soares, Claudio M/0000-0003-1154-556X; Costa, Teresa/0000-0001-6724-6126; Henriques, Adriano/0000-0003-4292-4802				AASA R, 1975, J MAGN RESON, V19, P308, DOI 10.1016/0022-2364(75)90045-1; Alexandre G, 2000, TRENDS BIOTECHNOL, V18, P41, DOI 10.1016/S0167-7799(99)01406-7; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Breen A, 1999, CURR OPIN BIOTECH, V10, P252, DOI 10.1016/S0958-1669(99)80044-5; Chefetz B, 1998, APPL ENVIRON MICROB, V64, P3175; Dong GQ, 1997, APPL ENVIRON MICROB, V63, P3577, DOI 10.1128/AEM.63.9.3577-3584.1997; DONOVAN W, 1987, J MOL BIOL, V196, P1, DOI 10.1016/0022-2836(87)90506-7; Driks A, 1999, MICROBIOL MOL BIOL R, V63, P1; Ducros V, 1998, NAT STRUCT BIOL, V5, P310, DOI 10.1038/nsb0498-310; Edens WA, 1999, APPL ENVIRON MICROB, V65, P3071; EGGERT C, 1995, FEBS LETT, V376, P202, DOI 10.1016/0014-5793(95)01274-9; FAURE D, 1994, APPL ENVIRON MICROB, V60, P3413, DOI 10.1128/AEM.60.9.3413-3415.1994; FREEMAN JC, 1993, BIOCHEMISTRY-US, V32, P4826, DOI 10.1021/bi00069a018; GIVAUDAN A, 1993, FEMS MICROBIOL LETT, V108, P205, DOI 10.1111/j.1574-6968.1993.tb06100.x; Henriques AO, 2000, METHODS, V20, P95, DOI 10.1006/meth.1999.0909; Henriques AO, 1998, J BACTERIOL, V180, P2285, DOI 10.1128/JB.180.9.2285-2291.1998; HENRIQUES AO, 1995, J BACTERIOL, V177, P3394, DOI 10.1128/jb.177.12.3394-3406.1995; Henriques AO, 2001, J INORG BIOCHEM, V86, P259; Hullo MF, 2001, J BACTERIOL, V183, P5426, DOI 10.1128/JB.183.18.5426-5430.2001; Isticato R, 2001, J BACTERIOL, V183, P6294, DOI 10.1128/JB.183.21.6294-6301.2001; Jones DT, 1999, J MOL BIOL, V287, P797, DOI 10.1006/jmbi.1999.2583; Kobayashi K, 1996, FEMS MICROBIOL LETT, V144, P157, DOI 10.1016/0378-1097(96)00353-9; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; MESSERSCHMIDT A, 1990, EUR J BIOCHEM, V187, P341, DOI 10.1111/j.1432-1033.1990.tb15311.x; MESSERSCHMIDT A, 1992, J MOL BIOL, V224, P179, DOI 10.1016/0022-2836(92)90583-6; Nicholls A., 1992, GRASP GRAPHICAL REPR; Ranocha P, 1999, EUR J BIOCHEM, V259, P485, DOI 10.1046/j.1432-1327.1999.00061.x; ROGOLSKY M, 1968, J BACTERIOL, V95, P2426, DOI 10.1128/JB.95.6.2426-2427.1968; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Sanchez-Amat A, 2001, BBA-PROTEIN STRUCT M, V1547, P104, DOI 10.1016/S0167-4838(01)00174-1; SanchezAmat A, 1997, BIOCHEM BIOPH RES CO, V240, P787, DOI 10.1006/bbrc.1997.7748; SANDMAN K, 1988, J MOL BIOL, V200, P461, DOI 10.1016/0022-2836(88)90536-0; Seyler RW, 1997, MOL MICROBIOL, V25, P955, DOI 10.1111/j.1365-2958.1997.mmi532.x; Solano F, 1997, APPL ENVIRON MICROB, V63, P3499, DOI 10.1128/AEM.63.9.3499-3506.1997; Solano F, 2001, FEMS MICROBIOL LETT, V204, P175, DOI 10.1111/j.1574-6968.2001.tb10882.x; Solomon EI, 1996, CHEM REV, V96, P2563, DOI 10.1021/cr950046o; Stragier P, 1996, ANNU REV GENET, V30, P297, DOI 10.1146/annurev.genet.30.1.297; SULLIVAN MA, 1984, GENE, V29, P21, DOI 10.1016/0378-1119(84)90161-6; Suzuki S, 2000, BIOSCI BIOTECH BIOCH, V64, P2344, DOI 10.1271/bbb.64.2344; THURSTON CF, 1994, MICROBIOL-SGM, V140, P19, DOI 10.1099/13500872-140-1-19; Tsai HF, 1999, J BACTERIOL, V181, P6469, DOI 10.1128/JB.181.20.6469-6477.1999; Williamson PR, 1998, J BACTERIOL, V180, P1570, DOI 10.1128/JB.180.6.1570-1572.1998; Xu F, 1997, J BIOL CHEM, V272, P924, DOI 10.1074/jbc.272.2.924; Xu F, 1996, BBA-PROTEIN STRUCT M, V1292, P303, DOI 10.1016/0167-4838(95)00210-3; ZHENG LB, 1988, GENE DEV, V2, P1047, DOI 10.1101/gad.2.8.1047; ZHENG LB, 1990, J MOL BIOL, V212, P645, DOI 10.1016/0022-2836(90)90227-D	49	401	444	6	114	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 24	2002	277	21					18849	18859		10.1074/jbc.M200827200	http://dx.doi.org/10.1074/jbc.M200827200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	558PM	11884407	hybrid			2022-12-27	WOS:000175975800079
J	Zhang, Y; Zhai, QW; Luo, Y; Dorf, ME				Zhang, Y; Zhai, QW; Luo, Y; Dorf, ME			RANTES-mediated chemokine transcription in astrocytes involves activation and translocation of p90 ribosomal S6 protein kinase (RSK)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; KAPPA-B-ALPHA; RECEPTOR EXPRESSION; MURINE ASTROCYTES; NERVOUS-SYSTEM; T-CELLS; PHOSPHORYLATION; PROLIFERATION; GROWTH; INFLAMMATION	RANTES (regulated on activation normal T cell expressed and secreted) (greater than or equal to10 ng/ml) stimulates the induction of KC and other chemokines in astrocytes. Elements of the signal transduction pathway controlling this response were identified. RANTES induced phosphorylation of MEK, ERK1/2, p90 ribosomal S6 kinases (RSK), and cAMP-response element-binding protein (CREB) in astrocytes. U0126, a pharmacological inhibitor of MEK, blocked the phosphorylation of the downstream elements ERK, RSK, and CREB, inhibited chemokine synthesis, and reduced transcription from a KC promoter construct. Dominant negative mutants of RSK or CREB blocked the transcription driven by the KC promoter. Finally, RANTES treatment induces nuclear translocation of phosphorylated RSK in astrocytes. This novel role for RSK in signaling chemokine responses and synthesis in astrocytes may contribute to the amplification mechanisms responsible for prolonging inflammatory responses in the central nervous system.	Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Dorf, ME (corresponding author), Harvard Univ, Sch Med, Dept Pathol, Armenise Bldg,D530,200 Longwood Ave, Boston, MA 02115 USA.		Zhang, Ye/D-5015-2011	Zhang, Ye/0000-0002-3494-7206	NATIONAL CANCER INSTITUTE [R01CA067416] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS037284] Funding Source: NIH RePORTER; NCI NIH HHS [CA67416] Funding Source: Medline; NINDS NIH HHS [NS37284] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Abromson-Leeman S, 2001, EUR J IMMUNOL, V31, P527, DOI 10.1002/1521-4141(200102)31:2<527::AID-IMMU527>3.0.CO;2-D; Asensio VC, 1999, TRENDS NEUROSCI, V22, P504, DOI 10.1016/S0166-2236(99)01453-8; Bacon KB, 2000, J NEUROIMMUNOL, V104, P92, DOI 10.1016/S0165-5728(99)00266-0; Bajetto A, 2001, J NEUROCHEM, V77, P1226, DOI 10.1046/j.1471-4159.2001.00350.x; Bakhiet M, 2001, NAT CELL BIOL, V3, P150, DOI 10.1038/35055057; Buck M, 1999, MOL CELL, V4, P1087, DOI 10.1016/S1097-2765(00)80237-3; CHEN RH, 1993, P NATL ACAD SCI USA, V90, P10952, DOI 10.1073/pnas.90.23.10952; CORNELLBELL AH, 1990, SCIENCE, V247, P470, DOI 10.1126/science.1967852; Dorf ME, 2000, J NEUROIMMUNOL, V111, P109, DOI 10.1016/S0165-5728(00)00371-4; DORF ME, 2002, UNIVERSES DELICATE B, P257; Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872; Fischer FR, 2000, J NEUROIMMUNOL, V110, P195, DOI 10.1016/S0165-5728(00)00351-9; Fisher TL, 1996, MOL CELL BIOL, V16, P1212; Frodin M, 1999, MOL CELL ENDOCRINOL, V151, P65, DOI 10.1016/S0303-7207(99)00061-1; Ghoda L, 1997, J BIOL CHEM, V272, P21281, DOI 10.1074/jbc.272.34.21281; Grunfeld C, 1990, Adv Intern Med, V35, P45; Han YL, 2000, GLIA, V30, P1; Han YL, 2001, J CLIN INVEST, V108, P425, DOI 10.1172/JCI12629; Huang DR, 2000, IMMUNOL REV, V177, P52, DOI 10.1034/j.1600-065X.2000.17709.x; Janabi N, 1999, J IMMUNOL, V162, P1701; Joel PB, 1998, MOL CELL BIOL, V18, P1978, DOI 10.1128/MCB.18.4.1978; Klein RS, 1999, J IMMUNOL, V163, P1636; Kwon EM, 2000, BLOOD, V95, P2552, DOI 10.1182/blood.V95.8.2552.008k30_2552_2558; Lane TE, 1998, J IMMUNOL, V160, P970; Lazarini F, 2000, EUR J NEUROSCI, V12, P117, DOI 10.1046/j.1460-9568.2000.00894.x; Luo Y, 2000, J IMMUNOL, V165, P4015, DOI 10.4049/jimmunol.165.7.4015; Luo Y, 1999, J IMMUNOL, V163, P3985; Luster AD, 1998, NEW ENGL J MED, V338, P436, DOI 10.1056/NEJM199802123380706; Ma Q, 1998, P NATL ACAD SCI USA, V95, P9448, DOI 10.1073/pnas.95.16.9448; McManus CM, 2000, AM J PATHOL, V156, P1441, DOI 10.1016/S0002-9440(10)65013-4; Molina-Holgado E, 2000, BRIT J PHARMACOL, V131, P152, DOI 10.1038/sj.bjp.0703557; Morgan BP, 1997, IMMUNOPHARMACOLOGY, V38, P43; Muller A, 2001, NATURE, V410, P50, DOI 10.1038/35065016; Nakajima T, 1996, CELL, V86, P465, DOI 10.1016/S0092-8674(00)80119-1; NEDERGAARD M, 1994, SCIENCE, V263, P1768, DOI 10.1126/science.8134839; NORENBERG MD, 1997, IMMUNOLOGY NERVOUS S, P173; PARPURA V, 1994, NATURE, V369, P744, DOI 10.1038/369744a0; Pindon A, 2000, J NEUROSCI, V20, P2543; Probert L, 1997, J NEUROIMMUNOL, V72, P137, DOI 10.1016/S0165-5728(96)00184-1; Richards SA, 2001, MOL CELL BIOL, V21, P7470, DOI 10.1128/MCB.21.21.7470-7480.2001; Robinson S, 1998, J NEUROSCI, V18, P10457; Rottman JB, 1997, AM J PATHOL, V151, P1341; Sassone-Corsi P, 1999, SCIENCE, V285, P886, DOI 10.1126/science.285.5429.886; Sayah S, 1999, J NEUROCHEM, V72, P2426, DOI 10.1046/j.1471-4159.1999.0722426.x; Schouten GJ, 1997, EMBO J, V16, P3133, DOI 10.1093/emboj/16.11.3133; Tanabe S, 1997, J NEUROSCI, V17, P6522; Wong M, 2001, J BIOL CHEM, V276, P11427, DOI 10.1074/jbc.M010750200; Wu Q, 2000, J NEUROSCI, V20, P2609; Xing J, 1996, SCIENCE, V273, P959, DOI 10.1126/science.273.5277.959; YAMAMOTO KK, 1990, CELL, V60, P611, DOI 10.1016/0092-8674(90)90664-Z; Zhang PS, 1996, J NEUROSCI RES, V46, P114, DOI 10.1002/(SICI)1097-4547(19961001)46:1<114::AID-JNR14>3.0.CO;2-5; Zou YR, 1998, NATURE, V393, P595, DOI 10.1038/31269	52	26	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 24	2002	277	21					19042	19048		10.1074/jbc.M112442200	http://dx.doi.org/10.1074/jbc.M112442200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	558PM	11893739	hybrid			2022-12-27	WOS:000175975800104
J	Nixon, AB; Grenningloh, G; Casey, PJ				Nixon, AB; Grenningloh, G; Casey, PJ			The interaction of RGSZ1 with SCG10 attenuates the ability of SCG10 to promote microtubule disassembly	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE GROWTH-FACTOR; HETEROTRIMERIC G-PROTEINS; IN-VITRO PHOSPHORYLATION; YEAST 2-HYBRID SYSTEM; SACCHAROMYCES-CEREVISIAE; SIGNALING PROTEINS; NEURITE OUTGROWTH; BINDING DOMAINS; AXONAL GROWTH; GENE FAMILY	RGS proteins (regulators of G protein signaling) are a diverse family of proteins that act to negatively regulate signaling by heterotrimeric G proteins. Initially characterized as GTPase-activating proteins for Galpha subunits, recent data have implied additional functions for RGS proteins. We previously identified an RGS protein (termed RGSZ1) whose expression is quite specific to neuronal tissue (Glick, J. L., Meigs, T. E., Miron, A., and Casey, P. J. (1998) J. Biol. Chem. 273, 26008-26013). In a continuing effort to understand the role of RGSZ1 in cellular signaling, the yeast two-hybrid system was employed to identify potential effector proteins of RGSZ1. The microtubule-destabilizing protein SCG10 (superior cervical ganglia, neural specific 10) was found to directly interact with RGSZ1 in the yeast system, and this interaction was further verified using direct binding assays. Treatment of PC12 cells with nerve growth factor resulted in Golgi-specific distribution of SCG10. A green fluorescent protein-tagged variant of RGSZ1 translocated to the Golgi complex upon treatment of PC 12 cells with nerve growth factor, providing evidence that RGSZ1 and SCG10 interact in cells as well as in vitro. Analysis of in vitro microtubule polymerization/depolymerization showed that binding of RGSZ1 to SCG10 effectively blocked the ability of SCG10 to induce microtubule disassembly as determined by both turbidimetric and microscopy-based assays. These results identify a novel connection between RGS proteins and the cytoskeletal network that points to a broader role than previously envisioned for RGS proteins in regulating biological processes.	Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA; Univ Lausanne, Inst Biol Cellulaire & Morphol, CH-1005 Lausanne, Switzerland	Duke University; Duke University; University of Lausanne	Casey, PJ (corresponding author), Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, C133 LSRC,Res Dr, Durham, NC 27710 USA.		Nixon, Andrew/AAJ-4712-2020	Nixon, Andrew/0000-0003-3971-2964; Casey, Patrick/0000-0002-7366-9309	NIGMS NIH HHS [F32 GM19663, R01 GM55717] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM055717, F32GM019663] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Antonsson B, 1998, J BIOL CHEM, V273, P8439, DOI 10.1074/jbc.273.14.8439; Antonsson B, 1997, PROTEIN EXPRES PURIF, V9, P363, DOI 10.1006/prep.1996.0710; Bai C, 1996, METHOD ENZYMOL, V273, P331; Bai C, 1997, METHOD ENZYMOL, V283, P141; Belmont LD, 1996, CELL, V84, P623, DOI 10.1016/S0092-8674(00)81037-5; Benzing T, 2000, J BIOL CHEM, V275, P28167; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Burchett SA, 2000, J NEUROCHEM, V75, P1335, DOI 10.1046/j.1471-4159.2000.0751335.x; Cabrera JL, 1998, BIOCHEM BIOPH RES CO, V249, P898, DOI 10.1006/bbrc.1998.9218; Challacombe JF, 1997, J NEUROSCI, V17, P3085; Curmi PA, 1997, J BIOL CHEM, V272, P25029, DOI 10.1074/jbc.272.40.25029; DeVries L, 1996, P NATL ACAD SCI USA, V93, P15203, DOI 10.1073/pnas.93.26.15203; Di Paolo G, 1997, J NEUROSCI RES, V50, P1000, DOI 10.1002/(SICI)1097-4547(19971215)50:6<1000::AID-JNR10>3.0.CO;2-8; DiPaolo G, 1997, J BIOL CHEM, V272, P5175, DOI 10.1074/jbc.272.8.5175; DiTella MC, 1996, J CELL SCI, V109, P467; DOHLMAN HG, 1995, MOL CELL BIOL, V15, P3635; Dohlman HG, 1996, MOL CELL BIOL, V16, P5194; DRUBIN DG, 1985, J CELL BIOL, V101, P1799, DOI 10.1083/jcb.101.5.1799; ESMAELIAZAD B, 1994, J CELL SCI, V107, P869; GASKIN F, 1974, J MOL BIOL, V89, P737, DOI 10.1016/0022-2836(74)90048-5; Gavet O, 1998, J CELL SCI, V111, P3333; Glick JL, 1998, J BIOL CHEM, V273, P26008, DOI 10.1074/jbc.273.40.26008; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; Hepler JR, 1999, TRENDS PHARMACOL SCI, V20, P376, DOI 10.1016/S0165-6147(99)01369-3; HEPLER JR, 1992, TRENDS BIOCHEM SCI, V17, P383, DOI 10.1016/0968-0004(92)90005-T; HIGASHIJIMA T, 1987, J BIOL CHEM, V262, P757; Howell B, 1999, J CELL SCI, V112, P3713; Howell B, 1999, MOL BIOL CELL, V10, P105, DOI 10.1091/mbc.10.1.105; Jourdain L, 1997, BIOCHEMISTRY-US, V36, P10817, DOI 10.1021/bi971491b; Lutjens R, 2000, EUR J NEUROSCI, V12, P2224, DOI 10.1046/j.1460-9568.2000.00112.x; NEER EJ, 1995, CELL, V80, P249, DOI 10.1016/0092-8674(95)90407-7; OKAZAKI T, 1993, GENOMICS, V18, P360, DOI 10.1006/geno.1993.1477; Ozon S, 1997, EUR J BIOCHEM, V248, P794, DOI 10.1111/j.1432-1033.1997.t01-2-00794.x; Ponting CP, 1996, TRENDS BIOCHEM SCI, V21, P245, DOI 10.1016/S0968-0004(96)30027-3; Ponting CP, 1999, J MOL MED, V77, P695, DOI 10.1007/s001099900054; Posner BA, 1999, J BIOL CHEM, V274, P31087, DOI 10.1074/jbc.274.43.31087; Riederer BM, 1997, P NATL ACAD SCI USA, V94, P741, DOI 10.1073/pnas.94.2.741; Rochlin MW, 1996, J NEUROSCI, V16, P3236; Ross EM, 2000, ANNU REV BIOCHEM, V69, P795, DOI 10.1146/annurev.biochem.69.1.795; SCHUBART UK, 1989, DNA-J MOLEC CELL BIO, V8, P389, DOI 10.1089/dna.1.1989.8.389; SHELANSK.ML, 1973, P NATL ACAD SCI USA, V70, P765, DOI 10.1073/pnas.70.3.765; Siderovski DP, 1999, TRENDS BIOCHEM SCI, V24, P340, DOI 10.1016/S0968-0004(99)01441-3; Snow BE, 1998, P NATL ACAD SCI USA, V95, P13307, DOI 10.1073/pnas.95.22.13307; Snow BE, 1998, J BIOL CHEM, V273, P17749, DOI 10.1074/jbc.273.28.17749; STEIN R, 1988, DEV BIOL, V127, P316, DOI 10.1016/0012-1606(88)90318-1; TANAKA E, 1995, J CELL BIOL, V128, P139, DOI 10.1083/jcb.128.1.139; Tint I, 1998, J NEUROSCI, V18, P8660; VUONG TM, 1991, P NATL ACAD SCI USA, V88, P9813, DOI 10.1073/pnas.88.21.9813; Wang J, 1998, J BIOL CHEM, V273, P26014, DOI 10.1074/jbc.273.40.26014; Zhang SL, 2000, ACTA MATH SCI, V20, P1	50	30	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 17	2002	277	20					18127	18133		10.1074/jbc.M201065200	http://dx.doi.org/10.1074/jbc.M201065200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	553PR	11882662	hybrid			2022-12-27	WOS:000175685100094
J	Salamanca, S; Villegas, V; Vendrell, J; Li, L; Aviles, FX; Chang, JY				Salamanca, S; Villegas, V; Vendrell, J; Li, L; Aviles, FX; Chang, JY			The unfolding pathway of leech carboxypeptidase inhibitor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBRINOLYSIS INHIBITOR; DENATURED STATES; PROTEINS; MECHANISM; COMPLEX; UREA	The unfolding and denaturation curves of leech carboxypeptidase inhibitor (LCI) were elucidated using the technique of disulfide scrambling. In the presence of thiol initiator and denaturant, the native LCI denatures by shuffling its native disulfide bonds and transforms into a mixture of scrambled species. 9 of 104 possible scrambled isomers of LCI, amounting to 90% of total denatured LCI, can be distinguished. The denaturation curve that plots the fraction of native LCI converted into scrambled isomers upon increasing concentrations of denaturant shows that the concentration of guanidine thiocyanate and guanidine hydrochloride required to reach 50% of denaturation is 2.4 and 3.6 M, respectively. In contrast, native LCI is resistant to urea denaturation even at high concentration (8 m). The LCI unfolding pathway was defined based on the evolution of the relative concentration of scrambled isoforms of LCI upon denaturation. Two populations of scrambled species suffer variations along the unfolding pathway. One accumulates as intermediates under strong denaturing conditions and corresponds to open or relaxed structures, among which the beads-form isomer is found. The other population shows an inverse correlation between their relative abundances and the denaturing conditions and should have another kind of non-native structure that is more compact than the unfolded state. The rate constants of unfolding of LCI are low when compared with other disulfide-containing proteins. Overall, the results presented in this study show that LCI, a molecule with potential biotechnological applications, has slow kinetics of unfolding and is highly stable.	Univ Autonoma Barcelona, Inst Biotecnol & Biomed, E-08193 Barcelona, Spain; Univ Autonoma Barcelona, Dept Bioquim & Biol Mol, E-08193 Barcelona, Spain; Univ Texas, Inst Mol Med, Res Ctr Prot Chem, Houston, TX 77030 USA; Univ Texas, Dept Biochem & Mol Biol, Houston, TX 77030 USA	Autonomous University of Barcelona; Autonomous University of Barcelona; University of Texas System; University of Texas System	Aviles, FX (corresponding author), Univ Autonoma Barcelona, Inst Biotecnol & Biomed, E-08193 Barcelona, Spain.		Villegas, Sandra/D-8789-2011; Avilés, Francesc Xavier/A-2664-2015; Aviles, Francesc Xavier/F-3482-2019; Villegas, Sandra/ABF-8206-2021; Vendrell, Josep/A-6731-2010	Villegas, Sandra/0000-0001-8644-4304; Avilés, Francesc Xavier/0000-0002-1399-6789; Aviles, Francesc Xavier/0000-0002-1399-6789; Villegas, Sandra/0000-0001-8644-4304; Vendrell, Josep/0000-0002-9378-4742				ANFINSEN CB, 1973, SCIENCE, V181, P223, DOI 10.1126/science.181.4096.223; Bajzar L, 2000, ARTERIOSCL THROM VAS, V20, P2511, DOI 10.1161/01.ATV.20.12.2511; Chang JY, 1999, PROTEIN SCI, V8, P1463, DOI 10.1110/ps.8.7.1463; Chang JY, 1999, J BIOL CHEM, V274, P123, DOI 10.1074/jbc.274.1.123; Chang JY, 1997, J BIOL CHEM, V272, P69; Chang JY, 2000, J BIOL CHEM, V275, P14205, DOI 10.1074/jbc.275.19.14205; Chang JY, 1998, BIOCHEMISTRY-US, V37, P6745, DOI 10.1021/bi9714565; CLORE GM, 1987, BIOCHEMISTRY-US, V26, P8012, DOI 10.1021/bi00398a069; DILL KA, 1991, ANNU REV BIOCHEM, V60, P795, DOI 10.1146/annurev.bi.60.070191.004051; HABER E, 1962, J BIOL CHEM, V237, P1839; LIEPINSH E, 1994, J AM CHEM SOC, V116, P9670, DOI 10.1021/ja00100a036; MATOUSCHEK A, 1992, J MOL BIOL, V224, P819, DOI 10.1016/0022-2836(92)90564-Z; Pace C N, 1986, Methods Enzymol, V131, P266; PACE CN, 1990, BIOCHEMISTRY-US, V29, P2564, DOI 10.1021/bi00462a019; REES DC, 1982, J MOL BIOL, V160, P475, DOI 10.1016/0022-2836(82)90309-6; Reverter D, 1998, J BIOL CHEM, V273, P32927, DOI 10.1074/jbc.273.49.32927; Reverter D, 2000, NAT STRUCT BIOL, V7, P322, DOI 10.1038/74092; Tanford C, 1968, Adv Protein Chem, V23, P121, DOI 10.1016/S0065-3233(08)60401-5; Wang W, 1998, J BIOL CHEM, V273, P27176, DOI 10.1074/jbc.273.42.27176	19	24	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 17	2002	277	20					17538	17543		10.1074/jbc.M200040200	http://dx.doi.org/10.1074/jbc.M200040200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	553PR	11893741	hybrid			2022-12-27	WOS:000175685100020
J	Zhang, YJ; O'Neal, WK; Randell, SH; Blackburn, K; Moyer, MB; Boucher, RC; Ostrowski, LE				Zhang, YJ; O'Neal, WK; Randell, SH; Blackburn, K; Moyer, MB; Boucher, RC; Ostrowski, LE			Identification of dynein heavy chain 7 as an inner arm component of human cilia that is synthesized but not assembled in a case of primary ciliary dyskinesia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHROMOSOMAL LOCALIZATION; GENOMIC STRUCTURE; EPITHELIAL-CELLS; SITUS-INVERSUS; GENE; DIFFERENTIATION; EXPRESSION; MUTATIONS; FLAGELLA; MOVEMENT	Although the basic structure of the axoneme has been highly conserved throughout evolution, the varied functions of specialized axonemes require differences in structure and regulation. Cilia lining the respiratory tract propel mucus along airway surfaces, providing a critical function to the defense mechanisms of the pulmonary system, yet little is known of their molecular structure. We have identified and cloned a dynein heavy chain that is a component of the inner dynein arm. Bronchial epithelial cells were obtained from normal donors and from a patient with primary ciliary dyskinesia (PCD) whose cilia demonstrated an absence of inner dynein arms by electron microscopy. Cilia from normal and PCD cells were compared by gel electrophoresis, and mass spectrometry was used to identify DNAH7 as a protein absent in PCD cilia. The full-length DNAH7 cDNA was cloned and shares 68% similarity with an inner arm dynein heavy chain from Drosophila. DNAH7 was induced during ciliated cell differentiation, and immunohistochemistry demonstrated the presence of DNAH7 in normal cilia. In cilia from PCD cells, DNAH7 was undetectable, whereas intracellular DNAH7 was clearly present. These studies identify DNAH7 as an inner arm component of human cilia that is synthesized but not assembled in a case of PCD.	Univ N Carolina, Sch Med, Cyst Fibrosis Pulm Res & Treatment Ctr, Chapel Hill, NC 27599 USA; GlaxoSmithKline, Proteom Technol Dept, Res Triangle Pk, NC 27709 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; GlaxoSmithKline	Ostrowski, LE (corresponding author), Univ N Carolina, Sch Med, Cyst Fibrosis Pulm Res & Treatment Ctr, CB 7248,6123A Thurston Bowles Bldg, Chapel Hill, NC 27599 USA.	ostro@med.unc.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL063103, P01HL034322] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL63103, P0IHL34322] Funding Source: Medline; NIOSH CDC HHS [P5OHL60280] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIOSH CDC HHS		Andrews KL, 1996, MOL BIOL CELL, V7, P71, DOI 10.1091/mbc.7.1.71; Asai DJ, 2001, TRENDS CELL BIOL, V11, P196, DOI 10.1016/S0962-8924(01)01970-5; Bartoloni L, 2001, GENOMICS, V72, P21, DOI 10.1006/geno.2000.6462; Bernacki SH, 1999, AM J RESP CELL MOL, V20, P595, DOI 10.1165/ajrcmb.20.4.3442; Chapelin C, 1997, FEBS LETT, V412, P325, DOI 10.1016/S0014-5793(97)00800-4; GIBBONS IR, 1981, J CELL BIOL, V91, pS107, DOI 10.1083/jcb.91.3.107s; Gray TE, 1996, AM J RESP CELL MOL, V14, P104, DOI 10.1165/ajrcmb.14.1.8534481; Guichard C, 2001, AM J HUM GENET, V68, P1030, DOI 10.1086/319511; HAIMO LT, 1981, J CELL BIOL, V91, pS125, DOI 10.1083/jcb.91.3.125s; HASTIE AT, 1988, CELL MOTIL CYTOSKEL, V11, P157, DOI 10.1002/cm.970110303; HASTIE AT, 1986, CELL MOTIL CYTOSKEL, V6, P25, DOI 10.1002/cm.970060105; ISHIJIMA S, 1987, CELL MOTIL CYTOSKEL, V8, P375, DOI 10.1002/cm.970080410; King SM, 2000, BBA-MOL CELL RES, V1496, P60, DOI 10.1016/S0167-4889(00)00009-4; Koc EC, 2000, J BIOL CHEM, V275, P32585, DOI 10.1074/jbc.M003596200; Maiti AK, 2000, EUR J HUM GENET, V8, P923, DOI 10.1038/sj.ejhg.5200555; Marszalek JR, 1999, P NATL ACAD SCI USA, V96, P5043, DOI 10.1073/pnas.96.9.5043; Matsui H, 1998, CELL, V95, P1005, DOI 10.1016/S0092-8674(00)81724-9; Meeks M, 2000, PEDIATR PULM, V29, P307, DOI 10.1002/(SICI)1099-0496(200004)29:4<307::AID-PPUL11>3.0.CO;2-2; Nagase T, 2000, DNA RES, V7, P65, DOI 10.1093/dnares/7.1.65; NAITOH Y, 1972, SCIENCE, V176, P523, DOI 10.1126/science.176.4034.523; Neesen J, 1997, GENE, V200, P193, DOI 10.1016/S0378-1119(97)00417-4; Nonaka S, 1998, CELL, V95, P829, DOI 10.1016/S0092-8674(00)81705-5; Noone PG, 1999, AM J MED GENET, V82, P155, DOI 10.1002/(SICI)1096-8628(19990115)82:2<155::AID-AJMG11>3.0.CO;2-T; Olbrich H, 2002, NAT GENET, V30, P143, DOI 10.1038/ng817; Pazour GJ, 2000, J CELL BIOL, V151, P709, DOI 10.1083/jcb.151.3.709; Pennarun G, 1999, AM J HUM GENET, V65, P1508, DOI 10.1086/302683; Porter ME, 2000, J CELL BIOL, V151, pF37, DOI 10.1083/jcb.151.5.F37; Reed W, 2000, AM J RESP CELL MOL, V23, P734, DOI 10.1165/ajrcmb.23.6.4045; RENTHAL R, 1993, CELL MOTIL CYTOSKEL, V25, P19, DOI 10.1002/cm.970250104; SALATHE M, 1995, J CELL SCI, V108, P431; SATIR P, 1990, ANNU REV PHYSIOL, V52, P137, DOI 10.1146/annurev.ph.52.030190.001033; SCHIDLOW DV, 1994, ANN ALLERGY, V73, P457; Taulman PD, 2001, MOL BIOL CELL, V12, P589, DOI 10.1091/mbc.12.3.589; Vaisberg EA, 1996, J CELL BIOL, V133, P831, DOI 10.1083/jcb.133.4.831; Zariwala M, 2001, AM J RESP CELL MOL, V25, P577, DOI 10.1165/ajrcmb.25.5.4619	35	53	56	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 17	2002	277	20					17906	17915		10.1074/jbc.M200348200	http://dx.doi.org/10.1074/jbc.M200348200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	553PR	11877439	hybrid, Green Published			2022-12-27	WOS:000175685100067
J	Radons, J; Gabler, S; Wesehe, H; Korherr, C; Hofmeister, R; Falk, W				Radons, J; Gabler, S; Wesehe, H; Korherr, C; Hofmeister, R; Falk, W			Identification of essential regions in the cytoplasmic tail of interleukin-1 receptor accessory protein critical for interleukin-1 signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; IL-1 RECEPTOR; MESSENGER-RNA; TRANSCRIPTION FACTOR; ADAPTER PROTEIN; KINASE PATHWAY; TAK1 MAPKKK; ACTIVATION; TRANSDUCTION; IRAK	Interleukin (IL)-1 plays an important role in inflammation and regulation of immune responses. The activated IL-1 receptor complex, which consists of the IL-1 receptor type I and the IL-1 receptor accessory protein (IL-1RAcP), generates multiple cellular responses including NF-kappaB activation, IL-2 secretion, and IL-2 promoter activation. Reconstitution experiments in EL4D6/76 cells lacking IL-1RAcP expression and IL-1 responsiveness were used to analyze structure-function relationships of the IL-1RAcP cytoplasmic tail. Mutating a potential tyrosine kinase phosphorylation motif and various conserved amino acid (aa) residues had no effect on IL-1 responsiveness. Truncation analyses revealed that box 3 of the TIR domain was required for NF-kappaB activation, IL-2 production, and c-Jun N-terminal kinase (JNK) activation, whereas IL-2 promoter activation was only partially inhibited. Surprisingly, deletion of aa 527-534 resulted in almost complete loss of all IL-1 responsiveness. Replacement of these aa with alanyl residues did not reconstitute NF-kappaB activation, IL-2 production, or JNK activation but partly restored IL-2 promoter activation. Immunoprecipitation data revealed a strong correlation between MyD88 binding with NF-kappaB activation and IL-2 production but not with IL-2 promoter activation. Taken together, our data indicate that box 3 of IL-1RAcP is critical for IL-1-dependent NF-kappaB activation and stabilization of IL-2 mRNA via JNK, whereas aa 527-534 largely contribute to IL-2 promoter activation.	Univ Regensburg, Klin & Poliklin Innere Med 1, D-93042 Regensburg, Germany; Tularik Inc, San Francisco, CA 94080 USA	University of Regensburg	Radons, J (corresponding author), Univ Regensburg, Klin & Poliklin Innere Med 1, D-93042 Regensburg, Germany.							Adachi O, 1998, IMMUNITY, V9, P143, DOI 10.1016/S1074-7613(00)80596-8; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Barnes PJ, 1997, NEW ENGL J MED, V336, P1066, DOI 10.1056/NEJM199704103361506; Bowie A, 2000, J LEUKOCYTE BIOL, V67, P508, DOI 10.1002/jlb.67.4.508; Burns K, 1998, J BIOL CHEM, V273, P12203, DOI 10.1074/jbc.273.20.12203; Burns K, 2000, NAT CELL BIOL, V2, P346, DOI 10.1038/35014038; Cao ZD, 1996, NATURE, V383, P443, DOI 10.1038/383443a0; Cao ZD, 1996, SCIENCE, V271, P1128, DOI 10.1126/science.271.5252.1128; Chen CY, 1998, SCIENCE, V280, P1945, DOI 10.1126/science.280.5371.1945; COLOTTA F, 1994, IMMUNOL TODAY, V15, P562, DOI 10.1016/0167-5699(94)90217-8; COLOTTA F, 1993, SCIENCE, V261, P472, DOI 10.1126/science.8332913; CROSTON GE, 1995, J BIOL CHEM, V270, P16514, DOI 10.1074/jbc.270.28.16514; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; Dinarello CA, 1996, BLOOD, V87, P2095, DOI 10.1182/blood.V87.6.2095.bloodjournal8762095; DRIPPS DJ, 1991, J BIOL CHEM, V266, P10331; Fitzgerald KA, 2001, NATURE, V413, P78, DOI 10.1038/35092578; Greene C, 1999, BBA-MOL CELL RES, V1451, P109, DOI 10.1016/S0167-4889(99)00079-8; GREENFEDER SA, 1995, J BIOL CHEM, V270, P13757, DOI 10.1074/jbc.270.23.13757; GREENFEDER SA, 1995, J BIOL CHEM, V270, P22460, DOI 10.1074/jbc.270.38.22460; HEGUY A, 1991, CELL GROWTH DIFFER, V2, P311; Hofmeister R, 1997, J BIOL CHEM, V272, P27730, DOI 10.1074/jbc.272.44.27730; Horng T, 2001, NAT IMMUNOL, V2, P835, DOI 10.1038/ni0901-835; Huang JN, 1997, P NATL ACAD SCI USA, V94, P12829, DOI 10.1073/pnas.94.24.12829; Kawai T, 1999, IMMUNITY, V11, P115, DOI 10.1016/S1074-7613(00)80086-2; Korherr C, 1997, EUR J IMMUNOL, V27, P262, DOI 10.1002/eji.1830270139; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Li XX, 1999, MOL CELL BIOL, V19, P4643; LORD KA, 1990, ONCOGENE, V5, P1095; Malinin NL, 1997, NATURE, V385, P540, DOI 10.1038/385540a0; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; MINDEN A, 1994, MOL CELL BIOL, V14, P6683, DOI 10.1128/MCB.14.10.6683; Ninomiya-Tsuji J, 1999, NATURE, V398, P252, DOI 10.1038/18465; ONeill LAJ, 1997, BIOCHEM SOC T, V25, P295, DOI 10.1042/bst0250295; ONeill LAJ, 1995, INT J CLIN LAB RES, V25, P169, DOI 10.1007/BF02592694; Qian YC, 2001, J BIOL CHEM, V276, P41661, DOI 10.1074/jbc.M102262200; Ragheb JA, 1999, J IMMUNOL, V163, P120; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; Shibuya H, 1996, SCIENCE, V272, P1179, DOI 10.1126/science.272.5265.1179; SIMS JE, 1993, P NATL ACAD SCI USA, V90, P6155, DOI 10.1073/pnas.90.13.6155; Slack JL, 2000, J BIOL CHEM, V275, P4670, DOI 10.1074/jbc.275.7.4670; STRICKER K, 1993, EUR J IMMUNOL, V23, P1475, DOI 10.1002/eji.1830230712; SU B, 1994, CELL, V77, P727, DOI 10.1016/0092-8674(94)90056-6; Swantek JL, 2000, J IMMUNOL, V164, P4301, DOI 10.4049/jimmunol.164.8.4301; Takaesu G, 2000, MOL CELL, V5, P649, DOI 10.1016/S1097-2765(00)80244-0; Takaesu G, 2001, MOL CELL BIOL, V21, P2475, DOI 10.1128/MCB.21.7.2475-2484.2001; VONHOEGEN I, 1989, EUR J IMMUNOL, V19, P329; Wesche H, 1997, IMMUNITY, V7, P837, DOI 10.1016/S1074-7613(00)80402-1; Wesche H, 1997, J BIOL CHEM, V272, P7727, DOI 10.1074/jbc.272.12.7727; Winzen R, 1999, EMBO J, V18, P4969, DOI 10.1093/emboj/18.18.4969; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Xu YW, 2000, NATURE, V408, P111, DOI 10.1038/35040600; Yamin TT, 1997, J BIOL CHEM, V272, P21540, DOI 10.1074/jbc.272.34.21540; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7; Zhang GL, 2002, J BIOL CHEM, V277, P7059, DOI 10.1074/jbc.M109537200	56	32	33	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 10	2002	277	19					16456	16463		10.1074/jbc.M201000200	http://dx.doi.org/10.1074/jbc.M201000200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	551MB	11880380	hybrid			2022-12-27	WOS:000175564500017
J	Rayner, TF; Gray, JV; Thorner, JW				Rayner, TF; Gray, JV; Thorner, JW			Direct and novel regulation of cAMP-dependent protein kinase by Mck1p, a yeast glycogen synthase kinase-3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OVEREXPRESSING GLYCOLYTIC-ENZYMES; SACCHAROMYCES-CEREVISIAE; PYRUVATE-KINASE; BINDING PROTEIN; GENE-PRODUCT; REVERSIBLE PHOSPHORYLATION; NEGATIVE REGULATOR; SIGNALING PATHWAY; ESCHERICHIA-COLI; SHUTTLE VECTORS	The MCK1 gene of Saccharomyces cerevisiae encodes a protein kinase homologous to metazoan glycogen synthase kinase-3. Previous studies implicated Mck1p in negative regulation of pyruvate kinase. In this study we find that purified Mck1p does not phosphorylate pyruvate kinase, suggesting that the link is indirect. We find that purified Tpk1p, a cAMP-dependent protein kinase catalytic subunit, phosphorylates purified pyruvate kinase in vitro, and that loss of the cAMP-dependent protein kinase regulatory subunit, Bcy1p, increases pyruvate kinase activity in vivo. We find that purified Mck1p inhibits purified Tpk1p in vitro, in the presence or absence of Bcy1p. Mck1p must be catalytically active to inhibit Tpk1p, but Mck1p does not phosphorylate this target. We find that abolition of Mck1p autophosphorylation on tyrosine prevents the kinase from efficiently phosphorylating exogenous substrates, but does not block its ability to inhibit Tpk1p in vitro. We find that this mutant form of Mck1p appears to retain the ability to negatively regulate cAMP-dependent protein kinase in vivo. We propose that Mck1p, in addition to phosphorylating some target proteins, also acts by a separate, novel mechanism: autophosphorylated Mck1p, binds to and directly inhibits, but does not phosphorylate, the catalytic subunits of cAMP-dependent protein kinase.	Univ Calif Berkeley, Dept Mol & Cell Biol, Div Biochem & Mol Biol, Berkeley, CA 94720 USA; Univ Glasgow, Fac Biomed & Life Sci, Div Mol Genet, Glasgow G11 6NU, Lanark, Scotland	University of California System; University of California Berkeley; University of Glasgow	Rayner, TF (corresponding author), Univ Calif Berkeley, Dept Mol & Cell Biol, Div Biochem & Mol Biol, Berkeley, CA 94720 USA.	t.rayner@bio.gla.ac.uk	THORNER, Jeremy/O-6132-2019	THORNER, Jeremy/0000-0002-2583-500X; Rayner, Tim/0000-0002-6992-5592	NIGMS NIH HHS [GM21841] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM021841, R37GM021841] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALANI E, 1987, GENETICS, V116, P541, DOI 10.1534/genetics.112.541.test; Andoh T, 2000, MOL CELL BIOL, V20, P6712, DOI 10.1128/MCB.20.18.6712-6720.2000; Avruch J, 1998, MOL CELL BIOCHEM, V182, P31, DOI 10.1023/A:1006823109415; BENTON BM, 1994, J CELL BIOL, V127, P623, DOI 10.1083/jcb.127.3.623; BOWDISH KS, 1994, MOL CELL BIOL, V14, P7909, DOI 10.1128/MCB.14.12.7909; Brachmann CB, 1998, YEAST, V14, P115; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brazill DT, 1997, J BACTERIOL, V179, P4415, DOI 10.1128/jb.179.13.4415-4418.1997; CHENG HC, 1986, J BIOL CHEM, V261, P989; Cook JG, 1997, NATURE, V390, P85, DOI 10.1038/36355; Cowan KJ, 1999, MOL CELL BIOCHEM, V195, P173, DOI 10.1023/A:1006932221288; Cytrynska M, 2001, FEMS MICROBIOL LETT, V203, P223, DOI 10.1016/S0378-1097(01)00354-8; DAILEY D, 1990, MOL CELL BIOL, V10, P6244, DOI 10.1128/MCB.10.12.6244; ENGSTROM L, 1987, ENZYMES, V8, P47; HILL JE, 1986, YEAST, V2, P163, DOI 10.1002/yea.320020304; HIXSON CS, 1980, J BIOL CHEM, V255, P2137; Hoshi M, 1996, P NATL ACAD SCI USA, V93, P2719, DOI 10.1073/pnas.93.7.2719; Hunter T, 1997, TRENDS BIOCHEM SCI, V22, P18, DOI 10.1016/S0968-0004(96)10068-2; Ikeda S, 1998, EMBO J, V17, P1371, DOI 10.1093/emboj/17.5.1371; JIANG WD, 1995, MOL GEN GENET, V246, P360, DOI 10.1007/BF00288609; Jiang WD, 1996, MOL GEN GENET, V251, P153; JOHNSON KE, 1987, J BIOL CHEM, V262, P8636; JONES EW, 1991, METHOD ENZYMOL, V194, P428; Jurica MS, 1998, STRUCTURE, V6, P195, DOI 10.1016/S0969-2126(98)00021-5; KELLOGG DR, 1995, J CELL BIOL, V130, P661, DOI 10.1083/jcb.130.3.661; Kim L, 2000, CURR OPIN GENET DEV, V10, P508, DOI 10.1016/S0959-437X(00)00120-9; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIM MY, 1993, J BIOL CHEM, V268, P21155; Madhani HD, 1997, SCIENCE, V275, P1314, DOI 10.1126/science.275.5304.1314; MARTIN GA, 1990, CELL, V63, P843, DOI 10.1016/0092-8674(90)90150-D; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; NEIGEBORN L, 1991, GENE DEV, V5, P533, DOI 10.1101/gad.5.4.533; Pan XW, 1999, MOL CELL BIOL, V19, P4874; Piao HL, 1999, PLANT PHYSIOL, V119, P1527, DOI 10.1104/pp.119.4.1527; PLYTE SE, 1992, BIOCHIM BIOPHYS ACTA, V1114, P147, DOI 10.1016/0304-419X(92)90012-N; PUZISS JW, 1994, MOL CELL BIOL, V14, P831, DOI 10.1128/MCB.14.1.831; ROBERTS RL, 1994, GENE DEV, V8, P2974, DOI 10.1101/gad.8.24.2974; Robertson LS, 1998, P NATL ACAD SCI USA, V95, P13783, DOI 10.1073/pnas.95.23.13783; ROSENZWEIG RF, 1992, GENET RES, V59, P35, DOI 10.1017/S0016672300030159; ROSENZWEIG RF, 1992, GENET RES, V59, P167, DOI 10.1017/S0016672300030445; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Sherman F, 1986, LAB COURSE MANUAL ME; SHERO JH, 1991, GENE DEV, V5, P549, DOI 10.1101/gad.5.4.549; SIKORSKI RS, 1989, GENETICS, V122, P19; TODA T, 1987, MOL CELL BIOL, V7, P1371, DOI 10.1128/MCB.7.4.1371; Welsh GI, 1996, TRENDS CELL BIOL, V6, P274, DOI 10.1016/0962-8924(96)10023-4; WHITWAM RE, 1990, J EXP BIOL, V154, P321; WINGENDERDRISSEN R, 1983, FEBS LETT, V163, P28, DOI 10.1016/0014-5793(83)81155-7; WOODGETT J, 1995, PROTEIN KINASE FACTS, V1, P231; Zhan XL, 2000, MOL BIOL CELL, V11, P663, DOI 10.1091/mbc.11.2.663; ZOLLER MJ, 1988, J BIOL CHEM, V263, P9142	51	22	22	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 10	2002	277	19					16814	16822		10.1074/jbc.M112349200	http://dx.doi.org/10.1074/jbc.M112349200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	551MB	11877433	hybrid			2022-12-27	WOS:000175564500063
J	Serre, MC; Letzelter, C; Garel, JR; Duguet, M				Serre, MC; Letzelter, C; Garel, JR; Duguet, M			Cleavage properties of an archaeal site-specific recombinase, the SSV1 integrase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; SULFOLOBUS-SHIBATAE; GENETIC ELEMENTS; TOPOISOMERASE-I; STRAND EXCHANGE; ACTIVE-SITE; FAMILY; DNA; VIRUS; SIMILARITIES	SSV1 is a virus infecting the extremely thermophilic archaeon Sulfolobus shibatae. The viral-encoded integrase is responsible for site-specific integration of SSV1 into its host genome. The recombinant enzyme was expressed in Escherichia coli, purified to homogeneity, and its biochemical properties investigated in vitro. We show that the SSV1 integrase belongs to the tyrosine recombinases family and that Tyr(314) is involved in the formation of a 3'-phosphotyrosine intermediate. The integrase cleaves both strands of a synthetic substrate in a temperature-dependent reaction, the cleavage efficiency increasing with temperature. A discontinuity was observed in the Arrhenius plot above 50 degreesC, suggesting that a conformational transition may occur in the integrase at this temperature. Analysis of cleavage time course suggested that noncovalent binding of the integrase to its substrate is rate-limiting in the cleavage reaction. The cleavage positions were localized on each side of the anticodon loop of the tRNA gene where SSV1 integration takes place. Finally, the SSV1 integrase is able to cut substrates harboring mismatches in the binding site. For the cleavage step, the chemical nature of the base in position -1 of cleavage seems to be more important than its pairing to the opposite strand.	CNRS, Lab Enzymol & Biochim Struct, F-91198 Gif Sur Yvette, France; Univ Paris 11, Inst Genet & Microbiol, Lab Enzymol Acides Nucl, F-91405 Orsay, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; UDICE-French Research Universities; Universite Paris Saclay	Serre, MC (corresponding author), CNRS, Lab Enzymol & Biochim Struct, Bat 34,Ave Terrasse, F-91198 Gif Sur Yvette, France.		Serre, Marie-Claude/B-4159-2008	SERRE, Marie-Claude/0000-0002-7899-9833				ABREMSKI KE, 1992, PROTEIN ENG, V5, P87, DOI 10.1093/protein/5.1.87; ARGOS P, 1986, EMBO J, V5, P433, DOI 10.1002/j.1460-2075.1986.tb04229.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brand L., 1967, METHODS ENZYMOL, P776, DOI [10.1016/S0076-6879(67)11091-4, DOI 10.1016/S0076-6879(67)11091-4]; CAMPBELL AM, 1992, J BACTERIOL, V174, P7495, DOI 10.1128/JB.174.23.7495-7499.1992; CASADABAN MJ, 1980, J MOL BIOL, V138, P179, DOI 10.1016/0022-2836(80)90283-1; Cheng CH, 1998, CELL, V92, P841, DOI 10.1016/S0092-8674(00)81411-7; DUPONT L, 1995, J BACTERIOL, V177, P586, DOI 10.1128/jb.177.3.586-595.1995; Esposito D, 1997, NUCLEIC ACIDS RES, V25, P3605, DOI 10.1093/nar/25.18.3605; Grainge I, 1999, MOL MICROBIOL, V33, P449, DOI 10.1046/j.1365-2958.1999.01493.x; GUZMAN LM, 1995, J BACTERIOL, V177, P4121, DOI 10.1128/jb.177.14.4121-4130.1995; Hallet B, 1997, FEMS MICROBIOL REV, V21, P157, DOI 10.1016/S0168-6445(97)00055-7; HAUSER MA, 1992, J BIOL CHEM, V267, P6859; HENSEL R, 1987, EUR J BIOCHEM, V170, P325, DOI 10.1111/j.1432-1033.1987.tb13703.x; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Maniatis T., 1982, MOL CLONING LAB MANU; MESSING J, 1983, METHOD ENZYMOL, V101, P20; MUSKHELISHVILI G, 1994, SYST APPL MICROBIOL, V16, P605; MUSKHELISHVILI G, 1993, MOL GEN GENET, V237, P334, DOI 10.1007/BF00279436; Nash H, 1996, ESCHERICHIA COLI SAL, V2, P2363; Nunes-Duby SE, 1998, NUCLEIC ACIDS RES, V26, P391, DOI 10.1093/nar/26.2.391; PALM P, 1991, VIROLOGY, V185, P242, DOI 10.1016/0042-6822(91)90771-3; Pena CEA, 1996, J BACTERIOL, V178, P5533, DOI 10.1128/jb.178.18.5533-5536.1996; PIERSON LS, 1987, J MOL BIOL, V196, P487, DOI 10.1016/0022-2836(87)90026-X; Raynal A, 1998, MOL MICROBIOL, V28, P333, DOI 10.1046/j.1365-2958.1998.00799.x; REITER WD, 1989, NUCLEIC ACIDS RES, V17, P1907, DOI 10.1093/nar/17.5.1907; SCHLEPER C, 1992, P NATL ACAD SCI USA, V89, P7645, DOI 10.1073/pnas.89.16.7645; Sherratt DJ, 1998, CELL, V93, P149, DOI 10.1016/S0092-8674(00)81566-4; SHUMAN S, 1991, J BIOL CHEM, V266, P11372; WRBA A, 1990, BIOCHEMISTRY-US, V29, P7584, DOI 10.1021/bi00485a007; YEATS S, 1982, EMBO J, V1, P1035, DOI 10.1002/j.1460-2075.1982.tb01292.x	32	34	35	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 10	2002	277	19					16758	16767		10.1074/jbc.M200707200	http://dx.doi.org/10.1074/jbc.M200707200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	551MB	11875075	hybrid			2022-12-27	WOS:000175564500056
J	Heron-Milhavet, L; LeRoith, D				Heron-Milhavet, L; LeRoith, D			Insulin-like growth factor I induces MDM2-dependent degradation of p53 via the p38 MAPK pathway in response to DNA damage	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE EXCISION-REPAIR; NUCLEAR EXCLUSION; SIGNALING PATHWAY; HUMAN FIBROBLASTS; UV-RADIATION; MDM2; RECEPTOR; CELLS; PHOSPHORYLATION; ERCC-1	In many tissues, the insulin-like growth factor I (IGF-I) receptor (IGF-IR) is known to functionally oppose apoptosis. Recently, we demonstrated a direct role for the IGF-IR in the rescue of DNA-damaged fibroblasts by activating a DNA repair pathway (Heron-Milhavet, L., Karas, M., Goldsmith, C. M., Baum, B. J., and LeRoith, D. (2001) J. Biol. Chem. 276, 18185-18192). p53 is a nuclear transcription factor that can block progression of the cell cycle, modulate DNA repair, and trigger apoptosis. In this work, we tested the effect of IGF-I on the regulation of the p53 signaling cascade. The DNA-damaging agent 4-nitroquinoline 1-oxide was applied to NIH-3T3 cells overexpressing normal IGF-IRs (NWTb3 cells). We showed that after 4-nitroquinoline 1-oxide-induced DNA damage, IGF-I induced exclusion of the p53 protein from the nucleus and led to its degradation in the cytoplasm, whereas p53 mRNA was unaffected. Degradation of the p53 protein was associated with an increase in MDM2, an upstream modulator of the half-life and activity of the p53 protein. p53 degradation was also associated with down-regulation of p21. We further showed that the effects of IGF-I on mdm2 transcription and on MDM2/p19 ARF association were mediated by the p38 MAPK pathway. In conclusion, we describe a novel role for IGF-I in the regulation of the MDM2/p53/p21 signaling pathway during DNA damage.	NIDDK, Sect Cellular & Mol Physiol, Clin Endocrinol Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	LeRoith, D (corresponding author), NIDDK, Sect Cellular & Mol Physiol, Clin Endocrinol Branch, NIH, Bldg 10,Rm 8D12, Bethesda, MD 20892 USA.	Derek@helix.nih.gov	Heron-Milhavet, Lisa/O-4339-2017; Roszak, Joanna/F-4003-2010	Heron-Milhavet, Lisa/0000-0002-7099-0850; 				Boyd SD, 2000, NAT CELL BIOL, V2, P563, DOI 10.1038/35023500; Buschmann T, 2001, MOL CELL BIOL, V21, P2743, DOI 10.1128/MCB.21.8.2743-2754.2001; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; Heron-Milhavet L, 2001, J BIOL CHEM, V276, P18185, DOI 10.1074/jbc.M011490200; HIRAI H, 1995, MOL CELL BIOL, V15, P2672; Honda R, 1999, EMBO J, V18, P22, DOI 10.1093/emboj/18.1.22; Kannan K, 2001, ONCOGENE, V20, P2225, DOI 10.1038/sj.onc.1204319; KATO H, 1993, J BIOL CHEM, V268, P2655; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Kulik G, 1997, MOL CELL BIOL, V17, P1595, DOI 10.1128/MCB.17.3.1595; Latonen L, 2001, ONCOGENE, V20, P6784, DOI 10.1038/sj.onc.1204883; Lee-Kwon W, 1998, BIOCHEM J, V331, P591, DOI 10.1042/bj3310591; Lee-Kwon W, 1998, EXP CELL RES, V241, P458, DOI 10.1006/excr.1998.4087; Leri A, 1999, AM J PATHOL, V154, P567, DOI 10.1016/S0002-9440(10)65302-3; LEROITH D, 1995, ENDOCR REV, V16, P143, DOI 10.1210/er.16.2.143; Llanos S, 2001, NAT CELL BIOL, V3, P445, DOI 10.1038/35074506; Maki CG, 1996, CANCER RES, V56, P2649; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; Perfetti R, 1997, ENDOCRINOLOGY, V138, P1829, DOI 10.1210/en.138.5.1829; Roth J, 1998, EMBO J, V17, P554, DOI 10.1093/emboj/17.2.554; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; Smith ML, 2000, MOL CELL BIOL, V20, P3705, DOI 10.1128/MCB.20.10.3705-3714.2000; Stommel JM, 1999, EMBO J, V18, P1660, DOI 10.1093/emboj/18.6.1660; TAKAHASHI K, 1993, INT J CANCER, V55, P453, DOI 10.1002/ijc.2910550322; Takimoto R, 2001, P NATL ACAD SCI USA, V98, P781, DOI 10.1073/pnas.98.3.781; Tao WK, 1999, P NATL ACAD SCI USA, V96, P6937, DOI 10.1073/pnas.96.12.6937; Thoma F, 1999, EMBO J, V18, P6585, DOI 10.1093/emboj/18.23.6585; Valentinis, 1997, BIOCHIM BIOPHYS ACTA, V1332, P105; VANDUIN M, 1986, CELL, V44, P913, DOI 10.1016/0092-8674(86)90014-0; Wu L, 1997, MOL MED, V3, P441, DOI 10.1007/BF03401691; Zhang YP, 2001, CELL GROWTH DIFFER, V12, P175; Zhao HC, 2000, EXP CELL RES, V258, P92, DOI 10.1006/excr.2000.4906; Zhu QZ, 2000, MOL CARCINOGEN, V28, P215	34	95	97	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 3	2002	277	18					15600	15606		10.1074/jbc.M111142200	http://dx.doi.org/10.1074/jbc.M111142200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	550PA	11877395	hybrid			2022-12-27	WOS:000175510400052
J	Masaike, T; Muneyuki, E; Noji, H; Kinosita, K; Yoshida, M				Masaike, T; Muneyuki, E; Noji, H; Kinosita, K; Yoshida, M			F-1-ATPase changes its conformations upon phosphate release	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYOSIN MOTOR DOMAIN; ESCHERICHIA-COLI F1-ATPASE; THERMOPHILIC BACILLUS PS3; 2 BETA-SUBUNITS; ALPHA(3)BETA(3)GAMMA COMPLEX; CATALYTIC SITES; CRYSTAL-STRUCTURE; MOLECULAR MOTOR; ATP HYDROLYSIS; CLOSED CONFORMATION	Motor proteins, myosin, and kinesin have gamma-phosphate sensors in the switch H loop that play key roles in conformational changes that support motility. Here we report that a rotary motor, F-1-ATPase, also changes its conformations upon phosphate release. The tryptophan mutation was introduced into Arg-333 in the beta subunit of F-1-ATPase from thermophilic Bacillus PS3 as a probe of conformational changes. This residue interacts with the switch II loop (residues 308-315) of the beta subunit in a nucleotide-bound conformation. The addition of ATP to the mutant F-1 subcomplex alpha(3)beta(R333W)(3)gamma caused transient increase and subsequent decay of the Trp fluorescence. The increase was caused by conformational changes on ATP binding. The rate of decay agreed well with that of phosphate release monitored by phosphate-binding protein assays. This is the first evidence that the beta subunit changes its conformation upon phosphate release, which may share a common mechanism of exerting motility with other motor proteins.	Tokyo Inst Technol, Chem Resources Lab, Yokohama, Kanagawa 2268503, Japan; Japan Sci & Technol Corp, PRESTO, Kawaguchi 3320012, Japan; Univ Tokyo, Inst Ind Sci, Meguro Ku, Tokyo 1538505, Japan; Okazaki Natl Res Inst, Ctr Integrat Biosci, Aichi 4448585, Japan; Teikyo Univ, Biotechnol Ctr 3F, CREST, Genet Programming Team 13,Miyamae Ku, Kawasaki, Kanagawa 2160001, Japan; Japan Sci & Technol Corp, ERATO, Kawaguchi 3320012, Japan	Tokyo Institute of Technology; Japan Science & Technology Agency (JST); University of Tokyo; National Institutes of Natural Sciences (NINS) - Japan; Okazaki Institute for Integrative Bioscience (OIIB); Japan Science & Technology Agency (JST); Teikyo University; Japan Science & Technology Agency (JST)	Yoshida, M (corresponding author), Tokyo Inst Technol, Chem Resources Lab, 4259 Nagatsuta, Yokohama, Kanagawa 2268503, Japan.	myoshida@res.titech.ac.jp		Masaike, Tomoko/0000-0003-3290-1893				ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; BOYER PD, 1993, BIOCHIM BIOPHYS ACTA, V1140, P215, DOI 10.1016/0005-2728(93)90063-L; BOYER PD, 1981, ENERGY COUPLING PHOT, P407; Brune M, 1998, BIOCHEMISTRY-US, V37, P10370, DOI 10.1021/bi9804277; BRUNNING J, 1994, PERSPEKT ANALYT PHIL, V1, P33; Dominguez R, 1998, CELL, V94, P559, DOI 10.1016/S0092-8674(00)81598-6; DUNCAN TM, 1995, P NATL ACAD SCI USA, V92, P10964, DOI 10.1073/pnas.92.24.10964; FISHER AJ, 1995, BIOCHEMISTRY-US, V34, P8960, DOI 10.1021/bi00028a004; GRUBMEYER C, 1982, J BIOL CHEM, V257, P2092; Hirono-Hara Y, 2001, P NATL ACAD SCI USA, V98, P13649, DOI 10.1073/pnas.241365698; HISABORI T, 1992, J BIOL CHEM, V267, P4551; Houdusse A, 1999, CELL, V97, P459, DOI 10.1016/S0092-8674(00)80756-4; Jault JM, 1995, BIOCHEMISTRY-US, V34, P16412, DOI 10.1021/bi00050a023; Kikkawa M, 2001, NATURE, V411, P439, DOI 10.1038/35078000; KUNKEL TA, 1991, METHOD ENZYMOL, V204, P125; Kuzmic P, 1996, ANAL BIOCHEM, V237, P260, DOI 10.1006/abio.1996.0238; Lambright DG, 1996, NATURE, V379, P311, DOI 10.1038/379311a0; MATSUI T, 1995, BBA-BIOENERGETICS, V1231, P139, DOI 10.1016/0005-2728(95)00070-Y; Matsui T, 1997, J BIOL CHEM, V272, P8215, DOI 10.1074/jbc.272.13.8215; Menz RI, 2001, CELL, V106, P331, DOI 10.1016/S0092-8674(01)00452-4; Milgrom YM, 1998, BIOCHEM J, V330, P1037; Milgrom YM, 1997, J BIOL CHEM, V272, P32211, DOI 10.1074/jbc.272.51.32211; Noji H, 1997, NATURE, V386, P299, DOI 10.1038/386299a0; ODAKA M, 1994, J BIOCHEM-TOKYO, V115, P789, DOI 10.1093/oxfordjournals.jbchem.a124410; RAYMENT I, 1993, SCIENCE, V261, P50, DOI 10.1126/science.8316857; Ren H, 1999, J BIOL CHEM, V274, P31366, DOI 10.1074/jbc.274.44.31366; Rice S, 1999, NATURE, V402, P778, DOI 10.1038/45483; Sasaki N, 1998, J BIOL CHEM, V273, P20334, DOI 10.1074/jbc.273.32.20334; Shirakihara Y, 1997, STRUCTURE, V5, P825, DOI 10.1016/S0969-2126(97)00236-0; Smith CA, 1996, BIOCHEMISTRY-US, V35, P5404, DOI 10.1021/bi952633+; Suzuki Y, 1998, NATURE, V396, P380, DOI 10.1038/24640; TOZAWA K, 1995, FEBS LETT, V376, P190, DOI 10.1016/0014-5793(95)01276-2; Tsunoda SP, 1999, J BIOL CHEM, V274, P5701, DOI 10.1074/jbc.274.9.5701; TURINA P, 1994, J BIOL CHEM, V269, P13465; TURINA P, 1994, BIOCHEMISTRY-US, V33, P14275, DOI 10.1021/bi00251a040; Vale RD, 2000, SCIENCE, V288, P88, DOI 10.1126/science.288.5463.88; WEBER J, 1993, J BIOL CHEM, V268, P20126; Weber J, 1996, J BIOL CHEM, V271, P18711, DOI 10.1074/jbc.271.31.18711; Weber J, 1998, BIOCHEMISTRY-US, V37, P12042, DOI 10.1021/bi981089c; Yagi H, 1999, BIOPHYS J, V77, P2175, DOI 10.1016/S0006-3495(99)77057-8; Yasuda R, 2001, NATURE, V410, P898, DOI 10.1038/35073513; Yasuda R, 1998, CELL, V93, P1117, DOI 10.1016/S0092-8674(00)81456-7; YOSHIDA M, 1977, J BIOL CHEM, V252, P3480	43	34	34	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 14	2002	277	24					21643	21649		10.1074/jbc.M110297200	http://dx.doi.org/10.1074/jbc.M110297200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	563YR	11880367	hybrid			2022-12-27	WOS:000176286000071
J	Cussac, D; Schaak, S; Denis, C; Paris, H				Cussac, D; Schaak, S; Denis, C; Paris, H			alpha(2B)-adrenergic receptor activates MAPK via a pathway involving arachidonic acid metabolism, matrix metalloproteinases, and epidermal growth factor receptor transactivation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; ALPHA(2)-ADRENERGIC RECEPTORS; KINASE ACTIVATION; EPITHELIAL-CELLS; ANGIOTENSIN-II; STIMULATION; PHOSPHORYLATION; ENDOCYTOSIS; PROLIFERATION; ADRENOCEPTORS	We have investigated the mechanisms whereby a,,adrenergic receptor (alpha(2B)-AR) promotes MAPK activation in a clone of the renal tubular cell line, LLC-PK1, transfected with the rat nonglycosylated alpha(2)-AR gene. Treatment of LLC-PK1-alpha(2B) with UK14304 or dexmedetomidine caused arachidonic acid (AA) release and ERK2 phosphorylation. AA release was abolished by prior treatment of the cells with pertussis toxin, quinacrine, or methyl arachidonyl fluorophosphonate but not by the addition of the MEK inhibitor U0126. The effects of alpha(2)-agonists on MAPK phosphorylation were mimicked by cell exposure to exogenous AA. On the other hand, quinacrine abolished the effects of UK14304, but not of AA, suggesting that AA released through PLA2 is responsible for MAPK activation by alpha(2B)-AR. The effects of alpha(2)-agonists or AA were PKC-independent and were attenuated by indomethacin and nordihydroguaiaretic acid. Treatment with batimastat, CRM 197, or tyrphostin AG1478 suppressed MAPK phosphorylation promoted by alpha(2)-agonist or AA. Furthermore, conditioned culture medium from UK14304-treated LLC-PK1-alpha(2B) induced MAPK phosphorylation in wild-type LLC-PK1. Based on these data, we propose a model whereby activation of MAPK by alpha(2B)-AR is mediated through stimulation of PLA2, AA release, generation of AA derivatives, activation of matrix metalloproteinases, release of heparin-binding EGF-like growth factor, transactivation of epidermal growth factor receptor, and recruitment of She. Whether this pathway is particular to alpha(2B)-AR and LLC-PK1 or whether it can be extended to other cell types and/or other G-protein-coupled receptors remains to be established.	CHU Rangueil, Inst Louis Bugnard, INSERM Unit 388, F-31403 Toulouse 4, France	CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm)	Paris, H (corresponding author), CHU Rangueil, Inst Louis Bugnard, INSERM Unit 388, Bat L3, F-31403 Toulouse 4, France.		Denis, Colette/K-1571-2019; Denis, Colette/U-5267-2017; Cussac, Daniel/AAP-1544-2020	Denis, Colette/0000-0002-8376-8351; Cussac, Daniel/0000-0002-7227-898X				Attiga FA, 2000, CANCER RES, V60, P4629; BOULOUMIE A, 1994, J BIOL CHEM, V269, P30254; BYLUND DB, 1994, PHARMACOL REV, V46, P121; Capodici C, 1998, J CLIN INVEST, V102, P165, DOI 10.1172/JCI592; Chen JK, 1999, J BIOL CHEM, V274, P4764, DOI 10.1074/jbc.274.8.4764; Cussac D, 2002, AM J PHYSIOL-RENAL, V282, pF943, DOI 10.1152/ajprenal.0108.2001; DeGraff JL, 1999, J BIOL CHEM, V274, P11253, DOI 10.1074/jbc.274.16.11253; Della Rocca GJ, 1999, J BIOL CHEM, V274, P13978, DOI 10.1074/jbc.274.20.13978; DellaRocca GJ, 1997, J BIOL CHEM, V272, P19125, DOI 10.1074/jbc.272.31.19125; Dulin NO, 1998, P NATL ACAD SCI USA, V95, P8098, DOI 10.1073/pnas.95.14.8098; Dulin NO, 1998, HYPERTENSION, V32, P1089, DOI 10.1161/01.HYP.32.6.1089; ERMAN A, 1985, J BIOL CHEM, V260, P4679; FLORDELLIS CS, 1995, J BIOL CHEM, V270, P3491, DOI 10.1074/jbc.270.8.3491; HAWES BE, 1995, J BIOL CHEM, V270, P17148, DOI 10.1074/jbc.270.29.17148; Hii CST, 1998, J BIOL CHEM, V273, P19277, DOI 10.1074/jbc.273.30.19277; Jiao HY, 1998, P NATL ACAD SCI USA, V95, P7417, DOI 10.1073/pnas.95.13.7417; Kable JW, 2000, J PHARMACOL EXP THER, V293, P1; Kribben A, 1997, N-S ARCH PHARMACOL, V356, P225, DOI 10.1007/PL00005045; Lin WW, 1999, BRIT J PHARMACOL, V126, P1419, DOI 10.1038/sj.bjp.0702436; Liu FM, 2001, AM J PHYSIOL-RENAL, V280, pF415, DOI 10.1152/ajprenal.2001.280.3.F415; Nally JE, 1996, PULM PHARMACOL THER, V9, P211, DOI 10.1006/pulp.1996.0026; NORD EP, 1987, J CLIN INVEST, V80, P1755, DOI 10.1172/JCI113268; Oyekan A, 1997, AM J PHYSIOL-REG I, V273, pR293, DOI 10.1152/ajpregu.1997.273.1.R293; Pierce KL, 2001, ONCOGENE, V20, P1532, DOI 10.1038/sj.onc.1204184; Pierce KL, 2001, J BIOL CHEM, V276, P23155, DOI 10.1074/jbc.M101303200; Pierce KL, 2000, P NATL ACAD SCI USA, V97, P1489, DOI 10.1073/pnas.97.4.1489; RAO GN, 1994, J BIOL CHEM, V269, P32586; Sano H, 2001, J IMMUNOL, V166, P3515, DOI 10.4049/jimmunol.166.5.3515; Schaak S, 2000, GUT, V47, P242, DOI 10.1136/gut.47.2.242; Schramm NL, 1999, J BIOL CHEM, V274, P24935, DOI 10.1074/jbc.274.35.24935; Tsujii M, 1997, P NATL ACAD SCI USA, V94, P3336, DOI 10.1073/pnas.94.7.3336	31	45	47	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 31	2002	277	22					19882	19888		10.1074/jbc.M110142200	http://dx.doi.org/10.1074/jbc.M110142200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	557EH	11891218	hybrid			2022-12-27	WOS:000175894800085
J	Gu, JG; Fujibayashi, A; Yamada, KM; Sekiguchi, K				Gu, JG; Fujibayashi, A; Yamada, KM; Sekiguchi, K			Laminin-10/11 and fibronectin differentially prevent apoptosis induced by serum removal via phosphatidylinositol 3-kinase/Akt- and MEK1/ERK-dependent pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL ADHESION KINASE; ACTIVATED PROTEIN-KINASE; PROGRAMMED CELL-DEATH; SIGNALING PATHWAYS; EPITHELIAL-CELLS; TYROSINE KINASE; CARCINOMA CELLS; GROWTH-FACTOR; MAP KINASE; SURVIVAL	Cell adhesion to the extracellular matrix inhibits apoptosis, but the molecular mechanisms underlying the signals transduced by different matrix components are not well understood. Here, we examined integrin-mediated antiapoptotic signals from laminin-10/11 in comparison with those from fibronectin, the best characterized extracellular adhesive ligand. We found that the activation of protein kinase B/Akt in cells adhering to laminin-10/11 can rescue cell apoptosis induced by serum removal. Consistent with this, wortmannin, a specific inhibitor of phosphatidylinositol 3-kinase, or ectopic expression of a dominant-negative mutant of Akt selectively accelerated cell death upon serum removal. In contrast to laminin-10/11, fibronectin rescued cells from serum depletion-induced apoptosis mainly through the extracellular signal-regulated kinase pathway. Cell survival on fibronectin but not laminin was significantly reduced by treatment with PD98059, a specific inhibitor of mitogen- or extracellular signal-regulated kinase kinase-1 (MEK1) and by expression of a dominant-negative mutant of MEK1. Laminin-10/11 was more potent than fibronectin in preventing apoptosis induced by serum depletion. These results, taken together, demonstrate laminin-10/11 potency as a survival factor and demonstrate that different extracellular matrix components can transduce distinct survival signals through preferential activation of subsets of multiple integrin-mediated signaling pathways.	Osaka Univ, Inst Prot Res, Div Prot Chem, Suita, Osaka 5650871, Japan; NIDCR, Craniofacial Dev Biol & Regenerat Branch, NIH, Bethesda, MD 20892 USA	Osaka University; National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)	Sekiguchi, K (corresponding author), Osaka Univ, Inst Prot Res, Div Prot Chem, 3-2 Yamadaoka, Suita, Osaka 5650871, Japan.	sekiguch@protein.osaka-u.ac.jp	Gu, Jianguo/ABC-9257-2020	Yamada, Kenneth/0000-0003-1512-6805	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [ZIADE000525, ZIADE000524] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [Z01DE000525, Z01DE000524] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Almeida EAC, 2000, J CELL BIOL, V149, P741, DOI 10.1083/jcb.149.3.741; Bachelder RE, 1999, J CELL BIOL, V147, P1063, DOI 10.1083/jcb.147.5.1063; Barberis L, 2000, J BIOL CHEM, V275, P36532, DOI 10.1074/jbc.M002487200; BROOKS PC, 1994, CELL, V79, P1157, DOI 10.1016/0092-8674(94)90007-8; Chen HC, 1996, J BIOL CHEM, V271, P26329, DOI 10.1074/jbc.271.42.26329; COBB BS, 1994, MOL CELL BIOL, V14, P147, DOI 10.1128/MCB.14.1.147; Colognato H, 2000, DEV DYNAM, V218, P213, DOI 10.1002/(SICI)1097-0177(200006)218:2<213::AID-DVDY1>3.0.CO;2-R; Coniglio SJ, 2001, J BIOL CHEM, V276, P28113, DOI 10.1074/jbc.M102299200; Dolfi F, 1998, P NATL ACAD SCI USA, V95, P15394, DOI 10.1073/pnas.95.26.15394; Downward J, 1998, CURR OPIN GENET DEV, V8, P49, DOI 10.1016/S0959-437X(98)80061-0; Downward J, 1998, CURR OPIN CELL BIOL, V10, P262, DOI 10.1016/S0955-0674(98)80149-X; Erhardt P, 1999, MOL CELL BIOL, V19, P5308; Farrelly N, 1999, J CELL BIOL, V144, P1337, DOI 10.1083/jcb.144.6.1337; Frisch SM, 1996, J CELL BIOL, V134, P793, DOI 10.1083/jcb.134.3.793; FRISCH SM, 1994, J CELL BIOL, V124, P619, DOI 10.1083/jcb.124.4.619; Frisch SM, 2001, CURR OPIN CELL BIOL, V13, P555, DOI 10.1016/S0955-0674(00)00251-9; Frisch SM, 1996, J CELL BIOL, V135, P1377, DOI 10.1083/jcb.135.5.1377; Fujiwara H, 2001, J BIOL CHEM, V276, P17550, DOI 10.1074/jbc.M010155200; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Gu JG, 2001, J BIOL CHEM, V276, P27090, DOI 10.1074/jbc.M102284200; Gu JG, 1999, J CELL BIOL, V146, P389, DOI 10.1083/jcb.146.2.389; Hanks SK, 1997, BIOESSAYS, V19, P137, DOI 10.1002/bies.950190208; Hemler ME, 1998, CURR OPIN CELL BIOL, V10, P578, DOI 10.1016/S0955-0674(98)80032-X; Jost M, 2001, MOL BIOL CELL, V12, P1519, DOI 10.1091/mbc.12.5.1519; Khwaja A, 1997, EMBO J, V16, P2783, DOI 10.1093/emboj/16.10.2783; Khwaja A, 1997, J CELL BIOL, V139, P1017, DOI 10.1083/jcb.139.4.1017; Kikkawa Y, 1998, J BIOL CHEM, V273, P15854, DOI 10.1074/jbc.273.25.15854; Kikkawa Y, 2000, J CELL SCI, V113, P869; King WG, 1997, MOL CELL BIOL, V17, P4406, DOI 10.1128/MCB.17.8.4406; Le Gall M, 2000, MOL BIOL CELL, V11, P1103, DOI 10.1091/mbc.11.3.1103; Lee JW, 2000, MOL BIOL CELL, V11, P1973, DOI 10.1091/mbc.11.6.1973; Lin TH, 1997, J CELL BIOL, V136, P1385, DOI 10.1083/jcb.136.6.1385; Matter ML, 1998, J CELL BIOL, V141, P1019, DOI 10.1083/jcb.141.4.1019; MINER JH, 1995, J BIOL CHEM, V270, P28523, DOI 10.1074/jbc.270.48.28523; Montanaro F, 1999, J CELL BIOL, V145, P1325, DOI 10.1083/jcb.145.6.1325; OBrien V, 1996, EXP CELL RES, V224, P208, DOI 10.1006/excr.1996.0130; Pullan S, 1996, J CELL SCI, V109, P631; Reiske HR, 1999, J BIOL CHEM, V274, P12361, DOI 10.1074/jbc.274.18.12361; Schlaepfer DD, 1999, PROG BIOPHYS MOL BIO, V71, P435, DOI 10.1016/S0079-6107(98)00052-2; Schlaepfer DD, 1998, MOL CELL BIOL, V18, P2571, DOI 10.1128/MCB.18.5.2571; SCHLAEPFER DD, 1994, NATURE, V372, P786; Schwartz MA, 1995, ANNU REV CELL DEV BI, V11, P549, DOI 10.1146/annurev.cellbio.11.1.549; Sorokin LM, 1997, DEV BIOL, V189, P285, DOI 10.1006/dbio.1997.8668; Tamura M, 1998, SCIENCE, V280, P1614, DOI 10.1126/science.280.5369.1614; Tamura M, 1999, J BIOL CHEM, V274, P20693, DOI 10.1074/jbc.274.29.20693; Tournier C, 2000, SCIENCE, V288, P870, DOI 10.1126/science.288.5467.870; Tran SEF, 2001, J BIOL CHEM, V276, P16484, DOI 10.1074/jbc.M010384200; Walker F, 1998, MOL CELL BIOL, V18, P7192, DOI 10.1128/MCB.18.12.7192; Wary KK, 1998, CELL, V94, P625, DOI 10.1016/S0092-8674(00)81604-9; Wary KK, 1996, CELL, V87, P733, DOI 10.1016/S0092-8674(00)81392-6; Welsh CF, 2000, BBA-REV CANCER, V1471, pM21, DOI 10.1016/S0304-419X(00)00016-0; XING Z, 1994, MOL BIOL CELL, V5, P413, DOI 10.1091/mbc.5.4.413; Xiong WC, 1997, J CELL BIOL, V139, P529, DOI 10.1083/jcb.139.2.529; Yauch RL, 1998, MOL BIOL CELL, V9, P2751, DOI 10.1091/mbc.9.10.2751; Yujiri T, 1998, SCIENCE, V282, P1911, DOI 10.1126/science.282.5395.1911; Zhang ZH, 1996, CELL, V85, P61, DOI 10.1016/S0092-8674(00)81082-X; Zhao JH, 1998, J CELL BIOL, V143, P1997, DOI 10.1083/jcb.143.7.1997; Zugasti O, 2001, MOL CELL BIOL, V21, P6706, DOI 10.1128/MCB.21.19.6706-6717.2001	58	99	106	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 31	2002	277	22					19922	19928		10.1074/jbc.M200383200	http://dx.doi.org/10.1074/jbc.M200383200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	557EH	11891225	hybrid, Green Submitted			2022-12-27	WOS:000175894800090
J	Segawa, H; Kaneko, I; Takahashi, A; Kuwahata, M; Ito, M; Ohkido, I; Tatsumi, S; Miyamoto, K				Segawa, H; Kaneko, I; Takahashi, A; Kuwahata, M; Ito, M; Ohkido, I; Tatsumi, S; Miyamoto, K			Growth-related renal type IINa/P-i cotransporter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PHOSPHATE COTRANSPORTER; BORDER MEMBRANE-VESICLES; AMINO-ACID TRANSPORTER; RAT-KIDNEY; IDENTIFICATION; EXPRESSION; NAPI-2; REABSORPTION; ONTOGENY; OOCYTES	Growth is critically dependent on the retention of a variety of nutrients. The kidney contributes to this positive external balance. In the present study, we isolated a cDNA from the human and rat kidney that encodes a growth-related Na+-dependent inorganic phosphate (P-i) cotransporter (type IIc). Microinjection of type IIc cRNA into Xenopus oocytes demonstrated sodium-dependent P-i cotransport activity. Affinity for P-i was 0.07 mm in 100 mm Na+. The transport activity was dependent on extracellular pH. In electrophysiological studies, type IIc Na/P-i cotransport was electroneutral, whereas type IIa was highly electrogenic. In Northern blotting analysis, the type IIc transcript was only expressed in the kidney and highly in weaning animals. In immunohistochemical analysis, the type IIc protein was shown to be localized at the apical membrane of the proximal tubular cells in superficial and midcortical nephrons of weaning rat kidney. Hybrid depletion experiments suggested that type IIc could function as a Na/P-i cotransporter in weaning animals, but its role is reduced in adults. The finding of the present study suggest that the type IIc is a growth-related renal Na/P-i cotransporter, which has a high affinity for P-i and is electroneutral.	Univ Tokushima, Sch Med, Dept Nutr, Tokushima 7708503, Japan	Tokushima University	Miyamoto, K (corresponding author), Univ Tokushima, Sch Med, Dept Nutr, Kuramoto Cho 3, Tokushima 7708503, Japan.			Tatsumi, Sawako/0000-0002-4862-2955				Arar M, 1999, AM J PHYSIOL-RENAL, V276, pF72, DOI 10.1152/ajprenal.1999.276.1.F72; BARACNIETO M, 1991, AM J PHYSIOL, V261, pF153, DOI 10.1152/ajprenal.1991.261.1.F153; Beck L, 1998, P NATL ACAD SCI USA, V95, P5372, DOI 10.1073/pnas.95.9.5372; BUSCH A, 1994, P NATL ACAD SCI USA, V91, P8205, DOI 10.1073/pnas.91.17.8205; CAVERZASIO J, 1982, PFLUG ARCH EUR J PHY, V394, P217, DOI 10.1007/BF00589094; Chairoungdua A, 1999, J BIOL CHEM, V274, P28845, DOI 10.1074/jbc.274.41.28845; CHENG L, 1981, J BIOL CHEM, V256, P1556; Field J.A., 1999, BIOCHEM BIOPH RES CO, V258, P578; Forster I, 1998, J GEN PHYSIOL, V112, P1, DOI 10.1085/jgp.112.1.1; FORSTER I, 1991, J GEN PHYSIOL, V261, pF663; Hoag HM, 1999, J CLIN INVEST, V104, P679, DOI 10.1172/JCI7103; HOFFMANN N, 1976, PFLUG ARCH EUR J PHY, V362, P147, DOI 10.1007/BF00583641; Katai K, 1997, J BIOCHEM-TOKYO, V121, P50, DOI 10.1093/oxfordjournals.jbchem.a021569; LUCKEY TD, 1954, J NUTR, V54, P345; MAGAGNIN S, 1992, J BIOL CHEM, V267, P15384; MAGAGNIN S, 1993, P NATL ACAD SCI USA, V90, P5979, DOI 10.1073/pnas.90.13.5979; MIYAMOTO KI, 1995, BIOCHEM J, V305, P81, DOI 10.1042/bj3050081; MUER H, 2000, PHYSIOL REV, V80, P1373; NEIBERGER RE, 1989, AM J PHYSIOL, V257, pF268, DOI 10.1152/ajprenal.1989.257.2.F268; OHARA B, 1990, CELL GROWTH DIFFER, V1, P119; Segawa H, 1999, J BIOL CHEM, V274, P19745, DOI 10.1074/jbc.274.28.19745; Silverstein D, 1996, KIDNEY INT, V49, P1023, DOI 10.1038/ki.1996.148; Silverstein DM, 1997, AM J PHYSIOL-REG I, V273, pR928, DOI 10.1152/ajpregu.1997.273.3.R928; Sorribas V, 1996, KIDNEY INT, V50, P855, DOI 10.1038/ki.1996.385; Spitzer A, 2001, PEDIATR NEPHROL, V16, P763, DOI 10.1007/s004670100629; Tatsumi S, 1998, J BIOL CHEM, V273, P28568, DOI 10.1074/jbc.273.44.28568; TAUFIQ A, 1997, AM J PHYSIOL, V272, pR134; Traebert M, 1999, J AM SOC NEPHROL, V10, P1407	28	220	248	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 31	2002	277	22					19665	19672		10.1074/jbc.M200943200	http://dx.doi.org/10.1074/jbc.M200943200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	557EH	11880379	hybrid			2022-12-27	WOS:000175894800057
J	Tydell, CC; Yount, N; Tran, D; Yuan, J; Selsted, ME				Tydell, CC; Yount, N; Tran, D; Yuan, J; Selsted, ME			Isolation, characterization, and antimicrobial properties of bovine oligosaccharide-binding protein - A microbicidal granule protein of eosinophils and neutrophils	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PEPTIDOGLYCAN RECOGNITION PROTEIN; PERMEABILITY-INCREASING PROTEIN; INNATE IMMUNE-SYSTEM; CUTICULAR PROTEIN; REACTIVE OXYGEN; CLEAVAGE SITES; BETA-DEFENSINS; BOMBYX-MORI; ACTIVATION; ENDOTOXIN	Peptidoglycan recognition proteins (PGRPs) constitute a recently characterized family of pattern-recognition molecules that are conserved from insects to humans and are implicated in mammalian innate immunity. Here we report the isolation, characterization, cDNA cloning, and antimicrobial activities of a bovine PGRP ortholog termed bovine oligosaccharide-binding protein (bOBP). Milligram quantities of bOBP were purified from peripheral leukocytes, thus allowing for the characterization of the disulfide array and for determining the in vitro antimicrobial activities of the native protein. Of the tissues analyzed, bOBP mRNA was detected only in bone marrow where the protein is synthesized as a 190 amino acid precursor. The mature 169 amino acid protein is stored in the cytoplasmic granules of neutrophils and eosinophils but is absent from lymphocytes, monocytes, and platelets. bOBP was microbicidal for Gram-positive and Gram-negative bacteria and yeast at low micromolar concentrations. The finding that bOBP was microbicidal for organisms in which peptidoglycan is absent (Cryptococcus neoformans) or buried (Salmonella typhimurium) indicates that previous conclusions about the specificity of peptidoglycan recognition proteins must be reevaluated and suggests that other envelope components may mediate the antimicrobial action of PGRP family members.	Univ Calif Irvine, Coll Med, Dept Pathol, Irvine, CA 92697 USA; Univ Calif Irvine, Coll Med, Dept Microbiol & Mol Genet, Irvine, CA 92697 USA	University of California System; University of California Irvine; University of California System; University of California Irvine	Selsted, ME (corresponding author), Univ Calif Irvine, Coll Med, Dept Pathol, Irvine, CA 92697 USA.			Yount, Nannette/0000-0002-7079-5211	NIAID NIH HHS [AI22931] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI022931, R01AI022931] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Akira S, 2001, NAT IMMUNOL, V2, P675, DOI 10.1038/90609; AMREIN PC, 1980, BLOOD, V56, P442; BARANY G, 1992, INNOVATION PERSPECTI, P29; Beamer LJ, 1999, BIOCHEM PHARMACOL, V57, P225, DOI 10.1016/S0006-2952(98)00279-2; BJELLQVIST B, 1993, ELECTROPHORESIS, V14, P1023, DOI 10.1002/elps.11501401163; Bogdan C, 2000, CURR OPIN IMMUNOL, V12, P64, DOI 10.1016/S0952-7915(99)00052-7; BORREGAARD N, 1983, J CELL BIOL, V97, P52, DOI 10.1083/jcb.97.1.52; Calafat J, 2000, APMIS, V108, P201, DOI 10.1034/j.1600-0463.2000.d01-45.x; Calafat J, 1998, BLOOD, V91, P4770, DOI 10.1182/blood.V91.12.4770.412k33_4770_4775; CHONCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156; Hayashi F, 2001, NATURE, V410, P1099, DOI 10.1038/35074106; Hemmi H, 2000, NATURE, V408, P740, DOI 10.1038/35047123; HILLENKAMP F, 1991, ANAL CHEM, V63, pA1193; Hoffmann JA, 1999, SCIENCE, V284, P1313, DOI 10.1126/science.284.5418.1313; JACOBSON G, 1990, ELECTROPHORESIS, V11, P46, DOI 10.1002/elps.1150110111; Kaisho T, 2001, TRENDS IMMUNOL, V22, P78, DOI 10.1016/S1471-4906(00)01811-1; Kang DW, 1998, P NATL ACAD SCI USA, V95, P10078, DOI 10.1073/pnas.95.17.10078; KUHLMAN M, 1989, J EXP MED, V169, P1733, DOI 10.1084/jem.169.5.1733; LEHRER RI, 1991, J IMMUNOL METHODS, V137, P167, DOI 10.1016/0022-1759(91)90021-7; Lemaitre B, 1996, CELL, V86, P973, DOI 10.1016/S0092-8674(00)80172-5; Liu C, 2000, J BIOL CHEM, V275, P24490, DOI 10.1074/jbc.M001239200; Liu C, 2001, J BIOL CHEM, V276, P34686, DOI 10.1074/jbc.M105566200; Marcu O, 1998, INSECT BIOCHEM MOLEC, V28, P659, DOI 10.1016/S0965-1748(98)00048-4; Marcu O, 1999, J INSECT PHYSIOL, V45, P861, DOI 10.1016/S0022-1910(99)00070-0; Medzhitov R, 2000, TRENDS MICROBIOL, V8, P452, DOI 10.1016/S0966-842X(00)01845-X; Medzhitov R, 1997, CELL, V91, P295, DOI 10.1016/S0092-8674(00)80412-2; Nathan C, 2000, P NATL ACAD SCI USA, V97, P8841, DOI 10.1073/pnas.97.16.8841; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; Ochiai M, 1999, J BIOL CHEM, V274, P11854, DOI 10.1074/jbc.274.17.11854; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; Qureshi ST, 1999, J EXP MED, V189, P615, DOI 10.1084/jem.189.4.615; Schwandner R, 1999, J BIOL CHEM, V274, P17406, DOI 10.1074/jbc.274.25.17406; SELSTED ME, 1993, J BIOL CHEM, V268, P6641; SELSTED ME, 1984, INFECT IMMUN, V45, P150, DOI 10.1128/IAI.45.1.150-154.1984; SUMMERFIELD JA, 1995, LANCET, V345, P886, DOI 10.1016/S0140-6736(95)90009-8; Tobias PS, 1997, J BIOL CHEM, V272, P18682, DOI 10.1074/jbc.272.30.18682; Turner MW, 1996, IMMUNOL TODAY, V17, P532, DOI 10.1016/0167-5699(96)10062-1; ULEVITCH RJ, 1995, ANNU REV IMMUNOL, V13, P437, DOI 10.1146/annurev.iy.13.040195.002253; Ulevitch RJ, 1999, CURR OPIN IMMUNOL, V11, P19, DOI 10.1016/S0952-7915(99)80004-1; VANABEL RJ, 1995, INT J PEPT PROT RES, V45, P401; VONDERMOHLEN MAM, 1995, J INFECT DIS, V172, P144, DOI 10.1093/infdis/172.1.144; VONHEIJNE G, 1983, EUR J BIOCHEM, V133, P17; WEISS J, 1978, J BIOL CHEM, V253, P1664; Werner T, 2000, P NATL ACAD SCI USA, V97, P13772, DOI 10.1073/pnas.97.25.13772; Wilkins MR, 1997, ELECTROPHORESIS, V18, P403, DOI 10.1002/elps.1150180314; Yoshida H, 1996, J BIOL CHEM, V271, P13854, DOI 10.1074/jbc.271.23.13854; YOUNT NY, 1995, J IMMUNOL, V155, P4476; Yount NY, 1999, J BIOL CHEM, V274, P26249, DOI 10.1074/jbc.274.37.26249	48	107	117	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 31	2002	277	22					19658	19664		10.1074/jbc.M200659200	http://dx.doi.org/10.1074/jbc.M200659200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	557EH	11880375	hybrid			2022-12-27	WOS:000175894800056
J	Gorski, JP; Liu, FT; Artigues, A; Castagna, LF; Osdoby, P				Gorski, JP; Liu, FT; Artigues, A; Castagna, LF; Osdoby, P			New alternatively spliced form of galectin-3, a member of the beta-galactoside-binding animal lectin family, contains a predicted transmembrane-spanning domain and a leucine zipper motif	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BONE ACIDIC GLYCOPROTEIN-75; IN-GEL DIGESTION; MEMBRANE-PROTEIN; OSTEOCLAST PRECURSORS; CALCITONIN RECEPTORS; CHICKEN OSTEOCLASTS; CRYSTAL-STRUCTURE; MAC-2 ANTIGEN; EXPRESSION; CELLS	Osteoclasts or their precursors interact with the glycoprotein-enriched matrix of bone during extravasation from the vasculature, and upon attachment prior to resorption. Reverse transcriptase-PCR studies showed that two new alternatively spliced forms of chicken galectin-3, termed Gal-3TM1 and Gal-3TR1, were enriched and preferentially expressed in highly purified chicken osteoclast-like cells. Gal-3TM1 and Gal-3TR1 mRNA were also detected in chicken intestinal tissue, but not in kidney, liver, or lung. Gal-3TM1 and Gal-3TR1 messages both contain an open reading frame encoding a predicted 70-amino acid TM1 sequence inserted between the N-terminal Gly/Pro repeat domain and the carbohydrate recognition domain (exons 3 and 4). Gal-3TR1 mRNA contains an additional 241-bp sequence, which encodes a truncated open reading frame between the 4th and 5th exons, and, whose translation is expected to terminate within the carbohydrate recognition domain encompassing exons 4, 5, and 6. Immunoblotting and affinity chromatography showed that purified osteoclast preparations and intestinal homogenates contained a 36-kDa lactose-binding galectin. Matrix-assisted laser desorption/ionization time-of-flight mass spectrometric analyses on chymotryptic peptides from the 36-kDa lectin confirmed its identity as Gal-3TM1. The TM1 insert contains a single transmembrane-spanning region and a leucine zipper-like stalk domain that is predicted to position the intact carbohydrate recognition domain of Gal-3TM1 on the exterior surface of the plasma membrane. Immunofluorescent staining of chicken osteoclasts confirmed the expression of Gal-3TM1 at the plasma membrane. Gal-3TM1 is the first example of a galectin superfamily member capable of being expressed as a soluble protein and as a transmembrane protein.	Univ Missouri, Sch Biol Sci, Div Mol Biol & Biochem, Kansas City, MO 64110 USA; Univ Missouri, Sch Dent, Dept Oral Biol, Kansas City, MO 64110 USA; Univ Calif Davis, Sch Med, Dept Dermatol, Sacramento, CA 95817 USA; Univ Missouri, Sch Biol Sci, Mass Spectrometry Core Facil, Kansas City, MO 64110 USA; Agencia Cordoba Ciencia SE Unidad Ctr Excellence, RA-6420 Cordoba, Argentina; Washington Univ, Dept Biol, St Louis, MO 63130 USA	University of Missouri System; University of Missouri Kansas City; University of Missouri System; University of Missouri Kansas City; University of California System; University of California Davis; University of Missouri System; University of Missouri Kansas City; Washington University (WUSTL)	Gorski, JP (corresponding author), Univ Missouri, Sch Biol Sci, Div Mol Biol & Biochem, Rm 109B BSB,5007 Rockhill Rd, Kansas City, MO 64110 USA.		Liu, FU-TONG/A-5749-2019	Liu, FU-TONG/0000-0002-3354-1001	NIA NIH HHS [AG-1543] Funding Source: Medline; NIDCR NIH HHS [DE-11157] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R03DE011157] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		ALBRANDT K, 1987, P NATL ACAD SCI USA, V84, P6859, DOI 10.1073/pnas.84.19.6859; Balch SG, 1998, J BIOL CHEM, V273, P18656, DOI 10.1074/jbc.273.29.18656; BEYER EC, 1980, J BIOL CHEM, V255, P4236; CASTAGNA LF, 1994, J NEUROSCI RES, V37, P750, DOI 10.1002/jnr.490370609; CHERAYIL BJ, 1990, P NATL ACAD SCI USA, V87, P7324, DOI 10.1073/pnas.87.18.7324; CHERAYIL BJ, 1989, J EXP MED, V170, P1959, DOI 10.1084/jem.170.6.1959; COLLINOSDOBY P, 1991, J BONE MINER RES, V6, P1353; COLLINOSDOBY P, 1995, J BONE MINER RES, V10, P45; Colnot C, 1999, CELL MOL BIOL, V45, P1191; Colucci S., 1993, Bollettino Societa Italiana Biologia Sperimentale, V69, P295; Colucci S, 1996, J CELL SCI, V109, P1527; CROCKER PR, 1991, EMBO J, V10, P1661, DOI 10.1002/j.1460-2075.1991.tb07689.x; DAGHER SF, 1995, P NATL ACAD SCI USA, V92, P1213, DOI 10.1073/pnas.92.4.1213; ELIAM MC, 1988, J ENDOCRINOL, V119, P243, DOI 10.1677/joe.0.1190243; Essen LO, 1998, P NATL ACAD SCI USA, V95, P11673, DOI 10.1073/pnas.95.20.11673; FRIGERI LG, 1992, J IMMUNOL, V148, P861; Gitt MA, 1998, J BIOL CHEM, V273, P2954, DOI 10.1074/jbc.273.5.2954; GORSKI JP, 1990, J BIOL CHEM, V265, P14956; Gorski JP, 2000, BONE, V27, P103, DOI 10.1016/S8756-3282(00)00295-7; GORSKI JP, 1988, J BIOL CHEM, V263, P15938; HAMANN J, 1993, J IMMUNOL, V150, P4920; HELFRICH MH, 1992, J BONE MINER RES, V7, P335; HELLMAN U, 1995, ANAL BIOCHEM, V224, P451, DOI 10.1006/abio.1995.1070; Higuchi Y, 1999, BONE, V25, P17, DOI 10.1016/S8756-3282(99)00103-9; HSU DK, 1992, J BIOL CHEM, V267, P14167; HUBERT M, 1995, EXP CELL RES, V220, P397, DOI 10.1006/excr.1995.1331; Iglesias MM, 1998, GLYCOBIOLOGY, V8, P59, DOI 10.1093/glycob/8.1.59; Kadrofske MM, 1998, ARCH BIOCHEM BIOPHYS, V349, P7, DOI 10.1006/abbi.1997.0447; Kukita T, 1998, CALCIFIED TISSUE INT, V63, P140, DOI 10.1007/s002239900504; KUKITA T, 1989, LAB INVEST, V60, P532; LAKKAKORPI P, 1989, J BONE MINER RES, V4, P817; LAKKAKORPI PT, 1991, J CELL BIOL, V115, P1179, DOI 10.1083/jcb.115.4.1179; LEFFLER H, 1989, BIOCHEMISTRY-US, V28, P9222, DOI 10.1021/bi00449a039; Menon RP, 1999, EUR J BIOCHEM, V264, P569, DOI 10.1046/j.1432-1327.1999.00671.x; Midura RJ, 1996, GLYCOBIOLOGY, V6, P677, DOI 10.1093/glycob/6.7.677; MIYAUCHI A, 1991, J BIOL CHEM, V266, P20369; NICHOLSON GC, 1987, J BONE MINER RES, V2, P53; NIIDA S, 1994, J BONE MINER RES, V9, P873; Nurminskaya M, 1996, DEV DYNAM, V206, P260, DOI 10.1002/(SICI)1097-0177(199607)206:3<260::AID-AJA4>3.0.CO;2-G; Olives B, 1996, FEBS LETT, V386, P156, DOI 10.1016/0014-5793(96)00425-5; OSBORN L, 1990, CELL, V62, P3, DOI 10.1016/0092-8674(90)90230-C; OSDOBY P, 1982, J EXP ZOOL, V224, P331, DOI 10.1002/jez.1402240306; REINHOLT FP, 1990, P NATL ACAD SCI USA, V87, P4473, DOI 10.1073/pnas.87.12.4473; ROBERTSON MW, 1990, BIOCHEMISTRY-US, V29, P8093, DOI 10.1021/bi00487a015; ROSENBERG I, 1991, J BIOL CHEM, V266, P18731; ROSENBERG IM, 1993, J BIOL CHEM, V268, P12393; ROSENFELD J, 1992, ANAL BIOCHEM, V203, P173, DOI 10.1016/0003-2697(92)90061-B; ROSS FP, 1993, J BIOL CHEM, V268, P9901; SAKAKURA Y, 1990, J BIOL CHEM, V265, P21573; SATO M, 1992, FASEB J, V6, P2966, DOI 10.1096/fasebj.6.11.1644260; Seetharaman J, 1998, J BIOL CHEM, V273, P13047, DOI 10.1074/jbc.273.21.13047; SHINAR DM, 1993, J BONE MINER RES, V8, P403; TAKAHASHI N, 1994, DEV BIOL, V163, P212, DOI 10.1006/dbio.1994.1137; TAKAO M, 1988, VISION RES, V28, P471, DOI 10.1016/0042-6989(88)90169-1; TAYLOR ME, 1990, J BIOL CHEM, V265, P12156; Tsurukai T, 1998, J CELL PHYSIOL, V177, P26, DOI 10.1002/(SICI)1097-4652(199810)177:1<26::AID-JCP3>3.0.CO;2-G; Vinogradov AE, 1999, J MOL EVOL, V49, P376, DOI 10.1007/PL00006561; VONHEIJNE G, 1992, J MOL BIOL, V225, P487, DOI 10.1016/0022-2836(92)90934-C; Wada J, 1997, J CLIN INVEST, V99, P2452, DOI 10.1172/JCI119429; Wahlberg JM, 1997, J CELL BIOL, V137, P555, DOI 10.1083/jcb.137.3.555; WOO HJ, 1990, J BIOL CHEM, V265, P7097; Yang RY, 1996, P NATL ACAD SCI USA, V93, P6737, DOI 10.1073/pnas.93.13.6737; YIN XM, 1994, NATURE, V369, P321, DOI 10.1038/369321a0; Yoshikawa T, 1999, MOL IMMUNOL, V36, P1223, DOI 10.1016/S0161-5890(99)00139-X; Zhang H, 2000, BBA-GENE STRUCT EXPR, V1494, P14, DOI 10.1016/S0167-4781(00)00198-6; [No title captured]	66	30	33	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 24	2002	277	21					18840	18848		10.1074/jbc.M109578200	http://dx.doi.org/10.1074/jbc.M109578200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	558PM	11886849	hybrid			2022-12-27	WOS:000175975800078
J	Marchenko, ND; Marchenko, GN; Strongin, AY				Marchenko, ND; Marchenko, GN; Strongin, AY			Unconventional activation mechanisms of MMP-26, a human matrix metalloproteinase with a unique PHCGXXD cysteine-switch motif	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAMILY MEMBERS; EXPRESSION; SEQUENCE; CELLS; TUMOR; STROMELYSIN-1; SECRETION; INVASION; CLONING; BIOLOGY	ProMMP-26 has the unique Pro-His(81)-Cys-Gly-Xaa-Xaa-Asp cysteine-switch motif that discriminates this protease from all other matrix metalloproteinases (MMPs) known so far. The conserved, free cysteine residue of the conventional PRCXXPD sequence interacts with the zinc ion of the catalytic domain and provides the fourth coordination site for the catalytic zinc, thereby preventing latent proMMPs from becoming active. MMPs become functionally active when proteolytic cleavage releases the prodomain and the PRCXXPD sequence and exposes the zinc atom. Here, we report that the Pro-His(81)-Cys-Gly-Xaa-Xaa-Asp motif is not functional in proMMP-26 and consequently is not involved in the activation mechanisms. Organomercurial treatment failed to activate proMMP-26. The autolytic Lys-Lys-Gln(59)down arrowGln(60)-Phe-His cleavage upstream of the Pro-His(81)-Cys-Gly-Xaa-Xaa-Asp motif induced the proteolytic activity of recombinant proMMP-26 whereas any further cleavage inactivated the enzyme. The His(81) --> Arg(81) mutation restored the conventional cysteine-switch sequence in the prodomain but failed to induce the cysteine-switch activation mechanism. These data and computer modeling studies allowed us to hypothesize that the presence of His(81) significantly modified the fold of proMMP-26, abolished the functionality of the cysteine-switch motif, and stimulated an alternative intramolecular activation pathway of the proenzyme.	Burnham Inst, La Jolla, CA 92037 USA	Sanford Burnham Prebys Medical Discovery Institute	Strongin, AY (corresponding author), Burnham Inst, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.		Strongin, Alex/R-6609-2019	Strongin, Alex/0000-0003-3765-3016	NCI NIH HHS [CA83017, CA77470] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA083017, R01CA077470] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		CHEN LC, 1993, BIOCHEMISTRY-US, V32, P10289, DOI 10.1021/bi00090a003; de Coignac AB, 2000, EUR J BIOCHEM, V267, P3323; Deryugina EI, 2001, EXP CELL RES, V263, P209, DOI 10.1006/excr.2000.5118; Fingleton B, 2001, NEOPLASIA, V3, P459, DOI 10.1038/sj.neo.7900190; Galazka G, 1996, BIOCHEMISTRY-US, V35, P11221, DOI 10.1021/bi960618e; Heppner KJ, 1996, AM J PATHOL, V149, P273; Hotary K, 2000, J CELL BIOL, V149, P1309, DOI 10.1083/jcb.149.6.1309; Hotary KB, 2002, J EXP MED, V195, P295, DOI 10.1084/jem.20010815; John Anitha, 2001, Pathology and Oncology Research, V7, P14; Kotra LP, 2001, J AM CHEM SOC, V123, P3108, DOI 10.1021/ja001896a; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Lee RT, 2001, TRENDS CARDIOVAS MED, V11, P202, DOI 10.1016/S1050-1738(01)00113-X; Marchenko GN, 2002, BIOCHEM J, V363, P253, DOI 10.1042/0264-6021:3630253; Marchenko GN, 2001, BIOCHEM J, V356, P705, DOI 10.1042/0264-6021:3560705; Marchenko GN, 2001, GENE, V265, P87, DOI 10.1016/S0378-1119(01)00360-2; Marie-Claire C, 1998, J BIOL CHEM, V273, P5697, DOI 10.1074/jbc.273.10.5697; Massova I, 1998, FASEB J, V12, P1075, DOI 10.1096/fasebj.12.12.1075; Milla ME, 1999, J BIOL CHEM, V274, P30563, DOI 10.1074/jbc.274.43.30563; Murphy G, 1999, APMIS, V107, P38, DOI 10.1111/j.1699-0463.1999.tb01524.x; Nagase H, 1999, J BIOL CHEM, V274, P21491, DOI 10.1074/jbc.274.31.21491; Opdenakker G, 2001, J LEUKOCYTE BIOL, V69, P851; Park HI, 2000, J BIOL CHEM, V275, P20540, DOI 10.1074/jbc.M002349200; Parks WC, 2001, RESP RES, V2, P10, DOI 10.1186/rr33; Pei DQ, 2000, J BIOL CHEM, V275, P33988, DOI 10.1074/jbc.M006493200; Rychlewski L, 2000, PROTEIN SCI, V9, P232, DOI 10.1110/ps.9.2.232; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Sternlicht MD, 2001, ANNU REV CELL DEV BI, V17, P463, DOI 10.1146/annurev.cellbio.17.1.463; STRONGIN AY, 1995, J BIOL CHEM, V270, P5331, DOI 10.1074/jbc.270.10.5331; Uria JA, 2000, CANCER RES, V60, P4745; VanMeter TE, 2001, J NEURO-ONCOL, V53, P213, DOI 10.1023/A:1012280925031; VANWART HE, 1990, P NATL ACAD SCI USA, V87, P5578, DOI 10.1073/pnas.87.14.5578; Velasco G, 1999, J BIOL CHEM, V274, P4570, DOI 10.1074/jbc.274.8.4570	32	38	39	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 24	2002	277	21					18967	18972		10.1074/jbc.M201197200	http://dx.doi.org/10.1074/jbc.M201197200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	558PM	11889136	hybrid			2022-12-27	WOS:000175975800094
J	Cui, Y; Miyoshi, K; Claudio, E; Siebenlist, UK; Gonzalez, FJ; Flaws, J; Wagner, KU; Hennighausen, L				Cui, Y; Miyoshi, K; Claudio, E; Siebenlist, UK; Gonzalez, FJ; Flaws, J; Wagner, KU; Hennighausen, L			Loss of the peroxisome proliferation-activated receptor gamma (PPAR gamma) does not affect mammary development and propensity for tumor formation but leads to reduced fertility	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN BREAST-CANCER; IN-VITRO; TERMINAL DIFFERENTIATION; INDUCE APOPTOSIS; RETINOIC ACID; LUTEIN CELLS; EXPRESSION; LIGAND; MICE; GENE	The peroxisome proliferation-activated receptor gamma (PPARgamma) is expressed in many cell types including mammary epithelium, ovary, macrophages, and Band T-cells. PPARgamma has an anti-proliferative effect in pre-adipocytes and mammary epithelial cells, and treatment with its ligands reduced the progression of carcinogen-induced mammary tumors in mice. Because PPARgamma-null mice die in utero it has not been possible to study its role in development and tumorigenesis in vivo. To investigate whether PPARgamma is required for the establishment and physiology of different cell types, a cell-specific deletion of the gene was carried out in mice using the Cre-loxP recombination system. We deleted the PPARgamma gene in mammary epithelium using WAP-Cre transgenic mice and in epithelial cells, B- and T-cells, and ovary cells using MMTV-Cre mice. The presence of PPARgamma was not required for functional development of the mammary gland during pregnancy and for the establishment of B- and T-cells. In addition, no increase in mammary tumors was observed. However, loss of the PPARgamma gene in oocytes and granulosa cells resulted in impaired fertility. These mice have normal populations of follicles, they ovulate and develop corpora lutea. Although progesterone levels are decreased and implantation rates are reduced, the exact cause of the impaired fertility remains to be determined.	NIDDK, Lab Genet & Physiol, NIH, Bethesda, MD 20892 USA; NIAID, Immunoregulat Lab, Immune Activat Sect, NIH, Bethesda, MD 20892 USA; NCI, Lab Metab, NIH, Bethesda, MD 20892 USA; Univ Maryland, Sch Med, Dept Epidemiol & Prevent Med, Baltimore, MD 21201 USA; Univ Nebraska, Med Ctr, Eppley Inst Res Canc & Allied Dis, Omaha, NE 68198 USA; Univ Tokushima, Sch Dent, Dept Biochem, Tokushima 7708504, Japan	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University System of Maryland; University of Maryland Baltimore; University of Nebraska System; University of Nebraska Medical Center; Tokushima University	Hennighausen, L (corresponding author), NIDDK, Lab Genet & Physiol, NIH, Bldg 8,Rm 107,8 Ctr Dr, Bethesda, MD 20892 USA.		Wagner, Kay-Uwe/B-6044-2009	Hennighausen, Lothar/0000-0001-8319-9841; Wagner, Kay-Uwe/0000-0002-5081-0226; Miyoshi, Keiko/0000-0001-6910-4172; Flaws, Jodi/0000-0001-5579-9268	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000722, ZIAAI000722] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [ZIADK061000, Z01DK061000] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Akiyama TE, 2002, MOL CELL BIOL, V22, P2607, DOI 10.1128/MCB.22.8.2607-2619.2002; Barak Y, 1999, MOL CELL, V4, P585, DOI 10.1016/S1097-2765(00)80209-9; Binart N, 2000, ENDOCRINOLOGY, V141, P2691, DOI 10.1210/en.141.7.2691; Braissant O, 1996, ENDOCRINOLOGY, V137, P354, DOI 10.1210/en.137.1.354; Chang TH, 2000, CANCER RES, V60, P1129; CHAWLA A, 1994, ENDOCRINOLOGY, V135, P798, DOI 10.1210/en.135.2.798; Clark RB, 2000, J IMMUNOL, V164, P1364, DOI 10.4049/jimmunol.164.3.1364; DEOME KB, 1959, CANCER RES, V19, P515; Elstner E, 1998, P NATL ACAD SCI USA, V95, P8806, DOI 10.1073/pnas.95.15.8806; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; Gasic S, 1998, ENDOCRINOLOGY, V139, P4962, DOI 10.1210/en.139.12.4962; Hennighausen L, 2001, DEV CELL, V1, P467, DOI 10.1016/S1534-5807(01)00064-8; Keelan JA, 1999, BIOCHEM BIOPH RES CO, V262, P579, DOI 10.1006/bbrc.1999.1257; KLIEWER SA, 1992, NATURE, V358, P771, DOI 10.1038/358771a0; Komar CM, 2001, ENDOCRINOLOGY, V142, P4831, DOI 10.1210/en.142.11.4831; KORDON EC, 1995, DEV BIOL, V168, P47, DOI 10.1006/dbio.1995.1060; Kubota N, 1999, MOL CELL, V4, P597, DOI 10.1016/S1097-2765(00)80210-5; Kubota T, 1998, CANCER RES, V58, P3344; Lambe KG, 1996, EUR J BIOCHEM, V239, P1, DOI 10.1111/j.1432-1033.1996.0001u.x; Law RE, 2000, CIRCULATION, V101, P1311, DOI 10.1161/01.CIR.101.11.1311; Lefebvre AM, 1998, NAT MED, V4, P1053, DOI 10.1038/2036; LEHMANN JM, 1995, J BIOL CHEM, V270, P12953, DOI 10.1074/jbc.270.22.12953; Lohrke B, 1998, J ENDOCRINOL, V159, P429, DOI 10.1677/joe.0.1590429; Mehta RG, 2000, J NATL CANCER I, V92, P418, DOI 10.1093/jnci/92.5.418; Mueller E, 1998, MOL CELL, V1, P465, DOI 10.1016/S1097-2765(00)80047-7; Padilla J, 2000, J IMMUNOL, V165, P6941, DOI 10.4049/jimmunol.165.12.6941; Pighetti GM, 2001, ANTICANCER RES, V21, P825; Reese J, 2000, ENDOCRINOLOGY, V141, P1872, DOI 10.1210/en.141.5.1872; Robinson GW, 2001, ONCOGENE, V20, P7115, DOI 10.1038/sj.onc.1204888; Rosen ED, 1999, MOL CELL, V4, P611, DOI 10.1016/S1097-2765(00)80211-7; Saez E, 1998, NAT MED, V4, P1058, DOI 10.1038/2042; Sarraf P, 1998, NAT MED, V4, P1046, DOI 10.1038/2030; Soriano P, 1999, NAT GENET, V21, P70, DOI 10.1038/5007; Spiegelman B M, 1997, Eur J Med Res, V2, P457; Spiegelman BM, 1996, CELL, V87, P377, DOI 10.1016/S0092-8674(00)81359-8; Spiegelman BM, 1998, CELL, V93, P153, DOI 10.1016/S0092-8674(00)81567-6; Sundvold H, 1997, BIOCHEM BIOPH RES CO, V239, P857, DOI 10.1006/bbrc.1997.7564; Tontonoz P, 1997, P NATL ACAD SCI USA, V94, P237, DOI 10.1073/pnas.94.1.237; TONTONOZ P, 1994, GENE DEV, V8, P1224, DOI 10.1101/gad.8.10.1224; Tontonoz P, 1998, CELL, V93, P241, DOI 10.1016/S0092-8674(00)81575-5; Viergutz T, 2000, J REPROD FERTIL, V118, P153, DOI 10.1530/reprod/118.1.153; Wagner KU, 1997, NUCLEIC ACIDS RES, V25, P4323, DOI 10.1093/nar/25.21.4323; Wagner KU, 2001, TRANSGENIC RES, V10, P545, DOI 10.1023/A:1013063514007	43	148	157	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 17	2002	277	20					17830	17835		10.1074/jbc.M200186200	http://dx.doi.org/10.1074/jbc.M200186200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	553PR	11884400	hybrid			2022-12-27	WOS:000175685100057
J	Gu, CH; Limberg, BJ; Whitaker, GB; Perman, B; Leahy, DJ; Rosenbaum, JS; Ginty, DD; Kolodkin, AL				Gu, CH; Limberg, BJ; Whitaker, GB; Perman, B; Leahy, DJ; Rosenbaum, JS; Ginty, DD; Kolodkin, AL			Characterization of neuropilin-1 structural features that confer binding to semaphorin 3A and vascular endothelial growth factor 165	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-SURFACE MOLECULE; NERVOUS-SYSTEM; AXON GUIDANCE; RECEPTOR; DOMAIN; TRANSMEMBRANE; VERTEBRATES; EXPRESSION; EPHRIN-B2; PROTEIN	Neuropilin-1 (Npn-1) is a receptor for both semaphorin 3A (Sema3A) and vascular endothelial growth factor 165 (VEGF(165)). To understand the role Npn-1 plays as a receptor for these structurally and functionally unrelated ligands, we set out to identify structural features of Npn-1 that confer binding to Sema3A or VEGF(165). We constructed Npn-1 variants containing deletions within the "a" and "b" domains of Npn-1. More than 16 variants were expressed in COS-1 cells and tested for alkaline phosphatase-Sema3A as well as alkaline phosphatase-VEGF(165) binding. Our results indicate that each of the two Npn-1 CUB domains and the amino-terminal coagulation factor V/VIII domain (CF V/VIII) are essential for Sema3A binding, but only the amino-terminal Npn-1 CF V/VIII domain is required for binding to VEGF(165). Guided by the structure of the bovine spermadhesin CUB domain, point mutants targeting defined surfaces of the Npn-1 a1 CUB domain were generated and tested for Sema3A and VEGF(165) binding. One Npn-1 variant, Npn-1(2ABC), exhibits complete loss of Sema3A binding while retaining normal VEGF165 binding. Moreover, co-immunoprecipitation experiments show that Npn-1(2ABC) can form a signaling complex with the VEGF(165) signaling receptor KDR/VEGFR-2. These results establish the identity of contact sites between Npn-1 and its semaphorin ligands, and they provide a foundation for understanding how Npn-1 functions as a receptor for distinct classes of ligands in vivo.	Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Howard Hughes Med Inst, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Biophys & Biophys Chem, Baltimore, MD 21205 USA; Procter & Gamble Pharmaceut, Mason, OH 45040 USA	Johns Hopkins University; Howard Hughes Medical Institute; Johns Hopkins University; Johns Hopkins University; Procter & Gamble	Ginty, DD (corresponding author), Johns Hopkins Univ, Sch Med, Dept Neurosci, 725 N Wolfe St, Baltimore, MD 21205 USA.				NIMH NIH HHS [R01MH59199] Funding Source: Medline; NINDS NIH HHS [5F32NS11016-02] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH059199] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [F32NS011016] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Bagnard D, 2001, J NEUROSCI, V21, P3332, DOI 10.1523/JNEUROSCI.21-10-03332.2001; Brunger A. T., 1992, XPLOR VERSION 3 1 SY; Chen H, 1998, NEURON, V21, P1283, DOI 10.1016/S0896-6273(00)80648-0; Cheng HJ, 2001, NEURON, V32, P249, DOI 10.1016/S0896-6273(01)00478-0; EVANS SV, 1993, J MOL GRAPHICS, V11, P127; Feiner L, 2001, DEVELOPMENT, V128, P3061; Ferrara N, 2001, AM J PHYSIOL-CELL PH, V280, pC1358, DOI 10.1152/ajpcell.2001.280.6.C1358; FLANAGAN JG, 1990, CELL, V63, P185, DOI 10.1016/0092-8674(90)90299-T; Fujisawa H, 1997, CELL TISSUE RES, V290, P465, DOI 10.1007/s004410050954; Gerety SS, 1999, MOL CELL, V4, P403, DOI 10.1016/S1097-2765(00)80342-1; Giger RJ, 1998, NEURON, V21, P1079, DOI 10.1016/S0896-6273(00)80625-X; Goodman CS, 1999, CELL, V97, P551, DOI 10.1016/S0092-8674(00)80766-7; He ZG, 1997, CELL, V90, P739, DOI 10.1016/S0092-8674(00)80534-6; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kawakami A, 1996, J NEUROBIOL, V29, P1, DOI 10.1002/(SICI)1097-4695(199601)29:1<1::AID-NEU1>3.0.CO;2-F; Kawasaki T, 1999, DEVELOPMENT, V126, P4895; Kitsukawa T, 1997, NEURON, V19, P995, DOI 10.1016/S0896-6273(00)80392-X; Kolodkin AL, 1997, CELL, V90, P753, DOI 10.1016/S0092-8674(00)80535-8; Miao HQ, 1999, J CELL BIOL, V146, P233, DOI 10.1083/jcb.146.1.233; MOTULSKY HJ, 1987, FASEB J, V1, P365, DOI 10.1096/fasebj.1.5.3315805; Nakamura F, 1998, NEURON, V21, P1093, DOI 10.1016/S0896-6273(00)80626-1; Nakamura F, 2000, J NEUROBIOL, V44, P219, DOI 10.1002/1097-4695(200008)44:2<219::AID-NEU11>3.0.CO;2-W; Neufeld G, 1999, FASEB J, V13, P9, DOI 10.1096/fasebj.13.1.9; Raper JA, 2000, CURR OPIN NEUROBIOL, V10, P88, DOI 10.1016/S0959-4388(99)00057-4; Renzi MJ, 1999, J NEUROSCI, V19, P7870; Romero A, 1997, NAT STRUCT BIOL, V4, P783, DOI 10.1038/nsb1097-783; Shimizu M, 2000, J CELL BIOL, V148, P1283, DOI 10.1083/jcb.148.6.1283; Soker S, 1998, CELL, V92, P735, DOI 10.1016/S0092-8674(00)81402-6; Sondell M, 2000, EUR J NEUROSCI, V12, P4243, DOI 10.1046/j.0953-816X.2000.01326.x; TAKAGI S, 1987, DEV BIOL, V122, P90, DOI 10.1016/0012-1606(87)90335-6; TAKAGI S, 1991, NEURON, V7, P295, DOI 10.1016/0896-6273(91)90268-5; TAKAGI S, 1995, DEV BIOL, V170, P207, DOI 10.1006/dbio.1995.1208; Takahashi T, 2001, NEURON, V29, P429, DOI 10.1016/S0896-6273(01)00216-1; Takahashi T, 1999, CELL, V99, P59, DOI 10.1016/S0092-8674(00)80062-8; Tamagnone L, 1999, CELL, V99, P71, DOI 10.1016/S0092-8674(00)80063-X; TessierLavigne M, 1996, SCIENCE, V274, P1123, DOI 10.1126/science.274.5290.1123; Wang HU, 1998, CELL, V93, P741, DOI 10.1016/S0092-8674(00)81436-1; Whitaker GB, 2001, J BIOL CHEM, V276, P25520, DOI 10.1074/jbc.M102315200; Wilkinson DG, 2000, INT REV CYTOL, V196, P177	39	185	194	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 17	2002	277	20					18069	18076		10.1074/jbc.M201681200	http://dx.doi.org/10.1074/jbc.M201681200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	553PR	11886873	hybrid			2022-12-27	WOS:000175685100086
J	Jeong, DW; Yoo, MH; Kim, TS; Kim, JH; Kim, IY				Jeong, DW; Yoo, MH; Kim, TS; Kim, JH; Kim, IY			Protection of mice from allergen-induced asthma by selenite - prevention of eosinophil infiltration by inhibition of NF-kappa B activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOTHELIAL-CELLS; AIRWAY HYPERRESPONSIVENESS; TRANSCRIPTION FACTOR; CANCER PREVENTION; PROINFLAMMATORY CYTOKINE; GLUTATHIONE-PEROXIDASE; THIOREDOXIN REDUCTASE; HYDROGEN-PEROXIDE; OXIDATIVE STRESS; REDOX MECHANISM	The potential anti-inflammatory effect of sodium selenite in a mouse model of asthma was investigated. Selenite was injected into the peritoneum of allergen (ovalbumin) -sensitized mice before allergen challenge. Ovalbumin challenge resulted in activation of the transcription factor NF-kappaB and an increase in the expression of cell adhesion molecules (intercellular adhesion molecule 1, vascular cell adhesion molecule 1, and E-selectin, which are encoded by NF-kappaB-dependent genes) in lung tissue as well as in the recruitment of eosinophils to lung airways. These effects of ovalbumin challenge were all inhibited by pretreatment of mice with selenite. Selenite administration also increased the activity of selenium-dependent glutathione peroxidase in lung tissue. Furthermore, supplementation of A549 human airway epithelial cell cultures with selenite increased glutathione peroxidase activity as well as inhibited both the generation of hydrogen peroxide and the activation of NF-kappaB induced by tumor necrosis factor alpha in these cells. Selenite also reversed in vitro the activation of NF-kappaB induced by this cytokine in intact A549 cells. These results suggest that selenite regulates the activity of NF-kappaB by increasing the activity of glutathione peroxidase, thereby removing potential activators of NF-kappaB, and possibly also by direct oxidation of critical sulfhydryl groups of this transcription factor. These effects of selenite likely underlie its anti-inflammatory action in asthma.	Korea Univ, Grad Sch Biotechnol, Lab Cellular & Mol Biochem, Seoul 136701, South Korea; Kwangju Inst Sci & Technol, Dept Life Sci, Kwangju 500712, South Korea	Korea University; Gwangju Institute of Science & Technology (GIST)	Kim, IY (corresponding author), Korea Univ, Grad Sch Biotechnol, Lab Cellular & Mol Biochem, 1 5-Ka, Seoul 136701, South Korea.		Kim, Jae-Hong/B-2530-2009	Kim, Jae-Hong/0000-0002-8019-0208				Adler V, 1996, CARCINOGENESIS, V17, P1849, DOI 10.1093/carcin/17.9.1849; Baker JC, 2000, RESP MED, V94, P925, DOI 10.1053/rmed.2000.0873; BERGAD PL, 1986, CURR EYE RES, V5, P919, DOI 10.3109/02713688608995172; BERRY MJ, 1991, NATURE, V353, P273, DOI 10.1038/353273a0; Bonizzi G, 1999, MOL CELL BIOL, V19, P1950; Caffrey PB, 2000, CANCER CHEMOTH PHARM, V46, P74, DOI 10.1007/s002800000127; Chen F, 1999, CLIN CHEM, V45, P7; Cheng TH, 1999, CARDIOVASC RES, V41, P654, DOI 10.1016/S0008-6363(98)00275-2; Choi JH, 2000, INFLAMMATION, V24, P385, DOI 10.1023/A:1007068010645; Christman JW, 2000, CHEST, V117, P1482, DOI 10.1378/chest.117.5.1482; Clark LC, 1996, JAMA-J AM MED ASSOC, V276, P1957, DOI 10.1001/jama.276.24.1957; Collard CD, 1998, IMMUNOPHARMACOLOGY, V39, P39, DOI 10.1016/S0162-3109(97)00096-9; Elias JA, 1999, J CLIN INVEST, V104, P1001, DOI 10.1172/JCI8124; EPP O, 1983, EUR J BIOCHEM, V133, P51, DOI 10.1111/j.1432-1033.1983.tb07429.x; Feghali CA, 1997, FRONT BIOSCI, V2, P12; Ganther HE, 1999, CARCINOGENESIS, V20, P1657, DOI 10.1093/carcin/20.9.1657; Gladyshev VN, 1996, P NATL ACAD SCI USA, V93, P6146, DOI 10.1073/pnas.93.12.6146; Gopalakrishna R, 1997, ARCH BIOCHEM BIOPHYS, V348, P37, DOI 10.1006/abbi.1997.0335; Hamelmann E, 1999, AM J RESP CELL MOL, V21, P480, DOI 10.1165/ajrcmb.21.4.3659; HANDEL ML, 1995, P NATL ACAD SCI USA, V92, P4497, DOI 10.1073/pnas.92.10.4497; Hart L, 2000, AM J RESP CRIT CARE, V161, P224, DOI 10.1164/ajrccm.161.1.9809019; Haycock JW, 2000, J BIOL CHEM, V275, P15629, DOI 10.1074/jbc.275.21.15629; Helmy MH, 2000, TOXICOLOGY, V144, P57, DOI 10.1016/S0300-483X(99)00190-0; Holben DH, 1999, J AM DIET ASSOC, V99, P836, DOI 10.1016/S0002-8223(99)00198-4; Ip C, 1998, J NUTR, V128, P1845, DOI 10.1093/jn/128.11.1845; IP C, 1985, FED PROC, V44, P2573; ISLAM F, 1991, ARCH BIOCHEM BIOPHYS, V289, P161, DOI 10.1016/0003-9861(91)90456-S; Kanehiro A, 2001, AM J RESP CRIT CARE, V163, P173, DOI 10.1164/ajrccm.163.1.2001118; Kang SW, 1998, J BIOL CHEM, V273, P6297, DOI 10.1074/jbc.273.11.6297; Kim I, 2001, J BIOL CHEM, V276, P7614, DOI 10.1074/jbc.M009705200; Kim IY, 1997, P NATL ACAD SCI USA, V94, P12904, DOI 10.1073/pnas.94.24.12904; KretzRemy C, 1996, J CELL BIOL, V133, P1083, DOI 10.1083/jcb.133.5.1083; Lewis AJ, 1999, CURR OPIN CHEM BIOL, V3, P489, DOI 10.1016/S1367-5931(99)80071-4; Lu SC, 1999, FASEB J, V13, P1169, DOI 10.1096/fasebj.13.10.1169; Makropoulos V, 1996, ARCH TOXICOL, V70, P277, DOI 10.1007/s002040050274; Matsukura S, 1999, J IMMUNOL, V163, P6876; Oitzinger W, 2001, BLOOD, V97, P1611, DOI 10.1182/blood.V97.6.1611; Pallud S, 1997, J BIOL CHEM, V272, P18104, DOI 10.1074/jbc.272.29.18104; Park HS, 2000, J BIOL CHEM, V275, P8487, DOI 10.1074/jbc.275.12.8487; Park HS, 2000, J BIOL CHEM, V275, P2527, DOI 10.1074/jbc.275.4.2527; Picado C, 2001, ALLERGY, V56, P43, DOI 10.1034/j.1398-9995.2001.00793.x; Rao CV, 2000, CARCINOGENESIS, V21, P617, DOI 10.1093/carcin/21.4.617; Schieke SM, 1999, FEBS LETT, V448, P301, DOI 10.1016/S0014-5793(99)00372-5; SCHMIDT KN, 1995, CHEM BIOL, V2, P13, DOI 10.1016/1074-5521(95)90076-4; SCHULZEOSTHOFF K, 1993, EMBO J, V12, P3095, DOI 10.1002/j.1460-2075.1993.tb05978.x; Sinha R, 1997, CARCINOGENESIS, V18, P1541, DOI 10.1093/carcin/18.8.1541; Soutar A, 1997, THORAX, V52, P166, DOI 10.1136/thx.52.2.166; Stapleton SR, 1997, BBA-MOL CELL RES, V1355, P259, DOI 10.1016/S0167-4889(96)00140-1; Stewart MS, 1999, FREE RADICAL BIO MED, V26, P42, DOI 10.1016/S0891-5849(98)00147-6; TASHIMA Y, 1989, J BIOCHEM-TOKYO, V105, P358, DOI 10.1093/oxfordjournals.jbchem.a122668; Teixeira MM, 1997, J CLIN INVEST, V100, P1657, DOI 10.1172/JCI119690; Tolando R, 2000, FREE RADICAL BIO MED, V28, P979, DOI 10.1016/S0891-5849(00)00183-0; Tomkinson A, 2001, J IMMUNOL, V166, P5792, DOI 10.4049/jimmunol.166.9.5792; Webb DC, 2001, IMMUNOL CELL BIOL, V79, P165, DOI 10.1046/j.1440-1711.2001.00989.x; Yamamoto Y, 2001, J CLIN INVEST, V107, P135, DOI 10.1172/JCI11914; Yang LY, 1998, J EXP MED, V188, P1739, DOI 10.1084/jem.188.9.1739	56	78	83	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 17	2002	277	20					17871	17876		10.1074/jbc.M200808200	http://dx.doi.org/10.1074/jbc.M200808200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	553PR	11897787	hybrid			2022-12-27	WOS:000175685100062
J	Mukherjee, S; Gurevich, VV; Preninger, A; Hamm, HE; Bader, MF; Fazleabas, AT; Birnbaumer, L; Hunzicker-Dunn, M				Mukherjee, S; Gurevich, VV; Preninger, A; Hamm, HE; Bader, MF; Fazleabas, AT; Birnbaumer, L; Hunzicker-Dunn, M			Aspartic acid 564 in the third cytoplasmic loop of the luteinizing hormone/choriogonadotropin receptor is crucial for phosphorylation-independent interaction with arrestin2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OVARIAN FOLLICULAR MEMBRANES; 3RD INTRACELLULAR LOOP; CHORIONIC-GONADOTROPIN RECEPTOR; PROTEIN-COUPLED RECEPTORS; LUTROPIN-CHORIOGONADOTROPIN RECEPTOR; AGONIST-INDUCED PHOSPHORYLATION; BETA-ADRENERGIC-RECEPTOR; RIBOSYLATION FACTOR ARF; ADP-RIBOSYLATION; LUTROPIN/CHORIOGONADOTROPIN RECEPTOR	Arrestin2 binding to the active but unphosphorylated luteinizing hormone/choriogonadotropin receptor (LH/CG R) in ovarian follicles is triggered by activation of ADP-ribosylation factor 6 (ARF6) and leads to uncoupling of this receptor from cAMP signaling. We sought to determine how arrestin2 binds to LH/CG It, if binding is of high affinity, and if the receptor also binds arrestin3. Desensitization of intact LH/CG R was equally sensitive to ectopic constructs of arrestin2 that bind other G protein-coupled receptors (GPCRs) either in a phosphorylation-independent or -dependent manner. Intact LH/CG R was not desensitized by ectopic arrestin3 constructs. Surface plasmon resonance studies showed that arrestin2 bound a synthetic third intracellular (3i) LH/CG R loop peptide with picomolar affinity; arrestin3 bound with millimolar affinity. To determine whether Asp-564 in the 3i loop mimicked the phosphorylated residue of other GPCRs, human embryonic kidney (HEK) cells were transfected with wild-type (WT) and D564G LH/CG R, An agonist-stimulated ARF6-dependent arrestin2 undocking pathway to drive desensitization of WT receptor was recapitulated in HEK cell membranes, and ectopic arrestin2 promoted desensitization of WT LH/CG R. However, D564G LH/CG R in HEK cells was not desensitized, and synthetic 3i D564G peptide did not bind arrestin2. Synthetic 3i loop peptides containing D564E, D564V, or D564N also did not bind arrestin2. We conclude that the ARF6-mediated mechanism to release a pool of membrane-delimited arrestin to bind GPCRs may be a widespread mechanism to deliver arrestin to GPCRs for receptor desensitization. Unlike other GPCRs that additionally require receptor phosphorylation, LH/CG R activation is sufficient to expose a conformation in which Asp-564 in the 3i loop confers high affinity binding selectively to arrestin2.	Northwestern Univ, Sch Med, Dept Cell & Mol Biol, Chicago, IL 60611 USA; Northwestern Univ, Sch Med, Dept Mol Pharmacol & Biol Chem, Chicago, IL 60611 USA; Northwestern Univ, Sch Med, Inst Neurosci, Chicago, IL 60611 USA; Vanderbilt Univ, Sch Med, Dept Pharmacol, Nashville, TN 37232 USA; CNRS, UPR 2356, F-67084 Strasbourg, France; Univ Illinois, Coll Med, Dept Obstet & Gynecol, Chicago, IL 60612 USA; NIEHS, Lab Signal Transduct, NIH, Res Triangle Pk, NC 27709 USA	Northwestern University; Northwestern University; Northwestern University; Vanderbilt University; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Hunzicker-Dunn, M (corresponding author), Northwestern Univ, Sch Med, Dept Cell & Mol Biol, 303 E Chicago Ave, Chicago, IL 60611 USA.		Bader, Marie-France/O-2098-2016; Gurevich, Vsevolod/A-3236-2008; Hamm, Heidi E/G-2374-2014	Gurevich, Vsevolod/0000-0002-3950-5351; 	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD038060] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R01EY006062, R01EY010291, R01EY011500] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM063097] Funding Source: NIH RePORTER; NEI NIH HHS [R01 EY 10291, EY 06062, R01 EY 11500] Funding Source: Medline; NICHD NIH HHS [R01 HD 38060] Funding Source: Medline; NIGMS NIH HHS [GM 63097] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Barak LS, 2001, P NATL ACAD SCI USA, V98, P93, DOI 10.1073/pnas.011303698; BENDER FE, 1982, STAT METHODS FOOD AG; Bennett TA, 2000, J BIOL CHEM, V275, P24590, DOI 10.1074/jbc.C000314200; BOCKAERT J, 1976, J BIOL CHEM, V251, P2653; Caumont AS, 1998, J BIOL CHEM, V273, P1373, DOI 10.1074/jbc.273.3.1373; Celver J, 2002, J BIOL CHEM, V277, P9043, DOI 10.1074/jbc.M107400200; Chen CK, 1999, P NATL ACAD SCI USA, V96, P3718, DOI 10.1073/pnas.96.7.3718; Cheng ZJ, 2000, J BIOL CHEM, V275, P2479, DOI 10.1074/jbc.275.4.2479; Claing A, 2001, J BIOL CHEM, V276, P42509, DOI 10.1074/jbc.M108399200; EKSTROM RC, 1989, ENDOCRINOLOGY, V125, P2470, DOI 10.1210/endo-125-5-2470; EKSTROM RC, 1989, ENDOCRINOLOGY, V124, P956, DOI 10.1210/endo-124-2-956; Ferguson SSG, 2001, PHARMACOL REV, V53, P1; Freedman NJ, 1996, RECENT PROG HORM RES, V51, P319; Galas MC, 1997, J BIOL CHEM, V272, P2788, DOI 10.1074/jbc.272.5.2788; GUREVICH VV, 1993, J BIOL CHEM, V268, P11628; Gurevich VV, 1997, J BIOL CHEM, V272, P28849, DOI 10.1074/jbc.272.46.28849; GUREVICH VV, 1995, J BIOL CHEM, V270, P720, DOI 10.1074/jbc.270.2.720; Gurevich VV, 1997, MOL PHARMACOL, V51, P161, DOI 10.1124/mol.51.1.161; Han M, 2001, STRUCTURE, V9, P869, DOI 10.1016/S0969-2126(01)00644-X; HIPKIN RW, 1993, MOL ENDOCRINOL, V7, P823, DOI 10.1210/me.7.7.823; HIPKIN RW, 1995, MOL ENDOCRINOL, V9, P151, DOI 10.1210/me.9.2.151; Hirsch JA, 1999, CELL, V97, P257, DOI 10.1016/S0092-8674(00)80735-7; HOULE MG, 1995, J BIOL CHEM, V270, P22795, DOI 10.1074/jbc.270.39.22795; Iacovelli L, 1996, MOL ENDOCRINOL, V10, P1138, DOI 10.1210/me.10.9.1138; Jaber M, 1996, P NATL ACAD SCI USA, V93, P12974, DOI 10.1073/pnas.93.23.12974; KAHN RA, 1992, J BIOL CHEM, V267, P13039; KNOSPE V, 1988, CURR EYE RES, V7, P1137, DOI 10.3109/02713688809001885; Kohout TA, 2001, P NATL ACAD SCI USA, V98, P1601, DOI 10.1073/pnas.041608198; Kosugi S, 1998, MOL PHARMACOL, V53, P894; Kovoor A, 1999, J BIOL CHEM, V274, P6831, DOI 10.1074/jbc.274.11.6831; Krupnick JG, 1997, J BIOL CHEM, V272, P18125, DOI 10.1074/jbc.272.29.18125; Kudo M, 1996, J BIOL CHEM, V271, P22470, DOI 10.1074/jbc.271.37.22470; KUHN H, 1984, FEBS LETT, V176, P473, DOI 10.1016/0014-5793(84)81221-1; KWATRA MM, 1987, J BIOL CHEM, V262, P16314; LAMM MLG, 1994, ENDOCRINOLOGY, V134, P1745, DOI 10.1210/en.134.4.1745; LAMM MLG, 1994, MOL ENDOCRINOL, V8, P1537, DOI 10.1210/me.8.11.1537; LAUE L, 1995, P NATL ACAD SCI USA, V92, P1906, DOI 10.1073/pnas.92.6.1906; Lazari RDM, 1998, J BIOL CHEM, V273, P18316, DOI 10.1074/jbc.273.29.18316; LEFKOWITZ RJ, 1993, CELL, V74, P409, DOI 10.1016/0092-8674(93)80042-D; LENHARD JM, 1992, J BIOL CHEM, V267, P13047; Lin FT, 1997, J BIOL CHEM, V272, P31051, DOI 10.1074/jbc.272.49.31051; LOHSE MJ, 1992, J BIOL CHEM, V267, P8558; LOHSE MJ, 1990, SCIENCE, V248, P1547, DOI 10.1126/science.2163110; Luttrell LM, 2001, P NATL ACAD SCI USA, V98, P2449, DOI 10.1073/pnas.041604898; McDonald PH, 2000, SCIENCE, V290, P1574, DOI 10.1126/science.290.5496.1574; Min L, 2002, J BIOL CHEM, V277, P702, DOI 10.1074/jbc.M106082200; Mitchell R, 1998, NATURE, V392, P411, DOI 10.1038/32937; Mukherjee S, 1999, J BIOL CHEM, V274, P12984, DOI 10.1074/jbc.274.19.12984; Mukherjee S, 1999, P NATL ACAD SCI USA, V96, P493, DOI 10.1073/pnas.96.2.493; Mukherjee S, 2001, J BIOL CHEM, V276, P6524, DOI 10.1074/jbc.C000725200; Mukherjee S, 2000, P NATL ACAD SCI USA, V97, P5901, DOI 10.1073/pnas.100127097; Munshi UM, 2001, EUR J BIOCHEM, V268, P1631, DOI 10.1046/j.1432-1033.2001.02032.x; Nakamura K, 2000, J BIOL CHEM, V275, P241, DOI 10.1074/jbc.275.1.241; Nakamura K, 1999, MOL ENDOCRINOL, V13, P1295, DOI 10.1210/me.13.8.1295; Orsini MJ, 1998, J BIOL CHEM, V273, P34616, DOI 10.1074/jbc.273.51.34616; PALCZEWSKI K, 1994, PROTEIN SCI, V3, P1355, DOI 10.1002/pro.5560030901; Rajagopalan-Gupta RM, 1999, ENDOCRINOLOGY, V140, P1612, DOI 10.1210/en.140.4.1612; RajagopalanGupta RM, 1997, MOL ENDOCRINOL, V11, P538, DOI 10.1210/me.11.5.538; RUMENAPP U, 1995, EUR J BIOCHEM, V234, P240, DOI 10.1111/j.1432-1033.1995.240_c.x; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; Salvador LM, 2001, J BIOL CHEM, V276, P33773, DOI 10.1074/jbc.M101498200; SANCHEZYAGUE J, 1992, J BIOL CHEM, V267, P7217; Santini F, 2000, J CELL SCI, V113, P2463; Schulz A, 2000, J BIOL CHEM, V275, P37860, DOI 10.1074/jbc.M006709200; Schulz A, 1999, MOL ENDOCRINOL, V13, P181, DOI 10.1210/me.13.2.181; SEGALOFF DL, 1993, ENDOCR REV, V14, P324, DOI 10.1210/er.14.3.324; Troispoux C, 1999, MOL ENDOCRINOL, V13, P1599, DOI 10.1210/me.13.9.1599; Vishnivetskiy SK, 1999, J BIOL CHEM, V274, P11451, DOI 10.1074/jbc.274.17.11451; Wang Z, 1997, MOL ENDOCRINOL, V11, P183, DOI 10.1210/me.11.2.183; Wang Z, 1996, MOL ENDOCRINOL, V10, P748, DOI 10.1210/me.10.6.748; WILDEN U, 1986, P NATL ACAD SCI USA, V83, P1174, DOI 10.1073/pnas.83.5.1174; Wonerow P, 1998, J BIOL CHEM, V273, P7900, DOI 10.1074/jbc.273.14.7900; ZHU X, 1993, J BIOL CHEM, V268, P1723	73	52	53	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 17	2002	277	20					17916	17927		10.1074/jbc.M110479200	http://dx.doi.org/10.1074/jbc.M110479200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	553PR	11867621	hybrid			2022-12-27	WOS:000175685100068
J	Smith, JD; Waelde, C; Horwitz, A; Zheng, P				Smith, JD; Waelde, C; Horwitz, A; Zheng, P			Evaluation of the role of phosphatidylserine translocase activity in ABCA1-mediated lipid efflux	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MDR3 P-GLYCOPROTEIN; PLASMA-MEMBRANE; CHOLESTEROL EFFLUX; ABCA1 TRANSPORTER; APOPTOTIC CELLS; ENGULFMENT; BINDING; PHOSPHATIDYLCHOLINE; REDISTRIBUTION; PHOSPHOLIPIDS	The following two theories for the mechanism of ABCA1 in lipid efflux to apolipoprotein acceptors have been proposed: 1) that ABCA1 directly binds the apolipoprotein ligand and then facilitates lipid efflux and 2) that ABCA1 acts as a phosphatidylserine (PS) translocase, increasing PS levels in the plasma membrane exofacial leaflet, and that this is sufficient to facilitate apolipoprotein binding and lipid assembly. Upon induction of ABCA1 in RAW264.7 cells by cAMP analogues there was a moderate increase in cell surface PS as detected by annexin V binding, whereas apoAI binding was increased more robustly. Apoptosis induced large increases in annexin V and apoAI binding; however, apoptotic cells did not efflux lipids to apoAI. Annexin V did not act as a cholesterol acceptor, and it did not compete for the cholesterol acceptor or cell binding activity of apoAI. ApoAI binds to ABCA1-expressing cells, and with incubation at 37 degreesC apoAI is co-localized within the cells in ABCA1-containing endosomes. Fluorescent recovery after photobleaching demonstrated that apoAI bound to ABCA1-expressing cells was relatively immobile, suggesting that it was bound either directly or indirectly to an integral membrane protein. Although ABCA1 induction was associated with a small increase in cell surface PS, these results argue against the notion that this cell surface PS is sufficient to mediate cellular apoA1 binding and lipid efflux.	Rockefeller Univ, New York, NY 10021 USA	Rockefeller University	Smith, JD (corresponding author), Rockefeller Univ, 1230 York Ave, New York, NY 10021 USA.		Smith, Jonathan D./H-9723-2013	Smith, Jonathan D./0000-0002-0415-386X	NHLBI NIH HHS [R01HL66082] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL066082] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bevers EM, 1999, BBA-MOL CELL BIOL L, V1439, P317, DOI 10.1016/S1388-1981(99)00110-9; Borst P, 2000, BBA-MOL CELL BIOL L, V1486, P128, DOI 10.1016/S1388-1981(00)00053-6; Chambenoit O, 2001, J BIOL CHEM, V276, P9955, DOI 10.1074/jbc.M010265200; Dekkers DWC, 1998, BIOCHEMISTRY-US, V37, P14833, DOI 10.1021/bi981011w; Hamon Y, 2000, NAT CELL BIOL, V2, P399, DOI 10.1038/35017029; Luciani MF, 1996, EMBO J, V15, P226, DOI 10.1002/j.1460-2075.1996.tb00353.x; Marguet D, 1999, NAT CELL BIOL, V1, P454, DOI 10.1038/15690; Neufeld EB, 2001, J BIOL CHEM, V276, P27584, DOI 10.1074/jbc.M103264200; Oram JF, 2000, J BIOL CHEM, V275, P34508, DOI 10.1074/jbc.M006738200; Oram JF, 2001, J LIPID RES, V42, P1173; Orso E, 2000, NAT GENET, V24, P192, DOI 10.1038/72869; Raggers RJ, 2001, BIOCHEM J, V357, P859, DOI 10.1042/0264-6021:3570859; Serra MV, 1996, BBA-BIOMEMBRANES, V1282, P263; SMIT JJM, 1994, LAB INVEST, V71, P638; SMITH AJ, 1994, FEBS LETT, V354, P263, DOI 10.1016/0014-5793(94)01135-4; Szakacs G, 2001, BIOCHEM BIOPH RES CO, V288, P1258, DOI 10.1006/bbrc.2001.5905; Takahashi Y, 2000, BBA-GENE STRUCT EXPR, V1492, P385, DOI 10.1016/S0167-4781(00)00133-0; Takahashi Y, 1999, P NATL ACAD SCI USA, V96, P11358, DOI 10.1073/pnas.96.20.11358; vanHelvoort A, 1996, CELL, V87, P507, DOI 10.1016/S0092-8674(00)81370-7; Wang N, 2000, J BIOL CHEM, V275, P33053, DOI 10.1074/jbc.M005438200; Wu YC, 1998, CELL, V93, P951, DOI 10.1016/S0092-8674(00)81201-5; Zha XH, 2001, J BIOL CHEM, V276, P39476, DOI 10.1074/jbc.M105067200; Zheng P, 2001, BBA-MOL CELL BIOL L, V1534, P121, DOI 10.1016/S1388-1981(01)00183-4	23	98	103	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 17	2002	277	20					17797	17803		10.1074/jbc.M201594200	http://dx.doi.org/10.1074/jbc.M201594200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	553PR	11893753	hybrid			2022-12-27	WOS:000175685100053
J	Berggard, T; Miron, S; Onnerfjord, P; Thulin, E; Akerfeldt, KS; Enghild, JJ; Akke, M; Linse, S				Berggard, T; Miron, S; Onnerfjord, P; Thulin, E; Akerfeldt, KS; Enghild, JJ; Akke, M; Linse, S			Calbindin D-28k eExhibits properties characteristic of a Ca2+ sensor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-BINDING PROTEIN; CONFORMATIONAL-CHANGES; CA2+-BINDING PROTEINS; PARTICULATE FRACTION; BUFFERING PROPERTIES; HIPPOCAMPAL-NEURONS; IN-VITRO; CALRETININ; D28K; PARVALBUMIN	Calbindin D-28k is a member of the calmodulin superfamily of Ca2+-binding proteins and contains six EF-hands. The protein is generally believed to function as a Ca2+ buffer, but the studies presented in this work indicate that it may also act as a Ca2+ sensor. The results show that Mg2+ binds to the same sites as Ca2+ with an association constant of similar to1.4.10(3) M-1 in 0.15 M KCl. The four high affinity sites in calbindin D-28k bind Ca2+ in a non-sequential, parallel manner. In the presence of physiological concentrations of Mg2+ the Ca2+ affinity is reduced by a factor of 2, and the cooperativity, which otherwise is modest, increases. Based on the binding constants determined in the presence of physiological salt concentrations, we estimate that at the Ca2+ concentration in a resting cell calbindin D-28k is saturated to 40-75% with Mg2+ but to less than 9% with Ca2+. In contrast, the protein is expected to be nearly fully saturated with Ca2+ at the Ca2+ level of an activated cell. A substantial conformational change is observed upon Ca2+ binding, but only minor structural changes take place upon Mg2+ binding. This suggests that calbindin D-28k undergoes Ca2+-induced structural changes upon Ca2+ activation of a cell. Thus, calbindin D-28k displays several properties that would be expected for a protein involved in Ca2+-induced signal transmission and hence may function not only as a Ca2+ buffer but also as a Ca2+ sensor. Digestion patterns resulting from limited proteolysis of the protein suggest that the loop of EF-hand 2, a variant site that does not bind Ca2+, becomes exposed upon Ca2+ binding.	Lund Univ, Dept Biophys Chem, SE-22100 Lund, Sweden; Haverford Coll, Dept Chem, Haverford, PA 19041 USA; Aarhus Univ, Dept Biol Mol & Struct, DK-8000 Aarhus, Denmark; Lund Univ, BMC, Sect Connect Tissue Biol, SE-22184 Lund, Sweden	Lund University; Haverford College; Aarhus University; Lund University	Berggard, T (corresponding author), Lund Univ, Dept Biophys Chem, SE-22100 Lund, Sweden.		Onnerfjord, Patrik/R-3131-2019; Miron, Simona/M-9223-2018	Onnerfjord, Patrik/0000-0002-2345-2937; Akke, Mikael/0000-0002-2395-825X; Enghild, Jan Johannes/0000-0001-9292-9172; Linse, Sara/0000-0001-9629-7109				Airaksinen MS, 1997, P NATL ACAD SCI USA, V94, P1488, DOI 10.1073/pnas.94.4.1488; Akerfeldt KS, 1996, BIOCHEMISTRY-US, V35, P3662, DOI 10.1021/bi9527956; Ames JB, 1997, NATURE, V389, P198, DOI 10.1038/38310; Andersson M, 1997, PROTEIN SCI, V6, P1139, DOI 10.1002/pro.5560060602; Berggard T, 2000, BIOCHEMISTRY-US, V39, P6864, DOI 10.1021/bi992394g; Berggard T, 2000, PROTEIN SCI, V9, P2094, DOI 10.1110/ps.9.11.2094; CHARD PS, 1995, P NATL ACAD SCI USA, V92, P5144, DOI 10.1073/pnas.92.11.5144; CHARD PS, 1993, J PHYSIOL-LONDON, V472, P341, DOI 10.1113/jphysiol.1993.sp019950; CHRISTAKOS S, 1989, ENDOCR REV, V10, P3, DOI 10.1210/edrv-10-1-3; DOWD DR, 1992, MOL ENDOCRINOL, V6, P1843, DOI 10.1210/me.6.11.1843; GROSS MD, 1993, J BIOL CHEM, V268, P20917; GROSS MD, 1987, J BIOL CHEM, V262, P6539; GRZESIEK S, 1993, J AM CHEM SOC, V115, P12593, DOI 10.1021/ja00079a052; Guo Q, 1998, P NATL ACAD SCI USA, V95, P3227, DOI 10.1073/pnas.95.6.3227; HUBBARD MJ, 1995, FEBS LETT, V374, P333, DOI 10.1016/0014-5793(95)01135-2; HUBBARD MJ, 1995, EUR J BIOCHEM, V230, P68, DOI 10.1111/j.1432-1033.1995.0068i.x; IACOPINO AM, 1990, P NATL ACAD SCI USA, V87, P4078, DOI 10.1073/pnas.87.11.4078; Ikura M, 1996, TRENDS BIOCHEM SCI, V21, P14, DOI 10.1016/0968-0004(96)80879-6; Kawatsuki N, 1998, RRD POLYM SCI, V2, P277; KAY LE, 1992, J AM CHEM SOC, V114, P10663, DOI 10.1021/ja00052a088; Klapstein GJ, 1998, NEUROSCIENCE, V85, P361, DOI 10.1016/S0306-4522(97)00632-5; KLOTZ IM, 1979, ARCH BIOCHEM BIOPHYS, V193, P314, DOI 10.1016/0003-9861(79)90036-5; KUZNICKI J, 1995, BIOCHEM J, V308, P607; LaBella V, 1996, BIOCHEM MOL BIOL INT, V38, P1199; LI ZH, 1995, J PHYSIOL-LONDON, V488, P601, DOI 10.1113/jphysiol.1995.sp020993; Linse S, 1997, PROTEIN SCI, V6, P2385; LINSE S, 1993, PROTEIN SCI, V2, P985, DOI 10.1002/pro.5560020612; LINSE S, 1987, BIOCHEMISTRY-US, V26, P6723, DOI 10.1021/bi00395a023; LINSE S, 1991, J BIOL CHEM, V266, P8050; LINSE S, 1990, BIOCHEMISTRY-US, V29, P5925, DOI 10.1021/bi00477a007; LUKAS W, 1994, NEUROSCIENCE, V61, P307, DOI 10.1016/0306-4522(94)90233-X; MATTSON MP, 1991, NEURON, V6, P41, DOI 10.1016/0896-6273(91)90120-O; MORGAN DW, 1986, BIOCHEM BIOPH RES CO, V138, P547, DOI 10.1016/S0006-291X(86)80531-9; NORMAN AW, 1982, BIOCHEM BIOPH RES CO, V108, P220, DOI 10.1016/0006-291X(82)91854-X; OBERHOLTZER JC, 1988, P NATL ACAD SCI USA, V85, P3387, DOI 10.1073/pnas.85.10.3387; PALMER AG, 1991, J MAGN RESON, V93, P151, DOI 10.1016/0022-2364(91)90036-S; Pauls TL, 1996, BBA-GENE STRUCT EXPR, V1306, P39, DOI 10.1016/0167-4781(95)00221-9; REISNER PD, 1992, FEBS LETT, V297, P127, DOI 10.1016/0014-5793(92)80342-E; Sayer RJ, 2000, CELL TISSUE RES, V302, P171, DOI 10.1007/s004410000285; Schwaller B, 1997, J BIOL CHEM, V272, P29663, DOI 10.1074/jbc.272.47.29663; SHAKA AJ, 1985, J MAGN RESON, V64, P547, DOI 10.1016/0022-2364(85)90122-2; Thulin E, 1999, PROTEIN EXPRES PURIF, V15, P265, DOI 10.1006/prep.1999.1028; WINSKY L, 1995, J NEUROCHEM, V65, P381; WISHART DS, 1991, J MOL BIOL, V222, P311, DOI 10.1016/0022-2836(91)90214-Q; Yap KL, 1999, PROTEINS, V37, P499, DOI 10.1002/(SICI)1097-0134(19991115)37:3<499::AID-PROT17>3.0.CO;2-Y; Zhang MJ, 1998, BIOCHEM CELL BIOL, V76, P313, DOI 10.1139/bcb-76-2-3-313	46	102	105	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 10	2002	277	19					16662	16672		10.1074/jbc.M200415200	http://dx.doi.org/10.1074/jbc.M200415200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	551MB	11872749	hybrid			2022-12-27	WOS:000175564500044
J	Deucher, A; Efimova, T; Eckert, RL				Deucher, A; Efimova, T; Eckert, RL			Calcium-dependent involucrin expression is inversely regulated by protein kinase C (PKC)alpha and PKC delta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN EPIDERMAL-KERATINOCYTES; SIGNAL-TRANSDUCTION PATHWAY; GROWTH-FACTOR RECEPTOR; TYROSINE PHOSPHORYLATION; INDUCED-DIFFERENTIATION; MOUSE KERATINOCYTES; PROMOTER ACTIVITY; GENE-EXPRESSION; PHORBOL ESTER; TERMINAL DIFFERENTIATION	Calcium is an important physiologic regulator of keratinocyte function that may regulate keratinocyte differentiation via modulation of protein kinase C (PKC) activity. PKCalpha and PKCdelta are two PKC isoforms that are expressed at high levels in keratinocytes. In the present study, we examine the effect of PKCdelta and PKCalpha on calcium-dependent keratinocyte differentiation as measured by effects on involucrin (hINV) gene expression. Our studies indicate that calcium increases hINV promoter activity and endogenous hINV gene expression. This response requires PKCdelta, as evidenced by the observation that treatment with dominant-negative PKCdelta inhibits calcium-dependent hINV promoter activity, whereas wild type PKCdelta increases activity. PKCalpha, in contrast, inhibits calcium-dependent hINV promoter activation, a finding that is consistent with the ability of dominant-negative PKCalpha and the PKCalpha inhibitor, Go6976, to increase hINV gene expression. The calcium-dependent regulatory response is mediated by an AP1 transcription factor-binding site located within the hINV promoter distal regulatory region that is also required for PKCdelta-dependent regulation; moreover, both calcium and PKCdelta produce similar, but not identical, changes in AP1 factor expression. A key question is whether calcium directly influences PKC isoform function. Our studies show that calcium does not regulate PKCalpha or delta levels or cause a marked redistribution to membranes. However, tyrosine phosphorylation of PKCdelta is markedly increased following calcium treatment. These findings suggest that PKCalpha and PKCdelta are required for, and modulate, calcium-dependent keratinocyte differentiation in opposing directions.	Case Western Reserve Univ, Sch Med, Dept Physiol Biophys, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Dept Biochem, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Dept Reprod Biol, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Dept Oncol, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Dept Dermatol, Cleveland, OH 44106 USA	Case Western Reserve University; Case Western Reserve University; Case Western Reserve University; Case Western Reserve University; Case Western Reserve University	Eckert, RL (corresponding author), Case Western Reserve Univ, Sch Med, Dept Physiol Biophys, Rm E532,2109 Adelbert Rd, Cleveland, OH 44106 USA.			Efimova, Tatiana/0000-0002-9869-1545				Ahn SK, 1999, J INVEST DERMATOL, V113, P189, DOI 10.1046/j.1523-1747.1999.00650.x; Banks EB, 1999, BIOCHEM J, V337, P507, DOI 10.1042/0264-6021:3370507; BANKS EB, 1998, BIOCHEM J, V331, pS1; Bollag WB, 2001, MOL CELL ENDOCRINOL, V177, P173, DOI 10.1016/S0303-7207(01)00440-3; CHAKRAVARTHY BR, 1995, J BIOL CHEM, V270, P1362, DOI 10.1074/jbc.270.3.1362; Crish JF, 1998, J BIOL CHEM, V273, P30460, DOI 10.1074/jbc.273.46.30460; CRISH JF, 1993, DIFFERENTIATION, V53, P191, DOI 10.1111/j.1432-0436.1993.tb00708.x; Dashti SR, 2001, J BIOL CHEM, V276, P27214, DOI 10.1074/jbc.M100465200; Denning MF, 2000, EXP DERMATOL, V9, P192, DOI 10.1034/j.1600-0625.2000.009003192.x; Denning MF, 1998, J BIOL CHEM, V273, P29995, DOI 10.1074/jbc.273.45.29995; DENNING MF, 1993, J BIOL CHEM, V268, P26079; DENNING MF, 1995, CELL GROWTH DIFFER, V6, P149; Denning MF, 1996, J BIOL CHEM, V271, P5325, DOI 10.1074/jbc.271.10.5325; Deszo EL, 2001, J BIOL CHEM, V276, P10212, DOI 10.1074/jbc.M010589200; Dietrich C, 2001, BIOCHEM BIOPH RES CO, V282, P575, DOI 10.1006/bbrc.2001.4530; DLUGOSZ AA, 1992, MOL CARCINOGEN, V5, P286, DOI 10.1002/mc.2940050409; DLUGOSZ AA, 1994, J INVEST DERMATOL, V102, P409, DOI 10.1111/1523-1747.ep12372171; DLUGOSZ AA, 1993, J CELL BIOL, V120, P217, DOI 10.1083/jcb.120.1.217; Eckert RL, 1996, MOL BIOL REP, V23, P59, DOI 10.1007/BF00357073; ECKERT RL, 1986, CELL, V46, P583, DOI 10.1016/0092-8674(86)90884-6; Efimova T, 1998, J BIOL CHEM, V273, P24387, DOI 10.1074/jbc.273.38.24387; Efimova T, 2000, J BIOL CHEM, V275, P1601, DOI 10.1074/jbc.275.3.1601; Fujii T, 2000, J BIOL CHEM, V275, P7574, DOI 10.1074/jbc.275.11.7574; FYNAN TM, 1994, CELL GROWTH DIFFER, V5, P1293; Gniadecki R, 1998, ACTA DERM-VENEREOL, V78, P164; HALEEMSMITH H, 1995, P NATL ACAD SCI USA, V92, P9112, DOI 10.1073/pnas.92.20.9112; Jang SI, 1996, J BIOL CHEM, V271, P24105, DOI 10.1074/jbc.271.39.24105; Johansen C, 2000, J INVEST DERMATOL, V114, P1174, DOI 10.1046/j.1523-1747.2000.00003.x; Jost M, 2001, J BIOL CHEM, V276, P6320, DOI 10.1074/jbc.M008210200; Kajimoto T, 2001, MOL CELL BIOL, V21, P1769, DOI 10.1128/MCB.21.5.1769-1783.2001; Kashiwagi M, 2000, ONCOGENE, V19, P6334, DOI 10.1038/sj.onc.1204028; Konishi H, 1997, P NATL ACAD SCI USA, V94, P11233, DOI 10.1073/pnas.94.21.11233; Konishi H, 2001, P NATL ACAD SCI USA, V98, P6587, DOI 10.1073/pnas.111158798; LaCelle PT, 1998, SKIN PHARMACOL APPL, V11, P214, DOI 10.1159/000029830; Lee YS, 1998, J INVEST DERMATOL, V111, P762, DOI 10.1046/j.1523-1747.1998.00365.x; Lee YS, 1997, MOL CARCINOGEN, V18, P44, DOI 10.1002/(SICI)1098-2744(199701)18:1<44::AID-MC6>3.0.CO;2-R; Li LW, 1999, MOL CELL BIOL, V19, P8547; LI LW, 1995, CELL GROWTH DIFFER, V6, P1171; Li WQ, 1999, ONCOGENE, V18, P6564, DOI 10.1038/sj.onc.1203065; LI WQ, 1994, J BIOL CHEM, V269, P2349; MARTINYBARON G, 1993, J BIOL CHEM, V268, P9194; MATSUI MS, 1992, J INVEST DERMATOL, V99, P565, DOI 10.1111/1523-1747.ep12667411; MCCOY C, 1995, MOL CELL BIOL, V15, P6100; Mellor H, 1998, BIOCHEM J, V332, P281, DOI 10.1042/bj3320281; MENON GK, 1985, J INVEST DERMATOL, V84, P508, DOI 10.1111/1523-1747.ep12273485; Mitev V, 1999, EXP DERMATOL, V8, P96, DOI 10.1111/j.1600-0625.1999.tb00355.x; MIZUNO K, 1991, EUR J BIOCHEM, V202, P931, DOI 10.1111/j.1432-1033.1991.tb16453.x; Murakami A, 1996, J INVEST DERMATOL, V106, P790, DOI 10.1111/1523-1747.ep12346391; Neuzil J, 2001, FASEB J, V15, P403, DOI 10.1096/fj.00-0251com; Newton AC, 1997, CURR OPIN CELL BIOL, V9, P161, DOI 10.1016/S0955-0674(97)80058-0; Ng DC, 2000, J BIOL CHEM, V275, P24080, DOI 10.1074/jbc.M002508200; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; Noe V, 2001, EUR J BIOCHEM, V268, P3163, DOI 10.1046/j.1432-1327.2001.02198.x; Ohba M, 1998, MOL CELL BIOL, V18, P5199, DOI 10.1128/MCB.18.9.5199; Ohmori S, 1998, MOL CELL BIOL, V18, P5263, DOI 10.1128/MCB.18.9.5263; OHNO S, 1987, NATURE, V325, P161, DOI 10.1038/325161a0; OHNO S, 1988, BIOCHEMISTRY-US, V27, P2083, DOI 10.1021/bi00406a040; Osada K, 1997, J INVEST DERMATOL, V108, P482, DOI 10.1111/1523-1747.ep12289726; PUNNONEN K, 1993, J INVEST DERMATOL, V101, P719, DOI 10.1111/1523-1747.ep12371682; REYNOLDS NJ, 1994, J INVEST DERMATOL, V103, P364, DOI 10.1111/1523-1747.ep12394957; RICE RH, 1977, CELL, V11, P417, DOI 10.1016/0092-8674(77)90059-9; RICE RH, 1979, CELL, V18, P681, DOI 10.1016/0092-8674(79)90123-5; Rossi A, 1998, J INVEST DERMATOL, V110, P34, DOI 10.1046/j.1523-1747.1998.00071.x; RUBIN AL, 1988, IN VITRO CELL DEV B, V24, P857; Rutberg SE, 1996, ONCOGENE, V13, P167; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Shen S, 2001, DIABETES, V50, P255, DOI 10.2337/diabetes.50.2.255; SIMON M, 1985, CELL, V40, P677, DOI 10.1016/0092-8674(85)90216-8; Soh JW, 1999, MOL CELL BIOL, V19, P1313; Stanwell C, 1996, J INVEST DERMATOL, V106, P482, DOI 10.1111/1523-1747.ep12343690; Takahashi H, 1998, J INVEST DERMATOL, V110, P218, DOI 10.1046/j.1523-1747.1998.00110.x; Tu CL, 1999, J INVEST DERMATOL, V113, P340, DOI 10.1046/j.1523-1747.1999.00698.x; Tu CL, 2001, J BIOL CHEM, V276, P41079, DOI 10.1074/jbc.M107122200; Ueda E, 1996, J BIOL CHEM, V271, P9790, DOI 10.1074/jbc.271.16.9790; Vicanova J, 1998, J INVEST DERMATOL, V111, P97, DOI 10.1046/j.1523-1747.1998.00251.x; Vuong H, 2000, J BIOL CHEM, V275, P32250, DOI 10.1074/jbc.M005227200; Wang HQ, 2001, MOL PHARMACOL, V59, P860, DOI 10.1124/mol.59.4.860; WELTER JF, 1995, J BIOL CHEM, V270, P12614, DOI 10.1074/jbc.270.21.12614; Whelan RDH, 1998, ONCOGENE, V16, P1939, DOI 10.1038/sj.onc.1201725; WHITFIELD JF, 1995, J CELL BIOCHEM, P74; Xie ZJ, 1999, J BIOL CHEM, V274, P20421, DOI 10.1074/jbc.274.29.20421; YAAR M, 1993, CLIN RES, V41, pA486, DOI 10.1006/excr.1993.1143; YAFFE MB, 1992, J BIOL CHEM, V267, P12233; Zezula J, 1997, J BIOL CHEM, V272, P29967, DOI 10.1074/jbc.272.47.29967	84	74	80	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 10	2002	277	19					17032	17040		10.1074/jbc.M109076200	http://dx.doi.org/10.1074/jbc.M109076200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	551MB	11864971	hybrid			2022-12-27	WOS:000175564500092
J	Hinks, JA; Evans, MCW; de Miguel, Y; Sartori, AA; Jiricny, J; Pearl, LH				Hinks, JA; Evans, MCW; de Miguel, Y; Sartori, AA; Jiricny, J; Pearl, LH			An iron-sulfur cluster in the Family 4 uracil-DNA glycosylases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							URACIL-DNA GLYCOSYLASE; ARCHAEON PYROBACULUM-AEROPHILUM; ENZYME ENDONUCLEASE-III; CRYSTAL-STRUCTURE; RECOGNITION; PROTEIN; MUTY; REPLICATION; SUPERFAMILY; ACONITASE	The 25-kDa Family 4 uracil-DNA glycosylase (UDG) from Pyrobaculum aerophilum has been expressed and purified in large quantities for structural analysis. In the process we observed it to be colored and subsequently found that it contained iron. Here we demonstrate that 1 aerophilum UDG has an iron-sulfur center with the EPR characteristics typical of a 4Fe4S high potential iron protein. Interestingly, it does not share any sequence similarity with the classic iron-sulfur proteins, although four cysteines (which are strongly conserved in the thermophilic members of Family 4 UDGs) may represent the metal coordinating residues. The conservation of these residues in other members of the family suggest that 4Fe4S clusters are a common feature. Although 4Fe4S clusters have been observed previously in Nth/MutY DNA repair enzymes, this is the first observation of such a feature in the UDG structural superfamily. Similar to the Nth/MutY enzymes, the Family 4 UDG centers probably play a structural rather than a catalytic role.	Inst Canc Res, Sect Struct Biol, Canc Res UK DNA Repair Enzyme Grp, London SW3 6JB, England; UCL, Dept Biol, London WC1E 6BT, England; Kings Coll London, Dept Chem, London WC2R 2LS, England; Univ Zurich, Inst Med Radiobiol, CH-8008 Zurich, Switzerland	Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; University of London; University College London; University of London; King's College London; University of Zurich	Pearl, LH (corresponding author), Inst Canc Res, Sect Struct Biol, Canc Res UK DNA Repair Enzyme Grp, 237 Fulham Rd, London SW3 6JB, England.	l.pearl@icr.ac.uk	Sartori, Alessandro/AAK-7840-2021; de Miguel, Dr. Yolanda R./A-5526-2016	Sartori, Alessandro/0000-0003-2770-0333; Pearl, Laurence/0000-0002-6910-1809; de Miguel, Dr. Yolanda R./0000-0001-8650-5875				Barrett TE, 1999, EMBO J, V18, P6599, DOI 10.1093/emboj/18.23.6599; Barrett TE, 1998, CELL, V92, P117, DOI 10.1016/S0092-8674(00)80904-6; CUNNINGHAM RP, 1989, BIOCHEMISTRY-US, V28, P4450, DOI 10.1021/bi00436a049; FitzGibbon S, 1997, EXTREMOPHILES, V1, P36, DOI 10.1007/s007920050013; FOCHER F, 1992, CHROMOSOMA, V102, pS67, DOI 10.1007/BF02451788; FU WG, 1992, J BIOL CHEM, V267, P16135; Gallinari P, 1996, NATURE, V383, P735, DOI 10.1038/383735a0; Golinelli MP, 1999, BIOCHEMISTRY-US, V38, P6997, DOI 10.1021/bi982300n; Jacobs KL, 1997, J BACTERIOL, V179, P3298, DOI 10.1128/jb.179.10.3298-3303.1997; KENNEDY MC, 1988, J BIOL CHEM, V263, P8194; KENNEDY MC, 1983, J BIOL CHEM, V258, P1098; Koulis A, 1996, FEMS MICROBIOL LETT, V143, P267; KUO CF, 1992, SCIENCE, V258, P434, DOI 10.1126/science.1411536; LINDAHL T, 1993, NATURE, V362, P709, DOI 10.1038/362709a0; LINDAHL T, 1974, BIOCHEMISTRY-US, V13, P3405, DOI 10.1021/bi00713a035; MICHAELS ML, 1990, NUCLEIC ACIDS RES, V18, P3841, DOI 10.1093/nar/18.13.3841; Nash HM, 1996, CURR BIOL, V6, P968, DOI 10.1016/S0960-9822(02)00641-3; NEDDERMANN P, 1993, J BIOL CHEM, V268, P21218; Pearl LH, 2000, MUTAT RES-DNA REPAIR, V460, P165, DOI 10.1016/S0921-8777(00)00025-2; Porello SL, 1998, BIOCHEMISTRY-US, V37, P6465, DOI 10.1021/bi972433t; Sandigursky M, 1999, CURR BIOL, V9, P531, DOI 10.1016/S0960-9822(99)80237-1; Sandigursky M, 2000, J BIOL CHEM, V275, P19146, DOI 10.1074/jbc.M001995200; Sartori AA, 2001, J BIOL CHEM, V276, P29979, DOI 10.1074/jbc.M102985200; THAYER MM, 1995, EMBO J, V14, P4108, DOI 10.1002/j.1460-2075.1995.tb00083.x; TYE BK, 1978, P NATL ACAD SCI USA, V75, P233, DOI 10.1073/pnas.75.1.233; VOLKL P, 1993, APPL ENVIRON MICROB, V59, P2918; Yang HJ, 2000, J BACTERIOL, V182, P1272, DOI 10.1128/JB.182.5.1272-1279.2000	27	59	61	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 10	2002	277	19					16936	16940		10.1074/jbc.M200668200	http://dx.doi.org/10.1074/jbc.M200668200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	551MB	11877410	hybrid, Green Accepted			2022-12-27	WOS:000175564500080
J	Ilias, A; Urban, Z; Seidl, TL; Le Saux, O; Sinko, E; Boyd, CD; Sarkadi, B; Varadi, A				Ilias, A; Urban, Z; Seidl, TL; Le Saux, O; Sinko, E; Boyd, CD; Sarkadi, B; Varadi, A			Loss of ATP-dependent transport activity in pseudoxanthoma elasticum-associated mutants of human ABCC6 (MRP6)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIDRUG-RESISTANCE PROTEIN; CYSTIC-FIBROSIS GENE; INSECT CELLS; SULFONYLUREA RECEPTOR; CRYSTAL-STRUCTURE; DRUG-RESISTANCE; P-GLYCOPROTEIN; MUTATIONS; BINDING; NUCLEOTIDE	Mutations in the ABCC6 (MRP6) gene cause pseudoxanthoma elasticum (PXE), a rare heritable disorder resulting in the calcification of elastic fibers. In the present study a cDNA encoding a full-length normal variant of ABCC6 was amplified from a human kidney cDNA library, and the protein was expressed in Sf9 insect cells. In isolated membranes ATP binding as well as ATP-dependent active transport by ABCC6 was demonstrated. We found that glutathione conjugates, including leukotriene C-4 and N-ethylmaleimide S-glutathione (NEM-GS), were actively transported by human ABCC6. Organic anions (probenecid, benzbromarone, indomethacin), known to interfere with glutathione conjugate transport of human ABCC1 and ABCC2, inhibited the ABCC6-mediated NEM-GS transport in a specific manner, indicating that ABCC6 has a unique substrate specificity. We have also expressed three missense mutant forms of ABCC6, which have recently been shown to cause PXE. MgATP binding was normal in these proteins; ATP-dependent NEM-GS or leukotriene C-4 transport, however, was abolished. Our data indicate that human ABCC6 is a primary active transporter for organic anions. In the three ABCC6 mutant forms examined, the loss of transport activity suggests that these mutations result in a PXE phenotype through a direct influence on the transport activity of this ABC transporter.	Hungarian Acad Sci, Inst Enzymol, H-1113 Budapest, Hungary; Univ Hawaii, Pacific Biomed Res Ctr, Lab Matrix Pathobiol, Honolulu, HI 96822 USA; Hungarian Acad Sci, Res Grp, Inst Haematol & Immunol, Natl Med Ctr, H-1113 Budapest, Hungary	Hungarian Academy of Sciences; Hungarian Research Centre for Natural Sciences; University of Hawaii System; Hungarian Academy of Sciences	Varadi, A (corresponding author), Hungarian Acad Sci, Inst Enzymol, Karolina Ut 29, H-1113 Budapest, Hungary.		Le Saux, Olivier/P-4668-2017; Varadi, Andras/A-2055-2012; Sarkadi, Balazs/I-5024-2013; Urban, Zsolt/B-1977-2008; Iliás, Attila/I-7072-2017; Urban, Zsolt/A-2018-2013	Le Saux, Olivier/0000-0002-5605-3617; Iliás, Attila/0000-0003-3196-0795; Urban, Zsolt/0000-0003-3890-1843	NCRR NIH HHS [P20 RR016453, RR03061] Funding Source: Medline; NEI NIH HHS [EY13019] Funding Source: Medline; NIAMS NIH HHS [AR46379] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR016453] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R01EY013019] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R03AR046379] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Aridor M, 2000, TRAFFIC, V1, P836, DOI 10.1034/j.1600-0854.2000.011104.x; Bakos E, 1996, J BIOL CHEM, V271, P12322, DOI 10.1074/jbc.271.21.12322; Bakos E, 1998, J BIOL CHEM, V273, P32167, DOI 10.1074/jbc.273.48.32167; Bakos E, 2000, MOL PHARMACOL, V57, P760, DOI 10.1124/mol.57.4.760; Belinsky MG, 1999, BRIT J CANCER, V80, P1342, DOI 10.1038/sj.bjc.6690527; Bergen AAB, 2000, NAT GENET, V25, P228, DOI 10.1038/76109; Borst P, 2000, JNCI-J NATL CANCER I, V92, P1295, DOI 10.1093/jnci/92.16.1295; Borst P, 1999, BBA-BIOMEMBRANES, V1461, P347, DOI 10.1016/S0005-2736(99)00167-4; Chang XB, 1997, J BIOL CHEM, V272, P30962, DOI 10.1074/jbc.272.49.30962; Cui YH, 1999, MOL PHARMACOL, V55, P929; Diederichs K, 2000, EMBO J, V19, P5951, DOI 10.1093/emboj/19.22.5951; Gao M, 1996, J BIOL CHEM, V271, P27782, DOI 10.1074/jbc.271.44.27782; Germain D P, 2000, Hum Mutat, V16, P449, DOI 10.1002/1098-1004(200011)16:5<449::AID-HUMU24>3.0.CO;2-O; Germain DP, 2000, BIOCHEM BIOPH RES CO, V274, P297, DOI 10.1006/bbrc.2000.3101; GERMANN UA, 1990, BIOCHEMISTRY-US, V29, P2295, DOI 10.1021/bi00461a013; Hipfner DR, 1996, CANCER RES, V56, P3307; Hipfner DR, 1999, BBA-BIOMEMBRANES, V1461, P359, DOI 10.1016/S0005-2736(99)00168-6; Hirohashi T, 1999, J BIOL CHEM, V274, P15181, DOI 10.1074/jbc.274.21.15181; Hopfner KP, 2000, CELL, V101, P789, DOI 10.1016/S0092-8674(00)80890-9; Hung LW, 1998, NATURE, V396, P703, DOI 10.1038/25393; Kartenbeck J, 1996, HEPATOLOGY, V23, P1061; KEREM BS, 1989, SCIENCE, V245, P1073, DOI 10.1126/science.2570460; Konig J, 1999, BBA-BIOMEMBRANES, V1461, P377, DOI 10.1016/S0005-2736(99)00169-8; Kool M, 1999, CANCER RES, V59, P175; Le Saux O, 2001, AM J HUM GENET, V69, P749, DOI 10.1086/323704; Le Saux O, 2000, NAT GENET, V25, P223, DOI 10.1038/76102; Madon J, 2000, MOL PHARMACOL, V57, P634, DOI 10.1124/mol.57.3.634; Muller M, 1996, J BIOL CHEM, V271, P1877; Paulusma CC, 1996, SCIENCE, V271, P1126, DOI 10.1126/science.271.5252.1126; Ringpfeil F, 2001, AM J HUM GENET, V68, P642, DOI 10.1086/318807; Ringpfeil F, 2000, P NATL ACAD SCI USA, V97, P6001, DOI 10.1073/pnas.100041297; RIORDAN JR, 1989, SCIENCE, V245, P1066; ROMMENS JM, 1989, SCIENCE, V245, P1059, DOI 10.1126/science.2772657; Sankaran B, 1997, ARCH BIOCHEM BIOPHYS, V341, P160, DOI 10.1006/abbi.1997.9944; SARKADI B, 1992, J BIOL CHEM, V267, P4854; STEMMER WPC, 1992, BIOTECHNIQUES, V13, P214; Struk B, 2000, J MOL MED, V78, P282, DOI 10.1007/s001090000114; Szabo K, 1999, J BIOL CHEM, V274, P12209, DOI 10.1074/jbc.274.18.12209; Szakacs G, 2000, BIOCHEM BIOPH RES CO, V276, P1314, DOI 10.1006/bbrc.2000.3576; THOMAS PM, 1995, SCIENCE, V268, P426, DOI 10.1126/science.7716548; Tusnady GE, 1997, FEBS LETT, V402, P1, DOI 10.1016/S0014-5793(96)01478-0; Ueda K, 1999, P NATL ACAD SCI USA, V96, P1268, DOI 10.1073/pnas.96.4.1268; Uitto J, 2001, TRENDS MOL MED, V7, P13, DOI 10.1016/S1471-4914(00)01869-4; URBATSCH IL, 1995, J BIOL CHEM, V270, P19383, DOI 10.1074/jbc.270.33.19383; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; Wang J, 2001, J HUM GENET, V46, P699, DOI 10.1007/s100380170003; ZAMAN GJR, 1995, P NATL ACAD SCI USA, V92, P7690, DOI 10.1073/pnas.92.17.7690; Zeng H, 2000, CANCER RES, V60, P4779	48	190	197	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 10	2002	277	19					16860	16867		10.1074/jbc.M110918200	http://dx.doi.org/10.1074/jbc.M110918200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	551MB	11880368	hybrid			2022-12-27	WOS:000175564500069
J	Sesma, L; Montserrat, V; Lamas, JR; Marina, A; Vazquez, J; de Castro, JAL				Sesma, L; Montserrat, V; Lamas, JR; Marina, A; Vazquez, J; de Castro, JAL			The peptide repertoires of HLA-B27 subtypes differentially associated to spondyloarthropathy (B*2704 and B*2706) differ by specific changes at three anchor positions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-TERMINAL ANCHOR; HL-A 27; ANKYLOSING-SPONDYLITIS; NUCLEOTIDE-SEQUENCE; SUSCEPTIBILITY; BINDING; HLA-B-ASTERISK-2706; POLYMORPHISM; RECOGNITION; MECHANISM	HLA-B*2704 is strongly associated with ankylosing spondylitis. B*2706, which differs from B*2704 by two amino acid changes, is not associated with this disease. A systematic comparison of the B*2704- and B*2706-bound peptide repertoires was carried out to elucidate their overlap and differential features and to correlate them with disease susceptibility. Both subtypes shared about 90%, of their peptide repertoires, consisting of peptides with Arg(2) and C-terminal aliphatic or Phe residues. B*2706 polymorphism influenced specificity at three anchor positions: it favored basic residues at P3 and POmega-2 and impaired binding of Tyr and Arg at POmega. Thus, the main structural feature of peptides differentially bound to B*2704 was the presence of C-terminal Tyr or Arg, together with a strong preference for aliphatic/aromatic P3 residues. This is the only known feature of B*2704 and B*2706 that correlates to their differential association with spondyloarthropathy. The concomitant presence of basic P3 and POmega-2 residues was observed only among peptides differentially bound to B*2706, suggesting that it impairs binding to B*2704. Similarity between peptide overlap and the degree of cross-reaction with alloreactive T lymphocytes suggested that the majority of shared ligands maintain unaltered antigenic features in the context of both subtypes.	Univ Autonoma Madrid, Fac Ciencias, Ctr Biol Mol Severo Ochoa, E-28049 Madrid, Spain	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Biologia Molecular Severo Ochoa (CBM)	de Castro, JAL (corresponding author), Univ Autonoma Madrid, Fac Ciencias, Ctr Biol Mol Severo Ochoa, E-28049 Madrid, Spain.		Vazquez, Jesus/B-7697-2015; Ramírez, Anabel Marina/ABG-7125-2021; Lamas, José Ramón/C-8318-2012	Vazquez, Jesus/0000-0003-1461-5092; Ramírez, Anabel Marina/0000-0003-2927-6396; Lamas, José Ramón/0000-0003-1913-7261				Allen RL, 1999, J IMMUNOL, V162, P5045; Alvarez I, 2001, J BIOL CHEM, V276, P48740, DOI 10.1074/jbc.M108882200; Alvarez I, 2001, J BIOL CHEM, V276, P32729, DOI 10.1074/jbc.M104663200; APARICIO P, 1987, J EXP MED, V165, P428, DOI 10.1084/jem.165.2.428; BARNSTABLE CJ, 1978, CELL, V14, P9, DOI 10.1016/0092-8674(78)90296-9; BENJAMIN R, 1990, IMMUNOL TODAY, V11, P137, DOI 10.1016/0167-5699(90)90051-A; Boyle LH, 2001, J IMMUNOL, V167, P2619, DOI 10.4049/jimmunol.167.5.2619; BREWERTON DA, 1973, LANCET, V2, P996, DOI 10.1016/S0140-6736(73)91091-X; BREWERTON DA, 1973, LANCET, V1, P904; Colbert RA, 2000, MOL MED TODAY, V6, P224, DOI 10.1016/S1357-4310(00)01699-3; DAMATO M, 1995, EUR J IMMUNOL, V25, P3199, DOI 10.1002/eji.1830251133; Edwards JCW, 2000, IMMUNOL TODAY, V21, P256, DOI 10.1016/S0167-5699(00)01625-X; ELLIS SA, 1982, HUM IMMUNOL, V5, P49, DOI 10.1016/0198-8859(82)90030-1; Fiorillo MT, 1997, EUR J IMMUNOL, V27, P368, DOI 10.1002/eji.1830270205; FIORILLO MT, 1995, IMMUNOGENETICS, V41, P38, DOI 10.1007/BF00188430; FRUCI D, 1994, HUM IMMUNOL, V41, P34, DOI 10.1016/0198-8859(94)90081-7; Galocha B, 1996, TISSUE ANTIGENS, V48, P509, DOI 10.1111/j.1399-0039.1996.tb02664.x; Garcia F, 1997, TISSUE ANTIGENS, V49, P215, DOI 10.1111/j.1399-0039.1997.tb02741.x; Garcia-Fernandez S, 2001, TISSUE ANTIGENS, V58, P259, DOI 10.1034/j.1399-0039.2001.580407.x; GonzalezRoces S, 1997, TISSUE ANTIGENS, V49, P116, DOI 10.1111/j.1399-0039.1997.tb02724.x; Huang F, 1997, ARTHRITIS RHEUM, V40, P694, DOI 10.1002/art.1780400414; JARDETZKY TS, 1991, NATURE, V353, P326, DOI 10.1038/353326a0; KHARE SD, 1995, J EXP MED, V182, P1153, DOI 10.1084/jem.182.4.1153; Laitio P, 1997, EUR J IMMUNOL, V27, P1331, DOI 10.1002/eji.1830270606; Lamas JR, 1999, ARTHRITIS RHEUM-US, V42, P1975, DOI 10.1002/1529-0131(199909)42:9<1975::AID-ANR25>3.0.CO;2-V; LJUNGGREN HG, 1985, J EXP MED, V162, P1745, DOI 10.1084/jem.162.6.1745; LOPEZLARREA C, 1995, TISSUE ANTIGENS, V45, P169, DOI 10.1111/j.1399-0039.1995.tb02436.x; MADDEN DR, 1992, CELL, V70, P1035, DOI 10.1016/0092-8674(92)90252-8; Marina A, 1999, J MASS SPECTROM, V34, P17, DOI 10.1002/(SICI)1096-9888(199901)34:1<17::AID-JMS746>3.3.CO;2-Y; Mear JP, 1999, J IMMUNOL, V163, P6665; Nasution AR, 1997, J RHEUMATOL, V24, P1111; Paradela A, 2000, J IMMUNOL, V164, P329, DOI 10.4049/jimmunol.164.1.329; Paradela A, 1998, J IMMUNOL, V161, P5481; PARKER KC, 1994, BIOCHEMISTRY-US, V33, P7736, DOI 10.1021/bi00190a029; Ren EC, 1997, TISSUE ANTIGENS, V49, P67, DOI 10.1111/j.1399-0039.1997.tb02713.x; Rudwaleit M, 1996, IMMUNOGENETICS, V43, P160; Smith KJ, 1996, IMMUNITY, V4, P215, DOI 10.1016/S1074-7613(00)80430-6; STORKUS WJ, 1987, J IMMUNOL, V138, P1657; Sudarsono D, 1999, J RHEUMATOL, V26, P1534; Tieng V, 1997, IMMUNOGENETICS, V47, P103, DOI 10.1007/s002510050334; TOWNSEND A, 1989, NATURE, V340, P443, DOI 10.1038/340443a0; VEGA MA, 1986, J IMMUNOL, V137, P3557; VILCHES C, 1994, IMMUNOGENETICS, V39, P219, DOI 10.1007/BF00241265; Yague J, 1998, TISSUE ANTIGENS, V52, P416, DOI 10.1111/j.1399-0039.1998.tb03067.x; ZEMMOUR J, 1992, J IMMUNOL, V148, P1941	45	55	58	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 10	2002	277	19					16744	16749		10.1074/jbc.M200371200	http://dx.doi.org/10.1074/jbc.M200371200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	551MB	11875071	hybrid			2022-12-27	WOS:000175564500054
J	Trivedi, V; Gupta, A; Jala, VR; Saravanan, P; Rao, GSJ; Rao, NA; Savithri, HS; Subramanya, HS				Trivedi, V; Gupta, A; Jala, VR; Saravanan, P; Rao, GSJ; Rao, NA; Savithri, HS; Subramanya, HS			Crystal structure of binary and ternary complexes of serine hydroxymethyltransferase from Bacillus stearothermophilus - Insights into the catalytic mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; ANGSTROM RESOLUTION; REFINEMENT; BINDING; SUBSTRATE; ORIGIN	Serine hydroxymethyltransferase (SHMT), a member of the alpha-class of pyridoxal phosphate-dependent enzymes, catalyzes the reversible conversion of serine to glycine and tetrahydrofolate to 5,10-methylene tetrahydrofolate. We present here the crystal structures of the native enzyme and its complexes with serine, glycine, glycine, and 5-formyl tetrahydrofolate (FTHF) from Bacillus stearothermophilus. The first structure of the serine-bound form of SHMT allows identification of residues involved in serine binding and catalysis. The SHMT-serine complex does not show any significant conformational change compared with the native enzyme, contrary to that expected for a conversion from an "open" to "closed" form of the enzyme. However, the ternary complex with FTHF and glycine shows the reported conformational changes. In contrast to the Escherichia coli enzyme, this complex shows asymmetric binding of the FTHF to the two monomers within the dimer in a way similar to the murine SHMT. Comparison of the ternary complex with the native enzyme reveals the structural basis for the conformational change and asymmetric binding of FTHF. The four structures presented here correspond to the various reaction intermediates of the catalytic pathway and provide evidence for a direct displacement mechanism for the hydroxymethyl transfer rather than a retroaldol cleavage.	Cent Drug Res Inst, Mol & Struct Biol Div, Lucknow 226001, Uttar Pradesh, India; Indian Inst Sci, Dept Biochem, Bangalore 560012, Karnataka, India	Council of Scientific & Industrial Research (CSIR) - India; CSIR - Central Drug Research Institute (CDRI); Indian Institute of Science (IISC) - Bangalore	Subramanya, HS (corresponding author), Cent Drug Res Inst, Mol & Struct Biol Div, Chatter Manzil Palace,Mahatma Gandhi Marg,PB 173, Lucknow 226001, Uttar Pradesh, India.	subshs@rediffmail.com	Jala, Venkatakrishna R/K-7255-2018	Jala, Venkatakrishna R/0000-0002-4206-7305				ANGELACCIO S, 1992, BIOCHEMISTRY-US, V31, P155, DOI 10.1021/bi00116a023; APPLING DR, 1991, FASEB J, V5, P2645, DOI 10.1096/fasebj.5.12.1916088; Arnone A, 1985, TRANSAMINASES, P138; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BHASKAR B, 1994, BBA-PROTEIN STRUCT M, V1209, P40, DOI 10.1016/0167-4838(94)90134-1; BLAKELEY RL, 1995, BIOCHEM J, V61, P315; BRUNGER AT, 1989, ACTA CRYSTALLOGR A, V45, P50, DOI 10.1107/S0108767388009195; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; Contestabile R, 2000, BIOCHEMISTRY-US, V39, P7492, DOI 10.1021/bi000032z; Cowtan K., 1994, JOINT CCP4 ESF EACBM, V31, P34; EICHLER HG, 1981, BIOSCIENCE REP, V1, P101, DOI 10.1007/BF01117006; GORB CA, 1969, ANGEW CHEM INT EDIT, V8, P535; Huang T, 1998, BIOCHEMISTRY-US, V37, P13536, DOI 10.1021/bi980827u; Jagath JR, 1997, J BIOL CHEM, V272, P24355, DOI 10.1074/jbc.272.39.24355; JAGER J, 1994, J MOL BIOL, V239, P285, DOI 10.1006/jmbi.1994.1368; JORDAN PM, 1970, BIOCHEM J, V247, P372; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; MARCH J, 1999, ADV ORGANIC CHEM REA, P294; Matthews RG, 1998, ADV ENZYME REGUL, V38, P377, DOI 10.1016/S0065-2571(97)00006-X; MATTHEWS RG, 1990, CHEM REV, V90, P1275, DOI 10.1021/cr00105a010; MCPHALEN CA, 1992, J MOL BIOL, V227, P197, DOI 10.1016/0022-2836(92)90691-C; MCPHALEN CA, 1992, J MOL BIOL, V225, P495, DOI 10.1016/0022-2836(92)90935-D; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; OKAMOTO A, 1994, J BIOCHEM, V116, P95, DOI 10.1093/oxfordjournals.jbchem.a124509; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Rao JVK, 2000, EUR J BIOCHEM, V267, P5967, DOI 10.1046/j.1432-1327.2000.01667.x; RAO NA, 1991, NEW TRENDS BIOL CHEM, P333; Renwick SB, 1998, STRUCTURE, V6, P1105, DOI 10.1016/S0969-2126(98)00112-9; ROUSSEL A, 1989, SILICON GRAPHICS GEO, P77; Scarsdale JN, 2000, J MOL BIOL, V296, P155, DOI 10.1006/jmbi.1999.3453; Scarsdale JN, 1999, BIOCHEMISTRY-US, V38, P8347, DOI 10.1021/bi9904151; Schirch L. V., 1984, FOLATES PTERINS CHEM, V1, P399; SCHIRCH V, 1991, J BIOL CHEM, V266, P759; STOVER P, 1992, BIOCHEMISTRY-US, V31, P2155, DOI 10.1021/bi00122a037; STOVER P, 1991, J BIOL CHEM, V266, P1543; STOVER P, 1992, J BIOL CHEM, V267, P17679; Szebenyi DME, 2000, BIOCHEMISTRY-US, V39, P13313, DOI 10.1021/bi000635a; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; THORNDIKE J, 1979, CANCER RES, V39, P3435	41	65	66	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 10	2002	277	19					17161	17169		10.1074/jbc.M111976200	http://dx.doi.org/10.1074/jbc.M111976200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	551MB	11877399	hybrid			2022-12-27	WOS:000175564500109
J	Jones, JA; Hannun, YA				Jones, JA; Hannun, YA			Tight binding inhibition of protein phosphatase-1 by phosphatidic acid - Specificity of inhibition by the phospholipid	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLECKSTRIN-HOMOLOGY-DOMAIN; LIPID 2ND-MESSENGER; CATALYTIC SUBUNIT; GROWTH-FACTOR; RAF-1 KINASE; CELLS; PHOSPHORYLATION; STIMULATION; ACTIVATION; TRANSITION	Phosphatidic acid (PA) has been identified as a bioactive lipid second messenger, yet despite extensive investigation, no cellular target has emerged as a mediator of its described biological effects. In this study, we identify the gamma isoform of the human protein phosphatase-1 catalytic subunit (PP1cgamma) as a high affinity in vitro target of PA. PA inhibited the enzyme dose-dependently with an IC50 of 15 nM. Mechanistically, PA inhibited the enzyme noncompetitively with the kinetics of a tight binding inhibitor and a K-i value of 0.97 +/- 0.24 nM. Together, these data describe one of the most potent in vitro effects of PA. To further elucidate the interaction between PA and PP1cgamma, structure/function analysis of the lipid was carried out using commercially available and synthetically generated analogs of PA. These studies disclosed that the lipid-protein interaction is dependent on the presence of the lipid phosphate as well as the presence of the fatty acid side chains, because lipids lacking either of these substituents resulted in complete loss of inhibition. However, the specific composition of the fatty acid side chains was not important for inhibition. Using 1-O-hexadecyl,2-oleoyl-PA, it was also shown that the carbonyl group of the sn-1 acyl linkage is not required for the lipid-protein interaction. Finally, using a lipid-protein overlay assay, it was demonstrated that PP1cgamma specifically and directly interacts with phosphatidic acid while not significantly binding other phospholipids. These results identify PA as a tight binding and specific inhibitor of PP1, and they raise the hypothesis that PP1cgamma may function as a mediator of PA action in cells. They also argue for the existence of a specific high affinity PA-binding domain on the enzyme.	Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA; Med Univ S Carolina, Mol & Cellular Biol & Pathobiol Program, Charleston, SC 29425 USA	Medical University of South Carolina; Medical University of South Carolina	Hannun, YA (corresponding author), Med Univ S Carolina, Dept Biochem & Mol Biol, 171 Ashley Ave, Charleston, SC 29425 USA.			Jones, Jeffrey/0000-0002-5133-0427	NCI NIH HHS [CA-87584] Funding Source: Medline; NIGMS NIH HHS [GM-43825] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA087584] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM043825, R01GM043825] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALESSI DR, 1993, EUR J BIOCHEM, V213, P1055, DOI 10.1111/j.1432-1033.1993.tb17853.x; AMES BN, 1960, J BIOL CHEM, V235, P769; BARTON PG, 1975, J BIOL CHEM, V250, P4470; Bligh E., 1959, CAN J BIOCH PHYSL, V37, P341, DOI [10.1139/y59-099, DOI 10.1139/Y59-099]; BOLLEN M, 1992, CRIT REV BIOCHEM MOL, V27, P227, DOI 10.3109/10409239209082564; Bollen M, 2001, TRENDS BIOCHEM SCI, V26, P426, DOI 10.1016/S0968-0004(01)01836-9; BURSTEN S, 1994, CIRC SHOCK, V44, P14; BURSTEN SL, 1994, AM J PHYSIOL, V266, pC1093, DOI 10.1152/ajpcell.1994.266.4.C1093; Chalfant CE, 1999, J BIOL CHEM, V274, P20313, DOI 10.1074/jbc.274.29.20313; Cohen PTW, 1997, TRENDS BIOCHEM SCI, V22, P245, DOI 10.1016/S0968-0004(97)01060-8; DOHADWALA M, 1994, P NATL ACAD SCI USA, V91, P6408, DOI 10.1073/pnas.91.14.6408; Dowler S, 2000, BIOCHEM J, V351, P19, DOI 10.1042/0264-6021:3510019; ElBawab S, 1997, EUR J BIOCHEM, V247, P1151, DOI 10.1111/j.1432-1033.1997.01151.x; Endo S, 1997, BIOCHEMISTRY-US, V36, P6986, DOI 10.1021/bi970418i; Frank C, 1999, BIOCHEMISTRY-US, V38, P11993, DOI 10.1021/bi982586w; FUKAMI K, 1992, J BIOL CHEM, V267, P10988; Ghosh S, 1997, BIOCHEM SOC T, V25, P561, DOI 10.1042/bst0250561; Ghosh S, 1996, J BIOL CHEM, V271, P8472, DOI 10.1074/jbc.271.14.8472; HUBBARD MJ, 1993, TRENDS BIOCHEM SCI, V18, P172, DOI 10.1016/0968-0004(93)90109-Z; Ito M, 1997, BIOCHEMISTRY-US, V36, P7607, DOI 10.1021/bi9702647; JACKOWSKI S, 1989, ARCH BIOCHEM BIOPHYS, V268, P516, DOI 10.1016/0003-9861(89)90318-4; KASZKIN M, 1992, CANCER RES, V52, P5627; Kishikawa K, 1999, J BIOL CHEM, V274, P21335, DOI 10.1074/jbc.274.30.21335; Liu CWY, 1999, J BIOL CHEM, V274, P29470, DOI 10.1074/jbc.274.41.29470; McPhail LC, 1999, BBA-MOL CELL BIOL L, V1439, P277, DOI 10.1016/S1388-1981(99)00100-6; MERIDA I, 1993, DNA CELL BIOL, V12, P473, DOI 10.1089/dna.1993.12.473; SIDDIQUI RA, 1995, CELL SIGNAL, V7, P247, DOI 10.1016/0898-6568(94)00083-N; Silvius J.R., 1982, LIPID PROTEIN INTERA; Stevenson JM, 1998, J BIOL CHEM, V273, P22761, DOI 10.1074/jbc.273.35.22761; Strum JC, 1997, ADV EXP MED BIOL, V407, P421; Waite KA, 1997, J BIOL CHEM, V272, P15569, DOI 10.1074/jbc.272.24.15569; Watanabe T, 2001, P NATL ACAD SCI USA, V98, P3080, DOI 10.1073/pnas.051003898; WERA S, 1995, BIOCHEM J, V311, P17, DOI 10.1042/bj3110017; Xu YQ, 2001, J BIOL CHEM, V276, P18407, DOI 10.1074/jbc.M101204200; Zhu H, 2001, SCIENCE, V293, P2101, DOI 10.1126/science.1062191	35	77	77	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 3	2002	277	18					15530	15538		10.1074/jbc.M111555200	http://dx.doi.org/10.1074/jbc.M111555200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	550PA	11856740	hybrid			2022-12-27	WOS:000175510400042
J	Kashlev, M; Komissarova, N				Kashlev, M; Komissarova, N			Transcription termination: Primary intermediates and secondary adducts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLI RNA-POLYMERASE; ESCHERICHIA-COLI; ELONGATION COMPLEX; NASCENT RNA; TERNARY COMPLEXES; CHAIN ELONGATION; CLEAVAGE FACTORS; IN-VIVO; DNA; MECHANISM	In living organisms, stable elongation complexes of RNA polymerase dissociate at specific template positions in a process of transcription termination. It has been suggested that the dissociation is not the immediate cause of termination but is preceded by catalytic inactivation of the elongation complex. In vitro reducing ionic strength can be used to stabilize very unstable and catalytically inactive complex at the point of termination; the previous biochemical characterization of this complex has led to important conclusions regarding termination mechanism. Here we analyze in detail the complexes formed between DNA template, nascent RNA, and Escherichia coli RNA polymerase during transcription through the tR2 terminator of bacteriophage A. At low ionic strength, the majority of elongation complexes fall apart upon reaching the terminator. Released RNA and DNA efficiently rebind RNA polymerase (RNAP) and form binary RNAP.RNA and RNAP.DNA complexes, which are indistinguishable from binary complexes obtained by direct mixing of the purified nucleic acids and the enzyme. A small fraction of elongation complexes that reach termination point escapes dissociation because RNA polymerase has backtracked from the terminator to an upstream DNA position. Thus, transcription elongation to a terminator site produces no termination intermediates that withstand dissociation in the time scale appropriate for biochemical studies.	NCI, Frederick Canc Res & Dev Ctr, Frederick, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	Kashlev, M (corresponding author), NCI, Frederick Canc Res & Dev Ctr, Bldg 539,Rm 222, Frederick, MD 21702 USA.	mkashlev@mail.ncifcrf.gov						ALTMANN CR, 1994, P NATL ACAD SCI USA, V91, P3784, DOI 10.1073/pnas.91.9.3784; ARNDT KM, 1990, J MOL BIOL, V213, P79, DOI 10.1016/S0022-2836(05)80123-8; Artsimovitch I, 2000, P NATL ACAD SCI USA, V97, P7090, DOI 10.1073/pnas.97.13.7090; BERLIN V, 1983, J BIOL CHEM, V258, P1714; Borukhov S, 1996, METHOD ENZYMOL, V274, P315; BORUKHOV S, 1993, CELL, V72, P459, DOI 10.1016/0092-8674(93)90121-6; Darst SA, 2001, CURR OPIN STRUC BIOL, V11, P155; DORVAL BC, 1991, J MOL BIOL, V221, P837, DOI 10.1016/0022-2836(91)80179-X; FULLER RS, 1978, NUCLEIC ACIDS RES, V5, P4613; Gnatt AL, 2001, SCIENCE, V292, P1876, DOI 10.1126/science.1059495; Gusarov I, 1999, MOL CELL, V3, P495, DOI 10.1016/S1097-2765(00)80477-3; JOHNSON TL, 1994, CELL, V77, P217, DOI 10.1016/0092-8674(94)90314-X; Kashlev M, 1996, METHOD ENZYMOL, V274, P326; KASHLEV M, 1993, GENE, V130, P9, DOI 10.1016/0378-1119(93)90340-9; Komissarova N, 1997, J BIOL CHEM, V272, P15329, DOI 10.1074/jbc.272.24.15329; Komissarova N, 1998, P NATL ACAD SCI USA, V95, P14699, DOI 10.1073/pnas.95.25.14699; Komissarova N, 1997, P NATL ACAD SCI USA, V94, P1755, DOI 10.1073/pnas.94.5.1755; Korzheva N, 2000, SCIENCE, V289, P619, DOI 10.1126/science.289.5479.619; Landick R, 1999, SCIENCE, V284, P598, DOI 10.1126/science.284.5414.598; Landick R, 2001, CELL, V105, P567, DOI 10.1016/S0092-8674(01)00381-6; MCDOWELL JC, 1994, SCIENCE, V266, P822, DOI 10.1126/science.7526463; NUDLER E, 1995, CELL, V81, P351, DOI 10.1016/0092-8674(95)90388-7; Nudler E, 1998, SCIENCE, V281, P424, DOI 10.1126/science.281.5375.424; Nudler E, 1996, SCIENCE, V273, P211, DOI 10.1126/science.273.5272.211; ORLOVA M, 1995, P NATL ACAD SCI USA, V92, P4596, DOI 10.1073/pnas.92.10.4596; Sidorenkov I, 1998, MOL CELL, V2, P55, DOI 10.1016/S1097-2765(00)80113-6; SURRATT CK, 1991, P NATL ACAD SCI USA, V88, P7983, DOI 10.1073/pnas.88.18.7983; Toulme F, 1999, EMBO J, V18, P5052, DOI 10.1093/emboj/18.18.5052; Toulme F, 2000, EMBO J, V19, P6853, DOI 10.1093/emboj/19.24.6853; Toulokhonov I, 2001, SCIENCE, V292, P730, DOI 10.1126/science.1057738; Uptain SM, 1997, P NATL ACAD SCI USA, V94, P13548, DOI 10.1073/pnas.94.25.13548; Uptain SM, 1997, ANNU REV BIOCHEM, V66, P117, DOI 10.1146/annurev.biochem.66.1.117; von Hippel PH, 1998, SCIENCE, V281, P660, DOI 10.1126/science.281.5377.660; WILSON KS, 1995, P NATL ACAD SCI USA, V92, P8793, DOI 10.1073/pnas.92.19.8793; Wilson KS, 1999, J MOL BIOL, V289, P1179, DOI 10.1006/jmbi.1999.2814; WILSON KS, 1994, J MOL BIOL, V244, P36, DOI 10.1006/jmbi.1994.1702; YAGER TD, 1991, BIOCHEMISTRY-US, V30, P1097, DOI 10.1021/bi00218a032; Yarnell WS, 1999, SCIENCE, V284, P611, DOI 10.1126/science.284.5414.611; Yin H, 1999, P NATL ACAD SCI USA, V96, P13124, DOI 10.1073/pnas.96.23.13124; ZAYCHIKOV E, 1995, P NATL ACAD SCI USA, V92, P1739, DOI 10.1073/pnas.92.5.1739; Zhang GY, 1999, CELL, V98, P811, DOI 10.1016/S0092-8674(00)81515-9	41	27	31	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 26	2002	277	17					14501	14508		10.1074/jbc.M200215200	http://dx.doi.org/10.1074/jbc.M200215200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	545EH	11856750	hybrid			2022-12-27	WOS:000175203000021
J	Tkachenko, E; Simons, M				Tkachenko, E; Simons, M			Clustering induces redistribution of syndecan-4 core protein into raft membrane domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOPLASMIC DOMAIN; KINASE; PHOSPHORYLATION; PATHWAY	Syndecan-4 is a heparan sulfate-carrying core protein that has been directly implicated in fibroblast growth factor 2 (FGF2) signaling. Recent studies have suggested that many signaling proteins localize to the raft compartment of the plasma cell membrane. To establish whether syndecan-4 is present in the raft compartment, we have studied the distribution of the core protein and an Fc receptor (FcR)-syndecan-4 chimera prior to and following clustering with FGF2 or antibodies. Whereas unclustered syndecan-4 was present predominantly in the non-raft membrane compartment, clustering induced extensive syndecan-4 redistribution to the rafts as demonstrated by the sucrose gradient centrifugation and life confocal microscopy. Although syndecan-4 and caveolin-1 moved in tandem, syndecan-4 was not present in caveolae, a major subset of raft compartments. We conclude that syndecan-4 clustering induces its redistribution to the non-caveolae raft compartment. This process may play an important role in syndecan-4-mediation of FGF2 signaling.	Dartmouth Coll Sch Med, Dartmouth Hitchcock Med Ctr, Cardiol Sect, Dept Med, Lebanon, NH 03756 USA; Dartmouth Coll Sch Med, Angiogenesis Res Ctr, Lebanon, NH 03756 USA	Dartmouth College; Dartmouth College	Simons, M (corresponding author), Dartmouth Coll Sch Med, Dartmouth Hitchcock Med Ctr, Cardiol Sect, Dept Med, 1 Med Ctr Dr, Lebanon, NH 03756 USA.	michael.simons@dartmouth.edu	Tkachenko, Eugene/A-9779-2012; Simons, Michael/G-8553-2014	Simons, Michael/0000-0003-0348-7734; Tkachenko, Eugene/0000-0002-7964-484X				Brodsky RA, 2000, AM J CLIN PATHOL, V114, P459, DOI 10.1093/ajcp/114.3.459; Carey DJ, 1996, J BIOL CHEM, V271, P15253, DOI 10.1074/jbc.271.25.15253; Couchman JR, 2001, INT REV CYTOL, V207, P113; Fuki IV, 2000, BIOCHEM J, V351, P607, DOI 10.1042/0264-6021:3510607; Galbiati F, 2001, CELL, V106, P403, DOI 10.1016/S0092-8674(01)00472-X; Horowitz A, 1998, J BIOL CHEM, V273, P25548, DOI 10.1074/jbc.273.40.25548; Horowitz A, 1998, J BIOL CHEM, V273, P10914, DOI 10.1074/jbc.273.18.10914; *J WIL SONS INC, 2001, CURR PROT IMM ONL; Kabouridis PS, 1997, EMBO J, V16, P4983, DOI 10.1093/emboj/16.16.4983; Oh ES, 1997, J BIOL CHEM, V272, P8133, DOI 10.1074/jbc.272.13.8133; Pelkmans L, 2001, NAT CELL BIOL, V3, P473, DOI 10.1038/35074539; Pralle A, 2000, J CELL BIOL, V148, P997, DOI 10.1083/jcb.148.5.997; Rapraeger AC, 2000, J CELL BIOL, V149, P995, DOI 10.1083/jcb.149.5.995; Rodrigueza WV, 1997, ARTERIOSCL THROM VAS, V17, P383, DOI 10.1161/01.ATV.17.2.383; SCHNITZER JE, 1995, P NATL ACAD SCI USA, V92, P1759, DOI 10.1073/pnas.92.5.1759; SHWORAK NW, 1994, J BIOL CHEM, V269, P21204; Simons M, 2001, CELL SIGNAL, V13, P855, DOI 10.1016/S0898-6568(01)00190-5; Smart EJ, 1999, MOL CELL BIOL, V19, P7289; Tumova S, 2000, INT J BIOCHEM CELL B, V32, P269, DOI 10.1016/S1357-2725(99)00116-8; Volk R, 1999, J BIOL CHEM, V274, P24417, DOI 10.1074/jbc.274.34.24417; Waugh MG, 2001, BIOCHEM SOC T, V29, P509, DOI 10.1042/BST0290509; Williams K J, 2001, Methods Mol Biol, V171, P457; Woods A, 2001, CURR OPIN CELL BIOL, V13, P578, DOI 10.1016/S0955-0674(00)00254-4; Zimmermann P, 1999, FASEB J, V13, pS91	24	94	98	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 31	2002	277	22					19946	19951		10.1074/jbc.M200841200	http://dx.doi.org/10.1074/jbc.M200841200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	557EH	11889131	hybrid			2022-12-27	WOS:000175894800093
J	Domkin, V; Thelander, L; Chabes, A				Domkin, V; Thelander, L; Chabes, A			Yeast DNA damage-inducible Rnr3 has a very low catalytic activity strongly stimulated after the formation of a cross-talking Rnr1/Rnr3 complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOUSE RIBONUCLEOTIDE REDUCTASE; SACCHAROMYCES-CEREVISIAE; CELL-CYCLE; CHECKPOINT PATHWAYS; SUBUNIT INTERACTION; ESCHERICHIA-COLI; PROTEIN; TRANSCRIPTION; KINASE; REPLICATION	The ribonucleotide reductase system in Saccharomyces cerevisiae includes four genes (RNR1 and RNR3 encoding the large subunit and RNR2 and RNR4 encoding the small subunit). RNR3 expression, nearly undetectable during normal growth, is strongly induced by DNA damage. Yet an rnr3 null mutant has no obvious phenotype even under DNA damaging conditions, and the contribution of RNR3 to ribonucleotide reduction is not clear. To investigate the role of RNR3 we expressed and characterized the Rnr3 protein. The in vitro activity of Rnr3 was less than 1% of the Rnr1 activity. However, a strong synergism between Rnr3 and Rnr1 was observed, most clearly demonstrated in experiments with the catalytically inactive Rnr1-C428A mutant, which increased the endogenous activity of Rnr3 by at least 10-fold. In vivo, the levels of Rnr3 after DNA damage never reached more than one-tenth of the Rnr1 levels. We propose that heterodimerization of Rnr3 with Rnr1 facilitates the recruitment of Rnr3 to the ribonucleotide reductase holoenzyme, which may be important when Rnr1 is limiting for dNTP production. In complex with inactive Rnr1-C428A, the activity of Rnr3 is controlled by effector binding to Rnr1-C428A. This result indicates cross-talk between the Rnr1 and Rnr3 polypeptides of the large subunit.	Umea Univ, Dept Med Biochem & Biophys, SE-90187 Umea, Sweden	Umea University	Chabes, A (corresponding author), Cold Spring Harbor Lab, 1 Bungtown Rd,POB 100, Cold Spring Harbor, NY 11724 USA.	chabes@cshl.org		Chabes, Andrei/0000-0003-1708-8259				ABERG A, 1989, J BIOL CHEM, V264, P12249; Chabes A, 2000, J BIOL CHEM, V275, P17747, DOI 10.1074/jbc.M000799200; Chabes A, 2000, P NATL ACAD SCI USA, V97, P2474, DOI 10.1073/pnas.97.6.2474; Chabes A, 1999, J BIOL CHEM, V274, P36679, DOI 10.1074/jbc.274.51.36679; DAVIS R, 1994, J BIOL CHEM, V269, P23171; Desany BA, 1998, GENE DEV, V12, P2956, DOI 10.1101/gad.12.18.2956; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; ELLEDGE SJ, 1990, GENE DEV, V4, P740, DOI 10.1101/gad.4.5.740; ELLEDGE SJ, 1992, TRENDS BIOCHEM SCI, V17, P119, DOI 10.1016/0968-0004(92)90249-9; Ho Y, 1997, P NATL ACAD SCI USA, V94, P581, DOI 10.1073/pnas.94.2.581; Huang MX, 1997, MOL CELL BIOL, V17, P6105, DOI 10.1128/MCB.17.10.6105; Huang MX, 1998, CELL, V94, P595, DOI 10.1016/S0092-8674(00)81601-3; Ingemarson R, 1996, BIOCHEMISTRY-US, V35, P8603, DOI 10.1021/bi960184n; Jordan A, 1998, ANNU REV BIOCHEM, V67, P71, DOI 10.1146/annurev.biochem.67.1.71; Li B, 2001, J BIOL CHEM, V276, P33788, DOI 10.1074/jbc.M104220200; MAO SS, 1992, BIOCHEMISTRY-US, V31, P9752, DOI 10.1021/bi00155a031; Paesi-Toresan SO, 1998, CURR GENET, V34, P124, DOI 10.1007/s002940050376; Reichard P, 2000, J BIOL CHEM, V275, P33021, DOI 10.1074/jbc.M005337200; REICHARD P, 1988, ANNU REV BIOCHEM, V57, P349, DOI 10.1146/annurev.bi.57.070188.002025; Rotman G, 1999, ONCOGENE, V18, P6135, DOI 10.1038/sj.onc.1203124; Ruiz MAD, 2000, FEBS LETT, V485, P205, DOI 10.1016/S0014-5793(00)02198-0; Wang PJ, 1997, MOL CELL BIOL, V17, P6114, DOI 10.1128/MCB.17.10.6114; Weinert T, 1998, CELL, V94, P555, DOI 10.1016/S0092-8674(00)81597-4; Zhao XL, 2001, EMBO J, V20, P3544, DOI 10.1093/emboj/20.13.3544; Zhao XL, 1998, MOL CELL, V2, P329, DOI 10.1016/S1097-2765(00)80277-4; Zhao XL, 2000, MOL CELL BIOL, V20, P9076, DOI 10.1128/MCB.20.23.9076-9083.2000; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005; ZHOU Z, 1992, GENETICS, V131, P851; ZHOU Z, 1993, CELL, V75, P1119, DOI 10.1016/0092-8674(93)90321-G	29	44	50	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 24	2002	277	21					18574	18578		10.1074/jbc.M201553200	http://dx.doi.org/10.1074/jbc.M201553200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	558PM	11893751	hybrid			2022-12-27	WOS:000175975800044
J	Gonzalez, MM; Carlberg, C				Gonzalez, MM; Carlberg, C			Cross-repression, a functional consequence of the physical interaction of non-liganded nuclear receptors and POU domain transcription factors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROLIFERATOR-ACTIVATED RECEPTOR; THYROID-HORMONE RECEPTOR; VITAMIN-D-RECEPTOR; RESPONSE ELEMENTS; SYNERGISTIC ACTIVATION; BINDING PROTEIN; COACTIVATOR; GENE; PROMOTER; PATHWAY	Nuclear receptors (NRs) and POU domain factors form two important transcription factor families for which several levels of functional interference have been described. In this study, the adopted orphan receptors constitutive androstane receptor (CAR) and pregnane X receptor (PXR) were found to perform direct protein-protein interactions with Pit-1, a representative POU domain factor. The ligand-dependent interaction profile of Pit-1 with CAR, PXR, and the vitamin D receptor in solution was shown to be that of a corepressor. In the absence of receptor agonist Pit-1 inhibited the complex formation of NRs with the retinoid X receptor on DNA. Also in living cells, Pit-1 and Oct-1, another POU domain factor, behaved like corepressors of NR signaling, and Pit-1-mediated repression was found to involve histone deacetylases. Conversely vitamin D receptor, CAR, and PXR were shown to act as repressors of Pit-1 signaling in different cell lines (MCF-7, HaCaT, and GH4C1). This repression was found to be independent of histone deacetylases and seems to be based on a competition of NRs with coactivator and corepressor proteins for overlaying interaction interfaces on the surface of Pit-1. Taken together this study suggests that cross-repression should occur in all tissues in which POU domain factors and non-liganded NRs meet each other.	Univ Kuopio, Dept Biochem, FIN-70211 Kuopio, Finland	Finland National Institute for Health & Welfare; University of Eastern Finland	Carlberg, C (corresponding author), Univ Kuopio, Dept Biochem, POB 1627, FIN-70211 Kuopio, Finland.		Carlberg, Carsten/C-9075-2011	Carlberg, Carsten/0000-0003-2633-0684				Altucci L, 2001, TRENDS ENDOCRIN MET, V12, P460, DOI 10.1016/S1043-2760(01)00502-1; Auwerx J, 1999, CELL, V97, P161; BAES M, 1994, MOL CELL BIOL, V14, P1544, DOI 10.1128/MCB.14.3.1544; BAKER AR, 1988, P NATL ACAD SCI USA, V85, P3294, DOI 10.1073/pnas.85.10.3294; Bertilsson G, 1998, P NATL ACAD SCI USA, V95, P12208, DOI 10.1073/pnas.95.21.12208; Bourguet W, 2000, TRENDS PHARMACOL SCI, V21, P381, DOI 10.1016/S0165-6147(00)01548-0; Burke LJ, 2000, FASEB J, V14, P1876, DOI 10.1096/fj.99-0943rev; Castillo AI, 1999, MOL ENDOCRINOL, V13, P1141, DOI 10.1210/me.13.7.1141; Choi HS, 1997, J BIOL CHEM, V272, P23565, DOI 10.1074/jbc.272.38.23565; Darimont BD, 1998, GENE DEV, V12, P3343, DOI 10.1101/gad.12.21.3343; DREYER C, 1992, CELL, V68, P879, DOI 10.1016/0092-8674(92)90031-7; Feng WJ, 1998, SCIENCE, V280, P1747, DOI 10.1126/science.280.5370.1747; Herdick M, 2000, MOL PHARMACOL, V57, P1206; Honkakoski P, 1996, J BIOL CHEM, V271, P9746, DOI 10.1074/jbc.271.16.9746; Honkakoski P, 2000, BIOCHEM J, V347, P321, DOI 10.1042/0264-6021:3470321; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; Hu X, 1999, NATURE, V402, P93, DOI 10.1038/47069; INGRAHAM HA, 1988, CELL, V55, P519, DOI 10.1016/0092-8674(88)90038-4; Kliewer SA, 1998, CELL, V92, P73, DOI 10.1016/S0092-8674(00)80900-9; KRUST A, 1989, P NATL ACAD SCI USA, V86, P5310, DOI 10.1073/pnas.86.14.5310; Leo C, 2000, GENE, V245, P1, DOI 10.1016/S0378-1119(00)00024-X; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; Moore LB, 2000, J BIOL CHEM, V275, P15122, DOI 10.1074/jbc.M001215200; Ng HH, 2000, TRENDS BIOCHEM SCI, V25, P121; ONATE SA, 1995, SCIENCE, V270, P1354; Palomino T, 1998, FASEB J, V12, P1201, DOI 10.1096/fasebj.12.12.1201; Quack M, 2000, J MOL BIOL, V296, P743, DOI 10.1006/jmbi.2000.3499; RHODES SJ, 1993, GENE DEV, V7, P913, DOI 10.1101/gad.7.6.913; Ryan AK, 1997, GENE DEV, V11, P1207, DOI 10.1101/gad.11.10.1207; SANCHEZPACHECO A, 1995, MOL CELL BIOL, V15, P6322; SAP J, 1986, NATURE, V324, P635, DOI 10.1038/324635a0; Schaufele F, 2000, MOL ENDOCRINOL, V14, P2024, DOI 10.1210/me.14.12.2024; SCHAUFELE F, 1992, MOL ENDOCRINOL, V6, P656, DOI 10.1210/me.6.4.656; Scully KM, 2000, SCIENCE, V290, P1127, DOI 10.1126/science.290.5494.1127; SHER T, 1993, BIOCHEMISTRY-US, V32, P5598, DOI 10.1021/bi00072a015; STURM RA, 1988, GENE DEV, V2, P1582, DOI 10.1101/gad.2.12a.1582; Sueyoshi T, 1999, J BIOL CHEM, V274, P6043, DOI 10.1074/jbc.274.10.6043; Toell A, 2002, J CELL BIOCHEM, V85, P72, DOI 10.1002/jcb.10104; Toell A, 2000, BIOCHEM J, V352, P301, DOI 10.1042/0264-6021:3520301; Tolon RM, 1998, J BIOL CHEM, V273, P26652, DOI 10.1074/jbc.273.41.26652; Tzameli I, 2001, TRENDS ENDOCRIN MET, V12, P7, DOI 10.1016/S1043-2760(00)00332-5; WALTERS MR, 1992, ENDOCR REV, V13, P719, DOI 10.1210/er.13.4.719	42	28	30	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 24	2002	277	21					18501	18509		10.1074/jbc.M200205200	http://dx.doi.org/10.1074/jbc.M200205200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	558PM	11891224	hybrid			2022-12-27	WOS:000175975800034
J	Holden, JH; Czajkowski, C				Holden, JH; Czajkowski, C			Different residues in the GABA(A) receptor alpha(1)T60-alpha(1)K70 region mediate GABA and SR-95531 actions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINOBUTYRIC ACID(A) RECEPTOR; LIGAND-BINDING DOMAIN; BENZODIAZEPINE BINDING; ACETYLCHOLINE-RECEPTOR; NICOTINIC RECEPTORS; XENOPUS OOCYTES; DELTA-SUBUNIT; ALPHA-SUBUNIT; CHANNEL; SITE	Although gamma-aminobutyric acid type A receptor agonists and antagonists bind to a common site, they produce different conformational changes within the site because agonists cause channel opening and antagonists do not. We used the substituted cysteine accessibility method and two-electrode voltage clamping to identify residues within the binding pocket that are important for mediating these different actions. Each residue from alpha(1)T60 to alpha(1)K70 was mutated to cysteine and expressed with wild-type beta(2) subunits in Xenopus oocytes. Methanethiosulfonate reagents reacted with alpha(1)T60C, alpha(1)D62C, alpha(1)F64C, alpha(1)R66C, alpha(1)S6SC, and alpha(1)K70C. gamma-Aminobutyric acid (GABA) slowed methanethiosulfonate modification of alpha(1)F64C, alpha(1)R66C, and alpha(1)S68C, whereas SR-95531 slowed modification of alpha(1)D62C, alpha(1)F64C, and alpha(1)R66C, demonstrating that different residues are important for mediating GABA and SR-95531 actions. In addition, methanethiosulfonate reaction rates were fastest for alpha(1)F64C and alpha(1)R66C, indicating that these residues are located in an open, aqueous environment lining the core of the binding pocket. Positively charged methanethiosulfonate reagents derivatized alpha(1)F64C and alpha(1)R66C significantly faster than a negatively charged reagent, suggesting that a negative subsite important for interacting with the ammonium group of GABA exists within the binding pocket. Pentobarbital activation of the receptor increased the rate of methanethiosulfonate modification of alpha(1)D62C and alpha(1)S68C, demonstrating that parts of the binding site undergo structural rearrangements during channel gating.	Univ Wisconsin, MSC, Dept Physiol, Madison, WI 53706 USA; Univ Wisconsin, Mol & Cellular Pharmacol Program, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Czajkowski, C (corresponding author), Univ Wisconsin, MSC, Dept Physiol, 1300 Univ Ave,Rm 197, Madison, WI 53706 USA.				NINDS NIH HHS [NS34727] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS034727, R56NS034727] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AMIN J, 1993, NATURE, V366, P565, DOI 10.1038/366565a0; Barnard EA, 1998, PHARMACOL REV, V50, P291; Boileau AJ, 1999, J NEUROSCI, V19, P4847; Boileau AJ, 1998, MOL PHARMACOL, V53, P295, DOI 10.1124/mol.53.2.295; Boileau AJ, 2002, J BIOL CHEM, V277, P2931, DOI 10.1074/jbc.M109334200; Bonnert TP, 1999, P NATL ACAD SCI USA, V96, P9891, DOI 10.1073/pnas.96.17.9891; Brejc K, 2001, NATURE, V411, P269, DOI 10.1038/35077011; CAVALLA D, 1985, J NEUROCHEM, V44, P916, DOI 10.1111/j.1471-4159.1985.tb12904.x; Chang YC, 1996, J NEUROSCI, V16, P5415; Cheung M, 1997, J GEN PHYSIOL, V109, P289, DOI 10.1085/jgp.109.3.289; CHOU TC, 1974, MOL PHARMACOL, V10, P235; Corringer PJ, 2000, ANNU REV PHARMACOL, V40, P431, DOI 10.1146/annurev.pharmtox.40.1.431; CZAJKOWSKI C, 1993, P NATL ACAD SCI USA, V90, P6285, DOI 10.1073/pnas.90.13.6285; Davies PA, 1997, NATURE, V385, P820, DOI 10.1038/385820a0; Dougherty DA, 1996, SCIENCE, V271, P163, DOI 10.1126/science.271.5246.163; Hedblom E, 1997, J BIOL CHEM, V272, P15346, DOI 10.1074/jbc.272.24.15346; Jones MV, 1998, J NEUROSCI, V18, P8590; Karlin A, 1998, METHOD ENZYMOL, V293, P123; Kucken AM, 2000, MOL PHARMACOL, V57, P932; LEVITAN ES, 1988, NEURON, V1, P773, DOI 10.1016/0896-6273(88)90125-0; LIMAN ER, 1992, NEURON, V9, P861, DOI 10.1016/0896-6273(92)90239-A; MACDONALD RL, 1994, ANNU REV NEUROSCI, V17, P569, DOI 10.1146/annurev.neuro.17.1.569; Martin M, 1996, J BIOL CHEM, V271, P13497, DOI 10.1074/jbc.271.23.13497; McKernan RM, 1996, TRENDS NEUROSCI, V19, P139, DOI 10.1016/S0166-2236(96)80023-3; NICOLL RA, 1980, BRAIN RES, V191, P225, DOI 10.1016/0006-8993(80)90325-X; NICOLL RA, 1975, NATURE, V258, P625, DOI 10.1038/258625a0; ORTELLS MO, 1995, TRENDS NEUROSCI, V18, P121, DOI 10.1016/0166-2236(95)93887-4; Pascual JM, 1998, J GEN PHYSIOL, V111, P717, DOI 10.1085/jgp.111.6.717; ROBERTS DD, 1986, BIOCHEMISTRY-US, V25, P5595, DOI 10.1021/bi00367a038; Robertson GA, 1996, NEUROPHARMACOLOGY, V35, P841, DOI 10.1016/0028-3908(96)00113-X; ROGNAN D, 1992, J MED CHEM, V35, P1969, DOI 10.1021/jm00089a005; SIGEL E, 1992, EMBO J, V11, P2017, DOI 10.1002/j.1460-2075.1992.tb05258.x; SIGEL E, 1990, NEURON, V5, P703, DOI 10.1016/0896-6273(90)90224-4; SMITH GB, 1994, J BIOL CHEM, V269, P20380; STAUFFER DA, 1994, BIOCHEMISTRY-US, V33, P6840, DOI 10.1021/bi00188a013; Wagner DA, 2001, J NEUROSCI, V21, P67, DOI 10.1523/JNEUROSCI.21-01-00067.2001; Westh-Hansen SE, 1999, NEUROREPORT, V10, P2417, DOI 10.1097/00001756-199908020-00036; WesthHansen SE, 1997, EUR J PHARMACOL, V329, P253, DOI 10.1016/S0014-2999(97)89186-8; Whiting PJ, 1999, ANN NY ACAD SCI, V868, P645, DOI 10.1111/j.1749-6632.1999.tb11341.x; Yan D, 1999, J BIOL CHEM, V274, P5537, DOI 10.1074/jbc.274.9.5537; Yang NB, 1997, BIOPHYS J, V73, P2260, DOI 10.1016/S0006-3495(97)78258-4	41	59	60	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 24	2002	277	21					18785	18792		10.1074/jbc.M111778200	http://dx.doi.org/10.1074/jbc.M111778200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	558PM	11896052	hybrid			2022-12-27	WOS:000175975800072
J	Miyoshi, K; Tsujii, R; Yoshida, H; Maki, Y; Wada, A; Matsui, Y; Toh-e, A; Mizuta, K				Miyoshi, K; Tsujii, R; Yoshida, H; Maki, Y; Wada, A; Matsui, Y; Toh-e, A; Mizuta, K			Normal assembly of 60 S ribosomal subunits is required for the signaling in response to a secretory defect in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI RIBOSOMES; TERMINAL SILENCING DOMAIN; RNA SYNTHESIS; PROTEINS L5; 5S RNA; YEAST; REPRESSION; PATHWAY; GENE; L16	A secretory defect leads to transcriptional repression of both ribosomal protein and rRNA genes in yeast. To elucidate the mechanism of the signaling, we previously isolated rrs mutants that were unable to respond to a secretory defect, and we cloned RRS1 encoding a nuclear protein that was required for ribosome biogenesis (Tsuno, A., Miyoshi, K., Tsujii, R., Miyakawa, T., and Mizuta, K (2000) Mol Cell Biol. 20, 2066-2074). We identified duplicated genes encoding ribosomal protein L11, RPL11B as a wild-type allele complementing the rrs2 mutation, and RPL11A in two-hybrid screening using RRS1 as bait. Rpl11p was copurified with Rrs1p in immunoprecipitation analysis. Ultracentrifugation analysis revealed that Rrs1p associated fairly tightly with 60 S preribosomal subunits. These results suggest that signaling in response to a secretory defect requires the normal assembly of 60 S ribosomal subunits including Rrs1p and Rpl11p.	Hiroshima Univ, Grad Sch Biosphere Sci, Dept Biol Sci, Higashihiroshima 7398528, Japan; Hiroshima Univ, Grad Sch Adv Sci Matter, Dept Mol Biotechnol, Higashihiroshima 7398528, Japan; Osaka Med Coll, Dept Phys, Osaka 5690084, Japan; Univ Tokyo, Grad Sch Sci, Dept Biol Sci, Bunkyo Ku, Tokyo 1130033, Japan	Hiroshima University; Hiroshima University; Osaka Medical College; University of Tokyo	Mizuta, K (corresponding author), Hiroshima Univ, Grad Sch Biosphere Sci, Dept Biol Sci, Kagamiyama 1-4-4, Higashihiroshima 7398528, Japan.			Yoshida, Hideji/0000-0001-7213-4735				CHENSCHMEISSER U, 1977, FEBS LETT, V74, P287, DOI 10.1016/0014-5793(77)80866-1; Eisinger DP, 1997, MOL CELL BIOL, V17, P5136, DOI 10.1128/MCB.17.9.5136; Fath S, 2000, J CELL BIOL, V149, P575, DOI 10.1083/jcb.149.3.575; Gadal O, 2001, MOL CELL BIOL, V21, P3405, DOI 10.1128/MCB.21.10.3405-3415.2001; HORNE JR, 1972, MOL GEN GENET, V119, P337, DOI 10.1007/BF00272091; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; Kaiser C., 1994, METHODS YEAST GENETI; Kressler D, 1999, MOL CELL BIOL, V19, P7897; LEER RJ, 1984, FEBS LETT, V175, P371, DOI 10.1016/0014-5793(84)80771-1; Li BJ, 1996, J BIOL CHEM, V271, P16813, DOI 10.1074/jbc.271.28.16813; Li Y, 2000, MOL CELL BIOL, V20, P3843, DOI 10.1128/MCB.20.11.3843-3851.2000; Mager WH, 1997, NUCLEIC ACIDS RES, V25, P4872, DOI 10.1093/nar/25.24.4872; Milkereit P, 2001, CELL, V105, P499, DOI 10.1016/S0092-8674(01)00358-0; Miyoshi K, 2001, NUCLEIC ACIDS RES, V29, P3297, DOI 10.1093/nar/29.16.3297; Mizuta K, 1998, NUCLEIC ACIDS RES, V26, P1063, DOI 10.1093/nar/26.4.1063; MIZUTA K, 1994, MOL CELL BIOL, V14, P2493, DOI 10.1128/MCB.14.4.2493; MORITZ M, 1991, MOL CELL BIOL, V11, P5681, DOI 10.1128/MCB.11.11.5681; MORITZ M, 1990, J CELL BIOL, V111, P2261, DOI 10.1083/jcb.111.6.2261; NELSON RJ, 1992, CELL, V71, P97, DOI 10.1016/0092-8674(92)90269-I; Nierras CR, 1999, J BIOL CHEM, V274, P13235, DOI 10.1074/jbc.274.19.13235; ROSE MD, 1987, GENE, V60, P237, DOI 10.1016/0378-1119(87)90232-0; ROTENBERG MO, 1988, GENE DEV, V2, P160, DOI 10.1101/gad.2.2.160; SMITH N, 1978, EUR J BIOCHEM, V89, P501, DOI 10.1111/j.1432-1033.1978.tb12554.x; Spahn CMT, 2001, CELL, V107, P373, DOI 10.1016/S0092-8674(01)00539-6; SPIERER P, 1978, BIOCHEMISTRY-US, V17, P2474, DOI 10.1021/bi00606a002; SYNETOS D, 1992, J BIOL CHEM, V267, P3008; TEEM JL, 1984, NUCLEIC ACIDS RES, V12, P8295, DOI 10.1093/nar/12.22.8295; THIERRY T, 1995, J BIOL CHEM, V270, P9961; TSAY YF, 1994, J BIOL CHEM, V269, P7579; Tsujii R, 2000, GENES CELLS, V5, P543, DOI 10.1046/j.1365-2443.2000.00346.x; Tsuno A, 2000, MOL CELL BIOL, V20, P2066, DOI 10.1128/MCB.20.6.2066-2074.2000; UDEM SA, 1972, J MOL BIOL, V65, P227, DOI 10.1016/0022-2836(72)90279-3; Venema J, 1999, ANNU REV GENET, V33, P261, DOI 10.1146/annurev.genet.33.1.261; Warner JR, 1999, TRENDS BIOCHEM SCI, V24, P437, DOI 10.1016/S0968-0004(99)01460-7; Woolford Jr JL, 1991, MOL CELLULAR BIOL YE, P587	35	43	43	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 24	2002	277	21					18334	18339		10.1074/jbc.M201667200	http://dx.doi.org/10.1074/jbc.M201667200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	558PM	11893754	hybrid			2022-12-27	WOS:000175975800012
J	Brennan, ML; Wu, WJ; Fu, XM; Shen, ZZ; Song, W; Frost, H; Vadseth, C; Narine, L; Lenkiewicz, E; Borchers, MT; Lusis, AJ; Lee, JJ; Lee, NA; Abu-Soud, HM; Ischiropoulos, H; Hazen, SL				Brennan, ML; Wu, WJ; Fu, XM; Shen, ZZ; Song, W; Frost, H; Vadseth, C; Narine, L; Lenkiewicz, E; Borchers, MT; Lusis, AJ; Lee, JJ; Lee, NA; Abu-Soud, HM; Ischiropoulos, H; Hazen, SL			A tale of two controversies - Defining both the role of peroxidases in nitrotyrosine formation in vivo using eosinophil peroxidase and myeloperoxidase-deficient mice, and the nature of peroxidase-generated reactive nitrogen species	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE; HUMAN NEUTROPHILS; BROMINATING OXIDANTS; CATALYZED OXIDATION; LIPID-PEROXIDATION; TYROSINE NITRATION; HYDROGEN-PEROXIDE; PROTEIN OXIDATION; MOUSE MODELS; PEROXYNITRITE	Nitrotyrosine is widely used as a marker of post-translational modification by the nitric oxide ((NO)-N-circle, nitrogen monoxide)-derived oxidant peroxynitrite (ONOO-). However, since the discovery that myeloperoxidase (MPO) and eosinophil peroxidase (EPO) can generate nitrotyrosine via oxidation of nitrite (NO2-), several questions have arisen. First, the relative contribution of peroxidases to nitrotyrosine formation in vivo is unknown. Further, although evidence suggests that the one-electron oxidation product, nitrogen dioxide ((NO2)-N-circle), is the primary species formed, neither a direct demonstration that peroxidases form this gas nor studies designed to test for the possible concomitant formation of the two-electron oxidation product, ONOO-, have been reported. Using multiple distinct models of acute inflammation with EPO- and MPO-knockout mice, we now demonstrate that leukocyte peroxidases participate in nitrotyrosine formation in vivo. In some models, MPO and EPO played a dominant role, accounting for the majority of nitrotyrosine formed. However, in other leukocyte-rich acute inflammatory models, no contribution for either MPO or EPO to nitrotyrosine formation could be demonstrated. Head-space gas analysis of helium-swept reaction mixtures provides direct evidence that leukocyte peroxidases catalytically generate (NO2)-N-circle formation using H2O2 and NO2- as substrates. However, formation of an additional oxidant was suggested since both enzymes promote NO2--dependent hydroxylation of targets under acidic conditions, a chemical reactivity shared with ONOO- but not (NO2)-N-circle. Collectively, our results demonstrate that: 1) MPO and EPO contribute to tyrosine nitration in vivo; 2) the major reactive nitrogen species formed by leukocyte peroxidase-catalyzed oxidation of NO2- is the one-electron oxidation product, circleNO(2); 3) as a minor reaction, peroxidases may also catalyze the two-electron oxidation of NO2-, producing a ONOO--like product. We speculate that the latter reaction generates a labile Fe-ONOO complex, which may be released following protonation under acidic conditions such as might exist at sites of inflammation.	Cleveland Clin Fdn, Dept Cell Biol, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Dept Cardiovasc Med, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Ctr Cardiovasc Diagnost & Prevent, Cleveland, OH 44195 USA; Univ Penn, Childrens Hosp Philadelphia, Stokes Res Inst, Philadelphia, PA 19104 USA; Mayo Clin Scottsdale, Dept Biochem, Scottsdale, AZ 85259 USA; Mayo Clin Scottsdale, Dept Mol Biol, Scottsdale, AZ 85259 USA; Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Human Genet, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Microbiol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Immunol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Mol Genet, Los Angeles, CA 90095 USA	Cleveland Clinic Foundation; Cleveland Clinic Foundation; Cleveland Clinic Foundation; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; Mayo Clinic; Mayo Clinic Phoenix; Mayo Clinic; Mayo Clinic Phoenix; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	Hazen, SL (corresponding author), Cleveland Clin Fdn, Dept Cell Biol, 9500 Euclid Ave,NC-10, Cleveland, OH 44195 USA.	hazens@ccf.org	Hazen, Stanley L/ABD-5845-2021		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL054926, R01HL065228, R01HL061878, P01HL030568, R01HL060793, R01HL062526] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL54926, HL30568, HL61878, HL60793, HL65228, HL62526] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abu-Soud HM, 2001, BIOCHEMISTRY-US, V40, P11866, DOI 10.1021/bi011206v; BAKKENIST ARJ, 1980, BIOCHIM BIOPHYS ACTA, V613, P337, DOI 10.1016/0005-2744(80)90088-1; Baldus S, 2001, J CLIN INVEST, V108, P1759; Beckman JS, 1996, AM J PHYSIOL-CELL PH, V271, pC1424; BECKMANN JS, 1994, BIOL CHEM H-S, V375, P81, DOI 10.1515/bchm3.1994.375.2.81; BOS A, 1978, BIOCHIM BIOPHYS ACTA, V525, P37, DOI 10.1016/0005-2744(78)90197-3; Brennan ML, 2001, J CLIN INVEST, V107, P419, DOI 10.1172/JCI8797; Burner U, 2000, J BIOL CHEM, V275, P20597, DOI 10.1074/jbc.M000181200; CARLSON MGC, 1985, J IMMUNOL, V134, P1875; Davey CA, 1996, BIOCHEMISTRY-US, V35, P10967, DOI 10.1021/bi960577m; Denzler KL, 2000, J IMMUNOL, V165, P5509, DOI 10.4049/jimmunol.165.10.5509; Denzler KL, 2001, J IMMUNOL, V167, P1672, DOI 10.4049/jimmunol.167.3.1672; DUNFORD HB, 1982, ADV INORG BIOCHEM, V4, P41; Eiserich JP, 1998, NATURE, V391, P393, DOI 10.1038/34923; Evans TJ, 1996, P NATL ACAD SCI USA, V93, P9553, DOI 10.1073/pnas.93.18.9553; FLORIS R, 1993, EUR J BIOCHEM, V215, P767, DOI 10.1111/j.1432-1033.1993.tb18091.x; FOOTE CS, 1983, NATURE, V301, P715, DOI 10.1038/301715a0; Fridovich I, 1985, CRC HDB METHODS OXYG, P213; Gow A, 1996, ARCH BIOCHEM BIOPHYS, V333, P42, DOI 10.1006/abbi.1996.0362; Halliwell B, 1999, FREE RADICAL RES, V31, P651, DOI 10.1080/10715769900301221; Hampton MB, 1998, BLOOD, V92, P3007, DOI 10.1182/blood.V92.9.3007.421k47_3007_3017; HARRISON JE, 1976, J BIOL CHEM, V251, P1371; Hazen SL, 1999, METHOD ENZYMOL, V300, P88; Hazen SL, 1999, CIRC RES, V85, P950; Hazen SL, 1996, J CLIN INVEST, V98, P1283, DOI 10.1172/JCI118914; HAZEN SL, 1997, J CLIN INVEST, V99, P1; HEINECKE JW, 1993, J BIOL CHEM, V268, P4069; Herold S, 1999, FEBS LETT, V443, P80, DOI 10.1016/S0014-5793(98)01591-9; HORI H, 1994, J BIOL CHEM, V269, P8388; HUGHES MN, 1968, J CHEM SOC A, P450, DOI 10.1039/j19680000450; HUIE RE, 1994, TOXICOLOGY, V89, P193, DOI 10.1016/0300-483X(94)90098-1; ISCHIROPOULOS H, 1992, ARCH BIOCHEM BIOPHYS, V298, P431, DOI 10.1016/0003-9861(92)90431-U; Jiang Q, 1997, J BIOL CHEM, V272, P32767, DOI 10.1074/jbc.272.52.32767; Koppenol WH, 2001, REDOX REP, V6, P229, DOI 10.1179/135100001101536373; Leeuwenburgh C, 1997, J BIOL CHEM, V272, P1433, DOI 10.1074/jbc.272.3.1433; Lymar SV, 1996, CHEM RES TOXICOL, V9, P845, DOI 10.1021/tx960046z; Lymar SV, 1996, BIOCHEMISTRY-US, V35, P7855, DOI 10.1021/bi960331h; MacPherson JC, 2001, J IMMUNOL, V166, P5763, DOI 10.4049/jimmunol.166.9.5763; Malm-Erjefalt M, 2001, AM J RESP CELL MOL, V24, P352, DOI 10.1165/ajrcmb.24.3.4357; MARQUEZ LA, 1994, J BIOL CHEM, V269, P7950; Marquez LA, 1995, J BIOL CHEM, V270, P30434, DOI 10.1074/jbc.270.51.30434; MAYO LA, 1990, METHOD ENZYMOL, V186, P567; Mitra SN, 2000, REDOX REP, V5, P215, DOI 10.1179/135100000101535771; NELSON DP, 1972, ANAL BIOCHEM, V49, P474, DOI 10.1016/0003-2697(72)90451-4; Patel RP, 1999, BBA-BIOENERGETICS, V1411, P385, DOI 10.1016/S0005-2728(99)00028-6; Podrez EA, 2000, FREE RADICAL BIO MED, V28, P1717, DOI 10.1016/S0891-5849(00)00229-X; Podrez EA, 1999, J CLIN INVEST, V103, P1547, DOI 10.1172/JCI5549; PRYOR WA, 1993, ANN NY ACAD SCI, V686, P12, DOI 10.1111/j.1749-6632.1993.tb39148.x; PRYOR WA, 1981, SCIENCE, V214, P435, DOI 10.1126/science.214.4519.435; Radi R, 1999, METHOD ENZYMOL, V301, P353; Sampson JB, 1998, ARCH BIOCHEM BIOPHYS, V356, P207, DOI 10.1006/abbi.1998.0772; SAMPSON JB, 1998, METHOD ENZYMOL, V269, P210; SCHULTZ J, 1962, ARCH BIOCHEM BIOPHYS, V96, P465, DOI 10.1016/0003-9861(62)90321-1; THOMAS HV, 1968, SCIENCE, V159, P532, DOI 10.1126/science.159.3814.532; van der Vliet A, 1999, AM J RESP CRIT CARE, V160, P1; vanderVliet A, 1997, J BIOL CHEM, V272, P7617, DOI 10.1074/jbc.272.12.7617; WEISS SJ, 1986, SCIENCE, V234, P200, DOI 10.1126/science.3018933; Whiteman M, 1999, BIOCHEM BIOPH RES CO, V258, P168, DOI 10.1006/bbrc.1999.0564; Wu WJ, 2000, J CLIN INVEST, V105, P1455, DOI 10.1172/JCI9702; Wu WJ, 1999, J BIOL CHEM, V274, P25933, DOI 10.1074/jbc.274.36.25933; Wu WJ, 1999, BIOCHEMISTRY-US, V38, P3538, DOI 10.1021/bi982401l; Zhang RL, 2002, BLOOD, V99, P1802, DOI 10.1182/blood.V99.5.1802.h8001802_1802_1810	62	427	438	0	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 17	2002	277	20					17415	17427		10.1074/jbc.M112400200	http://dx.doi.org/10.1074/jbc.M112400200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	553PR	11877405	hybrid			2022-12-27	WOS:000175685100007
J	Itahana, K; Dimri, GP; Hara, E; Itahana, Y; Zou, Y; Desprez, PY; Campisi, J				Itahana, K; Dimri, GP; Hara, E; Itahana, Y; Zou, Y; Desprez, PY; Campisi, J			A role for p53 in maintaining and establishing the quiescence growth arrest in human cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-DIPLOID FIBROBLASTS; HUMAN PAPILLOMAVIRUS TYPE-16; SENESCENT HUMAN FIBROBLASTS; DEVELOPMENTAL NEURON DEATH; CELLULAR SENESCENCE; DNA-DAMAGE; REPLICATIVE SENESCENCE; RETINOBLASTOMA PROTEIN; TUMOR-SUPPRESSOR; SIMIAN VIRUS-40	The p53 tumor suppressor protein induces transient growth arrest or apoptosis in response to genotoxic stress and mediates the irreversible growth arrest of cellular senescence. We present evidence here that p53 also contributes to the reversible, growth factor-dependent arrest of quiescence (G(o)). Microinjection of expression vectors encoding either MDM2 or a pRb-binding mutant of SV40 T antigen, both of which abrogate p53 function, stimulated quiescent normal human fibroblasts to initiate DNA synthesis and were 40-70% as effective as wild-type T antigen. Electrophoretic mobility shift and p53 transactivation assays showed that p53 activity was higher in quiescent and senescent cells compared with proliferating cells. As proliferating cells entered Go after growth factor withdrawal, the p53 mRNA level increased, followed by transient accumulation of the protein. Shortly thereafter, the expression (mRNA and protein) of p21, a p53 target gene and effector of cell cycle arrest, increased. Finally, stable expression of the HPV16 E6 oncogene or dominant negative p53 peptide, GSE-22, both of which inhibit p53 function, delayed entry into quiescence following growth factor withdrawal. Our data indicate that p53 is activated during both quiescence and senescence. They further suggest that p53 activity contributes, albeit not exclusively, to the quiescent growth arrest.	Univ Calif Berkeley, Lawrence Berkeley Lab, Div Life Sci, Berkeley, CA 94720 USA; Tufts Univ New England Med Ctr, Dept Radiat Oncol, Boston, MA 02111 USA; Paterson Inst Canc Res, Manchester M20 4BX, Lancs, England; Calif Pacific Med Ctr, San Francisco, CA 94115 USA	United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; Tufts Medical Center; Paterson Institute for Cancer Research; California Pacific Medical Center	Campisi, J (corresponding author), Univ Calif Berkeley, Lawrence Berkeley Lab, Div Life Sci, 1 Cyclotron Rd,MS 84-171, Berkeley, CA 94720 USA.		Dimri, Goberdhan/AAO-4210-2021; Itahana, Koji/J-5505-2013	Itahana, Koji/0000-0002-7241-2894	NATIONAL CANCER INSTITUTE [R01CA082548] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R37AG009909, R01AG009909] Funding Source: NIH RePORTER; NCI NIH HHS [CA82548] Funding Source: Medline; NIA NIH HHS [AG09909] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AFSHARI CA, 1993, EXP CELL RES, V209, P231, DOI 10.1006/excr.1993.1306; Aloyz RS, 1998, J CELL BIOL, V143, P1691, DOI 10.1083/jcb.143.6.1691; Amundson SA, 1998, ONCOGENE, V17, P3287, DOI 10.1038/sj.onc.1202576; ATADJA P, 1995, P NATL ACAD SCI USA, V92, P8348, DOI 10.1073/pnas.92.18.8348; Bond J, 1996, ONCOGENE, V13, P2097; BOND JA, 1994, ONCOGENE, V9, P1885; Brown JP, 1997, SCIENCE, V277, P831, DOI 10.1126/science.277.5327.831; Buschmann T, 2000, CANCER RES, V60, P896; Campisi J, 2000, IN VIVO, V14, P183; Cheng T, 2000, SCIENCE, V287, P1804, DOI 10.1126/science.287.5459.1804; Coats S, 1999, CURR BIOL, V9, P163, DOI 10.1016/S0960-9822(99)80086-4; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; Dimri GP, 2000, MOL CELL BIOL, V20, P273, DOI 10.1128/MCB.20.1.273-285.2000; Dimri GP, 1996, BIOL SIGNAL, V5, P154; DIMRI GP, 1994, J BIOL CHEM, V269, P16180; Dimri GP, 1996, MOL CELL BIOL, V16, P2987; DIMRI GP, 1994, MOL GENETICS CANC, P67; Dulic V, 2000, MOL CELL BIOL, V20, P6741, DOI 10.1128/MCB.20.18.6741-6754.2000; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; GORMAN SD, 1985, J CELL PHYSIOL, V125, P122, DOI 10.1002/jcp.1041250116; Hara E, 1996, DEV GENET, V18, P161; Hara E, 1996, MOL CELL BIOL, V16, P859; HARA E, 1991, BIOCHEM BIOPH RES CO, V179, P528, DOI 10.1016/0006-291X(91)91403-Y; Harbour JW, 2000, GENE DEV, V14, P2393, DOI 10.1101/gad.813200; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; HUPP TR, 1994, CURR BIOL, V4, P865, DOI 10.1016/S0960-9822(00)00195-0; IDE T, 1984, EXP CELL RES, V150, P321, DOI 10.1016/0014-4827(84)90575-5; Itahana K, 2001, EUR J BIOCHEM, V268, P2784, DOI 10.1046/j.1432-1327.2001.02228.x; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; KIERSTEAD TD, 1993, J VIROL, V67, P1817, DOI 10.1128/JVI.67.4.1817-1829.1993; Kirch HC, 1999, ONCOGENE, V18, P2728, DOI 10.1038/sj.onc.1202626; Klingelhutz AJ, 1996, NATURE, V380, P79, DOI 10.1038/380079a0; Kohn KW, 1999, MOL BIOL CELL, V10, P2703, DOI 10.1091/mbc.10.8.2703; Ladha MH, 1998, MOL CELL BIOL, V18, P6605, DOI 10.1128/MCB.18.11.6605; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; Mundt M, 1997, ONCOGENE, V15, P237, DOI 10.1038/sj.onc.1201174; NAKANISHI M, 1995, P NATL ACAD SCI USA, V92, P4352, DOI 10.1073/pnas.92.10.4352; Nakayama K, 1996, CELL, V85, P707, DOI 10.1016/S0092-8674(00)81237-4; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; Ohtani N, 2001, NATURE, V409, P1067, DOI 10.1038/35059131; Ossovskaya VS, 1996, P NATL ACAD SCI USA, V93, P10309, DOI 10.1073/pnas.93.19.10309; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; Pozniak CD, 2000, SCIENCE, V289, P304, DOI 10.1126/science.289.5477.304; Prives C, 1999, J PATHOL, V187, P112; Raman V, 2000, NATURE, V405, P974, DOI 10.1038/35016125; Reisman D, 1998, SEMIN CANCER BIOL, V8, P317, DOI 10.1006/scbi.1998.0094; Rivard N, 1996, J BIOL CHEM, V271, P18337, DOI 10.1074/jbc.271.31.18337; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; SAKAMOTO K, 1993, ONCOGENE, V8, P1887; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHLUTER C, 1993, J CELL BIOL, V123, P513, DOI 10.1083/jcb.123.3.513; SHAY JW, 1991, BIOCHIM BIOPHYS ACTA, V1072, P1, DOI 10.1016/0304-419X(91)90003-4; Sherr CJ, 2000, CANCER RES, V60, P3689; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Simmons DT, 2000, ADV VIRUS RES, V55, P75, DOI 10.1016/S0065-3527(00)55002-7; Vaziri H, 1997, EMBO J, V16, P6018, DOI 10.1093/emboj/16.19.6018; Webley K, 2000, MOL CELL BIOL, V20, P2803, DOI 10.1128/MCB.20.8.2803-2808.2000; Wright Woodring E., 1996, V16, P153; Zhang XH, 2000, MOL BIOL CELL, V11, P2117, DOI 10.1091/mbc.11.6.2117	61	80	84	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 17	2002	277	20					18206	18214		10.1074/jbc.M201028200	http://dx.doi.org/10.1074/jbc.M201028200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	553PR	11880381	hybrid			2022-12-27	WOS:000175685100103
J	Ma, ASW; Moran-Jones, K; Shan, J; Munro, TP; Snee, MJ; Hoek, KS; Smith, R				Ma, ASW; Moran-Jones, K; Shan, J; Munro, TP; Snee, MJ; Hoek, KS; Smith, R			Heterogeneous nuclear ribonucleoprotein A3, a novel RNA trafficking response element-binding protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIN MESSENGER-RNA; HNRNP A1; MOLECULAR CHARACTERIZATION; EXPORT SIGNAL; MYELIN; LOCALIZATION; TRANSPORT; EXPRESSION; GENE; OLIGODENDROCYTES	The cis-acting response element, A2RE, which is sufficient for cytoplasmic mRNA trafficking in oligodendrocytes, binds a small group of rat brain proteins. Predominant among these is heterogeneous nuclear ribonucleoprotein (hnRNP) A2, a trans-acting factor for cytoplasmic trafficking of RNAs bearing A2RE-like sequences. We have now identified the other A2RE-binding proteins as hnRNP A1/A1(B), hnRNP B1, and four isoforms of hnRNP A3. The rat and human hnRNP A3 cDNAs have been sequenced, revealing the existence of alternatively spliced mRNAs. In Western blotting, 38-, 39-, 41 -, and 41.5-kDa components were all recognized by antibodies against a peptide in the glycine-rich region of hnRNP A3, but only the 41- and 41.5-kDa bands bound antibodies to a 15-residue N-terminal peptide encoded by an alternatively spliced part of exon 1. The identities of these four proteins were verified by Edman sequencing and mass spectral analysis of tryptic fragments generated from electrophoretically separated bands. Sequence-specific binding of bacterially expressed hnRNP A3 to A2RE has been demonstrated by biosensor and UV cross-linking electrophoretic mobility shift assays. Mutational analysis and confocal microscopy data support the hypothesis that the hnRNP A3 isoforms have a role in cytoplasmic trafficking of RNA.	Univ Queensland, Dept Biochem & Mol Biol, Brisbane, Qld 4072, Australia	University of Queensland	Smith, R (corresponding author), Univ Queensland, Dept Biochem & Mol Biol, Brisbane, Qld 4072, Australia.	ross.s@mailbox.uq.edu.au	Munro, Trent/AAC-1129-2020; Munro, Trent/B-4856-2009	Munro, Trent/0000-0003-1987-2020; Snee, Mark/0000-0003-4018-816X				Ainger K, 1997, J CELL BIOL, V138, P1077, DOI 10.1083/jcb.138.5.1077; AINGER K, 1993, J CELL BIOL, V123, P431, DOI 10.1083/jcb.123.2.431; AMURUMARJEE S, 1993, J NEUROSCI RES, V36, P99, DOI 10.1002/jnr.490360111; BARBARESE E, 1995, J CELL SCI, V108, P2781; Bassell G, 1997, CURR OPIN CELL BIOL, V9, P109, DOI 10.1016/S0955-0674(97)80159-7; Bassell GJ, 1999, FASEB J, V13, P447, DOI 10.1096/fasebj.13.3.447; Bassell GJ, 1998, J NEUROSCI, V18, P251; BIAMONTI G, 1994, NUCLEIC ACIDS RES, V22, P1996, DOI 10.1093/nar/22.11.1996; Bogerd HP, 1999, J BIOL CHEM, V274, P9771, DOI 10.1074/jbc.274.14.9771; BUVOLI M, 1990, EMBO J, V9, P1229, DOI 10.1002/j.1460-2075.1990.tb08230.x; CAMPAGNONI AT, 1991, ANN NY ACAD SCI, V633, P178; Carson J H, 2001, Results Probl Cell Differ, V34, P69; Carson JH, 1997, CELL MOTIL CYTOSKEL, V38, P318, DOI 10.1002/(SICI)1097-0169(1997)38:4<318::AID-CM2>3.0.CO;2-#; Carson JH, 1998, CURR OPIN NEUROBIOL, V8, P607, DOI 10.1016/S0959-4388(98)80088-3; COLMAN DR, 1982, J CELL BIOL, V95, P598, DOI 10.1083/jcb.95.2.598; Dangli A, 1996, BIOCHEM J, V320, P761, DOI 10.1042/bj3200761; DAVIES RJ, 1994, TECHNIQUES PROTEIN C, V5; DING D, 1993, BIOESSAYS, V15, P651, DOI 10.1002/bies.950151004; GOOD PJ, 1993, NUCLEIC ACIDS RES, V21, P999, DOI 10.1093/nar/21.4.999; Grunert S, 1996, CURR OPIN GENET DEV, V6, P395, DOI 10.1016/S0959-437X(96)80059-1; Hamasaki M, 2001, ANTICANCER RES, V21, P979; Hoek KS, 1998, BIOCHEMISTRY-US, V37, P7021, DOI 10.1021/bi9800247; Izaurralde E, 1997, J CELL BIOL, V137, P27, DOI 10.1083/jcb.137.1.27; Jansen RP, 1999, FASEB J, V13, P455, DOI 10.1096/fasebj.13.3.455; Kamma H, 1999, EXP CELL RES, V246, P399, DOI 10.1006/excr.1998.4323; Kiebler MA, 2000, NEURON, V25, P19, DOI 10.1016/S0896-6273(00)80868-5; KOZU T, 1995, GENOMICS, V25, P365, DOI 10.1016/0888-7543(95)80035-K; Kwon S, 1999, J CELL BIOL, V147, P247, DOI 10.1083/jcb.147.2.247; Lasko P, 1999, FASEB J, V13, P421, DOI 10.1096/fasebj.13.3.421; Makeyev AV, 1999, J BIOL CHEM, V274, P24849, DOI 10.1074/jbc.274.35.24849; Matsui M, 2000, BBA-GENE STRUCT EXPR, V1493, P33, DOI 10.1016/S0167-4781(00)00154-8; MICHAEL WM, 1995, CELL, V83, P415; Mohr E, 1999, PROG NEUROBIOL, V57, P507, DOI 10.1016/S0301-0082(98)00066-5; Mowry KL, 1999, FASEB J, V13, P435, DOI 10.1096/fasebj.13.3.435; Munro TP, 1999, J BIOL CHEM, V274, P34389, DOI 10.1074/jbc.274.48.34389; Plomaritoglou A, 2000, BBA-GENE STRUCT EXPR, V1490, P54, DOI 10.1016/S0167-4781(99)00054-8; Pokrywka NJ, 1995, CURR TOP DEV BIOL, V31, P139; Schnapp BJ, 1999, CURR BIOL, V9, pR725, DOI 10.1016/S0960-9822(99)80468-0; Shan JG, 2000, J BIOL CHEM, V275, P38286, DOI 10.1074/jbc.M007642200; SIOMI H, 1995, J CELL BIOL, V129, P551, DOI 10.1083/jcb.129.3.551; Speicher K D, 2000, J Biomol Tech, V11, P74; STJOHNSTON D, 1995, CELL, V81, P161, DOI 10.1016/0092-8674(95)90324-0; Sueoka E, 1999, CANCER RES, V59, P1404; TAKIGUCHI S, 1993, CYTOGENET CELL GENET, V64, P128, DOI 10.1159/000133568; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TRAPP BD, 1987, P NATL ACAD SCI USA, V84, P7773, DOI 10.1073/pnas.84.21.7773; Truant R, 1999, J BIOL CHEM, V274, P32167, DOI 10.1074/jbc.274.45.32167; VERITY AN, 1988, J NEUROSCI RES, V21, P238, DOI 10.1002/jnr.490210216; WILKINS MR, 1998, 2 D PROTEOME ANAL PR, P531; Zhang HL, 1999, J CELL BIOL, V147, P59, DOI 10.1083/jcb.147.1.59	50	86	90	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 17	2002	277	20					18010	18020		10.1074/jbc.M200050200	http://dx.doi.org/10.1074/jbc.M200050200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	553PR	11886857	hybrid			2022-12-27	WOS:000175685100079
J	Nirthanan, S; Charpantier, E; Gopalakrishnakone, P; Gwee, MCE; Khoo, HE; Cheah, LS; Bertrand, D; Kini, RM				Nirthanan, S; Charpantier, E; Gopalakrishnakone, P; Gwee, MCE; Khoo, HE; Cheah, LS; Bertrand, D; Kini, RM			Candoxin, a novel toxin from Bungarus candidus, is a reversible antagonist of muscle (alpha beta gamma delta) but a poorly reversible antagonist of neuronal alpha 7 nicotinic acetylcholine receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID SEQUENCE; 3-DIMENSIONAL SOLUTION STRUCTURE; SITE-DIRECTED MUTAGENESIS; NAJA-NIGRICOLLIS VENOM; BLACK MAMBA VENOM; X-RAY STRUCTURE; SNAKE TOXINS; COBRA VENOM; FUNCTIONAL-PROPERTIES; CURAREMIMETIC TOXINS	In contrast to most short and long chain curaremimetic neurotoxins that produce virtually irreversible neuromuscular blockade in isolated nerve-muscle preparations, candoxin, a novel three-finger toxin from the Malayan krait Bungarus candidus, produced postjunctional neuromuscular blockade that was readily and completely reversible. Nanomolar concentrations of candoxin (IC50 = similar to10 nm) also blocked acetylcholine-evoked currents in oocyte-expressed rat muscle (alphabetagammadelta) nicotinic acetylcholine receptors in a reversible manner. In contrast, it produced a poorly reversible block (IC50 = similar to50 nm) of rat neuronal alpha7 receptors, clearly showing diverse functional profiles for the two nicotinic receptor subsets. Interestingly, candoxin lacks the helix-like segment cyclized by the fifth disulfide bridge at the tip of the middle loop of long chain neurotoxins, reported to be critical for binding to alpha7 receptors. However, its solution NMR structure showed the presence of some functionally invariant residues involved in the interaction of both short and long chain neurotoxins to muscle (alphabetagammadelta) and long chain neurotoxins to alpha7 receptors. Candoxin is therefore a novel toxin that shares a common scaffold with long chain alpha-neurotoxins but possibly utilizes additional functional determinants that assist in recognizing neuronal alpha7 receptors.	Natl Univ Singapore, Fac Med, Dept Anat, Venom & Toxin Res Programme, Singapore 119260, Singapore; Ctr Med Univ Geneva, Dept Physiol, CH-1211 Geneva 4, Switzerland; Natl Univ Singapore, Fac Sci, Dept Biol Sci, Singapore 119260, Singapore; Virginia Commonwealth Univ, Med Coll Virginia, Dept Biochem & Mol Biophys, Richmond, VA 23298 USA	National University of Singapore; University of Geneva; National University of Singapore; Virginia Commonwealth University	Gopalakrishnakone, P (corresponding author), Natl Univ Singapore, Fac Med, Dept Anat, Venom & Toxin Res Programme, 10 Kent Ridge Crescent, Singapore 119260, Singapore.	antgopal@nus.edu.sg	Kini, Manjunatha/H-8029-2012; Nirthanan, Selvanayagam/ABI-4281-2020	Kini, Manjunatha/0000-0002-6100-3251; Nirthanan, S. Niru/0000-0001-9888-8447				Aird SD, 1999, TOXICON, V37, P609, DOI 10.1016/S0041-0101(98)00199-8; ALBRAND JP, 1995, BIOCHEMISTRY-US, V34, P5923, DOI 10.1021/bi00017a022; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Antil S, 1999, J BIOL CHEM, V274, P34851, DOI 10.1074/jbc.274.49.34851; Antil-Delbeke S, 2000, J BIOL CHEM, V275, P29594, DOI 10.1074/jbc.M909746199; Arias HR, 2000, NEUROCHEM INT, V36, P595, DOI 10.1016/S0197-0186(99)00154-0; BASUS VJ, 1993, BIOCHEMISTRY-US, V32, P12290, DOI 10.1021/bi00097a004; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; BERTRAND D, 1992, NEUROSCI LETT, V146, P87, DOI 10.1016/0304-3940(92)90179-B; Bertrand D, 1991, METHODS NEUROSCIENCE, V4, P174; BETZEL C, 1991, J BIOL CHEM, V266, P21530; BILWES A, 1994, J MOL BIOL, V239, P122, DOI 10.1006/jmbi.1994.1357; BOULTER J, 1987, P NATL ACAD SCI USA, V84, P7763, DOI 10.1073/pnas.84.21.7763; Buisson B, 1998, J PHYSIOL-PARIS, V92, P89, DOI 10.1016/S0928-4257(98)80144-7; CARLSSON FHH, 1975, BIOCHIM BIOPHYS ACTA, V400, P310, DOI 10.1016/0005-2795(75)90186-5; Cervenansky C., 1991, P303; Chang C.C., 1979, SNAKE VENOMS, P309; CHANGEUX JP, 1990, TRENDS PHARMACOL SCI, V11, P485, DOI 10.1016/0165-6147(90)90049-E; Chiappinelli VA, 1996, TOXICON, V34, P1243, DOI 10.1016/S0041-0101(96)00110-9; Cordero-Erausquin M, 2000, TRENDS PHARMACOL SCI, V21, P211, DOI 10.1016/S0165-6147(00)01489-9; CORFIELD PWR, 1989, J BIOL CHEM, V264, P9239; COUTURIER S, 1990, NEURON, V5, P847, DOI 10.1016/0896-6273(90)90344-F; DANSE JM, 1990, NUCLEIC ACIDS RES, V18, P1045, DOI 10.1093/nar/18.4.1045; DEWEILLE JR, 1991, P NATL ACAD SCI USA, V88, P2437, DOI 10.1073/pnas.88.6.2437; DRASDO A, 1992, MOL CELL NEUROSCI, V3, P237, DOI 10.1016/1044-7431(92)90043-2; Ducancel F, 1996, J BIOL CHEM, V271, P31345, DOI 10.1074/jbc.271.49.31345; EAKER DL, 1967, JPN J MICROBIOL, V11, P353, DOI 10.1111/j.1348-0421.1967.tb00356.x; Endo T., 1991, P165; FERTUCK HC, 1975, J CELL BIOL, V66, P209, DOI 10.1083/jcb.66.1.209; FLEMING TJ, 1993, J IMMUNOL, V150, P5379; GINSBORG BL, 1960, BRIT J PHARM CHEMOTH, V15, P410, DOI 10.1111/j.1476-5381.1960.tb01264.x; Grant GA, 1998, BIOCHEMISTRY-US, V37, P12166, DOI 10.1021/bi981227y; GRANT GA, 1988, BIOCHEMISTRY-US, V27, P3794, DOI 10.1021/bi00410a041; GRANT GA, 1985, BIOCHEMISTRY-US, V24, P1532, DOI 10.1021/bi00327a036; GUMLEY TP, 1995, IMMUNOL CELL BIOL, V73, P277, DOI 10.1038/icb.1995.45; Jacobsen RB, 1999, BIOCHEMISTRY-US, V38, P13310, DOI 10.1021/bi9907476; JERUSALINSKY D, 1994, TRENDS PHARMACOL SCI, V15, P424, DOI 10.1016/0165-6147(94)90092-2; JOHNSON DS, 1995, MOL PHARMACOL, V48, P194; JOUBERT FJ, 1980, H-S Z PHYSIOL CHEM, V361, P425, DOI 10.1515/bchm2.1980.361.1.425; JOUBERT FJ, 1975, H-S Z PHYSIOL CHEM, V356, P1901; KARLSSON E, 1971, EUR J BIOCHEM, V21, P1, DOI 10.1111/j.1432-1033.1971.tb01433.x; KIM HS, 1982, BIOCHEM J, V207, P215, DOI 10.1042/bj2070215; KOSEN PA, 1988, BIOCHEMISTRY-US, V27, P2775, DOI 10.1021/bi00408a018; Kuhn P, 2000, ACTA CRYSTALLOGR D, V56, P1401, DOI 10.1107/S0907444900011501; Lim B L, 1970, Med J Malaya, V25, P128; LOW BW, 1986, EUR J BIOCHEM, V161, P579, DOI 10.1111/j.1432-1033.1986.tb10481.x; Maslennikov IV, 1999, FEBS LETT, V444, P275, DOI 10.1016/S0014-5793(99)00069-1; MCDOWELL RS, 1992, BIOCHEMISTRY-US, V31, P4766, DOI 10.1021/bi00135a004; MCINTOSH M, 1982, ARCH BIOCHEM BIOPHYS, V218, P329, DOI 10.1016/0003-9861(82)90351-4; Mebs D., 1991, SNAKE TOXINS, P425; Menez A, 1998, TOXICON, V36, P1557, DOI 10.1016/S0041-0101(98)00148-2; Miwa JM, 1999, NEURON, V23, P105, DOI 10.1016/S0896-6273(00)80757-6; Parvathy VR, 2000, CURR SCI INDIA, V79, P219; PILLET L, 1993, J BIOL CHEM, V268, P909; PLOUG M, 1994, FEBS LETT, V349, P163, DOI 10.1016/0014-5793(94)00674-1; Qian YC, 1998, BIOCHEM MOL BIOL INT, V46, P821; SATO S, 1971, BIOCHEM J, V122, P453, DOI 10.1042/bj1220453; SEGUELA P, 1993, J NEUROSCI, V13, P596; Servent D, 1997, J BIOL CHEM, V272, P24279, DOI 10.1074/jbc.272.39.24279; Servent D, 1998, J PHYSIOLOGY-PARIS, V92, P107, DOI 10.1016/S0928-4257(98)80146-0; Servent D, 2000, EUR J PHARMACOL, V393, P197, DOI 10.1016/S0014-2999(00)00095-9; SHAFQAT J, 1991, FEBS LETT, V284, P70, DOI 10.1016/0014-5793(91)80764-T; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TREMEAU O, 1995, J BIOL CHEM, V270, P9362, DOI 10.1074/jbc.270.16.9362; Tsetlin V, 1999, EUR J BIOCHEM, V264, P281, DOI 10.1046/j.1432-1327.1999.00623.x; Utkin YN, 2001, J BIOL CHEM, V276, P15810, DOI 10.1074/jbc.M100788200; Utkin YN, 2001, TOXICON, V39, P921, DOI 10.1016/S0041-0101(00)00223-3; WALKINSHAW MD, 1980, P NATL ACAD SCI-BIOL, V77, P2400, DOI 10.1073/pnas.77.5.2400; ZINNJUSTIN S, 1992, BIOCHEMISTRY-US, V31, P11335, DOI 10.1021/bi00161a011	69	85	90	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 17	2002	277	20					17811	17820		10.1074/jbc.M111152200	http://dx.doi.org/10.1074/jbc.M111152200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	553PR	11884390	hybrid			2022-12-27	WOS:000175685100055
J	Ong, E; Suzuki, M; Belot, F; Yeh, JC; Franceschini, I; Angata, K; Hindsgaul, O; Fukuda, M				Ong, E; Suzuki, M; Belot, F; Yeh, JC; Franceschini, I; Angata, K; Hindsgaul, O; Fukuda, M			Biosynthesis of HNK-1 glycans on O-linked oligosaccharides attached to the neural cell adhesion molecule (NCAM) - The requirement for core 2 beta 1,6-N-acetylglucosaminyltransferase and the muscle-specific domain in NCAM	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLY-N-ACETYLLACTOSAMINE; LYSOSOMAL MEMBRANE-GLYCOPROTEINS; MYELIN-ASSOCIATED GLYCOPROTEIN; MONOCLONAL-ANTIBODY HNK-1; SULFATED GLUCURONIC-ACID; CARBOHYDRATE EPITOPE; NERVOUS-SYSTEM; EXPRESSION CLONING; POLYSIALIC ACID; DIFFERENTIATION ANTIGEN	The HNK-1 glycan, sulfo-->3G1cAbeta1-->3Galbeta1-->4GlcNAcbeta1-->R, is highly expressed in neuronal cells and apparently plays critical roles in neuronal cell migration and axonal extension. The HNK-1 glycan synthesis is initiated by the addition of beta1,3-linked GlcA to N-acetyllactosamine followed by sulfation of the C-3 position of GlcA. The cDNAs encoding beta1,3-glucuronyltransferase (GlcAT-P) and HNK-1 sulfotransferase (HNK-1ST) have been recently cloned. Among various adhesion molecules, the neural cell adhesion molecule (NCAM) was shown to contain HNK-1 glycan on N-glycans. In the present study, we first demonstrated that NCAM also bears HNK-1 glycan attached to O-glycans when NCAM contains the O-glycan attachment scaffold, muscle-specific domain, and is synthesized in the presence of core 2 beta1,6-N-acetylglucosaminyltransferase, GlcAT-P and HNK-1ST. Structural analysis of the HNK-1 glycan revealed that the HNK-1 glycan is attached on core 2 branched O-glycans, sulfo-->3GlcAbeta1-->3Galbeta1-->4GlcNAcbeta1-->6(Galbeta1-->3)GalNAc. Using synthetic oligosaccharides as acceptors, we found that GlcAT-P and HNK-1ST almost equally act on oligosaccharides, mimicking N- and O-glycans. By contrast, HNK-1 glycan was much more efficiently added to N-glycans than O-glycans when NCAM was used as an acceptor. These results are consistent with our results showing that HNK-1 glycan is minimally attached to O-glycans of NCAM in fetal brain, heart, and the myoblast cell line, C2C12. These results combined together indicate that HNK-1 glycan can be synthesized on core 2 branched O-glycans but that the HNK-1 glycan is preferentially added on N-glycans over O-glycans of NCAM, probably because N-glycans are extended further than O-glycans attached to NCAM containing the muscle-specific domain.	Burnham Inst, Canc Res Ctr, Glycobiol Program, La Jolla, CA 92037 USA	Sanford Burnham Prebys Medical Discovery Institute	Fukuda, M (corresponding author), Burnham Inst, Canc Res Ctr, Glycobiol Program, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.		Angata, Kiyohiko/M-2749-2018	Angata, Kiyohiko/0000-0001-5561-1368	NATIONAL CANCER INSTITUTE [R01CA033895, R37CA033000, P01CA071932] Funding Source: NIH RePORTER; NCI NIH HHS [R37CA33000, R01CA33895, P01CA71932] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABO T, 1981, J IMMUNOL, V127, P1024; Angata K, 1998, J BIOL CHEM, V273, P28524, DOI 10.1074/jbc.273.43.28524; Angata K, 2000, J BIOL CHEM, V275, P18594, DOI 10.1074/jbc.M910204199; ARIGA T, 1987, J BIOL CHEM, V262, P848; BAENZIGER J, 1974, J BIOL CHEM, V249, P7270; Bakker H, 1997, J BIOL CHEM, V272, P29942, DOI 10.1074/jbc.272.47.29942; Belot F, 2000, CARBOHYD RES, V326, P88, DOI 10.1016/S0008-6215(00)00032-X; BIERHUIZEN MFA, 1992, P NATL ACAD SCI USA, V89, P9326, DOI 10.1073/pnas.89.19.9326; BIERHUIZEN MFA, 1994, J BIOL CHEM, V269, P4473; Bistrup A, 1999, J CELL BIOL, V145, P899, DOI 10.1083/jcb.145.4.899; BRONNERFRASER M, 1986, DEV BIOL, V115, P44, DOI 10.1016/0012-1606(86)90226-5; CARLSSON SR, 1986, J BIOL CHEM, V261, P2787; CARLSSON SR, 1993, ARCH BIOCHEM BIOPHYS, V304, P65, DOI 10.1006/abbi.1993.1322; CHOU DKH, 1986, J BIOL CHEM, V261, P1717; CHOU DKH, 1993, J BIOL CHEM, V268, P330; DEUTSCHER SL, 1984, CELL, V39, P295, DOI 10.1016/0092-8674(84)90007-2; DICKSON G, 1987, CELL, V50, P1119, DOI 10.1016/0092-8674(87)90178-4; EDELMAN GM, 1991, ANNU REV BIOCHEM, V60, P155, DOI 10.1146/annurev.bi.60.070191.001103; Figarella-Branger D, 1999, AM J PATHOL, V155, P1261, DOI 10.1016/S0002-9440(10)65228-5; FINNE J, 1982, J BIOL CHEM, V257, P1966; Franceschini I, 2001, GLYCOBIOLOGY, V11, P231, DOI 10.1093/glycob/11.3.231; FUKUDA M, 1991, J BIOL CHEM, V266, P21327; Hiraoka N, 1999, IMMUNITY, V11, P79, DOI 10.1016/S1074-7613(00)80083-7; KELM S, 1994, CURR BIOL, V4, P965, DOI 10.1016/S0960-9822(00)00220-7; KRUSE J, 1984, NATURE, V311, P153, DOI 10.1038/311153a0; Kudo M, 1996, J BIOL CHEM, V271, P32667, DOI 10.1074/jbc.271.51.32667; KUMAR R, 1990, P NATL ACAD SCI USA, V87, P9948, DOI 10.1073/pnas.87.24.9948; KUNEMUND V, 1988, J CELL BIOL, V106, P213, DOI 10.1083/jcb.106.1.213; Li FG, 1996, J BIOL CHEM, V271, P6342, DOI 10.1074/jbc.271.11.6342; Li FG, 1996, J BIOL CHEM, V271, P3255, DOI 10.1074/jbc.271.6.3255; Liedtke S, 2001, GLYCOBIOLOGY, V11, P373, DOI 10.1093/glycob/11.5.373; MAEMURA K, 1992, J BIOL CHEM, V267, P24379; MARGOLIS RK, 1987, BIOCHEM BIOPH RES CO, V145, P1142, DOI 10.1016/0006-291X(87)91556-7; MARTINI R, 1992, EUR J NEUROSCI, V4, P628, DOI 10.1111/j.1460-9568.1992.tb00171.x; MARTINI R, 1994, J NEUROSCI, V14, P7180; McAuliffe JC, 1999, BIOORG MED CHEM LETT, V9, P2855, DOI 10.1016/S0960-894X(99)00485-0; MERKLE RK, 1987, J BIOL CHEM, V262, P8179; Misra AK, 2001, BIOORG MED CHEM LETT, V11, P2667, DOI 10.1016/S0960-894X(01)00550-9; NAGASAWA K, 1979, J BIOCHEM-TOKYO, V86, P1323, DOI 10.1093/oxfordjournals.jbchem.a132648; Nakayama J, 1998, PATHOL INT, V48, P665, DOI 10.1111/j.1440-1827.1998.tb03967.x; NELSON RW, 1995, J BIOL CHEM, V270, P17171, DOI 10.1074/jbc.270.29.17171; OBATA K, 1988, NEUROSCI RES, V6, P131, DOI 10.1016/0168-0102(88)90015-6; Ong E, 1999, J BIOL CHEM, V274, P25608, DOI 10.1074/jbc.274.36.25608; Ong E, 1998, J BIOL CHEM, V273, P5190, DOI 10.1074/jbc.273.9.5190; Priatel JJ, 2000, IMMUNITY, V12, P273, DOI 10.1016/S1074-7613(00)80180-6; SARKAR M, 1991, P NATL ACAD SCI USA, V88, P234, DOI 10.1073/pnas.88.1.234; SCHACHNER M, 1995, TRENDS NEUROSCI, V18, P183, DOI 10.1016/0166-2236(95)93899-9; SCHWARTING GA, 1987, DEV BIOL, V120, P65, DOI 10.1016/0012-1606(87)90104-7; SIMMONS DL, 1993, CELLULAR INTERACTION, P93; STANLEY P, 1975, P NATL ACAD SCI USA, V72, P3323, DOI 10.1073/pnas.72.9.3323; Terayama K, 1997, P NATL ACAD SCI USA, V94, P6093, DOI 10.1073/pnas.94.12.6093; TSUZUKIDA Y, 1979, P NATL ACAD SCI USA, V76, P1104, DOI 10.1073/pnas.76.3.1104; Ujita M, 1998, J BIOL CHEM, V273, P34843, DOI 10.1074/jbc.273.52.34843; Ujita M, 1999, J BIOL CHEM, V274, P16717, DOI 10.1074/jbc.274.24.16717; VIITALA J, 1988, P NATL ACAD SCI USA, V85, P3743, DOI 10.1073/pnas.85.11.3743; von der Ohe M, 2002, GLYCOBIOLOGY, V12, P47, DOI 10.1093/glycob/12.1.47; Voshol H, 1996, J BIOL CHEM, V271, P22957, DOI 10.1074/jbc.271.38.22957; WALSH FS, 1989, DEVELOPMENT, V105, P803; Yeh JC, 1999, J BIOL CHEM, V274, P3215, DOI 10.1074/jbc.274.5.3215; Yoshida A, 2001, DEV CELL, V1, P717, DOI 10.1016/S1534-5807(01)00070-3; Yuen CT, 1997, J BIOL CHEM, V272, P8924	61	24	24	2	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 17	2002	277	20					18182	18190		10.1074/jbc.M201312200	http://dx.doi.org/10.1074/jbc.M201312200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	553PR	11891229	hybrid			2022-12-27	WOS:000175685100100
J	Sanchez-Piris, M; Posas, F; Alemany, V; Winge, I; Hidalgo, E; Bachs, O; Aligue, R				Sanchez-Piris, M; Posas, F; Alemany, V; Winge, I; Hidalgo, E; Bachs, O; Aligue, R			The serine/threonine kinase Cmk2 is required for oxidative stress response in fission yeast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; ATF1 TRANSCRIPTION FACTOR; CELL-CYCLE CONTROL; MAP KINASE; SCHIZOSACCHAROMYCES-POMBE; SACCHAROMYCES-CEREVISIAE; SIGNAL-TRANSDUCTION; 2-COMPONENT SYSTEM; SEXUAL DEVELOPMENT; HIGH OSMOLARITY	Cmk2, a fission yeast Ser/Thr protein kinase homologous to mammalian calmodulin kinases, is essential for oxidative stress response. Cells lacking cmk2 gene were specifically sensitive to oxidative stress conditions. Upon stress, Cmk2 was phosphorylated in vivo, and this phosphorylation was dependent on the stress-activated MAPK Sty1/Spc1. Co-precipitation assays demonstrated that Cmk2 binds Sty1. Furthermore, in vivo or in vitro activated Sty1 was able to phosphorylate Cmk2, and the phosphorylation occurred at the C-terminal regulatory domain at Thr-411. Cell lethality caused by overexpression of Wis1 MAPK kinase was abolished by deletion of cmk2 or by mutation of Thr-411 of Cmk2. Taken together, our data suggest that Cmk2 acts downstream of Sty1 and is an essential kinase for oxidative stress responses.	Univ Barcelona, IDIBAPS, Dept Cell Biol, E-08036 Barcelona, Spain; Univ Pompeu Fabra, Dept Ciencies Expt & Salut, Cell Signalling Unit, E-08003 Barcelona, Spain	University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS; Pompeu Fabra University	Aligue, R (corresponding author), Univ Barcelona, IDIBAPS, Dept Cell Biol, E-08036 Barcelona, Spain.	aligue@medicina.ub.es	Hidalgo, Elena/K-2919-2014; Posas, Francesc/K-1364-2013; Aligue, Rosa/AAA-2520-2019	Hidalgo, Elena/0000-0002-3768-6785; Posas, Francesc/0000-0002-4164-7076; Aligue, Rosa/0000-0002-2085-325X; Winge, Ingeborg/0000-0001-6139-5999				Arthur JSC, 2000, FEBS LETT, V482, P44, DOI 10.1016/S0014-5793(00)02031-7; Banuett F, 1998, MICROBIOL MOL BIOL R, V62, P249, DOI 10.1128/MMBR.62.2.249-274.1998; Bilsland-Marchesan E, 2000, MOL CELL BIOL, V20, P3887, DOI 10.1128/MCB.20.11.3887-3895.2000; BREWSTER JL, 1993, SCIENCE, V259, P1760, DOI 10.1126/science.7681220; Buck V, 2001, MOL BIOL CELL, V12, P407, DOI 10.1091/mbc.12.2.407; Cohen P, 1997, TRENDS CELL BIOL, V7, P353, DOI 10.1016/S0962-8924(97)01105-7; Cottarel G, 1997, GENETICS, V147, P1043; DAHLKVIST A, 1995, MOL GEN GENET, V246, P316, DOI 10.1007/BF00288604; Degols G, 1996, MOL CELL BIOL, V16, P2870; Gaits F, 1998, GENE DEV, V12, P1464, DOI 10.1101/gad.12.10.1464; Ip YT, 1998, CURR OPIN CELL BIOL, V10, P205, DOI 10.1016/S0955-0674(98)80143-9; Kanoh J, 1996, GENES CELLS, V1, P391, DOI 10.1046/j.1365-2443.1996.d01-247.x; Kato T, 1996, FEBS LETT, V378, P207, DOI 10.1016/0014-5793(95)01442-X; MAEDA T, 1994, NATURE, V369, P242, DOI 10.1038/369242a0; Melcher ML, 1996, J BIOL CHEM, V271, P29958, DOI 10.1074/jbc.271.47.29958; MILLAR JBA, 1995, GENE DEV, V9, P2117, DOI 10.1101/gad.9.17.2117; MORENO S, 1991, METHOD ENZYMOL, V194, P795; NAKAGAWA CW, 1995, J BIOCHEM-TOKYO, V118, P109, DOI 10.1093/oxfordjournals.jbchem.a124864; New L, 1998, EMBO J, V17, P3372, DOI 10.1093/emboj/17.12.3372; Nguyen AN, 2000, MOL BIOL CELL, V11, P1169, DOI 10.1091/mbc.11.4.1169; Posas F, 1996, CELL, V86, P865, DOI 10.1016/S0092-8674(00)80162-2; Posas F, 1998, EMBO J, V17, P1385, DOI 10.1093/emboj/17.5.1385; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Samejima I, 1997, EMBO J, V16, P6162, DOI 10.1093/emboj/16.20.6162; Samejima I, 1998, MOL BIOL CELL, V9, P2325, DOI 10.1091/mbc.9.8.2325; SCHULLER C, 1994, EMBO J, V13, P4382, DOI 10.1002/j.1460-2075.1994.tb06758.x; Shieh JC, 1998, J CELL SCI, V111, P2799; Shieh JC, 1997, GENE DEV, V11, P1008, DOI 10.1101/gad.11.8.1008; Shiozaki K, 1997, MOL BIOL CELL, V8, P409, DOI 10.1091/mbc.8.3.409; SHIOZAKI K, 1995, NATURE, V378, P739, DOI 10.1038/378739a0; Shiozaki K, 1996, GENE DEV, V10, P2276, DOI 10.1101/gad.10.18.2276; Takeda T, 1995, EMBO J, V14, P6193, DOI 10.1002/j.1460-2075.1995.tb00310.x; Teige M, 2001, P NATL ACAD SCI USA, V98, P5625, DOI 10.1073/pnas.091610798; Thomson S, 1999, EMBO J, V18, P4779, DOI 10.1093/emboj/18.17.4779; TODA T, 1991, GENE DEV, V5, P60, DOI 10.1101/gad.5.1.60; Toone WM, 1998, GENE DEV, V12, P1453, DOI 10.1101/gad.12.10.1453; WASKIEWICZ AJ, 1995, CURR OPIN CELL BIOL, V7, P798, DOI 10.1016/0955-0674(95)80063-8; Wilkinson MG, 1999, EMBO J, V18, P4210, DOI 10.1093/emboj/18.15.4210; Wilkinson MG, 1998, GENE DEV, V12, P1391, DOI 10.1101/gad.12.10.1391; Wilkinson MG, 1996, GENE DEV, V10, P2289, DOI 10.1101/gad.10.18.2289	40	46	52	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 17	2002	277	20					17722	17727		10.1074/jbc.M200104200	http://dx.doi.org/10.1074/jbc.M200104200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	553PR	11886858	hybrid			2022-12-27	WOS:000175685100043
J	Sonnenburg, JL; van Halbeek, H; Varki, A				Sonnenburg, JL; van Halbeek, H; Varki, A			Characterization of the acid stability of glycosidically linked neuraminic acid - Use in detecting de-N-acetyl-gangliosides in human melanoma	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; SIALIC ACIDS; CELL-ADHESION; LIQUID-CHROMATOGRAPHY; MONOCLONAL-ANTIBODY; ENDOTHELIAL-CELLS; SIGNALING DOMAIN; O-ACETYL; BINDING; EXPRESSION	The glycosidic linkage of sialic acids is much more sensitive to acid hydrolysis than those of other monosaccharides in vertebrates. The commonest sialic acids in nature are neuraminic acid (Neu)-based and are typically N-acylated at the C5 position. Unsubstituted Neu is thought to occur on native gangliosides of certain tumors and cell lines, and synthetic de-N-acetyl-gangliosides have potent biological properties in vitro. However, claims for their natural existence are based upon monoclonal antibodies and pulse-chase experiments, and there have been no reports of their chemical detection. Here we report that one of these antibodies shows nonspecific cross-reactivity with a polypeptide epitope, further emphasizing the need for definitive chemical proof of unsubstituted Neu on naturally occurring gangliosides. While pursuing this, we found that alpha2-3-linked Neu on chemically de-N-acetylated G(M3) ganglioside resists acid hydrolysis under conditions where the N-acetylated form is completely labile. To ascertain the generality of this finding, we investigated the stability of glycosidically linked alpha- and beta-methyl glycosides of Neu. Using NMR spectroscopy to monitor glycosidic linkage hydrolysis, we find that only 47% of Neualpha2Me is hydrolyzed after 3 h in 10 mm HCl at 80degreesC, whereas Neu5Acalpha2Me is 95% hydrolyzed after 20 min under the same conditions. Notably, Neubeta2Me is hydrolyzed even slower than Neualpha2Me, indicating that acid resistance is a general property of glycosidically linked Neu. Taking advantage of this, we modified classical purification techniques for de-N-acetyl-ganglioside isolation using acid to first eliminate conventional gangliosides. We also introduce a phospholipase-based approach to remove contaminating phospholipids that previously hindered efforts to study de-N-acetyl-gangliosides. The partially purified sample can then be N-propionylated, allowing acid release and mass spectrometric detection of any originally existing Neu as Neu5Pr. These advances allowed us to detect covalently bound Neu in lipid extracts of a human melanoma tumor, providing the first chemical proof for naturally occurring de-N-acetyl-gangliosides.	Univ Calif San Diego, Sch Med 0687, Glycobiol Res & Training Ctr, Dept Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Glycobiol Res & Training Ctr, Dept Cellular & Mol Med, La Jolla, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego	Varki, A (corresponding author), Univ Calif San Diego, Sch Med 0687, Glycobiol Res & Training Ctr, Dept Med, La Jolla, CA 92093 USA.	avarki@ucsd.edu			NCI NIH HHS [P01 CA58689] Funding Source: Medline; NIGMS NIH HHS [R01-GM323373] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA058689] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Brown DA, 1998, ANNU REV CELL DEV BI, V14, P111, DOI 10.1146/annurev.cellbio.14.1.111; Chammas R, 1999, CANCER RES, V59, P1337; CHERESH DA, 1986, J CELL BIOL, V102, P688, DOI 10.1083/jcb.102.3.688; Collins BE, 2000, GLYCOBIOLOGY, V10, P11, DOI 10.1093/glycob/10.1.11; COLLINS PM, 1995, MONOSACCHARIDES, P73; DAVIDSON EA, 1966, METHOD ENZYMOL, V8, P52; DOHI T, 1988, CANCER RES, V48, P5680; FEATHER MS, 1965, J ORG CHEM, V30, P153, DOI 10.1021/jo01012a035; GOTTSCHALK A, 1960, HEM BIOL SIALIC ACID; HAKOMORI SI, 1981, ANNU REV BIOCHEM, V50, P733, DOI 10.1146/annurev.bi.50.070181.003505; HANAI N, 1988, J BIOL CHEM, V263, P6296; HARA S, 1989, ANAL BIOCHEM, V179, P162, DOI 10.1016/0003-2697(89)90218-2; HAVERKAMP J, 1982, EUR J BIOCHEM, V122, P305, DOI 10.1111/j.1432-1033.1982.tb05881.x; HIDARI KIPJ, 1993, BIOCHEM J, V296, P259, DOI 10.1042/bj2960259; Iwabuchi K, 1998, J BIOL CHEM, V273, P33766, DOI 10.1074/jbc.273.50.33766; KARLSSON KA, 1989, ANNU REV BIOCHEM, V58, P309, DOI 10.1146/annurev.bi.58.070189.001521; Kasahara K, 1997, J BIOL CHEM, V272, P29947, DOI 10.1074/jbc.272.47.29947; Kazui A, 2000, BIOCHEM BIOPH RES CO, V273, P159, DOI 10.1006/bbrc.2000.2903; Khan AA, 2001, SCIENCE, V292, P1681, DOI 10.1126/science.1056594; Klein A, 1997, GLYCOBIOLOGY, V7, P421, DOI 10.1093/glycob/7.3.421; KOJIMA N, 1992, J BIOL CHEM, V267, P17264; LUTZ MS, 1994, J BIOL CHEM, V269, P29227; MAGNANI JL, 1982, METHOD ENZYMOL, V83, P235; MANZI AE, 1990, J BIOL CHEM, V265, P13091; MARKWELL MAK, 1981, P NATL ACAD SCI-BIOL, V78, P5406, DOI 10.1073/pnas.78.9.5406; Mitsuoka C, 1999, P NATL ACAD SCI USA, V96, P1597, DOI 10.1073/pnas.96.4.1597; Moggridge RCG, 1938, J CHEM SOC, P745, DOI 10.1039/jr9380000745; NAGAI Y, 1995, BEHAV BRAIN RES, V66, P99, DOI 10.1016/0166-4328(94)00130-8; NORES GA, 1988, CARBOHYD RES, V179, P393, DOI 10.1016/0008-6215(88)84135-1; NORES GA, 1989, METHOD ENZYMOL, V179, P242; NORGARDSUMNICHT KE, 1995, J BIOL CHEM, V270, P27634, DOI 10.1074/jbc.270.46.27634; Prinetti A, 1999, J BIOL CHEM, V274, P20916, DOI 10.1074/jbc.274.30.20916; Probstmeier R, 1999, GLYCOBIOLOGY, V9, P101, DOI 10.1093/glycob/9.2.101; PUKEL CS, 1982, J EXP MED, V155, P1133, DOI 10.1084/jem.155.4.1133; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; SJOBERG ER, 1995, J BIOL CHEM, V270, P2921, DOI 10.1074/jbc.270.7.2921; Srikrishna G, 2001, J IMMUNOL, V166, P624, DOI 10.4049/jimmunol.166.1.624; STULTS CLM, 1989, METHOD ENZYMOL, V179, P167; SVENNERHOLM L, 1963, J NEUROCHEM, V10, P613, DOI 10.1111/j.1471-4159.1963.tb08933.x; VANECHTEN G, 1993, J BIOL CHEM, V268, P5341; VARKI A, 1984, ANAL BIOCHEM, V137, P236, DOI 10.1016/0003-2697(84)90377-4; Vyas AA, 2001, BIOCHIMIE, V83, P677, DOI 10.1016/S0300-9084(01)01308-6; WALTON KM, 1988, J BIOL CHEM, V263, P2055; WEIS FMB, 1990, J BIOL CHEM, V265, P12059; Zanetta JP, 2001, GLYCOBIOLOGY, V11, P663, DOI 10.1093/glycob/11.8.663; ZELLER CB, 1992, AM J PHYSIOL, V262, pC1341, DOI 10.1152/ajpcell.1992.262.6.C1341; ZHOU QG, 1994, J BIOL CHEM, V269, P1959; ZWALL RFA, 1974, METHOD ENZYMOL, V32, P154	48	23	25	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 17	2002	277	20					17502	17510		10.1074/jbc.M110867200	http://dx.doi.org/10.1074/jbc.M110867200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	553PR	11884388	hybrid			2022-12-27	WOS:000175685100016
J	Barata, H; de Meis, L				Barata, H; de Meis, L			Uncoupled ATP hydrolysis and thermogenic activity of the sarcoplasmic reticulum Ca2+-ATPase - Coupling effects of dimethyl sulfoxide and low temperature	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-PRODUCTION; CALCIUM-PUMP; CA2+; TRANSPORT; VESICLES; MUSCLE; EFFLUX; MEMBRANES; MECHANISM; RELEASE	The sarcoplasmic reticulum. Ca2+-ATPase transports Ca2+ using the energy derived from ATP hydrolysis. During catalysis, part of the energy is used to translocate Ca2+ across the membrane, and part is dissipated as heat. At 35 degreesC the heat released during the hydrolysis of each ATP molecule varies depending on the formation of a Ca2+ gradient across the membrane. With leaky vesicles (no gradient) the heat released varies between 9 and 12 kcal/mol of ATP cleaved, and with intact vesicles (gradient), the heat released increases to 20-24 kcal/mol of ATP. After Ca2+ accumulation, 82% of the Ca2+-ATPase activity is not coupled to Ca2+ transport, and the ratio between Ca2+ transported and ATP cleaved is 0.3. The addition of 20% dimethyl sulfoxide (v/v) to the medium or decreasing the temperature from 35 to 20 degreesC abolishes the difference of heat produced during ATP hydrolysis in the presence and absence of a gradient. This is accompanied by a simultaneous inhibition of the uncoupled ATPase activity and an increase of the Ca2+/ATP ratio from 0.3 to 1.3-1.4. It is concluded that the uncoupled Ca2+-ATPase is responsible for both the low Ca2+/ATP ratio measured during transport and the difference of heat produced during ATP hydrolysis in the presence and absence of a gradient.	Univ Fed Rio de Janeiro, Ctr Ciencias Saude, Inst Ciencias Biomed, Dept Bioquim Med, BR-21941590 Rio De Janeiro, Brazil	Universidade Federal do Rio de Janeiro	de Meis, L (corresponding author), Univ Fed Rio de Janeiro, Ctr Ciencias Saude, Inst Ciencias Biomed, Dept Bioquim Med, Cidade Univ, BR-21941590 Rio De Janeiro, Brazil.	demeis@biqmed.ufrj.br						BARLOGIE B, 1971, FEBS LETT, V12, P267, DOI 10.1016/0014-5793(71)80194-1; BLOCK BA, 1994, ANNU REV PHYSIOL, V56, P535; CHIESI M, 1979, J BIOL CHEM, V254, P370; CHINET A, 1992, J PHYSIOL-LONDON, V455, P663, DOI 10.1113/jphysiol.1992.sp019321; De Meis L, 1998, AM J PHYSIOL-CELL PH, V274, pC1738, DOI 10.1152/ajpcell.1998.274.6.C1738; de Meis L, 2001, J BIOL CHEM, V276, P25078, DOI 10.1074/jbc.M103318200; de Meis L, 2001, BIOSCIENCE REP, V21, P113, DOI 10.1023/A:1013640006611; de Meis L, 2000, BIOCHEM BIOPH RES CO, V276, P35, DOI 10.1006/bbrc.2000.3418; deMeis L, 1996, BBA-BIOENERGETICS, V1275, P105, DOI 10.1016/0005-2728(96)00058-8; DEMEIS L, 1979, ANNU REV BIOCHEM, V48, P275; deMeis L, 1997, FEBS LETT, V406, P201, DOI 10.1016/S0014-5793(97)00244-5; DEMEIS L, 1991, J BIOL CHEM, V266, P5736; DEMEIS L, 1981, TRANSPORT LIFE SCI, V2, P1; DEMEIS L, 1988, METHOD ENZYMOL, V157, P190; ELETR S, 1972, BIOCHIM BIOPHYS ACTA, V282, P174, DOI 10.1016/0005-2736(72)90321-5; Fortea MI, 2000, J BIOL CHEM, V275, P12521, DOI 10.1074/jbc.275.17.12521; HASSELBACH W, 1978, BIOCHIM BIOPHYS ACTA, V515, P23, DOI 10.1016/0304-4157(78)90007-2; HASSELBACH W, 1964, PROGR BIOPHYS MOL BI, V14, P169; INESI G, 1985, ANNU REV PHYSIOL, V47, P573, DOI 10.1146/annurev.ph.47.030185.003041; INESI G, 1980, J BIOL CHEM, V255, P3025; Inesi G, 1978, Ann N Y Acad Sci, V307, P224, DOI 10.1111/j.1749-6632.1978.tb41947.x; JANSKY L, 1995, PHYSIOL REV, V75, P237, DOI 10.1152/physrev.1995.75.2.237; Logan-Smith MJ, 2001, J BIOL CHEM, V276, P46905, DOI 10.1074/jbc.M108778200; MAKINOSE M, 1971, FEBS LETT, V12, P269, DOI 10.1016/0014-5793(71)80195-3; MCWHIRTER JM, 1987, BIOCHEM J, V245, P731, DOI 10.1042/bj2450731; MELTZER S, 1984, J BIOL CHEM, V259, P4244; Mitidieri F, 1999, J BIOL CHEM, V274, P28344, DOI 10.1074/jbc.274.40.28344; Reis M, 2001, J BIOL CHEM, V276, P42793, DOI 10.1074/jbc.M107625200; Silva JE, 2001, J CLIN INVEST, V108, P35, DOI 10.1172/JCI13397; Sumbilla C, 2002, J BIOL CHEM, V277, P13900, DOI 10.1074/jbc.M111155200; TANFORD C, 1984, CRC CR REV BIOCH MOL, V17, P123, DOI 10.3109/10409238409113603; YU X, 1995, J BIOL CHEM, V270, P4361, DOI 10.1074/jbc.270.9.4361	32	21	22	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 10	2002	277	19					16868	16872		10.1074/jbc.M200648200	http://dx.doi.org/10.1074/jbc.M200648200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	551MB	11880374	hybrid			2022-12-27	WOS:000175564500070
J	Harper, CC; South, ST; McCaffery, JM; Gould, SJ				Harper, CC; South, ST; McCaffery, JM; Gould, SJ			Peroxisomal membrane protein import does not require Pex17p	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR DOCKING COMPLEX; PICHIA-PASTORIS; ZELLWEGER-SYNDROME; TARGETING SIGNAL; SACCHAROMYCES-CEREVISIAE; FUNCTIONAL COMPLEMENTATION; BIOGENESIS DISORDERS; YARROWIA-LIPOLYTICA; GENE ENCODES; CDNA CLONING	Of the similar to20 proteins required for peroxisome biogenesis, only four have been implicated in the process of peroxisomal membrane protein (PMP) import: Pex3p, Pex16p, Pex17p, and Pex19p. To improve our understanding of the role that Pex17p plays in PMP import, we examined the behavior of PMPs in a Pichia pastoris pex17 mutant. Relative to wild-type cells, pex17 cells appeared to have a mild reduction in PMP stability and slightly aberrant PMP behavior in subcellular fractionation experiments. However, we also found that the behavior of PMPs in the pex17 mutant was indistinguishable from PMP behavior in a pex5 mutant, which has no defect in PMP import, and was far different from PMP behavior in a pex3 mutant, which has a bona fide defect in PMP import. Furthermore, we found that a pex14 mutant, which has no defect in PMP import, lacks detectable levels of Pex17p. Based on these and other results, we propose that Pex17p acts primarily in the matrix protein import pathway and does not play an important role in PMP import.	Johns Hopkins Univ, Sch Med, Dept Biol Chem, Baltimore, MD 21205 USA; Johns Hopkins Univ, Integrated Imaging Ctr, Dept Biol, Baltimore, MD 21218 USA	Johns Hopkins University; Johns Hopkins University	Gould, SJ (corresponding author), Johns Hopkins Univ, Sch Med, Dept Biol Chem, Baltimore, MD 21205 USA.	agould@jhmi.edu			NIDDK NIH HHS [DK59479, DK45787] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045787, R01DK059479] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Albertini M, 1997, CELL, V89, P83, DOI 10.1016/S0092-8674(00)80185-3; Baes M, 1997, NAT GENET, V17, P49, DOI 10.1038/ng0997-49; BAKERBRACHMANN C, 1998, YEAST, V14, P115; Chang CC, 1999, J CELL SCI, V112, P1579; CRANE DI, 1994, J BIOL CHEM, V269, P21835; DODT G, 1995, NAT GENET, V9, P115, DOI 10.1038/ng0295-115; Eitzen GA, 1997, J CELL BIOL, V137, P1265, DOI 10.1083/jcb.137.6.1265; Fransen M, 2001, MOL CELL BIOL, V21, P4413, DOI 10.1128/MCB.21.13.4413-4424.2001; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; Gatto GJ, 2000, NAT STRUCT BIOL, V7, P1091; Girzalsky W, 1999, J CELL BIOL, V144, P1151, DOI 10.1083/jcb.144.6.1151; Gotte K, 1998, MOL CELL BIOL, V18, P616; GOULD SG, 2001, METABOLIC MOL BASES, V2, P3181; Gould SJ, 2000, TRENDS GENET, V16, P340, DOI 10.1016/S0168-9525(00)02056-4; HEINEMANN P, 1992, FEBS LETT, V300, P179, DOI 10.1016/0014-5793(92)80191-I; Hettema EH, 2000, EMBO J, V19, P223, DOI 10.1093/emboj/19.2.223; Hettema EH, 2000, BBA-MOL CELL BIOL L, V1486, P18, DOI 10.1016/S1388-1981(00)00045-7; Honsho M, 1998, AM J HUM GENET, V63, P1622, DOI 10.1086/302161; Huhse B, 1998, J CELL BIOL, V140, P49, DOI 10.1083/jcb.140.1.49; Johnson MA, 2001, YEAST, V18, P621, DOI 10.1002/yea.711; Jones JM, 2001, J CELL BIOL, V153, P1141, DOI 10.1083/jcb.153.6.1141; KALISH JE, 1995, MOL CELL BIOL, V15, P6406; Kalish JE, 1996, EMBO J, V15, P3275, DOI 10.1002/j.1460-2075.1996.tb00692.x; Kinoshita N, 1998, J BIOL CHEM, V273, P24122, DOI 10.1074/jbc.273.37.24122; Komori M, 1997, EMBO J, V16, P44, DOI 10.1093/emboj/16.1.44; Matsuzono Y, 1999, P NATL ACAD SCI USA, V96, P2116, DOI 10.1073/pnas.96.5.2116; MCCOLLUM D, 1993, J CELL BIOL, V121, P761, DOI 10.1083/jcb.121.4.761; Sacksteder KA, 2000, J CELL BIOL, V148, P931, DOI 10.1083/jcb.148.5.931; Schliebs W, 1999, J BIOL CHEM, V274, P5666, DOI 10.1074/jbc.274.9.5666; Shimizu N, 1999, J BIOL CHEM, V274, P12593, DOI 10.1074/jbc.274.18.12593; Snyder WB, 1999, MOL BIOL CELL, V10, P1745, DOI 10.1091/mbc.10.6.1745; Snyder WB, 1999, MOL BIOL CELL, V10, P4005, DOI 10.1091/mbc.10.12.4005; South ST, 2000, J CELL BIOL, V149, P1345, DOI 10.1083/jcb.149.7.1345; South ST, 1999, J CELL BIOL, V144, P255, DOI 10.1083/jcb.144.2.255; Subramani S, 2000, ANNU REV BIOCHEM, V69, P399, DOI 10.1146/annurev.biochem.69.1.399; Tabak HF, 1999, TRENDS CELL BIOL, V9, P447, DOI 10.1016/S0962-8924(99)01650-5; Titorenko VI, 2000, J CELL BIOL, V148, P29, DOI 10.1083/jcb.148.1.29; Titorenko VI, 2000, J CELL BIOL, V150, P881, DOI 10.1083/jcb.150.4.881; VANDERKLEI IJ, 1995, J BIOL CHEM, V270, P17229, DOI 10.1074/jbc.270.29.17229; VANDERLEIJ I, 1993, P NATL ACAD SCI USA, V90, P11782, DOI 10.1073/pnas.90.24.11782; vanRoermund CWT, 1995, BBA-GEN SUBJECTS, V1245, P348, DOI 10.1016/0304-4165(95)00099-2; Wanders RJA, 1998, MOL ASPECTS MED, V19, P71, DOI 10.1016/S0098-2997(98)00003-X; Wanders RJA, 2001, BIOCHEM SOC T, V29, P250, DOI 10.1042/0300-5127:0290250; Wiemer EAC, 1996, J BIOL CHEM, V271, P18973, DOI 10.1074/jbc.271.31.18973	44	14	14	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 10	2002	277	19					16498	16504		10.1074/jbc.M111728200	http://dx.doi.org/10.1074/jbc.M111728200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	551MB	11859077	hybrid			2022-12-27	WOS:000175564500023
J	Lassak, A; Del Valle, L; Peruzzi, F; Wang, JY; Enam, S; Croul, S; Khalili, K; Reiss, K				Lassak, A; Del Valle, L; Peruzzi, F; Wang, JY; Enam, S; Croul, S; Khalili, K; Reiss, K			Insulin receptor substrate 1 translocation to the nucleus by the human JC virus T-antigen	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-I; PLECKSTRIN HOMOLOGY DOMAIN; MOUSE EMBRYO FIBROBLASTS; IRS-1 SIGNALING SYSTEM; LARGE TUMOR-ANTIGEN; BIOLOGICAL PROPERTIES; SIMIAN VIRUS-40; CANCER CELLS; TRANSFORMATION; EXPRESSION	Insulin receptor substrate 1 (IRS-1) is the major signaling molecule for the insulin and insulin-like growth factor I receptors, which transduces both metabolic and growth-promoting signals, and has transforming properties when overexpressed in the cells. Here we show that IRS-1 is translocated to the nucleus in the presence of the early viral protein-T-antigen of the human polyomavirus JC. Nuclear IRS-1 was detected in T-antigen-positive cell lines and in T-antigen-positive biopsies from patients diagnosed with medulloblastoma. The IRS-1 domain responsible for a direct JC virus T-antigen binding was localized within the N-terminal portion of IRS-1 molecule, and the binding was independent from IRS-1 tyrosine phosphorylation and was strongly inhibited by IRS-1 serine phosphorylation. In addition, competition for the IRS-1-T-antigen binding by a dominant negative mutant of IRS-1 inhibited growth and survival of JC virus T-antigen-transformed cells in anchorage-independent culture conditions. Based on these findings, we propose a novel role for the IRS-1-T-antigen complex in controlling cellular equilibrium during viral infection. It may involve uncoupling of IRS-1 from its surface receptor and translocation of its function to the nucleus.	Temple Univ, Coll Sci & Technol, Ctr Neurovirol & Canc Biol, Philadelphia, PA 19122 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Reiss, K (corresponding author), Temple Univ, Coll Sci & Technol, Ctr Neurovirol & Canc Biol, 1900 N 12th St,Biol Life Sci Bldg,Rm 238, Philadelphia, PA 19122 USA.		Del Valle, Luis/J-4085-2015; Peruzzi, Francesca/M-9804-2014	Del Valle, Luis/0000-0003-3894-9206; Croul, Sidney/0000-0002-2224-5485	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS036466] Funding Source: NIH RePORTER; NINDS NIH HHS [P01 NS 36466] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Bergmann U, 1996, BIOCHEM BIOPH RES CO, V220, P886, DOI 10.1006/bbrc.1996.0500; Brodsky JL, 1998, J VIROL, V72, P5329, DOI 10.1128/JVI.72.7.5329-5334.1998; Burks DJ, 1998, J BIOL CHEM, V273, P31061, DOI 10.1074/jbc.273.47.31061; BUTEL JS, 1986, BIOCHIM BIOPHYS ACTA, V865, P171, DOI 10.1016/0304-419X(86)90027-2; CRAPARO A, 1995, J BIOL CHEM, V270, P15639, DOI 10.1074/jbc.270.26.15639; CSERMELY P, 1993, J BIOL CHEM, V268, P9747; DAmbrosio C, 1997, CANCER RES, V57, P3264; DAMBROSIO C, 1995, CELL GROWTH DIFFER, V6, P557; Del Valle L, 2001, CANCER RES, V61, P4287; Dhe-Paganon S, 1999, P NATL ACAD SCI USA, V96, P8378, DOI 10.1073/pnas.96.15.8378; FEI ZL, 1995, MOL CELL BIOL, V15, P4232; Jackson JG, 1998, J BIOL CHEM, V273, P9994, DOI 10.1074/jbc.273.16.9994; Khalili K, 1999, LANCET, V353, P1152, DOI 10.1016/S0140-6736(99)00357-8; Krynska B, 1999, ONCOGENE, V18, P39, DOI 10.1038/sj.onc.1202278; Krynska B, 2000, VIROLOGY, V274, P65, DOI 10.1006/viro.2000.0450; Krynska B, 1999, P NATL ACAD SCI USA, V96, P11519, DOI 10.1073/pnas.96.20.11519; LANFORD RE, 1985, MOL CELL BIOL, V5, P1043, DOI 10.1128/MCB.5.5.1043; LEMMON MA, 1995, P NATL ACAD SCI USA, V92, P10472, DOI 10.1073/pnas.92.23.10472; Major E O, 1983, Prog Clin Biol Res, V105, P289; MAJOR EO, 1984, VIROLOGY, V136, P359, DOI 10.1016/0042-6822(84)90172-7; MORRIONE A, 1995, J VIROL, V69, P5300, DOI 10.1128/JVI.69.9.5300-5303.1995; Mothe I, 1996, J BIOL CHEM, V271, P11222, DOI 10.1074/jbc.271.19.11222; MYERS MG, 1994, TRENDS BIOCHEM SCI, V19, P289, DOI 10.1016/0968-0004(94)90007-8; Nehrbass D, 1998, AM J PATHOL, V152, P341; PADGETT BL, 1973, J INFECT DIS, V127, P467, DOI 10.1093/infdis/127.4.467; PINKERT CA, 1987, VIROLOGY, V160, P169, DOI 10.1016/0042-6822(87)90057-2; PITCHER JA, 1995, J BIOL CHEM, V270, P11707, DOI 10.1074/jbc.270.20.11707; Reiss K, 2000, ONCOGENE, V19, P2687, DOI 10.1038/sj.onc.1203587; Reiss K, 2001, ONCOGENE, V20, P490, DOI 10.1038/sj.onc.1204112; Reiss K, 1998, EXP CELL RES, V242, P361, DOI 10.1006/excr.1998.4113; ROSE DW, 1994, P NATL ACAD SCI USA, V91, P797, DOI 10.1073/pnas.91.2.797; Rubini M, 1997, EXP CELL RES, V230, P284, DOI 10.1006/excr.1996.3430; Safak M, 1999, J VIROL, V73, P10146, DOI 10.1128/JVI.73.12.10146-10157.1999; SELL C, 1994, MOL CELL BIOL, V14, P3604, DOI 10.1128/MCB.14.6.3604; SELL C, 1993, P NATL ACAD SCI USA, V90, P11217, DOI 10.1073/pnas.90.23.11217; Sullivan CS, 2000, MOL CELL BIOL, V20, P5749, DOI 10.1128/MCB.20.15.5749-5757.2000; Valentinis B, 1997, MOL CELL BIOL, V17, P3744, DOI 10.1128/MCB.17.7.3744; Valentinis B, 1998, J CELL PHYSIOL, V176, P648, DOI 10.1002/(SICI)1097-4652(199809)176:3<648::AID-JCP22>3.3.CO;2-6; VUORI K, 1994, SCIENCE, V266, P1576, DOI 10.1126/science.7527156; Wang JY, 2001, ONCOGENE, V20, P3857, DOI 10.1038/sj.onc.1204532; WATERS SB, 1993, J BIOL CHEM, V268, P22231; WHITE MF, 1994, CURR OPIN GENET DEV, V4, P47, DOI 10.1016/0959-437X(94)90090-6; White MF, 1998, RECENT PROG HORM RES, V53, P119; WHITE MF, 1997, DIABETOLOGIA, V40, P2	45	102	104	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 10	2002	277	19					17231	17238		10.1074/jbc.M110885200	http://dx.doi.org/10.1074/jbc.M110885200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	551MB	11877394	hybrid			2022-12-27	WOS:000175564500117
J	Lutsenko, EA; Carcamo, JM; Golde, DW				Lutsenko, EA; Carcamo, JM; Golde, DW			Vitamin C prevents DNA mutation induced by oxidative stress	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEHYDROASCORBIC ACID; ASCORBIC-ACID; DAMAGE; TRANSPORT; ACCUMULATION; ANTIOXIDANT; INHIBITION; SUPPLEMENTATION; GLYCOSYLASE; MUTAGENESIS	The precise role of vitamin C in the prevention of DNA mutations is controversial. Although ascorbic acid has strong antioxidant properties, it also has pro-oxidant effects in the presence of free transition metals. Vitamin C was recently reported to induce the decomposition of lipid hydroperoxides independent of metal interactions, suggesting that it may cause DNA damage. To directly address the role of vitamin C in maintaining genomic integrity we developed a genetic system for quantifying guanine base mutations induced in human cells under oxidative stress. The assay utilized a plasmid construct encoding the cDNA for chloramphenicol acetyl transferase modified to contain an amber stop codon, which was restored to wild type by G to T transversion induced by oxidative stress. The mutation frequency was determined from the number of plasmids containing the wild type chloramphenicol acetyl transferase gene rescued from oxidatively stressed cells. Cells were loaded with vitamin C by exposing them to dehydroascorbic acid, thereby avoiding transition metal-related pro-oxidant effects of ascorbic acid. We found that vitamin C loading resulted in substantially decreased mutations induced by H2O2. Depletion of glutathione led to cytotoxicity and an increase in H2O2-induced mutation frequency; however, mutation frequency was prominently decreased in depleted cells preloaded with vitamin C. The mutation results correlated with a decrease in total 8-oxo-guanine measured in genomic DNA of cells loaded with vitamin C and oxidatively stressed. These findings directly support the concept that high intracellular concentrations of vitamin C can prevent oxidation-induced mutations in human cells.	Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center	Golde, DW (corresponding author), Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA.	d-golde@ski.mskcc.org						AMES BN, 1993, P NATL ACAD SCI USA, V90, P7915, DOI 10.1073/pnas.90.17.7915; BERGSTEN P, 1990, J BIOL CHEM, V265, P2584; Brennan LA, 2000, BRIT J NUTR, V84, P195, DOI 10.1017/S0007114500001422; Cai L, 2001, CHEM-BIOL INTERACT, V137, P75, DOI 10.1016/S0009-2797(01)00210-1; DIZDAROGLU M, 1985, BIOCHEMISTRY-US, V24, P4476, DOI 10.1021/bi00337a032; FRAGA CG, 1991, P NATL ACAD SCI USA, V88, P11003, DOI 10.1073/pnas.88.24.11003; FREI B, 1989, P NATL ACAD SCI USA, V86, P6377, DOI 10.1073/pnas.86.16.6377; FREI B, 1988, P NATL ACAD SCI USA, V85, P9748, DOI 10.1073/pnas.85.24.9748; GALLOWAY SM, 1979, MUTAT RES, V60, P321, DOI 10.1016/0027-5107(79)90022-8; Guaiquil VH, 1997, J BIOL CHEM, V272, P9915; Guaiquil VH, 2001, J BIOL CHEM, V276, P40955, DOI 10.1074/jbc.M106878200; Halliwell B, 2000, AM J CLIN NUTR, V72, P1082; Halliwell B, 1999, FREE RADICAL BIO MED, P48; Kasai H, 1997, MUTAT RES-REV MUTAT, V387, P147, DOI 10.1016/S1383-5742(97)00035-5; KRINSKY NI, 1993, ANN NY ACAD SCI, V686, P229, DOI 10.1111/j.1749-6632.1993.tb39180.x; Lee BM, 1998, CANCER LETT, V132, P219, DOI 10.1016/S0304-3835(98)00227-4; Lee SH, 2001, SCIENCE, V292, P2083, DOI 10.1126/science.1059501; Levine M, 2001, P NATL ACAD SCI USA, V98, P9842, DOI 10.1073/pnas.171318198; Levine M, 1996, P NATL ACAD SCI USA, V93, P3704, DOI 10.1073/pnas.93.8.3704; May JM, 1999, FREE RADICAL BIO MED, V26, P1513, DOI 10.1016/S0891-5849(99)00017-9; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Podmore ID, 1998, NATURE, V392, P559, DOI 10.1038/33308; Rivas CI, 1997, J BIOL CHEM, V272, P5814, DOI 10.1074/jbc.272.9.5814; ROSIN MP, 1980, CANCER LETT, V8, P299, DOI 10.1016/0304-3835(80)90145-7; Rumsey SC, 2000, J BIOL CHEM, V275, P28246; Sambrook J., 1989, MOL CLONING, pA1; Schneider M, 2001, FREE RADICAL RES, V34, P209, DOI 10.1080/10715760100300201; SHIBUTANI S, 1991, NATURE, V349, P431, DOI 10.1038/349431a0; Sonntag C, 1987, CHEM BASIS RAD BIOL; SPEIT G, 1980, MUTAT RES, V78, P273, DOI 10.1016/0165-1218(80)90109-3; STICH HF, 1979, CANCER RES, V39, P4145; STICH HF, 1976, NATURE, V260, P722, DOI 10.1038/260722a0; Sweetman SF, 1997, NUTR CANCER, V27, P122, DOI 10.1080/01635589709514513; TCHOU J, 1991, P NATL ACAD SCI USA, V88, P4690, DOI 10.1073/pnas.88.11.4690; TSAIWU JJ, 1992, P NATL ACAD SCI USA, V89, P8779, DOI 10.1073/pnas.89.18.8779; Tsukaguchi H, 1999, NATURE, V399, P70, DOI 10.1038/19986; VERA JC, 1994, BLOOD, V84, P1628; VERA JC, 1995, J BIOL CHEM, V270, P23706, DOI 10.1074/jbc.270.40.23706; VERA JC, 1993, NATURE, V364, P79, DOI 10.1038/364079a0; WAGNER JR, 1992, P NATL ACAD SCI USA, V89, P3380, DOI 10.1073/pnas.89.8.3380; WOOD ML, 1990, BIOCHEMISTRY-US, V29, P7024, DOI 10.1021/bi00482a011; Zhu L, 1996, Methods Mol Biol, V57, P13	42	122	133	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 10	2002	277	19					16895	16899		10.1074/jbc.M201151200	http://dx.doi.org/10.1074/jbc.M201151200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	551MB	11884413	hybrid			2022-12-27	WOS:000175564500074
J	Hara-Kuge, S; Ohkura, T; Ideo, H; Shimada, O; Atsumi, S; Yamashita, K				Hara-Kuge, S; Ohkura, T; Ideo, H; Shimada, O; Atsumi, S; Yamashita, K			Involvement of VIP36 in intracellular transport and secretion of glycoproteins in polarized Madin-Darby canine kidney (MDCK) cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APICAL SECRETION; MOLECULAR CHAPERONE; LEGUMINOUS LECTINS; EPITHELIAL-CELLS; N-GLYCOSYLATION; PROTEIN; PATHWAY; GLYCANS; COMPONENT; ERGIC-53	VIP36, an intracellular lectin that recognizes high mannose-type glycans (Hara-Ruge, S., Ohkura, T., Seko, A., and Yamashita, K. (1999) Glycobiology 9, 833-839), was shown to localize not only to the early secretory pathway but also to the plasma membrane of Madin-Darby canine kidney (MDCK) cells. In the plasma membrane, VIP36 exhibited an apical-predominant distribution, the apical/basolateral ratio being similar to2. Like VIP36, plasma membrane glycoproteins recognized by VIP36 were found in the apical and basolateral membranes in the ratio of similar to2 to 1. In addition, secretory glycoproteins recognized by VIP36 were secreted similar to2-fold more efficiently from the apical membrane than from the basolateral membrane. Thus, the apical/basolateral ratio of the transport of VIP36-recognized glycoproteins was correlated with that of VIP36 in MDCK cells. Upon overproduction of VIP36 in MDCK cells, the apical/basolateral ratios of both VIP36 and VIP36-recognized glycoproteins were changed from similar to2 to similar to4, and the secretion of VIP36-recognized glycoproteins was greatly stimulated. In contrast to the overproduction of VIP36, that of a mutant version of VIP36, which has no lectin activity, was of no effect on the distribution of glycoproteins to apical and basolateral membranes and inhibited the secretion of VIP36-recognized glycoproteins. Furthermore, the overproduction of VIP36 greatly stimulated the secretion of a major apical secretory glycoprotein of MDCK cells, clusterin, which was found to carry at least one high mannose-type glycan and to be recognized by VIP36. In contrast to the secretion of clusterin, that of a non-glycosylated apical-secretion protein, galectin-3, was not stimulated through the overproduction of VIP36. These results indicated that VIP36 was involved in the transport and sorting of glycoproteins carrying high mannose-type glycan(s).	Sasaki Inst, Dept Biochem, Chiyoda Ku, Tokyo 1010062, Japan; Japan Sci & Technol Corp, CREST, Chiyoda Ku, Tokyo 1010062, Japan; Yamanashi Med Univ, Dept Anat, Yamanashi 4093898, Japan	Japan Science & Technology Agency (JST); University of Yamanashi	Yamashita, K (corresponding author), Sasaki Inst, Dept Biochem, Chiyoda Ku, 2-2 Kanda Surugadai, Tokyo 1010062, Japan.							Appenzeller C, 1999, NAT CELL BIOL, V1, P330, DOI 10.1038/14020; ARAR C, 1995, J BIOL CHEM, V270, P3351; Dahm T, 2001, MOL BIOL CELL, V12, P1481, DOI 10.1091/mbc.12.5.1481; DAHMS NM, 1989, J BIOL CHEM, V264, P12115; FIEDLER K, 1994, EMBO J, V13, P1729, DOI 10.1002/j.1460-2075.1994.tb06437.x; FIEDLER K, 1994, CELL, V77, P625, DOI 10.1016/0092-8674(94)90047-7; Fukushima K, 1997, J BIOL CHEM, V272, P10579; Fullekrug J, 1999, J CELL SCI, V112, P2813; Hanada K, 1997, J BIOL CHEM, V272, P32108, DOI 10.1074/jbc.272.51.32108; Hara-Kuge S, 1999, GLYCOBIOLOGY, V9, P833, DOI 10.1093/glycob/9.8.833; HARTMANN K, 1991, J BIOL CHEM, V266, P9924; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; Itin C, 1996, MOL BIOL CELL, V7, P483, DOI 10.1091/mbc.7.3.483; KITAGAWA Y, 1994, EXP CELL RES, V213, P449, DOI 10.1006/excr.1994.1222; Kobata A., 1993, GLYCOBIOLOGY PRACTIC, P103; LINDSTEDT R, 1993, J BIOL CHEM, V268, P11750; LISANTI MP, 1988, P NATL ACAD SCI USA, V85, P9557, DOI 10.1073/pnas.85.24.9557; Martinez-Maza R, 2001, J BIOL CHEM, V276, P2168, DOI 10.1074/jbc.M006774200; NAUSEEF WM, 1995, J BIOL CHEM, V270, P4741, DOI 10.1074/jbc.270.9.4741; OU WJ, 1993, NATURE, V364, P771, DOI 10.1038/364771a0; SCHEIFFELE P, 1995, NATURE, V378, P96, DOI 10.1038/378096a0; SCHWEIZER A, 1988, J CELL BIOL, V107, P1643, DOI 10.1083/jcb.107.5.1643; TAKASAKI S, 1982, METHOD ENZYMOL, V83, P263; URBAN J, 1987, J CELL BIOL, V105, P2735, DOI 10.1083/jcb.105.6.2735; WARE FE, 1995, J BIOL CHEM, V270, P4697, DOI 10.1074/jbc.270.9.4697; YAMASHITA K, 1980, BIOCHEM BIOPH RES CO, V96, P1335, DOI 10.1016/0006-291X(80)90097-2; YAMASHITA K, 1992, BIOCHEMISTRY-US, V31, P11647, DOI 10.1021/bi00161a052	27	73	75	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 3	2002	277	18					16332	16339		10.1074/jbc.M112188200	http://dx.doi.org/10.1074/jbc.M112188200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	550PA	11872745	hybrid			2022-12-27	WOS:000175510400144
J	Lapucci, A; Donnini, M; Papucci, L; Witort, E; Tempestini, A; Bevilacqua, A; Nicolin, A; Brewer, G; Schiavone, N; Capaccioli, S				Lapucci, A; Donnini, M; Papucci, L; Witort, E; Tempestini, A; Bevilacqua, A; Nicolin, A; Brewer, G; Schiavone, N; Capaccioli, S			AUF1 is a bcl-2 A+U-rich element-binding protein involved in bcl-2 mRNA destabilization during apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3' UNTRANSLATED REGION; 3'-UNTRANSLATED REGION; GENE-EXPRESSION; DOWN-REGULATION; 1ST STEP; SEQUENCE; IDENTIFICATION; HUR; STABILIZATION; PURIFICATION	We previously identified a conserved A + U-rich element (ARE) in the 3'-untranslated region of bcl-2 mRNA. We have also recently demonstrated that the bcl-2 ARE interacts with a number of ARE-binding proteins (AUBPs) whose pattern changes during apoptosis in association with bcl-2 mRNA half-life reduction. Here we show that the AUBP AUF1 binds in vitro to bcl-2 mRNA. The results obtained in a yeast RNA three-hybrid system have demonstrated that the 1-257-amino acid portion of p37 AUF1 (conserved in all isoforms), containing the two RNA recognition motifs, also binds to the bcl-2 ARE in vivo. UVC irradiation-induced apoptosis results in an increase of AUF1. Inhibition of apoptosis by a general caspase inhibitor reduces this increase by 2-3-fold. These results indicate involvement of AUF1 in the ARE/ AUBP-mediated modulation of bcl-2 mRNA decay during apoptosis.	Univ Florence, Sch Med, Dept Expt Pathol & Oncol, I-50134 Florence, Italy; Univ Milan, Sch Med, Dept Pharmacol, I-20129 Milan, Italy; Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Mol Genet & Microbiol, Piscataway, NJ 08854 USA	University of Florence; University of Milan; Rutgers State University New Brunswick; Rutgers State University Medical Center	Schiavone, N (corresponding author), Univ Florence, Sch Med, Dept Expt Pathol & Oncol, Viale GB Morgagni 50, I-50134 Florence, Italy.	nicola@unifi.it; sergio@unifi.it	Lapucci, Andrea/AAA-6645-2019; Bevilacqua, Annamaria/C-6357-2008	Bevilacqua, Annamaria/0000-0002-3136-3424; Schiavone, Nicola/0000-0002-1592-4244; LAPUCCI, Andrea/0000-0001-9613-7164; Papucci, Laura/0000-0002-8450-7428	NATIONAL CANCER INSTITUTE [R01CA052443] Funding Source: NIH RePORTER; NCI NIH HHS [CA 52443] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Arao Y, 2000, ARCH BIOCHEM BIOPHYS, V380, P228, DOI 10.1006/abbi.2000.1938; BICKEL M, 1992, P NATL ACAD SCI USA, V89, P10001, DOI 10.1073/pnas.89.21.10001; Blaxall BC, 2000, MOL CARCINOGEN, V28, P76; Breitschopf K, 2000, MOL CELL BIOL, V20, P1886, DOI 10.1128/MCB.20.5.1886-1896.2000; BREWER G, 1991, MOL CELL BIOL, V11, P2460, DOI 10.1128/MCB.11.5.2460; CHEN CYA, 1995, TRENDS BIOCHEM SCI, V20, P465, DOI 10.1016/S0968-0004(00)89102-1; Chung SM, 1996, J BIOL CHEM, V271, P11518, DOI 10.1074/jbc.271.19.11518; Claffey KP, 1998, MOL BIOL CELL, V9, P469, DOI 10.1091/mbc.9.2.469; CLEARY ML, 1986, CELL, V47, P19, DOI 10.1016/0092-8674(86)90362-4; DeMaria CT, 1996, J BIOL CHEM, V271, P12179, DOI 10.1074/jbc.271.21.12179; Donnini M, 2001, BIOCHEM BIOPH RES CO, V287, P1063, DOI 10.1006/bbrc.2001.5700; DREYFUSS G, 1993, ANNU REV BIOCHEM, V62, P289, DOI 10.1146/annurev.bi.62.070193.001445; Fan XHC, 1998, EMBO J, V17, P3448, DOI 10.1093/emboj/17.12.3448; GILLIS P, 1991, J BIOL CHEM, V266, P3172; Huang Y, 1999, ONCOGENE, V18, P3431, DOI 10.1038/sj.onc.1202685; Kiledjian M, 1997, MOL CELL BIOL, V17, P4870, DOI 10.1128/MCB.17.8.4870; Kingma BR, 2000, INTERLEND DOC SUPPLY, V28, P20, DOI 10.1108/02641610010314858; Kraemer B, 2000, METHOD ENZYMOL, V328, P297, DOI 10.1016/S0076-6879(00)28404-8; Krecic AM, 1999, CURR OPIN CELL BIOL, V11, P363, DOI 10.1016/S0955-0674(99)80051-9; Levy NS, 1998, J BIOL CHEM, V273, P6417, DOI 10.1074/jbc.273.11.6417; Loflin P, 1999, GENE DEV, V13, P1884, DOI 10.1101/gad.13.14.1884; Madireddi MT, 2000, ONCOGENE, V19, P1362, DOI 10.1038/sj.onc.1203424; Maurer F, 1999, NUCLEIC ACIDS RES, V27, P1664, DOI 10.1093/nar/27.7.1664; MIYASHITA T, 1994, ONCOGENE, V9, P1799; NAKAMAKI T, 1995, J CELL PHYSIOL, V165, P484, DOI 10.1002/jcp.1041650306; PENG SS, 1988, EMBO J, V17, P3461; Perillo B, 2000, MOL CELL BIOL, V20, P2890, DOI 10.1128/MCB.20.8.2890-2901.2000; Putz U, 1996, NUCLEIC ACIDS RES, V24, P4838, DOI 10.1093/nar/24.23.4838; Rodriguez-Pascual F, 2000, J BIOL CHEM, V275, P26040, DOI 10.1074/jbc.M910460199; Schiavone N, 2000, FASEB J, V14, P174, DOI 10.1096/fasebj.14.1.174; Sela-Brown A, 2000, J BIOL CHEM, V275, P7424, DOI 10.1074/jbc.275.10.7424; SETO M, 1988, EMBO J, V7, P123, DOI 10.1002/j.1460-2075.1988.tb02791.x; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; Sheflin LG, 2000, AM J PHYSIOL-ENDOC M, V278, pE50, DOI 10.1152/ajpendo.2000.278.1.E50; Suzuki A, 1996, ONCOGENE, V13, P31; Tsujimoto Y, 2000, FEBS LETT, V466, P6, DOI 10.1016/S0014-5793(99)01761-5; Wagner BJ, 1998, GENOMICS, V48, P195, DOI 10.1006/geno.1997.5142; Wang WG, 2000, MOL CELL BIOL, V20, P760, DOI 10.1128/MCB.20.3.760-769.2000; Wilson GM, 1999, J BIOL CHEM, V274, P33374, DOI 10.1074/jbc.274.47.33374; Wilson GM, 1999, METHODS, V17, P74, DOI 10.1006/meth.1998.0709; WINSTALL E, 1995, MOL CELL BIOL, V15, P3796; Xu NH, 1998, NUCLEIC ACIDS RES, V26, P558, DOI 10.1093/nar/26.2.558; YOU Y, 1992, MOL CELL BIOL, V12, P2931, DOI 10.1128/MCB.12.7.2931; YOUNG RL, 1993, MOL CELL BIOL, V13, P3686, DOI 10.1128/MCB.13.6.3686; ZHANG W, 1993, MOL CELL BIOL, V13, P7652, DOI 10.1128/MCB.13.12.7652	45	78	78	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 3	2002	277	18					16139	16146		10.1074/jbc.M201377200	http://dx.doi.org/10.1074/jbc.M201377200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	550PA	11856759	hybrid			2022-12-27	WOS:000175510400122
J	Salicioni, AM; Mizelle, KS; Loukinova, E; Mikhailenko, I; Strickland, DK; Gonias, SL				Salicioni, AM; Mizelle, KS; Loukinova, E; Mikhailenko, I; Strickland, DK; Gonias, SL			The low density lipoprotein receptor-related protein mediates fibronectin catabolism and inhibits fibronectin accumulation on cell surfaces	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID PRECURSOR PROTEIN; GROWTH FACTOR-BB; ALPHA-2-MACROGLOBULIN RECEPTOR; UROKINASE RECEPTOR; EXTRACELLULAR-MATRIX; PLASMA FIBRONECTIN; IN-VIVO; PLASMINOGEN ACTIVATORS; BIOLOGICAL-ACTIVITIES; BINDING-PROTEINS	Low density lipoprotein receptor-related protein (LRP) is a member of the low density lipoprotein receptor family, which functions as an endocytic receptor for diverse ligands. In this study, we demonstrate that murine embryonic fibroblasts (MEF-2 cells) and 13-5-1 Chinese hamster ovary cells, which are LRP-deficient, accumulate greatly increased levels of cell-surface fibronectin (Fn), compared with LRP-expressing MEF-1 and CHO-K1 cells. Increased Fn was also detected in conditioned medium from LRP-deficient MEF-2 cells; however, biosynthesis of Fn by MEF-1 and MEF-2 cells was not significantly different. When LRP-deficient cells were dissociated from monolayer culture, increased levels of Fn remained with the cells, as determined by cell-surface protein biotinylation, suggesting an intimate relationship with cell surface-binding sites. The LRP antagonist, receptor-associated protein (RAP), promoted Fn accumulation in association with MEF-1 cells, whereas expression of full-length LRP in MEF-2 cells substantially decreased Fn accumulation, confirming the role of LRP in this process. Purified LRP bound directly to immobilized Fn, and this interaction was inhibited by RAP. Furthermore, MEF-1 cells degraded I-125-Fn at an increased rate, compared with MEF-2 cells. I-125-Fn degradation by MEF-1 cells was inhibited by RAP. These results demonstrate that LRP functions as a catabolic receptor for Fn. The function of LRP in Fn degradation and the ability of LRP to regulate levels of other plasma membrane proteins represent possible mechanisms whereby LRP prevents Fn accumulation on cell surfaces.	Univ Virginia, Sch Med, Dept Pathol, Charlottesville, VA 22908 USA; Univ Virginia, Sch Med, Dept Biochem, Charlottesville, VA 22908 USA; Univ Virginia, Sch Med, Dept Mol Genet, Charlottesville, VA 22908 USA; Amer Red Cross, Holland Lab, Dept Vasc Biol, Rockville, MD 20855 USA	University of Virginia; University of Virginia; University of Virginia; American Red Cross	Gonias, SL (corresponding author), Univ Virginia, Sch Med, Dept Pathol, Box 800214, Charlottesville, VA 22908 USA.	slg2t@virginia.edu	Salicioni, Ana Maria/ABD-8384-2021	Salicioni, Ana Maria/0000-0002-8951-3587	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL060551, R01HL050784, P01HL054710] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL50784, HL54710, HL60551] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Aguirre-Ghiso JA, 2001, MOL BIOL CELL, V12, P863, DOI 10.1091/mbc.12.4.863; Akamatsu H, 1996, CANCER RES, V56, P4541; Akimov SS, 2001, J CELL SCI, V114, P2989; ASHCOM JD, 1990, J CELL BIOL, V110, P1041, DOI 10.1083/jcb.110.4.1041; Barmina OY, 1999, J BIOL CHEM, V274, P30087, DOI 10.1074/jbc.274.42.30087; Berry H, 1998, ANN NY ACAD SCI, V864, P198, DOI 10.1111/j.1749-6632.1998.tb10304.x; Bonnefoy A, 2000, THROMB RES, V98, P323, DOI 10.1016/S0049-3848(99)00242-X; Bonni A, 1999, SCIENCE, V286, P1358, DOI 10.1126/science.286.5443.1358; BRETSCHER MS, 1989, EMBO J, V8, P1341, DOI 10.1002/j.1460-2075.1989.tb03514.x; Bu GJ, 2000, TRENDS CARDIOVAS MED, V10, P148, DOI 10.1016/S1050-1738(00)00045-1; CHEN WJ, 1990, J BIOL CHEM, V265, P3116; CONESE M, 1995, J CELL BIOL, V131, P1609, DOI 10.1083/jcb.131.6.1609; CROOKSTON KP, 1993, BIOCHEM J, V293, P443, DOI 10.1042/bj2930443; FITZGERALD DJ, 1995, J CELL BIOL, V129, P1533, DOI 10.1083/jcb.129.6.1533; FUKAI F, 1995, BIOCHEMISTRY-US, V34, P11453, DOI 10.1021/bi00036a018; GLIEMANN J, 1994, ANN NY ACAD SCI, V737, P20, DOI 10.1111/j.1749-6632.1994.tb44299.x; GODYNA S, 1995, J CELL BIOL, V129, P1403, DOI 10.1083/jcb.129.5.1403; GOLD LI, 1989, BIOCHEM J, V262, P529, DOI 10.1042/bj2620529; Hamik A, 1999, J BIOL CHEM, V274, P4962, DOI 10.1074/jbc.274.8.4962; Herz J, 2001, J CLIN INVEST, V108, P779, DOI 10.1172/JCI200113992; Hocking DC, 1998, J CELL BIOL, V141, P241, DOI 10.1083/jcb.141.1.241; HYNES RO, 1990, SPRINGER SERIES MOL, P200; Ilic D, 1998, J CELL BIOL, V143, P547; Kapila YL, 2002, J BIOL CHEM, V277, P8482, DOI 10.1074/jbc.M108932200; King WG, 1997, MOL CELL BIOL, V17, P4406, DOI 10.1128/MCB.17.8.4406; Knauer MF, 1997, J BIOL CHEM, V272, P29039, DOI 10.1074/jbc.272.46.29039; Koide A, 1998, J MOL BIOL, V284, P1141, DOI 10.1006/jmbi.1998.2238; KORNBLIHTT AR, 1985, EMBO J, V4, P1755, DOI 10.1002/j.1460-2075.1985.tb03847.x; KOUNNAS MZ, 1995, CELL, V82, P331, DOI 10.1016/0092-8674(95)90320-8; KOUNNAS MZ, 1995, J BIOL CHEM, V270, P9307, DOI 10.1074/jbc.270.16.9307; LAMARRE J, 1991, J CLIN INVEST, V87, P39, DOI 10.1172/JCI114998; Laukaitis CM, 2001, J CELL BIOL, V153, P1427, DOI 10.1083/jcb.153.7.1427; LAWSON MA, 1995, NATURE, V377, P75, DOI 10.1038/377075a0; Mikhailenko I, 1999, J CELL SCI, V112, P3269; MIKHAILENKO I, 1995, J BIOL CHEM, V270, P9543, DOI 10.1074/jbc.270.16.9543; MOLLA A, 1988, BIOCHIM BIOPHYS ACTA, V955, P77; MOSHER DF, 1984, ANNU REV MED, V35, P561, DOI 10.1146/annurev.me.35.020184.003021; MOSHER DF, 1991, ANN NY ACAD SCI, V614, P167; Okada SS, 1996, ARTERIOSCL THROM VAS, V16, P1269, DOI 10.1161/01.ATV.16.10.1269; Parsons JT, 1996, CURR OPIN CELL BIOL, V8, P146, DOI 10.1016/S0955-0674(96)80059-7; Pinson KI, 2000, NATURE, V407, P535, DOI 10.1038/35035124; Plump AS, 1999, ARTERIOSCL THROM VAS, V19, P1105, DOI 10.1161/01.ATV.19.4.1105; Rostagno AA, 1999, BIOCHEM J, V338, P375, DOI 10.1042/0264-6021:3380375; Rotundo RF, 1999, AM J PHYSIOL-GASTR L, V277, pG1189, DOI 10.1152/ajpgi.1999.277.6.G1189; RUOSLAHTI E, 1991, J CLIN INVEST, V87, P1, DOI 10.1172/JCI114957; RUOSLAHTI E, 1982, METHOD ENZYMOL, V82, P803; SCHWARZBAUER JE, 1991, BIOESSAYS, V13, P527, DOI 10.1002/bies.950131006; Schwarzbauer JE, 1999, CURR OPIN CELL BIOL, V11, P622, DOI 10.1016/S0955-0674(99)00017-4; Schwarzbauer JE, 1991, CURR OPIN CELL BIOL, V3, P786, DOI 10.1016/0955-0674(91)90051-Y; Short SM, 2000, J BIOL CHEM, V275, P12970, DOI 10.1074/jbc.275.17.12970; SKORSTENGAARD K, 1986, EUR J BIOCHEM, V154, P15, DOI 10.1111/j.1432-1033.1986.tb09353.x; STRICKLAND DK, 1991, J BIOL CHEM, V266, P13364; STRICKLAND DK, 1990, J BIOL CHEM, V265, P17401; Swertfeger DK, 2002, J BIOL CHEM, V277, P4141, DOI 10.1074/jbc.M109124200; Trommsdorff M, 1999, CELL, V97, P689, DOI 10.1016/S0092-8674(00)80782-5; Ulery PG, 2000, J BIOL CHEM, V275, P7410, DOI 10.1074/jbc.275.10.7410; WARSHAWSKY I, 1994, ANN NY ACAD SCI, V737, P70, DOI 10.1111/j.1749-6632.1994.tb44302.x; Watanabe K, 2000, BIOCHEMISTRY-US, V39, P7138, DOI 10.1021/bi992670r; Weaver AM, 1996, J BIOL CHEM, V271, P24894, DOI 10.1074/jbc.271.40.24894; Webb DJ, 2000, J CELL SCI, V113, P123; Webb DJ, 1999, J BIOL CHEM, V274, P7412, DOI 10.1074/jbc.274.11.7412; WILLNOW TE, 1994, J CELL SCI, V107, P719; Yamada KM, 1989, CURR OPIN CELL BIOL, V1, P956, DOI 10.1016/0955-0674(89)90065-3; YAMADA KM, 1983, ANNU REV BIOCHEM, V52, P761, DOI 10.1146/annurev.bi.52.070183.003553; Yang ZT, 2001, J BIOL CHEM, V276, P8403, DOI 10.1074/jbc.M008925200; ZHANG ZH, 1995, P NATL ACAD SCI USA, V92, P6161, DOI 10.1073/pnas.92.13.6161	66	35	36	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 3	2002	277	18					16160	16166		10.1074/jbc.M201401200	http://dx.doi.org/10.1074/jbc.M201401200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	550PA	11867643	hybrid			2022-12-27	WOS:000175510400125
J	Hertzog, M; Yarmola, EG; Didry, D; Bubb, MR; Carlier, MF				Hertzog, M; Yarmola, EG; Didry, D; Bubb, MR; Carlier, MF			Control of actin dynamics by proteins made of beta-thymosin repeats - The actobindin family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACANTHAMOEBA ACTOBINDIN; ARP2/3 COMPLEX; F-ACTIN; BINDING PROTEIN; LATRUNCULIN-A; POLYMERIZATION; PROFILIN; FILAMENT; MODULATION; PURIFICATION	Actobindin is an actin-binding protein from amoeba, which consists of two beta-thymosin repeats and has been shown to inhibit actin polymerization by sequestering G-actin and by stabilizing actin dimers. Here we show that actobindin has the same biochemical properties as the Drosophila or Caenorhabditis elegans homologous protein that consists of three beta-thymosin repeats. These proteins define a new family of actin-binding proteins. They bind G-actin in a 1:1 complex with thermodynamic and kinetic parameters similar to beta-thymosins. Like beta-thymosins, they slow down nucleotide exchange on G-actin and make a ternary complex with G-actin and Latrunculin A. On the other hand, they behave as functional homologs of profilin because their complex with MgATP-G-actin, unlike beta-thymosin-actin, participates in filament barbed end growth, like profilin-actin complex. Therefore these proteins play an active role in actin-based motility processes. In addition, proteins of the actobindin family interact with the pointed end of actin filaments and inhibit pointed end growth, maybe via the interaction of the beta-thymosin repeats with two terminal subunits.	CNRS, Lab Enzymol & Biochim Struct, F-91198 Gif Sur Yvette, France; Univ Florida, Div Rheumatol, Gainesville, FL 32608 USA	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; State University System of Florida; University of Florida	Carlier, MF (corresponding author), CNRS, Lab Enzymol & Biochim Struct, F-91198 Gif Sur Yvette, France.							Boquet I, 2000, CELL, V102, P797, DOI 10.1016/S0092-8674(00)00068-4; Boujemaa-Paterski R, 2001, BIOCHEMISTRY-US, V40, P11390, DOI 10.1021/bi010486b; BUBB MR, 1991, J BIOL CHEM, V266, P3820; BUBB MR, 1995, BIOCHEMISTRY-US, V34, P3921, DOI 10.1021/bi00012a008; BUBB MR, 1994, J BIOL CHEM, V269, P25592; BUBB MR, 1994, J BIOL CHEM, V269, P25587; CARLIER MF, 1993, P NATL ACAD SCI USA, V90, P5034, DOI 10.1073/pnas.90.11.5034; CARLIER MF, 1985, J BIOL CHEM, V260, P6565; CASELLA JF, 1986, J BIOL CHEM, V261, P915; CASSIMERIS L, 1992, J CELL BIOL, V119, P1261, DOI 10.1083/jcb.119.5.1261; COUE M, 1987, FEBS LETT, V213, P316, DOI 10.1016/0014-5793(87)81513-2; De La Cruz EM, 2000, BIOPHYS J, V78, P2516, DOI 10.1016/S0006-3495(00)76797-X; DETMERS P, 1981, J BIOL CHEM, V256, P99; Didry D, 1998, J BIOL CHEM, V273, P25602, DOI 10.1074/jbc.273.40.25602; Egile C, 1999, J CELL BIOL, V146, P1319, DOI 10.1083/jcb.146.6.1319; ELZINGA M, 1984, P NATL ACAD SCI-BIOL, V81, P6599, DOI 10.1073/pnas.81.21.6599; Higgs HN, 1999, J BIOL CHEM, V274, P32531, DOI 10.1074/jbc.274.46.32531; HUFF T, 1995, EUR J BIOCHEM, V230, P650; JEAN C, 1994, J MUSCLE RES CELL M, V15, P278; KOUYAMA T, 1981, EUR J BIOCHEM, V114, P33; LAMBOOY PK, 1986, J BIOL CHEM, V261, P7150; Malinda KM, 1997, FASEB J, V11, P474, DOI 10.1096/fasebj.11.6.9194528; Manuel M, 2000, J MOL EVOL, V51, P378, DOI 10.1007/s002390010100; Nachmias VT, 1993, CURR OPIN CELL BIOL, V5, P56, DOI 10.1016/S0955-0674(05)80008-0; PANTALONI D, 1993, CELL, V75, P1007, DOI 10.1016/0092-8674(93)90544-Z; PAUNOLA E, 2001, FEBS LETT, P1; PERELROIZEN I, 1995, J BIOL CHEM, V270, P1501, DOI 10.1074/jbc.270.4.1501; Perelroizen I, 1996, J BIOL CHEM, V271, P12302, DOI 10.1074/jbc.271.21.12302; SAFER D, 1991, J BIOL CHEM, V266, P4029; Safer D, 1997, BIOCHEMISTRY-US, V36, P5806, DOI 10.1021/bi970185v; SAFER D, 1994, BIOESSAYS, V16, P473, DOI 10.1002/bies.950160706; Safer D, 1997, CELL MOTIL CYTOSKEL, V38, P163, DOI 10.1002/(SICI)1097-0169(1997)38:2<163::AID-CM5>3.0.CO;2-8; SANGER JM, 1995, CELL MOTIL CYTOSKEL, V31, P305; Simenel C, 2000, EUR J BIOCHEM, V267, P3530, DOI 10.1046/j.1432-1327.2000.01380.x; Stoeva S, 1997, J PEPT SCI, V3, P282; VANCOMPERNOLLE K, 1992, EMBO J, V11, P4739, DOI 10.1002/j.1460-2075.1992.tb05579.x; VANCOMPERNOLLE K, 1991, J BIOL CHEM, V266, P15427; VANDEKERCKHOVE J, 1990, J BIOL CHEM, V265, P12801; WEBER A, 1994, BIOCHEMISTRY-US, V33, P4780, DOI 10.1021/bi00182a005; WEBER A, 1992, BIOCHEMISTRY-US, V31, P6179, DOI 10.1021/bi00142a002; Yarmola EG, 2001, J BIOL CHEM, V276, P45555, DOI 10.1074/jbc.M105723200; Yarmola EG, 2000, J BIOL CHEM, V275, P28120; YU FX, 1993, J BIOL CHEM, V268, P502	43	63	65	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 26	2002	277	17					14786	14792		10.1074/jbc.M112064200	http://dx.doi.org/10.1074/jbc.M112064200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	545EH	11856744	Green Submitted, hybrid			2022-12-27	WOS:000175203000057
J	Shen, JL; Montecino, M; Lian, JB; Stein, GS; van Wijnen, AJ; Stein, JL				Shen, JL; Montecino, M; Lian, JB; Stein, GS; van Wijnen, AJ; Stein, JL			Historic acetylation in vivo at the osteocalcin locus is functionally linked to vitamin D-dependent, bone tissue-specific transcription.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-DNA INTERACTIONS; CHROMATIN-STRUCTURE; PROMOTER ELEMENTS; GENE-EXPRESSION; RETINOIC ACID; UP-REGULATION; RECEPTOR; HYPERACETYLATION; ACTIVATION; HORMONE	The accessibility of regulatory elements in chromatin represents a principal rate-limiting parameter of gene transcription and is modulated by enzymatic transcriptional co-factors that alter the topology of chromatin or covalently modify histones (e.g. by acetylation). The bone-specific activation and 1,25-dihydroxyvitamin D-3 enhancement of osteocalcin (OC) gene transcription are both functionally linked to modifications in nucleosomal organization. The initiation of tissue-specific basal transcription is accompanied by the induction of two DNase I hypersensitive sites, and this chromatin remodeling event requires binding of the key osteogenic factor RUNX2/CBFA1 to the OC promoter. Here, we analyzed the acetylation status of histones H3 and H4 when the OC gene is active (in osteoblastic ROS17/2.8 cells) or inactive (in fibroblastic ROS24/1 cells) using chromatin immunoprecipitation assays. We find that acetylated histone H3 and H4 proteins are associated with the OC promoter only when the gene is transcriptionally active and that the acetylation status is relatively uniform across the OC locus under basal conditions. Acetylation of H4 at the OC gene is selectively increased following vitamin D3 enhancement of OC transcription, with the most prominent changes occurring in the region between the vitamin D3 enhancer and basal promoter. Thus, our results suggest functional linkage of H3 and H4 acetylation in specific regions of the OC promoter to chromatin remodeling that accompanies tissue-specific transcriptional activation and vitamin D enhancement of OC gene expression. These findings provide mechanistic insights into bone-specific gene activation within a native genomic context in response to steroid hormone-related regulatory cues.	Univ Massachusetts, Sch Med, Dept Cell Biol, Worcester, MA 01655 USA; Univ Concepcion, Dept Mol Biol, Concepcion, Chile	University of Massachusetts System; University of Massachusetts Worcester; Universidad de Concepcion	Stein, JL (corresponding author), Univ Massachusetts, Sch Med, Dept Cell Biol, 55 Lake Ave N, Worcester, MA 01655 USA.	janet.stein@umassmed.edu	van Wijnen, Andre J./AAG-3578-2019	van Wijnen, Andre J./0000-0002-4458-0946	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR045689, R01AR039588] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R37DE012528] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE012528] Funding Source: NIH RePORTER; FIC NIH HHS [TW00990] Funding Source: Medline; NIAMS NIH HHS [AR39588, AR45689] Funding Source: Medline; NIDCR NIH HHS [DE12528] Funding Source: Medline; NIDDK NIH HHS [DK52320] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aalfs JD, 2000, TRENDS BIOCHEM SCI, V25, P548, DOI 10.1016/S0968-0004(00)01689-3; Agalioti T, 2000, CELL, V103, P667, DOI 10.1016/S0092-8674(00)00169-0; Alberts AS, 1998, CELL, V92, P475, DOI 10.1016/S0092-8674(00)80941-1; ALLFREY VG, 1964, P NATL ACAD SCI USA, V51, P786, DOI 10.1073/pnas.51.5.786; Aubin JE, 1998, J CELL BIOCHEM, P73, DOI 10.1002/(SICI)1097-4644(1998)72:30/31+<73::AID-JCB11>3.0.CO;2-L; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; BARAN DT, 1991, J BONE MINER RES, V6, P1269; Braunstein M, 1996, MOL CELL BIOL, V16, P4349; BREEN EC, 1994, P NATL ACAD SCI USA, V91, P12902, DOI 10.1073/pnas.91.26.12902; Chen HW, 1999, CELL, V98, P675, DOI 10.1016/S0092-8674(00)80054-9; CHESKIS B, 1994, MOL CELL BIOL, V14, P3329, DOI 10.1128/MCB.14.5.3329; Christenson LK, 2001, J BIOL CHEM, V276, P27392, DOI 10.1074/jbc.M101650200; DEMAY MB, 1990, P NATL ACAD SCI USA, V87, P369, DOI 10.1073/pnas.87.1.369; DEMAY MB, 1989, J BIOL CHEM, V264, P2279; Emiliani S, 1998, P NATL ACAD SCI USA, V95, P2795, DOI 10.1073/pnas.95.6.2795; Fry CJ, 2001, CURR BIOL, V11, pR185, DOI 10.1016/S0960-9822(01)00090-2; Gilbert SL, 1999, P NATL ACAD SCI USA, V96, P13825, DOI 10.1073/pnas.96.24.13825; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; Gui CY, 2001, MOL CELL BIOL, V21, P1155, DOI 10.1128/MCB.21.4.1155-1163.2001; Guo B, 1997, P NATL ACAD SCI USA, V94, P121, DOI 10.1073/pnas.94.1.121; Hassan AH, 2001, CELL, V104, P817, DOI 10.1016/S0092-8674(01)00279-3; HEBBES TR, 1994, EMBO J, V13, P1823, DOI 10.1002/j.1460-2075.1994.tb06451.x; Hendzel MJ, 1997, CHROMOSOMA, V106, P348, DOI 10.1007/s004120050256; Javed A, 1999, MOL CELL BIOL, V19, P7491; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; KLIEWER SA, 1992, NATURE, V355, P446, DOI 10.1038/355446a0; Lian JB, 1999, VITAM HORM, V55, P443; Lian JB, 1998, BIOCHEM SOC T, V26, P14, DOI 10.1042/bst0260014; LIN R, 1989, J CELL BIOL, V108, P1577, DOI 10.1083/jcb.108.5.1577; MACDONALD PN, 1993, MOL CELL BIOL, V13, P5907, DOI 10.1128/MCB.13.9.5907; MAJESKA RJ, 1980, ENDOCRINOLOGY, V107, P1494, DOI 10.1210/endo-107-5-1494; MARKOSE ER, 1990, P NATL ACAD SCI USA, V87, P1701, DOI 10.1073/pnas.87.5.1701; Mizzen CA, 1996, CELL, V87, P1261, DOI 10.1016/S0092-8674(00)81821-8; Montecino M, 1999, BIOCHEMISTRY-US, V38, P1338, DOI 10.1021/bi982171a; Montecino M, 1996, BIOCHEMISTRY-US, V35, P5093, DOI 10.1021/bi952489s; MONTECINO M, 1994, BIOCHEMISTRY-US, V33, P348, DOI 10.1021/bi00167a045; MORRISON NA, 1989, SCIENCE, V246, P1158, DOI 10.1126/science.2588000; Nagata T, 1999, NAT STRUCT BIOL, V6, P615; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; OWEN TA, 1990, J CELL PHYSIOL, V143, P420, DOI 10.1002/jcp.1041430304; OWEN TA, 1991, ENDOCRINOLOGY, V128, P1496, DOI 10.1210/endo-128-3-1496; OWEN TA, 1993, P NATL ACAD SCI USA, V90, P1503, DOI 10.1073/pnas.90.4.1503; PERRY CA, 1993, BIOCHEMISTRY-US, V32, P13615, DOI 10.1021/bi00212a029; Peterson CL, 2000, CURR OPIN GENET DEV, V10, P187, DOI 10.1016/S0959-437X(00)00068-X; Rachez C, 2000, GENE, V246, P9, DOI 10.1016/S0378-1119(00)00052-4; RODAN SB, 1986, J BONE MINER RES, V1, P213; Sambucetti LC, 1999, J BIOL CHEM, V274, P34940, DOI 10.1074/jbc.274.49.34940; Spencer VA, 1999, GENE, V240, P1, DOI 10.1016/S0378-1119(99)00405-9; Staal A, 1996, MOL ENDOCRINOL, V10, P1444, DOI 10.1210/me.10.11.1444; Stein GS, 1996, PHYSIOL REV, V76, P593, DOI 10.1152/physrev.1996.76.2.593; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Taunton J, 1996, SCIENCE, V272, P408, DOI 10.1126/science.272.5260.408; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.bi.63.070194.002315; Urnov FD, 2001, ONCOGENE, V20, P2991, DOI 10.1038/sj.onc.1204323; Vitolo JM, 2000, MOL CELL BIOL, V20, P2167, DOI 10.1128/MCB.20.6.2167-2175.2000; Wei Y, 1999, CELL, V97, P99, DOI 10.1016/S0092-8674(00)80718-7; WOLFE SA, 1989, BIOCHIM BIOPHYS ACTA, V1007, P140, DOI 10.1016/0167-4781(89)90032-8; Wolffe AP, 2000, J STRUCT BIOL, V129, P102, DOI 10.1006/jsbi.2000.4217	59	62	64	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 7	2002	277	23					20284	20292		10.1074/jbc.M112440200	http://dx.doi.org/10.1074/jbc.M112440200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	562NJ	11893738	hybrid			2022-12-27	WOS:000176204500026
J	Smith, GAM; Tsui, HW; Newell, EW; Jiang, XP; Zhu, XP; Tsui, FWL; Schlichter, LC				Smith, GAM; Tsui, HW; Newell, EW; Jiang, XP; Zhu, XP; Tsui, FWL; Schlichter, LC			Functional up-regulation of HERG K+ channels in neoplastic hematopoietic cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG QT SYNDROME; POTASSIUM CHANNEL; CARDIAC-ARRHYTHMIA; VOLUME REGULATION; T-LYMPHOCYTES; NEURONAL DEVELOPMENT; NEUROBLASTOMA-CELLS; MOUSE FIBROBLASTS; RAT LACTOTROPHS; LEUKEMIA-CELLS	Kv1.3 channels regulate proliferation of normal lymphocytes, but the role of voltage-gated potassium channels in transformed hematopoietic cells is not known. We examined transcripts for Kv1.3, h-erg, h-eag, and BEC1 genes in primary lymphocytes and leukemias and in several hematopoietic cell lines. Surprisingly, BEC1, formerly thought to be brain-specific, was present in all the primary leukemias examined, in resting peripheral blood lymphocytes, and in proliferating activated tonsillar cells, lymphocytes from Sjogren's patients, and Epstein-Barr virus-transformed B-cells. Only h-erg mRNA was up-regulated in the cancer cells, but this was not due to proliferation per se, because it was not elevated in any of the proliferating noncancerous lymphocyte types examined. Nor did h-erg transcript levels correlate with the B-cell subset, because it was elevated in immature neoplastic B-CLL cells (CD5(+)) and in a CD5(-) Burkitt's lymphoma cell line (Raji) but not in Sjogren's syndrome cells (enriched in CD5(+) B-cells) or Epstein-Barr virus-transformed B-cells, which are mature CD5(-) B-cells. The protein and whole cell current levels roughly corresponded with the amount of mRNA expressed in three hematopoietic cell lines: CEM (an acute lymphoblastic leukemic line), K562 (a chronic myelogenous leukemic line), and U937 (an acute promyelocytic leukemic line). The selective HERG channel blocker, E-4031, reduced proliferation of CEM, U937, and K562 cells, and this appears to be the first direct evidence of a functional role for the HERG current in cancer cells. Selective up-regulation of h-erg appears to occur in neoplastic hematopoietic cells, thus providing a marker and potential therapeutic target.	Toronto Western Res Inst, Div Cellular & Mol Biol, Toronto, ON M5T 2S8, Canada; Univ Toronto, Dept Physiol, Toronto, ON M5S 1A8, Canada; Univ Toronto, Dept Immunol, Toronto, ON M5S 1A8, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University of Toronto	Schlichter, LC (corresponding author), Toronto Western Res Inst, Div Cellular & Mol Biol, 399 Bathurst St, Toronto, ON M5T 2S8, Canada.		Newell, Evan W/F-9711-2012	Newell, Evan W/0000-0002-2889-243X				Ackerman MJ, 1997, NEW ENGL J MED, V336, P1575, DOI 10.1056/NEJM199705293362207; Arcangeli A, 1999, J NEUROBIOL, V40, P214; Arcangeli A, 1997, EUR J NEUROSCI, V9, P2596, DOI 10.1111/j.1460-9568.1997.tb01689.x; Arcangeli A, 1995, J PHYSIOL-LONDON, V489, P455, DOI 10.1113/jphysiol.1995.sp021065; Avdonin V, 1998, P NATL ACAD SCI USA, V95, P11703, DOI 10.1073/pnas.95.20.11703; Barros F, 1998, J PHYSIOL-LONDON, V511, P333, DOI 10.1111/j.1469-7793.1998.333bh.x; Bauer CK, 1999, MOL CELL ENDOCRINOL, V148, P37, DOI 10.1016/S0303-7207(98)00241-X; Beeton C, 2001, P NATL ACAD SCI USA, V98, P13942, DOI 10.1073/pnas.241497298; Bianchi L, 1998, CANCER RES, V58, P815; Bruggemann A, 1997, P NATL ACAD SCI USA, V94, P537, DOI 10.1073/pnas.94.2.537; Cabado AG, 2000, CELL SIGNAL, V12, P573, DOI 10.1016/S0898-6568(00)00101-7; Cahalan MD, 2001, J CLIN IMMUNOL, V21, P235, DOI 10.1023/A:1010958907271; CAYABYAB FS, 2002, J BIOL CHEM     0207; Cherubini A, 2000, BRIT J CANCER, V83, P1722, DOI 10.1054/bjoc.2000.1497; Chiesa N, 1997, J PHYSIOL-LONDON, V501, P313, DOI 10.1111/j.1469-7793.1997.313bn.x; Cui J, 2000, CURR BIOL, V10, P671, DOI 10.1016/S0960-9822(00)00516-9; CURRAN ME, 1995, CELL, V80, P795, DOI 10.1016/0092-8674(95)90358-5; Decker K, 1998, N-S ARCH PHARMACOL, V357, P378, DOI 10.1007/PL00005182; DECOURSEY TE, 1999, INFLAMMATION BASIC P, P639; DEUTSCH C, 1993, P NATL ACAD SCI USA, V90, P10036, DOI 10.1073/pnas.90.21.10036; DIGHIERO G, 1991, BLOOD, V78, P581; DRAHEIM HJ, 1995, BBA-MOL CELL RES, V1269, P57, DOI 10.1016/0167-4889(95)00106-3; DUBOIS JM, 1993, PROG BIOPHYS MOL BIO, V59, P1, DOI 10.1016/0079-6107(93)90005-5; Emmi A, 2000, J NEUROSCI, V20, P3915, DOI 10.1523/JNEUROSCI.20-10-03915.2000; Ficker E, 2001, MOL PHARMACOL, V60, P1343, DOI 10.1124/mol.60.6.1343; Furutani M, 1999, CIRCULATION, V99, P2290, DOI 10.1161/01.CIR.99.17.2290; GRINSTEIN S, 1990, ANNU REV PHYSIOL, V52, P399; Hofmann G, 2001, J BIOL CHEM, V276, P4923, DOI 10.1074/jbc.M005682200; HUANG Y, 1994, J BIOL CHEM, V269, P31183; Jones LJ, 2001, J IMMUNOL METHODS, V254, P85, DOI 10.1016/S0022-1759(01)00404-5; KAPURAL L, 1995, BLOOD, V86, P1043; Khanna R, 2001, AM J PHYSIOL-CELL PH, V280, pC796, DOI 10.1152/ajpcell.2001.280.4.C796; Khanna R, 1999, J BIOL CHEM, V274, P14838, DOI 10.1074/jbc.274.21.14838; Kiehn J, 1999, AM J PHYSIOL-HEART C, V277, pH199, DOI 10.1152/ajpheart.1999.277.1.H199; Koo GC, 1997, J IMMUNOL, V158, P5120; Kotecha SA, 1999, J NEUROSCI, V19, P10680, DOI 10.1523/JNEUROSCI.19-24-10680.1999; LEWIS RS, 1995, ANNU REV IMMUNOL, V13, P623, DOI 10.1146/annurev.iy.13.040195.003203; LU L, 1993, J MEMBRANE BIOL, V132, P267; Miyake A, 1999, J BIOL CHEM, V274, P25018, DOI 10.1074/jbc.274.35.25018; Nerbonne JM, 1998, J NEUROBIOL, V37, P37, DOI 10.1002/(SICI)1097-4695(199810)37:1<37::AID-NEU4>3.0.CO;2-9; NILIUS B, 1994, NEWS PHYSIOL SCI, V9, P105; NILIUS B, 1992, J PHYSIOL-LONDON, V445, P537, DOI 10.1113/jphysiol.1992.sp018938; Pardo LA, 1999, EMBO J, V18, P5540, DOI 10.1093/emboj/18.20.5540; Pardo LA, 1998, J CELL BIOL, V143, P767, DOI 10.1083/jcb.143.3.767; PRICE M, 1989, P NATL ACAD SCI USA, V86, P10171, DOI 10.1073/pnas.86.24.10171; Reed JC, 1997, SEMIN HEMATOL, V34, P9; REPP H, 1993, P NATL ACAD SCI USA, V90, P3403, DOI 10.1073/pnas.90.8.3403; Sanguinetti MC, 1997, NEUROPHARMACOLOGY, V36, P755, DOI 10.1016/S0028-3908(97)00029-4; SANGUINETTI MC, 1995, CELL, V81, P299, DOI 10.1016/0092-8674(95)90340-2; Schafer R, 1999, J PHYSIOL-LONDON, V518, P401, DOI 10.1111/j.1469-7793.1999.0401p.x; SCHLICHTER L, 1986, P NATL ACAD SCI USA, V83, P451, DOI 10.1073/pnas.83.2.451; Schonherr R, 1999, EUR J NEUROSCI, V11, P753, DOI 10.1046/j.1460-9568.1999.00493.x; Schwarz J R, 1999, Ross Fiziol Zh Im I M Sechenova, V85, P195; Shi WM, 1997, J NEUROSCI, V17, P9423; Skryma RN, 1997, PROSTATE, V33, P112, DOI 10.1002/(SICI)1097-0045(19971001)33:2<112::AID-PROS5>3.0.CO;2-M; Smith JS, 2001, J NEUROSCI, V21, P1096; Smith PL, 1996, NATURE, V379, P833, DOI 10.1038/379833a0; Spector PS, 1996, CIRC RES, V78, P499, DOI 10.1161/01.RES.78.3.499; Spector PS, 1996, J GEN PHYSIOL, V107, P611, DOI 10.1085/jgp.107.5.611; Szabo I, 1996, J BIOL CHEM, V271, P20465, DOI 10.1074/jbc.271.34.20465; TEULON J, 1992, J CELL PHYSIOL, V151, P113, DOI 10.1002/jcp.1041510116; Titus SA, 1997, J NEUROSCI, V17, P875; Voutsadakis IA, 2000, ACTA ONCOL, V39, P151, DOI 10.1080/028418600430707; Wang L, 1997, AM J PHYSIOL-CELL PH, V273, pC1657, DOI 10.1152/ajpcell.1997.273.5.C1657; Wang SM, 1997, J PHYSIOL-LONDON, V502, P45, DOI 10.1111/j.1469-7793.1997.045bl.x; Wonderlin WF, 1996, J MEMBRANE BIOL, V154, P91, DOI 10.1007/s002329900135; Wymore RS, 1997, CIRC RES, V80, P261, DOI 10.1161/01.RES.80.2.261; Xu B, 1996, AM J PHYSIOL-CELL PH, V271, pC2037, DOI 10.1152/ajpcell.1996.271.6.C2037; Xu DZ, 1999, BLOOD, V94, P139, DOI 10.1182/blood.V94.1.139.413k11_139_145; Yoshida Hideaki, 2000, Hokkaido Journal of Medical Science, V75, P375; Zhou W, 1998, J GEN PHYSIOL, V111, P781, DOI 10.1085/jgp.111.6.781; Zhou ZF, 1998, J BIOL CHEM, V273, P21061, DOI 10.1074/jbc.273.33.21061; Zigrino P, 1996, BIOCHEM BIOPH RES CO, V221, P51, DOI 10.1006/bbrc.1996.0543	73	165	178	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 24	2002	277	21					18528	18534		10.1074/jbc.M200592200	http://dx.doi.org/10.1074/jbc.M200592200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	558PM	11893742	hybrid			2022-12-27	WOS:000175975800038
J	Bottcher, B; Scheide, D; Hesterberg, M; Nagel-Steger, L; Friedrich, T				Bottcher, B; Scheide, D; Hesterberg, M; Nagel-Steger, L; Friedrich, T			A novel, enzymatically active conformation of the Escherichia coli NADH : ubiquinone oxidoreductase (complex I)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTON-TRANSLOCATING NADH; MITOCHONDRIAL NADH; NADHUBIQUINONE-OXIDOREDUCTASE; 3-DIMENSIONAL STRUCTURE; ELECTRON-MICROSCOPY; MEMBRANE; DEHYDROGENASE; SUBUNIT; GENERATION; PROTEINS	Electron microscopy has demonstrated the unusual L-shaped structure of the respiratory complex I consisting of two arms, which are arranged perpendicular to each other. We found that the Escherichia coli complex I has an additional stable conformation, with the two arms arranged side by side, resulting in a horseshoe-shaped structure. The structure of both conformations was determined by means of electron microscopy of gold thioglucose-stained single particles. They were distinguished from each other by titration of the complex with polyethylene glycol and by means of analytical ultracentrifugation. The transition between the two conformations is induced by the ionic strength of the buffer and is reversible. Only the horseshoe-shaped complex I exhibits enzyme activity in detergent solution, which is abolished by the addition of salt. Therefore, it is proposed that this structure is the native conformation of the complex in the membrane.	European Mol Biol Lab, Struct Biol & Biocomp Programme, D-69117 Heidelberg, Germany; Univ Dusseldorf, Inst Phys Biol, D-40225 Dusseldorf, Germany	European Molecular Biology Laboratory (EMBL); Heinrich Heine University Dusseldorf	Friedrich, T (corresponding author), Univ Freiburg, Inst Org Chem & Biochem, Albertstr 21, D-79104 Freiburg, Germany.	tfriedri@uni-freiburg.de	Bottcher, Bettina/E-9397-2010; Nagel-Steger, Luitgard/H-6415-2013	Bottcher, Bettina/0000-0002-7962-4849; Nagel-Steger, Luitgard/0000-0001-5232-2149				BLOOMFIE.V, 1967, BIOPOLYMERS, V5, P135, DOI 10.1002/bip.1967.360050202; Brandt U, 1997, BBA-BIOENERGETICS, V1318, P79, DOI 10.1016/S0005-2728(96)00141-7; Buchanan SK, 1996, BIOCHEM J, V318, P343, DOI 10.1042/bj3180343; Crowther RA, 1996, J STRUCT BIOL, V116, P9, DOI 10.1006/jsbi.1996.0003; Djafarzadeh R, 2000, BBA-BIOENERGETICS, V1459, P230, DOI 10.1016/S0005-2728(00)00154-7; Dupuis A, 2001, J BIOENERG BIOMEMBR, V33, P159, DOI 10.1023/A:1010770600418; Fearnley IM, 2001, J BIOL CHEM, V276, P38345, DOI 10.1074/jbc.C100444200; FRIEDRICH T, 1989, EUR J BIOCHEM, V180, P173, DOI 10.1111/j.1432-1033.1989.tb14629.x; Friedrich T, 1997, J THEOR BIOL, V187, P529, DOI 10.1006/jtbi.1996.0387; Friedrich T, 1998, BBA-BIOENERGETICS, V1364, P134, DOI 10.1016/S0005-2728(98)00024-3; FRIEDRICH T, 1995, FEBS LETT, V367, P107, DOI 10.1016/0014-5793(95)00548-N; Friedrich T, 2001, J BIOENERG BIOMEMBR, V33, P169, DOI 10.1023/A:1010722717257; Friedrich T, 2000, FEBS LETT, V479, P1, DOI 10.1016/S0014-5793(00)01867-6; Grigorieff N, 1998, J MOL BIOL, V277, P1033, DOI 10.1006/jmbi.1998.1668; Grigorieff N, 1999, CURR OPIN STRUC BIOL, V9, P476, DOI 10.1016/S0959-440X(99)80067-0; Grivennikova VG, 2001, J BIOL CHEM, V276, P9038, DOI 10.1074/jbc.M009661200; Guenebaut V, 1997, J MOL BIOL, V265, P409, DOI 10.1006/jmbi.1996.0753; Guenebaut V, 1998, J MOL BIOL, V276, P105, DOI 10.1006/jmbi.1997.1518; HOFHAUS G, 1991, J MOL BIOL, V221, P1027, DOI 10.1016/0022-2836(91)80190-6; HOPPER EA, 1999, THESIS U PENNSYLVANI; Ito M, 2001, FEBS LETT, V496, P117, DOI 10.1016/S0014-5793(01)02417-6; LEIF H, 1995, EUR J BIOCHEM, V230, P538, DOI 10.1111/j.1432-1033.1995.tb20594.x; LEONARD K, 1987, J MOL BIOL, V194, P277, DOI 10.1016/0022-2836(87)90375-5; Lustig A, 2000, BBA-BIOMEMBRANES, V1464, P199, DOI 10.1016/S0005-2736(99)00254-0; Musatov A, 2000, BIOCHEMISTRY-US, V39, P12996, DOI 10.1021/bi000884z; Rasmussen T, 2001, BIOCHEMISTRY-US, V40, P6124, DOI 10.1021/bi0026977; REYNOLDS JA, 1976, P NATL ACAD SCI USA, V73, P4467, DOI 10.1073/pnas.73.12.4467; Sazanov LA, 2000, J MOL BIOL, V302, P455, DOI 10.1006/jmbi.2000.4079; Schulte U, 1999, J MOL BIOL, V292, P569, DOI 10.1006/jmbi.1999.3096; Schulte U, 1995, METHOD ENZYMOL, V260, P3, DOI 10.1016/0076-6879(95)60126-0; Spehr V, 1999, BIOCHEMISTRY-US, V38, P16261, DOI 10.1021/bi9919605; Steuber J, 2000, MOL MICROBIOL, V35, P428, DOI 10.1046/j.1365-2958.2000.01712.x; Tersteegen A, 1999, EUR J BIOCHEM, V264, P930, DOI 10.1046/j.1432-1327.1999.00692.x; VANHEEL M, 1984, ULTRAMICROSCOPY, V13, P165, DOI 10.1016/0304-3991(84)90066-4; vanHeel M, 1996, J STRUCT BIOL, V116, P17, DOI 10.1006/jsbi.1996.0004; VANHOLDE KE, 1978, BIOPOLYMERS, V17, P1387, DOI 10.1002/bip.1978.360170602; Vinogradov AD, 1998, BBA-BIOENERGETICS, V1364, P169, DOI 10.1016/S0005-2728(98)00026-7; WALKER JE, 1992, Q REV BIOPHYS, V25, P253, DOI 10.1017/S003358350000425X; WEIDNER U, 1993, J MOL BIOL, V233, P109, DOI 10.1006/jmbi.1993.1488; WEISS H, 1991, EUR J BIOCHEM, V197, P563, DOI 10.1111/j.1432-1033.1991.tb15945.x; YAGI T, 1998, BIOCHIM BIOPHYS ACTA, V1364, P112	41	82	84	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 17	2002	277	20					17970	17977		10.1074/jbc.M112357200	http://dx.doi.org/10.1074/jbc.M112357200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	553PR	11880370	hybrid			2022-12-27	WOS:000175685100074
J	Burgess, HA; Reiner, O				Burgess, HA; Reiner, O			Alternative splice variants of doublecortin-like kinase are differentially expressed and have different kinase activities	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; CALPAIN-MEDIATED PROTEOLYSIS; TRACT-BINDING-PROTEIN; RNA-BINDING; RAT HIPPOCAMPUS; GENE STRUCTURE; MESSENGER-RNA; MU-CALPAIN; AUTOINHIBITION; KIAA0369	Alternative splicing of mRNA transcripts expands the range of protein products from a single gene locus. Several splice variants of DCLK (doublecortin-like kinase) have previously been reported. Here, we report the genomic organization underlying the splice variants of DCLK and examine the expression profile of two splice variants affecting the kinase domain of DCLK and CPG16 (candidate plasticity gene 16), one containing an Arg-rich domain and the other affecting the C terminus of the protein. These splice alternatives were differentially expressed in embryonic and adult brain. Both splice variants disrupted DCLK PEST domains; however, all splice variants remained sensitive to proteolysis by calpain. The adult-specific C-terminal splice variant of DCLK had reduced autophosphorylation activity, but similar kinase activity for myelin basic protein relative to the embryonic splice variant. The splice variant adding an Arg-rich domain gained an autophosphorylation site at Ser-382. Although this protein isoform was expressed mainly in the adult brain, the phosphorylated form was strongly enriched in embryonic brain and adult olfactory bulb, suggesting a possible role in migrating neurons.	Weizmann Inst Sci, Dept Mol Genet, IL-76100 Rehovot, Israel	Weizmann Institute of Science	Reiner, O (corresponding author), Weizmann Inst Sci, Dept Mol Genet, Herzl 2, IL-76100 Rehovot, Israel.	Orly.Reiner@weizmann.ac.il	Reiner, Orly/E-9455-2010; Burgess, Harold/B-8474-2015	Reiner, Orly/0000-0001-7560-9599; Burgess, Harold/0000-0003-1966-7801				AMARA SG, 1982, NATURE, V298, P240, DOI 10.1038/298240a0; Batzoglou S, 2000, GENOME RES, V10, P950, DOI 10.1101/gr.10.7.950; Berke JD, 1998, J NEUROSCI, V18, P5301, DOI 10.1523/JNEUROSCI.18-14-05301.1998; Burgess HA, 2001, J BIOL CHEM, V276, P36397, DOI 10.1074/jbc.M105153200; Burgess HA, 1999, J NEUROSCI RES, V58, P567, DOI 10.1002/(SICI)1097-4547(19991115)58:4<567::AID-JNR9>3.3.CO;2-K; Burgess HA, 2000, MOL CELL NEUROSCI, V16, P529, DOI 10.1006/mcne.2000.0891; CACERES JF, 1994, SCIENCE, V265, P1706, DOI 10.1126/science.8085156; Carillo S, 1996, BIOCHEM J, V313, P245, DOI 10.1042/bj3130245; Cegielska A, 1998, J BIOL CHEM, V273, P1357, DOI 10.1074/jbc.273.3.1357; Chou MY, 2000, MOL CELL, V5, P949, DOI 10.1016/S1097-2765(00)80260-9; Decatur AL, 2000, SCIENCE, V290, P992, DOI 10.1126/science.290.5493.992; Francis SH, 1996, J BIOL CHEM, V271, P20748, DOI 10.1074/jbc.271.34.20748; Goldberg J, 1996, CELL, V84, P875, DOI 10.1016/S0092-8674(00)81066-1; Gonczy P, 2001, DEV CELL, V1, P363, DOI 10.1016/S1534-5807(01)00046-6; Groenen PJTA, 2000, HUM MOL GENET, V9, P605, DOI 10.1093/hmg/9.4.605; Hirano F, 1998, MOL CELL BIOL, V18, P2596, DOI 10.1128/MCB.18.5.2596; Jensen KB, 2000, NEURON, V25, P359, DOI 10.1016/S0896-6273(00)80900-9; Kan ZY, 2001, GENOME RES, V11, P889, DOI 10.1101/gr.155001; KOBAYASHI Y, 1990, P NATL ACAD SCI USA, V87, P5548, DOI 10.1073/pnas.87.14.5548; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Lazaridis KN, 2000, P NATL ACAD SCI USA, V97, P11092, DOI 10.1073/pnas.200325297; Lin PT, 2000, J NEUROSCI, V20, P9152; Lopez AJ, 1998, ANNU REV GENET, V32, P279, DOI 10.1146/annurev.genet.32.1.279; Matsumoto N, 1999, GENOMICS, V56, P179, DOI 10.1006/geno.1998.5673; Mironov AA, 1999, GENOME RES, V9, P1288, DOI 10.1101/gr.9.12.1288; Mizuguchi M, 1999, AM J PATHOL, V155, P1713, DOI 10.1016/S0002-9440(10)65486-7; MOLINARI M, 1995, J BIOL CHEM, V270, P2032, DOI 10.1074/jbc.270.5.2032; MOLINARI M, 1995, J BIOL CHEM, V270, P14576, DOI 10.1074/jbc.270.24.14576; Omori Y, 1998, J HUM GENET, V43, P169, DOI 10.1007/s100380050063; Petersen-Mahrt SK, 1999, EMBO J, V18, P1014, DOI 10.1093/emboj/18.4.1014; Polydorides AD, 2000, P NATL ACAD SCI USA, V97, P6350, DOI 10.1073/pnas.110128397; PoteetSmith CE, 1997, J BIOL CHEM, V272, P379; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; Shumway SD, 1999, J BIOL CHEM, V274, P30874, DOI 10.1074/jbc.274.43.30874; SILVA AJ, 1992, SCIENCE, V257, P201, DOI 10.1126/science.1378648; Silverman MA, 1999, J BIOL CHEM, V274, P2631, DOI 10.1074/jbc.274.5.2631; Sossey-Alaoui K, 1999, GENOMICS, V56, P121, DOI 10.1006/geno.1998.5718; STAMM S, 1994, NUCLEIC ACIDS RES, V22, P1515, DOI 10.1093/nar/22.9.1515; Sultana T, 2000, ENDOCRINOLOGY, V141, P4413, DOI 10.1210/en.141.12.4413; Tokumitsu H, 1999, J BIOL CHEM, V274, P15803, DOI 10.1074/jbc.274.22.15803; Vreugdenhil E, 2001, MOL BRAIN RES, V94, P67, DOI 10.1016/S0169-328X(01)00213-3; Vreugdenhil E, 1999, J NEUROBIOL, V39, P41, DOI 10.1002/(SICI)1097-4695(199904)39:1<41::AID-NEU4>3.0.CO;2-X; Wakamatsu Y, 1997, DEVELOPMENT, V124, P3449; WANG KKW, 1989, BIOCHEM J, V262, P693, DOI 10.1042/bj2620693; WANG KKW, 1989, BIOCHEM CELL BIOL, V67, P703, DOI 10.1139/o89-105; WANG KKW, 1988, ARCH BIOCHEM BIOPHYS, V267, P317, DOI 10.1016/0003-9861(88)90037-9; Wei N, 1997, RNA, V3, P1275; Xie HQ, 1998, J NEUROSCI RES, V53, P153, DOI 10.1002/(SICI)1097-4547(19980715)53:2<153::AID-JNR4>3.3.CO;2-5; Xie JY, 2001, NATURE, V410, P936, DOI 10.1038/35073593	49	55	58	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 17	2002	277	20					17696	17705		10.1074/jbc.M111981200	http://dx.doi.org/10.1074/jbc.M111981200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	553PR	11884394	hybrid			2022-12-27	WOS:000175685100040
J	Carozzi, AJ; Roy, S; Morrow, IC; Pol, A; Wyse, B; Clyde-Smith, J; Prior, IA; Nixon, SJ; Hancock, JF; Parton, RG				Carozzi, AJ; Roy, S; Morrow, IC; Pol, A; Wyse, B; Clyde-Smith, J; Prior, IA; Nixon, SJ; Hancock, JF; Parton, RG			Inhibition of lipid raft-dependent signaling by a dystrophy-associated mutant of caveolin-3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GIRDLE MUSCULAR-DYSTROPHY; DEVELOPING T-TUBULES; PLASMA-MEMBRANE; SKELETAL-MUSCLE; H-RAS; GLYCOPROTEIN COMPLEX; FREE-CHOLESTEROL; BINDING PROTEIN; GOLGI-COMPLEX; N-RAS	Specific point mutations in caveolin-3, a predominantly muscle-specific member of the caveolin family, have been implicated in limb-girdle muscular dystrophy and in rippling muscle disease. We examined the effect of these mutations on caveolin-3 localization and function. Using two independent assay systems, Raf activation in fibroblasts and neurite extension in PC12 cells, we show that one of the caveolin-3 point mutants, caveolin-3-C71W, specifically inhibits signaling by activated H-Ras but not by K-Ras. To gain insights into the effect of the mutant protein on H-Ras signaling, we examined the localization of the mutant proteins in fibroblastic cells and in differentiating myotubes. Unlike the previously characterized caveolin-3-DGV mutant, the inhibitory caveolin-3-C71W mutant reached the plasma membrane and colocalized with wild type caveolins. In BHK cells, caveolin-3-C71W associated with caveolae and in differentiating muscle cells with the developing T-tubule system. In contrast, the caveolin-3-P104L mutant accumulated in the Golgi complex and had no effect on H-Ras-mediated Raf activation. Inhibition by caveolin-3-C71W was rescued by cholesterol addition, suggesting that the mutant protein perturbs cholesterol-rich raft domains. Thus, we have demonstrated that a naturally occurring caveolin-3 mutation can inhibit signaling involving cholesterol-sensitive raft domains.	Univ Queensland, Ctr Microscopy & Microanal, Inst Mol Biosci, Brisbane, Qld 4072, Australia; Univ Queensland, Sch Biomed Sci, Brisbane, Qld 4072, Australia; Univ Queensland, Sch Med, Dept Pathol, Queenslanbd Canc Fund Lab Expt Oncol, Brisbane, Qld 4006, Australia	University of Queensland; University of Queensland; University of Queensland	Parton, RG (corresponding author), Univ Queensland, Ctr Microscopy & Microanal, Inst Mol Biosci, Brisbane, Qld 4072, Australia.		Parton, Robert G/C-5673-2009; Morrow, Isabel/E-8632-2012; Pol, Albert/M-1865-2014; Clyde-Smith, Jodi/R-8910-2016; Nixon, Susan/D-4588-2017	Parton, Robert G/0000-0002-7494-5248; Pol, Albert/0000-0002-1750-1085; Clyde-Smith, Jodi/0000-0001-9798-9924; Prior, Ian/0000-0002-4055-5161; Nixon, Susan/0000-0003-0346-9683; Hancock, John/0000-0003-0542-4710				Arbuzova A, 2000, BIOCHEMISTRY-US, V39, P10330, DOI 10.1021/bi001039j; Betz RC, 2001, NAT GENET, V28, P218, DOI 10.1038/90050; Bist A, 1997, P NATL ACAD SCI USA, V94, P10693, DOI 10.1073/pnas.94.20.10693; Carbone I, 2000, NEUROLOGY, V54, P1373, DOI 10.1212/WNL.54.6.1373; Carozzi AJ, 2000, TRAFFIC, V1, P326, DOI 10.1034/j.1600-0854.2000.010406.x; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; Crosbie RH, 1998, FEBS LETT, V427, P279, DOI 10.1016/S0014-5793(98)00442-6; de Paula F, 2001, AM J MED GENET, V99, P303, DOI 10.1002/1096-8628(2001)9999:9999<::AID-AJMG1168>3.0.CO;2-O; Esteban LM, 2001, MOL CELL BIOL, V21, P1444, DOI 10.1128/MCB.21.5.1444-1452.2001; Fielding CJ, 1997, P NATL ACAD SCI USA, V94, P3753, DOI 10.1073/pnas.94.8.3753; FRA AM, 1995, P NATL ACAD SCI USA, V92, P8655, DOI 10.1073/pnas.92.19.8655; Furuchi T, 1998, J BIOL CHEM, V273, P21099, DOI 10.1074/jbc.273.33.21099; Galbiati F, 2001, J BIOL CHEM, V276, P21425, DOI 10.1074/jbc.M100828200; Galbiati F, 1999, J BIOL CHEM, V274, P25632, DOI 10.1074/jbc.274.36.25632; Hailstones D, 1998, J LIPID RES, V39, P369; Henderson LP, 2000, J BIOL CHEM, V275, P20179, DOI 10.1074/jbc.M001793200; Herrmann R, 2000, HUM MOL GENET, V9, P2335, DOI 10.1093/oxfordjournals.hmg.a018926; ISHIKAWA H, 1968, J CELL BIOL, V38, P51, DOI 10.1083/jcb.38.1.51; Johnson L, 1997, GENE DEV, V11, P2468, DOI 10.1101/gad.11.19.2468; Kurzchalia TV, 1999, CURR OPIN CELL BIOL, V11, P424, DOI 10.1016/S0955-0674(99)80061-1; Luetterforst R, 1999, J CELL BIOL, V145, P1443, DOI 10.1083/jcb.145.7.1443; McNally EM, 1998, HUM MOL GENET, V7, P871, DOI 10.1093/hmg/7.5.871; Minetti C, 1998, NAT GENET, V18, P365, DOI 10.1038/ng0498-365; MURATA M, 1995, P NATL ACAD SCI USA, V92, P10339, DOI 10.1073/pnas.92.22.10339; Parton RG, 1997, J CELL BIOL, V136, P137, DOI 10.1083/jcb.136.1.137; Parton RG, 2001, METHOD ENZYMOL, V333, P172; Pol A, 2001, J CELL BIOL, V152, P1057, DOI 10.1083/jcb.152.5.1057; Pol A, 1999, HEPATOLOGY, V29, P1848, DOI 10.1002/hep.510290602; Prior IA, 2001, NAT CELL BIOL, V3, P368, DOI 10.1038/35070050; Rahkila P, 2001, EXP CELL RES, V267, P61, DOI 10.1006/excr.2001.5101; Ralston E, 1999, EXP CELL RES, V246, P510, DOI 10.1006/excr.1998.4305; Razani B, 2000, J CELL SCI, V113, P2103; Rojo M, 1997, J CELL BIOL, V139, P1119, DOI 10.1083/jcb.139.5.1119; Roy S, 1997, J BIOL CHEM, V272, P20139, DOI 10.1074/jbc.272.32.20139; Roy S, 1999, NAT CELL BIOL, V1, P98, DOI 10.1038/10067; Schlegel A, 1999, J BIOL CHEM, V274, P22660, DOI 10.1074/jbc.274.32.22660; Smart EJ, 1996, J BIOL CHEM, V271, P29427, DOI 10.1074/jbc.271.46.29427; Song KS, 1996, J BIOL CHEM, V271, P15160, DOI 10.1074/jbc.271.25.15160; Sotgia F, 2000, J BIOL CHEM, V275, P38048, DOI 10.1074/jbc.M005321200; Sunada Y, 2001, HUM MOL GENET, V10, P173, DOI 10.1093/hmg/10.3.173; Tang ZL, 1996, J BIOL CHEM, V271, P2255, DOI 10.1074/jbc.271.4.2255; Trigatti BL, 1999, BIOCHEM BIOPH RES CO, V255, P34, DOI 10.1006/bbrc.1998.0123; WAY M, 1995, FEBS LETT, V376, P108, DOI 10.1016/0014-5793(95)01256-7	44	44	46	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 17	2002	277	20					17944	17949		10.1074/jbc.M110879200	http://dx.doi.org/10.1074/jbc.M110879200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	553PR	11884389	hybrid			2022-12-27	WOS:000175685100071
J	Fu, ZJ; Wang, M; Potter, D; Miziorko, HM; Kim, JJP				Fu, ZJ; Wang, M; Potter, D; Miziorko, HM; Kim, JJP			The structure of a binary complex between a mammalian mevalonate kinase and ATP - Insights into the reaction mechanism and human inherited disease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERIODIC FEVER SYNDROME; ACTIVE-SITE; CATALYTIC RESIDUES; CRYSTAL-STRUCTURES; HYPER-IGD; IDENTIFICATION; PROTEIN; BIOSYNTHESIS; MUTATIONS; HEXOKINASE	Mevalonate kinase catalyzes the ATP-dependent phosphorylation of mevalonic acid to form mevalonate 5-phosphate, a key intermediate in the pathways of isoprenoids and sterols. Deficiency in mevalonate kinase activity has been linked to mevalonic aciduria and hyperimmunoglobulinemia D/periodic fever syndrome (HIDS). The crystal structure of rat mevalonate kinase in complex with MgATP has been determined at 2.4-Angstrom resolution. Each monomer of this dimeric protein is composed of two domains with its active site located at the domain interface. The enzyme-bound ATP adopts an anti conformation, in contrast to the syn conformation reported for Methanococcus jannaschii homoserine kinase. The Mg2+ ion is coordinated to both beta- and gamma-phosphates of ATP and side chains of Glu(193) and Ser(146). Asp(204) is making a salt bridge with Lys(13) which in turn interacts with the gamma-phosphate. A model of mevalonic acid can be placed near the gamma-phosphoryl group of ATP; thus, the C5 hydroxyl is located within 4 Angstrom from Asp(204), Lys(13), and the gamma-phosphoryl of ATP. This arrangement of residues strongly suggests: 1) Asp(204) abstracts the proton from C5 hydroxyl of mevalonate; 2) the penta-coordinated gamma-phosphoryl group may be stabilized by Mg2+, Lys(13), and Glu(193); and 3) Lys(13) is likely to influence the pK(a) of the C5 hydroxyl of the substrate. V377I and I268T are the most common mutations found in patients with HIDS. Val(377) is located over 18 Angstrom away from the active site and a conservative replacement with Ile is unlikely to yield an inactive or unstable protein. Ile-268 is located at the dimer interface, and its Thr substitution may disrupt dimer formation.	Med Coll Wisconsin, Dept Biochem, Milwaukee, WI 53226 USA	Medical College of Wisconsin	Kim, JJP (corresponding author), Med Coll Wisconsin, Dept Biochem, Milwaukee, WI 53226 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK053766] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK53766] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aleshin AE, 2000, J MOL BIOL, V296, P1001, DOI 10.1006/jmbi.1999.3494; AMDUR BH, 1957, J AM CHEM SOC, V79, P2646, DOI 10.1021/ja01567a077; BERGER SA, 1992, BIOCHEMISTRY-US, V31, P9237, DOI 10.1021/bi00153a017; BEYTIA E, 1970, J BIOL CHEM, V245, P5450; BORK P, 1993, PROTEIN SCI, V2, P31; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cho YK, 2001, J BIOL CHEM, V276, P12573, DOI 10.1074/jbc.M011478200; CODIER H, 1999, CURR MICROBIOL, V38, P290; Cuisset L, 2001, EUR J HUM GENET, V9, P260, DOI 10.1038/sj.ejhg.5200614; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; DORSEY JK, 1968, J BIOL CHEM, V243, P4667; Drenth JPH, 1999, NAT GENET, V22, P178, DOI 10.1038/9696; Hinson DD, 1997, J BIOL CHEM, V272, P26756, DOI 10.1074/jbc.272.42.26756; Hinson DD, 1999, AM J HUM GENET, V65, P327, DOI 10.1086/302489; Houten SM, 1999, HUM MOL GENET, V8, P1523, DOI 10.1093/hmg/8.8.1523; Houten SM, 2001, EUR J HUM GENET, V9, P253, DOI 10.1038/sj.ejhg.5200595; Huang KX, 1999, PROTEIN EXPRES PURIF, V17, P33, DOI 10.1006/prep.1999.1106; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Krishna SS, 2001, BIOCHEMISTRY-US, V40, P10810, DOI 10.1021/bi010851z; Lange BM, 1999, P NATL ACAD SCI USA, V96, P13714, DOI 10.1073/pnas.96.24.13714; Luttgen H, 2000, P NATL ACAD SCI USA, V97, P1062, DOI 10.1073/pnas.97.3.1062; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Potter D, 1997, J BIOL CHEM, V272, P5741, DOI 10.1074/jbc.272.9.5741; Potter D, 1997, J BIOL CHEM, V272, P25449, DOI 10.1074/jbc.272.41.25449; Rios SE, 2001, BBA-MOL CELL BIOL L, V1531, P165, DOI 10.1016/S1388-1981(01)00105-6; ROUSSEL A, 1994, TURBO FRODO MANUAL V; TANAKA RD, 1990, P NATL ACAD SCI USA, V87, P2872, DOI 10.1073/pnas.87.8.2872; TCHEN TT, 1958, J BIOL CHEM, V233, P1100; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; THAMSEN J, 1952, ACTA CHEM SCAND, V6, P270, DOI 10.3891/acta.chem.scand.06-0270; TSAY YH, 1991, MOL CELL BIOL, V11, P620, DOI 10.1128/MCB.11.2.620; Yang D, 2002, J BIOL CHEM, V277, P9462, DOI 10.1074/jbc.M110787200; ZHENG JH, 1993, PROTEIN SCI, V2, P1559, DOI 10.1002/pro.5560021003; ZHOU T, 2000, STRUCTURE FOLD DES, V12, P1247	37	99	104	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 17	2002	277	20					18134	18142		10.1074/jbc.M200912200	http://dx.doi.org/10.1074/jbc.M200912200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	553PR	11877411	hybrid			2022-12-27	WOS:000175685100095
J	Kotaja, N; Vihinen, M; Palvimo, JJ; Janne, OA				Kotaja, N; Vihinen, M; Palvimo, JJ; Janne, OA			Androgen receptor-interacting protein 3 and other PIAS proteins cooperate with glucocorticoid receptor-interacting protein 1 in steroid receptor-dependent signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HORMONE-BINDING DOMAINS; NUCLEAR-RECEPTOR; TRANSCRIPTIONAL COACTIVATOR; SIGNATURE MOTIF; ACTIVATION; INHIBITOR; GRIP1; COREGULATOR; FAMILY; SRC-1	Androgen receptor (AR)-interacting protein 3 (ARIP3/PIASxalpha) is a coregulator capable of modulating transcriptional activity of various steroid receptors. We have characterized functional regions of ARIP3 and studied its interaction with the glucocorticoid receptor (GR)-interacting protein 1 (GRIP1). We find that the potential zinc-binding domain is critical for ARIP3 to function as a coactivator; the deletion of amino acids 347-418 or the mutation of the conserved cysteines 385 and 388 to serines converts ARIP3 to a transcriptional repressor from AR-dependent minimal promoters and abolishes its ability to activate GR. By contrast, mutations in the two LXXLL motifs of ARIP3 have relatively minor effects on its ability to regulate AR or GR function. ARIP3 is able to interact with different regions of GRIP1, but the strongest interaction is detected with the C-terminal region (amino acids 1122-1462) of GRIP1. The interaction of ARIP3 with the latter GRIP1 domain or full-length GRIP1 and the ability of ARIP3 to cooperate with GRIP1 in the regulation of AR- or GR-dependent transcription are dependent on the ARIP3 zinc-binding region. We also find a strong synergism between GRIP1 and two other PIAS family members, Miz1 and PLAS1. Taken together, our results suggest that PIAS proteins and GRIP1 interact functionally in transcriptional regulation.	Univ Helsinki, Inst Biomed Physiol, Biomedicum Helsinki, FIN-00014 Helsinki, Finland; Univ Helsinki, Inst Biotechnol, FIN-00014 Helsinki, Finland; Univ Helsinki, Dept Clin Chem, FIN-00014 Helsinki, Finland; Univ Helsinki, Cent Hosp, FIN-00014 Helsinki, Finland	University of Helsinki; University of Helsinki; University of Helsinki; University of Helsinki; Helsinki University Central Hospital	Janne, OA (corresponding author), Univ Helsinki, Inst Biomed, Biomedicum Helsinki, POB 63, FIN-00014 Helsinki, Finland.			Kotaja, Noora/0000-0003-1503-9170; Palvimo, Jorma/0000-0003-2373-0578				Anzick SL, 1997, SCIENCE, V277, P965, DOI 10.1126/science.277.5328.965; Aravind L, 2000, TRENDS BIOCHEM SCI, V25, P112, DOI 10.1016/S0968-0004(99)01537-6; Baumann CT, 2001, MOL ENDOCRINOL, V15, P485, DOI 10.1210/me.15.4.485; BEATO M, 1995, CELL, V83, P851, DOI 10.1016/0092-8674(95)90201-5; Blanco JCG, 1998, GENE DEV, V12, P1638, DOI 10.1101/gad.12.11.1638; Chen DG, 1999, SCIENCE, V284, P2174, DOI 10.1126/science.284.5423.2174; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; Chung CD, 1997, SCIENCE, V278, P1803, DOI 10.1126/science.278.5344.1803; Darimont BD, 1998, GENE DEV, V12, P3343, DOI 10.1101/gad.12.21.3343; Ding XF, 1998, MOL ENDOCRINOL, V12, P302, DOI 10.1210/me.12.2.302; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; Hong H, 1996, P NATL ACAD SCI USA, V93, P4948, DOI 10.1073/pnas.93.10.4948; Hong H, 1999, J BIOL CHEM, V274, P3496, DOI 10.1074/jbc.274.6.3496; Huang SM, 2000, MOL CELL BIOL, V20, P1855, DOI 10.1128/MCB.20.5.1855-1867.2000; Ikonen T, 1997, J BIOL CHEM, V272, P29821, DOI 10.1074/jbc.272.47.29821; Junicho A, 2000, BIOCHEM BIOPH RES CO, V278, P9, DOI 10.1006/bbrc.2000.3753; Kahyo T, 2001, MOL CELL, V8, P713, DOI 10.1016/S1097-2765(01)00349-5; KALLIO PJ, 1995, MOL ENDOCRINOL, V9, P1017, DOI 10.1210/me.9.8.1017; Korzus E, 1998, SCIENCE, V279, P703, DOI 10.1126/science.279.5351.703; Kotaja N, 2000, MOL ENDOCRINOL, V14, P1986, DOI 10.1210/me.14.12.1986; Leo C, 2000, GENE, V245, P1, DOI 10.1016/S0378-1119(00)00024-X; Li H, 1997, P NATL ACAD SCI USA, V94, P8479, DOI 10.1073/pnas.94.16.8479; Liao JY, 2000, P NATL ACAD SCI USA, V97, P5267, DOI 10.1073/pnas.97.10.5267; Liu B, 1998, P NATL ACAD SCI USA, V95, P10626, DOI 10.1073/pnas.95.18.10626; Liu B, 2001, P NATL ACAD SCI USA, V98, P3203, DOI 10.1073/pnas.051489598; McKenna NJ, 1999, ENDOCR REV, V20, P321, DOI 10.1210/er.20.3.321; Moilanen AM, 1999, J BIOL CHEM, V274, P3700, DOI 10.1074/jbc.274.6.3700; Moilanen AM, 1998, MOL CELL BIOL, V18, P5128, DOI 10.1128/MCB.18.9.5128; Onate SA, 1998, J BIOL CHEM, V273, P12101, DOI 10.1074/jbc.273.20.12101; PALVIMO JJ, 1993, MOL ENDOCRINOL, V7, P1399, DOI 10.1210/me.7.11.1399; Palvimo JJ, 1996, J BIOL CHEM, V271, P24151, DOI 10.1074/jbc.271.39.24151; ROSENTHAL N, 1987, METHOD ENZYMOL, V152, P704; Sturm S, 2000, J MOL NEUROSCI, V14, P107, DOI 10.1385/JMN:14:1-2:107; Takeshita A, 1997, J BIOL CHEM, V272, P27629, DOI 10.1074/jbc.272.44.27629; Tan JA, 2000, MOL ENDOCRINOL, V14, P14, DOI 10.1210/me.14.1.14; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; Valdez BC, 1997, BIOCHEM BIOPH RES CO, V234, P335, DOI 10.1006/bbrc.1997.6642; Voegel JJ, 1998, EMBO J, V17, P507, DOI 10.1093/emboj/17.2.507; Wu L, 1997, MECH DEVELOP, V65, P3, DOI 10.1016/S0925-4773(97)00032-4; Xu JM, 2000, P NATL ACAD SCI USA, V97, P6379, DOI 10.1073/pnas.120166297; Xu JM, 1998, SCIENCE, V279, P1922, DOI 10.1126/science.279.5358.1922	41	51	53	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 17	2002	277	20					17781	17788		10.1074/jbc.M106354200	http://dx.doi.org/10.1074/jbc.M106354200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	553PR	11893729	hybrid			2022-12-27	WOS:000175685100051
J	Haggie, PM; Stanton, BA; Verkman, AS				Haggie, PM; Stanton, BA; Verkman, AS			Diffusional mobility of the cystic fibrosis transmembrane conductance regulator mutant, Delta F508-CFTR, in the endoplasmic reticulum measured by photobleaching of GFP-CFTR chimeras	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GREEN FLUORESCENT PROTEIN; CONFORMATIONAL MATURATION; DEGRADATION; PROTEASOME; MEMBRANE; TRAFFICKING; CHAPERONES; AGGRESOMES; RETENTION; TRANSPORT	Mutations in the cystic fibrosis transmembrane conductance regulator protein (CFTR) cause cystic fibrosis. The most common disease-causing mutation, DeltaF508, is retained in the endoplasmic reticulum (ER) and is unable to function as a plasma membrane chloride channel. To investigate whether the ER retention of DeltaF508-CFTR is caused by immobilization and/or aggregation, we have measured the diffusional mobility of green fluorescent protein (GFP) chimeras of wild type (wt)-CFTR and DeltaF508-CFTR by fluorescence recovery after photo-bleaching. GFP-labeled DeltaF508-CFTR was localized in the ER and wt-CFTR in the plasma membrane and intracellular membranes in transfected COS7 and Chinese hamster ovary K1 cells. Both chimeras localized to the ER after brefeldin A treatment. Spot photobleaching showed that CFTR diffusion (diffusion coefficient similar to10(-9) cm(2)/s) was not significantly slowed by the DeltaF508 mutation and that nearly all wt-CFTR and DeltaF508-CFTR diffused throughout the ER without restriction. Stabilization of molecular chaperone interactions by ATP depletion produced remarkable DeltaF508-CFTR immobilization (similar to50%) and slowed diffusion (6.5 x 10(-10) cm(2)/s) but had little effect on wt-CFTR. Fluorescence depletion experiments revealed that the immobilized DeltaF508-CFTR in ATP-depleted cells remained in an ER pattern. The mobility of wt-CFTR and DeltaF508-CFTR was reduced by maneuvers that alter CFTR processing or interactions with molecular chaperones, including tunicamycin, geldanamycin, and lactacystin. Photobleaching of the fluorescent ER lipid diOC(4)(3) showed that neither ER restructuring nor fragmentation during these maneuvers was responsible for the slowing and immobilization of CFTR. These results suggest that (a) the ER retention of DeltaF508-CFTR is not due to restricted ER mobility, (b) the majority of DeltaF508-CFTR is not aggregated or bound to slowly moving membrane proteins, and (e) DeltaF508-CFTR may interact to a greater extent with molecular chaperones than does wt-CFTR.	Univ Calif San Francisco, Cardiovasc Res Inst, Dept Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Cardiovasc Res Inst, Dept Physiol, San Francisco, CA 94143 USA; Dartmouth Coll Sch Med, Hanover, NH 03755 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; Dartmouth College	Verkman, AS (corresponding author), Univ Calif San Francisco, Cardiovasc Res Inst, Dept Med, 1246 Hlth Sci E Tower, San Francisco, CA 94143 USA.	verkman@itsa.ucsf.edu			NEI NIH HHS [EY13574] Funding Source: Medline; NHLBI NIH HHS [HL60288, HL59198] Funding Source: Medline; NIBIB NIH HHS [EB00415] Funding Source: Medline; NIDDK NIH HHS [DK45881, DK43840, DK34533] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY013574] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL060288, R01HL059198] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [R37EB000415, R01EB000415] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045881, R01DK043840, R01DK034533] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIBIB NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bannykh SI, 2000, TRAFFIC, V1, P852, DOI 10.1034/j.1600-0854.2000.011105.x; Bebok Z, 1998, J BIOL CHEM, V273, P29873, DOI 10.1074/jbc.273.45.29873; Brown CR, 1996, CELL STRESS CHAPERON, V1, P117, DOI 10.1379/1466-1268(1996)001<0117:CCCTMP>2.3.CO;2; CHENG SH, 1990, CELL, V63, P827, DOI 10.1016/0092-8674(90)90148-8; Cole NB, 1996, SCIENCE, V273, P797, DOI 10.1126/science.273.5276.797; Dayel MJ, 1999, BIOPHYS J, V76, P2843, DOI 10.1016/S0006-3495(99)77438-2; DENNING GM, 1992, NATURE, V358, P761, DOI 10.1038/358761a0; Helenius A, 2001, SCIENCE, V291, P2364, DOI 10.1126/science.291.5512.2364; JENSEN TJ, 1995, CELL, V83, P129, DOI 10.1016/0092-8674(95)90241-4; Johnston JA, 1998, J CELL BIOL, V143, P1883, DOI 10.1083/jcb.143.7.1883; Kopito RR, 2000, TRENDS CELL BIOL, V10, P524, DOI 10.1016/S0962-8924(00)01852-3; Levin MH, 2001, J BIOL CHEM, V276, P21331, DOI 10.1074/jbc.M101901200; Loffing-Cueni D, 2001, AM J PHYSIOL-CELL PH, V281, pC1889, DOI 10.1152/ajpcell.2001.281.6.C1889; Loo MA, 1998, EMBO J, V17, P6879, DOI 10.1093/emboj/17.23.6879; LUKACS GL, 1994, EMBO J, V13, P6076, DOI 10.1002/j.1460-2075.1994.tb06954.x; Marguet D, 1999, IMMUNITY, V11, P231, DOI 10.1016/S1074-7613(00)80098-9; Meacham GC, 1999, EMBO J, V18, P1492, DOI 10.1093/emboj/18.6.1492; Meacham GC, 2001, NAT CELL BIOL, V3, P100, DOI 10.1038/35050509; Moyer BD, 1998, J BIOL CHEM, V273, P21759, DOI 10.1074/jbc.273.34.21759; Moyer BD, 1999, J CLIN INVEST, V104, P1353, DOI 10.1172/JCI7453; Nehls S, 2000, NAT CELL BIOL, V2, P288, DOI 10.1038/35010558; Olveczky BP, 1997, BIOPHYS J, V73, P2836, DOI 10.1016/S0006-3495(97)78312-7; Partikian A, 1998, J CELL BIOL, V140, P821, DOI 10.1083/jcb.140.4.821; PASYK EA, 1995, J BIOL CHEM, V270, P12347, DOI 10.1074/jbc.270.21.12347; PIND S, 1994, J BIOL CHEM, V269, P12784; Qu BH, 1996, J BIOL CHEM, V271, P7261, DOI 10.1074/jbc.271.13.7261; Qu BH, 1997, J BIOL CHEM, V272, P15739, DOI 10.1074/jbc.272.25.15739; Seksek O, 1997, J CELL BIOL, V138, P131, DOI 10.1083/jcb.138.1.131; Szczesna-Skorupa E, 1998, P NATL ACAD SCI USA, V95, P14793, DOI 10.1073/pnas.95.25.14793; Tatu U, 1997, J CELL BIOL, V136, P555, DOI 10.1083/jcb.136.3.555; Umenishi F, 2000, BIOPHYS J, V78, P1024, DOI 10.1016/S0006-3495(00)76661-6; WARD CL, 1994, J BIOL CHEM, V269, P25710; WARD CL, 1995, CELL, V83, P121, DOI 10.1016/0092-8674(95)90240-6; Wigley WC, 1999, J CELL BIOL, V145, P481; YANG YP, 1993, P NATL ACAD SCI USA, V90, P9480, DOI 10.1073/pnas.90.20.9480; Zhang F, 1998, NAT STRUCT BIOL, V5, P180, DOI 10.1038/nsb0398-180	36	24	24	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 10	2002	277	19					16419	16425		10.1074/jbc.M112361200	http://dx.doi.org/10.1074/jbc.M112361200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	551MB	11877404	hybrid			2022-12-27	WOS:000175564500012
J	Myung, KS; Beetham, JK; Wilson, ME; Donelson, JE				Myung, KS; Beetham, JK; Wilson, ME; Donelson, JE			Comparison of the post-transcriptional regulation of the mRNAs for the surface proteins PSA (GP46) and MSP (GP63) of Leishmania chagasi	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA ABUNDANCE; TRYPANOSOMA-BRUCEI; 3'-UNTRANSLATED REGION; CUTANEOUS LEISHMANIASIS; DONOVANI-CHAGASI; GENE-EXPRESSION; DIFFERENTIAL EXPRESSION; UNTRANSLATED REGION; INTERGENIC REGIONS; GLYCOPROTEIN GP63	MSP (GP63) and PSA (GP46) are abundant 63- and 46-kDa glycolipid-anchored proteins on the surface of the promastigote form of most Leishmania species. MSP is a zinc metalloprotease that confers resistance to host complement-mediated lysis. PSA contains internal repeats of 24 amino acids, and its function is unknown. The steady state levels of mRNAs for both glycoproteins are regulated post-transcriptionally, resulting in about a 30-fold increase as Leishmania chagasi promastigotes grow in vitro from logarithmic phase to stationary phase. Previous studies showed the 3'-untranslated regions (3'-UTRs) of these mRNAs are essential for this post-transcriptional regulation. These two 3'-UTRs of 1.0 and 1.3 kilobases were cloned immediately downstream of a beta-galactosidase reporter gene in a plasmid, and segments were systematically deleted to examine which portions of the 3'-UTRs contribute to the post-transcriptional regulation. The 92-nucleotide segment of greatest similarity between the two 3'-UTRs was deleted without loss of regulation, but the segments flanking this similarity region have positive regulatory elements essential for the regulation. We propose that similar, but non-identical, molecular mechanisms regulate the parallel expression of these two L. chagasi mRNAs despite their lack of sequence identity. These post-transcriptional mechanisms resemble the mechanism recently suggested for the regulation of mRNAs encoding the dipeptide (EP) and pentapeptide (GPEET) repeat proteins in Trypanosoma brucei that involves interactions between positive and negative regulatory elements in the 3'-UTR.	Univ Iowa, Dept Biochem, Iowa City, IA 52242 USA; Univ Iowa, Dept Microbiol, Iowa City, IA 52242 USA; Univ Iowa, Dept Internal Med, Iowa City, IA 52242 USA; Univ Iowa, Med Sci Training Program, Iowa City, IA 52242 USA; Vet Affairs Med Ctr, Iowa City, IA 52242 USA	University of Iowa; University of Iowa; University of Iowa; University of Iowa; US Department of Veterans Affairs; Veterans Health Administration (VHA); Iowa City VA Health Care System	Donelson, JE (corresponding author), Univ Iowa, Dept Biochem, Iowa City, IA 52242 USA.		Donelson, John E/F-5795-2010	Wilson, Mary/0000-0001-8680-7275	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI032135, R21AI032135, R01AI043050] Funding Source: NIH RePORTER; NIAID NIH HHS [AI32135, AI43050] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALY R, 1994, NUCLEIC ACIDS RES, V22, P2922, DOI 10.1093/nar/22.15.2922; Beetham JK, 1997, J BIOL CHEM, V272, P17360, DOI 10.1074/jbc.272.28.17360; Biebinger S, 1996, NUCLEIC ACIDS RES, V24, P1202, DOI 10.1093/nar/24.7.1202; Bringaud F, 1998, MOL BIOCHEM PARASIT, V94, P249, DOI 10.1016/S0166-6851(98)00080-2; BRINGAUD F, 1994, MOL BIOL EVOL, V11, P220; BRITTINGHAM A, 1995, J IMMUNOL, V155, P3102; Brittingham A, 2001, MOL BIOCHEM PARASIT, V112, P51, DOI 10.1016/S0166-6851(00)00346-7; Charest H, 1996, J BIOL CHEM, V271, P17081, DOI 10.1074/jbc.271.29.17081; Clayton C, 1998, MOL BIOCHEM PARASIT, V97, P221, DOI 10.1016/S0166-6851(98)00115-7; Coughlin BC, 2000, J BIOL CHEM, V275, P12051, DOI 10.1074/jbc.275.16.12051; Drozdz M, 1999, RNA, V5, P1632, DOI 10.1017/S1355838299990623; Frankenburg S, 1996, VACCINE, V14, P923, DOI 10.1016/0264-410X(95)00245-V; Furger A, 1997, MOL CELL BIOL, V17, P4372, DOI 10.1128/MCB.17.8.4372; GRAHAM SV, 1995, PARASITOL TODAY, V11, P217, DOI 10.1016/0169-4758(95)80081-6; Handman E, 2000, VACCINE, V18, P3011, DOI 10.1016/S0264-410X(00)00109-2; HEHL A, 1994, P NATL ACAD SCI USA, V91, P370, DOI 10.1073/pnas.91.1.370; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; Hotz HR, 1995, MOL BIOCHEM PARASIT, V75, P1, DOI 10.1016/0166-6851(95)02503-0; Hotz HR, 1998, MOL BIOCHEM PARASIT, V91, P131, DOI 10.1016/S0166-6851(97)00196-5; Jimenez-Ruiz A, 1998, EUR J BIOCHEM, V251, P389, DOI 10.1046/j.1432-1327.1998.2510389.x; KAHL LP, 1987, J IMMUNOL, V138, P1587; Kelly BL, 2001, MOL BIOCHEM PARASIT, V116, P101, DOI 10.1016/S0166-6851(01)00307-3; KWEIDER M, 1989, PARASITE IMMUNOL, V11, P197, DOI 10.1111/j.1365-3024.1989.tb00659.x; LEBOWITZ JH, 1994, METHOD CELL BIOL, V45, P65; LEBOWITZ JH, 1990, P NATL ACAD SCI USA, V87, P9736, DOI 10.1073/pnas.87.24.9736; MAMOHONPRATT D, 1992, MOL BIOCHEM PARASIT, V50, P151; MCMAHONPRATT D, 1993, INFECT IMMUN, V61, P3351, DOI 10.1128/IAI.61.8.3351-3359.1993; MURRAY PJ, 1989, J IMMUNOL, V143, P4221; Noormohammadi AH, 2001, VACCINE, V19, P4043, DOI 10.1016/S0264-410X(01)00132-3; Nozaki T, 1995, MOL BIOCHEM PARASIT, V75, P55, DOI 10.1016/0166-6851(95)02512-X; OLOBO JO, 1995, VET PARASITOL, V60, P199, DOI 10.1016/0304-4017(95)00788-6; Quijada L, 2000, MOL BIOCHEM PARASIT, V110, P79, DOI 10.1016/S0166-6851(00)00258-9; RAMAMOORTHY R, 1992, J BIOL CHEM, V267, P1888; RAMAMOORTHY R, 1995, J BIOL CHEM, V270, P12133, DOI 10.1074/jbc.270.20.12133; ROBERTS SC, 1995, J BIOL CHEM, V270, P8884, DOI 10.1074/jbc.270.15.8884; ROBERTS SC, 1993, MOL BIOCHEM PARASIT, V62, P157, DOI 10.1016/0166-6851(93)90106-8; Roditi I, 1999, MOL BIOCHEM PARASIT, V103, P99, DOI 10.1016/S0166-6851(99)00124-3; Roditi I, 1998, MOL BIOCHEM PARASIT, V91, P117, DOI 10.1016/S0166-6851(97)00195-3; RUSSELL DG, 1986, J IMMUNOL, V136, P2613; Seay MB, 1996, INFECT IMMUN, V64, P5129, DOI 10.1128/IAI.64.12.5129-5137.1996; SYMONS FM, 1994, MOL BIOCHEM PARASIT, V67, P103, DOI 10.1016/0166-6851(94)90100-7; TEIXEIRA SMR, 1995, J BIOL CHEM, V270, P22586, DOI 10.1074/jbc.270.38.22586; WILSON ME, 1989, J IMMUNOL, V143, P678; ZARLEY JH, 1991, J CLIN INVEST, V88, P1511, DOI 10.1172/JCI115461	44	38	43	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 10	2002	277	19					16489	16497		10.1074/jbc.M200174200	http://dx.doi.org/10.1074/jbc.M200174200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	551MB	11856749	hybrid			2022-12-27	WOS:000175564500022
J	Sobczak, K; Krzyzosiak, WJ				Sobczak, K; Krzyzosiak, WJ			Structural determinants of BRCA1 translational regulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA SECONDARY STRUCTURE; SPORADIC BREAST-CANCER; EUKARYOTIC MESSENGER-RNAS; OVARIAN-CANCER; PROMOTER REGION; SOMATIC MUTATIONS; ALU REPEATS; GENE; METHYLATION; EXPRESSION	The BRCA1 gene is involved in sporadic breast and ovarian cancer mainly through reduced expression. BRCA1 mRNAs containing different leader sequences show different patterns of expression. In a normal mammary gland mRNA with a shorter leader sequence, 5'-UTRa is expressed only, whereas in breast cancer tissue mRNA with a longer leader, 5'-UTRb is expressed also. We show that the translation efficiency of transcripts containing 5'-UTRb is 10 times lower than those containing 5'-UTRa. The structures of 5'-UTRa and 5'-UTRb were determined by chemical and enzymatic probing aided by a new method developed for monitoring the number of co-existing stable conformers. Specific factors responsible for reduced translation of mRNA containing 5'-UTRb were determined using a variety of transcripts with mutations in the leader sequence. These factors include a stable secondary structure formed by truncated Alu element and upstream AUG codons. The novel mechanism by which BRCA1 may be involved in sporadic breast and ovarian cancer is proposed. It is based on the expression patterns of BRCA1 mRNAs and differences in their translatability. According to this mechanism the deregulation of the BRCA1 transcription in cancer, resulting in a higher proportion of translationally inhibited transcripts containing 5'-UTRb, contributes to the decrease in the BRCA1 protein observed in sporadic breast and ovarian cancers.	Polish Acad Sci, Inst Bioorgan Chem, Canc Genet Lab, PL-61704 Poznan, Poland	Polish Academy of Sciences; Institute of Bioorganic Chemistry of the Polish Academy of Sciences	Krzyzosiak, WJ (corresponding author), Polish Acad Sci, Inst Bioorgan Chem, Canc Genet Lab, Noskowskiego 12-14, PL-61704 Poznan, Poland.	wlodkrzy@man.poznan.pl		Sobczak, Krzysztof/0000-0001-8352-9812				Batzer MA, 1996, J MOL EVOL, V42, P3, DOI 10.1007/BF00163204; Beger C, 2001, P NATL ACAD SCI USA, V98, P130, DOI 10.1073/pnas.98.1.130; Bianco T, 2000, CARCINOGENESIS, V21, P147, DOI 10.1093/carcin/21.2.147; BORMAN AM, 1995, NUCLEIC ACIDS RES, V23, P3656, DOI 10.1093/nar/23.18.3656; Brunel C, 2000, METHOD ENZYMOL, V318, P3; Budhram-Mahadeo V, 1999, ONCOGENE, V18, P6684, DOI 10.1038/sj.onc.1203072; Catteau A, 1999, ONCOGENE, V18, P1957, DOI 10.1038/sj.onc.1202509; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Chou WL, 2001, BBA-GENE STRUCT EXPR, V1519, P209, DOI 10.1016/S0167-4781(01)00241-X; Ciesiolka J, 1998, J MOL BIOL, V275, P211, DOI 10.1006/jmbi.1997.1462; Deininger PL, 1999, MOL GENET METAB, V67, P183, DOI 10.1006/mgme.1999.2864; Deragon JM, 2000, ANN MED, V32, P264, DOI 10.3109/07853890009011771; Dobrovic A, 1997, CANCER RES, V57, P3347; Duga S, 1999, EUR J BIOCHEM, V259, P188, DOI 10.1046/j.1432-1327.1999.00029.x; EHRESMANN C, 1987, NUCLEIC ACIDS RES, V15, P9109, DOI 10.1093/nar/15.22.9109; Esteller M, 2000, JNCI-J NATL CANCER I, V92, P564, DOI 10.1093/jnci/92.7.564; FUTREAL PA, 1994, SCIENCE, V266, P120, DOI 10.1126/science.7939630; GORNICKI P, 1989, J BIOMOL STRUCT DYN, V6, P971, DOI 10.1080/07391102.1989.10506525; Hamdi H, 1999, J MOL BIOL, V289, P861, DOI 10.1006/jmbi.1999.2797; Holt JT, 1996, NAT GENET, V12, P298, DOI 10.1038/ng0396-298; Jackson RJ, 1995, CURR TOP MICROBIOL, V203, P1; Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947; Jurka J, 1998, CURR OPIN STRUC BIOL, V8, P333, DOI 10.1016/S0959-440X(98)80067-5; Khoo US, 1999, ONCOGENE, V18, P4643, DOI 10.1038/sj.onc.1202847; Kinzler KW, 1997, NATURE, V386, P761, DOI 10.1038/386761a0; Kochetov AV, 1998, FEBS LETT, V440, P351, DOI 10.1016/S0014-5793(98)01482-3; Kozak M, 1997, EMBO J, V16, P2482, DOI 10.1093/emboj/16.9.2482; KOZAK M, 1987, MOL CELL BIOL, V7, P3438, DOI 10.1128/MCB.7.10.3438; KOZAK M, 1986, P NATL ACAD SCI USA, V83, P2850, DOI 10.1073/pnas.83.9.2850; Kozak M, 1999, GENE, V234, P187, DOI 10.1016/S0378-1119(99)00210-3; KOZAK M, 1989, MOL CELL BIOL, V9, P5134, DOI 10.1128/MCB.9.11.5134; KOZAK M, 1991, J BIOL CHEM, V266, P19867; KRZYZOSIAK WJ, 1988, BIOCHEMISTRY-US, V27, P5771, DOI 10.1021/bi00415a056; Krzyzosiak WJ, 1999, NATO ASI 3 HIGH TECH, V70, P303; LUUKKONEN BGM, 1995, J VIROL, V69, P4086, DOI 10.1128/JVI.69.7.4086-4094.1995; Magdinier F, 1998, ONCOGENE, V17, P3169, DOI 10.1038/sj.onc.1202248; Mancini DN, 1998, ONCOGENE, V16, P1161, DOI 10.1038/sj.onc.1201630; Marcotrigiano J, 1997, CELL, V89, P951, DOI 10.1016/S0092-8674(00)80280-9; Mathews DH, 1999, J MOL BIOL, V288, P911, DOI 10.1006/jmbi.1999.2700; MERAJVER SD, 1995, NAT GENET, V9, P439, DOI 10.1038/ng0495-439; Michalowski D, 1996, BIOCHEMISTRY-US, V35, P10727, DOI 10.1021/bi9530393; MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954; Napierala M, 1997, J BIOL CHEM, V272, P31079, DOI 10.1074/jbc.272.49.31079; NEWMAN B, 1988, P NATL ACAD SCI USA, V85, P3044, DOI 10.1073/pnas.85.9.3044; Ozcelik H, 1998, INT J CANCER, V77, P1; Rice JC, 1998, ONCOGENE, V17, P1807, DOI 10.1038/sj.onc.1202086; Sachs AB, 1997, CELL, V89, P831, DOI 10.1016/S0092-8674(00)80268-8; Scully R, 2000, NATURE, V408, P429, DOI 10.1038/35044000; SINNETT D, 1991, J BIOL CHEM, V266, P8675; Sourvinos G, 1998, BIOCHEM BIOPH RES CO, V245, P75, DOI 10.1006/bbrc.1998.8379; Suen TC, 2001, ONCOGENE, V20, P440, DOI 10.1038/sj.onc.1204078; Sugimura T, 2000, MUTAT RES-REV MUTAT, V462, P235, DOI 10.1016/S1383-5742(00)00005-3; Taylor J, 1998, INT J CANCER, V79, P334, DOI 10.1002/(SICI)1097-0215(19980821)79:4<334::AID-IJC5>3.0.CO;2-W; THOMPSON ME, 1995, NAT GENET, V9, P444, DOI 10.1038/ng0495-444; Vallejo Abbe N., 1995, P603; Welcsh PL, 2001, HUM MOL GENET, V10, P705, DOI 10.1093/hmg/10.7.705; Wilson CA, 1999, NAT GENET, V21, P236, DOI 10.1038/6029; XU CF, 1995, HUM MOL GENET, V4, P2259, DOI 10.1093/hmg/4.12.2259; Xu CF, 1997, J BIOL CHEM, V272, P20994, DOI 10.1074/jbc.272.34.20994; Zheng WX, 2000, GYNECOL ONCOL, V76, P294, DOI 10.1006/gyno.1999.5664	60	86	89	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 10	2002	277	19					17349	17358		10.1074/jbc.M109162200	http://dx.doi.org/10.1074/jbc.M109162200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	551MB	11877386	hybrid			2022-12-27	WOS:000175564500131
J	Xie, Q; Zhang, Y; Zhai, CB; Bonanno, JA				Xie, Q; Zhang, Y; Zhai, CB; Bonanno, JA			Calcium influx factor from cytochrome P-450 metabolism and secretion-like coupling mechanisms for capacitative calcium entry in corneal endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTRACELLULAR CA2+ STORES; INOSITOL 1,4,5-TRISPHOSPHATE RECEPTOR; CURRENT I-CRAC; INDUCED <CA2+>(I) OSCILLATIONS; OPERATED CATION CHANNELS; INHIBITORS OKADAIC ACID; GTP-BINDING PROTEIN; 2-AMINOETHOXYDIPHENYL BORATE; HUMAN PLATELETS; ACTIN CYTOSKELETON	Notwithstanding extensive efforts, the mechanism of capacitative calcium entry (CCE) remains unclear. Two seemingly opposed theories have been proposed: secretion-like coupling (Patterson, R. L., van Rossum, D. B., and Gill, D. L. (1999) Cell 98, 487-499) and the calcium influx factor (CIF) (Randriamampita, C., and Tsien, R. Y. (1993) Nature 364, 809-814). In the current study, a combinatorial approach was taken to investigate the mechanism of CCE in corneal endothelial cells. Induction of cytochrome P-450s by beta-naphthoflavone (BN) enhanced CCE measured by Sr2+ entry after store depletion. 5,6-Epoxyeicosatrienoic acid (5,6-EET), a proposed CIF generated by cytochrome P-450s (Rzigalinski, B. A., Willoughby, K. A., Hoffman, S. W., Falck, J. R., and Ellis, E. F. (1999) J. Biol. Chem. 274, 175-182), induced Ca2+ entry. Both BN-enhanced CCE and the 5,6-EET-induced Ca2+ entry were inhibited by the CCE blocker 2-aminoethoxydiphenyl borate, indicating a role for cytochrome P-450s in CCE. Treatment with calyculin A (CalyA), which causes condensation of cortical cytoskeleton, inhibited CCE. The actin polymerization inhibitor cytochalasin D partially reversed the inhibition of CCE by CalyA, suggesting a secretion-like coupling mechanism for CCE. However, CalyA could not inhibit CCE in BN-treated cells, and 5,6-EET caused a partial activation of CCE in CalyA-treated cells. These results further support the notion that cytochrome P-450 metabolites may be CIFs. The vesicular transport inhibitor brefeldin A inhibited CCE in both vehicle- and BN-treated cells. Surprisingly, Sr2+ entry in the absence of store depletion was enhanced in BN-treated cells, which was also inhibited by 2-aminoethoxydiphenyl borate. An integrative model suggests that both CIF from cytochrome P-450 metabolism and secretion-like coupling mechanisms play roles in CCE in corneal endothelial cells.	Indiana Univ, Sch Optometry, Bloomington, IN 47405 USA	Indiana University System; Indiana University Bloomington	Bonanno, JA (corresponding author), Indiana Univ, Sch Optometry, 800 E Atwater Ave, Bloomington, IN 47405 USA.							Alderton JM, 2000, CELL CALCIUM, V28, P161, DOI 10.1054/ceca.2000.0144; ALONSO MT, 1991, BIOCHEM J, V280, P783, DOI 10.1042/bj2800783; ALONSOTORRE SR, 1993, BIOCHEM J, V289, P761, DOI 10.1042/bj2890761; ALVAREZ J, 1991, BIOCHEM J, V274, P193, DOI 10.1042/bj2740193; Ascher-Landsberg J, 1999, BIOCHEM BIOPH RES CO, V264, P979, DOI 10.1006/bbrc.1999.1602; Auld A, 2000, BBA-MOL CELL RES, V1497, P11, DOI 10.1016/S0167-4889(00)00045-8; Bakowski D, 2001, J PHYSIOL-LONDON, V532, P55, DOI 10.1111/j.1469-7793.2001.0055g.x; Berridge MJ, 2000, NAT REV MOL CELL BIO, V1, P11, DOI 10.1038/35036035; Birnbaumer L, 2000, RECENT PROG HORM RES, V55, P127; Boulay G, 1999, P NATL ACAD SCI USA, V96, P14955, DOI 10.1073/pnas.96.26.14955; Braun FJ, 2001, J BIOL CHEM, V276, P1063, DOI 10.1074/jbc.M008348200; Broad LM, 2001, J BIOL CHEM, V276, P15945, DOI 10.1074/jbc.M011571200; Bruce JIE, 2000, BRIT J PHARMACOL, V131, P761, DOI 10.1038/sj.bjp.0703631; Capdevila JH, 2000, J LIPID RES, V41, P163; Chorna-Ornan I, 2001, J NEUROSCI, V21, P2622, DOI 10.1523/JNEUROSCI.21-08-02622.2001; Christian EP, 1996, BRIT J PHARMACOL, V119, P647, DOI 10.1111/j.1476-5381.1996.tb15722.x; Clapham DE, 2001, NAT REV NEUROSCI, V2, P387, DOI 10.1038/35077544; Csutora P, 1999, P NATL ACAD SCI USA, V96, P121, DOI 10.1073/pnas.96.1.121; Dobryndeva Y, 2001, MOL PHARMACOL, V60, P541; Fernando KC, 1997, BIOCHEM J, V328, P463; Fisslthaler B, 1999, NATURE, V401, P493, DOI 10.1038/46816; FOX JEB, 1981, NATURE, V292, P650, DOI 10.1038/292650a0; Gailly P, 1998, CELL CALCIUM, V24, P293, DOI 10.1016/S0143-4160(98)90053-7; GRAIER WF, 1993, BIOCHEM J, V291, P263, DOI 10.1042/bj2910263; GRAIER WF, 1995, J PHYSIOL-LONDON, V482, P259, DOI 10.1113/jphysiol.1995.sp020515; Gregory RB, 2001, BIOCHEM J, V354, P285, DOI 10.1042/0264-6021:3540285; Hoebel BG, 1997, BRIT J PHARMACOL, V121, P1579, DOI 10.1038/sj.bjp.0701304; Holda JR, 1997, FEBS LETT, V403, P191, DOI 10.1016/S0014-5793(97)00051-3; Kiselyov K, 1999, TRENDS NEUROSCI, V22, P334, DOI 10.1016/S0166-2236(99)01426-5; Kiselyov K, 2001, BIOCHEM J, V360, P17, DOI 10.1042/0264-6021:3600017; Kiselyov K, 1998, NATURE, V396, P478, DOI 10.1038/24890; Kiselyov K, 1999, MOL CELL, V4, P423, DOI 10.1016/S1097-2765(00)80344-5; Kiselyov KI, 2000, MOL CELL, V6, P421, DOI 10.1016/S1097-2765(00)00041-1; KOCH BD, 1994, BIOCHEM J, V302, P187, DOI 10.1042/bj3020187; KREIENBUHL P, 1992, BLOOD, V80, P2911; Kukkonen JP, 2001, CELL CALCIUM, V30, P117, DOI 10.1054/ceca.2001.0219; Kunzelmann-Marche C, 2001, J BIOL CHEM, V276, P5134, DOI 10.1074/jbc.M007924200; KWAN CY, 1990, J BIOL CHEM, V265, P678; Liu XB, 2000, J BIOL CHEM, V275, P3403, DOI 10.1074/jbc.275.5.3403; Luo D, 2001, J BIOL CHEM, V276, P5613, DOI 10.1074/jbc.M007524200; Ma HT, 2000, SCIENCE, V287, P1647, DOI 10.1126/science.287.5458.1647; Ma HT, 2002, J BIOL CHEM, V277, P6915, DOI 10.1074/jbc.M107755200; Ma HT, 2001, J BIOL CHEM, V276, P18888, DOI 10.1074/jbc.M100944200; Maruyama T, 1997, J BIOCHEM-TOKYO, V122, P498; MAURICE DM, 1951, BRIT J OPHTHALMOL, V35, P791, DOI 10.1136/bjo.35.12.791; Missiaen L, 2001, CELL CALCIUM, V29, P111, DOI 10.1054/ceca.2000.0163; MONTERO M, 1992, BIOCHEM J, V288, P519, DOI 10.1042/bj2880519; Parekh AB, 1997, PHYSIOL REV, V77, P901, DOI 10.1152/physrev.1997.77.4.901; Patterson RL, 1999, CELL, V98, P487, DOI 10.1016/S0092-8674(00)81977-7; PINTO A, 1986, J PHARMACOL EXP THER, V236, P445; Prakriya M, 2001, J PHYSIOL-LONDON, V536, P3, DOI 10.1111/j.1469-7793.2001.t01-1-00003.x; Putney J W Jr, 2001, Mol Interv, V1, P84; PUTNEY JW, 1986, CELL CALCIUM, V7, P1, DOI 10.1016/0143-4160(86)90026-6; Putney JW, 2001, J CELL SCI, V114, P2223; RANDRIAMAMPITA C, 1993, NATURE, V364, P809, DOI 10.1038/364809a0; Ribeiro CMP, 1997, J BIOL CHEM, V272, P26555, DOI 10.1074/jbc.272.42.26555; Rosado JA, 2000, J BIOL CHEM, V275, P7527, DOI 10.1074/jbc.275.11.7527; Rosado JA, 2000, TRENDS CARDIOVAS MED, V10, P327, DOI 10.1016/S1050-1738(01)00073-1; Rosado JA, 2001, AM J PHYSIOL-CELL PH, V280, pC1636, DOI 10.1152/ajpcell.2001.280.6.C1636; Rzigalinski BA, 1996, BBA-LIPID LIPID MET, V1299, P342, DOI 10.1016/0005-2760(95)00224-3; Rzigalinski BA, 1999, J BIOL CHEM, V274, P175, DOI 10.1074/jbc.274.1.175; Schievella AR, 1995, J BIOL CHEM, V270, P30749, DOI 10.1074/jbc.270.51.30749; SCHILLING WP, 1989, J BIOL CHEM, V264, P12838; Sergeeva M, 2000, NEUROSCIENCE, V97, P765, DOI 10.1016/S0306-4522(00)00062-2; Simons PC, 1998, BIOCHEM BIOPH RES CO, V253, P561, DOI 10.1006/bbrc.1998.9823; Singh BB, 2000, J BIOL CHEM, V275, P36483, DOI 10.1074/jbc.C000529200; Srinivas SP, 1998, CURR EYE RES, V17, P994, DOI 10.1076/ceyr.17.10.994.5242; Sun XC, 2000, AM J PHYSIOL-CELL PH, V279, pC1648, DOI 10.1152/ajpcell.2000.279.5.C1648; Tang J, 2001, J BIOL CHEM, V276, P21303, DOI 10.1074/jbc.M102316200; TESFAI Y, 2001, BIOCH J, V358; Trepakova ES, 2000, J BIOL CHEM, V275, P26158, DOI 10.1074/jbc.M004666200; Tsukita S, 1997, TRENDS BIOCHEM SCI, V22, P53, DOI 10.1016/S0968-0004(96)10071-2; van Rossum DB, 2000, J BIOL CHEM, V275, P28562, DOI 10.1074/jbc.M003147200; Vazquez G, 2001, P NATL ACAD SCI USA, V98, P11777, DOI 10.1073/pnas.201238198; YANO Y, 1995, BIOCHEM J, V307, P439, DOI 10.1042/bj3070439; Yao Y, 1999, CELL, V98, P475, DOI 10.1016/S0092-8674(00)81976-5; Zhu X, 1996, CELL, V85, P661, DOI 10.1016/S0092-8674(00)81233-7	77	52	62	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 10	2002	277	19					16559	16566		10.1074/jbc.M109518200	http://dx.doi.org/10.1074/jbc.M109518200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	551MB	11867616	hybrid			2022-12-27	WOS:000175564500031
J	Zhou, J; Panda, D; Landen, JW; Wilson, L; Joshi, HC				Zhou, J; Panda, D; Landen, JW; Wilson, L; Joshi, HC			Minor alteration of microtubule dynamics causes loss of tension across kinetochore pairs and activates the spindle checkpoint	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CENP-E; CHROMOSOME ALIGNMENT; MITOTIC CHECKPOINT; KINETIC STABILIZATION; STEADY-STATE; INDIVIDUAL MICROTUBULES; TRANSITION FREQUENCIES; EJECTION PROPERTIES; DEPENDENT CHANGES; INTERPHASE CELLS	We have previously identified the opium alkaloid noscapine as a microtubule interacting agent that binds stoichiometrically to tubulin and alters its conformation. Here we show that, unlike many other microtubule inhibitors, noscapine does not significantly promote or inhibit microtubule polymerization. Instead, it alters the steady-state dynamics of microtubule assembly, primarily by increasing the amount of time that the microtubules spend in an attenuated (pause) state. Further studies reveal that even at high concentrations, noscapine does not alter the tubulin polymer/monomer ratio in HeLa cells. C ells treated with noscapine arrest at mitosis with nearly normal bipolar spindles. Strikingly, although most of the chromosomes in these cells are aligned at the metaphase plate, the rest remain near the spindle poles, both of which exhibit loss of tension across kinetochore pairs. Furthermore, levels of the spindle checkpoint proteins Mad2, Bub1, and BubR1 decrease by 138-, 3.7-, and 3.9-fold, respectively, at the kinetochore region upon chromosome alignment. Our results thus suggest that an exquisite control of microtubule dynamics is required for kinetochore tension generation and chromosome alignment during mitosis. Our data also support the idea that Mad2 and Bub1/BubR1 respond to kinetochore-microtubule attachment and/or tension to different degrees.	Emory Univ, Sch Med, Dept Cell Biol, Atlanta, GA 30322 USA; Emory Univ, Sch Med, Grad Program Biochem Cell & Dev Biol, Atlanta, GA 30322 USA; Univ Calif Santa Barbara, Dept Mol Cellular & Dev Biol, Santa Barbara, CA 93106 USA	Emory University; Emory University; University of California System; University of California Santa Barbara	Joshi, HC (corresponding author), Emory Univ, Sch Med, Dept Cell Biol, 1648 Pierce Dr, Atlanta, GA 30322 USA.							Amon A, 1999, CURR OPIN GENET DEV, V9, P69, DOI 10.1016/S0959-437X(99)80010-0; Antonio C, 2000, CELL, V102, P425, DOI 10.1016/S0092-8674(00)00048-9; AULT JG, 1991, J CELL SCI, V99, P701; BELMONT LD, 1990, CELL, V62, P579, DOI 10.1016/0092-8674(90)90022-7; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cahill DP, 1998, NATURE, V392, P300, DOI 10.1038/32688; CASSIMERIS L, 1994, J CELL SCI, V107, P285; Chan GKT, 1999, J CELL BIOL, V146, P941, DOI 10.1083/jcb.146.5.941; Chan GKT, 1998, J CELL BIOL, V143, P49, DOI 10.1083/jcb.143.1.49; DHAMODHARAN R, 1995, MOL BIOL CELL, V6, P1215, DOI 10.1091/mbc.6.9.1215; Dustin P., 1984, MICROTUBULES; Funabiki H, 2000, CELL, V102, P411, DOI 10.1016/S0092-8674(00)00047-7; GILDERSLEEVE RF, 1992, J BIOL CHEM, V267, P7995; GLIKSMAN NR, 1993, MOL BIOL CELL, V4, P1035, DOI 10.1091/mbc.4.10.1035; Hoffman DB, 2001, MOL BIOL CELL, V12, P1995, DOI 10.1091/mbc.12.7.1995; Jordan MA, 1999, METHOD CELL BIOL, V61, P267; Joshi HC, 1998, CURR OPIN CELL BIOL, V10, P35, DOI 10.1016/S0955-0674(98)80084-7; JOSHI HC, 1989, J CELL BIOL, V109, P663, DOI 10.1083/jcb.109.2.663; King JM, 2000, J CELL BIOL, V151, P739, DOI 10.1083/jcb.151.4.739; Li Y, 1996, SCIENCE, V274, P246, DOI 10.1126/science.274.5285.246; MARGOLIS RL, 1978, CELL, V13, P1, DOI 10.1016/0092-8674(78)90132-0; McEwen BF, 2001, MOL BIOL CELL, V12, P2776, DOI 10.1091/mbc.12.9.2776; MITCHISON T, 1986, CELL, V45, P515, DOI 10.1016/0092-8674(86)90283-7; MITCHISON T, 1984, NATURE, V312, P232, DOI 10.1038/312232a0; Nicklas RB, 1997, SCIENCE, V275, P632, DOI 10.1126/science.275.5300.632; Nogales E, 2000, ANNU REV BIOCHEM, V69, P277, DOI 10.1146/annurev.biochem.69.1.277; PANDA D, 1995, BIOCHEMISTRY-US, V34, P11117, DOI 10.1021/bi00035a017; PANDA D, 1995, BIOCHEMISTRY-US, V34, P9921, DOI 10.1021/bi00031a014; PANDA D, 1994, P NATL ACAD SCI USA, V91, P11358, DOI 10.1073/pnas.91.24.11358; PEPPERKOK R, 1990, J CELL BIOL, V111, P3003, DOI 10.1083/jcb.111.6.3003; RIEDER CL, 1986, J CELL BIOL, V103, P581, DOI 10.1083/jcb.103.2.581; Rieder CL, 1998, TRENDS CELL BIOL, V8, P310, DOI 10.1016/S0962-8924(98)01299-9; Sambrook J., 2002, MOL CLONING LAB MANU; SAXTON WM, 1984, J CELL BIOL, V99, P2175, DOI 10.1083/jcb.99.6.2175; Schaar BT, 1997, J CELL BIOL, V139, P1373, DOI 10.1083/jcb.139.6.1373; SCHULZE E, 1986, J CELL BIOL, V102, P1020, DOI 10.1083/jcb.102.3.1020; Shah JV, 2000, CELL, V103, P997, DOI 10.1016/S0092-8674(00)00202-6; Shelby RD, 1996, J CELL BIOL, V135, P545, DOI 10.1083/jcb.135.3.545; Skoufias DA, 2001, P NATL ACAD SCI USA, V98, P4492, DOI 10.1073/pnas.081076898; Taylor SS, 1998, J CELL BIOL, V142, P1, DOI 10.1083/jcb.142.1.1; TOSO RJ, 1993, BIOCHEMISTRY-US, V32, P1285, DOI 10.1021/bi00056a013; WALKER RA, 1988, J CELL BIOL, V107, P1437, DOI 10.1083/jcb.107.4.1437; Waters JC, 1996, J CELL SCI, V109, P2823; WILSON L, 1995, CHEM BIOL, V2, P569, DOI 10.1016/1074-5521(95)90119-1; WISE D, 1991, CELL MOTIL CYTOSKEL, V18, P131, DOI 10.1002/cm.970180208; Yao XB, 2000, NAT CELL BIOL, V2, P484, DOI 10.1038/35019518; Ye KQ, 1998, P NATL ACAD SCI USA, V95, P1601, DOI 10.1073/pnas.95.4.1601	47	174	182	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 10	2002	277	19					17200	17208		10.1074/jbc.M110369200	http://dx.doi.org/10.1074/jbc.M110369200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	551MB	11864974	hybrid			2022-12-27	WOS:000175564500113
J	Perry, AM; Ton-That, H; Mazmanian, SK; Schneewind, O				Perry, AM; Ton-That, H; Mazmanian, SK; Schneewind, O			Anchoring of surface proteins to the cell wall of Staphylococcus aureus - III. Lipid II is an in vivo peptidoglycan substrate for sortase-catalyzed surface protein anchoring	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GRAM-POSITIVE BACTERIA; ESCHERICHIA-COLI; LPXTG MOTIF; BIOSYNTHESIS; PURIFICATION; PRECURSOR; BINDING; TRANSPEPTIDASE; PENICILLIN; PEPTIDE	Surface proteins of Staphylococcus aureus are anchored to the cell wall peptidoglycan by a mechanism requiring a C-terminal sorting signal with an LPXTG motif. Surface proteins are first synthesized in the bacterial cytoplasm and then transported across the cytoplasmic membrane. Cleavage of the N-terminal signal peptide of the cytoplasmic surface protein P1 precursor generates the extracellular P2 species, which is the substrate for the cell wall anchoring reaction. Sortase, a membrane-anchored transpeptidase, cleaves P2 between the threonine (T) and the glycine (G) of the LPXTG motif and catalyzes the formation of an amide bond between the carboxyl group of threonine and the amino group of cell wall cross-bridges. We have used metabolic labeling of staphylococcal cultures with [P-32]phosphoric acid to reveal a P3 intermediate. The P-32-label of immunoprecipitated surface protein is removed by treatment with lysostaphin, a glycyl-glycine endopeptidase that separates the cell wall anchor structure. Furthermore, the appearance of P3 is prevented in the absence of sortase or by the inhibition of cell wall synthesis. P-32-Labeled cell wall anchor species bind to nisin, an antibiotic that is known to form a complex with lipid II. Thus, it appears that the P3 intermediate represents surface protein linked to the lipid II peptidoglycan precursor. The data support a model whereby lipid II-linked polypeptides are incorporated into the growing peptidoglycan via the transpeptidation and transglycosylation reactions of cell wall synthesis, generating mature cell wall-linked surface protein.	Univ Chicago, Comm Microbiol, Chicago, IL 60637 USA	University of Chicago	Schneewind, O (corresponding author), Univ Chicago, Comm Microbiol, 920 E 58th St, Chicago, IL 60637 USA.	oschnee@delphi.bsd.uchicago.edu	Ton-That, Hung/AAB-6155-2020; Mazmanian, Sarkis/ABD-7729-2021	Mazmanian, Sarkis/0000-0003-2713-1513; Ton-That, Hung/0000-0003-1611-0469	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI038897] Funding Source: NIH RePORTER; NIAID NIH HHS [AI38897] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANDERSON JS, 1965, P NATL ACAD SCI USA, V53, P881, DOI 10.1073/pnas.53.4.881; BHUSHAN R, 1996, HDB THIN LAYER CHROM, V71, P427; BUGG TDH, 1991, BIOCHEMISTRY-US, V30, P10408, DOI 10.1021/bi00107a007; CHATTERJEE AN, 1964, P NATL ACAD SCI USA, V51, P9, DOI 10.1073/pnas.51.1.9; Giesbrecht P, 1998, MICROBIOL MOL BIOL R, V62, P1371, DOI 10.1128/MMBR.62.4.1371-1414.1998; HANDWERGER S, 1992, J BACTERIOL, V174, P5982, DOI 10.1128/jb.174.18.5982-5984.1992; Heijenoort J.V, 1994, NEW COMPR BIOCH, V27, P39, DOI 10.1016/S0167-7306(08)60406-8; HIGASHI Y, 1967, P NATL ACAD SCI USA, V57, P1878, DOI 10.1073/pnas.57.6.1878; IZAKI K, 1966, P NATL ACAD SCI USA, V55, P656, DOI 10.1073/pnas.55.3.656; KUO SC, 1976, ARCH BIOCHEM BIOPHYS, V172, P574, DOI 10.1016/0003-9861(76)90110-7; LABISCHINSKI H, 1994, BACTERIAL CELL WALL, P23; LINNETT PE, 1973, ANTIMICROB AGENTS CH, V4, P231, DOI 10.1128/AAC.4.3.231; MATSUHAS.M, 1967, J BIOL CHEM, V242, P3191; MATSUHASHI M, 1965, P NATL ACAD SCI USA, V54, P587, DOI 10.1073/pnas.54.2.587; Matsuhashi M., 1994, BACTERIAL CELL WALL, P55; Mazmanian SK, 1999, SCIENCE, V285, P760, DOI 10.1126/science.285.5428.760; Mazmanian SK, 2000, P NATL ACAD SCI USA, V97, P5510, DOI 10.1073/pnas.080520697; Mazmanian SK, 2001, MOL MICROBIOL, V40, P1049, DOI 10.1046/j.1365-2958.2001.02411.x; MOVITZ J, 1974, EUR J BIOCHEM, V48, P131, DOI 10.1111/j.1432-1033.1974.tb03750.x; NAKAGAWA J, 1984, J BIOL CHEM, V259, P3937; Navarre WW, 1999, J BIOL CHEM, V274, P15847, DOI 10.1074/jbc.274.22.15847; Navarre WW, 1996, J BACTERIOL, V178, P441, DOI 10.1128/jb.178.2.441-446.1996; Navarre WW, 1998, J BIOL CHEM, V273, P29135, DOI 10.1074/jbc.273.44.29135; Navarre WW, 1999, MICROBIOL MOL BIOL R, V63, P174, DOI 10.1128/MMBR.63.1.174-229.1999; NAVARRE WW, 1994, MOL MICROBIOL, V14, P115, DOI 10.1111/j.1365-2958.1994.tb01271.x; NOVICK RP, 1991, METHOD ENZYMOL, V204, P587; PETIT JF, 1968, J BIOL CHEM, V243, P757; REISINGER P, 1980, ARCH MICROBIOL, V127, P187, DOI 10.1007/BF00427192; SANDERMANN H, 1972, J BIOL CHEM, V247, P5123; SCHINDLER CA, 1964, P NATL ACAD SCI USA, V51, P414, DOI 10.1073/pnas.51.3.414; SCHNEEWIND O, 1995, SCIENCE, V268, P103, DOI 10.1126/science.7701329; SCHNEEWIND O, 1993, EMBO J, V12, P4803, DOI 10.1002/j.1460-2075.1993.tb06169.x; SCHNEEWIND O, 1992, CELL, V70, P267, DOI 10.1016/0092-8674(92)90101-H; SIEWERT G, 1967, P NATL ACAD SCI USA, V57, P767, DOI 10.1073/pnas.57.3.767; SJODAHL J, 1977, EUR J BIOCHEM, V73, P343, DOI 10.1111/j.1432-1033.1977.tb11324.x; Strominger J L, 1968, Harvey Lect, V64, P179; STROMINGER JL, 1967, FED PROC, V26, P9; TAKATSUKI A, 1971, J ANTIBIOT, V24, P215, DOI 10.7164/antibiotics.24.215; TAMURA G, 1976, AGR BIOL CHEM TOKYO, V40, P447, DOI 10.1080/00021369.1976.10862071; TIPPER DJ, 1965, P NATL ACAD SCI USA, V54, P1133, DOI 10.1073/pnas.54.4.1133; TIPPER DJ, 1968, J BIOL CHEM, V243, P3169; Ton-That H, 1998, J BIOL CHEM, V273, P29143, DOI 10.1074/jbc.273.44.29143; Ton-That H, 1999, J BIOL CHEM, V274, P24316, DOI 10.1074/jbc.274.34.24316; Ton-That H, 2000, J BIOL CHEM, V275, P9876, DOI 10.1074/jbc.275.13.9876; Ton-That H, 2002, J BIOL CHEM, V277, P7447, DOI 10.1074/jbc.M109945200; Ton-That H, 1999, P NATL ACAD SCI USA, V96, P12424, DOI 10.1073/pnas.96.22.12424; TonThat H, 1997, J BIOL CHEM, V272, P22285, DOI 10.1074/jbc.272.35.22285; VANHEIJENOORT Y, 1987, J GEN MICROBIOL, V133, P667; WARD JB, 1977, FEBS LETT, V78, P151, DOI 10.1016/0014-5793(77)80294-9; Wiedemann I, 2001, J BIOL CHEM, V276, P1772, DOI 10.1074/jbc.M006770200; YOKOGAWA K, 1974, ANTIMICROB AGENTS CH, V6, P156, DOI 10.1128/AAC.6.2.156	51	178	188	0	23	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 3	2002	277	18					16241	16248		10.1074/jbc.M109194200	http://dx.doi.org/10.1074/jbc.M109194200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	550PA	11856734	Green Accepted, hybrid			2022-12-27	WOS:000175510400134
J	Katona, G; Wilmouth, RC; Wright, PA; Berglund, GI; Hajdu, J; Neutze, R; Schofield, CJ				Katona, G; Wilmouth, RC; Wright, PA; Berglund, GI; Hajdu, J; Neutze, R; Schofield, CJ			X-ray structure of a serine protease acyl-enzyme complex at 0.95-angstrom resolution	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PORCINE PANCREATIC ELASTASE; BARRIER HYDROGEN-BOND; ATOMIC-RESOLUTION; CATALYTIC TRIAD; ACTIVE-SITES; ANGSTROM; CRYSTALLOGRAPHY; INTERMEDIATE; MECHANISM; ERRORS	Kinetic analyses led to the discovery that N-acetylated tripeptides with polar residues at P-3 are inhibitors of porcine pancreatic elastase (PPE) that form unusually stable acyl-enzyme complexes. Peptides terminating in a C-terminal carboxylate were more potent than those terminating in a C-terminal amide, suggesting recognition by the oxy-anion hole is important in binding. X-ray diffraction data were recorded to 0.95-Angstrom resolution for an acyl-enzyme complex formed between PPE and N-acetyl-Asn-Pro-Ile-Co2H at similar topH 5. The accuracy of the crystallographic coordinates allows structural issues concerning the mechanism of serine proteases to be addressed. Significantly, the ester bond of the acyl-enzyme showed a high level of planarity, suggesting geometric strain of the ester link is not important during catalysis. Several hydrogen atoms could be clearly identified and were included within the model. In keeping with a recent x-ray structure of subtilisin at 0.78 Angstrom (1), limited electron density is visible consistent with the putative location of a hydrogen atom approximately equidistant between the histidine and aspartate residues of the catalytic triad. Comparison of this high resolution crystal structure of the acyl-enzyme complex with that of native elastase at 1.1 Angstrom (2) showed that binding of the N-terminal part of the substrate can be accommodated with negligible structural rearrangements. In contrast, comparison with structures obtained as part of "time-resolved" studies on the reacting acyl-enzyme complex at >pH 7 (3) indicate small but significant structural differences, consistent with the proposed synchronization of ester hydrolysis and substrate release.	Chalmers Univ Technol, Dept Mol Biotechnol, S-40530 Gothenburg, Sweden; Dyson Perrins Lab, Oxford OX1 3QY, England; Oxford Ctr Mol Sci, Oxford OX1 3QY, England; Uppsala Univ, Ctr Biomed, Dept Biochem, S-75123 Uppsala, Sweden	Chalmers University of Technology; University of Oxford; University of Oxford; Uppsala University	Neutze, R (corresponding author), Chalmers Univ Technol, Dept Mol Biotechnol, Box 462, S-40530 Gothenburg, Sweden.	neutze@molbiotech.chalmers.se; christopher.schofield@chem.ox.ac.uk	Katona, Gergely/B-3491-2008; Neutze, Richard/A-7573-2010	Katona, Gergely/0000-0002-2031-8716; Neutze, Richard/0000-0003-0986-6153; Schofield, Christopher/0000-0002-0290-6565				Ash EL, 1997, SCIENCE, V278, P1128, DOI 10.1126/science.278.5340.1128; Ash EL, 2000, P NATL ACAD SCI USA, V97, P10371, DOI 10.1073/pnas.97.19.10371; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Betzel C, 2001, BIOCHEMISTRY-US, V40, P3080, DOI 10.1021/bi002538n; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Dauter Z, 1995, CURR OPIN STRUC BIOL, V5, P784, DOI 10.1016/0959-440X(95)80011-5; DEREWENDA ZS, 1994, J MOL BIOL, V241, P83, DOI 10.1006/jmbi.1994.1475; Dodson G, 1998, TRENDS BIOCHEM SCI, V23, P347, DOI 10.1016/S0968-0004(98)01254-7; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; FREER ST, 1970, BIOCHEMISTRY-US, V9, P1997, DOI 10.1021/bi00811a022; FREY PA, 1994, SCIENCE, V264, P1927, DOI 10.1126/science.7661899; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; HENDERSON R, 1970, Journal of Molecular Biology, V54, P341, DOI 10.1016/0022-2836(70)90434-1; Hooft RWW, 1996, NATURE, V381, P272, DOI 10.1038/381272a0; Jones TA, 1997, METHOD ENZYMOL, V277, P173, DOI 10.1016/S0076-6879(97)77012-5; KLEYWEGT GJ, 1994, ESF CCP4 NEWSLETTER, V31, P9; KRAUT J, 1971, COLD SPRING HARB SYM, V36, P117, DOI 10.1101/SQB.1972.036.01.017; Kuhn P, 1998, BIOCHEMISTRY-US, V37, P13446, DOI 10.1021/bi9813983; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; MATTHEWS BW, 1967, NATURE, V214, P652, DOI 10.1038/214652a0; Merritt EA, 1999, ACTA CRYSTALLOGR D, V55, P1109, DOI 10.1107/S0907444999003789; MEYER E, 1988, ACTA CRYSTALLOGR B, V44, P26, DOI 10.1107/S0108768187007559; MEYER EF, 1986, J MOL BIOL, V189, P533, DOI 10.1016/0022-2836(86)90322-0; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; Rypniewski WR, 2001, ACTA CRYSTALLOGR D, V57, P8, DOI 10.1107/S0907444900014116; SCHELDRICK G, 1997, METHOD ENZYMOL, V277, P319; Schneider TR, 2000, ACTA CRYSTALLOGR D, V56, P714, DOI 10.1107/S0907444900003723; Topf M, 2001, THEOR CHEM ACC, V106, P146, DOI 10.1007/s002140000246; Warshel A, 1998, J BIOL CHEM, V273, P27035, DOI 10.1074/jbc.273.42.27035; WATSON H C, 1970, Nature (London), V225, P806, DOI 10.1038/225806a0; WHITING AK, 1994, BIOCHEMISTRY-US, V33, P552, DOI 10.1021/bi00168a021; Wilmouth RC, 1997, NAT STRUCT BIOL, V4, P456, DOI 10.1038/nsb0697-456; Wilmouth RC, 2001, NAT STRUCT BIOL, V8, P689, DOI 10.1038/90401; WRIGHT CS, 1969, NATURE, V221, P235, DOI 10.1038/221235a0; Wright PA, 2001, EUR J BIOCHEM, V268, P2969, DOI 10.1046/j.1432-1327.2001.02186.x; Wurtele M, 2000, ACTA CRYSTALLOGR D, V56, P520, DOI 10.1107/S0907444900000299	36	55	56	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 14	2002	277	24					21962	21970		10.1074/jbc.M200676200	http://dx.doi.org/10.1074/jbc.M200676200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	563YR	11896054	hybrid			2022-12-27	WOS:000176286000109
J	Brinker, A; Scheufler, C; von der Mulbe, F; Fleckenstein, B; Herrmann, C; Jung, G; Moarefi, I; Hartl, FU				Brinker, A; Scheufler, C; von der Mulbe, F; Fleckenstein, B; Herrmann, C; Jung, G; Moarefi, I; Hartl, FU			Ligand discrimination by TPR domains - Relevance and selectivity of EEVD-recognition in Hsp70 center dot Hop center dot Hsp90 complexes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEINS; TETRATRICOPEPTIDE REPEAT; MOLECULAR CHAPERONE; COGNATE PROTEIN; SNAP HELIX; BINDING; HSP90; CO; MOTIF; HOP	Protein-protein interaction modules containing so-called tetratricopeptide repeats (TPRs) mediate the assembly of Hsp70/Hsp90 multi-chaperone complexes. The TPR1 and TPR2A domains of the Hsp70/Hsp90 adapter protein p60/Hop specifically bind to short peptides corresponding to the C-terminal tails of Hsp70 and Hsp90, respectively, both of which contain the highly conserved sequence motif EEVD-COOH. Here, we quantitatively assessed the contribution of TPR-mediated peptide recognition to Hsp70.Hop.Hsp90 complex formation. The interaction of TPR2A with the C-terminal pentapeptide of Hsp90 (AMEVD) is identified as the core contact for Hop binding to Hsp90. (In peptide sequences, italics are used to highlight residues specific for Hsp70 or Hsp90.) In contrast, formation of the Hsp70.Hop complex depends not only on recognition of the C-terminal Hsp70 heptapeptide (PTIEEVD) by TPR1 but also on additional contacts between Hsp70 and Hop. The sequence motifs for TPR1 and TPR2A binding were defined by alanine scanning of the C-terminal octapeptides of Hsp70 and Hsp90 and by screening of combinatorial peptide libraries. Asp0 and Val-1 of the EEVD motif are identified as general anchor residues, but the highly conserved glutamates of the EEVD sequence, which are critical in Hsp90 binding by TPR2A, do not contribute appreciably to the interaction of Hsp70 with TPR1. Rather, TPR1 prefers hydrophobic amino acids in these positions. Moreover, the TPR domains display a pronounced tendency to interact preferentially with hydrophobic aliphatic and aromatic side chains in positions -4 and -6 of their respective peptide ligands. Ile-4 in Hsp70 and Met-4 in Hsp90 are most important in determining the specific binding of TPR1 and TPR2A, respectively.	Max Planck Inst Biochem, Dept Cellular Biochem, D-85152 Martinsried, Germany; Univ Tubingen, Inst Organ Chem, D-72076 Tubingen, Germany; Max Planck Inst Mol Physiol, Dept Biol Struct, D-44227 Dortmund, Germany	Max Planck Society; Eberhard Karls University of Tubingen; Max Planck Society	Moarefi, I (corresponding author), SiREEN, Am Klopferspitz 19, D-82512 Martinsried, Germany.	moarefi@sireen.com; uhartl@biochem.mpg.de	Hartl, F. Ulrich/Y-8206-2019	Scheufler, Clemens/0000-0002-3693-3529				Abe Y, 2000, CELL, V100, P551, DOI 10.1016/S0092-8674(00)80691-1; Ballinger CA, 1999, MOL CELL BIOL, V19, P4535; Barral JM, 2002, SCIENCE, V295, P669, DOI 10.1126/science.1066648; Blatch GL, 1999, BIOESSAYS, V21, P932, DOI 10.1002/(SICI)1521-1878(199911)21:11<932::AID-BIES5>3.0.CO;2-N; Bose S, 1996, SCIENCE, V274, P1715, DOI 10.1126/science.274.5293.1715; Brinker A, 2000, EUR J BIOCHEM, V267, P5085, DOI 10.1046/j.1432-1327.2000.01570.x; Buchner J, 1999, TRENDS BIOCHEM SCI, V24, P136, DOI 10.1016/S0968-0004(99)01373-0; Caplan AJ, 1999, TRENDS CELL BIOL, V9, P262, DOI 10.1016/S0962-8924(99)01580-9; Carrello A, 1999, J BIOL CHEM, V274, P2682, DOI 10.1074/jbc.274.5.2682; Chen SY, 1996, MOL ENDOCRINOL, V10, P682, DOI 10.1210/me.10.6.682; Chen SY, 1998, J BIOL CHEM, V273, P35194, DOI 10.1074/jbc.273.52.35194; Chen SY, 1998, CELL STRESS CHAPERON, V3, P118, DOI 10.1379/1466-1268(1998)003<0118:DIOPAT>2.3.CO;2; Connell P, 2001, NAT CELL BIOL, V3, P93, DOI 10.1038/35050618; Das AK, 1998, EMBO J, V17, P1192, DOI 10.1093/emboj/17.5.1192; Demand J, 1998, MOL CELL BIOL, V18, P2023, DOI 10.1128/MCB.18.4.2023; Fleckenstein B, 1996, EUR J BIOCHEM, V240, P71, DOI 10.1111/j.1432-1033.1996.0071h.x; FREEMAN BC, 1995, EMBO J, V14, P2281, DOI 10.1002/j.1460-2075.1995.tb07222.x; Gatto GJ, 2000, NAT STRUCT BIOL, V7, P1091; Gebauer M, 1998, MOL CELL BIOL, V18, P6238, DOI 10.1128/MCB.18.11.6238; Gebauer M, 1997, FEBS LETT, V417, P109, DOI 10.1016/S0014-5793(97)01267-2; GOEBL M, 1991, TRENDS BIOCHEM SCI, V16, P173, DOI 10.1016/0968-0004(91)90070-C; Grizot S, 2001, J BIOL CHEM, V276, P21627, DOI 10.1074/jbc.M100893200; HIRANO T, 1990, CELL, V60, P319, DOI 10.1016/0092-8674(90)90746-2; HOHFELD J, 1995, CELL, V83, P589; Irmer H, 1997, J BIOL CHEM, V272, P2230; LAMB JR, 1995, TRENDS BIOCHEM SCI, V20, P257, DOI 10.1016/S0968-0004(00)89037-4; Lapouge K, 2000, MOL CELL, V6, P899, DOI 10.1016/S1097-2765(00)00087-3; Lassle M, 1997, J BIOL CHEM, V272, P1876, DOI 10.1074/jbc.272.3.1876; Liu FH, 1999, J BIOL CHEM, V274, P34425, DOI 10.1074/jbc.274.48.34425; LOFAS S, 1990, J CHEM SOC CHEM COMM, P1526, DOI 10.1039/c39900001526; Mayer MP, 1999, CURR BIOL, V9, pR322, DOI 10.1016/S0960-9822(99)80203-6; Meacham GC, 2001, NAT CELL BIOL, V3, P100, DOI 10.1038/35050509; METZGER JW, 1994, ANAL BIOCHEM, V219, P261, DOI 10.1006/abio.1994.1266; Morishima Y, 2000, J BIOL CHEM, V275, P6894, DOI 10.1074/jbc.275.10.6894; OSHANNESSY DJ, 1992, ANAL BIOCHEM, V205, P132, DOI 10.1016/0003-2697(92)90589-Y; Pratt WB, 1998, P SOC EXP BIOL MED, V217, P420; Prodromou C, 1999, EMBO J, V18, P754, DOI 10.1093/emboj/18.3.754; Ramsey AJ, 2000, J BIOL CHEM, V275, P17857, DOI 10.1074/jbc.M001625200; Russell LC, 1999, J BIOL CHEM, V274, P20060, DOI 10.1074/jbc.274.29.20060; Scheufler C, 2000, CELL, V101, P199, DOI 10.1016/S0092-8674(00)80830-2; SIKORSKI RS, 1990, CELL, V60, P307, DOI 10.1016/0092-8674(90)90745-Z; Stebbins CE, 1997, CELL, V89, P239, DOI 10.1016/S0092-8674(00)80203-2; STEVANOVIC S, 1993, ANAL BIOCHEM, V212, P212, DOI 10.1006/abio.1993.1314; Taylor P, 2001, STRUCTURE, V9, P431, DOI 10.1016/S0969-2126(01)00603-7; van der Spuy J, 2000, BIOCHEM J, V345, P645, DOI 10.1042/0264-6021:3450645; WISEMAN T, 1989, ANAL BIOCHEM, V179, P131, DOI 10.1016/0003-2697(89)90213-3; Young JC, 1997, FEBS LETT, V418, P139, DOI 10.1016/S0014-5793(97)01363-X; Young JC, 1998, J BIOL CHEM, V273, P18007, DOI 10.1074/jbc.273.29.18007; Young JC, 2001, J CELL BIOL, V154, P267, DOI 10.1083/jcb.200104079; [No title captured]	50	185	188	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 31	2002	277	22					19265	19275		10.1074/jbc.M109002200	http://dx.doi.org/10.1074/jbc.M109002200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	557EH	11877417	hybrid			2022-12-27	WOS:000175894800005
J	Cabedo, H; Luna, C; Fernandez, AM; Gallar, J; Ferrer-Montiel, A				Cabedo, H; Luna, C; Fernandez, AM; Gallar, J; Ferrer-Montiel, A			Molecular determinants of the sensory and motor neuron-derived factor insertion into plasma membrane	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GPI-ANCHORED PROTEINS; LIPID RAFTS; CELL-SURFACE; ASSOCIATION; NEUREGULIN; TRANSPORT; RECEPTORS; MICRODOMAINS; HEREGULIN; SYNAPSES	The sensory and motor neuron-derived factor (SMDF) is a type III neuregulin that regulates development and proliferation of Schwann cells. Although SMDF has been shown to be a type II protein, the molecular determinants of membrane biogenesis, insertion, and topology remain elusive. Here we used heterologous expression of a yellow fluorescent protein-SMDF fusion protein along with a stepwise deletion strategy to show that the apolar/uncharged segment (Ile(76)-Val(100)) acts as an internal, uncleaved membrane insertion signal that defines the topology of the protein. Unexpectedly, removal of the transmembrane segment (TM) did not eliminate completely membrane association of C-terminal fragments. TM-deleted fusion proteins, bearing the amino acid segment (Ser(283)-Glu(296)) located downstream to the epidermal growth factor-like motif, strongly interacted with plasma membrane fractions. However, synthetic peptides patterned after this segment did not insert into artificial lipid vesicles, suggesting that membrane interaction of the SMDF C terminus may be the result of a post-translational modification. Subcellular localization studies demonstrated that the 40-kDa form, but not the 83-kDa form, of SMDF was segregated into lipid rafts. Deletion of the N-terminal TM did not affect the interaction of the protein with these lipid microdomains. In contrast, association with membrane rafts was abolished completely by truncation of the protein C terminus. Collectively, these findings are consistent with a topological model for SMDF in which the protein associates with the plasma membrane through both the TM and the C-terminal end domains resembling the topology of other type III neuregulins. The TM defines its characteristic type II membrane topology, whereas the C terminus is a newly recognized anchoring motif that determines its compartmentalization into lipid rafts. The differential localization of the 40- and 83-kDa forms of the neuregulin into rafts and non-raft domains implies a central role in the protein biological activity.	Univ Miguel Hernandez, CSIC, Ctr Biol Mol & Celular, Alicante 03202, Spain; Univ Miguel Hernandez, CSIC, Inst Neurociencias, Alicante 03202, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); Universidad Miguel Hernandez de Elche; Consejo Superior de Investigaciones Cientificas (CSIC); Universidad Miguel Hernandez de Elche; CSIC-UMH - Instituto de Neurociencias de Alicante (IN)	Ferrer-Montiel, A (corresponding author), Univ Miguel Hernandez, CSIC, Ctr Biol Mol & Celular, Avenida Ferrocarrril S-N, Alicante 03202, Spain.		Gallar, Juana/B-4563-2011; Cabedo, Hugo/F-9404-2016; Ferrer-Montiel, Antonio/C-3072-2015; Carvajal, Asia Fernandez/G-8877-2015	Gallar, Juana/0000-0002-3559-3649; Cabedo, Hugo/0000-0002-1322-6290; Ferrer-Montiel, Antonio/0000-0002-2973-6607; Fernandez-Carvajal, Asia/0000-0003-2741-1427				Alfalah M, 1999, CURR BIOL, V9, P593, DOI 10.1016/S0960-9822(99)80263-2; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brown DA, 2000, J BIOL CHEM, V275, P17221, DOI 10.1074/jbc.R000005200; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; Buonanno A, 2001, CURR OPIN NEUROBIOL, V11, P287, DOI 10.1016/S0959-4388(00)00210-5; Burden S, 1997, NEURON, V18, P847, DOI 10.1016/S0896-6273(00)80324-4; Encinar JA, 1996, BIOPHYS J, V71, P1313, DOI 10.1016/S0006-3495(96)79331-1; Frenzel KE, 2001, J NEUROCHEM, V77, P1; Galbiati F, 2001, CELL, V106, P403, DOI 10.1016/S0092-8674(01)00472-X; HO WH, 1995, J BIOL CHEM, V270, P14523, DOI 10.1074/jbc.270.24.14523; Ikonen E, 2001, CURR OPIN CELL BIOL, V13, P470, DOI 10.1016/S0955-0674(00)00238-6; Ingham PW, 2001, SCIENCE, V294, P1879, DOI 10.1126/science.1064115; Johnston JA, 1998, J CELL BIOL, V143, P1883, DOI 10.1083/jcb.143.7.1883; Kennedy MB, 1997, TRENDS NEUROSCI, V20, P264, DOI 10.1016/S0166-2236(96)01033-8; Lafont F, 1999, P NATL ACAD SCI USA, V96, P3734, DOI 10.1073/pnas.96.7.3734; Ledesma MD, 1998, P NATL ACAD SCI USA, V95, P3966, DOI 10.1073/pnas.95.7.3966; Li QF, 2001, J BIOL CHEM, V276, P38068; Manes S, 1999, EMBO J, V18, P6211, DOI 10.1093/emboj/18.22.6211; Muniz M, 2000, EMBO J, V19, P10, DOI 10.1093/emboj/19.1.10; Osheroff PL, 1999, GROWTH FACTORS, V16, P241, DOI 10.3109/08977199909002133; Rietveld A, 1999, J BIOL CHEM, V274, P12049, DOI 10.1074/jbc.274.17.12049; Schroering A, 1998, J BIOL CHEM, V273, P30643, DOI 10.1074/jbc.273.46.30643; Wang JY, 2001, J BIOL CHEM, V276, P2841, DOI 10.1074/jbc.M005700200; Wolpowitz D, 2000, NEURON, V25, P79, DOI 10.1016/S0896-6273(00)80873-9	24	24	24	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 31	2002	277	22					19905	19912		10.1074/jbc.M201587200	http://dx.doi.org/10.1074/jbc.M201587200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	557EH	11896060	hybrid			2022-12-27	WOS:000175894800088
J	Biard, DSF; Miccoli, L; Despras, E; Frobert, Y; Creminon, C; Angulo, JF				Biard, DSF; Miccoli, L; Despras, E; Frobert, Y; Creminon, C; Angulo, JF			Ionizing radiation triggers chromatin-bound kin17 complex formation in human cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOUBLE-STRAND BREAKS; REPLICATION PROTEIN-A; DNA-BINDING-PROTEIN; CURVED DNA; NUCLEAR-PROTEIN; CELLULAR-RESPONSE; ESCHERICHIA-COLI; MAMMALIAN-CELLS; CROSS-LINKING; MOUSE PROTEIN	The human DNA-binding (HSA)kin17 protein cross-reacts with antibodies raised against the stress-activated Escherichia coli RecA protein. We show here that HSAkin17 protein is directly associated with chromosomal DNA as judged by cross-linking experiments on living cells. We detected increased amounts of DNA-bound HSAkin17 protein 24 h after gamma irradiation, with 2.6-fold more (HSA)kin17 molecules after 6 Gy of irradiation (46,000-117,000 molecules). At this time we observed that highly proliferating RKO cells displayed the concentration and co-localization of (HSA)kin17 and replication protein A in nucleoplasmic foci. Our results suggest that 24 h post-irradiation HSAkin17 protein may localize at the sites of unrepaired DNA damages. RKO clones expressing an (HSA)KIN17 antisense transcript (RASK.5 and RASK.13 cells) revealed that reduced (HSA)kin17 protein levels are correlated with a decrease in clonogenic cell growth and cell proliferation, as well as an accumulation of cells in early and mid-S phase. Taken together our observations support the idea that HSAkin17 protein is a DNA maintenance protein involved in the cellular response to the presence of DNA damage and suggest that it helps to overcome the perturbation of DNA replication produced by unrepaired lesions.	CEA, DSV, DRR, Lab Genet Radiosensibil, F-92265 Fontenay Aux Roses, France; Ctr Etud Saclay, Direct Sci Vivant, Dept Rech Med,Serv Pharmacol & Immunol, CEA, F-91191 Gif Sur Yvette, France	CEA; CEA; UDICE-French Research Universities; Universite Paris Saclay	Biard, DSF (corresponding author), CEA, DSV, DRR, Lab Genet Radiosensibil, BP 6, F-92265 Fontenay Aux Roses, France.		miccoli, laurent/N-6638-2018; ANGULO, Jaime F./B-3024-2009	miccoli, laurent/0000-0002-5242-4388; ANGULO MORA, Jaime Francisco/0000-0003-1447-2263; BIARD, Denis Serge Francois/0000-0001-9697-4392				ANGULO JF, 1989, MUTAT RES, V217, P123, DOI 10.1016/0921-8777(89)90064-5; ANGULO JF, 1991, NUCLEIC ACIDS RES, V19, P5117, DOI 10.1093/nar/19.19.5117; Araneda S, 2001, BRAIN RES BULL, V56, P139, DOI 10.1016/S0361-9230(01)00620-7; Balajee AS, 2001, NUCLEIC ACIDS RES, V29, P1341, DOI 10.1093/nar/29.6.1341; Bensaad K, 2001, ONCOGENE, V20, P3766, DOI 10.1038/sj.onc.1204492; Biard DSF, 1997, RADIAT RES, V147, P442, DOI 10.2307/3579501; Biard DSF, 1999, EXP CELL RES, V250, P499, DOI 10.1006/excr.1999.4515; Biard DSF, 1997, ARCH DERMATOL RES, V289, P448, DOI 10.1007/s004030050220; Blattner C, 2000, MOL CELL BIOL, V20, P3616, DOI 10.1128/MCB.20.10.3616-3625.2000; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Dasika GK, 1999, ONCOGENE, V18, P7883, DOI 10.1038/sj.onc.1203283; Gohring F, 1997, BIOCHEMISTRY-US, V36, P8276, DOI 10.1021/bi970480f; Golub EI, 1998, NUCLEIC ACIDS RES, V26, P5388, DOI 10.1093/nar/26.23.5388; GRASSI J, 1989, J IMMUNOL METHODS, V123, P193, DOI 10.1016/0022-1759(89)90223-8; Haaf T, 1999, J CELL BIOL, V144, P11, DOI 10.1083/jcb.144.1.11; Kannouche P, 2000, CARCINOGENESIS, V21, P1701, DOI 10.1093/carcin/21.9.1701; Kannouche P, 1998, CARCINOGENESIS, V19, P781, DOI 10.1093/carcin/19.5.781; Kurumizaka H, 1996, J BIOL CHEM, V271, P33515, DOI 10.1074/jbc.271.52.33515; Li L, 2000, NUCLEIC ACIDS RES, V28, P1424, DOI 10.1093/nar/28.6.1424; Liang F, 1998, P NATL ACAD SCI USA, V95, P5172, DOI 10.1073/pnas.95.9.5172; MacPhail SH, 2001, RADIAT RES, V155, P672, DOI 10.1667/0033-7587(2001)155[0672:RFAAWC]2.0.CO;2; Maser RS, 1997, MOL CELL BIOL, V17, P6087, DOI 10.1128/MCB.17.10.6087; MAZIN A, 1994, NUCLEIC ACIDS RES, V22, P4335, DOI 10.1093/nar/22.20.4335; MAZIN A, 1994, MOL GEN GENET, V244, P435, DOI 10.1007/BF00286696; Mermet N, 1998, NEUROSCI LETT, V243, P97, DOI 10.1016/S0304-3940(98)00094-9; NUNEZ MI, 1995, BRIT J CANCER, V71, P311, DOI 10.1038/bjc.1995.62; Oakley GG, 2001, MOL BIOL CELL, V12, P1199, DOI 10.1091/mbc.12.5.1199; Paull TT, 2000, CURR BIOL, V10, P886, DOI 10.1016/S0960-9822(00)00610-2; Rogakou EP, 1999, J CELL BIOL, V146, P905, DOI 10.1083/jcb.146.5.905; Rothkamm K, 2001, CANCER RES, V61, P3886; Schultz LB, 2000, J CELL BIOL, V151, P1381, DOI 10.1083/jcb.151.7.1381; Schweizer U, 1999, NUCLEIC ACIDS RES, V27, P3183, DOI 10.1093/nar/27.15.3183; Timchenko T, 1996, EMBO J, V15, P3986, DOI 10.1002/j.1460-2075.1996.tb00772.x; Wang M, 2000, BIOCHEMISTRY-US, V39, P6433, DOI 10.1021/bi000472q; Wang Y, 2000, GENE DEV, V14, P927; Zhong Q, 1999, SCIENCE, V285, P747, DOI 10.1126/science.285.5428.747	36	26	29	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 24	2002	277	21					19156	19165		10.1074/jbc.M200321200	http://dx.doi.org/10.1074/jbc.M200321200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	558PM	11880372	hybrid			2022-12-27	WOS:000175975800118
J	Galvagni, F; Cantini, M; Oliviero, S				Galvagni, F; Cantini, M; Oliviero, S			The utrophin gene is transcriptionally up-regulated in regenerating muscle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DYSTROPHIN-RELATED PROTEIN; SKELETAL-MUSCLE; MUSCULAR-DYSTROPHY; SATELLITE CELL; DIFFERENTIAL EXPRESSION; FUNCTIONAL-ANALYSIS; ACTIN-BINDING; MDX; PROMOTER; MICE	The utrophin gene codes for a large cytoskeletal protein closely related to dystrophin, the gene mutated in Duchenne's muscular dystrophy. Although utrophin could functionally substitute for dystrophin, in Duchenne's muscular dystrophy patients it did not compensate for the absence of dystrophin because in adult muscle utrophin was poorly expressed and limited to subsynaptic nuclei. However, increased levels of utrophin have been observed in regenerated muscles fibers suggesting that utrophin up-regulation in muscle is feasible. We observed that utrophin mRNA was transiently up-regulated at early time points after muscle Injury with a peak already 24 h after muscle damage and utrophin induction in activated satellite cells before fusion into young regenerated fibers. Injection of utrophin lacZ constructs into regenerating muscle demonstrated that the utrophin upstream promoter under the control of its intronic enhancer activated the transcription that leads to the expression of the reporter gene in the newly formed fibers, which was not limited to neuromuscular junctions. Utrophin enhancer activity was dependent on an AP-1 site, and in satellite cells of regenerating muscle the AP-1 factors Fra1, Fra2, and JunD were strongly induced. These results establish that utrophin was induced in adult muscle independently from neuromuscular junctions and suggest that growth factors and cytokines that mediate the muscle repair up-regulate utrophin transcription.	Univ Siena, Dept Biol Mol, I-53100 Siena, Italy; Univ Padua, Dipartimento Sci Biomed, Padua, Italy	University of Siena; University of Padua	Oliviero, S (corresponding author), Univ Siena, Dept Biol Mol, Via Fiorentina 1, I-53100 Siena, Italy.	oliviero@unisi.it	Galvagni, Federico/F-9186-2013; oliviero, salvatore/R-6657-2019	oliviero, salvatore/0000-0002-3405-765X	Telethon [GP0275Y01] Funding Source: Medline	Telethon(Fondazione Telethon)		Amann KJ, 1999, J BIOL CHEM, V274, P35375, DOI 10.1074/jbc.274.50.35375; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; BERGERS G, 1995, MOL CELL BIOL, V15, P3748; Birchmeier C, 1998, TRENDS CELL BIOL, V8, P404, DOI 10.1016/S0962-8924(98)01359-2; Burton EA, 1999, P NATL ACAD SCI USA, V96, P14025, DOI 10.1073/pnas.96.24.14025; CANTINI M, 1994, BIOCHEM BIOPH RES CO, V202, P1688, DOI 10.1006/bbrc.1994.2129; CANTINI M, 1995, J NEUROPATH EXP NEUR, V54, P121, DOI 10.1097/00005072-199501000-00014; CANTINI M, 1993, CELL BIOL INT, V17, P979, DOI 10.1006/cbir.1993.1025; CANTINI M, 1994, IN VITRO CELL DEV-AN, V30A, P131; Cooper RN, 1999, J CELL SCI, V112, P2895; Deconinck AE, 1997, CELL, V90, P717, DOI 10.1016/S0092-8674(00)80532-2; Dennis CL, 1996, NUCLEIC ACIDS RES, V24, P1646, DOI 10.1093/nar/24.9.1646; di Vignano AT, 2000, FEBS LETT, V471, P229, DOI 10.1016/S0014-5793(00)01400-9; Fabbro C, 1999, J BIOL CHEM, V274, P1759, DOI 10.1074/jbc.274.3.1759; Floss T, 1997, GENE DEV, V11, P2040, DOI 10.1101/gad.11.16.2040; Fromm L, 1998, GENE DEV, V12, P3074, DOI 10.1101/gad.12.19.3074; Galvagni F, 1998, J BIOL CHEM, V273, P33708, DOI 10.1074/jbc.273.50.33708; Galvagni F, 1997, MOL CELL BIOL, V17, P1731, DOI 10.1128/MCB.17.3.1731; Galvagni F, 2000, J BIOL CHEM, V275, P3168, DOI 10.1074/jbc.275.5.3168; Galvagni F, 2001, J MOL BIOL, V306, P985, DOI 10.1006/jmbi.2000.4335; Grady RM, 1997, CELL, V90, P729, DOI 10.1016/S0092-8674(00)80533-4; Gramolini AO, 1999, J NEUROPATH EXP NEUR, V58, P235, DOI 10.1097/00005072-199903000-00003; Gramolini AO, 1999, NUCLEIC ACIDS RES, V27, P3603, DOI 10.1093/nar/27.17.3603; Gramolini AO, 1997, J BIOL CHEM, V272, P8117, DOI 10.1074/jbc.272.13.8117; Gramolini AO, 1999, P NATL ACAD SCI USA, V96, P3223, DOI 10.1073/pnas.96.6.3223; HELLIWELL TR, 1992, NEUROMUSCULAR DISORD, V2, P177, DOI 10.1016/0960-8966(92)90004-P; Khurana T S, 1991, Neuromuscul Disord, V1, P185, DOI 10.1016/0960-8966(91)90023-L; KHURANA TS, 1990, J BIOL CHEM, V265, P16717; Khurana TS, 1999, MOL BIOL CELL, V10, P2075, DOI 10.1091/mbc.10.6.2075; KLAMUT HJ, 1990, MOL CELL BIOL, V10, P193, DOI 10.1128/MCB.10.1.193; KOELLE GB, 1949, P SOC EXP BIOL MED, V70, P617; LAW DJ, 1994, J CELL SCI, V107, P1477; Lescaudron L, 1999, NEUROMUSCULAR DISORD, V9, P72, DOI 10.1016/S0960-8966(98)00111-4; Lin S, 1998, J NEUROPATH EXP NEUR, V57, P780, DOI 10.1097/00005072-199808000-00007; Lin S, 2000, DEV BRAIN RES, V119, P289, DOI 10.1016/S0165-3806(99)00165-0; LOVE DR, 1989, NATURE, V339, P55, DOI 10.1038/339055a0; LOVE DR, 1991, P NATL ACAD SCI USA, V88, P3243, DOI 10.1073/pnas.88.8.3243; MATSUMURA K, 1993, FEBS LETT, V334, P281, DOI 10.1016/0014-5793(93)80695-Q; MATSUMURA K, 1992, NATURE, V360, P588, DOI 10.1038/360588a0; Matsuo K, 2000, NAT GENET, V24, P184, DOI 10.1038/72855; Mechta-Grigoriou F, 2001, ONCOGENE, V20, P2378, DOI 10.1038/sj.onc.1204381; Megeney LA, 1996, GENE DEV, V10, P1173, DOI 10.1101/gad.10.10.1173; Megeney LA, 1999, P NATL ACAD SCI USA, V96, P220, DOI 10.1073/pnas.96.1.220; NUDEL U, 1988, NATURE, V331, P635, DOI 10.1038/331635a0; ORIMO S, 1991, MUSCLE NERVE, V14, P515, DOI 10.1002/mus.880140605; PEARCE M, 1993, HUM MOL GENET, V2, P1765, DOI 10.1093/hmg/2.11.1765; PONS F, 1993, NEUROMUSCULAR DISORD, V3, P507, DOI 10.1016/0960-8966(93)90106-T; Rafael JA, 1998, NAT GENET, V19, P79, DOI 10.1038/ng0598-79; Rybakova IN, 2000, J CELL BIOL, V150, P1209, DOI 10.1083/jcb.150.5.1209; Schaeffer L, 1998, EMBO J, V17, P3078, DOI 10.1093/emboj/17.11.3078; SCHOFIELD J, 1993, DEV DYNAM, V198, P254, DOI 10.1002/aja.1001980403; Seale P, 2000, DEV BIOL, V218, P115, DOI 10.1006/dbio.1999.9565; Tatusova TA, 1999, FEMS MICROBIOL LETT, V174, P247, DOI 10.1016/S0378-1097(99)00149-4; Tinsley J, 1998, NAT MED, V4, P1441, DOI 10.1038/4033; Tinsley JM, 1996, NATURE, V384, P349, DOI 10.1038/384349a0; VITADELLO M, 1994, HUM GENE THER, V5, P11, DOI 10.1089/hum.1994.5.1-11; WINDER SJ, 1995, J CELL SCI, V108, P63; Yamamoto K, 2000, HUM GENE THER, V11, P669, DOI 10.1089/10430340050015572	58	35	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 24	2002	277	21					19106	19113		10.1074/jbc.M109642200	http://dx.doi.org/10.1074/jbc.M109642200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	558PM	11875058	hybrid			2022-12-27	WOS:000175975800112
J	Lavenu-Bombled, C; Trainor, CD; Makeh, I; Romeo, PH; Max-Audit, I				Lavenu-Bombled, C; Trainor, CD; Makeh, I; Romeo, PH; Max-Audit, I			Interleukin-13 gene expression is regulated by GATA-3 in T cells - Role of a critical association of a GATA and two GATG motifs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR GATA-3; TRANSGENIC MICE; DNA-BINDING; EMBRYONIC LETHALITY; ENFORCED EXPRESSION; GAMMA PRODUCTION; NERVOUS-SYSTEM; CUTTING EDGE; TH1 CELLS; ELEMENTS	Using a transgenic approach, we studied the role of GATA-3 in T cells. As previously shown, enforced GATA-3 expression in transgenic mice inhibits Th1 differentiation of CD4 T cells, but unexpectedly, both type 1 (interferon gamma) and type 2 (interleukin (IL)-4 and IL-13) cytokine genes were activated in the transgenic CD8 T cells. Because IL-13 gene expression was highly enhanced in vivo by GATA-3 expression, we studied the human and the mouse IL-13 gene promoters and found an evolutionary-conserved association of a consensus GATA binding site and two GATG motifs. We showed that efficient GATA-3 binding to this regulatory sequence required these three motifs and that the affinity of the GATA zinc fingers for this association was five times higher than for the consensus GATA binding site alone. Transfections in a T cell line or transactivation by GATA-3 showed that the combination of the three sites was required for full transcriptional activity of the IL-13 gene promoter. Finally we showed that this association of binding sites causes a very high sensitivity of the IL-13 gene promoter to small variations in the level of GATA-3 protein. Altogether, these results indicate an important role of GATA-3 in CD8 cytokine gene expression and demonstrate that a critical network of GATA binding sites highly modulates GATA-3 activity.	Univ Paris 05, Matern Port Royal, Dept Hematol, Inst Cochen,CNRS,INSERM, F-75014 Paris, France; NIDDK, Mol Biol Lab, NIH, Bethesda, MD 20892 USA	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Max-Audit, I (corresponding author), Univ Paris 05, Matern Port Royal, Dept Hematol, Inst Cochen,CNRS,INSERM, 123 Bd Port Royal, F-75014 Paris, France.		Lavenu-Bombled, Cecile/B-4812-2018; Romeo, Paul-Henri/L-5989-2017	Lavenu-Bombled, Cecile/0000-0002-4860-8395; Romeo, Paul-Henri/0000-0002-8294-0367				Abbas AK, 1996, NATURE, V383, P787, DOI 10.1038/383787a0; Aune TM, 1997, MOL CELL BIOL, V17, P199, DOI 10.1128/MCB.17.1.199; Carter LL, 1999, J EXP MED, V189, P1355, DOI 10.1084/jem.189.8.1355; Dolganov G, 1996, BLOOD, V87, P3316, DOI 10.1182/blood.V87.8.3316.bloodjournal8783316; ERARD F, 1993, SCIENCE, V260, P1802, DOI 10.1126/science.8511588; Ferber IA, 1999, CLIN IMMUNOL, V91, P134, DOI 10.1006/clim.1999.4718; Finotto S, 2001, J EXP MED, V193, P1247, DOI 10.1084/jem.193.11.1247; FONG TAT, 1990, J IMMUNOL, V144, P1744; Fowler DH, 1996, J IMMUNOL, V157, P4811; GEORGE KM, 1994, DEVELOPMENT, V120, P2673; GREAVES DR, 1989, CELL, V56, P979, DOI 10.1016/0092-8674(89)90631-4; Grunig G, 1998, SCIENCE, V282, P2261, DOI 10.1126/science.282.5397.2261; Hattori N, 1996, J EXP MED, V184, P1137, DOI 10.1084/jem.184.3.1137; KO LJ, 1993, MOL CELL BIOL, V13, P4011, DOI 10.1128/MCB.13.7.4011; Lee GR, 2001, IMMUNITY, V14, P447, DOI 10.1016/S1074-7613(01)00125-X; Lee HJ, 2000, J EXP MED, V192, P105, DOI 10.1084/jem.192.1.105; Lee HJ, 1998, J IMMUNOL, V160, P2343; LEROYVIARD K, 1995, EMBO J, V14, P2341, DOI 10.1002/j.1460-2075.1995.tb07229.x; LIBLAU RS, 1995, IMMUNOL TODAY, V16, P34, DOI 10.1016/0167-5699(95)80068-9; Lim KC, 2000, NAT GENET, V25, P209, DOI 10.1038/76080; MAXAUDIT I, 1993, J BIOL CHEM, V268, P5431; MCKENZIE ANJ, 1993, J IMMUNOL, V150, P5436; Nawijn MC, 2001, J IMMUNOL, V167, P715, DOI 10.4049/jimmunol.167.2.715; Nawijn MC, 2001, J IMMUNOL, V167, P724, DOI 10.4049/jimmunol.167.2.724; Ouyang W, 1998, IMMUNITY, V9, P745, DOI 10.1016/S1074-7613(00)80671-8; Ouyang WJ, 2000, IMMUNITY, V12, P27, DOI 10.1016/S1074-7613(00)80156-9; PAGANELLI R, 1995, J EXP MED, V181, P423, DOI 10.1084/jem.181.1.423; PANDOLFI PP, 1995, NAT GENET, V11, P40, DOI 10.1038/ng0995-40; Pedone PV, 1997, EMBO J, V16, P2874, DOI 10.1093/emboj/16.10.2874; PENIX L, 1993, J EXP MED, V178, P1483, DOI 10.1084/jem.178.5.1483; Ranganath S, 2001, MOL CELL BIOL, V21, P2716, DOI 10.1128/MCB.21.8.2716-2725.2001; RINCON M, 1997, CURR BIOL, V7, P729; ROBINSON DS, 1992, NEW ENGL J MED, V326, P298, DOI 10.1056/NEJM199201303260504; ROMAGNANI S, 1994, ANNU REV IMMUNOL, V12, P227, DOI 10.1146/annurev.iy.12.040194.001303; SAD S, 1995, IMMUNITY, V2, P271, DOI 10.1016/1074-7613(95)90051-9; Suzuki A, 1998, CURR BIOL, V8, P1169, DOI 10.1016/S0960-9822(07)00488-5; Szabo SJ, 2000, CELL, V100, P655, DOI 10.1016/S0092-8674(00)80702-3; Takemoto N, 2000, J IMMUNOL, V165, P6687, DOI 10.4049/jimmunol.165.12.6687; Ting CN, 1996, NATURE, V384, P474, DOI 10.1038/384474a0; Trainor CD, 2000, J BIOL CHEM, V275, P28157; Vizler C, 2000, J IMMUNOL, V165, P6314, DOI 10.4049/jimmunol.165.11.6314; Wills-Karp M, 1998, SCIENCE, V282, P2258, DOI 10.1126/science.282.5397.2258; Yang D, 2001, MOL CELL BIOL, V21, P1581, DOI 10.1128/MCB.21.5.1581-1592.2001; Zhang DH, 1999, IMMUNITY, V11, P473, DOI 10.1016/S1074-7613(00)80122-3; Zhang DH, 1998, J IMMUNOL, V161, P3817; Zhang YK, 2001, J EXP MED, V194, P165, DOI 10.1084/jem.194.2.165; Zheng WP, 1997, CELL, V89, P587, DOI 10.1016/S0092-8674(00)80240-8	47	61	62	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 24	2002	277	21					18313	18321		10.1074/jbc.M110013200	http://dx.doi.org/10.1074/jbc.M110013200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	558PM	11893731	hybrid			2022-12-27	WOS:000175975800010
J	Pandey, A; Ibarrola, N; Kratchmarova, I; Fernandez, MM; Constantinescu, SN; Ohara, O; Sawasdikosol, S; Lodish, HF; Mann, M				Pandey, A; Ibarrola, N; Kratchmarova, I; Fernandez, MM; Constantinescu, SN; Ohara, O; Sawasdikosol, S; Lodish, HF; Mann, M			A novel Src homology 2 domain-containing molecule, Src-like adapter protein-2 (SLAP-2), which negatively regulates T cell receptor signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SH3 DOMAINS; TYROSINE KINASE; ANTIGEN RECEPTOR; ACTIVATION; TRANSDUCTION; MYRISTYLATION; SELECTION; CLONING; CALCIUM; ZAP-70	We have cloned a novel adapter protein containing Src homology 2 and Src homology 3 domains similar to the Src family of tyrosine kinases. This molecule lacks a catalytic tyrosine kinase domain and is related to a previously identified protein, Src-like adapter protein (SLAP), and is therefore designated SLAP-2. Northern blot analysis indicates that SLAP-2 is predominantly expressed in the immune system. Jurkat, T cells express SLAP-2 protein and overexpression of SLAP-2 in these cells negatively regulates T cell receptor signaling as assessed by interleukin-2 promoter or NF-AT promoter reporter constructs. Mutational analysis revealed that an intact SH2 domain of SLAP-2 is essential for this inhibitory effect, whereas mutation of the SH3 domain alone has no effect. This inhibitory effect is upstream of the activation of Ras and increase of intracellular calcium levels, as no inhibition was observed when the cells were activated by phorbol ester plus ionomycin. SLAP-2 interacts with Cbl in vivo in a phosphorylation independent manner and with ZAP-70 and T cell receptor chain upon T cell receptor activation. Finally, we show that the mutation of a predicted myristoylation site within the NH2-terminal of SLAP-2 is essential for its inhibitory effect. This report therefore implicates SLAP and SLAP-2 as a family of adapter proteins that negatively regulate T cell receptor signaling.	Whitehead Inst Biomed Res, Cambridge, MA 02142 USA; Harvard Univ, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA; Univ So Denmark, Ctr Expt Bioinformat, DK-5230 Odense, Denmark; Ludwig Inst Canc Res, B-1200 Brussels, Belgium; Christian de Duve Inst Cellular Pathol, B-1200 Brussels, Belgium; Kazusa DNA Res Inst, Chiba 2920812, Japan; RIKEN Res Ctr Allergy & Immunol, Chiba 2920812, Japan; NYU, Sch Med, Skirball Inst Biomed Res, New York, NY 10016 USA	Massachusetts Institute of Technology (MIT); Whitehead Institute; Harvard University; Brigham & Women's Hospital; Harvard Medical School; University of Southern Denmark; Ludwig Institute for Cancer Research; Kazusa DNA Research Institute; RIKEN; New York University	Mann, M (corresponding author), Whitehead Inst Biomed Res, 9 Cambridge Ctr, Cambridge, MA 02142 USA.	mann@bmb.sdu.dk	Constantinescu, Stefan N/E-5277-2012; Ohara, Osamu/A-9119-2012; Mann, Matthias/A-3454-2013; Ohara, Osamu/G-5448-2015; Pandey, Akhilesh/B-4127-2009	Mann, Matthias/0000-0003-1292-4799; Ohara, Osamu/0000-0002-3328-9571; Pandey, Akhilesh/0000-0001-9943-6127; Constantinescu, Stefan N./0000-0002-8599-2699; Kratchmarova, Irina/0000-0001-6613-7315	NATIONAL CANCER INSTITUTE [K01CA075447] Funding Source: NIH RePORTER; NCI NIH HHS [KO1 CA75447] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABRAHAM N, 1990, MOL CELL BIOL, V10, P5197, DOI 10.1128/MCB.10.10.5197; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; DEFRANCO AL, 1995, CURR OPIN CELL BIOL, V7, P163, DOI 10.1016/0955-0674(95)80024-7; DONOVAN JA, 1994, J BIOL CHEM, V269, P22921; ECK MJ, 1994, NATURE, V368, P764, DOI 10.1038/368764a0; Hogquist KA, 2001, CURR OPIN IMMUNOL, V13, P225, DOI 10.1016/S0952-7915(00)00208-9; Holland SJ, 2001, J EXP MED, V194, P1263, DOI 10.1084/jem.194.9.1263; JAIN J, 1995, CURR OPIN IMMUNOL, V7, P333, DOI 10.1016/0952-7915(95)80107-3; JOHNSON DR, 1994, ANNU REV BIOCHEM, V63, P869, DOI 10.1146/annurev.bi.63.070194.004253; Kane LP, 2000, CURR OPIN IMMUNOL, V12, P242, DOI 10.1016/S0952-7915(00)00083-2; Larson SM, 2000, PROTEIN SCI, V9, P2170, DOI 10.1110/ps.9.11.2170; Latour S, 2001, CURR OPIN IMMUNOL, V13, P299, DOI 10.1016/S0952-7915(00)00219-3; Leo A, 2001, CURR OPIN IMMUNOL, V13, P307, DOI 10.1016/S0952-7915(00)00220-X; Lin J, 1999, J BIOL CHEM, V274, P28861, DOI 10.1074/jbc.274.41.28861; Makarova O, 2000, BIOTECHNIQUES, V29, P970, DOI 10.2144/00295bm08; Manes G, 2000, MOL CELL BIOL, V20, P3396, DOI 10.1128/MCB.20.10.3396-3406.2000; Mayer BJ, 1998, CURR TOP MICROBIOL, V228, P1; Mayer BJ, 2001, J CELL SCI, V114, P1253; MILLIGAN G, 1995, TRENDS BIOCHEM SCI, V20, P181, DOI 10.1016/S0968-0004(00)89004-0; NORTHROP JP, 1993, J BIOL CHEM, V268, P2917; PADGETT RA, 1986, ANNU REV BIOCHEM, V55, P1119, DOI 10.1146/annurev.bi.55.070186.005351; Padlan EA, 1997, CURR BIOL, V7, pR17, DOI 10.1016/S0960-9822(06)00010-8; Pandey A, 1999, TRENDS BIOCHEM SCI, V24, P276, DOI 10.1016/S0968-0004(99)01400-0; PANDEY A, 1995, J BIOL CHEM, V270, P19201, DOI 10.1074/jbc.270.33.19201; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; PAWSON T, 1994, ADV CANCER RES, V64, P87, DOI 10.1016/S0065-230X(08)60835-0; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; RAVICHANDRAN KS, 1993, SCIENCE, V262, P902, DOI 10.1126/science.8235613; RESH MD, 1994, CELL, V76, P411, DOI 10.1016/0092-8674(94)90104-X; Roche S, 1998, CURR BIOL, V8, P975, DOI 10.1016/S0960-9822(98)70400-2; SCHLESSINGER J, 1994, CURR OPIN GENET DEV, V4, P25, DOI 10.1016/0959-437X(94)90087-6; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; Sosinowski T, 2000, J EXP MED, V191, P463, DOI 10.1084/jem.191.3.463; Sosinowski T, 2001, IMMUNITY, V15, P457, DOI 10.1016/S1074-7613(01)00195-9; Tailor P, 1996, EUR J BIOCHEM, V237, P736, DOI 10.1111/j.1432-1033.1996.0736p.x; Tang J, 1999, P NATL ACAD SCI USA, V96, P9775, DOI 10.1073/pnas.96.17.9775; TRUNEH A, 1985, NATURE, V313, P318, DOI 10.1038/313318a0; WAKSMAN G, 1992, NATURE, V358, P646, DOI 10.1038/358646a0; Wang HY, 2001, J BIOL CHEM, V276, P26004, DOI 10.1074/jbc.M010738200; WEISS A, 1984, P NATL ACAD SCI-BIOL, V81, P4169, DOI 10.1073/pnas.81.13.4169; Wilson IA, 1997, CURR OPIN STRUC BIOL, V7, P839, DOI 10.1016/S0959-440X(97)80156-X; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303; Zhang WG, 1998, CELL, V92, P83, DOI 10.1016/S0092-8674(00)80901-0; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	44	30	35	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 24	2002	277	21					19131	19138		10.1074/jbc.M110318200	http://dx.doi.org/10.1074/jbc.M110318200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	558PM	11891219	hybrid			2022-12-27	WOS:000175975800115
J	Ramadan, K; Shevelev, IV; Maga, G; Hubscher, U				Ramadan, K; Shevelev, IV; Maga, G; Hubscher, U			DNA polymerase lambda from calf thymus preferentially replicates damaged DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASE EXCISION-REPAIR; BETA; PROTEINS; EXONUCLEASES; FIDELITY; ENZYME	A new gene (POLL), has been identified encoding the novel DNA polymerase lambda and mapped to mouse chromosome 19 and at human chromosome 10. DNA polymerase lambda contains all the critical residues involved in DNA binding, nucleotide binding, nucleotide selection, and catalysis of DNA polymerization and has been assigned to family X based on sequence homology with polymerase beta, lambda, mu, and terminal deoxynucleotidyltransferase. Here we describe a purification of DNA polymerase lambda from calf thymus that preferentially can replicate damaged DNA. By testing polymerase activity on non-damaged and damaged DNA, DNA polymerase lambda was purified trough five chromatographic steps to near homogeneity and identified as a 67-kDa polypeptide that cross-reacted with monoclonal antibodies against DNA polymerase beta and polyclonal antibodies against DNA polymerase lambda. DNA polymerase lambda had no detectable nuclease activities and, in contrast to DNA polymerase beta, was aphidicolin-sensitive. DNA polymerase lambda was a 6-fold more accurate enzyme in an M13mp2 forward mutation assay and 5-fold more accurate in an M13mp2T90 reversion system than human recombinant DNA polymerase beta. The biochemical properties of the calf thymus DNA polymerase lambda, described here for the first time, are discussed in relationship to the proposed role for this DNA polymerase in vivo.	Univ Zurich Irchel, Inst Vet Biochem & Mol Biol, CH-8057 Zurich, Switzerland; Petersburg Nucl Phys Inst, Dept Mol & Radiat Biophys, Gatchina 188300, Russia; CNR, Ist Genet Mol, I-27100 Pavia, Italy	University of Zurich; National Research Centre - Kurchatov Institute; Petersburg Nuclear Physics Institute; Consiglio Nazionale delle Ricerche (CNR); Istituto di Genetica Molecolare (IGM-CNR)	Hubscher, U (corresponding author), Univ Zurich Irchel, Inst Vet Biochem & Mol Biol, Winterthurerstr 190, CH-8057 Zurich, Switzerland.		Maga, Giovanni/C-5409-2009	Maga, Giovanni/0000-0001-8092-1552				Bork P, 1997, FASEB J, V11, P68, DOI 10.1096/fasebj.11.1.9034168; Dominguez O, 2000, EMBO J, V19, P1731, DOI 10.1093/emboj/19.7.1731; Garcia-Diaz M, 2002, J BIOL CHEM, V277, P13184, DOI 10.1074/jbc.M111601200; Garcia-Diaz M, 2001, J BIOL CHEM, V276, P34659, DOI 10.1074/jbc.M106336200; Garcia-Diaz M, 2000, J MOL BIOL, V301, P851, DOI 10.1006/jmbi.2000.4005; Hoss M, 1999, EMBO J, V18, P3868, DOI 10.1093/emboj/18.13.3868; Hubscher U, 2002, ANNU REV BIOCHEM, V71, P133, DOI 10.1146/annurev.biochem.71.090501.150041; Kunkel TA, 2000, ANNU REV BIOCHEM, V69, P497, DOI 10.1146/annurev.biochem.69.1.497; KUNKEL TA, 1984, P NATL ACAD SCI-BIOL, V81, P1494, DOI 10.1073/pnas.81.5.1494; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Osheroff WP, 1999, J BIOL CHEM, V274, P3642, DOI 10.1074/jbc.274.6.3642; Shevelev IV, 2000, MUTAT RES-DNA REPAIR, V459, P237, DOI 10.1016/S0921-8777(00)00004-5; SHIMIZU K, 1993, J BIOL CHEM, V268, P27148; SPANOS A, 1981, NUCLEIC ACIDS RES, V9, P1825, DOI 10.1093/nar/9.8.1825; Stucki M, 1998, ONCOGENE, V17, P835, DOI 10.1038/sj.onc.1202001; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WASER J, 1979, EUR J BIOCHEM, V97, P361, DOI 10.1111/j.1432-1033.1979.tb13122.x; Zhang XD, 1998, EMBO J, V17, P6404, DOI 10.1093/emboj/17.21.6404	18	62	66	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 24	2002	277	21					18454	18458		10.1074/jbc.M200421200	http://dx.doi.org/10.1074/jbc.M200421200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	558PM	11886860	Green Accepted, hybrid			2022-12-27	WOS:000175975800027
J	Ray, K; Northup, J				Ray, K; Northup, J			Evidence for distinct cation and calcimimetic compound (NPS 568) recognition domains in the transmembrane regions of the human Ca2+ receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METABOTROPIC GLUTAMATE-RECEPTOR; PROTEIN-COUPLED RECEPTORS; CALCIUM-SENSING RECEPTOR; CELL-SURFACE EXPRESSION; EXTRACELLULAR DOMAIN; SIGNAL-TRANSDUCTION; CHIMERIC RECEPTORS; LIGAND-BINDING; IDENTIFICATION; SPECIFICITY	The Ca2+ receptor, a member of the family 3 of G protein-coupled receptors (GPCR), responds not only to its primary physiological ligand Ca2+ but also to other di- and trivalent metals (Mg2+, Gd3+) and the organic polycations spermine and poly-L-Arginine. As has been found for other family 3 GPCRs, the large amino-terminal extracellular domain (ECD) of the Ca2+ receptor is the primary Ca2+ binding domain. To examine how the signal is propagated from the ECD to the seven-transmembrane core domain (7TM) we constructed a Ca2+ receptor mutant (T903-Rhoc) lacking the entire ECD but containing the 7TM. We have found that this structure initiates signaling in human embryonic kidney (HEK) 293 cells stably expressing the construct. One or more cation recognition sites are also located within the 7TM. Not only Ca2+, but also several other Ca2+ receptor-specific agonists, Mg2+, Gd3+, spermine, and poly-L-Arginine, can activate T903-Rhoc truncated receptor-initiated phosphoinositide hydrolysis in HEK 293 cells. The phenylalkylamine compound, N-PS 568, identified as a positive allosteric modulator of the Ca2+ receptor can selectively potentiate the actions of Ca2+ and other polycationic agonists on the T903-Rhoc receptor. Similarly, organic polycations synergistically activate T903-Rhoc with di- and trivalent metals. Alanine substitution of all the acidic residues in the second extracellular loop of the T903-Rhoc receptor significantly impairs activation by metal ions and organic polycations in the presence of NPS 568 but not the synergistic activation of Ca2+ with poly-L-Arginine. These data indicate that although the ECD has been thought to be the main determinant for Ca2+ recognition, the 7TM core of the Ca2+ receptor contains activating site(s) recognizing Ca2+ and Gd3+ as well as the allosteric modulators NPS 568 and organic polycations that may play important roles in the regulation of receptor activation.	NIDCD, Lab Cellular Biol, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Deafness & Other Communication Disorders (NIDCD)	Ray, K (corresponding author), NIDCD, Lab Cellular Biol, 5 Res Ct,Rm 2A-11, Rockville, MD 20850 USA.				NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [ZIADC000047, Z01DC000047] Funding Source: NIH RePORTER	NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		ADAMUS G, 1991, VISION RES, V31, P17, DOI 10.1016/0042-6989(91)90069-H; Bockaert J, 1999, EMBO J, V18, P1723, DOI 10.1093/emboj/18.7.1723; Brauner-Osborne H, 1999, J BIOL CHEM, V274, P18382, DOI 10.1074/jbc.274.26.18382; Brown EM, 2001, PHYSIOL REV, V81, P239, DOI 10.1152/physrev.2001.81.1.239; Chandrashekar J, 2000, CELL, V100, P703, DOI 10.1016/S0092-8674(00)80706-0; CONKLIN BR, 1994, NATURE, V367, P22, DOI 10.1038/367022a0; FAWZI AB, 1990, BIOCHEMISTRY-US, V29, P3804, DOI 10.1021/bi00467a030; Galvez T, 1999, J BIOL CHEM, V274, P13362, DOI 10.1074/jbc.274.19.13362; Hammerland LG, 1999, MOL PHARMACOL, V55, P642; Han GM, 1999, J BIOL CHEM, V274, P10008, DOI 10.1074/jbc.274.15.10008; Hauache OM, 2000, ENDOCRINOLOGY, V141, P4156, DOI 10.1210/en.141.11.4156; Hellmich MR, 1997, P NATL ACAD SCI USA, V94, P751, DOI 10.1073/pnas.94.2.751; Hu JX, 2000, J BIOL CHEM, V275, P16382, DOI 10.1074/jbc.M000277200; Ji TH, 1998, J BIOL CHEM, V273, P17299, DOI 10.1074/jbc.273.28.17299; Krautwurst D, 1998, CELL, V95, P917, DOI 10.1016/S0092-8674(00)81716-X; Kunishima N, 2000, NATURE, V407, P971, DOI 10.1038/35039564; Nemeth EF, 1999, TRENDS ENDOCRIN MET, V10, P66, DOI 10.1016/S1043-2760(98)00119-2; Nemeth EF, 1998, P NATL ACAD SCI USA, V95, P4040, DOI 10.1073/pnas.95.7.4040; Okamoto T, 1998, J BIOL CHEM, V273, P13089, DOI 10.1074/jbc.273.21.13089; Pearce SHS, 1996, J CLIN INVEST, V98, P1860, DOI 10.1172/JCI118987; Ray K, 1998, J BIOL CHEM, V273, P34558, DOI 10.1074/jbc.273.51.34558; Ray K, 1999, J BIOL CHEM, V274, P27642, DOI 10.1074/jbc.274.39.27642; Ray K, 1997, J BIOL CHEM, V272, P31355, DOI 10.1074/jbc.272.50.31355; RAY K, 2001, LIFEXY, P1027; Ruat M, 1996, J BIOL CHEM, V271, P5972, DOI 10.1074/jbc.271.11.5972; Samson M, 1997, J BIOL CHEM, V272, P24934, DOI 10.1074/jbc.272.40.24934; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; Sohma H, 1999, BIOCHEM J, V341, P203, DOI 10.1042/0264-6021:3410203; Sun YM, 2001, J BIOL CHEM, V276, P7754, DOI 10.1074/jbc.M009020200; Zhao XM, 1999, FEBS LETT, V448, P180, DOI 10.1016/S0014-5793(99)00368-3	30	88	92	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 24	2002	277	21					18908	18913		10.1074/jbc.M202113200	http://dx.doi.org/10.1074/jbc.M202113200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	558PM	11880385	hybrid			2022-12-27	WOS:000175975800086
J	Chambeyron, S; Bucheton, A; Busseau, I				Chambeyron, S; Bucheton, A; Busseau, I			Tandem UAA repeats at the 3 '-end of the transcript are essential for the precise initiation of reverse transcription of the I factor in Drosophila melanogaster	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-FREQUENCY RETROTRANSPOSITION; R HYBRID DYSGENESIS; MESSENGER-RNA; ORF1 PROTEIN; TRANSPOSABLE ELEMENTS; PROCESSED PSEUDOGENES; L1 RETROTRANSPOSITION; MAMMALIAN-CELLS; IDENTIFICATION; SEQUENCES	Non-long terminal repeat retrotransposons, widespread among eukaryotic genomes, transpose by reverse transcription of an RNA intermediate. Some of them, like L1 in the human, terminate at the T-end with a poly(dA) stretch whereas others, like the I factor in Drosophila melanogaster, have instead a short sequence repeated in tandem. This suggests different requirements for the initiation of reverse transcription. Here, we have used an RNA circularization/reverse transcription-PCR technique to analyze the 5'- and T-ends of the full-length transcripts produced by the I factor at the time of active retrotransposition. These transcripts are capped and polyadenylated similar to conventional messenger RNAs. We have analyzed the 3'-ends of transcripts and transposed copies produced by I elements mutated at the 3'-ends. Transcripts devoid of tandem UAA repeats, although capable of building the components of the retrotransposition machinery, are inefficiently used as retrotransposition intermediates. Such transcripts produce rare new integrated copies issued from the inaccurate initiation of reverse transcription near the 3'-end of the element. The tandem UAA repeats at the T-end of the transcripts of I are required for the efficient and precise initiation of reverse transcription. This strong specificity of the I factor reverse transcriptase for its own transcript has implications for the impact of I factor retrotransposition on the host genome.	CNRS, Inst Genet Humaine, F-34396 Montpellier 5, France	Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier	Busseau, I (corresponding author), CNRS, Inst Genet Humaine, 141 Rue Cardonille, F-34396 Montpellier 5, France.	busseau@igh.cnrs.fr		Chambeyron, severine/0000-0003-2775-6556				ABAD P, 1989, P NATL ACAD SCI USA, V86, P8887, DOI 10.1073/pnas.86.22.8887; Akhmanova A, 1998, GENOME, V41, P396; Boeke JD, 1999, NATURE, V398, P108, DOI 10.1038/18118; BOUHIDEL K, 1994, NUCLEIC ACIDS RES, V22, P2370, DOI 10.1093/nar/22.12.2370; BUCHETON A, 1984, CELL, V38, P153, DOI 10.1016/0092-8674(84)90536-1; BUCHETON A, 2002, MOBILE DNA, V2, P796; Busseau I, 1998, GENETICS, V148, P267; Capri M, 1997, MECH DEVELOP, V68, P91, DOI 10.1016/S0925-4773(97)00130-5; CHABOISSIER MC, 1990, EMBO J, V9, P3557, DOI 10.1002/j.1460-2075.1990.tb07566.x; Chaboissier MC, 2000, NUCLEIC ACIDS RES, V28, P2467, DOI 10.1093/nar/28.13.2467; CHEN F, 1995, NUCLEIC ACIDS RES, V23, P2614, DOI 10.1093/nar/23.14.2614; Couttet P, 1997, P NATL ACAD SCI USA, V94, P5628, DOI 10.1073/pnas.94.11.5628; Dawson A, 1997, EMBO J, V16, P4448, DOI 10.1093/emboj/16.14.4448; Eickbush T, 1999, SCIENCE, V283, P1465, DOI 10.1126/science.283.5407.1465; Esnault C, 2000, NAT GENET, V24, P363, DOI 10.1038/74184; FAWCETT DH, 1986, CELL, V47, P1007, DOI 10.1016/0092-8674(86)90815-9; Feng QH, 1996, CELL, V87, P905, DOI 10.1016/S0092-8674(00)81997-2; FROMONTRACINE M, 1993, NUCLEIC ACIDS RES, V21, P1683, DOI 10.1093/nar/21.7.1683; Goodier JL, 2000, HUM MOL GENET, V9, P653, DOI 10.1093/hmg/9.4.653; Graber JH, 1999, P NATL ACAD SCI USA, V96, P14055, DOI 10.1073/pnas.96.24.14055; Hohjoh H, 1996, EMBO J, V15, P630, DOI 10.1002/j.1460-2075.1996.tb00395.x; JEFFS P, 1991, P ROY SOC B-BIOL SCI, V244, P151, DOI 10.1098/rspb.1991.0064; Kazazian HH, 2000, SCIENCE, V289, P1152, DOI 10.1126/science.289.5482.1152; Kuhn J, 2002, NUCLEIC ACIDS RES, V30, P439, DOI 10.1093/nar/30.2.439; LUAN DD, 1993, CELL, V72, P595, DOI 10.1016/0092-8674(93)90078-5; MANDL CW, 1991, BIOTECHNIQUES, V10, P484; MARTIN F, 1995, J MOL BIOL, V247, P49, DOI 10.1006/jmbi.1994.0121; Martin F, 1996, TRENDS BIOCHEM SCI, V21, P283, DOI 10.1016/S0968-0004(96)80130-7; Martin SL, 2001, MOL CELL BIOL, V21, P467, DOI 10.1128/MCB.21.2.467-475.2001; MCLEAN C, 1993, MOL CELL BIOL, V13, P1042, DOI 10.1128/MCB.13.2.1042; Moran JV, 1999, SCIENCE, V283, P1530, DOI 10.1126/science.283.5407.1530; Moran JV, 1996, CELL, V87, P917, DOI 10.1016/S0092-8674(00)81998-4; Ostertag EM, 2001, ANNU REV GENET, V35, P501, DOI 10.1146/annurev.genet.35.102401.091032; PICARD G, 1978, MOL GEN GENET, V164, P235, DOI 10.1007/BF00333152; PICARD G, 1976, CR ACAD SCI D NAT, V282, P1813; Pickeral OK, 2000, GENOME RES, V10, P411, DOI 10.1101/gr.10.4.411; PontKingdon G, 1997, NUCLEIC ACIDS RES, V25, P3088, DOI 10.1093/nar/25.15.3088; PRITCHARD MA, 1988, MOL GEN GENET, V214, P533, DOI 10.1007/BF00330491; Saint Andre CD, 1998, GENETICS, V148, P1875; Seleme MD, 1999, GENETICS, V151, P761; Sugahara Y, 2001, GENE, V263, P93, DOI 10.1016/S0378-1119(00)00557-6; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; Yang J, 1998, MOL CELL BIOL, V18, P3455, DOI 10.1128/MCB.18.6.3455; Yang J, 1999, P NATL ACAD SCI USA, V96, P7847, DOI 10.1073/pnas.96.14.7847; YUE X, 1988, MOL BIOL EVOL, V5, P675	45	21	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 17	2002	277	20					17877	17882		10.1074/jbc.M200996200	http://dx.doi.org/10.1074/jbc.M200996200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	553PR	11882661	hybrid			2022-12-27	WOS:000175685100063
J	Hillion, J; Canals, M; Torvinen, M; Casado, V; Scott, R; Terasmaa, A; Hansson, A; Watson, S; Olah, ME; Mallol, J; Canela, EI; Zoli, M; Agnati, LF; Ibanez, CF; Lluis, C; Franco, R; Ferre, S; Fuxe, K				Hillion, J; Canals, M; Torvinen, M; Casado, V; Scott, R; Terasmaa, A; Hansson, A; Watson, S; Olah, ME; Mallol, J; Canela, EI; Zoli, M; Agnati, LF; Ibanez, CF; Lluis, C; Franco, R; Ferre, S; Fuxe, K			Coaggregation, cointernalization, and codesensitization of adenosine A(2A) receptors and dopamine D-2 receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							A(1); D-1; DESENSITIZATION; TRANSMISSION; IDENTIFICATION; MODULATION; DYSKINESIA; CAFFEINE; NUCLEUS; NEURONS	Antagonistic and reciprocal interactions are known to exist between adenosine and dopamine receptors in the striatum. In the present study, double immunofluorescence experiments with confocal laser microscopy showed a high degree of colocalization of adenosine A A receptors (A(2A)R) and dopamine D-2 receptors (D2R) in cell membranes of SH-SY5Y human neuroblastoma cells stably transfected with human D2R and in cultured striatal cells. A(2A)R/D2R heteromeric complexes were demonstrated in coimmunoprecipitation experiments in membrane preparations from D2R-transfected SH-SY5Y cells and from mouse fibroblast Ltk(-) cells stably transfected with human D2R (long form) and transiently cotransfected with the A(2A)R double-tagged with hemagglutinin. Long term exposure to A(2A)R and D2R agonists in D2R-cotransfected SH-SY5Y cells resulted in coaggregation, cointernalization and codesensitization of A(2A)R and D2R. These results give a molecular basis for adenosine-dopamine antagonism at the membrane level and have implications for treatment of Parkinson's disease and schizophrenia, in which D2R are involved.	Karolinska Inst, Dept Neurosci, S-17177 Stockholm, Sweden; Univ Barcelona, Dept Biochem & Mol Biol, E-08028 Barcelona, Spain; Univ Michigan, Mental Hlth Inst, Ann Arbor, MI 48109 USA; Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA; Univ Modena, Dept Biomed Sci, I-41100 Modena, Italy; NIDA, Baltimore, MD 21224 USA	Karolinska Institutet; University of Barcelona; University of Michigan System; University of Michigan; Duke University; Universita di Modena e Reggio Emilia; National Institutes of Health (NIH) - USA; NIH National Institute on Drug Abuse (NIDA)	Hillion, J (corresponding author), NINCDS, Stroke Branch, NIH, Bethesda, MD 20892 USA.	hillionj@ninds.nih.gov	Scott, Rizaldy/AAC-5264-2020; Terasmaa, Anton/I-3312-2015; Casadó, Vicent/K-1660-2014; Franco, Rafael/C-3694-2015; soler, martha maricel m gomez/L-6025-2014; Mallol, Josefa/I-4194-2015; Ferre, Sergi/K-6115-2014; Canela, Enric I./M-8726-2013; Hansson, Anita C/K-8146-2013; Zoli, Michele/C-8899-2016; Canals, Meritxell/A-6422-2013; Scott, Rizaldy/Y-7584-2019	Terasmaa, Anton/0000-0002-5139-1764; Casadó, Vicent/0000-0002-1764-3825; Franco, Rafael/0000-0003-2549-4919; soler, martha maricel m gomez/0000-0002-4412-8108; Mallol, Josefa/0000-0002-2479-4162; Ferre, Sergi/0000-0002-1747-1779; Canela, Enric I./0000-0003-4992-7440; Zoli, Michele/0000-0002-8034-2849; Scott, Rizaldy/0000-0002-0288-8862; Fuxe, Kjell/0000-0001-8491-4288; Canals, Meritxell/0000-0002-7942-5006	NATIONAL INSTITUTE ON DRUG ABUSE [ZIADA000003, Z01DA000003] Funding Source: NIH RePORTER	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		AGNATI LF, 1982, NEUROSCI LETT, V32, P253, DOI 10.1016/0304-3940(82)90302-0; Akhondzadeh S, 2000, J CLIN PHARM THER, V25, P131; Bjelke B, 1996, J CHEM NEUROANAT, V12, P37, DOI 10.1016/S0891-0618(96)00176-7; Chase TN, 2000, TRENDS NEUROSCI, V23, pS86, DOI 10.1016/S1471-1931(00)00018-5; Ciruela F, 1995, J NEUROSCI RES, V42, P818, DOI 10.1002/jnr.490420610; Dasgupta S, 1996, EUR J PHARMACOL, V316, P325, DOI 10.1016/S0014-2999(96)00665-6; DUNCAN OD, 1977, MATH DEMOGRAPHY, P349; Fenu S, 2000, BEHAV BRAIN RES, V114, P97, DOI 10.1016/S0166-4328(00)00190-X; Ferre S, 1996, EUR J NEUROSCI, V8, P1545, DOI 10.1111/j.1460-9568.1996.tb01617.x; Ferre S, 1997, PSYCHOPHARMACOLOGY, V133, P107, DOI 10.1007/s002130050380; Ferre S, 2000, PROG BRAIN RES, V125, P353; Ferre S, 1998, J BIOL CHEM, V273, P4718, DOI 10.1074/jbc.273.8.4718; Ferre S, 1997, TRENDS NEUROSCI, V20, P482, DOI 10.1016/S0166-2236(97)01096-5; FERRE S, 1991, P NATL ACAD SCI USA, V88, P7238, DOI 10.1073/pnas.88.16.7238; FINK JS, 1992, MOL BRAIN RES, V14, P186, DOI 10.1016/0169-328X(92)90173-9; FISHBURN CS, 1995, J BIOL CHEM, V270, P29819; Fuxe K, 1998, BRAIN RES REV, V26, P258, DOI 10.1016/S0165-0173(97)00049-0; GARRETT BE, 1994, EUR J PHARMACOL, V262, P65, DOI 10.1016/0014-2999(94)90029-9; Gines S, 2000, P NATL ACAD SCI USA, V97, P8606, DOI 10.1073/pnas.150241097; Kanda T, 1998, ANN NEUROL, V43, P507, DOI 10.1002/ana.410430415; Kull B, 1999, BIOCHEM PHARMACOL, V58, P1035, DOI 10.1016/S0006-2952(99)00184-7; Mundell SJ, 1998, BRIT J PHARMACOL, V125, P1594, DOI 10.1038/sj.bjp.0702234; Ng GYK, 1997, ENDOCRINOLOGY, V138, P4199, DOI 10.1210/en.138.10.4199; Nomoto M, 2000, J NEUROL, V247, P16, DOI 10.1007/PL00007779; Olah ME, 1997, J BIOL CHEM, V272, P337; PALMER TM, 1994, MOL PHARMACOL, V45, P1082; POPOLI P, 1994, EUR J PHARMACOL, V257, pR5, DOI 10.1016/0014-2999(94)90715-3; Richter A, 2000, EUR J PHARMACOL, V404, P299, DOI 10.1016/S0014-2999(00)00627-0; Salim H, 2000, J NEUROCHEM, V74, P432, DOI 10.1046/j.1471-4159.2000.0740432.x; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; Sarrio S, 2000, MOL CELL BIOL, V20, P5164, DOI 10.1128/MCB.20.14.5164-5174.2000; Saura CK, 1998, J BIOL CHEM, V273, P17610, DOI 10.1074/jbc.273.28.17610; SCHIFFMANN SN, 1991, J NEUROCHEM, V57, P1062, DOI 10.1111/j.1471-4159.1991.tb08257.x; Stromberg I, 2000, EUR J NEUROSCI, V12, P4033, DOI 10.1046/j.1460-9568.2000.00288.x; Zeng BY, 2000, EUR J NEUROSCI, V12, P1096, DOI 10.1046/j.1460-9568.2000.00988.x	35	403	414	1	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 17	2002	277	20					18091	18097		10.1074/jbc.M107731200	http://dx.doi.org/10.1074/jbc.M107731200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	553PR	11872740	Green Published, hybrid			2022-12-27	WOS:000175685100089
J	Libri, D; Duconge, F; Levy, L; Vinauger, M				Libri, D; Duconge, F; Levy, L; Vinauger, M			A role for the Psi-U mismatch in the recognition of the 5 ' splice site of yeast introns by the U1 small nuclear ribonucleoprotein particle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRE-MESSENGER-RNA; SACCHAROMYCES-CEREVISIAE; 5'-SPLICE-SITE RECOGNITION; THERMODYNAMIC PARAMETERS; SECONDARY STRUCTURE; COMPLEX-FORMATION; SNRNP; PROTEIN; IDENTIFICATION; SELECTION	The U1 small nuclear ribonucleoprotein particle (snRNP)/5' splice site (5'SS) interaction in yeast is essential for the splicing process and depends on the formation of a short RNA duplex between the 5' arm of U1 snRNA and the 1st intronic nucleotides. This RNA/RNA interaction is characterized by the presence of a mismatch that occurs with almost all yeast introns and concerns nucleotides 4 on the pre-mRNA (a U) and 5 on U1 snRNA (a P). The latter nucleotide is well conserved from yeast to vertebrates, but its role in yeast and the significance of the associated mismatch in the U1 snRNA/5'SS interaction have never been fully explained. We report here that the presence of this mismatch is a determinant of stability that mainly affects the off rate of the interaction. To our knowledge this is the first report assigning a function to this noncanonical interaction. We also performed SELEX (systematic evolution of ligands by exponential enrichment) experiments by immunoprecipitating U1 snRNP and the associated RNA. The artificial phylogeny derived from these experiments allows the isolation of the selective pressure due to U1 snRNP binding on the 5'SS of yeast introns.	CNRS, Ctr Genet Mol, F-91190 Gif Sur Yvette, France; Serv Hosp Frederic Joliot, Commissariat Energie Atom, INSERM, Equipe Rech & Innovat Tech & Methodol 0103, F-91401 Orsay, France; Inst Pasteur, F-75015 Paris, France; CNRS, Inst Sci Vegetales, F-91190 Gif Sur Yvette, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; CEA; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); Universite Paris Saclay; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay	Libri, D (corresponding author), CNRS, Ctr Genet Mol, F-91190 Gif Sur Yvette, France.		Duconge, Frederic/C-6729-2012	Duconge, Frederic/0000-0002-8595-0050				ABOVICH N, 1994, GENE DEV, V8, P843, DOI 10.1101/gad.8.7.843; Berglund JA, 1997, CELL, V89, P781, DOI 10.1016/S0092-8674(00)80261-5; Berglund JA, 1998, GENE DEV, V12, P858, DOI 10.1101/gad.12.6.858; Breckenridge DG, 1999, P NATL ACAD SCI USA, V96, P852, DOI 10.1073/pnas.96.3.852; BURGE CB, 1998, RNA WORLD, V2, P525; Chen Q, 2000, CELL DEATH DIFFER, V7, P227, DOI 10.1038/sj.cdd.4400629; Collins CA, 1999, GENE DEV, V13, P1970, DOI 10.1101/gad.13.15.1970; Du H, 2001, RNA, V7, P133, DOI 10.1017/S1355838201001844; Forch P, 2000, MOL CELL, V6, P1089, DOI 10.1016/S1097-2765(00)00107-6; Gottschalk A, 1998, RNA, V4, P374; HEINRICHS V, 1990, SCIENCE, V247, P69, DOI 10.1126/science.2136774; JAMISON SF, 1995, NUCLEIC ACIDS RES, V23, P3260, DOI 10.1093/nar/23.16.3260; Kao HY, 1996, MOL CELL BIOL, V16, P960; Kistler AL, 2001, GENE DEV, V15, P42, DOI 10.1101/gad.851301; KOHTZ JD, 1994, NATURE, V368, P119, DOI 10.1038/368119a0; KRETZNER L, 1990, P NATL ACAD SCI USA, V87, P851, DOI 10.1073/pnas.87.2.851; Libri D, 2001, GENE DEV, V15, P36, DOI 10.1101/gad.852101; Libri D, 2000, RNA, V6, P352, DOI 10.1017/S1355838200991222; Long MY, 1997, CELL, V91, P739, DOI 10.1016/S0092-8674(00)80462-6; Lopez PJ, 1999, RNA, V5, P1135, DOI 10.1017/S135583829999091X; Massenet S, 1999, MOL CELL BIOL, V19, P2142; Mathews DH, 1999, J MOL BIOL, V288, P911, DOI 10.1006/jmbi.1999.2700; McConnell TS, 2001, EMBO J, V20, P3577, DOI 10.1093/emboj/20.13.3577; Moore M., 1993, RNA WORLD, P303; NEWMAN AJ, 1992, CELL, V68, P743, DOI 10.1016/0092-8674(92)90149-7; Nilsen TW, 2002, MOL CELL, V9, P8, DOI 10.1016/S1097-2765(02)00430-6; ODay CL, 1996, J BIOL CHEM, V271, P33261, DOI 10.1074/jbc.271.52.33261; Puig O, 1999, GENE DEV, V13, P569, DOI 10.1101/gad.13.5.569; Reyes J, 1996, RNA, V2, P213; SERAPHIN B, 1993, CELL, V73, P803, DOI 10.1016/0092-8674(93)90258-R; SERAPHIN B, 1989, GENE, V82, P145, DOI 10.1016/0378-1119(89)90039-5; SERAPHIN B, 1988, EMBO J, V7, P2533, DOI 10.1002/j.1460-2075.1988.tb03101.x; Siatecka M, 1999, GENE DEV, V13, P1983, DOI 10.1101/gad.13.15.1983; SILICIANO PG, 1988, GENE DEV, V2, P1258, DOI 10.1101/gad.2.10.1258; Staley JP, 1999, MOL CELL, V3, P55, DOI 10.1016/S1097-2765(00)80174-4; Staley JP, 1998, CELL, V92, P315, DOI 10.1016/S0092-8674(00)80925-3; Stevens SW, 2002, MOL CELL, V9, P31, DOI 10.1016/S1097-2765(02)00436-7; TEIGELKAMP S, 1995, EMBO J, V14, P2602, DOI 10.1002/j.1460-2075.1995.tb07258.x; UMEN JG, 1995, GENE DEV, V9, P855, DOI 10.1101/gad.9.7.855; WACH A, 1994, YEAST, V10, P1793, DOI 10.1002/yea.320101310; WYATT JR, 1992, GENE DEV, V6, P2542, DOI 10.1101/gad.6.12b.2542; Xia TB, 1998, BIOCHEMISTRY-US, V37, P14719, DOI 10.1021/bi9809425; Zhang D, 1999, GENE DEV, V13, P581, DOI 10.1101/gad.13.5.581; Zhang D, 2001, MOL CELL, V7, P319, DOI 10.1016/S1097-2765(01)00180-0; Zhang M, 2001, GENE DEV, V15, P30, DOI 10.1101/gad.851701; Zuker M., 1999, V70, P11	46	11	12	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 17	2002	277	20					18173	18181		10.1074/jbc.M112460200	http://dx.doi.org/10.1074/jbc.M112460200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	553PR	11877437	hybrid			2022-12-27	WOS:000175685100099
J	Nakagawa, J; Ishikura, S; Asami, J; Isaji, T; Usami, N; Hara, A; Sakurai, T; Tsuritani, K; Oda, K; Takahashi, M; Yoshimoto, M; Otsuka, N; Kitamura, K				Nakagawa, J; Ishikura, S; Asami, J; Isaji, T; Usami, N; Hara, A; Sakurai, T; Tsuritani, K; Oda, K; Takahashi, M; Yoshimoto, M; Otsuka, N; Kitamura, K			Molecular characterization of mammalian dicarbonyl/L-xylulose reductase and its localization in kidney	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOSYLATION END-PRODUCTS; D-ERYTHRULOSE REDUCTASE; ALDEHYDE REDUCTASE; CARBONYL REDUCTASE; TISSUE DISTRIBUTION; SPERM PROTEIN; PURIFICATION; DIACETYL; EXPRESSION; DEHYDROGENASE	In this report, we first cloned a cDNA for a protein that is highly expressed in mouse kidney and then isolated its counterparts in human, rat hamster, and guinea pig by polymerase chain reaction-based cloning. The cDNAs of the five species encoded polypeptides of 244 amino acids, which shared more than 85% identity with each other and showed high identity with a human sperm 34-kDa protein, P34H, as well as a murine lung-specific carbonyl reductase of the short-chain dehydrogenase/reductase superfamily. In particular, the human protein is identical to P34H, except for one amino acid substitution. The purified recombinant proteins of the five species were about 100-kDa homotetramers with NADPH-linked reductase activity for alpha-dicarbonyl compounds, catalyzed the oxidoreduction between xylitol and L-xylulose, and were inhibited competitively by n-butyric acid. Therefore, the proteins are designated as dicarbonyl/L-xylulose reductases (DCXRs). The substrate specificity and kinetic constants of DCXRs for dicarbonyl compounds and sugars are similar to those of mammalian diacetyl reductase and L-xylulose reductase, respectively, and the identity of the DCXRs with these two enzymes was demonstrated by their co-purification from hamster and guinea pig livers and by protein sequencing of the hepatic enzymes. Both DCXR and its mRNA are highly expressed in kidney and liver of human and rodent tissues, and the protein was localized primarily to the inner membranes of the proximal renal tubules in murine kidneys. The results imply that P34H and diacetyl reductase (EC 1.1.1.5) are identical to L-xylulose reductase (EC 1.1.1.10), which is involved in the uronate cycle of glucose metabolism, and the unique localization of the enzyme in kidney suggests that it has a role other than in general carbohydrate metabolism.	Taisho Pharmaceut Co Ltd, Med Res Labs, Saitama 3308530, Japan; Gifu Pharmaceut Univ, Biochem Lab, Gifu 5028585, Japan	Taisho Pharmaceutical Holdings Co Ltd; Gifu Pharmaceutical University	Nakagawa, J (corresponding author), Taisho Pharmaceut Co Ltd, Med Res Labs, 1-403 Yoshino Cho, Saitama 3308530, Japan.	junichi.nakagawa@po.rd.taisho.co.jp	Isaji, Tomoya/ABC-9285-2021	Oda, Koji/0000-0002-4322-7809				ARSENIS C, 1969, J BIOL CHEM, V244, P3895; BERNARDO A, 1984, INT J BIOCHEM, V16, P1065, DOI 10.1016/0020-711X(84)90089-2; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUCALA R, 1993, P NATL ACAD SCI USA, V90, P6434, DOI 10.1073/pnas.90.14.6434; BURG MB, 1988, KIDNEY INT, V33, P635, DOI 10.1038/ki.1988.46; DVORNIK D, 1987, ALDOSE REDUCTASE INH, P222; DYER DG, 1993, J CLIN INVEST, V91, P2463, DOI 10.1172/JCI116481; FEATHER MS, 1995, BIOCHIM BIOPHYS ACTA, V197, P373; Gaudreault C, 1999, BIOL REPROD, V61, P264, DOI 10.1095/biolreprod61.1.264; GRANT ME, 1975, EUR J BIOCHEM, V54, P531, DOI 10.1111/j.1432-1033.1975.tb04166.x; Gugliucci A, 1996, DIABETOLOGIA, V39, P149, DOI 10.1007/BF00403957; HAMMES HP, 1991, P NATL ACAD SCI USA, V88, P11555, DOI 10.1073/pnas.88.24.11555; HARA A, 1983, EUR J BIOCHEM, V133, P207, DOI 10.1111/j.1432-1033.1983.tb07449.x; HARA A, 1985, ENZYMOLOGY CARBONYL, V2, P291; HAYWARD LD, 1977, CARBOHYD RES, V53, P13; HICKMAN J, 1959, J BIOL CHEM, V234, P758; HOLLMANN S, 1959, H-S Z PHYSIOL CHEM, V317, P193, DOI 10.1515/bchm2.1959.317.1.193; HORIUCHI S, 1986, J BIOL CHEM, V261, P4962; HSU SM, 1981, AM J CLIN PATHOL, V75, P816, DOI 10.1093/ajcp/75.6.816; Ishikura S, 2001, BIOCHEMISTRY-US, V40, P214, DOI 10.1021/bi001804u; JORNVALL H, 1995, BIOCHEMISTRY-US, V34, P6003, DOI 10.1021/bi00018a001; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANE AB, 1985, BIOCHEM GENET, V23, P61, DOI 10.1007/BF00499113; Legare C, 1999, ENDOCRINOLOGY, V140, P3318, DOI 10.1210/en.140.7.3318; Maeda M, 1998, J BIOCHEM-TOKYO, V123, P602; MAKITA Z, 1991, NEW ENGL J MED, V325, P836, DOI 10.1056/NEJM199109193251202; MAKITA Z, 1994, LANCET, V343, P1519, DOI 10.1016/S0140-6736(94)92935-1; Medvedev AE, 1996, BIOCHEM PHARMACOL, V52, P385, DOI 10.1016/0006-2952(96)00206-7; NAKANISHI M, 1995, EUR J BIOCHEM, V228, P381, DOI 10.1111/j.1432-1033.1995.tb20274.x; Niwa T, 1999, J CHROMATOGR B, V731, P23, DOI 10.1016/S0378-4347(99)00113-9; O'Connor T, 1999, BIOCHEM J, V343, P487, DOI 10.1042/0264-6021:3430487; OKUBO K, 1992, NAT GENET, V2, P173, DOI 10.1038/ng1192-173; Ortwerth BJ, 1998, BIOCHEM BIOPH RES CO, V245, P161, DOI 10.1006/bbrc.1998.8401; OTSUKA M, 1992, J CHROMATOGR-BIOMED, V577, P215, DOI 10.1016/0378-4347(92)80242-I; Otsuka M, 1996, J BIOCHEM-TOKYO, V119, P246; PROVECHO F, 1984, INT J BIOCHEM, V16, P423, DOI 10.1016/0020-711X(84)90142-3; Raj DSC, 2000, AM J KIDNEY DIS, V35, P365, DOI 10.1016/S0272-6386(00)70189-2; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SATO K, 1993, ARCH BIOCHEM BIOPHYS, V307, P286, DOI 10.1006/abbi.1993.1591; SCHMIDT AM, 1992, J BIOL CHEM, V267, P14987; SELL DR, 1990, J CLIN INVEST, V85, P380, DOI 10.1172/JCI114449; SUEOKA T, 1985, BIOCHIM BIOPHYS ACTA, V843, P193, DOI 10.1016/0304-4165(85)90139-4; Takenaka M, 1998, KIDNEY INT, V53, P562, DOI 10.1046/j.1523-1755.1998.00808.x; Tanaka N, 1996, STRUCTURE, V4, P33, DOI 10.1016/S0969-2126(96)00007-X; Tanaka N, 2001, CURR ORG CHEM, V5, P89, DOI 10.2174/1385272013375751; Tanji N, 2000, J AM SOC NEPHROL, V11, P1656, DOI 10.1681/ASN.V1191656; THORNALLEY PJ, 1996, GEN PHARMACOL, V27, P567; TOUSTER O, 1956, J BIOL CHEM, V221, P697; UEHARA K, 1974, J BIOCHEM, V75, P333, DOI 10.1093/oxfordjournals.jbchem.a130400; WANG YM, 1970, NEW ENGL J MED, V282, P892, DOI 10.1056/NEJM197004162821604; Weiss MF, 2000, KIDNEY INT, V57, P2571, DOI 10.1046/j.1523-1755.2000.00117.x; WINEGRAD AI, 1967, INT S METABOLISM PHY, P258; Zabner J, 2000, P NATL ACAD SCI USA, V97, P11614, DOI 10.1073/pnas.97.21.11614	53	86	93	0	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 17	2002	277	20					17883	17891		10.1074/jbc.M110703200	http://dx.doi.org/10.1074/jbc.M110703200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	553PR	11882650	hybrid			2022-12-27	WOS:000175685100064
J	Karpinich, NO; Tafani, M; Rothman, RJ; Russo, MA; Farber, JL				Karpinich, NO; Tafani, M; Rothman, RJ; Russo, MA; Farber, JL			The course of etoposide-induced apoptosis from damage to DNA and p53 activation to mitochondrial release of cytochrome c	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; PROGRAMMED CELL-DEATH; PERMEABILITY TRANSITION; TOPOISOMERASE-II; INTRACELLULAR PH; BAX; PHOSPHORYLATION; INHIBITION; TRANSLOCATION; WITHDRAWAL	Treatment of L929 fibroblasts by the topoisomerase II inhibitor etoposide killed 50% of the cells within 72 h. The cell killing was preceded by the release of cytochrome c from the mitochondria. Simultaneous treatment of the cells with wortmannin, cycloheximide, furosemide, cyclosporin A, or decylubiquinone prevented the release of cytochrome c and significantly reduced the loss of viability. Etoposide caused the phosphorylation of p53 within 6 h, an effect prevented by wortmannin, an inhibitor of DNA-dependent protein kinase (DNA-PK). The activation of p53 by etoposide resulted in the up-regulation of the pro-apoptotic protein Bax, a result that was prevented by the protein synthesis inhibitor cycloheximide. The increase in the content of Bax was followed by the translocation of this protein from the cytosol to the mitochondria, an event that was inhibited by furosemide, a chloride channel inhibitor. Stably transfected L929 fibroblasts that overexpress Akt were resistant to etoposide and did not translocate Bax to the mitochondria or release cytochrome c. Bax levels in these transfected cells were comparable with the wild-type cells. The release of cytochrome c upon translocation of Bax has been attributed to induction of the mitochondrial permeability transition (MPT). Cyclosporin A and decylubiquinone, inhibitors of MPT, prevented the release of cytochrome c without affecting Bax translocation. These data define a sequence of biochemical events that mediates the apoptosis induced by etoposide. This cascade proceeds by coupling DNA damage to p53 phosphorylation through the action of DNA-PK. The activation of p53 increases Bax synthesis. The translocation of Bax to the mitochondria induces the MPT, the event that releases cytochrome c and culminates in the death of the cells.	Thomas Jefferson Univ, Dept Pathol, Philadelphia, PA 19107 USA; Univ Roma La Sapienza, Dept Expt Med & Pathol, I-00161 Rome, Italy	Jefferson University; Sapienza University Rome	Farber, JL (corresponding author), Thomas Jefferson Univ, Dept Pathol, Rm 208,Jefferson alimni Hall, Philadelphia, PA 19107 USA.	john.farber@mail.tju.edu	Tafani, Marco/C-3275-2017; Tafani, Marco/U-7230-2019	Tafani, Marco/0000-0001-7128-810X; Tafani, Marco/0000-0001-7128-810X	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038305] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [T32AA007463] Funding Source: NIH RePORTER; NIAAA NIH HHS [T32 AA07463] Funding Source: Medline; NIDDK NIH HHS [DK 38305] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSON CW, 1993, TRENDS BIOCHEM SCI, V18, P433, DOI 10.1016/0968-0004(93)90144-C; Antonsson B, 2000, EXP CELL RES, V256, P50, DOI 10.1006/excr.2000.4839; Belaud-Rotureau MA, 2000, APOPTOSIS, V5, P551, DOI 10.1023/A:1009693630664; Broekemeier KM, 1995, BIOCHEMISTRY-US, V34, P16440, DOI 10.1021/bi00050a027; Burden DA, 1998, BBA-GENE STRUCT EXPR, V1400, P139, DOI 10.1016/S0167-4781(98)00132-8; Burns TF, 1999, J CELL PHYSIOL, V181, P231, DOI 10.1002/(SICI)1097-4652(199911)181:2<231::AID-JCP5>3.0.CO;2-L; Chao C, 2000, P NATL ACAD SCI USA, V97, P11936, DOI 10.1073/pnas.220252297; Cooper GJ, 1997, J PHYSIOL-LONDON, V498, P49, DOI 10.1113/jphysiol.1997.sp021840; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Deshmukh M, 1997, MOL PHARMACOL, V51, P897, DOI 10.1124/mol.51.6.897; Eskes R, 2000, MOL CELL BIOL, V20, P929, DOI 10.1128/MCB.20.3.929-935.2000; Fontaine E, 1998, J BIOL CHEM, V273, P25734, DOI 10.1074/jbc.273.40.25734; Goping IS, 1998, J CELL BIOL, V143, P207, DOI 10.1083/jcb.143.1.207; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; Hande KR, 1998, EUR J CANCER, V34, P1514, DOI 10.1016/S0959-8049(98)00228-7; Jackson SP, 1997, INT J BIOCHEM CELL B, V29, P935, DOI 10.1016/S1357-2725(97)00006-X; Kennedy SG, 1999, MOL CELL BIOL, V19, P5800; Khaled AR, 1999, P NATL ACAD SCI USA, V96, P14476, DOI 10.1073/pnas.96.25.14476; LEESMILLER SP, 1992, MOL CELL BIOL, V12, P5041, DOI 10.1128/MCB.12.11.5041; Loeffler M, 2000, EXP CELL RES, V256, P19, DOI 10.1006/excr.2000.4833; Martinou JC, 2000, NAT CELL BIOL, V2, pE41, DOI 10.1038/35004069; McConnell K, 1996, CURR OPIN CELL BIOL, V8, P325, DOI 10.1016/S0955-0674(96)80005-6; MIYASHITA T, 1995, CELL, V80, P293; MIZUMOTO K, 1994, MOL PHARMACOL, V46, P890; Narita M, 1998, P NATL ACAD SCI USA, V95, P14681, DOI 10.1073/pnas.95.25.14681; Pastorino JG, 1999, J BIOL CHEM, V274, P19411, DOI 10.1074/jbc.274.27.19411; Pastorino JG, 1998, J BIOL CHEM, V273, P7770, DOI 10.1074/jbc.273.13.7770; Pastorino JG, 1999, J BIOL CHEM, V274, P31734, DOI 10.1074/jbc.274.44.31734; Pawlowski J, 2000, P NATL ACAD SCI USA, V97, P529, DOI 10.1073/pnas.97.2.529; Robertson JD, 2000, J BIOL CHEM, V275, P32438, DOI 10.1074/jbc.C000518200; Sarkaria JN, 1998, CANCER RES, V58, P4375; Scheid MP, 1998, P NATL ACAD SCI USA, V95, P7439, DOI 10.1073/pnas.95.13.7439; Scheid MP, 1999, J BIOL CHEM, V274, P31108, DOI 10.1074/jbc.274.43.31108; Siliciano JD, 1997, GENE DEV, V11, P3471, DOI 10.1101/gad.11.24.3471; Smith GCM, 1999, BIOCHEM SOC SYMP, P91; Thornborrow EC, 2001, J BIOL CHEM, V276, P15598, DOI 10.1074/jbc.M011643200; Vander Heiden MG, 1999, MOL CELL, V3, P159; Wang S, 2000, P NATL ACAD SCI USA, V97, P1584, DOI 10.1073/pnas.97.4.1584; WANG Y, 1992, P NATL ACAD SCI USA, V89, P4231, DOI 10.1073/pnas.89.10.4231; Wolter KG, 1997, J CELL BIOL, V139, P1281, DOI 10.1083/jcb.139.5.1281; Zhou HL, 1998, J BIOL CHEM, V273, P16568, DOI 10.1074/jbc.273.26.16568	41	250	255	0	23	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 10	2002	277	19					16547	16552		10.1074/jbc.M110629200	http://dx.doi.org/10.1074/jbc.M110629200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	551MB	11864976	hybrid			2022-12-27	WOS:000175564500029
J	Kim, C; Crane, FL; Faulk, WP; Morre, DJ				Kim, C; Crane, FL; Faulk, WP; Morre, DJ			Purification and characterization of a doxorubicin-inhibited NADH-quinone (NADH-ferricyanide) reductase from rat liver plasma membranes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIFERRIC TRANSFERRIN REDUCTASE; COENZYME-Q REDUCTASE; HELA-CELL GROWTH; ELECTRON-TRANSPORT; OXIDASE ACTIVITY; 2-PHASE PARTITION; REDOX SYSTEMS; ADRIAMYCIN; STIMULATION; REQUIREMENT	Plasma membrane-associated redox systems play important roles in regulation of cell growth, internal pH, signal transduction, apoptosis, and defense against pathogens. Stimulation of cell growth and stimulation of the redox system of plasma membranes are correlated. When cell growth is inhibited by antitumor agents such as doxorubicin, capsaicin, and antitumor sulfonylureas, redox activities of the plasma membrane also are inhibited. A doxorubicin-inhibited NADH-quinone reductase was characterized and purified from plasma membranes of rat liver. First, an NADH-cytochrome b(5), reductase, which was doxorubicin-insensitive, was removed from the plasma membranes by the lysosomal protease, cathepsin D. After removal of the NADH-cytochrome b(5). reductase, the plasma membranes retained a doxorubicin-inhibited NADH-quinone reductase activity. The enzyme, with an apparent molecular mass of 57 kDa, was purified 200-fold over the cathepsin D-treated plasma membranes. The purified enzyme had also an NADH-coenzyme Q(o) reductase (NADH: external acceptor (quinone) reductase; EC 1.6.5..) activity. Partial amino acid sequence of the enzyme showed that it was unique with no sequence homology to any known protein. Antibody against the enzyme (peptide sequence) was produced and affinity-purified. The purified antibody immunoprecipitated both the NADH-ferricyanide reductase activity and NADH-coenzyme Qo reductase activity of plasma membranes and cross-reacted with human chronic myelogenous leukemia K562 cells and doxorubicin-resistant human chronic myelogenous leukemia K562R cells. Localization by fluorescence microscopy showed that the reaction was with the external surface of the plasma membranes. The doxorubicin-inhibited NADH-quinone reductase may provide a target for the anthracycline antitumor agents and a candidate ferricyanide reductase for plasma membrane electron transport.	Purdue Univ, Dept Med Chem & Mol Pharmacol, W Lafayette, IN 47907 USA; Purdue Univ, Dept Biol Sci, W Lafayette, IN 47907 USA; Faulk Pharmaceut Res, Indianapolis, IN 46240 USA	Purdue University System; Purdue University; Purdue University West Lafayette Campus; Purdue University System; Purdue University; Purdue University West Lafayette Campus	Kim, C (corresponding author), Purdue Univ, Dept Med Chem & Mol Pharmacol, Hansen Life Sci Res Bldg, W Lafayette, IN 47907 USA.							Albertsson P A, 1982, Methods Biochem Anal, V28, P115, DOI 10.1002/9780470110485.ch2; BARABAS K, 1992, J BIOL CHEM, V267, P9437; BARABAS K, 1991, AM J REPROD IMMUNOL, V25, P120, DOI 10.1111/j.1600-0897.1991.tb01078.x; BARABAS K, 1993, BIOCHEM BIOPH RES CO, V197, P702, DOI 10.1006/bbrc.1993.2536; BERCZI A, 1995, ARCH BIOCHEM BIOPHYS, V320, P65, DOI 10.1006/abbi.1995.1343; BRIGHTMAN AO, 1988, PLANT PHYSIOL, V86, P1264, DOI 10.1104/pp.86.4.1264; BRUNO M, 1992, BIOCHEM J, V284, P625, DOI 10.1042/bj2840625; CASTILLOOLIVARE.A, 1996, BIOCHEM J, V314, P587; CHOURY D, 1981, J CLIN INVEST, V67, P149, DOI 10.1172/JCI110007; Chueh PJ, 2000, ANTIOXID REDOX SIGN, V2, P177, DOI 10.1089/ars.2000.2.2-177; CRANE FL, 1991, J BIOENERG BIOMEMBR, V23, P773, DOI 10.1007/BF00786001; CRANE FL, 1985, BIOCHIM BIOPHYS ACTA, V811, P233, DOI 10.1016/0304-4173(85)90013-8; CRANE FL, 1994, MOL ASPECTS MED, V15, P1; ELLEM KAO, 1983, BIOCHEM BIOPH RES CO, V112, P183, DOI 10.1016/0006-291X(83)91814-4; FAULK WP, 1991, BIOCHEM INT, V25, P815; GomezDiaz C, 1997, J BIOENERG BIOMEMBR, V29, P251, DOI 10.1023/A:1022410127104; HENDERSON LM, 1987, BIOCHEM J, V246, P325, DOI 10.1042/bj2460325; ISRAEL M, 1978, CANCER RES, V38, P365; KIM C, 1995, PROTOPLASMA, V184, P111, DOI 10.1007/BF01276907; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LALIBERTE JF, 1987, J BIOENERG BIOMEMBR, V19, P69; Lesuisse E, 1996, J BIOL CHEM, V271, P13578, DOI 10.1074/jbc.271.23.13578; LOW H, 1986, BIOCHEM BIOPH RES CO, V139, P1117, DOI 10.1016/S0006-291X(86)80293-5; Luthje S, 1997, BBA-REV BIOMEMBRANES, V1331, P81, DOI 10.1016/S0304-4157(96)00016-0; Medina MA, 1997, BIOESSAYS, V19, P977, DOI 10.1002/bies.950191107; MISHRA RK, 1969, J MEMBRANE BIOL, V1, P214, DOI 10.1007/BF01869782; MORRE DJ, 1991, J BIOENERG BIOMEMBR, V23, P469, DOI 10.1007/BF00771015; MORRE DJ, 1989, BIOTECHNIQUES, V7, P946; MORRE DJ, 1995, BBA-BIOMEMBRANES, V1240, P11, DOI 10.1016/0005-2736(95)00164-7; Morre DJ, 2000, J APPL TOXICOL, V20, P157, DOI 10.1002/(SICI)1099-1263(200003/04)20:2<157::AID-JAT648>3.0.CO;2-9; MORRE DJ, 1995, P NATL ACAD SCI USA, V92, P1831, DOI 10.1073/pnas.92.6.1831; NAVARRO F, 1995, BIOCHEM BIOPH RES CO, V212, P138, DOI 10.1006/bbrc.1995.1947; NAVAS P, 1989, CANCER RES, V49, P2147; OAKEY BR, 1980, ANAL BIOCHEM, V105, P361; Santos-Ocana C, 1998, J BIOENERG BIOMEMBR, V30, P465, DOI 10.1023/A:1020542230308; SHAGGER H, 1987, ANAL BIOCHEM, V166, P368; SUN IL, 1990, BIOCHEM BIOPH RES CO, V172, P979, DOI 10.1016/0006-291X(90)91542-Z; SUN IL, 1992, P NATL ACAD SCI USA, V89, P11126, DOI 10.1073/pnas.89.23.11126; SUN IL, 1987, BIOCHEM INT, V14, P119; SUN IL, 1984, J BIOENERG BIOMEMBR, V16, P209, DOI 10.1007/BF00751050; SUN IL, 1984, BIOCHEM INT, V9, P299; SUN IL, 1984, BIOCHEM BIOPH RES CO, V125, P649, DOI 10.1016/0006-291X(84)90588-6; SUN IL, 1985, BIOCHEM PHARMACOL, V34, P617, DOI 10.1016/0006-2952(85)90254-0; SUN IL, 1992, BIOCHIM BIOPHYS ACTA, V1105, P84, DOI 10.1016/0005-2736(92)90165-I; SUN IL, 1985, EXP CELL RES, V156, P528, DOI 10.1016/0014-4827(85)90559-2; SUN IL, 1987, J BIOL CHEM, V262, P15915; SZEKELY M, 1952, ACTA PHYSIOL HUNG, V3, P571; TAKESUE S, 1968, BIOCHEM BIOPH RES CO, V30, P723, DOI 10.1016/0006-291X(68)90573-1; TRITTON TR, 1982, SCIENCE, V217, P248, DOI 10.1126/science.7089561; VILLALBA JM, 1995, P NATL ACAD SCI USA, V92, P4887, DOI 10.1073/pnas.92.11.4887; WANG CS, 1978, J SUPRAMOL STR CELL, V9, P1, DOI 10.1002/jss.400090102; Wang S, 2001, BBA-MOL CELL RES, V1539, P192, DOI 10.1016/S0167-4889(01)00107-0; Wilkinson F, 1996, ARCH BIOCHEM BIOPHYS, V336, P275, DOI 10.1006/abbi.1996.0558	53	23	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 10	2002	277	19					16441	16447		10.1074/jbc.M112311200	http://dx.doi.org/10.1074/jbc.M112311200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	551MB	11875069	hybrid			2022-12-27	WOS:000175564500015
J	Lefrancois, S; May, T; Knight, C; Bourbeau, D; Morales, CR				Lefrancois, S; May, T; Knight, C; Bourbeau, D; Morales, CR			The lysosomal transport of prosaposin requires the conditional interaction of its highly conserved D domain with sphingomyelin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPHINGOLIPID ACTIVATOR PROTEINS; GAUCHER DISEASE VARIANT; SERTOLI CELLS; SAPOSIN-D; IN-VITRO; DEGRADATION; RAT; ENZYMES; OLIGOSACCHARIDES; IDENTIFICATION	Lysosomal prosaposin (65 kDa) is a nonenzymic protein that is transported to the lysosomes in a mannose 6-phosphate-independent manner. Selective deletion of the functional domains of prosaposin indicates that the D domain and the carboxyl-terminal region are necessary for its transport to the lysosomes. Inhibitors of sphingolipid biosynthesis, such as fumonisin B-1 (FB1) and tricyclodecan-9-yl xanthate potassium salt (D609), also interfere with the trafficking of prosaposin to lysosomes. In this study, we examine sphingomyelin as a direct candidate for the trafficking of prosaposin. Chinese hamster ovary and COS-7 cells overexpressing prosaposin or an albumin/prosaposin construct were incubated with these inhibitors, treated with sphingolipids, and then immunostained. Sphingomyelin restored the immunostaining in lysosomes in both FB1- and D609-treated cells and ceramide reestablished the immunostaining in FB1-treated cells only. D-Threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol (PDMP), which inhibits glycosphingolipids, had no effect on the immunostaining pattern. To determine whether sphingomyelin has the same effect on the transport of endogenous prosaposin, testicular explants were treated with FB1 and D609. Sphingomyelin restored prosaposin immunogold labeling in the lysosomes of FB1- and D609-treated Sertoli cells, whereas ceramide restored the label in FB1 treatment only. Albumin linked to the D and COOH-terminal domains of prosaposin was used as a dominant negative competitor. The construct blocked the targeting of prosaposin and induced accumulation of membrane in the lysosomes, demonstrating that the construct uses the same transport pathway as endogenous prosaposin. In conclusion, our results showed that sphingomyelin, the D domain, and its adjacent COOH-terminal region play a crucial role in the transport of prosaposin to lysosomes. Although the precise nature of this lipid-protein interaction is not well established, it is proposed that sphingomyelin microdomains (lipid rafts) are part of a mechanism ensuring correct intercellular trafficking of prosaposin.	McGill Univ, Dept Anat & Cell Biol, Montreal, PQ H3A 2B2, Canada	McGill University	Morales, CR (corresponding author), McGill Univ, Dept Anat & Cell Biol, 3640 Univ St, Montreal, PQ H3A 2B2, Canada.		Morales, Carlos R./H-1055-2011					CHRISTOMANOU H, 1986, BIOL CHEM H-S, V367, P879, DOI 10.1515/bchm3.1986.367.2.879; Ciaffoni F, 2001, J BIOL CHEM, V276, P31583, DOI 10.1074/jbc.M102736200; CONZELMANN E, 1978, P NATL ACAD SCI USA, V75, P3979, DOI 10.1073/pnas.75.8.3979; FUTERMAN AH, 1990, J BIOL CHEM, V265, P8650; GARTNER S, 1983, J BIOL CHEM, V258, P2378; HASILIK A, 1981, BIOCHEM BIOPH RES CO, V98, P761, DOI 10.1016/0006-291X(81)91177-3; Hiraiwa M, 1997, ARCH BIOCHEM BIOPHYS, V341, P17, DOI 10.1006/abbi.1997.9958; HO MW, 1971, P NATL ACAD SCI USA, V68, P2810, DOI 10.1073/pnas.68.11.2810; IGDOURA SA, 1995, MOL REPROD DEV, V40, P91, DOI 10.1002/mrd.1080400112; Igdoura SA, 1996, CELL TISSUE RES, V283, P385, DOI 10.1007/s004410050549; Ikonen E, 2001, CURR OPIN CELL BIOL, V13, P470, DOI 10.1016/S0955-0674(00)00238-6; KAPLAN A, 1977, P NATL ACAD SCI USA, V74, P2026, DOI 10.1073/pnas.74.5.2026; KLEINSCHMIDT T, 1987, BIOL CHEM H-S, V368, P1571, DOI 10.1515/bchm3.1987.368.2.1571; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; KORNFELD S, 1986, J CLIN INVEST, V77, P1, DOI 10.1172/JCI112262; KOVAL M, 1991, BIOCHIM BIOPHYS ACTA, V1082, P113, DOI 10.1016/0005-2760(91)90184-J; Lefrancois S, 1999, J LIPID RES, V40, P1593; Lin S, 1996, J BIOL CHEM, V271, P19689, DOI 10.1074/jbc.271.33.19689; Luberto C, 1998, J BIOL CHEM, V273, P14550, DOI 10.1074/jbc.273.23.14550; Morales CR, 2001, MOL REPROD DEV, V59, P54, DOI 10.1002/mrd.1007; Moran JF, 1996, PLANT PHYSIOL, V111, P327; MORIMOTO S, 1988, BIOCHEM BIOPH RES CO, V156, P403, DOI 10.1016/S0006-291X(88)80855-6; Mort JS, 1997, INT J BIOCHEM CELL B, V29, P715, DOI 10.1016/S1357-2725(96)00152-5; NOLAN CM, 1989, METABOLIC BASIS INHE, P1589; OBRIEN JS, 1988, SCIENCE, V241, P1098, DOI 10.1126/science.2842863; OBRIEN JS, 1991, FASEB J, V5, P301, DOI 10.1096/fasebj.5.3.2001789; REITMAN ML, 1981, J BIOL CHEM, V256, P1977; RIJNBOUTT S, 1991, J BIOL CHEM, V266, P4862; Sandhoff K, 1997, CLIN CHIM ACTA, V266, P51, DOI 10.1016/S0009-8981(97)00166-6; SANO A, 1994, BIOCHEM BIOPH RES CO, V204, P994, DOI 10.1006/bbrc.1994.2558; SCHWARZ A, 1995, J BIOL CHEM, V270, P10990, DOI 10.1074/jbc.270.18.10990; Scriver CS, 2000, METABOLIC MOL BASES, P3421; Sleat DE, 1996, J BIOL CHEM, V271, P19191, DOI 10.1074/jbc.271.32.19191; STEVENS RL, 1981, AM J HUM GENET, V33, P255; VARKI A, 1980, J BIOL CHEM, V255, P8398; Zhao Q, 2000, J BIOL CHEM, V275, P24829, DOI 10.1074/jbc.M003497200; Zhao Q, 1997, MOL REPROD DEV, V48, P1, DOI 10.1002/(SICI)1098-2795(199709)48:1&lt;1::AID-MRD1&gt;3.0.CO;2-N	37	24	25	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 10	2002	277	19					17188	17199		10.1074/jbc.M200343200	http://dx.doi.org/10.1074/jbc.M200343200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	551MB	11856752	hybrid			2022-12-27	WOS:000175564500112
J	Pardo-Lopez, L; Zhang, M; Liu, J; Jiang, M; Possani, LD; Tseng, GN				Pardo-Lopez, L; Zhang, M; Liu, J; Jiang, M; Possani, LD; Tseng, GN			Mapping the binding site of a human ether-a-go-go-related gene-specific peptide toxin (ErgTx) to the channel's outer vestibule	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POTASSIUM CHANNEL; K+ CHANNEL; I-KR; CHARYBDOTOXIN BLOCK; SCORPION VENOMS; RECEPTOR-SITE; HERG-CHANNEL; MECHANISM; PORE; RECTIFICATION	The goals of this study are to investigate the mechanism and site of action whereby a human ether-a-go-go-related gene (HERG)-specific scorpion peptide toxin, ErgTx, suppresses HERG current. We apply cysteine-scanning mutagenesis to the S5-P and P-S6 linkers of HERG and examine the resulting changes in ErgTx potency. Data are compared with the characteristics of charybdotoxin (ChTx, or its analogs) binding to the Shaker channel. ErgTx binds to the outer vestibule of HERG but may not physically occlude the pore. In contrast to ChTx-Shaker interaction, elevating [K](o) (from 2 to 98 mm) does not affect ErgTx potency, and through-solution electrostatic forces only play a minor role in influencing ErgTx.HERG interaction. Cysteine mutations of three positions in S5-P linker (Trp-585, Gly-590, and Ile-593) and 1 position in P-S6 linker (Pro-632) induce profound changes in ErgTx binding (DeltaDeltaG > 2 kcal/ mol). We propose that the long S5-P linker of the HERG channel forms an amphipathic a-helix that, together with the P-S6 linker, forms a hydrophobic ErgTx binding site. This study paves the way for future mutant cycle analysis of interacting residues in the ErgTx.HERG complex, which, in conjunction with NMR determination of the ErgTx solution structure, will yield information about the topology of HERG's outer vestibule.	Virginia Commonwealth Univ, Dept Physiol, Richmond, VA 23298 USA; Univ Nacl Autonoma Mexico, Inst Biotechnol, Cuernavaca 62210, Morelos, Mexico	Virginia Commonwealth University; Universidad Nacional Autonoma de Mexico	Tseng, GN (corresponding author), Virginia Commonwealth Univ, Dept Physiol, 1101 E Marshall St, Richmond, VA 23298 USA.	gtseng@hsc.vcu.edu	Possani, Lourival D/J-2397-2013	Pardo Lopez, Liliana/0000-0002-8927-1733	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL046451] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 46451] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; Dun W, 1999, PFLUG ARCH EUR J PHY, V439, P141, DOI 10.1007/s004240051138; EISENBERG D, 1984, P NATL ACAD SCI-BIOL, V81, P140, DOI 10.1073/pnas.81.1.140; Fan JS, 1999, BIOPHYS J, V76, P3128, DOI 10.1016/S0006-3495(99)77464-3; Garcia ML, 2001, TOXICON, V39, P739, DOI 10.1016/S0041-0101(00)00214-2; GOLDSTEIN SAN, 1993, BIOPHYS J, V65, P1613, DOI 10.1016/S0006-3495(93)81200-1; GOLDSTEIN SAN, 1994, NEURON, V12, P1377, DOI 10.1016/0896-6273(94)90452-9; Gross A, 1996, NEURON, V16, P399, DOI 10.1016/S0896-6273(00)80057-4; Gurrola GB, 1999, FASEB J, V13, P953, DOI 10.1096/fasebj.13.8.953; HEGINBOTHAM L, 1992, NEURON, V8, P483, DOI 10.1016/0896-6273(92)90276-J; HIDALGO P, 1995, SCIENCE, V268, P307, DOI 10.1126/science.7716527; Imredy JP, 2000, J MOL BIOL, V296, P1283, DOI 10.1006/jmbi.2000.3522; Jiang M, 1999, AM J PHYSIOL-HEART C, V277, pH1283, DOI 10.1152/ajpheart.1999.277.4.H1283; MACKINNON R, 1989, SCIENCE, V245, P1382, DOI 10.1126/science.2476850; MACKINNON R, 1990, NEURON, V5, P767, DOI 10.1016/0896-6273(90)90335-D; MACKINNON R, 1988, NEURON, V1, P997, DOI 10.1016/0896-6273(88)90156-0; Naranjo D, 1996, NEURON, V16, P123, DOI 10.1016/S0896-6273(00)80029-X; Numaguchi H, 2000, CIRC RES, V87, P1012, DOI 10.1161/01.RES.87.11.1012; Pardo-Lopez L, 2002, FEBS LETT, V510, P45, DOI 10.1016/S0014-5793(01)03218-5; Possani LD, 1999, PERSPECT DRUG DISCOV, V16, P15; Ranganathan R, 1996, NEURON, V16, P131, DOI 10.1016/S0896-6273(00)80030-6; Rauer H, 2000, J BIOL CHEM, V275, P1201, DOI 10.1074/jbc.275.2.1201; Roden DM, 1999, CARDIOVASC RES, V44, P242, DOI 10.1016/S0008-6363(99)00224-2; SANGUINETTI MC, 1995, CELL, V81, P299, DOI 10.1016/0092-8674(95)90340-2; SCALONI A, 2000, FEBS LETT, V479, P155; SCHREIBMAYER W, 1994, PFLUG ARCH EUR J PHY, V426, P453, DOI 10.1007/BF00388310; Smith PL, 1996, NATURE, V379, P833, DOI 10.1038/379833a0; Spector PS, 1996, J GEN PHYSIOL, V107, P611, DOI 10.1085/jgp.107.5.611; STOCKER M, 1994, P NATL ACAD SCI USA, V91, P9509, DOI 10.1073/pnas.91.20.9509; Tseng GN, 2001, J MOL CELL CARDIOL, V33, P835, DOI 10.1006/jmcc.2000.1317; TSENGCRANK JCL, 1990, FEBS LETT, V268, P63, DOI 10.1016/0014-5793(90)80973-M; Tytgat J, 1999, TRENDS PHARMACOL SCI, V20, P444, DOI 10.1016/S0165-6147(99)01398-X; Wang SM, 1997, FEBS LETT, V417, P43, DOI 10.1016/S0014-5793(97)01245-3	33	87	91	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 10	2002	277	19					16403	16411		10.1074/jbc.M200460200	http://dx.doi.org/10.1074/jbc.M200460200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	551MB	11864985	hybrid			2022-12-27	WOS:000175564500010
J	Wick, MJ; Wick, KR; Chen, H; He, HL; Dong, LQ; Quon, MJ; Liu, F				Wick, MJ; Wick, KR; Chen, H; He, HL; Dong, LQ; Quon, MJ; Liu, F			Substitution of the autophosphorylation site Thr(516) with a negatively charged residue confers constitutive activity to mouse 3-phosphoinositide-dependent protein kinase-1 in cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATION; PHOSPHORYLATION; INSULIN; TRANSLOCATION; MECHANISM; 3-KINASE; SERUM; LOCALIZATION; EXPRESSION; SIGNALS	3-Phosphoinositide-dependent protein kinase-1 (PDK-1) is a serine/threonine kinase that has been found to phosphorylate and activate several members of the AGC protein kinase family including protein kinase B (Akt), p70 S6 kinase, and protein kinase Czeta. However, the mechanism(s) by which PDK-1 is regulated remains unclear. Here we show that mouse PDK-1 (mPDK-1) undergoes autophosphorylation in vitro on both serine and threonine residues. In addition, we have identified Ser(399) and Thr(516) as the major mPDK-1 autophosphorylation sites in vitro. Furthermore, we have found that these two residues, as well as Ser(244) in the activation loop, are phosphorylated in cells and demonstrated that Ser(244) is a major in vivo phosphorylation site. Abolishment of phosphorylation at Ser(244), but not at Ser(399) or Thr(516), led to a significant decrease of mPDK-1 autophosphorylation and kinase activity in vitro, indicating that autophosphorylation at Ser(399) or Thr(516) is not essential for mPDK-1 autokinase activity. However, overexpression of mPDK-1(T516E), but not of mPDK-1(S244E) or mPDK-1(S399D), in Chinese hamster ovary and HEK293 cells was sufficient to induce Akt phosphorylation at Thr(308) to a level similar to that of insulin stimulation. Furthermore, this increase in phosphorylation was independent of the Pleckstrin homology domain of Akt. Taken together, our results suggest that mPDK-1 undergoes autophosphorylation at multiple sites and that this phosphorylation may be essential for PDK-1 to interact with and phosphorylate its downstream substrates in vivo.	Univ Texas, Hlth Sci Ctr, Dept Pharmacol, San Antonio, TX 78229 USA; Univ Texas, Hlth Sci Ctr, Dept Biochem, San Antonio, TX 78229 USA; NHLBI, Cardiol Branch, NIH, Bethesda, MD 20892 USA	University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Liu, F (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Pharmacol, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA.	liuf@uthscsa.edu	Quon, Michael/B-1970-2008	QUON, MICHAEL/0000-0002-5289-3707; Quon, Michael/0000-0002-9601-9915	NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE [ZIAAT000002, Z01AT000002] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK056166] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [T32AG000205] Funding Source: NIH RePORTER; NIA NIH HHS [2T32AG00205-11] Funding Source: Medline; NIDDK NIH HHS [DK56166] Funding Source: Medline	NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Alessi DR, 1998, CURR OPIN GENET DEV, V8, P55, DOI 10.1016/S0959-437X(98)80062-2; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Alessi DR, 1998, CURR BIOL, V8, P69, DOI 10.1016/S0960-9822(98)70037-5; Anderson KE, 1998, CURR BIOL, V8, P684, DOI 10.1016/S0960-9822(98)70274-X; Andjelkovic M, 1997, J BIOL CHEM, V272, P31515, DOI 10.1074/jbc.272.50.31515; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; Casamayor A, 1999, BIOCHEM J, V342, P287, DOI 10.1042/0264-6021:3420287; Chen H, 2001, BIOCHEMISTRY-US, V40, P11851, DOI 10.1021/bi010743c; Chou MM, 1998, CURR BIOL, V8, P1069, DOI 10.1016/S0960-9822(98)70444-0; Currie RA, 1999, BIOCHEM J, V337, P575, DOI 10.1042/0264-6021:3370575; Dong LQ, 1999, J BIOL CHEM, V274, P8117, DOI 10.1074/jbc.274.12.8117; Dong LQ, 2000, P NATL ACAD SCI USA, V97, P5089, DOI 10.1073/pnas.090491897; Dong LQ, 1997, J BIOL CHEM, V272, P29104, DOI 10.1074/jbc.272.46.29104; Dutil EM, 1998, CURR BIOL, V8, P1366, DOI 10.1016/S0960-9822(98)00017-7; Filippa N, 2000, MOL CELL BIOL, V20, P5712, DOI 10.1128/MCB.20.15.5712-5721.2000; Flynn P, 2000, J BIOL CHEM, V275, P11064, DOI 10.1074/jbc.275.15.11064; Kobayashi T, 1999, BIOCHEM J, V344, P189, DOI 10.1042/0264-6021:3440189; Kobayashi T, 1999, BIOCHEM J, V339, P319, DOI 10.1042/0264-6021:3390319; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; Le Good JA, 1998, SCIENCE, V281, P2042, DOI 10.1126/science.281.5385.2042; Paradis S, 1998, GENE DEV, V12, P2488, DOI 10.1101/gad.12.16.2488; Park J, 1999, EMBO J, V18, P3024, DOI 10.1093/emboj/18.11.3024; Park J, 2001, J BIOL CHEM, V276, P37459, DOI 10.1074/jbc.M105916200; Pullen N, 1998, SCIENCE, V279, P707, DOI 10.1126/science.279.5351.707; Stephens L, 1998, SCIENCE, V279, P710, DOI 10.1126/science.279.5351.710; Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567; Toker A, 2000, CELL, V103, P185, DOI 10.1016/S0092-8674(00)00110-0; Vanhaesebroeck B, 2000, BIOCHEM J, V346, P561, DOI 10.1042/0264-6021:3460561; Wick K. L. R., 2001, Current Drug Targets - Immune Endocrine and Metabolic Disorders, V1, P209; Wick MJ, 2000, J BIOL CHEM, V275, P40400, DOI 10.1074/jbc.M003937200	31	38	39	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 10	2002	277	19					16632	16638		10.1074/jbc.M112402200	http://dx.doi.org/10.1074/jbc.M112402200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	551MB	11877406	hybrid			2022-12-27	WOS:000175564500040
J	Huang, YZ; Roelink, H; McKnight, GS				Huang, YZ; Roelink, H; McKnight, GS			Protein kinase A deficiency causes axially localized neural tube defects in mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TERMINAL CLEAVAGE PRODUCT; PROGENITOR-CELL IDENTITY; SONIC-HEDGEHOG; CATALYTIC SUBUNIT; OOCYTE MATURATION; SIGNALING PATHWAY; GENE-EXPRESSION; NEURONAL FATE; SITE UPSTREAM; FLOOR PLATE	We have studied the function of protein kinase A (PKA) during embryonic development using a PKA-deficient mouse that retains only one functional catalytic subunit allele, either Calpha or Cbeta, of PKA. The reduced PKA activity results in neural tube defects that are specifically localized posterior to the forelimb buds and lead to spina bifida. The affected neural tube has closed appropriately but exhibits an enlarged lumen and abnormal neuroepithelium. Decreased PKA activity causes dorsal expansion of Sonic hedgehog signal response in the thoracic to sacral regions correlating with the regions of morphological abnormalities. Other regions of the neural tube appear normal. The regional sensitivity to changes in PKA activity indicates that downstream signaling pathways differ along the anterior-posterior axis and suggests a functional role for PKA activation in neural tube development.	Univ Washington, Sch Med, Dept Pharmacol, Seattle, WA 98195 USA; Univ Washington, Sch Med, Dept Biol Struct, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	McKnight, GS (corresponding author), Univ Washington, Sch Med, Dept Pharmacol, Seattle, WA 98195 USA.	mcknight@u.washington.edu		Roelink, Henk/0000-0002-5260-3634	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032875] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM32875] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alcedo J, 2000, MOL CELL, V6, P457, DOI 10.1016/S1097-2765(00)00044-7; Altaba ARI, 1998, DEVELOPMENT, V125, P2203; ARMSTRONG JF, 1995, CURR BIOL, V5, P931, DOI 10.1016/S0960-9822(95)00183-7; BORNSLAEGER EA, 1986, DEV BIOL, V114, P453, DOI 10.1016/0012-1606(86)90209-5; Briscoe J, 1999, NATURE, V398, P622, DOI 10.1038/19315; Briscoe J, 2000, CELL, V101, P435, DOI 10.1016/S0092-8674(00)80853-3; CADD G, 1989, NEURON, V3, P71, DOI 10.1016/0896-6273(89)90116-5; Chiang C, 1996, NATURE, V383, P407, DOI 10.1038/383407a0; CLEGG CH, 1987, J BIOL CHEM, V262, P13111; Copp Andrew J., 1994, Current Opinion in Pediatrics, V6, P624, DOI 10.1097/00008480-199412000-00002; Cross TG, 2000, EXP CELL RES, V256, P34, DOI 10.1006/excr.2000.4836; Desseyn JL, 2000, P NATL ACAD SCI USA, V97, P6433, DOI 10.1073/pnas.97.12.6433; Epstein DJ, 1996, DEVELOPMENT, V122, P2885; Ericson J, 1997, CELL, V90, P169, DOI 10.1016/S0092-8674(00)80323-2; Ericson J, 1996, CELL, V87, P661, DOI 10.1016/S0092-8674(00)81386-0; FAN CM, 1995, CELL, V81, P457, DOI 10.1016/0092-8674(95)90398-4; FRANZ T, 1993, ANAT EMBRYOL, V187, P371; Goodrich LV, 1998, NEURON, V21, P1243, DOI 10.1016/S0896-6273(00)80645-5; Goodrich LV, 1997, SCIENCE, V277, P1109, DOI 10.1126/science.277.5329.1109; Guthrie CR, 1997, J BIOL CHEM, V272, P29560, DOI 10.1074/jbc.272.47.29560; Hannaford PC, 1996, BAILLIERE CLIN OB GY, V10, P647, DOI 10.1016/S0950-3552(96)80010-1; Harris MJ, 1999, TERATOLOGY, V60, P292, DOI 10.1002/(SICI)1096-9926(199911)60:5<292::AID-TERA10>3.3.CO;2-Y; HOMANICS GE, 1995, TERATOLOGY, V51, P1, DOI 10.1002/tera.1420510102; HUI CC, 1994, DEV BIOL, V162, P402, DOI 10.1006/dbio.1994.1097; HUI CC, 1993, NAT GENET, V3, P241, DOI 10.1038/ng0393-241; HYNES M, 1995, NEURON, V15, P35, DOI 10.1016/0896-6273(95)90062-4; Ingham PW, 1998, EMBO J, V17, P3505, DOI 10.1093/emboj/17.13.3505; Juriloff DM, 2000, HUM MOL GENET, V9, P993, DOI 10.1093/hmg/9.6.993; MARTI E, 1995, DEVELOPMENT, V121, P2537; MARTI E, 1995, NATURE, V375, P322, DOI 10.1038/375322a0; MATTEN W, 1994, MOL CELL BIOL, V14, P4419, DOI 10.1128/MCB.14.7.4419; McKnight GS, 1991, CURR OPIN CELL BIOL, V3, P213; Orlov SN, 1999, CELL DEATH DIFFER, V6, P661, DOI 10.1038/sj.cdd.4400539; Parvathenani LK, 1998, J BIOL CHEM, V273, P6736, DOI 10.1074/jbc.273.12.6736; PERRIMON N, 1995, CELL, V80, P517, DOI 10.1016/0092-8674(95)90503-0; POUEYMIROU WT, 1989, DEV BIOL, V133, P588, DOI 10.1016/0012-1606(89)90061-4; Qi M, 1996, P NATL ACAD SCI USA, V93, P1571, DOI 10.1073/pnas.93.4.1571; ROELINK H, 1995, CELL, V81, P445, DOI 10.1016/0092-8674(95)90397-6; ROELINK H, 1994, CELL, V76, P761, DOI 10.1016/0092-8674(94)90514-2; Roelink H, 1996, CURR OPIN NEUROBIOL, V6, P33, DOI 10.1016/S0959-4388(96)80006-7; SAH VP, 1995, NAT GENET, V10, P175, DOI 10.1038/ng0695-175; Sasaki H, 1999, DEVELOPMENT, V126, P3915; Skalhegg BS, 2002, MOL ENDOCRINOL, V16, P630, DOI 10.1210/me.16.3.630; Spector D. L., 1998, CELLS LAB MANUAL; STUMPO DJ, 1995, P NATL ACAD SCI USA, V92, P944, DOI 10.1073/pnas.92.4.944; Theil T, 1999, DEVELOPMENT, V126, P3561; Wang BL, 2000, CELL, V100, P423, DOI 10.1016/S0092-8674(00)80678-9; Ying LT, 2000, NAT NEUROSCI, V3, P979, DOI 10.1038/79916; Zimmermann B, 1999, J BIOL CHEM, V274, P5370, DOI 10.1074/jbc.274.9.5370	49	79	80	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 31	2002	277	22					19889	19896		10.1074/jbc.M111412200	http://dx.doi.org/10.1074/jbc.M111412200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	557EH	11886853	hybrid			2022-12-27	WOS:000175894800086
J	Ren, J; Li, YQ; Kufe, D				Ren, J; Li, YQ; Kufe, D			Protein kinase C beta regulates function of the DF3/MUC1 carcinoma antigen in beta-catenin signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; MEDIATED CELL-ADHESION; TRANSCRIPTION FACTOR LEF-1; TUMOR-SUPPRESSOR PROTEIN; E-CADHERIN; TYROSINE PHOSPHORYLATION; PROTEOLYTIC ACTIVATION; CYTOPLASMIC DOMAIN; GENETIC-DEFECTS; MAMMARY-GLAND	The DF3/MUC1 mucin-like glycoprotein is aberrantly overexpressed in most human carcinomas. The MUC1 cytoplasmic domain interacts directly with beta-catenin, a component of the adherens junction of mammalian epithelial cells. The present results demonstrate that MUC1 associates with protein kinase Cdelta (PKCdelta). A TDR sequence adjacent to the beta-catenin binding motif in the MUC1 cytoplasmic domain functions as a site for PKCdelta phosphorylation. We show that phosphorylation of MUC1 by PKCdelta increases binding of MUC1 and beta-catenin in vitro and in vivo. The functional significance of the MUC1-PKCdelta interaction is further supported by the demonstration that mutation of the PKCdelta phosphorylation site abrogates MUC1-mediated decreases in binding of beta-catenin to E-cadherin. We also show that the stimulatory effects of MUC1 on anchorage-independent growth are abrogated by mutation of the PKCdelta phosphorylation site. These findings support a novel role for PKCdelta in regulating the interaction between MUC1 and the beta-catenin signaling pathway.	Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School	Kufe, D (corresponding author), Harvard Univ, Sch Med, Dana Farber Canc Inst, 44 Binney St, Boston, MA 02115 USA.				NCI NIH HHS [CA87421] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R21CA087421] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Baruch A, 1997, INT J CANCER, V71, P741; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; BOYER JC, 1995, CANCER RES, V55, P6063; DENNING MF, 1993, J BIOL CHEM, V268, P26079; Denning MF, 1996, J BIOL CHEM, V271, P5325, DOI 10.1074/jbc.271.10.5325; Emoto Y, 1995, EMBO J, V14, P6148, DOI 10.1002/j.1460-2075.1995.tb00305.x; GENDLER S, 1988, J BIOL CHEM, V263, P12820; Ghayur T, 1996, J EXP MED, V184, P2399, DOI 10.1084/jem.184.6.2399; Guilford P, 1998, NATURE, V392, P402, DOI 10.1038/32918; HILKENS J, 1984, INT J CANCER, V34, P197, DOI 10.1002/ijc.2910340210; Hornia A, 1999, MOL CELL BIOL, V19, P7672; Huber O, 1996, MECH DEVELOP, V59, P3, DOI 10.1016/0925-4773(96)00597-7; KINTNER C, 1992, CELL, V69, P225, DOI 10.1016/0092-8674(92)90404-Z; Kondo K, 1998, CANCER RES, V58, P2014; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; KUFE D, 1984, HYBRIDOMA, V3, P223, DOI 10.1089/hyb.1984.3.223; Li LW, 1999, MOL CELL BIOL, V19, P8547; LI WQ, 1994, MOL CELL BIOL, V14, P6727, DOI 10.1128/MCB.14.10.6727; Li YQ, 1998, MOL CELL BIOL, V18, P7216, DOI 10.1128/MCB.18.12.7216; Li YQ, 2001, J BIOL CHEM, V276, P35239, DOI 10.1074/jbc.C100359200; Li YQ, 2001, J BIOL CHEM, V276, P6061, DOI 10.1074/jbc.C000754200; Lu ZM, 1997, MOL CELL BIOL, V17, P3418, DOI 10.1128/MCB.17.6.3418; Majumder PK, 2000, J BIOL CHEM, V275, P21793, DOI 10.1074/jbc.C000048200; Majumder PK, 2001, CELL GROWTH DIFFER, V12, P465; Matassa AA, 2001, J BIOL CHEM, V276, P29719, DOI 10.1074/jbc.M100273200; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; MUNEMITSU S, 1995, P NATL ACAD SCI USA, V92, P3046, DOI 10.1073/pnas.92.7.3046; NAGAFUCHI A, 1994, J CELL BIOL, V127, P235, DOI 10.1083/jcb.127.1.235; NAGAFUCHI A, 1989, CELL REGUL, V1, P37, DOI 10.1091/mbc.1.1.37; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; OZAWA M, 1990, P NATL ACAD SCI USA, V87, P4246, DOI 10.1073/pnas.87.11.4246; Rubinfeld B, 1997, SCIENCE, V275, P1790, DOI 10.1126/science.275.5307.1790; RUBINFELD B, 1993, SCIENCE, V262, P1731, DOI 10.1126/science.8259518; Schroeder JA, 2001, J BIOL CHEM, V276, P13057, DOI 10.1074/jbc.M011248200; Shiozaki H, 1996, CANCER, V77, P1605, DOI 10.1002/(SICI)1097-0142(19960415)77:8+<1605::AID-CNCR4>3.3.CO;2-R; SIDDIQUI J, 1988, P NATL ACAD SCI USA, V85, P2320, DOI 10.1073/pnas.85.7.2320; SU LK, 1993, SCIENCE, V262, P1734, DOI 10.1126/science.8259519; TAKEICHI M, 1990, ANNU REV BIOCHEM, V59, P237, DOI 10.1146/annurev.biochem.59.1.237; VLEMINCKX K, 1991, CELL, V66, P107, DOI 10.1016/0092-8674(91)90143-M; Yamamoto M, 1997, J BIOL CHEM, V272, P12492, DOI 10.1074/jbc.272.19.12492; Yuan ZM, 1998, ONCOGENE, V16, P1643, DOI 10.1038/sj.onc.1201698; Zang Q, 1997, J BIOL CHEM, V272, P13275, DOI 10.1074/jbc.272.20.13275	44	127	147	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 17	2002	277	20					17616	17622		10.1074/jbc.M200436200	http://dx.doi.org/10.1074/jbc.M200436200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	553PR	11877440	hybrid			2022-12-27	WOS:000175685100030
J	Dorenbos, R; Stein, T; Kabel, J; Bruand, C; Bolhuis, A; Bron, S; Quax, WJ; van Dijl, JM				Dorenbos, R; Stein, T; Kabel, J; Bruand, C; Bolhuis, A; Bron, S; Quax, WJ; van Dijl, JM			Thiol-disulfide oxidoreductases are essential for the production of the lantibiotic sublancin 168	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACILLUS-SUBTILIS ATCC-6633; GRAM-POSITIVE BACTERIA; LACTOCOCCUS-LACTIS; NUCLEOTIDE-SEQUENCE; MASS-SPECTROMETRY; GENE-CLUSTER; PROTEIN; PEPTIDE; IMMUNITY; NISIN	Thiol-disulfide oxidoreductases are required for disulfide bond formation in proteins that are exported from the cytoplasm. Four enzymes of this type, termed BdbA, BdbB, BdbC, and BdbD, have been identified in the Gram-positive eubacterium Bacillus subtilis. BdbC and BdbD have been shown to be critical for the folding of a protein required for DNA uptake during natural competence. In contrast, no function has been assigned so far to the BdbA and BdbB proteins. The bdbA and bdbB genes are located in one operon that also contains the genes specifying the lantibiotic sublancin 168 and the ATP-binding cassette transporter SunT. Interestingly sublancin 168 contains two disulfide bonds. The present studies demonstrate that SunT and BdbB, but not BdbA, are required for the production of active sublancin 168. In addition, the BdbB paralogue BdbC is at least partly able to replace BdbB in sublancin 168 production. These observations show the unprecedented involvement of thiol-disulfide oxidoreductases in the synthesis of a peptide antibiotic. Notably BdbB cannot complement BdbC in competence development, showing that these two closely related thiol-disulfide oxidoreductases have different, but partly overlapping, substrate specificities.	Univ Groningen, Dept Pharmaceut Biol, NL-9713 AV Groningen, Netherlands; Univ Frankfurt, Inst Mikrobiol, D-60439 Frankfurt, Germany; INRA, F-78352 Jouy En Josas, France; Univ Groningen, Dept Genet, NL-9750 AA Haren, Netherlands	University of Groningen; Goethe University Frankfurt; INRAE; UDICE-French Research Universities; Universite Paris Saclay; University of Groningen	Quax, WJ (corresponding author), Univ Warwick, Dept Biol Sci, Coventry CV4 7AL, W Midlands, England.		Quax, Wim/O-2875-2019; Bolhuis, Albert/E-9932-2010; Bruand, Claude/AAF-7695-2020; van Dijl, Jan Maarten/G-1205-2013; Quax, Wim/K-2802-2012	Quax, Wim/0000-0002-5162-9947; Bolhuis, Albert/0000-0001-9307-0515; Quax, Wim/0000-0002-5162-9947; Bruand, Claude/0000-0002-2367-0782				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; BABASAKI K, 1985, J BIOCHEM, V98, P585, DOI 10.1093/oxfordjournals.jbchem.a135315; BARDWELL JCA, 1993, P NATL ACAD SCI USA, V90, P1038, DOI 10.1073/pnas.90.3.1038; Bolhuis A, 1999, J BIOL CHEM, V274, P24531, DOI 10.1074/jbc.274.35.24531; CHAKICHERLA A, 1995, J BIOL CHEM, V270, P23533, DOI 10.1074/jbc.270.40.23533; CHUNG YJ, 1992, J BACTERIOL, V174, P1417, DOI 10.1128/jb.174.4.1417-1422.1992; Chung YS, 1998, MOL MICROBIOL, V29, P905, DOI 10.1046/j.1365-2958.1998.00989.x; FATH MJ, 1993, MICROBIOL REV, V57, P995, DOI 10.1128/MMBR.57.4.995-1017.1993; Franke CM, 1999, J BIOL CHEM, V274, P8484, DOI 10.1074/jbc.274.13.8484; FREMAUX C, 1995, MICROBIOL-SGM, V141, P1637, DOI 10.1099/13500872-141-7-1637; Guder A, 2000, BIOPOLYMERS, V55, P62, DOI 10.1002/1097-0282(2000)55:1<62::AID-BIP60>3.3.CO;2-P; HEMPHILL HE, 1980, CAN J MICROBIOL, V28, P1328; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; ISHIHARA T, 1995, J BACTERIOL, V177, P745, DOI 10.1128/jb.177.3.745-749.1995; JACK RW, 1995, MICROBIOL REV, V59, P171, DOI 10.1128/MMBR.59.2.171-200.1995; Kiesau P, 1997, J BACTERIOL, V179, P1475, DOI 10.1128/jb.179.5.1475-1481.1997; Kim L, 1996, GENE, V181, P71, DOI 10.1016/S0378-1119(96)00466-0; KLEIN C, 1994, APPL ENVIRON MICROB, V60, P2793, DOI 10.1128/AEM.60.8.2793-2801.1994; KUIPERS OP, 1993, EUR J BIOCHEM, V216, P281, DOI 10.1111/j.1432-1033.1993.tb18143.x; Kunst F, 1997, NATURE, V390, P249, DOI 10.1038/36786; KUNST F, 1995, J BACTERIOL, V177, P2403, DOI 10.1128/jb.177.9.2403-2407.1995; Kussmann M, 1997, J MASS SPECTROM, V32, P593; Landry F, 2000, ANAL BIOCHEM, V279, P1, DOI 10.1006/abio.1999.4468; Lazarevic V, 1999, MICROBIOL-UK, V145, P1055, DOI 10.1099/13500872-145-5-1055; Leenhouts K, 1996, MOL GEN GENET, V253, P217, DOI 10.1007/s004380050315; Marx R, 2001, J PROTEIN CHEM, V20, P501, DOI 10.1023/A:1012562631268; McAuliffe O, 2001, FEMS MICROBIOL REV, V25, P285, DOI 10.1016/S0168-6445(00)00065-6; McLaughlin RE, 1999, FEMS MICROBIOL LETT, V175, P171, DOI 10.1016/S0378-1097(99)00189-5; Meima R, 2002, J BIOL CHEM, V277, P6994, DOI 10.1074/jbc.M111380200; Moller S, 2001, BIOINFORMATICS, V17, P646, DOI 10.1093/bioinformatics/17.7.646; NORRANDER J, 1983, GENE, V26, P101, DOI 10.1016/0378-1119(83)90040-9; Paik SH, 1998, J BIOL CHEM, V273, P23134, DOI 10.1074/jbc.273.36.23134; Peschel A, 1996, J BACTERIOL, V178, P531, DOI 10.1128/jb.178.2.531-536.1996; Ritz D, 2001, ANNU REV MICROBIOL, V55, P21, DOI 10.1146/annurev.micro.55.1.21; Sahl HG, 1998, ANNU REV MICROBIOL, V52, P41, DOI 10.1146/annurev.micro.52.1.41; Sambrook J., 2002, MOL CLONING LAB MANU; Saris PEJ, 1996, ANTON LEEUW INT J G, V69, P151, DOI 10.1007/BF00399420; SIEGERS K, 1995, APPL ENVIRON MICROB, V61, P1082, DOI 10.1128/AEM.61.3.1082-1089.1995; Sonenshein A.L., 2001, BACILLUS SUBTILIS IT; Stein T, 2002, J BACTERIOL, V184, P1703, DOI 10.1128/JB.184.6.1703-1711.2002; STODDARD GW, 1992, APPL ENVIRON MICROB, V58, P1952, DOI 10.1128/AEM.58.6.1952-1961.1992; Tjalsma H, 2000, MICROBIOL MOL BIOL R, V64, P515, DOI 10.1128/MMBR.64.3.515-547.2000; Vagner V, 1998, MICROBIOL-SGM, V144, P3097, DOI 10.1099/00221287-144-11-3097; VANDERMEER JR, 1994, J BIOL CHEM, V269, P3555; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; Zheng GL, 2000, J BACTERIOL, V182, P3266, DOI 10.1128/JB.182.11.3266-3273.2000	47	94	105	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 10	2002	277	19					16682	16688		10.1074/jbc.M201158200	http://dx.doi.org/10.1074/jbc.M201158200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	551MB	11872755	Green Published, hybrid			2022-12-27	WOS:000175564500046
J	Guerranti, R; Aguiyi, JC; Neri, S; Leoncini, R; Pagani, R; Marinello, E				Guerranti, R; Aguiyi, JC; Neri, S; Leoncini, R; Pagani, R; Marinello, E			Proteins from Mucuna pruriens and enzymes from Echis carinatus venom - Characterization and cross-reactions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SAW-SCALED VIPER; PLATELET-AGGREGATION INHIBITOR; AMINO-ACID-SEQUENCE; PHOSPHOLIPASE A(2); PROTHROMBIN ACTIVATOR; ANIMAL LECTINS; PURIFICATION; BINDING; COMPLEX	Mucuna pruriens seeds have been widely used against snakebite in traditional medicine. The antivenin property of a water extract of seeds was assessed in vivo in mice. The serum of mice treated with extract was tested for its immunological properties. Two proteins of Echis carinatus venom with apparent molecular masses of 25 and 16 kDa were detected by Western blot analysis carried out using IgG of mice immunized with extract or its partially purified protein fractions. By enzymatic in-gel digestion and electrospray ionization-mass spectrometry/mass spectrometry analysis of immunoreactive venom proteins, phospholipase A(2), the most toxic enzyme of snake venom, was identified. These results demonstrate that the observed antivenin activity has an immune mechanism. Antibodies of mice treated with non-lethal doses of venom reacted against some proteins of M. pruriens extract. Proteins of E. carinatus venom and M. pruriens extract have at least one epitope in common as confirmed by immunodiffusion assay.	Univ Siena, Inst Biochem & Enzymol, I-53100 Siena, Italy; Univ Jos, Dept Pharmacol, Jos, Nigeria	University of Siena; University of Jos	Marinello, E (corresponding author), Univ Siena, Inst Biochem & Enzymol, Via A Moro 2, I-53100 Siena, Italy.		Leoncini, Roberto/D-4050-2012; Leoncini, Roberto/D-2247-2012	Leoncini, Roberto/0000-0001-5587-2074; 				Aguiyi JC, 1999, FITOTERAPIA, V70, P21, DOI 10.1016/S0367-326X(98)00004-5; Bateman A, 1999, NUCLEIC ACIDS RES, V27, P260, DOI 10.1093/nar/27.1.260; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chen YL, 1996, BIOCHEMISTRY-US, V35, P5264, DOI 10.1021/bi952520q; Chippaux JP, 1998, TOXICON, V36, P823, DOI 10.1016/S0041-0101(97)00160-8; Desterro JMP, 1999, J BIOL CHEM, V274, P10618, DOI 10.1074/jbc.274.15.10618; DRENTH J, 1980, J BIOL CHEM, V255, P2652; DRICKAMER K, 1988, J BIOL CHEM, V263, P9557; DRICKAMER K, 1993, PROG NUCLEIC ACID RE, V45, P207, DOI 10.1016/S0079-6603(08)60870-3; GAN ZR, 1988, J BIOL CHEM, V263, P19827; Guerranti R, 2001, J ETHNOPHARMACOL, V75, P175, DOI 10.1016/S0378-8741(00)00401-3; GUERRANTI R, 1999, J PREV MED HYG, V1, P25; Hofmann K, 1999, NUCLEIC ACIDS RES, V27, P215, DOI 10.1093/nar/27.1.215; Kemparaju K, 1999, TOXICON, V37, P1659, DOI 10.1016/S0041-0101(99)00104-X; KEMPARAJU K, 1994, TOXICON, V32, P1187, DOI 10.1016/0041-0101(94)90348-4; Kerns RT, 1999, ARCH BIOCHEM BIOPHYS, V369, P107, DOI 10.1006/abbi.1999.1345; KIELISZEWSKI MJ, 1994, PLANT J, V5, P849, DOI 10.1046/j.1365-313X.1994.5060849.x; Kini RM, 1996, TOXICON, V34, P1287, DOI 10.1016/S0041-0101(96)00107-9; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Machuka J, 2000, FOOD CHEM, V68, P421, DOI 10.1016/S0308-8146(99)00211-3; Marcinkiewicz C, 1999, J BIOL CHEM, V274, P12468, DOI 10.1074/jbc.274.18.12468; Marcinkiewicz C, 2000, J BIOL CHEM, V275, P31930, DOI 10.1074/jbc.M003209200; MARTZ W, 1992, TOXICON, V30, P1131, DOI 10.1016/0041-0101(92)90429-9; MO HQ, 1994, GLYCOCONJUGATE J, V11, P424, DOI 10.1007/BF00731278; MORITA T, 1978, J BIOCHEM, V83, P559, DOI 10.1093/oxfordjournals.jbchem.a131944; Nagpal A, 1999, ACTA CRYSTALLOGR D, V55, P1240, DOI 10.1107/S0907444999004783; NISHIDA S, 1995, BIOCHEMISTRY-US, V34, P1771, DOI 10.1021/bi00005a034; OUCHTERLONY O, 1986, HDB EXPT IMMUNOLOGY, P321; PENG ML, 1994, BIOCHEM BIOPH RES CO, V205, P68, DOI 10.1006/bbrc.1994.2630; Polgar J, 1996, BIOCHEM J, V319, P961, DOI 10.1042/bj3190961; PRAS N, 1993, PHARM WORLD SCI, V15, P263, DOI 10.1007/BF01871128; RAJYALAKSHMI P, 1994, PLANT FOOD HUM NUTR, V46, P53, DOI 10.1007/BF01088461; REVILLEZA MJR, 1990, PLANT FOOD HUM NUTR, V40, P83, DOI 10.1007/BF02193782; SCHAEFFER RC, 1987, TOXICON, V25, P1343, DOI 10.1016/0041-0101(87)90012-2; Siddhuraju P, 1996, J AGR FOOD CHEM, V44, P2636, DOI 10.1021/jf950776x; Yamada D, 1996, J BIOL CHEM, V271, P5200, DOI 10.1074/jbc.271.9.5200; Yen TY, 2000, J MASS SPECTROM, V35, P990, DOI 10.1002/1096-9888(200008)35:8<990::AID-JMS27>3.0.CO;2-K	37	33	35	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 10	2002	277	19					17072	17078		10.1074/jbc.M201387200	http://dx.doi.org/10.1074/jbc.M201387200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	551MB	11867642	hybrid			2022-12-27	WOS:000175564500097
J	Hamada, S; Ito, H; Hiraga, S; Inagaki, K; Nozaki, K; Isono, N; Yoshimoto, Y; Takeda, Y; Matsui, H				Hamada, S; Ito, H; Hiraga, S; Inagaki, K; Nozaki, K; Isono, N; Yoshimoto, Y; Takeda, Y; Matsui, H			Differential characteristics and subcellular localization of two starch-branching enzyme Isoforms encoded by a single gene in Phaseolus vulgaris L.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNTHASE-I; MAIZE ENDOSPERM; MULTIPLE FORMS; CHAIN-LENGTH; PURIFICATION; SUBSTRATE; AMYLOSE; PROTEIN; MECHANISM; GRANULES	Starch-branching enzymes (SBE) have a dominant role for amylopectin structure as they define chain length and frequency of branch points. We have previously shown that one of the SBE isoforms of kidney bean (Phaseolus vulgaris L.), designated PvSBE2, has a molecular mass (82 kDa) significantly smaller than those reported for isologous SBEs from pea (SBEI), maize (BEIIb), and rice (RBE3). Additionally, in contrast to the dual location of the pea SBEI in both the soluble and starch granule fractions, PvSBE2 was found only in the soluble fraction during seed development. Analysis of a pvsbe2 cDNA suggested that PvSBE2 is generated from a larger precursor with a putative plastid targeting sequence of 156 residues. Here we describe the occurrence of a larger 100-kDa form (LF-PvSBE2) of PvSBE2 found both in the soluble and starch granule fractions of the developing seeds. The determined N-terminal sequence, VKSSHDSD, of LF-PvSBE2 corresponded to a peptide sequence located 111 amino acids upstream from the N terminus of purified PvSBE2, suggesting that LF-PvSBE2 and PvSBE2 are products of the same gene. Analysis of the products by 5'-RACE (rapid amplification of cDNA ends) and reverse transcription PCR indicated that the two transcripts for pre-LF-PvSBE2 and pre-PvSBE2 are generated by alternative splicing. Recombinant LF-PvSBE2 (rLF-PvSBE2) was purified from Escherichia coli and the kinetic properties were compared with those of recombinant PvSBE2 (rPvSBE2). rLF-PvSBE2 had much higher affinity for amylopectin (K-m = 4.4 mg/ml) than rPvSBE2 (18.4 mg/ml), whereas the V-max of rLF-PvSBE2 (135 units/mg) for this substrate was much lower than that of rPvSBE2 (561 units/mg). These results suggest that the N-terminal extension of LF-PvSBE2 plays a critical role for localization in starch granules by altering its enzymatic properties.	Hokkaido Univ, Grad Sch Agr, Dept Appl Biosci, Sapporo, Hokkaido 0608589, Japan; Kagoshima Univ, Dept Biochem Sci & Technol, Kagoshima 8900065, Japan	Hokkaido University; Kagoshima University	Ito, H (corresponding author), Hokkaido Univ, Grad Sch Agr, Dept Appl Biosci, Sapporo, Hokkaido 0608589, Japan.	otih@chem.agr.hokudai.ac.jp		Isono, Naoto/0000-0002-2118-8677				Baga M, 1999, PLANT MOL BIOL, V40, P1019, DOI 10.1023/A:1006286807176; Baga M, 2000, PLANT PHYSIOL, V124, P253, DOI 10.1104/pp.124.1.253; BELSHAW NJ, 1990, FEBS LETT, V269, P350, DOI 10.1016/0014-5793(90)81191-P; BOROVSKY D, 1976, EUR J BIOCHEM, V62, P307, DOI 10.1111/j.1432-1033.1976.tb10162.x; BOROVSKY D, 1975, FEBS LETT, V54, P201, DOI 10.1016/0014-5793(75)80074-3; BOYER CD, 1978, CARBOHYD RES, V61, P321, DOI 10.1016/S0008-6215(00)84492-4; BOYER CD, 1978, BIOCHEM BIOPH RES CO, V80, P169, DOI 10.1016/0006-291X(78)91119-1; BURTON RA, 1995, PLANT J, V7, P3, DOI 10.1046/j.1365-313X.1995.07010003.x; CHATTERJEE B, 1992, J APPL BACTERIOL, V72, P208, DOI 10.1111/j.1365-2672.1992.tb01825.x; Commuri PD, 2001, PLANT J, V25, P475, DOI 10.1046/j.1365-313x.2001.00955.x; DENYER K, 1995, PLANTA, V196, P256, DOI 10.1007/BF00201382; DENYER K, 1993, PLANT J, V4, P191, DOI 10.1046/j.1365-313X.1993.04010191.x; Edwards A, 1996, PLANT PHYSIOL, V112, P89, DOI 10.1104/pp.112.1.89; FISHER DK, 1993, PLANT PHYSIOL, V102, P1045, DOI 10.1104/pp.102.3.1045; GUAN HP, 1993, PLANT PHYSIOL, V102, P1269, DOI 10.1104/pp.102.4.1269; Hamada S, 2001, BIOCHEM J, V359, P23, DOI 10.1042/0264-6021:3590023; Hanashiro I, 1996, CARBOHYD RES, V283, P151, DOI 10.1016/0008-6215(95)00408-4; Hong SJ, 2000, ARCH BIOCHEM BIOPHYS, V378, P349, DOI 10.1006/abbi.2000.1845; Hong SJ, 2001, ARCH BIOCHEM BIOPHYS, V386, P62, DOI 10.1006/abbi.2000.2179; Imparl-Radosevich JM, 1998, ARCH BIOCHEM BIOPHYS, V353, P64, DOI 10.1006/abbi.1998.0613; JESPERSEN HM, 1993, J PROTEIN CHEM, V12, P791, DOI 10.1007/BF01024938; Kuriki T, 1997, J BIOL CHEM, V272, P28999, DOI 10.1074/jbc.272.46.28999; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARTIN C, 1995, PLANT CELL, V7, P971, DOI 10.1105/tpc.7.7.971; MIZUNO K, 1993, J BIOL CHEM, V268, P19084; Morell MK, 1997, PLANT PHYSIOL, V113, P201, DOI 10.1104/pp.113.1.201; MuForster C, 1996, PLANT PHYSIOL, V111, P821, DOI 10.1104/pp.111.3.821; MURRAY MG, 1980, NUCLEIC ACIDS RES, V8, P4321, DOI 10.1093/nar/8.19.4321; NAKAI K, 1992, GENOMICS, V14, P897, DOI 10.1016/S0888-7543(05)80111-9; Nishi A, 2001, PLANT PHYSIOL, V127, P459, DOI [10.1104/pp.010127, 10.1104/pp.127.2.459]; Nozaki K, 2001, BIOSCI BIOTECH BIOCH, V65, P1141, DOI 10.1271/bbb.65.1141; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Simpson GG, 1996, PLANT MOL BIOL, V32, P1, DOI 10.1007/BF00039375; SIVAK MN, 1998, ADV FOOD NUTR RES, V41, P89; Slattery CJ, 2000, TRENDS PLANT SCI, V5, P291, DOI 10.1016/S1360-1385(00)01657-5; SMITH AM, 1988, PLANTA, V175, P270, DOI 10.1007/BF00392437; Smith AM, 1997, ANNU REV PLANT PHYS, V48, P65, DOI 10.1146/annurev.arplant.48.1.67; SMITH AM, 1990, PLANTA, V182, P599, DOI 10.1007/BF02341037; SVENSSON B, 1989, BIOCHEM J, V264, P309, DOI 10.1042/bj2640309; Takaoka M, 1997, J AGR FOOD CHEM, V45, P2929, DOI 10.1021/jf9702656; TAKEDA Y, 1993, CARBOHYD RES, V240, P253, DOI 10.1016/0008-6215(93)84188-C; TAKEDA Y, 1985, AGR BIOL CHEM TOKYO, V49, P1633, DOI 10.1080/00021369.1985.10866963	42	23	27	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 10	2002	277	19					16538	16546		10.1074/jbc.M110497200	http://dx.doi.org/10.1074/jbc.M110497200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	551MB	11864975	hybrid			2022-12-27	WOS:000175564500028
J	Hideshima, T; Chauhan, D; Richardson, P; Mitsiades, C; Mitsiades, N; Hayashi, T; Munshi, N; Dang, L; Castro, A; Palombella, V; Adams, J; Anderson, KC				Hideshima, T; Chauhan, D; Richardson, P; Mitsiades, C; Mitsiades, N; Hayashi, T; Munshi, N; Dang, L; Castro, A; Palombella, V; Adams, J; Anderson, KC			NF-kappa B as a therapeutic target in multiple myeloma	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; MARROW STROMAL CELLS; DRUG-RESISTANCE; APOPTOSIS; ACTIVATION; INTERLEUKIN-6; THALIDOMIDE; INHIBITION; GROWTH; EXPRESSION	We have shown that thalidomide (Thal) and its immunomodulatory derivatives (IMiDs), proteasome inhibitor PS-341, and As2O3 act directly on multiple myeloma (MM) cells and in the bone marrow (BM) milieu to overcome drug resistance. Although Thal/IMiDs, PS-341, and As2O3 inhibit nuclear factor (NF)-kappaB activation, they also have multiple and varied other actions. In this study, we therefore specifically address the role of NF-kappaB blockade in mediating anti-AM activity. To characterize the effect of specific NF-kappaB blockade on AM cell growth and survival in vitro, we used an IkappaB kinase (IKK) inhibitor (PS-1145). Our studies demonstrate that PS-1145 and PS-341 block TNFalpha-induced NF-kappaB activation in a dose- and time-dependent fashion in AM cells through inhibition of IkappaBalpha phosphorylation and degradation of IkappaBalpha, respectively. Dexamethasone (Dex) which up-regulates IkappaBalpha protein, enhances blockade of NF-kappaB activation by PS-1145. Moreover, PS-1145 blocks the protective effect of IL-6 against Dex-induced apotosis. TNFa-induced intracellular adhesion molecule (ICAM)-1 expression on both RPM18226 and MMAS cells is also inhibited by PS-1145. Moreover, PS-1145 inhibits both IL-6 secretion from BMSCs triggered by AM cell adhesion and proliferation of AM cells adherent to BMSCs. However, in contrast to PS-341, PS-1145 only partially (20-50%) inhibits AM cell proliferation, suggesting that NF-kappaB blockade cannot account for all of the anti-AM activity of PS-341. Importantly, however, TNFalpha induces AM cell toxicity in the presence of PS-1145. These studies demonstrate that specific targeting of NF-kappaB can overcome the growth and survival advantage conferred both by tumor cell binding to BMSCs and cytokine secretion in the BM milieu. Furthermore, they provide the framework for clinical evaluation of novel AM therapies based upon targeting NF-kappaB.	Dana Farber Canc Inst, Jerome Lipper Multiple Myeloma Ctr, Boston, MA 02115 USA; Millennium Pharmaceut Inc, Cambridge, MA 02139 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Takeda Pharmaceutical Company Ltd; Millennium Pharmaceuticals; Harvard University; Harvard Medical School	Anderson, KC (corresponding author), Dana Farber Canc Inst, Jerome Lipper Multiple Myeloma Ctr, 44 Binney St, Boston, MA 02115 USA.	kenneth_anderson@dfci.harvard.edu	Munshi, Nikhil/ABE-2338-2021	Dang, Lenny/0000-0002-2073-6109	PHS HHS [P0-1 78378] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		AUPHAN N, 1995, SCIENCE, V270, P286, DOI 10.1126/science.270.5234.286; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Baldwin AS, 2001, J CLIN INVEST, V107, P241, DOI 10.1172/JCI11991; BALDWIN AS, 1991, MOL CELL BIOL, V11, P4943, DOI 10.1128/MCB.11.10.4943; Bargou RC, 1997, J CLIN INVEST, V100, P2961, DOI 10.1172/JCI119849; Barlogie B, 2001, BLOOD, V98, P492, DOI 10.1182/blood.V98.2.492; BEG AA, 1995, NATURE, V376, P167, DOI 10.1038/376167a0; BEG AA, 1993, GENE DEV, V7, P2064, DOI 10.1101/gad.7.11.2064; Boothby MR, 1997, J EXP MED, V185, P1897, DOI 10.1084/jem.185.11.1897; BORSET M, 1994, EUR J HAEMATOL, V53, P31; Brostjan C, 1996, J BIOL CHEM, V271, P19612, DOI 10.1074/jbc.271.32.19612; Chauhan D, 1999, ONCOGENE, V18, P6733, DOI 10.1038/sj.onc.1203082; Chauhan D, 1997, BLOOD, V89, P227, DOI 10.1182/blood.V89.1.227.227_227_234; Chauhan D, 1996, BLOOD, V87, P1104, DOI 10.1182/blood.V87.3.1104.bloodjournal8731104; Chauhan D, 2001, J BIOL CHEM, V276, P24453, DOI 10.1074/jbc.C100074200; Damiano JS, 1999, BLOOD, V93, P1658, DOI 10.1182/blood.V93.5.1658; Dankbar B, 2000, BLOOD, V95, P2630, DOI 10.1182/blood.V95.8.2630; Davies FE, 2001, BLOOD, V98, P210, DOI 10.1182/blood.V98.1.210; Franzoso G, 1997, GENE DEV, V11, P3482, DOI 10.1101/gad.11.24.3482; GULTRIDGE DC, 1999, MOL CELL BIOL, V19, P5785; Hazlehurst LA, 2000, ONCOGENE, V19, P4319, DOI 10.1038/sj.onc.1203782; Hideshima T, 2001, CANCER RES, V61, P3071; Hideshima T, 2000, BLOOD, V96, P2943, DOI 10.1182/blood.V96.9.2943; Hideshima T, 2001, ONCOGENE, V20, P5991, DOI 10.1038/sj.onc.1204833; Hideshima T, 2001, ONCOGENE, V20, P4519, DOI 10.1038/sj.onc.1204623; Hinz M, 1999, MOL CELL BIOL, V19, P2690; Kapahi P, 2000, J BIOL CHEM, V275, P36062, DOI 10.1074/jbc.M007204200; Keifer JA, 2001, J BIOL CHEM, V276, P22382, DOI 10.1074/jbc.M100938200; Keller SA, 2000, BLOOD, V96, P2537; Khoshnan A, 2000, J IMMUNOL, V165, P1743, DOI 10.4049/jimmunol.165.4.1743; Klement JF, 1996, MOL CELL BIOL, V16, P2341; Li P, 2000, J IMMUNOL, V164, P5990, DOI 10.4049/jimmunol.164.11.5990; LICHTENSTEIN A, 1995, CELL IMMUNOL, V162, P248, DOI 10.1006/cimm.1995.1076; Mayo MW, 1997, SCIENCE, V278, P1812, DOI 10.1126/science.278.5344.1812; Ogata A, 1997, J IMMUNOL, V159, P2212; Otsuka G, 1999, CANCER RES, V59, P4446; Palombella VJ, 1998, P NATL ACAD SCI USA, V95, P15671, DOI 10.1073/pnas.95.26.15671; Raje N, 1999, NEW ENGL J MED, V341, P1606, DOI 10.1056/NEJM199911183412110; Rath PC, 1999, J CLIN IMMUNOL, V19, P350, DOI 10.1023/A:1020546615229; SCHEINMAN RI, 1995, SCIENCE, V270, P283, DOI 10.1126/science.270.5234.283; Senftleben U, 2001, IMMUNITY, V14, P217, DOI 10.1016/S1074-7613(01)00104-2; Singhal S, 1999, NEW ENGL J MED, V341, P1565, DOI 10.1056/NEJM199911183412102; UCHIYAMA H, 1993, BLOOD, V82, P3712; Yin L, 2000, J BIOL CHEM, V275, P36671, DOI 10.1074/jbc.M007378200; Zandi E, 1999, MOL CELL BIOL, V19, P4547	45	773	845	2	55	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 10	2002	277	19					16639	16647		10.1074/jbc.M200360200	http://dx.doi.org/10.1074/jbc.M200360200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	551MB	11872748	hybrid			2022-12-27	WOS:000175564500041
J	Melendez, AJ; Khaw, AK				Melendez, AJ; Khaw, AK			Dichotomy of Ca2+ signals triggered by different phospholipid pathways in antigen stimulation of human mast cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FC-GAMMA-RI; HIGH-AFFINITY RECEPTOR; PROTEIN-KINASE-C; SPHINGOSINE KINASE; CALCIUM MOBILIZATION; MOLECULAR-CLONING; EPSILON-RI; FUNCTIONAL-CHARACTERIZATION; MEDIATED ACTIVATION; IGE RECEPTOR	Mast cell activation triggers Ca2+ signals and the release of enzyme-containing granules, events that play a major role in allergic/hypersensitivity reactions. However, the precise molecular mechanisms that regulate antigen-triggered degranulation and Ca2+ fluxes in human mast cells are still poorly understood. Here we show, for the first time, that a receptor can trigger Ca2+ via two separate molecular mechanisms. Using an antisense approach, we show that IgE-antigen stimulation of human bone marrow-derived mast cells triggers a sphingosine kinase (SPHK) 1-mediated fast and transient Ca2+ release from intracellular stores. However, phospholipase C (PLC) gamma1 triggers a second (slower) wave of calcium release from intracellular stores, and it is this PLCgamma1-generated signal that is responsible for Ca2+ entry. Surprisingly, FcepsilonRI (a high affinity receptor for IgE)-triggered mast cell degranulation depends on the first, sphingosine kinase-mediated Ca2+ signal. These two pathways act independently because antisense knock down of either enzyme does not interfere with the activity of the other enzyme. Of interest, similar to PLCgamma1, SPHK1 translocates rapidly to the membrane after FcepsilonRI cross-linking. Here we also show that SPHK1 activity depends on phospholipase D1 and that FcepsilonRI-triggered mast cell degranulation depends primarily on the activation of both phospholipase D1 and SPHK1.	Natl Univ Singapore, Dept Physiol, Fac Med, Singapore 117597, Singapore	National University of Singapore	Melendez, AJ (corresponding author), Natl Univ Singapore, Dept Physiol, Fac Med, 2 Med Dr,MD 9, Singapore 117597, Singapore.	phsmraj@nus.edu.sg						ATKINSON TP, 1992, J IMMUNOL, V148, P2194; Barnes PJ, 1998, PHARMACOL REV, V50, P515; BEAVEN MA, 1993, IMMUNOL TODAY, V14, P222, DOI 10.1016/0167-5699(93)90167-J; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; Brown FD, 1998, CURR BIOL, V8, P835, DOI 10.1016/S0960-9822(98)70326-4; CAMBIER JC, 1995, J IMMUNOL, V155, P3281; Caumont AS, 1998, J BIOL CHEM, V273, P1373, DOI 10.1074/jbc.273.3.1373; Choi OH, 1996, NATURE, V380, P634; Cohen JS, 2001, BIOCHEMISTRY-US, V40, P6589, DOI 10.1021/bi0103011; Cuvillier O, 1996, NATURE, V381, P800, DOI 10.1038/381800a0; Dolmetsch RE, 1997, NATURE, V386, P855, DOI 10.1038/386855a0; English D, 1996, CHEM PHYS LIPIDS, V80, P117, DOI 10.1016/0009-3084(96)02549-2; Exton JH, 1997, PHYSIOL REV, V77, P303, DOI 10.1152/physrev.1997.77.2.303; Finch EA, 1998, NATURE, V396, P753, DOI 10.1038/25541; GHOSH TK, 1990, SCIENCE, V248, P1653, DOI 10.1126/science.2163543; JIANG H, 1995, NATURE, V378, P409, DOI 10.1038/378409a0; JOUVIN MHE, 1994, J BIOL CHEM, V269, P5918; KIHARA H, 1994, J BIOL CHEM, V269, P22427; Kinet JP, 1999, ANNU REV IMMUNOL, V17, P931, DOI 10.1146/annurev.immunol.17.1.931; Ktistakis NT, 1996, J CELL BIOL, V134, P295, DOI 10.1083/jcb.134.2.295; Kusner DJ, 1999, J IMMUNOL, V162, P2266; Le Stunff H, 2000, BIOCHEM J, V352, P491, DOI 10.1042/0264-6021:3520491; Liu H, 2000, J BIOL CHEM, V275, P19513, DOI 10.1074/jbc.M002759200; Mao CG, 1996, P NATL ACAD SCI USA, V93, P1993, DOI 10.1073/pnas.93.5.1993; MATTIE M, 1994, J BIOL CHEM, V269, P3181; Melendez A, 1998, J BIOL CHEM, V273, P9393, DOI 10.1074/jbc.273.16.9393; Melendez AJ, 2000, GENE, V251, P19, DOI 10.1016/S0378-1119(00)00205-5; Melendez AJ, 1999, IMMUNOLOGY, V96, P457; Melendez AJ, 1999, IMMUNOLOGY, V98, P1; Melendez AJ, 2001, BLOOD, V98, P3421, DOI 10.1182/blood.V98.12.3421; Melendez AJ, 2001, CURR BIOL, V11, P869, DOI 10.1016/S0960-9822(01)00260-3; Metcalfe DD, 1997, PHYSIOL REV, V77, P1033, DOI 10.1152/physrev.1997.77.4.1033; METZGER H, 1992, IMMUNOL REV, V125, P37, DOI 10.1111/j.1600-065X.1992.tb00624.x; Morgan CP, 1997, BIOCHEM J, V325, P581, DOI 10.1042/bj3250581; Olivera A, 1998, J BIOL CHEM, V273, P12576, DOI 10.1074/jbc.273.20.12576; OLIVERA A, 1994, J BIOL CHEM, V269, P17924; Olivera A, 1996, J CELL BIOCHEM, V60, P529, DOI 10.1002/(SICI)1097-4644(19960315)60:4<529::AID-JCB9>3.0.CO;2-U; PARK DJ, 1991, J BIOL CHEM, V266, P24237; Postma FR, 1996, EMBO J, V15, P2388, DOI 10.1002/j.1460-2075.1996.tb00595.x; PRIBLUDA VS, 1994, P NATL ACAD SCI USA, V91, P11246, DOI 10.1073/pnas.91.23.11246; QUALLIOTINEMANN D, 1993, J BIOL CHEM, V268, P23843; RA C, 1989, NATURE, V341, P752, DOI 10.1038/341752a0; ROTTEM M, 1994, EXP HEMATOL, V22, P1147; Vietor I, 2001, EMBO REP, V2, P306, DOI 10.1093/embo-reports/kve066; Vonakis BM, 1997, J BIOL CHEM, V272, P24072, DOI 10.1074/jbc.272.38.24072; Way G, 2000, BIOCHEM J, V346, P63, DOI 10.1042/0264-6021:3460063; WU J, 1995, J BIOL CHEM, V270, P11484, DOI 10.1074/jbc.270.19.11484	47	141	144	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 10	2002	277	19					17255	17262		10.1074/jbc.M110944200	http://dx.doi.org/10.1074/jbc.M110944200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	551MB	11856736	hybrid, Green Published			2022-12-27	WOS:000175564500120
J	Yamazaki, M; Miyazaki, H; Watanabe, H; Sasaki, T; Maehama, T; Frohman, MA; Kanaho, Y				Yamazaki, M; Miyazaki, H; Watanabe, H; Sasaki, T; Maehama, T; Frohman, MA; Kanaho, Y			Phosphatidylinositol 4-phosphate 5-kinase is essential for ROCK-mediated neurite remodeling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RHO-ASSOCIATED KINASE; GROWTH CONE COLLAPSE; STRESS-FIBER FORMATION; BINDING PROTEIN-RHO; ACTIN CYTOSKELETON; LIM-KINASE; LYSOPHOSPHATIDIC ACID; ADP-RIBOSYLATION; FOCAL ADHESIONS; MAMMALIAN-CELLS	Phosphatidylinositol 4-phosphate 5-kinase (PIP-5kin) regulates actin cytoskeletal reorganization through its product phosphatidylinositol 4,5-bisphosphate. In the present study we demonstrate that PIP-5kin is essential for neurite remodeling, which is regulated by actin cytoskeletal reorganization in neuroblastoma N1E-115 cells. Overexpression of wild-type mouse PIP-5kin-alpha inhibits the neurite formation that is normally stimulated by serum depletion, whereas a lipid kinase-defective mutant of PIP-5kin-alpha, D266A, triggers neurite extension even in the presence of serum and blocks lysophosphatidic acid-induced neurite retraction. These results phenocopy those previously reported for the small GTPase RhoA and its effector p160 Rho-associated coiled coil-forming protein kinase (ROCK). However, the ROCK-specific inhibitor Y-27632 failed to block the inhibition by PIP-5kin-alpha of neurite extension, whereas D266A did block the neurite retraction induced by overexpression of ROCK. These results, taken together, suggest that PIP-5kin-alpha functions as a downstream effector for RhoA/ROCK to couple lysophosphatidic acid signaling to neurite retraction presumably through its product phosphatidylinositol 4,5-bisphosphate.	Tokyo Metropolitan Inst Med Sci, Bunkyo Ku, Tokyo 1138613, Japan; Tokyo Inst Technol, Dept Biol Informat, Midori Ku, Yokohama, Kanagawa 2268501, Japan; SUNY Stony Brook, Ctr Dev Genet, Stony Brook, NY 11794 USA; SUNY Stony Brook, Dept Pharmacol, Stony Brook, NY 11794 USA	Tokyo Metropolitan Institute of Medical Science; Tokyo Institute of Technology; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Kanaho, Y (corresponding author), Tokyo Metropolitan Inst Med Sci, Bunkyo Ku, 3-18-22 Honkomagome, Tokyo 1138613, Japan.	ykanaho@rinshoken.or.jp	Maehama, Tomohiko/AAX-8926-2020; Watanabe, Hiroshi/GOP-0177-2022; Maehama, Tomohiko/HGB-4896-2022	Watanabe, Hiroshi/0000-0001-8887-5407; Maehama, Tomohiko/0000-0002-9685-2317; Sasaki, Takehiko/0000-0003-1837-3748	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054813] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM54813] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aizawa H, 2001, NAT NEUROSCI, V4, P367, DOI 10.1038/86011; Amano M, 1997, SCIENCE, V275, P1308, DOI 10.1126/science.275.5304.1308; Amano M, 1998, GENES CELLS, V3, P177, DOI 10.1046/j.1365-2443.1998.00181.x; Amano M, 1996, J BIOL CHEM, V271, P20246, DOI 10.1074/jbc.271.34.20246; Anderson RA, 1999, J BIOL CHEM, V274, P9907, DOI 10.1074/jbc.274.15.9907; Aoki J, 2000, BIOCHEM BIOPH RES CO, V278, P604, DOI 10.1006/bbrc.2000.3842; Arber S, 1998, NATURE, V393, P805, DOI 10.1038/31729; Arimura N, 2000, J BIOL CHEM, V275, P23973, DOI 10.1074/jbc.M001032200; Bito H, 2000, NEURON, V26, P431, DOI 10.1016/S0896-6273(00)81175-7; Bradke F, 2000, CURR OPIN NEUROBIOL, V10, P574, DOI 10.1016/S0959-4388(00)00124-0; Bradke F, 1999, SCIENCE, V283, P1931, DOI 10.1126/science.283.5409.1931; CHONG LD, 1994, CELL, V79, P507, DOI 10.1016/0092-8674(94)90259-3; FAN JH, 1993, J CELL BIOL, V121, P867, DOI 10.1083/jcb.121.4.867; Fritsche J, 1999, MOL CELL NEUROSCI, V14, P398, DOI 10.1006/mcne.1999.0777; FUKAMI K, 1992, NATURE, V359, P150, DOI 10.1038/359150a0; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hinchliffe KA, 1998, BBA-MOL CELL BIOL L, V1436, P87, DOI 10.1016/S0005-2760(98)00140-4; Hirose M, 1998, J CELL BIOL, V141, P1625, DOI 10.1083/jcb.141.7.1625; Honda A, 1999, CELL, V99, P521, DOI 10.1016/S0092-8674(00)81540-8; Ishihara H, 1996, J BIOL CHEM, V271, P23611, DOI 10.1074/jbc.271.39.23611; Ishihara H, 1998, J BIOL CHEM, V273, P8741, DOI 10.1074/jbc.273.15.8741; Ishizaki T, 1997, FEBS LETT, V404, P118, DOI 10.1016/S0014-5793(97)00107-5; JALINK K, 1994, J CELL BIOL, V126, P801, DOI 10.1083/jcb.126.3.801; JALINK K, 1993, CELL GROWTH DIFFER, V4, P247; JANMEY PA, 1987, NATURE, V325, P362, DOI 10.1038/325362a0; Jin Z, 1997, J NEUROSCI, V17, P6256; Jones DH, 2000, J BIOL CHEM, V275, P13962, DOI 10.1074/jbc.C901019199; Jones DR, 2000, FEBS LETT, V476, P160, DOI 10.1016/S0014-5793(00)01702-6; JOSHI HC, 1985, J CELL BIOL, V101, P697, DOI 10.1083/jcb.101.3.697; Kaibuchi K, 1999, ANNU REV BIOCHEM, V68, P459, DOI 10.1146/annurev.biochem.68.1.459; Katoh H, 1998, J BIOL CHEM, V273, P2489, DOI 10.1074/jbc.273.5.2489; Keynes Roger J., 1995, Current Opinion in Neurobiology, V5, P75, DOI 10.1016/0959-4388(95)80090-5; Kimura K, 1996, SCIENCE, V273, P245, DOI 10.1126/science.273.5272.245; Kozma R, 1997, MOL CELL BIOL, V17, P1201, DOI 10.1128/MCB.17.3.1201; Kranenburg O, 1997, J CELL SCI, V110, P2417; LASSING I, 1985, NATURE, V314, P472, DOI 10.1038/314472a0; LEUNG S, 1995, MOL CELL BIOL, V15, P1312; Lin Chi-Hung, 1994, Current Opinion in Neurobiology, V4, P640, DOI 10.1016/0959-4388(94)90004-3; Loijens JC, 1996, J BIOL CHEM, V271, P32937, DOI 10.1074/jbc.271.51.32937; Luo LQ, 1997, CURR OPIN NEUROBIOL, V7, P81, DOI 10.1016/S0959-4388(97)80124-9; Maekawa M, 1999, SCIENCE, V285, P895, DOI 10.1126/science.285.5429.895; Meberg PJ, 2000, J NEUROSCI, V20, P2459; Moolenaar WH, 1999, EXP CELL RES, V253, P230, DOI 10.1006/excr.1999.4702; Narumiya S, 1997, FEBS LETT, V410, P68, DOI 10.1016/S0014-5793(97)00317-7; Ohashi K, 2000, J BIOL CHEM, V275, P3577, DOI 10.1074/jbc.275.5.3577; Park SJ, 2001, J BIOL CHEM, V276, P4781, DOI 10.1074/jbc.M010177200; Rao VD, 1998, CELL, V94, P829, DOI 10.1016/S0092-8674(00)81741-9; Raucher D, 2000, CELL, V100, P221, DOI 10.1016/S0092-8674(00)81560-3; Rozelle AL, 2000, CURR BIOL, V10, P311, DOI 10.1016/S0960-9822(00)00384-5; Shibasaki Y, 1997, J BIOL CHEM, V272, P7578, DOI 10.1074/jbc.272.12.7578; SPERO DA, 1985, DEV BRAIN RES, V23, P155, DOI 10.1016/0165-3806(85)90016-1; SUIDAN HS, 1992, NEURON, V8, P363, DOI 10.1016/0896-6273(92)90302-T; TANAKA E, 1995, CELL, V83, P171, DOI 10.1016/0092-8674(95)90158-2; TessierLavigne M, 1996, SCIENCE, V274, P1123, DOI 10.1126/science.274.5290.1123; Toker A, 1998, CURR OPIN CELL BIOL, V10, P254, DOI 10.1016/S0955-0674(98)80148-8; Uehata M, 1997, NATURE, V389, P990, DOI 10.1038/40187; Wahl S, 2000, J CELL BIOL, V149, P263, DOI 10.1083/jcb.149.2.263; Weernink PAO, 2000, J BIOL CHEM, V275, P10168, DOI 10.1074/jbc.275.14.10168; Yamamoto M, 2001, J CELL BIOL, V152, P867, DOI 10.1083/jcb.152.5.867; Yang N, 1998, NATURE, V393, P809, DOI 10.1038/31735	60	65	66	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 10	2002	277	19					17226	17230		10.1074/jbc.M109795200	http://dx.doi.org/10.1074/jbc.M109795200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	551MB	11877391	hybrid			2022-12-27	WOS:000175564500116
J	Golan, A; Yudkovsky, Y; Hershko, A				Golan, A; Yudkovsky, Y; Hershko, A			The cyclin-ubiquitin ligase activity of cyclosome/APC is jointly activated by protein kinases Cdk1-cyclin B and Plk	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANAPHASE-PROMOTING COMPLEX; XENOPUS EGG EXTRACTS; CELL-DIVISION; MITOSIS; PHOSPHORYLATION; PLX1; PURIFICATION; DESTRUCTION; APC; REGULATORS	The cyclosome/anaphase-promoting complex is a multisubunit ubiquitin ligase that targets for degradation mitotic cyclins and some other cell cycle regulators in exit from mitosis. It becomes enzymatically active at the end of mitosis. The activation of the cyclosome is initiated by its phosphorylation, a process necessary for its conversion to an active form by the ancillary protein Cdc20/Fizzy. Previous reports have implicated either cyclin-dependent kinase 1-cyclin B or polo-like kinase as the major protein kinase that directly phosphorylates and activates the cyclosome. These conflicting results could be due to the use of partially purified cyclosome preparations or of immunoprecipitated cyclosome, whose interactions with protein kinases or ancillary factors may be hampered by binding to immobilized antibody. To examine this problem, we have purified cyclo. some from HeLa cells by a combination of affinity chromatography and ion exchange procedures. With the use of purified preparations, we found that both cyclin-dependent kinase 1-cyclin B and polo-like kinase directly phosphorylated the cyclosome, but the pattern of the phosphorylation of the different cyclosome subunits by the two protein kinases was not similar. Each protein kinase could restore only partially the cyclin-ubiquitin ligase activity of dephosphorylated cyclosome. However, following phosphorylation by both protein kinases, an additive and nearly complete restoration of cyclin-ubiquitin ligase activity was observed. It is suggested that this joint activation may be due to the complementary phosphorylation of different cyclosome subunits by the two protein kinases.	Technion Israel Inst Technol, Biochem Unit, IL-31096 Haifa, Israel; Technion Israel Inst Technol, Bruce Rappaport Fac Med, IL-31096 Haifa, Israel	Technion Israel Institute of Technology; Technion Israel Institute of Technology; Rappaport Faculty of Medicine	Hershko, A (corresponding author), Technion Israel Inst Technol, Biochem Unit, IL-31096 Haifa, Israel.							Amon A, 1999, CURR OPIN GENET DEV, V9, P69, DOI 10.1016/S0959-437X(99)80010-0; Descombes P, 1998, EMBO J, V17, P1328, DOI 10.1093/emboj/17.5.1328; Fang GW, 1998, MOL CELL, V2, P163, DOI 10.1016/S1097-2765(00)80126-4; Harlow E., 1988, ANTIBODIES LAB MANUA; IRNIGER S, 1995, CELL, V81, P269, DOI 10.1016/0092-8674(95)90337-2; KING RW, 1995, CELL, V81, P279, DOI 10.1016/0092-8674(95)90338-0; Kotani S, 1998, MOL CELL, V1, P371, DOI 10.1016/S1097-2765(00)80037-4; Kotani S, 1999, J CELL BIOL, V146, P791, DOI 10.1083/jcb.146.4.791; Kramer ER, 2000, MOL BIOL CELL, V11, P1555, DOI 10.1091/mbc.11.5.1555; Kumagai A, 1996, SCIENCE, V273, P1377, DOI 10.1126/science.273.5280.1377; LAHAVBARATZ S, 1995, P NATL ACAD SCI USA, V92, P9303, DOI 10.1073/pnas.92.20.9303; Landrieu I, 2001, J BIOL CHEM, V276, P1434, DOI 10.1074/jbc.M006420200; Morgan DO, 1999, NAT CELL BIOL, V1, pE47, DOI 10.1038/10039; Nigg EA, 1998, CURR OPIN CELL BIOL, V10, P776, DOI 10.1016/S0955-0674(98)80121-X; Patra D, 1998, GENE DEV, V12, P2549, DOI 10.1101/gad.12.16.2549; Peters JM, 1999, EXP CELL RES, V248, P339, DOI 10.1006/excr.1999.4443; Pines J, 1996, CURR BIOL, V6, P1399, DOI 10.1016/S0960-9822(96)00741-5; Qian YW, 1999, MOL CELL BIOL, V19, P8625; Qian YW, 1998, MOL CELL BIOL, V18, P4262, DOI 10.1128/MCB.18.7.4262; Rudner AD, 2000, J CELL BIOL, V149, P1377, DOI 10.1083/jcb.149.7.1377; Shah JV, 2000, CELL, V103, P997, DOI 10.1016/S0092-8674(00)00202-6; Shteinberg M, 1999, BIOCHEM BIOPH RES CO, V260, P193, DOI 10.1006/bbrc.1999.0884; Shteinberg M, 1999, BIOCHEM BIOPH RES CO, V257, P12, DOI 10.1006/bbrc.1999.0409; SUDAKIN V, 1995, MOL BIOL CELL, V6, P185, DOI 10.1091/mbc.6.2.185; Sudakin V, 1997, J BIOL CHEM, V272, P18051, DOI 10.1074/jbc.272.29.18051; TUGENDREICH S, 1995, CELL, V81, P261, DOI 10.1016/0092-8674(95)90336-4; Yudkovsky Y, 2000, BIOCHEM BIOPH RES CO, V271, P299, DOI 10.1006/bbrc.2000.2622; Zachariae W, 1999, GENE DEV, V13, P2039, DOI 10.1101/gad.13.16.2039; ZHUO S, 1993, J BIOL CHEM, V268, P17754	29	144	151	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 3	2002	277	18					15552	15557		10.1074/jbc.M111476200	http://dx.doi.org/10.1074/jbc.M111476200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	550PA	11859075	hybrid			2022-12-27	WOS:000175510400045
J	Lee, CW; Ji, IH; Ryu, KS; Song, YS; Conn, PM; Ji, TH				Lee, CW; Ji, IH; Ryu, KS; Song, YS; Conn, PM; Ji, TH			Two defective heterozygous luteinizing hormone receptors can rescue hormone action	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOLLICLE-STIMULATING-HORMONE; HORMONE/CHORIONIC GONADOTROPIN RECEPTOR; LUTROPIN-CHORIOGONADOTROPIN RECEPTOR; LEYDIG-CELL HYPOPLASIA; LEUCINE-RICH REPEATS; HIGH-AFFINITY; EXTRACELLULAR DOMAIN; LUTROPIN/CHORIOGONADOTROPIN RECEPTOR; FUNCTIONAL EXPRESSION; TRANSMEMBRANE DOMAIN	Luteinizing hormone receptor is a G protein-coupled receptor and consists of two halves: the N-terminal extracellular half (exodomain) and C-terminal membrane-associated half (endodomain). Hormone binds to the exodomain, and the resulting hormone-exodomain complex modulates the endodomain to generate signals. There are mutations that impair either hormone binding or signal generation. We report that the coexpression of a binding defective mutant and a signal-defective mutant rescues signal generation to produce cAMP. This rescue requires both types of mutant receptors and is dependent on the human chorionic gonadotropin dose, the surface concentration of mutant receptors, and the amino acid position of mutations. Furthermore, random collisions among mutant receptors are not involved in the rescue. Our observations provide new in. sights into the mechanisms of the functional and structural relationship of the exo- and endodomain, signal transduction, and receptor genetics, in particular for defective heterozygotes.	Univ Kentucky, Dept Chem, Lexington, KY 40506 USA; Oregon Hlth Sci Univ, Oregon Reg Primate Res Ctr, Portland, OR 97201 USA; Oregon Hlth Sci Univ, Dept Physiol & Pharmacol, Portland, OR 97201 USA	University of Kentucky; Oregon Health & Science University; Oregon National Primate Research Center; Oregon Health & Science University	Ji, TH (corresponding author), Univ Kentucky, Dept Chem, Lexington, KY 40506 USA.		Song, Yong Sang/E-7824-2012	SONG, YONGSANG/0000-0001-7115-4021	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD018702] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK051469] Funding Source: NIH RePORTER; NICHD NIH HHS [HD-18702] Funding Source: Medline; NIDDK NIH HHS [DK-51469] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bhowmick N, 1996, MOL ENDOCRINOL, V10, P1147, DOI 10.1210/me.10.9.1147; BRAUN T, 1991, EMBO J, V10, P1885, DOI 10.1002/j.1460-2075.1991.tb07714.x; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; DAVIS D, 1995, MOL ENDOCRINOL, V9, P159, DOI 10.1210/me.9.2.159; Dufau ML, 1998, ANNU REV PHYSIOL, V60, P461, DOI 10.1146/annurev.physiol.60.1.461; Hong SH, 1999, MOL ENDOCRINOL, V13, P1285, DOI 10.1210/me.13.8.1285; Hong SH, 1998, J BIOL CHEM, V273, P13835, DOI 10.1074/jbc.273.22.13835; Hong SH, 1997, J BIOL CHEM, V272, P4166, DOI 10.1074/jbc.272.7.4166; Hong SH, 1999, ENDOCRINOLOGY, V140, P2486, DOI 10.1210/en.140.6.2486; JI I, 1980, P NATL ACAD SCI-BIOL, V77, P7167, DOI 10.1073/pnas.77.12.7167; JI IH, 1991, J BIOL CHEM, V266, P14953; JI IH, 1991, ENDOCRINOLOGY, V128, P2648, DOI 10.1210/endo-128-5-2648; Ji IH, 1995, ENDOCRINE, V3, P907, DOI 10.1007/BF02738896; Ji TH, 1998, J BIOL CHEM, V273, P17299, DOI 10.1074/jbc.273.28.17299; JI TH, 1995, ENDOCRINE, V3, P187, DOI 10.1007/BF02994442; Kosugi S, 1996, J BIOL CHEM, V271, P31813, DOI 10.1074/jbc.271.50.31813; KOSUGI S, 1995, HUM MOL GENET, V4, P183, DOI 10.1093/hmg/4.2.183; Laue LL, 1996, MOL ENDOCRINOL, V10, P987, DOI 10.1210/me.10.8.987; LIU XX, 1994, ENDOCRINOLOGY, V135, P682, DOI 10.1210/en.135.2.682; LOOSFELT H, 1989, SCIENCE, V245, P525, DOI 10.1126/science.2502844; MCFARLAND KC, 1989, SCIENCE, V245, P494, DOI 10.1126/science.2502842; McGee EA, 2000, ENDOCR REV, V21, P200, DOI 10.1210/er.21.2.200; Misrahi M, 1997, J CLIN ENDOCR METAB, V82, P2159, DOI 10.1210/jcem.82.7.4039; MOYLE WR, 1994, NATURE, V368, P251, DOI 10.1038/368251a0; NAGAYAMA Y, 1989, BIOCHEM BIOPH RES CO, V165, P1184, DOI 10.1016/0006-291X(89)92727-7; Nakabayashi K, 2000, J BIOL CHEM, V275, P30264, DOI 10.1074/jbc.M005568200; Nishi S, 2002, J BIOL CHEM, V277, P3958, DOI 10.1074/jbc.M109617200; Osuga Y, 1997, J BIOL CHEM, V272, P25006, DOI 10.1074/jbc.272.40.25006; REMY JJ, 1993, BIOCHEM BIOPH RES CO, V193, P1023, DOI 10.1006/bbrc.1993.1727; Ryu K, 1998, J BIOL CHEM, V273, P28953, DOI 10.1074/jbc.273.44.28953; Ryu KS, 1998, J BIOL CHEM, V273, P6285, DOI 10.1074/jbc.273.11.6285; Ryu KS, 1996, J BIOL CHEM, V271, P7301, DOI 10.1074/jbc.271.13.7301; Song YS, 2001, J BIOL CHEM, V276, P3426, DOI 10.1074/jbc.M003772200; Song YS, 2001, J BIOL CHEM, V276, P3436, DOI 10.1074/jbc.M003773200; SPRENGEL R, 1990, MOL ENDOCRINOL, V4, P525, DOI 10.1210/mend-4-4-525; Thomas D, 1996, MOL ENDOCRINOL, V10, P760, DOI 10.1210/me.10.6.760; TILLY JL, 1992, ENDOCRINOLOGY, V131, P799, DOI 10.1210/en.131.2.799; TSAIMORRIS CH, 1990, J BIOL CHEM, V265, P19385; Wu SM, 1998, MOL ENDOCRINOL, V12, P1651, DOI 10.1210/me.12.11.1651; XIE YB, 1990, J BIOL CHEM, V265, P21411; Zeng HW, 2001, J BIOL CHEM, V276, P3451, DOI 10.1074/jbc.M007488200	41	59	61	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 3	2002	277	18					15795	15800		10.1074/jbc.M111818200	http://dx.doi.org/10.1074/jbc.M111818200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	550PA	11859079	hybrid			2022-12-27	WOS:000175510400078
J	Berkhout, B; Ooms, M; Beerens, N; Huthoff, H; Southern, E; Verhoef, K				Berkhout, B; Ooms, M; Beerens, N; Huthoff, H; Southern, E; Verhoef, K			In vitro evidence that the untranslated leader of the HIV-1 genome is an RNA checkpoint that regulates multiple functions through conformational changes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; DIMERIZATION INITIATION SITE; REVERSE TRANSCRIPTION; SECONDARY STRUCTURE; STRAND TRANSFER; IN-VITRO; TAR RNA; TYPE-1; HAIRPIN; BINDING	The HIV-1 RNA genome forms dimers through base pairing of a palindromic 6-mer sequence that is exposed in the loop of the dimer initiation signal (DIS) hairpin structure (loop-loop kissing). The HIV-1 leader RNA can adopt a secondary structure conformation that is not able to dimerize because the DIS hairpin is not folded. Instead, this DIS motif is base-paired in a long distance interaction (LDI) that extends the stem of the primer-binding site domain. In this study, we show that targeting of the LDI by either antisense oligonucleotides or specific mutations can induce the conformational switch to a branched multiple hairpin (BAIH) structure, and this LDI-to-BMH switch coincides with increased RNA dimerization. Another interesting finding is that the extended LDI stem can resist a certain level of destabilization, indicating that a buffer is created to prevent a premature conformational switch and early dimerization. Because the tRNA(Lys3) primer for reverse transcription anneals to multiple sequence elements of the HIV-1 leader RNA, including sequences in the LDI stem, we tested whether tRNA-annealing can destabilize the LDI stem such that RNA dimerization is triggered. Using a combination of stem-destabilizing approaches, we indeed measured a small but significant effect of tRNA-annealing on the ability of the RNA template to form dimers. This observation suggests that HIV-1 RNA can act as a checkpoint to control and coordinate different leader functions through conformational switches. This in vitro result should be verified in subsequent in vivo studies with HIV-infected cells.	Univ Amsterdam, Acad Med Ctr, Dept Human Retrovirol, NL-1105 AZ Amsterdam, Netherlands; Univ Oxford, Dept Biochem, Oxford OX1 3QU, England	University of Amsterdam; Academic Medical Center Amsterdam; University of Oxford	Berkhout, B (corresponding author), Univ Amsterdam, Acad Med Ctr, Dept Human Retrovirol, Meibergdreef 15, NL-1105 AZ Amsterdam, Netherlands.			Ooms, Marcel/0000-0002-0750-5832				Albert R, 2000, NATURE, V406, P378, DOI 10.1038/35019019; Balakrishnan M, 2001, J BIOL CHEM, V276, P36482, DOI 10.1074/jbc.M102860200; Beerens N, 2000, J BIOL CHEM, V275, P15474, DOI 10.1074/jbc.275.20.15474; Beerens N, 2000, NUCLEIC ACIDS RES, V28, P4130, DOI 10.1093/nar/28.21.4130; Beerens N, 2002, J VIROL, V76, P2329, DOI 10.1128/JVI.76.5.2329-2339.2002; Beerens N, 2002, RNA, V8, P357, DOI 10.1017/S1355838202028194; Beerens N, 2001, J BIOL CHEM, V276, P31247, DOI 10.1074/jbc.M102441200; BERKHOUT B, 1995, VIROLOGY, V207, P276, DOI 10.1006/viro.1995.1077; Berkhout B, 1996, PROG NUCLEIC ACID RE, V54, P1, DOI 10.1016/S0079-6603(08)60359-1; BERKHOUT B, 1989, CELL, V59, P273, DOI 10.1016/0092-8674(89)90289-4; Berkhout B, 2001, RNA, V7, P1097, DOI 10.1017/S1355838201002035; Berkhout B, 1998, VIROLOGY, V249, P211, DOI 10.1006/viro.1998.9321; Berkhout B, 1996, J VIROL, V70, P6723, DOI 10.1128/JVI.70.10.6723-6732.1996; Berkhout B, 2000, Adv Pharmacol, V48, P29; Berkhout B, 2000, RNA, V6, P282, DOI 10.1017/S1355838200991684; BIETH E, 1990, NUCLEIC ACIDS RES, V18, P119, DOI 10.1093/nar/18.1.119; CLEVER J, 1995, J VIROL, V69, P2101, DOI 10.1128/JVI.69.4.2101-2109.1995; Das AT, 1997, J VIROL, V71, P2346, DOI 10.1128/JVI.71.3.2346-2356.1997; De Guzman RN, 1998, SCIENCE, V279, P384, DOI 10.1126/science.279.5349.384; DINGWALL C, 1989, P NATL ACAD SCI USA, V86, P6925, DOI 10.1073/pnas.86.18.6925; Hughes TR, 2001, NAT BIOTECHNOL, V19, P342, DOI 10.1038/86730; Huthoff H, 2001, RNA, V7, P143, DOI 10.1017/S1355838201001881; Huthoff H, 2001, NUCLEIC ACIDS RES, V29, P2594, DOI 10.1093/nar/29.12.2594; Jossinet F, 1999, RNA, V5, P1222, DOI 10.1017/S1355838299990982; Klasens BIF, 1998, NUCLEIC ACIDS RES, V26, P1870, DOI 10.1093/nar/26.8.1870; Klasens BIF, 1999, NUCLEIC ACIDS RES, V27, P446, DOI 10.1093/nar/27.2.446; LAUGHREA M, 1994, BIOCHEMISTRY-US, V33, P13464, DOI 10.1021/bi00249a035; Lodmell JS, 2000, RNA, V6, P1267, DOI 10.1017/S1355838200000698; Mujeeb A, 1999, FEBS LETT, V458, P387, DOI 10.1016/S0014-5793(99)01183-7; Paillart JC, 1996, J VIROL, V70, P8348, DOI 10.1128/JVI.70.12.8348-8354.1996; PEDEN KWC, 1996, HIV PRACTICAL APPROA; Shen N, 2001, J VIROL, V75, P10543, DOI 10.1128/JVI.75.21.10543-10549.2001; Shoemaker DD, 2001, NATURE, V409, P922, DOI 10.1038/35057141; SKRIPKIN E, 1994, P NATL ACAD SCI USA, V91, P4945, DOI 10.1073/pnas.91.11.4945; Sohail M., 2000, Molecular Cell Biology Research Communications, V3, P67, DOI 10.1006/mcbr.2000.0178; Sohail M, 2001, NUCLEIC ACIDS RES, V29, P2041, DOI 10.1093/nar/29.10.2041; Takahashi KI, 2000, RNA, V6, P96, DOI 10.1017/S1355838200991635; Wei P, 1998, CELL, V92, P451, DOI 10.1016/S0092-8674(00)80939-3	38	73	76	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 31	2002	277	22					19967	19975		10.1074/jbc.M200950200	http://dx.doi.org/10.1074/jbc.M200950200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	557EH	11896057	hybrid			2022-12-27	WOS:000175894800096
J	Biesiadecki, BJ; Jin, JP				Biesiadecki, BJ; Jin, JP			Exon skipping in cardiac troponin T of turkeys with inherited dilated cardiomyopathy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NH2-TERMINAL VARIABLE REGION; METAL-BINDING CLUSTER; ROUND HEART-DISEASE; SKELETAL-MUSCLE; ADULT ISOFORMS; TROPOMYOSIN ISOFORMS; ALPHA-TROPOMYOSIN; TERMINAL REGION; MOLECULAR-BASIS; EXPRESSION	Troponin T is a central component of the thin filament-associated troponin-tropomyosin system and plays an essential role in the Ca2+ regulation of striated muscle contraction. The importance of the structure and function of troponin T is evident in the regulated isoform expression during development and the point mutations resulting in familial hypertrophic and dilated cardiomyopathies. We report here that turkeys with inherited dilated cardiomyopathy and heart failure express an unusual low molecular weight cardiac troponin T missing 11 amino acids due to the splice out of the normally conserved exon 8-encoded segment. The deletion of a 9-bp segment from intron 7 of the turkey cardiac troponin T gene may be responsible for the weakened splicing of the downstream exon 8 during mRNA processing. The exclusion of the exon S-encoded segment results in conformational changes in cardiac troponin T, an altered binding affinity for troponin I and tropomyosin, and an increased calcium sensitivity of the actomyosin ATPase. Expression of the exon 8-deleted cardiac troponin T prior to the development of cardiomyopathy in turkeys indicates a novel RNA splicing disease and provides evidence for the role of troponin T structure-function variation in myocardial pathogenesis and heart failure.	Case Western Reserve Univ, Sch Med, Dept Physiol & Biophys, Cleveland, OH 44106 USA	Case Western Reserve University	Jin, JP (corresponding author), Case Western Reserve Univ, Sch Med, Dept Physiol & Biophys, 10900 Euclid Ave, Cleveland, OH 44106 USA.	jxj12@po.cwru.edu		Jin, JP/0000-0001-9932-1063	NHLBI NIH HHS [T32-HL07887] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007887] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AKELLA AB, 1995, CIRC RES, V76, P600, DOI 10.1161/01.RES.76.4.600; ANDERSON PAW, 1995, CIRC RES, V76, P681, DOI 10.1161/01.RES.76.4.681; BAYKOV AA, 1988, ANAL BIOCHEM, V171, P266, DOI 10.1016/0003-2697(88)90484-8; BRIGGS MM, 1993, DEV BIOL, V158, P503, DOI 10.1006/dbio.1993.1208; Burhop J, 2001, J BIOL CHEM, V276, P20788, DOI 10.1074/jbc.M101110200; Chandra M, 1999, J MOL CELL CARDIOL, V31, P867, DOI 10.1006/jmcc.1999.0928; COOPER TA, 1985, J BIOL CHEM, V260, P1140; CZARNECKI CM, 1984, COMP BIOCHEM PHYS A, V77, P591, DOI 10.1016/0300-9629(84)90169-5; EINZIG S, 1972, AM J VET RES, V33, P557; Elrick LL, 1998, MOL CELL BIOL, V18, P343, DOI 10.1128/MCB.18.1.343; Genao A, 1996, LAB ANIM SCI, V46, P399; GREIG A, 1994, CIRC RES, V74, P41, DOI 10.1161/01.RES.74.1.41; HAJJAR RJ, 1993, CARDIOVASC RES, V27, P2212, DOI 10.1093/cvr/27.12.2212; HEELEY DH, 1987, J BIOL CHEM, V262, P9971; Huang QQ, 1999, J PHYSIOL-LONDON, V520, P231, DOI 10.1111/j.1469-7793.1999.00231.x; Huang QQ, 1999, J MOL EVOL, V49, P780, DOI 10.1007/PL00006600; Huang QQ, 1999, BIOPHYS J, V76, pA281; HUNSAKER WG, 1971, POULTRY SCI, V50, P1720, DOI 10.3382/ps.0501720; JANKUS EF, 1973, RES ANIMALS MED, P53; Jin JP, 2000, BIOCHEMISTRY-US, V39, P11702, DOI 10.1021/bi9927437; JIN JP, 1988, J BIOL CHEM, V263, P7309; JIN JP, 1992, J MOL BIOL, V227, P1269, DOI 10.1016/0022-2836(92)90540-Z; JIN JP, 1989, J BIOL CHEM, V264, P14471; Jin JP, 2001, J MOL EVOL, V52, P103, DOI 10.1007/s002390010139; Jin JP, 2001, BIOCHEMISTRY-US, V40, P2623, DOI 10.1021/bi002423j; Jin JP, 1996, GENE, V168, P217, DOI 10.1016/0378-1119(95)00803-9; Jin JP, 1996, BIOCHEM BIOPH RES CO, V225, P883, DOI 10.1006/bbrc.1996.1267; Kamisago M, 2000, NEW ENGL J MED, V343, P1688, DOI 10.1056/NEJM200012073432304; LEAVIS PC, 1984, CRC CR REV BIOCH MOL, V16, P235, DOI 10.3109/10409238409108717; LESZYK J, 1987, BIOCHEMISTRY-US, V26, P7035, DOI 10.1021/bi00396a027; LIN JJC, 1985, HYBRIDOMA, V4, P223, DOI 10.1089/hyb.1985.4.223; LIU SK, 1980, YALE J BIOL MED, V53, P191; Maytum R, 1999, BIOCHEMISTRY-US, V38, P1102, DOI 10.1021/bi981603e; MesnardRouiller L, 1997, J MOL CELL CARDIOL, V29, P3043, DOI 10.1006/jmcc.1997.0519; Ogut O, 1999, AM J PHYSIOL-CELL PH, V276, pC1162, DOI 10.1152/ajpcell.1999.276.5.C1162; Ogut O, 1996, BIOCHEMISTRY-US, V35, P16581, DOI 10.1021/bi961712y; Ogut O, 2000, J BIOL CHEM, V275, P26089, DOI 10.1074/jbc.M910360199; Ogut O, 1998, J BIOL CHEM, V273, P27858, DOI 10.1074/jbc.273.43.27858; PAN BS, 1991, J BIOL CHEM, V266, P12432; Perry SV, 1998, J MUSCLE RES CELL M, V19, P575; Philips AV, 1998, SCIENCE, V280, P737, DOI 10.1126/science.280.5364.737; Redwood CS, 1999, CARDIOVASC RES, V44, P20, DOI 10.1016/S0008-6363(99)00213-8; REISER PJ, 1992, J PHYSIOL-LONDON, V449, P573, DOI 10.1113/jphysiol.1992.sp019102; Seidman CE, 1998, BASIC RES CARDIOL, V93, P13; SMILLIE LB, 1982, METHOD ENZYMOL, V85, P234; Stanley SE, 1999, MOL BIOL EVOL, V16, P1575, DOI 10.1093/oxfordjournals.molbev.a026070; Sweeney HL, 1998, P NATL ACAD SCI USA, V95, P14406, DOI 10.1073/pnas.95.24.14406; Tardiff JC, 1998, J CLIN INVEST, V101, P2800, DOI 10.1172/JCI2389; TOBACMAN LS, 1988, J BIOL CHEM, V263, P2668; Tobacman LS, 1999, J BIOL CHEM, V274, P28363, DOI 10.1074/jbc.274.40.28363; Tobacman LS, 1996, ANNU REV PHYSIOL, V58, P447, DOI 10.1146/annurev.physiol.58.1.447; TOWNSEND PJ, 1995, J MOL CELL CARDIOL, V27, P2223, DOI 10.1016/S0022-2828(95)91587-7; Wang J, 1998, BIOCHEMISTRY-US, V37, P14519, DOI 10.1021/bi9812322; Wang J, 1997, GENE, V193, P105, DOI 10.1016/S0378-1119(97)00100-5; WATKINS H, 1995, NEW ENGL J MED, V332, P1058, DOI 10.1056/NEJM199504203321603; ZOT AS, 1987, ANNU REV BIOPHYS BIO, V16, P535; [No title captured]	57	43	45	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 24	2002	277	21					18459	18468		10.1074/jbc.M200788200	http://dx.doi.org/10.1074/jbc.M200788200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	558PM	11886865	hybrid			2022-12-27	WOS:000175975800028
J	Kuma, A; Mizushima, N; Ishihara, N; Ohsumi, Y				Kuma, A; Mizushima, N; Ishihara, N; Ohsumi, Y			Formation of the similar to 350-kDa Apg12-Apg5 center dot Apg16 multimeric complex, mediated by Apg16 oligomerization, is essential for autophagy in yeast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN CONJUGATION SYSTEM; SACCHAROMYCES-CEREVISIAE; AMINOPEPTIDASE-I; VACUOLE; DEGRADATION; CYTOPLASM; PATHWAYS; MUTANTS; TOR; MACROAUTOPHAGY	Autophagy, responsible for the delivery of cytoplasmic components to the lysosome/vacuole for degradation, is the major degradative pathway in eukaryotic cells. This process requires a ubiquitin-like protein conjugation system, in which Apg12 is covalently bound to Apg5. In the yeast Saccharomyces cerevisiae, the Apg12-Apg5 conjugate further interacts with a small coiled-coil protein, Apg16. The Apg12-Apg5 and Apg16 are localized in the cytosol and pre-autophagosomal structures and play an essential role in autophagosome formation. Here we show that the Apg12-Apg5 conjugate and Apg16 form a similar to350-kDa complex in the cytosol. Because Apg16 was suggested to form a homo-oligomer, we generated an in vivo system that allowed us to control the oligomerization state of Apg16. With this system, we demonstrated that formation of the similar to350-kDa complex and autophagic activity depended on the oligomerization state of Apg16. These results suggest that the Apg12-Apg5 conjugate and Apg16 form a multimeric complex mediated by the Apg16 homo-oligomer, and formation of the similar to350-kDa complex is required for autophagy in yeast.	Natl Inst Basic Biol, Dept Cell Biol, Okazaki, Aichi 4448585, Japan; Grad Univ Adv Studies, Sch Life Sci, Dept Mol Biomech, Okazaki, Aichi 4448585, Japan; Japan Sci & Technol Corp, PRESTO, Kawaguchi 3320012, Japan	National Institutes of Natural Sciences (NINS) - Japan; National Institute for Basic Biology (NIBB); Graduate University for Advanced Studies - Japan; Japan Science & Technology Agency (JST)	Ohsumi, Y (corresponding author), Natl Inst Basic Biol, Dept Cell Biol, 38 Nishigonaka, Okazaki, Aichi 4448585, Japan.		Mizushima, Noboru/C-3635-2009; Ohsumi, Yoshinori/C-6449-2009	Mizushima, Noboru/0000-0002-6258-6444; Ohsumi, Yoshinori/0000-0003-2384-2166; Ishihara, Naotada/0000-0002-6305-7149				Amara JF, 1997, P NATL ACAD SCI USA, V94, P10618, DOI 10.1073/pnas.94.20.10618; Baba M, 1997, J CELL BIOL, V139, P1687, DOI 10.1083/jcb.139.7.1687; Berggrun A, 2001, P NATL ACAD SCI USA, V98, P2301, DOI 10.1073/pnas.041612198; Cabezon E, 2000, J BIOL CHEM, V275, P25460, DOI 10.1074/jbc.M003859200; Clackson T, 1998, P NATL ACAD SCI USA, V95, P10437, DOI 10.1073/pnas.95.18.10437; Cupers P, 1997, J BIOL CHEM, V272, P33430, DOI 10.1074/jbc.272.52.33430; DAWSON AL, 1975, HISTOCHEM J, V7, P77, DOI 10.1007/BF01004834; Dunn William A. Jr., 1994, Trends in Cell Biology, V4, P139, DOI 10.1016/0962-8924(94)90069-8; George MD, 2000, MOL BIOL CELL, V11, P969, DOI 10.1091/mbc.11.3.969; Kim J, 1999, MOL BIOL CELL, V10, P1337, DOI 10.1091/mbc.10.5.1337; Kim J, 2001, J CELL BIOL, V152, P51, DOI 10.1083/jcb.152.1.51; Klionsky DJ, 2000, SCIENCE, V290, P1717, DOI 10.1126/science.290.5497.1717; KLIONSKY DJ, 1992, J CELL BIOL, V119, P287, DOI 10.1083/jcb.119.2.287; Lupas A, 1996, TRENDS BIOCHEM SCI, V21, P375, DOI 10.1016/0968-0004(96)10052-9; Mizushima N, 1998, NATURE, V395, P395, DOI 10.1038/26506; Mizushima N, 2001, J CELL BIOL, V152, P657, DOI 10.1083/jcb.152.4.657; Mizushima N, 1998, J BIOL CHEM, V273, P33889, DOI 10.1074/jbc.273.51.33889; Mizushima N, 1999, EMBO J, V18, P3888, DOI 10.1093/emboj/18.14.3888; Noda T, 1998, J BIOL CHEM, V273, P3963, DOI 10.1074/jbc.273.7.3963; Raught B, 2001, P NATL ACAD SCI USA, V98, P7037, DOI 10.1073/pnas.121145898; Schmelzle T, 2000, CELL, V103, P253, DOI 10.1016/S0092-8674(00)00117-3; Scott SV, 1997, J CELL BIOL, V138, P37, DOI 10.1083/jcb.138.1.37; SEGLEN PO, 1992, EXPERIENTIA, V48, P158, DOI 10.1007/BF01923509; Shintani T, 1999, EMBO J, V18, P5234, DOI 10.1093/emboj/18.19.5234; Suzuki K, 2001, EMBO J, V20, P5971, DOI 10.1093/emboj/20.21.5971; TAKESHIGE K, 1992, J CELL BIOL, V119, P301, DOI 10.1083/jcb.119.2.301; Tanida I, 1999, MOL BIOL CELL, V10, P1367, DOI 10.1091/mbc.10.5.1367; THUMM M, 1994, FEBS LETT, V349, P275, DOI 10.1016/0014-5793(94)00672-5; TSUKADA M, 1993, FEBS LETT, V333, P169, DOI 10.1016/0014-5793(93)80398-E; Yuan WP, 1999, MOL BIOL CELL, V10, P1353, DOI 10.1091/mbc.10.5.1353	30	326	345	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 24	2002	277	21					18619	18625		10.1074/jbc.M111889200	http://dx.doi.org/10.1074/jbc.M111889200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	558PM	11897782	hybrid			2022-12-27	WOS:000175975800051
J	Stapleton, MR; Norte, VA; Read, RC; Green, J				Stapleton, MR; Norte, VA; Read, RC; Green, J			Interaction of the Salmonella typhimurium transcription and virulence factor SlyA with target DNA and identification of members of the SlyA regulon	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIPLE-ANTIBIOTIC-RESISTANCE; ESCHERICHIA-COLI; CRYSTAL-STRUCTURE; GENE; REGULATOR; SURVIVAL; EXPRESSION; HEMOLYSIN; MARR; PROTEIN	The SlyA protein from Salmonella typhimurium is a transcription factor that contributes to virulence. It is shown that a slyA mutant is attenuated in the presence of murine macrophages compared with the parent strain. Moreover, after growth in minimal medium, survival of the slyA mutant was reduced. Altered levels of flagellin (fliC), PagC, IroN, and outer membrane proteins suggest that the slyA mutation affects the surface properties of Salmonella. The isolated SlyA protein is a cofactor-free homodimer that recognizes five sites within the promoter region of the slyA gene. One of these sites contained a near perfect inverted repeat TTAGCAAGCTAA. The other four sites contained related sequences. Occupation of the SlyA sites in the slyA promoter prevented open-complex formation, consistent with the pattern of slyA::lacZ expression parental and slyA mutant strains. By combining the footprinting data with potential SlyA binding sites recovered from a pool of random DNA sequences, a consensus was defined and used to probe the NIH Salmonella unfinished genomes data base. These searches revealed the presence of consensus SlyA sites upstream of omp, ispA, xseB, slyA, and a gene encoding a protein with homology to a hemagglutinin. Accordingly, transcription of an omp::lacZ fusion was reduced in a slyA mutant. Given the difficulties in obtaining a comprehensive picture of intracellular gene expression, the definition of the DNA sequence recognized by a transcription factor (SlyA) that is essential for survival in the macrophage environment should allow a complete regulon of genes with altered expression upon exposure to macrophages to be determined once the S. typhimurium genome annotation is complete.	Univ Sheffield, Dept Mol Biol & Biotechnol, Krebs Inst Biomol Res, Sheffield S10 2TN, S Yorkshire, England; Univ Sheffield, Sch Med, Div Genom Med, Sheffield S10 2RX, S Yorkshire, England	University of Sheffield; University of Sheffield	Green, J (corresponding author), Univ Sheffield, Dept Mol Biol & Biotechnol, Krebs Inst Biomol Res, Sheffield S10 2TN, S Yorkshire, England.	jeff.green@sheffield.ac.uk		Read, Robert/0000-0002-4297-6728				AIBA H, 1981, J BIOL CHEM, V256, P1905; Alekshun MN, 2001, NAT STRUCT BIOL, V8, P710, DOI 10.1038/90429; Alekshun MN, 2000, MOL MICROBIOL, V35, P1394, DOI 10.1046/j.1365-2958.2000.01802.x; BAUMLER AJ, 1994, INFECT IMMUN, V62, P1623; Buchmeier N, 1997, INFECT IMMUN, V65, P3725, DOI 10.1128/IAI.65.9.3725-3730.1997; Daigle F, 2001, MOL MICROBIOL, V41, P1211, DOI 10.1046/j.1365-2958.2001.02593.x; Daniels JJD, 1996, INFECT IMMUN, V64, P5075, DOI 10.1128/IAI.64.12.5075-5084.1996; delCastillo FJ, 1997, MOL MICROBIOL, V25, P107, DOI 10.1046/j.1365-2958.1997.4391813.x; GERISCHER U, 1992, J BACTERIOL, V174, P426, DOI 10.1128/jb.174.2.426-433.1992; Green J, 1997, MICROBIOL-SGM, V143, P3785, DOI 10.1099/00221287-143-12-3785; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; Kawakami T, 1999, MICROBIOL IMMUNOL, V43, P351, DOI 10.1111/j.1348-0421.1999.tb02415.x; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; LIBBY SJ, 1994, P NATL ACAD SCI USA, V91, P489, DOI 10.1073/pnas.91.2.489; LODGE J, 1990, FEMS MICROBIOL LETT, V67, P221, DOI 10.1016/0378-1097(90)90199-Z; Ludwig A, 1995, MOL GEN GENET, V249, P474, DOI 10.1007/BF00290573; Ludwig A, 1999, MOL MICROBIOL, V31, P557, DOI 10.1046/j.1365-2958.1999.01196.x; MARTIN RG, 1995, P NATL ACAD SCI USA, V92, P5456, DOI 10.1073/pnas.92.12.5456; Maxam A M, 1980, Methods Enzymol, V65, P499; Miller PF, 1996, MOL MICROBIOL, V21, P441, DOI 10.1111/j.1365-2958.1996.tb02553.x; Nagel G, 2001, MOL MICROBIOL, V41, P1249, DOI 10.1046/j.1365-2958.2001.02522.x; Negm RS, 1999, CAN J MICROBIOL, V45, P658, DOI 10.1139/cjm-45-8-658; Oscarsson J, 1996, MOL MICROBIOL, V20, P191, DOI 10.1111/j.1365-2958.1996.tb02500.x; Revell PA, 2000, MOL MICROBIOL, V35, P677, DOI 10.1046/j.1365-2958.2000.01740.x; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Silhavy T. J., 1984, EXPT GENE FUSIONS; Wallace AJ, 2000, CELL, V100, P265, DOI 10.1016/S0092-8674(00)81564-0; WING HJ, 1995, J BACTERIOL, V177, P6704, DOI 10.1128/jb.177.23.6704-6710.1995	28	80	83	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 17	2002	277	20					17630	17637		10.1074/jbc.M110178200	http://dx.doi.org/10.1074/jbc.M110178200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	553PR	11882648	hybrid			2022-12-27	WOS:000175685100032
J	Varaklioti, A; Vassilaki, N; Georgopoulou, U; Mavromara, P				Varaklioti, A; Vassilaki, N; Georgopoulou, U; Mavromara, P			Alternate translation occurs within the core coding region of the hepatitis C viral genome	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article; Proceedings Paper	7th International Meeting on Hepatitis C and Related Viruses	DEC 03-07, 2000	GOLD COAST, AUSTRALIA				RIBOSOME ENTRY SITES; VIRUS CORE; MOLECULAR VIROLOGY; GENE-PRODUCTS; FACTOR-ALPHA; PROTEIN; SUBSTITUTIONS; LOCALIZATION; APOPTOSIS; GROWTH	The majority of hepatitis C virus (HCV) isolates contain an open reading frame (ORF) overlapping with the core coding sequences in the +1 frame, which was assumed. to be untranslated. We present evidence supporting the expression of this ORF (designated core+1 ORF) via novel translation mechanisms. First, fusion of the luciferase gene with the HCV-1 core+1 ORF followed by in vitro translation resulted in the synthesis of a chimeric protein (core+1-luciferase) that exhibited similar to54% luciferase activity relative to the positive control (core-luciferase). Second, antisera raised against two different synthetic core+ 1 peptides recognized the previously identified p16 (but not p21) core protein band expressed from HCV-1, indicating the presence of epitopes from the core+1 ORF within the p16 protein. Third, HCV-positive sera specifically recognized lysates of Escherichia coli cells expressing recombinant core+ 1 protein, suggesting the presence of anti-core+1 antibodies in HCV-infected patients. Finally, luciferase tagging experiments designed to assess for -1 frameshifting combined with site-directed mutagenesis experiments supported the presence of +1/-1 ribosomal frameshift translation mechanisms within the core coding region. In conclusion, our data provide evidence for novel translation mechanisms within the core coding region and demonstrate the expression of the core+1 ORF, at least for some HCV isolates.	Hellenic Pasteur Inst, Mol Virol Lab, Athens 11521, Greece		Varaklioti, A (corresponding author), Hellenic Pasteur Inst, Mol Virol Lab, 127 Vassilisis Sofias Ave, Athens 11521, Greece.		Varaklioti, Agoritsa/AAP-7116-2020; Georgopoulou, Urania/AAQ-3831-2020	Varaklioti, Agoritsa/0000-0002-3897-819X				Atkins JF, 1999, NAT STRUCT BIOL, V6, P206, DOI 10.1038/6642; Barba G, 1997, P NATL ACAD SCI USA, V94, P1200, DOI 10.1073/pnas.94.4.1200; CHAMORRO M, 1992, P NATL ACAD SCI USA, V89, P713, DOI 10.1073/pnas.89.2.713; Chang J, 1998, J VIROL, V72, P3060, DOI 10.1128/JVI.72.4.3060-3065.1998; CHOO QL, 1989, SCIENCE, V244, P359, DOI 10.1126/science.2523562; Clarke B, 1997, J GEN VIROL, V78, P2397, DOI 10.1099/0022-1317-78-10-2397; Farabaugh PJ, 1996, MICROBIOL REV, V60, P103, DOI 10.1128/MMBR.60.1.103-134.1996; Hayashi J, 2000, HEPATOLOGY, V32, P958, DOI 10.1053/jhep.2000.19343; HOUGHTON M, 1996, FIELDS VIROLOGY, P1035; Hussy P, 1996, VIROLOGY, V224, P93, DOI 10.1006/viro.1996.0510; INA Y, 1994, J MOL EVOL, V38, P50; Kunkel M, 2001, J VIROL, V75, P2119, DOI 10.1128/JVI.75.5.2119-2129.2001; Large MK, 1999, J IMMUNOL, V162, P931; Le SY, 1996, VIRUS GENES, V12, P135, DOI 10.1007/BF00572952; Lemon SM, 1997, SEMIN VIROL, V8, P274, DOI 10.1006/smvy.1997.0129; LO SY, 1994, VIROLOGY, V199, P124, DOI 10.1006/viro.1994.1104; LO SY, 1995, VIROLOGY, V213, P455, DOI 10.1006/viro.1995.0018; Major ME, 1997, HEPATOLOGY, V25, P1527, DOI 10.1002/hep.510250637; Makarova KS, 2000, TRENDS BIOCHEM SCI, V25, P50, DOI 10.1016/S0968-0004(99)01530-3; Marusawa H, 1999, J VIROL, V73, P4713, DOI 10.1128/JVI.73.6.4713-4720.1999; MATSUURA Y, 1993, SEMIN VIROL, V4, P297, DOI 10.1006/smvy.1993.1026; McLauchlan J, 2000, J VIRAL HEPATITIS, V7, P2; Moradpour D, 1996, VIROLOGY, V222, P51, DOI 10.1006/viro.1996.0397; Moriya K, 1997, J GEN VIROL, V78, P1527, DOI 10.1099/0022-1317-78-7-1527; Ray RB, 2001, FEMS MICROBIOL LETT, V202, P149, DOI 10.1111/j.1574-6968.2001.tb10796.x; Reed KE, 2000, CURR TOP MICROBIOL, V242, P55; Rumenapf T, 1998, J VIROL, V72, P2544; SAITO I, 1990, P NATL ACAD SCI USA, V87, P6547, DOI 10.1073/pnas.87.17.6547; Smith DB, 1997, J MOL EVOL, V45, P238, DOI 10.1007/PL00006226; Suzuki R, 2001, VIROLOGY, V280, P301, DOI 10.1006/viro.2000.0785; Tsuchihara K, 1999, VIROLOGY, V258, P100, DOI 10.1006/viro.1999.9694; Walewski JL, 2001, RNA, V7, P710, DOI 10.1017/S1355838201010111; Xu ZM, 2001, EMBO J, V20, P3840, DOI 10.1093/emboj/20.14.3840; Yasui K, 1998, J VIROL, V72, P6048, DOI 10.1128/JVI.72.7.6048-6055.1998; Yeh CT, 2000, J GASTROEN HEPATOL, V15, P182, DOI 10.1046/j.1440-1746.2000.02066.x; Zhu NL, 1998, J VIROL, V72, P3691, DOI 10.1128/JVI.72.5.3691-3697.1998	36	123	135	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 17	2002	277	20					17713	17721		10.1074/jbc.M201722200	http://dx.doi.org/10.1074/jbc.M201722200			9	Biochemistry & Molecular Biology	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	553PR	11884417	hybrid			2022-12-27	WOS:000175685100042
J	Wu, SY; Hu, YY; Wang, JL; Chatterjee, M; Shi, YG; Kaufman, RJ				Wu, SY; Hu, YY; Wang, JL; Chatterjee, M; Shi, YG; Kaufman, RJ			Ultraviolet light inhibits translation through activation of the unfolded protein response kinase PERK in the lumen of the endoplasmic reticulum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UV-IRRADIATION; INDUCED APOPTOSIS; ER STRESS; MAMMALIAN-CELLS; MESSENGER-RNA; IRE1; GENE; DIMERIZATION; EXPRESSION; PKR	Exposure to ultraviolet light can cause inflammation, premature skin aging, and cancer. UV irradiation alters the expression of multiple genes that encode functions to repair DNA damage, arrest cell growth, and induce apoptosis. In addition, UV irradiation inhibits protein synthesis, although the mechanism is not known. In this report, we show that UV irradiation induces phosphorylation of eukaryotic translation initiation factor 2 on the alpha-subunit (eIF2alpha) and inhibits protein synthesis in a dosage- and time-dependent manner. The UV-induced phosphorylation of eIF2alpha was prevented by the overexpression of a non-phosphorylatable mutant of eIF2alpha (S51A). PERK is an eIF2alpha protein kinase localized to the endoplasmic reticulum that is activated by the accumulation of unfolded proteins in the endoplasmic reticulum. Expression of trans-dominant-negative mutants of PERK also prevented eIF2alpha phosphorylation upon UV treatment and protected from the associated translation attenuation. The luminal domain of dominant-negative mutant PERK formed heterodimers with endogenous PERK to inhibit the PERK signaling pathway. In contrast, eIF2alpha phosphorylation was not inhibited by overexpression of a trans-dominant-negative mutant kinase, PKR, supporting the theory that UV-induced eIF2alpha phosphorylation is specifically mediated by PERK. These results support a novel mechanism by which UV irradiation regulates translation via an endoplasmic reticulum-stress signaling pathway.	Univ Michigan, Med Ctr, Howard Hughes Med Inst, Dept Radiat Oncol, Ann Arbor, MI 48109 USA; Univ Michigan, Med Ctr, Howard Hughes Med Inst, Dept Biol Chem, Ann Arbor, MI 48109 USA; Eli Lilly & Co, Lilly Res Labs, Div Endocrine, Indianapolis, IN 46285 USA	Howard Hughes Medical Institute; University of Michigan System; University of Michigan; Howard Hughes Medical Institute; University of Michigan System; University of Michigan; Eli Lilly	Wu, SY (corresponding author), Rm 4131,1331 E Ann St, Ann Arbor, MI 48109 USA.		Wu, Shiyong/I-3359-2013	Wu, Shiyong/0000-0002-4104-4160	NCI NIH HHS [R01 CA86926] Funding Source: Medline; NIAID NIH HHS [R01 AI42394] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI042394] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Bender K, 1997, J PHOTOCH PHOTOBIO B, V37, P1, DOI 10.1016/S1011-1344(96)07459-3; Bertolotti A, 2000, NAT CELL BIOL, V2, P326, DOI 10.1038/35014014; Bertolotti A, 2001, J CELL SCI, V114, P3207; Bissonnette N, 1998, ONCOGENE, V16, P3461, DOI 10.1038/sj.onc.1201899; Chatterjee M, 2001, MOL CELL BIOCHEM, V219, P21, DOI 10.1023/A:1011083818452; DeGracia DJ, 1997, J CEREBR BLOOD F MET, V17, P1291, DOI 10.1097/00004647-199712000-00004; Der SD, 1997, P NATL ACAD SCI USA, V94, P3279, DOI 10.1073/pnas.94.7.3279; Fernandez J, 2002, J BIOL CHEM, V277, P11780, DOI 10.1074/jbc.M110778200; Fernandez J, 2002, J BIOL CHEM, V277, P2050, DOI 10.1074/jbc.M109199200; Fernandez J, 2001, J BIOL CHEM, V276, P12285, DOI 10.1074/jbc.M009714200; Fritz G, 1999, MOL CELL BIOL, V19, P1768; Harding HP, 1999, NATURE, V397, P271, DOI 10.1038/16729; Harding HP, 2000, MOL CELL, V6, P1099, DOI 10.1016/S1097-2765(00)00108-8; HINNEBUSCH AG, 1994, TRENDS BIOCHEM SCI, V19, P409, DOI 10.1016/0968-0004(94)90089-2; Huang CS, 1997, J BIOL CHEM, V272, P27753, DOI 10.1074/jbc.272.44.27753; Iordanov MS, 1998, J BIOL CHEM, V273, P15794, DOI 10.1074/jbc.273.25.15794; Iwawaki T, 2001, NAT CELL BIOL, V3, P158, DOI 10.1038/35055065; Kaufman RJ, 1999, GENE DEV, V13, P1211, DOI 10.1101/gad.13.10.1211; Liu CY, 2000, J BIOL CHEM, V275, P24881, DOI 10.1074/jbc.M004454200; LUETHY JD, 1990, J BIOL CHEM, V265, P16521; MERRICK WC, 1992, MICROBIOL REV, V56, P291, DOI 10.1128/MMBR.56.2.291-315.1992; Novoa I, 2001, J CELL BIOL, V153, P1011, DOI 10.1083/jcb.153.5.1011; REDPATH NT, 1990, BIOCHEM J, V272, P175, DOI 10.1042/bj2720175; Rehemtulla A, 1997, J BIOL CHEM, V272, P25783, DOI 10.1074/jbc.272.41.25783; Scheuner D, 2001, MOL CELL, V7, P1165, DOI 10.1016/S1097-2765(01)00265-9; Shi YG, 1998, MOL CELL BIOL, V18, P7499, DOI 10.1128/MCB.18.12.7499; Silverman RH, 1999, NATURE, V397, P208, DOI 10.1038/16586; Smith ML, 1997, P NATL ACAD SCI USA, V94, P12255, DOI 10.1073/pnas.94.23.12255; Tirasophon W, 2000, GENE DEV, V14, P2725, DOI 10.1101/gad.839400; Urano F, 2000, SCIENCE, V287, P664, DOI 10.1126/science.287.5453.664; Wang XZ, 1998, EMBO J, V17, P5708, DOI 10.1093/emboj/17.19.5708; Wu L, 1997, MOL MED, V3, P441, DOI 10.1007/BF03401691; Wu SY, 1997, J BIOL CHEM, V272, P1291, DOI 10.1074/jbc.272.2.1291; Wu SY, 1996, J BIOL CHEM, V271, P1756, DOI 10.1074/jbc.271.3.1756; Zinszner H, 1998, GENE DEV, V12, P982, DOI 10.1101/gad.12.7.982	35	96	99	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 17	2002	277	20					18077	18083		10.1074/jbc.M110164200	http://dx.doi.org/10.1074/jbc.M110164200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	553PR	11877419	hybrid			2022-12-27	WOS:000175685100087
J	Feng, W; Yasumura, D; Matthes, MT; LaVail, MM; Vollrath, D				Feng, W; Yasumura, D; Matthes, MT; LaVail, MM; Vollrath, D			Mertk triggers uptake of photoreceptor outer segments during phagocytosis by cultured retinal pigment epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARREST-SPECIFIC GENE-6; MANNOSE RECEPTOR; RCS RAT; APOPTOTIC CELLS; ROYAL-COLLEGE; RPE CELLS; ROD; DYSTROPHY; BINDING; INTEGRIN	The RCS rat is a widely studied model of recessively inherited retinal degeneration. The genetic defect, known as rdy (retinal dystrophy), results in failure of the retinal pigment epithelium (RPE) to phagocytize shed photoreceptor outer segment membranes. We previously used positional cloning and in vivo genetic complementation to demonstrate that Mertk is the gene for rdy. We have now used a rat primary RPE cell culture system. to demonstrate that the RPE is the site of action of Mertk and to obtain functional evidence for a key role of Mertk in RPE phagocytosis. We found that Mertk protein is absent from RCS, but not wild-type, tissues and cultured RPE cells. Delivery of rat Mertk to cultured RCS RPE cells by means of a recombinant adenovirus restored the cells to complete phagocytic competency. Infected RCS RPE cells ingested exogenous outer segments to the same extent as wild-type RPE cells, but outer segment binding was unaffected. Mertk protein progressively co-localized with outer segment material during phagocytosis by primary RPE cells, and activated Mertk accumulated during the early stages of phagocytosis by RPE-J cells. We conclude that Mertk likely functions directly in the RPE phagocytic process as a signaling molecule triggering outer segment ingestion.	Stanford Univ, Sch Med, Dept Genet, Stanford, CA 94305 USA; Univ Calif San Francisco, Sch Med, Dept Anat, San Francisco, CA 94143 USA; Univ Calif San Francisco, Sch Med, Dept Ophthalmol, San Francisco, CA 94143 USA	Stanford University; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Vollrath, D (corresponding author), Stanford Univ, Sch Med, Dept Genet, Stanford, CA 94305 USA.				NEI NIH HHS [EY06842, EY01919, EY02162] Funding Source: Medline; NATIONAL EYE INSTITUTE [U01EY006842, R37EY001919, R01EY006842, R01EY001919, P30EY002162] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Albert ML, 2000, NAT CELL BIOL, V2, P899, DOI 10.1038/35046549; Alberts B., 1994, MOL BIOL CELL, P604; BOK D, 1971, J CELL BIOL, V49, P664, DOI 10.1083/jcb.49.3.664; Bok D., 1979, RETINAL PIGMENT EPIT, P148; BOYLE D, 1991, INVEST OPHTH VIS SCI, V32, P1464; CHAITIN MH, 1983, INVEST OPHTH VIS SCI, V24, P812; CHAITIN MH, 1983, INVEST OPHTH VIS SCI, V24, P821; CHANG CW, 1991, CURR EYE RES, V10, P1081, DOI 10.3109/02713689109020348; Chen J, 1997, ONCOGENE, V14, P2033, DOI 10.1038/sj.onc.1201039; D'Cruz PM, 2000, HUM MOL GENET, V9, P645, DOI 10.1093/hmg/9.4.645; da Cruz L, 1998, CURR EYE RES, V17, P668; DOWLING JE, 1962, J CELL BIOL, V14, P73, DOI 10.1083/jcb.14.1.73; FADOK VA, 1992, J IMMUNOL, V148, P2207; FENG W, 1996, INVESTIG OPHTHALMOL, V37, P378; Finnemann SC, 1997, P NATL ACAD SCI USA, V94, P12932, DOI 10.1073/pnas.94.24.12932; Gal A, 2000, NAT GENET, V26, P270, DOI 10.1038/81555; HALL MO, 1987, EXP EYE RES, V45, P907, DOI 10.1016/S0014-4835(87)80105-7; Hall MO, 2001, EXP EYE RES, V73, P509, DOI 10.1006/exer.2001.1062; HETH CA, 1994, INVEST OPHTH VIS SCI, V35, P409; HETH CA, 1992, INVEST OPHTH VIS SCI, V33, P2839; LAIRD DW, 1988, INVEST OPHTH VIS SCI, V29, P419; Leverrier Y, 2001, CURR BIOL, V11, P195, DOI 10.1016/S0960-9822(01)00047-1; Lin H, 1998, INVEST OPHTH VIS SCI, V39, P1703; MAYERSON PL, 1986, J CELL BIOL, V103, P299, DOI 10.1083/jcb.103.1.299; Miceli MV, 1997, INVEST OPHTH VIS SCI, V38, P1588; MULLEN RJ, 1976, SCIENCE, V192, P799, DOI 10.1126/science.1265483; NABI IR, 1993, J CELL SCI, V104, P37; Nagata K, 1996, J BIOL CHEM, V271, P30022, DOI 10.1074/jbc.271.47.30022; Nakano T, 1997, J BIOL CHEM, V272, P29411, DOI 10.1074/jbc.272.47.29411; Reddien PW, 2000, NAT CELL BIOL, V2, P131, DOI 10.1038/35004000; Ryeom SW, 1996, J CELL SCI, V109, P387; Scott RS, 2001, NATURE, V411, P207, DOI 10.1038/35075603; SHEPHERD VL, 1991, INVEST OPHTH VIS SCI, V32, P1779; SILVERSTEIN RL, 1998, EXP EYE RES, V67, P534; Strauss O, 1998, ACTA ANAT, V162, P101; Vollrath D, 2001, P NATL ACAD SCI USA, V98, P12584, DOI 10.1073/pnas.221364198; Wilt SD, 1999, EXP EYE RES, V69, P405, DOI 10.1006/exer.1999.0714; YOUNG RW, 1969, J CELL BIOL, V42, P392, DOI 10.1083/jcb.42.2.392; YOUNG RW, 1978, INVEST OPHTH VIS SCI, V17, P105	39	178	185	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 10	2002	277	19					17016	17022		10.1074/jbc.M107876200	http://dx.doi.org/10.1074/jbc.M107876200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	551MB	11861639	hybrid			2022-12-27	WOS:000175564500090
J	Lu, ZCJ; Markham, GD				Lu, ZCJ; Markham, GD			Enzymatic properties of S-Adenosylmethionine synthetase from the archaeon Methanococcus jannaschii	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENOSYL-L-METHIONINE; RADICAL MECHANISMS; CRYSTAL-STRUCTURE; ACTIVE-SITE; ADENOSYLTRANSFERASE; INTERMEDIATE; METHYLATION; CATALYSIS; PROTEINS; ANALOGS	S-Adenosylmethionine synthetase (ATP:L-methionine S-adenosyltransferase, MAT) catalyzes a unique enzymatic reaction that leads to formation of the primary biological alkylating agent. NUT from the hyperthermophilic archaeon Methanococcus jannaschii (MjMAT) is a prototype of the newly discovered archaeal class of NUT proteins that are nearly unrecognizable in sequence when compared with the class that encompasses both the eucaryal and bacterial enzymes. In this study the functional properties of purified recombinant MjMAT have been evaluated. The products of the reaction are AdoMet, PPi, and P-i; >90%, of the P-i originates from the gamma-phosphoryl group of ATP. The circular dichroism spectrum of the dimeric MjMAT indicates that the secondary structure is more helical than the Escherichia coli counterpart (EcMAT), suggesting a different protein topology. The steady state kinetic mechanism is sequential, with random addition of ATP and methionine; AdoMet is the first product released, followed by release of PPi and P-i. The substrate specificity differs remarkably from the previously characterized MATs; the nucleotide binding site has a very broad tolerance of alterations in the adenosine moiety. MjMAT has activity at 70 degreesC comparable with that of EcMAT at 37 degreesC, consistent with the higher temperature habitat of M. jannaschii. The activation energy for AdoMet formation is larger than that for the E. coli MAT-catalyzed reaction, in accord with the notion that enzymes from thermophilic organisms are often more rigid than their mesophilic counterparts. The broad substrate tolerance of this enzyme proffers routes to preparation of novel AdoMet analogs.	Fox Chase Canc Ctr, Inst Canc Res, Philadelphia, PA 19111 USA	Fox Chase Cancer Center	Markham, GD (corresponding author), Fox Chase Canc Ctr, Inst Canc Res, 7701 Burholme Ave, Philadelphia, PA 19111 USA.				NCI NIH HHS [CA06927] Funding Source: Medline; NIGMS NIH HHS [GM31186] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA006927] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031186] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		CANTONI GL, 1975, ANNU REV BIOCHEM, V44, P435, DOI 10.1146/annurev.bi.44.070175.002251; Chiang PK, 1996, FASEB J, V10, P471, DOI 10.1096/fasebj.10.4.8647346; Cleland W W, 1979, Methods Enzymol, V63, P103; Cooper A, 2001, BIOPHYS CHEM, V93, P215, DOI 10.1016/S0301-4622(01)00222-8; COULTER AW, 1974, MOL PHARMACOL, V10, P319; DUNAWAYMARIANO D, 1980, BIOCHEMISTRY-US, V19, P1496, DOI 10.1021/bi00548a037; Frey PA, 2001, ANNU REV BIOCHEM, V70, P121, DOI 10.1146/annurev.biochem.70.1.121; *GEN COMP GROUP, 1999, PEPT VERS 10; Gonzalez B, 2000, J MOL BIOL, V300, P363, DOI 10.1006/jmbi.2000.3858; Graham DE, 2000, J BIOL CHEM, V275, P4055, DOI 10.1074/jbc.275.6.4055; HOFFMAN JL, 1986, BIOCHEMISTRY-US, V25, P4444, DOI 10.1021/bi00363a041; KAISER II, 1983, J BIOL CHEM, V258, P1747; Kotb M, 1997, TRENDS GENET, V13, P51, DOI 10.1016/S0168-9525(97)01013-5; KOTB M, 1993, PHARMACOL THERAPEUT, V59, P125, DOI 10.1016/0163-7258(93)90042-C; Lonhienne T, 2000, BBA-PROTEIN STRUCT M, V1543, P1, DOI 10.1016/S0167-4838(00)00210-7; MA QF, 1990, BIOCHEMISTRY-US, V29, P1412, DOI 10.1021/bi00458a011; MARKHAM GD, 1980, J BIOL CHEM, V255, P9082; Mato JM, 1997, PHARMACOL THERAPEUT, V73, P265, DOI 10.1016/S0163-7258(96)00197-0; McQueney MS, 2000, BIOCHEMISTRY-US, V39, P4443, DOI 10.1021/bi992876s; MUDD SH, 1973, ENZYMES, V8, P21; MURPHY KP, 1992, ADV PROTEIN CHEM, V43, P313, DOI 10.1016/S0065-3233(08)60556-2; Park J, 1996, BIOORGAN MED CHEM, V4, P2179, DOI 10.1016/S0968-0896(96)00228-3; Reczkowski RS, 1998, BIOCHEMISTRY-US, V37, P13499, DOI 10.1021/bi9811011; Reczkowski RS, 1999, BIOCHEMISTRY-US, V38, P9063, DOI 10.1021/bi990528k; Segel IH, 1975, ENZYME KINETICS BEHA; Sofia HJ, 2001, NUCLEIC ACIDS RES, V29, P1097, DOI 10.1093/nar/29.5.1097; SOMERO GN, 1995, ANNU REV PHYSIOL, V57, P43, DOI 10.1146/annurev.ph.57.030195.000355; SUFRIN JR, 1982, BIOCHEM BIOPH RES CO, V106, P251, DOI 10.1016/0006-291X(82)91102-0; SZEDLACSEK SE, 1995, METHOD ENZYMOL, V249, P144; TABOR CW, 1984, ANNU REV BIOCHEM, V53, P749, DOI 10.1146/annurev.bi.53.070184.003533; TABOR CW, 1984, ADV ENZYMOL RAMB, V56, P251; Takusagawa F, 1996, J BIOL CHEM, V271, P136, DOI 10.1074/jbc.271.1.136; Taylor JC, 2000, J BIOL CHEM, V275, P4060, DOI 10.1074/jbc.275.6.4060; TROWBRIDGE DB, 1972, J AM CHEM SOC, V94, P3816, DOI 10.1021/ja00766a026	34	36	39	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 10	2002	277	19					16624	16631		10.1074/jbc.M110456200	http://dx.doi.org/10.1074/jbc.M110456200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	551MB	11872742	hybrid			2022-12-27	WOS:000175564500039
J	Makagiansar, IT; Nguyen, PD; Ikesue, A; Kuczera, KR; Dentler, W; Urbauer, JL; Galeva, N; Alterman, M; Siahaan, TJ				Makagiansar, IT; Nguyen, PD; Ikesue, A; Kuczera, KR; Dentler, W; Urbauer, JL; Galeva, N; Alterman, M; Siahaan, TJ			Disulfide bond formation promotes the cis- and trans-dimerization of the E-cadherin-derived first repeat	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASSISTED-LASER-DESORPTION/IONIZATION; CELL-CELL ADHESION; ESCHERICHIA-COLI; EXTRACELLULAR DOMAIN; EPITHELIAL CADHERIN; STRUCTURAL BASIS; CALCIUM-BINDING; ISOMERASE DSBA; N-CADHERIN; IN-VIVO	Cadherin is a cell adhesion molecule crucial for epithelial and endothelial cell monolayer integrity. The previously solved x-ray crystallographic structure of the E-CAD12 cis-dimer displayed an unpaired Cys(9), which protruded away from the Cys(9) on the other protomer. To investigate the possible biological function of Cys9 within the first repeat (the E-cadherin-derived N-terminal repeat), E-CAD1 was overexpressed and secreted into the periplasmic space of Escherichia coli cells. Recombinant E-CAD1 produced a mixed monomer and dimer in an equilibrium fashion. The dimer was linked by a disulfide through Cys(9) pairing. Analysis by high pressure liquid chromatography and electron microscopy suggested the existence of oligomeric complexes. Mutation at Trp(2) appears to indicate that these oligomeric complexes trans-dimerize. Interestingly, mutation of Cys(9) affected not only the cis-dimerization, but also the trans-oligomerization of E-CAD1. Accordingly, it is plausible that, under oxidative stress, the homophilic interactions of E-cadherin through E-CAD1 may be promoted and stabilized by this disulfide bond.	Univ Kansas, Dept Pharmaceut Chem, Lawrence, KS 66047 USA; Univ Kansas, Dept Mol Biosci, Lawrence, KS 66047 USA; Univ Kansas, Biochem Res Lab, Lawrence, KS 66047 USA	University of Kansas; University of Kansas; University of Kansas	Siahaan, TJ (corresponding author), Univ Kansas, Dept Pharmaceut Chem, Simons Bldg,2095 Constant Ave, Lawrence, KS 66047 USA.				NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [R01EB000226] Funding Source: NIH RePORTER; NIBIB NIH HHS [R01 EB000226, R01 EB000226-03, EB-00226] Funding Source: Medline	NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NIBIB NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB))		Alattia JR, 1997, FEBS LETT, V417, P405, DOI 10.1016/S0014-5793(97)01333-1; Beavon IRG, 2000, EUR J CANCER, V36, P1607, DOI 10.1016/S0959-8049(00)00158-1; BLASCHUK OW, 1990, DEV BIOL, V139, P227, DOI 10.1016/0012-1606(90)90290-Y; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; BROOKS CL, 1988, PROTEINS THEORETICAL; Chappuis-Flament S, 2001, J CELL BIOL, V154, P231, DOI 10.1083/jcb.200103143; Corada M, 2001, BLOOD, V97, P1679, DOI 10.1182/blood.V97.6.1679; DERMAN AI, 1991, J BACTERIOL, V173, P7719, DOI 10.1128/jb.173.23.7719-7722.1991; Farmer TB, 1998, J MASS SPECTROM, V33, P697, DOI 10.1002/(SICI)1096-9888(199808)33:8<697::AID-JMS711>3.0.CO;2-H; Jia L, 1996, NATURE, V380, P221, DOI 10.1038/380221a0; Jonda S, 1999, EMBO J, V18, P3271, DOI 10.1093/emboj/18.12.3271; JORGENSEN WL, 1983, J CHEM PHYS, V79, P926, DOI 10.1063/1.445869; Kim WK, 1999, NEURON, V24, P461, DOI 10.1016/S0896-6273(00)80859-4; Kitagawa M, 2000, BIOCHEM BIOPH RES CO, V271, P358, DOI 10.1006/bbrc.2000.2636; Koch AW, 1999, CURR OPIN STRUC BIOL, V9, P275, DOI 10.1016/S0959-440X(99)80038-4; LARUE L, 1994, P NATL ACAD SCI USA, V91, P8263, DOI 10.1073/pnas.91.17.8263; Mach H, 1995, Methods Mol Biol, V40, P91; Makagiansar IT, 2001, PHARMACEUT RES, V18, P446, DOI 10.1023/A:1011094025008; Masur K, 2001, MOL BIOL CELL, V12, P1973, DOI 10.1091/mbc.12.7.1973; Miyaguchi K, 2000, J STRUCT BIOL, V132, P169, DOI 10.1006/jsbi.2000.4244; Murase S, 2000, BIOCHEM BIOPH RES CO, V276, P1191, DOI 10.1006/bbrc.2000.3590; Nagar B, 1996, NATURE, V380, P360, DOI 10.1038/380360a0; NOSE A, 1990, CELL, V61, P147, DOI 10.1016/0092-8674(90)90222-Z; Overduin M, 1996, J BIOMOL NMR, V7, P173; OVERDUIN M, 1995, SCIENCE, V267, P386, DOI 10.1126/science.7824937; Perl AK, 1998, NATURE, V392, P190, DOI 10.1038/32433; Pertz O, 1999, EMBO J, V18, P1738, DOI 10.1093/emboj/18.7.1738; POKUTTA S, 1994, EUR J BIOCHEM, V223, P1019, DOI 10.1111/j.1432-1033.1994.tb19080.x; REID RA, 1990, NUCLEIC ACIDS RES, V18, P5896, DOI 10.1093/nar/18.19.5896; SHAPIRO L, 1995, NATURE, V374, P327, DOI 10.1038/374327a0; Sivasankar S, 2001, BIOPHYS J, V80, P1758, DOI 10.1016/S0006-3495(01)76146-2; SKERRA A, 1988, SCIENCE, V240, P1038, DOI 10.1126/science.3285470; Takeda H, 1999, NAT STRUCT BIOL, V6, P310, DOI 10.1038/7542; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; Tamura K, 1998, NEURON, V20, P1153, DOI 10.1016/S0896-6273(00)80496-1; Tomschy A, 1996, EMBO J, V15, P3507, DOI 10.1002/j.1460-2075.1996.tb00719.x; TONG KI, 1994, FEBS LETT, V352, P318; Woods AS, 2001, J AM SOC MASS SPECTR, V12, P88, DOI 10.1016/S1044-0305(00)00197-5; WUNDERLICH M, 1993, J BIOL CHEM, V268, P24547; WUNDERLICH M, 1993, J MOL BIOL, V233, P559, DOI 10.1006/jmbi.1993.1535; Yan BX, 2000, J BIOL CHEM, V275, P39964, DOI 10.1074/jbc.M007041200; Yap AS, 1997, CURR BIOL, V7, P308, DOI 10.1016/S0960-9822(06)00154-0; ZAPUN A, 1995, BIOCHEMISTRY-US, V34, P5075, DOI 10.1021/bi00015a019	43	20	22	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 3	2002	277	18					16002	16010		10.1074/jbc.M200916200	http://dx.doi.org/10.1074/jbc.M200916200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	550PA	11856755	hybrid			2022-12-27	WOS:000175510400105
J	Sibinga, NES; Feinberg, MW; Yang, HY; Werner, F; Jain, MK				Sibinga, NES; Feinberg, MW; Yang, HY; Werner, F; Jain, MK			Macrophage-restrieted and interferon gamma-inducible expression of the allograft inflammatory factor-1 gene requires Pu.1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR PU.1; FACTOR-I; CD11B PROMOTER; PROTEIN; BINDS; IDENTIFICATION; REJECTION; ELEMENTS; RECEPTOR; HEARTS	Expression of allograft inflammatory factor-1 (Aif-1), a 17-kDa protein bearing an EF-hand Ca2+ binding motif, increases markedly in monocytes and macrophages participating in allo- and autoimmune reactions, including the perivascular inflammation in transplanted hearts, microglial infiltrates in experimental autoimmune neuritis, and the inflamed pancreas of prediabetic BB rats. To investigate the mechanism of this regulation, we isolated the mouse aif-1 gene and determined its genomic organization. The gene has six exons distributed over 1.6 kilobases, an interferon gamma-inducible DNase I-hypersensitive site near -900, and flanking sequences on either side predicted to associate with nuclear matrix. Reporter gene analyses identified sequences between -902 and -789, including consensus Ets and interferon regulatory factor elements, required for macrophage-specific and interferon gamma-inducible transcriptional activity. Pu.1 bound to the Ets site in electromobility shift assay and forced expression of Pu.1 activated the aif-1 promoter in 3T3 fibroblasts, in which it is normally inactive. However, the transcriptional activity of a con-catamer of the Ets site alone did not increase with interferon gamma treatment. Cooperation between Pu.1 and proteins binding to the interferon regulatory factor element appears to be necessary for both macrophage-specific and interferon gamma-inducible expression of the aif-1 gene.	Albert Einstein Coll Med, Div Cardiovasc, Dept Med, Bronx, NY 10461 USA; Brigham & Womens Hosp, Dept Med, Div Cardiovasc, Boston, MA 02115 USA	Yeshiva University; Albert Einstein College of Medicine; Harvard University; Brigham & Women's Hospital	Sibinga, NES (corresponding author), Albert Einstein Coll Med, Div Cardiovasc, Dept Med, Forcheimer G46,1300 Morris Pk Ave, Bronx, NY 10461 USA.		Sibinga, Nicholas/GOJ-8544-2022	Feinberg, Mark/0000-0001-9523-3859; Sibinga, Nicholas/0000-0003-4838-910X	NHLBI NIH HHS [HL03274, HL03747] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Anderson KL, 1999, BLOOD, V94, P2310, DOI 10.1182/blood.V94.7.2310.419k34_2310_2318; Ausubel F.M., 1993, CURRENT PROTOCOLS MO; CHEN HM, 1993, J BIOL CHEM, V268, P8230; Chen ZW, 1997, P NATL ACAD SCI USA, V94, P13879, DOI 10.1073/pnas.94.25.13879; DRIGGERS PH, 1990, P NATL ACAD SCI USA, V87, P3743, DOI 10.1073/pnas.87.10.3743; FEINMAN R, 1994, EMBO J, V13, P3852, DOI 10.1002/j.1460-2075.1994.tb06696.x; Imai Y, 1996, BIOCHEM BIOPH RES CO, V224, P855, DOI 10.1006/bbrc.1996.1112; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; KRETSINGER RH, 1993, J MOL EVOL, V36, P477, DOI 10.1007/BF02406723; Li AC, 1998, J BIOL CHEM, V273, P5389, DOI 10.1074/jbc.273.9.5389; Marecki S, 2001, J IMMUNOL, V166, P6829, DOI 10.4049/jimmunol.166.11.6829; Meraro D, 1999, J IMMUNOL, V163, P6468; MIYAMOTO M, 1988, CELL, V54, P903, DOI 10.1016/S0092-8674(88)91307-4; MOULTON KS, 1994, MOL CELL BIOL, V14, P4408, DOI 10.1128/MCB.14.7.4408; Nguyen Hannah, 1997, Cytokine and Growth Factor Reviews, V8, P293, DOI 10.1016/S1359-6101(97)00019-1; PAHL HL, 1993, J BIOL CHEM, V268, P5014; Sambrook J., 2002, MOL CLONING LAB MANU; Schluesener HJ, 1998, GLIA, V24, P244, DOI 10.1002/(SICI)1098-1136(199810)24:2<244::AID-GLIA9>3.0.CO;2-3; SCOTT EW, 1994, SCIENCE, V265, P1573, DOI 10.1126/science.8079170; Sibinga NES, 1999, J BIOL CHEM, V274, P12139, DOI 10.1074/jbc.274.17.12139; Simon MC, 1998, SEMIN IMMUNOL, V10, P111, DOI 10.1006/smim.1998.0112; Singh GB, 1997, NUCLEIC ACIDS RES, V25, P1419, DOI 10.1093/nar/25.7.1419; Tanaka S, 1998, J NEUROSCI, V18, P6358; UTANS U, 1994, P NATL ACAD SCI USA, V91, P6463, DOI 10.1073/pnas.91.14.6463; UTANS U, 1995, J CLIN INVEST, V95, P2954, DOI 10.1172/JCI118003; Utans U, 1996, TRANSPLANTATION, V61, P1387, DOI 10.1097/00007890-199605150-00018; Wingender E, 2000, NUCLEIC ACIDS RES, V28, P316, DOI 10.1093/nar/28.1.316; ZHANG DE, 1994, MOL CELL BIOL, V14, P373, DOI 10.1128/MCB.14.1.373	28	31	31	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 3	2002	277	18					16202	16210		10.1074/jbc.M200935200	http://dx.doi.org/10.1074/jbc.M200935200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	550PA	11861656	hybrid			2022-12-27	WOS:000175510400130
J	Holland, MJ				Holland, MJ			Transcript abundance in yeast varies over six orders of magnitude	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; EXPRESSION; BINDING; STATES	In the current era of functional genomics, it is remarkable that the intracellular range of transcript abundance is largely unknown. For the yeast Saccharomyces cerevisiae, hybridization-based complexity analysis and SAGE analysis showed that the majority of yeast mRNAs are present at one or fewer copies per cell; however, neither method provides an accurate estimate of the full range of low abundance transcripts. Here we examine the range of intracellular transcript abundance in yeast using kinetically monitored, reverse transcriptase-initiated PCR (kRT-PCR). Steady-state transcript levels encoded by all 65 genes on the left arm of chromosome III and 185 transcription factor genes are quantitated. Abundant transcripts encoded by glycolytic genes, previously quantitated by kRT-PCR, are present at a few hundred copies per cell whereas genes encoding physiologically important transcription factors are expressed at levels as low as one-thousandth transcript per cell. Of the genes assessed, only the silent mating type loci, HML and HMR, are transcriptionally silent. The results show that transcript abundance in yeast varies over six orders of magnitude. Finally, kRT-PCR, cDNA microarray, and high density oligonucleotide array assays are compared for their ability to detect and quantitate the complete yeast transcriptome.	Univ Calif Davis, Sch Med, Dept Biol Chem, Davis, CA 95616 USA	University of California System; University of California Davis	Holland, MJ (corresponding author), Univ Calif Davis, Sch Med, Dept Biol Chem, 1 Shields Ave, Davis, CA 95616 USA.				NHGRI NIH HHS [R01-HG1736] Funding Source: Medline; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG001736] Funding Source: NIH RePORTER	NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		Cunningham TS, 2000, J BACTERIOL, V182, P6584, DOI 10.1128/JB.182.23.6584-6591.2000; DeRisi JL, 1997, SCIENCE, V278, P680, DOI 10.1126/science.278.5338.680; Grant PA, 1997, GENE DEV, V11, P1640, DOI 10.1101/gad.11.13.1640; Hampsey M, 1998, MICROBIOL MOL BIOL R, V62, P465, DOI 10.1128/MMBR.62.2.465-503.1998; HEREFORD LM, 1977, CELL, V10, P453, DOI 10.1016/0092-8674(77)90032-0; HERNANDEZ N, 1993, GENE DEV, V7, P1291, DOI 10.1101/gad.7.7b.1291; HERSKOWITZ I, 1988, MICROBIOL REV, V52, P536, DOI 10.1128/MMBR.52.4.536-553.1988; Hinnebusch AG, 1997, J BIOL CHEM, V272, P21661, DOI 10.1074/jbc.272.35.21661; Holstege FCP, 1998, CELL, V95, P717, DOI 10.1016/S0092-8674(00)81641-4; Kang J J, 2000, Nucleic Acids Res, V28, pe2, DOI 10.1093/nar/28.2.e2; Kang JJ, 1997, METHODS, V13, P437, DOI 10.1006/meth.1997.0549; KANG JJ, 1999, PCR APPL PROTOCOLS F, P429; KOCH C, 1993, SCIENCE, V261, P1551, DOI 10.1126/science.8372350; LAURENSON P, 1992, MICROBIOL REV, V56, P543, DOI 10.1128/MMBR.56.4.543-560.1992; McANulty MM, 1996, BIOCHEMISTRY-US, V35, P6089, DOI 10.1021/bi952877u; PINTO I, 1992, CELL, V68, P977, DOI 10.1016/0092-8674(92)90040-J; Velculescu VE, 1997, CELL, V88, P243, DOI 10.1016/S0092-8674(00)81845-0	17	130	133	2	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 26	2002	277	17					14363	14366		10.1074/jbc.C200101200	http://dx.doi.org/10.1074/jbc.C200101200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	545EH	11882647	hybrid			2022-12-27	WOS:000175203000004
J	Ogawa, A; Takayama, Y; Sakai, H; Chong, KT; Takeuchi, S; Nakagawa, A; Nada, S; Okada, M; Tsukihara, T				Ogawa, A; Takayama, Y; Sakai, H; Chong, KT; Takeuchi, S; Nakagawa, A; Nada, S; Okada, M; Tsukihara, T			Structure of the carboxyl-terminal Src kinase, Csk	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASE; ACTIVATION; DOMAINS; SUPPRESSION; MECHANISM; COMPLEX; SITE; SH2; LCK	The carboxyl-terminal Src kinase (Csk) is an indispensable negative regulator for the Src family tyrosine kinases (SFKs) that play pivotal roles in various cell signalings. To understand the molecular basis of the Csk-mediated regulation of SFKs, we elucidated the crystal structure of full-length Csk. The Csk crystal consists of six molecules classified as active or inactive states according to the coordinations of catalytic residues. Csk assembles the SH2 and SH3 domains differently from inactive SFKs, and their binding pockets are oriented outward enabling the intermolecular interaction. In active molecules, the SH2-kinase and SH2-SH3 linkers are tightly stuck to the N-lobe of the kinase domain to stabilize the active conformation, and there is a direct linkage between the SH2 and the kinase domains. In inactive molecules, the SH2 domains are rotated destroying the linkage to the kinase domain. Cross-correlation matrices for the active molecules reveal that the SH2 domain and the N-lobe of the kinase domain move as a unit. These observations suggest that Csk can be regulated through coupling of the SH2 and kinase domains and that Csk provides a novel built-in activation mechanism for cytoplasmic tyrosine kinases.	Osaka Univ, Microbial Dis Res Inst, Osaka 5650871, Japan; Osaka Univ, Inst Prot Res, Osaka 5650871, Japan	Osaka University; Osaka University	Okada, M (corresponding author), Osaka Univ, Microbial Dis Res Inst, 3-1 Yamadaoka, Osaka 5650871, Japan.	atsushi@protein.osaka-u.ac.jp; okadam@biken.osaka-u.ac.jp	Takayama, Yoshiharu/E-3662-2010; Nakagawa, Atsushi/D-4329-2009; Takayama, Yoshiharu/M-8826-2019; Nakagawa, Atsushi/M-5731-2019	Takayama, Yoshiharu/0000-0003-4532-7114; Nakagawa, Atsushi/0000-0002-1700-7861; Takayama, Yoshiharu/0000-0003-4532-7114; Nakagawa, Atsushi/0000-0002-1700-7861				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BORCHERT TV, 1994, FEBS LETT, V341, P79, DOI 10.1016/0014-5793(94)80244-0; Brdicka T, 2000, J EXP MED, V191, P1591, DOI 10.1084/jem.191.9.1591; Brown MT, 1996, BBA-REV CANCER, V1287, P121, DOI 10.1016/0304-419X(96)00003-0; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CHOW LML, 1993, NATURE, V365, P156, DOI 10.1038/365156a0; CLOUTIER JF, 1995, MOL CELL BIOL, V15, P5937; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; Gonfloni S, 2000, NAT STRUCT BIOL, V7, P281; HOWELL BW, 1994, MOL CELL BIOL, V14, P5402, DOI 10.1128/MCB.14.8.5402; JEFFREY PD, 1995, NATURE, V376, P313, DOI 10.1038/376313a0; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kawabuchi M, 2000, NATURE, V404, P999, DOI 10.1038/35010121; Lamers MBAC, 1999, J MOL BIOL, V285, P713, DOI 10.1006/jmbi.1998.2369; NADA S, 1993, CELL, V73, P1125, DOI 10.1016/0092-8674(93)90642-4; NADA S, 1991, NATURE, V351, P69, DOI 10.1038/351069a0; OKADA M, 1989, J BIOL CHEM, V264, P20886; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; SABE H, 1994, P NATL ACAD SCI USA, V91, P3984, DOI 10.1073/pnas.91.9.3984; Shekhtman A, 2001, J MOL BIOL, V314, P129, DOI 10.1006/jmbi.2001.5126; Sheldrick GM, 1997, METHOD ENZYMOL, V276, P628, DOI 10.1016/S0076-6879(97)76083-X; Sondhi D, 1999, BIOCHEMISTRY-US, V38, P11147, DOI 10.1021/bi990827+; Sun GQ, 1999, ARCH BIOCHEM BIOPHYS, V367, P167, DOI 10.1006/abbi.1999.1253; Sun GQ, 2002, ARCH BIOCHEM BIOPHYS, V397, P11, DOI 10.1006/abbi.2001.2627; Takeuchi S, 2000, J BIOL CHEM, V275, P29183, DOI 10.1074/jbc.C000326200; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0; Yamaguchi H, 1996, NATURE, V384, P484, DOI 10.1038/384484a0; Young MA, 2001, CELL, V105, P115, DOI 10.1016/S0092-8674(01)00301-4; Zhu XT, 1999, STRUCTURE, V7, P651, DOI 10.1016/S0969-2126(99)80086-0	30	116	119	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 26	2002	277	17					14351	14354		10.1074/jbc.C200086200	http://dx.doi.org/10.1074/jbc.C200086200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	545EH	11884384	hybrid, Green Published			2022-12-27	WOS:000175203000001
J	Harikumar, KG; Pinon, DL; Wessels, WS; Prendergast, FG; Miller, LJ				Harikumar, KG; Pinon, DL; Wessels, WS; Prendergast, FG; Miller, LJ			Environment and mobility of a series of fluorescent reporters at the amino terminus of structurally related peptide agonists and antagonists bound to the cholecystokinin receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTOR; CONFORMATIONAL-CHANGES; A RECEPTOR; DIRECT IDENTIFICATION; SITE; LIGAND; RHODOPSIN; DOMAIN; ACTIVATION; PROBE	Fluorescence is a powerful biophysical tool for the analysis of the structure and dynamics of proteins. Here, we have developed two series of new fluorescent probes of the cholecystokinin (CCK) receptor, representing structurally related peptide agonists and antagonists. Each ligand had one of three distinct fluorophores (Alexa(488), nitrobenzoxadiazolyl, or acrylodan) incorporated in analogous positions at the amino terminus just outside the hormone's pharmacophore. All of the probes bound to the CCK receptor specifically and with high affinity, and intracellular calcium signaling studies showed the chemically modified peptides to be fully biologically active. Quenching by iodide and measurement of fluorescence spectra, anisotropy, and lifetimes were used to characterize the response of the fluorescence of the probe in the peptide-receptor complex for agonists and antagonists. All three fluorescence indicators provided the same insights into differences in the environment of the same indicator in the analogous position for agonist and antagonist peptides bound to the CCK receptor. Each agonist had its fluorescence quenched more easily and showed lower anisotropy (higher mobility of the probe) and shorter lifetime than the analogous antagonist. Treatment of agonist-occupied receptors with a non-hydrolyzable GTP analogue shifted the receptor into its inactive low affinity state and increased probe fluorescence lifetimes toward values observed with antagonist probes. These data are consistent with a molecular conformational change associated with receptor activation that causes the amino terminus of the ligand (situated above transmembrane segment six) to move away from its somewhat protected environment and toward the aqueous milieu.	Mayo Clin & Mayo Fdn, Ctr Basic Res Digest Dis, Dept Mol Pharmacol & Expt Therapeut, Rochester, MN 55905 USA	Mayo Clinic	Miller, LJ (corresponding author), Mayo Clin & Mayo Fdn, Ctr Basic Res Digest Dis, Dept Mol Pharmacol & Expt Therapeut, 200 1st St SW, Rochester, MN 55905 USA.			Harikumar, Kaleeckal/0000-0003-0411-5334	NIDDK NIH HHS [DK32878] Funding Source: Medline; NIGMS NIH HHS [GM34847-16] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK032878, R01DK032878] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034847] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Altenbach C, 2001, BIOCHEMISTRY-US, V40, P15493, DOI 10.1021/bi011545o; BEECHEM JM, 1992, METHOD ENZYMOL, V210, P37; BODANSZKY M, 1977, J MED CHEM, V20, P1047, DOI 10.1021/jm00218a011; BODANSZKY M, 1980, INT J PEPT PROT RES, V16, P402; Ding XQ, 2001, J BIOL CHEM, V276, P4236, DOI 10.1074/jbc.M003798200; Dong MQ, 1999, J BIOL CHEM, V274, P4778, DOI 10.1074/jbc.274.8.4778; DOUST TAM, 1984, BIOCHEM SOC T, V12, P630, DOI 10.1042/bst0120630; Dunham TD, 1999, J BIOL CHEM, V274, P1683, DOI 10.1074/jbc.274.3.1683; Farrens DL, 1996, SCIENCE, V274, P768, DOI 10.1126/science.274.5288.768; GAISANO HY, 1989, J CLIN INVEST, V83, P321, DOI 10.1172/JCI113877; Ganguli SC, 1998, J PHARMACOL EXP THER, V286, P593; Gether U, 1997, EMBO J, V16, P6737, DOI 10.1093/emboj/16.22.6737; GETHER U, 1995, J BIOL CHEM, V270, P28268; Gether U, 1997, J BIOL CHEM, V272, P2587, DOI 10.1074/jbc.272.5.2587; Gether U, 1998, J BIOL CHEM, V273, P17979, DOI 10.1074/jbc.273.29.17979; GHIGGINO KP, 1981, BIOCHEMISTRY-US, V20, P5381, DOI 10.1021/bi00522a005; Gigoux V, 1999, PROTEIN SCI, V8, P2347; Gigoux V, 1999, J BIOL CHEM, V274, P20457, DOI 10.1074/jbc.274.29.20457; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Hadac EM, 1999, J MED CHEM, V42, P2105, DOI 10.1021/jm980732q; Hadac EM, 1998, J BIOL CHEM, V273, P12988, DOI 10.1074/jbc.273.21.12988; Hadac EM, 1996, PANCREAS, V13, P130, DOI 10.1097/00006676-199608000-00003; Hubbell WL, 2000, NAT STRUCT BIOL, V7, P735, DOI 10.1038/78956; Ji TH, 1998, J BIOL CHEM, V273, P17299, DOI 10.1074/jbc.273.28.17299; Ji ZS, 1997, J BIOL CHEM, V272, P24393, DOI 10.1074/jbc.272.39.24393; Kennedy K, 1997, J BIOL CHEM, V272, P2920, DOI 10.1074/jbc.272.5.2920; LAKOWICZ JR, 1980, J BIOCHEM BIOPH METH, V2, P91, DOI 10.1016/0165-022X(80)90077-9; Loewen MC, 2001, P NATL ACAD SCI USA, V98, P4888, DOI 10.1073/pnas.051633098; MILLER LJ, 1981, J BIOL CHEM, V256, P2417; MOLERO X, 1991, MOL PHARMACOL, V39, P150; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; PEARSON RK, 1987, BIOCHEM BIOPH RES CO, V147, P346, DOI 10.1016/S0006-291X(87)80128-6; POWERS SP, 1988, INT J PEPT PROT RES, V31, P429; Roettger BF, 1997, MOL PHARMACOL, V51, P357; Schwartz Thue W., 1994, Current Opinion in Biotechnology, V5, P434, DOI 10.1016/0958-1669(94)90054-X; TURCATTI G, 1995, BIOCHEMISTRY-US, V34, P3972, DOI 10.1021/bi00012a015	37	46	46	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 24	2002	277	21					18552	18560		10.1074/jbc.M201164200	http://dx.doi.org/10.1074/jbc.M201164200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	558PM	11893747	hybrid			2022-12-27	WOS:000175975800041
J	Thiagarajah, JR; Verkman, AS				Thiagarajah, JR; Verkman, AS			Aquaporin deletion in mice reduces corneal water permeability and delays restoration of transparency after swelling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VIVO CONFOCAL MICROSCOPY; TRANSGENIC MICE; FLUID TRANSPORT; NULL MICE; MOLECULAR-IDENTIFICATION; KNOCKOUT MICE; ENDOTHELIUM; THICKNESS; CHANNELS; BICARBONATE	Two aquaporin (AQP)-type water channels are expressed in mammalian cornea, AQP1 in endothelial cells and AQP5 in epithelial cells. To test whether these aquaporins are involved in corneal fluid transport and transparency, we compared corneal thickness, water permeability, and response to experimental swelling in wild type mice and transgenic null mice lacking AQP1 and AQP5. Corneal thickness in fixed sections was remarkably reduced in AQP1 null mice and increased in AQP5 null mice. By z-scanning confocal microscopy, corneal thickness in vivo was (in mum, mean +/- S.E., n = 5 mice) 123 +/- 1 (wild type), 101 +/- 2 (AQP1 null), and 144 +/- 2 (AQP5 null). After exposure of the external corneal surface to hypotonic saline (100 mosM), the rate of corneal swelling (5.0 +/- 0.3 mum/min, wild type) was reduced by AQP5 deletion (2.7 +/- 0.1 mum/min). After exposure of the endothelial surface to hypotonic saline by anterior chamber perfusion, the rate of corneal swelling (7.1 +/- 1.0 mum/min, wild type) was reduced by AQP1 deletion (1.6 +/- 0.4 mum/min). Base-line corneal transparency was not impaired by AQP1 or AQP5 deletion. However, the recovery of corneal transparency and thickness after hypotonic swelling (10-min exposure of corneal surface to hypotonic saline) was remarkably delayed in AQP1 null mice with similar to75% recovery at 7 min in wild type mice compared with 5% recovery in AQP1 null mice. Our data indicate that AQP1 and AQP5 provide the principal routes for corneal water transport across the endothelial and epithelial barriers, respectively. The impaired recovery of corneal transparency in AQP1 null mice provides evidence for the involvement of. AQP1 in active extrusion of fluid from the corneal stroma across the corneal endothelium. The up-regulation of AQP1 expression and/or function in corneal endothelium may reduce corneal swelling and opacification following injury.	Univ Calif San Francisco, Cardiovasc Res Inst, Dept Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Cardiovasc Res Inst, Dept Physiol, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	Verkman, AS (corresponding author), Univ Calif San Francisco, Cardiovasc Res Inst, Dept Med, 1246 Hlth Sci E Tower,Box 0521, San Francisco, CA 94143 USA.				NEI NIH HHS [EY13574] Funding Source: Medline; NHLBI NIH HHS [HL59198, HL60288] Funding Source: Medline; NIBIB NIH HHS [EB00415] Funding Source: Medline; NIDDK NIH HHS [DK43840, DK35124] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY013574] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL059198, P50HL060288] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [R37EB000415, R01EB000415] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043840, R01DK035124, R37DK035124] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIBIB NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bai CX, 1999, J CLIN INVEST, V103, P555, DOI 10.1172/JCI4138; Chang JH, 1999, CURR EYE RES, V19, P171, DOI 10.1076/ceyr.19.2.171.5326; Chew S J, 1992, Lens Eye Toxic Res, V9, P275; Chou CL, 1999, J CLIN INVEST, V103, P491, DOI 10.1172/JCI5704; Cooper GJ, 1998, AM J PHYSIOL-CELL PH, V275, pC1481, DOI 10.1152/ajpcell.1998.275.6.C1481; FANG X, 2002, IN PRESS J PHYSL LON; FISCHBARG J, 1974, J PHYSIOL-LONDON, V241, P647, DOI 10.1113/jphysiol.1974.sp010676; Funaki H, 1998, AM J PHYSIOL-CELL PH, V275, pC1151, DOI 10.1152/ajpcell.1998.275.4.C1151; Hamann S, 1998, AM J PHYSIOL-CELL PH, V274, pC1332, DOI 10.1152/ajpcell.1998.274.5.C1332; HODSON S, 1976, J PHYSIOL-LONDON, V263, P563, DOI 10.1113/jphysiol.1976.sp011645; Jester JV, 1999, METHOD ENZYMOL, V307, P230; Jester JV, 2001, VISION RES, V41, P1283, DOI 10.1016/S0042-6989(00)00222-4; Kang FY, 1999, INVEST OPHTH VIS SCI, V40, P253; KLYCE SD, 1975, AM J PHYSIOL, V228, P1446, DOI 10.1152/ajplegacy.1975.228.5.1446; Kuang KY, 2001, AM J PHYSIOL-CELL PH, V280, pC491, DOI 10.1152/ajpcell.2001.280.3.C491; Kubota S, 1998, JPN J OPHTHALMOL, V42, P12, DOI 10.1016/S0021-5155(97)00111-1; LANAHAN A, 1992, MOL CELL BIOL, V12, P3919, DOI 10.1128/MCB.12.9.3919; Lane J, 2000, BIOPHYS J, V78, P2493, DOI 10.1016/S0006-3495(00)76794-4; Li J, 1999, INVEST OPHTH VIS SCI, V40, P1288; Ma TH, 1998, J BIOL CHEM, V273, P4296, DOI 10.1074/jbc.273.8.4296; Ma TH, 1999, J BIOL CHEM, V274, P20071, DOI 10.1074/jbc.274.29.20071; Ma TH, 2001, AM J PHYSIOL-CELL PH, V280, pC126; Ma TH, 2000, J CLIN INVEST, V105, P93, DOI 10.1172/JCI8258; Masters B R, 1992, Scanning Microsc Suppl, V6, P71; MAURICE DM, 1972, J PHYSIOL-LONDON, V221, P43, DOI 10.1113/jphysiol.1972.sp009737; Moore M, 2000, EXP EYE RES, V70, P557, DOI 10.1006/exer.1999.0814; OSHIO K, 2001, J AM SOC NEPHROL, V12, P35; Patil RV, 1997, EXP EYE RES, V64, P203, DOI 10.1006/exer.1996.0196; RILEY MV, 1994, INVEST OPHTH VIS SCI, V35, P560; RILEY MV, 1995, INVEST OPHTH VIS SCI, V36, P103; Riley MV, 1998, INVEST OPHTH VIS SCI, V39, P2076; Schnermann J, 1998, P NATL ACAD SCI USA, V95, P9660, DOI 10.1073/pnas.95.16.9660; Song YL, 2001, J BIOL CHEM, V276, P41288, DOI 10.1074/jbc.M107257200; Song YL, 2000, J PHYSIOL-LONDON, V525, P771, DOI 10.1111/j.1469-7793.2000.00771.x; Sun XC, 2001, INVEST OPHTH VIS SCI, V42, P417; Verkman AS, 2000, CURR OPIN NEPHROL HY, V9, P517, DOI 10.1097/00041552-200009000-00010; Yang BX, 2000, J BIOL CHEM, V275, P2686, DOI 10.1074/jbc.275.4.2686; YTTEBORG J, 1965, ARCH OPHTHALMOL-CHIC, V74, P477, DOI 10.1001/archopht.1965.00970040479008; ZHANG D, 2002, IN PRESS FASEB J	39	98	112	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 24	2002	277	21					19139	19144		10.1074/jbc.M202071200	http://dx.doi.org/10.1074/jbc.M202071200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	558PM	11891232	hybrid			2022-12-27	WOS:000175975800116
J	Agou, F; Ye, F; Goffinont, S; Courtois, G; Yamaoka, S; Israel, A; Veron, M				Agou, F; Ye, F; Goffinont, S; Courtois, G; Yamaoka, S; Israel, A; Veron, M			NEMO trimerizes through its coiled-coil C-terminal domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; TRANSFER-RNA SYNTHETASE; KINASE COMPLEX; IKK-GAMMA; REGULATORY SUBUNIT; ACTIVATION; PROTEIN; ALPHA; EXPRESSION; PEPTIDE	NEMO/IkappaB kinase (IKK) gamma is the regulatory component of the IKK complex comprising the two protein kinases, IKKalpha and IKKbeta. To investigate the self-assembly properties of NEMO and to understand further the mechanism of activation of the IKK complex, we purified wildtype and mutant NEMO expressed in Escherichia coli. In the absence of its IKK partners, recombinant NEMO (rNEMO) is a metastable functional monomer correctly folded, according to its fluorescence and far-UV CD spectra, which is binding specifically to the IKK complex. A minor fraction of rNEMO was found tightly associated with DnaK (E. coli Hsp70). We also examined the interaction of NEMO with prokaryotic and eukaryotic Hsp70, and we showed that the Hsp70-NEMO complex forms a supramolecular structure probably corresponding to an assembly intermediate. In vivo crosslinking experiments indicate that native NEMO in association with IKK is in equilibrium between a dimeric and a trimeric form. Similarly to native NEMO, a NEMO mutant deleted from its IKK binding N-terminal domain (residues 242-388) forms a stable trimeric coiled-coil, suggesting that the association of NEMO with IKK or with Hsp70 prevents incorrect interdomain pairing reactions that could lead to aggregation or to an non-native oligomeric state of rNEMO. We propose a model in which the activation of the IKK complex occurs through the trimerization of NEMO upon binding to a not yet identified upstream activator.	Inst Pasteur, Unite Regulat Enzymat Act Cellulaires, F-75724 Paris 15, France; Inst Pasteur, Unite Biol Mol Express Gen, CNRS, FRE 2364, F-75724 Paris, France; Tokyo Med & Dent Univ, Dept Microbiol, Bunkyo Ku, Tokyo, Japan	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Tokyo Medical & Dental University (TMDU)	Agou, F (corresponding author), Inst Pasteur, Unite Regulat Enzymat Act Cellulaires, 25 Rue Docteur Roux, F-75724 Paris 15, France.		, AGOU/GXA-2760-2022	COURTOIS, Gilles/0000-0003-3117-9595				Agou F, 1996, BIOCHEMISTRY-US, V35, P15322, DOI 10.1021/bi9617926; AGOU F, 1995, BIOCHEMISTRY-US, V34, P569, DOI 10.1021/bi00002a023; Agou F, 1996, J BIOL CHEM, V271, P29295, DOI 10.1074/jbc.271.46.29295; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; BAEUERLE PA, 1989, GENE DEV, V3, P1689, DOI 10.1101/gad.3.11.1689; Byrd CA, 1999, P NATL ACAD SCI USA, V96, P5645, DOI 10.1073/pnas.96.10.5645; CHANG CT, 1978, ANAL BIOCHEM, V91, P13, DOI 10.1016/0003-2697(78)90812-6; Chen GQ, 2002, MOL CELL, V9, P401, DOI 10.1016/S1097-2765(02)00450-1; DevilleBonne D, 1996, BIOCHEMISTRY-US, V35, P14643, DOI 10.1021/bi960945m; Devin A, 2001, MOL CELL BIOL, V21, P3986, DOI 10.1128/MCB.21.12.3986-3994.2001; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; Doffinger R, 2001, NAT GENET, V27, P277, DOI 10.1038/85837; FONTAN E, 1994, P NATL ACAD SCI USA, V91, P8353, DOI 10.1073/pnas.91.18.8353; Freeman BC, 1996, SCIENCE, V274, P1718, DOI 10.1126/science.274.5293.1718; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; HENNESSEY JP, 1982, ANAL BIOCHEM, V125, P177, DOI 10.1016/0003-2697(82)90400-6; Hu YL, 2001, NATURE, V410, P710, DOI 10.1038/35070605; Israel A, 2000, TRENDS CELL BIOL, V10, P129, DOI 10.1016/S0962-8924(00)01729-3; Jackson-Fisher AJ, 1999, MOL CELL, V3, P717, DOI 10.1016/S1097-2765(01)80004-6; Johnson M.L., 1994, MODERN ANAL ULTRACEN, P37; Karin M, 1999, J BIOL CHEM, V274, P27339, DOI 10.1074/jbc.274.39.27339; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; King RD, 1996, PROTEIN SCI, V5, P2298, DOI 10.1002/pro.5560051116; Laue T.M., 1992, ANAL ULTRACENTRIFUGA, P90; Li XH, 2001, J BIOL CHEM, V276, P4494, DOI 10.1074/jbc.M008353200; Li YG, 1998, MOL CELL BIOL, V18, P1601, DOI 10.1128/MCB.18.3.1601; Lustig A, 2000, BBA-BIOMEMBRANES, V1464, P199, DOI 10.1016/S0005-2736(99)00254-0; May MJ, 2000, SCIENCE, V289, P1550, DOI 10.1126/science.289.5484.1550; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; Miller BS, 2001, J BIOL CHEM, V276, P36320, DOI 10.1074/jbc.M104051200; NATHAN DF, 1995, MOL CELL BIOL, V15, P3917; OSHEA EK, 1991, SCIENCE, V254, P539, DOI 10.1126/science.1948029; Poyet JL, 2000, J BIOL CHEM, V275, P37966, DOI 10.1074/jbc.M006643200; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; REYNOLDS JA, 1976, P NATL ACAD SCI USA, V73, P4467, DOI 10.1073/pnas.73.12.4467; Rothwarf DM, 1998, NATURE, V395, P297, DOI 10.1038/26261; Rudiger S, 1997, EMBO J, V16, P1501, DOI 10.1093/emboj/16.7.1501; SCHMID D, 1994, SCIENCE, V263, P971, DOI 10.1126/science.8310296; SCHONFELD HJ, 1995, J BIOL CHEM, V270, P2183, DOI 10.1074/jbc.270.5.2183; Schwamborn K, 2000, J BIOL CHEM, V275, P22780, DOI 10.1074/jbc.M001500200; Smahi A, 2000, NATURE, V405, P466; STAFFORD WF, 1994, METHOD ENZYMOL, V240, P478; Taggart AKP, 1996, SCIENCE, V272, P1331, DOI 10.1126/science.272.5266.1331; TELLER DC, 1976, NATURE, V260, P729, DOI 10.1038/260729a0; Triantafilou K, 2001, NAT IMMUNOL, V2, P338, DOI 10.1038/86342; Wolf E, 1997, PROTEIN SCI, V6, P1179, DOI 10.1002/pro.5560060606; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Xiao GT, 2000, J BIOL CHEM, V275, P34060, DOI 10.1074/jbc.M002970200; Yamaoka S, 1998, CELL, V93, P1231, DOI 10.1016/S0092-8674(00)81466-X; Ye JJ, 2000, J BIOL CHEM, V275, P9882, DOI 10.1074/jbc.275.13.9882; Zhu XT, 1996, SCIENCE, V272, P1606, DOI 10.1126/science.272.5268.1606; [No title captured]	53	67	73	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 17	2002	277	20					17464	17475		10.1074/jbc.M201964200	http://dx.doi.org/10.1074/jbc.M201964200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	553PR	11877453	hybrid			2022-12-27	WOS:000175685100012
J	Carl, VS; Brown-Steinke, K; Nicklin, MJH; Smith, MF				Carl, VS; Brown-Steinke, K; Nicklin, MJH; Smith, MF			Toll-like receptor 2 and 4 (TLR2 and TLR4) agonists differentially regulate secretory interleukin-1 receptor antagonist gene expression in macrophages	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; SEQUENCE-BINDING PROTEIN; IL-1 RECEPTOR; HUMAN-MONOCYTES; SIGNAL-TRANSDUCTION; GP91(PHOX) EXPRESSION; PU.1; P38; INHIBITOR; PROMOTER	Treatment of macrophages with lipopolysaccharide (LPS) from Gram-negative bacteria or peptidoglyean (PGN) from Gram-positive bacteria activates multiple intracellular signaling pathways and a large, diverse group of nuclear transcription factors. The signaling receptors for PGN and LPS are now known to be the Toll-like receptors 2 and 4 (TLR2 and -4, respectively). While a large body of literature indicates that the members of the TLR family activate nearly identical cytoplasmic signaling programs, several recent reports have suggested that the functional outcomes of signaling via TLR2 or TLR4 are not equivalent. In the current studies, we compared the responses of the secretory IL-1 receptor antagonist (sIL-1Ra) gene to both LPS and PGN. Both LPS and PGN induced IL-1Ra gene expression; however, the combination of both stimuli synergistically increased sIL-1Ra mRNA expression and promoter activity, suggesting that the signals induced by PGN and LPS are not equivalent. While both LPS and PGN utilized the PU.1-binding sites in the proximal sIL-1Ra promoter region to generate a full response, additional distinct promoter elements were utilized by LPS or PGN. Activation of p38 stress-activated protein kinase was required for LPS- or PGN-induced IL-1Ra gene expression, but the p38-responsive promoter elements localized to distinct regions of the sIL-1Ra gene. Additionally, while the LPS-induced, p38-dependent response was dependent upon PU.1 binding, the PGN-induced, p38 response was not. Collectively, these data indicated that while some of the intracellular signaling events by TLR2 and TLR4 agonists are similar, there are clearly distinct differences in the responses elicited by these two bacterial products.	Univ Virginia Hlth Syst, Digest Hlth Ctr Excellence, Charlottesville, VA 22908 USA; Univ Virginia Hlth Syst, Dept Microbiol, Charlottesville, VA 22908 USA; Univ Sheffield, Royal Hallamshire Hosp, Div Genom Med, Sheffield S10 2JF, S Yorkshire, England	University of Virginia; University of Virginia; University of Sheffield	Smith, MF (corresponding author), Univ Virginia Hlth Syst, Digest Hlth Ctr Excellence, Bldg MR4,Rm 1031, Charlottesville, VA 22908 USA.			Nicklin, Martin/0000-0002-0127-1131	NIAID NIH HHS [AI34358] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI034358, R29AI034358] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANDERSSON J, 1992, EUR J IMMUNOL, V22, P2617, DOI 10.1002/eji.1830221022; AREND WP, 1991, J IMMUNOL, V147, P1530; AREND WP, 1989, J IMMUNOL, V143, P1851; AREND WP, 1993, ADV IMMUNOL, V54, P167, DOI 10.1016/S0065-2776(08)60535-0; Bowie A, 2000, J LEUKOCYTE BIOL, V67, P508, DOI 10.1002/jlb.67.4.508; Brook M, 2000, FEBS LETT, V483, P57, DOI 10.1016/S0014-5793(00)02084-6; Burack WR, 2000, CURR OPIN CELL BIOL, V12, P211, DOI 10.1016/S0955-0674(99)00078-2; CARTER DB, 1990, NATURE, V344, P633, DOI 10.1038/344633a0; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; DRIPPS DJ, 1991, J BIOL CHEM, V266, P10331; Dziarski R, 1996, J INFECT DIS, V174, P777, DOI 10.1093/infdis/174.4.777; Egan BS, 1999, J BIOL CHEM, V274, P9098, DOI 10.1074/jbc.274.13.9098; EISENBERG SP, 1991, P NATL ACAD SCI USA, V88, P5232, DOI 10.1073/pnas.88.12.5232; EISENBERG SP, 1990, NATURE, V343, P341, DOI 10.1038/343341a0; Eklund EA, 1999, J IMMUNOL, V163, P6095; Eklund EA, 1998, J BIOL CHEM, V273, P13957, DOI 10.1074/jbc.273.22.13957; Enslen H, 1998, J BIOL CHEM, V273, P1741, DOI 10.1074/jbc.273.3.1741; Fitzgerald KA, 2001, NATURE, V413, P78, DOI 10.1038/35092578; Gabay C, 1999, CYTOKINE, V11, P561, DOI 10.1006/cyto.1998.0451; Garrington TP, 1999, CURR OPIN CELL BIOL, V11, P211, DOI 10.1016/S0955-0674(99)80028-3; Guha M, 2001, CELL SIGNAL, V13, P85, DOI 10.1016/S0898-6568(00)00149-2; HASKILL S, 1991, P NATL ACAD SCI USA, V88, P3681, DOI 10.1073/pnas.88.9.3681; Hayashi F, 2001, NATURE, V410, P1099, DOI 10.1038/35074106; Hemmi H, 2000, NATURE, V408, P740, DOI 10.1038/35047123; Hirschfeld M, 2001, INFECT IMMUN, V69, P1477, DOI 10.1128/IAI.69.3.1477-1482.2001; Hirschfeld M, 2000, J IMMUNOL, V165, P618, DOI 10.4049/jimmunol.165.2.618; Horng T, 2001, NAT IMMUNOL, V2, P835, DOI 10.1038/ni0901-835; Jones BW, 2001, J LEUKOCYTE BIOL, V69, P1036; Lali FV, 2000, J BIOL CHEM, V275, P7395, DOI 10.1074/jbc.275.10.7395; Lodie TA, 1997, J IMMUNOL, V158, P1848; Malyak M, 1998, J IMMUNOL, V161, P1997; Manthey CL, 1998, J LEUKOCYTE BIOL, V64, P409, DOI 10.1002/jlb.64.3.409; Means TK, 2000, CYTOKINE GROWTH F R, V11, P219, DOI 10.1016/S1359-6101(00)00006-X; Means TK, 1999, J IMMUNOL, V163, P6748; Medzhitov R, 2000, TRENDS MICROBIOL, V8, P452, DOI 10.1016/S0966-842X(00)01845-X; Ozinsky A, 2000, P NATL ACAD SCI USA, V97, P13766, DOI 10.1073/pnas.250476497; Rao KMK, 2001, J LEUKOCYTE BIOL, V69, P3; Schwandner R, 1999, J BIOL CHEM, V274, P17406, DOI 10.1074/jbc.274.25.17406; SMITH MF, 1994, J IMMUNOL, V153, P3584; SMITH MF, 1992, J IMMUNOL, V149, P2000; Smith MF, 1998, J BIOL CHEM, V273, P24272, DOI 10.1074/jbc.273.37.24272; Stutz AM, 1999, J IMMUNOL, V163, P4383; Wang SW, 1999, INFLAMM RES, V48, P533, DOI 10.1007/s000110050499; Wang ZM, 2000, J BIOL CHEM, V275, P20260, DOI 10.1074/jbc.M909168199; Whitmarsh AJ, 1998, TRENDS BIOCHEM SCI, V23, P481, DOI 10.1016/S0968-0004(98)01309-7; Winzen R, 1999, EMBO J, V18, P4969, DOI 10.1093/emboj/18.18.4969; Yamamoto H, 1999, ONCOGENE, V18, P1495, DOI 10.1038/sj.onc.1202427; Yang ZY, 2000, J BIOL CHEM, V275, P21272, DOI 10.1074/jbc.M000145200	48	48	51	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 17	2002	277	20					17448	17456		10.1074/jbc.M111847200	http://dx.doi.org/10.1074/jbc.M111847200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	553PR	11877429	hybrid, Green Accepted			2022-12-27	WOS:000175685100010
J	Gilchrist, D; Mykytka, B; Rexach, M				Gilchrist, D; Mykytka, B; Rexach, M			Accelerating the rate of disassembly of karyopherin center dot cargo complexes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-PORE COMPLEX; IMPORTIN-ALPHA; YEAST NUCLEOPORIN; PROTEIN IMPORT; SACCHAROMYCES-CEREVISIAE; EXPORT RECEPTOR; TRANSPORT; NUP2P; SIGNAL; CSE1P	Transport of macromolecules across the nuclear pore complex (NPC) occurs in seconds and involves assembly of a karyopherin-cargo complex and docking to the NPC, translocation of the complex across the NPC via interaction with nucleoporins (Nups), and dissociation of the complex in the nucleoplasm. To identify rate-limiting steps in the Kap95p.Kap60p-mediated nuclear import pathway of Saccharomyces cerevisiae, we reconstituted key intermediate complexes and measured their rates of dissociation and affinities of interaction. We found that a nuclear localization signal-containing protein (NLS-cargo) dissociates slowly from Kap60p monomers and Kap60p.Kap95p heterodimers with half-lives (t(1/2)) of 7 and 73 min, respectively; that Kap60p and Kap60p.NLS-cargo complexes dissociate slowly from Kap95p (t(1/2) = 36 and 73 min, respectively); and that Kap95p.Kap60p-NLS-cargo complexes and Kap95p.Kap60p heterodimers dissociate rapidly from the nucleoporin Nup1p (t(1/2) less than or equal to 21 s) and other Nups. A search for factors that accelerate disassembly of the long-lived intermediates revealed that Nup1p and Nup2p accelerate 16- and 19-fold the rate of dissociation of NLS-cargo from Kap60p.Kap95p heterodimers; that Gsp1p-GTP accelerates greater than or equal to 447-fold the rate of dissociation of Kap60p.NLS-cargo from Kap95p; and that Nup2p and the Cse1p-Gsp1p-GTP complex independently accelerate greater than or equal to 22- and greater than or equal to 39-fold the rate of dissociation of NLS-cargo from Kap60p. We suggest that Nup1p, Nup2p, Cse1p, and Gsp1p accelerate disassembly of Kap95p.Kap60p-NLS-cargo complexes by triggering allosteric mechanisms within Kaps that cause rapid release of binding partners. In that way, Nup1p, Nup2p, Cse1p, and Gsp1p may function as karyopherin release factors (or KaRFs) in the nuclear basket structure of the S. cerevisiae NPC.	Stanford Univ, Dept Biol Sci, Stanford, CA 94305 USA	Stanford University	Rexach, M (corresponding author), Stanford Univ, Dept Biol Sci, Stanford, CA 94305 USA.			Gilchrist, Daniel/0000-0003-1668-2790				AEBI M, 1990, MOL GEN GENET, V224, P72, DOI 10.1007/BF00259453; Allen NPC, 2001, J BIOL CHEM, V276, P29268, DOI 10.1074/jbc.M102629200; Bayliss R, 2000, CELL, V102, P99, DOI 10.1016/S0092-8674(00)00014-3; BELANGER KD, 1994, J CELL BIOL, V126, P619, DOI 10.1083/jcb.126.3.619; BERG OG, 1985, ANNU REV BIOPHYS BIO, V14, P131, DOI 10.1146/annurev.biophys.14.1.131; BOGERD AM, 1994, J CELL BIOL, V127, P319, DOI 10.1083/jcb.127.2.319; Booth JW, 1999, J BIOL CHEM, V274, P32360, DOI 10.1074/jbc.274.45.32360; Catimel B, 2001, J BIOL CHEM, V276, P34189, DOI 10.1074/jbc.M103531200; Conti E, 2001, CURR OPIN CELL BIOL, V13, P310, DOI 10.1016/S0955-0674(00)00213-1; Denning D, 2001, J CELL BIOL, V154, P937, DOI 10.1083/jcb.200101007; Dilworth DJ, 2001, J CELL BIOL, V153, P1465, DOI 10.1083/jcb.153.7.1465; ENENKEL C, 1995, J BIOL CHEM, V270, P16499, DOI 10.1074/jbc.270.28.16499; Floer M, 1997, J BIOL CHEM, V272, P19538, DOI 10.1074/jbc.272.31.19538; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; Gorlich D, 1996, CELL, V87, P21, DOI 10.1016/S0092-8674(00)81319-7; Gorlich D, 1999, ANNU REV CELL DEV BI, V15, P607, DOI 10.1146/annurev.cellbio.15.1.607; Gorlich D, 1996, EMBO J, V15, P5584, DOI 10.1002/j.1460-2075.1996.tb00943.x; Hood JK, 1998, J BIOL CHEM, V273, P35142, DOI 10.1074/jbc.273.52.35142; Hood JK, 2000, J CELL SCI, V113, P1471; HOPPER AK, 1990, J CELL BIOL, V111, P309, DOI 10.1083/jcb.111.2.309; Hu W, 1999, J BIOL CHEM, V274, P15820, DOI 10.1074/jbc.274.22.15820; Iovine MK, 1997, J CELL BIOL, V137, P797, DOI 10.1083/jcb.137.4.797; Keminer O, 1999, P NATL ACAD SCI USA, V96, P11842, DOI 10.1073/pnas.96.21.11842; Kobe B, 1999, NAT STRUCT BIOL, V6, P388, DOI 10.1038/7625; Kunzler M, 1998, FEBS LETT, V433, P185, DOI 10.1016/S0014-5793(98)00892-8; Kutay U, 1997, CELL, V90, P1061, DOI 10.1016/S0092-8674(00)80372-4; LOEB JDJ, 1993, MOL BIOL CELL, V4, P209, DOI 10.1091/mbc.4.2.209; Nemergut ME, 2000, J CELL BIOL, V149, P835, DOI 10.1083/jcb.149.4.835; OHTSUBO M, 1989, J CELL BIOL, V109, P1389, DOI 10.1083/jcb.109.4.1389; REXACH M, 1995, CELL, V83, P683, DOI 10.1016/0092-8674(95)90181-7; Ribbeck K, 2001, EMBO J, V20, P1320, DOI 10.1093/emboj/20.6.1320; Rout MP, 2000, J CELL BIOL, V148, P635, DOI 10.1083/jcb.148.4.635; Shulga N, 1996, J CELL BIOL, V135, P329, DOI 10.1083/jcb.135.2.329; Solsbacher J, 2000, MOL CELL BIOL, V20, P8468, DOI 10.1128/MCB.20.22.8468-8479.2000; Solsbacher J, 1998, MOL CELL BIOL, V18, P6805, DOI 10.1128/MCB.18.11.6805	35	99	102	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 17	2002	277	20					18161	18172		10.1074/jbc.M112306200	http://dx.doi.org/10.1074/jbc.M112306200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	553PR	11867631	hybrid			2022-12-27	WOS:000175685100098
J	Keller, SR; Davis, AC; Clairmont, KB				Keller, SR; Davis, AC; Clairmont, KB			Mice deficient in the insulin-regulated membrane aminopeptidase show substantial decreases in glucose transporter GLUT4 levels but maintain normal glucose homeostasis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLACENTAL LEUCINE AMINOPEPTIDASE; RAT SKELETAL-MUSCLE; CELL-SURFACE; ADIPOSE-CELLS; STIMULATED TRANSLOCATION; MATERNAL SERUM; RECEPTOR; IDENTIFICATION; OXYTOCINASE; RESISTANCE	The insulin-regulated aminopeptidase (IRAP) is a zinc-dependent membrane aminopeptidase. It is the homologue of the human placental leucine aminopeptidase. In fat and muscle cells, IRAP colocalizes with the insulin-responsive glucose transporter GLUT4 in intracellular vesicles and redistributes to the cell surface in response to insulin, as GLUT4 does. To address the question of the physiological function of IRAP, we generated mice with a targeted disruption of the IRAP gene (IRAP-/-). Herein, we describe the characterization of these mice with regard to glucose homeostasis and regulation of GLUT4. Fed and fasted blood glucose and insulin levels in the IRAP-/- mice were normal. Whereas IRAP-/- mice responded to glucose administration like control mice, they exhibited an impaired response to insulin. Basal and insulin-stimulated glucose uptake in extensor digitorum. longus muscle, and adipocytes isolated from IRAP-/- mice were decreased by 30-60% but were normal for soleus muscle from male IRAP-/- mice. Total GLUT4 levels were diminished by 40-85% in the IRAP-/- mice in the different muscles and in adipocytes. The relative distribution of GLUT4 in subcellular fractions of basal and insulin-stimulated IRAP-/- adipocytes was the same as in control cells. We conclude that IRAP-/- mice maintain normal glucose homeostasis despite decreased glucose uptake into muscle and fat cells. The absence of IRAP does not affect the subcellular distribution of GLUT4 in adipocytes. However, it leads to substantial decreases in GLUT4 expression.	Univ Virginia, Dept Internal Med, Div Endocrinol, Charlottesville, VA 22908 USA; Bayer Corp, Div Pharmaceut, Dept Metab Disorders Res, West Haven, CT 06516 USA	University of Virginia; Bayer AG	Keller, SR (corresponding author), Univ Virginia, Dept Internal Med, Div Endocrinol, MR4 Bldg,Rm 5147,Lane Rd,POB 801405, Charlottesville, VA 22908 USA.	srk4@virginia.edu	Clairmont, Kevin/ABG-6161-2021	Clairmont, Kevin/0000-0003-4198-2437	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK058051, R56DK025336, R55DK025336, R01DK025336] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK58051, DK25336] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abel ED, 2001, NATURE, V409, P729, DOI 10.1038/35055575; Abel ED, 1999, J CLIN INVEST, V104, P1703, DOI 10.1172/JCI7605; AHMAD S, 1990, J PHARMACOL EXP THER, V252, P643; Aledo JC, 1997, BIOCHEM J, V325, P727, DOI 10.1042/bj3250727; CAMPS M, 1992, BIOCHEM J, V282, P765, DOI 10.1042/bj2820765; Carayannopoulos MO, 2000, P NATL ACAD SCI USA, V97, P7313, DOI 10.1073/pnas.97.13.7313; Champion HC, 1998, AM J PHYSIOL-ENDOC M, V274, pE115, DOI 10.1152/ajpendo.1998.274.1.E115; Cline GW, 1999, NEW ENGL J MED, V341, P240, DOI 10.1056/NEJM199907223410404; DEFRONZO RA, 1981, DIABETES, V30, P1000, DOI 10.2337/diab.30.12.1000; Doege H, 2001, BIOCHEM J, V359, P443, DOI 10.1042/0264-6021:3590443; Etgen GJ, 1999, BIOCHEM J, V337, P51, DOI 10.1042/bj3370051; Fantin VR, 2000, AM J PHYSIOL-ENDOC M, V278, pE127, DOI 10.1152/ajpendo.2000.278.1.E127; FERACCI H, 1981, BIOCHIM BIOPHYS ACTA, V658, P148, DOI 10.1016/0005-2744(81)90258-8; Garvey WT, 1998, J CLIN INVEST, V101, P2377, DOI 10.1172/JCI1557; Ginsberg HN, 2000, J CLIN INVEST, V106, P453, DOI 10.1172/JCI10762; GORDGE MP, 1995, CLIN ENDOCRINOL, V42, P51, DOI 10.1111/j.1365-2265.1995.tb02598.x; Herbst JJ, 1997, AM J PHYSIOL-ENDOC M, V272, pE600, DOI 10.1152/ajpendo.1997.272.4.E600; Hoenack C, 1996, DIABETES, V45, pS82, DOI 10.2337/diab.45.1.S82; HOFMANN C, 1991, ENDOCRINOLOGY, V129, P1915, DOI 10.1210/endo-129-4-1915; HOLMAN GD, 1990, J BIOL CHEM, V265, P18172; JAMES DE, 1985, AM J PHYSIOL, V248, pE567, DOI 10.1152/ajpendo.1985.248.5.E567; Jiang H, 2001, BIOCHEM BIOPH RES CO, V284, P519, DOI 10.1006/bbrc.2001.4994; KAHN BB, 1991, J CLIN INVEST, V87, P561, DOI 10.1172/JCI115031; KANDROR K, 1994, J BIOL CHEM, V269, P138; KANDROR KV, 1995, BIOCHEM J, V307, P383, DOI 10.1042/bj3070383; KATZ EB, 1995, NATURE, V377, P151, DOI 10.1038/377151a0; KELLER SR, 1995, J BIOL CHEM, V270, P23612, DOI 10.1074/jbc.270.40.23612; KENNY J, 1986, TRENDS BIOCHEM SCI, V11, P40, DOI 10.1016/0968-0004(86)90231-8; Kozaki H, 2001, INT J GYNECOL OBSTET, V73, P207, DOI 10.1016/S0020-7292(01)00372-1; LALU K, 1986, BIOCHIM BIOPHYS ACTA, V873, P190, DOI 10.1016/0167-4838(86)90045-2; Laustsen PG, 2001, EUR J BIOCHEM, V268, P98, DOI 10.1046/j.1432-1327.2001.01848.x; Lee W, 1997, J BIOL CHEM, V272, P21427, DOI 10.1074/jbc.272.34.21427; Liu SCH, 1999, J BIOL CHEM, V274, P18093, DOI 10.1074/jbc.274.25.18093; Lund S, 1997, DIABETES, V46, P1965, DOI 10.2337/diabetes.46.12.1965; Malide D, 1997, FEBS LETT, V409, P461, DOI 10.1016/S0014-5793(97)00563-2; MARETTE A, 1993, DIABETES, V42, P1195, DOI 10.2337/diabetes.42.8.1195; MARETTE A, 1992, AM J PHYSIOL, V263, pC443, DOI 10.1152/ajpcell.1992.263.2.C443; Martin S, 1997, J CELL SCI, V110, P2281; MASTICK CC, 1994, J BIOL CHEM, V269, P6089; Matsumoto H, 1998, ZOOL SCI, V15, P111, DOI 10.2108/zsj.15.111; Melvin DR, 1999, BIOCHEMISTRY-US, V38, P1456, DOI 10.1021/bi980988y; Moeller I, 1998, J HUM HYPERTENS, V12, P289, DOI 10.1038/sj.jhh.1000640; Nakamura H, 2000, ENDOCRINOLOGY, V141, P4481, DOI 10.1210/en.141.12.4481; Pessin JE, 1999, J BIOL CHEM, V274, P2593, DOI 10.1074/jbc.274.5.2593; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; Rogi T, 1996, J BIOL CHEM, V271, P56, DOI 10.1074/jbc.271.1.56; Ross SA, 1996, J BIOL CHEM, V271, P3328, DOI 10.1074/jbc.271.6.3328; RYDER JW, 1999, BIOCHEM J, V342, P31; Shepherd PR, 1999, NEW ENGL J MED, V341, P248, DOI 10.1056/NEJM199907223410406; SIMPSON IA, 1983, BIOCHIM BIOPHYS ACTA, V763, P393, DOI 10.1016/0167-4889(83)90101-5; SLIEKER LJ, 1992, DIABETES, V41, P187, DOI 10.2337/diabetes.41.2.187; SLOT JW, 1991, J CELL BIOL, V113, P123, DOI 10.1083/jcb.113.1.123; Stenbit AE, 1997, NAT MED, V3, P1096, DOI 10.1038/nm1097-1096; Subtil A, 2000, J BIOL CHEM, V275, P4787, DOI 10.1074/jbc.275.7.4787; Sumitani S, 1997, ENDOCRINOLOGY, V138, P1029, DOI 10.1210/en.138.3.1029; TSUJIMOTO M, 1992, ARCH BIOCHEM BIOPHYS, V292, P388, DOI 10.1016/0003-9861(92)90007-J; WARD PE, 1990, BIOCHEM PHARMACOL, V40, P1725, DOI 10.1016/0006-2952(90)90348-O; Waters SB, 1997, J BIOL CHEM, V272, P23323, DOI 10.1074/jbc.272.37.23323; Wu-Wong JR, 2000, J CARDIOVASC PHARM, V36, pS179, DOI 10.1097/00005344-200036001-00055; Wu-Wong JSR, 1999, J BIOL CHEM, V274, P8103, DOI 10.1074/jbc.274.12.8103; Yamahara N, 2000, LIFE SCI, V66, P1401, DOI 10.1016/S0024-3205(00)00451-3; Zini S, 1996, P NATL ACAD SCI USA, V93, P11968, DOI 10.1073/pnas.93.21.11968; Zisman A, 2000, NAT MED, V6, P924, DOI 10.1038/78693; ZORZANO A, 1989, J BIOL CHEM, V264, P12358	64	96	99	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 17	2002	277	20					17677	17686		10.1074/jbc.M202037200	http://dx.doi.org/10.1074/jbc.M202037200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	553PR	11884418	hybrid			2022-12-27	WOS:000175685100038
J	Rockwell, NC; Fuller, RS				Rockwell, NC; Fuller, RS			Specific modulation of Kex2/furin family proteases by potassium	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANS-GOLGI NETWORK; PROHORMONE-PROCESSING ENZYME; KEX2 PROTEASE; SECRETORY GRANULES; SUBTILISIN BPN'; YEAST; LOCALIZATION; FURIN; CONVERTASE-2; EXCHANGER	Kex2 protease is the prototype for a family of proteases responsible for endoproteolytic cleavage at multibasic motifs in the eukaryotic secretory pathway. Here we demonstrate that potassium ion can act as a modulator of Kex2 activity with an apparent affinity of similar to20 mM. Other monovalent cations (Li+, Na+, etc.) display similar effects, but affinities are all over 20-fold lower. Potassium ion binding stimulates turnover at physiologically relevant Lys-Arg cleavage sites but reduces turnover with at least one incorrect sequence. Furthermore, the mammalian Kex2 homolog furin displays similar effects. In contrast, the neuroendocrine homolog PC2 is inhibited by potassium ion with all substrates examined. The pre-steady-state behavior of Kex2 is also altered upon binding of potassium ion, with opposite effects on acylation and deacylation rates. These biochemical data indicate that potassium ion concentration may function as a regulator of processing protease specificity and activity in the eukaryotic secretory pathway, with such enzymes potentially encountering compartments high in potassium ion caused by the action of antiporters such as yeast NHX1 (VPS44) or the mammalian NHE7.	Univ Michigan, Med Ctr, Dept Biol Chem, Ann Arbor, MI 48109 USA; Stanford Univ, Dept Biochem, Stanford, CA 94305 USA	University of Michigan System; University of Michigan; Stanford University	Fuller, RS (corresponding author), Univ Michigan, Med Ctr, Dept Biol Chem, Rm 5413,Med Sci I,1301 E Catherine, Ann Arbor, MI 48109 USA.				NIGMS NIH HHS [GM 39697, 2T32GM07599] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R55GM039697, T32GM007599, R01GM039697] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARSHOP BA, 1983, ANAL BIOCHEM, V130, P134, DOI 10.1016/0003-2697(83)90660-7; Bevan A, 1998, P NATL ACAD SCI USA, V95, P10384, DOI 10.1073/pnas.95.18.10384; Bowers K, 2000, MOL BIOL CELL, V11, P4277, DOI 10.1091/mbc.11.12.4277; BRAVO DA, 1994, J BIOL CHEM, V269, P25830; BRAXTON S, 1992, BIOCHEMISTRY-US, V31, P7796, DOI 10.1021/bi00149a008; BRENNER C, 1993, CURR BIOL, V3, P498, DOI 10.1016/0960-9822(93)90040-U; BRENNER C, 1992, P NATL ACAD SCI USA, V89, P922, DOI 10.1073/pnas.89.3.922; BRENNER C, 1994, METHOD ENZYMOL, V244, P152; Brickner JH, 1997, J CELL BIOL, V139, P23, DOI 10.1083/jcb.139.1.23; BRYAN P, 1992, BIOCHEMISTRY-US, V31, P4937, DOI 10.1021/bi00136a003; Cameron A., 2001, ENZYMES, V22, P291; Day R, 1998, J BIOL CHEM, V273, P829, DOI 10.1074/jbc.273.2.829; Forgac M, 1999, J BIOL CHEM, V274, P12951, DOI 10.1074/jbc.274.19.12951; FULLER R, 1986, MICROBIOLOGY 1986, P273; FULLER RS, 1988, ANNU REV PHYSIOL, V50, P345, DOI 10.1146/annurev.ph.50.030188.002021; FULLER RS, 1989, P NATL ACAD SCI USA, V86, P1434, DOI 10.1073/pnas.86.5.1434; GALLAGHER T, 1993, PROTEINS, V16, P205, DOI 10.1002/prot.340160207; GRON H, 1992, BIOCHEMISTRY-US, V31, P6011, DOI 10.1021/bi00141a008; HATSUZAWA K, 1992, J BIOL CHEM, V267, P16094; HUTTON JC, 1983, BIOCHEM J, V210, P297, DOI 10.1042/bj2100297; JEAN F, 1995, J BIOL CHEM, V270, P19225, DOI 10.1074/jbc.270.33.19225; Johanning K, 1998, J BIOL CHEM, V273, P22672, DOI 10.1074/jbc.273.35.22672; JULIUS D, 1984, CELL, V37, P1075, DOI 10.1016/0092-8674(84)90442-2; Krysan DJ, 1999, J BIOL CHEM, V274, P23229, DOI 10.1074/jbc.274.33.23229; Lamango NS, 1996, ARCH BIOCHEM BIOPHYS, V330, P238, DOI 10.1006/abbi.1996.0249; MELLMAN I, 1986, ANNU REV BIOCHEM, V55, P663, DOI 10.1146/annurev.biochem.55.1.663; Molloy SS, 2002, ENZYMES, VXXII, P199; MULLER L, 1999, PROGR NUCL ACIDS RES; Nass R, 1998, J BIOL CHEM, V273, P21054, DOI 10.1074/jbc.273.33.21054; Numata M, 2001, J BIOL CHEM, V276, P17387, DOI 10.1074/jbc.M101319200; PHILIPP M, 1983, MOL CELL BIOCHEM, V51, P5, DOI 10.1007/BF00215583; Rockwell NC, 1997, BIOCHEMISTRY-US, V36, P1912, DOI 10.1021/bi961779l; Rockwell NC, 2000, ANAL BIOCHEM, V280, P201, DOI 10.1006/abio.2000.4541; Rockwell NC, 1998, BIOCHEMISTRY-US, V37, P3386, DOI 10.1021/bi972534r; Rockwell NC, 2001, J BIOL CHEM, V276, P38394, DOI 10.1074/jbc.M105782200; Rockwell NC, 2001, BIOCHEMISTRY-US, V40, P3657, DOI 10.1021/bi0020877; Rockwell NC, 2002, ENZYMES, V22, P259, DOI 10.1016/S1874-6047(02)80011-7; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; SEIDAH NG, 2001, ENZYMES, V22, P237; Steiner D. F., 2002, ENZYMES, V22, P163; TAKAHASHI S, 1995, J BIOL CHEM, V270, P28397; Uehara M, 2001, CELL TISSUE RES, V304, P43, DOI 10.1007/s004410100364; Wan L, 1998, CELL, V94, P205, DOI 10.1016/S0092-8674(00)81420-8; WELLS JA, 1986, PHILOS T R SOC A, V317, P415, DOI 10.1098/rsta.1986.0051; ZIMMERMAN M, 1977, ANAL BIOCHEM, V78, P47, DOI 10.1016/0003-2697(77)90006-9	45	30	33	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 17	2002	277	20					17531	17537		10.1074/jbc.M111909200	http://dx.doi.org/10.1074/jbc.M111909200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	553PR	11893737	hybrid			2022-12-27	WOS:000175685100019
J	Stefanovic, B; Schnabl, B; Brenner, DA				Stefanovic, B; Schnabl, B; Brenner, DA			Inhibition of collagen alpha 1(I) expression by the 5 ' stem-loop as a molecular decoy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STELLATE CELL ACTIVATION; FAT-STORING CELLS; MESSENGER-RNA; EXTRACELLULAR-MATRIX; HEPATIC LIPOCYTES; LIVER-CIRRHOSIS; SNRNA; PATTERNS; FIBROSIS; SITE	Collagen alpha1(I) mRNA is posttranscriptionally regulated in hepatic stellate cells (HSCs). Binding of protein factors to the evolutionary conserved stem-loop in the 5'-untranslated region (5' stem-loop) is required for a high level of expression in activated HSCs. The 5' stem-loop is also found in alpha2(I) and alpha1(III) mRNAs. Titration of the 5' stem-loop binding factors by a stably expressed RNA containing the 5' stem-loop (molecular decoy) may decrease the expression of these collagen mRNAs. We designed a 108-nt RNA that is transcribed from the optimized mouse U7 small nuclear RNA gene and contains the 5' stem-loop (p74WT decoy). This decoy accumulates in the nucleus and in the cytoplasm. When expressed in NTH 3T3 fibroblasts, the p74WT decoy decreased collagen alpha1(I) mRNA level by 60% and decreased collagen type I secreted into the cellular medium by 50%. We also expressed this decoy in quiescent rat HSCs by adenoviral gene transfer. Quiescent HSCs undergo activation in culture, resulting in a 60-70-fold increase in collagen alpha1(I) mRNA. The decoy decreases collagen alpha1(I) mRNA expression by 50-60% during activation of HSCs. It also decreases collagen a2(I) mRNA expression and collagen alpha1(III) mRNA expression. The cellular levels of collagen alpha1(I) propeptide and of disulfide-bonded collagen type I trimer are reduced by 70%. However, the p74WT decoy did not decrease a smooth muscle actin protein or the mRNA levels of glyceraldehyde-3-phosphate dehydrogenase and interleukin-6. The p74WT decoy was also introduced into activated human HSCs. In these cells, the decoy decreased collagen alpha1(I) propeptide and disulfide-bonded collagen trimer by 50-60%. These results indicate that the 5' stem-loop specifically regulates fibrillar collagen synthesis and represents a novel target for antifibrotic therapy. The molecular decoys provide a generalized method of assessing the functional significance of blocking the interactions of mRNA and proteins.	Univ N Carolina, Dept Med, Div Digest Dis & Nutr, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Stefanovic, B (corresponding author), Univ N Carolina, Dept Med, Div Digest Dis & Nutr, CB 7038,154 Glaxo Bldg, Chapel Hill, NC 27599 USA.	stefbra@med.unc.edu		Brenner, David/0000-0003-2573-525X				AYCOCK RS, 1989, CONNECT TISSUE RES, V23, P19, DOI 10.3109/03008208909103901; BLANCK TJJ, 1975, ARCH BIOCHEM BIOPHYS, V171, P259, DOI 10.1016/0003-9861(75)90031-4; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DALESSIO M, 1990, J BIOL CHEM, V265, P7050; DELEEUW AM, 1984, HEPATOLOGY, V4, P392; Friedman SL, 1999, ALCOHOL CLIN EXP RES, V23, P904, DOI 10.1097/00000374-199905000-00020; FRIEDMAN SL, 1992, HEPATOLOGY, V15, P234, DOI 10.1002/hep.1840150211; FRIEDMAN SL, 1989, J BIOL CHEM, V264, P10756; Gorman L, 1998, P NATL ACAD SCI USA, V95, P4929, DOI 10.1073/pnas.95.9.4929; GRIMM C, 1993, EMBO J, V12, P1229, DOI 10.1002/j.1460-2075.1993.tb05764.x; HAMM J, 1990, CELL, V62, P569, DOI 10.1016/0092-8674(90)90021-6; HAMM J, 1990, CELL, V63, P109, DOI 10.1016/0092-8674(90)90292-M; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Hellerbrand C, 1999, J HEPATOL, V30, P77, DOI 10.1016/S0168-8278(99)80010-5; HENDRIKS HFJ, 1985, EXP CELL RES, V160, P138, DOI 10.1016/0014-4827(85)90243-5; Herfarth HH, 1996, GUT, V39, P836, DOI 10.1136/gut.39.6.836; Iimuro Y, 2000, HEPATOLOGY, V32, p321A; JACOBSON MR, 1993, MOL CELL BIOL, V13, P1119, DOI 10.1128/MCB.13.2.1119; Knittel T, 1999, GASTROENTEROLOGY, V117, P1205, DOI 10.1016/S0016-5085(99)70407-5; Lindquist JN, 2000, NUCLEIC ACIDS RES, V28, P4306, DOI 10.1093/nar/28.21.4306; MAHER JJ, 1990, J CLIN INVEST, V86, P1641, DOI 10.1172/JCI114886; MATTAJ IW, 1986, CELL, V46, P905, DOI 10.1016/0092-8674(86)90072-3; MILANI S, 1990, AM J PATHOL, V137, P59; Niederreither K, 1995, MATRIX BIOL, V14, P705, DOI 10.1016/S0945-053X(05)80013-7; Raker VA, 1999, MOL CELL BIOL, V19, P6554; Salgado S, 2000, MOL THER, V2, P545, DOI 10.1006/mthe.2000.0210; SCHUPPAN D, 1990, SEMIN LIVER DIS, V10, P1, DOI 10.1055/s-2008-1040452; SMITH HO, 1991, P NATL ACAD SCI USA, V88, P9784, DOI 10.1073/pnas.88.21.9784; Stefanovic A, 2000, NUCLEIC ACIDS RES, V28, P641, DOI 10.1093/nar/28.2.641; STEFANOVIC B, 1995, NUCLEIC ACIDS RES, V23, P3152, DOI 10.1093/nar/23.16.3152; Stefanovic B, 1999, MOL CELL BIOL, V19, P4334; Stefanovic B, 1997, MOL CELL BIOL, V17, P5201, DOI 10.1128/MCB.17.9.5201; STEFANOVIC B, 1995, NUCLEIC ACIDS RES, V23, P3141, DOI 10.1093/nar/23.16.3141; SU MW, 1991, J CELL BIOL, V115, P565, DOI 10.1083/jcb.115.2.565; Ueki T, 1999, NAT MED, V5, P226, DOI 10.1038/5593; YAMADA Y, 1983, J BIOL CHEM, V258, P4914	36	36	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 17	2002	277	20					18229	18237		10.1074/jbc.M108065200	http://dx.doi.org/10.1074/jbc.M108065200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	553PR	11889120	hybrid			2022-12-27	WOS:000175685100106
J	Eide, EJ; Vielhaber, EL; Hinz, WA; Virshup, DM				Eide, EJ; Vielhaber, EL; Hinz, WA; Virshup, DM			The circadian regulatory proteins BMAL1 and cryptochromes are substrates of casein kinase I epsilon	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DROSOPHILA CLOCK GENE; DOUBLE-TIME; NUCLEAR ENTRY; PHOSPHORYLATION; PERIOD; TRANSCRIPTION; MECHANISMS; MUTATION; CLONING; RNAS	The serine/threonine protein kinase casein kinase I epsilon (CKIepsilon) is a key regulator of metazoan circadian rhythm. Genetic and biochemical data suggest that CKIepsilon binds to and phosphorylates the PERIOD proteins. However, the PERIOD proteins interact with a variety of circadian regulators, suggesting the possibility that CKIepsilon may interact with and phosphorylate additional clock components as well. We find that CRY1 and BMAL1 are phosphoproteins in cultured cells. Mammalian PERIOD proteins act as a scaffold with distinct domains that simultaneously bind CKIepsilon and mCRY1 and mCRY2 (mCRY). mCRY is phosphorylated by CKIepsilon only when both proteins are bound to mammalian PERIOD proteins. BMAL1 is also a substrate for CKIepsilon in vitro, and CKIepsilon kinase activity positively regulates BMAL1-dependent transcription from circadian promoters in reporter assays. We conclude that CKIepsilon phosphorylates multiple circadian substrates and may exert its effects on circadian rhythm in part by a direct effect on BMAL1-dependent transcription.	Univ Utah, Sch Med, Huntsman Canc Inst, Ctr Children, Salt Lake City, UT 84112 USA; Univ Utah, Sch Med, Dept Oncol Sci, Salt Lake City, UT 84112 USA; Univ Utah, Sch Med, Dept Pediat, Salt Lake City, UT 84112 USA	Huntsman Cancer Institute; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah	Virshup, DM (corresponding author), Univ Utah, Sch Med, Huntsman Canc Inst, Ctr Children, 2000 Circle Hope, Salt Lake City, UT 84112 USA.	david.virshup@hci.utah.edu	Virshup, David M/C-1449-2009	Virshup, David M/0000-0001-6976-850X	NCI NIH HHS [P30CA42014, P30 CA042014, R01CA71074] Funding Source: Medline; NIGMS NIH HHS [R01 GM060387-04] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA071074, P30CA042014] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060387] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Allada R, 2001, ANNU REV NEUROSCI, V24, P1091, DOI 10.1146/annurev.neuro.24.1.1091; Camacho F, 2001, FEBS LETT, V489, P159, DOI 10.1016/S0014-5793(00)02434-0; Cegielska A, 1998, J BIOL CHEM, V273, P1357, DOI 10.1074/jbc.273.3.1357; Eide EJ, 2001, CHRONOBIOL INT, V18, P389, DOI 10.1081/CBI-100103963; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Field MD, 2000, NEURON, V25, P437, DOI 10.1016/S0896-6273(00)80906-X; FISH KJ, 1995, J BIOL CHEM, V270, P14875, DOI 10.1074/jbc.270.25.14875; Griffin EA, 1999, SCIENCE, V286, P768, DOI 10.1126/science.286.5440.768; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; Ishida Y, 2001, J NEUROSCI RES, V64, P612, DOI 10.1002/jnr.1114; KARIN M, 1995, CURR BIOL, V5, P747, DOI 10.1016/S0960-9822(95)00151-5; Keesler GA, 2000, NEUROREPORT, V11, P951, DOI 10.1097/00001756-200004070-00011; Kloss B, 2001, NEURON, V30, P699, DOI 10.1016/S0896-6273(01)00320-8; Kloss B, 1998, CELL, V94, P97, DOI 10.1016/S0092-8674(00)81225-8; Kume K, 1999, CELL, V98, P193, DOI 10.1016/S0092-8674(00)81014-4; Lee C, 2001, CELL, V107, P855, DOI 10.1016/S0092-8674(01)00610-9; Lowrey PL, 2000, ANNU REV GENET, V34, P533, DOI 10.1146/annurev.genet.34.1.533; Lowrey PL, 2000, SCIENCE, V288, P483, DOI 10.1126/science.288.5465.483; Miyazaki K, 2001, MOL CELL BIOL, V21, P6651, DOI 10.1128/MCB.21.19.6651-6659.2001; Peters JM, 1999, NATURE, V401, P345, DOI 10.1038/43830; Price JL, 1998, CELL, V94, P83, DOI 10.1016/S0092-8674(00)81224-6; Reppert SM, 2001, ANNU REV PHYSIOL, V63, P647, DOI 10.1146/annurev.physiol.63.1.647; Rothenfluh A, 2000, CURR BIOL, V10, P1399, DOI 10.1016/S0960-9822(00)00786-7; Sakanaka C, 1999, P NATL ACAD SCI USA, V96, P12548, DOI 10.1073/pnas.96.22.12548; Sanada K, 2002, J BIOL CHEM, V277, P267, DOI 10.1074/jbc.M107850200; Shearman LP, 2000, SCIENCE, V288, P1013, DOI 10.1126/science.288.5468.1013; Suri V, 2000, J NEUROSCI, V20, P7547; Takano A, 2000, FEBS LETT, V477, P106, DOI 10.1016/S0014-5793(00)01755-5; Toh KL, 2001, SCIENCE, V291, P1040, DOI 10.1126/science.1057499; Vielhaber E, 2000, MOL CELL BIOL, V20, P4888, DOI 10.1128/MCB.20.13.4888-4899.2000; Vielhaber E, 2001, IUBMB LIFE, V51, P73, DOI 10.1080/15216540152122049; Vielhaber EL, 2001, J BIOL CHEM, V276, P45921, DOI 10.1074/jbc.M107726200; Yagita K, 2000, GENE DEV, V14, P1353	33	237	245	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 10	2002	277	19					17248	17254		10.1074/jbc.M111466200	http://dx.doi.org/10.1074/jbc.M111466200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	551MB	11875063	Green Accepted, hybrid			2022-12-27	WOS:000175564500119
J	Ignjatovic, T; Tan, FL; Brovkovych, V; Skidgel, RA; Erdos, EG				Ignjatovic, T; Tan, FL; Brovkovych, V; Skidgel, RA; Erdos, EG			Novel mode of action of angiotensin I converting enzyme inhibitors - Direct activation of bradykinin B-1 receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYOCARDIAL-INFARCTION; NITRIC-OXIDE; ACE-INHIBITORS; HUMAN B1; KININS; EXPRESSION; CLONING; HEART; POTENTIATION; SUPEROXIDE	Angiotensin I converting enzyme (kininase II; ACE) inhibitors are important therapeutic agents widely used for treatment in cardiovascular and renal diseases. They inhibit angiotensin II release and bradykinin inactivation; these actions do not explain completely the clinical benefits. We found that enalaprilat and other ACE inhibitors in nanomolar concentrations activate human bradykinin B-1 receptors directly in the absence of ACE and the B-1 agonist des-Arg(10)-Lys(1)-bradykinin. These inhibitors activate at the Zn2+-binding consensus sequence HEXXH (195-199) in B-1 which is present also in ACE but not in the B-2 receptor. Activation elevates [Ca2+](i) and releases NO from endothelial or transfected cells expressing the B-1 receptor but is blocked by Ca-EDTA, a B-1 receptor antagonist, the synthetic undecapeptide sequence (192-202) of B-1, and the mutagenesis of His(195) to Ala(195). Except for the B-1 antagonist, these agents and manipulations did not block activation by a peptide ligand. Thus, Zn2+ is essential for B-1 receptor activation by ACE inhibitors at the zinc-binding consensus sequence. Ischemia or cytokines induce abundant B-1 receptor expression. B-1 receptor activation by ACE inhibitors, a novel mode of action reported here first, can contribute to their therapeutic effects by releasing NO in the heart and to some side effects.	Univ Illinois, Coll Med, Dept Pharmacol, Chicago, IL 60612 USA; Univ Illinois, Coll Med, Dept Anesthesiol, Chicago, IL 60612 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Erdos, EG (corresponding author), Univ Illinois, Coll Med, Dept Pharmacol, MC 868,835 S wolcott Ave,Room E403, Chicago, IL 60612 USA.				NHLBI NIH HHS [HL58118, HL36473] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058118, R01HL036473, R37HL036473] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Agata J, 2000, HYPERTENSION, V36, P364, DOI 10.1161/01.HYP.36.3.364; AMBROSIONI E, 1995, NEW ENGL J MED, V332, P80, DOI 10.1056/NEJM199501123320203; BHOOLA KD, 1992, PHARMACOL REV, V44, P1; Bouchard JF, 1998, BRIT J PHARMACOL, V123, P413, DOI 10.1038/sj.bjp.0701619; Brovkovych V, 2001, HYPERTENSION, V37, P34, DOI 10.1161/01.HYP.37.1.34; CASTANO MEM, 2002, CIRCULATION, V105, P627; CHAHINE R, 1993, BRIT J PHARMACOL, V108, P318, DOI 10.1111/j.1476-5381.1993.tb12802.x; Duka I, 2001, CIRC RES, V88, P275, DOI 10.1161/01.RES.88.3.275; Erdos EG, 1999, TRENDS ENDOCRIN MET, V10, P223, DOI 10.1016/S1043-2760(99)00156-3; Erdos EG, 1997, KININ SYSTEM, P111; Fathy DB, 2000, MOL PHARMACOL, V57, P171; Fathy DB, 1998, J BIOL CHEM, V273, P12210, DOI 10.1074/jbc.273.20.12210; Gaudron P, 2000, AM J CARDIOL, V86, P139, DOI 10.1016/S0002-9149(00)00849-3; GAVRAS H, 1974, NEW ENGL J MED, V291, P817, DOI 10.1056/NEJM197410172911603; HESS JF, 1992, BIOCHEM BIOPH RES CO, V184, P260, DOI 10.1016/0006-291X(92)91187-U; HOOPER NM, 1994, FEBS LETT, V354, P1, DOI 10.1016/0014-5793(94)01079-X; Kojima H, 1998, ANAL CHEM, V70, P2446, DOI 10.1021/ac9801723; Lever AF, 1998, LANCET, V352, P179, DOI 10.1016/S0140-6736(98)03228-0; LINZ W, 1995, PHARMACOL REV, V47, P25; Lonn EM, 2001, CIRCULATION, V103, P919; Marceau F, 1998, PHARMACOL REV, V50, P357; Marcic B, 2000, J BIOL CHEM, V275, P16110, DOI 10.1074/jbc.M909490199; McLean PG, 2000, CARDIOVASC RES, V48, P194, DOI 10.1016/S0008-6363(00)00184-X; Menard J, 2001, ADV PROTEIN CHEM, V56, P13; MENKE JG, 1994, J BIOL CHEM, V269, P21583; Minshall RD, 1997, CIRC RES, V81, P848; ONDETTI MA, 1971, BIOCHEMISTRY-US, V10, P4033, DOI 10.1021/bi00798a004; PFEFFER M, 2001, ANGIOTENSIN CONVERTI, P219; PFEFFER MA, 1993, AM HEART J, V126, P789, DOI 10.1016/0002-8703(93)90931-X; Phagoo SB, 1999, MOL PHARMACOL, V56, P325, DOI 10.1124/mol.56.2.325; POWELL JS, 1989, SCIENCE, V245, P186, DOI 10.1126/science.2526370; Schetz JA, 1999, J PHARMACOL EXP THER, V289, P956; Siebeck M, 1996, IMMUNOPHARMACOLOGY, V33, P81, DOI 10.1016/0162-3109(96)00060-4; Skidgel R.A., 1993, RENIN ANGIOTENSIN SY, V1, DOI DOI 10.1-10.10; SMITH JAM, 1995, MOL PHARMACOL, V47, P525; SOUBRIER F, 1988, P NATL ACAD SCI USA, V85, P9386, DOI 10.1073/pnas.85.24.9386; STEWART JM, 1971, BIOCHEM PHARMACOL, V20, P1557, DOI 10.1016/0006-2952(71)90284-X; Tschope C, 2000, BRIT J PHARMACOL, V129, P1537, DOI 10.1038/sj.bjp.0703239; Vergnani L, 2000, CIRCULATION, V101, P1261, DOI 10.1161/01.CIR.101.11.1261; WEI L, 1992, J BIOL CHEM, V267, P13398; Wittstein IS, 2001, J AM COLL CARDIOL, V38, P429, DOI 10.1016/S0735-1097(01)01404-8; YANG HYT, 1971, J PHARMACOL EXP THER, V177, P291; Yusuf S, 2000, NEW ENGL J MED, V342, P145; Zahler S, 1999, IMMUNOPHARMACOLOGY, V44, P27, DOI 10.1016/S0162-3109(99)00108-3	44	88	91	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 10	2002	277	19					16847	16852		10.1074/jbc.M200355200	http://dx.doi.org/10.1074/jbc.M200355200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	551MB	11880373	hybrid			2022-12-27	WOS:000175564500067
J	Joly, N; Danot, O; Schlegel, A; Boos, W; Richet, E				Joly, N; Danot, O; Schlegel, A; Boos, W; Richet, E			The Aes protein directly controls the activity of MalT, the central transcriptional activator of the Escherichia coli maltose regulon	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING DOMAIN; ATP-BINDING; MUTATIONS; SYSTEM; OPERON; ENZYME; TRANSPORT; REGULATOR; ESTERASE; GLUCOSE	MalT, the transcriptional activator of the maltose regulon from Escherichia coli, is the prototype of a new family of transcription factors. Its activity is controlled by multiple regulatory signals. ATP and maltotriose (the inducer) are two effectors of the activator that positively control its multimerization, a critical step in promoter binding. In addition, MalK, the ABC component of the maltodextrin transport system, and the two enzymes MalY and Aes down-regulate MalT activity in vivo. By using a biochemical approach, we demonstrate here that (i) Aes controls MalT activity through direct protein-protein interaction, (ii) Aes competes with maltotriose for MalT binding, (iii) ATP and ADP differentially affect the competition between Aes and the inducer, and (iv) part, if not all, of the Aes binding site is located in DT1, the N-terminal domain of the activator, which also contains the ATP binding site. All of these characteristics point toward an identical mode of action for MalY and Aes. However, we have identified an amino acid substitution in MalT that suppresses MalT inhibition by Aes without interfering with its inhibition by MalY, suggesting that the binding sites of the two inhibitory proteins do not coincide. The differential effects of ATP and ADP on the competition between the inducer and Aes (or MalY) suggest that the ATPase activity displayed by MalT plays a role in the negative control of its activity.	Inst Pasteur, Unite Genet Mol, CNRS, FRE 2364, F-75724 Paris 15, France; Univ Konstanz, Dept Biol, D-78457 Constance, Germany	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; University of Konstanz	Richet, E (corresponding author), Inst Pasteur, Unite Genet Mol, CNRS, FRE 2364, 25 Rue Dr Roux, F-75724 Paris 15, France.		Joly, Nicolas/H-6851-2018	Joly, Nicolas/0000-0003-2731-3827; Danot, Olivier/0000-0003-0002-7097				Bohm A, 2002, J BIOL CHEM, V277, P3708, DOI 10.1074/jbc.M107905200; Boos W, 1998, MICROBIOL MOL BIOL R, V62, P204, DOI 10.1128/MMBR.62.1.204-229.1998; BREMER E, 1985, J BACTERIOL, V162, P1092, DOI 10.1128/JB.162.3.1092-1099.1985; CLAUSEN T, 1999, EMBO J; Danot O, 1996, J MOL BIOL, V262, P1, DOI 10.1006/jmbi.1996.0493; DANOT O, 1994, MOL MICROBIOL, V14, P335, DOI 10.1111/j.1365-2958.1994.tb01294.x; Danot O, 2001, P NATL ACAD SCI USA, V98, P435, DOI 10.1073/pnas.98.2.435; DARDONVILLE B, 1990, J BACTERIOL, V172, P1846, DOI 10.1128/jb.172.4.1846-1852.1990; De Schrijver A, 1999, MICROBIOL-UK, V145, P1287, DOI 10.1099/13500872-145-6-1287; EDELHOCH H, 1967, BIOCHEMISTRY-US, V6, P1948, DOI 10.1021/bi00859a010; EHRMANN M, 1987, J BACTERIOL, V169, P3539, DOI 10.1128/jb.169.8.3539-3545.1987; HOFNUNG M, 1974, J BACTERIOL, V117, P40, DOI 10.1128/JB.117.1.40-47.1974; Kanaya S, 1998, BIOCHEM J, V332, P75, DOI 10.1042/bj3320075; KUHNAU S, 1991, J BACTERIOL, V173, P2180; LOHMAN TM, 1989, J BIOL CHEM, V264, P10139; MCCLURE WR, 1980, P NATL ACAD SCI-BIOL, V77, P5634, DOI 10.1073/pnas.77.10.5634; Miller J.H., 1972, EXPT MOL GENETICS; Notley-McRobb L, 1999, ENVIRON MICROBIOL, V1, P45, DOI 10.1046/j.1462-2920.1999.00003.x; Panagiotidis CH, 1998, MOL MICROBIOL, V30, P535, DOI 10.1046/j.1365-2958.1998.01084.x; Peist R, 1997, J BACTERIOL, V179, P7679, DOI 10.1128/jb.179.24.7679-7686.1997; RAIBAUD O, 1985, J BACTERIOL, V161, P1201, DOI 10.1128/JB.161.3.1201-1208.1985; REIDL J, 1991, J BACTERIOL, V173, P4862, DOI 10.1128/jb.173.15.4862-4876.1991; REYES M, 1988, J BACTERIOL, V170, P4598, DOI 10.1128/jb.170.10.4598-4602.1988; RICHET E, 1989, EMBO J, V8, P981, DOI 10.1002/j.1460-2075.1989.tb03461.x; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; SCHLEGEL A, 2002, IN PRESS J BACTERIOL; Schreiber V, 1999, J BIOL CHEM, V274, P33220, DOI 10.1074/jbc.274.47.33220; Schreiber V, 2000, MOL MICROBIOL, V35, P765, DOI 10.1046/j.1365-2958.2000.01747.x; SEWITZ S, 1998, THESIS U KONSTANZ KO; Steegborn C, 2001, STRUCTURE, V9, P1051, DOI 10.1016/S0969-2126(01)00665-7; Valdez F, 1999, MICROBIOL-UK, V145, P2365, DOI 10.1099/00221287-145-9-2365; VIDALINGIGLIARDI D, 1993, J BIOL CHEM, V268, P24527; ZDYCH E, 1995, J BACTERIOL, V177, P5035, DOI 10.1128/jb.177.17.5035-5039.1995	33	26	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 10	2002	277	19					16606	16613		10.1074/jbc.M200991200	http://dx.doi.org/10.1074/jbc.M200991200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	551MB	11867639	hybrid			2022-12-27	WOS:000175564500037
J	Nonato, MC; Widom, J; Clardy, J				Nonato, MC; Widom, J; Clardy, J			Crystal structure of the N-terminal segment of human eukaryotic translation initiation factor 2 alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUANINE-NUCLEOTIDE-EXCHANGE; BINDING DOMAIN; BETA-SUBUNIT; FACTOR 5A; RNA; REFINEMENT; EXPRESSION; MECHANISM; SEQUENCES; ALIGNMENT	Eukaryotic translation initiation factor 2alpha (eIF2alpha) is a member of the eIF2 heterotrimeric complex that binds and delivers Met-tRNA(i)(Met) to the 40 S ribosomal subunit in a GTP-dependent manner. Phosphorylation/dephosphorylation of eIF2alpha at Ser-51 is the major regulator of protein synthesis in eukaryotic cells. Here, we report the first structural analysis on eIF2, the three-dimensional structure of a 22-kDa N-terminal portion of human eIF2alpha by x-ray diffraction at 1.9 Angstrom resolution. This structure contains two major domains. The N terminus is a beta-barrel with five antiparallel beta-strands in an oligonucleotide binding domain (OB domain) fold. The phosphorylation site (Ser-51) is on the loop connecting beta3 and beta4 in the OB domain. A helical domain follows the OB domain, and the first helix has extensive interactions, including a disulfide bridge, to fix its orientation with respect to the OB domain. The two domains meet along a negatively charged groove with highly conserved residues, indicating a likely site for protein-protein interaction.	Cornell Univ, Baker Lab, Dept Chem & Biol Chem, Ithaca, NY 14853 USA	Cornell University	Clardy, J (corresponding author), Cornell Univ, Baker Lab, Dept Chem & Biol Chem, Ithaca, NY 14853 USA.	jcc12@cornell.edu	Nonato, Maria Cristina C/C-5659-2012	Nonato, Maria Cristina C/0000-0002-4916-1505	NCI NIH HHS [CA59021] Funding Source: Medline; NCRR NIH HHS [RR-01646] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA059021] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR001646] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Abrahams JP, 1996, ACTA CRYSTALLOGR D, V52, P30, DOI 10.1107/S0907444995008754; ANTHONY DD, 1990, ARCH BIOCHEM BIOPHYS, V281, P157, DOI 10.1016/0003-9861(90)90426-Y; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BARTON GJ, 1993, PROTEIN ENG, V6, P37, DOI 10.1093/protein/6.1.37; Bellizzi JJ, 1999, STRUCTURE, V7, pR263, DOI 10.1016/S0969-2126(00)80020-9; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Bycroft M, 1997, CELL, V88, P235, DOI 10.1016/S0092-8674(00)81844-9; Christopher JA, 1998, J MOL GRAPH MODEL, V16, P285; Clemens MJ, 1996, TRANSLATIONAL CONTRO, P139; CORPET F, 1988, NUCLEIC ACIDS RES, V16, P10881, DOI 10.1093/nar/16.22.10881; Das S, 1997, J BIOL CHEM, V272, P31712, DOI 10.1074/jbc.272.50.31712; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; DORRIS DR, 1995, EMBO J, V14, P2239, DOI 10.1002/j.1460-2075.1995.tb07218.x; Erickson FL, 1996, EMBO J, V15, P6311, DOI 10.1002/j.1460-2075.1996.tb01021.x; GASPAR NJ, 1994, J BIOL CHEM, V269, P3415; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; HENDRICKSON WA, 1991, SCIENCE, V254, P51, DOI 10.1126/science.1925561; Hinnebusch Alan G., 1994, Seminars in Cell Biology, V5, P417, DOI 10.1006/scel.1994.1049; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kim KK, 1998, P NATL ACAD SCI USA, V95, P10419, DOI 10.1073/pnas.95.18.10419; Kimball SR, 1998, J BIOL CHEM, V273, P12841, DOI 10.1074/jbc.273.21.12841; Kozak M, 1999, GENE, V234, P187, DOI 10.1016/S0378-1119(99)00210-3; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Laurino JP, 1999, MOL CELL BIOL, V19, P173; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; MCPHERSON A, 1982, PREPARATION ANAL PRO, P96; MERRICK WC, 1992, MICROBIOL REV, V56, P291, DOI 10.1128/MMBR.56.2.291-315.1992; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; MURZIN AG, 1993, EMBO J, V12, P861, DOI 10.1002/j.1460-2075.1993.tb05726.x; MURZIN AG, 1995, J MOL BIOL, V247, P536, DOI 10.1006/jmbi.1995.0159; Nika J, 2001, J BIOL CHEM, V276, P1051, DOI 10.1074/jbc.M007398200; Pain VM, 1996, EUR J BIOCHEM, V236, P747, DOI 10.1111/j.1432-1033.1996.00747.x; PATHAK VK, 1988, CELL, V54, P633, DOI 10.1016/S0092-8674(88)80007-2; Peat TS, 1998, STRUCT FOLD DES, V6, P1207, DOI 10.1016/S0969-2126(98)00120-8; PRICE N, 1994, BIOCHIMIE, V76, P748, DOI 10.1016/0300-9084(94)90079-5; RHOADS RE, 1993, J BIOL CHEM, V268, P3017; ROWLANDS AG, 1988, J BIOL CHEM, V263, P5526; RUFF M, 1991, SCIENCE, V252, P1682, DOI 10.1126/science.2047877; SCHINDELIN H, 1994, P NATL ACAD SCI USA, V91, P5119, DOI 10.1073/pnas.91.11.5119; SCHINDELIN H, 1993, NATURE, V364, P164, DOI 10.1038/364164a0; Sette M, 1997, EMBO J, V16, P1436, DOI 10.1093/emboj/16.6.1436; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Thompson GM, 2000, BIOCHEM J, V347, P703, DOI 10.1042/0264-6021:3470703; TRACHSEL H, 1996, TRANSLATIONAL CONTRO, P113; WESTERMANN P, 1980, NUCLEIC ACIDS RES, V8, P3065, DOI 10.1093/nar/8.14.3065	47	52	57	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 10	2002	277	19					17057	17061		10.1074/jbc.M111804200	http://dx.doi.org/10.1074/jbc.M111804200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	551MB	11859078	hybrid			2022-12-27	WOS:000175564500095
J	Xu, HP; Ito, T; Tawada, A; Maeda, H; Yamanokuchi, H; Isahara, K; Yoshida, K; Uchiyama, Y; Asari, A				Xu, HP; Ito, T; Tawada, A; Maeda, H; Yamanokuchi, H; Isahara, K; Yoshida, K; Uchiyama, Y; Asari, A			Effect of hyaluronan oligosaccharides on the expression of heat shock protein 72	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK RESPONSE; STRESS-INDUCED APOPTOSIS; GENE-TRANSCRIPTION; FACTOR-I; PROTEIN; CELLS; ACID; OSTEOARTHRITIS; ACTIVATION; OLIGOMERIZATION	We have previously shown that intraarticular treatment with a hyaluronan (HA) preparation (840 kDa), HA84, up-regulates heat shock protein 72 (Hsp72) expression and suppresses degeneration of synovial cells in an arthritis model. In that study, the RA84 administered was degraded into HA oligosaccharides in the synovial tissue, suggesting that HA84 or degradation products of RA may up-regulate Hsp72 expression. Thus, in the present study, we examined the effects of HA of various molecular sizes on Hsp72 expression and cell death in stressed cells. Western blotting analysis showed that treatment of K562 cells with HA tetrasaccharides up-regulated Hsp72 expression after exposure to hyperthermia. On the other hand, treatment of the cells with HA of other sizes (di-, hexa-, deca-, dodecasaccharides), HA84, or tetrasaccharides of keratan sulfate did not elicit any change in expression of the Hsp72 protein. Treatment of the cells with tetrasaccharides of HA up-regulated not only expression of the Hsp72 protein but also Hsp72 mRNA expression and enhanced activation of HSF1, a transcription factor controlling Hsp72 expression, after exposure to hyperthermia. Because the level of Hsp72 protein was not affected by tetrasaccharides of RA when the K562 cells were kept at 37 degreesC without any stress, it is evident that tetrasaccharides of HA did not act as a stress factor. In addition, tetrasaccharides of HA suppressed cell death in the case of K562 cells exposed to hyperthermia and of PC12 cells under serum deprivation. These results suggest that a certain size of oligosaccharides, i.e. the tetrasaccharides of HA, up-regulates Hsp72 expression by enhancing the activation of HSF1 under stress conditions and suppresses cell death.	Seikagaku Corp, Tokyo 2070021, Japan; Osaka Univ, Sch Med, Dept Anat & Cell Biol, Suita, Osaka 5650871, Japan	Seikagaku Corporation; Osaka University	Asari, A (corresponding author), Seikagaku Corp, Tateno 3-1253, Tokyo 2070021, Japan.	asari@seikagaku.co.jp	Xu, Heping/A-4430-2008	Xu, Heping/0000-0003-4000-931X				AMICI C, 1995, CANCER RES, V55, P4452; Asari A, 1998, ARCH HISTOL CYTOL, V61, P125, DOI 10.1679/aohc.61.125; Asari A, 1996, OSTEOARTHR CARTILAGE, V4, P213, DOI 10.1016/S1063-4584(96)80018-5; ASHBURNER M, 1979, CELL, V17, P241, DOI 10.1016/0092-8674(79)90150-8; Buzzard KA, 1998, J BIOL CHEM, V273, P17147, DOI 10.1074/jbc.273.27.17147; Cotto JJ, 1996, J BIOL CHEM, V271, P3355; Deguine V, 1998, INT J BIOL MACROMOL, V22, P17, DOI 10.1016/S0141-8130(97)00084-6; DOUGHERTY GJ, 1991, J EXP MED, V174, P1, DOI 10.1084/jem.174.1.1; INOUE Y, 1985, CARBOHYD RES, V141, P99, DOI 10.1016/S0008-6215(00)90759-6; Isahara K, 1999, NEUROSCIENCE, V91, P233, DOI 10.1016/S0306-4522(98)00566-1; JURIVICH DA, 1992, SCIENCE, V255, P1243, DOI 10.1126/science.1546322; KIRINO T, 1991, J CEREBR BLOOD F MET, V11, P299, DOI 10.1038/jcbfm.1991.62; KNUDSON CB, 1993, FASEB J, V7, P1233, DOI 10.1096/fasebj.7.13.7691670; KNUDSON CB, 1993, J CELL BIOL, V120, P825, DOI 10.1083/jcb.120.3.825; Kubota M, 2000, EUR J MASS SPECTROM, V6, P193, DOI 10.1255/ejms.338; LINDQUIST S, 1986, ANNU REV BIOCHEM, V55, P1151, DOI 10.1146/annurev.bi.55.070186.005443; Lokeshwar VB, 2001, J BIOL CHEM, V276, P11922, DOI 10.1074/jbc.M008432200; Mosser DD, 1997, MOL CELL BIOL, V17, P5317, DOI 10.1128/MCB.17.9.5317; Nagaya H, 1999, ANN RHEUM DIS, V58, P186, DOI 10.1136/ard.58.3.186; Neumann A, 1999, FEBS LETT, V453, P283, DOI 10.1016/S0014-5793(99)00731-0; Noble PW, 1998, WENN GR INT, V72, P219; Ohsawa Y, 1998, ARCH HISTOL CYTOL, V61, P395, DOI 10.1679/aohc.61.395; SARGE KD, 1993, MOL CELL BIOL, V13, P1392, DOI 10.1128/MCB.13.3.1392; Schrager HM, 1998, J CLIN INVEST, V101, P1708, DOI 10.1172/JCI2121; SISTONEN L, 1994, MOL CELL BIOL, V14, P2087, DOI 10.1128/MCB.14.3.2087; Takahashi K, 1999, OSTEOARTHR CARTILAGE, V7, P182, DOI 10.1053/joca.1998.0207; WEST DC, 1989, CIBA F SYMP, V143, P187; West DC, 1998, WENN GR INT, V72, P227; WESTWOOD JT, 1991, NATURE, V353, P822, DOI 10.1038/353822a0; Wu C, 1995, ANNU REV CELL DEV BI, V11, P441, DOI 10.1146/annurev.cellbio.11.1.441; Xia WL, 1997, J BIOL CHEM, V272, P4094, DOI 10.1074/jbc.272.7.4094	31	91	98	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 10	2002	277	19					17308	17314		10.1074/jbc.M112371200	http://dx.doi.org/10.1074/jbc.M112371200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	551MB	11864979	hybrid			2022-12-27	WOS:000175564500126
J	Baader, M; Gnerre, C; Stegeman, JJ; Meyer, UA				Baader, M; Gnerre, C; Stegeman, JJ; Meyer, UA			Transcriptional activation of cytochrome P450CYP2C45 by drugs is mediated by the chicken xenobiotic receptor (CXR) interacting with a phenobarbital response enhancer unit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONSTITUTIVE ANDROSTANE RECEPTOR; ORPHAN NUCLEAR RECEPTOR; PREGNANE-X RECEPTOR; GENE; IDENTIFICATION; INDUCTION; EXPRESSION; ELEMENT; CYP2H1; UPDATE	Cytochromes P450 (CYP)-2C enzymes fulfill an important role in xenobiotic metabolism and therefore have extensively been studied in rodents and humans. However, no CYP2C genes have been described in avian species to date. In this paper, we report the cloning, functional analysis, and regulation of chicken CYP2C45. The sequence shares up to 58% amino acid identity with CYP2Cs in other species. The overexpression of CYP2C45 in chicken hepatoma cells leghorn male hepatoma (LMH) led to increased scoparone metabolism. CYP2C45 regulation was studied in LMH cells at the mRNA level and in reporter gene assays using a construct containing 2.6 kb of its 5'-flanking region. Exposure of LMH cells to phenobarbital or metyrapone led to a 95- or 210-fold increase in CYP2C45 mRNA and a 140- or 290-fold increase in reporter gene expression, respectively. A phenobarbital response enhancer unit (PBRU) of 239 bp containing a DR-4 nuclear receptor binding site was identified within the 2.6-kb fragment. Site-specific mutation of the DR-4 revealed the requirement of this motif for CYP2C45 induction by drugs. The chicken xenobiotic receptor CXR interacted with the PBRU in electromobility shift and transactivation assays. Furthermore, the related nuclear receptors, mouse PXR and mouse CAR, transactivated this enhancer element, suggesting evolutionary conservation of nuclear receptor-DNA interactions in CYP2C induction.	Univ Basel, Biozentrum, Dept Pharmacol Neurobiol, CH-4056 Basel, Switzerland; Woods Hole Oceanog Inst, Dept Biol, Woods Hole, MA 02543 USA	University of Basel; Woods Hole Oceanographic Institution	Meyer, UA (corresponding author), Univ Basel, Biozentrum, Dept Pharmacol Neurobiol, Klingelbergstr 50-70, CH-4056 Basel, Switzerland.	Urs-A.Meyer@unibas.ch		Stegeman, John/0000-0001-8204-5357	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P42ES007381] Funding Source: NIH RePORTER; NIEHS NIH HHS [P42 ES07381] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Czerniak R, 2001, INT J TOXICOL, V20, P161, DOI 10.1080/109158101317097746; Gerbal-Chaloin S, 2001, DRUG METAB DISPOS, V29, P242; Handschin C, 2000, J BIOL CHEM, V275, P13362, DOI 10.1074/jbc.275.18.13362; Handschin C, 2001, MOL PHARMACOL, V60, P681; Handschin C, 2001, MOL ENDOCRINOL, V15, P1571, DOI 10.1210/me.15.9.1571; Handschin C, 2000, P NATL ACAD SCI USA, V97, P10769, DOI 10.1073/pnas.97.20.10769; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Honkakoski P, 1998, MOL CELL BIOL, V18, P5652, DOI 10.1128/MCB.18.10.5652; Honkakoski P, 2000, BIOCHEM J, V347, P321, DOI 10.1042/0264-6021:3470321; IniguezLluhi JA, 1997, J BIOL CHEM, V272, P4149, DOI 10.1074/jbc.272.7.4149; IOANNIDES C, 1996, HUMAN CYP2C, P162; JAISWAL AK, 1990, NUCLEIC ACIDS RES, V18, P4237, DOI 10.1093/nar/18.14.4237; Kemper B, 1998, PROG NUCLEIC ACID RE, V61, P25, DOI 10.1016/S0079-6603(08)60824-7; Kim J, 2001, J BIOL CHEM, V276, P7559, DOI 10.1074/jbc.M008090200; Kliewer SA, 1998, CELL, V92, P73, DOI 10.1016/S0092-8674(00)80900-9; Klose TS, 1999, J BIOCHEM MOL TOXIC, V13, P289, DOI 10.1002/(SICI)1099-0461(1999)13:6<289::AID-JBT1>3.0.CO;2-N; LeCluyse EL, 2001, CHEM-BIOL INTERACT, V134, P283, DOI 10.1016/S0009-2797(01)00163-6; LEVY RH, 1995, EPILEPSIA, V36, pS8, DOI 10.1111/j.1528-1157.1995.tb06007.x; Masahiko N, 2000, EUR J PHARM SCI, V11, P259, DOI 10.1016/S0928-0987(00)00112-3; McGinnity DF, 2000, DRUG METAB DISPOS, V28, P1327; Meyer RP, 2001, BIOCHEM BIOPH RES CO, V285, P32, DOI 10.1006/bbrc.2001.5111; Michalets EL, 1998, PHARMACOTHERAPY, V18, P84; MOREL F, 1990, EUR J BIOCHEM, V191, P437, DOI 10.1111/j.1432-1033.1990.tb19140.x; Nelson DR, 1996, PHARMACOGENETICS, V6, P1, DOI 10.1097/00008571-199602000-00002; Okey AB, 1992, PHARMACOGENETICS DRU, P549; Ourlin JC, 2000, ARCH BIOCHEM BIOPHYS, V373, P375, DOI 10.1006/abbi.1999.1566; Pereira TM, 1998, DNA CELL BIOL, V17, P39, DOI 10.1089/dna.1998.17.39; Quattrochi LC, 2001, DRUG METAB DISPOS, V29, P615; RETTIE AE, 1992, CHEM RES TOXICOL, V5, P54, DOI 10.1021/tx00025a009; Schuetz JD, 1996, MOL PHARMACOL, V49, P63; Sueyoshi T, 2001, ANNU REV PHARMACOL, V41, P123, DOI 10.1146/annurev.pharmtox.41.1.123; Sueyoshi T, 1999, J BIOL CHEM, V274, P6043, DOI 10.1074/jbc.274.10.6043; Warrington JS, 2000, DRUG METAB DISPOS, V28, P392; YASUMORI T, 1993, PHARMACOGENETICS, V3, P291, DOI 10.1097/00008571-199312000-00003	34	29	30	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 3	2002	277	18					15647	15653		10.1074/jbc.M109882200	http://dx.doi.org/10.1074/jbc.M109882200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	550PA	11867618	hybrid			2022-12-27	WOS:000175510400058
J	Budinger, GRS; Tso, M; McClintock, DS; Dean, DA; Sznajder, JI; Chandel, NS				Budinger, GRS; Tso, M; McClintock, DS; Dean, DA; Sznajder, JI; Chandel, NS			Hyperoxia-induced apoptosis does not require mitochondrial reactive oxygen species and is regulated by Bcl-2 proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED LUNG INJURY; SUPEROXIDE-DISMUTASE; CELL-DEATH; ELECTRON-TRANSPORT; TRANSGENIC MICE; CYTOCHROME-C; GENE-EXPRESSION; FAMILY MEMBERS; DNA-DAMAGE; RAT LUNGS	Exposure of animals to hyperoxia results in lung injury that is characterized by apoptosis and necrosis of the alveolar epithelium and endothelium. The mechanism by which hyperoxia results in cell death, however, remains unclear. We sought to test the hypothesis that exposure to hyperoxia causes mitochondria-dependent apoptosis that requires the generation of reactive oxygen species from mitochondrial electron transport. Rat1a cells exposed to hyperoxia underwent apoptosis characterized by the release of cytochrome c, activation of caspase-9, and nuclear fragmentation that was prevented by the overexpression of Bcl-X-L. Murine embryonic fibroblasts from bax(-/-) bak(-/-) mice were resistant to hyperoxia-induced cell death. The administration of the antioxidants manganese (III) tetrakis (4-benzoic acid) porphyrin, ebselen, and N-acetylcysteine failed to prevent cell death following exposure to hyperoxia. Human fibrosarcoma cells (HT1080) lacking mitochondrial DNA (rho(0) cells) that failed to generate reactive oxygen species during exposure to hyperoxia were not protected against cell death following exposure to hyperoxia. We conclude that exposure to hyperoxia results in apoptosis that requires Bax or Bak and can be prevented by the overexpression of Bcl-X-L. The mitochondrial generation of reactive oxygen species is not required for cell death following exposure to hyperoxia.	Northwestern Univ, Div Pulm & Crit Care Med, Chicago, IL 60611 USA	Northwestern University	Budinger, GRS (corresponding author), Northwestern Univ, Div Pulm & Crit Care Med, 303 E Chicago Ave,Tarry 14-707, Chicago, IL 60611 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL067835] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060472] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL67835-01] Funding Source: Medline; NIGMS NIH HHS [GM60472] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Annis MG, 2001, ONCOGENE, V20, P1939, DOI 10.1038/sj.onc.1204288; Barazzone C, 2000, AM J RESP CELL MOL, V22, P517, DOI 10.1165/ajrcmb.22.5.f180; Barazzone C, 1998, AM J RESP CELL MOL, V19, P573, DOI 10.1165/ajrcmb.19.4.3173; BOVERIS A, 1972, BIOCHEM J, V128, P617, DOI 10.1042/bj1280617; Chandel NS, 1998, P NATL ACAD SCI USA, V95, P11715, DOI 10.1073/pnas.95.20.11715; Chandel NS, 1999, FEBS LETT, V454, P173, DOI 10.1016/S0014-5793(99)00783-8; Cheng EHYA, 2001, MOL CELL, V8, P705, DOI 10.1016/S1097-2765(01)00320-3; CRAPO JD, 1980, AM REV RESPIR DIS, V122, P123; DEL PL, 1997, SCIENCE, V278, P687; Folz RJ, 1999, J CLIN INVEST, V103, P1055, DOI 10.1172/JCI3816; FREEMAN BA, 1981, J BIOL CHEM, V256, P986; Gottlob K, 2001, GENE DEV, V15, P1406, DOI 10.1101/gad.889901; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; GUIDOT DM, 1993, J BIOL CHEM, V268, P26699; Juin P, 1999, GENE DEV, V13, P1367, DOI 10.1101/gad.13.11.1367; Kazzaz JA, 1996, J BIOL CHEM, V271, P15182, DOI 10.1074/jbc.271.25.15182; Kennedy SG, 1999, MOL CELL BIOL, V19, P5800; KING MP, 1989, SCIENCE, V246, P500, DOI 10.1126/science.2814477; KLEFSTROM J, 1994, EMBO J, V13, P5442, DOI 10.1002/j.1460-2075.1994.tb06879.x; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; Lindsten T, 2000, MOL CELL, V6, P1389, DOI 10.1016/S1097-2765(00)00136-2; Lu YB, 2001, J EXP MED, V193, P545, DOI 10.1084/jem.193.4.545; McClintock DS, 2002, MOL CELL BIOL, V22, P94, DOI 10.1128/MCB.22.1.94-104.2002; O'Reilly MA, 2001, AM J PHYSIOL-LUNG C, V281, pL291, DOI 10.1152/ajplung.2001.281.2.L291; O'Reilly MA, 2000, LAB INVEST, V80, P1845, DOI 10.1038/labinvest.3780195; OLIVERA WG, 1995, AM J RESP CRIT CARE, V152, P1229, DOI 10.1164/ajrccm.152.4.7551375; Otterbein LE, 1999, J CLIN INVEST, V103, P1047, DOI 10.1172/JCI5342; Porras A, 1999, J VIROL, V73, P3102; SANDERS SP, 1993, J CLIN INVEST, V91, P46, DOI 10.1172/JCI116198; Senturker S, 2002, ARCH BIOCHEM BIOPHYS, V397, P262, DOI 10.1006/abbi.2001.2681; STRASSER A, 1994, CELL, V79, P329, DOI 10.1016/0092-8674(94)90201-1; TLSTY T, 1995, METHOD ENZYMOL, V254, P125; Vander Heiden MG, 1999, NAT CELL BIOL, V1, pE209, DOI 10.1038/70237; VanderHeiden MG, 1997, CELL, V91, P627, DOI 10.1016/S0092-8674(00)80450-X; Wang JM, 2001, P NATL ACAD SCI USA, V98, P4038, DOI 10.1073/pnas.061038798; Ward NS, 2000, AM J RESP CELL MOL, V22, P535, DOI 10.1165/ajrcmb.22.5.3808; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; WHITE CW, 1991, J CLIN INVEST, V87, P2162, DOI 10.1172/JCI115249; WISPE JR, 1992, J BIOL CHEM, V267, P23937; Xie ZJ, 1999, J BIOL CHEM, V274, P19323, DOI 10.1074/jbc.274.27.19323	40	84	95	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 3	2002	277	18					15654	15660		10.1074/jbc.M109317200	http://dx.doi.org/10.1074/jbc.M109317200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	550PA	11877388	hybrid			2022-12-27	WOS:000175510400059
J	de Kreij, A; van den Burg, B; Venema, G; Vriend, G; Eijsink, VGH; Nielsen, JE				de Kreij, A; van den Burg, B; Venema, G; Vriend, G; Eijsink, VGH; Nielsen, JE			The effects of modifying the surface charge on the catalytic activity of a thermolysin-like protease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACILLUS-STEAROTHERMOPHILUS; NEUTRAL PROTEASE; 3-DIMENSIONAL STRUCTURE; SUBSTRATE-SPECIFICITY; TRANSITION-STATE; AMINO-ACID; SITE; STABILITY; SUBTILISIN; ENZYME	The impact of long range electrostatic interactions on catalysis in the thermolysin-like protease from Bacillus stearothermophilus was studied by analyzing the effects of inserting or removing charges on the protein surface. Various mutations were introduced at six different positions, and double-mutant cycle analysis was used to study the extent to which mutational effects were interdependent. The effects of single point mutations on the k(cat)/K-m were non-additive, even in cases where the point mutations were located 10, or more from the active site Zn2+ and separated from each other by up to 25 Angstrom. This shows that catalysis is affected by large electrostatic networks that involve major parts of the enzyme. The interdependence of mutations at positions as much as 25 Angstrom apart in space also indicates that other effects, such as active site dynamics, play an important role in determining active site electrostatics. Several mutations yielded a significant increase in the activity, the most active (quadruple) mutant being almost four times as active as the wild type. In some cases the shape of the pH-activity profile was changed significantly. Remarkably, large changes in the pH-optimum were not observed.	Univ Groningen, Groningen Biomol Sci & Biotechnol Inst, Dept Genet, NL-9751 NN Haren, Netherlands; Catholic Univ Nijmegen, Ctr Mol & Biomol Informat, NL-6525 ED Nijmegen, Netherlands; Agr Univ Norway, Dept Chem & Biotechnol, N-1432 As, Norway; European Mol Biol Lab, D-69117 Heidelberg, Germany	University of Groningen; Radboud University Nijmegen; Norwegian University of Life Sciences; European Molecular Biology Laboratory (EMBL)	Venema, G (corresponding author), Univ Groningen, Groningen Biomol Sci & Biotechnol Inst, Dept Genet, Kerklaan 30, NL-9751 NN Haren, Netherlands.		Vriend, G./H-8112-2014; Vriend, Gert/D-6730-2011	Nielsen, Jens Erik/0000-0002-2831-7718				Albeck S, 2000, J MOL BIOL, V298, P503, DOI 10.1006/jmbi.2000.3656; Albeck S, 1999, BIOCHEMISTRY-US, V38, P11, DOI 10.1021/bi981772z; Banbula A, 1998, STRUCTURE, V6, P1185, DOI 10.1016/S0969-2126(98)00118-X; BEAUMONT A, 1998, HDB PROTEOLYTIC ENZY, P350; CARTER PJ, 1984, CELL, V38, P835, DOI 10.1016/0092-8674(84)90278-2; de Kreij A, 2001, EUR J BIOCHEM, V268, P4985, DOI 10.1046/j.0014-2956.2001.02434.x; EIJSINK VGH, 1995, NAT STRUCT BIOL, V2, P374, DOI 10.1038/nsb0595-374; EIJSINK VGH, 1990, PROTEIN ENG, V4, P99, DOI 10.1093/protein/4.1.99; FEDER J, 1968, BIOCHEMISTRY-US, V6, P2088; Fersht A, 1998, STRUCTURE MECH PROTE, P103; FERSHT AR, 1992, J MOL BIOL, V224, P771, DOI 10.1016/0022-2836(92)90561-W; FUJII M, 1983, J BACTERIOL, V154, P831, DOI 10.1128/JB.154.2.831-837.1983; Gaucher JF, 1999, BIOCHEMISTRY-US, V38, P12569, DOI 10.1021/bi991043z; GRAYCAR TP, 1992, ANN NY ACAD SCI, V673, P70; HANGAUER DG, 1984, BIOCHEMISTRY-US, V23, P5730, DOI 10.1021/bi00319a011; HARDY F, 1993, FEBS LETT, V317, P89, DOI 10.1016/0014-5793(93)81497-N; HAUSRATH AC, 1994, J BIOL CHEM, V269, P18839; Hernandez G, 2000, P NATL ACAD SCI USA, V97, P3166, DOI 10.1073/pnas.040569697; HOLMES MA, 1983, BIOCHEMISTRY-US, V22, P236, DOI 10.1021/bi00270a034; HONIG B, 1995, SCIENCE, V268, P1144, DOI 10.1126/science.7761829; JACKSON SE, 1993, BIOCHEMISTRY-US, V32, P13909, DOI 10.1021/bi00213a021; Jin YH, 1998, BIOORG MED CHEM LETT, V8, P3515, DOI 10.1016/S0960-894X(98)00643-X; KESTER WR, 1977, BIOCHEMISTRY-US, V16, P2506, DOI 10.1021/bi00630a030; KIDOKORO S, 1995, FEBS LETT, V367, P73, DOI 10.1016/0014-5793(95)00537-J; Mansfeld J, 1997, J BIOL CHEM, V272, P11152, DOI 10.1074/jbc.272.17.11152; MATTHEWS BW, 1988, ACCOUNTS CHEM RES, V21, P333, DOI 10.1021/ar00153a003; Mei HC, 1998, PROTEIN ENG, V11, P109, DOI 10.1093/protein/11.2.109; MOCK WL, 1994, BIOCHEM J, V302, P57, DOI 10.1042/bj3020057; Mock WL, 1996, BIOCHEMISTRY-US, V35, P7369, DOI 10.1021/bi952827p; MOSIMANN S, 1995, PROTEINS, V23, P301, DOI 10.1002/prot.340230305; NICHOLLS A, 1991, J COMPUT CHEM, V12, P435, DOI 10.1002/jcc.540120405; Nielsen JE, 1999, PROTEIN ENG, V12, P657, DOI 10.1093/protein/12.8.657; Nielsen JE, 1999, EUR J BIOCHEM, V264, P816, DOI 10.1046/j.1432-1327.1999.00664.x; RUSSELL AJ, 1987, NATURE, V328, P496, DOI 10.1038/328496a0; RUSSELL AJ, 1987, J MOL BIOL, V193, P803, DOI 10.1016/0022-2836(87)90360-3; STARK W, 1992, FEBS EUR J BIOCH, V984, P1; THAYER MM, 1991, J BIOL CHEM, V266, P2864; Van den Burg B, 1998, P NATL ACAD SCI USA, V95, P2056, DOI 10.1073/pnas.95.5.2056; VANDENBURG B, 1989, J BIOCHEM BIOPH METH, V18, P209, DOI 10.1016/0165-022X(89)90005-5; Veltman OR, 1998, BIOCHEMISTRY-US, V37, P5305, DOI 10.1021/bi972374j; Veltman OR, 1997, FEBS LETT, V405, P241, DOI 10.1016/S0014-5793(97)00193-2; VRIEND G, 1990, J MOL GRAPHICS, V8, P52, DOI 10.1016/0263-7855(90)80070-V; VRIEND G, 1993, J COMPUT AID MOL DES, V7, P367, DOI 10.1007/BF02337558; Vriend G, 1998, J BIOL CHEM, V273, P35074, DOI 10.1074/jbc.273.52.35074; WEAVER LH, 1977, J MOL BIOL, V114, P119, DOI 10.1016/0022-2836(77)90286-8; WILKINSON AJ, 1983, BIOCHEMISTRY-US, V22, P3581, DOI 10.1021/bi00284a007; Zhao HM, 1999, PROTEIN ENG, V12, P47, DOI 10.1093/protein/12.1.47	47	42	45	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 3	2002	277	18					15432	15438		10.1074/jbc.M200807200	http://dx.doi.org/10.1074/jbc.M200807200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	550PA	11859085	Green Published, hybrid			2022-12-27	WOS:000175510400029
J	Niu, SL; Mitchell, DC; Litman, BJ				Niu, SL; Mitchell, DC; Litman, BJ			Manipulation of cholesterol levels in rod disk membranes by methyl-beta-cyclodextrin. Effects on receptor activation.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHAIN PHOSPHATIDYLCHOLINE VESICLES; PROTEIN-COUPLED RECEPTOR; OUTER SEGMENT MEMBRANES; HIGHER-ORDER ANALYSIS; LIPID-COMPOSITION; METARHODOPSIN-II; ANISOTROPY DECAY; MOLECULAR ORDER; RHODOPSIN; EQUILIBRIUM	The effect of cholesterol on rod outer segment disk membrane structure and rhodopsin activation was investigated. Disk membranes with varying cholesterol concentrations were prepared using methyl-beta-cyclodextrin as a cholesterol donor or acceptor. Cholesterol exchange followed a simple equilibrium partitioning model with a partition coefficient of 5.2 +/- 0.8 in favor of the disk membrane. Reduced cholesterol in disk membranes resulted in a higher proportion of photolyzed rhodopsin being converted to the G protein-activating metarhodopsin II (MII) conformation, whereas enrichment of cholesterol reduced the extent of MII formation. Time-resolved fluorescence anisotropy measurements using 1,6-diphenyl-1,3,5-hexatriene showed that increasing cholesterol reduced membrane acyl chain packing free volume as characterized by the parameter f(v).. The level of MII formed showed a positive linear correlation with f(v) over the range of 4 to 38 mol % cholesterol. In addition, the thermal stability of rhodopsin increased with mol % of cholesterol in disk membranes. No evidence was observed for the direct interaction of cholesterol with rhodopsin in either its agonist- or antagonist-bound form. These results indicate that cholesterol mediates the function of the G protein-coupled receptor, rhodopsin, by influencing membrane lipid properties, i.e. reducing acyl chain packing free volume, rather than interacting specifically with rhodopsin.	NIAAA, Lab Membrane Biochem & Biophys, Sect Fluorescences Studies, NIH, Rockville, MD 20852 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)	Litman, BJ (corresponding author), 12420 Parklawn Dr,Rm 158, Rockville, MD 20852 USA.				NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [Z01AA000080, Z01AA000072, ZIAAA000080] Funding Source: NIH RePORTER	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		Albert AD, 1996, BBA-PROTEIN STRUCT M, V1297, P77, DOI 10.1016/0167-4838(96)00102-1; ALLAIN CC, 1974, CLIN CHEM, V20, P470; ATTWOOD PV, 1980, FEBS LETT, V119, P323, DOI 10.1016/0014-5793(80)80281-X; BARTLETT GR, 1959, J BIOL CHEM, V234, P587; Bastiaanse EML, 1997, CARDIOVASC RES, V33, P272, DOI 10.1016/S0008-6363(96)00193-9; BOESZEBATTAGLIA K, 1989, J BIOL CHEM, V264, P8151; BOESZEBATTAGLIA K, 1990, J BIOL CHEM, V265, P20727; Gimpl G, 1997, BIOCHEMISTRY-US, V36, P10959, DOI 10.1021/bi963138w; Hargrave PA, 2001, INVEST OPHTH VIS SCI, V42, P3; JACKSON ML, 1985, BIOCHIM BIOPHYS ACTA, V812, P369, DOI 10.1016/0005-2736(85)90311-6; JOHNSON BL, 1992, J EXPO ANAL ENV EPID, V1, P1; LAMOLA AA, 1974, BIOCHEMISTRY-US, V13, P738, DOI 10.1021/bi00701a016; LEWIS JW, 1992, J BIOENERG BIOMEMBR, V24, P201, DOI 10.1007/BF00762678; LITMAN BJ, 1996, LIPIDS S, V31, P193; LITMAN BJ, 1996, BIOMEMBRANE, P1; London E, 2000, BBA-BIOMEMBRANES, V1508, P182, DOI 10.1016/S0304-4157(00)00007-1; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MILLER JL, 1986, BIOCHEMISTRY-US, V25, P4983, DOI 10.1021/bi00366a002; Mitchell DC, 1998, BIOPHYS J, V74, P879, DOI 10.1016/S0006-3495(98)74011-1; Mitchell DC, 1998, BIOPHYS J, V75, P896, DOI 10.1016/S0006-3495(98)77578-2; MITCHELL DC, 1992, BIOCHEMISTRY-US, V31, P662, DOI 10.1021/bi00118a005; MITCHELL DC, 1990, BIOCHEMISTRY-US, V29, P9143, DOI 10.1021/bi00491a007; Mitchell DC, 2001, J BIOL CHEM, V276, P42801, DOI 10.1074/jbc.M105772200; Niu SL, 2001, J BIOL CHEM, V276, P42807, DOI 10.1074/jbc.M105778200; NUNEZ MT, 1982, BIOCHEMISTRY-US, V21, P4139, DOI 10.1021/bi00260a034; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; PANT L, 1999, BIOCHEMISTRY-US, V38, P12003; PAPERMASTER DS, 1974, BIOCHEMISTRY-US, V13, P2438, DOI 10.1021/bi00708a031; Polozova A, 2000, BIOPHYS J, V79, P2632, DOI 10.1016/S0006-3495(00)76502-7; Seno K, 2001, J BIOL CHEM, V276, P20813, DOI 10.1074/jbc.C100032200; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; SMITH HG, 1982, METHOD ENZYMOL, V81, P57; Sooksawate T, 2001, NEUROPHARMACOLOGY, V40, P178, DOI 10.1016/S0028-3908(00)00159-3; STINSON AM, 1991, EXP EYE RES, V52, P213, DOI 10.1016/0014-4835(91)90261-C; STRAUME M, 1987, BIOCHEMISTRY-US, V26, P5121, DOI 10.1021/bi00390a034; STRAUME M, 1990, BIOCHEMISTRY-US, V29, P9135, DOI 10.1021/bi00491a006; STRAUME M, 1987, BIOCHEMISTRY-US, V26, P5113, DOI 10.1021/bi00390a033; YOSHIZAWA T, 1984, VISION RES, V24, P1455, DOI 10.1016/0042-6989(84)90306-7; Yuan C, 1998, COMP BIOCHEM PHYS B, V120, P785, DOI 10.1016/S0305-0491(98)10079-2	39	115	118	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 7	2002	277	23					20139	20145		10.1074/jbc.M200594200	http://dx.doi.org/10.1074/jbc.M200594200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	562NJ	11889130	Green Submitted, hybrid			2022-12-27	WOS:000176204500008
J	Hang, J; Dasso, M				Hang, J; Dasso, M			Association of the human SUMO-1 protease SENP2 with the nuclear pore	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTPASE-ACTIVATING PROTEIN; AXIN-BINDING PROTEIN; NUCLEOPORIN NUP153; COMPLEX PROTEIN; UBIQUITIN; IMPORT; RANGAP1; EXPORT; YEAST; LOCALIZATION	SUMO-1 is a small ubiquitin-like protein that can be covalently conjugated to other proteins. A family of proteases catalyzes deconjugation of SUMO-1-containing species. Members of this family also process newly synthesized SUMO-1 into its conjugatable form. To understand these enzymes better, we have examined the localization and behavior of the human SUMO-1 protease SENP2. Here we have shown that SENP2 associates with the nuclear face of nuclear pores and that this association requires protein sequences near the N terminus of SENP2. We have also shown that SENP2 binds to Nup153, a nucleoporin that is localized to the nucleoplasmic face of the pore. Nup153 binding requires the same domain of SENP2 that mediates its targeting in vivo. Removal of the Nup153-interacting region of SENP2 results in a significant change in the spectrum of SUMO-1 conjugates within the cell. Our results suggest that association with the pore plays an important negative role in the regulation of SENP2, perhaps by restricting its activity to a subset of the conjugated proteins within the nucleus.	NICHHD, Lab Gene Regulat & Dev, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Dasso, M (corresponding author), NICHHD, Lab Gene Regulat & Dev, NIH, Bethesda, MD 20892 USA.			Dasso, Mary/0000-0002-5410-1371	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD001902] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD001902] Funding Source: NIH RePORTER; NICHD NIH HHS [Z01 HD 01902-05] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ADAM SA, 1990, J CELL BIOL, V111, P807, DOI 10.1083/jcb.111.3.807; Azuma Y, 2001, FASEB J, V15, P1825, DOI 10.1096/fj.00-0818fje; Gong LM, 2000, J BIOL CHEM, V275, P3355, DOI 10.1074/jbc.275.5.3355; Kadoya T, 2000, J BIOL CHEM, V275, P37030, DOI 10.1074/jbc.M005984200; Kim KI, 2000, J BIOL CHEM, V275, P14102, DOI 10.1074/jbc.275.19.14102; Li SJ, 2000, MOL CELL BIOL, V20, P2367, DOI 10.1128/MCB.20.7.2367-2377.2000; Li SJ, 1999, NATURE, V398, P246, DOI 10.1038/18457; Love DC, 1998, P NATL ACAD SCI USA, V95, P10608, DOI 10.1073/pnas.95.18.10608; Mahajan R, 1997, CELL, V88, P97, DOI 10.1016/S0092-8674(00)81862-0; Matunis MJ, 1996, J CELL BIOL, V135, P1457, DOI 10.1083/jcb.135.6.1457; Matunis MJ, 1998, J CELL BIOL, V140, P499, DOI 10.1083/jcb.140.3.499; MEIER E, 1995, J CELL BIOL, V129, P1459, DOI 10.1083/jcb.129.6.1459; Melchior F, 2000, ANNU REV CELL DEV BI, V16, P591, DOI 10.1146/annurev.cellbio.16.1.591; Nishida T, 2000, EUR J BIOCHEM, V267, P6423, DOI 10.1046/j.1432-1327.2000.01729.x; Nishida T, 2001, J BIOL CHEM, V276, P39060, DOI 10.1074/jbc.M103955200; PANTE N, 1994, J CELL BIOL, V126, P603, DOI 10.1083/jcb.126.3.603; Pichler A, 2002, CELL, V108, P109, DOI 10.1016/S0092-8674(01)00633-X; Powers MA, 1997, J CELL BIOL, V136, P241, DOI 10.1083/jcb.136.2.241; Senger B, 1998, EMBO J, V17, P2196, DOI 10.1093/emboj/17.8.2196; SMYTHE C, 1991, METHOD CELL BIOL, V35, P449; Sternsdorf T, 1999, J BIOL CHEM, V274, P12555, DOI 10.1074/jbc.274.18.12555; Strunnikov AV, 2001, GENETICS, V158, P95; SUKEGAWA J, 1993, CELL, V72, P29, DOI 10.1016/0092-8674(93)90047-T; Takahashi Y, 2000, J BIOCHEM-TOKYO, V128, P723, DOI 10.1093/oxfordjournals.jbchem.a022807; Ullman KS, 1999, MOL BIOL CELL, V10, P649, DOI 10.1091/mbc.10.3.649; Vasu SK, 2001, CURR OPIN CELL BIOL, V13, P363, DOI 10.1016/S0955-0674(00)00221-0; Walther TC, 2001, EMBO J, V20, P5703, DOI 10.1093/emboj/20.20.5703; Yeh ETH, 2000, GENE, V248, P1, DOI 10.1016/S0378-1119(00)00139-6	28	189	200	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 31	2002	277	22					19961	19966		10.1074/jbc.M201799200	http://dx.doi.org/10.1074/jbc.M201799200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	557EH	11896061	hybrid			2022-12-27	WOS:000175894800095
J	Karmakar, P; Piotrowski, J; Brosh, RM; Sommers, JA; Miller, SPL; Cheng, WH; Snowden, CM; Ramsden, DA; Bohr, VA				Karmakar, P; Piotrowski, J; Brosh, RM; Sommers, JA; Miller, SPL; Cheng, WH; Snowden, CM; Ramsden, DA; Bohr, VA			Werner protein is a target of DNA-dependent protein kinase in vivo and in vitro, and its catalytic activities are regulated by phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HELICASE ACTIVITY; SYNDROME CELLS; STRANDED-DNA; WRN PROTEIN; KU; BINDING; SUBUNIT; DAMAGE; INHIBITION; PHENOTYPE	Human Werner Syndrome is characterized by early onset of aging, elevated chromosomal instability, and a high incidence of cancer. Werner protein (WRN) is a member of the recQ gene family, but unlike other members of the recQ family, it contains a unique 3'-->5' exonuclease activity. We have reported previously that human Ku heterodimer interacts physically with WRN and functionally stimulates WRN exonuclease activity. Because Ku and DNA-PKcs, the catalytic subunit of DNA-dependent protein kinase (DNA-PK), form a complex at DNA ends, we have now explored the possibility of functional modulation of WRN exonuclease activity by DNA-PK. We find that although DNA-PKcs alone does not affect the WRN exonuclease activity, the additional presence of Ku mediates a marked inhibition of it. The inhibition of WRN exonuclease by DNA-PKcs requires the kinase activity of DNA-PKcs. WRN is a target for DNA-PKcs phosphorylation, and this phosphorylation requires the presence of Ku. We also find that treatment of recombinant WRN with a Ser/Thr phosphatase enhances WRN exonuclease and helicase activities and that WRN catalytic activity can be inhibited by rephosphorylation of WRN with DNA-PK. Thus, the level of phosphorylation of WRN appears to regulate its catalytic activities. WRN forms a complex, both in vitro and in vivo, with DNA-PKC. WRN is phosphorylated in vivo after treatment of cells with DNA-damaging agents in a pathway that requires DNA-PKcs. Thus, WRN protein is a target for DNA-PK phosphorylation in vitro and in vivo, and this phosphorylation may be a way of regulating its different catalytic activities, possibly in the repair of DNA dsb.	NIA, Lab Mol Gerontol, NIH, Baltimore, MD 21224 USA; Univ Calgary, Dept Biochem & Mol Biol, Calgary, AB T2N 1N4, Canada; Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA; Univ N Carolina, Curriculum Genet & Mol Biol, Chapel Hill, NC 27599 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); University of Calgary; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Bohr, VA (corresponding author), NIA, Lab Mol Gerontol, NIH, Box 1,5600 Nathan Shock Dr, Baltimore, MD 21224 USA.	vbohr@nih.gov	Bohr, Vilhelm/AAP-5931-2020	Ramsden, Dale/0000-0003-1575-4748; Lees-Miller, Susan/0000-0001-5809-2516	NCI NIH HHS [CA84442-01, R01 CA084442] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA084442] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [Z01AG000726, Z01AG000741] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Anderson Carl W., 1992, Critical Reviews in Eukaryotic Gene Expression, V2, P283; Anderson CW, 2000, RADIAT RES, V154, P473, DOI 10.1667/0033-7587(2000)154[0473:HTFTMG]2.0.CO;2; Balajee AS, 1999, MOL BIOL CELL, V10, P2655, DOI 10.1091/mbc.10.8.2655; Barbaro BA, 2000, J VIROL, V74, P8601, DOI 10.1128/JVI.74.18.8601-8613.2000; Barlev NA, 1998, MOL CELL BIOL, V18, P1349, DOI 10.1128/MCB.18.3.1349; Baumann P, 1998, TRENDS BIOCHEM SCI, V23, P247, DOI 10.1016/S0968-0004(98)01232-8; Bohr VA, 2000, EXP GERONTOL, V35, P695, DOI 10.1016/S0531-5565(00)00145-5; Brosh RM, 1999, J BIOL CHEM, V274, P18341, DOI 10.1074/jbc.274.26.18341; Brosh RM, 2001, J BIOL CHEM, V276, P3024, DOI 10.1074/jbc.M006784200; Chan DW, 1996, BIOCHEM CELL BIOL, V74, P67, DOI 10.1139/o96-007; Chan DW, 1998, INT J RADIAT BIOL, V74, P217, DOI 10.1080/095530098141591; Chan DW, 1996, J BIOL CHEM, V271, P8936, DOI 10.1074/jbc.271.15.8936; Cooper MP, 2000, GENE DEV, V14, P907; Douglas P, 2001, J BIOL CHEM, V276, P18992, DOI 10.1074/jbc.M011703200; Dynan WS, 1998, NUCLEIC ACIDS RES, V26, P1551, DOI 10.1093/nar/26.7.1551; Featherstone C, 1999, MUTAT RES-DNA REPAIR, V434, P3, DOI 10.1016/S0921-8777(99)00006-3; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES; FUKUCHI K, 1989, P NATL ACAD SCI USA, V86, P5893, DOI 10.1073/pnas.86.15.5893; Gell D, 1999, NUCLEIC ACIDS RES, V27, P3494, DOI 10.1093/nar/27.17.3494; Giffin W, 1996, NATURE, V380, P265, DOI 10.1038/380265a0; Gray MD, 1997, NAT GENET, V17, P100, DOI 10.1038/ng0997-100; Grigorova M, 2000, MUTAGENESIS, V15, P303, DOI 10.1093/mutage/15.4.303; Gu YS, 1997, IMMUNITY, V7, P653, DOI 10.1016/S1074-7613(00)80386-6; Huang SR, 1998, NAT GENET, V20, P114, DOI 10.1038/2410; Ishimi Y, 2000, J BIOL CHEM, V275, P16235, DOI 10.1074/jbc.M909040199; Izzard RA, 1999, CANCER RES, V59, P2581; Jeggo PA, 1998, ADV GENET, V38, P185, DOI 10.1016/S0065-2660(08)60144-3; Kamath-Loeb AS, 1998, J BIOL CHEM, V273, P34145, DOI 10.1074/jbc.273.51.34145; Kurimasa A, 1999, MOL CELL BIOL, V19, P3877; Lebel M, 1998, P NATL ACAD SCI USA, V95, P13097, DOI 10.1073/pnas.95.22.13097; LEESMILLER SP, 1995, SCIENCE, V267, P1183, DOI 10.1126/science.7855602; Li BM, 2000, J BIOL CHEM, V275, P39800; Machwe A, 2000, NUCLEIC ACIDS RES, V28, P2762, DOI 10.1093/nar/28.14.2762; Martin GM, 1996, NAT GENET, V13, P25, DOI 10.1038/ng0596-25; MARTIN GM, 1970, LAB INVEST, V23, P86; McElhinny SAN, 2000, MOL CELL BIOL, V20, P2996, DOI 10.1128/MCB.20.9.2996-3003.2000; Nuesch JPF, 1998, J VIROL, V72, P9966; Nussenzweig A, 1997, P NATL ACAD SCI USA, V94, P13588, DOI 10.1073/pnas.94.25.13588; Ogburn CE, 1997, HUM GENET, V101, P121, DOI 10.1007/s004390050599; Orren DK, 1999, NUCLEIC ACIDS RES, V27, P3557, DOI 10.1093/nar/27.17.3557; Poot M, 2001, FASEB J, V15, P1224, DOI 10.1096/fj.00-0611fje; Shen JC, 1998, NUCLEIC ACIDS RES, V26, P2879, DOI 10.1093/nar/26.12.2879; Singleton BK, 1997, MOL CELL BIOL, V17, P1264, DOI 10.1128/MCB.17.3.1264; Smith GCM, 1999, GENE DEV, V13, P916, DOI 10.1101/gad.13.8.916; Spillare EA, 1999, GENE DEV, V13, P1355, DOI 10.1101/gad.13.11.1355; STEFANINI M, 1989, MUTAT RES, V219, P179, DOI 10.1016/0921-8734(89)90013-1; Ting NSY, 1998, J BIOL CHEM, V273, P2136, DOI 10.1074/jbc.273.4.2136; TUTEJA N, 1994, EMBO J, V13, P4991, DOI 10.1002/j.1460-2075.1994.tb06826.x; Vogel H, 1999, P NATL ACAD SCI USA, V96, P10770, DOI 10.1073/pnas.96.19.10770; VOIT R, 1995, NUCLEIC ACIDS RES, V23, P2593, DOI 10.1093/nar/23.14.2593; Yannone SM, 2001, J BIOL CHEM, V276, P38242; Yu CE, 1996, SCIENCE, V272, P258, DOI 10.1126/science.272.5259.258	52	127	132	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 24	2002	277	21					18291	18302		10.1074/jbc.M111523200	http://dx.doi.org/10.1074/jbc.M111523200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	558PM	11889123	hybrid, Green Published			2022-12-27	WOS:000175975800008
J	Karthikeyan, S; Leung, TL; Ladias, JAA				Karthikeyan, S; Leung, TL; Ladias, JAA			Structural determinants of the Na+/H+ exchanger regulatory factor interaction with the beta(2) adrenergic and platelet-derived growth factor receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSMEMBRANE CONDUCTANCE REGULATOR; PDZ-DOMAIN; CRYSTAL-STRUCTURE; BETA(2)-ADRENERGIC RECEPTOR; LIGAND INTERACTIONS; NHE-RF; PROTEIN; RECOGNITION; PEPTIDE; PROGRAM	The Na+/H+ exchanger regulatory factor (NHERF) binds through its PDZ1 domain to the carboxyl-terminal sequences NDSLL and EDSFL of the beta(2) adrenergic receptor (beta(2)AR) and platelet-derived growth factor receptor, respectively, and plays a critical role in the membrane localization and physiological regulation of these receptors. The crystal structures of the human NHERF PDZ1 domain bound to the sequences NDSLL and EDSFL have been determined at 1.9- and 2.2-Angstrom resolution, respectively. The beta(2)AR and platelet-derived growth factor receptor ligands insert into the PDZ1 binding pocket by a beta-sheet augmentation process and are stabilized by largely similar networks of hydrogen bonds and hydrophobic contacts. In the PDZ1-beta(2)AR complex, the side chain of asparagine at position -4 in the beta(2)AR peptide forms two additional hydrogen bonds with Gly(30) of PDZ1, which contribute to the higher affinity of this interaction. Remarkably, both complexes are further stabilized by hydrophobic interactions involving the side chains of the penultimate amino acids of the peptide ligands, whereas the PDZ1 residues Asn(22) and Glu(43) undergo conformational changes to accommodate these side chains. These results provide structural insights into the mechanisms by which different side chains at the position -1 of peptide ligands interact with PDZ domains and contribute to the affinity of the PDZ-ligand interaction.	Harvard Univ, Sch Med, Inst Med, Div Expt Med,Mol Med Lab, Boston, MA 02115 USA; Harvard Univ, Sch Med, Inst Med, Div Expt Med,Macromol Crystallog Unit, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	Ladias, JAA (corresponding author), Harvard Univ, Sch Med, Inst Med, Div Expt Med,Mol Med Lab, Rm 354,4 Blackfan Circle, Boston, MA 02115 USA.		Karthikeyan, Subramanian/F-8808-2010					Cabral JHM, 1996, NATURE, V382, P649, DOI 10.1038/382649a0; Cao TT, 1999, NATURE, V401, P286, DOI 10.1038/45816; Daniels DL, 1998, NAT STRUCT BIOL, V5, P317, DOI 10.1038/nsb0498-317; Doyle DA, 1996, CELL, V85, P1067, DOI 10.1016/S0092-8674(00)81307-0; Ediger TR, 1999, ENDOCRINOLOGY, V140, P2976, DOI 10.1210/en.140.7.2976; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; Fuh G, 2000, J BIOL CHEM, V275, P21486, DOI 10.1074/jbc.275.28.21486; Hall RA, 1998, NATURE, V392, P626, DOI 10.1038/33458; Hall RA, 1998, P NATL ACAD SCI USA, V95, P8496, DOI 10.1073/pnas.95.15.8496; Harris BZ, 2001, J CELL SCI, V114, P3219; Harrison SC, 1996, CELL, V86, P341, DOI 10.1016/S0092-8674(00)80105-1; Hillier BJ, 1999, SCIENCE, V284, P812, DOI 10.1126/science.284.5415.812; Hung AY, 2002, J BIOL CHEM, V277, P5699, DOI 10.1074/jbc.R100065200; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Karthikeyan S, 2001, J BIOL CHEM, V276, P19683, DOI 10.1074/jbc.C100154200; Karthikeyan S, 2001, J MOL BIOL, V308, P963, DOI 10.1006/jmbi.2001.4634; Kimple ME, 2001, EMBO J, V20, P4414, DOI 10.1093/emboj/20.16.4414; Kozlov G, 2000, BIOCHEMISTRY-US, V39, P2572, DOI 10.1021/bi991913c; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; MacDonald TJ, 2001, NAT GENET, V29, P143, DOI 10.1038/ng731; Maudsley S, 2000, MOL CELL BIOL, V20, P8352, DOI 10.1128/MCB.20.22.8352-8363.2000; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Moyer BD, 2000, J BIOL CHEM, V275, P27069; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Murthy A, 1998, J BIOL CHEM, V273, P1273, DOI 10.1074/jbc.273.3.1273; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Raghuram V, 2001, P NATL ACAD SCI USA, V98, P1300, DOI 10.1073/pnas.031538898; Reczek D, 1997, J CELL BIOL, V139, P169, DOI 10.1083/jcb.139.1.169; Schultz J, 1998, NAT STRUCT BIOL, V5, P19, DOI 10.1038/nsb0198-19; Shenolikar S, 2001, AM J PHYSIOL-RENAL, V280, pF389, DOI 10.1152/ajprenal.2001.280.3.F389; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; Stemmer-Rachamimov AO, 2001, AM J PATHOL, V158, P57, DOI 10.1016/S0002-9440(10)63944-2; Tochio H, 1999, NAT STRUCT BIOL, V6, P417; Vagin A, 1997, J APPL CRYSTALLOGR, V30, P1022, DOI 10.1107/S0021889897006766; WALLACE AC, 1995, PROTEIN ENG, V8, P127, DOI 10.1093/protein/8.2.127; Wang SS, 1998, FEBS LETT, V427, P103, DOI 10.1016/S0014-5793(98)00402-5; WEINMAN EJ, 1995, J CLIN INVEST, V95, P2143, DOI 10.1172/JCI117903	38	67	71	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 24	2002	277	21					18973	18978		10.1074/jbc.M201507200	http://dx.doi.org/10.1074/jbc.M201507200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	558PM	11882663	hybrid			2022-12-27	WOS:000175975800095
J	Potamitou, A; Holmgren, A; Vlamis-Gardikas, A				Potamitou, A; Holmgren, A; Vlamis-Gardikas, A			Protein levels of Escherichia coli thioredoxins and glutaredoxins and their relation to null mutants, growth phase, and function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DISULFIDE BOND FORMATION; OXYR TRANSCRIPTION FACTOR; SENSITIVE SANDWICH ELISA; HYDROGEN-PEROXIDE; OXIDATIVE STRESS; IN-VIVO; RIBONUCLEOTIDE REDUCTASE; GENE-EXPRESSION; HUMAN SERUM; GLUTATHIONE	Levels of Escherichia coli thioredoxin 1 (Trx1), Trx2, glutaredoxin 1 (Grx1), Grx2, and Grx3 have been determined by novel sensitive sandwich enzyme-linked immunosorbent assay. In a wild type strain, levels of Trx1 increased from the exponential to the stationary phase of growth (1.5-fold to 3400 ng/mg), as did levels of Grx2 (from similar to2500 to similar to8000 ng/mg). Grx3 and Trx2 levels were quite stable during growth (similar to4500 and similar to200 ng/mg, respectively). Grx1 levels decreased from similar to600 ng/mg at the exponential phase to similar to285 ng/mg at the stationary phase. A large elevation of Grx1 (20-30-fold), was observed in null mutants for the thioredoxin system whereas levels of the other redoxins in all combinations of examined null mutants barely exceeded a 2-3-fold increase. Measurements of thymidine incorporation in newly synthesized DNA suggested that mainly Grx1 and, to a lesser extent, Trx1 contribute to the reduction of ribonucleotides. All glutaredoxin species were elevated in catalase-deficient strains, implying an antioxidant role for the glutaredoxins. Trx1, Trx2, and Grx1 levels increased after exposure to hydrogen peroxide and decreased after exposure to mercaptoethanol. The levels of Grx2 and Grx3 behaved exactly the opposite, suggesting that the transcription factor OxyR does not regulate their expression.	Karolinska Inst, Dept Med Biochem & Biophys, Med Nobel Inst Biochem, S-17177 Stockholm, Sweden	Karolinska Institutet	Holmgren, A (corresponding author), Karolinska Inst, Dept Med Biochem & Biophys, Med Nobel Inst Biochem, S-17177 Stockholm, Sweden.		Fernandes, Aristi/D-2507-2015; Vlamis, Alexios/AAF-5152-2020	Vlamis, Alexios/0000-0001-5068-6459				Arnold CN, 2001, J BACTERIOL, V183, P2178, DOI 10.1128/JB.183.7.2178-2186.2001; Aslund F, 1999, P NATL ACAD SCI USA, V96, P6161, DOI 10.1073/pnas.96.11.6161; ASLUND F, 1994, P NATL ACAD SCI USA, V91, P9813, DOI 10.1073/pnas.91.21.9813; BECKERHAPAK M, 1995, FEMS MICROBIOL LETT, V134, P39, DOI 10.1111/j.1574-6968.1995.tb07911.x; Bjornberg O, 1991, Protein Expr Purif, V2, P287, DOI 10.1016/1046-5928(91)90085-W; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CARLIN A, 1995, J BACTERIOL, V177, P981, DOI 10.1128/jb.177.4.981-986.1995; Cashel M., 1996, ESCHERICHIA COLI SAL, P1458; CHRISTMAN MF, 1985, CELL, V41, P753, DOI 10.1016/S0092-8674(85)80056-8; Das KC, 1998, J IMMUNOL METHODS, V211, P9, DOI 10.1016/S0022-1759(97)00163-4; Davis R., 1980, ADV BACTERIAL GENETI; DERMAN AI, 1993, SCIENCE, V262, P1744, DOI 10.1126/science.8259521; DYSON HJ, 1989, BIOCHEMISTRY-US, V28, P7074, DOI 10.1021/bi00443a044; FISHER MT, 1992, J BIOL CHEM, V267, P1872; Gallardo-Madueno R, 1998, J BIOL CHEM, V273, P18382, DOI 10.1074/jbc.273.29.18382; Hengge-Aronis R., 1996, ESCHERICHIA COLI SAL, V5, P1497; HOLMGREN A, 1985, ANNU REV BIOCHEM, V54, P237, DOI 10.1146/annurev.bi.54.070185.001321; HOLMGREN A, 1979, J BIOL CHEM, V254, P3672; HOLMGREN A, 1989, J BIOL CHEM, V264, P13963; Lillig CH, 1999, J BIOL CHEM, V274, P7695, DOI 10.1074/jbc.274.12.7695; LIU JY, 1995, BIOCHEMISTRY-US, V34, P13472, DOI 10.1021/bi00041a026; Miranda-Vizuete A, 1997, J BIOL CHEM, V272, P30841, DOI 10.1074/jbc.272.49.30841; MirandaVizuete A, 1996, J BIOL CHEM, V271, P19099, DOI 10.1074/jbc.271.32.19099; Monje-Casas F, 2001, J BIOL CHEM, V276, P18031, DOI 10.1074/jbc.M011728200; NOE G, 1992, BRIT J HAEMATOL, V80, P285; Prieto-Alamo MJ, 2000, J BIOL CHEM, V275, P13398, DOI 10.1074/jbc.275.18.13398; Prinz WA, 1997, J BIOL CHEM, V272, P15661, DOI 10.1074/jbc.272.25.15661; Ritz D, 2000, J BIOL CHEM, V275, P2505, DOI 10.1074/jbc.275.4.2505; RUSSEL M, 1988, P NATL ACAD SCI USA, V85, P990, DOI 10.1073/pnas.85.4.990; Shi J, 1999, J BIOL CHEM, V274, P36039, DOI 10.1074/jbc.274.51.36039; Stewart EJ, 1998, EMBO J, V17, P5543, DOI 10.1093/emboj/17.19.5543; Takemoto T, 1998, FREE RADICAL BIO MED, V24, P556, DOI 10.1016/S0891-5849(97)00287-6; Tao K, 1997, J BACTERIOL, V179, P5967, DOI 10.1128/jb.179.18.5967-5970.1997; Vlamis-Gardikas A, 2002, J BIOL CHEM, V277, P10861, DOI 10.1074/jbc.M111024200; Vlamis-Gardikas A, 2002, METHOD ENZYMOL, V347, P286; VlamisGardikas A, 1997, J BIOL CHEM, V272, P11236; Xia B, 2001, J MOL BIOL, V310, P907, DOI 10.1006/jmbi.2001.4721; YONEI S, 1987, BIOCHEM BIOPH RES CO, V143, P638, DOI 10.1016/0006-291X(87)91401-X; Zheng M, 1998, SCIENCE, V279, P1718, DOI 10.1126/science.279.5357.1718; Zheng M, 2001, J BACTERIOL, V183, P4562, DOI 10.1128/JB.183.15.4562-4570.2001	40	53	59	2	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 24	2002	277	21					18561	18567		10.1074/jbc.M201225200	http://dx.doi.org/10.1074/jbc.M201225200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	558PM	11893749	hybrid			2022-12-27	WOS:000175975800042
J	Spencer, ML; Shao, H; Tucker, HM; Andres, DA				Spencer, ML; Shao, H; Tucker, HM; Andres, DA			Nerve Growth Factor-dependent activation of the small GTPase rin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEURITE OUTGROWTH; MAP KINASE; SIGNAL-TRANSDUCTION; PC12 CELLS; NEURONAL DIFFERENTIATION; PHEOCHROMOCYTOMA CELLS; EXCHANGE FACTORS; RHO GTPASES; RAS; PROTEIN	The Rit and Rin proteins comprise a distinct and evolutionarily conserved subfamily of Ras-related small GTPases. Although we have defined a role for Rit-mediated signal transduction in the regulation of cell proliferation and transformation, the function of Rin remains largely unknown. Because we demonstrate that Rin is developmentally regulated and expressed in adult neurons, we examined its role in neuronal signaling. In this study, we show that stimulation of PC6 cells with either epidermal growth factor or nerve growth factor (NGF) results in rapid activation of Rin. This activation correlates with the onset of Ras activation, and dominant-negative Ras completely inhibits Rin activation induced by NGF. Further examination of Ras-mediated Rin activation suggests that this process is dependent upon neuronally expressed regulatory factors. Expression of mutationally activated H-Ras fails to activate Rin in non-neuronal cells, but results in potent stimulation of Rin-GTP levels in a variety of neuronal cell lines. Furthermore, although constitutively activated Rin does not induce neurite outgrowth on its own, both NGF-induced and oncogenic Ras-induced neurite outgrowth were inhibited by the expression of dominant-negative Rin. Together, these studies indicate that Rin activation is a direct downstream effect of growth factor-dependent signaling in neuronal cells and suggest that Rin may function to transduce signals within the mature nervous system.	Univ Kentucky, Coll Med, Dept Mol & Cellular Biochem, Lexington, KY 40536 USA; Univ Kentucky, Coll Med, Dept Physiol, Lexington, KY 40536 USA	University of Kentucky; University of Kentucky	Andres, DA (corresponding author), Univ Kentucky, Coll Med, Dept Mol & Cellular Biochem, 800 Rose St, Lexington, KY 40536 USA.	dandres@pop.uky.edu						Andres DA, 1997, ARCH BIOCHEM BIOPHYS, V346, P113, DOI 10.1006/abbi.1997.0296; Bar-Sagi D, 2000, CELL, V103, P227, DOI 10.1016/S0092-8674(00)00115-X; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BARSAGI D, 1985, CELL, V42, P841, DOI 10.1016/0092-8674(85)90280-6; Bibel M, 2000, GENE DEV, V14, P2919, DOI 10.1101/gad.841400; Bos JL, 1998, EMBO J, V17, P6776, DOI 10.1093/emboj/17.23.6776; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BURSTEIN DE, 1978, P NATL ACAD SCI USA, V75, P6059, DOI 10.1073/pnas.75.12.6059; Campbell SL, 1998, ONCOGENE, V17, P1395, DOI 10.1038/sj.onc.1202174; CHANDLER CE, 1983, J CELL PHYSIOL, V114, P321, DOI 10.1002/jcp.1041140311; Chen XQ, 1999, J BIOL CHEM, V274, P19901, DOI 10.1074/jbc.274.28.19901; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; Curtis J, 1999, J NEUROSCI RES, V58, P88, DOI 10.1002/(SICI)1097-4547(19991001)58:1<88::AID-JNR9>3.3.CO;2-I; Daniels RH, 1998, EMBO J, V17, P754, DOI 10.1093/emboj/17.3.754; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; deRooij J, 1997, ONCOGENE, V14, P623, DOI 10.1038/sj.onc.1201005; ESTUS S, 1994, J CELL BIOL, V127, P1717, DOI 10.1083/jcb.127.6.1717; Estus S, 1997, J NEUROSCI, V17, P7736; Feig LA, 1999, NAT CELL BIOL, V1, pE25, DOI 10.1038/10018; Finlin BS, 1997, J BIOL CHEM, V272, P21982, DOI 10.1074/jbc.272.35.21982; Finlin BS, 2000, BIOCHEM J, V347, P223, DOI 10.1042/0264-6021:3470223; FUKUDA M, 1995, ONCOGENE, V11, P239; Furukawa K, 1997, J CELL BIOL, V136, P1137, DOI 10.1083/jcb.136.5.1137; GREENE LA, 1995, CURR OPIN NEUROBIOL, V5, P579, DOI 10.1016/0959-4388(95)80062-X; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; Grewal SS, 1999, CURR OPIN NEUROBIOL, V9, P544, DOI 10.1016/S0959-4388(99)00010-0; GUERRERO I, 1986, J CELL PHYSIOL, V129, P71, DOI 10.1002/jcp.1041290111; HAGAG N, 1986, NATURE, V319, P680, DOI 10.1038/319680a0; Hofer F, 1998, CURR BIOL, V8, P839, DOI 10.1016/S0960-9822(98)70327-6; HOFER F, 1994, P NATL ACAD SCI USA, V91, P11089, DOI 10.1073/pnas.91.23.11089; HUFF K, 1981, J CELL BIOL, V88, P189, DOI 10.1083/jcb.88.1.189; Impey S, 1999, NEURON, V23, P11, DOI 10.1016/S0896-6273(00)80747-3; Kao SC, 2001, J BIOL CHEM, V276, P18169, DOI 10.1074/jbc.M008870200; Kaplan DR, 1997, CURR OPIN CELL BIOL, V9, P213, DOI 10.1016/S0955-0674(97)80065-8; Kaplan DR, 2000, CURR OPIN NEUROBIOL, V10, P381, DOI 10.1016/S0959-4388(00)00092-1; KREMER NE, 1991, J CELL BIOL, V115, P809, DOI 10.1083/jcb.115.3.809; Lee CHJ, 1996, J NEUROSCI, V16, P6784; Luo LQ, 2000, NAT REV NEUROSCI, V1, P173, DOI 10.1038/35044547; Malumbres M, 1998, FRONT BIOSCI-LANDMRK, V3, P887; Marshall CJ, 1996, CURR OPIN CELL BIOL, V8, P197, DOI 10.1016/S0955-0674(96)80066-4; NODA M, 1985, NATURE, V318, P73, DOI 10.1038/318073a0; Orban PC, 1999, TRENDS NEUROSCI, V22, P38, DOI 10.1016/S0166-2236(98)01306-X; PITTMAN RN, 1993, J NEUROSCI, V13, P3669; QUILLIAM LA, 1995, BIOESSAYS, V17, P395, DOI 10.1002/bies.950170507; Quilliam LA, 2001, METHOD ENZYMOL, V333, P187; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; RodriguezViciana P, 1996, EMBO J, V15, P2442, DOI 10.1002/j.1460-2075.1996.tb00602.x; Rusyn EV, 2000, ONCOGENE, V19, P4685, DOI 10.1038/sj.onc.1203836; Sarner S, 2000, MOL CELL BIOL, V20, P158, DOI 10.1128/MCB.20.1.158-172.2000; Segal RA, 1996, ANNU REV NEUROSCI, V19, P463, DOI 10.1146/annurev.ne.19.030196.002335; Shao HP, 2000, J BIOL CHEM, V275, P26914; Shao HP, 1999, ARCH BIOCHEM BIOPHYS, V371, P207, DOI 10.1006/abbi.1999.1448; SZEBERENYI J, 1990, MOL CELL BIOL, V10, P5324, DOI 10.1128/MCB.10.10.5324; Takai Y, 2001, PHYSIOL REV, V81, P153, DOI 10.1152/physrev.2001.81.1.153; Taylor SJ, 1996, CURR BIOL, V6, P1621, DOI 10.1016/S0960-9822(02)70785-9; Urano T, 1996, EMBO J, V15, P810, DOI 10.1002/j.1460-2075.1996.tb00416.x; VAN AL, 1997, GENE DEV, V11, P2295; Wes PD, 1996, EMBO J, V15, P5839, DOI 10.1002/j.1460-2075.1996.tb00971.x; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; Wolthuis RMF, 1998, CURR BIOL, V8, P471, DOI 10.1016/S0960-9822(98)70183-6; Wolthuis RMF, 1999, CURR OPIN GENET DEV, V9, P112, DOI 10.1016/S0959-437X(99)80016-1; WOOD KW, 1993, P NATL ACAD SCI USA, V90, P5016, DOI 10.1073/pnas.90.11.5016; York RD, 1998, NATURE, V392, P622, DOI 10.1038/33451; Zwartkruis FJT, 1998, EMBO J, V17, P5905, DOI 10.1093/emboj/17.20.5905	65	25	27	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 17	2002	277	20					17605	17615		10.1074/jbc.M111400200	http://dx.doi.org/10.1074/jbc.M111400200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	553PR	11877426	hybrid			2022-12-27	WOS:000175685100029
J	Tseng, Y; An, KM; Wirtz, D				Tseng, Y; An, KM; Wirtz, D			Microheterogeneity controls the rate of gelation of actin filament networks	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIFFUSING WAVE SPECTROSCOPY; PARTICLE-TRACKING MICRORHEOLOGY; DYNAMIC CROSS-LINKING; ALPHA-ACTININ; MECHANICAL-PROPERTIES; F-ACTIN; ARP2/3 COMPLEX; VISCOELASTICITY; POLYMERIZATION; POLYMERS	Rapid sol-gel transitions of the actin cytoskeleton are required for many key cellular processes, including cell spreading and cell locomotion. Actin monomers assemble into semiflexible polymers that rapidly intertwine into a network, a process that in vitro takes similar to1 min for an actin concentration of 1 mg/ml. The same actin filament network, however, takes similar to1 h to exhibit a steadystate elasticity. We hypothesize that the slow gelation of F-actin is due to the slow establishment of a homogeneous meshwork. Using a novel method, time-resolved multiple particle tracking, which monitors the range of thermally excited displacements of microspheres imbedded in the network, we show that the increase in elasticity in a polymerizing solution of actin parallels the progressive decline of the network microheterogeneity. The rates of gelation and network homogenization slightly decrease with actin concentration and in the presence of the F-actin cross-linking proteins alpha-actinin and fascin, whereas the rate of actin polymerization increases dramatically with actin concentration. Our measurements show that the slow spatial homogenization of the actin filament network, not actin polymerization or the formation of polymer overlaps, is the rate-limiting step in the establishment of an elastic actin network and suggest that a new activity of F-actin binding proteins may be required for the rapid formation of a homogeneous stiff gel.	Johns Hopkins Univ, Dept Chem Engn, Baltimore, MD 21218 USA; Johns Hopkins Univ, Program Mol Biophys, Baltimore, MD 21218 USA; Johns Hopkins Univ, Dept Mat Sci & Engn, Baltimore, MD 21218 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University	Wirtz, D (corresponding author), Johns Hopkins Univ, Dept Chem Engn, Baltimore, MD 21218 USA.		Wirtz, Denis/A-3257-2010					Amblard F, 1996, PHYS REV LETT, V77, P4470, DOI 10.1103/PhysRevLett.77.4470; Andrianantoandro E, 2001, J MOL BIOL, V312, P721, DOI 10.1006/jmbi.2001.5005; Apgar J, 2000, BIOPHYS J, V79, P1095, DOI 10.1016/S0006-3495(00)76363-6; Borisy GG, 2000, CURR OPIN CELL BIOL, V12, P104, DOI 10.1016/S0955-0674(99)00063-0; Bray D, 2001, CELL MOVEMENTS MOL M; CASELLA JF, 1995, CELL MOTIL CYTOSKEL, V30, P164, DOI 10.1002/cm.970300208; CONDEELIS J, 1992, CELL MOTIL CYTOSKEL, V22, P1, DOI 10.1002/cm.970220102; COOPER JA, 1983, J MUSCLE RES CELL M, V4, P253, DOI 10.1007/BF00712034; Coulombe PA, 2000, TRENDS CELL BIOL, V10, P420, DOI 10.1016/S0962-8924(00)01828-6; CRAIG SW, 1982, METHOD ENZYMOL, V85, P316; de Gennes P. G., 1991, SCALING CONCEPTS POL; GITTES F, 1993, J CELL BIOL, V120, P923, DOI 10.1083/jcb.120.4.923; Gittes F, 1998, PHYS REV E, V58, pR1241, DOI 10.1103/PhysRevE.58.R1241; Haber C, 2000, P NATL ACAD SCI USA, V97, P10792, DOI 10.1073/pnas.190320097; Hinner B, 1998, PHYS REV LETT, V81, P2614, DOI 10.1103/PhysRevLett.81.2614; Isambert H, 1996, MACROMOLECULES, V29, P1036, DOI 10.1021/ma946418x; KOUYAMA T, 1981, EUR J BIOCHEM, V114, P33; LeDuc P, 1999, NATURE, V399, P564, DOI 10.1038/21148; Liverpool TB, 2001, PHYS REV LETT, V86, P4171, DOI 10.1103/PhysRevLett.86.4171; MACLEANFLETCHER SD, 1980, J CELL BIOL, V85, P414, DOI 10.1083/jcb.85.2.414; Mason TG, 1997, PHYS REV LETT, V79, P3282, DOI 10.1103/PhysRevLett.79.3282; McGrath JL, 2000, BIOPHYS J, V79, P3258, DOI 10.1016/S0006-3495(00)76558-1; Morse DC, 1998, MACROMOLECULES, V31, P7030, DOI 10.1021/ma9803032; Mullins RD, 1998, MOL BIOL CELL, V9, P841, DOI 10.1091/mbc.9.4.841; Palmer A, 1998, RHEOL ACTA, V37, P97, DOI 10.1007/s003970050095; Palmer A, 1999, BIOPHYS J, V76, P1063, DOI 10.1016/S0006-3495(99)77271-1; POLLARD TD, 1986, ANNU REV BIOCHEM, V55, P987, DOI 10.1146/annurev.bi.55.070186.005011; Pollard TD, 2000, ANNU REV BIOPH BIOM, V29, P545, DOI 10.1146/annurev.biophys.29.1.545; POLLARD TD, 1992, J BIOL CHEM, V267, P20339; Sept D, 1999, BIOPHYS J, V77, P2911, DOI 10.1016/S0006-3495(99)77124-9; STOSSEL TP, 1993, SCIENCE, V260, P1086, DOI 10.1126/science.8493552; Svitkina TM, 1999, J CELL BIOL, V145, P1009, DOI 10.1083/jcb.145.5.1009; Tang JX, 1999, BIOPHYS J, V76, P2208, DOI 10.1016/S0006-3495(99)77376-5; Tseng Y, 2001, BIOPHYS J, V81, P1643, DOI 10.1016/S0006-3495(01)75818-3; Tseng Y, 2001, J MOL BIOL, V310, P351, DOI 10.1006/jmbi.2001.4716; VERKHOVSKY AB, 1995, J CELL BIOL, V131, P989, DOI 10.1083/jcb.131.4.989; WACHSSTOCK DH, 1994, BIOPHYS J, V66, P801, DOI 10.1016/S0006-3495(94)80856-2; Xu JY, 1998, BIOPHYS J, V74, P2731, DOI 10.1016/S0006-3495(98)77979-2; Xu JY, 2002, BIOMACROMOLECULES, V3, P92, DOI 10.1021/bm015586b; Xu JY, 1998, MACROMOLECULES, V31, P6486, DOI 10.1021/ma9717754; Xu JY, 1998, RHEOL ACTA, V37, P387, DOI 10.1007/s003970050125; Xu JY, 1998, J BIOL CHEM, V273, P9570, DOI 10.1074/jbc.273.16.9570; Xu JY, 2000, J BIOL CHEM, V275, P35886, DOI 10.1074/jbc.M002377200; Yamada S, 2000, BIOPHYS J, V78, P1736, DOI 10.1016/S0006-3495(00)76725-7	44	53	53	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 17	2002	277	20					18143	18150		10.1074/jbc.M110868200	http://dx.doi.org/10.1074/jbc.M110868200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	553PR	11889122	hybrid			2022-12-27	WOS:000175685100096
J	Camenisch, G; Pisabarro, MT; Sherman, D; Kowalski, J; Nagel, M; Hass, P; Xie, MH; Gurney, A; Bodary, S; Liang, XH; Clark, K; Beresini, M; Ferrara, N; Gerber, HP				Camenisch, G; Pisabarro, MT; Sherman, D; Kowalski, J; Nagel, M; Hass, P; Xie, MH; Gurney, A; Bodary, S; Liang, XH; Clark, K; Beresini, M; Ferrara, N; Gerber, HP			ANGPTL3 stimulates endothelial cell adhesion and migration via integrin alpha(v)beta(3) and induces blood vessel formation in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR; GAMMA-CHAIN; MOLECULAR-CLONING; TIE2 RECEPTOR; PROTEIN; ANGIOPOIETIN-1; EXPRESSION; IDENTIFICATION; LIGANDS; SPECIFICITY	The angiopoietin family of secreted factors is functionally defined by the C-terminal fibrinogen (FBN)-like domain, which mediates binding to the Tie2 receptor and thereby facilitates a cascade of events ultimately regulating blood vessel formation. By screening expressed sequence tag data bases for homologies to a consensus FBN-like motive, we have identified ANGPTL3, a liver-specific, secreted factor consisting of an N-terminal coiled-coil domain and the C-terminal FBN-like domain. Co-immunoprecipitation experiments, however, failed to detect binding of ANGPTL3 to the Tie2 receptor. A molecular model of the FBN-like domain of ANGPTL3 was generated and predicted potential binding to integrins. This hypothesis was experimentally confirmed by the finding that recombinant ANGPTL3 bound to alpha(v)beta(3) and induced integrin alpha(v)beta(3)-dependent haptotactic endothelial cell adhesion and migration and stimulated signal transduction pathways characteristic for integrin activation, including phosphorylation of Akt, mitogen-activated protein kinase, and focal adhesion kinase. When tested in the rat corneal assay, ANGPTL3 strongly induced angiogenesis with comparable magnitude as observed for vascular endothelial growth factor-A. Moreover, the C-terminal FBN-like domain alone was sufficient to induce endothelial cell adhesion and in vivo angiogenesis. Taken together, our data demonstrate that ANGPTL3 is the first member of the angiopoietin-like family of secreted factors binding to integrin alpha(v)beta(3) and suggest a possible role in the regulation of angiogenesis.	Genentech Inc, Dept Mol Oncol, San Francisco, CA 94080 USA; Genentech Inc, Dept Prot Engn, San Francisco, CA 94080 USA; Genentech Inc, Dept Prot Chem, San Francisco, CA 94080 USA; Genentech Inc, Dept Mol Biol, San Francisco, CA 94080 USA; Genentech Inc, Dept Immunol, San Francisco, CA 94080 USA; Genentech Inc, Dept Bioanalyt Res & Dev, San Francisco, CA 94080 USA	Roche Holding; Genentech; Roche Holding; Genentech; Roche Holding; Genentech; Roche Holding; Genentech; Roche Holding; Genentech; Roche Holding; Genentech	Gerber, HP (corresponding author), Genentech Inc, Dept Mol Oncol, 1 DNA Way, San Francisco, CA 94080 USA.	gerberhp@gene.com	Pisabarro, M. Teresa/D-4270-2012					Asahara T, 1998, CIRC RES, V83, P233, DOI 10.1161/01.RES.83.3.233; BREM RB, 1994, INVEST OPHTH VIS SCI, V35, P3466; Byzova TV, 2000, EXP CELL RES, V254, P299, DOI 10.1006/excr.1999.4765; Byzova TV, 2000, MOL CELL, V6, P851, DOI 10.1016/S1097-2765(05)00076-6; Carlson TR, 2001, J BIOL CHEM, V276, P26516, DOI 10.1074/jbc.M100282200; CHUNTHARAPAI A, 1993, EXP CELL RES, V205, P345, DOI 10.1006/excr.1993.1096; Conklin D, 1999, GENOMICS, V62, P477, DOI 10.1006/geno.1999.6041; Davis S, 1996, CELL, V87, P1161, DOI 10.1016/S0092-8674(00)81812-7; Eliceiri BP, 1998, MOL MED, V4, P741, DOI 10.1007/BF03401768; Eliceiri BP, 2000, CANCER J, V6, pS245; Ferrara N, 2000, RECENT PROG HORM RES, V55, P15; Gadek TR, 2002, SCIENCE, V295, P1086, DOI 10.1126/science.295.5557.1086; Giancotti FG, 2000, NAT CELL BIOL, V2, pE13, DOI 10.1038/71397; HOSHIGA M, 1995, CIRC RES, V77, P1129, DOI 10.1161/01.RES.77.6.1129; Hynes RO, 1999, BRAZ J MED BIOL RES, V32, P501, DOI 10.1590/S0100-879X1999000500002; Hynes RO, 1997, THROMB HAEMOSTASIS, V78, P83; Jones N, 2001, NAT REV MOL CELL BIO, V2, P257, DOI 10.1038/35067005; Kim I, 1999, FEBS LETT, V443, P353, DOI 10.1016/S0014-5793(99)00008-3; Klein RD, 1997, NATURE, V387, P717, DOI 10.1038/42722; Koishi R, 2002, NAT GENET, V30, P151, DOI 10.1038/ng814; Kwak HJ, 1999, FEBS LETT, V448, P249, DOI 10.1016/S0014-5793(99)00378-6; LANDEGREN U, 1984, J IMMUNOL METHODS, V67, P379, DOI 10.1016/0022-1759(84)90477-0; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; Maisonpierre PC, 1997, SCIENCE, V277, P55, DOI 10.1126/science.277.5322.55; Marsters SA, 2000, CURR BIOL, V10, P785, DOI 10.1016/S0960-9822(00)00566-2; McHugh KP, 2000, J CLIN INVEST, V105, P433, DOI 10.1172/JCI8905; Munger JS, 1998, MOL BIOL CELL, V9, P2627, DOI 10.1091/mbc.9.9.2627; Peek R, 1998, INVEST OPHTH VIS SCI, V39, P1782; Procopio WN, 1999, J BIOL CHEM, V274, P30196, DOI 10.1074/jbc.274.42.30196; Qi MS, 2001, J BIOL CHEM, V276, P15868, DOI 10.1074/jbc.M005911200; Sierra-Honigmann MR, 1998, SCIENCE, V281, P1683, DOI 10.1126/science.281.5383.1683; Suzuma K, 1998, INVEST OPHTH VIS SCI, V39, P1028; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Ugarova TP, 1998, J BIOL CHEM, V273, P22519, DOI 10.1074/jbc.273.35.22519; Walton HL, 2000, J CELL BIOCHEM, V78, P674, DOI 10.1002/1097-4644(20000915)78:4<674::AID-JCB16>3.0.CO;2-G; Xie MH, 1999, CYTOKINE, V11, P729, DOI 10.1006/cyto.1999.0485; Xin XH, 2001, AM J PATHOL, V158, P1111, DOI 10.1016/S0002-9440(10)64058-8; Yee VC, 1997, STRUCTURE, V5, P125, DOI 10.1016/S0969-2126(97)00171-8; Yokoyama K, 2000, J BIOL CHEM, V275, P16891, DOI 10.1074/jbc.M000610200	39	180	220	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 10	2002	277	19					17281	17290		10.1074/jbc.M109768200	http://dx.doi.org/10.1074/jbc.M109768200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	551MB	11877390	hybrid			2022-12-27	WOS:000175564500123
J	Falsone, SF; Weichel, M; Crameri, R; Breitenbach, M; Kungl, AJ				Falsone, SF; Weichel, M; Crameri, R; Breitenbach, M; Kungl, AJ			Unfolding and double-stranded DNA binding of the cold shock protein homologue Cla h 8 from Cladosporium herbarum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACILLUS-SUBTILIS CSPB; FUMIGATUS ALLERGEN-I/A; SOLUTION NMR STRUCTURE; ESCHERICHIA-COLI; CRYSTAL-STRUCTURE; CDNA LIBRARIES; IGE-BINDING; TRANSCRIPTION; CLONING; DOMAIN	The cloning, purification, and biophysical characterization of the first eukaryotic cold shock protein homologue, Cla h 8, expressed as single functional polypeptide is reported here. It was discovered as a minor allergen of the mold Cladosporium herbarum by phage display using a library selectively enriched for IgE-binding proteins. Based on the sequence homology of Cla h 8 with bacterial cold shock proteins (CSPs), a homology-based computer model of the allergen was computed indicating an all-beta structure of Cla h 8. This major structural feature was confirmed by CD spectroscopy. Despite the structural similarities with bacterial CSPs, the DNA-binding and unfolding behavior of Cla h 8 exhibited unique and previously undescribed characteristics. High affinities of Cla h 8 for single-stranded DNA as well as for double-stranded DNA corresponding to the human Y-box were detected. The affinity for double-stranded DNA increased significantly with decreasing temperature, which was paralleled by an increase in the beta sheet content of the protein. Temperature-dependent fluorescence anisotropy and far-UV CD measurements revealed different unfolding transitions at 28 and at 35.7 degreesC, respectively, indicating a multistate transition, which is uncommon for CSPs. The enhanced affinity for DNA at low temperatures together with the low unfolding transition refer to the functional significance of Cla h 8 at reduced temperatures.	Graz Univ, Inst Phamraceut Chem & Pharmaceut Technol, Dept Prot Chem & Biophys, A-8010 Graz, Austria; Salzburg Univ, Inst Genet & Gen Biol, A-5020 Salzburg, Austria; Swiss Inst Allergy & Asthma Res, CH-7270 Davos, Switzerland	University of Graz; Salzburg University; Swiss Institute of Allergy & Asthma Research	Kungl, AJ (corresponding author), Graz Univ, Inst Phamraceut Chem & Pharmaceut Technol, Dept Prot Chem & Biophys, A-8010 Graz, Austria.	andreas.kungl@kfunigraz.ac.at		Falsone, Salvatore Fabio/0000-0002-3724-5824; Kungl, Andreas/0000-0003-3362-797X				ACHATZ G, 1995, MOL IMMUNOL, V32, P213, DOI 10.1016/0161-5890(94)00108-D; Bae WH, 2000, P NATL ACAD SCI USA, V97, P7784, DOI 10.1073/pnas.97.14.7784; BOUVET P, 1994, CELL, V77, P931, DOI 10.1016/0092-8674(94)90141-4; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CRAMERI R, 1994, EUR J BIOCHEM, V226, P53, DOI 10.1111/j.1432-1033.1994.tb20025.x; Crameri R, 1996, J EXP MED, V184, P265, DOI 10.1084/jem.184.1.265; Crameri R, 2001, INT ARCH ALLERGY IMM, V124, P43, DOI 10.1159/000053664; Crameri R, 2001, COMB CHEM HIGH T SCR, V4, P145; Crameri R, 1997, GENE CLONING ANAL CU, P29; CRAMERI R, 2001, METHOD MOL BIOL, P461; DIDIER DK, 1988, P NATL ACAD SCI USA, V85, P7322, DOI 10.1073/pnas.85.19.7322; Falsone SF, 2001, BIOCHEM BIOPH RES CO, V285, P1180, DOI 10.1006/bbrc.2001.5318; Feng WQ, 1998, BIOCHEMISTRY-US, V37, P10881, DOI 10.1021/bi980269j; Goger B, 2002, BIOCHEMISTRY-US, V41, P1640, DOI 10.1021/bi011944j; GOLDSTEIN J, 1990, P NATL ACAD SCI USA, V87, P283, DOI 10.1073/pnas.87.1.283; GRAUMANN P, 1994, FEBS LETT, V338, P157, DOI 10.1016/0014-5793(94)80355-2; Graumann PL, 1998, TRENDS BIOCHEM SCI, V23, P286, DOI 10.1016/S0968-0004(98)01255-9; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; HASEGAWA SL, 1991, NUCLEIC ACIDS RES, V19, P4915, DOI 10.1093/nar/19.18.4915; Hillier BJ, 1998, FOLD DES, V3, P87, DOI 10.1016/S1359-0278(98)00014-5; Izumi H, 2001, NUCLEIC ACIDS RES, V29, P1200, DOI 10.1093/nar/29.5.1200; Jiang WN, 1997, J BIOL CHEM, V272, P196; JONES PG, 1987, J BACTERIOL, V169, P2092, DOI 10.1128/jb.169.5.2092-2095.1987; JONES PG, 1992, J BACTERIOL, V174, P5798, DOI 10.1128/jb.174.18.5798-5802.1992; Kristl S, 2000, FEBS LETT, V467, P87, DOI 10.1016/S0014-5793(00)01118-2; Lakowicz J.R., 2010, PRINCIPLE FLUORESCEN, DOI 10.1007/978-0-387-46312-4/COVER; LATEANA A, 1991, P NATL ACAD SCI USA, V88, P10907, DOI 10.1073/pnas.88.23.10907; Lopez MM, 2000, BBA-PROTEIN STRUCT M, V1479, P196, DOI 10.1016/S0167-4838(00)00048-0; Lopez MM, 2001, J BIOL CHEM, V276, P15511, DOI 10.1074/jbc.M010474200; Lopez MM, 1999, J BIOL CHEM, V274, P33601, DOI 10.1074/jbc.274.47.33601; LUMRY R, 1966, BIOPOLYMERS, V4, P917, DOI 10.1002/bip.1966.360040808; MAIER E, 1994, J BIOTECHNOL, V12, P433; Matsumoto K, 1998, TRENDS CELL BIOL, V8, P318, DOI 10.1016/S0962-8924(98)01300-2; MOSER M, 1992, J IMMUNOL, V149, P454; MOSER M, 1994, J ALLERGY CLIN IMMUN, V93, P1, DOI 10.1016/0091-6749(94)90227-5; Mueller U, 2000, J MOL BIOL, V297, P975, DOI 10.1006/jmbi.2000.3602; MURZIN AG, 1993, EMBO J, V12, P861, DOI 10.1002/j.1460-2075.1993.tb05726.x; NEWKIRK K, 1994, P NATL ACAD SCI USA, V91, P5114, DOI 10.1073/pnas.91.11.5114; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; Phadtare S, 1999, CURR OPIN MICROBIOL, V2, P175, DOI 10.1016/S1369-5274(99)80031-9; Rodriguez HM, 2000, PROTEIN SCI, V9, P1993, DOI 10.1110/ps.9.10.1993; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHINDELIN H, 1994, P NATL ACAD SCI USA, V91, P5119, DOI 10.1073/pnas.91.11.5119; SCHINDELIN H, 1993, NATURE, V364, P164, DOI 10.1038/364164a0; Schindler T, 1998, PROTEINS, V30, P401, DOI 10.1002/(SICI)1097-0134(19980301)30:4<401::AID-PROT7>3.3.CO;2-G; SCHNUCHEL A, 1993, NATURE, V364, P169, DOI 10.1038/364169a0; SHORT JM, 1988, NUCLEIC ACIDS RES, V16, P7583, DOI 10.1093/nar/16.15.7583; Simon-Nobbe B, 2000, J ALLERGY CLIN IMMUN, V106, P887, DOI 10.1067/mai.2000.110799; SREERAMA N, 1993, ANAL BIOCHEM, V209, P32, DOI 10.1006/abio.1993.1079; Wang N, 2000, MOL MICROBIOL, V38, P526, DOI 10.1046/j.1365-2958.2000.02146.x; Wassenberg D, 1999, J MOL BIOL, V289, P187, DOI 10.1006/jmbi.1999.2772; Yamanaka K, 2001, GENES CELLS, V6, P279, DOI 10.1046/j.1365-2443.2001.00424.x	53	15	15	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 10	2002	277	19					16512	16516		10.1074/jbc.M200833200	http://dx.doi.org/10.1074/jbc.M200833200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	551MB	11861653	hybrid			2022-12-27	WOS:000175564500025
J	Prado, F; Vicent, G; Cardalda, C; Beato, M				Prado, F; Vicent, G; Cardalda, C; Beato, M			Differential role of the proline-rich domain of nuclear factor 1-C splice variants in DNA binding and transactivation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-TERMINAL DOMAIN; RNA-POLYMERASE-II; TRANSCRIPTIONAL ACTIVATION; SACCHAROMYCES-CEREVISIAE; REPLICATION; PROTEINS; YEAST; EXPRESSION; GENES; HETERODIMERS	We have addressed the functional significance of the existence of several natural splice variants of NF1-C* differing in their COOH-terminal proline-rich transactivation domain (PRD) by studying their specific DNA binding and transactivation in the yeast Saccharomyces cerevisiae. These parameters yielded the intrinsic transactivation potential (ITP), defined as the activation observed with equal amounts of DNA bound protein. Exchange of 83 amino acids at the COOH-terminal end of the PRD by 16 unrelated amino acids, as found in NF1-C2, and splicing out the central region of the PRD, as found in NF1-C7, enhanced DNA binding in vivo and in vitro. However, the ITP of the splice variants NF1-C2 and NF1-C7 was found to be similar to that of the intact NF1-C1. Additional mutations showed that the ITP of NF1-C requires the synergistic action of the PRD and a novel domain encoded in exons 5 and 6. Intriguingly the carboxyl-terminal domain-like motif encoded in exons 9/10 is not essential for transactivation of a reporter with a single NF1 site but is required for activation of a reporter with six NF1 sites in tandem. Our results imply that differential splicing is used to regulate transcription by generating variants with different DNA binding affinities but similar ITPs.	Univ Marburg, Inst Mol Biol & Tumorforsch, D-35033 Marburg, Germany	Philipps University Marburg	Beato, M (corresponding author), Univ Marburg, Inst Mol Biol & Tumorforsch, Emil Mannkopff Str 2, D-35033 Marburg, Germany.		Beato, Miguel/B-5564-2015; Prado, Felix/G-7700-2015; Vicent, Guillermo P./K-5432-2015	Beato, Miguel/0000-0002-2878-2222; Prado, Felix/0000-0001-9805-782X; Vicent, Guillermo P./0000-0002-0554-2226				Alevizopoulos A, 1995, GENE DEV, V9, P3051, DOI 10.1101/gad.9.24.3051; ALTMANN H, 1994, P NATL ACAD SCI USA, V91, P3901, DOI 10.1073/pnas.91.9.3901; AMMERER G, 1983, METHOD ENZYMOL, V101, P192; ARMENTERO MT, 1994, P NATL ACAD SCI USA, V91, P11537, DOI 10.1073/pnas.91.24.11537; Baetz K, 1999, MOL CELL BIOL, V19, P6729; BOUSSET K, 1993, ONCOGENE, V8, P3211; Candau R, 1996, J STEROID BIOCHEM, V57, P19, DOI 10.1016/0960-0760(96)00262-2; Chaudhry AZ, 1997, DEV DYNAM, V208, P313; CHAVEZ S, 1995, MOL CELL BIOL, V15, P6987; das Neves L, 1999, P NATL ACAD SCI USA, V96, P11946, DOI 10.1073/pnas.96.21.11946; Dekker J, 1996, MOL CELL BIOL, V16, P4073; Di Croce L, 1999, MOL CELL, V4, P45, DOI 10.1016/S1097-2765(00)80186-0; DUSSERRE Y, 1992, MOL CELL BIOL, V12, P5228, DOI 10.1128/MCB.12.11.5228; Graveley BR, 2001, TRENDS GENET, V17, P100, DOI 10.1016/S0168-9525(00)02176-4; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; GUARENTE L, 1983, METHOD ENZYMOL, V101, P181; HEMESATH TJ, 1994, GENE DEV, V8, P2770, DOI 10.1101/gad.8.22.2770; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JONES KA, 1987, CELL, V48, P79, DOI 10.1016/0092-8674(87)90358-8; KIM TK, 1994, NUCLEIC ACIDS RES, V22, P251, DOI 10.1093/nar/22.2.251; KIM TK, 1993, J BIOL CHEM, V268, P20866; KRUSE U, 1994, FEBS LETT, V348, P46, DOI 10.1016/0014-5793(94)00585-0; KRUSE U, 1994, J MOL BIOL, V238, P860, DOI 10.1006/jmbi.1994.1343; Lemon B, 2000, GENE DEV, V14, P2551, DOI 10.1101/gad.831000; Lopez AJ, 1995, DEV BIOL, V172, P396, DOI 10.1006/dbio.1995.8050; MCNABB DS, 1995, GENE DEV, V9, P47, DOI 10.1101/gad.9.1.47; MEISTERERNST M, 1989, BIOCHEMISTRY-US, V28, P8191, DOI 10.1021/bi00446a034; MERMOD N, 1989, CELL, V58, P741, DOI 10.1016/0092-8674(89)90108-6; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MUMBERG D, 1994, NUCLEIC ACIDS RES, V22, P5767, DOI 10.1093/nar/22.25.5767; NAGATA K, 1982, P NATL ACAD SCI-BIOL, V79, P6438, DOI 10.1073/pnas.79.21.6438; PAONESSA G, 1988, EMBO J, V7, P3115, DOI 10.1002/j.1460-2075.1988.tb03178.x; Prado F, 2002, J BIOL CHEM, V277, P4911, DOI 10.1074/jbc.M110094200; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; ROULET E, 1995, MOL CELL BIOL, V15, P5552; RUPP RAW, 1990, NUCLEIC ACIDS RES, V18, P2607, DOI 10.1093/nar/18.9.2607; SANTORO C, 1988, NATURE, V334, P218, DOI 10.1038/334218a0; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; Sherman F., 1986, METHODS YEAST GENETI; SUN XH, 1991, CELL, V64, P459, DOI 10.1016/0092-8674(91)90653-G; TANESE N, 1991, GENE DEV, V5, P2212, DOI 10.1101/gad.5.12a.2212; WENDLER W, 1994, NUCLEIC ACIDS RES, V22, P2601, DOI 10.1093/nar/22.13.2601; Wenzelides S, 1996, NUCLEIC ACIDS RES, V24, P2416, DOI 10.1093/nar/24.12.2416; XIAO H, 1994, NUCLEIC ACIDS RES, V22, P1966, DOI 10.1093/nar/22.11.1966	44	7	7	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 10	2002	277	19					16383	16390		10.1074/jbc.M200418200	http://dx.doi.org/10.1074/jbc.M200418200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	551MB	11861650	hybrid			2022-12-27	WOS:000175564500007
J	Tarr, PE; Roncarati, R; Pelicci, G; Pelicci, PG; D'Adamio, L				Tarr, PE; Roncarati, R; Pelicci, G; Pelicci, PG; D'Adamio, L			Tyrosine phosphorylation of the beta-amyloid precursor protein cytoplasmic tail promotes interaction with Shc	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOTYROSINE-BINDING DOMAIN; N-TERMINAL KINASE; ALZHEIMERS-DISEASE; AXONAL-TRANSPORT; OXIDATIVE STRESS; GAMMA-SECRETASE; APOPTOSIS; FE65; ACTIVATION; TAU	beta-Amyloid precursor protein (APP) is a widely expressed transmembrane protein of unknown function that is involved in the pathogenesis of Alzheimer's disease. The cytoplasmic tail of APP interacts with phosphotyrosine binding (PTB) domain containing proteins (Fe65, X11, mDab-1, and JIP-1) and may modulate gene expression and apoptosis. We now identify Shc A and She C, PTB-containing adapter proteins that signal to cellular differentiation and survival pathways, as novel APP-interacting proteins. The APP cytoplasmic tail contains a PTB-binding Motif (Y-682 ENPTY687) that, when phosphorylated on Tyr(682), precipitated the PTB domain of Shc A and Shc C, as well as endogenous full-length Shc A. APP and Shc C were physically associated in adult mouse brain homogenates. Increase in phosphorylation of APP by overexpression of the nerve growth factor receptor Trk A in 293T cells promoted the interaction of transfected APP and endogenous Shc A. Pervanadate treatment of N2a neuroblastoma cells resulted in tyrosine phosphorylation and association of endogenous APP and Shc A. Thus, APP and Shc proteins interact in vitro, in cells, and in the mouse brain. Tyrosine phosphorylation of APP may promote the interaction with Shc proteins.	Yeshiva Univ Albert Einstein Coll Med, Dept Microbiol & Immunol, Bronx, NY 10461 USA; European Inst Oncol, Dept Expt Oncol, I-20149 Milan, Italy	Yeshiva University; Albert Einstein College of Medicine; IRCCS European Institute of Oncology (IEO)	D'Adamio, L (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Microbiol & Immunol, 1300 Morris Pk Ave,Ullmann 1209, Bronx, NY 10461 USA.	Ldadamio@aecom.yu.edu	Pelicci, Pier Giuseppe/AAL-6572-2020; Pelicci, Giuliana/AAA-8921-2022	Pelicci, Giuliana/0000-0003-0986-8255; TARR, Philip/0000-0002-1488-5407; D'Adamio, Luciano/0000-0002-9820-4882; D'Adamio, Luciano/0000-0002-2204-9441; roncarati, roberta/0000-0002-2371-3316	NATIONAL CANCER INSTITUTE [T32CA009173] Funding Source: NIH RePORTER; NCI NIH HHS [T32 CA 09173] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ando K, 2001, J BIOL CHEM, V276, P40353, DOI 10.1074/jbc.M104059200; BLAIKIE P, 1994, J BIOL CHEM, V269, P32031; Borg JP, 1996, MOL CELL BIOL, V16, P6229; Cao XW, 2001, SCIENCE, V293, P115, DOI 10.1126/science.1058783; Chong YH, 2001, J BIOL CHEM, V276, P23511, DOI 10.1074/jbc.M009466200; Conti L, 2001, NAT NEUROSCI, V4, P579, DOI 10.1038/88395; Cupers P, 2001, J NEUROCHEM, V78, P1168, DOI 10.1046/j.1471-4159.2001.00516.x; De Strooper B, 2000, J CELL SCI, V113, P1857; De Strooper B, 1999, NATURE, V398, P518, DOI 10.1038/19083; DIKIC I, 1995, J BIOL CHEM, V270, P15125, DOI 10.1074/jbc.270.25.15125; Esler WP, 2001, SCIENCE, V293, P1449, DOI 10.1126/science.1064638; ESTUS S, 1992, SCIENCE, V255, P726, DOI 10.1126/science.1738846; Ferrer I, 2001, BRAIN PATHOL, V11, P144; Fiore F, 1995, J BIOL CHEM, V270, P30853, DOI 10.1074/jbc.270.52.30853; Gartner U, 1999, NEUROSCIENCE, V91, P1, DOI 10.1016/S0306-4522(99)00059-7; Gervais FG, 1999, CELL, V97, P395, DOI 10.1016/S0092-8674(00)80748-5; Goedert M, 1997, FEBS LETT, V409, P57, DOI 10.1016/S0014-5793(97)00483-3; Gu HH, 2000, MOL CELL BIOL, V20, P7109, DOI 10.1128/MCB.20.19.7109-7120.2000; Guo Q, 1997, J NEUROSCI, V17, P4212; Heber S, 2000, J NEUROSCI, V20, P7951; Howell BW, 1999, MOL CELL BIOL, V19, P5179; Iijima K, 2000, J NEUROCHEM, V75, P1085, DOI 10.1046/j.1471-4159.2000.0751085.x; Kamal A, 2000, NEURON, V28, P449, DOI 10.1016/S0896-6273(00)00124-0; Kamal A, 2001, NATURE, V414, P643, DOI 10.1038/414643a; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; LeBlanc A, 1999, J BIOL CHEM, V274, P23426, DOI 10.1074/jbc.274.33.23426; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Matsuda S, 2001, J NEUROSCI, V21, P6597; Migliaccio E, 1999, NATURE, V402, P309, DOI 10.1038/46311; Minopoli G, 2001, J BIOL CHEM, V276, P6545, DOI 10.1074/jbc.M007340200; OKAMOTO T, 1995, J BIOL CHEM, V270, P4205, DOI 10.1074/jbc.270.9.4205; Passer Brent, 2000, Journal of Alzheimer's Disease, V2, P289; Pelicci G, 1996, ONCOGENE, V13, P633; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; Pellegrini L, 1999, J BIOL CHEM, V274, P21011, DOI 10.1074/jbc.274.30.21011; Perry G, 1999, NEUROREPORT, V10, P2411, DOI 10.1097/00001756-199908020-00035; Ramelot TA, 2001, J MOL BIOL, V307, P871, DOI 10.1006/jmbi.2001.4535; Reynolds CH, 2000, J NEUROCHEM, V74, P1587, DOI 10.1046/j.1471-4159.2000.0741587.x; Reynolds CH, 1997, J NEUROCHEM, V69, P191; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; Russo C, 2001, NEUROBIOL DIS, V8, P173, DOI 10.1006/nbdi.2000.0357; Sakai R, 2000, NEURON, V28, P819, DOI 10.1016/S0896-6273(00)00156-2; Scheinfeld MH, 2002, J BIOL CHEM, V277, P3767, DOI 10.1074/jbc.M108357200; Schroeter EH, 1998, NATURE, V393, P382, DOI 10.1038/30756; SELKOE DJ, 1988, P NATL ACAD SCI USA, V85, P7341, DOI 10.1073/pnas.85.19.7341; Vito P, 1999, J BIOL CHEM, V274, P1533, DOI 10.1074/jbc.274.3.1533; Vito P, 1996, J BIOL CHEM, V271, P31025, DOI 10.1074/jbc.271.49.31025; Weidemann A, 1999, J BIOL CHEM, V274, P5823, DOI 10.1074/jbc.274.9.5823; Wolozin B, 1996, SCIENCE, V274, P1710, DOI 10.1126/science.274.5293.1710; Yamatsuji T, 1996, EMBO J, V15, P498, DOI 10.1002/j.1460-2075.1996.tb00382.x; Zambrano N, 2001, J BIOL CHEM, V276, P19787, DOI 10.1074/jbc.M100792200; Zhu XW, 2001, J NEUROCHEM, V76, P435, DOI 10.1046/j.1471-4159.2001.00046.x	52	108	115	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 10	2002	277	19					16798	16804		10.1074/jbc.M110286200	http://dx.doi.org/10.1074/jbc.M110286200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	551MB	11877420	hybrid			2022-12-27	WOS:000175564500061
J	Ching, YP; Pang, ASH; Lam, WH; Qi, RZ; Wang, JH				Ching, YP; Pang, ASH; Lam, WH; Qi, RZ; Wang, JH			Identification of a neuronal Cdk5 activator-binding protein as Cdk5 inhibitor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIN-DEPENDENT KINASE-5; BRAIN-SPECIFIC ACTIVATOR; CDC2-LIKE KINASE; INK4 INHIBITORS; BOVINE BRAIN; DOMAIN	Neuronal Cdc2-like kinase (Nclk) plays an important role in a variety of cellular processes, including neuronal cell differentiation, apoptosis, neuron migration, and formation of neuromuscular junction. The active kinase consists of a catalytic subunit, Cdk5, and an essential regulatory subunit, neuronal Cdk5 activator (p35(nck5a) or p25(nck5a)), which is expressed primarily in neurons of central nervous tissue. In our previous study using the yeast two-hybrid screening method, three novel p35(nck5a)-associated proteins were isolated. Here we show that one of these proteins, called C42, specifically inhibits the activation of Cdk5 by Nck5a. Co-immunoprecipitation data suggested that C42 and p35(nck5a) could form a complex within cultured mammalian cells. Deletion analysis has mapped the inhibitory domain of C42 to a region of 135 amino acids, which is conserved in Pho81, a yeast protein that inhibits the yeast cyclin-dependent protein kinase Pho85. The Pho85.Pho80 kinase complex has been shown to be the yeast functional homologue of the mammalian Cdk5/p35(nck5a) kinase.	Hong Kong Univ Sci & Technol, Dept Biochem, Kowloon, Hong Kong, Peoples R China; Univ Calgary, Fac Med, Dept Biochem Med, Calgary, AB T2N 1N4, Canada	Hong Kong University of Science & Technology; University of Calgary	Wang, JH (corresponding author), Hong Kong Univ Sci & Technol, Dept Biochem, Clear Water Bay, Kowloon, Hong Kong, Peoples R China.		Ching, Yick Pang/C-4244-2009	CHING, Yick Pang/0000-0002-6461-8358; Qi, Robert Zhong/0000-0001-5596-8172				Ching YP, 2000, GENE, V242, P285, DOI 10.1016/S0378-1119(99)00499-0; Dhavan R, 2001, NAT REV MOL CELL BIO, V2, P749, DOI 10.1038/35096019; Grant P, 2001, EUR J BIOCHEM, V268, P1534, DOI 10.1046/j.1432-1033.2001.02025.x; Huang DQ, 1999, P NATL ACAD SCI USA, V96, P14445, DOI 10.1073/pnas.96.25.14445; Huang SD, 2001, MOL CELL BIOL, V21, P6695, DOI 10.1128/MCB.21.19.6695-6705.2001; Jeffrey PD, 2000, GENE DEV, V14, P3115, DOI 10.1101/gad.851100; Lee KY, 1996, J BIOL CHEM, V271, P1538, DOI 10.1074/jbc.271.3.1538; LEW J, 1992, J BIOL CHEM, V267, P13383; LEW J, 1995, TRENDS BIOCHEM SCI, V20, P33, DOI 10.1016/S0968-0004(00)88948-3; LEW J, 1994, NATURE, V371, P423, DOI 10.1038/371423a0; Morgan DO, 1997, ANNU REV CELL DEV BI, V13, P261, DOI 10.1146/annurev.cellbio.13.1.261; Pavletich NP, 1999, J MOL BIOL, V287, P821, DOI 10.1006/jmbi.1999.2640; Qi Z, 1998, J BIOL CHEM, V273, P2329, DOI 10.1074/jbc.273.4.2329; QI Z, 1995, J BIOL CHEM, V270, P10847, DOI 10.1074/jbc.270.18.10847; TANG DM, 1995, J BIOL CHEM, V270, P26897, DOI 10.1074/jbc.270.45.26897; Tang DM, 1997, J BIOL CHEM, V272, P12318, DOI 10.1074/jbc.272.19.12318; TSAI LH, 1994, NATURE, V371, P419, DOI 10.1038/371419a0	17	55	61	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 3	2002	277	18					15237	15240		10.1074/jbc.C200032200	http://dx.doi.org/10.1074/jbc.C200032200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	550PA	11882646	hybrid			2022-12-27	WOS:000175510400005
J	Westhoff, CM; Ferreri-Jacobia, M; Mak, DOD; Foskett, JK				Westhoff, CM; Ferreri-Jacobia, M; Mak, DOD; Foskett, JK			Identification of the erythrocyte Rh blood group glycoprotein as a mammalian ammonium transporter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RED-CELL MEMBRANE; GROUP SYSTEM; KIDNEY; PROTEIN; NH4+; ANTIGEN	The Rh blood group proteins are well known as the erythrocyte targets of the potent antibody response that causes hemolytic disease of the newborn. These proteins have been described in molecular detail; however, little is known about their function. A transport function is suggested by their predicted structure and from phylogenetic analysis. To obtain evidence for a role in solute transport, we expressed Rh proteins in Xenopus oocytes and now demonstrate that the erythroid Rh-associated glycoprotein mediates uptake of ammonium across cell membranes. Rh-associated glycoprotein carrier-mediated uptake, characterized with the radioactive analog of ammonium [C-14]methylamine (MA), had an apparent EC50 of 1.6 mm and a maximum uptake rate (V-max) of 190 pmol/oocyte/min. Uptake was independent of the membrane potential and the Na+ gradient. RA transport was stimulated by raising extracellular pH or by lowering intracellular pH, suggesting that uptake was coupled to an outwardly directed H+ gradient. MA uptake was insensitive to additions of amiloride, amine-containing compounds tetramethyl. and tetraethylammonium chloride, glutamine, and urea. However, MA uptake was significantly antagonized by ammonium chloride with inhibition kinetics (IC50 = 1.14 mm) consistent with the hypothesis that the uptake of MA and ammonium involves a similar H+-coupled counter-transport mechanism.	Univ Penn, Dept Pathol & Lab Med, Sch Med, Philadelphia, PA 19104 USA; Univ Penn, Dept Physiol, Sch Med, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania	Westhoff, CM (corresponding author), Univ Penn, Dept Pathol & Lab Med, Sch Med, 510 Stellar Chance, Philadelphia, PA 19104 USA.		Foskett, Kevin/R-2549-2019		NHLBI NIH HHS [T32 HL007775] Funding Source: Medline; NIDDK NIH HHS [DK 02751] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007775] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K01DK002751] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AGRE P, 1987, J BIOL CHEM, V262, P17497; Avent ND, 2000, BLOOD, V95, P375, DOI 10.1182/blood.V95.2.375; BALLAS SK, 1984, BLOOD, V63, P1046; BURCKHARDT BC, 1992, PFLUG ARCH EUR J PHY, V420, P83, DOI 10.1007/BF00378645; CHERIFZAHAR B, 1990, P NATL ACAD SCI USA, V87, P6243, DOI 10.1073/pnas.87.16.6243; Choe H, 1997, AM J PHYSIOL-RENAL, V273, pF516, DOI 10.1152/ajprenal.1997.273.4.F516; Huang CH, 2000, SEMIN HEMATOL, V37, P150, DOI 10.1016/S0037-1963(00)90040-4; HUIZENGA JR, 1994, ANN CLIN BIOCHEM, V31, P529, DOI 10.1177/000456329403100602; KINNE R, 1986, J MEMBRANE BIOL, V94, P279, DOI 10.1007/BF01869723; KINSELLA JL, 1981, AM J PHYSIOL, V241, pC220, DOI 10.1152/ajpcell.1981.241.5.C220; Kitano T, 2000, IMMUNOGENETICS, V51, P856, DOI 10.1007/s002510000202; KLEINER D, 1981, BIOCHIM BIOPHYS ACTA, V639, P41, DOI 10.1016/0304-4173(81)90004-5; KNEPPER MA, 1989, PHYSIOL REV, V69, P179, DOI 10.1152/physrev.1989.69.1.179; Liu Z, 2000, J BIOL CHEM, V275, P25641, DOI 10.1074/jbc.M003353200; Liu Z, 2001, J BIOL CHEM, V276, P1424, DOI 10.1074/jbc.M007528200; Mak DOD, 2000, J GEN PHYSIOL, V115, P241, DOI 10.1085/jgp.115.3.241; MALLINSON G, 1990, TRANSFUSION, V30, P222, DOI 10.1046/j.1537-2995.1990.30390194341.x; Marini AM, 2000, NAT GENET, V26, P341, DOI 10.1038/81656; NINNEMANN O, 1994, EMBO J, V13, P3464, DOI 10.1002/j.1460-2075.1994.tb06652.x; Race RR., 1975, BLOOD GROUPS MAN; RIDGWELL K, 1994, J BIOL CHEM, V269, P6410; ROON RJ, 1975, J BACTERIOL, V122, P502, DOI 10.1128/JB.122.2.502-509.1975; SINGH SK, 1995, P NATL ACAD SCI USA, V92, P11573, DOI 10.1073/pnas.92.25.11573; Soupene E, 2001, MOL CELL BIOL, V21, P5733, DOI 10.1128/MCB.21.17.5733-5741.2001; STURGEON P, 1970, BLOOD-J HEMATOL, V36, P310, DOI 10.1182/blood.V36.3.310.310; TSAI TD, 1995, AM J PHYSIOL-CELL PH, V268, pC1173, DOI 10.1152/ajpcell.1995.268.5.C1173; Wall SM, 1996, MINER ELECTROL METAB, V22, P311	27	132	138	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 12	2002	277	15					12499	12502		10.1074/jbc.C200060200	http://dx.doi.org/10.1074/jbc.C200060200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	542GZ	11861637	hybrid			2022-12-27	WOS:000175036300004
J	Ferreira, T; Mason, AB; Pypaert, M; Allen, KE; Slayman, CW				Ferreira, T; Mason, AB; Pypaert, M; Allen, KE; Slayman, CW			Quality control in the yeast secretory pathway - A misfolded Pma1 H+-ATPase reveals two checkpoints	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMA-MEMBRANE ATPASE; UNFOLDED-PROTEIN RESPONSE; ENDOPLASMIC-RETICULUM; SACCHAROMYCES-CEREVISIAE; CELL-SURFACE; SARCOPLASMIC-RETICULUM; EPITHELIAL-CELLS; URACIL PERMEASE; SHUTTLE VECTORS; ER	The yeast plasma-membrane H+-ATPase, encoded by PMA1, is delivered to the cell surface via the secretory pathway and has recently emerged as an excellent system for identifying quality control mechanisms along the pathway. In the present study, we have tracked the biogenesis of Pmal-G381A, a misfolded mutant form of the H+-ATPase. Although this mutant ATPase is arrested transiently in the peripheral endoplasmic reticulum, it does not become a substrate for endoplasmic reticulum-associated degradation nor does it appear to stimulate an unfolded protein response. Instead, Pma1-G381A accumulates in Kar2p-containing vesicular-tubular clusters that resemble those previously described in mammalian cells. Like their mammalian counterparts, the yeast vesicular-tubular clusters may correspond to specific exit ports from the endoplasmic reticulum, since Pmal-G381A eventually escapes from them (still in a misfolded, trypsin-sensitive form) to reach the plasma membrane. By comparison with wild-type ATPase, Pmal-G381A spends a short half-life at the plasma membrane before being removed and sent to the vacuole for degradation in a process that requires both End4p and Pep4p. Finally, in a separate set of experiments, Pma1-G381A was found to impose its phenotype on co-expressed wild-type ATPase, transiently retarding the wild-type protein in the ER and later stimulating its degradation in the vacuole. Both effects serve to lower the steady-state amount of wild-type ATPase in the plasma membrane and, thus, can explain the co-dominant genetic behavior of the G381A mutation. Taken together, the results of this study establish Pmal-G381A as a useful new probe for the yeast secretory system.	Yale Univ, Sch Med, Dept Genet, New Haven, CT 06510 USA; Yale Univ, Sch Med, Ctr Cell & Mol Imaging, New Haven, CT 06510 USA	Yale University; Yale University	Mason, AB (corresponding author), Yale Univ, Sch Med, Dept Genet, 333 Cedar St, New Haven, CT 06510 USA.	cw.slaymanlab@yale.edu	Mason, Anne B/A-6754-2008		NIGMS NIH HHS [GM15761] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM015761, R37GM015761] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABEIJON C, 1989, P NATL ACAD SCI USA, V86, P6935, DOI 10.1073/pnas.86.18.6935; Ambesi A, 1997, ANAL BIOCHEM, V251, P127, DOI 10.1006/abio.1997.2257; Ambesi A, 1996, J BIOL CHEM, V271, P22999, DOI 10.1074/jbc.271.38.22999; Auer M, 1998, NATURE, V392, P840, DOI 10.1038/33967; Bagnat M, 2000, P NATL ACAD SCI USA, V97, P3254, DOI 10.1073/pnas.060034697; BALCH WE, 1994, CELL, V76, P841, DOI 10.1016/0092-8674(94)90359-X; Bannykh SI, 1997, J CELL BIOL, V138, P1, DOI 10.1083/jcb.138.1.1; BARCO A, 1995, EMBO J, V14, P3349, DOI 10.1002/j.1460-2075.1995.tb07341.x; BARLOWE C, 1993, NATURE, V365, P347, DOI 10.1038/365347a0; BENITO B, 1991, BIOCHIM BIOPHYS ACTA, V1063, P265, DOI 10.1016/0005-2736(91)90381-H; BIEMANS R, 1991, DNA CELL BIOL, V10, P191, DOI 10.1089/dna.1991.10.191; BOWMAN BJ, 1985, J BIOL CHEM, V260, P8726; BOWMAN BJ, 1983, J BIOL CHEM, V258, P3002; BRADA D, 1988, J BACTERIOL, V170, P2775, DOI 10.1128/jb.170.6.2775-2783.1988; Brodsky JL, 1999, SEMIN CELL DEV BIOL, V10, P507, DOI 10.1006/scdb.1999.0321; CHANG A, 1995, J CELL BIOL, V128, P39, DOI 10.1083/jcb.128.1.39; CHANG A, 1991, J CELL BIOL, V115, P289, DOI 10.1083/jcb.115.2.289; Chapman R, 1998, ANNU REV CELL DEV BI, V14, P459, DOI 10.1146/annurev.cellbio.14.1.459; DeWitt ND, 1998, J BIOL CHEM, V273, P21744, DOI 10.1074/jbc.273.34.21744; dExaerde AD, 1996, YEAST, V12, P907; DEXAERDE AD, 1995, J BIOL CHEM, V270, P23828, DOI 10.1074/jbc.270.40.23828; Dubreuil RR, 2000, J CELL BIOL, V149, P647, DOI 10.1083/jcb.149.3.647; Elgersma Y, 1997, EMBO J, V16, P7326, DOI 10.1093/emboj/16.24.7326; FELDMAN RI, 1987, J BIOL CHEM, V262, P9332; Ferreira T, 2001, J BIOL CHEM, V276, P29613, DOI 10.1074/jbc.R100022200; FRANZUSOFF A, 1991, J CELL BIOL, V112, P27, DOI 10.1083/jcb.112.1.27; Friedlander R, 2000, NAT CELL BIOL, V2, P379, DOI 10.1038/35017001; Galan JM, 1996, J BIOL CHEM, V271, P10946, DOI 10.1074/jbc.271.18.10946; Gething MJ, 1999, SEMIN CELL DEV BIOL, V10, P465, DOI 10.1006/scdb.1999.0318; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; GOFF CG, 1984, GENE, V27, P35, DOI 10.1016/0378-1119(84)90236-1; Gong XH, 2001, P NATL ACAD SCI USA, V98, P9104, DOI 10.1073/pnas.161282998; HAMMERTON RW, 1991, SCIENCE, V254, P847, DOI 10.1126/science.1658934; HARRIS SL, 1994, P NATL ACAD SCI USA, V91, P10531, DOI 10.1073/pnas.91.22.10531; HAURI H-P, 1992, Current Opinion in Cell Biology, V4, P600, DOI 10.1016/0955-0674(92)90078-Q; HEINEMEYER W, 1993, J BIOL CHEM, V268, P5115; Hicke L, 1997, FASEB J, V11, P1215, DOI 10.1096/fasebj.11.14.9409540; Hicke L, 1999, TRENDS CELL BIOL, V9, P107, DOI 10.1016/S0962-8924(98)01491-3; HOLCOMB CL, 1988, J CELL BIOL, V106, P641, DOI 10.1083/jcb.106.3.641; Hong E, 1996, J CELL BIOL, V135, P623, DOI 10.1083/jcb.135.3.623; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; Kolling R, 1997, EMBO J, V16, P2251, DOI 10.1093/emboj/16.9.2251; Kolling R, 1996, EUR J BIOCHEM, V239, P356, DOI 10.1111/j.1432-1033.1996.0356u.x; KOPITO RR, 1999, PHYSIOL REV, V79, P167; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lucero P, 1997, APPL ENVIRON MICROB, V63, P3831, DOI 10.1128/AEM.63.10.3831-3836.1997; Luo WJ, 1997, J CELL BIOL, V138, P731, DOI 10.1083/jcb.138.4.731; Luo WJ, 2000, MOL BIOL CELL, V11, P579, DOI 10.1091/mbc.11.2.579; LUTSENKO S, 1995, BIOCHEMISTRY-US, V34, P15607, DOI 10.1021/bi00048a001; MOLDANO AM, 1998, GENETICS, V150, P11; Mori K, 2000, CELL, V101, P451, DOI 10.1016/S0092-8674(00)80855-7; Morsomme P, 2000, BBA-REV BIOMEMBRANES, V1469, P133, DOI 10.1016/S0304-4157(00)00015-0; MULHOLLAND J, 1994, J CELL BIOL, V125, P381, DOI 10.1083/jcb.125.2.381; Muniz M, 2001, CELL, V104, P313, DOI 10.1016/S0092-8674(01)00215-X; Nakamoto RK, 1998, J BIOL CHEM, V273, P7338, DOI 10.1074/jbc.273.13.7338; NAKAMOTO RK, 1991, J BIOL CHEM, V266, P7940; NAO SQ, 1995, J BIOL CHEM, V270, P6815, DOI 10.1074/jbc.270.12.6815; NISHIKAWA S, 1994, MOL BIOL CELL, V5, P1129, DOI 10.1091/mbc.5.10.1129; Patil C, 2001, CURR OPIN CELL BIOL, V13, P349, DOI 10.1016/S0955-0674(00)00219-2; POTENZA M, 1992, YEAST, V8, P549, DOI 10.1002/yea.320080706; PREUSS D, 1991, YEAST, V7, P891, DOI 10.1002/yea.320070902; RAO R, 1992, ANN NY ACAD SCI, V671, P195, DOI 10.1111/j.1749-6632.1992.tb43796.x; RATHS S, 1993, J CELL BIOL, V120, P55, DOI 10.1083/jcb.120.1.55; REDDING K, 1991, J CELL BIOL, V113, P527, DOI 10.1083/jcb.113.3.527; RICHTERRUOFF B, 1994, FEBS LETT, V354, P50, DOI 10.1016/0014-5793(94)01085-4; Roberg KJ, 1999, J CELL BIOL, V145, P659, DOI 10.1083/jcb.145.4.659; ROSE MD, 1989, CELL, V57, P1211, DOI 10.1016/0092-8674(89)90058-5; Rose MD., 1990, METHODS YEAST GENETI; Rossanese OW, 1999, J CELL BIOL, V145, P69, DOI 10.1083/jcb.145.1.69; ROSSI G, 1995, MOL BIOL CELL, V6, P1769, DOI 10.1091/mbc.6.12.1769; Roth AF, 1998, J CELL BIOL, V142, P949, DOI 10.1083/jcb.142.4.949; SERRANO R, 1986, NATURE, V319, P689, DOI 10.1038/319689a0; Sherman F., 1986, METHODS YEAST GENETI; SIKORSKI RS, 1989, GENETICS, V122, P19; Sommer T, 1997, FASEB J, V11, P1227, DOI 10.1096/fasebj.11.14.9409541; SUPPLY P, 1993, J BIOL CHEM, V268, P19744; THOMAS BJ, 1989, CELL, V56, P619, DOI 10.1016/0092-8674(89)90584-9; Toyoshima C, 2000, NATURE, V405, P647, DOI 10.1038/35015017; Travers KJ, 2000, CELL, V101, P249, DOI 10.1016/S0092-8674(00)80835-1; Umebayashi K, 1999, EUR J CELL BIOL, V78, P726, DOI 10.1016/S0171-9335(99)80041-7; Umebayashi K, 1997, YEAST, V13, P1009; VERGERES G, 1993, J CELL SCI, V106, P249; VILLALBA JM, 1992, J BIOL CHEM, V267, P12341; VOLLAND C, 1992, J BIOL CHEM, V267, P23767; WALWORTH NC, 1987, J CELL BIOL, V105, P163, DOI 10.1083/jcb.105.1.163; Wang QQ, 1999, EMBO J, V18, P5972, DOI 10.1093/emboj/18.21.5972; WANKER EE, 1995, J CELL BIOL, V130, P29, DOI 10.1083/jcb.130.1.29; Wesp A, 1997, MOL BIOL CELL, V8, P2291, DOI 10.1091/mbc.8.11.2291; Wilson MH, 2000, BIOCHEMISTRY-US, V39, P693, DOI 10.1021/bi9920275; WOOLFORD CA, 1986, MOL CELL BIOL, V6, P2500, DOI 10.1128/MCB.6.7.2500; WRIGHT R, 1988, J CELL BIOL, V107, P101, DOI 10.1083/jcb.107.1.101	91	38	41	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 7	2002	277	23					21027	21040		10.1074/jbc.M112281200	http://dx.doi.org/10.1074/jbc.M112281200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	562NJ	11877403	hybrid			2022-12-27	WOS:000176204500118
J	Mould, AP; Askari, JA; Barton, S; Kline, AD; McEwan, PA; Craig, SE; Humphries, MJ				Mould, AP; Askari, JA; Barton, S; Kline, AD; McEwan, PA; Craig, SE; Humphries, MJ			Integrin activation involves a conformational change in the alpha 1 helix of the beta subunit A-domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGAND-BINDING SITES; I-DOMAIN; ALPHA-5-BETA-1-FIBRONECTIN INTERACTIONS; INHIBITORY ANTI-ALPHA-5; MONOCLONAL-ANTIBODY; CRYSTAL-STRUCTURE; MOLECULAR-BASIS; ALPHA(5)BETA(1); IDENTIFICATION; RECOGNITION	The ligand-binding region of integrin beta subunits contains a von Willebrand factor type A-domain: an alpha/beta "Rossmann" fold containing a metal ion-dependent adhesion site (MIDAS) on its top face. Although there is evidence to suggest that the betaA-domain undergoes changes in tertiary structure during receptor activation, the identity of the secondary structure elements that change position is unknown. The mAb 12G10 recognizes a unique cation-regulated epitope on the beta(1) A-domain, induction of which parallels the activation state of the integrin (i.e. competency for ligand recognition). The ability of Mn2+ and Mg2+ to stimulate 12G10 binding is abrogated by mutation of the MIDAS motif, demonstrating that the MIDAS is a Mn2+/Mg2+ binding site and that occupancy of this site induces conformational changes in the A-domain. The cation-regulated region of the 12G10 epitope maps to Arg(154)/Arg(155) in the alpha1 helix. Our results demonstrate that the al helix undergoes conformational alterations during integrin activation and suggest that Mn2+ acts as a potent activator of beta(1) integrins because it can promote a shift in the position of this helix. The mechanism of beta subunit A-domain activation appears to be distinct from that of the A-domains found in some integrin alpha subunits.	Univ Manchester, Sch Biol Sci, Wellcome Trust Ctr Cell Matrix Res, Manchester M13 9PT, Lancs, England	University of Manchester	Mould, AP (corresponding author), Univ Manchester, Sch Biol Sci, Wellcome Trust Ctr Cell Matrix Res, 2-205 Stopford Bldg,Oxford Rd, Manchester M13 9PT, Lancs, England.			Humphries, Martin/0000-0002-4331-6967; mcewan, paul/0000-0001-6097-1528; Mould, Paul/0000-0003-0076-6228				BAJT ML, 1992, J BIOL CHEM, V267, P22211; Belkin AM, 1997, J CELL BIOL, V139, P1583, DOI 10.1083/jcb.139.6.1583; Burrows L, 1999, BIOCHEM J, V344, P527, DOI 10.1042/0264-6021:3440527; Chen LL, 2001, J BIOL CHEM, V276, P36520, DOI 10.1074/jbc.M106216200; Coe APF, 2001, J BIOL CHEM, V276, P35854, DOI 10.1074/jbc.M103639200; Curley GP, 1999, CELL MOL LIFE SCI, V56, P427, DOI 10.1007/s000180050443; Davies DR, 1996, P NATL ACAD SCI USA, V93, P7, DOI 10.1073/pnas.93.1.7; DRANSFIELD I, 1992, J CELL BIOL, V116, P219, DOI 10.1083/jcb.116.1.219; Emsley J, 2000, CELL, V101, P47, DOI 10.1016/S0092-8674(00)80622-4; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; Huang CC, 2000, J BIOL CHEM, V275, P21514, DOI 10.1074/jbc.M002286200; Humphries JD, 2000, J BIOL CHEM, V275, P20337, DOI 10.1074/jbc.M000568200; Humphries MJ, 2001, SCIENCE, V294, P316, DOI 10.1126/science.1066240; Humphries MJ, 2000, BIOCHEM SOC T, V28, P311, DOI 10.1042/0300-5127:0280311; Huth JR, 2000, P NATL ACAD SCI USA, V97, P5231, DOI 10.1073/pnas.97.10.5231; KAMATA T, 1995, BIOCHEM J, V305, P945, DOI 10.1042/bj3050945; KLINE AD, 2001, THESIS U MANCHESTER; Lee C, 2001, IBM SYST J, V40, P592, DOI 10.1147/sj.402.0592; LEE JO, 1995, CELL, V80, P631, DOI 10.1016/0092-8674(95)90517-0; Lee JO, 1995, STRUCTURE, V3, P1333, DOI 10.1016/S0969-2126(01)00271-4; LEVITT M, 1983, J MOL BIOL, V170, P723, DOI 10.1016/S0022-2836(83)80129-6; LEVITT M, 1992, J MOL BIOL, V226, P507, DOI 10.1016/0022-2836(92)90964-L; Lu CF, 2001, J BIOL CHEM, V276, P14642, DOI 10.1074/jbc.M100600200; Lu CF, 2001, P NATL ACAD SCI USA, V98, P2393, DOI 10.1073/pnas.041618598; Mastrangelo AM, 1999, J CELL SCI, V112, P217; Mould AP, 2000, J BIOL CHEM, V275, P20324, DOI 10.1074/jbc.M000572200; MOULD AP, 1995, J BIOL CHEM, V270, P26270, DOI 10.1074/jbc.270.44.26270; Mould AP, 1997, J BIOL CHEM, V272, P17283, DOI 10.1074/jbc.272.28.17283; Mould AP, 1996, J BIOL CHEM, V271, P20365, DOI 10.1074/jbc.271.34.20365; Mould AP, 1998, BIOCHEM J, V331, P821, DOI 10.1042/bj3310821; Mould AP, 1996, J CELL SCI, V109, P2613; MOULD AP, 1995, FEBS LETT, V363, P118, DOI 10.1016/0014-5793(95)00301-O; Oxvig C, 1999, P NATL ACAD SCI USA, V96, P2215, DOI 10.1073/pnas.96.5.2215; PuzonMcLaughlin W, 1996, J BIOL CHEM, V271, P20438, DOI 10.1074/jbc.271.34.20438; Ridgway JBB, 1996, PROTEIN ENG, V9, P617, DOI 10.1093/protein/9.7.617; Sheppard D, 2000, MATRIX BIOL, V19, P203, DOI 10.1016/S0945-053X(00)00065-2; SHI DT, 1997, J CELL SCI, V110, P2619; Shimaoka M, 2001, P NATL ACAD SCI USA, V98, P6009, DOI 10.1073/pnas.101130498; TAKADA Y, 1992, J CELL BIOL, V119, P913, DOI 10.1083/jcb.119.4.913; TAKADA Y, 1993, J BIOL CHEM, V268, P17597; Tuckwell DS, 1997, FEBS LETT, V400, P297, DOI 10.1016/S0014-5793(96)01368-3; Xiong JP, 2001, SCIENCE, V294, P339, DOI 10.1126/science.1064535; Xiong JP, 2000, J BIOL CHEM, V275, P38762, DOI 10.1074/jbc.C000563200; Xiong YM, 2001, J BIOL CHEM, V276, P19340, DOI 10.1074/jbc.M008903200; Zang Q, 2000, J BIOL CHEM, V275, P22202, DOI 10.1074/jbc.M002883200	45	108	109	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 31	2002	277	22					19800	19805		10.1074/jbc.M201571200	http://dx.doi.org/10.1074/jbc.M201571200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	557EH	11893752	hybrid			2022-12-27	WOS:000175894800073
J	Anderson, RM; Bitterman, KJ; Wood, JG; Medvedik, O; Cohen, H; Lin, SS; Manchester, JK; Gordon, JI; Sinclair, DA				Anderson, RM; Bitterman, KJ; Wood, JG; Medvedik, O; Cohen, H; Lin, SS; Manchester, JK; Gordon, JI; Sinclair, DA			Manipulation of a nuclear NAD(+) salvage pathway delays aging without altering steady-state NAD(+) levels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NICOTINIC-ACID PHOSPHORIBOSYLTRANSFERASE; SILENCING PROTEIN SIR2; RNA-POLYMERASE-I; SACCHAROMYCES-CEREVISIAE; LIFE-SPAN; CALORIC RESTRICTION; RIBOSOMAL DNA; NMN ADENYLYLTRANSFERASE; SALMONELLA-TYPHIMURIUM; CAENORHABDITIS-ELEGANS	Yeast deprived of nutrients exhibit a marked life span extension that requires the activity of the NAD(+)-dependent histone deacetylase, Sir2p. Here we show that increased dosage of NPT1, encoding a nicotinate phosphoribosyltransferase critical for the NAD+ salvage pathway, increases Sir2-dependent silencing, stabilizes the rDNA locus, and extends yeast replicative life span by up to 60%. Both NPT1 and SIR2 provide resistance against heat shock, demonstrating that these genes act in a more general manner to promote cell survival. We show that Npt1 and a previously uncharacterized salvage pathway enzyme, Nma2, are both concentrated in the nucleus, indicating that a significant amount of NAD(+) is regenerated in this organelle. Additional copies of the salvage pathway genes, PNC1, NMA1, and NMA2, increase telomeric and rDNA silencing, implying that multiple steps affect the rate of the pathway. Although SIR2-dependent processes are enhanced by additional NPT1, steady-state NAD(+) levels and NAD(+)/NADH ratios remain unaltered. This finding suggests that yeast life span extension may be facilitated by an increase in the availability of NAD(+) to Sir2, although not through a simple increase in steady-state levels. We propose a model in which increased flux through the NAD(+) salvage pathway is responsible for the Sir2-dependent extension of life span.	Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA; Washington Univ, Sch Med, Dept Mol Biol & Pharmacol, St Louis, MO 63110 USA	Harvard University; Harvard Medical School; Washington University (WUSTL)	Sinclair, DA (corresponding author), Harvard Univ, Sch Med, Dept Pathol, 200 Longwood Ave, Boston, MA 02115 USA.			Sinclair, David/0000-0002-9936-436X; Cohen, Haim Y./0000-0002-6613-8710				Afshar G, 1999, GENE, V234, P161, DOI 10.1016/S0378-1119(99)00162-6; Ashrafi K, 2000, GENE DEV, V14, P1872; BARTON AA, 1950, J GEN MICROBIOL, V4, P84, DOI 10.1099/00221287-4-1-84; BECKER DM, 1991, P NATL ACAD SCI USA, V88, P1968, DOI 10.1073/pnas.88.5.1968; Bedalov A, 2001, P NATL ACAD SCI USA, V98, P15113, DOI 10.1073/pnas.261574398; Bernstein BE, 2000, P NATL ACAD SCI USA, V97, P13708, DOI 10.1073/pnas.250477697; Campisi J, 2000, SCIENCE, V289, P2062, DOI 10.1126/science.289.5487.2062; Clancy DJ, 2001, SCIENCE, V292, P104, DOI 10.1126/science.1057991; D'Angelo I, 2000, STRUCTURE, V8, P993, DOI 10.1016/S0969-2126(00)00190-8; De Antoni A, 2000, GENE, V246, P179, DOI 10.1016/S0378-1119(00)00083-4; Defossez PA, 1999, MOL CELL, V3, P447, DOI 10.1016/S1097-2765(00)80472-4; Emanuelli M, 1999, FEBS LETT, V455, P13, DOI 10.1016/S0014-5793(99)00852-2; FELL D, 1997, FRONTIERS METABOLISM, P18; FOSTER JW, 1979, J BACTERIOL, V137, P1165, DOI 10.1128/JB.137.3.1165-1175.1979; Ghislain M, 2002, YEAST, V19, P215, DOI 10.1002/yea.810; GOTTSCHLING DE, 1990, CELL, V63, P751, DOI 10.1016/0092-8674(90)90141-Z; Grubmeyer CT, 1999, METHOD ENZYMOL, V308, P28; Guarente L, 2000, GENE DEV, V14, P1021; Guarente L, 2000, NATURE, V408, P255, DOI 10.1038/35041700; Guldener U, 1996, NUCLEIC ACIDS RES, V24, P2519, DOI 10.1093/nar/24.13.2519; HOGEBOOM G, 1950, J BIOL CHEM, V197, P611; HUGHES KT, 1988, J BACTERIOL, V170, P2113, DOI 10.1128/jb.170.5.2113-2120.1988; Imai S, 2000, NATURE, V403, P795, DOI 10.1038/35001622; IMSANDE J, 1964, BIOCHIM BIOPHYS ACTA, V85, P255, DOI 10.1016/0926-6569(64)90246-9; Jazwinski SM, 2001, MECH AGEING DEV, V122, P865, DOI 10.1016/S0047-6374(01)00244-5; Jiang JC, 2000, FASEB J, V14, P2135; Kaeberlein M, 1999, GENE DEV, V13, P2570, DOI 10.1101/gad.13.19.2570; KEIL RL, 1993, GENETICS, V135, P711; Kennedy BK, 1996, TRENDS GENET, V12, P355, DOI 10.1016/0168-9525(96)10039-1; KENNEDY BK, 1994, J CELL BIOL, V127, P1985, DOI 10.1083/jcb.127.6.1985; Kenyon C, 2001, CELL, V105, P165, DOI 10.1016/S0092-8674(01)00306-3; Kim S, 1996, BIOCHEM BIOPH RES CO, V219, P370, DOI 10.1006/bbrc.1996.0240; KIRKWOOD TBL, 1991, PHILOS T R SOC B, V332, P15, DOI 10.1098/rstb.1991.0028; LALO D, 1993, P NATL ACAD SCI USA, V90, P5524, DOI 10.1073/pnas.90.12.5524; Landry J, 2000, BIOCHEM BIOPH RES CO, V278, P685, DOI 10.1006/bbrc.2000.3854; Landry J, 2000, P NATL ACAD SCI USA, V97, P5807, DOI 10.1073/pnas.110148297; LAURENSON P, 1992, MICROBIOL REV, V56, P543, DOI 10.1128/MMBR.56.4.543-560.1992; Lin SJ, 2000, SCIENCE, V289, P2126, DOI 10.1126/science.289.5487.2126; Lin SS, 2001, J BIOL CHEM, V276, P36000, DOI 10.1074/jbc.M103509200; Longo VD, 1999, NEUROBIOL AGING, V20, P479, DOI 10.1016/S0197-4580(99)00089-5; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.3.CO;2-L; Masoro EJ, 2000, EXP GERONTOL, V35, P299, DOI 10.1016/S0531-5565(00)00084-X; Mills KD, 1999, CELL, V97, P609, DOI 10.1016/S0092-8674(00)80772-2; MORTIMER RK, 1959, NATURE, V183, P1751, DOI 10.1038/1831751a0; Olland AM, 2002, J BIOL CHEM, V277, P3698, DOI 10.1074/jbc.M109670200; Park PU, 1999, MOL CELL BIOL, V19, P3848; Perrod S, 2001, EMBO J, V20, P197, DOI 10.1093/emboj/20.1.197; Rajavel M, 1998, BIOCHEMISTRY-US, V37, P4181, DOI 10.1021/bi9720134; Saridakis V, 2001, J BIOL CHEM, V276, P7225, DOI 10.1074/jbc.M008810200; Shore D, 2000, P NATL ACAD SCI USA, V97, P14030, DOI 10.1073/pnas.011506198; Shou WY, 1999, CELL, V97, P233, DOI 10.1016/S0092-8674(00)80733-3; Shou WY, 2001, MOL CELL, V8, P45, DOI 10.1016/S1097-2765(01)00291-X; SIKORSKI RS, 1989, GENETICS, V122, P19; Sinclair DA, 1997, CELL, V91, P1033, DOI 10.1016/S0092-8674(00)80493-6; Sinclair DA, 1997, SCIENCE, V277, P1313, DOI 10.1126/science.277.5330.1313; Smith JS, 2000, P NATL ACAD SCI USA, V97, P6658, DOI 10.1073/pnas.97.12.6658; Smith JS, 1997, GENE DEV, V11, P241, DOI 10.1101/gad.11.2.241; Smith JS, 1999, MOL CELL BIOL, V19, P3184; Straight AF, 1999, CELL, V97, P245, DOI 10.1016/S0092-8674(00)80734-5; Tanner KG, 2000, P NATL ACAD SCI USA, V97, P14178, DOI 10.1073/pnas.250422697; Tanny JC, 2001, P NATL ACAD SCI USA, V98, P415, DOI 10.1073/pnas.031563798; Tissenbaum HA, 2001, NATURE, V410, P227, DOI 10.1038/35065638; Uetz P, 2000, NATURE, V403, P623, DOI 10.1038/35001009; Vanfleteren JR, 1999, NEUROBIOL AGING, V20, P487, DOI 10.1016/S0197-4580(99)00087-1; VINITSKY A, 1991, J BACTERIOL, V173, P536, DOI 10.1128/jb.173.2.536-540.1991; Winzeler EA, 1999, SCIENCE, V285, P901, DOI 10.1126/science.285.5429.901; WUBBOLTS MG, 1990, J BIOL CHEM, V265, P17665; Zainal TA, 2000, FASEB J, V14, P1825, DOI 10.1096/fj.99-0881com	68	236	255	1	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 24	2002	277	21					18881	18890		10.1074/jbc.M111773200	http://dx.doi.org/10.1074/jbc.M111773200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	558PM	11884393	hybrid, Green Published			2022-12-27	WOS:000175975800083
J	Massant, J; Verstreken, P; Durbecq, V; Kholti, A; Legrain, C; Beeckmans, S; Cornelis, P; Glansdorff, N				Massant, J; Verstreken, P; Durbecq, V; Kholti, A; Legrain, C; Beeckmans, S; Cornelis, P; Glansdorff, N			Metabolic channeling of carbamoyl phosphate, a thermolabile intermediate - Evidence for physical interaction between carbamate kinase-like carbamoyl-phosphate synthetase and ornithine carbamoyltransferase from the hyperthermophile Pyrococcus furiosus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PYRIMIDINE PATHWAY ENZYMES; CITRIC-ACID CYCLE; SACCHAROMYCES-CEREVISIAE; CRYSTAL-STRUCTURE; ASPARTATE-TRANSCARBAMYLASE; MALATE-DEHYDROGENASE; EXTREME ENVIRONMENTS; HIGH-TEMPERATURES; ESCHERICHIA-COLI; STABILITY	Two different approaches provided evidence for a physical interaction between the carbamate kinase-like carbamoyl-phosphate synthetase (CKase) and ornithine carbamoyltransferase (OTCase) from the hyperthermophilic archaeon Pyrococcus furiosus. Affinity electrophoresis indicated that CKase and OTCase associate into a multienzyme cluster. Further evidence for a biologically significant interaction between CKase and OTCase was obtained by co-immunoprecipitation combined with formaldehyde cross-linking experiments. These experiments support the hypothesis that CKase and OTCase form an efficient channeling cluster for carbamoyl phosphate, an extremely thermolabile and potentially toxic metabolic intermediate. Therefore, by physically interacting with each other, CKase and OTCase prevent the thermodenaturation of carbamoyl. phosphate in the aqueous cytoplasmic environment.	Free Univ Brussels VIB, Dept Microbiol, B-1070 Brussels, Belgium; Inst Rech JM Wiame, B-1070 Brussels, Belgium; Free Univ Brussels, Microbiol Lab, B-1070 Brussels, Belgium; Free Univ Brussels VIB, Dept Immunol Parasitol & Ultrastruct, Lab Microbial Interact, B-1640 Rhode St Genese, Belgium; Free Univ Brussels, Prot Chem Lab, B-1640 Rhode St Genese, Belgium	Flanders Institute for Biotechnology (VIB); Vrije Universiteit Brussel; Universite Libre de Bruxelles; Vrije Universiteit Brussel; Flanders Institute for Biotechnology (VIB); Vrije Universiteit Brussel	Massant, J (corresponding author), Free Univ Brussels VIB, Dept Microbiol, 808 Route Lennik, B-1070 Brussels, Belgium.	jan.massant@vub.ac.be; nglansdo@vub.ac.be	Hu, Ruogu/B-2203-2008; Cornelis, Pierre/H-3058-2019; Verstreken, Patrik/AAC-7591-2022	Verstreken, Patrik/0000-0002-5073-5393				ADAMS MWW, 1993, ANNU REV MICROBIOL, V47, P627, DOI 10.1146/annurev.micro.47.1.627; ALLEN CM, 1964, BIOCHEMISTRY-US, V3, P1238, DOI 10.1021/bi00897a010; Anderson KS, 1999, METHOD ENZYMOL, V308, P111; BEECKMANS S, 1981, EUR J BIOCHEM, V117, P527; BEECKMANS S, 1989, EUR J BIOCHEM, V183, P449, DOI 10.1111/j.1432-1033.1989.tb14948.x; Beeckmans S, 1999, METHODS, V19, P278, DOI 10.1006/meth.1999.0857; BEECKMANS S, 1993, J MOL RECOGNIT, V6, P195, DOI 10.1002/jmr.300060408; BELKAID M, 1988, ARCH BIOCHEM BIOPHYS, V262, P171, DOI 10.1016/0003-9861(88)90179-8; Bera AK, 2000, J BIOL CHEM, V275, P7975, DOI 10.1074/jbc.275.11.7975; BUCKLE PE, 1993, BIOSENS BIOELECTRON, V8, P355, DOI 10.1016/0956-5663(93)80074-Y; BURNS VW, 1964, SCIENCE, V146, P1056, DOI 10.1126/science.146.3647.1056; Caspary F, 1999, EMBO J, V18, P3463, DOI 10.1093/emboj/18.12.3463; CHRISTOPHERSON RI, 1980, J BIOL CHEM, V255, P1381; Clantin B, 2001, EUR J BIOCHEM, V268, P3937, DOI 10.1046/j.1432-1327.2001.02302.x; COHEN NS, 1992, BIOCHEM J, V282, P173, DOI 10.1042/bj2820173; CONSALVI V, 1991, EUR J BIOCHEM, V202, P1189, DOI 10.1111/j.1432-1033.1991.tb16489.x; CULLIN C, 1994, YEAST, V10, P105, DOI 10.1002/yea.320100110; CUSH R, 1993, BIOSENS BIOELECTRON, V8, P347, DOI 10.1016/0956-5663(93)80073-X; Daniel RM, 2000, CELL MOL LIFE SCI, V57, P250, DOI 10.1007/PL00000688; DEGUNZBURG J, 1989, P NATL ACAD SCI USA, V86, P4007; Durbecq V, 1997, P NATL ACAD SCI USA, V94, P12803, DOI 10.1073/pnas.94.24.12803; FIALA G, 1986, ARCH MICROBIOL, V145, P56, DOI 10.1007/BF00413027; HARLOW E, 1999, USING ANTIBODIES LAB, P221; Holden HM, 1998, CURR OPIN STRUC BIOL, V8, P679, DOI 10.1016/S0959-440X(98)80086-9; HUANG S, 1991, NATURE, V350, P160, DOI 10.1038/350160a0; Irvine HS, 1997, EUR J BIOCHEM, V247, P1063, DOI 10.1111/j.1432-1033.1997.01063.x; JAENICKE R, 1991, EUR J BIOCHEM, V202, P715, DOI 10.1111/j.1432-1033.1991.tb16426.x; Jaenicke R, 1998, CURR OPIN STRUC BIOL, V8, P738, DOI 10.1016/S0959-440X(98)80094-8; LEGRAIN C, 1976, EUR J BIOCHEM, V63, P289, DOI 10.1111/j.1432-1033.1976.tb10230.x; Legrain C, 2001, METHOD ENZYMOL, V331, P227; Legrain C, 1997, EUR J BIOCHEM, V247, P1046, DOI 10.1111/j.1432-1033.1997.01046.x; LEGRAIN C, 1995, MICROBIOL-SGM, V141, P1093, DOI 10.1099/13500872-141-5-1093; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MEISTER A, 1989, ADV ENZYMOL RAMB, V62, P315; MESSENGUY F, 1976, J BACTERIOL, V128, P49, DOI 10.1128/JB.128.1.49-55.1976; OVADI J, 1991, J THEOR BIOL, V152, P1, DOI 10.1016/S0022-5193(05)80500-4; PENVERNE B, 1994, ARCH BIOCHEM BIOPHYS, V309, P85, DOI 10.1006/abbi.1994.1089; PRESCOTT LM, 1969, ANAL BIOCHEM, V32, P408, DOI 10.1016/S0003-2697(69)80008-4; PROSSNITZ E, 1988, J BIOL CHEM, V263, P17917; Purcarea C, 1996, EUR J BIOCHEM, V236, P189, DOI 10.1111/j.1432-1033.1996.00189.x; Purcarea C, 1999, J BIOL CHEM, V274, P6122, DOI 10.1074/jbc.274.10.6122; Purcarea C, 2001, EXTREMOPHILES, V5, P229, DOI 10.1007/s007920100201; Ramon-Maiques S, 2000, J MOL BIOL, V299, P463, DOI 10.1006/jmbi.2000.3779; Roovers M, 1997, EUR J BIOCHEM, V247, P1038, DOI 10.1111/j.1432-1033.1997.01038.x; SRERE PA, 1987, ANNU REV BIOCHEM, V56, P89, DOI 10.1146/annurev.bi.56.070187.000513; SRIVASTAVA DK, 1987, ANNU REV BIOPHYS BIO, V16, P175; SRIVASTAVA DK, 1986, SCIENCE, V234, P1081, DOI 10.1126/science.3775377; STALON V, 1972, EUR J BIOCHEM, V29, P25, DOI 10.1111/j.1432-1033.1972.tb01953.x; Uriarte M, 1999, J BIOL CHEM, V274, P16295, DOI 10.1074/jbc.274.23.16295; Uriarte M, 2001, METHOD ENZYMOL, V331, P236; VandeCasteele M, 1997, COMP BIOCHEM PHYS A, V118, P463, DOI 10.1016/S0300-9629(97)00007-8; Vieille C, 2001, MICROBIOL MOL BIOL R, V65, P1, DOI 10.1128/MMBR.65.1.1-43.2001; VILLERET V, 1995, P NATL ACAD SCI USA, V92, P10762, DOI 10.1073/pnas.92.23.10762; Villeret V, 1998, P NATL ACAD SCI USA, V95, P2801, DOI 10.1073/pnas.95.6.2801; WANDERS RJA, 1984, EUR J BIOCHEM, V142, P247, DOI 10.1111/j.1432-1033.1984.tb08278.x; WERNER M, 1987, CELL, V49, P805, DOI 10.1016/0092-8674(87)90618-0; WILLIAMS LG, 1970, BIOCHEMISTRY-US, V9, P4329, DOI 10.1021/bi00824a013; WILLIAMS LG, 1971, J BIOL CHEM, V246, P973; Zierenberg RA, 2000, P NATL ACAD SCI USA, V97, P12961, DOI 10.1073/pnas.210395997	59	18	19	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 24	2002	277	21					18517	18522		10.1074/jbc.M111481200	http://dx.doi.org/10.1074/jbc.M111481200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	558PM	11893735	Green Published, hybrid			2022-12-27	WOS:000175975800036
J	Watanabe, A; Yoshimura, T; Mikami, B; Hayashi, H; Kagamiyama, H; Esaki, N				Watanabe, A; Yoshimura, T; Mikami, B; Hayashi, H; Kagamiyama, H; Esaki, N			Reaction mechanism of alanine racemase from Bacillus stearothermophilus - X-ray crystallographic studies of the enzyme bound with N-(5 '-phosphopyridoxyl)alanine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE-265	The crystal structures of alanine racemase bound with reaction intermediate analogs, N-(5'-phosphopyridoxyl)-L-alanine (PLP-L-Ala) and N-(5'-phosphopyridoxyl)-D-alanine (PLP-D-Ala), were determined at 2.0-Angstrom resolution with the crystallographic R factor of 17.2 for PLP-L-Ala and 16.9 for PLP-D-Ala complexes. They were quite similar not only to each other but also to the structure of the native pyridoxal 5'-phosphate (PLP)-form enzyme; root mean square deviations at Calpha among the three structures were less than 0.28 Angstrom. The side chains of the amino acid residues around the PLP-L-Ala and PLP-D-Ala were virtually superimposable on each other as well as on those around PLP of the native holoenzyme. The alpha-hydrogen of the alanine moiety of PLP-L-Ala was located near the OH of Tyr(265'), whereas that of PLP-D-Ala was near the NZ of Lys(39). These support the previous findings that Tyr(265)' and Lys(39) are the catalytic bases removing alpha-hydrogen from L- and D-alanine, respectively. The prerequisite for this two-base mechanism is that the alpha-proton abstracted from the substrate is transferred (directly or indirectly) between the NZ of Lys(39) and the OH of Tyr(265'); otherwise the enzyme reaction stops after a single turnover. Only the carboxylate oxygen atom of either PLP-Ala enantiomer occurred at a reasonable position that can mediate the proton transfer, neither the amino acid side chains nor the water molecules were located in the vicinity. Therefore, we propose a mechanism of alanine racemase reaction in which the substrate carboxyl group directly participates in the catalysis by mediating the proton transfer between the two catalytic bases, Lys(39) and Tyr(265'). The results of molecular orbital calculation also support this mechanism.	Kyoto Univ, Inst Chem Res, Kyoto 6110011, Japan; Kyoto Univ, Grad Sch Agr, Dept Agron & Hort Sci, Kyoto 6110011, Japan; Osaka Med Coll, Dept Biochem, Takatsuki, Osaka 5698686, Japan	Kyoto University; Kyoto University; Osaka Medical College	Esaki, N (corresponding author), Kyoto Univ, Inst Chem Res, Kyoto 6110011, Japan.							AHRENS H., 1970, Methods in Enzymology, V18A, P489, DOI 10.1016/0076-6879(71)18349-8; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; BRUNGER AT, 1996, XPLOR VERSION 3 851; FARACI WS, 1988, BIOCHEMISTRY-US, V27, P3267, DOI 10.1021/bi00409a022; GRISHIN NV, 1995, PROTEIN SCI, V4, P1291, DOI 10.1002/pro.5560040705; IKAWA M, 1967, ARCH BIOCHEM BIOPHYS, V118, P497, DOI 10.1016/0003-9861(67)90378-5; KLEYWEGT GJ, 1995, ESF CCP4 NEWSLETT, V31, P45; Kurokawa Y, 1998, J BIOCHEM-TOKYO, V124, P1163, DOI 10.1093/oxfordjournals.jbchem.a022234; Morollo AA, 1999, BIOCHEMISTRY-US, V38, P3293, DOI 10.1021/bi9822729; Peisach D, 1998, BIOCHEMISTRY-US, V37, P4958, DOI 10.1021/bi972884d; Shaw JP, 1997, BIOCHEMISTRY-US, V36, P1329, DOI 10.1021/bi961856c; Stamper CGF, 1998, BIOCHEMISTRY-US, V37, P10438, DOI 10.1021/bi980692s; Sun SX, 1999, BIOCHEMISTRY-US, V38, P4058, DOI 10.1021/bi982924t; WALSH CT, 1989, J BIOL CHEM, V264, P2393; Watababe A, 1999, J BIOL CHEM, V274, P4189, DOI 10.1074/jbc.274.7.4189; Watanabe A, 1999, J BIOCHEM-TOKYO, V125, P987, DOI 10.1093/oxfordjournals.jbchem.a022406; Watanabe A, 1999, J BIOCHEM-TOKYO, V126, P781, DOI 10.1093/oxfordjournals.jbchem.a022517	18	114	123	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 24	2002	277	21					19166	19172		10.1074/jbc.M201615200	http://dx.doi.org/10.1074/jbc.M201615200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	558PM	11886871	hybrid			2022-12-27	WOS:000175975800119
J	Talley, EM; Bayliss, DA				Talley, EM; Bayliss, DA			Modulation of TASK-1 (Kcnk3) and TASK-3 (Kcnk9) potassium channels - Volatile anesthetics and neurotransmitters share a molecular site of action	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACKGROUND K+ CHANNEL; INHALATION ANESTHETICS; FUNCTIONAL EXPRESSION; PHOSPHOLIPASE-C; PROTEIN-KINASE; DOMAIN; FAMILY; PORE; INHIBITION; ACID	TASK-1 and TASK-3, members of the two-pore-domain channel family, are widely expressed leak potassium channels responsible for maintenance of cell membrane potential and input resistance. They are sites of action for a variety of modulatory agents, including volatile anesthetics and neurotransmitters/hormones, the latter acting via mechanisms that have remained elusive. To clarify these mechanisms, we generated mutant channels and found that alterations disrupting anesthetic (halothane) activation of these channels also disrupted transmitter (thyrotropin-releasing hormone, TRH) inhibition and did so to a similar degree. For both TASK-1 and TASK-3, mutations (substitutions with corresponding residues from TREK-1) in a six-residue sequence at the beginning of the cytoplasmic C terminus virtually abolished both anesthetic activation and transmitter inhibition. The only sequence motif identified with a classical signaling mechanism in this region is a potential phosphorylation site; however, mutation of this site failed to disrupt modulation. TASK-1 and TASK-3 differed insofar as a large portion of the C terminus was necessary for the full effects of halothane and TRH on TASK-3 but not on TASK-1. Finally, tandem-linked TASK-1/TA.SK-3 heterodimeric channels were fully modulated by anesthetic and transmitter, and introduction of the identified mutations either into the TASK-1 or the TASK-3 portion of the channel was sufficient to disrupt both effects. Thus, both anesthetic activation and transmitter inhibition of these channels require a region at the interface between the final transmembrane domain and the cytoplasmic C terminus that has not been associated previously with receptor signal transduction. Our results also indicate a close molecular relationship between these two forms of modulation, one endogenous and the other clinically applied.	Univ Virginia, Dept Pharmacol, Charlottesville, VA 22908 USA	University of Virginia	Talley, EM (corresponding author), Univ Virginia Hlth Syst, Dept Pharmacol, POB 800735, Charlottesville, VA 22908 USA.	emt3m@virginia.edu			NIGMS NIH HHS [R01 GM066181] Funding Source: Medline; NINDS NIH HHS [NS33583] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM066181] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS033583, R29NS033583] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Ashmole I, 2001, PFLUG ARCH EUR J PHY, V442, P828, DOI 10.1007/s004240100620; Bayliss DA, 2001, RESP PHYSIOL, V129, P159, DOI 10.1016/S0034-5687(01)00288-2; Boyd DF, 2000, J PHYSIOL-LONDON, V529, P321, DOI 10.1111/j.1469-7793.2000.00321.x; Buckler KJ, 2000, J PHYSIOL-LONDON, V525, P135, DOI 10.1111/j.1469-7793.2000.00135.x; Czirjak G, 2002, J BIOL CHEM, V277, P5426, DOI 10.1074/jbc.M107138200; Czirjak G, 2000, MOL ENDOCRINOL, V14, P863, DOI 10.1210/me.14.6.863; Czirjak G, 2001, AM J PHYSIOL-CELL PH, V281, pC700, DOI 10.1152/ajpcell.2001.281.2.C700; Decher N, 2001, FEBS LETT, V492, P84, DOI 10.1016/S0014-5793(01)02222-0; Duprat F, 1997, EMBO J, V16, P5464, DOI 10.1093/emboj/16.17.5464; Fink M, 1998, EMBO J, V17, P3297, DOI 10.1093/emboj/17.12.3297; Fink M, 1996, EMBO J, V15, P6854, DOI 10.1002/j.1460-2075.1996.tb01077.x; Flynn GE, 2001, NAT REV NEUROSCI, V2, P643, DOI 10.1038/35090015; Girard C, 2001, BIOCHEM BIOPH RES CO, V282, P249, DOI 10.1006/bbrc.2001.4562; Goldstein SAN, 2001, NAT REV NEUROSCI, V2, P175, DOI 10.1038/35058574; Hilgemann D W, 2001, Sci STKE, V2001, pre19, DOI 10.1126/stke.2001.111.re19; Karschin C, 2001, MOL CELL NEUROSCI, V18, P632, DOI 10.1006/mcne.2001.1045; Kim D, 2001, BIOCHEM BIOPH RES CO, V284, P923, DOI 10.1006/bbrc.2001.5064; Kim D, 1998, CIRC RES, V82, P513, DOI 10.1161/01.RES.82.4.513; KIM GD, 1994, J BIOL CHEM, V269, P19933; Kim Y, 2000, J BIOL CHEM, V275, P9340, DOI 10.1074/jbc.275.13.9340; Kobrinsky E, 2000, NAT CELL BIOL, V2, P507, DOI 10.1038/35019544; Koh SD, 2001, J BIOL CHEM, V276, P44338, DOI 10.1074/jbc.M108125200; Lei WB, 2001, J BIOL CHEM, V276, P16720, DOI 10.1074/jbc.M100207200; Leonoudakis D, 1998, J NEUROSCI, V18, P868; Lesage F, 2000, AM J PHYSIOL-RENAL, V279, pF793, DOI 10.1152/ajprenal.2000.279.5.F793; Lopes CMB, 2001, J BIOL CHEM, V276, P24449, DOI 10.1074/jbc.C100184200; Lopes CMB, 2000, J BIOL CHEM, V275, P16969, DOI 10.1074/jbc.M001948200; Maejima T, 2001, NEURON, V31, P463, DOI 10.1016/S0896-6273(01)00375-0; Maingret F, 2001, EMBO J, V20, P47, DOI 10.1093/emboj/20.1.47; MATTINGLY RR, 1994, MOL CELL BIOL, V14, P7943, DOI 10.1128/MCB.14.12.7943; Meadows HJ, 2001, NEUROPHARMACOLOGY, V40, P551, DOI 10.1016/S0028-3908(00)00189-1; Millar JA, 2000, P NATL ACAD SCI USA, V97, P3614, DOI 10.1073/pnas.050012597; Patel AJ, 1999, NAT NEUROSCI, V2, P422, DOI 10.1038/8084; Patel AJ, 1998, EMBO J, V17, P4283, DOI 10.1093/emboj/17.15.4283; Patel AJ, 2001, TRENDS NEUROSCI, V24, P339, DOI 10.1016/S0166-2236(00)01810-5; Rajan S, 2000, J BIOL CHEM, V275, P16650, DOI 10.1074/jbc.M000030200; Reyes R, 1998, J BIOL CHEM, V273, P30863, DOI 10.1074/jbc.273.47.30863; Sambrook J., 2001, MOL CLONING LAB MANU; Sirois JE, 1998, J PHYSIOL-LONDON, V512, P851, DOI 10.1111/j.1469-7793.1998.851bd.x; Talley EM, 2001, J NEUROSCI, V21, P7491, DOI 10.1523/JNEUROSCI.21-19-07491.2001; Talley EM, 2000, NEURON, V25, P399, DOI 10.1016/S0896-6273(00)80903-4; Vega-Saenz de Miera E, 2001, J NEUROPHYSIOL, V86, P130, DOI 10.1152/jn.2001.86.1.130; Washburn CP, 2002, J NEUROSCI, V22, P1256, DOI 10.1523/JNEUROSCI.22-04-01256.2002; White RR, 1998, J BIOL CHEM, V273, P3166, DOI 10.1074/jbc.273.6.3166	45	164	169	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 17	2002	277	20					17733	17742		10.1074/jbc.M200502200	http://dx.doi.org/10.1074/jbc.M200502200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	553PR	11886861	hybrid			2022-12-27	WOS:000175685100045
J	Farrell, CM; Mackey, AT; Klumpp, LM; Gilbert, SP				Farrell, CM; Mackey, AT; Klumpp, LM; Gilbert, SP			The role of ATP hydrolysis for kinesin processivity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOTOR PROTEINS; DICTYOSTELIUM MYOSIN; CRYSTAL-STRUCTURE; MOLECULAR MOTORS; DIMERIC KINESIN; SALT-BRIDGE; DOMAIN; MECHANISM; KINETICS; SITE	Conventional kinesin is a highly processive, plus-end-directed microtubule-based motor that drives membranous organelles toward the synapse in neurons. Although recent structural, biochemical, and mechanical measurements are beginning to converge into a common view of how kinesin converts the energy from ATP turnover into motion, it remains difficult to dissect experimentally the intermolecular domain cooperativity required for kinesin processivity. We report here our pre-steady-state kinetic analysis of a kinesin switch I mutant at Arg(210) (NXXSSRSH, residues 205-212 in Drosophila kinesin). The results show that the R210A substitution results in a dimeric kinesin that is defective for ATP hydrolysis and a motor that cannot detach from the microtubule although ATP binding and microtubule association occur. We propose a mechanistic model in which ATP binding at head 1 leads to the plus-end-directed motion of the neck linker to position head 2 forward at the next microtubule binding site. However, ATP hydrolysis is required at head 1 to lock head 2 onto the microtubule in a tight binding state before head 1 dissociation from the microtubule. This mechanism optimizes forward movement and processivity by ensuring that one motor domain is tightly bound to the microtubule before the second can detach.	Univ Pittsburgh, Dept Biol Sci, Pittsburgh, PA 15260 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Gilbert, SP (corresponding author), Univ Pittsburgh, Dept Biol Sci, 518 Langley Hall, Pittsburgh, PA 15260 USA.				NIGMS NIH HHS [R01 GM054141, GM 54141] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM054141, R01GM054141] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Brendza KM, 1999, J BIOL CHEM, V274, P31506, DOI 10.1074/jbc.274.44.31506; Brendza KM, 2000, J BIOL CHEM, V275, P22187, DOI 10.1074/jbc.M001124200; CORREIA JJ, 1995, BIOCHEMISTRY-US, V34, P4898, DOI 10.1021/bi00014a047; Crevel I, 1999, EMBO J, V18, P5863, DOI 10.1093/emboj/18.21.5863; Foster KA, 1998, J BIOL CHEM, V273, P35307, DOI 10.1074/jbc.273.52.35307; Foster KA, 2000, BIOCHEMISTRY-US, V39, P1784, DOI 10.1021/bi991500b; Furch M, 1999, J MOL BIOL, V290, P797, DOI 10.1006/jmbi.1999.2921; Geeves MA, 1999, ANNU REV BIOCHEM, V68, P687, DOI 10.1146/annurev.biochem.68.1.687; GILBERT SP, 1995, NATURE, V373, P671, DOI 10.1038/373671a0; GILBERT SP, 1994, BIOCHEMISTRY-US, V33, P1951, DOI 10.1021/bi00173a044; GILBERT SP, 1993, BIOCHEMISTRY-US, V32, P4677, DOI 10.1021/bi00068a028; Gilbert SP, 1998, BIOCHEMISTRY-US, V37, P792, DOI 10.1021/bi971117b; Gilbert SP, 2000, METHODS, V22, P337, DOI 10.1006/meth.2000.1086; HACKNEY DD, 1994, P NATL ACAD SCI USA, V91, P6865, DOI 10.1073/pnas.91.15.6865; HACKNEY DD, 1989, J BIOL CHEM, V264, P15943; HOWARD J, 1989, NATURE, V342, P154, DOI 10.1038/342154a0; Hua W, 1997, NATURE, V388, P390, DOI 10.1038/41118; Kozielski F, 1997, CELL, V91, P985, DOI 10.1016/S0092-8674(00)80489-4; Kull FJ, 1998, J MUSCLE RES CELL M, V19, P877, DOI 10.1023/A:1005489907021; Kull FJ, 1996, NATURE, V380, P550, DOI 10.1038/380550a0; LOCKHART A, 1995, FEBS LETT, V368, P531, DOI 10.1016/0014-5793(95)00723-M; Ma YZ, 1997, J BIOL CHEM, V272, P724, DOI 10.1074/jbc.272.2.724; MA YZ, 1995, BIOCHEMISTRY-US, V34, P13242, DOI 10.1021/bi00040a040; Mandelkow E, 1998, TRENDS BIOCHEM SCI, V23, P429, DOI 10.1016/S0968-0004(98)01278-X; Minehardt TJ, 2001, BIOPHYS J, V80, P1151, DOI 10.1016/S0006-3495(01)76092-4; Moyer ML, 1998, BIOCHEMISTRY-US, V37, P800, DOI 10.1021/bi9711184; MOYER ML, 1998, THESIS PENNSYLVANIA; Muller J, 1999, BIOL CHEM, V380, P981, DOI 10.1515/BC.1999.122; Onishi H, 1998, P NATL ACAD SCI USA, V95, P6653, DOI 10.1073/pnas.95.12.6653; Pate E, 1997, BIOCHEMISTRY-US, V36, P12155, DOI 10.1021/bi970996z; Rice S, 1999, NATURE, V402, P778, DOI 10.1038/45483; Sack S, 1997, BIOCHEMISTRY-US, V36, P16155, DOI 10.1021/bi9722498; Sack S, 1999, EUR J BIOCHEM, V262, P1, DOI 10.1046/j.1432-1327.1999.00341.x; SADHU A, 1992, J BIOL CHEM, V267, P11352; Sasaki N, 1998, J BIOL CHEM, V273, P20334, DOI 10.1074/jbc.273.32.20334; Schief WR, 2001, CURR OPIN CELL BIOL, V13, P19, DOI 10.1016/S0955-0674(00)00169-1; Schnitzer MJ, 2000, NAT CELL BIOL, V2, P718, DOI 10.1038/35036345; Schnitzer MJ, 1997, NATURE, V388, P386, DOI 10.1038/41111; Shimada T, 1997, BIOCHEMISTRY-US, V36, P14037, DOI 10.1021/bi971837i; Smith CA, 1996, BIOPHYS J, V70, P1590, DOI 10.1016/S0006-3495(96)79745-X; Song YH, 2001, EMBO J, V20, P6213, DOI 10.1093/emboj/20.22.6213; Sosa H, 2001, NAT STRUCT BIOL, V8, P540, DOI 10.1038/88611; Suzuki Y, 1998, NATURE, V396, P380, DOI 10.1038/24640; Vale RD, 2000, SCIENCE, V288, P88, DOI 10.1126/science.288.5463.88; Vale RD, 1996, J CELL BIOL, V135, P291, DOI 10.1083/jcb.135.2.291; Visscher K, 1999, NATURE, V400, P184, DOI 10.1038/22146; WOODWARD SKA, 1991, BIOCHEMISTRY-US, V30, P422, DOI 10.1021/bi00216a017; Wriggers W, 1998, BIOPHYS J, V75, P646, DOI 10.1016/S0006-3495(98)77555-1; Xing J, 2000, J BIOL CHEM, V275, P35413, DOI 10.1074/jbc.M004232200; Yun MY, 2001, EMBO J, V20, P2611, DOI 10.1093/emboj/20.11.2611	50	46	50	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 10	2002	277	19					17079	17087		10.1074/jbc.M108793200	http://dx.doi.org/10.1074/jbc.M108793200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	551MB	11864969	hybrid			2022-12-27	WOS:000175564500098
J	Hu, XT; Bryington, M; Fisher, AB; Liang, XM; Zhang, XH; Cui, DM; Datta, I; Zuckerman, KS				Hu, XT; Bryington, M; Fisher, AB; Liang, XM; Zhang, XH; Cui, DM; Datta, I; Zuckerman, KS			Ubiquitin/proteasome-dependent degradation of D-type cyclins is linked to tumor necrosis factor-induced cell cycle arrest	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; FACTOR-ALPHA; PROGENITOR CELLS; GENE-EXPRESSION; IN-VITRO; PROLIFERATION; PHOSPHORYLATION; ACTIVATION; INHIBITION; INTERLEUKIN-1	Tumor necrosis factor-alpha (TNF) is well known for its cytotoxic effect on malignant cells. Its role in cell cycle control is relatively less known. In this study, we found that TNF induced G(1) arrest of TF-1 and MV4-11 cells while simultaneously causing apoptosis. Treatment of the cells with TNF for 48 h caused cell cycle arrest, accompanied by dephosphorylation of pRb and reduction in D-type cyclin expression. The down-regulation of the D-type cyclins resulted in similar to50-80% decrease of the cyclin-dependent kinase activities. Cells treated with calpain-dependent inhibitor ALLN and apoptosis inhibitor zVAD-FMK suppressed degradation of IkappaBalpha and activation of caspase 3, respectively. However, treatment of cells with these two inhibitors was not able to prevent TNF-induced down-regulation of the D-type cyclins. In contrast, proteasome inhibitor MG-132 and lactacystin blocked both TNF-induced degradation of IkappaBalpha and down-regulation of D-type cyclins. These data suggest that down-regulation of D-type cyclins by TNF may be proteasome-proteolysis dependent. Additional support for this conclusion was obtained from experiments showing an increase of proteasome activity in TNF-treated cells and in vitro degradation of cyclin D3 by 26 S proteasome.	Univ S Florida, Dept Biochem & Mol Biol, Tampa, FL 33612 USA; Univ S Florida, Dept Internal Med, Tampa, FL 33612 USA	State University System of Florida; University of South Florida; State University System of Florida; University of South Florida	Hu, XT (corresponding author), Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Hematol Malignancies Program, MDC44,MCC3142,12902 Magnolia Dr, Tampa, FL 33612 USA.	hu@moffitt.usf.edu						ANDO K, 1993, P NATL ACAD SCI USA, V90, P9571, DOI 10.1073/pnas.90.20.9571; BALLARD DW, 1992, P NATL ACAD SCI USA, V89, P1875, DOI 10.1073/pnas.89.5.1875; BEG AA, 1993, MOL CELL BIOL, V13, P3301, DOI 10.1128/MCB.13.6.3301; BROWN K, 1993, P NATL ACAD SCI USA, V90, P2532, DOI 10.1073/pnas.90.6.2532; CARSWELL EA, 1975, P NATL ACAD SCI USA, V72, P3666, DOI 10.1073/pnas.72.9.3666; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; CROALL DE, 1991, PHYSIOL REV, V71, P813, DOI 10.1152/physrev.1991.71.3.813; Diehl JA, 1997, GENE DEV, V11, P957, DOI 10.1101/gad.11.8.957; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; ELIAS L, 1988, BIOCHEM BIOPH RES CO, V157, P963, DOI 10.1016/S0006-291X(88)80968-9; GAMBLE JR, 1985, P NATL ACAD SCI USA, V82, P8667, DOI 10.1073/pnas.82.24.8667; GHOSH S, 1990, NATURE, V344, P678, DOI 10.1038/344678a0; Hochstrasser M, 1998, GENE DEV, V12, P901, DOI 10.1101/gad.12.7.901; Hu XT, 1999, J IMMUNOL, V163, P3106; Hu XT, 2000, BIOCHEM BIOPH RES CO, V276, P930, DOI 10.1006/bbrc.2000.3556; Hu XT, 2001, CANCER RES, V61, P6290; JACOBSEN SEW, 1992, J EXP MED, V175, P1759, DOI 10.1084/jem.175.6.1759; JIANG W, 1993, ONCOGENE, V8, P3447; KATO JY, 1993, P NATL ACAD SCI USA, V90, P11513, DOI 10.1073/pnas.90.24.11513; Leist M, 1997, J EXP MED, V185, P1481, DOI 10.1084/jem.185.8.1481; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; Orr-Weaver TL, 1998, NATURE, V392, P223, DOI 10.1038/32520; Pahl HL, 1996, CURR OPIN CELL BIOL, V8, P340, DOI 10.1016/S0955-0674(96)80007-X; Richter C, 1996, FEBS LETT, V378, P107, DOI 10.1016/0014-5793(95)01431-4; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; RUSTEN LS, 1994, J CLIN INVEST, V94, P165, DOI 10.1172/JCI117303; SALA A, 1992, P NATL ACAD SCI USA, V89, P10415, DOI 10.1073/pnas.89.21.10415; SUGARMAN BJ, 1985, SCIENCE, V230, P943, DOI 10.1126/science.3933111; TARTAGLIA LA, 1993, CELL, V74, P845, DOI 10.1016/0092-8674(93)90464-2; YUE X, 1991, CELL, V65, P691, DOI 10.1016/0092-8674(91)90100-D; ZHANG Y, 1995, BLOOD, V86, P2930; ZUCALI JR, 1987, J CLIN INVEST, V80, P772, DOI 10.1172/JCI113133	34	40	40	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 10	2002	277	19					16528	16537		10.1074/jbc.M109929200	http://dx.doi.org/10.1074/jbc.M109929200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	551MB	11864973	hybrid			2022-12-27	WOS:000175564500027
J	Shu, LL; Zhang, XW; Houghton, PJ				Shu, LL; Zhang, XW; Houghton, PJ			Myogenic differentiation is dependent on both the kinase function and the N-terminal sequence of mammalian target of rapamycin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOOP-HELIX PROTEINS; P70 S6 KINASE; 4E-BP1 PHOSPHORYLATION; GROWTH; INHIBITION; BLOCKS; INACTIVATION; FIBROBLASTS; TRANSLATION; ACTIVATION	The mammalian target of rapamycin (mTOR) is a serine/threonine protein kinase known to control initiation of translation through two downstream pathways: eukaryotic initiation factor 4E-binding protein 1 (4E-BP1)/eukaryotic initiation factor 4E and ribosomal p70 S6 kinase (S6K1). We previously showed in C2C12 murine myoblasts that rapamycin arrests cells in G(1) phase and completely inhibits terminal myogenesis. To elucidate the pathways that regulate myogenesis'. we established stable C2C12 cell lines that express rapamycin-resistant mTOR mutants (mTORrr; S2035I) that have N-terminal deletions (Delta10 or Delta91) or are full-length kinase-dead mTORrr proteins. Additional clones expressing a constitutively active S6K1 were also studied. Our results show that Delta10mTORrr signals 4E-BP1 and permits rapamycin-treated myoblasts to differentiate, confirming the mTOR dependence of the inhibition of myogenesis by rapamycin. C2C12 cells expressing either Delta91 mTORrr or kinase-dead mTORrr(D2338A) could not phosphorylate 4E-BP1 in the presence of rapamycin and could not abrogate the inhibition of myogenesis. Taken together, our results indicate that both the kinase function of mTOR and the N terminus (residues 11-91, containing part of the first HEAT domain) are essential for myogenic differentiation. In contrast, constitutive activation of S6K1 does not abrogate rapamycin inhibition of either proliferation or myogenic differentiation.	St Jude Childrens Res Hosp, Dept Mol Pharmacol, Memphis, TN 38105 USA	St Jude Children's Research Hospital	Houghton, PJ (corresponding author), St Jude Childrens Res Hosp, Dept Mol Pharmacol, 332 N Lauderdale St, Memphis, TN 38105 USA.	peter.houghton@stjude.org	Houghton, Peter/E-3265-2011		NATIONAL CANCER INSTITUTE [P01CA023099, P30CA021765] Funding Source: NIH RePORTER; NCI NIH HHS [CA7776, CA23099, CA21765] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANDRADE MA, 1995, NAT GENET, V11, P115, DOI 10.1038/ng1095-115; Arnold HH, 1996, INT J DEV BIOL, V40, P345; Beretta L, 1996, EMBO J, V15, P658, DOI 10.1002/j.1460-2075.1996.tb00398.x; BRAUN T, 1989, EMBO J, V8, P701, DOI 10.1002/j.1460-2075.1989.tb03429.x; BROWN EJ, 1994, NATURE, V369, P756, DOI 10.1038/369756a0; BROWN EJ, 1995, NATURE, V377, P441, DOI 10.1038/377441a0; Brunn GJ, 1997, SCIENCE, V277, P99, DOI 10.1126/science.277.5322.99; Burnett PE, 1998, P NATL ACAD SCI USA, V95, P1432, DOI 10.1073/pnas.95.4.1432; CHAKRABORTY T, 1991, J BIOL CHEM, V266, P2878; Chook YM, 1999, NATURE, V399, P230, DOI 10.1038/20375; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; Cingolani G, 1999, NATURE, V399, P221, DOI 10.1038/20367; Coolican SA, 1997, J BIOL CHEM, V272, P6653, DOI 10.1074/jbc.272.10.6653; Cuenda A, 1999, J BIOL CHEM, V274, P4341, DOI 10.1074/jbc.274.7.4341; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; DILLING MB, 1994, CANCER RES, V54, P903; Dudkin L, 2001, CLIN CANCER RES, V7, P1758; Erbay E, 2001, J BIOL CHEM, V276, P36079, DOI 10.1074/jbc.C100406200; Florini JR, 1996, ENDOCR REV, V17, P481, DOI 10.1210/edrv-17-5-481; Gingras AC, 1999, GENE DEV, V13, P1422, DOI 10.1101/gad.13.11.1422; Gingras AC, 1998, GENE DEV, V12, P502, DOI 10.1101/gad.12.4.502; Groves MR, 1999, CELL, V96, P99, DOI 10.1016/S0092-8674(00)80963-0; Groves MR, 1999, CURR OPIN STRUC BIOL, V9, P383, DOI 10.1016/S0959-440X(99)80052-9; Hosoi H, 1998, MOL PHARMACOL, V54, P815, DOI 10.1124/mol.54.5.815; Hosoi H, 1999, CANCER RES, V59, P886; JAYARAMAN T, 1993, J BIOL CHEM, V268, P25385; JEFFERIES HBJ, 1994, P NATL ACAD SCI USA, V91, P4441, DOI 10.1073/pnas.91.10.4441; KUO CJ, 1992, NATURE, V358, P70, DOI 10.1038/358070a0; LANE HA, 1993, NATURE, V363, P170, DOI 10.1038/363170a0; LASSAR AB, 1989, CELL, V58, P823, DOI 10.1016/0092-8674(89)90935-5; Liu LN, 1998, CELL GROWTH DIFFER, V9, P699; Marcotrigiano J, 2001, MOL CELL, V7, P193, DOI 10.1016/S1097-2765(01)00167-8; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; PEARSON RB, 1995, EMBO J, V14, P5279, DOI 10.1002/j.1460-2075.1995.tb00212.x; PRICE DJ, 1992, SCIENCE, V257, P973, DOI 10.1126/science.1380182; RHODES SJ, 1989, GENE DEV, V3, P2050, DOI 10.1101/gad.3.12b.2050; Shu L., 1999, Proceedings of the American Association for Cancer Research Annual Meeting, V40, P12; Sonenberg N, 1996, TRANSLATIONAL CONTRO, P245; Vetter IR, 1999, CELL, V97, P635, DOI 10.1016/S0092-8674(00)80774-6; vonManteuffel SR, 1996, P NATL ACAD SCI USA, V93, P4076, DOI 10.1073/pnas.93.9.4076; WRIGHT WE, 1989, CELL, V56, P607, DOI 10.1016/0092-8674(89)90583-7; YUTZEY KE, 1990, MOL CELL BIOL, V10, P3934, DOI 10.1128/MCB.10.8.3934	42	55	55	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 10	2002	277	19					16726	16732		10.1074/jbc.M112285200	http://dx.doi.org/10.1074/jbc.M112285200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	551MB	11875068	hybrid			2022-12-27	WOS:000175564500052
J	Foley, HA; Ofori-Acquah, SF; Yoshimura, A; Critz, S; Baliga, BS; Pace, BS				Foley, HA; Ofori-Acquah, SF; Yoshimura, A; Critz, S; Baliga, BS; Pace, BS			Stat3 beta inhibits gamma-globin gene expression in erythroid cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-BINDING; TRANSCRIPTIONAL ACTIVITY; ACTIVATION; PROTEIN; STAT1; BETA; PROMOTER; SURVIVAL; REQUIRES; ELEMENTS	We demonstrated previously gamma-globin gene inhibition in K562 cells and primary erythroid progenitors treated with interleukin-6. Although several cis-acting elements have been identified in the globin promoters, the precise mechanism for cytokine-mediated globin gene regulation remains to be elucidated. In this report we demonstrate inhibitors of Stat3 phosphorylation abrogate interleukin-6-mediated gamma gene silencing in erythroid cells. DNA-protein binding studies established Stat3 interaction in the 5'-untranslated gamma-globin promoter region. Furthermore, co-transfection experiments with Stat3beta demonstrate gamma promoter inhibition in a concentration-dependent manner, which was significantly reversed when the cognate Stat3-binding site in the 5'-untranslated region was mutated. These studies establish a novel mechanism for gamma gene silencing through the STAT signal transduction pathway.	Univ S Alabama, Dept Cell Biol & Neurosci, Mobile, AL 36688 USA; Kyushu Univ, Dept Mol & Cellular Immunol, Fukuoka 812, Japan; Univ S Alabama, Dept Pediat, Mobile, AL 36606 USA	University of South Alabama; Kyushu University; University of South Alabama	Pace, BS (corresponding author), Univ S Alabama, Dept Cell Biol & Neurosci, 307 Univ Blvd,MSB 2406, Mobile, AL 36688 USA.	bpace@usouthal.edu	Yoshimura, Akihiko/K-5515-2013	Ofori-Acquah, Solomon/0000-0001-5000-3048; Pace, Betty/0000-0002-1275-4112	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P60HL038639] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 38639] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AMROLIA PJ, 1995, J BIOL CHEM, V270, P12892, DOI 10.1074/jbc.270.21.12892; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Auernhammer CJ, 1998, MOL ENDOCRINOL, V12, P954, DOI 10.1210/me.12.7.954; Baliga BS, 2000, AM J HEMATOL, V65, P227, DOI 10.1002/1096-8652(200011)65:3<227::AID-AJH9>3.0.CO;2-V; Boosalis MS, 2001, BLOOD, V97, P3259, DOI 10.1182/blood.V97.10.3259; CAI SP, 1992, BLOOD, V79, P1342; Caldenhoven E, 1996, J BIOL CHEM, V271, P13221, DOI 10.1074/jbc.271.22.13221; Chaturvedi P, 1997, MOL CELL BIOL, V17, P3295, DOI 10.1128/MCB.17.6.3295; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; EVANS T, 1990, ANNU REV CELL BIOL, V6, P95, DOI 10.1146/annurev.cellbio.6.1.95; Fernandez MN, 2001, BONE MARROW TRANSPL, V28, P355, DOI 10.1038/sj.bmt.1703143; Ferry AE, 1997, J BIOL CHEM, V272, P20030, DOI 10.1074/jbc.272.32.20030; Filipe A, 1999, EMBO J, V18, P687, DOI 10.1093/emboj/18.3.687; GEAHLEN RL, 1989, BIOCHEM BIOPH RES CO, V165, P241, DOI 10.1016/0006-291X(89)91060-7; Gotze KS, 2001, EXP HEMATOL, V29, P822, DOI 10.1016/S0301-472X(01)00652-X; GUMUCIO DL, 1992, MOL CELL BIOL, V12, P4919, DOI 10.1128/MCB.12.11.4919; Han B, 2001, INT J HEMATOL, V74, P42, DOI 10.1007/BF02982548; Helman D, 1998, FEBS LETT, V441, P287, DOI 10.1016/S0014-5793(98)01555-5; Hirano T, 2000, ONCOGENE, V19, P2548, DOI 10.1038/sj.onc.1203551; Hoey T, 1998, CURR OPIN GENET DEV, V8, P582, DOI 10.1016/S0959-437X(98)80015-4; IHLE JN, 1995, TRENDS GENET, V11, P69, DOI 10.1016/S0168-9525(00)89000-9; IHLE JN, 1995, ANNU REV IMMUNOL, V13, P369, DOI 10.1146/annurev.iy.13.040195.002101; LEVITZKI A, 1990, BIOCHEM PHARMACOL, V40, P913, DOI 10.1016/0006-2952(90)90474-Y; Lewis BA, 2000, P NATL ACAD SCI USA, V97, P7172, DOI 10.1073/pnas.120181197; Li QL, 1997, P NATL ACAD SCI USA, V94, P2444, DOI 10.1073/pnas.94.6.2444; Li QL, 1998, J BIOL CHEM, V273, P17361, DOI 10.1074/jbc.273.28.17361; LUI B, 1998, P NATL ACAD SCI USA, V95, P10626; ORKIN SH, 1995, J BIOL CHEM, V270, P4955, DOI 10.1074/jbc.270.10.4955; Pace BS, 2000, EXP HEMATOL, V28, P283, DOI 10.1016/S0301-472X(99)00153-8; Schaefer LK, 2000, CELL SIGNAL, V12, P143, DOI 10.1016/S0898-6568(99)00077-7; Schaefer TS, 1997, MOL CELL BIOL, V17, P5307, DOI 10.1128/MCB.17.9.5307; SCHAEFER TS, 1995, P NATL ACAD SCI USA, V92, P9097, DOI 10.1073/pnas.92.20.9097; SEIDEL HM, 1995, P NATL ACAD SCI USA, V92, P3041, DOI 10.1073/pnas.92.7.3041; Shuai K, 2000, ONCOGENE, V19, P2638, DOI 10.1038/sj.onc.1203522; TANIGUCHI T, 1995, SCIENCE, V268, P251, DOI 10.1126/science.7716517; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; Wen ZL, 1997, NUCLEIC ACIDS RES, V25, P2062, DOI 10.1093/nar/25.11.2062; Yang YM, 1997, AM J HEMATOL, V56, P252, DOI 10.1002/(SICI)1096-8652(199712)56:4<252::AID-AJH10>3.0.CO;2-B; Zhang XK, 2001, J BIOL CHEM, V276, P33576, DOI 10.1074/jbc.M104978200	39	23	23	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 3	2002	277	18					16211	16219		10.1074/jbc.M106556200	http://dx.doi.org/10.1074/jbc.M106556200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	550PA	11856732	hybrid			2022-12-27	WOS:000175510400131
J	Kienlen-Campard, P; Miolet, S; Tasiaux, B; Octave, JN				Kienlen-Campard, P; Miolet, S; Tasiaux, B; Octave, JN			Intracellular amyloid-beta 1-42, but not extracellular soluble amyloid-beta peptides, induces neuronal apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAMILIAL ALZHEIMERS-DISEASE; PRECURSOR PROTEIN; TRANSGENIC MICE; SECRETASE CLEAVAGE; TRANSFECTED CELLS; AXONAL-TRANSPORT; PLAQUE-FORMATION; GAMMA-SECRETASE; GENE-TRANSFER; ACCUMULATION	Alzheimer disease (AD), the most frequent cause of dementia, is characterized by an important neuronal loss. A typical histological hallmark of AD is the extracellular deposition of beta-amyloid peptide (Abeta), which is produced by the cleavage of the amyloid precursor protein (APP). Most of the gene mutations that segregate with the inherited forms of AD result in increasing the ratio of A42/Abeta40 production. Abeta42 also accumulates in neurons of AD patients. Altogether, these data strongly suggest that the neuronal production of Abeta42 is a critical event in AD, but the intraneuronal Abeta42 toxicity has never been demonstrated. Here, we report that the long term expression of human APP in rat cortical neurons induces apoptosis. Although APP processing leads to production of extracellular Abeta1-40 and soluble APP, these extracellular derivatives do not induce neuronal death. On the contrary, neurons undergo apoptosis as soon as they accumulate intracellular Abeta1-42 following the expression of full-length APP or a C-terminal deleted APP isoform. The inhibition of intraneuronal Abeta1-42 production by a functional gamma-secretase inhibitor increases neuronal survival. Therefore, the accumulation of intraneuronal Abeta1-42 is the key event in the neurodegenerative process that we observed.	Catholic Univ Louvain, FARL UCL 54 10, B-1200 Brussels, Belgium	Universite Catholique Louvain	Octave, JN (corresponding author), Catholic Univ Louvain, FARL UCL 54 10, Av Hippocrate 54, B-1200 Brussels, Belgium.	octave@nchm.ucl.ac.be		Kienlen-Campard, Pascal/0000-0003-1086-2942				BEHL C, 1994, CELL, V77, P817, DOI 10.1016/0092-8674(94)90131-7; BRAAK H, 1991, ACTA NEUROPATHOL, V82, P239, DOI 10.1007/BF00308809; BREWER GJ, 1995, J NEUROSCI RES, V42, P674, DOI 10.1002/jnr.490420510; Calhoun ME, 1998, NATURE, V395, P755, DOI 10.1038/27351; Campard PK, 1997, DNA CELL BIOL, V16, P323, DOI 10.1089/dna.1997.16.323; Chui DH, 1999, NAT MED, V5, P560, DOI 10.1038/8438; Cook DG, 1997, NAT MED, V3, P1021, DOI 10.1038/nm0997-1021; Cotman CW, 1996, BRAIN PATHOL, V6, P493, DOI 10.1111/j.1750-3639.1996.tb00878.x; Czech C, 1997, MOL BRAIN RES, V47, P108, DOI 10.1016/S0169-328X(97)00039-9; Dovey HF, 2001, J NEUROCHEM, V76, P173, DOI 10.1046/j.1471-4159.2001.00012.x; EDWARDS SN, 1994, J CELL BIOL, V124, P537, DOI 10.1083/jcb.124.4.537; Essalmani R, 1996, BIOCHEM BIOPH RES CO, V218, P89, DOI 10.1006/bbrc.1996.0017; GEORGEHYSLOP PH, 2000, BIOL PSYCHIAT, V47, P183; GomezIsla T, 1997, ANN NEUROL, V41, P17, DOI 10.1002/ana.410410106; Gouras GK, 2000, AM J PATHOL, V156, P15, DOI 10.1016/S0002-9440(10)64700-1; Gunawardena S, 2001, NEURON, V32, P389, DOI 10.1016/S0896-6273(01)00496-2; Hardy J, 1997, TRENDS NEUROSCI, V20, P154, DOI 10.1016/S0166-2236(96)01030-2; Hartmann T, 1997, NAT MED, V3, P1016, DOI 10.1038/nm0997-1016; Ida N, 1996, J BIOL CHEM, V271, P22908, DOI 10.1074/jbc.271.37.22908; Kamal A, 2001, NATURE, V414, P643, DOI 10.1038/414643a; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; KOO EH, 1994, J BIOL CHEM, V269, P17386; Lammich S, 1999, P NATL ACAD SCI USA, V96, P3922, DOI 10.1073/pnas.96.7.3922; LEMARCHAND P, 1992, P NATL ACAD SCI USA, V89, P6482, DOI 10.1073/pnas.89.14.6482; Lorenzo A, 2000, NAT NEUROSCI, V3, P460, DOI 10.1038/74833; Lu DC, 2000, NAT MED, V6, P397, DOI 10.1038/74656; Macq AF, 1998, J BIOL CHEM, V273, P28931, DOI 10.1074/jbc.273.44.28931; Mochizuki A, 2000, LANCET, V355, P42, DOI 10.1016/S0140-6736(99)04937-5; Murphy MP, 1999, J BIOL CHEM, V274, P11914, DOI 10.1074/jbc.274.17.11914; Neve RL, 2000, BRAIN RES, V886, P54, DOI 10.1016/S0006-8993(00)02869-9; Nishimura I, 1998, J NEUROSCI, V18, P2387, DOI 10.1523/jneurosci.18-07-02387.1998; Octave JN, 1995, REV NEUROSCIENCE, V6, P287; OKAMOTO T, 1995, J BIOL CHEM, V270, P4205, DOI 10.1074/jbc.270.9.4205; Paschen W, 2001, J NEUROCHEM, V79, P719, DOI 10.1046/j.1471-4159.2001.00623.x; PIKE CJ, 1993, J NEUROSCI, V13, P1676; Skovronsky DM, 1998, J CELL BIOL, V141, P1031, DOI 10.1083/jcb.141.4.1031; STRATFORDPERRICAUDET LD, 1992, J CLIN INVEST, V90, P626, DOI 10.1172/JCI115902; SU JH, 1994, NEUROREPORT, V5, P2529, DOI 10.1097/00001756-199412000-00031; Tanzi RE, 1996, NEUROBIOL DIS, V3, P159, DOI 10.1006/nbdi.1996.0016; Uetsuki T, 1999, J NEUROSCI, V19, P6955, DOI 10.1523/JNEUROSCI.19-16-06955.1999; Vassar R, 1999, SCIENCE, V286, P735, DOI 10.1126/science.286.5440.735; WEST MJ, 1994, LANCET, V344, P769, DOI 10.1016/S0140-6736(94)92338-8; Wirths O, 2001, NEUROSCI LETT, V306, P116, DOI 10.1016/S0304-3940(01)01876-6; Xu J, 2001, J NEUROSCI, V21, part. no., DOI 10.1523/JNEUROSCI.21-01-j0001.2001; Yamatsuji T, 1996, SCIENCE, V272, P1349, DOI 10.1126/science.272.5266.1349; Yang AJ, 1999, J BIOL CHEM, V274, P20650, DOI 10.1074/jbc.274.29.20650; YANG AJ, 1995, J BIOL CHEM, V270, P14786, DOI 10.1074/jbc.270.24.14786	47	155	160	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 3	2002	277	18					15666	15670		10.1074/jbc.M200887200	http://dx.doi.org/10.1074/jbc.M200887200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	550PA	11861655	hybrid			2022-12-27	WOS:000175510400061
J	Kim, YM; Yun, J; Lee, CK; Lee, H; Min, KR; Kim, Y				Kim, YM; Yun, J; Lee, CK; Lee, H; Min, KR; Kim, Y			Oxyresveratrol and hydroxystilbene compounds - Inhibitory effect on tyrosinase and mechanism of action	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOPA OXIDASE ACTIVITY; TRANS-RESVERATROL; BOMBYX-MORI; KOJIC ACID; PIGMENTATION; PHENOLOXIDASE; PURIFICATION; HYDROQUINONE; TAUTOMERASE; CATECHOLASE	Tyrosinase is responsible for the molting process in insects, undesirable browning of fruits and vegetables, and coloring of skin, hair, and eyes in animals. To clarify the mechanism of the depigmenting property of hydroxystilbene compounds, inhibitory actions of oxyresveratrol and its analogs on tyrosinases from mushroom and murine melanoma B-16 have been elucidated in this study. Oxyresveratrol showed potent inhibitory effect with an IC50 value of 1.2 muM on mushroom tyrosinase activity, which was 32-fold stronger inhibition than kojic acid, a depigmenting agent used as the cosmetic material with skin-whitening effect and the medical agent for hyperpigmentation disorders. Hydroxystilbene compounds of resveratrol, 3,5-dihydroxy-4'-methoxystilbene, and rhapontigenin also showed more than 50% inhibition at 100 muM on mushroom tyrosinase activity, but other methylated or glycosylated hydroxystilbenes of 3,4-dimethoxy-5-hydroxystilbene, trimethylresveratrol, piceid, and rhaponticin did not inhibit significantly. None of the hydroxystilbene compounds except oxyresveratrol exhibited more than 50% inhibition at 100 muM on L-tyrosine oxidation by murine tyrosinase activity; oxyresveratrol showed an IC50 value of 52.7 muM on the enzyme activity. The kinetics and mechanism for inhibition of mushroom tyrosinase exhibited the reversibility of oxyresveratrol as a noncompetitive inhibitor with L-tyrosine as the substrate. The interaction between oxyresveratrol and tyrosinase exhibited a high affinity reflected in a K-i value of 3.2-4.2 x 10(-7) M. Oxyresveratrol did not affect the promoter activity of the tyrosinase gene in murine melanoma B-16 at 10 and 100 muM. Therefore, the depigmenting effect of oxyresveratrol works through reversible inhibition of tyrosinase activity rather than suppression of the expression and synthesis of the enzyme. The number and position of hydroxy substituents seem to play an important role in the inhibitory effects of hydroxystilbene compounds on tyrosinase activity.	Chungbuk Natl Univ, Coll Pharm, Cheongju 361763, South Korea; Chungbuk Natl Univ, Res Ctr Bioresource & Hlth, Cheongju 361763, South Korea; Chonnam Natl Univ, Coll Nat Sci, Kwangju 500757, South Korea	Chungbuk National University; Chungbuk National University; Chonnam National University	Kim, Y (corresponding author), Chungbuk Natl Univ, Coll Pharm, Cheongju 361763, South Korea.							April CS, 1998, GENE, V219, P45, DOI 10.1016/S0378-1119(98)00403-X; Asano T, 2001, J BIOL CHEM, V276, P11100, DOI 10.1074/jbc.M008426200; Battaini G, 2000, J BIOL INORG CHEM, V5, P262, DOI 10.1007/s007750050370; Bhat KPL, 2001, CANCER RES, V61, P7456; Burkitt MJ, 2000, ARCH BIOCHEM BIOPHYS, V381, P253, DOI 10.1006/abbi.2000.1973; Busca R, 2000, PIGM CELL RES, V13, P60, DOI 10.1034/j.1600-0749.2000.130203.x; CANANES J, 1994, J PHARM PHARMACOL, V46, P982; Fremont L, 2000, LIFE SCI, V66, P663, DOI 10.1016/S0024-3205(99)00410-5; GALEAZZI MAM, 1984, ARCH LATINOAM NUTR, V34, P269; Gillespie JP, 1997, ANNU REV ENTOMOL, V42, P611, DOI 10.1146/annurev.ento.42.1.611; Guevara IL, 2001, INT J DERMATOL, V40, P212, DOI 10.1046/j.1365-4362.2001.01167-2.x; Holmes-McNary M, 2000, CANCER RES, V60, P3477; HUGHES L, 1975, J INSECT PHYSIOL, V21, P1373, DOI 10.1016/0022-1910(75)90263-2; IOZUMI K, 1993, J INVEST DERMATOL, V100, P806, DOI 10.1111/1523-1747.ep12476630; Jang MS, 1997, SCIENCE, V275, P218, DOI 10.1126/science.275.5297.218; Kang BS, 1998, MED SCI RES, V26, P235; KUBO I, 1995, J NAT PRODUCTS, V58, P739, DOI 10.1021/np50119a013; Kubo I, 2000, BIOORGAN MED CHEM, V8, P1749, DOI 10.1016/S0968-0896(00)00102-4; Kuriyama T, 1998, BBA-PROTEIN STRUCT M, V1388, P506, DOI 10.1016/S0167-4838(98)00214-3; LERCH K, 1981, MET IONS BIOL SYST, V13, P143; Lim JTE, 1999, DERMATOL SURG, V25, P282, DOI 10.1046/j.1524-4725.1999.08236.x; Maeda K, 1996, J PHARMACOL EXP THER, V276, P765; Marmaras VJ, 1996, ARCH INSECT BIOCHEM, V31, P119, DOI 10.1002/(SICI)1520-6327(1996)31:2&lt;119::AID-ARCH1&gt;3.0.CO;2-V; Mills AA, 2001, GENE DEV, V15, P1461, DOI 10.1101/gad.909301; Moreno JJ, 2000, J PHARMACOL EXP THER, V294, P333; NAPPI AJ, 1993, PIGM CELL RES, V6, P117, DOI 10.1111/j.1600-0749.1993.tb00590.x; NGUYEN QH, 1995, INT J DERMATOL, V34, P75, DOI 10.1111/j.1365-4362.1995.tb03583.x; Oetting WS, 1999, HUM MUTAT, V13, P99, DOI 10.1002/(SICI)1098-1004(1999)13:2<99::AID-HUMU2>3.3.CO;2-3; Okan G, 1999, J EUR ACAD DERMATOL, V13, P218, DOI 10.1111/j.1468-3083.1999.tb00887.x; Olivares C, 2002, BIOCHEMISTRY-US, V41, P679, DOI 10.1021/bi011535n; Parkinson N, 2001, INSECT BIOCHEM MOLEC, V31, P57, DOI 10.1016/S0965-1748(00)00105-3; Perez-Bernal A, 2000, Am J Clin Dermatol, V1, P261; Perez-Gilabert M, 2000, J AGR FOOD CHEM, V48, P695, DOI 10.1021/jf990292r; Perez-Gilabert M, 2001, BIOCHEM BIOPH RES CO, V285, P257, DOI 10.1006/bbrc.2001.5189; PYE AE, 1974, NATURE, V251, P610, DOI 10.1038/251610a0; Riley PA, 2000, J THEOR BIOL, V203, P1, DOI 10.1006/jtbi.1999.1061; Riley PA, 1997, INT J BIOCHEM CELL B, V29, P1235, DOI 10.1016/S1357-2725(97)00013-7; RYU S Y, 1988, Archives of Pharmacal Research (Seoul), V11, P230, DOI 10.1007/BF02861314; Seo B, 1999, PLANTA MED, V65, P683, DOI 10.1055/s-1999-14092; Shin N. H., 1997, NAT PROD SCI, V3, P111; Shin NH, 1998, BIOCHEM BIOPH RES CO, V243, P801, DOI 10.1006/bbrc.1998.8169; Sturm RA, 1998, BIOESSAYS, V20, P712, DOI 10.1002/(SICI)1521-1878(199809)20:9<712::AID-BIES4>3.0.CO;2-I; SUGUMARAN M, 1992, ARCH INSECT BIOCHEM, V19, P271, DOI 10.1002/arch.940190406; Takahashi S, 1996, J ANTIBIOT, V49, P513, DOI 10.7164/antibiotics.49.513; TSUKAMOTO T, 1992, BIOCHEM BIOPH RES CO, V184, P86, DOI 10.1016/0006-291X(92)91161-I; Wang ZR, 2002, INT J MOL MED, V9, P77; WINDER AJ, 1991, EUR J BIOCHEM, V198, P317, DOI 10.1111/j.1432-1033.1991.tb16018.x; Yang CS, 2001, ANNU REV NUTR, V21, P381, DOI 10.1146/annurev.nutr.21.1.381; YOSHIMOTO T, 1985, J BIOCHEM, V97, P1747, DOI 10.1093/oxfordjournals.jbchem.a135233; ZHAO XL, 1995, DEV COMP IMMUNOL, V19, P205, DOI 10.1016/0145-305X(95)00005-E; Zou JG, 1999, BIOCHEM MOL BIOL INT, V47, P1089	51	346	364	2	97	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 3	2002	277	18					16340	16344		10.1074/jbc.M200678200	http://dx.doi.org/10.1074/jbc.M200678200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	550PA	11864987	hybrid			2022-12-27	WOS:000175510400145
J	Lee, VY; McClintock, DS; Santore, MT; Budinger, GRS; Chandel, NS				Lee, VY; McClintock, DS; Santore, MT; Budinger, GRS; Chandel, NS			Hypoxia sensitizes cells to nitric oxide-induced apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOCHONDRIAL RESPIRATORY-CHAIN; CYTOCHROME-C; BCL-2 FAMILY; PEROXYNITRITE; INHIBITION; SUPEROXIDE; OXYGEN; GLUTATHIONE; MECHANISMS; DEATH	Nitric oxide (NO) can induce apoptosis in a variety of cell types. A non-toxic concentration of nitric oxide under normal oxygen conditions triggered cell death under hypoxic conditions (1.5% O-2) in fibroblasts. Nitric oxide administered during hypoxia induced the release of cytochrome c, caspase-9 activation, and the loss of mitochondrial membrane potential followed by DNA fragmentation and lactate dehydrogenase release (markers of cell death). Bcl-X-L protected cells from nitric oxide-induced apoptosis during hypoxia by preventing the release of cytochrome c, caspase-9 activation, and by maintaining a mitochondrial membrane potential. Murine embryonic fibroblasts from bax(-/-) bak(-/-) mice exposed to nitric oxide during hypoxia did not die, indicating that pro-apoptotic Bcl-2 family members are required for NO-induced apoptosis during hypoxia. The nitric oxide-induced cell death during hypoxia was independent of cGMP and peroxynitrite. Cells devoid of mitochondrial DNA (rhodegrees-cells) lack a functional electron transport chain and were resistant to nitric oxide-induced cell death during hypoxia, suggesting that a functional electron transport chain is required for nitric oxide-induced apoptosis during hypoxia.	Northwestern Univ, Sch Med, Dept Med, Div Pulm & Crit Care Med, Chicago, IL 60611 USA	Northwestern University	Chandel, NS (corresponding author), Northwestern Univ, Sch Med, Dept Med, Div Pulm & Crit Care Med, Tarry Bldg 14-707,303 E Chicago Ave, Chicago, IL 60611 USA.				NHLBI NIH HHS [HL68456-01] Funding Source: Medline; NIGMS NIH HHS [GM60472-02] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [F32HL068456] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060472] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bal-Price A, 1999, ANN NY ACAD SCI, V893, P376, DOI 10.1111/j.1749-6632.1999.tb07859.x; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; Beltran B, 2000, P NATL ACAD SCI USA, V97, P14602, DOI 10.1073/pnas.97.26.14602; BOLANOS JP, 1995, J NEUROCHEM, V64, P1965; Borutaite V, 2000, FEBS LETT, V467, P155, DOI 10.1016/S0014-5793(00)01140-6; Brookes PS, 2000, J BIOL CHEM, V275, P20474, DOI 10.1074/jbc.M001077200; BROWN GC, 1994, FEBS LETT, V356, P295, DOI 10.1016/0014-5793(94)01290-3; Brown GC, 1999, BIOCHEM SOC SYMP, V66, P17, DOI 10.1042/bss0660017; Byun Y, 2001, CELL DEATH DIFFER, V8, P443, DOI 10.1038/sj.cdd.4400840; Chandel NS, 1998, P NATL ACAD SCI USA, V95, P11715, DOI 10.1073/pnas.95.20.11715; Chandel NS, 1999, FEBS LETT, V454, P173, DOI 10.1016/S0014-5793(99)00783-8; Christopherson KS, 1997, J CLIN INVEST, V100, P2424, DOI 10.1172/JCI119783; Chung HT, 2001, BIOCHEM BIOPH RES CO, V282, P1075, DOI 10.1006/bbrc.2001.4670; CLEETER MWJ, 1994, FEBS LETT, V345, P50, DOI 10.1016/0014-5793(94)00424-2; Clementi E, 1999, P NATL ACAD SCI USA, V96, P1559, DOI 10.1073/pnas.96.4.1559; Clementi E, 1998, P NATL ACAD SCI USA, V95, P7631, DOI 10.1073/pnas.95.13.7631; Estevez AG, 1998, J NEUROSCI, V18, P923; Gottlob K, 2001, GENE DEV, V15, P1406, DOI 10.1101/gad.889901; Green DR, 2000, CELL, V102, P1, DOI 10.1016/S0092-8674(00)00003-9; HAUSLADEN A, 1994, J BIOL CHEM, V269, P29405; Hortelano S, 1997, FEBS LETT, V410, P373, DOI 10.1016/S0014-5793(97)00623-6; King M P, 1996, Methods Enzymol, V264, P304, DOI 10.1016/S0076-6879(96)64029-4; Koivisto A, 1997, FEBS LETT, V417, P75, DOI 10.1016/S0014-5793(97)01258-1; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9; Lizasoain I, 1996, BIOCHEM J, V314, P877, DOI 10.1042/bj3140877; Martinou JC, 2001, NAT REV MOL CELL BIO, V2, P63, DOI 10.1038/35048069; Messmer UK, 1996, J BIOL CHEM, V271, P20192, DOI 10.1074/jbc.271.33.20192; MONCADA S, 1993, NEW ENGL J MED, V329, P2002; RADI R, 1994, ARCH BIOCHEM BIOPHYS, V308, P89, DOI 10.1006/abbi.1994.1013; SCHWEIZER M, 1994, BIOCHEM BIOPH RES CO, V204, P169, DOI 10.1006/bbrc.1994.2441; Shen YH, 1998, FEBS LETT, V433, P125, DOI 10.1016/S0014-5793(98)00844-8; Sies H, 2000, FREE RADICAL BIO MED, V28, P1451, DOI 10.1016/S0891-5849(00)00253-7; STAMLER JS, 1994, CELL, V78, P931, DOI 10.1016/0092-8674(94)90269-0; Szabo C, 1996, FREE RADICAL BIO MED, V21, P855, DOI 10.1016/0891-5849(96)00170-0; Tamatani M, 1998, J NEUROCHEM, V71, P1588; VanderHeiden MG, 1997, CELL, V91, P627, DOI 10.1016/S0092-8674(00)80450-X; WANG JF, 1992, HEPATOLOGY, V15, P1112, DOI 10.1002/hep.1840150623; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Zong WX, 2001, GENE DEV, V15, P1481, DOI 10.1101/gad.897601	40	48	49	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 3	2002	277	18					16067	16074		10.1074/jbc.M111177200	http://dx.doi.org/10.1074/jbc.M111177200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	550PA	11861645	hybrid			2022-12-27	WOS:000175510400113
J	Oh, JI; Kaplan, S				Oh, JI; Kaplan, S			Oxygen adaptation - The role of the CcoQ subunit of the cbb(3) cytochrome c oxidase of Rhodobacter sphaeroides 2.4.1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOTOSYNTHESIS GENE-EXPRESSION; GRAM-NEGATIVE BACTERIA; ESCHERICHIA-COLI; UBIQUINOL OXIDASE; PARACOCCUS-DENITRIFICANS; BRADYRHIZOBIUM-JAPONICUM; TERMINAL OXIDASE; RHODOBACTER-SPHAEROIDES-2.4.1; IV; MUTAGENESIS	The cbb(3) cytochrome c oxidase of Rhodobacter sphaeroides consists of four nonidentical subunits. Three subunits (CcoN, CcoO, and CcoP) comprise the catalytic "core" complex required for the reduction of O-2 and the oxidation of a c-type cytochrome. On the other hand, the functional role of subunit IV (CcoQ) of the cbb(3) oxidase was not obvious, although we previously suggested that it is involved in the signal transduction pathway controlling photosynthesis gene expression (Oh, J. I., and Kaplan, S. (1999) Biochemistry 38, 2688-2696). Here we go on to demonstrate that subunit IV protects the core complex, in the presence of O-2, from proteolytic degradation by a serine metalloprotease. In the absence of CcoQ, we suggest that the presence of O-2 leads to the loss of heme from the core complex, which destabilizes the cbb(3) oxidase into a "degradable" form, perhaps by altering its conformation. Under aerobic conditions the absence of CcoQ appears to affect the CcoP subunit most severely. It was further demonstrated, using a series of COOH-terminal deletion derivatives of CcoQ, that the minimum length of CcoQ required for stabilization of the core complex under aerobic conditions is the amino-terminal similar to48-50 amino acids.	Univ Texas, Hlth Sci Ctr, Sch Med, Dept Microbiol & Mol Genet, Houston, TX 77030 USA	University of Texas System; University of Texas Health Science Center Houston	Kaplan, S (corresponding author), Univ Texas, Hlth Sci Ctr, Sch Med, Dept Microbiol & Mol Genet, 6431 Fannin, Houston, TX 77030 USA.				NIGMS NIH HHS [GM15590] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abramson J, 2000, NAT STRUCT BIOL, V7, P910; BERRY EA, 1987, ANAL BIOCHEM, V161, P1, DOI 10.1016/0003-2697(87)90643-9; Bratton MR, 1999, BIOCHEMISTRY-US, V38, P16236, DOI 10.1021/bi9914107; CHEPURI V, 1990, J BIOL CHEM, V265, P11185; CHEPURI V, 1990, J BIOL CHEM, V265, P12978; DAVIS J, 1988, J BACTERIOL, V170, P320, DOI 10.1128/jb.170.1.320-329.1988; DONOHUE TJ, 1988, BIOCHEMISTRY-US, V27, P1918, DOI 10.1021/bi00406a018; GARCIAHORSMAN JA, 1994, J BACTERIOL, V176, P5587, DOI 10.1128/JB.176.18.5587-5600.1994; GARCIAHORSMAN JA, 1994, BIOCHEMISTRY-US, V33, P3113, DOI 10.1021/bi00176a046; GRAY KA, 1994, BIOCHEMISTRY-US, V33, P3120, DOI 10.1021/bi00176a047; IWATA S, 1995, NATURE, V376, P660, DOI 10.1038/376660a0; Jessee J., 1986, FOCUS, V8, P9; Jones C. W., 1985, METHOD MICROBIOL, V18, P285; KEEN NT, 1988, GENE, V70, P191, DOI 10.1016/0378-1119(88)90117-5; KOBACH ME, 1994, BIOTECHNIQUES, V16, P800; LENZ O, 1994, J BACTERIOL, V176, P4385, DOI 10.1128/jb.176.14.4385-4393.1994; LUDWIG B, 1980, P NATL ACAD SCI-BIOL, V77, P196, DOI 10.1073/pnas.77.1.196; Mouncey NJ, 1998, J BACTERIOL, V180, P2228, DOI 10.1128/JB.180.8.2228-2231.1998; Myllykallio H, 1999, P NATL ACAD SCI USA, V96, P4348, DOI 10.1073/pnas.96.8.4348; O'Gara JP, 1998, J BACTERIOL, V180, P4044; OGara JP, 1997, J BACTERIOL, V179, P1951, DOI 10.1128/jb.179.6.1951-1961.1997; Oh JI, 1999, BIOCHEMISTRY-US, V38, P2688, DOI 10.1021/bi9825100; Oh JI, 2001, MOL MICROBIOL, V39, P1116, DOI 10.1046/j.1365-2958.2001.02299.x; Oh JI, 2000, EMBO J, V19, P4237, DOI 10.1093/emboj/19.16.4237; Saiki K, 1996, J BIOL CHEM, V271, P15336, DOI 10.1074/jbc.271.26.15336; SIMON R, 1983, BIO-TECHNOL, V1, P784, DOI 10.1038/nbt1183-784; THOMAS PE, 1976, ANAL BIOCHEM, V75, P168, DOI 10.1016/0003-2697(76)90067-1; Toledo-Cuevas M, 1998, BBA-BIOENERGETICS, V1365, P421, DOI 10.1016/S0005-2728(98)00095-4; Tsukihara T, 1996, SCIENCE, V272, P1136, DOI 10.1126/science.272.5265.1136; van Niel CB, 1944, BACTERIOL REV, V8, P1; VILLANI G, 1995, BBA-BIOENERGETICS, V1232, P67, DOI 10.1016/0005-2728(95)00112-5; Witt H, 1997, J BIOL CHEM, V272, P5514, DOI 10.1074/jbc.272.9.5514; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; Zufferey R, 1998, J BIOL CHEM, V273, P6452, DOI 10.1074/jbc.273.11.6452; Zufferey R, 1996, J BIOL CHEM, V271, P9114, DOI 10.1074/jbc.271.15.9114	35	46	50	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 3	2002	277	18					16220	16228		10.1074/jbc.M200198200	http://dx.doi.org/10.1074/jbc.M200198200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	550PA	11864982	hybrid			2022-12-27	WOS:000175510400132
J	Tokumitsu, H; Inuzuka, H; Ishikawa, Y; Ikeda, M; Saji, I; Kobayashi, R				Tokumitsu, H; Inuzuka, H; Ishikawa, Y; Ikeda, M; Saji, I; Kobayashi, R			STO-609, a specific inhibitor of the Ca2+/calmodulin-dependent protein kinase kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-CLONING; REGULATORY MECHANISM; CALMODULIN; IV; ACTIVATION; PHOSPHORYLATION; CASCADE; IDENTIFICATION; EXPRESSION; CREB	STO-609, a selective inhibitor of Ca2+/calmodulin-dependent protein kinase kinase (CaM-KK) was synthesized, and its inhibitory properties were investigated both in vitro and in vivo. STO-609 inhibits the activities of recombinant CaM-KKalpha and CaM-KKbeta isoforms, with K-i values of 80 and 15 ng/ml, respectively, and also inhibits their autophosphorylation activities. Comparison of the inhibitory potency of the compound against various protein kinases revealed that STO-609 is highly selective for CaM-KK without any significant effect on the downstream CaM kinases (CaM-KI and -IV), and the IC50 value of the compound against CaM-KII is similar to10 mug/ ml. STO-609 inhibits constitutively active CaM-KKa (glutathione S-transferase (GST)-CaM-KK-(84-434)) as well as the wild-type enzyme. Kinetic analysis indicates that the compound is a competitive inhibitor of ATP. In transfected HeLa cells, STO-609 suppresses the Ca2+- induced activation of CaM-KIV in a dose-dependent manner. In agreement with this observation, the inhibitor significantly reduces the endogenous activity of CaM-KK in SH-SY5Y neuroblastoma cells at a concentration of 1 mug/ml (similar to80% inhibitory rate). Taken together, these results indicate that STO-609 is a selective and cell-permeable inhibitor of CaM-KK and that it may be a useful tool for evaluating the physiological significance of the CaM-KK-mediated pathway in vivo as well as in vitro.	Kagawa Med Univ, Dept Chem, Miki, Kagawa 7610793, Japan; Sumitomo Pharmaceut Co Ltd, Div Res, Exploratory Res Grp, Takarazuka, Hyogo 665, Japan	Kagawa University	Tokumitsu, H (corresponding author), Kagawa Med Univ, Dept Chem, 1750-1 Miki Cho, Miki, Kagawa 7610793, Japan.	tokumit@kms.ac.jp	Tokumitsu, Hiroshi/M-3978-2015	Tokumitsu, Hiroshi/0000-0002-2193-6794				Aletta JM, 1996, J BIOL CHEM, V271, P20930, DOI 10.1074/jbc.271.34.20930; Anderson KA, 1998, J BIOL CHEM, V273, P31880, DOI 10.1074/jbc.273.48.31880; BADING H, 1993, SCIENCE, V260, P181, DOI 10.1126/science.8097060; Bito H, 1996, CELL, V87, P1203, DOI 10.1016/S0092-8674(00)81816-4; Chatila T, 1996, J BIOL CHEM, V271, P21542, DOI 10.1074/jbc.271.35.21542; Corcoran EE, 2001, J BIOL CHEM, V276, P2975, DOI 10.1074/jbc.R000027200; Edelman AM, 1996, J BIOL CHEM, V271, P10806, DOI 10.1074/jbc.271.18.10806; Enslen H, 1996, P NATL ACAD SCI USA, V93, P10803, DOI 10.1073/pnas.93.20.10803; ENSLEN H, 1994, J BIOL CHEM, V269, P15520; Eto K, 1999, J BIOL CHEM, V274, P22556, DOI 10.1074/jbc.274.32.22556; Hayashi N, 1998, PROTEIN EXPRES PURIF, V12, P25, DOI 10.1006/prep.1997.0807; Joseph JD, 2000, J BIOL CHEM, V275, P38230, DOI 10.1074/jbc.M006422200; Kang HJ, 2001, CELL, V106, P771, DOI 10.1016/S0092-8674(01)00497-4; Kitani T, 1997, J BIOCHEM-TOKYO, V122, P243; Kurokawa H, 2001, J MOL BIOL, V312, P59, DOI 10.1006/jmbi.2001.4822; Matsushita M, 1998, J BIOL CHEM, V273, P21473, DOI 10.1074/jbc.273.34.21473; Matsushita M, 1999, J BIOL CHEM, V274, P10086, DOI 10.1074/jbc.274.15.10086; MATTHEWS RP, 1994, MOL CELL BIOL, V14, P6107, DOI 10.1128/MCB.14.9.6107; Nakaya K, 2001, B CHEM SOC JPN, V74, P173, DOI 10.1246/bcsj.74.173; Osawa M, 1999, NAT STRUCT BIOL, V6, P819; Park IK, 1995, J BIOL CHEM, V270, P30464, DOI 10.1074/jbc.270.51.30464; Ribar TJ, 2000, J NEUROSCI, V20, DOI 10.1523/JNEUROSCI.20-22-j0004.2000; ROSKOSKI R, 1983, METHOD ENZYMOL, V99, P3; SELBERT MA, 1995, J BIOL CHEM, V270, P17616, DOI 10.1074/jbc.270.29.17616; Soderling TR, 1999, TRENDS BIOCHEM SCI, V24, P232, DOI 10.1016/S0968-0004(99)01383-3; SUN PQ, 1994, GENE DEV, V8, P2527, DOI 10.1101/gad.8.21.2527; Tokumitsu H, 2000, J BIOL CHEM, V275, P20090, DOI 10.1074/jbc.M002193200; Tokumitsu H, 1999, J BIOL CHEM, V274, P15803, DOI 10.1074/jbc.274.22.15803; Tokumitsu H, 1996, J BIOL CHEM, V271, P5617, DOI 10.1074/jbc.271.10.5617; Tokumitsu H, 1997, BIOCHEMISTRY-US, V36, P12823, DOI 10.1021/bi971348i; TOKUMITSU H, 1994, J BIOL CHEM, V269, P28640; Tokumitsu H, 2001, BIOCHEMISTRY-US, V40, P13925, DOI 10.1021/bi010863k; TOKUMITSU H, 1995, J BIOL CHEM, V270, P19320, DOI 10.1074/jbc.270.33.19320; TOKUMITSU H, 1990, J BIOL CHEM, V265, P4315; Wayman GA, 1997, J BIOL CHEM, V272, P16073, DOI 10.1074/jbc.272.26.16073; Wu JY, 2000, ENDOCRINOLOGY, V141, P4777, DOI 10.1210/en.141.12.4777; Wu JY, 2000, NAT GENET, V25, P448, DOI 10.1038/78153	37	229	237	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 3	2002	277	18					15813	15818		10.1074/jbc.M201075200	http://dx.doi.org/10.1074/jbc.M201075200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	550PA	11867640	hybrid			2022-12-27	WOS:000175510400081
J	Burakov, D; Crofts, LA; Chang, CPB; Freedman, LP				Burakov, D; Crofts, LA; Chang, CPB; Freedman, LP			Reciprocal recruitment of DRIP/mediator and p160 coactivator complexes in vivo by estrogen receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR RECEPTORS; BINDING PROTEIN; LIVING CELLS; TRANSCRIPTION; ALPHA; ACTIVATION; INITIATION; INTERACTS; EXCHANGE; DYNAMICS	Two functionally distinct classes of coactivators are recruited by liganded estrogen receptor, the DRIP/Mediator complex and p160 proteins, although the relative dynamics of recruitment is unclear. Previously, we have shown a direct, estradiol-dependent interaction between the DRIP205 subunit of the DRIP complex and the estrogen receptor (ER) AF2 domain. Here we demonstrate the in vivo recruitment of other endogenous DRIP subunits to ER in response to estradiol treatment in MCF-7 cells. To explore the relationship between DRIP and p160 coactivators, we examined the kinetics of coactivator recruitment to the ER target promoter, pS2, by chromatin immunoprecipitation. We observed a cyclic association and dissociation of coactivators with the promoter, with recruitment of p160s and DRIPS occurring in opposite phases, suggesting an exchange between these coactivator complexes at the target promoter.	Cornell Univ, Joan & Sanford I Weill Grad Sch Med Sci, Mem Sloan Kettering Canc Ctr, Sloan Kettering Div,Cell Biol Program, New York, NY 10021 USA	Cornell University; Memorial Sloan Kettering Cancer Center	Freedman, LP (corresponding author), Merck Res Labs, Dept Bone Biol, WP26A-1000, W Point, PA 19486 USA.				NIDDK NIH HHS [DK45460] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK045460, R01DK045460] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Burakov D, 2000, J BIOL CHEM, V275, P20928, DOI 10.1074/jbc.M002013200; Chen HW, 1999, CELL, V98, P675, DOI 10.1016/S0092-8674(00)80054-9; Chiba N, 2000, J BIOL CHEM, V275, P10719, DOI 10.1074/jbc.275.15.10719; Demarest SJ, 2002, NATURE, V415, P549, DOI 10.1038/415549a; Freedman LP, 1999, CELL, V97, P5, DOI 10.1016/S0092-8674(00)80708-4; Gamble MJ, 2002, TRENDS BIOCHEM SCI, V27, P165, DOI 10.1016/S0968-0004(02)02076-5; Glass CK, 2000, GENE DEV, V14, P121; JELTSCH JM, 1987, NUCLEIC ACIDS RES, V15, P1401, DOI 10.1093/nar/15.4.1401; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Kang YK, 2002, P NATL ACAD SCI USA, V99, P2642, DOI 10.1073/pnas.261715899; Kim MY, 2001, EMBO J, V20, P6084, DOI 10.1093/emboj/20.21.6084; Kraus WL, 1998, GENE DEV, V12, P331, DOI 10.1101/gad.12.3.331; Lemon BD, 1999, CURR OPIN GENET DEV, V9, P499, DOI 10.1016/S0959-437X(99)00010-6; Llopis J, 2000, P NATL ACAD SCI USA, V97, P4363, DOI 10.1073/pnas.97.8.4363; Mak HY, 2001, MOL CELL BIOL, V21, P4379, DOI 10.1128/MCB.21.13.4379-4390.2001; Malik S, 2000, TRENDS BIOCHEM SCI, V25, P277, DOI 10.1016/S0968-0004(00)01596-6; Margeat E, 2001, J MOL BIOL, V306, P433, DOI 10.1006/jmbi.2000.4418; McNally JG, 2000, SCIENCE, V287, P1262, DOI 10.1126/science.287.5456.1262; Rachez C, 1999, NATURE, V398, P824, DOI 10.1038/19783; Rachez C, 1998, GENE DEV, V12, P1787, DOI 10.1101/gad.12.12.1787; Rachez C, 2001, CURR OPIN CELL BIOL, V13, P274, DOI 10.1016/S0955-0674(00)00209-X; Shang YF, 2000, CELL, V103, P843, DOI 10.1016/S0092-8674(00)00188-4; Stenoien DL, 2001, MOL CELL BIOL, V21, P4404, DOI 10.1128/MCB.21.13.4404-4412.2001; Warnmark A, 2001, J BIOL CHEM, V276, P23397, DOI 10.1074/jbc.M011651200; Yuan CX, 1998, P NATL ACAD SCI USA, V95, P7939, DOI 10.1073/pnas.95.14.7939; Zhu YJ, 1999, P NATL ACAD SCI USA, V96, P10848, DOI 10.1073/pnas.96.19.10848	26	109	112	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 26	2002	277	17					14359	14362		10.1074/jbc.C200099200	http://dx.doi.org/10.1074/jbc.C200099200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	545EH	11893728	hybrid			2022-12-27	WOS:000175203000003
J	Shi, L; Kishore, R; McMullen, MR; Nagy, LE				Shi, L; Kishore, R; McMullen, MR; Nagy, LE			Chronic ethanol increases lipopolysaccharide-stimulated Egr-1 expression in RAW 264.7 macrophages - Contribution to enhanced tumor necrosis factor alpha production	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; ALCOHOLIC LIVER-DISEASE; SIGNAL-REGULATED KINASE; EARLY GROWTH RESPONSE-1; NITRIC-OXIDE SYNTHASE; HUMAN MONOCYTIC CELLS; MESSENGER-RNA; PLASMA ENDOTOXIN; PC12 CELLS; PATHWAY	Increased production of tumor necrosis factor alpha (TNFalpha) is associated with the development of alcoholic liver disease. Culture of RAW264.7 macrophages with 25 mm ethanol for 48 h increased lipopolysaccharide (LPS)-stimulated accumulation of tumor necrosis factor alpha (TNFalpha) peptide and mRNA by 2-fold. We investigated whether chronic ethanol-induced increases in the DNA binding and/or promoter activity of the key transcription factors regulating LPS-stimulated TNFalpha promoter activity contribute to increased TNFalpha expression. Binding of Egr-1 to the TNFalpha promoter was increased by 2.5-fold after ethanol exposure, whereas NFkappaB binding was decreased to 30% of control. AP-1 binding was not affected. Changes in binding activity were paralleled by an increased contribution of the Egr-1 binding site and a decreased contribution of the NFkappaB site to LPS-stimulated TNFalpha promoter activity. Overexpression of dominant negative Egr-1 prevented the ethanol-induced increase in LPS-stimulated TNFalpha mRNA accumulation. Chronic ethanol exposure enhanced LPS-stimulated Egr-1 promoter-driven CAT expression and transcription of Egr-1. Induction of Egr-1 is dependent on ERK1/2 activation in other systems. Therefore, we investigated whether the ERK1/2 pathway mediated the chronic ethanol-induced increases in Egr-1 and TNFalpha. Increased Egr-1 promoter activity and TNFalpha mRNA accumulation after chronic ethanol were both prevented by overexpression of dominant negative ERK1/2. LPS-stimulated ERK1/2 phosphorylation was increased 2-fold in cells cultured with ethanol compared with controls. These results demonstrate that enhanced LPS-dependent activation of Egr-1 contributes to increased TNFalpha production after chronic ethanol exposure.	Case Western Reserve Univ, Dept Nutr, Cleveland, OH 44106 USA	Case Western Reserve University	Nagy, LE (corresponding author), Case Western Reserve Univ, Dept Nutr, 2123 Abington Rd,Rm 201, Cleveland, OH 44106 USA.		Shi, Lei/AAV-1321-2020	Shi, Lei/0000-0002-4137-096X; Javitch, Jonathan/0000-0001-7395-2967	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R56AA011975, R01AA011975] Funding Source: NIH RePORTER; NIAAA NIH HHS [AA-11975] Funding Source: Medline	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		Aggarwal B.B., 1995, HUMAN CYTOKINES THEI; Aldred A, 1999, AM J PHYSIOL-GASTR L, V276, pG98, DOI 10.1152/ajpgi.1999.276.1.G98; Bjorbaek C, 2001, J BIOL CHEM, V276, P4747, DOI 10.1074/jbc.M007439200; BODE C, 1987, J HEPATOL, V4, P8, DOI 10.1016/S0168-8278(87)80003-X; Chen CC, 1999, J BIOL CHEM, V274, P31559, DOI 10.1074/jbc.274.44.31559; Chen JP, 1998, BIOCHEM J, V334, P669, DOI 10.1042/bj3340669; COLEMAN DL, 1992, J IMMUNOL, V149, P3045; DeFranco AL, 1998, PROG CLIN BIOL RES, V397, P119; Diamond I, 1997, PHYSIOL REV, V77, P1, DOI 10.1152/physrev.1997.77.1.1; DiDonato J, 1996, MOL CELL BIOL, V16, P1295; Dieckgraefe BK, 1999, AM J PHYSIOL-GASTR L, V276, pG322, DOI 10.1152/ajpgi.1999.276.2.G322; Efimova T, 1998, J BIOL CHEM, V273, P24387, DOI 10.1074/jbc.273.38.24387; FUKUI H, 1991, J HEPATOL, V12, P162, DOI 10.1016/0168-8278(91)90933-3; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; Greenberg SS, 1998, ALCOHOL, V16, P167, DOI 10.1016/S0741-8329(97)00187-0; Guha M, 2001, BLOOD, V98, P1429, DOI 10.1182/blood.V98.5.1429; Harada T, 2001, NAT CELL BIOL, V3, P453, DOI 10.1038/35074516; HONCHEL R, 1992, ALCOHOL CLIN EXP RES, V16, P665, DOI 10.1111/j.1530-0277.1992.tb00656.x; HUANG RP, 1994, J CELL BIOCHEM, V56, P469, DOI 10.1002/jcb.240560407; KHORUTS A, 1991, HEPATOLOGY, V13, P267, DOI 10.1016/0270-9139(91)92439-F; Kishore R, 2002, AM J PHYSIOL-GASTR L, V282, pG6, DOI 10.1152/ajpgi.00328.2001; Kishore R, 2001, J BIOL CHEM, V276, P41930, DOI 10.1074/jbc.M107181200; MCCLAIN CJ, 1989, HEPATOLOGY, V9, P349, DOI 10.1002/hep.1840090302; Means TK, 2000, J LEUKOCYTE BIOL, V67, P885, DOI 10.1002/jlb.67.6.885; Motomura K, 2001, AM J PHYSIOL-ENDOC M, V281, pE420, DOI 10.1152/ajpendo.2001.281.3.E420; NANJI AA, 1993, AM J PATHOL, V142, P367; Papadakis KA, 2000, GASTROENTEROLOGY, V119, P1148, DOI 10.1053/gast.2000.18160; Papanikolaou NA, 2000, J BIOL CHEM, V275, P26683; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; Qu ZC, 1998, J CELL BIOL, V142, P1075, DOI 10.1083/jcb.142.4.1075; Reddy MA, 1996, BIOCHEM PHARMACOL, V51, P661, DOI 10.1016/S0006-2952(95)02239-2; ROIVAINEN R, 1995, P NATL ACAD SCI USA, V92, P1891, DOI 10.1073/pnas.92.6.1891; Rokos CL, 1997, J BIOL CHEM, V272, P13452, DOI 10.1074/jbc.272.20.13452; Sato K, 1999, MOL BRAIN RES, V74, P182, DOI 10.1016/S0169-328X(99)00279-X; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SHI L, 2002, AM J PHYSIOL, V10, P1152; Silverman ES, 2001, AM J RESP CRIT CARE, V163, P778, DOI 10.1164/ajrccm.163.3.2003123; Sweet MJ, 1996, J LEUKOCYTE BIOL, V60, P8, DOI 10.1002/jlb.60.1.8; Tilg H, 2000, NEW ENGL J MED, V343, P1467, DOI 10.1056/NEJM200011163432007; Tsai EY, 2000, MOL CELL BIOL, V20, P6084, DOI 10.1128/MCB.20.16.6084-6094.2000; Weng YI, 2000, EUR J PHARMACOL, V398, P323, DOI 10.1016/S0014-2999(00)00313-7; Wung BS, 1999, CIRC RES, V84, P804; Yan SF, 2000, J CLIN INVEST, V105, P553, DOI 10.1172/JCI9513; Yan SF, 2000, NAT MED, V6, P1355, DOI 10.1038/82168; Yao J, 1997, J BIOL CHEM, V272, P17795, DOI 10.1074/jbc.272.28.17795; Yin M, 1999, GASTROENTEROLOGY, V117, P942, DOI 10.1016/S0016-5085(99)70354-9	46	308	319	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 26	2002	277	17					14777	14785		10.1074/jbc.M108967200	http://dx.doi.org/10.1074/jbc.M108967200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	545EH	11856733	hybrid			2022-12-27	WOS:000175203000056
J	Chen, HL; Demiralp, B; Schneider, A; Koh, AJ; Silve, C; Wang, CY; McCauley, LK				Chen, HL; Demiralp, B; Schneider, A; Koh, AJ; Silve, C; Wang, CY; McCauley, LK			Parathyroid hormone and parathyroid hormone-related protein exert both pro- and anti-apoptotic effects in mesenchymal cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BONE MORPHOGENETIC PROTEIN-2; FIBROBLAST-GROWTH-FACTOR; PTH/PTHRP RECEPTOR; OSTEOBLASTIC CELLS; PEPTIDE RECEPTOR; OSTEOGENIC DIFFERENTIATION; COLLAGENASE-3 PROMOTER; TRANSCRIPTION FACTOR; PLASMA-MEMBRANE; FOS PROMOTER	During bone formation, multipotential mesenchymal cells proliferate and differentiate into osteoblasts, and subsequently many die because of apoptosis. Evidence suggests that the receptor for parathyroid hormone (PTH) and parathyroid hormone-related protein (PTHrP), the PTH-1 receptor (PTH-1R), plays an important role in this process. Multipotential mesenchymal cells (C3H10T1/2) transfected with normal or mutant PTH-1Rs and MC3T3-E1 osteoblastic cells were used to explore the roles of PTH, PTHrP, and the PTH-1R in cell viability relative to osteoblastic differentiation. Overexpression of wild-type PTH-1R increased cell numbers and promoted osteocalcin gene expression versus inactivated mutant receptors. Furthermore, the effects of PTH and PTHrP on apoptosis were dramatically dependent on cell status. In preconfluent C3H10T1/2 and MC3T3-E1 cells, PTH and PTHrP protected against dexamethasone-induced reduction in cell viability, which was dependent on CAMP activation. Conversely, PTH and PTHrP resulted in reduced cell viability in postconfluent cells, which was also dependent on LAMP activation. Further, the proapoptotic-like effects were associated with an inhibition of Akt phosphorylation. These data suggest that parathyroid hormones accelerate turnover of osteoblasts by promoting cell viability early and promoting cell departure from the differentiation program later in their developmental scheme. Both of these actions occur at least in part via the protein kinase A pathway.	Univ Michigan, Dept Periodont Prevent & Geriatr, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Biol & Mat Sci, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Pathol, Ann Arbor, MI 48109 USA; Hacettepe Univ, Dept Periodontol, Fac Dent, TR-06100 Ankara, Turkey; INSERM, U426, Fac Med Xavier Bichat, F-75870 Paris, France	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Hacettepe University; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bichat-Claude Bernard - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	McCauley, LK (corresponding author), Univ Michigan, Dept Periodont Prevent & Geriatr, 1011 N Univ Ave, Ann Arbor, MI 48109 USA.	mccauley@umich.edu			NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE013788] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK053904] Funding Source: NIH RePORTER; NIDCR NIH HHS [DE13788] Funding Source: Medline; NIDDK NIH HHS [DK53904] Funding Source: Medline	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABOUSAMRA AB, 1992, P NATL ACAD SCI USA, V89, P2732, DOI 10.1073/pnas.89.7.2732; Albanese C, 1999, J BIOL CHEM, V274, P34186, DOI 10.1074/jbc.274.48.34186; Banerjee C, 1996, P NATL ACAD SCI USA, V93, P4968, DOI 10.1073/pnas.93.10.4968; BROWN PH, 1994, ONCOGENE, V9, P791; Calvi LM, 2001, J CLIN INVEST, V107, P277, DOI 10.1172/JCI11296; CANALIS E, 1989, J CLIN INVEST, V83, P60, DOI 10.1172/JCI113885; Chen SQ, 2001, J CELL BIOL, V152, P87, DOI 10.1083/jcb.152.1.87; D'Alonzo RC, 2002, J BIOL CHEM, V277, P816, DOI 10.1074/jbc.M107082200; DEBARTOLO TF, 1982, CALCIFIED TISSUE INT, V34, P495, DOI 10.1007/BF02411291; Divieti P, 1998, J BONE MINER RES, V13, P1835, DOI 10.1359/jbmr.1998.13.12.1835; Ducy P, 1999, GENE DEV, V13, P1025, DOI 10.1101/gad.13.8.1025; Dudek H, 1997, SCIENCE, V275, P661, DOI 10.1126/science.275.5300.661; FRANCESCHI RT, 1992, J BONE MINER RES, V7, P235; Gerstenfeld LC, 2002, J BONE MINER RES, V17, P221, DOI 10.1359/jbmr.2002.17.2.221; HABENER JF, 1984, PHYSIOL REV, V64, P985, DOI 10.1152/physrev.1984.64.3.985; HERRMANNERLEE MPM, 1976, ENDOCR RES COMMUN, V3, P21, DOI 10.3109/07435807609057738; HOCK JM, 1989, ENDOCRINOLOGY, V125, P2022, DOI 10.1210/endo-125-4-2022; INOMATA N, 1995, ENDOCRINOLOGY, V136, P4732, DOI 10.1210/en.136.11.4732; Jacobs-Helber SM, 1998, MOL CELL BIOL, V18, P3699, DOI 10.1128/MCB.18.7.3699; Jilka RL, 1999, J CLIN INVEST, V104, P439, DOI 10.1172/JCI6610; Jobert AS, 1998, J CLIN INVEST, V102, P34, DOI 10.1172/JCI2918; Johnson AC, 2000, MOL MED, V6, P17, DOI 10.1007/BF03401931; Ju WJ, 2000, J BONE MINER RES, V15, P1889, DOI 10.1359/jbmr.2000.15.10.1889; JUPPNER H, 1991, SCIENCE, V254, P1024, DOI 10.1126/science.1658941; JUPPNER H, 1988, J BIOL CHEM, V263, P8557; KATAGIRI T, 1990, BIOCHEM BIOPH RES CO, V172, P295, DOI 10.1016/S0006-291X(05)80208-6; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; Kern B, 2001, J BIOL CHEM, V276, P7101, DOI 10.1074/jbc.M006215200; Kim S, 2001, J BIOL CHEM, V276, P12864, DOI 10.1074/jbc.M001492200; Lanske B, 1999, J CLIN INVEST, V104, P399, DOI 10.1172/JCI6629; Lanske B, 1996, SCIENCE, V273, P663, DOI 10.1126/science.273.5275.663; Lee KS, 2000, MOL CELL BIOL, V20, P8783, DOI 10.1128/MCB.20.23.8783-8792.2000; Lenczowski JM, 1997, MOL CELL BIOL, V17, P170, DOI 10.1128/MCB.17.1.170; Leppa S, 1999, ONCOGENE, V18, P6158, DOI 10.1038/sj.onc.1203173; Machwate M, 1998, MOL PHARMACOL, V54, P70, DOI 10.1124/mol.54.1.70; Madrid LV, 2000, MOL CELL BIOL, V20, P1626, DOI 10.1128/MCB.20.5.1626-1638.2000; Mansukhani A, 2000, J CELL BIOL, V149, P1297, DOI 10.1083/jcb.149.6.1297; MARTIN SJ, 1995, J EXP MED, V182, P1545, DOI 10.1084/jem.182.5.1545; MARTIN TJ, 1991, CRIT REV BIOCHEM MOL, V26, P377, DOI 10.3109/10409239109114073; MCCARTHY TL, 1989, ENDOCRINOLOGY, V124, P1247, DOI 10.1210/endo-124-3-1247; MCCAULEY LK, 1992, ENDOCRINOLOGY, V130, P300, DOI 10.1210/en.130.1.300; McCauley LK, 2001, ENDOCRINOLOGY, V142, P1975, DOI 10.1210/en.142.5.1975; MCCAULEY LK, 1994, MOL CELL ENDOCRINOL, V101, P331, DOI 10.1016/0303-7207(94)90250-X; McCauley LK, 1996, J CELL BIOCHEM, V61, P638, DOI 10.1002/(SICI)1097-4644(19960616)61:4<638::AID-JCB18>3.0.CO;2-B; MOSELEY JM, 1995, CRIT REV CL LAB SCI, V32, P299, DOI 10.3109/10408369509084687; Nakamura T, 1997, BIOCHEM BIOPH RES CO, V237, P465, DOI 10.1006/bbrc.1997.7156; Neer RM, 2001, NEW ENGL J MED, V344, P1434, DOI 10.1056/NEJM200105103441904; OFIR R, 1991, GENE EXPRESSION, V1, P55; Parfitt AM., 1990, BONE TREATISE, VI, P351; Pearman AT, 1996, J BIOL CHEM, V271, P25715, DOI 10.1074/jbc.271.41.25715; PITARU S, 1993, J BONE MINER RES, V8, P919; REZNIKOFF CA, 1973, CANCER RES, V33, P3231; Riccio A, 1999, SCIENCE, V286, P2358, DOI 10.1126/science.286.5448.2358; Sabatini M, 1996, BONE, V18, P59, DOI 10.1016/8756-3282(95)00427-0; Schipani E, 1999, J CLIN ENDOCR METAB, V84, P3052, DOI 10.1210/jc.84.9.3052; SCHIPANI E, 1995, SCIENCE, V268, P98, DOI 10.1126/science.7701349; Schipani E, 1996, NEW ENGL J MED, V335, P708, DOI 10.1056/NEJM199609053351004; Selvamurugan N, 2000, J BIOL CHEM, V275, P5037, DOI 10.1074/jbc.275.7.5037; Spinella-Jaegle S, 2001, BONE, V29, P323, DOI 10.1016/S8756-3282(01)00580-4; TAYLOR SM, 1979, CELL, V17, P771, DOI 10.1016/0092-8674(79)90317-9; Turner PR, 2000, MOL ENDOCRINOL, V14, P241, DOI 10.1210/me.14.2.241; USDIN TB, 1995, J BIOL CHEM, V270, P15455, DOI 10.1074/jbc.270.26.15455; VERMES I, 1995, J IMMUNOL METHODS, V184, P39, DOI 10.1016/0022-1759(95)00072-I; WANG EA, 1993, GROWTH FACTORS, V9, P57, DOI 10.3109/08977199308991582; Wang JM, 1999, MOL CELL BIOL, V19, P6195; Watson PH, 2000, BONE, V26, P221, DOI 10.1016/S8756-3282(99)00264-1; WILSON JM, 1989, SCIENCE, V244, P1344, DOI 10.1126/science.2734614; ZAJAC JD, 1992, MOL CELL ENDOCRINOL, V87, P69, DOI 10.1016/0303-7207(92)90234-W; Zerega B, 1999, J BONE MINER RES, V14, P1281, DOI 10.1359/jbmr.1999.14.8.1281; Zhang P, 1998, J CLIN ENDOCR METAB, V83, P3365, DOI 10.1210/jc.83.9.3373; Zhou HL, 2000, J CELL BIOL, V151, P483, DOI 10.1083/jcb.151.3.483	71	125	129	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 31	2002	277	22					19374	19381		10.1074/jbc.M108913200	http://dx.doi.org/10.1074/jbc.M108913200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	557EH	11897779	hybrid			2022-12-27	WOS:000175894800019
J	DiCamillo, SJ; Carreras, I; Panchenko, MV; Stone, PJ; Nugent, MA; Foster, JA; Panchenko, MP				DiCamillo, SJ; Carreras, I; Panchenko, MV; Stone, PJ; Nugent, MA; Foster, JA; Panchenko, MP			Elastase-released epidermal growth factor recruits epidermal growth factor receptor and extracellular signal-regulated kinases to down-regulate tropoelastin mRNA in lung fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; SMOOTH-MUSCLE CELLS; HEPARAN-SULFATE PROTEOGLYCANS; HUMAN-LEUKOCYTE ELASTASE; EGF RECEPTOR; FACTOR-ALPHA; NEUTROPHIL ELASTASE; TYROSINE PHOSPHORYLATION; MAP KINASE; CARCINOMA-CELLS	Elastase/anti-elastase imbalance is a hallmark of emphysema, a chronic obstructive pulmonary disease associated with the rupture and inefficient repair of interstitial elastin. We report that neutrophil elastase (NE) at low physiologic concentrations, ranging from 35 nM to 1 mum, invokes transient, peaking at 15 min, activation of extracellular signal-regulated kinases 1 and 2 (ERK) in elastogenic lung fibroblasts. ERK activation is preceded by the release of soluble 25-26-kDa forms of epidermal growth factor (EGF) and transactivation of EGF receptor (EGFR) in NE-exposed cells. The stimulatory effect of NE on ERK is abrogated in the presence of anti-EGF-neutralizing antibodies, EGFR tyrosine kinase inhibitor (AG1478), and ERK kinase inhibitor (PD98059), as well as abolished in both EGFR-desensitized and endocytosis-arrested fibroblasts. Nuclear accumulation of activated ERK is associated with transient, peaking at 30 min, induction of c-Fos and sustained, observed at 24-48 h, decrease of tropoelastin mRNA levels in NE-challenged cells. Pretreatment of fibroblasts with AG1478 or PD98059 abrogates the NE-initiated tropoelastin mRNA suppression. We conclude that proteolytically released EGF signals directly via EGFR and ERK to down-regulate tropoelastin mRNA in NE-challenged lung fibroblasts.	Boston Univ, Sch Med, Dept Biochem, Boston, MA 02118 USA; Boston Univ, Sch Med, Dept Med, Boston, MA 02118 USA	Boston University; Boston University	Panchenko, MP (corresponding author), Boston Univ, Sch Med, Dept Biochem, 715 Albany St, Boston, MA 02118 USA.	panchenko@biochem.bumc.bu.edu		Stone, Phillip/0000-0001-6220-690X; Panchenko, Maria/0000-0001-6247-6598; carreras, isabel/0000-0002-7120-6749; Nugent, Matthew/0000-0002-8630-4712	NHLBI NIH HHS [P01HL013262, HL-07035, P01HL046902] Funding Source: Medline; NIA NIH HHS [AG-00115] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL013262, P01HL046902, T32HL007035] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Barnes Peter J., 2001, Current Opinion in Pharmacology, V1, P217, DOI 10.1016/S1471-4892(01)00039-X; Belaaouaj A, 1998, NAT MED, V4, P615, DOI 10.1038/nm0598-615; Belaaouaj AA, 2000, SCIENCE, V289, P1185, DOI 10.1126/science.289.5482.1185; Belmokhtar CA, 2000, EXP CELL RES, V254, P99, DOI 10.1006/excr.1999.4737; BIETH JG, 1986, BIOL EXTRACELLULAR M, V1, P217; BODE W, 1989, BIOCHEMISTRY-US, V28, P1951, DOI 10.1021/bi00431a001; Bowers G, 2001, ONCOGENE, V20, P1388, DOI 10.1038/sj.onc.1204255; Buczek-Thomas JA, 1999, J BIOL CHEM, V274, P25167, DOI 10.1074/jbc.274.35.25167; BURGERING BMT, 1993, EMBO J, V12, P4211, DOI 10.1002/j.1460-2075.1993.tb06105.x; Cai TQ, 1996, J EXP MED, V184, P1213, DOI 10.1084/jem.184.4.1213; Carpenter G, 1999, J CELL BIOL, V146, P697, DOI 10.1083/jcb.146.4.697; Carreras I, 2001, AM J PHYSIOL-LUNG C, V281, pL766, DOI 10.1152/ajplung.2001.281.4.L766; Ceresa BP, 2000, CURR OPIN CELL BIOL, V12, P204, DOI 10.1016/S0955-0674(99)00077-0; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; CHOMCZYNSKI P, 1993, BIOTECHNIQUES, V15, P532; COFFER PJ, 1995, ONCOGENE, V11, P561; Daub H, 1996, NATURE, V379, P557, DOI 10.1038/379557a0; DAVIDSON JM, 1993, J CELL PHYSIOL, V155, P149, DOI 10.1002/jcp.1041550119; DAVIS RJ, 1995, MOL REPROD DEV, V42, P459, DOI 10.1002/mrd.1080420414; Dempsey EC, 2000, AM J PHYSIOL-LUNG C, V279, pL429, DOI 10.1152/ajplung.2000.279.3.L429; DUNLAP RP, 1987, BIOCHEM BIOPH RES CO, V145, P509, DOI 10.1016/0006-291X(87)91350-7; GAMOU S, 1995, FEBS LETT, V357, P161, DOI 10.1016/0014-5793(94)01335-X; GATES RE, 1985, BIOCHEMISTRY-US, V24, P5209, DOI 10.1021/bi00340a038; GOISHI K, 1995, MOL BIOL CELL, V6, P967, DOI 10.1091/mbc.6.8.967; Goldkorn T, 1997, BBA-MOL CELL RES, V1358, P289, DOI 10.1016/S0167-4889(97)00063-3; HANSEN SH, 1993, J CELL BIOL, V121, P61, DOI 10.1083/jcb.121.1.61; Hardie WD, 1997, AM J PATHOL, V151, P1075; Hardie WD, 1996, AM J RESP CELL MOL, V15, P499, DOI 10.1165/ajrcmb.15.4.8879184; Hardie WD, 2001, AM J PHYSIOL-LUNG C, V281, pL1088, DOI 10.1152/ajplung.2001.281.5.L1088; Hashimoto S, 1999, LIFE SCI, V64, P1465, DOI 10.1016/S0024-3205(99)00080-6; HOIDAL JR, 1983, CHEST, V83, P679, DOI 10.1378/chest.83.4.679; ICHIRO T, 1990, BIOCHEM BIOPH RES CO, V168, P850, DOI 10.1016/0006-291X(90)92399-K; IGNOTZ RA, 1986, P NATL ACAD SCI USA, V83, P6307, DOI 10.1073/pnas.83.17.6307; Izumi Y, 1998, EMBO J, V17, P7260, DOI 10.1093/emboj/17.24.7260; JANOFF A, 1988, INFLAMMATION BASIC P, P803; Jones PL, 1997, J CELL BIOL, V139, P279, DOI 10.1083/jcb.139.1.279; Kainulainen V, 1998, J BIOL CHEM, V273, P11563, DOI 10.1074/jbc.273.19.11563; KING CR, 1989, ONCOGENE, V4, P13; Kranenburg O, 1999, J BIOL CHEM, V274, P35301, DOI 10.1074/jbc.274.50.35301; Kucich U, 1997, AM J RESP CELL MOL, V17, P10, DOI 10.1165/ajrcmb.17.1.2816; Kuwada SK, 2000, MOL BIOL CELL, V11, P2485, DOI 10.1091/mbc.11.7.2485; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Li J, 2000, J BIOL CHEM, V275, P2951, DOI 10.1074/jbc.275.4.2951; Li Y, 2000, J BIOL CHEM, V275, P37443, DOI 10.1074/jbc.M004373200; Lin SY, 2001, NAT CELL BIOL, V3, P802, DOI 10.1038/ncb0901-802; Lucey EC, 1998, AM J RESP CRIT CARE, V158, P555, DOI 10.1164/ajrccm.158.2.9705021; LUETTEKE NC, 1988, BIOCHEMISTRY-US, V27, P6487, DOI 10.1021/bi00417a043; Macfarlane SR, 2001, PHARMACOL REV, V53, P245; McGowan SE, 1997, AM J RESP CELL MOL, V17, P25, DOI 10.1165/ajrcmb.17.1.2686; Miettinen PJ, 1997, DEV BIOL, V186, P224, DOI 10.1006/dbio.1997.8593; Moro L, 1998, EMBO J, V17, P6622, DOI 10.1093/emboj/17.22.6622; MROCZKOWSKI B, 1989, MOL CELL BIOL, V9, P2771, DOI 10.1128/MCB.9.7.2771; MUELLER SG, 1990, MOL CELL BIOL, V10, P4596, DOI 10.1128/MCB.10.9.4596; NOGUCHI A, 1989, EXP LUNG RES, V15, P537, DOI 10.3109/01902148909069617; Nugent MA, 2000, INT J BIOCHEM CELL B, V32, P115, DOI 10.1016/S1357-2725(99)00123-5; PANDIELLA A, 1991, J BIOL CHEM, V266, P5769; Parks WC, 1997, AM J RESP CELL MOL, V17, P1; Peschon JJ, 1998, SCIENCE, V282, P1281, DOI 10.1126/science.282.5392.1281; Pierce KL, 2001, J BIOL CHEM, V276, P23155, DOI 10.1074/jbc.M101303200; PORTEU F, 1991, J BIOL CHEM, V266, P18846; Prenzel N, 2001, ENDOCR-RELAT CANCER, V8, P11, DOI 10.1677/erc.0.0080011; Prenzel N, 1999, NATURE, V402, P884, DOI 10.1038/47260; Rich CB, 1996, J BIOL CHEM, V271, P23043, DOI 10.1074/jbc.271.38.23043; RICH CB, 1989, ARCH BIOCHEM BIOPHYS, V268, P551, DOI 10.1016/0003-9861(89)90322-6; Rosette C, 1996, SCIENCE, V274, P1194, DOI 10.1126/science.274.5290.1194; Roudabush FL, 2000, J BIOL CHEM, V275, P22583, DOI 10.1074/jbc.M002915200; SACHSENMAIER C, 1994, CELL, V78, P963, DOI 10.1016/0092-8674(94)90272-0; Shapiro SD, 2000, CLIN CHEST MED, V21, P621, DOI 10.1016/S0272-5231(05)70172-6; Si-Tahar M, 1997, J BIOL CHEM, V272, P11636; Skold CM, 1999, AM J RESP CRIT CARE, V159, P1138; SNIDER GL, 1991, ANN NY ACAD SCI, V624, P45, DOI 10.1111/j.1749-6632.1991.tb17005.x; Taipale J, 1997, FASEB J, V11, P51, DOI 10.1096/fasebj.11.1.9034166; Thompson K, 1996, J CELL PHYSIOL, V166, P495, DOI 10.1002/(SICI)1097-4652(199603)166:3<495::AID-JCP4>3.0.CO;2-K; Towbin H, 1992, Biotechnology, V24, P145; Trevani AS, 1996, LAB INVEST, V74, P711; TWUMASI DY, 1977, J BIOL CHEM, V252, P1917; Wakasugi K, 1999, SCIENCE, V284, P147, DOI 10.1126/science.284.5411.147; WARBURTON D, 1992, DEV BIOL, V149, P123, DOI 10.1016/0012-1606(92)90269-M; Wendel DP, 2000, AM J RESP CELL MOL, V23, P320, DOI 10.1165/ajrcmb.23.3.3906; Widmann C, 1999, PHYSIOL REV, V79, P143, DOI 10.1152/physrev.1999.79.1.143; WU J, 1993, SCIENCE, V262, P1065, DOI 10.1126/science.7694366; Yamauchi T, 1997, NATURE, V390, P91, DOI 10.1038/36369; Yang JJ, 1996, AM J PATHOL, V149, P1617; ZORBAS MA, 1993, EXP CELL RES, V206, P49, DOI 10.1006/excr.1993.1119; [No title captured]	85	46	47	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 24	2002	277	21					18938	18946		10.1074/jbc.M200243200	http://dx.doi.org/10.1074/jbc.M200243200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	558PM	11889128	hybrid			2022-12-27	WOS:000175975800090
J	Pelletier, I; Sato, S				Pelletier, I; Sato, S			Specific recognition and cleavage of galectin-3 by Leishmania major through species-specific polygalactose epitope	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IGE-BINDING-PROTEIN; SURFACE EXPRESSION; MATRIX METALLOPROTEINASES; MONOCLONAL-ANTIBODIES; ENDOGENOUS LECTIN; CRYSTAL-STRUCTURE; LIPOPHOSPHOGLYCAN; PROMASTIGOTES; MACROPHAGES; MAC-2	Lipophosphoglycan is a major surface molecule of Leishmania, protozoa parasites, which are the causative agents of leishmaniasis, a disease that annually afflicts millions of people worldwide. The oligosaccharide structures of lipophosphoglycan varies among species, and epitopes of these species-specific oligosaccharides are suggested to be implicated in the interaction of Leishmania with macrophages as well as species-specific tissue tropism observed in leishmaniasis. The recognition of the species-specific variation of oligosaccharides is likely to be mediated by host carbohydrate-binding proteins, lectins, but the identities of the lectins remain elusive. Galectin-3 is a mammalian soluble beta-galactoside-binding lectin and is expressed in macrophages, dendritic cells, and keratinocytes, as well as fibroblasts, all of which are present in the site of Leishmania infection. In this paper, we found that galectin-3 binds to lipophosphoglycan of Leishmania major but not to those of Leishmania donovani through L. major-specific polygalactose epitopes. Association of galectin-3 with L. major led to the cleavage of galectin-3, resulting in truncated galectin-3 containing the C-terminal lectin domain but lacking the N-terminal domain implicated in lectin oligomerization. This cleavage was inhibited by the galectin-3 antagonist lactose, as well as 1,10-orthophenanthroline, suggesting that galectin-3 is cleaved by zinc metalloproteases after its binding to lipophosphoglycans. The modulation of various innate immunity reactions by galectin-3 is affected by its oligomerization; therefore, we propose the L. major-specific truncation of galectin-3 may contribute to the species-specific immune responses induced by Leishmania.	Univ Laval, Med Ctr, Ctr Hosp Univ Quebec, Res Ctr Infect Dis,Glycobiol Lab, Quebec City, PQ G1V 4G2, Canada	Laval University	Sato, S (corresponding author), CHU Laval, Ctr Rech Infectiol, Glycobiol Lab, 2705 Blvd Laurier, Quebec City, PQ G1V 4G2, Canada.	sachiko.sato@crchul.ulaval.ca						AHMED H, 1990, BIOCHEMISTRY-US, V29, P5315, DOI 10.1021/bi00474a015; Berman JD, 1997, CLIN INFECT DIS, V24, P684, DOI 10.1093/clind/24.4.684; Bogdan C, 1996, CURR OPIN IMMUNOL, V8, P517, DOI 10.1016/S0952-7915(96)80040-9; BOUVIER J, 1990, BIOCHEMISTRY-US, V29, P10113, DOI 10.1021/bi00495a015; BOUVIER J, 1995, METHOD ENZYMOL, V248, P614; BRUN R, 1979, ACTA TROP, V36, P289; Butcher BA, 1996, J BIOL CHEM, V271, P20573, DOI 10.1074/jbc.271.34.20573; BUTTON LL, 1988, J EXP MED, V167, P724, DOI 10.1084/jem.167.2.724; CHERAYIL BJ, 1989, J EXP MED, V170, P1959, DOI 10.1084/jem.170.6.1959; Cooper DNW, 1999, GLYCOBIOLOGY, V9, P979, DOI 10.1093/glycob/9.10.979; Demetriou M, 2001, NATURE, V409, P733, DOI 10.1038/35055582; Descoteaux A, 1999, BBA-MOL BASIS DIS, V1455, P341, DOI 10.1016/S0925-4439(99)00065-4; ETGES R, 1986, J BIOL CHEM, V261, P9098; FLOTTE TJ, 1983, AM J PATHOL, V111, P112; FRIGERI LG, 1992, J IMMUNOL, V148, P861; Funk VA, 1997, MOL BIOCHEM PARASIT, V84, P33, DOI 10.1016/S0166-6851(96)02780-6; HANDMAN E, 1985, EMBO J, V4, P329, DOI 10.1002/j.1460-2075.1985.tb03633.x; HSU DK, 1992, J BIOL CHEM, V267, P14167; Hughes RC, 1997, BIOCHEM SOC T, V25, P1194, DOI 10.1042/bst0251194; ILG T, 1992, J BIOL CHEM, V267, P6834; Kane MM, 2000, CURR OPIN HEMATOL, V7, P26, DOI 10.1097/00062752-200001000-00006; KELLEHER M, 1994, MOL BIOCHEM PARASIT, V66, P187, DOI 10.1016/0166-6851(94)90146-5; KELLEHER M, 1992, P NATL ACAD SCI USA, V89, P6, DOI 10.1073/pnas.89.1.6; Kuwabara I, 1996, J IMMUNOL, V156, P3939; Liu FT, 2000, CLIN IMMUNOL, V97, P79, DOI 10.1006/clim.2000.4912; Lowe JB, 2001, CELL, V104, P809, DOI 10.1016/S0092-8674(01)00277-X; MASSA SM, 1993, BIOCHEMISTRY-US, V32, P260, DOI 10.1021/bi00052a033; MCCONVILLE MJ, 1992, EMBO J, V11, P3593, DOI 10.1002/j.1460-2075.1992.tb05443.x; MCCONVILLE MJ, 1990, J BIOL CHEM, V265, P19611; MCMASTER WR, 1994, PARASITOLOGY, V108, pS29, DOI 10.1017/S0031182000075697; MOODY SF, 1993, J BIOL CHEM, V268, P18457; MOODY SF, 1993, ACTA TROP, V53, P185, DOI 10.1016/0001-706X(93)90029-B; NG K, 1994, GLYCOBIOLOGY, V4, P845, DOI 10.1093/glycob/4.6.845; Ng K, 1996, BIOCHEM J, V317, P247, DOI 10.1042/bj3170247; Ochieng J, 1998, BBA-GEN SUBJECTS, V1379, P97, DOI 10.1016/S0304-4165(97)00086-X; OCHIENG J, 1994, BIOCHEMISTRY-US, V33, P14109, DOI 10.1021/bi00251a020; PIMENTA PFP, 1992, SCIENCE, V256, P1812, DOI 10.1126/science.1615326; REINER SL, 1995, ANNU REV IMMUNOL, V13, P151, DOI 10.1146/annurev.iy.13.040195.001055; Sacchettini JC, 2001, BIOCHEMISTRY-US, V40, P3009, DOI 10.1021/bi002544j; Sakanari JA, 1997, EXP PARASITOL, V85, P63, DOI 10.1006/expr.1996.4116; Sato S, 2002, J IMMUNOL, V168, P1813, DOI 10.4049/jimmunol.168.4.1813; SATO S, 1992, J BIOL CHEM, V267, P6983; SATO S, 1994, EUR J IMMUNOL, V24, P216, DOI 10.1002/eji.1830240134; SATO S, 1994, J BIOL CHEM, V269, P4424; SATO S, 1993, EXP CELL RES, V207, P8, DOI 10.1006/excr.1993.1157; Schlagenhauf E, 1998, STRUCTURE, V6, P1035, DOI 10.1016/S0969-2126(98)00104-X; SCHNEIDER P, 1993, MOL BIOCHEM PARASIT, V62, P223, DOI 10.1016/0166-6851(93)90111-A; Seetharaman J, 1998, J BIOL CHEM, V273, P13047, DOI 10.1074/jbc.273.21.13047; Selzer PM, 1999, P NATL ACAD SCI USA, V96, P11015, DOI 10.1073/pnas.96.20.11015; SPARROW CP, 1987, J BIOL CHEM, V262, P7383; THOMAS JR, 1992, J BIOL CHEM, V267, P6829; TURCO SJ, 1992, ANNU REV MICROBIOL, V46, P65, DOI 10.1146/annurev.mi.46.100192.000433; Warfield PR, 1997, INVAS METAST, V17, P101; WEBB JR, 1991, MOL BIOCHEM PARASIT, V48, P173, DOI 10.1016/0166-6851(91)90113-K; WOLLENBERG A, 1993, J EXP MED, V178, P777, DOI 10.1084/jem.178.3.777; WOO HJ, 1990, J BIOL CHEM, V265, P7097	56	93	96	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 17	2002	277	20					17663	17670		10.1074/jbc.M201562200	http://dx.doi.org/10.1074/jbc.M201562200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	553PR	11882664	hybrid			2022-12-27	WOS:000175685100036
J	Geha, RM; Chen, K; Wouters, J; Ooms, F; Shih, JC				Geha, RM; Chen, K; Wouters, J; Ooms, F; Shih, JC			Analysis of conserved active site residues in monoamine oxidase A and B and their three-dimensional molecular modeling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID OXIDASE; CRYSTAL-STRUCTURE; INHIBITOR SPECIFICITIES; SUBSTRATE-SPECIFICITY; DIRECTED MUTAGENESIS; POLYAMINE OXIDASE; BINDING SITE; METABOLISM; MUTANT; EXPRESSION	Monoamine oxidase (MAO) is a key enzyme responsible for the degradation of serotonin, norepinephrine, dopamine, and phenylethylamine. It is an outer membrane mitochondrial enzyme existing in two isoforms, A and B. We have recently generated 14 site-directed mutants of human MAO A and B, and we found that four key amino acids, Lys-305, Trp-397, Tyr-407, and Tyr-444, in MAO A and their corresponding amino acids in MAO B, Lys-296, Trp-388, Tyr-398, and Tyr-435, play important roles in MAO catalytic activity. Based on the polyamine oxidase three-dimensional crystal structure, it is suggested that Lys-305, Trp-397, and Tyr-407 in MAO A and Lys-296, Trp-388, and Tyr-398 in MAO B may be involved in the non-covalent binding to FAD. Tyr-407 and Tyr-444 in MAO A (Tyr-398 and Tyr-435 in MAO B) may form an aromatic sandwich that stabilizes the substrate binding. Asp-132 in MAO A (Asp-123 in MAO B) located at the entrance of the U-shaped substrate-binding site has no effect on MAO A nor MAO B catalytic activity. The similar impact of analogous mutants in MAO A and MAO B suggests that these amino acids have the same function in both isoenzymes. Three-dimensional modeling of MAO A and B using polyamine oxidase as template suggests that the overall tertiary structure and the active sites of MAO A and B may be similar.	Univ So Calif, Sch Pharm, Dept Mol Pharmacol & Toxicol, Los Angeles, CA 90089 USA; Univ So Calif, Sch Med, Dept Cell & Neurobiol, Los Angeles, CA 90089 USA; Fac Univ Notre Dame Paix, B-5000 Namur, Belgium	University of Southern California; University of Southern California; University of Namur	Shih, JC (corresponding author), 1985 Zonal Ave, Los Angeles, CA 90089 USA.			Wouters, Johan/0000-0002-4920-6857	NIMH NIH HHS [R01 MH037020-16, R37 MH039085, R37 MH39085, R37 MH039085-23, R01 MH37020] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R37MH039085, R01MH037020] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		BACK AJW, 1988, P NATL ACAD SCI USA, V85, P4934; Binda C, 1999, STRUCTURE, V7, P265, DOI 10.1016/S0969-2126(99)80037-9; Binda C, 2002, NAT STRUCT BIOL, V9, P22, DOI 10.1038/nsb732; Cesura AM, 1996, EUR J BIOCHEM, V236, P996, DOI 10.1111/j.1432-1033.1996.00996.x; CHEN K, 1994, MOL PHARMACOL, V46, P1226; CHIBA K, 1984, BIOCHEM BIOPH RES CO, V120, P574, DOI 10.1016/0006-291X(84)91293-2; Dailey TA, 1998, J BIOL CHEM, V273, P13658, DOI 10.1074/jbc.273.22.13658; de Fays K, 1999, PROTEIN ENG, V12, P217, DOI 10.1093/protein/12.3.217; De Zutter GS, 2001, P NATL ACAD SCI USA, V98, P6168, DOI 10.1073/pnas.111027698; Depiereux E, 1997, COMPUT APPL BIOSCI, V13, P249; FRITZ RR, 1985, FEBS LETT, V186, P224, DOI 10.1016/0014-5793(85)80713-4; Geha RM, 2000, J NEUROCHEM, V75, P1304, DOI 10.1046/j.1471-4159.2000.751304.x; Geha RM, 2001, J BIOL CHEM, V276, P9877, DOI 10.1074/jbc.M006972200; GOTTOWIK J, 1993, FEBS LETT, V317, P152, DOI 10.1016/0014-5793(93)81512-X; GOTTOWIK J, 1995, EUR J BIOCHEM, V230, P934, DOI 10.1111/j.1432-1033.1995.tb20639.x; GRIMSBY J, 1991, P NATL ACAD SCI USA, V88, P3637, DOI 10.1073/pnas.88.9.3637; GRIMSBY J, 1997, NAT GENET, V17, P1; JOHNSTON JP, 1968, BIOCHEM PHARMACOL, V17, P1285, DOI 10.1016/0006-2952(68)90066-X; KEARNEY EB, 1971, EUR J BIOCHEM, V24, P321, DOI 10.1111/j.1432-1033.1971.tb19689.x; Knoll J, 1972, Adv Biochem Psychopharmacol, V5, P393; KRISKEY TJ, 1998, BIOCHEMISTRY-US, V37, P12360; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Mattevi A, 1996, P NATL ACAD SCI USA, V93, P7496, DOI 10.1073/pnas.93.15.7496; Miller JR, 1999, J BIOL CHEM, V274, P23515, DOI 10.1074/jbc.274.33.23515; MITOMA J, 1992, J BIOCHEM-TOKYO, V111, P20, DOI 10.1093/oxfordjournals.jbchem.a123712; Nandigama RK, 2001, BIOCHEMISTRY-US, V40, P14839, DOI 10.1021/bi011113d; Nandigama RK, 2000, J BIOL CHEM, V275, P20527, DOI 10.1074/jbc.M002132200; Pawelek PD, 2000, EMBO J, V19, P4204, DOI 10.1093/emboj/19.16.4204; PEGG AE, 1995, CANCER LETT, V95, P247, DOI 10.1016/0304-3835(95)03897-6; Rebrin I, 2001, J BIOL CHEM, V276, P29499, DOI 10.1074/jbc.M100431200; Roh JH, 2000, BIOCHEM BIOPH RES CO, V268, P293, DOI 10.1006/bbrc.2000.2113; SCHREUDER HA, 1988, J MOL BIOL, V199, P637, DOI 10.1016/0022-2836(88)90307-5; Shih JC, 1999, AM J HUM GENET, V65, P593, DOI 10.1086/302562; Shih JC, 1999, ANNU REV NEUROSCI, V22, P197, DOI 10.1146/annurev.neuro.22.1.197; TABOR CW, 1984, ANNU REV BIOCHEM, V53, P749, DOI 10.1146/annurev.bi.53.070184.003533; Tiburcio AF, 1997, PHYSIOL PLANTARUM, V100, P664, DOI 10.1034/j.1399-3054.1997.1000330.x; TSUGENO Y, 1995, J BIOCHEM-TOKYO, V118, P974, DOI 10.1093/jb/118.5.974; WEYLER W, 1992, J NEURAL TRANSM-SUPP, V41, P3; Wouters J, 1998, PROTEINS, V32, P97; Wouters J, 1998, CURR MED CHEM, V5, P137; WOUTERS J, 1995, BIOCHEM BIOPH RES CO, V208, P773, DOI 10.1006/bbrc.1995.1404; WU HF, 1993, MOL PHARMACOL, V43, P888; WURTMAN RJ, 1963, BIOCHEM PHARMACOL, V12, P1439, DOI 10.1016/0006-2952(63)90215-6; YU PH, 1981, CAN J BIOCHEM CELL B, V59, P30, DOI 10.1139/o81-005; Zhou BP, 1998, J BIOL CHEM, V273, P14862, DOI 10.1074/jbc.273.24.14862	45	62	65	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 10	2002	277	19					17209	17216		10.1074/jbc.M110920200	http://dx.doi.org/10.1074/jbc.M110920200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	551MB	11861643	hybrid, Green Accepted			2022-12-27	WOS:000175564500114
J	Ghilardi, N; Li, J; Hongo, JA; Yi, S; Gurney, A; de Sauvage, FJ				Ghilardi, N; Li, J; Hongo, JA; Yi, S; Gurney, A; de Sauvage, FJ			A novel type I cytokine receptor is expressed on monocytes, signals proliferation, and activates STAT-3 and STAT-5	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHRONIC ENTEROCOLITIS; HELICAL CYTOKINES; GENE; CLONING; CELLS; DIFFERENTIATION; TRANSCRIPTION; INTERLEUKIN-3; STIMULATION; REGULATOR	Here we report the cloning of a novel type I cytokine receptor, gp130-like monocyte receptor (GLM-R), with homology to the interleukin-6 receptor signal transducing chain, gp130, and granulocyte colony-stimulating factor receptor. Human and murine GLM-R cDNAs encode open reading frames of 732 and 716 amino acids, respectively, and the corresponding genes are located in close proximity to gp130 genes on human chromosome 5 and mouse chromosome 13. GLM-R is specifically expressed on CD14-positive cells and is up-regulated more than 50-fold upon activation of those cells. To address the question of whether GLM-R is a signaling receptor, we constructed a chimeric molecule, consisting of the extracellular domain of human growth hormone (hGH) receptor, and the intracellular domain of GLM-R. When transfected into factor-dependent 32D cells, this chimeric molecule could signal for proliferation and activate signal transducer and activator of transcription (STAT)-3 and STAT-5 upon stimulation with hGH. Thus, GLM-R is a novel signaling receptor chain potentially involved in the development and function of monocytes and macrophages.	Genentech Inc, Dept Mol Oncol, San Francisco, CA 94080 USA; Genentech Inc, Dept Antibody Technol, San Francisco, CA 94080 USA; Genentech Inc, Dept Mol Biol, San Francisco, CA 94080 USA	Roche Holding; Genentech; Roche Holding; Genentech; Roche Holding; Genentech	de Sauvage, FJ (corresponding author), Genentech Inc, Dept Mol Oncol, 1-DNA Way,Mailstop 40, San Francisco, CA 94080 USA.		de Sauvage, Frederic/ABE-8400-2020	de Sauvage, Frederic/0000-0002-5275-2584; Ghilardi, Nico/0000-0003-4945-3097				BAZAN JF, 1990, IMMUNOL TODAY, V11, P350, DOI 10.1016/0167-5699(90)90139-Z; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; Bunting KD, 2002, BLOOD, V99, P479, DOI 10.1182/blood.V99.2.479; Burge C, 1997, J MOL BIOL, V268, P78, DOI 10.1006/jmbi.1997.0951; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; DESAUVAGE FJ, 1994, NATURE, V369, P533, DOI 10.1038/369533a0; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; Feldman GM, 1997, BLOOD, V90, P1768, DOI 10.1182/blood.V90.5.1768; GREENBERGER JS, 1983, P NATL ACAD SCI-BIOL, V80, P2931, DOI 10.1073/pnas.80.10.2931; HIBI M, 1990, CELL, V63, P1149, DOI 10.1016/0092-8674(90)90411-7; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Ihle JN, 1997, STEM CELLS, V15, P105, DOI 10.1002/stem.5530150814; Ihle JN, 2001, CURR OPIN CELL BIOL, V13, P211, DOI 10.1016/S0955-0674(00)00199-X; IHLE JN, 1995, NATURE, V377, P591, DOI 10.1038/377591a0; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; ITOH N, 1990, SCIENCE, V247, P324, DOI 10.1126/science.2404337; Kawashima T, 2001, J IMMUNOL, V167, P3652, DOI 10.4049/jimmunol.167.7.3652; KUHN R, 1993, CELL, V75, P263, DOI 10.1016/0092-8674(93)80068-P; LARSEN A, 1990, J EXP MED, V172, P1559, DOI 10.1084/jem.172.6.1559; LEVY DE, 1989, GENE DEV, V3, P1362, DOI 10.1101/gad.3.9.1362; LOK S, 1994, NATURE, V369, P565, DOI 10.1038/369565a0; MU SX, 1995, BLOOD, V86, P4532, DOI 10.1182/blood.V86.12.4532.bloodjournal86124532; Nosaka T, 1999, EMBO J, V18, P4754, DOI 10.1093/emboj/18.17.4754; O'Farrell AM, 1998, EMBO J, V17, P1006, DOI 10.1093/emboj/17.4.1006; PALLARD C, 1995, J BIOL CHEM, V270, P15942, DOI 10.1074/jbc.270.27.15942; Parrish-Novak J, 2000, NATURE, V408, P57, DOI 10.1038/35040504; Presky DH, 1996, P NATL ACAD SCI USA, V93, P14002, DOI 10.1073/pnas.93.24.14002; REICH N, 1987, P NATL ACAD SCI USA, V84, P6394, DOI 10.1073/pnas.84.18.6394; Riley JK, 1999, J BIOL CHEM, V274, P16513, DOI 10.1074/jbc.274.23.16513; ROZWARSKI DA, 1994, STRUCTURE, V2, P159, DOI 10.1016/S0969-2126(00)00018-6; SCHMITT-NEY M, 1991, MOL CELL BIOL, V11, P3745, DOI 10.1128/MCB.11.7.3745; Takeda K, 1999, IMMUNITY, V10, P39, DOI 10.1016/S1074-7613(00)80005-9; WAGNER BJ, 1990, EMBO J, V9, P4477, DOI 10.1002/j.1460-2075.1990.tb07898.x	33	65	79	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 10	2002	277	19					16831	16836		10.1074/jbc.M201140200	http://dx.doi.org/10.1074/jbc.M201140200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	551MB	11877449	hybrid			2022-12-27	WOS:000175564500065
J	Haq, R; Halupa, A; Beattie, BK; Mason, JM; Zanke, BW; Barber, DL				Haq, R; Halupa, A; Beattie, BK; Mason, JM; Zanke, BW; Barber, DL			Regulation of erythropoietin-induced STAT serine phosphorylation by distinct mitogen-activated protein kinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED ERYTHROID-DIFFERENTIATION; DEPENDENT HCD57 CELLS; P38 MAP KINASE; TYROSINE PHOSPHORYLATION; SIGNAL-TRANSDUCTION; DNA-BINDING; IFN-GAMMA; TARGETED DISRUPTION; TRANSCRIPTIONAL ACTIVATION; GLUCOCORTICOID RECEPTOR	The STAT proteins are a family of latent transcription factors that are activated by a wide variety of cytokines. Upon receptor engagement, STATs become tyrosine phosphorylated, translocate to the nucleus, and induce expression of target genes. In addition to tyrosine phosphorylation, maximal activation of some STAT proteins requires serine phosphorylation within the transactivation domain. Here we focus on STAT phosphorylation after engagement of the erythropoietin receptor (EPOR). In Ba/F3-EPO-R cells, EPO induces tyrosine and serine phosphorylation of STAT1, STAT3, STAT5A, and STAT5B. Identical regions of the EPO-R couple to both tyrosine and serine phosphorylation of each cognate STAT protein. A proximal region of the EPO-R lacking cytoplasmic tyrosines couples to STAT1 and STAT3 phosphorylation as well as ERK and p38(HOG) activation, but not JNK/SAPK. STAT1 serine phosphorylation was perturbed by inhibition of ERK and p38 pathways, whereas only inhibition of ERK activation blocked STAT3 serine phosphorylation in response to EPO. STAT5A/B phosphorylation is downstream of EPO-R Tyr(343), however, STAT5A/B serine phosphorylation is unaffected by either ERK or p38 inhibition. Physiological responses induced by EPO may depend on regulation of serine phosphorylation of the STAT molecules by p38(HOG) and the ERK family of kinases as well as additional serine/threonine kinases.	Univ Toronto, Inst Med Sci, Toronto, ON M5G 2M9, Canada; Univ Toronto, Dept Med Biophys, Toronto, ON M5G 2M9, Canada; Univ Toronto, Lab Med & Pathobiol, Toronto, ON M5G 2M9, Canada; Ontario Canc Inst, Toronto, ON M5G 2M9, Canada	University of Toronto; University of Toronto; University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto	Zanke, BW (corresponding author), Univ Toronto, Inst Med Sci, Toronto, ON M5G 2M9, Canada.			Barber, Dwayne/0000-0001-5528-8150				Aznar S, 2001, MOL BIOL CELL, V12, P3282, DOI 10.1091/mbc.12.10.3282; Bao HF, 1999, BLOOD, V93, P3757, DOI 10.1182/blood.V93.11.3757.411a34_3757_3773; BARBER DL, 1994, MOL CELL BIOL, V14, P6506, DOI 10.1128/MCB.14.10.6506; BARBER DL, 1994, MOL CELL BIOL, V14, P2257, DOI 10.1128/MCB.14.4.2257; Barber DL, 2001, BLOOD, V97, P2230, DOI 10.1182/blood.V97.8.2230; Bhattacharya S, 1996, NATURE, V383, P344, DOI 10.1038/383344a0; Boudot C, 1999, J BIOL CHEM, V274, P33966, DOI 10.1074/jbc.274.48.33966; Chida D, 1999, BLOOD, V93, P1567, DOI 10.1182/blood.V93.5.1567.405k29_1567_1578; Chretien S, 1996, EMBO J, V15, P4174, DOI 10.1002/j.1460-2075.1996.tb00792.x; Chung CD, 1997, SCIENCE, V278, P1803, DOI 10.1126/science.278.5344.1803; Chung JK, 1997, MOL CELL BIOL, V17, P6508, DOI 10.1128/MCB.17.11.6508; DAMEN JE, 1995, J BIOL CHEM, V270, P23402, DOI 10.1074/jbc.270.40.23402; DAMEN JE, 1995, EMBO J, V14, P5557, DOI 10.1002/j.1460-2075.1995.tb00243.x; DANDREA AD, 1989, CELL, V57, P277, DOI 10.1016/0092-8674(89)90965-3; Decker T, 2000, ONCOGENE, V19, P2628, DOI 10.1038/sj.onc.1203481; Durbin JE, 1996, CELL, V84, P443, DOI 10.1016/S0092-8674(00)81289-1; Endo TA, 1997, NATURE, V387, P921, DOI 10.1038/43213; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Gobert S, 1996, EMBO J, V15, P2434, DOI 10.1002/j.1460-2075.1996.tb00601.x; Goh KC, 1999, EMBO J, V18, P5601, DOI 10.1093/emboj/18.20.5601; Horvai AE, 1997, P NATL ACAD SCI USA, V94, P1074, DOI 10.1073/pnas.94.4.1074; HORVATH CM, 1995, GENE DEV, V9, P984, DOI 10.1101/gad.9.8.984; Jacobs-Helber SM, 2000, BLOOD, V96, P933, DOI 10.1182/blood.V96.3.933.015k52_933_940; Jain N, 1998, ONCOGENE, V17, P3157, DOI 10.1038/sj.onc.1202238; Kieran MW, 1996, P NATL ACAD SCI USA, V93, P9126, DOI 10.1073/pnas.93.17.9126; Kirito K, 1998, BLOOD, V92, P462, DOI 10.1182/blood.V92.2.462.414k15_462_471; Kirito K, 1997, J BIOL CHEM, V272, P16507, DOI 10.1074/jbc.272.26.16507; Kirito K, 2002, BLOOD, V99, P102, DOI 10.1182/blood.V99.1.102; Klingmuller U, 1996, P NATL ACAD SCI USA, V93, P8324, DOI 10.1073/pnas.93.16.8324; KLINGMULLER U, 1995, CELL, V80, P729, DOI 10.1016/0092-8674(95)90351-8; KOMATSU N, 1993, BLOOD, V82, P456; KOURY MJ, 1990, SCIENCE, V248, P378, DOI 10.1126/science.2326648; Kovarik P, 1999, P NATL ACAD SCI USA, V96, P13956, DOI 10.1073/pnas.96.24.13956; Kovarik P, 1998, EMBO J, V17, P3660, DOI 10.1093/emboj/17.13.3660; Kovarik P, 2001, EMBO J, V20, P91, DOI 10.1093/emboj/20.1.91; Krebs DL, 2001, STEM CELLS, V19, P378, DOI 10.1634/stemcells.19-5-378; Lawson AE, 2000, BLOOD, V96, P2084, DOI 10.1182/blood.V96.6.2084.h8002084_2084_2092; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; Lim CP, 1999, J BIOL CHEM, V274, P31055, DOI 10.1074/jbc.274.43.31055; Lin CS, 1996, GENE DEV, V10, P154, DOI 10.1101/gad.10.2.154; Liu B, 1998, P NATL ACAD SCI USA, V95, P10626, DOI 10.1073/pnas.95.18.10626; Mason JM, 2000, J BIOL CHEM, V275, P4398, DOI 10.1074/jbc.275.6.4398; Meraz MA, 1996, CELL, V84, P431, DOI 10.1016/S0092-8674(00)81288-X; Moriggl R, 1999, IMMUNITY, V10, P249, DOI 10.1016/S1074-7613(00)80025-4; Morooka T, 1998, J BIOL CHEM, V273, P24285, DOI 10.1074/jbc.273.38.24285; Nagata Y, 1999, BLOOD, V94, P853, DOI 10.1182/blood.V94.3.853.415a12_853_863; Nagata Y, 1998, BLOOD, V92, P1859, DOI 10.1182/blood.V92.6.1859.418k37_1859_1869; Neubauer H, 1998, CELL, V93, P397, DOI 10.1016/S0092-8674(00)81168-X; OHASHI T, 1995, BLOOD, V85, P1454, DOI 10.1182/blood.V85.6.1454.bloodjournal8561454; Ohashi Takashi, 1997, Leukemia (Basingstoke), V11, P251; Pang QS, 2000, MOL CELL BIOL, V20, P4724, DOI 10.1128/MCB.20.13.4724-4735.2000; Parganas E, 1998, CELL, V93, P385, DOI 10.1016/S0092-8674(00)81167-8; Paulson M, 1999, J BIOL CHEM, V274, P25343, DOI 10.1074/jbc.274.36.25343; Penta K, 1995, J BIOL CHEM, V270, P31282, DOI 10.1074/jbc.270.52.31282; Quelle FW, 1996, MOL CELL BIOL, V16, P1622; REN HY, 1994, J BIOL CHEM, V269, P19633; Sawyer ST, 1996, J BIOL CHEM, V271, P32430, DOI 10.1074/jbc.271.50.32430; Socolovsky M, 1999, CELL, V98, P181, DOI 10.1016/S0092-8674(00)81013-2; Socolovsky M, 2001, BLOOD, V98, P3261, DOI 10.1182/blood.V98.12.3261; Stocklin E, 1996, NATURE, V383, P726, DOI 10.1038/383726a0; Stoecklin E, 1997, MOL CELL BIOL, V17, P6708, DOI 10.1128/MCB.17.11.6708; Takaoka A, 1999, EMBO J, V18, P2480, DOI 10.1093/emboj/18.9.2480; Takeda K, 1997, P NATL ACAD SCI USA, V94, P3801, DOI 10.1073/pnas.94.8.3801; Tauchi T, 1996, BLOOD, V87, P4495, DOI 10.1182/blood.V87.11.4495.bloodjournal87114495; Teglund S, 1998, CELL, V93, P841, DOI 10.1016/S0092-8674(00)81444-0; Turkson J, 1999, MOL CELL BIOL, V19, P7519; Turkson J, 1998, MOL CELL BIOL, V18, P2545, DOI 10.1128/MCB.18.5.2545; Uddin S, 1999, J BIOL CHEM, V274, P30127, DOI 10.1074/jbc.274.42.30127; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; Winston LA, 1995, J BIOL CHEM, V270, P30837, DOI 10.1074/jbc.270.52.30837; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L; Wojchowski DM, 1999, EXP CELL RES, V253, P143, DOI 10.1006/excr.1999.4673; WU H, 1995, CELL, V83, P59, DOI 10.1016/0092-8674(95)90234-1; Xia K, 1996, P NATL ACAD SCI USA, V93, P11681, DOI 10.1073/pnas.93.21.11681; Yamashita H, 1998, J BIOL CHEM, V273, P30218, DOI 10.1074/jbc.273.46.30218; Yasukawa H, 1999, EMBO J, V18, P1309, DOI 10.1093/emboj/18.5.1309; Zang HS, 2001, EMBO J, V20, P3156, DOI 10.1093/emboj/20.12.3156; Zauberman A, 1999, ONCOGENE, V18, P3886, DOI 10.1038/sj.onc.1202738; Zhu MH, 1999, CELL, V96, P121, DOI 10.1016/S0092-8674(00)80965-4; Zhu T, 2000, J BIOL CHEM, V275, P2103, DOI 10.1074/jbc.275.3.2103; Zhu XJ, 1997, MOL CELL BIOL, V17, P6618, DOI 10.1128/MCB.17.11.6618	81	69	69	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 10	2002	277	19					17359	17366		10.1074/jbc.M201842200	http://dx.doi.org/10.1074/jbc.M201842200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	551MB	11875080	hybrid			2022-12-27	WOS:000175564500132
J	Marinovic, AC; Zheng, B; Mitch, WE; Price, SR				Marinovic, AC; Zheng, B; Mitch, WE; Price, SR			Ubiquitin (UbC) expression in muscle cells is increased by glucocorticoids through a mechanism involving Sp1 and MEK1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; DNA-BINDING ACTIVITY; END RULE PATHWAY; SKELETAL-MUSCLE; PROTEASOME PATHWAY; MESSENGER-RNA; TRANSCRIPTION FACTOR; GENE-EXPRESSION; PROMOTER; ACTIVATION	The muscle protein catabolism present in rats with insulin-dependent diabetes and other catabolic conditions is generally associated with increased glucocorticoid production and mRNAs encoding components of the ubiquitin-proteasome system. The mechanisms that increase ubiquitin (UbC) expression have not been identified. We studied the regulation of UbC expression in L6 muscle cells because dexamethasone stimulates the transcription of this gene and others encoding components of the ubiquitin-proteasome pathway. Results of in vivo genomic DNA footprinting experiments indicate that a protein(s) binds to Sp1 sites similar to50 bp upstream from the UbC transcription start site; dexamethasone changes the methylation pattern at these sites. Sp1 binds to DNA probes corresponding to the rat or human UbC promoter, and treating cells with dexamethasone increases this binding. Deletion and mutation analyses of the rat and human UbC promoters are consistent with an important role of Sp1 in UbC induction by glucocorticoids. Dexamethasone-induced ubiquitin expression is blocked by mithramycin, an inhibitor of Sp1 binding. UO126, a pharmacologic inhibitor of MEK1, also blocks UbC transcriptional activation by dexamethasone; L6 cells transfected to express constitutively active AMK1 exhibit increased UbC promoter activity. Thus, glucocorticoids increase UbC expression in muscle cells by a novel transcriptional mechanism involving Sp1 and MEK1.	Emory Univ, Div Renal, Atlanta, GA 30322 USA	Emory University	Price, SR (corresponding author), Emory Univ, Div Renal, Rm 338,WMB,1639 Pierce Dr, Atlanta, GA 30322 USA.				NIDDK NIH HHS [DK50740, DK37175, R37 DK037175] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK037175, R01DK037175, R01DK050740] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alroy I, 1999, MOL CELL BIOL, V19, P1961; Armstrong SA, 1997, J BIOL CHEM, V272, P13489, DOI 10.1074/jbc.272.21.13489; Bailey JL, 1996, J CLIN INVEST, V97, P1447, DOI 10.1172/JCI118566; BARACOS VE, 1995, AM J PHYSIOL-ENDOC M, V268, pE996, DOI 10.1152/ajpendo.1995.268.5.E996; Bell LM, 2000, J BIOL CHEM, V275, P25262, DOI 10.1074/jbc.M002076200; Biesiada E, 1999, MOL CELL BIOL, V19, P2577; Black AR, 1999, J BIOL CHEM, V274, P1207, DOI 10.1074/jbc.274.3.1207; CHEN LI, 1994, MOL CELL BIOL, V14, P4380, DOI 10.1128/MCB.14.7.4380; Chupreta S, 2000, AM J PHYSIOL-CELL PH, V278, pC697, DOI 10.1152/ajpcell.2000.278.4.C697; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Du J, 2000, J BIOL CHEM, V275, P19661, DOI 10.1074/jbc.M907258199; FOJAS DB, 2001, EMBO J, V20, P5737; Gambari R, 2000, J PHARMACOL EXP THER, V294, P370; Giraudo E, 1998, J BIOL CHEM, V273, P22128, DOI 10.1074/jbc.273.34.22128; Greenwel P, 1997, J BIOL CHEM, V272, P19738, DOI 10.1074/jbc.272.32.19738; GROUDINE M, 1981, MOL CELL BIOL, V1, P281, DOI 10.1128/MCB.1.3.281; HALLANGERAS M, 1991, SURGERY, V109, P468; Ibrahim NM, 2000, BIOTECHNIQUES, V29, P782, DOI 10.2144/00294st04; Jamieson CAM, 2000, P NATL ACAD SCI USA, V97, P7319, DOI 10.1073/pnas.97.13.7319; JENTSCH S, 1991, BIOCHIM BIOPHYS ACTA, V1089, P127, DOI 10.1016/0167-4781(91)90001-3; JONES KA, 1986, SCIENCE, V232, P755, DOI 10.1126/science.3008338; Lazarus DD, 1999, AM J PHYSIOL-ENDOC M, V277, pE332, DOI 10.1152/ajpendo.1999.277.2.E332; Lecker SH, 1999, J CLIN INVEST, V104, P1411, DOI 10.1172/JCI7300; LEGGETT RW, 1995, J BIOL CHEM, V270, P25879, DOI 10.1074/jbc.270.43.25879; Liu A, 2001, J BIOL CHEM, V276, P45372, DOI 10.1074/jbc.M105399200; LLovera M, 1998, INT J MOL MED, V2, P69; Mansoor O, 1996, P NATL ACAD SCI USA, V93, P2714, DOI 10.1073/pnas.93.7.2714; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; Marinovic AC, 2000, BIOCHEM BIOPH RES CO, V274, P537, DOI 10.1006/bbrc.2000.3171; MEDINA R, 1995, BIOCHEM J, V307, P631, DOI 10.1042/bj3070631; Merchant JL, 1999, BIOCHEM BIOPH RES CO, V254, P454, DOI 10.1006/bbrc.1998.9964; Mitch WE, 1999, AM J PHYSIOL-CELL PH, V276, pC1132, DOI 10.1152/ajpcell.1999.276.5.C1132; Mitch WE, 1996, NEW ENGL J MED, V335, P1897, DOI 10.1056/NEJM199612193352507; Nenoi M, 1996, GENE, V179, P297, DOI 10.1016/S0378-1119(96)00380-0; Parks CL, 1996, J BIOL CHEM, V271, P4417; Pickering WP, 2002, KIDNEY INT, V61, P1286, DOI 10.1046/j.1523-1755.2002.00276.x; Ping DS, 2000, J BIOL CHEM, V275, P1708, DOI 10.1074/jbc.275.3.1708; PRICE SR, 1994, AM J PHYSIOL-CELL PH, V267, pC955, DOI 10.1152/ajpcell.1994.267.4.C955; Price SR, 1996, J CLIN INVEST, V98, P1703, DOI 10.1172/JCI118968; SIF S, 1993, ONCOGENE, V8, P2501; Solomon V, 1998, P NATL ACAD SCI USA, V95, P12602, DOI 10.1073/pnas.95.21.12602; SWICK AG, 1989, NUCLEIC ACIDS RES, V17, P9291, DOI 10.1093/nar/17.22.9291; Tiao G, 1997, AM J PHYSIOL-REG I, V272, pR849, DOI 10.1152/ajpregu.1997.272.3.R849; Tiao G, 1996, J CLIN INVEST, V97, P339, DOI 10.1172/JCI118421; Vinals F, 1997, J BIOL CHEM, V272, P12913, DOI 10.1074/jbc.272.20.12913; WING SS, 1993, AM J PHYSIOL, V264, pE668, DOI 10.1152/ajpendo.1993.264.4.E668; WING SS, 1995, BIOCHEM J, V307, P639, DOI 10.1042/bj3070639	48	66	69	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 10	2002	277	19					16673	16681		10.1074/jbc.M200501200	http://dx.doi.org/10.1074/jbc.M200501200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	551MB	11872750	hybrid			2022-12-27	WOS:000175564500045
J	Tan, JA; Hall, SH; Hamil, KG; Grossman, G; Petrusz, P; French, FS				Tan, JA; Hall, SH; Hamil, KG; Grossman, G; Petrusz, P; French, FS			Protein inhibitors of activated STAT resemble scaffold attachment factors and function as interacting nuclear receptor coregulators	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ANDROGEN RECEPTOR; LIGAND-BINDING DOMAIN; THYROID-HORMONE RECEPTOR; ZINC FINGER REGION; DNA-BINDING; GLUCOCORTICOID RECEPTOR; MATRIX PROTEIN; HISTONE ACETYLTRANSFERASE; TRANSCRIPTION FACTORS; ESTROGEN-RECEPTOR	Protein inhibitor of activated STAT1 (PIAS1) functions as a nuclear receptor coregulator and is expressed in several cell types of human testis. However, the mechanism of PIAS1 coregulation is unknown. We report here that PIAS1 has characteristics of a scaffold attachment protein. PIAS1 localized in nuclei in a speckled pattern and bound A-T-rich double-stranded DNA, a function of scaffold attachment proteins in chromatin regions of active transcription. DNA binding was dependent on a 35-amino acid sequence conserved among members of the PIAS family and in scaffold attachment proteins. The PIAS family also bound the androgen receptor DNA binding domain, and binding required the second zinc finger of this domain. PIAS1 contained an intrinsic activation domain but had bi-directional effects on androgen receptor transactivation; lower expression levels inhibited and higher levels increased transactivation in CV1 cells. Other PIAS family members also had dose-dependent effects on transactivation, but they were in a direction opposite to those of PIAS1. When coexpressed with PIAS1, other PIAS family members counteracted PIAS1 coregulation of androgen receptor transactivation. The interaction of PIAS1 with other members of the PIAS family suggests a transcription coregulatory mechanism involving a multicomponent PUS nuclear scaffold.	Univ N Carolina, Sch Med, Labs Reprod Biol, Dept Pediat, Chapel Hill, NC 27599 USA; Univ N Carolina, Sch Med, Labs Reprod Biol, Dept Cell & Dev Biol, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine	French, FS (corresponding author), Univ N Carolina, Sch Med, Labs Reprod Biol, Dept Pediat, Chapel Hill, NC 27599 USA.	fsfrench@med.unc.edu	Hamil, Katherine G/D-5964-2015	Hamil, Katherine G/0000-0001-7430-8313	NICHD NIH HHS [HD-04466, U54 HD-35041] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R37HD004466, U54HD035041, R01HD004466] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Aarnisalo P, 1999, ENDOCRINOLOGY, V140, P3097, DOI 10.1210/en.140.7.3097; Alen P, 1999, MOL CELL BIOL, V19, P6085; Aravind L, 2000, TRENDS BIOCHEM SCI, V25, P112, DOI 10.1016/S0968-0004(99)01537-6; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; Bevan CL, 1999, MOL CELL BIOL, V19, P8383; Blanco JCG, 1998, GENE DEV, V12, P1638, DOI 10.1101/gad.12.11.1638; Bode J, 2000, CRIT REV EUKAR GENE, V10, P73; BROWN TR, 1995, J ANDROL, V16, P299; Budhram-Mahadeo V, 1998, MOL CELL BIOL, V18, P1029, DOI 10.1128/MCB.18.2.1029; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; Cho SY, 2000, BIOCHEM J, V352, P645, DOI 10.1042/0264-6021:3520645; Chung CD, 1997, SCIENCE, V278, P1803, DOI 10.1126/science.278.5344.1803; Darimont BD, 1998, GENE DEV, V12, P3343, DOI 10.1101/gad.12.21.3343; Eggert M, 1997, J BIOL CHEM, V272, P28471, DOI 10.1074/jbc.272.45.28471; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FACKELMAYER FO, 1994, EUR J BIOCHEM, V221, P749, DOI 10.1111/j.1432-1033.1994.tb18788.x; Farrants AKO, 1997, MOL CELL BIOL, V17, P895, DOI 10.1128/MCB.17.2.895; FERRELL JE, 2000, SCI STKE; FREEDMAN LP, 1992, ENDOCR REV, V13, P129, DOI 10.1210/er.13.2.129; Freedman LP, 1999, CELL, V97, P5, DOI 10.1016/S0092-8674(00)80708-4; Fryer CJ, 1998, NATURE, V393, P88, DOI 10.1038/30032; Glass CK, 1997, CURR OPIN CELL BIOL, V9, P222, DOI 10.1016/S0955-0674(97)80066-X; Grant PA, 1998, CELL, V94, P45, DOI 10.1016/S0092-8674(00)81220-9; Gross M, 2001, ONCOGENE, V20, P3880, DOI 10.1038/sj.onc.1204489; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; Hampsey M, 1999, CURR OPIN GENET DEV, V9, P132, DOI 10.1016/S0959-437X(99)80020-3; Hari KL, 2001, GENE DEV, V15, P1334, DOI 10.1101/gad.877901; He B, 2000, J BIOL CHEM, V275, P22986, DOI 10.1074/jbc.M002807200; He B, 1999, J BIOL CHEM, V274, P37219, DOI 10.1074/jbc.274.52.37219; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; Horvai AE, 1997, P NATL ACAD SCI USA, V94, P1074, DOI 10.1073/pnas.94.4.1074; Horwitz KB, 1996, MOL ENDOCRINOL, V10, P1167, DOI 10.1210/me.10.10.1167; Johnson ES, 2001, CELL, V106, P735, DOI 10.1016/S0092-8674(01)00491-3; Kadonaga JT, 1998, CELL, V92, P307, DOI 10.1016/S0092-8674(00)80924-1; Kahyo T, 2001, MOL CELL, V8, P713, DOI 10.1016/S1097-2765(01)00349-5; Kentsis A, 2002, P NATL ACAD SCI USA, V99, P667, DOI 10.1073/pnas.012317299; Kipp M, 2000, MOL CELL BIOL, V20, P7480, DOI 10.1128/MCB.20.20.7480-7489.2000; Korzus E, 1998, SCIENCE, V279, P703, DOI 10.1126/science.279.5351.703; Kotaja N, 2000, MOL ENDOCRINOL, V14, P1986, DOI 10.1210/me.14.12.1986; Kuryshev YA, 2000, AM J PHYSIOL-CELL PH, V278, pC931, DOI 10.1152/ajpcell.2000.278.5.C931; Kuryshev YA, 2001, AM J PHYSIOL-CELL PH, V281, pC290, DOI 10.1152/ajpcell.2001.281.1.C290; LANGLEY E, 1995, J BIOL CHEM, V270, P29983; Liao JY, 2000, P NATL ACAD SCI USA, V97, P5267, DOI 10.1073/pnas.97.10.5267; Liao MM, 1999, BIOCHEMISTRY-US, V38, P9718, DOI 10.1021/bi990589i; Lichtarge O, 1997, J MOL BIOL, V274, P325, DOI 10.1006/jmbi.1997.1395; Liu B, 1998, P NATL ACAD SCI USA, V95, P10626, DOI 10.1073/pnas.95.18.10626; Liu B, 2001, P NATL ACAD SCI USA, V98, P3203, DOI 10.1073/pnas.051489598; LUBAHN DB, 1988, MOL ENDOCRINOL, V2, P1265, DOI 10.1210/mend-2-12-1265; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; Matias PM, 2000, J BIOL CHEM, V275, P26164, DOI 10.1074/jbc.M004571200; McEwan IJ, 1997, P NATL ACAD SCI USA, V94, P8485, DOI 10.1073/pnas.94.16.8485; McKenna NJ, 1999, ENDOCR REV, V20, P321, DOI 10.1210/er.20.3.321; MCPHAUL MJ, 1993, J CLIN ENDOCR METAB, V76, P17, DOI 10.1210/jc.76.1.17; MOHR SE, 1999, GENE, V299, P109; Moilanen AM, 1999, J BIOL CHEM, V274, P3700, DOI 10.1074/jbc.274.6.3700; Moilanen AM, 1998, MOL CELL BIOL, V18, P5128, DOI 10.1128/MCB.18.9.5128; Moilanen AM, 1998, MOL BIOL CELL, V9, P2527, DOI 10.1091/mbc.9.9.2527; Nayler O, 1998, NUCLEIC ACIDS RES, V26, P3542, DOI 10.1093/nar/26.15.3542; NUOVO GJ, 1997, PCR IN SITU HYBRIDIZ, P123; Oesterreich S, 2000, MOL ENDOCRINOL, V14, P369, DOI 10.1210/me.14.3.369; Oesterreich S, 1997, J CELL BIOCHEM, V67, P275, DOI 10.1002/(SICI)1097-4644(19971101)67:2<275::AID-JCB13>3.0.CO;2-E; ORDRONNEAU P, 1981, J HISTOCHEM CYTOCHEM, V29, P1397, DOI 10.1177/29.12.7033366; Powers CA, 1998, MOL ENDOCRINOL, V12, P4, DOI 10.1210/mend.12.1.0043; Prefontaine GG, 1998, MOL CELL BIOL, V18, P3416, DOI 10.1128/MCB.18.6.3416; Puigserver P, 1998, CELL, V92, P829, DOI 10.1016/S0092-8674(00)81410-5; QUIGLEY CA, 1995, ENDOCR REV, V16, P271, DOI 10.1210/er.16.3.271; RABURN DJ, 1995, ENDOCRINOLOGY, V136, P5769, DOI 10.1210/en.136.12.5769; Renz A, 1996, NUCLEIC ACIDS RES, V24, P843, DOI 10.1093/nar/24.5.843; Rodel B, 2000, EMBO J, V19, P5845, DOI 10.1093/emboj/19.21.5845; Roy AK, 1999, VITAM HORM, V55, P309; SCHDEV S, 2001, GENE DEV, V15, P3088; SCHENA M, 1989, GENE DEV, V3, P1590, DOI 10.1101/gad.3.10.1590; SCHLEGEL PN, 2001, 83 ANN M END SOC JUN, P401; SCHWABE JWR, 1993, CELL, V75, P567, DOI 10.1016/0092-8674(93)90390-C; SIMENTAL JA, 1991, J BIOL CHEM, V266, P510; Smith CL, 1996, P NATL ACAD SCI USA, V93, P8884, DOI 10.1073/pnas.93.17.8884; Spencer TE, 1997, NATURE, V389, P194, DOI 10.1038/38304; Struhl K, 1998, CELL, V94, P1, DOI 10.1016/S0092-8674(00)81213-1; Takahashi K, 2001, J BIOL CHEM, V276, P37556, DOI 10.1074/jbc.M101730200; Tan JA, 2000, ENDOCRINOLOGY, V141, P3440, DOI 10.1210/en.141.9.3440; Tan JA, 2000, MOL ENDOCRINOL, V14, P14, DOI 10.1210/me.14.1.14; Tang YT, 1998, MOL ENDOCRINOL, V12, P1420, DOI 10.1210/me.12.9.1420; Utley RT, 1998, NATURE, V394, P498, DOI 10.1038/28886; Valdez BC, 1998, BIOTECHNIQUES, V24, P1032, DOI 10.2144/98246cr03; Valdez BC, 1997, BIOCHEM BIOPH RES CO, V234, P335, DOI 10.1006/bbrc.1997.6642; Voegel JJ, 1996, EMBO J, V15, P3667, DOI 10.1002/j.1460-2075.1996.tb00736.x; WAGNER RL, 1995, NATURE, V378, P690, DOI 10.1038/378690a0; Wible BA, 1998, J BIOL CHEM, V273, P11745, DOI 10.1074/jbc.273.19.11745; Williams SP, 1998, NATURE, V393, P392, DOI 10.1038/30775; WONG CI, 1993, J BIOL CHEM, V268, P19004; Wu L, 1997, MECH DEVELOP, V65, P3, DOI 10.1016/S0925-4773(97)00032-4; Wurtz JM, 1996, NAT STRUCT BIOL, V3, P87, DOI 10.1038/nsb0196-87; Xu L, 1999, CURR OPIN GENET DEV, V9, P140, DOI 10.1016/S0959-437X(99)80021-5; ZHOU ZX, 1994, RECENT PROG HORM RES, V49, P249; ZILLIACUS J, 1995, MOL ENDOCRINOL, V9, P389, DOI 10.1210/me.9.4.389	95	59	61	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 10	2002	277	19					16993	17001		10.1074/jbc.M109217200	http://dx.doi.org/10.1074/jbc.M109217200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	551MB	11877418	Green Published, hybrid			2022-12-27	WOS:000175564500087
J	Jiang, YL; Drohat, AC; Ichikawa, Y; Stivers, JT				Jiang, YL; Drohat, AC; Ichikawa, Y; Stivers, JT			Probing the limits of electrostatic catalysis by uracil DNA glycosylase using transition state mimicry and mutagenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VIRAL REPLICATION; BINDING-ENERGY; SUBSTRATE; ANALOGS; NMR; RECOGNITION; MECHANISM; INSIGHTS; PYRENE; PK(A)	The DNA repair enzyme uracil DNA glycosylase (UDG) hydrolyzes the glycosidic bond of deoxyuridine in DNA by a remarkable mechanism involving formation of a positively charged oxacarbenium ion-uracil anion intermediate. We have proposed that the positively charged intermediate is stabilized by being sandwiched between the combined negative charges of the anionic uracil leaving group and a conserved aspartate residue that are located on opposite faces of the sugar ring. Here we establish that a duplex DNA oligonucleotide containing a cationic 1-aza-deoxyribose (1) oxacarbenium ion mimic is a potent inhibitor of UDG that binds tightly to the enzyme-uracil anion (EU-) product complex (K-D of EU- = 110 pM). The tight binding of I to the EU- complex results from its extremely slow off rate (k(off) = 0.0008 s(-1)), which is 25,000-fold slower than substrate analogue DNA. Removal of Asp(64) and His(187), which are involved in stabilization of the cationic sugar and the anionic uracil leaving group, respectively, specifically weakens binding of I to the UDG-uracil complex by 154,000-fold, without significantly affecting substrate or product binding. These results suggest that electrostatic effects can effectively stabilize such an intermediate by at least -7 kcal/mol, without leading to anticatalytic stabilization of the substrate and products.	Johns Hopkins Univ, Sch Med, Dept Pharmacol & Mol Sci, Baltimore, MD 21205 USA; Optimer Pharmaceut Inc, San Diego, CA 92121 USA	Johns Hopkins University	Stivers, JT (corresponding author), Johns Hopkins Univ, Sch Med, Dept Pharmacol & Mol Sci, 725 N Wolfe St, Baltimore, MD 21205 USA.			Drohat, Alex/0000-0002-7458-8770	NIGMS NIH HHS [GM56834, R01 GM056834, GM52324] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056834] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bruice TC, 2000, BIOCHEMISTRY-US, V39, P6267, DOI 10.1021/bi0003689; Bulow A, 2000, J AM CHEM SOC, V122, P8567, DOI 10.1021/ja001762x; Dinner AR, 2001, NATURE, V413, P752, DOI 10.1038/35099587; Dong J, 2000, BIOCHEMISTRY-US, V39, P13241, DOI 10.1021/bi001437m; Drohat AC, 2000, BIOCHEMISTRY-US, V39, P11865, DOI 10.1021/bi000922e; Drohat AC, 1999, BIOCHEMISTRY-US, V38, P11876, DOI 10.1021/bi9910880; Drohat AC, 1999, BIOCHEMISTRY-US, V38, P11866, DOI 10.1021/bi9910878; Drohat AC, 2000, J AM CHEM SOC, V122, P1840, DOI 10.1021/ja993254x; Hansen SU, 1998, ACTA CHEM SCAND, V52, P1214, DOI 10.3891/acta.chem.scand.52-1214; JENCKS WP, 1975, ADV ENZYMOL RAMB, V43, P219; Jiang YL, 2001, J BIOL CHEM, V276, P42347, DOI 10.1074/jbc.M106594200; Jiang YL, 2001, BIOCHEMISTRY-US, V40, P7710, DOI 10.1021/bi010622c; Makino K, 1998, TETRAHEDRON LETT, V39, P8245, DOI 10.1016/S0040-4039(98)01781-X; Prichard MN, 1996, J VIROL, V70, P3018, DOI 10.1128/JVI.70.5.3018-3025.1996; PYLES RB, 1994, J VIROL, V68, P4963, DOI 10.1128/JVI.68.8.4963-4972.1994; Ren RXF, 1996, J AM CHEM SOC, V118, P7671, DOI 10.1021/ja9612763; Sekino Y, 2000, J BIOL CHEM, V275, P36506, DOI 10.1074/jbc.C000585200; Stivers JT, 1996, BIOCHEMISTRY-US, V35, P814, DOI 10.1021/bi9510789; Stivers JT, 1999, BIOCHEMISTRY-US, V38, P952, DOI 10.1021/bi9818669; Stivers JT, 2001, ARCH BIOCHEM BIOPHYS, V396, P1, DOI 10.1006/abbi.2001.2605; STUART DT, 1993, J VIROL, V67, P2503, DOI 10.1128/JVI.67.5.2503-2512.1993; Warshel A, 1998, J BIOL CHEM, V273, P27035, DOI 10.1074/jbc.273.42.27035; Werner RM, 2000, BIOCHEMISTRY-US, V39, P14054, DOI 10.1021/bi0018178; Werner RM, 2000, BIOCHEMISTRY-US, V39, P12585, DOI 10.1021/bi001532v; Wolfenden R, 2001, ACCOUNTS CHEM RES, V34, P938, DOI 10.1021/ar000058i; Xiao GY, 1999, PROTEINS, V35, P13	26	44	44	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 3	2002	277	18					15385	15392		10.1074/jbc.M200634200	http://dx.doi.org/10.1074/jbc.M200634200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	550PA	11859082	hybrid			2022-12-27	WOS:000175510400022
J	Bewley, CA; Louis, JM; Ghirlando, R; Clore, GM				Bewley, CA; Louis, JM; Ghirlando, R; Clore, GM			Design of a novel peptide inhibitor of HIV fusion that disrupts the internal trimeric coiled-coil of gp41	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIV GP41; ENVELOPE GLYCOPROTEINS; ACTIVE CONFORMATION; SYNTHETIC PEPTIDE; ATOMIC-STRUCTURE; VIRUS-INFECTION; TYPE-1 GP41; ENTRY; ECTODOMAIN; PROTEIN	The pre-hairpin intermediate of gp41 from the human immunodeficiency virus (HIV) is the target for two classes of fusion inhibitors that bind to the C-terminal region or the trimeric coiled-coil of N-terminal helices, thereby preventing formation of the fusogenic trimer of hairpins. Using rational design, two 36-residue peptides, N36(Mut(e,g)) and N36(Mut(a,d)), were derived from the parent N36 peptide comprising the N-terminal helix of the gp41 ectodomain (residues 546-581 of HIV-1 envelope), characterized by analytical ultracentrifugation and CD, and assessed for their ability to inhibit HIV fusion using a quantitative vaccinia virus-based fusion assay. N36(Mut(e,g)) contains nine amino acid substitutions designed to disrupt interactions with the C-terminal region of gp41 while preserving contacts governing the formation of the trimeric coiled-coil. N36(Mut(a,d)) contains nine substitutions designed to block formation of the trimeric coiled-coil but retains residues that interact with the C-terminal region of gp41. N36(Mut(a,d)) is monomeric, is largely random coil, does not interact with the C34 peptide derived from the C-terminal region of gp41 (residues 628-661), and does not inhibit fusion. The trimeric coiled-coil structure is therefore a prerequisite for interaction with the C-terminal region of gp41. N36(Mut(e,g)) forms a monodisperse, helical trimer in solution, does not interact with C34, and yet inhibits fusion about 50-fold more effectively than the parent N36 peptide (IC50 -similar to308 nM versus similar to16 muM). These results indicate that N36(Mut(e,g)) acts by disrupting the homotrimeric coiled-coil of N-terminal helices in the pre-hairpin intermediate to form heterotrimers. Thus N36(Mut(e,g)) represents a novel third class of gp41-targeted HIV fusion inhibitor. A quantitative model describing the interaction of N36(Mut(e,g)) with the pre-hairpin intermediate is presented.	NIDDK, Chem Phys Lab, NIH, Bethesda, MD 20892 USA; NIDDK, Bioorgan Chem Lab, NIH, Bethesda, MD 20892 USA; NIDDK, Mol Biol Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Clore, GM (corresponding author), NIDDK, Chem Phys Lab, NIH, Bldg 8, Bethesda, MD 20892 USA.		Clore, G Marius/L-2546-2018; Ghirlando, Rodolfo/A-8880-2009; Clore, G. Marius/A-3511-2008	Clore, G Marius/0000-0003-3809-1027; Clore, G. Marius/0000-0003-3809-1027; Louis, John M/0000-0002-0052-1899; Bewley, Carole/0000-0003-2203-0852	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK032103, Z01DK029023, ZIADK032103, ZIADK029023] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BOHM G, 1992, PROTEIN ENG, V5, P191, DOI 10.1093/protein/5.3.191; Caffrey M, 1998, EMBO J, V17, P4572, DOI 10.1093/emboj/17.16.4572; Caffrey M, 1999, PROTEIN SCI, V8, P1904, DOI 10.1110/ps.8.9.1904; Chan DC, 1997, CELL, V89, P263, DOI 10.1016/S0092-8674(00)80205-6; Chan DC, 1998, P NATL ACAD SCI USA, V95, P15613, DOI 10.1073/pnas.95.26.15613; Chan DC, 1998, CELL, V93, P681, DOI 10.1016/S0092-8674(00)81430-0; CHANCE EM, 1979, R8775 AT EN RES EST; Clore G. M., 1983, COMPUTING BIOL SCI, P313; Eckert DM, 2001, P NATL ACAD SCI USA, V98, P11187, DOI 10.1073/pnas.201392898; FREED EO, 1995, J BIOL CHEM, V270, P23883, DOI 10.1074/jbc.270.41.23883; Furuta RA, 1998, NAT STRUCT BIOL, V5, P276, DOI 10.1038/nsb0498-276; Jones PLS, 1998, J BIOL CHEM, V273, P404, DOI 10.1074/jbc.273.1.404; Kilby JM, 1998, NAT MED, V4, P1302, DOI 10.1038/3293; Kliger Y, 2000, J MOL BIOL, V295, P163, DOI 10.1006/jmbi.1999.3368; Louis JM, 2001, J BIOL CHEM, V276, P29485, DOI 10.1074/jbc.C100317200; LU M, 1995, NAT STRUCT BIOL, V2, P1075, DOI 10.1038/nsb1295-1075; Malashkevich VN, 1998, P NATL ACAD SCI USA, V95, P9134, DOI 10.1073/pnas.95.16.9134; Moore JP, 1997, CURR OPIN IMMUNOL, V9, P551, DOI 10.1016/S0952-7915(97)80110-0; Munoz-Barroso I, 1998, J CELL BIOL, V140, P315, DOI 10.1083/jcb.140.2.315; Peisajovich SG, 2001, J MOL BIOL, V311, P249, DOI 10.1006/jmbi.2001.4875; PERKINS SJ, 1986, EUR J BIOCHEM, V157, P169, DOI 10.1111/j.1432-1033.1986.tb09653.x; POZNIAK A, 2001, J HIV RES, V6, P92; Root MJ, 2001, SCIENCE, V291, P884, DOI 10.1126/science.1057453; Salzwedel K, 2000, J VIROL, V74, P326, DOI 10.1128/JVI.74.1.326-333.2000; Tan KM, 1997, P NATL ACAD SCI USA, V94, P12303, DOI 10.1073/pnas.94.23.12303; Weissenhorn W, 1999, MOL MEMBR BIOL, V16, P3, DOI 10.1080/096876899294706; Weissenhorn W, 1997, NATURE, V387, P426, DOI 10.1038/387426a0; WILD C, 1992, P NATL ACAD SCI USA, V89, P10537, DOI 10.1073/pnas.89.21.10537; WILD CT, 1994, P NATL ACAD SCI USA, V91, P9770, DOI 10.1073/pnas.91.21.9770; Wingfield PT, 1997, PROTEIN SCI, V6, P1653, DOI 10.1002/pro.5560060806	30	121	135	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 19	2002	277	16					14238	14245		10.1074/jbc.M201453200	http://dx.doi.org/10.1074/jbc.M201453200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	543HR	11859089	Green Submitted, hybrid			2022-12-27	WOS:000175096000115
J	Missiaen, L; Vanoevelen, J; Parys, JB; Raeymaekers, L; De Smedt, H; Callewaert, G; Erneux, C; Wuytack, F				Missiaen, L; Vanoevelen, J; Parys, JB; Raeymaekers, L; De Smedt, H; Callewaert, G; Erneux, C; Wuytack, F			Ca2+ uptake and release properties of a thapsigargin-insensitive nonmitochondrial Ca2+ store in A7r5 and 16HBE14o-cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INOSITOL 1,4,5-TRISPHOSPHATE; ENDOPLASMIC-RETICULUM; CALCIUM-RELEASE; GOLGI-APPARATUS; FUNCTIONAL-PROPERTIES; PROPERTIES DISTINCT; CELLS; CA-2+-ATPASE; INHIBITOR; RECEPTOR	In a previous study we overexpressed the thapsigargin (tg)-insensitive Pmr1 Ca2+ pump of the Golgi apparatus of Caenorhabditis elegans in COS-1 cells and studied the properties of the Ca2+ store into which it was integrated. Here we assessed the properties of an endogenous tg-insensitive nonmitochondrial Ca2+ store in A7r5 and 16HBE14o- cells, which express a mammalian homologue of Pmr1. The tg-insensitive Ca2+ store was considerably less leaky for Ca2+ than the sarco(endo)plasmic-reticulum Ca2+-ATPase (SERCA)-containing Ca2+ store. Moreover like for the worm Pmr1 Ca2+ pump expressed in COS-1 cells, Ca2+ accumulation into the endogenous tg-insensitive store showed a 2 orders of magnitude lower sensitivity to cyclopiazonic acid than the SERCA-mediated transport. 2,5-Di-(tert-butyl)-1,4-benzohydroquinone was only a very weak inhibitor of the tg-insensitive Ca2+ uptake in A7r5 and 16HBE14o-cells and in COS-1 cells overexpressing the worm Pmr1. Inositol 1,4,5-trisphosphate released 11% of the Ca2+ accumulated in permeabilized A7r5 cells pretreated with tg with an EC50 that was 5 times higher than for the SERCA-containing Ca2+ store but failed to release Ca2+ in 16HBE14o- cells. In the presence of tg, 15% of intact A7r5 cells responded to 10 muM arginine-vasopressin with a small rise in cytosolic Ca2+ concentration after a long latency. In conclusion, A7r5 and 16HBE14o- cells express a Pmr1-containing Ca2+ store with properties that differ substantially from the SERCA-containing Ca2+ store.	Katholieke Univ Leuven, Fysiol Lab, B-3000 Louvain, Belgium; Free Univ Brussels, IRIBHN, Interdisciplinary Res Inst, B-1070 Brussels, Belgium	KU Leuven; Universite Libre de Bruxelles; Vrije Universiteit Brussel	Missiaen, L (corresponding author), Katholieke Univ Leuven, Fysiol Lab, Campus Gasthuisberg O-N,Herestr 49, B-3000 Louvain, Belgium.		Vanoevelen, Jo M/F-2686-2013	Vanoevelen, Jo M/0000-0003-1830-8858; Parys, Jan/0000-0002-3591-4967				ANTEBI A, 1992, MOL BIOL CELL, V3, P633, DOI 10.1091/mbc.3.6.633; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; Galione A, 2000, BIOL CELL, V92, P197, DOI 10.1016/S0248-4900(00)01070-4; GUNTESKIHAMBLIN AM, 1992, BIOCHEMISTRY-US, V31, P7600, DOI 10.1021/bi00148a023; Lin P, 1999, J CELL BIOL, V145, P279, DOI 10.1083/jcb.145.2.279; LYTTON J, 1991, J BIOL CHEM, V266, P17067; Missiaen L, 1998, J BIOL CHEM, V273, P8983, DOI 10.1074/jbc.273.15.8983; Missiaen L, 1996, BIOCHEM J, V317, P849, DOI 10.1042/bj3170849; Missiaen L, 2001, J BIOL CHEM, V276, P39161, DOI 10.1074/jbc.M104044200; MISSIAEN L, 1992, NATURE, V357, P599, DOI 10.1038/357599a0; MOORE GA, 1987, FEBS LETT, V224, P331, DOI 10.1016/0014-5793(87)80479-9; Pinton P, 1998, EMBO J, V17, P5298, DOI 10.1093/emboj/17.18.5298; Rojas P, 2000, CELL BIOL INT, V24, P229, DOI 10.1006/cbir.2000.0496; SEIDLER NW, 1989, J BIOL CHEM, V264, P17816; Sorin A, 1997, J BIOL CHEM, V272, P9895; Surroca A, 2000, J MEMBRANE BIOL, V177, P243, DOI 10.1007/s002320010008; Taylor RS, 1997, MOL BIOL CELL, V8, P1911, DOI 10.1091/mbc.8.10.1911; Van Baelen K, 2001, J BIOL CHEM, V276, P10683, DOI 10.1074/jbc.M010553200; YOSHIMOTO A, 1990, CELL BIOCHEM FUNCT, V8, P191, DOI 10.1002/cbf.290080402; Yusufi ANK, 2001, BIOCHEM J, V353, P531, DOI 10.1042/0264-6021:3530531; ZHA XH, 1995, AM J PHYSIOL-CELL PH, V268, pC1133, DOI 10.1152/ajpcell.1995.268.5.C1133	22	40	40	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAR 1	2002	277	9					6898	6902		10.1074/jbc.M110939200	http://dx.doi.org/10.1074/jbc.M110939200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	525ZQ	11861657	hybrid			2022-12-27	WOS:000174104300021
J	Kanuri, M; Minko, IG; Nechev, LV; Harris, TM; Harris, CM; Lloyd, RS				Kanuri, M; Minko, IG; Nechev, LV; Harris, TM; Harris, CM; Lloyd, RS			Error prone translesion synthesis past gamma-hydroxypropano deoxyguanosine, the primary acrolein-derived adduct in mammalian cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-POLYMERASE-DELTA; IN-VIVO; ESCHERICHIA-COLI; MUTAGENESIS; PROPANODEOXYGUANOSINE; REPLICATION; LESIONS; REPAIR; VITRO	8-Hydroxy-5,6,7,8-tetrahydropyrimido[1,2-a]purin-10(3H)-one,3-(2'-deoxyriboside) (1,N-2-gamma-hydroxypropano deoxyguanosine, gamma-HOPdG) is a major DNA adduct that forms as a result of exposure to acrolein, an environmental pollutant and a product of endogenous lipid peroxidation. gamma-HOPdG has been shown previously not to be a miscoding lesion when replicated in Escherichia coli. In contrast to those prokaryotic studies, in vivo replication and mutagenesis assays in COS-7 cells using single stranded DNA containing a specific gamma-HOPdG adduct, revealed that the gamma-HOPdG adduct was significantly mutagenic. Analyses revealed both transversion and transition types of mutations at an overall mutagenic frequency of 7.4 x 10(-2)/translesion synthesis. In vitro gamma-HOPdG strongly blocks DNA synthesis by two major polymerases, pol delta and pol epsilon. Replicative blockage of pol delta by gamma-HOPdG could be diminished by the addition of proliferating cell nuclear antigen, leading to highly mutagenic translesion bypass across this adduct. The differential functioning and processing capacities of the mammalian polymerases may be responsible for the higher mutation frequencies observed in this study when compared with the accurate and efficient nonmutagenic bypass observed in the bacterial system.	Univ Texas, Med Branch, Sealy Ctr Mol Sci, Galveston, TX 77555 USA; Vanderbilt Univ, Dept Chem, Nashville, TN 37235 USA; Vanderbilt Univ, Ctr Mol Toxicol, Nashville, TN 37235 USA	University of Texas System; University of Texas Medical Branch Galveston; Vanderbilt University; Vanderbilt University	Lloyd, RS (corresponding author), Univ Texas, Med Branch, Sealy Ctr Mol Sci, Galveston, TX 77555 USA.	rslloyd@utmb.edu		Lloyd, R. Stephen/0000-0001-7273-372X	NIEHS NIH HHS [ES00267, ES05355, ES06676] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES006676, P01ES005355, P30ES000267] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BENAMIRA M, 1992, J BIOL CHEM, V267, P22392; BROCK N, 1979, ARZNEIMITTEL-FORSCH, V29-1, P659; BURCHAM PC, 1994, J BIOL CHEM, V269, P28844; Burcham PC, 1998, MUTAGENESIS, V13, P287, DOI 10.1093/mutage/13.3.287; Carmical JR, 2000, CHEM RES TOXICOL, V13, P18, DOI 10.1021/tx9901332; CHARY P, 1995, J BIOL CHEM, V270, P4990, DOI 10.1074/jbc.270.10.4990; CHAUDHARY AK, 1994, SCIENCE, V265, P1580, DOI 10.1126/science.8079172; Chen XL, 2000, J BIOL CHEM, V275, P17677, DOI 10.1074/jbc.M910278199; CHUI G, 1995, J BIOL CHEM, V270, P7799, DOI 10.1074/jbc.270.14.7799; CHUNG FL, 1984, CANCER RES, V44, P990; COHEN SM, 1992, CANCER RES, V52, P3577; CURREN RD, 1988, MUTAT RES, V209, P17, DOI 10.1016/0165-7992(88)90104-2; de los Santos C, 2001, J BIOL CHEM, V276, P9077, DOI 10.1074/jbc.M009028200; DOWNEY KM, 1988, CANCER CELLS EUKARYO, V6, P403; Fink SP, 1997, P NATL ACAD SCI USA, V94, P8652, DOI 10.1073/pnas.94.16.8652; Friedberg EC, 2000, P NATL ACAD SCI USA, V97, P5681, DOI 10.1073/pnas.120152397; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; Johnson KA, 1997, J BIOL CHEM, V272, P11434; Kawanishi M, 1998, MUTAT RES-GEN TOX EN, V417, P65, DOI 10.1016/S1383-5718(98)00093-X; Khullar S, 1999, J MED CHEM, V42, P947, DOI 10.1021/jm980605u; Kozekov ID, 2001, CHEM RES TOXICOL, V14, P1482, DOI 10.1021/tx010127h; LEE MYWT, 1984, BIOCHEMISTRY-US, V23, P1906, DOI 10.1021/bi00304a003; Lee Y, 1998, J BIOL CHEM, V273, P19490, DOI 10.1074/jbc.273.31.19490; Levine RL, 2001, J BIOL CHEM, V276, P18717, DOI 10.1074/jbc.M102158200; Marnett LJ, 2000, CARCINOGENESIS, V21, P361, DOI 10.1093/carcin/21.3.361; MARNETT LJ, 1985, MUTAT RES, V148, P25; MARNETT LJ, 1994, DNA ADDUCTS IDENTIFI, P151; MCDIARMID MA, 1991, MUTAT RES, V248, P93, DOI 10.1016/0027-5107(91)90091-2; McNees AG, 1997, J BIOL CHEM, V272, P33211, DOI 10.1074/jbc.272.52.33211; MORIYA M, 1993, P NATL ACAD SCI USA, V90, P1122, DOI 10.1073/pnas.90.3.1122; MORIYA M, 1994, P NATL ACAD SCI USA, V91, P11899, DOI 10.1073/pnas.91.25.11899; Mozzherin DJ, 1997, P NATL ACAD SCI USA, V94, P6126, DOI 10.1073/pnas.94.12.6126; Mozzherin DJ, 1996, J BIOL CHEM, V271, P31711, DOI 10.1074/jbc.271.49.31711; NATH RG, 1994, P NATL ACAD SCI USA, V91, P7491, DOI 10.1073/pnas.91.16.7491; Nechev LV, 2000, CHEM RES TOXICOL, V13, P421, DOI 10.1021/tx990167+; ODAY CL, 1992, NUCLEIC ACIDS RES, V20, P5403, DOI 10.1093/nar/20.20.5403; Penn A, 2001, ENVIRON HEALTH PERSP, V109, P219, DOI 10.2307/3434688; PERKINS EG, 1992, ACS SYM SER, P310; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SINGER B, 1999, IARC SCI PUBLICATION, V150; Stucki M, 2001, PROG NUCLEIC ACID RE, V65, P261; SYVAOJA J, 1990, P NATL ACAD SCI USA, V87, P6664, DOI 10.1073/pnas.87.17.6664; TAN CK, 1986, J BIOL CHEM, V261, P2310; VanderVeen LA, 2001, J BIOL CHEM, V276, P9066, DOI 10.1074/jbc.M008900200; Yang IY, 2001, J BIOL CHEM, V276, P9071, DOI 10.1074/jbc.M008918200	45	69	71	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 24	2002	277	21					18257	18265		10.1074/jbc.M112419200	http://dx.doi.org/10.1074/jbc.M112419200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	558PM	11889127	hybrid			2022-12-27	WOS:000175975800004
J	Price, MO; Atkinson, SJ; Knaus, UG; Dinauer, MC				Price, MO; Atkinson, SJ; Knaus, UG; Dinauer, MC			Rac activation induces NADPH oxidase activity in transgenic COSphox cells, and the level of superoxide production is exchange factor-dependent	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESPIRATORY BURST OXIDASE; HUMAN NEUTROPHILS; SH3 DOMAIN; FLAVOCYTOCHROME B(558); COMPONENTS P47(PHOX); STRUCTURAL BASIS; EFFECTOR REGION; INSERT REGION; GTPASE RAC2; RHO-GTPASES	Transient expression of constitutively active Rac1 derivatives, (G12V) or Q61L), was sufficient to induce phagocyte NADPH oxidase activity in a COS-7 cell model in which human cDNAs for essential oxidase components, gp91(phox)) p22(phox), p47(phox), and p67(phox), were expressed as stable transgenes. Expression of constitutively active Rac1 in "COSphox,, cells induced translocation of p47(phox) and p67(phox) to the membrane. Furthermore, translocation of p47(phox) was induced in the absence of p67(phox) expression, even though Rac does not directly bind p47(phox). Rac effector domain point substitutions (A27K, G30S, D38A, Y40C), which can selectively eliminate interaction with different effector proteins, impaired Rac1V12-induced superoxide production. Activation of endogenous Rac1 by expression of constitutively active Rac-guanine nucleotide exchange factor (GEF) derivatives was sufficient to induce high level NADPH oxidase activity in COSphox cells. The constitutively active form of the hematopoietic-specific GEF, Vav1, was the most effective at activating superoxide production, despite detection of higher levels of Rac1-GTP upon expression of constitutively active Vav2 or Tiam1 derivatives. These data suggest that Rac can play a dual role in NADPH oxidase activation, both by directly participating in the oxidase complex and by activating signaling events leading to oxidase assembly, and that Vav1 may be the physiologically relevant GEF responsible for activating this Rac-regulated complex.	James Whitcomb Riley Hosp Children, Herman B Wells Ctr Pediat Res, Indianapolis, IN 46202 USA; James Whitcomb Riley Hosp Children, Dept Pediat Hematol Oncol, Indianapolis, IN 46202 USA; Indiana Univ, Med Ctr, Dept Med & Mol Genet, Indianapolis, IN 46202 USA; Indiana Univ, Med Ctr, Dept Med Nephrol, Indianapolis, IN 46202 USA; Scripps Res Inst, Res Inst, Dept Immunol, La Jolla, CA 92037 USA	James Whitcomb Riley Hospital Children; James Whitcomb Riley Hospital Children; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Scripps Research Institute	Dinauer, MC (corresponding author), Wells Ctr Pediat Res, 1044 W Walnut St,R4,Rm 402A, Indianapolis, IN 46202 USA.	mdinauer@iupui.edu		Price, Marianne/0000-0002-6652-534X	NCI NIH HHS [P30CA82709] Funding Source: Medline; NHLBI NIH HHS [R01HL45635] Funding Source: Medline; NIAID NIH HHS [AI35947] Funding Source: Medline; NIDDK NIH HHS [P50DK49218] Funding Source: Medline; NIGMS NIH HHS [GM37696] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA082709] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045635] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI035947] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P50DK049218] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM037696] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abe K, 2000, J BIOL CHEM, V275, P10141, DOI 10.1074/jbc.275.14.10141; Abe R, 1999, J BIOL CHEM, V274, P30410, DOI 10.1074/jbc.274.43.30410; ABO A, 1992, J BIOL CHEM, V267, P16767; ABO A, 1991, NATURE, V353, P668, DOI 10.1038/353668a0; Adams ER, 1997, BIOCHEM J, V325, P249, DOI 10.1042/bj3250249; Ago T, 1999, J BIOL CHEM, V274, P33644, DOI 10.1074/jbc.274.47.33644; Akasaki T, 1999, J BIOL CHEM, V274, P18055, DOI 10.1074/jbc.274.25.18055; Ambruso DR, 2000, P NATL ACAD SCI USA, V97, P4654, DOI 10.1073/pnas.080074897; Babior BM, 1999, BLOOD, V93, P1464, DOI 10.1182/blood.V93.5.1464.405a32_1464_1476; Benard V, 1999, J BIOL CHEM, V274, P13198, DOI 10.1074/jbc.274.19.13198; Billadeau DD, 2000, J EXP MED, V192, P381, DOI 10.1084/jem.192.3.381; Bishop AL, 2000, BIOCHEM J, V348, P241, DOI 10.1042/0264-6021:3480241; Bustelo XR, 2000, MOL CELL BIOL, V20, P1461, DOI 10.1128/MCB.20.5.1461-1477.2000; Cherfils J, 1999, TRENDS BIOCHEM SCI, V24, P306, DOI 10.1016/S0968-0004(99)01429-2; CLARK RA, 1990, J CLIN INVEST, V85, P714, DOI 10.1172/JCI114496; Crompton AM, 2000, J BIOL CHEM, V275, P25751, DOI 10.1074/jbc.M002050200; Cross AR, 2000, BIOCHEM J, V349, P113, DOI 10.1042/0264-6021:3490113; Cross AR, 1999, J BIOL CHEM, V274, P15519, DOI 10.1074/jbc.274.22.15519; DeLeo FR, 1996, J LEUKOCYTE BIOL, V60, P677, DOI 10.1002/jlb.60.6.677; DEMENDEZ I, 1995, BLOOD, V85, P1104, DOI 10.1182/blood.V85.4.1104.bloodjournal8541104; DEMENDEZ I, 1994, J BIOL CHEM, V269, P16326; deMendez I, 1996, EMBO J, V15, P1211, DOI 10.1002/j.1460-2075.1996.tb00462.x; Diebold BA, 2001, NAT IMMUNOL, V2, P211, DOI 10.1038/85259; DIEKMANN D, 1994, SCIENCE, V265, P531, DOI 10.1126/science.8036496; DINAUER M, 1998, HEMATOLOGY INFANCY C, V1, P889; Doody GM, 2001, NAT IMMUNOL, V2, P542, DOI 10.1038/88748; DORSEUIL O, 1995, J LEUKOCYTE BIOL, V58, P108, DOI 10.1002/jlb.58.1.108; Dorseuil O, 1996, J BIOL CHEM, V271, P83, DOI 10.1074/jbc.271.1.83; Dusi S, 1996, BIOCHEM J, V314, P409, DOI 10.1042/bj3140409; El Benna J, 1999, J LEUKOCYTE BIOL, V66, P1014; Ellson CD, 2001, NAT CELL BIOL, V3, P679, DOI 10.1038/35083076; Freeman JL, 1996, J BIOL CHEM, V271, P22578, DOI 10.1074/jbc.271.37.22578; Freeman JL, 1996, J BIOL CHEM, V271, P19794, DOI 10.1074/jbc.271.33.19794; Gorzalczany Y, 2000, J BIOL CHEM, V275, P40073, DOI 10.1074/jbc.M006013200; HEYWORTH P, 1998, MOL CELLULAR BASIS I, P165; HEYWORTH PG, 1991, J CLIN INVEST, V87, P352, DOI 10.1172/JCI114993; HEYWORTH PG, 1994, J BIOL CHEM, V269, P30749; Huang J, 1999, J BIOL CHEM, V274, P19731, DOI 10.1074/jbc.274.28.19731; JACKSON JH, 1988, HEMATOL ONCOL CLIN N, V2, P317, DOI 10.1016/S0889-8588(18)30624-5; Kanai F, 2001, NAT CELL BIOL, V3, P675, DOI 10.1038/35083070; Kim C, 2001, J IMMUNOL, V166, P1223, DOI 10.4049/jimmunol.166.2.1223; KNAUS UG, 1991, SCIENCE, V254, P1512, DOI 10.1126/science.1660188; Koga H, 1999, J BIOL CHEM, V274, P25051, DOI 10.1074/jbc.274.35.25051; Koshkin V, 1996, J BIOL CHEM, V271, P30326, DOI 10.1074/jbc.271.48.30326; Kreck ML, 1996, BIOCHEMISTRY-US, V35, P15683, DOI 10.1021/bi962064l; KWONG CH, 1995, J BIOL CHEM, V270, P19868, DOI 10.1074/jbc.270.34.19868; Lamarche N, 1996, CELL, V87, P519, DOI 10.1016/S0092-8674(00)81371-9; Lapouge K, 2000, MOL CELL, V6, P899, DOI 10.1016/S1097-2765(00)00087-3; Lavigne MC, 1999, BLOOD, V94, p207A; Li Q, 1999, J BIOL CHEM, V274, P3764, DOI 10.1074/jbc.274.6.3764; McPhail LC, 1999, BBA-MOL CELL BIOL L, V1439, P277, DOI 10.1016/S1388-1981(99)00100-6; Michaelson D, 2001, J CELL BIOL, V152, P111, DOI 10.1083/jcb.152.1.111; Moores SL, 2000, MOL CELL BIOL, V20, P6364, DOI 10.1128/MCB.20.17.6364-6373.2000; Nisimoto Y, 1997, J BIOL CHEM, V272, P18834, DOI 10.1074/jbc.272.30.18834; Park HS, 1999, BIOCHEM BIOPH RES CO, V259, P38, DOI 10.1006/bbrc.1999.0721; Price MO, 2002, BLOOD, V99, P2653, DOI 10.1182/blood.V99.8.2653; PRIGMORE E, 1995, J BIOL CHEM, V270, P10717, DOI 10.1074/jbc.270.18.10717; QUILLIAM LA, 1995, BIOESSAYS, V17, P395, DOI 10.1002/bies.950170507; QUINN MT, 1993, J BIOL CHEM, V268, P20983; Rinckel LA, 1999, BIOCHEM BIOPH RES CO, V263, P118, DOI 10.1006/bbrc.1999.1334; Roberts AW, 1999, IMMUNITY, V10, P183, DOI 10.1016/S1074-7613(00)80019-9; ROTROSEN D, 1992, SCIENCE, V256, P1459, DOI 10.1126/science.1318579; Sathyamoorthy M, 1997, J BIOL CHEM, V272, P9141; Scita G, 2000, EMBO J, V19, P2393, DOI 10.1093/emboj/19.11.2393; Shiose A, 2000, J BIOL CHEM, V275, P13793, DOI 10.1074/jbc.275.18.13793; Sumimoto H, 1996, J BIOL CHEM, V271, P22152, DOI 10.1074/jbc.271.36.22152; Tedford K, 2001, NAT IMMUNOL, V2, P548, DOI 10.1038/88756; Toporik A, 1998, BIOCHEMISTRY-US, V37, P7147, DOI 10.1021/bi9800404; UHLINGER DJ, 1994, J BIOL CHEM, V269, P22095; VAN AL, 1997, GENE DEV, V11, P2295; Vergnaud S, 2000, EUR J BIOCHEM, V267, P1059, DOI 10.1046/j.1432-1327.2000.01097.x; Westwick JK, 1997, MOL CELL BIOL, V17, P1324, DOI 10.1128/MCB.17.3.1324; Wientjes FB, 2001, BIOCHEM BIOPH RES CO, V289, P382, DOI 10.1006/bbrc.2001.5982; Williams DA, 2000, BLOOD, V96, P1646; Xu XM, 1997, BIOCHEMISTRY-US, V36, P626, DOI 10.1021/bi962059h; XU XM, 1994, J BIOL CHEM, V269, P23569; ZHEN L, 1993, P NATL ACAD SCI USA, V90, P9832, DOI 10.1073/pnas.90.21.9832; Zhou KM, 1998, J BIOL CHEM, V273, P16782, DOI 10.1074/jbc.273.27.16782	78	98	101	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 24	2002	277	21					19220	19228		10.1074/jbc.M200061200	http://dx.doi.org/10.1074/jbc.M200061200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	558PM	11896053	hybrid			2022-12-27	WOS:000175975800126
J	Zhang, RG; Kim, Y; Skarina, T; Beasley, S; Laskowski, R; Arrowsmith, C; Edwards, A; Joachimiak, A; Savchenko, A				Zhang, RG; Kim, Y; Skarina, T; Beasley, S; Laskowski, R; Arrowsmith, C; Edwards, A; Joachimiak, A; Savchenko, A			Crystal structure of Thermotoga maritima 0065, a member of the IclR transcriptional factor family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; FUNCTIONAL-CHARACTERIZATION; HELIX PROTEIN; DNA COMPLEX; REPRESSOR; OPERON; GENES; PURIFICATION; EXPRESSION; REVEALS	Members of the IclR family of transcription regulators modulate signal-dependent expression of genes involved in carbon metabolism in bacteria and archaea. The Thermotoga maritima TM0065 gene codes for a protein (TM-IclR) that is homologous to the IclR family. We have determined the crystal structure of TM-IclR at 2.2 Angstrom resolution using MAD phasing and synchrotron radiation. The protein is composed of two domains: the N-terminal DNA-binding domain contains the winged helix-turn-helix motif, and the C-terminal presumed regulatory domain is involved in binding signal molecule. In a proposed signal-binding site, a bound Zn2+ ion was found. In the crystal, TM-IclR forms a dimer through interactions between DNA-binding domains. In the dimer, the DNA-binding domains are 2-fold related, but the dimer is asymmetric with respect to the orientation of signal-binding domains. Crystal packing analysis showed that TM-IclR dimers form a tetramer through interactions exclusively by signal-binding domains. A model is proposed for binding of IclR-like factors to DNA, and it suggests that signal-dependent transcription regulation is accomplished by affecting an oligomerization state of IclR and therefore its affinity for DNA target.	Univ Toronto, Banting & Best Dept Med Res, Toronto, ON M5G 1L6, Canada; Argonne Natl Lab, Biosci Div, Argonne, IL 60439 USA; Argonne Natl Lab, Struct Biol Ctr, Argonne, IL 60439 USA; Univ Hlth Network, Clin Genom Ctr Proteom, Toronto, ON M5G 1L7, Canada; Univ London Birkbeck Coll, Dept Crystallog, London WC1E 7HX, England	University of Toronto; United States Department of Energy (DOE); Argonne National Laboratory; United States Department of Energy (DOE); Argonne National Laboratory; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of London; Birkbeck University London	Joachimiak, A (corresponding author), Univ Toronto, Banting & Best Dept Med Res, 112 Coll St, Toronto, ON M5G 1L6, Canada.	andrzejj@anl.gov	Beasley, Steven/B-8106-2019	Laskowski, Roman/0000-0001-5528-0087; Arrowsmith, Cheryl/0000-0002-4971-3250; Edwards, Aled/0000-0002-4782-6016; Beasley, Steven/0000-0002-8702-5651; Kim, Youngchang/0000-0002-1610-4889	NIGMS NIH HHS [P50 GM062414, P50 GM062414-02, GM62414] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P50GM062414] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bateman A, 2000, NUCLEIC ACIDS RES, V28, P263, DOI 10.1093/nar/28.1.263; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CLARK KL, 1993, NATURE, V364, P412, DOI 10.1038/364412a0; CLUBB RT, 1994, STRUCTURE, V2, P1041, DOI 10.1016/S0969-2126(94)00107-3; Cook WJ, 1998, J MOL BIOL, V275, P337, DOI 10.1006/jmbi.1997.1443; CORTAY JC, 1991, EMBO J, V10, P675, DOI 10.1002/j.1460-2075.1991.tb07996.x; Donald LJ, 1996, PROTEIN SCI, V5, P1613, DOI 10.1002/pro.5560050815; Donald LJ, 2001, PROTEIN SCI, V10, P1370, DOI 10.1110/ps.780101; FRIEDMAN AM, 1995, SCIENCE, V268, P1721, DOI 10.1126/science.7792597; Gajiwala KS, 2000, NATURE, V403, P916, DOI 10.1038/35002634; Gui LZ, 1996, J BACTERIOL, V178, P4704, DOI 10.1128/jb.178.15.4704-4709.1996; HINDLE Z, 1994, MOL MICROBIOL, V12, P737, DOI 10.1111/j.1365-2958.1994.tb01061.x; Ibanez E, 2000, J BACTERIOL, V182, P4617, DOI 10.1128/JB.182.16.4617-4624.2000; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KLEYWEGT GJ, 1994, ACTA CRYSTALLOGR D, V50, P178, DOI 10.1107/S0907444993011333; Kok RG, 1998, J BACTERIOL, V180, P5058, DOI 10.1128/JB.180.19.5058-5069.1998; Korolev S, 2002, NAT STRUCT BIOL, V9, P27, DOI 10.1038/nsb737; LASKOWSKI RA, 1995, J MOL GRAPHICS, V13, P323, DOI 10.1016/0263-7855(95)00073-9; MALOY SR, 1982, J BACTERIOL, V149, P173, DOI 10.1128/JB.149.1.173-180.1982; *MOL SIM INC, 2000, QUANTA; NASSER W, 1994, J MOL BIOL, V236, P427, DOI 10.1006/jmbi.1994.1155; NASSER W, 1992, MOL MICROBIOL, V6, P257, DOI 10.1111/j.1365-2958.1992.tb02007.x; Nomura K, 1998, P NATL ACAD SCI USA, V95, P14034, DOI 10.1073/pnas.95.24.14034; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pan B, 1996, J BACTERIOL, V178, P3982, DOI 10.1128/jb.178.13.3982-3984.1996; Passner JM, 1997, P NATL ACAD SCI USA, V94, P2843, DOI 10.1073/pnas.94.7.2843; Pohl E, 1999, J MOL BIOL, V292, P653, DOI 10.1006/jmbi.1999.3073; SUNNARBORG A, 1990, J BACTERIOL, V172, P2642, DOI 10.1128/jb.172.5.2642-2649.1990; van Wezel GP, 2000, J BACTERIOL, V182, P5653, DOI 10.1128/JB.182.20.5653-5662.2000; Wintjens R, 1996, J MOL BIOL, V262, P294, DOI 10.1006/jmbi.1996.0514	30	59	63	2	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 24	2002	277	21					19183	19190		10.1074/jbc.M112171200	http://dx.doi.org/10.1074/jbc.M112171200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	558PM	11877432	Green Accepted, hybrid			2022-12-27	WOS:000175975800121
J	Kannius-Janson, M; Johansson, EM; Bjursell, G; Nilsson, J				Kannius-Janson, M; Johansson, EM; Bjursell, G; Nilsson, J			Nuclear factor 1-C2 contributes to the tissue-specific activation of a milk protein gene in the differentiating mammary gland	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESTER LIPASE GENE; TRANSCRIPTION FACTOR NF1; RECEPTOR-BINDING SITES; TUMOR VIRUS PROMOTER; FACTOR-I FAMILY; GLUCOCORTICOID RECEPTOR; EXOCRINE PANCREAS; DNA-REPLICATION; CELL-LINES; EXPRESSION	Members of the nuclear factor 1 (NF1) transcription factor family have been postulated to be involved in the regulation of milk genes. In this work we have been able to identify the splice variant NF1-C2 as an important member of a tissue-specific activating complex that regulates the milk gene encoding carboxyl ester lipase (CEL). Mutation of the NF1-binding site in the CEL gene promoter results in a drastic reduction of the gene expression to about 15% in mammary epithelial cells. Furthermore, we demonstrate that the NF1-C2 protein interacts with a higher affinity to the NF1-binding site in the CEL gene promoter than other NF1 family members do and that NF1-C2 in the mouse mammary gland is a phosphorylated protein. During development of the mouse mammary gland, binding of NF1-C2 to the CEL gene promoter is induced at midpregnancy, in correlation with the induction of CEL gene expression. The fact that the NF1-C2 involving complex remains throughout the lactation period and decreases during the weaning period, when the CEL gene is down-regulated, supports its importance in the regulation of CEL gene expression. To our knowledge, this is the first report identifying a specific, endogenously expressed NF1 isoform to be involved in the tissue-specific activation of a gene.	Dept CMB Mol Biol, S-40530 Gothenburg, Sweden		Kannius-Janson, M (corresponding author), Dept CMB Mol Biol, Box 462, S-40530 Gothenburg, Sweden.		Kannius Janson, Marie/M-3052-2015; Nilsson, Jeanette/M-3051-2015					Alevizopoulos A, 1995, GENE DEV, V9, P3051, DOI 10.1101/gad.9.24.3051; ALTMANN H, 1994, P NATL ACAD SCI USA, V91, P3901, DOI 10.1073/pnas.91.9.3901; APT D, 1994, NUCLEIC ACIDS RES, V22, P3825, DOI 10.1093/nar/22.19.3825; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; Behrens M, 2000, EUR J NEUROSCI, V12, P1372, DOI 10.1046/j.1460-9568.2000.00032.x; Bisgrove DA, 2000, J BIOL CHEM, V275, P30668, DOI 10.1074/jbc.M003828200; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CATO ACB, 1988, EMBO J, V7, P1403, DOI 10.1002/j.1460-2075.1988.tb02957.x; Chaudhry AZ, 1999, J BIOL CHEM, V274, P7072, DOI 10.1074/jbc.274.11.7072; Chaudhry AZ, 1998, J BIOL CHEM, V273, P18538, DOI 10.1074/jbc.273.29.18538; Chaudhry AZ, 1997, DEV DYNAM, V208, P313; Cooke DW, 1999, BIOCHEM BIOPH RES CO, V260, P600, DOI 10.1006/bbrc.1999.0959; de Jong RN, 1999, GENE, V236, P1, DOI 10.1016/S0378-1119(99)00249-8; DOPPLER W, 1995, J BIOL CHEM, V270, P17962, DOI 10.1074/jbc.270.30.17962; DUSSERRE Y, 1992, MOL CELL BIOL, V12, P5228, DOI 10.1128/MCB.12.11.5228; Furlong EEM, 1996, J BIOL CHEM, V271, P29688, DOI 10.1074/jbc.271.47.29688; Gao B, 1998, J BIOL CHEM, V273, P31784, DOI 10.1074/jbc.273.48.31784; GOYAL N, 1990, MOL CELL BIOL, V10, P1041, DOI 10.1128/MCB.10.3.1041; Gronostajski RM, 2000, GENE, V249, P31, DOI 10.1016/S0378-1119(00)00140-2; HUANG Y, 1991, J BIOL CHEM, V266, P6720; INOUE T, 1990, J BIOL CHEM, V265, P19065; Kane R, 2000, ADV EXP MED BIOL, V480, P117; Kannius-Janson M, 1998, BIOCHEM J, V336, P577, DOI 10.1042/bj3360577; Kannius-Janson M, 2000, BIOCHEM J, V351, P367, DOI 10.1042/0264-6021:3510367; KRUSE U, 1994, FEBS LETT, V348, P46, DOI 10.1016/0014-5793(94)00585-0; Kulkarni S, 1996, CELL GROWTH DIFFER, V7, P501; LI S, 1995, MOL CELL BIOL, V15, P2063; Lidberg U, 1998, J BIOL CHEM, V273, P31417, DOI 10.1074/jbc.273.47.31417; Liu YC, 1997, J BIOL CHEM, V272, P10739; MIKSICEK R, 1987, EMBO J, V6, P1355, DOI 10.1002/j.1460-2075.1987.tb02375.x; Mukhopadhyay SS, 2001, MOL CELL BIOL, V21, P6859, DOI 10.1128/MCB.21.20.6859-6869.2001; NEBL G, 1994, J BIOL CHEM, V269, P7371; NEBL G, 1995, CELL MOL BIOL RES, V41, P85; Osada S, 1999, BIOCHEM J, V342, P189, DOI 10.1042/0264-6021:3420189; REIFELMILLER AE, 1994, J BIOL CHEM, V269, P23861; ROY RJ, 1994, EUR J BIOCHEM, V219, P799, DOI 10.1111/j.1432-1033.1994.tb18560.x; SANTORO C, 1988, NATURE, V334, P218, DOI 10.1038/334218a0; Singh MV, 1998, BBA-GENE STRUCT EXPR, V1398, P148, DOI 10.1016/S0167-4781(98)00037-2; STREULI CH, 1995, J BIOL CHEM, V270, P21639, DOI 10.1074/jbc.270.37.21639; TOPPER YJ, 1980, PHYSIOL REV, V60, P1049, DOI 10.1152/physrev.1980.60.4.1049; WAKAO H, 1994, EMBO J, V13, P2182, DOI 10.1002/j.1460-2075.1994.tb06495.x; WELTE T, 1993, J STEROID BIOCHEM, V47, P75, DOI 10.1016/0960-0760(93)90059-6; Wenzelides S, 1996, NUCLEIC ACIDS RES, V24, P2416, DOI 10.1093/nar/24.12.2416; YANG BS, 1993, MOL CELL BIOL, V13, P3093, DOI 10.1128/MCB.13.5.3093	44	23	23	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 17	2002	277	20					17589	17596		10.1074/jbc.M105979200	http://dx.doi.org/10.1074/jbc.M105979200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	553PR	11877413	hybrid			2022-12-27	WOS:000175685100027
J	Li, L; Shaw, PE				Li, L; Shaw, PE			Autocrine-mediated activation of STAT3 correlates with cell proliferation in breast carcinoma lines	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; TYROSINE KINASE INHIBITOR; PROTEIN-COUPLED RECEPTORS; CANCER-CELLS; EGF RECEPTOR; CONSTITUTIVE ACTIVATION; ANGIOTENSIN-II; MAMMARY-TUMORS; NIH-3T3 CELLS; SRC	The intracellular signals driving the proliferation of breast carcinoma (BC) cells have been widely studied. Both the mitotic and metastatic potential of BC cells have been linked to the frequent overexpression of ErbB family members. Other signaling molecules, including the estrogen receptor, the tyrosine kinases c-Src and Syk, and STAT proteins, especially STAT3, have also been implicated in BC tumor growth. Here we have examined ErbB and STAT protein expression and activation in six BC-derived cell lines. ErbB expression and tyrosine phosphorylation varied considerably among the six cell lines. However, STAT protein expression and activation were more consistent. Two levels of STAT3 activation were distinguished in DNA-binding assays: an epidermal growth factor-inducible, high level that requires both ErbB1 and Janus kinase (JAK) activity and an elevated serum-dependent level that is maintained by autocrine/paracrine signaling and requires JAK activity but is independent of ErbB1 kinase activity. BC cell growth could be inhibited by dominant-negative versions of STAT3 and the JAR inhibitor AG490 but not by PD153035 or PD168393, inhibitors of ErbB1 kinase activity. This indicates that BC cell proliferation may be a consequence of STAT3 activation by autocrine/paracrine signals.	Univ Nottingham, Queens Med Ctr, Sch Biomed Sci, Nottingham NG7 2UH, England	University of Nottingham	Shaw, PE (corresponding author), Univ Nottingham, Queens Med Ctr, Sch Biomed Sci, Nottingham NG7 2UH, England.			SHAW, Peter/0000-0002-2598-4283				Biscardi JS, 1999, J BIOL CHEM, V274, P8335, DOI 10.1074/jbc.274.12.8335; Bowman T, 2000, ONCOGENE, V19, P2474, DOI 10.1038/sj.onc.1203527; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Coopman PJP, 2000, NATURE, V406, P742, DOI 10.1038/35021086; Daub H, 1997, EMBO J, V16, P7032, DOI 10.1093/emboj/16.23.7032; De Vos J, 2000, BRIT J HAEMATOL, V109, P823, DOI 10.1046/j.1365-2141.2000.02127.x; DIFIORE PP, 1987, SCIENCE, V237, P178, DOI 10.1126/science.2885917; Fry DW, 1998, P NATL ACAD SCI USA, V95, P12022, DOI 10.1073/pnas.95.20.12022; FRY DW, 1994, SCIENCE, V265, P1093, DOI 10.1126/science.8066447; Garcia R, 1997, CELL GROWTH DIFFER, V8, P1267; Garcia R, 2001, ONCOGENE, V20, P2499, DOI 10.1038/sj.onc.1204349; Hackel PO, 1999, CURR OPIN CELL BIOL, V11, P184, DOI 10.1016/S0955-0674(99)80024-6; Horvath CM, 1997, CURR OPIN CELL BIOL, V9, P233, DOI 10.1016/S0955-0674(97)80067-1; HUDZIAK RM, 1987, P NATL ACAD SCI USA, V84, P7159, DOI 10.1073/pnas.84.20.7159; HYNES NE, 1994, BBA-REV CANCER, V1198, P165, DOI 10.1016/0304-419X(94)90012-4; Ihara S, 1997, EMBO J, V16, P5345, DOI 10.1093/emboj/16.17.5345; IMAI Y, 1982, CANCER RES, V42, P4394; Karunagaran D, 1996, EMBO J, V15, P254, DOI 10.1002/j.1460-2075.1996.tb00356.x; Kodama H, 1998, CIRC RES, V82, P244; Leaman DW, 1996, MOL CELL BIOL, V16, P369; Leonard WJ, 2000, J ALLERGY CLIN IMMUN, V105, P877, DOI 10.1067/mai.2000.106899; LUPU R, 1995, SEMIN CANCER BIOL, V6, P135, DOI 10.1006/scbi.1995.0016; Luttrell LM, 1999, CURR OPIN CELL BIOL, V11, P177, DOI 10.1016/S0955-0674(99)80023-4; Matsuda T, 1999, EMBO J, V18, P4261, DOI 10.1093/emboj/18.15.4261; Meydan N, 1996, NATURE, V379, P645, DOI 10.1038/379645a0; Ni Z, 2000, CANCER RES, V60, P1225; OTTENHOFFKALFF AE, 1992, CANCER RES, V52, P4773; Prenzel N, 1999, NATURE, V402, P884, DOI 10.1038/47260; Ram PT, 2000, SCIENCE, V287, P142, DOI 10.1126/science.287.5450.142; SADOWSKI HB, 1993, NATURE, V362, P79, DOI 10.1038/362079a0; Sano M, 2000, BIOCHEM BIOPH RES CO, V269, P798, DOI 10.1006/bbrc.2000.2364; Sartor CI, 1997, CANCER RES, V57, P978; SHUAL K, 1993, NATURE, V366, P580, DOI 10.1038/366580a0; Siegel PM, 1999, EMBO J, V18, P2149, DOI 10.1093/emboj/18.8.2149; SIEGEL PM, 1994, MOL CELL BIOL, V14, P7068, DOI 10.1128/MCB.14.11.7068; Spencer KSR, 2000, J CELL BIOL, V148, P385, DOI 10.1083/jcb.148.2.385; STERN DF, 1988, MOL CELL BIOL, V8, P3969, DOI 10.1128/MCB.8.9.3969; Tice DA, 1999, P NATL ACAD SCI USA, V96, P1415, DOI 10.1073/pnas.96.4.1415; Turkson J, 1998, MOL CELL BIOL, V18, P2545, DOI 10.1128/MCB.18.5.2545; VELU TJ, 1987, SCIENCE, V238, P1408, DOI 10.1126/science.3500513; WAGNER BJ, 1990, EMBO J, V9, P4477, DOI 10.1002/j.1460-2075.1990.tb07898.x; Yamauchi T, 2000, J BIOL CHEM, V275, P33937, DOI 10.1074/jbc.M000743200; Zhang Y, 2000, J BIOL CHEM, V275, P24935, DOI 10.1074/jbc.M002383200	43	94	108	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 17	2002	277	20					17397	17405		10.1074/jbc.M109962200	http://dx.doi.org/10.1074/jbc.M109962200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	553PR	11859072	hybrid			2022-12-27	WOS:000175685100005
J	Sakwe, AM; Engstrom, A; Larsson, M; Rask, L				Sakwe, AM; Engstrom, A; Larsson, M; Rask, L			Biosynthesis and secretion of parathyroid hormone are sensitive to proteasome inhibitors in dispersed bovine parathyroid cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTICATALYTIC PROTEINASE COMPLEX; ENDOPLASMIC-RETICULUM CHAPERONES; DIBUTYRYL CYCLIC-AMP; POSTTRANSCRIPTIONAL REGULATION; GENE-EXPRESSION; VITAMIN-D; PREPROPARATHYROID HORMONE; EXTRACELLULAR CALCIUM; MOLECULAR CHAPERONES; SIGNAL PEPTIDASES	Preproparathyroid hormone (prepro-PTH) is one of the proteins abundantly synthesized by parathyroid chief cells; yet under normal growth conditions, little or no prepro-PTH can be detected in these cells. Although this may be attributed to effective cotranslational translocation and proteolytic processing, proteasome-mediated degradation of PTH precursors may be important in the regulation of the levels of these precursors and hence PTH secretion. The effects of N-acetyl-Leu-Leu-norleucinal, N-acetyl-Leu-Leu-methional, carbobenzoxy-Leu-Leu-leucinal (MG132), benzyloxycarbonyl-Ile-Glu(t-butyl)-Ala-leucinal (proteasome inhibitor I), and lactacystin on the biosynthesis and secretion of PTH were examined in dispersed bovine parathyroid cells. We demonstrate that treatment of these cells with proteasome inhibitors caused the accumulation of prepro-PTH and pro-PTH. Compared with mock-treated cells, the processing of pro-PTH to PTH was delayed, and the secretion of intact PTH decreased in proteasome inhibitor-treated cells. Relieving the inhibition of the proteasome by chasing MG132-treated cells in medium without the inhibitor led to the rapid disappearance of the accumulated prepro-PTH, and the rate of PTH secretion was restored to levels comparable to those in mock-treated cells. Furthermore, overexpression of the Hsp70 family of molecular chaperones was observed in proteasome inhibitor-treated cells, and we show that PTH/PTH precursors interact with these molecular chaperones. These data suggest the involvement of parathyroid cell proteasomes in the quality control of PTH biosynthesis.	Uppsala Univ, Uppsala Biomed Ctr, Dept Med Biochem & Microbiol, SE-75123 Uppsala, Sweden	Uppsala University	Sakwe, AM (corresponding author), Uppsala Univ, Uppsala Biomed Ctr, Dept Med Biochem & Microbiol, POB 582, SE-75123 Uppsala, Sweden.	Amos.Sakwe@imbim.uu.se	Larsson, Marten/A-5992-2012; Rask, Lars B/L-4177-2013; Sakwe, Amos/AAU-7639-2020	Sakwe, Amos/0000-0002-2283-794X				Andersson M, 1999, EXP EYE RES, V69, P129, DOI 10.1006/exer.1999.0688; Bauskin AR, 2000, EMBO J, V19, P2212, DOI 10.1093/emboj/19.10.2212; Bercovich B, 1997, J BIOL CHEM, V272, P9002; Black MT, 1998, CURR PHARM DESIGN, V4, P133; Bochtler M, 1999, ANNU REV BIOPH BIOM, V28, P295, DOI 10.1146/annurev.biophys.28.1.295; Brewer JW, 1997, EMBO J, V16, P7207, DOI 10.1093/emboj/16.23.7207; Brodsky JL, 1999, J BIOL CHEM, V274, P3453, DOI 10.1074/jbc.274.6.3453; Brodsky JL, 1999, SEMIN CELL DEV BIOL, V10, P507, DOI 10.1006/scdb.1999.0321; Brown E M, 1993, Curr Opin Nephrol Hypertens, V2, P541, DOI 10.1097/00041552-199307000-00004; BROWN EM, 1993, NATURE, V366, P575, DOI 10.1038/366575a0; BROWN EM, 1983, METABOLISM, V32, P1038, DOI 10.1016/0026-0495(83)90074-4; Bush KT, 1997, J BIOL CHEM, V272, P9086; CHIRICO WJ, 1988, NATURE, V332, P805, DOI 10.1038/332805a0; CHU LLH, 1973, J CLIN INVEST, V52, P3089, DOI 10.1172/JCI107508; CHU LLH, 1983, MOL CELL ENDOCRINOL, V33, P157, DOI 10.1016/0303-7207(83)90164-8; Ciechanover A, 1998, EMBO J, V17, P7151, DOI 10.1093/emboj/17.24.7151; COHN DV, 1986, VITAM HORM, V43, P283; Dalbey RE, 1997, PROTEIN SCI, V6, P1129, DOI 10.1002/pro.5560060601; Fisher EA, 1997, J BIOL CHEM, V272, P20427, DOI 10.1074/jbc.272.33.20427; Geier E, 1999, SCIENCE, V283, P978, DOI 10.1126/science.283.5404.978; Gething MJ, 1999, SEMIN CELL DEV BIOL, V10, P465, DOI 10.1006/scdb.1999.0318; Glickman MH, 2000, SEMIN CELL DEV BIOL, V11, P149, DOI 10.1006/scdb.2000.0161; HABENER JF, 1979, ENDOCRINOLOGY, V104, P265, DOI 10.1210/endo-104-1-265; HAMILTON JW, 1986, MOL CELL ENDOCRINOL, V44, P179, DOI 10.1016/0303-7207(86)90061-4; HAMILTON JW, 1983, ENDOCRINOLOGY, V113, P285, DOI 10.1210/endo-113-1-285; HENDY GN, 1995, J BIOL CHEM, V270, P9517, DOI 10.1074/jbc.270.16.9517; Hurwitz S, 1996, CRIT REV BIOCHEM MOL, V31, P41, DOI 10.3109/10409239609110575; Kawazoe Y, 1998, EUR J BIOCHEM, V255, P356, DOI 10.1046/j.1432-1327.1998.2550356.x; Kim D, 1999, BIOCHEM BIOPH RES CO, V254, P264, DOI 10.1006/bbrc.1998.9840; Kopp F, 1997, P NATL ACAD SCI USA, V94, P2939, DOI 10.1073/pnas.94.7.2939; Lee DH, 1998, TRENDS CELL BIOL, V8, P397, DOI 10.1016/S0962-8924(98)01346-4; Lightcap ES, 2000, CLIN CHEM, V46, P673; MACGREGOR RR, 1975, ENDOCRINOLOGY, V97, P178, DOI 10.1210/endo-97-1-178; MACGREGOR RR, 1989, BIOCHEM BIOPH RES CO, V160, P1339, DOI 10.1016/S0006-291X(89)80150-0; MACGREGOR RR, 1978, CLIN ORTHOP RELAT R, P244; MACGREGOR RR, 1979, J BIOL CHEM, V254, P4428; Marambaud P, 1997, J NEUROCHEM, V68, P698; Meacham GC, 2001, NAT CELL BIOL, V3, P100, DOI 10.1038/35050509; Meerovitch K, 1997, J BIOL CHEM, V272, P6706, DOI 10.1074/jbc.272.10.6706; Moallem E, 1998, J BIOL CHEM, V273, P5253, DOI 10.1074/jbc.273.9.5253; Morris JA, 1997, J BIOL CHEM, V272, P4327, DOI 10.1074/jbc.272.7.4327; MORRISSEY JJ, 1979, J CELL BIOL, V82, P93, DOI 10.1083/jcb.82.1.93; MORRISSEY JJ, 1979, J CELL BIOL, V83, P521, DOI 10.1083/jcb.83.3.521; MURAKAMI Y, 1992, NATURE, V360, P597, DOI 10.1038/360597a0; Muresan Z, 1998, MOL ENDOCRINOL, V12, P458, DOI 10.1210/me.12.3.458; Nakayama K, 1997, BIOCHEM J, V327, P625, DOI 10.1042/bj3270625; Naveh-Many T, 1999, CURR OPIN NEPHROL HY, V8, P415, DOI 10.1097/00041552-199907000-00004; NAVEHMANY T, 1990, J CLIN INVEST, V86, P1313, DOI 10.1172/JCI114840; Onyango I, 1999, EXP CELL RES, V247, P9, DOI 10.1006/excr.1998.4324; ORLOWSKI M, 1993, BIOCHEMISTRY-US, V32, P1563, DOI 10.1021/bi00057a022; Ostrowska H, 1997, BIOCHEM BIOPH RES CO, V234, P729, DOI 10.1006/bbrc.1997.6434; RIDEFELT P, 1992, BIOCHEM BIOPH RES CO, V186, P556, DOI 10.1016/S0006-291X(05)80844-7; RIVETT AJ, 1994, METHOD ENZYMOL, V244, P331; RUSSELL J, 1993, ENDOCRINOLOGY, V132, P2639, DOI 10.1210/en.132.6.2639; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Sela-Brown A, 1999, MINER ELECTROL METAB, V25, P342, DOI 10.1159/000057471; Sherman M Y, 1996, EXS, V77, P57; VINITSKY A, 1992, BIOCHEMISTRY-US, V31, P9421, DOI 10.1021/bi00154a014; Voges D, 1999, ANNU REV BIOCHEM, V68, P1015, DOI 10.1146/annurev.biochem.68.1.1015; WASSLER M, 1987, BIOCHEM J, V247, P407, DOI 10.1042/bj2470407; WATSON PH, 1995, J MOL ENDOCRINOL, V15, P61, DOI 10.1677/jme.0.0150061; WATSON PH, 1993, CLIN INVEST MED, V16, P58; YAMAMOTO M, 1989, J CLIN INVEST, V83, P1053, DOI 10.1172/JCI113946; ZULL JE, 1985, J BIOL CHEM, V260, P1608	64	9	11	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 17	2002	277	20					17687	17695		10.1074/jbc.M108576200	http://dx.doi.org/10.1074/jbc.M108576200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	553PR	11884387	hybrid			2022-12-27	WOS:000175685100039
J	Sun-Wada, GH; Imai-Senga, Y; Yamamoto, A; Murata, Y; Hirata, T; Wada, Y; Futai, M				Sun-Wada, GH; Imai-Senga, Y; Yamamoto, A; Murata, Y; Hirata, T; Wada, Y; Futai, M			A proton pump ATPase with testis-specific E1-subunit isoform required for acrosome acidification	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VACUOLAR H+-ATPASE; RENAL TUBULAR-ACIDOSIS; MOLECULAR-CLONING; SACCHAROMYCES-CEREVISIAE; PROTEOLIPID SUBUNIT; 116-KDA SUBUNIT; V-ATPASE; GENE; EXPRESSION; PROTEIN	The vacuolar-type H+-ATPases (V-ATPases) are a family of multimeric proton pumps involved in a wide variety of physiological processes. We have identified two novel mouse genes, Atp6e1 and Atp6e2, encoding testis-specific (E1) and ubiquitous (E2) V-ATPase subunit E isoforms, respectively. The E1 transcript appears about 3 weeks after birth, corresponding to the start of meiosis, and is expressed specifically in round spermatids in seminiferous tubules. Immunohistochemistry with isoform-specific antibodies revealed that the V-ATPase with E1 and a2 isoforms is located specifically in developing acrosomes of spermatids and acrosomes in mature sperm. In contrast, the E2 isoform was expressed in all tissues examined and present in the perinuclear compartments of spermatocytes. The E1 isoform exhibits 70% identity with the E2, and both isoforms functionally complemented a null mutation of the yeast counterpart VMA4, indicating that they are bona fide V-ATPase subunits. The chimeric enzymes showed slightly lower K-m(ATP) than yeast V-ATPase. Consistent with the temperature-sensitive growth of Deltavma4-expressing E1 isoform, vacuolar membrane vesicles exhibited temperature-sensitive coupling between ATP hydrolysis and proton transport. These results suggest that E1 isoform is essential for energy coupling involved in acidification of acrosome.	Osaka Univ, Inst Sci & Ind Res, Div Biol Sci, Japan Sci & Technol Corp,CREST, Osaka 5670047, Japan; Kansai Med Univ, Dept Physiol, Osaka 5708506, Japan	Japan Science & Technology Agency (JST); Osaka University; Kansai Medical University	Futai, M (corresponding author), Osaka Univ, Inst Sci & Ind Res, Div Biol Sci, Japan Sci & Technol Corp,CREST, Osaka 5670047, Japan.	m-futai@sanken.osaka-u.ac.jp						Bardin C.W., 1988, P933; Carninci P, 2000, GENOME RES, V10, P1617, DOI 10.1101/gr.145100; Futai M, 2000, J EXP BIOL, V203, P107; GLASSNER M, 1991, DEV BIOL, V146, P438, DOI 10.1016/0012-1606(91)90245-X; Gluck SL, 1996, ANNU REV PHYSIOL, V58, P427, DOI 10.1146/annurev.physiol.58.1.427; HANADA H, 1991, BIOCHEM BIOPH RES CO, V176, P1062, DOI 10.1016/0006-291X(91)90391-J; Hayami K, 2001, GENE, V273, P199, DOI 10.1016/S0378-1119(01)00590-X; HERMO L, 1980, AM J ANAT, V157, P357, DOI 10.1002/aja.1001570405; Hirata R, 1997, J BIOL CHEM, V272, P4795, DOI 10.1074/jbc.272.8.4795; Hirata T, 2000, J BIOL CHEM, V275, P386, DOI 10.1074/jbc.275.1.386; HO MN, 1993, J BIOL CHEM, V268, P18286; Inoue H, 1999, BBA-BIOENERGETICS, V1413, P130, DOI 10.1016/S0005-2728(99)00096-1; Karet FE, 1999, NAT GENET, V21, P84, DOI 10.1038/5022; Kawa G, 2000, INT J ANDROL, V23, P278, DOI 10.1046/j.1365-2605.2000.00244.x; Kawamura Y, 2000, J BIOL CHEM, V275, P6515, DOI 10.1074/jbc.275.9.6515; Kawasaki-Nishi S, 2001, J BIOL CHEM, V276, P47411, DOI 10.1074/jbc.M108310200; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Leng XH, 1999, J BIOL CHEM, V274, P14655, DOI 10.1074/jbc.274.21.14655; Li YP, 1999, NAT GENET, V23, P447, DOI 10.1038/70563; Lu M, 2001, J BIOL CHEM, V276, P30407, DOI 10.1074/jbc.M008768200; Mattsson JP, 2000, EUR J BIOCHEM, V267, P4115, DOI 10.1046/j.1432-1327.2000.01445.x; Murata Y, 1997, PEDIATR RES, V42, P436, DOI 10.1203/00006450-199710000-00003; Nakanishi T, 2001, DEV BIOL, V237, P222, DOI 10.1006/dbio.2001.0353; Nelson N, 1999, PHYSIOL REV, V79, P361, DOI 10.1152/physrev.1999.79.2.361; NEZU J, 1992, J BIOCHEM, V112, P212, DOI 10.1093/oxfordjournals.jbchem.a123879; Nishi T, 2000, J BIOL CHEM, V275, P6824, DOI 10.1074/jbc.275.10.6824; Oka T, 2001, J BIOL CHEM, V276, P33079, DOI 10.1074/jbc.M101652200; Oka T, 2001, J BIOL CHEM, V276, P40050, DOI 10.1074/jbc.M106488200; Peng SB, 1999, J BIOL CHEM, V274, P2549, DOI 10.1074/jbc.274.4.2549; ROMRELL LJ, 1976, DEV BIOL, V49, P119, DOI 10.1016/0012-1606(76)90262-1; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SINOWATZ F, 1981, CELL TISSUE RES, V219, P511, DOI 10.1007/BF00209990; Smith AN, 2001, J BIOL CHEM, V276, P42382, DOI 10.1074/jbc.M107267200; Smith AN, 2000, NAT GENET, V26, P71, DOI 10.1038/79208; Stevens TH, 1997, ANNU REV CELL DEV BI, V13, P779, DOI 10.1146/annurev.cellbio.13.1.779; Sun-Wada GH, 2000, DEV BIOL, V228, P315, DOI 10.1006/dbio.2000.9963; TAKESHIGE K, 1992, J CELL BIOL, V119, P301, DOI 10.1083/jcb.119.2.301; TANAKA K, 1990, MOL CELL BIOL, V10, P4303, DOI 10.1128/MCB.10.8.4303; Tomashek JJ, 1997, J BIOL CHEM, V272, P26787, DOI 10.1074/jbc.272.42.26787; Toyomura T, 2000, J BIOL CHEM, V275, P8760, DOI 10.1074/jbc.275.12.8760; Wada Y, 1997, J CELL SCI, V110, P1299; Wieczorek H, 1999, BIOESSAYS, V21, P637, DOI 10.1002/(SICI)1521-1878(199908)21:8<637::AID-BIES3>3.3.CO;2-N; YAMASHIRO CT, 1990, MOL CELL BIOL, V10, P3737, DOI 10.1128/MCB.10.7.3737; Zhang JW, 1998, J BIOL CHEM, V273, P18470, DOI 10.1074/jbc.273.29.18470	44	97	100	0	15	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 17	2002	277	20					18098	18105		10.1074/jbc.M111567200	http://dx.doi.org/10.1074/jbc.M111567200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	553PR	11872743	hybrid			2022-12-27	WOS:000175685100090
J	Swatton, JE; Taylor, CW				Swatton, JE; Taylor, CW			Fast biphasic regulation of type 3 inositol trisphosphate receptors by cytosolic calcium	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							1,4,5-TRISPHOSPHATE RECEPTOR; ENDOPLASMIC-RETICULUM; FUNCTIONAL-PROPERTIES; ADENOPHOSTIN-A; CA2+ RELEASE; PARTIAL INACTIVATION; RAPID ACTIVATION; INSP(3) RECEPTOR; CELLS; INHIBITION	In cytosol-like medium (CLM) with a free [Ca2+] of 200 nM, a supramaximal concentration of inositol 1,4,5-trisphosphate (IP3) (30 muM) evoked Ca-45(2+) release from type 3 IP3 receptors only after a latency of 48+/-6 ms; this latency could not be reduced by increasing the IP3 concentration. In CLM containing a low free [Ca2+] (similar to4 nM), 300 muM IP3 evoked Ca-45(2+) release after a latency of 66+/-11 ms; this was reduced to 14+/-3 ms when the [Ca2+] was 1 mM. Preincubation with CLM containing 100 mum Ca2+ caused a rapid (half-time=33+/-9ms), complete, and fully reversible inhibition that could not be overcome by a high concentration of IP3 (300 muM). Hepatic (type 2) IP3 receptors were not inhibited by Ca2+ once they had bound IP3, but 100 muM Ca2+ rapidly inhibited type 3 IP3 receptors whether it was delivered before addition of IP3 or at any stage during a response to IP3. Ca2+ increases the affinity of IP3 for hepatic receptors by slowing IP3 dissociation, but Ca2+ had no effect on IP3 binding to type 3 receptors. The rate of inhibition of type 3 IP3 receptors by Ca2+ was faster than the rate of IP3 dissociation, and occurred at similar rates whether receptors had bound a high (adenophostin) or low affinity (3-deoxy-3-fluoro-IP3) agonist. Dissociation of agonist is not therefore required for Ca2+ to inhibit type 3 IP3 receptors. We conclude that type 2 and 3 IP3 receptors are each biphasically regulated by Ca2+, but by different mechanisms. For both, IP3 binding causes a stimulatory Ca2+-binding site to be exposed allowing Ca2+ to bind and open the channel. IP3 binding protects type 2 receptors from Ca2+ inhibition, but type 3 receptors are inhibited by Ca2+ whether or not they have IP3 bound. Increases in cytosolic [Ca2+] will immediately inhibit type 3 receptors, but inhibit type 2 receptors only after IP3 has dissociated.	Univ Cambridge, Dept Pharmacol, Cambridge CB2 1PD, England	University of Cambridge	Taylor, CW (corresponding author), Univ Cambridge, Dept Pharmacol, Tennis Court Rd, Cambridge CB2 1PD, England.	cwt1000@cam.ac.uk	Taylor, Colin/G-2447-2010	Taylor, Colin/0000-0001-7771-1044				Adkins CE, 1999, CURR BIOL, V9, P1115, DOI 10.1016/S0960-9822(99)80481-3; Adkins CE, 2000, BIOCHEM J, V352, P929, DOI 10.1042/0264-6021:3520929; BAUMANN O, 1989, J COMP PHYSIOL A, V165, P627, DOI 10.1007/BF00610994; Berridge MJ, 2000, NAT REV MOL CELL BIO, V1, P11, DOI 10.1038/35036035; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BEZPROZVANNY I, 1991, NATURE, V351, P751, DOI 10.1038/351751a0; Boehning D, 2000, J BIOL CHEM, V275, P21492, DOI 10.1074/jbc.M001724200; Boehning D, 2000, EMBO J, V19, P5450, DOI 10.1093/emboj/19.20.5450; Boehning D, 2001, J BIOL CHEM, V276, P13509, DOI 10.1074/jbc.C100094200; Cardy TJA, 1997, BIOCHEM J, V328, P785, DOI 10.1042/bj3280785; Cardy TJA, 1998, BIOCHEM J, V334, P447, DOI 10.1042/bj3340447; Carter TD, 1997, J PHYSIOL-LONDON, V504, P17, DOI 10.1111/j.1469-7793.1997.00017.x; Correa V, 2001, MOL PHARMACOL, V59, P1206, DOI 10.1124/mol.59.5.1206; DANOFF SK, 1988, BIOCHEM J, V254, P701, DOI 10.1042/bj2540701; El-Daher SS, 2000, BLOOD, V95, P3412, DOI 10.1182/blood.V95.11.3412.011k03_3412_3422; Galvan DL, 1999, J BIOL CHEM, V274, P29483, DOI 10.1074/jbc.274.41.29483; Hagar RE, 1998, NATURE, V396, P81, DOI 10.1038/23954; Hirata K, 1999, INVEST OPHTH VIS SCI, V40, P2046; HIROTA J, 1995, J BIOL CHEM, V270, P19046, DOI 10.1074/jbc.270.32.19046; Mak DOD, 2000, J GEN PHYSIOL, V115, P241, DOI 10.1085/jgp.115.3.241; Mak DOD, 1998, P NATL ACAD SCI USA, V95, P15821, DOI 10.1073/pnas.95.26.15821; Mak DOD, 2001, J GEN PHYSIOL, V117, P435, DOI 10.1085/jgp.117.5.435; Marchant JS, 1997, CURR BIOL, V7, P510, DOI 10.1016/S0960-9822(06)00222-3; Marchant JS, 1998, BIOCHEMISTRY-US, V37, P11524, DOI 10.1021/bi980808k; Marchant JS, 1997, BIOCHEMISTRY-US, V36, P12780, DOI 10.1021/bi971397v; MARSHALL ICB, 1993, J BIOL CHEM, V268, P13214; MARSHALL ICB, 1994, BIOCHEM J, V301, P591, DOI 10.1042/bj3010591; Michikawa T, 1999, NEURON, V23, P799, DOI 10.1016/S0896-6273(01)80037-4; Missiaen L, 1998, J BIOL CHEM, V273, P8983, DOI 10.1074/jbc.273.15.8983; Missiaen L, 1999, J BIOL CHEM, V274, P13748, DOI 10.1074/jbc.274.20.13748; Miyakawa T, 1999, EMBO J, V18, P1303, DOI 10.1093/emboj/18.5.1303; Miyakawa T, 2001, EMBO J, V20, P1674, DOI 10.1093/emboj/20.7.1674; MONKAWA T, 1995, J BIOL CHEM, V270, P14700, DOI 10.1074/jbc.270.24.14700; Nerou EP, 2001, BIOCHEM J, V355, P59, DOI 10.1042/bj3550059; Ogden D, 1997, J GEN PHYSIOL, V109, P741, DOI 10.1085/jgp.109.6.741; Parker I, 1996, BIOPHYS J, V70, P222, DOI 10.1016/S0006-3495(96)79565-6; Patel S, 1999, CELL CALCIUM, V25, P247, DOI 10.1054/ceca.1999.0021; PIETRI F, 1990, J BIOL CHEM, V265, P17478; Ramos-Franco J, 1998, BIOPHYS J, V75, P834, DOI 10.1016/S0006-3495(98)77572-1; Swatton JE, 1999, BIOCHEM J, V344, P55, DOI 10.1042/0264-6021:3440055; Swatton JE, 2001, BIOCHEM J, V359, P435, DOI 10.1042/0264-6021:3590435; TAKAHASHI M, 1994, J BIOL CHEM, V269, P369; Taylor C.W., 1999, SIGNAL TRANSDUCTION, P361; Taylor CW, 1999, CELL CALCIUM, V26, P237, DOI 10.1054/ceca.1999.0090; Taylor CW, 1998, BBA-MOL CELL BIOL L, V1436, P19, DOI 10.1016/S0005-2760(98)00122-2; WOJCIKIEWICZ RJH, 1995, J BIOL CHEM, V270, P11678, DOI 10.1074/jbc.270.19.11678; WOJCIKIEWICZ RJH, 1995, BIOCHEM BIOPH RES CO, V213, P334, DOI 10.1006/bbrc.1995.2134; Yoneshima H, 1997, BIOCHEM J, V322, P591, DOI 10.1042/bj3220591; Yule DI, 2001, J GEN PHYSIOL, V117, P431, DOI 10.1085/jgp.117.5.431	49	23	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 17	2002	277	20					17571	17579		10.1074/jbc.M200524200	http://dx.doi.org/10.1074/jbc.M200524200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	553PR	11875073	hybrid			2022-12-27	WOS:000175685100025
J	Done, SC; Leibiger, IB; Efendiev, R; Katz, AI; Leibiger, B; Berggren, PO; Pedemonte, CH; Bertorello, AM				Done, SC; Leibiger, IB; Efendiev, R; Katz, AI; Leibiger, B; Berggren, PO; Pedemonte, CH; Bertorello, AM			Tyrosine 537 within the Na+,K+-ATPase alpha-subunit is essential for AP-2 binding and clathrin-dependent endocytosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMA-MEMBRANE; PHOSPHORYLATION; CELLS; RECRUITMENT; DOPAMINE; TRANSCRIPTION; NA,K-ATPASE; PROTEINS; SIGNAL; PUMP	In renal epithelial cells endocytosis of Na+,K+-ATPase molecules is initiated by phosphorylation of its alpha(1)-subunit, leading to activation of phosphoinositide 3-kinase and adaptor protein-2 (AP-2)/clathrin recruitment. The present study was performed to establish the identity of the AP-2 recognition domain(s) within the Na+,K+-ATPase alpha(1)-subunit. We identified a conserved sequence ((YLEL)-L-537) within the alpha(1)-subunit that represents an AP-2 binding site. Binding of AP-2 to the Na+,K+-ATPase alpha(1)-subunit in response to dopamine (DA) was increased in OK cells stably expressing the wild type rodent alpha-subunit (OK-WT), but not in cells expressing the Y537A mutant (OK-Y537A). DA treatment was associated with increased alpha(1)-subunit abundance in clathrin vesicles from OK-WT but not from OK-Y537A cells. In addition, this mutation also impaired the ability of DA to inhibit Na+,K+-ATPase activity. Because phorbol esters increase Na+,K+-ATPase activity in OK cells, and this effect was not affected by the Y537A mutation, the present results suggest that the identified motif is specifically required for DA-induced AP-2 binding and Na+,K+-ATPase endocytosis.	Karolinska Hosp, Dept Mol Med, Rolf Luft Ctr Diabet Res, S-17176 Stockholm, Sweden; Univ Houston, Coll Pharm, Houston, TX 77204 USA; Univ Chicago, Dept Med, Chicago, IL 60637 USA	Karolinska Institutet; Karolinska University Hospital; University of Houston System; University of Houston; University of Chicago	Bertorello, AM (corresponding author), Karolinska Hosp, Dept Mol Med, Rolf Luft Ctr Diabet Res, L3, S-17176 Stockholm, Sweden.	Alejandro.Bertoello@molmed.ki.se		Berggren, Per-Olof/0000-0001-8991-413X	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK053460] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 53460] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bertorello AM, 1999, AM J PHYSIOL-LUNG C, V276, pL20, DOI 10.1152/ajplung.1999.276.1.L20; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Caplan MJ, 1997, AM J PHYSIOL-RENAL, V272, pF425, DOI 10.1152/ajprenal.1997.272.4.F425; Carranza ML, 1998, J PHYSIOL-LONDON, V511, P235, DOI 10.1111/j.1469-7793.1998.235bi.x; Chibalin AV, 1998, J BIOL CHEM, V273, P8814, DOI 10.1074/jbc.273.15.8814; Chibalin AV, 1997, AM J PHYSIOL-CELL PH, V273, pC1458, DOI 10.1152/ajpcell.1997.273.5.C1458; Chibalin AV, 1998, MOL BIOL CELL, V9, P1209, DOI 10.1091/mbc.9.5.1209; Chibalin AV, 1999, J BIOL CHEM, V274, P1920, DOI 10.1074/jbc.274.4.1920; Efendiev R, 1999, FEBS LETT, V456, P45, DOI 10.1016/S0014-5793(99)00925-4; Efendiev R, 2000, BIOCHEMISTRY-US, V39, P9884, DOI 10.1021/bi0007831; HAMMOND TG, 1994, AM J PHYSIOL-RENAL, V267, pF516, DOI 10.1152/ajprenal.1994.267.4.F516; Kirchhausen T, 1999, ANNU REV CELL DEV BI, V15, P705, DOI 10.1146/annurev.cellbio.15.1.705; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Leibiger B, 1998, P NATL ACAD SCI USA, V95, P9307, DOI 10.1073/pnas.95.16.9307; Moede T, 1999, FEBS LETT, V461, P229, DOI 10.1016/S0014-5793(99)01446-5; Ogimoto G, 2000, P NATL ACAD SCI USA, V97, P3242, DOI 10.1073/pnas.060025597; OHNO H, 1995, SCIENCE, V269, P1872, DOI 10.1126/science.7569928; Pedemonte CH, 1997, J MEMBRANE BIOL, V155, P219, DOI 10.1007/s002329900174; PIETRINI G, 1992, P NATL ACAD SCI USA, V89, P8414, DOI 10.1073/pnas.89.18.8414; ROSE JK, 1991, BIOTECHNIQUES, V10, P520; SERI I, 1990, AM J PHYSIOL, V258, pF52, DOI 10.1152/ajprenal.1990.258.1.F52; Stoorvogel W, 1996, J CELL BIOL, V132, P21, DOI 10.1083/jcb.132.1.21; Sweeney G, 2001, AM J PHYSIOL-CELL PH, V281, pC1797, DOI 10.1152/ajpcell.2001.281.6.C1797; Toyoshima C, 2000, NATURE, V405, P647, DOI 10.1038/35015017; van Dam EM, 2002, MOL BIOL CELL, V13, P169, DOI 10.1091/mbc.01-07-0380; Yudowski GA, 2000, P NATL ACAD SCI USA, V97, P6556, DOI 10.1073/pnas.100128297	26	51	52	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 10	2002	277	19					17108	17111		10.1074/jbc.M201326200	http://dx.doi.org/10.1074/jbc.M201326200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	551MB	11859087	hybrid			2022-12-27	WOS:000175564500102
J	Kaneda, Y; Whittier, RF; Yamanaka, H; Carredano, E; Gotoh, M; Sota, H; Hasegawa, Y; Shinohara, Y				Kaneda, Y; Whittier, RF; Yamanaka, H; Carredano, E; Gotoh, M; Sota, H; Hasegawa, Y; Shinohara, Y			The high specificities of Phaseolus vulgaris erythro- and leukoagglutinating lectins for bisecting GlcNAc or beta 1-6-linked branch structures, respectively, are attributable to loop B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBOHYDRATE-BINDING PEPTIDES; LEGUME LECTINS; PHYTOHEMAGGLUTININ-L; AFFINITY-CHROMATOGRAPHY; OLIGOSACCHARIDES; GLYCANS; SITE; GLYCOSYLATION; GLYCOPROTEIN; PROTEIN	Despite very similar tertiary structures based upon a common framework, legume lectins exhibit an amazing variety of sugar binding specificities. While most of these lectins recognize rather discrete sugar linkages, Phaseolus vulgaris erythroagglutinating and leukoagglutinating lectins (E-4- and L-4-PHA) are unique in recognizing larger structures. E-4- and L-4-PHA are known to recognize complex type N-glycans containing bisecting GlcNAc or a beta1,6-linked branch, respectively. However, the detailed mechanisms of molecular recognition are poorly understood. In order to dissect the contributions of different portions of each lectin, we carried out region-swapping mutagenesis between E-4 and L-4-PHA. We prepared six chimeric lectins by exchanging different combinations of loop B and the central portion of loop C, two of four loops thought to be important for the recognition of monosaccharides (Sharma, V., and Surolia, A. (1997) J. Mol. Biol. 267, 433-445). The chimeric lectins' sugar binding activities were evaluated quantitatively by surface plasmon resonance. These comparisons indicate that the high specificities of E-4- and L-4- PHA toward bisecting GlcNAc and beta1,6-linked branch structures are almost solely attributable to loop B. The contribution of the central portion of loop C to the recognition of those structural motifs was found to be negligible. Instead, it modulates affinity toward LacNAc residues present at the nonreducing terminus. Moreover, some of the chimeric lectins prepared in this study showed even higher specificities/affinities than native E-4- and L-4-PHA toward complex sugar chains containing either a bisecting GlcNAc residue or a beta1,6-linked branch.	Amersham Biosci, Tokyo Res & Dev, Shinjuku Ku, Tokyo 1690073, Japan; Amersham Biosci, Uppsala Res & Dev, SE-75125 Uppsala, Sweden		Shinohara, Y (corresponding author), Amersham Biosci, Tokyo Res & Dev, Shinjuku Ku, 3-25-1 Hyakunincho, Tokyo 1690073, Japan.	yasuro.shinohara@jp.amershambiosciences.com						Asada M, 1997, CANCER RES, V57, P1073; BIERHUIZEN MFA, 1988, EUR J BIOCHEM, V175, P387, DOI 10.1111/j.1432-1033.1988.tb14208.x; BIERHUIZEN MFA, 1988, GLYCOCONJUGATE J, V5, P85, DOI 10.1007/BF01048334; BompardGilles C, 1996, STRUCTURE, V4, P1441, DOI 10.1016/S0969-2126(96)00151-7; CUMMINGS RD, 1982, J BIOL CHEM, V257, P1230; DaoThi MH, 1996, PROTEINS, V24, P134, DOI 10.1002/(SICI)1097-0134(199601)24:1<134::AID-PROT9>3.0.CO;2-K; EGORIN MJ, 1979, J BIOL CHEM, V254, P894; Etzler ME, 1998, TRENDS GLYCOSCI GLYC, V10, P247, DOI 10.4052/tigg.10.247; FERNANDES B, 1991, CANCER RES, V51, P718; Goldstein I., 1986, LECTINS, DOI DOI 10.1016/B978-0-12-449945-4.50007-5; GREEN ED, 1987, J BIOL CHEM, V262, P12018; Hakomori S, 1996, CANCER RES, V56, P5309; Hamelryck TW, 1996, J BIOL CHEM, V271, P32796, DOI 10.1074/jbc.271.51.32796; Hamelryck TW, 1996, J BIOL CHEM, V271, P20479, DOI 10.1074/jbc.271.34.20479; HAMMARSTROM S, 1982, P NATL ACAD SCI-BIOL, V79, P1611, DOI 10.1073/pnas.79.5.1611; HOFFMAN LM, 1982, NUCLEIC ACIDS RES, V10, P7819, DOI 10.1093/nar/10.23.7819; HOFFMAN LM, 1987, BIO-TECHNOL, V5, P157, DOI 10.1038/nbt0287-157; HOFFMAN LM, 1985, EMBO J, V4, P883, DOI 10.1002/j.1460-2075.1985.tb03714.x; Karlsson Robert, 1994, Methods (Orlando), V6, P99, DOI 10.1006/meth.1994.1013; KOBATA A, 1992, J CHROMATOGR, V597, P111, DOI 10.1016/0021-9673(92)80101-Y; KOBATA A, 1989, METHOD ENZYMOL, V179, P46; KONAMI Y, 1992, J CHROMATOGR, V597, P213, DOI 10.1016/0021-9673(92)80113-9; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LEAVITT RD, 1977, J BIOL CHEM, V252, P2961; Loris R, 1998, BBA-PROTEIN STRUCT M, V1383, P9, DOI 10.1016/S0167-4838(97)00182-9; MASTRYUKOV VS, 1993, THEOCHEM, V99, P199; MIRKOV TE, 1993, GLYCOBIOLOGY, V3, P581, DOI 10.1093/glycob/3.6.581; OSHANNESSY DJ, 1993, ANAL BIOCHEM, V212, P457, DOI 10.1006/abio.1993.1355; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; Rarey M, 1996, J MOL BIOL, V261, P470, DOI 10.1006/jmbi.1996.0477; RINI JM, 1995, ANNU REV BIOPH BIOM, V24, P551, DOI 10.1146/annurev.biophys.24.1.551; Sharma V, 1997, J MOL BIOL, V267, P433, DOI 10.1006/jmbi.1996.0863; SHARON N, 1990, FASEB J, V4, P3198, DOI 10.1096/fasebj.4.14.2227211; Shinohara Y, 1996, ANAL CHEM, V68, P2573, DOI 10.1021/ac960004f; Shinohara Y, 1997, GLYCOBIOLOGY, V7, P1201, DOI 10.1093/glycob/7.8.1201; VANEIJSDEN RR, 1992, PLANT MOL BIOL, V20, P1049, DOI 10.1007/BF00028892; Yamamoto H, 2000, CANCER RES, V60, P134; Yamamoto K, 2000, J BIOCHEM-TOKYO, V127, P137, DOI 10.1093/oxfordjournals.jbchem.a022575; YAMAMOTO K, 1992, J BIOCHEM-TOKYO, V111, P436, DOI 10.1093/oxfordjournals.jbchem.a123775; YOUNG NM, 1992, J MOL BIOL, V228, P924, DOI 10.1016/0022-2836(92)90875-K	40	36	37	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 10	2002	277	19					16928	16935		10.1074/jbc.M112382200	http://dx.doi.org/10.1074/jbc.M112382200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	551MB	11864980	hybrid			2022-12-27	WOS:000175564500079
J	Kosugi, S; Ohashi, Y				Kosugi, S; Ohashi, Y			E2Ls, E2F-like Repressors of Arabidopsis that bind to E2F sites in a monomeric form	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE; RETINOBLASTOMA PROTEIN; TRANSCRIPTION FACTORS; NUCLEAR-LOCALIZATION; HISTONE DEACETYLASE; S-PHASE; SUBCELLULAR-LOCALIZATION; FAMILY MEMBERS; PLANT E2F; GENE	E2F transcription factors are major regulators of cell proliferation, and each factor contributes differently to cell cycle control. Arabidopsis contains six E2F homologs, of which three are proteins that exhibit an overall similarity to animal E2Fs and interact with DPa and DPb to stimulate DNA binding. Here we describe the other three E2F-like proteins from Arabidopsis, E2L1-3, which have two copies of a domain with a limited similarity only to the DNA binding domain of E2F. Unlike known E2Fs, the three E2L proteins failed to interact with DPa and DPb and could efficiently bind E2F sites in a monomeric form through the dual-type domain. Transfection assays revealed that E2Ls repress the transcription of reporter genes under the control of E2F-regulated promoters, indicating that E2Ls function to antagonize transactivation mediated by E2F-DP. When fused to green fluorescence protein, E2L1 and E2L3 were predominantly localized to the nucleus whereas E2L2 was detected in both the nucleus and cytoplasm. Because the transcripts of E2Ls were abundant in meristematic rather than fully differentiated tissues, E2Ls may balance the activities of E2F-DP and play a role in restraining cell proliferation.	Natl Inst Agrobiol Sci, Dept Mol Genet, Tsukuba, Ibaraki 3058602, Japan; Japan Sci & Technol Corp, Core Res Evolut Sci & Technol, Chiyoda Ku, Tokyo 1010062, Japan	National Institute of Agrobiological Sciences - Japan; Japan Science & Technology Agency (JST)	Ohashi, Y (corresponding author), Natl Inst Agrobiol Sci, Dept Mol Genet, Tsukuba, Ibaraki 3058602, Japan.							Albani D, 2000, J BIOL CHEM, V275, P19258, DOI 10.1074/jbc.M909390199; Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; Cartwright P, 1998, ONCOGENE, V17, P611, DOI 10.1038/sj.onc.1201975; Chaboute ME, 2000, PLANT CELL, V12, P1987, DOI 10.1105/tpc.12.10.1987; Chiu WL, 1996, CURR BIOL, V6, P325, DOI 10.1016/S0960-9822(02)00483-9; Choo Y, 2000, CURR OPIN STRUC BIOL, V10, P411, DOI 10.1016/S0959-440X(00)00107-X; de Jager SM, 2001, PLANT MOL BIOL, V47, P555, DOI 10.1023/A:1011848528377; delaLuna S, 1996, J CELL SCI, V109, P2443; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Egelkrout EM, 2001, PLANT CELL, V13, P1437, DOI 10.1105/tpc.13.6.1437; FLEMINGTON EK, 1993, P NATL ACAD SCI USA, V90, P6914, DOI 10.1073/pnas.90.15.6914; Frolov MV, 2001, GENE DEV, V15, P2146, DOI 10.1101/gad.903901; Gaubatz S, 1998, P NATL ACAD SCI USA, V95, P9190, DOI 10.1073/pnas.95.16.9190; Gaubatz S, 2000, MOL CELL, V6, P729, DOI 10.1016/S1097-2765(00)00071-X; Harbour JW, 2000, GENE DEV, V14, P2393, DOI 10.1101/gad.813200; Helin K, 1998, CURR OPIN GENET DEV, V8, P28, DOI 10.1016/S0959-437X(98)80058-0; HELIN K, 1993, MOL CELL BIOL, V13, P6501, DOI 10.1128/MCB.13.10.6501; Ishida S, 2001, MOL CELL BIOL, V21, P4684, DOI 10.1128/MCB.21.14.4684-4699.2001; Jin HL, 1999, PLANT MOL BIOL, V41, P577, DOI 10.1023/A:1006319732410; Kim JS, 1998, P NATL ACAD SCI USA, V95, P2812, DOI 10.1073/pnas.95.6.2812; KOSUGI S, 1991, NUCLEIC ACIDS RES, V19, P1571, DOI 10.1093/nar/19.7.1571; Kosugi S, 2000, NUCLEIC ACIDS RES, V28, P960, DOI 10.1093/nar/28.4.960; Kosugi S, 1997, PLANT CELL, V9, P1607, DOI 10.1105/tpc.9.9.1607; Kosugi S, 2002, PLANT J, V29, P45, DOI 10.1046/j.1365-313x.2002.01196.x; Kosugi S, 2002, PLANT PHYSIOL, V128, P833, DOI 10.1104/pp.010642; Lavia P, 1999, BIOESSAYS, V21, P221; Lindeman GJ, 1998, GENE DEV, V12, P1092, DOI 10.1101/gad.12.8.1092; Lindeman GJ, 1997, P NATL ACAD SCI USA, V94, P5095, DOI 10.1073/pnas.94.10.5095; Luo RX, 1998, CELL, V92, P463, DOI 10.1016/S0092-8674(00)80940-X; Magae J, 1996, J CELL SCI, V109, P1717; Magnaghi-Jaulin L, 1998, NATURE, V391, P601, DOI 10.1038/35410; Magyar Z, 2000, FEBS LETT, V486, P79, DOI 10.1016/S0014-5793(00)02238-9; Meloni AR, 1999, P NATL ACAD SCI USA, V96, P9574, DOI 10.1073/pnas.96.17.9574; Muller H, 1997, MOL CELL BIOL, V17, P5508; Muller H, 2001, GENE DEV, V15, P267, DOI 10.1101/gad.864201; Nevins JR, 1998, CELL GROWTH DIFFER, V9, P585; Paramio JM, 2000, J BIOL CHEM, V275, P41219, DOI 10.1074/jbc.M004973200; POMERANTZ JL, 1995, SCIENCE, V267, P93, DOI 10.1126/science.7809612; Ramirez-Parra E, 1999, NUCLEIC ACIDS RES, V27, P3527, DOI 10.1093/nar/27.17.3527; Ramirez-Parra E, 2000, FEBS LETT, V486, P73, DOI 10.1016/S0014-5793(00)02239-0; Ross JF, 2001, GENE DEV, V15, P392, DOI 10.1101/gad.858501; Sawado T, 1998, BIOCHEM BIOPH RES CO, V251, P409, DOI 10.1006/bbrc.1998.9407; Sekine M, 1999, FEBS LETT, V460, P117, DOI 10.1016/S0014-5793(99)01296-X; SELLERS WR, 1995, P NATL ACAD SCI USA, V92, P11544, DOI 10.1073/pnas.92.25.11544; Trimarchi JM, 1998, P NATL ACAD SCI USA, V95, P2850, DOI 10.1073/pnas.95.6.2850; Trimarchi JM, 2001, P NATL ACAD SCI USA, V98, P1519, DOI 10.1073/pnas.041597698; Verona R, 1997, MOL CELL BIOL, V17, P7268, DOI 10.1128/MCB.17.12.7268; Wang DW, 2000, MOL CELL BIOL, V20, P3417, DOI 10.1128/MCB.20.10.3417-3424.2000; Wu LZ, 2001, NATURE, V414, P457, DOI 10.1038/35106593; Zhang HS, 2000, CELL, V101, P79, DOI 10.1016/S0092-8674(00)80625-X	50	67	91	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 10	2002	277	19					16553	16558		10.1074/jbc.M200913200	http://dx.doi.org/10.1074/jbc.M200913200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	551MB	11867638	hybrid			2022-12-27	WOS:000175564500030
J	Shenton, D; Perrone, G; Quinn, KA; Dawes, IW; Grant, CM				Shenton, D; Perrone, G; Quinn, KA; Dawes, IW; Grant, CM			Regulation of protein S-thiolation by glutaredoxin 5 in the yeast Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE GENES; HUMAN ENDOTHELIAL-CELLS; OXIDATIVE STRESS; MIXED-DISULFIDES; THIOLTRANSFERASE GLUTAREDOXIN; ESCHERICHIA-COLI; REDOX REGULATION; GLUTATHIONE; THIOREDOXIN; REDUCTION	The irreversible oxidation of cysteine residues can be prevented by protein S-thiolation, a process by which protein -SH groups form mixed disulfides with low molecular weight thiols such as glutathione. We report here that this protein modification is not a simple response to the cellular redox state, since different oxidants lead to different patterns of protein S-thiolation. SDS-polyacrylamide gel electrophoresis shows that glyceraldehyde-3-phosphate dehydrogenase (GAPDH) is the major target for modification following treatment with hydroperoxides (hydrogen peroxide or tert-butylhydroperoxide), whereas this enzyme is unaffected following cellular exposure to the thiol oxidant diamide. Further evidence that protein S-thiolation is tightly regulated in response to oxidative stress is provided by the finding that the Tdh3 GAPDH isoenzyme, and not the Tdh2 isoenzyme, is S-thiolated following exposure to H2O2 in vivo, whereas both GAPDH isoenzymes are S-thiolated when H2O2 is added to cell-free extracts. This indicates that cellular factors are likely to be responsible for the difference in GAPDH S-thiolation observed in vivo rather than intrinsic structural differences between the GAPDH isoenzymes. To begin to search for factors that can regulate the S-thiolation process, we investigated the role of the glutaredoxin family of oxidoreductases. We provide the first evidence that protein dethiolation in vivo is regulated by a monothiol-glutaredoxin rather than the classical glutaredoxins, which contain two active site cysteine residues. In particular, glutaredoxin 5 is required for efficient dethiolation of the Tdh3 GAPDH isoenzyme.	UMIST, Dept Biomol Sci, Manchester M60 1QD, Lancs, England; Univ New S Wales, Sch Biochem & Mol Genet, Sydney, NSW 2052, Australia	University of Manchester; University of New South Wales Sydney	Grant, CM (corresponding author), UMIST, Dept Biomol Sci, POB 88, Manchester M60 1QD, Lancs, England.			Grant, Chris/0000-0002-0616-6576				BUSHWELLER JH, 1992, BIOCHEMISTRY-US, V31, P9288, DOI 10.1021/bi00153a023; Carmel-Harel O, 2000, ANNU REV MICROBIOL, V54, P439, DOI 10.1146/annurev.micro.54.1.439; Chrestensen CA, 2000, J BIOL CHEM, V275, P26556, DOI 10.1074/jbc.M004097200; COAN C, 1992, ARCH BIOCHEM BIOPHYS, V295, P369, DOI 10.1016/0003-9861(92)90530-A; Cotgreave IA, 1998, BIOCHEM BIOPH RES CO, V242, P1, DOI 10.1006/bbrc.1997.7812; Davis DA, 1997, J BIOL CHEM, V272, P25935, DOI 10.1074/jbc.272.41.25935; Grant CM, 2001, MOL MICROBIOL, V39, P533, DOI 10.1046/j.1365-2958.2001.02283.x; Grant CM, 1999, MOL CELL BIOL, V19, P2650; Grant CM, 1998, BIOCHEM BIOPH RES CO, V253, P893, DOI 10.1006/bbrc.1998.9864; Grant CM, 1996, MOL MICROBIOL, V22, P739, DOI 10.1046/j.1365-2958.1996.d01-1727.x; Jung CH, 1996, ARCH BIOCHEM BIOPHYS, V335, P61, DOI 10.1006/abbi.1996.0482; Klatt P, 1999, FASEB J, V13, P1481, DOI 10.1096/fasebj.13.12.1481; Klatt P, 2000, EUR J BIOCHEM, V267, P4928, DOI 10.1046/j.1432-1327.2000.01601.x; KOSOWER NS, 1995, METHOD ENZYMOL, V251, P123, DOI 10.1016/0076-6879(95)51116-4; Luikenhuis S, 1998, MOL BIOL CELL, V9, P1081, DOI 10.1091/mbc.9.5.1081; MCALISTER L, 1985, J BIOL CHEM, V260, P5013; MCALISTER L, 1985, J BIOL CHEM, V260, P5019; MEISTER A, 1988, J BIOL CHEM, V263, P17205; MILLER RM, 1991, ARCH BIOCHEM BIOPHYS, V287, P112, DOI 10.1016/0003-9861(91)90395-Y; Muller EGD, 1996, MOL BIOL CELL, V7, P1805, DOI 10.1091/mbc.7.11.1805; Obin M, 1998, FASEB J, V12, P561, DOI 10.1096/fasebj.12.7.561; Rietsch A, 1998, ANNU REV GENET, V32, P163, DOI 10.1146/annurev.genet.32.1.163; Rodriguez-Manzaneque MT, 1999, MOL CELL BIOL, V19, P8180; Ruoppolo M, 1997, BIOCHEMISTRY-US, V36, P12259, DOI 10.1021/bi970851s; SCHUPPE I, 1992, BIOCHEM PHARMACOL, V44, P1757, DOI 10.1016/0006-2952(92)90069-U; SCHUPPEKOISTINEN I, 1994, ARCH BIOCHEM BIOPHYS, V315, P226, DOI 10.1006/abbi.1994.1494; Seres T, 1996, J IMMUNOL, V156, P1973; THOMAS JA, 1994, METHOD ENZYMOL, V233, P385; THOMAS JA, 1995, ARCH BIOCHEM BIOPHYS, V319, P1, DOI 10.1006/abbi.1995.1261; YOSHITAKE S, 1994, J BIOCHEM-TOKYO, V116, P42, DOI 10.1093/oxfordjournals.jbchem.a124500	30	78	79	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 10	2002	277	19					16853	16859		10.1074/jbc.M200559200	http://dx.doi.org/10.1074/jbc.M200559200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	551MB	11882660	hybrid			2022-12-27	WOS:000175564500068
J	Stadheim, TA; Suh, N; Ganju, N; Sporn, MB; Eastman, A				Stadheim, TA; Suh, N; Ganju, N; Sporn, MB; Eastman, A			The novel triterpenoid 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid (CDDO) potently enhances apoptosis induced by tumor necrosis factor in human leukemia cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-TERMINAL KINASE; ACTIVATED PROTEIN-KINASE; DNA-DAMAGING AGENTS; KAPPA-B ACTIVATION; CYTOCHROME-C; SIGNALING PATHWAYS; JNK ACTIVATION; FACTOR-ALPHA; DEATH; INDUCTION	Tumor necrosis factor (TNF) is a potent activator of the nuclearfactor-kappaB (NF-kappaB) pathway that leads to upregulation of anti-apoptotic proteins. Hence, TNF induces apoptosis in the presence of inhibitors of protein or RNA synthesis. We report that a novel triterpenoid, 2-cyano-3,12-dioxooleana-1,9,-dien-28-oic acid (CDDO) inhibits NF-kappaB-mediated gene expression at a step after translocation of activated NF-kappaB to the nucleus. This effect appears specific for the NF-kappaB pathway as CDDO does not inhibit gene expression induced by the phorbol ester 12-0-tetradecanoylphorbol-13-acetate (TPA). CDDO in combination with TNF caused a dramatic increase in apoptosis in ML-1 leukemia cells that was associated with activation of caspase-8, cleavage of Bid, translocation of Bax, cytochrome c release, and caspase-3 activation. Experiments with caspase inhibitors demonstrated that caspase-8 was an initiator of this pathway. TNF also induced a transient activation of c-Jun N-terminal kinase (JNK), which upon addition of CDDO was converted to a sustained activation. The activation of JNK was also dependent on caspase-8. Sustained activation of JNK is frequently pro-apoptotic, yet inhibition of JNK did not prevent Bax translocation or cytochrome c release, demonstrating its lack of involvement in CDDO/TNF-induced apoptosis. Apoptosis was acutely induced by CDDO/TNF in every leukemia cell line tested including those that overexpress Bcl-X-L, suggesting that the mitochondrial pathway is not required for apoptosis by this combination. These results suggest that the apoptotic potency of the CDDO/TNF combination occurs through selective inhibition of NF-kappaB-dependent anti-apoptotic proteins, bypassing potential mitochondrial resistance mechanisms, and thus may provide a basis for the development of novel approaches to the treatment of leukemia.	Dartmouth Coll Sch Med, Dept Pharmacol & Toxicol, Hanover, NH 03755 USA	Dartmouth College	Eastman, A (corresponding author), Dartmouth Coll Sch Med, Dept Pharmacol & Toxicol, Hanover, NH 03755 USA.				NATIONAL CANCER INSTITUTE [R01CA050224, F32CA086476, R55CA050224] Funding Source: NIH RePORTER; NCI NIH HHS [CA50224, F32 CA86476] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Akashi M, 1999, BIOCHEM J, V337, P607, DOI 10.1042/0264-6021:3370607; Barchowsky A, 1995, AM J PHYSIOL-LUNG C, V269, pL829, DOI 10.1152/ajplung.1995.269.6.L829; Baud V, 2001, TRENDS CELL BIOL, V11, P372, DOI 10.1016/S0962-8924(01)02064-5; Bennett BL, 2001, P NATL ACAD SCI USA, V98, P13681, DOI 10.1073/pnas.251194298; Chen YR, 1996, J BIOL CHEM, V271, P31929, DOI 10.1074/jbc.271.50.31929; Datta R, 1996, BLOOD, V88, P1936, DOI 10.1182/blood.V88.6.1936.bloodjournal8861936; De Smaele E, 2001, NATURE, V414, P308, DOI 10.1038/35104560; Deak JC, 1998, P NATL ACAD SCI USA, V95, P5595, DOI 10.1073/pnas.95.10.5595; Erhardt P, 1996, J BIOL CHEM, V271, P17601, DOI 10.1074/jbc.271.30.17601; Guo YL, 1998, J BIOL CHEM, V273, P4027, DOI 10.1074/jbc.273.7.4027; Ibrado AM, 1996, CELL GROWTH DIFFER, V7, P1087; Ibrado AM, 1997, CANCER RES, V57, P1109; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; Ip YT, 1998, CURR OPIN CELL BIOL, V10, P205, DOI 10.1016/S0955-0674(98)80143-9; Ito Y, 2001, MOL PHARMACOL, V59, P1094, DOI 10.1124/mol.59.5.1094; Ito Y, 2000, CELL GROWTH DIFFER, V11, P261; Karin M, 1999, J BIOL CHEM, V274, P27339, DOI 10.1074/jbc.274.39.27339; Krieser RJ, 1999, CELL DEATH DIFFER, V6, P412, DOI 10.1038/sj.cdd.4400515; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Mudipalli A, 2001, LEUKEMIA, V15, P808, DOI 10.1038/sj.leu.2402083; SALEEM A, 1995, CELL GROWTH DIFFER, V6, P1651; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Single B, 1998, CELL DEATH DIFFER, V5, P1001, DOI 10.1038/sj.cdd.4400462; Stadheim TA, 2002, LEUKEMIA RES, V26, P55, DOI 10.1016/S0145-2126(01)00099-6; Stadheim TA, 2000, BIOCHEM PHARMACOL, V59, P407, DOI 10.1016/S0006-2952(99)00330-5; Stadheim TA, 2001, CANCER RES, V61, P1533; Suh NJ, 1999, CANCER RES, V59, P336; Sun XM, 1999, J BIOL CHEM, V274, P5053, DOI 10.1074/jbc.274.8.5053; Tang GL, 2001, NATURE, V414, P313, DOI 10.1038/35104568; Tournier C, 2000, SCIENCE, V288, P870, DOI 10.1126/science.288.5467.870; Townsend KJ, 1998, ONCOGENE, V17, P1223, DOI 10.1038/sj.onc.1202035; VAN AD, 1996, SCIENCE, V274, P787; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Wang YP, 2000, MOL ENDOCRINOL, V14, P1550, DOI 10.1210/me.14.10.1550; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Yamamoto K, 1995, J BIOL CHEM, V270, P31315, DOI 10.1074/jbc.270.52.31315; Yang T, 1996, J CELL PHYSIOL, V166, P523, DOI 10.1002/(SICI)1097-4652(199603)166:3<523::AID-JCP7>3.0.CO;2-R	40	87	115	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 10	2002	277	19					16448	16455		10.1074/jbc.M108974200	http://dx.doi.org/10.1074/jbc.M108974200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	551MB	11880365	hybrid			2022-12-27	WOS:000175564500016
J	Sigoillot, FD; Evans, DR; Guy, HI				Sigoillot, FD; Evans, DR; Guy, HI			Growth-dependent regulation of mammalian pyrimidine biosynthesis by the protein kinase A and NLAPK signaling cascades	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBAMOYL-PHOSPHATE SYNTHETASE; MULTIFUNCTIONAL PROTEIN; ESCHERICHIA-COLI; ASPARTATE-TRANSCARBAMYLASE; HAMSTER-CELLS; NUCLEOTIDE BIOSYNTHESIS; MAP KINASE; CAD; ENZYMES; ACID	The carbamoyl phosphate synthetase domain of the multifunctional protein CAD catalyzes the initial, rate-limiting step in mammalian de novo pyrimidine biosynthesis. In addition to allosteric regulation by the inhibitor UTP and the activator PRPP, the carbamoyl phosphate synthetase activity is controlled by mitogen-activated protein kinase (MAPK)- and protein kinase A (PKA)-mediated phosphorylation. MAPK phosphorylation, both in vivo and in vitro, increases sensitivity to PRPP and decreases sensitivity to the inhibitor UTP, whereas PKA phosphorylation reduces the response to both allosteric effectors. To elucidate the factors responsible for growth state-dependent regulation of pyrimidine biosynthesis, the activity of the de novo pyrimidine pathway, the MAPK and PKA activities, the phosphorylation state, and the allosteric regulation of CAD were measured as a function of growth state. As cells entered the exponential growth phase, there was an 8-fold increase in pyrimidine biosynthesis that was accompanied by a 40-fold increase in MAPK activity and a 4-fold increase in CAD threonine phosphorylation. PRPP activation increased to 21-fold, and UTP became a modest activator. These changes were reversed when the cultures approach confluence and growth ceases. Moreover, CAD phosphoserine, a measure of PKA phosphorylation, increased 2-fold in confluent cells. These results are consistent with the activation of CAD by MAPK during periods of rapid growth and its down-regulation in confluent cells associated with decreased MAPK phosphorylation and a concomitant increase in PKA phosphorylation. A scheme is proposed that could account for growth-dependent regulation of pyrimidine biosynthesis based on the sequential action of MAPK and PKA on the carbamoyl phosphate synthetase activity of CAD.	Wayne State Univ, Sch Med, Dept Biochem & Mol Biol, Detroit, MI 48201 USA	Wayne State University	Guy, HI (corresponding author), Wayne State Univ, Sch Med, Dept Biochem & Mol Biol, 540 E Canfield Ave, Detroit, MI 48201 USA.	hguy@cmb.biosci.wayne.edu		Sigoillot, Frederic/0000-0002-8695-4838	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060371] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM/CA60371, R01 GM060371] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AOKI T, 1981, SCIENCE, V212, P463, DOI 10.1126/science.7209543; Banerjei LC, 1997, SOMAT CELL MOLEC GEN, V23, P37, DOI 10.1007/BF02679954; CALVA E, 1959, CANCER RES, V19, P679; CARREY EA, 1985, EMBO J, V4, P3735, DOI 10.1002/j.1460-2075.1985.tb04142.x; CHEN JJ, 1978, MICROENVIRONMENTS ME, P211; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; COLEMAN PF, 1977, J BIOL CHEM, V252, P6379; DAVIDSON JN, 1981, J BIOL CHEM, V256, P5220; Fairbanks LD, 1999, J CHROMATOGR B, V732, P487, DOI 10.1016/S0378-4347(99)00303-5; Graves LM, 1996, TRENDS ENDOCRIN MET, V7, P43, DOI 10.1016/1043-2760(95)00204-9; Graves LM, 2000, NATURE, V403, P328, DOI 10.1038/35002111; GRAYSON DR, 1985, J BIOL CHEM, V260, P5840; GUY HI, 1994, J BIOL CHEM, V269, P23808; GUY HI, 1994, ADV EXP MED BIOL, V370, P729; HAGER SE, 1967, J BIOL CHEM, V242, P5674; HAGER SE, 1967, J BIOL CHEM, V242, P5667; HUISMAN WH, 1979, J BIOL CHEM, V254, P2595; Irvine HS, 1997, EUR J BIOCHEM, V247, P1063, DOI 10.1111/j.1432-1033.1997.01063.x; ITO K, 1973, J BIOL CHEM, V248, P389; JACKSON RC, 1980, CANCER RES, V40, P1286; JONES ME, 1980, ANNU REV BIOCHEM, V49, P253, DOI 10.1146/annurev.bi.49.070180.001345; KIM HS, 1992, J BIOL CHEM, V267, P7177; KIM S, 1965, ARCH BIOCHEM BIOPHYS, V109, P421, DOI 10.1016/0003-9861(65)90385-1; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVINE EM, 1965, P NATL ACAD SCI USA, V53, P350, DOI 10.1073/pnas.53.2.350; LEVINE RL, 1971, BIOCHEMISTRY-US, V10, P3694; Lewis TS, 1998, ADV CANCER RES, V74, P49, DOI 10.1016/S0065-230X(08)60765-4; LIAO WSL, 1986, J BIOL CHEM, V261, P5577; LIU X, 1994, J BIOL CHEM, V269, P27747; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MALLY MI, 1980, J BIOL CHEM, V255, P1372; MALLY MI, 1981, P NATL ACAD SCI-BIOL, V78, P6647, DOI 10.1073/pnas.78.11.6647; MORI M, 1975, BIOCHEMISTRY-US, V14, P2622, DOI 10.1021/bi00683a010; NORDMANN Y, 1964, NATURE, V201, P616, DOI 10.1038/201616a0; PASTRALANDIS SC, 1981, ANAL BIOCHEM, V118, P358, DOI 10.1016/0003-2697(81)90594-7; PRESCOTT LM, 1969, ANAL BIOCHEM, V32, P408, DOI 10.1016/S0003-2697(69)80008-4; Purcarea C, 1997, J BACTERIOL, V179, P4143, DOI 10.1128/jb.179.13.4143-4157.1997; ROUX JM, 1973, J BIOL CHEM, V248, P1196; Sahay N, 1998, J BIOL CHEM, V273, P31195, DOI 10.1074/jbc.273.47.31195; SHAMBAUGH GE, 1974, DEV BIOL, V37, P171, DOI 10.1016/0012-1606(74)90177-8; SHAW SM, 1992, EUR J BIOCHEM, V207, P957, DOI 10.1111/j.1432-1033.1992.tb17130.x; SHOAF WT, 1973, BIOCHEMISTRY-US, V12, P4039, DOI 10.1021/bi00745a004; SMITH ML, 1979, J CELL PHYSIOL, V101, P293, DOI 10.1002/jcp.1041010210; SWYRYD EA, 1974, J BIOL CHEM, V249, P6945; TATIBANA M, 1969, J BIOL CHEM, V244, P5403; TATIBANA M, 1972, BIOCHEM BIOPH RES CO, V46, P491, DOI 10.1016/S0006-291X(72)80165-7; Thoden JB, 1997, BIOCHEMISTRY-US, V36, P6305, DOI 10.1021/bi970503q; WAHL GM, 1979, J BIOL CHEM, V254, P8679; WARD GA, 1973, J CELL PHYSL, V73, P213	49	31	33	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 3	2002	277	18					15745	15751		10.1074/jbc.M201112200	http://dx.doi.org/10.1074/jbc.M201112200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	550PA	11872754	hybrid			2022-12-27	WOS:000175510400071
J	Torrungruang, K; Alvarez, M; Shah, R; Onyia, JE; Rhodes, SJ; Bidwell, JP				Torrungruang, K; Alvarez, M; Shah, R; Onyia, JE; Rhodes, SJ; Bidwell, JP			DNA binding and gene activation properties of the Nmp4 nuclear matrix transcription factors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ZINC-FINGER PROTEIN; TRANSACTIVATION FUNCTION; PROMOTER ELEMENT; RECOGNITION; DOMAINS; EXPRESSION; OSTEOBLAST; SEQUENCES; SPECIFICITY; MOTIFS	Splice variants of the Nmp4 gene include nuclear matrix transcription factors that regulate the type I collagen alpha1(I) polypeptide chain (COL1A1) promoter and several matrix metalloproteinase (MMP) genes. To date, these are the only Cys(2)His(2) zinc finger proteins known to bind within the minor groove of homopolymeric (dA.dT) DNA. Nmp4 isoforms contain from 5 to 8 Cys(2)His(2) zinc fingers, an SH3-binding domain that overlaps with a putative AT-hook and a polyglutamine-alanine repeat (poly(QA)). To determine the mechanistic significance of Cys(2)His(2) zinc finger association with this unusual consensus DNA binding element, we identified the Nmp4 DNA-binding and transcriptional activation domains. Zinc fingers 2, 3, and 6 mediated association with the homopolymeric (dA.dT) COL1A1/MMP DNA consensus element. The N terminus of the Nmp4 protein exhibited a strong trans-activation capacity when fused to the GAL4 DNA-binding domain, but this activity was masked within the context of the full-length Nmp4-GAL4 DNA-binding domain chimera. However, upon binding to the COL1A1/MMP homopolymeric (dA.dT) element, the native Nmp4 protein up-regulated transcription, and the poly(QA) domain acquired a significant role in trans-activation. We propose that allosteric effects induced upon zinc finger association with the homopolymeric (dA.dT) minor groove confer context-specific functionality to this unusual family of Cys(2)His(2) transcription factors.	Indiana Univ, Sch Med, Dept Anat & Cell Biol, Indianapolis, IN 46202 USA; Indiana Univ, Sch Dent, Dept Periodont, Indianapolis, IN 46202 USA; Lilly Res Labs, Gene Regulat Bone & Inflammat Res Div, Indianapolis, IN 46285 USA; Indiana Univ Purdue Univ, Dept Biol, Indianapolis, IN 46202 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Eli Lilly; Indiana University System; Indiana University-Purdue University Indianapolis	Bidwell, JP (corresponding author), Indiana Univ, Sch Med, Dept Anat & Cell Biol, Med Sci Bldg 5035,635 Barnhill Dr, Indianapolis, IN 46202 USA.	jbidwell@iupui.edu	torrungruang, kitti/ABH-5125-2020		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK053796, R01DK053796] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK53796-01A1] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abu-Daya A, 1997, NUCLEIC ACIDS RES, V25, P4962, DOI 10.1093/nar/25.24.4962; Alvarez M, 1998, J CELL BIOCHEM, V69, P336, DOI 10.1002/(SICI)1097-4644(19980601)69:3<336::AID-JCB11>3.0.CO;2-A; Alvarez M, 1997, ENDOCRINOLOGY, V138, P482, DOI 10.1210/en.138.1.482; Aravind L, 1998, NUCLEIC ACIDS RES, V26, P4413, DOI 10.1093/nar/26.19.4413; Beilin J, 2000, J MOL ENDOCRINOL, V25, P85, DOI 10.1677/jme.0.0250085; Bewley CA, 1998, ANNU REV BIOPH BIOM, V27, P105, DOI 10.1146/annurev.biophys.27.1.105; Bode J, 2000, CRIT REV EUKAR GENE, V10, P73; Bushmeyer SM, 1998, J CELL BIOCHEM, V68, P484, DOI 10.1002/(SICI)1097-4644(19980315)68:4<484::AID-JCB8>3.3.CO;2-F; Bustin M, 2001, TRENDS BIOCHEM SCI, V26, P152, DOI 10.1016/S0968-0004(00)01777-1; Bustin M, 1999, MOL CELL BIOL, V19, P5237; Chin MT, 1998, J BIOL CHEM, V273, P9755, DOI 10.1074/jbc.273.16.9755; CHURCHILL MEA, 1991, TRENDS BIOCHEM SCI, V16, P92, DOI 10.1016/0968-0004(91)90040-3; Currie RA, 1997, J BIOL CHEM, V272, P30880, DOI 10.1074/jbc.272.49.30880; Dreier B, 2001, J BIOL CHEM, V276, P29466, DOI 10.1074/jbc.M102604200; Feister HA, 2000, J CELL BIOCHEM, V79, P506, DOI 10.1002/1097-4644(20001201)79:3<506::AID-JCB150>3.3.CO;2-1; Furuya K, 2000, EXP CELL RES, V261, P329, DOI 10.1006/excr.2000.5051; Gogos JA, 1996, P NATL ACAD SCI USA, V93, P2159, DOI 10.1073/pnas.93.5.2159; GOGOS JA, 1992, SCIENCE, V257, P1951, DOI 10.1126/science.1290524; Grondin B, 1996, J BIOL CHEM, V271, P15458, DOI 10.1074/jbc.271.26.15458; He XY, 2000, J BIOL CHEM, V275, P11799, DOI 10.1074/jbc.275.16.11799; HSU T, 1992, SCIENCE, V257, P1946, DOI 10.1126/science.1411512; Iuchi S, 2001, CELL MOL LIFE SCI, V58, P625, DOI 10.1007/PL00000885; IYER V, 1995, EMBO J, V14, P2570, DOI 10.1002/j.1460-2075.1995.tb07255.x; JOHANSEN FE, 1993, MOL CELL BIOL, V13, P4640, DOI 10.1128/MCB.13.8.4640; KIM SK, 1993, FEBS LETT, V315, P61, DOI 10.1016/0014-5793(93)81133-K; Koch KA, 1999, J BIOL CHEM, V274, P23752, DOI 10.1074/jbc.274.34.23752; Lascaris RF, 2000, NUCLEIC ACIDS RES, V28, P1390, DOI 10.1093/nar/28.6.1390; Lefstin JA, 1998, NATURE, V392, P885, DOI 10.1038/31860; Li XY, 1996, GENE DEV, V10, P517, DOI 10.1101/gad.10.5.517; Lukens AK, 2000, NUCLEIC ACIDS RES, V28, P3853, DOI 10.1093/nar/28.20.3853; LUNDIN M, 1994, MOL CELL BIOL, V14, P1979, DOI 10.1128/MCB.14.3.1979; Luo X, 1996, MOL CELL BIOL, V16, P1367; Mackay JP, 1998, TRENDS BIOCHEM SCI, V23, P1, DOI 10.1016/S0968-0004(97)01168-7; McBryant SJ, 1996, NUCLEIC ACIDS RES, V24, P2567, DOI 10.1093/nar/24.13.2567; MUSACCHIO A, 1994, PROG BIOPHYS MOL BIO, V61, P283, DOI 10.1016/0079-6107(94)90003-5; Nakamoto T, 2000, MOL CELL BIOL, V20, P1649, DOI 10.1128/MCB.20.5.1649-1658.2000; NELSON HCM, 1987, NATURE, V330, P221, DOI 10.1038/330221a0; Nolte RT, 1998, P NATL ACAD SCI USA, V95, P2938, DOI 10.1073/pnas.95.6.2938; Reeves R, 2000, ENVIRON HEALTH PERSP, V108, P803, DOI 10.2307/3454310; Scully KM, 2000, SCIENCE, V290, P1127, DOI 10.1126/science.290.5494.1127; Segal DJ, 1999, P NATL ACAD SCI USA, V96, P2758, DOI 10.1073/pnas.96.6.2758; SEIPEL K, 1992, EMBO J, V11, P4961, DOI 10.1002/j.1460-2075.1992.tb05603.x; Shaw PE, 2000, METH MOL B, V148, P221; STANOJEVIC D, 1989, NATURE, V341, P331, DOI 10.1038/341331a0; Sune C, 1997, MOL CELL BIOL, V17, P6029, DOI 10.1128/MCB.17.10.6029; Suter B, 2000, NUCLEIC ACIDS RES, V28, P4083, DOI 10.1093/nar/28.21.4083; Tang HK, 1998, J BIOL CHEM, V273, P7210, DOI 10.1074/jbc.273.13.7210; THANOS D, 1992, CELL, V71, P777, DOI 10.1016/0092-8674(92)90554-P; Thirunavukkarasu K, 1998, MOL CELL BIOL, V18, P4197, DOI 10.1128/MCB.18.7.4197; Thunyakitpisal P, 2001, J BONE MINER RES, V16, P10, DOI 10.1359/jbmr.2001.16.1.10; Wolfe SA, 2000, ANNU REV BIOPH BIOM, V29, P183, DOI 10.1146/annurev.biophys.29.1.183; Zhang L, 2000, J BIOL CHEM, V275, P33850, DOI 10.1074/jbc.M005341200; ZHU H, 1993, MOL CELL BIOL, V13, P4432, DOI 10.1128/MCB.13.7.4432	53	25	29	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 3	2002	277	18					16153	16159		10.1074/jbc.M107496200	http://dx.doi.org/10.1074/jbc.M107496200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	550PA	11867614	hybrid			2022-12-27	WOS:000175510400124
J	Wang, YQ; Dohlman, HG				Wang, YQ; Dohlman, HG			Pheromone-dependent ubiquitination of the mitogen-activated protein kinase kinase Ste7	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOA4 DEUBIQUITINATING ENZYME; FREE POLYUBIQUITIN CHAINS; SACCHAROMYCES-CEREVISIAE; RESPONSE PATHWAY; SIGNAL-TRANSDUCTION; MAP KINASE; TRANSCRIPTION FACTOR; MATING PHEROMONE; FACTOR RECEPTOR; 26S PROTEASOME	Many cell signaling pathways are regulated by phosphorylation, ubiquitination, and degradation of constituent proteins. As with phosphorylation, protein ubiquitination can be reversed, through the action of ubiquitin-specific processing proteases (UBPs). Here we have analyzed 15 UBP disruption mutants in the yeast Saccharomyces cerevisiae and identified one (ubp3Delta) that acts specifically in the pheromone response pathway. Upon pheromone stimulation, ubp3Delta mutants accumulate unconjugated polyubiquitin chains as well as polyubiquitinated forms of the mitogen-activated protein kinase kinase Ste7. The ubp3Delta mutants exhibit a potentiated response to pheromone, as measured by in vivo MAP kinase activity, transcriptional induction, and cell cycle arrest. Signaling is likewise enhanced upon direct activation of Ste4 (G protein beta subunit) and Ste11 (Ste7 kinase) but not the downstream transcription factor Ste12. These findings reveal a mechanism by which pheromone-triggered ubiquitination of Ste7 can modulate the pheromone response in vivo.	Univ N Carolina, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill	Dohlman, HG (corresponding author), Univ N Carolina, Dept Biochem & Biophys, 405 Mary Ellen Jones Bldg,Campus Box 7260, Chapel Hill, NC 27599 USA.			Dohlman, Henrik/0000-0003-2443-0729	NIGMS NIH HHS [GM59167, R01 GM055316, R01 GM059167, GM55316] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059167, R01GM055316, R29GM055316] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Amerik AY, 2000, BIOL CHEM, V381, P981, DOI 10.1515/BC.2000.121; Amerik AY, 1997, EMBO J, V16, P4826; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BAKER RT, 1992, J BIOL CHEM, V267, P23364; Bardwell L, 1998, GENE DEV, V12, P2887, DOI 10.1101/gad.12.18.2887; Bardwell L, 1996, MOL CELL BIOL, V16, P3637; Beal R, 1996, P NATL ACAD SCI USA, V93, P861, DOI 10.1073/pnas.93.2.861; Chen ZJ, 1996, CELL, V84, P853, DOI 10.1016/S0092-8674(00)81064-8; Chung CY, 1998, GENE DEV, V12, P3564, DOI 10.1101/gad.12.22.3564; COLE GM, 1991, CELL, V64, P703, DOI 10.1016/0092-8674(91)90500-X; COLE GM, 1990, MOL CELL BIOL, V10, P510, DOI 10.1128/MCB.10.2.510; Cook JG, 1997, NATURE, V390, P85, DOI 10.1038/36355; DiAntonio A, 2001, NATURE, V412, P449, DOI 10.1038/35086595; Dohlman HG, 2001, ANNU REV BIOCHEM, V70, P703, DOI 10.1146/annurev.biochem.70.1.703; DOHLMAN HG, 1995, MOL CELL BIOL, V15, P3635; DOLAN JW, 1990, GENE DEV, V4, P492, DOI 10.1101/gad.4.4.492; Farley FW, 1999, GENETICS, V151, P1425; Garrison TR, 1999, J BIOL CHEM, V274, P36387, DOI 10.1074/jbc.274.51.36387; GHISLAIN M, 1993, NATURE, V366, P358, DOI 10.1038/366358a0; GUPTA K, 1993, ONCOGENE, V8, P2307; GUPTA K, 1994, ONCOGENE, V9, P1729; HADARI T, 1992, J BIOL CHEM, V267, P719; Hicke L, 1996, CELL, V84, P277, DOI 10.1016/S0092-8674(00)80982-4; Hicke L, 2001, NAT REV MOL CELL BIO, V2, P195, DOI 10.1038/35056583; Hicke L, 1998, J CELL BIOL, V141, P349, DOI 10.1083/jcb.141.2.349; HOCHSTRASSER M, 1990, CELL, V61, P697, DOI 10.1016/0092-8674(90)90481-S; Hochstrasser M, 1996, ANNU REV GENET, V30, P405, DOI 10.1146/annurev.genet.30.1.405; Hoffman GA, 2002, METHOD ENZYMOL, V344, P617; Huang YZ, 1996, DEVELOPMENT, V122, P3207; HUANG YZ, 1995, SCIENCE, V270, P1828, DOI 10.1126/science.270.5243.1828; Johnston SC, 1997, EMBO J, V16, P3787, DOI 10.1093/emboj/16.13.3787; Kaiser P, 2000, CELL, V102, P303, DOI 10.1016/S0092-8674(00)00036-2; Kim E, 1999, P NATL ACAD SCI USA, V96, P6371, DOI 10.1073/pnas.96.11.6371; Krupnick JG, 1998, ANNU REV PHARMACOL, V38, P289, DOI 10.1146/annurev.pharmtox.38.1.289; Larsen CN, 1996, BIOCHEMISTRY-US, V35, P6735, DOI 10.1021/bi960099f; Lindsey DF, 1998, J BIOL CHEM, V273, P29178, DOI 10.1074/jbc.273.44.29178; MADURA K, 1994, SCIENCE, V265, P1454, DOI 10.1126/science.8073290; Marchese A, 2001, J BIOL CHEM, V276, P45509, DOI 10.1074/jbc.C100527200; Moazed D, 1996, CELL, V86, P667, DOI 10.1016/S0092-8674(00)80139-7; NAKAMURA T, 1992, ONCOGENE, V7, P733; NOMOTO S, 1990, EMBO J, V9, P691, DOI 10.1002/j.1460-2075.1990.tb08161.x; Obin MS, 1996, J BIOL CHEM, V271, P14473, DOI 10.1074/jbc.271.24.14473; PAOLINI R, 1993, EMBO J, V12, P779, DOI 10.1002/j.1460-2075.1993.tb05712.x; Papa FR, 1999, MOL BIOL CELL, V10, P741, DOI 10.1091/mbc.10.3.741; PAPA FR, 1993, NATURE, V366, P313, DOI 10.1038/366313a0; Penela P, 1998, J BIOL CHEM, V273, P35238, DOI 10.1074/jbc.273.52.35238; Pickart CM, 2001, ANNU REV BIOCHEM, V70, P503, DOI 10.1146/annurev.biochem.70.1.503; RINE J, 1987, GENETICS, V116, P9; Roth AF, 1998, J CELL BIOL, V142, P949, DOI 10.1083/jcb.142.4.949; Shenoy SK, 2001, SCIENCE, V294, P1307, DOI 10.1126/science.1063866; Springael JY, 1999, J CELL SCI, V112, P1375; STEVENSON BJ, 1992, GENE DEV, V6, P1293, DOI 10.1101/gad.6.7.1293; Swaminathan S, 1999, MOL BIOL CELL, V10, P2583, DOI 10.1091/mbc.10.8.2583; Verma R, 2000, MOL BIOL CELL, V11, P3425, DOI 10.1091/mbc.11.10.3425; Voges D, 1999, ANNU REV BIOCHEM, V68, P1015, DOI 10.1146/annurev.biochem.68.1.1015; WHITEWAY M, 1990, MOL CELL BIOL, V10, P217, DOI 10.1128/MCB.10.1.217; Wilkinson KD, 2000, SEMIN CELL DEV BIOL, V11, P141, DOI 10.1006/scdb.2000.0164; WILKINSON KD, 1995, BIOCHEMISTRY-US, V34, P14535, DOI 10.1021/bi00044a032; ZHOU ZQ, 1993, MOL CELL BIOL, V13, P2069, DOI 10.1128/MCB.13.4.2069; Zhu Y, 1996, P NATL ACAD SCI USA, V93, P3275, DOI 10.1073/pnas.93.8.3275	60	39	39	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 3	2002	277	18					15766	15772		10.1074/jbc.M111733200	http://dx.doi.org/10.1074/jbc.M111733200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	550PA	11864977	hybrid			2022-12-27	WOS:000175510400074
J	Wolf, AA; Fujinaga, Y; Lencer, WI				Wolf, AA; Fujinaga, Y; Lencer, WI			Uncoupling of the cholera toxin-G(M1) ganglioside receptor complex from endocytosis, retrograde Golgi trafficking, and downstream signal transduction by depletion of membrane cholesterol	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GPI-ANCHORED PROTEINS; DETERGENT-RESISTANT MEMBRANES; TOXIN B-SUBUNIT; CELL-SURFACE; EPITHELIAL-CELLS; PHOSPHATIDYLCHOLINE BILAYERS; BIOLOGICAL-MEMBRANES; POLARIZED EPITHELIA; HIPPOCAMPAL-NEURONS; LABILE TOXIN	To induce toxicity, cholera toxin (CT) must first bind ganglioside G(M1) at the plasma membrane, enter the cell by endocytosis, and then traffic retrograde into the endoplasmic reticulum. We recently proposed that G(M1) provides the sorting motif necessary for retrograde trafficking into the biosynthetic/secretory pathway of host cells, and that such trafficking depends on association with lipid rafts and lipid raft function. To test this idea, we examined whether CT action in human intestinal T84 cells depends on membrane cholesterol. Chelation of cholesterol with 2-hydroxypropyl beta-cyclodextrin or methyl beta-cyclodextrin reversibly inhibited CT-induced chloride secretion and prolonged the time required for CT to enter the cell and induce toxicity. These effects were specific to CT, as identical conditions did not alter the potency or toxicity of anthrax edema toxin that enters the cell by another mechanism. We found that endocytosis and trafficking of CT into the Golgi apparatus depended on membrane cholesterol. Cholesterol depletion also changed the density and specific protein content of CT-associated lipid raft fractions but did not entirely displace the CT-G(M1) complex from these lipid raft microdomains. Taken together these data imply that cholesterol may function to couple the CT-G(M1) complex with raft domains and with other membrane components of the lipid raft required for CT entry into the cell.	Childrens Hosp, Dept Pediat, Gastrointestinal Cell Biol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; Harvard Digest Dis Ctr, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	Lencer, WI (corresponding author), Childrens Hosp, Dept Pediat, Gastrointestinal Cell Biol, 300 Longwood Ave, Boston, MA 02115 USA.			Lencer, Wayne/0000-0001-7346-2730	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK048106, R37DK048106, P30DK034854, F32DK009863] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK34854, DK48106, F32 DK09863] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abrami L, 1999, J CELL BIOL, V147, P175, DOI 10.1083/jcb.147.1.175; Badizadegan K, 2000, AM J PHYSIOL-GASTR L, V278, pG895, DOI 10.1152/ajpgi.2000.278.6.G895; Bagnat M, 2000, P NATL ACAD SCI USA, V97, P3254, DOI 10.1073/pnas.060034697; Beauregard KE, 1999, INFECT IMMUN, V67, P3026, DOI 10.1128/IAI.67.6.3026-3030.1999; Brown DA, 1997, BIOCHEM BIOPH RES CO, V240, P1, DOI 10.1006/bbrc.1997.7575; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; Brown DA, 1998, J MEMBRANE BIOL, V164, P103, DOI 10.1007/s002329900397; Bundgaard JR, 1997, J BIOL CHEM, V272, P21700, DOI 10.1074/jbc.272.35.21700; Christian AE, 1997, J LIPID RES, V38, P2264; Falguieres T, 2001, MOL BIOL CELL, V12, P2453, DOI 10.1091/mbc.12.8.2453; FIEDLER K, 1993, BIOCHEMISTRY-US, V32, P6365, DOI 10.1021/bi00076a009; Francis SA, 1999, EUR J CELL BIOL, V78, P473, DOI 10.1016/S0171-9335(99)80074-0; Fuki IV, 2000, BIOCHEM J, V351, P607, DOI 10.1042/0264-6021:3510607; Furuchi T, 1998, J BIOL CHEM, V273, P21099, DOI 10.1074/jbc.273.33.21099; Gimpl G, 1997, BIOCHEMISTRY-US, V36, P10959, DOI 10.1021/bi963138w; Green JM, 1999, J CELL BIOL, V146, P673, DOI 10.1083/jcb.146.3.673; Grimmer S, 2000, MOL BIOL CELL, V11, P4205, DOI 10.1091/mbc.11.12.4205; Hansen GH, 2000, J BIOL CHEM, V275, P5136, DOI 10.1074/jbc.275.7.5136; HUTTNER WB, 1988, ANNU REV PHYSIOL, V50, P363, DOI 10.1146/annurev.ph.50.030188.002051; Iwabuchi K, 1998, J BIOL CHEM, V273, P33766, DOI 10.1074/jbc.273.50.33766; Katagiri YU, 1999, J BIOL CHEM, V274, P35278, DOI 10.1074/jbc.274.49.35278; Keller P, 1998, J CELL BIOL, V140, P1357, DOI 10.1083/jcb.140.6.1357; KILSDONK EPC, 1995, J BIOL CHEM, V270, P17250, DOI 10.1074/jbc.270.29.17250; LENCER WI, 1992, J CELL BIOL, V117, P1197, DOI 10.1083/jcb.117.6.1197; LENCER WI, 1995, P NATL ACAD SCI USA, V92, P10094, DOI 10.1073/pnas.92.22.10094; LENCER WI, 1995, J CELL BIOL, V131, P951, DOI 10.1083/jcb.131.4.951; Lencer WI, 1999, BBA-MOL CELL RES, V1450, P177, DOI 10.1016/S0167-4889(99)00070-1; Lencer WI, 2001, AM J PHYSIOL-GASTR L, V280, pG781, DOI 10.1152/ajpgi.2001.280.5.G781; Lencer WI, 1997, J BIOL CHEM, V272, P15562, DOI 10.1074/jbc.272.24.15562; MAYOR S, 1994, SCIENCE, V264, P1948, DOI 10.1126/science.7516582; Mayor S, 1998, EMBO J, V17, P4626, DOI 10.1093/emboj/17.16.4626; MOYA M, 1985, J CELL BIOL, V101, P548, DOI 10.1083/jcb.101.2.548; Neufeld EB, 1996, J BIOL CHEM, V271, P21604, DOI 10.1074/jbc.271.35.21604; Nichols BJ, 2001, J CELL BIOL, V153, P529, DOI 10.1083/jcb.153.3.529; Nusrat A, 2000, J CELL SCI, V113, P1771; Orlandi PA, 1998, J CELL BIOL, V141, P905, DOI 10.1083/jcb.141.4.905; Parpal S, 2001, J BIOL CHEM, V276, P9670, DOI 10.1074/jbc.M007454200; PARTON RG, 1994, J HISTOCHEM CYTOCHEM, V42, P155, DOI 10.1177/42.2.8288861; PARTON RG, 1995, SCIENCE, V269, P1398, DOI 10.1126/science.7660120; Peyron P, 2000, J IMMUNOL, V165, P5186, DOI 10.4049/jimmunol.165.9.5186; Pike LJ, 1998, J BIOL CHEM, V273, P22298, DOI 10.1074/jbc.273.35.22298; RESTA R, 1993, GENE, V133, P171, DOI 10.1016/0378-1119(93)90635-G; ROCK P, 1990, BIOCHEMISTRY-US, V29, P8484, DOI 10.1021/bi00488a040; ROCK P, 1991, BIOCHEMISTRY-US, V30, P19, DOI 10.1021/bi00215a003; Rodal SK, 1999, MOL BIOL CELL, V10, P961, DOI 10.1091/mbc.10.4.961; Rodighiero C, 1999, J BIOL CHEM, V274, P3962, DOI 10.1074/jbc.274.7.3962; Rodighiero C, 2001, J BIOL CHEM, V276, P36939, DOI 10.1074/jbc.M104245200; SCHNITZER JE, 1994, J CELL BIOL, V127, P1217, DOI 10.1083/jcb.127.5.1217; SCHROEDER R, 1994, P NATL ACAD SCI USA, V91, P12130, DOI 10.1073/pnas.91.25.12130; Schroeder RJ, 1998, J BIOL CHEM, V273, P1150, DOI 10.1074/jbc.273.2.1150; Sheets ED, 1999, J CELL BIOL, V145, P877, DOI 10.1083/jcb.145.4.877; Shogomori H, 2001, J BIOL CHEM, V276, P9182, DOI 10.1074/jbc.M009414200; Simons K, 2000, SCIENCE, V290, P1721, DOI 10.1126/science.290.5497.1721; Sooksawate T, 2001, NEUROPHARMACOLOGY, V40, P178, DOI 10.1016/S0028-3908(00)00159-3; Stulnig TM, 1997, J BIOL CHEM, V272, P19242, DOI 10.1074/jbc.272.31.19242; Subtil A, 1999, P NATL ACAD SCI USA, V96, P6775, DOI 10.1073/pnas.96.12.6775; Tsai B, 2001, CELL, V104, P937, DOI 10.1016/S0092-8674(01)00289-6; VAN MEER G, 1987, J CELL BIOL, V105, P1623, DOI 10.1083/jcb.105.4.1623; Wolf AA, 1998, J CELL BIOL, V141, P917, DOI 10.1083/jcb.141.4.917	59	87	89	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 3	2002	277	18					16249	16256		10.1074/jbc.M109834200	http://dx.doi.org/10.1074/jbc.M109834200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	550PA	11859071	hybrid			2022-12-27	WOS:000175510400135
J	Kim, HJ; Song, EJ; Lee, KJ				Kim, HJ; Song, EJ; Lee, KJ			Proteomic analysis of protein phosphorylations in heat shock response and thermotolerance	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL-GROWTH-FACTOR; FLIGHT-MASS-SPECTROMETRY; FACTOR-RECEPTOR KINASE; TYROSINE PHOSPHORYLATION; PHOSPHOLIPASE-C; DNA-BINDING; VIMENTIN FILAMENTS; MAMMALIAN-CELLS; MAPKAP KINASE-2; ACTIVATION	Heat shock (HS) induces a wide variety of biological processes, including inhibition of protein synthesis, elevated expression of heat shock proteins, induction of thermotolerance, and apoptotic cell death in a dose-dependent manner. We compared phosphorylated proteins in heat-shocked and thermotolerant cells using proteome analysis. After HS treatment of control RIF-1 and their thermotolerant derivatives, TR-RIF-1 cells, cellular proteins were separated by two-dimensional gel electrophoresis and the phosphorylated proteins were detected with the anti-phosphotyrosine antibodies. We found that 93 proteins showed significant changes in phosphorylation between control and thermotolerant cells as a function of recovery time after HS; we identified 81 of these proteins with peptide mass fingerprinting using MALDI-TOF MS after in-gel trypsin digestion. These phosphorylated proteins exhibit various cellular functions, including chaperones, ion channels, signaling molecules, in transcription and translation processes, amino acid biosynthesis, oxidoreduction, energy metabolism, and cell motility or structure, suggesting that HS turns on the various signaling pathways by activating protein-tyrosine kinases (PTKs). Of these, 20 proteins were previously identified phosphorylated proteins and 64 were newly identified. These proteins can be grouped into three families: 1) proteins highly phosphorylated in TR-RIF-1 cells at basal level and phosphorylated more significantly by HS in RIF-1 than TR-RIF-1; 2) proteins highly phosphorylated in control RIF-1 cells at basal level and phosphorylated more easily by HS in TR-RIF-1 than in RIF-1 cells; and 3) proteins with a similar basal phosphorylation level in both RIF-1 and TR-RIF-1 cells and responding to HS similarly in both cells. Most of the phosphorylated proteins are presumably involved in HS signaling in different ways, with the first and second families of proteins influencing thermotolerance. The possible tyrosine phosphorylation sites, the possible PTKs phosphorylating these proteins, and the proteins binding to these phosphorylated sites were predicted by the Netphos, ScanProsite, and Scansite programs. These results suggest that HS can activate various PTKs and HS responses can be regulated by phosphorylations of proteins having various functions.	Ewha Womans Univ, Div Mol Life Sci, Seoul 120750, South Korea; Ewha Womans Univ, Coll Pharm, Seoul 120750, South Korea; Ewha Womans Univ, Ctr Cell Signaling Res, Seoul 120750, South Korea	Ewha Womans University; Ewha Womans University; Ewha Womans University	Lee, KJ (corresponding author), Ewha Womans Univ, Div Mol Life Sci, Seoul 120750, South Korea.	kjl@mm.ewha.ac.kr		Song, Eun Joo/0000-0002-2420-6666; Lee, Kong-Joo/0000-0001-7972-6020				ADLER V, 1995, J BIOL CHEM, V270, P26071, DOI 10.1074/jbc.270.44.26071; Bellagamba C, 1997, J BIOL CHEM, V272, P3195, DOI 10.1074/jbc.272.6.3195; BENDINELLI P, 1995, BIOCHEM BIOPH RES CO, V216, P54, DOI 10.1006/bbrc.1995.2591; CALDERWOOD SK, 1993, J CELL PHYSIOL, V155, P248, DOI 10.1002/jcp.1041550205; CALDERWOOD SK, 1993, J CELL PHYSIOL, V156, P153, DOI 10.1002/jcp.1041560121; CHEN F, 1995, BIOCHEM J, V312, P341, DOI 10.1042/bj3120341; COOPER JA, 1984, J BIOL CHEM, V259, P7835; CRAIG EA, 1985, CRC CR REV BIOCH MOL, V18, P239, DOI 10.3109/10409238509085135; DUBOIS MF, 1991, CR ACAD SCI III-VIE, V313, P165; DUBOIS MF, 1993, FEBS LETT, V324, P191, DOI 10.1016/0014-5793(93)81391-C; DUNCAN RF, 1989, J CELL BIOL, V109, P467; ERDOS G, 1995, J CELL PHYSIOL, V164, P404, DOI 10.1002/jcp.1041640221; ERIKSON RL, 1991, J BIOL CHEM, V266, P6007; GLOVER CVC, 1981, CELL, V23, P73, DOI 10.1016/0092-8674(81)90271-3; GRIMA DT, 1994, BIOCHEMISTRY-US, V33, P2921, DOI 10.1021/bi00176a023; HAHN GM, 1988, CANCER RES, V48, P1803; JURIVICH DA, 1991, J CELL PHYSIOL, V148, P252, DOI 10.1002/jcp.1041480210; KARASIK A, 1988, J BIOL CHEM, V263, P11862; KIANG JG, 1993, AM J PHYSIOL, V264, pC1561, DOI 10.1152/ajpcell.1993.264.6.C1561; Kim HJ, 2002, MOL CELL BIOCHEM, V229, P139, DOI 10.1023/A:1017941131744; Knowlton AA, 2000, AM J PHYSIOL-HEART C, V278, pH2143, DOI 10.1152/ajpheart.2000.278.6.H2143; KRISHNAN HB, 1987, BIOCHEM BIOPH RES CO, V148, P762, DOI 10.1016/0006-291X(87)90941-7; LANDER HM, 1992, CELL IMMUNOL, V145, P146, DOI 10.1016/0008-8749(92)90319-K; LANDRY J, 1988, RADIAT RES, V113, P426, DOI 10.2307/3577240; LARSON JS, 1988, NATURE, V335, P372, DOI 10.1038/335372a0; Lee SY, 2001, CELL DEATH DIFFER, V8, P1093, DOI 10.1038/sj.cdd.4400923; LEGAGNEUX V, 1990, EUR J BIOCHEM, V193, P121, DOI 10.1111/j.1432-1033.1990.tb19312.x; Lin RZ, 1997, J BIOL CHEM, V272, P31196, DOI 10.1074/jbc.272.49.31196; LINDQUIST S, 1986, ANNU REV BIOCHEM, V55, P1151, DOI 10.1146/annurev.bi.55.070186.005443; LIS JT, 1992, TRANSCRIPTIONAL REGU, V2, P907; LUTZ Y, 1988, EXP CELL RES, V175, P109, DOI 10.1016/0014-4827(88)90259-5; MAHER PA, 1989, J CELL BIOL, V108, P2029, DOI 10.1083/jcb.108.6.2029; Marcus K, 2000, ELECTROPHORESIS, V21, P2622, DOI 10.1002/1522-2683(20000701)21:13<2622::AID-ELPS2622>3.0.CO;2-3; Otto H, 2001, EUR J BIOCHEM, V268, P420, DOI 10.1046/j.1432-1033.2001.01901.x; PEPINSKY RB, 1991, METHOD ENZYMOL, V198, P260; PYPE S, 1994, J BIOL CHEM, V269, P31457; Quadroni M, 1999, ELECTROPHORESIS, V20, P664, DOI 10.1002/(SICI)1522-2683(19990101)20:4/5<664::AID-ELPS664>3.0.CO;2-A; REISS N, 1986, BIOCHEM J, V239, P691, DOI 10.1042/bj2390691; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; SARGE KD, 1993, MOL CELL BIOL, V13, P1392, DOI 10.1128/MCB.13.3.1392; Sechi S, 1998, ANAL CHEM, V70, P5150, DOI 10.1021/ac9806005; Sheffield LG, 1998, J ENDOCRINOL, V159, P111, DOI 10.1677/joe.0.1590111; Skouteris GG, 1996, J BIOL CHEM, V271, P27266, DOI 10.1074/jbc.271.44.27266; SORGER PK, 1988, CELL, V54, P855, DOI 10.1016/S0092-8674(88)91219-6; Soskic V, 1999, BIOCHEMISTRY-US, V38, P1757, DOI 10.1021/bi982093r; Steen H, 2002, J BIOL CHEM, V277, P1031, DOI 10.1074/jbc.M109992200; STOKOE D, 1992, FEBS LETT, V313, P307, DOI 10.1016/0014-5793(92)81216-9; SUBJECK JR, 1986, AM J PHYSIOL, V250, pC1, DOI 10.1152/ajpcell.1986.250.1.C1; SYGUSCH J, 1990, ARCH BIOCHEM BIOPHYS, V283, P227, DOI 10.1016/0003-9861(90)90636-D; Valgeirsdottir S, 1998, J CELL SCI, V111, P1973; van Oordt WV, 2000, J CELL BIOL, V149, P307, DOI 10.1083/jcb.149.2.307; Welch W J, 1987, Adv Exp Med Biol, V225, P287; Yanagida M, 2000, ELECTROPHORESIS, V21, P1890; YANG JM, 1995, BIOCHEM BIOPH RES CO, V210, P21, DOI 10.1006/bbrc.1995.1622	54	49	51	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 28	2002	277	26					23193	23207		10.1074/jbc.M201007200	http://dx.doi.org/10.1074/jbc.M201007200			15	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	567FX	11886868	hybrid			2022-12-27	WOS:000176475700015
J	Brin, E; Leis, J				Brin, E; Leis, J			HIV-1 integrase interaction with U3 and U5 terminal sequences in vitro defined using substrates with random sequences	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; VIRAL-DNA; IN-VITRO; REVERSE TRANSCRIPTION; RETROVIRAL DNA; PROTEIN; COMPLEXES; ENDS; RECOGNITION; INITIATION	Successful integration of viral genome into a host chromosome depends on interaction between viral integrase and its recognition sequences. We have used a reconstituted concerted human immunodeficiency virus, type 1 (HIV-1), integration system to analyze the role of integrase (IN) recognition sequences in formation of the IN-viral DNA complex capable of concerted integration. HIV-1 integrase was presented with substrates that contained all 4 bases at 8 mismatched positions that define the inverted repeat relationship between U3 and U5 long terminal repeats (LTR) termini and at positions 17-19, which are conserved in the termini. Evidence presented indicates that positions 17-20 of the IN recognition sequences are needed for a concerted DNA integration mechanism. All 4 bases were found at each randomized position in sequenced concerted DNA integrants, although in some instances there were preferences for specific bases. These results indicate that integrase tolerates a significant amount of plasticity as to what constitutes an IN recognition sequence. By having several positions randomized, the concerted integrants were examined for statistically significant relationships between selections of bases at different positions. The results of this analysis show not only relationships between different positions within the same LTR end but also between different positions belonging to opposite DNA termini.	Northwestern Univ, Sch Med, Dept Microbiol & Immunol, Chicago, IL 60611 USA	Northwestern University	Leis, J (corresponding author), Northwestern Univ, Sch Med, Dept Microbiol & Immunol, 303 E Chicago Ave, Chicago, IL 60611 USA.				NATIONAL CANCER INSTITUTE [R01CA038046, R01CA052047] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA038046-16, CA38046, R01 CA052047-12, CA52047, R01 CA052047] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AIYAR A, 1994, J VIROL, V68, P611, DOI 10.1128/JVI.68.2.611-618.1994; Aiyar A, 1996, J VIROL, V70, P3571, DOI 10.1128/JVI.70.6.3571-3580.1996; Brin E, 2002, J BIOL CHEM, V277, P10938, DOI 10.1074/jbc.M108116200; Carteau S, 1999, J VIROL, V73, P6670, DOI 10.1128/JVI.73.8.6670-6679.1999; COBRINIK D, 1991, J VIROL, V65, P3864, DOI 10.1128/JVI.65.7.3864-3872.1991; ENGELMAN A, 1991, CELL, V67, P1211, DOI 10.1016/0092-8674(91)90297-C; Esposito D, 1998, EMBO J, V17, P5832, DOI 10.1093/emboj/17.19.5832; Farnet CM, 1997, CELL, V88, P483, DOI 10.1016/S0092-8674(00)81888-7; Gao K, 2001, EMBO J, V20, P3565, DOI 10.1093/emboj/20.13.3565; Hindmarsh P, 1999, J VIROL, V73, P2994, DOI 10.1128/JVI.73.4.2994-3003.1999; Hindmarsh P, 1999, MICROBIOL MOL BIOL R, V63, P836, DOI 10.1128/MMBR.63.4.836-843.1999; KATZMAN M, 1989, J VIROL, V63, P5319, DOI 10.1128/JVI.63.12.5319-5327.1989; McCord M, 1999, VIROLOGY, V259, P392, DOI 10.1006/viro.1999.9782; Miller JT, 1997, J VIROL, V71, P7648, DOI 10.1128/JVI.71.10.7648-7656.1997; Morgan AL, 2000, J GEN VIROL, V81, P839, DOI 10.1099/0022-1317-81-3-839; MUESING MA, 1985, NATURE, V313, P450, DOI 10.1038/313450a0; MURPHY JE, 1992, J VIROL, V66, P5092, DOI 10.1128/JVI.66.8.5092-5095.1992; NISSEN MS, 1995, J BIOL CHEM, V270, P4355, DOI 10.1074/jbc.270.9.4355; Rice PA, 2001, NAT STRUCT BIOL, V8, P302, DOI 10.1038/86166; SHERMAN PA, 1992, J VIROL, V66, P3593, DOI 10.1128/JVI.66.6.3593-3601.1992; Wei SQ, 1998, P NATL ACAD SCI USA, V95, P10535, DOI 10.1073/pnas.95.18.10535; Yi JZ, 1999, BIOCHEMISTRY-US, V38, P8458, DOI 10.1021/bi982870n; Zhou HB, 2001, J VIROL, V75, P1359, DOI 10.1128/JVI.75.3.1359-1370.2001	23	16	16	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 24	2002	277	21					18357	18364		10.1074/jbc.M201354200	http://dx.doi.org/10.1074/jbc.M201354200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	558PM	11897790	Green Accepted, hybrid			2022-12-27	WOS:000175975800015
J	Garcia-Ortega, L; Masip, M; Mancheno, JM; Onaderra, M; Lizarbe, MA; Garcia-Mayoral, MF; Bruix, M; del Pozo, AM; Gavilanes, JG				Garcia-Ortega, L; Masip, M; Mancheno, JM; Onaderra, M; Lizarbe, MA; Garcia-Mayoral, MF; Bruix, M; del Pozo, AM; Gavilanes, JG			Deletion of the NH2-terminal beta-hairpin of the ribotoxin alpha-sarcin produces a nontoxic but active ribonuclease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBOSOME-INACTIVATING PROTEIN; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; FUNGAL RIBOTOXINS; CYTOTOXIN; PURIFICATION; RECOGNITION; MITOGILLIN; MECHANISM; SEQUENCE	Ribotoxins are a family of highly specific fungal ribonucleases that inactivate the ribosomes by hydrolysis of a single phosphodiester bond of the 28 S rRNA. alpha-Sarcin, the best characterized member of this family, is a potent cytotoxin that promotes apoptosis of human tumor cells after internalization via endocytosis. This latter ability is related to its interaction with phospholipid bilayers. These proteins share a common structural core with nontoxic ribonucleases of the RNase T1 family. However, significant structural differences between these two groups of proteins are related to the presence of a long amino-terminal beta-hairpin in ribotoxins and to the different length of their unstructured loops. The amino-terminal deletion mutant Delta(7-22) of alpha-sarcin has been produced in Escherichia coli and purified to homogeneity. It retains the same conformation as the wild-type protein as ascertained by complete spectroscopic characterization based on circular dichroism, fluorescence, and NMR techniques. This mutant exhibits ribonuclease activity against naked rRNA and synthetic substrates but lacks the specific ability of the wild-type protein to degrade rRNA in intact ribosomes. The results indicate that alpha-sarcin interacts with the ribosome at two regions, i.e. the well known sarcin-ricin loop of the rRNA and a different region recognized by the beta-hairpin of the protein. In addition, this latter protein portion is involved in interaction with cell membranes. The mutant displays decreased interaction with lipid vesicles and shows behavior compatible with the absence of one vesicle-interacting region. In agreement with this conclusion, the deletion mutant exhibits a very low cytotoxicity on human rhabdomyosarcoma cells.	Univ Complutense, Fac Quim, Dept Bioquim & Biol Mol 1, E-28040 Madrid, Spain; CSIC, Inst Quim Fis Rocasolano, E-28006 Madrid, Spain	Complutense University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Quimica Fisica Rocasolano (IQFR)	del Pozo, AM (corresponding author), Univ Complutense, Fac Quim, Dept Bioquim & Biol Mol, E-28040 Madrid, Spain.	alvaro@bbm1.ucm.es; ppgf@bbm1.ucm.es	OÑADERRA, Mercedes/H-2527-2015; Mancheno, Jose/K-4984-2014; Lizarbe, M Antonia/K-5219-2014; Gavilanes, Jose G./K-5307-2014; Bruix, Marta/H-4161-2011; Garcia-Ortega, Lucia/J-3278-2016; Martinez-del-Pozo, Alvaro/L-8556-2014	OÑADERRA, Mercedes/0000-0003-2564-5609; Mancheno, Jose/0000-0001-6943-3291; Lizarbe, M Antonia/0000-0003-1722-1240; Gavilanes, Jose G./0000-0002-6852-341X; Bruix, Marta/0000-0002-0096-3558; Garcia-Ortega, Lucia/0000-0003-3479-2213; Martinez-del-Pozo, Alvaro/0000-0003-0043-5939				Barlett G.R., 1959, J BIOL CHEM, V234, P466; BAX A, 1985, J MAGN RESON, V65, P355, DOI 10.1016/0022-2364(85)90018-6; BECKTEL WJ, 1987, BIOPOLYMERS, V26, P1859, DOI 10.1002/bip.360261104; BETTER M, 1992, J BIOL CHEM, V267, P16712; BLANK A, 1982, ANAL BIOCHEM, V120, P267, DOI 10.1016/0003-2697(82)90347-5; CamposOlivas R, 1996, PROTEIN SCI, V5, P969; Correll CC, 1999, J MOL BIOL, V292, P275, DOI 10.1006/jmbi.1999.3072; Correll CC, 1998, P NATL ACAD SCI USA, V95, P13436, DOI 10.1073/pnas.95.23.13436; de Antonio C, 2000, PROTEINS, V41, P350, DOI 10.1002/1097-0134(20001115)41:3<350::AID-PROT70>3.0.CO;2-V; EFTINK MR, 1983, BIOCHEMISTRY-US, V22, P5134, DOI 10.1021/bi00291a012; EGAMI F, 1980, MOL BIOL BIOCH BIOPH, P250; ENDO Y, 1990, J BIOL CHEM, V265, P2216; ENDO Y, 1982, J BIOL CHEM, V257, P9054; Garcia-Ortega L, 2000, LETT APPL MICROBIOL, V30, P298, DOI 10.1046/j.1472-765x.2000.00714.x; Garcia-Ortega L, 2001, PROTEIN SCI, V10, P1658, DOI 10.1110/ps.9601; GASSET M, 1989, BIOCHEM J, V258, P569, DOI 10.1042/bj2580569; GASSET M, 1990, BIOCHEM J, V265, P815, DOI 10.1042/bj2650815; HERTLER AA, 1989, J CLIN ONCOL, V7, P1932, DOI 10.1200/JCO.1989.7.12.1932; KANAYA S, 1995, J BIOCHEM-TOKYO, V118, P681, DOI 10.1093/oxfordjournals.jbchem.a124964; Kao R, 1999, J BIOL CHEM, V274, P12576, DOI 10.1074/jbc.274.18.12576; Kao R, 1995, BIOCHEM CELL BIOL, V73, P1151, DOI 10.1139/o95-124; Kao R, 2001, METHOD ENZYMOL, V341, P324, DOI 10.1016/S0076-6879(01)41161-X; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; KRAULIS PJ, 1994, BIOCHEMISTRY-US, V33, P3515, DOI 10.1021/bi00178a008; KUMAR A, 1980, BIOCHEM BIOPH RES CO, V95, P1, DOI 10.1016/0006-291X(80)90695-6; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KURUP VP, 1991, CLIN MICROBIOL REV, V4, P439, DOI 10.1128/CMR.4.4.439-456.1991; Lacadena J, 1999, PROTEINS, V37, P474, DOI 10.1002/(SICI)1097-0134(19991115)37:3<474::AID-PROT14>3.0.CO;2-N; LACADENA J, 1994, GENE, V142, P147, DOI 10.1016/0378-1119(94)90370-0; LACADENA J, 1995, BIOCHEM J, V309, P581, DOI 10.1042/bj3090581; Lacadena J, 1998, FEBS LETT, V424, P46, DOI 10.1016/S0014-5793(98)00137-9; Lamy B., 1992, GENETICALLY ENG TOXI, P237; Loverix S, 1998, EUR J BIOCHEM, V257, P286, DOI 10.1046/j.1432-1327.1998.2570286.x; MANCHENO JM, 1994, BIOPHYS J, V67, P1117, DOI 10.1016/S0006-3495(94)80578-8; MANCHENO JM, 1995, BIOPHYS J, V68, P2387, DOI 10.1016/S0006-3495(95)80421-2; MANCHENO JM, 1995, J THEOR BIOL, V172, P259, DOI 10.1006/jtbi.1995.0022; Mancheno JM, 1998, J PEPT RES, V51, P142; Martinez-Ruiz A, 2000, FEMS MICROBIOL LETT, V189, P165, DOI 10.1111/j.1574-6968.2000.tb09224.x; Martinez-Ruiz A, 2001, METHODS ENZYMOL, V341, P335, DOI 10.1016/S0076-6879(01)41162-1; Masip M, 2001, EUR J BIOCHEM, V268, P6190, DOI 10.1046/j.0014-2956.2001.02566.x; MOSER M, 1992, J IMMUNOL, V149, P454; Moussaoui M, 1998, J BIOL CHEM, V273, P25565, DOI 10.1074/jbc.273.40.25565; NOGUCHI S, 1995, BIOCHEMISTRY-US, V34, P15583, DOI 10.1021/bi00047a025; Olmo N, 2001, EUR J BIOCHEM, V268, P2113, DOI 10.1046/j.1432-1327.2001.02086.x; OLSON BH, 1965, APPL MICROBIOL, V13, P314, DOI 10.1128/AEM.13.3.314-321.1965; ONADERRA M, 1993, BIOCHEM J, V295, P221, DOI 10.1042/bj2950221; Onaderra M, 1998, MOL MEMBR BIOL, V15, P141, DOI 10.3109/09687689809074525; PERCZEL A, 1991, PROTEIN ENG, V4, P669, DOI 10.1093/protein/4.6.669; Perez-Canadillas JM, 1998, BIOCHEMISTRY-US, V37, P15865, DOI 10.1021/bi981672t; Perez-Canadillas JM, 2000, J MOL BIOL, V299, P1061, DOI 10.1006/jmbi.2000.3813; PIOTTO M, 1992, J BIOMOL NMR, V2, P661, DOI 10.1007/BF02192855; RUSHIZKY GW, 1970, BIOCHEMISTRY-US, V9, P4966, DOI 10.1021/bi00827a021; SACCO G, 1983, J BIOL CHEM, V258, P5811; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SATO S, 1975, BIOCHEM J, V145, P353, DOI 10.1042/bj1450353; SCHINDLER DG, 1977, NUCLEIC ACIDS RES, V4, P1097, DOI 10.1093/nar/4.4.1097; Steyaert J, 1997, EUR J BIOCHEM, V247, P1, DOI 10.1111/j.1432-1033.1997.t01-1-00001.x; TURNAY J, 1993, MOL CELL BIOCHEM, V122, P39, DOI 10.1007/BF00925735; Uchida T., 1971, ENZYMES, V4, P205; WAWRZYNCZAK EJ, 1991, EUR J BIOCHEM, V196, P203, DOI 10.1111/j.1432-1033.1991.tb15805.x; Wuthrich K, 1986, NMR PROTEINS NUCL AC; Yang XJ, 1996, STRUCTURE, V4, P837, DOI 10.1016/S0969-2126(96)00090-1; Yang XJ, 2001, NAT STRUCT BIOL, V8, P968, DOI 10.1038/nsb1101-968; YASUKAWA T, 1995, J BIOL CHEM, V270, P25328, DOI 10.1074/jbc.270.43.25328; Yoshida H, 2001, METHOD ENZYMOL, V341, P28, DOI 10.1016/S0076-6879(01)41143-8	65	44	45	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 24	2002	277	21					18632	18639		10.1074/jbc.M200922200	http://dx.doi.org/10.1074/jbc.M200922200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	558PM	11897788	Green Published, hybrid			2022-12-27	WOS:000175975800053
J	Schafer, MA; Tastan, AO; Patzke, S; Blaha, G; Spahn, CMT; Wilson, DN; Nierhaus, KH				Schafer, MA; Tastan, AO; Patzke, S; Blaha, G; Spahn, CMT; Wilson, DN; Nierhaus, KH			Codon-anticodon interaction at the P site is a prerequisite for tRNA interaction with the small ribosomal subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI RIBOSOMES; TRANSFER-RNA BINDING; ANGSTROM RESOLUTION; A-SITE; CRYSTAL-STRUCTURE; DECODING REGION; 70S RIBOSOME; PROTEIN L2; TRANSLOCATION; LOOP	The arrival of high resolution crystal structures for the ribosomal subunits opens a new phase of molecular analysis and asks for corresponding analyses of ribosomal function. Here we apply the phosphorothioate technique to dissect tRNA interactions with the ribosome. We demonstrate that a tRNA bound to the P site of non-programmed 70 S ribosomes contacts predominantly the 50 S, as opposed to the 30 S subunit, indicating that codon-anticodon interaction at the P site is a prerequisite for 30 S binding. Protection patterns of tRNAs bound to isolated subunits and programmed 70 S ribosomes were compared. The results suggest the presence of a movable domain in the large ribosomal subunit that carries tRNA and reveal that only similar to15% of a tRNA, namely residues 30 +/- 1 to 43 +/- 1, contact the 30 S subunit of programmed 70 S ribosomes, whereas the remaining 85% make contact with the 50 S subunit. Identical protection patterns of two distinct elongator tRNAs at the P site were identified as tRNA species-independent phosphate backbone contacts. The sites of protection correlate nicely with the predicted ribosomal-tRNA contacts deduced from a 5.5-Angstrom crystal structure of a programmed 70 S ribosome, thus refining which ribosomal components are critical for tRNA fixation at the P site.	AG Ribosomen, Max Planck Inst Mol Genet, D-14195 Berlin, Germany	Max Planck Society	Nierhaus, KH (corresponding author), AG Ribosomen, Max Planck Inst Mol Genet, Ihnestr 73, D-14195 Berlin, Germany.		Bishop, Ozlem Tastan/J-3084-2016; Wilson, Daniel/AAE-8504-2019; Patzke, Sebastian/G-9909-2019	Bishop, Ozlem Tastan/0000-0001-6861-7849; Wilson, Daniel/0000-0003-3816-3828; Patzke, Sebastian/0000-0001-6821-197X				Agrawal RK, 1999, J BIOL CHEM, V274, P8723, DOI 10.1074/jbc.274.13.8723; Agrawal RK, 2000, J CELL BIOL, V150, P447, DOI 10.1083/jcb.150.3.447; Ban N, 2000, SCIENCE, V289, P905, DOI 10.1126/science.289.5481.905; BOMMER U, 1996, SUBCELLULAR FRACTION, P271; Brodersen DE, 2000, CELL, V103, P1143, DOI 10.1016/S0092-8674(00)00216-6; Carter AP, 2001, SCIENCE, V291, P498, DOI 10.1126/science.1057766; Carter AP, 2000, NATURE, V407, P340, DOI 10.1038/35030019; CORPET F, 1988, NUCLEIC ACIDS RES, V16, P10881, DOI 10.1093/nar/16.22.10881; Dabrowski M, 1998, J BIOL CHEM, V273, P32793, DOI 10.1074/jbc.273.49.32793; DABROWSKI M, 1995, EMBO J, V14, P4872, DOI 10.1002/j.1460-2075.1995.tb00168.x; Diedrich G, 2000, EMBO J, V19, P5241, DOI 10.1093/emboj/19.19.5241; DORING T, 1994, EMBO J, V13, P2677, DOI 10.1002/j.1460-2075.1994.tb06558.x; ECKSTEIN F, 1989, TRENDS BIOCHEM SCI, V14, P97, DOI 10.1016/0968-0004(89)90130-8; Gabashvili IS, 2000, CELL, V100, P537, DOI 10.1016/S0092-8674(00)80690-X; GNIRKE A, 1986, J BIOL CHEM, V261, P4506; Harms J, 2001, CELL, V107, P679, DOI 10.1016/S0092-8674(01)00546-3; HARTZ D, 1989, GENE DEV, V3, P1899, DOI 10.1101/gad.3.12a.1899; Joseph S, 1998, EMBO J, V17, P3478, DOI 10.1093/emboj/17.12.3478; Joseph S, 1996, EMBO J, V15, P910, DOI 10.1002/j.1460-2075.1996.tb00425.x; KIRILLOV SV, 1983, FEBS LETT, V157, P91, DOI 10.1016/0014-5793(83)81122-3; MOAZED D, 1989, NATURE, V342, P142, DOI 10.1038/342142a0; Nierhaus KH, 2000, RIBOSOME: STRUCTURE, FUNCTION, ANTIBIOTICS, AND CELLULAR INTERACTIONS, P319; NIERHAUS KH, 1996, RIBOSOMAL RNA GROUP, P69; Ogle JM, 2001, SCIENCE, V292, P897, DOI 10.1126/science.1060612; Pioletti M, 2001, EMBO J, V20, P1829, DOI 10.1093/emboj/20.8.1829; QUIGLEY GJ, 1978, P NATL ACAD SCI USA, V75, P64, DOI 10.1073/pnas.75.1.64; RHEINBERGER HJ, 1987, J BIOMOL STRUCT DYN, V5, P435, DOI 10.1080/07391102.1987.10506403; Schluenzen F, 2000, CELL, V102, P615, DOI 10.1016/S0092-8674(00)00084-2; Schnitzer W, 1997, P NATL ACAD SCI USA, V94, P12823, DOI 10.1073/pnas.94.24.12823; TRIANAALONSO FJ, 1995, J BIOL CHEM, V270, P6298, DOI 10.1074/jbc.270.11.6298; VanLoock MS, 2000, J MOL BIOL, V304, P507, DOI 10.1006/jmbi.2000.4213; Willumeit R, 2001, J MOL BIOL, V305, P167, DOI 10.1006/jmbi.2000.4289; Wimberly BT, 2000, NATURE, V407, P327, DOI 10.1038/35030006; Yusupov MM, 2001, SCIENCE, V292, P883, DOI 10.1126/science.1060089; Yusupova GZ, 2001, CELL, V106, P233, DOI 10.1016/S0092-8674(01)00435-4	36	21	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 24	2002	277	21					19095	19105		10.1074/jbc.M108902200	http://dx.doi.org/10.1074/jbc.M108902200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	558PM	11867615	hybrid			2022-12-27	WOS:000175975800111
J	Chaboute, ME; Clement, B; Philipps, G				Chaboute, ME; Clement, B; Philipps, G			S phase and weristem-specific expression of the tobacco RNR1b gene is mediated by an E2F element located in the 5 ' leader sequence	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOUSE RIBONUCLEOTIDE REDUCTASE; CYCLE-REGULATED TRANSCRIPTION; SYNCHRONIZED PLANT-CELLS; DNA-DAMAGE; ARABIDOPSIS-THALIANA; NUCLEAR ANTIGEN; ROOT-MERISTEMS; PROMOTER; BINDING; PROTEIN	The RB/E2F pathway is involved in the control of the G(1)/S transition of the eukaryotic cell cycle where various S phase genes are activated by specific E2F factors. Ribonucleotide reductase (RN-R) plays an essential role in the DNA synthesis pathway. Earlier studies showed that there are at least two RNR1 genes (RNR1a and RNR1b) and one RNR2 gene in tobacco. In synchronized tobacco BY2 cells, RNR1b gene expression is at its highest level in S phase. To investigate transcriptional regulation of the RNR1b gene, its promoter region was cloned and sequenced. Unlike its animal counterparts, the tobacco RNR1b promoter contains a consensus E2F-binding site. Surprisingly, this site is found in the leader sequence of the gene. We show here by gel shift analysis and antibody competition that one nuclear complex specifically binds this motif, and an E2F factor is part of this complex. Using reporter gene analysis, tobacco RNR1b promoter activity was detected during S phase in synchronized cells and in plant meristematic tissues. Mutation of the E2F element substantially reduced both activities. For the first time in plants, a single E2F motif found in the leader sequence plays an important role in the meristem and S phase-specific expression of the tobacco RNR1b gene.	Univ Strasbourg 1, CNRS, Inst Biol Mol Plantes, F-67084 Strasbourg, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Chaboute, ME (corresponding author), Univ Strasbourg 1, CNRS, Inst Biol Mol Plantes, 12 Rue Gen Zimmer, F-67084 Strasbourg, France.			Chaboute, Marie-Edith/0000-0001-8688-721X				Afroze T, 2000, J BIOL CHEM, V275, P9062, DOI 10.1074/jbc.275.12.9062; Albani D, 2000, J BIOL CHEM, V275, P19258, DOI 10.1074/jbc.M909390199; AN G, 1987, METHOD ENZYMOL, V153, P292; Bartek J, 2001, FEBS LETT, V490, P117, DOI 10.1016/S0014-5793(01)02114-7; Bartley PA, 2001, BLOOD CELL MOL DIS, V27, P409, DOI 10.1006/bcmd.2001.0398; Black AR, 1999, GENE, V237, P281, DOI 10.1016/S0378-1119(99)00305-4; Brown SC, 1991, LAB GUIDE CELLULAR M, P326; Chabes A, 2000, J BIOL CHEM, V275, P17747, DOI 10.1074/jbc.M000799200; Chaboute ME, 1998, PLANT MOL BIOL, V38, P797, DOI 10.1023/A:1006083318906; Chaboute ME, 2000, PLANT CELL, V12, P1987, DOI 10.1105/tpc.12.10.1987; Chaubet N, 1996, PLANT J, V10, P425, DOI 10.1046/j.1365-313X.1996.10030425.x; Darbinian N, 1999, ONCOGENE, V18, P6398, DOI 10.1038/sj.onc.1203011; de Jager SM, 2001, PLANT MOL BIOL, V47, P555, DOI 10.1023/A:1011848528377; Di Fiore B, 1999, J BIOL CHEM, V274, P10339, DOI 10.1074/jbc.274.15.10339; Durfee T, 2000, PLANT MOL BIOL, V43, P635, DOI 10.1023/A:1006426808185; Egelkrout EM, 2001, PLANT CELL, V13, P1437, DOI 10.1105/tpc.13.6.1437; ELLEDGE SJ, 1990, GENE DEV, V4, P740, DOI 10.1101/gad.4.5.740; ELLEDGE SJ, 1992, TRENDS BIOCHEM SCI, V17, P119, DOI 10.1016/0968-0004(92)90249-9; FAISST S, 1992, NUCLEIC ACIDS RES, V20, P3, DOI 10.1093/nar/20.1.3; Filatov D, 1995, BIOCHEM SOC T, V23, P903, DOI 10.1042/bst0230903; FILATOV D, 1995, J BIOL CHEM, V270, P25239, DOI 10.1074/jbc.270.42.25239; Fry CJ, 1999, J BIOL CHEM, V274, P29583, DOI 10.1074/jbc.274.42.29583; GOODALL GJ, 1990, METHOD ENZYMOL, V181, P148; Helin K, 1998, CURR OPIN GENET DEV, V8, P28, DOI 10.1016/S0959-437X(98)80058-0; HORSCH RB, 1985, SCIENCE, V227, P1229, DOI 10.1126/science.227.4691.1229; JEFFERSON RA, 1987, EMBO J, V6, P3901; JOHANSSON E, 1995, J BIOL CHEM, V270, P30162, DOI 10.1074/jbc.270.50.30162; KOSUGI S, 1995, PLANT J, V7, P877, DOI 10.1046/j.1365-313X.1995.07060877.x; Koziczak M, 2000, MOL CELL BIOL, V20, P2014, DOI 10.1128/MCB.20.6.2014-2022.2000; KRAKOFF IH, 1968, CANCER RES, V28, P1559; Le Cam L, 1999, EMBO J, V18, P1878, DOI 10.1093/emboj/18.7.1878; Liu NS, 1998, ONCOGENE, V16, P2957, DOI 10.1038/sj.onc.1201838; Magyar Z, 2000, FEBS LETT, V486, P79, DOI 10.1016/S0014-5793(00)02238-9; Manevski A, 2000, FEBS LETT, V483, P43, DOI 10.1016/S0014-5793(00)02056-1; Mankin SL, 1997, PLANT MOL BIOL REP, V15, P186, DOI 10.1007/BF02812270; Muller H, 2001, GENE DEV, V15, P267, DOI 10.1101/gad.864201; MULLER R, 1995, TRENDS GENET, V11, P173, DOI 10.1016/S0168-9525(00)89039-3; NAGATA T, 1992, INT REV CYTOL, V132, P1, DOI 10.1016/S0074-7696(08)62452-3; Oswald F, 1996, MOL CELL BIOL, V16, P1889; Ramirez-Parra E, 1999, NUCLEIC ACIDS RES, V27, P3527, DOI 10.1093/nar/27.17.3527; Ramirez-Parra E, 2000, FEBS LETT, V486, P73, DOI 10.1016/S0014-5793(00)02239-0; REGAD F, 1995, MOL GEN GENET, V248, P703, DOI 10.1007/BF02191710; REICHARD P, 1988, ANNU REV BIOCHEM, V57, P349, DOI 10.1146/annurev.bi.57.070188.002025; REICHHELD JP, 1995, PLANT J, V7, P245, DOI 10.1046/j.1365-313X.1995.7020245.x; Romero I, 1998, PLANT J, V14, P273, DOI 10.1046/j.1365-313X.1998.00113.x; Sekine M, 1999, FEBS LETT, V460, P117, DOI 10.1016/S0014-5793(99)01296-X; Slansky JE, 1996, CURR TOP MICROBIOL, V208, P1; Tanaka H, 2000, NATURE, V404, P42, DOI 10.1038/35003506; Tremousaygue D, 1999, PLANT J, V20, P553, DOI 10.1046/j.1365-313X.1999.00627.x; Wang PJ, 1997, MOL CELL BIOL, V17, P6114, DOI 10.1128/MCB.17.10.6114	50	53	55	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 17	2002	277	20					17845	17851		10.1074/jbc.M200959200	http://dx.doi.org/10.1074/jbc.M200959200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	553PR	11884409	hybrid			2022-12-27	WOS:000175685100059
J	Kuloglu, ES; McCaslin, DR; Markley, JL; Volkman, BF				Kuloglu, ES; McCaslin, DR; Markley, JL; Volkman, BF			Structural rearrangement of human lymphotactin, a C chemokine, under physiological solution conditions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN SECONDARY STRUCTURE; CHEMICAL-SHIFT INDEX; NMR-SPECTROSCOPY; NOESY-HSQC; T-CELLS; 3-DIMENSIONAL STRUCTURE; BINDING SURFACE; XCR1 RECEPTOR; SH3 DOMAIN; IDENTIFICATION	NMR spectra of human lymphotactin (hLtn), obtained under various solution conditions, have revealed that the protein undergoes a major conformational rearrangement dependent on temperature and salt concentration. At high salt (200 mm NaCl) and low temperature (10degreesC), hLtn adopts a chemokine-like fold, which consists of a three-stranded antiparallel beta-sheet and a C-terminal alpha-helix (Kuloglu, E. S., McCaslin, D. R., Kitabwalla, M., Pauza, C. D., Markley, J. L., and Volkman, B. F. (2001) Biochemistry 40,12486-12496). We have used NMR spectroscopy, sedimentation equilibrium, and intrinsic fluorescence to monitor the reversible conformational change undergone by hLtn as a function of temperature and ionic strength. We have used two-, three- and four-dimensional NMR spectroscopy of isotopically enriched protein samples to determine structural properties of the conformational state stabilized at 45 degreesC and 0 ram NaCl. Patterns of NOEs and H-1(alpha) and C-13 chemical shifts show that hLtn rearranges under these conditions to form a four-stranded, antiparallel beta-sheet with a pattern of hydrogen bonding that is completely different from that of the chemokine fold stabilized at 10 degreesC and 200 ram NaCl. The C-terminal alpha-helix observed at 10degreesC and 200 mm NaCl, which is conserved in other chemokines, is absent at 45 degreesC and no salt, and the last 38 residues of the protein are completely disordered, as indicated by heteronuclear N-15-H-1 NOEs. Temperature dependence of the tryptophan fluorescence of hLtn in low and high salt confirmed that the chemokine conformation is stabilized by increased ionic strength. Sedimentation equilibrium analytical ultracentrifugation showed that hLtn at 40 degreesC in the presence of 100 mm NaCl exists mainly as a dimer. Under near physiological conditions of temperature, pH, and ionic strength, both the chemokine-like and non-chemokine-like conformations of hLtn are significantly populated. The functional relevance of this structural interconversion remains to be elucidated.	Med Coll Wisconsin, Dept Biochem, Milwaukee, WI 53226 USA; Univ Wisconsin, Dept Biochem, Madison, WI 53706 USA; Univ Wisconsin, Biophys Instrumentat Facil, Madison, WI 53706 USA; Univ Wisconsin, Natl Magnet Resonance Facil Madison, Madison, WI 53706 USA	Medical College of Wisconsin; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Volkman, BF (corresponding author), Med Coll Wisconsin, Dept Biochem, Milwaukee, WI 53226 USA.		Volkman, Brian F./ABE-7312-2020; Volkman, Brian F./ABE-7306-2020	Volkman, Brian F./0000-0002-6681-5179; Volkman, Brian F./0000-0002-6681-5179	NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR002301, S10RR013790, S10RR002781, S10RR008438] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI045843, R01AI045843] Funding Source: NIH RePORTER; NCRR NIH HHS [P41 RR002301, S10 RR002781, S10 RR013790, S10 RR008438] Funding Source: Medline; NIAID NIH HHS [R01 AI045843-02, R01 AI045843, AI45843, R01 AI045843-01] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Baggiolini M, 1998, NATURE, V392, P565, DOI 10.1038/33340; Baggiolini M, 1997, ANNU REV IMMUNOL, V15, P675, DOI 10.1146/annurev.immunol.15.1.675; Bazan JF, 1997, NATURE, V385, P640, DOI 10.1038/385640a0; Billeter M, 1995, J BIOMOL NMR, V5, P1; Boismenu R, 1996, J IMMUNOL, V157, P985; Cairns CM, 2001, J IMMUNOL, V167, P57, DOI 10.4049/jimmunol.167.1.57; Campbell JJ, 1998, SCIENCE, V279, P381, DOI 10.1126/science.279.5349.381; CHUNG CW, 1995, BIOCHEMISTRY-US, V34, P9307, DOI 10.1021/bi00029a005; CLORE GM, 1990, BIOCHEMISTRY-US, V29, P1689, DOI 10.1021/bi00459a004; CLORE GM, 1995, FASEB J, V9, P57, DOI 10.1096/fasebj.9.1.7821760; Crump MP, 1997, EMBO J, V16, P6996, DOI 10.1093/emboj/16.23.6996; Czaplewski LG, 1999, J BIOL CHEM, V274, P16077, DOI 10.1074/jbc.274.23.16077; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; FARROW NA, 1994, BIOCHEMISTRY-US, V33, P5984, DOI 10.1021/bi00185a040; Gale LM, 1999, BIOESSAYS, V21, P17, DOI 10.1002/(SICI)1521-1878(199901)21:1<17::AID-BIES3>3.0.CO;2-4; Garrett DS, 1997, BIOCHEMISTRY-US, V36, P4393, DOI 10.1021/bi970221q; Goger B, 2002, BIOCHEMISTRY-US, V41, P1640, DOI 10.1021/bi011944j; Grzesiek S, 1996, NAT STRUCT BIOL, V3, P340, DOI 10.1038/nsb0496-340; GRZESIEK S, 1992, J MAGN RESON, V96, P432, DOI 10.1016/0022-2364(92)90099-S; GRZESIEK S, 1993, J MAGN RESON SER B, V101, P114, DOI 10.1006/jmrb.1993.1019; Guan E, 2001, J BIOL CHEM, V276, P12404, DOI 10.1074/jbc.M006327200; Handel TM, 1996, BIOCHEMISTRY-US, V35, P6569, DOI 10.1021/bi9602270; Hedrick JA, 1997, J IMMUNOL, V158, P1533; Hedrick JA, 1997, METHOD ENZYMOL, V287, P206; Hoover DM, 2000, J BIOL CHEM, V275, P23187, DOI 10.1074/jbc.M002584200; Huang H, 2001, BIOCHEM BIOPH RES CO, V281, P378, DOI 10.1006/bbrc.2001.4363; KAY LE, 1994, J MAGN RESON SER A, V109, P129, DOI 10.1006/jmra.1994.1145; KAY LE, 1993, J MAGN RESON SER B, V101, P333, DOI 10.1006/jmrb.1993.1053; KELNER GS, 1994, SCIENCE, V266, P1395, DOI 10.1126/science.7973732; KENNEDY J, 1995, J IMMUNOL, V155, P203; Kuloglu ES, 2001, BIOCHEMISTRY-US, V40, P12486, DOI 10.1021/bi011106p; Laurence JS, 1998, BIOCHEMISTRY-US, V37, P9346, DOI 10.1021/bi980329l; Laurence JS, 2000, BIOCHEMISTRY-US, V39, P3401, DOI 10.1021/bi9923196; Leong SR, 1997, PROTEIN SCI, V6, P609; Liwang AC, 1999, PROTEIN SCI, V8, P2270; LODI PJ, 1994, SCIENCE, V263, P1762, DOI 10.1126/science.8134838; Lubkowski J, 1997, NAT STRUCT BIOL, V4, P64, DOI 10.1038/nsb0197-64; Luther SA, 2001, NAT IMMUNOL, V2, P102, DOI 10.1038/84205; Mackay CR, 2001, NAT IMMUNOL, V2, P95, DOI 10.1038/84298; Marcaurelle LA, 2001, CHEM-EUR J, V7, P1129, DOI 10.1002/1521-3765(20010302)7:5<1129::AID-CHEM1129>3.0.CO;2-W; Markley JL, 1998, EUR J BIOCHEM, V256, P1, DOI 10.1046/j.1432-1327.1998.2560001.x; Mayer KL, 2000, BIOCHEMISTRY-US, V39, P8382, DOI 10.1021/bi000523j; Meunier S, 1997, BIOCHEMISTRY-US, V36, P4412, DOI 10.1021/bi9627929; Middel P, 2001, AM J PATHOL, V159, P1751, DOI 10.1016/S0002-9440(10)63022-2; Mizoue LS, 1999, BIOCHEMISTRY-US, V38, P1402, DOI 10.1021/bi9820614; Morshauser RC, 1999, J MAGN RESON, V139, P232, DOI 10.1006/jmre.1999.1802; MUHANDIRAM DR, 1994, J MAGN RESON SER B, V103, P203, DOI 10.1006/jmrb.1994.1032; MUHANDIRAM DR, 1993, J MAGN RESON SER B, V102, P317, DOI 10.1006/jmrb.1993.1102; Paavola CD, 1998, J BIOL CHEM, V273, P33157, DOI 10.1074/jbc.273.50.33157; Pace N., 1997, PROTEIN STRUCTURE PR, P253; PATEL SR, 1993, BIOCHEMISTRY-US, V32, P5466, DOI 10.1021/bi00071a024; Proudfoot AEI, 1998, EUR J DERMATOL, V8, P147; RAJARATHNAM K, 1994, SCIENCE, V264, P90, DOI 10.1126/science.8140420; Rossi D, 2000, ANNU REV IMMUNOL, V18, P217, DOI 10.1146/annurev.immunol.18.1.217; Royer C A, 1995, Methods Mol Biol, V40, P65; Sallusto F, 2000, ANNU REV IMMUNOL, V18, P593, DOI 10.1146/annurev.immunol.18.1.593; Shan LX, 2000, BIOCHEM BIOPH RES CO, V268, P938, DOI 10.1006/bbrc.2000.2235; Shao WP, 1998, BIOCHEMISTRY-US, V37, P8303, DOI 10.1021/bi980112r; SKELTON NJ, 1995, BIOCHEMISTRY-US, V34, P5329, DOI 10.1021/bi00016a004; Sticht H, 1999, BIOCHEMISTRY-US, V38, P5995, DOI 10.1021/bi990065i; Talluri S, 1996, J MAGN RESON SER B, V112, P200, DOI 10.1006/jmrb.1996.0132; Varley PG, 1997, EUR BIOPHYS J BIOPHY, V25, P437, DOI 10.1007/s002490050058; Wang JD, 1998, IMMUNOLOGY, V95, P56; WISHART DS, 1994, J BIOMOL NMR, V4, P171; WISHART DS, 1992, BIOCHEMISTRY-US, V31, P1647, DOI 10.1021/bi00121a010; Worthylake RA, 2001, CURR OPIN CELL BIOL, V13, P569, DOI 10.1016/S0955-0674(00)00253-2; Yoshida T, 1998, J BIOL CHEM, V273, P16551, DOI 10.1074/jbc.273.26.16551; Young H, 1999, BIOCHEM J, V338, P591, DOI 10.1042/0264-6021:3380591; ZHANG OW, 1994, J BIOMOL NMR, V4, P845, DOI 10.1007/BF00398413; ZHANG YJ, 1995, MOL CELL BIOL, V15, P4851	70	59	60	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 17	2002	277	20					17863	17870		10.1074/jbc.M200402200	http://dx.doi.org/10.1074/jbc.M200402200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	553PR	11889129	Green Accepted, hybrid			2022-12-27	WOS:000175685100061
J	Mulholland, DJ; Cheng, H; Reid, K; Rennie, PS; Nelson, CC				Mulholland, DJ; Cheng, H; Reid, K; Rennie, PS; Nelson, CC			The androgen receptor can promote beta-catenin nuclear translocation independently of adenomatous polyposis coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GREEN FLUORESCENT PROTEIN; TRANSCRIPTIONAL ACTIVATION; SUBCELLULAR-LOCALIZATION; GLUCOCORTICOID RECEPTOR; GENE-EXPRESSION; LIVING CELLS; TRAFFICKING; IDENTIFICATION; VISUALIZATION; DOMAINS	We provide evidence that the androgen receptor (AR) can promote nuclear translocation of beta-catenin in LNCaP and PC3 prostate cancer cells. Using AR-expressing cells (LNCaP) and non-AR-expressing cells (PC3) we showed by time course cell fractionation that the AR can shuttle beta-catenin into the nucleus when exposed to exogenous androgen. Cells exposed to the synthetic androgen, R1881, show distinct, punctate, nuclear co-localization of the AR and beta-catenin. We further showed that the AR does not interact with adenomatous polyposis coli or glycogen synthase kinase-3beta and, therefore, conclude that androgen-mediated transport of beta-catenin occurs through a distinct pathway. The minimal necessary components of the AR and beta-catenin required for binding nuclear accumulation of beta-catenin nuclear import appears to be the DNA/ligand binding regions and the Armadillo repeats of B-catenin. We also employed a novel DNA binding assay to illustrate that beta-catenin has the capacity to bind to the probasin promoter in an AR-dependent manner. The physiological relevance of AR-mediated transport of beta-catenin and binding to an AR promoter appeared to be a substantial increase in AR transcriptional reporter activity. AR-mediated import represents a novel mode of nuclear accumulation of beta-catenin.	Vancouver Gen Hosp, Prostate Res Ctr, Vancouver, BC V6H 3Z6, Canada	University of British Columbia	Mulholland, DJ (corresponding author), Vancouver Gen Hosp, Prostate Res Ctr, 2660 Oak St,Jack Bell Res, Vancouver, BC V6H 3Z6, Canada.	djm@interchange.ubc.ca		Reid, Kim/0000-0001-5484-7205				Barker N, 2000, BIOESSAYS, V22, P961; Bieche I, 2001, CARCINOGENESIS, V22, P1521, DOI 10.1093/carcin/22.9.1521; Bunn CF, 2001, MOL ENDOCRINOL, V15, P512, DOI 10.1210/mend.15.4.0619; DANIELIAN PS, 1992, EMBO J, V11, P1025, DOI 10.1002/j.1460-2075.1992.tb05141.x; Easwaran V, 1999, CURR BIOL, V9, P1415, DOI 10.1016/S0960-9822(00)80088-3; Eleftheriou A, 2001, J BIOL CHEM, V276, P25883, DOI 10.1074/jbc.M102656200; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; Fearnhead NS, 2001, HUM MOL GENET, V10, P721, DOI 10.1093/hmg/10.7.721; Fejes-Toth G, 1998, P NATL ACAD SCI USA, V95, P2973, DOI 10.1073/pnas.95.6.2973; Georget V, 1997, MOL CELL ENDOCRINOL, V129, P17, DOI 10.1016/S0303-7207(97)04034-3; Hache RJG, 1999, J BIOL CHEM, V274, P1432, DOI 10.1074/jbc.274.3.1432; Hager GL, 2000, J STEROID BIOCHEM, V74, P249, DOI 10.1016/S0960-0760(00)00100-X; Hart MJ, 1998, CURR BIOL, V8, P573, DOI 10.1016/S0960-9822(98)70226-X; Hecht A, 2000, EMBO REP, V1, P24, DOI 10.1093/embo-reports/kvd012; Helmbrecht K, 2001, ENDOCRINOLOGY, V142, P5261, DOI 10.1210/en.142.12.5261; Henderson BR, 2000, NAT CELL BIOL, V2, P653, DOI 10.1038/35023605; Htun H, 1999, MOL BIOL CELL, V10, P471, DOI 10.1091/mbc.10.2.471; Htun H, 1996, P NATL ACAD SCI USA, V93, P4845, DOI 10.1073/pnas.93.10.4845; Ikonen T, 1997, J BIOL CHEM, V272, P29821, DOI 10.1074/jbc.272.47.29821; Janne OA, 2000, BIOCHEM SOC T, V28, P401, DOI 10.1042/0300-5127:0280401; JENSTER G, 1991, MOL ENDOCRINOL, V5, P1396, DOI 10.1210/mend-5-10-1396; MacLean HE, 1997, J STEROID BIOCHEM, V62, P233, DOI 10.1016/S0960-0760(97)00049-6; NELSON C, 2001, IN PRESS BIOTECHNIQU; OGAWA H, 1995, P NATL ACAD SCI USA, V92, P11899, DOI 10.1073/pnas.92.25.11899; Polakis P, 2001, CELL, V105, P563, DOI 10.1016/S0092-8674(01)00379-8; QUIGLEY CA, 1995, ENDOCR REV, V16, P271, DOI 10.1210/er.16.3.271; RAKESH KT, 2000, MOL ENDOCRINOL, V14, P1162; Reid KJ, 2001, J BIOL CHEM, V276, P2943, DOI 10.1074/jbc.M009170200; RENNIE PS, 1993, MOL ENDOCRINOL, V7, P23, DOI 10.1210/me.7.1.23; Reutens AT, 2001, MOL ENDOCRINOL, V15, P797, DOI 10.1210/me.15.5.797; SIMENTAL JA, 1991, J BIOL CHEM, V266, P510; Snoek R, 1998, PROSTATE, V36, P256; Stenoien DL, 2000, MOL ENDOCRINOL, V14, P518, DOI 10.1210/me.14.4.518; Stewart DB, 1997, J BIOL CHEM, V272, P29652, DOI 10.1074/jbc.272.47.29652; Tomura A, 2001, J BIOL CHEM, V276, P28395, DOI 10.1074/jbc.M101755200; Truica CI, 2000, CANCER RES, V60, P4709; Tyagi RK, 2000, MOL ENDOCRINOL, V14, P1162, DOI 10.1210/me.14.8.1162; Wodarz A, 1998, ANNU REV CELL DEV BI, V14, P59, DOI 10.1146/annurev.cellbio.14.1.59; WONG W, 2000, CANCER RES, V60, P6841; YEH S, 1999, KEIO J MED, V2, P87; Yokoya F, 1999, MOL BIOL CELL, V10, P1119, DOI 10.1091/mbc.10.4.1119; Zhang F, 2000, P NATL ACAD SCI USA, V97, P12577, DOI 10.1073/pnas.230435597; Zhu XG, 1998, J BIOL CHEM, V273, P27058, DOI 10.1074/jbc.273.42.27058	43	145	147	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 17	2002	277	20					17933	17943		10.1074/jbc.M200135200	http://dx.doi.org/10.1074/jbc.M200135200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	553PR	11856748	hybrid			2022-12-27	WOS:000175685100070
J	Sindice, A; Basoglu, C; Cerci, A; Hirsch, JR; Potthast, R; Kuhn, M; Ghanekar, Y; Visweswariah, SS; Schlatter, E				Sindice, A; Basoglu, C; Cerci, A; Hirsch, JR; Potthast, R; Kuhn, M; Ghanekar, Y; Visweswariah, SS; Schlatter, E			Guanylin, uroguanylin, and heat-stable euterotoxin activate guanylate cyclase C and/or a pertussis toxin-sensitive G protein in human proximal tubule cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KIDNEY EPITHELIAL-CELLS; HCO3-SECRETION; MICE LACKING; K+ CHANNELS; KINASE-II; RECEPTOR; ENTEROTOXIN; TRANSPORT; PEPTIDE; PLASMA	Membrane guanylate cyclase C (GC-C) is the receptor for guanylin, uroguanylin, and heat-stable enterotoxin (STa) in the intestine. GC-C-deficient mice show resistance to STa in intestine but saluretic and diuretic effects of uroguanylin and STa are not disturbed. Here we describe the cellular effects of these peptides using immortalized human kidney epithelial (IHKE-1) cells with properties of the proximal tubule, analyzed with the slow-whole-cell patch clamp technique. Uroguanylin (10 or 100 nM) either hyperpolarized or depolarized membrane voltages (V-m). Guanylin and STa (both 10 or 100 nM), as well as 8-Br-cGMP (100 muM), depolarized V-m. All peptide effects were absent in the presence of 1 mm Ba2+. Uroguanylin and guanylin changed V-m pH dependently. Pertussis toxin (1 mug/ml, 24 h) inhibited hyperpolarizations caused by uroguanylin. Depolarizations caused by guanylin and uroguanylin were blocked by the tyrosine kinase inhibitor, genistein (10 muM). All three peptides increased cellular cGMP. mRNA for GC-C was detected in IHKE-1 cells and in isolated human proximal tubules. In IHKE-1 cells GC-C was also detected by immunostaining. These findings suggest that GC-C is probably the receptor for guanylin and STa. For uroguanylin two distinct signaling pathways exist in IHKE-1 cells, one involves GC-C and cGMP as second messenger, the other is cGMP-independent and connected to a pertussis toxin-sensitive G protein.	Univ Klinikum Munster, Med Klin & Poliklin D, D-48149 Munster, Germany; Univ Klinikum Munster, Inst Pharmakol & Toxikol, D-48149 Munster, Germany; Indian Inst Sci, Dept Mol Reprod Dev & Genet, Bangalore 560012, Karnataka, India	University of Munster; University of Munster; Indian Institute of Science (IISC) - Bangalore	Schlatter, E (corresponding author), Univ Klinikum Munster, Med Klin & Poliklin D, Domagkstr 3A, D-48149 Munster, Germany.	eberhard.schlatter@uni-muenster.de	Visweswariah, Sandhya/Q-7500-2019	Visweswariah, Sandhya/0000-0003-2786-7344				Bhandari R, 2001, BIOCHEMISTRY-US, V40, P9196, DOI 10.1021/bi002595g; Bhandari R, 2000, J BIOSCIENCES, V25, P339, DOI 10.1007/BF02703787; BROWN AM, 1991, J BIOENERG BIOMEMBR, V23, P499, DOI 10.1007/BF00785808; Carrithers SL, 2000, REGUL PEPTIDES, V95, P65, DOI 10.1016/S0167-0115(00)00139-7; Carrithers SL, 1999, BRAZ J MED BIOL RES, V32, P1337, DOI 10.1590/S0100-879X1999001100003; Charney AN, 2001, AM J PHYSIOL-GASTR L, V280, pG216, DOI 10.1152/ajpgi.2001.280.2.G216; CRANE JK, 1989, INFECT IMMUN, V57, P1186, DOI 10.1128/IAI.57.4.1186-1191.1989; CRANE MR, 1992, MOL PHARMACOL, V41, P1073; CURRIE MG, 1992, P NATL ACAD SCI USA, V89, P947, DOI 10.1073/pnas.89.3.947; Derst C, 2001, KIDNEY INT, V59, P2197; Fonteles MC, 1998, AM J PHYSIOL-RENAL, V275, pF191, DOI 10.1152/ajprenal.1998.275.2.F191; FROMTER E, 1982, PFLUG ARCH EUR J PHY, V393, P179, DOI 10.1007/BF00582942; Fujimoto S, 2000, NEPHRON, V84, P88, DOI 10.1159/000045548; Furuya S, 1997, ANAT EMBRYOL, V196, P185, DOI 10.1007/s004290050090; Greenberg RN, 1997, J INVEST MED, V45, P276; GREGER R, 1991, PFLUG ARCH EUR J PHY, V419, P209, DOI 10.1007/BF00373009; Guba M, 1996, GASTROENTEROLOGY, V111, P1558, DOI 10.1016/S0016-5085(96)70018-5; GUDERMANN T, 1995, J MOL MED, V73, P51, DOI 10.1007/BF00270578; Hamra FK, 1997, P NATL ACAD SCI USA, V94, P2705, DOI 10.1073/pnas.94.6.2705; Hamra FK, 1996, ENDOCRINOLOGY, V137, P257, DOI 10.1210/en.137.1.257; HAMRA FK, 1993, P NATL ACAD SCI USA, V90, P10464, DOI 10.1073/pnas.90.22.10464; HAUGEN A, 1994, ENVIRON HEALTH PERSP, V102, P117, DOI 10.2307/3431773; Hirsch JR, 1999, J PHYSIOL-LONDON, V519, P645, DOI 10.1111/j.1469-7793.1999.0645n.x; Hirsch JR, 1999, J AM SOC NEPHROL, V10, P472; Joo NS, 1998, AM J PHYSIOL-GASTR L, V274, pG633, DOI 10.1152/ajpgi.1998.274.4.G633; Kinoshita H, 1999, NEPHRON, V81, P160, DOI 10.1159/000045272; Kinoshita H, 1997, KIDNEY INT, V52, P1028, DOI 10.1038/ki.1997.424; Kinoshita H, 1997, CLIN NEPHROL, V47, P28; KUHN M, 1993, FEBS LETT, V318, P205, DOI 10.1016/0014-5793(93)80022-M; LIMA AAM, 1992, PHARMACOL TOXICOL, V70, P163, DOI 10.1111/j.1600-0773.1992.tb00449.x; London RM, 1999, AM J PHYSIOL-RENAL, V276, pF882, DOI 10.1152/ajprenal.1999.276.6.F882; Lucas KA, 2000, PHARMACOL REV, V52, P375; Mann EA, 1997, BIOCHEM BIOPH RES CO, V239, P463, DOI 10.1006/bbrc.1997.7487; MEROT J, 1989, BIOCHIM BIOPHYS ACTA, V978, P134, DOI 10.1016/0005-2736(89)90508-7; OKAMOTO T, 1990, CELL, V62, P709, DOI 10.1016/0092-8674(90)90116-V; PAULMICHL M, 1988, FEBS LETT, V234, P263, DOI 10.1016/0014-5793(88)80094-2; Pfeifer A, 1996, SCIENCE, V274, P2082, DOI 10.1126/science.274.5295.2082; Potthast R, 2001, ENDOCRINOLOGY, V142, P3087, DOI 10.1210/en.142.7.3087; Schafer JA, 1997, AM J PHYSIOL-RENAL, V273, pF650, DOI 10.1152/ajprenal.1997.273.4.F650; SCHLATTER E, 1992, PFLUG ARCH EUR J PHY, V421, P381, DOI 10.1007/BF00374227; SCHULZ S, 1990, CELL, V63, P941, DOI 10.1016/0092-8674(90)90497-3; Selvaraj NG, 2000, BBA-MOL CELL RES, V1498, P32, DOI 10.1016/S0167-4889(00)00075-6; TVEITO G, 1989, CANCER RES, V49, P1829; Vaandrager AB, 2000, GASTROENTEROLOGY, V118, P108, DOI 10.1016/S0016-5085(00)70419-7; Vijayachandra K, 2000, BIOCHEMISTRY-US, V39, P16075, DOI 10.1021/bi0013849	45	51	67	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 17	2002	277	20					17758	17764		10.1074/jbc.M110627200	http://dx.doi.org/10.1074/jbc.M110627200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	553PR	11889121	hybrid			2022-12-27	WOS:000175685100048
J	Johnson, EN; Druey, KM				Johnson, EN; Druey, KM			Functional characterization of the G protein regulator RGS13	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTPASE-ACTIVATING PROTEINS; SIGNALING RGS; EXPRESSION; GAIP; LOCALIZATION; RECEPTOR; DOMAIN; BINDS; PALMITOYLATION; CLONING	The signaling cascades evoked by G protein-coupled receptors are a predominant mechanism of cellular communication. The regulators of G protein signaling (RGS) comprise a family of proteins that attenuate G protein-mediated signal transduction. Here we report the characterization of RGS13, the smallest member of the RGS family, which has been cloned from human lung. RGS13 has been found most abundantly in human tonsil, followed by thymus, lung, lymph node, and spleen. RGS13 is a GTPase-activating protein for Galpha(i) and Galpha(o) but not Galpha(s). RGS13 binds Galpha(q) in the presence of aluminum magnesium fluoride, suggesting that it bears GTPase-activating protein activity toward Galpha(q). RGS13 blocks MAPK activity induced by Ga-i- or Galpha(q)-coupled receptors. RGS13 also attenuates GTPase-deficient Galpha(q) (Galpha(q)QL) mediated cAMP response element activation but not transcription evoked by constitutively active Galpha(12) or Galpha(13). Surprisingly, RGS13 inhibits cAMP generation elicited by stimulation of the beta(2)-adrenergic receptor. These data suggest that RGS13 may regulate Galpha(i)-, Galpha(q)-, and Galpha(s)-coupled signaling cascades.	NIAID, Mol Signal Transduct Sect, Lab Allerg Dis, NIH, Rockville, MD 20852 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Druey, KM (corresponding author), 12441 Parklawn Dr,Rm 200E, Rockville, MD 20852 USA.	kdruey@niaid.nih.gov						Beadling C, 1999, J IMMUNOL, V162, P2677; Berman DM, 1996, CELL, V86, P445, DOI 10.1016/S0092-8674(00)80117-8; Bernstein LS, 2000, J BIOL CHEM, V275, P18520, DOI 10.1074/jbc.M000618200; Chatterjee TK, 2000, J BIOL CHEM, V275, P24013, DOI 10.1074/jbc.M002082200; Chatterjee TK, 1997, J BIOL CHEM, V272, P15481, DOI 10.1074/jbc.272.24.15481; Chen CH, 1997, J BIOL CHEM, V272, P8679, DOI 10.1074/jbc.272.13.8679; Chen CK, 2000, NATURE, V403, P557, DOI 10.1038/35000601; Chen CK, 1996, P NATL ACAD SCI USA, V93, P12885, DOI 10.1073/pnas.93.23.12885; Chen Z, 2001, NAT STRUCT BIOL, V8, P805, DOI 10.1038/nsb0901-805; De Vries L, 2000, ANNU REV PHARMACOL, V40, P235, DOI 10.1146/annurev.pharmtox.40.1.235; DeVries L, 1996, P NATL ACAD SCI USA, V93, P15203, DOI 10.1073/pnas.93.26.15203; Druey KM, 1996, NATURE, V379, P742, DOI 10.1038/379742a0; Druey KM, 1999, J BIOL CHEM, V274, P18836, DOI 10.1074/jbc.274.26.18836; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; Gold SJ, 1997, J NEUROSCI, V17, P8024; Grafstein-Dunn E, 2001, MOL BRAIN RES, V88, P113, DOI 10.1016/S0169-328X(01)00038-9; He W, 1998, NEURON, V20, P95, DOI 10.1016/S0896-6273(00)80437-7; Hepler JR, 1997, P NATL ACAD SCI USA, V94, P428, DOI 10.1073/pnas.94.2.428; Heximer SP, 2001, J BIOL CHEM, V276, P14195, DOI 10.1074/jbc.M009942200; JOHNSON EN, 2002, IN RESS J ALLERGY CL; Longenecker KL, 2001, STRUCTURE, V9, P559, DOI 10.1016/S0969-2126(01)00620-7; MANNING DR, 1999, G PROTEINS TECHNIQUE, P23; Mukhopadhyay S, 1999, P NATL ACAD SCI USA, V96, P9539, DOI 10.1073/pnas.96.17.9539; Norlin EM, 2001, MOL CELL NEUROSCI, V17, P872, DOI 10.1006/mcne.2001.0976; Parks IK, 2001, J BIOL CHEM, V276, P915, DOI 10.1074/jbc.M005947200; Peppelenbosch MP, 1996, J BIOL CHEM, V271, P7883, DOI 10.1074/jbc.271.14.7883; Reif K, 2000, J IMMUNOL, V164, P4720, DOI 10.4049/jimmunol.164.9.4720; Ross EM, 2000, ANNU REV BIOCHEM, V69, P795, DOI 10.1146/annurev.biochem.69.1.795; Siderovski DP, 1999, CRIT REV BIOCHEM MOL, V34, P215, DOI 10.1080/10409239991209273; SIDEROVSKI DP, 1994, DNA CELL BIOL, V13, P125, DOI 10.1089/dna.1994.13.125; Sinnarajah S, 2001, NATURE, V409, P1051, DOI 10.1038/35059104; Snow BE, 1998, GENE, V206, P247, DOI 10.1016/S0378-1119(97)00593-3; Tesmer JJG, 1997, CELL, V89, P251, DOI 10.1016/S0092-8674(00)80204-4; Tu YP, 2001, J BIOL CHEM, V276, P20160, DOI 10.1074/jbc.M101599200; Watson N, 1996, NATURE, V383, P172, DOI 10.1038/383172a0; Yowe D, 2001, BIOCHEM J, V359, P109, DOI 10.1042/0264-6021:3590109; Zheng B, 2001, SCIENCE, V294, P1939, DOI 10.1126/science.1064757	37	44	44	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 10	2002	277	19					16768	16774		10.1074/jbc.M200751200	http://dx.doi.org/10.1074/jbc.M200751200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	551MB	11875076	hybrid			2022-12-27	WOS:000175564500057
J	Ma, TH; Hara, M; Sougrat, R; Verbavatz, JM; Verkman, AS				Ma, TH; Hara, M; Sougrat, R; Verbavatz, JM; Verkman, AS			Impaired stratum corneum hydration in mice lacking epidermal water channel aquaporin-3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTRON-PROBE ANALYSIS; KIDNEY COLLECTING DUCT; LUNG FLUID TRANSPORT; HUMAN-SKIN; PERMEABILITY; EXPRESSION; GLYCEROL; SECRETION; MEMBRANE; BARRIER	The water and solute transporting properties of the epidermis have been proposed to be important determinants of skin moisture content and barrier properties. The water/small solute-transporting protein aquaporin-3 (AQP3) was found by immunofluorescence and immunogold electron microscopy to be expressed at the plasma membrane of epidermal keratinocytes in mouse skin. We studied the role of AQP3 in stratum corneum (SC) hydration by comparative measurements in wildtype and AQP3 null mice generated in a hairless SKH1 genetic background. The hairless AQP3 null mice had normal perinatal survival, growth, and serum chemistries but were polyuric because of defective urinary concentrating ability. AQP3 deletion resulted in a >4-fold reduced osmotic water permeability and >2-fold reduced glycerol permeability in epidermis. Epidermal, dermal, and SC thickness and morphology were not grossly affected by AQP3 deletion. Surface conductance measurements showed remarkably reduced SC water content in AQP3 null mice in the hairless genetic background (165 +/- 10 versus 269 +/- 12 microsiemens (muS), p < 0.001), as well as in a CD1 genetic background (209 +/- 21 versus 469 +/- 11 mu S). Reduced SC hydration was seen from 3 days after birth. SC hydration in hairless wild-type and AQP3 null mice was reduced to comparable levels (90-100 mu S) after a 24-h exposure to a dry atmosphere, but the difference was increased when surface evaporation was prevented by occlusion or exposure to a humidified atmosphere (179 +/- 13 versus 441 +/- 34 mu S). Conductance measurements after serial tape stripping suggested reduced water content throughout the SC in AQP3 null mice. Water sorption-desorption experiments indicated reduced water holding capacity in the SC of AQP3 null mice. The impaired skin hydration in AQP3 null mice provides the first functional evidence for the involvement of AQP3 in skin physiology. Modulation of AQP3 expression or function may thus alter epidermal moisture content and water loss in skin diseases.	Univ Calif San Francisco, Cardiovasc Res Inst, Dept Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Cardiovasc Res Inst, Dept Physiol, San Francisco, CA 94143 USA; Kanebo Ltd, Basic Res Lab, Odawara, Kanagawa 2500002, Japan; CEA, Serv Biol Cellulaire, F-91191 Gif Sur Yvette, France	University of California System; University of California San Francisco; University of California System; University of California San Francisco; CEA; UDICE-French Research Universities; Universite Paris Saclay	Ma, TH (corresponding author), Univ Calif San Francisco, Cardiovasc Res Inst, Dept Med, 1246 Hlth Sci E Tower,Box 0521, San Francisco, CA 94143 USA.	tonghui@itsa.ucsf.edu		Verbavatz, Jean-Marc/0000-0002-4654-1174; Sougrat, Rachid/0000-0001-6476-1886	NATIONAL EYE INSTITUTE [R01EY013574] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL060288, R01HL059198] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [R01EB000415, R37EB000415] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043840, R01DK035124, R37DK035124] Funding Source: NIH RePORTER	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bai CX, 1999, J CLIN INVEST, V103, P555, DOI 10.1172/JCI4138; BLANK IH, 1965, J INVEST DERMATOL, V45, P249, DOI 10.1038/jid.1965.125; Chou CL, 1999, J CLIN INVEST, V103, P491, DOI 10.1172/JCI5704; ELIAS PM, 1983, J INVEST DERMATOL, V80, pS44, DOI 10.1038/jid.1983.12; Farinas J, 1997, J GEN PHYSIOL, V110, P283, DOI 10.1085/jgp.110.3.283; FRIGERI A, 1995, J CELL SCI, V108, P2993; HARA M, 1993, ACTA DERM-VENEREOL, V73, P283; HORII I, 1989, BRIT J DERMATOL, V121, P587, DOI 10.1111/j.1365-2133.1989.tb08190.x; ISHIBASHI K, 1994, P NATL ACAD SCI USA, V91, P6269, DOI 10.1073/pnas.91.14.6269; LANDMANN L, 1988, ANAT EMBRYOL, V178, P1, DOI 10.1007/BF00305008; Li J, 2001, J BIOL CHEM, V276, P31233, DOI 10.1074/jbc.M104368200; Ma TH, 1999, J BIOL CHEM, V274, P20071, DOI 10.1074/jbc.274.29.20071; MA TH, 1994, J BIOL CHEM, V269, P21845; Ma TH, 2001, AM J PHYSIOL-CELL PH, V280, pC126; Ma TH, 2000, J CLIN INVEST, V105, P93, DOI 10.1172/JCI8258; Ma TH, 2000, P NATL ACAD SCI USA, V97, P4386, DOI 10.1073/pnas.080499597; Manley GT, 2000, NAT MED, V6, P159, DOI 10.1038/72256; Matsuzaki T, 1999, J HISTOCHEM CYTOCHEM, V47, P1275, DOI 10.1177/002215549904701007; OBATA M, 1989, J INVEST DERMATOL, V92, P854, DOI 10.1111/1523-1747.ep12696875; Schnermann J, 1998, P NATL ACAD SCI USA, V95, P9660, DOI 10.1073/pnas.95.16.9660; Song YL, 2001, J BIOL CHEM, V276, P41288, DOI 10.1074/jbc.M107257200; Song YL, 2001, J GEN PHYSIOL, V117, P573, DOI 10.1085/jgp.117.6.573; SOUGRAT R, 2002, IN PRESS J INVESTIG; SPRUIT D, 1970, DERMATOLOGICA, V141, P54, DOI 10.1159/000252436; Sugiyama Y, 2001, BBA-GENE STRUCT EXPR, V1522, P82, DOI 10.1016/S0167-4781(01)00320-7; TAGAMI H, 1994, ACTA DERM-VENEREOL, P29; TAGAMI H, 1985, ARCH DERMATOL, V121, P642, DOI 10.1001/archderm.121.5.642; TAGAMI H, 1980, J INVEST DERMATOL, V75, P500, DOI 10.1111/1523-1747.ep12524316; TAKENOUCHI M, 1986, J INVEST DERMATOL, V87, P574, DOI 10.1111/1523-1747.ep12455817; Tanaka M, 1997, AM J PHYSIOL-LUNG C, V273, pL1090, DOI 10.1152/ajplung.1997.273.5.L1090; THUNE P, 1989, ACTA DERM-VENEREOL, P133; WARNER RR, 1988, J INVEST DERMATOL, V90, P218, DOI 10.1111/1523-1747.ep12462252; WARNER RR, 1988, J INVEST DERMATOL, V90, P78, DOI 10.1111/1523-1747.ep12462576; Warner RR, 1999, J INVEST DERMATOL, V113, P960, DOI 10.1046/j.1523-1747.1999.00774.x; WARNER RR, 1995, J INVEST DERMATOL, V104, P530, DOI 10.1111/1523-1747.ep12606037; WATANABE M, 1991, ARCH DERMATOL, V127, P1689, DOI 10.1001/archderm.127.11.1689; Yang BX, 2001, J BIOL CHEM, V276, P624, DOI 10.1074/jbc.M008664200; Yang BX, 1997, J BIOL CHEM, V272, P16140, DOI 10.1074/jbc.272.26.16140; Zeuthen T, 1999, J BIOL CHEM, V274, P21631, DOI 10.1074/jbc.274.31.21631	39	187	199	1	7	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 10	2002	277	19					17147	17153		10.1074/jbc.M200925200	http://dx.doi.org/10.1074/jbc.M200925200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	551MB	11880378	hybrid			2022-12-27	WOS:000175564500107
J	Mofid, MR; Finking, R; Marahiel, MA				Mofid, MR; Finking, R; Marahiel, MA			Recognition of hybrid peptidyl carrier proteins/Acyl carrier proteins in nonribosomal peptide synthetase modules by the 4 '-phophopantetheinyl transferases AcpS and Sfp	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GRAMICIDIN-S SYNTHETASE; BACILLUS-SUBTILIS; PHOSPHOPANTETHEINYL TRANSFERASE; BIOCHEMICAL-CHARACTERIZATION; ESCHERICHIA-COLI; BIOSYNTHESIS; SYNTHASE; DOMAIN; IDENTIFICATION; EPIMERIZATION	The acyl carrier proteins (ACPs) of fatty acid synthase and polyketide synthase as well as peptidyl carrier proteins (PCPs) of nonribosomal peptide synthetases are modified by 4'-phosphopantetheinyl transferases from inactive apo-enzymes to their active holo forms by transferring the 4'-phosphopantetheinyl moiety of coenzyme A to a conserved serine residue of the carrier protein. 4'-Phosphopantetheinyl transferases have been classified into two types; the AcpS type accepts ACPs of fatty acid synthase and some ACPs of type If polyketide synthase as substrates, whereas the Sfp type exhibits an extraordinarily broad substrate specificity. Based on the previously published co-crystal structure of Bacillus subtilis AcpS and ACP that provided detailed information about the interacting residues of the two proteins, we designed a novel hybrid PCP by replacing the Bacillus brevis TycC3-PCP helix 2 with the corresponding helix of B. subtilis ACP that contains the interacting residues. This was performed for the PCP domain as a single protein as well as for the TycA-PCP domain within the nonribosomal peptide synthetase module TycA from B. brevis. Both resulting proteins, designated hybrid PCP (hPCP) and hybrid TycA (hTycA), were modified in vivo during heterologous expression in Escherichia coli (hPCP, 51%; hTycA, 75%) and in vitro with AcpS as well as Sfp to 100%,. The designated hTycA module contains two other domains: an adenylation domain (activating phenylalanine to Phe-AMP and afterward transferring the Phe to the PCP domain) and an epimerization domain (converting the PCP-bound L-Phe to DPhe). We show here that the modified PCP domain of hTycA communicates with the adenylation domain and that the co-factor of holo-hPCP is loaded with Phe. However, communication between the hybrid PCP and the epimerization domain seems to be disabled. Nevertheless, hTycA is recognized by the next proline-activating elongation module TycB1 in vitro, and the dipeptide is formed and released as diketopiperazine.	Univ Marburg, Fachbereich Chem Biochem, D-35032 Marburg, Germany	Philipps University Marburg	Marahiel, MA (corresponding author), Univ Marburg, Fachbereich Chem Biochem, Hans Meerwein Str, D-35032 Marburg, Germany.			mofid, mohammad reza/0000-0002-0347-8152				Debabov DV, 1996, J BACTERIOL, V178, P3869, DOI 10.1128/jb.178.13.3869-3876.1996; DECRECYLAGARD V, 1995, CR ACAD SCI III-VIE, V318, P927; Flaman AS, 2001, J BIOL CHEM, V276, P35934, DOI 10.1074/jbc.M101849200; Flugel RS, 2000, J BIOL CHEM, V275, P959, DOI 10.1074/jbc.275.2.959; Lambalot RH, 1996, CHEM BIOL, V3, P923, DOI 10.1016/S1074-5521(96)90181-7; LAMBALOT RH, 1995, J BIOL CHEM, V270, P24658, DOI 10.1074/jbc.270.42.24658; Linne U, 2001, BIOCHEMISTRY-US, V40, P15824, DOI 10.1021/bi011595t; Luo LS, 2001, BIOCHEMISTRY-US, V40, P5329, DOI 10.1021/bi015518+; Marahiel MA, 1997, CHEM REV, V97, P2651, DOI 10.1021/cr960029e; McAllister KA, 2000, J BIOL CHEM, V275, P30864, DOI 10.1074/jbc.M004475200; Mofid MR, 1999, ACTA CRYSTALLOGR D, V55, P1098, DOI 10.1107/S0907444999003674; Mootz HD, 1997, J BACTERIOL, V179, P6843, DOI 10.1128/jb.179.21.6843-6850.1997; Mootz HD, 2000, P NATL ACAD SCI USA, V97, P5848, DOI 10.1073/pnas.100075897; Mootz HD, 2001, J BIOL CHEM, V276, P37289, DOI 10.1074/jbc.M103556200; NAKANO MM, 1992, MOL GEN GENET, V232, P313, DOI 10.1007/BF00280011; Parris KD, 2000, STRUCT FOLD DES, V8, P883, DOI 10.1016/S0969-2126(00)00178-7; Quadri LEN, 1998, BIOCHEMISTRY-US, V37, P1585, DOI 10.1021/bi9719861; Reuter K, 1999, EMBO J, V18, P6823, DOI 10.1093/emboj/18.23.6823; RITSEMA T, 1994, J BACTERIOL, V176, P7740, DOI 10.1128/JB.176.24.7740-7743.1994; Sambrook J., 2002, MOL CLONING LAB MANU; Schwarzer D, 2001, NATURWISSENSCHAFTEN, V88, P93, DOI 10.1007/s001140100211; STACHELHAUS T, 1995, J BIOL CHEM, V270, P6163, DOI 10.1074/jbc.270.11.6163; Stachelhaus T, 1996, CHEM BIOL, V3, P913, DOI 10.1016/S1074-5521(96)90180-5; Stachelhaus T, 1998, J BIOL CHEM, V273, P22773, DOI 10.1074/jbc.273.35.22773; Stachelhaus T, 2000, BIOCHEMISTRY-US, V39, P5775, DOI 10.1021/bi9929002; STACHELHAUS T, 2002, NONRIBOSOMAL ASSEMBL, P415; Stein T, 1996, J BIOL CHEM, V271, P15428, DOI 10.1074/jbc.271.26.15428; TURGAY K, 1992, MOL MICROBIOL, V6, P2743, DOI 10.1111/j.1365-2958.1992.tb01451.x; Walsh CT, 1997, CURR OPIN CHEM BIOL, V1, P309, DOI 10.1016/S1367-5931(97)80067-1; Weber W, 2000, SUPPORT CARE CANCER, V8, P1; Xu GY, 2001, STRUCTURE, V9, P277, DOI 10.1016/S0969-2126(01)00586-X; YANG JT, 1986, METHOD ENZYMOL, V130, P208; Zhang YM, 2001, J BIOL CHEM, V276, P8231, DOI 10.1074/jbc.M008042200	33	70	75	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 10	2002	277	19					17023	17031		10.1074/jbc.M200120200	http://dx.doi.org/10.1074/jbc.M200120200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	551MB	11867633	hybrid			2022-12-27	WOS:000175564500091
J	Taschenberger, G; Mougey, A; Shen, S; Lester, LB; LaFranchi, S; Shyng, SL				Taschenberger, G; Mougey, A; Shen, S; Lester, LB; LaFranchi, S; Shyng, SL			Identification of a familial hyperinsulinism-causing mutation in the sulfonylurea receptor 1 that prevents normal trafficking and function of K-ATP channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SENSITIVE POTASSIUM CHANNELS; PANCREATIC BETA-CELLS; SUBUNIT STOICHIOMETRY; HYPOGLYCEMIA; INFANCY; SUR1; COMPLEX; BINDING; KIR6.2; MGADP	Mutations in the pancreatic ATP-sensitive potassium (K-ATP) channel subunits sulfonylurea receptor 1 (SUR1) and the inwardly rectifying potassium channel Kir6.2 cause persistent hyperinsulinemic hypoglycemia of infancy. We have identified a SUR1 mutation, L1544P, in a patient with the disease. Channels formed by co-transfection of Kir6.2 and the mutant SUR1 in COS cells have reduced response to MgADP (similar to10% that of the wild-type channels) and reduced surface expression (similar to19% that of the wild-type channels). However, the steady-state level of the SUR1 protein is unaffected. Treating cells with lysosomal or proteasomal inhibitors did not improve surface expression of the mutant channels, suggesting that increased degradation of mutant channels by either pathway is unlikely to account for the reduced surface expression. Removal of the RKR endoplasmic reticulum retention/retrieval trafficking motif in either SUR1 or Kir6.2 increased the surface expression of the mutant channel by similar to35 and similar to20%, respectively. The simultaneous removal of the RKR motif in both channel subunits restored surface expression of the mutant channel to the wild-type channel levels. Thus, the L1544P mutation may interfere with normal trafficking of K-ATP channels by causing improper shielding of the RKR endoplasmic reticulum retention/retrieval trafficking signals in the two channel subunits.	Oregon Hlth & Sci Univ, Ctr Res Occupat & Environm Toxicol, Portland, OR 97201 USA; Oregon Hlth & Sci Univ, Dept Med, Portland, OR 97201 USA; Oregon Hlth & Sci Univ, Dept Pediat, Portland, OR 97201 USA	Oregon Health & Science University; Oregon Health & Science University; Oregon Health & Science University	Shyng, SL (corresponding author), Oregon Hlth & Sci Univ, Ctr Res Occupat & Environm Toxicol, 3181 SW Sam Jackson Pk Rd, Portland, OR 97201 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK057699] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK57699, R01 DK057699] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aguilar-Bryan L, 1999, ENDOCR REV, V20, P101, DOI 10.1210/er.20.2.101; Ashcroft FM, 1998, TRENDS NEUROSCI, V21, P288, DOI 10.1016/S0166-2236(98)01225-9; AYNSLEYGREEN A, 1981, ARCH DIS CHILD, V56, P496, DOI 10.1136/adc.56.7.496; Bienengraeber M, 2000, FASEB J, V14, P1943, DOI 10.1096/fj.00-0027com; Bonifacino JS, 1998, ANNU REV CELL DEV BI, V14, P19, DOI 10.1146/annurev.cellbio.14.1.19; Cartier EA, 2001, P NATL ACAD SCI USA, V98, P2882, DOI 10.1073/pnas.051499698; Clement JP, 1997, NEURON, V18, P827, DOI 10.1016/S0896-6273(00)80321-9; Conti LR, 2001, J BIOL CHEM, V276, P41270, DOI 10.1074/jbc.M106555200; Dunne MJ, 1999, TRENDS ENDOCRIN MET, V10, P146, DOI 10.1016/S1043-2760(98)00135-0; Dunne MJ, 1997, NEW ENGL J MED, V336, P703, DOI 10.1056/NEJM199703063361005; Enkvetchakul D, 2000, BIOPHYS J, V78, P2334, DOI 10.1016/S0006-3495(00)76779-8; Glaser B, 2000, SEMIN PERINATOL, V24, P150, DOI 10.1053/sp.2000.6365; Huopio H, 2000, J CLIN INVEST, V106, P897, DOI 10.1172/JCI9804; Inagaki N, 1997, FEBS LETT, V409, P232, DOI 10.1016/S0014-5793(97)00488-2; INAGAKI N, 1995, SCIENCE, V270, P1166, DOI 10.1126/science.270.5239.1166; Kane C, 1996, NAT MED, V2, P1344, DOI 10.1038/nm1296-1344; LANDAU H, 1991, PEDIATRIC SURGERY LI, P187; Loo TW, 1998, J BIOL CHEM, V273, P14671, DOI 10.1074/jbc.273.24.14671; Margeta-Mitrovic M, 2000, NEURON, V27, P97, DOI 10.1016/S0896-6273(00)00012-X; Matsuo M, 2000, J BIOL CHEM, V275, P41184, DOI 10.1074/jbc.M006503200; Miki T, 1999, J MOL ENDOCRINOL, V22, P113, DOI 10.1677/jme.0.0220113; Nestorowicz A, 1997, DIABETES, V46, P1743, DOI 10.2337/diabetes.46.11.1743; Nichols CG, 1996, SCIENCE, V272, P1785, DOI 10.1126/science.272.5269.1785; Partridge CJ, 2001, J BIOL CHEM, V276, P35947, DOI 10.1074/jbc.M104762200; PERMUTT MA, 1996, DIABETES REV, V4, P347; Sharma N, 2000, KIDNEY INT, V57, P803, DOI 10.1046/j.1523-1755.2000.00918.x; Sharma N, 1999, J BIOL CHEM, V274, P20628, DOI 10.1074/jbc.274.29.20628; Shyng SL, 1998, DIABETES, V47, P1145, DOI 10.2337/diabetes.47.7.1145; Shyng SL, 1997, J GEN PHYSIOL, V110, P655, DOI 10.1085/jgp.110.6.655; Tucker SJ, 1997, NATURE, V387, P179, DOI 10.1038/387179a0; Ueda K, 1999, P NATL ACAD SCI USA, V96, P1268, DOI 10.1073/pnas.96.4.1268; Ueda K, 1997, J BIOL CHEM, V272, P22983, DOI 10.1074/jbc.272.37.22983; Zerangue N, 1999, NEURON, V22, P537, DOI 10.1016/S0896-6273(00)80708-4; Zhou ZF, 1999, J BIOL CHEM, V274, P31123, DOI 10.1074/jbc.274.44.31123; Zingman LV, 2001, NEURON, V31, P233, DOI 10.1016/S0896-6273(01)00356-7	35	101	104	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 10	2002	277	19					17139	17146		10.1074/jbc.M200363200	http://dx.doi.org/10.1074/jbc.M200363200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	551MB	11867634	hybrid			2022-12-27	WOS:000175564500106
J	Macpherson, P; Kostrominova, T; Tang, HB; Goldman, D				Macpherson, P; Kostrominova, T; Tang, HB; Goldman, D			Protein kinase c and calcium/calmodulin-activated protein kinase II (CaMIK II) suppress nicotinic acetylcholine receptor gene expression in mammalian muscle - A specific role for CaMK II in activity-dependent gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUBUNIT MESSENGER-RNA; E-BOX ELEMENTS; ELECTRICAL-ACTIVITY; ALPHA-SUBUNIT; SKELETAL-MUSCLE; MYOGENIC FACTORS; GAMMA-SUBUNIT; BETA-SUBUNIT; RAT; PHOSPHORYLATION	Nicotinic acetylcholine receptor (nAChR) gene expression is regulated by both muscle activity and increased intracellular calcium. This regulation is an important developmental event that rids receptors from the extrajunctional region of the developing muscle fiber. In avian muscle, it has been proposed that muscle activity suppresses nAChR gene expression via calcium-activated protein kinase C (PKC)-dependent phosphorylation of the myogenic transcription factor, myogenin. Here, we examined the role that PKC and other kinases play in mediating calcium- and activity-dependent suppression of nAChR genes in rat primary myotubes. We found that although activated PKC could regulate nAChR promoter activity and transiently suppressed both nAChR and myogenin gene expression, it did not appear to be required for calcium- or activity-dependent control of nAChR gene expression in mammalian muscle. Neither depletion of PKC from myotubes nor specific pharmacological inhibition of PKC blocked the suppression of nAChR gene expression produced by calcium or muscle depolarization. In contrast, we provide evidence that calcium/calmodulin-activated protein kinase II participates in mediating the effects of muscle depolarization on nAChR and myogenin gene expression.	Univ Michigan, Mental Hlth Res Inst, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Biol Chem, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Goldman, D (corresponding author), Univ Michigan, Mental Hlth Res Inst, 205 Zina Pitcher Pl, Ann Arbor, MI 48109 USA.	neuroman@umich.edu	Kostrominova, Tatiana/AAS-2371-2020		NIA NIH HHS [P01 AG10821] Funding Source: Medline; NINDS NIH HHS [R01 NS25153] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS025153] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG010821] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Adams L, 1998, J NEUROBIOL, V35, P245, DOI 10.1002/(SICI)1097-4695(19980605)35:3<245::AID-NEU2>3.0.CO;2-Z; ADAMS L, 1995, J CELL BIOL, V131, P1341, DOI 10.1083/jcb.131.5.1341; Altiok N, 2001, FEBS LETT, V487, P333, DOI 10.1016/S0014-5793(00)02311-5; BERBERICH C, 1993, EUR J BIOCHEM, V216, P395, DOI 10.1111/j.1432-1033.1993.tb18157.x; BRASIER AR, 1989, BIOTECHNIQUES, V7, P1116; CHAHINE KG, 1993, J BIOL CHEM, V268, P2893; CHAHINE KG, 1992, DEVELOPMENT, V115, P213; CHENG TC, 1995, P NATL ACAD SCI USA, V92, P561, DOI 10.1073/pnas.92.2.561; De Koninck P, 1998, SCIENCE, V279, P227, DOI 10.1126/science.279.5348.227; Dolmetsch RE, 1997, NATURE, V386, P855, DOI 10.1038/386855a0; DUCLERT A, 1991, NEUROREPORT, V2, P25, DOI 10.1097/00001756-199101000-00006; DURR I, 1994, EUR J BIOCHEM, V224, P353, DOI 10.1111/j.1432-1033.1994.00353.x; EDMONDSON DG, 1991, J BIOL CHEM, V266, P21343; Fields RD, 1997, J NEUROSCI, V17, P7252; GOLDMAN D, 1988, NEURON, V1, P329, DOI 10.1016/0896-6273(88)90081-5; GOLDMAN D, 1991, NEURON, V7, P649, DOI 10.1016/0896-6273(91)90377-C; GU X, 1995, SCIENCE, V234, P80; GUNDERSEN K, 1995, MOL CELL BIOL, V15, P7127; HUANG CF, 1992, NEURON, V9, P671, DOI 10.1016/0896-6273(92)90030-H; HUANG CF, 1994, NEURON, V13, P167, DOI 10.1016/0896-6273(94)90467-7; JAMES G, 1992, J CELL BIOL, V116, P863, DOI 10.1083/jcb.116.4.863; KLARSFELD A, 1985, P NATL ACAD SCI USA, V82, P4558, DOI 10.1073/pnas.82.13.4558; KLARSFELD A, 1989, NEURON, V2, P1229, DOI 10.1016/0896-6273(89)90307-3; Kostrominova TY, 2000, AM J PHYSIOL-REG I, V279, pR179, DOI 10.1152/ajpregu.2000.279.1.R179; LI L, 1992, CELL, V71, P1181, DOI 10.1016/S0092-8674(05)80066-2; MENDELZON D, 1994, BIOCHEMISTRY-US, V33, P2568, DOI 10.1021/bi00175a028; MERLIE JP, 1984, J CELL BIOL, V99, P332, DOI 10.1083/jcb.99.1.332; NEVILLE C, 1991, NEUROREPORT, V2, P655, DOI 10.1097/00001756-199111000-00005; NEVILLE CM, 1992, CELL MOL NEUROBIOL, V12, P511, DOI 10.1007/BF00711232; NIEDEL JE, 1986, PHOSPHOINOSITIDES RE, V7, P47; PADGETT RA, 1986, ANNU REV BIOCHEM, V55, P1119, DOI 10.1146/annurev.bi.55.070186.005351; Sanes JR, 1999, ANNU REV NEUROSCI, V22, P389, DOI 10.1146/annurev.neuro.22.1.389; Song A, 1998, MOL CELL BIOL, V18, P4994, DOI 10.1128/MCB.18.9.4994; Tang HB, 2001, J BIOL CHEM, V276, P26057, DOI 10.1074/jbc.M101670200; THAYER MJ, 1989, CELL, V58, P241, DOI 10.1016/0092-8674(89)90838-6; TOKUMITSU H, 1990, J BIOL CHEM, V265, P4315; WALKE W, 1994, J BIOL CHEM, V269, P19447; Walke W, 1996, J NEUROSCI, V16, P3641; Way KJ, 2000, TRENDS PHARMACOL SCI, V21, P181, DOI 10.1016/S0165-6147(00)01468-1; Wilusz CJ, 2001, NAT REV MOL CELL BIO, V2, P237, DOI 10.1038/35067025; WITZEMANN V, 1991, J CELL BIOL, V114, P125, DOI 10.1083/jcb.114.1.125; ZHOU JM, 1994, MOL CELL BIOL, V14, P6232, DOI 10.1128/MCB.14.9.6232	42	31	34	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 3	2002	277	18					15638	15646		10.1074/jbc.M109864200	http://dx.doi.org/10.1074/jbc.M109864200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	550PA	11877392	hybrid			2022-12-27	WOS:000175510400057
J	Austin, J; First, EA				Austin, J; First, EA			Catalysis of tyrosyl-adenylate formation by the human tyrosyl-tRNA synthetase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER-RNA-SYNTHETASE; SITE-DIRECTED MUTAGENESIS; MULTIPLE SEQUENCE ALIGNMENT; NATURAL PRODUCT SB-219383; CRYSTAL-STRUCTURE; MOBILE LOOP; SP I; INHIBITORS; ANALOGS; POTENT	Although the active site residues in the Bacillus stearothermophilus and human tyrosyl-tRNA synthetases are largely conserved, several differences exist between the two enzymes. In particular, three amino acids that stabilize the transition state for the activation of tyrosine in B. stearothermophilus tyrosyl-tRNA synthetase (Cys-35, His-48, and Lys-233) are not present in the human enzyme. This raises the question of whether the activation energy for the tyrosine activation step is higher for the human tyrosyl-tRNA synthetase than for the B. stearothermophilus enzyme. In this paper, we demonstrate that intrinsic fluorescence changes can be used to monitor the pre-steady state kinetics of human tyrosyl-tRNA synthetase. In contrast to the B. stearothermophilus enzyme, catalysis of the tyrosine activation step is potassium-dependent in the human tyrosyl-tRNA synthetase. Specifically, potassium increases the forward rate constant for tyrosine activation 260-fold in the human tyrosyl-tRNA synthetase. Comparison of the forward rate constants for catalysis of tyrosine activation by the human and B. stearothermophilus enzymes indicates that despite differences in their active sites and the potassium requirement of the human enzyme, the activation energies for tyrosine activation are identical for the two enzymes. The results of these investigations suggest that differences exist between the active sites of the bacterial and human tyrosyl-tRNA synthetases that could be exploited to design antimicrobials that target the bacterial enzyme.	Louisiana State Univ, Hlth Sci Ctr, Dept Biochem & Mol Biol, Shreveport, LA 71130 USA	Louisiana State University System; Louisiana State University Health Sciences Center at Shreveport	First, EA (corresponding author), Louisiana State Univ, Hlth Sci Ctr, Dept Biochem & Mol Biol, Shreveport, LA 71130 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM053693] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM53693] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		APPEL RD, 1994, TRENDS BIOCHEM SCI, V19, P258, DOI 10.1016/0968-0004(94)90153-8; BEIKIRCH H, 1972, EUR J BIOCHEM, V26, P182, DOI 10.1111/j.1432-1033.1972.tb01755.x; Berge JM, 2000, BIOORG MED CHEM LETT, V10, P1811, DOI 10.1016/S0960-894X(00)00348-6; Berge JM, 2000, J ANTIBIOT, V53, P1282, DOI 10.7164/antibiotics.53.1282; Brown MJB, 2000, BIOCHEMISTRY-US, V39, P6003, DOI 10.1021/bi000148v; Brown P, 2001, BIOORG MED CHEM LETT, V11, P711, DOI 10.1016/S0960-894X(01)00039-7; Bush K, 1997, CURR OPIN CHEM BIOL, V1, P169, DOI 10.1016/S1367-5931(97)80006-3; Casas C, 2001, J NEUROCHEM, V77, P904, DOI 10.1046/j.1471-4159.2001.00314.x; Engel P. C., 1996, ENZYMOLOGY LABFAX; FERSHT AR, 1975, BIOCHEMISTRY-US, V14, P5, DOI 10.1021/bi00672a002; FERSHT AR, 1988, BIOCHEMISTRY-US, V27, P1581, DOI 10.1021/bi00405a028; FERSHT AR, 1975, BIOCHEMISTRY-US, V14, P13, DOI 10.1021/bi00672a003; FERSHT AR, 1987, BIOCHEMISTRY-US, V26, P8031, DOI 10.1021/bi00399a001; FIRST EA, 1993, BIOCHEMISTRY-US, V32, P13651, DOI 10.1021/bi00212a033; FIRST EA, 1995, BIOCHEMISTRY-US, V34, P5030, DOI 10.1021/bi00015a014; FIRST EA, 1993, BIOCHEMISTRY-US, V32, P13658, DOI 10.1021/bi00212a034; FIRST EA, 1998, COMPREHENSIVE BIOL C, V1, P573; FISHER PA, 1976, BIOCHEMISTRY-US, V15, P4065, DOI 10.1021/bi00663a023; HO CK, 1986, BIOCHEMISTRY-US, V25, P1891, DOI 10.1021/bi00356a009; Houge-Frydrych CSV, 2000, J ANTIBIOT, V53, P351, DOI 10.7164/antibiotics.53.351; Jarvest RL, 1999, BIOORG MED CHEM LETT, V9, P2859, DOI 10.1016/S0960-894X(99)00488-6; Jarvest RL, 2001, BIOORG MED CHEM LETT, V11, P2499, DOI 10.1016/S0960-894X(01)00475-9; Jarvest RL, 2001, BIOORG MED CHEM LETT, V11, P715, DOI 10.1016/S0960-894X(01)00040-3; KIM JS, 1993, PROTEIN SCI, V2, P348; Kirillov S, 1997, RNA, V3, P905; Kleeman TA, 1997, J BIOL CHEM, V272, P14420, DOI 10.1074/jbc.272.22.14420; KOCH GLE, 1974, NATURE, V249, P316, DOI 10.1038/249316a0; KOCH GLE, 1974, BIOCHEMISTRY-US, V13, P2307, DOI 10.1021/bi00708a011; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDES C, 1995, BIOCHIMIE, V77, P194, DOI 10.1016/0300-9084(96)88125-9; Lodish H., 1995, MOL CELL BIOL; LOWE DM, 1985, BIOCHEMISTRY-US, V24, P5106, DOI 10.1021/bi00340a022; Macarron R, 2000, ANAL BIOCHEM, V284, P183, DOI 10.1006/abio.2000.4665; Martinis Susan A., 1999, EMBO (European Molecular Biology Organization) Journal, V18, P4591, DOI 10.1093/emboj/18.17.4591; PORATH J, 1975, NATURE, V258, P598, DOI 10.1038/258598a0; Qiu XY, 2001, PROTEIN SCI, V10, P2008, DOI 10.1110/ps.18001; QUIVY JP, 1988, J BIOL CHEM, V263, P15277; Raczniak G, 2001, TOXICOLOGY, V160, P181, DOI 10.1016/S0300-483X(00)00454-6; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; Schimmel P, 1998, FASEB J, V12, P1599, DOI 10.1096/fasebj.12.15.1599; Stefanska AL, 2000, J ANTIBIOT, V53, P345, DOI 10.7164/antibiotics.53.345; Stefanska AL, 2000, J ANTIBIOT, V53, P357, DOI 10.7164/antibiotics.53.357; Stefanska AL, 2000, J ANTIBIOT, V53, P1346, DOI 10.7164/antibiotics.53.1346; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Wakasugi K, 1999, J BIOL CHEM, V274, P23155, DOI 10.1074/jbc.274.33.23155; WARNER CK, 1976, CAN J BIOCHEM CELL B, V54, P650, DOI 10.1139/o76-094; WELLS TNC, 1991, BIOCHEMISTRY-US, V30, P5151, DOI 10.1021/bi00235a006; WELLS TNC, 1986, BIOCHEMISTRY-US, V25, P1881, DOI 10.1021/bi00356a007; WELLS TNC, 1985, NATURE, V316, P656, DOI 10.1038/316656a0; WILKINSON AJ, 1983, BIOCHEMISTRY-US, V22, P3581, DOI 10.1021/bi00284a007; WILKINSON AJ, 1984, NATURE, V307, P187, DOI 10.1038/307187a0	51	16	16	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 26	2002	277	17					14812	14820		10.1074/jbc.M103396200	http://dx.doi.org/10.1074/jbc.M103396200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	545EH	11856731	hybrid			2022-12-27	WOS:000175203000060
J	Clayton, DA; Grosshans, DR; Browning, MD				Clayton, DA; Grosshans, DR; Browning, MD			Aging and surface expression of hippocampal NMDA receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA EXPRESSION; LONG-TERM POTENTIATION; AGE; SUBUNIT; DEFICITS; NR1; DECLINES; MEMORY; LTP	Aging is known to alter many physiological processes within the brain including synaptic responses, long-term potentiation, learning, and memory. Aging has also been shown to alter the expression and distribution of N-methyl-D-aspartate (NMDA) receptors in many different brain regions, including the hippocampus. Additionally, we have recently reported that young adult rats show an activity-dependent increase in the surface expression of NMDA receptors. We have extended these observations in the present study in aged animals and have found that aged Fischer 344 rats fail to show activity-dependent changes in the surface distribution of NMDA receptors. In conjunction with this observation we have also noted that aged rats show an expression deficit in the C2 splice variant of the NR1 subunit. This subunit is preferentially shifted to the surface following stimulation in young adult animals. As the NMDA receptor is thought to play an important role in neuronal signaling, these observations suggest possible new areas of dysfunction in this receptor that might underlie age-related deficits in neuronal physiology.	Univ Colorado, Hlth Sci Ctr, Program Neurosci, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Med Scientist Training Program, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Dept Pharmacol, Denver, CO 80262 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Browning, MD (corresponding author), Univ Colorado, Hlth Sci Ctr, Program Neurosci, Box C236,4200 E 9th Ave, Denver, CO 80262 USA.	Michael.Browning@uchsc.edu						Bach ME, 1999, P NATL ACAD SCI USA, V96, P5280, DOI 10.1073/pnas.96.9.5280; Barnes CA, 1997, NEUROBIOL AGING, V18, P445, DOI 10.1016/S0197-4580(97)00044-4; Clayton DA, 2001, NEUROBIOL AGING, V22, P165, DOI 10.1016/S0197-4580(00)00196-2; CLAYTON DAM, 2002, IN PRESS J NEUROSCI; Desjardins S, 1997, NEUROBIOL AGING, V18, P37, DOI 10.1016/S0197-4580(96)00206-0; DETOLEDOMORRELL L, 1988, NEUROBIOL AGING, V9, P581, DOI 10.1016/S0197-4580(88)80117-9; Eckles-Smith K, 2000, MOL BRAIN RES, V78, P154, DOI 10.1016/S0169-328X(00)00088-7; Grosshans DR, 2002, NAT NEUROSCI, V5, P27, DOI 10.1038/nn779; Herman JP, 1998, NEUROBIOL AGING, V19, P581, DOI 10.1016/S0197-4580(98)00099-2; Huh KH, 1999, J BIOL CHEM, V274, P151, DOI 10.1074/jbc.274.1.151; Kuehl-Kovarik MC, 2000, MECH AGEING DEV, V115, P39, DOI 10.1016/S0047-6374(00)00104-4; Lynch MA, 1998, PROG NEUROBIOL, V56, P571, DOI 10.1016/S0301-0082(98)00054-9; Magnusson KR, 2000, J NEUROSCI, V20, P1666; McGahon BM, 1999, NEUROBIOL AGING, V20, P655, DOI 10.1016/S0197-4580(99)00050-0; Okabe S, 1999, J NEUROSCI, V19, P7781; Sonntag WE, 2000, BRAIN RES BULL, V51, P331, DOI 10.1016/S0361-9230(99)00259-2; Wenk GL, 2000, BRAIN RES, V885, P1, DOI 10.1016/S0006-8993(00)02792-X; Winkler A, 1999, MOL BRAIN RES, V72, P166, DOI 10.1016/S0169-328X(99)00218-1	19	52	55	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 26	2002	277	17					14367	14369		10.1074/jbc.C200074200	http://dx.doi.org/10.1074/jbc.C200074200			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	545EH	11891215	hybrid			2022-12-27	WOS:000175203000005
J	Pierrel, F; Bjork, GR; Fontecave, M; Atta, M				Pierrel, F; Bjork, GR; Fontecave, M; Atta, M			Enzymatic modification of tRNAs - MiaB is an iron-sulfur protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IN-VITRO SYNTHESIS; ESCHERICHIA-COLI; SALMONELLA-TYPHIMURIUM; RADICAL MECHANISMS; BIOTIN; DIMETHYLALLYLTRANSFERASE; QUANTITATION; RECOGNITION; ANTICODON; SYNTHASE	The product of the miaB gene, MiaB, from Escherichia coli participates in the methylthiolation of the adenosine 37 residue during modification of tRNAs that read codons beginning with uridine. A His-tagged version of MiaB has been overproduced and purified to homogeneity. Gel electrophoresis and size exclusion chromatography revealed that MiaB protein is a monomer. As isolated MiaB contains both iron and sulfide and an apoprotein form can chelate as much as 2.5-3 iron and 3-3.5 sulfur atoms per polypeptide chain. UV-visible and EPR spectroscopy of MiaB indicate the presence of a [4Fe-4S] cluster under reducing and anaerobic conditions, whereas [2Fe-2S] and [3Fe-4S] forms are generated under aerobic conditions. Preliminary site-directed mutagenesis studies suggest that Cys(157), Cys(161), and Cys(164) are involved in iron chelation and that the cluster is essential for activity. Together with the previously shown requirement of S-adenosylmethionine (AdoMet) for the methylthiolation reaction, the finding that MiaB is an iron-sulfur protein suggests that it belongs to a superfamily of enzymes that uses [Fe-S] centers and AdoMet to initiate radical catalysis. MiaB is the first and only tRNA modification enzyme known to contain an Fe-S cluster.	Univ Grenoble 1, Lab Chim & Biochim, Ctr Redox Biol,CEA, Dept Biol Mol & Struct Chim Biol,CNRS,UMR 5047, F-38054 Grenoble 09, France; Umea Univ, Dept Mol Biol, S-90187 Umea, Sweden	CEA; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); Umea University	Fontecave, M (corresponding author), Univ Grenoble 1, Lab Chim & Biochim, Ctr Redox Biol,CEA, Dept Biol Mol & Struct Chim Biol,CNRS,UMR 5047, 17 Ave Martyrs, F-38054 Grenoble 09, France.	mfontecave@cea.fr; mohamed.atta@cea.fr	Björk, Glenn/AAE-8219-2022; PIERREL, Fabien/M-6016-2014	PIERREL, Fabien/0000-0003-2083-3002				AGRIS PF, 1975, NUCLEIC ACIDS RES, V2, P691, DOI 10.1093/nar/2.5.691; Ausubel FM, 1998, CURRENT PROTOCOLS MO; BALDWIN JE, 1990, CHEM REV, V90, P1079, DOI 10.1021/cr00105a001; Begley TP, 1999, CURR OPIN CHEM BIOL, V3, P623, DOI 10.1016/S1367-5931(99)00018-6; BEINERT H, 1983, ANAL BIOCHEM, V131, P373, DOI 10.1016/0003-2697(83)90186-0; BJORK GR, 1995, TRNA STRUCTURE BIOSY, P95; BJORK GR, 1996, CELLULAR MOL BIOL, P861; Bjork GR, 1992, TRANSFER RNA PROTEIN, P23; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUCK M, 1983, ANAL BIOCHEM, V129, P1, DOI 10.1016/0003-2697(83)90044-1; CAMMACK R, 1992, ADV INORG CHEM, V38, P281, DOI 10.1016/S0898-8838(08)60066-5; CONNOLLY DM, 1991, J BACTERIOL, V173, P1711, DOI 10.1128/jb.173.5.1711-1721.1991; CONNOLLY DM, 1989, J BACTERIOL, V171, P3233, DOI 10.1128/jb.171.6.3233-3246.1989; Esberg B, 1999, J BACTERIOL, V181, P7256, DOI 10.1128/JB.181.23.7256-7265.1999; FISH WW, 1988, METHOD ENZYMOL, V158, P357, DOI 10.1016/0076-6879(88)58067-9; Fontecave M, 2001, CURR OPIN CHEM BIOL, V5, P506, DOI 10.1016/S1367-5931(00)00237-4; Frey PA, 2001, ANNU REV BIOCHEM, V70, P121, DOI 10.1146/annurev.biochem.70.1.121; GEFTER ML, 1969, BIOCHEM BIOPH RES CO, V36, P435, DOI 10.1016/0006-291X(69)90583-X; Gehrke CW, 1990, J CHROMATOGRAPHY LIB, pA3; GROSJEAN H, 1985, NUCLEIC ACIDS RES, V13, P5697, DOI 10.1093/nar/13.15.5697; Hewitson KS, 2002, J BIOL INORG CHEM, V7, P83, DOI 10.1007/s007750100268; JOHNSON MK, 1994, ENCY INORGANIC CHEM, V4, P1896; Kulzer R, 1998, J BIOL CHEM, V273, P4897, DOI 10.1074/jbc.273.9.4897; Leimkuhler S, 2001, J BIOL CHEM, V276, P22024, DOI 10.1074/jbc.M102072200; Leung HCE, 1997, J BIOL CHEM, V272, P13073, DOI 10.1074/jbc.272.20.13073; Marquet A, 2001, VITAM HORM, V61, P51; Moore JA, 1997, BIOCHEMISTRY-US, V36, P604, DOI 10.1021/bi962225l; Mueller EG, 2001, J BIOL CHEM, V276, P33588, DOI 10.1074/jbc.M104067200; Muhlenhoff U, 2000, BBA-BIOENERGETICS, V1459, P370, DOI 10.1016/S0005-2728(00)00174-2; ROSENBERG AH, 1969, J MOL BIOL, V46, P581, DOI 10.1016/0022-2836(69)90197-1; Soderberg T, 2000, BIOCHEMISTRY-US, V39, P6546, DOI 10.1021/bi992775u; Sofia HJ, 2001, NUCLEIC ACIDS RES, V29, P1097, DOI 10.1093/nar/29.5.1097; Tamarit J, 1999, J BIOL CHEM, V274, P31291, DOI 10.1074/jbc.274.44.31291	33	87	88	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 19	2002	277	16					13367	13370		10.1074/jbc.C100609200	http://dx.doi.org/10.1074/jbc.C100609200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	543HR	11882645	hybrid			2022-12-27	WOS:000175096000003
J	Forman, BM				Forman, BM			The antidiabetic agent LG100754 sensitizes cells to low concentrations of peroxisome proliferator-activated receptor gamma ligands	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PPAR-GAMMA; INSULIN-RESISTANCE; DIABETES-MELLITUS; TARGET GENE; EXPRESSION; MICE; DIFFERENTIATION; LIPODYSTROPHY; TROGLITAZONE; EFFICACY	Insulin resistance and non-insulin-dependent diabetes mellitus are major causes of morbidity and mortality in industrialized nations. Despite the alarming rise in the prevalence of this disorder, the initial molecular events that promote insulin resistance remain unclear. The data presented here demonstrate that LG100754, an antidiabetic RXR ligand, defines a novel type of nuclear receptor agonist. Surprisingly, LG100754 has minimal intrinsic transcriptional activity, instead it enhances the potency of proliferator-activated receptor (PPAR) gamma-retinoid X receptor heterodimers for PPARgamma ligands. The ability of LG100754 to both increase PPARgamma sensitivity and relieve insulin resistance implies that a deficiency in endogenous PPARgamma ligands may represent an early step in the development of insulin resistance.	City Hope Natl Med Ctr, Beckman Res Inst, Gonda Diabet & Genet Res Ctr, Div Mol Med, Duarte, CA 91010 USA	City of Hope; Beckman Research Institute of City of Hope	Forman, BM (corresponding author), City Hope Natl Med Ctr, Beckman Res Inst, Gonda Diabet & Genet Res Ctr, Div Mol Med, 1500 E Duarte Rd, Duarte, CA 91010 USA.							Arioglu E, 2000, ANN INTERN MED, V133, P263, DOI 10.7326/0003-4819-133-4-200008150-00009; Barak Y, 1999, MOL CELL, V4, P585, DOI 10.1016/S1097-2765(00)80209-9; Barroso I, 1999, NATURE, V402, P880, DOI 10.1038/47254; Berg AH, 2001, NAT MED, V7, P947, DOI 10.1038/90992; Caron M, 2001, DIABETES, V50, P1378, DOI 10.2337/diabetes.50.6.1378; Carr A, 1998, AIDS, V12, pF51, DOI 10.1097/00002030-199807000-00003; Cesario RM, 2001, MOL ENDOCRINOL, V15, P1360, DOI 10.1210/me.15.8.1360; Chawla A, 2001, MOL CELL, V7, P161, DOI 10.1016/S1097-2765(01)00164-2; Dowell P, 2000, J BIOL CHEM, V275, P41325, DOI 10.1074/jbc.M006474200; Ducluzeau PH, 2001, DIABETES, V50, P1134, DOI 10.2337/diabetes.50.5.1134; Forman Barry Marc, 2001, Trends in Molecular Medicine, V7, P331, DOI 10.1016/S1471-4914(01)02074-3; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; Hu ED, 1996, SCIENCE, V274, P2100, DOI 10.1126/science.274.5295.2100; Inzucchi SE, 1998, NEW ENGL J MED, V338, P867, DOI 10.1056/NEJM199803263381303; Kersten S, 2000, J BIOL CHEM, V275, P28488, DOI 10.1074/jbc.M004029200; Kim JB, 1998, P NATL ACAD SCI USA, V95, P4333, DOI 10.1073/pnas.95.8.4333; Kishida K, 2001, J BIOL CHEM, V276, P48572, DOI 10.1074/jbc.M108213200; Kolehmainen M, 2001, OBES RES, V9, P706, DOI 10.1038/oby.2001.95; Kubota N, 1999, MOL CELL, V4, P597, DOI 10.1016/S1097-2765(00)80210-5; Miles PDG, 2000, J CLIN INVEST, V105, P287, DOI 10.1172/JCI8538; Mukherjee R, 1997, NATURE, V386, P407, DOI 10.1038/386407a0; Nadler ST, 2000, P NATL ACAD SCI USA, V97, P11371, DOI 10.1073/pnas.97.21.11371; Olefsky JM, 2000, TRENDS ENDOCRIN MET, V11, P362, DOI 10.1016/S1043-2760(00)00306-4; Olefsky JM, 2000, J CLIN INVEST, V106, P467, DOI 10.1172/JCI10843; Reginato MJ, 1999, TRENDS ENDOCRIN MET, V10, P9, DOI 10.1016/S1043-2760(98)00110-6; Rosen ED, 1999, MOL CELL, V4, P611, DOI 10.1016/S1097-2765(00)80211-7; Rosen ED, 2001, J BIOL CHEM, V276, P37731, DOI 10.1074/jbc.R100034200; Rosenfeld MG, 2001, J BIOL CHEM, V276, P36865, DOI 10.1074/jbc.R100041200; Saltiel AR, 2001, CELL, V104, P517, DOI 10.1016/S0092-8674(01)00239-2; Savage DB, 2001, DIABETES, V50, P2199, DOI 10.2337/diabetes.50.10.2199; Spiegelman BM, 2001, CELL, V104, P531, DOI 10.1016/S0092-8674(01)00240-9; Steppan CM, 2001, NATURE, V409, P307, DOI 10.1038/35053000; Synold TW, 2001, NAT MED, V7, P584, DOI 10.1038/87912; TONTONOZ P, 1995, MOL CELL BIOL, V15, P351, DOI 10.1128/MCB.15.1.351; Way JM, 2001, J BIOL CHEM, V276, P25651, DOI 10.1074/jbc.C100189200; Willson TM, 2000, J MED CHEM, V43, P527, DOI 10.1021/jm990554g; YAO TP, 1993, NATURE, V366, P476, DOI 10.1038/366476a0; Yoon JC, 2000, MOL CELL BIOL, V20, P5343, DOI 10.1128/MCB.20.14.5343-5349.2000; Young PW, 1998, J PHARMACOL EXP THER, V284, P751; Zhang B, 1996, J BIOL CHEM, V271, P9455, DOI 10.1074/jbc.271.16.9455	40	22	22	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 12	2002	277	15					12503	12506		10.1074/jbc.C200004200	http://dx.doi.org/10.1074/jbc.C200004200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	542GZ	11877384	hybrid			2022-12-27	WOS:000175036300005
J	Stansel, RM; Subramanian, D; Griffith, JD				Stansel, RM; Subramanian, D; Griffith, JD			p53 binds telomeric single strand overhangs and t-loop junctions in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA; PROTEIN; END; KU; YEAST; TRF2	The interaction of p53 with a human model telomere in vitro was examined by electron microscopy. p53 demonstrated a sequence-independent affinity for telomeric DNA in vitro, localizing to the 3' single strand overhang and the t-loop junction both in the presence and absence of associated TRF2. Binding was not observed above background along the duplex telomeric repeats. However, the efficiency of TRF2-catalyzed t-loop formation on the model DNA was increased 2-fold in the presence of p53 although a variety of single strand or Holliday junction-binding proteins did not facilitate t-loop formation. These results suggest that p53 has an active role in telomere maintenance and structure through association with the t-loop junction.	Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill	Griffith, JD (corresponding author), Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA.	jdg@med.unc.edu			NCI NIH HHS [CA70343] Funding Source: Medline; NIGMS NIH HHS [GM31819] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA070343] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031819] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAKALKIN G, 1994, P NATL ACAD SCI USA, V91, P413, DOI 10.1073/pnas.91.1.413; Bianchi A, 1999, J BIOL CHEM, V274, P21223, DOI 10.1074/jbc.274.30.21223; BIANCHI A, 1999, THESIS ROCKEFELLER U; CHASE JW, 1980, NUCLEIC ACIDS RES, V8, P3215, DOI 10.1093/nar/8.14.3215; de Bruin D, 2000, MOL CELL BIOL, V20, P7991, DOI 10.1128/MCB.20.21.7991-8000.2000; de Bruin D, 2001, NATURE, V409, P109, DOI 10.1038/35051119; Gradia S, 1997, CELL, V91, P995, DOI 10.1016/S0092-8674(00)80490-0; Gravel S, 1998, SCIENCE, V280, P741, DOI 10.1126/science.280.5364.741; Griffith JD, 1999, CELL, V97, P503, DOI 10.1016/S0092-8674(00)80760-6; Grunstein M, 1997, CURR OPIN CELL BIOL, V9, P383, DOI 10.1016/S0955-0674(97)80011-7; Hsu HL, 2000, GENE DEV, V14, P2807, DOI 10.1101/gad.844000; Hsu HL, 1999, P NATL ACAD SCI USA, V96, P12454, DOI 10.1073/pnas.96.22.12454; JAYARAMAN L, 1995, CELL, V81, P1021, DOI 10.1016/S0092-8674(05)80007-8; Karlseder J, 1999, SCIENCE, V283, P1321, DOI 10.1126/science.283.5406.1321; KERN SE, 1991, SCIENCE, V252, P1708, DOI 10.1126/science.2047879; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Lee SM, 1997, J BIOL CHEM, V272, P7532, DOI 10.1074/jbc.272.11.7532; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Munoz-Jordan JL, 2001, EMBO J, V20, P579, DOI 10.1093/emboj/20.3.579; Murti KG, 1999, P NATL ACAD SCI USA, V96, P14436, DOI 10.1073/pnas.96.25.14436; NISSEN MS, 1991, J BIOL CHEM, V266, P19945; Oren M, 1999, CELL MOL LIFE SCI, V55, P9, DOI 10.1007/s000180050265; Song K, 2000, FEBS LETT, V481, P81, DOI 10.1016/S0014-5793(00)01958-X; Stansel RM, 2001, EMBO J, V20, P5532; STEINMEYER K, 1988, ONCOGENE, V3, P501; Tong WM, 2001, MOL CELL BIOL, V21, P4046, DOI 10.1128/MCB.21.12.4046-4054.2001; van Steensel B, 1998, CELL, V92, P401, DOI 10.1016/S0092-8674(00)80932-0; WU L, 1995, MOL CELL BIOL, V15, P497, DOI 10.1128/MCB.15.1.497	28	46	46	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 5	2002	277	14					11625	11628		10.1074/jbc.C100764200	http://dx.doi.org/10.1074/jbc.C100764200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	539AC	11859067	Green Published, hybrid			2022-12-27	WOS:000174846400003
J	Cho, HJ; Jeong, HG; Lee, JS; Woo, ER; Hyun, JW; Chung, MH; You, HJ				Cho, HJ; Jeong, HG; Lee, JS; Woo, ER; Hyun, JW; Chung, MH; You, HJ			Oncogenic H-Ras enhances DNA repair through the Ras/phosphatidylinositol 3-kinase/Rac1 pathway in NIH3T3 cells - Evidence for association with reactive oxygen species	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; CISPLATIN RESISTANCE; TRANSCRIPTION FACTOR; SIGNAL-TRANSDUCTION; MESSENGER-RNA; CROSS-LINKS; N-RAS; P53; EXPRESSION; TRANSFORMATION	This study investigated the role of oncogenic H-Ras in DNA repair capacity in NIH3T3 cells. Expression of dominant-positive H-Ras (V12-H-Ras) enhanced the host cell reactivation of luciferase activity from UV-irradiated and cisplatin-treated plasmids and also increased the unscheduled DNA synthesis following cisplatin or UV treatment of cells. This observed enhancement of DNA repair capacity was inhibited by transient transfection with dominant-negative H-Ras (N17-H-Ras) or Rac1 (N17-Rac1) plasmids. Moreover, stable transfection of dominant-positive Rac1 (V12-Rac1) further enhanced DNA repair capacity. Because reactive oxygen species (ROS) are known to be a downstream effector of oncogenic Ras, we examined the role of ROS in DNA repair capacity. We found that ROS production by V12-H-Ras expression was mediated by the Ras/phosphatidylinositol 3-kinase (PI3K)/Rac1/NADPH oxidase-dependent pathway and that pretreatment of V12-H-Ras-transformed cells with an antioxidant (N-acetylcysteine) and an NADPH oxidase inhibitor (diphenyleneiodonium) decreased DNA repair capacity. Similarly, treatment with PI3K inhibitors (wortmannin and LY294002) inhibited the ability of oncogenic H-Ras to enhance DNA repair capacity. Furthermore, inhibition of the Ras/PI3K/Rac1/NADPH oxidase pathway resulted in increased sensitivity to cisplatin and UV in V12-H-Ras-expressing NIH3T3 cells. Taken together, these results provide evidence that oncogenic H-Ras activates DNA repair capacity through the RaS/PI3K/Rac1/NADPH oxidase-dependent pathway and that increased ROS production via this signaling pathway is required for enhancement of the DNA repair capacity induced by oncogenic H-Ras.	Chosun Univ, Dept Pharmacol, Sch Med, Kwangju 501759, South Korea; Chosun Univ, Res Ctr Proteineous Mat, Kwangju 501759, South Korea; Chosun Univ, Dept Pharm, Kwangju 501759, South Korea; Chosun Univ, Dept Biol Sci, Kwangju 501759, South Korea; Seoul Natl Univ, Coll Med, Dept Pharmacol, Seoul 110799, South Korea	Chosun University; Chosun University; Chosun University; Chosun University; Seoul National University (SNU)	You, HJ (corresponding author), Chosun Univ, Dept Pharmacol, Sch Med, 375 Seosuk Dong, Kwangju 501759, South Korea.	hjyou@mail.chosun.ac.kr		Jeong, Hye Gwang/0000-0002-8020-8914; You, Ho Jin/0000-0002-0530-4017				Abe J, 1998, TRENDS CARDIOVAS MED, V8, P59, DOI 10.1016/S1050-1738(97)00133-3; AUCHSCHWELK W, 1992, J CARDIOVASC PHARM S, V9, P62; BAAS AS, 1995, CIRC RES, V77, P29, DOI 10.1161/01.RES.77.1.29; Bae YS, 2000, J BIOL CHEM, V275, P10527, DOI 10.1074/jbc.275.14.10527; BASNAK'YAN A G, 1989, Molekulyarnaya Biologiya (Moscow), V23, P750; Bernhard EJ, 2000, CANCER RES, V60, P6597; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BOS JL, 1989, CANCER RES, V49, P4682; Bouziane M, 2000, MUTAT RES-DNA REPAIR, V461, P15, DOI 10.1016/S0921-8777(00)00036-7; Burdon RH, 1996, FREE RADICAL RES, V24, P81, DOI 10.3109/10715769609088004; CHILAKAMARTI VR, 1998, P NATL ACAD SCI USA, V95, P5061; Costa M, 1999, NUCLEIC ACIDS RES, V27, P817, DOI 10.1093/nar/27.3.817; Crul M, 1997, CANCER TREAT REV, V23, P341, DOI 10.1016/S0305-7372(97)90032-3; Dempke W, 2000, ANTI-CANCER DRUG, V11, P225, DOI 10.1097/00001813-200004000-00001; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; Dhenaut A, 2000, MUTAT RES-DNA REPAIR, V461, P109, DOI 10.1016/S0921-8777(00)00042-2; Fan JG, 1997, BIOCHEM PHARMACOL, V53, P1203, DOI 10.1016/S0006-2952(97)00101-9; Fan SJ, 2000, ONCOGENE, V19, P2212, DOI 10.1038/sj.onc.1203566; Fang L, 2001, EMBO J, V20, P1931, DOI 10.1093/emboj/20.8.1931; FITZGERALD TJ, 1985, AM J CLIN ONCOL-CANC, V8, P517, DOI 10.1097/00000421-198512000-00012; Gupta A, 1999, CARCINOGENESIS, V20, P2063, DOI 10.1093/carcin/20.11.2063; Guyton KZ, 1996, J BIOL CHEM, V271, P4138, DOI 10.1074/jbc.271.7.3604; HAGAG N, 1986, NATURE, V319, P680, DOI 10.1038/319680a0; HALLIWELL B, 1989, BRIT J EXP PATHOL, V70, P737; HERMENS AF, 1992, CANCER RES, V52, P3073; Holford J, 1998, INT J CANCER, V77, P94, DOI 10.1002/(SICI)1097-0215(19980703)77:1<94::AID-IJC15>3.3.CO;2-Y; HURTA RAR, 1995, J CELL BIOCHEM, V57, P543, DOI 10.1002/jcb.240570319; Hwang BJ, 1999, P NATL ACAD SCI USA, V96, P424, DOI 10.1073/pnas.96.2.424; Imai K, 1998, GENE, V222, P287, DOI 10.1016/S0378-1119(98)00485-5; Irani K, 1997, SCIENCE, V275, P1649, DOI 10.1126/science.275.5306.1649; Ishii T, 2000, J BIOL CHEM, V275, P16023, DOI 10.1074/jbc.275.21.16023; ISONISHI S, 1991, CANCER RES, V51, P5903; Joneson T, 1996, SCIENCE, V271, P810, DOI 10.1126/science.271.5250.810; KHOSRAVIFAR R, 1994, CANCER METAST REV, V13, P67, DOI 10.1007/BF00690419; Korzets A, 1999, J LAB CLIN MED, V133, P362, DOI 10.1016/S0022-2143(99)90067-7; Lee SW, 2000, P NATL ACAD SCI USA, V97, P8302, DOI 10.1073/pnas.150024397; Lee-Kwon W, 1998, BIOCHEM J, V331, P591, DOI 10.1042/bj3310591; LEVY E, 1994, CARCINOGENESIS, V15, P845, DOI 10.1093/carcin/15.5.845; Liu RG, 2001, ONCOGENE, V20, P1486, DOI 10.1038/sj.onc.1204214; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Masumoto N, 1999, INT J CANCER, V80, P731, DOI 10.1002/(SICI)1097-0215(19990301)80:5<731::AID-IJC17>3.0.CO;2-H; McKay BC, 1999, CARCINOGENESIS, V20, P1389, DOI 10.1093/carcin/20.8.1389; NIE ZR, 1995, CANCER RES, V55, P4760; NIIMI S, 1991, BRIT J CANCER, V63, P237, DOI 10.1038/bjc.1991.56; PEREZ RP, 1993, CANCER RES, V53, P3771; PETERS GJ, 1993, INT J CANCER, V54, P450, DOI 10.1002/ijc.2910540316; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; Scherer SJ, 2000, J BIOL CHEM, V275, P37469, DOI 10.1074/jbc.M006990200; SKLAR MD, 1988, SCIENCE, V239, P645, DOI 10.1126/science.3277276; SKLER MD, 1908, CANCER RES, V48, P793; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; STAMPFER MJ, 1993, NEW ENGL J MED, V328, P1444, DOI 10.1056/NEJM199305203282003; Suzukawa K, 2000, J BIOL CHEM, V275, P13175, DOI 10.1074/jbc.275.18.13175; Thannickal VJ, 2000, AM J PHYSIOL-LUNG C, V279, pL1005; Ward RA, 2000, J BIOL CHEM, V275, P36713, DOI 10.1074/jbc.M003017200; White MA, 1996, J BIOL CHEM, V271, P16439, DOI 10.1074/jbc.271.28.16439; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; Woo RA, 1998, NATURE, V394, P700, DOI 10.1038/29343; WUKI, 1998, AM J PHYSIOL, V275, pL780; Yang JQ, 1999, MOL CARCINOGEN, V26, P180; Yen L, 1997, ONCOGENE, V14, P1827, DOI 10.1038/sj.onc.1201019; ZAUBERMAN A, 1995, NUCLEIC ACIDS RES, V23, P2584, DOI 10.1093/nar/23.14.2584; Zeng L, 1999, METH MOL B, V113, P87; Zhou JM, 2001, EMBO J, V20, P914, DOI 10.1093/emboj/20.4.914; Zhu QZ, 2000, J BIOL CHEM, V275, P11492, DOI 10.1074/jbc.275.15.11492; Ziemann C, 1999, CARCINOGENESIS, V20, P407, DOI 10.1093/carcin/20.3.407	66	48	49	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 31	2002	277	22					19358	19366		10.1074/jbc.M200933200	http://dx.doi.org/10.1074/jbc.M200933200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	557EH	11884408	hybrid			2022-12-27	WOS:000175894800017
J	Arai, Y; Kondo, T; Tanabe, K; Zhao, QL; Li, FJ; Ogawa, R; Li, M; Kasuya, M				Arai, Y; Kondo, T; Tanabe, K; Zhao, QL; Li, FJ; Ogawa, R; Li, M; Kasuya, M			Enhancement of hyperthermia-induced apoptosis by local anesthetics on human histiocytic lymphoma U937 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RANDOMIZED-TRIAL; LEUKEMIA-CELLS; MELANOMA; ATP; MITOCHONDRIA; POTENTIATION; RADIOTHERAPY; IRRADIATION; LIDOCAINE; MECHANISM	The combined effects of hyperthermia. at 44 degreesC and local anesthetics on apoptosis in human histiocytic lymphoma U937 cells were investigated. When the cells were exposed to hyperthermia for 10 min marginal DNA fragmentation and nuclear fragmentation were observed. In the presence of amide-type local anesthetics further enhancement was found depending on concentration. The order of the concentration required for maximum induction was the reverse order of the lipophilicity (prilocaine > lidocaine > bupivacaine). Western blotting revealed that in hyperthermia there was initial release of Ca2+ from the intracellular store site as indicated by increased expression of the type 1 inositol-1,4,5-trisphosphate receptor. However, the combination with lidocaine did not induce any further enhancement. Lidocaine enhanced the decrease in ATP content and the increase in intracellular Ca2+ concentration in individual cells induced by hyperthermia. In addition, superoxide formation, decrease in the mitochondrial membrane potential, and activation of intracellular caspase-3 were found in the cells treated with hyperthermia and lidocaine. All of these were suppressed in part in the presence of the intracellular Ca2+ ion chelator BAPTA-AM (bis-(O-aminophenoxy)-ethane-N,N,N',N'-tetraacetic acid-acetoxymethyl). The present results indicate that local anesthetics at optimal concentrations enhance hyperthermia-induced apoptosis via Ca2+- and mitochondria-dependent pathways. Initial release of Ca2+ from intracellular store sites caused by hyperthermia and followed by the subsequent increase in the intracellular Ca2+ concentration and the additional activation of the mitochondrial caspase-dependent pathway (partly regulated by intracellular Ca2+ concentration) plays a crucial role in the enhancement of apoptosis induced by the combination of hyperthermia and lidocaine.	Toyama Med & Pharmaceut Univ, Fac Med, Dept Radiol Sci, Toyama 9300194, Japan; Toyama Med & Pharmaceut Univ, Fac Med, Dept Publ Hlth, Toyama 9300194, Japan	University of Toyama; University of Toyama	Kondo, T (corresponding author), Toyama Med & Pharmaceut Univ, Fac Med, Dept Radiol Sci, 2630 Sugitani, Toyama 9300194, Japan.	kondot@ms.toyama-mpu.ac.jp						Arita K, 2000, BIOCHEM PHARMACOL, V60, P905, DOI 10.1016/S0006-2952(00)00406-8; Bruno T, 1998, ONCOL RES, V10, P143; BUTTERWORTH JF, 1990, ANESTHESIOLOGY, V72, P711, DOI 10.1097/00000542-199004000-00022; CLARK AW, 1983, CANCER RES, V43, P1716; COSS RA, 1989, INT J HYPERTHER, V5, P383, DOI 10.3109/02656738909140465; Eguchi Y, 1997, CANCER RES, V57, P1835; Eguchi Y, 1999, CANCER RES, V59, P2174; Gorman A, 1997, FEBS LETT, V404, P27, DOI 10.1016/S0014-5793(97)00069-0; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; GROUSELLE M, 1990, BIOCHEM J, V271, P269, DOI 10.1042/bj2710269; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HABARA Y, 1991, CELL CALCIUM, V12, P533, DOI 10.1016/0143-4160(91)90073-N; Hopcia KL, 1996, RADIAT RES, V145, P315, DOI 10.2307/3578987; Jayaraman T, 1997, MOL CELL BIOL, V17, P3005, DOI 10.1128/MCB.17.6.3005; Kameda K, 2001, INT J RADIAT ONCOL, V49, P1369, DOI 10.1016/S0360-3016(01)01437-7; Karniel M, 2000, MOL GENET METAB, V69, P40, DOI 10.1006/mgme.1999.2954; Khan AA, 1996, SCIENCE, V273, P503, DOI 10.1126/science.273.5274.503; Kimura C, 1998, EXP CELL RES, V239, P411, DOI 10.1006/excr.1997.3912; KINGSTON CA, 1993, ANTICANCER RES, V13, P2335; KONDO T, 1993, CELL CALCIUM, V14, P621, DOI 10.1016/0143-4160(93)90087-M; Li M, 2000, J BIOL CHEM, V275, P39702, DOI 10.1074/jbc.M007369200; MIZUNO S, 1982, CANCER RES, V42, P4726; OVERGAARD J, 1989, INT J RADIAT ONCOL, V16, P535, DOI 10.1016/0360-3016(89)90470-7; Overgaard J, 1996, INT J HYPERTHER, V12, P3, DOI 10.3109/02656739609023685; ROBINS HI, 1984, CANCER, V54, P2831, DOI 10.1002/1097-0142(19841215)54:12<2831::AID-CNCR2820541202>3.0.CO;2-8; ROBINS HI, 1983, CANCER RES, V43, P3187; SCURR C, 1990, SCI FDN ANESTHESIA, P636; Seegenschmiedt M. H., 1995, Strahlentherapie und Onkologie, V171, P560; SELLINS KS, 1987, J IMMUNOL, V139, P3199; Senisterra GA, 2000, INT J HYPERTHER, V16, P1, DOI 10.1080/026567300285385; Sneed PK, 1998, INT J RADIAT ONCOL, V40, P287, DOI 10.1016/S0360-3016(97)00731-1; UEDA I, 1977, ANESTHESIOLOGY, V46, P327, DOI 10.1097/00000542-197705000-00004; van der Zee J, 2000, LANCET, V355, P1119, DOI 10.1016/S0140-6736(00)02059-6; VANHEERDE WL, 1995, THROMB HAEMOSTASIS, V73, P172; Vernon CC, 1996, INT J RADIAT ONCOL, V35, P731; Wessalowski R, 1998, CANCER, V82, P793, DOI 10.1002/(SICI)1097-0142(19980215)82:4<793::AID-CNCR24>3.3.CO;2-Q; YATVIN MB, 1979, SCIENCE, V205, P195, DOI 10.1126/science.451588; YAU TM, 1979, RADIAT RES, V80, P523, DOI 10.2307/3574994; Zapata JM, 1998, J BIOL CHEM, V273, P6916, DOI 10.1074/jbc.273.12.6916	39	68	71	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 24	2002	277	21					18986	18993		10.1074/jbc.M108084200	http://dx.doi.org/10.1074/jbc.M108084200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	558PM	11861640	hybrid			2022-12-27	WOS:000175975800097
J	Hotokezaka, Y; Tobben, U; Hotokezaka, H; van Leyen, K; Beatrix, B; Smith, DH; Nakamura, T; Wiedmann, M				Hotokezaka, Y; Tobben, U; Hotokezaka, H; van Leyen, K; Beatrix, B; Smith, DH; Nakamura, T; Wiedmann, M			Interaction of the eukaryotic elongation factor 1A with newly synthesized polypeptides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL RECOGNITION PARTICLE; FACTOR EF-TU; ENDOPLASMIC-RETICULUM; FACTOR 1-ALPHA; MESSENGER-RNA; SECRETORY PROTEIN; CROSS-LINKING; IN-VIVO; COMPLEX; TRANSLOCATION	eEF1A, the eukaryotic homologue of bacterial elongation factor Tu, is a well characterized translation elongation factor responsible for delivering aminoacyl-tRNAs to the A-site at the ribosome. Here we show for the first time that eEF1A also associates with the nascent chain distal to the peptidyltransferase center. This is demonstrated for a variety of nascent chains of different lengths and sequences. Interestingly, unlike other ribosome-associated factors, eEF1A also interacts with polypeptides after their release from the ribosome. We demonstrate that eEF1A does not bind to correctly folded full-length proteins but interacts specifically with proteins that are unable to fold correctly in a cytosolic environment. This association was demonstrated both by photo-cross-linking and by a functional refolding assay.	Mem Sloan Kettering Canc Ctr, Cellular Biochem & Biophys Program, New York, NY 10021 USA; Nagasaki Univ, Sch Dent, Dept Orthodont, Nagasaki 8528588, Japan; Free Univ Berlin, Inst Kristallog, D-14195 Berlin, Germany	Memorial Sloan Kettering Cancer Center; Nagasaki University; Free University of Berlin	Wiedmann, M (corresponding author), Mem Sloan Kettering Canc Ctr, Cellular Biochem & Biophys Program, 1275 York Ave, New York, NY 10021 USA.	m-wiedmann@ski.mskcc.org			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050920] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM50920-01] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Beatrix B, 2000, J BIOL CHEM, V275, P37838, DOI 10.1074/jbc.M006368200; BLOBEL G, 1980, P NATL ACAD SCI-BIOL, V77, P1496, DOI 10.1073/pnas.77.3.1496; BRUNNER J, 1993, ANNU REV BIOCHEM, V62, P483, DOI 10.1146/annurev.bi.62.070193.002411; Bukau B, 2000, CELL, V101, P119, DOI 10.1016/S0092-8674(00)80806-5; Caldas TD, 1998, J BIOL CHEM, V273, P11478, DOI 10.1074/jbc.273.19.11478; CONDEELIS J, 1995, TRENDS BIOCHEM SCI, V20, P169, DOI 10.1016/S0968-0004(00)88998-7; DESHAIES RJ, 1988, TRENDS BIOCHEM SCI, V13, P384, DOI 10.1016/0968-0004(88)90180-6; Ellis RJ, 2001, TRENDS BIOCHEM SCI, V26, P597, DOI 10.1016/S0968-0004(01)01938-7; ERICKSON AH, 1983, METHOD ENZYMOL, V96, P38; FRYDMAN J, 1992, EMBO J, V11, P4767, DOI 10.1002/j.1460-2075.1992.tb05582.x; FRYDMAN J, 1994, NATURE, V370, P111, DOI 10.1038/370111a0; Funfschilling U, 1999, MOL BIOL CELL, V10, P3289, DOI 10.1091/mbc.10.10.3289; George R, 1998, P NATL ACAD SCI USA, V95, P2296, DOI 10.1073/pnas.95.5.2296; GILMORE R, 1991, METHOD CELL BIOL, V34, P223; GONEN H, 1994, P NATL ACAD SCI USA, V91, P7648, DOI 10.1073/pnas.91.16.7648; GORLICH D, 1991, METHOD CELL BIOL, V34, P241; HENDRICK JP, 1993, P NATL ACAD SCI USA, V90, P10216, DOI 10.1073/pnas.90.21.10216; JACKSON RJ, 1983, METHOD ENZYMOL, V96, P50; Keenan RJ, 2001, ANNU REV BIOCHEM, V70, P755, DOI 10.1146/annurev.biochem.70.1.755; Kudlicki W, 1997, J BIOL CHEM, V272, P32206, DOI 10.1074/jbc.272.51.32206; KURZCHALIA TV, 1986, NATURE, V320, P634, DOI 10.1038/320634a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAURING B, 1995, P NATL ACAD SCI USA, V92, P9435, DOI 10.1073/pnas.92.21.9435; Liu G, 1996, J CELL BIOL, V135, P953, DOI 10.1083/jcb.135.4.953; Moller I, 1998, P NATL ACAD SCI USA, V95, P13425, DOI 10.1073/pnas.95.23.13425; Moller I, 1998, FEBS LETT, V441, P1, DOI 10.1016/S0014-5793(98)01440-9; MOTHES W, 1994, EMBO J, V13, P3973, DOI 10.1002/j.1460-2075.1994.tb06713.x; Naylor DJ, 2001, BIOCHEM SOC SYMP, V68, P45, DOI 10.1042/bss0680045; Paschen SA, 2001, IUBMB LIFE, V52, P101, DOI 10.1080/15216540152845894; Pfanner N, 2001, NAT REV MOL CELL BIO, V2, P339, DOI 10.1038/35073006; Pfund C, 1998, EMBO J, V17, P3981, DOI 10.1093/emboj/17.14.3981; Plath K, 2000, J CELL BIOL, V151, P167, DOI 10.1083/jcb.151.1.167; Rapoport TA, 1996, ANNU REV BIOCHEM, V65, P271; Schubert U, 2000, NATURE, V404, P770, DOI 10.1038/35008096; SHIINA N, 1994, SCIENCE, V266, P282, DOI 10.1126/science.7939665; STRYER L, 1995, BIOCHEMISTRY-US, P898; Turner GC, 2000, SCIENCE, V289, P2117, DOI 10.1126/science.289.5487.2117; WALTER P, 1981, J CELL BIOL, V91, P545, DOI 10.1083/jcb.91.2.545; Wickner S, 1999, SCIENCE, V286, P1888, DOI 10.1126/science.286.5446.1888; WIEDMANN B, 1994, NATURE, V370, P434, DOI 10.1038/370434a0	40	67	72	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 24	2002	277	21					18545	18551		10.1074/jbc.M201022200	http://dx.doi.org/10.1074/jbc.M201022200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	558PM	11893745	hybrid			2022-12-27	WOS:000175975800040
J	Strano, S; Fontemaggi, G; Costanzo, A; Rizzo, MG; Monti, O; Baccarini, A; Del Sal, G; Levrero, M; Sacchi, A; Oren, M; Blandino, G				Strano, S; Fontemaggi, G; Costanzo, A; Rizzo, MG; Monti, O; Baccarini, A; Del Sal, G; Levrero, M; Sacchi, A; Oren, M; Blandino, G			Physical interaction with human tumor-derived p53 mutants inhibits p63 activities	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAIN-OF-FUNCTION; KINASE C-ABL; P73 GENE; DNA-DAMAGE; CELL-LINES; WILD-TYPE; HEPATOCELLULAR-CARCINOMA; TRANSCRIPTIONAL ACTIVITY; APOPTOTIC RESPONSE; FUNCTION MUTATIONS	The p53 tumor suppressor gene is the most frequent target for genetic alterations in human cancers, whereas the recently discovered homologues p73 and p63 are rarely mutated. We and others have previously reported that human tumor-derived p53 mutants can engage in a physical association with different isoforms of p73, inhibiting their transcriptional activity. Here, we report that human tumor-derived p53 mutants can associate in vitro and in vivo with p63 through their respective core domains. We show that the interaction with mutant p53 impairs in vitro and in vivo sequence-specific DNA binding of p63 and consequently affects its transcriptional activity. We also report that in cells carrying endogenous mutant p53, such as T47D cells, p63 is unable to recruit some of its target gene promoters. Unlike wild-type p53, the binding to specific p53 mutants markedly counteracts p63-induced growth inhibition. This effect is, at least partially, mediated by the core domain of mutant p53. Thus, inactivation of p53 family members may contribute to the biological properties of specific p53 mutants in promoting tumorigenesis and in conferring selective survival advantage to cancer cells.	Regina Elena Inst Canc Res, Mol Oncogenesis Lab, I-00158 Rome, Italy; Univ Roma La Sapienza, Fdn Andrea Cesalpino, Lab Gene Express, I-00161 Rome, Italy; Dipartimento Biochim Biofis & Chim Macromol, Lab Nazl CIB, I-34012 Trieste, Italy; Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel	IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; Sapienza University Rome; Weizmann Institute of Science	Blandino, G (corresponding author), Regina Elena Inst Canc Res, Mol Oncogenesis Lab, Via Messi Doro 156, I-00158 Rome, Italy.	blandino@ifo.it	strano, sabrina/B-6743-2013; Costanzo, Antonio/D-3896-2012; Blandino, Giovanni/B-1137-2013; Rizzo, Maria Giulia/B-2107-2018; Strano, Sabrina/K-9654-2016; Costanzo, Antonio/GZG-2433-2022; Fontemaggi, Giulia/K-9702-2016; Levrero, Massimo/G-5680-2016	strano, sabrina/0000-0002-6341-4230; Blandino, Giovanni/0000-0002-6970-2241; Rizzo, Maria Giulia/0000-0002-5009-2412; Costanzo, Antonio/0000-0001-9697-2557; Fontemaggi, Giulia/0000-0001-8332-8842; Oren, Moshe/0000-0003-4311-7172; Levrero, Massimo/0000-0002-4978-0875				Aas T, 1996, NAT MED, V2, P811, DOI 10.1038/nm0796-811; Agami R, 1999, NATURE, V399, P809; BARAK Y, 1994, GENE DEV, V8, P1739, DOI 10.1101/gad.8.15.1739; Blagosklonny MV, 2000, FASEB J, V14, P1901, DOI 10.1096/fj.99-1078rev; Blandino G, 1999, ONCOGENE, V18, P477, DOI 10.1038/sj.onc.1202314; BUCKBINDER L, 1995, NATURE, V377, P646, DOI 10.1038/377646a0; Bullock AN, 2001, NAT REV CANCER, V1, P68, DOI 10.1038/35094077; Celli J, 1999, CELL, V99, P143, DOI 10.1016/S0092-8674(00)81646-3; Chan TA, 1999, NATURE, V401, P616, DOI 10.1038/44188; Costanzo A, 2002, MOL CELL, V9, P175, DOI 10.1016/S1097-2765(02)00431-8; Crook T, 2000, ONCOGENE, V19, P3439, DOI 10.1038/sj.onc.1203656; CROOK T, 1992, EMBO J, V11, P3935, DOI 10.1002/j.1460-2075.1992.tb05487.x; De Laurenzi V, 1999, CELL DEATH DIFFER, V6, P389, DOI 10.1038/sj.cdd.4400521; De Laurenzi V, 1998, J EXP MED, V188, P1763, DOI 10.1084/jem.188.9.1763; Di Como CJ, 1999, MOL CELL BIOL, V19, P1438; DITTMER D, 1993, NAT GENET, V4, P42, DOI 10.1038/ng0593-42; Frazier MW, 1998, MOL CELL BIOL, V18, P3735, DOI 10.1128/MCB.18.7.3735; Gaiddon C, 2001, MOL CELL BIOL, V21, P1874, DOI 10.1128/MCB.21.5.1874-1887.2001; Gong JG, 1999, NATURE, V399, P806; Gualberto A, 1998, P NATL ACAD SCI USA, V95, P5166, DOI 10.1073/pnas.95.9.5166; Hainaut P, 1997, NUCLEIC ACIDS RES, V25, P151, DOI 10.1093/nar/25.1.151; Hermeking H, 1997, MOL CELL, V1, P3, DOI 10.1016/S1097-2765(00)80002-7; Hollstein M, 1997, Recent Results Cancer Res, V143, P369; HSIAO M, 1994, AM J PATHOL, V145, P702; Hussain SP, 1998, CANCER RES, V58, P4023; Jost CA, 1997, NATURE, V389, P191, DOI 10.1038/38298; Kaelin WG, 1999, J NATL CANCER I, V91, P594, DOI 10.1093/jnci/91.7.594; Kaghad M, 1997, CELL, V90, P809, DOI 10.1016/S0092-8674(00)80540-1; Kovalev S, 1998, CELL GROWTH DIFFER, V9, P897; Lee YI, 2000, ONCOGENE, V19, P3717, DOI 10.1038/sj.onc.1203694; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Levrero M, 2000, J CELL SCI, V113, P1661; Li RZ, 1998, ONCOGENE, V16, P3269, DOI 10.1038/sj.onc.1201867; LIN JY, 1995, ONCOGENE, V10, P2387; Marin MC, 2000, NAT GENET, V25, P47, DOI 10.1038/75586; Matas D, 2001, EMBO J, V20, P4163, DOI 10.1093/emboj/20.15.4163; Mills AA, 1999, NATURE, V398, P708, DOI 10.1038/19531; MIYASHITA T, 1995, CELL, V80, P293; Murphy KL, 2000, FASEB J, V14, P2291, DOI 10.1096/fj.00-0128com; Nylander K, 2000, INT J CANCER, V87, P368, DOI 10.1002/1097-0215(20000801)87:3<368::AID-IJC9>3.3.CO;2-A; Oda K, 2000, CELL, V102, P849, DOI 10.1016/S0092-8674(00)00073-8; Okamoto K, 1999, ONCOGENE, V18, P4606, DOI 10.1038/sj.onc.1202821; Oren M, 1997, CELL, V90, P829, DOI 10.1016/S0092-8674(00)80347-5; Osada M, 1998, NAT MED, V4, P839, DOI 10.1038/nm0798-839; Park BJ, 2000, CANCER RES, V60, P3370; Prives C, 1999, J PATHOL, V187, P112; Schmale H, 1997, ONCOGENE, V15, P1363, DOI 10.1038/sj.onc.1201500; SHAULSKY G, 1991, CANCER RES, V51, P5232; Sigal A, 2000, CANCER RES, V60, P6788; Strano S, 2001, J BIOL CHEM, V276, P15164, DOI 10.1074/jbc.M010484200; Strano S, 2001, FEBS LETT, V490, P163, DOI 10.1016/S0014-5793(01)02119-6; Strano S, 2000, J BIOL CHEM, V275, P29503, DOI 10.1074/jbc.M003360200; SUDOL M, 1994, ONCOGENE, V9, P2145; Sunahara M, 1998, INT J ONCOL, V13, P319; Tannapfel A, 1999, J NATL CANCER I, V91, P1154, DOI 10.1093/jnci/91.13.1154; Trink B, 1998, NAT MED, V4, P747, DOI 10.1038/nm0798-747; Whitesell L, 1998, MOL CELL BIOL, V18, P1517, DOI 10.1128/MCB.18.3.1517; Yagi R, 1999, EMBO J, V18, P2551, DOI 10.1093/emboj/18.9.2551; Yamaguchi K, 2000, INT J CANCER, V86, P684, DOI 10.1002/(SICI)1097-0215(20000601)86:5<684::AID-IJC13>3.0.CO;2-M; Yang A, 2000, NAT REV MOL CELL BIO, V1, P199, DOI 10.1038/35043127; Yang A, 1999, NATURE, V398, P714, DOI 10.1038/19539; Yang A, 2000, NATURE, V404, P99, DOI 10.1038/35003607; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0; Yokomizo A, 1999, ONCOGENE, V18, P1629, DOI 10.1038/sj.onc.1202474; Yuan ZM, 1999, NATURE, V399, P814, DOI 10.1038/21704; Zaika AI, 1999, CANCER RES, V59, P3257; ZAUBERMAN A, 1995, ONCOGENE, V10, P2361	67	175	175	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 24	2002	277	21					18817	18826		10.1074/jbc.M201405200	http://dx.doi.org/10.1074/jbc.M201405200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	558PM	11893750	hybrid			2022-12-27	WOS:000175975800076
J	Weber, J; Wilke-Mounts, S; Senior, AE				Weber, J; Wilke-Mounts, S; Senior, AE			Quantitative determination of binding affinity of delta-subunit in Escherichia coli F-1-ATPase - Effects of mutation, Mg2+, and pH on K-d	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SENSITIVITY CONFERRING PROTEIN; PROTON-TRANSLOCATING ATPASE; CROSS-LINKING; CATALYTIC SITES; ALPHA-SUBUNIT; EPSILON-SUBUNIT; B-SUBUNIT; ADENOSINE-TRIPHOSPHATASE; MITOCHONDRIAL F1-ATPASE; ELECTRON-MICROSCOPY	To study the stator function in ATP synthase, a fluorimetric assay has been devised for quantitative determination of binding affinity of delta-subunit to Escherichia coli F-1-ATPase. The signal used is that of the natural tryptophan at residue delta28, which is enhanced by 50% upon binding of delta-subunit to alpha(3)beta(3)gammaepsilon complex. K-d for delta binding is 1.4 nM, which is energetically equivalent (50.2 kJ/mol) to that required to resist the rotor strain. Only one site for 8 binding was detected. The deltaW28L mutation increased K-d to 4.6 nM, equivalent to a loss of 2.9 kJ/mol binding energy. While this was insufficient to cause detectable functional impairment, it did facilitate preparation of delta-depleted F-1. The alphaG29D mutation reduced K-d to 26 nM, equivalent to a loss of 7.2 kJ/mol binding energy. This mutation did cause serious functional impairment, referable to interruption of binding of delta to F-1. Results with the two mutants illuminate how finely balanced is the stator resistance function. delta' fragment, consisting of residues delta1-134, bound with the same K-d as intact delta, showing that, at least in absence of F-o subunits, the C-terminal domain of 5 contributes zero binding energy. Mg2+ ions had a strong effect on increasing delta binding affinity, supporting the possibility of bridging metal ion involvement in stator function. High pH environment greatly reduced 5 binding affinity, suggesting the involvement of protonatable side-chains in the binding site.	Univ Rochester, Med Ctr, Dept Biochem & Biophys, Rochester, NY 14642 USA	University of Rochester	Senior, AE (corresponding author), Univ Rochester, Med Ctr, Dept Biochem & Biophys, Box 712, Rochester, NY 14642 USA.							ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; ABRAMS A, 1976, BIOCHEM BIOPH RES CO, V69, P804, DOI 10.1016/0006-291X(76)90946-3; AGGELER R, 1992, BIOCHEMISTRY-US, V31, P2956, DOI 10.1021/bi00126a016; Altendorf K, 2000, J EXP BIOL, V203, P19; Cain BD, 2000, J BIOENERG BIOMEMBR, V32, P365, DOI 10.1023/A:1005575919638; Capaldi RA, 2000, J EXP BIOL, V203, P29; Deckers-Hebestreit G, 2000, BBA-BIOENERGETICS, V1458, P364, DOI 10.1016/S0005-2728(00)00087-6; DeckersHebestreit G, 1996, ANNU REV MICROBIOL, V50, P791, DOI 10.1146/annurev.micro.50.1.791; Dunn SD, 2000, BBA-BIOENERGETICS, V1458, P356, DOI 10.1016/S0005-2728(00)00086-4; DUNN SD, 1980, J BIOL CHEM, V255, P6891; Dunn SD, 1998, J BIOL CHEM, V273, P8646, DOI 10.1074/jbc.273.15.8646; DUPUIS A, 1985, BIOCHEMISTRY-US, V24, P734, DOI 10.1021/bi00324a030; DUPUIS A, 1985, BIOCHEMISTRY-US, V24, P728, DOI 10.1021/bi00324a029; DUPUIS A, 1987, BIOCHEMISTRY-US, V26, P410, DOI 10.1021/bi00376a011; DUPUIS A, 1983, FEBS LETT, V156, P99, DOI 10.1016/0014-5793(83)80256-7; Fillingame RH, 2000, J EXP BIOL, V203, P9; Golden TR, 1998, BIOCHEMISTRY-US, V37, P13871, DOI 10.1021/bi981120a; Hasler K, 1999, BIOCHEMISTRY-US, V38, P13759, DOI 10.1021/bi991236m; HAZARD AL, 1994, J BIOL CHEM, V269, P418; HUNDAL T, 1983, FEBS LETT, V162, P5, DOI 10.1016/0014-5793(83)81038-2; JOUNOUCHI M, 1992, ARCH BIOCHEM BIOPHYS, V292, P376, DOI 10.1016/0003-9861(92)90005-H; Junge W, 2001, FEBS LETT, V504, P152, DOI 10.1016/S0014-5793(01)02745-4; Kaim G, 1998, EMBO J, V17, P688, DOI 10.1093/emboj/17.3.688; Kato-Yamada Y, 1998, J BIOL CHEM, V273, P19375, DOI 10.1074/jbc.273.31.19375; Ketchum CJ, 1998, BIOCHEM J, V330, P707; KLIONSKY DJ, 1984, J BACTERIOL, V160, P1055, DOI 10.1128/JB.160.3.1055-1060.1984; KUMAMOTO CA, 1986, J BIOL CHEM, V261, P37; Lill H, 1996, J BIOL CHEM, V271, P32737, DOI 10.1074/jbc.271.51.32737; MABUCHI K, 1981, BIOCHEM BIOPH RES CO, V102, P172, DOI 10.1016/0006-291X(81)91504-7; MAGGIO MB, 1988, J BIOL CHEM, V263, P4619; McLachlin DT, 2000, BIOCHEMISTRY-US, V39, P3486, DOI 10.1021/bi992586b; McLachlin DT, 1998, J BIOL CHEM, V273, P15162, DOI 10.1074/jbc.273.24.15162; McLachlin DT, 2000, J BIOL CHEM, V275, P17571, DOI 10.1074/jbc.M000375200; MENDELHARTVIG J, 1991, BIOCHIM BIOPHYS ACTA, V1060, P115, DOI 10.1016/S0005-2728(05)80126-4; Menz RI, 2001, CELL, V106, P331, DOI 10.1016/S0092-8674(01)00452-4; Nakamoto RK, 1999, ANNU REV BIOPH BIOM, V28, P205, DOI 10.1146/annurev.biophys.28.1.205; Noji H, 1997, NATURE, V386, P299, DOI 10.1038/386299a0; Noji H, 2001, J BIOL CHEM, V276, P1665, DOI 10.1074/jbc.R000021200; Ogilvie I, 1997, J BIOL CHEM, V272, P16652, DOI 10.1074/jbc.272.26.16652; Panke O, 2000, FEBS LETT, V472, P34, DOI 10.1016/S0014-5793(00)01436-8; PERLIN DS, 1983, J BIOL CHEM, V258, P9793; RAO R, 1988, J BIOL CHEM, V263, P5569; Rastogi VK, 1999, NATURE, V402, P263, DOI 10.1038/46224; Rodgers AJW, 1997, J BIOL CHEM, V272, P31058, DOI 10.1074/jbc.272.49.31058; Rodgers AJW, 1998, J BIOL CHEM, V273, P29406, DOI 10.1074/jbc.273.45.29406; Sambongi Y, 1999, SCIENCE, V286, P1722, DOI 10.1126/science.286.5445.1722; SENIOR AE, 2002, IN PRESS BIOCH BIOPH; SMITH JB, 1975, J SUPRAMOL STRUCT, V2, P248; SMITH RA, 1985, BIOCHEMISTRY-US, V24, P4490, DOI 10.1021/bi00337a034; TOZER RG, 1986, EUR J BIOCHEM, V161, P513, DOI 10.1111/j.1432-1033.1986.tb10472.x; Vik SB, 2000, BBA-BIOENERGETICS, V1458, P457, DOI 10.1016/S0005-2728(00)00094-3; Weber J, 1997, BBA-BIOENERGETICS, V1319, P19, DOI 10.1016/S0005-2728(96)00121-1; Weber J, 2000, FEBS LETT, V483, P1, DOI 10.1016/S0014-5793(00)02071-8; WEBER J, 1992, J BIOL CHEM, V267, P1712; Weber J, 2000, BIOCHEMISTRY-US, V39, P5287, DOI 10.1021/bi992730t; WEBER J, 1993, J BIOL CHEM, V268, P20126; Weber J, 1998, BIOCHEMISTRY-US, V37, P12042, DOI 10.1021/bi981089c; WILKEMOUNTS S, 1994, ARCH BIOCHEM BIOPHYS, V309, P363, DOI 10.1006/abbi.1994.1125; Wilkens S, 2000, J MOL BIOL, V295, P387, DOI 10.1006/jmbi.1999.3381; WILKENS S, 1997, NAT STRUCT BIOL, V4, P197; Yasuda R, 1998, CELL, V93, P1117, DOI 10.1016/S0092-8674(00)81456-7; ZIEGLER M, 1994, J BIOL CHEM, V269, P4233	62	31	35	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 24	2002	277	21					18390	18396		10.1074/jbc.M201047200	http://dx.doi.org/10.1074/jbc.M201047200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	558PM	11864990	hybrid			2022-12-27	WOS:000175975800019
J	Bowler, RP; Nicks, M; Olsen, DA; Thogersen, IB; Valnickova, Z; Hojrup, P; Franzusoff, A; Enghild, JJ; Crapo, JD				Bowler, RP; Nicks, M; Olsen, DA; Thogersen, IB; Valnickova, Z; Hojrup, P; Franzusoff, A; Enghild, JJ; Crapo, JD			Furin proteolytically processes the heparin-binding region of extracellular superoxide dismutase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EC-SOD GENE; TRANSGENE OVEREXPRESSION; EMBRYONIC-DEVELOPMENT; MYOCARDIAL-FUNCTION; CARBOXYPEPTIDASE-E; CEREBRAL-ISCHEMIA; CELL-LINES; MUTATION; AFFINITY; SERUM	Extracellular superoxide dismutase (EC-SOD) is an antioxidant enzyme that attenuates brain and lung injury from oxidative stress. A polybasic region in the carboxyl terminus distinguishes EC-SOD from other superoxide dismutases and determines EC-SOD's tissue half-life and affinity for heparin. There are two types of EC-SOD that differ based on the presence or absence of this heparin-binding region. It has recently been shown that proteolytic removal of the heparin-binding region is an intracellular event (Enghild, J. J., Thogersen, I. B., Oury, T. D., Valnickova, Z., Hojrup, P., and Crapo, J. D. (1999) J. Biol. Chem. 274, 14818-14822). By using mammalian cell lines, we have now determined that removal of the heparin-binding region occurs after passage through the Golgi network but before being secreted into the extracellular space. Specific protease inhibitors and overexpression of intracellular proteases implicate furin as a processing protease. In vitro experiments using furin and purified EC-SOD suggest that furin proteolytically cleaves EC-SOD in the middle of the polybasic region and then requires an additional carboxypeptidase to remove the remaining lysines and arginines. A mutation in Arg(213) renders EC-SOD resistant to furin processing. These results indicate that furin-dependent processing of EC-SOD is important for determining the tissue distribution and half-life of EC-SOD.	Natl Jewish Med & Res Ctr, Denver, CO 80206 USA; Univ Colorado, Hlth Sci Ctr, Dept Cell & Struct Biol, Denver, CO 80220 USA; Aarhus Univ, Dept Biol Mol & Struct, DK-8000 Aarhus, Denmark; Odense Univ, Dept Biochem & Mol Biol, DK-5230 Odense, Denmark	National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Aarhus University; University of Southern Denmark	Bowler, RP (corresponding author), Natl Jewish Med & Res Ctr, K736A,1400 Jackson St, Denver, CO 80206 USA.		Højrup, Peter/ABG-8477-2020; Bowler, Russell P/J-8283-2015	Bowler, Russell P/0000-0003-4651-363X; Enghild, Jan Johannes/0000-0001-9292-9172; Hojrup, Peter/0000-0002-7838-6180	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL031992, P01HL042444] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-42444, HL-31992, HL-04407] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADACHI T, 1992, ARCH BIOCHEM BIOPHYS, V297, P155, DOI 10.1016/0003-9861(92)90654-F; Adachi T, 1996, BIOCHEM J, V313, P235, DOI 10.1042/bj3130235; ADACHI T, 1992, CLIN CHIM ACTA, V212, P89, DOI 10.1016/0009-8981(92)90176-Q; Adachi T, 1996, J BIOCHEM, V120, P184; Adachi T, 1998, BIOL PHARM BULL, V21, P1090; Bowler RP, 2001, AM J RESP CRIT CARE, V164, P290, DOI 10.1164/ajrccm.164.2.2011054; Chen EP, 1998, J THORAC CARDIOV SUR, V115, P450, DOI 10.1016/S0022-5223(98)70289-2; Chen EP, 1996, CIRCULATION, V94, P412; Cui YZ, 1998, EMBO J, V17, P4735, DOI 10.1093/emboj/17.16.4735; DREWS R, 1995, P NATL ACAD SCI USA, V92, P10462, DOI 10.1073/pnas.92.23.10462; Enghild JJ, 1999, J BIOL CHEM, V274, P14818, DOI 10.1074/jbc.274.21.14818; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; Folz RJ, 1999, J CLIN INVEST, V103, P1055, DOI 10.1172/JCI3816; FOLZ RJ, 1994, HUM MOL GENET, V3, P2251, DOI 10.1093/hmg/3.12.2251; FRICKER LD, 1988, ANNU REV PHYSIOL, V50, P309, DOI 10.1146/annurev.ph.50.030188.001521; Fukai T, 1999, CIRC RES, V85, P23; HENDY GN, 1995, J BIOL CHEM, V270, P9517, DOI 10.1074/jbc.270.16.9517; HJALMARSSON K, 1987, P NATL ACAD SCI USA, V84, P6340, DOI 10.1073/pnas.84.18.6340; KALRA J, 1992, MOL CELL BIOCHEM, V110, P165, DOI 10.1007/BF02454194; KARLSSON K, 1993, BIOCHEM J, V290, P623, DOI 10.1042/bj2900623; KARLSSON K, 1994, LAB INVEST, V70, P705; KARLSSON K, 1993, FREE RADICAL BIO MED, V14, P185, DOI 10.1016/0891-5849(93)90009-J; Lookene A, 2000, BIOCHEMISTRY-US, V39, P230, DOI 10.1021/bi991512x; MARKLUND SL, 1982, P NATL ACAD SCI-BIOL, V79, P7634, DOI 10.1073/pnas.79.24.7634; MARKLUND SL, 1984, J CLIN INVEST, V74, P1398, DOI 10.1172/JCI111550; Marklund SL, 1997, J INTERN MED, V242, P5, DOI 10.1046/j.1365-2796.1997.00160.x; MISUMI Y, 1991, J BIOL CHEM, V266, P16954; Nabarra B, 1997, MECH AGEING DEV, V96, P59, DOI 10.1016/S0047-6374(97)01892-7; Nakayama K, 1997, BIOCHEM J, V327, P625, DOI 10.1042/bj3270625; Nakayama T, 2000, CELL MOL LIFE SCI, V57, P943, DOI 10.1007/PL00000736; Nozik-Grayck E, 2000, AM J PHYSIOL-LUNG C, V279, pL977, DOI 10.1152/ajplung.2000.279.5.L977; OURY TD, 1994, LAB INVEST, V70, P889; Oury TD, 1996, BIOCHEM J, V317, P51, DOI 10.1042/bj3170051; Oury TD, 1999, BRAIN RES, V850, P96, DOI 10.1016/S0006-8993(99)02103-4; PLUMMER TH, 1984, J BIOL CHEM, V259, P700; SALVESEN G, 1991, BIOMED BIOCHIM ACTA, V50, P665; SALVESEN G, 1989, PROTEOLYTIC ENZYMES, P259; SANDSTROM J, 1992, J BIOL CHEM, V267, P18205; Sheng H, 2000, EXP NEUROL, V163, P392, DOI 10.1006/exnr.2000.7363; Sheng HX, 1999, NEUROSCI LETT, V267, P13, DOI 10.1016/S0304-3940(99)00316-X; SONG LX, 1995, J BIOL CHEM, V270, P25007, DOI 10.1074/jbc.270.42.25007; TAKAHASHI S, 1993, BIOCHEM BIOPH RES CO, V195, P1019, DOI 10.1006/bbrc.1993.2146; THOGERSEN IB, 1995, J BIOL CHEM, V270, P18700; Varlamov O, 1999, J BIOL CHEM, V274, P14040, DOI 10.1074/jbc.274.20.14040; VEY M, 1994, J CELL BIOL, V127, P1829, DOI 10.1083/jcb.127.6.1829; Yamada H, 2000, NEPHRON, V84, P218, DOI 10.1159/000045580; Yamada H, 1997, JPN J HUM GENET, V42, P353, DOI 10.1007/BF02766958	47	54	60	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 10	2002	277	19					16505	16511		10.1074/jbc.M105409200	http://dx.doi.org/10.1074/jbc.M105409200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	551MB	11861638	hybrid			2022-12-27	WOS:000175564500024
J	Lu, RQ; Moore, PA; Pitha, PM				Lu, RQ; Moore, PA; Pitha, PM			Stimulation of IRF-7 gene expression by tumor necrosis factor alpha - Requirement for NF kappa B transcription factor and gene accessibility	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERFERON REGULATORY FACTOR; POSITIVE FEEDBACK; SWI/SNF COMPLEX; ACTIVATION; SEQUENCE; DISTINCT; REGION; 11P15; IDENTIFICATION; RECRUITMENT	Interferon regulatory factor 7 (IRF-7) plays an important role in innate immunity, where, together with IRF-3, it controls the expression of interferon A/B genes as well as chemokine RANTES (regulated on activation normal T cell expressed and secreted). Previously, we characterized human IRF-7 promoter and showed that an interferon-stimulated response element site in the first intron binds interferon-stimulated gene factor 3 (ISGF3) and confers the response to interferon. Here we report the stimulation of IRF-7 expression by 12-O-tetradecanoylphorbol-13-acetate (TPA) and tumor necrosis factor alpha (TNFalpha) in human peripheral blood monocytes. Using promoter analysis in combination with electrophoretic mobility shift assays, we have demonstrated that an NFkappaB site located next to the TATA box, binds p50 and p65 heterodimer and is required for the induction of the IRF-7 gene by TPA and TNFalpha. In addition, we report stimulation of IRF-7 gene expression by topoisomerase II (TOPII) inhibitors. We show by chromatin immunoprecipitation assay that treatment with the TOPII inhibitor etoposide induces association of acetylated histone 3 with the promoter of IRF-7 gene, indicating that TOPII-mediated changes in chromatin structure could be responsible for the induction. This suggests that the IRF-7 gene is localized in the condensed area of the chromosome where it is inaccessible to transcription factors that would promote its constitutive expression.	Johns Hopkins Univ, Sch Med, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD 21231 USA; Johns Hopkins Univ, Sch Med, Dept Mol Biol & Genet, Baltimore, MD 21231 USA; Human Genome Sci Inc, Rockville, MD 20850 USA	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; GlaxoSmithKline; Human Genome Sciences Inc	Pitha, PM (corresponding author), Johns Hopkins Univ, Sch Med, Sidney Kimmel Comprehens Canc Ctr, Bunting & Blaustein Canc Res Bldg,Rm 351,1650 Orl, Baltimore, MD 21231 USA.	parowe@jhmi.edu			NIAID NIH HHS [AI19737-19] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI019737, R01AI019737] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Au WC, 1998, J BIOL CHEM, V273, P29210, DOI 10.1074/jbc.273.44.29210; Au WC, 2001, J BIOL CHEM, V276, P41629, DOI 10.1074/jbc.M105121200; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Barnes BJ, 2001, J BIOL CHEM, V276, P23382, DOI 10.1074/jbc.M101216200; Boland MP, 2000, J BIOL CHEM, V275, P25231, DOI 10.1074/jbc.275.33.25231; Brown CE, 2000, TRENDS BIOCHEM SCI, V25, P15, DOI 10.1016/S0968-0004(99)01516-9; Chen HW, 2001, CURR OPIN CELL BIOL, V13, P218, DOI 10.1016/S0955-0674(00)00200-3; Collins I, 2001, MOL CELL BIOL, V21, P8437, DOI 10.1128/MCB.21.24.8437-8451.2001; Feinberg AP, 1999, CANCER RES, V59, p1743S; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; HERRERO JA, 1995, J VIROL, V69, P2168, DOI 10.1128/JVI.69.4.2168-2174.1995; Hu RJ, 1997, GENOMICS, V46, P9, DOI 10.1006/geno.1997.4981; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Karnik P, 1998, ONCOGENE, V17, P237, DOI 10.1038/sj.onc.1201959; Krebs JE, 2000, CELL, V102, P587, DOI 10.1016/S0092-8674(00)00081-7; Lin RT, 1999, MOL CELL BIOL, V19, P959; Lin RT, 1998, MOL CELL BIOL, V18, P2986, DOI 10.1128/MCB.18.5.2986; LIU LF, 1989, ANNU REV BIOCHEM, V58, P351, DOI 10.1146/annurev.bi.58.070189.002031; Lowther WJ, 1999, DNA CELL BIOL, V18, P685, DOI 10.1089/104454999314962; Lu RQ, 2000, P NATL ACAD SCI USA, V97, P3993, DOI 10.1073/pnas.97.8.3993; Lu RQ, 2001, J BIOL CHEM, V276, P45491, DOI 10.1074/jbc.C100421200; Lu RQ, 2000, J BIOL CHEM, V275, P31805, DOI 10.1074/jbc.M005288200; Marie I, 1998, EMBO J, V17, P6660, DOI 10.1093/emboj/17.22.6660; Marmorstein R, 2001, NAT REV MOL CELL BIO, V2, P422, DOI 10.1038/35073047; MARTINEZBALBAS MA, 1995, CELL, V83, P29, DOI 10.1016/0092-8674(95)90231-7; Natarajan K, 1999, MOL CELL, V4, P657, DOI 10.1016/S1097-2765(00)80217-8; Neely KE, 1999, MOL CELL, V4, P649, DOI 10.1016/S1097-2765(00)80216-6; Nguyen Hannah, 1997, Cytokine and Growth Factor Reviews, V8, P293, DOI 10.1016/S1359-6101(97)00019-1; Onyango P, 2000, GENOME RES, V10, P1697, DOI 10.1101/gr.161800; Paris MJ, 2000, GENOMICS, V69, P196, DOI 10.1006/geno.2000.6339; PETERSON G, 1995, J NUTR, V125, pS784, DOI 10.1093/jn/125.suppl_3.784S; Sato M, 2000, IMMUNITY, V13, P539, DOI 10.1016/S1074-7613(00)00053-4; Sato M, 1998, FEBS LETT, V441, P106, DOI 10.1016/S0014-5793(98)01514-2; Schwienbacher C, 1998, P NATL ACAD SCI USA, V95, P3873, DOI 10.1073/pnas.95.7.3873; Taniguchi T, 2001, ANNU REV IMMUNOL, V19, P623, DOI 10.1146/annurev.immunol.19.1.623; Tsai SC, 2000, NAT GENET, V26, P349, DOI 10.1038/81671; Urnov FD, 2001, ONCOGENE, V20, P2991, DOI 10.1038/sj.onc.1204323; VargaWeisz PD, 1997, NATURE, V388, P598, DOI 10.1038/41587; Wallberg AE, 2000, MOL CELL BIOL, V20, P2004, DOI 10.1128/MCB.20.6.2004-2013.2000; Wathelet MG, 1998, MOL CELL, V1, P507, DOI 10.1016/S1097-2765(00)80051-9; Wong JM, 1997, EMBO J, V16, P3158, DOI 10.1093/emboj/16.11.3158; Yeow WS, 2000, J BIOL CHEM, V275, P6313, DOI 10.1074/jbc.275.9.6313; Yeow WS, 2001, J VIROL, V75, P3021, DOI 10.1128/JVI.75.6.3021-3027.2001; Zhang LW, 1997, MOL CELL BIOL, V17, P5748, DOI 10.1128/MCB.17.10.5748; Zhang LW, 2000, J VIROL, V74, P1061, DOI 10.1128/JVI.74.3.1061-1068.2000	45	51	53	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 10	2002	277	19					16592	16598		10.1074/jbc.M111440200	http://dx.doi.org/10.1074/jbc.M111440200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	551MB	11877397	hybrid			2022-12-27	WOS:000175564500035
J	Paine, ML; Lei, YP; Dickerson, K; Snead, ML				Paine, ML; Lei, YP; Dickerson, K; Snead, ML			Altered amelogenin self-assembly based on mutations observed in human X-linked amelogenesis imperfecta (AIH1)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN INTERACTIONS; PORCINE AMELOGENIN; SECRETORY-STAGE; ENAMEL; NANOSPHERES	A hallmark of biological systems is a reliance on protein assemblies to perform complex functions. We have focused attention on mammalian enamel formation because it relies on a self-assembling protein complex to direct mineral habit. The principle protein of enamel is amelogenin, a 180-amino acid hydrophobic protein that self-assembles to form nanospheres. We have used independent technical methods, consisting of the yeast two-hybrid (Y2H) assay and surface plasmon resonance (SPR), to demonstrate the importance of amelogenin self-assembly domains. In addition, we have analyzed mutations in amelogenin observed in patients with amelogenesis imperfecta who demonstrate defects in enamel formation. Assessments of self-assembly of these mutant amelogenins by either SPR or Y2H assay yield concordant data. These data support the conclusion that the amelogenin amino-terminal self-assembly domain is essential to the creation of an enamel extracellular organic matrix capable of directing mineral formation. It also suggests that a pathway through which point mutations in the amelogenin protein can adversely impact on the formation of the enamel organ is by disturbing self-assembly of the organic matrix. These data support the utilization of the Y2H assay to search for protein interactions among extracellular matrix proteins that contribute to biomineralization and provide functional information on protein-protein and protein-mineral interactions.	Univ So Calif, Sch Dent, Ctr Craniofacial Mol Biol, Los Angeles, CA 90033 USA; Biacore Inc, San Diego, CA 92121 USA	University of Southern California	Paine, ML (corresponding author), Univ So Calif, Sch Dent, Ctr Craniofacial Mol Biol, 2250 Alcazar St,CSA Room 142, Los Angeles, CA 90033 USA.	paine@hsc.usc.edu			NIDCR NIH HHS [DE13404, DE13405] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE013405, R01DE013404] Funding Source: NIH RePORTER	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		AOBA T, 1987, CALCIFIED TISSUE INT, V41, P86, DOI 10.1007/BF02555250; Bartlett JD, 1999, CRIT REV ORAL BIOL M, V10, P425, DOI 10.1177/10454411990100040101; FINCHAM AG, 1995, J STRUCT BIOL, V115, P50, DOI 10.1006/jsbi.1995.1029; FINCHAM AG, 1994, CALCIFIED TISSUE INT, V55, P398, DOI 10.1007/BF00299322; GOTO Y, 1993, J BIOCHEM-TOKYO, V113, P55, DOI 10.1093/oxfordjournals.jbchem.a124003; Kirkham J, 2000, J DENT RES, V79, P1943, DOI 10.1177/00220345000790120401; Korneeva NL, 2001, J BIOL CHEM, V276, P2872, DOI 10.1074/jbc.M006345200; LENCH NJ, 1995, HUM MUTAT, V5, P251, DOI 10.1002/humu.1380050310; Moradian-Oldak J, 2000, J STRUCT BIOL, V131, P27, DOI 10.1006/jsbi.2000.4237; Nielsen VH, 2000, MAMM GENOME, V11, P1087, DOI 10.1007/s003350010212; Paine ML, 1998, J DENT RES, V77, P496, DOI 10.1177/00220345980770030901; Paine ML, 1997, J BONE MINER RES, V12, P221, DOI 10.1359/jbmr.1997.12.2.221; Paine ML, 2000, J STRUCT BIOL, V132, P191, DOI 10.1006/jsbi.2000.4324; Ravassipour DB, 2000, J DENT RES, V79, P1476, DOI 10.1177/00220345000790070801; Sarikaya M, 1999, P NATL ACAD SCI USA, V96, P14183, DOI 10.1073/pnas.96.25.14183; SIMMER JP, 1994, CALCIFIED TISSUE INT, V54, P312, DOI 10.1007/BF00295956; TERMINE JD, 1980, BIOPOLYMERS, V19, P741, DOI 10.1002/bip.1980.360190403; Wen HB, 2001, MATRIX BIOL, V20, P387, DOI 10.1016/S0945-053X(01)00144-5; White SN, 2000, J AM CERAM SOC, V83, P238, DOI 10.1111/j.1151-2916.2000.tb01181.x	19	30	30	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 10	2002	277	19					17112	17116		10.1074/jbc.M110473200	http://dx.doi.org/10.1074/jbc.M110473200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	551MB	11877393	hybrid			2022-12-27	WOS:000175564500103
J	Hanzelmann, P; Schwarz, G; Mendel, RR				Hanzelmann, P; Schwarz, G; Mendel, RR			Functionality of alternative splice forms of the first enzymes involved in human molybdenum cofactor biosynthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; MOLYBDOPTERIN SYNTHASE; ARTHROBACTER NICOTINOVORANS; UBIQUITIN ACTIVATION; RADICAL MECHANISMS; CONVERTING FACTOR; CRYSTAL-STRUCTURE; READING FRAMES; EARLY STEPS; PRECURSOR-Z	In humans, genetic deficiencies of enzymes involved in molybdenum cofactor biosynthesis trigger an autosomal recessive and usually fatal disease with severe mostly neurological symptoms. In each of the three biosynthesis steps, at least two proteins or domains are linked for catalysis. For steps 1 and 2, bicistronic mocs (molybdenum cofactor synthesis) mRNAs were found (mocs1 and mocs2) that have been proposed to encode two separate proteins (A and B). In both cases, the A proteins share a highly conserved ubiquitin-like double glycine motif, which is functionally important at least for the small subunit of molybdopterin (MPT) synthase (MOCS2A). Besides the bicistronic form of mocs1, two alternative splice transcripts were found, resulting in the expression of multidomain proteins embodying both MOCS1A, but without the double glycine motif, and the entire MOCS1B. Here we describe the first functional characterization of the human proteins MOCS1A and MOCS1B as well as the MOCS1A-MOCS1B fusion proteins that catalyze the formation of precursor Z, a 6-alkyl pterin with a cyclic phosphate, the immediate precursor of MPT in molybdenum cofactor biosynthesis. High level expression of MOCS1A and MOCS1B in Escherichia coli resulted in the formation and accumulation of precursor Z that was subsequently converted to MPT. We showed that for catalytic activity MOCS1A needs an accessible C-terminal double glycine motif. In the MOCS1A-MOCS1B fusion proteins lacking the MOCS1A double glycines, only MOCS1B activity could be detected. No evidence was found for an expression of MOCS1B from the bicistronic mocs1A-mocs1B splice type I cDNA, indicating that MOCS1B is only expressed as a fusion to an inactive MOCS1A. Comparative mutational studies of MOCS1A and the small subunit of the E. coli MPT synthase (MoaD) indicate a different function of the double glycine motifs in both proteins.	Tech Univ Carolo Wilhelmina Braunschweig, Inst Plant Biol, D-38023 Braunschweig, Germany	Braunschweig University of Technology	Mendel, RR (corresponding author), Tech Univ Carolo Wilhelmina Braunschweig, Inst Plant Biol, D-38023 Braunschweig, Germany.		Schwarz, Guenter/ABE-9643-2021	Schwarz, Guenter/0000-0002-2118-9338				Bacher A., 1991, CHEM BIOCH FLAVOPROT, P215; BAKER KP, 1991, MOL MICROBIOL, V5, P901, DOI 10.1111/j.1365-2958.1991.tb00764.x; Begley TP, 1999, CURR OPIN CHEM BIOL, V3, P623, DOI 10.1016/S1367-5931(99)00018-6; BROWN GM, 1985, FOLATES PTERINS, V2, P299; CASADABAN MJ, 1976, J MOL BIOL, V104, P541, DOI 10.1016/0022-2836(76)90119-4; Cheek J, 2001, J BIOL INORG CHEM, V6, P209, DOI 10.1007/s007750100210; Feng GP, 1998, SCIENCE, V282, P1321, DOI 10.1126/science.282.5392.1321; Frey PA, 2001, ANNU REV BIOCHEM, V70, P121, DOI 10.1146/annurev.biochem.70.1.121; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; Gray TA, 2000, RNA, V6, P928, DOI 10.1017/S1355838200000182; Gutzke G, 2001, J BIOL CHEM, V276, P36268, DOI 10.1074/jbc.M105321200; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; HOFF T, 1995, J BIOL CHEM, V270, P6100, DOI 10.1074/jbc.270.11.6100; JOHNSON JL, 1993, ADV EXP MED BIOL, V338, P373; JOHNSON JL, 1989, J CLIN INVEST, V83, P897, DOI 10.1172/JCI113974; JOHNSON ME, 1987, J BACTERIOL, V169, P117, DOI 10.1128/jb.169.1.117-125.1987; JOHNSON ME, 1987, J BACTERIOL, V169, P110, DOI 10.1128/jb.169.1.110-116.1987; Kisker C, 1998, FEMS MICROBIOL REV, V22, P503, DOI 10.1111/j.1574-6976.1998.tb00384.x; Lake MW, 2001, NATURE, V414, P325, DOI 10.1038/35104586; Leimkuhler S, 2001, J BIOL CHEM, V276, P34695, DOI 10.1074/jbc.M102787200; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MACGREGOR CH, 1974, J BIOL CHEM, V249, P5321; Menendez C, 1996, FEBS LETT, V391, P101, DOI 10.1016/0014-5793(96)00712-0; MENENDEZ C, 1995, ARCH MICROBIOL, V164, P142, DOI 10.1007/s002030050246; PITTERLE DM, 1993, J BIOL CHEM, V268, P13499; PITTERLE DM, 1993, J BIOL CHEM, V268, P13506; RAJAGOPALAN KV, 1992, J BIOL CHEM, V267, P10199; RAJAGOPALAN KV, 1996, ESCHERICHIA COLI SAL, P674; REISS J, 1987, MOL GEN GENET, V206, P352, DOI 10.1007/BF00333594; Reiss J, 2000, HUM GENET, V106, P157, DOI 10.1007/s004390051023; Reiss J, 1998, NAT GENET, V20, P51, DOI 10.1038/1706; Reiss J, 1998, HUM GENET, V103, P639, DOI 10.1007/s004390050884; Reiss J, 2001, AM J HUM GENET, V68, P208, DOI 10.1086/316941; Rieder C, 1998, EUR J BIOCHEM, V255, P24, DOI 10.1046/j.1432-1327.1998.2550024.x; RIVERS SL, 1993, MOL MICROBIOL, V8, P1071, DOI 10.1111/j.1365-2958.1993.tb01652.x; Rudolph MJ, 2001, NAT STRUCT BIOL, V8, P42; Schwarz G, 1997, J BIOL CHEM, V272, P26811, DOI 10.1074/jbc.272.43.26811; Sofia HJ, 2001, NUCLEIC ACIDS RES, V29, P1097, DOI 10.1093/nar/29.5.1097; Solomon PS, 1999, MICROBIOL-UK, V145, P1421, DOI 10.1099/13500872-145-6-1421; Stallmeyer B, 1999, AM J HUM GENET, V64, P698, DOI 10.1086/302295; Stallmeyer B, 1999, P NATL ACAD SCI USA, V96, P1333, DOI 10.1073/pnas.96.4.1333; Unkles SE, 1997, J BIOL CHEM, V272, P28381, DOI 10.1074/jbc.272.45.28381; WUEBBENS MM, 1993, J BIOL CHEM, V268, P13493; Wuebbens MM, 2000, STRUCTURE, V8, P709, DOI 10.1016/S0969-2126(00)00157-X; WUEBBENS MM, 1995, J BIOL CHEM, V270, P1082, DOI 10.1074/jbc.270.3.1082	45	55	59	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 24	2002	277	21					18303	18312		10.1074/jbc.M200947200	http://dx.doi.org/10.1074/jbc.M200947200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	558PM	11891227	hybrid			2022-12-27	WOS:000175975800009
J	Panopoulos, AD; Bartos, D; Zhang, L; Watowich, SS				Panopoulos, AD; Bartos, D; Zhang, L; Watowich, SS			Control of myeloid-specific integrin alpha(M)beta(2) (CD11b/CD18) expression by cytokines is regulated by Stat3-dependent activation of PU.1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLONY-STIMULATING FACTOR; G-CSF RECEPTOR; HEMATOPOIETIC PROGENITOR CELLS; GRANULOCYTIC DIFFERENTIATION; DEPENDENT PROLIFERATION; TRANSCRIPTION FACTORS; TARGETED DISRUPTION; GENE-EXPRESSION; BONE-MARROW; IN-VIVO	Granulocyte colony-stimulating factor (G-CSF) plays an essential role in regulating multiple aspects of hematopoiesis. To elucidate the role of G-CSF in controlling hematopoietic cell migration capabilities, we studied inducible expression of the myeloid-specific marker, integrin alpha(M)beta(2) (CD11b/CD18, Mac-1), in the myeloid cell line, 32D. We found that G-CSF stimulates the synthesis and cell surface expression of alpha(M) and beta(2) integrin subunits. Induction of both alpha(M) and beta(2) is dependent on Stat3, a major G-CSF-responsive signaling protein. However, the kinetics of expression suggested the involvement of an intermediate protein regulated by Stat3. Our results demonstrate that Stat3 signaling stimulates the expression of PU.1, a critical regulator of myelopoiesis. Furthermore, we show that PU.1 is an essential intermediate for the inducible expression of alpha(M)beta(2) integrin. Thus, Stat3 promotes alpha(M)beta(2) integrin expression through its activation of PU.1. These findings indicate that G-CSF-dependent Stat3 signals stimulate the changes in cell adhesion and migration capabilities that occur during myeloid cell development. These data also demonstrate a link between Stat3 and PU.1, suggesting that Stat3 may play an instructive role in hematopoiesis.	Univ Texas, MD Anderson Canc Ctr, Dept Immunol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Watowich, SS (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Immunol, Box 178,1515 Holcombe Blvd, Houston, TX 77030 USA.			Panopoulos, Athanasia/0000-0002-9610-2604; Watowich, Stephanie/0000-0003-1969-659X	NCI NIH HHS [CA 77447, R01 CA077447-03, R01 CA077447-02] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA077447] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Anderson KL, 1999, BLOOD, V94, P2310, DOI 10.1182/blood.V94.7.2310.419k34_2310_2318; Auernhammer CJ, 1999, P NATL ACAD SCI USA, V96, P6964, DOI 10.1073/pnas.96.12.6964; Betsuyaku T, 1999, J CLIN INVEST, V103, P825, DOI 10.1172/JCI5191; CHEN HM, 1995, ONCOGENE, V11, P1549; Cheng T, 1996, P NATL ACAD SCI USA, V93, P13158, DOI 10.1073/pnas.93.23.13158; de Koning JP, 1998, BLOOD, V91, P1924, DOI 10.1182/blood.V91.6.1924.1924_1924_1933; de Koning JP, 2000, ONCOGENE, V19, P3290, DOI 10.1038/sj.onc.1203627; DeKoter RP, 1998, EMBO J, V17, P4456, DOI 10.1093/emboj/17.15.4456; DeKoter RP, 2000, SCIENCE, V288, P1439, DOI 10.1126/science.288.5470.1439; DUHRSEN U, 1988, BLOOD, V72, P2074; Etzioni A, 1999, BLOOD, V94, P3281, DOI 10.1182/blood.V94.10.3281.422k37_3281_3288; Faust N, 2000, BLOOD, V96, P719; Fisher RC, 1999, BLOOD, V94, P1283, DOI 10.1182/blood.V94.4.1283.416k16_1283_1290; Goldsmith MA, 1998, P NATL ACAD SCI USA, V95, P7006, DOI 10.1073/pnas.95.12.7006; HORVATH CM, 1995, GENE DEV, V9, P984, DOI 10.1101/gad.9.8.984; KATO JY, 1993, P NATL ACAD SCI USA, V90, P11513, DOI 10.1073/pnas.90.24.11513; Klemsz MJ, 1996, MOL CELL BIOL, V16, P390; Levesque JP, 2001, BLOOD, V98, P1289, DOI 10.1182/blood.V98.5.1289; Li YL, 2001, BLOOD, V98, P2958, DOI 10.1182/blood.V98.10.2958; LIESCHKE GJ, 1994, BLOOD, V84, P1737; Liu FL, 2000, BLOOD, V95, P3025, DOI 10.1182/blood.V95.10.3025.010k32_3025_3031; Liu FL, 1996, IMMUNITY, V5, P491, DOI 10.1016/S1074-7613(00)80504-X; Longmore GD, 1998, BLOOD, V91, P870, DOI 10.1182/blood.V91.3.870.870_870_878; McKercher SR, 1996, EMBO J, V15, P5647, DOI 10.1002/j.1460-2075.1996.tb00949.x; McLemore ML, 1998, J CLIN INVEST, V102, P483, DOI 10.1172/JCI3216; McLemore ML, 2001, IMMUNITY, V14, P193, DOI 10.1016/S1074-7613(01)00101-7; Nakajima H, 2001, BLOOD, V98, P897, DOI 10.1182/blood.V98.4.897; Nicholson SE, 1996, J BIOL CHEM, V271, P26947, DOI 10.1074/jbc.271.43.26947; PAHL HL, 1993, J BIOL CHEM, V268, P5014; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Rekhtman N, 1999, GENE DEV, V13, P1398, DOI 10.1101/gad.13.11.1398; ROSMARIN AG, 1995, P NATL ACAD SCI USA, V92, P801, DOI 10.1073/pnas.92.3.801; SCOTT EW, 1994, SCIENCE, V265, P1573, DOI 10.1126/science.8079170; Semerad CL, 1999, IMMUNITY, V11, P153, DOI 10.1016/S1074-7613(00)80090-4; Shimozaki K, 1997, J BIOL CHEM, V272, P25184, DOI 10.1074/jbc.272.40.25184; Takeda K, 1999, IMMUNITY, V10, P39, DOI 10.1016/S1074-7613(00)80005-9; Takeda K, 1997, P NATL ACAD SCI USA, V94, P3801, DOI 10.1073/pnas.94.8.3801; Tenen DG, 1997, BLOOD, V90, P489, DOI 10.1182/blood.V90.2.489.489_489_519; Wang XP, 1999, BLOOD, V94, P560, DOI 10.1182/blood.V94.2.560.414k41_560_571; Welte K, 1996, BLOOD, V88, P1907, DOI 10.1182/blood.V88.6.1907.bloodjournal8861907; Wooten DK, 2000, J BIOL CHEM, V275, P26566, DOI 10.1074/jbc.M003495200	41	46	47	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 24	2002	277	21					19001	19007		10.1074/jbc.M112271200	http://dx.doi.org/10.1074/jbc.M112271200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	558PM	11889125	Green Accepted, hybrid			2022-12-27	WOS:000175975800099
J	Roepstorff, K; Thomsen, P; Sandvig, K; van Deurs, B				Roepstorff, K; Thomsen, P; Sandvig, K; van Deurs, B			Sequestration of epidermal growth factor receptors in non-caveolar lipid rafts inhibits ligand binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHOLESTEROL DEPLETION; SIGNAL-TRANSDUCTION; PLASMA-MEMBRANE; DOMAINS; KINASE; GANGLIOSIDE; ACTIVATION; TYROSINE	Cholesterol depletion has been shown to increase mitogen-activated protein kinase activation in response to stimulation with epidermal growth factor (EGF) (Furuchi, T., and Anderson, R. G. W. (1998) J. Biol. Chem. 273,21099-21104). However, the underlying mechanisms are unknown. We show that cholesterol depletion increases EGF binding, whereas cholesterol loading lowers EGF binding. Based on binding analyses, we demonstrate that the observed changes in EGF binding are caused by alterations in the number of EGF receptors available for ligand binding, whereas the affinity of the receptor for EGF remains unaltered. We also show by immunofluorescence that in unstimulated cells the EGF receptor is localized in non-caveolar lipid rafts containing the ganglioside GM1 and that patching of these rafts by cholera toxin B-chain causes co-patching of EGF receptors. Experiments with solubilization in different detergents at 4 degreesC show that the association of the EGF receptor with these rafts is sensitive to Triton X-100 extraction but insensitive to extraction with another non-ionic detergent, Brij 58. Furthermore, experiments with cholesterol-depleted cells show that the association is cholesterol-dependent. We propose that non-caveolar lipid rafts function as negative regulators of EGF receptor signaling by sequestering a fraction of the EGF receptors in a state inaccessible for ligand binding.	Univ Copenhagen, Panum Inst, Dept Med Anat, Struct Cell Biol Unit, DK-2200 Copenhagen N, Denmark; Norwegian Radium Hosp, Inst Canc Res, N-0310 Oslo, Norway	University of Copenhagen; University of Oslo	van Deurs, B (corresponding author), Univ Copenhagen, Panum Inst, Dept Med Anat, Struct Cell Biol Unit, DK-2200 Copenhagen N, Denmark.							Couet J, 1997, J BIOL CHEM, V272, P30429, DOI 10.1074/jbc.272.48.30429; Engelman JA, 1998, FEBS LETT, V428, P205, DOI 10.1016/S0014-5793(98)00470-0; Furuchi T, 1998, J BIOL CHEM, V273, P21099, DOI 10.1074/jbc.273.33.21099; Gimpl G, 1997, BIOCHEMISTRY-US, V36, P10959, DOI 10.1021/bi963138w; Grimmer S, 2000, MOL BIOL CELL, V11, P4205, DOI 10.1091/mbc.11.12.4205; Hailstones D, 1998, J LIPID RES, V39, P369; Harder T, 1998, J CELL BIOL, V141, P929, DOI 10.1083/jcb.141.4.929; Janes PW, 1999, J CELL BIOL, V147, P447, DOI 10.1083/jcb.147.2.447; Jang IH, 2001, FEBS LETT, V491, P4, DOI 10.1016/S0014-5793(01)02165-2; Lang DM, 1998, J NEUROBIOL, V37, P502, DOI 10.1002/(SICI)1097-4695(199812)37:4<502::AID-NEU2>3.0.CO;2-S; Miljan EA, 2002, J BIOL CHEM, V277, P10108, DOI 10.1074/jbc.M111669200; Mineo C, 1999, J BIOL CHEM, V274, P30636, DOI 10.1074/jbc.274.43.30636; Mobius W, 1999, J HISTOCHEM CYTOCHEM, V47, P1005; Orlandi PA, 1998, J CELL BIOL, V141, P905, DOI 10.1083/jcb.141.4.905; Pang L, 1999, BIOCHEMISTRY-US, V38, P12003, DOI 10.1021/bi990227a; Pike LJ, 1998, J BIOL CHEM, V273, P22298, DOI 10.1074/jbc.273.35.22298; Rodal SK, 1999, MOL BIOL CELL, V10, P961, DOI 10.1091/mbc.10.4.961; Roper K, 2000, NAT CELL BIOL, V2, P582, DOI 10.1038/35023524; Rybin VO, 2000, J BIOL CHEM, V275, P41447, DOI 10.1074/jbc.M006951200; Schlegel A, 2001, CYTOKINE GROWTH F R, V12, P41, DOI 10.1016/S1359-6101(00)00022-8; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; Wang XQ, 2001, J INVEST DERMATOL, V116, P69, DOI 10.1046/j.1523-1747.2001.00222.x; Waugh MG, 1999, BIOCHEM J, V337, P591, DOI 10.1042/0264-6021:3370591	23	153	157	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 24	2002	277	21					18954	18960		10.1074/jbc.M201422200	http://dx.doi.org/10.1074/jbc.M201422200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	558PM	11886870	hybrid			2022-12-27	WOS:000175975800092
J	Vlasie, M; Chowdhury, S; Banerjee, R				Vlasie, M; Chowdhury, S; Banerjee, R			Importance of the histidine ligand to coenzyme B-12 in the reaction catalyzed by methylmalonyl-CoA mutase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COBALT-CARBON BOND; X-RAY STRUCTURE; GLUTAMATE MUTASE; C-BOND; CLOSTRIDIUM-TETANOMORPHUM; B-12-BINDING SUBUNIT; METHIONINE SYNTHASE; DIOL DEHYDRATASE; LONG COBALT; A MUTASE	Methylmalonyl-CoA mutase is an adenosylcobalamin (AdoCbl)-dependent enzyme that catalyzes the rearrangement of methylmalonyl-CoA to succinyl-CoA. The crystal structure of this protein revealed that binding of the cofactor is accompanied by a significant conformational change in which dimethylbenzimidazole, the lower axial ligand to the cobalt in solution, is replaced by His-610 donated by the active site. The contribution of the lower axial base to the similar to10(12)-fold rate acceleration of the homolytic cleavage of the upper axial cobalt-carbon bond has been the subject of intense scrutiny in the model inorganic literature. In contrast, trans ligand effects in methylmalonyl-CoA mutase and indeed the significance of the ligand replacement are poorly understood. In this study, we have used site-directed mutagenesis to create the H610A and H610N variants of methylmalonyl-CoA mutase and report that both mutations exhibit both diminished activity (5,000- and 40,000-fold, respectively) and profoundly weakened affinity for the native cofactor, AdoCbl. In contrast, binding of the truncated cofactor analog, adenosylcobinamide, lacking the nucleotide tail, is less impaired. The catalytic failure of the His-610 mutants is in marked contrast to the phenotype of the adenosylcobinamide-GDP reconstituted wild type enzyme that exhibits only a 4-fold decrease in activity, although His-610 fails to coordinate when this cofactor analog is bound. Together, these studies suggest that His-610 may: (i) play a structural role in organizing a high affinity cofactor binding site possibly via electrostatic interactions with Asp-608 and Lys-604, as suggested by the crystal structure and (ii) play a role in catalyzing the displacement of dimethylbenzimidazole thereby facilitating the conformational change that must precede cofactor docking to the mutase active site.	Univ Nebraska, Dept Biochem, Lincoln, NE 68588 USA	University of Nebraska System; University of Nebraska Lincoln	Banerjee, R (corresponding author), Univ Nebraska, Dept Biochem, Lincoln, NE 68588 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045776, R29DK045776] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK45776] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abend A, 1999, ARCH BIOCHEM BIOPHYS, V370, P138, DOI 10.1006/abbi.1999.1382; Banerjee R, 2001, BIOCHEMISTRY-US, V40, P6191, DOI 10.1021/bi0104423; BROWN KL, 1984, J AM CHEM SOC, V106, P7894, DOI 10.1021/ja00337a043; BROWN KL, 1991, INORG CHEM, V30, P3420, DOI 10.1021/ic00018a011; CHEMALY SM, 1980, J CHEM SOC DALTON, P2274, DOI 10.1039/dt9800002274; Chen HP, 1997, BIOCHEMISTRY-US, V36, P7884, DOI 10.1021/bi970169y; Chowdhury S, 2000, BIOCHEMISTRY-US, V39, P7998, DOI 10.1021/bi992535e; Chowdhury S, 1999, BIOCHEMISTRY-US, V38, P15287, DOI 10.1021/bi9914762; Chowdhury S, 2001, J BIOL CHEM, V276, P1015, DOI 10.1074/jbc.M006842200; DRENNAN CL, 1994, SCIENCE, V266, P1669, DOI 10.1126/science.7992050; Garr CD, 1996, INORG CHEM, V35, P5912, DOI 10.1021/ic951272j; GENO MK, 1987, J AM CHEM SOC, V109, P1238, DOI 10.1021/ja00238a039; GRATE JH, 1979, J AM CHEM SOC, V101, P4601, DOI 10.1021/ja00510a027; HAY BP, 1987, J AM CHEM SOC, V109, P8012, DOI 10.1021/ja00260a011; HAY BP, 1988, POLYHEDRON, V7, P1469, DOI 10.1016/S0277-5387(00)81775-1; ISHIDA A, 1993, BIOCHEMISTRY-US, V32, P1535, DOI 10.1021/bi00057a018; Jarrett JT, 1996, BIOCHEMISTRY-US, V35, P2464, DOI 10.1021/bi952389m; Lawrence CC, 1999, J BIOL CHEM, V274, P7039, DOI 10.1074/jbc.274.11.7039; LENHERT PG, 1961, NATURE, V192, P937, DOI 10.1038/192937a0; Maiti N, 1999, J BIOL CHEM, V274, P32733, DOI 10.1074/jbc.274.46.32733; Mancia F, 1996, STRUCTURE, V4, P339, DOI 10.1016/S0969-2126(96)00037-8; MARZILLI LG, 1979, J AM CHEM SOC, V101, P6754, DOI 10.1021/ja00516a049; MCKIE N, 1990, BIOCHEM J, V269, P293, DOI 10.1042/bj2690293; NG FTT, 1982, J AM CHEM SOC, V104, P621, DOI 10.1021/ja00366a045; PADMAKUMAR R, 1995, J BIOL CHEM, V270, P9295, DOI 10.1074/jbc.270.16.9295; Padmakumar R, 1997, BIOCHEMISTRY-US, V36, P3713, DOI 10.1021/bi962503g; RANDACCIO L, 1980, J AM CHEM SOC, V102, P7373; Reitzer R, 1999, STRUCTURE, V7, P891, DOI 10.1016/S0969-2126(99)80116-6; Shibata N, 1999, STRUCTURE, V7, P997, DOI 10.1016/S0969-2126(99)80126-9; Sirovatka JM, 1997, J AM CHEM SOC, V119, P3057, DOI 10.1021/ja963380q; STUPPERICH E, 1990, EUR J BIOCHEM, V193, P105, DOI 10.1111/j.1432-1033.1990.tb19310.x; SUMMERS MF, 1983, J AM CHEM SOC, V105, P6259, DOI 10.1021/ja00358a012; TAOKA S, 1994, J BIOL CHEM, V269, P31630; Tollinger M, 1998, STRUCTURE, V6, P1021, DOI 10.1016/S0969-2126(98)00103-8; Tollinger M, 2001, J MOL BIOL, V309, P777, DOI 10.1006/jmbi.2001.4696; WADDINGTON MD, 1993, J AM CHEM SOC, V115, P4629, DOI 10.1021/ja00064a026; Yamanishi M, 1998, BIOCHEMISTRY-US, V37, P4799, DOI 10.1021/bi972572a; [No title captured]	38	21	21	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 24	2002	277	21					18523	18527		10.1074/jbc.M111809200	http://dx.doi.org/10.1074/jbc.M111809200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	558PM	11893736	hybrid			2022-12-27	WOS:000175975800037
J	Wang, J; Vock, VM; Li, SL; Olivas, OR; Wilkinson, MF				Wang, J; Vock, VM; Li, SL; Olivas, OR; Wilkinson, MF			A quality control pathway that down-regulates aberrant T-cell receptor (TCR) transcripts by a mechanism requiring UPF2 and translation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA DECAY; NONSENSE CODONS; GENE-EXPRESSION; MEDIATED DECAY; IN-VIVO; SURVEILLANCE; SEQUENCES; NUCLEAR; TERMINATION; INITIATION	Nonsense-mediated decay (NMD) is an RNA surveillance pathway that degrades mRNAs containing premature termination codons (PTC). T-cell receptor (TCR) and immunoglobulin (Ig) transcripts, which are encoded by genes that very frequently acquire PTCs during lymphoid ontogeny, are down-regulated much more dramatically in response to PTCs than are other known transcripts. Another feature unique to TCR, Ig, and a subset of other mRNAs is that they are down-regulated in response to nonsense codons in the nuclear fraction of cells. This is paradoxical, as the only well recognized entity that recognizes nonsense codons is the cytoplasmic translation apparatus. Therefore, we investigated whether translation is responsible for this nuclear-associated mechanism. We found that the down-regulation of TCR-beta transcripts in response to nonsense codons requires several features of translation, including an initiator ATG and the ability to scan. We also found that optimal down-regulation depends on a Kozak consensus sequence surrounding the initiator ATG and that it can be initiated by an internal ribosome entry site, neither of which has been demonstrated before for any other PTC-bearing mRNA. At least a portion of this down-regulatory response is mediated by the NMD pathway as antisense hUPF2 transcripts increased the levels of PTC-bearing TCR-beta transcripts in the nuclear fraction of cells. We conclude that a hUPF2-dependent RNA surveillance pathway with translation-like features operating in the nuclear fraction of cells prevents the expression of potentially deleterious truncated proteins encoded by non-productively rearranged TCR genes.	Univ Texas, MD Anderson Canc Ctr, Dept Immunol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Wilkinson, MF (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Immunol, Box 180,1515 Holcombe Blvd, Houston, TX 77030 USA.	mwilkins@mail.mdanderson.org	Li, Shulin/D-6478-2011		NIGMS NIH HHS [GM 58595] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058595] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARKER GF, 1994, MOL CELL BIOL, V14, P1986, DOI 10.1128/MCB.14.3.1986; BELGRADER P, 1993, P NATL ACAD SCI USA, V90, P482, DOI 10.1073/pnas.90.2.482; Buzina A, 1999, MOL BIOL CELL, V10, P515, DOI 10.1091/mbc.10.3.515; Carter MS, 2000, COLD SPRING HARBOR M, V39, P615; Carter MS, 1996, EMBO J, V15, P5965, DOI 10.1002/j.1460-2075.1996.tb00983.x; CARTER MS, 1995, J BIOL CHEM, V270, P28995, DOI 10.1074/jbc.270.48.28995; CONNOR A, 1994, J BIOL CHEM, V269, P25178; Culbertson MR, 1999, TRENDS GENET, V15, P74, DOI 10.1016/S0168-9525(98)01658-8; DIRKS W, 1993, GENE, V128, P247, DOI 10.1016/0378-1119(93)90569-O; Dostie J, 2000, J CELL BIOL, V148, P239, DOI 10.1083/jcb.148.2.239; Frischmeyer PA, 1999, HUM MOL GENET, V8, P1893, DOI 10.1093/hmg/8.10.1893; Gonzalez CI, 2001, GENE, V274, P15, DOI 10.1016/S0378-1119(01)00552-2; Gudikote JP, 2002, EMBO J, V21, P125, DOI 10.1093/emboj/21.1.125; GUNNING P, 1987, P NATL ACAD SCI USA, V84, P4831, DOI 10.1073/pnas.84.14.4831; Hennecke M, 2001, NUCLEIC ACIDS RES, V29, P3327, DOI 10.1093/nar/29.16.3327; Hentze MW, 1999, CELL, V96, P307, DOI 10.1016/S0092-8674(00)80542-5; Hilleren P, 1999, RNA, V5, P711, DOI 10.1017/S1355838299990519; Iborra FJ, 2001, SCIENCE, V293, P1139, DOI 10.1126/science.1061216; Jacobson A, 2000, COLD SPRING HARBOR M, V39, P827; Kessler O, 1996, MOL CELL BIOL, V16, P4426; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; Li SL, 1997, J EXP MED, V185, P985, DOI 10.1084/jem.185.6.985; Li SL, 1998, IMMUNITY, V8, P135, DOI 10.1016/S1074-7613(00)80466-5; LOZANO F, 1994, EMBO J, V13, P4617, DOI 10.1002/j.1460-2075.1994.tb06783.x; Lykke-Andersen J, 2000, CELL, V103, P1121, DOI 10.1016/S0092-8674(00)00214-2; Maquat LE, 2000, COLD SPRING HARBOR M, V39, P849; MEEROVITCH K, 1991, J VIROL, V65, P5895, DOI 10.1128/JVI.65.11.5895-5901.1991; Mendell JT, 2000, MOL CELL BIOL, V20, P8944, DOI 10.1128/MCB.20.23.8944-8957.2000; Moriarty PM, 1998, MOL CELL BIOL, V18, P2932, DOI 10.1128/MCB.18.5.2932; Muhlemann O, 2001, MOL CELL, V8, P33, DOI 10.1016/S1097-2765(01)00288-X; Noensie EN, 2001, NAT BIOTECHNOL, V19, P434, DOI 10.1038/88099; PELLETIER J, 1988, MOL CELL BIOL, V8, P1103, DOI 10.1128/MCB.8.3.1103; PELLETIER J, 1988, NATURE, V334, P320, DOI 10.1038/334320a0; QIAN L, 1993, J IMMUNOL, V151, P6801; SARNOW P, 1989, J VIROL, V63, P467, DOI 10.1128/JVI.63.1.467-470.1989; Shyu AB, 2000, CELL, V102, P135, DOI 10.1016/S0092-8674(00)00018-0; Thermann R, 1998, EMBO J, V17, P3484, DOI 10.1093/emboj/17.12.3484; TRONO D, 1988, SCIENCE, V241, P445, DOI 10.1126/science.2839901; Wang J, 2000, BIOTECHNIQUES, V29, P976, DOI 10.2144/00295bm09; Wang J, 2002, EMBO REP, V3, P274, DOI 10.1093/embo-reports/kvf036; WHITFIELD TT, 1994, DEV BIOL, V165, P731, DOI 10.1006/dbio.1994.1289; Wilkinson MF, 2001, BIOESSAYS, V23, P775, DOI 10.1002/bies.1113	42	58	59	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 24	2002	277	21					18489	18493		10.1074/jbc.M111781200	http://dx.doi.org/10.1074/jbc.M111781200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	558PM	11889124	hybrid			2022-12-27	WOS:000175975800032
J	Chen, XQ; Edwards, JAS; Logsdon, CD; Ernst, SA; Williams, JA				Chen, XQ; Edwards, JAS; Logsdon, CD; Ernst, SA; Williams, JA			Dominant negative Rab3D inhibits amylase release from mouse pancreatic acini	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE EXCHANGE FACTOR; GTP-BINDING PROTEINS; CA2+-DEPENDENT EXOCYTOSIS; NEUROENDOCRINE CELLS; PC12 CELLS; EXPRESSION; SECRETION; RAT; CHOLECYSTOKININ; MUTANTS	Rab3 proteins are believed to play an important role in regulated exocytosis and previous work has demonstrated the presence of Rab3D on pancreatic zymogen granules. To further understand the function of Rab3D in acinar cell exocytosis, adenoviral constructs were prepared encoding hemagglutinin-tagged wild type Rab3D and three mutant forms, N135I and T36N (both deficient in guanine nucleotide binding) and Q81L (deficient in GTP hydrolysis), which also expressed enhanced green fluorescent protein driven by a separate promoter. When isolated mouse pancreatic acini were cultured with 5 x 10(6) pfu/ml adenovirus, nearly 100% of acini were infected as visualized by expression of green fluorescent protein. Cultured acini showed a biphasic dose-response to cholecystokinin (CCK); basal amylase secretion was 1.8 +/- 0.30%/30 min, peak release was 7.3 +/- 0.2%/30 min at 30 pm CCK and reduced secretion was observed at higher CCK concentrations. Control beta-galactosidase virus infection had no effect on either basal or CCK-induced secretion in the titer range from 0.5 to 10 x 10(6) pfu/ml. While the expression of Rab3D and Rab3D Q81L had no effect on amylase secretion, Rab3D N135I and T36N functioned as dominant negative mutants and inhibited CCK-induced amylase release by 40-50% at all points on the CCK dose-response curve from 3 to 300 pm. Inhibition was stronger during the first 5 min (71 +/- 5%) than over 30 min (36% +/- 5%). Similar inhibition was found using other agonists including bombesin, carbachol, A23187, and cAMP. Localization of adenoviral expressed Rab protein showed wild type Rab3D localized to zymogen granules. The two dominant negative mutants did not localize to granules and were primarily in the basolateral region of the cell. Since both dominant negative Rab3D mutants had no effect on intracellular calcium increase induced by CCK, it is unlikely that they acted at receptors or transmembrane signaling. These results suggest that Rab3D plays an important role in regulating the terminal steps of acinar exocytosis and that this effect is greatest on the early phase of amylase release.	Univ Michigan, Dept Physiol, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Cell & Dev Biol, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Internal Med, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Chen, XQ (corresponding author), Univ Michigan, Dept Physiol, 7734 Med Sci Bldg 2, Ann Arbor, MI 48109 USA.	xuequnc@umich.edu		Williams, John/0000-0002-6063-7615				Baldini G, 1998, J CELL BIOL, V140, P305, DOI 10.1083/jcb.140.2.305; Bean AJ, 1997, NEURON, V19, P751, DOI 10.1016/S0896-6273(00)80957-5; BHULLAR RP, 1987, BIOCHEM J, V245, P617, DOI 10.1042/bj2450617; BRONDYK WH, 1993, J BIOL CHEM, V268, P9410; Bucci C, 2000, MOL BIOL CELL, V11, P467, DOI 10.1091/mbc.11.2.467; BURSTEIN ES, 1992, J BIOL CHEM, V267, P22715; Chung SH, 1999, J BIOL CHEM, V274, P18113, DOI 10.1074/jbc.274.25.18113; Collins RN, 1997, J BIOL CHEM, V272, P18281, DOI 10.1074/jbc.272.29.18281; Demo SD, 1999, CYTOMETRY, V36, P340, DOI 10.1002/(SICI)1097-0320(19990801)36:4<340::AID-CYTO9>3.0.CO;2-C; Feig LA, 1999, NAT CELL BIOL, V1, pE25, DOI 10.1038/10018; Geppert M, 1998, ANNU REV NEUROSCI, V21, P75, DOI 10.1146/annurev.neuro.21.1.75; Geppert M, 1997, NATURE, V387, P810, DOI 10.1038/42954; Han B, 2000, AM J PHYSIOL-CELL PH, V278, pC344, DOI 10.1152/ajpcell.2000.278.2.C344; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; HOLZ RW, 1994, J BIOL CHEM, V269, P10229; Hume AN, 2001, J CELL BIOL, V152, P795, DOI 10.1083/jcb.152.4.795; Iezzi M, 1999, MOL ENDOCRINOL, V13, P202, DOI 10.1210/me.13.2.202; JAMIESON JD, 1967, J CELL BIOL, V34, P597, DOI 10.1083/jcb.34.2.597; JAMIESON JD, 1971, J CELL BIOL, V50, P135, DOI 10.1083/jcb.50.1.135; Ji BA, 2000, J BIOL CHEM, V275, P19115, DOI 10.1074/jbc.M001685200; JOHANNES L, 1994, EMBO J, V13, P2029, DOI 10.1002/j.1460-2075.1994.tb06476.x; JONES S, 1995, J CELL BIOL, V130, P1051, DOI 10.1083/jcb.130.5.1051; LI GP, 1994, J BIOL CHEM, V269, P14631; LLEDO PM, 1993, NATURE, V364, P540, DOI 10.1038/364540a0; Luo HR, 2001, NEURON, V31, P439, DOI 10.1016/S0896-6273(01)00384-1; Martelli AM, 2000, TRAFFIC, V1, P976, DOI 10.1034/j.1600-0854.2000.011207.x; MUALLEM S, 1995, J CELL BIOL, V128, P589, DOI 10.1083/jcb.128.4.589; Nicke B, 1999, AM J PHYSIOL-GASTR L, V276, pG499, DOI 10.1152/ajpgi.1999.276.2.G499; Ohnishi H, 1996, AM J PHYSIOL-GASTR L, V271, pG531, DOI 10.1152/ajpgi.1996.271.3.G531; Ohnishi H, 1997, J CLIN INVEST, V100, P3044, DOI 10.1172/JCI119859; Padfield PJ, 1998, BIOCHEM J, V330, P329; PALADE G, 1975, SCIENCE, V189, P347, DOI 10.1126/science.1096303; Pfeffer SR, 2001, TRENDS CELL BIOL, V11, P487, DOI 10.1016/S0962-8924(01)02147-X; Roa M, 1997, J IMMUNOL, V159, P2815; Segev N, 2001, CURR OPIN CELL BIOL, V13, P500, DOI 10.1016/S0955-0674(00)00242-8; Takai Y, 2001, PHYSIOL REV, V81, P153, DOI 10.1152/physrev.2001.81.1.153; Tanaka M, 2001, MOL BIOL CELL, V12, P1421, DOI 10.1091/mbc.12.5.1421; TISDALE EJ, 1992, J CELL BIOL, V119, P749, DOI 10.1083/jcb.119.4.749; Valentijn JA, 1996, EUR J CELL BIOL, V71, P129; Valentijn JA, 1996, EUR J CELL BIOL, V70, P33; Wada M, 1997, J BIOL CHEM, V272, P3875, DOI 10.1074/jbc.272.7.3875; WALWORTH NC, 1989, EMBO J, V8, P1685, DOI 10.1002/j.1460-2075.1989.tb03560.x; Weber E, 1996, J BIOL CHEM, V271, P6963, DOI 10.1074/jbc.271.12.6963; WEBER E, 1994, J CELL BIOL, V125, P583, DOI 10.1083/jcb.125.3.583; Williams JA, 2001, ANNU REV PHYSIOL, V63, P77, DOI 10.1146/annurev.physiol.63.1.77; WILLIAMS JA, 1978, AM J PHYSIOL, V235, pE517, DOI 10.1152/ajpendo.1978.235.5.E517; YULE DI, 1992, J BIOL CHEM, V267, P13830; YULE DI, 1994, PHYSL GASTROINTESTIN	48	63	64	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 17	2002	277	20					18002	18009		10.1074/jbc.M201248200	http://dx.doi.org/10.1074/jbc.M201248200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	553PR	11875077	hybrid			2022-12-27	WOS:000175685100078
J	Penheiter, AR; Caride, AJ; Enyedi, A; Penniston, JT				Penheiter, AR; Caride, AJ; Enyedi, A; Penniston, JT			Tryptophan 1093 is largely responsible for the slow off rate of calmodulin from plasma membrane Ca2+ pump 4b	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING DOMAIN; CALCIUM-PUMP; CA-2+ PUMP; COMPLEX; RECOGNITION; ACTIVATION; PEPTIDE; CELLS; 2B	Tryptophan 1093 resides in the 28-residue calmodulin-binding/autoinhibitory domain of the plasma membrane Ca2+ pump (PMCA). Previous studies with the isolated calmodulin-binding/autoinhibitory peptide from PMCA have shown that mutations of the tryptophan residue decrease the affinity of the peptide for calmodulin and its affinity as an inhibitor of proteolytically activated pump. In this study, the PMCA mutation in which tryptophan 1093 is converted to alanine (W1093A) was constructed in the full-length PMCA isoform 4b. The mutant pump was expressed in COS cells, and its steady state and pre-steady state kinetic properties were examined. The W1093A pump exhibited an increased basal activity in the absence of calmodulin, so the activation was similar to2-fold (it is 10-fold in the wild type). The W1093A mutation also lowered the steady state affinity for calmodulin from K-0.5 of 9 nM for wild type to 144 nM (assayed at 700 nM free Ca2+). Pre-steady state measurements of the rate of activation by Ca2+-calmodulin revealed that the W1093A mutant responded 2.5-fold faster to calmodulin. In contrast to these relatively modest effects, the half-time of inactivation of the mutant was reduced by more than 2 orders of magnitude from 41 min to 7 s. We conclude that tryptophan 1093 does not play a substantial role in Ca2+-calmodulin recognition; rather it functions primarily to slow the inactivation of the calmodulin-activated pump.	Mayo Clin, Dept Biochem & Mol Biol, Rochester, MN 55905 USA; Natl Inst Haematol & Immunol, H-1113 Budapest, Hungary	Mayo Clinic	Penniston, JT (corresponding author), Mayo Clin, Dept Biochem & Mol Biol, 200 1st St SW, Rochester, MN 55905 USA.		Enyedi, Agnes/N-9742-2013	Enyedi, Agnes/0000-0002-7366-9376	NIDCD NIH HHS [DC04200] Funding Source: Medline; NIGMS NIH HHS [GM28835] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028835] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC004200] Funding Source: NIH RePORTER	NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		ADAMO HP, 1992, BIOCHEM J, V285, P791, DOI 10.1042/bj2850791; Caride AJ, 1999, J BIOL CHEM, V274, P35227, DOI 10.1074/jbc.274.49.35227; Caride AJ, 2001, J BIOL CHEM, V276, P39797, DOI 10.1074/jbc.M104380200; Caride AJ, 2001, CELL CALCIUM, V30, P49, DOI 10.1054/ceca.2001.0212; Elshorst B, 1999, BIOCHEMISTRY-US, V38, P12320, DOI 10.1021/bi9908235; Elwess NL, 1997, J BIOL CHEM, V272, P17981, DOI 10.1074/jbc.272.29.17981; ENYEDI A, 1993, J BIOL CHEM, V268, P17120; ENYEDI A, 1989, J BIOL CHEM, V264, P12313; ENYEDI A, 1994, J BIOL CHEM, V269, P41; Filoteo AG, 2000, J BIOL CHEM, V275, P4323, DOI 10.1074/jbc.275.6.4323; IKURA M, 1992, CELL CALCIUM, V13, P391, DOI 10.1016/0143-4160(92)90052-T; KATAOKA M, 1991, BIOCHEMISTRY-US, V30, P6247, DOI 10.1021/bi00239a024; LINSE S, 1991, J BIOL CHEM, V266, P8050; MEADOR WE, 1993, SCIENCE, V262, P1718, DOI 10.1126/science.8259515; MEADOR WE, 1992, SCIENCE, V257, P1251, DOI 10.1126/science.1519061; Strehler EE, 2001, PHYSIOL REV, V81, P21, DOI 10.1152/physrev.2001.81.1.21; Verma AK, 1996, J BIOL CHEM, V271, P3714; VERMA AK, 1994, J BIOL CHEM, V269, P1687; VORHERR T, 1990, BIOCHEMISTRY-US, V29, P355, DOI 10.1021/bi00454a008	19	17	17	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 17	2002	277	20					17728	17732		10.1074/jbc.M111608200	http://dx.doi.org/10.1074/jbc.M111608200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	553PR	11886854	hybrid			2022-12-27	WOS:000175685100044
J	Shakarian, AM; Joshi, MB; Ghedin, E; Dwyer, DM				Shakarian, AM; Joshi, MB; Ghedin, E; Dwyer, DM			Molecular dissection of the functional domains of a unique, tartrate-resistant, surface membrane acid phosphatase in the primitive human pathogen Leishmania donovani	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROMASTIGOTES; AMASTIGOTES; MEXICANA; CLONING; PROTEIN; GENES	The primitive trypanosomatid pathogen of humans, Leishmania donovani, constitutively expresses a unique externally oriented, tartrate-resistant, acid phosphatase on its surface membrane. This is of interest because these organisms are obligate intracellular protozoan parasites that reside and multiply within the hydrolytic milieu of mammalian macrophage phago-lysosomes. Here we report the identification of the gene encoding this novel L. donovani enzyme. In addition, we characterized its structure, demonstrated its constitutive expression in both parasite developmental forms, and determined the cell surface membrane localization of its translated protein product. Further, we used a variety of green fluorescent protein chimeric constructs as reporters in a homologous leishmanial expression system to dissect the functional domains of this unique, tartrate-resistant, surface membrane enzyme.	NIAID, Cell Biol Sect, Parasit Dis Lab, NIH, Bethesda, MD 20892 USA; Salva Regina Univ, Dept Biol & Biomed Sci, Newport, RI 02840 USA; Inst Genom Res, Rockville, MD 20850 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); J. Craig Venter Institute	Dwyer, DM (corresponding author), NIAID, Cell Biol Sect, Parasit Dis Lab, NIH, Bldg 4,Rm 126,4 Ctr Dr,MSC-0425, Bethesda, MD 20892 USA.		Ghedin, Elodie/Y-5654-2019	Ghedin, Elodie/0000-0002-1515-725X	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI000745, Z01AI000745, Z01AI000162] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BATES PA, 1987, MOL BIOCHEM PARASIT, V26, P289, DOI 10.1016/0166-6851(87)90081-8; Clayton C, 1998, MOL BIOCHEM PARASIT, V97, P221, DOI 10.1016/S0166-6851(98)00115-7; DAS S, 1986, MOL BIOCHEM PARASIT, V20, P143, DOI 10.1016/0166-6851(86)90026-5; Debrabant A, 2000, J BIOL CHEM, V275, P16366, DOI 10.1074/jbc.M908725199; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DWYER DM, 1974, Z PARASITENKD, V43, P227, DOI 10.1007/BF00328879; Ellis SL, 1998, EXP PARASITOL, V89, P161, DOI 10.1006/expr.1998.4298; GBENLE GO, 1992, BIOCHEM J, V285, P41, DOI 10.1042/bj2850041; GOTTLIEB M, 1981, SCIENCE, V212, P939, DOI 10.1126/science.7233189; GOTTLIEB M, 1982, MOL CELL BIOL, V2, P76, DOI 10.1128/MCB.2.1.76; GOTTLIEB M, 1981, EXP PARASITOL, V52, P117, DOI 10.1016/0014-4894(81)90067-9; JOSHI M, 1993, MOL BIOCHEM PARASIT, V58, P345, DOI 10.1016/0166-6851(93)90057-5; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LaCount MW, 1998, J BIOL CHEM, V273, P30406, DOI 10.1074/jbc.273.46.30406; Lamp EC, 2000, LEUKEMIA LYMPHOMA, V39, P477, DOI 10.3109/10428190009113378; MCCARTHYBURKE C, 1991, EXP PARASITOL, V73, P385, DOI 10.1016/0014-4894(91)90112-A; McCombie W R, 1992, DNA Seq, V2, P289, DOI 10.3109/10425179209030961; Oddie GW, 2000, BONE, V27, P575, DOI 10.1016/S8756-3282(00)00368-9; REMALEY AT, 1985, J BIOL CHEM, V260, P880; SCHNEIDER G, 1993, EMBO J, V12, P2609, DOI 10.1002/j.1460-2075.1993.tb05921.x; Shakarian AM, 1997, GENE, V196, P127, DOI 10.1016/S0378-1119(97)00218-7; Shakarian AM, 1998, GENE, V208, P315, DOI 10.1016/S0378-1119(98)00011-0; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; *UNDP WORLD BANK W, 1999, TROP DIS RES PROGR 1; VONHEIJNE G, 1985, J MOL BIOL, V184, P99, DOI 10.1016/0022-2836(85)90046-4; Wiese M, 1996, MOL BIOCHEM PARASIT, V82, P153, DOI 10.1016/0166-6851(96)02729-6; WIESE M, 1995, EMBO J, V14, P1067, DOI 10.1002/j.1460-2075.1995.tb07089.x; ZANG WW, 1996, MOL BIOCHEM PARASIT, V78, P79	28	27	27	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 17	2002	277	20					17994	18001		10.1074/jbc.M200114200	http://dx.doi.org/10.1074/jbc.M200114200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	553PR	11882658	hybrid			2022-12-27	WOS:000175685100077
J	Silkov, A; Wolstein, O; Shachar, I; Dikstein, R				Silkov, A; Wolstein, O; Shachar, I; Dikstein, R			Enhanced apoptosis of B and T lymphocytes in TAF(II)105 dominant-negative transgenic mice is linked to nuclear factor-kappa B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION IN-VIVO; THYROID-HORMONE RECEPTORS; CELL-CYCLE PROGRESSION; HISTONE-LIKE TAFS; MAMMALIAN-CELLS; ACTIVATION; COMPLEX; YEAST; BINDING; SAGA	The general transcription factor TFIID is composed of the TATA-binding protein (TBP) and 12-14 TBP-associated factors (TAF(II)s). Some TAF(II)s act as bridges between transcription activators and the general transcription machinery through direct interaction with activation domains. Although TAF-mediated transcription activation has been established, there is little genetic evidence connecting it to binding of an activator. TAF(II)105 is a substoichiometric subunit of transcription factor IID highly expressed in B lymphocytes. In this study, we examined the physiological role of TAF(II)105 and its mechanism of action in vivo by expressing two forms of dominant-negative mutant TAF(II)105 in mice. We show that TAF(II)105 has a pro-survival role in B and T lymphocytes, where the native protein is expressed. In addition, TAF(II)105 is important for T cell maturation and for production of certain antibody isotypes. These phenotypic alterations were absent in mice expressing a dominant-negative mutant that lacks one of the domains mediating p65/RelA binding in vitro. These findings provide support to the notion that interaction between the activator and TAF is important for their function in vivo.	Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel; Weizmann Inst Sci, Dept Immunol, IL-76100 Rehovot, Israel	Weizmann Institute of Science; Weizmann Institute of Science	Dikstein, R (corresponding author), Weizmann Inst Sci, Dept Biol Chem, 2 Hertzel St, IL-76100 Rehovot, Israel.							Albright SR, 2000, GENE, V242, P1, DOI 10.1016/S0378-1119(99)00495-3; Apone LM, 1996, GENE DEV, V10, P2368, DOI 10.1101/gad.10.18.2368; Apone LM, 1998, MOL CELL, V2, P653, DOI 10.1016/S1097-2765(00)80163-X; Barkett M, 1999, ONCOGENE, V18, P6910, DOI 10.1038/sj.onc.1203238; Bertolotti A, 1999, ONCOGENE, V18, P8000, DOI 10.1038/sj.onc.1203207; Chalkley GE, 1999, EMBO J, V18, P4835, DOI 10.1093/emboj/18.17.4835; COHEN JJ, 1992, ANNU REV IMMUNOL, V10, P267, DOI 10.1146/annurev.immunol.10.1.267; de Martin R, 1999, MUTAT RES-REV MUTAT, V437, P231, DOI 10.1016/S1383-5742(99)00089-7; Dikstein R, 1996, CELL, V87, P137, DOI 10.1016/S0092-8674(00)81330-6; EGERTON M, 1990, P NATL ACAD SCI USA, V87, P2579, DOI 10.1073/pnas.87.7.2579; Foo SY, 1999, TRENDS GENET, V15, P229; Freiman RN, 2001, SCIENCE, V293, P2084, DOI 10.1126/science.1061935; Furukawa T, 2000, J BIOL CHEM, V275, P29847, DOI 10.1074/jbc.M002989200; Grant PA, 1998, CELL, V94, P45, DOI 10.1016/S0092-8674(00)81220-9; Grossmann M, 2000, EMBO J, V19, P6351, DOI 10.1093/emboj/19.23.6351; Hoffmann A, 1997, P NATL ACAD SCI USA, V94, P8928, DOI 10.1073/pnas.94.17.8928; Horwitz BH, 1999, J IMMUNOL, V162, P1941; HUESMANN M, 1991, CELL, V66, P533, DOI 10.1016/0092-8674(81)90016-7; KAUFMANN J, 1994, GENE DEV, V8, P821, DOI 10.1101/gad.8.7.821; Komarnitsky PB, 1999, GENE DEV, V13, P2484, DOI 10.1101/gad.13.19.2484; KRIKOS A, 1992, J BIOL CHEM, V267, P17971; Lavigne AC, 1999, MOL CELL BIOL, V19, P5486; MARTINEZ E, 1994, EMBO J, V13, P3115, DOI 10.1002/j.1460-2075.1994.tb06610.x; May M, 1996, EMBO J, V15, P3093, DOI 10.1002/j.1460-2075.1996.tb00672.x; Mengus G, 1997, GENE DEV, V11, P1381, DOI 10.1101/gad.11.11.1381; Metzger D, 1999, EMBO J, V18, P4823, DOI 10.1093/emboj/18.17.4823; Michel B, 1998, MOL CELL, V2, P663, DOI 10.1016/S1097-2765(00)80164-1; Moqtaderi Z, 1998, MOL CELL, V2, P675, DOI 10.1016/S1097-2765(00)80165-3; Moqtaderi Z, 1996, NATURE, V383, P188, DOI 10.1038/383188a0; Natarajan K, 1998, MOL CELL, V2, P683, DOI 10.1016/S1097-2765(00)80166-5; Ogryzko VV, 1998, CELL, V94, P35, DOI 10.1016/S0092-8674(00)81219-2; Orlando V, 1997, METHODS, V11, P205, DOI 10.1006/meth.1996.0407; Pham AD, 1999, MECH DEVELOP, V84, P3, DOI 10.1016/S0925-4773(99)00051-9; Reese JC, 2000, J BIOL CHEM, V275, P17391, DOI 10.1074/jbc.M001635200; ROEDER RG, 1991, TRENDS BIOCHEM SCI, V16, P402, DOI 10.1016/0968-0004(91)90164-Q; Sambrook J., 2002, MOL CLONING LAB MANU; Sanders SL, 1999, J BIOL CHEM, V274, P18847, DOI 10.1074/jbc.274.27.18847; Smale ST, 1997, BBA-GENE STRUCT EXPR, V1351, P73, DOI 10.1016/S0167-4781(96)00206-0; SURH CD, 1994, NATURE, V372, P100, DOI 10.1038/372100a0; TEWARI M, 1995, J IMMUNOL, V154, P1699; VANLOHUIZEN M, 1989, CELL, V56, P673, DOI 10.1016/0092-8674(89)90589-8; VERRIJZER CP, 1994, SCIENCE, V264, P933, DOI 10.1126/science.8178153; VERRIJZER CP, 1996, GENE DEV, V11, P3020; Walker SS, 1996, NATURE, V383, P185, DOI 10.1038/383185a0; WILLIAMS GT, 1994, BIOCHEM CELL BIOL, V72, P447, DOI 10.1139/o94-059; Wolstein O, 2000, J BIOL CHEM, V275, P16459, DOI 10.1074/jbc.275.22.16459; WYLLIE AH, 1987, INT REV CYTOL S, V17, P755; Yamit-Hezi A, 1998, EMBO J, V17, P5161, DOI 10.1093/emboj/17.17.5161; Yamit-Hezi E, 2000, J BIOL CHEM, V275, P18180, DOI 10.1074/jbc.275.24.18180; Zhou JM, 1998, P NATL ACAD SCI USA, V95, P13483, DOI 10.1073/pnas.95.23.13483	50	14	14	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 17	2002	277	20					17821	17829		10.1074/jbc.M200696200	http://dx.doi.org/10.1074/jbc.M200696200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	553PR	11856754	hybrid			2022-12-27	WOS:000175685100056
J	Wang, HY; Gauthier, BR; Hagenfeldt-Johansson, KA; Iezzi, M; Wollheim, CB				Wang, HY; Gauthier, BR; Hagenfeldt-Johansson, KA; Iezzi, M; Wollheim, CB			Foxa2 (HNF3 beta) controls multiple genes implicated in metabolism-secretion coupling of glucose-induced insulin release	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR FACTOR 3-BETA; PANCREATIC BETA-CELLS; PERSISTENT HYPERINSULINEMIC HYPOGLYCEMIA; SULFONYLUREA RECEPTOR GENE; UNCOUPLING PROTEIN-2; FAMILIAL HYPERINSULINISM; TRANSCRIPTION FACTORS; MOLECULAR-BASIS; HEPATOCYTE; EXPRESSION	The transcription factor Foxa2 is implicated in blood glucose homeostasis. Conditional expression of Foxa2 or its dominant-negative mutant DN-Foxa2 in INS-1 cells reveals that Foxa2 regulates the expression of genes important for glucose sensing in pancreatic beta-cells. Overexpression of Foxa2 results in blunted glucose-stimulated insulin secretion, whereas induction of DN-Foxa2 causes a left shift of glucose-induced insulin release. The mRNA levels of GLUT2 and glucokinase are drastically decreased after induction of Foxa2. In contrast, loss of Foxa2 function leads to up-regulation of hexokinase (HK) I and II and glucokinase (HK-IV) mRNA expression. The glucokinase and the low K-m hexokinase activities as well as glycolysis are increased proportionally. In addition, induction of DN-Foxa2 a so reduces the expression of beta-cell K-ATP channel subunits Sur1 and Kir6.2 by 70%. Furthermore, in contrast to previous reports, induction of Foxa2 causes pronounced decreases in the HNF4alpha and HNF1alpha mRNA levels. Foxa2 fails to regulate the expression of Pdx1 transcripts. The expression of insulin and islet amyloid polypeptide is markedly suppressed after induction of Foxa2, while the glucagon mRNA levels are significantly increased. Conversely, Foxa2 is required for glucagon expression in these INS-1-derived cells. These results suggest that Foxa2 is a vital transcription factor evolved to control the expression of genes essential for maintaining beta-cell glucose sensing and glucose homeostasis.	Ctr Med Univ Geneva, Dept Internal Med, Div Clin Biochem, CH-1211 Geneva 4, Switzerland	University of Geneva	Wang, HY (corresponding author), Ctr Med Univ Geneva, Dept Med Interne, Div Biochim Clin & Diabetol Expt, CH-1211 Geneva 4, Switzerland.	Haiyan.Wang@medicine.unige.ch	Gauthier, Benoit R/C-3138-2017	Gauthier, Benoit R/0000-0001-8146-7486				Abderrahmani A, 2000, DIABETES, V49, P306, DOI 10.2337/diabetes.49.2.306; Ahlgren U, 1998, GENE DEV, V12, P1763, DOI 10.1101/gad.12.12.1763; BECKER TC, 1994, J BIOL CHEM, V269, P21234; Chan CB, 2001, DIABETES, V50, P1302, DOI 10.2337/diabetes.50.6.1302; Clocquet AR, 2000, DIABETES, V49, P1856, DOI 10.2337/diabetes.49.11.1856; Duncan SA, 1998, SCIENCE, V281, P692, DOI 10.1126/science.281.5377.692; Gauthier BR, 2002, MOL ENDOCRINOL, V16, P170, DOI 10.1210/me.16.1.170; Gerrish K, 2000, J BIOL CHEM, V275, P3485, DOI 10.1074/jbc.275.5.3485; Glaser B, 1998, NEW ENGL J MED, V338, P226, DOI 10.1056/NEJM199801223380404; GOSSEN M, 1995, SCIENCE, V268, P1766, DOI 10.1126/science.7792603; Hattersley AT, 1998, DIABETIC MED, V15, P15, DOI 10.1002/(SICI)1096-9136(199801)15:1<15::AID-DIA562>3.0.CO;2-M; Hinokio Y, 2000, DIABETES, V49, P302, DOI 10.2337/diabetes.49.2.302; Kaestner KH, 2000, TRENDS ENDOCRIN MET, V11, P281, DOI 10.1016/S1043-2760(00)00271-X; Kaestner KH, 1999, GENE DEV, V13, P495, DOI 10.1101/gad.13.4.495; Kaestner KH, 1998, MOL CELL BIOL, V18, P4245, DOI 10.1128/MCB.18.7.4245; Kane C, 1996, NAT MED, V2, P1344, DOI 10.1038/nm1296-1344; Lameloise N, 2001, DIABETES, V50, P803, DOI 10.2337/diabetes.50.4.803; Matschinsky FM, 1996, DIABETES, V45, P223, DOI 10.2337/diabetes.45.2.223; Matschinsky FM, 1998, DIABETES, V47, P307, DOI 10.2337/diabetes.47.3.307; Meissner T, 1999, HUM MUTAT, V13, P351, DOI 10.1002/(SICI)1098-1004(1999)13:5<351::AID-HUMU3>3.0.CO;2-R; Miki T, 1997, P NATL ACAD SCI USA, V94, P11969, DOI 10.1073/pnas.94.22.11969; Miki T, 1998, P NATL ACAD SCI USA, V95, P10402, DOI 10.1073/pnas.95.18.10402; Nestorowicz A, 1996, HUM MOL GENET, V5, P1813, DOI 10.1093/hmg/5.11.1813; PHILIPPE J, 1995, MOL ENDOCRINOL, V9, P368, DOI 10.1210/me.9.3.368; Pontoglio M, 1998, J CLIN INVEST, V101, P2215, DOI 10.1172/JCI2548; Postic C, 1999, J BIOL CHEM, V274, P305, DOI 10.1074/jbc.274.1.305; Rausa FM, 2000, MOL CELL BIOL, V20, P8264, DOI 10.1128/MCB.20.21.8264-8282.2000; Ryffel GU, 2001, J MOL ENDOCRINOL, V27, P11, DOI 10.1677/jme.0.0270011; SCHREIBER E, 1988, EMBO J, V7, P4221, DOI 10.1002/j.1460-2075.1988.tb03319.x; Schuit FC, 2001, DIABETES, V50, P1, DOI 10.2337/diabetes.50.1.1; Seghers V, 2000, J BIOL CHEM, V275, P9270, DOI 10.1074/jbc.275.13.9270; Seino S, 1999, ANNU REV PHYSIOL, V61, P337, DOI 10.1146/annurev.physiol.61.1.337; Shih DQ, 1999, P NATL ACAD SCI USA, V96, P10152, DOI 10.1073/pnas.96.18.10152; Stanley CA, 2000, DIABETES, V49, P667, DOI 10.2337/diabetes.49.4.667; Sund NJ, 2000, MOL CELL BIOL, V20, P5175, DOI 10.1128/MCB.20.14.5175-5183.2000; Sund NJ, 2001, GENE DEV, V15, P1706, DOI 10.1101/gad.901601; Tan YJ, 2002, HEPATOLOGY, V35, P30, DOI 10.1053/jhep.2002.30317; THOMAS PM, 1995, SCIENCE, V268, P426, DOI 10.1126/science.7716548; THORENS B, 1988, CELL, V55, P281, DOI 10.1016/0092-8674(88)90051-7; VALLET V, 1995, MOL CELL BIOL, V15, P5453; Wang HY, 1997, P NATL ACAD SCI USA, V94, P4372, DOI 10.1073/pnas.94.9.4372; Wang HY, 1998, EMBO J, V17, P6701, DOI 10.1093/emboj/17.22.6701; Wang HY, 2001, J BIOL CHEM, V276, P25279, DOI 10.1074/jbc.M101233200; Wang HY, 2000, J BIOL CHEM, V275, P35953, DOI 10.1074/jbc.M006612200; Wang JC, 2000, J BIOL CHEM, V275, P14717, DOI 10.1074/jbc.275.19.14717; WEINSTEIN DC, 1994, CELL, V78, P575, DOI 10.1016/0092-8674(94)90523-1; Wu KL, 1997, MOL CELL BIOL, V17, P6002, DOI 10.1128/MCB.17.10.6002; Zhang CY, 2001, CELL, V105, P745, DOI 10.1016/S0092-8674(01)00378-6; Zingman LV, 2001, NEURON, V31, P233, DOI 10.1016/S0896-6273(01)00356-7	49	80	83	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 17	2002	277	20					17564	17570		10.1074/jbc.M111037200	http://dx.doi.org/10.1074/jbc.M111037200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	553PR	11875061	Green Published, hybrid			2022-12-27	WOS:000175685100024
J	Expert-Bezancon, A; Le Caer, JP; Marie, J				Expert-Bezancon, A; Le Caer, JP; Marie, J			Heterogeneous nuclear ribonucleoprotein (hnRNP) K is a component of an intronic splicing enhancer complex that activates the splicing of the alternative Exon 6A from Chicken beta-tropomyosin Pre-mRNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRACT-BINDING-PROTEIN; FACTOR RECEPTOR 2; IN-VIVO; SECONDARY STRUCTURE; SILENCER ELEMENT/; EXCLUSIVE EXONS; A/B PROTEINS; BRANCH POINT; SITES; GENE	Splicing of the chicken beta-tropomyosin exon 6A is stimulated, both in vivo and in vitro, by an intronic pyrimidine-rich element (S4) located 37 nucleotides downstream of exon 6A. Several pyrimidine-rich sequences are able to substitute for the natural S4 enhancer with various stimulatory effects. We show that the different enhancer sequences recruit U1 small nuclear ribonucleoprotein (SnRNP) to the exon 6A 5' splice site, with an efficiency that correlates with the splicing activation. By using RNA affinity and two-dimensional gel electrophoresis, we characterized several proteins that bind to the different enhancer sequences. Heterogeneous nuclear ribonucleoprotein (hnRNP) K and hnRNP I (polypyrimidine track-binding protein, PTB) exhibit a higher level of interaction with the strong enhancer sequences (S4) than with the weakest enhancers. Functional analysis shows that hnRNP K is a component of the enhancer complex that promotes exon 6A splicing through the wild-type S4 sequence. The addition of recombinant hnRNP K to nuclear extracts preincubated with poly(rC) RNA competitor completely restores splicing efficiency to the original level. hnRNP I (PTB) was also found associated with the strong enhancer sequences. Its function in the splicing of exon 6A is discussed.	CNRS, Ctr Genet Mol, F-91190 Gif Sur Yvette, France; Ecole Super Phys & Chim Ind Ville Paris, F-75005 Paris, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay; UDICE-French Research Universities; PSL Research University Paris; Ecole Superieure de Physique et de Chimie Industrielles de la Ville de Paris (ESPCI)	Marie, J (corresponding author), CNRS, Ctr Genet Mol, F-91190 Gif Sur Yvette, France.	marie@cgm.cnrs-gif.fr						Adams MD, 1997, GENE DEV, V11, P129, DOI 10.1101/gad.11.1.129; Ashiya M, 1997, RNA, V3, P996; BALVAY L, 1992, NUCLEIC ACIDS RES, V20, P3987, DOI 10.1093/nar/20.15.3987; Bilodeau PS, 2001, J VIROL, V75, P8487, DOI 10.1128/JVI.75.18.8487-8497.2001; BLACK DL, 1995, RNA, V1, P763; BLACK DL, 1985, CELL, V42, P737, DOI 10.1016/0092-8674(85)90270-3; Blanchette M, 1999, EMBO J, V18, P1939, DOI 10.1093/emboj/18.7.1939; Bomsztyk K, 1997, FEBS LETT, V403, P113, DOI 10.1016/S0014-5793(97)00041-0; Caputi M, 1999, EMBO J, V18, P4060, DOI 10.1093/emboj/18.14.4060; Carlo T, 2000, MOL CELL BIOL, V20, P3988, DOI 10.1128/MCB.20.11.3988-3995.2000; Carstens RP, 1998, MOL CELL BIOL, V18, P2205, DOI 10.1128/MCB.18.4.2205; Carstens RP, 2000, MOL CELL BIOL, V20, P7388, DOI 10.1128/MCB.20.19.7388-7400.2000; Chabot B, 1997, MOL CELL BIOL, V17, P1776, DOI 10.1128/MCB.17.4.1776; Chabot B, 1996, TRENDS GENET, V12, P472, DOI 10.1016/0168-9525(96)10037-8; Chen CD, 1999, GENE DEV, V13, P593, DOI 10.1101/gad.13.5.593; Chou MY, 2000, MOL CELL, V5, P949, DOI 10.1016/S1097-2765(00)80260-9; Chou MY, 1999, MOL CELL BIOL, V19, P69; Cote J, 2001, J BIOL CHEM, V276, P8535, DOI 10.1074/jbc.M008924200; DEJGAARD K, 1994, J MOL BIOL, V236, P33, DOI 10.1006/jmbi.1994.1116; Del Gato-Konczak F, 2000, MOL CELL BIOL, V20, P6287, DOI 10.1128/MCB.20.17.6287-6299.2000; Del Gatto-Konczak F, 1999, MOL CELL BIOL, V19, P251; DelGatto F, 1997, MOL CELL BIOL, V17, P5106, DOI 10.1128/MCB.17.9.5106; DORVAL BC, 1991, SCIENCE, V252, P1823, DOI 10.1126/science.2063195; DREYFUSS G, 1993, ANNU REV BIOCHEM, V62, P289, DOI 10.1146/annurev.bi.62.070193.001445; Eperon IC, 2000, MOL CELL BIOL, V20, P8303, DOI 10.1128/MCB.20.22.8303-8318.2000; Forch P, 2000, MOL CELL, V6, P1089, DOI 10.1016/S1097-2765(00)00107-6; FU XD, 1995, RNA, V1, P663; GALLEGO ME, 1992, MOL CELL BIOL, V12, P5415, DOI 10.1128/MCB.12.12.5415; Gallego ME, 1997, EMBO J, V16, P1772, DOI 10.1093/emboj/16.7.1772; Gooding C, 1998, RNA, V4, P85; GOUXPELLETAN M, 1990, EMBO J, V9, P241, DOI 10.1002/j.1460-2075.1990.tb08101.x; Hahm B, 1998, FEBS LETT, V425, P401, DOI 10.1016/S0014-5793(98)00269-5; Hertel KJ, 1998, MOL CELL, V1, P449, DOI 10.1016/S1097-2765(00)80045-3; Kim JH, 2000, J MOL BIOL, V298, P395, DOI 10.1006/jmbi.2000.3687; Krecic AM, 1999, CURR OPIN CELL BIOL, V11, P363, DOI 10.1016/S0955-0674(99)80051-9; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Le Guiner C, 2001, J BIOL CHEM, V276, P43677, DOI 10.1074/jbc.M107381200; LEFFERS H, 1995, EUR J BIOCHEM, V230, P447, DOI 10.1111/j.1432-1033.1995.tb20581.x; LIBRI D, 1992, MOL CELL BIOL, V12, P3204, DOI 10.1128/MCB.12.7.3204; LIBRI D, 1991, SCIENCE, V252, P1842, DOI 10.1126/science.2063196; Lopez AJ, 1998, ANNU REV GENET, V32, P279, DOI 10.1146/annurev.genet.32.1.279; Markovtsov V, 2000, MOL CELL BIOL, V20, P7463, DOI 10.1128/MCB.20.20.7463-7479.2000; MATUNIS MJ, 1992, MOL CELL BIOL, V12, P164, DOI 10.1128/MCB.12.1.164; MAYEDA A, 1992, CELL, V68, P365, DOI 10.1016/0092-8674(92)90477-T; McCullough AJ, 2000, MOL CELL BIOL, V20, P9225, DOI 10.1128/MCB.20.24.9225-9235.2000; Min HS, 1997, GENE DEV, V11, P1023, DOI 10.1101/gad.11.8.1023; MULLEN MP, 1991, GENE DEV, V5, P642, DOI 10.1101/gad.5.4.642; MULLIGAN GJ, 1992, J BIOL CHEM, V267, P25480; OFARRELL PZ, 1977, CELL, V12, P1133, DOI 10.1016/0092-8674(77)90176-3; Perez I, 1997, RNA, V3, P764; Pret AM, 1999, DNA CELL BIOL, V18, P671, DOI 10.1089/104454999314953; Reed R, 2000, CURR OPIN CELL BIOL, V12, P340, DOI 10.1016/S0955-0674(00)00097-1; RUSKIN B, 1984, CELL, V38, P317, DOI 10.1016/0092-8674(84)90553-1; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Shih SC, 1999, J BIOL CHEM, V274, P1359, DOI 10.1074/jbc.274.3.1359; Shnyreva M, 2000, J BIOL CHEM, V275, P15498, DOI 10.1074/jbc.275.20.15498; Smith CWJ, 2000, TRENDS BIOCHEM SCI, V25, P381, DOI 10.1016/S0968-0004(00)01604-2; SMITH CWJ, 1989, ANNU REV GENET, V23, P527, DOI 10.1146/annurev.genet.23.1.527; Southby J, 1999, MOL CELL BIOL, V19, P2699; Tacke R, 1999, CURR OPIN CELL BIOL, V11, P358, DOI 10.1016/S0955-0674(99)80050-7; Tange TO, 2001, EMBO J, V20, P5748; Thisted T, 2001, J BIOL CHEM, V276, P17484, DOI 10.1074/jbc.M010594200; Wagner EJ, 2001, MOL CELL BIOL, V21, P3281, DOI 10.1128/MCB.21.10.3281-3288.2001; Wollerton MC, 2001, RNA, V7, P819, DOI 10.1017/S1355838201010214	64	67	70	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 10	2002	277	19					16614	16623		10.1074/jbc.M201083200	http://dx.doi.org/10.1074/jbc.M201083200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	551MB	11867641	hybrid			2022-12-27	WOS:000175564500038
J	Gong, F; Yanofsky, C				Gong, F; Yanofsky, C			Analysis of tryptophanase operon expression in vitro - Accumulation of TnaC-peptidyl-tRNA in a release factor 2-depleted S-30 extract prevents Rho factor action, simulating induction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT TRANSCRIPTION TERMINATION; ESCHERICHIA-COLI; LEADER PEPTIDE; NUCLEOTIDE-SEQUENCE; ANTITERMINATION; BOXA; TRANSLATION; PROTEIN; REGION; NUSA	Expression of the tryptophanase (tna) operon in Escherichia coli is regulated by catabolite repression and tryptophan-induced transcription antitermination. The key feature of this antitermination mechanism has been shown to be the retention of uncleaved TnaC-peptidyl-tRNA in the translating ribosome. This ribosome remains stalled at the tna stop codon and blocks the access of Rho factor to the tna transcript, thereby preventing transcription termination. In normal S-30 preparations, synthesis of a TnaC peptide containing arginine instead of tryptophan at position 12 (Arg(12)-TnaC) was shown to be insensitive to added tryptophan, i.e. Arg(12)-TnaC-peptidyl-tRNA was cleaved, and there was normal Rho-dependent transcription termination. When the S-30 extract used was depleted of release factor 2, Arg(12)-TnaC-tRNA(Pro) was accumulated in the absence or presence of added tryptophan. Under these conditions the accumulation of Arg(12)-TnaC-tRNA(Pro) prevented Rho-dependent transcription termination, mimicking normal induction. Using a minimal in vitro transcription system consisting of a tna template, RNA polymerase, and Rho, it was shown that RNA sequences immediately adjacent to the tnaC stop codon, the presumed boxA and rut sites, contributed most significantly to Rho-dependent termination. The tna boxA-like sequence appeared to serve as a segment of the Rho "entry" site, despite its likeness to the boxA element.	Stanford Univ, Dept Biol Sci, Stanford, CA 94305 USA	Stanford University	Yanofsky, C (corresponding author), Stanford Univ, Dept Biol Sci, Stanford, CA 94305 USA.	yanofsky@cmgm.stanford.edu						BERG KL, 1989, J MOL BIOL, V209, P345, DOI 10.1016/0022-2836(89)90002-8; BOTSFORD JL, 1971, J BACTERIOL, V105, P303, DOI 10.1128/JB.105.1.303-312.1971; CHEN CYA, 1986, CELL, V46, P1023, DOI 10.1016/0092-8674(86)90701-4; CHEN CYA, 1987, J BIOL CHEM, V262, P11292; DEELEY MC, 1981, J BACTERIOL, V147, P787, DOI 10.1128/JB.147.3.787-796.1981; EDWARDS RM, 1982, BIOCHEM J, V204, P617, DOI 10.1042/bj2040617; FAUS I, 1989, BIOCHEMISTRY-US, V28, P3510, DOI 10.1021/bi00434a054; FRIEDMAN DI, 1983, CELL, V34, P143, DOI 10.1016/0092-8674(83)90144-7; Gaba A, 2001, EMBO J, V20, P6453, DOI 10.1093/emboj/20.22.6453; Geballe AP, 2000, COLD SPRING HARBOR M, V39, P595; GISH K, 1995, J BACTERIOL, V177, P7245, DOI 10.1128/jb.177.24.7245-7254.1995; GOLLNICK P, 1990, J BACTERIOL, V172, P3100, DOI 10.1128/jb.172.6.3100-3107.1990; Gong F, 2001, J BIOL CHEM, V276, P1974, DOI 10.1074/jbc.M008892200; Gong F, 2001, P NATL ACAD SCI USA, V98, P8997, DOI 10.1073/pnas.171299298; Graham JE, 1998, J BIOL CHEM, V273, P20764, DOI 10.1074/jbc.273.33.20764; Gusarov I, 2001, CELL, V107, P437, DOI 10.1016/S0092-8674(01)00582-7; Hopkins FG, 1903, J PHYSIOL-LONDON, V29, P451; KAMATH AV, 1992, J BIOL CHEM, V267, P19978; KAZARINOFF MN, 1977, J BIOL CHEM, V252, P7598; Konan KV, 2000, J BACTERIOL, V182, P3981, DOI 10.1128/JB.182.14.3981-3988.2000; LANDICK R, 1985, P NATL ACAD SCI USA, V82, P4663, DOI 10.1073/pnas.82.14.4663; LAU LF, 1985, J BIOL CHEM, V260, P574; LI SC, 1984, CELL, V38, P851, DOI 10.1016/0092-8674(84)90280-0; Lovett PS, 1996, MICROBIOL REV, V60, P366, DOI 10.1128/MMBR.60.2.366-385.1996; Mogridge J, 1998, J BIOL CHEM, V273, P4143, DOI 10.1074/jbc.273.7.4143; MORGAN WD, 1985, NUCLEIC ACIDS RES, V13, P3739, DOI 10.1093/nar/13.10.3739; NODWELL JR, 1993, CELL, V72, P261, DOI 10.1016/0092-8674(93)90665-D; OLSON ER, 1984, J MOL BIOL, V180, P1053, DOI 10.1016/0022-2836(84)90270-5; Richardson J. P., 1996, ESCHERICHIA COLI SAL, P822; ROBERTS JW, 1993, CELL, V72, P653, DOI 10.1016/0092-8674(93)90394-6; ROBLEDO R, 1991, J MOL BIOL, V220, P613, DOI 10.1016/0022-2836(91)90104-E; SARKAR G, 1990, BIOTECHNIQUES, V8, P404; SQUIRES CL, 1993, P NATL ACAD SCI USA, V90, P970, DOI 10.1073/pnas.90.3.970; STEWART V, 1986, J BACTERIOL, V166, P217, DOI 10.1128/jb.166.1.217-223.1986; STEWART V, 1986, J BACTERIOL, V167, P383, DOI 10.1128/jb.167.1.383-386.1986; STEWART V, 1985, J BACTERIOL, V164, P731, DOI 10.1128/JB.164.2.731-740.1985; WARD DF, 1983, J MOL BIOL, V168, P73, DOI 10.1016/S0022-2836(83)80323-4; Weisberg RA, 1999, J BACTERIOL, V181, P359, DOI 10.1128/JB.181.2.359-367.1999; WINKLER ME, 1981, BIOCHEMISTRY-US, V20, P3738, DOI 10.1021/bi00516a011; YANOFSKY C, 1995, J BACTERIOL, V177, P4451, DOI 10.1128/jb.177.15.4451-4456.1995; ZALATAN F, 1992, J BIOL CHEM, V267, P19082; ZUBAY G, 1973, ANNU REV GENET, V7, P267, DOI 10.1146/annurev.ge.07.120173.001411; Zuker M, 2000, CURR OPIN STRUC BIOL, V10, P303, DOI 10.1016/S0959-440X(00)00088-9	43	41	42	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 10	2002	277	19					17095	17100		10.1074/jbc.M201213200	http://dx.doi.org/10.1074/jbc.M201213200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	551MB	11880383	hybrid			2022-12-27	WOS:000175564500100
J	Rosconi, MP; London, E				Rosconi, MP; London, E			Topography of helices 5-7 in membrane-inserted diphtheria toxin T domain - Identification and insertion boundaries of two hydrophobic sequences that do not form a stable transmembrane hairpin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN SECONDARY STRUCTURE; PENETRATION DEPTH; PARALLAX ANALYSIS; CRYSTAL-STRUCTURE; REFINED STRUCTURE; MODEL MEMBRANES; PLASMA-MEMBRANE; B-FRAGMENT; FLUORESCENCE; TOPOLOGY	The T domain of diphtheria toxin undergoes a low pH-induced conformational change that allows it to penetrate cell membranes. T domain hydrophobic helices 8 and 9 can adopt two conformations, one close to the membrane surface (P state) and a second in which they apparently form a transmembrane hairpin (TM state). We have now studied T domain helices 5-7, a second cluster of hydrophobic helices, using Cys-scanning mutagenesis. After fluorescently labeling a series of Cys residues, penetration into a non-polar environment, accessibility to externally added antibodies, and relative depth in the bilayer were monitored. It was found that helices 5-7 insert shallowly in the P state and deeply in the TM state. Thus, the conformational changes in helices 5-7 are both similar and somehow linked to those in helices 8 and 9. The boundaries of deeply inserting sequences were also identified. One deeply inserted segment was found to span residues 270 to 290, which overlaps helix 5, and a second spanned residues 300 to 320, which includes most of helix 6 and all of helix 7. This indicates that helices 6 and 7 form a continuous hydrophobic segment despite their separation by a Pro-containing kink. Additionally, it is found that in the TM state some residues in the hydrophilic loop between helices 5 and 6 become more highly exposed than they are in the P state. Their exposure to external solution in the TM state indicates that helices 5-7 do not form a stable transmembrane hairpin. However, helix 5 and/or helices 6 plus 7 could form transmembrane structures that are in equilibrium with non-transmembrane states, or be kinetically prevented from forming a transmembrane structure. How helices 5-7 might influence the mechanism by which the T domain aids translocation of the diphtheria toxin A chain across membranes is discussed.	SUNY Stony Brook, Dept Biochem & Cell Biol, Stony Brook, NY 11794 USA; SUNY Stony Brook, Dept Chem, Stony Brook, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	London, E (corresponding author), SUNY Stony Brook, Dept Biochem & Cell Biol, Stony Brook, NY 11794 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031986] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 31986] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAMS FS, 1993, BIOCHEMISTRY-US, V32, P10826, DOI 10.1021/bi00091a038; Bell CE, 1997, BIOCHEMISTRY-US, V36, P481, DOI 10.1021/bi962214s; BENNETT MJ, 1994, PROTEIN SCI, V3, P1464, DOI 10.1002/pro.5560030912; BENNETT MJ, 1994, PROTEIN SCI, V3, P1444, DOI 10.1002/pro.5560030911; CABIAUX V, 1994, MOL MICROBIOL, V11, P43, DOI 10.1111/j.1365-2958.1994.tb00288.x; CHATTOPADHYAY A, 1987, BIOCHEMISTRY-US, V26, P39, DOI 10.1021/bi00375a006; CHOE S, 1992, NATURE, V357, P216, DOI 10.1038/357216a0; D'Silva PR, 2000, J BIOL CHEM, V275, P11771, DOI 10.1074/jbc.275.16.11771; GREENFIELD L, 1983, P NATL ACAD SCI-BIOL, V80, P6853, DOI 10.1073/pnas.80.22.6853; JOHNSON ID, 1991, ANAL BIOCHEM, V198, P228, DOI 10.1016/0003-2697(91)90418-S; Kachel K, 1998, J BIOL CHEM, V273, P22950, DOI 10.1074/jbc.273.36.22950; Kaiser RD, 1998, BBA-BIOMEMBRANES, V1375, P13, DOI 10.1016/S0005-2736(98)00127-8; KAROLIN J, 1994, J AM CHEM SOC, V116, P7801, DOI 10.1021/ja00096a042; MADSHUS IH, 1994, J BIOL CHEM, V269, P4648; Malenbaum SE, 1998, BIOCHEMISTRY-US, V37, P17915, DOI 10.1021/bi981230h; Mansoor SE, 1999, BIOCHEMISTRY-US, V38, P16383, DOI 10.1021/bi991331v; MINDELL JA, 1994, P NATL ACAD SCI USA, V91, P5272, DOI 10.1073/pnas.91.12.5272; MOSKAUG JO, 1991, J BIOL CHEM, V266, P2652; Nishiyama KI, 1996, CELL, V85, P71, DOI 10.1016/S0092-8674(00)81083-1; Oh KJ, 1999, BIOCHEMISTRY-US, V38, P10336, DOI 10.1021/bi990520a; Oh KJ, 1996, SCIENCE, V273, P810, DOI 10.1126/science.273.5276.810; PAPPENHEIMER AM, 1977, ANNU REV BIOCHEM, V46, P69, DOI 10.1146/annurev.bi.46.070177.000441; Quertenmont P, 1996, MOL MICROBIOL, V21, P1283, DOI 10.1046/j.1365-2958.1996.851446.x; Ren JH, 1999, BIOCHEMISTRY-US, V38, P976, DOI 10.1021/bi981576s; Ren JH, 1999, SCIENCE, V284, P955, DOI 10.1126/science.284.5416.955; Senzel L, 1998, J GEN PHYSIOL, V112, P317, DOI 10.1085/jgp.112.3.317; Senzel L, 2000, J GEN PHYSIOL, V115, P421, DOI 10.1085/jgp.115.4.421; Sharpe JC, 1999, J MEMBRANE BIOL, V171, P209, DOI 10.1007/s002329900572; SILVERMAN JA, 1994, J BIOL CHEM, V269, P22524; Sreerama N, 2000, ANAL BIOCHEM, V287, P252, DOI 10.1006/abio.2000.4880; Wang Y, 1997, BIOCHEMISTRY-US, V36, P16300, DOI 10.1021/bi971281z; Wang Y, 1997, J BIOL CHEM, V272, P25091, DOI 10.1074/jbc.272.40.25091; Zakharov SD, 1999, BIOCHEMISTRY-US, V38, P11325, DOI 10.1021/bi9903087; ZHAN HJ, 1994, BIOCHEMISTRY-US, V33, P11254, DOI 10.1021/bi00203a022; ZHAN HJ, 1995, BIOCHEMISTRY-US, V34, P4856, DOI 10.1021/bi00014a043	35	26	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 10	2002	277	19					16517	16527		10.1074/jbc.M200442200	http://dx.doi.org/10.1074/jbc.M200442200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	551MB	11859081	hybrid			2022-12-27	WOS:000175564500026
J	Saito, T; Miyoshi, E; Sasai, K; Nakano, N; Eguchi, H; Honke, K; Taniguchi, N				Saito, T; Miyoshi, E; Sasai, K; Nakano, N; Eguchi, H; Honke, K; Taniguchi, N			A secreted type of beta 1,6-N-acetylglucosaminyltransferase V (GnT-V) induces tumor angiogenesis without mediation of glycosylation - A novel function of GnT-V distinct from the original glycosyltransferase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-ACETYLGLUCOSAMINYLTRANSFERASE-V; ENDOTHELIAL GROWTH-FACTOR; HAMSTER-KIDNEY CELLS; BREAST-CANCER CELLS; LINKED OLIGOSACCHARIDES; EXPRESSION; METASTASIS; CARCINOMA; PLACENTA; PURIFICATION	Angiogenesis is the first regulatory step of tumor progression. Herein, we report on some findings that show that beta1,6-N-acetylglucosaminyltransferase V (GnT-V) functions as an inducer of angiogenesis that has a novel and completely different function from the original function of glycosyltransferase. A secreted type of GnT-V protein itself promoted angiogenesis in vitro and in vivo at physiological concentrations. The highly basic domain of GnT-V induced the release of fibroblast growth factor-2 from heparan sulfate proteoglycan on the cell surface and/or extracellular matrix, leading to angiogenesis. These findings provide some novel information on the relationship between GnT-V and tumor metastasis. The inhibition of GnT-V secretion or its expression represents a novel potential strategy for the inhibition of tumor angiogenesis.	Osaka Univ, Sch Med, Dept Biochem, Suita, Osaka 5650871, Japan	Osaka University	Taniguchi, N (corresponding author), Osaka Univ, Sch Med, Dept Biochem, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.	proftani@biochem.med.osaka-u.ac.jp	Saito, Takashi/G-2563-2015; Eguchi, Hiromi/GWC-5633-2022; Taniguchi, Naoyuki/I-4182-2014; Taniguchi, Naoyuki/A-7086-2016	Saito, Takashi/0000-0002-9659-9251; Taniguchi, Naoyuki/0000-0001-5889-5968; 				Ashton AW, 1999, J BIOL CHEM, V274, P35562, DOI 10.1074/jbc.274.50.35562; Barillari G, 1998, AM J PATHOL, V152, P1161; Bernardini G, 2000, BLOOD, V96, P4039, DOI 10.1182/blood.V96.13.4039.h8004039_4039_4045; BIARD A, 1988, P NATL ACAD SCI USA, V85, P2324; CHEN L, 1995, GLYCOCONJUGATE J, V12, P813, DOI 10.1007/BF00731243; Delehedde M, 1996, EXP CELL RES, V229, P398, DOI 10.1006/excr.1996.0385; Demetriou M, 2001, NATURE, V409, P733, DOI 10.1038/35055582; DEMETRIOU M, 1995, J CELL BIOL, V130, P383, DOI 10.1083/jcb.130.2.383; DENNIS JW, 1989, CANCER RES, V49, P945; DENNIS JW, 1987, SCIENCE, V236, P582, DOI 10.1126/science.2953071; FOLKMAN J, 1971, NEW ENGL J MED, V285, P1182; FOLKMAN J, 1972, ANN SURG, V175, P409, DOI 10.1097/00000658-197203000-00014; GOHDA E, 1988, J CLIN INVEST, V81, P414, DOI 10.1172/JCI113334; Granovsky M, 2000, NAT MED, V6, P306; GU JG, 1993, J BIOCHEM, V113, P614, DOI 10.1093/oxfordjournals.jbchem.a124091; HAUSER S, 1993, GROWTH FACTORS, V9, P259, DOI 10.3109/08977199308991586; Ikeda Y, 2000, J BIOCHEM, V128, P609, DOI 10.1093/oxfordjournals.jbchem.a022793; Ko JH, 1999, J BIOL CHEM, V274, P22941, DOI 10.1074/jbc.274.33.22941; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lu PP, 1996, BIOORGAN MED CHEM, V4, P2011, DOI 10.1016/S0968-0896(96)00180-0; MACAFFERY G, 1993, COMP BIOCH PHYSL B, V104, P91; MAREZ A, 1987, BIOCHIMIE, V69, P125, DOI 10.1016/0300-9084(87)90244-6; Murata K, 2000, CLIN CANCER RES, V6, P1772; Nurcombe V, 2000, J BIOL CHEM, V275, P30009, DOI 10.1074/jbc.M003038200; OREILLY MS, 1994, CELL, V79, P315, DOI 10.1016/0092-8674(94)90200-3; OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6; Petretti T, 2000, GUT, V46, P359, DOI 10.1136/gut.46.3.359; PIERCE M, 1986, J BIOL CHEM, V261, P772; RISAU W, 1988, EMBO J, V7, P959, DOI 10.1002/j.1460-2075.1988.tb02901.x; ROTHENTHAL RA, 1990, GROWTH FACTORS, V4, P53; Sasai K, 2002, GLYCOBIOLOGY, V12, P119, DOI 10.1093/glycob/12.2.119; Soker S, 1997, J BIOL CHEM, V272, P31582, DOI 10.1074/jbc.272.50.31582; STROUS GJ, 1986, CRC CR REV BIOCH MOL, V21, P119, DOI 10.3109/10409238609113610; SUZUKI K, 1993, AM J PHYSIOL, V265, pH1173, DOI 10.1152/ajpheart.1993.265.4.H1173; TISCHER E, 1991, J BIOL CHEM, V266, P11947; UGARTE MA, 1991, INT J BIOCHEM, V23, P719, DOI 10.1016/0020-711X(91)90043-M; YAMASHITA K, 1985, J BIOL CHEM, V260, P3963; Yao M, 1998, J CANCER RES CLIN, V124, P27, DOI 10.1007/s004320050129; Yen L, 2000, ONCOGENE, V19, P3460, DOI 10.1038/sj.onc.1203685; Zeng HY, 2001, J BIOL CHEM, V276, P32714, DOI 10.1074/jbc.M103130200; Zhu TY, 1997, J CANCER RES CLIN, V123, P296, DOI 10.1007/s004320050061	41	75	80	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 10	2002	277	19					17002	17008		10.1074/jbc.M200521200	http://dx.doi.org/10.1074/jbc.M200521200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	551MB	11872751	hybrid			2022-12-27	WOS:000175564500088
J	Holland, PM; Milne, A; Garka, K; Johnson, RS; Willis, C; Sims, JE; Rauch, CT; Bird, TA; Virca, GD				Holland, PM; Milne, A; Garka, K; Johnson, RS; Willis, C; Sims, JE; Rauch, CT; Bird, TA; Virca, GD			Purification, cloning, and characterization of Nek8, a novel NIMA-related kinase, and its candidate substrate Bicd2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUANINE-NUCLEOTIDE EXCHANGE; TUMOR-NECROSIS-FACTOR; CELL-CYCLE REGULATORS; BETA-CASEIN KINASE; PROTEIN-KINASE; ASPERGILLUS-NIDULANS; MITOTIC REGULATOR; BICAUDAL-D; CHROMATIN CONDENSATION; HUMAN HOMOLOG	We describe the isolation, cloning, and characterization of human Nek8, a new mammalian NIMA-related kinase, and its candidate substrate Bicd2. Nek8 was isolated as a beta-casein kinase activity in rabbit lung and has an N-terminal catalytic domain homologous to the Nek family of protein kinases. Nek8 also contains a central domain with homology to RCC1, a guanine nucleotide exchange factor for the GTPase Ran, and a C-terminal coiled-coil domain. Like Nek2, Nek8 prefers beta-casein over other exogenous substrates, has shared biochemical requirements for kinase activity, and is capable of autophosphorylation and oligomerization. Nek8 activity is not cell cycle regulated, but like Nek3, levels are consistently higher in G(0)-arrested cells. During the purification of Nek8 a second protein co-chromatographed with Nek8 activity. This protein, Bicd2, is a human homolog of the Drosophila protein Bicaudal D, a coiled-coil protein. Bicd2 is phosphorylated by Nek8 in vitro, and the endogenous proteins associate in vivo. Bicd2 localizes to cytoskeletal structures, and its subcellular localization is dependent on microtubule morphology. Treatment of cells with nocodazole leads to dramatic reorganization of Bicd2, and correlates with Nek8 phosphorylation. This may be indicative of a role for Nek8 and Bicd2 associated with cell cycle independent microtubule dynamics.	Immunex Res & Dev Corp, Seattle, WA 98101 USA		Holland, PM (corresponding author), Immunex Res & Dev Corp, 51 Univ St, Seattle, WA 98101 USA.	hollandp@immunex.com		Sims, John/0000-0002-5667-9185				Anderson DM, 1997, NATURE, V390, P175, DOI 10.1038/36593; Azuma Y, 1999, J MOL BIOL, V289, P1119, DOI 10.1006/jmbi.1999.2820; Baens M, 1997, GENOMICS, V45, P601, DOI 10.1006/geno.1997.4971; Belham C, 2001, CURR BIOL, V11, P1155, DOI 10.1016/S0960-9822(01)00369-4; Bird TA, 1997, J BIOL CHEM, V272, P32606, DOI 10.1074/jbc.272.51.32606; Chen A, 1999, GENE, V234, P127, DOI 10.1016/S0378-1119(99)00165-1; COSMAN D, 1984, NATURE, V312, P768, DOI 10.1038/312768a0; Debant A, 1996, P NATL ACAD SCI USA, V93, P5466, DOI 10.1073/pnas.93.11.5466; Fry AM, 1999, J BIOL CHEM, V274, P16304, DOI 10.1074/jbc.274.23.16304; Fry AM, 1998, J CELL BIOL, V141, P1563, DOI 10.1083/jcb.141.7.1563; FRY AM, 1995, J BIOL CHEM, V270, P12899, DOI 10.1074/jbc.270.21.12899; Fry AM, 1997, METHOD ENZYMOL, V283, P270; Fry AM, 1998, EMBO J, V17, P470, DOI 10.1093/emboj/17.2.470; GUESDON F, 1993, J BIOL CHEM, V268, P4236; Guesdon F, 1997, CYTOKINE, V9, P471, DOI 10.1006/cyto.1996.0190; GUESDON F, 1994, BIOCHEM J, V304, P761, DOI 10.1042/bj3040761; Gundersen GG, 1999, CURR OPIN CELL BIOL, V11, P81, DOI 10.1016/S0955-0674(99)80010-6; Guo QB, 1998, P NATL ACAD SCI USA, V95, P9172, DOI 10.1073/pnas.95.16.9172; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; Hayashi K, 1999, BIOCHEM BIOPH RES CO, V264, P449, DOI 10.1006/bbrc.1999.1536; Helps NR, 2000, BIOCHEM J, V349, P509, DOI 10.1042/0264-6021:3490509; Hoogenraad CC, 2001, EMBO J, V20, P4041, DOI 10.1093/emboj/20.15.4041; Ishikawa K, 1998, DNA Res, V5, P169, DOI 10.1093/dnares/5.3.169; Jordan MA, 1998, CURR OPIN CELL BIOL, V10, P123, DOI 10.1016/S0955-0674(98)80095-1; Kandli M, 2000, GENOMICS, V68, P187, DOI 10.1006/geno.2000.6293; KOCH EA, 1983, CELL TISSUE RES, V228, P21; Krien MJE, 1998, J CELL SCI, V111, P967; Lehman AL, 1998, P NATL ACAD SCI USA, V95, P9436, DOI 10.1073/pnas.95.16.9436; LETWIN K, 1992, EMBO J, V11, P3521, DOI 10.1002/j.1460-2075.1992.tb05435.x; Lu K P, 1995, Prog Cell Cycle Res, V1, P187; LU KP, 1993, J BIOL CHEM, V268, P8769; Mayor T, 2000, J CELL BIOL, V151, P837, DOI 10.1083/jcb.151.4.837; Meindl A, 1996, NAT GENET, V13, P35, DOI 10.1038/ng0596-35; Moore JD, 2001, BIOESSAYS, V23, P77, DOI 10.1002/1521-1878(200101)23:1<77::AID-BIES1010>3.3.CO;2-5; NOGUCHI PD, 1991, CURRENT PROTOCOLS IM; OCONNELL MJ, 1994, EMBO J, V13, P4926, DOI 10.1002/j.1460-2075.1994.tb06820.x; OSMANI AH, 1991, CELL, V67, P283, DOI 10.1016/0092-8674(91)90180-7; PU RT, 1995, J BIOL CHEM, V270, P18110, DOI 10.1074/jbc.270.30.18110; Renault L, 1998, NATURE, V392, P97, DOI 10.1038/32204; Rosa JL, 1996, EMBO J, V15, P4262, DOI 10.1002/j.1460-2075.1996.tb00801.x; ROSENFELD J, 1992, ANAL BIOCHEM, V203, P173, DOI 10.1016/0003-2697(92)90061-B; SUTER B, 1989, GENE DEV, V3, P1957, DOI 10.1101/gad.3.12a.1957; SUTER B, 1991, CELL, V67, P917, DOI 10.1016/0092-8674(91)90365-6; Tanaka K, 1999, J BIOL CHEM, V274, P13491, DOI 10.1074/jbc.274.19.13491; THEURKAUF WE, 1993, DEVELOPMENT, V118, P1169, DOI 10.1016/0168-9525(93)90134-4; Upadhya P, 2000, P NATL ACAD SCI USA, V97, P217, DOI 10.1073/pnas.97.1.217; WHARTON RP, 1989, CELL, V59, P881, DOI 10.1016/0092-8674(89)90611-9; YE XS, 1995, EMBO J, V14, P986, DOI 10.1002/j.1460-2075.1995.tb07079.x	48	44	47	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 3	2002	277	18					16229	16240		10.1074/jbc.M108662200	http://dx.doi.org/10.1074/jbc.M108662200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	550PA	11864968	hybrid			2022-12-27	WOS:000175510400133
J	Hyman, LE; Kwon, E; Ghosh, S; McGee, J; Chachulska, AMB; Jackson, T; Baricos, WH				Hyman, LE; Kwon, E; Ghosh, S; McGee, J; Chachulska, AMB; Jackson, T; Baricos, WH			Binding to Elongin C inhibits degradation of interacting proteins in yeast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-SUPPRESSOR PROTEIN; RNA-POLYMERASE-II; CYCLIN-DEPENDENT KINASE; SACCHAROMYCES-CEREVISIAE; UBIQUITIN SYSTEM; 3'-END FORMATION; BUDDING YEAST; SNF4 PROTEIN; HIF-ALPHA; COMPLEX	Elongin C is a highly conserved, low molecular weight protein found in a variety of multiprotein complexes in human, rat, fly, worm, and yeast cells. Among the best characterized of these complexes is a mammalian E3 ligase that targets proteins for ubiquitination and subsequent degradation by the 26 S proteasome. Despite its crucial role as a component of such E3 ligases and other complexes, the specific function of Elongin C is unknown. In yeast, Elongin C is a non-essential gene and there is no obvious phenotype as associated with its absence. We previously reported that in Saccharomyces cerevisiae Elongin C (Elc1) interacts specifically and strongly with a class of proteins loosely defined as stress response proteins. In the present study, we examined the role of yeast Elc1 in the turnover of two of these binding partners, Snf4 and Pcl6. Deletion of Elc1 resulted in decreased steady-state levels of Snf4 and Pcl6 as indicated by Western blot analysis. Northern blot analysis of mRNA prepared from elc1 null and wild type strains revealed no difference in mRNA levels for Snf4 and Pc16 establishing that the effects of Elc1 are not transcriptionally mediated. Reintroduction of either yeast or human Elongin C into Elc1 null strains abrogated this effect. Taken together, these data document that the levels of Snf4 and Pcl6 are dependent on the presence of Elc1 and that binding to Elc1 inhibits the degradation of these proteins. The results suggest a new function for yeast Elongin C that is distinct from a direct role in targeting proteins for ubiquitination and subsequent proteolysis.	Tulane Univ, Hlth Sci Ctr, Dept Biochem, New Orleans, LA 70112 USA	Tulane University	Hyman, LE (corresponding author), Tulane Univ, Hlth Sci Ctr, Dept Biochem, 1430 Tulane Ave, New Orleans, LA 70112 USA.			Hyman, Linda/0000-0002-2511-2928	NCI NIH HHS [CA84095, CA65436] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R21CA084095, T32CA065436] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AGATEP R, 1998, TRANSFORMATION SACCH; Aso T, 1997, BIOCHEM BIOPH RES CO, V241, P334, DOI 10.1006/bbrc.1997.7819; ASO T, 1995, FASEB J, V9, P1419, DOI 10.1096/fasebj.9.14.7589983; Ausubel FM, 1994, CURRENT PROTOCOLS MO; Botuyan MV, 1999, P NATL ACAD SCI USA, V96, P9033, DOI 10.1073/pnas.96.16.9033; CELENZA JL, 1989, MOL CELL BIOL, V9, P5045, DOI 10.1128/MCB.9.11.5045; CELENZA JL, 1989, MOL CELL BIOL, V9, P5034, DOI 10.1128/MCB.9.11.5034; CHEN P, 1995, EMBO J, V14, P2620, DOI 10.1002/j.1460-2075.1995.tb07260.x; Chi Y, 2001, GENE DEV, V15, P1078, DOI 10.1101/gad.867501; Cockman ME, 2000, J BIOL CHEM, V275, P25733, DOI 10.1074/jbc.M002740200; Connelly C, 1996, CELL, V86, P275, DOI 10.1016/S0092-8674(00)80099-9; Conrad NK, 2000, GENETICS, V154, P557; CULLIN C, 1994, YEAST, V10, P105, DOI 10.1002/yea.320100110; DUAN DR, 1995, SCIENCE, V269, P1402, DOI 10.1126/science.7660122; DUAN DR, 1995, P NATL ACAD SCI USA, V92, P6459, DOI 10.1073/pnas.92.14.6459; GUTHRIE C, 1991, GUIDE YEAST GENETICS, P12; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; HERSHKO A, 1983, CELL, V34, P11, DOI 10.1016/0092-8674(83)90131-9; Hochstrasser M, 1998, GENE DEV, V12, P901, DOI 10.1101/gad.12.7.901; Hochstrasser M, 1996, CELL, V84, P813, DOI 10.1016/S0092-8674(00)81058-2; HYMAN LE, 1993, MOL CELL BIOL, V13, P5159, DOI 10.1128/MCB.13.9.5159; HYMAN LE, 1991, MOL CELL BIOL, V11, P2004, DOI 10.1128/MCB.11.4.2004; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Ivan M, 2001, CURR OPIN GENET DEV, V11, P27, DOI 10.1016/S0959-437X(00)00152-0; Ivanova AV, 2001, J BIOL CHEM, V276, P15306, DOI 10.1074/jbc.M010516200; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Jackson T, 2000, BBA-GENE STRUCT EXPR, V1491, P161, DOI 10.1016/S0167-4781(00)00052-X; Kaelin WG, 1998, J INTERN MED, V243, P535; Kamura T, 2000, P NATL ACAD SCI USA, V97, P10430, DOI 10.1073/pnas.190332597; Kamura T, 1999, SCIENCE, V284, P657, DOI 10.1126/science.284.5414.657; Kamura T, 1999, GENE DEV, V13, P2928, DOI 10.1101/gad.13.22.2928; Kamura T, 1998, GENE DEV, V12, P3872, DOI 10.1101/gad.12.24.3872; KIBEL A, 1995, SCIENCE, V269, P1444, DOI 10.1126/science.7660130; Krek W, 2000, NAT CELL BIOL, V2, pE121, DOI 10.1038/35017129; Lee M, 2000, MOL MICROBIOL, V38, P411, DOI 10.1046/j.1365-2958.2000.02140.x; Magrath C, 1999, GENETICS, V152, P129; Mathias N, 1999, MOL CELL BIOL, V19, P1759; Measday V, 1997, MOL CELL BIOL, V17, P1212, DOI 10.1128/MCB.17.3.1212; Miller CA, 1998, NUCLEIC ACIDS RES, V26, P3577, DOI 10.1093/nar/26.15.3577; Moffat J, 2000, Prog Cell Cycle Res, V4, P97; NEIGEBORN L, 1984, GENETICS, V108, P845; Ohh M, 2000, NAT CELL BIOL, V2, P423, DOI 10.1038/35017054; Schoenfeld AR, 2000, P NATL ACAD SCI USA, V97, P8507, DOI 10.1073/pnas.97.15.8507; SHERMAN F, 1986, LABORATORY COURSE MA, P163; Skowyra D, 1999, SCIENCE, V284, P662, DOI 10.1126/science.284.5414.662; Smothers DB, 2000, MOL CELL BIOL, V20, P7845, DOI 10.1128/MCB.20.21.7845-7852.2000; Tanimoto K, 2000, EMBO J, V19, P4298, DOI 10.1093/emboj/19.16.4298; Tyers M, 1999, SCIENCE, V284, P601, DOI 10.1126/science.284.5414.601; Varshavsky A, 1997, TRENDS BIOCHEM SCI, V22, P383, DOI 10.1016/S0968-0004(97)01122-5	49	5	7	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 3	2002	277	18					15586	15591		10.1074/jbc.M200800200	http://dx.doi.org/10.1074/jbc.M200800200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	550PA	11864988	hybrid			2022-12-27	WOS:000175510400050
J	Stangler, T; Mayr, LM; Willbold, D				Stangler, T; Mayr, LM; Willbold, D			Solution structure of human GABA(A) receptor-associated protein GABARAP - Implications for biological function and its regulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-15 RESONANCE ASSIGNMENTS; PROGRAM; C-13; GATE-16; BINDING; SYSTEM; H-1	Control of neurotransmitter receptor expression and delivery to the postsynaptic membrane is of critical importance for neural signal transduction at synapses. The gamma-aminobutyric acid, type A (GABA(A)) receptor-associated protein GABARAP was reported to have an important role for movement and sorting of GABA(A) receptor molecules to the postsynaptic membrane. GABARAP not only binds to GABA(A) receptor gamma2-subunit but also to tubulin, gephyrin, and ULK1. We present for the first time the high resolution structure of human GABARAP determined by nuclear magnetic resonance in aqueous solution. One part of the molecule, despite being well ordered and rigid on a MHz time scale, exists in at least two different conformations that interchange with each other on a time scale slower than 25 Hz. An important feature of the solution structure is the observation that amino- and carboxyl-terminal ends of the protein directly interact with each other, which is not seen in recently reported crystal structures. The possible biological relevance of these observations for the regulation of GABARAP interactions and functions is discussed.	Univ Dusseldorf, Inst Biol Phys, D-40225 Dusseldorf, Germany; Inst Mol Biotechnol, D-07745 Jena, Germany; Novartis Pharma AG, CH-4002 Basel, Switzerland; Forschungszentrum Julich, D-52425 Julich, Germany	Heinrich Heine University Dusseldorf; Novartis; Helmholtz Association; Research Center Julich	Willbold, D (corresponding author), Univ Dusseldorf, Inst Biol Phys, D-40225 Dusseldorf, Germany.	dieter.willbold@uni-duesseldorf.de	Willbold, Dieter/A-6280-2013	Willbold, Dieter/0000-0002-0065-7366				Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Chen L, 2000, P NATL ACAD SCI USA, V97, P11557, DOI 10.1073/pnas.190133497; Coyle JE, 2002, NEURON, V33, P63, DOI 10.1016/S0896-6273(01)00558-X; FARROW NA, 1994, BIOCHEMISTRY-US, V33, P5984, DOI 10.1021/bi00185a040; Harris R, 2001, J BIOMOL NMR, V21, P185, DOI 10.1023/A:1012473609468; JOHNSON BA, 1994, J BIOMOL NMR, V4, P603, DOI 10.1007/BF00404272; Kneussel M, 2000, P NATL ACAD SCI USA, V97, P8594, DOI 10.1073/pnas.97.15.8594; Kneussel M, 2000, TRENDS NEUROSCI, V23, P429, DOI 10.1016/S0166-2236(00)01627-1; Knight D, 2002, J BIOL CHEM, V277, P5556, DOI 10.1074/jbc.M109753200; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Mizushima N, 1998, NATURE, V395, P395, DOI 10.1038/26506; MUHANDIRAM DR, 1993, J MAGN RESON SER B, V102, P317, DOI 10.1006/jmrb.1993.1102; Nilges M, 1998, PROG NUCL MAG RES SP, V32, P107, DOI 10.1016/S0079-6565(97)00025-3; NILGES M, 1993, PROTEINS, V17, P297, DOI 10.1002/prot.340170307; Okazaki N, 2000, MOL BRAIN RES, V85, P1, DOI 10.1016/S0169-328X(00)00218-7; Paz Y, 2000, J BIOL CHEM, V275, P25445, DOI 10.1074/jbc.C000307200; Stangler T, 2001, J BIOMOL NMR, V21, P183, DOI 10.1023/A:1012416810974; Tanida I, 2001, J BIOL CHEM, V276, P1701, DOI 10.1074/jbc.C000752200; VRIEND G, 1990, J MOL GRAPHICS, V8, P52, DOI 10.1016/0263-7855(90)80070-V; Wang HB, 1999, NATURE, V397, P69, DOI 10.1038/16264; ZUIDERWEG ERP, 1989, BIOCHEMISTRY-US, V28, P2387, DOI 10.1021/bi00432a008	22	59	60	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 19	2002	277	16					13363	13366		10.1074/jbc.C200050200	http://dx.doi.org/10.1074/jbc.C200050200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	543HR	11875056	hybrid			2022-12-27	WOS:000175096000002
J	Yang, HB; Kim, O; Wu, J; Qiu, Y				Yang, HB; Kim, O; Wu, J; Qiu, Y			Interaction between tyrosine kinase Etk and a RUN domain- and FYVE domain-containing protein RUFY1 - A possible role of Etk in regulation of vesicle trafficking	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROSTATE-CANCER CELLS; FOCAL ADHESION KINASE; PHOSPHATIDYLINOSITOL 3-PHOSPHATE; ENDOSOMAL LOCALIZATION; PH-DOMAIN; FINGER; ACTIVATION; ETK/BMX; EFFECTOR; RECEPTOR	Etk/BMX tyrosine kinase is involved in regulation of various cellular processes including proliferation, differentiation, motility, and apoptosis. Through a yeast two-hybrid screening for the effectors of Etk, a new gene family designated as RUFY was identified. The RUFY gene family (RUFY1 and RUFY2) contains an N-terminal RUN domain and a C-terminal FYVE domain with two coiled-coil domains in-between. They appear to be homologues of a recently identified mouse Rabip4 (Cormant, M., Mari, M., Galmiche, A., Hofman, P., and Le Marchand-Brustel, Y. (2001) Proc. Natl. Acad Sci. U. S. A. 98, 1637-1642). RUFY proteins are localized predominantly to endosomes as evidenced by their co-localization with early endosome antigen marker (EEA1). Etk interacts with RUFY1 through its SH3 and SH2 domains. RUFY1 is tyrosine-phosphorylated and appears to be a substrate of Etk. The RUFY1 mutant lacking the phosphorylation sites failed to go to the endosomes. Furthermore, overexpression of Etk in COS-1 and B82L cells resulted in increased plasma membrane localization of the epidermal growth factor receptor and delayed its induced endocytosis in COS-1 cells. The effects of Etk were blocked by the FYVE domain of RUFY1. Interestingly, the FYVE domain of RUFY1 is targeted to the plasma membrane through an interaction between its proline-rich motif and the SH3 domain of Etk or possibly some other membrane-associated SH3 domain-containing protein(s), whereas the lipid binding activity of the FYVE domain is not required. Our data suggest that Etk may be involved in regulation of endocytosis through its interaction with an endosomal protein RUFY1.	Univ Minnesota, Dept Lab Med & Pathol, Minneapolis, MN 55455 USA; Univ Minnesota, Ctr Canc, Minneapolis, MN 55455 USA; Univ Minnesota, Dept Pharmacol, Minneapolis, MN 55455 USA; Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Mol Oncol Program, Tampa, FL 33612 USA	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida	Qiu, Y (corresponding author), Univ Maryland, Dept Pharmacol & Expt Tech, 655 W Baltimore St, Baltimore, MD 21201 USA.	yqiu@som.umaryland.edu			NATIONAL CANCER INSTITUTE [R01CA085380] Funding Source: NIH RePORTER; NCI NIH HHS [CA85380] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Chen RY, 2001, J BIOL CHEM, V276, P31858, DOI 10.1074/jbc.C100271200; Chen RY, 2001, NAT CELL BIOL, V3, P439, DOI 10.1038/35074500; Cormont M, 2001, P NATL ACAD SCI USA, V98, P1637, DOI 10.1073/pnas.031586998; Cunnick JM, 1998, J BIOL CHEM, V273, P14468, DOI 10.1074/jbc.273.23.14468; Gaullier JM, 1999, CHEM PHYS LIPIDS, V98, P87, DOI 10.1016/S0009-3084(99)00021-3; Gaullier JM, 2000, J BIOL CHEM, V275, P24595, DOI 10.1074/jbc.M906554199; Gaullier JM, 1998, NATURE, V394, P432, DOI 10.1038/28767; Gillooly DJ, 2000, EMBO J, V19, P4577, DOI 10.1093/emboj/19.17.4577; Hayakawa A, 2000, J BIOL CHEM, V275, P29636, DOI 10.1074/jbc.M002696200; Hunter T, 2000, CELL, V100, P113, DOI 10.1016/S0092-8674(00)81688-8; Lee LF, 2001, MOL CELL BIOL, V21, P8385, DOI 10.1128/MCB.21.24.8385-8397.2001; Mari M, 2001, J BIOL CHEM, V276, P42501, DOI 10.1074/jbc.M104885200; Qiu Y, 1998, P NATL ACAD SCI USA, V95, P3644, DOI 10.1073/pnas.95.7.3644; Qiu Y, 2000, ONCOGENE, V19, P5651, DOI 10.1038/sj.onc.1203958; Rawlings D J, 1995, Semin Immunol, V7, P237, DOI 10.1006/smim.1995.0028; Robinson D, 1996, P NATL ACAD SCI USA, V93, P5958, DOI 10.1073/pnas.93.12.5958; Saharinen P, 1997, BLOOD, V90, P4341; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; Seet LF, 2001, J BIOL CHEM, V276, P42445, DOI 10.1074/jbc.M105917200; Shin ME, 2001, J BIOL CHEM, V276, P41388, DOI 10.1074/jbc.M105665200; Stenmark H, 1996, J BIOL CHEM, V271, P24048, DOI 10.1074/jbc.271.39.24048; Tsai YT, 2000, MOL CELL BIOL, V20, P2043, DOI 10.1128/MCB.20.6.2043-2054.2000; Vihinen Mauno, 1997, Frontiers in Bioscience (online), V2, pD27; Xue LY, 1999, ONCOGENE, V18, P3391, DOI 10.1038/sj.onc.1202687	24	45	51	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 16	2002	277	33					30219	30226		10.1074/jbc.M111933200	http://dx.doi.org/10.1074/jbc.M111933200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	585DW	11877430	hybrid			2022-12-27	WOS:000177509300107
J	Jiang, FL; Yi, L; Moore, M; Chen, MY; Rohl, T; van Wijk, KJ; de Gier, JWL; Henry, R; Dalbey, RE				Jiang, FL; Yi, L; Moore, M; Chen, MY; Rohl, T; van Wijk, KJ; de Gier, JWL; Henry, R; Dalbey, RE			Chloroplast YidC homolog Albino3 can functionally complement the bacterial YidC depletion strain and promote membrane insertion of both bacterial and chloroplast thylakoid proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-RECOGNITION PARTICLE; CHLOROPHYLL-BINDING PROTEIN; COLI INNER MEMBRANE; ESCHERICHIA-COLI; CYTOPLASMIC MEMBRANE; TARGETING PATHWAY; SEC-TRANSLOCASE; PLASMA-MEMBRANE; COAT PROTEIN; OXA1P	A new component of the bacterial translocation machinery, YidC, has been identified that specializes in the integration of membrane proteins. YidC is homologous to the mitochondrial Oxa1p and the chloroplast Alb3, which functions in a novel pathway for the insertion of membrane proteins from the mitochondrial matrix and chloroplast stroma, respectively. We find that Alb3 can functionally complement the Escherichia coli YidC depletion strain and promote the membrane insertion of the M13 procoat and leader peptidase that were previously shown to depend on the bacterial YidC for membrane translocation. In addition, the chloroplast Alb3 that is expressed in bacteria is essential for the insertion of chloroplast cpSecE protein into the bacterial inner membrane. Surprisingly, Alb3 is not required for the insertion of cpSecE into the thylakoid membrane. These results underscore the importance of Oxa1p homologs for membrane protein insertion in bacteria and demonstrate that the requirement for Oxa1p homologs is different in the bacterial and thylakoid membrane systems.	Ohio State Univ, Dept Chem, Mol Cellular Dev Biol Program, Columbus, OH 43210 USA; Ohio State Univ, Prot Res Grp, Columbus, OH 43210 USA; Univ Arkansas, Dept Biol Sci, Fayetteville, AR 72701 USA; Cornell Univ, Dept Plant Biol, Ithaca, NY 14853 USA; Stockholm Univ, Dept Biochem & Biophys, Arrhenius Labs, S-106 Stockholm, Sweden	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University of Arkansas System; University of Arkansas Fayetteville; Cornell University; Stockholm University	Dalbey, RE (corresponding author), Ohio State Univ, Dept Chem, Mol Cellular Dev Biol Program, 120 W 18Th Ave, Columbus, OH 43210 USA.				NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR015569] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM063862] Funding Source: NIH RePORTER; NCRR NIH HHS [1P20 RR15569-02] Funding Source: Medline; NIGMS NIH HHS [GM63862] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSSON H, 1993, EMBO J, V12, P683, DOI 10.1002/j.1460-2075.1993.tb05702.x; ARNON DI, 1949, PLANT PHYSIOL, V24, P1, DOI 10.1104/pp.24.1.1; Beck K, 2001, EMBO REP, V2, P709, DOI 10.1093/embo-reports/kve154; Chen MY, 2002, J BIOL CHEM, V277, P7670, DOI 10.1074/jbc.M110644200; CLINE K, 1992, J BIOL CHEM, V267, P2688; CLINE K, 1993, EMBO J, V12, P4105, DOI 10.1002/j.1460-2075.1993.tb06094.x; CLINE K, 1989, J BIOL CHEM, V264, P14225; Cristobal S, 1999, J BIOL CHEM, V274, P20068, DOI 10.1074/jbc.274.29.20068; Dalbey RE, 1999, TRENDS BIOCHEM SCI, V24, P17, DOI 10.1016/S0968-0004(98)01333-4; Dalbey RE, 2000, ANNU REV CELL DEV BI, V16, P51, DOI 10.1146/annurev.cellbio.16.1.51; Dalbey RE, 2000, CURR OPIN CELL BIOL, V12, P435, DOI 10.1016/S0955-0674(00)00113-7; de Gier JW, 2001, MOL MICROBIOL, V40, P314, DOI 10.1046/j.1365-2958.2001.02392.x; de Gier JWL, 1998, P NATL ACAD SCI USA, V95, P14646, DOI 10.1073/pnas.95.25.14646; deGier JWL, 1996, FEBS LETT, V399, P307, DOI 10.1016/S0014-5793(96)01354-3; Driessen AJM, 2001, NAT STRUCT BIOL, V8, P492, DOI 10.1038/88549; Froderberg L, 2001, FEBS LETT, V498, P52, DOI 10.1016/S0014-5793(01)02494-2; Hell K, 1998, P NATL ACAD SCI USA, V95, P2250, DOI 10.1073/pnas.95.5.2250; Hell K, 1997, FEBS LETT, V418, P367, DOI 10.1016/S0014-5793(97)01412-9; Hell K, 2001, EMBO J, V20, P1281, DOI 10.1093/emboj/20.6.1281; HENRY R, 1994, J BIOL CHEM, V269, P10189; Henry R, 1997, J CELL BIOL, V136, P823, DOI 10.1083/jcb.136.4.823; Houben ENG, 2000, FEBS LETT, V476, P229, DOI 10.1016/S0014-5793(00)01735-X; HULFORD A, 1994, J BIOL CHEM, V269, P3251; ITO K, 1980, J BIOL CHEM, V255, P2123; Kiefer D, 1999, EMBO J, V18, P6299, DOI 10.1093/emboj/18.22.6299; Kim SJ, 1999, J BIOL CHEM, V274, P4715, DOI 10.1074/jbc.274.8.4715; Kim SJ, 1998, FEBS LETT, V424, P105, DOI 10.1016/S0014-5793(98)00148-3; KOHORN BD, 1991, J BIOL CHEM, V266, P12048; KUHN A, 1988, EUR J BIOCHEM, V177, P267, DOI 10.1111/j.1432-1033.1988.tb14372.x; Luirink J, 2001, FEBS LETT, V501, P1, DOI 10.1016/S0014-5793(01)02616-3; MACFARLANE J, 1995, EUR J BIOCHEM, V233, P766, DOI 10.1111/j.1432-1033.1995.766_3.x; Mant A, 2001, J BIOL CHEM, V276, P36200, DOI 10.1074/jbc.M102914200; Manting EH, 2000, EMBO J, V19, P852, DOI 10.1093/emboj/19.5.852; Meyer TH, 1999, J MOL BIOL, V285, P1789, DOI 10.1006/jmbi.1998.2413; Moore M, 2000, J BIOL CHEM, V275, P1529, DOI 10.1074/jbc.275.3.1529; Mori H, 2001, BBA-MOL CELL RES, V1541, P80, DOI 10.1016/S0167-4889(01)00150-1; Neumann-Haefelin C, 2000, EMBO J, V19, P6419, DOI 10.1093/emboj/19.23.6419; Qi HY, 1999, J BIOL CHEM, V274, P8993, DOI 10.1074/jbc.274.13.8993; Ridder ANJA, 2000, BIOCHEMISTRY-US, V39, P6521, DOI 10.1021/bi000073v; Saaf A, 1998, J BIOL CHEM, V273, P30415, DOI 10.1074/jbc.273.46.30415; Samuelson JC, 2000, NATURE, V406, P637, DOI 10.1038/35020586; SAMUELSON JC, 2001, J BIOL CHEM, V16, P16; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Schuenemann D, 1998, P NATL ACAD SCI USA, V95, P10312, DOI 10.1073/pnas.95.17.10312; Scotti PA, 2000, EMBO J, V19, P542, DOI 10.1093/emboj/19.4.542; Settles AM, 1998, TRENDS CELL BIOL, V8, P494, DOI 10.1016/S0962-8924(98)01387-7; Stuart RA, 2000, NATURE, V406, P575, DOI 10.1038/35020668; Sundberg E, 1997, PLANT CELL, V9, P717, DOI 10.1105/tpc.9.5.717; Traxler B, 1996, J BIOL CHEM, V271, P12394, DOI 10.1074/jbc.271.21.12394; Ulbrandt ND, 1997, CELL, V88, P187, DOI 10.1016/S0092-8674(00)81839-5; WICKNER WT, 1994, SCIENCE, V266, P1197, DOI 10.1126/science.7973701; WOLFE PB, 1985, J BIOL CHEM, V260, P1836; Woolhead CA, 2001, J BIOL CHEM, V276, P40841, DOI 10.1074/jbc.M106523200	53	73	76	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 31	2002	277	22					19281	19288		10.1074/jbc.M110857200	http://dx.doi.org/10.1074/jbc.M110857200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	557EH	11891220	hybrid			2022-12-27	WOS:000175894800007
J	Karlson, L; Pejler, G; Froman, G; Hellman, L				Karlson, L; Pejler, G; Froman, G; Hellman, L			Rat mast cell protease 4 is a beta-chymase with unusually stringent substrate recognition profile	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERINE PROTEASES; SPECIFICITY; TRYPTASE; LIBRARIES; MECHANISM; HEPARIN	Activated mast cells release a variety of potent inflammatory mediators including histamine, cytokines, proteoglycans, and serine proteases. The serine proteases belong to either the chymase (chymotrypsin-like substrate specificity) or tryptase (trypsin-like specificity) family. In this report we have investigated the substrate specificity of a recently identified mast cell protease, rat mast cell protease-4 (rMCP-4). Based on structural homology, rMCP-4 is predicted to belong to the chymase family, although rMCP-4 has previously not been characterized at the protein level. rMCP-4 was expressed with an N-terminal His tag followed by an enterokinase site substituting for the native activation peptide. The enterokinase-cleaved fusion protein was labeled by diisopropyl fluorophosphate, demonstrating that it is an active serine protease. Moreover, rMCP-4 hydrolyzed MeO-Suc-Arg-Ala-Tyr-pNA, thus verifying that this protease belongs to the chymase family. rMCP-4 bound to heparin, and the enzymatic activity toward MeO-Suc-Arg-Ala-Tyr-pNA was strongly enhanced in the presence of heparin. Detailed analysis of the substrate specificity was performed using peptide phage display technique. After six rounds of amplification a consensus sequence, Leu-Val-Trp-Phe-Arg-Gly, was obtained. The corresponding peptide was synthesized, and rMCP-4 was shown to cleave only the Phe-Arg bond in this peptide. This demonstrates that rMCP-4 displays a striking preference for bulky/aromatic amino acid residues in both the P1 and P2 positions.	Uppsala Univ, Dept Cell & Mol Biol, Biomed Ctr, SE-75124 Uppsala, Sweden; Swedish Univ Agr Sci, Dept Vet Med Chem, Biomed Ctr, SE-75123 Uppsala, Sweden; Uppsala Univ, Biomed Ctr, Dept Med Biochem & Microbiol, SE-75123 Uppsala, Sweden	Uppsala University; Swedish University of Agricultural Sciences; Uppsala University	Hellman, L (corresponding author), Uppsala Univ, Dept Cell & Mol Biol, Biomed Ctr, Box 596, SE-75124 Uppsala, Sweden.							Backes BJ, 2000, NAT BIOTECHNOL, V18, P187, DOI 10.1038/72642; Caughey GH, 2000, BBA-PROTEIN STRUCT M, V1480, P245, DOI 10.1016/S0167-4838(00)00076-5; Chandrasekharan UM, 1996, SCIENCE, V271, P502, DOI 10.1126/science.271.5248.502; CWIRLA SE, 1990, P NATL ACAD SCI USA, V87, P6378, DOI 10.1073/pnas.87.16.6378; Hallgren J, 2000, BIOCHEMISTRY-US, V39, P13068, DOI 10.1021/bi000973b; Harris JL, 2000, P NATL ACAD SCI USA, V97, P7754, DOI 10.1073/pnas.140132697; Huang CF, 2001, J BIOL CHEM, V276, P26276, DOI 10.1074/jbc.M102356200; Hudaky P, 1999, EUR J BIOCHEM, V259, P528, DOI 10.1046/j.1432-1327.1999.00075.x; Hunt JE, 1997, J BIOL CHEM, V272, P29158, DOI 10.1074/jbc.272.46.29158; Knight PA, 2000, J EXP MED, V192, P1849, DOI 10.1084/jem.192.12.1849; Lutzelschwab C, 1997, J EXP MED, V185, P13, DOI 10.1084/jem.185.1.13; Lutzelschwab C, 1998, EUR J IMMUNOL, V28, P3730, DOI 10.1002/(SICI)1521-4141(199811)28:11&lt;3730::AID-IMMU3730&gt;3.0.CO;2-0; Mekori YA, 2000, IMMUNOL REV, V173, P131, DOI 10.1034/j.1600-065X.2000.917305.x; Miller HRP, 1996, VET IMMUNOL IMMUNOP, V54, P331, DOI 10.1016/S0165-2427(96)05696-6; Pejler G, 1999, BIOCHEMISTRY-US, V38, P12187, DOI 10.1021/bi991046b; Pemberton AD, 1998, BBA-GEN SUBJECTS, V1379, P29, DOI 10.1016/S0304-4165(97)00078-0; POWERS JC, 1985, BIOCHEMISTRY-US, V24, P2048, DOI 10.1021/bi00329a037; REMINGTON SJ, 1988, BIOCHEMISTRY-US, V27, P8097, DOI 10.1021/bi00421a019; SALI A, 1993, J BIOL CHEM, V268, P9023; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; Scudamore CL, 1998, EUR J CELL BIOL, V75, P321, DOI 10.1016/S0171-9335(98)80065-4; TRONG HL, 1989, BIOCHEMISTRY-US, V28, P391; Welle M, 1997, J LEUKOCYTE BIOL, V61, P233, DOI 10.1002/jlb.61.3.233	23	44	44	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 24	2002	277	21					18579	18585		10.1074/jbc.M110356200	http://dx.doi.org/10.1074/jbc.M110356200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	558PM	11896050	hybrid			2022-12-27	WOS:000175975800045
J	Xie, WS; Han, SY; Khan, M; DeJong, J				Xie, WS; Han, SY; Khan, M; DeJong, J			Regulation of ALF gene expression in somatic and male germ line tissues involves partial and site-specific patterns of methylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONVERTING ENZYME ACE; BINDING PROTEIN GENE; CPG-RICH PROMOTER; DNA METHYLATION; TRANSCRIPTION FACTORS; MOUSE PROTAMINE-1; TRANSGENIC MICE; TESTIS; SPERMATOGENESIS; DEMETHYLATION	ALF (TFIIAalpha/beta-like factor) is a germ cell-specific counterpart of the large (alpha/beta) subunit of general transcription factor TFIIA. Here we isolated homologous GC-rich promoters from the mouse and human ALF genes and used promoter deletion analysis to identify sequences active in COS-7 and 293 cells. Further, bisulfite sequence analysis of the mouse ALF promoter showed that all 21 CpG dinucleotides between -179 and +207 were partially methylated in five somatic tissues, brain, heart, liver, lung, and muscle, and in epididymal spermatozoa from adult mice. In contrast, DNA from prepubertal mouse testis and from purified spermatocytes were unmethylated except at C(+19)G and C(+170)G. We also found that ALF expression correlates with a strong promoter-proximal DNase I-hypersensitive site present in nuclei from testis but not from liver. Finally we show that in vitro methylation of the ALF promoter inhibits activity and that 5-aza-2'-deoxycytidine treatment reactivates the endogenous ALF gene in a panel of seven different mouse and human somatic cell lines. Overall the results show that silencing in somatic cells is methylation-dependent and reversible and that a unique CpG-specific methylation pattern at the ALF promoter precedes expression in pachytene spermatocytes. This pattern is transient as remethylation of the ALF promoter in haploid germ cell DNA has occurred by the time spermatozoa are present in the epididymis.	Univ Texas, Dept Mol & Cell Biol, Richardson, TX 75080 USA	University of Texas System; University of Texas Dallas	DeJong, J (corresponding author), Univ Texas, Dept Mol & Cell Biol, 2601 N Floyd Rd, Richardson, TX 75080 USA.							Aoyagi N, 2001, MOL CELL BIOL, V21, P6808, DOI 10.1128/MCB.21.20.6808-6819.2001; ARIEL M, 1991, P NATL ACAD SCI USA, V88, P2317, DOI 10.1073/pnas.88.6.2317; ARIEL M, 1994, NAT GENET, V7, P59, DOI 10.1038/ng0594-59; Ballestar E, 2001, EUR J BIOCHEM, V268, P1, DOI 10.1046/j.1432-1327.2001.01869.x; Bestor TH, 2000, HUM MOL GENET, V9, P2395, DOI 10.1093/hmg/9.16.2395; Bird AP, 1999, CELL, V99, P451, DOI 10.1016/S0092-8674(00)81532-9; BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; BONNY C, 1995, DEV GENET, V16, P210, DOI 10.1002/dvg.1020160213; BRANDEIS M, 1994, NATURE, V371, P435, DOI 10.1038/371435a0; Choi YC, 1997, MAMM GENOME, V8, P317, DOI 10.1007/s003359900431; CHOI YC, 1991, J BIOL CHEM, V266, P20504; De Smet C, 1999, MOL CELL BIOL, V19, P7327; FREIMAN RN, 2001, NATURE, V293, P2084; FROMMER M, 1992, P NATL ACAD SCI USA, V89, P1827, DOI 10.1073/pnas.89.5.1827; Gibbons RJ, 2000, NAT GENET, V24, P368, DOI 10.1038/74191; Han SY, 2001, BIOL REPROD, V64, P507, DOI 10.1095/biolreprod64.2.507; Hiller MA, 2001, GENE DEV, V15, P1021, DOI 10.1101/gad.869101; HOWARD T, 1993, MOL CELL BIOL, V13, P18, DOI 10.1128/MCB.13.1.18; HOWARD TE, 1990, MOL CELL BIOL, V10, P4294, DOI 10.1128/MCB.10.8.4294; Hsieh CL, 1999, MOL CELL BIOL, V19, P46; HSIEH CL, 1994, MOL CELL BIOL, V14, P5487, DOI 10.1128/MCB.14.8.5487; Iannello RC, 2000, J BIOL CHEM, V275, P19603, DOI 10.1074/jbc.M001867200; Iannello RC, 1997, MOL CELL BIOL, V17, P612, DOI 10.1128/MCB.17.2.612; JONES PA, 1980, CELL, V20, P85, DOI 10.1016/0092-8674(80)90237-8; Jones PA, 2001, SCIENCE, V293, P1068, DOI 10.1126/science.1063852; JUTTERMANN R, 1994, P NATL ACAD SCI USA, V91, P11797, DOI 10.1073/pnas.91.25.11797; KAFRI T, 1992, GENE DEV, V6, P705, DOI 10.1101/gad.6.5.705; KEENE KC, 2001, MECH DEVELOP, V106, P3; Kirillov A, 1996, NAT GENET, V13, P435, DOI 10.1038/ng0895-435; Kumari M, 1996, J BIOL CHEM, V271, P14390, DOI 10.1074/jbc.271.24.14390; LI E, 1993, NATURE, V366, P362, DOI 10.1038/366362a0; Li SM, 1998, J BIOL CHEM, V273, P31191, DOI 10.1074/jbc.273.47.31191; Liu F, 1997, J BIOL CHEM, V272, P5056, DOI 10.1074/jbc.272.8.5056; MACLEOD D, 1994, GENE DEV, V8, P2282, DOI 10.1101/gad.8.19.2282; Martianov I, 2001, MOL CELL, V7, P509, DOI 10.1016/S1097-2765(01)00198-8; Matsuo K, 1998, EMBO J, V17, P1446, DOI 10.1093/emboj/17.5.1446; McCarrey J, 1993, CELL MOL BIOL TESTIS, P58; McCarrey JR, 1998, SEMIN CELL DEV BIOL, V9, P459, DOI 10.1006/scdb.1998.0199; Meistrich M L, 1977, Methods Cell Biol, V15, P15, DOI 10.1016/S0091-679X(08)60207-1; MONK M, 1987, DEVELOPMENT, V99, P371; Muller C, 2000, MOL CELL BIOL, V20, P3316, DOI 10.1128/MCB.20.9.3316-3329.2000; Ozer J, 2000, J BIOL CHEM, V275, P122, DOI 10.1074/jbc.275.1.122; Panning B, 1996, GENE DEV, V10, P1991, DOI 10.1101/gad.10.16.1991; Persengiev SP, 1996, MOL ENDOCRINOL, V10, P742, DOI 10.1210/me.10.6.742; Schmidt EE, 1997, J BIOL CHEM, V272, P5326, DOI 10.1074/jbc.272.8.5326; SCHMIDT EE, 1995, DEVELOPMENT, V121, P2373; SIERRA F, 1993, GENE TRANSCRIPTION P, P129; Singer T, 2001, GENE DEV, V15, P591, DOI 10.1101/gad.193701; SMALE S.T., 1994, TRANSCRIPTION MECHAN, P63; Teichmann M, 1999, P NATL ACAD SCI USA, V96, P13720, DOI 10.1073/pnas.96.24.13720; TRASLER JM, 1990, MOL CELL BIOL, V10, P1828, DOI 10.1128/MCB.10.4.1828; Trasler JM, 1998, SEMIN CELL DEV BIOL, V9, P467, DOI 10.1006/scdb.1998.0225; Upadhyaya AB, 1999, J BIOL CHEM, V274, P18040, DOI 10.1074/jbc.274.25.18040; Veenstra GJC, 2001, TRENDS BIOCHEM SCI, V26, P665, DOI 10.1016/S0968-0004(01)01970-3; Walsh CP, 1999, GENE DEV, V13, P26, DOI 10.1101/gad.13.1.26; ZAMBROWICZ BP, 1993, P NATL ACAD SCI USA, V90, P5071, DOI 10.1073/pnas.90.11.5071; Zhang D, 2001, SCIENCE, V292, P1153, DOI 10.1126/science.1059188	57	32	33	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 17	2002	277	20					17765	17774		10.1074/jbc.M200954200	http://dx.doi.org/10.1074/jbc.M200954200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	553PR	11889132	hybrid			2022-12-27	WOS:000175685100049
J	Jeon, S; Kim, S; Park, JB; Suh, PG; Kim, YS; Bae, CD; Park, J				Jeon, S; Kim, S; Park, JB; Suh, PG; Kim, YS; Bae, CD; Park, J			RhoA and Rho kinase-dependent phosphorylation of moesin at Thr-558 in hippocampal neuronal cells by glutamate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTROCONVULSIVE SHOCK INCREASES; ELEMENT-BINDING PROTEIN; EPIDERMAL GROWTH-FACTOR; RAT HIPPOCAMPUS; ERM PROTEINS; TYROSINE PHOSPHORYLATION; EZRIN/RADIXIN/MOESIN PROTEINS; CONE MORPHOLOGY; IN-VIVO; ACTIVATION	When we were studying phosphorylated proteins in the rat brain after electroconvulsive shock (ECS), we observed the rapid phosphorylation of a 75-kDa protein, which cross-reacted with the anti-phospho-p70 S6 kinase antibody. The phosphorylated protein was purified and identified as moesin, a member of the ezrin/radixin/moesin (ERM) family and a general cross-linker between cortical actin filaments and plasma membranes. The purified moesin from rat brain was phosphorylated at serine and threonine residues. Moesin was rapidly phosphorylated at the threonine 558 residue after ECS in the rat hippocampus, peaked at 1 min, and returned to the basal level by 2 min after ECS. To investigate the mechanism of moesin phosphorylation in neuronal cells, we stimulated a rat hippocampal progenitor cell, H19-7/IGF-IR, with glutamate, and observed the increased phosphorylation of moesin at Thr-558. Glutamate transiently activated RhoA, and constitutively active RhoA increased the basal level phosphorylation of moesin. The inhibition of RhoA and its effector, Rho kinase, abolished increased Thr-558 phosphorylation by glutamate in H19-7/IGF-IR cells, suggesting that the phosphorylation of moesin at Thr-558 in H19-7/IGF-IR cells by glutamate is mediated by RhoA and Rho kinase activation.	Sungkyunkwan Univ, Sch Med, Samsung Biomed Res Inst, Dept Mol Cell Biol, Suwon 440746, South Korea; Pohang Inst Sci & Technol, Dept Life Sci, Pohang 790784, South Korea; Seoul Natl Univ, Coll Med, Dept Psychiat, Seoul 110744, South Korea	Sungkyunkwan University (SKKU); Pohang University of Science & Technology (POSTECH); Seoul National University (SNU)	Park, JB (corresponding author), Sungkyunkwan Univ, Sch Med, Samsung Biomed Res Inst, Dept Mol Cell Biol, Suwon 440746, South Korea.	jbpark@med.skku.ac.kr	Suh, Pann-Ghill/F-3610-2010					AKTORIES K, 1989, TRENDS PHARMACOL SCI, V10, P415, DOI 10.1016/0165-6147(89)90191-0; AMIEVA MR, 1995, EXP CELL RES, V219, P180, DOI 10.1006/excr.1995.1218; Baron C, 1996, J NEUROCHEM, V66, P1005; BERRYMAN M, 1993, J CELL SCI, V105, P1025; BRETSCHER A, 1989, J CELL BIOL, V108, P921, DOI 10.1083/jcb.108.3.921; Bretscher A, 1999, CURR OPIN CELL BIOL, V11, P109, DOI 10.1016/S0955-0674(99)80013-1; Bretscher A, 1997, J CELL SCI, V110, P3011; del Pozo MA, 1998, CELL ADHES COMMUN, V6, P125, DOI 10.3109/15419069809004468; FOCHTMANN LJ, 1994, PSYCHOPHARMACOL BULL, V30, P321; Fukata Y, 1998, J CELL BIOL, V141, P409, DOI 10.1083/jcb.141.2.409; GonzalezAgosti C, 1996, CELL MOTIL CYTOSKEL, V34, P122, DOI 10.1002/(SICI)1097-0169(1996)34:2<122::AID-CM4>3.0.CO;2-D; Jeon SH, 1997, NEUROPHARMACOLOGY, V36, P411; Jeon SH, 2001, BIOCHEM BIOPH RES CO, V282, P1026, DOI 10.1006/bbrc.2001.4686; KANG UG, 1994, J NEUROCHEM, V63, P1979; Kang UG, 2000, NEUROPHARMACOLOGY, V39, P703, DOI 10.1016/S0028-3908(99)00184-7; Kosako H, 2000, ONCOGENE, V19, P6059, DOI 10.1038/sj.onc.1203987; KRIEG J, 1992, J BIOL CHEM, V267, P19258; LEE YH, 1993, BIOCHEM BIOPH RES CO, V194, P665, DOI 10.1006/bbrc.1993.1873; Mackay DJG, 1997, J CELL BIOL, V138, P927, DOI 10.1083/jcb.138.4.927; Mackay DJG, 1998, J BIOL CHEM, V273, P20685, DOI 10.1074/jbc.273.33.20685; Mangeat P, 1999, TRENDS CELL BIOL, V9, P187, DOI 10.1016/S0962-8924(99)01544-5; Matsui T, 1999, CURR BIOL, V9, P1259, DOI 10.1016/S0960-9822(99)80508-9; Matsui T, 1998, J CELL BIOL, V140, P647, DOI 10.1083/jcb.140.3.647; Nakamura F, 1995, J BIOL CHEM, V270, P31377, DOI 10.1074/jbc.270.52.31377; Nakamura N, 2000, GENES CELLS, V5, P571, DOI 10.1046/j.1365-2443.2000.00348.x; Oh SW, 1999, NEUROSCI LETT, V271, P101, DOI 10.1016/S0304-3940(99)00535-2; Oshiro N, 1998, J BIOL CHEM, V273, P34663, DOI 10.1074/jbc.273.52.34663; Paglini G, 1998, J CELL BIOL, V143, P443, DOI 10.1083/jcb.143.2.443; Pende M, 1997, J NEUROSCI, V17, P1291; Pietromonaco SF, 1998, J BIOL CHEM, V273, P7594, DOI 10.1074/jbc.273.13.7594; Ren XD, 1999, EMBO J, V18, P578, DOI 10.1093/emboj/18.3.578; ROWLEY HL, 1995, NEUROSCIENCE, V68, P415, DOI 10.1016/0306-4522(95)00159-G; SCHWARTZALBIEZ R, 1995, EUR J CELL BIOL, V67, P189; Shaw RJ, 1998, MOL BIOL CELL, V9, P403, DOI 10.1091/mbc.9.2.403; Tsukita S, 1997, CURR OPIN CELL BIOL, V9, P70, DOI 10.1016/S0955-0674(97)80154-8; Vaheri A, 1997, CURR OPIN CELL BIOL, V9, P659, DOI 10.1016/S0955-0674(97)80119-6; VAN AL, 1997, GENE DEV, V11, P2295; Zhang WD, 1999, J NEUROSCI, V19, P96, DOI 10.1523/JNEUROSCI.19-01-00096.1999	38	51	57	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 10	2002	277	19					16576	16584		10.1074/jbc.M110380200	http://dx.doi.org/10.1074/jbc.M110380200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	551MB	11867620	hybrid			2022-12-27	WOS:000175564500033
J	Mann, J; Oakley, F; Johnson, PWM; Mann, DA				Mann, J; Oakley, F; Johnson, PWM; Mann, DA			CD40 induces interleukin-6 gene transcription in dendritic cells - Regulation by TRAF2, AP-1, NF-kappa B, and CBF1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TERMINAL KINASE; T-CELLS; IN-VIVO; ACTIVATION; INDUCTION; EXPRESSION; IL-6; ALPHA; PHOSPHORYLATION; DETERMINANTS	CD40-induced activation of cytokine gene expression in dendritic cells (DC) is an important process in the initiation of primary immune responses. We have determined the intracellular signaling events that lead to CD40 ligation-induced activation of interleukin-6 (IL-6) gene transcription in a murine DC line, FSDC, that is phenotypically representative of bone marrow-derived DC. IL-6 reverse transcriptase-PCR and promoter assays established the responsiveness of FSDC to anti-CD40 ligation. Further promoter assays showed that the transcription factors NF-kappaB and AP-1 are downstream transcriptional mediators of CD40-induced IL-6 gene expression. Anti-CD40 treatment of FSDC stimulated increased expression of specific NF-kappaB (p50:p65) and AP-1 (c-Jun, JunB, JunD, and c-Fos) DNA-protein complexes. Overexpression of an IkappaB-alpha super-repressor or a dominant negative JunD resulted in a strong inhibition of CD40-inducible IL-6 promoter activity supporting a role for both transcription factors. Upstream signal transduction events were studied by transfection of wild type and mutant human CD40 expression constructs into FSDC followed by stimulation with an anti-human CD40 antibody. These experiments revealed that anti-CD40 stimulation of NF-kappaB and IL-6 gene transcription requires specific amino acid residues in the cytoplasmic region of CD40 involved in the recruitment of TRAF2. Induction of IL-6 mRNA by anti-CD40 treatment was found to be a transient event (24 h) and was followed by a diminution of IL-6 transcript to levels below those found in unstimulated cells. This loss of IL-6 expression was associated with reduced p50:p65 NF-kappaB DNA binding and elevated binding of CBF1 to a site overlapping the NF-kappaB site. Overexpression of CBF1 resulted in a profound inhibition of basal and anti-CD40-induced IL-6 promoter activities indicating that prolonged induction of CBF1 may contribute to the transient nature of the IL-6 response. The physiological relevance of these molecular events to DC function is discussed.	Univ Southampton, Southampton Gen Hosp, Div Infect Inflammat & Repair, Liver Grp, Southampton SO16 6YD, Hants, England; Univ Southampton, Southampton Gen Hosp, Div Canc Sci, Southampton SO16 6YD, Hants, England	University of Southampton; University of Southampton	Mann, DA (corresponding author), Univ Southampton, Southampton Gen Hosp, Div Infect Inflammat & Repair, Liver Grp, Level D, Southampton SO16 6YD, Hants, England.	dam2@soton.ac.uk	Johnson, Peter/O-3529-2019; Johnson, Peter/L-2403-2018	Johnson, Peter/0000-0003-2306-4974; Johnson, Peter/0000-0003-2306-4974; Mann, Derek/0000-0003-0950-243X				AKIRA S, 1993, ADV IMMUNOL, V54, P1, DOI 10.1016/S0065-2776(08)60532-5; Baccam M, 1999, EUR J IMMUNOL, V29, P3855, DOI 10.1002/(SICI)1521-4141(199912)29:12<3855::AID-IMMU3855>3.0.CO;2-S; Banchereau J, 2000, ANNU REV IMMUNOL, V18, P767, DOI 10.1146/annurev.immunol.18.1.767; Demoulin JB, 1999, EUR CYTOKINE NETW, V10, P49; DENDORFER U, 1994, MOL CELL BIOL, V14, P4443, DOI 10.1128/MCB.14.7.4443; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Drakesmith H, 1998, P NATL ACAD SCI USA, V95, P14903, DOI 10.1073/pnas.95.25.14903; Eickelberg O, 1999, J BIOL CHEM, V274, P12933, DOI 10.1074/jbc.274.18.12933; Elsharkawy AM, 1999, HEPATOLOGY, V30, P761, DOI 10.1002/hep.510300327; Franchimont N, 1999, J BIOL CHEM, V274, P6783, DOI 10.1074/jbc.274.10.6783; Franchimont N, 1997, J CLIN INVEST, V100, P1797, DOI 10.1172/JCI119707; GAJEWSKI TF, 1995, J IMMUNOL, V154, P5637; GIROLOMONI G, 1995, EUR J IMMUNOL, V25, P2163, DOI 10.1002/eji.1830250807; Grammer AC, 2001, ADV IMMUNOL, V76, P61, DOI 10.1016/S0065-2776(01)76019-1; Grassl C, 1999, J AM SOC NEPHROL, V10, P1466; Grohmann U, 2001, J IMMUNOL, V167, P708, DOI 10.4049/jimmunol.167.2.708; Hanissian SH, 1997, IMMUNITY, V6, P379, DOI 10.1016/S1074-7613(00)80281-2; HASBOLD J, 1994, EUR J IMMUNOL, V24, P1835, DOI 10.1002/eji.1830240817; Hsing Y, 1997, J IMMUNOL, V159, P4898; HUO L, 1995, J IMMUNOL, V154, P3300; Huo L, 1996, J IMMUNOL, V157, P3812; ITO CY, 1994, NUCLEIC ACIDS RES, V22, P3787, DOI 10.1093/nar/22.18.3787; Jalukar SV, 2000, J IMMUNOL, V164, P623, DOI 10.4049/jimmunol.164.2.623; Jefferies C, 2001, MOL CELL BIOL, V21, P4544, DOI 10.1128/MCB.21.14.4544-4552.2001; Jobin C, 1999, J IMMUNOL, V162, P4447; Kannan R, 1997, RANDOM STRUCT ALGOR, V11, P1, DOI 10.1002/(SICI)1098-2418(199708)11:1<1::AID-RSA1>3.0.CO;2-X; La Flamme AC, 1999, J IMMUNOL, V162, P5829; Leal IS, 1999, INFECT IMMUN, V67, P5747, DOI 10.1128/IAI.67.11.5747-5754.1999; Lee HH, 1999, P NATL ACAD SCI USA, V96, P1421, DOI 10.1073/pnas.96.4.1421; Leo E, 1999, J BIOL CHEM, V274, P22414, DOI 10.1074/jbc.274.32.22414; Palmieri M, 1999, NUCLEIC ACIDS RES, V27, P2785, DOI 10.1093/nar/27.13.2785; Pullen SS, 1999, J BIOL CHEM, V274, P14246, DOI 10.1074/jbc.274.20.14246; Revy P, 1999, J IMMUNOL, V163, P787; Shen CH, 2001, J IMMUNOL, V166, P411, DOI 10.4049/jimmunol.166.1.411; Shen ZH, 1997, J IMMUNOL, V158, P2723; Smart DE, 2001, J BIOL CHEM, V276, P24414, DOI 10.1074/jbc.M101840200; SUN SC, 1995, J BIOL CHEM, V270, P18347, DOI 10.1074/jbc.270.31.18347; Sutherland CL, 1999, J IMMUNOL, V162, P4720; Suzuki Y, 1997, INFECT IMMUN, V65, P2339, DOI 10.1128/IAI.65.6.2339-2345.1997; Teague TK, 1997, J IMMUNOL, V158, P5791; Teague TK, 2000, J EXP MED, V191, P915, DOI 10.1084/jem.191.6.915; Thomson AW, 1995, TRANSPLANTATION, V60, P1555, DOI 10.1097/00007890-199560120-00030; Tsukamoto N, 1999, P NATL ACAD SCI USA, V96, P1234, DOI 10.1073/pnas.96.4.1234; VAN SJ, 1990, ANNU REV IMMUNOL, V8, P253	44	74	77	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 10	2002	277	19					17125	17138		10.1074/jbc.M109250200	http://dx.doi.org/10.1074/jbc.M109250200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	551MB	11886848	hybrid			2022-12-27	WOS:000175564500105
J	Doi, J; Takemori, H; Lin, XZ; Horike, N; Katoh, Y; Okamoto, M				Doi, J; Takemori, H; Lin, XZ; Horike, N; Katoh, Y; Okamoto, M			Salt-inducible kinase represses cAMP-dependent protein kinase-mediated activation of human cholesterol side chain cleavage cytochrome P450 promoter through the CREB basic leucine zipper domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELEMENT-BINDING PROTEIN; BOVINE ADRENOCORTICAL-CELLS; TRANSCRIPTION FACTOR; CYCLIC-AMP; GENE-TRANSCRIPTION; EXPRESSION; CYP11A1; PHOSPHORYLATION; CLONING; REGION	Salt-inducible kinase (SIK), one of the serine/threonine protein kinases, was transiently expressed in Y1 cells during the early phase of the ACTH/cAMP-dependent protein kinase (PKA)-mediated signal transduction. The overexpression of SIK(N), the SIK's N-terminal kinase domain, repressed the expression of the side chain cleavage cytochrome P450 (CYP11A) gene. To elucidate the mechanism of the repression by SIK, several CYP11A promoter constructs were tested for the promoter activities in the presence of PKA and/or SIK(N). A cAMP-response element (CRE)-like sequence present in the promoter was shown to be responsible not only for the PKA-mediated promoter activation but also for the SIK(N)-mediated repression. When the Gal4 DNA binding domain-linked full-length CRE-binding protein (CREB) construct was cotransfected with Gal4 reporter gene, SIK(N) repressed the PKA-induced reporter gene expression. However, SIK(N) could not repress the PKA. induced reporter activity conferred by Gal4 DNA binding domain-linked basic leucine zipper (bZIP)-less CREB or bZIP-disrupted CREB. On the other hand, SIK(N) could repress the kinase-inducible domain-disrupted CREB-dependent reporter gene expression in the presence of PKA. The in vitro kinase reaction studies showed that SIK(N) could not phosphorylate CREB, and PKA failed to phosphorylate SIK(N). Taken together, these results suggest that SIK(N), cooperating with PKA, may act on the CREB's bZIP domain and repress the CREB-mediated transcriptional activation of the CYP11A gene.	Osaka Univ, Med Sch H 1, Dept Mol Physiol Chem, Suita, Osaka 5650871, Japan; Kinran Coll, Dept Life Sci, Osaka 5650873, Japan	Osaka University	Okamoto, M (corresponding author), Osaka Univ, Med Sch H 1, Dept Mol Physiol Chem, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan.	mokamoto@mr-mbio.med.osaka-u.ac.jp						AHLGREN R, 1990, J BIOL CHEM, V265, P3313; Andrisani OM, 1999, CRIT REV EUKAR GENE, V9, P19, DOI 10.1615/CritRevEukaryotGeneExpr.v9.i1.20; Ariyoshi N, 1998, J BIOL CHEM, V273, P7610, DOI 10.1074/jbc.273.13.7610; Bassett MH, 2000, ENDOCR RES, V26, P941, DOI 10.3109/07435800009048620; Bird IM, 1998, J CLIN ENDOCR METAB, V83, P1592, DOI 10.1210/jc.83.5.1592; BRINDLE P, 1993, NATURE, V364, P821, DOI 10.1038/364821a0; Cardinaux JR, 2000, MOL CELL BIOL, V20, P1546, DOI 10.1128/MCB.20.5.1546-1552.2000; Chen CC, 2000, LIFE SCI, V67, P2045, DOI 10.1016/S0024-3205(00)00790-6; CHEN RH, 1991, MOL CELL BIOL, V11, P1861, DOI 10.1128/MCB.11.4.1861; Chung BC, 1997, STEROIDS, V62, P37, DOI 10.1016/S0039-128X(96)00156-0; CLARK BJ, 1994, J BIOL CHEM, V269, P28314; CORTON JM, 1994, CURR BIOL, V4, P315, DOI 10.1016/S0960-9822(00)00070-1; De Cesare D, 2000, PROG NUCLEIC ACID RE, V64, P343, DOI 10.1016/S0079-6603(00)64009-6; DELEGEANE AM, 1987, MOL CELL BIOL, V7, P3994, DOI 10.1128/MCB.7.11.3994; DWARKI VJ, 1990, EMBO J, V9, P225, DOI 10.1002/j.1460-2075.1990.tb08099.x; Fass DM, 2001, J BIOL CHEM, V276, P2992, DOI 10.1074/jbc.M008274200; Felinski EA, 1999, J BIOL CHEM, V274, P11672, DOI 10.1074/jbc.274.17.11672; Felinski EA, 2001, MOL CELL BIOL, V21, P1001, DOI 10.1128/MCB.21.4.1001-1010.2001; FERRERI K, 1994, P NATL ACAD SCI USA, V91, P1210, DOI 10.1073/pnas.91.4.1210; FOULKES NS, 1991, CELL, V64, P739, DOI 10.1016/0092-8674(91)90503-Q; Gavaravarapu S, 2000, BIOCHEM BIOPH RES CO, V269, P758, DOI 10.1006/bbrc.2000.2358; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; Groussin L, 2000, J CLIN ENDOCR METAB, V85, P345, DOI 10.1210/jc.85.1.345; GUO IC, 1994, J BIOL CHEM, V269, P6362; HAI TW, 1989, GENE DEV, V3, P2083, DOI 10.1101/gad.3.12b.2083; Hardie DG, 1998, ANNU REV BIOCHEM, V67, P821, DOI 10.1146/annurev.biochem.67.1.821; Hirai S, 1996, ONCOGENE, V12, P641; HOEFFLER JP, 1988, SCIENCE, V242, P1430, DOI 10.1126/science.2974179; HOLZMAN LB, 1994, J BIOL CHEM, V269, P30808; Hong SH, 2001, J BIOL CHEM, V276, P28098, DOI 10.1074/jbc.M010912200; Hu MC, 2001, MOL ENDOCRINOL, V15, P812, DOI 10.1210/me.15.5.812; INOUE H, 1991, EUR J BIOCHEM, V195, P563, DOI 10.1111/j.1432-1033.1991.tb15738.x; JOHN ME, 1986, MOL CELL ENDOCRINOL, V45, P197, DOI 10.1016/0303-7207(86)90148-6; Kamine J, 1996, VIROLOGY, V216, P357, DOI 10.1006/viro.1996.0071; Kim J, 2001, J BIOL CHEM, V276, P19102, DOI 10.1074/jbc.M011579200; KRAMER RE, 1984, J BIOL CHEM, V259, P707; KRAMER RE, 1983, STEROIDS, V41, P207, DOI 10.1016/0039-128X(83)90008-9; Lefebvre DL, 2001, BIOCHEM J, V355, P297, DOI 10.1042/0264-6021:3550297; Lin XZ, 2001, MOL ENDOCRINOL, V15, P1264, DOI 10.1210/me.15.8.1264; LIU F, 1990, CELL, V61, P1217, DOI 10.1016/0092-8674(90)90686-9; Mayr B, 2001, NAT REV MOL CELL BIO, V2, P599, DOI 10.1038/35085068; MILLER WL, 1988, ENDOCR REV, V9, P295, DOI 10.1210/edrv-9-3-295; MOROHASHI K, 1993, MOL ENDOCRINOL, V7, P1196, DOI 10.1210/me.7.9.1196; Nakajima T, 1997, GENE DEV, V11, P738, DOI 10.1101/gad.11.6.738; Nakajima T, 1996, CELL, V86, P465, DOI 10.1016/S0092-8674(00)80119-1; OLSON MF, 1993, MOL ENDOCRINOL, V7, P477, DOI 10.1210/me.7.4.477; Parker D, 1996, MOL CELL BIOL, V16, P694; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; QUINN PG, 1993, J BIOL CHEM, V268, P16999; Reddy UR, 1999, ONCOGENE, V18, P4474, DOI 10.1038/sj.onc.1202813; REDDY UR, 1994, BIOCHEM BIOPH RES CO, V202, P613, DOI 10.1006/bbrc.1994.1972; RICE DA, 1990, J BIOL CHEM, V265, P11713; Schumacher MA, 2000, J BIOL CHEM, V275, P35242, DOI 10.1074/jbc.M007293200; Shaywitz AJ, 2000, MOL CELL BIOL, V20, P9409, DOI 10.1128/MCB.20.24.9409-9422.2000; Shaywitz AJ, 1999, ANNU REV BIOCHEM, V68, P821, DOI 10.1146/annurev.biochem.68.1.821; Shimomura A, 1996, J BIOL CHEM, V271, P17957, DOI 10.1074/jbc.271.30.17957; Stocco DM, 2000, BBA-MOL CELL BIOL L, V1486, P184, DOI 10.1016/S1388-1981(00)00056-1; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; TAKAYAMA K, 1994, J BIOCHEM-TOKYO, V116, P193, DOI 10.1093/oxfordjournals.jbchem.a124493; Takemori H, 2001, EUR J BIOCHEM, V268, P205, DOI 10.1046/j.1432-1327.2001.01847.x; Wang ZN, 1999, FEBS LETT, V453, P135, DOI 10.1016/S0014-5793(99)00708-5; WATANABE N, 1994, EUR J BIOCHEM, V222, P825, DOI 10.1111/j.1432-1033.1994.tb18929.x; WHITE PC, 1987, NEW ENGL J MED, V316, P1519, DOI 10.1056/NEJM198706113162406; Wu XL, 2001, J BIOL CHEM, V276, P1735, DOI 10.1074/jbc.M006727200	64	44	47	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 3	2002	277	18					15629	15637		10.1074/jbc.M109365200	http://dx.doi.org/10.1074/jbc.M109365200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	550PA	11864972	hybrid			2022-12-27	WOS:000175510400056
J	Obukhov, AG; Nowycky, MC				Obukhov, AG; Nowycky, MC			TRPC4 can be activated by G-protein-coupled receptors and provides sufficient Ca2+ to trigger exocytosis in neuroendocrine cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADRENAL CHROMAFFIN CELLS; PDZ-DOMAIN PROTEIN; TRANSIENT RECEPTOR; CALCIUM CURRENT; ANGIOTENSIN-II; PC12 CELLS; CHANNEL; ENTRY; DEPLETION; RELEASE	Transient receptor potential (TRP) channels form a large family of plasma membrane cation channels. Mammalian members of the "short" TRP family (TRP channel (TRPC) 1-7 are Ca2+-permeant, non-selective cation channels that are widely expressed in various cell types, including neurons. TRPC activity is linked through unknown mechanisms to G-protein-coupled receptors or receptor tyrosine kinases that activate phospholipase C. To investigate the properties and function of TRPC4 in neuronally derived cells, we transiently expressed mouse TRPC4 and histamine H-1 receptor in mouse adrenal chromaffin cells and PC12 cells. Histamine, but not thapsigargin, stimulated Mn2+ influx in transfected cells. In the whole-cell patch clamp mode, histamine triggered a transient current in TRPC4-expressing cells. No current was evoked by perfusion with inositol 1,4,5-trisphosphate. When exocytosis was monitored with the capacitance detection technique, the magnitude of the membrane capacitance increase (DeltaC(m)) on application of histamine in H-1 receptor/TRPC4-expressing chromaffin cells was comparable with that triggered by a train of depolarizing pulses. Our results indicate that TRPC4 channels behave as receptor, but not store-operated, channels in neuronally derived cells. TRPC4 channels can provide sufficient Ca2+ influx to trigger a robust secretory response in voltage-clamped neurosecretory cells. Similar mechanisms may modulate exocytosis in other neuronal systems.	Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Physiol & Pharmacol, Newark, NJ 07103 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center	Nowycky, MC (corresponding author), Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Physiol & Pharmacol, 185 S Orange Ave, Newark, NJ 07103 USA.	mnowycky@compuserve.com	Obukhov, Alexander G/C-7246-2008	Obukhov, Alexander G/0000-0002-3862-6004	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS040167] Funding Source: NIH RePORTER; NINDS NIH HHS [NS40167] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Catterall WA, 1999, ANN NY ACAD SCI, V868, P144, DOI 10.1111/j.1749-6632.1999.tb11284.x; CHEEK TR, 1993, J CELL SCI, V105, P913; Chevesich J, 1997, NEURON, V18, P95, DOI 10.1016/S0896-6273(01)80049-0; Clapham DE, 2001, NAT REV NEUROSCI, V2, P387, DOI 10.1038/35077544; COSENS DJ, 1969, NATURE, V224, P285, DOI 10.1038/224285a0; Currie KPM, 2000, J NEUROPHYSIOL, V83, P1435, DOI 10.1152/jn.2000.83.3.1435; Elhamdani A, 2000, J NEUROSCI, V20, P2495; Fomina AF, 1999, J NEUROSCI, V19, P3711; Freichel M, 2001, NAT CELL BIOL, V3, P121, DOI 10.1038/35055019; Gillis KD, 1996, NEURON, V16, P1209, DOI 10.1016/S0896-6273(00)80147-6; Gillis Kevin D., 1995, P155; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HARDIE RC, 1992, NEURON, V8, P643, DOI 10.1016/0896-6273(92)90086-S; Harteneck C, 2000, TRENDS NEUROSCI, V23, P159, DOI 10.1016/S0166-2236(99)01532-5; Hofmann T, 1999, NATURE, V397, P259, DOI 10.1038/16711; HOTH M, 1992, NATURE, V355, P353, DOI 10.1038/355353a0; Inoue R, 2001, CIRC RES, V88, P325, DOI 10.1161/01.RES.88.3.325; Jungnickel MK, 2001, NAT CELL BIOL, V3, P499, DOI 10.1038/35074570; Kiselyov K, 1999, TRENDS NEUROSCI, V22, P334, DOI 10.1016/S0166-2236(99)01426-5; Kiselyov KI, 2000, MOL CELL, V6, P421, DOI 10.1016/S1097-2765(00)00041-1; Li HS, 1999, NEURON, V24, P261, DOI 10.1016/S0896-6273(00)80838-7; Liman ER, 1999, P NATL ACAD SCI USA, V96, P5791, DOI 10.1073/pnas.96.10.5791; MONTELL C, 1989, NEURON, V2, P1313, DOI 10.1016/0896-6273(89)90069-X; Mori Y, 1998, NEUROREPORT, V9, P507; Moser T, 1997, P NATL ACAD SCI USA, V94, P6735, DOI 10.1073/pnas.94.13.6735; Okada T, 1999, J BIOL CHEM, V274, P27359, DOI 10.1074/jbc.274.39.27359; Philipp S, 2000, J BIOL CHEM, V275, P23965, DOI 10.1074/jbc.M003408200; Philipp S, 1998, EMBO J, V17, P4274, DOI 10.1093/emboj/17.15.4274; Schaefer M, 2000, J BIOL CHEM, V275, P17517, DOI 10.1074/jbc.275.23.17517; SEWARD EP, 1995, J NEUROSCI, V15, P3390; Sheng ZH, 1998, J BIOENERG BIOMEMBR, V30, P335, DOI 10.1023/A:1021985521748; Singh BB, 2001, FASEB J, V15, P1652, DOI 10.1096/fj.00-0749fje; Smith C, 1999, J NEUROSCI, V19, P589; Strubing C, 2001, NEURON, V29, P645, DOI 10.1016/S0896-6273(01)00240-9; Tang Y, 2000, J BIOL CHEM, V275, P37559, DOI 10.1074/jbc.M006635200; Teschemacher AG, 2000, J NEUROSCI, V20, P4776; Tesfai Y, 2001, BIOCHEM J, V358, P717, DOI 10.1042/0264-6021:3580717; Thomas AP, 1996, FASEB J, V10, P1505, DOI 10.1096/fasebj.10.13.8940296; Tischler AS, 1997, FUND APPL TOXICOL, V35, P216, DOI 10.1006/faat.1996.2277; Tsunoda S, 1997, NATURE, V388, P243, DOI 10.1038/40805; VITALE ML, 1995, NEURON, V14, P353, DOI 10.1016/0896-6273(95)90291-0; Zerbes M, 1998, CELL CALCIUM, V23, P379, DOI 10.1016/S0143-4160(98)90094-X; Zerbes M, 2001, CELL CALCIUM, V29, P49, DOI 10.1054/ceca.2000.0160; Zhu X, 1996, CELL, V85, P661, DOI 10.1016/S0092-8674(00)81233-7; ZWEIFACH A, 1995, J BIOL CHEM, V270, P14445, DOI 10.1074/jbc.270.24.14445	45	66	74	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 3	2002	277	18					16172	16178		10.1074/jbc.M111664200	http://dx.doi.org/10.1074/jbc.M111664200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	550PA	11856742	hybrid			2022-12-27	WOS:000175510400127
J	Stone, JR; Collins, T				Stone, JR; Collins, T			Rapid phosphorylation of heterogeneous nuclear ribonucleoprotein C1/C2 in response to Physiologic levels of hydrogen peroxide in human endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; NF-KAPPA-B; OXYR TRANSCRIPTION FACTOR; LAMINAR SHEAR-STRESS; GROWTH-FACTOR; NADPH OXIDASE; C-PROTEINS; HNRNP C; TYROSINE PHOSPHORYLATION; H2O2 GENERATION	Hydrogen peroxide (H2O2) has been implicated as a signaling agent in numerous signal transduction pathways in mammalian cells. However, to date, no sensor for low concentrations (<10 mu M) of H2O2 has been identified. Using a functional proteomic approach, nuclear extracts from human umbilical vein endothelial cells were analyzed by two-dimensional PAGE with or without prior treatment with a low concentration of H2O2. A protein doublet with a molecular mass of 39-41 kDa and a pI of similar to 5.0 was observed to be consistently altered by the treatment. Using proteolytic peptide mass fingerprinting, the protein was identified as heterogeneous nuclear ribonucleoprotein C1/C2, a nuclear restricted, pre-mRNA-binding protein. Upon two-dimensional PAGE, each heterogeneous nuclear ribonucleoprotein-C splice form was present as multiple spots because of differing levels of phosphorylation. Upon treatment with H2O2, there was an increase in phosphorylation at 10-20 min, which partially reversed by 30 min. Subsequently, at 60 min after treatment, a population of unphosphorylated protein was transiently present. The effects were observed with as little as 1 mu M H2O2 and were maximal with 5-8 mu M H2O2. The H2O2-stimulated phosphorylation was inhibited by catalase, but not by the transcriptional inhibitor actinomycin D.	Childrens Hosp, Dept Pathol, Boston, MA 02115 USA; Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Pathol, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Harvard University; Brigham & Women's Hospital; Harvard Medical School	Collins, T (corresponding author), Childrens Hosp, Dept Pathol, 300 Longwood Ave, Boston, MA 02115 USA.	tcollins@rics.bwh.harvard.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL035716, T32HL007627] Funding Source: NIH RePORTER; NHLBI NIH HHS [T32 HL07627, R37 HL35716] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abe J, 1999, J BIOL CHEM, V274, P21003, DOI 10.1074/jbc.274.30.21003; Abid MR, 2001, FASEB J, V15, P2548, DOI 10.1096/fj.01-0338fje; Aslund F, 1999, P NATL ACAD SCI USA, V96, P6161, DOI 10.1073/pnas.96.11.6161; Bae YS, 1997, J BIOL CHEM, V272, P217, DOI 10.1074/jbc.272.1.217; Barchowsky A, 1995, AM J PHYSIOL-LUNG C, V269, pL829, DOI 10.1152/ajplung.1995.269.6.L829; BARNETT SF, 1989, MOL CELL BIOL, V9, P492, DOI 10.1128/MCB.9.2.492; BOVERIS A, 1973, BIOCHEM J, V134, P707, DOI 10.1042/bj1340707; Brown MR, 1999, CIRC RES, V85, P524, DOI 10.1161/01.RES.85.6.524; BURD CG, 1989, P NATL ACAD SCI USA, V86, P9788, DOI 10.1073/pnas.86.24.9788; BURDON RH, 1995, FREE RADICAL BIO MED, V18, P775, DOI 10.1016/0891-5849(94)00198-S; Burdon RH, 1996, FREE RADICAL RES, V24, P81, DOI 10.3109/10715769609088004; Cadenas E, 2000, FREE RADICAL BIO MED, V29, P222, DOI 10.1016/S0891-5849(00)00317-8; Chae HJ, 2000, IMMUNOPHARM IMMUNOT, V22, P317, DOI 10.3109/08923970009016423; CHEN QL, 1995, J BIOL CHEM, V270, P28499, DOI 10.1074/jbc.270.48.28499; Davies KJA, 1999, IUBMB LIFE, V48, P41, DOI 10.1080/152165499307404; De Keulenaer GW, 1998, CIRC RES, V82, P1094, DOI 10.1161/01.RES.82.10.1094; DREYFUSS G, 1984, MOL CELL BIOL, V4, P1104, DOI 10.1128/MCB.4.6.1104; DREYFUSS G, 1993, ANNU REV BIOCHEM, V62, P289, DOI 10.1146/annurev.bi.62.070193.001445; Ferrara N, 1997, ENDOCR REV, V18, P4, DOI 10.1210/er.18.1.4; Fung PA, 1997, P NATL ACAD SCI USA, V94, P1064, DOI 10.1073/pnas.94.4.1064; GAMOU S, 1995, FEBS LETT, V357, P161, DOI 10.1016/0014-5793(94)01335-X; Gimbrone M A Jr, 1976, Prog Hemost Thromb, V3, P1; Greene EL, 2000, AM J PHYSIOL-RENAL, V278, pF650, DOI 10.1152/ajprenal.2000.278.4.F650; Griendling KK, 2000, CIRC RES, V86, P494, DOI 10.1161/01.RES.86.5.494; Guyton KZ, 1996, J BIOL CHEM, V271, P4138, DOI 10.1074/jbc.271.7.3604; HARDWICK JS, 1995, P NATL ACAD SCI USA, V92, P4527, DOI 10.1073/pnas.92.10.4527; Heinloth A, 2000, J AM SOC NEPHROL, V11, P1819, DOI 10.1681/ASN.V11101819; Herbert JM, 1996, FEBS LETT, V395, P43, DOI 10.1016/0014-5793(96)00998-2; HOLCOMB ER, 1984, J BIOL CHEM, V259, P31; Junn E, 2000, J IMMUNOL, V165, P2190, DOI 10.4049/jimmunol.165.4.2190; Konishi H, 1997, P NATL ACAD SCI USA, V94, P11233, DOI 10.1073/pnas.94.21.11233; KriegerBrauer HI, 1997, J BIOL CHEM, V272, P10135; Lakshminarayanan V, 1998, J BIOL CHEM, V273, P32670, DOI 10.1074/jbc.273.49.32670; Lambeth JD, 2000, TRENDS BIOCHEM SCI, V25, P459, DOI 10.1016/S0968-0004(00)01658-3; Lee SL, 1999, AM J PHYSIOL-LUNG C, V277, pL282, DOI 10.1152/ajplung.1999.277.2.L282; MAYRAND SH, 1993, P NATL ACAD SCI USA, V90, P7764, DOI 10.1073/pnas.90.16.7764; Mayrand SH, 1996, MOL CELL BIOL, V16, P1241; MONCADA S, 1991, PHARMACOL REV, V43, P109; Nakielny S, 1996, J CELL BIOL, V134, P1365, DOI 10.1083/jcb.134.6.1365; Ohguro N, 1999, BRIT J OPHTHALMOL, V83, P1064, DOI 10.1136/bjo.83.9.1064; OHNO Y, 1985, J BIOL CHEM, V260, P8438; Ostrovidov S, 1998, IN VITRO CELL DEV-AN, V34, P259; Patterson C, 1999, J BIOL CHEM, V274, P19814, DOI 10.1074/jbc.274.28.19814; PICK E, 1980, J IMMUNOL METHODS, V38, P161, DOI 10.1016/0022-1759(80)90340-3; PINOLROMA S, 1993, MOL CELL BIOL, V13, P5762, DOI 10.1128/MCB.13.9.5762; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; SEGAL AW, 1993, TRENDS BIOCHEM SCI, V18, P43, DOI 10.1016/0968-0004(93)90051-N; Sella O, 1999, MOL CELL BIOL, V19, P5429; Slomiany BA, 2000, BIOTECHNIQUES, V28, P938, DOI 10.2144/00285st08; SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296; Thannickal VJ, 2000, FASEB J, V14, P1741, DOI 10.1096/fj.99-0878com; Torres M, 1999, ARCH BIOCHEM BIOPHYS, V366, P231, DOI 10.1006/abbi.1999.1225; Traub O, 1998, ARTERIOSCL THROM VAS, V18, P677, DOI 10.1161/01.ATV.18.5.677; van Oordt WV, 2000, J CELL BIOL, V149, P307, DOI 10.1083/jcb.149.2.307; Williamson DJ, 2000, MOL CELL BIOL, V20, P4094, DOI 10.1128/MCB.20.11.4094-4105.2000; Yasuda M, 1998, LIFE SCI, V64, P249, DOI 10.1016/S0024-3205(98)00560-8; Yoshizumi M, 2000, J BIOL CHEM, V275, P11706, DOI 10.1074/jbc.275.16.11706; Zhang WZ, 2000, ANAL CHEM, V72, P2482, DOI 10.1021/ac991363o; Zheng M, 1998, SCIENCE, V279, P1718, DOI 10.1126/science.279.5357.1718	59	33	34	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 3	2002	277	18					15621	15628		10.1074/jbc.M112153200	http://dx.doi.org/10.1074/jbc.M112153200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	550PA	11877401	hybrid			2022-12-27	WOS:000175510400055
J	Zheng, XL; Sadler, JE				Zheng, XL; Sadler, JE			Mucin-like domain of enteropeptidase directs apical targeting in Madin-Darby canine kidney cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INFLUENZA-VIRUS HEMAGGLUTININ; INTRACELLULAR-TRANSPORT; SORTING SIGNALS; TRANSMEMBRANE DOMAIN; ENTEROKINASE; CHOLESTEROL; GLYCANS; PROTEIN; GLYCOSYLATION; ASSOCIATION	Enteropeptidase, a type II transmembrane protein of the enterocyte brush border, is sorted directly to the apical membrane of Madin-Darby canine kidney II cells. Apical targeting appears to be mediated by an N-terminal segment that contains a 27-amino acid residue O-glycosylated mucin-like domain consisting of two short mucin-like repeats, A and B. Targeting signals within these repeats were characterized by using green fluorescent protein (GFP) as a reporter. Constructs with a cleavable signal peptide and both repeats A and B were secreted apically. Similar constructs lacking mucin repeats were secreted randomly. Either repeat A or B was sufficient to direct apical targeting of GFP. O-linked oligosaccharides alone were not sufficient for targeting because fusion to a different O-glycosylated motif did not alter the random secretion of GFP, and several constructs with mutations in either repeat A or B were O-glycosylated and secreted randomly. In addition, repeat B appears to contain an apical. targeting signal that functions in the absence of glycosylation. Density gradient centrifugation indicated that, unlike several other apically targeted membrane and soluble proteins, apical sorting of mucin-GFP chimeric proteins does not appear to utilize lipid rafts.	Washington Univ, Sch Med, Howard Hughes Med Inst, Dept Med, St Louis, MO 63110 USA; Washington Univ, Sch Med, Howard Hughes Med Inst, Dept Biochem & Mol Biophys, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO 63110 USA	Howard Hughes Medical Institute; Washington University (WUSTL); Howard Hughes Medical Institute; Washington University (WUSTL); Washington University (WUSTL)	Sadler, JE (corresponding author), Washington Univ, Sch Med, Howard Hughes Med Inst, Dept Med, 660 S Euclid Ave,Box 8022, St Louis, MO 63110 USA.	esadler@im.wustl.edu	Zheng, X. Long/ABD-7362-2021; Sadler, Evan/D-8556-2011	Zheng, X. Long/0000-0003-1680-5295; 	NIDDK NIH HHS [DK 50053] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK050053] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alfalah M, 1999, CURR BIOL, V9, P593, DOI 10.1016/S0960-9822(99)80263-2; Blazquez M, 2000, BIOCHEM J, V349, P843, DOI 10.1042/bj3490843; BROWN DA, 1989, SCIENCE, V245, P1499, DOI 10.1126/science.2571189; DANIELSEN EM, 1995, BIOCHEMISTRY-US, V34, P1596, DOI 10.1021/bi00005a016; Graichen R, 1996, J BIOL CHEM, V271, P15854, DOI 10.1074/jbc.271.27.15854; Gut A, 1998, EMBO J, V17, P1919, DOI 10.1093/emboj/17.7.1919; HERMONTAYLOR J, 1977, GUT, V18, P259, DOI 10.1136/gut.18.4.259; Huet G, 1998, J CELL BIOL, V141, P1311, DOI 10.1083/jcb.141.6.1311; Jacob R, 2000, J BIOL CHEM, V275, P6566, DOI 10.1074/jbc.275.9.6566; Jacob R, 1999, J BIOL CHEM, V274, P8061, DOI 10.1074/jbc.274.12.8061; KITAMOTO Y, 1994, P NATL ACAD SCI USA, V91, P7588, DOI 10.1073/pnas.91.16.7588; Kundu A, 1996, J VIROL, V70, P6508, DOI 10.1128/JVI.70.9.6508-6515.1996; Lin SS, 1998, J CELL BIOL, V142, P51, DOI 10.1083/jcb.142.1.51; Lipardi C, 2000, MOL BIOL CELL, V11, P531, DOI 10.1091/mbc.11.2.531; Lisanti M, 1989, Soc Gen Physiol Ser, V44, P167; Lu DS, 1997, J BIOL CHEM, V272, P31293, DOI 10.1074/jbc.272.50.31293; Martin-Belmonte F, 2000, J BIOL CHEM, V275, P41074, DOI 10.1074/jbc.M005429200; Milewski MI, 2001, J CELL SCI, V114, P719; Monlauzeur L, 1998, J BIOL CHEM, V273, P30263, DOI 10.1074/jbc.273.46.30263; Moyer BD, 1999, J CLIN INVEST, V104, P1353, DOI 10.1172/JCI7453; Panzer P, 1998, J BIOL CHEM, V273, P13861, DOI 10.1074/jbc.273.22.13861; Rodriguez-Boulan E, 1999, TRENDS CELL BIOL, V9, P291, DOI 10.1016/S0962-8924(99)01595-0; Scheiffele P, 1997, EMBO J, V16, P5501, DOI 10.1093/emboj/16.18.5501; SCHEIFFELE P, 1995, NATURE, V378, P96, DOI 10.1038/378096a0; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Slimane TA, 2000, EXP CELL RES, V258, P184; Spodsberg N, 2001, J BIOL CHEM, V276, P23506, DOI 10.1074/jbc.C100219200; Tsien RY, 1998, ANNU REV BIOCHEM, V67, P509, DOI 10.1146/annurev.biochem.67.1.509; UMEMOTO J, 1977, J BIOL CHEM, V252, P8609; VOGEL LK, 1992, FEBS LETT, V308, P14, DOI 10.1016/0014-5793(92)81039-O; Yeaman C, 1997, J CELL BIOL, V139, P929, DOI 10.1083/jcb.139.4.929; Yuan X, 1998, AM J PHYSIOL-GASTR L, V274, pG342, DOI 10.1152/ajpgi.1998.274.2.G342; Zheng XL, 1999, J BIOL CHEM, V274, P1596, DOI 10.1074/jbc.274.3.1596	33	23	23	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAR 1	2002	277	9					6858	6863		10.1074/jbc.M109857200	http://dx.doi.org/10.1074/jbc.M109857200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	525ZQ	11878264	hybrid			2022-12-27	WOS:000174104300016
J	Toko, H; Zhu, WD; Takimoto, E; Shiojima, I; Hiroi, Y; Zou, YZ; Oka, T; Akazawa, H; Mizukami, M; Sakamoto, M; Terasaki, F; Kitaura, Y; Takano, H; Nagai, T; Nagai, R; Komuro, I				Toko, H; Zhu, WD; Takimoto, E; Shiojima, I; Hiroi, Y; Zou, YZ; Oka, T; Akazawa, H; Mizukami, M; Sakamoto, M; Terasaki, F; Kitaura, Y; Takano, H; Nagai, T; Nagai, R; Komuro, I			Csx/Nkx2-5 is required for homeostasis and survival of cardiac myocytes in the adult heart	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TINMAN-RELATED GENES; FACTOR NKX2-5; TRANSCRIPTION; DOXORUBICIN; EXPRESSION; DIFFERENTIATION; MUTATIONS; DISEASE; APOPTOSIS; PROTEIN	Csx/Nkx2-5, which is essential for cardiac development of the embryo, is abundantly expressed in the adult heart. We here examined the role of Csx/Nkx2-5 in the adult heart using two kinds of transgenic mice. Transgenic mice that overexpress a dominant negative mutant of Csx/Nkx2-5 (DN-TG mice) showed degeneration of cardiac myocytes and impairment of cardiac function. Doxorubicin induced more marked cardiac dysfunction in DN-TG mice and less in transgenic mice that overexpress wild type Csx/Nkx2-5 (WT-TG mice) compared with non-transgenic mice. Doxorubicin induced cardiomyocyte apoptosis, and the number of apoptotic cardiomyocytes was high in the order of DN-TG mice, non-transgenic mice, and WT-TG mice. Overexpression of the dominant negative mutant of Csx/Nkx2-5 induced apoptosis in cultured cardiomyocytes, while expression of wild type Csx/Nkx2-5 protected cardiomyocytes from doxorubicin-induced apoptotic death. These results suggest that Csx/Nkx2-5 plays a critical role in maintaining highly differentiated cardiac phenotype and in protecting the heart from stresses including doxorubicin.	Chiba Univ, Grad Sch Med, Dept Cardiovasc Sci & Med, Chuo Ku, Chiba 2608670, Japan; Univ Tokyo, Grad Sch Med, Dept Cardiovasc Med, Bunkyo Ku, Tokyo 1138655, Japan; Shinshu Univ, Sch Med, Dept Internal Med, Matsumoto, Nagano 3908621, Japan; Osaka Med Coll, Dept Internal Med 3, Takatsuki, Osaka 5698686, Japan	Chiba University; University of Tokyo; Shinshu University; Osaka Medical College	Komuro, I (corresponding author), Chiba Univ, Grad Sch Med, Dept Cardiovasc Sci & Med, Chuo Ku, 1-8-1 Inohana, Chiba 2608670, Japan.			Akazawa, Hiroshi/0000-0002-3574-9607				Benson DW, 1999, J CLIN INVEST, V104, P1567, DOI 10.1172/JCI8154; Biben C, 1997, GENE DEV, V11, P1357, DOI 10.1101/gad.11.11.1357; Chen JN, 1996, DEVELOPMENT, V122, P3809; Chen SC, 1999, HYPERTENSION, V34, P1223, DOI 10.1161/01.HYP.34.6.1223; Cleaver OB, 1996, DEVELOPMENT, V122, P3549; Grow MW, 1998, DEV BIOL, V204, P187, DOI 10.1006/dbio.1998.9080; GULICK J, 1991, J BIOL CHEM, V266, P9180; Haunstetter A, 1998, CIRC RES, V82, P1111, DOI 10.1161/01.RES.82.11.1111; ITO H, 1990, P NATL ACAD SCI USA, V87, P4275, DOI 10.1073/pnas.87.11.4275; Kasahara H, 2001, J BIOL CHEM, V276, P4570, DOI 10.1074/jbc.M004995200; KOMURO I, 1993, P NATL ACAD SCI USA, V90, P8145, DOI 10.1073/pnas.90.17.8145; KURABAYASHI M, 1994, J BIOL CHEM, V269, P6031; LEWIS W, 1987, LAB INVEST, V56, P295; LINTS TJ, 1993, DEVELOPMENT, V119, P1654; LYONS I, 1995, GENE DEV, V9, P1654, DOI 10.1101/gad.9.13.1654; Monzen K, 1999, MOL CELL BIOL, V19, P7096; Poizat C, 2000, MOL CELL BIOL, V20, P8643, DOI 10.1128/MCB.20.23.8643-8654.2000; RAHMAN A, 1982, CANCER RES, V42, P1817; Saadane N, 1999, BRIT J PHARMACOL, V127, P1165, DOI 10.1038/sj.bjp.0702676; Schott JJ, 1998, SCIENCE, V281, P108, DOI 10.1126/science.281.5373.108; SOMEYA A, 1978, BIOCHEM BIOPH RES CO, V85, P1542, DOI 10.1016/0006-291X(78)91178-6; Takimoto E, 2000, BIOCHEM BIOPH RES CO, V270, P1074, DOI 10.1006/bbrc.2000.2561; Tanaka M, 1999, DEVELOPMENT, V126, P1269; Thompson JT, 1998, AM J PHYSIOL-HEART C, V274, pH1569, DOI 10.1152/ajpheart.1998.274.5.H1569; Zhu WD, 2000, J BIOL CHEM, V275, P35291, DOI 10.1074/jbc.M000525200; Zhu WD, 1999, CIRCULATION, V100, P2100, DOI 10.1161/01.CIR.100.20.2100; Zou YM, 1997, DEVELOPMENT, V124, P793	27	60	64	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	2002	277	27					24735	24743		10.1074/jbc.M107669200	http://dx.doi.org/10.1074/jbc.M107669200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	569PV	11889119	hybrid			2022-12-27	WOS:000176611800100
J	Mitchell, JW; Church, FC				Mitchell, JW; Church, FC			Aspartic acid residues 72 and 75 and tyrosine-sulfate 73 of heparin cofactor II promote intramolecular interactions during glycosaminoglycan binding and thrombin inhibition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DERMATAN SULFATE; BLOOD-COAGULATION; REACTIVE-SITE; PROTEINASE-INHIBITORS; PROTEASE RECEPTORS; ANTITHROMBIN-III; SERPINS; INFLAMMATION; HEMOSTASIS; ACTIVATION	We used site-directed mutagenesis to investigate the role of Glu(69), Asp(70), Asp(71), Asp(72), Tyr-sulfate(73), and Asp(75) in the second acidic region (AR2) of the serpin heparin cofactor 11 (HCII) during formation of the thrombin(.)HCII complex with and without glycosaminoglycans. E69Q/D70N/D71N recombinant (r)HCII, D72N/Y73F/D75N rHCII, and E69Q/D70N/D71N/D72N/Y73F/D75N rHCII were prepared to localize acidic residues important for thrombin inhibition. Interestingly, D72N/Y73F/D75N rHCII had significantly enhanced thrombin inhibition without glycosaminoglycan (4-fold greater) and with heparin (6-fold greater), showing maximal activity at 2 mug/ml heparin compared with wild-type recombinant HCII (wt-rHCII) with maximal activity at 20 mug/ml heparin. The other rHCII mutants had lesser-enhanced activities, but they all eluted from heparin-Sepharose at significantly higher ionic strengths compared with wt-rHCII. Neutralizing and reversing the charge of Asp(72), Tyr-sulfate(73), and Asp(75) were done to characterize their individual contribution to HCII activity. Only Y73K rHCII and D75K rHCII have significantly increased heparin cofactor activity compared with wt-rHCII; however, all of the individual rHCII mutants required substantially less glycosaminoglycan at maximal inhibition than did wt-rHCII. Inhibition of either alpha-thrombin/hirugen or gamma(T)-thrombin (both with an altered anion-binding exosite-1) by the AR2 rHCII mutants was similar to wt-rHCII. D72N/Y73F/D75N rHCII and D75K rHCII were significantly more active than wt-rHCII in a plasma-based thrombin inhibition assay with glycosaminoglycans. These results indicate that improved thrombin inhibition in the AR2 HCII mutants is mediated by enhanced interactions between the acidic domain and anion-binding exosite-1 of thrombin and that AR2 may be a "molecular rheostat" to promote thrombin inhibition in the presence of glycosaminoglycans.	Univ N Carolina, Sch Med, Dept Pathol & Lab Med, Ctr Thrombosis & Hemostasis,Div Hematol Oncol Med, Chapel Hill, NC 27599 USA; Univ N Carolina, Sch Med, Dept Pharmacol, Ctr Thrombosis & Hemostasis, Chapel Hill, NC 27599 USA; Univ N Carolina, Sch Med, Dept Med, Ctr Thrombosis & Hemostasis, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine	Church, FC (corresponding author), Univ N Carolina, Sch Med, Dept Pathol & Lab Med, Ctr Thrombosis & Hemostasis,Div Hematol Oncol Med, Campus Box 7035,932 Mary Ellen Jones Bldg, Chapel Hill, NC 27599 USA.	fchurch@email.unc.edu			NHLBI NIH HHS [HL32656] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL032656] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAGLIN TP, 2001, INT SOC THROMB HAEM; Bauman SJ, 1999, J BIOL CHEM, V274, P34556, DOI 10.1074/jbc.274.49.34556; BLINDER MA, 1988, BIOCHEMISTRY-US, V27, P752, DOI 10.1021/bi00402a039; BRINKMEYER S, 2001, INT SOC THROMB HAEM, pP2082; CHURCH FC, 1986, ANAL BIOCHEM, V157, P77, DOI 10.1016/0003-2697(86)90198-3; CHURCH FC, 1994, TRENDS CARDIOVAS MED, V4, P140, DOI 10.1016/1050-1738(94)90066-3; CHURCH FC, 1997, ADV EXP MED BIOL, V425, P358; Ciaccia AV, 1997, J BIOL CHEM, V272, P14074, DOI 10.1074/jbc.272.22.14074; Ciaccia AV, 1997, J BIOL CHEM, V272, P888, DOI 10.1074/jbc.272.2.888; Ciaccia AV, 1995, PROTEIN EXPRES PURIF, V6, P806, DOI 10.1006/prep.1995.0012; Cirino G, 2000, TRENDS PHARMACOL SCI, V21, P170, DOI 10.1016/S0165-6147(00)01469-3; Cocks TM, 2000, TRENDS PHARMACOL SCI, V21, P103, DOI 10.1016/S0165-6147(99)01440-6; Dahlback B, 2000, LANCET, V355, P1627, DOI 10.1016/S0140-6736(00)02225-X; DAVIE EW, 1991, BIOCHEMISTRY-US, V30, P10363, DOI 10.1021/bi00107a001; Esmon CT, 2000, BBA-PROTEIN STRUCT M, V1477, P349, DOI 10.1016/S0167-4838(99)00266-6; GETTINS PGW, 1996, SERPIUS STRUCTURE FU; GRIFFITH MJ, 1985, J BIOL CHEM, V260, P2218; GRIFFITH MJ, 1983, BLOOD, V61, P111; GRIFFITH MJ, 1985, BIOCHEMISTRY-US, V24, P6777, DOI 10.1021/bi00345a008; Hoffman M, 2001, THROMB HAEMOSTASIS, V85, P958, DOI 10.1055/s-0037-1615947; Holland CA, 2000, FEBS LETT, V484, P87, DOI 10.1016/S0014-5793(00)02131-1; HORTIN G, 1986, J BIOL CHEM, V261, P5827; HORTIN GL, 1989, J BIOL CHEM, V264, P13979; HUBER R, 1989, BIOCHEMISTRY-US, V28, P8951, DOI 10.1021/bi00449a001; Liaw PCY, 1999, J BIOL CHEM, V274, P27597, DOI 10.1074/jbc.274.39.27597; Mann KG, 1999, THROMB HAEMOSTASIS, V82, P165; MCGUIRE EA, 1987, J BIOL CHEM, V262, P169; Myles T, 1998, J BIOL CHEM, V273, P31203, DOI 10.1074/jbc.273.47.31203; POTEMPA J, 1994, J BIOL CHEM, V269, P15957; PRATT CW, 1992, J BIOL CHEM, V267, P8795; PRATT CW, 1993, BLOOD COAGUL FIBRIN, V4, P479, DOI 10.1097/00001721-199306000-00013; PRATT CW, 1991, SEMIN HEMATOL, V28, P3; Preissner KT, 2000, J PATHOL, V190, P360; RAGG H, 1990, J BIOL CHEM, V265, P5211; RAGG H, 1990, J BIOL CHEM, V265, P22386; RAGG H, 1986, NUCLEIC ACIDS RES, V14, P1073, DOI 10.1093/nar/14.2.1073; ROGERS SJ, 1992, J BIOL CHEM, V267, P3613; RUOSLAHTI E, 1988, ANNU REV CELL BIOL, V4, P229, DOI 10.1146/annurev.cb.04.110188.001305; SHEEHAN JP, 1993, J BIOL CHEM, V268, P3639; SHEEHAN JP, 1994, J BIOL CHEM, V269, P32747; Shirk RA, 2000, J BIOL CHEM, V275, P18085, DOI 10.1074/jbc.M001659200; Shirk RA, 1996, ARTERIOSCL THROM VAS, V16, P1138, DOI 10.1161/01.ATV.16.9.1138; Silverman GA, 2001, J BIOL CHEM, V276, P33293, DOI 10.1074/jbc.R100016200; TEIEN AN, 1976, THROMB RES, V8, P859, DOI 10.1016/0049-3848(76)90014-1; TOLLEFSEN DM, 1995, THROMB HAEMOSTASIS, V74, P1209; TOLLEFSEN DM, 1985, BLOOD, V66, P769; TOLLEFSEN DM, 1989, ANN NY ACAD SCI, V556, P116; VANDEERLIN VMD, 1991, J BIOL CHEM, V266, P20223; WHINNA HC, 1993, J BIOL CHEM, V268, P3920	49	23	24	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 31	2002	277	22					19823	19830		10.1074/jbc.M200630200	http://dx.doi.org/10.1074/jbc.M200630200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	557EH	11856753	hybrid			2022-12-27	WOS:000175894800077
J	Pei, Y; Shuman, S				Pei, Y; Shuman, S			Interactions between fission yeast mRNA capping enzymes and elongation factor Spt5	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBOXYL-TERMINAL DOMAIN; POLYMERASE-II ELONGATION; SACCHAROMYCES-CEREVISIAE; P-TEFB; TRANSCRIPTION; TRIPHOSPHATASE; GUANYLYLTRANSFERASE; PHOSPHORYLATION; COMPLEX; DSIF	Elongating RNA polymerase 11 is targeted by macromolecular assemblies that regulate mRNA synthesis and processing. The capping apparatus is the first of the assemblies to act on the nascent pre-mRNA. Although recruitment of the capping enzymes to the transcription complex is dependent on phosphorylation of the C-terminal domain of the Rpb1 subunit of polymerase 11 (Pol-II), there may be additional levels of control that coordinate capping with elongation. Here we show that the triphosphatase (Pct1) and guanylyltransferase (Peel) enzymes of the fission yeast capping apparatus bind independently to the elongation factor Spt5. The C-terminal domain of the 990-amino acid Schizosaccharomyces pombe Spt5 protein, composed of repeats of a nonapeptide motif (consensus sequence TPAWNSGSK), is necessary and sufficient for binding to the capping enzymes in vivo (in a two-hybrid assay) and in vitro. As few as four nonamer repeats suffice for Spt5 binding to Pct1 in vitro, whereas six repeats are required for Spt5 binding to Peel. A 116-amino acid fragment of the guanylyltransferase Peel suffices for binding to the Spt5 C-terminal domain (CTD) but not for binding to the Pol-II CTD. Pct1 and Peel can bind simultaneously to the Spt5 CTD in vitro. We find that Spt5 is essential for viability of S. pombe and that it interacts in vivo with S. pombe Spt4 via a central domain distinct from the Spt5 CTD. We suggest that Spt5-induced arrest of elongation at promoter proximal positions ensures a temporal window for recruitment of the capping enzymes.	Sloan Kettering Inst, Program Mol Biol, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center	Shuman, S (corresponding author), Sloan Kettering Inst, Program Mol Biol, New York, NY 10021 USA.	s-shuman@ski.mskcc.org	Pei, Yi/D-8998-2011	Pei, Yi/0000-0002-3466-760X	NIGMS NIH HHS [GM52470] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052470] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Andrulis ED, 2000, GENE DEV, V14, P2635, DOI 10.1101/gad.844200; Changela A, 2001, EMBO J, V20, P2575, DOI 10.1093/emboj/20.10.2575; Chiu YL, 2001, J BIOL CHEM, V276, P12959, DOI 10.1074/jbc.M007901200; Cho EJ, 1998, GENE DEV, V12, P3482, DOI 10.1101/gad.12.22.3482; Cho EJ, 1997, GENE DEV, V11, P3319, DOI 10.1101/gad.11.24.3319; Guo S, 2000, NATURE, V408, P366, DOI 10.1038/35042590; Hakansson K, 1997, CELL, V89, P545, DOI 10.1016/S0092-8674(00)80236-6; Hartzog GA, 1998, GENE DEV, V12, P357, DOI 10.1101/gad.12.3.357; Ho CK, 1999, NUCLEIC ACIDS RES, V27, P4671, DOI 10.1093/nar/27.24.4671; Ho CK, 1998, MOL CELL BIOL, V18, P5189, DOI 10.1128/MCB.18.9.5189; Ho CK, 1998, J BIOL CHEM, V273, P9577, DOI 10.1074/jbc.273.16.9577; Ho CK, 1999, MOL CELL, V3, P405, DOI 10.1016/S1097-2765(00)80468-2; INOUE K, 1989, GENE DEV, V3, P1472, DOI 10.1101/gad.3.9.1472; Ivanov D, 2000, MOL CELL BIOL, V20, P2970, DOI 10.1128/MCB.20.9.2970-2983.2000; Kaplan CD, 2000, GENE DEV, V14, P2623, DOI 10.1101/gad.831900; Kim JB, 2001, J BIOL CHEM, V276, P12317, DOI 10.1074/jbc.M010908200; Lehman K, 1999, J BIOL CHEM, V274, P22668, DOI 10.1074/jbc.274.32.22668; Lima CD, 1999, CELL, V99, P533, DOI 10.1016/S0092-8674(00)81541-X; McCracken S, 1997, GENE DEV, V11, P3306, DOI 10.1101/gad.11.24.3306; Mossessova E, 2000, MOL CELL, V5, P865, DOI 10.1016/S1097-2765(00)80326-3; OHNO M, 1987, P NATL ACAD SCI USA, V84, P5187, DOI 10.1073/pnas.84.15.5187; Pei Y, 2001, J BIOL CHEM, V276, P28075, DOI 10.1074/jbc.M102170200; Pei Y, 2001, NUCLEIC ACIDS RES, V29, P387, DOI 10.1093/nar/29.2.387; Ping YH, 2001, J BIOL CHEM, V276, P12951, DOI 10.1074/jbc.M006130200; Price DH, 2000, MOL CELL BIOL, V20, P2629, DOI 10.1128/MCB.20.8.2629-2634.2000; Renner DB, 2001, J BIOL CHEM, V276, P42601, DOI 10.1074/jbc.M104967200; Schroeder SC, 2000, GENE DEV, V14, P2435, DOI 10.1101/gad.836300; Schwer B, 1998, NUCLEIC ACIDS RES, V26, P2050, DOI 10.1093/nar/26.9.2050; Shuman S, 2001, PROG NUCLEIC ACID RE, V66, P1; SHUMAN S, 1994, P NATL ACAD SCI USA, V91, P12046, DOI 10.1073/pnas.91.25.12046; SWANSON MS, 1991, MOL CELL BIOL, V11, P3009, DOI 10.1128/MCB.11.6.3009; Wada T, 1998, EMBO J, V17, P7395, DOI 10.1093/emboj/17.24.7395; Wada T, 1998, GENE DEV, V12, P343, DOI 10.1101/gad.12.3.343; Wen YX, 1999, GENE DEV, V13, P1774, DOI 10.1101/gad.13.14.1774; Yamaguchi Y, 1999, CELL, V97, P41, DOI 10.1016/S0092-8674(00)80713-8; Yamaguchi Y, 1999, J BIOL CHEM, V274, P8085, DOI 10.1074/jbc.274.12.8085; Yue ZY, 1997, P NATL ACAD SCI USA, V94, P12898, DOI 10.1073/pnas.94.24.12898	37	102	104	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 31	2002	277	22					19639	19648		10.1074/jbc.M200015200	http://dx.doi.org/10.1074/jbc.M200015200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	557EH	11893740	hybrid			2022-12-27	WOS:000175894800054
J	Constantinescu, A; Gordon, AS; Diamond, I				Constantinescu, A; Gordon, AS; Diamond, I			CAMP-dependent protein kinase types I and II differentially regulate cAMP response element-mediated gene expression - Implications for neuronal responses to ethanol	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CREB-BINDING-PROTEIN; CATALYTIC SUBUNIT; CYCLIC-AMP; ANCHORING PROTEIN; CELL-LINE; RII-BETA; NUCLEAR; ADENOSINE; LOCALIZATION; MECHANISM	We have shown that ethanol induces translocation of cAMP-dependent protein kinase (PKA) to the nucleus, cAMP response element-binding protein (CREB) phosphorylation, and cAMP response element-mediated gene transcription in NG108-15 cells. However, little is known about which PKA types regulate this process. We show here that under basal conditions NG108-15 cells contain type I PKA (CbetaRIbeta) primarily in cytosol and type H PKA (CalphaRIIbeta) in the particulate and nuclear fractions. Antagonists of both type I and type H PKA inhibit forskolin- and ethanol-induced cAMP response element-mediated gene transcription. However, only the typeII PKA antagonist inhibits forskolin-induced Cot and ethanol-induced Calpha and RIIbeta translocation to the nucleus and CREB phosphorylation; the type I antagonist is without effect. Our data suggest that forskolin- and ethanol-induced CREB phosphorylation and gene activation are differentially mediated by the two types of PKA. We propose that type II PKA is translocated and activated in the nucleus and induces CREB phosphorylation that is necessary but not sufficient for gene transcription. By contrast, type I PKA is activated in the cytoplasm, turning on a downstream pathway that activates other transcription cofactors that interact with phosphorylated CREB to induce gene transcription.	Univ Calif San Francisco, Ernest Gallo Clin & Res Ctr, Dept Neurol, Emeryville, CA 94608 USA; Univ Calif San Francisco, Ernest Gallo Clin & Res Ctr, Dept Mol & Cellular Pharmacol, Emeryville, CA 94608 USA; Univ Calif San Francisco, Grad Program Neurosci, Emeryville, CA 94608 USA; Univ Calif San Francisco, Ctr Neurobiol Addict, Emeryville, CA 94608 USA	University of California System; University of California San Francisco; Ernest Gallo Clinic & Research Center; University of California System; University of California San Francisco; Ernest Gallo Clinic & Research Center; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Constantinescu, A (corresponding author), Univ Calif San Francisco, Ernest Gallo Clin & Res Ctr, Dept Neurol, 5858 Horton St,Suite 200, Emeryville, CA 94608 USA.	anconst@itsa.ucsf.edu			NIAAA NIH HHS [R37 AA10030] Funding Source: Medline; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R37AA010030] Funding Source: NIH RePORTER	NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		Abel T, 1997, CELL, V88, P615, DOI 10.1016/S0092-8674(00)81904-2; Adams MR, 1997, P NATL ACAD SCI USA, V94, P12157, DOI 10.1073/pnas.94.22.12157; Akileswaran L, 2001, J BIOL CHEM, V276, P17448, DOI 10.1074/jbc.M101171200; Asher O, 2002, J PHARMACOL EXP THER, V301, P66, DOI 10.1124/jpet.301.1.66; Brandon EP, 1998, J NEUROSCI, V18, P3639; Brandon EP, 1997, CURR OPIN NEUROBIOL, V7, P397, DOI 10.1016/S0959-4388(97)80069-4; BRINDLE P, 1995, P NATL ACAD SCI USA, V92, P10521, DOI 10.1073/pnas.92.23.10521; BUDILLON A, 1995, P NATL ACAD SCI USA, V92, P10634, DOI 10.1073/pnas.92.23.10634; CADD GG, 1990, J BIOL CHEM, V265, P19502; Cardinaux JR, 2000, MOL CELL BIOL, V20, P1546, DOI 10.1128/MCB.20.5.1546-1552.2000; COGHLAN VM, 1994, J BIOL CHEM, V269, P7658; Constantinescu A, 1999, J BIOL CHEM, V274, P26985, DOI 10.1074/jbc.274.38.26985; CORBIN JD, 1975, J BIOL CHEM, V250, P218; DellAcqua ML, 1997, J BIOL CHEM, V272, P12881, DOI 10.1074/jbc.272.20.12881; Diamond I, 1997, PHYSIOL REV, V77, P1, DOI 10.1152/physrev.1997.77.1.1; DIAMOND I, 1987, P NATL ACAD SCI USA, V84, P1413, DOI 10.1073/pnas.84.5.1413; Dohrman DP, 2002, ALCOHOL CLIN EXP RES, V26, P407, DOI 10.1111/j.1530-0277.2002.tb02553.x; Dohrman DP, 1996, P NATL ACAD SCI USA, V93, P10217, DOI 10.1073/pnas.93.19.10217; Eide T, 1998, EXP CELL RES, V238, P305, DOI 10.1006/excr.1997.3855; Gamm DM, 1996, J BIOL CHEM, V271, P15736, DOI 10.1074/jbc.271.26.15736; GJERTSEN BT, 1995, J BIOL CHEM, V270, P20599, DOI 10.1074/jbc.270.35.20599; Goodman RH, 2000, GENE DEV, V14, P1553; GORDON AS, 1986, P NATL ACAD SCI USA, V83, P2105, DOI 10.1073/pnas.83.7.2105; HAROOTUNIAN AT, 1993, MOL BIOL CELL, V4, P993, DOI 10.1091/mbc.4.10.993; Impey S, 1998, NEURON, V21, P869, DOI 10.1016/S0896-6273(00)80602-9; Janknecht R, 1996, CURR BIOL, V6, P951, DOI 10.1016/S0960-9822(02)00636-X; KEMP BE, 1980, J BIOL CHEM, V255, P2914; Mayford M, 1999, TRENDS GENET, V15, P463, DOI 10.1016/S0168-9525(99)01846-6; MEINKOTH JL, 1993, MOL CELL BIOCHEM, V128, P179, DOI 10.1007/BF01076769; Michael LF, 2000, MOL CELL BIOL, V20, P1596, DOI 10.1128/MCB.20.5.1596-1603.2000; Montminy M, 1997, ANNU REV BIOCHEM, V66, P807, DOI 10.1146/annurev.biochem.66.1.807; NAGY LE, 1989, MOL PHARMACOL, V36, P744; Nestler EJ, 2001, AM J ADDICTION, V10, P201, DOI 10.1080/105504901750532094; Newlon MG, 1999, NAT STRUCT BIOL, V6, P222; Newlon MG, 2001, EMBO J, V20, P1651, DOI 10.1093/emboj/20.7.1651; Paolillo M, 1999, J BIOL CHEM, V274, P6546, DOI 10.1074/jbc.274.10.6546; Park SK, 2000, J BIOL CHEM, V275, P20588, DOI 10.1074/jbc.M002460200; RIOS RM, 1992, EMBO J, V11, P1723, DOI 10.1002/j.1460-2075.1992.tb05224.x; SAPRU MK, 1994, J PHARMACOL EXP THER, V271, P542; Schwede F, 2000, PHARMACOL THERAPEUT, V87, P199, DOI 10.1016/S0163-7258(00)00051-6; Skalhegg BS, 2000, FRONT BIOSCI-LANDMRK, V5, pD678, DOI 10.2741/Skalhegg; SOLBERG R, 1994, EXP CELL RES, V214, P595, DOI 10.1006/excr.1994.1297; TABAKOFF B, 1988, NEW ENGL J MED, V318, P134, DOI 10.1056/NEJM198801213180302; Thiele TE, 2000, J NEUROSCI, V20, part. no., DOI 10.1523/JNEUROSCI.20-10-j0003.2000; Tibbs VC, 1998, J BIOL CHEM, V273, P25783, DOI 10.1074/jbc.273.40.25783; TORTORA G, 1990, J BIOL CHEM, V265, P18067; TRINCZEK B, 1993, EUR J CELL BIOL, V60, P196; Ventra C, 1996, J NEUROCHEM, V66, P1752; Wand G, 2001, J NEUROSCI, V21, P5297, DOI 10.1523/JNEUROSCI.21-14-05297.2001; Wiley JC, 1999, J BIOL CHEM, V274, P6381, DOI 10.1074/jbc.274.10.6381; Xu L, 1998, NATURE, V395, P301, DOI 10.1038/26270; Zanger K, 1999, MOL ENDOCRINOL, V13, P268, DOI 10.1210/me.13.2.268	52	35	35	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 24	2002	277	21					18810	18816		10.1074/jbc.M112107200	http://dx.doi.org/10.1074/jbc.M112107200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	558PM	11886856	hybrid			2022-12-27	WOS:000175975800075
J	Fernandez, J; Yaman, I; Sarnow, P; Snider, MD; Hatzoglou, M				Fernandez, J; Yaman, I; Sarnow, P; Snider, MD; Hatzoglou, M			Regulation of internal ribosomal entry site-mediated translation by phosphorylation of the translation initiation factor eIF2 alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-SYNTHESIS; MESSENGER-RNA; C-MYC; IDENTIFICATION; RECRUITMENT; CELLS	Initiation of translation from most cellular mRNAs occurs via scanning; the 40 S ribosomal subunit binds to the m(7)G-cap and then moves along the mRNA until an initiation codon is encountered. Some cellular mRNAs contain internal ribosome entry sequences (IRESs) within their 5'-untranslated regions, which allow initiation independently of the 5'-cap. This study investigated the ability of cellular stress to regulate the activity of IRESs in cellular mRNAs. Three stresses were studied that cause the phosphonylation of the translation initiation factor, eIF2alpha, by activating specific kinases: W amino acid starvation, which activates GCN2; (ii) endoplasmic reticulum (ER) stress, which activates PKR-like ER kinase, PERK kinase; and (iii) double-stranded RNA, which activates double-stranded RNA-dependent protein kinase (PKR) by mimicking viral infection. Amino acid starvation and ER stress caused transient phosphorylation of eIF2a during the first hour of treatment, whereas double-stranded RNA caused a sustained phosphorylation of eIF2alpha after 2 h. The effects of these treatments on IRES-mediated initiation were investigated using bicistronic mRNA expression vectors. No effect was seen for the IRESs from the mRNAs for the chaperone BiP and the protein kinase Pim-1. In contrast, translation mediated by the IRESs from the cationic amino acid transporter, cat-1, and of the cricket paralysis virus intergenic region, were stimulated 3- to 10-fold by all three treatments. eIF2alpha phosphorylation was required for the response because inactivation of phosphorylation prevented the stimulation. It is concluded that cellular stress can stimulate translation from some cellular IRESs via a mechanism that requires the phosphorylation of eIF2a. Moreover, there are distinct regulatory patterns for different cellular mRNAs that contain IRESs within their 5'-untranslated regions.	Case Western Reserve Univ, Sch Med, Dept Nutr, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Dept Biochem, Cleveland, OH 44106 USA; Stanford Univ, Dept Microbiol & Immunol, Sch Med, Stanford, CA 94305 USA	Case Western Reserve University; Case Western Reserve University; Stanford University	Hatzoglou, M (corresponding author), Case Western Reserve Univ, Sch Med, Dept Nutr, 109 Euclid Ave, Cleveland, OH 44106 USA.	mxh8@po.cwru.edu	yaman, ibrahim/A-7192-2016	yaman, ibrahim/0000-0002-3987-1984; Sarnow, Peter/0000-0002-2043-2770	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK053307, T32DK007319, R01DK060596] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM055979] Funding Source: NIH RePORTER; NIDDK NIH HHS [5T32 DK07319, DK60596-01, R01 DK53307-01] Funding Source: Medline; NIGMS NIH HHS [GM 55979] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Brewer JW, 2000, P NATL ACAD SCI USA, V97, P12625, DOI 10.1073/pnas.220247197; CHOI SY, 1992, J BIOL CHEM, V267, P286; Clemens MJ, 2000, CELL DEATH DIFFER, V7, P603, DOI 10.1038/sj.cdd.4400695; Clemens MJ, 1999, INT J BIOCHEM CELL B, V31, P1, DOI 10.1016/S1357-2725(98)00127-7; Cornelis S, 2000, MOL CELL, V5, P597, DOI 10.1016/S1097-2765(00)80239-7; Creancier L, 2000, J CELL BIOL, V150, P275, DOI 10.1083/jcb.150.1.275; Fernandez J, 2002, J BIOL CHEM, V277, P2050, DOI 10.1074/jbc.M109199200; Fernandez J, 2001, J BIOL CHEM, V276, P12285, DOI 10.1074/jbc.M009714200; FERNANDEZ JM, 2002, J BIOL CHEM, V7, P7; Gingras AC, 1999, ANNU REV BIOCHEM, V68, P913, DOI 10.1146/annurev.biochem.68.1.913; Harding HP, 2000, MOL CELL, V6, P1099, DOI 10.1016/S1097-2765(00)00108-8; Hellen CUT, 2001, GENE DEV, V15, P1593, DOI 10.1101/gad.891101; Hershey JWB, 2000, COLD SPRING HARBOR M, V39, P33; Hinnebusch Alan G., 1994, Seminars in Cell Biology, V5, P417, DOI 10.1006/scel.1994.1049; Holcik M, 2000, TRENDS GENET, V16, P469, DOI 10.1016/S0168-9525(00)02106-5; Hyatt SL, 1997, J BIOL CHEM, V272, P19951, DOI 10.1074/jbc.272.32.19951; Jackson RJ, 1995, RNA, V1, P985; Johannes G, 1999, P NATL ACAD SCI USA, V96, P13118, DOI 10.1073/pnas.96.23.13118; Johannes G, 1998, RNA, V4, P1500, DOI 10.1017/S1355838298981080; Kaufman RJ, 1999, GENE DEV, V13, P1211, DOI 10.1101/gad.13.10.1211; Kieft JS, 2001, RNA, V7, P194, DOI 10.1017/S1355838201001790; Kimball Sr, 2000, COLD SPRING HARBOR M, V39, P561; Leahy P, 1999, J BIOL CHEM, V274, P8813, DOI 10.1074/jbc.274.13.8813; Lee AS, 2001, TRENDS BIOCHEM SCI, V26, P504, DOI 10.1016/S0968-0004(01)01908-9; MACEJAK DG, 1991, NATURE, V353, P90, DOI 10.1038/353090a0; Martinez-Salas E, 2001, J GEN VIROL, V82, P973, DOI 10.1099/0022-1317-82-5-973; PAIN VM, 1994, BIOCHIMIE, V76, P718, DOI 10.1016/0300-9084(94)90076-0; Pestova TV, 2001, P NATL ACAD SCI USA, V98, P7029, DOI 10.1073/pnas.111145798; PROUD CG, 1995, TRENDS BIOCHEM SCI, V20, P241, DOI 10.1016/S0968-0004(00)89025-8; Pyronnet S, 2000, MOL CELL, V5, P607, DOI 10.1016/S1097-2765(00)80240-3; SARIS CJM, 1991, EMBO J, V10, P655, DOI 10.1002/j.1460-2075.1991.tb07994.x; SARNOW P, 1989, P NATL ACAD SCI USA, V86, P5795, DOI 10.1073/pnas.86.15.5795; Stoneley M, 2000, MOL CELL BIOL, V20, P1162, DOI 10.1128/MCB.20.4.1162-1169.2000; Thompson SR, 2001, P NATL ACAD SCI USA, V98, P12972, DOI 10.1073/pnas.241286698; Wilson JE, 2000, CELL, V102, P511, DOI 10.1016/S0092-8674(00)00055-6; Wilson JE, 2000, MOL CELL BIOL, V20, P4990, DOI 10.1128/MCB.20.14.4990-4999.2000; Yang YL, 1995, EMBO J, V14, P6095, DOI 10.1002/j.1460-2075.1995.tb00300.x	37	162	167	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 24	2002	277	21					19198	19205		10.1074/jbc.M201052200	http://dx.doi.org/10.1074/jbc.M201052200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	558PM	11877448	hybrid			2022-12-27	WOS:000175975800123
J	Graness, A; Chwieralski, CE; Reinhold, D; Thim, L; Hoffmann, W				Graness, A; Chwieralski, CE; Reinhold, D; Thim, L; Hoffmann, W			Protein kinase C and ERK activation are required for TFF-peptide-stimulated bronchial epithelial cell migration and tumor necrosis factor-alpha-induced interleukin-6 (IL-6) and IL-8 secretion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; INTESTINAL TREFOIL FACTOR; HUMAN SPASMOLYTIC POLYPEPTIDE; SIGNAL-TRANSDUCTION PATHWAYS; GENE-EXPRESSION; TRANSCRIPTION FACTORS; INFLAMMATORY CYTOKINES; FACTOR RECEPTOR; GROWTH-FACTOR; CANCER CELLS	TFF-peptides (formerly P-domain peptides, trefoil factors) are typical secretory products of many mucous epithelia and are aberrantly secreted during chronic inflammatory diseases. They are known to enhance the migration of intestinal, corneal, and bronchial epithelial cells. Using the human bronchial epithelial cell line BEAS-2B as a model, it is shown here for the first time that TFF-peptides are capable of modulating the inflammatory response in vitro by regulating tumor necrosis factor-alpha-induced secretion of interleukin (IL)-6 and IL-8. In contrast, TFF2 itself does not change IL-6 and IL-8 secretion but triggers sustained activation of the extracellular signal-regulated kinases (ERK1/2) as well as phosphorylation of c-Jun N-terminal kinase (JN-K). A complex differential regulation of tumor necrosis factor-a-induced IL-6 and IL-8 secretion by TFF2 is observed that involves signaling via protein kinase C and ERK1/2. Furthermore, the motogenic effect of TFF2 on BEAS-2B cells is analyzed using a modified Boyden chamber assay. This migratory effect is shown to be dependent not only on protein kinase C and ERK1/2 but also on the activation of the Src family of tyrosine kinases. Taken together, the data presented indicate an important physiological role of TFF-peptides during inflammatory conditions of mucous epithelia.	Otto von Guericke Univ, Inst Mol Biol & Med Chem, D-39120 Magdeburg, Germany; Otto von Guericke Univ, Inst Immunol, D-39120 Magdeburg, Germany; Novo Nordisk AS, Dept Prot Chem, DK-2880 Bagsvaerd, Denmark	Otto von Guericke University; Otto von Guericke University; Novo Nordisk	Hoffmann, W (corresponding author), Univ Klinikum, Inst Mol Biol & Med Chem, Leipziger Str 44, D-39120 Magdeburg, Germany.		Hoffmann, Werner/AAY-9182-2020					Akira S, 1997, ADV IMMUNOL, V65, P1, DOI 10.1016/S0065-2776(08)60740-3; AKIRA S, 1990, FASEB J, V4, P2860, DOI 10.1096/fasebj.4.11.2199284; Basu A, 2001, BIOCHEM BIOPH RES CO, V280, P883, DOI 10.1006/bbrc.2000.4209; Beyaert R, 1996, EMBO J, V15, P1914, DOI 10.1002/j.1460-2075.1996.tb00542.x; Bin W, 2001, AM J PHYSIOL-LUNG C, V280, pL675, DOI 10.1152/ajplung.2001.280.4.L675; Bousquet J, 2000, AM J RESP CRIT CARE, V161, P1720, DOI 10.1164/ajrccm.161.5.9903102; Boxberger Hans-Juergen, 1998, European Journal of Cell Biology, V75, P56; Brasier AR, 1998, J BIOL CHEM, V273, P3551, DOI 10.1074/jbc.273.6.3551; Brinkman BMN, 1999, J BIOL CHEM, V274, P30882, DOI 10.1074/jbc.274.43.30882; Carter AB, 1999, AM J RESP CELL MOL, V20, P751, DOI 10.1165/ajrcmb.20.4.3420; Chen D, 1999, J IMMUNOL, V163, P5796; Chen YH, 2000, BIOCHEM BIOPH RES CO, V274, P576, DOI 10.1006/bbrc.2000.3176; De Bosscher K, 2000, P NATL ACAD SCI USA, V97, P3919, DOI 10.1073/pnas.97.8.3919; DEVLIN RB, 1994, AM J PHYSIOL, V266, P612; Emami S, 2001, FASEB J, V15, P351, DOI 10.1096/fj.00-0355com; Graness A, 1997, BIOCHEM J, V327, P147, DOI 10.1042/bj3270147; Graness A, 1998, J BIOL CHEM, V273, P32016, DOI 10.1074/jbc.273.48.32016; Hall CL, 1996, ONCOGENE, V13, P2213; HANBY AM, 1993, GASTROENTEROLOGY, V105, P1110, DOI 10.1016/0016-5085(93)90956-D; HAUSER F, 1993, P NATL ACAD SCI USA, V90, P6961, DOI 10.1073/pnas.90.15.6961; Hoffmann W, 2002, INT REV CYTOL, V213, P147; Hoffmann W, 2001, HISTOL HISTOPATHOL, V16, P319, DOI 10.14670/HH-16.319; Hollande F, 2001, J BIOL CHEM, V276, P40402, DOI 10.1074/jbc.M105090200; Holtmann H, 1999, MOL CELL BIOL, V19, P6742; Jin YJ, 2001, J BIOL CHEM, V276, P30342, DOI 10.1074/jbc.M102404200; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; Kilpatrick LE, 2000, AM J PHYSIOL-CELL PH, V279, pC2011, DOI 10.1152/ajpcell.2000.279.6.C2011; Kinoshita K, 2000, MOL CELL BIOL, V20, P4680, DOI 10.1128/MCB.20.13.4680-4690.2000; KISHIMOTO T, 1994, CELL, V76, P253, DOI 10.1016/0092-8674(94)90333-6; Klemke RL, 1997, J CELL BIOL, V137, P481, DOI 10.1083/jcb.137.2.481; Krause A, 1998, J BIOL CHEM, V273, P23681, DOI 10.1074/jbc.273.37.23681; Krueger JS, 2001, ONCOGENE, V20, P4209, DOI 10.1038/sj.onc.1204541; Kyriakis JM, 1996, BIOESSAYS, V18, P567, DOI 10.1002/bies.950180708; Lakshminarayanan V, 1998, J BIOL CHEM, V273, P32670, DOI 10.1074/jbc.273.49.32670; Lakshminarayanan V, 1997, J BIOL CHEM, V272, P32910, DOI 10.1074/jbc.272.52.32910; Lalani EN, 1999, LAB INVEST, V79, P537; Leong KG, 2000, HISTOL HISTOPATHOL, V15, P1303, DOI 10.14670/HH-15.1303; LIBERMANN TA, 1990, MOL CELL BIOL, V10, P2327, DOI 10.1128/MCB.10.5.2327; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; MARTINYBARON G, 1993, J BIOL CHEM, V268, P9194; MATSUSAKA T, 1993, P NATL ACAD SCI USA, V90, P10193, DOI 10.1073/pnas.90.21.10193; Monton C, 1998, Monaldi Arch Chest Dis, V53, P56; MUKAIDA N, 1990, J BIOL CHEM, V265, P21128; NAKAJIMA T, 1993, P NATL ACAD SCI USA, V90, P2207, DOI 10.1073/pnas.90.6.2207; NAKAMURA H, 1991, J BIOL CHEM, V266, P19611; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; Oertel M, 2001, AM J RESP CELL MOL, V25, P418, DOI 10.1165/ajrcmb.25.4.4429; Pitman RS, 2000, J GASTROENTEROL, V35, P805, DOI 10.1007/s005350070017; Quay JL, 1998, AM J RESP CELL MOL, V19, P98, DOI 10.1165/ajrcmb.19.1.3132; REDDEL RR, 1988, CANCER RES, V48, P1904; Reibman J, 2000, J IMMUNOL, V165, P1618, DOI 10.4049/jimmunol.165.3.1618; Remacle-Bonnet MM, 2000, CANCER RES, V60, P2007; Richards CD, 1998, CYTOKINES, P87, DOI 10.1016/B978-012498340-3/50007-5; Roebuck KA, 1999, J INTERF CYTOK RES, V19, P429, DOI 10.1089/107999099313866; Romashkova JA, 1999, NATURE, V401, P86, DOI 10.1038/43474; Taupin D, 1999, J CLIN INVEST, V103, pR31, DOI 10.1172/JCI3304; Taupin DR, 2000, P NATL ACAD SCI USA, V97, P799, DOI 10.1073/pnas.97.2.799; Thim L, 1997, CELL MOL LIFE SCI, V53, P888, DOI 10.1007/s000180050108; THIM L, 1993, FEBS LETT, V318, P345, DOI 10.1016/0014-5793(93)80543-4; THIM L, 1995, BIOCHEMISTRY-US, V34, P4757, DOI 10.1021/bi00014a033; Thim L, 2000, REGUL PEPTIDES, V90, P61, DOI 10.1016/S0167-0115(00)00110-5; TOMASETTO C, 1990, EMBO J, V9, P407, DOI 10.1002/j.1460-2075.1990.tb08125.x; Tomasetto C, 2000, GASTROENTEROLOGY, V118, P70, DOI 10.1016/S0016-5085(00)70415-X; Van Linden AA, 2000, J BIOL CHEM, V275, P6996, DOI 10.1074/jbc.275.10.6996; VANDENABEELE P, 1995, TRENDS CELL BIOL, V5, P392, DOI 10.1016/S0962-8924(00)89088-1; VASALLI P, 1992, ANNU REV IMMUNOL, V10, P411; Wiede A, 1999, AM J RESP CRIT CARE, V159, P1330, DOI 10.1164/ajrccm.159.4.9804149; WILKINSON SE, 1993, BIOCHEM J, V294, P335, DOI 10.1042/bj2940335; Williams R, 1996, J CELL SCI, V109, P63; Wright NA, 1998, PHILOS T R SOC B, V353, P925, DOI 10.1098/rstb.1998.0257; Wright NA, 1997, FEBS LETT, V408, P121, DOI 10.1016/S0014-5793(97)00424-9; Wyatt TA, 1997, AM J PHYSIOL-LUNG C, V273, pL1007, DOI 10.1152/ajplung.1997.273.5.L1007; Xing Z, 1999, HISTOL HISTOPATHOL, V14, P185, DOI 10.14670/HH-14.185; Yuasa T, 1998, J BIOL CHEM, V273, P22681, DOI 10.1074/jbc.273.35.22681; Zhao DZ, 2001, J BIOL CHEM, V276, P44464, DOI 10.1074/jbc.M104942200	75	80	84	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 24	2002	277	21					18440	18446		10.1074/jbc.M200468200	http://dx.doi.org/10.1074/jbc.M200468200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	558PM	11884401	hybrid			2022-12-27	WOS:000175975800025
J	Lee, JH; Koo, TH; Hwang, BY; Lee, JJ				Lee, JH; Koo, TH; Hwang, BY; Lee, JJ			Kaurane diterpene, kamebakaurin, inhibits NF-kappa B by directly targeting the DNA-binding activity of p50 and blocks the expression of antiapoptotic NF-kappa B target genes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; SESQUITERPENE LACTONES; PROTEASOME PATHWAY; INDUCED APOPTOSIS; NITRIC-OXIDE; ACTIVATION; PROTEINS; SUBUNIT; KINASE; CELLS	Kaurane diterpenes have been identified from numerous medicinal plants, which have been used for treatment of inflammation and cancer, however, their molecular mechanism of action remains unclear. We have previously shown that kamebakaurin and other three kaurane diterpenes selectively inhibit activation of transcription factor NF-kappaB, a central mediator of apoptosis and immune responses. We here demonstrate that kamebakaurin is a potent inhibitor of NF-kappaB activation by directly targeting DNA-binding activity of p50. Kamebakaurin prevented the activation of NF-kappaB by different stimuli in various cell types. Kamebakaurin did not prevent either stimuli-induced degradation of IkappaB-alpha or nuclear translocation of NF-kappaB, however, it significantly interfered DNA binding activity of activated NF-kappaB in cell and in vitro and preferentially prevented p50-mediated DNA-binding activity of NF-kappaB rather than that of RelA as measured using in vitro translated p50 and RelA proteins. Moreover, a p50 mutant with a Cys-62 --> Ser mutation was not inhibited with kamebakaurin, indicating that the effect of kamebakaurin was probably due to its interaction with cysteine 62 in p50. The covalent modification of p50 by kamebakaurin was further demonstrated by mass spectrometry analysis that showed an increase in the molecular mass of kamebakaurin-treated p50, and this modification was not reverted by addition of dithiothreitol. These results suggested that kamebakaurin exhibited its inhibitory activity by a direct covalent modification of cysteine 62 in the p50. Also, treatment of cells with kamebakaurin prevented the tumor necrosis factor-alpha (TNF-alpha)-induced expression of antiapoptotic NF-kappaB target genes encoding c-IAP1 (hiap-2) and c-IAP2 (hiap-1), members of the inhibitor of apoptosis family, and Bfl-1/A1, a prosurvival Bcl-2 homologue, and augmented the TNF-alpha-induced caspase 8 activity, thereby resulting in sensitizing MCF-7 cells to TNF-alpha-induced apoptosis. Taken together, kamebakaurin is a valuable candidate for the intervention of NF-kappaB-dependent pathological conditions such as inflammation and cancer.	Korea Res Inst Biosci & Biotechnol, Anticanc Res Lab, Yuseong 305600, Daejeon, South Korea	Korea Research Institute of Bioscience & Biotechnology (KRIBB)	Lee, JJ (corresponding author), Korea Res Inst Biosci & Biotechnol, Anticanc Res Lab, POB 115, Yuseong 305600, Daejeon, South Korea.	jjlee@mail.kribb.re.kr						ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; BAEUERLE PA, 1989, GENE DEV, V3, P1689, DOI 10.1101/gad.3.11.1689; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; BALLARD DW, 1992, P NATL ACAD SCI USA, V89, P1875, DOI 10.1073/pnas.89.5.1875; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; Castrillo A, 2001, J BIOL CHEM, V276, P15854, DOI 10.1074/jbc.M100010200; Cernuda-Morollon E, 2001, J BIOL CHEM, V276, P35530, DOI 10.1074/jbc.M104518200; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; FUJITA E, 1976, CHEM PHARM BULL, V24, P2118; FUJITA T, 1988, PLANTA MED, P414, DOI 10.1055/s-2006-962485; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Griscavage JM, 1996, P NATL ACAD SCI USA, V93, P3308, DOI 10.1073/pnas.93.8.3308; Heck S, 1997, EMBO J, V16, P4698, DOI 10.1093/emboj/16.15.4698; Hehner SP, 1998, J BIOL CHEM, V273, P1288, DOI 10.1074/jbc.273.3.1288; HENKEL T, 1992, CELL, V68, P1121, DOI 10.1016/0092-8674(92)90083-O; Hwang BY, 2001, PLANTA MED, V67, P406, DOI 10.1055/s-2001-15808; Klatt P, 2000, BIOCHEM J, V349, P567, DOI 10.1042/0264-6021:3490567; KRIKOS A, 1992, J BIOL CHEM, V267, P17971; KUMAR S, 1992, MOL CELL BIOL, V12, P3094, DOI 10.1128/MCB.12.7.3094; Kwok BHB, 2001, CHEM BIOL, V8, P759, DOI 10.1016/S1074-5521(01)00049-7; Lee KY, 1999, J BIOL CHEM, V274, P13451, DOI 10.1074/jbc.274.19.13451; Lyss G, 1998, J BIOL CHEM, V273, P33508, DOI 10.1074/jbc.273.50.33508; Marshall HE, 2001, BIOCHEMISTRY-US, V40, P1688, DOI 10.1021/bi002239y; Matthews JR, 1996, NUCLEIC ACIDS RES, V24, P2236, DOI 10.1093/nar/24.12.2236; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; MIHM S, 1991, AIDS, V5, P497, DOI 10.1097/00002030-199105000-00004; MULLER CW, 1995, NATURE, V373, P311, DOI 10.1038/373311a0; Rungeler P, 1999, BIOORGAN MED CHEM, V7, P2343, DOI 10.1016/S0968-0896(99)00195-9; SCHERER DC, 1995, P NATL ACAD SCI USA, V92, P11259, DOI 10.1073/pnas.92.24.11259; SCHMITZ ML, 1991, EMBO J, V10, P3805, DOI 10.1002/j.1460-2075.1991.tb04950.x; SCHRECK R, 1992, J EXP MED, V175, P1181, DOI 10.1084/jem.175.5.1181; SINGH S, 1995, J BIOL CHEM, V270, P24995, DOI 10.1074/jbc.270.42.24995; TAKEDA Y, 1987, J CHEM SOC PERK T 1, P2403, DOI 10.1039/p19870002403; Tang W, 1992, CHINESE DRUGS PLANT, P817; TOLEDANO MB, 1993, MOL CELL BIOL, V13, P852, DOI 10.1128/MCB.13.2.852; TRAENCKNER EBM, 1994, EMBO J, V13, P5433, DOI 10.1002/j.1460-2075.1994.tb06878.x; VAN AD, 1996, SCIENCE, V274, P787; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Wu MX, 1998, SCIENCE, V281, P998, DOI 10.1126/science.281.5379.998; Yamaoka S, 1998, CELL, V93, P1231, DOI 10.1016/S0092-8674(00)81466-X; Zong WX, 1999, GENE DEV, V13, P382, DOI 10.1101/gad.13.4.382	44	136	142	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 24	2002	277	21					18411	18420		10.1074/jbc.M201368200	http://dx.doi.org/10.1074/jbc.M201368200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	558PM	11877450	hybrid			2022-12-27	WOS:000175975800022
J	Santos, M; Paramio, JM; Bravo, A; Ramirez, A; Jorcano, JL				Santos, M; Paramio, JM; Bravo, A; Ramirez, A; Jorcano, JL			The expression of keratin K10 in the basal layer of the epidermis inhibits cell proliferation and prevents skin tumorigenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-B; TRANSGENIC MOUSE SKIN; TUMOR-SUPPRESSOR PTEN; GROWTH-FACTOR-I; PHOSPHATIDYLINOSITOL 3-KINASE; INTERMEDIATE FILAMENTS; EPIDERMOLYTIC HYPERKERATOSIS; GENE-EXPRESSION; MICE; DIFFERENTIATION	Forced expression of K10, a keratin normally expressed in postmitotic, terminally differentiating epidermal keratinocytes, inhibits the progression of the cell cycle in cultured cells (Paramio, J. M., Casanova, M. Ll., Segrelles, C., Mittnacht, S., Lane, E. B., and Jorcano, J. L. (1999) Mol CelL Biol. 19, 3086-3094). This process requires a functional retinoblastoma (pRb) gene product and is mediated by K10-induced inhibition of Akt and PKCzeta, two signaling intermediates belonging to the phosphoinositide (PI) 3-kinase signal transduction pathway (Paramio, J. M., Segrelles, C., Ruiz, S., and Jorcano, J. L. (2001) Mol. Cell Biol. 21, 7449-7459). Extending earlier in vitro studies to the in vivo situation, this work analyzes the alterations found in transgemic mice that ectopically express K10 in the proliferative basal cells of the epidermis. Increased expression of K10 led to a hypoplasic and hyperkeratotic epidermis due to a dramatic decrease in skin keratinocyte proliferation in association with the inhibition of Akt and PKCzeta activities. The inhibition of cell proliferation and Akt and PKCzeta activities was also observed although to a minor extent in low hK10-expressing mice. These animals displayed no overt epidermal phenotype nor overexpression of K10. In these non-phenotypic mice, ectopic K10 expression also resulted in decreased skin tumorigenesis. Collectively, these data demonstrate that keratin K10 in vivo functions include the control of epithelial proliferation in skin epidermis.	CIEMAT, Project Cell & Mol Biol & Gene Therapy, E-28040 Madrid, Spain; Univ Santiago Compostela, Sch Vet, Dept Anim Pathol, E-27002 Lugo, Spain	Centro de Investigaciones Energeticas, Medioambientales Tecnologicas; Universidade de Santiago de Compostela	Paramio, JM (corresponding author), CIEMAT, Project Cell & Mol Biol & Gene Therapy, Av Complutense 22, E-28040 Madrid, Spain.		Santos, Mirentxu/AAA-1727-2020; Paramio, Jesus M/M-8482-2014; Ramirez, Angel/A-4800-2018; Moral, Ana María Bravo/AAD-3339-2021	Paramio, Jesus M/0000-0001-7520-3177; Ramirez, Angel/0000-0001-7745-5108; Moral, Ana María Bravo/0000-0002-5282-8921				ALBERS KM, 1995, J CELL BIOL, V128, P157, DOI 10.1083/jcb.128.1.157; Alt JR, 2000, GENE DEV, V14, P3102, DOI 10.1101/gad.854900; Bakin AV, 2000, J BIOL CHEM, V275, P36803, DOI 10.1074/jbc.M005912200; Bang OS, 2001, J CELL SCI, V114, P81; BLESSING M, 1993, J CELL BIOL, V120, P743, DOI 10.1083/jcb.120.3.743; Brennan P, 1997, IMMUNITY, V7, P679, DOI 10.1016/S1074-7613(00)80388-X; Casanova ML, 1999, J CLIN INVEST, V103, P1587, DOI 10.1172/JCI5343; Caulin C, 2000, J CELL BIOL, V149, P17, DOI 10.1083/jcb.149.1.17; CHENG J, 1992, CELL, V70, P811, DOI 10.1016/0092-8674(92)90314-3; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; DiGiovanni J, 2000, CANCER RES, V60, P1561; EICHNER R, 1986, J CELL BIOL, V102, P1767, DOI 10.1083/jcb.102.5.1767; FUCHS E, 1980, CELL, V19, P1033, DOI 10.1016/0092-8674(80)90094-X; FUCHS E, 1994, ANNU REV BIOCHEM, V63, P345, DOI 10.1146/annurev.biochem.63.1.345; FUCHS E, 1992, P NATL ACAD SCI USA, V89, P6906, DOI 10.1073/pnas.89.15.6906; FUCHS EV, 1997, MOL BIOL CELL, V69, P899; Fukumoto S, 2001, J BIOL CHEM, V276, P17479, DOI 10.1074/jbc.C000880200; Gilbert S, 2001, J CELL BIOL, V154, P763, DOI 10.1083/jcb.200102130; HENNINGS H, 1980, CELL, V19, P245, DOI 10.1016/0092-8674(80)90406-7; Inada H, 2001, J CELL BIOL, V155, P415, DOI 10.1083/jcb.200103078; Irvine AD, 1999, BRIT J DERMATOL, V140, P815, DOI 10.1046/j.1365-2133.1999.02810.x; Jiang BH, 1999, P NATL ACAD SCI USA, V96, P2077, DOI 10.1073/pnas.96.5.2077; Klippel A, 1998, MOL CELL BIOL, V18, P5699, DOI 10.1128/MCB.18.10.5699; Ku NO, 1998, EMBO J, V17, P1892, DOI 10.1093/emboj/17.7.1892; Kulik G, 1998, MOL CELL BIOL, V18, P6711, DOI 10.1128/MCB.18.11.6711; LEDER A, 1990, P NATL ACAD SCI USA, V87, P9178, DOI 10.1073/pnas.87.23.9178; Liao J, 1996, J CELL BIOL, V133, P345, DOI 10.1083/jcb.133.2.345; LLOYD C, 1995, J CELL BIOL, V129, P1329, DOI 10.1083/jcb.129.5.1329; MCLEAN WHI, 1995, CURR OPIN CELL BIOL, V7, P118; Okano J, 2000, J BIOL CHEM, V275, P30934, DOI 10.1074/jbc.M004112200; OMARY MB, 1992, J CELL BIOL, V117, P583, DOI 10.1083/jcb.117.3.583; Paladini RD, 1999, J CELL BIOL, V146, P1185, DOI 10.1083/jcb.146.5.1185; Paladini RD, 1998, J CELL BIOL, V142, P1035, DOI 10.1083/jcb.142.4.1035; Paramio JM, 1999, MOL CELL BIOL, V19, P3086; Paramio JM, 1999, ONCOGENE, V18, P7462, DOI 10.1038/sj.onc.1203151; PARAMIO JM, 1994, EXP CELL RES, V215, P319, DOI 10.1006/excr.1994.1348; Paramio JM, 2001, J BIOL CHEM, V276, P44203, DOI 10.1074/jbc.M105650200; Paramio JM, 2001, MOL CELL BIOL, V21, P7449, DOI 10.1128/MCB.21.21.7449-7459.2001; Paramio JM, 1998, ONCOGENE, V17, P949, DOI 10.1038/sj.onc.1202031; RAMIREZ A, 1994, DIFFERENTIATION, V58, P53, DOI 10.1007/s002580050065; RAMIREZ A, 1995, P NATL ACAD SCI USA, V92, P4783, DOI 10.1073/pnas.92.11.4783; Ramirez A, 2001, GENETICS, V158, P341; Reichelt J, 2001, MOL BIOL CELL, V12, P1557, DOI 10.1091/mbc.12.6.1557; Robles AI, 1998, GENE DEV, V12, P2469, DOI 10.1101/gad.12.16.2469; Rommel C, 1999, SCIENCE, V286, P1738, DOI 10.1126/science.286.5445.1738; ROOP DR, 1988, CANCER RES, V48, P3245; Roussel MF, 1999, ONCOGENE, V18, P5311, DOI 10.1038/sj.onc.1202998; Santos M, 1997, MOL CARCINOGEN, V20, P3, DOI 10.1002/(SICI)1098-2744(199709)20:1<3::AID-MC2>3.0.CO;2-R; Sasaki T, 2000, SCIENCE, V287, P1040, DOI 10.1126/science.287.5455.1040; Segrelles C, 2002, ONCOGENE, V21, P53, DOI 10.1038/sj.onc.1205032; Sharpless NE, 1999, CURR OPIN GENET DEV, V9, P22, DOI 10.1016/S0959-437X(99)80004-5; Sibilia M, 2000, CELL, V102, P211, DOI 10.1016/S0092-8674(00)00026-X; TAKAHASHI K, 1994, J CELL BIOL, V127, P505, DOI 10.1083/jcb.127.2.505; Tamura M, 1998, SCIENCE, V280, P1614, DOI 10.1126/science.280.5369.1614; Tamura M, 1999, CANCER RES, V59, P442; Vandromme M, 2001, J BIOL CHEM, V276, P8173, DOI 10.1074/jbc.M005587200; Wan YS, 2001, INT J ONCOL, V18, P461; Wawersik M, 2000, MOL BIOL CELL, V11, P3315, DOI 10.1091/mbc.11.10.3315; WEISS RA, 1984, J CELL BIOL, V98, P1397, DOI 10.1083/jcb.98.4.1397	59	86	89	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 24	2002	277	21					19122	19130		10.1074/jbc.M201001200	http://dx.doi.org/10.1074/jbc.M201001200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	558PM	11889133	hybrid			2022-12-27	WOS:000175975800114
J	Smirnov, SP; McDearmon, EL; Li, SH; Ervasti, JM; Tryggvason, K; Yurchenco, PD				Smirnov, SP; McDearmon, EL; Li, SH; Ervasti, JM; Tryggvason, K; Yurchenco, PD			Contributions of the LG modules and furin processing to laminin-2 functions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONGENITAL MUSCULAR-DYSTROPHY; EXTRAEMBRYONIC ENDODERMAL CELLS; ALPHA-DYSTROGLYCAN BINDING; BASEMENT-MEMBRANES; ALPHA-7-BETA-1 INTEGRIN; HEPARIN-BINDING; SHORT-ARM; MEROSIN; RECEPTOR; CHAIN	The alpha2-laminin subunit contributes to basement membrane functions in muscle, nerve, and other tissues, and mutations in its gene are causes of congenital muscular dystrophy. The alpha2 G-domain modules, mutated in several of these disorders, are thought to mediate different cellular interactions. To analyze these contributions, we expressed recombinant laminin-2 (alpha(2)beta(1)gamma(1)) with LG4-5, LG1-3, and LG1-5 modular deletions. Wild-type and LG4-5 deleted-laminins were isolated from medium intact and cleaved within LG3 by a furin-like convertase. Myoblasts adhered predominantly through LG1-3 while alpha-dystroglycan bound to both LG1-3 and LG4-5. Recombinant laminin stimulated acetylcholine receptor (AChR) clustering; however, clustering was induced only by the proteolytic processed form, even in the absence of LG4-5. Furthermore, clustering required alpha(6)beta(1) integrin and alpha-dystroglycan binding activities available on LG1-3, acting in concert with laminin polymerization. The ability of the modified laminins to mediate basement membrane assembly was also evaluated in embryoid bodies where it was found that both LG1-3 and LG4-5, but not processing, were required. In conclusion, there is a division of labor among LG-modules in which (i) LG4-5 is required for basement membrane assembly but not for AChR clustering, and (ii) laminin-induced AChR clustering requires furin cleavage of LG3 as well as alpha-dystroglycan and alpha(6)beta(1) integrin binding.	Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Pathol & Lab Med, Piscataway, NJ 08854 USA; Univ Wisconsin, Dept Physiol, Madison, WI 53706 USA; Karolinska Inst, Dept Med Biochem & Biophys, S-17177 Stockholm, Sweden	Rutgers State University New Brunswick; Rutgers State University Medical Center; University of Wisconsin System; University of Wisconsin Madison; Karolinska Institutet	Yurchenco, PD (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Pathol & Lab Med, Piscataway, NJ 08854 USA.		Ervasti, James/AAZ-4786-2020	Yurchenco, Peter/0000-0003-0387-2317	NIAMS NIH HHS [ARO1985] Funding Source: Medline; NIDDK NIH HHS [DK36425] Funding Source: Medline; NINDS NIH HHS [NS38469] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [K02AR001985] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK036425, R01DK036425] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS038469] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Burkin DJ, 2001, J CELL BIOL, V152, P1207, DOI 10.1083/jcb.152.6.1207; Burkin DJ, 1998, J CELL BIOL, V143, P1067, DOI 10.1083/jcb.143.4.1067; Burkin DJ, 2000, J CELL SCI, V113, P2877; Cheng YS, 1997, J BIOL CHEM, V272, P31525, DOI 10.1074/jbc.272.50.31525; Cohen MW, 1997, J CELL BIOL, V136, P1047, DOI 10.1083/jcb.136.5.1047; Colognato H, 2000, DEV DYNAM, V218, P213, DOI 10.1002/(SICI)1097-0177(200006)218:2<213::AID-DVDY1>3.0.CO;2-R; Colognato H, 1999, J CELL BIOL, V145, P619, DOI 10.1083/jcb.145.3.619; COLOGNATOPYKE H, 1995, J BIOL CHEM, V270, P9398, DOI 10.1074/jbc.270.16.9398; Cote PD, 2002, J BIOL CHEM, V277, P4672, DOI 10.1074/jbc.M106879200; Cote PD, 1999, NAT GENET, V23, P338, DOI 10.1038/15519; Edwards JP, 1998, BRAIN RES, V788, P262, DOI 10.1016/S0006-8993(98)00010-9; EHRIG K, 1990, P NATL ACAD SCI USA, V87, P3264, DOI 10.1073/pnas.87.9.3264; Feltri ML, 2002, J CELL BIOL, V156, P199, DOI 10.1083/jcb.200109021; Guicheney P, 1997, NEUROMUSCULAR DISORD, V7, P180, DOI 10.1016/S0960-8966(97)00460-4; Jacobson C, 2001, J CELL BIOL, V152, P435, DOI 10.1083/jcb.152.3.435; Kuang W, 1998, J CLIN INVEST, V102, P844, DOI 10.1172/JCI3705; Kuang W, 1999, LAB INVEST, V79, P1601; LAW PK, 1983, EXP NEUROL, V80, P361, DOI 10.1016/0014-4886(83)90289-3; LEIVO I, 1988, P NATL ACAD SCI USA, V85, P1544, DOI 10.1073/pnas.85.5.1544; Mallet WG, 1999, J CELL BIOL, V146, P345, DOI 10.1083/jcb.146.2.345; Matsumura K, 1997, NEUROMUSCULAR DISORD, V7, P7, DOI 10.1016/S0960-8966(96)00402-6; MCMAHAN UJ, 1990, COLD SPRING HARB SYM, V55, P407; Montanaro F, 1998, J NEUROSCI, V18, P1250; Montanaro F, 1999, J CELL BIOL, V145, P1325, DOI 10.1083/jcb.145.6.1325; Murray P, 2000, J CELL BIOL, V150, P1215, DOI 10.1083/jcb.150.5.1215; Murray P, 2001, J CELL SCI, V114, P931; Murray P, 2001, MECH DEVELOP, V101, P213, DOI 10.1016/S0925-4773(00)00554-2; Pall EA, 1996, J BIOL CHEM, V271, P3817; Patton BL, 1997, J CELL BIOL, V139, P1507, DOI 10.1083/jcb.139.6.1507; PIKKARAINEN T, 1987, J BIOL CHEM, V262, P10454; PIKKARAINEN T, 1992, EUR J BIOCHEM, V209, P571, DOI 10.1111/j.1432-1033.1992.tb17322.x; PIKKARAINEN T, 1988, J BIOL CHEM, V263, P6751; Rambukkana A, 1998, SCIENCE, V282, P2076, DOI 10.1126/science.282.5396.2076; Sewry CA, 1997, NEUROPEDIATRICS, V28, P217, DOI 10.1055/s-2007-973703; Smyth N, 1999, J CELL BIOL, V144, P151, DOI 10.1083/jcb.144.1.151; Sugiyama JE, 1997, J CELL BIOL, V139, P181, DOI 10.1083/jcb.139.1.181; SUNG U, 1993, J CELL BIOL, V123, P1255, DOI 10.1083/jcb.123.5.1255; Talts JF, 1999, FEBS LETT, V458, P319, DOI 10.1016/S0014-5793(99)01180-1; Talts JF, 1998, FEBS LETT, V426, P71, DOI 10.1016/S0014-5793(98)00312-3; Tisi D, 2000, EMBO J, V19, P1432, DOI 10.1093/emboj/19.7.1432; TREMBLAY JP, 1988, SYNAPSE, V2, P148, DOI 10.1002/syn.890020206; Tsiper MV, 2002, J CELL SCI, V115, P1005; VUOLTEENAHO R, 1994, J CELL BIOL, V124, P381, DOI 10.1083/jcb.124.3.381; Yurchenco PD, 1997, P NATL ACAD SCI USA, V94, P10189, DOI 10.1073/pnas.94.19.10189; YURCHENCO PD, 1993, J BIOL CHEM, V268, P17286	45	77	80	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 24	2002	277	21					18928	18937		10.1074/jbc.M201880200	http://dx.doi.org/10.1074/jbc.M201880200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	558PM	11886875	hybrid			2022-12-27	WOS:000175975800089
J	Tarumi, T; Kravtsov, DV; Zhao, MM; Williams, SM; Gailani, D				Tarumi, T; Kravtsov, DV; Zhao, MM; Williams, SM; Gailani, D			Cloning and characterization of the human factor XI gene promoter - Transcription factor hepatocyte nuclear factor 4 alpha (HNF-4 alpha) is required for hepatocyte-specific expression of factor XI	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BLOOD-COAGULATION FACTOR; HUMAN-PLASMA PREKALLIKREIN; HEMOPHILIA-B LEYDEN; ACYL-COA THIOESTERS; BINDING-SITE; RECEPTOR SUPERFAMILY; FACTOR HNF-4; DEFICIENCY; IDENTIFICATION; FAMILY	Factor XI is the zymogen of a plasma protease produced primarily in liver that is required for normal blood coagulation. We cloned similar to2600 base pairs of the human factor XI gene upstream of exon one, identified transcription start sites, and conducted a functional analysis. Luciferase reporter assays demonstrate that the 381 base pairs upstream of exon one are sufficient for maximum promoter activity in HepG2 hepatocellular carcinoma cells. The removal of 19 base pairs between -381 and -363 results in a nearly complete loss of promoter activity. This region contains the sequence ACTTTG, a motif required for binding of the transcription factor hepatocyte nuclear factor 4alpha (HNF-4alpha) to the promoters of several genes. Gel mobility shift assays using HepG2 or rat hepatocyte nuclear extract confirm HNF-4alpha binds between bp -375 and -360. Scrambling the ACTTTG motif completely abolishes promoter activity in luciferase assays. The factor XI promoter functions poorly when transfected into HeLa carcinoma cells, and gel mobility shift experiments with HeLa nuclear extracts demonstrate no HNF-4alpha binding to the ACTTTG sequence. When a rat HNF-4alpha expression construct is co-transfected into HeLa cells, factor XI promoter activity is enhanced similar to10-fold. We conclude that HNF-4alpha is required for hepatocyte-specific expression of factor XI.	Vanderbilt Univ, Div Hematol Oncol, Dept Pathol, Nashville, TN 37232 USA; Vanderbilt Univ, Dept Med, Nashville, TN 37232 USA; Meharry Med Coll, Dept Microbiol, Nashville, TN 37208 USA	Vanderbilt University; Vanderbilt University; Meharry Medical College	Gailani, D (corresponding author), Vanderbilt Univ, Div Hematol Oncol, Dept Pathol, 777 Preston Res Bldg,2220 Pierce Ave, Nashville, TN 37232 USA.	dave.gailani@mcmail.vanderbilt.edu	Williams, Scott/B-9491-2012; Williams, Scott/Q-4812-2019	Williams, Scott/0000-0002-4835-9544	NHLBI NIH HHS [HL58837] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058837] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Arbini AA, 1997, BLOOD, V89, P176, DOI 10.1182/blood.V89.1.176.176_176_182; ASAKAI R, 1987, BIOCHEMISTRY-US, V26, P7221, DOI 10.1021/bi00397a004; ASAKAI R, 1991, NEW ENGL J MED, V325, P153, DOI 10.1056/NEJM199107183250303; BANCROFT JD, 1992, BIOCHEMISTRY-US, V31, P12469, DOI 10.1021/bi00164a025; BEAUBIEN G, 1991, BIOCHEMISTRY-US, V30, P1628, DOI 10.1021/bi00220a027; Carew JA, 2000, BLOOD, V96, P4370; Chan JCY, 2001, AM J PATHOL, V158, P469, DOI 10.1016/S0002-9440(10)63989-2; CHUNG DW, 1986, BIOCHEMISTRY-US, V25, P2410, DOI 10.1021/bi00357a017; Colman R. W., 2001, HEMOSTASIS THROMBOSI, P103; COSTA RH, 1989, MOL CELL BIOL, V9, P1415, DOI 10.1128/MCB.9.4.1415; CROSSLEY M, 1992, SCIENCE, V257, P377, DOI 10.1126/science.1631558; DAVIE EW, 1991, BIOCHEMISTRY-US, V30, P10363, DOI 10.1021/bi00107a001; de Visser MCH, 2001, THROMB HAEMOSTASIS, V85, P1011; Degen JL, 2001, THROMB HAEMOSTASIS, V86, P130; Degen SJF, 1998, CRIT REV EUKAR GENE, V8, P203, DOI 10.1615/CritRevEukarGeneExpr.v8.i2.60; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Duncan SA, 1997, DEVELOPMENT, V124, P279; DZIK WH, 1987, NEW ENGL J MED, V316, P1217; ERDMANN D, 1995, J BIOL CHEM, V270, P22988, DOI 10.1074/jbc.270.39.22988; FUJIKAWA K, 1986, BIOCHEMISTRY-US, V25, P2417, DOI 10.1021/bi00357a018; FURIE B, 1992, NEW ENGL J MED, V326, P800; Gailani D, 1997, BLOOD, V90, P1055, DOI 10.1182/blood.V90.3.1055.1055_1055_1064; GAILANI D, 2001, METABOLIC MOL BASIS, V3, P4433; Greenberg D, 1995, P NATL ACAD SCI USA, V92, P12347, DOI 10.1073/pnas.92.26.12347; Greenberg D L, 2001, HEMOSTASIS THROMBOSI, P21; HadzopoulouCladaras M, 1997, J BIOL CHEM, V272, P539; Hertz R, 1998, NATURE, V392, P512, DOI 10.1038/33185; Hertz R, 2001, BIOCHEM PHARMACOL, V61, P1057, DOI 10.1016/S0006-2952(01)00578-0; HUANG MN, 1992, J BIOL CHEM, V267, P15440; Hung HL, 1996, J BIOL CHEM, V271, P2323, DOI 10.1074/jbc.271.4.2323; Iacoviello L, 1998, NEW ENGL J MED, V338, P79, DOI 10.1056/NEJM199801083380202; KATO A, 1989, CYTOGENET CELL GENET, V52, P77, DOI 10.1159/000132844; KUO CJ, 1992, NATURE, V355, P457, DOI 10.1038/355457a0; LADIAS JAA, 1992, J BIOL CHEM, V267, P15849; Li JX, 2000, GENE DEV, V14, P464; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; Martincic D, 1998, BLOOD, V92, P3309, DOI 10.1182/blood.V92.9.3309.421k36_3309_3317; MEADE TW, 1986, LANCET, V2, P533, DOI 10.1016/S0140-6736(86)90111-X; Meijers JCM, 2000, NEW ENGL J MED, V342, P696, DOI 10.1056/NEJM200003093421004; MILLS KA, 1995, MAMM GENOME, V6, P278, DOI 10.1007/BF00352416; MIQUEROL L, 1994, J BIOL CHEM, V269, P8944; Neth P, 2001, THROMB HAEMOSTASIS, V85, P1043, DOI 10.1055/s-0037-1615961; OHKUBO Y, 1990, THROMB HAEMOSTASIS, V63, P417; PATTHY L, 1990, SEMIN THROMB HEMOST, V16, P245, DOI 10.1055/s-2007-1002677; Pollak ES, 1996, J BIOL CHEM, V271, P1738, DOI 10.1074/jbc.271.3.1738; REIJNEN MJ, 1992, P NATL ACAD SCI USA, V89, P6300, DOI 10.1073/pnas.89.14.6300; REIJNEN MJ, 1993, BLOOD, V82, P151, DOI 10.1182/blood.V82.1.151.bloodjournal821151; SLADEK FM, 1990, GENE DEV, V4, P2353, DOI 10.1101/gad.4.12b.2353; SLADEK FM, 1994, LIVER GENE EXPRESSIO, P207; Sladek R, 2000, ADV PHARMACOL, V47, P23; Sun YH, 1996, J BIOL CHEM, V271, P29023, DOI 10.1074/jbc.271.46.29023; SWICK AG, 1989, NUCLEIC ACIDS RES, V17, P9291, DOI 10.1093/nar/17.22.9291; Tarumi T, 2000, GENOMICS, V70, P269, DOI 10.1006/geno.2000.6393; TIAN JM, 1991, GENE DEV, V5, P2225, DOI 10.1101/gad.5.12a.2225; Tordai H, 1999, FEBS LETT, V461, P63, DOI 10.1016/S0014-5793(99)01416-7; Vlieg AV, 2000, BLOOD, V95, P3678; XANTHOPOULOS KG, 1991, P NATL ACAD SCI USA, V88, P3807, DOI 10.1073/pnas.88.9.3807; Yu HR, 2000, GENOMICS, V69, P225, DOI 10.1006/geno.2000.6330	58	31	32	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 24	2002	277	21					18510	18516		10.1074/jbc.M201886200	http://dx.doi.org/10.1074/jbc.M201886200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	558PM	11891231	hybrid			2022-12-27	WOS:000175975800035
J	Brouard, S; Berberat, PO; Tobiasch, E; Seldon, MP; Bach, FH; Soares, MP				Brouard, S; Berberat, PO; Tobiasch, E; Seldon, MP; Bach, FH; Soares, MP			Heme oxygenase-1-derived carbon monoxide requires the activation of transcription factor NF-kappa B to protect endothelial cells from tumor necrosis factor-alpha-mediated apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ZINC FINGER PROTEIN; SUPEROXIDE-DISMUTASE; SIGNALING COMPLEX; INHIBITOR; DEATH; EXPRESSION; INDUCTION; BCL-2; GENE; PHOSPHORYLATION	We have shown that carbon monoxide (CO) generated by heme oxygenase-1 (HO-1) protects endothelial cells (EC) from tumor necrosis alpha (TNF-alpha)-mediated apoptosis. This effect relies on the activation of p38 MAPK. We now demonstrate that HO-1/CO requires the activation of the transcription factor NF-kappaB to exert this anti-apoptotic effect. Our data suggest that EC have basal levels of NF-kappaB activity that sustain the expression of NF-kappaB-dependent anti-apoptotic genes required to support the anti-apoptotic effect of HO-1/CO. Over-expression of the inhibitor of NF-kappaB alpha (IkappaBalpha) suppresses the anti-apoptotic action of HO-1/CO. Reconstitution of NF-kappaB activity, by co-expression of IkappaBalpha with different members of the NF-kappaB family, ie. p65/RelA or p65/RelA plus c-Rel, restores the anti-apoptotic effect of HO-1/CO. Expression of the NF-kappaB family members p65/RelA or p65/RelA with p50 or c-Rel up-regulates the expression of the anti-apoptotic genes A1, A20, c-LAP2, and manganese superoxide dismutase (MnSOD). Inhibition of NF-kappaB activity by overexpression of IkappaBalpha suppresses the expression of some of these anti-apoptotic genes, i.e. c-LAP2. Under inhibition of NF-kappaB, co-expression of some of these anti-apoptotic genes, ie. c-LAP2 and A1, restores the anti-apoptotic action of HO-1/CO, whereas expression of A20 or MnSOD cannot. The ability of c-IAP2 and/or A1 to restore the anti-apoptotic action of HO-1/CO is abolished when p38 MAPK activation is blocked by over-expression of a p38 MAPK dominant negative mutant. In conclusion, we demonstrate that HO-1/CO cooperates with NF-kappaB-dependent anti-apoptotic genes, i.e. c-LAP2 and A1, to protect EC from TNF-alpha-mediated apoptosis. This effect is dependent on the ability of HO-1/CO to activate the p38 MAPK signal transduction pathway.	Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Immunobiol Res Ctr,Dept Surg, Boston, MA 02115 USA; Inst Gulbenkian Ciencias, P-2781901 Oeiras, Portugal	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Instituto Gulbenkian de Ciencia	Soares, MP (corresponding author), Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Surg,Immunobiol Res Ctr, 99 Brookline Ave, Boston, MA 02215 USA.		brouard, sophie c/Q-1285-2016; Soares, Miguel P/G-4188-2011	Soares, Miguel/0000-0002-9314-4833	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058688, R01HL067040] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL58688, HL67040] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ackermann EJ, 1999, J BIOL CHEM, V274, P11245, DOI 10.1074/jbc.274.16.11245; Anrather J, 1999, J BIOL CHEM, V274, P13594, DOI 10.1074/jbc.274.19.13594; Anrather J, 1997, J CLIN INVEST, V99, P763, DOI 10.1172/JCI119222; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Badrichani AZ, 1999, J CLIN INVEST, V103, P543, DOI 10.1172/JCI2517; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BALLA G, 1992, J BIOL CHEM, V267, P18148; BALLA J, 1993, P NATL ACAD SCI USA, V90, P9285, DOI 10.1073/pnas.90.20.9285; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; Breitschopf K, 2000, MOL CELL BIOL, V20, P1886, DOI 10.1128/MCB.20.5.1886-1896.2000; Brouard S, 2000, J EXP MED, V192, P1015, DOI 10.1084/jem.192.7.1015; Carlotti F, 2000, J BIOL CHEM, V275, P41028, DOI 10.1074/jbc.M006179200; Choi AMK, 1996, AM J RESP CELL MOL, V15, P9, DOI 10.1165/ajrcmb.15.1.8679227; Chu ZL, 1997, P NATL ACAD SCI USA, V94, P10057, DOI 10.1073/pnas.94.19.10057; Cooper JT, 1996, J BIOL CHEM, V271, P18068, DOI 10.1074/jbc.271.30.18068; Deveraux QL, 1999, GENE DEV, V13, P239, DOI 10.1101/gad.13.3.239; Franzoso G, 1996, EMBO J, V15, P3403, DOI 10.1002/j.1460-2075.1996.tb00706.x; GAN HX, 1995, J IMMUNOL, V155, P1304; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Grumont RJ, 1999, GENE DEV, V13, P400, DOI 10.1101/gad.13.4.400; Hong SY, 2000, J BIOL CHEM, V275, P18022, DOI 10.1074/jbc.M001202200; Jones PL, 1997, MOL CELL BIOL, V17, P6970, DOI 10.1128/MCB.17.12.6970; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; KRIKOS A, 1992, J BIOL CHEM, V267, P17971; Lee EG, 2000, SCIENCE, V289, P2350, DOI 10.1126/science.289.5488.2350; Lee PJ, 1996, P NATL ACAD SCI USA, V93, P10393, DOI 10.1073/pnas.93.19.10393; Maines MD, 1997, ANNU REV PHARMACOL, V37, P517, DOI 10.1146/annurev.pharmtox.37.1.517; Medema JP, 1997, EMBO J, V16, P2794, DOI 10.1093/emboj/16.10.2794; Muzio M, 1996, CELL, V85, P817, DOI 10.1016/S0092-8674(00)81266-0; OPIPARI AW, 1990, J BIOL CHEM, V265, P14705; Otterbein LE, 2000, NAT MED, V6, P422, DOI 10.1038/74680; Peter ME, 1998, CURR OPIN IMMUNOL, V10, P545, DOI 10.1016/S0952-7915(98)80222-7; Petrache I, 2000, AM J PHYSIOL-LUNG C, V278, pL312, DOI 10.1152/ajplung.2000.278.2.L312; Sato K, 2001, J IMMUNOL, V166, P4185, DOI 10.4049/jimmunol.166.6.4185; Soares MP, 1998, J IMMUNOL, V161, P4572; Soares MP, 1998, NAT MED, V4, P1073, DOI 10.1038/2063; Soares MP, 2000, EMERGING THERAPEUTIC, V4, P11; STOCKER R, 1987, SCIENCE, V235, P1043, DOI 10.1126/science.3029864; Stroka DM, 1999, BLOOD, V93, P3803, DOI 10.1182/blood.V93.11.3803.411a27_3803_3810; TENHUNEN R, 1968, P NATL ACAD SCI USA, V61, P748, DOI 10.1073/pnas.61.2.748; THORNBERRY NA, 1998, SCIENCE, V281; TRAENCKNER EBM, 1995, EMBO J, V14, P2876, DOI 10.1002/j.1460-2075.1995.tb07287.x; TRAENCKNER EBM, 1994, EMBO J, V13, P5433, DOI 10.1002/j.1460-2075.1994.tb06878.x; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; WONG GHW, 1989, CELL, V58, P923, DOI 10.1016/0092-8674(89)90944-6; Wrighton CJ, 1996, J EXP MED, V183, P1013, DOI 10.1084/jem.183.3.1013; Wu MX, 1998, SCIENCE, V281, P998, DOI 10.1126/science.281.5379.998; Zong WX, 1999, GENE DEV, V13, P382, DOI 10.1101/gad.13.4.382	50	265	288	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 17	2002	277	20					17950	17961		10.1074/jbc.M108317200	http://dx.doi.org/10.1074/jbc.M108317200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	553PR	11880364	hybrid			2022-12-27	WOS:000175685100072
J	Kashiwagi, K; Shirai, Y; Kuriyama, M; Sakai, N; Saito, N				Kashiwagi, K; Shirai, Y; Kuriyama, M; Sakai, N; Saito, N			Importance of C1B domain for lipid messenger-induced targeting of protein kinase C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHORBOL ESTER BINDING; CYSTEINE-RICH DOMAINS; NERVE GROWTH-FACTOR; ARACHIDONIC-ACID; CELL-DEATH; SYNAPTIC TRANSMISSION; INDUCED TRANSLOCATION; SIGNAL TRANSDUCTION; PHOSPHOLIPASE A(2); LIVING CELLS	The molecular mechanisms by which arachidonic acid (AA) and ceramide elicit translocation of protein kinase C (PKC) were investigated. Ceramide translocated epsilonPKC from the cytoplasm to the Golgi complex, but with a mechanism distinct from that utilized by AA. Using fluorescence recovery after photobleaching, we showed that, upon treatment with AA, epsilonPKC was tightly associated with the Golgi complex; ceramide elicited an accumulation of epsilonPKC which was exchangeable with the cytoplasm. Stimulation with ceramide after AA converted the AA-induced Golgi complex staining to one elicited by ceramide alone; AA had no effect on the ceramide-stimulated localization. Using point mutants and deletions of epsilonPKC, we determined that the epsilonC1B domain was responsible for the ceramide- and AA-induced translocation. Switch chimeras, containing the C1B from epsilonPKC in the context of deltaPKC (delta(epsilonC1B)) and vice versa (epsilon(deltaC1B)), were generated and tested for their translocation in response to ceramide and AA. delta(epsilonCIB) translocated upon treatment with both ceramide and AA, epsilon(deltaC1B) responded only to ceramide. Thus, through the C1B domain, AA and ceramide induce different patterns of epsilonPKC translocation and the C1B domain defines the subtype specific sensitivity of PKCs to lipid second messengers.	Kobe Univ, Biosignal Res Ctr, Mol Pharmacol Lab, Kobe, Hyogo 6578501, Japan	Kobe University	Saito, N (corresponding author), 1-1 Rokkodai Cho,Nada Ku, Kobe, Hyogo 6578501, Japan.		Shirai, Yasuhito/O-3255-2018					AKIMOTO K, 1994, J BIOL CHEM, V269, P12677; Bittova L, 2001, J BIOL CHEM, V276, P4218, DOI 10.1074/jbc.M008491200; Bogi K, 1999, FEBS LETT, V456, P27, DOI 10.1016/S0014-5793(99)00927-8; Brann AB, 1999, J NEUROSCI, V19, P8199; DRAPEAU C, 1990, NEUROSCI LETT, V115, P286, DOI 10.1016/0304-3940(90)90470-T; Hannun YA, 1996, SCIENCE, V274, P1855, DOI 10.1126/science.274.5294.1855; HERRERO I, 1992, NATURE, V360, P163, DOI 10.1038/360163a0; Huang XP, 1997, J CELL SCI, V110, P1625; HUG H, 1993, BIOCHEM J, V291, P329, DOI 10.1042/bj2910329; Hundle B, 1997, J BIOL CHEM, V272, P15028, DOI 10.1074/jbc.272.23.15028; Huwiler A, 1998, BIOCHEMISTRY-US, V37, P14556, DOI 10.1021/bi981401i; Irie K, 1998, J AM CHEM SOC, V120, P9159, DOI 10.1021/ja981087f; Johnson JA, 1996, J BIOL CHEM, V271, P24962, DOI 10.1074/jbc.271.40.24962; Kajimoto T, 2001, MOL CELL BIOL, V21, P1769, DOI 10.1128/MCB.21.5.1769-1783.2001; KASAHARA K, 1995, J BIOCHEM-TOKYO, V117, P648, DOI 10.1093/oxfordjournals.jbchem.a124758; KAZANIETZ MG, 1995, J BIOL CHEM, V270, P21852, DOI 10.1074/jbc.270.37.21852; Llopis J, 1998, P NATL ACAD SCI USA, V95, P6803, DOI 10.1073/pnas.95.12.6803; Macdonald NJ, 1999, J NEUROSCI RES, V57, P219, DOI 10.1002/(SICI)1097-4547(19990715)57:2<219::AID-JNR7>3.0.CO;2-C; Newton AC, 1997, CURR OPIN CELL BIOL, V9, P161, DOI 10.1016/S0955-0674(97)80058-0; NEWTON AC, 1995, CURR BIOL, V5, P973, DOI 10.1016/S0960-9822(95)00191-6; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; Nojima H, 2000, BRAIN RES, V852, P233, DOI 10.1016/S0006-8993(99)02206-4; Nomura T, 2001, LIFE SCI, V68, P2885, DOI 10.1016/S0024-3205(01)01072-4; O'Flaherty JT, 2001, J BIOL CHEM, V276, P24743, DOI 10.1074/jbc.M101093200; Oancea E, 1998, J CELL BIOL, V140, P485, DOI 10.1083/jcb.140.3.485; OBEID LM, 1993, SCIENCE, V259, P1769, DOI 10.1126/science.8456305; Ohmori S, 1998, MOL CELL BIOL, V18, P5263, DOI 10.1128/MCB.18.9.5263; OKAZAKI T, 1990, J BIOL CHEM, V265, P15823; ONO Y, 1988, NUCLEIC ACIDS RES, V16, P5199, DOI 10.1093/nar/16.11.5199; ONO Y, 1989, P NATL ACAD SCI USA, V86, P4868, DOI 10.1073/pnas.86.13.4868; OSADA S, 1992, MOL CELL BIOL, V12, P3930, DOI 10.1128/MCB.12.9.3930; Prekeris R, 1998, J BIOL CHEM, V273, P26790, DOI 10.1074/jbc.273.41.26790; QUEST AFG, 1994, J BIOL CHEM, V269, P20000; SAITO N, 1993, BRAIN RES, V607, P241, DOI 10.1016/0006-8993(93)91512-Q; Sawai H, 1997, J BIOL CHEM, V272, P2452; Scorrano L, 2001, J BIOL CHEM, V276, P12035, DOI 10.1074/jbc.M010603200; SELBIE LA, 1993, J BIOL CHEM, V268, P24296; SHIEH HL, 1995, MOL CARCINOGEN, V12, P166, DOI 10.1002/mc.2940120308; Shieh HL, 1996, CANCER DETECT PREV, V20, P576; SHINOMURA T, 1991, P NATL ACAD SCI USA, V88, P5149, DOI 10.1073/pnas.88.12.5149; Shiose A, 2000, J BIOL CHEM, V275, P13793, DOI 10.1074/jbc.275.18.13793; Shirai Y, 2000, J CELL SCI, V113, P1335; Shirai Y, 1998, J CELL BIOL, V143, P511, DOI 10.1083/jcb.143.2.511; WILLIAMS JH, 1989, NATURE, V341, P739, DOI 10.1038/341739a0; Yang SN, 2000, NEUROSCIENCE, V96, P253, DOI 10.1016/S0306-4522(99)00582-5; Yao LB, 1997, J BIOL CHEM, V272, P13033, DOI 10.1074/jbc.272.20.13033; YELIN MM, 1997, MOL BIOL CELL, V8, P1889	50	67	71	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 17	2002	277	20					18037	18045		10.1074/jbc.M111761200	http://dx.doi.org/10.1074/jbc.M111761200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	553PR	11877428	hybrid			2022-12-27	WOS:000175685100082
J	Naumann, TA; Reznikoff, WS				Naumann, TA; Reznikoff, WS			Tn5 transposase active site mutants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3-DIMENSIONAL STRUCTURE; HIV-1 INTEGRASE; RESIDUES; BINDING	Tn5 transposase (Tnp) is a 53.3-kDa protein that is encoded by and facilitates movement of transposon Tn5. Tnp monomers contain a single active site that is responsible for catalyzing a series of four DNA breaking/joining reactions at one transposon end. Based on primary sequence homology and protein structural information, we designed and constructed a series of plasmids that encode for Tnps containing active site mutations. Following Tnp expression and purification, the active site mutants were tested for their ability to form protein-DNA complexes and perform each of the four catalytic steps in the transposition pathway in vitro. The results demonstrate that Asp-97, Asp-188, and Glu-326, visible in the active site of Tn5 crystal structures, are absolutely required for all catalytic steps. Mutations within a series of amino acid residues that are conserved in the IS4 family of transposases and retroviral integrases also impair Trip catalytic activity. Mutations at either Tyr-319 or Arg-322 reduce both hairpin resolution and strand transfer activity within protein-DNA complexes. Mutations at Lys-333 reduce the ability of Tnps to form protein-DNA complexes, whereas mutations at the less strongly conserved Lys-330 have less of an effect on both synaptic complex formation and catalytic activity.	Univ Wisconsin, Dept Biochem, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Reznikoff, WS (corresponding author), Univ Wisconsin, Dept Biochem, 433 Babcock Dr, Madison, WI 53706 USA.	Reznikoff@biochem.wisc.edu			NIGMS NIH HHS [GM08349, GM50692] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Allingham JS, 2001, EMBO J, V20, P2931, DOI 10.1093/emboj/20.11.2931; Allingham JS, 1999, J MOL BIOL, V289, P1195, DOI 10.1006/jmbi.1999.2837; Bhasin A, 1999, J BIOL CHEM, V274, P37021, DOI 10.1074/jbc.274.52.37021; Bhasin A, 2000, J MOL BIOL, V302, P49, DOI 10.1006/jmbi.2000.4048; Bolland S, 1996, CELL, V84, P223, DOI 10.1016/S0092-8674(00)80977-0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bujacz G, 1997, J BIOL CHEM, V272, P18161, DOI 10.1074/jbc.272.29.18161; Bujacz G, 1996, STRUCTURE, V4, P89, DOI 10.1016/S0969-2126(96)00012-3; Davies DR, 2000, SCIENCE, V289, P77, DOI 10.1126/science.289.5476.77; Davies DR, 1999, J BIOL CHEM, V274, P11904, DOI 10.1074/jbc.274.17.11904; DELONG A, 1991, P NATL ACAD SCI USA, V88, P6072, DOI 10.1073/pnas.88.14.6072; Goldgur Y, 1998, P NATL ACAD SCI USA, V95, P9150, DOI 10.1073/pnas.95.16.9150; Goryshin IY, 1998, J BIOL CHEM, V273, P7367, DOI 10.1074/jbc.273.13.7367; HANIFORD DB, 1989, CELL, V59, P385, DOI 10.1016/0092-8674(89)90299-7; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; Jenkins TM, 1997, EMBO J, V16, P6849, DOI 10.1093/emboj/16.22.6849; Kennedy AK, 1998, CELL, V95, P125, DOI 10.1016/S0092-8674(00)81788-2; Kennedy AK, 1996, J MOL BIOL, V256, P533, DOI 10.1006/jmbi.1996.0106; KREBS MP, 1988, GENE, V63, P277, DOI 10.1016/0378-1119(88)90531-8; MARTIN A, 1995, NUCLEIC ACIDS RES, V23, P1642, DOI 10.1093/nar/23.9.1642; Naumann TA, 2000, P NATL ACAD SCI USA, V97, P8944, DOI 10.1073/pnas.160107997; Reznikoff WS, 1999, BIOCHEM BIOPH RES CO, V266, P729, DOI 10.1006/bbrc.1999.1891; REZSOHAZY R, 1993, MOL MICROBIOL, V9, P1283, DOI 10.1111/j.1365-2958.1993.tb01258.x; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Steiniger-White M, 2000, J BIOL CHEM, V275, P23127, DOI 10.1074/jbc.M003411200; Tavakoli NP, 1997, J MOL BIOL, V274, P491, DOI 10.1006/jmbi.1997.1410; Twining SS, 2001, J BIOL CHEM, V276, P23135, DOI 10.1074/jbc.M010748200; WEINREICH MD, 1994, GENE DEV, V8, P2363, DOI 10.1101/gad.8.19.2363; Zhou M, 1998, J MOL BIOL, V276, P913, DOI 10.1006/jmbi.1997.1579; Zhou M, 1997, J MOL BIOL, V271, P362, DOI 10.1006/jmbi.1997.1188	30	31	36	4	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 17	2002	277	20					17623	17629		10.1074/jbc.M200742200	http://dx.doi.org/10.1074/jbc.M200742200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	553PR	11877443	hybrid			2022-12-27	WOS:000175685100031
J	Zhang, Y; Qiu, WJ; Chan, SC; Han, JH; He, X; Lin, SC				Zhang, Y; Qiu, WJ; Chan, SC; Han, JH; He, X; Lin, SC			Casein kinase I and casein kinase II differentially regulate Axin function in Wnt and JNK pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENOMATOUS POLYPOSIS-COLI; ACTIVATED PROTEIN-KINASE; BETA-CATENIN; SIGNALING PATHWAY; HEPATOCELLULAR CARCINOMAS; NEGATIVE REGULATOR; PHOSPHATASE 2A; EPSILON; PHOSPHORYLATION; TRANSCRIPTION	Axin uses different combinations of functional domains in down-regulation of the Wnt pathway and activation of the MEKK1/JNK pathway. We are interested in the elucidation of the functional switch of Axin. In the present study, we show that the Wnt activator CKIepsilon, but not CKIIalpha, Frat1, LRP5, or LRP6, inhibited Axin-mediated JNK activation. We also found that both CKIalpha and CKIepsilon interacted with Axin, whereas CKIIalpha did not bind to Axin and had no effect on Axin-mediated JNK activity even though CKIIalpha has also been suggested to be an activator for the Wnt pathway. The COOH-terminal region and the MEKK1-interacting domain of Axin are important for CKIalpha-Axin and CKIepsilon-Axin interaction. We further demonstrated that CKIepsilon and CKIalpha binding to Axin excluded MEKK1 binding, indicating that a competitive physical occupancy may underlie the inhibitory effect. Moreover, our data indicated that CKIepsilon kinase activity plays an additive role in this effect. Taken together, we have demonstrated that CKI and CKII exhibit differential effects on Axin-MEKK1 interaction and Axin-mediated JNK activation. Furthermore, our data suggest that CKI may provide a possible switch mechanism for Axin function in the regulation of Wnt and JNK pathways.	Hong Kong Univ Sci & Technol, Dept Biochem, Kowloon, Hong Kong, Peoples R China; Inst Mol & Cell Biol, Singapore 117609, Singapore; Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA; Harvard Univ, Sch Med, Childrens Hosp, Div Neurosci, Boston, MA 02115 USA	Hong Kong University of Science & Technology; Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); Scripps Research Institute; Harvard University; Boston Children's Hospital; Harvard Medical School	Lin, SC (corresponding author), Hong Kong Univ Sci & Technol, Dept Biochem, Kowloon, Hong Kong, Peoples R China.	linsc@ust.hk	Lin, SC/G-4666-2010; QIU, WENJING/GZL-9992-2022; Han, J/G-4671-2010	Zhang, Yi/0000-0003-2785-1780				Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; Brown JD, 1998, CURR OPIN CELL BIOL, V10, P182, DOI 10.1016/S0955-0674(98)80140-3; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; Cegielska A, 1998, J BIOL CHEM, V273, P1357, DOI 10.1074/jbc.273.3.1357; Clevers H, 2000, NAT GENET, V24, P206, DOI 10.1038/73396; Fagotto F, 1999, J CELL BIOL, V145, P741, DOI 10.1083/jcb.145.4.741; Farr GH, 2000, J CELL BIOL, V148, P691, DOI 10.1083/jcb.148.4.691; FISH KJ, 1995, J BIOL CHEM, V270, P14875, DOI 10.1074/jbc.270.25.14875; Fukumoto S, 2001, J BIOL CHEM, V276, P17479, DOI 10.1074/jbc.C000880200; Grietzen KF, 1999, J BIOL CHEM, V274, P32063, DOI 10.1074/jbc.274.45.32063; Hart MJ, 1998, CURR BIOL, V8, P573, DOI 10.1016/S0960-9822(98)70226-X; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Hsu W, 1999, J BIOL CHEM, V274, P3439, DOI 10.1074/jbc.274.6.3439; Ikeda S, 1998, EMBO J, V17, P1371, DOI 10.1093/emboj/17.5.1371; Itoh K, 1998, CURR BIOL, V8, P591, DOI 10.1016/S0960-9822(98)70229-5; Jonkers J, 1997, EMBO J, V16, P441, DOI 10.1093/emboj/16.3.441; Kadoya T, 2000, J BIOL CHEM, V275, P37030, DOI 10.1074/jbc.M005984200; Kishida M, 2001, J BIOL CHEM, V276, P33147, DOI 10.1074/jbc.M103555200; Kishida M, 1999, ONCOGENE, V18, P979, DOI 10.1038/sj.onc.1202388; Kishida S, 1999, MOL CELL BIOL, V19, P4414; Kishida S, 1998, J BIOL CHEM, V273, P10823, DOI 10.1074/jbc.273.18.10823; Landesman-Bollag E, 2001, ONCOGENE, V20, P3247, DOI 10.1038/sj.onc.1204411; Lowrey PL, 2000, SCIENCE, V288, P483, DOI 10.1126/science.288.5465.483; McKay RM, 2001, DEV BIOL, V235, P378, DOI 10.1006/dbio.2001.0307; McKay RM, 2001, DEV BIOL, V235, P388, DOI 10.1006/dbio.2001.0308; Molenaar M, 1996, CELL, V86, P391, DOI 10.1016/S0092-8674(00)80112-9; Neo SY, 2000, BIOCHEM BIOPH RES CO, V272, P144, DOI 10.1006/bbrc.2000.2751; Peifer M, 2000, SCIENCE, V287, P1606, DOI 10.1126/science.287.5458.1606; Peters JM, 1999, NATURE, V401, P345, DOI 10.1038/43830; Rivers A, 1998, J BIOL CHEM, V273, P15980, DOI 10.1074/jbc.273.26.15980; Rubinfeld B, 2001, J BIOL CHEM, V276, P39037, DOI 10.1074/jbc.M105148200; Sakanaka C, 2000, RECENT PROG HORM RES, V55, P225; Sakanaka C, 1998, P NATL ACAD SCI USA, V95, P3020, DOI 10.1073/pnas.95.6.3020; Sakanaka C, 1999, P NATL ACAD SCI USA, V96, P12548, DOI 10.1073/pnas.96.22.12548; Satoh S, 2000, NAT GENET, V24, P245, DOI 10.1038/73448; Seeling JM, 1999, SCIENCE, V283, P2089, DOI 10.1126/science.283.5410.2089; Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522; Song DH, 2000, J BIOL CHEM, V275, P23790, DOI 10.1074/jbc.M909107199; Spink KE, 2000, EMBO J, V19, P2270, DOI 10.1093/emboj/19.10.2270; Tamai K, 2000, NATURE, V407, P530, DOI 10.1038/35035117; Vielhaber E, 2000, MOL CELL BIOL, V20, P4888, DOI 10.1128/MCB.20.13.4888-4899.2000; Vielhaber E, 2001, IUBMB LIFE, V51, P73, DOI 10.1080/15216540152122049; Willert K, 1997, EMBO J, V16, P3089, DOI 10.1093/emboj/16.11.3089; Wodarz A, 1998, ANNU REV CELL DEV BI, V14, P59, DOI 10.1146/annurev.cellbio.14.1.59; Zeng L, 1997, CELL, V90, P181, DOI 10.1016/S0092-8674(00)80324-4; Zhang Y, 1999, J BIOL CHEM, V274, P35247, DOI 10.1074/jbc.274.49.35247; Zhang Y, 2001, J BIOL CHEM, V276, P32152, DOI 10.1074/jbc.M104451200; Zhang Y, 2000, J BIOL CHEM, V275, P25008, DOI 10.1074/jbc.M002491200	48	41	42	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 17	2002	277	20					17706	17712		10.1074/jbc.M111982200	http://dx.doi.org/10.1074/jbc.M111982200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	553PR	11884395	hybrid			2022-12-27	WOS:000175685100041
J	Zhou, NM; Luo, ZW; Luo, JS; Fan, XJ; Cayabyab, M; Hiraoka, M; Liu, DX; Han, XB; Pesavento, J; Dong, CZ; Wang, YL; An, J; Kaji, H; Sodroski, JG; Huang, ZW				Zhou, NM; Luo, ZW; Luo, JS; Fan, XJ; Cayabyab, M; Hiraoka, M; Liu, DX; Han, XB; Pesavento, J; Dong, CZ; Wang, YL; An, J; Kaji, H; Sodroski, JG; Huang, ZW			Exploring the stereochemistry of CXCR4-peptide recognition and inhibiting HIV-1 entry with D-peptides derived from chemokines	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; RECEPTOR CXCR4; SMALL-MOLECULE; CORECEPTOR ACTIVITY; BIOLOGICAL FUNCTION; MEMBRANE-FUSION; CELL-ADHESION; TROPIC HIV-1; FACTOR-I; VMIP-II	Chemokine receptor CXCR4 plays an important role in the immune system and the cellular entry of human immunodeficiency virus type 1 (HIV-1). To probe the stereospecificity of the CXCR4-ligand interface, D-amino acid peptides derived from natural chemokines, viral macrophage inflammatory protein II (vMIP-II) and stromal cell-derived factor-1alpha (SDF-1alpha), were synthesized and found to compete with I-125-SDF-1alpha and monoclonal antibody 12G5 binding to CXCR4 with potency and selectivity comparable with or higher than their L-peptide counterparts. This was surprising because of the profoundly different side chain topologies between D- and L-enantiomers, which circular dichroism spectroscopy showed adopt mirror image conformations. Further direct binding experiments using D-peptide labeled with fluorescein (designated as FAM-DV1) demonstrated that D- and L-peptides shared similar or at least overlapping binding site(s) on the CXCR4 receptor. Structure-activity analyses of related peptide analogs of mixed chiralities or containing alanine replacements revealed specific residues at the N-terminal half of the peptides as key binding determinants. Acting as CXCR4 antagonists and with much higher biological stability than L-counterparts, the D-peptides showed significant activity in inhibiting the replication of CXCR4-dependent HIV-1 strains. These results show the remarkable stereochemical flexibility of the CXCR4-peptide interface. Further studies to understand the mechanism of this unusual feature of the CXCR4 binding surface might aid the development of novel CXCR4-binding molecules like the D-peptides that have high affinity and stability.	Univ Illinois, Dept Biochem, Sch Mol & Cellular Biol, Urbana, IL 61801 USA; Thomas Jefferson Univ, Jefferson Med Coll, Dept Mol Pharmacol & Biochem, Philadelphia, PA 19107 USA; Thomas Jefferson Univ, Kimmel Canc Ctr, Philadelphia, PA 19107 USA; Harvard Univ, Sch Med, Dept Canc Immunol & AIDS, Dana Farber Canc Inst, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Dept Immunol & Infect Dis, Boston, MA 02115 USA	University of Illinois System; University of Illinois Urbana-Champaign; Jefferson University; Jefferson University; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health	Huang, ZW (corresponding author), Univ Illinois, Dept Biochem, Sch Mol & Cellular Biol, 302 Burrill Hall,MC-119,407 S Goodwin Ave, Urbana, IL 61801 USA.			Dong, Changzhi/0000-0001-7927-6306; Pesavento, James/0000-0001-6107-3666	NIAID NIH HHS [AI42848, AI24755, AI41851, AI45414] Funding Source: Medline; NIGMS NIH HHS [GM57761] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI041851, P30AI042848, R01AI024755, R37AI024755, R21AI045414] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057761] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alkhatib G, 1996, SCIENCE, V272, P1955, DOI 10.1126/science.272.5270.1955; Baba M, 1999, P NATL ACAD SCI USA, V96, P5698, DOI 10.1073/pnas.96.10.5698; Bleul CC, 1996, NATURE, V382, P829, DOI 10.1038/382829a0; Blondelle SE, 2000, J PEPT RES, V55, P148, DOI 10.1034/j.1399-3011.2000.00162.x; Boshoff C, 1997, SCIENCE, V278, P290, DOI 10.1126/science.278.5336.290; Brelot A, 2000, J BIOL CHEM, V275, P23736, DOI 10.1074/jbc.M000776200; Brelot A, 1997, J VIROL, V71, P4744, DOI 10.1128/JVI.71.6.4744-4751.1997; Butcher DJ, 1997, FEBS LETT, V409, P183, DOI 10.1016/S0014-5793(97)00504-8; Chabot DJ, 2000, J BIOL CHEM, V275, P23774, DOI 10.1074/jbc.M003438200; Chabot DJ, 1999, J VIROL, V73, P6598, DOI 10.1128/JVI.73.8.6598-6609.1999; Chabot DJ, 2000, J VIROL, V74, P4404, DOI 10.1128/JVI.74.9.4404-4413.2000; Choe H, 1998, J VIROL, V72, P6113, DOI 10.1128/JVI.72.7.6113-6118.1998; CLARKLEWIS I, 1995, J LEUKOCYTE BIOL, V57, P703, DOI 10.1002/jlb.57.5.703; Crump MP, 1997, EMBO J, V16, P6996, DOI 10.1093/emboj/16.23.6996; Dealwis C, 1998, P NATL ACAD SCI USA, V95, P6941, DOI 10.1073/pnas.95.12.6941; Deng HK, 1996, NATURE, V381, P661, DOI 10.1038/381661a0; Doranz BJ, 1997, J EXP MED, V186, P1395, DOI 10.1084/jem.186.8.1395; Doranz BJ, 1999, J VIROL, V73, P2752, DOI 10.1128/JVI.73.4.2752-2761.1999; Dragic T, 1996, NATURE, V381, P667, DOI 10.1038/381667a0; Endres MJ, 1996, CELL, V87, P745, DOI 10.1016/S0092-8674(00)81393-8; Feifel B, 1998, J BIOL CHEM, V273, P11999, DOI 10.1074/jbc.273.20.11999; Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872; FISHER PJ, 1994, NATURE, V368, P651, DOI 10.1038/368651a0; FUJIHASHI T, 1995, AIDS RES HUM RETROV, V11, P461, DOI 10.1089/aid.1995.11.461; HELSETH E, 1990, J VIROL, V64, P2416, DOI 10.1128/JVI.64.5.2416-2420.1990; Heveker N, 1998, CURR BIOL, V8, P369, DOI 10.1016/S0960-9822(98)70155-1; Kajumo F, 2000, VIROLOGY, V271, P240, DOI 10.1006/viro.2000.0308; Kledal TN, 1997, SCIENCE, V277, P1656, DOI 10.1126/science.277.5332.1656; Lee B, 1999, J BIOL CHEM, V274, P9617, DOI 10.1074/jbc.274.14.9617; Li CF, 1997, BIOCHEMISTRY-US, V36, P15404, DOI 10.1021/bi971817g; Li S, 1998, J BIOL CHEM, V273, P16442, DOI 10.1074/jbc.273.26.16442; Loetscher P, 1998, J BIOL CHEM, V273, P22279, DOI 10.1074/jbc.273.35.22279; Lu ZH, 1997, P NATL ACAD SCI USA, V94, P6426, DOI 10.1073/pnas.94.12.6426; Luo JS, 1999, BIOCHEM BIOPH RES CO, V264, P42, DOI 10.1006/bbrc.1999.1476; Luo ZW, 1997, PROTEIN ENG, V10, P1039, DOI 10.1093/protein/10.9.1039; Luo ZW, 2000, BIOCHEMISTRY-US, V39, P13545, DOI 10.1021/bi000633q; Luo ZW, 1999, BIOCHEM BIOPH RES CO, V263, P691, DOI 10.1006/bbrc.1999.1441; Ma Q, 1998, P NATL ACAD SCI USA, V95, P9448, DOI 10.1073/pnas.95.16.9448; MILES AJ, 1994, J BIOL CHEM, V269, P30939; Moore PS, 1996, SCIENCE, V274, P1739, DOI 10.1126/science.274.5293.1739; Murakami T, 1997, J EXP MED, V186, P1389, DOI 10.1084/jem.186.8.1389; MURPHY PM, 1994, ANNU REV IMMUNOL, V12, P593, DOI 10.1146/annurev.iy.12.040194.003113; Nagasawa T, 1996, NATURE, V382, P635, DOI 10.1038/382635a0; Oberlin E, 1996, NATURE, V382, P833, DOI 10.1038/382833a0; Picard L, 1997, VIROLOGY, V231, P105, DOI 10.1006/viro.1997.8506; Satoh T, 1997, J BIOL CHEM, V272, P12175, DOI 10.1074/jbc.272.18.12175; Schols D, 1997, J EXP MED, V186, P1383, DOI 10.1084/jem.186.8.1383; Sodroski JG, 1999, CELL, V99, P243, DOI 10.1016/S0092-8674(00)81655-4; STRADER CD, 1994, ANNU REV BIOCHEM, V63, P101, DOI 10.1146/annurev.bi.63.070194.000533; THALI M, 1992, J VIROL, V66, P5635, DOI 10.1128/JVI.66.9.5635-5641.1992; Wang ZX, 1998, J BIOL CHEM, V273, P15007, DOI 10.1074/jbc.273.24.15007; Zhou NM, 2001, J BIOL CHEM, V276, P42826, DOI 10.1074/jbc.M106582200; Zhou NM, 2000, EUR J IMMUNOL, V30, P164, DOI 10.1002/1521-4141(200001)30:1<164::AID-IMMU164>3.0.CO;2-X; Zhou NM, 2000, BIOCHEMISTRY-US, V39, P3782, DOI 10.1021/bi992750v; Zou YR, 1998, NATURE, V393, P595, DOI 10.1038/31269	56	112	116	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 17	2002	277	20					17476	17485		10.1074/jbc.M202063200	http://dx.doi.org/10.1074/jbc.M202063200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	553PR	11880384	hybrid			2022-12-27	WOS:000175685100013
J	Takahashi, N; Kawada, T; Yamamoto, T; Goto, T; Taimatsu, A; Aoki, N; Kawasaki, H; Taira, K; Yokoyama, KK; Kamei, Y; Fushiki, T				Takahashi, N; Kawada, T; Yamamoto, T; Goto, T; Taimatsu, A; Aoki, N; Kawasaki, H; Taira, K; Yokoyama, KK; Kamei, Y; Fushiki, T			Overexpression and ribozyme-mediated targeting of transcriptional coactivators CREB-binding protein and p300 revealed their indispensable roles in adipocyte differentiation through the regulation of peroxisome proliferator-activated receptor gamma	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PPAR-GAMMA; INSULIN-RESISTANCE; C/EBP-BETA; RETINOIC-ACID; MICE LACKING; ADIPOGENESIS; ADIPONECTIN; EXPRESSION; OBESITY; CBP	The cAMP-response element-binding protein-binding protein (CBP) and p300 are common coactivators for several transcriptional factors. It has been reported that both CDP and p300 are significant for the activation of peroxisome proliferator-activated receptor gamma (PPAR-gamma), which is a crucial nuclear receptor in adipogenesis. However, it remains unclear whether CDP and/or p300 is physiologically essential to the activation of PPARgamma in adipocytes and adipocyte differentiation. In this study, we investigated the physiological significance of CBP/p300 in NIH3T3 cells transiently expressing PPARgamma and CDP and in 3T3-L1 preadipocytes stably expressing CDP- or p300-specific ribozymes. In PPARgamma-transfected NIH3T3 cells, induction of expression of PPARgamma target genes such as adipocyte fatty acid-binding protein (aP2) and lipoprotein lipase (LPL) by adding thiazolidinedione was enhanced, depending on the amount of a CDP expression plasmid transfected. Expression of aP2 and LPL genes, as well as glycerol-3-phosphate dehydrogenase activity and triacylglyceride accumulation after adipogenic induction, was largely suppressed in 3T3-L1 adipocytes expressing either the CDP- or p300-specific active ribozyme, but not in inactive ribozyme-expressing cells. These data suggest that both CDP and p300 are indispensable for the full activation of PPARgamma and adipocyte differentiation and that CDP and p300 do not mutually complement in the process.	Kyoto Univ, Grad Sch Agr, Div Food Sci & Biotechnol, Nutr Chem Lab,Sakyo Ku, Kyoto 6068502, Japan; Biooriented Res Advancement Inst, Project Obes & Lipid Metab Regulat, Tokyo 1050001, Japan; Nagoya Univ, Grad Sch Bioagr Sci, Dept Appl Mol Biosci, Nagoya, Aichi 4648601, Japan; Univ Tokyo, Sch Engn, Dept Chem & Biotechnol, Tokyo 1138656, Japan; Natl Inst Adv Ind Sci & Technol, Gene Discovery Res Ctr, Tsukuba, Ibaraki 3058562, Japan; Inst Phys & Chem Res, Tsukuba Life Sci Ctr, Tsukuba, Ibaraki 3050074, Japan; Japan Sci & Technol Corp, Precursory Res Embryon Sci & Technol, Tokyo 1628636, Japan	Kyoto University; National Agriculture & Food Research Organization - Japan; Nagoya University; University of Tokyo; National Institute of Advanced Industrial Science & Technology (AIST); RIKEN; Japan Science & Technology Agency (JST)	Kawada, T (corresponding author), Kyoto Univ, Grad Sch Agr, Div Food Sci & Biotechnol, Nutr Chem Lab,Sakyo Ku, Kyoto 6068502, Japan.	fat@kais.kyoto-u.ac.jp	Takahashi, Nobuyuki/AAX-8671-2021; Goto, Tsuyoshi/AAY-2344-2020	Takahashi, Nobuyuki/0000-0002-9705-662X; Goto, Tsuyoshi/0000-0003-1283-147X; Takahashi, Nobuyuki/0000-0003-0126-6292				Adachi M, 2000, NEW ENGL J MED, V343, P856, DOI 10.1056/NEJM200009213431205; Bradley RL, 2001, RECENT PROG HORM RES, V56, P329, DOI 10.1210/rp.56.1.329; Castillo G, 1999, EMBO J, V18, P3676, DOI 10.1093/emboj/18.13.3676; Chakravarti D, 1996, NATURE, V383, P99, DOI 10.1038/383099a0; Clarke SL, 1997, BIOCHEM BIOPH RES CO, V240, P99, DOI 10.1006/bbrc.1997.7627; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; Elberg G, 2000, J BIOL CHEM, V275, P27815; Gelman L, 1999, J BIOL CHEM, V274, P7681, DOI 10.1074/jbc.274.12.7681; Goodman RH, 2000, GENE DEV, V14, P1553; Guo SD, 2001, J BIOL CHEM, V276, P8516, DOI 10.1074/jbc.M008542200; Hamm JK, 2001, J BIOL CHEM, V276, P18464, DOI 10.1074/jbc.M100797200; Hotamisligil GS, 1996, SCIENCE, V274, P1377, DOI 10.1126/science.274.5291.1377; Hotta K, 2001, DIABETES, V50, P1126, DOI 10.2337/diabetes.50.5.1126; HU ED, 1995, P NATL ACAD SCI USA, V92, P9856, DOI 10.1073/pnas.92.21.9856; HUNT CR, 1986, P NATL ACAD SCI USA, V83, P3786, DOI 10.1073/pnas.83.11.3786; Hwang CS, 1997, ANNU REV CELL DEV BI, V13, P231, DOI 10.1146/annurev.cellbio.13.1.231; KAMEI Y, 1993, BIOCHEM J, V293, P807, DOI 10.1042/bj2930807; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Kawada T, 1996, INT J OBESITY, V20, pS52; Kawasaki H, 1998, NATURE, V393, P284, DOI 10.1038/30538; Kodera Y, 2000, J BIOL CHEM, V275, P33201, DOI 10.1074/jbc.C000517200; Lala DS, 1996, NATURE, V383, P450, DOI 10.1038/383450a0; LUNDBLAD JR, 1995, NATURE, V374, P85, DOI 10.1038/374085a0; Maeda N, 2001, DIABETES, V50, P2094, DOI 10.2337/diabetes.50.9.2094; Mink S, 1997, MOL CELL BIOL, V17, P6609, DOI 10.1128/MCB.17.11.6609; Misawa K, 2000, P NATL ACAD SCI USA, V97, P3062, DOI 10.1073/pnas.060489597; Mizukami J, 1997, BIOCHEM BIOPH RES CO, V240, P61, DOI 10.1006/bbrc.1997.7602; ONATE SA, 1995, SCIENCE, V270, P1354; PETRIJ F, 1995, NATURE, V376, P348, DOI 10.1038/376348a0; Puigserver P, 1998, CELL, V92, P829, DOI 10.1016/S0092-8674(00)81410-5; Rasmussen R, 2001, RAPID CYCLE REAL TIM, P21, DOI [10.1007/978-3-642-59524-0_3, DOI 10.1007/978-3-642-59524-0_3]; Reginato MJ, 1998, J BIOL CHEM, V273, P32679, DOI 10.1074/jbc.273.49.32679; Robinson CE, 1998, BIOCHEM BIOPH RES CO, V244, P671, DOI 10.1006/bbrc.1998.8305; Rosen ED, 2001, J BIOL CHEM, V276, P37731, DOI 10.1074/jbc.R100034200; Spiegelman BM, 2001, CELL, V104, P531, DOI 10.1016/S0092-8674(01)00240-9; Tanaka T, 1997, EMBO J, V16, P7432, DOI 10.1093/emboj/16.24.7432; Tanaka Y, 2000, MECH DEVELOP, V95, P133, DOI 10.1016/S0925-4773(00)00360-9; TONTONOZ P, 1994, NUCLEIC ACIDS RES, V22, P5628, DOI 10.1093/nar/22.25.5628; TONTONOZ P, 1994, GENE DEV, V8, P1224, DOI 10.1101/gad.8.10.1224; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X; Trayhurn P, 2001, P NUTR SOC, V60, P329, DOI 10.1079/PNS200194; Uysal KT, 1997, NATURE, V389, P610, DOI 10.1038/39335; Wu ZD, 1999, MOL CELL, V3, P151, DOI 10.1016/S1097-2765(00)80306-8; Yamauchi T, 2001, NAT MED, V7, P941, DOI 10.1038/90984; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; Yuan ZM, 1999, ONCOGENE, V18, P5714, DOI 10.1038/sj.onc.1202930	46	128	132	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 10	2002	277	19					16906	16912		10.1074/jbc.M200585200	http://dx.doi.org/10.1074/jbc.M200585200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	551MB	11884404	hybrid			2022-12-27	WOS:000175564500076
J	Wu, F; Yan, W; Pan, JL; Morser, J; Wu, QY				Wu, F; Yan, W; Pan, JL; Morser, J; Wu, QY			Processing of pro-atrial natriuretic peptide by corin in cardiac myocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONGESTIVE-HEART-FAILURE; SERINE-PROTEASE; RAT-HEART; CELLS; RECEPTOR; FAMILY; ENZYME; MOUSE; GENES; LOCALIZATION	Corin is a type II transmembrane serine protease abundantly expressed in the heart. In a previous study using transfected 293 cells, we showed that corin converted pro-atrial natriuretic peptide (pro-ANP) to atrial natriuretic peptide (ANP), suggesting that corin is likely the pro-ANP convertase. Because other serine proteases such as thrombin and kallikrein had previously also been shown to cleave pro-ANP in vitro, it remained to demonstrate that corin is indeed the endogenous pro-ANP convertase in cardiomyocytes. In this study, we examined pro-ANP processing in a murine cardiac muscle cell line, HL-5. Northern analysis showed that corin mRNA was present in HL-5 cells. In HL-5 cells transfected with a plasmid expressing pro-ANP, recombinant pro-ANP was converted to mature ANP as determined by Western analysis, indicating the presence of the endogenous pro-ANP convertase in these cells. The processed recombinant ANP was shown to be active in an enzyme-linked immunosorbent assay-based cGMP assay in baby hamster kidney cells. The processing of recombinant pro-ANP in HL-5 cells was highly sequence-specific, because mutation R98A, but not mutations R101A and R102A, in pro-ANP prevented the conversion of pro-ANP to ANP. Expression of recombinant wild-type corin enhanced the processing of pro-ANP in HL-5 cells. In contrast, overexpression of active site mutant corm S985A or transfection of oligonucleotide small interfering RNA duplexes directed against the mouse corin gene completely inhibited the processing of recombinant pro-ANP in HL-5 cells. These results indicate that corin is the physiological pro-ANP convertase in cardiac myocytes.	Berlex Biosci, Dept Cardiovasc Res, Richmond, CA 94804 USA		Wu, QY (corresponding author), Berlex Biosci, Dept Cardiovasc Res, 15049 San Pablo Ave, Richmond, CA 94804 USA.			Wu, Qingyu/0000-0003-0561-9315				Allgren RL, 1997, NEW ENGL J MED, V336, P828, DOI 10.1056/NEJM199703203361203; ALONSO S, 1986, J MOL EVOL, V23, P11, DOI 10.1007/BF02100994; BARR PJ, 1991, CELL, V66, P1, DOI 10.1016/0092-8674(91)90129-M; BEYER EC, 1987, J CELL BIOL, V105, P2621, DOI 10.1083/jcb.105.6.2621; Bhanot P, 1996, NATURE, V382, P225, DOI 10.1038/382225a0; BORISOV AB, 1995, ANN NY ACAD SCI, V752, P80, DOI 10.1111/j.1749-6632.1995.tb17408.x; Brown MS, 1997, NATURE, V388, P629, DOI 10.1038/41672; BURNETT JC, 1986, SCIENCE, V231, P1145, DOI 10.1126/science.2935937; Claycomb WC, 1998, P NATL ACAD SCI USA, V95, P2979, DOI 10.1073/pnas.95.6.2979; Colucci WS, 2000, NEW ENGL J MED, V343, P246, DOI 10.1056/NEJM200007273430403; CORTHORN J, 1991, MOL CELL BIOCHEM, V103, P31; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; FIELD LJ, 1988, SCIENCE, V239, P1029, DOI 10.1126/science.2964082; GOTTLIEB SS, 1989, J AM COLL CARDIOL, V13, P1534, DOI 10.1016/0735-1097(89)90344-6; Hayashi M, 2001, J AM COLL CARDIOL, V37, P1820, DOI 10.1016/S0735-1097(01)01233-5; Hooper JD, 2000, EUR J BIOCHEM, V267, P6931, DOI 10.1046/j.1432-1327.2000.01806.x; Hooper JD, 2001, J BIOL CHEM, V276, P857, DOI 10.1074/jbc.R000020200; IMADA T, 1988, J BIOL CHEM, V263, P9515; ITO T, 1988, P NATL ACAD SCI USA, V85, P8365, DOI 10.1073/pnas.85.21.8365; JOHN SWM, 1995, SCIENCE, V267, P679, DOI 10.1126/science.7839143; KITAMOTO Y, 1994, P NATL ACAD SCI USA, V91, P7588, DOI 10.1073/pnas.91.16.7588; Levin ER, 1998, NEW ENGL J MED, V339, P321; LEYTUS SP, 1988, BIOCHEMISTRY-US, V27, P1067, DOI 10.1021/bi00403a032; LOPEZ MJ, 1995, NATURE, V378, P65, DOI 10.1038/378065a0; MATSUMOTO A, 1990, P NATL ACAD SCI USA, V87, P9133, DOI 10.1073/pnas.87.23.9133; MOREAU T, 1995, BBA-PROTEIN STRUCT M, V1249, P168, DOI 10.1016/0167-4838(95)00038-V; PANDEY KN, 1991, BIOCHEM BIOPH RES CO, V180, P437, DOI 10.1016/S0006-291X(05)81312-9; ROBBINS J, 1990, J BIOL CHEM, V265, P11905; SCHWARTZ D, 1985, SCIENCE, V229, P397, DOI 10.1126/science.3160114; SEI CA, 1992, MOL ENDOCRINOL, V6, P309, DOI 10.1210/me.6.3.309; Seidah NG, 1999, BRAIN RES, V848, P45, DOI 10.1016/S0006-8993(99)01909-5; SEIDAH NG, 1986, BIOSCIENCE REP, V6, P835, DOI 10.1007/BF01117107; SEIDMAN CE, 1984, SCIENCE, V226, P1206, DOI 10.1126/science.6542248; SHIELDS PP, 1988, J BIOL CHEM, V263, P8091; SHIONO S, 1986, BIOCHEM BIOPH RES CO, V135, P728, DOI 10.1016/0006-291X(86)90989-7; THIBAULT G, 1987, BIOCHEM J, V241, P265, DOI 10.1042/bj2410265; Tomita Y, 1998, J BIOCHEM-TOKYO, V124, P784, DOI 10.1093/oxfordjournals.jbchem.a022180; Wilkins MR, 1997, LANCET, V349, P1307, DOI 10.1016/S0140-6736(96)07424-7; Wu QY, 2001, FRONT BIOSCI-LANDMRK, V6, pD192; Yan W, 1999, J BIOL CHEM, V274, P14926, DOI 10.1074/jbc.274.21.14926; Yan W, 2000, P NATL ACAD SCI USA, V97, P8525, DOI 10.1073/pnas.150149097	41	122	131	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 10	2002	277	19					16900	16905		10.1074/jbc.M201503200	http://dx.doi.org/10.1074/jbc.M201503200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	551MB	11884416	hybrid			2022-12-27	WOS:000175564500075
J	Leach, JK; Black, SM; Schmidt-Ullrich, RK; Mikkelson, RB				Leach, JK; Black, SM; Schmidt-Ullrich, RK; Mikkelson, RB			Activation of constitutive nitric-oxide sythase activity is an early signaling event induced by ionizing radiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; MANGANESE-SUPEROXIDE-DISMUTASE; DOMINANT-NEGATIVE MUTANTS; SMOOTH-MUSCLE CELLS; CYCLIC-GMP; OXIDATIVE STRESS; GENE-EXPRESSION; TUMOR-CELLS; IN-VITRO; PEROXYNITRITE	Ionizing radiation at clinical dose levels activates both pro- and anti-proliferative signal transduction pathways, the balance of which determines cell fate. The initiating and amplifying mechanisms involved in the activation are poorly understood. We demonstrate that one mechanism involves stimulation of constitutive nitric-oxide synthase (NOS) activity. NOS activity of Chinese hamster ovary cells was measured by the arginine --> citrulline conversion assay. Irradiation stimulated a transient activation of NOS with maximal activity at 5 min of post-irradiation. Western blot analysis and genetic manipulation by overexpression of wild type or dominant negative NOS mutant identify the radiation-induced isoform. as NOS-1. Further evidence that NOS-1 is activated by radiation was the demonstration of radiation-induced cGMP formation in cells transiently transfected with the NO-dependent soluble guanylate cyclase. Protein Tyr nitration, a footprint of peroxynitrite formation, followed radiation exposure and was inhibited by expression of a dominant negative NOS-1 mutant. Radiation-induced ERK1/2 kinase activity, a cytoprotective response to radiation, was also blocked by inhibiting NOS activity. These experiments establish NO-dependent signal transduction pathways as being radioresponsive. Given the lipophilic and relatively stable properties of NO, these results also suggest a possible mechanism by which ionization events in one cell may activate signaling processes in adjacent cells.	Virginia Commonwealth Univ, Dept Radiat Oncol, Richmond, VA 23298 USA; Northwestern Univ, Div Neonatol, Chicago, IL 60611 USA	Virginia Commonwealth University; Northwestern University	Mikkelson, RB (corresponding author), Virginia Commonwealth Univ, Dept Radiat Oncol, Richmond, VA 23298 USA.				NATIONAL CANCER INSTITUTE [P01CA072955, R01CA065896] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL060190] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007150] Funding Source: NIH RePORTER; NCI NIH HHS [CA65896, CA72955] Funding Source: Medline; NHLBI NIH HHS [HL60190] Funding Source: Medline; NICHD NIH HHS [HD398110] Funding Source: Medline; NIDDK NIH HHS [5T32DK07150] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Balazy M, 1998, J BIOL CHEM, V273, P32009, DOI 10.1074/jbc.273.48.32009; Barrett WC, 1999, J BIOL CHEM, V274, P34543, DOI 10.1074/jbc.274.49.34543; Becker EM, 1999, NITRIC OXIDE-BIOL CH, V3, P55, DOI 10.1006/niox.1999.0207; Beckman JS, 1996, AM J PHYSIOL-CELL PH, V271, pC1424; Bonner JA, 1998, INT J RADIAT ONCOL, V42, P921, DOI 10.1016/S0360-3016(98)00325-3; Browning DD, 2000, J BIOL CHEM, V275, P2811, DOI 10.1074/jbc.275.4.2811; Chiche JD, 1998, J BIOL CHEM, V273, P34263, DOI 10.1074/jbc.273.51.34263; Clutton SM, 1996, CARCINOGENESIS, V17, P1633, DOI 10.1093/carcin/17.8.1633; Collins SP, 1999, J BIOL CHEM, V274, P8391, DOI 10.1074/jbc.274.13.8391; Cordelier P, 1999, FASEB J, V13, P2037, DOI 10.1096/fasebj.13.14.2037; Crow JP, 1997, NITRIC OXIDE-BIOL CH, V1, P145, DOI 10.1006/niox.1996.0113; Deora AA, 2000, BIOCHEMISTRY-US, V39, P9901, DOI 10.1021/bi992954b; Ducrocq C, 1999, CELL MOL LIFE SCI, V55, P1068, DOI 10.1007/s000180050357; Goda N, 1996, AM J PHYSIOL-HEART C, V271, pH1893, DOI 10.1152/ajpheart.1996.271.5.H1893; Gow AJ, 1996, FEBS LETT, V385, P63, DOI 10.1016/0014-5793(96)00347-X; Gu MF, 2000, J BIOL CHEM, V275, P11389, DOI 10.1074/jbc.275.15.11389; Gudi T, 1996, J BIOL CHEM, V271, P4597; HAIMOVITZFRIEDMAN A, 1994, J EXP MED, V180, P525, DOI 10.1084/jem.180.2.525; Ibuki Y, 1997, FREE RADICAL BIO MED, V22, P1029, DOI 10.1016/S0891-5849(96)00500-X; JANSSEN MYW, 1998, AM J PHYSIOL, V275, pL1100; Janssens MY, 1998, CANCER RES, V58, P5646; Kamisaki Y, 1998, P NATL ACAD SCI USA, V95, P11584, DOI 10.1073/pnas.95.20.11584; Kanai AJ, 2001, P NATL ACAD SCI USA, V98, P14126, DOI 10.1073/pnas.241380298; Kasid U, 1996, NATURE, V382, P813, DOI 10.1038/382813a0; Kavanagh BD, 1998, RADIAT RES, V149, P579, DOI 10.2307/3579904; KHARBANDA S, 1994, P NATL ACAD SCI USA, V91, P5416, DOI 10.1073/pnas.91.12.5416; KHARBANDA S, 1994, J BIOL CHEM, V269, P20739; Komalavilas P, 1999, J BIOL CHEM, V274, P34301, DOI 10.1074/jbc.274.48.34301; Kuo WN, 1999, MOL CELL BIOCHEM, V201, P11, DOI 10.1023/A:1007024126947; LANDER HM, 1995, J BIOL CHEM, V270, P21195, DOI 10.1074/jbc.270.36.21195; Leach JK, 2001, CANCER RES, V61, P3894; Lopez F, 1997, J BIOL CHEM, V272, P24448, DOI 10.1074/jbc.272.39.24448; MacMillanCrow LA, 1996, P NATL ACAD SCI USA, V93, P11853, DOI 10.1073/pnas.93.21.11853; Marshall HE, 2000, FASEB J, V14, P1889, DOI 10.1096/fj.00.011rev; Miranda S, 1999, BIOCHEM BIOPH RES CO, V258, P44, DOI 10.1006/bbrc.1999.0580; Morales A, 1998, INT J RADIAT ONCOL, V42, P191, DOI 10.1016/S0360-3016(98)00185-0; Narayanan PK, 1997, CANCER RES, V57, P3963; Niu XF, 1996, CIRC RES, V79, P992, DOI 10.1161/01.RES.79.5.992; Phung YT, 1999, IUBMB LIFE, V48, P333, DOI 10.1080/152165499307062; Possel H, 1997, FEBS LETT, V416, P175, DOI 10.1016/S0014-5793(97)01197-6; Schmidt-Ullrich RK, 2000, RADIAT RES, V153, P245, DOI 10.1667/0033-7587(2000)153[0245:STACRR]2.0.CO;2; Stamler JS, 1997, NEURON, V18, P691, DOI 10.1016/S0896-6273(00)80310-4; STEPHENSON MA, 1994, CANCER RES, V54, P12; Stuehr DJ, 1999, BBA-BIOENERGETICS, V1411, P217, DOI 10.1016/S0005-2728(99)00016-X; Suhasini M, 1998, MOL CELL BIOL, V18, P6983, DOI 10.1128/MCB.18.12.6983; TODD DG, 1994, CANCER RES, V54, P5224; Tonks NK, 1996, CELL, V87, P365, DOI 10.1016/S0092-8674(00)81357-4; WARD JF, 1994, RADIAT RES, V138, pS85, DOI 10.2307/3578769; WINK DA, 1993, P NATL ACAD SCI USA, V90, P9813, DOI 10.1073/pnas.90.21.9813; Yamakura F, 1998, J BIOL CHEM, V273, P14085, DOI 10.1074/jbc.273.23.14085; YAMAUCHI K, 1995, P NATL ACAD SCI USA, V92, P664, DOI 10.1073/pnas.92.3.664; YUEN PST, 1994, J BIOL CHEM, V269, P791; Zhou XB, 1996, J BIOL CHEM, V271, P19760, DOI 10.1074/jbc.271.33.19760; Zorov DB, 2000, J EXP MED, V192, P1001, DOI 10.1084/jem.192.7.1001	54	113	122	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 3	2002	277	18					15400	15406		10.1074/jbc.M110309200	http://dx.doi.org/10.1074/jbc.M110309200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	550PA	11856735	hybrid			2022-12-27	WOS:000175510400024
J	Tassotto, ML; Mathews, CK				Tassotto, ML; Mathews, CK			Assessing the metabolic function of the MutT 8-oxodeoxyguanosine triphosphatase in Escherichia coli by nucleotide pool analysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STATE KINETIC-ANALYSIS; MUTAGENIC SUBSTRATE; DNA-SYNTHESIS; REPLICATION FIDELITY; STEADY-STATE; PROTEIN; CELLS; 8-HYDROXYGUANINE; BACTERIOPHAGE-T4; 5'-TRIPHOSPHATE	In Escherichia coli the mutT gene is one of several that acts to minimize mutagenesis by reactive oxygen species. The bacterial MutT protein and its mammalian homolog have been shown to catalyze in vitro the hydrolysis of the oxidized deoxyguanosine nucleotide, 8-oxo-dGTP, to its corresponding monophosphate. Thus, the protein is thought to "sanitize" the nucleotide pool by ridding the cell of a nucleotide whose incorporation into DNA would be intensely mutagenic. However, because others have shown mutT mutations to be mutagenic under some conditions of anaerobic growth, and have shown 8-oxo-dGTP to be a poor DNA polymerase substrate, there is reason to question this model. We have devised an assay for 8-oxo-dGTP in bacterial extracts. Using this assay, which involves reversed-phase high-performance liquid chromatography and electrochemical detection, we have been unable to detect 8-oxo. dGTP in extracts of three different mutT mutants of E. coli, even after growth of the bacteria in the presence of hydrogen peroxide. Our estimated upper limit for 8-oxo-dGTP content of these bacteria is about 200 molecules/ cell, corresponding to a concentration of about 0.34 muM. When 8-oxo-dGTP was added at 0.34 muM to an in vitro DNA replication system primed with a DNA template that permits scoring of replication errors and with the four normal dNTPs at their estimated intracellular concentrations, there was no detectable effect upon the frequency of replication errors. These findings lead us to question the conclusion that 8-oxo-dGTP is the most significant physiological substrate for the MutT protein.	Oregon State Univ, Dept Biochem & Biophys, Corvallis, OR 97331 USA	Oregon State University	Mathews, CK (corresponding author), Oregon State Univ, Dept Biochem & Biophys, Corvallis, OR 97331 USA.				NIGMS NIH HHS [GM 55134] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM055134] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BHATNAGAR SK, 1991, J BIOL CHEM, V266, P9050; Bialkowski K, 1998, NUCLEIC ACIDS RES, V26, P3194, DOI 10.1093/nar/26.13.3194; CHENG KC, 1992, J BIOL CHEM, V267, P166; DIPIERRO D, 1995, ANAL BIOCHEM, V231, P407, DOI 10.1006/abio.1995.0071; Einolf HJ, 2001, J BIOL CHEM, V276, P3764, DOI 10.1074/jbc.M006696200; Einolf HJ, 1998, BIOCHEMISTRY-US, V37, P13300, DOI 10.1021/bi981346d; FOWLER RG, 1994, J BACTERIOL, V176, P7727, DOI 10.1128/JB.176.24.7727-7729.1994; Fujikawa K, 1999, J BIOL CHEM, V274, P18201, DOI 10.1074/jbc.274.26.18201; HAYAKAWA H, 1995, BIOCHEMISTRY-US, V34, P89, DOI 10.1021/bi00001a011; Hayakawa H, 1999, BIOCHEMISTRY-US, V38, P3610, DOI 10.1021/bi982361l; Helbock HJ, 1998, P NATL ACAD SCI USA, V95, P288, DOI 10.1073/pnas.95.1.288; KAKUMA T, 1995, J BIOL CHEM, V270, P25942, DOI 10.1074/jbc.270.43.25942; MAKI H, 1992, NATURE, V355, P273, DOI 10.1038/355273a0; Martomo SA, 2002, MUTAT RES-FUND MOL M, V499, P197, DOI 10.1016/S0027-5107(01)00283-4; MATHEWS CK, 1972, J BIOL CHEM, V247, P7430; MICHAELS ML, 1992, J BACTERIOL, V174, P6321, DOI 10.1128/JB.174.20.6321-6325.1992; MINNICK DT, 1994, NUCLEIC ACIDS RES, V22, P5658, DOI 10.1093/nar/22.25.5658; MO JY, 1992, P NATL ACAD SCI USA, V89, P11021, DOI 10.1073/pnas.89.22.11021; PAVLOV YI, 1994, BIOCHEMISTRY-US, V33, P4695, DOI 10.1021/bi00181a029; ROBERTS JD, 1988, P NATL ACAD SCI USA, V85, P7064, DOI 10.1073/pnas.85.19.7064; SAKUMI K, 1993, J BIOL CHEM, V268, P23524; SARGENT RG, 1987, J BIOL CHEM, V262, P5546; Taddei F, 1997, SCIENCE, V278, P128, DOI 10.1126/science.278.5335.128; TAJIRI T, 1995, MUTAT RES-DNA REPAIR, V336, P257, DOI 10.1016/0921-8777(94)00062-B; ZHANG XL, 1995, J BIOL CHEM, V270, P8401, DOI 10.1074/jbc.270.15.8401	25	42	43	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 3	2002	277	18					15807	15812		10.1074/jbc.M200965200	http://dx.doi.org/10.1074/jbc.M200965200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	550PA	11856756	hybrid			2022-12-27	WOS:000175510400080
J	Wang, X; Yang, Y; Guo, XJ; Sampson, ER; Hsu, CL; Tsai, MY; Yeh, SY; Wu, G; Guo, YL; Chang, CS				Wang, X; Yang, Y; Guo, XJ; Sampson, ER; Hsu, CL; Tsai, MY; Yeh, SY; Wu, G; Guo, YL; Chang, CS			Suppression of androgen receptor transactivation by Pyk2 via interaction and phosphorylation of the ARA55 coregulator	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROSTATE-CANCER CELLS; TYROSINE KINASE; SIGNALING PATHWAY; ESTROGEN-RECEPTOR; GROWTH-FACTOR; ACTIVATION; PROTEIN; IDENTIFICATION; COACTIVATOR; EXPRESSION	The proline-rich tyrosine kinase 2 (Pyk2) was first identified as a key kinase linked to the MAP kinase and JNK signaling pathways that play important roles in cell growth and adhesion. The linkage between Pyk2 and the androgen receptor (AR), an important transcription factor in prostate cancer progression, however, remains unclear. Here we report that using the full-length androgen receptor-associated protein, ARA55, coregulator as bait, we were able to isolate an ARA55-interacting protein, Pyk2, and demonstrated that Pyk2 could repress AR transactivation via inactivation of ARA55. This inactivation may result from the direct phosphorylation of ARA55 by Pyk2 at tyrosine 43, impairing the coactivator activity of ARA55 and/or sequestering ARA55 to reduce its interaction with AR. Our finding that Pyk2 can indirectly modulate AR function via interaction and/or phosphorylation of ARA55 not only expands the role of Pyk2 in AR-mediated prostate cancer growth but also strengthens the role of ARA55 as an AR coregulator.	Univ Rochester, Dept Urol, George Whipple Lab Canc Res, Rochester, NY 14642 USA; Univ Rochester, Dept Pathol, George Whipple Lab Canc Res, Rochester, NY 14642 USA; Univ Rochester, Dept Radiat Oncol, George Whipple Lab Canc Res, Rochester, NY 14642 USA; Univ Rochester, Ctr Canc, Rochester, NY 14642 USA; Peking Univ, Hosp 1, Beijing 100034, Peoples R China	University of Rochester; University of Rochester; University of Rochester; University of Rochester; Peking University	Chang, CS (corresponding author), Univ Rochester, Dept Urol, George Whipple Lab Canc Res, 601 Elmwood Ave, Rochester, NY 14642 USA.			Chang, Chawnshang/0000-0001-8510-3516	NCI NIH HHS [CA71570] Funding Source: Medline	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Avraham H, 2000, CELL SIGNAL, V12, P123, DOI 10.1016/S0898-6568(99)00076-5; Brinson AE, 1998, J BIOL CHEM, V273, P1711, DOI 10.1074/jbc.273.3.1711; CHANG CS, 1995, CRIT REV EUKAR GENE, V5, P97, DOI 10.1615/CritRevEukarGeneExpr.v5.i2.10; CHANG CS, 1988, SCIENCE, V240, P324, DOI 10.1126/science.3353726; de Mora JF, 2000, MOL CELL BIOL, V20, P5041, DOI 10.1128/MCB.20.14.5041-5047.2000; Dikic I, 1996, NATURE, V383, P547, DOI 10.1038/383547a0; Fujimoto N, 1999, J BIOL CHEM, V274, P8316, DOI 10.1074/jbc.274.12.8316; Fujimoto N, 2001, UROLOGY, V58, P289, DOI 10.1016/S0090-4295(01)01117-7; Hammer GD, 1999, MOL CELL, V3, P521, DOI 10.1016/S1097-2765(00)80480-3; Hiregowdara D, 1997, J BIOL CHEM, V272, P10804; Hsiao PW, 1999, J BIOL CHEM, V274, P20229, DOI 10.1074/jbc.274.29.20229; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; Li JZ, 1996, BLOOD, V88, P417, DOI 10.1182/blood.V88.2.417.bloodjournal882417; Lin HK, 2001, P NATL ACAD SCI USA, V98, P7200, DOI 10.1073/pnas.121173298; McKenna NJ, 1999, ENDOCR REV, V20, P321, DOI 10.1210/er.20.3.321; Miyazaki T, 1998, GENE DEV, V12, P770, DOI 10.1101/gad.12.6.770; MIZOKAMI A, 1994, MOL ENDOCRINOL, V8, P77, DOI 10.1210/me.8.1.77; Nazareth LV, 1996, J BIOL CHEM, V271, P19900, DOI 10.1074/jbc.271.33.19900; Rowan BG, 2000, J BIOL CHEM, V275, P4475, DOI 10.1074/jbc.275.6.4475; Sampson ER, 2001, J BIOL REG HOMEOS AG, V15, P123; SHIBANUMA M, 1994, J BIOL CHEM, V269, P26767; Stanzione R, 2001, LAB INVEST, V81, P51, DOI 10.1038/labinvest.3780211; Strathdee CA, 1999, GENE, V229, P21, DOI 10.1016/S0378-1119(99)00045-1; Takaoka A, 1999, EMBO J, V18, P2480, DOI 10.1093/emboj/18.9.2480; Tokiwa G, 1996, SCIENCE, V273, P792, DOI 10.1126/science.273.5276.792; Tremblay A, 1999, MOL CELL, V3, P513, DOI 10.1016/S1097-2765(00)80479-7; Wang X, 2001, J BIOL CHEM, V276, P40417, DOI 10.1074/jbc.M104765200; Yang L, 2000, MOL BIOL CELL, V11, P2007, DOI 10.1091/mbc.11.6.2007; Yeh SY, 2000, P NATL ACAD SCI USA, V97, P11256, DOI 10.1073/pnas.190353897; Yeh SY, 1999, P NATL ACAD SCI USA, V96, P5458, DOI 10.1073/pnas.96.10.5458; Yeh SY, 1996, P NATL ACAD SCI USA, V93, P5517, DOI 10.1073/pnas.93.11.5517; Zheng CH, 1998, J BIOL CHEM, V273, P2384, DOI 10.1074/jbc.273.4.2384	32	38	49	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 3	2002	277	18					15426	15431		10.1074/jbc.M111218200	http://dx.doi.org/10.1074/jbc.M111218200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	550PA	11856738	hybrid			2022-12-27	WOS:000175510400028
J	Zhang, YM; Marrakchi, H; Rock, CO				Zhang, YM; Marrakchi, H; Rock, CO			The FabR (YijC) transcription factor regulates unsaturated fatty acid biosynthesis in Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACYL-COENZYME; THERMAL REGULATION; FACTOR FADR; DEPENDENT REGULATION; SYNTHASE-I; BINDING; GENE; METABOLISM; EXPRESSION; BACTERIA	Unsaturated fatty acid biosynthesis is a vital facet of Escherichia coli physiology and requires the expression of two genes, fabA and fabB, in the type II fatty acid synthase system. This study links the FabR (YijC) transcription factor to the regulation of unsaturated fatty acid content through the regulation of fabB gene expression. The yijC (fabR) gene was deleted by replacement with a selectable cassette, and the resulting strains (fabR::kan) possessed significantly elevated levels of unsaturated fatty acids, particularly cis-vaccenate, in their membrane phospholipids. The altered fatty acid composition was observed in the fabR::kan fabF1 double mutant pinpointing fabB as the condensing enzyme responsible for the increased cis-vaccenate production. The fabR::kan strains had 4- to 8-fold higher levels of fabB and a 2- to 3-fold increase in fabA transcripts as judged by Northern blotting, Affymetrix array analysis, and real-time PCR. FabR did not regulate the enzymes of fatty acid beta-oxidation. The elevated level of fabB mRNA was reflected by higher condensing enzyme activity in fabR::kan fabF1 double mutants. Thus, FabR functions as a repressor that potently controls the expression of the fabB gene, which in turn, modulates the physical properties of the membrane by altering the level of unsaturated fatty acid production.	St Jude Childrens Res Hosp, Prot Sci Div, Dept Infect Dis, Memphis, TN 38105 USA; Univ Tennessee, Ctr Hlth Sci, Dept Mol Biosci, Memphis, TN 38163 USA	St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center	Rock, CO (corresponding author), St Jude Childrens Res Hosp, Prot Sci Div, Dept Infect Dis, 332 N Lauderdale St, Memphis, TN 38105 USA.	charles.rock@stjude.org	Marrakchi, Hedia/AAF-2657-2020		NCI NIH HHS [CA 21765] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bateman A, 2000, NUCLEIC ACIDS RES, V28, P263, DOI 10.1093/nar/28.1.263; Black PN, 2000, J NUTR, V130, p305S, DOI 10.1093/jn/130.2.305S; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BLOCH K, 1971, ENZYMES, P441; BOOTH BR, 1980, BIOCHEM BIOPH RES CO, V94, P1029, DOI 10.1016/0006-291X(80)90522-7; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN T, 1994, CURRENT PROTOCOLS MO; Campbell JW, 2001, J BACTERIOL, V183, P5982, DOI 10.1128/JB.183.20.5982-5990.2001; Campbell JW, 2001, ANNU REV MICROBIOL, V55, P305, DOI 10.1146/annurev.micro.55.1.305; CLARK DP, 1983, BIOCHEMISTRY-US, V22, P5897, DOI 10.1021/bi00294a032; Cronan JE, 1998, MOL MICROBIOL, V29, P937, DOI 10.1046/j.1365-2958.1998.00917.x; CRONAN JE, 1975, BACTERIOL REV, V39, P232, DOI 10.1128/MMBR.39.3.232-256.1975; Cronan JE, 1997, J BACTERIOL, V179, P1819, DOI 10.1128/jb.179.5.1819-1823.1997; Cronan JE, 1996, ESCHERICHIA COLI SAL, V1, P612; DEMENDOZA D, 1983, TRENDS BIOCHEM SCI, V8, P49, DOI 10.1016/0968-0004(83)90388-2; DEMENDOZA D, 1983, J BIOL CHEM, V258, P2098; DiRusso CC, 1999, PROG LIPID RES, V38, P129, DOI 10.1016/S0163-7827(98)00022-8; DiRusso CC, 1998, J BIOL CHEM, V273, P33652, DOI 10.1074/jbc.273.50.33652; DIRUSSO CC, 1992, J BIOL CHEM, V267, P8685; DIRUSSO CC, 1985, J BACTERIOL, V161, P583, DOI 10.1128/JB.161.2.583-588.1985; GARWIN JL, 1980, J BIOL CHEM, V255, P3263; GARWIN JL, 1980, J BIOL CHEM, V255, P1949; Gui LZ, 1996, J BACTERIOL, V178, P4704, DOI 10.1128/jb.178.15.4704-4709.1996; Heath RJ, 1996, J BIOL CHEM, V271, P27795, DOI 10.1074/jbc.271.44.27795; HENRY MF, 1992, CELL, V70, P671, DOI 10.1016/0092-8674(92)90435-F; HENRY MF, 1991, J MOL BIOL, V222, P843, DOI 10.1016/0022-2836(91)90574-P; KAUPPINEN S, 1988, CARLSBERG RES COMMUN, V53, P357, DOI 10.1007/BF02983311; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; Lockhart DJ, 1996, NAT BIOTECHNOL, V14, P1675, DOI 10.1038/nbt1296-1675; McCue LA, 2001, NUCLEIC ACIDS RES, V29, P774, DOI 10.1093/nar/29.3.774; MOHAN S, 1994, J BIOL CHEM, V269, P32896; MURRAY MG, 1980, NUCLEIC ACIDS RES, V8, P4321, DOI 10.1093/nar/8.19.4321; NUNN WD, 1983, J BACTERIOL, V154, P554, DOI 10.1128/JB.154.2.554-560.1983; OVERATH P, 1969, EUR J BIOCHEM, V7, P559; RAMAN N, 1995, J BIOL CHEM, V270, P1092, DOI 10.1074/jbc.270.3.1092; Rock C O, 1981, Methods Enzymol, V72, P397; Rock CO, 1996, BBA-LIPID LIPID MET, V1302, P1, DOI 10.1016/0005-2760(96)00056-2; van Aalten DMF, 2000, EMBO J, V19, P5167, DOI 10.1093/emboj/19.19.5167; van Aalten DMF, 2001, EMBO J, V20, P2041, DOI 10.1093/emboj/20.8.2041; Xu YB, 2001, J BIOL CHEM, V276, P17373, DOI 10.1074/jbc.M100195200; YANG SY, 1988, J BACTERIOL, V170, P2543, DOI 10.1128/jb.170.6.2543-2548.1988	41	86	117	2	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 3	2002	277	18					15558	15565		10.1074/jbc.M201399200	http://dx.doi.org/10.1074/jbc.M201399200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	550PA	11859088	hybrid			2022-12-27	WOS:000175510400046
J	Krajewski, WA				Krajewski, WA			Histone acetylation status and DNA sequence modulate ATP-dependent nucleosome repositioning	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHROMATIN; TRANSCRIPTION; DROSOPHILA; ORGANIZATION; HYPERACETYLATION; RECRUITMENT; COMPLEX; ENERGY; GENE	A cell-free system derived from Drosophila embryos was used to investigate positioning of nucleosomes on specific DNA sequences. This system can be used to reconstitute differently acetylated nucleosome arrays possessing ATP-dependent dynamic properties that are not observed with chromatin assembled from pure components. Nucleosome positioning on different DNA sequences was studied by restriction endonuclease assay. The sequence of DNA and the acetylation status of histories had profound effects on the distribution of nucleosomes, suggesting their cooperative effect on nucleosome repositioning.	Russian Acad Sci, Inst Dev Biol, Biochem Lab, Moscow 117808, Russia	Russian Academy of Sciences; Koltzov Institute of Developmental Biology of the Russian Academy of Sciences	Krajewski, WA (corresponding author), Russian Acad Sci, Inst Dev Biol, Biochem Lab, Vavilova St 26, Moscow 117808, Russia.	wkrajewski@hotmail.com	Krajewski, Wladyslaw/J-5414-2018	Krajewski, Wladyslaw/0000-0002-9669-5614				Annunziato AT, 2000, GENE EXPRESSION, V9, P37; Anselmi C, 2000, BIOPHYS J, V79, P601, DOI 10.1016/S0006-3495(00)76319-3; AUSIO J, 1986, BIOCHEMISTRY-US, V25, P1421, DOI 10.1021/bi00354a035; BECKER PB, 1992, MOL CELL BIOL, V12, P2241, DOI 10.1128/MCB.12.5.2241; Boyer LA, 2000, J BIOL CHEM, V275, P18864, DOI 10.1074/jbc.M002810200; Cosma MP, 1999, CELL, V97, P299, DOI 10.1016/S0092-8674(00)80740-0; Esposito F, 1988, Oxf Surv Eukaryot Genes, V5, P1; Filesi I, 2000, BIOPHYS CHEM, V83, P223, DOI 10.1016/S0301-4622(99)00143-X; GARCIARAMIREZ M, 1995, J BIOL CHEM, V270, P17923, DOI 10.1074/jbc.270.30.17923; Gu WG, 2000, EMBO J, V19, P5202, DOI 10.1093/emboj/19.19.5202; Hayes JJ, 2001, CURR OPIN GENET DEV, V11, P124, DOI 10.1016/S0959-437X(00)00168-4; Ito T, 2000, GENE DEV, V14, P1899; Kingston RE, 1999, GENE DEV, V13, P2339, DOI 10.1101/gad.13.18.2339; Krajewski WA, 1999, METH MOL B, V119, P207; Krajewski WA, 2000, MOL GEN GENET, V263, P38, DOI 10.1007/PL00008674; Krajewski WA, 1996, MOL GEN GENET, V252, P249; Krajewski WA, 1999, FEBS LETT, V452, P215, DOI 10.1016/S0014-5793(99)00637-7; KRAJEWSKI WA, 1992, MOL GEN GENET, V235, P381, DOI 10.1007/BF00279384; Krebs JE, 1999, GENE DEV, V13, P1412, DOI 10.1101/gad.13.11.1412; Lee DH, 2000, DATA KNOWL ENG, V34, P77, DOI 10.1016/S0169-023X(00)00009-4; Logie C, 1999, BIOCHEMISTRY-US, V38, P2514, DOI 10.1021/bi982109d; Luger K, 1998, CURR OPIN STRUC BIOL, V8, P33, DOI 10.1016/S0959-440X(98)80007-9; LUTTER LC, 1989, P NATL ACAD SCI USA, V86, P8712, DOI 10.1073/pnas.86.22.8712; MUYLDERMANS S, 1994, J MOL BIOL, V235, P855, DOI 10.1006/jmbi.1994.1044; Nightingale KP, 1998, EMBO J, V17, P2865, DOI 10.1093/emboj/17.10.2865; NORTON VG, 1989, CELL, V57, P449, DOI 10.1016/0092-8674(89)90920-3; Paro R, 2000, NATURE, V406, P579, DOI 10.1038/35020675; Peterson CL, 2000, J CELL BIOCHEM, V78, P179, DOI 10.1002/(SICI)1097-4644(20000801)78:2<179::AID-JCB1>3.0.CO;2-E; Ramakrishnan V, 1997, ANNU REV BIOPH BIOM, V26, P83, DOI 10.1146/annurev.biophys.26.1.83; Sterner DE, 2000, MICROBIOL MOL BIOL R, V64, P435, DOI 10.1128/MMBR.64.2.435-459.2000; Syntichaki P, 2000, NATURE, V404, P414, DOI 10.1038/35006136; Travers AA, 1996, J MOL BIOL, V257, P486, DOI 10.1006/jmbi.1996.0178; TURNER BM, 1993, CELL, V75, P5, DOI 10.1016/S0092-8674(05)80078-9; VARGAWEISZ PD, 1995, EMBO J, V14, P2209, DOI 10.1002/j.1460-2075.1995.tb07215.x; Whitehouse I, 2000, BIOCHEM SOC T, V28, P376, DOI 10.1042/0300-5127:0280376; ZHURKIN VB, 1985, J BIOMOL STRUCT DYN, V2, P785, DOI 10.1080/07391102.1985.10506324	36	13	13	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 26	2002	277	17					14509	14513		10.1074/jbc.M107510200	http://dx.doi.org/10.1074/jbc.M107510200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	545EH	11859068	hybrid			2022-12-27	WOS:000175203000022
J	Reichard, P				Reichard, P			Osvald T. Avery and the Nobel Prize in Medicine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Editorial Material							NUCLEIC-ACID; CHROMOSOMES		Karolinska Inst, MBB, Med Nobel Inst, Dept Biochem, S-17177 Stockholm, Sweden	Karolinska Institutet	Reichard, P (corresponding author), Karolinska Inst, MBB, Med Nobel Inst, Dept Biochem, S-17177 Stockholm, Sweden.							ALEXANDER HE, 1953, J EXP MED, V97, P17, DOI 10.1084/jem.97.1.17; Astbury W.T., 1938, NATURE, V141, P747, DOI [10.1038/141747b0, DOI 10.1038/141747B0]; Avery OT, 1944, J EXP MED, V79, P137, DOI 10.1084/jem.79.2.137; BOIVIN A, 1947, COLD SPRING HARB SYM, V12, P7, DOI 10.1101/SQB.1947.012.01.004; BOIVIN A, 1948, CR HEBD ACAD SCI, V226, P1061; Brachet J., 1937, Archives de Biologie Liege, V48, P529; Caspersson T, 1938, NATURE, V142, P294, DOI 10.1038/142294a0; CASPERSSON T, 1968, EXP CELL RES, V49, P219, DOI 10.1016/0014-4827(68)90538-7; Caspersson T., 1937, Protoplasma Leipzig, V27, P463, DOI 10.1007/BF01599413; Caspersson T, 1934, BIOCHEM Z, V270, P161; Caspersson T, 1935, T FARADAY SOC, V31, P0367, DOI 10.1039/tf9353100367; CASPERSSON T, 1936, SCAND ARCH PHYSIO S8, V73, P1; CASPERSSON T, 1938, NATURE, V143, P602; Caspersson T., 1941, CHROMOSOMA, V2, P132; HAMMARSTEN E, 1946, ACTA PHYSIOL SCAND, V11, P335, DOI 10.1111/j.1748-1716.1946.tb00354.x; Hammarsten E, 1924, BIOCHEM Z, V144, P383; HAMMARSTEN E, 1939, J MT SINAI HOSP, V6, P115; HAMMARSTEN E, 1922, Z PHYSL CHEM, V118, P224; HERSHEY AD, 1952, J GEN PHYSIOL, V36, P39, DOI 10.1085/jgp.36.1.39; HOTCHKISS RD, 1951, COLD SPRING HARB SYM, V16, P457, DOI 10.1101/SQB.1951.016.01.032; Jorpes E, 1928, ACTA MED SCAND, V68, P503; KUNITZ M, 1948, SCIENCE, V108, P19, DOI 10.1126/science.108.2792.19-a; KUNITZ M., 1940, JOUR GEN PHYSIOL, V24, P15, DOI 10.1085/jgp.24.1.15; Levene P. A., 1931, NUCL ACIDS; MALMGREN B, 1948, ACTA PATHOL MIC SC, V24, P437; MCCARTHY M, TRANSFORMING PRINCIP; MCCARTY M, 1946, J EXP MED, V83, P97, DOI 10.1084/jem.83.2.97; MCCARTY M, 1946, J GEN PHYSIOL, V29, P123, DOI 10.1085/jgp.29.3.123; REICHARD P, 1995, ANNU REV BIOCHEM, V64, P1; Schoenheimer R, 1949, DYNAMIC STATE BODY C; SIGNER W, 1938, NATURE, V141, P122; Stahl F. W., 2000, WE CAN SLEEP LATER A; WATSON JD, 1953, NATURE, V171, P737, DOI 10.1038/171737a0	33	7	9	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 19	2002	277	16					13355	13362		10.1074/jbc.R200002200	http://dx.doi.org/10.1074/jbc.R200002200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	543HR	11872756	hybrid			2022-12-27	WOS:000175096000001
J	Reid, J; Kelly, SM; Watt, K; Price, NC; McEwan, IJ				Reid, J; Kelly, SM; Watt, K; Price, NC; McEwan, IJ			Conformational analysis of the androgen receptor amino-terminal domain involved in transactivation - Influence of structure-stabilizing solutes and protein-protein interactions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTIONAL ACTIVATION DOMAIN; HUMAN GLUCOCORTICOID RECEPTOR; LIGAND-BINDING DOMAIN; NUCLEAR RECEPTOR; SECONDARY STRUCTURE; ALPHA-HELIX; IN-VITRO; COACTIVATOR; REGIONS; VP16	The androgen receptor (AR) is a member of the nuclear receptor superfamily. Sequences within the large amino-terminal domain of the receptor have been shown to be important for transactivation and protein-protein interactions; however, little is known about the structure and folding of this region. In the present study we show that a 344-amino acid polypeptide representing the main determinants for transactivation has the propensity to form a-helical structure and that mutations which disrupt putative helical regions alter conformation. Folding of the AR was observed in the presence of the helix-stabilizing solvent trifluoroethanol and the natural osmolyte trimethylamine N-oxide (TMAO). TMAO resulted in the movement of two tryptophan residues to a less solvent-exposed environment and the formation of secondary/tertiary structure resistant to protease cleavage. Critically, binding to the RAP74 subunit of the general transcription factor TFIIF resulted in extensive protease resistance, consistent with induced folding of the receptor transactivation domain. These data indicate that this region of the AR is structurally flexible and folds into a stable conformation upon interactions with a component of the general transcription machinery.	Univ Aberdeen, Inst Med Sci, Dept Mol & Cell Biol, Aberdeen AB25 2ZD, Scotland; Univ Glasgow, IBLS, Div Biochem & Mol Biol, Glasgow G12 8QQ, Lanark, Scotland	University of Aberdeen; University of Glasgow	McEwan, IJ (corresponding author), Univ Aberdeen, Inst Med Sci, Dept Mol & Cell Biol, Foresterhill, Aberdeen AB25 2ZD, Scotland.		Kelly, Sharon/K-4611-2013	Kelly, Sharon/0000-0002-3516-1387				Alen P, 1999, MOL CELL BIOL, V19, P6085; Bain DL, 2000, J BIOL CHEM, V275, P7313, DOI 10.1074/jbc.275.10.7313; Baskakov I, 1998, J BIOL CHEM, V273, P4831, DOI 10.1074/jbc.273.9.4831; Baskakov IV, 1999, J BIOL CHEM, V274, P10693, DOI 10.1074/jbc.274.16.10693; Berrevoets CA, 1998, MOL ENDOCRINOL, V12, P1172, DOI 10.1210/me.12.8.1172; Bevan CL, 1999, MOL CELL BIOL, V19, P8383; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CammersGoodwin A, 1996, J AM CHEM SOC, V118, P3082, DOI 10.1021/ja952900z; Cato ACB, 1998, TRENDS ENDOCRIN MET, V9, P150, DOI 10.1016/S1043-2760(98)00039-3; Chamberlain NL, 1996, J BIOL CHEM, V271, P26772, DOI 10.1074/jbc.271.43.26772; Choong CS, 1998, J MOL ENDOCRINOL, V21, P235, DOI 10.1677/jme.0.0210235; DahlmanWright K, 1996, BIOCHEMISTRY-US, V35, P1323, DOI 10.1021/bi952409k; DAHLMANWRIGHT K, 1995, P NATL ACAD SCI USA, V92, P1699, DOI 10.1073/pnas.92.5.1699; Doesburg P, 1997, BIOCHEMISTRY-US, V36, P1052, DOI 10.1021/bi961775g; DONALDSON L, 1992, J BIOL CHEM, V267, P1411; EFTINK MR, 1976, BIOCHEMISTRY-US, V15, P672, DOI 10.1021/bi00648a035; Gao TS, 1996, J STEROID BIOCHEM, V59, P9, DOI 10.1016/S0960-0760(96)00097-0; He B, 2000, J BIOL CHEM, V275, P22986, DOI 10.1074/jbc.M002807200; He B, 1999, J BIOL CHEM, V274, P37219, DOI 10.1074/jbc.274.52.37219; Hi R, 1999, J BIOL CHEM, V274, P35152, DOI 10.1074/jbc.274.49.35152; Hiipakka RA, 1998, TRENDS ENDOCRIN MET, V9, P317, DOI 10.1016/S1043-2760(98)00081-2; Hsiao PW, 1999, J BIOL CHEM, V274, P22373, DOI 10.1074/jbc.274.32.22373; Hua QX, 1998, BIOCHEMISTRY-US, V37, P5858, DOI 10.1021/bi9800808; Ikonen T, 1997, J BIOL CHEM, V272, P29821, DOI 10.1074/jbc.272.47.29821; JENSTER G, 1995, J BIOL CHEM, V270, P7341, DOI 10.1074/jbc.270.13.7341; JENSTER G, 1994, BIOCHEMISTRY-US, V33, P14064, DOI 10.1021/bi00251a015; JENSTER G, 1991, MOL ENDOCRINOL, V5, P1396, DOI 10.1210/mend-5-10-1396; Kumar R, 1999, STEROIDS, V64, P310, DOI 10.1016/S0039-128X(99)00014-8; Kumar R, 1999, J BIOL CHEM, V274, P24737, DOI 10.1074/jbc.274.35.24737; Kumar R, 2001, J BIOL CHEM, V276, P18146, DOI 10.1074/jbc.M100825200; Langley E, 1998, J BIOL CHEM, V273, P92, DOI 10.1074/jbc.273.1.92; LANGLEY E, 1995, J BIOL CHEM, V270, P29983; Lee DK, 2000, J BIOL CHEM, V275, P9308, DOI 10.1074/jbc.275.13.9308; Lee H, 2000, J BIOL CHEM, V275, P29426, DOI 10.1074/jbc.M003107200; Ma H, 1999, MOL CELL BIOL, V19, P6164; Matias PM, 2000, J BIOL CHEM, V275, P26164, DOI 10.1074/jbc.M004571200; McEwan IJ, 1997, P NATL ACAD SCI USA, V94, P8485, DOI 10.1073/pnas.94.16.8485; McEwan IJ, 2001, BIOCHEM SOC T, V29, P222; McEwan IJ, 1996, BIOCHEMISTRY-US, V35, P9584, DOI 10.1021/bi960793v; Nagadoi A, 1999, J MOL BIOL, V287, P593, DOI 10.1006/jmbi.1999.2620; OHARE P, 1992, BIOCHEMISTRY-US, V31, P4150, DOI 10.1021/bi00131a035; Parker D, 1999, MOL CELL BIOL, V19, P5601; Poujol N, 2000, J BIOL CHEM, V275, P24022, DOI 10.1074/jbc.M001999200; Radhakrishnan I, 1997, CELL, V91, P741, DOI 10.1016/S0092-8674(00)80463-8; RAJUN R, 1996, INT J PEPT PROT RES, V48, P328; SCHMITZ ML, 1994, J BIOL CHEM, V269, P25613; Shen F, 1996, J BIOL CHEM, V271, P4819; Shen F, 1996, J BIOL CHEM, V271, P4827; SIMENTAL JA, 1991, J BIOL CHEM, V266, P510; SREERAMA N, 1993, ANAL BIOCHEM, V209, P32, DOI 10.1006/abio.1993.1079; Tan JA, 2000, ENDOCRINOLOGY, V141, P3440, DOI 10.1210/en.141.9.3440; Uesugi M, 1997, SCIENCE, V277, P1310, DOI 10.1126/science.277.5330.1310; WANG BQ, 1995, J BIOL CHEM, V270, P27035, DOI 10.1074/jbc.270.45.27035; Warnmark A, 2001, J BIOL CHEM, V276, P45939, DOI 10.1074/jbc.M107875200; Wright PE, 1999, J MOL BIOL, V293, P321, DOI 10.1006/jmbi.1999.3110; Yamamoto A, 2000, J CELL BIOL, V150, P873, DOI 10.1083/jcb.150.4.873	56	108	119	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 31	2002	277	22					20079	20086		10.1074/jbc.M201003200	http://dx.doi.org/10.1074/jbc.M201003200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	557EH	11896058	hybrid			2022-12-27	WOS:000175894800109
J	Sweet, CR; Preston, A; Toland, E; Ramirez, SM; Cotter, RJ; Maskell, DJ; Raetz, CRH				Sweet, CR; Preston, A; Toland, E; Ramirez, SM; Cotter, RJ; Maskell, DJ; Raetz, CRH			Relaxed acyl chain specificity of Bordetella UDP-N-acetylglucosamine acyltransferases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIPID-A BIOSYNTHESIS; ESCHERICHIA-COLI ENCODES; LIPOPOLYSACCHARIDE BIOSYNTHESIS; BRONCHISEPTICA INFECTION; ENDOTOXIN BIOSYNTHESIS; CARRIER PROTEIN; KENNEL COUGH; GENE; PERTUSSIS; IDENTIFICATION	Lipid A (endotoxin) is a major structural component of Gram-negative outer membranes. It also serves as the hydrophobic anchor of lipopolysaccharide and is a potent activator of the innate immune response. Lipid A molecules from the genus Bordetella are reported to exhibit unusual structural asymmetry with respect to the acyl chains at the 3- and 3'-positions. These acyl chains are attached by LTDP-N-acetylglucosamine acyltransferase (LpxA). To determine the origin of the acyl variability, the single lpxA ortholog present in each of the genomes of Bordetella bronchiseptica (lpxA(Br)), Bordetella parapertussis (lpxA(Pa)), and Bordetella pertussis (lpxA(Pe)) was cloned and expressed in Escherichia coli. In contrast to all LpxA proteins studied to date, LpxA]3, and LpxA(Pe) display relaxed acyl chain length specificity in vitro, utilizing C10OH-ACP, C12OH-ACP, and C14OH-ACP at similar rates. Furthermore, hybrid lipid A molecules synthesized at 42 degreesC by an E. coli lpxA mutant complemented with lpxA(Pe) contain C10OH, C12OH, and C14OH at both the 3- and 3'-positions, as determined by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. In contrast, LpxA from B. parapertussis did not display relaxed specificity but was selective for C10OH-ACP. This study provides an enzymatic explanation for some of the unusual acyl chain variations found in Bordetella lipid A.	Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA; Univ Cambridge, Dept Clin Vet Med, Ctr Vet Sci, Cambridge CB3 0ES, England; Johns Hopkins Univ, Dept Pharmacol & Mol Sci, Middle Atlantic Mass Spectrometry Facil, Baltimore, MD 21205 USA	Duke University; University of Cambridge; Johns Hopkins University	Raetz, CRH (corresponding author), Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA.	raetz@biochem.duke.edu		Preston, Andrew/0000-0002-1489-280X; Kalb, Suzanne/0000-0002-8067-136X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008558, R01GM054882, R01GM051310] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM54882, GM51310, GM08558] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Allen A, 1996, MOL MICROBIOL, V19, P37, DOI 10.1046/j.1365-2958.1996.354877.x; AMANO K, 1990, J GEN MICROBIOL, V136, P481, DOI 10.1099/00221287-136-3-481; ANDERSON MS, 1985, J BIOL CHEM, V260, P5536; ANDERSON MS, 1987, J BIOL CHEM, V262, P5159; Aussel L, 2000, RAPID COMMUN MASS SP, V14, P595, DOI 10.1002/(SICI)1097-0231(20000415)14:7<595::AID-RCM919>3.0.CO;2-4; Ausubel FM, 1988, MOL REPROD DEV; Babinski KJ, 1998, FASEB J, V12, pA1288; BURNS EH, 1993, J CLIN MICROBIOL, V31, P1838, DOI 10.1128/JCM.31.7.1838-1844.1993; Caroff M, 2001, J ENDOTOXIN RES, V7, P63, DOI 10.1177/09680519010070011101; CAROFF M, 1990, J BACTERIOL, V172, P1121, DOI 10.1128/jb.172.2.1121-1128.1990; Caroff M, 2000, FEBS LETT, V477, P8, DOI 10.1016/S0014-5793(00)01720-8; CAROFF M, 1994, 17 INT CARB S; Chaby R, 1988, PATHOGENESIS IMMUNIT, P247; Cherry JD, 1996, J INFECT DIS, V174, pS259, DOI 10.1093/infdis/174.Supplement_3.S259; CHERRY JD, 1992, VACCINE, V10, P1033, DOI 10.1016/0264-410X(92)90113-X; CLEMENTZ T, 1991, J BIOL CHEM, V266, P9687; Clementz T, 1996, J BIOL CHEM, V271, P12095, DOI 10.1074/jbc.271.20.12095; Clementz T, 1997, J BIOL CHEM, V272, P10353; COLEMAN J, 1988, J BACTERIOL, V170, P1268, DOI 10.1128/jb.170.3.1268-1274.1988; COSTELLO CE, 1990, METHOD ENZYMOL, V193, P738, DOI 10.1016/0076-6879(90)93448-T; COTTER PA, 1994, INFECT IMMUN, V62, P3381, DOI 10.1128/IAI.62.8.3381-3390.1994; Cotter PA, 2001, PRINCIPLES BACTERIAL, P619; CROWELL DN, 1986, J BACTERIOL, V168, P152, DOI 10.1128/jb.168.1.152-159.1986; GALANOS C, 1985, EUR J BIOCHEM, V148, P1, DOI 10.1111/j.1432-1033.1985.tb08798.x; GALLOWAY SM, 1990, J BIOL CHEM, V265, P6394; Garrett TA, 1997, J BIOL CHEM, V272, P21855, DOI 10.1074/jbc.272.35.21855; GUEIRARD P, 1995, J CLIN MICROBIOL, V33, P2002, DOI 10.1128/JCM.33.8.2002-2006.1995; HEININGER U, 1994, PEDIATR INFECT DIS J, V13, P306, DOI 10.1097/00006454-199404000-00011; KELLY TM, 1993, J BIOL CHEM, V268, P19866; Khan SA, 1998, MOL MICROBIOL, V29, P571, DOI 10.1046/j.1365-2958.1998.00952.x; LEBBAR S, 1994, CARBOHYD RES, V259, P257, DOI 10.1016/0008-6215(94)84061-X; LUDERITZ O, 1966, ANN NY ACAD SCI, V133, P349, DOI 10.1111/j.1749-6632.1966.tb52376.x; MOHAN S, 1994, J BIOL CHEM, V269, P32896; Nennig ME, 1996, JAMA-J AM MED ASSOC, V275, P1672, DOI 10.1001/jama.275.21.1672; Odegaard TJ, 1997, J BIOL CHEM, V272, P19688, DOI 10.1074/jbc.272.32.19688; Onishi HR, 1996, SCIENCE, V274, P980, DOI 10.1126/science.274.5289.980; Pichichero ME, 1997, ARCH PEDIAT ADOL MED, V151, P35, DOI 10.1001/archpedi.1997.02170380039006; PORTER JF, 1995, FEMS MICROBIOL LETT, V132, P195, DOI 10.1111/j.1574-6968.1995.tb07833.x; Porter JF, 1996, FEMS MICROBIOL LETT, V135, P131, DOI 10.1111/j.1574-6968.1996.tb07977.x; PORTER JF, 1994, MICROBIOL-SGM, V140, P255, DOI 10.1099/13500872-140-2-255; RAETZ CRH, 1995, SCIENCE, V270, P997, DOI 10.1126/science.270.5238.997; RAETZ CRH, 1996, ESCHERICHIA COLI SAL, P1035; RAY A, 1991, FEMS MICROBIOL LETT, V79, P211, DOI 10.1016/0378-1097(91)90088-R; REINA J, 1991, INFECTION, V19, P46, DOI 10.1007/BF01643760; Rick PD, 1999, ENDOTOXIN IN HEALTH AND DISEASE, P283; RIETSCHEL ET, 1994, FASEB J, V8, P217, DOI 10.1096/fasebj.8.2.8119492; RUTTER JM, 1981, VET REC, V108, P451, DOI 10.1136/vr.108.21.451; SCHNAITMAN CA, 1993, MICROBIOL REV, V57, P655, DOI 10.1128/MMBR.57.3.655-682.1993; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; STIBITZ S, 1989, NATURE, V338, P266, DOI 10.1038/338266a0; Sweet CR, 2001, J BIOL CHEM, V276, P19565, DOI 10.1074/jbc.M101868200; Tamion F, 1996, SCAND J INFECT DIS, V28, P197, DOI 10.3109/00365549609049077; THRUSFIELD MV, 1991, J SMALL ANIM PRACT, V32, P215, DOI 10.1111/j.1748-5827.1991.tb00550.x; THRUSFIELD MV, 1991, J SMALL ANIM PRACT, V32, P455, DOI 10.1111/j.1748-5827.1991.tb00987.x; TOMASIEWICZ HG, 1987, J BACTERIOL, V169, P5735, DOI 10.1128/jb.169.12.5735-5744.1987; VanderZee A, 1997, J BACTERIOL, V179, P6609, DOI 10.1128/jb.179.21.6609-6617.1997; WATANABE M, 1990, J GEN MICROBIOL, V136, P489, DOI 10.1099/00221287-136-3-489; WESTPHAL O, 1983, PROG ALLERGY, V33, P9; Wyckoff TJO, 1998, TRENDS MICROBIOL, V6, P154, DOI 10.1016/S0966-842X(98)01230-X; Wyckoff TJO, 1998, J BIOL CHEM, V273, P32369, DOI 10.1074/jbc.273.49.32369; Wyckoff TJO, 1999, J BIOL CHEM, V274, P27047, DOI 10.1074/jbc.274.38.27047; Young K, 1995, J BIOL CHEM, V270, P30384, DOI 10.1074/jbc.270.51.30384; Zahringer U, 1999, ENDOTOXIN IN HEALTH AND DISEASE, P93; Zarrouk H, 1997, J BACTERIOL, V179, P3756, DOI 10.1128/jb.179.11.3756-3760.1997	64	31	32	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 24	2002	277	21					18281	18290		10.1074/jbc.M201057200	http://dx.doi.org/10.1074/jbc.M201057200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	558PM	11889134	hybrid			2022-12-27	WOS:000175975800007
J	Voss, TS; Mini, T; Jenoe, P; Beck, HP				Voss, TS; Mini, T; Jenoe, P; Beck, HP			Plasmodium falciparum possesses a cell cycle-regulated short type replication protein A large subunit encoded by an unusual transcript	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE-STRANDED-DNA; SIMIAN VIRUS-40 DNA; STAGE-SPECIFIC EXPRESSION; POLYMERASE-ALPHA; BINDING-PROTEIN; MALARIA PARASITE; FACTOR-A; MOLECULAR CHARACTERIZATION; CRITHIDIA-FASCICULATA; FUNCTIONAL DOMAINS	DNA replication in Plasmodium parasites takes place at multiple distinct points during their complex life cycle in the mosquito and vertebrate hosts. Although several parasite proteins involved in DNA replication have been described, the various mechanisms engaged in DNA metabolism of this major pathogen remain largely unexplored. As a step toward understanding this complex network, we describe the identification of Plasmodium falciparum replication protein A large subunit (pfRPA1) through affinity purification and mass spectral analysis of a purified 55-kDa factor. Gel retardation experiments revealed that pfRPA is the major single-stranded DNA binding activity in parasite protein extracts. The activity was expressed in a cell cycle-dependent manner with peak activities in late trophozoites and schizonts, thus correlating with the beginning of chromosomal DNA replication. Accordingly, the pfrpa1 message was detected in parasites 20-24 h post-invasion which is in agreement with the expression of other P. falciparum DNA replication genes. Our results show that pfRPA1 is encoded by an unusual 6.5-kb transcript containing a single open reading frame of which only the C-terminal 42% of the deduced protein sequence shows homologies to other reported RPA1s. Like the orthologues of other protozoan parasites, pfRPA1 lacks the N-terminal protein interaction domain and is thus remarkably smaller than the RPA1s of higher eukaryotes.	Swiss Trop Inst, Dept Med Parasitol & Infect Biol, CH-4051 Basel, Switzerland; Univ Basel, Biozentrum, CH-4056 Basel, Switzerland	University of Basel; Swiss Tropical & Public Health Institute; University of Basel	Beck, HP (corresponding author), Swiss Trop Inst, Dept Med Parasitol & Infect Biol, Socinstr 59, CH-4051 Basel, Switzerland.			Beck, Hans-Peter/0000-0001-8326-4834				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BLACKWELL LJ, 1994, MOL CELL BIOL, V14, P3993, DOI 10.1128/MCB.14.6.3993; Bowman S, 1999, NATURE, V400, P532, DOI 10.1038/22964; Braun KA, 1997, BIOCHEMISTRY-US, V36, P8443, DOI 10.1021/bi970473r; BRILL SJ, 1989, NATURE, V342, P92, DOI 10.1038/342092a0; BROWN GW, 1994, MOL BIOCHEM PARASIT, V63, P135, DOI 10.1016/0166-6851(94)90016-7; BROWN GW, 1992, P NATL ACAD SCI USA, V89, P10227, DOI 10.1073/pnas.89.21.10227; Brush GS, 1995, METHOD ENZYMOL, V262, P522; Carlton J, 2000, PARASITOL TODAY, V16, P409, DOI 10.1016/S0169-4758(00)01781-6; CHAVALITSHEWINKOON P, 1993, MOL BIOCHEM PARASIT, V61, P243, DOI 10.1016/0166-6851(93)90070-E; CHEESMAN S, 1994, NUCLEIC ACIDS RES, V22, P2547, DOI 10.1093/nar/22.13.2547; Cheesman S, 1998, MOL BIOCHEM PARASIT, V92, P39, DOI 10.1016/S0166-6851(97)00223-5; Crabb BS, 1996, P NATL ACAD SCI USA, V93, P7289, DOI 10.1073/pnas.93.14.7289; DORNREITER I, 1992, EMBO J, V11, P769, DOI 10.1002/j.1460-2075.1992.tb05110.x; DUTTA A, 1993, NATURE, V365, P79, DOI 10.1038/365079a0; ERDILE LF, 1991, J BIOL CHEM, V266, P12090; FAIRMAN MP, 1988, EMBO J, V7, P1211, DOI 10.1002/j.1460-2075.1988.tb02933.x; FIRMENICH AA, 1995, MOL CELL BIOL, V15, P1620; FOX BA, 1993, MOL BIOCHEM PARASIT, V61, P37, DOI 10.1016/0166-6851(93)90156-R; FOX BA, 1991, MOL BIOCHEM PARASIT, V49, P289, DOI 10.1016/0166-6851(91)90072-E; GarciaMaya MM, 1997, FEBS LETT, V413, P181, DOI 10.1016/S0014-5793(97)00897-1; Gardner MJ, 1998, SCIENCE, V282, P1126, DOI 10.1126/science.282.5391.1126; GEORGAKI A, 1992, FEBS LETT, V308, P240, DOI 10.1016/0014-5793(92)81283-R; GEORGAKI A, 1993, NUCLEIC ACIDS RES, V21, P3659, DOI 10.1093/nar/21.16.3659; Gomes XV, 1996, BIOCHEMISTRY-US, V35, P10558, DOI 10.1021/bi9607517; HE ZG, 1995, NATURE, V374, P566, DOI 10.1038/374566a0; HE ZG, 1993, CELL, V73, P1223, DOI 10.1016/0092-8674(93)90650-F; HOPPESEYLER F, 1991, NUCLEIC ACIDS RES, V19, P5080, DOI 10.1093/nar/19.18.5080; Horrocks P, 1996, MOL BIOCHEM PARASIT, V79, P177, DOI 10.1016/0166-6851(96)02657-6; INSELBURG J, 1984, MOL BIOCHEM PARASIT, V10, P79, DOI 10.1016/0166-6851(84)90020-3; Ishiai M, 1996, J BIOL CHEM, V271, P20868, DOI 10.1074/jbc.271.34.20868; JAIKARIA NS, 1993, MOL BIOCHEM PARASIT, V57, P269, DOI 10.1016/0166-6851(93)90203-A; KENNY MK, 1989, P NATL ACAD SCI USA, V86, P9757, DOI 10.1073/pnas.86.24.9757; KILBEY BJ, 1993, NUCLEIC ACIDS RES, V21, P239, DOI 10.1093/nar/21.2.239; KIM CS, 1992, MOL CELL BIOL, V12, P3050, DOI 10.1128/MCB.12.7.3050; Kim DK, 1996, J BIOL CHEM, V271, P15124, DOI 10.1074/jbc.271.25.15124; Kyes S, 2000, MOL BIOCHEM PARASIT, V105, P311, DOI 10.1016/S0166-6851(99)00193-0; LAMBROS C, 1979, J PARASITOL, V65, P418, DOI 10.2307/3280287; LI R, 1993, CELL, V73, P1207, DOI 10.1016/0092-8674(93)90649-B; LI WB, 1989, NUCLEIC ACIDS RES, V17, P9621, DOI 10.1093/nar/17.23.9621; LI WB, 1991, MOL BIOCHEM PARASIT, V46, P229, DOI 10.1016/0166-6851(91)90047-A; Lin YL, 1996, J BIOL CHEM, V271, P17190, DOI 10.1074/jbc.271.29.17190; LONGHESE MP, 1994, MOL CELL BIOL, V14, P7884, DOI 10.1128/MCB.14.12.7884; Martin D, 2000, MOL BIOCHEM PARASIT, V110, P93, DOI 10.1016/S0166-6851(00)00260-7; Matsunaga T, 1996, J BIOL CHEM, V271, P11047, DOI 10.1074/jbc.271.19.11047; MCCUTCHAN TF, 1984, SCIENCE, V225, P808, DOI 10.1126/science.6382604; MELENDY T, 1993, J BIOL CHEM, V268, P3389; Park MS, 1996, J BIOL CHEM, V271, P18996, DOI 10.1074/jbc.271.31.18996; POLLACK Y, 1982, NUCLEIC ACIDS RES, V10, P539, DOI 10.1093/nar/10.2.539; RIDLEY RG, 1991, NUCLEIC ACIDS RES, V19, P6731, DOI 10.1093/nar/19.24.6731; Scaife J.G., 1988, Genetic Engineering, V7, P57; SEROUSSI E, 1993, J BIOL CHEM, V268, P7147; Stahl DC, 1996, J AM SOC MASS SPECTR, V7, P532, DOI 10.1016/1044-0305(96)00057-8; TOSH K, 1995, GENE, V163, P151, DOI 10.1016/0378-1119(95)00376-H; Tosh K, 1999, EXP PARASITOL, V91, P126, DOI 10.1006/expr.1998.4362; TRAGER W, 1978, NATURE, V273, P621, DOI 10.1038/273621a0; Treuner K, 1996, J MOL BIOL, V259, P104, DOI 10.1006/jmbi.1996.0305; TSURIMOTO T, 1989, EMBO J, V8, P3883, DOI 10.1002/j.1460-2075.1989.tb08567.x; TSURIMOTO T, 1991, J BIOL CHEM, V266, P1961; TSURIMOTO T, 1991, J BIOL CHEM, V266, P1950; Voss TS, 2000, MOL BIOCHEM PARASIT, V107, P103, DOI 10.1016/S0166-6851(00)00176-6; WEBER JL, 1987, GENE, V52, P103, DOI 10.1016/0378-1119(87)90399-4; White JH, 1996, PARASITOL TODAY, V12, P151, DOI 10.1016/0169-4758(96)10005-3; WHITE JH, 1993, NUCLEIC ACIDS RES, V21, P3643, DOI 10.1093/nar/21.16.3643; WOBBE CR, 1987, P NATL ACAD SCI USA, V84, P1834, DOI 10.1073/pnas.84.7.1834; Wold MS, 1997, ANNU REV BIOCHEM, V66, P61, DOI 10.1146/annurev.biochem.66.1.61; WOLD MS, 1989, J BIOL CHEM, V264, P2801; WOLD MS, 1988, P NATL ACAD SCI USA, V85, P2523, DOI 10.1073/pnas.85.8.2523; YATES JR, 1995, ANAL CHEM, V67, P1426, DOI 10.1021/ac00104a020; Zhu G, 1999, FEMS MICROBIOL LETT, V176, P367, DOI 10.1111/j.1574-6968.1999.tb13685.x	70	48	50	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 17	2002	277	20					17493	17501		10.1074/jbc.M200100200	http://dx.doi.org/10.1074/jbc.M200100200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	553PR	11880371	hybrid			2022-12-27	WOS:000175685100015
J	Friedrich, EB; Sinha, S; Li, L; Dedhar, S; Force, T; Rosenzweig, A; Gerszten, RE				Friedrich, EB; Sinha, S; Li, L; Dedhar, S; Force, T; Rosenzweig, A; Gerszten, RE			Role of integrin-linked kinase in leukocyte recruitment	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FLOW CONDITIONS; CELL-ADHESION; PHOSPHOINOSITIDE 3-KINASE-GAMMA; VASCULAR ENDOTHELIUM; EXTRACELLULAR-MATRIX; SIGNAL-TRANSDUCTION; PROTEIN-KINASE; BETA-GAMMA; IN-VITRO; ACTIVATION	Chemokines modulate leukocyte integrin avidity to coordinate adhesion and subsequent transendothelial migration, although the sequential signaling pathways involved remain poorly characterized. Here we show that integrin-linked kinase (ILK), a 59-kDa serine-threonine protein kinase that interacts principally with beta(1), integrins, is highly expressed in human mononuclear cells and is activated by exposure of leukocytes to the chemokine monocyte chemoattractant protein-1. Biochemical inhibitor studies show that chemokine-triggered activation of ILK is downstream of phosphoinositide 3-kinase. In functional assays under physiologically relevant flow conditions, overexpression of wild-type ILK in human monocytic cells diminishes beta(1), integrin/vascular cell adhesion molecule-1-dependent firm adhesion to human endothelial cells. These data implicate ILK in the dynamic signaling events involved in the regulation of leukocyte integrin avidity for endothelial substrates.	Massachusetts Gen Hosp, Ctr Immunol & Inflammatory Dis, Charlestown, MA 02129 USA; Massachusetts Gen Hosp, Program Cardiovasc Gene Therapy, Cardiovasc Res Ctr, Charlestown, MA 02129 USA; Harvard Med Sch, Boston, MA USA; Univ British Columbia, Dept Biochem & Mol Biol, Vancouver, BC V6H 3Z6, Canada; Vancouver Gen Hosp & Hlth Serv Ctr, Jack Bell Canc Ctr, Vancouver, BC V6H 3Z6, Canada; Tufts Univ, Sch Med, New England Med Ctr, Mol Cardiol Res Inst, Boston, MA 02111 USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; University of British Columbia; University of British Columbia; Tufts Medical Center; Tufts University	Gerszten, RE (corresponding author), Massachusetts Gen Hosp, Ctr Immunol & Inflammatory Dis, E 8307,149 13tg St, Charlestown, MA 02129 USA.			Dedhar, Shoukat/0000-0003-4355-1657; Force, Thomas/0000-0002-0450-8659	NHLBI NIH HHS [HL59521, HL61688, HL67768, HL65584, HL54202] Funding Source: Medline; NIAID NIH HHS [AI40970] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL054202, K02HL067768, R01HL061688, R29HL054202, R01HL059521, R01HL065584] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI040970] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Al-Aoukaty A, 1999, J IMMUNOL, V162, P3249; BEVILACQUA MP, 1987, P NATL ACAD SCI USA, V84, P9238, DOI 10.1073/pnas.84.24.9238; CYBULSKY MI, 1991, SCIENCE, V251, P788, DOI 10.1126/science.1990440; Dedhar S, 1996, CURR OPIN CELL BIOL, V8, P657, DOI 10.1016/S0955-0674(96)80107-4; Dedhar S, 2000, CURR OPIN CELL BIOL, V12, P250, DOI 10.1016/S0955-0674(99)00083-6; Delcommenne M, 1998, P NATL ACAD SCI USA, V95, P11211, DOI 10.1073/pnas.95.19.11211; Gerszten RE, 1999, NATURE, V398, P718, DOI 10.1038/19546; Gerszten RE, 1996, CIRC RES, V79, P1205, DOI 10.1161/01.RES.79.6.1205; Gerszten RE, 2001, J BIOL CHEM, V276, P26846, DOI 10.1074/jbc.M011235200; Grabovsky V, 2000, J EXP MED, V192, P495, DOI 10.1084/jem.192.4.495; Hannigan GE, 1996, NATURE, V379, P91, DOI 10.1038/379091a0; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Hirsch E, 2000, SCIENCE, V287, P1049, DOI 10.1126/science.287.5455.1049; Hughes PE, 1997, CELL, V88, P521, DOI 10.1016/S0092-8674(00)81892-9; Jin T, 2000, SCIENCE, V287, P1034, DOI 10.1126/science.287.5455.1034; Li Z, 2000, SCIENCE, V287, P1046, DOI 10.1126/science.287.5455.1046; LUSCINSKAS FW, 1991, J IMMUNOL, V146, P1617; Matsui T, 1999, CIRCULATION, V100, P2373, DOI 10.1161/01.CIR.100.23.2373; Persad S, 2001, J CELL BIOL, V153, P1161, DOI 10.1083/jcb.153.6.1161; Persad S, 2001, J BIOL CHEM, V276, P27462, DOI 10.1074/jbc.M102940200; Sasaki T, 2000, SCIENCE, V287, P1040, DOI 10.1126/science.287.5455.1040; Servant G, 2000, SCIENCE, V287, P1037, DOI 10.1126/science.287.5455.1037; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; Stockwell BR, 1998, CHEM BIOL, V5, P385, DOI 10.1016/S1074-5521(98)90072-2; TAICHMAN DB, 1991, CELL REGUL, V2, P347, DOI 10.1091/mbc.2.5.347; TURNER L, 1995, J IMMUNOL, V155, P2437; Turner SJ, 1998, J BIOL CHEM, V273, P25987, DOI 10.1074/jbc.273.40.25987; Weber C, 1996, J CELL BIOL, V134, P1063, DOI 10.1083/jcb.134.4.1063; Wu CY, 1999, J CELL SCI, V112, P4485; Wu CY, 2001, J CELL BIOL, V155, P505, DOI 10.1083/jcb.200108077; Youn BS, 2001, BLOOD, V98, P925, DOI 10.1182/blood.V98.4.925; Zhang YJ, 2002, J BIOL CHEM, V277, P318, DOI 10.1074/jbc.M108257200	32	44	46	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 10	2002	277	19					16371	16375		10.1074/jbc.M201240200	http://dx.doi.org/10.1074/jbc.M201240200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	551MB	11856758	hybrid			2022-12-27	WOS:000175564500005
J	Kvaratskhelia, M; Budihas, SR; Le Grice, SFJ				Kvaratskhelia, M; Budihas, SR; Le Grice, SFJ			Pre-existing distortions in nucleic acid structure aid polypurine tract selection by HIV-1 reverse transcriptase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; SEQUENCE FEATURES IMPORTANT; MURINE LEUKEMIA-VIRUS; STRAND DNA-SYNTHESIS; HOLLIDAY JUNCTION; CRYSTAL-STRUCTURE; RNA; COMPLEX; INITIATION; POLYMERASE	Precise cleavage at the polypurine tract (PPT)/U3 junction by human immunodeficiency virus type 1 (HIV-1) reverse transcriptase RNase H is critical for generating a correct viral DNA end for subsequent integration. Using potassium permanganate (KMnO4) modification, we have identified a significant distortion in the nucleic acid structure at the HIV-1 PPT/U3 junction in the absence of trans-acting factors. Unusually high reactivity of template thymine +1 is detected when the PPT primer is extended by DNA or RNA at its 3' terminus. Chemical footprinting suggests that the extent of base unstacking in the wild-type species is comparable when the +1 A:T base pair is replaced by a C:T mismatch. However, reactivity of this template base is diminished after alterations to upstream (rA)(4):(dT)(4) or (rG)(6):(dC)(6) tracts. Importantly, there is a correlation between the structural deformation at base pair +1 and precise cleavage at the PPT/U3 junction by HIV-1 reverse transcriptase/RNase H. KMnO4 modification also revealed unusually high reactivity for one of two (dT)(4): (rA)(4) duplexes upstream of the PPT/U3 junction, suggesting a significant structural distortion within the PPT itself in the absence of the retroviral polymerase. Structural abnormalities in this region are not only essential for resistance of the PPT to hydrolysis but also significantly impact the conformation of the PPT/U3 junction. Our data collectively suggest that the entire PPT sequence contributes to the structural distortion at the PPT/U3 junction, potentially providing a mechanism for its selective processing.	NCI Frederick, Reverse Transcriptase Biochem Sect, Resistance Mech Lab, HIV Drug Resistance Program,NIH, Frederick, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC)	Le Grice, SFJ (corresponding author), NCI Frederick, Reverse Transcriptase Biochem Sect, Resistance Mech Lab, HIV Drug Resistance Program,NIH, 535 Sultan St, Frederick, MD 21702 USA.	slegrice@ncifcrf.gov						ARIYOSHI M, 1994, CELL, V78, P1063, DOI 10.1016/0092-8674(94)90280-1; Bacharach E, 2000, J VIROL, V74, P4755, DOI 10.1128/JVI.74.10.4755-4764.2000; BENNETT RJ, 1995, J MOL BIOL, V252, P213, DOI 10.1006/jmbi.1995.0489; BOROWIEC JA, 1987, J MOL BIOL, V196, P101, DOI 10.1016/0022-2836(87)90513-4; CHAMPOUX JJ, 1993, REVERSE TRANSCRIPTAS, P103; Declais AC, 2000, J MOL BIOL, V296, P421, DOI 10.1006/jmbi.1999.3479; Esposito D, 1999, ADV VIRUS RES, V52, P319, DOI 10.1016/S0065-3527(08)60304-8; Farah JA, 1997, J MOL BIOL, V272, P699, DOI 10.1006/jmbi.1997.1259; Fedoroff OY, 1997, J MOL BIOL, V269, P225, DOI 10.1006/jmbi.1997.1024; Friant S, 1996, BIOCHIMIE, V78, P674, DOI 10.1016/S0300-9084(96)80013-7; FUENTES GM, 1995, J BIOL CHEM, V270, P28169, DOI 10.1074/jbc.270.47.28169; FURFINE ES, 1991, J BIOL CHEM, V266, P406; Ghosh M, 1997, BIOCHEMISTRY-US, V36, P5758, DOI 10.1021/bi963045e; Gotte M, 1999, J BIOL CHEM, V274, P11159, DOI 10.1074/jbc.274.16.11159; Gralla JD, 1996, METHOD ENZYMOL, V273, P99; Han GW, 2001, ACTA CRYSTALLOGR D, V57, P213, DOI 10.1107/S0907444900017595; Huang JB, 2000, J MOL BIOL, V303, P347, DOI 10.1006/jmbi.2000.4150; Ilyinskii PO, 1998, EMBO J, V17, P3766, DOI 10.1093/emboj/17.13.3766; Kahl BF, 2000, J MOL BIOL, V299, P75, DOI 10.1006/jmbi.2000.3743; Katz RA, 2001, J BIOL CHEM, V276, P34213, DOI 10.1074/jbc.M104632200; Kvaratskhelia M, 2000, J BIOL CHEM, V275, P25540, DOI 10.1074/jbc.M003420200; LeGrice SFJ, 1995, METHOD ENZYMOL, V262, P130, DOI 10.1016/0076-6879(95)62015-X; MCCLARIN JA, 1986, SCIENCE, V234, P1526, DOI 10.1126/science.3024321; Monsalve M, 1996, EMBO J, V15, P383, DOI 10.1002/j.1460-2075.1996.tb00368.x; Powell MD, 1997, J BIOL CHEM, V272, P13262, DOI 10.1074/jbc.272.20.13262; Powell MD, 1996, J VIROL, V70, P5288, DOI 10.1128/JVI.70.8.5288-5296.1996; PULLEN KA, 1993, J BIOL CHEM, V268, P6221; Qureshi M, 1997, BIOCHEMISTRY-US, V36, P12303, DOI 10.1021/bi9701179; RATTRAY AJ, 1989, J MOL BIOL, V208, P445, DOI 10.1016/0022-2836(89)90508-1; Rausch JW, 1997, J BIOL CHEM, V272, P8602, DOI 10.1074/jbc.272.13.8602; Rausch JW, 2000, J BIOL CHEM, V275, P13879, DOI 10.1074/jbc.275.18.13879; Reddy YVR, 2000, J MOL BIOL, V298, P597, DOI 10.1006/jmbi.2000.3673; Sarafianos SG, 2001, EMBO J, V20, P1449, DOI 10.1093/emboj/20.6.1449; Smith CM, 1998, J VIROL, V72, P6805, DOI 10.1128/JVI.72.8.6805-6812.1998; Telesnitsky A., 1997, P121; WINKLER FK, 1993, EMBO J, V12, P1781, DOI 10.1002/j.1460-2075.1993.tb05826.x; Zou Y, 1999, EMBO J, V18, P4889, DOI 10.1093/emboj/18.17.4889	37	50	51	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 10	2002	277	19					16689	16696		10.1074/jbc.M109914200	http://dx.doi.org/10.1074/jbc.M109914200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	551MB	11875059	hybrid			2022-12-27	WOS:000175564500047
J	Manivet, P; Schneider, B; Smith, JC; Choi, DS; Maroteaux, L; Kellermann, O; Launay, JM				Manivet, P; Schneider, B; Smith, JC; Choi, DS; Maroteaux, L; Kellermann, O; Launay, JM			The serotonin binding site of human and murine 5-HT2B-receptors - Molecular modeling and site-directed mutagenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; 5-HYDROXYTRYPTAMINE(2A) RECEPTORS; 3-DIMENSIONAL MODELS; 5-HT2B RECEPTORS; AGONIST BINDING; LIGAND-BINDING; ACTIVATION; RESIDUES; RHODOPSIN; BACTERIORHODOPSIN	Bacteriorhodopsin and rhodopsin crystal structures were used as templates to build structural models of the mouse and human serotonin (5-HT)-2B receptors (5-HT(2B)Rs). Serotonin was docked to the receptors, and the amino acids predicted to participate to its binding were subjected to mutagenesis. 5-HT binding affinity and 5-HT-induced inositol triphosphate production were measured in LMTK- cells transfected with either wildtype or mutated receptor genes. According to these measurements, the bacteriorhodopsin-based models of the 5-HT(2B)Rs appear more confident than the rhodopsin-based ones. Residues belonging to the transmembrane domains 3 and 6, i.e. Asp(3.32), Ser(3.36), Phe(6.52), and Asn(6.55), make direct contacts with 5-HT. In addition, Trp(3.28), Phe(3.35), Phe(6.52) and Phe(7.38) form an aromatic box surrounding 5-HT. The specificity of human and mouse 5-HT(2B)Rs may be reflected by different rear-rangements of the aromatic network upon 5-HT binding. Two amino acids close to Pro(5.50) in the human transmembrane domain 5 sequence were permuted to introduce a "mouse-like" sequence. This change was enough to confer the human 5-HT2BR properties similar to those of the mouse. Taken together, the computed models and the site-directed mutagenesis experiments give a structural explanation to (i) the different 5-HT pK(D) values measured with the human and mouse 5-HT(2B)Rs (7.9 and 5.8, respectively) and (ii) the specificity of 5-HT binding to 5-HT(2B)Rs as compared with other serotonergic G-protein coupled receptors.	Hop Lariboisiere, Serv Biochim, Ctr Rech Claude Bernard Pathol Expt & Commun Cell, IFR 6, F-75475 Paris 10, France; Ecole Polytech, Lab Dept Chim Mecan React, F-91112 Palaiseau, France; Inst Andre Lwoff, CNRS, UPR 1983, F-94801 Villejuif, France; Univ Heidelberg, Leturstuhl Biocomp, IWR, D-69120 Heidelberg, Germany; Univ Strasbourg, CNRS, INSERM, Inst Genet & Biol Mol & Cellulaire, F-67404 Illkirch Graffenstaden, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Lariboisiere-Fernand-Widal - APHP; UDICE-French Research Universities; Universite Paris Cite; Institut Polytechnique de Paris; Centre National de la Recherche Scientifique (CNRS); Ruprecht Karls University Heidelberg; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Launay, JM (corresponding author), Hop Lariboisiere, Serv Biochim, Ctr Rech Claude Bernard Pathol Expt & Commun Cell, IFR 6, 2 Rue Ambroise PAre, F-75475 Paris 10, France.		Choi, Doo-Sup/G-9474-2012; smith, jeremy c/B-7287-2012; Schneider, Benoit/AAF-3850-2019; Manivet, Philippe/AAA-1884-2021; Maroteaux, Luc/H-4585-2019	Choi, Doo-Sup/0000-0002-6796-9938; smith, jeremy c/0000-0002-2978-3227; Maroteaux, Luc/0000-0002-9499-8603; Schneider, Benoit/0000-0002-1377-2670				Almaula N, 1996, J BIOL CHEM, V271, P14672, DOI 10.1074/jbc.271.25.14672; Almaula N, 1996, MOL PHARMACOL, V50, P34; BALDWIN JM, 1994, CURR OPIN CELL BIOL, V6, P180, DOI 10.1016/0955-0674(94)90134-1; Ballesteros J. A., 1995, RECEPTOR MOL BIOL, V25, P366, DOI [10.1016/S1043-9471(05)80049-7, DOI 10.1016/S1043-9471(05)80049-7]; BARAK LS, 1995, BIOCHEMISTRY-US, V34, P15407, DOI 10.1021/bi00047a003; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; Brouland JP, 2001, ENDOCR PATHOL, V12, P77, DOI 10.1385/EP:12:1:77; Chattopadhyay A, 1996, BIOPHYS J, V71, P1952, DOI 10.1016/S0006-3495(96)79393-1; Choi DS, 1995, BEHAV BRAIN RES, V73, P253; CHOI DS, 1994, FEBS LETT, V352, P393, DOI 10.1016/0014-5793(94)00968-6; CHOUDHARY MS, 1995, MOL PHARMACOL, V47, P450; Deane CM, 2001, J BIOL CHEM, V276, P37962; DONNELLY D, 1994, RECEPTOR CHANNEL, V2, P61; EDVARDSEN O, 1992, MOL BRAIN RES, V14, P166, DOI 10.1016/0169-328X(92)90171-7; FOGUET M, 1992, EMBO J, V11, P3481, DOI 10.1002/j.1460-2075.1992.tb05427.x; GHINEA G, 1995, PROTEIN-STRUCT FUNCT, V23, P415; HIBERT MF, 1991, MOL PHARMACOL, V40, P8; HOYER D, 1994, PHARMACOL REV, V46, P157; Hulme EC, 1999, EUR J PHARMACOL, V375, P247, DOI 10.1016/S0014-2999(99)00297-6; Kristiansen K, 1996, EUR J PHARMACOL, V306, P195, DOI 10.1016/0014-2999(96)00180-X; LORIC S, 1995, MOL PHARMACOL, V47, P458; LORIC S, 1992, FEBS LETT, V312, P203, DOI 10.1016/0014-5793(92)80936-B; Lu ZL, 2001, J BIOL CHEM, V276, P34098, DOI 10.1074/jbc.M104217200; Meng EC, 2001, TRENDS PHARMACOL SCI, V22, P587, DOI 10.1016/S0165-6147(00)01825-3; Nebigil CG, 2001, CIRCULATION, V103, P2973, DOI 10.1161/01.CIR.103.24.2973; OLIVEIRA L, 1993, J COMPUT AID MOL DES, V7, P649, DOI 10.1007/BF00125323; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; Roth BL, 1997, MOL PHARMACOL, V52, P259, DOI 10.1124/mol.52.2.259; Roth BL, 1998, PHARMACOL THERAPEUT, V79, P231, DOI 10.1016/S0163-7258(98)00019-9; Schmuck K, 1996, EUR J NEUROSCI, V8, P959, DOI 10.1111/j.1460-9568.1996.tb01583.x; SEALFON SC, 1995, J BIOL CHEM, V270, P16683, DOI 10.1074/jbc.270.28.16683; Shapiro DA, 2000, MOL PHARMACOL, V58, P877, DOI 10.1124/mol.58.5.877; Teller DC, 2001, BIOCHEMISTRY-US, V40, P7761, DOI 10.1021/bi0155091; Thompson JD, 1999, NUCLEIC ACIDS RES, V27, P2682, DOI 10.1093/nar/27.13.2682; TRUMPPKALLMEYER S, 1992, J MED CHEM, V35, P3448, DOI 10.1021/jm00097a002; VONHEIJNE G, 1991, J MOL BIOL, V218, P499, DOI 10.1016/0022-2836(91)90695-3; Wainscott DB, 1996, J PHARMACOL EXP THER, V276, P720; WANG CD, 1993, MOL PHARMACOL, V43, P931; WESTKAEMPER RB, 1993, MED CHEM RES, V3, P317; ZHANG DQ, 1994, FEBS LETT, V337, P207, DOI 10.1016/0014-5793(94)80274-2	41	61	62	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 10	2002	277	19					17170	17178		10.1074/jbc.M200195200	http://dx.doi.org/10.1074/jbc.M200195200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	551MB	11859080	hybrid			2022-12-27	WOS:000175564500110
J	Oberkofler, H; Esterbauer, H; Linnemayr, V; Strosberg, AD; Krempler, F; Patsch, W				Oberkofler, H; Esterbauer, H; Linnemayr, V; Strosberg, AD; Krempler, F; Patsch, W			Peroxisome proliferator-activated receptor (PPAR) gamma coactivator-1 recruitment regulates PPAR subtype specificity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UNCOUPLING PROTEIN GENE; NUCLEAR RECEPTOR; BROWN-FAT; RETINOIC ACID; TRANSCRIPTION FACTOR; SIGNALING PATHWAY; UCP1 GENE; EXPRESSION; ALPHA; ADIPOCYTES	The peroxisome proliferator-activated receptors (PPAR) alpha and gamma play key roles in the transcriptional control of contrasting metabolic pathways such as adipogenesis and fatty acid beta-oxidation. Both ligand-activated nuclear receptors bind to common target gene response elements and interact with distinct domains of the transcriptional coactivator PGC-1 to attain their full transcriptional potency. Thus, PPAR subtype specificity may be determined by ligand availability and transcription factor or coactivator expression levels. To identify other, perhaps more precise mechanisms contributing to PPAR subtype specificity, we studied PGC-1 recruitment by PPARs using a previously described hormone response element in the human UCP1 promoter and a human brown adipocyte cell line as our model system. As in rodents, PGC-1 is involved in the transcriptional regulation of the UCP1 gene in humans and mediates the effects of PPARalpha and PPARgamma agonists and retinoic acid. Interestingly, a previously postulated PGC-1 repressor selectively affects the PPARalpha-mediated activation of UCP1 gene expression. Furthermore, inhibition of p38 MAPK signaling, known to regulate the PGC-1-/repressor interaction, decreases the stimulatory effect of PPARalpha agonist treatment without reducing the response to thiazolidinedione or retinoic acid. These data support a model whereby PPAR subtype specificity is regulated by recruitment of PGC-1.	Landeskliniken Salzburg, Dept Lab Med, A-5020 Salzburg, Austria; Krankenhaus Hallein, Dept Internal Med, A-5400 Hallein, Austria; Inst Cochin Genet Mol, F-75014 Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Patsch, W (corresponding author), Landeskliniken Salzburg, Dept Lab Med, A-5020 Salzburg, Austria.			Esterbauer, Harald/0000-0001-7343-7455				ALVAREZ R, 1995, J BIOL CHEM, V270, P5666, DOI 10.1074/jbc.270.10.5666; Barbera MJ, 2001, J BIOL CHEM, V276, P1486, DOI 10.1074/jbc.M006246200; Barger PM, 2001, J BIOL CHEM, V276, P44495, DOI 10.1074/jbc.M105945200; BOUILLAUD F, 1984, J BIOL CHEM, V259, P1583; Brandt JM, 1998, J BIOL CHEM, V273, P23786, DOI 10.1074/jbc.273.37.23786; Cao WH, 2001, J BIOL CHEM, V276, P27077, DOI 10.1074/jbc.M101049200; CASSARDDOULCIER AM, 1994, J BIOL CHEM, V269, P24335; Delerive P, 2002, J BIOL CHEM, V277, P3913, DOI 10.1074/jbc.M109409200; Digby JE, 1998, DIABETES, V47, P138, DOI 10.2337/diabetes.47.1.138; Ek J, 2001, DIABETOLOGIA, V44, P2220, DOI 10.1007/s001250100032; Esterbauer H, 1999, GENOMICS, V62, P98, DOI 10.1006/geno.1999.5977; Esterbauer H, 2002, DIABETES, V51, P1281, DOI 10.2337/diabetes.51.4.1281; Esterbauer H, 2001, NAT GENET, V28, P178, DOI 10.1038/88911; Gonzalez-Barroso MD, 2000, J BIOL CHEM, V275, P31722, DOI 10.1074/jbc.M001678200; GULICK T, 1994, P NATL ACAD SCI USA, V91, P11012, DOI 10.1073/pnas.91.23.11012; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; HU ED, 1995, P NATL ACAD SCI USA, V92, P9856, DOI 10.1073/pnas.92.21.9856; JugeAubry C, 1997, J BIOL CHEM, V272, P25252, DOI 10.1074/jbc.272.40.25252; Kliewer SA, 1998, CURR OPIN GENET DEV, V8, P576, DOI 10.1016/S0959-437X(98)80014-2; Knutti D, 2000, MOL CELL BIOL, V20, P2411, DOI 10.1128/MCB.20.7.2411-2422.2000; Knutti D, 2001, P NATL ACAD SCI USA, V98, P9713, DOI 10.1073/pnas.171184698; KOZAK UC, 1994, MOL CELL BIOL, V14, P59, DOI 10.1128/MCB.14.1.59; Larose M, 1996, J BIOL CHEM, V271, P31533, DOI 10.1074/jbc.271.49.31533; Lemberger T, 1996, ANNU REV CELL DEV BI, V12, P335, DOI 10.1146/annurev.cellbio.12.1.335; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; Mark M, 1999, P NUTR SOC, V58, P609, DOI 10.1017/S0029665199000798; Michael LF, 2001, P NATL ACAD SCI USA, V98, P3820, DOI 10.1073/pnas.061035098; NICHOLLS DG, 1984, PHYSIOL REV, V64, P1, DOI 10.1152/physrev.1984.64.1.1; Puigserver P, 1999, SCIENCE, V286, P1368, DOI 10.1126/science.286.5443.1368; Puigserver P, 1998, CELL, V92, P829, DOI 10.1016/S0092-8674(00)81410-5; Puigserver P, 2001, MOL CELL, V8, P971, DOI 10.1016/S1097-2765(01)00390-2; REHNMARK S, 1990, J BIOL CHEM, V265, P16464; SAFONOVA I, 1994, MOL CELL ENDOCRINOL, V104, P201, DOI 10.1016/0303-7207(94)90123-6; Sears IB, 1996, MOL CELL BIOL, V16, P3410; SILVA JE, 1988, MOL ENDOCRINOL, V2, P706, DOI 10.1210/mend-2-8-706; Tcherepanova I, 2000, J BIOL CHEM, V275, P16302, DOI 10.1074/jbc.M001364200; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X; Valmaseda A, 1999, MOL CELL ENDOCRINOL, V154, P101, DOI 10.1016/S0303-7207(99)00081-7; Vega RB, 2000, MOL CELL BIOL, V20, P1868, DOI 10.1128/MCB.20.5.1868-1876.2000; Wu YF, 2002, J BIOL CHEM, V277, P8898, DOI 10.1074/jbc.M110761200; Wu ZD, 1999, CELL, V98, P115, DOI 10.1016/S0092-8674(00)80611-X; Zilberfarb V, 1997, J CELL SCI, V110, P801	42	66	70	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 10	2002	277	19					16750	16757		10.1074/jbc.M200475200	http://dx.doi.org/10.1074/jbc.M200475200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	551MB	11875072	hybrid			2022-12-27	WOS:000175564500055
J	Yan, KS; Kuti, M; Yan, S; Mujtaba, S; Farooq, A; Goldfarb, MP; Zhou, MM				Yan, KS; Kuti, M; Yan, S; Mujtaba, S; Farooq, A; Goldfarb, MP; Zhou, MM			FRS2 PTB domain conformation regulates interactions with divergent neurotrophic receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOTYROSINE-BINDING DOMAIN; FIBROBLAST-GROWTH-FACTOR; AMYLOID PRECURSOR PROTEIN; INSULIN-RECEPTOR; SIGNAL-TRANSDUCTION; ADAPTER PROTEINS; STRUCTURAL BASIS; TYROSINE KINASE; SH3 DOMAINS; IN-VIVO	Membrane-anchored adaptor proteins FRS2alpha/beta (also known as SNT-1/2) mediate signaling of fibroblast growth factor receptors (FGFRs) and neurotrophin receptors (TRKs) through their N-terminal phosphotyrosine binding (PTB) domains. The FRS2 PTB domain recognizes tyrosine-phosphorylated TRKs at an NPXpY (where pY is phosphotyrosine) motif, whereas its constitutive association with FGFR involves a receptor juxtamembrane region lacking Tyr and Asn residues. Here we show by isothermal titration calorimetry that the FRS2alpha PTB domain binding to peptides derived from TRKs or FGFR is thermodynamically different. TRK binding is largely enthalpy-driven, whereas the FGFR interaction is governed by a favorable entropic contribution to the free energy of binding. Furthermore, our NMR spectral analysis suggests that disruption of an unstructured region C-terminal to the PTB domain alters local conformation and dynamics of the residues at the ligand-binding site, and that structural disruption of the beta8-strand directly weakens the PTB domain association with the FGFR ligand. Together, our new findings support a molecular mechanism by which conformational dynamics of the FRS2alpha PTB domain dictates its association with either fibroblast growth factor or neurotrophin receptors in neuronal development.	NYU, Mt Sinai Sch Med, Dept Physiol & Biophys, Struct Biol Program, New York, NY 10029 USA; NYU, Mt Sinai Sch Med, Dept Biochem & Mol Biol, New York, NY 10029 USA	Icahn School of Medicine at Mount Sinai; New York University; Icahn School of Medicine at Mount Sinai; New York University	Zhou, MM (corresponding author), NYU, Mt Sinai Sch Med, Dept Physiol & Biophys, Struct Biol Program, 1425 Madison Ave,Box 1677, New York, NY 10029 USA.		Farooq, Amjad/B-5084-2012		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059432] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM059432-03] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BLAIKIE P, 1994, J BIOL CHEM, V269, P32031; Borg JP, 1996, MOL CELL BIOL, V16, P6229; Burgar HR, 2002, J BIOL CHEM, V277, P4018, DOI 10.1074/jbc.M107785200; Chien CT, 1998, MOL CELL BIOL, V18, P598, DOI 10.1128/MCB.18.1.598; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Dhalluin C, 2000, MOL CELL, V6, P921, DOI 10.1016/S1097-2765(00)00089-7; Eck MJ, 1996, CELL, V85, P695, DOI 10.1016/S0092-8674(00)81236-2; Farooq A, 1999, J BIOL CHEM, V274, P6114, DOI 10.1074/jbc.274.10.6114; Forman-Kay JD, 1999, CURR OPIN STRUC BIOL, V9, P690, DOI 10.1016/S0959-440X(99)00031-7; GUSTAFSON TA, 1995, MOL CELL BIOL, V15, P2500; Hadari YR, 1998, MOL CELL BIOL, V18, P3966, DOI 10.1128/MCB.18.7.3966; Howell BW, 1999, MOL CELL BIOL, V19, P5179; IP NY, 1994, NEURON, V13, P443, DOI 10.1016/0896-6273(94)90359-X; Jelesarov I, 1999, J MOL RECOGNIT, V12, P3, DOI 10.1002/(SICI)1099-1352(199901/02)12:1<3::AID-JMR441>3.0.CO;2-6; JOHNSON BA, 1994, J BIOMOL NMR, V4, P603, DOI 10.1007/BF00404272; KAVANAUGH WM, 1995, SCIENCE, V268, P1177, DOI 10.1126/science.7539155; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; Kouhara H, 1997, CELL, V89, P693, DOI 10.1016/S0092-8674(00)80252-4; KURIYAN J, 1993, CURR OPIN STRUC BIOL, V3, P828, DOI 10.1016/0959-440X(93)90145-B; Kurokawa K, 2001, ONCOGENE, V20, P1929, DOI 10.1038/sj.onc.1204290; Lemmon MA, 1996, CELL, V85, P621, DOI 10.1016/S0092-8674(00)81022-3; Li SC, 1998, NAT STRUCT BIOL, V5, P1075, DOI 10.1038/4185; Li SC, 1997, P NATL ACAD SCI USA, V94, P7204, DOI 10.1073/pnas.94.14.7204; Mayer BJ, 2001, J CELL SCI, V114, P1253; Meakin SO, 1999, J BIOL CHEM, V274, P9861, DOI 10.1074/jbc.274.14.9861; Melillo RM, 2001, MOL CELL BIOL, V21, P4177, DOI 10.1128/MCB.21.13.4177-4187.2001; Ong SH, 2000, MOL CELL BIOL, V20, P979, DOI 10.1128/MCB.20.3.979-989.2000; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; Pawson T, 2000, GENE DEV, V14, P1027; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PENG X, 1995, NEURON, V15, P395, DOI 10.1016/0896-6273(95)90043-8; Ravichandran KS, 1997, MOL CELL BIOL, V17, P5540, DOI 10.1128/MCB.17.9.5540; Sudol M, 2001, FEBS LETT, V490, P190, DOI 10.1016/S0014-5793(01)02122-6; Wang JK, 1996, ONCOGENE, V13, P721; WISEMAN T, 1989, ANAL BIOCHEM, V179, P131, DOI 10.1016/0003-2697(89)90213-3; Xu H, 1998, J BIOL CHEM, V273, P17987, DOI 10.1074/jbc.273.29.17987; Xu H, 2001, J BIOL CHEM, V276, P13049, DOI 10.1074/jbc.M009925200; Yan KS, 2002, FEBS LETT, V513, P67, DOI 10.1016/S0014-5793(01)03305-1; Zambrano N, 1997, J BIOL CHEM, V272, P6399, DOI 10.1074/jbc.272.10.6399; Zhang ZT, 1997, EMBO J, V16, P6141, DOI 10.1093/emboj/16.20.6141; Zhou MM, 1996, NAT STRUCT BIOL, V3, P388, DOI 10.1038/nsb0496-388; ZHOU MM, 1995, NATURE, V378, P584, DOI 10.1038/378584a0; Zwahlen C, 2000, EMBO J, V19, P1505, DOI 10.1093/emboj/19.7.1505	43	24	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 10	2002	277	19					17088	17094		10.1074/jbc.M107963200	http://dx.doi.org/10.1074/jbc.M107963200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	551MB	11877385	hybrid			2022-12-27	WOS:000175564500099
J	Little, R; Colombo, V; Leech, A; Dixon, R				Little, R; Colombo, V; Leech, A; Dixon, R			Direct interaction of the NifL regulatory protein with the GlnK signal transducer enables the Azotobacter vinelandii NifL-NifA regulatory system to respond to conditions replete for nitrogen	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUTAMINE-SYNTHETASE ADENYLYLATION; ESCHERICHIA-COLI; P-II; TRANSCRIPTIONAL ACTIVATION; IN-VITRO; KLEBSIELLA-PNEUMONIAE; INTERNAL GLUTAMINE; ENTERIC BACTERIA; GENE-EXPRESSION; FIXATION GENES	The Azotobacter vinelandii NifL-NifA regulatory system integrates metabolic signals for redox, energy, and nitrogen status to fine tune regulation of the synthesis of molybdenum nitrogenase. The NifL protein utilizes discrete mechanisms to perceive these signals leading to the formation of a protein-protein complex, which inhibits NifA activity. Whereas redox signaling is mediated via a flavin-containing PAS domain in the N-terminal region of NifL, the nitrogen status is sensed via interaction with PII-like signal transduction proteins and small molecular weight effectors. The nonuridylylated form of the PII-like protein encoded by A vinelandii glnK (Av GlnK) stimulates NifL to inhibit transcriptional activation by NifA in vitro. Here we demonstrate that the nonmodified form of Av GlnK directly interacts with A vinelandii NifL and that this interaction is dependent on Mg2+, ATP, and 2-oxoglutarate. Differences were observed in the regulation of the Av GlnK-NifL interaction by 2-oxoglutarate compared with the role of this effector in modulating the interaction of enteric PII-like proteins with their receptors. We also report that the interaction between Av GlnK and NifL is abolished by site-directed substitution of a single amino acid in the T-loop region of Av GlnK and that uridylylation of the conserved tyrosine residue in the T-loop inhibits the interaction. No association was detected between Av GlnK and the N-terminal region of NifL and our results demonstrate that Av GlnK directly interacts with the C-terminal histidine protein kinase-like domain.	John Innes Ctr Plant Sci Res, Dept Mol Microbiol, Norwich NR4 7UH, Norfolk, England; Univ E Anglia, Sch Biol Sci, Norwich NR4 7TJ, Norfolk, England	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); John Innes Center; University of East Anglia	Dixon, R (corresponding author), John Innes Ctr Plant Sci Res, Dept Mol Microbiol, Norwich NR4 7UH, Norfolk, England.			Dixon, Ray/0000-0002-6348-639X; Colombo Rodriguez, Maria Victoria/0000-0003-4540-882X	Biotechnology and Biological Sciences Research Council [BBS/E/J/00000016] Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))		Arcondeguy T, 2000, J BIOL CHEM, V275, P38452, DOI 10.1074/jbc.M001935200; Arcondeguy T, 2001, MICROBIOL MOL BIOL R, V65, P80, DOI 10.1128/MMBR.65.1.80-105.2001; ATKINSON MR, 1994, J BIOL CHEM, V269, P28288; Atkinson MR, 1999, MOL MICROBIOL, V32, P301, DOI 10.1046/j.1365-2958.1999.01349.x; AUSTIN S, 1994, J BACTERIOL, V176, P3460, DOI 10.1128/JB.176.12.3460-3465.1994; Barrett J, 2001, MOL MICROBIOL, V39, P480, DOI 10.1046/j.1365-2958.2001.02243.x; BLANCO G, 1993, MOL MICROBIOL, V9, P869, DOI 10.1111/j.1365-2958.1993.tb01745.x; Carr PD, 1996, ACTA CRYSTALLOGR D, V52, P93, DOI 10.1107/S0907444995007293; CHEAH E, 1994, STRUCTURE, V2, P981, DOI 10.1016/S0969-2126(94)00100-6; Colnaghi R, 2001, MICROBIOL-SGM, V147, P1267, DOI 10.1099/00221287-147-5-1267; CONTRERAS A, 1991, J BACTERIOL, V173, P7741, DOI 10.1128/jb.173.24.7741-7749.1991; Dixon R, 1998, ARCH MICROBIOL, V169, P371, DOI 10.1007/s002030050585; EYDMANN T, 1995, J BACTERIOL, V177, P1186, DOI 10.1128/jb.177.5.1186-1195.1995; Forchhammer K, 1997, EUR J BIOCHEM, V244, P869, DOI 10.1111/j.1432-1033.1997.00869.x; He LH, 1998, J BACTERIOL, V180, P6661, DOI 10.1128/JB.180.24.6661-6667.1998; Hill S, 1996, P NATL ACAD SCI USA, V93, P2143, DOI 10.1073/pnas.93.5.2143; Ikeda TP, 1996, J MOL BIOL, V259, P589, DOI 10.1006/jmbi.1996.0342; Jack R, 1999, J BACTERIOL, V181, P1156, DOI 10.1128/JB.181.4.1156-1162.1999; Jaggi R, 1997, EMBO J, V16, P5562, DOI 10.1093/emboj/16.18.5562; Jaggi R, 1996, FEBS LETT, V391, P223, DOI 10.1016/0014-5793(96)00737-5; Jiang P, 2000, BIOCHEMISTRY-US, V39, P13433, DOI 10.1021/bi000794u; Jiang P, 1997, J BACTERIOL, V179, P4342, DOI 10.1128/jb.179.13.4342-4353.1997; Jiang P, 1997, J BACTERIOL, V179, P4354, DOI 10.1128/jb.179.13.4354-4360.1997; Jiang P, 1998, BIOCHEMISTRY-US, V37, P12802, DOI 10.1021/bi980666u; Jiang P, 1998, BIOCHEMISTRY-US, V37, P12795, DOI 10.1021/bi9802420; Jiang P, 1999, J BACTERIOL, V181, P1906, DOI 10.1128/JB.181.6.1906-1911.1999; Jiang P, 1998, BIOCHEMISTRY-US, V37, P12782, DOI 10.1021/bi980667m; KAMBEROV ES, 1994, CELL MOL BIOL RES, V40, P175; KAMBEROV ES, 1995, J BIOL CHEM, V270, P17797, DOI 10.1074/jbc.270.30.17797; Little R, 2000, EMBO J, V19, P6041, DOI 10.1093/emboj/19.22.6041; Macheroux P, 1998, BIOCHEM J, V332, P413, DOI 10.1042/bj3320413; Martinez-Argudo I, 2002, J BACTERIOL, V184, P200, DOI 10.1128/JB.184.1.200-206.2002; Meletzus D, 1998, J BACTERIOL, V180, P3260, DOI 10.1128/JB.180.12.3260-3264.1998; Money T, 1999, J BACTERIOL, V181, P4461, DOI 10.1128/JB.181.15.4461-4468.1999; Money T, 2001, J BACTERIOL, V183, P1359, DOI 10.1128/JB.183.4.1359-1368.2001; Ninfa AJ, 2000, CURR TOP CELL REGUL, V36, P31; Ninfa AJ, 2000, TRENDS MICROBIOL, V8, P172, DOI 10.1016/S0966-842X(00)01709-1; Pioszak AA, 2000, BIOCHEMISTRY-US, V39, P13450, DOI 10.1021/bi000795m; Reyes-Ramirez F, 2001, J BACTERIOL, V183, P3076, DOI 10.1128/JB.183.10.3076-3082.2001; Rudnick P, 2002, J BACTERIOL, V184, P812, DOI 10.1128/JB.184.3.812-820.2002; RUDNICK P, 1998, BIOL NITROGEN FIXATI, P123; Schmitz RA, 2000, CURR MICROBIOL, V41, P357, DOI 10.1007/s002840010149; SENIOR PJ, 1975, J BACTERIOL, V123, P407, DOI 10.1128/JB.123.2.407-418.1975; Soderback E, 1998, MOL MICROBIOL, V28, P179, DOI 10.1046/j.1365-2958.1998.00788.x; WOODLEY P, 1994, MOL MICROBIOL, V13, P619, DOI 10.1111/j.1365-2958.1994.tb00456.x; Xu YB, 1998, J MOL BIOL, V282, P149, DOI 10.1006/jmbi.1998.1979; Zhulin IB, 1997, TRENDS BIOCHEM SCI, V22, P331, DOI 10.1016/S0968-0004(97)01110-9	47	58	59	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 3	2002	277	18					15472	15481		10.1074/jbc.M112262200	http://dx.doi.org/10.1074/jbc.M112262200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	550PA	11856746	hybrid			2022-12-27	WOS:000175510400035
J	Ponamarev, MV; Longley, MJ; Nguyen, D; Kunkel, TA; Copeland, WC				Ponamarev, MV; Longley, MJ; Nguyen, D; Kunkel, TA; Copeland, WC			Active site mutation in DNA polymerase gamma associated with progressive external ophthalmoplegia causes error-prone DNA synthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P55 ACCESSORY SUBUNIT; MITOCHONDRIAL-DNA; MULTIPLE DELETIONS; ESCHERICHIA-COLI; KLENOW FRAGMENT; FIDELITY; REPLICATION; MTDNA; IDENTIFICATION; DISORDER	Progressive external ophthalmoplegia (PEO) is a heritable mitochondrial disorder characterized by the accumulation of multiple point mutations and large deletions in mtDNA. Autosomal dominant PEO was recently shown to co-segregate with a heterozygous Y955C mutation in the human gene encoding the sole mitochondrial DNA polymerase, DNA polymerase gamma (pol gamma). Since Tyr-955 is a highly conserved residue critical for nucleotide recognition among family A DNA polymerases, we analyzed the effects of the Y955C mutation on the kinetics and fidelity of DNA synthesis by the purified human mutant polymerase in complex with its accessory subunit. The Y955C enzyme retains a wild-type catalytic rate (k(cat)) but suffers a 45-fold decrease in apparent binding affinity for the incoming nucleoside triphosphate (K-m). The Y955C derivative is 2-fold less accurate for base pair substitutions than wild-type pol gamma despite the action of intrinsic exonucleolytic proofreading. The fall mutator effect of the Y955C substitution was revealed by genetic inactivation of the exonuclease, and error rates for certain mismatches were elevated by 10-100-fold. The error-prone DNA synthesis observed for the Y955C pol gamma is consistent with the accumulation of mtDNA mutations in patients with PEO.	NIEHS, Genet Mol Lab, NIH, Res Triangle Pk, NC 27709 USA; NIEHS, Struct Biol Lab, NIH, Res Triangle Pk, NC 27709 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)	Copeland, WC (corresponding author), NIEHS, Genet Mol Lab, NIH, POB 12233, Res Triangle Pk, NC 27709 USA.		Copeland, William/C-4242-2019; Kunkel, Thomas A./D-5088-2019	Copeland, William/0000-0002-0359-0953; Kunkel, Thomas A./0000-0002-9900-1788	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES065070, ZIAES065070, Z01ES065078, ZIAES065078] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Bebenek K, 1995, METHOD ENZYMOL, V262, P217; Bell JB, 1997, J BIOL CHEM, V272, P7345, DOI 10.1074/jbc.272.11.7345; BESTWICK RK, 1982, J BIOL CHEM, V257, P9300; CARROLL SS, 1991, BIOCHEMISTRY-US, V30, P804, DOI 10.1021/bi00217a034; Doublie S, 1998, NATURE, V391, P251, DOI 10.1038/34593; Esposito LA, 1999, P NATL ACAD SCI USA, V96, P4820, DOI 10.1073/pnas.96.9.4820; Hirano M, 2001, SEMIN CELL DEV BIOL, V12, P417, DOI 10.1006/scdb.2001.0279; JOHNS DR, 1989, P NATL ACAD SCI USA, V86, P8059, DOI 10.1073/pnas.86.20.8059; Kaukonen J, 2000, SCIENCE, V289, P782, DOI 10.1126/science.289.5480.782; Kaukonen JA, 1996, AM J HUM GENET, V58, P763; KUNKEL TA, 1988, J BIOL CHEM, V263, P4450; Lim SE, 2001, J BIOL CHEM, V276, P23616, DOI 10.1074/jbc.M101114200; Lim SE, 1999, J BIOL CHEM, V274, P38197, DOI 10.1074/jbc.274.53.38197; Longley MJ, 1998, BIOCHEMISTRY-US, V37, P10529, DOI 10.1021/bi980772w; Longley MJ, 2001, J BIOL CHEM, V276, P38555, DOI 10.1074/jbc.M105230200; Nishino I, 1999, SCIENCE, V283, P689, DOI 10.1126/science.283.5402.689; POLESKY AH, 1990, J BIOL CHEM, V265, P14579; Ropp PA, 1996, GENOMICS, V36, P449, DOI 10.1006/geno.1996.0490; Saveson CJ, 1997, GENETICS, V146, P457; SHOFFNER JM, 1989, P NATL ACAD SCI USA, V86, P7952, DOI 10.1073/pnas.86.20.7952; Spelbrink JN, 2001, NAT GENET, V28, P223, DOI 10.1038/90058; Van Goethem G, 2001, NAT GENET, V28, P211, DOI 10.1038/90034; Van Goethem G, 2000, J MED GENET, V37, P547, DOI 10.1136/jmg.37.7.547; VanGoethem G, 1997, EUR J NEUROL, V4, P476; Wallace DC, 1999, SCIENCE, V283, P1482, DOI 10.1126/science.283.5407.1482; WALLACE DC, 1992, ANNU REV BIOCHEM, V61, P1175, DOI 10.1146/annurev.bi.61.070192.005523; WERNETTE CM, 1988, BIOCHEMISTRY-US, V27, P6046, DOI 10.1021/bi00416a033; ZEVIANI M, 1989, NATURE, V339, P309, DOI 10.1038/339309a0; Zhang DK, 2000, GENOMICS, V69, P151, DOI 10.1006/geno.2000.6333	29	103	107	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 3	2002	277	18					15225	15228		10.1074/jbc.C200100200	http://dx.doi.org/10.1074/jbc.C200100200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	550PA	11897778	hybrid			2022-12-27	WOS:000175510400002
J	Wang, XJ; Michael, D; de Murcia, G; Oren, M				Wang, XJ; Michael, D; de Murcia, G; Oren, M			p53 activation by nitric oxide involves down-regulation of Mdm2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ATM-DEPENDENT PHOSPHORYLATION; HYPOXIA-RESPONSIVE ELEMENT; DNA-DAMAGE CHECKPOINT; POLY(ADP-RIBOSE) BINDS; CELL-CYCLE; EXPRESSION; ACCUMULATION; STABILITY; PROTEIN; LOCALIZATION	Nitric oxide (NO) is an important bioactive molecule involved in a variety of physiological and pathological processes. At the same time, NO is also an inducer of stress signaling, owing to its ability to damage proteins and DNA. NO was reported to be a potent activator of the p53 tumor suppressor protein. However, the mechanisms underlying p53 activation by NO remain to be elucidated. We report here that NO induces the accumulation of transcriptionally active p53 in a variety of cell types and that NO signaling to p53 does not require ataxia telangiectasia-mutated (ATM), poly(ADP-ribose) polymerase 1, or the ARF tumor suppressor protein. In mouse embryonic fibroblasts, NO elicits a down-regulation of Mdm2 protein levels that precedes the rise in p53. NO-induced down-regulation of Mdm2 protein but not its mRNA also occurs in several p53-deficient cell types and is thus p53-independent. The drop in endogenous Mdm2 levels following NO treatment is accompanied by a corresponding reduction in the rate of p53 ubiquitination. Thus, the down-regulation of Mdm2 by NO is likely to contribute to the activation of p53.	Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel; Ecole Super Biotechnol Strasbourg, CNRS, Unite 9003, F-67400 Illkirch Graffenstaden, France	Weizmann Institute of Science; Centre National de la Recherche Scientifique (CNRS)	Oren, M (corresponding author), Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel.	moshe.oren@weizmann.ac.il		Michael, Dan/0000-0003-2942-4301; Oren, Moshe/0000-0003-4311-7172	NATIONAL CANCER INSTITUTE [R01CA040099] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA 40099] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alarcon R, 1999, CANCER RES, V59, P6046; Ame JC, 1999, J BIOL CHEM, V274, P17860, DOI 10.1074/jbc.274.25.17860; Ashcroft M, 2000, MOL CELL BIOL, V20, P3224, DOI 10.1128/MCB.20.9.3224-3233.2000; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Burney S, 1999, MUTAT RES-FUND MOL M, V424, P37, DOI 10.1016/S0027-5107(99)00006-8; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Chehab NH, 2000, GENE DEV, V14, P278; Damalas A, 2001, EMBO J, V20, P4912, DOI 10.1093/emboj/20.17.4912; Evan GI, 2001, NATURE, V411, P342, DOI 10.1038/35077213; Forrester K, 1996, P NATL ACAD SCI USA, V93, P2442, DOI 10.1073/pnas.93.6.2442; Gaston B, 1999, BBA-BIOENERGETICS, V1411, P323, DOI 10.1016/S0005-2728(99)00023-7; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Hess DT, 2001, NAT CELL BIOL, V3, pE46, DOI 10.1038/35055152; Ho YS, 1996, MOL CARCINOGEN, V16, P20, DOI 10.1002/(SICI)1098-2744(199605)16:1<20::AID-MC4>3.3.CO;2-I; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Honda R, 1999, EMBO J, V18, P22, DOI 10.1093/emboj/18.1.22; Hupp TR, 1999, CELL MOL LIFE SCI, V55, P88, DOI 10.1007/s000180050272; Israeli D, 1997, EMBO J, V16, P4384, DOI 10.1093/emboj/16.14.4384; Kastan MB, 2000, NAT REV MOL CELL BIO, V1, P179, DOI 10.1038/35043058; Khosravi R, 1999, P NATL ACAD SCI USA, V96, P14973, DOI 10.1073/pnas.96.26.14973; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Lowe SW, 1999, ENDOCR-RELAT CANCER, V6, P45, DOI 10.1677/erc.0.0060045; Ma Yongxian, 2000, Molecular Cell Biology Research Communications, V3, P122, DOI 10.1006/mcbr.2000.0201; Malanga M, 1998, J BIOL CHEM, V273, P11839, DOI 10.1074/jbc.273.19.11839; Matsumoto H, 1999, NITRIC OXIDE-BIOL CH, V3, P180, DOI 10.1006/niox.1999.0221; Maya R, 2001, GENE DEV, V15, P1067, DOI 10.1101/gad.886901; Melillo G, 1997, J BIOL CHEM, V272, P12236, DOI 10.1074/jbc.272.18.12236; MELILLO G, 1995, J EXP MED, V182, P1683, DOI 10.1084/jem.182.6.1683; MESSMER UK, 1994, FEBS LETT, V355, P23; Nakaya N, 2000, ONCOGENE, V19, P6369, DOI 10.1038/sj.onc.1204100; Oliver FJ, 1999, EMBO J, V18, P4446, DOI 10.1093/emboj/18.16.4446; Oren M, 1999, J BIOL CHEM, V274, P36031, DOI 10.1074/jbc.274.51.36031; Pieper AA, 1999, TRENDS PHARMACOL SCI, V20, P171, DOI 10.1016/S0165-6147(99)01292-4; Pleschke JM, 2000, J BIOL CHEM, V275, P40974, DOI 10.1074/jbc.M006520200; Prives C, 1999, J PATHOL, V187, P112; RADONS J, 1994, BIOCHEM BIOPH RES CO, V199, P1270, DOI 10.1006/bbrc.1994.1368; SCHMIDT HHHW, 1994, CELL, V78, P919, DOI 10.1016/0092-8674(94)90267-4; Sherr CJ, 2000, CURR OPIN GENET DEV, V10, P94, DOI 10.1016/S0959-437X(99)00038-6; Shieh SY, 2000, GENE DEV, V14, P289; Shiloh Y, 2001, CURR OPIN GENET DEV, V11, P71, DOI 10.1016/S0959-437X(00)00159-3; Stommel JM, 1999, EMBO J, V18, P1660, DOI 10.1093/emboj/18.6.1660; Tao WK, 1999, P NATL ACAD SCI USA, V96, P6937, DOI 10.1073/pnas.96.12.6937; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Wang XJ, 1998, ONCOGENE, V17, P2819, DOI 10.1038/sj.onc.1202216; Weber JD, 2000, MOL CELL BIOL, V20, P2517, DOI 10.1128/MCB.20.7.2517-2528.2000; Wesierska-Gadek J, 1999, CANCER RES, V59, P28; Wesierska-Gadek J, 2001, CELL MOL BIOL LETT, V6, P117; WHITACRE CM, 1995, CANCER RES, V55, P3697; Woods DB, 2001, EXP CELL RES, V264, P56, DOI 10.1006/excr.2000.5141; Wu L, 1997, MOL MED, V3, P441, DOI 10.1007/BF03401691; WU XW, 1993, GENE DEV, V7, P1126, DOI 10.1101/gad.7.7a.1126; Zweier JL, 1999, BBA-BIOENERGETICS, V1411, P250, DOI 10.1016/S0005-2728(99)00018-3	54	94	100	2	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 3	2002	277	18					15697	15702		10.1074/jbc.M112068200	http://dx.doi.org/10.1074/jbc.M112068200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	550PA	11867628	hybrid			2022-12-27	WOS:000175510400065
J	Willets, JM; Challiss, RAJ; Nahorski, SR				Willets, JM; Challiss, RAJ; Nahorski, SR			Endogenous G protein-coupled receptor kinase 6 regulates M-3 muscarinic acetylcholine receptor phosphorylation and desensitization in human SH-SY5Y neuroblastoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ADRENERGIC-RECEPTOR; SELECTIVE REGULATION; AGONIST; INTERNALIZATION; IDENTIFICATION; SITES; G-ALPHA(Q/11); INVOLVEMENT; ALPHA	We have previously shown that overexpression of G protein-coupled receptor kinase 6 (GRK6) enhanced the phosphorylation and desensitization of the endogenously expressed M, muscarinic acetylcholine (mACh) receptor in human SH-SY5Y neuroblastoma cells. In this study we have examined the potential role of endogenous GRK6 in the regulation of M-3 mACh receptor by blocking its action through the introduction of a kinase-dead, dominant-negative GRK6 ((K215R)GPK6). (K215R)GRK6 expression inhibited methacholine-stimulated M-3 mACh receptor phosphorylation by 50% compared with plasmid transfected control cells. Guanosine-5'-O-(3-[S-35]thio)triphosphate binding and immunoprecipitation studies, conducted after agonist pretreatment (3 min), indicated that M-3 mACh receptor-Galpha(q/11), uncoupling was attenuated by 50% in cells expressing (K215R)GRK6 when compared with control cells. In contrast, expression of the related dominant-negative kinase (K215R)GRK5 had no effect on M-3 mACh receptor phosphorylation or uncoupling. Time course studies also showed that agonist-stimulated [H-3]inositol phosphate accumulations were more sustained in cells expressing (K215R)GRK6 compared with control and (K215R)GRK5-expressing cells, whereas (K215R)GRK6 expression had no effect on the phospholipase C response to direct stimulation of G proteins with AlF4-. The ability of (K215R)GRK6 to inhibit agonist-mediated M-3 mACh receptor phosphorylation and G protein uncoupling suggests that endogenous GRK6 mediates, at least in part, M-3 mACh receptor desensitization in the SH-SY5Y cell line.	Univ Leicester, Dept Cell Physiol & Pharmacol, Leicester LE1 9HN, Leics, England	University of Leicester	Willets, JM (corresponding author), Univ Leicester, Dept Cell Physiol & Pharmacol, Maurice Shock Med Sci Bldg,Univ Rd, Leicester LE1 9HN, Leics, England.	jmw23@le.ac.uk	Challiss, R.A. John/A-9412-2008	Challiss, John/0000-0001-5506-2848				Aiyar N, 2000, EUR J PHARMACOL, V403, P1, DOI 10.1016/S0014-2999(00)00419-2; Akam EC, 2001, BRIT J PHARMACOL, V132, P950, DOI 10.1038/sj.bjp.0703892; Barr AJ, 1997, J BIOL CHEM, V272, P2223; BENOVIC JL, 1985, J BIOL CHEM, V260, P7094; Blaukat A, 2001, J BIOL CHEM, V276, P40431, DOI 10.1074/jbc.M107024200; Budd DC, 2000, J BIOL CHEM, V275, P19667, DOI 10.1074/jbc.M000492200; Bundey RA, 2001, BRIT J PHARMACOL, V134, P257, DOI 10.1038/sj.bjp.0704229; Bunemann M, 1999, J PHYSIOL-LONDON, V517, P5, DOI 10.1111/j.1469-7793.1999.0005z.x; Carman CV, 1999, J BIOL CHEM, V274, P34483, DOI 10.1074/jbc.274.48.34483; CHALLISS RAJ, 1993, NEUROPROTOCOLS, V3, P135; CLARK RB, 1989, MOL PHARMACOL, V36, P343; Ferguson SSG, 2001, PHARMACOL REV, V53, P1; Fredericks ZL, 1996, J BIOL CHEM, V271, P13796, DOI 10.1074/jbc.271.23.13796; Gainetdinov RR, 1999, NEURON, V24, P1029, DOI 10.1016/S0896-6273(00)81048-X; Kellerbauer A, 2001, N-S ARCH PHARMACOL, V363, pR21; Krupnick JG, 1998, ANNU REV PHARMACOL, V38, P289, DOI 10.1146/annurev.pharmtox.38.1.289; Lazari MDM, 1999, MOL ENDOCRINOL, V13, P866, DOI 10.1210/me.13.6.866; Maestes DC, 1999, J BIOL CHEM, V274, P29791, DOI 10.1074/jbc.274.42.29791; Mundell SJ, 1998, BRIT J PHARMACOL, V125, P347, DOI 10.1038/sj.bjp.0702081; PalsRylaarsdam R, 1997, J BIOL CHEM, V272, P14152, DOI 10.1074/jbc.272.22.14152; PITCHER J, 1992, BIOCHEMISTRY-US, V31, P3193, DOI 10.1021/bi00127a021; Pitcher JA, 1996, J BIOL CHEM, V271, P24907, DOI 10.1074/jbc.271.40.24907; Pitcher JA, 1998, ANNU REV BIOCHEM, V67, P653, DOI 10.1146/annurev.biochem.67.1.653; Pronin AN, 1997, J BIOL CHEM, V272, P18273, DOI 10.1074/jbc.272.29.18273; Sallese M, 2000, MOL PHARMACOL, V57, P826, DOI 10.1124/mol.57.4.826; Seibold A, 1998, J BIOL CHEM, V273, P7637, DOI 10.1074/jbc.273.13.7637; SterneMarr R, 1995, VITAM HORM, V51, P193, DOI 10.1016/S0083-6729(08)61039-0; Tiruppathi C, 2000, P NATL ACAD SCI USA, V97, P7440, DOI 10.1073/pnas.97.13.7440; TOBIN AB, 1993, J BIOL CHEM, V268, P9817; Tsuga H, 1998, J PHARMACOL EXP THER, V284, P1218; Willars GB, 1999, AM J PHYSIOL-CELL PH, V277, pC859, DOI 10.1152/ajpcell.1999.277.5.C859; Willets J, 2001, EUR J PHARMACOL, V431, P133, DOI 10.1016/S0014-2999(01)01360-7; Willets JM, 2001, MOL PHARMACOL, V60, P321, DOI 10.1124/mol.60.2.321; Wu GY, 2000, J BIOL CHEM, V275, P9026, DOI 10.1074/jbc.275.12.9026; Zhou HP, 2001, J PHARMACOL EXP THER, V298, P1243	35	41	42	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 3	2002	277	18					15523	15529		10.1074/jbc.M111217200	http://dx.doi.org/10.1074/jbc.M111217200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	550PA	11856737	hybrid			2022-12-27	WOS:000175510400041
J	Numazaki, M; Tominaga, T; Toyooka, H; Tominaga, M				Numazaki, M; Tominaga, T; Toyooka, H; Tominaga, M			Direct phosphorylation of capsaicin receptor VR1 by protein Kinase C epsilon and identification of two target serine residues	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MICE LACKING; PAIN; SENSITIZATION; PATHWAY; CHANNEL	The capsaicin receptor, VR1, is a sensory neuron-specific ion channel that serves as a polymodal detector of pain-producing chemical and physical stimuli. It has been reported that ATP, one of the inflammatory mediators, potentiates the VR1 currents evoked by capsaicin or protons and reduces the temperature threshold for activation of VR1 through metabotropic P2Y(1) receptors in a protein Kinase C (PKC)-dependent pathway, suggesting the phosphorylation of VR1 by PKC. In this study, direct phosphorylation of VR1 upon application of phorbol 12-myristate 13-acetate (PMA) was proven biochemically in cells expressing VR1. An in vitro kinase assay using glutathione S-transferase fusion proteins with cytoplasmic segments of VR1 showed that both the first intracellular loop and carboxyl terminus of VR1 were phosphorylated by PKCepsilon. Patch clamp analysis of the point mutants where Ser or Thr residues were replaced with Ala in the total 16 putative phosphorylation sites showed that two Ser residues, Ser(502) and Ser(800) were involved in the potentiation of the capsaicin-evoked currents by either PMA or ATP. In the cells expressing S502A/S800A double mutant, the temperature threshold for activation was not reduced upon PMA treatment. The two sites would be promising targets for the development of substance modulating VR1 function, thereby reducing pain.	Mie Univ, Sch Med, Dept Physiol, Tsu, Mie 5148507, Japan; Univ Tsukuba, Sch Med, Dept Anesthesiol, Tsukuba, Ibaraki 3050006, Japan; Fdn Advancement Int Sci, Tsukuba, Ibaraki 3050062, Japan	Mie University; University of Tsukuba	Tominaga, M (corresponding author), Mie Univ, Sch Med, Dept Physiol, Edobashi 2-174, Tsu, Mie 5148507, Japan.	tominaga@doc.medic.mie-u.ac.jp						Aley KO, 2000, J NEUROSCI, V20, P4680, DOI 10.1523/JNEUROSCI.20-12-04680.2000; Caterina MJ, 2000, SCIENCE, V288, P306, DOI 10.1126/science.288.5464.306; Caterina MJ, 1997, NATURE, V389, P816, DOI 10.1038/39807; Caterina MJ, 1999, CURR OPIN NEUROBIOL, V9, P525, DOI 10.1016/S0959-4388(99)00009-4; Caterina MJ, 1999, NATURE, V398, P436, DOI 10.1038/18906; Cesare P, 1999, P NATL ACAD SCI USA, V96, P7658, DOI 10.1073/pnas.96.14.7658; Cesare P, 1996, P NATL ACAD SCI USA, V93, P15435, DOI 10.1073/pnas.93.26.15435; Cesare P, 1999, NEURON, V23, P617, DOI 10.1016/S0896-6273(00)80813-2; Chuang HH, 2001, NATURE, V411, P957, DOI 10.1038/35082088; Davis JB, 2000, NATURE, V405, P183, DOI 10.1038/35012076; Fields H. L., 1987, PAIN; Francesconi A, 2000, P NATL ACAD SCI USA, V97, P6185, DOI 10.1073/pnas.97.11.6185; Julius D, 2001, NATURE, V413, P203, DOI 10.1038/35093019; Khasar SG, 1999, NEURON, V24, P253, DOI 10.1016/S0896-6273(00)80837-5; Malmberg AB, 1997, SCIENCE, V278, P279, DOI 10.1126/science.278.5336.279; Martin WJ, 2001, J NEUROSCI, V21, P5321, DOI 10.1523/JNEUROSCI.21-14-05321.2001; Premkumar LS, 2000, NATURE, V408, P985, DOI 10.1038/35050121; Szallasi A, 1999, PHARMACOL REV, V51, P159; Tominaga M, 1998, NEURON, V21, P531, DOI 10.1016/S0896-6273(00)80564-4; Tominaga M, 2000, PAIN REV, V7, P97, DOI 10.1191/096813000678809447; Tominaga M, 2001, P NATL ACAD SCI USA, V98, P6951, DOI 10.1073/pnas.111025298; Tominaga T, 1998, EMBO J, V17, P4712, DOI 10.1093/emboj/17.16.4712; Vellani V, 2001, J PHYSIOL-LONDON, V534, P813, DOI 10.1111/j.1469-7793.2001.00813.x; Wood JN, 1999, CURR OPIN GENET DEV, V9, P328, DOI 10.1016/S0959-437X(99)80049-5; Woolf CJ, 2000, SCIENCE, V288, P1765, DOI 10.1126/science.288.5472.1765	25	377	401	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 19	2002	277	16					13375	13378		10.1074/jbc.C200104200	http://dx.doi.org/10.1074/jbc.C200104200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	543HR	11884385	hybrid			2022-12-27	WOS:000175096000005
J	Reuther, GW; Lambert, QT; Rebhun, JF; Caligiuri, MA; Quilliam, LA; Der, CJ				Reuther, GW; Lambert, QT; Rebhun, JF; Caligiuri, MA; Quilliam, LA; Der, CJ			RasGRP4 is a novel Ras activator isolated from acute myeloid leukemia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEMATOPOIETIC-CELL LINE; EXCHANGE FACTOR; PROTEIN; TRANSFORMATION; EXPRESSION; DIFFERENTIATION; IDENTIFICATION; SPECIFICITY; INHIBITION; MUTATIONS	Although a number of genetic defects are commonly associated with acute myeloid leukemia (AML), a large percentage of AML cases are cytogenetically normal. This suggests a functional screen for transforming genes is required to identify genetic mutations that are missed by cytogenetic analyses. We utilized a retrovirus-based cDNA expression system to identify transforming genes expressed in cytogenetically normal AML patients. We identified a new member of the Ras guanyl nucleotide-releasing protein (RasGRP) family of Ras guanine nucleotide exchange factors, designating it RasGRP4. Subsequently, cDNA sequences encoding rodent and human RasGRP4 protei. Ins were deposited in GenBank(TM). RasGRP4 contains the same protein domain structure as other members of the RasGRP family, including a Ras exchange motif, a CDC25 homology domain, a C1/diacyglycerol-binding domain, and putative calcium-binding EF hands. We show that expression of RasGRP4 induces anchorage-independent growth of Rat1 fibroblasts. RasGRP4 is a Ras-specific activator and, interestingly, is highly expressed in peripheral blood leukocytes and myeloid cell lines. Unlike other RasGRP proteins, RasGRP4 is not expressed in the brain or in lymphoid cells. We demonstrated that 32D myeloid cells expressing RasGRP4 have elevated levels of activated Ras compared with control cells, and phorbol 12-myristate 13-acetate (PMA) treatment greatly enhanced Ras activation. PMA induced membrane localization of RasGRP4 and 32D cells expressing RasGRP4 were capable of cytokine-independent proliferation in the presence of PMA. We conclude that RasGRP4 is a member of the RasGRP family of Ras guanine nucleotide exchange factors that may play a role in myeloid cell signaling growth regulation pathways that are responsive to diacylglycerol levels.	Univ N Carolina, Lineberger Comprehens Canc Ctr, Dept Pharmacol, Chapel Hill, NC 27599 USA; Indiana Univ, Sch Med, Dept Biochem & Mol Biol, Walther Oncol Ctr, Indianapolis, IN 46202 USA; Ohio State Univ, Ctr Comprehens Canc, Dept Internal Med, Columbus, OH 43210 USA	University of North Carolina; University of North Carolina Chapel Hill; Indiana University System; Indiana University-Purdue University Indianapolis; Walther Cancer Institute; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University	Reuther, GW (corresponding author), Univ N Carolina, Lineberger Comprehens Canc Ctr, Dept Pharmacol, CB 7295, Chapel Hill, NC 27599 USA.		Rebhun, John F/H-7235-2019; Quilliam, Lawrence/Q-4987-2019; Reuther, Gary/AFR-2892-2022; Quilliam, Lawrence/B-6447-2015	Rebhun, John F/0000-0002-0764-5210; Der, Channing/0000-0002-7751-2747	NCI NIH HHS [CA 42978] Funding Source: Medline; PHS HHS [T32 H 07774] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA042978] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BOS JL, 1987, BLOOD, V69, P1237; CLARK GJ, 1995, METHOD ENZYMOL, V255, P395; Clyde-Smith J, 2000, J BIOL CHEM, V275, P32260, DOI 10.1074/jbc.M006087200; CORTEZ D, 1995, MOL CELL BIOL, V15, P5531; COX AD, 1995, METHOD ENZYMOL, V255, P195; DER CJ, 1988, ONCOGENE, V3, P105; Dower NA, 2000, NAT IMMUNOL, V1, P317, DOI 10.1038/79766; Dupuy AJ, 2001, J BIOL CHEM, V276, P11804, DOI 10.1074/jbc.M008970200; Ebinu JO, 1998, SCIENCE, V280, P1082, DOI 10.1126/science.280.5366.1082; Ebinu JO, 2000, BLOOD, V95, P3199; Gilliland DG, 2001, CURR OPIN HEMATOL, V8, P189, DOI 10.1097/00062752-200107000-00001; GREENBERGER JS, 1983, P NATL ACAD SCI-BIOL, V80, P2931, DOI 10.1073/pnas.80.10.2931; Kawasaki H, 1998, P NATL ACAD SCI USA, V95, P13278, DOI 10.1073/pnas.95.22.13278; Kazanietz MG, 2000, MOL CARCINOGEN, V28, P5, DOI 10.1002/(SICI)1098-2744(200005)28:1<5::AID-MC2>3.0.CO;2-G; Kedra D, 1997, HUM GENET, V100, P611, DOI 10.1007/s004390050562; KINOSHITA T, 1995, ONCOGENE, V10, P2207; LANEUVILLE P, 1994, CANCER RES, V54, P1360; LEE JC, 1982, J IMMUNOL, V128, P2393; Lin R, 1997, CURR BIOL, V7, P794, DOI 10.1016/S0960-9822(06)00338-1; Look AT, 1997, SCIENCE, V278, P1059, DOI 10.1126/science.278.5340.1059; Lorenzo PS, 2001, CANCER RES, V61, P943; MAVILIO F, 1989, ONCOGENE, V4, P301; METCALF D, 1985, BLOOD, V65, P357; Miller Kenneth B., 1995, P993; MITELMAN F, 2002, MITELMAN DATABASE CH; Mizuki M, 2000, BLOOD, V96, P3907, DOI 10.1182/blood.V96.12.3907; Mrozek K, 1997, SEMIN ONCOL, V24, P17; NEEDLEMAN SW, 1986, BLOOD, V67, P753; PRENDERGAST GC, 1994, MOL CELL BIOL, V14, P4193, DOI 10.1128/MCB.14.6.4193; Qiu RG, 1997, MOL CELL BIOL, V17, P3449, DOI 10.1128/MCB.17.6.3449; Quilliam LA, 2002, PROG NUCLEIC ACID RE, V71, P391, DOI 10.1016/S0079-6603(02)71047-7; Rebhun JF, 2000, J BIOL CHEM, V275, P13406, DOI 10.1074/jbc.C000085200; Reuther GW, 2000, CURR OPIN CELL BIOL, V12, P157, DOI 10.1016/S0955-0674(99)00071-X; Reuther GW, 2000, MOL CELL BIOL, V20, P8655, DOI 10.1128/MCB.20.23.8655-8666.2000; Taylor SJ, 1996, CURR BIOL, V6, P1621, DOI 10.1016/S0960-9822(02)70785-9; Tognon CE, 1998, MOL CELL BIOL, V18, P6995, DOI 10.1128/MCB.18.12.6995; Towatari M, 1997, LEUKEMIA, V11, P479, DOI 10.1038/sj.leu.2400617; Van Triest M, 2001, METHOD ENZYMOL, V333, P343; WHITEHEAD I, 1995, MOL CELL BIOL, V15, P704; Williams RL, 1999, BBA-MOL CELL BIOL L, V1441, P255, DOI 10.1016/S1388-1981(99)00150-X; Wolthuis RMF, 1996, ONCOGENE, V13, P353; Yamashita S, 2000, J BIOL CHEM, V275, P25488, DOI 10.1074/jbc.M003414200	42	69	75	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 23	2002	277	34					30508	30514		10.1074/jbc.M111330200	http://dx.doi.org/10.1074/jbc.M111330200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	586JA	11880369	hybrid, Green Published			2022-12-27	WOS:000177579800016
J	Chang, JS; Seok, H; Kwon, TK; Min, DS; Ahn, BH; Lee, YH; Suh, JW; Kim, JW; Iwashita, S; Omori, A; Ichinose, S; Numata, O; Seo, JK; Oh, YS; Suh, PG				Chang, JS; Seok, H; Kwon, TK; Min, DS; Ahn, BH; Lee, YH; Suh, JW; Kim, JW; Iwashita, S; Omori, A; Ichinose, S; Numata, O; Seo, JK; Oh, YS; Suh, PG			Interaction of elongation factor-1 alpha and pleckstrin homology domain of phospholipase C-gamma 1 with activating its activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATIDYLINOSITOL 4-KINASE; TYROSINE KINASE; SIGNALING MOLECULES; FACTOR 1-ALPHA; COMMON FOLD; C ISOZYMES; PH DOMAINS; MEMBRANE; BINDING; CELLS	The pleckstrin homology (PH) domain is a small motif for membrane targeting in the signaling molecules. Phospholipase C (PLC)-gamma1 has two putative PH domains, an NH2-terminal and a split PH domain. Here we report studies on the interaction of the PH domain of PLC-gamma1 with translational elongation factor (Ef)-1alpha, which has been shown to be a phosphatidylinositol 4-kinase activator. By pull-down of cell extract with the glutathione S-transferase (GST) fusion proteins with various domains of PLC-gamma1 followed by peptide sequence analysis, we identified EF-1alpha as a binding partner of a split PH domain of PLC-gamma1. Analysis by site-directed mutagenesis of the PH domain revealed that the beta2-sheet of a split PH domain is critical for the interaction with EF-1alpha. Moreover, Dot-blot assay shows that a split PH domain specifically binds to phosphoinositides including phosphatidylinositol 4-phosphate and phosphatidylinositol 4,5-bisphosphate (PIP2). So the PH domain of PLC-gamma1 binds to both EF-1alpha and PIP2. The binding affinity of EF-1alpha to the GST-PH domain fusion protein increased in the presence of PIP2. although PIP2 does not bind to EF-1alpha directly. This suggests that EF-1alpha may control the binding affinity between the PH domain and PIP2. PLC-gamma1 is substantially activated in the presence of EF-1alpha with a bell-shaped curve in relation to the molar ratio between them, whereas a double point mutant PLC-gamma1 (Y509A/F510A) that lost its binding affinity to EF-1a shows basal level activity. Taken together, our data show that EF-1alpha plays a direct role in phosphoinositide metabolism of cellular signaling by regulating PLC-gamma1 activity via a split PH domain.	Daejin Univ, Coll Nat Sci, Dept Life Sci, Kyonggi Do 487711, South Korea; Keimyung Univ, Coll Med, Dept Immunol, Taegu 700712, South Korea; Catholic Univ Korea, Coll Med, Dept Physiol, Seoul 137701, South Korea; Yeungnam Univ, Coll Med, Dept Biochem, Taegu 705717, South Korea; Myongji Univ, Coll Nat Sci, Dept Biol Sci, Kyonggi Do 449728, South Korea; Mitsubishi Kasei Inst Life Sci, Machida, Tokyo 194, Japan; Univ Tsukuba, Inst Biol Sci, Tsukuba, Ibaraki 3058572, Japan; Seoul Natl Univ, Coll Med, Inst Canc Res, In2Gen, Seoul 110799, South Korea; Pohang Univ Sci & Technol, Dept Life Sci, Kyungbuk 790784, South Korea	Daejin University; Keimyung University; Catholic University of Korea; Yeungnam University; Myongji University; University of Tsukuba; Seoul National University (SNU); Pohang University of Science & Technology (POSTECH)	Chang, JS (corresponding author), Daejin Univ, Coll Nat Sci, Dept Life Sci, Kyonggi Do 487711, South Korea.		Seo, Jeong Kon/H-4770-2016; Suh, Pann-Ghill/F-3610-2010	Oh, Yong-Seok/0000-0002-9039-2014				Bae SS, 2000, FASEB J, V14, P1083, DOI 10.1096/fasebj.14.9.1083; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; CARVALHO MDD, 1984, ARCH BIOCHEM BIOPHYS, V234, P603, DOI 10.1016/0003-9861(84)90310-2; Chang JS, 1997, CANCER RES, V57, P5465; COCKCROFT S, 1992, BIOCHEM J, V288, P1; CONDEELIS J, 1995, TRENDS BIOCHEM SCI, V20, P169, DOI 10.1016/S0968-0004(00)88998-7; Edmonds BT, 1998, J BIOL CHEM, V273, P10288, DOI 10.1074/jbc.273.17.10288; Falasca M, 1998, EMBO J, V17, P414, DOI 10.1093/emboj/17.2.414; GIBSON TJ, 1994, TRENDS BIOCHEM SCI, V19, P349, DOI 10.1016/0968-0004(94)90108-2; HASLAM RJ, 1993, NATURE, V363, P309, DOI 10.1038/363309b0; HEPLER JR, 1993, J BIOL CHEM, V268, P14367; Ji QS, 1997, P NATL ACAD SCI USA, V94, P2999, DOI 10.1073/pnas.94.7.2999; KAUR KJ, 1994, J BIOL CHEM, V269, P23045; Kavran JM, 1998, J BIOL CHEM, V273, P30497, DOI 10.1074/jbc.273.46.30497; KIM HK, 1991, CELL, V65, P435, DOI 10.1016/0092-8674(91)90461-7; Lemmon MA, 2000, BIOCHEM J, V350, P1, DOI 10.1042/0264-6021:3500001; Lemmon MA, 1998, CURR TOP MICROBIOL, V228, P39; Lemmon MA, 1997, TRENDS CELL BIOL, V7, P237, DOI 10.1016/S0962-8924(97)01065-9; Lemmon MA, 1996, CELL, V85, P621, DOI 10.1016/S0092-8674(00)81022-3; MACIAS MJ, 1994, NATURE, V369, P675, DOI 10.1038/369675a0; MAYER BJ, 1993, CELL, V73, P629, DOI 10.1016/0092-8674(93)90244-K; Negrutskii BS, 1998, PROG NUCLEIC ACID RE, V60, P47, DOI 10.1016/S0079-6603(08)60889-2; NISHIKI T, 1994, J BIOL CHEM, V269, P10498; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; Numata O, 2000, J BIOCHEM, V127, P51, DOI 10.1093/oxfordjournals.jbchem.a022583; PITCHER JA, 1995, J BIOL CHEM, V270, P11707, DOI 10.1074/jbc.270.20.11707; Razzini G, 2000, J BIOL CHEM, V275, P14873, DOI 10.1074/jbc.275.20.14873; Rebecchi MJ, 1998, ANNU REV BIOPH BIOM, V27, P503, DOI 10.1146/annurev.biophys.27.1.503; Rhee SG, 2001, ANNU REV BIOCHEM, V70, P281, DOI 10.1146/annurev.biochem.70.1.281; Rhee SG, 1997, J BIOL CHEM, V272, P15045, DOI 10.1074/jbc.272.24.15045; RIIS B, 1990, TRENDS BIOCHEM SCI, V15, P420, DOI 10.1016/0968-0004(90)90279-K; SHIRASAWA T, 1992, NUCLEIC ACIDS RES, V20, P909, DOI 10.1093/nar/20.4.909; Stevenson JM, 1998, J BIOL CHEM, V273, P22761, DOI 10.1074/jbc.273.35.22761; SUH PG, 1988, P NATL ACAD SCI USA, V85, P5419, DOI 10.1073/pnas.85.15.5419; TAKEDA T, 1995, J BIOCHEM-TOKYO, V117, P869, DOI 10.1093/oxfordjournals.jbchem.a124789; TANIGUCHI S, 1991, NUCLEIC ACIDS RES, V19, P6949, DOI 10.1093/nar/19.24.6949; TATSUKA M, 1992, NATURE, V359, P333, DOI 10.1038/359333a0; TOUHARA K, 1994, J BIOL CHEM, V269, P10217; Yagisawa H, 1998, J BIOL CHEM, V273, P417, DOI 10.1074/jbc.273.1.417; YANG W, 1994, J BIOL CHEM, V269, P3852; YANG WN, 1993, J BIOL CHEM, V268, P392; Yang WY, 1997, P NATL ACAD SCI USA, V94, P604, DOI 10.1073/pnas.94.2.604; Yao LB, 1997, J BIOL CHEM, V272, P13033, DOI 10.1074/jbc.272.20.13033; Yao LB, 1999, J BIOL CHEM, V274, P19752, DOI 10.1074/jbc.274.28.19752; YOON HS, 1994, NATURE, V369, P672, DOI 10.1038/369672a0	45	36	38	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 31	2002	277	22					19697	19702		10.1074/jbc.M111206200	http://dx.doi.org/10.1074/jbc.M111206200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	557EH	11886851	hybrid, Green Published			2022-12-27	WOS:000175894800061
J	Lin, DCH; Bullock, CM; Ehlert, FJ; Chen, JL; Tian, H; Zhou, QY				Lin, DCH; Bullock, CM; Ehlert, FJ; Chen, JL; Tian, H; Zhou, QY			Identification and molecular characterization of two closely related G protein-coupled receptors activated by prokineticins/endocrine gland vascular endothelial growth factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MANAGEMENT; MOTILITY	We previously described two mammalian secreted proteins, prokineticin 1 and prokineticin 2, that potently contract gastrointestinal smooth muscle. Prokineticin 1 has also been shown to promote angiogenesis by stimulating proliferation, migration, and fenestration of endocrine organ-derived endothelial cells. Here we report the cloning and characterization of two closely related G protein-coupled receptors as receptors for prokineticins. Expression of prokineticin receptors in heterologous systems shows that these receptors bind to and are activated by nanomolar concentrations of recombinant prokineticins. Activation of prokineticin receptors leads to mobilization of calcium, stimulation of phosphoinositide turnover, and activation of p44/p42 MAPK signaling pathways that are consistent with the effects of prokineticins on smooth muscle contraction and angiogenesis. mRNA expression analysis reveals that prokineticin receptors are expressed in gastrointestinal organs, endocrine glands, and other tissues.	Tularik Inc, San Francisco, CA 94080 USA; Univ Calif Irvine, Dept Pharmacol, Irvine, CA 92697 USA	University of California System; University of California Irvine	Tian, H (corresponding author), Tularik Inc, 2 Corp Dr, San Francisco, CA 94080 USA.		Ehlert, Frederick J/T-4220-2019					An SZ, 2001, P NATL ACAD SCI USA, V98, P7576, DOI 10.1073/pnas.131200698; Baldi P, 1994, J Comput Biol, V1, P311, DOI 10.1089/cmb.1994.1.311; Bermak JC, 2001, NAT CELL BIOL, V3, P492, DOI 10.1038/35074561; Camilleri M, 2001, GASTROENTEROLOGY, V120, P652, DOI 10.1053/gast.2001.21908; De Ponti F, 1998, PHARMACOL THERAPEUT, V80, P49, DOI 10.1016/S0163-7258(98)00021-7; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; Fujimiya M, 2000, PEPTIDES, V21, P1565, DOI 10.1016/S0196-9781(00)00313-2; LeCouter J, 2001, NATURE, V412, P877, DOI 10.1038/35091000; Li M, 2001, MOL PHARMACOL, V59, P692, DOI 10.1124/mol.59.4.692; PAGES G, 2000, ANN NY ACAD SCI, V902, P182; Pandolfino JE, 2000, GASTROENTEROLOGY, V118, pS32, DOI 10.1016/S0016-5085(00)70005-9; Parker R, 2000, BBA-GENE STRUCT EXPR, V1491, P369, DOI 10.1016/S0167-4781(00)00023-3; RUBANYI GM, 2000, ANGIOGENESIS HLTH DI; Sawyer GW, 1999, J PHARMACOL EXP THER, V289, P464	14	257	283	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 31	2002	277	22					19276	19280		10.1074/jbc.M202139200	http://dx.doi.org/10.1074/jbc.M202139200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	557EH	11886876	hybrid			2022-12-27	WOS:000175894800006
J	Baud, S; Margeat, E; Lumbroso, S; Paris, F; Sultan, C; Royer, C; Poujol, N				Baud, S; Margeat, E; Lumbroso, S; Paris, F; Sultan, C; Royer, C; Poujol, N			Equilibrium binding assays reveal the elevated stoichiometry and salt dependence of the interaction between full-length human sex-determining region on the Y chromosome (SRY) and DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TESTIS-DETERMINING FACTOR; ESTROGEN-RECEPTOR-ALPHA; FLUORESCENCE ANISOTROPY; GONADAL-DYSGENESIS; DETERMINING GENE; BOX; PROTEIN; REVERSAL; DOMAIN; RECOGNITION	In an effort to better define the molecular mechanism of the functional specificity of human sex-determining region on the Y chromosome (SRY), we have carried out equilibrium binding assays to study the interaction of the full-length bacterial-expressed protein with a DNA response element derived from the CD3epsilon gene enhancer. These assays are based on the observation of the fluorescence anisotropy of a fluorescein moiety covalently bound to the target oligonucleotide. The low anisotropy value due to the fast tumbling of the free oligonucleotide in solution increases substantially upon binding the protein to the labeled target DNA. Our results indicate that the full-length human wild-type SRY (SRYWT) forms a complex of high stoichiometry with its target DNA. Moreover, we have demonstrated a strong salt dependence of both the affinity and specificity of the interaction. We have also addressed the DNA bending properties of full-length human SRYWT in solution by fluorescence resonance energy transfer and revealed that maximal bending is achieved with a protein to DNA ratio significantly higher than the classical 1:1. Oligomerization thus appears, at least in vitro, to be tightly coupled to SRY-DNA interactions. Alteration of protein-protein interactions observed for the mutant protein SRYY129N,identified in a patient presenting with 46,XY sex reversal, suggests that oligomerization may play an important role in vivo as well.	Univ Montpellier 1, Ctr Biochim Struct, UMR INSERM 554, CNRS 5048, F-34090 Montpellier, France; CHU Montpellier, Lab Hormonol, INSERM, U439, F-34295 Montpellier, France; CHU Montpellier, Hop A de Villeneuve, Unite Endocrinol Pediat, F-34295 Montpellier, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier; CHU de Montpellier; Universite de Montpellier; CHU de Montpellier	Poujol, N (corresponding author), Ctr Med Biol, Lab Anal Med, 16 Rue 8 Mai 1945, F-34200 Sete, France.		Lumbroso, Serge/AFS-0438-2022; Margeat, Emmanuel/AAY-9167-2021; Paris, Francoise/AAC-6553-2019; Royer, Catherine A/E-5266-2016	Margeat, Emmanuel/0000-0001-6063-6420; Royer, Catherine A/0000-0002-2670-3391				BAXEVANIS AD, 1995, NUCLEIC ACIDS RES, V23, P1604, DOI 10.1093/nar/23.9.1604; BERTA P, 1990, NATURE, V348, P448, DOI 10.1038/348448A0; Boyer M, 2000, NUCLEIC ACIDS RES, V28, P2494, DOI 10.1093/nar/28.13.2494; Brown S, 1998, AM J HUM GENET, V62, P189, DOI 10.1086/301684; Chene P, 2001, ONCOGENE, V20, P2611, DOI 10.1038/sj.onc.1204373; Deckert J, 1999, NUCLEIC ACIDS RES, V27, P3518, DOI 10.1093/nar/27.17.3518; Desclozeaux M, 1998, BBA-GENE STRUCT EXPR, V1397, P247, DOI 10.1016/S0167-4781(98)00041-4; Domenice S, 1998, HUM GENET, V102, P213, DOI 10.1007/s004390050680; Engel J, 2000, MATRIX BIOL, V19, P283, DOI 10.1016/S0945-053X(00)00075-5; FERRARI S, 1992, EMBO J, V11, P4497, DOI 10.1002/j.1460-2075.1992.tb05551.x; GIESE K, 1994, P NATL ACAD SCI USA, V91, P3368, DOI 10.1073/pnas.91.8.3368; Grillo AO, 1999, J MOL BIOL, V287, P539, DOI 10.1006/jmbi.1999.2625; HAQQ CM, 1993, P NATL ACAD SCI USA, V90, P1097, DOI 10.1073/pnas.90.3.1097; HARLEY VR, 1994, MOL REPROD DEV, V39, P184, DOI 10.1002/mrd.1080390211; HARLEY VR, 1992, SCIENCE, V255, P453, DOI 10.1126/science.1734522; Kim CA, 2001, EMBO J, V20, P4173, DOI 10.1093/emboj/20.15.4173; LnenicekAllen M, 1996, NUCLEIC ACIDS RES, V24, P1047, DOI 10.1093/nar/24.6.1047; Margeat E, 2001, J MOL BIOL, V306, P433, DOI 10.1006/jmbi.2000.4418; MCELREAVEY K, 1993, P NATL ACAD SCI USA, V90, P3368, DOI 10.1073/pnas.90.8.3368; McElreavey K, 1996, P NATL ACAD SCI USA, V93, P8590, DOI 10.1073/pnas.93.16.8590; NASRIN N, 1991, NATURE, V354, P317, DOI 10.1038/354317a0; Ozers MS, 1997, J BIOL CHEM, V272, P30405, DOI 10.1074/jbc.272.48.30405; PETERS R, 1995, BIOCHEMISTRY-US, V34, P4569, DOI 10.1021/bi00014a009; PONTIGGIA A, 1994, EMBO J, V13, P6115, DOI 10.1002/j.1460-2075.1994.tb06958.x; RECORD MT, 1991, METHOD ENZYMOL, V208, P291; Schaffler A, 2000, J CLIN ENDOCR METAB, V85, P2287, DOI 10.1210/jc.85.6.2287; SINCLAIR AH, 1990, NATURE, V346, P240, DOI 10.1038/346240a0; TEO SH, 1995, EUR J BIOCHEM, V230, P943, DOI 10.1111/j.1432-1033.1995.tb20640.x; Trimmer EE, 1998, BIOCHEMISTRY-US, V37, P352, DOI 10.1021/bi971675q; Ukiyama E, 2001, MOL ENDOCRINOL, V15, P363, DOI 10.1210/me.15.3.363; Veitia RA, 2001, MOL CELL ENDOCRINOL, V179, P3, DOI 10.1016/S0303-7207(01)00460-9; WERNER MH, 1995, CELL, V81, P705, DOI 10.1016/0092-8674(95)90532-4	32	8	10	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 24	2002	277	21					18404	18410		10.1074/jbc.M112366200	http://dx.doi.org/10.1074/jbc.M112366200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	558PM	11877434	hybrid			2022-12-27	WOS:000175975800021
J	Konieczny, I; Liberek, K				Konieczny, I; Liberek, K			Cooperative action of Escherichia coli ClpB protein and DnaK chaperone in the activation of a replication initiation protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RANGE PLASMID RK2; HEAT-SHOCK PROTEINS; DISTANTLY RELATED BACTERIA; MOLECULAR CHAPERONES; CLP/HSP100 FAMILY; ENCODED PROTEINS; IN-VIVO; TRFA; ORIGIN; GRPE	The Escherichia coli molecular chaperone protein ClpB is a member of the highly conserved Hsp100/Clp protein family. Previous studies have shown that the ClpB protein is needed for bacterial thermotolerance. Purified ClpB protein has been shown to reactivate chemically and heat-denatured proteins. In this work we demonstrate that the combined action of ClpB and the DnaK, DnaJ, and GrpE chaperones leads to the activation of DNA replication of the broad-host-range plasmid RK2. In contrast, ClpB is not needed for the activation of the oriC-dependent replication of E. coli. Using purified protein components we show that the ClpB/DnaK/DnaJ/GrpE synergistic action activates the plasmid RK2 replication initiation protein TrfA by converting inactive dimers to an active monomer form. In contrast, Hsp78/Ssc1/Mdj1/Mge1, the corresponding protein system from yeast mitochondria, cannot activate the TrfA replication protein. Our results demonstrate for the first time that the CIpB/DnaK/DnaJ/GrpE system is involved in protein monomerization and in the activation of a DNA replication factor.	Univ Gdansk, Fac Biotechnol, Dept Mol & Cellular Biol, PL-80822 Gdansk, Poland	Fahrenheit Universities; University of Gdansk	Konieczny, I (corresponding author), Univ Gdansk, Fac Biotechnol, Dept Mol & Cellular Biol, 24 Kladki, PL-80822 Gdansk, Poland.		Liberek, Krzysztof/F-5812-2011	Konieczny, Igor/0000-0002-1588-5601; Liberek, Krzysztof/0000-0002-7532-9279				Banecki B, 1998, BBA-GENE STRUCT EXPR, V1442, P39, DOI 10.1016/S0167-4781(98)00118-3; Blasina A, 1996, P NATL ACAD SCI USA, V93, P3559, DOI 10.1073/pnas.93.8.3559; BOLLIGER L, 1994, EMBO J, V13, P1998, DOI 10.1002/j.1460-2075.1994.tb06469.x; Caspi R, 2000, J BIOL CHEM, V275, P18454, DOI 10.1074/jbc.M000552200; CEREGHINO JL, 1993, J BIOL CHEM, V268, P24926; Diamant S, 2000, J BIOL CHEM, V275, P21107, DOI 10.1074/jbc.M001293200; Doran KS, 1998, J BIOL CHEM, V273, P8447, DOI 10.1074/jbc.273.14.8447; Doran KS, 1999, MOL MICROBIOL, V33, P490, DOI 10.1046/j.1365-2958.1999.01491.x; Doran KS, 1999, J BIOL CHEM, V274, P17918, DOI 10.1074/jbc.274.25.17918; DURLAND RH, 1990, J BACTERIOL, V172, P3859, DOI 10.1128/jb.172.7.3859-3867.1990; DURLAND RH, 1987, PLASMID, V18, P164, DOI 10.1016/0147-619X(87)90044-8; FANG FC, 1991, J BACTERIOL, V173, P5861, DOI 10.1128/jb.173.18.5861-5868.1991; Glover JR, 1998, CELL, V94, P73, DOI 10.1016/S0092-8674(00)81223-4; Goloubinoff P, 1999, P NATL ACAD SCI USA, V96, P13732, DOI 10.1073/pnas.96.24.13732; GOTTESMAN S, 1993, J BIOL CHEM, V268, P22618; HEINEMANN JA, 1989, NATURE, V340, P205, DOI 10.1038/340205a0; HWANG DS, 1990, J BIOL CHEM, V265, P19244; Kim YI, 2000, MOL CELL, V5, P639, DOI 10.1016/S1097-2765(00)80243-9; KITAGAWA M, 1991, J BACTERIOL, V173, P4247, DOI 10.1128/JB.173.14.4247-4253.1991; KITTELL BL, 1991, P NATL ACAD SCI USA, V88, P1389, DOI 10.1073/pnas.88.4.1389; Konieczny I, 1997, J BIOL CHEM, V272, P20173, DOI 10.1074/jbc.272.32.20173; Konieczny I, 1997, J BIOL CHEM, V272, P33312, DOI 10.1074/jbc.272.52.33312; Konieczny I, 1997, P NATL ACAD SCI USA, V94, P14378, DOI 10.1073/pnas.94.26.14378; KONIECZNY I, 1999, GENETICS ENG, P95; KORNACKI JA, 1984, PLASMID, V11, P48, DOI 10.1016/0147-619X(84)90006-4; Krzewska J, 2001, FEBS LETT, V489, P92, DOI 10.1016/S0014-5793(00)02423-6; Laskowska E, 1996, MOL MICROBIOL, V22, P555, DOI 10.1046/j.1365-2958.1996.1231493.x; LEHNHERR H, 1995, P NATL ACAD SCI USA, V92, P3274, DOI 10.1073/pnas.92.8.3274; Levchenko I, 1997, CELL, V91, P939, DOI 10.1016/S0092-8674(00)80485-7; LIBEREK K, 1992, P NATL ACAD SCI USA, V89, P3516, DOI 10.1073/pnas.89.8.3516; LIN J, 1992, J BACTERIOL, V174, P4110, DOI 10.1128/jb.174.12.4110-4119.1992; LINDQUIST S, 1999, MOL CHAPERONES FOLDI, P347; Liu JJ, 1999, MOL MICROBIOL, V33, P415, DOI 10.1046/j.1365-2958.1999.01489.x; Makovets S, 1998, MOL MICROBIOL, V28, P25, DOI 10.1046/j.1365-2958.1998.00767.x; Mogk A, 1999, EMBO J, V18, P6934, DOI 10.1093/emboj/18.24.6934; Motohashi K, 1999, P NATL ACAD SCI USA, V96, P7184, DOI 10.1073/pnas.96.13.7184; PERRI S, 1991, J BIOL CHEM, V266, P12536; PINKNEY M, 1988, J MOL BIOL, V203, P927, DOI 10.1016/0022-2836(88)90118-0; SCHMIDHAUSER TJ, 1983, PLASMID, V9, P325, DOI 10.1016/0147-619X(83)90010-0; SHINGLER V, 1984, J MOL BIOL, V175, P229, DOI 10.1016/0022-2836(84)90346-2; SQUIRES CL, 1991, J BACTERIOL, V173, P4254, DOI 10.1128/JB.173.14.4254-4262.1991; STALKER DM, 1981, MOL GEN GENET, V181, P8, DOI 10.1007/BF00338997; Thomas CM, 1989, PROMISCUOUS PLASMIDS, P1; TILLY K, 1990, New Biologist, V2, P812; TILLY K, 1989, J BACTERIOL, V171, P6025, DOI 10.1128/jb.171.11.6025-6029.1989; Toukdarian AE, 1998, GENE, V223, P205, DOI 10.1016/S0378-1119(98)00370-9; Toukdarian AE, 1996, J BIOL CHEM, V271, P7072, DOI 10.1074/jbc.271.12.7072; Wawrzynow A, 1996, MOL MICROBIOL, V21, P895, DOI 10.1046/j.1365-2958.1996.421404.x; WAWRZYNOW A, 1995, EMBO J, V14, P1867, DOI 10.1002/j.1460-2075.1995.tb07179.x; Wickner S, 1999, SCIENCE, V286, P1888, DOI 10.1126/science.286.5446.1888; WICKNER S, 1992, P NATL ACAD SCI USA, V89, P10345, DOI 10.1073/pnas.89.21.10345; WICKNER S, 1994, P NATL ACAD SCI USA, V91, P12218, DOI 10.1073/pnas.91.25.12218; WOO KM, 1992, J BIOL CHEM, V267, P20429; Zolkiewski M, 1999, J BIOL CHEM, V274, P28083, DOI 10.1074/jbc.274.40.28083; ZYLICZ M, 1989, EMBO J, V8, P1601, DOI 10.1002/j.1460-2075.1989.tb03544.x	55	39	40	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 24	2002	277	21					18483	18488		10.1074/jbc.M107580200	http://dx.doi.org/10.1074/jbc.M107580200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	558PM	11889118	hybrid			2022-12-27	WOS:000175975800031
J	Spagnoli, A; Torello, M; Nagalla, SR; Horton, WA; Pattee, P; Hwa, V; Chiarelli, F; Roberts, CT; Rosenfeld, RG				Spagnoli, A; Torello, M; Nagalla, SR; Horton, WA; Pattee, P; Hwa, V; Chiarelli, F; Roberts, CT; Rosenfeld, RG			Identification of STAT-1 as a molecular target of IGFBP-3 in the process of chondrogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-BINDING PROTEIN-3; BREAST-CANCER CELLS; CHONDROCYTE PROLIFERATION; GROWTH-HORMONE; RECEPTOR; BETA; APOPTOSIS; DIFFERENTIATION; EXPRESSION; MICE	The chondrogenesis process requires the ordered proliferation and differentiation of chondrocytes. Insulinlike growth factor-binding protein (IGFBP)-3, well characterized as the carrier of insulin-like growth factor (IGF), has been reported to have intrinsic bioactivity that is independent of IGF binding. The mechanisms involved in this IGF-independent action are still unclear. Using the RCJ3.1C5.18 chondrogenic cells, which in culture progresses from undifferentiated to terminally differentiated chondrocytes, we have shown previously that IGFBP-3 has an IGF-independent, antiproliferative effect in undifferentiated and early differentiated but not in terminally differentiated chondrocytes. In the present study, cDNA microarray analysis was used to screen for genes: 1) that were regulated by IGFBP-3 in early but not in terminally differentiated chondrocytes; 2) that were regulated specifically by IGFBP-3, but not by IGF-I; and 3) whose regulation was abolished by coincubation of IGFBP-3 with IGF-I. Signal transducer and activator of transcription (STAT)-1 was the gene that, fulfilling the screening criteria, exhibited the greatest up-regulation by IGFBP-3 (>40-fold). STAT-1 gene up-regulation was confirmed by Northern analysis of cells treated with IGFBP-3 or transfected with an IGFBP-3 expression vector. Remarkably, similar results were obtained when cells were transfected with an IGFBP-3 mutant unable to bind IGFs, definitively demonstrating the IGF-independent action of IGFBP-3. Consistent with the up-regulation of STAT-1 mRNA, IGFBP-3 also increased STAT-1 protein expression. Furthermore, both IGFBP-3 and the IGFBP-3 mutant induced STAT-1 phosphorylation and its nuclear localization. An antisense STAT-1 oligonucleotide abolished the IGF-independent cell apoptosis induced by IGFBP-3. We have demonstrated that STAT-1 is a major intracellular signaling and transcriptional target of the IGF-independent apoptotic effect of IGFBP-3 in chondrogenesis.	Vanderbilt Univ, Med Ctr, Dept Pediat, Med Ctr N T0107, Nashville, TN 37232 USA; Shriners Hosp Children, Res Ctr, Portland, OR 97201 USA; Oregon Hlth & Sci Univ, Dept Pediat, Portland, OR 97201 USA; Univ G dAnnunzio, Dept Pediat, I-66013 Chieti, Italy	Vanderbilt University; Oregon Health & Science University; G d'Annunzio University of Chieti-Pescara	Spagnoli, A (corresponding author), Vanderbilt Univ, Med Ctr, Dept Pediat, Med Ctr N T0107, Nashville, TN 37232 USA.	anna.spagnoli@mcmail.vanderbilt.edu	Roberts, Charles/K-6953-2017	Roberts, Charles/0000-0003-1756-5772				Baxter RC, 2000, AM J PHYSIOL-ENDOC M, V278, pE967, DOI 10.1152/ajpendo.2000.278.6.E967; BLUYSSEN HAR, 1995, P NATL ACAD SCI USA, V92, P5645, DOI 10.1073/pnas.92.12.5645; Booth BA, 1996, GROWTH REGULAT, V6, P206; Bromberg J, 2000, ONCOGENE, V19, P2468, DOI 10.1038/sj.onc.1203476; Buckway CK, 2001, J CLIN ENDOCR METAB, V86, P4943, DOI 10.1210/jc.86.10.4943; Butt AJ, 2000, J BIOL CHEM, V275, P39174, DOI 10.1074/jbc.M908888199; Conover CA, 2000, ENDOCRINOLOGY, V141, P3098, DOI 10.1210/en.141.9.3098; Der SD, 1998, P NATL ACAD SCI USA, V95, P15623, DOI 10.1073/pnas.95.26.15623; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Fanayan S, 2000, J BIOL CHEM, V275, P39146, DOI 10.1074/jbc.M006964200; Fernihough JK, 1996, ARTHRITIS RHEUM, V39, P1556, DOI 10.1002/art.1780390916; Gill ZP, 1997, J BIOL CHEM, V272, P25602, DOI 10.1074/jbc.272.41.25602; GRIGORIADIS AE, 1990, DEV BIOL, V142, P313, DOI 10.1016/0012-1606(90)90352-J; Grigoriadis AE, 1996, DIFFERENTIATION, V60, P299, DOI 10.1046/j.1432-0436.1996.6050299.x; Horton William A., 1997, Current Opinion in Pediatrics, V9, P437, DOI 10.1097/00008480-199708000-00021; Johnson GA, 2001, BIOL REPROD, V64, P1392, DOI 10.1095/biolreprod64.5.1392; Knudtson KL, 2001, ENDOCRINOLOGY, V142, P3749, DOI 10.1210/en.142.9.3749; Leal SM, 1997, J BIOL CHEM, V272, P20572, DOI 10.1074/jbc.272.33.20572; Legeai-Mallet L, 1998, J BIOL CHEM, V273, P13007, DOI 10.1074/jbc.273.21.13007; Li CL, 1999, HUM MOL GENET, V8, P35, DOI 10.1093/hmg/8.1.35; Liu BR, 2000, J BIOL CHEM, V275, P33607, DOI 10.1074/jbc.M002547200; LIU JP, 1993, CELL, V75, P59, DOI 10.1016/0092-8674(93)90679-K; Lunstrum GP, 1999, J HISTOCHEM CYTOCHEM, V47, P1, DOI 10.1177/002215549904700101; Martel-Pelletier J, 1998, INFLAMM RES, V47, P90, DOI 10.1007/s000110050288; Matsumoto T, 1996, J ENDOCRINOL, V148, P355, DOI 10.1677/joe.0.1480355; Modric T, 2001, ENDOCRINOLOGY, V142, P1958, DOI 10.1210/en.142.5.1958; OH Y, 1993, J BIOL CHEM, V268, P26045; OH YM, 1993, J BIOL CHEM, V268, P14964; Rajah R, 1997, J BIOL CHEM, V272, P12181, DOI 10.1074/jbc.272.18.12181; Sahni M, 1999, GENE DEV, V13, P1361, DOI 10.1101/gad.13.11.1361; Sahni M, 2001, DEVELOPMENT, V128, P2119; Schedlich LJ, 2000, J BIOL CHEM, V275, P23462, DOI 10.1074/jbc.M002208200; SPAGNOLI A, 1995, J CLIN ENDOCR METAB, V80, P3668, DOI 10.1210/jc.80.12.3668; Spagnoli A, 1996, ENDOCRIN METAB CLIN, V25, P615, DOI 10.1016/S0889-8529(05)70343-1; Spagnoli A, 2001, J BIOL CHEM, V276, P5533, DOI 10.1074/jbc.M005088200; SPAGNOLI A, 1997, CURR OPIN ENDOCRINOL, V4, P1; Stark GR, 1998, ANNU REV BIOCHEM, V67, P227, DOI 10.1146/annurev.biochem.67.1.227; Stewart DM, 2001, ENDOCRINOLOGY, V142, P98, DOI 10.1210/en.142.1.98; Stewart MD, 2001, ENDOCRINOLOGY, V142, P1786, DOI 10.1210/en.142.5.1786; Su WCS, 1997, NATURE, V386, P288, DOI 10.1038/386288a0; Summerton J, 1997, ANTISENSE NUCLEIC A, V7, P187, DOI 10.1089/oli.1.1997.7.187; VALENTINIS B, 1995, MOL ENDOCRINOL, V9, P361, DOI 10.1210/me.9.3.361; Wu HB, 2000, J CELL BIOCHEM, V77, P288, DOI 10.1002/(SICI)1097-4644(20000501)77:2<288::AID-JCB11>3.0.CO;2-J; Yakar S, 1999, P NATL ACAD SCI USA, V96, P7324, DOI 10.1073/pnas.96.13.7324	45	42	45	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 24	2002	277	21					18860	18867		10.1074/jbc.M200218200	http://dx.doi.org/10.1074/jbc.M200218200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	558PM	11886859	hybrid			2022-12-27	WOS:000175975800080
J	Sun, LJ; Halaihel, N; Zhang, WP; Rogers, T; Levi, M				Sun, LJ; Halaihel, N; Zhang, WP; Rogers, T; Levi, M			Role of sterol regulatory element-binding protein 1 in regulation of renal lipid metabolism and glomerulosclerosis in diabetes mellitus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOUND TRANSCRIPTION FACTOR; FATTY-ACID BIOSYNTHESIS; LEUCINE ZIPPER PROTEIN; GROWTH-FACTOR-BETA; MESANGIAL CELLS; TRANSGENIC MICE; CHOLESTEROL-SYNTHESIS; AUTOCRINE ACTIVATION; GENE-EXPRESSION; CULTURED-CELLS	Diabetic renal disease is associated with lipid deposits in the kidney. The purpose of our study was to determine whether there is altered regulation of the sterol regulatory element-binding proteins (SREBPs) in the diabetic kidney and whether SREBPs mediate the abnormal renal lipid metabolism and diabetic renal disease. In streptozotocin-induced diabetes in the rat, there were marked increases in SREBP-1 and fatty acid synthase (FAS) expression, resulting in increased triglyceride (TG) accumulation. Treatment of diabetic rats with insulin prevented the increased renal expression of SREBP-1 and the accumulation of TG. The role of hyperglycemia in the up-regulation of SREBP-1 was confirmed in renal cells cultured in a high glucose media. High glucose induced increased expression of SREBP-1a and -1c mRNA, SREBP-1 protein, and FAS, resulting in increased TG content. To determine a direct role for SREBP in mediating the increase in renal lipids and glomerulosclerosis, we studied SREBP-1a transgenic mice with increased renal expression of SREBP-1. The increase in SREBP-1 was associated with increased expression of FAS and acetyl CoA carboxylase, resulting in increased TG content, increased expression of transforming growth factor beta1 and vascular endothelial growth factor, mesangial expansion, glomerulosclerosis, and proteinuria. Our study therefore indicates that renal SREBP-1 expression is increased in diabetes and that SREBP-1 plays an important role in the increased lipid synthesis, TG accumulation, mesangial expansion, glomerulosclerosis, and proteinuria by increasing the expression of transforming growth factor beta and vascular endothelial growth factor.	Univ Texas, SW Med Ctr, Vet Affairs Med Ctr, Dept Med, Dallas, TX 75216 USA; Univ Texas, SW Med Ctr, Vet Affairs Med Ctr, Dept Pathol, Dallas, TX 75216 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Levi, M (corresponding author), Univ Texas, SW Med Ctr, Vet Affairs Med Ctr, Dept Med, 4500 S Lancaster Rd,MC 151, Dallas, TX 75216 USA.	Moshe.Levi@UTSouthwestern.edu	Halaihel, Nabil/J-2973-2016	Levi, Moshe/0000-0002-6225-946X				[Anonymous], 1999, USRDS 1999 ANN DAT R; Basile DP, 1999, CURR OPIN NEPHROL HY, V8, P21, DOI 10.1097/00041552-199901000-00005; Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; Brown MS, 1999, P NATL ACAD SCI USA, V96, P11041, DOI 10.1073/pnas.96.20.11041; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; De Vriese A, 2001, J AM SOC NEPHROL, V12, P993, DOI 10.1681/ASN.V125993; Di Paolo S, 1999, CLIN EXP IMMUNOL, V117, P355; Duymelinck C, 1997, KIDNEY INT, V51, P1818, DOI 10.1038/ki.1997.249; FOLCH J, 1957, J BIOL CHEM, V226, P497; Fried LF, 2001, KIDNEY INT, V59, P260, DOI 10.1046/j.1523-1755.2001.00487.x; GREEN H, 1975, CELL, V5, P19, DOI 10.1016/0092-8674(75)90087-2; GUIJARRO C, 1995, AM J KIDNEY DIS, V26, P152, DOI 10.1016/0272-6386(95)90169-8; Han DC, 1999, J AM SOC NEPHROL, V10, P1891; Hannah VC, 2001, J BIOL CHEM, V276, P4365, DOI 10.1074/jbc.M007273200; Hasty AH, 2000, J BIOL CHEM, V275, P31069, DOI 10.1074/jbc.M003335200; Horton JD, 1999, CURR OPIN LIPIDOL, V10, P143, DOI 10.1097/00041433-199904000-00008; Horton JD, 1998, J CLIN INVEST, V101, P2331, DOI 10.1172/JCI2961; HUA XX, 1993, P NATL ACAD SCI USA, V90, P11603, DOI 10.1073/pnas.90.24.11603; Keane WF, 2000, KIDNEY INT, V57, pS27, DOI 10.1046/j.1523-1755.2000.07503.x; Kim JB, 1998, J CLIN INVEST, V101, P1, DOI 10.1172/JCI1411; Kimmelstiel P, 1936, AM J PATHOL, V12, P83; Kirschenbaum MA, 1996, MINER ELECTROL METAB, V22, P47; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee HS, 1996, KIDNEY INT, V50, P1582, DOI 10.1038/ki.1996.474; Lee YS, 1999, COMPUT IND ENG, V36, P67, DOI 10.1016/S0360-8352(99)00002-9; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Nishida Y, 1999, KIDNEY INT, V56, pS51, DOI 10.1046/j.1523-1755.1999.07113.x; OBARA K, 1993, CLIN NEPHROL, V39, P59; Oda H, 1997, KIDNEY INT, V52, pS36; Pai JT, 1998, J BIOL CHEM, V273, P26138, DOI 10.1074/jbc.273.40.26138; Repa JJ, 2000, GENE DEV, V14, P2819, DOI 10.1101/gad.844900; ROVIN BH, 1993, KIDNEY INT, V43, P218, DOI 10.1038/ki.1993.35; Sakai J, 1996, CELL, V85, P1037, DOI 10.1016/S0092-8674(00)81304-5; SCHLEIFFER T, 1994, HAEMOSTASIS, V24, P49; Shimano H, 1996, J CLIN INVEST, V98, P1575, DOI 10.1172/JCI118951; Shimano H, 1997, J CLIN INVEST, V99, P846, DOI 10.1172/JCI119248; Shimano H, 1997, J CLIN INVEST, V100, P2115, DOI 10.1172/JCI119746; Shimomura I, 1997, J CLIN INVEST, V99, P838, DOI 10.1172/JCI119247; Shimomura L, 1999, P NATL ACAD SCI USA, V96, P13656, DOI 10.1073/pnas.96.24.13656; Smulders YM, 1997, EUR J CLIN INVEST, V27, P997, DOI 10.1046/j.1365-2362.1997.2330779.x; TONTONOZ P, 1993, MOL CELL BIOL, V13, P4753, DOI 10.1128/MCB.13.8.4753; WANG XD, 1994, CELL, V77, P53, DOI 10.1016/0092-8674(94)90234-8; Xu J, 2001, J BIOL CHEM, V276, P9800, DOI 10.1074/jbc.M008973200; YOKOYAMA C, 1993, CELL, V75, P187, DOI 10.1016/S0092-8674(05)80095-9; ZIYADEH FN, 1994, J CLIN INVEST, V93, P536, DOI 10.1172/JCI117004	45	255	277	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 24	2002	277	21					18919	18927		10.1074/jbc.M110650200	http://dx.doi.org/10.1074/jbc.M110650200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	558PM	11875060	hybrid			2022-12-27	WOS:000175975800088
J	Bodelon, G; Labrada, L; Martinez-Costas, J; Benavente, J				Bodelon, G; Labrada, L; Martinez-Costas, J; Benavente, J			Modification of late membrane permeability in avian reovirus-infected cells - Viroporin activity of the S1-encoded nonstructural p10 protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI-CELLS; ADENOVIRUS DEATH PROTEIN; TYPE-1 VPU PROTEIN; ANIMAL VIRUSES; INDUCIBLE EXPRESSION; ATTACHMENT PROTEIN; CYSTEINE RESIDUES; BREFELDIN-A; M2 PROTEIN; HELA-CELLS	Infection of chicken embryo fibroblasts by avian reovirus induces an increase in the permeability of the host plasma membrane at late, but not early, infection times. The absence of permeability changes at early infection times, as well as the dependence of late membrane modification on both viral protein synthesis and an active exocytic route, suggest that a virus-encoded membrane protein is required for avian reovirus to permeabilize cells. Further studies revealed that expression of nonstructural p10 protein in bacterial cells arrested cell growth and enhanced membrane permeability. Membrane leakiness was also observed following transient expression of p10 in BSC-40 monkey cells. Both its permeabilizing effect and the fact that p10 shares several structural and physical characteristics with other membrane-active viral proteins indicate that p10 is an avian reovirus viroporin. Furthermore, the fusogenic extracellular NH2-terminal domain of p10 appears to be dispensable for permeabilizing activity, because its deletion entirely abolished the fusogenic activity of p10, without affecting its ability to associate with cell membranes and to enhance membrane permeability. Similar properties have reported previously for immunodeficiency virus type I transmembrane glycoprotein gp41. Thus, like gp41, p10 appears to be a multifunctional protein that plays key roles in virus-host interaction.	Univ Santiago de Compostela, Fac Farm, Dept Bioquim & Biol Mol, Santiago De Compostela 15782, Spain	Universidade de Santiago de Compostela	Benavente, J (corresponding author), Univ Santiago de Compostela, Fac Farm, Dept Bioquim & Biol Mol, Santiago De Compostela 15782, Spain.	bnjbena@usc.es	Martinez-Costas, Jose/E-9005-2011; Benavente, Javier/N-6475-2016; Bodelon, Gustavo/H-2870-2013	Martinez-Costas, Jose/0000-0002-8877-7775; Benavente, Javier/0000-0003-4857-0312; Bodelon, Gustavo/0000-0003-2815-7635				Aldabe R, 1996, J BIOL CHEM, V271, P23134, DOI 10.1074/jbc.271.38.23134; ARROYO J, 1995, J VIROL, V69, P4095, DOI 10.1128/JVI.69.7.4095-4102.1995; BENEDETTO A, 1980, VIROLOGY, V106, P123, DOI 10.1016/0042-6822(80)90227-5; Bodelon G, 2001, VIROLOGY, V290, P181, DOI 10.1006/viro.2001.1159; Browne EP, 2000, J GEN VIROL, V81, P1955, DOI 10.1099/0022-1317-81-8-1955; Caballero M, 1998, J VIROL, V72, P8198, DOI 10.1128/JVI.72.10.8198-8204.1998; CARRASCO L, 1993, NATO ADV SCI INST SE, V240, P283; CARRASCO L, 1978, NATURE, V272, P694, DOI 10.1038/272694a0; CARRASCO L, 1995, ADV VIRUS RES, V45, P61, DOI 10.1016/S0065-3527(08)60058-5; CARRASCO L, 1976, NATURE, V264, P807, DOI 10.1038/264807a0; CARRASCO L, 1989, PHARMACOL THERAPEUT, V40, P171, DOI 10.1016/0163-7258(89)90096-X; CASTRILLO JL, 1987, J GEN VIROL, V68, P325, DOI 10.1099/0022-1317-68-2-325; Castrucci MR, 1997, VIROLOGY, V238, P128, DOI 10.1006/viro.1997.8809; Chang YS, 1999, J VIROL, V73, P6257, DOI 10.1128/JVI.73.8.6257-6264.1999; Ciccaglione AR, 1998, VIROLOGY, V250, P1, DOI 10.1006/viro.1998.9380; CONTRERAS A, 1979, J VIROL, V29, P114, DOI 10.1128/JVI.29.1.114-122.1979; DOEDENS JR, 1995, EMBO J, V14, P894, DOI 10.1002/j.1460-2075.1995.tb07071.x; DOMES R, 1989, J CELL BIOL, V109, P61; Duncan R, 1998, VIROLOGY, V250, P263, DOI 10.1006/viro.1998.9371; Duncan R, 1996, VIROLOGY, V224, P453, DOI 10.1006/viro.1996.0552; DUNCAN R, 1995, VIROLOGY, V212, P752, DOI 10.1006/viro.1995.1536; FUCHS P, 1983, CURR TOP MICROBIOL, V102, P57; GAEDIGKNITSCHKO K, 1990, VIROLOGY, V175, P282, DOI 10.1016/0042-6822(90)90210-I; GARD G, 1970, J VIROL, V6, P100, DOI 10.1128/JVI.6.1.100-106.1970; Gonzalez ME, 1998, BIOCHEMISTRY-US, V37, P13710, DOI 10.1021/bi981527f; Grande A, 2000, VIROLOGY, V274, P367, DOI 10.1006/viro.2000.0473; Grande A, 2000, J VIROL METHODS, V85, P43, DOI 10.1016/S0166-0934(99)00155-X; GUINEA R, 1994, FEBS LETT, V343, P242, DOI 10.1016/0014-5793(94)80564-4; Hausmann J, 1998, VIROLOGY, V244, P343, DOI 10.1006/viro.1998.9135; Jecht M, 1998, VIROLOGY, V252, P218, DOI 10.1006/viro.1998.9451; KNIPE DM, 1996, VIROLOGY, P273; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LACAL JC, 1980, J ANTIBIOT, V33, P441, DOI 10.7164/antibiotics.33.441; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMA J, 1995, FEBS LETT, V367, P5, DOI 10.1016/0014-5793(95)00523-C; LAMA J, 1992, BIOCHEM BIOPH RES CO, V188, P972, DOI 10.1016/0006-291X(92)91327-M; MACEJAK DG, 1991, NATURE, V353, P90, DOI 10.1038/353090a0; MartinezCostas J, 1997, J VIROL, V71, P59; MILLER SG, 1992, J CELL BIOL, V118, P267, DOI 10.1083/jcb.118.2.267; MUNOZ A, 1984, VIROLOGY, V137, P150, DOI 10.1016/0042-6822(84)90018-7; NAIR CN, 1984, J GEN VIROL, V65, P1135, DOI 10.1099/0022-1317-65-6-1135; Nibert ML, 1996, J VIROL, V70, P7295, DOI 10.1128/JVI.70.10.7295-7300.1996; NUSS DL, 1975, P NATL ACAD SCI USA, V72, P1258, DOI 10.1073/pnas.72.4.1258; PELHAM HRB, 1991, CELL, V67, P449, DOI 10.1016/0092-8674(91)90517-3; Perez M, 1997, VIROLOGY, V235, P342, DOI 10.1006/viro.1997.8696; PISANI G, 1995, BIOCHEM BIOPH RES CO, V211, P627, DOI 10.1006/bbrc.1995.1859; RANKIN JT, 1989, VIROLOGY, V168, P147, DOI 10.1016/0042-6822(89)90413-3; ROBERTSON MD, 1986, VET B, V56, P759; SANZ MA, 1994, J BIOL CHEM, V269, P12106; Shmulevitz M, 2002, J VIROL, V76, P609, DOI 10.1128/JVI.76.2.609-618.2002; Shmulevitz M, 2000, EMBO J, V19, P902, DOI 10.1093/emboj/19.5.902; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; Tiganos E, 1998, VIROLOGY, V251, P96, DOI 10.1006/viro.1998.9368; Tollefson AE, 1996, J VIROL, V70, P2296, DOI 10.1128/JVI.70.4.2296-2306.1996; van Niekerk M, 2001, VIROLOGY, V279, P499, DOI 10.1006/viro.2000.0709; VanKuppeveld FJM, 1997, VIROLOGY, V227, P111, DOI 10.1006/viro.1996.8320; YANG CL, 1995, P NATL ACAD SCI USA, V92, P9871, DOI 10.1073/pnas.92.21.9871	57	53	56	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 17	2002	277	20					17789	17796		10.1074/jbc.M202018200	http://dx.doi.org/10.1074/jbc.M202018200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	553PR	11893756	hybrid			2022-12-27	WOS:000175685100052
J	Pichler, A; Schroeder, R				Pichler, A; Schroeder, R			Folding problems of the 5 ' splice site containing the P1 stem of the group I thymidylate synthase intron - Substrate binding inhibition in vitro and mis-splicing in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TETRAHYMENA-THERMOPHILA RIBOZYME; RIBOSOMAL-RNA EXONS; PHAGE-T4 TD INTRON; ACTIVE-SITE; TERTIARY INTERACTIONS; CATALYTIC CORE; SEQUENCE; HELIX; COMPLEMENTARY; RECOGNITION	We developed an in vitro cleaving assay for the thymidylate synthase (td) group I intron and observed that the off-rate of the substrate is faster than cleavage. From the sequence stems P1 and P2 can vary from 4 to 8 and from 6 to 10 base pairs, respectively, with folding of a long P1 stem being in competition with folding of a long P2 stem. Shorter substrates, which cannot compete with the formation of an extended P2, result in faster cleavage, suggesting that binding of the substrate indeed interferes with folding of stem P2. In vivo splicing analyses of mutants containing alterations in stems P1 and P2 indicate that the wild-type exon sequence of P1 is suboptimal for splicing. Furthermore, folding of P1 in vivo is in competition with an alternative cryptic P1 stem resulting in mis-splicing. Translation promotes splicing at the correct 5' splice site, whereas in the absence of translation, mis-splicing is favored. The combination of the in vitro and in vivo assays clearly displays the folding problems for correct splice site selection in this group I intron.	Univ Vienna, Vienna Bioctr, Inst Microbiol & Genet, A-1030 Vienna, Austria	University of Vienna; Vienna Biocenter (VBC)	Schroeder, R (corresponding author), Univ Vienna, Vienna Bioctr, Inst Microbiol & Genet, Dr Bohrgasse 9-4, A-1030 Vienna, Austria.	renee@gem.univie.ac.at						BELFORT M, 1987, COLD SPRING HARB SYM, V52, P181, DOI 10.1101/SQB.1987.052.01.023; BEVILACQUA PC, 1992, SCIENCE, V258, P1355, DOI 10.1126/science.1455230; Brion P, 1999, RNA, V5, P947, DOI 10.1017/S1355838299990477; Cao Y, 2000, RNA, V6, P1248, DOI 10.1017/S1355838200000893; CECH TR, 1994, NAT STRUCT BIOL, V1, P273, DOI 10.1038/nsb0594-273; CECH TR, 1990, ANNU REV BIOCHEM, V59, P543, DOI 10.1146/annurev.bi.59.070190.002551; CHANDRY PS, 1987, GENE DEV, V1, P1028, DOI 10.1101/gad.1.9.1028; Clodi E, 1999, EMBO J, V18, P3776, DOI 10.1093/emboj/18.13.3776; Costa M, 1997, EMBO J, V16, P3289, DOI 10.1093/emboj/16.11.3289; HERSCHLAG D, 1992, BIOCHEMISTRY-US, V31, P1386, DOI 10.1021/bi00120a015; HERSCHLAG D, 1990, BIOCHEMISTRY-US, V29, P10159, DOI 10.1021/bi00496a003; HERSCHLAG D, 1993, BIOCHEMISTRY-US, V32, P8299, DOI 10.1021/bi00083a034; Ho Y, 1997, P NATL ACAD SCI USA, V94, P8994, DOI 10.1073/pnas.94.17.8994; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAZOWSKA J, 1980, CELL, V22, P333, DOI 10.1016/0092-8674(80)90344-X; Lehnert V, 1996, CHEM BIOL, V3, P993, DOI 10.1016/S1074-5521(96)90166-0; MICHEL F, 1990, J MOL BIOL, V216, P585, DOI 10.1016/0022-2836(90)90386-Z; MOHR G, 1992, CELL, V69, P483, DOI 10.1016/0092-8674(92)90449-M; Narlikar GJ, 1999, BIOCHEMISTRY-US, V38, P14192, DOI 10.1021/bi9914309; Narlikar GJ, 1997, BIOCHEMISTRY-US, V36, P2465, DOI 10.1021/bi9610820; Nikolcheva T, 1999, J MOL BIOL, V292, P557, DOI 10.1006/jmbi.1999.3083; Pan J, 1998, J MOL BIOL, V280, P597, DOI 10.1006/jmbi.1998.1901; PYLE AM, 1990, P NATL ACAD SCI USA, V87, P8187, DOI 10.1073/pnas.87.21.8187; Russell R, 1999, RNA, V5, P158, DOI 10.1017/S1355838299981839; SALVO JLG, 1990, J MOL BIOL, V211, P537, DOI 10.1016/0022-2836(90)90264-M; SCHROEDER R, 1991, BIOCHEMISTRY-US, V30, P3295, DOI 10.1021/bi00227a018; Semrad K, 1998, GENE DEV, V12, P1327, DOI 10.1101/gad.12.9.1327; Serra MJ, 1995, METHOD ENZYMOL, V259, P242; Strauss-Soukup JK, 2000, J MOL BIOL, V302, P339, DOI 10.1006/jmbi.2000.4056; Strobel SA, 1998, NAT STRUCT BIOL, V5, P60, DOI 10.1038/nsb0198-60; STROBEL SA, 1993, BIOCHEMISTRY-US, V32, P13593, DOI 10.1021/bi00212a027; Szewczak AA, 1999, P NATL ACAD SCI USA, V96, P11183, DOI 10.1073/pnas.96.20.11183; Treiber DK, 2001, CURR OPIN STRUC BIOL, V11, P309, DOI 10.1016/S0959-440X(00)00206-2; VONAHSEN U, 1992, J MOL BIOL, V226, P935, DOI 10.1016/0022-2836(92)91043-O; Waldsich C, 1998, RNA, V4, P1653, DOI 10.1017/S1355838298981444; Weeks KM, 1996, SCIENCE, V271, P345, DOI 10.1126/science.271.5247.345; WOODSON SA, 1993, MOL CELL BIOL, V13, P1137, DOI 10.1128/MCB.13.2.1137; ZAUG AJ, 1988, BIOCHEMISTRY-US, V27, P8924, DOI 10.1021/bi00425a008	38	21	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 17	2002	277	20					17987	17993		10.1074/jbc.M111798200	http://dx.doi.org/10.1074/jbc.M111798200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	553PR	11867626	hybrid			2022-12-27	WOS:000175685100076
J	Reynolds, TH; Bodine, SC; Lawrence, JC				Reynolds, TH; Bodine, SC; Lawrence, JC			Control of Ser(2448) phosphorylation in the mammalian target of rapamycin by insulin and skeletal muscle load	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-B; P70 S6 KINASE; SIGNALING PATHWAY; RAT PLANTARIS; PHAS-I; ACTIVATION; MECHANISM; SITES; HYPERTROPHY; TRANSLATION	We have investigated the effects of insulin, amino acids, and the degree of muscle loading on the phosphorylation of Ser(2448), a site in the mammalian target of rapamycin (mTOR) phosphorylated by protein kinase B (PKB) in vitro. Phosphorylation was assessed by immunoblotting with a phosphospecific antibody (antiSer(P)(2448)) and with mTAb1, an activating antibody whose binding is inhibited by phosphorylation in the region of mTOR that contains Ser(2448). Incubating rat diaphragm muscles with insulin increased Ser(2448) phosphorylation but did not change the total amount of mTOR. Insulin, but not amino acids, activated PKB, as evidenced by increased phosphorylation of both Ser(308). and Thr(473) in the kinase. Ser(2448) phosphorylation was also modulated by muscle-loading. Overloading the rat plantaris muscle by synergist muscle ablation, which promotes hypertrophy of the plantaris muscle, increased Ser(2448) phosphorylation. In contrast, unloading the gastrocnemius muscle by hindlimb suspension, which promotes atrophy of the muscle, decreased Ser(2448) phosphorylation, an effect that was fully reversible. Neither overloading nor hindlimb suspension significantly changed the total amount of mTOR. In summary, our results demonstrate that atrophy and hypertrophy of skeletal muscle are associated with decreases and increases in Ser(2448) phosphorylation, suggesting that modulation of this site may have an important role in the control of protein synthesis.	Univ Virginia Hlth Syst, Dept Pharmacol, Charlottesville, VA 22908 USA; Univ Virginia Hlth Syst, Dept Med, Charlottesville, VA 22908 USA; Regeneron Pharmaceut Inc, Tarrytown, NY 10591 USA	University of Virginia; University of Virginia; Regeneron	Lawrence, JC (corresponding author), Univ Virginia Hlth Syst, Dept Pharmacol, POB 800735,1300 Jefferson Pk Ave, Charlottesville, VA 22908 USA.	jc13p@virginia.edu		Bodine, Sue/0000-0002-5742-9145; Reynolds, Thomas/0000-0002-0290-528X	NIAMS NIH HHS [AR-41180] Funding Source: Medline; NIDDK NIH HHS [DK-52753] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052753] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abraham RT, 1996, ANNU REV IMMUNOL, V14, P483, DOI 10.1146/annurev.immunol.14.1.483; Alessi DR, 1996, FEBS LETT, V399, P333, DOI 10.1016/S0014-5793(96)01370-1; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; [Anonymous], 1980, PRINCIPLES PROCEDURE; Azpiazu I, 1996, J BIOL CHEM, V271, P5033; Baar K, 1999, AM J PHYSIOL-CELL PH, V276, pC120, DOI 10.1152/ajpcell.1999.276.1.C120; Bodine SC, 2001, NAT CELL BIOL, V3, P1014, DOI 10.1038/ncb1101-1014; Brunn GJ, 1997, J BIOL CHEM, V272, P32547, DOI 10.1074/jbc.272.51.32547; Burnett PE, 1998, P NATL ACAD SCI USA, V95, P1432, DOI 10.1073/pnas.95.4.1432; Charlton M, 1998, J NUTR, V128, p323S, DOI 10.1093/jn/128.2.323S; FLAIM KE, 1980, AM J PHYSIOL, V239, pE88, DOI 10.1152/ajpendo.1980.239.1.E88; Grzelkowska K, 1999, J ENDOCRINOL, V160, P137, DOI 10.1677/joe.0.1600137; Hara K, 1998, J BIOL CHEM, V273, P14484, DOI 10.1074/jbc.273.23.14484; Hornberger TA, 2001, AM J PHYSIOL-CELL PH, V281, pC179, DOI 10.1152/ajpcell.2001.281.1.C179; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Mothe-Satney I, 2000, MOL CELL BIOL, V20, P3558, DOI 10.1128/MCB.20.10.3558-3567.2000; MUNOZ KA, 1994, METABOLISM, V43, P994, DOI 10.1016/0026-0495(94)90179-1; Nave BT, 1999, BIOCHEM J, V344, P427, DOI 10.1042/0264-6021:3440427; NOBLE EG, 1984, CAN J PHYSIOL PHARM, V62, P1178, DOI 10.1139/y84-197; PAIN VM, 1974, J BIOL CHEM, V249, P4510; Patti ME, 1998, J CLIN INVEST, V101, P1519, DOI 10.1172/JCI1326; Price SR, 1996, J CLIN INVEST, V98, P1703, DOI 10.1172/JCI118968; Roy RR, 1997, J APPL PHYSIOL, V83, P280, DOI 10.1152/jappl.1997.83.1.280; SABERS CJ, 1995, J BIOL CHEM, V270, P815, DOI 10.1074/jbc.270.2.815; Schmelzle T, 2000, CELL, V103, P253, DOI 10.1016/S0092-8674(00)00117-3; Scott PH, 1998, P NATL ACAD SCI USA, V95, P7772, DOI 10.1073/pnas.95.13.7772; Sekulic A, 2000, CANCER RES, V60, P3504; Shah OJ, 2000, AM J PHYSIOL-ENDOC M, V279, pE715, DOI 10.1152/ajpendo.2000.279.4.E715; THOMASON DB, 1987, J APPL PHYSIOL, V63, P130, DOI 10.1152/jappl.1987.63.1.130	29	217	226	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 17	2002	277	20					17657	17662		10.1074/jbc.M201142200	http://dx.doi.org/10.1074/jbc.M201142200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	553PR	11884412	hybrid			2022-12-27	WOS:000175685100035
J	Zhang, T; Seow, KT; Ong, CT; Cao, XM				Zhang, T; Seow, KT; Ong, CT; Cao, XM			Interdomain interaction of Stat3 regulates its Src homology 2 domain-mediated receptor binding activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL TRANSDUCER GP130; EPIDERMAL GROWTH-FACTOR; TYROSINE PHOSPHORYLATION; SERINE PHOSPHORYLATION; CYTOKINE RECEPTORS; CYTOPLASMIC DOMAIN; ACTIVATION; TRANSCRIPTION; INTERLEUKIN-6; ASSOCIATION	Activation of Stat proteins by cytokines is initiated by their Src homology 2 (SH2) domain-mediated association with the cytokine receptors. Previously, we identified an essential role of the coiled-coil domain of Stat3 in binding of the receptor peptides derived from the interleukin-6 receptor subunit, gp130. In this study, we further investigated the molecular basis of this regulation. We found that the C-terminal domain of Stat3 negatively regulates its receptor binding activity only in the absence of the first alpha-helix of the coiled-coil domain, which leads to a hypothesis of intramolecular interaction. Physical interactions between the coiled-coil domain and the C-terminal domain, as well as the SH2 domain, were indeed detected. Furthermore, a sub-region of the C-terminal domain (amino acids 720-740), which is also involved in the interaction with the coiled-coil domain, was demonstrated to be critical for the regulation of the receptor binding. Correspondingly, phosphorylation on Ser-727 within this region inhibits this interaction. In agreement with the peptide binding results, both the coiled-coil domain and the C-terminal sub-region are necessary for the functional recruitment of Stat3 to the cellular gp130 in response to interleukin-6, suggesting that the interdomain interaction is a prerequisite for the SH2-mediated receptor binding in interleukin-6 signaling.	Inst Mol & Cell Biol, Singapore 117609, Singapore	Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB)	Cao, XM (corresponding author), Inst Mol & Cell Biol, 30 Med Dr, Singapore 117609, Singapore.							AKIRA S, 1994, CELL, V77, P63, DOI 10.1016/0092-8674(94)90235-6; Becker S, 1998, NATURE, V394, P145, DOI 10.1038/28101; Bhattacharya S, 1996, NATURE, V383, P344, DOI 10.1038/383344a0; Cao XM, 1996, MOL CELL BIOL, V16, P1595; Catlett-Falcone R, 1999, IMMUNITY, V10, P105, DOI 10.1016/S1074-7613(00)80011-4; Chen XM, 1998, CELL, V93, P827, DOI 10.1016/S0092-8674(00)81443-9; Chung JK, 1997, MOL CELL BIOL, V17, P6508, DOI 10.1128/MCB.17.11.6508; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; Fukada T, 1996, IMMUNITY, V5, P449, DOI 10.1016/S1074-7613(00)80501-4; GREENLUND AC, 1995, IMMUNITY, V2, P677, DOI 10.1016/1074-7613(95)90012-8; Haan S, 2000, BIOCHEM J, V345, P417, DOI 10.1042/0264-6021:3450417; HEIM MH, 1995, SCIENCE, V267, P1347, DOI 10.1126/science.7871432; Hemmann U, 1996, J BIOL CHEM, V271, P12999, DOI 10.1074/jbc.271.22.12999; Horvath CM, 1996, MOL CELL BIOL, V16, P6957; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; Jain N, 1999, J BIOL CHEM, V274, P24392, DOI 10.1074/jbc.274.34.24392; Jain N, 1998, ONCOGENE, V17, P3157, DOI 10.1038/sj.onc.1202238; Kammerer RA, 1997, MATRIX BIOL, V15, P555, DOI 10.1016/S0945-053X(97)90031-7; Lim CP, 1999, J BIOL CHEM, V274, P31055, DOI 10.1074/jbc.274.43.31055; LUTTICKEN C, 1994, SCIENCE, V263, P89, DOI 10.1126/science.8272872; Manser E, 1998, MOL CELL, V1, P183, DOI 10.1016/S1097-2765(00)80019-2; MURAKAMI M, 1993, SCIENCE, V260, P1808, DOI 10.1126/science.8511589; Murphy TL, 2000, MOL CELL BIOL, V20, P7121, DOI 10.1128/MCB.20.19.7121-7131.2000; Ndubuisi MI, 1999, J BIOL CHEM, V274, P25499, DOI 10.1074/jbc.274.36.25499; Novak U, 1998, BIOCHEM BIOPH RES CO, V247, P558, DOI 10.1006/bbrc.1998.8829; Pluk H, 2002, CELL, V108, P247, DOI 10.1016/S0092-8674(02)00623-2; SCHAEFER TS, 1995, P NATL ACAD SCI USA, V92, P9097, DOI 10.1073/pnas.92.20.9097; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; SHUAI K, 1994, CELL, V76, P821, DOI 10.1016/0092-8674(94)90357-3; SILVENNOINEN O, 1993, SCIENCE, V261, P1736, DOI 10.1126/science.8378775; STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; Stancato LF, 1996, J BIOL CHEM, V271, P4134; VAN SJ, 1990, ANNU REV IMMUNOL, V8, P253; Vinkemeier U, 1998, SCIENCE, V279, P1048, DOI 10.1126/science.279.5353.1048; Wang DM, 2000, EMBO J, V19, P392, DOI 10.1093/emboj/19.3.392; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; WONG SH, 1993, J BIOL CHEM, V268, P22853; Xu XA, 1996, SCIENCE, V273, P794, DOI 10.1126/science.273.5276.794; Yang E, 1999, MOL CELL BIOL, V19, P5106; Zhang T, 2000, MOL CELL BIOL, V20, P7132, DOI 10.1128/MCB.20.19.7132-7139.2000; Zhang XK, 1999, MOL CELL BIOL, V19, P7138; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E; Zhou YJ, 2001, MOL CELL, V8, P959, DOI 10.1016/S1097-2765(01)00398-7; Zhu MH, 1999, CELL, V96, P121, DOI 10.1016/S0092-8674(00)80965-4	46	23	24	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 17	2002	277	20					17556	17563		10.1074/jbc.M105525200	http://dx.doi.org/10.1074/jbc.M105525200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	553PR	11872739	hybrid			2022-12-27	WOS:000175685100023
J	Belorgey, D; Crowther, DC; Mahadeva, R; Lomas, DA				Belorgey, D; Crowther, DC; Mahadeva, R; Lomas, DA			Mutant neuroserpin (S49P) that causes familial encephalopathy with neuroserpin inclusion bodies is a poor proteinase inhibitor and readily forms polymers in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TISSUE-PLASMINOGEN ACTIVATOR; SERINE-PROTEASE INHIBITOR; LONG-TERM POTENTIATION; CONFORMATIONAL DISEASE; REACTIVE LOOP; NEURODEGENERATIVE DISEASE; NEURONAL DEGENERATION; NEUTROPHIL ELASTASE; CRYSTAL-STRUCTURE; LATE-PHASE	Familial encephalopathy with neuroserpin inclusion bodies (FENIB) is an autosomal dominant dementia that is characterized by intraneuronal inclusions of mutant neuroserpin. We report here the expression, purification, and characterization of wild-type neuroserpin and neuroserpin containing the S49P mutation that causes FENIB. Wild-type neuroserpin formed SDS-stable complexes with tPA with an association rate constant and K-i of 1.2 x 10(4) M-1 s(-1) and 5.8 nM, respectively. In contrast, S49P neuroserpin formed unstable complexes with an association rate constant and K-i of 0.3 x 10(4) M-1 s(-1) and 533.3 nM, respectively. Am assessment by circular dichroism showed that S49P neuroserpin had a lower melting temperature than wild-type protein (49.9 and 56.6 degreesC, respectively) and more readily formed loop-sheet polymers under physiological conditions. Neither the wildtype nor S49P neuroserpin accepted the P7-P2 alpha(1)-antitrypsin or P14-P3 antithrombin-reactive loop peptides that have been shown to block polymer formation in other members of the serpin superfamily. Taken together, these data demonstrate that S49P neuroserpin is a poor proteinase inhibitor and readily forms loop-sheet polymers. These findings provide strong support for the role of neuroserpin polymerization in the formation of the intraneuronal inclusions that are characteristic of FENIB.	Univ Cambridge, Dept Med, Neurol Unit, Cambridge Inst Med Res, Cambridge CB2 2XY, England; Univ Cambridge, Dept Med, Resp Med Unit, Cambridge Inst Med Res, Cambridge CB2 2XY, England	University of Cambridge; University of Cambridge	Belorgey, D (corresponding author), Univ Cambridge, Dept Med, Neurol Unit, Cambridge Inst Med Res, Wellcome Trust Med Res Council Bldg,Hills Rd, Cambridge CB2 2XY, England.	db301@cam.ac.uk						Baranes D, 1998, NEURON, V21, P813, DOI 10.1016/S0896-6273(00)80597-8; Belorgey D, 1998, BIOCHEMISTRY-US, V37, P16416, DOI 10.1021/bi981536o; Berger P, 1999, MOL CELL NEUROSCI, V14, P455, DOI 10.1006/mcne.1999.0804; BIETH JG, 1995, METHOD ENZYMOL, V248, P59; BJORK I, 1992, J BIOL CHEM, V267, P1976; Bradshaw CB, 2001, ARCH NEUROL-CHICAGO, V58, P1429, DOI 10.1001/archneur.58.9.1429; Briand C, 2001, FEBS LETT, V505, P18, DOI 10.1016/S0014-5793(01)02764-8; Carrell RW, 1997, LANCET, V350, P134, DOI 10.1016/S0140-6736(97)02073-4; Carrell RW, 1998, CURR OPIN STRUC BIOL, V8, P799, DOI 10.1016/S0959-440X(98)80101-2; Carrell RW, 2002, NEW ENGL J MED, V346, P45, DOI 10.1056/NEJMra010772; Chen ZL, 1997, CELL, V91, P917, DOI 10.1016/S0092-8674(00)80483-3; Dafforn TR, 1999, J BIOL CHEM, V274, P9548, DOI 10.1074/jbc.274.14.9548; Dafforn TR, 2001, J BIOL CHEM, V276, P49310, DOI 10.1074/jbc.M108896200; Davis RL, 1999, AM J PATHOL, V155, P1901, DOI 10.1016/S0002-9440(10)65510-1; Davis RL, 1999, NATURE, V401, P376, DOI 10.1038/43897; Elliott PR, 1996, NAT STRUCT BIOL, V3, P910, DOI 10.1038/nsb1196-910; ERIKSSON S, 1986, NEW ENGL J MED, V314, P736, DOI 10.1056/NEJM198603203141202; FALLER B, 1993, BIOCHEMISTRY-US, V32, P9230, DOI 10.1021/bi00086a031; Fitton HL, 1997, BIOL CHEM, V378, P1059; Frey U, 1996, J NEUROSCI, V16, P2057; Gooptu B, 2000, P NATL ACAD SCI USA, V97, P67, DOI 10.1073/pnas.97.1.67; Hastings GA, 1997, J BIOL CHEM, V272, P33062, DOI 10.1074/jbc.272.52.33062; Hill RM, 2000, BIOCHEM J, V345, P595, DOI 10.1042/0264-6021:3450595; Huang YY, 1996, P NATL ACAD SCI USA, V93, P8699, DOI 10.1073/pnas.93.16.8699; Huntington JA, 2000, NATURE, V407, P923, DOI 10.1038/35038119; Kakizuka A, 1998, TRENDS GENET, V14, P396, DOI 10.1016/S0168-9525(98)01559-5; Krueger SR, 1997, J NEUROSCI, V17, P8984; Lansbury PT, 1997, NEURON, V19, P1151, DOI 10.1016/S0896-6273(00)80406-7; LAWRENCE DA, 1994, BIOCHEMISTRY-US, V33, P3643, DOI 10.1021/bi00178a022; LOMAS DA, 1992, NATURE, V357, P605, DOI 10.1038/357605a0; LOMAS DA, 1995, J BIOL CHEM, V270, P16864, DOI 10.1074/jbc.270.28.16864; LOMAS DA, 1993, J BIOL CHEM, V268, P15333; Mahadeva R, 2002, J BIOL CHEM, V277, P6771, DOI 10.1074/jbc.C100722200; MORRISON JF, 1988, ADV ENZYMOL RAMB, V61, P201; Osterwalder T, 1998, J BIOL CHEM, V273, P2312, DOI 10.1074/jbc.273.4.2312; Osterwalder T, 1996, EMBO J, V15, P2944, DOI 10.1002/j.1460-2075.1996.tb00657.x; QIAN Z, 1993, NATURE, V361, P453, DOI 10.1038/361453a0; Renatus M, 1997, EMBO J, V16, P4797, DOI 10.1093/emboj/16.16.4797; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; Schrimpf SP, 1997, GENOMICS, V40, P55, DOI 10.1006/geno.1996.4514; SCHULZE AJ, 1990, EUR J BIOCHEM, V194, P51, DOI 10.1111/j.1432-1033.1990.tb19425.x; SEEDS NW, 1995, SCIENCE, V270, P1992, DOI 10.1126/science.270.5244.1992; Silverman GA, 2001, J BIOL CHEM, V276, P33293, DOI 10.1074/jbc.R100016200; Sivasothy P, 2000, J BIOL CHEM, V275, P33663, DOI 10.1074/jbc.M004054200; Skinner R, 1998, J MOL BIOL, V283, P9, DOI 10.1006/jmbi.1998.2083; STOECKLI ET, 1989, EUR J BIOCHEM, V180, P249, DOI 10.1111/j.1432-1033.1989.tb14640.x; Takao M, 2000, J NEUROPATH EXP NEUR, V59, P1070, DOI 10.1093/jnen/59.12.1070; Tran PB, 1999, TRENDS NEUROSCI, V22, P194, DOI 10.1016/S0166-2236(99)01409-5; Tsirka SE, 1997, J NEUROSCI, V17, P543; Wang YMF, 1998, NAT MED, V4, P228, DOI 10.1038/nm0298-228; Yazaki M, 2001, AM J PATHOL, V158, P227, DOI 10.1016/S0002-9440(10)63961-2; Yepes M, 2000, BLOOD, V96, P569; Zhou A, 2001, J BIOL CHEM, V276, P9115, DOI 10.1074/jbc.M010631200; Zhou AW, 2001, J BIOL CHEM, V276, P27541, DOI 10.1074/jbc.M102594200	54	81	83	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 10	2002	277	19					17367	17373		10.1074/jbc.M200680200	http://dx.doi.org/10.1074/jbc.M200680200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	551MB	11880376	hybrid			2022-12-27	WOS:000175564500133
J	Chen, F; Kamradt, M; Mulcahy, M; Byun, Y; Xu, HL; McKay, MJ; Cryns, VL				Chen, F; Kamradt, M; Mulcahy, M; Byun, Y; Xu, HL; McKay, MJ; Cryns, VL			Caspase proteolysis of the cohesin component RAD21 promotes apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SISTER-CHROMATID COHESION; DEPENDENT PROTEIN-KINASE; STRAND-BREAK REPAIR; SCHIZOSACCHAROMYCES-POMBE; POLY(ADP-RIBOSE) POLYMERASE; CHROMOSOME SEGREGATION; DNA FRAGMENTATION; FAMILY PROTEASES; ENDONUCLEASE-G; HUMAN SURVIVIN	Caspases are a conserved family of proteases that play a critical role in the execution of apoptosis by cleaving key cellular proteins at Asp residues and modifying their function. Using an expression cloning strategy we recently developed, we isolated human RAD21/SCC1/MCD1 as a novel caspase substrate. RAD21 is a component of the cohesin complex that holds sister chromatids together during mitosis and repairs double-strand DNA breaks. Interestingly, RAD21 is cleaved by a caspase-like Esp1/separase at the onset of anaphase to trigger sister chromatid separation. Here, we demonstrate that human RAD21 is preferentially cleaved at Asp 279 by caspases-3 and -7 in vitro to generate two major proteolytic products of similar to65 and 48 kDa. Moreover, we show that RAD21 is specifically proteolyzed by caspases into a similarly sized 65-kDa carboxyl-terminal product in cells undergoing apoptosis in response to diverse stimuli. We also demonstrate that caspase proteolysis of RAD21 precedes apoptotic chromatin condensation and has important functional consequences, viz. the partial removal of RAD21 from chromatin and the production of a proapoptotic carboxyl-terminal cleavage product that amplifies the cell death signal. Taken together, these findings point to an entirely novel function of RAD21 in the execution of apoptosis.	Northwestern Univ, Sch Med, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA; Northwestern Univ, Sch Med, Dept Med, Chicago, IL 60611 USA; Peter MacCallum Canc Inst, Melbourne, Vic 8006, Australia	Ann & Robert H. Lurie Children's Hospital of Chicago; Northwestern University; Robert H. Lurie Comprehensive Cancer Center; Northwestern University; Peter Maccallum Cancer Center	Cryns, VL (corresponding author), Northwestern Univ, Sch Med, Robert H Lurie Comprehens Canc Ctr, Tarry 15-755,303 E Chicago Ave, Chicago, IL 60611 USA.		McKay, Michael/ABA-9029-2021		NATIONAL CANCER INSTITUTE [T32CA070085, T32CA079447] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS031957] Funding Source: NIH RePORTER; NCI NIH HHS [CA79447, 5T32-CA70085] Funding Source: Medline; NINDS NIH HHS [NS31957] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Ambrosini G, 1997, NAT MED, V3, P917, DOI 10.1038/nm0897-917; BIRKENBIHL RP, 1992, NUCLEIC ACIDS RES, V20, P6605, DOI 10.1093/nar/20.24.6605; BIRKENBIHL RP, 1995, J BIOL CHEM, V270, P7703, DOI 10.1074/jbc.270.13.7703; BUMP NJ, 1995, SCIENCE, V269, P1885, DOI 10.1126/science.7569933; Buonomo SBC, 2000, CELL, V103, P387, DOI 10.1016/S0092-8674(00)00131-8; Byun Y, 2001, CELL DEATH DIFFER, V8, P443, DOI 10.1038/sj.cdd.4400840; Cardone MH, 1997, CELL, V90, P315, DOI 10.1016/S0092-8674(00)80339-6; CASCIOLAROSEN LA, 1995, J EXP MED, V182, P1625, DOI 10.1084/jem.182.6.1625; Cryns V, 1998, GENE DEV, V12, P1551, DOI 10.1101/gad.12.11.1551; Cryns VL, 1997, J BIOL CHEM, V272, P29449, DOI 10.1074/jbc.272.47.29449; Cryns VL, 1996, J BIOL CHEM, V271, P31277, DOI 10.1074/jbc.271.49.31277; Emoto Y, 1995, EMBO J, V14, P6148, DOI 10.1002/j.1460-2075.1995.tb00305.x; Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112; Faleiro L, 2000, J CELL BIOL, V151, P951, DOI 10.1083/jcb.151.5.951; Guacci V, 1997, CELL, V91, P47, DOI 10.1016/S0092-8674(01)80008-8; Han ZY, 1996, J BIOL CHEM, V271, P25035, DOI 10.1074/jbc.271.40.25035; Hauf S, 2001, SCIENCE, V293, P1320, DOI 10.1126/science.1061376; Hirano T, 2000, ANNU REV BIOCHEM, V69, P115, DOI 10.1146/annurev.biochem.69.1.115; Hoque MT, 2001, J BIOL CHEM, V276, P5059, DOI 10.1074/jbc.M007809200; Hotti A, 2000, ONCOGENE, V19, P2354, DOI 10.1038/sj.onc.1203567; Huang YY, 1999, MOL CELL BIOL, V19, P2986; Jallepalli PV, 2001, CELL, V105, P445, DOI 10.1016/S0092-8674(01)00340-3; Janicke RU, 1998, J BIOL CHEM, V273, P9357, DOI 10.1074/jbc.273.16.9357; Kamradt MC, 2001, J BIOL CHEM, V276, P16059, DOI 10.1074/jbc.C100107200; LAZEBNIK YA, 1995, P NATL ACAD SCI USA, V92, P9042, DOI 10.1073/pnas.92.20.9042; LAZEBNIK YA, 1994, NATURE, V371, P346, DOI 10.1038/371346a0; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Li LY, 2001, NATURE, V412, P95, DOI 10.1038/35083620; Liu XS, 1997, CELL, V89, P175, DOI 10.1016/S0092-8674(00)80197-X; Losada A, 1998, GENE DEV, V12, P1986, DOI 10.1101/gad.12.13.1986; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Lustig KD, 1997, METHOD ENZYMOL, V283, P83; McKay MJ, 1996, GENOMICS, V36, P305, DOI 10.1006/geno.1996.0466; Morishima N, 1999, GENES CELLS, V4, P401, DOI 10.1046/j.1365-2443.1999.00270.x; Nasmyth K, 2000, SCIENCE, V288, P1379, DOI 10.1126/science.288.5470.1379; Parisi S, 1999, MOL CELL BIOL, V19, P3515; Parrish J, 2001, NATURE, V412, P90, DOI 10.1038/35083608; Rao H, 2001, NATURE, V410, P955, DOI 10.1038/35073627; Rao L, 1996, J CELL BIOL, V135, P1441, DOI 10.1083/jcb.135.6.1441; Sahara S, 1999, NATURE, V401, P168, DOI 10.1038/43678; Sakahira H, 1998, NATURE, V391, P96, DOI 10.1038/34214; Shin S, 2001, BIOCHEMISTRY-US, V40, P1117, DOI 10.1021/bi001603q; Skoufias DA, 2000, J CELL BIOL, V151, P1575, DOI 10.1083/jcb.151.7.1575; Smith GCM, 1999, MOL CELL BIOL, V19, P6076; Song QZ, 1996, EMBO J, V15, P3238, DOI 10.1002/j.1460-2075.1996.tb00688.x; Sonoda E, 2001, DEV CELL, V1, P759, DOI 10.1016/S1534-5807(01)00088-0; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; Susin SA, 2000, J EXP MED, V192, P571, DOI 10.1084/jem.192.4.571; Takahashi A, 1996, P NATL ACAD SCI USA, V93, P8395, DOI 10.1073/pnas.93.16.8395; Talanian RV, 1997, J BIOL CHEM, V272, P9677; Tamm I, 1998, CANCER RES, V58, P5315; Tatebayashi K, 1998, GENETICS, V148, P49; Thornberry NA, 1997, J BIOL CHEM, V272, P17907, DOI 10.1074/jbc.272.29.17907; Tomonaga T, 2000, GENE DEV, V14, P2757, DOI 10.1101/gad.832000; Uhlmann F, 1999, NATURE, V400, P37, DOI 10.1038/21831; Uhlmann F, 2000, CELL, V103, P375, DOI 10.1016/S0092-8674(00)00130-6; Uren AG, 2000, CURR BIOL, V10, P1319, DOI 10.1016/S0960-9822(00)00769-7; Warren WD, 2000, CURR BIOL, V10, P1463, DOI 10.1016/S0960-9822(00)00806-X; Watanabe Y, 1999, NATURE, V400, P461, DOI 10.1038/22774	61	47	53	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 10	2002	277	19					16775	16781		10.1074/jbc.M201322200	http://dx.doi.org/10.1074/jbc.M201322200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	551MB	11875078	hybrid			2022-12-27	WOS:000175564500058
J	Kotamraju, S; Chitambar, CR; Kalivendi, SV; Joseph, J; Kalyanaraman, B				Kotamraju, S; Chitambar, CR; Kalivendi, SV; Joseph, J; Kalyanaraman, B			Transferrin receptor-dependent iron uptake is responsible for doxorubicin-mediated apoptosis in endothelial cells - Role of oxidant-induced iron signaling in apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE; REGULATORY PROTEIN-1; REACTIVE OXYGEN; OXIDATIVE STRESS; SUPEROXIDE-DISMUTASE; LIPID PEROXIDATION; HYDROGEN-PEROXIDE; RADICAL FORMATION; CARDIAC TOXICITY; FERRITIN	In the past, investigators have successfully used iron chelators to mitigate the cardiotoxicity of doxorubicin (DOX), a widely used anticancer drug that induces reactive oxygen species (ROS), oxidative damage, and apoptosis. Although intracellular iron plays a critical role in initiating DOX-induced apoptosis, the molecular mechanism(s) that link iron, ROS, and apoptosis are still unknown. In this study, we demonstrate that apoptosis results from the exposure of bovine aortic endothelial cells to DOX and that the apoptotic cell death is accompanied by a significant increase in cellular iron (Fe-55) uptake and activation of iron regulatory protein-1. Furthermore, DOX-induced iron uptake was shown to be mediated by the transferrin receptor (TfR)-dependent mechanism. Treatment with the anti-TfR antibody (IgA class) dramatically inhibited DOX-induced apoptosis, iron uptake, and intracellular oxidant formation as measured by fluorescence using dichlorodihydrofluorescein. Treatment with cell-permeable iron chelators and ROS scavengers inhibited DOX-induced cellular Fe-55 uptake, ROS formation, and apoptosis. Based on these findings, we conclude that DOX-induced iron signaling is regulated by the cell surface TfR expression, intracellular oxidant levels, and iron regulatory proteins. The implications of TfR-dependent iron transport in oxidant-induced apoptosis in endothelial cells are discussed.	Med Coll Wisconsin, Biophys Res Inst, Milwaukee, WI 53226 USA; Med Coll Wisconsin, Free Radical Res Ctr, Milwaukee, WI 53226 USA; Med Coll Wisconsin, Div Neoplast Dis, Milwaukee, WI 53226 USA	Medical College of Wisconsin; Medical College of Wisconsin; Medical College of Wisconsin	Kalyanaraman, B (corresponding author), Med Coll Wisconsin, Biophys Res Inst, 8701 Watertown Plank Rd, Milwaukee, WI 53226 USA.	balarama@mcw.edu			NATIONAL CANCER INSTITUTE [R01CA077822] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR001008] Funding Source: NIH RePORTER; NCI NIH HHS [CA77822] Funding Source: Medline; NCRR NIH HHS [RR01008] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Arnold RS, 2001, P NATL ACAD SCI USA, V98, P5550, DOI 10.1073/pnas.101505898; BACHUR NR, 1977, MOL PHARMACOL, V13, P901; BALLA G, 1992, J BIOL CHEM, V267, P18148; Benov L, 1998, FREE RADICAL BIO MED, V25, P826, DOI 10.1016/S0891-5849(98)00163-4; Bergeron RJ, 1999, BLOOD, V93, P370, DOI 10.1182/blood.V93.1.370.401k29_370_375; BLUM RH, 1974, ANN INTERN MED, V80, P249, DOI 10.7326/0003-4819-80-2-249; BRISTOW MR, 1978, CANCER TREAT REP, V62, P873; Burkitt MJ, 2001, BIOCHEM BIOPH RES CO, V282, P329, DOI 10.1006/bbrc.2001.4578; CHITAMBAR CR, 1986, J CLIN INVEST, V78, P1538, DOI 10.1172/JCI112746; CURRAN CF, 1991, CANCER TREAT REV, V18, P241, DOI 10.1016/0305-7372(91)90015-R; DAVIES KJA, 1986, J BIOL CHEM, V261, P3060; Day BJ, 1995, J PHARMACOL EXP THER, V275, P1227; Drummond GR, 2000, CIRC RES, V86, P347, DOI 10.1161/01.RES.86.3.347; Duffy SJ, 2001, CIRCULATION, V103, P2799; GARDNER PR, 1991, J BIOL CHEM, V266, P19328; Gehring NH, 1999, J BIOL CHEM, V274, P6219, DOI 10.1074/jbc.274.10.6219; GOODMAN J, 1977, BIOCHEM BIOPH RES CO, V77, P797, DOI 10.1016/S0006-291X(77)80048-X; Green D, 1998, TRENDS CELL BIOL, V8, P267, DOI 10.1016/S0962-8924(98)01273-2; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Griendling KK, 1999, CIRC RES, V85, P562, DOI 10.1161/01.RES.85.6.562; HANDA K, 1976, GANN, V67, P523; Harrison PM, 1996, BBA-BIOENERGETICS, V1275, P161, DOI 10.1016/0005-2728(96)00022-9; HASINOFF BB, 1993, AGENTS ACTIONS, V39, P72, DOI 10.1007/BF01975717; Haunstetter A, 1998, CIRC RES, V82, P1111, DOI 10.1161/01.RES.82.11.1111; Hausladen A, 1996, METHOD ENZYMOL, V269, P37; HENTZE MW, 1989, SCIENCE, V244, P357, DOI 10.1126/science.2711187; HERMAN EH, 1985, CANCER RES, V45, P276; Imrich A, 1999, J LEUKOCYTE BIOL, V65, P499, DOI 10.1002/jlb.65.4.499; JANZEN EG, 1990, ADV FREE RADICAL CHE, P253; Kalivendi SV, 2001, J BIOL CHEM, V276, P47266, DOI 10.1074/jbc.M106829200; KALYANARAMAN B, 1980, BIOCHIM BIOPHYS ACTA, V630, P119, DOI 10.1016/0304-4165(80)90142-7; KENNEDY MC, 1983, J BIOL CHEM, V258, P1098; KLAUSNER RD, 1983, P NATL ACAD SCI-BIOL, V80, P2263, DOI 10.1073/pnas.80.8.2263; KLAUSNER RD, 1983, J BIOL CHEM, V258, P4715; Konorev EA, 1999, ARCH BIOCHEM BIOPHYS, V368, P421, DOI 10.1006/abbi.1999.1337; Kotamraju S, 2000, J BIOL CHEM, V275, P33585, DOI 10.1074/jbc.M003890200; LEBEL CP, 1992, CHEM RES TOXICOL, V5, P227, DOI 10.1021/tx00026a012; Lee JB, 1998, J AM CHEM SOC, V120, P7493, DOI 10.1021/ja980507y; LEIBOLD EA, 1988, P NATL ACAD SCI USA, V85, P2171, DOI 10.1073/pnas.85.7.2171; Li WG, 2001, J BIOL CHEM, V276, P29251, DOI 10.1074/jbc.M102124200; Minotti G, 1998, FASEB J, V12, P541, DOI 10.1096/fasebj.12.7.541; Minotti G, 2001, CANCER RES, V61, P8422; Minotti G, 1999, FASEB J, V13, P199, DOI 10.1096/fasebj.13.2.199; MINOW RA, 1975, CANCER CHEMOTH REP 3, V6, P195; Monnier VM, 2001, J CLIN INVEST, V107, P799, DOI 10.1172/JCI12635; MUINDI JRF, 1984, FEBS LETT, V172, P226, DOI 10.1016/0014-5793(84)81130-8; MYERS CE, 1982, BIOCHEMISTRY-US, V21, P1707, DOI 10.1021/bi00537a001; MYERS CE, 1977, SCIENCE, V197, P165, DOI 10.1126/science.877547; PANTOPOULOS K, 1995, EMBO J, V14, P2917, DOI 10.1002/j.1460-2075.1995.tb07291.x; Pantopoulos K, 1997, J BIOL CHEM, V272, P9802; Patel M, 1999, TRENDS PHARMACOL SCI, V20, P359, DOI 10.1016/S0165-6147(99)01336-X; Pennathur S, 2001, J CLIN INVEST, V107, P853, DOI 10.1172/JCI11194; PRITCHARD KA, 1994, J BIOL CHEM, V269, P8504; Quinlan GJ, 2001, CLIN SCI, V100, P169, DOI 10.1042/CS20000155; Rehman A, 1999, FEBS LETT, V448, P120, DOI 10.1016/S0014-5793(99)00339-7; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; Rota C, 1999, J BIOL CHEM, V274, P28161, DOI 10.1074/jbc.274.40.28161; Sarvazyan N, 1996, AM J PHYSIOL-HEART C, V271, pH2079, DOI 10.1152/ajpheart.1996.271.5.H2079; Sawyer DB, 1999, CIRC RES, V84, P257, DOI 10.1161/01.RES.84.3.257; Schueck ND, 2001, MITOCHONDRION, V1, P51, DOI 10.1016/S1567-7249(01)00004-6; SIES H, 1993, FREE RADICAL BIO MED, V14, P313, DOI 10.1016/0891-5849(93)90028-S; SPEYER JL, 1988, NEW ENGL J MED, V319, P745, DOI 10.1056/NEJM198809223191203; SVINGEN BA, 1981, ARCH BIOCHEM BIOPHYS, V209, P119, DOI 10.1016/0003-9861(81)90263-0; TAETLE R, 1986, CANCER RES, V46, P1759; Tarpey MM, 2001, CIRC RES, V89, P224, DOI 10.1161/hh1501.094365; TESTA U, 1993, CRIT REV ONCOGENESIS, V4, P241; THOMAS CE, 1985, J BIOL CHEM, V260, P3275; THOMAS CE, 1986, ARCH BIOCHEM BIOPHYS, V248, P684, DOI 10.1016/0003-9861(86)90523-0; van Reyk DM, 2001, FREE RADICAL BIO MED, V30, P82, DOI 10.1016/S0891-5849(00)00449-4; VasquezVivar J, 1997, BIOCHEMISTRY-US, V36, P11293, DOI 10.1021/bi971475e; WORWOOD M, 1989, J INTERN MED, V226, P381, DOI 10.1111/j.1365-2796.1989.tb01412.x; YOUNG RC, 1981, NEW ENGL J MED, V305, P139, DOI 10.1056/NEJM198107163050305	72	165	171	2	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 10	2002	277	19					17179	17187		10.1074/jbc.M111604200	http://dx.doi.org/10.1074/jbc.M111604200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	551MB	11856741	hybrid			2022-12-27	WOS:000175564500111
J	Lin, TK; Hughes, G; Muratovska, A; Blaikie, FH; Brookes, PS; Darley-Usmar, V; Smith, RAJ; Murphy, MP				Lin, TK; Hughes, G; Muratovska, A; Blaikie, FH; Brookes, PS; Darley-Usmar, V; Smith, RAJ; Murphy, MP			Specific modification of mitochondrial protein thiols in response to oxidative stress - A proteomics approach	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE SYNTHASE; RAT-LIVER MITOCHONDRIA; PERMEABILITY TRANSITION; S-NITROSYLATION; COMPLEX-I; SULFHYDRYL-GROUPS; CELL RESPIRATION; PEROXYNITRITE; GLUTATHIONE; STATE	Mitochondria play a central role in redox-linked processes in the cell through mechanisms that are thought to involve modification of specific protein thiols, but this has proved difficult to assess. In particular, specific labeling and quantitation of mitochondrial protein cysteine residues have not been achieved due to the lack of reagents available that can be applied to the intact organelle or cell. To overcome these problems we have used a combination of mitochondrial proteomics and targeted labeling of mitochondrial thiols using a novel compound, (4-iodobutyl)triphenylphosphonium (IBTP). This lipophilic cation is accumulated by mitochondria and yields stable thioether adducts in a thiol-specific reaction. The selective uptake into mitochondria, due to the large membrane potential across the inner membrane, and the high pH of the matrix results in specific labeling of mitochondrial protein thiols by IBTP. Individual mitochondrial proteins that changed thiol redox state following oxidative stress could then be identified by their decreased reaction with IBTP and isolated by two-dimensional electrophoresis. We demonstrate the selectivity of IBTP labeling and use it to show that glutathione oxidation and exposure to an S-nitrosothiol or to peroxynitrite cause extensive redox changes to mitochondrial thiol proteins. In conjunction with blue native gel electrophoresis, we used IBTP labeling to demonstrate that thiols are exposed on the matrix faces of respiratory Complexes I, II, and IV. This novel approach enables measurement of the thiol redox state of individual mitochondrial proteins during oxidative stress and cell death. In addition the methodology has the potential to identify novel redox-dependent modulation of mitochondrial proteins.	MRC, Dunn Human Nutr Unit, Cambridge CB2 2XY, England; Univ Otago, Dept Biochem, Dunedin, New Zealand; Univ Otago, Dept Chem, Dunedin, New Zealand; Chang Gung Mem Hosp, Dept Neurol, Kaohsiung 833, Taiwan; Univ Alabama, Ctr Free Rad Biol, Birmingham, AL 35294 USA; Univ Alabama, Dept Pathol, Birmingham, AL 35294 USA	UK Research & Innovation (UKRI); Medical Research Council UK (MRC); MRC Human Nutrition Research; University of Otago; University of Otago; Chang Gung Memorial Hospital; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	Murphy, MP (corresponding author), MRC, Dunn Human Nutr Unit, MRC Wellcome Trust Bldg,Hills Rd, Cambridge CB2 2XY, England.		Murphy, Michael P/C-2120-2009	Murphy, Michael P/0000-0003-1115-9618; Brookes, Paul/0000-0002-8639-8413; Filipovska, Aleksandra/0000-0002-6998-8403; Darley-Usmar, Victor/0000-0001-8921-7086	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058031] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL58031] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Akerboom T P, 1981, Methods Enzymol, V77, P373; ANDERSON ME, 1985, METHOD ENZYMOL, V113, P548; Appleby RD, 1999, EUR J BIOCHEM, V262, P108, DOI 10.1046/j.1432-1327.1999.00350.x; BECKMAN JS, 1990, P NATL ACAD SCI USA, V87, P1620, DOI 10.1073/pnas.87.4.1620; Beltran B, 2000, P NATL ACAD SCI USA, V97, P14602, DOI 10.1073/pnas.97.26.14602; Beltran B, 2000, BRIT J PHARMACOL, V129, P953, DOI 10.1038/sj.bjp.0703147; BROWN GC, 1985, BIOCHEM J, V225, P399, DOI 10.1042/bj2250399; BRUNE B, 1995, REV PHYSL BIOCH PHAR, V127, P1; BURNS RJ, 1995, ARCH BIOCHEM BIOPHYS, V322, P60, DOI 10.1006/abbi.1995.1436; Chappell J. B., 1972, SUBCELLULAR COMPONEN, P77; Clementi E, 1998, P NATL ACAD SCI USA, V95, P7631, DOI 10.1073/pnas.95.13.7631; DARLEYUSMAR VM, 1985, J BIOCHEM, V97, P1767, DOI 10.1093/oxfordjournals.jbchem.a135235; Demple B, 1998, SCIENCE, V279, P1655, DOI 10.1126/science.279.5357.1655; DIMONTE D, 1984, ARCH BIOCHEM BIOPHYS, V235, P334, DOI 10.1016/0003-9861(84)90206-6; ELLMAN G, 1979, ANAL BIOCHEM, V93, P98, DOI 10.1016/S0003-2697(79)80122-0; Gavrikova EV, 1999, FEBS LETT, V455, P36, DOI 10.1016/S0014-5793(99)00850-9; Ghafourifar P, 1999, J BIOL CHEM, V274, P31185, DOI 10.1074/jbc.274.44.31185; Ghafourifar P, 1997, FEBS LETT, V418, P291, DOI 10.1016/S0014-5793(97)01397-5; Gitler C, 1997, ANAL BIOCHEM, V252, P48, DOI 10.1006/abio.1997.2294; GORNALL AG, 1949, J BIOL CHEM, V177, P751; Hall AG, 1999, EUR J CLIN INVEST, V29, P238; Jha N, 2000, J BIOL CHEM, V275, P26096, DOI 10.1074/jbc.M000120200; Kelso GF, 2001, J BIOL CHEM, V276, P4588, DOI 10.1074/jbc.M009093200; LEQUOC D, 1989, ARCH BIOCHEM BIOPHYS, V273, P466, DOI 10.1016/0003-9861(89)90506-7; LEQUOC K, 1981, BIOCHEMISTRY-US, V20, P1705, DOI 10.1021/bi00510a001; LIBERMAN EA, 1969, NATURE, V222, P1076, DOI 10.1038/2221076a0; Marchetti P, 1997, EUR J IMMUNOL, V27, P289, DOI 10.1002/eji.1830270142; Muratovska A, 2001, NUCLEIC ACIDS RES, V29, P1852, DOI 10.1093/nar/29.9.1852; Murphy MP, 1997, TRENDS BIOTECHNOL, V15, P326, DOI 10.1016/S0167-7799(97)01068-8; PACKER MA, 1994, FEBS LETT, V345, P237, DOI 10.1016/0014-5793(94)00461-7; PETRONILLI V, 1994, J BIOL CHEM, V269, P16638; RADI R, 1991, J BIOL CHEM, V266, P4244; Ragan MT, 1987, MITOCHONDRIA PRACTIC, P79; RIGOBELLO MP, 1995, ARCH BIOCHEM BIOPHYS, V319, P225, DOI 10.1006/abbi.1995.1286; Scarlett JL, 1996, BIOCHEM PHARMACOL, V52, P1047, DOI 10.1016/0006-2952(96)99426-5; Schagger H, 1995, METHOD ENZYMOL, V260, P190, DOI 10.1016/0076-6879(95)60137-6; Shiva S, 2001, P NATL ACAD SCI USA, V98, P7212, DOI 10.1073/pnas.131128898; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Stamler JS, 1998, NAT STRUCT BIOL, V5, P247, DOI 10.1038/nsb0498-247; STAMLER JS, 1994, CELL, V78, P931, DOI 10.1016/0092-8674(94)90269-0; TABUCHI A, 1994, FEBS LETT, V351, P123, DOI 10.1016/0014-5793(94)00839-6; Tatoyan A, 1998, J BIOL CHEM, V273, P11044, DOI 10.1074/jbc.273.18.11044; THOMAS JA, 1995, ARCH BIOCHEM BIOPHYS, V319, P1, DOI 10.1006/abbi.1995.1261; VEDIA LM, 1992, J BIOL CHEM, V267, P24929; WINTERBOURN CC, 1993, FREE RADICAL BIO MED, V14, P85, DOI 10.1016/0891-5849(93)90512-S	45	170	176	3	22	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 10	2002	277	19					17048	17056		10.1074/jbc.M110797200	http://dx.doi.org/10.1074/jbc.M110797200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	551MB	11861642	hybrid			2022-12-27	WOS:000175564500094
J	Han, Q; Fang, JM; Li, JY				Han, Q; Fang, JM; Li, JY			3-hydroxy-kynurenine transaminase identity with alanine glyoxylate transaminase - A probable detoxification protein in Aedes aegypti	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAJOR BRANCH PATHWAY; NEURONAL CELL-DEATH; XANTHURENIC ACID; KYNURENINE AMINOTRANSFERASE; ENDOGENOUS NEUROTOXIN; HUNTINGTONS-DISEASE; FRONTAL-CORTEX; RAT-BRAIN; 3-HYDROXYKYNURENINE; MOSQUITO	This study describes the functional characterization of a specific mosquito transaminase responsible for catalyzing the transamination. of 3-hydroxykynurenine (3-HK) to xanthurenic acid (XA). The enzyme was purified from Aedes aegypti larvae by ammonium sulfate fractionation, heat treatment, and various chromatographic techniques, plus non-denaturing electrophoresis. The purified transaminase has a relative molecular mass of 42,500 by SDS-PAGE. N-terminal and internal sequencing of the purified protein and its tryptic fragments resolved a partial N-terminal sequence of 19 amino acid residues and 3 partial internal peptide sequences with 7, 10, and 7 amino acid residues. Using degenerate primers based on the partial internal sequences for PCR amplification and cDNA library screening, a full-length cDNA clone with a 1,167-bp open reading frame was isolated. Its deduced amino acid sequence consists of 389 amino acid residues with a predicted molecular mass of 43,239 and shares 45-46% sequence identity with mammalian alanine glyoxylate transaminases. Northern analysis shows the active transcription of the enzyme in larvae and developing eggs. Substrate specificity analysis of this mosquito transaminase demonstrates that the enzyme is active with 3-HK, kynurenine, or alanine substrates. The enzyme has greater affinity and catalytic efficiency for 3-HK than for kynurenine and alanine. The biochemical characteristics of the enzyme in conjunction with the profiles of 3-HK transaminase, activity and XA accumulation during mosquito development clearly point out its physiological function in the 3-HK to XA pathway. Our data suggest that the mosquito transaminase was evolved in a manner precisely reflecting the physiological requirement of detoxifying 3-HK produced in the tryptophan oxidation pathway in the mosquito.	Univ Illinois, Dept Pathobiol, Urbana, IL 61802 USA	University of Illinois System; University of Illinois Urbana-Champaign	Li, JY (corresponding author), Univ Illinois, Dept Pathobiol, Urbana, IL 61802 USA.	jli2@uiuc.edu	Han, Qian/AAS-2134-2020; Han, Qian/J-8696-2014	Han, Qian/0000-0001-6245-5252	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI044399] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 44399] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Antoine FR, 1999, J AGR FOOD CHEM, V47, P5100, DOI 10.1021/jf990032+; Aquilina JA, 2000, BIOCHEMISTRY-US, V39, P16176, DOI 10.1021/bi001230t; Billker O, 1998, NATURE, V392, P289, DOI 10.1038/32667; Chiarugia A, 1999, FEBS LETT, V453, P197, DOI 10.1016/S0014-5793(99)00724-3; Chiou SJ, 1998, BIOCHEM BIOPH RES CO, V246, P457, DOI 10.1006/bbrc.1998.8644; CHRISTENSEN BM, 1984, J INVERTEBR PATHOL, V44, P267, DOI 10.1016/0022-2011(84)90024-7; ELASRAR AM, 1993, INVEST OPHTH VIS SCI, V33, P3463; FANG J, 2002, IN PRESS INSECT BIOC; Garcia GE, 1998, J BIOL CHEM, V273, P12003, DOI 10.1074/jbc.273.20.12003; Goldstein AJ, 2000, J CONSULT CLIN PSYCH, V68, P947, DOI 10.1037/0022-006X.68.6.947; GUILARTE TR, 1993, J NEUROL SCI, V116, P227, DOI 10.1016/0022-510X(93)90330-2; Han Q, 2001, BIOCHEM J, V360, P617, DOI 10.1042/0264-6021:3600617; HIRAKU Y, 1995, CARCINOGENESIS, V16, P349, DOI 10.1093/carcin/16.2.349; Hood BD, 1999, J BIOL CHEM, V274, P32547, DOI 10.1074/jbc.274.46.32547; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Li JY, 1997, INSECT BIOCHEM MOLEC, V27, P859, DOI 10.1016/S0965-1748(97)00068-4; Li JY, 1999, INSECT BIOCHEM MOLEC, V29, P329, DOI 10.1016/S0965-1748(99)00007-7; MOSCA M, 1994, FEBS LETT, V353, P21, DOI 10.1016/0014-5793(94)01003-X; Nakagami Y, 1996, NEUROSCI LETT, V216, P211; Okuda S, 1998, J NEUROCHEM, V70, P299; Okuda S, 1996, P NATL ACAD SCI USA, V93, P12553, DOI 10.1073/pnas.93.22.12553; OKUNO E, 1991, J NEUROCHEM, V57, P533, DOI 10.1111/j.1471-4159.1991.tb03783.x; OKUNO E, 1990, BRAIN RES, V534, P37, DOI 10.1016/0006-8993(90)90109-O; PEARSON SJ, 1991, J CHROMATOGR-BIOMED, V565, P436, DOI 10.1016/0378-4347(91)80406-3; PEARSON SJ, 1992, NEUROSCI LETT, V144, P199, DOI 10.1016/0304-3940(92)90749-W; Plant N, 1997, EUR J DRUG METAB PH, V22, P335, DOI 10.1007/BF03190967; SARDAR AM, 1995, J NEUROCHEM, V64, P932; SARDAR AM, 1995, NEUROSCI LETT, V187, P9, DOI 10.1016/0304-3940(95)11324-P; STONE TW, 1993, PHARMACOL REV, V45, P309; Toma S, 1997, FEBS LETT, V408, P5, DOI 10.1016/S0014-5793(97)00374-8; Urenjak J, 2000, NEUROREPORT, V11, P1341, DOI 10.1097/00001756-200004270-00038; Wei HF, 2000, J NEUROCHEM, V75, P81, DOI 10.1046/j.1471-4159.2000.0750081.x	32	28	29	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 3	2002	277	18					15781	15787		10.1074/jbc.M201202200	http://dx.doi.org/10.1074/jbc.M201202200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	550PA	11880382	hybrid			2022-12-27	WOS:000175510400076
J	Mbebi, C; See, V; Mercken, L; Pradier, L; Muller, U; Loeffler, JP				Mbebi, C; See, V; Mercken, L; Pradier, L; Muller, U; Loeffler, JP			Amyloid precursor protein family-induced neuronal death is mediated by impairment of the neuroprotective calcium/calmodulin protein kinase IV-dependent signaling pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROGRAMMED CELL-DEATH; ELEMENT-BINDING PROTEIN; CYCLASE-ACTIVATING POLYPEPTIDE; CEREBELLAR GRANULE NEURONS; ALZHEIMERS-DISEASE; OXIDATIVE STRESS; GENE-EXPRESSION; TRANSCRIPTION FACTOR; CULTURED NEURONS; CREB PHOSPHORYLATION	The aberrant metabolism of beta-amyloid precursor protein (APP) and the progressive deposition of its derived fragment beta-amyloid peptide are early and constant pathological hallmarks of Alzheimer's disease. Because APP is able to function as a cell surface receptor, we investigated here whether a disruption of the normal function of APP may contribute to the pathogenic mechanisms in Alzheimer's disease. To this aim, we generated a specific chicken polyclonal antibody directed against the extracellular domain of APP, which is common with the beta-amyloid precursor-like protein type 2. Exposure of cultured cortical neurons to this antibody (APP-Ab) induced cell death preceded by neurite degeneration, oxidative stress, and nuclear condensation. Interestingly, caspase-3-like protease was not activated in this neurotoxic action suggesting a different mode of cell death than classical apoptosis. Further analysis of the molecular mechanisms revealed a calpain- and calcineurin-dependent proteolysis of the neuroprotective calcium/ calmodulin-dependent protein kinase IV and its nuclear target protein cAMP responsive element binding protein. These effects were abolished by the G protein inhibitor pertussis toxin, strongly suggesting that APP binding operates via a GTPase-dependent pathway to cause neuronal death.	Univ Strasbourg, Fac Med, EA Mol Signaling & Neurodegenerat 3433, F-67000 Strasbourg, France; Aventis Pharma, Dept Neurodegenerat Dis Grp, F-94400 Vitry Sur Seine, France; Max Planck Inst Brain Res, Dept Neurochem, D-60528 Frankfurt, Germany	UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Sanofi-Aventis; Sanofi France; Max Planck Society	Loeffler, JP (corresponding author), Univ Strasbourg, Fac Med, EA Mol Signaling & Neurodegenerat 3433, 11 Rue Humann, F-67000 Strasbourg, France.	loeffler@neurochem.u-strasbg.fr	LOEFFLER, Jean-Philippe/AAS-4401-2020					Asai A, 1999, J BIOL CHEM, V274, P34450, DOI 10.1074/jbc.274.48.34450; BEHL C, 1994, CELL, V77, P817, DOI 10.1016/0092-8674(94)90131-7; Bito H, 1996, CELL, V87, P1203, DOI 10.1016/S0092-8674(00)81816-4; Bito H, 1997, CURR OPIN NEUROBIOL, V7, P419, DOI 10.1016/S0959-4388(97)80072-4; BOUSSIF O, 1995, P NATL ACAD SCI USA, V92, P7297, DOI 10.1073/pnas.92.16.7297; Brouillet E, 1999, J NEUROSCI, V19, P1717; Bursztajn S, 1998, J NEUROSCI, V18, P9790; Campard PK, 1997, DNA CELL BIOL, V16, P323, DOI 10.1089/dna.1997.16.323; CATALDO AM, 1994, BRAIN RES, V640, P68, DOI 10.1016/0006-8993(94)91858-9; Chan SL, 1999, J NEUROSCI RES, V58, P167, DOI 10.1002/(SICI)1097-4547(19991001)58:1<167::AID-JNR16>3.0.CO;2-K; CHENG SV, 1988, P NATL ACAD SCI USA, V85, P6032, DOI 10.1073/pnas.85.16.6032; D'Mello SR, 2000, J NEUROSCI RES, V59, P24, DOI 10.1002/(SICI)1097-4547(20000101)59:1<24::AID-JNR4>3.3.CO;2-#; Finkbeiner S, 1997, NEURON, V19, P1031, DOI 10.1016/S0896-6273(00)80395-5; Finkbeiner S, 1996, NEURON, V16, P233, DOI 10.1016/S0896-6273(00)80040-9; Gervais FG, 1999, CELL, V97, P395, DOI 10.1016/S0092-8674(00)80748-5; Giambarella U, 1997, EMBO J, V16, P4897, DOI 10.1093/emboj/16.16.4897; GOLDGABER D, 1987, SCIENCE, V235, P877, DOI 10.1126/science.3810169; Grewal SS, 2000, J BIOL CHEM, V275, P34433, DOI 10.1074/jbc.M004728200; Gringhuis SI, 1997, J BIOL CHEM, V272, P31809, DOI 10.1074/jbc.272.50.31809; Hajnoczky G, 2000, CELL CALCIUM, V28, P349, DOI 10.1054/ceca.2000.0169; Heber S, 2000, J NEUROSCI, V20, P7951; HENSLEY K, 1994, P NATL ACAD SCI USA, V91, P3270, DOI 10.1073/pnas.91.8.3270; Ho N, 2000, J NEUROSCI, V20, P6459, DOI 10.1523/JNEUROSCI.20-17-06459.2000; Ishihara I, 2000, NEUROSCI LETT, V279, P97, DOI 10.1016/S0304-3940(99)00960-X; Ivins KJ, 1999, NEUROBIOL DIS, V6, P440, DOI 10.1006/nbdi.1999.0268; Ivins KJ, 1998, NEUROBIOL DIS, V5, P365, DOI 10.1006/nbdi.1998.0228; Jung SS, 1996, J NEUROSCI RES, V46, P336, DOI 10.1002/(SICI)1097-4547(19961101)46:3<336::AID-JNR7>3.3.CO;2-L; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; Kitanaka C, 1999, CELL DEATH DIFFER, V6, P508, DOI 10.1038/sj.cdd.4400526; Kuan CY, 2000, TRENDS NEUROSCI, V23, P291, DOI 10.1016/S0166-2236(00)01581-2; Kuida K, 1998, CELL, V94, P325, DOI 10.1016/S0092-8674(00)81476-2; Kuida K, 1996, NATURE, V384, P368, DOI 10.1038/384368a0; LAFERLA FM, 1995, NAT GENET, V9, P21, DOI 10.1038/ng0195-21; LAZEBNIK YA, 1995, P NATL ACAD SCI USA, V92, P9042, DOI 10.1073/pnas.92.20.9042; LeBlanc A, 1999, J BIOL CHEM, V274, P23426, DOI 10.1074/jbc.274.33.23426; Li MT, 2000, MOL CELL BIOL, V20, P9356, DOI 10.1128/MCB.20.24.9356-9363.2000; Masumura M, 2000, MOL BRAIN RES, V80, P219, DOI 10.1016/S0169-328X(00)00163-7; MATTHEWS RP, 1994, MOL CELL BIOL, V14, P6107, DOI 10.1128/MCB.14.9.6107; Mattson MP, 1997, PHYSIOL REV, V77, P1081, DOI 10.1152/physrev.1997.77.4.1081; Morioka M, 1999, PROG NEUROBIOL, V58, P1, DOI 10.1016/S0301-0082(98)00073-2; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; MULLER U, 1994, CELL, V79, P755, DOI 10.1016/0092-8674(94)90066-3; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; NISHIMOTO I, 1993, NATURE, V362, P75, DOI 10.1038/362075a0; Nishimura I, 1998, J NEUROSCI, V18, P2387, DOI 10.1523/jneurosci.18-07-02387.1998; Okamoto T, 1996, EMBO J, V15, P3769, DOI 10.1002/j.1460-2075.1996.tb00750.x; OKAMOTO T, 1995, J BIOL CHEM, V270, P4205, DOI 10.1074/jbc.270.9.4205; Oppenheim RW, 2001, J NEUROSCI, V21, P4752, DOI 10.1523/JNEUROSCI.21-13-04752.2001; PAPPOLLA MA, 1992, AM J PATHOL, V140, P621; Patel M, 1998, J NEUROCHEM, V71, P1068, DOI 10.1046/j.1471-4159.1998.71031068.x; Pike CJ, 1997, J NEUROCHEM, V69, P1601; PIKE CJ, 1993, J NEUROSCI, V13, P1676; Przywara DA, 1998, J NEUROCHEM, V71, P1889; Pugazhenthi S, 1999, J BIOL CHEM, V274, P27529, DOI 10.1074/jbc.274.39.27529; Ray SK, 2000, BRAIN RES, V852, P326, DOI 10.1016/S0006-8993(99)02148-4; Riccio A, 1999, SCIENCE, V286, P2358, DOI 10.1126/science.286.5448.2358; Rohn TT, 2000, J NEUROCHEM, V74, P2331, DOI 10.1046/j.1471-4159.2000.0742331.x; SAITO KI, 1993, P NATL ACAD SCI USA, V90, P2628, DOI 10.1073/pnas.90.7.2628; Sandbrink R, 1994, Neurobiol Dis, V1, P13, DOI 10.1006/nbdi.1994.0003; SCHWARZ MA, 1994, J BIOL CHEM, V269, P15238; See V, 2001, J BIOL CHEM, V276, P35049, DOI 10.1074/jbc.M104988200; See V, 2001, FASEB J, V15, P134, DOI 10.1096/fj.00-0106com; SELKOE DJ, 1991, NEURON, V6, P487, DOI 10.1016/0896-6273(91)90052-2; Shieh PB, 1998, NEURON, V20, P727, DOI 10.1016/S0896-6273(00)81011-9; SLUNT HH, 1994, J BIOL CHEM, V269, P2637; SMITH CD, 1991, P NATL ACAD SCI USA, V88, P10540, DOI 10.1073/pnas.88.23.10540; Smith MA, 2000, BBA-MOL BASIS DIS, V1502, P139, DOI 10.1016/S0925-4439(00)00040-5; Sorimachi H, 1997, BIOCHEM J, V328, P721, DOI 10.1042/bj3280721; SPRECHER CA, 1993, BIOCHEMISTRY-US, V32, P4481, DOI 10.1021/bi00068a002; Sudo H, 2000, MOL CELL NEUROSCI, V16, P708, DOI 10.1006/mcne.2000.0910; SUN PQ, 1994, GENE DEV, V8, P2527, DOI 10.1101/gad.8.21.2527; Tao X, 1998, NEURON, V20, P709, DOI 10.1016/S0896-6273(00)81010-7; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Uetsuki T, 1999, J NEUROSCI, V19, P6955, DOI 10.1523/JNEUROSCI.19-16-06955.1999; Vaudry D, 1998, NEUROSCIENCE, V84, P801, DOI 10.1016/S0306-4522(97)00545-9; Von Koch CS, 1997, NEUROBIOL AGING, V18, P661, DOI 10.1016/S0197-4580(97)00151-6; WAITE J, 1992, NEUROBIOL AGING, V13, P595, DOI 10.1016/0197-4580(92)90062-3; Walton M, 1999, J NEUROCHEM, V73, P1836; Wang KKW, 2000, TRENDS NEUROSCI, V23, P20, DOI 10.1016/S0166-2236(99)01479-4; WASCO W, 1992, P NATL ACAD SCI USA, V89, P10758, DOI 10.1073/pnas.89.22.10758; Webster MT, 1999, NEUROSCI LETT, V276, P107, DOI 10.1016/S0304-3940(99)00800-9; White AR, 1999, J NEUROSCI, V19, P9170; White AR, 1998, J NEUROSCI, V18, P6207; Xie HQ, 1998, J NEUROSCI RES, V53, P153, DOI 10.1002/(SICI)1097-4547(19980715)53:2<153::AID-JNR4>3.3.CO;2-5; Yamatsuji T, 1996, SCIENCE, V272, P1349, DOI 10.1126/science.272.5266.1349; YAMAZAKI T, 1995, J CELL BIOL, V129, P431, DOI 10.1083/jcb.129.2.431; YAN GZ, 1994, MOL CELL ENDOCRINOL, V101, pR25, DOI 10.1016/0303-7207(94)90255-0; YOSHIKAWA K, 1992, NATURE, V359, P64, DOI 10.1038/359064a0; ZAMZAMI N, 1995, J EXP MED, V182, P367, DOI 10.1084/jem.182.2.367	90	47	48	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 7	2002	277	23					20979	20990		10.1074/jbc.M107948200	http://dx.doi.org/10.1074/jbc.M107948200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	562NJ	11877414	hybrid			2022-12-27	WOS:000176204500113
J	Li, JM; Shah, AM				Li, JM; Shah, AM			Intracellular localization and preassembly of the NADPH oxidase complex in cultured endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED SUPEROXIDE FORMATION; PLASMA-MEMBRANE; NAD(P)H OXIDASE; EXPRESSION; ACTIN; GP91(PHOX); FLAVOCYTOCHROME; BIOSYNTHESIS; COMPONENTS; MATURATION	The phagocyte-type NADPH oxidase expressed in endothelial cells differs from the neutrophil enzyme in that it exhibits low level activity even in the absence of agonist stimulation, and it generates intracellular reactive oxygen species. The mechanisms underlying these differences are unknown. We studied the subcellular location of (a) oxidase subunits and (b) functionally active enzyme in unstimulated endothelial cells. Confocal microscopy revealed co-localization of the major oxidase subunits, i.e. gp91(phox), p22(phox), p47(phox), and p67(phox), in a mainly perinuclear distribution. Plasma membrane biotinylation experiments confirmed the predominantly (>90%) intracellular distribution of gp91(phox) and p22(phox). After subcellular protein fractionation, similar to50% of the gp91(phox) (91-kDa band), p22(phox), p67(phox), and p40(phox) pools and similar to30% of the p47(phox) were present in the 1475 X g ("nucleus-rich") fraction. Likewise, similar to50% of total NADPH-dependent O-2(.-) production (assessed by lucigenin (5 muM) chemiluminescence) was found in the 1475 x g fraction. Co-immunoprecipitation studies and measurement of NADPH-dependent reactive oxygen species production (cytochrome c reduction assay) demonstrated that p22(phox), gp91(phox), p47(phox), p67(phox), and p40(phox) existed as a functional complex in the cytoskeletal fraction. These results indicate that, in contrast to the neutrophil enzyme, a substantial proportion of the NADPH oxidase in unstimulated endothelial cells exists as a preassembled intracellular complex associated with the cytoskeleton.	Kings Coll London, GKT Sch Med, Dept Cardiol, London SE5 9PJ, England	University of London; King's College London	Shah, AM (corresponding author), Kings Coll London, GKT Sch Med, Dept Cardiol, Bessemer Rd, London SE5 9PJ, England.	ajay.shah@kcl.ac.uk		Shah, Ajay/0000-0002-6547-0631				Al-Mehdi AB, 1998, CIRC RES, V83, P730, DOI 10.1161/01.RES.83.7.730; Babior BM, 1999, BLOOD, V93, P1464, DOI 10.1182/blood.V93.5.1464.405a32_1464_1476; Bayraktutan U, 1998, CARDIOVASC RES, V38, P256, DOI 10.1016/S0008-6363(98)00003-0; BAYRAKTUTAN U, 2000, ARTERIOSCLER THROMB, V20, P1093; Crawford LE, 1996, J BIOL CHEM, V271, P26863, DOI 10.1074/jbc.271.43.26863; De Keulenaer GW, 1998, CIRC RES, V82, P1094, DOI 10.1161/01.RES.82.10.1094; El Benna J, 1999, J LEUKOCYTE BIOL, V66, P1014; Gorlach A, 2000, CIRC RES, V87, P26, DOI 10.1161/01.RES.87.1.26; Griendling KK, 2000, CIRC RES, V86, P494, DOI 10.1161/01.RES.86.5.494; Harrison DG, 1997, J CLIN INVEST, V100, P2153, DOI 10.1172/JCI119751; Hinton R. H., 1997, SUBCELLULAR FRACTION, P31; Hua J, 2000, J LEUKOCYTE BIOL, V68, P216; Inoue I, 2000, LIFE SCI, V67, P863, DOI 10.1016/S0024-3205(00)00680-9; JESAITIS AJ, 1990, J CLIN INVEST, V85, P821, DOI 10.1172/JCI114509; Jones SA, 1996, AM J PHYSIOL-HEART C, V271, pH1626, DOI 10.1152/ajpheart.1996.271.4.H1626; Kunsch C, 1999, CIRC RES, V85, P753, DOI 10.1161/01.RES.85.8.753; Lassegue B, 2001, CIRC RES, V88, P888, DOI 10.1161/hh0901.090299; Li AE, 1999, CIRC RES, V85, P304, DOI 10.1161/01.RES.85.4.304; Li JM, 1998, AM J PHYSIOL-HEART C, V275, pH814, DOI 10.1152/ajpheart.1998.275.3.H814; Li JM, 2001, J MOL CELL CARDIOL, V33, P1119, DOI 10.1006/jmcc.2001.1372; Li JM, 1997, J MOL CELL CARDIOL, V29, P2213, DOI 10.1006/jmcc.1997.0457; Li YB, 1998, J BIOL CHEM, V273, P2015, DOI 10.1074/jbc.273.4.2015; MARUI N, 1993, J CLIN INVEST, V92, P1866, DOI 10.1172/JCI116778; Mohazzab HKM, 1994, AM J PHYSIOL, V266, P2568; MOHAZZABH KM, 1994, AM J PHYSIOL-LUNG C, V267, pL815, DOI 10.1152/ajplung.1994.267.6.L815; Moldovan L, 2000, CIRC RES, V86, P549, DOI 10.1161/01.RES.86.5.549; PIPER HM, 1990, CELL CULTURE TECHNIQ, P178; Smith KR, 2001, AM J PHYSIOL-LUNG C, V280, pL442, DOI 10.1152/ajplung.2001.280.3.L442; Sohn HY, 2000, J BIOL CHEM, V275, P18745, DOI 10.1074/jbc.M000026200; Stitt M., 1984, METHOD ENZYMAT AN, P359; Suh YA, 1999, NATURE, V401, P79, DOI 10.1038/43459; Tamura M, 2000, BIOCHEM BIOPH RES CO, V276, P1186, DOI 10.1006/bbrc.2000.3598; Tamura M, 2000, BIOCHEM J, V349, P369, DOI 10.1042/0264-6021:3490369; Tanaka K, 1999, J BIOL CHEM, V274, P33979, DOI 10.1074/jbc.274.48.33979; Vassault A, 1983, METHOD ENZYMAT AN, P119; VERHOEVEN AJ, 1989, BLOOD, V73, P1686; Wallach TM, 1997, BIOCHEM J, V321, P583, DOI 10.1042/bj3210583; Wientjes FB, 1997, J LEUKOCYTE BIOL, V61, P303, DOI 10.1002/jlb.61.3.303; WOODMAN RC, 1991, J CLIN INVEST, V87, P1345, DOI 10.1172/JCI115138; Yu LX, 1999, J BIOL CHEM, V274, P4364, DOI 10.1074/jbc.274.7.4364; Yu LX, 1997, J BIOL CHEM, V272, P27288, DOI 10.1074/jbc.272.43.27288; Yun S, 1998, TRANSPLANTATION, V66, P103, DOI 10.1097/00007890-199807150-00016; ZULUETA JJ, 1995, AM J RESP CELL MOL, V12, P41, DOI 10.1165/ajrcmb.12.1.7529030	43	325	337	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 31	2002	277	22					19952	19960		10.1074/jbc.M110073200	http://dx.doi.org/10.1074/jbc.M110073200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	557EH	11893732	hybrid			2022-12-27	WOS:000175894800094
J	Ustinov, VA; Plow, EF				Ustinov, VA; Plow, EF			Delineation of the key amino acids involved in neutrophil inhibitory factor binding to the I-domain supports a mosaic model for the capacity of integrin alpha(M)beta(2) to recognize multiple ligands	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT ADHESION SITE; A-DOMAIN; COMPLEMENT RECEPTOR; MONOCLONAL-ANTIBODY; LEUKOCYTE ADHESION; CD11B/CD18 INTEGRIN; CRYSTAL-STRUCTURE; MAC-1 CD11B/CD18; BETA-2 INTEGRINS; ADHERENCE	To gain insight into the mechanism by which the alpha(M)I-domain of integrin alpha(M)beta(2) interacts with multiple and unrelated ligands, the identity of the neutrophil inhibitory factor (NIF) recognition site was sought. A systematic strategy in which individual amino acid residues within three previously implicated segments were changed to those in the alpha(L)I-domain, which is structurally very similar but does not bind NIF, was implemented. The capacity of the resulting mutants, expressed as glutathione S-transferase fusion proteins, to recognize NIF was assessed. These analyses ultimately identified Asp(149), Arg(151), Gly(207), Tyr(252), and Glu(258) as critical for NIF binding. Cation binding, a function of the metal ion-dependent adhesion site (MIDAS) motif, was assessed by terbium luminescence to evaluate conformational perturbations induced by the mutations. All five mutants bound terbium with unaltered affinities. When the five residues were inserted into the alpha(L)I-domain, the chimera bound NIF with high affinity. Another ligand of alpha(M)beta(2) C3bi, which is known to use the same segments of the alpha(M)I-domain in engaging the receptor, failed to bind to the chimeric alpha(L)I-domain. Thus, the alpha(M)I-domain appears to present a mosaic of exposed amino acids within surface loops on its MIDAS face, and different ligands interact with different residues to attain high affinity binding.	Cleveland Clin Fdn, Joseph J Jacobs Ctr Thrombosis & Vasc Biol, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Dept Mol Cardiol NB50, Cleveland, OH 44195 USA	Cleveland Clinic Foundation; Cleveland Clinic Foundation	Plow, EF (corresponding author), Cleveland Clin Fdn, Joseph J Jacobs Ctr Thrombosis & Vasc Biol, 9500 Euclid Ave, Cleveland, OH 44195 USA.	plowe@ccf.org	Ustinov, Valentin/J-6301-2018		NHLBI NIH HHS [HL 66197] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL066197] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALTIERI DC, 1988, J IMMUNOL, V141, P2656; ALTIERI DC, 1988, J CELL BIOL, V107, P1893, DOI 10.1083/jcb.107.5.1893; ALTIERI DC, 1990, J BIOL CHEM, V265, P12119; ANDERSON DC, 1987, ANNU REV MED, V38, P175, DOI 10.1146/annurev.med.38.1.175; ANDERSON DC, 1986, J IMMUNOL, V137, P15; ARNAOUT MA, 1990, IMMUNOL REV, V114, P145, DOI 10.1111/j.1600-065X.1990.tb00564.x; Arnaout MA, 2000, KIDNEY INT, V58, P2599, DOI 10.1046/j.1523-1755.2000.00446.x; BARNARD JW, 1995, J IMMUNOL, V155, P4876; BAUER C, 1995, SHOCK, V4, P187, DOI 10.1097/00024382-199509000-00006; BILSLAND CAG, 1994, J IMMUNOL, V152, P4582; BJORNHOLM B, 1993, BIOCHEMISTRY-US, V32, P2954; BOHNSACK JF, 1992, J IMMUNOL, V149, P1340; Bouvard D, 2001, CIRC RES, V89, P211, DOI 10.1161/hh1501.094874; BRITTAIN HG, 1976, J AM CHEM SOC, V98, P8255, DOI 10.1021/ja00441a060; CARLOS TM, 1994, BLOOD, V84, P2068; CIERNIEWSKI CS, 1994, BIOCHEMISTRY-US, V33, P12238, DOI 10.1021/bi00206a029; Coxon A, 1996, IMMUNITY, V5, P653, DOI 10.1016/S1074-7613(00)80278-2; DAVIS GE, 1992, EXP CELL RES, V200, P242, DOI 10.1016/0014-4827(92)90170-D; DIAMOND MS, 1993, J CELL BIOL, V120, P1031, DOI 10.1083/jcb.120.4.1031; DIAMOND MS, 1991, CELL, V65, P961, DOI 10.1016/0092-8674(91)90548-D; Dickeson SK, 1998, BIOCHEMISTRY-US, V37, P11280, DOI 10.1021/bi9727848; DIRENZO L, 1991, EUR J IMMUNOL, V21, P1755, DOI 10.1002/eji.1830210726; ELEMER GS, 1994, J IMMUNOL, V152, P5836; Forsyth CB, 1998, J IMMUNOL, V161, P6198; Goodman TG, 1996, J BIOL CHEM, V271, P23729, DOI 10.1074/jbc.271.39.23729; Harris ES, 2000, J BIOL CHEM, V275, P23409, DOI 10.1074/jbc.R000004200; Humphries MJ, 2000, BIOCHEM SOC T, V28, P311, DOI 10.1042/0300-5127:0280311; HYNES RO, 1987, CELL, V48, P549, DOI 10.1016/0092-8674(87)90233-9; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE JO, 1995, CELL, V80, P631, DOI 10.1016/0092-8674(95)90517-0; Lee JO, 1995, STRUCTURE, V3, P1333, DOI 10.1016/S0969-2126(01)00271-4; Leitinger B, 2000, NAT STRUCT BIOL, V7, P614, DOI 10.1038/77895; Li R, 1998, J CELL BIOL, V143, P1523, DOI 10.1083/jcb.143.6.1523; Lo SK, 1999, MOL PHARMACOL, V56, P926, DOI 10.1124/mol.56.5.926; LUK CK, 1971, BIOPOLYMERS, V10, P1317, DOI 10.1002/bip.360100806; Madden K, 1997, INFLAMM RES, V46, P216, DOI 10.1007/s000110050176; MALHOTRA V, 1986, EUR J IMMUNOL, V16, P1117, DOI 10.1002/eji.1830160915; McDonald JA, 2000, J BIOL CHEM, V275, P21783, DOI 10.1074/jbc.R000007200; MCGUIRE SL, 1995, J BIOL CHEM, V270, P25866, DOI 10.1074/jbc.270.43.25866; MICHISHITA M, 1993, CELL, V72, P857, DOI 10.1016/0092-8674(93)90575-B; MOYLE M, 1994, J BIOL CHEM, V269, P10008; MUCHOWSKI PJ, 1994, J BIOL CHEM, V269, P26419; NATHAN C, 1989, J CELL BIOL, V109, P1341, DOI 10.1083/jcb.109.3.1341; Orchekowski RP, 2000, J LEUKOCYTE BIOL, V68, P641; ORTLEPP S, 1995, EUR J IMMUNOL, V25, P637, DOI 10.1002/eji.1830250302; Oxvig C, 1999, P NATL ACAD SCI USA, V96, P2215, DOI 10.1073/pnas.96.5.2215; Plow EF, 2000, J BIOL CHEM, V275, P21785, DOI 10.1074/jbc.R000003200; QU AD, 1995, P NATL ACAD SCI USA, V92, P10277, DOI 10.1073/pnas.92.22.10277; Rieu P, 1996, J BIOL CHEM, V271, P15858, DOI 10.1074/jbc.271.27.15858; RIEU P, 1994, J CELL BIOL, V127, P2081, DOI 10.1083/jcb.127.6.2081; ROSS GD, 1982, J EXP MED, V155, P96, DOI 10.1084/jem.155.1.96; Ruoslahti E, 1997, J CLIN INVEST, V99, P1149, DOI 10.1172/JCI119269; RUSSELL DG, 1988, J EXP MED, V168, P279, DOI 10.1084/jem.168.1.279; SCHMALSTIEG FC, 1988, PEDIATR INFECT DIS J, V7, P867; SHAPPELL SB, 1990, J IMMUNOL, V144, P2702; SMITH CW, 1989, J CLIN INVEST, V83, P2008, DOI 10.1172/JCI114111; Springer T A, 1990, Scand J Immunol, V32, P211, DOI 10.1111/j.1365-3083.1990.tb02912.x; UEDA T, 1994, P NATL ACAD SCI USA, V91, P10680, DOI 10.1073/pnas.91.22.10680; VAUGHAN DE, 1990, CIRC RES, V67, P1281, DOI 10.1161/01.RES.67.5.1281; VONASMUTH EJU, 1991, J IMMUNOL, V147, P3869; Woska JR, 2001, J LEUKOCYTE BIOL, V70, P329; WRIGHT SD, 1983, P NATL ACAD SCI-BIOL, V80, P5699, DOI 10.1073/pnas.80.18.5699; WRIGHT SD, 1986, J EXP MED, V164, P1876, DOI 10.1084/jem.164.6.1876; XIE JL, 1995, J IMMUNOL, V155, P3619; Xiong JP, 2000, J BIOL CHEM, V275, P38762, DOI 10.1074/jbc.C000563200; Yakubenko VP, 2001, J BIOL CHEM, V276, P13995, DOI 10.1074/jbc.M010174200; Zhang L, 1999, BIOCHEMISTRY-US, V38, P8064, DOI 10.1021/bi990141h; Zhang L, 1996, J BIOL CHEM, V271, P29953, DOI 10.1074/jbc.271.47.29953; Zhang L, 1997, J BIOL CHEM, V272, P17558, DOI 10.1074/jbc.272.28.17558; ZHOU LB, 1994, J BIOL CHEM, V269, P17075	71	22	23	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 24	2002	277	21					18769	18776		10.1074/jbc.M110242200	http://dx.doi.org/10.1074/jbc.M110242200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	558PM	11880366	hybrid			2022-12-27	WOS:000175975800070
J	Vlcek, S; Korbei, B; Foisner, R				Vlcek, S; Korbei, B; Foisner, R			Distinct functions of the unique C terminus of LAP2 alpha in cell proliferation and nuclear assembly	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LAMINA-ASSOCIATED POLYPEPTIDE-2; DREIFUSS MUSCULAR-DYSTROPHY; A-TYPE LAMINS; MEMBRANE PROTEIN; DNA-REPLICATION; LEM-DOMAIN; TRANSCRIPTIONAL REPRESSION; STRUCTURE DYNAMICS; ENVELOPE FORMATION; TARGETING DOMAIN	The non-membrane-bound lamina-associated polypeptide 2 isoform, LAP2alpha, forms nucleoskeletal structures with A-type lamins and interacts with chromosomes in a cell cycle-dependent manner. LAP2alpha contains a LEM (LAP2, emerin, and MAN1) domain in the constant N terminus that binds to chromosomal barrier-to-autointegration factor, and a C-terminal unique region that is essential for chromosome binding. Here we show that C-terminal LAP2alpha fragment efficiently bound to mitotic chromosomes and inhibited assembly of endogenous LAP2alpha, nuclear membranes, and lamins A/C in in vitro nuclear assembly assays. Full-length recombinant LAP2alpha, which bound to chromosomes, and N-terminal fragment, which did not bind, had no effect on assembly. This suggested an essential role for the LAP2alpha C terminus in chromosome association and for the N-terminal LEM domain in subsequent assembly stages. In vivo analysis upon transient expression of GFP-tagged LAP2alpha fragments confirmed that, unlike the N-terminal fragment, the C-terminal fragment was able to bind to chromosomes during mitosis, if expressed weakly. At higher expression levels, C-terminal LAP2alpha fragment and full-length protein led to cell cycle arrest in interphase and apoptosis, as shown by fluorescence-activated cell sorter analysis, time lapse microscopy, and BrdUrd incorporation assays. These data indicated distinct functions of LAP2alpha in cell cycle progression during interphase and in nuclear reassembly during mitosis.	Univ Vienna, Vienna Bioctr, Dept Biochem & Mol Cell Biol, A-1030 Vienna, Austria	University of Vienna; Vienna Biocenter (VBC)	Foisner, R (corresponding author), Univ Vienna, Vienna Bioctr, Dept Biochem & Mol Cell Biol, Dr Bohrgasse 9, A-1030 Vienna, Austria.		Foisner, Roland/AAD-1833-2019	Foisner, Roland/0000-0003-4734-4647; Korbei, Barbara/0000-0002-0439-0435				Berger R, 1996, GENOME RES, V6, P361, DOI 10.1101/gr.6.5.361; Bonne G, 2000, ANN NEUROL, V48, P170, DOI 10.1002/1531-8249(200008)48:2<170::AID-ANA6>3.0.CO;2-J; BRIDGER JM, 1993, J CELL SCI, V104, P297; Broers JLV, 1999, J CELL SCI, V112, P3463; Buendia B, 1999, J CELL SCI, V112, P1743; BURKE B, 1986, CELL, V44, P639, DOI 10.1016/0092-8674(86)90273-4; Burke B, 2001, J CELL BIOL, V153, pF5, DOI 10.1083/jcb.153.3.F5; Cai ML, 2001, EMBO J, V20, P4399, DOI 10.1093/emboj/20.16.4399; Chen FL, 2000, SCIENCE, V287, P1485, DOI 10.1126/science.287.5457.1485; Clements L, 2000, BIOCHEM BIOPH RES CO, V267, P709, DOI 10.1006/bbrc.1999.2023; Cohen M, 2001, TRENDS BIOCHEM SCI, V26, P41, DOI 10.1016/S0968-0004(00)01727-8; CZERNY T, 1995, MOL CELL BIOL, V15, P2858; de la Luna S, 1999, EMBO J, V18, P212, DOI 10.1093/emboj/18.1.212; Dechat T, 2000, J CELL SCI, V113, P3473; Dechat T, 2000, J STRUCT BIOL, V129, P335, DOI 10.1006/jsbi.2000.4212; Dechat T, 1998, EMBO J, V17, P4887, DOI 10.1093/emboj/17.16.4887; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; Ellenberg J, 1997, J CELL BIOL, V138, P1193, DOI 10.1083/jcb.138.6.1193; Ellis DJ, 1997, J CELL SCI, V110, P2507; FOISNER R, 1993, CELL, V73, P1267, DOI 10.1016/0092-8674(93)90355-T; Furukawa K, 1997, BIOCHEM BIOPH RES CO, V238, P240, DOI 10.1006/bbrc.1997.7235; Furukawa K, 1999, J CELL SCI, V112, P2485; Furukawa K, 1998, J BIOL CHEM, V273, P4213, DOI 10.1074/jbc.273.7.4213; Gant TM, 1999, J CELL BIOL, V144, P1083, DOI 10.1083/jcb.144.6.1083; Gotzmann J, 1999, CRIT REV EUKAR GENE, V9, P257, DOI 10.1615/CritRevEukarGeneExpr.v9.i3-4.100; Gotzmann J, 2000, J CELL SCI, V113, P3769; Gruenbaum Y, 2000, J STRUCT BIOL, V129, P313, DOI 10.1006/jsbi.2000.4216; Haraguchi T, 2000, J CELL SCI, V113, P779; HARRIS CA, 1994, P NATL ACAD SCI USA, V91, P6283, DOI 10.1073/pnas.91.14.6283; HOZAK P, 1995, J CELL SCI, V108, P635; Hutchison CJ, 2001, J CELL SCI, V114, P9; Jagatheesan G, 1999, J CELL SCI, V112, P4651; Kaelin WG, 1999, BIOESSAYS, V21, P950, DOI 10.1002/(SICI)1521-1878(199911)21:11<950::AID-BIES7>3.0.CO;2-D; Laguri C, 2001, STRUCTURE, V9, P503, DOI 10.1016/S0969-2126(01)00611-6; Lang C, 1999, J CELL SCI, V112, P749; Lavia P, 1999, BIOESSAYS, V21, P221; LenzBohme B, 1997, J CELL BIOL, V137, P1001, DOI 10.1083/jcb.137.5.1001; Lin F, 2000, J BIOL CHEM, V275, P4840, DOI 10.1074/jbc.275.7.4840; Liu J, 2000, MOL BIOL CELL, V11, P3937, DOI 10.1091/mbc.11.11.3937; LOEWINGER L, 1988, EMBO J, V7, P2301, DOI 10.1002/j.1460-2075.1988.tb03073.x; MANCINI MA, 1994, P NATL ACAD SCI USA, V91, P418, DOI 10.1073/pnas.91.1.418; Moir RD, 2000, J CELL BIOL, V149, P1179, DOI 10.1083/jcb.149.6.1179; Moir RD, 2000, J CELL BIOL, V151, P1155, DOI 10.1083/jcb.151.6.1155; Morris GE, 1999, HUM MOL GENET, V8, P1847, DOI 10.1093/hmg/8.10.1847; Nagano A, 2000, CURR OPIN NEUROL, V13, P533, DOI 10.1097/00019052-200010000-00005; Neri LM, 1999, J CELL PHYSIOL, V178, P284, DOI 10.1002/(SICI)1097-4652(199903)178:3<284::AID-JCP2>3.0.CO;2-P; NEWPORT JW, 1990, J CELL BIOL, V111, P2247, DOI 10.1083/jcb.111.6.2247; Nili E, 2001, J CELL SCI, V114, P3297; Rao L, 1996, J CELL BIOL, V135, P1441, DOI 10.1083/jcb.135.6.1441; Sakaki M, 2001, J BIOCHEM-TOKYO, V129, P321, DOI 10.1093/oxfordjournals.jbchem.a002860; Schirmer EC, 2001, J CELL BIOL, V153, P479, DOI 10.1083/jcb.153.3.479; Shumaker DK, 2001, EMBO J, V20, P1754, DOI 10.1093/emboj/20.7.1754; Spann TP, 1997, J CELL BIOL, V136, P1201, DOI 10.1083/jcb.136.6.1201; Steen RL, 2001, J CELL BIOL, V153, P621, DOI 10.1083/jcb.153.3.621; Stuurman N, 1998, J STRUCT BIOL, V122, P42, DOI 10.1006/jsbi.1998.3987; Sullivan T, 1999, J CELL BIOL, V147, P913, DOI 10.1083/jcb.147.5.913; Vlcek S, 1999, EMBO J, V18, P6370, DOI 10.1093/emboj/18.22.6370; Wilson KL, 2000, TRENDS CELL BIOL, V10, P125, DOI 10.1016/S0962-8924(99)01708-0; Wilson KL, 2001, CELL, V104, P647, DOI 10.1016/S0092-8674(02)01452-6; Wolff N, 2001, FEBS LETT, V501, P171, DOI 10.1016/S0014-5793(01)02649-7; Yang L, 1997, J CELL BIOL, V139, P1077, DOI 10.1083/jcb.139.5.1077	61	43	43	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 24	2002	277	21					18898	18907		10.1074/jbc.M200048200	http://dx.doi.org/10.1074/jbc.M200048200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	558PM	11864981	hybrid			2022-12-27	WOS:000175975800085
J	Butler, GS; Sim, D; Tam, E; Devine, D; Overall, CM				Butler, GS; Sim, D; Tam, E; Devine, D; Overall, CM			Mannose-binding lectin (MBL) mutants are susceptible to matrix metalloproteinase proteolysis - Potential role in human MBL deficiency	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLLAGEN-LIKE DOMAIN; GELATINASE-A; COMPLEMENT ACTIVATION; EXTRACELLULAR-MATRIX; SEVERE INFECTIONS; SERINE PROTEASES; VARIANT ALLELES; IV COLLAGENASE; PROTEIN; ASSOCIATION	Mannose-binding lectin (MBL) plays a critical role in innate immunity. Point mutations in the collagen-like domain (R32C, G34D, or G37E) of MBL cause a serum deficiency, predisposing patients to infections and diseases such as rheumatoid arthritis. We examined whether MBL mutants show enhanced susceptibility to proteolysis by matrix metalloproteinases (MMPs), which are important mediators in inflammatory tissue destruction. Human and rat MBL were resistant to proteolysis in the native state but were cleaved selectively within the collagen-like domain by multiple MMPs after heat denaturation. In contrast, rat MBL with mutations homologous to those of the human variants (R23C, G25D, or G28E) was cleaved efficiently without denaturation in the collagen-like domain by MMP-2 and MMP-9 (gelatinases A and B) and MMP-14 (membrane type-1 MMP), as well as by MMP-1 (collagenase-1), MMP-8 (neutrophil collagenase), MMP-3 (stromelysin-1), neutrophil elastase, and bacterial collagenase. Sites and order of cleavage of the rat MBL mutants for MMP-2 and MMP-9 were: Gly(45)-Lys(46)-->Gly(51)-Ser(52)-->Gly(63)-Gln(64)-->Asn(80)-Met(81) which differed from that of MMP-14, Gly(39)-Leu(40)-->Asn(80)-Mets(81), revealing that the MMPs were not functionally interchangeable. These sites were homologous to those cleaved in denatured human MBL. Hence, perturbation of the collagen-like structure of MBL by natural mutations or by denaturation renders MBL susceptible to MMP cleavage. MMPs are likely to contribute to MBL deficiency in individuals with variant alleles and may also be involved in clearance of MBL and modulation of the host response in normal individuals.	Univ British Columbia, Dept Oral Biol & Med Sci, Vancouver, BC V6T 1Z3, Canada; Univ British Columbia, Dept Biochem & Mol Biol, Vancouver, BC V6T 1Z3, Canada; Univ British Columbia, Dept Pathol, Vancouver, BC V6T 1Z3, Canada	University of British Columbia; University of British Columbia; University of British Columbia	Butler, GS (corresponding author), Univ British Columbia, Dept Oral Biol & Med Sci, JB Macdonald Bldg,2199 Wesbrook Mall, Vancouver, BC V6T 1Z3, Canada.	gsbutler@interchange.ubc.ca; chris.overall@ubc.ca	Butler, Georgina/GQP-7553-2022	Butler, Georgina/0000-0003-1172-1578				Arora M, 2001, J BIOL CHEM, V276, P43087, DOI 10.1074/jbc.M105455200; Bigg HF, 2001, CANCER RES, V61, P3610; Cawson T, 1998, MOL MED TODAY, V4, P130, DOI 10.1016/S1357-4310(97)01192-1; Chung L, 2000, J BIOL CHEM, V275, P29610, DOI 10.1074/jbc.M004039200; Colombatti A, 2000, MATRIX BIOL, V19, P289, DOI 10.1016/S0945-053X(00)00074-3; Curran S, 1999, J PATHOL, V189, P300, DOI 10.1002/(SICI)1096-9896(199911)189:3<300::AID-PATH456>3.0.CO;2-C; DAVIES EJ, 1995, ARTHRITIS RHEUM, V38, P110, DOI 10.1002/art.1780380117; DOLO V, 1994, J SUBMICR CYTOL PATH, V26, P173; DRICKAMER K, 1986, J BIOL CHEM, V261, P6878; EZEKOWITZ RAB, 1988, J EXP MED, V167, P1034, DOI 10.1084/jem.167.3.1034; FUJITA T, 1995, JPN J CANCER RES, V86, P187, DOI 10.1111/j.1349-7006.1995.tb03038.x; Gabolde M, 1999, BRIT MED J, V319, P1166, DOI 10.1136/bmj.319.7218.1166; Garred P, 1997, LANCET, V349, P236, DOI 10.1016/S0140-6736(96)08440-1; Garred P, 1999, ARTHRITIS RHEUM, V42, P2145, DOI 10.1002/1529-0131(199910)42:10<2145::AID-ANR15>3.0.CO;2-#; Garred P, 1999, J CLIN INVEST, V104, P431, DOI 10.1172/JCI6861; Garred P, 2000, J RHEUMATOL, V27, P26; Graudal NA, 2000, ARTHRITIS RHEUM, V43, P515, DOI 10.1002/1529-0131(200003)43:3<515::AID-ANR6>3.0.CO;2-T; Harrington DJ, 1996, INFECT IMMUN, V64, P1885, DOI 10.1128/IAI.64.6.1885-1891.1996; Heise CT, 2000, J IMMUNOL, V165, P1403, DOI 10.4049/jimmunol.165.3.1403; HOPPE HJ, 1994, PROTEIN SCI, V3, P1143, DOI 10.1002/pro.5560030801; Kishore U, 2000, IMMUNOPHARMACOLOGY, V49, P159, DOI 10.1016/S0162-3109(00)80301-X; Kleiner DE, 1999, CANCER CHEMOTH PHARM, V43, pS42, DOI 10.1007/s002800051097; KNIGHT CG, 1992, FEBS LETT, V296, P263, DOI 10.1016/0014-5793(92)80300-6; KURATA H, 1993, BIOCHEM BIOPH RES CO, V191, P1204, DOI 10.1006/bbrc.1993.1345; LIPSCOMBE RJ, 1995, IMMUNOLOGY, V85, P660; Ma Y, 1999, P NATL ACAD SCI USA, V96, P371, DOI 10.1073/pnas.96.2.371; Madsen HO, 1998, J IMMUNOL, V161, P3169; MADSEN HO, 1995, J IMMUNOL, V155, P3013; Marshall DCL, 1998, NEUROSCI LETT, V254, P97, DOI 10.1016/S0304-3940(98)00674-0; Matsushita M, 2001, IMMUNOL REV, V180, P78, DOI 10.1034/j.1600-065X.2001.1800107.x; MATSUSHITA M, 1995, BIOCHEM J, V311, P1021, DOI 10.1042/bj3111021; McQuibban GA, 2000, SCIENCE, V289, P1202, DOI 10.1126/science.289.5482.1202; McQuibban GA, 2001, J BIOL CHEM, V276, P43503, DOI 10.1074/jbc.M107736200; Neth O, 2001, LANCET, V358, P614, DOI 10.1016/S0140-6736(01)05776-2; Ohtani K, 1999, J BIOL CHEM, V274, P13681, DOI 10.1074/jbc.274.19.13681; Okamoto T, 1997, J BIOL CHEM, V272, P6059, DOI 10.1074/jbc.272.9.6059; Overall CM, 2000, METH MOL B, V151, P79, DOI 10.1385/1-59259-046-2:079; Overall CM, 2000, J BIOL CHEM, V275, P39497, DOI 10.1074/jbc.M005932200; Parks WC, 2001, RESP RES, V2, P10, DOI 10.1186/rr33; Perides G, 1999, J NEUROSCI RES, V58, P779, DOI 10.1002/(SICI)1097-4547(19991215)58:6&lt;779::AID-JNR5&gt;3.0.CO;2-L; Peterslund NA, 2001, LANCET, V358, P637, DOI 10.1016/S0140-6736(01)05785-3; Ruiz S, 1999, J LEUKOCYTE BIOL, V66, P416, DOI 10.1002/jlb.66.3.416; STEFFENSEN B, 1995, J BIOL CHEM, V270, P11555, DOI 10.1074/jbc.270.19.11555; SUMMERFIELD JA, 1995, LANCET, V345, P886, DOI 10.1016/S0140-6736(95)90009-8; SUPER M, 1989, LANCET, V2, P1236; Tan SM, 1996, BIOCHEM J, V319, P329, DOI 10.1042/bj3190329; Tenner AJ, 1999, CURR OPIN IMMUNOL, V11, P34, DOI 10.1016/S0952-7915(99)80007-7; THIEL S, 1989, FEBS LETT, V250, P78, DOI 10.1016/0014-5793(89)80689-1; Trinder PKE, 1996, IMMUNOLOGY, V87, P355, DOI 10.1046/j.1365-2567.1996.495559.x; Turner MW, 1996, IMMUNOL TODAY, V17, P532, DOI 10.1016/0167-5699(96)10062-1; Wallis R, 1999, J BIOL CHEM, V274, P3580, DOI 10.1074/jbc.274.6.3580; Wallis R, 1999, J IMMUNOL, V163, P4953; Wallis R, 2000, J BIOL CHEM, V275, P30962, DOI 10.1074/jbc.M004030200; Wallon UM, 1997, J BIOL CHEM, V272, P7473, DOI 10.1074/jbc.272.11.7473; Wang ZP, 2000, J BIOL CHEM, V275, P26411, DOI 10.1074/jbc.M001270200; Watford WT, 2001, J IMMUNOL, V167, P6593, DOI 10.4049/jimmunol.167.11.6593; Weis WI, 1998, IMMUNOL REV, V163, P19, DOI 10.1111/j.1600-065X.1998.tb01185.x; Wong NKH, 1999, MOL IMMUNOL, V36, P853, DOI 10.1016/S0161-5890(99)00106-6; Yeo SJ, 1999, ARCH VIROL, V144, P1361, DOI 10.1007/s007050050592; Yokota T, 2000, BLOOD, V96, P1723, DOI 10.1182/blood.V96.5.1723; YOKOTA Y, 1995, J BIOCHEM-TOKYO, V117, P414, DOI 10.1093/jb/117.2.414; ZUCKER S, 1987, BIOCHIM BIOPHYS ACTA, V924, P225, DOI 10.1016/0304-4165(87)90091-2	62	42	47	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 17	2002	277	20					17511	17519		10.1074/jbc.M201461200	http://dx.doi.org/10.1074/jbc.M201461200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	553PR	11891230	hybrid			2022-12-27	WOS:000175685100017
J	Lin, X; Taube, R; Fujinaga, K; Peterlin, BM				Lin, X; Taube, R; Fujinaga, K; Peterlin, BM			P-TEFb containing cyclin K and Cdk9 can activate transcription via RNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBOXYL-TERMINAL DOMAIN; POLYMERASE-II; HIV-1 TAT; ELONGATION-FACTOR; IN-VITRO; HIGH-AFFINITY; KINASE; DSIF; T1; IDENTIFICATION	Different positive transcription elongation factor b (P-TEFb) complexes isolated from mammalian cells contain a common catalytic subunit (Cdk9) and the unique regulatory cyclins CycT1, CycT2a, CycT2b, or CycK. The role of CycK as a transcriptional cyclin was demonstrated in this study. First, CycK activated transcription when tethered heterologously to RNA, which required the kinase activity of Cdk9. Although this P-TEFb could phosphorylate the C-terminal domain (CTD) of RNA polymerase II (RNAPII) in vitro, in contrast to CycT1 and CycT2, CycK did not activate transcription when tethered to DNA. Interestingly, when the C termini of CycT1 and CycT2 or only the histidine-rich stretch from positions 481 to 551 in CycT1 were added to CycK, the extended chimeras activated transcription equivalently via DNA. Moreover, these transcriptional effects required the CTD of RNAPII in cells. Thus, CycK functions as P-TEFb only via RNA, which suggests the presence of cellular RNA-bound activators that require CycK for their transcriptional activity.	Univ Calif San Francisco, Mt Zion Canc Ctr, Dept Med, San Francisco, CA 94115 USA; Univ Calif San Francisco, Dept Microbiol, San Francisco, CA 94115 USA; Univ Calif San Francisco, Dept Immunol, San Francisco, CA 94115 USA	University of California System; University of California San Francisco; UCSF Medical Center; UCSF Medical Center at Mount Zion; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Peterlin, BM (corresponding author), Univ Calif San Francisco, Mt Zion Canc Ctr, Dept Med, Rm N215 ,2340 Sutter St, San Francisco, CA 94115 USA.	matija@itsa.ucsf.edu	TAUBE, RAN/F-2029-2012	TAUBE, RAN/0000-0002-2062-4537	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI049104] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI49104-01] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Barboric M, 2001, MOL CELL, V8, P327, DOI 10.1016/S1097-2765(01)00314-8; Bieniasz PD, 1998, EMBO J, V17, P7056, DOI 10.1093/emboj/17.23.7056; Chen D, 1999, P NATL ACAD SCI USA, V96, P13468, DOI 10.1073/pnas.96.23.13468; Conaway JW, 2000, TRENDS BIOCHEM SCI, V25, P375, DOI 10.1016/S0968-0004(00)01615-7; Cramer Patrick, 2001, Science (Washington D C), V292, P1863, DOI 10.1126/science.1059493; Cujec TP, 1997, GENE DEV, V11, P2645, DOI 10.1101/gad.11.20.2645; Eberhardy SR, 2001, J BIOL CHEM, V276, P48562, DOI 10.1074/jbc.M109014200; Edwards MC, 1998, MOL CELL BIOL, V18, P4291, DOI 10.1128/MCB.18.7.4291; Fu TJ, 1999, J BIOL CHEM, V274, P34527, DOI 10.1074/jbc.274.49.34527; Fujinaga K, 1999, P NATL ACAD SCI USA, V96, P1285, DOI 10.1073/pnas.96.4.1285; Fujinaga K, 1998, J VIROL, V72, P7154, DOI 10.1128/JVI.72.9.7154-7159.1998; Garber ME, 1999, CURR OPIN IMMUNOL, V11, P460, DOI 10.1016/S0952-7915(99)80077-6; Hartzog GA, 1998, GENE DEV, V12, P357, DOI 10.1101/gad.12.3.357; JONES KA, 1994, ANNU REV BIOCHEM, V63, P717, DOI 10.1146/annurev.bi.63.070194.003441; Kanazawa S, 2000, IMMUNITY, V12, P61, DOI 10.1016/S1074-7613(00)80159-4; KAO SY, 1987, NATURE, V330, P489, DOI 10.1038/330489a0; Kiernan RE, 2001, MOL CELL BIOL, V21, P7956, DOI 10.1128/MCB.21.23.7956-7970.2001; Kwak YT, 1999, J MOL BIOL, V288, P57, DOI 10.1006/jmbi.1999.2664; Lee DK, 2001, J BIOL CHEM, V276, P9978, DOI 10.1074/jbc.M002285200; MA J, 1987, CELL, V48, P847, DOI 10.1016/0092-8674(87)90081-X; Mancebo HSY, 1997, GENE DEV, V11, P2633, DOI 10.1101/gad.11.20.2633; MARSHALL NF, 1995, J BIOL CHEM, V270, P12335, DOI 10.1074/jbc.270.21.12335; Marshall NF, 1996, J BIOL CHEM, V271, P27176, DOI 10.1074/jbc.271.43.27176; MATERA AG, 1993, J CELL BIOL, V121, P715, DOI 10.1083/jcb.121.4.715; Meininghaus M, 2000, J BIOL CHEM, V275, P24375, DOI 10.1074/jbc.M001883200; Nguyen VT, 2001, NATURE, V414, P322, DOI 10.1038/35104581; Peng JM, 1998, GENE DEV, V12, P755, DOI 10.1101/gad.12.5.755; Ping YH, 2001, J BIOL CHEM, V276, P12951, DOI 10.1074/jbc.M006130200; Price DH, 2000, MOL CELL BIOL, V20, P2629, DOI 10.1128/MCB.20.8.2629-2634.2000; Reines D, 1999, CURR OPIN CELL BIOL, V11, P342, DOI 10.1016/S0955-0674(99)80047-7; SADOWSKI I, 1988, NATURE, V335, P563, DOI 10.1038/335563a0; Schulman BA, 1998, P NATL ACAD SCI USA, V95, P10453, DOI 10.1073/pnas.95.18.10453; Sengupta DJ, 1999, RNA, V5, P596, DOI 10.1017/S1355838299002113; Taube R, 2002, MOL CELL BIOL, V22, P321, DOI 10.1128/MCB.22.1.321-331.2002; TILEY LS, 1992, P NATL ACAD SCI USA, V89, P758, DOI 10.1073/pnas.89.2.758; Wada T, 1998, EMBO J, V17, P7395, DOI 10.1093/emboj/17.24.7395; Wada T, 1998, GENE DEV, V12, P343, DOI 10.1101/gad.12.3.343; Wei P, 1998, CELL, V92, P451, DOI 10.1016/S0092-8674(00)80939-3; Yamaguchi Y, 1999, J BIOL CHEM, V274, P8085, DOI 10.1074/jbc.274.12.8085; Yang ZY, 2001, NATURE, V414, P317, DOI 10.1038/35104575; Zhou MS, 2000, MOL CELL BIOL, V20, P5077, DOI 10.1128/MCB.20.14.5077-5086.2000; Zhu YR, 1997, GENE DEV, V11, P2622, DOI 10.1101/gad.11.20.2622	42	49	53	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 10	2002	277	19					16873	16878		10.1074/jbc.M200117200	http://dx.doi.org/10.1074/jbc.M200117200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	551MB	11884399	hybrid			2022-12-27	WOS:000175564500071
J	Moriarity, JL; Hurt, KJ; Resnick, AC; Storm, PB; Laroy, W; Schnaar, RL; Snyder, SH				Moriarity, JL; Hurt, KJ; Resnick, AC; Storm, PB; Laroy, W; Schnaar, RL; Snyder, SH			UDP-glucuronate decarboxylase, a key enzyme in proteoglycan synthesis - Cloning, characterization, and localization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-B; HEPARAN-SULFATE PROTEOGLYCANS; CAENORHABDITIS-ELEGANS; EPITHELIAL INVAGINATION; ENDOPLASMIC-RETICULUM; TOUT-VELU; DROSOPHILA; BIOSYNTHESIS; GLYCOSYLATION; PURIFICATION	UDP-glucuronate decarboxylase (UGD) catalyzes the formation of UDP-xylose from UDP-glucuronate. UDP-xylose is then used to initiate glycosaminoglycan biosynthesis on the core protein of proteoglycans. In a yeast two-hybrid screen with the protein kinase Akt (protein kinase B), we detected interactions with a novel sequence, which we cloned and expressed. The expressed protein displayed UGD activity but did not display the activities of homologous nucleotide sugar epimerases or dehydratases. We did not detect phosphorylation of UGD by Akt nor did we detect any influence of Akt on UGD activity. Effects of UGD on Akt kinase activity were also absent. Northern blot and Western blot analyses revealed the presence of UGD in multiple tissues and brain regions. Subcellular studies and histochemistry localized UGD protein to the perinuclear Golgi where xylosylation of proteoglycan core proteins is known to occur.	Johns Hopkins Sch Med, Dept Neurosci, Baltimore, MD 21205 USA; Johns Hopkins Sch Med, Dept Neurol Surg, Baltimore, MD 21205 USA; Johns Hopkins Sch Med, Dept Pharmacol & Mol Sci, Baltimore, MD 21205 USA; Johns Hopkins Sch Med, Dept Psychiat & Behav Sci, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine; Johns Hopkins University; Johns Hopkins Medicine	Snyder, SH (corresponding author), Johns Hopkins Sch Med, Dept Neurosci, 725 N Wolfe St, Baltimore, MD 21205 USA.		Hurt, K. Joseph/J-8266-2019; Schnaar, Ronald L/S-8967-2016	Hurt, K. Joseph/0000-0001-6906-350X; Schnaar, Ronald L/0000-0002-7701-5484	NIDA NIH HHS [DA-00074] Funding Source: Medline; NIMH NIH HHS [MH20062, MH18501] Funding Source: Medline; NINDS NIH HHS [NS37096] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R37MH018501, R01MH018501, T32MH020062] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R37NS037096, R01NS037096] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Alessi DR, 1996, FEBS LETT, V399, P333, DOI 10.1016/S0014-5793(96)01370-1; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; ANKEL H, 1965, BIOCHEMISTRY-US, V4, P2468, DOI 10.1021/bi00887a028; ANKEL H, 1966, BIOCHEMISTRY-US, V5, P182, DOI 10.1021/bi00865a024; Bar-Peled M, 2001, P NATL ACAD SCI USA, V98, P12003, DOI 10.1073/pnas.211229198; BarPeled M, 1996, ANAL BIOCHEM, V241, P140, DOI 10.1006/abio.1996.0390; Bellaiche Y, 1998, NATURE, V394, P85, DOI 10.1038/27932; Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729; Berninsone P, 2001, P NATL ACAD SCI USA, V98, P3738, DOI 10.1073/pnas.061593098; Binari RC, 1997, DEVELOPMENT, V124, P2623; Bulik DA, 2000, P NATL ACAD SCI USA, V97, P10838, DOI 10.1073/pnas.97.20.10838; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; CHEVRAY PM, 1992, P NATL ACAD SCI USA, V89, P5789, DOI 10.1073/pnas.89.13.5789; Colley KJ, 1997, GLYCOBIOLOGY, V7, P1, DOI 10.1093/glycob/7.1.1-b; Hacker U, 1997, DEVELOPMENT, V124, P3565; Haerry TE, 1997, DEVELOPMENT, V124, P3055; Herman T, 1999, P NATL ACAD SCI USA, V96, P968, DOI 10.1073/pnas.96.3.968; Herman T, 1999, P NATL ACAD SCI USA, V96, P974, DOI 10.1073/pnas.96.3.974; Jackson SM, 1997, DEVELOPMENT, V124, P4113; JOHN KV, 1977, J BIOL CHEM, V252, P6707; JOHN KV, 1977, J BIOL CHEM, V252, P8013; KEARNS AE, 1993, J BIOL CHEM, V268, P11097; Krogh A, 2001, J MOL BIOL, V305, P567, DOI 10.1006/jmbi.2000.4315; Lander AD, 2000, J CELL BIOL, V148, P227, DOI 10.1083/jcb.148.2.227; LI XJ, 1995, NATURE, V378, P398, DOI 10.1038/378398a0; Lin XH, 1999, NATURE, V400, P281, DOI 10.1038/22343; Lin XH, 1999, DEVELOPMENT, V126, P3715; Ma YF, 2001, ANTIMICROB AGENTS CH, V45, P1407, DOI 10.1128/AAC.45.5.1407-1416.2001; MANDELES S, 1966, ANAL BIOCHEM, V17, P540, DOI 10.1016/0003-2697(66)90189-8; NG WG, 1967, NATURE, V214, P283, DOI 10.1038/214283a0; NUWAYHID N, 1986, J BIOL CHEM, V261, P2936; Prydz K, 2000, J CELL SCI, V113, P193; Selleck SB, 2000, TRENDS GENET, V16, P206, DOI 10.1016/S0168-9525(00)01997-1; SHEARS SB, 1997, SIGNALLING INOSITIDE; SILBERT JE, 1967, BIOCHIM BIOPHYS ACTA, V141, P193, DOI 10.1016/0304-4165(67)90263-2; The I, 1999, MOL CELL, V4, P633, DOI 10.1016/S1097-2765(00)80214-2; Thoden JB, 1997, BIOCHEMISTRY-US, V36, P6294, DOI 10.1021/bi970025j; Tsuda M, 1999, NATURE, V400, P276, DOI 10.1038/22336; VARA JA, 1988, J BIOL CHEM, V263, P14992; VERTEL BM, 1993, J BIOL CHEM, V268, P11105; ZARKOWSKY H, 1969, J BIOL CHEM, V244, P4750	41	59	61	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 10	2002	277	19					16968	16975		10.1074/jbc.M109316200	http://dx.doi.org/10.1074/jbc.M109316200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	551MB	11877387	hybrid			2022-12-27	WOS:000175564500084
J	Vermes, C; Jacobs, JJ; Zhang, J; Firneisz, G; Roebuck, KA; Glant, TT				Vermes, C; Jacobs, JJ; Zhang, J; Firneisz, G; Roebuck, KA; Glant, TT			Shedding of the interleukin-6 (IL-6) receptor (gp80) determines the ability of IL-6 to induce gp130 phosphorylation in human osteoblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MARROW STROMAL CELLS; PROTEIN-KINASE-C; BONE-MARROW; SIGNAL-TRANSDUCTION; MYELOMA CELLS; MESSENGER-RNA; OSTEOCLAST DIFFERENTIATION; GROWTH-FACTORS; CYTOKINES; EXPRESSION	Human osteoblasts produce interleukin-6 (IL-6) and respond to IL-6 in the presence of soluble IL-6 receptor (sIL-6R), but the cell surface expression of IL-6R and the mechanism of sIL-6R production are largely unknown. Three different human osteoblast-like cell lines (MG-63, HOS, and SaOS-2) and bone marrow-derived primary human osteoblasts expressed both IL-6R and gp130 as determined by flow cytometry and immunoprecipitation. However, the membrane-bound IL-6R was nonfunctional, as significant tyrosine phosphorylation of gp130 did not occur in the presence of IL-6. Phorbol myristate acetate induced a dramatic increase of both IL-6R shedding (i.e. the production of sIL-6R) and IL-6 release in osteoblast cultures, but the cell surface expression of gp130 remained unchanged. IL-6 complexed with sIL-6R, either exogenously introduced or derived from the nonfunctional cell surface form by shedding, induced rapid tyrosine phosphorylation of gp130. This effect was inhibited by neutralizing antibodies to either sIL-6R or gp130, indicating that the gp130 activation was induced by IL-6/sIL-6R/gp130 interaction. Protein kinase C inhibitors blocked phorbol myristate acetate-induced and spontaneous shedding of IL-6R resulting in the absence of sIL-6R in the culture medium, which in turn also prevented the activation of gp130. In conclusion, human osteoblasts express cell surface IL-6R, which is unable to transmit IL-6-induced signals until it is shed into its soluble form. This unique mechanism provides the flexibility for osteoblasts to control their own responsiveness to IL-6 via the activation of an IL-6R sheddase, resulting in an immediate production of functionally active osteoblast-derived sIL-6R.	Rush Univ, Rush Presbyterian St Lukes Med Ctr, Dept Orthoped Surg, Chicago, IL 60612 USA; Rush Univ, Rush Presbyterian St Lukes Med Ctr, Dept Biochem, Chicago, IL 60612 USA; Rush Univ, Rush Presbyterian St Lukes Med Ctr, Dept Immunol Microbiol, Chicago, IL 60612 USA	Rush University; Rush University; Rush University	Glant, TT (corresponding author), Rush Univ, Rush Presbyterian St Lukes Med Ctr, Dept Orthoped Surg, 1653 W Congress Pkwy, Chicago, IL 60612 USA.		Firneisz, Gabor/AAC-9654-2021; Jacobs, Joshua/AGG-8284-2022; Zhang, Jian/A-2564-2008	Firneisz, Gabor/0000-0002-9123-8131; Zhang, Jian/0000-0002-9523-5296; Jacobs, Joshua/0000-0003-3902-7334				Adebanjo OA, 1998, J CELL BIOL, V142, P1347, DOI 10.1083/jcb.142.5.1347; Althoff K, 2001, BIOCHEM J, V353, P663, DOI 10.1042/0264-6021:3530663; Bellido T, 1996, J CLIN INVEST, V97, P431, DOI 10.1172/JCI118432; Bellido T, 1997, ENDOCRINOLOGY, V138, P3666, DOI 10.1210/en.138.9.3666; BRUNS RF, 1991, BIOCHEM BIOPH RES CO, V176, P288, DOI 10.1016/0006-291X(91)90922-T; Franchimont N, 1997, ENDOCRINOLOGY, V138, P5248, DOI 10.1210/en.138.12.5248; Gao Y, 1998, BONE, V22, P487, DOI 10.1016/S8756-3282(98)00040-4; Girasole G, 1999, CLIN ENDOCRINOL, V51, P801, DOI 10.1046/j.1365-2265.1999.00896.x; Glant Tibor T., 1996, Am J Ther, V3, P27, DOI 10.1097/00045391-199601000-00006; GLANT TT, 1993, J BONE MINER RES, V8, P1071; GLITZ D, 1992, TXB BIOCH CLIN CORRE, P746; Hargreaves PG, 1998, BRIT J HAEMATOL, V101, P694, DOI 10.1046/j.1365-2141.1998.00754.x; Heinrich PC, 1998, BIOCHEM J, V334, P297, DOI 10.1042/bj3340297; Heymann D, 2000, CYTOKINE, V12, P1455, DOI 10.1006/cyto.2000.0747; HIBI M, 1990, CELL, V63, P1149, DOI 10.1016/0092-8674(90)90411-7; HORIUCHI S, 1994, EUR J IMMUNOL, V24, P1945, DOI 10.1002/eji.1830240837; JILKA RL, 1992, SCIENCE, V257, P88, DOI 10.1126/science.1621100; Jilka RL, 1998, J BONE MINER RES, V13, P793, DOI 10.1359/jbmr.1998.13.5.793; Jones SA, 1998, EUR J IMMUNOL, V28, P3514, DOI 10.1002/(SICI)1521-4141(199811)28:11<3514::AID-IMMU3514>3.3.CO;2-K; Jones SA, 2001, FASEB J, V15, P43, DOI 10.1096/fj.99-1003rev; Kim CH, 1997, ENDOCR RES, V23, P181, DOI 10.3109/07435809709031852; KISHIMOTO T, 1994, CELL, V76, P253, DOI 10.1016/0092-8674(94)90333-6; KISHIMOTO T, 1992, SCIENCE, V258, P593, DOI 10.1126/science.1411569; KISHIMOTO T, 1995, BLOOD, V86, P1243, DOI 10.1182/blood.V86.4.1243.bloodjournal8641243; KISHIMOTO T, 1992, INT J IMMUNOPHARMACO, V14, P431; Lin SC, 1997, J CLIN INVEST, V100, P1980, DOI 10.1172/JCI119729; LITTLEWOOD AJ, 1991, ENDOCRINOLOGY, V129, P1513, DOI 10.1210/endo-129-3-1513; LUST JA, 1992, CYTOKINE, V4, P96, DOI 10.1016/1043-4666(92)90043-Q; Majors AK, 1997, J ORTHOPAED RES, V15, P546, DOI 10.1002/jor.1100150410; Manolagas SC, 1998, ANN NY ACAD SCI, V840, P194, DOI 10.1111/j.1749-6632.1998.tb09563.x; Modur V, 1997, J CLIN INVEST, V100, P2752, DOI 10.1172/JCI119821; MULLBERG J, 1993, EUR J IMMUNOL, V23, P473, DOI 10.1002/eji.1830230226; Mullberg J, 1999, BIOCHEM SOC T, V27, P211; MULLBERG J, 1995, J IMMUNOL, V155, P5198; MullerNewen G, 1996, EUR J BIOCHEM, V236, P837, DOI 10.1111/j.1432-1033.1996.00837.x; MURAKAMI M, 1993, SCIENCE, V260, P1808, DOI 10.1126/science.8511589; Muschler GF, 1997, J BONE JOINT SURG AM, V79A, P1699, DOI 10.2106/00004623-199711000-00012; Nishimura R, 1998, J BONE MINER RES, V13, P777, DOI 10.1359/jbmr.1998.13.5.777; O'Brien CA, 1999, J BIOL CHEM, V274, P19301, DOI 10.1074/jbc.274.27.19301; O'Brien CA, 2000, J CELL BIOCHEM, V79, P532, DOI 10.1002/1097-4644(20001215)79:4<532::AID-JCB20>3.0.CO;2-U; Oh JW, 1996, CYTOKINE, V8, P401, DOI 10.1006/cyto.1996.0055; Romas E, 1996, J EXP MED, V183, P2581, DOI 10.1084/jem.183.6.2581; ROSEJOHN S, 1994, BIOCHEM J, V300, P281, DOI 10.1042/bj3000281; Taga T, 1997, ANN MED, V29, P63, DOI 10.3109/07853899708998744; Thabard W, 1999, CLIN CANCER RES, V5, P2693; Thabard W, 2001, BIOCHEM J, V358, P193, DOI 10.1042/0264-6021:3580193; UDAGAWA N, 1995, J EXP MED, V182, P1461, DOI 10.1084/jem.182.5.1461; Vermes C, 2000, J BONE MINER RES, V15, P1756, DOI 10.1359/jbmr.2000.15.9.1756; WANG Y, 1995, J CELL BIOCHEM, V57, P610, DOI 10.1002/jcb.240570405; YAO JL, 1995, J BONE MINER RES, V10, P1417	51	45	46	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 10	2002	277	19					16879	16887		10.1074/jbc.M200546200	http://dx.doi.org/10.1074/jbc.M200546200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	551MB	11884403	hybrid			2022-12-27	WOS:000175564500072
J	Hirbec, H; Perestenko, O; Nishimune, A; Meyer, G; Nakanishi, S; Henley, JM; Dev, KK				Hirbec, H; Perestenko, O; Nishimune, A; Meyer, G; Nakanishi, S; Henley, JM; Dev, KK			The PDZ proteins PICK1, GRIP, and syntenin bind multiple glutamate receptor subtypes - Analysis of PDZ binding motifs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOMAIN-CONTAINING PROTEIN; KINASE-C-ALPHA; AMPA RECEPTOR; INTERACTS; SURFACE; GLUR2; PHOSPHORYLATION; ORGANIZATION; RECOGNITION; SYNAPSES	Using sequence homology searches, yeast two-hybrid assays and glutathione S-transferase (GST)-pull-down approaches we have identified a series of glutamate receptor subunits that interact differentially with the PDZ proteins GRIP, PICK1, and syntenin. GST-pull-down experiments identified more interactions than detected by yeast two-hybrid assays. We report several receptor-protein interactions, strong ones include: W GRIP and syntenin with mGluR7a, mGluR4a, and mGluR6; (ii) PICK1 and GRIP with mGluR3; and (iii) syntenin with all forms of GluR1-4 and mGluR7b. We further characterized the novel mGluR7a-GRIP interaction found both in yeast two-hybrid and GST-pull-down assays and observed that mGluR7a localization overlapped with GRIP with in hippocampal neurons. The wide range of targets for PICK1, GRIP, and syntenin suggests they may represent a molecular mechanism that can concentrate and/or regulate a number of different receptors at a common site on a synapse. These data also suggest that the structural determinants involved in PDZ interactions are more complex than originally envisaged.	Univ Bristol, Sch Med, Dept Anat, MRC,Ctr Synapt Plast, Bristol BS8 1TD, Avon, England; Kyoto Univ, Dept Biol Sci, Fac Med, Kyoto 6068501, Japan	University of Bristol; Kyoto University	Dev, KK (corresponding author), Novartis Pharma AG, Nervous Syst Res, CH-4002 Basel, Switzerland.		Hirbec, Helene/ABE-4188-2021; Henley, Jeremy M/A-2776-2009	Hirbec, Helene/0000-0002-5593-5255; Dev, Kumlesh/0000-0003-4274-9119; Henley, Jeremy/0000-0003-3589-8335	Medical Research Council [G9629038] Funding Source: Medline; MRC [G9629038] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Bezprozvanny I, 2001, FEBS LETT, V509, P457, DOI 10.1016/S0014-5793(01)03214-8; Boudin H, 2000, NEURON, V28, P485, DOI 10.1016/S0896-6273(00)00127-6; Chung HJ, 2000, J NEUROSCI, V20, P7258; Daw MI, 2000, NEURON, V28, P873, DOI 10.1016/S0896-6273(00)00160-4; Dev KK, 1999, NEUROPHARMACOLOGY, V38, P635, DOI 10.1016/S0028-3908(98)00230-5; Dev KK, 2001, TRENDS PHARMACOL SCI, V22, P355, DOI 10.1016/S0165-6147(00)01684-9; Dev KK, 2000, J NEUROSCI, V20, P7252; Dong HL, 1997, NATURE, V386, P279, DOI 10.1038/386279a0; Dong HL, 1999, J NEUROSCI, V19, P6930, DOI 10.1523/JNEUROSCI.19-16-06930.1999; Fernandez-Larrea J, 1999, MOL CELL, V3, P423, DOI 10.1016/S1097-2765(00)80470-0; Grootjans JJ, 1997, P NATL ACAD SCI USA, V94, P13683, DOI 10.1073/pnas.94.25.13683; HOLLMANN M, 1994, ANNU REV NEUROSCI, V17, P31, DOI 10.1146/annurev.ne.17.030194.000335; Hsueh YP, 1998, NEURON, V21, P1227, DOI 10.1016/S0896-6273(00)80641-8; KOHLER M, 1994, J BIOL CHEM, V269, P17367; Koroll M, 2001, J BIOL CHEM, V276, P10646, DOI 10.1074/jbc.M010647200; Lin WJ, 2001, BIOCHEM J, V354, P635, DOI 10.1042/0264-6021:3540635; Matsuda S, 2000, EMBO J, V19, P2765, DOI 10.1093/emboj/19.12.2765; Osten P, 2000, NEURON, V27, P313, DOI 10.1016/S0896-6273(00)00039-8; Perez JL, 2001, J NEUROSCI, V21, P5417, DOI 10.1523/JNEUROSCI.21-15-05417.2001; Ponting CP, 1997, BIOESSAYS, V19, P469, DOI 10.1002/bies.950190606; Sheng M, 2001, ANNU REV NEUROSCI, V24, P1, DOI 10.1146/annurev.neuro.24.1.1; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; STAUDINGER J, 1995, J CELL BIOL, V128, P263, DOI 10.1083/jcb.128.3.263; Staudinger J, 1997, J BIOL CHEM, V272, P32019, DOI 10.1074/jbc.272.51.32019; Torres GE, 2001, NEURON, V30, P121, DOI 10.1016/S0896-6273(01)00267-7; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; Wyszynski M, 1999, J NEUROSCI, V19, P6528; Xia J, 1999, NEURON, V22, P179, DOI 10.1016/S0896-6273(00)80689-3; Ye B, 2000, NEURON, V26, P603, DOI 10.1016/S0896-6273(00)81198-8	29	114	118	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 3	2002	277	18					15221	15224		10.1074/jbc.C200112200	http://dx.doi.org/10.1074/jbc.C200112200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	550PA	11891216	Green Published, hybrid			2022-12-27	WOS:000175510400001
J	Lyle, JM; Clewell, A; Richmond, K; Richards, OC; Hope, DA; Schultz, SC; Kirkegaard, K				Lyle, JM; Clewell, A; Richmond, K; Richards, OC; Hope, DA; Schultz, SC; Kirkegaard, K			Similar structural basis for membrane localization and protein priming by an RNA-dependent RNA polymerase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DE-NOVO INITIATION; ACTING REPLICATION ELEMENT; SITE-DIRECTED MUTAGENESIS; POLIOVIRUS RNA; ENZYMATIC-ACTIVITY; 3D POLYMERASE; IN-VITRO; 3AB; IDENTIFICATION; VPG	Protein primers are used to initiate genomic synthesis of several RNA and DNA viruses, although the structural details of the primer-polymerase interactions are not yet known. Poliovirus polymerase binds with high affinity to the membrane-bound viral protein 3AB but uridylylates only the smaller peptide 3B in vitro. Mutational analysis of the polymerase identified four surface residues on the three-dimensional structure of poliovirus polymerase whose wild-type identity is required for 3AB binding. These mutants also decreased 3B uridylylation, arguing that the binding sites for the membrane tether and the protein primer overlap. Mutation of flanking residues between the 3AB binding site and the polymerase active site specifically decreased 3B uridylylation, likely affecting steps subsequent to binding. The physical overlap of sites for protein priming and membrane association should facilitate replication initiation in the membrane-associated complex.	Stanford Univ, Dept Microbiol & Immunol, Sch Med, Stanford, CA 94305 USA; Univ Colorado, Dept Mol Cellular & Dev Biol, Boulder, CO 80309 USA; Univ Colorado, Dept Chem & Biochem, Boulder, CO 80309 USA	Stanford University; University of Colorado System; University of Colorado Boulder; University of Colorado System; University of Colorado Boulder	Kirkegaard, K (corresponding author), Stanford Univ, Dept Microbiol & Immunol, Sch Med, 299 Campus Dr, Stanford, CA 94305 USA.	karlak@stanford.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI042119] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-42119] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BARCO A, 1995, GENE, V156, P19, DOI 10.1016/0378-1119(94)00872-P; BAROUDY BM, 1982, CELL, V28, P315, DOI 10.1016/0092-8674(82)90349-X; Barton DJ, 1996, VIROLOGY, V217, P459, DOI 10.1006/viro.1996.0140; Beckman MTL, 1998, J BIOL CHEM, V273, P6724, DOI 10.1074/jbc.273.12.6724; BIESSMANN H, 1990, CELL, V61, P663, DOI 10.1016/0092-8674(90)90478-W; BURNS CC, 1992, VIROLOGY, V189, P568, DOI 10.1016/0042-6822(92)90580-I; Butcher SJ, 2001, NATURE, V410, P235, DOI 10.1038/35065653; Chen JB, 2000, J VIROL, V74, P4310, DOI 10.1128/JVI.74.9.4310-4318.2000; Chen SJ, 1998, J BIOL CHEM, V273, P6050, DOI 10.1074/jbc.273.11.6050; DATTA U, 1994, J VIROL, V68, P4468, DOI 10.1128/JVI.68.7.4468-4477.1994; DELANGE AM, 1986, J VIROL, V59, P249, DOI 10.1128/JVI.59.2.249-259.1986; DIAMOND SE, 1994, J VIROL, V68, P863, DOI 10.1128/JVI.68.2.863-876.1994; Dufour E, 2000, J MOL BIOL, V304, P289, DOI 10.1006/jmbi.2000.4216; Fertala J, 2000, J BIOL CHEM, V275, P15246, DOI 10.1074/jbc.275.20.15246; Goodfellow I, 2000, J VIROL, V74, P4590, DOI 10.1128/JVI.74.10.4590-4600.2000; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; Hansen JL, 1997, STRUCTURE, V5, P1109, DOI 10.1016/S0969-2126(97)00261-X; Hobson SD, 2001, EMBO J, V20, P1153, DOI 10.1093/emboj/20.5.1153; HOBSON SD, 2000, THESIS U COLORADO; Hope DA, 1997, J VIROL, V71, P9490, DOI 10.1128/JVI.71.12.9490-9498.1997; JABLONSKI SA, 1991, J VIROL, V65, P4565, DOI 10.1128/JVI.65.9.4565-4572.1991; JABLONSKI SA, 1993, J VIROL, V67, P373, DOI 10.1128/JVI.67.1.373-381.1993; Jager Joachim, 1999, Current Opinion in Structural Biology, V9, P21, DOI 10.1016/S0959-440X(99)80004-9; Ke SH, 1997, NUCLEIC ACIDS RES, V25, P3371, DOI 10.1093/nar/25.16.3371; Kim MJ, 2000, J VIROL, V74, P10312, DOI 10.1128/JVI.74.22.10312-10322.2000; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAMA J, 1994, J BIOL CHEM, V269, P66; Luo GX, 2000, J VIROL, V74, P851, DOI 10.1128/JVI.74.2.851-863.2000; McBride AE, 1996, P NATL ACAD SCI USA, V93, P2296, DOI 10.1073/pnas.93.6.2296; Meijer WJJ, 2001, MICROBIOL MOL BIOL R, V65, P261, DOI 10.1128/MMBR.65.2.261-287.2001; PATA JD, 1995, RNA, V1, P466; Paul AV, 2000, J VIROL, V74, P10359, DOI 10.1128/JVI.74.22.10359-10370.2000; Paul AV, 1998, NATURE, V393, P280, DOI 10.1038/30529; PAUL AV, 1994, J BIOL CHEM, V269, P29173; PLOTCH SJ, 1995, J VIROL, V69, P7169, DOI 10.1128/JVI.69.11.7169-7179.1995; Richards OC, 1998, J BIOL CHEM, V273, P12832, DOI 10.1074/jbc.273.21.12832; Rieder E, 2000, J VIROL, V74, P10371, DOI 10.1128/JVI.74.22.10371-10380.2000; Rodriguez-Wells V, 2001, NUCLEIC ACIDS RES, V29, P2715, DOI 10.1093/nar/29.13.2715; SALAS M, 1991, ANNU REV BIOCHEM, V60, P39, DOI 10.1146/annurev.bi.60.070191.000351; Suhy DA, 2000, J VIROL, V74, P8953, DOI 10.1128/JVI.74.19.8953-8965.2000; Sun XL, 2000, BIOCHEM BIOPH RES CO, V268, P798, DOI 10.1006/bbrc.2000.2120; Teterina NL, 2001, J VIROL, V75, P3841, DOI 10.1128/JVI.75.8.3841-3850.2001; Towner JS, 1998, J VIROL, V72, P7191, DOI 10.1128/JVI.72.9.7191-7200.1998; Towner JS, 1996, J BIOL CHEM, V271, P26810, DOI 10.1074/jbc.271.43.26810; Wittschieben J, 1998, NUCLEIC ACIDS RES, V26, P490, DOI 10.1093/nar/26.2.490; Xiang WK, 1998, J VIROL, V72, P6732, DOI 10.1128/JVI.72.8.6732-6741.1998; Zhong WD, 2000, J VIROL, V74, P2017, DOI 10.1128/JVI.74.4.2017-2022.2000; Zhu CX, 1998, J BIOL CHEM, V273, P8783, DOI 10.1074/jbc.273.15.8783	50	62	62	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 3	2002	277	18					16324	16331		10.1074/jbc.M112429200	http://dx.doi.org/10.1074/jbc.M112429200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	550PA	11877407	hybrid			2022-12-27	WOS:000175510400143
J	Joubert, F; Mazet, JL; Mateo, P; Hoerter, JA				Joubert, F; Mazet, JL; Mateo, P; Hoerter, JA			(31)P NMR detection of subcellular creatine kinase fluxes in the perfused rat heart - Contractility modifies energy transfer pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADENINE-NUCLEOTIDE TRANSLOCASE; IN-VIVO REGULATION; OXIDATIVE-PHOSPHORYLATION; OXYGEN-CONSUMPTION; MITOCHONDRIAL RESPIRATION; SATURATION TRANSFER; METABOLIC-CONTROL; LEAST 2ND-ORDER; CARDIAC-MUSCLE; ATP	The subeellular fluxes of exchange of ATP and phosphocreatine (PCr) between mitochondria, cytosol, and ATPases were assessed by (31)P NMR spectroscopy to investigate the pathways of energy transfer in a steady state beating heart. Using a combined analysis of four protocols of inversion magnetization transfer associated with biochemical data, three different creatine kinase (CK) activities were resolved in the rat heart perfused in isovolumic control conditions: (i) a cytosolic CK functioning at equilibrium (forward, F(f) = PCr --> ATP, and reverse flux, F(r) = ATP --> PCr = 3.3 mM.s(-1)), (ii) a CK localized in the vicinity of ATPases (MM-CK bound isoform) favoring ATP synthesis (F(f) = 1.7 x F(r)), and (iii) a mitochondrial CK displaced toward PCr synthesis (Ff = 0.3 and F(r) = 2.6 mM,s(-1)). This study thus provides the first experimental evidence that the energy is carried from mitochondria to ATPases by PCr (i.e. CK shuttle) in the whole heart. In contrast, a single CK functioning at equilibrium was sufficient to describe the data when ATP synthesis was partly inhibited by cyanide (0.15 mM). In this case, ATP was directly transferred from mitochondria to cytosol suggesting that cardiac activity modified energy transfer pathways. Bioenergetic implications of the localization and activity of enzymes within myocardial cells are discussed.	Univ Paris Sud, Fac Pharm, INSERM, U446, F-92296 Chatenay Malabry, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay	Hoerter, JA (corresponding author), Univ Paris Sud, Fac Pharm, INSERM, U446, 5 Rue JB Clement, F-92296 Chatenay Malabry, France.	jacqueline.hoerter@cep.u-psud.fr		Joubert, Frederic/0000-0003-0239-1052				Aliev MK, 1997, BIOPHYS J, V73, P428, DOI 10.1016/S0006-3495(97)78082-2; ARRIODUPONT M, 1992, EUR J BIOCHEM, V207, P951, DOI 10.1111/j.1432-1033.1992.tb17129.x; Balschi JA, 1997, J MOL CELL CARDIOL, V29, P3123, DOI 10.1006/jmcc.1997.0539; BESSMAN SP, 1981, SCIENCE, V211, P448, DOI 10.1126/science.6450446; CHANCE B, 1955, J BIOL CHEM, V217, P385; Chung YR, 1999, AM J PHYSIOL-HEART C, V277, pH1410, DOI 10.1152/ajpheart.1999.277.4.H1410; Cieslar JH, 2000, J BIOL CHEM, V275, P6129, DOI 10.1074/jbc.275.9.6129; Crawford RM, 2001, FASEB J, V15, P102, DOI 10.1096/fj.01-0446fje; De Sousa E, 1999, CIRC RES, V85, P68; HEADRICK JP, 1994, AM J PHYSIOL, V267, pH1074, DOI 10.1152/ajpheart.1994.267.3.H1074; HOERTER JA, 1988, AM J PHYSIOL, V255, pC192, DOI 10.1152/ajpcell.1988.255.2.C192; JACOBUS WE, 1982, ARCH BIOCHEM BIOPHYS, V219, P167, DOI 10.1016/0003-9861(82)90146-1; JACOBUS WE, 1985, ANNU REV PHYSIOL, V47, P707; Jeneson JAL, 2000, AM J PHYSIOL-CELL PH, V279, pC813, DOI 10.1152/ajpcell.2000.279.3.C813; Jeneson JAL, 1996, J BIOL CHEM, V271, P27995, DOI 10.1074/jbc.271.45.27995; Joubert F, 2000, BIOPHYS J, V79, P1, DOI 10.1016/S0006-3495(00)76269-2; Joubert F, 2001, BIOPHYS J, V81, P2995, DOI 10.1016/S0006-3495(01)75940-1; Joubert F, 2001, BIOCHEMISTRY-US, V40, P2129, DOI 10.1021/bi001695j; KATZ LA, 1989, AM J PHYSIOL, V256, pH265, DOI 10.1152/ajpheart.1989.256.1.H265; Kay L, 2000, J BIOL CHEM, V275, P6937, DOI 10.1074/jbc.275.10.6937; Kemp GJ, 1998, MOL CELL BIOCHEM, V184, P249, DOI 10.1023/A:1006848726795; KORETSKY AP, 1986, BIOCHEMISTRY-US, V25, P77, DOI 10.1021/bi00349a012; Kowaltowski AJ, 2001, AM J PHYSIOL-HEART C, V280, pH649, DOI 10.1152/ajpheart.2001.280.2.H649; KUSHMERICK MJ, 1992, AM J PHYSIOL, V263, pC598, DOI 10.1152/ajpcell.1992.263.3.C598; Laclau MN, 2001, J MOL CELL CARDIOL, V33, P947, DOI 10.1006/jmcc.2001.1357; MATEO P, 1999, AM J PHYSIOL, V46, pH308; MCFARLAND EW, 1994, BIOPHYS J, V67, P1912, DOI 10.1016/S0006-3495(94)80674-5; Mekhfi H, 1996, CIRC RES, V78, P1016, DOI 10.1161/01.RES.78.6.1016; Minajeva A, 1996, PFLUG ARCH EUR J PHY, V432, P904, DOI 10.1007/s004240050214; MOREADITH RW, 1982, J BIOL CHEM, V257, P899; Nascimben L, 1996, CIRCULATION, V94, P1894, DOI 10.1161/01.CIR.94.8.1894; Saks VA, 1996, BBA-BIOENERGETICS, V1274, P81, DOI 10.1016/0005-2728(96)00011-4; SAKS VA, 1976, BIOCHEMISTRY-MOSCOW+, V41, P1701; SAKS VA, 1985, J BIOL CHEM, V260, P7757; SAKS VA, 1994, MOL CELL BIOCHEM, V133, P155, DOI 10.1007/BF01267954; Sata M, 1996, CIRCULATION, V93, P310, DOI 10.1161/01.CIR.93.2.310; Soboll S, 1999, J MOL CELL CARDIOL, V31, P857, DOI 10.1006/jmcc.1998.0925; STEPANOV V, 1997, AM J PHYSIOL, V42, pC1397; UGURBIL K, 1986, BIOCHEMISTRY-US, V25, P100, DOI 10.1021/bi00349a015; Vendelin M, 2000, AM J PHYSIOL-CELL PH, V278, pC747, DOI 10.1152/ajpcell.2000.278.4.C747; VENTURACLAPIER R, 1987, J GEN PHYSIOL, V89, P815, DOI 10.1085/jgp.89.5.815; WALLIMANN T, 1992, BIOCHEM J, V281, P21, DOI 10.1042/bj2810021; Wallimann T, 1996, J MUSCLE RES CELL M, V17, P177, DOI 10.1007/BF00124240; WYSS M, 1992, BIOCHIM BIOPHYS ACTA, V1102, P119, DOI 10.1016/0167-4838(92)90506-9; Ye Y, 2001, AM J PHYSIOL-HEART C, V281, pH376, DOI 10.1152/ajpheart.2001.281.1.H376; ZAHLER R, 1987, BIOPHYS J, V51, P883, DOI 10.1016/S0006-3495(87)83416-1	46	51	52	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 24	2002	277	21					18469	18476		10.1074/jbc.M200792200	http://dx.doi.org/10.1074/jbc.M200792200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	558PM	11886866	hybrid			2022-12-27	WOS:000175975800029
J	Engblom, AC; Carlson, BX; Olsen, RW; Schousboe, A; Kristiansen, U				Engblom, AC; Carlson, BX; Olsen, RW; Schousboe, A; Kristiansen, U			Point mutation in the first transmembrane region of the beta 2 subunit of the gamma-aminobutyric acid type a receptor alters desensitization kinetics of gamma-aminobutyric acid- and anesthetic-induced channel gating	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GABA(A) RECEPTORS; RECOMBINANT HUMAN; LINING RESIDUES; AMINO-ACID; DEACTIVATION; BENZODIAZEPINE; ACTIVATION; RESPONSES; RHO-1; IDENTIFICATION	A conserved glycine residue in the first transmembrane (TM1) domain of the beta2 subunit has been identified to be involved with desensitization induced by gamma-aminobutyric acid (GABA) and anesthetics. Recombinant GABA(A) receptors expressed in Sf9 cells were recorded using semi-fast agonist application. Upon direct activation by GABA or anesthetics, the main effect of the TM1 point mutation on the beta2 subunit (G219F) was to slow the time constant (tau) of desensitization. At GABA concentrations eliciting maximum currents, the corresponding median tau values were 0.87 s (25-75% interval (0.76; 1.04 s)), 0.93 s (0.76; 1.23 s), and 1.36 s (1.17; 1.57 s) for alpha1beta2gamma2, alpha1(G223F)beta2gamma2, and alpha1beta2(G219F)gamma2, respectively. The tau value for the beta2-mutant receptor was significantly longer than alpha1beta2gamma2 (p<0.01) and alpha 1(G223F)beta 2 gamma 2 (p<0.05). For pentobarbital-induced currents (500 muM), the corresponding median tau values were 1.36 s (0.81; 1.41 s), 1.47 s (1.31; 2.38 s), and 2.82 s (2.21; 5.56 s) for alpha1beta2gamma2, alpha1(G223F)beta2gamma2, and alpha1beta2(G219F)gamma2, respectively. The tau value for the beta2-mutant receptor was significantly longer than that for alpha1beta2gamma2 (p<0.01). The present findings suggest that this TM1 glycine residue is critical for the rate at which desensitization occurs and that both GABA and intravenous anesthetics implement an analogous pathway for generating desensitization.	Royal Danish Sch Pharm, Dept Pharmacol, DK-2100 Copenhagen, Denmark; Univ Calif Los Angeles, Sch Med, Dept Mol & Med Pharmacol, Los Angeles, CA 90095 USA	Royal Danish School of Pharmacy; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Kristiansen, U (corresponding author), Royal Danish Sch Pharm, Dept Pharmacol, Univ Pk 2, DK-2100 Copenhagen, Denmark.	uk@dfh.dk		Schousboe, Arne/0000-0001-9600-402X; Kristiansen, Uffe/0000-0001-9050-7806	NINDS NIH HHS [NS28772] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS028772] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AKABAS MH, 1995, BIOCHEMISTRY-US, V34, P12496, DOI 10.1021/bi00039a002; Akk G, 2000, BRIT J PHARMACOL, V130, P249, DOI 10.1038/sj.bjp.0703335; Amin J, 1999, MOL PHARMACOL, V55, P411; Bai DL, 1999, J NEUROSCI, V19, P10635, DOI 10.1523/JNEUROSCI.19-24-10635.1999; Belelli D, 1997, P NATL ACAD SCI USA, V94, P11031, DOI 10.1073/pnas.94.20.11031; Belelli D, 1999, TRENDS PHARMACOL SCI, V20, P496, DOI 10.1016/S0165-6147(99)01405-4; Bianchi MT, 2001, J NEUROSCI, V21, P1127; Carlson BX, 2000, MOL PHARMACOL, V57, P474, DOI 10.1124/mol.57.3.474; Chang YC, 1999, BIOPHYS J, V77, P2542, DOI 10.1016/S0006-3495(99)77089-X; CUTTING GR, 1991, P NATL ACAD SCI USA, V88, P2673, DOI 10.1073/pnas.88.7.2673; Dalziel JE, 2000, MOL PHARMACOL, V57, P875; Elster L, 2001, NEUROCHEM INT, V38, P581, DOI 10.1016/S0197-0186(00)00122-4; Findlay GS, 2001, NEUROSCI LETT, V305, P76, DOI 10.1016/S0304-3940(01)01879-1; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; JONES MV, 1995, NEURON, V15, P181, DOI 10.1016/0896-6273(95)90075-6; Kristiansen U, 1996, NEUROPHARMACOLOGY, V35, P1181, DOI 10.1016/S0028-3908(96)00070-6; KUSAMA T, 1993, BRIT J PHARMACOL, V109, P200, DOI 10.1111/j.1476-5381.1993.tb13554.x; Lavoie AM, 1997, BIOPHYS J, V73, P2518, DOI 10.1016/S0006-3495(97)78280-8; LI W, 2000, J NEUROSCI, V20, P898; Lobitz N, 2001, MOL PHARMACOL, V59, P844, DOI 10.1124/mol.59.4.844; Lu L, 1998, J MEMBRANE BIOL, V164, P115, DOI 10.1007/s002329900398; MACDONALD RL, 1994, ANNU REV NEUROSCI, V17, P569, DOI 10.1146/annurev.neuro.17.1.569; Martinez-Torres A, 2000, P NATL ACAD SCI USA, V97, P3562, DOI 10.1073/pnas.050582397; Mihic SJ, 1997, NATURE, V389, P385, DOI 10.1038/38738; Moody EJ, 1997, J NEUROCHEM, V69, P1310; Renard S, 1999, J BIOL CHEM, V274, P13370, DOI 10.1074/jbc.274.19.13370; SANNA E, 1995, J PHARMACOL EXP THER, V274, P353; SHIMADA S, 1992, MOL PHARMACOL, V41, P683; Thompson SA, 1999, BRIT J PHARMACOL, V127, P1349, DOI 10.1038/sj.bjp.0702687; Xu M, 1996, J GEN PHYSIOL, V107, P195, DOI 10.1085/jgp.107.2.195; Zhu WJ, 1997, J NEUROSCI, V17, P4022	31	16	16	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 17	2002	277	20					17438	17447		10.1074/jbc.M111215200	http://dx.doi.org/10.1074/jbc.M111215200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	553PR	11877425	hybrid			2022-12-27	WOS:000175685100009
J	Potamitou, A; Neubauer, P; Holmgren, A; Vlamis-Gardikas, A				Potamitou, A; Neubauer, P; Holmgren, A; Vlamis-Gardikas, A			Expression of Escherichia coli glutaredoxin 2 is mainly regulated by ppGpp and sigma(S)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CEREBELLAR GRANULE NEURONS; DOPAMINE-INDUCED APOPTOSIS; OXYR TRANSCRIPTION FACTOR; GENE-EXPRESSION; OXIDATIVE STRESS; HYDROGEN-PEROXIDE; RNA-POLYMERASE; GLUTATHIONE; RPOS; THIOREDOXIN	Escherichia coli glutaredoxin 2 (Grx2, encoded by grxB) differs greatly from the other two glutaredoxins in structure and catalytic properties. In a wild type strain, levels of Grx2 increased 3-fold in the stationary phase (up to 8 mug/mg). Guanosine-3',5'-tetraphoshate (ppGpp) and sigma(S), which regulate the transcription of genes in the stationary phase, dramatically affected the expression of Grx2. spoTrelA null mutants, lacking ppGpp, had very low levels of Grx2, while overproduction of full-length RelA or valine-induced starvation of isoleucine, both conditions elevating ppGpp levels, resulted in elevation of Grx2. Null mutants for the sigma(S)-specific protease ClpP, which have higher levels of sigma(S), exhibited a 3-fold Grx2 increase. sigma(S) in trans also increased the levels of Grx2. Therefore the stationary phase expression of Grx2 is determined by the sigma(S)-bound form of RNA polymerase in connection with ppGpp, while basal levels should be attributed to sigma(70)-RNA polymerase holoenzyme. Osmotic pressure and cAMP also affected the expression of Grx2, presumably via sigma(S). Furthermore, Grx2 levels were elevated in an oxyR(-) strain. In accordance with the role of Grx2 as a stationary phase protein, null mutants for grxB were shown to lyse under starvation conditions and exhibited a distorted morphology.	Karolinska Inst, Dept Med Biochem & Biophys, Med Nobel Inst Biochem, S-17177 Stockholm, Sweden; Univ Oulu, Dept Proc Environm Engn, Bioproc Engn Lab, FIN-90014 Oulu, Finland; Univ Oulu, Bioctr Oulu, FIN-90014 Oulu, Finland	Karolinska Institutet; University of Oulu; University of Oulu	Holmgren, A (corresponding author), Karolinska Inst, Dept Med Biochem & Biophys, Med Nobel Inst Biochem, S-17177 Stockholm, Sweden.		Fernandes, Aristi/D-2507-2015; Vlamis, Alexios/AAF-5152-2020; Neubauer, Peter/N-8146-2013; Neubauer, Peter/W-4518-2019	Vlamis, Alexios/0000-0001-5068-6459; Neubauer, Peter/0000-0002-1214-9713; 				Arnold CN, 2001, J BACTERIOL, V183, P2178, DOI 10.1128/JB.183.7.2178-2186.2001; Aslund F, 1999, P NATL ACAD SCI USA, V96, P6161, DOI 10.1073/pnas.96.11.6161; BECKERHAPAK M, 1995, FEMS MICROBIOL LETT, V134, P39, DOI 10.1111/j.1574-6968.1995.tb07911.x; Bianchi AA, 1999, MOL MICROBIOL, V34, P1029, DOI 10.1046/j.1365-2958.1999.01664.x; Board PG, 2000, J BIOL CHEM, V275, P24798, DOI 10.1074/jbc.M001706200; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Carmel-Harel O, 2000, ANNU REV MICROBIOL, V54, P439, DOI 10.1146/annurev.micro.54.1.439; CASHEL M, 1996, ESCHERICHIA COLI SAL, V1, P1458; CHRISTMAN MF, 1985, CELL, V41, P753, DOI 10.1016/S0092-8674(85)80056-8; Colland F, 2000, EMBO J, V19, P3028, DOI 10.1093/emboj/19.12.3028; Daily D, 2001, J BIOL CHEM, V276, P21618, DOI 10.1074/jbc.M101400200; Daily D, 2001, J BIOL CHEM, V276, P1335, DOI 10.1074/jbc.M008121200; Davis R., 1980, ADV BACTERIAL GENETI; Dukan S, 1998, GENE DEV, V12, P3431, DOI 10.1101/gad.12.21.3431; Dulhunty A, 2001, J BIOL CHEM, V276, P3319, DOI 10.1074/jbc.M007874200; Farewell A, 1998, MOL MICROBIOL, V29, P1039, DOI 10.1046/j.1365-2958.1998.00990.x; GENTRY DR, 1993, J BACTERIOL, V175, P7982, DOI 10.1128/JB.175.24.7982-7989.1993; HENGGEARONIS R, 1993, J BACTERIOL, V175, P259, DOI 10.1128/JB.175.1.259-265.1993; HenggeAronis R, 1996, MOL MICROBIOL, V21, P887, DOI 10.1046/j.1365-2958.1996.511405.x; HENGGEARONIS R, 1996, ESCHERICHIA COLI SAL, V1, P1497; HOLMGREN A, 1995, METHOD ENZYMOL, V252, P283; HOLMGREN A, 1989, J BIOL CHEM, V264, P13963; Holmgren A, 2000, ANTIOXID REDOX SIGN, V2, P811, DOI 10.1089/ars.2000.2.4-811; Kodym R, 1999, J BIOL CHEM, V274, P5131, DOI 10.1074/jbc.274.8.5131; Kvint K, 2000, J BIOL CHEM, V275, P14795, DOI 10.1074/jbc.C000128200; LANGE R, 1994, GENE DEV, V8, P1600, DOI 10.1101/gad.8.13.1600; LANGE R, 1991, MOL MICROBIOL, V5, P49, DOI 10.1111/j.1365-2958.1991.tb01825.x; Lillig CH, 1999, J BIOL CHEM, V274, P7695, DOI 10.1074/jbc.274.12.7695; Lim CJ, 2000, BBA-GENE STRUCT EXPR, V1491, P1, DOI 10.1016/S0167-4781(00)00026-9; LOEWEN PC, 1993, J BACTERIOL, V175, P2150, DOI 10.1128/JB.175.7.2150-2153.1993; LOEWEN PC, 1979, CAN J BIOCHEM CELL B, V57, P107, DOI 10.1139/o79-013; Loewen PC, 1998, CAN J MICROBIOL, V44, P707, DOI 10.1139/cjm-44-8-707; MARTIN JL, 1995, STRUCTURE, V3, P245, DOI 10.1016/S0969-2126(01)00154-X; Miller J.H., 1992, SHORT COURSE BACTERI, P150; Monje-Casas F, 2001, J BIOL CHEM, V276, P18031, DOI 10.1074/jbc.M011728200; POTAMITOU A, 2002, IN PRESS J BIOL CHEM, V277; Ritz D, 2000, J BIOL CHEM, V275, P2505, DOI 10.1074/jbc.275.4.2505; Ritz D, 2001, ANNU REV MICROBIOL, V55, P21, DOI 10.1146/annurev.micro.55.1.21; SARUBBI E, 1988, MOL GEN GENET, V213, P214, DOI 10.1007/BF00339584; SCHREIBER G, 1991, J BIOL CHEM, V266, P3760; Schweder T, 1996, J BACTERIOL, V178, P470, DOI 10.1128/jb.178.2.470-476.1996; Shi J, 1999, J BIOL CHEM, V274, P36039, DOI 10.1074/jbc.274.51.36039; Tao K, 1997, J BACTERIOL, V179, P5967, DOI 10.1128/jb.179.18.5967-5970.1997; Teich A, 1999, BIOTECHNOL PROGR, V15, P123, DOI 10.1021/bp980102h; Vlamis-Gardikas A, 2002, J BIOL CHEM, V277, P10861, DOI 10.1074/jbc.M111024200; VlamisGardikas A, 1997, J BIOL CHEM, V272, P11236; Xia B, 2001, J MOL BIOL, V310, P907, DOI 10.1006/jmbi.2001.4721; YIM HH, 1994, J BACTERIOL, V176, P100, DOI 10.1128/JB.176.1.100-107.1994; Zheng M, 1998, SCIENCE, V279, P1718, DOI 10.1126/science.279.5357.1718; Zheng M, 2001, J BACTERIOL, V183, P4562, DOI 10.1128/JB.183.15.4562-4570.2001	50	21	23	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 17	2002	277	20					17775	17780		10.1074/jbc.M201306200	http://dx.doi.org/10.1074/jbc.M201306200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	553PR	11889138	hybrid			2022-12-27	WOS:000175685100050
J	Smith, E; Coetzee, GA; Frenkel, B				Smith, E; Coetzee, GA; Frenkel, B			Glucocorticoids inhibit cell cycle progression in differentiating osteoblasts via glycogen synthase kinase-3 beta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-CATENIN; TRANSCRIPTION FACTOR; C-MYC; SUBCELLULAR-LOCALIZATION; SUBSTRATE-SPECIFICITY; INDUCED OSTEOPOROSIS; SIGNAL-TRANSDUCTION; KINASE 3-BETA; IN-VIVO; LITHIUM	Differentiating osteoblasts in culture undergo a commitment stage, during which cobblestone-like cells grow to high density past confluency. In contrast to earlier proliferative stages, the cell cycle during this commitment stage is inhibited by glucocorticoids (GC). Chronic GC treatment also impedes mineral deposition if steroid administration commences early enough during commitment. This study defines a role for glycogen synthase kinase-3beta (GSK3beta) and its target, c-Myc, in the GC-sensitive osteoblast persistent cell cycle. c-Myc levels decreased as cells reached confluence, but then increased during growth to high density. GC administration at this stage resulted in down-regulation of c-Myc. This was accompanied by GC-mediated attenuation of GSK3beta Ser(9) inhibitory phosphorylation and increased GSK3beta kinase activity. Down-regulation of c-Myc was attributable to enhanced Thr(58) phosphorylation, leading to accelerated degradation. In contrast, GC did not inhibit the c-Myc synthesis rate or the level of beta-catenin, a transcriptional coactivator of c-myc. The attenuated cell cycle and the reduced c-Myc level were returned to control levels by specific inhibition of GSK3beta using lithium chloride. These results suggest that tonal GSK3beta repression at the cobblestone stage of osteoblast differentiation permits osteoblast growth to high density. GC interfere with this growth-permissive axis by GSK3beta activation, resulting in c-Myc down-regulation and impediment of the G(1)/S cell cycle transition.	Univ So Calif, Keck Sch Med, Inst Med Genet, Dept Biochem & Mol Biol, Los Angeles, CA 90033 USA; Univ So Calif, Keck Sch Med, Inst Med Genet, Dept Orthoped Surg, Los Angeles, CA 90033 USA; Univ So Calif, Keck Sch Med, Inst Med Genet, Dept Urol, Los Angeles, CA 90033 USA; Univ So Calif, Keck Sch Med, Norris Canc Ctr, Los Angeles, CA 90033 USA	University of Southern California; University of Southern California; University of Southern California; University of Southern California	Frenkel, B (corresponding author), Univ So Calif, Keck Sch Med, Inst Med Genet, Dept Biochem & Mol Biol, 2250 Alcazar St,CSC IGM240, Los Angeles, CA 90033 USA.		coetzee, Gerhard/AAT-6203-2020; Coetzee, Gerhard/AAG-8439-2019	Coetzee, Gerhard/0000-0001-8820-8364	NATIONAL CANCER INSTITUTE [T32CA009659] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR047052] Funding Source: NIH RePORTER; NCI NIH HHS [T32-CA09659] Funding Source: Medline; NIAMS NIH HHS [R01-AR47052] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; Aizawa T, 1999, J BONE JOINT SURG BR, V81B, P921, DOI 10.1302/0301-620X.81B5.9492; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; BEIJERSBERGEN RL, 1994, GENE DEV, V8, P2680, DOI 10.1101/gad.8.22.2680; BROULIK PD, 1984, CLIN CHIM ACTA, V140, P151, DOI 10.1016/0009-8981(84)90339-5; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; Canalis E, 1996, J CLIN ENDOCR METAB, V81, P3441, DOI 10.1210/jc.81.10.3441; Cohen P, 2001, NAT REV MOL CELL BIO, V2, P769, DOI 10.1038/35096075; CROSS DAE, 1994, BIOCHEM J, V303, P21, DOI 10.1042/bj3030021; Dajani R, 2001, CELL, V105, P721, DOI 10.1016/S0092-8674(01)00374-9; DARZYNKIEWICZ Z, 1994, METHOD CELL BIOL, V41, P15; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; Frame S, 2001, MOL CELL, V7, P1321, DOI 10.1016/S1097-2765(01)00253-2; GOLD MR, 1995, INT REV CYTOL, V157, P181, DOI 10.1016/S0074-7696(08)62159-2; GRIGORIADIS AE, 1993, J CELL BIOL, V122, P685, DOI 10.1083/jcb.122.3.685; Haden ST, 1997, J CLIN ENDOCR METAB, V82, P2844, DOI 10.1210/jc.82.9.2844; Hall BK, 2000, BIOESSAYS, V22, P138, DOI 10.1002/(SICI)1521-1878(200002)22:2<138::AID-BIES5>3.3.CO;2-W; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; HECK S, 1994, EMBO J, V13, P4087, DOI 10.1002/j.1460-2075.1994.tb06726.x; Hobmayer B, 2000, NATURE, V407, P186, DOI 10.1038/35025063; HUGHES K, 1993, EMBO J, V12, P803, DOI 10.1002/j.1460-2075.1993.tb05715.x; Kim L, 1999, CELL, V99, P399, DOI 10.1016/S0092-8674(00)81526-3; Klein PS, 1996, P NATL ACAD SCI USA, V93, P8455, DOI 10.1073/pnas.93.16.8455; LAND H, 1983, NATURE, V304, P596, DOI 10.1038/304596a0; Liang JD, 1999, CALCIFIED TISSUE INT, V65, P369, DOI 10.1007/s002239900715; Linkhart TA, 1996, BONE, V19, pS1, DOI 10.1016/S8756-3282(96)00138-X; Lukert Barbara P., 1996, P533; MADIEHE AM, 1995, BIOCHEM BIOPH RES CO, V209, P768, DOI 10.1006/bbrc.1995.1565; Mak TWL, 1998, J CLIN ENDOCR METAB, V83, P3857, DOI 10.1210/jc.83.11.3857; Manolagas SC, 1999, J BONE MINER RES, V14, P1061, DOI 10.1359/jbmr.1999.14.7.1061; MILLER AD, 1984, CELL, V36, P51; Miller JR, 1996, GENE DEV, V10, P2527, DOI 10.1101/gad.10.20.2527; Orford K, 1999, J CELL BIOL, V146, P855, DOI 10.1083/jcb.146.4.855; Papkoff J, 1996, MOL CELL BIOL, V16, P2128; PULVERER BJ, 1994, ONCOGENE, V9, P59; Richon VM, 1997, J BIOL CHEM, V272, P10117, DOI 10.1074/jbc.272.15.10117; Rogatsky I, 1999, MOL CELL BIOL, V19, P5036; Rogatsky I, 1997, MOL CELL BIOL, V17, P3181, DOI 10.1128/MCB.17.6.3181; SAITO Y, 1994, BIOCHEM J, V303, P27, DOI 10.1042/bj3030027; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Sears R, 2000, GENE DEV, V14, P2501, DOI 10.1101/gad.836800; Shtutman M, 1999, P NATL ACAD SCI USA, V96, P5522, DOI 10.1073/pnas.96.10.5522; Smith E, 2000, J BIOL CHEM, V275, P19992, DOI 10.1074/jbc.M001758200; Troussard AA, 1999, MOL CELL BIOL, V19, P7420; Verona R, 1997, MOL CELL BIOL, V17, P7268, DOI 10.1128/MCB.17.12.7268; Vlach J, 1996, EMBO J, V15, P6595, DOI 10.1002/j.1460-2075.1996.tb01050.x; YEH WC, 1995, P NATL ACAD SCI USA, V92, P11086, DOI 10.1073/pnas.92.24.11086; Yost C, 1996, GENE DEV, V10, P1443, DOI 10.1101/gad.10.12.1443; Young CS, 1998, MOL CELL BIOL, V18, P2474, DOI 10.1128/MCB.18.5.2474	49	73	85	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 17	2002	277	20					18191	18197		10.1074/jbc.M109708200	http://dx.doi.org/10.1074/jbc.M109708200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	553PR	11877389	hybrid			2022-12-27	WOS:000175685100101
J	Zuhorn, IS; Kalicharan, R; Hoekstra, D				Zuhorn, IS; Kalicharan, R; Hoekstra, D			Lipoplex-mediated transfection of mammalian cells occurs through the cholesterol-dependent clathrin-mediated pathway of endocytosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATIONIC LIPOSOMES; GENE DELIVERY; DNA COMPLEXES; CAVEOLAE; EFFICIENT; ENTRY; INTERNALIZATION; INHIBITION; DEPLETION; REVEALS	Synthetic amphiphiles are widely used as a carrier system. However, to match transfection efficiencies as obtained for viral vectors, further insight is required into the properties of lipoplexes that dictate transfection efficiency, including the mechanism of delivery. Although endocytosis is often referred to as the pathway of lipoplex entry and transfection, its precise nature has been poorly defined. Here, we demonstrate that lipoplex-mediated transfection is inhibited by more than 80%, when plasma membrane cholesterol is depleted with methyl-beta-cyclodextrin. Cholesterol replenishment restores the transfection capacity. Investigation of the cellular distribution of lipoplexes after cholesterol depletion revealed an exclusive inhibition of internalization, whereas cell-association remained unaffected. These data strongly support the notion that complex internalization, rather than the direct translocation of plasmid across the plasma membrane, is a prerequisite for accomplishing effective lipoplex-mediated transfection. We demonstrate that internalized lipoplexes colocalize with transferrin in early endocytic compartments and that lipoplex internalization is inhibited in potassium-depleted cells and in cells overexpressing dominant negative Eps15 mutants. In conjunction with the notion that eaveolae-mediated internalization can be excluded, we conclude that efficient lipoplex-mediated transfection requires complex internalization via the cholesterol-dependent clathrin-mediated pathway of endocytosis.	Univ Groningen, Dept Membrane Cell Biol, NL-9713 AV Groningen, Netherlands; Univ Groningen, Lab Cell Biol & Electron Microscopy, NL-9713 EZ Groningen, Netherlands	University of Groningen; University of Groningen	Hoekstra, D (corresponding author), Univ Groningen, Dept Membrane Cell Biol, A Deusinglaan 1, NL-9713 AV Groningen, Netherlands.	d.hoekstra@med.rug.nl		Zuhorn, Inge/0000-0002-7695-915X				Audouy S, 2000, J GENE MED, V2, P465, DOI 10.1002/1521-2254(200011/12)2:6<465::AID-JGM141>3.0.CO;2-Z; Benmerah A, 1999, J CELL SCI, V112, P1303; Benmerah A, 1998, J CELL BIOL, V140, P1055, DOI 10.1083/jcb.140.5.1055; BENNETT CF, 1992, MOL PHARMACOL, V41, P1023; Boleti H, 1999, J CELL SCI, V112, P1487; Castanho MARB, 1999, BBA-BIOMEMBRANES, V1419, P1, DOI 10.1016/S0005-2736(99)00049-8; CROWTHER RA, 1976, J MOL BIOL, V103, P785, DOI 10.1016/0022-2836(76)90209-6; Erbacher P, 1996, EXP CELL RES, V225, P186, DOI 10.1006/excr.1996.0169; FARHOOD H, 1995, BBA-BIOMEMBRANES, V1235, P289, DOI 10.1016/0005-2736(95)80016-9; FELGNER JH, 1994, J BIOL CHEM, V269, P2550; FELGNER PL, 1987, P NATL ACAD SCI USA, V84, P7413, DOI 10.1073/pnas.84.21.7413; Francis SA, 1999, EUR J CELL BIOL, V78, P473, DOI 10.1016/S0171-9335(99)80074-0; Friend DS, 1996, BBA-BIOMEMBRANES, V1278, P41, DOI 10.1016/0005-2736(95)00219-7; Fujimoto T, 2000, J CELL SCI, V113, P3509; FUJITA H, 1981, HISTOCHEMISTRY, V73, P57, DOI 10.1007/BF00493133; Godbey WT, 1999, P NATL ACAD SCI USA, V96, P5177, DOI 10.1073/pnas.96.9.5177; KILSDONK EPC, 1995, J BIOL CHEM, V270, P17250, DOI 10.1074/jbc.270.29.17250; Kirchhausen T, 2000, ANNU REV BIOCHEM, V69, P699, DOI 10.1146/annurev.biochem.69.1.699; KLEIN U, 1995, BIOCHEMISTRY-US, V34, P13784, DOI 10.1021/bi00042a009; Koval M, 1998, EXP CELL RES, V242, P265, DOI 10.1006/excr.1998.4110; LARKIN JM, 1983, CELL, V33, P273, DOI 10.1016/0092-8674(83)90356-2; MATLIN KS, 1982, J MOL BIOL, V156, P609, DOI 10.1016/0022-2836(82)90269-8; Meekel AAP, 2000, EUR J ORG CHEM, V2000, P665; MONTESANO R, 1981, J CELL SCI, V51, P95; Mukherjee S, 1997, PHYSIOL REV, V77, P759, DOI 10.1152/physrev.1997.77.3.759; Oberle V, 2000, BIOPHYS J, V79, P1447, DOI 10.1016/S0006-3495(00)76396-X; Ohvo H, 1996, BIOCHEMISTRY-US, V35, P8018, DOI 10.1021/bi9528816; Orlandi PA, 1998, J CELL BIOL, V141, P905, DOI 10.1083/jcb.141.4.905; PEARSE BMF, 1982, P NATL ACAD SCI-BIOL, V79, P451, DOI 10.1073/pnas.79.2.451; PHILLIPS MC, 1987, BIOCHIM BIOPHYS ACTA, V906, P223, DOI 10.1016/0304-4157(87)90013-X; Pires P, 1999, BBA-BIOMEMBRANES, V1418, P71, DOI 10.1016/S0005-2736(99)00023-1; Pouton CW, 1998, J CONTROL RELEASE, V53, P289, DOI 10.1016/S0168-3659(98)00015-7; Puri V, 2001, J CELL BIOL, V154, P535, DOI 10.1083/jcb.200102084; Rodal SK, 1999, MOL BIOL CELL, V10, P961, DOI 10.1091/mbc.10.4.961; SCHNITZER JE, 1994, J CELL BIOL, V127, P1217, DOI 10.1083/jcb.127.5.1217; Shi FX, 2001, NUCLEIC ACIDS RES, V29, P2079, DOI 10.1093/nar/29.10.2079; Shin JS, 2001, SCIENCE, V293, P1447, DOI 10.1126/science.1061079; Shin JS, 2000, SCIENCE, V289, P785, DOI 10.1126/science.289.5480.785; STEGMANN T, 1997, BIOCHIM BIOPHYS ACTA, V3, P71; Subtil A, 1999, P NATL ACAD SCI USA, V96, P6775, DOI 10.1073/pnas.96.12.6775; VanDerWoude I, 1997, P NATL ACAD SCI USA, V94, P1160, DOI 10.1073/pnas.94.4.1160; WANG LH, 1993, J CELL BIOL, V123, P1107, DOI 10.1083/jcb.123.5.1107; WROBEL I, 1995, BBA-BIOMEMBRANES, V1235, P296, DOI 10.1016/0005-2736(95)80017-A; ZABNER J, 1995, J BIOL CHEM, V270, P18997, DOI 10.1074/jbc.270.32.18997; ZHOU XH, 1994, BBA-BIOMEMBRANES, V1189, P195, DOI 10.1016/0005-2736(94)90066-3; ZUHORN IS, 2002, BIOCHIM BIOPHYS ACTA, P1	46	276	283	2	34	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 17	2002	277	20					18021	18028		10.1074/jbc.M111257200	http://dx.doi.org/10.1074/jbc.M111257200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	553PR	11875062	hybrid			2022-12-27	WOS:000175685100080
J	Akhtar, S; Shamotienko, O; Papakosta, M; Ali, F; Dolly, JO				Akhtar, S; Shamotienko, O; Papakosta, M; Ali, F; Dolly, JO			Characteristics of brain Kv1 channels tailored to mimic native counterparts by tandem linkage of alpha subunits - Implications for K+ channelopathies	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GATED POTASSIUM CHANNELS; RAT-BRAIN; VOLTAGE-DEPENDENCE; SENSORY NEURONS; BETA-SUBUNITS; ION CHANNELS; DENDROTOXIN; EXPRESSION; SUBTYPES; IDENTIFICATION	Most neuronal Kv1 channels contain Kvl.1, Kv1.2 alpha, and Kvbeta2.1 subunits, yet the influences of their stoichiometries on properties of the (alpha)(4)(beta)(4) variants remain undefined. cDNAs were engineered to contain 0, 1, 2, or 4 copies of Kvl.1 with the requisite number of Kv1.2 and co-expressed in mammalian cells with Kvbeta2.1 to achieve "native-like" hetero-oligomers. The monomeric (Kv1.1 or 1.2), dimeric (Kv1.1-1.2 or 1.2-1.2), and tetrameric (Kv1.1-(1.2)(3)) constructs produced proteins Of M-r similar to62,000, 120,000, and 240,000, which assembled into (alpha)(4)(beta)(4) complexes. Each alpha cRNA yielded a distinct K+ current in oocytes, with voltage dependence of activation being shifted negatively as the Kv1.1 content in tetramers was increased. Channels containing 1, 2, or 4 copies of Kv1.1 were blocked by dendrotoxin k (DTX)(k) with similarly high potencies, whereas Kv(1.2)(4) proved nonsusceptible. Accordingly, Kv1.2/beta2.1 expressed in baby hamster kidney cells failed to bind DTXk; in contrast, oligomers containing only one Kv1.1 subunit in a tetramer exhibited high affinity, with additional copies causing modest increases. Thus, one Kv1.1 subunit largely confers high affinity for DTXk, whereas channel electrophysiological properties are tailored by the content of Kv1.1 relative to Kv1.2. This notable advance could explain the diversity of symptoms of human episodic ataxia 1, which is often accompanied by myokymia, due to mutated Kv1.1 being assembled in different combinations with wild-type and Kv1.2.	Univ London Imperial Coll Sci Technol & Med, Dept Biol Sci, Ctr Neurobiochem, London SW7 2AY, England	Imperial College London	Dolly, JO (corresponding author), Univ London Imperial Coll Sci Technol & Med, Dept Biol Sci, Ctr Neurobiochem, Exhibit Rd,S Kensington, London SW7 2AY, England.	o.dolly@ic.ac.uk	Dolly, Oliver/G-1532-2012; Dolly, Oliver/ABH-6677-2020	Dolly, Oliver/0000-0002-0861-5320; Dolly, Oliver/0000-0002-0861-5320				Adelman JP, 1995, NEURON, V15, P1449, DOI 10.1016/0896-6273(95)90022-5; Akhtar S, 1999, BIOCHEMISTRY-US, V38, P16984, DOI 10.1021/bi992114x; AWAN KA, 1991, NEUROSCIENCE, V40, P29, DOI 10.1016/0306-4522(91)90172-K; BROWNE DL, 1995, HUM MOL GENET, V4, P1671, DOI 10.1093/hmg/4.9.1671; COCHRAN SM, 1997, BRIT J PHARMACOL, V122, P256; Coleman SK, 1999, J NEUROCHEM, V73, P849, DOI 10.1046/j.1471-4159.1999.0730849.x; D'Adamo MC, 1998, EMBO J, V17, P1200, DOI 10.1093/emboj/17.5.1200; Dolly JO, 1996, J BIOENERG BIOMEMBR, V28, P231, DOI 10.1007/BF02110698; DOLLY JO, 1984, J PHYSIOL-PARIS, V79, P280; Gamkrelidze G, 1998, J NEUROSCI, V18, P1449; Gasparini S, 1998, J BIOL CHEM, V273, P25393, DOI 10.1074/jbc.273.39.25393; Gold MS, 1996, J NEUROPHYSIOL, V75, P2629, DOI 10.1152/jn.1996.75.6.2629; HALL A, 1994, BRIT J PHARMACOL, V113, P959, DOI 10.1111/j.1476-5381.1994.tb17086.x; Heinemann SH, 1995, FEBS LETT, V377, P383, DOI 10.1016/0014-5793(95)01377-6; Hollerer-Beitz G, 1999, PFLUG ARCH EUR J PHY, V438, P141, DOI 10.1007/s004240050891; Hopkins WF, 1998, J PHARMACOL EXP THER, V285, P1051; HURST RS, 1991, MOL PHARMACOL, V40, P572; Imredy JP, 2000, J MOL BIOL, V296, P1283, DOI 10.1006/jmbi.2000.3522; KEIGHLEY WW, 1994, J PHYSIOL-LONDON, V480P, pP68; Koschak A, 1998, J BIOL CHEM, V273, P2639, DOI 10.1074/jbc.273.5.2639; Lehmann-Horn F, 1999, PHYSIOL REV, V79, P1317, DOI 10.1152/physrev.1999.79.4.1317; Main MJ, 1998, FEBS LETT, V441, P6, DOI 10.1016/S0014-5793(98)01507-5; McIntosh P, 1997, PFLUG ARCH EUR J PHY, V435, P43, DOI 10.1007/s004240050482; PARCEJ DN, 1992, BIOCHEMISTRY-US, V31, P11084, DOI 10.1021/bi00160a018; Rasband M, 1998, J NEUROSCI, V18, P36; RETTIG J, 1994, NATURE, V369, P289, DOI 10.1038/369289a0; Rhodes KJ, 1997, J NEUROSCI, V17, P8246; Schweitz H, 1999, PERSPECT DRUG DISCOV, V16, P83; SCOTT VES, 1994, BIOCHEMISTRY-US, V33, P1617, DOI 10.1021/bi00173a001; Shamotienko O, 1999, BIOCHEMISTRY-US, V38, P16766, DOI 10.1021/bi991039n; Shamotienko OG, 1997, BIOCHEMISTRY-US, V36, P8195, DOI 10.1021/bi970237g; Shi GY, 1996, NEURON, V16, P843, DOI 10.1016/S0896-6273(00)80104-X; Smith LA, 1997, BIOCHEMISTRY-US, V36, P7690, DOI 10.1021/bi963105g; STANSFELD CE, 1986, NEUROSCI LETT, V64, P299, DOI 10.1016/0304-3940(86)90345-9; STOCKER M, 1991, P ROY SOC B-BIOL SCI, V245, P101, DOI 10.1098/rspb.1991.0094; STUHMER W, 1989, EMBO J, V8, P3235, DOI 10.1002/j.1460-2075.1989.tb08483.x; TYTGAT J, 1995, J BIOL CHEM, V270, P24776, DOI 10.1074/jbc.270.42.24776; Varshney A, 2000, NEUROREPORT, V11, P2913, DOI 10.1097/00001756-200009110-00017; Wang FC, 1999, EUR J BIOCHEM, V263, P230, DOI 10.1046/j.1432-1327.1999.00493.x; Wang FC, 1999, EUR J BIOCHEM, V263, P222, DOI 10.1046/j.1432-1327.1999.00494.x; Wang H, 1995, NEURON, V15, P1337, DOI 10.1016/0896-6273(95)90012-8; Yu WF, 1996, NEURON, V16, P441, DOI 10.1016/S0896-6273(00)80062-8	42	35	37	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 10	2002	277	19					16376	16382		10.1074/jbc.M109698200	http://dx.doi.org/10.1074/jbc.M109698200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	551MB	11859070	hybrid			2022-12-27	WOS:000175564500006
J	Hsu, YY; Wang, YH				Hsu, YY; Wang, YH			Human fragile site FRA16B DNA excludes nucleosomes in the presence of distamycin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROOVE BINDING LIGANDS; MENTAL-RETARDATION; CORE PARTICLES; CGG REPEAT; X SYNDROME; SEQUENCE; INSTABILITY; CHROMATIN; ALTER; RECONSTITUTION	Human fragile sites are weak staining gaps in chromosomes generated by specific culture conditions. The short CGG repeating DNA derived from folate-sensitive fragile sites has been shown to exclude single nucleosomes. To test whether this nucleosome exclusion model provides a general molecular mechanism for the formation of fragile sites, a different class of fragile site, the 33-base pair AT-rich repeating DNAs derived from the rare distamycin-inducible site, FRA16B, was examined for its ability to assemble single nucleosomes and nucleosome arrays using in vitro nucleosome reconstitution methods. The FRA16B DNA fragments strongly exclude nucleosome assembly only in the presence of distamycin, and increasing the number of 33-bp repeats increases the effect of distamycin in the destabilization of the nucleosome formation, suggesting a common mechanism for the formation of fragile sites.	Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Biochem, Piscataway, NJ 08854 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center	Wang, YH (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Biochem, Piscataway, NJ 08854 USA.				NCI NIH HHS [CA85826, R01 CA085826] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA085826] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABUDAYA A, 1995, NUCLEIC ACIDS RES, V23, P3385, DOI 10.1093/nar/23.17.3385; Brown PM, 1996, J MOL BIOL, V262, P671, DOI 10.1006/jmbi.1996.0544; Bulger M., 1994, METH MOL G, V5, P241; Chen FM, 1998, BIOCHEMISTRY-US, V37, P11143, DOI 10.1021/bi980950l; CHURCHILL MEA, 1990, BIOCHEMISTRY-US, V29, P6043, DOI 10.1021/bi00477a023; COLL M, 1987, P NATL ACAD SCI USA, V84, P8385, DOI 10.1073/pnas.84.23.8385; DEKABAN A, 1965, J NUCL MED, V6, P740; FOX KR, 1984, NUCLEIC ACIDS RES, V12, P9271, DOI 10.1093/nar/12.24.9271; FU YH, 1991, CELL, V67, P1047, DOI 10.1016/0092-8674(91)90283-5; Godde JS, 1996, J BIOL CHEM, V271, P24325, DOI 10.1074/jbc.271.40.24325; HSIEH CH, 1988, CELL, V52, P535, DOI 10.1016/0092-8674(88)90466-7; JONES C, 1995, NATURE, V376, P145, DOI 10.1038/376145a0; KAS E, 1989, J MOL BIOL, V210, P587, DOI 10.1016/0022-2836(89)90134-4; Kirkpatrick DT, 1999, MOL CELL BIOL, V19, P7661; KLEVIT RE, 1986, BIOCHEMISTRY-US, V25, P3296, DOI 10.1021/bi00359a032; KNIGHT SJL, 1993, CELL, V74, P127, DOI 10.1016/0092-8674(93)90300-F; KREMER EJ, 1991, SCIENCE, V252, P1711, DOI 10.1126/science.1675488; LeRoy G, 2000, J BIOL CHEM, V275, P14787, DOI 10.1074/jbc.C000093200; LOW CML, 1986, NUCLEIC ACIDS RES, V14, P6785, DOI 10.1093/nar/14.17.6785; Loyola A, 2001, GENE DEV, V15, P2837; Mann DB, 1997, P NATL ACAD SCI USA, V94, P2215, DOI 10.1073/pnas.94.6.2215; NANCARROW JK, 1994, SCIENCE, V264, P1938, DOI 10.1126/science.8009225; PARRISH JE, 1994, NAT GENET, V8, P229, DOI 10.1038/ng1194-229; POPESCU NC, 1994, CRIT REV ONCOGENESIS, V5, P121, DOI 10.1615/CritRevOncog.v5.i2-3.20; PORTUGAL J, 1987, NUCLEIC ACIDS RES, V15, P885, DOI 10.1093/nar/15.3.885; PORTUGAL J, 1987, FEBS LETT, V225, P195, DOI 10.1016/0014-5793(87)81156-0; PORTUGAL J, 1986, NUCLEIC ACIDS RES, V14, P8735, DOI 10.1093/nar/14.22.8735; SUTHERLAND GR, 1991, GENET ANAL-BIOMOL E, V8, P161, DOI 10.1016/1050-3862(91)90056-W; SUTHERLAND GR, 1984, AM J HUM GENET, V36, P110; VANDYKE MW, 1982, P NATL ACAD SCI-BIOL, V79, P5470; VERKERK AJMH, 1991, CELL, V65, P905, DOI 10.1016/0092-8674(91)90397-H; WANG YH, 1995, GENOMICS, V25, P570, DOI 10.1016/0888-7543(95)80061-P; Wang YH, 1996, P NATL ACAD SCI USA, V93, P8863, DOI 10.1073/pnas.93.17.8863; Wang YH, 1996, J BIOL CHEM, V271, P22937, DOI 10.1074/jbc.271.38.22937; Wang YH, 1996, J MOL BIOL, V263, P511, DOI 10.1006/jmbi.1996.0593; Wilke CM, 1996, HUM MOL GENET, V5, P187, DOI 10.1093/hmg/5.2.187; Yu S, 1997, CELL, V88, P367, DOI 10.1016/S0092-8674(00)81875-9	37	24	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 10	2002	277	19					17315	17319		10.1074/jbc.M200901200	http://dx.doi.org/10.1074/jbc.M200901200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	551MB	11880377	hybrid			2022-12-27	WOS:000175564500127
J	Lin, TH; Lai, HL; Kao, YY; Sun, CN; Hwang, MJ; Chern, YJ				Lin, TH; Lai, HL; Kao, YY; Sun, CN; Hwang, MJ; Chern, YJ			Protein kinase C inhibits type VI adenylyl cyclase by phosphorylating the regulatory N domain and two catalytic C1 and C2 domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IN-VIVO; RECEPTOR; BINDING; DESENSITIZATION; IDENTIFICATION; ACTIVATION; REGION; SITES	We previously showed that phosphorylation of Ser(10) of the N terminus domain of the type VI adenylyl cyclase (ACVI) partly mediated protein kinase C (PKC)-induced inhibition of ACVI. We now report that phosphorylation of the other two cytosolic domains (C1 and C2), which form the catalytic core complex of ACVI, also contributes to PKC-mediated inhibition. In vitro phosphorylation by PKC of the recombinant C1a and C2 domains, and of the synthetic peptides representing potential PKC phosphorylation sites, suggests that Ser(568) and Ser(674) of the C1 domain and Thr(931) of the C2 domain might act as substrates for PKC. We next created several full-length ACVI mutants in which one or more of the four likely PKC phosphorylation sites (Ser(10), Ser(568), Ser(674), and Thr(931)) were mutated to alanine. Simultaneous mutation of at least two of the three likely residues located in the N and C1 domains (Ser(10), Ser(568), and Ser(674)) was required to render ACVI variants completely insensitive to PKC treatment. In contrast, a single mutation of Thr(931) was sufficient to create a functional ACVI mutant that exhibited no detectable PKC-mediated inhibition, demonstrating the essentiality of Thr(931), to PKC-mediated regulation. Based on these results, we propose that the three cytosolic domains of ACVI might form a regulatory complex. Phosphorylation of this regulatory complex at different sites might induce a fine-tuning of the catalytic core complex and subsequently lead to alternation in the catalytic activity of ACVI.	Acad Sinica, Inst Biomed Sci, Taipei 115, Taiwan; Chung Shan Med Univ, Dept Life Sci, Taichung 402, Taiwan; Natl Yang Ming Univ, Inst Neurosci, Taipei 112, Taiwan	Academia Sinica - Taiwan; Chung Shan Medical University; National Yang Ming Chiao Tung University	Chern, YJ (corresponding author), Acad Sinica, Inst Biomed Sci, Taipei 115, Taiwan.		chern, yijuang/S-7013-2018; Hwang, Ming-jing/E-9210-2012	chern, yijuang/0000-0002-5842-5429; Hwang, Ming-jing/0000-0002-9657-5663; Lin, Ting-Hui/0000-0001-9669-362X				Bol GF, 1997, BIOCHEM BIOPH RES CO, V237, P251, DOI 10.1006/bbrc.1997.7123; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chen YB, 1997, P NATL ACAD SCI USA, V94, P14100, DOI 10.1073/pnas.94.25.14100; CHERN YJ, 1993, MOL PHARMACOL, V44, P950; CHERN YJ, 1995, MOL PHARMACOL, V48, P1; Chern YJ, 2000, CELL SIGNAL, V12, P195, DOI 10.1016/S0898-6568(99)00084-4; Dessauer CW, 1998, J BIOL CHEM, V273, P25831, DOI 10.1074/jbc.273.40.25831; GLANTZ SA, 1997, PRIMER BIOSTATISTICS, P99; GRAFF JM, 1989, J BIOL CHEM, V264, P2818; Gu C, 1999, J BIOL CHEM, V274, P8012, DOI 10.1074/jbc.274.12.8012; Gu C, 2001, CURR BIOL, V11, P185, DOI 10.1016/S0960-9822(01)00044-6; HONEGGER A, 1988, EMBO J, V7, P3053, DOI 10.1002/j.1460-2075.1988.tb03170.x; IWAMI G, 1995, J BIOL CHEM, V270, P12481, DOI 10.1074/jbc.270.21.12481; KAWABE J, 1994, J BIOL CHEM, V269, P16554; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lai HL, 1997, J BIOL CHEM, V272, P4970, DOI 10.1074/jbc.272.8.4970; Lai HL, 1999, MOL PHARMACOL, V56, P644, DOI 10.1124/mol.56.3.644; LEVIN LR, 1995, J BIOL CHEM, V270, P7573, DOI 10.1074/jbc.270.13.7573; Liu FC, 1998, FEBS LETT, V436, P92, DOI 10.1016/S0014-5793(98)01098-9; LUSCHER B, 1990, NATURE, V344, P517, DOI 10.1038/344517a0; Miyakawa Y, 2000, J BIOL CHEM, V275, P32214, DOI 10.1074/jbc.M005080200; Parent CA, 2002, J BIOL CHEM, V277, P1354, DOI 10.1074/jbc.M106430200; PATERSON JM, 1995, BIOCHEM BIOPH RES CO, V214, P1000, DOI 10.1006/bbrc.1995.2385; PREMONT RT, 1992, P NATL ACAD SCI USA, V89, P9809, DOI 10.1073/pnas.89.20.9809; Tan CM, 2001, BIOCHEMISTRY-US, V40, P1702, DOI 10.1021/bi0015818; TAUSSIG R, 1995, J BIOL CHEM, V270, P1, DOI 10.1074/jbc.270.1.1; Tesmer JJG, 1997, SCIENCE, V278, P1907, DOI 10.1126/science.278.5345.1907; Wayman GA, 1996, MOL CELL BIOL, V16, P6075; Wei J, 1996, J BIOL CHEM, V271, P24231, DOI 10.1074/jbc.271.39.24231; Weitmann S, 1999, BIOCHEMISTRY-US, V38, P3409, DOI 10.1021/bi982229l; Wu GC, 2001, J BIOL CHEM, V276, P35450, DOI 10.1074/jbc.M009704200; Yan SZ, 1998, MOL PHARMACOL, V53, P182, DOI 10.1124/mol.53.2.182; Yan SZ, 2001, J BIOL CHEM, V276, P8500, DOI 10.1074/jbc.M010361200; Yan SZ, 1996, J BIOL CHEM, V271, P10941, DOI 10.1074/jbc.271.18.10941	35	35	37	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 3	2002	277	18					15721	15728		10.1074/jbc.M111537200	http://dx.doi.org/10.1074/jbc.M111537200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	550PA	11877398	hybrid			2022-12-27	WOS:000175510400068
J	Chuang, JZ; Zhou, H; Zhu, M; Li, SH; Li, XJ; Sung, CH				Chuang, JZ; Zhou, H; Zhu, M; Li, SH; Li, XJ; Sung, CH			Characterization of a brain-enriched chaperone, MRJ, that inhibits huntingtin aggregation and toxicity independently	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI DNAJ; NEURONAL INTRANUCLEAR INCLUSIONS; N-TERMINAL HUNTINGTIN; HEAT-SHOCK PROTEINS; MOLECULAR CHAPERONES; NEGATIVE REGULATION; CULTURED NEURONS; STRIATAL NEURONS; ATPASE ACTIVITY; HUMAN HOMOLOG	Molecular chaperones are involved in a wide range of cellular events, such as protein folding and oligomeric protein complex assembly. DnaK- and DnaJ-Iike proteins are the two major classes of molecular chaperones in mammals. Recent studies have shown that DnaJ-Iike family proteins can inhibit polyglutamine aggregation, a hallmark of many neurodegenerative diseases, including Huntington's disease (HD). Although most DnaJ-Iike proteins studied are ubiquitously expressed, some have restricted expression, so it is possible that some specific chaperones may affect polyglutamine aggregation in specific neurons. In this report, we describe the isolation of a DnaJ-Iike protein MRJ and the characterization of its chaperone activity. Tissue distribution studies showed that MRJ is highly enriched in the central nervous system. In an in vitro cell model of HD, over-expressed MRJ effectively suppressed polyglutamine-dependent protein aggregation, caspase activity, and cellular toxicity. Collectively, these results suggest that MRJ has a relevant functional role in neurons.	Cornell Univ, Weill Med Coll, Margaret M Dyson Vis Res Inst, Dept Ophthalmol, New York, NY 10021 USA; Cornell Univ, Weill Med Coll, Dept Cell Biol & Anat, New York, NY 10021 USA; Emory Univ, Dept Human Genet, Atlanta, GA 30322 USA	Cornell University; Cornell University; Emory University	Sung, CH (corresponding author), Cornell Univ, Weill Med Coll, Margaret M Dyson Vis Res Inst, Dept Ophthalmol, 1300 York Ave,LC313, New York, NY 10021 USA.	chsung@mail.med.cornell.edu			NEI NIH HHS [R01 EY011307, EY11307] Funding Source: Medline; NIA NIH HHS [AG19206] Funding Source: Medline; NINDS NIH HHS [NS41449] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY011307] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG019206] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BARBE MF, 1988, SCIENCE, V241, P1817, DOI 10.1126/science.3175623; Becher MW, 1998, NEUROBIOL DIS, V4, P387, DOI 10.1006/nbdi.1998.0168; Beere HM, 2000, NAT CELL BIOL, V2, P469, DOI 10.1038/35019501; Berruti G, 1998, EXP CELL RES, V239, P430, DOI 10.1006/excr.1997.3879; BRIGHTMAN SE, 1995, GENE, V153, P249, DOI 10.1016/0378-1119(94)00741-A; Chai YH, 1999, J NEUROSCI, V19, P10338; CHEETHAM ME, 1992, BIOCHEM J, V284, P469, DOI 10.1042/bj2840469; CHUANG JZ, 1995, J CELL BIOL, V128, P1095, DOI 10.1083/jcb.128.6.1095; Chuang JZ, 1999, J NEUROSCI, V19, P2919; Cooper JK, 1998, HUM MOL GENET, V7, P783, DOI 10.1093/hmg/7.5.783; Cummings CJ, 1998, NAT GENET, V19, P148, DOI 10.1038/502; CYR DM, 1994, TRENDS BIOCHEM SCI, V19, P176, DOI 10.1016/0968-0004(94)90281-X; Davies SW, 1997, CELL, V90, P537, DOI 10.1016/S0092-8674(00)80513-9; Davis AR, 1998, INT J BIOCHEM CELL B, V30, P1203, DOI 10.1016/S1357-2725(98)00091-0; DiFiglia M, 1997, SCIENCE, V277, P1990, DOI 10.1126/science.277.5334.1990; FERRANTE RJ, 1985, SCIENCE, V230, P561, DOI 10.1126/science.2931802; GAESTEL M, 1993, GENE, V128, P279, DOI 10.1016/0378-1119(93)90575-N; Genevaux P, 2001, J BIOL CHEM, V276, P7906, DOI 10.1074/jbc.M003855200; GRAVELAND GA, 1985, SCIENCE, V227, P770, DOI 10.1126/science.3155875; Greene MK, 1998, P NATL ACAD SCI USA, V95, P6108, DOI 10.1073/pnas.95.11.6108; Gutekunst CA, 1999, J NEUROSCI, V19, P2522; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; HICKEY E, 1986, NUCLEIC ACIDS RES, V14, P4127, DOI 10.1093/nar/14.10.4127; Holmberg M, 1998, HUM MOL GENET, V7, P913, DOI 10.1093/hmg/7.5.913; Hunter PJ, 1999, DEVELOPMENT, V126, P1247; Igarashi S, 1998, NAT GENET, V18, P111, DOI 10.1038/ng0298-111; INGOLIA TD, 1982, P NATL ACAD SCI-BIOL, V79, P2360, DOI 10.1073/pnas.79.7.2360; Izawa I, 2000, J BIOL CHEM, V275, P34521, DOI 10.1074/jbc.M003492200; Jana NR, 2000, HUM MOL GENET, V9, P2009, DOI 10.1093/hmg/9.13.2009; KAJIWARA K, 1993, NAT GENET, V3, P208, DOI 10.1038/ng0393-208; KATO K, 1994, J BIOL CHEM, V269, P15302; Kazemi-Esfarjani P, 2000, SCIENCE, V287, P1837, DOI 10.1126/science.287.5459.1837; KLEMENZ R, 1991, P NATL ACAD SCI USA, V88, P3652, DOI 10.1073/pnas.88.9.3652; Lee DH, 1996, MOL CELL BIOL, V16, P4773; Li CY, 2000, J BIOL CHEM, V275, P25665, DOI 10.1074/jbc.M906383199; Li H, 2000, NAT GENET, V25, P385, DOI 10.1038/78054; Li M, 1998, ANN NEUROL, V44, P249, DOI 10.1002/ana.410440216; Li SH, 1999, J NEUROSCI, V19, P5159; Li SH, 1998, HUM MOL GENET, V7, P777, DOI 10.1093/hmg/7.5.777; LIBEREK K, 1991, P NATL ACAD SCI USA, V88, P2874, DOI 10.1073/pnas.88.7.2874; LOWENSTEIN DH, 1991, NEURON, V7, P1053, DOI 10.1016/0896-6273(91)90349-5; Martindale D, 1998, NAT GENET, V18, P150, DOI 10.1038/ng0298-150; Minami Y, 1996, J BIOL CHEM, V271, P19617, DOI 10.1074/jbc.271.32.19617; MOLDAY RS, 1987, INVEST OPHTH VIS SCI, V28, P50; Mosser DD, 2000, MOL CELL BIOL, V20, P7146, DOI 10.1128/MCB.20.19.7146-7159.2000; OH S, 1993, BIOCHIM BIOPHYS ACTA, V1174, P114, DOI 10.1016/0167-4781(93)90104-L; OHTSUKA K, 1993, BIOCHEM BIOPH RES CO, V197, P235, DOI 10.1006/bbrc.1993.2466; Pandey P, 2000, EMBO J, V19, P4310, DOI 10.1093/emboj/19.16.4310; Paulson HL, 1997, NEURON, V19, P333, DOI 10.1016/S0896-6273(00)80943-5; RAABE T, 1991, NUCLEIC ACIDS RES, V19, P6645, DOI 10.1093/nar/19.23.6645; RORDORF G, 1991, NEURON, V7, P1043, DOI 10.1016/0896-6273(91)90348-4; SADIS S, 1992, BIOCHEMISTRY-US, V31, P9406, DOI 10.1021/bi00154a012; Saleh A, 2000, NAT CELL BIOL, V2, P476, DOI 10.1038/35019510; Saudou F, 1998, CELL, V95, P55, DOI 10.1016/S0092-8674(00)81782-1; SCIDMORE MA, 1993, MOL BIOL CELL, V4, P1145, DOI 10.1091/mbc.4.11.1145; Seki N, 1999, J HUM GENET, V44, P185, DOI 10.1007/s100380050139; Skinner PJ, 1997, NATURE, V389, P971, DOI 10.1038/40153; Szabo A, 1996, EMBO J, V15, P408, DOI 10.1002/j.1460-2075.1996.tb00371.x; Tavaria M, 1996, CELL STRESS CHAPERON, V1, P23, DOI 10.1379/1466-1268(1996)001<0023:AHSGTT>2.3.CO;2; VONSATTEL JP, 1985, J NEUROPATH EXP NEUR, V44, P559, DOI 10.1097/00005072-198511000-00003; WALL D, 1994, J BIOL CHEM, V269, P5446; Warrick JM, 1999, NAT GENET, V23, P425, DOI 10.1038/70532; Wyttenbach A, 2000, P NATL ACAD SCI USA, V97, P2898, DOI 10.1073/pnas.97.6.2898; Yaglom JA, 1996, MOL CELL BIOL, V16, P3679; Yamamoto A, 2000, CELL, V101, P57, DOI 10.1016/S0092-8674(00)80623-6; Zhou H, 2001, J BIOL CHEM, V276, P48417, DOI 10.1074/jbc.M104140200	66	86	95	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 31	2002	277	22					19831	19838		10.1074/jbc.M109613200	http://dx.doi.org/10.1074/jbc.M109613200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	557EH	11896048	hybrid			2022-12-27	WOS:000175894800078
J	Shainoff, JR; Smejkal, GB; DiBello, PM; Sung, SS; Bush, LA; Di Cera, E				Shainoff, JR; Smejkal, GB; DiBello, PM; Sung, SS; Bush, LA; Di Cera, E			Allosteric effects potentiating the release of the second fibrinopeptide a from fibrinogen by thrombin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SLOW->FAST TRANSITION; POLYMERIZATION SITE; BINDING-SITES; IDENTIFICATION; INTERMEDIATE; MOLECULES; CLEAVAGE; CHAIN; FORMS	Fibrin formation depends on the release of the two N-terminal fibrinopeptides A (FPA) from fibrinogen, and its formation is accompanied by an intermediate, alpha-profibrin, which lacks only one of the FPA. In this study, we confirm that the maximal levels of alpha-profibrin found over the course of thrombin reactions with human fibrinogen are only half of what would be expected if the first and second FPA were being released independently with equal rate constants. The rapidity of release of the fibrinopeptides by thrombin had been shown to depend on an allosteric transformation that is induced when Na+ binds to a site defined by the 215-227 residues of thrombin, a transformation that results in the exposure of its fibrinogen-binding exosites transforming the thrombin from a slow to a fast acting form toward fibrinogen. When choline was substituted for sodium to transform thrombin to its slow form, the maximal levels of alpha-profibrin rose to those expected for independent release of the two FPA. Thus, it is only the fast thrombin that releases the second FPA fast, and that fast release only occurs when both FPA are present because of a partial coupling of its release with that of the first FPA. The release of the FPA from purified alpha-profibrin with the first FPA already missing is no faster than the release of any FPA. Surprisingly, we also found that slow thrombin became increasingly transformed to a fast form in the absence of sodium when the fibrinogen was elevated to high concentrations. This potentiation by concentrated fibrinogen also occurs with the recombinant mutant thrombin (Y225P), which is otherwise slow in both the presence and absence of Na+. The potentiation of thrombin by fibrinogen must be short-lived so that the thrombin reverts to its slow acting form in the interim among encounters with other fibrinogen molecules in dilute fibrinogen solutions lacking Na+, whereas at high fibrinogen concentrations the thrombin encounters other molecules before it reverts back to the slow form.	Cleveland State Univ, Dept Chem, Cleveland, OH 44115 USA; Washington Univ, Sch Med, Dept Biochem & Mol Biophys, St Louis, MO 63110 USA	Cleveland State University; Washington University (WUSTL)	Shainoff, JR (corresponding author), Cleveland State Univ, Dept Chem, 2351 Euclid Ave, Cleveland, OH 44115 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL049413, R01HL060896, R01HL049413, R01HL016361, R01HL058141] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL60896, HL58141, HL16361, HL49413] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AYALA YH, 1994, J MOL BIOL, V235, P733, DOI 10.1006/jmbi.1994.1024; BAILEY K, 1951, NATURE, V167, P233, DOI 10.1038/167233a0; BLOMBACK B, 1972, J BIOL CHEM, V247, P1496; BUCALA R, 1984, P NATL ACAD SCI-BIOL, V81, P105, DOI 10.1073/pnas.81.1.105; Dang QD, 1996, P NATL ACAD SCI USA, V93, P10653, DOI 10.1073/pnas.93.20.10653; Dang QD, 1997, NAT BIOTECHNOL, V15, P146, DOI 10.1038/nbt0297-146; DEMPFLE CE, 1993, BLOOD COAGUL FIBRIN, V4, P79, DOI 10.1097/00001721-199304010-00013; GLADNER JA, 1959, J BIOL CHEM, V234, P62; GUINTO ER, 1995, P NATL ACAD SCI USA, V92, P11185, DOI 10.1073/pnas.92.24.11185; HURLETJENSEN A, 1982, THROMB RES, V27, P419, DOI 10.1016/0049-3848(82)90059-7; LAUDANO AP, 1980, BIOCHEMISTRY-US, V19, P1013, DOI 10.1021/bi00546a028; LORAND L, 1951, NATURE, V167, P992, DOI 10.1038/167992a0; MARSHALL AG, 1978, BIOPHYSICAL CHEM PRI, P281; MATHUR A, 1993, BIOCHEMISTRY-US, V32, P7568, DOI 10.1021/bi00080a031; Meh DA, 1996, J BIOL CHEM, V271, P23121, DOI 10.1074/jbc.271.38.23121; MEH DA, 1995, J LAB CLIN MED, V125, P384; MIYATA T, 1987, J BIOCHEM-TOKYO, V102, P93, DOI 10.1093/oxfordjournals.jbchem.a122046; NASKI MC, 1990, J BIOL CHEM, V265, P1401; OLEXA SA, 1981, J BIOL CHEM, V256, P3544; Shainoff JR, 1996, J BIOL CHEM, V271, P24129, DOI 10.1074/jbc.271.39.24129; SHAINOFF JR, 1983, ANN NY ACAD SCI, V408, P254, DOI 10.1111/j.1749-6632.1983.tb23249.x; SHAINOFF JR, 1962, J EXP MED, V116, P687, DOI 10.1084/jem.116.5.687; Shainoff JR, 2001, ANN NY ACAD SCI, V936, P147; Shainoff JR, 2001, THROMB RES, V101, P91, DOI 10.1016/S0049-3848(00)00383-2; SHAINOFF JR, 1993, AD ELECTROP, V6, P61; Spraggon G, 1997, NATURE, V389, P455, DOI 10.1038/38947; Vindigni A, 1996, BIOCHEMISTRY-US, V35, P4417, DOI 10.1021/bi952834d; WEISEL JW, 1986, BIOPHYS J, V50, P1079, DOI 10.1016/S0006-3495(86)83552-4; Yang Z, 2001, BIOCHEMISTRY-US, V40, P12515, DOI 10.1021/bi011394p	29	5	5	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 31	2002	277	22					19367	19373		10.1074/jbc.M108804200	http://dx.doi.org/10.1074/jbc.M108804200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	557EH	11891217	hybrid			2022-12-27	WOS:000175894800018
J	Yu, CF; Liu, ZX; Cantley, LG				Yu, CF; Liu, ZX; Cantley, LG			ERK negatively regulates the epidermal growth factor-mediated interaction of Gab1 and the phosphatidylinositol 3-kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; RECEPTOR TYROSINE KINASE; EPITHELIAL MORPHOGENESIS; PHOSPHOINOSITIDE 3-KINASE; NEURITE OUTGROWTH; DOCKING PROTEIN; PC12 CELLS; C-MET; BINDING; SHP2	We have examined the ability of epidermal growth factor (EGF)-stimulated ERK activation to regulate Grb2-associated binder-1 (Gab1)/phosphatidylinositol 3-kinase (PI3K) interactions. Inhibiting ERK activation with the MEK inhibitor U0126 increased the EGF-stimulated association of Gab1 with either full-length glutathione S-transferase-p85 or the p85 C-terminal Src homology 2 (SH2) domain, a result reproduced by co-immunoprecipitation of the native proteins from intact cells. This increased association of Gab1 and the PI3K correlates with an increase in PI3K activity and greater phosphorylation of Akt. This result is in direct contrast to what we have previously reported following HGF stimulation where MEK inhibition decreased the HGF-stimulated association of Gab1 and p85. In support of this divergent effect of ERK on Gab1/PI3K association following HGF and EGF stimulation, U0126 decreased the HGF-stimulated association of p85 and the Gab1 c-Met binding domain but did not alter the EGF-stimulated association of p85 and the c-Met binding domain. An examination of the mechanism of this effect revealed that the treatment of cells with EGF + U0126 increased the tyrosine phosphorylation of Gab1 as well as its association with another SH2-containing protein, SHP2. Furthermore, overexpression of a catalytically inactive form of SHP2 or pretreatment with pervanadate markedly increased EGF-stimulated Gab1 tyrosine phosphorylation. These experiments demonstrate that EGF and HGF-mediated ERK activation result in divergent effects on Gab1/PI3K signaling. HGF-stimulated ERK activation increases the Gab1/PI3K association, whereas EGF-stimulated ERK activation results in a decrease in the tyrosine phosphorylation of Gab1 and a decreased association with the PI3K. SHP2 is shown to associate with and dephosphorylate Gab1, suggesting that EGF-stimulated ERK might act through the regulation of SHP2.	Yale Univ, Sch Med, Dept Internal Med, Nephrol Sect, New Haven, CT 06520 USA	Yale University	Yu, CF (corresponding author), Yale Univ, Sch Med, Dept Internal Med, Nephrol Sect, 333 Cedar St,LMP 2093, New Haven, CT 06520 USA.	chengfang.yu@yale.edu			NIDDK NIH HHS [DK54911] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054911] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; BARROS EJG, 1995, P NATL ACAD SCI USA, V92, P4412, DOI 10.1073/pnas.92.10.4412; Cunnick JM, 2000, J BIOL CHEM, V275, P13842, DOI 10.1074/jbc.275.18.13842; Cunnick JM, 2001, J BIOL CHEM, V276, P24380, DOI 10.1074/jbc.M010275200; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; DERMAN MP, 1995, AM J PHYSIOL-RENAL, V268, pF1211, DOI 10.1152/ajprenal.1995.268.6.F1211; Fan SJ, 2001, MOL CELL BIOL, V21, P4968, DOI 10.1128/MCB.21.15.4968-4984.2001; Fixman ED, 1997, J BIOL CHEM, V272, P20167, DOI 10.1074/jbc.272.32.20167; Frevert EU, 1998, J BIOL CHEM, V273, P25480, DOI 10.1074/jbc.273.39.25480; HolgadoMadruga M, 1996, NATURE, V379, P560, DOI 10.1038/379560a0; Kameda H, 2001, MOL CELL BIOL, V21, P6895, DOI 10.1128/MCB.21.20.6895-6905.2001; Karihaloo A, 2001, J BIOL CHEM, V276, P9166, DOI 10.1074/jbc.M009963200; KIMURA K, 1994, J BIOL CHEM, V269, P18961; Korhonen JM, 1999, J BIOL CHEM, V274, P37307, DOI 10.1074/jbc.274.52.37307; Leevers SJ, 1996, EMBO J, V15, P6584, DOI 10.1002/j.1460-2075.1996.tb01049.x; Maroun CR, 1999, MOL CELL BIOL, V19, P1784; Nishida K, 1999, BLOOD, V93, P1809, DOI 10.1182/blood.V93.6.1809.406k35_1809_1816; RAUCHMAN MI, 1993, AM J PHYSIOL, V265, pF416, DOI 10.1152/ajprenal.1993.265.3.F416; Roshan B, 1999, J BIOL CHEM, V274, P36362, DOI 10.1074/jbc.274.51.36362; Schaeper U, 2000, J CELL BIOL, V149, P1419, DOI 10.1083/jcb.149.7.1419; Takahashi-Tezuka M, 1998, MOL CELL BIOL, V18, P4109, DOI 10.1128/MCB.18.7.4109; Weidner KM, 1996, NATURE, V384, P173, DOI 10.1038/384173a0; Yart A, 2001, J BIOL CHEM, V276, P8856, DOI 10.1074/jbc.M006966200; Yu CF, 2001, J BIOL CHEM, V276, P32552, DOI 10.1074/jbc.M104493200	24	113	116	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 31	2002	277	22					19382	19388		10.1074/jbc.M200732200	http://dx.doi.org/10.1074/jbc.M200732200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	557EH	11896055	hybrid			2022-12-27	WOS:000175894800020
J	Alliegro, MC; Alliegro, MA				Alliegro, MC; Alliegro, MA			Nuclear injection of anti-pigpen antibodies inhibits endothelial cell division	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANGIOGENESIS; AMILORIDE; PHENOTYPE	Endothelial cell proliferation is required for angiogenesis in both embryonic and adult tissues. In rat brain tumors, it has recently been shown that the nuclear protein pigpen is expressed selectively in endothelial cells of developing microvasculature but not in the established peritumoral vessels (Blank, M., Weinschenk, T., Priemer, M., and Schluesener, H. (2001) J. Biol. Chem. 276,16464-16468). This finding suggests that pigpen may be important for promoting the undifferentiated, or "angiogenic" endothelial cell phenotype. Our studies show that pigpen protein and mRNA are expressed in actively dividing endothelial cells and down-regulated as they become confluent. Protein distribution is regulated in a cell cycle-dependent manner. We conclude that this expression pattern is important for and not simply ancillary to proliferation because nuclear microinjection of anti-pigpen Fab fragments inhibited endothelial cell division. Moreover, expression of the proliferating cell marker Ki67 was inhibited in antibody-injected cells. The absence of Ki67 suggests exit from rather than arrest within (for example, at the G(1)/S interface) the cell cycle. Together with earlier observations on the structure and expression of this molecule, our data support the hypothesis that pigpen helps regulate endothelial cell differentiation state.	Louisiana State Univ, Hlth Sci Ctr, Dept Cell Biol & Anat, New Orleans, LA 70112 USA	Louisiana State University System; Louisiana State University Health Sciences Center New Orleans	Alliegro, MC (corresponding author), Louisiana State Univ, Hlth Sci Ctr, Dept Cell Biol & Anat, 1901 Perdido St, New Orleans, LA 70112 USA.							Alliegro MC, 1996, DEV BIOL, V174, P288, DOI 10.1006/dbio.1996.0074; Alliegro MC, 2001, CELL BIOL INT, V25, P577, DOI 10.1006/cbir.2000.0735; ALLIEGRO MC, 1993, J EXP ZOOL, V267, P245, DOI 10.1002/jez.1402670302; Blank M, 2001, J BIOL CHEM, V276, P16464, DOI 10.1074/jbc.M100347200; Boudreau N, 1997, J CELL BIOL, V139, P257, DOI 10.1083/jcb.139.1.257; FENSELAU A, 1976, CANCER RES, V36, P3269; FOLKMAN J, 1992, J BIOL CHEM, V267, P10931; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; Goding J., 1986, MONOCLONAL ANTIBODIE, P108; HLA T, 1995, BIOCHIM BIOPHYS ACTA, V260, P227; Kohler A, 1999, ANAT EMBRYOL, V200, P313, DOI 10.1007/s004290050282; OKEEFE RT, 1994, J CELL BIOL, V124, P249, DOI 10.1083/jcb.124.3.249; PANET R, 1986, BIOCHEM J, V239, P745, DOI 10.1042/bj2390745; Scholzen T, 2000, J CELL PHYSIOL, V182, P311, DOI 10.1002/(SICI)1097-4652(200003)182:3<311::AID-JCP1>3.0.CO;2-9	14	8	8	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 24	2002	277	21					19037	19041		10.1074/jbc.M200737200	http://dx.doi.org/10.1074/jbc.M200737200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	558PM	11886863	hybrid			2022-12-27	WOS:000175975800103
J	Anterola, AM; Jeon, JH; Davin, LB; Lewis, NG				Anterola, AM; Jeon, JH; Davin, LB; Lewis, NG			Transcriptional control of monolignol biosynthesis in Pinus taeda - Factors affecting monolignol ratios and carbon allocation in phenylpropanoid metabolism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CINNAMYL ALCOHOL-DEHYDROGENASE; PHENYLALANINE AMMONIA-LYASE; ALTERED LIGNIN COMPOSITION; COA REDUCTASE CCR; LOBLOLLY-PINE; METHYLATION PATHWAY; ARABIDOPSIS-THALIANA; MOLECULAR-CLONING; DOWN-REGULATION; ENZYME	Transcriptional profiling of the phenylpropanoid pathway in Pinus taeda cell suspension cultures was carried out using quantitative real time PCR analyses of all known genes involved in the biosynthesis of the two monolignols, p-coumaryl and coniferyl alcohols (lignin/ lignan precursors). When the cells were transferred to a medium containing 8% sucrose and 20 mm potassium iodide, the monolignol/phenylpropanoid pathway was induced, and transcript levels for phenylalanine ammonia lyase, cinnamate 4-hydroxylase, p-coumarate 3-hydroxylase, 4-coumarate:CoA ligase, caffeoyl-CoA O-methyltransferase, cinnamoyl-CoA reductase, and cinnamyl alcohol dehydrogenase were coordinately up-regulated. Provision of increasing levels of exogenously supplied Phe to saturating levels (40 mM) to the induction medium resulted in further up-regulation of their transcript levels in the P. taeda cell cultures; this in turn was accompanied by considerable increases in both p-coumaryl and coniferyl alcohol formation and excretion. By contrast, transcript levels for both cinnamate 4-hydroxylase and p-coumarate 3-hydroxylase were only slightly up-regulated. These data, when considered together with metabolic profiling results and genetic manipulation of various plant species, reveal that carbon allocation to the pathway and its differential distribution into the two monolignols is controlled by Phe supply and differential modulation of cinnamate 4-hydroxylase and p-coumarate 3-hydroxylase activities, respectively. The coordinated up-regulation of phenylalanine ammonia lyase, 4-coumarate:CoA ligase, caffeoyl-CoA O-methyltransferase, cinnnamoyl-CoA reductase and cinnamyl alcohol dehydrogenase in the presence of increasing concentrations of Phe also indicates that these steps are not truly rate-limiting, because they are modulated according to metabolic demand. Finally, the transcript profile of a putative acid/ester O-methyltransferase, proposed as an alternative catalyst for O-methylation leading to coniferyl alcohol, was not up-regulated under any of the conditions employed, suggesting that it is not, in fact, involved in monolignol biosynthesis.	Washington State Univ, Inst Biol Chem, Pullman, WA 99164 USA	Washington State University	Lewis, NG (corresponding author), Washington State Univ, Inst Biol Chem, Pullman, WA 99164 USA.	lewisn@wsu.edu		Davin, Laurence/0000-0002-3248-6485; Lewis, Norman/0000-0001-5742-032X				Anterola AM, 1999, BIOCHEM BIOPH RES CO, V261, P652, DOI 10.1006/bbrc.1999.1097; ANTEROLA AM, 2002, PHYTOCHEMISTRY; ATANASSOVA R, 1995, PLANT J, V8, P465, DOI 10.1046/j.1365-313X.1995.8040465.x; Baucher M, 1999, PLANT MOL BIOL, V39, P437, DOI 10.1023/A:1006182925584; Baucher M, 1998, CRIT REV PLANT SCI, V17, P125, DOI 10.1016/S0735-2689(98)00360-8; Chabannes M, 2001, PLANT J, V28, P257, DOI 10.1046/j.1365-313X.2001.01140.x; Coruzzi GM, 2001, CURR OPIN PLANT BIOL, V4, P247, DOI 10.1016/S1369-5266(00)00168-0; Croteau R., 2000, BIOCH MOL BIOL PLANT, P1250, DOI DOI 10.1201/B11003-3; DESTEVENS G, 1953, P NATL ACAD SCI USA, V39, P80; Douglas CJ, 1996, TRENDS PLANT SCI, V1, P171, DOI 10.1016/1360-1385(96)10019-4; EBERHARDT TL, 1993, J BIOL CHEM, V268, P21088; Franke R, 2002, PLANT J, V30, P47, DOI 10.1046/j.1365-313X.2002.01267.x; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; GOFFNER D, 1994, PLANT PHYSIOL, V106, P625, DOI 10.1104/pp.106.2.625; GOWRI G, 1991, PLANT PHYSIOL, V97, P7, DOI 10.1104/pp.97.1.7; GRIMAPETTENATI J, 1994, PHYTOCHEMISTRY, V37, P941, DOI 10.1016/S0031-9422(00)89508-4; GROSS GG, 1973, FEBS LETT, V31, P283, DOI 10.1016/0014-5793(73)80123-1; GROSS GG, 1975, FEBS LETT, V54, P259, DOI 10.1016/0014-5793(75)80087-1; Guo DG, 2001, TRANSGENIC RES, V10, P457, DOI 10.1023/A:1012278106147; HOLLAND PM, 1991, P NATL ACAD SCI USA, V88, P7276, DOI 10.1073/pnas.88.16.7276; Holton TA, 1996, METHOD ENZYMOL, V272, P275, DOI 10.1016/S0076-6879(96)72033-5; Hu WJ, 1999, NAT BIOTECHNOL, V17, P808, DOI 10.1038/11758; Jin HL, 2000, EMBO J, V19, P6150, DOI 10.1093/emboj/19.22.6150; JUNG HG, 1986, J ANIM SCI, V62, P1703, DOI 10.2527/jas1986.6261703x; Kajita S, 1996, PLANT CELL PHYSIOL, V37, P957, DOI 10.1093/oxfordjournals.pcp.a029045; KUTSUKI H, 1982, PHYTOCHEMISTRY, V21, P19, DOI 10.1016/0031-9422(82)80006-X; Lacombe E, 1997, PLANT J, V11, P429, DOI 10.1046/j.1365-313X.1997.11030429.x; Lauvergeat V, 2001, PHYTOCHEMISTRY, V57, P1187, DOI 10.1016/S0031-9422(01)00053-X; Lee D, 1997, PLANT CELL, V9, P1985, DOI 10.1105/tpc.9.11.1985; Lewis N.G., 1999, COMPR NAT PROD CHEM, V3, P617, DOI [10.1016/B978-0-08-091283-7.00085-0, DOI 10.1016/B978-0-08-091283-7.00085-0]; LEWIS NG, 1990, ANNU REV PLANT PHYS, V41, P455, DOI 10.1146/annurev.pp.41.060190.002323; Li LG, 1997, P NATL ACAD SCI USA, V94, P5461, DOI 10.1073/pnas.94.10.5461; Li LG, 1999, PLANT MOL BIOL, V40, P555, DOI 10.1023/A:1006244325250; Moller SG, 1999, J MOL BIOL, V293, P219, DOI 10.1006/jmbi.1999.2992; NOSE M, 1995, PHYTOCHEMISTRY, V39, P71, DOI 10.1016/0031-9422(95)95268-Y; OMALLEY DM, 1992, PLANT PHYSIOL, V98, P1364, DOI 10.1104/pp.98.4.1364; ROBERTS JC, 1996, CHEM PAPER, P161; RUSSELL DW, 1967, ARCH BIOCHEM BIOPHYS, V122, P257, DOI 10.1016/0003-9861(67)90150-6; Schoch G, 2001, J BIOL CHEM, V276, P36566, DOI 10.1074/jbc.M104047200; SCURFIELD G, 1973, SCIENCE, V179, P647, DOI 10.1126/science.179.4074.647; Sewalt VJH, 1997, PLANT PHYSIOL, V115, P41, DOI 10.1104/pp.115.1.41; Tamagnone L, 1998, PLANT CELL, V10, P135, DOI 10.1105/tpc.10.2.135; Tyagi S, 1996, NAT BIOTECHNOL, V14, P303, DOI 10.1038/nbt0396-303; van Rensburg H, 2000, ACS SYM SER, V742, P118; vanHeerden PS, 1996, J BIOL CHEM, V271, P12350, DOI 10.1074/jbc.271.21.12350; VOO KS, 1995, PLANT PHYSIOL, V108, P85, DOI 10.1104/pp.108.1.85; WARSHAW MM, 1970, BIOPOLYMERS, V9, P1079, DOI 10.1002/bip.1970.360090910; WESTING ARTHUR H., 1965, BOT REV, V31, P381, DOI 10.1007/BF02859131; WHETTEN RW, 1992, PLANT PHYSIOL, V98, P380, DOI 10.1104/pp.98.1.380; Whitbred JM, 2000, PLANT PHYSIOL, V124, P47, DOI 10.1104/pp.124.1.47; YE ZH, 1994, PLANT CELL, V6, P1427, DOI 10.1105/tpc.6.10.1427; Zhang XH, 1997, PLANT PHYSIOL, V113, P65, DOI 10.1104/pp.113.1.65; ZUCKER M, 1965, PLANT PHYSIOL, V40, P779, DOI 10.1104/pp.40.5.779	53	115	133	0	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 24	2002	277	21					18272	18280		10.1074/jbc.M112051200	http://dx.doi.org/10.1074/jbc.M112051200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	558PM	11891223	hybrid			2022-12-27	WOS:000175975800006
J	Dodon, MD; Hamaia, S; Martin, J; Gazzolo, L				Dodon, MD; Hamaia, S; Martin, J; Gazzolo, L			Heterogeneous nuclear ribonucleoprotein A1 interferes with the binding of the human T cell leukemia virus type 1 Rex regulatory protein to its response element	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXON SPLICING SILENCER; HTLV-I REX; MESSENGER-RNA; HNRNP A1; MAMMALIAN-CELLS; EXPORT SIGNAL; TRANSCRIPTION; VIVO; TRANSFORMATION; REQUIREMENTS	The human T cell leukemia virus, type 1 (HTLV-1), Rex protein mediates the nuclear export of unspliced and incompletely spliced viral mRNAs. This post-transcriptional activity is dependent in part on the binding of this protein to cis-regulatory sequences termed the Rex-response element (XRE). We have proposed previously that the decreased functionality exhibited by Rex in human lymphoblastoid Jurkat T cells may be linked to alterations in the Rex/XRE interactions. The analysis of the ribonucleoprotein complexes formed between Jurkat nuclear proteins and XRE-RNA led to the identification of a 36-kDa protein as heterogeneous nuclear ribonucleoprotein (hnRNP) A1. In vitro binding assays revealed that hnRNP A1 proteins were found to interfere with the binding of Rex to XRE, whereas nuclear extracts depleted of these proteins were unable to disrupt Rex-XRE complexes. Furthermore, A1 proteins from Jurkat cells were acting in a concentration-dependent manner, suggesting that the amount of these RNA-binding proteins is a critical parameter in controlling Rex activity. We indeed observed a lower level of hnRNP A1 in in vitro HTLV-1-transformed virus-producing T cells than that detected in Jurkat cells. Likewise, overexpression of hnRNP A1 proteins in 293T cells and in Jurkat cells led to a decrease in the expression of a reporter gene dependent on Rex/XRE interactions. Such a decrease was not observed when the expression of the same reporter gene by cells overexpressing hnRNP A1 was dependent on the interactions of human immunodeficiency virus Rev protein with the Rev-response element. These findings indicate that hnRNP A1 by competing with Rex for the formation of REX-XRE complexes is specifically involved in the modulation of the post-transcriptional activity of Rex.	Univ Lyon 1, Fac Med RTH Laennec, CNRS, UMR 5537, F-69372 Lyon 8, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Claude Bernard Lyon 1	Dodon, MD (corresponding author), INSERM, U412, 46 Allee Italie, F-69364 Lyon 07, France.		Martin, Juliette/N-5545-2016; Duc-Dodon, Madeleine/I-6580-2016; Martin, Juliette/T-9457-2019	Martin, Juliette/0000-0002-4787-0885; Martin, Juliette/0000-0002-4787-0885				ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; BALLAUN C, 1991, J VIROL, V65, P4408, DOI 10.1128/JVI.65.8.4408-4413.1991; BLACK AC, 1994, VIROLOGY, V200, P29, DOI 10.1006/viro.1994.1159; BLACK AC, 1995, J VIROL, V69, P6852, DOI 10.1128/JVI.69.11.6852-6858.1995; Bogerd HP, 1996, MOL CELL BIOL, V16, P4207; BOGERD HP, 1991, P NATL ACAD SCI USA, V88, P5704, DOI 10.1073/pnas.88.13.5704; BURD CG, 1994, EMBO J, V13, P1197, DOI 10.1002/j.1460-2075.1994.tb06369.x; CACERES JF, 1997, EUKARYOTIC MRNA PROC, P174; Caputi M, 1999, EMBO J, V18, P4060, DOI 10.1093/emboj/18.14.4060; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CULLEN BR, 1992, MICROBIOL REV, V56, P375, DOI 10.1128/MMBR.56.3.375-394.1992; Del Gatto-Konczak F, 1999, MOL CELL BIOL, V19, P251; Diaz JJ, 1996, NATURE, V379, P273, DOI 10.1038/379273a0; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DREYFUSS G, 1993, ANNU REV BIOCHEM, V62, P289, DOI 10.1146/annurev.bi.62.070193.001445; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; GAZDAR AF, 1980, BLOOD, V55, P409; GRASSMANN R, 1991, J VIROL, V65, P3721, DOI 10.1128/JVI.65.7.3721-3727.1991; GREEN PL, 1994, RETROVIRIDAE, V3, P277; GRONE M, 1994, VIROLOGY, V204, P144, DOI 10.1006/viro.1994.1518; Hamaia S, 1997, J VIROL, V71, P8514, DOI 10.1128/JVI.71.11.8514-8521.1997; HANLY SM, 1989, GENE DEV, V3, P1534, DOI 10.1101/gad.3.10.1534; HOPE TJ, 1991, J VIROL, V65, P6001, DOI 10.1128/JVI.65.11.6001-6007.1991; Izaurralde E, 1997, J CELL BIOL, V137, P27, DOI 10.1083/jcb.137.1.27; KILEDJIAN M, 1996, RNA PROTEIN INTERACT, P127; Li HP, 1997, P NATL ACAD SCI USA, V94, P9544, DOI 10.1073/pnas.94.18.9544; MICHAEL WM, 1995, CELL, V83, P415; MIYOSHI I, 1981, NATURE, V294, P770, DOI 10.1038/294770a0; Najera I, 1999, J MOL BIOL, V285, P1951, DOI 10.1006/jmbi.1998.2473; NEUMANN JR, 1987, BIOTECHNIQUES, V5, P444; Parslow Tristram G., 1993, P101; PINOLROMA S, 1992, NATURE, V355, P730, DOI 10.1038/355730a0; POPOVIC M, 1983, P NATL ACAD SCI-BIOL, V80, P5402, DOI 10.1073/pnas.80.17.5402; RIMSKY L, 1988, NATURE, V335, P738, DOI 10.1038/335738a0; Shi ST, 2000, EMBO J, V19, P4701, DOI 10.1093/emboj/19.17.4701; SHUKLA RR, 1994, J VIROL, V68, P2224, DOI 10.1128/JVI.68.4.2224-2229.1994; Si ZH, 1997, NUCLEIC ACIDS RES, V25, P861, DOI 10.1093/nar/25.4.861; Stade K, 1997, CELL, V90, P1041, DOI 10.1016/S0092-8674(00)80370-0; UNGE T, 1991, P NATL ACAD SCI USA, V88, P7145, DOI 10.1073/pnas.88.16.7145; WEICHSELBRAUN I, 1992, J VIROL, V66, P2583, DOI 10.1128/JVI.66.4.2583-2587.1992; YOSHIDA M, 1995, J CANCER RES CLIN, V121, P521, DOI 10.1007/BF01197764	41	16	18	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 24	2002	277	21					18744	18752		10.1074/jbc.M109087200	http://dx.doi.org/10.1074/jbc.M109087200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	558PM	11893730	hybrid			2022-12-27	WOS:000175975800067
J	Bauer, H; Kanzok, SM; Schirmer, RH				Bauer, H; Kanzok, SM; Schirmer, RH			Thioredoxin-2 but not thioredoxin-1 is a substrate of thioredoxin peroxidase-1 from Drosophila melanogaster - Isolation and characterization of a second thioredoxin in D-melanogaster and evidence for distinct biological functions of Trx-1 and Trx-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUTATHIONE-REDUCTASE; PLASMODIUM-FALCIPARUM; HYDROGEN-PEROXIDE; OXIDATIVE STRESS; ACTIVE-SITE; PEROXIREDOXIN; MECHANISM; MALARIA; SYSTEM; ERYTHROCYTES	As Drosophila melanogaster does not contain glutathione reductase, the thioredoxin system has a key function for glutathione disulfide reduction in insects (Kanzok, S. M., Fechner, A., Bauer, H., Ulschmid, J. K., Muller, H. M., Botella-Munoz, J., Schneuwly, S., Schirmer, R. H., and Becker, K. (2001) Science 291, 643-646). In view of these unique conditions, the protein systems participating in peroxide metabolism and in redox signaling are of special interest. The genes for a second thioredoxin (DmTrx-2) and a thioredoxin peroxidase (DmTPx-1) were cloned and expressed, and the proteins were characterized. In its disulfide form, the 13-kDa protein thioredoxin-2 is a substrate of thioredoxin reductase-1 (K-m=5.2 muM, k(cat)=14.5 s(-1)) and in its dithiol form, an electron donor for TPx-1 (K-m=9 muM, k(cat)=5.4 s(-1)). DmTrx-2 is capable of reducing glutathione disulfide with a second order rate constant of 170 M-1 s(-1) at pH 7.4 and 25degreesC. Western blot analysis indicated that this thioredoxin represents up to 1% of the extractable protein of D. melanogaster Schneider cells or whole fruit flies. Recombinant thioredoxin peroxidase-1 (subunit molecular mass=23 kDa) was found to be a decameric protein that can efficiently use Trx-2 but not Trx-1 as a reducing substrate. The new electron pathway found in D. melanogaster is also representative for insects that serve as vectors of disease. As a first step we have cloned and functionally expressed the gene that is the orthologue of DmTrx-2 in the malaria mosquito Anopheles gambiae.	Univ Heidelberg, Biochem Ctr, D-69120 Heidelberg, Germany	Ruprecht Karls University Heidelberg	Bauer, H (corresponding author), Univ Heidelberg, Biochem Ctr, Neuenheimer Feld 328, D-69120 Heidelberg, Germany.							Arner ESJ, 2000, EUR J BIOCHEM, V267, P6102, DOI 10.1046/j.1432-1327.2000.01701.x; Arscott LD, 1997, P NATL ACAD SCI USA, V94, P3621, DOI 10.1073/pnas.94.8.3621; Bae YS, 1997, J BIOL CHEM, V272, P217, DOI 10.1074/jbc.272.1.217; Becker K, 2000, EUR J BIOCHEM, V267, P6118, DOI 10.1046/j.1432-1327.2000.01703.x; CHAE HZ, 1994, J BIOL CHEM, V269, P27670; Davioud-Charvet E, 2001, J MED CHEM, V44, P4268, DOI 10.1021/jm010268g; Flohe L, 1999, FREE RADICAL BIO MED, V27, P966, DOI 10.1016/S0891-5849(99)00172-0; Fritsche G, 2001, J INFECT DIS, V183, P1388, DOI 10.1086/319860; GILBERT HF, 1995, METHOD ENZYMOL, V251, P8, DOI 10.1016/0076-6879(95)51107-5; Gromer S, 2002, METHOD ENZYMOL, V347, P382; HOLMGREN A, 1984, METHOD ENZYMOL, V107, P295; HOLMGREN A, 1985, ANNU REV BIOCHEM, V54, P237, DOI 10.1146/annurev.bi.54.070185.001321; HOLMGREN A, 1989, J BIOL CHEM, V264, P13963; HUNT NH, 1990, BLOOD CELLS, V16, P499; Kang SW, 1998, J BIOL CHEM, V273, P6297, DOI 10.1074/jbc.273.11.6297; Kanzok SM, 2001, SCIENCE, V291, P643, DOI 10.1126/science.291.5504.643; Kanzok SM, 2000, J BIOL CHEM, V275, P40180, DOI 10.1074/jbc.M007633200; Missirlis F, 2002, J BIOL CHEM, V277, P11521, DOI 10.1074/jbc.M111692200; Missirlis F, 2001, CURR BIOL, V11, P1272, DOI 10.1016/S0960-9822(01)00393-1; Nishinaka Y, 2001, REDOX REP, V6, P289, DOI 10.1179/135100001101536427; Nordberg J, 2001, FREE RADICAL BIO MED, V31, P1287, DOI 10.1016/S0891-5849(01)00724-9; PellicenaPalle A, 1997, MECH DEVELOP, V62, P61, DOI 10.1016/S0925-4773(96)00650-8; Radyuk SN, 2001, FREE RADICAL BIO MED, V31, P1090, DOI 10.1016/S0891-5849(01)00692-X; Rodriguez J, 2000, EUR J BIOCHEM, V267, P487, DOI 10.1046/j.1432-1327.2000.01022.x; Ross SJ, 2000, MOL BIOL CELL, V11, P2631, DOI 10.1091/mbc.11.8.2631; SALZ HK, 1994, GENETICS, V136, P1075; Sandalova T, 2001, P NATL ACAD SCI USA, V98, P9533, DOI 10.1073/pnas.171178698; Savvides SN, 2002, J BIOL CHEM, V277, P2779, DOI 10.1074/jbc.M108190200; SCHENK H, 1994, P NATL ACAD SCI USA, V91, P1672, DOI 10.1073/pnas.91.5.1672; SCHIRMER RH, 1995, ANGEW CHEM INT EDIT, V34, P141, DOI 10.1002/anie.199501411; Schroder E, 2000, STRUCTURE, V8, P605, DOI 10.1016/S0969-2126(00)00147-7; SOHAL RS, 1990, MECH AGEING DEV, V56, P223, DOI 10.1016/0047-6374(90)90084-S; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Wang PF, 1999, BIOCHEMISTRY-US, V38, P3187, DOI 10.1021/bi982674g; Williams CH, 2000, EUR J BIOCHEM, V267, P6110, DOI 10.1046/j.1432-1327.2000.01702.x; Williams Jr C. H., 1992, CHEM BIOCH FLAVOENZY, P121; Zhang P, 1997, J BIOL CHEM, V272, P30615, DOI 10.1074/jbc.272.49.30615; Zhong LW, 2000, P NATL ACAD SCI USA, V97, P5854, DOI 10.1073/pnas.100114897	38	67	77	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 17	2002	277	20					17457	17463		10.1074/jbc.M200636200	http://dx.doi.org/10.1074/jbc.M200636200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	553PR	11877442	hybrid			2022-12-27	WOS:000175685100011
J	Birolo, L; Dal Piaz, F; Pucci, P; Marino, G				Birolo, L; Dal Piaz, F; Pucci, P; Marino, G			Structural characterization of the M* partly folded intermediate of wild type and P138A aspartate aminotransferase from Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMIDE HYDROGEN-EXCHANGE; VIRUS NS3 PROTEASE; MASS-SPECTROMETRY; CONFORMATIONAL-CHANGES; LIMITED PROTEOLYSIS; SEMINAL RNASE; BINDING; COMPLEX; FLUORESCENCE; PROTEINS	A combination of spectroscopic techniques, hydrogen/deuterium exchange, and limited proteolysis experiments coupled to mass spectrometry analysis was used to depict the topology of the monomeric M* partly folded intermediate of aspartate aminotransferase from Escherichia coli in wild type (WT) as well as in a mutant form in which the highly conserved cis-proline at position 138 was replaced by a trans-alanine (P138A). Fluorescence analysis indicates that, although M* is an off-pathway intermediate in the folding of WT aspartate aminotransferase from E. coli, it seems to coincide with an on-pathway folding intermediate for the P138A mutant. Spectroscopic data, hydrogen/deuterium exchange, and limited proteolysis experiments demonstrated the occurrence of conformational differences between the two M* intermediates, with P138A-M* being conceivably more compact than WT-M*. Limited proteolysis data suggested that these conformational differences might be related to a different relative orientation of the small and large domains of the protein induced by the presence of the cis-proline residue at position 138. These differences between the two M* species indicated that in WT-M* Pro138 is in the cis conformation at this stage of the folding process. Moreover, hydrogen/deuterium exchange results showed the occurrence of few differences in the native N-2 forms of WT and P138A, the spectroscopic features and crystallographic structures of which are almost superimposable.	Univ Naples Federico II, Dipartimento Chim Organ & Biochim, I-80126 Naples, Italy	University of Naples Federico II	Birolo, L (corresponding author), Univ Naples Federico II, Dipartimento Chim Organ & Biochim, Complesso Univ Monte Sant Angelo,Via Cinthia, I-80126 Naples, Italy.		Dal Piaz, Fabrizio/D-1843-2010	Dal Piaz, Fabrizio/0000-0002-8643-5018; PUCCI, Pietro/0000-0002-5885-1495; BIROLO, Leila/0000-0002-0915-7501				Atkinson RA, 2000, BIOCHEMISTRY-US, V39, P5255, DOI 10.1021/bi991891u; BAI YW, 1993, PROTEINS, V17, P75, DOI 10.1002/prot.340170110; Bianchi E, 1999, BIOCHEMISTRY-US, V38, P13844, DOI 10.1021/bi991220w; Birolo L, 1999, BIOCHEMISTRY-US, V38, P905, DOI 10.1021/bi981467d; Chiti F, 2000, EMBO J, V19, P1441, DOI 10.1093/emboj/19.7.1441; De Lorenzo C, 1998, PROTEIN SCI, V7, P2653; Dobson Christopher M., 1999, Current Opinion in Structural Biology, V9, P92, DOI 10.1016/S0959-440X(99)80012-8; EFTINK MR, 1976, BIOCHEMISTRY-US, V15, P672, DOI 10.1021/bi00648a035; Engen JR, 1999, BIOCHEMISTRY-US, V38, P8926, DOI 10.1021/bi982611y; ENGLANDER SW, 1984, Q REV BIOPHYS, V16, P521; Esposito G, 2000, PROTEIN SCI, V9, P831, DOI 10.1110/ps.9.5.831; Halgand F, 1999, BIOCHEMISTRY-US, V38, P6025, DOI 10.1021/bi982412e; HEROLD M, 1992, FEBS LETT, V308, P26, DOI 10.1016/0014-5793(92)81042-K; HEROLD M, 1990, BIOCHEMISTRY-US, V29, P1907, DOI 10.1021/bi00459a035; JAGER J, 1994, J MOL BIOL, V239, P285, DOI 10.1006/jmbi.1994.1368; JOHNSON RS, 1994, PROTEIN SCI, V3, P2411, DOI 10.1002/pro.5560031224; KATTA V, 1991, RAPID COMMUN MASS SP, V5, P214, DOI 10.1002/rcm.1290050415; KURAMITSU S, 1990, BIOCHEMISTRY-US, V29, P5469, DOI 10.1021/bi00475a010; LEHRER SS, 1971, BIOCHEMISTRY-US, V10, P3254, DOI 10.1021/bi00793a015; LEISTLER B, 1992, EUR J BIOCHEM, V205, P603, DOI 10.1111/j.1432-1033.1992.tb16818.x; Li RH, 1999, PROTEIN SCI, V8, P1571, DOI 10.1110/ps.8.8.1571; Mattingly JR, 1998, J BIOL CHEM, V273, P23191, DOI 10.1074/jbc.273.36.23191; MCPHALEN CA, 1992, J MOL BIOL, V227, P197, DOI 10.1016/0022-2836(92)90691-C; MIRANKER A, 1993, SCIENCE, V262, P896, DOI 10.1126/science.8235611; Orru S, 1999, PROTEIN SCI, V8, P1445, DOI 10.1110/ps.8.7.1445; OVCHINNIKOV YA, 1973, FEBS LETT, V29, P31, DOI 10.1016/0014-5793(73)80008-0; Piccoli R, 2000, J BIOL CHEM, V275, P8000, DOI 10.1074/jbc.275.11.8000; Scaloni A, 1998, J MOL BIOL, V277, P945, DOI 10.1006/jmbi.1998.1629; Scaloni A, 1999, BIOCHEMISTRY-US, V38, P64, DOI 10.1021/bi981300k; Scognamiglio R, 2001, PROTEIN SCI, V10, P482, DOI 10.1110/ps.35701; Smith DL, 1997, J MASS SPECTROM, V32, P135, DOI 10.1002/(SICI)1096-9888(199702)32:2<135::AID-JMS486>3.0.CO;2-M; Torella C, 1998, J BIOL CHEM, V273, P3915, DOI 10.1074/jbc.273.7.3915; Urbani A, 1999, BIOCHEMISTRY-US, V38, P5206, DOI 10.1021/bi982773u; WOODWARD C, 1982, MOL CELL BIOCHEM, V48, P135, DOI 10.1007/BF00421225; YANO T, 1991, J BIOL CHEM, V266, P6079; Zappacosta F, 1996, PROTEIN SCI, V5, P802, DOI 10.1002/pro.5560050502; ZHANG ZQ, 1993, PROTEIN SCI, V2, P522; Zhang ZQ, 1996, PROTEIN SCI, V5, P1282	38	11	12	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 17	2002	277	20					17428	17437		10.1074/jbc.M200650200	http://dx.doi.org/10.1074/jbc.M200650200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	553PR	11875074	hybrid			2022-12-27	WOS:000175685100008
J	Balklava, Z; Verderio, E; Collighan, R; Gross, S; Adams, J; Griffin, M				Balklava, Z; Verderio, E; Collighan, R; Gross, S; Adams, J; Griffin, M			Analysis of tissue transglutaminase function in the migration of swiss 3T3 fibroblasts - The active-state conformation of the enzyme does not affect cell motility but is important for its secretion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CIS PEPTIDE-BONDS; GROWTH-FACTOR-I; CROSS-LINKING; GTP-BINDING; FIBRONECTIN; ADHESION; MATRIX; EXPRESSION; RELEASE; SURFACE	Increasing evidence suggests that tissue transglutaminase (tTGase; type II) is externalized from cells, where it may play a key role in cell attachment and spreading and in the stabilization of the extracellular matrix (ECM) through protein cross-linking. However, the relationship between these different functions and the enzyme's mechanism of secretion is not fully understood. We have investigated the role of tTGase in cell migration using two stably transfected fibroblast cell lines in which expression of tTGase in its active and inactive (C277S mutant) states is inducible through the tetracycline-regulated system. Cells overexpressing both forms of tTGase showed increased cell attachment and decreased cell migration on fibronectin. Both forms of the enzyme could be detected on the cell surface, but only the clone overexpressing catalytically active tTGase deposited the enzyme into the ECM and cell growth medium. Cells overexpressing the inactive form of tTGase did not deposit the enzyme into the ECM or secrete it into the cell culture medium. Similar results were obtained when cells were transfected with tTGase mutated at Tyr(274) (Y274A), the proposed site for the cis-, trans peptide bond, suggesting that tTGase activity and/or its tertiary conformation dependent on this bond may be essential for its externalization mechanism. These results indicate that tTGase regulates cell motility as a novel cell-surface adhesion protein rather than as a matrix-cross-linking enzyme. They also provide further important insights into the mechanism of externalization of the enzyme into the extracellular matrix.	Nottingham Trent Univ, Dept Life Sci, Nottingham NG11 8NS, England; Smith & Nephew Grp Res Ctr, York YO10 5DF, N Yorkshire, England	Nottingham Trent University; Smith & Nephew	Griffin, M (corresponding author), Nottingham Trent Univ, Dept Life Sci, Clifton Lane, Nottingham NG11 8NS, England.	martin.griffin@ntu.ac.uk	Verderio, Elisabetta/H-2789-2016; Balklava, Zita/AAU-6146-2021	Verderio, Elisabetta/0000-0001-9153-8997; gross, stephane/0000-0002-0867-8866; Griffin, Martin/0000-0003-3824-306X; Balklava, Zita/0000-0001-9039-9710				ACHYUTHAN KE, 1995, J IMMUNOL METHODS, V180, P69, DOI 10.1016/0022-1759(94)00300-L; AESCHLIMANN D, 1995, J CELL BIOL, V129, P881, DOI 10.1083/jcb.129.3.881; AESCHLIMANN D, 1994, THROMB HAEMOSTASIS, V71, P402; Akimov SS, 2000, J CELL BIOL, V148, P825, DOI 10.1083/jcb.148.4.825; AKIYAMA SK, 1989, J CELL BIOL, V109, P863, DOI 10.1083/jcb.109.2.863; Ball DJ, 2001, PHOTOCHEM PHOTOBIOL, V73, P47, DOI 10.1562/0031-8655(2001)073<0047:DEOTOC>2.0.CO;2; BARSIGIAN C, 1991, J BIOL CHEM, V266, P22501; BOWNESS JM, 1988, BIOCHIM BIOPHYS ACTA, V967, P234; BOWNESS JM, 1987, CONNECT TISSUE RES, V16, P57, DOI 10.3109/03008208709001994; BROWN RE, 1989, ANAL BIOCHEM, V180, P136, DOI 10.1016/0003-2697(89)90101-2; CAI D, 1991, BIOCHEM BIOPH RES CO, V175, P1119, DOI 10.1016/0006-291X(91)91681-2; CARIELLO L, 1994, BIOCHEM BIOPH RES CO, V205, P565, DOI 10.1006/bbrc.1994.2702; Di Venere A, 2000, J BIOL CHEM, V275, P3915, DOI 10.1074/jbc.275.6.3915; FOGERTY FJ, 1990, J CELL BIOL, V111, P699, DOI 10.1083/jcb.111.2.699; Folk J E, 1977, Adv Protein Chem, V31, P1, DOI 10.1016/S0065-3233(08)60217-X; FREUND KF, 1994, BIOCHEMISTRY-US, V33, P10109, DOI 10.1021/bi00199a039; Gaudry CA, 1999, J BIOL CHEM, V274, P30707, DOI 10.1074/jbc.274.43.30707; Gaudry CA, 1999, EXP CELL RES, V252, P104, DOI 10.1006/excr.1999.4633; GENTILE V, 1991, J BIOL CHEM, V266, P478; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GRIFFIN M, 1984, MOL CELL BIOCHEM, V58, P37, DOI 10.1007/BF00240603; Haroon ZA, 1999, FASEB J, V13, P1787, DOI 10.1096/fasebj.13.13.1787; Isobe T, 1999, EUR J CELL BIOL, V78, P876, DOI 10.1016/S0171-9335(99)80089-2; JACKSON A, 1995, J BIOL CHEM, V270, P33, DOI 10.1074/jbc.270.1.33; JEONG JM, 1995, J BIOL CHEM, V270, P5654, DOI 10.1074/jbc.270.10.5654; Johnson TS, 1997, J CLIN INVEST, V99, P2950, DOI 10.1172/JCI119490; JOHNSON TS, 1994, ONCOGENE, V9, P2935; Johnson TS, 1999, J AM SOC NEPHROL, V10, P2146; Jones RA, 1997, J CELL SCI, V110, P2461; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE KN, 1993, BIOCHIM BIOPHYS ACTA, V1202, P1, DOI 10.1016/0167-4838(93)90055-V; LORAND L, 1972, ANAL BIOCHEM, V50, P623, DOI 10.1016/0003-2697(72)90074-7; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MARTINEZ J, 1994, BIOCHEMISTRY-US, V33, P2538, DOI 10.1021/bi00175a024; MIAN S, 1995, FEBS LETT, V370, P27, DOI 10.1016/0014-5793(95)00782-5; Miyakawa K, 1999, J BIOL CHEM, V274, P29352, DOI 10.1074/jbc.274.41.29352; Palecek SP, 1997, NATURE, V385, P537, DOI 10.1038/385537a0; Piotrowicz RS, 1997, J BIOL CHEM, V272, P7042, DOI 10.1074/jbc.272.11.7042; Smethurst PA, 1996, BIOCHEM J, V313, P803, DOI 10.1042/bj3130803; STEWART DE, 1990, J MOL BIOL, V214, P253, DOI 10.1016/0022-2836(90)90159-J; TARANTINI F, 1995, J BIOL CHEM, V270, P29039, DOI 10.1074/jbc.270.49.29039; UPCHURCH HF, 1991, J CELL PHYSIOL, V149, P375, DOI 10.1002/jcp.1041490304; Verderio E, 1999, J HISTOCHEM CYTOCHEM, V47, P1417, DOI 10.1177/002215549904701108; Verderio E, 1998, EXP CELL RES, V239, P119, DOI 10.1006/excr.1997.3874; Weiss MS, 1998, FEBS LETT, V423, P291, DOI 10.1016/S0014-5793(98)00098-2	45	117	119	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 10	2002	277	19					16567	16575		10.1074/jbc.M109836200	http://dx.doi.org/10.1074/jbc.M109836200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	551MB	11867617	hybrid, Green Published, Green Accepted			2022-12-27	WOS:000175564500032
J	Bhunia, AK; Schwarzmann, G; Chatterjee, S				Bhunia, AK; Schwarzmann, G; Chatterjee, S			GD3 recruits reactive oxygen species to induce cell proliferation and apoptosis in human aortic smooth muscle cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-MELANOMA; SIGNAL-TRANSDUCTION; ENDOTHELIAL-CELLS; GENE-EXPRESSION; GANGLIOSIDE; LACTOSYLCERAMIDE; GROWTH; ADHESION; BCL-2; GLYCOSPHINGOLIPIDS	Sialic acid containing glycosphingolipids (gangliosides) are expressed on the surface of all mammalian cells and have been implicated in regulating various biological phenomena; however, the detailed signaling mechanisms involved in this process are not known. We report here a novel aspect of disialoganglioside, GD3-mediated regulation of cell proliferation and cell death via the recruitment of reactive oxygen species (ROS). A low concentration (2.5-10 muM) of GD3, incubated with human aortic smooth muscle cells for a short period of time (10-30 min), stimulates superoxide generation via the activation of both NADPH oxidase and NADH oxidase activity. This leads to downstream signaling leading to cell poliferation and apoptosis. However, [H-3]GD3 incubated with the cells under such conditions was found in a trypsin-sensitive fraction that was separable from endogenous GD3. The exact mechanism causing ROS generation and downstream signaling remains to be elucidated. The uptake of GD3 was accompanied by a 2.5-fold stimulation in the activity of mitogen-activated protein (MAP) kinase and 5-fold stimulation in cell proliferation. Preincubation of cells with membrane-permeable antioxidants, pyrrolidine dithiocarbamate, and N-acetylcysteine abrogated the superoxide generation and cell proliferation. In contrast, at higher concentrations (50-200 muM) GD3 inhibited the generation of superoxides but markedly stimulated the generation of nitric oxide (NO) (10-fold compared with control). This in turn stimulated mitochondrial cytochrome c release and intrachromosomal DNA fragmentation, which lead to apoptosis. In sum, at a low concentration, GD3 recruits superoxides to activate p44 MAPK and stimulates cell proliferation. In contrast, at high concentrations GD3 recruits nitric oxide to scavenge superoxide radicals that triggered signaling events that led to apoptosis. These observations might have relevance in regard to the potential role of GD3 in aortic smooth muscle cell proliferation and apoptosis that may contribute to plaque rupture in atherosclerosis.	Johns Hopkins Univ, Sch Med, Dept Pediat,Lipid Res Atherosclerosis Unit, Sphingoglycolipid Signaling & Vasc Biol Lab, Baltimore, MD 21044 USA; Univ Bonn, Kekule Inst Organ Chem & Biochem, D-53121 Bonn, Germany	Johns Hopkins University; University of Bonn	Chatterjee, S (corresponding author), Johns Hopkins Univ, Sch Med, Dept Pediat,Lipid Res Atherosclerosis Unit, Sphingoglycolipid Signaling & Vasc Biol Lab, 550 N Broadway,Suite 312, Baltimore, MD 21044 USA.	chatter@jhmi.edu						ALBINO AP, 1992, ONCOGENE, V7, P2315; Bhunia AK, 1997, J BIOL CHEM, V272, P15642, DOI 10.1074/jbc.272.25.15642; Bhunia AK, 1996, J BIOL CHEM, V271, P10660, DOI 10.1074/jbc.271.18.10660; Bhunia AK, 1998, J BIOL CHEM, V273, P34349, DOI 10.1074/jbc.273.51.34349; Chatterjee S, 1998, ARTERIOSCL THROM VAS, V18, P1523, DOI 10.1161/01.ATV.18.10.1523; Chatterjee S, 2000, METHOD ENZYMOL, V311, P73; Chatterjee SB, 1997, GLYCOBIOLOGY, V7, P57, DOI 10.1093/glycob/7.1.57; CHERESH DA, 1987, J CELL BIOL, V105, P1163, DOI 10.1083/jcb.105.3.1163; Fukumoto S, 2000, J BIOL CHEM, V275, P5832, DOI 10.1074/jbc.275.8.5832; Furukawa K., 1990, HUMAN MELANOMA BASIC, P15; Garcia-Ruiz C, 2000, FASEB J, V14, P847, DOI 10.1096/fasebj.14.7.847; Garcia-Ruiz C, 1999, HEPATOLOGY, V30, p411A; HAKOMORI SI, 1993, ADV LIPID RES, V25, P147; HAKOMORI SI, 1990, J BIOL CHEM, V265, P18713; HANNUN YA, 1994, J BIOL CHEM, V269, P3125; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; KANE DJ, 1993, SCIENCE, V262, P1274, DOI 10.1126/science.8235659; Khan BV, 1996, P NATL ACAD SCI USA, V93, P9114, DOI 10.1073/pnas.93.17.9114; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Maria R.D., 1997, SCIENCE, V277, P1652; MCCORD JM, 1993, CLIN BIOCHEM, V26, P351, DOI 10.1016/0009-9120(93)90111-I; MUKHIN DN, 1995, ARTERIOSCL THROM VAS, V15, P1607, DOI 10.1161/01.ATV.15.10.1607; NAKAKUMA H, 1984, J BIOCHEM-TOKYO, V96, P1471, DOI 10.1093/oxfordjournals.jbchem.a134976; Nakano J, 1996, J INVEST DERMATOL, V107, P543, DOI 10.1111/1523-1747.ep12582802; PUKEL CS, 1982, J EXP MED, V155, P1133, DOI 10.1084/jem.155.4.1133; ROSS R, 1971, J CELL BIOL, V50, P172, DOI 10.1083/jcb.50.1.172; Schreck R, 1991, Trends Cell Biol, V1, P39, DOI 10.1016/0962-8924(91)90072-H; SCHWARZMANN G, 1983, BIOCHEMISTRY-US, V22, P5041, DOI 10.1021/bi00290a025; SCHWARZMANN G, 1978, BIOCHIM BIOPHYS ACTA, V529, P106, DOI 10.1016/0005-2760(78)90108-X; SELLINS KS, 1987, J IMMUNOL, V139, P3199; SONDERFELD S, 1985, EUR J BIOCHEM, V149, P247, DOI 10.1111/j.1432-1033.1985.tb08919.x; SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296; TILLACK TW, 1993, BIOCHIM BIOPHYS ACTA, V793, P15; Zhang P, 1997, J BIOL CHEM, V272, P30615, DOI 10.1074/jbc.272.49.30615; Zimmerman JW, 1998, J BIOL CHEM, V273, P22014, DOI 10.1074/jbc.273.34.22014	35	61	61	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 10	2002	277	19					16396	16402		10.1074/jbc.M200877200	http://dx.doi.org/10.1074/jbc.M200877200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	551MB	11861654	hybrid			2022-12-27	WOS:000175564500009
J	DeLong, CJ; Hicks, AM; Cui, Z				DeLong, CJ; Hicks, AM; Cui, Z			Disruption of choline methyl group donation for phosphatidylethanolamine methylation in hepatocarcinoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER MITOCHONDRIA; N-METHYLTRANSFERASE; BETAINE ALDEHYDE; DNA METHYLATION; HEPATOCELLULAR CARCINOMAS; METHIONINE METABOLISM; GENE-EXPRESSION; HEPATOMA-CELLS; N-METHYLTRANSFERASE-2; HOMOCYSTEINE	Despite being widely hypothesized, the actual contribution of choline as a methyl source for phosphatidylethanolamine (PE) methylation has never been demonstrated, mainly due to the inability of conventional methods to distinguish the products from that of the CDP-choline pathway. Using a novel combination of stable-isotope labeling and tandem mass spectrometry, we demonstrated for the first time that choline contributed to phosphatidylcholine (PC) synthesis both as an intact choline moiety via the CDP-choline pathway and as a methyl donor via PE methylation pathway. When hepatocytes were labeled with d(9)-choline containing three deuterium atoms on each of the three methyl groups, d(3)-PC and d(6)-PC were detected, indicating that newly synthesized PC contained one or more individually mobilized methyl groups from d(9)-choline. The synthesis of d(3)-PC and d(6)-PC was sensitive to the general methylation inhibitor 3-deazaadenosine and were specific products of PE methylation using choline as a one-carbon donor. While the contribution to the CDP-choline pathway remained intact in hepatocarcinoma cells, contribution of choline to PE methylation was completely disrupted. In addition to a previously identified lack of PE methyltransferase, hepatocarcinoma cells were found to lack the abilities to oxidize choline to betaine and to donate the methyl group from betaine to homocysteine, whereas the usage of exogenous methionine as a methyl group donor was normal. The failure to use choline as a methyl source in hepatocarcinoma cells may contribute to methionine dependence, a widely observed aberration of one-carbon metabolism in malignancy.	Wake Forest Univ, Bowman Gray Sch Med, Dept Biochem, Winston Salem, NC 27157 USA; Wake Forest Univ, Bowman Gray Sch Med, Dept Canc Biol, Winston Salem, NC 27157 USA	Wake Forest University; Wake Forest Baptist Medical Center; Wake Forest University; Wake Forest Baptist Medical Center	Cui, Z (corresponding author), Wake Forest Univ, Bowman Gray Sch Med, Dept Biochem, Winston Salem, NC 27157 USA.	zhengcui@wfubmc.edu		DeLong, Cynthia/0000-0002-6823-8619	NCI NIH HHS [R01CA7960, CA-09422] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009422] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Avila MA, 2000, J HEPATOL, V33, P907, DOI 10.1016/S0168-8278(00)80122-1; BALAGHI M, 1993, BIOCHEM BIOPH RES CO, V193, P1184, DOI 10.1006/bbrc.1993.1750; Barak AJ, 1996, ALCOHOL, V13, P395, DOI 10.1016/0741-8329(96)00030-4; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; CHANDAR N, 1988, CARCINOGENESIS, V9, P259, DOI 10.1093/carcin/9.2.259; Chern MK, 1999, BIOCHEM CELL BIOL, V77, P179, DOI 10.1139/bcb-77-3-179; Chern MK, 2000, BIOCHEM PHARMACOL, V60, P1629, DOI 10.1016/S0006-2952(00)00469-X; CHIANG PK, 1979, BIOCHEM PHARMACOL, V28, P1897, DOI 10.1016/0006-2952(79)90642-7; COPELAND DH, 1946, AM J PATHOL, V22, P1059; CUI Z, 1994, J BIOL CHEM, V269, P24531; Cui Z, 1996, J BIOL CHEM, V271, P2839, DOI 10.1074/jbc.271.5.2839; Cui Z, 1997, BBA-LIPID LIPID MET, V1346, P10, DOI 10.1016/S0005-2760(97)00012-X; Cui Z, 1995, BIOCHEM J, V312, P939, DOI 10.1042/bj3120939; CUI Z, 1993, J BIOL CHEM, V268, P16655; DAVIS RA, 1979, J BIOL CHEM, V254, P2010; DeLong CJ, 2001, J LIPID RES, V42, P1959; DeLong CJ, 1999, J BIOL CHEM, V274, P29683, DOI 10.1074/jbc.274.42.29683; DIZIK M, 1991, CARCINOGENESIS, V12, P1307, DOI 10.1093/carcin/12.7.1307; FINKELSTEIN JD, 1984, J BIOL CHEM, V259, P9508; Heil SG, 2000, MOL GENET METAB, V71, P511, DOI 10.1006/mgme.2000.3078; Houweling M, 1997, BBA-LIPID LIPID MET, V1346, P1, DOI 10.1016/S0005-2760(97)00011-8; ISHIDATE K, 1989, PHOSPHATIDYLCHOLINE, P9; Kent C, 1997, BBA-LIPID LIPID MET, V1348, P79, DOI 10.1016/S0005-2760(97)00112-4; KRAMAR R, 1984, H-S Z PHYSIOL CHEM, V365, P1207, DOI 10.1515/bchm2.1984.365.2.1207; LIEBER CS, 1965, J CLIN INVEST, V44, P1009, DOI 10.1172/JCI105200; LOCKER J, 1986, CARCINOGENESIS, V7, P1309, DOI 10.1093/carcin/7.8.1309; MATTHEWS RG, 1987, ADV ENZYME REGUL, V26, P157, DOI 10.1016/0065-2571(87)90012-4; Park EI, 1999, J BIOL CHEM, V274, P7816, DOI 10.1074/jbc.274.12.7816; PRITCHARD PH, 1982, J BIOL CHEM, V257, P6362; Rampersaud GC, 2000, AM J CLIN NUTR, V72, P998; Sunden SLF, 1997, ARCH BIOCHEM BIOPHYS, V345, P171, DOI 10.1006/abbi.1997.0246; Tessitore L, 1999, CARCINOGENESIS, V20, P561, DOI 10.1093/carcin/20.4.561; Tessitore L, 1999, BIOCHEM J, V337, P23, DOI 10.1042/0264-6021:3370023; Tessitore L, 1997, BIOCHEM J, V322, P151, DOI 10.1042/bj3220151; Tessitore L, 2000, INT J CANCER, V86, P362, DOI 10.1002/(SICI)1097-0215(20000501)86:3&lt;362::AID-IJC10&gt;3.0.CO;2-A; Tsujiuchi T, 1999, JPN J CANCER RES, V90, P909, DOI 10.1111/j.1349-7006.1999.tb00834.x; Vance DE, 1996, ANTICANCER RES, V16, P1413; VANCE DE, 1989, PHOSPHATIDYLCHOLINE; Walkey CJ, 1998, J BIOL CHEM, V273, P27043, DOI 10.1074/jbc.273.42.27043; Walkey CJ, 1997, P NATL ACAD SCI USA, V94, P12880, DOI 10.1073/pnas.94.24.12880; WONG ER, 1972, BIOCHIM BIOPHYS ACTA, V260, P259, DOI 10.1016/0005-2760(72)90037-9; Zeisel SH, 1996, ADV EXP MED BIOL, V399, P131; ZHANG J, 1992, BIOCHIM BIOPHYS ACTA, V1117, P333, DOI 10.1016/0304-4165(92)90033-Q	43	26	26	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 10	2002	277	19					17217	17225		10.1074/jbc.M108911200	http://dx.doi.org/10.1074/jbc.M108911200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	551MB	11864970	hybrid			2022-12-27	WOS:000175564500115
J	Taniura, S; Kamitani, H; Watanabe, T; Eling, TE				Taniura, S; Kamitani, H; Watanabe, T; Eling, TE			Deacetylase inhibitors in normal human astrocyte cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROSTAGLANDIN ENDOPEROXIDE SYNTHASE; SIGNAL-TRANSDUCTION PATHWAY; HUMAN COLORECTAL-CARCINOMA; HISTONE DEACETYLASE; GROWTH-FACTOR; SP1 SITES; TRANSCRIPTIONAL REPRESSION; SODIUM-BUTYRATE; G/H SYNTHASE-2; GENE PROMOTER	While cyclooxygenase (COX)-2 is a highly inducible gene, COX-1 is widely known as a noninducible gene and is constitutively expressed in a variety of cell lines and human tissues. Recently, several reports have indicated that COX-1 is also regulated at the transcriptional level by various stimuli. We present evidence that histone deacetylase (HDAC) inhibitors induce COX-1 transcription and translation in normal human astrocyte (NHA) cells and glioma cell lines. HDAC inhibitors increased acetylated histone H4 protein expression in NHA cells. The levels of COX-1 mRNA and protein were maximal at 24 and 48 h, respectively, after treatment with the specific HDAC inhibitor, trichostatin A (TSA). In addition, TSA-treated NHA cells produced prostaglandin E-2 as determined by enzyme-linked immunosorbent assay after incubation with 10 muM exogenous arachidonic acid, indicating that the induced COX-1 is functionally active. In addition to NHA cells, this up-regulation of COX-1 after treatment with HDAC inhibitors was observed in 5 different glioma cell lines. The nucleotide sequence of the inducible COX-1 cDNA was confirmed identical to human COX-1 that was previously reported. HDAC inhibitors stimulated COX-1 promoter activity as measured by luciferase reporter assays, suggesting that the induction of COX-1 is regulated at the transcriptional level. Furthermore, mutation analysis of the COX-1 promoter suggests that TSA-responsive element exists in the proximal Sp1-binding site at +25 to +31. In conclusion, COX-1 is an inducible gene in glial-derived cells including immortalized cells, and appears to be transcriptionally regulated by a unique mechanism associated with histone acetylation.	NIEHS, Mol Carcinogenesis Lab, NIH, Res Triangle Pk, NC 27709 USA; Tottori Univ, Fac Med, Inst Neurol Sci, Div Neurosurg, Yonago, Tottori 6838504, Japan	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); Tottori University	Eling, TE (corresponding author), NIEHS, Mol Carcinogenesis Lab, NIH, POB 12233, Res Triangle Pk, NC 27709 USA.				NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES050143, Z01ES050144, ZIAES050144] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		AMRUTHESH SC, 1993, J NEUROCHEM, V61, P150, DOI 10.1111/j.1471-4159.1993.tb03550.x; Bernhard D, 1999, FASEB J, V13, P1991, DOI 10.1096/fasebj.13.14.1991; Bethea JR, 1997, J IMMUNOL, V158, P5815; Brightbill HD, 2000, J IMMUNOL, V164, P1940, DOI 10.4049/jimmunol.164.4.1940; Cohn SM, 1997, J CLIN INVEST, V99, P1367, DOI 10.1172/JCI119296; Doetzlhofer A, 1999, MOL CELL BIOL, V19, P5504; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; Han JW, 2000, CANCER RES, V60, P6068; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; Huang LL, 2000, ONCOGENE, V19, P5712, DOI 10.1038/sj.onc.1203963; Husmann M, 1996, EUR J IMMUNOL, V26, P3008, DOI 10.1002/eji.1830261228; JONES DA, 1993, J BIOL CHEM, V268, P9049; KADONAGA JT, 1988, SCIENCE, V242, P1566, DOI 10.1126/science.3059495; Kamitani H, 1998, J BIOL CHEM, V273, P21569, DOI 10.1074/jbc.273.34.21569; Kamitani H, 2001, CARCINOGENESIS, V22, P187, DOI 10.1093/carcin/22.1.187; Kao HY, 1998, GENE DEV, V12, P2269, DOI 10.1101/gad.12.15.2269; Kaplan MD, 1997, J BIOL CHEM, V272, P18534, DOI 10.1074/jbc.272.30.18534; KAWAGUCHI H, 1995, J CLIN INVEST, V96, P923, DOI 10.1172/JCI118140; KAWASAKI M, 1993, MOL BRAIN RES, V19, P39, DOI 10.1016/0169-328X(93)90146-G; Koyama Y, 1999, J NEUROCHEM, V73, P1004, DOI 10.1046/j.1471-4159.1999.0731004.x; Laherty CD, 1997, CELL, V89, P349, DOI 10.1016/S0092-8674(00)80215-9; LI JM, 1995, J BIOL CHEM, V270, P26750, DOI 10.1074/jbc.270.45.26750; Marks PA, 2000, JNCI-J NATL CANCER I, V92, P1210, DOI 10.1093/jnci/92.15.1210; Nakajima H, 1998, EXP CELL RES, V241, P126, DOI 10.1006/excr.1998.4027; Ng HH, 1999, CURR OPIN GENET DEV, V9, P158, DOI 10.1016/S0959-437X(99)80024-0; OBanion MK, 1996, J NEUROCHEM, V66, P2532; Pairet M, 1996, FUND CLIN PHARMACOL, V10, P1, DOI 10.1111/j.1472-8206.1996.tb00144.x; Pistritto G, 1998, NEUROSCI LETT, V246, P45, DOI 10.1016/S0304-3940(98)00226-2; Redner RL, 1999, BLOOD, V94, P417, DOI 10.1182/blood.V94.2.417.414k49_417_428; Rioux N, 2000, CARCINOGENESIS, V21, P1745, DOI 10.1093/carcin/21.9.1745; Saito A, 1999, P NATL ACAD SCI USA, V96, P4592, DOI 10.1073/pnas.96.8.4592; Salminen A, 1998, MOL BRAIN RES, V61, P203, DOI 10.1016/S0169-328X(98)00210-1; Satoh K, 2000, NEUROSCI LETT, V283, P221, DOI 10.1016/S0304-3940(00)00926-5; Schneider N, 2001, J NEUROCHEM, V77, P416, DOI 10.1046/j.1471-4159.2001.00264.x; Shankaranarayanan P, 2001, J BIOL CHEM, V276, P42753, DOI 10.1074/jbc.M102626200; Shaw-White JR, 1999, J BIOL CHEM, V274, P2658, DOI 10.1074/jbc.274.5.2658; SMITH CJ, 1993, BIOCHEM BIOPH RES CO, V192, P787, DOI 10.1006/bbrc.1993.1483; Smith WL, 1996, J BIOL CHEM, V271, P33157, DOI 10.1074/jbc.271.52.33157; Sowa Y, 1997, BIOCHEM BIOPH RES CO, V241, P142, DOI 10.1006/bbrc.1997.7786; Taplick J, 1998, FEBS LETT, V436, P349, DOI 10.1016/S0014-5793(98)01164-8; Vane JR, 1998, ANNU REV PHARMACOL, V38, P97, DOI 10.1146/annurev.pharmtox.38.1.97; Wade PA, 1997, TRENDS BIOCHEM SCI, V22, P128, DOI 10.1016/S0968-0004(97)01016-5; Xu XM, 1997, J BIOL CHEM, V272, P6943, DOI 10.1074/jbc.272.11.6943; Xu XM, 1996, AM J PHYSIOL-CELL PH, V270, pC259, DOI 10.1152/ajpcell.1996.270.1.C259; Yang JQ, 2001, J BIOL CHEM, V276, P25742, DOI 10.1074/jbc.M102821200; Yermakova AV, 1999, J NEUROPATH EXP NEUR, V58, P1135, DOI 10.1097/00005072-199911000-00003; YOKOYAMA C, 1989, BIOCHEM BIOPH RES CO, V165, P888, DOI 10.1016/S0006-291X(89)80049-X	47	64	67	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 10	2002	277	19					16823	16830		10.1074/jbc.M200527200	http://dx.doi.org/10.1074/jbc.M200527200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	551MB	11877441	hybrid			2022-12-27	WOS:000175564500064
J	Turek, JW; Halmos, T; Sullivan, NL; Antonakis, K; Le Breton, GC				Turek, JW; Halmos, T; Sullivan, NL; Antonakis, K; Le Breton, GC			Mapping of a ligand-binding site for the human thromboxane A(2) receptor protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROSTAGLANDIN; AGONIST; BIOSYNTHESIS; DOMAIN; ROLES	The human thromboxane A(2) (TP) receptor, a member of the G protein-coupled receptor superfamily, consists of seven transmembrane segments. Attempts to elucidate the specific segment(s) that define the receptor ligand-binding pocket have produced less than definitive and sometimes conflicting results. On this basis, the present work identified an amino acid sequence of the TP receptor that is directly involved in ligand binding. Mapping of this domain was confirmed by two separate approaches: photoaffinity labeling and site-specific antibodies. The newly synthesized, biotinylated photoaffinity probe, SQBAzide, was first shown to specifically label TP receptor protein. Sequential digestion of this protein with CNBr/trypsin revealed photolabeling of a 2.9-kDa peptide. Using anti-peptide antibodies directed against different regions of the receptor protein, it was established that this peptide represents the predicted cleavage product for CNBr/trypsin and corresponds to amino acids Arg(174)-Met(202) of the receptor protein. Furthermore, antibody screening revealed that inhibition of the amino acid region Cys(183)-Asp(193) was critical for radioligand binding and platelet aggregation, whereas inhibition of Gly(172)-Cys(183) was not. Collectively these findings provide evidence that ligands interact with amino acids contained within the C-terminal portion of the third extracellular domain (ED3) of the receptor protein. This information should be of significant value in the study of TP receptor structure and signaling.	Univ Illinois, Coll Med, Dept Pharmacol, Chicago, IL 60612 USA; Ecole Natl Super Chim Paris, CNRS, UMR 133, F-75231 Paris, France	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; Chimie ParisTech	Le Breton, GC (corresponding author), Univ Illinois, Coll Med, Dept Pharmacol, 835 S Wolcott Ave,M-C 868, Chicago, IL 60612 USA.	gcl@uic.edu		Turek, Joseph/0000-0002-4006-7555	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL024530] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL24530] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Alla SA, 1996, J BIOL CHEM, V271, P1748, DOI 10.1074/jbc.271.3.1748; ALTMAN R, 1994, BMJ-BRIT MED J, V308, P81, DOI 10.1136/bmj.308.6921.81; BORG C, 1993, BIOCHEM PHARMACOL, V45, P2071, DOI 10.1016/0006-2952(93)90018-R; Chiang N, 1996, ARCH BIOCHEM BIOPHYS, V334, P9, DOI 10.1006/abbi.1996.0423; CLARKE RJ, 1991, NEW ENGL J MED, V325, P1137, DOI 10.1056/NEJM199110173251605; Collaboration AT, 1994, BMJ-BRIT MED J, V308, P235; Collaboration AT, 1994, BMJ-BRIT MED J, V308, P159, DOI [10.1136/bmj.308.6922.159, DOI 10.1136/BMJ.308.6922.159]; DAngelo DD, 1996, J BIOL CHEM, V271, P6233, DOI 10.1074/jbc.271.11.6233; Dorn GW, 1997, J BIOL CHEM, V272, P12399, DOI 10.1074/jbc.272.19.12399; FINDLAY JBC, 1986, BIOCHEM J, V238, P625, DOI 10.1042/bj2380625; FITZGERALD GA, 1987, FASEB J, V46, P154; FUNK CD, 1993, MOL PHARMACOL, V44, P934; Gros E., 1967, METHOD ENZYMOL, V11, P238; HAGER KM, 1994, B BIORAD LAB, V1685; Halmos T, 1999, BIOORG MED CHEM LETT, V9, P2963, DOI 10.1016/S0960-894X(99)00511-9; HIRATA M, 1991, NATURE, V349, P617, DOI 10.1038/349617a0; KATTELMAN EJ, 1986, THROMB RES, V41, P471, DOI 10.1016/0049-3848(86)91692-0; Komiotis D, 1996, BIOCHEM PHARMACOL, V52, P763, DOI 10.1016/0006-2952(96)00359-0; MATSUI H, 1989, BIOCHEMISTRY-US, V28, P4125, DOI 10.1021/bi00435a075; MONCADA S, 1978, PHARMACOL REV, V30, P293; NARUMIYA S, 1993, J LIPID MEDIATOR, V6, P155; OATES JA, 1988, NEW ENGL J MED, V319, P689, DOI 10.1056/NEJM198809153191106; OGLETREE ML, 1987, FED PROC, V46, P133; PATRONO C, 1990, STROKE, V21, P130; PATRONO C, 1994, NEW ENGL J MED, V330, P1287; Ruan KH, 2001, BIOCHEMISTRY-US, V40, P275, DOI 10.1021/bi001867c; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; TUREK JW, 1998, B BIORAD LAB, V2344; WONG SKF, 1988, J BIOL CHEM, V263, P7925; YAMAMOTO Y, 1993, J MED CHEM, V36, P820, DOI 10.1021/jm00059a005	30	36	37	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 10	2002	277	19					16791	16797		10.1074/jbc.M105872200	http://dx.doi.org/10.1074/jbc.M105872200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	551MB	11877412	hybrid			2022-12-27	WOS:000175564500060
J	Broadwater, JA; Whittle, E; Shanklin, J				Broadwater, JA; Whittle, E; Shanklin, J			Desaturation and Hydroxylation - Residues 148 and 324 of Arabidopsis FAD2, in addition to substrate chain length, exert a major influence in partitioning of catalytic specificity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OLEATE DESATURASE; FATTY-ACIDS; GENE; ENZYME; THALIANA; YEAST; CRYPTOREGIOCHEMISTRY; TRANSFORMATION; MONOOXYGENASE; EXPRESSION	Exchanging the identity of amino acids at four key locations within the Arabidopsis thaliana oleate desaturase (FAD2) and the Lesquerella fendleri hydroxylase/desaturase (LFAH) was shown to influence partitioning between desaturation and hydroxylation (Broun, P., Shanklin, J., Whittle, E., and Somerville, C. (1998) Science 282, 1315-1317). We report that four analogous substitutions in the FAD2 sequence by their equivalents from the castor oleate hydroxylase result in hydroxy fatty acid accumulation in A. thaliana to the same levels as for the wild-type castor hydroxylase. We also describe the relative contribution of these substitutions, both individually and in combination, by analyzing the products resulting from their expression in A. thaliana and/or Saccharomyces cerevisiae. Yeast expression showed that M324V, a change reachable by a single point mutation, altered the product distribution similar to49-fold, and that residue 148 is also a predominant determinant of reaction outcome. Comparison of residues at position 148 of FAD2, LFAH, and the Ricinus oleate hydroxylase prompted us to rationally engineer LFAH-N149I, a variant with similar to1.9-fold increase in hydroxylation specificity compared with that of wild-type LFAH. Control experiments showed that the wild-type Arabidopsis thaliana FAD2 desaturase has inherent, low level, hydroxylation activity. Further, fatty acid desaturases from different kingdoms and with different regio-specificities exhibit similar intrinsic hydroxylase activity, underscoring fundamental mechanistic similarities between desaturation and hydroxylation. For LFAH mutants the hydroxylation:desaturation ratio is 5-9-fold higher for 18-carbon versus 16-carbon substrates, supporting our hypothesis that substrate positioning in the active site plays a key role in the partitioning of catalytic specificity.	Brookhaven Natl Lab, Dept Biol, Upton, NY 11973 USA	United States Department of Energy (DOE); Brookhaven National Laboratory	Shanklin, J (corresponding author), Brookhaven Natl Lab, Dept Biol, Bldg 463,50 Bell Ave, Upton, NY 11973 USA.			Shanklin, John/0000-0002-6774-8043				Aguilar PS, 1998, J BACTERIOL, V180, P2194, DOI 10.1128/JB.180.8.2194-2200.1998; Ausubel F.M., 1993, CURRENT PROTOCOLS MO; AWAYA J, 1975, BIOCHIM BIOPHYS ACTA, V409, P267, DOI 10.1016/0005-2760(75)90022-3; Behrouzian B, 2001, EUR J BIOCHEM, V268, P3545, DOI 10.1046/j.1432-1327.2001.02258.x; BOSSIE MA, 1989, J BACTERIOL, V171, P64089; Broun P, 1998, PLANT J, V13, P201, DOI 10.1046/j.1365-313X.1998.00023.x; Broun P, 1997, PLANT PHYSIOL, V113, P933, DOI 10.1104/pp.113.3.933; Broun P, 1998, SCIENCE, V282, P1315, DOI 10.1126/science.282.5392.1315; Brown AP, 1998, J AM OIL CHEM SOC, V75, P77, DOI 10.1007/s11746-998-0014-y; Buist PH, 1996, J AM CHEM SOC, V118, P6295, DOI 10.1021/ja953262n; Buist PH, 1998, J AM CHEM SOC, V120, P871, DOI 10.1021/ja971362i; Clough SJ, 1998, PLANT J, V16, P735, DOI 10.1046/j.1365-313x.1998.00343.x; CONACHER H B S, 1970, Lipids, V5, P137, DOI 10.1007/BF02531108; Covello PS, 1996, PLANT PHYSIOL, V111, P223, DOI 10.1104/pp.111.1.223; Dallerac R, 2000, P NATL ACAD SCI USA, V97, P9449, DOI 10.1073/pnas.150243997; DATLA RSS, 1992, GENE, V122, P383, DOI 10.1016/0378-1119(92)90232-E; Dyer JM, 2001, FEBS LETT, V494, P44, DOI 10.1016/S0014-5793(01)02315-8; Fauconnot L, 2001, BIOORG MED CHEM LETT, V11, P2879, DOI 10.1016/S0960-894X(01)00579-0; FEIG AL, 1994, CHEM REV, V94, P759, DOI 10.1021/cr00027a011; Gherman BF, 2001, J AM CHEM SOC, V123, P3836, DOI 10.1021/ja0055108; GIRKE T, 1998, ADV PLANT LIPID RES, P103; Jin Y, 2001, J BIOL INORG CHEM, V6, P717, DOI 10.1007/s007750100250; KANEKO H, 1976, LIPIDS, V11, P837, DOI 10.1007/BF02532989; Kim C, 1997, J AM CHEM SOC, V119, P3635, DOI 10.1021/ja963578a; Kinumi T, 2000, J MASS SPECTROM, V35, P417, DOI 10.1002/(SICI)1096-9888(200003)35:3<417::AID-JMS952>3.0.CO;2-#; Kridl J. C., 1991, Seed Science Research, V1, P209, DOI 10.1017/S0960258500000921; MORRIS LJ, 1967, BIOCHEM BIOPH RES CO, V29, P311, DOI 10.1016/0006-291X(67)90454-8; OKULEY J, 1994, PLANT CELL, V6, P147, DOI 10.1105/tpc.6.1.147; Pikus JD, 1997, BIOCHEMISTRY-US, V36, P9283, DOI 10.1021/bi971049t; RESNICK MA, 1966, J BACTERIOL, V92, P597, DOI 10.1128/JB.92.3.597-600.1966; SAVILE CK, 2001, J CHEM SOC P1, V9, P1116; SHANKLIN J, 1994, BIOCHEMISTRY-US, V33, P12787, DOI 10.1021/bi00209a009; Shanklin J, 1997, P NATL ACAD SCI USA, V94, P2981, DOI 10.1073/pnas.94.7.2981; Smith C. R., 1970, PROGR CHEM FATS OTHE, V11, P139, DOI [10.1002/food.19910350121, DOI 10.1002/FOOD.19910350121]; SMITH CR, 1961, J ORG CHEM, V26, P2903, DOI 10.1021/jo01066a067; Smith M, 2000, BIOCHEM SOC T, V28, P947, DOI 10.1042/BST0280947; SPERLING P, 1993, J BIOL CHEM, V268, P26935; STRITTMATTER P, 1974, P NATL ACAD SCI USA, V71, P4565, DOI 10.1073/pnas.71.11.4565; VANDELOO FJ, 1995, P NATL ACAD SCI USA, V92, P6743, DOI 10.1073/pnas.92.15.6743; Wallar BJ, 1996, CHEM REV, V96, P2625, DOI 10.1021/cr9500489; Whittle E, 2001, J BIOL CHEM, V276, P21500, DOI 10.1074/jbc.M102129200	41	128	147	0	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 3	2002	277	18					15613	15620		10.1074/jbc.M200231200	http://dx.doi.org/10.1074/jbc.M200231200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	550PA	11864983	hybrid			2022-12-27	WOS:000175510400054
J	Charvet, C; Auberger, P; Tartare-Deckert, S; Bernard, A; Deckert, M				Charvet, C; Auberger, P; Tartare-Deckert, S; Bernard, A; Deckert, M			Vav1 couples T cell receptor to serum response factor-dependent transcription via a MEK-dependent pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TERNARY COMPLEX FACTORS; NF-KAPPA-B; C-FOS; SIGNAL-TRANSDUCTION; PHOSPHATIDYLINOSITOL 3-KINASE; UP-REGULATION; ACTIVATION; FAMILY; KINASE; SRF	The Vav family of guanine nucleotide exchange factors for Rho family GTPases plays a critical role in lymphocyte proliferation, gene transcription, and cytoskeleton reorganization following immunoreceptor stimulation. However, its role in immediate early gene activation is unclear. In this study, we have investigated the mechanisms by which Vav1 can regulate c-fos serum response element transcriptional activity. We show that T cell antigen receptor (TCR) stimulation induces the phosphorylation of serum response factor (SRF) on serine 103 and increases the binding of SRF complexes on serum response element in a MEK- and p38-dependent pathway. The physiological relevance of our findings is supported by the inhibition of the interleukin-2 gene transcriptional activity by a dominant negative SRF mutant. Overexpression of Vav1, which partially mimics TCR stimulation, promotes SRF-dependent transcription, and dominant negative Vav1 mutants block SRF activation by TCR. SRF activation by Vav1 occurs through a signaling cascade consisting of Rac1/Cdc42 and the serine/threonine kinases Pak1 and MEK, but independently of the phosphatidylinositol 3-kinase pathway. Interestingly, Vav2 also enhances SRF through Rho GTPases, suggesting that Vav proteins are general regulators of SRF activation in lymphocytes. This report establishes Vav proteins as a direct link between antigen receptors and SRF-dependent early gene expression.	Hop Archet, INSERM, U343, IFR50, F-06202 Nice 3, France; Fac Med, INSERM, U526, F-06107 Nice 2, France; Fac Med, INSERM, U385, IFR50, F-06107 Nice 2, France	CHU Nice; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Cote d'Azur	Deckert, M (corresponding author), Hop Archet, INSERM, U343, IFR50, F-06202 Nice 3, France.	deckert@unice.ft	AUBERGER, Patrick/G-1491-2013; TARTARE-DECKERT, Sophie/P-6057-2015; Deckert, Marcel/M-4998-2016; Deckert, Marcel/T-3566-2019	AUBERGER, Patrick/0000-0002-2481-8275; TARTARE-DECKERT, Sophie/0000-0001-8680-5720; Deckert, Marcel/0000-0003-2094-559X				Abe K, 2000, J BIOL CHEM, V275, P10141, DOI 10.1074/jbc.275.14.10141; Alberts AS, 1998, EMBO J, V17, P4075, DOI 10.1093/emboj/17.14.4075; Altman A, 1999, ADV IMMUNOL, V72, P1, DOI 10.1016/S0065-2776(08)60017-6; Bagrodia S, 1999, TRENDS CELL BIOL, V9, P350, DOI 10.1016/S0962-8924(99)01618-9; Bertolotto C, 2000, J BIOL CHEM, V275, P12941, DOI 10.1074/jbc.275.17.12941; Bustelo XR, 2000, MOL CELL BIOL, V20, P1461, DOI 10.1128/MCB.20.5.1461-1477.2000; Chang JH, 1998, MOL CELL BIOL, V18, P4986, DOI 10.1128/MCB.18.9.4986; CHATTA GS, 1994, J IMMUNOL, V153, P5393; Collins TL, 1997, IMMUNOL TODAY, V18, P221; Costello PS, 1999, P NATL ACAD SCI USA, V96, P3035, DOI 10.1073/pnas.96.6.3035; Deckert M, 1996, IMMUNITY, V5, P591, DOI 10.1016/S1074-7613(00)80273-3; DeFranco AL, 2001, NAT IMMUNOL, V2, P482, DOI 10.1038/88669; Doody GM, 2001, NAT IMMUNOL, V2, P542, DOI 10.1038/88748; Frost JA, 1997, EMBO J, V16, P6426, DOI 10.1093/emboj/16.21.6426; Gineitis D, 2001, J BIOL CHEM, V276, P24531, DOI 10.1074/jbc.M102678200; Glimcher LH, 1999, CELL, V96, P13, DOI 10.1016/S0092-8674(00)80955-1; Goodman RH, 2000, GENE DEV, V14, P1553; Han JW, 1998, SCIENCE, V279, P558, DOI 10.1126/science.279.5350.558; Hehner SP, 2000, J BIOL CHEM, V275, P18160, DOI 10.1074/jbc.275.24.18160; Heidenreich O, 1999, J BIOL CHEM, V274, P14434, DOI 10.1074/jbc.274.20.14434; HILL CS, 1995, CELL, V81, P1159, DOI 10.1016/S0092-8674(05)80020-0; HIPSKIND RA, 1991, NATURE, V354, P531, DOI 10.1038/354531a0; Holsinger LJ, 1998, CURR BIOL, V8, P563, DOI 10.1016/S0960-9822(98)70225-8; JANKNECHT R, 1992, EMBO J, V11, P1045, DOI 10.1002/j.1460-2075.1992.tb05143.x; JOHANSEN FE, 1993, MOL CELL BIOL, V13, P4640, DOI 10.1128/MCB.13.8.4640; JOHANSEN FE, 1994, MOL CELL BIOL, V14, P5920, DOI 10.1128/MCB.14.9.5920; Kaminuma O, 2001, MOL CELL BIOL, V21, P3126, DOI 10.1128/MCB.21.9.3126-3136.2001; Kane LP, 2001, NAT IMMUNOL, V2, P37, DOI 10.1038/83144; Kane LP, 1999, CURR BIOL, V9, P601, DOI 10.1016/S0960-9822(99)80265-6; LAZAR DF, 1995, J BIOL CHEM, V270, P20801, DOI 10.1074/jbc.270.35.20801; Lin J, 2001, J CELL SCI, V114, P243; MagnaghiJaulin L, 1996, FEBS LETT, V391, P247, DOI 10.1016/0014-5793(96)00745-4; MANSER E, 1995, J BIOL CHEM, V270, P25070, DOI 10.1074/jbc.270.42.25070; MIRANTI CK, 1995, MOL CELL BIOL, V15, P3672; Movilla N, 1999, MOL CELL BIOL, V19, P7870; NORMAN C, 1988, CELL, V55, P989, DOI 10.1016/0092-8674(88)90244-9; Parry RV, 1997, EUR J IMMUNOL, V27, P2495, DOI 10.1002/eji.1830271006; Poser S, 2000, EMBO J, V19, P4955, DOI 10.1093/emboj/19.18.4955; Price MA, 1996, EMBO J, V15, P6552, DOI 10.1002/j.1460-2075.1996.tb01046.x; Reif K, 1996, CURR BIOL, V6, P1445, DOI 10.1016/S0960-9822(96)00749-X; RIVERA VM, 1993, MOL CELL BIOL, V13, P6260, DOI 10.1128/MCB.13.10.6260; Salojin KV, 1999, J IMMUNOL, V163, P844; Schuebel KE, 1998, EMBO J, V17, P6608, DOI 10.1093/emboj/17.22.6608; Schuebel KE, 1996, ONCOGENE, V13, P363; Shaulian E, 2001, ONCOGENE, V20, P2390, DOI 10.1038/sj.onc.1204383; SHORE P, 1994, MOL CELL BIOL, V14, P3283, DOI 10.1128/MCB.14.5.3283; Sotiropoulos A, 1999, CELL, V98, P159, DOI 10.1016/S0092-8674(00)81011-9; Tanti JF, 1996, J BIOL CHEM, V271, P25227, DOI 10.1074/jbc.271.41.25227; Tartare-Deckert S, 2001, J BIOL CHEM, V276, P20849, DOI 10.1074/jbc.M010588200; Tedford K, 2001, NAT IMMUNOL, V2, P548, DOI 10.1038/88756; Treisman R, 1996, CURR OPIN CELL BIOL, V8, P205, DOI 10.1016/S0955-0674(96)80067-6; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; Trenkle T, 2000, GENE, V245, P139, DOI 10.1016/S0378-1119(00)00026-3; Villalba M, 2000, EUR J IMMUNOL, V30, P1587, DOI 10.1002/1521-4141(200006)30:6<1587::AID-IMMU1587>3.0.CO;2-T; Wang Y, 1998, CELL GROWTH DIFFER, V9, P513; Wardenburg JB, 1998, IMMUNITY, V9, P607, DOI 10.1016/S1074-7613(00)80658-5; Woodside DG, 1998, J IMMUNOL, V161, P649; WU J, 1995, MOL CELL BIOL, V15, P4337; Yablonski D, 1998, EMBO J, V17, P5647, DOI 10.1093/emboj/17.19.5647	59	29	30	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 3	2002	277	18					15376	15384		10.1074/jbc.M111627200	http://dx.doi.org/10.1074/jbc.M111627200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	550PA	11859076	hybrid			2022-12-27	WOS:000175510400021
J	Dohke, Y; Turner, RJ				Dohke, Y; Turner, RJ			Evidence that the transmembrane biogenesis of aquaporin 1 is cotranslational in intact mammalian cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IN-VITRO TRANSLATION; ENDOPLASMIC-RETICULUM MEMBRANE; WATER CHANNELS; TOPOLOGY; PROTEIN; TRANSLOCATION; INSERTION; CHIP28; DETERMINANTS; INTEGRATION	Most polytopic membrane proteins are believed to integrate into the membrane of the endoplasmic reticulum (ER) cotranslationally. However, recent studies with Xenopus oocytes and dog pancreatic microsomes have suggested that this is not the case for human aquaporin 1 (AQP1). These experiments indicate that membrane-spanning segments (MSSs) 2 and 4 of AQP1 do not integrate into the membrane cotranslationally so that this protein initially adopts a four MSS topology. A later maturation event involving a 180-degree rotation of MSS 3 from an N-lum/C-cyt to an N-cyt/C-lum orientation and the concomitant integration of MSSs 2 and 4 into the membrane results in the final six MSS topology. Here we examine the biogenesis of AQP1 in the human embryonic kidney cell line HEK-293T. To do this, we constructed an expression vector for a fusion protein consisting of the enhanced green fluorescent protein followed by an insertion site for AQP1 sequences and a C-terminal glycosylation tag. We then transiently transfected HEK-293T cells with this vector containing the AQP1 sequence truncated after each MSS. Glycosylation of the C-terminal tag was used to monitor its location relative to the ER lumen and consequently the membrane integration and orientation of successive MSSs. In contrast to previous studies our results indicate that AQP1 integrates into the ER membrane cotranslationally in intact HEK-293T cells.	NIDCR, Membrane Biol Sect, Gene Therapy & Therapeut Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)	Turner, RJ (corresponding author), NIDCR, Membrane Biol Sect, Gene Therapy & Therapeut Branch, NIH, Bldg 10,Rm 1A01,10 Ctr Dr MSC 1190, Bethesda, MD 20892 USA.				NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [ZIADE000415, Z01DE000415] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		BAMBERG K, 1994, J BIOL CHEM, V269, P16909; BAYLE D, 1995, J BIOL CHEM, V270, P25678, DOI 10.1074/jbc.270.43.25678; Bayle D, 1997, J BIOL CHEM, V272, P19697, DOI 10.1074/jbc.272.32.19697; Borgnia M, 1999, ANNU REV BIOCHEM, V68, P425, DOI 10.1146/annurev.biochem.68.1.425; Gerelsaikhan T, 2000, J BIOL CHEM, V275, P40471, DOI 10.1074/jbc.M007751200; GRAHAM JM, 1992, CELL BIOL LABFAX, P7; Hermansson M, 2001, J MOL BIOL, V313, P1171, DOI 10.1006/jmbi.2001.5108; KUTAY U, 1995, EMBO J, V14, P217, DOI 10.1002/j.1460-2075.1995.tb06994.x; LIN JL, 1995, J BIOL CHEM, V270, P6935, DOI 10.1074/jbc.270.12.6935; Lu Y, 2000, MOL BIOL CELL, V11, P2973, DOI 10.1091/mbc.11.9.2973; Lu Y, 1998, J BIOL CHEM, V273, P568, DOI 10.1074/jbc.273.1.568; Matlack KES, 1998, CELL, V92, P381, DOI 10.1016/S0092-8674(00)80930-7; Murata K, 2000, NATURE, V407, P599, DOI 10.1038/35036519; Nilsson I, 2000, J BIOL CHEM, V275, P6207, DOI 10.1074/jbc.275.9.6207; Ota K, 1998, MOL CELL, V2, P495, DOI 10.1016/S1097-2765(00)80149-5; PRESTON GM, 1992, SCIENCE, V256, P385, DOI 10.1126/science.256.5055.385; PRESTON GM, 1994, J BIOL CHEM, V269, P1668; Ren G, 2001, P NATL ACAD SCI USA, V98, P1398, DOI 10.1073/pnas.041489198; SHI LB, 1995, BIOCHEMISTRY-US, V34, P8250, DOI 10.1021/bi00026a006; SKACH WR, 1994, J CELL BIOL, V125, P803, DOI 10.1083/jcb.125.4.803; SKACH WR, 1993, J BIOL CHEM, V268, P23552; von Heijne G, 1999, Q REV BIOPHYS, V32, P285, DOI 10.1017/S0033583500003541; Wilkinson BM, 1996, J BIOL CHEM, V271, P25590, DOI 10.1074/jbc.271.41.25590	23	24	25	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	APR 26	2002	277	17					15215	15219		10.1074/jbc.C100646200	http://dx.doi.org/10.1074/jbc.C100646200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	545EH	11884383	hybrid			2022-12-27	WOS:000175203000108
J	Matoba, Y; Katsube, Y; Sugiyama, M				Matoba, Y; Katsube, Y; Sugiyama, M			The crystal structure of prokaryotic phospholipase A(2)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSITION-STATE ANALOG; PANCREATIC PHOSPHOLIPASE-A2; VENOM PHOSPHOLIPASE-A2; MOLECULAR-DYNAMICS; PROTEIN STRUCTURES; FACTOR REFINEMENT; RESOLUTION; BOVINE; COMPLEX; PROGRAM	In this study, the x-ray crystal structures of the calcium-free and calcium-bound forms of phospholipase A(2) (PLA(2)), produced extracellularly by Streptomyces violaceoruber, were determined by using the multiple isomorphous replacement and molecular replacement methods, respectively. The former and latter structures were refined to an R-factor of 18.8% at a 1.4-Angstrom resolution and an R-factor of 15.0% at a 1.6-Angstrom resolution, respectively. The overall structure of the prokaryotic PLA(2) exhibits a novel folding topology that demonstrates that it is completely distinct from those of eukaryotic PLA(2)s, which have been already determined by x-ray and NMR analyses. Furthermore, the coordination geometry of the calcium(II) ion apparently deviated from that of eukaryotic PLA(2)s. Regardless of the evolutionary divergence, the catalytic mechanism including the calcium(II) ion on secreted PLA(2) seems to be conserved between prokaryotic and eukaryotic cells. Demonstrating that the overall structure determined by x-ray analysis is almost the same as that determined by NMR analysis is useful to discuss the catalytic mechanism at the molecular level of the bacterial PLA(2).	Hiroshima Univ, Fac Med, Inst Pharmaceut Sci, Fac Med Minami Ku, Hiroshima 7348551, Japan; Rigaku Co, Inst Xray Res, Akishima, Tokyo 1960003, Japan	Hiroshima University; Rigaku Corporation	Sugiyama, M (corresponding author), Hiroshima Univ, Fac Med, Inst Pharmaceut Sci, Fac Med Minami Ku, Kasumi 1-2-3, Hiroshima 7348551, Japan.		Hu, Ruogu/B-2203-2008					BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; BRUNIE S, 1985, J BIOL CHEM, V260, P9742; BRUNNETT B, 1993, SURVEYS MATH IND, V3, P1; CHOTHIA C, 1981, J MOL BIOL, V145, P215, DOI 10.1016/0022-2836(81)90341-7; DENNIS EA, 1994, J BIOL CHEM, V269, P13057; DIJKSTRA BW, 1984, BIOCHEMISTRY-US, V23, P2759, DOI 10.1021/bi00307a035; DIJKSTRA BW, 1981, J MOL BIOL, V147, P97, DOI 10.1016/0022-2836(81)90081-4; DIJKSTRA BW, 1982, ACTA CRYSTALLOGR B, V38, P793, DOI 10.1107/S0567740882004099; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; FUREY W, 1990, METHOD ENZYMOL, V276, P472; Gelb MH, 2000, J BIOL CHEM, V275, P39823, DOI 10.1074/jbc.C000671200; GELB MH, 1995, ANNU REV BIOCHEM, V64, P653; HIGASHI T, 1990, J APPL CRYSTALLOGR, V23, P253, DOI 10.1107/S0021889890002461; Kleywegt GJ, 1996, STRUCTURE, V4, P1395, DOI 10.1016/S0969-2126(96)00147-5; KONNERT JH, 1980, ACTA CRYSTALLOGR A, V36, P344, DOI 10.1107/S0567739480000794; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LUZZATI V, 1952, ACTA CRYSTALLOGR, V5, P802, DOI 10.1107/S0365110X52002161; Matoba Y, 2000, J INORG BIOCHEM, V82, P221, DOI 10.1016/S0162-0134(00)00147-1; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; MCPHERSON A, 1982, PREPARATION ANAL PRO, P96; McRee DE, 1992, J MOL GRAPHICS, V10, P44, DOI DOI 10.1016/0263-7855(92)80022-6; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; NOEL JP, 1991, BIOCHEMISTRY-US, V30, P11801, DOI 10.1021/bi00115a010; RAMACHANDRAN GN, 1963, J MOL BIOL, V7, P95, DOI 10.1016/S0022-2836(63)80023-6; SCOTT DL, 1990, SCIENCE, V250, P1541, DOI 10.1126/science.2274785; SCOTT DL, 1990, SCIENCE, V250, P1563, DOI 10.1126/science.2274788; Sheldrick GM, 1997, METHOD ENZYMOL, V277, P319, DOI 10.1016/S0076-6879(97)77018-6; Six DA, 2000, BBA-MOL CELL BIOL L, V1488, P1, DOI 10.1016/S1388-1981(00)00105-0; Snitko Y, 1999, BIOCHEMISTRY-US, V38, P7803, DOI 10.1021/bi990600e; Sugiyama M, 2002, J BIOL CHEM, V277, P20051, DOI 10.1074/jbc.M200264200; Sumandea M, 1999, BIOCHEMISTRY-US, V38, P16290, DOI 10.1021/bi9921384; THUNNISSEN MMG, 1990, NATURE, V374, P689; TOMOO K, 1994, PROTEINS, V19, P330, DOI 10.1002/prot.340190408; VANDENBERG B, 1995, J BIOMOL NMR, V5, P110, DOI 10.1007/BF00208802; VANDENBERG B, 1995, NAT STRUCT BIOL, V2, P402, DOI 10.1038/nsb0595-402; VANDENBERG B, 1995, EMBO J, V14, P4123, DOI 10.1002/j.1460-2075.1995.tb00086.x; WERY JP, 1991, NATURE, V352, P79, DOI 10.1038/352079a0; WHITE SP, 1990, SCIENCE, V250, P1560, DOI 10.1126/science.2274787; ZHANG KYJ, 1990, ACTA CRYSTALLOGR A, V46, P377, DOI 10.1107/S0108767389012158; ZHU HX, 1995, BIOCHEMISTRY-US, V34, P15307, DOI 10.1021/bi00046a040	41	34	36	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 31	2002	277	22					20059	20069		10.1074/jbc.M200263200	http://dx.doi.org/10.1074/jbc.M200263200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	557EH	11897785	hybrid			2022-12-27	WOS:000175894800107
J	Baillat, G; Gaillard, S; Castets, F; Monneron, A				Baillat, G; Gaillard, S; Castets, F; Monneron, A			Interactions of phocein with nucleoside-diphosphate kinase, Eps15, and dynamin I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALMODULIN-BINDING PROTEIN; NERVE-TERMINALS; ENDOCYTIC PATHWAY; DENDRITIC SPINES; STRIATIN; MEMBRANE; GTPASE; FAMILY; RAT; COMPONENTS	Phocein, an intracellular protein interacting with striatin, bears a few homologies with the sigma-subunits of clathrin adaptor proteins (Baillat, G., Moqrich, A., Castets, F., Baude, A., Bailly, Y., Benmerah, A., and Monneron, A. (2001) Mol. Biol. Cell 12, 663-673). Using phocein as a bait in a yeast two-hybrid screen, we identified two novel interacting proteins, nucleoside-diphosphate kinase (NDPK) and Eps15. Immunoprecipitation and pull-down experiments involving native and/or recombinant phocein and, respectively, NDPK and Eps15, biochemically validated their interactions. NDPK and Eps15 were recently shown to be functional neighbors of dynamin. Dynamin I is shown here to directly interact with NDPK through its C-terminal proline-rich domain, whereas recombinant phocein associates with native dynamin I. Immunocytochemical studies of rat embryonic hippocampal neurons demonstrated partial co-localization of phocein and dynamin I. Phocein thus appears to be a component of the complexes involved in some steps of the vesicular traffic machinery.	Fac Med Nord, INSERM, U464, F-13916 Marseille 20, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite	Castets, F (corresponding author), Fac Med Nord, INSERM, U464, Bd Pierre Dramard, F-13916 Marseille 20, France.			Gaillard, Stephane/0000-0001-9326-5363				Baillat G, 2001, MOL BIOL CELL, V12, P663, DOI 10.1091/mbc.12.3.663; Bartoli M, 1999, J NEUROBIOL, V40, P234, DOI 10.1002/(SICI)1097-4695(199908)40:2<234::AID-NEU9>3.3.CO;2-K; Bartoli M, 1998, J BIOL CHEM, V273, P22248, DOI 10.1074/jbc.273.35.22248; Benmerah A, 1999, J CELL SCI, V112, P1303; Benmerah A, 1996, J BIOL CHEM, V271, P12111, DOI 10.1074/jbc.271.20.12111; Cao H, 2000, J CELL SCI, V113, P1993; Castets F, 2000, J BIOL CHEM, V275, P19970, DOI 10.1074/jbc.M909782199; Castets F, 1996, J CELL BIOL, V134, P1051, DOI 10.1083/jcb.134.4.1051; Dagher MC, 1997, BIOTECHNIQUES, V22, P916, DOI 10.2144/97225st05; Di Fiore PP, 2001, CELL, V106, P1, DOI 10.1016/S0092-8674(01)00428-7; Estes PS, 1996, J NEUROSCI, V16, P5443; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; Goslin K., 1998, CULTURING NERVE CELL, P339; Grabs D, 1997, J BIOL CHEM, V272, P13419, DOI 10.1074/jbc.272.20.13419; Hill E, 2001, J CELL BIOL, V152, P309, DOI 10.1083/jcb.152.2.309; Hinshaw JE, 2000, ANNU REV CELL DEV BI, V16, P483, DOI 10.1146/annurev.cellbio.16.1.483; Iannolo G, 1997, CANCER RES, V57, P240; Jones SM, 1998, SCIENCE, V279, P573, DOI 10.1126/science.279.5350.573; KIKKAWA S, 1990, J BIOL CHEM, V265, P21536; KIMMEL AR, 1987, METHOD ENZYMOL, V152, P307; Klinker JF, 1999, EUR J BIOCHEM, V261, P72, DOI 10.1046/j.1432-1327.1999.00209.x; Krishnan KS, 2001, NEURON, V30, P197, DOI 10.1016/S0896-6273(01)00273-2; Lamaze C, 2001, MOL CELL, V7, P661, DOI 10.1016/S1097-2765(01)00212-X; Marks B, 2001, NATURE, V410, P231, DOI 10.1038/35065645; Martina JA, 2001, J CELL BIOL, V153, P1111, DOI 10.1083/jcb.153.5.1111; McNiven MA, 2000, TRENDS BIOCHEM SCI, V25, P115, DOI 10.1016/S0968-0004(99)01538-8; MCPHERSON PS, 1994, J BIOL CHEM, V269, P30132; Moreno CS, 2001, J BIOL CHEM, V276, P24253, DOI 10.1074/jbc.M102398200; NODA Y, 1993, NEUROSCIENCE, V55, P113, DOI 10.1016/0306-4522(93)90459-S; Otsuki Y, 2001, P NATL ACAD SCI USA, V98, P4385, DOI 10.1073/pnas.071411598; Parks R.E., 1973, ENZYMES, V8, P307, DOI [10.1016/S1874-6047(08)60069-4, DOI 10.1016/S1874-6047(08)60069-4]; POWELL KA, 1995, NEUROSCIENCE, V64, P821, DOI 10.1016/0306-4522(94)00337-5; Salcini AE, 2001, NAT CELL BIOL, V3, P755, DOI 10.1038/35087075; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; Schmid SL, 1998, CURR OPIN CELL BIOL, V10, P504, DOI 10.1016/S0955-0674(98)80066-5; SHIMADA N, 1993, J BIOL CHEM, V268, P2583; SHPETNER HS, 1992, NATURE, V355, P733, DOI 10.1038/355733a0; TAKEI K, 1995, NATURE, V374, P186, DOI 10.1038/374186a0; Tebar F, 1996, J BIOL CHEM, V271, P28727, DOI 10.1074/jbc.271.46.28727; Torrisi MR, 1999, MOL BIOL CELL, V10, P417, DOI 10.1091/mbc.10.2.417; Zhu JH, 1999, P NATL ACAD SCI USA, V96, P14911, DOI 10.1073/pnas.96.26.14911	41	47	49	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 24	2002	277	21					18961	18966		10.1074/jbc.M108818200	http://dx.doi.org/10.1074/jbc.M108818200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	558PM	11872741	hybrid			2022-12-27	WOS:000175975800093
J	Caccuri, AM; Antonini, G; Allocati, N; Di Ilio, C; De Maria, F; Innocenti, F; Parker, MW; Masulli, M; Lo Bello, M; Turella, P; Federici, G; Ricci, G				Caccuri, AM; Antonini, G; Allocati, N; Di Ilio, C; De Maria, F; Innocenti, F; Parker, MW; Masulli, M; Lo Bello, M; Turella, P; Federici, G; Ricci, G			GSTB1-1 from Proteus mirabilis - A snapshot of an enzyme in the evolutionary pathway from a redox enzyme to a conjugating enzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUTATHIONE-S-TRANSFERASE; ACTIVE-SITE; CATALYTIC MECHANISM; CRYSTAL-STRUCTURE; DISULFIDE OXIDOREDUCTASE; 3-DIMENSIONAL STRUCTURE; PROTON RELEASE; BLOOD-CELLS; ALPHA-CLASS; THIOLTRANSFERASE	The native form of the bacterial glutathione transferase B1-1 (EC 2.5.1.18) is characterized by one glutathione (GSH) molecule covalently linked to Cys-10. This peculiar disulfide, only found in the Beta and Omega class glutathione S-transferases (GSTs) but absent in all other GSTs, prompts questions about its role and how GSH can be activated and utilized in the reaction normally performed by GSTs. Stopped-flow and spectroscopic experiments suggest that, in the native enzyme (GSTB1-1ox), a second GSH molecule is present, albeit transiently, in the active site. This second GSH binds to the enzyme through a bimolecular interaction followed by a fast thiol-disulfide exchange with the covalently bound GSH. The apparent pK(a) of the non-covalently bound GSH is lowered from 9.0 to 6.4 +/- 0.2 in similar fashion to other GSTs. The reduced form of GSTB1-1 (GSTB1-1red) binds GSH 100-fold faster and also induces a more active deprotonation of the substrate with an apparent pK(a) of 5.2 +/- 0.1. Apparently, the absence of the mixed disulfide does not affect k(cat), and K-m values in the GST conjugation activity, which is rate-limited by the chemical step both in GSTB1-1red and in GSTB1-1ox. However, GSTB1-1ox follows a steady-state random sequential mechanism whereas a rapid-equilibrium random sequential mechanism is adopted by GSTB1-1red. Remarkably, GSTB1-lox and GSTB1-1red are equally able to catalyze a glutaredoxin-like catalysis using cysteine S-sulfate and hydroxyethyl disulfide as substrates. Cys-10 is an essential residue in this redox activity, and its replacement by alanine abolishes this enzymatic activity completely. It appears that GSTB1-1 behaves like an "intermediate enzyme" between the thiol-disulfide oxidoreductase and the GST superfamilies.	Univ Roma Tor Vergata, Dept Biol, RM-00133 Rome, Italy; Univ Aquila, Dept Basic & Appl Biol, I-67010 Coppito, Italy; Univ Rome 3, Dept Biol, I-00145 Rome, Italy; Univ Chieti, Dept Biomed Sci, I-66013 Chieti, Italy; St Vincents Inst Med Res, Biota Struct Biol Lab, Fitzroy, Vic 3065, Australia; Univ Roma La Sapienza, Dept Biochem Sci, I-00185 Rome, Italy; Childrens Hosp, Ist Ric & Cura Carattere Sci, I-00165 Rome, Italy	University of Rome Tor Vergata; University of L'Aquila; Roma Tre University; G d'Annunzio University of Chieti-Pescara; St. Vincent's Institute of Medical Research; Sapienza University Rome	Ricci, G (corresponding author), Univ Roma Tor Vergata, Dept Biol, Viale Ric Sci, RM-00133 Rome, Italy.		Parker, Michael W/F-9069-2013; CACCURI, ANNA MARIA/AFU-2643-2022	Parker, Michael W/0000-0002-3101-1138; MASULLI, Michele/0000-0003-0235-709X; CACCURI, ANNA MARIA/0000-0002-3756-4163; Antonini, Giovanni/0000-0002-2115-8961; ALLOCATI, Nerino/0000-0003-2670-8085				Adler V, 1999, EMBO J, V18, P1321, DOI 10.1093/emboj/18.5.1321; ALLOCATI N, 1994, FEBS LETT, V354, P191, DOI 10.1016/0014-5793(94)01115-X; Armstrong RN, 1997, CHEM RES TOXICOL, V10, P2, DOI 10.1021/tx960072x; AXELSSON K, 1978, BIOCHEMISTRY-US, V17, P2978, DOI 10.1021/bi00608a006; Board PG, 1997, BIOCHEM J, V328, P929; Board PG, 2000, J BIOL CHEM, V275, P24798, DOI 10.1074/jbc.M001706200; BUETLER TM, 1992, J ENVIRON SCI HEAL C, V10, P181; Caccuri AM, 2002, BIOCHEMISTRY-US, V41, P4686, DOI 10.1021/bi0158425; Caccuri AM, 2001, J BIOL CHEM, V276, P5427, DOI 10.1074/jbc.M002819200; Caccuri AM, 1998, BIOCHEMISTRY-US, V37, P3028, DOI 10.1021/bi971903g; Caccuri AM, 1999, BIOCHEM J, V344, P419, DOI 10.1042/0264-6021:3440419; CAMERON AD, 1995, STRUCTURE, V3, P717, DOI 10.1016/S0969-2126(01)00206-4; Casalone E, 1998, FEBS LETT, V423, P122, DOI 10.1016/S0014-5793(98)00080-5; Chivers PT, 1997, BIOCHEMISTRY-US, V36, P15810, DOI 10.1021/bi971504l; DIILIO C, 1988, BIOCHEM J, V255, P971, DOI 10.1042/bj2550971; DIRR H, 1994, EUR J BIOCHEM, V220, P645, DOI 10.1111/j.1432-1033.1994.tb18666.x; Dulhunty A, 2001, J BIOL CHEM, V276, P3319, DOI 10.1074/jbc.M007874200; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; GRAMINSKI GF, 1989, BIOCHEMISTRY-US, V28, P3562, DOI 10.1021/bi00434a062; GRAVINA SA, 1993, BIOCHEMISTRY-US, V32, P3368, DOI 10.1021/bi00064a021; JAKOBY WB, 1980, ENZYMATIC BASIS DETO, V2, P63; Kampranis SC, 2000, J BIOL CHEM, V275, P29207, DOI 10.1074/jbc.M002359200; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LITWACK G, 1971, NATURE, V234, P466, DOI 10.1038/234466a0; LIU SX, 1992, J BIOL CHEM, V267, P4296; MANNERVIK B, 1985, P NATL ACAD SCI USA, V82, P7202, DOI 10.1073/pnas.82.21.7202; MANNERVIK B, 1986, CHEM SCRIPTA, V26B, P281; MARTIN JL, 1995, STRUCTURE, V3, P245, DOI 10.1016/S0969-2126(01)00154-X; MEYER DJ, 1995, BIOCHEM J, V311, P739, DOI 10.1042/bj3110739; MEYER DJ, 1991, BIOCHEM J, V274, P409, DOI 10.1042/bj2740409; MIEYAL JJ, 1991, BIOCHEMISTRY-US, V30, P6088, DOI 10.1021/bi00239a002; MIEYAL JJ, 1991, BIOCHEMISTRY-US, V30, P8883, DOI 10.1021/bi00100a023; Nishida M, 1998, J MOL BIOL, V281, P135, DOI 10.1006/jmbi.1998.1927; Nordstrand K, 1999, J MOL BIOL, V286, P541, DOI 10.1006/jmbi.1998.2444; Oakley AJ, 1997, J MOL BIOL, V274, P84, DOI 10.1006/jmbi.1997.1364; Pemble SE, 1996, BIOCHEM J, V319, P749, DOI 10.1042/bj3190749; Perito B, 1996, BIOCHEM J, V318, P157, DOI 10.1042/bj3180157; Piredda L, 1999, FASEB J, V13, P355, DOI 10.1096/fasebj.13.2.355; RAGHUNATHAN S, 1994, J MOL BIOL, V238, P815, DOI 10.1006/jmbi.1994.1336; Reinemer P, 1996, J MOL BIOL, V255, P289, DOI 10.1006/jmbi.1996.0024; Ricci G, 1996, J BIOL CHEM, V271, P16187, DOI 10.1074/jbc.271.27.16187; Rossjohn J, 1998, STRUCT FOLD DES, V6, P721, DOI 10.1016/S0969-2126(98)00074-4; Rossjohn J, 1998, STRUCTURE, V6, P309, DOI 10.1016/S0969-2126(98)00034-3; Schmidt DMZ, 2001, BIOCHEMISTRY-US, V40, P15707, DOI 10.1021/bi011640x; Segel IH, 1975, ENZYME KINETICS, P460; Srinivasan U, 1997, BIOCHEMISTRY-US, V36, P3199, DOI 10.1021/bi962017t; TOUNG YPS, 1993, J BIOL CHEM, V268, P9737; WILCE MCJ, 1995, EMBO J, V14, P2133, DOI 10.1002/j.1460-2075.1995.tb07207.x; Wilce MCJ, 1994, BIOCHIM BIOPHYS ACTA, V205, P1	49	37	38	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 24	2002	277	21					18777	18784		10.1074/jbc.M201137200	http://dx.doi.org/10.1074/jbc.M201137200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	558PM	11889135	hybrid			2022-12-27	WOS:000175975800071
J	Srisailam, S; Wang, HM; Kumar, TKS; Rajalingam, D; Sivaraja, V; Sheu, HS; Chang, YC; Yu, C				Srisailam, S; Wang, HM; Kumar, TKS; Rajalingam, D; Sivaraja, V; Sheu, HS; Chang, YC; Yu, C			Amyloid-like fibril formation in an all beta-barrel protein involves the formation of partially structured intermediate(s)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBROBLAST-GROWTH-FACTOR; ALZHEIMERS-DISEASE; PRION PROTEIN; SH3 DOMAIN; AGGREGATION; FIBRILLOGENESIS; TRANSTHYRETIN; PATHWAY; MODEL; STATE	In the present study, we demonstrate the thermal induced amyloid formation in a beta-barrel protein, such as the acidic fibroblast growth factor from Notopthalmus viridescens (nFGF-1). Fibril formation in nFGF-1 is observed to occur maximally at 65 degreesC. Electron microscope analysis of the thermal induced fibrils of nFGF-1 shows that they are filamentous with an average diameter of about 20 nm. X-ray diffraction analysis reveals that the thermal induced fibrils of nFGF-1 have a typical "cross-beta" structure with the beta-strands perpendicular to the fibril axis. By using a variety of biophysical techniques including multidimensional NMR, we demonstrate that fibril formation involves the formation of a partially structured intermediate(s) in the thermal unfolding pathway of the protein (nFGF-1). Results of the anilino-8-napthalene sulfonate binding experiments indicate that fibril formation occurs due to the coalescence of the protein (in the intermediate state(s)) through the solvent-exposed non-polar surface(s). In this study, we also demonstrate that organic osmolytes, such as proline, can efficiently prevent the thermal induced amyloid formation in nFGF-1. Proline is found to stabilize the native conformation of the protein. The addition, proline is observed to increase the cooperativity of the unfolding (native <-> denatured) reaction and consequently decrease the population of the "sticky" thermal equilibrium intermediate(s) responsible for the fibril formation.	Natl Tsing Hua Univ, Dept Chem, Hsinchu 30043, Taiwan; Synchrotron Radiat Res Ctr, Hsinchu 30043, Taiwan; Natl Tsing Hua Univ, Dept Life Sci, Hsinchu 30043, Taiwan	National Tsing Hua University; National Synchrotron Radiation Research Center; National Tsing Hua University	Yu, C (corresponding author), Natl Tsing Hua Univ, Dept Chem, Sci Based Ind Pk, Hsinchu 30043, Taiwan.	cyu@mx.nthu.edu.tw	Kumar, Suresh Thallapuranam/R-5606-2016; KUMAR, P. SURESH/AAT-8951-2020; Kumar, Dr Suresh/HHZ-2615-2022	Kumar, Suresh Thallapuranam/0000-0001-7262-1373; KUMAR, P. SURESH/0000-0003-3222-2604; Kumar, Dr Suresh/0000-0002-2539-6553				Arunkumar AI, 2000, J BIOMOL NMR, V17, P279, DOI 10.1023/A:1008339701691; Blackley HKL, 1999, EXP NEUROL, V158, P437, DOI 10.1006/exnr.1999.7114; CAIT E, 2000, J AM CHEM SOC, V122, P12707; Callahan NA, 2001, J BIOL CHEM, V276, P28022, DOI 10.1074/jbc.M103629200; Caughey B, 1997, J VIROL, V71, P4107, DOI 10.1128/JVI.71.5.4107-4110.1997; CHEN YH, 1972, BIOCHEMISTRY-US, V11, P4120, DOI 10.1021/bi00772a015; Chi YH, 2000, J BIOL CHEM, V275, P39444, DOI 10.1074/jbc.M007205200; Chiti F, 1999, P NATL ACAD SCI USA, V96, P3590, DOI 10.1073/pnas.96.7.3590; Chiti F, 2001, J BIOL CHEM, V276, P46714, DOI 10.1074/jbc.M107040200; Chiti F, 2001, PROTEIN SCI, V10, P2541, DOI 10.1110/ps.ps.10201; Dobson CM, 2001, PHILOS T R SOC B, V356, P133, DOI 10.1098/rstb.2000.0758; Donne DG, 1997, P NATL ACAD SCI USA, V94, P13452, DOI 10.1073/pnas.94.25.13452; Fink AL, 1998, FOLD DES, V3, pR9, DOI 10.1016/S1359-0278(98)00002-9; Guijarro JI, 1998, P NATL ACAD SCI USA, V95, P4224, DOI 10.1073/pnas.95.8.4224; HARIS PI, 1995, BIOPOLYMERS, V37, P251, DOI 10.1002/bip.360370404; Harper JD, 1999, BIOCHEMISTRY-US, V38, P8972, DOI 10.1021/bi9904149; Inouye H, 2000, J STRUCT BIOL, V130, P123, DOI 10.1006/jsbi.2000.4258; Kelly JW, 1997, STRUCTURE, V5, P595, DOI 10.1016/S0969-2126(97)00215-3; Kelly JW, 2000, NAT STRUCT BIOL, V7, P824, DOI 10.1038/82815; Lashuel HA, 1999, BIOCHEMISTRY-US, V38, P13560, DOI 10.1021/bi991021c; MacPhee CE, 2000, J MOL BIOL, V297, P1203, DOI 10.1006/jmbi.2000.3600; MATTHEWS CR, 1993, ANNU REV BIOCHEM, V62, P653, DOI 10.1146/annurev.bi.62.070193.003253; McLaurin J, 1999, EUR J BIOCHEM, V266, P1101, DOI 10.1046/j.1432-1327.1999.00957.x; Nettleton EJ, 1998, J MOL BIOL, V281, P553, DOI 10.1006/jmbi.1998.1937; Pertinhez TA, 2001, FEBS LETT, V495, P184, DOI 10.1016/S0014-5793(01)02384-5; PTITSYN OB, 1990, FEBS LETT, V262, P20, DOI 10.1016/0014-5793(90)80143-7; Rochet JC, 2000, CURR OPIN STRUC BIOL, V10, P60, DOI 10.1016/S0959-440X(99)00049-4; Samuel D, 2001, J BIOL CHEM, V276, P4134, DOI 10.1074/jbc.M005921200; Samuel D, 2000, PROTEIN SCI, V9, P344; Samuel D, 2000, J BIOL CHEM, V275, P34968, DOI 10.1074/jbc.M005147200; Selkoe DJ, 1996, J BIOL CHEM, V271, P18295, DOI 10.1074/jbc.271.31.18295; SERPELL LC, 1995, J MOL BIOL, V254, P113, DOI 10.1006/jmbi.1995.0604; Souillac PO, 2002, J BIOL CHEM, V277, P12666, DOI 10.1074/jbc.M109229200; SRINIVAS V, 1995, LANGMUIR, V11, P2830, DOI 10.1021/la00007a077; Sunde M, 1998, Q REV BIOPHYS, V31, P1, DOI 10.1017/S0033583598003400; Sunde M, 1997, ADV PROTEIN CHEM, V50, P123, DOI 10.1016/S0065-3233(08)60320-4; TIMASHEFF SN, 1993, ANNU REV BIOPH BIOM, V22, P67, DOI 10.1146/annurev.bb.22.060193.000435; Tjernberg LO, 1999, J BIOL CHEM, V274, P12619, DOI 10.1074/jbc.274.18.12619; Walsh DM, 1999, J BIOL CHEM, V274, P25945, DOI 10.1074/jbc.274.36.25945; Wang AJ, 1997, BIOCHEMISTRY-US, V36, P9101, DOI 10.1021/bi970247h; WETZEL R, 1994, TRENDS BIOTECHNOL, V12, P193, DOI 10.1016/0167-7799(94)90082-5; YANCEY PH, 1982, SCIENCE, V217, P1214, DOI 10.1126/science.7112124; Yang DS, 1999, J BIOL CHEM, V274, P32970, DOI 10.1074/jbc.274.46.32970; Zurdo J, 2001, J MOL BIOL, V311, P325, DOI 10.1006/jmbi.2001.4858; Zurdo J, 2001, J AM CHEM SOC, V123, P8141, DOI 10.1021/ja016229b	45	59	59	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 24	2002	277	21					19027	19036		10.1074/jbc.M110762200	http://dx.doi.org/10.1074/jbc.M110762200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	558PM	11877422	hybrid			2022-12-27	WOS:000175975800102
J	Tristani-Firouzi, M; Chen, J; Sanguinetti, MC				Tristani-Firouzi, M; Chen, J; Sanguinetti, MC			Interactions between S4-S5 linker and S6 transmembrane domain modulate gating of HERG K+ channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POTASSIUM CHANNEL; VOLTAGE SENSOR; ACTIVATION; INACTIVATION; REGION; CONDUCTION; MOVEMENT; CURRENTS; PARTS; PORE	Outward movement of the voltage sensor is coupled to activation in voltage-gated ion channels; however, the precise mechanism and structural basis of this gating event are poorly understood. Potential insight into the coupling mechanism was provided by our previous finding that mutation to Lys of a single residue (Asp(540)) located in the S4-S5 linker endowed HERG (human ether-a-go-go-related gene) K+ channels with the unusual ability to open in response to membrane depolarization and hyperpolarization in a voltage-dependent manner. We hypothesized that the unusual hyperpolarization-induced gating occurred through an interaction between Lys(540) and the C-terminal end of the S6 domain, the region proposed to form the activation gate. Therefore, we mutated six residues located in this region of S6 (Ile(662)-Tyr(667)) to Ala in D540K HERG channels. Mutation of Arg(665), but not the other five residues, prevented hyperpolarization-dependent reopening of D540K HERG channels. Mutation of Arg(665) to Gln or Asp also prevented reopening. In addition, D540R and D540K/R665K BERG reopened in response to hyperpolarization. Together these findings suggest that a single residue (Arg(665)) in the S6 domain interacts with Lys(540) by electrostatic repulsion to couple voltage sensing to hyperpolarization-dependent opening of D540K EIERG K+ channels. Moreover, our findings suggest that the C-terminal ends of S4 and S6 are in close proximity at hyperpolarized membrane potentials.	Univ Utah, Sch Med, Dept Pediat, Salt Lake City, UT 84112 USA; Univ Utah, Sch Med, Dept Med, Salt Lake City, UT 84112 USA; Univ Utah, Sch Med, Eccles Program Human Mol Biol & Genet, Salt Lake City, UT 84112 USA	Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah	Tristani-Firouzi, M (corresponding author), Univ Utah, Sch Med, Suite 1500 PCMC,100 N Med Dr, Salt Lake City, UT 84113 USA.	mfirouzi@hmbg.utah.edu	Sanguinetti, Michael/AAN-2615-2020		NHLBI NIH HHS [HL03816, HL65299] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL065299] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BEZANILLA F, 1994, BIOPHYS J, V66, P1011, DOI 10.1016/S0006-3495(94)80882-3; Caprini M, 2001, J BIOL CHEM, V276, P21070, DOI 10.1074/jbc.M100487200; Cha A, 1999, NATURE, V402, P809, DOI 10.1038/45552; Chiavegatto S, 2001, P NATL ACAD SCI USA, V98, P1277, DOI 10.1073/pnas.031487198; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; Durell SR, 1998, J STRUCT BIOL, V121, P263, DOI 10.1006/jsbi.1998.3962; Gillian AL, 2001, BIOPHYS J, V80, p212A; Glauner KS, 1999, NATURE, V402, P813, DOI 10.1038/45561; Holmgren M, 1996, J GEN PHYSIOL, V108, P195, DOI 10.1085/jgp.108.3.195; Liu Y, 1997, NEURON, V19, P175, DOI 10.1016/S0896-6273(00)80357-8; Liu YS, 2001, NAT STRUCT BIOL, V8, P883, DOI 10.1038/nsb1001-883; Lu Z, 2001, NATURE, V413, P809, DOI 10.1038/35101535; Mitcheson JS, 2000, J GEN PHYSIOL, V115, P229, DOI 10.1085/jgp.115.3.229; Mitcheson JS, 2000, P NATL ACAD SCI USA, V97, P12329, DOI 10.1073/pnas.210244497; PEROZO E, 1992, BIOPHYS J, V62, P160, DOI 10.1016/S0006-3495(92)81802-7; Perozo E, 1999, SCIENCE, V285, P73, DOI 10.1126/science.285.5424.73; SANGUINETTI MC, 1995, CELL, V81, P299, DOI 10.1016/0092-8674(95)90340-2; Sanguinetti MC, 1999, J PHYSIOL-LONDON, V514, P667, DOI 10.1111/j.1469-7793.1999.667ad.x; SARKAR G, 1990, BIOTECHNIQUES, V8, P404; Shieh CC, 1997, J GEN PHYSIOL, V109, P767, DOI 10.1085/jgp.109.6.767; STEFANI E, 1994, BIOPHYS J, V66, P996, DOI 10.1016/S0006-3495(94)80881-1; STUHMER W, 1989, NATURE, V339, P597, DOI 10.1038/339597a0; STUHMER W, 1992, METHOD ENZYMOL, V207, P319; Tang CY, 2000, J GEN PHYSIOL, V115, P319, DOI 10.1085/jgp.115.3.319; TRUDEAU MC, 1995, SCIENCE, V269, P92, DOI 10.1126/science.7604285; Yellen G, 1998, Q REV BIOPHYS, V31, P239, DOI 10.1017/S0033583598003448	26	142	146	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 24	2002	277	21					18994	19000		10.1074/jbc.M200410200	http://dx.doi.org/10.1074/jbc.M200410200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	558PM	11864984	hybrid			2022-12-27	WOS:000175975800098
J	Wang, CG; Risteli, M; Heikkinen, J; Hussa, AK; Uitto, L; Myllyla, R				Wang, CG; Risteli, M; Heikkinen, J; Hussa, AK; Uitto, L; Myllyla, R			Identification of amino acids important for the catalytic activity of the collagen glucosyltransferase associated with the multifunctional lysyl hydroxylase 3 (LH3)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CROSS-LINKS; GLYCOSYLTRANSFERASES; CLONING; ISOFORM; MOUSE; RESIDUES	Collagen glucosyltransferase (GGT) activity has recently been shown to be associated with human lysyl hydroxylase (LH) isoform. 3 (LH3) (Heikkinen, J., Risteli, M., Wang, C., Latvala, J., Rossi, M., Valtavaara, M., Myllyla, R. (2000) J. Biol. Chem. 275, 36158-36163). The LH and GGT activities of the multifunctional LH3 protein modify lysyl residues in collagens posttranslationally to form hydroxylysyl and glucosylgalactosyl hydroxylysyl residues respectively. We now report that in the nematode, Caenorhabditis elegans, where only one ortholog is found for lysyl hydroxylase, the LH and GGT activities are also associated with the same gene product. The aim of the present studies is the identification of amino acids important for the catalytic activity of GGT. Our data indicate that the GGT active site is separate from the carboxyl-terminal LH active site of human LH3, the amino acids important for the GGT activity being located at the amino-terminal part of the molecule. Site-directed mutagenesis of a conserved cysteine at position 144 to isoleucine and a leucine at position 208 to isoleucine caused a marked reduction in GGT activity. These amino acids were conserved in C elegans LH and mammalian LH3, but not in LH1 or LH2, which lack GGT activity. The data also reveal a DXD-like motif in LH3 characteristic of many glycosyltransferases and the mutagenesis of aspartates of this motif eliminated the GGT activity. Reduction in GGT activity was not accompanied by a change in the LH activity of the molecule. Thus GGT activity can be manipulated independently of LH activity in LH3. These data provide the information needed to design knock-out studies for investigation of the function of glucosylgalactosyl hydroxylysyl residues of collagens in vivo.	Univ Oulu, Bioctr Oulu, Dept Biochem, FIN-90014 Oulu, Finland	Finland National Institute for Health & Welfare; University of Oulu	Myllyla, R (corresponding author), Univ Oulu, Bioctr Oulu, Dept Biochem, POB 3000, FIN-90014 Oulu, Finland.	raili.myllyla@oulu.fi	Wang, Chunguang/AAE-6997-2020; Wang, Chunguang/AAE-7054-2020	Wang, Chunguang/0000-0001-5569-321X				Adams MD, 2000, SCIENCE, V287, P2185, DOI 10.1126/science.287.5461.2185; AYAD S, 1998, EXTRACELLULAR MATRIX, P43; BATEMAN JF, 1996, EXTRACELLULAR MATRIX, V2, P22; Blaxter M, 2000, YEAST, V17, P37, DOI 10.1002/(SICI)1097-0061(200004)17:1<37::AID-YEA11>3.0.CO;2-P; BRAAKMAN I, 1992, EMBO J, V11, P1717, DOI 10.1002/j.1460-2075.1992.tb05223.x; Brinckmann J, 1999, J INVEST DERMATOL, V113, P617, DOI 10.1046/j.1523-1747.1999.00735.x; Dennis JW, 1999, BIOESSAYS, V21, P412, DOI 10.1002/(SICI)1521-1878(199905)21:5<412::AID-BIES8>3.0.CO;2-5; Gastinel LN, 2001, EMBO J, V20, P638, DOI 10.1093/emboj/20.4.638; HAUTALA T, 1992, GENOMICS, V13, P62, DOI 10.1016/0888-7543(92)90202-4; Heikkinen J, 2000, J BIOL CHEM, V275, P36158, DOI 10.1074/jbc.M006203200; KADLER K, 1994, PROTEIN PROFILE, V1, P519; Kielty Cay M., 1993, P103; Kivirikko K I, 1979, Int Rev Connect Tissue Res, V8, P23; KIVIRIKKO KI, 1982, METHOD ENZYMOL, V82, P245; Knott L, 1998, BONE, V22, P181, DOI 10.1016/S8756-3282(97)00279-2; Moro L, 2000, CALCIFIED TISSUE INT, V66, P151, DOI 10.1007/s002230010030; MYLLYLA R, 1975, EUR J BIOCHEM, V52, P401, DOI 10.1111/j.1432-1033.1975.tb04008.x; Norman KR, 2000, DEV BIOL, V227, P690, DOI 10.1006/dbio.2000.9897; Notbohm H, 1999, J BIOL CHEM, V274, P8988, DOI 10.1074/jbc.274.13.8988; Passoja K, 1998, P NATL ACAD SCI USA, V95, P10482, DOI 10.1073/pnas.95.18.10482; Passoja K, 1998, FEBS LETT, V434, P145, DOI 10.1016/S0014-5793(98)00966-1; Pirskanen A, 1996, J BIOL CHEM, V271, P9398, DOI 10.1074/jbc.271.16.9398; PROCKOP DJ, 1995, ANNU REV BIOCHEM, V64, P403, DOI 10.1146/annurev.biochem.64.1.403; Ruotsalainen H, 1999, MATRIX BIOL, V18, P325, DOI 10.1016/S0945-053X(99)00016-5; Sipila L, 2000, MAMM GENOME, V11, P1132, DOI 10.1007/s003350010214; Unligil UM, 2000, EMBO J, V19, P5269, DOI 10.1093/emboj/19.20.5269; Valtavaara M, 1997, J BIOL CHEM, V272, P6831, DOI 10.1074/jbc.272.11.6831; Valtavaara M, 1998, J BIOL CHEM, V273, P12881, DOI 10.1074/jbc.273.21.12881; Vollrath B, 2001, MOL CELL BIOL, V21, P5688, DOI 10.1128/MCB.21.16.5688-5697.2001; Wassen MHM, 2000, J BONE MINER RES, V15, P1776, DOI 10.1359/jbmr.2000.15.9.1776	30	43	48	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 24	2002	277	21					18568	18573		10.1074/jbc.M201389200	http://dx.doi.org/10.1074/jbc.M201389200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	558PM	11896059	hybrid			2022-12-27	WOS:000175975800043
J	Johnson, BA; Stehn, JR; Yaffe, MB; Blackwell, TK				Johnson, BA; Stehn, JR; Yaffe, MB; Blackwell, TK			Cytoplasmic localization of tristetraprolin involves 14-3-3-dependent and -independent mechanisms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AU-RICH ELEMENTS; ACTIVATED PROTEIN-KINASE; ALPHA MESSENGER-RNA; FINGER TRANSCRIPTION FACTOR; EARLY RESPONSE GENES; TNF-ALPHA; C-ELEGANS; NUCLEOCYTOPLASMIC TRANSPORT; DEFICIENCY SYNDROME; P38 MAPK	The immediate early gene tristetraprolin (TTP) is induced transiently in many cell types by numerous extracellular stimuli TTP encodes a zinc finger protein that can bind and destabilize mRNAs that encode tumor necrosis factor-alpha (TNFalpha) and other cytokines. We hypothesize that TTP also has a broader role in growth factor-responsive pathways. In support of this model, we have previously determined that TTP induces apoptosis through the mitochondrial pathway, analogously to certain oncogenes and other immediate-early genes, and that TTP sensitizes cells to the pro-apoptotic signals of TNFa. In this study, we show that TTP and the related proteins TIS11b and TIS11d bind specifically to 14-3-3 proteins and that individual 14-3-3 isoforms preferentially bind to different phosphorylated TTP species. 14-3-3 binding does not appear to inhibit or promote induction of apoptosis by TTP but is one of multiple mechanisms that localize TTP to the cytoplasm. Our results provide the first example of 14-3-3 interacting functionally with an RNA binding protein and binding in vivo to a Type 11 14-3-3 binding site. They also suggest that 14-3-3 binding is part of a complex network of stimuli and interactions that regulate TTP function.	Harvard Univ, Sch Med, Ctr Blood Res, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA; MIT, Ctr Canc Res, Dept Biol, Cambridge, MA 02139 USA	Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Harvard Medical School; Harvard University; Harvard Medical School; Massachusetts Institute of Technology (MIT)	Blackwell, TK (corresponding author), Harvard Univ, Sch Med, Ctr Blood Res, 200 Longwood Ave, Boston, MA 02115 USA.	blackwell@cbr.med.harvard.edu	Stehn, Justine/G-5115-2013	Stehn, Justine/0000-0002-2136-5450	NCI NIH HHS [CA84418] Funding Source: Medline; NIGMS NIH HHS [GM60594] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA084418] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060594] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bustin SA, 1999, DNA CELL BIOL, V18, P653, DOI 10.1089/104454999315060; Carballo E, 1997, J CLIN INVEST, V100, P986, DOI 10.1172/JCI119649; Carballo E, 2000, BLOOD, V95, P1891, DOI 10.1182/blood.V95.6.1891; Carballo E, 1998, SCIENCE, V281, P1001, DOI 10.1126/science.281.5379.1001; Carballo E, 2001, J BIOL CHEM, V276, P42580, DOI 10.1074/jbc.M104953200; Carballo E, 2001, BLOOD, V98, P2389, DOI 10.1182/blood.V98.8.2389; CHEN CYA, 1995, TRENDS BIOCHEM SCI, V20, P465, DOI 10.1016/S0968-0004(00)89102-1; DUBOIS RN, 1995, CELL GROWTH DIFFER, V6, P523; Dumitru CD, 2000, CELL, V103, P1071, DOI 10.1016/S0092-8674(00)00210-5; Gorlich D, 1996, SCIENCE, V271, P1513, DOI 10.1126/science.271.5255.1513; Guedes S, 1997, DEVELOPMENT, V124, P731; HAAS CA, 1993, NEUROSCIENCE, V53, P91, DOI 10.1016/0306-4522(93)90287-P; Harkin DP, 1999, CELL, V97, P575, DOI 10.1016/S0092-8674(00)80769-2; HEXIMER SP, 1993, DNA CELL BIOL, V12, P73, DOI 10.1089/dna.1993.12.73; Johnson BA, 2000, ONCOGENE, V19, P1657, DOI 10.1038/sj.onc.1203474; JOHNSON BA, 2002, IN PRESS ONCOGENE; Kontoyiannis D, 1999, IMMUNITY, V10, P387, DOI 10.1016/S1074-7613(00)80038-2; Kontoyiannis D, 2001, EMBO J, V20, P3760, DOI 10.1093/emboj/20.14.3760; Kotlyarov A, 1999, NAT CELL BIOL, V1, P94, DOI 10.1038/10061; Kronnie GT, 2001, DEV GENES EVOL, V211, P261, DOI 10.1007/s004270100145; Lai WS, 2000, J BIOL CHEM, V275, P17827, DOI 10.1074/jbc.M001696200; LAI WS, 1990, J BIOL CHEM, V265, P16556; Lai WS, 1999, MOL CELL BIOL, V19, P4311; Mahtani KR, 2001, MOL CELL BIOL, V21, P6461, DOI 10.1128/MCB.21.9.6461-6469.2001; MESNER PW, 1995, J NEUROSCI, V15, P7357; Ming XF, 2001, MOL CELL BIOL, V21, P5778, DOI 10.1128/MCB.21.17.5778-5789.2001; MITTELSTADT PR, 1993, J IMMUNOL, V150, P4822; Muslin AJ, 1996, CELL, V84, P889, DOI 10.1016/S0092-8674(00)81067-3; Muslin AJ, 2000, CELL SIGNAL, V12, P703, DOI 10.1016/S0898-6568(00)00131-5; Nigg EA, 1997, NATURE, V386, P779, DOI 10.1038/386779a0; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; Phillips RS, 2002, J BIOL CHEM, V277, P11606, DOI 10.1074/jbc.M111457200; Rittinger K, 1999, MOL CELL, V4, P153, DOI 10.1016/S1097-2765(00)80363-9; Rutault K, 2001, J BIOL CHEM, V276, P6666, DOI 10.1074/jbc.M005486200; Schubert CM, 2000, MOL CELL, V5, P671, DOI 10.1016/S1097-2765(00)80246-4; Tabara H, 1999, DEVELOPMENT, V126, P1; Taylor GA, 1996, IMMUNITY, V4, P445, DOI 10.1016/S1074-7613(00)80411-2; TAYLOR GA, 1995, J BIOL CHEM, V270, P13341, DOI 10.1074/jbc.270.22.13341; Taylor GA, 1996, MOL ENDOCRINOL, V10, P140, DOI 10.1210/me.10.2.140; Tenenhaus C, 2001, GENE DEV, V15, P1031, DOI 10.1101/gad.876201; TURNER R, 1989, SCIENCE, V243, P1689, DOI 10.1126/science.2494701; van Hemert MJ, 2001, BIOESSAYS, V23, P936, DOI 10.1002/bies.1134; VARNUM BC, 1989, ONCOGENE, V4, P119; Vasudevan S, 2001, MOL CELL, V7, P1191, DOI 10.1016/S1097-2765(01)00279-9; VIDAL M, 1997, YEAST 2 HYBRID SYSTE, P109; Winzen R, 1999, EMBO J, V18, P4969, DOI 10.1093/emboj/18.18.4969; Yaffe MB, 1997, CELL, V91, P961, DOI 10.1016/S0092-8674(00)80487-0; Yaffe MB, 2001, CURR OPIN CELL BIOL, V13, P131, DOI 10.1016/S0955-0674(00)00189-7; Zeng Y, 1999, MOL CELL BIOL, V19, P7410	49	102	104	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 17	2002	277	20					18029	18036		10.1074/jbc.M110465200	http://dx.doi.org/10.1074/jbc.M110465200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	553PR	11886850	hybrid			2022-12-27	WOS:000175685100081
J	Kanduri, C; Fitzpatrick, G; Mukhopadhyay, R; Kanduri, M; Lobanenkov, V; Higgins, M; Ohlsson, R				Kanduri, C; Fitzpatrick, G; Mukhopadhyay, R; Kanduri, M; Lobanenkov, V; Higgins, M; Ohlsson, R			A differentially methylated imprinting control region within the Kcnq1 locus harbors a methylation-sensitive chromatin insulator	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BECKWITH-WIEDEMANN-SYNDROME; ENHANCER-BLOCKING ACTIVITY; GENE; CTCF; EXPRESSION; DISRUPTION; TRANSCRIPT; ELEMENTS; KVLQT1; H19	The mechanisms underlying the phenomenon of genomic imprinting remain poorly understood. In one instance, a differentially methylated imprinting control region (ICR) at the H19 locus has been shown to involve a methylation-sensitive chromatin insulator function that apparently partitions the neighboring Igf2 and H19 genes in different expression domains in a parent of origin-dependent manner. It is not known, however, if this mechanism is unique to the Igf2/H19 locus or if insulator function is a common feature in the regulation of imprinted genes. To address this question, we have studied an ICR in the Kcnq1 locus that regulates long range repression on the paternally derived p57Kip2 and Kcnq1 alleles in an imprinting domain that includes Igf2 and H19. We show that this ICR appears to possess a unidirectional chromatin insulator function in somatic cells of both mesodermal and endodermal origins. Moreover, we document that CpG methylation regulates this insulator function suggesting that a methylation-sensitive chromatin insulator is a common theme in the phenomenon of genomic imprinting.	Uppsala Univ, Evolut Biol Ctr, Dept Genet & Dev, S-75236 Uppsala, Sweden; Roswell Pk Canc Inst, Dept Canc Genet, Buffalo, NY 14263 USA; NIAID, Immunopathol Lab, NIH, Bethesda, MD 20892 USA	Uppsala University; Roswell Park Cancer Institute; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Kanduri, C (corresponding author), Uppsala Univ, Evolut Biol Ctr, Dept Genet & Dev, Norbyvagen 18A, S-75236 Uppsala, Sweden.		Lobanenkov, Victor V./AGQ-8903-2022; Lobanenkov, Victor/ABD-5710-2021; kanduri, meena/AAG-1813-2019; KANDURI, MEENA/AAI-6169-2021	KANDURI, MEENA/0000-0003-2781-4779; Kanduri, Chandrasekhar/0000-0001-6271-9078; Lobanenkov, Victor/0000-0001-6665-3635	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI000860, ZIAAI000860, Z01AI000859] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Bell AC, 2001, SCIENCE, V291, P447, DOI 10.1126/science.291.5503.447; Bell AC, 2000, NATURE, V405, P482, DOI 10.1038/35013100; Cleary MA, 2001, NAT GENET, V29, P78, DOI 10.1038/ng715; Engel JR, 2000, J MED GENET, V37, P921, DOI 10.1136/jmg.37.12.921; Gould TD, 1998, HUM MOL GENET, V7, P483, DOI 10.1093/hmg/7.3.483; Hark AT, 2000, NATURE, V405, P486, DOI 10.1038/35013106; Holmgren C, 2001, CURR BIOL, V11, P1128, DOI 10.1016/S0960-9822(01)00314-1; Horike S, 2000, HUM MOL GENET, V9, P2075, DOI 10.1093/hmg/9.14.2075; John RM, 2001, HUM MOL GENET, V10, P1601, DOI 10.1093/hmg/10.15.1601; Kanduri C, 2000, CURR BIOL, V10, P853, DOI 10.1016/S0960-9822(00)00597-2; Kanduri C, 2000, CURR BIOL, V10, P449, DOI 10.1016/S0960-9822(00)00442-5; Lee MP, 1999, P NATL ACAD SCI USA, V96, P5203, DOI 10.1073/pnas.96.9.5203; Maher ER, 2000, J CLIN INVEST, V105, P247, DOI 10.1172/JCI9340; Onyango P, 2000, GENOME RES, V10, P1697, DOI 10.1101/gr.161800; Paulsen M, 1998, HUM MOL GENET, V7, P1149, DOI 10.1093/hmg/7.7.1149; Smilinich NJ, 1999, P NATL ACAD SCI USA, V96, P8064, DOI 10.1073/pnas.96.14.8064; Zhong XP, 1999, J IMMUNOL, V163, P295	17	74	78	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 17	2002	277	20					18106	18110		10.1074/jbc.M200031200	http://dx.doi.org/10.1074/jbc.M200031200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	553PR	11877438	hybrid			2022-12-27	WOS:000175685100091
J	Ihara, S; Miyoshi, E; Ko, JH; Murata, K; Nakahara, S; Honke, K; Dickson, RB; Lin, CY; Taniguchi, N				Ihara, S; Miyoshi, E; Ko, JH; Murata, K; Nakahara, S; Honke, K; Dickson, RB; Lin, CY; Taniguchi, N			Prometastatic effect of N-acetylglucosaminyltransferase V is due to modification and stabilization of active matriptase by adding beta 1-6 GlcNAc branching	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-BREAST-CANCER; PLASMINOGEN-ACTIVATOR; SERINE-PROTEASE; TRANSCRIPTIONAL REGULATION; LINKED OLIGOSACCHARIDES; CARBOHYDRATE ANTIGENS; CARCINOMA-CELLS; METASTASIS; INHIBITOR; EXPRESSION	Oligosaccharide moieties of glycoproteins are structurally altered during development, carcinogenesis, and malignant transformations. It is well known that beta1-6 GlcNAc branching, a product of UDP-GlcNAc alpha-mannoside beta1-6-N-acetylglucosaminyltransferase (GnT-V), is associated with malignant transformation as the results of such alterations. However, the mechanism by which beta1-6 GlcNAc branching is linked to metastasis remains unclear, because the identification of specific glycoprotein(s) that are glycosylated by GnT-V and its biological function have not been examined. We herein report that matriptase, which activates both urokinase-type plasminogen activator and hepatocyte growth factor, is a target protein for GnT-V. The overexpression of GnT-V in gastric cancer cells leads to severe peritoneal dissemination in athymic mice, which can be attributed to the increased expression of matriptase. This increase was due to the acquired resistance of matriptase to degradation, since it is glycosylated by GnT-V and a corresponding increase in the active form. These results indicate that this process is a key element in malignant transformation, its the direct result of oligosaccharide modification.	Osaka Univ, Sch Med, Grad Sch Med, Dept Biochem, Suita, Osaka 5650871, Japan; KRIBB, Proteome Res Lab, Taejon 305333, South Korea; Osaka Med Ctr Canc & Cardiovasc Dis, Dept Surg Oncol, Osaka 5378511, Japan; Georgetown Univ, Med Ctr, Lombardi Canc Ctr, Dept Oncol, Washington, DC 20007 USA	Osaka University; Korea Research Institute of Bioscience & Biotechnology (KRIBB); Osaka Medical Center for Cancer & Cardiovascular Diseases; Georgetown University	Taniguchi, N (corresponding author), Osaka Univ, Sch Med, Grad Sch Med, Dept Biochem, B1,2-2 Yamadaoka, Suita, Osaka 5650871, Japan.	proftani@biochem.med.osaka-u.ac.jp	Ihara, Shinji/AAH-6730-2019; Taniguchi, Naoyuki/I-4182-2014; Taniguchi, Naoyuki/A-7086-2016	Taniguchi, Naoyuki/0000-0001-5889-5968; 				Andreasen PA, 1997, INT J CANCER, V72, P1, DOI 10.1002/(SICI)1097-0215(19970703)72:1<1::AID-IJC1>3.0.CO;2-Z; Buckhaults P, 1997, J BIOL CHEM, V272, P19575, DOI 10.1074/jbc.272.31.19575; Chen L, 1998, ONCOGENE, V17, P2087, DOI 10.1038/sj.onc.1202124; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CUMMINGS RD, 1982, J BIOL CHEM, V257, P1230; DANO K, 1985, ADV CANCER RES, V44, P139, DOI 10.1016/S0065-230X(08)60028-7; Demetriou M, 2001, NATURE, V409, P733, DOI 10.1038/35055582; DEMETRIOU M, 1995, J CELL BIOL, V130, P383, DOI 10.1083/jcb.130.2.383; DENNIS JW, 1987, SCIENCE, V236, P582, DOI 10.1126/science.2953071; FERNANDES B, 1991, CANCER RES, V51, P718; Fukuda M, 1996, CANCER RES, V56, P2237; Galang CK, 1996, J BIOL CHEM, V271, P7992, DOI 10.1074/jbc.271.14.7992; Granovsky M, 2000, NAT MED, V6, P306; GU JG, 1993, J BIOCHEM, V113, P614, DOI 10.1093/oxfordjournals.jbchem.a124091; HAKOMORI SI, 1989, ADV CANCER RES, V52, P257; Ito Y, 2001, INT J CANCER, V91, P631, DOI 10.1002/1097-0215(200002)9999:9999<::AID-IJC1118>3.3.CO;2-6; Kang R, 1996, J BIOL CHEM, V271, P26706, DOI 10.1074/jbc.271.43.26706; Ko JH, 1999, J BIOL CHEM, V274, P22941, DOI 10.1074/jbc.274.33.22941; Lee SL, 2000, J BIOL CHEM, V275, P36720, DOI 10.1074/jbc.M007802200; Lin CY, 1999, J BIOL CHEM, V274, P18237, DOI 10.1074/jbc.274.26.18237; Lin CY, 1999, J BIOL CHEM, V274, P18231, DOI 10.1074/jbc.274.26.18231; Lin CY, 1997, J BIOL CHEM, V272, P9147; MIWA K, 1985, GENE, V39, P281; Miyata S, 2000, J BIOL CHEM, V275, P4592, DOI 10.1074/jbc.275.7.4592; MIYOSHI E, 1993, CANCER RES, V53, P3899; Murata K, 2000, CLIN CANCER RES, V6, P1772; NAITO K, 1993, AGENTS ACTIONS, V39, P182, DOI 10.1007/BF01998972; NISHIKAWA A, 1990, BIOCHIM BIOPHYS ACTA, V1035, P313, DOI 10.1016/0304-4165(90)90094-D; PIERCE M, 1986, J BIOL CHEM, V261, P772; QUAX PHA, 1991, J CELL BIOL, V115, P191, DOI 10.1083/jcb.115.1.191; RADEMACHER TW, 1988, ANNU REV BIOCHEM, V57, P785, DOI 10.1146/annurev.bi.57.070188.004033; SAITO H, 1994, BIOCHEM BIOPH RES CO, V198, P318, DOI 10.1006/bbrc.1994.1045; Seberger PJ, 1999, GLYCOBIOLOGY, V9, P235, DOI 10.1093/glycob/9.3.235; Seelentag WKF, 1998, CANCER RES, V58, P5559; SHI YE, 1993, CANCER RES, V53, P1409; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Takeuchi T, 2000, J BIOL CHEM, V275, P26333, DOI 10.1074/jbc.M002941200; Takeuchi T, 1999, P NATL ACAD SCI USA, V96, P11054, DOI 10.1073/pnas.96.20.11054; WANG CI, 1995, J BIOL CHEM, V270, P12250, DOI 10.1074/jbc.270.20.12250; YOSHIMURA M, 1995, P NATL ACAD SCI USA, V92, P8754, DOI 10.1073/pnas.92.19.8754	40	165	179	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 10	2002	277	19					16960	16967		10.1074/jbc.M200673200	http://dx.doi.org/10.1074/jbc.M200673200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	551MB	11864986	hybrid			2022-12-27	WOS:000175564500083
J	Sargsyan, E; Baryshev, M; Szekely, L; Sharipo, A; Mkrtchian, S				Sargsyan, E; Baryshev, M; Szekely, L; Sharipo, A; Mkrtchian, S			Identification of ERp29, an endoplasmic reticulum lumenal protein, as a new member of the thyroglobulin folding complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LUMINAL ER PROTEINS; MOLECULAR CHAPERONES; SECRETORY PATHWAY; GENE-EXPRESSION; RAT-LIVER; CELLS; THYROCYTES; WINDBEUTEL; DROSOPHILA; RESIDENT	Folding and post-translational modification of the thyroid hormone precursor, thyroglobulin (Tg), in the endoplasmic reticulum (ER) of the thyroid epithelial cells is facilitated by several molecular chaperones and folding enzymes, such as BiP, GRP94, calnexin, protein disulfide isomerase, ERp72, and others. They have been shown to associate simultaneously and/or sequentially with Tg in the course of its maturation, thus forming large heterocomplexes in the ER of thyrocytes. Here we present evidence that such complexes include a novel member, an Ell-resident lumenal protein, ERp29, which is present in all mammalian tissues with exceptionally high levels of expression in the secretory cells. ERp29 was induced upon treatment of FRTL-5 rat thyrocytes with the thyroid-stimulating hormone, which is essential for the maintenance of thyroid cells and Tg biosynthesis. Chemical cross-linking followed by the cell lysis and immunoprecipitation of ERp29 or Tg revealed association of these proteins and additionally, immunocomplexes that also included major ER chaperones, BiP and GRP94. Sucrose density gradient analysis indicated co-localization of ERp29 with Tg and BiP in the fractions containing large macromolecular complexes. This was supported by immunofluorescent microscopy showing co-localization of ERp29 with Tg in the putative transport vesicular structures. Affinity chromatography using Tg as an affinity ligand demonstrated that ERp29 might be selectively isolated from the FRTL-5 cell lysate or purified lumenal fraction of rat liver microsomes along with the other ER chaperones. Preferential association with the urea-denatured Tg-Sepharose was indicative of either direct or circuitous ERp29/Tg interactions in a chaperone-like manner. Despite the presence of the C-terminal ER-retrieval signal, significant amounts of ERp29 were also recovered from the culture medium of stimulated thyrocytes, indicating ERp29 secretion. Based on these data, we suggest that the function of ERp29 in thyroid cells is connected with folding and/or secretion of Tg.	Karolinska Inst, Div Mol Toxicol, Inst Environm Med, S-17177 Stockholm, Sweden; Karolinska Inst, Ctr Microbiol & Tumor Biol, S-17177 Stockholm, Sweden; Univ Latvia, Biomed Res & Study Ctr, LV-1067 Riga, Latvia	Karolinska Institutet; Karolinska Institutet; Latvian Biomedical Research & Study Centre; University of Latvia	Mkrtchian, S (corresponding author), Karolinska Inst, Div Mol Toxicol, Inst Environm Med, S-17177 Stockholm, Sweden.	souren.mkrtchian@imm.ki.se	Szekely, Laszlo/B-1268-2009	Szekely, Laszlo/0000-0001-6144-6573; Mkrtchian, Souren/0000-0001-9801-2736				Argon Y, 1999, SEMIN CELL DEV BIOL, V10, P495, DOI 10.1006/scdb.1999.0320; Arvan P, 1997, THYROID, V7, P89, DOI 10.1089/thy.1997.7.89; Bruneau N, 2000, MICROSC RES TECHNIQ, V49, P329, DOI 10.1002/(SICI)1097-0029(20000515)49:4<329::AID-JEMT2>3.0.CO;2-H; Demmer J, 1997, FEBS LETT, V402, P145, DOI 10.1016/S0014-5793(96)01513-X; DORNER AJ, 1990, J BIOL CHEM, V265, P22029; EKHOLM R, 1990, INT REV CYTOL, V120, P243; ENDO T, 1991, MOL ENDOCRINOL, V5, P905, DOI 10.1210/mend-5-7-905; Fang C, 1997, BIOTECHNIQUES, V23, P52, DOI 10.2144/97231bm09; Ferrari DM, 1998, EUR J BIOCHEM, V255, P570, DOI 10.1046/j.1432-1327.1998.2550570.x; Gething MJ, 1999, SEMIN CELL DEV BIOL, V10, P465, DOI 10.1006/scdb.1999.0318; Helenius A, 2001, PHILOS T ROY SOC B, V356, P147, DOI 10.1098/rstb.2000.0759; Herrmann JM, 1999, TRENDS CELL BIOL, V9, P5, DOI 10.1016/S0962-8924(98)01414-7; HERZOG V, 1992, J CELL BIOL, V118, P1071, DOI 10.1083/jcb.118.5.1071; Hubbard MJ, 2000, EUR J BIOCHEM, V267, P1945, DOI 10.1046/j.1432-1327.2000.01193.x; JOHANSSON I, 1988, BIOCHEMISTRY-US, V27, P1925, DOI 10.1021/bi00406a019; Johnson S, 2001, TRENDS CELL BIOL, V11, P122, DOI 10.1016/S0962-8924(01)01926-2; KIM PS, 1993, J BIOL CHEM, V268, P4873; Kim PS, 1996, J CELL BIOL, V133, P517, DOI 10.1083/jcb.133.3.517; Konsolaki M, 1998, GENE DEV, V12, P120, DOI 10.1101/gad.12.1.120; KUZNETSOV G, 1994, J BIOL CHEM, V269, P22990; Kwon OY, 2000, FEBS LETT, V475, P27, DOI 10.1016/S0014-5793(00)01617-3; Liepinsh E, 2001, STRUCTURE, V9, P457, DOI 10.1016/S0969-2126(01)00607-4; Marino M, 2001, MOL ENDOCRINOL, V15, P1829, DOI 10.1210/me.15.10.1829; Mezghrani A, 2000, J BIOL CHEM, V275, P1920, DOI 10.1074/jbc.275.3.1920; Mkrtchian S, 1998, EUR J BIOCHEM, V251, P304, DOI 10.1046/j.1432-1327.1998.2510304.x; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; NIGAM SK, 1994, J BIOL CHEM, V269, P1744; Sargsyan E, 2002, GENE, V285, P127, DOI 10.1016/S0378-1119(02)00417-1; SEMENZA JC, 1990, CELL, V61, P1349, DOI 10.1016/0092-8674(90)90698-E; Sen J, 2000, DEVELOPMENT, V127, P5541; Stevens FJ, 1999, SEMIN CELL DEV BIOL, V10, P443, DOI 10.1006/scdb.1999.0315; Szekely L, 1999, J GEN VIROL, V80, P2889, DOI 10.1099/0022-1317-80-11-2889; Wiest DL, 1997, P NATL ACAD SCI USA, V94, P1884, DOI 10.1073/pnas.94.5.1884; Willnow TE, 1999, NAT CELL BIOL, V1, pE157, DOI 10.1038/14109; WILLNOW TE, 1992, J BIOL CHEM, V267, P26172; Xiao GQ, 1999, MOL BRAIN RES, V72, P121, DOI 10.1016/S0169-328X(99)00188-6	36	86	96	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 10	2002	277	19					17009	17015		10.1074/jbc.M200539200	http://dx.doi.org/10.1074/jbc.M200539200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	551MB	11884402	hybrid			2022-12-27	WOS:000175564500089
J	Hellstern, S; Sasaki, T; Fauser, C; Lustig, A; Timpl, R; Engel, J				Hellstern, S; Sasaki, T; Fauser, C; Lustig, A; Timpl, R; Engel, J			Functional studies on recombinant domains of Mac-2-binding protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAC-2 BINDING-PROTEIN; CYSTEINE-RICH DOMAIN; RING-LIKE STRUCTURES; EXTRACELLULAR-MATRIX; CRYSTAL-STRUCTURE; CALCIUM-BINDING; BTB/POZ DOMAIN; ANTIGEN; SUPERFAMILY; ONCOPROTEIN	Mac-2-binding protein (M2BP) is a secreted glycoprotein suggested to have a role in host defense. It forms linear and ring-shaped oligomers, with each ring segment being composed of two monomers. We have produced recombinant human M2BP fragments comprising domains 1 and 2 (M2BP-1,2) and domains 3 and 4 (M2BP-3,4) in 293 human kidney cells to characterize structural and functional properties of M2BP. Both fragments were obtained in a native and glycosylated form, as analyzed by CD spectroscopy, trypsin susceptibility, and enzymatic deglycosylation. These results strongly suggest that both fragments are autonomous folding units. All three potential N-glycosylation sites in M2BP-1,2 and all four in M2BP-3,4 were found to be occupied. M2BP-1,2 expressed in tunicamycin-treated cells contained no glycosyl residues, indicating that O-glycosylation is not occurring. Ultracentrifugation revealed that M2BP-1,2 is homogeneously dimeric in the nanomolar range reflecting the properties of intact M2BP. Domain 2 (BTB/POZ domain) is thus identified as the dimerization domain of M2BP, because it has been formerly shown that recombinant domain 1 is monomeric. M2BP-3,4 showed a concentration-dependent self-association, and aggregates of different size and shape were shown by electron microscopy. In contrast to this irregular aggregation of M2BP-3,4, it has been formerly shown that a fragment comprising domains 2-4 still has the ability to form ring-like structures, although the rings are protein-filled, and thus domain 2 appears to be indispensable for ring formation. Solid phase assays showed that M2BP-3,4 contains binding sites for galectin-3, nidogen, and collagens V and VI, whereas M2BP-1,2 is inactive in binding. Both fragments showed no cell adhesive activity in contrast to native M2BP, suggesting that a concerted binding action and/or multivalent interactions of rings are necessary for cell attachment.	Univ Basel, Biozentrum, Dept Biophys Chem, CH-4056 Basel, Switzerland; Max Planck Inst Biochem, D-82152 Martinsried, Germany	University of Basel; Max Planck Society	Engel, J (corresponding author), Univ Basel, Biozentrum, Dept Biophys Chem, Klingelbergstr 70, CH-4056 Basel, Switzerland.							Ahmad KF, 1998, P NATL ACAD SCI USA, V95, P12123, DOI 10.1073/pnas.95.21.12123; ENGEL J, 1994, METHOD ENZYMOL, V245, P469; HEUKESHOVEN J, 1988, ELECTROPHORESIS, V9, P28, DOI 10.1002/elps.1150090106; Hohenester E, 1999, NAT STRUCT BIOL, V6, P228, DOI 10.1038/6669; IACOBELLI S, 1988, BREAST CANCER RES TR, V11, P19, DOI 10.1007/BF01807554; INOHARA H, 1994, BIOCHEM BIOPH RES CO, V201, P1366, DOI 10.1006/bbrc.1994.1854; Inohara H, 1996, CANCER RES, V56, P4530; Kohfeldt E, 1997, FEBS LETT, V414, P557, DOI 10.1016/S0014-5793(97)01070-3; KOTHS K, 1993, J BIOL CHEM, V268, P14245; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Li XM, 1997, J BIOL CHEM, V272, P27324, DOI 10.1074/jbc.272.43.27324; Li XM, 1999, CANCER RES, V59, P5275; LONGO G, 1993, BRIT J HAEMATOL, V85, P207, DOI 10.1111/j.1365-2141.1993.tb08674.x; Melnick A, 2000, MOL CELL BIOL, V20, P6550, DOI 10.1128/MCB.20.17.6550-6567.2000; Muller SA, 1999, J MOL BIOL, V291, P801, DOI 10.1006/jmbi.1999.2996; PACE CN, 1995, PROTEIN SCI, V4, P2411, DOI 10.1002/pro.5560041120; POKUTTA S, 1994, EUR J BIOCHEM, V223, P1019, DOI 10.1111/j.1432-1033.1994.tb19080.x; POWELL TJ, 1995, J IMMUNOTHER, V17, P209, DOI 10.1097/00002371-199505000-00003; Ralston G., 1993, INTRO ANAL ULTRACENT; ROSENBERG I, 1991, J BIOL CHEM, V266, P18731; Sasaki T, 1998, EMBO J, V17, P1606, DOI 10.1093/emboj/17.6.1606; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SPECKS U, 1992, EMBO J, V11, P4281, DOI 10.1002/j.1460-2075.1992.tb05527.x; Trahey M, 1999, P NATL ACAD SCI USA, V96, P3006, DOI 10.1073/pnas.96.6.3006; ULLRICH A, 1994, J BIOL CHEM, V269, P18401	25	43	44	2	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 3	2002	277	18					15690	15696		10.1074/jbc.M200386200	http://dx.doi.org/10.1074/jbc.M200386200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	550PA	11867635	hybrid			2022-12-27	WOS:000175510400064
J	Valenzuela-Fernandez, A; Planchenault, T; Baleux, F; Staropoli, I; Le-Barillec, K; Leduc, D; Delaunay, T; Lazarini, F; Virelizier, JL; Chignard, M; Pidard, D; Arenzana-Seisdedos, F				Valenzuela-Fernandez, A; Planchenault, T; Baleux, F; Staropoli, I; Le-Barillec, K; Leduc, D; Delaunay, T; Lazarini, F; Virelizier, JL; Chignard, M; Pidard, D; Arenzana-Seisdedos, F			Leukocyte elastase negatively regulates stromal cell-derived factor-1 (SDF-1)/CXCR4 binding and functions by amino-terminal processing of SDF-1 and CXCR4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHEMOKINE RECEPTOR CXCR4; IMMUNODEFICIENCY-VIRUS CORECEPTOR; HEMATOPOIETIC PROGENITOR CELLS; ENCODING NEUTROPHIL ELASTASE; CATHEPSIN-G; BONE-MARROW; LYMPHOCYTE CHEMOATTRACTANT; INTERLEUKIN-8 IL-8; THROMBIN-RECEPTOR; T-LYMPHOCYTES	Activation of CXCR4 by the CXC chemokine stromal cell-derived factor-1 (SDF-1) requires interaction of the amino-terminal domains of both molecules. We report that proteinases released from either mononucleated blood cells or polymorphonuclear neutrophils degranulated by inflammatory stimuli generate an SDF-1 fragment that is deleted from amino-terminal residues Lys(1)-Pro(2)-Val(3), as characterized by mass spectrometry analysis. The proteolyzed chemokine fails to induce agonistic functions and is unable to prevent the fusogenic capacity of CXCR4-tropic human immunodeficiency viruses. Furthermore, we observed that exposure of CXCR4-expressing cells to leukocyte proteinases results in the proteolysis of the extracellular amino. terminal domain of the receptor, as assessed by flow cytometry analysis and electrophoretic separation of immunoprecipitated CXCR4. Blockade of SDF-1 and CXCR4 proteolysis by the specific leukocyte elastase inhibitor, N-methoxysuccinyl-alanine-alanine-proline-valine-chloromethyl ketone, identified elastase as the major enzyme among leukocyte-secreted proteinases that accounts for inactivation of both SDF-1 and CXCR4. Indeed, purified leukocyte elastase generated in either SDF-1 or CXCR4 a pattern of cleavage indistinguishable from that observed with leukocyte-secreted proteinases. Our findings suggest that elastase-mediated proteolysis of SDF-1/CXCR4 is part of a mechanism regulating their biological functions in both homeostatic and pathologic processes.	Inst Pasteur, Dept Mol Med, Unite Immunol Virale, F-75724 Paris 15, France; Inst Pasteur, Unite Chim Organ, F-75724 Paris 15, France; Inst Pasteur, Unite Def Innee & Inflammat, INSERM, U485, F-75724 Paris 15, France; INRA, Pathol Vegetale Stn, F-33883 Villenave Dornon, France; Inst Pasteur, Unite Neurovirol & Regenerat Syst Nerveux, F-75724 Paris 15, France	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; INRAE; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Arenzana-Seisdedos, F (corresponding author), Inst Pasteur, Dept Mol Med, Unite Immunol Virale, 28 Rue Dr Roux, F-75724 Paris 15, France.	farenzan@pasteur.fr	Arenzana-Seisdedos, Fernando/E-5835-2016; Chignard, Michel/B-4351-2008; Valenzuela-Fernández, Agustín/P-1638-2019; Valenzuela-Fernández, Agustín/B-6219-2014	Chignard, Michel/0000-0003-3810-6575; Valenzuela-Fernández, Agustín/0000-0002-2585-8703; Valenzuela-Fernández, Agustín/0000-0002-2585-8703; Pidard, Dominique/0000-0002-5732-3279; Lazarini, Francoise/0000-0001-5572-6982				Abi-Younes S, 2000, CIRC RES, V86, P131, DOI 10.1161/01.RES.86.2.131; Agace WW, 2000, CURR BIOL, V10, P325, DOI 10.1016/S0960-9822(00)00380-8; Aiuti A, 1997, J EXP MED, V185, P111, DOI 10.1084/jem.185.1.111; Amara A, 1999, J BIOL CHEM, V274, P23916, DOI 10.1074/jbc.274.34.23916; Amara A, 1997, J EXP MED, V186, P139, DOI 10.1084/jem.186.1.139; Bank U, 2001, J LEUKOCYTE BIOL, V69, P197; Bleul CC, 1996, NATURE, V382, P829, DOI 10.1038/382829a0; Bleul CC, 1997, P NATL ACAD SCI USA, V94, P1925, DOI 10.1073/pnas.94.5.1925; Bleul CC, 1996, J EXP MED, V184, P1101, DOI 10.1084/jem.184.3.1101; Brelot A, 2000, J BIOL CHEM, V275, P23736, DOI 10.1074/jbc.M000776200; Brelot A, 1997, J VIROL, V71, P4744, DOI 10.1128/JVI.71.6.4744-4751.1997; Buckley CD, 2000, J IMMUNOL, V165, P3423, DOI 10.4049/jimmunol.165.6.3423; Burger JA, 2001, J CLIN INVEST, V107, P305, DOI 10.1172/JCI11092; CAMPBELL EJ, 1989, J IMMUNOL, V143, P2961; COLDITZ IG, 1987, LEUKOCYTE EMIGRATION, P14; Coulomb-L'Hermine A, 2000, AIDS RES HUM RETROV, V16, P1097, DOI 10.1089/08892220050075372; Crump MP, 1997, EMBO J, V16, P6996, DOI 10.1093/emboj/16.23.6996; Dale DC, 2000, BLOOD, V96, P2317, DOI 10.1182/blood.V96.7.2317.h8002317_2317_2322; DApuzzo M, 1997, EUR J IMMUNOL, V27, P1788, DOI 10.1002/eji.1830270729; De Meester I, 1999, IMMUNOL TODAY, V20, P367, DOI 10.1016/S0167-5699(99)01486-3; Deichmann M, 1997, BLOOD, V89, P3522, DOI 10.1182/blood.V89.10.3522.3522_3522_3528; Delgado MB, 2001, EUR J IMMUNOL, V31, P699, DOI 10.1002/1521-4141(200103)31:3<699::AID-IMMU699>3.0.CO;2-6; Dery O, 1998, AM J PHYSIOL-CELL PH, V274, pC1429, DOI 10.1152/ajpcell.1998.274.6.C1429; Detheux M, 2000, J EXP MED, V192, P1501, DOI 10.1084/jem.192.10.1501; Doranz BJ, 1999, J VIROL, V73, P2752, DOI 10.1128/JVI.73.4.2752-2761.1999; Falanga A, 1999, BLOOD, V93, P2506, DOI 10.1182/blood.V93.8.2506.408k31_2506_2514; Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872; Gerard C, 2001, NAT IMMUNOL, V2, P108, DOI 10.1038/84209; Gonzalo JA, 2000, J IMMUNOL, V165, P499, DOI 10.4049/jimmunol.165.1.499; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Hargreaves DC, 2001, J EXP MED, V194, P45, DOI 10.1084/jem.194.1.45; HEBERT CA, 1990, J IMMUNOL, V145, P3033; Hecquet C, 2000, MOL PHARMACOL, V58, P828, DOI 10.1124/mol.58.4.828; Hoglund M, 1997, EUR J HAEMATOL, V58, P195; Horwitz M, 1999, NAT GENET, V23, P433, DOI 10.1038/70544; Iikura M, 2001, J LEUKOCYTE BIOL, V70, P113; Imai K, 1999, BRIT J HAEMATOL, V106, P905, DOI 10.1046/j.1365-2141.1999.01644.x; Jo DY, 2000, J CLIN INVEST, V105, P101, DOI 10.1172/JCI7954; Juremalm M, 2000, EUR J IMMUNOL, V30, P3614, DOI 10.1002/1521-4141(200012)30:12<3614::AID-IMMU3614>3.0.CO;2-B; Kawabata T, 1999, P NATL ACAD SCI USA, V96, P5663, DOI 10.1073/pnas.96.10.5663; KOSTMANN R, 1956, Acta Paediatr Suppl, V45, P1; Le-Barillec K, 2000, J LEUKOCYTE BIOL, V68, P209; Lee WL, 2001, AM J RESP CRIT CARE, V164, P896, DOI 10.1164/ajrccm.164.5.2103040; Levesque JP, 2001, BLOOD, V98, P1289, DOI 10.1182/blood.V98.5.1289; LILJESTROM P, 1991, BIO-TECHNOL, V9, P1356, DOI 10.1038/nbt1291-1356; Locati M, 1999, ANNU REV MED, V50, P425, DOI 10.1146/annurev.med.50.1.425; Luster AD, 1998, NEW ENGL J MED, V338, P436, DOI 10.1056/NEJM199802123380706; Ma Q, 1999, IMMUNITY, V10, P463, DOI 10.1016/S1074-7613(00)80046-1; Ma Q, 1998, P NATL ACAD SCI USA, V95, P9448, DOI 10.1073/pnas.95.16.9448; McQuibban GA, 2000, SCIENCE, V289, P1202, DOI 10.1126/science.289.5482.1202; McQuibban GA, 2001, J BIOL CHEM, V276, P43503, DOI 10.1074/jbc.M107736200; NAGASAWA T, 1994, P NATL ACAD SCI USA, V91, P2305, DOI 10.1073/pnas.91.6.2305; Nagasawa T, 1996, NATURE, V382, P635, DOI 10.1038/382635a0; Nagase H, 2000, J IMMUNOL, V164, P5935, DOI 10.4049/jimmunol.164.11.5935; Nanki T, 2000, J IMMUNOL, V165, P6590, DOI 10.4049/jimmunol.165.11.6590; Oberlin E, 1996, NATURE, V382, P833, DOI 10.1038/382833a0; Opdenakker G, 1998, IMMUNOL TODAY, V19, P182, DOI 10.1016/S0167-5699(97)01243-7; Pablos JL, 1999, AM J PATHOL, V155, P1577, DOI 10.1016/S0002-9440(10)65474-0; PADRINES M, 1994, FEBS LETT, V352, P231, DOI 10.1016/0014-5793(94)00952-X; Peled A, 2000, BLOOD, V95, P3289, DOI 10.1182/blood.V95.11.3289.011k33_3289_3296; Peled A, 1999, SCIENCE, V283, P845, DOI 10.1126/science.283.5403.845; Ponomaryov T, 2000, J CLIN INVEST, V106, P1331, DOI 10.1172/JCI10329; Price B, 2000, J BIOL CHEM, V275, P28308; Proost P, 1998, J IMMUNOL, V160, P4034; Reeves PJ, 1996, P NATL ACAD SCI USA, V93, P11487, DOI 10.1073/pnas.93.21.11487; Reinhold D, 1998, J NEUROIMMUNOL, V87, P203, DOI 10.1016/S0165-5728(98)00100-3; RENESTO P, 1993, BLOOD, V82, P139, DOI 10.1182/blood.V82.1.139.bloodjournal821139; Renesto P, 1997, BLOOD, V89, P1944, DOI 10.1182/blood.V89.6.1944; Sadir R, 2001, J BIOL CHEM, V276, P8288, DOI 10.1074/jbc.M008110200; Samis John A., 1998, Blood, V92, P1287; SCHWARTZ O, 1994, VIROLOGY, V198, P360, DOI 10.1006/viro.1994.1042; SEEMULLER U, 1977, H-S Z PHYSIOL CHEM, V358, P1105, DOI 10.1515/bchm2.1977.358.2.1105; SHI YF, 1993, J IMMUNOL METHODS, V164, P149, DOI 10.1016/0022-1759(93)90307-S; Shioda T, 1998, P NATL ACAD SCI USA, V95, P6331, DOI 10.1073/pnas.95.11.6331; SHIROZU M, 1995, GENOMICS, V28, P495, DOI 10.1006/geno.1995.1180; STEIN RL, 1986, BIOCHEMISTRY-US, V25, P5414, DOI 10.1021/bi00367a011; STETLERSTEVENSON WG, 1993, FASEB J, V7, P1434, DOI 10.1096/fasebj.7.15.8262328; Struyf S, 1998, EUR J IMMUNOL, V28, P1262, DOI 10.1002/(SICI)1521-4141(199804)28:04<1262::AID-IMMU1262>3.0.CO;2-G; SUIDAN HS, 1994, P NATL ACAD SCI USA, V91, P8112, DOI 10.1073/pnas.91.17.8112; Tachibana K, 1998, NATURE, V393, P591, DOI 10.1038/31261; Taub DD, 1996, J CLIN INVEST, V97, P1931, DOI 10.1172/JCI118625; TRAVIS J, 1988, AM J MED, V84, P37; Valenzuela-Fernandez A, 2001, J BIOL CHEM, V276, P26550, DOI 10.1074/jbc.M100411200; VANDAMME J, 1989, EUR J BIOCHEM, V181, P337; Vender RL, 1996, J INVEST MED, V44, P531; VOURETCRAVIARI V, 1995, J BIOL CHEM, V270, P8367, DOI 10.1074/jbc.270.14.8367; VU TKH, 1991, NATURE, V353, P674, DOI 10.1038/353674a0; Watanabe T, 1999, BLOOD, V93, P1157, DOI 10.1182/blood.V93.4.1157.404k13_1157_1163; Welte K, 1997, SEMIN HEMATOL, V34, P267; WRIGHT DG, 1988, METHOD ENZYMOL, V162, P538; Wuyts A, 1999, EUR J BIOCHEM, V260, P421, DOI 10.1046/j.1432-1327.1999.00166.x; YOSHIMURA T, 1989, MOL IMMUNOL, V26, P87; Zou YR, 1998, NATURE, V393, P595, DOI 10.1038/31269	93	177	191	0	3	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 3	2002	277	18					15677	15689		10.1074/jbc.M111388200	http://dx.doi.org/10.1074/jbc.M111388200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	550PA	11867624	Green Published, hybrid			2022-12-27	WOS:000175510400063
J	Arsham, AM; Plas, DR; Thompson, CB; Simon, MC				Arsham, AM; Plas, DR; Thompson, CB; Simon, MC			Phosphatidylinositol 3-kinase/Akt signaling is neither required for hypoxic stabilization of HIF-1 alpha nor sufficient for HIF-1-dependent target gene transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOTHELIAL GROWTH-FACTOR; INDUCIBLE FACTOR-I; FACTOR 1-ALPHA HIF-1-ALPHA; ACTIVATED PROTEIN-KINASE; FACTOR EXPRESSION; TUMOR ANGIOGENESIS; NITRIC-OXIDE; FACTOR-ALPHA; HIF-ALPHA; CELLS	The serine/threonine kinase Akt/PKB and the oxygen-responsive transcription factor HIF-1 share the ability to induce such processes as angiogenesis, glucose uptake, and glycolysis. Akt activity and HIF-1 are both essential for development and implicated in tumor growth. Upon activation by products of phosphatidylinositol 3-kinase (PI3K), Akt phosphorylates downstream targets that stimulate growth and inhibit apoptosis. Previous reports suggest that Akt may achieve its effects on angiogenesis and glucose metabolism by stimulating HIF-1 activity. We report here that, whereas serum stimulation can induce a slight accumulation of HIF-1alpha protein in a PI3K/Akt pathway-dependent fashion, hypoxia induces much higher levels of HIF-1alpha protein and HIF-1 DNA binding activity independently of PI3K and mTOR activity. In addition, we find the effects of constitutively active Akt on HIF-1 activity are cell-type specific. High levels of Akt signaling can modestly increase HIF-1alpha protein, but this increase does not affect HIF-1 target gene expression. Therefore, the PI3K/ Akt pathway is not necessary for hypoxic induction of HIF-1 subunits or activity, and constitutively active Akt is not itself sufficient to induce HIF-1 activity.	Univ Penn, Sch Med, Abramson Family Canc Res Inst, Philadelphia, PA 19104 USA; Univ Chicago, Comm Genet, Chicago, IL 60637 USA; Univ Penn, Sch Med, Howard Hughes Med Inst, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; University of Chicago; Howard Hughes Medical Institute; University of Pennsylvania	Simon, MC (corresponding author), Univ Penn, Sch Med, Abramson Family Canc Res Inst, 450 BRB 2-3,421 Curie Blvd, Philadelphia, PA 19104 USA.	celeste2@mail.med.upenn.edu	Simon, Celeste/AAG-3941-2021	Arsham, Andrew/0000-0002-5274-8710				Adi S, 2001, ENDOCRINOLOGY, V142, P498, DOI 10.1210/en.142.1.498; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; Baek SH, 2001, J CELL PHYSIOL, V188, P223, DOI 10.1002/jcp.1117; Barthel A, 1999, J BIOL CHEM, V274, P20281, DOI 10.1074/jbc.274.29.20281; Blancher C, 2001, CANCER RES, V61, P7349; BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N; BRUICK RK, 2001, SCIENCE, V11, P11; Cantley LC, 1999, P NATL ACAD SCI USA, V96, P4240, DOI 10.1073/pnas.96.8.4240; Chandel NS, 2000, J BIOL CHEM, V275, P25130, DOI 10.1074/jbc.M001914200; Chandel NS, 1998, P NATL ACAD SCI USA, V95, P11715, DOI 10.1073/pnas.95.20.11715; Chen CH, 2001, J BIOL CHEM, V276, P9519, DOI 10.1074/jbc.M010144200; Chilov D, 1999, J CELL SCI, V112, P1203; Epstein ACR, 2001, CELL, V107, P43, DOI 10.1016/S0092-8674(01)00507-4; Ferrara N, 1999, J MOL MED, V77, P527, DOI 10.1007/s001099900019; FIRTH JD, 1994, P NATL ACAD SCI USA, V91, P6496, DOI 10.1073/pnas.91.14.6496; Gingras AC, 2001, GENE DEV, V15, P807, DOI 10.1101/gad.887201; Gorlach A, 2001, CIRC RES, V89, P47, DOI 10.1161/hh1301.092678; Gottlob K, 2001, GENE DEV, V15, P1406, DOI 10.1101/gad.889901; Gu YZ, 2000, ANNU REV PHARMACOL, V40, P519, DOI 10.1146/annurev.pharmtox.40.1.519; Hirota K, 2001, J BIOL CHEM, V276, P21166, DOI 10.1074/jbc.M100677200; Hofer T, 2001, FASEB J, V15, P2715, DOI 10.1096/fj.01-0546fje; Huang LE, 1998, P NATL ACAD SCI USA, V95, P7987, DOI 10.1073/pnas.95.14.7987; Hur E, 2001, MOL PHARMACOL, V59, P1216, DOI 10.1124/mol.59.5.1216; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Ivan M, 2001, CURR OPIN GENET DEV, V11, P27, DOI 10.1016/S0959-437X(00)00152-0; Iyer NV, 1998, GENE DEV, V12, P149, DOI 10.1101/gad.12.2.149; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Jiang BH, 2001, CELL GROWTH DIFFER, V12, P363; Jiang BH, 2000, P NATL ACAD SCI USA, V97, P1749, DOI 10.1073/pnas.040560897; Jones A, 2001, CLIN CANCER RES, V7, P1263; Kandel ES, 1999, EXP CELL RES, V253, P210, DOI 10.1006/excr.1999.4690; Kung AL, 2000, NAT MED, V6, P1335, DOI 10.1038/82146; Laughner E, 2001, MOL CELL BIOL, V21, P3995, DOI 10.1128/MCB.21.12.3995-4004.2001; Maltepe E, 2000, BIOCHEM BIOPH RES CO, V273, P231, DOI 10.1006/bbrc.2000.2928; Maltepe E, 1997, NATURE, V386, P403, DOI 10.1038/386403a0; Masson N, 2001, EMBO J, V20, P5197, DOI 10.1093/emboj/20.18.5197; Mazure NM, 1997, BLOOD, V90, P3322, DOI 10.1182/blood.V90.9.3322; MCKEARN JP, 1985, P NATL ACAD SCI USA, V82, P7414, DOI 10.1073/pnas.82.21.7414; MILLER AG, 1981, J BIOL CHEM, V256, P2433; MILLER AG, 1983, J BIOL CHEM, V258, P3523; Minet E, 2000, FEBS LETT, V468, P53, DOI 10.1016/S0014-5793(00)01181-9; Plas DR, 2001, J BIOL CHEM, V276, P12041, DOI 10.1074/jbc.M010551200; PONTEN J, 1978, MED BIOL, V56, P184; Richard DE, 1999, J BIOL CHEM, V274, P32631, DOI 10.1074/jbc.274.46.32631; Ryan HE, 2000, CANCER RES, V60, P4010; Ryan HE, 1998, EMBO J, V17, P3005, DOI 10.1093/emboj/17.11.3005; Sandau KB, 2000, BIOCHEM BIOPH RES CO, V278, P263, DOI 10.1006/bbrc.2000.3789; Sandau KB, 2001, J BIOL CHEM, V276, P39805, DOI 10.1074/jbc.M107689200; SEMENZA GL, 1992, MOL CELL BIOL, V12, P5447, DOI 10.1128/MCB.12.12.5447; Semenza GL, 2001, CURR OPIN CELL BIOL, V13, P167, DOI 10.1016/S0955-0674(00)00194-0; Sodhi A, 2000, CANCER RES, V60, P4873; Sodhi A, 2001, BIOCHEM BIOPH RES CO, V287, P292, DOI 10.1006/bbrc.2001.5532; Tacchini L, 2001, CARCINOGENESIS, V22, P1363, DOI 10.1093/carcin/22.9.1363; Treins C, 2001, J BIOL CHEM, V276, P43836, DOI 10.1074/jbc.M106534200; Yu F, 2001, P NATL ACAD SCI USA, V98, P9630, DOI 10.1073/pnas.181341498; Zelzer E, 1998, EMBO J, V17, P5085, DOI 10.1093/emboj/17.17.5085; Zhong H, 2000, CANCER RES, V60, P1541; Zhu H, 1999, RESP PHYSIOL, V115, P239, DOI 10.1016/S0034-5687(99)00024-9; Zundel W, 2000, GENE DEV, V14, P391	59	156	162	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 26	2002	277	17					15162	15170		10.1074/jbc.M111162200	http://dx.doi.org/10.1074/jbc.M111162200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	545EH	11859074	hybrid			2022-12-27	WOS:000175203000102
J	Sugiyama, M; Ohtani, K; Izuhara, M; Koike, T; Suzuki, K; Imamura, S; Misaki, H				Sugiyama, M; Ohtani, K; Izuhara, M; Koike, T; Suzuki, K; Imamura, S; Misaki, H			A novel prokaryotic phospholipase A(2) - Characterization, gene cloning, and solution structure	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSITION-STATE ANALOG; CANCER CELL-LINE; CRYSTAL-STRUCTURE; VENOM PHOSPHOLIPASES-A2; SNAKE-VENOM; RESOLUTION; EXPRESSION; MECHANISM; COMPLEX; GROWTH	Until now, phospholipase A(2) (PLA(2); EC 3.1.14) has been found only from eukaryotic sources. In the present study, we found a secreted PIA, which is produced by a soil bacterium, Streptomyces violaceoruber A-2688, demonstrating that the enzyme is the first phospholipase A(2) identified in prokaryote. After characterization of the novel PLA(2), a gene encoding the enzyme was cloned, sequenced, and overexpressed using a Streptomyces host-vector system. The amino acid sequence showed that the prokaryotic PLA(2) has only four cysteines and less homology to the eukaryotic ones, which have 12-16 cysteines. The solution structures of the prokaryotic PLA(2), bound and unbound with calcium(II) ion, were determined by using the NMR technique and structure calculation. The overall structure of the S. violaceoruber PLA(2), which is composed of only five a-helices, is completely different from those of eukaryotic PLA(2)s, which consist of beta-sheets and alpha-helices. The structure of the calcium-binding domain is obviously distinct from that without the ion; the ligands for the calcium(II) ion are the two carboxylates of Asp(43) (monodentate) and Asp(65) (bidentate), the carbonyl oxygen of Leu(44), and three water molecules. A calcium-binding experiment showed that the calcium dissociation constant (similar to5 mm) for the prokaryotic PLA(2) is much larger than those of eukaryotic ones.	Hiroshima Univ, Fac Med, Inst Pharmaceut Sci, Minami Ku, Hiroshima 7348551, Japan; Asahi Kasei Corp, Fine Chem & Diagnost Div, Diagnost Res & Dev, Shizuoka 4102321, Japan	Hiroshima University; Asahi Kasei Corporation	Sugiyama, M (corresponding author), Hiroshima Univ, Fac Med, Inst Pharmaceut Sci, Minami Ku, Kasumi 1-2-3, Hiroshima 7348551, Japan.							BRUNIE S, 1985, J BIOL CHEM, V260, P9742; DAUBEROSGUTHORPE P, 1988, PROTEINS, V4, P31, DOI 10.1002/prot.340040106; DAVIDSON FF, 1990, J MOL EVOL, V31, P228, DOI 10.1007/BF02109500; DEHAAS GH, 1968, BIOCHIM BIOPHYS ACTA, V159, P118, DOI 10.1016/0005-2744(68)90249-0; DENNIS EA, 1987, BIO-TECHNOL, V5, P1294, DOI 10.1038/nbt1287-1294; DENNIS EA, 1994, J BIOL CHEM, V269, P13057; DENNIS EA, 1987, DRUG DEVELOP RES, V10, P205, DOI 10.1002/ddr.430100404; DIJKSTRA BW, 1981, J MOL BIOL, V147, P97, DOI 10.1016/0022-2836(81)90081-4; DIJKSTRA BW, 1982, ACTA CRYSTALLOGR B, V38, P793, DOI 10.1107/S0567740882004099; DRANKENBERG T, 1984, BIOCHEMISTRY-US, V23, P2387; Gelb MH, 2000, J BIOL CHEM, V275, P39823, DOI 10.1074/jbc.C000671200; HANADA K, 1995, FEBS LETT, V373, P85, DOI 10.1016/0014-5793(95)01005-Y; Hawgood B., 1991, HDB NATURAL TOXINS R, V5, P3; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; Hopwood D.A., 1985, GENETIC MANIPULATION; HRARA S, 1989, J BIOCHEM-TOKYO, V105, P395; IRVINE RF, 1982, BIOCHEM J, V204, P3, DOI 10.1042/bj2040003; KARMER RM, 1989, J BIOL CHEM, V264, P5768; KINI RM, 1989, TOXICON, V27, P613, DOI 10.1016/0041-0101(89)90013-5; Kinoshita E, 1997, FEBS LETT, V407, P343, DOI 10.1016/S0014-5793(97)00373-6; Kinoshita E, 1996, INT J ONCOL, V9, P1219; LECHEVALIER MP, 1977, BIOCHEM SYST ECOL, V5, P249, DOI 10.1016/0305-1978(77)90021-7; Matoba Y, 2002, J BIOL CHEM, V277, P20059, DOI 10.1074/jbc.M200263200; MCINTOSH JM, 1995, J BIOL CHEM, V270, P3518, DOI 10.1074/jbc.270.8.3518; MIZUSAWA S, 1986, NUCLEIC ACIDS RES, V14, P1319, DOI 10.1093/nar/14.3.1319; MORRIS AL, 1992, PROTEINS, V12, P345, DOI 10.1002/prot.340120407; POWERS R, 1993, BIOCHEMISTRY-US, V32, P6744, DOI 10.1021/bi00077a030; SCOTT DL, 1990, SCIENCE, V250, P1541, DOI 10.1126/science.2274785; SCOTT DL, 1990, SCIENCE, V250, P1563, DOI 10.1126/science.2274788; SHINE J, 1974, Proceedings of the National Academy of Sciences of the United States of America, V71, P1342, DOI 10.1073/pnas.71.4.1342; Six DA, 2000, BBA-MOL CELL BIOL L, V1488, P1, DOI 10.1016/S1388-1981(00)00105-0; SOLAGNI E, 2001, EMBO J, V20, P5079; SUZUKI K, 1992, BIOSCI BIOTECH BIOCH, V56, P432, DOI 10.1271/bbb.56.432; TESHIMA K, 1981, J BIOCHEM, V89, P13, DOI 10.1093/oxfordjournals.jbchem.a133173; THUNNISSEN MMGM, 1990, NATURE, V347, P689, DOI 10.1038/347689a0; VANDENBERG B, 1995, EMBO J, V14, P4123, DOI 10.1002/j.1460-2075.1995.tb00086.x; WERY JP, 1991, NATURE, V352, P79, DOI 10.1038/352079a0; WHITE SP, 1990, SCIENCE, V250, P1560, DOI 10.1126/science.2274787	38	46	56	2	22	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 31	2002	277	22					20051	20058		10.1074/jbc.M200264200	http://dx.doi.org/10.1074/jbc.M200264200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	557EH	11897786	hybrid			2022-12-27	WOS:000175894800106
J	Tao, GZ; Rott, LS; Lowe, AW; Omary, MB				Tao, GZ; Rott, LS; Lowe, AW; Omary, MB			Hyposmotic stress induces cell growth arrest via proteasome activation and cyclin/cyclin-dependent kinase degradation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OSMOTIC-STRESS; SIGNAL-TRANSDUCTION; ACTIN CYTOSKELETON; INDUCED APOPTOSIS; VOLUME REGULATION; ESCHERICHIA-COLI; PROTEIN-KINASE; CYCLIN-E; PHOSPHORYLATION; PATHWAYS	Ordered cell cycle progression requires the expression and activation of several cyclins and cyclin-dependent kinases (Cdks). Hyperosmotic stress causes growth arrest possibly via proteasome-mediated degradation of cyclin D1. We studied the effect of hyposmotic conditions on three colonic (Caco2, HRT18, HT29) and two pancreatic (AsPC-1 and PaCa-2) cell lines. Hyposmosis caused reversible cell growth arrest of the five cell lines in a cell cycle-independent fashion, although some cell lines accumulated at the G(1)/S interface. Growth arrest was followed by apoptosis or by formation of multinucleated giant cells, which is consistent with cell cycle catastrophe. Hyposmosis dramatically decreased Cdc2, Cdk2, Cdk4, cyclin B1, and cyclin D3 expression in a time-dependent fashion, in association with an overall decrease in cellular protein synthesis. However, some protein levels remained unaltered, including cyclin E and keratin 8. Selective proteasome inhibition prevented Cdk and cyclin degradation and reversed hyposmotic stress-induced growth arrest, whereas calpain and lysosome enzyme inhibitors had no measurable effect on cell cycle protein degradation. Therefore, hyposmotic stress inhibits cell growth and, depending on the cell type, causes cell cycle catastrophe with or without apoptosis. The growth arrest is due to decreased protein synthesis and proteasome activation, with subsequent degradation of several cyclins and Cdks.	Palo Alto Vet Affairs Med Ctr, Dept Med, Palo Alto, CA 94034 USA; Stanford Univ, Ctr Digest Dis, Stanford, CA 94305 USA	Stanford University	Omary, MB (corresponding author), Palo Alto Vet Affairs Med Ctr, Dept Med, Palo Alto, CA 94034 USA.			Omary, Bishr/0000-0002-8624-2347	NIDDK NIH HHS [DK56339, DK47918] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK056339, R01DK047918] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ahmad N, 2001, CLIN CANCER RES, V7, P1466; Alepuz PM, 2001, MOL CELL, V7, P767, DOI 10.1016/S1097-2765(01)00221-0; Alexander MR, 2001, MOL BIOL CELL, V12, P53, DOI 10.1091/mbc.12.1.53; Ashrafian H, 2001, EUR J NEUROL, V8, P103, DOI 10.1046/j.1468-1331.2001.00176.x; Blount P, 1999, TRENDS MICROBIOL, V7, P420, DOI 10.1016/S0966-842X(99)01594-2; Bode JG, 1999, J BIOL CHEM, V274, P30222, DOI 10.1074/jbc.274.42.30222; BREWSTER JL, 1994, YEAST, V10, P425, DOI 10.1002/yea.320100402; Burg MB, 1996, FASEB J, V10, P1598, DOI 10.1096/fasebj.10.14.9002551; Calamita G, 2000, MOL MICROBIOL, V37, P254, DOI 10.1046/j.1365-2958.2000.02016.x; Canman CE, 2001, CURR BIOL, V11, pR121, DOI 10.1016/S0960-9822(01)00057-4; Casanovas O, 2000, J BIOL CHEM, V275, P35091, DOI 10.1074/jbc.M006324200; Chan TA, 1999, NATURE, V401, P616, DOI 10.1038/44188; Chinni SR, 2001, ONCOGENE, V20, P2927, DOI 10.1038/sj.onc.1204365; CHOU CF, 1993, J BIOL CHEM, V268, P4465; Clurman BE, 1996, GENE DEV, V10, P1979, DOI 10.1101/gad.10.16.1979; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; Du LT, 2001, INT J ONCOL, V19, P811; Evan G, 1998, SCIENCE, V281, P1317, DOI 10.1126/science.281.5381.1317; Evan GI, 2001, NATURE, V411, P342, DOI 10.1038/35077213; Fan XM, 2001, INT J CANCER, V93, P481, DOI 10.1002/ijc.1373; Gatsios P, 1998, J BIOL CHEM, V273, P22962, DOI 10.1074/jbc.273.36.22962; Hershko A, 2000, NAT MED, V6, P1073, DOI 10.1038/80384; Hohmann S, 2000, TRENDS MICROBIOL, V8, P33, DOI 10.1016/S0966-842X(99)01645-5; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; Jackle T, 2001, AM J PHYSIOL-CELL PH, V281, pC1716, DOI 10.1152/ajpcell.2001.281.5.C1716; Johnson DG, 1999, ANNU REV PHARMACOL, V39, P295, DOI 10.1146/annurev.pharmtox.39.1.295; Kim RD, 2000, J SURG RES, V90, P58, DOI 10.1006/jsre.2000.5866; KING KL, 1995, J CELL BIOCHEM, V58, P175, DOI 10.1002/jcb.240580206; Koyama T, 2001, J PHYSIOL-LONDON, V532, P759, DOI 10.1111/j.1469-7793.2001.0759e.x; Ku NO, 1998, EMBO J, V17, P1892, DOI 10.1093/emboj/17.7.1892; Ku NO, 2001, J BIOL CHEM, V276, P26792, DOI 10.1074/jbc.M103315200; Kultz D, 1998, J EXP BIOL, V201, P3015; Kultz D, 1998, J BIOL CHEM, V273, P13645, DOI 10.1074/jbc.273.22.13645; Kuwayama H, 1996, SCIENCE, V271, P207, DOI 10.1126/science.271.5246.207; Kyriakis JM, 2001, PHYSIOL REV, V81, P807, DOI 10.1152/physrev.2001.81.2.807; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Laroia G, 1999, SCIENCE, V284, P499, DOI 10.1126/science.284.5413.499; Leers MPG, 1999, J PATHOL, V187, P567, DOI 10.1002/(SICI)1096-9896(199904)187:5<567::AID-PATH288>3.0.CO;2-J; Leitch V, 2001, P NATL ACAD SCI USA, V98, P2894, DOI 10.1073/pnas.041616498; Liu F, 1999, MOL CELL BIOL, V19, P5113; Malek AM, 1998, STROKE, V29, P2631, DOI 10.1161/01.STR.29.12.2631; MCMANUS ML, 1995, NEW ENGL J MED, V333, P1260, DOI 10.1056/NEJM199511093331906; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; Mountian I, 1998, EUR J CELL BIOL, V77, P196, DOI 10.1016/S0171-9335(98)80107-6; Nakayama K, 2000, EMBO J, V19, P2069, DOI 10.1093/emboj/19.9.2069; Nurse P, 2000, CELL, V100, P71, DOI 10.1016/S0092-8674(00)81684-0; Nurse P, 1997, CELL, V91, P865, DOI 10.1016/S0092-8674(00)80476-6; NYSTROM T, 1994, MOL MICROBIOL, V11, P537, DOI 10.1111/j.1365-2958.1994.tb00334.x; Okada Y, 2001, J PHYSIOL-LONDON, V532, P3, DOI 10.1111/j.1469-7793.2001.0003g.x; OKADA Y, 1997, AM J PHYSIOL, V273, P775; Rizoli SB, 2000, AM J PHYSIOL-CELL PH, V279, pC619, DOI 10.1152/ajpcell.2000.279.3.C619; Rizoli SB, 1999, J BIOL CHEM, V274, P22072, DOI 10.1074/jbc.274.31.22072; Rosette C, 1996, SCIENCE, V274, P1194, DOI 10.1126/science.274.5290.1194; Rui LY, 2001, J BIOL CHEM, V276, P40362, DOI 10.1074/jbc.M105332200; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; Tarran R, 2001, MOL CELL, V8, P149, DOI 10.1016/S1097-2765(01)00286-6; Toivola DM, 2000, EXP CELL RES, V255, P156, DOI 10.1006/excr.1999.4787; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; van der Wijk T, 2000, CELL PHYSIOL BIOCHEM, V10, P289, DOI 10.1159/000016359; Volonte D, 2001, J BIOL CHEM, V276, P8094, DOI 10.1074/jbc.M009245200; Yamada Y, 2000, EUR J HAEMATOL, V64, P315, DOI 10.1034/j.1600-0609.2000.90110.x; Yang J, 1998, GENE DEV, V12, P2131, DOI 10.1101/gad.12.14.2131; Yoshikawa R, 2001, CANCER RES, V61, P1029; Zhang Z., 1998, AM J PHYSIOL, V275, P1104; Zischka H, 1999, EMBO J, V18, P4241, DOI 10.1093/emboj/18.15.4241	66	23	34	2	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 31	2002	277	22					19295	19303		10.1074/jbc.M109654200	http://dx.doi.org/10.1074/jbc.M109654200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	557EH	11897780	hybrid			2022-12-27	WOS:000175894800009
J	Frank, S; Schulthess, T; Landwehr, R; Lustig, A; Mini, T; Jeno, P; Engel, J; Kammerer, RA				Frank, S; Schulthess, T; Landwehr, R; Lustig, A; Mini, T; Jeno, P; Engel, J; Kammerer, RA			Characterization of the matrilin coiled-coil domains reveals seven novel isoforms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VON-WILLEBRAND-FACTOR; ALPHA-HELICAL PROTEIN; C-TERMINAL DOMAIN; EXTRACELLULAR-MATRIX; A-DOMAIN; FILAMENTOUS NETWORK; MOLECULAR-STRUCTURE; TISSUE DISTRIBUTION; AMINO-ACID; CARTILAGE	Matrilins constitute a family of four oligomeric extracellular proteins that are involved in the development and homeostasis of cartilage and bone. To reveal their homo- and heterotypic oligomerization propensities, we analyzed the four human matrilin coiled-coil domains by biochemical and biophysical methods. These studies not only confirmed the homo- and heterotypic oligomerization states reported for the full-length proteins but revealed seven novel matrilin isoforms. Specific heterotrimeric interactions of variable chain stoichiometries were observed between matrilin-1 and matrilin-2, matrilin-1 and matrilin-4, and matrilin-2 and matrilin-4. In addition, matrilin-1 formed two different specific heterotetramers with matrilin-3. Interestingly, a distinct heterotrimer consisting of three different chains was formed between matrilin-1, matrilin-2, and matrilin-4. No interactions, however, were observed between matrilin-2 and matrilin-3 or between matrilin-3 and matrilin-4. Both homo- and heterotypic oligomers folded into parallel disulfide-linked structures, although coiled-coil formation was not dependent on disulfide bridge formation. Our results indicate that the heterotypic preferences seen for the matrilin coiled-coil domains are the result of the packing of the hydrophobic core rather than ionic interactions. Mass spectrometry revealed that the concentrations of the individual chains statistically determined the stoichiometry of the heteromers, suggesting that formation of the different matrillin chain combinations is controlled by expression levels.	Univ Basel, Bioctr, Dept Biophys Chem, CH-4056 Basel, Switzerland; Univ Basel, Bioctr, Dept Biochem, CH-4056 Basel, Switzerland; Univ Manchester, Wellcome Trust Ctr Cell Matrix Res, Manchester M13 9PT, Lancs, England	University of Basel; University of Basel; University of Manchester	Engel, J (corresponding author), Univ Basel, Bioctr, Dept Biophys Chem, Klingelbergstr 70, CH-4056 Basel, Switzerland.	juergen.engel@unibas.ch		Kammerer, Richard/0000-0003-4570-5197				Aszodi A, 1996, EUR J BIOCHEM, V236, P970, DOI 10.1111/j.1432-1033.1996.00970.x; Beck K, 1996, J MOL BIOL, V256, P909, DOI 10.1006/jmbi.1996.0137; Beck K, 1997, EMBO J, V16, P3767, DOI 10.1093/emboj/16.13.3767; Belluoccio D, 1998, GENOMICS, V53, P391, DOI 10.1006/geno.1998.5519; Belluoccio D, 1997, FEBS LETT, V415, P212, DOI 10.1016/S0014-5793(97)01126-5; Chanut-Delalande H, 2001, J BIOL CHEM, V276, P24352, DOI 10.1074/jbc.M101182200; Chapman KL, 2001, NAT GENET, V28, P393, DOI 10.1038/ng573; CHEN Q, 1995, MOL BIOL CELL, V6, P1743, DOI 10.1091/mbc.6.12.1743; Chen Q, 1999, MOL BIOL CELL, V10, P2149, DOI 10.1091/mbc.10.7.2149; CHEN YH, 1974, BIOCHEMISTRY-US, V13, P3350, DOI 10.1021/bi00713a027; Cheng YS, 1997, J BIOL CHEM, V272, P31525, DOI 10.1074/jbc.272.50.31525; COHEN C, 1990, PROTEINS, V7, P1, DOI 10.1002/prot.340070102; Colognato H, 2000, DEV DYNAM, V218, P213, DOI 10.1002/(SICI)1097-0177(200006)218:2<213::AID-DVDY1>3.0.CO;2-R; COLOMBATTI A, 1991, BLOOD, V77, P2305; Dames SA, 1998, NAT STRUCT BIOL, V5, P687, DOI 10.1038/1382; DAVIS MT, 1995, ANAL CHEM, V67, P4549, DOI 10.1021/ac00120a019; Deak F, 1999, MATRIX BIOL, V18, P55, DOI 10.1016/S0945-053X(98)00006-7; Deak F, 1997, J BIOL CHEM, V272, P9268; Dong HJ, 1996, J MOL BIOL, V260, P649, DOI 10.1006/jmbi.1996.0428; EDELHOCH H, 1967, BIOCHEMISTRY-US, V6, P1948, DOI 10.1021/bi00859a010; Efimov VP, 1996, PROTEINS, V24, P259, DOI 10.1002/(SICI)1097-0134(199602)24:2<259::AID-PROT13>3.0.CO;2-M; Guo Y, 2000, BIOPHYS CHEM, V85, P179, DOI 10.1016/S0301-4622(00)00119-8; HARBURY PB, 1993, SCIENCE, V262, P1401, DOI 10.1126/science.8248779; Hauser N, 1996, J BIOL CHEM, V271, P32247, DOI 10.1074/jbc.271.50.32247; HAUSER N, 1994, J BIOL CHEM, V269, P25747; Hodges RS, 1996, BIOCHEM CELL BIOL, V74, P133, DOI 10.1139/o96-015; Huang XM, 1999, DEV DYNAM, V216, P434, DOI 10.1002/(SICI)1097-0177(199912)216:4/5<434::AID-DVDY11>3.3.CO;2-O; Kammerer RA, 1999, EMBO J, V18, P6762, DOI 10.1093/emboj/18.23.6762; Kammerer RA, 1997, MATRIX BIOL, V15, P555, DOI 10.1016/S0945-053X(97)90031-7; Keating AE, 2001, P NATL ACAD SCI USA, V98, P14825, DOI 10.1073/pnas.261563398; Klatt AR, 2000, J BIOL CHEM, V275, P3999, DOI 10.1074/jbc.275.6.3999; Klatt AR, 2001, J BIOL CHEM, V276, P17267, DOI 10.1074/jbc.M100587200; Kleemann-Fischer D, 2001, ARCH BIOCHEM BIOPHYS, V387, P209, DOI 10.1006/abbi.2000.2256; Kohn WD, 1997, J BIOL CHEM, V272, P2583, DOI 10.1074/jbc.272.5.2583; LEE JO, 1995, CELL, V80, P631, DOI 10.1016/0092-8674(95)90517-0; Lupas A, 1996, TRENDS BIOCHEM SCI, V21, P375, DOI 10.1016/0968-0004(96)10052-9; Makihira S, 1999, J BIOL CHEM, V274, P11417, DOI 10.1074/jbc.274.16.11417; MCLACHLAN AD, 1975, J MOL BIOL, V98, P293, DOI 10.1016/S0022-2836(75)80119-7; OROURKE KM, 1992, J BIOL CHEM, V267, P24921; Pace C N, 1986, Methods Enzymol, V131, P266; Pan OH, 1998, J BIOL CHEM, V273, P14205, DOI 10.1074/jbc.273.23.14205; PAULSSON M, 1979, BIOCHEM J, V183, P539, DOI 10.1042/bj1830539; PAULSSON M, 1982, BIOCHEM J, V207, P207, DOI 10.1042/bj2070207; Paulsson M, 1999, BIOCHEM SOC T, V27, P824, DOI 10.1042/bst0270824; PETERS J, 1995, J MOL BIOL, V245, P385, DOI 10.1006/jmbi.1994.0032; Peters J, 1996, J MOL BIOL, V257, P1031, DOI 10.1006/jmbi.1996.0221; Piecha D, 1999, J BIOL CHEM, V274, P13353, DOI 10.1074/jbc.274.19.13353; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; Segat D, 2000, MATRIX BIOL, V19, P649, DOI 10.1016/S0945-053X(00)00112-8; SODEK J, 1972, P NATL ACAD SCI USA, V69, P3800, DOI 10.1073/pnas.69.12.3800; TIMPL R, 1994, MATRIX BIOL, V14, P275, DOI 10.1016/0945-053X(94)90192-9; Van Holde K. E., 1985, PHYSICAL BIOCH, P93; Wagener R, 1998, FEBS LETT, V438, P165, DOI 10.1016/S0014-5793(98)01293-9; Wagener R, 1997, FEBS LETT, V413, P129, DOI 10.1016/S0014-5793(97)00895-8; Wagener R, 1998, FEBS LETT, V436, P123, DOI 10.1016/S0014-5793(98)01111-9; WINTERBOTTOM N, 1992, DEV DYNAM, V193, P266, DOI 10.1002/aja.1001930307; WOOLFSON DN, 1995, PROTEIN SCI, V4, P1596, DOI 10.1002/pro.5560040818; Wu JJ, 1998, J BIOL CHEM, V273, P17433, DOI 10.1074/jbc.273.28.17433; Zhang Y, 2000, J BIOL CHEM, V275, P32628, DOI 10.1074/jbc.M002594200	59	42	43	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 24	2002	277	21					19071	19079		10.1074/jbc.M202146200	http://dx.doi.org/10.1074/jbc.M202146200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	558PM	11896063	hybrid			2022-12-27	WOS:000175975800108
J	Fukuda, T; Kiuchi, K; Takahashi, M				Fukuda, T; Kiuchi, K; Takahashi, M			Novel mechanism of regulation of Rac activity and lamellipodia formation by RET tyrosine kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MICE LACKING; PHOSPHATIDYLINOSITOL 3-KINASE; DOCKING SITE; RHO GTPASES; PROTEIN; RECEPTOR; SHC; ACTIVATION; NEURONS; BINDING	Rac activation in neuronal cells plays an important role in lamellipodia formation that is a critical event for neuritogenesis. It is well known that the Rac activity is regulated via activation of phosphatidylinositol 3-kinase (PI3K) by a variety of receptor tyrosine kinases. Here we show that increased serine phosphorylation on RET receptor tyrosine kinase following cAMP elevation promotes lamellipodia formation of neuronal cells induced by glial cell line-derived neurotrophic factor (GDNF). We identified serine 696 in RET as a putative phosphorylation site by protein kinase A and found that mutation of this serine almost completely inhibited lamellipodia formation by GDNF without affecting activation of the PI3K/ AKT signaling pathway. Mutation of tyrosine 1062 in RET, whose phosphorylation is crucial for activation of PI3K, also inhibited lamellipodia formation by GDNF. Inhibition of lamellipodia formation by mutation of either serine 696 or tyrosine 1062 was associated with decrease of the Rac1-guanine nucleotide exchange factor (GEF) activity, suggesting that this activity is regulated by two different signaling pathways via serine 696 and tyrosine 1062 in RET. Moreover, in the presence of serine 696 mutation, lamellipodia formation was rescued by replacing tyrosine 687 with phenylalanine. These findings propose a novel mechanism that receptor tyrosine kinase modulates actin dynamics in neuronal cells via its cAMP-dependent phosphorylation.	Nagoya Univ, Grad Sch Med, Dept Pathol, Showa Ku, Nagoya, Aichi 4668550, Japan; RIKEN, Inst Phys & Chem Res, Biomomet Control Res Ctr, Lab Genes Motor Syst,Moriyama Ku, Nagoya, Aichi 4630003, Japan	Nagoya University; RIKEN	Takahashi, M (corresponding author), Nagoya Univ, Grad Sch Med, Dept Pathol, Showa Ku, 65 Tsurumai Cho, Nagoya, Aichi 4668550, Japan.	mtakaha@med.nagoya-u.ac.jp	TAKAHASHI, Masahide/I-7244-2014; Takahashi, Masahide/AAN-4770-2020	Takahashi, Masahide/0000-0002-2803-2683				Alberti L, 1998, ONCOGENE, V17, P1079, DOI 10.1038/sj.onc.1202046; Arighi E, 1997, ONCOGENE, V14, P773, DOI 10.1038/sj.onc.1200896; Asai N, 1996, J BIOL CHEM, V271, P17644, DOI 10.1074/jbc.271.30.17644; Barone MV, 2001, ONCOGENE, V20, P6973, DOI 10.1038/sj.onc.1204886; Benard V, 1999, J BIOL CHEM, V274, P13198, DOI 10.1074/jbc.274.19.13198; Besset V, 2000, J BIOL CHEM, V275, P39159, DOI 10.1074/jbc.M006908200; Bohm SK, 1997, BIOCHEM J, V322, P1; Borrello MG, 1996, MOL CELL BIOL, V16, P2151; Cai DM, 1999, NEURON, V22, P89, DOI 10.1016/S0896-6273(00)80681-9; Chern YJ, 2000, CELL SIGNAL, V12, P195, DOI 10.1016/S0898-6568(99)00084-4; Chiariello M, 1998, ONCOGENE, V16, P2435, DOI 10.1038/sj.onc.1201778; Dell'Acqua ML, 1998, EMBO J, V17, P2246, DOI 10.1093/emboj/17.8.2246; DellAcqua ML, 1997, J BIOL CHEM, V272, P12881, DOI 10.1074/jbc.272.20.12881; Dickson BJ, 2001, CURR OPIN NEUROBIOL, V11, P103, DOI 10.1016/S0959-4388(00)00180-X; Durick K, 1998, MOL CELL BIOL, V18, P2298, DOI 10.1128/MCB.18.4.2298; Engele J, 1996, CELL TISSUE RES, V286, P235, DOI 10.1007/s004410050692; GLANTZ SB, 1992, MOL BIOL CELL, V3, P1215, DOI 10.1091/mbc.3.11.1215; Grimm J, 2001, J CELL BIOL, V154, P345, DOI 10.1083/jcb.200102032; Hanson MG, 1998, J NEUROSCI, V18, P7361; Hayashi H, 2000, ONCOGENE, V19, P4469, DOI 10.1038/sj.onc.1203799; Hayashi Y, 2001, BIOCHEM BIOPH RES CO, V281, P682, DOI 10.1006/bbrc.2001.4338; Kjoller L, 1999, EXP CELL RES, V253, P166, DOI 10.1006/excr.1999.4674; Kurokawa K, 2001, ONCOGENE, V20, P1929, DOI 10.1038/sj.onc.1204290; Liu X, 1996, J BIOL CHEM, V271, P5309, DOI 10.1074/jbc.271.10.5309; Lorenzo MJ, 1997, ONCOGENE, V14, P763, DOI 10.1038/sj.onc.1200894; Luo LQ, 2000, NAT REV NEUROSCI, V1, P173, DOI 10.1038/35044547; Manie S, 2001, TRENDS GENET, V17, P580, DOI 10.1016/S0168-9525(01)02420-9; Melillo RM, 2001, MOL CELL BIOL, V21, P4177, DOI 10.1128/MCB.21.13.4177-4187.2001; Melillo RM, 2001, ONCOGENE, V20, P209, DOI 10.1038/sj.onc.1204049; Moore MW, 1996, NATURE, V382, P76, DOI 10.1038/382076a0; Mueller BK, 1999, ANNU REV NEUROSCI, V22, P351, DOI 10.1146/annurev.neuro.22.1.351; Murakami H, 1999, ONCOGENE, V18, P1975, DOI 10.1038/sj.onc.1202514; Murakami H, 1999, BIOCHEM BIOPH RES CO, V262, P68, DOI 10.1006/bbrc.1999.1186; PANDEY A, 1995, J BIOL CHEM, V270, P21461, DOI 10.1074/jbc.270.37.21461; Pichel JG, 1996, NATURE, V382, P73, DOI 10.1038/382073a0; Qiao S, 2001, J BIOL CHEM, V276, P9460, DOI 10.1074/jbc.M008744200; Sanchez MP, 1996, NATURE, V382, P70, DOI 10.1038/382070a0; SCHUCHARDT A, 1994, NATURE, V367, P380, DOI 10.1038/367380a0; Scita G, 2000, EMBO J, V19, P2393, DOI 10.1093/emboj/19.11.2393; Segouffin-Cariou C, 2000, J BIOL CHEM, V275, P3568, DOI 10.1074/jbc.275.5.3568; Shamah SM, 2001, CELL, V105, P233, DOI 10.1016/S0092-8674(01)00314-2; Song HJ, 1997, NATURE, V388, P275, DOI 10.1038/40864; Takahashi M, 2001, CYTOKINE GROWTH F R, V12, P361, DOI 10.1016/S1359-6101(01)00012-0; vanWeering DHJ, 1997, J BIOL CHEM, V272, P249	44	110	112	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 24	2002	277	21					19114	19121		10.1074/jbc.M200643200	http://dx.doi.org/10.1074/jbc.M200643200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	558PM	11886862	hybrid			2022-12-27	WOS:000175975800113
J	Jackson, AD; Denu, JM				Jackson, AD; Denu, JM			Structural identification of 2 '- and 3 '-O-acetyl-ADP-ribose as novel metabolites derived from the Sir2 family of beta-NAD(+)-dependent histone/protein deacetylases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SILENCING PROTEIN SIR2; SACCHAROMYCES-CEREVISIAE; ACYL MIGRATION; LIFE-SPAN; YEAST; NAD; GLUCURONIDE; EXPRESSION; STABILITY; LONGEVITY	The Sir2 (silent information regulator 2) family of histone/protein deacetylases has been implicated in a wide range of biological activities, including gene silencing, life-span extension, and chromosomal stability. Their dependence on beta-NAD(+) for activity is unique among the known classes of histone/protein deacetylase. Sir2 enzymes have been shown to couple substrate deacetylation and beta-NAD(+) cleavage to the formation of O-acetyl-ADP-ribose, a newly described metabolite. To gain a better understanding of the catalytic mechanism and of the biological implications of producing this molecule, we have performed a detailed enzymatic and structural characterization of O-acetyl-ADP-ribose. Through the use of mass spectrometry, rapid quenching techniques, and NMR structural analyses, 2'-O-acetyl-ADP-ribose and 3'-O-acetyl-ADP-ribose were found to be the solution products produced by the Sir2 family of enzymes. Rapid quenching approaches under single-turnover conditions identified 2'-O-acetyl-ADP-ribose as the enzymatic product, whereas 3'-O-acetyl-ADP-ribose was formed by intramolecular transesterification after enzymatic release into bulk solvent, where 2'- and 3'-O-acetyl-ADP-ribose exist in equilibrium (48:52). In addition to H-1 and C-13 chemical shift assignments for each regioisomer, heteronuclear multiple-bond correlation spectroscopy was used to assign unambiguously the position of the acetyl group. These findings are highly significant, because they differ from the previous conclusion, which suggested that 1'-O-acetyl-ADP-ribose was the solution product of the reaction. Possible mechanisms for the generation of 2'-O-acetyl-ADP-ribose are discussed.	Oregon Hlth Sci Univ, Dept Biochem & Mol Biol, Portland, OR 97201 USA	Oregon Health & Science University	Denu, JM (corresponding author), Oregon Hlth Sci Univ, Dept Biochem & Mol Biol, 3181 SW Sam Jackson Pk Rd, Portland, OR 97201 USA.	denuj@ohsu.edu			NIDDK NIH HHS [DK07680-12] Funding Source: Medline	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		APARICIO OM, 1991, CELL, V66, P1279, DOI 10.1016/0092-8674(91)90049-5; BARKER R, 1961, J ORG CHEM, V26, P4605, DOI 10.1021/jo01069a095; BORRA MT, 2002, J BIOL CHEM     0125; BRACHMANN CB, 1995, GENE DEV, V9, P2888, DOI 10.1101/gad.9.23.2888; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bryk M, 1997, GENE DEV, V11, P255, DOI 10.1101/gad.11.2.255; Corcoran O, 2001, CHEM RES TOXICOL, V14, P1363, DOI 10.1021/tx010015q; Fritze CE, 1997, EMBO J, V16, P6495, DOI 10.1093/emboj/16.21.6495; Frye RA, 2000, BIOCHEM BIOPH RES CO, V273, P793, DOI 10.1006/bbrc.2000.3000; GOTTSCHLING DE, 1990, CELL, V63, P751, DOI 10.1016/0092-8674(90)90141-Z; Hasegawa H, 2001, BIOL PHARM BULL, V24, P852, DOI 10.1248/bpb.24.852; Imai S, 2000, NATURE, V403, P795, DOI 10.1038/35001622; Jemnitz K, 2000, EUR J DRUG METAB PH, V25, P153, DOI 10.1007/BF03192307; Kaeberlein M, 1999, GENE DEV, V13, P2570, DOI 10.1101/gad.13.19.2570; Kim Y, 2000, ANAL BIOCHEM, V280, P308, DOI 10.1006/abio.2000.4546; Landry J, 2000, P NATL ACAD SCI USA, V97, P5807, DOI 10.1073/pnas.110148297; Lin SJ, 2000, SCIENCE, V289, P2126, DOI 10.1126/science.289.5487.2126; Loo S, 1995, ANNU REV CELL DEV BI, V11, P519, DOI 10.1146/annurev.cellbio.11.1.519; Min JR, 2001, CELL, V105, P269, DOI 10.1016/S0092-8674(01)00317-8; Mortensen RW, 2001, DRUG METAB DISPOS, V29, P375; RINE J, 1987, GENETICS, V116, P9; Sauve AA, 2001, BIOCHEMISTRY-US, V40, P15456, DOI 10.1021/bi011858j; Shou WY, 1999, CELL, V97, P233, DOI 10.1016/S0092-8674(00)80733-3; Smith JS, 2000, P NATL ACAD SCI USA, V97, P6658, DOI 10.1073/pnas.97.12.6658; Smith JS, 1997, GENE DEV, V11, P241, DOI 10.1101/gad.11.2.241; StrahlBolsinger S, 1997, GENE DEV, V11, P83, DOI 10.1101/gad.11.1.83; Tanner KG, 2000, P NATL ACAD SCI USA, V97, P14178, DOI 10.1073/pnas.250422697; Tanny JC, 2001, P NATL ACAD SCI USA, V98, P415, DOI 10.1073/pnas.031563798; Tissenbaum HA, 2001, NATURE, V410, P227, DOI 10.1038/35065638; Tsukamoto Y, 1997, NATURE, V388, P900, DOI 10.1038/42288	30	175	178	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 24	2002	277	21					18535	18544		10.1074/jbc.M200671200	http://dx.doi.org/10.1074/jbc.M200671200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	558PM	11893743	hybrid			2022-12-27	WOS:000175975800039
J	Jin, SB; Zhao, J; Bjork, P; Schmekel, K; Ljungdahl, PO; Wieslander, L				Jin, SB; Zhao, J; Bjork, P; Schmekel, K; Ljungdahl, PO; Wieslander, L			Mrd1p is required for processing of pre-rRNA and for maintenance of steady-state levels of 40 S ribosomal subunits in yeast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMALL NUCLEOLAR RIBONUCLEOPROTEIN; EXTERNAL TRANSCRIBED SPACER; RNA RECOGNITION MOTIFS; TRANS-ACTING FACTORS; SMALL NUCLEAR-RNA; SACCHAROMYCES-CEREVISIAE; CRYSTAL-STRUCTURE; SNORNP PROTEIN; U3 SNORNP; IN-VIVO	Ribosome biogenesis is a conserved process in eukaryotes that requires a large number of small nucleolar RNAs and trans-acting proteins. The Saccharomyces cerevisiae MRD1 (Multiple RNA-binding domain) gene encodes a novel protein that contains five consensus RNA-binding domains. Mrd1p is essential for viability. Mrd1p partially co-localizes with the nucleolar protein Nop1p. Depletion of Mrd1p leads to a selective reduction of 18 S rRNA and 40 S ribosomal subunits. Mrd1p associates with the 35 S precursor rRNA (pre-rRNA) and U3 small nucleolar RNAs and is necessary for the initial processing at the A(0)-A(2) cleavage sites in pre-rRNA. The presence of five RNA-binding domains in Mrd1p suggests that Mrd1p may function to correctly fold pre-rRNA, a requisite for proper cleavage. Sequence comparisons suggest that Mrd1p homologues exist in all eukaryotes.	Stockholm Univ, Dept Mol Biol & Funct Genom, SE-10691 Stockholm, Sweden; Karolinska Inst, Ludwig Inst Canc Res, SE-17177 Stockholm, Sweden	Stockholm University; Karolinska Institutet; Ludwig Institute for Cancer Research	Wieslander, L (corresponding author), Stockholm Univ, Dept Mol Biol & Funct Genom, SE-10691 Stockholm, Sweden.		Wieslander, Lars/B-4670-2016; Ljungdahl, Per O/M-5258-2013; Zhao, Jian/F-9991-2019	Wieslander, Lars/0000-0003-3271-6946; Ljungdahl, Per O/0000-0002-6625-3540; Zhao, Jian/0000-0001-5659-730X				Allain FHT, 2000, EMBO J, V19, P6870, DOI 10.1093/emboj/19.24.6870; ALLEN JB, 1994, YEAST, V10, P1267, DOI 10.1002/yea.320101003; Allmang C, 1996, RNA, V2, P63; ANTEBI A, 1992, MOL BIOL CELL, V3, P633, DOI 10.1091/mbc.3.6.633; BELTRAME M, 1994, NUCLEIC ACIDS RES, V22, P4057, DOI 10.1093/nar/22.20.4057; Billy E, 2000, EMBO J, V19, P2115, DOI 10.1093/emboj/19.9.2115; Brachmann CB, 1998, YEAST, V14, P115; BURD CG, 1994, SCIENCE, V265, P615, DOI 10.1126/science.8036511; Colley A, 2000, MOL CELL BIOL, V20, P7238, DOI 10.1128/MCB.20.19.7238-7246.2000; Deo RC, 1999, CELL, V98, P835, DOI 10.1016/S0092-8674(00)81517-2; Dunbar DA, 1997, MOL CELL BIOL, V17, P5803, DOI 10.1128/MCB.17.10.5803; EICHLER DC, 1994, PROG NUCLEIC ACID RE, V49, P197; Enright CA, 1996, RNA, V2, P1094; Filipowicz W, 1999, ACTA BIOCHIM POL, V46, P377, DOI 10.18388/abp.1999_4171; Gautier T, 1997, MOL CELL BIOL, V17, P7088, DOI 10.1128/MCB.17.12.7088; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; Ginisty H, 1999, J CELL SCI, V112, P761; GIRARD JP, 1992, EMBO J, V11, P673, DOI 10.1002/j.1460-2075.1992.tb05099.x; Guthrie C, 1991, METHODS ENZYMOLOGY, V194; Handa N, 1999, NATURE, V398, P579, DOI 10.1038/19242; HERSCHLAG D, 1995, J BIOL CHEM, V270, P20871, DOI 10.1074/jbc.270.36.20871; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Hong B, 1997, MOL CELL BIOL, V17, P378, DOI 10.1128/MCB.17.1.378; HUGHES JMX, 1991, EMBO J, V10, P4231, DOI 10.1002/j.1460-2075.1991.tb05001.x; Hurt E, 1999, J CELL BIOL, V144, P389, DOI 10.1083/jcb.144.3.389; JANSEN R, 1993, EMBO J, V12, P2549, DOI 10.1002/j.1460-2075.1993.tb05910.x; KASS S, 1990, CELL, V60, P897, DOI 10.1016/0092-8674(90)90338-F; Kressler D, 1999, MOL CELL BIOL, V19, P7897; Kressler D, 1997, MOL CELL BIOL, V17, P7283, DOI 10.1128/MCB.17.12.7283; LAFONTAINE D, 1995, GENE DEV, V9, P2470, DOI 10.1101/gad.9.20.2470; Lafontaine DLJ, 1999, RNA, V5, P455, DOI 10.1017/S135583829998192X; Lalev AI, 2000, J MOL BIOL, V302, P65, DOI 10.1006/jmbi.2000.4015; Leary DJ, 2001, FEBS LETT, V509, P145, DOI 10.1016/S0014-5793(01)03143-X; Lee SJ, 1999, MOL CELL BIOL, V19, P5441; LEE WC, 1991, J CELL BIOL, V113, P1, DOI 10.1083/jcb.113.1.1; LI HV, 1990, MOL CELL BIOL, V10, P1145, DOI 10.1128/MCB.10.3.1145; MORRISSEY JP, 1995, TRENDS BIOCHEM SCI, V20, P78, DOI 10.1016/S0968-0004(00)88962-8; MORRISSEY JP, 1993, MOL CELL BIOL, V13, P2469, DOI 10.1128/MCB.13.4.2469; MOUGEY EB, 1993, MOL CELL BIOL, V13, P5990, DOI 10.1128/MCB.13.10.5990; Moy TI, 1999, GENE DEV, V13, P2118, DOI 10.1101/gad.13.16.2118; ODay CL, 1996, NUCLEIC ACIDS RES, V24, P3201, DOI 10.1093/nar/24.16.3201; Olson MOJ, 2000, TRENDS CELL BIOL, V10, P189, DOI 10.1016/S0962-8924(00)01738-4; ORRICK LR, 1973, P NATL ACAD SCI USA, V70, P1316, DOI 10.1073/pnas.70.5.1316; OUBRIDGE C, 1994, NATURE, V372, P432, DOI 10.1038/372432a0; Pintard L, 2000, MOL CELL BIOL, V20, P1370, DOI 10.1128/MCB.20.4.1370-1381.2000; Price SR, 1998, NATURE, V394, P645, DOI 10.1038/29234; Sambrook J, 2001, MOL CLONING LAB MANU, V3rd; SIKORSKI RS, 1989, GENETICS, V122, P19; Smith J.A., 2000, CURRENT PROTOCOLS MO; Stage-Zimmermann T, 2000, MOL BIOL CELL, V11, P3777, DOI 10.1091/mbc.11.11.3777; Sun C, 1997, J BIOL CHEM, V272, P25345, DOI 10.1074/jbc.272.40.25345; THOMAS BJ, 1989, CELL, V56, P619, DOI 10.1016/0092-8674(89)90584-9; TOLLERVEY D, 1991, EMBO J, V10, P573, DOI 10.1002/j.1460-2075.1991.tb07984.x; Tollervey D, 1996, EXP CELL RES, V229, P226, DOI 10.1006/excr.1996.0364; Tollervey D, 1997, CURR OPIN CELL BIOL, V9, P337, DOI 10.1016/S0955-0674(97)80005-1; TRAPMAN J, 1975, EXP CELL RES, V90, P95, DOI 10.1016/0014-4827(75)90361-4; UDEM SA, 1973, J BIOL CHEM, V248, P1412; Varani G, 1998, ANNU REV BIOPH BIOM, V27, P407, DOI 10.1146/annurev.biophys.27.1.407; Venema J, 2000, RNA, V6, P1660, DOI 10.1017/S1355838200001369; Venema J, 1997, MOL CELL BIOL, V17, P3398, DOI 10.1128/MCB.17.6.3398; VENEMA J, 1995, EMBO J, V14, P4883, DOI 10.1002/j.1460-2075.1995.tb00169.x; Venema J, 1996, EMBO J, V15, P5701, DOI 10.1002/j.1460-2075.1996.tb00954.x; Venema J, 1999, ANNU REV GENET, V33, P261, DOI 10.1146/annurev.genet.33.1.261; Watkins NJ, 2000, CELL, V103, P457, DOI 10.1016/S0092-8674(00)00137-9; Weinstein LB, 1999, CURR OPIN CELL BIOL, V11, P378, DOI 10.1016/S0955-0674(99)80053-2; Wiederkehr T, 1998, RNA, V4, P1357, DOI 10.1017/S1355838298980955; Wu P, 1998, J BIOL CHEM, V273, P16453, DOI 10.1074/jbc.273.26.16453; Yelin R, 2001, BBA-BIOMEMBRANES, V1510, P426, DOI 10.1016/S0005-2736(00)00374-6	68	26	27	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 24	2002	277	21					18431	18439		10.1074/jbc.M112395200	http://dx.doi.org/10.1074/jbc.M112395200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	558PM	11884397	hybrid			2022-12-27	WOS:000175975800024
J	Miake, H; Mizusawa, H; Iwatsubo, T; Hasegawa, M				Miake, H; Mizusawa, H; Iwatsubo, T; Hasegawa, M			Biochemical characterization of the core structure of alpha-synuclein filaments	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIPLE SYSTEM ATROPHY; PAIRED HELICAL FILAMENTS; GLIAL CYTOPLASMIC INCLUSIONS; PARKINSONS-DISEASE; LEWY BODIES; ALZHEIMERS-DISEASE; FIBRIL FORMATION; PROTEIN-TAU; IN-VITRO; MUTATIONS	Intracellular filamentous aggregates comprised of alpha-synuclein such as Lewy bodies and glial cytoplasmic inclusions are the defining hallmarks of a subset of neurodegenerative diseases including Parkinson's disease, dementia with Lewy bodies, and multiple system atrophy. We have analyzed biochemical and structural properties of alpha-synuclein filaments assembled in vitro or extracted from brains of patients with multiple system atrophy and found that both types of filaments are insoluble to detergents and partially resistant to proteinase K digestion. Immunoelectron microscopy and immunoblot analysis showed that both amino and carboxyl termini of alpha-synuclein in in vitro assembled filaments were degraded by proteinase K treatment, whereas the central portion of alpha-synuclein is resistant to proteinase K and retains filamentous structures. Protein sequencing and mass spectrometric analyses of the proteinase K-resistant, minimal fragment of 7 kDa revealed that amino acid residues 31-109 of alpha-synuclein constitute the core unit of the filaments. These observations suggest that the central half of the alpha-synuclein polypeptide, containing five tandem repeats as well as a part of the carboxyl-terminal acidic region, forms the core structure of alpha-synuclein filaments, which is coated by the amino- and carboxyl-terminaI portions at the periphery.	Tokyo Metropolitan Org Med Res, Tokyo Inst Psychiat, Dept Mol Neurobiol, Setagaya Ku, Tokyo 1568585, Japan; Univ Tokyo, Grad Sch Pharmaceut Sci, Dept Neuropathol & Neurosci, Bunkyo Ku, Tokyo 1130033, Japan; Tokyo Med & Dent Univ, Grad Sch Med, Dept Neurol & Neurol Sci, Bunkyo Ku, Tokyo 1138519, Japan	Tokyo Institute of Psychiatry; Tokyo Metropolitan Institute of Medical Science; University of Tokyo; Tokyo Medical & Dental University (TMDU)	Hasegawa, M (corresponding author), Tokyo Metropolitan Org Med Res, Tokyo Inst Psychiat, Dept Mol Neurobiol, Setagaya Ku, 2-1-8 Kamikitazawa, Tokyo 1568585, Japan.							Baba M, 1998, AM J PATHOL, V152, P879; Biere AL, 2000, J BIOL CHEM, V275, P34574, DOI 10.1074/jbc.M005514200; Conway KA, 2000, BIOCHEMISTRY-US, V39, P2552, DOI 10.1021/bi991447r; Conway KA, 2000, P NATL ACAD SCI USA, V97, P571, DOI 10.1073/pnas.97.2.571; Conway KA, 1998, NAT MED, V4, P1318, DOI 10.1038/3311; CROWTHER RA, 1992, FEBS LETT, V309, P199, DOI 10.1016/0014-5793(92)81094-3; Crowther RA, 1998, FEBS LETT, V436, P309, DOI 10.1016/S0014-5793(98)01146-6; Crowther RA, 2000, NEUROSCI LETT, V292, P128, DOI 10.1016/S0304-3940(00)01440-3; Culvenor JG, 1999, AM J PATHOL, V155, P1173, DOI 10.1016/S0002-9440(10)65220-0; Dickson DW, 1999, AM J PATHOL, V155, P1241, DOI 10.1016/S0002-9440(10)65226-1; El-Agnaf OMA, 1998, FEBS LETT, V440, P67, DOI 10.1016/S0014-5793(98)01419-7; Fujiwara H, 2002, NAT CELL BIOL, V4, P160, DOI 10.1038/ncb748; Giasson BI, 2001, J BIOL CHEM, V276, P2380, DOI 10.1074/jbc.M008919200; Goedert M, 2001, CURR OPIN GENET DEV, V11, P343, DOI 10.1016/S0959-437X(00)00200-8; Goedert M, 1996, NATURE, V383, P550, DOI 10.1038/383550a0; HASEGAWA M, 1993, J NEUROCHEM, V60, P2068, DOI 10.1111/j.1471-4159.1993.tb03491.x; Irizarry MC, 1998, J NEUROPATH EXP NEUR, V57, P334, DOI 10.1097/00005072-199804000-00005; JAKES R, 1994, FEBS LETT, V345, P27, DOI 10.1016/0014-5793(94)00395-5; Jakes R, 1999, NEUROSCI LETT, V269, P13, DOI 10.1016/S0304-3940(99)00411-5; Jo EJ, 2000, J BIOL CHEM, V275, P34328, DOI 10.1074/jbc.M004345200; Kruger R, 1998, NAT GENET, V18, P106, DOI 10.1038/ng0298-106; KSIEZAKREDING H, 1991, NEURON, V6, P717, DOI 10.1016/0896-6273(91)90169-Z; Lippa CF, 1998, AM J PATHOL, V153, P1365, DOI 10.1016/S0002-9440(10)65722-7; McLean PJ, 2000, J BIOL CHEM, V275, P8812, DOI 10.1074/jbc.275.12.8812; Narhi L, 1999, J BIOL CHEM, V274, P9843, DOI 10.1074/jbc.274.14.9843; NOVAK M, 1993, EMBO J, V12, P365, DOI 10.1002/j.1460-2075.1993.tb05665.x; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; Serpell LC, 2000, P NATL ACAD SCI USA, V97, P4897, DOI 10.1073/pnas.97.9.4897; Spillantini MG, 1998, P NATL ACAD SCI USA, V95, P6469, DOI 10.1073/pnas.95.11.6469; Spillantini MG, 1997, NATURE, V388, P839, DOI 10.1038/42166; Spillantini MG, 1998, NEUROSCI LETT, V251, P205, DOI 10.1016/s0304-3940(98)00504-7; Tu PH, 1998, ANN NEUROL, V44, P415, DOI 10.1002/ana.410440324; Uversky VN, 2001, J BIOL CHEM, V276, P10737, DOI 10.1074/jbc.M010907200; Wakabayashi K, 1998, NEUROSCI LETT, V249, P180, DOI 10.1016/S0304-3940(98)00407-8; WILLE H, 1992, J CELL BIOL, V118, P573, DOI 10.1083/jcb.118.3.573	35	205	212	0	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 24	2002	277	21					19213	19219		10.1074/jbc.M110551200	http://dx.doi.org/10.1074/jbc.M110551200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	558PM	11893734	hybrid			2022-12-27	WOS:000175975800125
J	Takagaki, K; Iwafune, M; Kakizaki, I; Ishido, K; Kato, Y; Endo, M				Takagaki, K; Iwafune, M; Kakizaki, I; Ishido, K; Kato, Y; Endo, M			Cleavage of the xylosyl serine linkage between a core peptide and a glycosaminoglycan chain by cellulases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDO-BETA-XYLOSIDASE; SWARM RAT CHONDROSARCOMA; SPRAY MASS-SPECTROMETRY; HUMAN SKIN FIBROBLASTS; CARTILAGE PROTEOGLYCANS; ASPERGILLUS-NIGER; ANTITHROMBIN-III; BINDING SEQUENCE; SULFATE; HEPARIN	We previously found that endo-beta-xylosidase from Patinopecten is an endo-type glycosidase that cleaves the xylosyl serine linkage between a glycosaminoglycan chain and its core protein (Takagaki, K., Kon, A., Kawasaki, H., Nakamura, T., Tamura, S., and Endo, M. (1990) J. Biol. Chem. 265, 854-860). Screening for endo-beta-xylosidase activity in several cellulases detected this activity in the enzymes from Aspergillus niger, Penicillium funiculosum, Trichoderma reesei, Trichoderma viride, and Irpex lacteus. The cellulase derived from A. niger was purified, and its molecular weight was determined to be 26,000 by SDS-PAGE. Examination of the specificity of the cellulase revealed that 1) the enzyme acts on the linkage region (xylosyl serine) between a core peptide and a glycosaminoglycan chain; 2) enzymatic activity is greater with shorter glycosaminoglycan chains; 3) the enzyme readily hydrolyzes the linkage in glycosaminoglycan peptides, but intact proteoglycan is cleaved only slowly; and 4) the activity is unaffected by the glycosaminoglyean component (chondroitin sulfate, dermatan sulfate, and heparan sulfate). Judging from these enzymatic characteristics, this cellulase is different from the endo-beta-xylosidase of Patinopecten. We believe that this cellulase will become a useful tool in the further development of glycotechnology, because, like the endo-beta-xylosidase of Patinopecten, it enables the release of intact glycosaminoglyeans from glycosaminoglycan peptides.	Hirosaki Univ, Sch Med, Dept Biochem, Hirosaki, Aomori 0368562, Japan; Hirosaki Univ, Fac Educ, Food Sci Lab, Hirosaki, Aomori 0368560, Japan	Hirosaki University; Hirosaki University	Endo, M (corresponding author), Hirosaki Univ, Sch Med, Dept Biochem, 5 Zaifu Cho, Hirosaki, Aomori 0368562, Japan.		Kakizaki, Ikuko/AAO-5489-2020	Kakizaki, Ikuko/0000-0002-6702-5830				BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Byrne KA, 1999, GENE, V239, P317, DOI 10.1016/S0378-1119(99)00396-0; CASU B, 1981, BIOCHEM J, V197, P599, DOI 10.1042/bj1970599; CHERNOGLAZOV VM, 1989, ANAL BIOCHEM, V179, P186, DOI 10.1016/0003-2697(89)90222-4; FRANSSON LA, 1985, J BIOL CHEM, V260, P4722; FREEZE HH, 1993, J BIOL CHEM, V268, P1618; FUKUDA M, 1969, J BIOCHEM-TOKYO, V65, P191; FUKUDA M, 1969, J BIOCHEM-TOKYO, V66, P157, DOI 10.1093/oxfordjournals.jbchem.a129131; Girard C, 1999, INSECT BIOCHEM MOLEC, V29, P1129, DOI 10.1016/S0965-1748(99)00104-6; GROOTENHUIS PDJ, 1991, J AM CHEM SOC, V113, P2743, DOI 10.1021/ja00007a058; HASCALL VC, 1986, FUNCTIONS PROTEOGLYC, P1; HEINEGAR.D, 1972, BIOCHIM BIOPHYS ACTA, V285, P193, DOI 10.1016/0005-2795(72)90191-2; HEINEGARD D, 1974, J BIOL CHEM, V249, P4250; HUNTER GK, 1988, ARCH BIOCHEM BIOPHYS, V260, P161, DOI 10.1016/0003-9861(88)90437-7; HURST PL, 1977, BIOCHEM J, V165, P33, DOI 10.1042/bj1650033; Ishido K, 2002, J BIOL CHEM, V277, P11889, DOI 10.1074/jbc.M112183200; Kimura I, 1999, J BIOSCI BIOENG, V87, P538, DOI 10.1016/S1389-1723(99)80107-8; KON A, 1991, J BIOCHEM-TOKYO, V110, P132, DOI 10.1093/oxfordjournals.jbchem.a123531; Lindahl U., 1972, GLYCOPROTEINS THEIR, P491; Lo N, 2000, CURR BIOL, V10, P801, DOI 10.1016/S0960-9822(00)00561-3; MAIMONE MM, 1990, J BIOL CHEM, V265, P18263; MATSUE H, 1987, BIOCHIM BIOPHYS ACTA, V923, P470, DOI 10.1016/0304-4165(87)90056-0; OEGEMA TR, 1984, J BIOL CHEM, V259, P1720; OKADA G, 1985, AGR BIOL CHEM TOKYO, V49, P1257, DOI 10.1080/00021369.1985.10866894; RAAB G, 1997, BIOCHIM BIOPHYS ACTA, V1333, P179; ROBINSON D, 1967, BIOCHIM BIOPHYS ACTA, V132, P212, DOI 10.1016/0005-2744(67)90215-X; Roden L., 1980, BIOCH GLYCOPROTEINS, P267; ROUX L, 1988, J BIOL CHEM, V263, P8879; SAITO H, 1968, J BIOL CHEM, V243, P1536; SHIBATA S, 1995, J BIOL CHEM, V270, P13794, DOI 10.1074/jbc.270.23.13794; Smant G, 1998, P NATL ACAD SCI USA, V95, P4906, DOI 10.1073/pnas.95.9.4906; SUGAHARA K, 1988, J BIOL CHEM, V263, P10168; TAKAGAKI K, 1991, J BIOCHEM-TOKYO, V109, P514, DOI 10.1093/oxfordjournals.jbchem.a123413; TAKAGAKI K, 1985, FEBS LETT, V181, P271, DOI 10.1016/0014-5793(85)80274-X; Takagaki K, 1998, GLYCOBIOLOGY, V8, P719, DOI 10.1093/glycob/8.7.719; TAKAGAKI K, 1994, BIOCHEMISTRY-US, V33, P6503, DOI 10.1021/bi00187a017; TAKAGAKI K, 1992, GLYCOCONJUGATE J, V9, P174, DOI 10.1007/BF00731162; TAKAGAKI K, 1990, J BIOL CHEM, V265, P854; TAKAGAKI K, 1988, BIOCHIM BIOPHYS ACTA, V966, P94, DOI 10.1016/0304-4165(88)90132-8; TAKAGAKI K, 1989, J BIOCHEM BIOPH METH, V19, P207, DOI 10.1016/0165-022X(89)90027-4; TAKAGAKI K, 1994, J BIOCHEM BIOPH METH, V28, P313, DOI 10.1016/0165-022X(94)90007-8; TAKAGAKI K, 1990, J BIOCHEM BIOPH METH, V21, P209, DOI 10.1016/0165-022X(90)90014-4; THUNBERG L, 1982, CARBOHYD RES, V100, P393, DOI 10.1016/S0008-6215(00)81050-2; Tokuda G, 1999, BBA-GENE STRUCT EXPR, V1447, P146, DOI 10.1016/S0167-4781(99)00169-4; Watanabe H, 1998, NATURE, V394, P330, DOI 10.1038/28527; WEBER K, 1969, J BIOL CHEM, V244, P4406	46	21	21	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 24	2002	277	21					18397	18403		10.1074/jbc.M111985200	http://dx.doi.org/10.1074/jbc.M111985200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	558PM	11877400	hybrid			2022-12-27	WOS:000175975800020
J	Van Hooser, JP; Liang, Y; Maeda, T; Kuksa, V; Jang, GF; He, YG; Rieke, F; Fong, HKW; Detwiler, PB; Palczewski, K				Van Hooser, JP; Liang, Y; Maeda, T; Kuksa, V; Jang, GF; He, YG; Rieke, F; Fong, HKW; Detwiler, PB; Palczewski, K			Recovery of visual functions in a mouse model of Leber congenital amaurosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETINAL-PIGMENT EPITHELIUM; VERTEBRATE RETINA; RPE65 MUTATIONS; OUTER SEGMENTS; BLOOD-PLASMA; GENE; PROTEIN; RHODOPSIN; BINDING; CYCLE	The visual process is initiated by the photoisomerization of 11-cis-retinal to all-trans-retinal. For sustained vision the 11-cis-chromophore must be regenerated from all-trans-retinal. This requires RPE65, a dominant retinal pigment epithelium protein. Disruption of the RPE65 gene results in massive accumulation of all-trans-retinyl esters in the retinal pigment epithelium, lack of 11-cis-retinal and therefore rhodopsin, and ultimately blindness. We reported previously (Van Hooser, J. P., Aleman, T. S., He, Y. G., Cideciyan, A. V., Kuksa, V., Pittler, S. J., Stone, E. M., Jacobson, S. G., and Palczewski, K. (2000) Proc. Natl. Acad. Sci. U. S. A. 97, 8623-8628) that in Rpe65-/- mice, oral administration of 9-cis-retinal generated isorhodopsin, a rod photopigment, and restored light sensitivity to the electroretinogram. Here, we provide evidence that early intervention by 9-cis-retinal administration significantly attenuated retinal ester accumulation and supported rod retinal function for more than 6 months post-treatment. In single cell recordings rod light sensitivity was shown to be a function of the amount of regenerated isorhodopsin; high doses restored rod responses with normal sensitivity and kinetics. Highly attenuated residual rod function was observed in untreated Rpe65-/- mice. This rod function is likely a consequence of low efficiency production of 11-cis-retinal by photo-conversion of all-trans-retinal in the retina as demonstrated by retinoid analysis. These studies show that pharmacological intervention produces long lasting preservation of visual function in dark-reared Rpe65-/- mice and may be a useful therapeutic strategy in recovering vision in humans diagnosed with Leber congenital amaurosis caused by mutations in the RPE65 gene, an inherited group of early onset blinding and retinal degenerations.	Univ Washington, Dept Ophthalmol, Seattle, WA 98195 USA; Univ Washington, Dept Chem, Seattle, WA 98195 USA; Univ Washington, Dept Pharmacol, Seattle, WA 98195 USA; Univ Washington, Dept Physiol & Biophys, Seattle, WA 98195 USA; Univ So Calif, Sch Med, Dept Ophthalmol, Los Angeles, CA 90033 USA; Univ So Calif, Sch Med, Dept Microbiol, Los Angeles, CA 90033 USA; Doheny Eye Inst, Los Angeles, CA 90033 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Southern California; University of Southern California; Doheny Eye Institute	Palczewski, K (corresponding author), Univ Washington, Dept Ophthalmol, Box 356485, Seattle, WA 98195 USA.			Detwiler, Peter/0000-0003-3910-2023	NEI NIH HHS [EY66388, R01 EY008061, P30 EY001730, EY01730, R01 EY011850, EY11850, R01 EY002048, EY08061, EY02048, EY07031] Funding Source: Medline; NATIONAL EYE INSTITUTE [P30EY001730, R01EY002048, R01EY008061, R29EY008061, R01EY011850] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Alloway PG, 2000, NEURON, V28, P129, DOI 10.1016/S0896-6273(00)00091-X; BAYLOR DA, 1984, J PHYSIOL-LONDON, V354, P203, DOI 10.1113/jphysiol.1984.sp015372; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAEKEVELT CR, 1990, ANAT ANZEIGER, V171, P351; Chen P, 2001, NAT GENET, V28, P256, DOI 10.1038/90089; CORNWALL MC, 1994, J PHYSIOL-LONDON, V480, P261, DOI 10.1113/jphysiol.1994.sp020358; Denke MA, 2002, JAMA-J AM MED ASSOC, V287, P102, DOI 10.1001/jama.287.1.102; Dryja TP, 2001, AM J HUM GENET, V68, P1295, DOI 10.1086/320113; Gerber S, 2001, EUR J HUM GENET, V9, P561, DOI 10.1038/sj.ejhg.5200689; Gu SM, 1997, NAT GENET, V17, P194, DOI 10.1038/ng1097-194; Jang GF, 2001, J BIOL CHEM, V276, P32456, DOI 10.1074/jbc.M104949200; Jang GF, 2000, J BIOL CHEM, V275, P28128; Katz ML, 2001, INVEST OPHTH VIS SCI, V42, P3023; KROLL AJ, 1964, ARCH OPHTHALMOL-CHIC, V71, P683; LAMB TD, 1981, J PHYSIOL-LONDON, V319, P463, DOI 10.1113/jphysiol.1981.sp013921; LAVAIL MM, 1987, EXP EYE RES, V44, P877, DOI 10.1016/S0014-4835(87)80050-7; LEBER T, 1869, A VONGRAEFES ARCH OP, V15, P1, DOI DOI 10.1007/BF02721213; LI TS, 1995, P NATL ACAD SCI USA, V92, P3551, DOI 10.1073/pnas.92.8.3551; Lorenz B, 2000, INVEST OPHTH VIS SCI, V41, P2735; McBee JK, 2000, BIOCHEMISTRY-US, V39, P11370, DOI 10.1021/bi001061c; McBee JK, 2001, J BIOL CHEM, V276, P48483, DOI 10.1074/jbc.M105840200; McBee JK, 2001, PROG RETIN EYE RES, V20, P469, DOI 10.1016/S1350-9462(01)00002-7; Melia TJ, 1997, BIOPHYS J, V73, P3182, DOI 10.1016/S0006-3495(97)78344-9; NAPOLI JL, 1984, BIOCHEM J, V223, P267, DOI 10.1042/bj2230267; PAGHROEHL K, 1992, CELL MOTIL CYTOSKEL, V21, P235, DOI 10.1002/cm.970210307; Palczewski K, 1999, BIOCHEMISTRY-US, V38, P12012, DOI 10.1021/bi990504d; Perrault I, 1996, NAT GENET, V14, P461, DOI 10.1038/ng1296-461; Redmond TM, 1998, NAT GENET, V20, P344, DOI 10.1038/3813; Redmond TM, 2000, METHOD ENZYMOL, V316, P705; SANYAL S, 1988, EXP EYE RES, V46, P731, DOI 10.1016/S0014-4835(88)80059-9; Schweigert FJ, 1998, INT J VITAM NUTR RES, V68, P237; Schweigert FJ, 2000, INT J VITAM NUTR RES, V70, P84, DOI 10.1024/0300-9831.70.3.84; Seeliger MW, 2001, NAT GENET, V29, P70, DOI 10.1038/ng712; SIMON A, 1995, J BIOL CHEM, V270, P1107, DOI 10.1074/jbc.270.34.19979; Sohocki MM, 2000, NAT GENET, V24, P79, DOI 10.1038/71732; Stiles WS, 1933, P R SOC LOND B-CONTA, V112, P428, DOI 10.1098/rspb.1933.0020; Swaroop A, 1999, HUM MOL GENET, V8, P299, DOI 10.1093/hmg/8.2.299; Thompson DA, 2000, INVEST OPHTH VIS SCI, V41, P4293; Van Hooser JP, 2000, P NATL ACAD SCI USA, V97, P8623, DOI 10.1073/pnas.150236297	39	126	137	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 24	2002	277	21					19173	19182		10.1074/jbc.M112384200	http://dx.doi.org/10.1074/jbc.M112384200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	558PM	11897783	Green Accepted, hybrid			2022-12-27	WOS:000175975800120
J	Fernandis, AZ; Cherla, RP; Chernock, RD; Ganju, RK				Fernandis, AZ; Cherla, RP; Chernock, RD; Ganju, RK			CXCR4/CCR5 down-modulation and chemotaxis are regulated by the proteasome pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; CXC CHEMOKINE RECEPTOR-4; SIGNALING PATHWAYS; ALPHA-CHEMOKINE; HIV-1 INFECTION; CCR5 SIGNALS; T-CELLS; INHIBITION; DEGRADATION; PROTEIN	Chemokines and their receptors play a critical role in host immune surveillance and are important mediators of human immunodeficiency virus (HIV) pathogenesis and inflammatory response. The chemokine receptors CCR5 and CXCR4, which act as co-receptors along with CD4 for HIV docking and entry, are down-modulated by their respective ligands, MIP-1beta3/SDF-1alpha or by the HIV envelope protein, gp120. We have studied the role of the proteasome pathway in the down-regulation of these receptors. Using the yeast and mammalian two-hybrid systems, we observed that the CCR5 receptor is constitutively associated with the subunit of proteasome. Immunoprecipitation studies in CCR5 L1.2 cells revealed that this association was increased with MIP-1beta stimulation. The proteasome inhibitors, lactacystin and epoxomicin, attenuated MIP-1beta induced CCR5 down-modulation as detected by fluorescence-activated cell sorter analysis and confocal microscopy. The proteasome inhibitors also inhibited the SDF-1alpha and gp120 protein-induced down-modulation of the CXCR4 receptor in Jurkat cells. However, the inhibitors had no significant effect on the gp120-induced internalization of the CD4 receptor. These inhibitors also blocked cognate ligand-mediated chemotaxis but had no effect on SDF1alpha-induced p44/42 MAP kinase or MIP-1beta-induced p38 kinase activities, thus indicating differential effects of the inhibitors on signaling mediated by these receptors. These results indicate that the CCR5 and CXCR4 receptor down-modulation mechanism and chemotaxis mediated by these receptors are dependent upon proteasome activity.	Harvard Univ, Sch Med, Inst Med, Beth Israel Deaconess Med Ctr,Div Expt Med, Boston, MA 02115 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Ganju, RK (corresponding author), Harvard Univ, Sch Med, Inst Med, Beth Israel Deaconess Med Ctr,Div Expt Med, 4 Blackfan Cr,Rm 343, Boston, MA 02115 USA.		Fernandis, Aaron/C-3718-2012	Chernock, Rebecca/0000-0001-6253-0478	NATIONAL CANCER INSTITUTE [R29CA076950] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI049140] Funding Source: NIH RePORTER; NCI NIH HHS [CA76950] Funding Source: Medline; NIAID NIH HHS [AI49140] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Androlewicz MJ, 2001, CURR OPIN HEMATOL, V8, P12, DOI 10.1097/00062752-200101000-00003; Ansel KM, 2001, CURR OPIN IMMUNOL, V13, P172, DOI 10.1016/S0952-7915(00)00201-6; Baron V, 2000, J BIOL CHEM, V275, P39318, DOI 10.1074/jbc.M003618200; Brandt SM, 2002, J BIOL CHEM, V277, P17291, DOI 10.1074/jbc.M108232200; Broder CC, 1997, J LEUKOCYTE BIOL, V62, P20, DOI 10.1002/jlb.62.1.20; Broxmeyer HE, 2001, INT J HEMATOL, V74, P9, DOI 10.1007/BF02982544; Cherla RP, 2001, J IMMUNOL, V166, P3067, DOI 10.4049/jimmunol.166.5.3067; Chernock RD, 2001, BLOOD, V97, P608, DOI 10.1182/blood.V97.3.608; Christopherson K, 2001, STEM CELLS, V19, P388, DOI 10.1634/stemcells.19-5-388; De Groot C J, 2001, Prog Brain Res, V132, P533; DRISCOLL J, 1994, HISTOL HISTOPATHOL, V9, P197; Fujita K, 1997, J GEN VIROL, V78, P619, DOI 10.1099/0022-1317-78-3-619; Ganju RK, 2000, J BIOL CHEM, V275, P17263, DOI 10.1074/jbc.M000689200; Ganju RK, 1998, BLOOD, V91, P791, DOI 10.1182/blood.V91.3.791.791_791_797; Ganju RK, 1998, J BIOL CHEM, V273, P23169, DOI 10.1074/jbc.273.36.23169; Haribabu B, 1997, J BIOL CHEM, V272, P28726, DOI 10.1074/jbc.272.45.28726; He JL, 1997, NATURE, V385, P645, DOI 10.1038/385645a0; Horuk R, 2001, CYTOKINE GROWTH F R, V12, P313, DOI 10.1016/S1359-6101(01)00014-4; Ikebe T, 1998, INT J CANCER, V77, P578; Jiang Y, 1999, J HUMAN VIROL, V2, P123; Kim TK, 1996, SCIENCE, V273, P1717, DOI 10.1126/science.273.5282.1717; Kinter A, 2000, IMMUNOL REV, V177, P88, DOI 10.1034/j.1600-065X.2000.17708.x; Mack M, 1998, J EXP MED, V187, P1215, DOI 10.1084/jem.187.8.1215; Mackay CR, 2001, NAT IMMUNOL, V2, P95, DOI 10.1038/84298; Marchese A, 2001, J BIOL CHEM, V276, P45509, DOI 10.1074/jbc.C100527200; Moser B, 2001, NAT IMMUNOL, V2, P123, DOI 10.1038/84219; Muller A, 2001, NATURE, V410, P50, DOI 10.1038/35065016; Murakami T, 2000, INT J HEMATOL, V72, P412; Oberlin E, 1996, NATURE, V382, P833, DOI 10.1038/382833a0; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; Schubert U, 2000, P NATL ACAD SCI USA, V97, P13057, DOI 10.1073/pnas.97.24.13057; Schubert U, 1998, J VIROL, V72, P2280, DOI 10.1128/JVI.72.3.2280-2288.1998; Shioda T, 2001, J VIROL, V75, P3462, DOI 10.1128/JVI.75.7.3462-3468.2001; Signoret N, 2000, J CELL BIOL, V151, P1281, DOI 10.1083/jcb.151.6.1281; Signoret N, 1997, J CELL BIOL, V139, P651, DOI 10.1083/jcb.139.3.651; Simmons G, 1997, SCIENCE, V276, P276, DOI 10.1126/science.276.5310.276; Simmons G, 2000, IMMUNOL REV, V177, P112, DOI 10.1034/j.1600-065X.2000.17719.x; Stantchev TS, 2001, CYTOKINE GROWTH F R, V12, P219, DOI 10.1016/S1359-6101(00)00033-2; Su SB, 1999, J IMMUNOL, V162, P7128; Townson JR, 2000, J BIOL CHEM, V275, P39254, DOI 10.1074/jbc.M006768200; Valenzuela-Fernandez A, 2001, J BIOL CHEM, V276, P26550, DOI 10.1074/jbc.M100411200; Van Drenth C, 2000, J IMMUNOL, V165, P6356, DOI 10.4049/jimmunol.165.11.6356; Van Gassen G, 1999, NEUROBIOL DIS, V6, P376, DOI 10.1006/nbdi.1999.0265; van Kerkhof P, 2000, J BIOL CHEM, V275, P1575, DOI 10.1074/jbc.275.3.1575; Venkatesan S, 2002, J BIOL CHEM, V277, P2287, DOI 10.1074/jbc.M108321200; Venkatesan S, 2001, J BIOL CHEM, V276, P40133, DOI 10.1074/jbc.M105722200; Wang JH, 2001, J BIOL CHEM, V276, P49236, DOI 10.1074/jbc.M108523200; Wang JM, 1998, J IMMUNOL, V161, P4309; Wojcik C, 1999, CELL MOL LIFE SCI, V56, P908, DOI 10.1007/s000180050483; Yu AX, 2001, J BIOL CHEM, V276, P381, DOI 10.1074/jbc.M007991200	50	38	39	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 17	2002	277	20					18111	18117		10.1074/jbc.M200750200	http://dx.doi.org/10.1074/jbc.M200750200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	553PR	11877445	hybrid			2022-12-27	WOS:000175685100092
J	Sachdev, P; Zeng, L; Wang, LH				Sachdev, P; Zeng, L; Wang, LH			Distinct role of phosphatidylinositol 3-kinase and Rho family GTPases in Vav3-induced cell transformation, cell motility, and morphological changes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VAV PROTOONCOGENE PRODUCT; TUMOR-SUPPRESSOR GENE; MAP KINASE KINASE; EXTRACELLULAR-MATRIX; MAST-CELLS; ACTIVATION; RAC; BINDING; GROWTH; CDC42	Vav3 is a member of the Vav family of guanine nucleotide exchange factors (GEFs) for the Rho family GTPases. Deleting the N-terminal calponin homology (CH) domain to generate Vav3-(5-10) or deleting both the CH and the acidic domain to generate Vav3-(6-10) results in activating the transforming potential of Vav3. Expression of either the full-length Vav3 or its truncation mutants led to activation of phosphatidylinositol 3-kinase (PI3K), mitogen-activated protein kinase (MAPK), focal adhesion kinase (FAK), and Stat3. We investigated the requirement of these signaling molecules for Vav3-induced focus formation and found that PI3K and its downstream signaling molecules, Akt and p70 S6 kinase, are required, albeit to varying degrees. Inhibition of PI3K had a more dramatic effect than inhibition of MAPK on Vav3-(6-10)-induced focus formation. Activated PI3K enhanced the focus-forming activity of Vav3-(6-10). Wild type FAK but not Y397F mutant FAK enhanced Vav3-(6-10) -induced focus formation. Dominant negative(dn) mutant of Stat3 resulted in a 60% inhibition of the focus-forming activity of Vav3-(6-10). Moreover, Rac1, RhoA, and to a lesser extent, Cdc42, are important for Vav3-(6-10) -induced focus formation. Constitutively activated (ca) Rac synergizes with Vav3-(6-10) in focus formation. This synergy requires signaling via Rho-associated kinase (ROK) and p21-activated kinase (PAK), downstream effectors of Rac. Consistently, a ca PAK mutant enhanced, whereas a dn PAK mutant inhibited the focus-forming ability of Vav3-(6-10). Despite having potent focus-forming ability, Vav3-(6-10) has very weak colony-forming ability. This colony-forming ability of Vav3-(6-10) can be enhanced dramatically by co-expressing an activated PI3K and to some extent by co-expressing an activated PAK mutant or c-Myc. Interestingly, inhibition of PI3K and MAPK had no effect on the ability of either wild type or Vav3-(6-10) to induce cytoskeletal changes including formation of lamellipodia and filopodia in NIH 3T3 cells. Over expression of Vav3 or Vav3-(6-10) resulted in an enhancement of cell motility. This enhancement was dependent on PI3K, Rac1, and Cdc42 but not on Rho. Overall, our results show that signaling pathways of PI3K, MAPK, and Rho family GTPases are differentially required for Vav3-induced focus formation, colony formation, morphological changes, and cell motility.	CUNY Mt Sinai Sch Med, Dept Microbiol, New York, NY 10029 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Wang, LH (corresponding author), CUNY Mt Sinai Sch Med, Dept Microbiol, 1 Gustave L Levy Pl, New York, NY 10029 USA.	lu-hai.wang@mssm.edu	Wang, Lu-Hai/E-3986-2010		NATIONAL CANCER INSTITUTE [R01CA029339] Funding Source: NIH RePORTER; NCI NIH HHS [CA55054, CA29339] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abe K, 2000, J BIOL CHEM, V275, P10141, DOI 10.1074/jbc.275.14.10141; Abe R, 1999, J BIOL CHEM, V274, P30410, DOI 10.1074/jbc.274.43.30410; Barry ST, 1996, CELL ADHES COMMUN, V4, P387, DOI 10.3109/15419069709004456; Bishop AL, 2000, BIOCHEM J, V348, P241, DOI 10.1042/0264-6021:3480241; Bokoch GM, 1996, BIOCHEM J, V315, P775, DOI 10.1042/bj3150775; Bowman T, 2001, P NATL ACAD SCI USA, V98, P7319, DOI 10.1073/pnas.131568898; Bromberg JF, 1999, CELL, V98, P295, DOI 10.1016/S0092-8674(00)81959-5; Bustelo XR, 2000, MOL CELL BIOL, V20, P1461, DOI 10.1128/MCB.20.5.1461-1477.2000; Chen HC, 1996, J BIOL CHEM, V271, P26329, DOI 10.1074/jbc.271.42.26329; Clark EA, 2000, NATURE, V406, P532, DOI 10.1038/35020106; Clark EA, 1998, J CELL BIOL, V142, P573, DOI 10.1083/jcb.142.2.573; Collins TL, 1997, IMMUNOL TODAY, V18, P221; Costello PS, 1999, P NATL ACAD SCI USA, V96, P3035, DOI 10.1073/pnas.96.6.3035; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; Crespo P, 1997, NATURE, V385, P169, DOI 10.1038/385169a0; Dahia PLM, 2000, ENDOCR-RELAT CANCER, V7, P115, DOI 10.1677/erc.0.0070115; DeFranco AL, 2001, NAT IMMUNOL, V2, P482, DOI 10.1038/88669; Dekel I, 2000, FEBS LETT, V472, P99, DOI 10.1016/S0014-5793(00)01413-7; del Pozo MA, 2000, EMBO J, V19, P2008, DOI 10.1093/emboj/19.9.2008; DHAND R, 1994, EMBO J, V13, P511, DOI 10.1002/j.1460-2075.1994.tb06289.x; Djouder N, 2001, J IMMUNOL, V166, P1627, DOI 10.4049/jimmunol.166.3.1627; FREEDMAN VH, 1974, CELL, V3, P355, DOI 10.1016/0092-8674(74)90050-6; Fritz G, 1999, INT J CANCER, V81, P682, DOI 10.1002/(SICI)1097-0215(19990531)81:5<682::AID-IJC2>3.0.CO;2-B; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Han JW, 1998, SCIENCE, V279, P558, DOI 10.1126/science.279.5350.558; HAWKINS PT, 1992, NATURE, V358, P157, DOI 10.1038/358157a0; Hotchin NA, 1995, J CELL BIOL, V131, P1857, DOI 10.1083/jcb.131.6.1857; Karnoub AE, 2001, MOL CELL BIOL, V21, P2847, DOI 10.1128/MCB.21.8.2847-2857.2001; KATZAV S, 1991, MOL CELL BIOL, V11, P1912, DOI 10.1128/MCB.11.4.1912; Keely PJ, 1997, NATURE, V390, P632, DOI 10.1038/37656; Kjoller L, 1999, EXP CELL RES, V253, P166, DOI 10.1006/excr.1999.4674; Kobayashi M, 1997, J BIOL CHEM, V272, P16089, DOI 10.1074/jbc.272.26.16089; Lamarche N, 1996, CELL, V87, P519, DOI 10.1016/S0092-8674(00)81371-9; Leevers SJ, 1999, CURR OPIN CELL BIOL, V11, P219, DOI 10.1016/S0955-0674(99)80029-5; Liliental J, 2000, CURR BIOL, V10, P401, DOI 10.1016/S0960-9822(00)00417-6; Liu BP, 2000, MOL CELL BIOL, V20, P7160, DOI 10.1128/MCB.20.19.7160-7169.2000; Manetz TS, 2001, MOL CELL BIOL, V21, P3763, DOI 10.1128/MCB.21.11.3763-3774.2001; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; Marignani PA, 2001, J CELL BIOL, V154, P177, DOI 10.1083/jcb.200103134; MICHIELS F, 1995, NATURE, V375, P338, DOI 10.1038/375338a0; Moores SL, 2000, MOL CELL BIOL, V20, P6364, DOI 10.1128/MCB.20.17.6364-6373.2000; Movilla N, 1999, MOL CELL BIOL, V19, P7870; Nishida M, 2001, EMBO J, V20, P2995, DOI 10.1093/emboj/20.12.2995; Nobes CD, 1999, J CELL BIOL, V144, P1235, DOI 10.1083/jcb.144.6.1235; Rameh LE, 1997, J BIOL CHEM, V272, P22059, DOI 10.1074/jbc.272.35.22059; RAMOSMORALES F, 1995, ONCOGENE, V11, P1665; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; Rottner K, 1999, CURR BIOL, V9, P640, DOI 10.1016/S0960-9822(99)80286-3; Sachdev P, 2001, J BIOL CHEM, V276, P26461, DOI 10.1074/jbc.M010995200; Sander EE, 1999, J CELL BIOL, V147, P1009, DOI 10.1083/jcb.147.5.1009; Schuebel KE, 1998, EMBO J, V17, P6608, DOI 10.1093/emboj/17.22.6608; Schuringa JJ, 2000, BIOCHEM J, V347, P89, DOI 10.1042/0264-6021:3470089; Schwartz MA, 2000, TRENDS BIOCHEM SCI, V25, P388, DOI 10.1016/S0968-0004(00)01605-4; Shigematsu H, 1997, J BIOL CHEM, V272, P14334, DOI 10.1074/jbc.272.22.14334; Simon AR, 2000, SCIENCE, V290, P144, DOI 10.1126/science.290.5489.144; Symons M, 1996, TRENDS BIOCHEM SCI, V21, P178, DOI 10.1016/S0968-0004(96)10022-0; TOLIAS KF, 1995, J BIOL CHEM, V270, P17656, DOI 10.1074/jbc.270.30.17656; Trenkle T, 2000, GENE, V245, P139, DOI 10.1016/S0378-1119(00)00026-3; Turkson J, 1998, MOL CELL BIOL, V18, P2545, DOI 10.1128/MCB.18.5.2545; VAN AL, 1997, GENE DEV, V11, P2295; YE ZS, 1994, P NATL ACAD SCI USA, V91, P12629, DOI 10.1073/pnas.91.26.12629; Zeng LY, 2000, MOL CELL BIOL, V20, P9212, DOI 10.1128/MCB.20.24.9212-9224.2000; ZHENG Y, 1994, J BIOL CHEM, V269, P18727; Zong CS, 1998, J BIOL CHEM, V273, P28065, DOI 10.1074/jbc.273.43.28065	65	68	70	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 17	2002	277	20					17638	17648		10.1074/jbc.M111575200	http://dx.doi.org/10.1074/jbc.M111575200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	553PR	11884391	Green Published, hybrid			2022-12-27	WOS:000175685100033
J	Wible, BA; Wang, LM; Kuryshev, YA; Basu, A; Haldar, S; Brown, AM				Wible, BA; Wang, LM; Kuryshev, YA; Basu, A; Haldar, S; Brown, AM			Increased K+ efflux and apoptosis induced by the potassium channel modulatory protein KChAP/PIAS3 beta in prostate cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANDROGEN RECEPTOR; GENE ACTIVATION; YEAST SEPTINS; P53; INHIBITOR; CONJUGATION; SIGNAL; SUMO-1; PHOSPHORYLATION; TRANSACTIVATION	K+ channel-associated protein/protein inhibitor of activated STAT (KChAP/PIAS3beta) is a potassium (K+) channel modulatory protein that boosts protein expression of a subset of K+ channels and increases currents without affecting gating. Since increased K+ efflux is an early event in apoptosis, we speculated that KChAP might induce apoptosis through its up-regulation of K+ channel expression. KChAP belongs to the protein inhibitor of activated STAT family, members of which also interact with a variety of transcription factors including the proapoptotic protein, p53. Here we report that KChAP induces apoptosis in the prostate cancer cell line, LNCaP, which expresses both K+ currents and wild-type p53. Infection with a recombinant adenovirus encoding KChAP (Ad/KChAP) increases K+ efflux and reduces cell size as expected for an apoptotic volume decrease. The apoptosis inducer, staurosporine, increases endogenous KChAP levels, and LNCaP cells, 2 days after Ad/KChAP infection, show increased sensitivity to staurosporine. KChAP increases p53 levels and stimulates phosphorylation of p53 residue serine 15. Consistent with activation of p53 as a transcription factor, p21 levels are increased in infected cells. Wild-type p53 is not essential for induction of apoptosis by KChAP, however, since KChAP also induces apoptosis in DU145 cells, a prostate cancer cell line with mutant p53. Consistent with its proapoptotic properties, KChAP prevents growth of DU145 and LNCaP tumor xenografts in nude mice, indicating that infection with Ad/KChAP might represent a novel method of cancer treatment.	Case Western Reserve Univ, Rammelkamp Ctr Educ & Res, Cleveland, OH 44109 USA; Case Western Reserve Univ, Dept Biochem, Cleveland, OH 44109 USA; Case Western Reserve Univ, Dept Physiol & Biophys, Cleveland, OH 44109 USA; Case Western Reserve Univ, Dept Pharmacol, Cleveland, OH 44109 USA; Case Western Reserve Univ, Ireland Canc Ctr, Cleveland, OH 44109 USA	Case Western Reserve University; MetroHealth System; Case Western Reserve University; Case Western Reserve University; Case Western Reserve University; Case Western Reserve University	Wible, BA (corresponding author), Case Western Reserve Univ, Rammelkamp Ctr Educ & Res, Metrohlth Campus,2500 Metrohlth Dr, Cleveland, OH 44109 USA.				NHLBI NIH HHS [HL60759, HL-61642, HL-36930, HL-55404] Funding Source: Medline; NIDDK NIH HHS [3DK54178] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL060759, R01HL036930, R01HL055404, R01HL061642] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P50DK054178] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Appella E, 2001, EUR J BIOCHEM, V268, P2764, DOI 10.1046/j.1432-1327.2001.02225.x; Bargonetti J, 2002, CURR OPIN ONCOL, V14, P86, DOI 10.1097/00001622-200201000-00015; Chene P, 2001, ONCOGENE, V20, P2611, DOI 10.1038/sj.onc.1204373; Chung CD, 1997, SCIENCE, V278, P1803, DOI 10.1126/science.278.5344.1803; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; Dumaz N, 1999, EMBO J, V18, P7002, DOI 10.1093/emboj/18.24.7002; Gostissa M, 1999, EMBO J, V18, P6462, DOI 10.1093/emboj/18.22.6462; Gross M, 2001, ONCOGENE, V20, P3880, DOI 10.1038/sj.onc.1204489; Hughes FM, 1999, ADV ENZYME REGUL, V39, P157, DOI 10.1016/S0065-2571(98)00010-7; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; ISAACS WB, 1991, CANCER RES, V51, P4716; Johnson ES, 2001, CELL, V106, P735, DOI 10.1016/S0092-8674(01)00491-3; Kahyo T, 2001, MOL CELL, V8, P713, DOI 10.1016/S1097-2765(01)00349-5; Kotaja N, 2000, MOL ENDOCRINOL, V14, P1986, DOI 10.1210/me.14.12.1986; Krick S, 2001, AM J PHYSIOL-LUNG C, V281, pL887, DOI 10.1152/ajplung.2001.281.4.L887; Krick S, 2001, AM J PHYSIOL-CELL PH, V280, pC970, DOI 10.1152/ajpcell.2001.280.4.C970; Kuryshev YA, 2000, AM J PHYSIOL-CELL PH, V278, pC931, DOI 10.1152/ajpcell.2000.278.5.C931; Kuryshev YA, 2001, AM J PHYSIOL-CELL PH, V281, pC290, DOI 10.1152/ajpcell.2001.281.1.C290; Laniado ME, 2001, PROSTATE, V46, P262, DOI 10.1002/1097-0045(20010301)46:4<262::AID-PROS1032>3.0.CO;2-F; Liu B, 1998, P NATL ACAD SCI USA, V95, P10626, DOI 10.1073/pnas.95.18.10626; Liu B, 2001, J BIOL CHEM, V276, P36624, DOI 10.1074/jbc.M101085200; Megidish T, 2002, J BIOL CHEM, V277, P8255, DOI 10.1074/jbc.C200001200; Moilanen AM, 1999, J BIOL CHEM, V274, P3700, DOI 10.1074/jbc.274.6.3700; Nelson V, 2001, APOPTOSIS, V6, P221, DOI 10.1023/A:1011392811628; PINES J, 1994, EMBO J, V13, P3772, DOI 10.1002/j.1460-2075.1994.tb06688.x; Poukka H, 2000, P NATL ACAD SCI USA, V97, P14145, DOI 10.1073/pnas.97.26.14145; Reed JC, 2002, NAT REV DRUG DISCOV, V1, P111, DOI 10.1038/nrd726; Rodriguez MS, 1999, EMBO J, V18, P6455, DOI 10.1093/emboj/18.22.6455; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; SKYRMA RN, 1997, PROSTATE, V33, P112; Takahashi Y, 2001, J BIOL CHEM, V276, P48973, DOI 10.1074/jbc.M109295200; Takahashi Y, 2001, GENE, V275, P223, DOI 10.1016/S0378-1119(01)00662-X; Tan JA, 2000, MOL ENDOCRINOL, V14, P14, DOI 10.1210/me.14.1.14; Terstappen GC, 1999, ANAL BIOCHEM, V272, P149, DOI 10.1006/abio.1999.4179; Trimarchi JR, 2002, AM J PHYSIOL-CELL PH, V282, pC588, DOI 10.1152/ajpcell.00365.2001; Valdez BC, 1997, BIOCHEM BIOPH RES CO, V234, P335, DOI 10.1006/bbrc.1997.6642; WEINBERG RA, 1995, CELL, V81, P323, DOI 10.1016/0092-8674(95)90385-2; Wible BA, 1998, J BIOL CHEM, V273, P11745, DOI 10.1074/jbc.273.19.11745; Wu L, 1997, MECH DEVELOP, V65, P3, DOI 10.1016/S0925-4773(97)00032-4; Yu SP, 1997, SCIENCE, V278, P114, DOI 10.1126/science.278.5335.114; Yu SP, 2001, CURR OPIN CELL BIOL, V13, P405, DOI 10.1016/S0955-0674(00)00228-3; Yu SP, 1999, J NEUROCHEM, V73, P933, DOI 10.1046/j.1471-4159.1999.0730933.x	42	59	69	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 17	2002	277	20					17852	17862		10.1074/jbc.M201689200	http://dx.doi.org/10.1074/jbc.M201689200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	553PR	11877452	hybrid			2022-12-27	WOS:000175685100060
J	Bruck, I; Yuzhakov, A; Yurieva, O; Jeruzalmi, D; Skangalis, M; Kuriyan, J; O'Donnell, M				Bruck, I; Yuzhakov, A; Yurieva, O; Jeruzalmi, D; Skangalis, M; Kuriyan, J; O'Donnell, M			Analysis of a multicomponent thermostable DNA polymerase III replicase from an extreme thermophile	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LAGGING-STRAND REPLICATION; ONE HOLOENZYME PARTICLE; ESCHERICHIA-COLI; CLAMP LOADER; ACCESSORY PROTEINS; SLIDING CLAMPS; GAMMA-COMPLEX; DELTA-SUBUNIT; CRYSTAL-STRUCTURE; BINDING PROTEIN	This report takes a proteomic/genomic approach to characterize the DNA polymerase III replication apparatus of the extreme thermophile, Aquifex aeolicus. Genes (dnaX, holA, and holB) encoding the subunits required for clamp loading activity (tau, delta, and delta') were identified. The dnaX gene produces only the full-length product, tau, and therefore differs from Escherichia coli dnaX that produces two proteins (gamma and tau). Nonetheless, the A. aeolicus proteins form a taudeltadelta' complex. The dnaN gene encoding the beta clamp was identified, and the taudeltadelta' complex is active in loading beta onto DNA. A. aeolicus contains one dnaE homologue, encoding the alpha subunit of DNA polymerase III. Like E. coli, A aeolicus alpha and tau interact, although the interaction is not as tight as the alpha-tau contact in E. coli. In addition, the A. aeolicus homologue to dnaQ, encoding the epsilon proofreading 3'-5'-exonuclease, interacts with alpha but does not form a stable alpha.epsilon complex, suggesting a need for a brace or bridging protein to tightly couple the polymerase and exonuclease in this system. Despite these differences to the E. coli system, the A. aeolicus proteins function to yield a robust replicase that retains significant activity at 90 degreesC. Similarities and differences between the A. aeolicus and E. coli pol III systems are discussed, as is application of thermostable pol III to biotechnology.	Rockefeller Univ, New York, NY 10021 USA; Howard Hughes Med Inst, New York, NY 10021 USA	Rockefeller University; Howard Hughes Medical Institute	O'Donnell, M (corresponding author), Rockefeller Univ, 1230 York Ave, New York, NY 10021 USA.			O'Donnell, Michael/0000-0001-9002-4214	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038839] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 45547, R01 GM 38839] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ason B, 2000, J BIOL CHEM, V275, P3006, DOI 10.1074/jbc.275.4.3006; BARNES MH, 1979, NUCLEIC ACIDS RES, V6, P1203, DOI 10.1093/nar/6.3.1203; Bertram JG, 2000, J BIOL CHEM, V275, P28413, DOI 10.1074/jbc.M910441199; Bertram JG, 1998, J BIOL CHEM, V273, P24564, DOI 10.1074/jbc.273.38.24564; BLINKOVA A, 1993, J BACTERIOL, V175, P6018, DOI 10.1128/JB.175.18.6018-6027.1993; BLINKOWA AL, 1990, NUCLEIC ACIDS RES, V18, P1725, DOI 10.1093/nar/18.7.1725; Bruck I, 2000, J BIOL CHEM, V275, P28971, DOI 10.1074/jbc.M003565200; Bruck I, 2001, GENOME BIOL, V2; Davey MJ, 2000, CURR OPIN CHEM BIOL, V4, P581, DOI 10.1016/S1367-5931(00)00134-4; de Saro FJL, 2001, P NATL ACAD SCI USA, V98, P8376, DOI 10.1073/pnas.121009498; Deckert G, 1998, NATURE, V392, P353, DOI 10.1038/32831; DONG ZM, 1993, J BIOL CHEM, V268, P11758; FAY PJ, 1982, J BIOL CHEM, V257, P5692; FLOWER AM, 1990, P NATL ACAD SCI USA, V87, P3713, DOI 10.1073/pnas.87.10.3713; Gao DX, 2001, J BIOL CHEM, V276, P4433, DOI 10.1074/jbc.M009828200; Glover BP, 2000, J BIOL CHEM, V275, P3017, DOI 10.1074/jbc.275.5.3017; Glover BP, 1998, J BIOL CHEM, V273, P23476, DOI 10.1074/jbc.273.36.23476; Guenther B, 1997, CELL, V91, P335, DOI 10.1016/S0092-8674(00)80417-1; Hingorani MM, 1999, EMBO J, V18, P5131, DOI 10.1093/emboj/18.18.5131; Hingorani MM, 1998, J BIOL CHEM, V273, P24550, DOI 10.1074/jbc.273.38.24550; Jeruzalmi D, 2001, CELL, V106, P429, DOI 10.1016/S0092-8674(01)00463-9; Jeruzalmi D, 2001, CELL, V106, P417, DOI 10.1016/S0092-8674(01)00462-7; Kelman Z, 1998, EMBO J, V17, P2436, DOI 10.1093/emboj/17.8.2436; KELMAN Z, 1995, ANNU REV BIOCHEM, V64, P171, DOI 10.1146/annurev.bi.64.070195.001131; Kelman Z, 1995, METHOD ENZYMOL, V262, P430; Kim SS, 1996, CELL, V84, P643, DOI 10.1016/S0092-8674(00)81039-9; KONG XP, 1992, CELL, V69, P425, DOI 10.1016/0092-8674(92)90445-I; KURIYAN J, 1993, J MOL BIOL, V234, P915, DOI 10.1006/jmbi.1993.1644; LADUCA RJ, 1983, BIOCHEMISTRY-US, V22, P5177, DOI 10.1021/bi00291a018; Larsen B, 2000, P NATL ACAD SCI USA, V97, P1683, DOI 10.1073/pnas.97.4.1683; Leu FP, 2000, J BIOL CHEM, V275, P34609, DOI 10.1074/jbc.M005495200; LOHMAN TM, 1994, ANNU REV BIOCHEM, V63, P527, DOI 10.1146/annurev.biochem.63.1.527; MAKI H, 1985, J BIOL CHEM, V260, P2987; McHenry CS, 1997, J MOL BIOL, V272, P178, DOI 10.1006/jmbi.1997.1238; MCHENRY CS, 1979, J BIOL CHEM, V254, P1748; NAKTINIS V, 1995, J BIOL CHEM, V270, P13358, DOI 10.1074/jbc.270.22.13358; Neuwald AF, 1999, GENOME RES, V9, P27; O'Donnell M, 2001, CURR BIOL, V11, pR935, DOI 10.1016/S0960-9822(01)00559-0; ODONNELL M, 1993, NUCLEIC ACIDS RES, V21, P1, DOI 10.1093/nar/21.1.1; ONRUST R, 1993, J BIOL CHEM, V268, P11766; ONRUST R, 1991, J BIOL CHEM, V266, P21681; ONRUST R, 1995, J BIOL CHEM, V270, P13366, DOI 10.1074/jbc.270.22.13366; Pritchard AE, 2000, EMBO J, V19, P6536, DOI 10.1093/emboj/19.23.6536; ROWEN L, 1978, J BIOL CHEM, V253, P758; SCHEUERMANN RH, 1984, P NATL ACAD SCI-BIOL, V81, P7747, DOI 10.1073/pnas.81.24.7747; SLATER SC, 1994, J BACTERIOL, V176, P815, DOI 10.1128/jb.176.3.815-821.1994; Stewart J, 2001, J BIOL CHEM, V276, P19182, DOI 10.1074/jbc.M100592200; STUDWELL PS, 1990, J BIOL CHEM, V265, P1171; STUDWELLVAUGHAN PS, 1991, J BIOL CHEM, V266, P19833; STUDWELLVAUGHAN PS, 1993, J BIOL CHEM, V268, P11785; STUKENBERG PT, 1994, CELL, V78, P877, DOI 10.1016/S0092-8674(94)90662-9; STUKENBERG PT, 1991, J BIOL CHEM, V266, P11328; TSUCHIHASHI Z, 1989, J BIOL CHEM, V264, P17790; Turner J, 1995, METHOD ENZYMOL, V262, P442; Turner J, 1999, EMBO J, V18, P771, DOI 10.1093/emboj/18.3.771; Vieille C, 2001, MICROBIOL MOL BIOL R, V65, P1, DOI 10.1128/MMBR.65.1.1-43.2001; XIAO H, 1993, J BIOL CHEM, V268, P11779; Yurieva O, 1997, J BIOL CHEM, V272, P27131, DOI 10.1074/jbc.272.43.27131; Yuzhakov A, 1999, CELL, V96, P153, DOI 10.1016/S0092-8674(00)80968-X; Yuzhakov A, 1996, CELL, V86, P877, DOI 10.1016/S0092-8674(00)80163-4	60	20	23	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 10	2002	277	19					17334	17348		10.1074/jbc.M110198200	http://dx.doi.org/10.1074/jbc.M110198200			15	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	551MB	11859073	hybrid			2022-12-27	WOS:000175564500130
J	Honda, A; Yamagata, K; Sugiura, S; Watanabe, K; Baba, T				Honda, A; Yamagata, K; Sugiura, S; Watanabe, K; Baba, T			A mouse serine protease TESP5 is selectively included into lipid rafts of sperm membrane presumably as a glycosylphosphatidylinositol-anchored protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ZONA-PELLUCIDA; ACROSOME REACTION; MAMMALIAN SPERM; FERTILIZATION; PENETRATION; GENE; AMINOBENZAMIDINE; ORGANIZATION; ACTIVATION; MATURATION	We have previously indicated that at least in mouse, sperm serine protease(s) other than acrosin probably act on the limited proteolysis of egg zona pellucida to create a penetration pathway for motile sperm, although the participation of acrosin cannot be ruled out completely. A 42-kDa gelatin-hydrolyzing serine protease present in mouse sperm is a candidate enzyme involved in the sperm penetration of the zona pellucida. In this study, we have PCR-amplified an EST clone encoding a testicular serine protease, termed TESP5, and then screened a mouse genomic DNA library using the DNA fragment as a probe. The DNA sequence of the isolated genomic clones indicated that the TESP5 gene is identical to the genes coding for testicular testisin and eosinophilic esp-1. Immunochemical analysis using affinity-purified anti-TESP5 antibody revealed that 42- and 41-kDa forms of TESP5 with the isoelectric points of 5.0 to 5.5 are localized in the head, cytoplasmic droplet, and midpiece of cauda epididymal sperm probably as a membranous protein. Moreover, these two forms of TESP5 were selectively included into Triton X-100-insoluble microdomains, lipid rafts, of the sperm membranes These results show the identity between TESP5/testisin/esp-1 and the 42-kDa sperm serine protease. When HEK293 cells were transformed by an expression plasmid carrying the entire protein-coding region of TESP5, the recombinant protein produced was released from the cell membrane by treatment with Bacillus cereus phosphatidylinositol-specific phospholipase C, indicating that TESP5 is glycosylphosphatidylinositol-anchored on the cell surface. Enzymatic properties of recombinant TESP5 was similar to but distinguished from those of rat acrosin and pancreatic trypsin by the substrate specificity and inhibitory effects of serine protease inhibitors.	Univ Tsukuba, Inst Appl Biochem, Tsukuba, Ibaraki 3058572, Japan	University of Tsukuba	Baba, T (corresponding author), Univ Tsukuba, Inst Appl Biochem, Tsukuba, Ibaraki 3058572, Japan.							BABA T, 1989, J BIOL CHEM, V264, P11920; BABA T, 1994, J BIOL CHEM, V269, P31845; BABA T, 1994, J BIOL CHEM, V269, P10133; Bedford JM, 1998, BIOL REPROD, V59, P1275, DOI 10.1095/biolreprod59.6.1275; Davie E W, 1979, Adv Enzymol Relat Areas Mol Biol, V48, P277; FRASER LR, 1982, J REPROD FERTIL, V65, P185, DOI 10.1530/jrf.0.0650185; FULLER SA, 1991, CURRENT PROTOCOLS MO; GUTHER MLS, 1994, ANAL BIOCHEM, V219, P249, DOI 10.1006/abio.1994.1264; Harder T, 1997, CURR OPIN CELL BIOL, V9, P534, DOI 10.1016/S0955-0674(97)80030-0; Hooper JD, 1999, CANCER RES, V59, P3199; Inoue M, 1999, BIOCHEM BIOPH RES CO, V266, P564, DOI 10.1006/bbrc.1999.1870; Jacobson K, 1999, TRENDS CELL BIOL, V9, P87, DOI 10.1016/S0962-8924(98)01495-0; Johnson LR, 1997, DEV BIOL, V192, P340, DOI 10.1006/dbio.1997.8767; Kashiwabara S, 2000, DEV BIOL, V228, P106, DOI 10.1006/dbio.2000.9894; KLEMM U, 1991, HUM GENET, V87, P635; Kohno N, 1998, BIOCHEM BIOPH RES CO, V245, P658, DOI 10.1006/bbrc.1998.8501; MIYAMOTO H, 1973, BIOL REPROD, V9, P533, DOI 10.1093/biolreprod/9.5.533; Nishimura H, 2001, DEV BIOL, V233, P204, DOI 10.1006/dbio.2001.0166; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; Ohmura K, 1999, J BIOL CHEM, V274, P29426, DOI 10.1074/jbc.274.41.29426; Ohta K, 1999, BIOCHEM BIOPH RES CO, V258, P616, DOI 10.1006/bbrc.1999.0686; PERONA JJ, 1995, PROTEIN SCI, V4, P337; ROBERTS WL, 1988, J BIOL CHEM, V263, P18766; Rodgers W, 1996, J CELL BIOL, V135, P1515, DOI 10.1083/jcb.135.6.1515; Scarman AL, 2001, EUR J BIOCHEM, V268, P1250, DOI 10.1046/j.1432-1327.2001.01986.x; Seaton GJ, 2000, BIOL REPROD, V62, P1667, DOI 10.1095/biolreprod62.6.1667; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Stambaugh R., 1969, Biology of Reproduction, V1, P223, DOI 10.1095/biolreprod1.3.223; TANII I, 1994, CELL TISSUE RES, V277, P61, DOI 10.1007/BF00303081; TOSHIMORI K, 1995, MOL REPROD DEV, V42, P72, DOI 10.1002/mrd.1080420110; Varma R, 1998, NATURE, V394, P798, DOI 10.1038/29563; WALENSKY LD, 1995, J CELL BIOL, V130, P857, DOI 10.1083/jcb.130.4.857; WARD CR, 1993, DEV BIOL, V158, P9, DOI 10.1006/dbio.1993.1165; Wassarman PM, 1999, CELL, V96, P175, DOI 10.1016/S0092-8674(00)80558-9; Wassarman PM, 2001, NAT CELL BIOL, V3, pE59, DOI 10.1038/35055178; Wong GW, 2001, J BIOL CHEM, V276, P20648, DOI 10.1074/jbc.M010422200; Yamagata K, 1998, ZYGOTE, V6, P311, DOI 10.1017/S0967199498000264; Yamagata K, 1998, J BIOL CHEM, V273, P10470, DOI 10.1074/jbc.273.17.10470; Yamagata K, 1999, DEV GENET, V25, P115, DOI 10.1002/(SICI)1520-6408(1999)25:2&lt;115::AID-DVG5&gt;3.0.CO;2-1; Yanagimachi R., 1994, P189; ZANEVELD LJD, 1971, P INT RES C PROTEINA, P236	41	109	113	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 10	2002	277	19					16976	16984		10.1074/jbc.M112470200	http://dx.doi.org/10.1074/jbc.M112470200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	551MB	11861648	hybrid			2022-12-27	WOS:000175564500085
J	Noya, F; Chien, WM; Wu, XY; Banerjee, NS; Kappes, JC; Broker, TR; Chow, LT				Noya, F; Chien, WM; Wu, XY; Banerjee, NS; Kappes, JC; Broker, TR; Chow, LT			The promoter of the human proliferating cell nuclear antigen gene is not sufficient for cell cycle-dependent regulation in organotypic cultures of keratinocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-PAPILLOMAVIRUS TYPE-16; RETINOBLASTOMA TUMOR-SUPPRESSOR; ADENOVIRUS E1A ONCOPROTEIN; KINASE-II PHOSPHORYLATION; EPITHELIAL RAFT CULTURES; WILD-TYPE P53; DIFFERENTIATED KERATINOCYTES; TRANSCRIPTION FACTOR; DNA-SYNTHESIS; E7 PROTEIN	The proliferating cell nuclear antigen (PCNA) is essential for DNA replication of mammalian cells and their small DNA tumor viruses. The mechanism of the cell cycle-dependent regulation of the human PCNA promoter is not clear despite extensive investigations. In this report, we employed organotypic cultures of primary human keratinocytes, which closely resemble native skin comprising both proliferating and postmitotic, differentiated cells, to examine the cell cycle-dependent regulation of the human PCNA gene (hPCNA) in the absence or presence of the human papillomavirus type 18 (HPV-18) E7 protein. HPV-18 E7 promotes S phase re-entry in post-mitotic differentiated keratinocytes by abrogating the transcription repression of E2F transcription factors by the retinoblastoma susceptibility protein, pRb. We demonstrated that E7 reactivated the transcription of the endogenous hPCNA in differentiated keratinocytes. In contrast, with or without E7, the expression of a transduced hPCNA promoter-driven reporter did not correlate with that of the endogenous hPCNA gene in either proliferating or differentiated cells. Moreover, in Chinese hamster ovary and L-cells, HPV E7 and the adenovirus E1A protein repressed the transduced hPCNA promoter, but both activated an extended promoter construct spanning the first intron. Mutations of two E2F sites in the intron reduced the basal activity and abolished the response to E7 or E1A. Promoter repression or activation required the CR2 domain of E7 and, to a lesser extent, CR1. as well. However, in organotypic cultures, this extended promoter construct failed to recapitulate the cell cycle-dependent regulation of the endogenous hPCNA gene. Only when a full-length Myc-tagged hPCNA spanning the 5' promoter and all exons and introns was used was the native pattern of expression largely restored, indicative of the complexity of its regulation.	Univ Alabama, Dept Biochem & Mol Genet, Birmingham, AL 35294 USA; Univ Alabama, Dept Med, Birmingham, AL 35294 USA; Univ Alabama, Dept Hematol Oncol, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	Chow, LT (corresponding author), Univ Alabama, Dept Biochem & Mol Genet, 510 McCallum Basic Hlth Sci Bldt,1918 Univ Blvd, Birmingham, AL 35294 USA.				NATIONAL CANCER INSTITUTE [R01CA036200] Funding Source: NIH RePORTER; NCI NIH HHS [CA 36200] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ausubel FM, 1995, SHORT PROTOCOLS MOL, V3rd; BANKS L, 1990, ONCOGENE, V5, P1383; BRAVO R, 1986, EXP CELL RES, V163, P287, DOI 10.1016/0014-4827(86)90059-5; BRAVO R, 1987, NATURE, V326, P515, DOI 10.1038/326515a0; BURNS JC, 1993, P NATL ACAD SCI USA, V90, P8033, DOI 10.1073/pnas.90.17.8033; CHANG CD, 1990, MOL CELL BIOL, V10, P3289, DOI 10.1128/MCB.10.7.3289; CHANG CD, 1991, J BIOL CHEM, V266, P8663; Charollais Renee-Helene, 1992, Gene Expression, V2, P285; CHENG S, 1995, GENE DEV, V9, P2335, DOI 10.1101/gad.9.19.2335; CHESTERS PM, 1990, J GEN VIROL, V71, P449, DOI 10.1099/0022-1317-71-2-449; CHIANG CM, 1992, P NATL ACAD SCI USA, V89, P5799, DOI 10.1073/pnas.89.13.5799; Chien WM, 2000, CELL GROWTH DIFFER, V11, P425; Chien WM, 2002, J VIROL, V76, P2964, DOI 10.1128/JVI.76.6.2964-2972.2002; Chow Louise T., 1997, P267; Chow LT, 1997, CLIN DERMATOL, V15, P217, DOI 10.1016/S0738-081X(97)00069-2; Clurman BE, 1996, GENE DEV, V10, P1979, DOI 10.1101/gad.10.16.1979; DAVIES RC, 1992, J GEN VIROL, V73, P2135, DOI 10.1099/0022-1317-73-8-2135; DEGREGORI J, 1995, MOL CELL BIOL, V15, P4215; Demers GW, 1996, J VIROL, V70, P6862, DOI 10.1128/JVI.70.10.6862-6869.1996; DEMERS GW, 1994, VIROLOGY, V198, P169, DOI 10.1006/viro.1994.1019; DEMETER LM, 1994, HUM PATHOL, V25, P343, DOI 10.1016/0046-8177(94)90141-4; Dyson N, 1998, GENE DEV, V12, P2245, DOI 10.1101/gad.12.15.2245; EDMONDS C, 1989, J VIROL, V63, P2650, DOI 10.1128/JVI.63.6.2650-2656.1989; FIRZLAFF J M, 1989, New Biologist, V1, P44; FIRZLAFF JM, 1991, P NATL ACAD SCI USA, V88, P5187, DOI 10.1073/pnas.88.12.5187; Ghazizadeh S, 1997, J VIROL, V71, P9163, DOI 10.1128/JVI.71.12.9163-9169.1997; Gonzalez SL, 2001, J VIROL, V75, P7583, DOI 10.1128/JVI.75.16.7583-7591.2001; Helt AM, 2001, J VIROL, V75, P6737, DOI 10.1128/JVI.75.15.6737-6747.2001; Hingorani MM, 2000, CURR BIOL, V10, pR25, DOI 10.1016/S0960-9822(99)00252-3; Huang DY, 1996, J BIOL CHEM, V271, P1218, DOI 10.1074/jbc.271.2.1218; Izumi M, 2000, BBA-GENE STRUCT EXPR, V1492, P341, DOI 10.1016/S0167-4781(00)00117-2; JELSMA TN, 1989, VIROLOGY, V171, P120, DOI 10.1016/0042-6822(89)90518-7; Jian YC, 1999, CELL GROWTH DIFFER, V10, P101; Jian YC, 1998, ONCOGENE, V17, P2027, DOI 10.1038/sj.onc.1202142; Jones DL, 1997, VIROLOGY, V239, P97, DOI 10.1006/viro.1997.8851; Jonsson ZO, 1997, BIOESSAYS, V19, P967, DOI 10.1002/bies.950191106; KAELIN WG, 1991, CELL, V64, P521, DOI 10.1016/0092-8674(91)90236-R; Kannabiran C, 1999, ONCOGENE, V18, P7825, DOI 10.1038/sj.onc.1203294; Karuppayil SM, 1998, J BIOL CHEM, V273, P17303, DOI 10.1074/jbc.273.28.17303; Kelman Z, 1997, ONCOGENE, V14, P629, DOI 10.1038/sj.onc.1200886; KUO SR, 1994, J BIOL CHEM, V269, P24058; LABRIE C, 1993, MOL CELL BIOL, V13, P1697, DOI 10.1128/MCB.13.3.1697; LABRIE C, 1995, NUCLEIC ACIDS RES, V23, P3732, DOI 10.1093/nar/23.18.3732; Lee BH, 1997, P NATL ACAD SCI USA, V94, P4481, DOI 10.1073/pnas.94.9.4481; Lee BH, 1998, J VIROL, V72, P1138, DOI 10.1128/JVI.72.2.1138-1145.1998; Lee Hu-Hui, 1995, Gene Expression, V4, P95; Lee KY, 1998, J VIROL, V72, P4911, DOI 10.1128/JVI.72.6.4911-4917.1998; Li QL, 1999, TRENDS GENET, V15, P403, DOI 10.1016/S0168-9525(99)01780-1; LIANG CP, 1992, ELECTROPHORESIS, V13, P346, DOI 10.1002/elps.1150130172; MALIM MH, 1989, NATURE, V338, P254, DOI 10.1038/338254a0; May C, 2000, NATURE, V406, P82, DOI 10.1038/35017565; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; MORRIS GF, 1990, J BIOL CHEM, V265, P16116; MORRIS GF, 1994, MOL CELL BIOL, V14, P543, DOI 10.1128/MCB.14.1.543; MORRIS GF, 1991, J VIROL, V65, P6397, DOI 10.1128/JVI.65.12.6397-6406.1991; MORRIS GF, 1989, J BIOL CHEM, V264, P13856; MUNGER K, 1989, EMBO J, V8, P4099, DOI 10.1002/j.1460-2075.1989.tb08594.x; MURPHY GF, 1984, J INVEST DERMATOL, V82, P453, DOI 10.1111/1523-1747.ep12260945; NEUMANN JR, 1987, BIOTECHNIQUES, V5, P444; Noya F, 2001, J VIROL, V75, P6121, DOI 10.1128/JVI.75.13.6121-6134.2001; OTTAVIO L, 1990, MOL CELL BIOL, V10, P303, DOI 10.1128/MCB.10.1.303; OTTAVIO L, 1990, BIOCHEM BIOPH RES CO, V169, P509, DOI 10.1016/0006-291X(90)90360-Y; Parker JN, 1997, CELL GROWTH DIFFER, V8, P751; Patel D, 1999, EMBO J, V18, P5061, DOI 10.1093/emboj/18.18.5061; PEARSON BE, 1991, MOL CELL BIOL, V11, P2081, DOI 10.1128/MCB.11.4.2081; PRELICH G, 1987, NATURE, V326, P471, DOI 10.1038/326471a0; PRELICH G, 1988, CELL, V53, P117, DOI 10.1016/0092-8674(88)90493-X; Reinstein E, 2000, ONCOGENE, V19, P5944, DOI 10.1038/sj.onc.1203989; SAMBROOK J, 1989, MOL CLONING LABORATO, V2, P16; Seavey SE, 1999, J VIROL, V73, P7590, DOI 10.1128/JVI.73.9.7590-7598.1999; SELL C, 1992, J CELL PHYSIOL, V152, P177, DOI 10.1002/jcp.1041520122; SHIPMANAPPASAMY P, 1990, J BIOL CHEM, V265, P19180; SHIVAKUMAR CV, 1995, MOL CELL BIOL, V15, P6785; STAGGERS WR, 1995, GENE, V153, P297, DOI 10.1016/0378-1119(94)00731-7; SUBLER MA, 1992, J VIROL, V66, P4757, DOI 10.1128/JVI.66.8.4757-4762.1992; Tiainen M, 1996, MOL CELL BIOL, V16, P5302; Tommasi S, 1999, J BIOL CHEM, V274, P27829, DOI 10.1074/jbc.274.39.27829; TRAVALI S, 1989, J BIOL CHEM, V264, P7466; VASSAR R, 1989, P NATL ACAD SCI USA, V86, P1563, DOI 10.1073/pnas.86.5.1563; WATANABE S, 1990, J VIROL, V64, P207, DOI 10.1128/JVI.64.1.207-214.1990; WOODWORTH CD, 1992, ONCOGENE, V7, P619; Wu XY, 2000, MOL THER, V2, P47, DOI 10.1006/mthe.2000.0095; YAMAGUCHI M, 1995, J BIOL CHEM, V270, P25159, DOI 10.1074/jbc.270.42.25159; YU SF, 1986, P NATL ACAD SCI USA, V83, P3194, DOI 10.1073/pnas.83.10.3194; ZERLER B, 1987, MOL CELL BIOL, V7, P821, DOI 10.1128/MCB.7.2.821; Zhao W, 1997, J VIROL, V71, P8832, DOI 10.1128/JVI.71.11.8832-8840.1997; Zhao W, 1999, J VIROL, V73, P5026, DOI 10.1128/JVI.73.6.5026-5033.1999; Zimmermann H, 1999, J VIROL, V73, P6209, DOI 10.1128/JVI.73.8.6209-6219.1999	88	12	13	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 10	2002	277	19					17271	17280		10.1074/jbc.M112441200	http://dx.doi.org/10.1074/jbc.M112441200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	551MB	11877408	hybrid			2022-12-27	WOS:000175564500122
J	Rozhkova, EA; Fujimoto, N; Sagami, I; Daff, SN; Shimizu, T				Rozhkova, EA; Fujimoto, N; Sagami, I; Daff, SN; Shimizu, T			Interactions between the isolated oxygenase and reductase domains of neuronal nitric-oxide synthase - Assessing the role of calmodulin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTRON FLOW-THROUGH; FLAVIN; EXPRESSION; ACTIVATION; BINDING; SITE; IDENTIFICATION; RECONSTITUTION; COMPLEX	Nitric-oxide synthase (NOS) is a fusion protein composed of an oxygenase domain with a heme-active site and a reductase domain with an NADPH binding site and requires Ca2+/calmodulin (CaM) for NO formation activity. We studied NO formation activity in reconstituted systems consisting of the isolated oxygenase and reductase domains of neuronal NOS with and without the CaM binding site. Reductase domains with 33-amino acid C-terminal truncations were also examined. These were shown to have faster cytochrome c reduction rates in the absence of CaM. N-G-hydroxy-L-Arg, an intermediate in the physiological NO synthesis reaction, was found to be a viable substrate. Turnover rates for N-G-hydroxy-L-Arg in the absence of Ca2+/CaM in most of the reconstituted systems were 2.3-3.1 min(-1). Surprisingly, the NO formation activities with CaM binding sites on either reductase or oxygenase domains were decreased dramatically on addition of Ca2+/CaM. However, NADPH oxidation and cytochrome c reduction rates were increased by the same procedure. Activation of the reductase domains by CaM addition or by C-terminal deletion failed to increase the rate of NO synthesis. Therefore, both mechanisms appear to be less important than the domain-domain interaction, which is controlled by CaM binding in wild-type neuronal NOS, but not in the reconstituted systems.	Tohoku Univ, Inst Multidisciplinary Res Adv Mat, Aoba Ku, Sendai, Miyagi 9808577, Japan; Univ Edinburgh, Dept Chem, Edinburgh EH9 3JJ, Midlothian, Scotland	Tohoku University; University of Edinburgh	Shimizu, T (corresponding author), Tohoku Univ, Inst Multidisciplinary Res Adv Mat, Aoba Ku, 2-1-1 Katahira, Sendai, Miyagi 9808577, Japan.	shimizu@tagen.tohoku.ac.jp		Shimizu, Toru/0000-0002-3950-5554				Adak S, 2002, P NATL ACAD SCI USA, V99, P107, DOI 10.1073/pnas.012470099; Bec N, 1998, J BIOL CHEM, V273, P13502, DOI 10.1074/jbc.273.22.13502; Chen PF, 2000, J BIOL CHEM, V275, P13155, DOI 10.1074/jbc.275.17.13155; Chen PF, 1996, J BIOL CHEM, V271, P14631, DOI 10.1074/jbc.271.24.14631; Daff S, 1999, J BIOL CHEM, V274, P30589, DOI 10.1074/jbc.274.43.30589; GHOSH DK, 1995, BIOCHEMISTRY-US, V34, P11316, DOI 10.1021/bi00036a003; Hurshman AR, 1999, BIOCHEMISTRY-US, V38, P15689, DOI 10.1021/bi992026c; Ignarro LJ, 2000, NITRIC OXIDE BIOL PA; IYANAGI T, 1981, BIOCHEMISTRY-US, V20, P1722, DOI 10.1021/bi00510a004; Lee SJ, 2000, J BIOL CHEM, V275, P36067, DOI 10.1074/jbc.M003935200; Ludwig ML, 1999, STRUCTURE, V7, pR73, DOI 10.1016/S0969-2126(99)80047-1; Masters B.S., 2000, NITRIC OXIDE BIOL PA, P91; Matsuda H, 1999, BBA-GEN SUBJECTS, V1473, P345, DOI 10.1016/S0304-4165(99)00193-2; MATSUOKA A, 1994, J BIOL CHEM, V269, P20335; Mayer B, 2000, NITRIC OXIDE; MCMILLAN K, 1995, BIOCHEMISTRY-US, V34, P3686, DOI 10.1021/bi00011a025; Montgomery HJ, 2000, J BIOL CHEM, V275, P5052, DOI 10.1074/jbc.275.7.5052; Nakano R, 1996, J BIOL CHEM, V271, P8570, DOI 10.1074/jbc.271.15.8570; Newton DC, 1998, ARCH BIOCHEM BIOPHYS, V359, P249, DOI 10.1006/abbi.1998.0917; Nishida CR, 1999, J BIOL CHEM, V274, P14692, DOI 10.1074/jbc.274.21.14692; Nishida CR, 2001, J BIOL CHEM, V276, P20116, DOI 10.1074/jbc.M101548200; Panda K, 2001, J BIOL CHEM, V276, P23349, DOI 10.1074/jbc.M100687200; Pfeiffer S, 1999, ANGEW CHEM INT EDIT, V38, P1715, DOI 10.1002/(SICI)1521-3773(19990614)38:12<1714::AID-ANIE1714>3.0.CO;2-3; Raman CS, 1998, CELL, V95, P939, DOI 10.1016/S0092-8674(00)81718-3; RAMAN CS, 2000, PORPHYRIN HDB, V4, P293; Roman LJ, 2000, J BIOL CHEM, V275, P29225, DOI 10.1074/jbc.M004766200; Roman LJ, 2000, J BIOL CHEM, V275, P21914, DOI 10.1074/jbc.M002449200; ROMAN LJ, 1995, P NATL ACAD SCI USA, V92, P8428, DOI 10.1073/pnas.92.18.8428; Sagami I, 1998, J BIOL CHEM, V273, P2105, DOI 10.1074/jbc.273.4.2105; Sagami I, 2001, J BIOL CHEM, V276, P30036, DOI 10.1074/jbc.M104123200; Sagami I, 2000, J BIOL CHEM, V275, P26150, DOI 10.1074/jbc.M000534200; Salerno JC, 1997, J BIOL CHEM, V272, P29769, DOI 10.1074/jbc.272.47.29769; Shimanuki T, 1999, J BIOL CHEM, V274, P26956, DOI 10.1074/jbc.274.38.26956; Siddhanta U, 1998, J BIOL CHEM, V273, P18950, DOI 10.1074/jbc.273.30.18950; Stuehr DJ, 1999, BBA-BIOENERGETICS, V1411, P217, DOI 10.1016/S0005-2728(99)00016-X; Stuehr DJ, 2000, HANDB EXP PHARMACOL, V143, P33; YASUKOCHI Y, 1976, J BIOL CHEM, V251, P5337	37	26	26	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 10	2002	277	19					16888	16894		10.1074/jbc.M200642200	http://dx.doi.org/10.1074/jbc.M200642200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	551MB	11884406	hybrid			2022-12-27	WOS:000175564500073
J	Shuto, T; Imasato, A; Jono, H; Sakai, A; Xu, HD; Watanabe, T; Rixter, DD; Kai, H; Andalibi, A; Linthicum, F; Guan, YL; Han, JH; Cato, ACB; Lim, DJ; Akira, S; Li, JD				Shuto, T; Imasato, A; Jono, H; Sakai, A; Xu, HD; Watanabe, T; Rixter, DD; Kai, H; Andalibi, A; Linthicum, F; Guan, YL; Han, JH; Cato, ACB; Lim, DJ; Akira, S; Li, JD			Glucocorticoids synergistically enhance nontypeable Haemophilus influenzae-induced toll-like receptor 2 expression via a negative cross-talk with p38 MAP kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KAPPA-B-ALPHA; GENE-REGULATION; ACTIVATION; INNATE; TRANSCRIPTION; INDUCTION; PROTEINS; PATHWAY; POTENT	The recognition of invading microbes followed by the induction of effective innate immune response is crucial for host survival. Human surface epithelial cells are situated at host-environment boundaries and thus act as the first line of host defense against invading microbes. They recognize the microbial ligands via Toll-like receptors (TLRs) expressed on the surface of epithelial cells. TLR2 has gained importance as a major receptor for a variety of microbial ligands. In contrast to its high expression in lymphoid tissues, TLR2 is expressed at low level in epithelial cells. Thus, it remains unclear whether the low amount of TLR2 expressed in epithelial cells is sufficient for mediating bacteria-induced host defense and immune response and whether TLR2 expression can be upregulated by bacteria during infection. Here, we show that TLR2, although expressed at very low level in unstimulated human epithelial cells, is greatly up-regulated by nontypeable Hemophilus influenzae (NTHi), an important human bacterial pathogen causing otitis media and chronic obstructive pulmonary diseases. Activation of an IKKbeta-IkappaBalpha-dependent NF-kappaB pathway is required for TLR2 induction, whereas inhibition of the MKK3/6-p38alpha/beta pathway leads to enhancement of NTHi-induced TLR2 up-regulation. Surprisingly, glucocorticoids, well known potent anti-inflammatory agents, synergistically enhance NTRi-induced TLR2 up-regulation likely via a negative cross-talk with the p38 MAP kinase pathway. These studies may bring new insights into the role of bacteria and glucocorticoids in regulating host defense and immune response and lead to novel therapeutic strategies for modulating innate immune and inflammatory responses for otitis media and chronic obstructive pulmonary diseases.	Univ So Calif, House Ear Inst, Gonda Dept Cell & Mol Biol, Los Angeles, CA 90057 USA; Univ So Calif, Dept Otolaryngol, Los Angeles, CA 90057 USA; Kumamoto Univ, Dept Mol Med, Kumamoto 8620973, Japan; Univ So Calif, House Ear Inst, Dept Histopathol, Los Angeles, CA 90057 USA; Scripps Res Inst, Res Inst, Dept Immunol, La Jolla, CA 92037 USA; Forschungszentrum Karlsruhe, Inst Genet & Toxicol, D-76021 Karlsruhe, Germany; Osaka Univ, Microbial Dis Res Inst, Dept Host Def, Japan Sci & Technol Corp,CREST, Suita, Osaka 5650871, Japan	House Research Institute; University of Southern California; University of Southern California; Kumamoto University; House Research Institute; University of Southern California; Scripps Research Institute; Helmholtz Association; Karlsruhe Institute of Technology; Japan Science & Technology Agency (JST); Osaka University	Li, JD (corresponding author), Univ So Calif, House Ear Inst, Gonda Dept Cell & Mol Biol, 2100 W 3rd St, Los Angeles, CA 90057 USA.	jdli@hei.org	Han, J/G-4671-2010; Cato, Andrew C. B./H-2071-2013; Akira, Shizuo/C-3134-2009	Cato, Andrew C. B./0000-0001-8508-3834; Li, Jian-Dong/0000-0002-5593-050X	NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC004562] Funding Source: NIH RePORTER; NIDCD NIH HHS [R0-1 DC04562] Funding Source: Medline	NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		Adams J L, 1999, Curr Opin Drug Discov Devel, V2, P96; Aderem A, 2000, NATURE, V406, P782, DOI 10.1038/35021228; Akira S, 2001, NAT IMMUNOL, V2, P675, DOI 10.1038/90609; Beauparlant P, 1996, J VIROL, V70, P5777, DOI 10.1128/JVI.70.9.5777-5785.1996; Faure E, 2001, J IMMUNOL, V166, P2018, DOI 10.4049/jimmunol.166.3.2018; Hatada EN, 2000, CURR OPIN IMMUNOL, V12, P52, DOI 10.1016/S0952-7915(99)00050-3; Karin M, 1998, CELL, V93, P487, DOI 10.1016/S0092-8674(00)81177-0; Kassel O, 2001, EMBO J, V20, P7108, DOI 10.1093/emboj/20.24.7108; Krutzik SR, 2001, CURR OPIN IMMUNOL, V13, P104, DOI 10.1016/S0952-7915(00)00189-8; Lasa M, 2001, MOL CELL BIOL, V21, P771, DOI 10.1128/MCB.21.3.771-780.2001; Lemaitre B, 1996, CELL, V86, P973, DOI 10.1016/S0092-8674(00)80172-5; Means TK, 2000, LIFE SCI, V68, P241, DOI 10.1016/S0024-3205(00)00939-5; Medzhitov R, 2000, TRENDS MICROBIOL, V8, P452, DOI 10.1016/S0966-842X(00)01845-X; Natarajan K, 1996, P NATL ACAD SCI USA, V93, P9090, DOI 10.1073/pnas.93.17.9090; Neish AS, 2000, SCIENCE, V289, P1560, DOI 10.1126/science.289.5484.1560; O'Neill LAJ, 2000, IMMUNOL TODAY, V21, P206, DOI 10.1016/S0167-5699(00)01611-X; Ono K, 2000, CELL SIGNAL, V12, P1, DOI 10.1016/S0898-6568(99)00071-6; Shuto T, 2001, P NATL ACAD SCI USA, V98, P8774, DOI 10.1073/pnas.151236098; Subramaniam N, 1999, J BIOL CHEM, V274, P18121, DOI 10.1074/jbc.274.25.18121; Takeuchi O, 2000, J IMMUNOL, V165, P5392, DOI 10.4049/jimmunol.165.10.5392; Thoma-Uszynski S, 2001, SCIENCE, V291, P1544, DOI 10.1126/science.291.5508.1544; Visintin A, 2001, J IMMUNOL, V166, P249, DOI 10.4049/jimmunol.166.1.249; Wang BN, 2002, J BIOL CHEM, V277, P949, DOI 10.1074/jbc.M107484200; Webster JC, 1999, TRENDS ENDOCRIN MET, V10, P396, DOI 10.1016/S1043-2760(99)00186-1	24	128	134	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 10	2002	277	19					17263	17270		10.1074/jbc.M112190200	http://dx.doi.org/10.1074/jbc.M112190200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	551MB	11867630	hybrid			2022-12-27	WOS:000175564500121
J	Vidal, A; Millard, SS; Miller, JP; Koff, A				Vidal, A; Millard, SS; Miller, JP; Koff, A			Rho activity can alter the translation of p27 mRNA and is important for Ras(V12)-induced transformation in a manner dependent on p27 status	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASES; CELL-CYCLE PROGRESSION; GTP-BINDING PROTEINS; GROWTH-FACTOR; MICE LACKING; RETINOBLASTOMA-PROTEIN; RAS TRANSFORMATION; SIGNALING PATHWAY; TUMOR SUPPRESSION; MESSENGER-RNA	The amount of P27(Kip1) establishes a threshold to which G(1) cyclin-cyclin-dependent kinase complexes must surpass prior to cells progressing into S-phase. The amount of p27 is greatest in G(o) cells, intermediate in G(1) cells, and lowest in S-phase cells. However, there is little known regarding the pathways and mechanisms controlling p27 accumulation in G(o) cells. We report that inhibition of Rho, by either lovastatin or C3 exoenzyme, can increase the translational efficiency of p27 mRNA. Similar pharmacologic inhibition of the phosphatidylinositol 3-kinase, the S6 kinase, and the Mek1 kinase pathways all fail to increase translational efficiency in MDA468 cells. This Rho-responsive element lies within a 300-nucleotide region at the 3'-end of the mRNA. By supporting the significance of this signaling pathway to Rho function, we showed that the suppression of Ras(V12) transformation by RhoA(N19) is blocked in p27-/- cells. In contrast this activity is not blocked in Rb-/- or p16-/- cells. The resistance of p27-/- cells to RhoA(N19) is not associated with a failure of RhoA(N19) to accumulate to amounts sufficient to block Rho activity as measured by the organization of actin stress fibers. Together these results indicate a link between Rho and p27.	Mem Sloan Kettering Canc Ctr, Programs Mol Biol, New York, NY 10021 USA; Cornell Univ, Weill Grad Sch Med Sci, Grad Program Mol Biol & Cell Biol & Genet, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center; Cornell University	Koff, A (corresponding author), Mem Sloan Kettering Canc Ctr, Programs Mol Biol, RRL917D,Box 207,1275 York Ave, New York, NY 10021 USA.		Vidal, Anxo/B-5010-2015; Millard, Sean/A-8522-2013	Vidal, Anxo/0000-0002-0866-4202; Millard, Sean/0000-0001-8573-4625; Koff, Andrew/0000-0003-3271-3067	NATIONAL CANCER INSTITUTE [P30CA008748] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R55GM052597, R01GM052597] Funding Source: NIH RePORTER; NCI NIH HHS [CA08748] Funding Source: Medline; NIGMS NIH HHS [GM52597] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Agrawal D, 1996, MOL CELL BIOL, V16, P4327; Aktories K, 2000, BIOL CHEM, V381, P421, DOI 10.1515/BC.2000.054; Allal C, 2000, J BIOL CHEM, V275, P31001, DOI 10.1074/jbc.M005264200; Blain SW, 1997, J BIOL CHEM, V272, P25863, DOI 10.1074/jbc.272.41.25863; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; Cheng MG, 1999, EMBO J, V18, P1571, DOI 10.1093/emboj/18.6.1571; Coats S, 1999, CURR BIOL, V9, P163, DOI 10.1016/S0960-9822(99)80086-4; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; Danen EHJ, 2000, J CELL BIOL, V151, P1413, DOI 10.1083/jcb.151.7.1413; del Pozo MA, 2000, EMBO J, V19, P2008, DOI 10.1093/emboj/19.9.2008; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; Dijkers PF, 2000, MOL CELL BIOL, V20, P9138, DOI 10.1128/MCB.20.24.9138-9148.2000; Gardner LB, 2001, J BIOL CHEM, V276, P7919, DOI 10.1074/jbc.M010189200; Harper JW, 2001, CURR BIOL, V11, pR431, DOI 10.1016/S0960-9822(01)00253-6; Hengst L, 1996, SCIENCE, V271, P1861, DOI 10.1126/science.271.5257.1861; Hirano M, 2001, EXP CELL RES, V271, P356, DOI 10.1006/excr.2001.5384; Hu WM, 1999, J BIOL CHEM, V274, P3396, DOI 10.1074/jbc.274.6.3396; Inoue T, 1999, J BIOL CHEM, V274, P32309, DOI 10.1074/jbc.274.45.32309; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; Kamijo T, 1997, CELL, V91, P649, DOI 10.1016/S0092-8674(00)80452-3; KEYOMARSI K, 1991, CANCER RES, V51, P3602; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; Kiyokawa H, 1996, CELL, V85, P721, DOI 10.1016/S0092-8674(00)81238-6; KOH J, 1995, NATURE, V375, P506, DOI 10.1038/375506a0; Kranenburg O, 1997, J CELL SCI, V110, P2417; Krimpenfort P, 2001, NATURE, V413, P83, DOI 10.1038/35092584; Lebowitz PF, 1997, J BIOL CHEM, V272, P16093, DOI 10.1074/jbc.272.26.16093; LUKAS J, 1995, NATURE, V375, P503, DOI 10.1038/375503a0; Luo Y, 1996, MOL CELL BIOL, V16, P6744; Malek NP, 2001, NATURE, V413, P323, DOI 10.1038/35095083; MEDEMA RH, 1995, P NATL ACAD SCI USA, V92, P6289, DOI 10.1073/pnas.92.14.6289; Millard SS, 2000, MOL CELL BIOL, V20, P5947, DOI 10.1128/MCB.20.16.5947-5959.2000; Millard SS, 1997, J BIOL CHEM, V272, P7093, DOI 10.1074/jbc.272.11.7093; Nakayama K, 1996, CELL, V85, P707, DOI 10.1016/S0092-8674(00)81237-4; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; Olson MF, 1998, NATURE, V394, P295, DOI 10.1038/28425; Park MS, 1999, P NATL ACAD SCI USA, V96, P6382, DOI 10.1073/pnas.96.11.6382; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; PRENDERGAST GC, 1995, ONCOGENE, V10, P2289; QIU RG, 1995, P NATL ACAD SCI USA, V92, P11781, DOI 10.1073/pnas.92.25.11781; Rao S, 1999, P NATL ACAD SCI USA, V96, P7797, DOI 10.1073/pnas.96.14.7797; Rivard N, 1996, J BIOL CHEM, V271, P18337, DOI 10.1074/jbc.271.31.18337; Rodier G, 2001, EMBO J, V20, P6672, DOI 10.1093/emboj/20.23.6672; Sahai E, 1999, CURR BIOL, V9, P136, DOI 10.1016/S0960-9822(99)80067-0; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; Servant MJ, 2000, J CELL BIOL, V148, P543, DOI 10.1083/jcb.148.3.543; Sharpless NE, 2001, NATURE, V413, P86, DOI 10.1038/35092592; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Soos TJ, 1996, CELL GROWTH DIFFER, V7, P135; Takai Y, 2001, PHYSIOL REV, V81, P153, DOI 10.1152/physrev.2001.81.1.153; Takuwa N, 1997, MOL CELL BIOL, V17, P5348, DOI 10.1128/MCB.17.9.5348; Teramoto H, 1996, J BIOL CHEM, V271, P25731, DOI 10.1074/jbc.271.42.25731; Tsutsui T, 1999, MOL CELL BIOL, V19, P7011; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; Yang W, 2001, ONCOGENE, V20, P1688, DOI 10.1038/sj.onc.1204245	57	81	85	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 10	2002	277	19					16433	16440		10.1074/jbc.M112090200	http://dx.doi.org/10.1074/jbc.M112090200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	551MB	11875067	hybrid			2022-12-27	WOS:000175564500014
J	Akakura, R; Winans, SC				Akakura, R; Winans, SC			Mutations in the occQ operator that decrease OccR-induced DNA bending do not cause constitutive promoter activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTIONAL ACTIVATOR; SALMONELLA-TYPHIMURIUM; PSEUDOMONAS-PUTIDA; AGROBACTERIUM-TUMEFACIENS; REGIONS IMPORTANT; BINDING-SITES; NAHR PROTEIN; LYSR FAMILY; NOD BOX; REGULATOR	OccR is a LysR-type transcriptional regulator of Agrobacterium tumefaciens that positively regulates the octopine catabolism operon of the Ti plasmid. Positive control of the occ genes occurs in response to octopine, a metabolite released from plant tumors. Octopine causes DNA-bound OccR to undergo a conformational change from an inactive to an active state; this change is marked by a decrease in footprint length from 55 to 45 nucleotides as well as a relaxation of a high angle DNA bend. In this study, we first used gel filtration chromatography to show that OccR is dimeric in solution, and we used gel shift assays to show that OccR is tetrameric when bound to DNA. We then created a series of site-directed mutations in the OccR-binding site. Some mutations were designed to lock OccR-DNA complexes into a conformation resembling the inactive conformation, whereas other mutations were designed to lock complexes into the active conformation. These mutations altered the conformation of OccR-DNA complexes and their responses to octopine in ways that we had predicted. As expected, operator mutations that locked complexes into a conformation having a long footprint and a high angle DNA bend blocked activation by octopine in vivo. Surprisingly, however, mutations that lock OccR into a short footprint and low angle DNA bend failed to cause the protein to function constitutively. Furthermore, some of the latter mutations interfered with activation by octopine. We conclude that locking OccR into a conformation having a short footprint is not sufficient to cause constitutive activation, and octopine must cause at least one additional conformational change in the protein.	Cornell Univ, Dept Microbiol, Ithaca, NY 14853 USA	Cornell University	Winans, SC (corresponding author), Cornell Univ, Dept Microbiol, 360A Wing Hall, Ithaca, NY 14853 USA.				NIGMS NIH HHS [GM41892] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Akakura R, 2002, J BIOL CHEM, V277, P5866, DOI 10.1074/jbc.M110555200; Busby S, 1997, MOL MICROBIOL, V23, P853, DOI 10.1046/j.1365-2958.1997.2771641.x; CHANG M, 1991, J BACTERIOL, V173, P1590, DOI 10.1128/jb.173.5.1590-1597.1991; CHEN CY, 1991, J BACTERIOL, V173, P1139, DOI 10.1128/jb.173.3.1139-1144.1991; Cho KY, 1996, J BACTERIOL, V178, P1872, DOI 10.1128/jb.178.7.1872-1880.1996; CHO KY, 1993, J BACTERIOL, V175, P7715, DOI 10.1128/JB.175.23.7715-7719.1993; COCO WM, 1994, J BACTERIOL, V176, P5530, DOI 10.1128/JB.176.17.5530-5533.1994; Dessaux Y., 1992, MOL SIGNALS PLANT MI, P109; DWEN P, 1995, THESIS CORNELL U ITH; FISHER RF, 1993, J MOL BIOL, V233, P336, DOI 10.1006/jmbi.1993.1515; Fuqua C, 1996, MOL MICROBIOL, V20, P1199, DOI 10.1111/j.1365-2958.1996.tb02640.x; GAO J, 1991, EMBO J, V10, P4137, DOI 10.1002/j.1460-2075.1991.tb04991.x; GOETHALS K, 1992, P NATL ACAD SCI USA, V89, P1646, DOI 10.1073/pnas.89.5.1646; HABEEB LF, 1991, MOL PLANT MICROBE IN, V4, P279; HAJDUKIEWICZ P, 1994, PLANT MOL BIOL, V25, P989, DOI 10.1007/BF00014672; HENIKOFF S, 1988, P NATL ACAD SCI USA, V85, P6602, DOI 10.1073/pnas.85.18.6602; HRYNIEWICZ MM, 1994, J BACTERIOL, V176, P3673, DOI 10.1128/JB.176.12.3673-3682.1994; HRYNIEWICZ MM, 1995, J BACTERIOL, V177, P2343, DOI 10.1128/jb.177.9.2343-2353.1995; KULLIK I, 1995, J BACTERIOL, V177, P1285, DOI 10.1128/jb.177.5.1285-1291.1995; Liu ST, 1998, ANAL BIOCHEM, V255, P158, DOI 10.1006/abio.1997.2457; Lochowska A, 2001, J BIOL CHEM, V276, P2098, DOI 10.1074/jbc.M007192200; MAXON ME, 1990, P NATL ACAD SCI USA, V87, P7076, DOI 10.1073/pnas.87.18.7076; MILLER BE, 1987, J BIOL CHEM, V262, P6006; PARSEK MR, 1992, J BACTERIOL, V174, P7798, DOI 10.1128/JB.174.23.7798-7806.1992; PARSEK MR, 1995, MOL MICROBIOL, V15, P819, DOI 10.1111/j.1365-2958.1995.tb02352.x; Perez-Rueda E, 2000, NUCLEIC ACIDS RES, V28, P1838, DOI 10.1093/nar/28.8.1838; SCHELL MA, 1993, ANNU REV MICROBIOL, V47, P597, DOI 10.1146/annurev.micro.47.1.597; SCHELL MA, 1990, J BIOL CHEM, V265, P3844; SCHELL MA, 1989, J BACTERIOL, V171, P837, DOI 10.1128/jb.171.2.837-846.1989; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TIEDEMANN AA, 1998, NUCLEIC ACIDS RES, V8, P3587; TOLEDANO MB, 1994, CELL, V78, P897, DOI 10.1016/S0092-8674(94)90702-1; WANG L, 1995, J MOL BIOL, V253, P691, DOI 10.1006/jmbi.1995.0583; WANG L, 1995, J MOL BIOL, V253, P32, DOI 10.1006/jmbi.1995.0533; WANG L, 1992, CELL, V69, P659, DOI 10.1016/0092-8674(92)90229-6; WU HM, 1984, NATURE, V308, P509, DOI 10.1038/308509a0; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; Zhu J, 2001, P NATL ACAD SCI USA, V98, P1507, DOI 10.1073/pnas.98.4.1507; ZWIEB C, 1990, NUCLEIC ACIDS RES, V18, P583, DOI 10.1093/nar/18.3.583	39	43	46	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 3	2002	277	18					15773	15780		10.1074/jbc.M200109200	http://dx.doi.org/10.1074/jbc.M200109200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	550PA	11877409	hybrid			2022-12-27	WOS:000175510400075
J	Lee, SF; Ko, CY; Wang, CT; Chen, SSL				Lee, SF; Ko, CY; Wang, CT; Chen, SSL			Effect of point mutations in the N terminus of the lentivirus lytic peptide-1 sequence of human immunodeficiency virus type 1 transmembrane protein gp41 Env stability	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIV-1 ENVELOPE GLYCOPROTEIN; POLYMERASE CHAIN-REACTION; AMINO-ACID SUBSTITUTIONS; FAS-MEDIATED APOPTOSIS; CYTOPLASMIC DOMAIN; CALMODULIN-BINDING; CLATHRIN ADAPTER; MATRIX PROTEIN; LIPID BILAYERS; MATURE VIRIONS	To understand the role of the lentivirus lytic peptide-1 region of the human immunodeficiency virus type 1 transmembrane glycoprotein (gp) 41 in viral infection, we examined the effects on virus replication of single amino acid deletions spanning this region in an infectious provirus of the HXB2 strain. Among the mutants analyzed, only the deletion of one of the two adjacent valine residues located at positions 832 and 833 (termed the Delta833 mutant for simplicity) greatly reduced the steady-state, cell-associated levels of the Env precursor and gp120, as opposed to the wild-type virus. The altered Env phenotype resulted in severely impaired virus infectivity and gp120 incorporation into this mutant virion. Analyses of additional mutants with deletions at Ile-830, Ala-836, and He-840 demonstrated that the Delta830 mutant exhibited the most significant inhibitory effect on Env steady-state expression. These results indicate that the N terminus of the lentivirus lytic peptide-1 region is critical for Env steady-state expression. Among the mutant viruses encoding Env proteins in which residues Val-832 and Val-833 were individually substituted by nonconserved amino acids Ala, Ser, or Pro, which were expected to disrupt the a-helical structure in the increasingly severe manner of Pro > Ser > Ala, only the 833P mutant exhibited significantly reduced steady-state Env expression. Pulse labeling and pulse-chase studies demonstrated that the Delta830, Delta833, and 833P mutants of Env proteins degraded more rapidly in a time-dependent manner after biosynthesis than did the wildtype Env. The results indicate that residue 830 and 833 mutations are likely to induce a conformational change in Env that targets the mutant protein for cellular degradation. Our study has implications about the structural determinants located at the N terminus of the lentivirus lytic peptide-1 sequence of gp41 that affect the fate of Env in virus-infected cells.	Acad Sinica, Inst Biomed Sci, Div Infect Dis, Taipei 11529, Taiwan; Vet Gen Hosp, Dept Med Res & Educ, Taipei 11217, Taiwan; Natl Yang Ming Univ, Sch Med, Inst Clin Med, Taipei 11217, Taiwan	Academia Sinica - Taiwan; National Yang Ming Chiao Tung University	Chen, SSL (corresponding author), Acad Sinica, Inst Biomed Sci, Div Infect Dis, 128 Sect,2 Yen Chiu Yuan Rd, Taipei 11529, Taiwan.							Akari H, 2000, J VIROL, V74, P4891, DOI 10.1128/JVI.74.10.4891-4893.2000; ARROYO J, 1995, J VIROL, V69, P4095, DOI 10.1128/JVI.69.7.4095-4102.1995; Bartz SR, 1996, J VIROL, V70, P2324, DOI 10.1128/JVI.70.4.2324-2331.1996; Berlioz-Torrent C, 1999, J VIROL, V73, P1350, DOI 10.1128/JVI.73.2.1350-1361.1999; Boge M, 1998, J BIOL CHEM, V273, P15773, DOI 10.1074/jbc.273.25.15773; CHEN SSL, 1993, J VIROL, V67, P3615, DOI 10.1128/JVI.67.6.3615-3619.1993; Chen SSL, 1999, J VIROL, V73, P8290, DOI 10.1128/JVI.73.10.8290-8302.1999; Chen SSL, 1996, VIROLOGY, V226, P260, DOI 10.1006/viro.1996.0654; Chen SSL, 1998, J VIROL, V72, P4765, DOI 10.1128/JVI.72.6.4765-4774.1998; Chen SSL, 2001, J VIROL, V75, P9925, DOI 10.1128/JVI.75.20.9925-9938.2001; CHERNOMORDIK L, 1994, J VIROL, V68, P7115, DOI 10.1128/JVI.68.11.7115-7123.1994; Comardelle AM, 1997, AIDS RES HUM RETROV, V13, P1525, DOI 10.1089/aid.1997.13.1525; DORFMAN T, 1994, J VIROL, V68, P1689, DOI 10.1128/JVI.68.3.1689-1696.1994; DUBAY JW, 1992, J VIROL, V66, P6616, DOI 10.1128/JVI.66.11.6616-6625.1992; EARL PL, 1991, J VIROL, V65, P31, DOI 10.1128/JVI.65.1.31-41.1991; EISENBERG D, 1990, BIOPOLYMERS, V29, P171, DOI 10.1002/bip.360290122; FISHER AG, 1986, SCIENCE, V233, P655, DOI 10.1126/science.3014663; FREED EO, 1995, J VIROL, V69, P1984, DOI 10.1128/JVI.69.3.1984-1989.1995; Freed EO, 1996, J VIROL, V70, P341, DOI 10.1128/JVI.70.1.341-351.1996; GABUZDA DH, 1992, J VIROL, V66, P3306, DOI 10.1128/JVI.66.6.3306-3315.1992; GAWRISCH K, 1993, BIOCHEMISTRY-US, V32, P3112, DOI 10.1021/bi00063a024; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; JAMES P, 1995, TRENDS BIOCHEM SCI, V20, P38, DOI 10.1016/S0968-0004(00)88949-5; Kliger Y, 1997, BIOCHEMISTRY-US, V36, P5157, DOI 10.1021/bi962935r; KORBER B, 1998, HUMAN RETROVIRUSES A, pA1; KOWALSKI M, 1987, SCIENCE, V237, P1351, DOI 10.1126/science.3629244; Lee SF, 2000, J BIOL CHEM, V275, P15809, DOI 10.1074/jbc.M000601200; LEE SJ, 1989, AIDS RES HUM RETROV, V5, P441, DOI 10.1089/aid.1989.5.441; Lodge R, 1997, EMBO J, V16, P695, DOI 10.1093/emboj/16.4.695; LODGE R, 1994, J VIROL, V68, P4857, DOI 10.1128/JVI.68.8.4857-4861.1994; MANNANO F, 1995, J VIROL, V69, P3824; Micoli KJ, 2000, J BIOL CHEM, V275, P1233, DOI 10.1074/jbc.275.2.1233; MILLER MA, 1993, AIDS RES HUM RETROV, V9, P1057, DOI 10.1089/aid.1993.9.1057; MILLER RK, 1992, TROPHOBLAST RES, V6, P351; Murakami T, 2000, J VIROL, V74, P3548, DOI 10.1128/JVI.74.8.3548-3554.2000; Murakami T, 2000, P NATL ACAD SCI USA, V97, P343, DOI 10.1073/pnas.97.1.343; Ohno H, 1997, VIROLOGY, V238, P305, DOI 10.1006/viro.1997.8839; Pan ZG, 1996, AM J PATHOL, V149, P903; Piller SC, 2000, J VIROL, V74, P11717, DOI 10.1128/JVI.74.24.11717-11723.2000; RATNER L, 1987, AIDS RES HUM RETROV, V3, P57, DOI 10.1089/aid.1987.3.57; ROWELL JF, 1995, J IMMUNOL, V155, P473; SPIES CP, 1994, J VIROL, V68, P585, DOI 10.1128/JVI.68.2.585-591.1994; SRINIVAS SK, 1993, J BIOL CHEM, V268, P22895; SRINIVAS SK, 1992, J BIOL CHEM, V267, P7121; Tencza SB, 1997, AIDS RES HUM RETROV, V13, P263, DOI 10.1089/aid.1997.13.263; TENCZA SB, 1995, J VIROL, V69, P5199, DOI 10.1128/JVI.69.8.5199-5202.1995; TERWILLIGER E, 1986, J VIROL, V60, P754, DOI 10.1128/JVI.60.2.754-760.1986; VALLETTE F, 1989, NUCLEIC ACIDS RES, V17, P723, DOI 10.1093/nar/17.2.723; VENABLE RM, 1989, AIDS RES HUM RETROV, V5, P7, DOI 10.1089/aid.1989.5.7; WILD C, 1994, P NATL ACAD SCI USA, V91, P12676, DOI 10.1073/pnas.91.26.12676; WILK T, 1992, VIROLOGY, V189, P167, DOI 10.1016/0042-6822(92)90692-I; YEE JK, 1994, P NATL ACAD SCI USA, V91, P9564, DOI 10.1073/pnas.91.20.9564; YU XF, 1992, J VIROL, V66, P4966, DOI 10.1128/JVI.66.8.4966-4971.1992; YU XF, 1993, J VIROL, V67, P213, DOI 10.1128/JVI.67.1.213-221.1993	54	15	15	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 3	2002	277	18					15363	15375		10.1074/jbc.M201479200	http://dx.doi.org/10.1074/jbc.M201479200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	550PA	11859090	hybrid			2022-12-27	WOS:000175510400020
J	Rajas, F; Gautier, A; Bady, I; Montano, S; Mithieux, G				Rajas, F; Gautier, A; Bady, I; Montano, S; Mithieux, G			Polyunsaturated fatty acyl coenzyme A suppress the glucose-6-phosphatase promoter activity by modulating the DNA binding of hepatocyte nuclear factor 4 alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUCOSE-6 PHOSPHATASE GENE; TRANSCRIPTION FACTOR HNF-4; MUSCLE INSULIN-RESISTANCE; RAT SMALL-INTESTINE; DIABETIC RATS; DIETARY-FAT; LIVER GLUCOSE-6-PHOSPHATASE; REGULATORY ELEMENT; ACCESSORY FACTOR; FACTOR-IV	Glucose-6-phosphatase confers on gluconeogenic tissues the capacity to release endogenous glucose in blood. The expression of its gene is modulated by nutritional mechanisms dependent on dietary fatty acids, with specific inhibitory effects of polyunsaturated fatty acids (PUFA). The presence of consensus binding sites of hepatocyte nuclear factor 4 (HNF4) in the -1640/+60 bp region of the rat glucose-6-phosphatase gene has led us to consider the hypothesis that HNF4alpha could be involved in the regulation of glucose-6-phosphatase gene transcription by long chain fatty acid (LCFA). Our results have shown that the glucose-6-phosphatase promoter activity is specifically inhibited in the presence of PUFA in HepG2 hepatoma cells, whereas saturated LCFA have no effect. In HeLa cells, the glucose-6-phosphatase promoter activity is induced by the co-expression of HNF4alpha or HNF1alpha. PUFA repress the promoter activity only in HNF4alpha-cotransfected HeLa cells, whereas they have no effects on the promoter activity in HNF1alpha-cotransfected HeLa cells. From gel shift mobility assays, deletion, and mutagenesis experiments, two specific binding sequences have been identified that appear able to account for both transactivation by HNF4alpha and regulation by LCFA in cells. The binding of HNF4alpha to its cognate sites is specifically inhibited by polyunsaturated fatty acyl coenzyme A in vitro. These data strongly suggest that the mechanism by which PUFA suppress the glucose-6-phosphatase gene transcription involves an inhibition of the binding of HNF4alpha to its cognate sites in the presence of polyunsaturated fatty acyl-CoA thioesters.	Fac Med Laennec, INSERM, U449, F-69372 Lyon 08, France	Institut National de la Sante et de la Recherche Medicale (Inserm)	Rajas, F (corresponding author), Fac Med Laennec, INSERM, U449, Rue Guillaume Paradin, F-69372 Lyon 08, France.		RAJAS, Fabienne/P-4091-2016	RAJAS, Fabienne/0000-0002-9233-7633; Gilles, Mithieux/0000-0003-3579-8529; Gautier-Stein, Amandine/0000-0002-6003-1891				Argaud D, 1996, DIABETES, V45, P1563, DOI 10.2337/diabetes.45.11.1563; AUSABEL FM, 1999, CURRENT PROTOCOLS MO; Bogan AA, 2000, J MOL BIOL, V302, P831, DOI 10.1006/jmbi.2000.4099; Chatelain F, 1998, DIABETES, V47, P882, DOI 10.2337/diabetes.47.6.882; CHOUARD T, 1990, NUCLEIC ACIDS RES, V18, P5853, DOI 10.1093/nar/18.19.5853; Clarke SD, 2001, AM J PHYSIOL-GASTR L, V281, pG865, DOI 10.1152/ajpgi.2001.281.4.G865; Clore JN, 2000, DIABETES, V49, P969, DOI 10.2337/diabetes.49.6.969; Costet P, 1998, J BIOL CHEM, V273, P29577, DOI 10.1074/jbc.273.45.29577; Croset M, 2001, DIABETES, V50, P740, DOI 10.2337/diabetes.50.4.740; Daniele N, 1997, J NUTR, V127, P2289, DOI 10.1093/jn/127.12.2289; EFENDIC S, 1988, J CLIN INVEST, V81, P1953, DOI 10.1172/JCI113543; EFENDIC S, 1985, P NATL ACAD SCI USA, V82, P2965, DOI 10.1073/pnas.82.9.2965; Foretz M, 1999, BIOCHEM J, V341, P371, DOI 10.1042/0264-6021:3410371; Fourel G, 1996, J VIROL, V70, P8571, DOI 10.1128/JVI.70.12.8571-8583.1996; GARG ML, 1985, BIOCHEM INT, V10, P585; GINSBURG GS, 1995, J CLIN INVEST, V96, P528, DOI 10.1172/JCI118065; HALL RK, 1995, P NATL ACAD SCI USA, V92, P412, DOI 10.1073/pnas.92.2.412; Hertz R, 1998, NATURE, V392, P512, DOI 10.1038/33185; Hu CB, 1999, AM J PHYSIOL-GASTR L, V276, pG1181, DOI 10.1152/ajpgi.1999.276.5.G1181; Hung HL, 1996, J BIOL CHEM, V271, P2323, DOI 10.1074/jbc.271.4.2323; JIANG GQ, 1995, MOL CELL BIOL, V15, P5131; Jump DB, 1999, ANNU REV NUTR, V19, P63, DOI 10.1146/annurev.nutr.19.1.63; KRAEGEN EW, 1991, DIABETES, V40, P1397, DOI 10.2337/diabetes.40.11.1397; LEFF T, 1989, J BIOL CHEM, V264, P16132; LIIMATTA M, 1994, MOL ENDOCRINOL, V8, P1147, DOI 10.1210/me.8.9.1147; Lin BC, 1998, DNA CELL BIOL, V17, P967, DOI 10.1089/dna.1998.17.967; Massillon D, 1997, DIABETES, V46, P153, DOI 10.2337/diabetes.46.1.153; METZGER S, 1993, J BIOL CHEM, V268, P16831; MITHIEUX G, 1993, EUR J BIOCHEM, V213, P461, DOI 10.1111/j.1432-1033.1993.tb17782.x; Mithieux G, 1996, DIABETES, V45, P891, DOI 10.2337/diabetes.45.7.891; Mithieux G, 2002, DIABETES, V51, P139, DOI 10.2337/diabetes.51.1.139; Mithieux G, 1997, EUR J ENDOCRINOL, V136, P137, DOI 10.1530/eje.0.1360137; NEWMANN JR, 1987, BIOTECHNIQUES, V5, P444; Oakes ND, 1997, DIABETES, V46, P1768, DOI 10.2337/diabetes.46.11.1768; Rajas F, 1999, GASTROENTEROLOGY, V117, P132, DOI 10.1016/S0016-5085(99)70559-7; Rouet P, 1998, BIOCHEM J, V334, P577, DOI 10.1042/bj3340577; SLADEK FM, 1990, GENE DEV, V4, P2353, DOI 10.1101/gad.4.12b.2353; STORLIEN LH, 1987, SCIENCE, V237, P885, DOI 10.1126/science.3303333; STORLIEN LH, 1991, DIABETES, V40, P280, DOI 10.2337/diabetes.40.2.280; Streeper RS, 1998, P NATL ACAD SCI USA, V95, P9208, DOI 10.1073/pnas.95.16.9208; Streeper RS, 1997, J BIOL CHEM, V272, P11698, DOI 10.1074/jbc.272.18.11698; TIAN JM, 1991, GENE DEV, V5, P2225, DOI 10.1101/gad.5.12a.2225; VENKATRAMAN JT, 1991, LIPIDS, V26, P441, DOI 10.1007/BF02536070; Viollet B, 1997, MOL CELL BIOL, V17, P4208, DOI 10.1128/MCB.17.8.4208; Waltz SE, 1996, J BIOL CHEM, V271, P9024, DOI 10.1074/jbc.271.15.9024; XANTHOPOULOS KG, 1991, P NATL ACAD SCI USA, V88, P3807, DOI 10.1073/pnas.88.9.3807; Xu J, 1999, J BIOL CHEM, V274, P23577, DOI 10.1074/jbc.274.33.23577; Yamada K, 1997, BIOCHEM J, V324, P917, DOI 10.1042/bj3240917; Yanai K, 1999, J BIOL CHEM, V274, P34605, DOI 10.1074/jbc.274.49.34605; Yoon JC, 2001, NATURE, V413, P131, DOI 10.1038/35093050	50	69	74	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 3	2002	277	18					15736	15744		10.1074/jbc.M200971200	http://dx.doi.org/10.1074/jbc.M200971200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	550PA	11864989	hybrid			2022-12-27	WOS:000175510400070
J	Saito, S; Goodarzi, AA; Higashimoto, Y; Noda, Y; Lees-Miller, SP; Appella, E; Anderson, CW				Saito, S; Goodarzi, AA; Higashimoto, Y; Noda, Y; Lees-Miller, SP; Appella, E; Anderson, CW			ATM mediates phosphorylation at multiple p53 sites, including Ser(46), in response to ionizing radiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-DAMAGE; P53-DEPENDENT APOPTOSIS; KINASE; ACTIVATION; TRANSACTIVATION; CHECKPOINT; INHIBITION; CASCADE	The p53 tumor suppressor protein preserves genome integrity by regulating growth arrest and apoptosis in response to DNA damage. In response to ionizing radiation (111), ATM, the gene product mutated in ataxia telangiectasia, stabilizes and activates p53 through phosphorylation of Ser(15) and (indirectly) Ser(20). Here we show that phosphorylation of p53 on Ser(46), a residue important for p53 apoptotic activity, as well as on Ser(9), in response to IR also is dependent on the ATM protein kinase. IR-induced phosphorylation at Ser(46) was inhibited by wortmannin, a phosphatidylinositol 3-kinase inhibitor, but not PD169316, a p38 MAPK inhibitor. p53 C-terminal acetylation at Lys(320) and Lys(382), which may stabilize p53 and activate sequence-specific DNA binding, required Ser15 phosphorylation by ATM and was enhanced by phosphorylation at nearby residues including Ser(6), Ser(9), and Thr(18). These observations, together with the proposed role of Ser(46) phosphorylation in mediating apoptosis, suggest that ATM is involved in the initiation of p53-dependent apoptosis after IR in human lymphoblastoid cells.	Brookhaven Natl Lab, Dept Biol, Upton, NY 11973 USA; NCI, NIH, Cell Biol Lab, Bethesda, MD 20892 USA; Univ Calgary, Dept Biochem & Mol Biol, Calgary, AB T2N 1N4, Canada	United States Department of Energy (DOE); Brookhaven National Laboratory; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Calgary	Anderson, CW (corresponding author), Brookhaven Natl Lab, Dept Biol, 50 Bell Ave, Upton, NY 11973 USA.	cwa@bnl.gov		Higashimoto, Yuichiro/0000-0003-1382-8598; Lees-Miller, Susan/0000-0001-5809-2516				Abraham RT, 2001, GENE DEV, V15, P2177, DOI 10.1101/gad.914401; Appella E, 2001, EUR J BIOCHEM, V268, P2764, DOI 10.1046/j.1432-1327.2001.02225.x; Ashcroft M, 1999, MOL CELL BIOL, V19, P1751; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Bulavin DV, 1999, EMBO J, V18, P6845, DOI 10.1093/emboj/18.23.6845; Buschmann T, 2001, MOL CELL BIOL, V21, P2743, DOI 10.1128/MCB.21.8.2743-2754.2001; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Chao C, 2000, EMBO J, V19, P4967, DOI 10.1093/emboj/19.18.4967; Chao C, 2000, P NATL ACAD SCI USA, V97, P11936, DOI 10.1073/pnas.220252297; Chehab NH, 2000, GENE DEV, V14, P278; Chehab NH, 1999, P NATL ACAD SCI USA, V96, P13777, DOI 10.1073/pnas.96.24.13777; D'Orazi G, 2002, NAT CELL BIOL, V4, P11, DOI 10.1038/ncb714; Dumaz N, 1999, EMBO J, V18, P7002, DOI 10.1093/emboj/18.24.7002; Gallagher TF, 1997, BIOORGAN MED CHEM, V5, P49, DOI 10.1016/S0968-0896(96)00212-X; Higashimoto Y, 2000, J BIOL CHEM, V275, P23199, DOI 10.1074/jbc.M002674200; Hirao A, 2000, SCIENCE, V287, P1824, DOI 10.1126/science.287.5459.1824; Hofmann TG, 2002, NAT CELL BIOL, V4, P1, DOI 10.1038/ncb715; Isaacs JS, 2001, J BIOL CHEM, V276, P18497, DOI 10.1074/jbc.M100638200; Jabbur JR, 2000, ONCOGENE, V19, P6203, DOI 10.1038/sj.onc.1204017; Karlseder J, 1999, SCIENCE, V283, P1321, DOI 10.1126/science.283.5406.1321; Kussie PH, 1996, SCIENCE, V274, P948, DOI 10.1126/science.274.5289.948; Lambert PF, 1998, J BIOL CHEM, V273, P33048, DOI 10.1074/jbc.273.49.33048; Ludwig RL, 1996, MOL CELL BIOL, V16, P4952; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; Oda K, 2000, CELL, V102, P849, DOI 10.1016/S0092-8674(00)00073-8; Okamura S, 2001, MOL CELL, V8, P85, DOI 10.1016/S1097-2765(01)00284-2; Pettitt AR, 2001, BLOOD, V98, P814, DOI 10.1182/blood.V98.3.814; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; Sakaguchi K, 2000, J BIOL CHEM, V275, P9278, DOI 10.1074/jbc.275.13.9278; Sarkaria JN, 1998, CANCER RES, V58, P4375; Shieh SY, 1999, EMBO J, V18, P1815, DOI 10.1093/emboj/18.7.1815; Siliciano JD, 1997, GENE DEV, V11, P3471, DOI 10.1101/gad.11.24.3471; Tibbetts RS, 1999, GENE DEV, V13, P152, DOI 10.1101/gad.13.2.152; Wahl GM, 2001, NAT CELL BIOL, V3, pE277, DOI 10.1038/ncb1201-e277	35	200	204	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	APR 12	2002	277	15					12491	12494		10.1074/jbc.C200093200	http://dx.doi.org/10.1074/jbc.C200093200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	542GZ	11875057	hybrid			2022-12-27	WOS:000175036300002
J	Warner, RG; Hundt, C; Weiss, S; Turnbull, JE				Warner, RG; Hundt, C; Weiss, S; Turnbull, JE			Identification of the heparan sulfate binding sites in the cellular prion protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYRIAN GOLDEN-HAMSTER; S-TRANSFERASE FUSION; INCUBATION PERIOD; ESCHERICHIA-COLI; AMYLOID PLAQUES; COPPER-BINDING; REPEAT REGION; CONGO RED; PRP; SCRAPIE	Data from cell culture and animal models of prion disease support the separate involvement of both heparan sulfate proteoglycans and copper (II) ions in prion (PrP) metabolism. Though direct interactions between prion protein and heparin have been recorded, little is known of the structural features implicit in this interaction or of the involvement of copper (II) ions. Using biosensor and enzyme-linked immunosorbent assay methodology we report direct heparin and heparan sulfate-binding activity in recombinant cellular prion protein (PrPc). We also demonstrate that the interaction of recombinant PrPc with heparin is weakened in the presence of Cu(II) ions and is particularly sensitive to competition with dextran sulfate. Competitive inhibition experiments with chemically modified heparins also indicate that 2-O-sulfate groups (but not 6-O-sulfate groups) are essential for heparin recognition. We have also identified three regions of the prion protein capable of independent binding to heparin and heparan sulfate: residues 23-52, 53-93, and 110-128. Interestingly, the interaction of an octapeptide-spanning peptide motif amino acids 53-93 with heparin is enhanced by Cu(II) ions. Significantly, a peptide of this sequence is able to inhibit the binding of full-length prion molecule to heparin, suggesting a direct role in heparin recognition within the intact protein. The collective data suggest a complex interaction between prion protein and heparin/ heparan sulfate and has implications for the cellular and pathological functions of prion proteins.	Univ Birmingham, Sch Biosci, Mol Cell Biol Labs, Birmingham B15 2TT, W Midlands, England; LMU, Inst Biochem, Genzentrum, Mol Biol Lab, D-81377 Munich, Germany	University of Birmingham; University of Munich	Turnbull, JE (corresponding author), Univ Birmingham, Sch Biosci, Mol Cell Biol Labs, Birmingham B15 2TT, W Midlands, England.	j.e.turnbull@bham.ac.uk	Warner, Richard/C-8910-2011					Appel TR, 1999, BIOL CHEM, V380, P1295, DOI 10.1515/BC.1999.165; Beringue V, 2000, J VIROL, V74, P5432, DOI 10.1128/JVI.74.12.5432-5440.2000; Brimacombe DB, 1999, BIOCHEM J, V342, P605, DOI 10.1042/0264-6021:3420605; Brown DR, 2000, EMBO J, V19, P1180, DOI 10.1093/emboj/19.6.1180; Brown DR, 1997, NATURE, V390, P684, DOI 10.1038/37733; Caspi S, 1998, J BIOL CHEM, V273, P3484, DOI 10.1074/jbc.273.6.3484; CAUGHEY B, 1994, J VIROL, V68, P2135, DOI 10.1128/JVI.68.4.2135-2141.1994; CAUGHEY B, 1993, J VIROL, V67, P643, DOI 10.1128/JVI.67.2.643-650.1993; CHEN SG, 1995, J BIOL CHEM, V270, P19173, DOI 10.1074/jbc.270.32.19173; DEGIOIA L, 1994, J BIOL CHEM, V269, P7859; Edenhofer F, 1996, J VIROL, V70, P4724, DOI 10.1128/JVI.70.7.4724-4728.1996; FARQUHAR CF, 1986, J GEN VIROL, V67, P463, DOI 10.1099/0022-1317-67-3-463; Fischer M, 1996, EMBO J, V15, P1255, DOI 10.1002/j.1460-2075.1996.tb00467.x; Flechsig E, 2000, NEURON, V27, P399, DOI 10.1016/S0896-6273(00)00046-5; FORLONI G, 1993, NATURE, V362, P543, DOI 10.1038/362543a0; GABIZON R, 1993, J CELL PHYSIOL, V157, P319, DOI 10.1002/jcp.1041570215; GASSET M, 1992, P NATL ACAD SCI USA, V89, P10940, DOI 10.1073/pnas.89.22.10940; Gauczynski S, 2001, EMBO J, V20, P5863, DOI 10.1093/emboj/20.21.5863; GUIROY DC, 1991, ACTA NEUROPATHOL, V82, P87, DOI 10.1007/BF00293949; Horiuchi M, 1999, EMBO J, V18, P3193, DOI 10.1093/emboj/18.12.3193; HORNSHAW MP, 1995, BIOCHEM BIOPH RES CO, V214, P993, DOI 10.1006/bbrc.1995.2384; Hundt C, 2001, EMBO J, V20, P5876, DOI 10.1093/emboj/20.21.5876; JASEJA M, 1989, CAN J CHEM, V67, P1449, DOI 10.1139/v89-221; Jobling MF, 1999, J NEUROCHEM, V73, P1557, DOI 10.1046/j.1471-4159.1999.0731557.x; Jobling MF, 2001, BIOCHEMISTRY-US, V40, P8073, DOI 10.1021/bi0029088; LADOGANA A, 1992, J GEN VIROL, V73, P661, DOI 10.1099/0022-1317-73-3-661; LEE WT, 1984, J EXP MED, V159, P1790, DOI 10.1084/jem.159.6.1790; MACCARANA M, 1993, J BIOL CHEM, V268, P23898; MARKLUND SL, 1982, P NATL ACAD SCI-BIOL, V79, P7634, DOI 10.1073/pnas.79.24.7634; McBride PA, 1998, EXP NEUROL, V149, P447, DOI 10.1006/exnr.1997.6740; Miura T, 1999, BIOCHEMISTRY-US, V38, P11560, DOI 10.1021/bi9909389; MULTHAUP G, 1995, J MOL RECOGNIT, V8, P247; Nadkarni VD, 1997, BIOTECHNIQUES, V23, P382, DOI 10.2144/97233bm07; Ono K, 1999, GLYCOBIOLOGY, V9, P705, DOI 10.1093/glycob/9.7.705; Perez M, 1998, BIOCHEM J, V335, P369, DOI 10.1042/bj3350369; Qin KF, 2000, J BIOL CHEM, V275, P19121, DOI 10.1074/jbc.275.25.19121; Rahmoune H, 1998, J BIOL CHEM, V273, P7303, DOI 10.1074/jbc.273.13.7303; Rieger R, 1997, NAT MED, V3, P1383, DOI 10.1038/nm1297-1383; Shaked GM, 2001, J BIOL CHEM, V276, P14324, DOI 10.1074/jbc.M007815200; Shaked Y, 2001, J VIROL, V75, P7872, DOI 10.1128/JVI.75.17.7872-7874.2001; SHYNG SL, 1995, J BIOL CHEM, V270, P30221; SNOW AD, 1994, NEURON, V12, P219, DOI 10.1016/0896-6273(94)90165-1; SNOW AD, 1990, LAB INVEST, V63, P601; Stockel J, 1998, BIOCHEMISTRY-US, V37, P7185, DOI 10.1021/bi972827k; Supattapone S, 2001, J VIROL, V75, P1408, DOI 10.1128/JVI.75.3.1408-1413.2001; Supattapone S, 1999, P NATL ACAD SCI USA, V96, P14529, DOI 10.1073/pnas.96.25.14529; Telling GC, 1997, PROTEIN SCI, V6, P825; Toida T, 1997, J CHROMATOGR A, V787, P266, DOI 10.1016/S0021-9673(97)00658-4; Volkel D, 1998, EUR J BIOCHEM, V251, P462, DOI 10.1046/j.1432-1327.1998.2510462.x; WEISS S, 1995, J VIROL, V69, P4776, DOI 10.1128/JVI.69.8.4776-4783.1995; Weiss S, 1997, J VIROL, V71, P8790, DOI 10.1128/JVI.71.11.8790-8797.1997; Weiss S, 1996, BIOCHEM BIOPH RES CO, V219, P173, DOI 10.1006/bbrc.1996.0201; Wong BS, 2000, BIOCHEM BIOPH RES CO, V269, P726, DOI 10.1006/bbrc.2000.2355; Wong C, 2001, EMBO J, V20, P377, DOI 10.1093/emboj/20.3.377; Wrenshall LE, 1999, J IMMUNOL, V163, P3793; Yates EA, 1996, CARBOHYD RES, V294, P15; Zahn R, 1997, FEBS LETT, V417, P400, DOI 10.1016/S0014-5793(97)01330-6	57	178	188	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 24	2002	277	21					18421	18430		10.1074/jbc.M110406200	http://dx.doi.org/10.1074/jbc.M110406200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	558PM	11882649	hybrid			2022-12-27	WOS:000175975800023
J	Yamaguchi-Iwai, Y; Ueta, R; Fukunaka, A; Sasaki, R				Yamaguchi-Iwai, Y; Ueta, R; Fukunaka, A; Sasaki, R			Subcellular localization of Aft1 transcription factor responds to iron status in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR EXPORT SIGNAL; DNA-BINDING DOMAIN; OXIDATIVE STRESS; NUCLEOCYTOPLASMIC TRANSPORT; REGULATORY PROTEIN-2; ACTIVATION DOMAIN; GENE-EXPRESSION; MESSENGER-RNA; FACTOR PHO4; FACTOR PAP1	The Aft1 transcription factor regulates the iron regulon in response to iron availability in Saccharomyces cerevisiae. Aft1 activates a battery of genes required for iron uptake under iron-starved conditions, whereas Aft1 function is inactivated under iron-replete conditions. Previously, we have shown that iron-regulated DNA binding by Aft1 is responsible for the controlled expression of target genes. Here we show that this iron-regulated DNA binding by Aft1 is not due to the change in the total expression level of Aft1 or alteration of DNA binding activity. Rather, nuclear localization of Aft1 responds to iron status, leading to iron-regulated expression of the target genes. We identified the nuclear export signal (NES)-like sequence in the AFT1 open reading frame. Mutation of the NES-like sequence causes nuclear retention of Aft1 and the constitutive activation of Aft1 function independent of the iron status of the cells. These results suggest that the nuclear export of Aft1 is critical for ensuring iron-responsive transcriptional activation of the Aft1 regulon and that the nuclear import/export systems are involved in iron sensing by Aft1 in S. cerevisiae.	Kyoto Univ, Grad Sch Biostudies, Dept Appl Mol Biol, Sakyo Ku, Kyoto 6068502, Japan; Univ Shiga Prefecture, Sch Human Cultures, Dept Life Style Studies, Shiga 5228533, Japan	Kyoto University; University Shiga Prefecture	Yamaguchi-Iwai, Y (corresponding author), Kyoto Univ, Grad Sch Biostudies, Dept Appl Mol Biol, Sakyo Ku, Kyoto 6068502, Japan.	yukoiwai@kais.kyoto-u.ac.jp						Askwith CC, 1996, MOL MICROBIOL, V20, P27, DOI 10.1111/j.1365-2958.1996.tb02485.x; BEINERT H, 1993, FASEB J, V7, P1442, DOI 10.1096/fasebj.7.15.8262329; Bird AJ, 2000, EMBO J, V19, P3704, DOI 10.1093/emboj/19.14.3704; Bogerd HP, 1996, MOL CELL BIOL, V16, P4207; Brittenham GM, 2000, HEMATOLOGY BASIC PRI, P397; Casas C, 1997, YEAST, V13, P621, DOI 10.1002/(SICI)1097-0061(19970615)13:7<621::AID-YEA121>3.0.CO;2-U; Dancis A, 1998, J PEDIATR-US, V132, pS24, DOI 10.1016/S0022-3476(98)70524-4; DeVit MJ, 1997, MOL BIOL CELL, V8, P1603, DOI 10.1091/mbc.8.8.1603; FISCHER U, 1995, CELL, V82, P475, DOI 10.1016/0092-8674(95)90436-0; Fornerod M, 1997, CELL, V90, P1051, DOI 10.1016/S0092-8674(00)80371-2; Fritz CC, 1996, CURR BIOL, V6, P848, DOI 10.1016/S0960-9822(02)00608-5; Fukuda M, 1996, J BIOL CHEM, V271, P20024, DOI 10.1074/jbc.271.33.20024; Fukuda M, 1997, NATURE, V390, P308, DOI 10.1038/36894; GERACE L, 1995, CELL, V82, P341, DOI 10.1016/0092-8674(95)90420-4; Graden JA, 1997, P NATL ACAD SCI USA, V94, P5550, DOI 10.1073/pnas.94.11.5550; GUARENTE L, 1983, METHOD ENZYMOL, V101, P181; GUO B, 1995, J BIOL CHEM, V270, P21645, DOI 10.1074/jbc.270.37.21645; Halliwell B., 1991, FREE RADICALS BIOL M; Hentze MW, 1996, P NATL ACAD SCI USA, V93, P8175, DOI 10.1073/pnas.93.16.8175; Hood JK, 1999, CURR OPIN CELL BIOL, V11, P241, DOI 10.1016/S0955-0674(99)80032-5; IWAI K, 1995, EMBO J, V14, P5350, DOI 10.1002/j.1460-2075.1995.tb00219.x; Jensen LT, 1998, EMBO J, V17, P5400, DOI 10.1093/emboj/17.18.5400; JUNGMANN J, 1993, EMBO J, V12, P5051, DOI 10.1002/j.1460-2075.1993.tb06198.x; Kaffman A, 1998, GENE DEV, V12, P2673, DOI 10.1101/gad.12.17.2673; Kaffman A, 1998, NATURE, V396, P482, DOI 10.1038/24898; KLAUSNER RD, 1993, CELL, V72, P19, DOI 10.1016/0092-8674(93)90046-S; KOHRER K, 1991, METHOD ENZYMOL, V194, P398; Komeili A, 2000, CURR OPIN CELL BIOL, V12, P355, DOI 10.1016/S0955-0674(00)00100-9; Kudo N, 1999, J BIOL CHEM, V274, P15151, DOI 10.1074/jbc.274.21.15151; Kuge S, 1998, GENES CELLS, V3, P521, DOI 10.1046/j.1365-2443.1998.00209.x; Kuge S, 1997, EMBO J, V16, P1710, DOI 10.1093/emboj/16.7.1710; Labbe S, 1997, J BIOL CHEM, V272, P15951, DOI 10.1074/jbc.272.25.15951; Latimer M, 1998, MOL CELL BIOL, V18, P2640, DOI 10.1128/MCB.18.5.2640; LEFSTIN JA, 1994, GENE DEV, V8, P2842, DOI 10.1101/gad.8.23.2842; Lesuisse E, 1998, MICROBIOL-UK, V144, P3455, DOI 10.1099/00221287-144-12-3455; Li XY, 1996, GENE DEV, V10, P517, DOI 10.1101/gad.10.5.517; Lin SJ, 1997, J BIOL CHEM, V272, P9215; Malek S, 1998, J BIOL CHEM, V273, P25427, DOI 10.1074/jbc.273.39.25427; Mattaj IW, 1998, ANNU REV BIOCHEM, V67, P265, DOI 10.1146/annurev.biochem.67.1.265; Nakielny S, 1997, CURR OPIN CELL BIOL, V9, P420, DOI 10.1016/S0955-0674(97)80016-6; Nigg EA, 1997, NATURE, V386, P779, DOI 10.1038/386779a0; ONeill EM, 1996, SCIENCE, V271, P209, DOI 10.1126/science.271.5246.209; Ooi CE, 1996, EMBO J, V15, P3515, DOI 10.1002/j.1460-2075.1996.tb00720.x; OssarehNazari B, 1997, SCIENCE, V278, P141, DOI 10.1126/science.278.5335.141; PANTOPOULOS K, 1995, RNA, V1, P155; PANTOPOULOS K, 1999, IRON METABOLISM, P131; Stade K, 1997, CELL, V90, P1041, DOI 10.1016/S0092-8674(00)80370-0; TANG CK, 1992, J BIOL CHEM, V267, P24466; Toone WM, 1998, GENE DEV, V12, P1453, DOI 10.1101/gad.12.10.1453; Urbanowski JL, 1999, J BIOL CHEM, V274, P38061, DOI 10.1074/jbc.274.53.38061; Vandromme M, 1996, TRENDS BIOCHEM SCI, V21, P59, DOI 10.1016/S0968-0004(96)80182-4; WEN W, 1995, CELL, V82, P463, DOI 10.1016/0092-8674(95)90435-2; Winge DR, 1998, CURR OPIN CHEM BIOL, V2, P216, DOI 10.1016/S1367-5931(98)80063-X; YAMAGUCHIIWAI Y, 1995, EMBO J, V14, P1231, DOI 10.1002/j.1460-2075.1995.tb07106.x; YamaguchiIwai Y, 1996, EMBO J, V15, P3377, DOI 10.1002/j.1460-2075.1996.tb00703.x; Yan C, 1998, EMBO J, V17, P7416, DOI 10.1093/emboj/17.24.7416; Yun CW, 2000, J BIOL CHEM, V275, P10709, DOI 10.1074/jbc.275.14.10709; Zhao H, 1997, MOL CELL BIOL, V17, P5044, DOI 10.1128/MCB.17.9.5044	58	134	140	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 24	2002	277	21					18914	18918		10.1074/jbc.M200949200	http://dx.doi.org/10.1074/jbc.M200949200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	558PM	11877447	hybrid			2022-12-27	WOS:000175975800087
J	Desmots, F; Rissel, M; Gilot, D; Lagadic-Gossmann, D; Morel, F; Guguen-Guillouzo, C; Guillouzo, A; Loyer, P				Desmots, F; Rissel, M; Gilot, D; Lagadic-Gossmann, D; Morel, F; Guguen-Guillouzo, C; Guillouzo, A; Loyer, P			Pro-inflammatory cytokines tumor necrosis factor alpha and interleukin-6 and survival factor epidermal growth factor positively regulate the murine GSTA4 enzyme in hepatocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUTATHIONE S-TRANSFERASES; MITOGEN-ACTIVATED PROTEIN; ANTIOXIDANT RESPONSE ELEMENT; REGENERATING RAT-LIVER; FACTOR KAPPA-B; LIPID-PEROXIDATION; OXIDATIVE STRESS; RAPID ACTIVATION; SUPERGENE FAMILY; PRIMARY CULTURE	We hypothesized that glutathione transferases could be induced and may participate to cellular defenses against the oxidative stress occurring during liver regeneration. Here, we evidenced that murine GSTA1 (mGSTA1), A4, Pi, and Mu are up-regulated during mouse liver regeneration, exhibiting a biphasic pattern of induction correlating early G(1) phase and G(1)/S transition of the cell cycle. Using confocal microscopy Immunolocalization and subcellular fractionation, mGSTA4 was demonstrated in both mitochondria and cytosol and found preferentially increased in cytosol during liver regeneration. In addition, mGSTA4 was induced in vivo and in cultured hepatocytes by tumor necrosis factor a (TNFalpha), interleukin-6 (IL-6), and epidermal growth factor (EGF), factors that play crucial roles in hepatocyte survival and proliferation during liver regeneration. However, the mitogenic effect of EGF was not responsible for the induction of mGSTA4. In transient transfections, IL-6 and EGF, but not TNFalpha, transactivated the human GSTA4 (hGSTA4) promoter cloned upstream of the luciferase reporter gene suggesting that IL-6 and EGF up-regulated hGSTA4 at a transcriptional level, whereas TNFalpha could rather act at a post-transcriptional level. The inhibition of phosphoinositide 3-kinase, p38 MAPK, and MEK/ERK signaling pathways, using specific inhibitors, prevented EGF-dependent induction of mGSTA4 and transactivation of hGSTA4 promoter. Altogether, these data favor the conclusion that, in regenerating hepatocytes, several GST isoforms are induced and that cytokines TNFalpha and IL-6 and survival factor EGF positively regulate mGSTA4 via survival signaling pathways.	Univ Rennes 1, Fac Pharm, INSERM, U456, F-35043 Rennes, France; Hop Pontchaillou, INSERM, U522, F-35033 Rennes, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Rennes; CHU Rennes; Institut National de la Sante et de la Recherche Medicale (Inserm)	Guillouzo, A (corresponding author), Univ Rennes 1, Fac Pharm, INSERM, U456, 2 Ave Pr Leon Bernard, F-35043 Rennes, France.		LOYER, Pascal/K-1838-2019; GUILLOUZO, Andre/Z-2373-2019; LAGADIC-GOSSMANN, Dominique/I-5079-2015	LAGADIC-GOSSMANN, Dominique/0000-0002-4888-236X; LOYER, PASCAL/0000-0002-5656-2673				Albrecht JH, 1999, CELL GROWTH DIFFER, V10, P397; ALBRECHT JH, 1993, AM J PHYSIOL, V265, P857; AWASTHI YC, 1994, INT J BIOCHEM, V26, P295, DOI 10.1016/0020-711X(94)90050-7; Bhagwat SV, 1998, BIOCHEM PHARMACOL, V56, P831, DOI 10.1016/S0006-2952(98)00228-7; BOITIER E, 1995, CANCER RES, V55, P3028; Carnovale CE, 2000, J HEPATOL, V32, P798, DOI 10.1016/S0168-8278(00)80249-4; Chandel NS, 2001, J BIOL CHEM, V276, P42728, DOI 10.1074/jbc.M103074200; Chao DT, 1998, ANNU REV IMMUNOL, V16, P395, DOI 10.1146/annurev.immunol.16.1.395; Cheng JZ, 1999, ARCH BIOCHEM BIOPHYS, V372, P29, DOI 10.1006/abbi.1999.1479; Cressman DE, 1996, SCIENCE, V274, P1379, DOI 10.1126/science.274.5291.1379; CRESSMAN DE, 1995, HEPATOLOGY, V21, P1443, DOI 10.1016/0270-9139(95)90068-3; Desmots F, 2002, FREE RADICAL BIO MED, V32, P93, DOI 10.1016/S0891-5849(01)00767-5; Desmots F, 2001, J HISTOCHEM CYTOCHEM, V49, P1573, DOI 10.1177/002215540104901211; Desmots F, 1998, BIOCHEM J, V336, P437, DOI 10.1042/bj3360437; DiazGuerra MJM, 1997, BIOCHEM J, V326, P791, DOI 10.1042/bj3260791; FARDEL O, 1992, BIOCHEM PHARMACOL, V44, P2259, DOI 10.1016/0006-2952(92)90355-M; Fausto N, 2000, J HEPATOL, V32, P19, DOI 10.1016/S0168-8278(00)80412-2; FITZGERALD MJ, 1995, CELL GROWTH DIFFER, V6, P417; Gardner JL, 2001, ARCH BIOCHEM BIOPHYS, V390, P19, DOI 10.1006/abbi.2001.2352; GILOT D, 2002, IN PRESS J GENE MED; GOON D, 1993, TOXICOL APPL PHARM, V119, P175, DOI 10.1006/taap.1993.1058; GUGUEN C, 1975, BIOL GASTRO-ENTEROL, V8, P223; Habig W H, 1981, Methods Enzymol, V77, P398; Hayes JD, 1995, CRIT REV BIOCHEM MOL, V30, P445, DOI 10.3109/10409239509083491; HAYES JD, 1995, FREE RADICAL RES, V22, P193, DOI 10.3109/10715769509147539; Heinrich PC, 1998, BIOCHEM J, V334, P297, DOI 10.1042/bj3340297; Hong F, 2000, BIOCHEM BIOPH RES CO, V279, P974, DOI 10.1006/bbrc.2000.4044; JENSSON H, 1986, FEBS LETT, V203, P207, DOI 10.1016/0014-5793(86)80743-8; Kang KW, 2000, MOL PHARMACOL, V58, P1017, DOI 10.1124/mol.58.5.1017; LANGOUET S, 1995, BIOCHEM BIOPH RES CO, V216, P793, DOI 10.1006/bbrc.1995.2691; Lee FYJ, 1999, HEPATOLOGY, V29, P677, DOI 10.1002/hep.510290320; LEE SJ, 1993, BIOCHEM J, V293, P137, DOI 10.1042/bj2930137; Li JR, 1999, J BIOL CHEM, V274, P17325, DOI 10.1074/jbc.274.24.17325; Loyer P, 1996, J BIOL CHEM, V271, P11484, DOI 10.1074/jbc.271.19.11484; Maheo K, 1997, J BIOL CHEM, V272, P16125, DOI 10.1074/jbc.272.26.16125; Mori M, 1995, Nihon Ika Daigaku Zasshi, V62, P447; Plumpe J, 2000, AM J PHYSIOL-GASTR L, V278, pG173, DOI 10.1152/ajpgi.2000.278.1.G173; Rai RM, 1998, P NATL ACAD SCI USA, V95, P13829, DOI 10.1073/pnas.95.23.13829; SATOH K, 1995, CARCINOGENESIS, V16, P869, DOI 10.1093/carcin/16.4.869; SCHULZEOSTHOFF K, 1992, J BIOL CHEM, V267, P5317; Singh SP, 2002, J BIOL CHEM, V277, P4232, DOI 10.1074/jbc.M109678200; Spector MS, 1997, MOL CELL BIOL, V17, P3556, DOI 10.1128/MCB.17.7.3556; Talarmin H, 1999, MOL CELL BIOL, V19, P6003; TESHIGAWARA M, 1995, RES EXP MED, V195, P55, DOI 10.1007/BF02576774; Tjalkens RB, 1998, ARCH BIOCHEM BIOPHYS, V359, P42, DOI 10.1006/abbi.1998.0895; Tzung SP, 1997, AM J PATHOL, V150, P1985; Webber EM, 1998, HEPATOLOGY, V28, P1226, DOI 10.1002/hep.510280509; Yamada Y, 1998, HEPATOLOGY, V28, P959, DOI 10.1002/hep.510280410; Yamada Y, 1997, P NATL ACAD SCI USA, V94, P1441, DOI 10.1073/pnas.94.4.1441; Yang Y, 2001, J BIOL CHEM, V276, P19220, DOI 10.1074/jbc.M100551200; Yin ZM, 2000, CANCER RES, V60, P4053	51	34	35	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 17	2002	277	20					17892	17900		10.1074/jbc.M112351200	http://dx.doi.org/10.1074/jbc.M112351200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	553PR	11884396	hybrid			2022-12-27	WOS:000175685100065
J	Martin, A; Schneider, S; Schwer, B				Martin, A; Schneider, S; Schwer, B			Prp43 is an essential RNA-dependent ATPase required for release of lariat-intron from the spliceosome	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR RIBONUCLEOPROTEIN-PARTICLES; BOX SPLICING FACTOR; SACCHAROMYCES-CEREVISIAE; NUCLEOSIDE TRIPHOSPHATASE; MUTATIONAL ANALYSIS; HELICASE; PROTEIN; PRP16; MUTANTS; HOMOLOG	The essential Saccharomyces cerevisiae PRP43 gene encodes a 767-amino acid protein of the DEXH-box family. Prp43 has been implicated in spliceosome disassembly (Arenas, J. E., and Abelson, J. N. (1997) Proc. Natl. Acatl. Sci. U. S. A 94, 11798-11802). Here we show that purified recombinant Prp43 is an RNA-dependent ATPase. Alanine mutations at conserved residues within motifs I ((119)GSGKT(123)), II ((215)DEAH(218)) and VI ((423)QRAGRAGR(430)) that diminished ATPase activity in vitro were lethal in vivo, indicating that ATP hydrolysis is necessary for the biological function of Prp43. Overexpression of lethal, ATPase-defective mutants in a wild-type strain resulted in dominant-negative growth inhibition. The ATPase-defective mutant T123A interfered in trans with the in vitro splicing function of wild-type Prp43. T123A did not affect the chemical steps of splicing or the release of mature mRNA from the spliceosome, but it blocked the release of the excised lariat-intron from the spliceosome. We show that the lariat-intron is not accessible to debranching by purified Dbr1 when it is held in the T123A-arrested splicing complex. Our results define a new ATP-dependent step of splicing that is catalyzed by Prp43.	Cornell Univ, Weill Med Coll, Dept Microbiol & Immunol, New York, NY 10021 USA	Cornell University	Schwer, B (corresponding author), Cornell Univ, Weill Med Coll, Dept Microbiol & Immunol, New York, NY 10021 USA.				NIGMS NIH HHS [GM50288] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050288] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANSARI A, 1995, EMBO J, V14, P4001, DOI 10.1002/j.1460-2075.1995.tb00071.x; ARENAS J, 1987, J BIOL CHEM, V262, P4274; Arenas JE, 1997, P NATL ACAD SCI USA, V94, P11798, DOI 10.1073/pnas.94.22.11798; BINDEREIF A, 1986, MOL CELL BIOL, V6, P2582, DOI 10.1128/MCB.6.7.2582; Burge CB, 1999, RNA WORLD, P525; Campodonico E, 2002, GENETICS, V160, P407; CHAPMAN KB, 1991, CELL, V65, P483, DOI 10.1016/0092-8674(91)90466-C; Chen JYF, 2001, MOL CELL, V7, P227, DOI 10.1016/S1097-2765(01)00170-8; de la Cruz J, 1999, TRENDS BIOCHEM SCI, V24, P192, DOI 10.1016/S0968-0004(99)01376-6; Edwalds-Gilbert G, 2000, RNA, V6, P1106, DOI 10.1017/S1355838200992483; Gee S, 1997, P NATL ACAD SCI USA, V94, P11803, DOI 10.1073/pnas.94.22.11803; Gross CH, 1998, J VIROL, V72, P4729, DOI 10.1128/JVI.72.6.4729-4736.1998; Hall MC, 1999, MOL MICROBIOL, V34, P867, DOI 10.1046/j.1365-2958.1999.01659.x; Heilek GM, 1997, J VIROL, V71, P6264, DOI 10.1128/JVI.71.8.6264-6266.1997; Hotz HR, 1998, GENETICS, V149, P807; Jankowsky E, 2000, NUCLEIC ACIDS RES, V28, P333, DOI 10.1093/nar/28.1.333; Jankowsky E, 2001, SCIENCE, V291, P121, DOI 10.1126/science.291.5501.121; KIM SH, 1993, P NATL ACAD SCI USA, V90, P888, DOI 10.1073/pnas.90.3.888; Kim SH, 1996, MOL CELL BIOL, V16, P6810; Kistler AL, 2001, GENE DEV, V15, P42, DOI 10.1101/gad.851301; KONARSKA MM, 1987, CELL, V49, P763, DOI 10.1016/0092-8674(87)90614-3; Linder P, 2000, YEAST, V16, P507, DOI 10.1002/(SICI)1097-0061(200004)16:6<507::AID-YEA549>3.0.CO;2-N; MADHANI HD, 1994, ANNU REV GENET, V28, P1; NILSEN TW, 1994, CELL, V78, P1, DOI 10.1016/0092-8674(94)90563-0; PAUSE A, 1992, EMBO J, V11, P2643, DOI 10.1002/j.1460-2075.1992.tb05330.x; Raghunathan PL, 1998, SCIENCE, V279, P857, DOI 10.1126/science.279.5352.857; RUSKIN B, 1985, SCIENCE, V229, P135, DOI 10.1126/science.2990042; Schneider S, 2001, J BIOL CHEM, V276, P21184, DOI 10.1074/jbc.M101964200; SCHNEIDER S, 2002, J BIOL CHEM     0220; Schwer B, 1998, EMBO J, V17, P2086, DOI 10.1093/emboj/17.7.2086; SCHWER B, 1991, NATURE, V349, P494, DOI 10.1038/349494a0; Schwer B, 2001, NAT STRUCT BIOL, V8, P113, DOI 10.1038/84091; Schwer B, 2000, EMBO J, V19, P6582, DOI 10.1093/emboj/19.23.6582; Staley JP, 1998, CELL, V92, P315, DOI 10.1016/S0092-8674(00)80925-3; Stevens SW, 2002, MOL CELL, V9, P31, DOI 10.1016/S1097-2765(02)00436-7; Tanner NK, 2001, MOL CELL, V8, P251, DOI 10.1016/S1097-2765(01)00329-X; VIJAYRAGHAVAN U, 1989, GENE DEV, V3, P1206, DOI 10.1101/gad.3.8.1206; Wagner JDO, 1998, EMBO J, V17, P2926, DOI 10.1093/emboj/17.10.2926; Wang Y, 1998, RNA, V4, P1216, DOI 10.1017/S1355838298980992	39	142	144	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 17	2002	277	20					17743	17750		10.1074/jbc.M200762200	http://dx.doi.org/10.1074/jbc.M200762200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	553PR	11886864	hybrid			2022-12-27	WOS:000175685100046
J	Montplaisir, V; Lan, NC; Guimond, J; Savineau, C; Bhat, PV; Mader, S				Montplaisir, V; Lan, NC; Guimond, J; Savineau, C; Bhat, PV; Mader, S			Recombinant class I aldehyde dehydrogenases specific for all-trans- or 9-cis-retinal	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXIDIZING ENZYME-ACTIVITY; RETINOIC ACID; ESCHERICHIA-COLI; RAT-KIDNEY; GENE-EXPRESSION; OXIDATION; CDNA; CLONING; PURIFICATION; STOMACH	The molecular basis for the specificity of aldehyde dehydrogenases (ALDHs) for retinal, the precursor of the morphogen retinoic acid, is still poorly understood. We have expressed in Escherichia coli both retinal dehydrogenase (RALDH), a cytosolic aldehyde dehydrogenase originally isolated from rat kidney, and the highly homologous phenobarbital-induced aldehyde dehydrogenase (PB-ALDH). Oxidation of propanal was observed with both enzymes. On the other hand, recombinant RALDH efficiently catalyzed oxidation of 9-cis- and all-trans-retinal, whereas PB-ALDH was inactive with all-trans-retinal and poorly active with 9-cis-retinal. A striking difference between PB-ALDH and all other class I ALDHs is the identity of the amino acid immediately preceding the active nucleophile Cys(302) (Ile(301) instead of Cys(301)). Nevertheless, these amino acids could be exchanged in either RALDH or PB-ALDH without affecting substrate specificity. Characterization of chimeric enzymes demonstrates that distinct groups of amino acids control the differential activity of RALDH and PB-ALDH with all-trans- and 9-cis-retinal. Of 52 divergent amino acids, the first 17 are crucial for activity with all-trans-retinal, whereas the next 25 are important for catalysis of 9-cis-retinal oxidation. Recombinant enzymes with specificity for all-trans- or 9-cis-retinal were obtained, which should provide useful tools to study the relative importance of local production of all-trans- versus 9-cis-retinoic acid in development and tissue differentiation.	Univ Montreal, Fac Med, Dept Biochem, Montreal, PQ H3R 3N2, Canada; Univ Montreal, Dept Med, Montreal, PQ H3R 3N2, Canada; CHUM Res Ctr, Lab Nutr & Canc, Montreal, PQ H2W 1T8, Canada	Universite de Montreal; Universite de Montreal; Universite de Montreal	Bhat, PV (corresponding author), Univ Montreal, Fac Med, Dept Biochem, CP6128 Succursale Ctr Ville, Montreal, PQ H3R 3N2, Canada.	bhatp@medclin.umontreal.ca; sylvie.mader@umontreal.ca						Bhat PV, 1998, BIOCHEM CELL BIOL, V76, P59, DOI 10.1139/bcb-76-1-59; Bhat PV, 1998, FEBS LETT, V426, P260, DOI 10.1016/S0014-5793(98)00355-X; Bhat PV, 1995, GENE, V166, P303, DOI 10.1016/0378-1119(96)81752-5; Bhat PV, 1998, J HISTOCHEM CYTOCHEM, V46, P1025, DOI 10.1177/002215549804600906; Bhat PV, 1996, BIOCHEM CELL BIOL, V74, P695, DOI 10.1139/o96-076; BHAT PV, 1988, BIOCHIM BIOPHYS ACTA, V967, P211, DOI 10.1016/0304-4165(88)90011-6; Bhat PV, 1998, FASEB J, V12, pA841; BHAT PV, 1988, BIOCHEM CELL BIOL, V66, P735, DOI 10.1139/o88-084; BHAT PV, 1998, BIOCHEM PHARMACOL, V57, P195; Blaner William S., 1994, P229; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; DE LUCA LM, 1991, FASEB J, V5, P2924; Duester G, 1996, BIOCHEMISTRY-US, V35, P12221, DOI 10.1021/bi961176+; DUNN TJ, 1989, J BIOL CHEM, V264, P13057; ELAKAWI Z, 1994, BIOCHEMISTRY-US, V33, P1938, DOI 10.1021/bi00173a042; Hsu LC, 1999, BIOCHEM J, V339, P387, DOI 10.1042/0264-6021:3390387; HSU LC, 1992, J BIOL CHEM, V267, P3030; Kathmann EC, 2000, BIOCHEMISTRY-US, V39, P11170, DOI 10.1021/bi001120m; LABRECQUE J, 1995, BIOCHEM J, V305, P681, DOI 10.1042/bj3050681; LABRECQUE J, 1993, BIOCHEM CELL BIOL, V71, P85, DOI 10.1139/o93-013; Lamb AL, 1999, BIOCHEMISTRY-US, V38, P6003, DOI 10.1021/bi9900471; LEE MO, 1991, BIOCHEM PHARMACOL, V42, P1279, DOI 10.1016/0006-2952(91)90266-8; Li HX, 2000, MECH DEVELOP, V95, P283, DOI 10.1016/S0925-4773(00)00352-X; LINDAHL R, 1984, J BIOL CHEM, V259, P1991; LINDAHL R, 1992, CRIT REV BIOCHEM MOL, V27, P283, DOI 10.3109/10409239209082565; Liu ZJ, 1997, NAT STRUCT BIOL, V4, P317, DOI 10.1038/nsb0497-317; Mangelsdorf David J., 1994, P319; Moore SA, 1998, STRUCTURE, V6, P1541, DOI 10.1016/S0969-2126(98)00152-X; Penzes P, 1997, BBA-PROTEIN STRUCT M, V1342, P175, DOI 10.1016/S0167-4838(97)00102-7; Perozich J, 1999, PROTEIN SCI, V8, P137, DOI 10.1110/ps.8.1.137; ROBERTS AB, 1984, RETINOIDS, V2, P209; SAARI JC, 1995, VISUAL NEUROSCI, V12, P263, DOI 10.1017/S095252380000794X; SMITH SM, 1989, DEVELOPMENT, V107, P121; Steinmetz CG, 1997, STRUCTURE, V5, P701, DOI 10.1016/S0969-2126(97)00224-4; Wang XS, 1996, J BIOL CHEM, V271, P16288, DOI 10.1074/jbc.271.27.16288; YOSHIDA A, 1992, ENZYME, V46, P239, DOI 10.1159/000468794; Zhao D, 1996, EUR J BIOCHEM, V240, P15, DOI 10.1111/j.1432-1033.1996.0015h.x	37	19	22	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 17	2002	277	20					17486	17492		10.1074/jbc.M112445200	http://dx.doi.org/10.1074/jbc.M112445200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	553PR	11882655	hybrid			2022-12-27	WOS:000175685100014
J	Seo, YW; Sanyal, S; Kim, HJ; Won, DH; An, JY; Amano, T; Zavacki, AM; Kwon, HB; Shi, YB; Kim, WS; Kang, H; Moore, DD; Choi, HS				Seo, YW; Sanyal, S; Kim, HJ; Won, DH; An, JY; Amano, T; Zavacki, AM; Kwon, HB; Shi, YB; Kim, WS; Kang, H; Moore, DD; Choi, HS			FOR, a novel orphan nuclear receptor related to farnesoid X receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HORMONE-RECEPTOR; RETINOIC ACID; BILE-ACIDS; GENE; IDENTIFICATION; BINDING; SUPERFAMILY; TRANSCRIPTION; MEMBER; SPECIFICITY	We have identified and characterized a new amphibian orphan member of the nuclear receptor superfamily and termed it FOR1 (farnesoid X receptor (EXR)-like Orphan Receptor) because it shares the highest amino acid identity with the mammalian FXR. We also identified a variant of FOR1, called FOR2, which has 15 additional C-terminal amino acids. Both variants include an unusual insertion of 33 amino acids in the helix 7 region of the canonical ligand binding domain sequence, suggesting a unique structure for FOR. Northern blot analysis demonstrates that the FOR gene is highly expressed in adult and tadpole liver, kidney, and tail bud stage of the embryo. Detailed expression analysis using in situ hybridization indicates that FOR expression is first detectable at stage 30/31 in the presumptive liver region lasting until stage 41 with a peak level evident at stage 35/36. FOR forms heterodimeric complexes with retinoid X receptor (RXR) as demonstrated by biochemical and mammalian two-hybrid approaches. Gel mobility shift assays demonstrate that FORs form specific DNA-protein complexes on an FXR binding element consisting of an inverted repeat DNA element with 1 nucleotide spacing (IR1) from the phospholipid transfer protein gene promoter. Finally, although FORs do not exhibit constitutive transcriptional activity, frog gallbladder extract significantly augments the transcriptional activities of FORs.	Chonnam Natl Univ, Hormone Res Ctr, Kwangju 500757, South Korea; Chonnam Natl Univ, Dept Biol, Kwangju 500757, South Korea; Sogang Univ, Dept Life Sci, Seoul 121742, South Korea; Seoul Natl Univ, Sch Earth & Environm Sci, Marine Biotechnol Lab, Seoul 151, South Korea; NICHHD, Mol Embryol Lab, NIH, Bethesda, MD 20892 USA; Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Thyroid, Boston, MA 02115 USA; Baylor Coll Med, Dept Cellular & Mol Biol, Houston, TX 77030 USA	Chonnam National University; Chonnam National University; Sogang University; Seoul National University (SNU); National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Harvard University; Brigham & Women's Hospital; Harvard Medical School; Baylor College of Medicine	Choi, HS (corresponding author), Chonnam Natl Univ, Hormone Res Ctr, Kwangju 500757, South Korea.		Sanyal, Sabyasachi/E-8034-2010	Sanyal, Sabyasachi/0000-0002-8603-3828; Shi, Yun-Bo/0000-0002-6330-0639	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD001901] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD001901] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BAES M, 1994, MOL CELL BIOL, V14, P1544, DOI 10.1128/MCB.14.3.1544; Chiang JYL, 2000, J BIOL CHEM, V275, P10918, DOI 10.1074/jbc.275.15.10918; DUMAS B, 1994, MOL ENDOCRINOL, V8, P996, DOI 10.1210/me.8.8.996; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FORMAN BM, 1995, CELL, V81, P687, DOI 10.1016/0092-8674(95)90530-8; GIGUERE V, 1994, ENDOCR REV, V15, P61, DOI 10.1210/er.15.1.61; GIGUERE V, 1988, NATURE, V331, P91, DOI 10.1038/331091a0; Giguere V, 1999, ENDOCR REV, V20, P689, DOI 10.1210/er.20.5.689; Goodwin B, 2000, MOL CELL, V6, P517, DOI 10.1016/S1097-2765(00)00051-4; Grober J, 1999, J BIOL CHEM, V274, P29749, DOI 10.1074/jbc.274.42.29749; HARLAND RM, 1991, METHOD CELL BIOL, V36, P685; Hong H, 1999, J BIOL CHEM, V274, P22618, DOI 10.1074/jbc.274.32.22618; JONES BB, 1995, MOL CELL BIOL, V15, P5226; KOSTROUCH Z, 1995, P NATL ACAD SCI USA, V92, P156, DOI 10.1073/pnas.92.1.156; Laffitte BA, 2000, J BIOL CHEM, V275, P10638, DOI 10.1074/jbc.275.14.10638; Lee HK, 1998, J BIOL CHEM, V273, P14398, DOI 10.1074/jbc.273.23.14398; Liang V C, 1997, Cell Res, V7, P179; Lu TT, 2000, MOL CELL, V6, P507, DOI 10.1016/S1097-2765(00)00050-2; Makishima M, 1999, SCIENCE, V284, P1362, DOI 10.1126/science.284.5418.1362; NIEWKOOP P.D., 1994, NORMAL TABLE XENOPUS; NOMA Y, 1980, J LIPID RES, V21, P339; Parker KL, 1998, MOL CELL ENDOCRINOL, V145, P15, DOI 10.1016/S0303-7207(98)00164-6; Parks DJ, 1999, SCIENCE, V284, P1365, DOI 10.1126/science.284.5418.1365; Seol W, 1996, SCIENCE, V272, P1336, DOI 10.1126/science.272.5266.1336; Seol W, 1997, MOL CELL BIOL, V17, P7126, DOI 10.1128/MCB.17.12.7126; SEOL WG, 1995, MOL ENDOCRINOL, V9, P72, DOI 10.1210/me.9.1.72; UBBELS GA, 1983, J EMBRYOL EXP MORPH, V77, P15; UMESONO K, 1989, CELL, V57, P1139, DOI 10.1016/0092-8674(89)90051-2; UNE M, 1980, J LIPID RES, V21, P269; Wang HB, 1999, MOL CELL, V3, P543, DOI 10.1016/S1097-2765(00)80348-2; WEINSTEIN DC, 1994, CELL, V78, P575, DOI 10.1016/0092-8674(94)90523-1; WORONICZ JD, 1994, NATURE, V367, P277, DOI 10.1038/367277a0; Yamagata K, 1996, NATURE, V384, P458, DOI 10.1038/384458a0; ZANARIA E, 1994, NATURE, V372, P635, DOI 10.1038/372635a0; Zavacki AM, 1997, P NATL ACAD SCI USA, V94, P7909, DOI 10.1073/pnas.94.15.7909	35	29	29	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 17	2002	277	20					17836	17844		10.1074/jbc.M111795200	http://dx.doi.org/10.1074/jbc.M111795200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	553PR	11867625	hybrid			2022-12-27	WOS:000175685100058
J	Watanabe, Y; Shiratsuchi, A; Shimizu, K; Takizawa, T; Nakanishi, Y				Watanabe, Y; Shiratsuchi, A; Shimizu, K; Takizawa, T; Nakanishi, Y			Role of phosphatidylserine exposure and sugar chain desialylation at the surface of influenza virus-infected cells in efficient phagocytosis by macrophages	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INFLUENZA-A/UDORN/72 H3N2 VIRUS; TEMPERATURE-SENSITIVE MUTANTS; APOPTOTIC CELLS; ENCODING GENE; DEATH KNELL; RECOGNITION; LYMPHOCYTES; CLEARANCE; RECEPTOR; PROTEIN	HeLa cells infected with influenza A virus undergo typical caspase-dependent apoptosis and are efficiently phagocytosed by mouse peritoneal macrophages in a manner mediated by the membrane phospholipid phosphatidylserine, which is translocated to the surface of virus-infected cells during apoptosis. However, the extent of phagocytosis is not always parallel with the level of phosphatidylserine externalization. Here we examined the involvement of influenza virus neuraminidase (NA) in efficient phagocytosis of virus-infected cells. HeLa cells infected with an influenza virus strain expressing temperature-sensitive NA underwent apoptosis and produced viral proteins, including the defective NA, at a non-permissive temperature to almost the same extent as cells infected with the wild-type virus. The cells were, however, phagocytosed by macrophages with reduced efficiency. In addition, phagocytosis of cells infected with the wild-type virus was severely inhibited when the cells had been maintained in the presence of the NA inhibitor zanamivir. On the other hand, the binding of sialic acid-recognizing lectins to the cell surface declined after infection with the wild-type virus. The decrease in the extent of lectin binding was greatly attenuated when cells were infected with the mutant virus or when wild-type virus-infected cells were maintained in the presence of zanamivir. These results indicate that sugar chains are desialylated by NA at the surface of virus-infected cells. We conclude that the presence of both phosphatidylserine and asialoglycomoieties on the cell surface is required for efficient phagocytosis of influenza virus-infected cells by macrophages.	Kanazawa Univ, Grad Sch Med Sci, Kanazawa, Ishikawa 9200934, Japan; Nihon Univ, Sch Med, Itabashi Ku, Tokyo 1738610, Japan; Aichi Human Serv Ctr, Inst Dev Res, Aichi 4800392, Japan	Kanazawa University; Nihon University	Nakanishi, Y (corresponding author), Kanazawa Univ, Grad Sch Med Sci, 13-1 Takara Machi, Kanazawa, Ishikawa 9200934, Japan.		Nakanishi, Yoshinobu/D-4602-2014; Shiratsuchi, Akiko/D-8391-2015	Nakanishi, Yoshinobu/0000-0002-8767-3587; Shiratsuchi, Akiko/0000-0002-7811-4409				Albert ML, 1998, NATURE, V392, P86, DOI 10.1038/32183; Albert ML, 1998, J EXP MED, V188, P1359, DOI 10.1084/jem.188.7.1359; AMINOFF D, 1961, BIOCHEM J, V81, P384, DOI 10.1042/bj0810384; Chen WS, 2001, NAT MED, V7, P1306, DOI 10.1038/nm1201-1306; Chimini G, 2001, CELL DEATH DIFFER, V8, P545, DOI 10.1038/sj.cdd.4400833; DINI L, 1992, FEBS LETT, V296, P174, DOI 10.1016/0014-5793(92)80373-O; ELLIS RE, 1991, ANNU REV CELL BIOL, V7, P663, DOI 10.1146/annurev.cb.07.110191.003311; Fadok VA, 2000, NATURE, V405, P85, DOI 10.1038/35011084; Fadok VA, 2001, J BIOL CHEM, V276, P1071, DOI 10.1074/jbc.M003649200; FADOK VA, 1992, J IMMUNOL, V148, P2207; Fadok VA, 1998, CELL DEATH DIFFER, V5, P551, DOI 10.1038/sj.cdd.4400404; Fadok VA, 2001, CELL DEATH DIFFER, V8, P582, DOI 10.1038/sj.cdd.4400856; Falasca L, 1996, EXP CELL RES, V224, P152, DOI 10.1006/excr.1996.0123; Fujii C, 2001, CELL DEATH DIFFER, V8, P1113, DOI 10.1038/sj.cdd.4400920; Fujimoto I, 1998, CELL DEATH DIFFER, V5, P426, DOI 10.1038/sj.cdd.4400362; Fujimoto I, 2000, J VIROL, V74, P3399, DOI 10.1128/JVI.74.7.3399-3403.2000; Granville DJ, 1998, CELL DEATH DIFFER, V5, P653, DOI 10.1038/sj.cdd.4400388; Henson PM, 2001, CURR BIOL, V11, pR795, DOI 10.1016/S0960-9822(01)00474-2; Hoffmann PR, 2001, J CELL BIOL, V155, P649, DOI 10.1083/jcb.200108080; KOOPMAN G, 1994, BLOOD, V84, P1415, DOI 10.1182/blood.V84.5.1415.1415; Martin Seamus J., 1996, P107; Morris SJ, 1999, J GEN VIROL, V80, P137, DOI 10.1099/0022-1317-80-1-137; Pradhan D, 1997, MOL BIOL CELL, V8, P767, DOI 10.1091/mbc.8.5.767; Ren Y, 1998, CELL DEATH DIFFER, V5, P563, DOI 10.1038/sj.cdd.4400407; Savill J, 2000, NATURE, V407, P784, DOI 10.1038/35037722; Savill J, 1997, BRIT MED BULL, V53, P491; Schagat TL, 2001, J IMMUNOL, V166, P2727, DOI 10.4049/jimmunol.166.4.2727; Schlegel RA, 1999, CELL DEATH DIFFER, V6, P583, DOI 10.1038/sj.cdd.4400529; Schlegel RA, 2001, CELL DEATH DIFFER, V8, P551, DOI 10.1038/sj.cdd.4400817; Schultz-Cherry S, 2001, J VIROL, V75, P7875, DOI 10.1128/JVI.75.17.7875-7881.2001; Scott CB, 1996, J IMMUNOL, V157, P351; SHIMIZU K, 1974, VIROLOGY, V62, P90, DOI 10.1016/0042-6822(74)90305-5; SHIMIZU K, 1985, VACCINE, V3, P207, DOI 10.1016/0264-410X(85)90107-0; SHIMIZU K, 1982, VIROLOGY, V117, P45, DOI 10.1016/0042-6822(82)90506-2; SHIMIZU K, 1982, VIROLOGY, V117, P38, DOI 10.1016/0042-6822(82)90505-0; SHIMIZU K, 1984, SEGMENTED NEGATIVE S, P387; SHIMIZU K, 1981, REPLICATION NEGATIVE, P369; Shiratsuchi A, 2000, J VIROL, V74, P9240, DOI 10.1128/JVI.74.19.9240-9244.2000; Shiratsuchi A, 1998, BIOCHEM BIOPH RES CO, V246, P549, DOI 10.1006/bbrc.1998.8663; Shiratsuchi A, 1997, J BIOL CHEM, V272, P2354, DOI 10.1074/jbc.272.4.2354; TAKIZAWA T, 1995, VIROLOGY, V209, P288, DOI 10.1006/viro.1995.1260; TAKIZAWA T, 1993, J GEN VIROL, V74, P2347, DOI 10.1099/0022-1317-74-11-2347; Teodoro JG, 1997, J VIROL, V71, P1739, DOI 10.1128/JVI.71.3.1739-1746.1997; VONITZSTEIN M, 1993, NATURE, V363, P418, DOI 10.1038/363418a0; WADA N, 1995, J BIOL CHEM, V270, P18007, DOI 10.1074/jbc.270.30.18007; WILLIAMSON P, 1994, MOL MEMBR BIOL, V11, P199, DOI 10.3109/09687689409160430; Wyllie A H, 1980, Int Rev Cytol, V68, P251; ZACHOWSKI A, 1993, BIOCHEM J, V294, P1; Zhirnov OP, 2002, J VIROL, V76, P1617, DOI 10.1128/JVI.76.4.1617-1625.2002	49	39	41	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 17	2002	277	20					18222	18228		10.1074/jbc.M201074200	http://dx.doi.org/10.1074/jbc.M201074200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	553PR	11884410	hybrid, Green Submitted			2022-12-27	WOS:000175685100105
J	Anzai, N; Deval, E; Schaefer, L; Friend, V; Lazdunski, M; Lingueglia, E				Anzai, N; Deval, E; Schaefer, L; Friend, V; Lazdunski, M; Lingueglia, E			The multivalent PDZ domain-containing protein CIPP is a partner of acid-sensing ion channel 3 in sensory neurons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GATED NA+ CHANNEL; MUTATIONS CAUSING NEURODEGENERATION; MAMMALIAN DEGENERIN MDEG; CATION CHANNEL; CAENORHABDITIS-ELEGANS; MOLECULAR-CLONING; FAMILY; EXPRESSION; RECEPTOR; ISCHEMIA	Acid-sensing ion channels (ASICs) are cationic channels activated by extracellular pH. They are present in the brain, where they are thought to participate in signal transduction associated with local pH variations, and in sensory neurons, where they have been involved in pain perception associated with tissue acidosis and in mechanoperception. The ASIC3 subunit is mainly expressed in dorsal root ganglion neurons. Its expression is associated with a rapidly inactivating current followed by a slowly activating sustained current thought to be required for the tonic sensation of pain caused by acids. We report here the interaction of this channel subunit with the multivalent PDZ (PSD-95 Drosophila discs-large protein, Zonula occludens protein 1) domain-containing protein CIPP. This interaction requires the C-terminal region of ASIC3 and the fourth PDZ domain of CIPP. Co-expression of CIPP and ASIC3 in COS cells increases the maximal ASIC3 peak current density by a factor of 5 and slightly shifts the pH(0.5) for activation from pH 6.2 to pH 6.4. CIPP mRNA is found at a significant level in the same dorsal root ganglion neuronal cell population that expresses the ASIC3 subunit, i.e. mainly in the small nociceptive neurons. CIPP is thus a scaffolding protein that could both enhance the surface expression of ASIC3 and bring together ASIC3 and functionally related proteins in the membrane of sensory neurons.	Inst Pharmacol Mol & Cellulaire, CNRS, UMR 6097, F-06560 Valbonne, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur	Lazdunski, M (corresponding author), Inst Pharmacol Mol & Cellulaire, CNRS, UMR 6097, 660 Route Lucioles, F-06560 Valbonne, France.		LINGUEGLIA, Eric/F-5509-2013; ANZAI, NAOHIKO/K-9492-2017; DEVAL, Emmanuel/N-6280-2016	LINGUEGLIA, Eric/0000-0003-3902-3405; ANZAI, NAOHIKO/0000-0003-0605-0458; DEVAL, Emmanuel/0000-0002-0215-9379				Akopian AN, 2000, NEUROREPORT, V11, P2217, DOI 10.1097/00001756-200007140-00031; Babinski K, 1999, J NEUROCHEM, V72, P51, DOI 10.1046/j.1471-4159.1999.0720051.x; Babinski K, 2000, J BIOL CHEM, V275, P28519, DOI 10.1074/jbc.M004114200; BARON A, 2002, J PHYSL, P485; Bassilana F, 1997, J BIOL CHEM, V272, P28819, DOI 10.1074/jbc.272.46.28819; Bassler EL, 2001, J BIOL CHEM, V276, P33782, DOI 10.1074/jbc.M104030200; Benson CJ, 1999, CIRC RES, V84, P921; Cao TT, 1999, NATURE, V401, P286, DOI 10.1038/45816; Champigny G, 1998, J BIOL CHEM, V273, P15418, DOI 10.1074/jbc.273.25.15418; Chen CC, 1998, P NATL ACAD SCI USA, V95, P10240, DOI 10.1073/pnas.95.17.10240; CHESLER M, 1992, TRENDS NEUROSCI, V15, P396, DOI 10.1016/0166-2236(92)90191-A; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; de Weille JR, 1998, FEBS LETT, V433, P257, DOI 10.1016/S0014-5793(98)00916-8; DeVries SH, 2001, NEURON, V32, P1107, DOI 10.1016/S0896-6273(01)00535-9; Duggan A, 2002, J BIOL CHEM, V277, P5203, DOI 10.1074/jbc.M104748200; Escoubas P, 2000, J BIOL CHEM, V275, P25116, DOI 10.1074/jbc.M003643200; Fernandez-Larrea J, 1999, MOL CELL, V3, P423, DOI 10.1016/S1097-2765(00)80470-0; GarciaAnoveros J, 1997, P NATL ACAD SCI USA, V94, P1459, DOI 10.1073/pnas.94.4.1459; Garner CC, 2000, TRENDS CELL BIOL, V10, P274, DOI 10.1016/S0962-8924(00)01783-9; GOLEMIS EA, 1997, YEAST 2 HYBRID SYSTE; Grunder S, 2000, NEUROREPORT, V11, P1607; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Immke DC, 2001, NAT NEUROSCI, V4, P869, DOI 10.1038/nn0901-869; Kurschner C, 1998, MOL CELL NEUROSCI, V11, P161, DOI 10.1006/mcne.1998.0679; Lingueglia E, 1997, J BIOL CHEM, V272, P29778, DOI 10.1074/jbc.272.47.29778; Pan HL, 1999, J PHYSIOL-LONDON, V518, P857, DOI 10.1111/j.1469-7793.1999.0857p.x; Price MP, 1996, J BIOL CHEM, V271, P7879, DOI 10.1074/jbc.271.14.7879; Price MP, 2001, NEURON, V32, P1071, DOI 10.1016/S0896-6273(01)00547-5; Reeh PW, 1996, PROG BRAIN RES, V113, P143, DOI 10.1016/S0079-6123(08)61085-7; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; Sutherland SP, 2001, P NATL ACAD SCI USA, V98, P711, DOI 10.1073/pnas.011404498; Traynelis SF, 2001, NEURON, V32, P960, DOI 10.1016/S0896-6273(01)00549-9; Voilley N, 2001, J NEUROSCI, V21, P8026, DOI 10.1523/JNEUROSCI.21-20-08026.2001; Waldmann R, 1997, J BIOL CHEM, V272, P20975, DOI 10.1074/jbc.272.34.20975; Waldmann R, 1996, J BIOL CHEM, V271, P10433, DOI 10.1074/jbc.271.18.10433; Waldmann R, 1999, ANN NY ACAD SCI, V868, P67, DOI 10.1111/j.1749-6632.1999.tb11274.x; Waldmann R, 1997, NATURE, V386, P173, DOI 10.1038/386173a0; Waldmann R, 1998, CURR OPIN NEUROBIOL, V8, P418, DOI 10.1016/S0959-4388(98)80070-6	38	61	62	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 10	2002	277	19					16655	16661		10.1074/jbc.M201087200	http://dx.doi.org/10.1074/jbc.M201087200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	551MB	11872753	hybrid			2022-12-27	WOS:000175564500043
J	Han, ZY; Wei, WY; Dunaway, S; Darnowski, JW; Calabresi, P; Sedivy, J; Hendrickson, EA; Balan, KV; Pantazis, P; Wyche, JH				Han, ZY; Wei, WY; Dunaway, S; Darnowski, JW; Calabresi, P; Sedivy, J; Hendrickson, EA; Balan, KV; Pantazis, P; Wyche, JH			Role of p21 in apoptosis and senescence of human colon cancer cells treated with camptothecin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-DIPLOID FIBROBLASTS; BCL-2 FAMILY PROTEINS; DNA-DAMAGE; REPLICATIVE SENESCENCE; ANTICANCER AGENTS; GENE-EXPRESSION; IN-VIVO; CELLULAR SENESCENCE; DRUG DEVELOPMENT; GROWTH ARREST	Treatment of cells with the anti-cancer drug camptothecin (CPT) induces topoisomerase I (Top1)-mediated DNA damage, which in turn affects cell proliferation and survival. In this report, we demonstrate that treatment of the wild-type HCT116 (wt HCT116) human colon cancer cell line and the isogenic p53(-/-) HCT116 and p21(-/-) HCT116 cell lines with a high concentration (250 nM) of CPT resulted in apoptosis, indicating that apoptosis occurred by a p53- and p21-independent mechanism. In contrast, treatment with a low concentration (20 nM) of CPT induced cell cycle arrest and senescence of the wt HCT116 cells, but apoptosis of the p53(-/-) HCT116 and p21(-/-) HCT116 cells. Further investigations indicated that p53-dependent expression of p21 blocked apoptosis of wt HCT116 cells treated with 20 nM, but not 250 nM CPT. Interestingly, blocking of the apoptotic pathway, by Z-VAD-FMK, in p21(-/-) HCT116 cells following treatment with 20 nM CPT did not permit the cells to develop properties of senescence. These observations demonstrated that p21 was required for senescence development of HCT116 cells following treatment with low concentrations of CPT.	Brown Univ, Dept Mol Biol Cell Biol & Biochem, Providence, RI 02912 USA; Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Pharmacol, Piscataway, NJ 08854 USA; Rhode Isl Hosp, Dept Clin Pharmacol, Providence, RI 02903 USA; Univ Minnesota, Sch Med, Dept Biochem Mol Biol & Biophys, Minneapolis, MN 55455 USA	Brown University; Rutgers State University New Brunswick; Rutgers State University Medical Center; Lifespan Health Rhode Island; Rhode Island Hospital; University of Minnesota System; University of Minnesota Twin Cities	Han, ZY (corresponding author), Brown Univ, Dept MCB, Rm 130,69 Brown St, Providence, RI 02912 USA.		Balan, Kannan/P-8892-2015		NIAID NIH HHS [AI35763] Funding Source: Medline; NIA NIH HHS [AG16694] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI035763] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R37AG016694, R01AG016694] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Alcorta DA, 1996, P NATL ACAD SCI USA, V93, P13742, DOI 10.1073/pnas.93.24.13742; Bartek J, 2001, FEBS LETT, V490, P117, DOI 10.1016/S0014-5793(01)02114-7; BAYREUTHER K, 1988, P NATL ACAD SCI USA, V85, P5112, DOI 10.1073/pnas.85.14.5112; Brown JM, 1999, CANCER RES, V59, P1391; Brown JP, 1997, SCIENCE, V277, P831, DOI 10.1126/science.277.5327.831; Bunz F, 1999, J CLIN INVEST, V104, P263, DOI 10.1172/JCI6863; Bunz F, 1998, SCIENCE, V282, P1497, DOI 10.1126/science.282.5393.1497; Chang BD, 1999, ONCOGENE, V18, P4808, DOI 10.1038/sj.onc.1203078; Chang BD, 2000, P NATL ACAD SCI USA, V97, P4291, DOI 10.1073/pnas.97.8.4291; Chen QM, 1998, BIOCHEM J, V332, P43, DOI 10.1042/bj3320043; Colman MS, 2000, MUTAT RES-REV MUTAT, V462, P179, DOI 10.1016/S1383-5742(00)00035-1; Cristofalo VJ, 1996, EXP GERONTOL, V31, P111, DOI 10.1016/0531-5565(95)02018-7; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; Dimri GP, 2000, MOL CELL BIOL, V20, P273, DOI 10.1128/MCB.20.1.273-285.2000; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; DIMRI GP, 1994, J BIOL CHEM, V269, P16180; Eisenhauer EA, 1997, ANN ONCOL, V8, P963, DOI 10.1023/A:1008240421028; Gelmon KA, 1999, J NATL CANCER I, V91, P1281, DOI 10.1093/jnci/91.15.1281; Gerrits CJH, 1997, BRIT J CANCER, V76, P952, DOI 10.1038/bjc.1997.491; GOLDSTEIN S, 1990, SCIENCE, V249, P1129, DOI 10.1126/science.2204114; Good LF, 1996, J CELL PHYSIOL, V168, P580, DOI 10.1002/(SICI)1097-4652(199609)168:3<580::AID-JCP10>3.0.CO;2-3; Han ZY, 2001, J BIOL CHEM, V276, P38748, DOI 10.1074/jbc.M106214200; Han ZY, 1996, CANCER RES, V56, P1621; Herben VMM, 1997, BRIT J CANCER, V76, P1500, DOI 10.1038/bjc.1997.585; HICKMAN JA, 1994, PHILOS T ROY SOC B, V345, P319, DOI 10.1098/rstb.1994.0112; HOCHSTER H, 1994, J CLIN ONCOL, V12, P553, DOI 10.1200/JCO.1994.12.3.553; Huang YY, 1997, CANCER RES, V57, P3640; Huang ZW, 2000, ONCOGENE, V19, P6627, DOI 10.1038/sj.onc.1204087; ISHIZAKI Y, 1993, J CELL BIOL, V121, P899, DOI 10.1083/jcb.121.4.899; Itahana K, 2001, EUR J BIOCHEM, V268, P2784, DOI 10.1046/j.1432-1327.2001.02228.x; JACOBSON MD, 1994, BIOCHEM SOC T, V22, P600, DOI 10.1042/bst0220600; Jeggo PA, 1998, TRENDS GENET, V14, P312, DOI 10.1016/S0168-9525(98)01511-X; Kaufmann SH, 1998, BBA-GENE STRUCT EXPR, V1400, P195, DOI 10.1016/S0167-4781(98)00136-5; KAUFMANN WK, 1991, MOL CELL BIOL, V11, P3711, DOI 10.1128/MCB.11.7.3711; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; LEVIN MF, 1999, INT J RADIAT BIOL, V75, P1201; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Lin WC, 2001, GENE DEV, V15, P1833; Liu LF, 2000, ANN NY ACAD SCI, V922, P1; Lowe Scott W., 1995, Current Opinion in Oncology, V7, P547, DOI 10.1097/00001622-199511000-00013; LOWE SW, 1993, CELL, V74, P957, DOI 10.1016/0092-8674(93)90719-7; Makin G, 2001, TRENDS CELL BIOL, V11, pS22, DOI 10.1016/S0962-8924(01)82111-5; McConnell BB, 1998, CURR BIOL, V8, P351, DOI 10.1016/S0960-9822(98)70137-X; McGill G., 1997, FRONT BIOSCI, V2, P353; Mohamood AS, 1997, J SUBMICR CYTOL PATH, V29, P1; Morgan SE, 1997, ADV CANCER RES, V71, P1, DOI 10.1016/S0065-230X(08)60095-0; Mullauer L, 2001, MUTAT RES-REV MUTAT, V488, P211, DOI 10.1016/S1383-5742(01)00057-6; Nip J, 1997, MOL CELL BIOL, V17, P1049, DOI 10.1128/MCB.17.3.1049; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; O'Leary J, 1998, EUR J CANCER, V34, P1500, DOI 10.1016/S0959-8049(98)00229-9; Ogryzko VV, 1996, MOL CELL BIOL, V16, P5210; PANTAZIS P, 1994, CANCER RES, V54, P771; Phillips AC, 1999, MOL CELL, V4, P771, DOI 10.1016/S1097-2765(00)80387-1; Preston TJ, 2001, ADV DRUG DELIVER REV, V49, P45, DOI 10.1016/S0169-409X(01)00127-2; Reed JC, 2001, TRENDS MOL MED, V7, P314, DOI 10.1016/S1471-4914(01)02026-3; Reed JC, 1996, J CELL BIOCHEM, V60, P23, DOI 10.1002/(SICI)1097-4644(19960101)60:1<23::AID-JCB5>3.3.CO;2-3; Reed JC, 2000, CURR OPIN BIOTECH, V11, P586, DOI 10.1016/S0958-1669(00)00148-8; RICHTER KH, 1991, CANCER RES, V51, P6010; Robles SJ, 1998, ONCOGENE, V16, P1113, DOI 10.1038/sj.onc.1201862; Sarraj S, 2001, EXP CELL RES, V270, P268, DOI 10.1006/excr.2001.5352; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Severino J, 2000, EXP CELL RES, V257, P162, DOI 10.1006/excr.2000.4875; SLICHENMYER WJ, 1993, CANCER RES, V53, P4164; Smith JR, 1996, SCIENCE, V273, P63, DOI 10.1126/science.273.5271.63; Stein GH, 1999, MOL CELL BIOL, V19, P2109; STEIN GH, 1990, SCIENCE, V249, P666, DOI 10.1126/science.2166342; Suzuki K, 2001, RADIAT RES, V155, P248, DOI 10.1667/0033-7587(2001)155[0248:RISLGA]2.0.CO;2; TAHARA H, 1995, ONCOGENE, V10, P835; Taylor WR, 2001, ONCOGENE, V20, P1803, DOI 10.1038/sj.onc.1204252; Vaziri H, 1999, ONCOGENE, V18, P7676, DOI 10.1038/sj.onc.1203016; WALDMAN T, 1995, CANCER RES, V55, P5187; Waldman T, 1996, NATURE, V381, P713, DOI 10.1038/381713a0; Wei WY, 2001, MOL CELL BIOL, V21, P6748, DOI 10.1128/MCB.21.20.6748-6757.2001; Wei WY, 1999, EXP CELL RES, V253, P519, DOI 10.1006/excr.1999.4665; Weil M, 1996, J CELL BIOL, V133, P1053, DOI 10.1083/jcb.133.5.1053; Wong H, 1996, EXP GERONTOL, V31, P311, DOI 10.1016/0531-5565(95)00025-9; WynfordThomas D, 1996, J PATHOL, V180, P118, DOI 10.1002/(SICI)1096-9896(199610)180:2<118::AID-PATH673>3.0.CO;2-I; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0	78	209	221	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 10	2002	277	19					17154	17160		10.1074/jbc.M112401200	http://dx.doi.org/10.1074/jbc.M112401200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	551MB	11877436	hybrid			2022-12-27	WOS:000175564500108
J	Khan, NA; Wang, Y; Kim, KJ; Chung, JW; Wass, CA; Kim, KS				Khan, NA; Wang, Y; Kim, KJ; Chung, JW; Wass, CA; Kim, KS			Cytotoxic necrotizing factor-1 contributes to Escherichia coli K1 invasion of the central nervous system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MICROVASCULAR ENDOTHELIAL-CELLS; FOCAL ADHESION KINASE; MEMBRANE PROTEIN-A; FACTOR-I; ACTIN CYTOSKELETON; EXTRAINTESTINAL INFECTIONS; INDUCED ACTIVATION; FACTOR TYPE-1; GENE LOCUS; RHO	Escherichia coli K1 invasion of brain microvascular endothelial cells (BMECs) is a prerequisite for penetration into the central nervous system and requires actin cytoskeletal rearrangements. Here, we demonstrate that E. coli K1 invasion of BMECs requires RhoA activation. In addition, we show that cytotoxic necrotizing factor-1 (CNF1) contributes to E. coli K1 invasion of brain endothelial cells in vitro and traversal of the blood-brain barrier in the experimental hematogenous meningitis animal model. These in vitro and in vivo effects of CNF1 were dependent upon RhoA activation as shown by (a) decreased invasion and RhoA activation with the Deltacnf1 mutant of E. coli K1 and (b) restoration of invasion frequency of the Deltacnf1 mutant to the level of the parent E. coli K1 strain in BMECs with constitutively active RhoA. In addition, CNF1-enhanced E. coli invasion of brain endothelial cells and stress fiber formation were independent of focal adhesion kinase and phosphatidylinositol 3-kinase activation. This is the first demonstration that CNF1 contributes to E. coli K1 invasion of BMECs.	Johns Hopkins Univ, Sch Med, Div Pediat Infect Dis, Baltimore, MD 21287 USA; Univ So Calif, Childrens Hosp Los Angeles, Sch Med, Div Infect Dis, Los Angeles, CA 90027 USA	Johns Hopkins University; Children's Hospital Los Angeles; University of Southern California	Kim, KS (corresponding author), Johns Hopkins Univ, Sch Med, Div Pediat Infect Dis, 600 N Wolfe St,Pk 256, Baltimore, MD 21287 USA.	kwangkim@jhmi.edu	khan, Naveed Ahmed/F-2478-2015; Khan, Naveed/AAM-2892-2021; Khan, Naveed/AAJ-5377-2020	Khan, Naveed/0000-0001-7667-8553; Khan, Naveed/0000-0001-7667-8553	NHLBI NIH HHS [HL 61951] Funding Source: Medline; NIAID NIH HHS [AI 47225] Funding Source: Medline; NINDS NIH HHS [NS 26310] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL061951] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI047225] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS026310, R56NS026310] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Badger JL, 2000, INFECT IMMUN, V68, P5056, DOI 10.1128/IAI.68.9.5056-5061.2000; Badger JL, 1999, INFECT IMMUN, V67, P4208, DOI 10.1128/IAI.67.8.4208-4215.1999; Bodie SL, 2001, BIOCHEM BIOPH RES CO, V287, P71, DOI 10.1006/bbrc.2001.5547; Cantrell DA, 2001, J CELL SCI, V114, P1439; CAPRIOLI A, 1987, J CLIN MICROBIOL, V25, P146, DOI 10.1128/JCM.25.1.146-149.1987; CAPRIOLI A, 1983, INFECT IMMUN, V39, P1300, DOI 10.1128/IAI.39.3.1300-1306.1983; FALBO V, 1992, INFECT IMMUN, V60, P2182, DOI 10.1128/IAI.60.6.2182-2187.1992; FALBO V, 1993, INFECT IMMUN, V61, P4909, DOI 10.1128/IAI.61.11.4909-4914.1993; FALZANO L, 1993, MOL MICROBIOL, V9, P1247, DOI 10.1111/j.1365-2958.1993.tb01254.x; Fiorentini C, 1997, BIOCHEM BIOPH RES CO, V241, P341, DOI 10.1006/bbrc.1997.7723; Flatau G, 1997, NATURE, V387, P729, DOI 10.1038/42743; Fournout S, 2000, INFECT IMMUN, V68, P839, DOI 10.1128/IAI.68.2.839-847.2000; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Hoffman JA, 2000, INFECT IMMUN, V68, P5062, DOI 10.1128/IAI.68.9.5062-5067.2000; HUANG SH, 1995, INFECT IMMUN, V63, P4470, DOI 10.1128/IAI.63.11.4470-4475.1995; Huang SH, 1999, INFECT IMMUN, V67, P2103, DOI 10.1128/IAI.67.5.2103-2109.1999; Jin SH, 2000, BIOCHEM BIOPH RES CO, V277, P718, DOI 10.1006/bbrc.2000.3744; Johnson DE, 2000, FEMS IMMUNOL MED MIC, V28, P37, DOI 10.1111/j.1574-695X.2000.tb01454.x; KHOSRAVIFAR R, 1995, MOL CELL BIOL, V15, P6443; Kim K S, 2000, Subcell Biochem, V33, P47; KIM KS, 1992, J CLIN INVEST, V90, P897, DOI 10.1172/JCI115965; Lacerda HM, 1997, J BIOL CHEM, V272, P9587; Maekawa M, 1999, SCIENCE, V285, P895, DOI 10.1126/science.285.5429.895; Matsui T, 1998, J CELL BIOL, V140, P647, DOI 10.1083/jcb.140.3.647; Nizet V, 1997, INFECT IMMUN, V65, P5074, DOI 10.1128/IAI.65.12.5074-5081.1997; Prasadarao NV, 1999, INFECT IMMUN, V67, P5775, DOI 10.1128/IAI.67.11.5775-5783.1999; Prasadarao NV, 1999, INFECT IMMUN, V67, P1131, DOI 10.1128/IAI.67.3.1131-1138.1999; Prasadarao NV, 1996, INFECT IMMUN, V64, P146, DOI 10.1128/IAI.64.1.146-153.1996; Reddy MA, 2000, INFECT IMMUN, V68, P6423, DOI 10.1128/IAI.68.11.6423-6430.2000; Reddy MA, 2000, J BIOL CHEM, V275, P36769, DOI 10.1074/jbc.M007382200; Reif K, 1996, CURR BIOL, V6, P1445, DOI 10.1016/S0960-9822(96)00749-X; Rippere-Lampe KE, 2001, INFECT IMMUN, V69, P3954, DOI 10.1128/IAI.69.6.3954-3964.2001; Schmidt G, 1997, NATURE, V387, P725, DOI 10.1038/42735; Stins MF, 1997, J NEUROIMMUNOL, V76, P81, DOI 10.1016/S0165-5728(97)00036-2; TAYLOR RK, 1989, J BACTERIOL, V171, P1870, DOI 10.1128/jb.171.4.1870-1878.1989; Tzima E, 2001, EMBO J, V20, P4639, DOI 10.1093/emboj/20.17.4639; Vouret-Craviari V, 1999, INFECT IMMUN, V67, P3002, DOI 10.1128/IAI.67.6.3002-3008.1999; Wang Y, 1999, INFECT IMMUN, V67, P4751, DOI 10.1128/IAI.67.9.4751-4756.1999; Wymann MP, 1998, BBA-MOL CELL BIOL L, V1436, P127, DOI 10.1016/S0005-2760(98)00139-8	39	123	128	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 3	2002	277	18					15607	15612		10.1074/jbc.M112224200	http://dx.doi.org/10.1074/jbc.M112224200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	550PA	11877402	hybrid			2022-12-27	WOS:000175510400053
J	Petropoulos, H; Skerjanc, IS				Petropoulos, H; Skerjanc, IS			beta-catenin is essential and sufficient for skeletal Myogenesis in P19 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EMBRYONAL CARCINOMA-CELLS; DORSAL NEURAL-TUBE; PARAXIAL MESODERM; MUSCLE DEVELOPMENT; AXIS FORMATION; SIGNAL-TRANSDUCTION; WNT/BETA-CATENIN; GENE-EXPRESSION; MOUSE EMBRYOS; INDUCTION	Wnt1 and Wnt3a are signaling factors known to play a role in the induction of myogenesis in the myotome of the differentiating somite. Both factors may transduce their signal by a conserved pathway that leads to transcriptional regulation by beta-catenin/Lef1. beta-Catenin and Lef1 are found in the myotome prior to MyoD expression. We have utilized the P19 cell system to study the mechanisms by which Wnt3a may activate MyoD expression and subsequent skeletal muscle development. We have isolated P19 cell lines that stably express either Wnt3a or activated beta-catenin and found that aggregation of these cells results in the induction of myogenesis compared with control cells. Pax3, Gli2, Mox1, and Six1 were expressed during Wnt3a and beta-catenin-induced differentiation prior to MyoD expression. Furthermore, we have shown that the nuclear function of beta-catenin was essential for skeletal myogenesis in P19 cells by overexpression of a dominant negative beta-catenin/engrailed chimera. Primitive streak factors were present, but expression of Pax3, Mox1, Gli2, and Six1 was lost in these cells, indicating that nuclear beta-catenin is essential for specification of mesodermal precursors to the myogenic lineage. Therefore, Wnt signaling, acting via beta-catenin, is necessary and sufficient for skeletal myogenesis in P19 cells.	Univ Western Ontario, Dept Biochem, London, ON N6A 5C1, Canada	Western University (University of Western Ontario)	Skerjanc, IS (corresponding author), Univ Western Ontario, Dept Biochem, Med Sci Bldg, London, ON N6A 5C1, Canada.		Skerjanc, Ilona/AAN-3318-2020					ADRA CN, 1987, GENE, V60, P65, DOI 10.1016/0378-1119(87)90214-9; Angello JC, 1997, DEV BIOL, V192, P93, DOI 10.1006/dbio.1997.8722; Arnold SJ, 2000, MECH DEVELOP, V91, P249, DOI 10.1016/S0925-4773(99)00309-3; BADER D, 1982, J CELL BIOL, V95, P763, DOI 10.1083/jcb.95.3.763; Bailey P, 2001, CURR OPIN CELL BIOL, V13, P679, DOI 10.1016/S0955-0674(00)00271-4; Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0; Borello U, 1999, DEVELOPMENT, V126, P4247; Borycki AG, 2000, DEVELOPMENT, V127, P2075; Borycki AG, 2000, CURR TOP DEV BIOL, V48, P165; Boutros M, 1998, CELL, V94, P109, DOI 10.1016/S0092-8674(00)81226-X; Buckingham M, 2001, CURR OPIN GENET DEV, V11, P440, DOI 10.1016/S0959-437X(00)00215-X; CANDIA AF, 1992, DEVELOPMENT, V116, P1123; Capdevila J, 1998, DEV BIOL, V193, P182, DOI 10.1006/dbio.1997.8806; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; Cossu G, 1999, EMBO J, V18, P6867, DOI 10.1093/emboj/18.24.6867; EDWARDS MKS, 1983, MOL CELL BIOL, V3, P2280, DOI 10.1128/MCB.3.12.2280; Fan CM, 1997, DEV BIOL, V191, P160, DOI 10.1006/dbio.1997.8713; FUNAYAMA N, 1995, J CELL BIOL, V128, P959, DOI 10.1083/jcb.128.5.959; Galceran J, 2001, P NATL ACAD SCI USA, V98, P8668, DOI 10.1073/pnas.151258098; Gat U, 1998, CELL, V95, P605, DOI 10.1016/S0092-8674(00)81631-1; Goichberg P, 2001, J CELL SCI, V114, P1309; Goichberg P, 1998, MOL BIOL CELL, V9, P3119, DOI 10.1091/mbc.9.11.3119; Gustafsson MK, 2002, GENE DEV, V16, P114, DOI 10.1101/gad.940702; HAEGEL H, 1995, DEVELOPMENT, V121, P3529; Heanue TA, 1999, GENE DEV, V13, P3231, DOI 10.1101/gad.13.24.3231; Huelsken J, 2000, J CELL BIOL, V148, P567, DOI 10.1083/jcb.148.3.567; Ikeya M, 1998, DEVELOPMENT, V125, P4969; Imbert A, 2001, J CELL BIOL, V153, P555, DOI 10.1083/jcb.153.3.555; Li L, 1999, J BIOL CHEM, V274, P129, DOI 10.1074/jbc.274.1.129; Maroto M, 1997, CELL, V89, P139, DOI 10.1016/S0092-8674(00)80190-7; MCBURNEY MW, 1982, NATURE, V299, P165, DOI 10.1038/299165a0; MCBURNEY MW, 1994, SOMAT CELL MOLEC GEN, V20, P515, DOI 10.1007/BF02255842; Miller JR, 1999, ONCOGENE, V18, P7860, DOI 10.1038/sj.onc.1203245; Molenaar M, 1996, CELL, V86, P391, DOI 10.1016/S0092-8674(00)80112-9; Montross WT, 2000, J CELL SCI, V113, P1759; Moriguchi T, 1999, J BIOL CHEM, V274, P30957, DOI 10.1074/jbc.274.43.30957; MUNSTERBERG AE, 1995, GENE DEV, V9, P2911, DOI 10.1101/gad.9.23.2911; NORTON PA, 1985, MOL CELL BIOL, V5, P281, DOI 10.1128/MCB.5.2.281; PARR BA, 1993, DEVELOPMENT, V119, P247; Ridgeway AG, 2000, J BIOL CHEM, V275, P41, DOI 10.1074/jbc.275.1.41; Ridgeway AG, 2001, J BIOL CHEM, V276, P19033, DOI 10.1074/jbc.M011491200; Ridgeway AG, 2000, J BIOL CHEM, V275, P32398, DOI 10.1074/jbc.M004349200; Runnicki M.A., 1987, TERATOCARCINOMAS EMB, P19; Sabourin LA, 2000, CLIN GENET, V57, P16, DOI 10.1034/j.1399-0004.2000.570103.x; Schmidt M, 2000, DEVELOPMENT, V127, P4105; Seghatoleslami MR, 2000, J CELL BIOCHEM, V77, P252, DOI 10.1002/(SICI)1097-4644(20000501)77:2<252::AID-JCB8>3.0.CO;2-J; SKERJANC IS, 1994, MOL CELL BIOL, V14, P8451, DOI 10.1128/MCB.14.12.8451; Skerjanc IS, 1999, TRENDS CARDIOVAS MED, V9, P139, DOI 10.1016/S1050-1738(99)00017-1; Smith ST, 1996, DEVELOPMENT, V122, P3141; STERN HM, 1995, DEVELOPMENT, V121, P3675; Tada M, 2000, DEVELOPMENT, V127, P2227; Tajbakhsh S, 1997, CELL, V89, P127, DOI 10.1016/S0092-8674(00)80189-0; Tajbakhsh S, 1998, DEVELOPMENT, V125, P4155; Tolkunova EN, 1998, MOL CELL BIOL, V18, P2804, DOI 10.1128/MCB.18.5.2804; Wagner J, 2000, DEV BIOL, V228, P86, DOI 10.1006/dbio.2000.9921; Wang SW, 1997, BIOCHEM BIOPH RES CO, V236, P502, DOI 10.1006/bbrc.1997.6995; Wilton S, 1999, IN VITRO CELL DEV-AN, V35, P175; Wong MH, 1998, J CELL BIOL, V141, P765, DOI 10.1083/jcb.141.3.765; Yamaguchi TP, 1999, GENE DEV, V13, P3185, DOI 10.1101/gad.13.24.3185; Zhurinsky J, 2000, J CELL SCI, V113, P3127	60	115	124	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 3	2002	277	18					15393	15399		10.1074/jbc.M112141200	http://dx.doi.org/10.1074/jbc.M112141200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	550PA	11856745	hybrid			2022-12-27	WOS:000175510400023
J	Schneider, S; Hotz, HR; Schwer, B				Schneider, S; Hotz, HR; Schwer, B			Characterization of dominant-negative mutants of the DEAH-box splicing factors Prp22 and Prp16	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPATITIS-C VIRUS; RNA-DEPENDENT ATPASE; MESSENGER-RNA; MUTATIONAL ANALYSIS; SACCHAROMYCES-CEREVISIAE; HELICASE DOMAIN; NUCLEOSIDE TRIPHOSPHATASE; CRYSTAL-STRUCTURE; PROTEIN PRP22; NS3 PROTEIN	Saccharomyces cerevisiae Prp22 and Prp16 are RNA-dependent ATPases required for pre-mRNA splicing. Both proteins are members of the DEXH-box family of nucleic acid-dependent NTPases. Prior mutational analysis of Prp22 and Prp16 identified residues within conserved motifs I (GYGKT), II (DEAH), and VI (QRXGRXGR) that are required for their biological activity. Nonfunctional Prp22 and Prp16 mutants exerted a dominant negative effect on cell growth. Here we show that overexpression of lethal Prp22 mutants leads to accumulation of unspliced pre-mRNAs and excised introns in vivo. The biochemical basis for the lethality and inhibition of splicing in vivo was determined by purifying and characterizing recombinant mutant proteins. The lethal Prp22 mutants D603A and E604A in motif II and Q804A and R808A in motif VI were defective for ATP hydrolysis and mRNA release from the spliceosome, but were active in promoting step 2 transesterification. Lethal Prp16 mutants G378A and K379A in motif I; D473A and E474A in motif II; and Q685A, G688A, R689A, and R692A in motif VI were defective for ATP hydrolysis and step 2 transesterification chemistry. The ATPase-defective mutants of Prp16 and Prp22 bound to spliceosomes in vitro and blocked the function of the respective wild-type proteins in trans. Comparing the mutational effects in Prp16 and Prp22 highlights common as well as distinct structural requirements for the ATP-dependent steps in pre-mRNA splicing.	Cornell Univ, Weill Med Coll, Dept Microbiol & Immunol, New York, NY 10021 USA	Cornell University	Schwer, B (corresponding author), Cornell Univ, Weill Med Coll, Dept Microbiol & Immunol, New York, NY 10021 USA.				NIGMS NIH HHS [GM50288] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050288] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANSARI A, 1995, EMBO J, V14, P4001, DOI 10.1002/j.1460-2075.1995.tb00071.x; BURGESS S, 1990, CELL, V60, P705, DOI 10.1016/0092-8674(90)90086-T; BURGESS SM, 1993, CELL, V73, P1377, DOI 10.1016/0092-8674(93)90363-U; Campodonico E, 2002, GENETICS, V160, P407; Chanfreau G, 1999, RNA, V5, P876, DOI 10.1017/S1355838299990544; Cho HS, 1998, J BIOL CHEM, V273, P15045, DOI 10.1074/jbc.273.24.15045; COMPANY M, 1991, NATURE, V349, P487, DOI 10.1038/349487a0; de la Cruz J, 1999, TRENDS BIOCHEM SCI, V24, P192, DOI 10.1016/S0968-0004(99)01376-6; Edwalds-Gilbert G, 2000, RNA, V6, P1106, DOI 10.1017/S1355838200992483; Gross CH, 1998, J VIROL, V72, P4729, DOI 10.1128/JVI.72.6.4729-4736.1998; Gross CH, 1996, J VIROL, V70, P1706, DOI 10.1128/JVI.70.3.1706-1713.1996; GROSS CH, 1995, J VIROL, V69, P4727, DOI 10.1128/JVI.69.8.4727-4736.1995; Hall MC, 1999, MOL MICROBIOL, V34, P867, DOI 10.1046/j.1365-2958.1999.01659.x; Heilek GM, 1997, J VIROL, V71, P6264, DOI 10.1128/JVI.71.8.6264-6266.1997; HERRICK D, 1990, MOL CELL BIOL, V10, P2269, DOI 10.1128/MCB.10.5.2269; Hotz HR, 1998, GENETICS, V149, P807; Kim DH, 1999, RNA, V5, P959, DOI 10.1017/S135583829999012X; Kim JL, 1998, STRUCTURE, V6, P89, DOI 10.1016/S0969-2126(98)00010-0; Lee CG, 1997, EMBO J, V16, P2671, DOI 10.1093/emboj/16.10.2671; Linder P, 2000, YEAST, V16, P507, DOI 10.1002/(SICI)1097-0061(200004)16:6<507::AID-YEA549>3.0.CO;2-N; Martins A, 1999, J VIROL, V73, P1302, DOI 10.1128/JVI.73.2.1302-1308.1999; PAUSE A, 1993, MOL CELL BIOL, V13, P6789, DOI 10.1128/MCB.13.11.6789; PAUSE A, 1992, EMBO J, V11, P2643, DOI 10.1002/j.1460-2075.1992.tb05330.x; PLUMPTON M, 1994, EMBO J, V13, P879, DOI 10.1002/j.1460-2075.1994.tb06331.x; Schneider S, 2001, J BIOL CHEM, V276, P21184, DOI 10.1074/jbc.M101964200; SCHWER B, 1992, MOL CELL BIOL, V12, P3540, DOI 10.1128/MCB.12.8.3540; Schwer B, 1998, EMBO J, V17, P2086, DOI 10.1093/emboj/17.7.2086; SCHWER B, 1992, EMBO J, V11, P5033, DOI 10.1002/j.1460-2075.1992.tb05610.x; SCHWER B, 1991, NATURE, V349, P494, DOI 10.1038/349494a0; Schwer B, 2001, NAT STRUCT BIOL, V8, P113, DOI 10.1038/84091; Schwer B, 2000, EMBO J, V19, P6582, DOI 10.1093/emboj/19.23.6582; Tanner NK, 2001, MOL CELL, V8, P251, DOI 10.1016/S1097-2765(01)00329-X; VIJAYRAGHAVAN U, 1986, EMBO J, V5, P1683, DOI 10.1002/j.1460-2075.1986.tb04412.x; Wagner JDO, 1998, EMBO J, V17, P2926, DOI 10.1093/emboj/17.10.2926; Wardell AD, 1999, J GEN VIROL, V80, P701, DOI 10.1099/0022-1317-80-3-701; Yao NH, 1997, NAT STRUCT BIOL, V4, P463, DOI 10.1038/nsb0697-463; Zhang M, 2001, GENE DEV, V15, P30, DOI 10.1101/gad.851701; Zhang XP, 1997, NUCLEIC ACIDS RES, V25, P2146, DOI 10.1093/nar/25.11.2146	38	47	48	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 3	2002	277	18					15452	15458		10.1074/jbc.M112473200	http://dx.doi.org/10.1074/jbc.M112473200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	550PA	11856747	hybrid			2022-12-27	WOS:000175510400032
J	Shi, YY; Hsu, JH; Hu, LP; Gera, J; Lichtenstein, A				Shi, YY; Hsu, JH; Hu, LP; Gera, J; Lichtenstein, A			Signal pathways involved in activation of p70(S6K) and phosphorylation of 4E-BP1 following exposure of multiple myeloma tumor cells to interleukin-6	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P70 S6 KINASE; AKT KINASE; PROTEIN-SYNTHESIS; IN-VIVO; RAPAMYCIN; APOPTOSIS; SURVIVAL; GROWTH; INSULIN; IDENTIFICATION	Interleukin-6 (IL-6) is a prominent tumor growth factor for malignant multiple myeloma cells. In addition to its known activation of the Janus tyrosine kinase-STAT and RAS-MEK-ERK pathways, recent work suggests that IL-6 can also activate the phosphatidylinositol 3-kinase (PI3-K)/AKT kinase pathway in myeloma cells. Because activation of the PI3-K/AKT as well as RAS-MEK-ERK pathways may result in downstream stimulation of the p70(S6K) (p70) and phosphorylation of the 4E-BP1 translational repressor, we assessed these potential molecular targets in IL-6-treated myeloma cells. IL-6 rapidly activated p70 kinase activity and p70 phosphorylation. Activation was inhibited by wortmannin, rapamycin, and the ERK inhibitors PD98059 and UO126, as well as by a dominant negative mutant of AKT. The concurrent requirements for both ERK and PI3-K/AKT appeared to be a result of their ability to phosphorylate p70 on different residues. In contrast, IL-6-induced phosphorylation of 4E-BP1 was inhibited by rapamycin, wortmannin, and dominant negative ART but ERK inhibitors had no effect, indicating ERK function was dispensable. In keeping with these data, a dominant active AKT mutant was sufficient to induce 4E-BP1 phosphorylation but could not by itself activate p70 kinase activity. Prevention of IL-6-induced p70 activation and 4E-BP1 phosphorylation by the mammalian target of rapamycin inhibitors rapamycin and CCI-779 resulted in inhibition of IL-6-induced myeloma cell growth. These results indicate that both ERK and PI3-K/AKT pathways are required for optimal IL-6-induced p70 activity, but PI3-K/AKT is sufficient for 4E-BP1 phosphorylation. Both effects are mediated via mammalian target of rapamycin function, and, furthermore, these effects are critical for IL-6-induced tumor cell growth.	Univ Calif Los Angeles, W Los Angeles Vet Affairs Med Ctr, Dept Med, Los Angeles, CA 90073 USA; Jonsson Comprehens Canc Ctr, Los Angeles, CA 90073 USA	University of California System; University of California Los Angeles; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Greater Los Angeles Healthcare System; West Los Angeles VA Medical Center; UCLA Jonsson Comprehensive Cancer Center	Lichtenstein, A (corresponding author), Univ Calif Los Angeles, W Los Angeles Vet Affairs Med Ctr, Dept Med, Los Angeles, CA 90073 USA.	alichten@ucla.edu		Gera, Joseph/0000-0002-2908-6894				ANDERSON KC, 1989, BLOOD, V73, P1915; Aoki M, 1998, P NATL ACAD SCI USA, V95, P14950, DOI 10.1073/pnas.95.25.14950; Balendran A, 1999, J BIOL CHEM, V274, P37400, DOI 10.1074/jbc.274.52.37400; BATAILLE R, 1995, BLOOD, V86, P685, DOI 10.1182/blood.V86.2.685.bloodjournal862685; BATAILLE R, 1989, J CLIN INVEST, V84, P2008, DOI 10.1172/JCI114392; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; Burnett PE, 1998, P NATL ACAD SCI USA, V95, P1432, DOI 10.1073/pnas.95.4.1432; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Catlett-Falcone R, 1999, IMMUNITY, V10, P105, DOI 10.1016/S1074-7613(00)80011-4; Conus NM, 1998, J BIOL CHEM, V273, P4776, DOI 10.1074/jbc.273.8.4776; DAEIPOUR M, 1993, J IMMUNOL, V150, P4743; DEL PL, 1997, SCIENCE, V278, P687; Dennis PB, 1996, MOL CELL BIOL, V16, P6242; Dufner A, 1999, MOL CELL BIOL, V19, P4525; Dufner A, 1999, EXP CELL RES, V253, P100, DOI 10.1006/excr.1999.4683; Fukada T, 1996, IMMUNITY, V5, P449, DOI 10.1016/S1074-7613(00)80501-4; Geoerger B, 2001, CANCER RES, V61, P1527; Gingras AC, 1996, P NATL ACAD SCI USA, V93, P5578, DOI 10.1073/pnas.93.11.5578; Gingras AC, 1998, GENE DEV, V12, P502, DOI 10.1101/gad.12.4.502; Harada H, 2001, P NATL ACAD SCI USA, V98, P9666, DOI 10.1073/pnas.171301998; HAYSTEAD TAJ, 1994, J BIOL CHEM, V269, P23185; Herbert TP, 2000, J BIOL CHEM, V275, P11249, DOI 10.1074/jbc.275.15.11249; HILBERT DM, 1995, J EXP MED, V182, P243, DOI 10.1084/jem.182.1.243; Hosoi H, 1998, MOL PHARMACOL, V54, P815, DOI 10.1124/mol.54.5.815; Hsu JH, 2002, ONCOGENE, V21, P1391, DOI 10.1038/sj/onc/1205194; Hsu JH, 2001, BLOOD, V98, P2853, DOI 10.1182/blood.V98.9.2853; Isotani S, 1999, J BIOL CHEM, V274, P34493, DOI 10.1074/jbc.274.48.34493; JEFFERIES HBJ, 1996, TRANSLATIONAL CONTRO, P75; Kawasome H, 1998, P NATL ACAD SCI USA, V95, P5033, DOI 10.1073/pnas.95.9.5033; Kim AH, 2001, MOL CELL BIOL, V21, P893, DOI 10.1128/MCB.21.3.893-901.2001; KISHIMOTO T, 1995, BLOOD, V86, P1243, DOI 10.1182/blood.V86.4.1243.bloodjournal8641243; LICHTENSTEIN A, 1995, CELL IMMUNOL, V162, P248, DOI 10.1006/cimm.1995.1076; MUKHOPADHYAY NK, 1992, J BIOL CHEM, V267, P3325; MURAGUCHI A, 1988, J EXP MED, V167, P332, DOI 10.1084/jem.167.2.332; Ogata A, 1997, J IMMUNOL, V159, P2212; Oh H, 1998, J BIOL CHEM, V273, P9703, DOI 10.1074/jbc.273.16.9703; Peterson RT, 1999, P NATL ACAD SCI USA, V96, P4438, DOI 10.1073/pnas.96.8.4438; Pullen N, 1998, SCIENCE, V279, P707, DOI 10.1126/science.279.5351.707; SOONYANG Z, 1997, P NATL ACAD SCI USA, V94, P11345; Tu YP, 2000, CANCER RES, V60, P6763; Westphal RS, 1999, J BIOL CHEM, V274, P687, DOI 10.1074/jbc.274.2.687; Wu XY, 1998, P NATL ACAD SCI USA, V95, P15587, DOI 10.1073/pnas.95.26.15587; Xu FH, 1998, BLOOD, V92, P241, DOI 10.1182/blood.V92.1.241.413k28_241_251; Zhang YG, 2001, J BIOL CHEM, V276, P20913, DOI 10.1074/jbc.M009047200	45	89	96	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 3	2002	277	18					15712	15720		10.1074/jbc.M200043200	http://dx.doi.org/10.1074/jbc.M200043200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	550PA	11872747	hybrid			2022-12-27	WOS:000175510400067
